PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Varner, CE				Varner, Catherine E.			In adults, NSAID use vs. nonuse in the past 4 mo was not linked to increased risk for COVID-19-related mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Varner, Catherine E.] Mt Sinai Hosp, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Varner, CE (corresponding author), Mt Sinai Hosp, Toronto, ON, Canada.							Lund LC, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003308; Vaja R, 2021, BRIT J CLIN PHARMACO, V87, P776, DOI 10.1111/bcp.14514; Yousefifard M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13557	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY	2021	174	5					JC58	JC58		10.7326/ACPJ202105180-058	http://dx.doi.org/10.7326/ACPJ202105180-058			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SF2QB	33939487				2023-01-03	WOS:000652604800013
J	Ruff, C; Gerharz, A; Groll, A; Stoll, F; Wirbka, L; Haefeli, WE; Meid, AD				Ruff, Carmen; Gerharz, Alexander; Groll, Andreas; Stoll, Felicitas; Wirbka, Lucas; Haefeli, Walter E.; Meid, Andreas D.			Disease-dependent variations in the timing and causes of readmissions in Germany: A claims data analysis for six different conditions	PLOS ONE			English	Article							RISK-FACTORS; 30-DAY READMISSION; HEALTH INTERVIEW; RE-ADMISSIONS; HIP FRACTURE; DISCHARGE; ADULTS; PREVALENCE; PREDICTION; MORTALITY	Background Hospital readmissions place a major burden on patients and health care systems worldwide, but little is known about patterns and timing of readmissions in Germany. Methods We used German health insurance claims (AOK, 2011-2016) of patients >= 65 years hospitalized for acute myocardial infarction (AMI), heart failure (HF), a composite of stroke, transient ischemic attack, or atrial fibrillation (S/AF), chronic obstructive pulmonary disease (COPD), type 2 diabetes mellitus, or osteoporosis to identify hospital readmissions within 30 or 90 days. Readmissions were classified into all-cause, specific, and non-specific and their characteristics were analyzed. Results Within 30 and 90 days, about 14-22% and 27-41% index admissions were readmitted for any reason, respectively. HF and S/AF contributed most index cases, and HF and COPD accounted for most all-cause readmissions. Distributions and ratios of specific to non-specific readmissions were disease-specific with highest specific readmissions rates among COPD and AMI. Conclusion German claims are well-suited to investigate readmission causes if longer periods than 30 days are evaluated. Conditions closely related with the primary disease are the most frequent readmission causes, but multiple comorbidities among readmitted cases suggest that a multidisciplinary care approach should be implemented vigorously addressing comorbidities already during the index hospitalization.	[Ruff, Carmen; Stoll, Felicitas; Wirbka, Lucas; Haefeli, Walter E.; Meid, Andreas D.] Heidelberg Univ Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany; [Gerharz, Alexander; Groll, Andreas] TU Dortmund Univ, Fac Stat, Dortmund, Germany	Ruprecht Karls University Heidelberg; Dortmund University of Technology	Meid, AD (corresponding author), Heidelberg Univ Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany.	andreas.meid@med.uni-heidelberg.de		Meid, Andreas/0000-0003-3537-3205; Gerharz, Alexander/0000-0003-2148-4203; Groll, Andreas/0000-0001-6787-9118	German Innovation Funds [01VSF18019]; Physician-Scientist Programme of Heidelberg University, Faculty of Medicine	German Innovation Funds; Physician-Scientist Programme of Heidelberg University, Faculty of Medicine	This work was supported by the German Innovation Funds according to 92a (2) Volume V of the Social Insurance Code ( 92a Abs. 2, SGB V -Funftes Buch Sozialgesetzbuch), grant number: 01VSF18019. URL: https://innovationsfonds.g-ba.de/Andreas D. Meid is funded by the PhysicianScientist Programme of Heidelberg University, Faculty of Medicine. URL: http://www.medizinische-fakultaet-hd.uni-heidelberg.de/Physician-Scientist-Programm.111367.0.html The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AOK Baden-Wurttemberg Hauptverwaltung. DAS GEHT, 2017, UNT BAD WURTT AUSG 2; Ballard J, 2018, AM J MED QUAL, V33, P583, DOI 10.1177/1062860618775528; Barnett BS, 2020, INT J PSYCHIAT CLIN, V24, P25, DOI 10.1080/13651501.2019.1699116; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bottle A., 2018, FACTORS ASS HOSP EME; Braun BL, 1998, PHYS THER, V78, P1262, DOI 10.1093/ptj/78.12.1262; Brunner-La Rocca RH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233457; Choo S, 2018, CLIN NEUROL NEUROSUR, V174, P129, DOI 10.1016/j.clineuro.2018.08.014; CMS.gov-Centers for Medicare & Medicaid Services, HOSP READM RED PROGR; CMS.gov-QualityNet, HOSP SPEC REP; Counter D, 2018, BRIT J CLIN PHARMACO, V84, P1757, DOI 10.1111/bcp.13607; Dalleur O, 2021, J PATIENT SAF, V17, pE379, DOI 10.1097/PTS.0000000000000346; DESTATIS Statistisches Bundesamt, KRANK EINR BETT PAT; Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin e.V. Deutsche Atemwegsliga e.V. Osterreichische Gesellschaft fur Pneumologie, 2018, S2K LEITLINIE DIAGNO; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Dial BL, 2020, GLOB SPINE J, V10, P252, DOI 10.1177/2192568219843111; Dietrich E, 2019, SOUTH MED J, V112, P244, DOI 10.14423/SMJ.0000000000000959; Dodson JA, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.118.005320; Donaghy E, 2018, BMJ QUAL SAF, V27, P915, DOI 10.1136/bmjqs-2017-007513; Donze J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7171; Enomoto LM, 2017, J DIABETES COMPLICAT, V31, P122, DOI 10.1016/j.jdiacomp.2016.10.021; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Rutenberg TF, 2020, EUR J TRAUMA EMERG S, V46, P939, DOI 10.1007/s00068-018-0997-5; Fuchs J, 2013, BUNDESGESUNDHEITSBLA, V56, P678, DOI 10.1007/s00103-013-1687-4; Gau JT, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0041-0; Graumlich JF, 2008, J HOSP MED, V3, P446, DOI 10.1002/jhm.316; Heidemann C, 2013, BUNDESGESUNDHEITSBLA, V56, P668, DOI 10.1007/s00103-012-1662-5; Hoffmann CJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218902; Hoyer EH, 2018, J GEN INTERN MED, V33, P57, DOI 10.1007/s11606-017-4193-9; Hughes LD, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0883-3; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006, IARC Monogr Eval Carcinog Risks Hum, V88, P1; Iketani R, 2020, J CLIN NEUROSCI, V76, P189, DOI 10.1016/j.jocn.2020.04.009; Jacob Louis, 2016, Ger Med Sci, V14, pDoc03, DOI 10.3205/000230; Jacobs DM, 2018, ANN AM THORAC SOC, V15, P837, DOI 10.1513/AnnalsATS.201712-913OC; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Karrer S, 2011, HAUTARZT, V62, P493, DOI 10.1007/s00105-010-2112-7; Karunakaran A, 2018, MED CARE, V56, P634, DOI 10.1097/MLR.0000000000000931; Lin JCF, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1493-5; Medizinischer Dienst des Spitzenverbandes Bund der Krankenkassen e.V. (MDS), 2018, BEGUT RICHTL GKV SPI; Meid AD, 2018, VALUE HEALTH, V21, P1390, DOI 10.1016/j.jval.2018.05.007; Mongkhon P, 2018, BMJ QUAL SAF, V27, P902, DOI 10.1136/bmjqs-2017-007453; Moock J., 2012, GGW, V12, P24; Nair R., 2020, CIRC-CARDIOVASC QUAL, V13, pA357, DOI [10.1161/hcq.13.suppl_1.357, DOI 10.1161/HCQ.13.SUPPL_1.357]; Norden J, 2015, EUR J CLIN NUTR, V69, P256, DOI 10.1038/ejcn.2014.76; Ostling Stephanie, 2017, Clin Diabetes Endocrinol, V3, P3, DOI 10.1186/s40842-016-0040-x; Paull JO, 2021, J ROBOT SURG, V15, P87, DOI 10.1007/s11701-020-01071-w; Png ME, 2018, CURR MED RES OPIN, V34, P1071, DOI 10.1080/03007995.2018.1431617; Rives-Sanchez M, 2020, J NATL MED ASSOC, V112, P262, DOI 10.1016/j.jnma.2020.03.011; Ruppar TM, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002606; Castillo SS, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17020594; Schafer I, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1285; Sevilla-Cazes J, 2018, J GEN INTERN MED, V33, P1700, DOI 10.1007/s11606-018-4542-3; Sheikh HQ, 2019, EUR J ORTHOP SURG TR, V29, P1055, DOI 10.1007/s00590-019-02412-8; Stahmeyer JT, 2019, DTSCH ARZTEBL INT, V116, P711, DOI 10.3238/arztebl.2019.0711; Stone AV, 2018, INT ORTHOP, V42, P231, DOI 10.1007/s00264-017-3663-3; Swanson JO, 2018, HEALTH POLICY, V122, P737, DOI 10.1016/j.healthpol.2018.05.013; Swart E, 2005, GESUNDHEITSWESEN, V67, P101, DOI 10.1055/s-2005-857880; Takeda A, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002752.pub4; Terman SW, 2020, NEUROL-CLIN PRACT, V10, P122, DOI 10.1212/CPJ.0000000000000688; Thevelin S, 2019, DRUG AGING, V36, P453, DOI 10.1007/s40266-018-00635-8; Tung YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170061; van Walraven C, 2012, J EVAL CLIN PRACT, V18, P1211, DOI 10.1111/j.1365-2753.2011.01773.x; von Eiff W., 2011, DTSCH ARZTEBL, V108, pA 1164; Wang HJ, 2019, CLIN CARDIOL, V42, P889, DOI 10.1002/clc.23238; Wang Y, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014907; Weissman JS, 2001, INT J QUAL HEALTH C, V13, P183, DOI 10.1093/intqhc/13.3.183; Yam Carrie H. K., 2010, Hong Kong Medical Journal, V16, P383; Yii ACA, 2019, INT J CHRONIC OBSTR, V14, P719, DOI 10.2147/COPD.S194922; Zabawa C, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011085	69	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2021	16	4							e0250298	10.1371/journal.pone.0250298	http://dx.doi.org/10.1371/journal.pone.0250298			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0VQ	33901203	gold, Green Published			2023-01-03	WOS:000662169700028
J	Chen, KX; Worley, S; Foster, H; Edasery, D; Roknsharifi, S; Ifrah, C; Lipton, ML				Chen, Ke Xun; Worley, Sandie; Foster, Henry; Edasery, David; Roknsharifi, Shima; Ifrah, Chloe; Lipton, Michael L.			Oral contraceptive use is associated with smaller hypothalamic and pituitary gland volumes in healthy women: A structural MRI study	PLOS ONE			English	Article								The effects of hormonal contraceptives on structural features of the hypothalamus and pituitary are incompletely understood. One prior study reported microstructural changes in the hypothalamus with oral contraceptive pill (OCP) use. However, effects on hypothalamic volume have not been reported. One prior study reported volumetric changes in the pituitary. However, this study was limited by including participants evaluated for neurological symptoms. We sought to determine if OCP use is associated with alteration of hypothalamic or pituitary volume. High-resolution 3T MRI was performed for a prospective cohort of 50 healthy women from 2016 to 2018, which comprised 21 OCP users (age, 19-29) and 29 naturally cycling women (age, 18-36). Participants were excluded if they were pregnant or had significant medical conditions including neurological, psychiatric, and endocrine disorders. After confirming reliability of the image analysis techniques, 5 raters independently performed manual segmentation of the hypothalamus and semi-automated intensity threshold-based segmentation of the pituitary using ITK-SNAP. Total intracranial volume was estimated using FreeSurfer. A general linear model tested the association of OCP use with hypothalamic and pituitary volumes. Hypothalamic (B = -81.2 +/- 24.9, p = 0.002) and pituitary (B = -81.2 +/- 38.7, p = 0.04) volumes in OCP users were smaller than in naturally cycling women. These findings may be related to interference with known trophic effects of sex hormones and suggest a structural correlate of central OCP effects.	[Chen, Ke Xun; Edasery, David; Roknsharifi, Shima; Lipton, Michael L.] Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA; [Chen, Ke Xun; Foster, Henry; Edasery, David; Roknsharifi, Shima; Ifrah, Chloe; Lipton, Michael L.] Montefiore Hlth, Bronx, NY 10467 USA; [Worley, Sandie] NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; [Foster, Henry; Ifrah, Chloe; Lipton, Michael L.] Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10467 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; New York University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lipton, ML (corresponding author), Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Montefiore Hlth, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10467 USA.	michael.lipton@einsteinmed.org		Chen, Ke Xun/0000-0003-2171-6641	National Institutes of Health [R01NS082432]; Dana Foundation David Mahoney Neuroimaging Program (MLL)	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dana Foundation David Mahoney Neuroimaging Program (MLL)	This study was supported by the National Institutes of Health (R01NS082432) and the Dana Foundation David Mahoney Neuroimaging Program (MLL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baroncini M, 2010, NEUROIMAGE, V50, P428, DOI 10.1016/j.neuroimage.2009.11.074; Barth C, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00037; Bielau H, 2005, EUR ARCH PSY CLIN N, V255, P401, DOI 10.1007/s00406-005-0581-y; Bocchetta M, 2015, J NEUROL, V262, P2635, DOI 10.1007/s00415-015-7885-2; BRONSON R A, 1981, Clinical Obstetrics and Gynecology, V24, P869, DOI 10.1097/00003081-198109000-00014; Catenaccio E, 2016, BRAIN STRUCT FUNCT, V221, P3845, DOI 10.1007/s00429-016-1197-x; Cooke BM, 2005, J NEUROBIOL, V64, P34, DOI 10.1002/neu.20143; De Bondt T, 2013, BRAIN RES, V1530, P22, DOI 10.1016/j.brainres.2013.07.034; De Bondt T, 2016, BRAIN STRUCT FUNCT, V221, P4631, DOI 10.1007/s00429-016-1193-1; Fehring RJ, 2006, JOGNN-J OBST GYN NEO, V35, P376, DOI 10.1111/j.1552-6909.2006.00051.x; Gabery S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117593; Gabery S, 2010, ACTA NEUROPATHOL, V120, P777, DOI 10.1007/s00401-010-0742-6; GASPARD UJ, 1983, CONTRACEPTION, V27, P577, DOI 10.1016/0010-7824(83)90023-9; Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027; Goldstein JM, 2001, CEREB CORTEX, V11, P490, DOI 10.1093/cercor/11.6.490; Grams AE, 2010, NEUROENDOCRINOLOGY, V92, P128, DOI 10.1159/000314196; Jones J., 2013, CURRENT CONTRACEPTIV; Klomp A, 2012, INT J NEUROPSYCHOPH, V15, P281, DOI 10.1017/S1461145711000794; Kulkarni J., 2005, AUST FAM PHYSICIAN; Kulkarni J, 2007, EXPERT OPIN DRUG SAF, V6, P371, DOI 10.1517/14740338.6.4.371; Sanchez AM, 2013, MOL ENDOCRINOL, V27, P693, DOI 10.1210/me.2012-1278; Micevych P, 2012, FRONT NEUROENDOCRIN, V33, P331, DOI 10.1016/j.yfrne.2012.07.003; MISHELL DR, 1972, AM J OBSTET GYNECOL, V114, P923, DOI 10.1016/0002-9378(72)90098-1; Oinonen KA, 2002, J AFFECT DISORDERS, V70, P229, DOI 10.1016/S0165-0327(01)00356-1; Petersen N, 2015, HUM BRAIN MAPP, V36, P2644, DOI 10.1002/hbm.22797; Petitti DB, 2003, NEW ENGL J MED, V349, P1443, DOI 10.1056/NEJMcp030751; Pletzer B, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00592; Pletzer B, 2015, BRAIN RES, V1596, P108, DOI 10.1016/j.brainres.2014.11.025; Pletzer B, 2010, BRAIN RES, V1348, P55, DOI 10.1016/j.brainres.2010.06.019; Pletzer BA, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00256; Rivera R, 1999, AM J OBSTET GYNECOL, V181, P1263, DOI 10.1016/S0002-9378(99)70120-1; Robinson SA, 2004, MED HYPOTHESES, V63, P268, DOI 10.1016/j.mehy.2004.02.013; Schindler S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066394; Tognin S, 2012, PSYCHIAT RES-NEUROIM, V204, P75, DOI 10.1016/j.pscychresns.2012.10.006; Tu CH, 2013, PAIN, V154, P1718, DOI 10.1016/j.pain.2013.05.022; Witte AV, 2010, NEUROIMAGE, V49, P1205, DOI 10.1016/j.neuroimage.2009.09.046; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015	38	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2021	16	4							e0249482	10.1371/journal.pone.0249482	http://dx.doi.org/10.1371/journal.pone.0249482			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0BF	33882080	gold, Green Published			2023-01-03	WOS:000644133400009
J	Teshale, AB; Tesema, GA; Tessema, ZT				Teshale, Achamyeleh Birhanu; Tesema, Getayeneh Antehunegn; Tessema, Zemenu Tadesse			Spatial variations and associated factors of knowledge of ORS packet or pre-packaged liquids for the management of diarrhea among women of reproductive age in Ethiopia: A spatial and multilevel analysis	PLOS ONE			English	Article								Background Even though diarrhea is not lethal by itself, the lack of knowledge about its management results in devastating complications such as dehydration and lastly death. Using an oral rehydration solution (ORS) is an easy, inexpensive, and most reliable way of treating dehydration and reducing diarrhea-related mortalities. The literature revealed that Knowledge of ORS packet or pre-packaged liquids is a very important and critical factor for the utilization of ORS during the management of diarrhea. Methods We used the 2016 Ethiopian Demographic and Health Survey data, which is the fourth survey conducted by the Central Statistical Agency. A total weighted sample of 7590 reproductive-age women who gave birth within five years preceding the survey was used. Multilevel logistic regression analysis was done to assess factors associated with knowledge of ORS packet or pre-packaged liquids. Arc GIS version 10.3 and Kuldorff's SaTScan version 9.6 software were used for the spatial analysis. Results In the multilevel analysis maternal education, media exposure, residence, community illiteracy level, and region were significantly associated with knowledge of ORS packet or pre-packaged liquids. Besides, knowledge of ORS packet or pre-packaged liquids for the management of diarrhea was not random in Ethiopia (with Moran's Index = 0.46 and p-value <0.001), and the primary clusters spatial window was located in SNNPR, most parts of the Oromia region, and eastern parts of the Gambela region. Conclusion In this study knowledge of ORS packet or pre-packaged liquids was not random across the country. Lack of formal education, lack of media exposure, being from a rural area, and being from communities with a higher illiteracy level was associated with lower odds of knowledge of ORS packet or pre-packaged liquids. Therefore, special emphasis should be given to these high-risk groups and the hot spot regions (SNNPR, most parts of the Oromia region, and eastern parts of the Gambela region). Moreover, distributing information through different media regarding ORS packet or pre-packaged liquids is necessary.	[Teshale, Achamyeleh Birhanu; Tesema, Getayeneh Antehunegn; Tessema, Zemenu Tadesse] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia	University of Gondar	Teshale, AB (corresponding author), Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia.	achambir08@gmail.com	Tadesse, Zemenu/ABG-1690-2021; Teshale, Achamyeleh/HHN-8416-2022	Teshale, Achamyeleh/0000-0002-7572-9993				Abdinia B, 2014, ARCH PEDIATR INFECT, V2, DOI 10.5812/pedinfect.17581; Agbolade M. O., 2015, African Journal of Biomedical Research, V18, P7; ANSELIN L, 1992, ANN REGIONAL SCI, V26, P19, DOI 10.1007/BF01581478; Bello DA., KNOWLEDGE USE ORAL R; Desta BK, 2017, NURS RES PRACT, V2017, DOI 10.1155/2017/8084548; Dodicho T., 2016, J HLTH MED NURS, V27, P71; Ethiopia, 2016, DEM HLTH SURV 2016; Ghatam A., 2016, INT J COMMUNITY MED, V3, P1487, DOI [10.18203/2394-6040.ijcmph20161616, DOI 10.18203/2394-6040.IJCMPH20161616]; GIBBONS E, 1994, PUBLIC HEALTH REP, V109, P428; Hackett KM, 2015, MATERN CHILD NUTR, V11, P173, DOI 10.1111/mcn.12007; Kulldorff M, 2018, SATSCANTM USER GUIDE; Lamberti LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130845; Mengistie B, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1029; Mitasova H, 1999, GEOGRAPHICAL INFORM, V1; Munos MK, 2010, INT J EPIDEMIOL, V39, P75, DOI 10.1093/ije/dyq025; Ogunrinde OG, 2012, J TROP PEDIATRICS, V58, P143, DOI 10.1093/tropej/fmr048; Onwukwe S, 2016, S AFR FAM PRACT, V58, P42, DOI 10.1080/20786190.2015.1120933; Rao KV., KNOWLEDGE USE ORAL R; WHO, 2005, HDB IMCI INT MAN CHI; Wieczorek WF, 2009, WILEY INTERDISCIP RE, V1, P167, DOI 10.1002/wics.21; World Health Organization, 2017, STAT HLTH IN IND; Yasmin Mumtaz, 2014, Journal of the Dow University of Health Sciences, V8, P3	22	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2021	16	3							e0247772	10.1371/journal.pone.0247772	http://dx.doi.org/10.1371/journal.pone.0247772			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH6OZ	33780468	Green Published, gold			2023-01-03	WOS:000636336800047
J	Takla, A; Savulescu, J; Kappes, A; Wilkinson, DJC				Takla, Antony; Savulescu, Julian; Kappes, Andreas; Wilkinson, Dominic J. C.			British laypeople's attitudes towards gradual sedation, sedation to unconsciousness and euthanasia at the end of life	PLOS ONE			English	Article							TERMINAL SEDATION; PALLIATIVE SEDATION; LAST-RESORT; UNTIL DEATH; OPTIONS; OPIOIDS; CARE	Background Many patients at the end of life require analgesia to relieve pain. Additionally, up to 1/5 of patients in the UK receive sedation for refractory symptoms at the end of life. The use of sedation in end-of-life care (EOLC) remains controversial. While gradual sedation to alleviate intractable suffering is generally accepted, there is more opposition towards deliberate and rapid sedation to unconsciousness (so-called "terminal anaesthesia", TA). However, the general public's views about sedation in EOLC are not known. We sought to investigate the general public's views to inform policy and practice in the UK. Methods We performed two anonymous online surveys of members of the UK public, sampled to be representative for key demographic characteristics (n = 509). Participants were given a scenario of a hypothetical terminally ill patient with one week of life left. We sought views on the acceptability of providing titrated analgesia, gradual sedation, terminal anaesthesia, and euthanasia. We asked participants about the intentions of doctors, what risks of sedation would be acceptable, and the equivalence of terminal anaesthesia and euthanasia. Findings Of the 509 total participants, 84% and 72% indicated that it is permissible to offer titrated analgesia and gradual sedation (respectively); 75% believed it is ethical to offer TA. Eighty-eight percent of participants indicated that they would like to have the option of TA available in their EOLC (compared with 79% for euthanasia); 64% indicated that they would potentially wish for TA at the end of life (52% for euthanasia). Two-thirds indicated that doctors should be allowed to make a dying patient completely unconscious. More than 50% of participants believed that TA and euthanasia were non-equivalent; a third believed they were. Interpretation These novel findings demonstrate substantial support from the UK general public for the use of sedation and TA in EOLC. More discussion is needed about the range of options that should be offered for dying patients.	[Takla, Antony] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Takla, Antony; Savulescu, Julian; Wilkinson, Dominic J. C.] Univ Oxford, Fac Philosophy, Oxford Uehiro Ctr Pract Eth, Oxford, England; [Savulescu, Julian; Wilkinson, Dominic J. C.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Kappes, Andreas] City Univ London, Sch Arts & Social Sci, Dept Psychol, London, England; [Wilkinson, Dominic J. C.] John Radcliffe Hosp, Oxford, England	Monash University; University of Oxford; Murdoch Children's Research Institute; City University London; University of Oxford	Wilkinson, DJC (corresponding author), Univ Oxford, Fac Philosophy, Oxford Uehiro Ctr Pract Eth, Oxford, England.; Wilkinson, DJC (corresponding author), Murdoch Childrens Res Inst, Melbourne, Vic, Australia.; Wilkinson, DJC (corresponding author), John Radcliffe Hosp, Oxford, England.	dominic.wilkinson@philosophy.ox.ac.uk		Takla, Antony/0000-0001-6138-5184	Wellcome Trust [WT203132, WT104848]; Uehiro Centre for Practical Ethics, Oxford	Wellcome Trust(Wellcome Trust); Uehiro Centre for Practical Ethics, Oxford	The authors were supported by grants from the Wellcome Trust WT203132 (Julian Savulescu, Dominic Wilkinson) WT104848 (Julian Savulescu). Funding for this project was through the Uehiro Centre for Practical Ethics, Oxford.	Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; Cherny NI, 2009, PALLIATIVE MED, V23, P581, DOI 10.1177/0269216309107024; De Graeff A, 2007, J PALLIAT MED, V10, P67, DOI 10.1089/jpm.2006.0139; Fainsinger RL, 2000, PALLIATIVE MED, V14, P257, DOI 10.1191/026921600666097479; Fohr S A, 1998, J Palliat Med, V1, P315, DOI 10.1089/jpm.1998.1.315; Huber S, 2012, RELIGIONS, V3, P710, DOI 10.3390/rel3030710; Kaldjian LC, 2004, J MED ETHICS, V30, P499, DOI 10.1136/jme.2003.004895; Kirby D, 2008, PERSPECT SEX REPRO H, V40, P34, DOI 10.1363/4003408; Lipuma SH, 2013, J MED PHILOS, V38, P190, DOI 10.1093/jmp/jht005; Lundstrom S, 2005, J PAIN SYMPTOM MANAG, V30, P570, DOI 10.1016/j.jpainsymman.2005.05.017; Mazoyer J, 2017, SUPPORT CARE CANCER, V25, P2723, DOI 10.1007/s00520-017-3682-z; Mazoyer J, 2016, J MED ETHICS, V42, P627, DOI 10.1136/medethics-2016-103456; Mercadante S, 1999, CANCER-AM CANCER SOC, V85, P1849, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1849::AID-CNCR27>3.0.CO;2-6; Miele E, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015615; Morita T, 2002, J CLIN ONCOL, V20, P758, DOI 10.1200/JCO.2002.20.3.758; Morita T, 2001, J PAIN SYMPTOM MANAG, V21, P282, DOI 10.1016/S0885-3924(01)00258-5; National Institute of Health and Care Excellence, CAR DYING AD LAST DA; Office for National Statistics, 2019, POPULATION ESTIMATES; Office for National Statistics, EXPL REL ENGL WAL FE; Office for National Statistics, 2011, POP ENGL WAL; Putman MS, 2013, J PAIN SYMPTOM MANAG, V46, P326, DOI 10.1016/j.jpainsymman.2012.09.007; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Quill TE, 2009, ANN INTERN MED, V151, P421, DOI 10.7326/0003-4819-151-6-200909150-00007; Raho JA, 2015, J MED PHILOS, V40, P529, DOI 10.1093/jmp/jhv018; Raus K., 2014, OXFORD HDB ETHICS EN, P1, DOI [10.1093/oxfordhb/9780199974412.001.0001/oxfordhb-9780199974412, DOI 10.1093/OXFORDHB/9780199974412.001.0001/OXFORDHB-9780199974412]; Reid Thomas T., 2010, Pain Management, V1, P31; Rietjens JAC, 2005, SOC SCI MED, V61, P1723, DOI 10.1016/j.socscimed.2005.03.024; Rys S, 2012, J BIOETHIC INQ, V9, P171, DOI 10.1007/s11673-012-9369-8; Savulescu J, 2014, J MED ETHICS, V40, P110, DOI 10.1136/medethics-2013-101379; Seale C, 2010, J PAIN SYMPTOM MANAG, V39, P44, DOI 10.1016/j.jpainsymman.2009.06.007; Simon Alfred, 2007, BMC Palliat Care, V6, P4, DOI 10.1186/1472-684X-6-4; Sulmasy DP, 2018, THEOR MED BIOETH, V39, P233, DOI 10.1007/s11017-018-9459-7; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; Sykes N, 2003, ARCH INTERN MED, V163, P341, DOI 10.1001/archinte.163.3.341; Takla A, 2021, BIOETHICS, V35, P284, DOI 10.1111/bioe.12838; Twycross Robert, 2019, Palliat Care, V12, p1178224218823511, DOI 10.1177/1178224218823511; Verkerk M, 2007, J PAIN SYMPTOM MANAG, V34, P666, DOI 10.1016/j.jpainsymman.2007.01.005	37	4	4	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2021	16	3							e0247193	10.1371/journal.pone.0247193	http://dx.doi.org/10.1371/journal.pone.0247193			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RF4TU	33770083	Green Published, gold, Green Accepted			2023-01-03	WOS:000634833500036
J	Teasdale, CA; Geller, A; Shongwe, S; Mafukidze, A; Choy, M; Magaula, B; Yuengling, K; King, K; De Gusmao, EP; Ryan, C; Ao, T; Callahan, T; Modi, S; Abrams, EJ				Teasdale, Chloe A.; Geller, Amanda; Shongwe, Siphesihle; Mafukidze, Arnold; Choy, Michelle; Magaula, Bhekinkhosi; Yuengling, Katharine; King, Katherine; De Gusmao, Eduarda Pimentel; Ryan, Caroline; Ao, Trong; Callahan, Tegan; Modi, Surbhi; Abrams, Elaine J.			Patient feedback surveys among pregnant women in Eswatini to improve antenatal care retention	PLOS ONE			English	Article								Background Uptake and retention in antenatal care (ANC) is critical for preventing adverse pregnancy outcomes for both mothers and infants. Methods We implemented a rapid quality improvement project to improve ANC retention at seven health facilities in Eswatini (October-December 2017). All pregnant women attending ANC visits were eligible to participate in anonymous tablet-based audio assisted computer self-interview (ACASI) surveys. The 24-question survey asked about women's interactions with health facility staff (HFS) (nurses, mentor mothers, receptionists and lab workers) with a three-level symbolic response options (agree/happy, neutral, disagree/sad). Women were asked to self-report HIV status. Survey results were shared with HFS at monthly quality improvement sessions. Chi-square tests were used to assess differences in responses between months one and three, and between HIV-positive and negative women. Routine medical record data were used to compare retention among pregnant women newly enrolled in ANC two periods, January-February 2017 ('pre-period') and January-February 2018 ('post-period') at two of the participating health facilities. Proportions of women retained at 3 and 6 months were compared using Cochran-Mantel-Haenszel and Wilcoxon tests. Results A total of 1,483 surveys were completed by pregnant women attending ANC, of whom 508 (34.3%) self-reported to be HIV-positive. The only significant change in responses from month one to three was whether nurses listened with agreement increasing from 88.3% to 94.8% (p<0.01). Overall, WLHIV had significantly higher proportions of reported satisfaction with HFS interactions compared to HIV-negative women. A total of 680 pregnant women were included in the retention analysis; 454 (66.8%) HIV-negative and 226 (33.2%) WLHIV. In the pre- and post-periods, 59.4% and 64.6%, respectively, attended at least four ANC visits (p = 0.16). The proportion of women retained at six months increased from 60.9% in the pre-period to 72.7% in the post-period (p = 0.03). For HIV-negative women, pre- and post-period six-month retention significantly increased from 56.6% to 71.6% (p = 0.02); however, the increase in WLHIV retained at six months from 70.7% (pre-period) to 75.0% (post-period) was not statistically significant (p = 0.64). Conclusion The type of rapid quality improvement intervention we implemented may be useful in improving patient-provider relationships although whether it can improve retention remains unclear.	[Teasdale, Chloe A.] CUNY, Grad Sch Publ Hlth & Hlth Policy, Dept Epidemiol & Biostat, New York, NY 10021 USA; [Teasdale, Chloe A.; Shongwe, Siphesihle; Mafukidze, Arnold; Choy, Michelle; Magaula, Bhekinkhosi; Yuengling, Katharine; De Gusmao, Eduarda Pimentel; Abrams, Elaine J.] ICAP Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA; [Teasdale, Chloe A.; Abrams, Elaine J.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA; [Geller, Amanda; Callahan, Tegan; Modi, Surbhi] US Ctr Dis Control & Prevent, Atlanta, GA USA; [King, Katherine] NYC Dept Hlth & Mental Hyg, NYC Hlth Training Clin Operat & Tech Assistance P, New York, NY USA; [Ryan, Caroline; Ao, Trong] US Ctr Dis Control & Prevent, Mbabane, Eswatini; [Abrams, Elaine J.] Columbia Univ, Dept Pediat, Vagelos Coll Phys & Surg, New York, NY 10027 USA	City University of New York (CUNY) System; Columbia University; Centers for Disease Control & Prevention - USA; Columbia University	Teasdale, CA (corresponding author), CUNY, Grad Sch Publ Hlth & Hlth Policy, Dept Epidemiol & Biostat, New York, NY 10021 USA.; Teasdale, CA (corresponding author), ICAP Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA.; Teasdale, CA (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.	chloe.teasdale@sph.cuny.edu			ICAP at Columbia University; US Centers for Disease Control and Prevention [U2GGH00994]; Columbia University	ICAP at Columbia University; US Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Columbia University	Yes, the authors listed from ICAP at Columbia University received funding from the US Centers for Disease Control and Prevention (U2GGH00994) to complete the work described in the paper. All funding was received by Columbia University (no individual funding).	Abuya T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123606; Alli F, 2013, J COMMUN HEALTH, V38, P150, DOI 10.1007/s10900-012-9595-3; Asefa A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-57; Ataguba JEO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204822; Austin A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-S2-S1; Barry OM, 2012, AIDS CARE, V24, P680, DOI 10.1080/09540121.2011.630369; Benner P, 2008, PATIENT SAFETY QUALI; Berwick DM, 1998, ANN INTERN MED, V128, P651, DOI 10.7326/0003-4819-128-8-199804150-00009; Bohren MA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001847; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Colvin CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108150; Downe S, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0466-y; Duysburgh E, 2016, TROP MED INT HEALTH, V21, P70, DOI 10.1111/tmi.12627; Kearns AD, 2016, BJOG-INT J OBSTET GY, V123, P540, DOI 10.1111/1471-0528.13818; Kim YM, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-345; Knettel BA, 2018, JAIDS-J ACQ IMM DEF, V77, P427, DOI 10.1097/QAI.0000000000001616; Kruk ME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160764; Kruk ME, 2018, HEALTH POLICY PLANN, V33, pE26, DOI 10.1093/heapol/czu079; Mannava P, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0117-9; Okafor II, 2015, INT J GYNECOL OBSTET, V128, P110, DOI 10.1016/j.ijgo.2014.08.015; Organization WH, 2015, GUID START ANT THER; Oyeledun B, 2017, JAIDS-J ACQ IMM DEF, V75, pS156, DOI [10.1097/QAI.0000000000001363, 10.1097/qai.0000000000001363]; Rawlins BJ, 2013, MIDWIFERY, V29, P53, DOI 10.1016/j.midw.2011.10.005; Turan JM, 2013, AIDS BEHAV, V17, P2528, DOI 10.1007/s10461-013-0446-8; UNAIDS, ESW UNAIDS COUNT DAT; UNICEF, ESW KEY DEM IND 2018; Vo BN, 2012, AIDS CARE, V24, P1442, DOI 10.1080/09540121.2011.652357; Who, 2016, WHO REC ANT CAR POS; Yabo AN., 2015, AM J NURSING SCI, V4, P57	29	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2021	16	3							e0248685	10.1371/journal.pone.0248685	http://dx.doi.org/10.1371/journal.pone.0248685			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RC8FS	33760864	Green Published, gold			2023-01-03	WOS:000633030400023
J	Hofer, CK; Garcia, PDW; Heim, C; Ganter, MT				Hofer, Christoph Karl; Garcia, Pedro David Wendel; Heim, Christof; Ganter, Michael Thomas			Analysis of anaesthesia services to calculate national need and supply of anaesthetics in Switzerland during the COVID-19 pandemic	PLOS ONE			English	Article							REGIONAL ANESTHESIA; FRANCE	Background In Switzerland, details of current anaesthesia practice are unknown. However, they are urgently needed to manage anaesthesia drug supply in times of drug shortages due to the pandemic. Methods We surveyed all Swiss anaesthesia institutions in April 2020 to determine their annual anaesthesia activity. Together with a detailed analysis on anaesthetic drug use of a large, representative Swiss anaesthesia index institution, calculations and projections for the annual need of anaesthetics in Switzerland were made. Only those drugs have been analysed that are either being used very frequently or that have been classified critical with regard to their supply by the pharmacy of the index institution or the Swiss Federal Office of Public Health. Results The response rate to our questionnaire was 98%. Out of the present 188 Swiss anaesthesia institutions, 185 responded. In Switzerland, the annual number of anaesthesias was 1'071'054 (12'445 per 100'000 inhabitants) with a mean anaesthesia time of 2.03 hours. Teaching hospitals (n = 54) performed more than half (n = 572'231) and non-teaching hospitals (n = 103) provided almost half of all anaesthesias (n = 412'531). Thereby, private hospitals conducted a total of 290'690 anaesthesias. Finally, office-based anaesthesia institutions with mainly outpatients (n = 31) administered 86'292 anaesthesias. Regarding type of anaesthesia provided, two thirds were general anaesthesias (42% total intravenous, 17% inhalation, 8% combined), 20% regional and 12% monitored anaesthesia care. Projecting for example the annual need for propofol in anaesthesia, Switzerland requires 48'573 L of propofol 1% which corresponds to 5'644 L propofol 1% per 100'000 inhabitants every year. Conclusions To actively manage anaesthesia drug supply in the context of the current pandemic, it is mandatory to have a detailed understanding of the number and types of anaesthesias provided. On this basis, the Swiss annual consumption of anaesthetics could be projected and the replenishment organized.	[Hofer, Christoph Karl] Schulthess Clin, Anaesthesiol, Zurich, Switzerland; [Hofer, Christoph Karl; Heim, Christof; Ganter, Michael Thomas] Comm Data & Qual Management, Swiss Soc Anaesthesiol & Resuscitat SSAR, Bern, Switzerland; [Garcia, Pedro David Wendel; Ganter, Michael Thomas] Kantonsspital Winterthur, Inst Anaesthesiol, Winterthur, Switzerland	Schulthess Clinic	Ganter, MT (corresponding author), Comm Data & Qual Management, Swiss Soc Anaesthesiol & Resuscitat SSAR, Bern, Switzerland.; Ganter, MT (corresponding author), Kantonsspital Winterthur, Inst Anaesthesiol, Winterthur, Switzerland.	mt.ganter@gmail.com	Wendel Garcia, Pedro David/AAU-4579-2021	Wendel Garcia, Pedro David/0000-0001-7775-3279				Ammar MA, 2021, J INTENSIVE CARE MED, V36, P157, DOI 10.1177/0885066620951426; Au Yong Phui Sze Angie, 2020, SN Compr Clin Med, V2, P871, DOI 10.1007/s42399-020-00345-6; Bauer M, 2020, ANASTH INTENSIVMED, V61, P516, DOI 10.19224/ai2020.516; Clergue F, 1999, ANESTHESIOLOGY, V91, P1509, DOI 10.1097/00000542-199911000-00045; Clergue Francois, 2002, Best Pract Res Clin Anaesthesiol, V16, P459, DOI 10.1053/bean.2002.0226; Cozowicz C, 2015, BRIT J ANAESTH, V115, P57, DOI 10.1093/bja/aev381; Dadure C, 2015, ANAESTH CRIT CARE PA, V34, P191, DOI 10.1016/j.accpm.2014.12.003; Haller G., 2020, SAEZ, V101, P1358; Holmer H, 2019, BRIT J SURG, V106, pE138, DOI 10.1002/bjs.11061; Hubner M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241331; Kempthorne P, 2017, ANESTH ANALG, V125, P981, DOI 10.1213/ANE.0000000000002258; Lefrant JY, 2020, ANAESTH CRIT CARE PA, V39, P709, DOI 10.1016/j.accpm.2020.09.007; Mallhi TH, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.561924; Marie A, 2015, ANAESTH CRIT CARE PA, V34, P199, DOI 10.1016/j.accpm.2015.04.002; R Core Team, 2021, R LANG ENV STAT COMP; Siow WT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02971-x; Sites BD, 2010, REGION ANESTH PAIN M, V35, pS74, DOI 10.1097/AAP.0b013e3181d34ff5; Sury MRJ, 2014, BRIT J ANAESTH, V113, P575, DOI 10.1093/bja/aeu292; Weiser TG, 2015, LANCET, V385, P11, DOI 10.1016/S0140-6736(15)60806-6	19	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2021	16	3							e0248997	10.1371/journal.pone.0248997	http://dx.doi.org/10.1371/journal.pone.0248997			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QZ9HS	33740018	gold, Green Published, Green Accepted			2023-01-03	WOS:000631030200014
J	Chalard, K; Szabo, V; Pavillard, F; Djanikian, F; Dargazanli, C; Molinari, N; Manna, F; Costalat, V; Chanques, G; Perrigault, PF				Chalard, Kevin; Szabo, Vivien; Pavillard, Frederique; Djanikian, Flora; Dargazanli, Cyril; Molinari, Nicolas; Manna, Federico; Costalat, Vincent; Chanques, Gerald; Perrigault, Pierre-Francois			Long-term outcome in patients with aneurysmal subarachnoid hemorrhage requiring mechanical ventilation	PLOS ONE			English	Article								Background Patients affected with aneurysmal subarachnoid hemorrhage (aSAH) often require intensive care, and then present distinctive outcome from less severe patients. We aimed to specify their long-term outcome and to identify factors associated with poor outcome. Methods We conducted a retrospective study in a French university hospital intensive care unit. Patients with aSAH requiring mechanical ventilation hospitalized between 2010 and 2015 were included. At least one year after initial bleeding, survival and degree of disability were assessed using the modified Rankin Scale (mRS) via telephone interviews. A multivariable logistic regression analysis was performed to determine independent factors associated with poor outcome defined as mRS >= 3. Results Two-hundred thirty-six patients were included. Among them, 7 were lost to follow-up, and 229 were analyzed: 73 patients (32%) had a good outcome (mRS<3), and 156 (68%) had a poor outcome (mRS >= 3). The estimated 1-year survival rate was 63%. One-hundred sixty-three patients patients (71%) suffered from early brain injuries (EBI), 33 (14%) from rebleeding, 80 (35%) from vasospasm and 63 (27%) from delayed cerebral ischemia (DCI). Multivariable logistic regression identified independent factors associated with poor outcome including delay between aSAH diagnosis and mRS assessment (OR, 0.96; 95% CI, 0.95-0.98; p<.0001), age (OR per 10 points, 1.57; 95% CI, 1.12-2.19; p = 0.008), WFNS V versus WFNS III (OR, 5.71; 95% CI 1.51-21.61; p = 0.004), subarachnoid rebleeding (OR, 6.47; 95% CI 1.16-36.06; p = 0.033), EBI (OR, 4.52; 95% CI 1.81-11.29; p = 0.001) and DCI (OR, 4.73; 95% CI, 1.66-13.49; p = 0.004). Conclusion Among aSAH patients requiring assisted ventilation, two-third of them survived at one year, and one-third showed good long-term outcome. As it appears as an independant factor associated with poor outcome, DCI shoud retain particular attention in future studies beyond angiographic vasospasm.	[Chalard, Kevin; Szabo, Vivien; Pavillard, Frederique; Djanikian, Flora; Perrigault, Pierre-Francois] Gui Chauliac Univ Hosp Montpellier, Dept Crit Care Med & Anesthesiol DAR C, Montpellier, France; [Chalard, Kevin; Szabo, Vivien] Univ Montpellier, INSERM, CNRS, IGF, Montpellier, France; [Dargazanli, Cyril; Costalat, Vincent] Gui Chauliac Univ Hosp Montpellier, Dept Neuroradiol, Montpellier, France; [Molinari, Nicolas] Univ Montpellier, CHU Montpellier, CNRS, IMAG, Montpellier, France; [Manna, Federico] Univ Hosp Montpellier, Epidemiol & Clin Res Dept, Montpellier, France; [Chanques, Gerald] St Eloi Univ Hosp Montpellier, Dept Crit Care Med & Anesthesiol DAR B, Montpellier, France; [Chanques, Gerald] Univ Montpellier, CNRS, INSERM, PhyMedExp, Montpellier, France	Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Chalard, K (corresponding author), Gui Chauliac Univ Hosp Montpellier, Dept Crit Care Med & Anesthesiol DAR C, Montpellier, France.; Chalard, K (corresponding author), Univ Montpellier, INSERM, CNRS, IGF, Montpellier, France.	k-chalard@chu-montpellier.fr		Chalard, Kevin/0000-0002-0727-064X; Szabo, Vivien/0000-0002-0079-7596				Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Ayling OGS, 2016, STROKE, V47, P2945, DOI 10.1161/STROKEAHA.116.014794; Bashir A, 2016, NEURORADIOL J, V29, P72, DOI 10.1177/1971400915626429; Bruno A, 2011, STROKE, V42, P2276, DOI 10.1161/STROKEAHA.111.613273; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Cinotti R, 2019, ANAESTH CRIT CARE PA, V38, P251, DOI 10.1016/j.accpm.2018.10.002; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; D'Andrea A, 2016, J CARDIOVASC ECHOGR, V26, P28, DOI 10.4103/2211-4122.183746; de Oliveira Manoel AL, 2016, NEUROCRIT CARE, V25, P338, DOI 10.1007/s12028-016-0305-3; Fraticelli AT, 2008, STROKE, V39, P893, DOI 10.1161/STROKEAHA.107.492447; Friedrich B, 2012, J CEREBR BLOOD F MET, V32, P447, DOI 10.1038/jcbfm.2011.154; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; Galea JP, 2017, STROKE, V48, P2958, DOI 10.1161/STROKEAHA.117.017777; Goncalves B, 2018, WORLD NEUROSURG, V115, pE292, DOI 10.1016/j.wneu.2018.04.037; Hoh BL, 2005, NEUROSURG CLIN N AM, V16, P501, DOI 10.1016/j.nec.2005.04.004; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; Inamasu J, 2016, J CLIN NEUROSCI, V33, P142, DOI 10.1016/j.jocn.2016.03.035; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246; Manoel ALD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1193-9; Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8; Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7; Ostergaard L, 2013, J CEREBR BLOOD F MET, V33, P1825, DOI 10.1038/jcbfm.2013.173; RANKIN J, 1957, Scott Med J, V2, P200; Rowland MJ, 2012, BRIT J ANAESTH, V109, P315, DOI 10.1093/bja/aes264; Schmidt JM, 2007, NEUROCRIT CARE, V7, P10, DOI 10.1007/s12028-007-0003-2; Schwartz C, 2017, NEUROSURGERY, V80, P967, DOI 10.1093/neuros/nyw138; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Terpolilli NA, 2015, STROKE, V46, P3014, DOI 10.1161/STROKEAHA.115.006353; Toulouse E, 2018, ANAESTH CRIT CARE PA, V37, P607, DOI 10.1016/j.accpm.2018.10.013; Udy AA, 2017, CRIT CARE MED, V45, pE138, DOI 10.1097/CCM.0000000000002059; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275	34	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2021	16	3							e0247942	10.1371/journal.pone.0247942	http://dx.doi.org/10.1371/journal.pone.0247942			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX8KN	33711023	Green Published, gold			2023-01-03	WOS:000629591800001
J	Camus-Garcia, E; Gonzalez-Gonzalez, AI; Heijmans, M; de Guzman, EN; Valli, C; Beltran, J; Pardo-Hernandez, H; Ninov, L; Strammiello, V; Immonen, K; Mavridis, D; Ballester, M; Sunol, R; Orrego, C				Camus-Garcia, Estela; Isabel Gonzalez-Gonzalez, Ana; Heijmans, Monique; de Guzman, Ena Nino; Valli, Claudia; Beltran, Jessica; Pardo-Hernandez, Hector; Ninov, Lyudmil; Strammiello, Valentina; Immonen, Kaisa; Mavridis, Dimitris; Ballester, Marta; Sunol, Rosa; Orrego, Carola			Self-management interventions for adults living with Chronic Obstructive Pulmonary Disease (COPD): The development of a Core Outcome Set for COMPAR-EU project	PLOS ONE			English	Article								Background A large body of evidence suggests that self-management interventions (SMIs) may improve outcomes in chronic obstructive pulmonary disease (COPD). However, accurate comparisons of the relative effectiveness of SMIs are challenging, partly due to heterogeneity of outcomes across trials and uncertainty about the importance of these outcomes for patients. We aimed to develop a core set of patient-relevant outcomes (COS) for SMIs trials to enhance comparability of interventions and ensure person-centred care. Methods We undertook an innovative approach consisting of four interlinked stages: i) Development of an initial catalogue of outcomes from previous EU-funded projects and/or published studies, ii) Scoping review of reviews on patients and caregivers' perspectives to identify outcomes of interest, iii) Two-round Delphi online survey with patients and patient representatives to rate the importance of outcomes, and iv) Face-to-face consensus workshop with patients, patient representatives, health professionals and researchers to develop the COS. Results From an initial list of 79 potential outcomes, 16 were included in the COS plus one supplementary outcome relevant to all participants. These were related to patient and caregiver knowledge/competence, self-efficacy, patient activation, self-monitoring, adherence, smoking cessation, COPD symptoms, physical activity, sleep quality, caregiver quality of life, activities of daily living, coping with the disease, participation and decision-making, emergency room visits/admissions and cost effectiveness. Conclusion The development of the COPD COS for the evaluation of SMIs will increase consistency in the measurement and reporting of outcomes across trials. It will also contribute to more personalized health care and more informed health decisions in clinical practice as patients' preferences regarding COPD outcomes are more systematically included.	[Camus-Garcia, Estela; Isabel Gonzalez-Gonzalez, Ana; Ballester, Marta; Sunol, Rosa; Orrego, Carola] Univ Autonoma Barcelona, Avedis Donabedian Res Inst FAD, Barcelona, Spain; [Isabel Gonzalez-Gonzalez, Ana] Goethe Univ, Inst Gen Practice, Frankfurt, Germany; [Isabel Gonzalez-Gonzalez, Ana; Ballester, Marta; Sunol, Rosa; Orrego, Carola] Red Invest Serv Salud Enfermedades Cron REDISSEC, Barcelona, Spain; [Heijmans, Monique] Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands; [de Guzman, Ena Nino] Biomed Res Inst San Pau IIB St Pau, Dept Clin Epidemiol & Publ Hlth, Iberoamer Cochrane Ctr Barcelona, Barcelona, Spain; [Valli, Claudia] Univ Atonoma Barcelona, Dept Paediat Obstet Gynaecol & Prevent Med, Barcelona, Spain; [Valli, Claudia; Beltran, Jessica] Biomed Res Inst San Pau IIB St Pau, Iberoamer Cochrane Ctr Barcelona, Barcelona, Spain; [Pardo-Hernandez, Hector] Biomed Res Inst San Pau IIB St Pau CIBER Epidemio, Iberoamer Cochrane Ctr Barcelona, Barcelona, Spain; [Ninov, Lyudmil; Strammiello, Valentina; Immonen, Kaisa] European Patients Forum EPF, Brussels, Belgium; [Mavridis, Dimitris] Univ Ioannina, Dept Primary Educ, Ioannina, Greece	Autonomous University of Barcelona; Goethe University Frankfurt; Netherlands Institute for Health Services Research; Autonomous University of Barcelona; University of Ioannina	Gonzalez-Gonzalez, AI (corresponding author), Univ Autonoma Barcelona, Avedis Donabedian Res Inst FAD, Barcelona, Spain.; Gonzalez-Gonzalez, AI (corresponding author), Goethe Univ, Inst Gen Practice, Frankfurt, Germany.; Gonzalez-Gonzalez, AI (corresponding author), Red Invest Serv Salud Enfermedades Cron REDISSEC, Barcelona, Spain.	aigonzalez@fadq.org	Sunol, Rosa/AAS-7276-2021; Nino de Guzman, Ena Pery/W-3895-2017	Sunol, Rosa/0000-0003-1902-833X; Orrego, Carola/0000-0002-2978-6268; Valli, Claudia/0000-0002-4393-3690; Gonzalez-Gonzalez, Ana Isabel/0000-0001-7167-4211; Ballester, Marta/0000-0002-7803-8354; Nino de Guzman, Ena Pery/0000-0001-6587-2780	EU Horizon 2020 research and innovation programme [754936]	EU Horizon 2020 research and innovation programme	This work was supported by the EU Horizon 2020 research and innovation programme (grant agreement no. 754936).	Aaron SD, 2016, INT J CHRONIC OBSTR, V11, P37, DOI 10.2147/COPD.S113868; [Anonymous], 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19360; [Anonymous], 2020, EUROPEAN PATIENTS FO; Ballester M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034680; Bereza BG, 2015, INT J CHRONIC OBSTR, V10, P739, DOI 10.2147/COPD.S82179; Bjermer L, 2014, RESPIRATION, V88, P346, DOI 10.1159/000363771; Brundisini F, 2013, Ont Health Technol Assess Ser, V13, P1; Brunton L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139561; Bryant J, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-109; Bryant J, 2011, ADDICTION, V106, P1568, DOI 10.1111/j.1360-0443.2011.03467.x; Bulcun E, 2014, INT J CHRONIC OBSTR, V9, P363, DOI 10.2147/COPD.S56229; Cazzola M, 2008, EUR RESPIR J, V31, P416, DOI 10.1183/09031936.00099306; Clari M, 2018, COPD, V15, P79, DOI 10.1080/15412555.2017.1417373; Clari M, 2017, PATIENT, V10, P407, DOI 10.1007/s40271-017-0218-z; Collins PF, 2012, AM J CLIN NUTR, V95, P1385, DOI 10.3945/ajcn.111.023499; Cox NS, 2017, J PHYSIOTHER, V63, P84, DOI 10.1016/j.jphys.2017.02.002; Pinto JMD, 2013, CHRON RESP DIS, V10, P141, DOI 10.1177/1479972313493796; Disler RT, 2014, J PAIN SYMPTOM MANAG, V48, P1182, DOI 10.1016/j.jpainsymman.2014.03.009; Dretzke J, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19810; Einarson TR, 2015, J MED ECON, V18, P550, DOI 10.3111/13696998.2015.1025793; Eisner MD, 2010, AM J RESP CRIT CARE, V182, P693, DOI 10.1164/rccm.200811-1757ST; EMPATHiE Consortium, 2014, EMPATHIE EMP PAT MAN; Flodgren G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002098.pub2; Giacomini M, 2012, Ont Health Technol Assess Ser, V12, P1; Glaab T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-79; Gorst SL, 2014, ANN BEHAV MED, V48, P323, DOI 10.1007/s12160-014-9607-x; Gosselink R, 2011, EUR RESPIR J, V37, P416, DOI 10.1183/09031936.00031810; Gysels Marjolein, 2007, Palliat Support Care, V5, P281; Habraken JM, 2007, PATIENT EDUC COUNS, V68, P121, DOI 10.1016/j.pec.2007.05.011; Hamilton FL, 2013, TOB CONTROL, V22, P3, DOI 10.1136/tobaccocontrol-2011-050048; Harrison C, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004694; Harrison SL, 2015, CHEST, V147, P646, DOI 10.1378/chest.14-1658; Harrison SL, 2014, CHRONIC ILLN, V10, P31, DOI 10.1177/1742395313493122; Health Quality Ontario, 2013, Ont Health Technol Assess Ser, V13, P1; ICHOM, INT CONS HLTH OUTC M; Jadad A, 2004, CURR MED RES OPIN, V20, P1993, DOI 10.1185/030079904X15165; Jolly K, 2016, INT J CHRONIC OBSTR, V11, P305, DOI 10.2147/COPD.S90812; Jones AV, 2019, CHRON RESP DIS, V16, DOI 10.1177/1479973119867952; Jones JE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172937; Kaptein AA, 2008, J ASTHMA, V45, P625, DOI 10.1080/02770900802127048; Kaptein AA, 2014, INT J CHRONIC OBSTR, V9, P1, DOI 10.2147/COPD.S49622; Keating A, 2011, CHRON RESP DIS, V8, P89, DOI 10.1177/1479972310393756; Kessler R, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01612-2017; Kirkham JJ, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002447; Kirkham JJ, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002148; Kirkpatrick Pamela, 2012, JBI Libr Syst Rev, V10, P3649; Kruis AL, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009437.pub2; Lenferink A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011682.pub2; Li GC, 2014, COMPLEMENT THER MED, V22, P743, DOI 10.1016/j.ctim.2014.06.003; Lindenmeyer A, 2017, QUAL HEALTH RES, V27, P37, DOI 10.1177/1049732316644430; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Majothi S, 2015, INT J CHRONIC OBSTR, V10, P853, DOI 10.2147/COPD.S74162; Mathar H, 2016, SCAND J CARING SCI, V30, P432, DOI 10.1111/scs.12268; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3; McLean S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007718.pub2; Moayeri F, 2016, VALUE HEALTH, V19, P363, DOI 10.1016/j.jval.2016.01.012; Murphy LA, 2017, CHRON RESP DIS, V14, P276, DOI 10.1177/1479972316687208; Newham JJ, 2017, INT J CHRONIC OBSTR, V12, P1705, DOI 10.2147/COPD.S133317; Ng LWC, 2012, CHRON RESP DIS, V9, P17, DOI 10.1177/1479972311430335; Nino de Guzman E., 2020, F1000RESEARCH, V9, P120; Orrego C, 2019, DEV EXTERNAL VALIDAT; Polisena J, 2010, J TELEMED TELECARE, V16, P120, DOI 10.1258/jtt.2009.090812; Potter S, 2015, BRIT J SURG, V102, P1360, DOI 10.1002/bjs.9883; Prieto-Centurion Valentin, 2014, Ann Am Thorac Soc, V11, P417, DOI 10.1513/AnnalsATS.201308-254OC; Quinones AR, 2014, PATIENT EDUC COUNS, V95, P3, DOI 10.1016/j.pec.2013.12.021; Rosa F, 2017, NURS OPEN, V4, P61, DOI 10.1002/nop2.63; Rose L, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01567-2017; Rose S, 2017, CHRON RESP DIS, V14, P199, DOI 10.1177/1479972316680847; Russell S, 2018, NPJ PRIM CARE RESP M, V28, DOI 10.1038/s41533-017-0069-z; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; Selva A, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0698-5; Shaw G, 2020, NPJ PRIM CARE RESP M, V30, DOI 10.1038/s41533-020-0167-1; Sohanpal R, 2015, NPJ PRIM CARE RESP M, V25, DOI 10.1038/npjpcrm.2015.54; Sorensen SS, 2017, HOME HEALTH CARE SER, V36, P178, DOI 10.1080/01621424.2017.1393481; Spargo M, 2018, CHRON RESP DIS, V16, DOI 10.1177/1479972318804167; Tan JY, 2012, GERIATR NURS, V33, P280, DOI 10.1016/j.gerinurse.2012.03.001; Verburg AC, 2019, INT J CHRONIC OBSTR, V14, P2649, DOI 10.2147/COPD.S219851; Vieira DSR, 2010, CURR OPIN PULM MED, V16, P134, DOI 10.1097/MCP.0b013e32833642f2; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Walters JAE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005074.pub3; Webbe J, 2017, BMJ PAEDIATR OPEN, V1, DOI 10.1136/bmjpo-2017-000048; Williamson PR, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1978-4; Williamson PR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-132; Zhang Y, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00222-2018; Zwerink M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub3	86	4	4	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2021	16	3							e0247522	10.1371/journal.pone.0247522	http://dx.doi.org/10.1371/journal.pone.0247522			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QR6LP	33647039	Green Published, gold			2023-01-03	WOS:000625328100016
J	Fang, JQ; Hou, HP; Lu, CX; Pang, HY; Deng, QS; Ye, Y; Pan, LL				Fang, Jiaqi; Hou, Hanping; Lu, Changxiang; Pang, Haiyun; Deng, Qingshan; Ye, Yong; Pan, Lingle			A new scheduling method based on sequential time windows developed to distribute first-aid medicine for emergency logistics following an earthquake	PLOS ONE			English	Article							SUPPLY CHAIN; ALLOCATION; MODEL; NETWORK; MULTICOMMODITY; DISASTERS	After an earthquake, affected areas have insufficient medicinal supplies, thereby necessitating substantial distribution of first-aid medicine from other supply centers. To make a proper distribution schedule, we considered the timing of supply and demand. In the present study, a "sequential time window" is used to describe the time to generate of supply and demand and the time of supply delivery. Then, considering the sequential time window, we proposed two multiobjective scheduling models with the consideration of demand uncertainty; two multiobjective stochastic programming models were also proposed to solve the scheduling models. Moreover, this paper describes a simulation that was performed based on a first-aid medicine distribution problem during a Wenchuan earthquake response. The simulation results show that the methodologies proposed in this paper provide effective schedules for the distribution of first-aid medicine. The developed distribution schedule enables some supplies in the former time windows to be used in latter time windows. This schedule increases the utility of limited stocks and avoids the risk that all the supplies are used in the short-term, leaving no supplies for long-term use.	[Fang, Jiaqi; Hou, Hanping; Lu, Changxiang] Beijing Jiaotong Univ, Sch Econ & Management, Beijing, Peoples R China; [Pang, Haiyun] Zhejiang Univ Sci & Technol, Sch Econ & Management, Hangzhou, Zhejiang, Peoples R China; [Deng, Qingshan] Wenzhou Med Univ, Dept Radiol, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; [Ye, Yong] Wenzhou Med Univ, Sch Publ Hlth & Management, Wenzhou, Zhejiang, Peoples R China; [Pan, Lingle] Zhejiang Coll Secur Technol, Coll Emergency Management, Wenzhou, Zhejiang, Peoples R China	Beijing Jiaotong University; Zhejiang University of Science & Technology; Wenzhou Medical University; Wenzhou Medical University	Hou, HP (corresponding author), Beijing Jiaotong Univ, Sch Econ & Management, Beijing, Peoples R China.; Pan, LL (corresponding author), Zhejiang Coll Secur Technol, Coll Emergency Management, Wenzhou, Zhejiang, Peoples R China.	hanpinghou@126.com; panlynne@126.com	Fang, Jiaqi/AAU-4450-2021; Fang, Jiaqi/GRJ-7285-2022	Fang, Jiaqi/0000-0003-2764-2858; hou, hanping/0000-0002-7712-5763	Natural Science Foundation of Zhejiang Province (CN) [LY20G010009, Y17G030052]; National Key RD Plan of China [2016YFC0803207]; Natural Science Foundation of China [71601146]; Humanities and Social Sciences Foundation of Ministry of Education of China [17YJC630109]	Natural Science Foundation of Zhejiang Province (CN); National Key RD Plan of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Humanities and Social Sciences Foundation of Ministry of Education of China(Ministry of Education, China)	This work is supported by the Natural Science Foundation of Zhejiang Province (CN) (by YY, Grant No. LY20G010009 and by HYP, Grant No. Y17G030052), http://www.zjnsf.gov.cn/; National Key R&D Plan of China(by HPH, Grant No. 2016YFC0803207), https://service.most.gov.cn/; YY,JQF, Natural Science Foundation of China (Grant No. 71601146) http://www.nsfc.gov.cn/; Humanities and Social Sciences Foundation of Ministry of Education of China (by HYP, Grant No. 17YJC630109), https://www.sinoss.net/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhikary K., 2019, DECISION MAKING APPL, V2, P1; ARDEKANI SA, 1988, TRANSPORT Q, V42, P107; Biswas T.K., 2020, OPER RES ENG SCI, V3, P1, DOI [10.31181/oresta2030301b, DOI 10.31181/ORESTA2030301B]; Chen B., 2016, CHINA J DISASTER REL, V4, P213; Chen YX, 2020, CLUSTER COMPUT, V23, P203, DOI 10.1007/s10586-017-1366-6; Fang J, 2021, IEEE INTERNET THINGS, V8, P12771, DOI 10.1109/JIOT.2020.3007751; Feng HJ., 2010, CHINA LOGISTICS PROC, V6, P76; Fiedrich F, 2000, SAFETY SCI, V35, P41, DOI 10.1016/S0925-7535(00)00021-7; Ghasemi P, 2019, APPL MATH COMPUT, V350, P105, DOI 10.1016/j.amc.2018.12.061; Giri BC, 2019, COMPUT IND ENG, V129, P179, DOI 10.1016/j.cie.2019.01.035; Gschwind T, 2020, J SCHEDULING, V23, P363, DOI 10.1007/s10951-019-00620-y; Guo X, 2011, THESIS BEIJING JIAOT; Haghani A, 1996, TRANSPORT RES A-POL, V30, P231, DOI 10.1016/0965-8564(95)00020-8; He YX, 2015, TRANSPORT RES E-LOG, V79, P178, DOI 10.1016/j.tre.2015.04.007; He YX, 2016, THESIS ZHEJIANG U; Jabbarzadeh A, 2014, TRANSPORT RES E-LOG, V70, P225, DOI 10.1016/j.tre.2014.06.003; Liu L., 2014, LOGISTICS TECHNOLOGY, V5, P425; Mehrzadi S, 2021, NUTR CANCER, V73, P2039, DOI 10.1080/01635581.2020.1820053; Mori J, 2012, DRUG INF J, V46, P607, DOI 10.1177/0092861512448569; Najafi M, 2014, OR SPECTRUM, V36, P323, DOI 10.1007/s00291-012-0317-0; Norio O, 2011, INT J DISAST RISK SC, V2, P34, DOI 10.1007/s13753-011-0004-9; [潘立军 Pan Lijun], 2012, [系统工程理论与实践, Systems Engineering-Theory & Practice], V32, P319; SCHIFFER M, 2019, OPER RES, V59, P81, DOI DOI 10.1016/J.EJOR.2017.01.011; Sun YQ, 2020, MATH PROBL ENG, V2020, DOI 10.1155/2020/3045472; Tang ZP, 2018, INT J SYST ASSUR ENG, V9, P696, DOI 10.1007/s13198-017-0648-y; Thompson S, 2009, OPER RES, V57, P261, DOI 10.1287/opre.1080.0584; Tuzkaya UR, 2014, EUR J IND ENG, V8, P513, DOI 10.1504/EJIE.2014.064758; Wang K, 2017, FRONT ENG MANAG, V4, P221, DOI 10.15302/J-FEM-2017020; [王绍仁 Wang Shaoren], 2011, [运筹与管理, Operations Research and Management Science], V20, P63; Wex F, 2014, EUR J OPER RES, V235, P697, DOI 10.1016/j.ejor.2013.10.029; Xia P, 2010, THESIS BEIJING JIAOT; Xiao-cheng Fan, 2011, 2011 IEEE 18th International Conference on Industrial Engineering and Engineering Management (IE&EM 2011), P420, DOI 10.1109/ICIEEM.2011.6035190; Yan S, 2009, COMPUT OPER RES, V36, P2049, DOI 10.1016/j.cor.2008.07.002; Ye YC, 2017, MARINE GEO-HAZARDS IN CHINA, P1, DOI 10.1016/B978-0-12-812726-1.00001-2; Ye Y, 2017, INT J SHIP TRANS LOG, V9, P54, DOI 10.1504/IJSTL.2017.080572; Yu LN, 2019, IISE TRANS, V51, P887, DOI 10.1080/24725854.2017.1417655; Zhang JH, 2019, COMPUT IND ENG, V135, P1145, DOI 10.1016/j.cie.2019.02.003; Zhang LL, 2012, LANCET, V379, P853, DOI 10.1016/S0140-6736(11)61876-X; Zhou YW, 2017, TRANSPORT RES E-LOG, V99, P77, DOI 10.1016/j.tre.2016.12.011; Zhu L, 2019, ANN OPER RES, V283, P1573, DOI 10.1007/s10479-018-3089-3	41	2	2	14	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2021	16	2							e0247566	10.1371/journal.pone.0247566	http://dx.doi.org/10.1371/journal.pone.0247566			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QO8DE	33621257	gold, Green Published			2023-01-03	WOS:000623367700009
J	Bhogal, J; Solevag, AL; O'Reilly, M; Lee, TF; Joynt, C; Hornberger, LK; Schmolzer, GM; Cheung, PY				Bhogal, Jagmeet; Solevag, Anne Lee; O'Reilly, Megan; Lee, Tze-Fun; Joynt, Chloe; Hornberger, Lisa K.; Schmolzer, Georg M.; Cheung, Po-Yin			Hemodynamic effects of high frequency oscillatory ventilation with volume guarantee in a piglet model of respiratory distress syndrome	PLOS ONE			English	Article								Respiratory failure is a common condition faced by critically ill neonates with respiratory distress syndrome (RDS). High frequency oscillatory ventilation (HFOV) is often used for neonates with refractory respiratory failure related to RDS. Volume guarantee (VG) mode has been added to some HFOV ventilators for providing consistent tidal volume. We sought to examine the impact of adding the VG mode during HFOV on systemic and cerebral hemodynamics, which has not been studied to date. A neonatal piglet model of moderate to severe RDS was induced by saline lavage. Piglets (full term, age 1-3 days, weight 1.5-2.4 kg) were randomized to have RDS induced and receive either HFOV or HFOV+VG (n = 8/group) or sham-operation (n = 6) without RDS. Cardiac function measured by a Millar(R) catheter placed in the left ventricle as well as systemic and carotid hemodynamic and oxygen tissue saturation parameters were collected over 240 min of ventilation. Mean airway pressure, alveolar-arterial oxygen difference and left ventricular cardiac index of piglets on HFOV vs. HFOV+VG were not significantly different during the experimental period. Right common carotid artery flow index by in-situ ultrasonic flow measurement and cerebral tissue oxygen saturation (near-infrared spectroscopy) significantly decreased in HFOV+VG at 240 min compared to HFOV (14 vs. 31 ml/kg/min, and 30% vs. 43%, respectively; p<0.05). There were no significant differences in lung, brain and heart tissue markers of oxidative stress, ischemia and inflammation. HFOV+VG compared to HFOV was associated with similar left ventricular function, however HFOV+VG had a negative effect on cerebral blood flow and oxygenation.	[Bhogal, Jagmeet; O'Reilly, Megan; Lee, Tze-Fun; Joynt, Chloe; Hornberger, Lisa K.; Schmolzer, Georg M.; Cheung, Po-Yin] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Solevag, Anne Lee] Akershus Univ Hosp, Dept Paediat & Adolescent Med, Lrenskog, Norway; [Solevag, Anne Lee] Oslo Univ Hosp, Dept Paediat & Adolescent Med, Nydalen, Norway; [O'Reilly, Megan; Lee, Tze-Fun; Schmolzer, Georg M.; Cheung, Po-Yin] Royal Alexandra Hosp, Ctr Studies Asphyxia & Resuscitat, Edmonton, AB, Canada; [Cheung, Po-Yin] Univ Alberta, Dept Pharmacol, Edmonton, AB, Canada	University of Alberta; Royal Alexandra Hospital; University of Alberta	Bhogal, J (corresponding author), Univ Alberta, Dept Pediat, Edmonton, AB, Canada.	jagmeet.bhogal@ahs.ca	Schmölzer, Georg M/E-7883-2010; Solevåg, Anne Lee/AAH-9734-2021; Cheung, Po-Yin/C-2804-2013	Schmölzer, Georg M/0000-0001-9798-2415; Solevåg, Anne Lee/0000-0002-8009-7169; Bhogal, Jagmeet/0000-0002-1302-6133; Cheung, Po-Yin/0000-0002-7141-1523	Canadian Institutes of Health Research [MOP 130483]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	PYC received funding from the Canadian Institutes of Health Research, grant number MOP 130483 (http://www.cihr-irsc.gc.ca).The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai XF, 2010, OPEN CARDIOVASC MED, V4, P168, DOI 10.2174/1874192401004010168; Brierley J, 2009, CRIT CARE MED, V37, P666, DOI 10.1097/CCM.0b013e31819323c6; Bronicki RA., 2014, PEDIATR CRIT CARE ME, V2nd ed, P323; CHAN V, 1994, ARCH DIS CHILD-FETAL, V70, pF44, DOI 10.1136/fn.70.1.F44; CHANG HK, 1984, J APPL PHYSIOL, V56, P553, DOI 10.1152/jappl.1984.56.3.553; Cools F, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000104.pub4; Enomoto M, 2017, AM J PERINAT, V34, P26, DOI 10.1055/s-0036-1584141; Gleason C.A., 2012, AVERYS DIS NEWBORN; Goldsmith JP., 2011, ASSISTED VENTILATION, V5th ed; Grazioli S, 2015, RESP CARE, V60, P363, DOI 10.4187/respcare.03048; Gullberg N, 2004, ACTA ANAESTH SCAND, V48, P218, DOI 10.1111/j.1399-6576.2004.00299.x; Henderson-Smart DJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002974.pub2; Iscan B, 2015, NEONATOLOGY, V108, P277, DOI 10.1159/000437204; KAMITSUKA MD, 1990, PEDIATR RES, V27, P64, DOI 10.1203/00006450-199001000-00018; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; KINSELLA JP, 1991, PEDIATR RES, V29, P160, DOI 10.1203/00006450-199102000-00012; Klingenberg C, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003666.pub4; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kluckow M, 1996, J PEDIATR-US, V129, P506, DOI 10.1016/S0022-3476(96)70114-2; LACHMANN B, 1980, ACTA ANAESTH SCAND, V24, P231, DOI 10.1111/j.1399-6576.1980.tb01541.x; LAPTOOK A, 1982, EARLY HUM DEV, V6, P99, DOI 10.1016/0378-3782(82)90063-9; MIRRO R, 1985, CRIT CARE MED, V13, P724, DOI 10.1097/00003246-198509000-00006; Pillow JJ, 2002, PEDIATR RES, V52, P538, DOI 10.1203/01.PDR.0000030875.20888.64; Richards JG, 2006, RESUSCITATION, V69, P319, DOI 10.1016/j.resuscitation.2005.08.012; Luna MS, 2013, CRIT CARE RES PRACT, V2013, DOI 10.1155/2013/593915; Simma B, 2000, CRIT CARE MED, V28, P227, DOI 10.1097/00003246-200001000-00038; STANDAERT TA, 1991, PEDIATR PULM, V11, P294, DOI 10.1002/ppul.1950110405; STIRIS T, 1989, PEDIATR RES, V25, P205, DOI 10.1203/00006450-198902000-00025; Sweet DG, 2019, NEONATOLOGY, V115, P432, DOI 10.1159/000499361; van Alfen-van der Velden AAEM, 2006, BIOL NEONATE, V90, P197, DOI 10.1159/000093489; Vanderhaegen J, 2010, NEONATOLOGY, V98, P57, DOI 10.1159/000271224	31	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2021	16	2							e0246996	10.1371/journal.pone.0246996	http://dx.doi.org/10.1371/journal.pone.0246996			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8MA	33592023	Green Published, gold			2023-01-03	WOS:000620632800025
J	Banerdt, JK; Mateyo, K; Wang, L; Lindsell, CJ; Riviello, ED; Saylor, D; Heimburger, DC; Ely, EW				Banerdt, Justin K.; Mateyo, Kondwelani; Wang, Li; Lindsell, Christopher J.; Riviello, Elisabeth D.; Saylor, Deanna; Heimburger, Douglas C.; Ely, E. Wesley			Delirium as a predictor of mortality and disability among hospitalized patients in Zambia	PLOS ONE			English	Article							TERM COGNITIVE IMPAIRMENT; EARLY WARNING SCORE; PROGNOSTIC ACCURACY; CRITICAL ILLNESS; GLOBAL BURDEN; CRITICAL-CARE; CRITERIA; SEPSIS; SURVIVORS; ADULTS	Objective To study the epidemiology and outcomes of delirium among hospitalized patients in Zambia. Methods We conducted a prospective cohort study at the University Teaching Hospital in Lusaka, Zambia, from October 2017 to April 2018. The primary exposure was delirium duration over the initial 3 days of hospitalization, assessed daily using the Brief Confusion Assessment Method. The primary outcome was 6-month mortality. Secondary outcomes included 6-month disability, evaluated using the World Health Organization Disability Assessment Schedule 2.0. Findings 711 adults were included (median age, 39 years; 461 men; 459 medical, 252 surgical; 323 with HIV). Delirium prevalence was 48.5% (95% CI, 44.8%-52.3%). 6-month mortality was higher for delirious participants (44.6% [39.3%-50.1%]) versus non-delirious participants (20.0% [15.4%-25.2%]; P < .001). After adjusting for covariates, delirium duration independently predicted 6-month mortality and disability with a significant dose-response association between number of days with delirium and odds of worse clinical outcome. Compared to no delirium, presence of 1, 2 or 3 days of delirium resulted in odds ratios for 6-month mortality of 1.43 (95% CI, 0.73-2.80), 2.20 (1.07-4.51), and 3.92 (2.24-6.87), respectively (P < .001). Odds of 6-month disability were 1.20 (0.70-2.05), 1.73 (0.95-3.17), and 2.80 (1.78-4.43), respectively (P < .001). Conclusion Among hospitalized medical and surgical patients in Zambia, delirium prevalence was high and delirium duration independently predicted mortality and disability at 6 months. This work lays the foundation for prevention, detection, and management of delirium in low-income countries. Long-term follow up of outcomes of critical illness in resource-limited settings appears feasible using the WHO Disability Assessment Schedule.	[Banerdt, Justin K.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Banerdt, Justin K.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Banerdt, Justin K.; Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Crit Illness Brain Dysfunct & Survivorship CIBS C, Nashville, TN 37235 USA; [Mateyo, Kondwelani; Saylor, Deanna; Heimburger, Douglas C.] Univ Zambia, Sch Med, Lusaka, Zambia; [Mateyo, Kondwelani; Saylor, Deanna] Univ Teaching Hosp, Lusaka, Zambia; [Wang, Li; Lindsell, Christopher J.] Vanderbilt Univ, Dept Biostat, Med Ctr, Nashville, TN USA; [Riviello, Elisabeth D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Riviello, Elisabeth D.] Harvard Med Sch, Boston, MA 02115 USA; [Saylor, Deanna] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Heimburger, Douglas C.; Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Heimburger, Douglas C.] Vanderbilt Inst Global Hlth, Nashville, TN USA; [Ely, E. Wesley] Tennessee Valley Vet Affairs Geriatr Res Educ Cli, Nashville, TN USA	Yale University; Vanderbilt University; Vanderbilt University; University of Zambia; University of Zambia; Vanderbilt University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Johns Hopkins University; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center	Banerdt, JK (corresponding author), Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.; Banerdt, JK (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.; Banerdt, JK (corresponding author), Vanderbilt Univ, Med Ctr, Crit Illness Brain Dysfunct & Survivorship CIBS C, Nashville, TN 37235 USA.	justin.banerdt@yale.edu		Saylor, Deanna/0000-0002-9297-0244; Heimburger, Douglas/0000-0003-3551-9710; Riviello, Elisabeth/0000-0002-9443-3928	Fogarty International Center of the US National Institutes of Health [D43 TW009337]; Vanderbilt Institute for Clinical and Translational Research grant from the National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR002243]; School of Medicine, Vanderbilt University	Fogarty International Center of the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Vanderbilt Institute for Clinical and Translational Research grant from the National Center for Advancing Translational Sciences of the National Institutes of Health; School of Medicine, Vanderbilt University	JKB was supported by the Fogarty International Center of the US National Institutes of Health under award D43 TW009337 (https://www.vumc.org/vecd/home), Vanderbilt Institute for Clinical and Translational Research grant UL1TR002243 from the National Center for Advancing Translational Sciences of the National Institutes of Health (https://victr.vumc.org), and the School of Medicine, Vanderbilt University (https://medschool.vanderbilt.edu/curriculum/medicalscholars-program).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; Andrews B, 2017, JAMA-J AM MED ASSOC, V318, P1233, DOI 10.1001/jama.2017.10913; Dart PJ, 2017, ANAESTHESIA, V72, P172, DOI 10.1111/anae.13709; Devlin JW, 2018, CRIT CARE MED, V46, pE825, DOI 10.1097/CCM.0000000000003299; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Freund Y, 2017, JAMA-J AM MED ASSOC, V317, P301, DOI 10.1001/jama.2016.20329; Gardner-Thorpe J, 2006, ANN ROY COLL SURG, V88, P571, DOI 10.1308/003588406X130615; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Han JH, 2016, AM J EMERG MED, V34, P1031, DOI 10.1016/j.ajem.2016.02.069; Han JH, 2013, ANN EMERG MED, V62, P457, DOI 10.1016/j.annemergmed.2013.05.003; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hshieh TT, 2017, ANN SURG, V265, P647, DOI 10.1097/SLA.0000000000001952; Hsieh S Jean, 2013, Ann Am Thorac Soc, V10, P648, DOI 10.1513/AnnalsATS.201307-232FR; Jackson JC, 2014, LANCET RESP MED, V2, P369, DOI 10.1016/S2213-2600(14)70051-7; Kiely DK, 2009, J AM GERIATR SOC, V57, P55, DOI 10.1111/j.1532-5415.2008.02092.x; Kwizera A, 2015, CRIT CARE RES PRACT, V2015, DOI 10.1155/2015/491780; Leslie DL, 2005, ARCH INTERN MED, V165, P1657, DOI 10.1001/archinte.165.14.1657; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Moore CC, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000344; Murthy Srinivas, 2013, Ann Am Thorac Soc, V10, P509, DOI 10.1513/AnnalsATS.201307-246OT; Paddick SM, 2015, J NEUROL SCI, V348, P6, DOI 10.1016/j.jns.2014.10.034; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Raith EP, 2017, JAMA-J AM MED ASSOC, V317, P290, DOI 10.1001/jama.2016.20328; Riviello ED, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155858; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Rudolph JL, 2010, J AM GERIATR SOC, V58, P643, DOI 10.1111/j.1532-5415.2010.02762.x; Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923; Samanamalee S, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-017-0463-7; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Shi ZY, 2019, ANESTHESIOLOGY, V131, P492, DOI 10.1097/ALN.0000000000002849; Sousa RM, 2010, INT J METH PSYCH RES, V19, P1, DOI 10.1002/mpr.299; Subbe CP, 2001, QJM-MON J ASSOC PHYS, V94, P521, DOI 10.1093/qjmed/94.10.521; Ustun TB, 2010, B WORLD HEALTH ORGAN, V88, P815, DOI 10.2471/BLT.09.067231; Uldall KK, 2000, AIDS PATIENT CARE ST, V14, P95, DOI 10.1089/108729100318037; Uldall KK, 2000, COMPR PSYCHIAT, V41, P88, DOI 10.1016/S0010-440X(00)90138-X; Ustun T. B., 2010, Measuring health and disability: manual for WHO Disability Assessment Schedule (WHODAS 2.0); Vasilevskis EE, 2012, BEST PRACT RES-CLIN, V26, P277, DOI 10.1016/j.bpa.2012.07.003; Vukoja M, 2018, CURR OPIN CRIT CARE, V24, P421, DOI 10.1097/MCC.0000000000000528; World Health Organization, 2018, REG OFF WHO COUNTR C	40	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246330	10.1371/journal.pone.0246330	http://dx.doi.org/10.1371/journal.pone.0246330			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QH4VJ	33571227	Green Published, gold			2023-01-03	WOS:000618274000062
J	Moll, V; Mariano, ER; Kitzman, JM; O'Reilly-Shah, VN; Jabaley, CS				Moll, Vanessa; Mariano, Edward R.; Kitzman, Jamie M.; O'Reilly-Shah, Vikas N.; Jabaley, Craig S.			Regional anesthesia educational material utilization varies by World Bank income category: A mobile health application data study	PLOS ONE			English	Article							IN-APP SURVEY; PEDIATRIC ANESTHESIA; RESOURCE; SERVICES; CARE	Introduction Regional anesthesia offers an alternative to general anesthesia and may be advantageous in low resource environments. There is a paucity of data regarding the practice of regional anesthesia in low- and middle-income countries. Using access data from a free Android app with curated regional anesthesia learning modules, we aimed to estimate global interest in regional anesthesia and potential applications to clinical practice stratified by World Bank income level. Methods We retrospectively analyzed data collected from the free Android app "Anesthesiologist" from December 2015 to April 2020. The app performs basic anesthetic calculations and provides links to videos on performing 12 different nerve blocks. Users of the app were classified on the basis of whether or not they had accessed the links. Nerve blocks were also classified according to major use (surgical block, postoperative pain adjunct, rescue block). Results Practitioners in low- and middle-income countries accessed the app more frequently than in high-income countries as measured by clicks. Users from low- and middle-income countries focused mainly on surgical blocks: ankle, axillary, infraclavicular, interscalene, and supraclavicular blocks. In high-income countries, more users viewed postoperative pain blocks: adductor canal, popliteal, femoral, and transverse abdominis plane blocks. Utilization of the app was constant over time with a general decline with the start of the COVID-19 pandemic. Conclusion The use of an in app survey and analytics can help identify gaps and opportunities for regional anesthesia techniques and practices. This is especially impactful in limited-resource areas, such as lower-income environments and can lead to targeted educational initiatives.	[Moll, Vanessa; Jabaley, Craig S.] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Moll, Vanessa] Univ Hosp Zurich, Inst Anesthesiol, Zurich, Switzerland; [Mariano, Edward R.] Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA; [Mariano, Edward R.] Vet Affairs Palo Alto Hlth Care Syst, Anesthesiol & Perioperat Care Serv, Palo Alto, CA USA; [Kitzman, Jamie M.] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Dept Pediat Anesthesiol, Atlanta, GA USA; [O'Reilly-Shah, Vikas N.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA	Emory University; University of Zurich; University Zurich Hospital; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Children's Healthcare of Atlanta (CHOA); Emory University; University of Washington; University of Washington Seattle	O'Reilly-Shah, VN (corresponding author), Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.	voreill@uw.edu	Moll, Vanessa/AAD-4331-2022	O'Reilly-Shah, Vikas/0000-0003-0741-0291; Mariano, Edward/0000-0003-2735-248X	Emory University Department of Anesthesiology	Emory University Department of Anesthesiology	This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The Emory University Department of Anesthesiology supported this work with non-clinical time for the authors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, DIABETES CARE S1, V39, pS1, DOI 10.2337/dc16-S001; Ariyo P, 2016, ANESTHESIOLOGY, V124, P561, DOI 10.1097/ALN.0000000000000985; Barbour R, 2017, BJA EDUC, V17, P351, DOI 10.1093/bjaed/mkx030; Bensman RS, 2017, AM J TROP MED HYG, V97, P1285, DOI 10.4269/ajtmh.16-0936; Bourgouin S, 2017, HERNIA, V21, P749, DOI 10.1007/s10029-017-1631-x; Buckenmaier CC, 2003, REGION ANESTH PAIN M, V28, P321, DOI 10.1016/S1098-7339(03)00198-6; Burkholder TW, 2018, WEST J EMERG MED, V19, P600, DOI 10.5811/westjem.2018.3.36825; Chan TM, 2020, PERSPECT MED EDUC, V9, P20, DOI 10.1007/s40037-019-00542-7; Clevert A, 2019, INSIGHTS IMAGING, V10, DOI 10.1186/s13244-019-0775-x; Cozowicz C, 2016, REGION ANESTH PAIN M, V41, P43, DOI 10.1097/AAP.0000000000000342; Hadler RA, 2016, WORLD J SURG, V40, P1025, DOI 10.1007/s00268-016-3430-4; Ho M, 2019, PAN AFR MED J, V32, DOI 10.11604/pamj.2019.32.152.17246; Hodges SC, 2007, ANAESTHESIA, V62, P4, DOI 10.1111/j.1365-2044.2006.04907.x; Jabaley CS, 2018, THER ADV DRUG SAF, V9, P331, DOI 10.1177/2042098618769565; Kallander K, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2130; Kruse C, 2019, J MED INTERNET RES, V21, DOI 10.2196/13263; Kumar AH, 2020, INT ANESTHESIOL CLIN, V58, P52, DOI 10.1097/AIA.0000000000000287; Martinelli SM, 2019, ANESTHESIOLOGY, V131, P908, DOI 10.1097/ALN.0000000000002827; Mathais Q, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223497; O'Reilly-Shah VN, 2017, BRIT J ANAESTH, V119, P333, DOI 10.1093/bja/aex171; O'Reilly-Shah V, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000299; O'Reilly-Shah V, 2016, JMIR MHEALTH UHEALTH, V4, P17, DOI 10.2196/mhealth.5397; O'Reilly-Shah VN, 2018, PEDIATR ANESTH, V28, P167, DOI 10.1111/pan.13305; Ooms J., 2014, JSONLITE PACKAGE PRA; Palliam S, 2019, CUREUS, V11, DOI 10.7759/cureus.6223; R Core Team, 2021, R LANG ENV STAT COMP; Raza A, 2017, INT J SURG, V44, P252, DOI 10.1016/j.ijsu.2017.06.081; Rukewe A, 2010, ANESTH ANALG, V110, P243, DOI 10.1213/ANE.0b013e3181c0f00e; Schwenk Eric S, 2017, Curr Anesthesiol Rep, V7, P238, DOI 10.1007/s40140-017-0213-x; Shrime MG, 2015, LANCET GLOB HEALTH, V3, pS8, DOI 10.1016/S2214-109X(14)70384-5; South A, 2011, R J, V3, P35; Suhre W, 2020, BMC ANESTHESIOL, V20, DOI 10.1186/s12871-020-01036-4; Tennekes M, 2018, J STAT SOFTW, V84, P1, DOI 10.18637/jss.v084.i06; Thurtle N, 2016, AFR J EMERG MED, V6, P12, DOI 10.1016/j.afjem.2015.10.005; Turbitt LR, 2020, ANAESTHESIA, V75, P293, DOI 10.1111/anae.14768; World Health Organization, 2016, GLOB DIFF EHEALTH MA	36	1	1	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2021	16	2							e0244860	10.1371/journal.pone.0244860	http://dx.doi.org/10.1371/journal.pone.0244860			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF0FZ	33524031	gold, Green Published			2023-01-03	WOS:000616578400026
J	Zuniga, MAL; Moreno-Moral, A; Ocana-Granados, A; Padilla-Moreno, FA; Castillo-Fernandez, AM; Guillamon-Fernandez, D; Ramirez-Sanchez, C; Sanchez-Palop, M; Martinez-Colmenero, J; Pimentel-Villar, MA; Blazquez-Rosello, S; Moreno-Sanchez, JJ; Lopez-Vilchez, M; Prior-Sanchez, I; Jodar-Moreno, R; Ruz, MAL				Lopez Zuniga, Miguel Angel; Moreno-Moral, Aida; Ocana-Granados, Ana; Padilla-Moreno, Francisco Andres; Castillo-Fernandez, Alba Maria; Guillamon-Fernandez, Dionisio; Ramirez-Sanchez, Carolina; Sanchez-Palop, Maria; Martinez-Colmenero, Justo; Pimentel-Villar, Maria Amparo; Blazquez-Rosello, Sara; Moreno-Sanchez, Jose Juan; Lopez-Vilchez, Maria; Prior-Sanchez, Inmaculada; Jodar-Moreno, Rosario; Lopez Ruz, Miguel Angel			High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response	PLOS ONE			English	Article								Objective Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response. Provide some initial diagnostic criteria using laboratory markers to stratify these patients. Methods This is a prospective observational study, 318 met the inclusion criteria. 64 patients (20.1%) were treated with HDCPT by using at least 1.5mg/kg/24h of methylprednisolone or dexamethasone equivalent. A multivariate Cox regression (controlling for co-morbidities and other therapies) was carried out to determine whether HDCPT (among other interventions) was associated with decreased mortality. We also carried out a 30-day time course analysis of laboratory markers between survivors and non-survivors, to identify potential markers for patient stratification. Results HDCPT showed a statistically significant decrease in mortality (HR = 0.087 [95% CI 0.021-0.36]; P < 0.001). 30-day time course analysis of laboratory marker tests showed marked differences in pro-inflammatory markers between survivors and non-survivors. As diagnostic criteria to define the patients at risk of developing a COVID-19 hyper-inflammatory response, we propose the following parameters (IL-6 > = 40 pg/ml, and/or two of the following: C-reactive protein > = 100 mg/L, D-dimer > = 1000 ng/ml, ferritin > = 500 ng/ml and lactate dehydrogenase > = 300 U/L). Conclusions HDCPT can be an effective intervention to increase COVID-19 survival rates in patients at risk of developing a COVID-19 hyper-inflammatory response, laboratory marker tests can be used to stratify these patients who should be given HDCPT. This study is not a randomized clinical trial (RCT). Future RCTs should be carried out to confirm the efficacy of HDCPT to increase the survival rates of COVID-19.	[Lopez Zuniga, Miguel Angel; Lopez Ruz, Miguel Angel] Hosp Univ Virgen Nieves, Infect Dis Unit, Granada, Spain; [Lopez Zuniga, Miguel Angel; Martinez-Colmenero, Justo] Univ Jaen, Grp Invest CTS 990 GEAPACECP, Jaen, Spain; [Ocana-Granados, Ana] Complejo Hosp Jaen, Allergol Serv, Jaen, Spain; [Padilla-Moreno, Francisco Andres; Castillo-Fernandez, Alba Maria; Martinez-Colmenero, Justo; Moreno-Sanchez, Jose Juan; Lopez-Vilchez, Maria] Complejo Hosp Jaen, Internal Med Serv, Jaen, Spain; [Guillamon-Fernandez, Dionisio] Hosp Univ San Cecilio, Otorhinolaryngol Serv, Granada, Spain; [Ramirez-Sanchez, Carolina] Hosp Univ Virgen Victoria, Pathol Anat Serv, Malaga, Spain; [Sanchez-Palop, Maria] Pneumol Serv Complejo Hosp Jaen, Jaen, Spain; [Pimentel-Villar, Maria Amparo] Complejo Hosp Jaen, Haematol Serv, Jaen, Spain; [Blazquez-Rosello, Sara] Complejo Hosp Jaen, Nephrol Serv, Jaen, Spain; [Prior-Sanchez, Inmaculada] Complejo Hosp Jaen, Endocrinol Serv, Jaen, Spain; [Jodar-Moreno, Rosario] Complejo Hosp Jaen, Otorhinolaryngol Serv, Jaen, Spain	Hospital Universitario Virgen de las Nieves; Universidad de Jaen; Complejo Hospitalario de Jaen; Complejo Hospitalario de Jaen; Hospital Universitario San Cecilio; Hospital Virgen de la Victoria; Complejo Hospitalario de Jaen; Complejo Hospitalario de Jaen; Complejo Hospitalario de Jaen; Complejo Hospitalario de Jaen	Zuniga, MAL (corresponding author), Hosp Univ Virgen Nieves, Infect Dis Unit, Granada, Spain.; Zuniga, MAL (corresponding author), Univ Jaen, Grp Invest CTS 990 GEAPACECP, Jaen, Spain.	miguelangellopezzuniga@gmail.com		Martinez Colmenero, Justo/0000-0003-2949-1854; Lopez Zuniga, Miguel Angel/0000-0002-2583-316X				Alunno A, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen-2020-001295; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Campins L, 2020, CLIN EXP RHEUMATOL, V38, P578; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Dastan F, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106688; Fadel R, 2020, CLIN INFECT DIS, V71, P2114, DOI 10.1093/cid/ciaa601; Feng ZJ, 2020, CHINA CDC WEEKLY, V2, P113, DOI 10.46234/ccdcw2020.032; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Lerkvaleekul B, 2018, OPEN ACCESS RHEUMATO, V10, P117, DOI 10.2147/OARRR.S151013; Liu FF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70387-2; Luo P, 2020, J MED VIROL, V92, P814, DOI 10.1002/jmv.25801; Gimenez VMM, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117808; McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; NIH, 2020, CLIN PRES PEOPL SARS; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rubio JLC, 2020, MED CLIN-BARCELONA, V155, P159, DOI 10.1016/j.medcli.2020.04.018; Ruiz-Irastorza G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239401; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Weir EK, 2020, CLIN MED, V20, pE107, DOI 10.7861/clinmed.2020-0301; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yang SS, 2020, CAN J ANESTH, V67, P1462, DOI 10.1007/s12630-020-01700-w; Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237; Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393	34	25	25	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2021	16	1							e0243964	10.1371/journal.pone.0243964	http://dx.doi.org/10.1371/journal.pone.0243964			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF7LJ	33507958	Green Published, gold			2023-01-03	WOS:000635021400014
J	Simsa, R; Rothenbucher, T; Gurbuz, H; Ghosheh, N; Emneus, J; Jenndahl, L; Kaplan, DL; Bergh, N; Serrano, AM; Fogelstrand, P				Simsa, Robin; Rothenbucher, Theresa; Gurbuz, Hakan; Ghosheh, Nidal; Emneus, Jenny; Jenndahl, Lachmi; Kaplan, David L.; Bergh, Niklas; Serrano, Alberto Martinez; Fogelstrand, Per			Brain organoid formation on decellularized porcine brain ECM hydrogels	PLOS ONE			English	Article							EXTRACELLULAR-MATRIX; CEREBRAL ORGANOIDS; RHEOLOGICAL CHARACTERIZATION; BIOLOGIC SCAFFOLDS; NEURITE OUTGROWTH; MODEL; SYSTEM; IMPACT; RECELLULARIZATION; ELASTICITY	Human brain tissue models such as cerebral organoids are essential tools for developmental and biomedical research. Current methods to generate cerebral organoids often utilize Matrigel as an external scaffold to provide structure and biologically relevant signals. Matrigel however is a nonspecific hydrogel of mouse tumor origin and does not represent the complexity of the brain protein environment. In this study, we investigated the application of a decellularized adult porcine brain extracellular matrix (B-ECM) which could be processed into a hydrogel (B-ECM hydrogel) to be used as a scaffold for human embryonic stem cell (hESC)-derived brain organoids. We decellularized pig brains with a novel detergent- and enzyme-based method and analyzed the biomaterial properties, including protein composition and content, DNA content, mechanical characteristics, surface structure, and antigen presence. Then, we compared the growth of human brain organoid models with the B-ECM hydrogel or Matrigel controls in vitro. We found that the native brain source material was successfully decellularized with little remaining DNA content, while Mass Spectrometry (MS) showed the loss of several brain-specific proteins, while mainly different collagen types remained in the B-ECM. Rheological results revealed stable hydrogel formation, starting from B-ECM hydrogel concentrations of 5 mg/mL. hESCs cultured in B-ECM hydrogels showed gene expression and differentiation outcomes similar to those grown in Matrigel. These results indicate that B-ECM hydrogels can be used as an alternative scaffold for human cerebral organoid formation, and may be further optimized for improved organoid growth by further improving protein retention other than collagen after decellularization.	[Simsa, Robin; Jenndahl, Lachmi] VERIGRAFT AB, Gothenburg, Sweden; [Simsa, Robin; Bergh, Niklas; Fogelstrand, Per] Univ Gothenburg, Dept Mol & Clin Med, Wallenberg Lab, Gothenburg, Sweden; [Simsa, Robin; Bergh, Niklas; Fogelstrand, Per] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Simsa, Robin; Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; [Rothenbucher, Theresa; Serrano, Alberto Martinez] Univ Autonoma Madrid, Ctr Mol Biol Severo Ochoa UAM CSIC, Dept Mol Biol, Madrid, Spain; [Gurbuz, Hakan; Emneus, Jenny] Tech Univ Denmark, Dept Biotechnol & Biomed, Lyngby, Denmark; [Gurbuz, Hakan] FELIXROBOTICS BV, Utrecht, Netherlands; [Ghosheh, Nidal] Univ Skovde, Syst Biol Res Ctr, Sch Biosci, Skovde, Sweden	University of Gothenburg; Sahlgrenska University Hospital; Tufts University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Technical University of Denmark; University of Skovde	Simsa, R (corresponding author), VERIGRAFT AB, Gothenburg, Sweden.; Simsa, R; Bergh, N (corresponding author), Univ Gothenburg, Dept Mol & Clin Med, Wallenberg Lab, Gothenburg, Sweden.; Simsa, R; Bergh, N (corresponding author), Sahlgrens Univ Hosp, Gothenburg, Sweden.; Simsa, R (corresponding author), Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.	robin.simsa@verigraft.com; niklas.bergh@gu.se	; Emneus, Jenny/A-5763-2012	Gurbuz, Hakan/0000-0002-8839-431X; Emneus, Jenny/0000-0002-8061-201X	European Union's Horizon 2020 Research and Innovation Program under the Marie SklodowskaCurie Grant [722779]; AMS group (CBMSO-UAM) grant [MINECO SAF2017-83241-R]; ISC-III RETICS TerCel [RD16/0011/0032]; ASCTN597 Training [813851]; NIH [P41EB027062, R01NS092847]; VERIGRAFT AB; Felix Printers	European Union's Horizon 2020 Research and Innovation Program under the Marie SklodowskaCurie Grant; AMS group (CBMSO-UAM) grant; ISC-III RETICS TerCel; ASCTN597 Training; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VERIGRAFT AB(HOGANAS ABStatisticon AB); Felix Printers	This study was supported by the European Union's Horizon 2020 Research and Innovation Program under the Marie SklodowskaCurie Grant (No. 722779) awarded to RS; AMS group (CBMSO-UAM) grant (No. MINECO SAF2017-83241-R) awarded tp AMS, ISC-III RETICS TerCel (RD16/0011/0032) and ASCTN597 Training (No. 813851) awarded to AMS, and NIH grants ((P41EB027062 and R01NS092847) awarded to DLK. VERIGRAFT AB provided funding in the form of salary for RS. Felix Printers provided funding in the form of salary for HG. The specific roles of these authors are articulated in the `author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alovskaya A, 2007, BIOMATERIALS TISSUE, V3; Antoine EE, 2014, TISSUE ENG PART B-RE, V20, P683, DOI [10.1089/ten.teb.2014.0086, 10.1089/ten.TEB.2014.0086]; Aubin Hug, 2013, Methods Mol Biol, V1036, P163, DOI 10.1007/978-1-62703-511-8_14; Aurand ER, 2012, J FUNCT BIOMATER, V3, P839, DOI 10.3390/jfb3040839; Badylak SF, 2011, ANNU REV BIOMED ENG, V13, P27, DOI 10.1146/annurev-bioeng-071910-124743; Baiguera S, 2014, BIOMATERIALS, V35, P1205, DOI 10.1016/j.biomaterials.2013.10.060; Bonandrini B, 2014, TISSUE ENG PT A, V20, P1486, DOI [10.1089/ten.TEA.2013.0269, 10.1089/ten.tea.2013.0269]; Bonneh-Barkay D, 2009, BRAIN PATHOL, V19, P573, DOI 10.1111/j.1750-3639.2008.00195.x; Brown DA, 2007, BIOTECHNOL BIOENG, V97, P962, DOI 10.1002/bit.21295; Crapo PM, 2012, BIOMATERIALS, V33, P3539, DOI 10.1016/j.biomaterials.2012.01.044; Davis BH, 2007, ANN BIOMED ENG, V35, P1414, DOI 10.1007/s10439-007-9301-2; DeQuach JA, 2011, TISSUE ENG PT A, V17, P2583, DOI [10.1089/ten.tea.2010.0724, 10.1089/ten.TEA.2010.0724]; EDGAR D, 1984, EMBO J, V3, P1463, DOI 10.1002/j.1460-2075.1984.tb01997.x; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Erikson A, 2008, BIOPOLYMERS, V89, P135, DOI 10.1002/bip.20874; Faulk DM, 2014, ACTA BIOMATER, V10, P183, DOI 10.1016/j.actbio.2013.09.006; Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820; Freytes DO, 2008, BIOMATERIALS, V29, P1630, DOI 10.1016/j.biomaterials.2007.12.014; Freytes Donald O, 2014, Methods Mol Biol, V1181, P69, DOI 10.1007/978-1-4939-1047-2_7; Geerts S, 2016, TISSUE ENG PART C-ME, V22, P671, DOI [10.1089/ten.tec.2015.0571, 10.1089/ten.TEC.2015.0571]; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Gilbert TW, 2006, BIOMATERIALS, V27, P3675, DOI 10.1016/j.biomaterials.2006.02.014; Gilpin SE, 2014, J HEART LUNG TRANSPL, V33, P298, DOI 10.1016/j.healun.2013.10.030; Hoshiba T, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6397820; Hughes CS, 2010, PROTEOMICS, V10, P1886, DOI 10.1002/pmic.200900758; Hwang JM, 2017, ACTA BIOMATER, V53, P268, DOI 10.1016/j.actbio.2017.01.079; Ijima H, 2018, GELS-BASEL, V4, DOI 10.3390/gels4020039; Jabbari E, 2016, MATER TODAY, V19, P190, DOI 10.1016/j.mattod.2015.10.005; Jo J, 2016, CELL STEM CELL, V19, P248, DOI 10.1016/j.stem.2016.07.005; Johnson TD, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/49/494015; Keane TJ, 2015, METHODS, V84, P25, DOI 10.1016/j.ymeth.2015.03.005; Koh I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22681-3; Kucharz EJ., 1992, COLLAGENS BIOCH PATH, P261, DOI [10.1007/978-3-642-76197-3_19, DOI 10.1007/978-3-642-76197-3_19]; Kulak NA, 2014, NAT METHODS, V11, P319, DOI [10.1038/NMETH.2834, 10.1038/nmeth.2834]; Kuljanin M, 2017, BIOMATERIALS, V144, P130, DOI 10.1016/j.biomaterials.2017.08.012; Lam D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40128-1; Lancaster MA, 2014, NAT PROTOC, V9, P2329, DOI 10.1038/nprot.2014.158; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; Lin Q, 2017, INT J PHARMACEUT, V517, P383, DOI 10.1016/j.ijpharm.2016.12.028; Massensini AR, 2015, ACTA BIOMATER, V27, P116, DOI 10.1016/j.actbio.2015.08.040; Medberry CJ, 2013, BIOMATERIALS, V34, P1033, DOI 10.1016/j.biomaterials.2012.10.062; Monzel AS, 2017, STEM CELL REP, V8, P1144, DOI 10.1016/j.stemcr.2017.03.010; Nicholson C, 1998, TRENDS NEUROSCI, V21, P207, DOI 10.1016/S0166-2236(98)01261-2; O'Brien JJ, 2018, ANN APPL STAT, V12, P2075, DOI 10.1214/18-AOAS1144; Oksdath M, 2018, APL BIOENG, V2, DOI 10.1063/1.5045124; Poornejad N, 2016, J BIOMATER APPL, V31, P521, DOI 10.1177/0885328216656099; Qian XY, 2016, CELL, V165, P1238, DOI 10.1016/j.cell.2016.04.032; Raja WK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161969; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Rauch U, 2007, BIOCHEM SOC T, V35, P656, DOI 10.1042/BST0350656; Ribatti D, 2003, BRAIN RES, V989, P9, DOI 10.1016/S0006-8993(03)03225-6; Rothenbucher TSP, 2019, FUTUR NEUROL, V14, DOI 10.2217/fnl-2018-0043; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sackett SD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28857-1; Saldin LT, 2017, ACTA BIOMATER, V49, P1, DOI 10.1016/j.actbio.2016.11.068; Sauleau P, 2009, ANIMAL, V3, P1138, DOI 10.1017/S1751731109004649; Shayegan M, 2016, BIOPHYS J, V111, P2404, DOI 10.1016/j.bpj.2016.10.039; SHELLSWELL GB, 1979, FEBS LETT, V106, P305, DOI 10.1016/0014-5793(79)80520-7; Simsa R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220743; Simsa R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209269; Singelyn JM, 2011, MACROMOL BIOSCI, V11, P731, DOI 10.1002/mabi.201000423; Sood D, 2016, ACS BIOMATER SCI ENG, V2, P131, DOI 10.1021/acsbiomaterials.5b00446; Stachowiak EK, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/s41398-017-0054-x; Stiles J, 2010, NEUROPSYCHOL REV, V20, P327, DOI 10.1007/s11065-010-9148-4; Taylor Z, 2004, J BIOMECH, V37, P1263, DOI 10.1016/j.jbiomech.2003.11.027; Tonge DA, 2012, BRAIN RES, V1453, P8, DOI 10.1016/j.brainres.2012.03.024; Ushakova GA, 2002, NEUROCHEM INT, V40, P277, DOI 10.1016/S0197-0186(01)00028-6; Wang JW, 2017, SCI REP-UK, V7, DOI 10.1038/srep41042; Wechsler-Reya RJ, 2001, TRENDS NEUROSCI, V24, P680, DOI 10.1016/S0166-2236(00)02058-0; White LJ, 2017, ACTA BIOMATER, V50, P207, DOI 10.1016/j.actbio.2016.12.033; Wu Y, 2017, CELL TRANSPLANT, V26, P1224, DOI 10.1177/0963689717714090; Zuidema JM, 2014, J BIOMED MATER RES B, V102, P1063, DOI 10.1002/jbm.b.33088	72	18	18	15	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2021	16	1							e0245685	10.1371/journal.pone.0245685	http://dx.doi.org/10.1371/journal.pone.0245685			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF7LJ	33507989	Green Published, gold			2023-01-03	WOS:000635021400046
J	Yu, CY; Wan, SW; Weng, YC; Hsu, CH				Yu, Chun-Yen; Wan, Shih-Wen; Weng, Yih-Chyang; Hsu, Ching-Han			Three corrections for overshoot effect improved the dose for step-and-shoot intensity-modulated radiation therapy	PLOS ONE			English	Article							DELIVERY; IMRT; LIMITATIONS	We measured the overshoot effect in a linac and reduced it using block correction, reverse-sequence correction, and index correction. A StarTrack detector was used on a Varian iX. Five segments, 1 x 10 cm(2) in area, were designed; the centers were at -4, -2, 0, 2, and 4 cm on the x axis for measuring the overshoot effect on a 10 x 10 cm(2) collimator setting. Block correction was applied to two segments. The first was on the new first segment at -6 cm, and the other was on the new last segment at 6 cm. Both two new segments were obtained from the 10 x 10 cm(2) collimator setting. The order of segments was reversed in reverse-sequence correction. Reverse-sequence correction averages the dose at every segment after two irradiations. When we used MLC Shaper, index correction reduced the first segment's index (cumulative radiation occupation) by 60% and increased the last segment's radiation occupation by 60% in a new MLC.log file. As for relative dose, the first segment had an overdose of 52.4% and the last segment had an underdose of 48.6%, when irradiated at 1 MU at 600 MU/min. The relative doses at the first segment, irradiated at 1 MU, after block correction, reverse-sequence correction, and index correction were applied decreased from 152.5% to 95.1%, 104.8%, and 100.1%, respectively. The relative doses at the last segment, irradiated at 1 MU, after block correction, reverse-sequence correction, and index correction were applied increased from 48.6% to 97.3%, 91.1%, and 95.9%, respectively. The overshoot effect depended on the speed of irradiation. High irradiation speeds resulted in notable overdosing and underdosing at the first and last segments, respectively. The three corrections mitigated the overshoot effect on dose. To save time and effort, the MLC.log file should be edited with a program in the future.	[Yu, Chun-Yen; Hsu, Ching-Han] Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu, Taiwan; [Yu, Chun-Yen] Chung Shan Med Univ, Dept Med Imaging & Radiol Sci, Taichung, Taiwan; [Wan, Shih-Wen] Inst Nucl Energy Res, Dept Hlth, Phys Div, Taoyuan, Taiwan; [Weng, Yih-Chyang] Minist Hlth & Welf, Dept Radiat Oncol, Nantou Hosp, Nantou, Taiwan	National Tsing Hua University; Chung Shan Medical University; Institute of Nuclear Energy Research - Taiwan	Hsu, CH (corresponding author), Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu, Taiwan.	cghsu@mx.nthu.edu.tw	Hsu, Ching-Han/G-6029-2010	Hsu, Ching-Han/0000-0003-2351-2052				Ezzell G A, 2001, J Appl Clin Med Phys, V2, P138, DOI 10.1120/1.1386508; Ezzell GA, 2003, MED PHYS, V30, P2089, DOI 10.1118/1.1591194; Grigorov GN, 2006, PHYS MED BIOL, V51, P637, DOI 10.1088/0031-9155/51/3/011; Kuperman VY, 2006, MED PHYS, V33, P1067, DOI 10.1118/1.2174128; Low DA, 2001, MED PHYS, V28, P752, DOI 10.1118/1.1367863; Xia P, 2002, MED PHYS, V29, P412, DOI 10.1118/1.1449496; Zhen HM, 2016, J APPL CLIN MED PHYS, V17, P214, DOI 10.1120/jacmp.v17i4.6101; Zygmanski P, 2005, J APPL CLIN MED PHYS, V6, P33, DOI 10.1120/jacmp.2024.25335	8	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	4							e0250243	10.1371/journal.pone.0250243	http://dx.doi.org/10.1371/journal.pone.0250243			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR0PU	33891639	Green Published, gold			2023-01-03	WOS:000642811900020
J	MacDonald, DI; Sikandar, S; Weiss, J; Pyrski, M; Luiz, AP; Millet, Q; Emery, EC; Mancini, F; Iannetti, GD; Alles, SRA; Arcangeletti, M; Zhao, J; Cox, JJ; Brownstone, RM; Zufall, F; Wood, JN				MacDonald, Donald Iain; Sikandar, Shafaq; Weiss, Jan; Pyrski, Martina; Luiz, Ana P.; Millet, Queensta; Emery, Edward C.; Mancini, Flavia; Iannetti, Gian D.; Alles, Sascha R. A.; Arcangeletti, Manuel; Zhao, Jing; Cox, James J.; Brownstone, Robert M.; Zufall, Frank; Wood, John N.			A central mechanism of analgesia in mice and humans lacking the sodium channel Na(V)1.7	NEURON			English	Article							CONGENITAL INSENSITIVITY; SCN9A MUTATIONS; PAIN; GENE; NOCICEPTORS; DELETION; TARGETS; ABSENCE; HEAT	Deletion of SCN9A encoding the voltage-gated sodium channel Na(V)1.7 in humans leads to profound pain insensitivity and anosmia. Conditional deletion of Na(V)1.7 in sensory neurons of mice also abolishes pain, suggesting that the locus of analgesia is the nociceptor. Here we demonstrate, using in vivo calcium imaging and extracellular recording, that Na(V)1.7 knockout mice have essentially normal nociceptor activity. However, synaptic transmission from nociceptor central terminals in the spinal cord is greatly reduced by an opioid-dependent mechanism. Analgesia is also reversed substantially by central but not peripheral application of opioid antagonists. In contrast, the lack of neurotransmitter release from olfactory sensory neurons is opioid independent. Male and female humans with Na(V)1.7-null mutations show naloxone-reversible analgesia. Thus, inhibition of neurotransmitter release is the principal mechanism of anosmia and analgesia in mouse and human Nav1.7-null mutants.	[MacDonald, Donald Iain; Luiz, Ana P.; Millet, Queensta; Emery, Edward C.; Alles, Sascha R. A.; Arcangeletti, Manuel; Zhao, Jing; Cox, James J.; Wood, John N.] UCL, Wolfson Inst Biomed Res, Mol Nocicept Grp, Gower St, London WC1E 6BT, England; [Sikandar, Shafaq] Queen Mary Univ London, Ctr Expt Med & Rheumatol, Charterhouse Sq, London EC1M 6BQ, England; [Weiss, Jan; Pyrski, Martina; Zufall, Frank] Saarland Univ, Ctr Integrat Physiol & Mol Med, D-66421 Homburg, Germany; [Mancini, Flavia; Iannetti, Gian D.] UCL, Dept Neurosci Physiol & Pharmacol, Gower St, London WC1E 6BT, England; [Iannetti, Gian D.] Ist Italiano Tecnol, Neurosci & Behav Lab, Rome, Italy; [Brownstone, Robert M.] UCL Queen Sq Inst Neurol, London WC1N 3BG, England	University of London; University College London; University of London; Queen Mary University London; Universitatsklinikum des Saarlandes; University of London; University College London; Istituto Italiano di Tecnologia - IIT; University of London; University College London	MacDonald, DI; Wood, JN (corresponding author), UCL, Wolfson Inst Biomed Res, Mol Nocicept Grp, Gower St, London WC1E 6BT, England.	donald.macdonald.15@ucl.ac.uk; j.wood@ucl.ac.uk	Alles, Sascha/L-9018-2019	Alles, Sascha/0000-0001-8532-8950; Zhao, Jing/0000-0003-2587-1198; Brownstone, Robert/0000-0001-5135-2725; Luiz, Ana Paula/0000-0002-9465-0797; Sikandar, Shafaq/0000-0002-6010-5205; Pyrski, Martina/0000-0002-5751-178X	Wellcome Trust [200183/Z/15/Z]; Wolfson Foundation; Deutsche Forschungsgemeinschaft grants Sonderforschungsbereich [894/A17]; Sonderforschungsbereich Transregio [239283807]; Wellcome [110193]; Brain Research UK;  [20200]	Wellcome Trust(Wellcome TrustEuropean Commission); Wolfson Foundation; Deutsche Forschungsgemeinschaft grants Sonderforschungsbereich(German Research Foundation (DFG)); Sonderforschungsbereich Transregio(German Research Foundation (DFG)); Wellcome; Brain Research UK; 	We thank the Wellcome Trust (200183/Z/15/Z) and the MRC. D.I.M. was supported by a PhD fellowship from the Wolfson Foundation. S.S. is a Versus Arthritis fellow and lecturer in sensory biology, and Versus Arthritis supported A.P.L., Q.M., and J.N.W. with a program grant (20200). F.Z. was supported by Deutsche Forschungsgemeinschaft grants Sonderforschungsbereich 894/A17 and Sonderforschungsbereich Transregio TRR 152/P10, project 239283807. R.M.B. was supported by Wellcome grant 110193 and Brain Research UK. We thank Xinzhong Dong for Pirt-GCaMP3 mice, Sonia Santana-Varela for help with mouse colonies, and Marco Beato and Filipe Nascimento and members of the Molecular Nociception Group for help and advice.	Ahn HS, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-32; Alexandrou AJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152405; Alles SRA, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax4568; Black JA, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-82; Bolz F, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00028; Branco T, 2016, CELL, V165, P1749, DOI 10.1016/j.cell.2016.05.019; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Brenner DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039765; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen C, 2018, BRIT J PHARMACOL, V175, P3911, DOI 10.1111/bph.14461; Chen TW, 2013, NATURE, V499, P295, DOI 10.1038/nature12354; Churyukanov M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035817; Corder G, 2017, NAT MED, V23, P164, DOI 10.1038/nm.4262; Cox JJ, 2006, NATURE, V444, P894, DOI 10.1038/nature05413; Cummins TR, 1998, J NEUROSCI, V18, P9607; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; DEHEN H, 1977, LANCET, V2, P293; Deuis JR, 2017, SCI REP-UK, V7, DOI 10.1038/srep40883; Emery EC, 2019, CURR OPIN PHYSIOL, V11, P29, DOI 10.1016/j.cophys.2019.04.014; Emery EC, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600990; Emery EC, 2016, EXPERT OPIN THER TAR, V20, P975, DOI 10.1517/14728222.2016.1162295; FABBRI A, 1984, EXPERIENTIA, V40, P1365, DOI 10.1007/BF01951891; Faber CG, 2012, ANN NEUROL, V71, P26, DOI 10.1002/ana.22485; Fertleman CR, 2006, NEURON, V52, P767, DOI 10.1016/j.neuron.2006.10.006; Gingras J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105895; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Heinke B, 2011, J NEUROSCI, V31, P1313, DOI 10.1523/JNEUROSCI.4060-10.2011; Hoffmann T, 2018, PAIN, V159, P496, DOI 10.1097/j.pain.0000000000001119; Isensee J, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4874; Kanellopoulos AH, 2018, EMBO J, V37, P427, DOI 10.15252/embj.201796692; Kim YS, 2014, NEURON, V81, P873, DOI 10.1016/j.neuron.2013.12.011; Kingwell K, 2019, NAT REV DRUG DISCOV, V18, P321, DOI 10.1038/d41573-019-00065-0; Klein CJ, 2013, J NEUROL NEUROSUR PS, V84, P386, DOI 10.1136/jnnp-2012-303719; Kolesnikov YA, 2000, J PHARMACOL EXP THER, V295, P546; Lawson SN, 2019, CURR OPIN PHYSIOL, V11, P125, DOI 10.1016/j.cophys.2019.10.005; Legrain V, 2011, PROG NEUROBIOL, V93, P111, DOI 10.1016/j.pneurobio.2010.10.005; MANFREDI M, 1981, ARCH NEUROL-CHICAGO, V38, P507, DOI 10.1001/archneur.1981.00510080069010; Marchi M, 2018, J PERIPHER NERV SYST, V23, P202, DOI 10.1111/jns.12280; Marvin JS, 2013, NAT METHODS, V10, P162, DOI [10.1038/NMETH.2333, 10.1038/nmeth.2333]; McDermott LA, 2019, NEURON, V101, P905, DOI 10.1016/j.neuron.2019.01.047; Medvedeva YV, 2009, NEUROSCIENCE, V159, P559, DOI 10.1016/j.neuroscience.2008.12.029; Melo H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33620-7; Minett MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9967; Minett MS, 2014, CELL REP, V6, P301, DOI 10.1016/j.celrep.2013.12.033; Minett MS, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1795; Moreno AM, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aay9056; Mueller A, 2019, PAIN, V160, P1766, DOI 10.1097/j.pain.0000000000001567; Nassar MA, 2004, P NATL ACAD SCI USA, V101, P12706, DOI 10.1073/pnas.0404915101; Nilsen KB, 2009, PAIN, V143, P155, DOI 10.1016/j.pain.2009.02.016; Pereira Vanessa, 2018, Wellcome Open Res, V3, P101, DOI 10.12688/wellcomeopenres.14687.1; Ramirez JD, 2014, NEUROLOGY, V83, P1577, DOI 10.1212/WNL.0000000000000913; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Raouf R, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-21; Saraiva LR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18178; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Shaikh SS, 2018, EUR J HUM GENET, V26, P1559, DOI 10.1038/s41431-018-0214-3; Shields SD, 2018, J NEUROSCI, V38, P10180, DOI 10.1523/JNEUROSCI.1049-18.2018; Vetter I, 2017, PHARMACOL THERAPEUT, V172, P73, DOI 10.1016/j.pharmthera.2016.11.015; Vysokov N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49214-w; Wang F, 2018, CELL REP, V23, P2001, DOI 10.1016/j.celrep.2018.04.065; Weiss J, 2011, NATURE, V472, P186, DOI 10.1038/nature09975; YAKSH TL, 1980, NATURE, V286, P155, DOI 10.1038/286155a0; Yang Y, 2004, J MED GENET, V41, P171, DOI 10.1136/jmg.2003.012153; Zeisel A, 2018, CELL, V174, P999, DOI 10.1016/j.cell.2018.06.021; Zhou X, 2010, P NATL ACAD SCI USA, V107, P9424, DOI 10.1073/pnas.0914725107	65	16	18	5	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	MAY 5	2021	109	9					1497	+		10.1016/j.neuron.2021.03.012	http://dx.doi.org/10.1016/j.neuron.2021.03.012		MAY 2021	23	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UO7GL	33823138	Green Published, hybrid			2023-01-03	WOS:000694861200012
J	Chacon, P; Vega-Rioja, A; Doukkali, B; Rodriguez, AD; Bellido, V; Puente, Y; Alcaniz, L; Rodriguez, D; Palacios, R; Cornejo-Garcia, JA; Monteseirin, J; Rivas-Perez, D				Chacon, Pedro; Vega-Rioja, Antonio; Doukkali, Bouchra; del Valle Rodriguez, Alberto; Bellido, Virginia; Puente, Yolanda; Alcaniz, Lorena; Rodriguez, David; Palacios, Ricardo; Antonio Cornejo-Garcia, Jose; Monteseirin, Javier; Rivas-Perez, David			Targeted inhibition of allergen-induced histamine production by neutrophils	FASEB JOURNAL			English	Article						allergen immunotherapy; asthma; diamine oxidase; histamine; histidine decarboxylase	ACTIVATED PROTEIN-KINASE; LUNG MAST-CELLS; DIAMINE OXIDASE; CYCLOSPORINE-A; THERAPEUTIC VACCINES; ASTHMATIC-PATIENTS; MEDIATOR RELEASE; HUMAN BASOPHILS; IN-VITRO; IMMUNOTHERAPY	Histamine is a critical inflammatory mediator in allergic diseases. We showed in a previous work that neutrophils from allergic patients produce histamine in response to allergens to which the patients were sensitized. Here, we investigate the molecular mechanisms involved in this process using peripheral blood neutrophils. We challenged these cells in vitro with allergens and analyzed histamine release in the culture supernatants. We also explored the effect of common therapeutic drugs that ameliorate allergic symptoms, as well as allergen-specific immunotherapy. Additionally, we examined the expression of histidine decarboxylase and diamine oxidase, critical enzymes in the metabolism of histamine, under allergen challenge. We show that allergen-induced histamine release is dependent on the activation of the phosphoinositide 3-kinase, mitogen-activated protein kinase p38, and extracellular signal-regulated kinase 1/2 signaling pathways. We also found a contribution of the phosphatase calcineurin to lesser extent. Anti-histamines, glucocorticoids, anti-M3-muscarinic receptor antagonists, and mainly beta(2)-receptor agonists abolished the allergen-dependent histamine release. Interestingly, allergen-specific immunotherapy canceled the histamine release through the downregulation of histidine decarboxylase expression. Our observations describe novel molecular mechanisms involved in the allergen-dependent histamine release by human neutrophils and provide new targets to inhibit histamine production.	[Chacon, Pedro; Vega-Rioja, Antonio; Doukkali, Bouchra; del Valle Rodriguez, Alberto; Bellido, Virginia; Puente, Yolanda; Monteseirin, Javier] Hosp Univ Virgen Macarena, UGC Alergol, Edificio Policlin 1a Planta,Ave Dr Fedriani 3, Seville 41009, Spain; [Alcaniz, Lorena] Hosp Univ Virgen Macarena, UGC Dermatol, Seville, Spain; [Rodriguez, David; Palacios, Ricardo] Labs Diater, Madrid, Spain; [Antonio Cornejo-Garcia, Jose] IBIMA Hosp Univ Reg Malaga UMA, Lab Invest, Malaga, Spain; [Monteseirin, Javier] Univ Seville, Fac Med, Dept Med, Seville, Spain; [Rivas-Perez, David] Univ Seville, Fac Odontol, Seville, Spain; [Monteseirin, Javier] Calle Asuncion 27,3 Izqda, Seville 41011, Spain; [Monteseirin, Javier] Hosp Quiron Infanta Luisa, Seville 41010, Spain	Hospital Universitario Virgen Macarena; Hospital Universitario Virgen Macarena; University of Sevilla; University of Sevilla	Vega-Rioja, A (corresponding author), Hosp Univ Virgen Macarena, UGC Alergol, Edificio Policlin 1a Planta,Ave Dr Fedriani 3, Seville 41009, Spain.	macrofago@us.es; fmonteseirin@us.es	RIBAS PEREZ, DAVID/GZA-6697-2022; Cornejo-Garcia, Jose Antonio/S-7726-2016	RIBAS PEREZ, DAVID/0000-0001-6123-9216; Vega Rioja, Antonio/0000-0003-4698-9697; Chacon Fernandez, Pedro Jose/0000-0003-0925-814X; Cornejo-Garcia, Jose Antonio/0000-0003-3465-8735	EC vertical bar European Regional Development Fund (ERDF); MINECO vertical bar Instituto de Salud Carlos III (ISCIII) [RD16/0006/0035]; MINECO vertical bar Agencia Estatal de Investigacion (AEI) [SAF2014-60649-JIN]; Consejeria de Economia, Innovacion, Ciencia y Empleo, Junta de Andalucia (Ministry of Economy, Innovation, Science and Employment, Government of Andalucia) [PC--0217--2017]	EC vertical bar European Regional Development Fund (ERDF); MINECO vertical bar Instituto de Salud Carlos III (ISCIII); MINECO vertical bar Agencia Estatal de Investigacion (AEI); Consejeria de Economia, Innovacion, Ciencia y Empleo, Junta de Andalucia (Ministry of Economy, Innovation, Science and Employment, Government of Andalucia)	EC broken vertical bar European Regional Development Fund (ERDF); MINECO broken vertical bar Instituto de Salud Carlos III (ISCIII), Grant/Award Number: RD16/0006/0035; MINECO broken vertical bar Agencia Estatal de Investigacion (AEI), Grant/Award Number: SAF2014-60649-JIN; Consejeria de Economia, Innovacion, Ciencia y Empleo, Junta de Andalucia (Ministry of Economy, Innovation, Science and Employment, Government of Andalucia), Grant/Award Number: PC--0217--2017	Akabane Hirotomo, 2006, Allergol Int, V55, P387, DOI 10.2332/allergolint.55.387; Akdis CA, 2006, EUR J PHARMACOL, V533, P69; Alagha K, 2014, THER ADV CHRONIC DIS, V5, P85, DOI 10.1177/2040622313518227; Alcaniz L, 2013, FASEB J, V27, P2902; Aroca R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094558; Barcik W, 2017, CURR OPIN IMMUNOL, V48, P108, DOI 10.1016/j.coi.2017.08.011; Barnes PJ, 1999, J ALLERGY CLIN IMMUN, V104, pS10, DOI 10.1016/S0091-6749(99)70269-1; BERGSTRAND H, 1984, ALLERGY, V39, P217, DOI 10.1111/j.1398-9995.1984.tb02627.x; Bergstrand H, 1986, ALLERGY, V41, P319; BERTHON B, 1994, BIOCHEM PHARMACOL, V47, P789, DOI 10.1016/0006-2952(94)90478-2; Billington CK, 2017, HANDB EXP PHARMACOL, V237, P23, DOI 10.1007/164_2016_64; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Carballo M, 1999, J BIOL CHEM, V274, P93; Chong LK, 1998, BRIT J PHARMACOL, V123, P1009, DOI 10.1038/sj.bjp.0701703; Ciepiela O, 2015, RESP PHYSIOL NEUROBI, V209, P13, DOI 10.1016/j.resp.2014.12.004; Ciz M, 2013, BRIT J PHARMACOL, V170, P17, DOI 10.1111/bph.12107; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DVORAK AM, 1993, J HISTOCHEM CYTOCHEM, V41, P787, DOI 10.1177/41.6.8315271; El Bekay R, 2003, BLOOD, V102, P662, DOI 10.1182/blood-2002-09-2785; GALANT SP, 1980, J CLIN INVEST, V65, P577, DOI 10.1172/JCI109702; Gibbs BF, 2005, INT ARCH ALLERGY IMM, V136, P329, DOI 10.1159/000084226; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; Hosoki K, 2016, CURR OPIN ALLERGY CL, V16, P45, DOI 10.1097/ACI.0000000000000231; Ibarrola I, 2004, ANN ALLERG ASTHMA IM, V93, P589, DOI 10.1016/S1081-1206(10)61268-9; Jutel A, 2006, CHEM IMMUNOL ALLERGY, V91, P174; Kips JC, 2001, AM J RESP CRIT CARE, V164, P923, DOI 10.1164/ajrccm.164.6.2010107; Koprak S, 2003, CELL IMMUNOL, V223, P1, DOI 10.1016/S0008-8749(03)00130-8; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Matera MG, 2017, HANDB EXP PHARMACOL, V237, P41, DOI 10.1007/164_2016_68; Milara J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210188; Miyamoto M, 2004, EUR RESPIR J, V24, P231, DOI 10.1183/09031936.04.00035204; Monteseirin J, 2005, CLIN EXP ALLERGY, V35, P1204, DOI 10.1111/j.1365-2222.2005.02320.x; Monteseirin J, 2002, J ASTHMA, V39, P619, DOI 10.1081/JAS-120014926; Monteseirin J, 2009, J INVEST ALLERG CLIN, V19, P340; Monteseirin J, 2001, J ALLERGY CLIN IMMUN, V107, P623, DOI 10.1067/mai.2001.113566; Monteseirin J, 2004, J LEUKOCYTE BIOL, V76, P692, DOI 10.1189/jlb.0903441; Moote W, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0282-5; Profita M, 2005, ALLERGY, V60, P1361, DOI 10.1111/j.1398-9995.2005.00892.x; Ronchetti S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124090; Saklatvala J, 2002, ARTHRITIS RES, V4, P146, DOI 10.1186/ar398; Schwelberger HG, 1998, INFLAMM RES, V47, pS60; Shamji MH, 2015, J ALLERGY CLIN IMMUN, V135, P913, DOI 10.1016/j.jaci.2014.09.049; Sheikh A, 2013, CURR OPIN ALLERGY CL, V13, P263, DOI 10.1097/ACI.0b013e32836097f4; Shim JY, 2003, CLIN EXP ALLERGY, V33, P52, DOI 10.1046/j.1365-2222.2003.01567.x; Shiraishi M, 2000, BRIT J PHARMACOL, V129, P515, DOI 10.1038/sj.bjp.0703085; Simons FER, 2011, J ALLERGY CLIN IMMUN, V128, P1139, DOI 10.1016/j.jaci.2011.09.005; Smolinska S, 2014, ALLERGY, V69, P273, DOI 10.1111/all.12330; Smuda C, 2011, IMMUNOL LETT, V141, P102, DOI 10.1016/j.imlet.2011.08.002; Sperr WR, 1997, INT ARCH ALLERGY IMM, V114, P68, DOI 10.1159/000237645; Sperr WR, 1996, J ALLERGY CLIN IMMUN, V98, P389, DOI 10.1016/S0091-6749(96)70163-X; Strickland I, 2001, J EXP MED, V193, P585, DOI 10.1084/jem.193.5.585; Tedeschi A, 2000, INT J IMMUNOPHARMACO, V22, P797, DOI 10.1016/S0192-0561(00)00041-2; Thangam EB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01873; Tsang F, 1998, BRIT J PHARMACOL, V125, P61, DOI 10.1038/sj.bjp.0702049; Vega A, 2007, J CELL SCI, V120, P2328, DOI 10.1242/jcs.000331; Vega A, 2006, J LEUKOCYTE BIOL, V80, P152, DOI 10.1189/jlb.0705411; Ventura I, 2014, ALLERGY, V69, P898, DOI 10.1111/all.12414; Ventura I, 2014, PEDIAT ALLERG IMM-UK, V25, P129, DOI 10.1111/pai.12145; Virchow JC, 2019, LANCET, V394, P1737, DOI 10.1016/S0140-6736(19)32215-9; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xu XA, 2006, J EXP MED, V203, P2907, DOI 10.1084/jem.20061232	63	0	0	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2021	35	5							e21483	10.1096/fj.202001912R	http://dx.doi.org/10.1096/fj.202001912R			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU6MM	33788304				2023-01-03	WOS:000645260100001
J	van der Meij, A; Wermer, MJH				van der Meij, Anne; Wermer, Marieke J. H.			Vagus nerve stimulation: a potential new treatment for ischaemic stroke	LANCET			English	Editorial Material							REHABILITATION		[van der Meij, Anne; Wermer, Marieke J. H.] Leiden Univ, Dept Neurol, Med Ctr, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van der Meij, A (corresponding author), Leiden Univ, Dept Neurol, Med Ctr, NL-2333 ZA Leiden, Netherlands.	a.van_der_meij@lumc.nl						Ay I, 2016, BRAIN STIMUL, V9, P166, DOI 10.1016/j.brs.2015.11.008; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Bornstein NM, 2019, LANCET, V394, P219, DOI 10.1016/S0140-6736(19)31192-4; Dawson J, 2021, LANCET, V397, P1545, DOI 10.1016/S0140-6736(21)00475-X; Dawson J, 2016, STROKE, V47, P143, DOI 10.1161/STROKEAHA.115.010477; Goadsby PJ, 2018, CEPHALALGIA, V38, P959, DOI 10.1177/0333102417744362; Johnson C.O., 2019, LANCET NEUROL, V18, P439, DOI [10.1016/s1474-4422(19)30034-1, 10.1016/S1474-4422(19)30034-1]; Khodaparast N, 2014, NEUROREHAB NEURAL RE, V28, P698, DOI 10.1177/1545968314521006; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Schroeder CF, 2019, NEUROLOGY, V93, pE518, DOI 10.1212/WNL.0000000000007857; Tassorelli C, 2018, NEUROLOGY, V91, pE364, DOI 10.1212/WNL.0000000000005857	11	5	5	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	2021	397	10284					1520	1521						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR7QA	33894818				2023-01-03	WOS:000643286900002
J	Wyrostek, J; Piotrowska, A; Czerwinska-Ledwig, O; Zuziak, R; Szygula, Z; Cison, T; Zychowska, M; Pilch, W				Wyrostek, Joanna; Piotrowska, Anna; Czerwinska-Ledwig, Olga; Zuziak, Roxana; Szygula, Zbigniew; Cison, Tomasz; Zychowska, Malgorzata; Pilch, Wanda			Complex effects of whole body cryostimulation on hematological markers in patients with obesity	PLOS ONE			English	Article							BLOOD; CRYOTHERAPY; HEALTHY; BALANCE	Background Adaptation, including changes in blood properties, to whole-body cryostimulation may depend on many factors, including body mass. Aim This study investigates whether hematological parameters change similarly in a group of people with obesity and a group of men with normal body weight after 10 and 20 cryostimulation treatments. Methods In our non-randomized trial, the participants were divided into two groups based on their body fat percentage: 14 men with a high (HBF = 29.35%) and 10 with a normal percent of body fat (NBF = 11.40%) and subjected to 20 whole body cryostimulation treatments (-120 degrees C for 2-3 minutes). Blood samples were taken before the first and after the 10(th) and 20(th) cryostimulation. The following parameters were determined: red blood cells (RBC), hemoglobin concentration (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelets (PLT), red blood cell distribution width (RDW-SD), mean platelet volume (MPV), white blood cells (WBC), neutrophils (NEUT), lymphocytes (LYMPH), monocytes (MONO), eosinophils (EO) and basophiles (BASO). Results Statistically significant differences were found in red blood cells parameters such as RBC, HCT, MCV and MCHC. Time influence was noted for HCT, MCV and MCHC. Two-way ANOVA showed a significant correlation (for time and group) for 2 paramateres: RBC and MCV. For platelet parameters statistically significant differences were found for PLT (group influence) and MPV (time and group interaction). In white blood cells parameters statistically significant differences in levels of LYMPH were noted. Higher levels were observed for HBF group. Conclusions All observed changes were within the reference range, but hematological markers changed unevenly in people who are obese and non-obese. Therefore, it appears that an amount of fat tissue could be a factor causing the differences in adaptation to low temperature. It is suggested that 20 whole body cryostimulation sessions restore the state of homeostasis disturbed after 10 sessions.	[Wyrostek, Joanna] Univ Phys Educ Krakow, Fac Physiotherapy, Krakow, Poland; [Piotrowska, Anna; Czerwinska-Ledwig, Olga; Zuziak, Roxana; Pilch, Wanda] Univ Phys Educ Krakow, Fac Physiotherapy, Inst Basics Sci, Krakow, Poland; [Szygula, Zbigniew] Univ Phys Educ Krakow, Inst Biomed Sci, Dept Sports Med & Human Nutr, Krakow, Poland; [Cison, Tomasz] State Univ Appl Sci Nowy Sacz, Dept Physiotherapy, Nowy Sacz, Poland; [Zychowska, Malgorzata] Kazimierz Wielki Univ Bydgoszcz, Fac Phys Educ, Dept Sport, Bydgoszcz, Poland	Kazimierz Wielki University	Wyrostek, J (corresponding author), Univ Phys Educ Krakow, Fac Physiotherapy, Krakow, Poland.	joanna.wyrostek1@gmail.com	Piotrowska, Anna/ACM-3562-2022; Żychowska, Małgorzata/GZM-7973-2022; Czerwińska-Ledwig, Olga/ACW-5181-2022	Żychowska, Małgorzata/0000-0002-9475-0448; Czerwinska-Ledwig, Olga/0000-0003-1855-1276; Piotrowska, Anna/0000-0002-9535-173X; Zuziak, Roxana/0000-0002-7544-6096; Pilch, Wanda/0000-0001-6689-0155; Szygula, Zbigniew/0000-0002-6685-6579	University of Physical Education in Krakow [104/MN/KK/2017]	University of Physical Education in Krakow	The study was funded by University of Physical Education in Krakow (grant no. 104/MN/KK/2017).	Banffi G, 2008, BRIT J SPORT MED, V42, P858; Gallagher D, 2000, AM J CLIN NUTR, V72, P694, DOI 10.1093/ajcn/72.3.694; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Lombardi G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055803; Lubkowska A, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/803197; Lubkowska A, 2012, PHYSICAL THERAPY PERSPECTIVES IN THE 21ST CENTURY - CHALLENGES AND POSSIBILITIES, P155; Lubkowska A, 2010, EUR J APPL PHYSIOL, V109, P67, DOI 10.1007/s00421-009-1207-2; Lubkowska A, 2008, J THERM BIOL, V33, P464, DOI 10.1016/j.jtherbio.2008.08.003; Pilch W, 2021, REDOX REP, V26, P10, DOI 10.1080/13510002.2021.1881328; Pilch W, 2020, CRYOBIOLOGY, V94, P100, DOI 10.1016/j.cryobiol.2020.04.002; Pilch W, 2013, J HUM KINET, V39, P127, DOI 10.2478/hukin-2013-0075; Pournot H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022748; STANEK A, 2006, ACTA BIOOPT INFORM M, V12, P207; Straburzynska-Lupa A., 2007, FIZJOTERAPIA POL POL, V7, P15; Suresh Kp, 2012, J Hum Reprod Sci, V5, P7, DOI 10.4103/0974-1208.97779; Sutkowy P, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/402631; Szygula Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093096; WHO Consultation, 2000, WHO TECH REP SER, V894, P1; Wiecek M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092797; Ziemann E, 2014, EUR CYTOKINE NETW, V25, P14, DOI 10.1684/ecn.2014.0349; Ziemann E, 2013, J PHYSIOL SCI, V63, P333, DOI 10.1007/s12576-013-0269-4; Ziemann E, 2012, J ATHL TRAINING, V47, P664, DOI 10.4085/1062-6050-47.6.13; Zychowska M, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1685368	23	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0249812	10.1371/journal.pone.0249812	http://dx.doi.org/10.1371/journal.pone.0249812			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0DC	33886608	gold, Green Published			2023-01-03	WOS:000644138300023
J	Laupland, KB; Ramanan, M; Shekar, K; Edwards, F; Clement, P; Tabah, A				Laupland, Kevin B.; Ramanan, Mahesh; Shekar, Kiran; Edwards, Felicity; Clement, Pierre; Tabah, Alexis			Long-term outcome of prolonged critical illness: A multicentered study in North Brisbane, Australia	PLOS ONE			English	Article							PERSISTENT CRITICAL ILLNESS; CHARLSON COMORBIDITY INDEX; MECHANICAL VENTILATION; PROVENT SCORE; NEW-ZEALAND; MORTALITY; SURVIVAL; VALIDATION; MORBIDITY; MODEL	Background Although critical illness is usually of high acuity and short duration, some patients require prolonged management in intensive care units (ICU) and suffer long-term morbidity and mortality. Objective To describe the long-term survival and examine determinants of death among patients with prolonged ICU admission. Methods A retrospective cohort of adult Queensland residents admitted to ICUs for 14 days or longer in North Brisbane, Australia was assembled. Comorbid illnesses were classified using the Charlson definitions and all cause case fatality established using statewide vital statistics. Results During the study a total of 28,742 adult Queensland residents had first admissions to participating ICUs of which 1,157 (4.0%) had prolonged admissions for two weeks or longer. Patients with prolonged admissions included 645 (55.8%), 243 (21.0%), and 269 (23.3%) with ICU lengths of stay lasting 14-20, 21-27, and >= 28 days, respectively. Although the severity of illness at admission did not vary, pre-existing comorbid illnesses including myocardial infarction, congestive heart failure, kidney disease, and peptic ulcer disease were more frequent whereas cancer, cerebrovascular accidents, and plegia were less frequently observed among patients with increasing ICU lengths of stay lasting 14-20, 21-27, and >= 28 days. The ICU, hospital, 90-day, and one-year all cause case-fatality rates were 12.7%, 18.5%, 20.2%, and 24.9%, respectively, and were not different according to duration of ICU stay. The median duration of observation was 1,037 (interquartile range, 214-1888) days. Although comorbidity, age, and admitting diagnosis were significant, neither ICU duration of stay nor severity of illness at admission were associated with overall survival outcome in a multivariable Cox regression model. Conclusions Most patients with prolonged stays in our ICUs are alive at one year post-admission. Older age and previous comorbidities, but not severity of illness or duration of ICU stay, are associated with adverse long-term mortality outcome.	[Laupland, Kevin B.; Clement, Pierre] Royal Brisbane & Womens Hosp, Dept Intens Care Serv, Brisbane, Qld, Australia; [Laupland, Kevin B.; Edwards, Felicity] Queensland Univ Technol QUT, Brisbane, Qld, Australia; [Ramanan, Mahesh; Shekar, Kiran; Tabah, Alexis] Univ Queensland, Fac Med, Brisbane, Qld, Australia; [Ramanan, Mahesh] Caboolture Hosp, Intens Care Unit, Caboolture, Qld, Australia; [Shekar, Kiran] Prince Charles Hosp, Intens Care Unit, Brisbane, Qld, Australia; [Tabah, Alexis] Redcliffe Hosp, Intens Care Unit, Redcliffe, Qld, Australia	Royal Brisbane & Women's Hospital; Queensland University of Technology (QUT); University of Queensland; Prince Charles Hospital	Laupland, KB (corresponding author), Royal Brisbane & Womens Hosp, Dept Intens Care Serv, Brisbane, Qld, Australia.; Laupland, KB (corresponding author), Queensland Univ Technol QUT, Brisbane, Qld, Australia.	Kevin.laupland@qut.edu.au	; Tabah, Alexis/B-6982-2014	Laupland, kevin/0000-0002-1205-5354; Ramanan, Mahesh/0000-0003-4509-4015; Shekar, Kiran/0000-0002-1239-7514; Tabah, Alexis/0000-0003-3513-2778	Queensland University of Technology (QUT)	Queensland University of Technology (QUT)	This study was supported by a grant from the Queensland University of Technology (QUT) awarded to KL https://www.qut.edu.au.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], Hospitals and Services, Metro North Hospital and Health Service.; [Anonymous], QUEENSLAND HLTH DEAT; ANZICS, CTR OUTC RES EV AD P; Bagshaw SM, 2018, INTENS CARE MED, V44, P2134, DOI 10.1007/s00134-018-5440-1; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Combes A, 2003, CRIT CARE MED, V31, P1373, DOI 10.1097/01.CCM.0000065188.87029.C3; COMET (Core Outcome Measurement and Evaluation To, ANZICS; Damuth E, 2015, LANCET RESP MED, V3, P544, DOI 10.1016/S2213-2600(15)00150-2; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Garland A, 2015, ANN AM THORAC SOC, V12, P202, DOI 10.1513/AnnalsATS.201405-201CME; Guidry CA, 2017, SURG INFECT, V18, P664, DOI 10.1089/sur.2016.269; Hough CL, 2015, CRIT CARE MED, V43, P2339, DOI 10.1097/CCM.0000000000001205; Iwashyna TJ, 2016, LANCET RESP MED, V4, P566, DOI 10.1016/S2213-2600(16)30098-4; Iwashyna TJ, 2015, CRIT CARE RESUSC, V17, P153; Jaiswal S, 2012, J Nepal Health Res Counc, V10, P47; Laupland KB, 2006, CHEST, V129, P954, DOI 10.1378/chest.129.4.954; Laupland KB, 2019, CLIN EPIDEMIOL, V11, P47, DOI 10.2147/CLEP.S187381; Li B, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-12; Major Diagnostic Categories (MDC), AUSTR I HLTH WELF; Mok JH, 2016, J CRIT CARE, V33, P158, DOI 10.1016/j.jcrc.2016.02.017; Pintado MC, 2016, MED INTENSIVA, V40, P289, DOI 10.1016/j.medin.2015.08.002; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Roedl K, 2019, EUR J INTERN MED, V69, P71, DOI 10.1016/j.ejim.2019.08.024; Shaw Martin, 2020, Crit Care Explor, V2, pe0102, DOI 10.1097/CCE.0000000000000102; Stanley J, 2017, J CLIN EPIDEMIOL, V92, P99, DOI 10.1016/j.jclinepi.2017.08.005; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Udeh CI, 2015, ANN AM THORAC SOC, V12, P1845, DOI 10.1513/AnnalsATS.201504-200OC; Williams TA, 2008, CRIT CARE MED, V36, P1523, DOI 10.1097/CCM.0b013e318170a405	28	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2021	16	4							e0249840	10.1371/journal.pone.0249840	http://dx.doi.org/10.1371/journal.pone.0249840			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM0NQ	33831072	Green Published, gold			2023-01-03	WOS:000639359600071
J	Gaudry, S; Hajage, D; Martin-Lefevre, L; Lebbah, S; Louis, G; Moschietto, S; Titeca-Beauport, D; La Combe, B; Pons, B; de Prost, N; Besset, S; Combes, A; Robine, A; Beuzelin, M; Badie, J; Chevrel, G; Bohe, J; Coupez, E; Chudeau, N; Barbar, S; Vinsonneau, C; Forel, JM; Thevenin, D; Boulet, E; Lakhal, K; Aissaoui, N; Grange, S; Leone, M; Lacave, G; Nseir, S; Poirson, F; Mayaux, J; Asehnoune, K; Geri, G; Klouche, K; Thiery, G; Argaud, L; Rozec, B; Cadoz, C; Andreu, P; Reignier, J; Ricard, JD; Quenot, JP; Dreyfuss, D				Gaudry, Stephane; Hajage, David; Martin-Lefevre, Laurent; Lebbah, Said; Louis, Guillaume; Moschietto, Sebastien; Titeca-Beauport, Dimitri; La Combe, Beatrice; Pons, Bertrand; de Prost, Nicolas; Besset, Sebastien; Combes, Alain; Robine, Adrien; Beuzelin, Marion; Badie, Julio; Chevrel, Guillaume; Bohe, Julien; Coupez, Elisabeth; Chudeau, Nicolas; Barbar, Saber; Vinsonneau, Christophe; Forel, Jean-Marie; Thevenin, Didier; Boulet, Eric; Lakhal, Karim; Aissaoui, Nadia; Grange, Steven; Leone, Marc; Lacave, Guillaume; Nseir, Saad; Poirson, Florent; Mayaux, Julien; Asehnoune, Karim; Geri, Guillaume; Klouche, Kada; Thiery, Guillaume; Argaud, Laurent; Rozec, Bertrand; Cadoz, Cyril; Andreu, Pascal; Reignier, Jean; Ricard, Jean-Damien; Quenot, Jean-Pierre; Dreyfuss, Didier			Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trail	LANCET			English	Article							PATIENT	Background Delaying renal replacement therapy (RRT) for some time in critically ill patients with severe acute kidney injury and no severe complication is safe and allows optimisation of the use of medical devices. Major uncertainty remains concerning the duration for which RRT can be postponed without risk. Our aim was to test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy. Methods This was an unmasked, multicentre, prospective, open-label, randomised, controlled trial done in 39 intensive care units in France. We monitored critically ill patients with severe acute kidney injury (defined as Kidney Disease: Improving Global Outcomes stage 3) until they had oliguria for more than 72 h or a blood urea nitrogen concentration higher than 112 mg/dL Patients were then randomly assigned (1:1) to either a strategy (delayed strategy) in which RRT was started just after randomisation or to a more-delayed strategy. With the more-delayed strategy, RRT initiation was postponed until mandatory indication (noticeable hyperkalaemia or metabolic acidosis or pulmonary oedema) or until blood urea nitrogen concentration reached 140 mg/dL The primary outcome was the number of days alive and free of RRT between randomisation and day 28 and was done in the intention-to-treat population. The study is registered with ClinicalTriaLgov, NCT03396757 and is completed. Findings Between May 7, 2018, and Oct 11, 2019, of 5336 patients assessed, 278 patients underwent randomisation; 137 were assigned to the delayed strategy and 141 to the more-delayed strategy. The number of complications potentially related to acute kidney injury or to RRT were similar between groups. The median number of RRT-free days was 12 days (IQR 0-25) in the delayed strategy and 10 days (IQR 0-24) in the more-delayed strategy (p.O.93). In a multivariable analysis, the hazard ratio for death at 60 days was 1.65 (95% CI 1.09-2.50, p=0.018) with the moredelayed versus the delayed strategy. The number of complications potentially related to acute kidney injury or renal replacement therapy did not differ between groups. Interpretation In severe acute kidney injury patients with oliguria for more than 72 h or blood urea nitrogen concentration higher than 112 mg/dL and no severe complication that would mandate immediate RRT, longer postponing of RRT initiation did not confer additional benefit and was associated with potential harm. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Gaudry, Stephane; Poirson, Florent] Hop Avicenne, AP HP, Dept Reanimat Med Chirurg, Bobigny, France; [Gaudry, Stephane] Univ Sorbonne Paris Nord, HealthCare Simulat Ctr, UFR SMBH, Bobigny, France; [Gaudry, Stephane; Dreyfuss, Didier] Sorbonne Univ, Common & Rare Kidney Dis, INSERM, UMR S 1155, Paris, France; [Gaudry, Stephane] Invest Network Initiat Cardiovasc & Renal Clin Tr, Bobigny, France; [Hajage, David; Lebbah, Said] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, Hop Pitie Salpetriere, AP HP,INSERM,Dept Sante Publ,Ctr Pharmacoepidemio, Paris, France; [Combes, Alain] Sorbonne Univ, Hop Pitie Salpetriere, Serv Reanimat Med, Paris, France; [Mayaux, Julien] Sorbonne Univ, Hop Pitie Salpetriere, Pneumol & Reanimat Med, Paris, France; [Martin-Lefevre, Laurent] CHR Dept La Roche Sur Yon, Reanimat Polyvalente, La Roche SurYon, France; [Louis, Guillaume; Cadoz, Cyril] CHR Metz Thionville Hop Mercy, Reanimat Polyvalente, Metz, France; [Moschietto, Sebastien] CHG Avignon Henri Duffaut, Reanimat Polyvalente, Avignon, France; [Titeca-Beauport, Dimitri] CHU Amiens Picardie, Reanimat Med, Amiens, France; [La Combe, Beatrice] CH Bretagne Sud, Reanimat, Lorient, France; [Pons, Bertrand] CHU Pointe A Pitre Abymes, Reanimat, Pointe A Pitre, France; [de Prost, Nicolas] Hop Henri Mondor, Reanimat Med, Creteil, France; [Besset, Sebastien; Ricard, Jean-Damien; Dreyfuss, Didier] Univ Paris, Hop Louis Mourier, AP HP, ESPRIT,Med Intens Reanimat, Colombes, France; [Robine, Adrien] CH Bourg En Bresse Fleyriat, Reanimat Soins Continus, F-01012 Bourg En Bresse, France; [Beuzelin, Marion] CH Dieppe, Reanimat Polyvalente, Dieppe, France; [Badie, Julio] CH Belfort, Hop Nord Franche Comte, Reanimat Polyvalente, Belfort, France; [Chevrel, Guillaume] CH Sud Francilien, Reanimat Polyvalente, Corbeil Essonnes, France; [Bohe, Julien] CH Lyon Sud, Anesthesie Reanimat Med & Chirurg, Pierre Benite, France; [Coupez, Elisabeth] Hop G Montpied, Reanimat Polyvalente, Clermont Ferrand, France; [Chudeau, Nicolas] CH Mans, Reanimat Med Chirurg, Le Mans, France; [Barbar, Saber] Hop Caremeau, Reanimat, Nimes, France; [Vinsonneau, Christophe] CH Bethune Beuvry Bermont & Gauthier, Reanimat, Bethune, France; [Vinsonneau, Christophe] CH Bethune Beuvry Bermont & Gauthier, USC, Bethune, France; [Forel, Jean-Marie] Hop Nord Marseille, Reanimat Med, Marseille, France; [Thevenin, Didier] CH Dr Schaffner, Reanimat, Lens, France; [Thevenin, Didier] CH Dr Schaffner, USC, Lens, France; [Boulet, Eric] GH Carnelle Portes de IOise, Reanimat, Beaumont, TX, France; [Boulet, Eric] GH Carnelle Portes de IOise, USC, Beaumont, TX, France; [Lakhal, Karim] Hop Nord Iaennec, Reanimat Chirurg Polyvalente, Nantes, France; [Aissaoui, Nadia] Hop Georges Pompidou, Reanimat Med, Paris, France; [Grange, Steven] CHU Rouen, Reanimat Med, Rouen, France; [Leone, Marc] Hop Nord Marseille, Anesthesie Reanimat, Marseille, France; [Lacave, Guillaume] Hop Andre Mignot, Reanimat Med Chirurg, Versailles, France; [Nseir, Saad] CHRU Lille, Hop Roger Salengro, Reanimat Med, Lille, France; [Asehnoune, Karim] Hop Hotel Dieu, Anesthesie Reanimat, Nantes, France; [Andreu, Pascal; Reignier, Jean] Hop Hotel Dieu, Med Intens Reanimat, Nantes, France; [Geri, Guillaume] Hop Ambroise Pare, Reanimat Med Chirurg, Boulogne, France; [Klouche, Kada] Hop Lapeyronnie, Med Intens Reanimat, Montpellier, France; [Thiery, Guillaume] CHU St Etienne, Reanimat Med, St Priest En Jarez, France; [Argaud, Laurent] Hop Edouard Herriot, Reanimat Med, Lyon, France; [Rozec, Bertrand] Hop Nord Iaennec, Reanimat CTCV, Nantes, France; [Quenot, Jean-Pierre] Francois Mitterrand Univ Hosp, Dept Intens Care, Dijon, France; [Ricard, Jean-Damien] INSERM, IAME, U1137, Paris, France; [Quenot, Jean-Pierre] Univ Burgundy, Lipness Team, INSERM Res Ctr LNC UMR1231, Dijon, France; [Quenot, Jean-Pierre] Univ Burgundy, LabExLipSTIC, Dijon, France; [Quenot, Jean-Pierre] Univ Burgundy, Clin Epidemiol, INSERM CIC 1432, Dijon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHR Metz-Thionville; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; CHU Guadeloupe; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Sud Francilien; CHU Lyon; CHU Clermont Ferrand; Centre Hospitalier Le Mans; Universite de Montpellier; CHU de Nimes; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Rouen; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre Hospitalier de Versailles; Universite de Lille - ISITE; CHU Lille; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Universite de Montpellier; CHU de Montpellier; CHU de St Etienne; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Dreyfuss, D (corresponding author), Univ Paris, Hop Louis, AP HP, DMU ESPRIT,Med Intens Reanimat, Colombes, France.	didier.dreyfuss@aphp.fr	Carmen, Team3/Y-7384-2019; Leone, Marc/P-4835-2016; Hajage, David/D-5226-2014	Carmen, Team3/0000-0002-3614-0924; Leone, Marc/0000-0002-3097-758X; Hajage, David/0000-0002-8475-4090; Louis, Guillaume/0000-0002-4208-8122; Barbar, Saber Davide/0000-0002-5089-8088; QUENOT, Jean-Pierre/0000-0003-2351-682X; TITECA BEAUPORT, dimitri/0000-0003-2514-4193; Lab, Carmen/0000-0002-5935-3236	Programme Hospitalier de Recherche Clinique	Programme Hospitalier de Recherche Clinique	Programme Hospitalier de Recherche Clinique.	Aribisala BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080386; Asfar P, 2014, NEW ENGL J MED, V370, P1583, DOI 10.1056/NEJMoa1312173; Barbar SD, 2018, NEW ENGL J MED, V379, P1431, DOI 10.1056/NEJMoa1803213; Brochard L, 2010, AM J RESP CRIT CARE, V181, P1128, DOI 10.1164/rccm.200711-1664ST; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Gaudry S, 2020, LANCET, V395, P1506, DOI 10.1016/S0140-6736(20)30531-6; Gaudry S, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3774-9; Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017; Gibney N, 2008, CLIN J AM SOC NEPHRO, V3, P876, DOI 10.2215/CJN.04871107; Goldfarb DS, 2020, CLIN J AM SOC NEPHRO, V15, P880, DOI 10.2215/CJN.05180420; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7; Ioannidis JPA, 2016, J CLIN EPIDEMIOL, V73, P82, DOI 10.1016/j.jclinepi.2016.02.012; Fayad AII, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010612.pub2; Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5; Nieuwenhuijs-Moeke GJ, 2020, LANCET, V395, P1465, DOI 10.1016/S0140-6736(20)30805-9; Rahman A, 2016, CLIN NUTR, V35, P158, DOI 10.1016/j.clnu.2015.01.015; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; The STARRT-AKI Investigators, 2020, NEW ENGL J MED, V383, P240; Vinsonneau C, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0093-5; Wald R, 2015, KIDNEY INT, V88, P897, DOI 10.1038/ki.2015.184; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP; Zarbock A, 2016, JAMA-J AM MED ASSOC, V315, P2190, DOI 10.1001/jama.2016.5828	24	40	43	7	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2021	397	10281					1293	1300						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH2ZM	33812488	Green Submitted			2023-01-03	WOS:000636093400026
J	Pfister, D; Nunez, NG; Pinyol, R; Govaere, O; Pinter, M; Szydlowska, M; Gupta, R; Qiu, MJ; Deczkowska, A; Weiner, A; Muller, F; Sinha, A; Friebel, E; Engleitner, T; Lenggenhager, D; Moncsek, A; Heide, D; Stirm, K; Kosla, J; Kotsiliti, E; Leone, V; Dudek, M; Yousuf, S; Inverso, D; Singh, I; Teijeiro, A; Castet, F; Montironi, C; Haber, PK; Tiniakos, D; Bedossa, P; Cockell, S; Younes, R; Vacca, M; Marra, F; Schattenberg, JM; Allison, M; Bugianesi, E; Ratziu, V; Pressiani, T; D'Alessio, A; Personeni, N; Rimassa, L; Daly, AK; Scheiner, B; Pomej, K; Kirstein, MM; Vogel, A; Peck-Radosavljevic, M; Hucke, F; Finkelmeier, F; Waidmann, O; Trojan, J; Schulze, K; Wege, H; Koch, S; Weinmann, A; Bueter, M; Rossler, F; Siebenhuner, A; De Dosso, S; Mallm, JP; Umansky, V; Jugold, M; Luedde, T; Schietinger, A; Schirmacher, P; Emu, B; Augustin, HG; Billeter, A; Muller-Stich, B; Kikuchi, H; Duda, DG; Kutting, F; Waldschmidt, DT; Ebert, MP; Rahbari, N; Mei, HRE; Schulz, AR; Ringelhan, M; Malek, N; Spahn, S; Bitzer, M; de Galarreta, MR; Lujambio, A; Dufour, JF; Marron, TU; Kaseb, A; Kudo, M; Huang, YH; Djouder, N; Wolter, K; Zender, L; Marche, PN; Decaens, T; Pinato, DJ; Rad, R; Mertens, JC; Weber, A; Unger, K; Meissner, F; Roth, S; Jilkova, ZM; Claassen, M; Anstee, QM; Amit, I; Knolle, P; Becher, B; Llovet, JM; Heikenwalder, M				Pfister, Dominik; Nunez, Nicolas Gonzalo; Pinyol, Roser; Govaere, Olivier; Pinter, Matthias; Szydlowska, Marta; Gupta, Revant; Qiu, Mengjie; Deczkowska, Aleksandra; Weiner, Assaf; Mueller, Florian; Sinha, Ankit; Friebel, Ekaterina; Engleitner, Thomas; Lenggenhager, Daniela; Moncsek, Anja; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; Leone, Valentina; Dudek, Michael; Yousuf, Suhail; Inverso, Donato; Singh, Indrabahadur; Teijeiro, Ana; Castet, Florian; Montironi, Carla; Haber, Philipp K.; Tiniakos, Dina; Bedossa, Pierre; Cockell, Simon; Younes, Ramy; Vacca, Michele; Marra, Fabio; Schattenberg, Jorn M.; Allison, Michael; Bugianesi, Elisabetta; Ratziu, Vlad; Pressiani, Tiziana; D'Alessio, Antonio; Personeni, Nicola; Rimassa, Lorenza; Daly, Ann K.; Scheiner, Bernhard; Pomej, Katharina; Kirstein, Martha M.; Vogel, Arndt; Peck-Radosavljevic, Markus; Hucke, Florian; Finkelmeier, Fabian; Waidmann, Oliver; Trojan, Jorg; Schulze, Kornelius; Wege, Henning; Koch, Sandra; Weinmann, Arndt; Bueter, Marco; Rossler, Fabian; Siebenhuner, Alexander; De Dosso, Sara; Mallm, Jan-Philipp; Umansky, Viktor; Jugold, Manfred; Luedde, Tom; Schietinger, Andrea; Schirmacher, Peter; Emu, Brinda; Augustin, Hellmut G.; Billeter, Adrian; Mueller-Stich, Beat; Kikuchi, Hiroto; Duda, Dan G.; Kutting, Fabian; Waldschmidt, Dirk-Thomas; Ebert, Matthias Philip; Rahbari, Nuh; Mei, Henrik E.; Schulz, Axel Ronald; Ringelhan, Marc; Malek, Nisar; Spahn, Stephan; Bitzer, Michael; Ruiz de Galarreta, Marina; Lujambio, Amaia; Dufour, Jean-Francois; Marron, Thomas U.; Kaseb, Ahmed; Kudo, Masatoshi; Huang, Yi-Hsiang; Djouder, Nabil; Wolter, Katharina; Zender, Lars; Marche, Parice N.; Decaens, Thomas; Pinato, David J.; Rad, Roland; Mertens, Joachim C.; Weber, Achim; Unger, Kristian; Meissner, Felix; Roth, Susanne; Jilkova, Zuzana Macek; Claassen, Manfred; Anstee, Quentin M.; Amit, Ido; Knolle, Percy; Becher, Burkhard; Llovet, Josep M.; Heikenwalder, Mathias			NASH limits anti-tumour surveillance in immunotherapy-treated HCC	NATURE			English	Article							ADVANCED HEPATOCELLULAR-CARCINOMA; LIVER-CANCER; NONALCOHOLIC STEATOHEPATITIS; PHASE-III; R PACKAGE; T-CELLS; RNA-SEQ; NAFLD	Hepatocellular carcinoma (HCC) can have viral or non-viral causes(1-5). Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need(6,7). Here we report the progressive accumulation of exhausted, unconventionally activated CD8(+)PD1(+) T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8(+)PD1(+) T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH-HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8(+)PD1(+)CXCR6(+), TOX+, and TNF+ T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8(+) T cells or TNF neutralization, suggesting that CD8(+) T cells help to induce NASH-HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8(+)PD1(+) T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH-HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.	[Pfister, Dominik; Szydlowska, Marta; Mueller, Florian; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; Leone, Valentina; Singh, Indrabahadur; Emu, Brinda; Heikenwalder, Mathias] German Canc Res Ctr, Div Chron Inflammat & Canc, Heidelberg, Germany; [Nunez, Nicolas Gonzalo; Friebel, Ekaterina; Becher, Burkhard] Univ Zurich, Inst Expt Immunol, Zurich, Switzerland; [Pinyol, Roser; Castet, Florian; Montironi, Carla; Llovet, Josep M.] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Liver Unit, Liver Canc Translat Res Lab,Hosp Clin, Barcelona, Spain; [Govaere, Olivier; Tiniakos, Dina; Bedossa, Pierre; Younes, Ramy; Daly, Ann K.; Anstee, Quentin M.] Newcastle Univ, Translat & Clin Res Inst, Fac Med Sci, Newcastle, England; [Pinter, Matthias; Scheiner, Bernhard; Pomej, Katharina] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria; [Pinter, Matthias; Scheiner, Bernhard; Pomej, Katharina] Med Univ Vienna, Liver Canc HCC Study Grp Vienna, Vienna, Austria; [Gupta, Revant; Claassen, Manfred] Univ Tubingen, Univ Tubingen Hosp, Internal Med 1, Fac Med, Tubingen, Germany; [Gupta, Revant; Claassen, Manfred] Univ Tubingen, Dept Comp Sci, Tubingen, Germany; [Qiu, Mengjie; Yousuf, Suhail; Roth, Susanne; Claassen, Manfred] Univ Klinikum Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany; [Deczkowska, Aleksandra; Weiner, Assaf; Amit, Ido] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel; [Sinha, Ankit; Meissner, Felix] Max Planck Inst Biochem, Expt Syst Immunol Lab, Munich, Germany; [Sinha, Ankit] Tech Univ Munich, Inst Translat Canc Res & Expt Canc Therapy, Klinikum Rechts Isar, Munich, Germany; [Engleitner, Thomas; Rad, Roland] Tech Univ Munich, Ctr Translat Canc Res TranslaTUM, Munich, Germany; [Engleitner, Thomas; Rad, Roland] Tech Univ Munich, Dept Med 2, Klinikum Rechts Isar, Munich, Germany; [Engleitner, Thomas; Rad, Roland] German Canc Res Ctr, German Canc Consortium DKTK, Munich, Germany; [Lenggenhager, Daniela; Weber, Achim; Unger, Kristian] Univ Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland; [Lenggenhager, Daniela; Weber, Achim; Unger, Kristian] Univ Hosp Zurich, Zurich, Switzerland; [Moncsek, Anja; Mertens, Joachim C.] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland; [Leone, Valentina] Helmholtz Zentrum Munich, Res Unit Radiat Cytogenet, Munich, Germany; [Dudek, Michael; Knolle, Percy] Tech Univ Munich, Inst Mol Immunol & Expt Oncol, Munich, Germany; [Inverso, Donato; Augustin, Hellmut G.] German Canc Res Ctr DKFZ ZMBH Alliance, Div Vasc Oncol & Metastasis, Heidelberg, Germany; [Inverso, Donato; Augustin, Hellmut G.] Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, Heidelberg, Germany; [Singh, Indrabahadur] German Canc Res Ctr, Div Chron Inflammat & Canc, Emmy Noether Res Grp Epigenet Machineries & Canc, Heidelberg, Germany; [Teijeiro, Ana; Djouder, Nabil] CNIO, Growth Factors Nutrients & Canc Grp, Spanish Natl Canc Res Ctr, Cell Biol Programme, Madrid, Spain; [Haber, Philipp K.; Ruiz de Galarreta, Marina; Lujambio, Amaia; Marron, Thomas U.; Llovet, Josep M.] Icahn Sch Med Mt Sinai, Div Liver Dis, Mt Sinai Liver Canc Program, New York, NY 10029 USA; [Tiniakos, Dina] Natl & Kapodistrian Univ Athens, Aretae Hospita, Dept Pathol, Athens, Greece; [Cockell, Simon] Newcastle Univ, Bioinformat Support Unit, Fac Med Sci, Newcastle, England; [Younes, Ramy; Bugianesi, Elisabetta] Univ Turin, Div Gastrohepatol, Dept Med Sci, AO Citta Salute & Sci Torino, Turn, Italy; [Vacca, Michele] Univ Cambridge, Wellcome MRC Inst Metab Sci, Addenbrookes Hosp, Metab Res Labs, Cambridge, England; [Marra, Fabio] Univ Florence, Dipartimento Med Sperimentale Clin, Florence, Italy; [Schattenberg, Jorn M.] Univ Med Ctr Mainz, Dept Med 1, Metab Liver Res Program, Mainz, Germany; [Allison, Michael] Cambridge Univ NHS Fdn Trust, Dept Med, Liver Unit, Cambridge Biomed Res Ctr, Cambridge, England; [Ratziu, Vlad] Univ Paris Diderot, Hop Beaujon, AP HP, Paris, France; [Pressiani, Tiziana; D'Alessio, Antonio; Personeni, Nicola; Rimassa, Lorenza] Humanitas Clin & Res Ctr IRCCS, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Milan, Italy; [Personeni, Nicola; Rimassa, Lorenza] Humanitas Univ, Dept Biomed Sci, Milan, Italy; [Kirstein, Martha M.; Vogel, Arndt] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany; [Kirstein, Martha M.] Univ Med Ctr Schleswig Holstein, Schleswig Holstein, Germany; [Peck-Radosavljevic, Markus; Hucke, Florian] Klinikum Klagenfurt Worthersee, Hepatol Endocrinol Rheumatol & Nephrol Including, Dept Internal Med & Gastroenterol IMuG, Klagenfurt, Austria; [Finkelmeier, Fabian; Waidmann, Oliver; Trojan, Jorg] Univ Hosp Frankfurt, Dept Gastroenterol Hepatol & Endocrinol, Frankfurt, Germany; [Schulze, Kornelius; Wege, Henning] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med Gastroenterol & Hepatol, Hamburg, Germany; [Koch, Sandra; Weinmann, Arndt] Johannes Gutenberg Univ Mainz, Dept Internal Med, Univ Med Ctr, Mainz, Germany; [Bueter, Marco; Rossler, Fabian] Univ Hosp Zurich, Dept Surg & Transplantat, Zurich, Switzerland; [Siebenhuner, Alexander] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland; [Siebenhuner, Alexander] Univ Zurich, Zurich, Switzerland; [De Dosso, Sara] Oncol Inst Southern Switzerland, Bellinzona, Switzerland; [Mallm, Jan-Philipp] German Canc Res Ctr, Div Chromatin Networks, Heidelberg, Germany; [Mallm, Jan-Philipp] Bioquant, Heidelberg, Germany; [Umansky, Viktor] German Canc Res Ctr, Clin Cooperat Unit Dermatooncol, Heidelberg, Germany; [Umansky, Viktor] Ruprecht Karl Univ Heidelberg, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Heidelberg, Germany; [Jugold, Manfred] German Canc Res Ctr Heidelberg, Core Facil Small Anim Imaging, Heidelberg, Germany; [Luedde, Tom] Heinrich Heine Univ, Med Fac, Dept Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany; [Schietinger, Andrea] Mem Sloan Kettering Canc Ctr, Immunol Program, 1275 York Ave, New York, NY 10021 USA; [Schietinger, Andrea] Weill Cornell Grad Sch Med Sci, Immunol & Microbial Pathogenesis Program, New York, NY USA; [Schirmacher, Peter] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Billeter, Adrian; Mueller-Stich, Beat] Heidelberg Univ Hosp, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany; [Kikuchi, Hiroto; Duda, Dan G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Labs Tumor Biol, Boston, MA 02114 USA; [Kutting, Fabian; Waldschmidt, Dirk-Thomas] Univ Cologne, Dept Gastroenterol & Hepatol, Cologne, Germany; [Ebert, Matthias Philip] Heidelberg Univ, Med Fac Mannheim, Dept Med 2, Heidelberg, Germany; [Rahbari, Nuh] Heidelberg Univ, Univ Hosp Mannheim, Med Fac Mannheim, Dept Surg, Heidelberg, Germany; [Mei, Henrik E.; Schulz, Axel Ronald] Leibniz Inst, Deutsch Rheumaforschungszentrum Berlin, Mass Cytometry Lab, Berlin, Germany; [Ringelhan, Marc] Tech Univ Munich, Helmholtz Zentrum Munich, Inst Virol, Munich, Germany; [Ringelhan, Marc] Tech Univ Munich, Univ Hosp Rechts Isar, Dept Internal Med 2, Munich, Germany; [Ringelhan, Marc] German Ctr Infect Res DZIF, Partner Site Munich, Munich, Germany; [Malek, Nisar; Spahn, Stephan; Bitzer, Michael] Med Univ Hosp, Dept Internal Med 1, Tubingen, Germany; [Ruiz de Galarreta, Marina; Lujambio, Amaia] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Lujambio, Amaia] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA; [Dufour, Jean-Francois] Univ Clin Visceral Surg & Med, Inselspital, Bern, Switzerland; [Dufour, Jean-Francois] Univ Bern, Dept Biomed Res, Hepatol, Bern, Switzerland; [Marron, Thomas U.] Mt Sinai Hosp, Dept Med, Div Hematol Oncol, Tisch Canc Inst, New York, NY 10029 USA; [Kaseb, Ahmed] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Kudo, Masatoshi] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan; [Huang, Yi-Hsiang] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan; [Huang, Yi-Hsiang] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Taipei, Taiwan; [Wolter, Katharina; Zender, Lars] Univ Hosp Tubingen, Dept Med Oncol & Pneumol Internal Med 8, Tubingen, Germany; [Wolter, Katharina; Zender, Lars] Eberhard Karls Univ Tubingen, Cluster Excellence Image Guided & Functionally In, Tubingen, Germany; [Zender, Lars] German Canc Res Ctr, German Consortium Translat Canc Res DKTK, Partner Site Tubingen, Tubingen, Germany; [Marche, Parice N.; Decaens, Thomas; Jilkova, Zuzana Macek] Univ Grenoble Alpes, Grenoble, France; [Decaens, Thomas; Jilkova, Zuzana Macek] CNRS 5309, INSERM, Inst Adv Biosci, Res Ctr UGA,U1209, Grenoble, France; [Marche, Parice N.; Decaens, Thomas] CHU Grenoble Alpes, Serv Hepatogastroenterol, Pole Digidune, Grenoble, France; [Pinato, David J.; Jilkova, Zuzana Macek] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London, England; [Pinato, David J.] Univ Piemonte Orientale, Dept Translat Med, Div Oncol, Novara, Italy; [Weber, Achim] Univ Zurich, Inst Mol Canc Res IMCR, Zurich, Switzerland; [Anstee, Quentin M.] Newcastle upon Tyne Hosp NHS Trust, Newcastle NIHR Biomed Res Ctr, Newcastle, England; [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain; [Pfister, Dominik] Novo Nordisk AS, Liver Dis Res, Global Drug Discovery, Malov, Denmark	Helmholtz Association; German Cancer Research Center (DKFZ); University of Zurich; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Newcastle University - UK; Medical University of Vienna; Medical University of Vienna; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Ruprecht Karls University Heidelberg; Weizmann Institute of Science; Max Planck Society; Technical University of Munich; Technical University of Munich; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Centro Nacional de Investigaciones Oncologicas (CNIO); Icahn School of Medicine at Mount Sinai; National & Kapodistrian University of Athens; Newcastle University - UK; University of Turin; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Florence; Johannes Gutenberg University of Mainz; University of Cambridge; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Humanitas University; Hannover Medical School; University of Kiel; Schleswig Holstein University Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Johannes Gutenberg University of Mainz; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; Institute of Oncology Research (IOR); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Heinrich Heine University Dusseldorf; Memorial Sloan Kettering Cancer Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Harvard University; Massachusetts General Hospital; University of Cologne; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Deutsches Rheuma-Forschungszentrum (DRFZ); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich; German Center for Infection Research; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Bern; University Hospital of Bern; University of Bern; Icahn School of Medicine at Mount Sinai; University of Texas System; UTMD Anderson Cancer Center; Kindai University (Kinki University); National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Imperial College London; University of Eastern Piedmont Amedeo Avogadro; University of Zurich; Newcastle Upon Tyne Hospitals NHS Foundation Trust; ICREA; Novo Nordisk	Heikenwalder, M (corresponding author), German Canc Res Ctr, Div Chron Inflammat & Canc, Heidelberg, Germany.; Llovet, JM (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Liver Unit, Liver Canc Translat Res Lab,Hosp Clin, Barcelona, Spain.; Llovet, JM (corresponding author), Icahn Sch Med Mt Sinai, Div Liver Dis, Mt Sinai Liver Canc Program, New York, NY 10029 USA.; Llovet, JM (corresponding author), Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain.	jmllovet@clinic.cat; m.heikenwaelder@dkfz-heidelberg.de	Llovet, Josep M/ABB-6264-2021; Pfister, Dominik/AAK-7358-2021; Pressiani, Tiziana/HDN-8476-2022; Luedde, Tom/AAE-9135-2022; Rimassa, Lorenza/N-4884-2016; Inverso, Donato/AAA-5387-2022; Singh, Indrabahadur/R-7844-2016; Schattenberg, Jörn M./C-1301-2013; Llovet, Josep M/D-4340-2014; Duda, Dan G/H-8523-2014; Anstee, Quentin M./L-2981-2013; Govaere, Olivier/R-9372-2019; Friebel, Ekaterina/ABF-1308-2021; Weinmann, Arndt/X-7935-2019; Inverso, Donato/GOV-7283-2022; Macek Jílková, Zuzana/N-4051-2014; Marche, Patrice/K-5060-2013; Meissner, Felix/C-8767-2015; Vacca, Michele/B-4736-2013	Llovet, Josep M/0000-0003-0547-2667; Pfister, Dominik/0000-0002-0542-2638; Pressiani, Tiziana/0000-0001-6919-1536; Luedde, Tom/0000-0002-6288-8821; Rimassa, Lorenza/0000-0001-9957-3615; Schattenberg, Jörn M./0000-0002-4224-4703; Llovet, Josep M/0000-0003-0547-2667; Duda, Dan G/0000-0001-7065-8797; Anstee, Quentin M./0000-0002-9518-0088; Govaere, Olivier/0000-0002-4426-6930; Friebel, Ekaterina/0000-0003-1419-2376; Weinmann, Arndt/0000-0003-1198-1716; Macek Jílková, Zuzana/0000-0002-2553-5971; Marche, Patrice/0000-0002-8930-9340; Meissner, Felix/0000-0003-1000-7989; Daly, Ann/0000-0002-7321-0629; Singh, Indrabahadur/0000-0002-1474-7928; Personeni, Nicola/0000-0002-7995-272X; Castet, Florian/0000-0002-5416-5383; Bitzer, Michael/0000-0002-4463-8263; Nunez, Nicolas/0000-0003-3837-270X; Mallm, Jan-Philipp/0000-0002-7059-4030; D'Alessio, Antonio/0000-0002-9164-3671; Pinato, David James/0000-0002-3529-0103; Vacca, Michele/0000-0002-1973-224X; Vogel, Arndt/0000-0003-0560-5538; Scheiner, Bernhard/0000-0002-4904-5133; Montironi, Carla/0000-0002-1453-2193; Gupta, Revant/0000-0002-0881-5074; Muller-Stich, Beat Peter/0000-0002-8552-8538; Teijeiro, Ana/0000-0003-2276-7950; Ratziu, Vlad/0000-0002-6865-3791; Pinyol, Roser/0000-0002-0288-6314; Szydlowska, Marta/0000-0002-4660-899X; Ringelhan, Marc/0000-0003-3131-5657	'Deutsche Forschungsgemeinschaft' (DFG, Bonn Germany) through Emmy Noether program [SI 2620/1-1]; EMBO LT fellowship [ALTF 539-2018]; EPoS (Elucidating Pathways of Steatohepatitis) consortium - Horizon 2020 Framework Program of the European Union [634413]; LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium - Innovative Medicines Initiative (IMI2) Program of the European Union [777377]; Newcastle NIHR Biomedical Research Centre; Chan Zuckerberg Initiative (CZI); HHMI international scholar award; European Research Council consolidator grant (ERC-COG) [724471-HemTree2.0]; Thompson Family Foundation; MRA established investigator award [509044]; Israel Science Foundation [703/15]; Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine; Helen and Martin Kimmel award for innovative investigation; NeuroMac DFG/Transregional Collaborative Research Center grant; Adelis Foundation; SCA award of the Wolfson Foundation; Cancer Research UK [C9380/A26813, C57701/A26137]; Fondazione AIRC [C9380/A26813]; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (HUNTER) [C9380/A26813]; European Commission (EC)/Horizon 2020 Program (HEPCAR) [667273-2]; US Department of Defense [CA150272P3]; NCI Cancer Center Support Grant; Tisch Cancer Institute [P30-CA196521]; Samuel Waxman Cancer Research Foundation; Spanish National Health Institute [SAF2016-76390, PID2019-105378RB-I00]; Generalitat de Catalunya/AGAUR [SGR-1358]; HEPCAR; Rio Hortega grant from the ISCIII [CM19/00039]; European Social Fund; AECC; Swiss National Science Foundation (SNF); ERC Consolidator grant (HepatoMetaboPath); Wilhelm Sander-Stiftung; Research Foundation Flanders (FWO) [30826052]; Deutsche Krebshilfe projects [70113166, 70113167]; German-Israeli Cooperation in Cancer Research (DKFZ-MOST); Helmholtz-Gemeinschaft, Zukunftsthema 'Immunology and Inflammation' [ZT-0027]; German Research Foundation [HA 8754/1-1]; 'Deutsche Forschungsgemeinschaft' (DFG) [259332240/RTG 2099]; Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum (DKFZ); Israel's Ministry of Science, Technology and Space (MOST) [CA181]; Wellcome Trust Strategic Fund [PS3416]; ASCO/Conquer Cancer Foundation Global Oncology Young Investigator Award 2019 [14704]; Westminster Medical School Research Trust [JRC SG 009 2018-19]; German Cancer Aid [70113167, 70112720]; Swiss National Foundation; Swiss Foundation against Liver Cancer; DFG [Me3644/5-1]; Elke-Kroner-Fresenius foundation; Deutsche Forschungsgemeinschaft [FOR2314, SFB-TR209]; German Ministry for Education and Research (BMBF); DFG under Germany's excellence strategy [EXC 2180-390900677]; Landesstiftung Baden-Wuerttemberg; European Research Council (CholangioConcept); German Cancer Research Center (DKTK); Swiss National Science Foundation [733 310030_170320, 316030_150768, CRSII5_183478]; Swiss Cancer League; University Research Priority Program (URPP) postdoctoral fellowship; SNF Project Grant [310030 182679]; Canica Holding Research Grant; Norwegian PSC Research Center; Stiftung zur Krebsbekampfung; Bangerter-Rhyner Stiftung; Dangel Stiftung; Helmholtz Future topic Inflammation and Immunology; BMBF [031B0686B]; International Progressive MS Alliance/NMSS [PA-1604-08459]; National Cancer Institute; Rainer Hoenig Stiftung; Horizon 2020 grant (Hepcar); CW+;  [SFB 1335];  [SFBTR179];  [272983813];  [SFB/TR 209];  [314905040];  [SFBTR1335];  [360372040]	'Deutsche Forschungsgemeinschaft' (DFG, Bonn Germany) through Emmy Noether program(German Research Foundation (DFG)); EMBO LT fellowship; EPoS (Elucidating Pathways of Steatohepatitis) consortium - Horizon 2020 Framework Program of the European Union; LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium - Innovative Medicines Initiative (IMI2) Program of the European Union; Newcastle NIHR Biomedical Research Centre; Chan Zuckerberg Initiative (CZI); HHMI international scholar award(Howard Hughes Medical Institute); European Research Council consolidator grant (ERC-COG); Thompson Family Foundation; MRA established investigator award; Israel Science Foundation(Israel Science Foundation); Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine; Helen and Martin Kimmel award for innovative investigation; NeuroMac DFG/Transregional Collaborative Research Center grant; Adelis Foundation; SCA award of the Wolfson Foundation; Cancer Research UK(Cancer Research UK); Fondazione AIRC(Fondazione AIRC per la ricerca sul cancro); Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (HUNTER); European Commission (EC)/Horizon 2020 Program (HEPCAR)(European Commission); US Department of Defense(United States Department of Defense); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Tisch Cancer Institute; Samuel Waxman Cancer Research Foundation; Spanish National Health Institute(Spanish Government); Generalitat de Catalunya/AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya); HEPCAR; Rio Hortega grant from the ISCIII; European Social Fund(European Social Fund (ESF)); AECC; Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); ERC Consolidator grant (HepatoMetaboPath); Wilhelm Sander-Stiftung; Research Foundation Flanders (FWO)(FWO); Deutsche Krebshilfe projects; German-Israeli Cooperation in Cancer Research (DKFZ-MOST); Helmholtz-Gemeinschaft, Zukunftsthema 'Immunology and Inflammation'; German Research Foundation(German Research Foundation (DFG)); 'Deutsche Forschungsgemeinschaft' (DFG)(German Research Foundation (DFG)); Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum (DKFZ); Israel's Ministry of Science, Technology and Space (MOST); Wellcome Trust Strategic Fund; ASCO/Conquer Cancer Foundation Global Oncology Young Investigator Award 2019; Westminster Medical School Research Trust; German Cancer Aid(Deutsche Krebshilfe); Swiss National Foundation(Swiss National Science Foundation (SNSF)); Swiss Foundation against Liver Cancer; DFG(German Research Foundation (DFG)); Elke-Kroner-Fresenius foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); DFG under Germany's excellence strategy(German Research Foundation (DFG)); Landesstiftung Baden-Wuerttemberg; European Research Council (CholangioConcept); German Cancer Research Center (DKTK); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; University Research Priority Program (URPP) postdoctoral fellowship; SNF Project Grant; Canica Holding Research Grant; Norwegian PSC Research Center; Stiftung zur Krebsbekampfung; Bangerter-Rhyner Stiftung; Dangel Stiftung; Helmholtz Future topic Inflammation and Immunology; BMBF(Federal Ministry of Education & Research (BMBF)); International Progressive MS Alliance/NMSS; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Rainer Hoenig Stiftung; Horizon 2020 grant (Hepcar); CW+; ; ; ; ; ; ; 	We thank the Newcastle Molecular Pathology Node Proximity Laboratory for their technical support; P. Sinn for technical support; the DKFZ FACS core facility for support for sorting; G. Tiegs and K. Neumann for support with Pdcd1-/-mice; V. Eichwald for help with non-invasive imaging of mice; J. Schmid for help with human liver tissue sampling for flow cytometry; R. Ollinger for bulk sequencing support; A. Teufel for human cohort gathering; K. Inoue and Z. Ammozgar for help with the non-NASH mouse model; T. O'Connor, C. Groth, M. Matter, L. Terracciano, R. Kaeser, T. Boettler, R. Thimme, M. Yabal, T. Longerich and B. Mullhaupt for guidance and discussions; and S. Prokosch, U. Rothermel, J. Janzen, J. Hetzer, C. Gropp, S. Jung, L. Beideck, S. Torrecilla, K. E. Lindblad, E. Rist and T.-W. Kang for technical support. D. Pfister was supported by the Helmholtz Future topic Inflammation and Immunology. I.S. is funded by the `Deutsche Forschungsgemeinschaft' (DFG, Bonn Germany) through Emmy Noether program (SI 2620/1-1). A. Sinha is supported by EMBO LT fellowship ALTF 539-2018). F. Meissner is supported in this project by SFB 1335 and BMBF 031B0686B. Q.M.A., O.G., D.T., P.B., S.C., R.Y., M.V., F. Marra, J.M.S., M.A., E.B., V.R. and A.K.D. are supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413, the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the Innovative Medicines Initiative (IMI2) Program of the European Union under Grant Agreement 777377, and are collaborators in the European NAFLD Registry. Q.M.A. is also supported by the Newcastle NIHR Biomedical Research Centre. I.A. is supported by the Chan Zuckerberg Initiative (CZI), an HHMI international scholar award, European Research Council consolidator grant (ERC-COG) 724471-HemTree2.0, the Thompson Family Foundation, an MRA established investigator award (509044), the Israel Science Foundation (703/15), the Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine, a Helen and Martin Kimmel award for innovative investigation, a NeuroMac DFG/Transregional Collaborative Research Center grant, International Progressive MS Alliance/NMSS PA-1604-08459, an Adelis Foundation grant, and the SCA award of the Wolfson Foundation. I.A. is the incumbent of the Alan and Laraine Fischer Career Development Chair. A.D. is supported by Steven and Eden Romick. B.S. received travel support from AbbVie and Gilead. J.M.L. is supported through a partnership between Cancer Research UK, Fondazione AIRC, and Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (HUNTER, ref. C9380/A26813), by the European Commission (EC)/Horizon 2020 Program (HEPCAR, Ref. 667273-2), US Department of Defense (CA150272P3), NCI Cancer Center Support Grant, National Cancer Institute, Tisch Cancer Institute (P30-CA196521), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016-76390 and PID2019-105378RB-I00) and the Generalitat de Catalunya/AGAUR (SGR-1358). R.P. is supported by HEPCAR and AECC. C.M. is supported by a Rio Hortega grant (CM19/00039) from the ISCIII and the European Social Fund. F.C. is supported by grant funding from AECC. A. Weber is supported by a grant from the Swiss National Science Foundation (SNF). M.H.; r was supported by an ERC Consolidator grant (HepatoMetaboPath), SFBTR179 Project-ID 272983813, SFB/TR 209 Project-ID 314905040, SFBTR1335 Project-ID 360372040, the Wilhelm Sander-Stiftung, the Rainer Hoenig Stiftung, a Horizon 2020 grant (Hepcar), Research Foundation Flanders (FWO) under grant 30826052 (EOS Convention MODEL-IDI), Deutsche Krebshilfe projects 70113166 and 70113167, German-Israeli Cooperation in Cancer Research (DKFZ-MOST) and the Helmholtz-Gemeinschaft, Zukunftsthema `Immunology and Inflammation' (ZT-0027). P.K.H. is supported by the fellowship grant of the German Research Foundation (HA 8754/1-1). V.U. is supported by the `Deutsche Forschungsgemeinschaft' (DFG; 259332240/RTG 2099) and Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum (DKFZ) and Israel's Ministry of Science, Technology and Space (MOST) (CA181). D.J.P. is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416), ASCO/Conquer Cancer Foundation Global Oncology Young Investigator Award 2019 (14704), Cancer Research UK (C57701/A26137), CW+ and the Westminster Medical School Research Trust (JRC SG 009 2018-19) and received infrastructural support from the Imperial Experimental Cancer Medicine Centre, Cancer Research UK Imperial Centre, the Imperial College Healthcare NHS Trust Tissue Bank and the Imperial College BRC. M.Q., S.Y. and S.R. were supported by German Cancer Aid grants (70112720 and 70113167). J.-F.D. is supported by the Swiss National Foundation and the Swiss Foundation against Liver Cancer. H.E.M. and A.R.S. received support from DFG Me3644/5-1 and the Elke-Kroner-Fresenius foundation. This work was supported by the Deutsche Forschungsgemeinschaft (FOR2314, SFB-TR209, Gottfried Wilhelm Leibniz Program) and the German Ministry for Education and Research (BMBF). Further funding was provided by the DFG under Germany's excellence strategy EXC 2180-390900677 (Image Guided and Functionally Instructed Tumour Therapies (iFIT)), the Landesstiftung Baden-Wuerttemberg, the European Research Council (CholangioConcept) and the German Cancer Research Center (DKTK). B.B., N.G.N. and E.F. are supported by the Swiss National Science Foundation (grants 733 310030_170320, 316030_150768 and CRSII5_183478) and the Swiss Cancer League. N.G.N. is a recipient of a University Research Priority Program (URPP) postdoctoral fellowship. J.-P.M. is supported by SNF Project Grant 310030 182679, Canica Holding Research Grant, Norwegian PSC Research Center, Stiftung zur Krebsbekampfung, Bangerter-Rhyner Stiftung, Dangel Stiftung.	Anstee QM, 2019, NAT REV GASTRO HEPAT, V16, P411, DOI 10.1038/s41575-019-0145-7; Baran Y, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1812-2; Bergen V, 2020, NAT BIOTECHNOL, V38, DOI 10.1038/s41587-020-0591-3; Blighe K., 2018, ENHANCEDVOLCANO PUBL; Brummelman J, 2019, NAT PROTOC, V14, P1946, DOI 10.1038/s41596-019-0166-2; Carlson CM, 2005, P NATL ACAD SCI USA, V102, P17059, DOI 10.1073/pnas.0502974102; Chevrier S, 2018, CELL SYST, V6, P612, DOI 10.1016/j.cels.2018.02.010; Chung AS, 2020, CANCER PREV RES, V13, P911, DOI 10.1158/1940-6207.CAPR-20-0200; DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dudek M, 2021, NATURE, V592, DOI 10.1038/s41586-021-03233-8; Duffy AG, 2017, J HEPATOL, V66, P545, DOI 10.1016/j.jhep.2016.10.029; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; European Assoc Study Liver, 2018, J HEPATOL, V69, P154, DOI 10.1016/j.jhep.2018.03.018; Fessas P, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001033; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Finn RS, 2020, J CLIN ONCOL, V38, P193, DOI 10.1200/JCO.19.01307; Friedman SL, 2018, NAT MED, V24, P908, DOI 10.1038/s41591-018-0104-9; Govaere O, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aba4448; Hardy T, 2020, CONTEMP CLIN TRIALS, V98, DOI 10.1016/j.cct.2020.106175; Heinrich B, 2021, GASTROENTEROLOGY, V160, P331, DOI 10.1053/j.gastro.2020.09.031; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jaitin DA, 2014, SCIENCE, V343, P776, DOI 10.1126/science.1247651; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kerdiles YM, 2009, NAT IMMUNOL, V10, P176, DOI 10.1038/ni.1689; Kim CG, 2021, J HEPATOL, V74, DOI 10.1016/j.jhep.2020.08.010; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma C, 2016, NATURE, V531, P253, DOI 10.1038/nature16969; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Malehmir M, 2019, NAT MED, V25, P641, DOI 10.1038/s41591-019-0379-5; Mei HE, 2016, CYTOM PART A, V89A, P292, DOI 10.1002/cyto.a.22778; Mei HE, 2015, J IMMUNOL, V194, P2022, DOI 10.4049/jimmunol.1402661; Michelotti GA, 2013, NAT REV GASTRO HEPAT, V10, P656, DOI 10.1038/nrgastro.2013.183; Moeini A, 2019, GASTROENTEROLOGY, V157, P1383, DOI 10.1053/j.gastro.2019.07.028; Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Parekh S, 2016, SCI REP-UK, V6, DOI 10.1038/srep25533; Pinato DJ, 2020, CANCERS, V12, DOI 10.3390/cancers12071862; Pinter M, 2021, GUT, V70, P204, DOI 10.1136/gutjnl-2020-321702; Ringelhan M, 2018, NAT IMMUNOL, V19, P222, DOI 10.1038/s41590-018-0044-z; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roderburg C, 2020, HEPAT ONCOL, V7, DOI 10.2217/hep-2019-0007; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Sangro B, 2020, J HEPATOL, V73, P1460, DOI 10.1016/j.jhep.2020.07.026; Sangro B, 2013, J HEPATOL, V59, P81, DOI 10.1016/j.jhep.2013.02.022; Scheiner B, 2019, ALIMENT PHARM THER, V49, P1323, DOI 10.1111/apt.15245; Schulz AR, 2019, CYTOM PART A, V95A, P910, DOI 10.1002/cyto.a.23781; Shalapour S, 2017, NATURE, V551, P340, DOI 10.1038/nature24302; Shigeta K, 2020, HEPATOLOGY, V71, P1247, DOI 10.1002/hep.30889; Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor RS, 2020, GASTROENTEROLOGY, V158, P1611, DOI 10.1053/j.gastro.2020.01.043; Tummala KS, 2014, CANCER CELL, V26, P826, DOI 10.1016/j.ccell.2014.10.002; van der Leun AM, 2020, NAT REV CANCER, V20, P218, DOI 10.1038/s41568-019-0235-4; van der Poorten D, 2013, HEPATOLOGY, V57, P2180, DOI 10.1002/hep.26072; Veloza L, 2019, HISTOPATHOLOGY, V75, P799, DOI 10.1111/his.13857; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wang ZM, 2019, NAT MED, V25, P141, DOI 10.1038/s41591-018-0221-5; Wolf MJ, 2014, CANCER CELL, V26, P549, DOI 10.1016/j.ccell.2014.09.003; Yau T, 2019, ANN ONCOL, V30, P874; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zender L, 2005, COLD SH Q B, V70, P251, DOI 10.1101/sqb.2005.70.059; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6	68	162	162	31	51	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 15	2021	592	7854					450	456		10.1038/s41586-021-03362-0	http://dx.doi.org/10.1038/s41586-021-03362-0		MAR 2021	7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX5EB	33762733	Green Published, Green Submitted, Green Accepted, hybrid			2023-01-03	WOS:000632421900004
J	Paranjape, N; Staples, LL; Stradwick, CY; Ray, HG; Saldanha, IJ				Paranjape, Neha; Staples, Lauren L.; Stradwick, Christina Y.; Ray, Herman Gene; Saldanha, Ian J.			Development and validation of a predictive model for critical illness in adult patients requiring hospitalization for COVID-19	PLOS ONE			English	Article								Background Identifying factors that can predict severe disease in patients needing hospitalization for COVID-19 is crucial for early recognition of patients at greatest risk. Objective (1) Identify factors predicting intensive care unit (ICU) transfer and (2) develop a simple calculator for clinicians managing patients hospitalized with COVID-19. Methods A total of 2,685 patients with laboratory-confirmed COVID-19 admitted to a large metropolitan health system in Georgia, USA between March and July 2020 were included in the study. Seventy-five percent of patients were included in the training dataset (admitted March 1 to July 10). Through multivariable logistic regression, we developed a prediction model (probability score) for ICU transfer. Then, we validated the model by estimating its performance accuracy (area under the curve [AUC]) using data from the remaining 25% of patients (admitted July 11 to July 31). Results We included 2,014 and 671 patients in the training and validation datasets, respectively. Diabetes mellitus, coronary artery disease, chronic kidney disease, serum C-reactive protein, and serum lactate dehydrogenase were identified as significant risk factors for ICU transfer, and a prediction model was developed. The AUC was 0.752 for the training dataset and 0.769 for the validation dataset. We developed a free, web-based calculator to facilitate use of the prediction model (https://icucovid19.shinyapps.io/ICUCOVID19/). Conclusion Our validated, simple, and accessible prediction model and web-based calculator for ICU transfer may be useful in assisting healthcare providers in identifying hospitalized patients with COVID-19 who are at high risk for clinical deterioration. Triage of such patients for early aggressive treatment can impact clinical outcomes for this potentially deadly disease.	[Paranjape, Neha] Wellstar Med Grp, Dept Infect Dis, Marietta, GA 30060 USA; [Staples, Lauren L.; Stradwick, Christina Y.; Ray, Herman Gene] Kennesaw State Univ, Analyt & Data Sci Inst, Marietta, GA USA; [Saldanha, Ian J.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Ctr Evidence Synth Hlth, Providence, RI 02912 USA; [Saldanha, Ian J.] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02912 USA	University System of Georgia; Kennesaw State University; Brown University; Brown University	Paranjape, N (corresponding author), Wellstar Med Grp, Dept Infect Dis, Marietta, GA 30060 USA.	neha.paranjape@wellstar.org		Stradwick, Christina/0000-0002-1141-3148				Castro VM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.23934; CDC, COVID DAT TRACK; Centers for Disease Control and Prevention, 2020, EVIDENCE USED UPDATE; Centers for Disease Control and Prevention, 2020, COVID 19 HOSP DEATH, DOI [10.1007/s10903-020-01111-5, DOI 10.1007/S10903-020-01111-5]; Ciceri F, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108509; Collins Gary S., 2015, ANN INTERN MED; Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020; Henry BM, 2020, AM J EMERG MED, V38, P1722, DOI 10.1016/j.ajem.2020.05.073; Hu H, 2020, ACAD EMERG MED, V27, P461, DOI 10.1111/acem.13992; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Kiss Szabolcs, 2020, OBES REV; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; McKinney W., 2010, P 9 PYTH SCI C, V445, P51; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Sahu BR, 2020, CLIN CHIM ACTA, V509, P91, DOI 10.1016/j.cca.2020.06.013; Wellstar, 2019, COMMUNITY HLTH NEEDS; Zhang C, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00318; Zhao ZR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236618; Zhenga Zhaohai., 2020, J INFECTION; Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021	20	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2021	16	3							e0248891	10.1371/journal.pone.0248891	http://dx.doi.org/10.1371/journal.pone.0248891			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QZ9HS	33740030	gold, Green Published, Green Submitted			2023-01-03	WOS:000631030200040
J	Taylor, EP				Taylor, Emily Pinto			Somebody's Sunshine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								In this narrative medicine essay a geriatrics fellow describes the experience of preparing for and meeting her foster son and discusses her feelings of uncertainties that (mostly) melt away when sharing her new child's photo with a colleague the day after bringing him home.	[Taylor, Emily Pinto] Emory Univ, Sch Med, Atlanta, GA USA	Emory University	Taylor, EP (corresponding author), Emory Univ, Sch Med, Div Geriatr & Gerontol, 1841 Clifton Rd NE, Atlanta, GA 30329 USA.	epintotaylor@emory.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	2021	325	11					1045	1046		10.1001/jama.2021.1549	http://dx.doi.org/10.1001/jama.2021.1549			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ1BV	33724326				2023-01-03	WOS:000630471100015
J	Osborne, TF; Veigulis, ZP; Arreola, DM; Mahajan, SM; Roosli, E; Curtin, CM				Osborne, Thomas F.; Veigulis, Zachary P.; Arreola, David M.; Mahajan, Satish M.; Roosli, Eliane; Curtin, Catherine M.			Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration	PLOS ONE			English	Article								There is growing evidence that thrombotic and inflammatory pathways contribute to the severity of COVID-19. Common medications such as aspirin, that mitigate these pathways, may decrease COVID-19 mortality. This retrospective assessment was designed to quantify the correlation between pre-diagnosis aspirin and mortality for COVID-19 positive patients in our care. Data from the Veterans Health Administration national electronic health record database was utilized for the evaluation. Veterans from across the country with a first positive COVID-19 polymerase chain reaction lab result were included in the evaluation which comprised 35,370 patients from March 2, 2020 to September 13, 2020 for the 14-day mortality cohort and 32,836 patients from March 2, 2020 to August 28, 2020 for the 30-day mortality cohort. Patients were matched via propensity scores and the odds of mortality were then compared. Among COVID-19 positive Veterans, preexisting aspirin prescription was associated with a statistically and clinically significant decrease in overall mortality at 14-days (OR 0.38, 95% CI 0.32-0.46) and at 30-days (OR 0.38, 95% CI 0.33-0.45), cutting the odds of mortality by more than half. Findings demonstrated that pre-diagnosis aspirin prescription was strongly associated with decreased mortality rates for Veterans diagnosed with COVID-19. Prospective evaluation is required to more completely assess this correlation and its implications for patient care.	[Osborne, Thomas F.; Arreola, David M.; Mahajan, Satish M.; Curtin, Catherine M.] Palo Alto Healthcare Syst, US Dept Vet Affairs, Palo Alto, CA 94304 USA; [Osborne, Thomas F.] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA; [Veigulis, Zachary P.] Cent Iowa Hlth Care Syst, US Dept Vet Affairs, Des Moines, IA USA; [Roosli, Eliane] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Curtin, Catherine M.] Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; US Department of Veterans Affairs; Stanford University; Stanford University	Osborne, TF (corresponding author), Palo Alto Healthcare Syst, US Dept Vet Affairs, Palo Alto, CA 94304 USA.; Osborne, TF (corresponding author), Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA.	thomas.osborne@va.gov		Veigulis, Zachary/0000-0002-9026-1604; Roosli, Eliane/0000-0003-0557-6239; Osborne, Thomas/0000-0002-8896-2487; Curtin, Catherine/0000-0003-0850-9277				Albandar HJ, 2018, J GASTROINTEST ONCOL, V9, P1133, DOI 10.21037/jgo.2018.08.13; [Anonymous], 2020, WHO2019NCOVSCIBRIEFN; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Cheruiyot I, 2021, ANN VASC SURG, V70, P273, DOI 10.1016/j.avsg.2020.08.087; Chow JH, 2020, ASPIRIN USE IS ASS D; Diaz T, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.562708; Elgar FJ, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113365; Glatthaar-Saalmuller B, 2017, INFLUENZA OTHER RESP, V11, P85, DOI 10.1111/irv.12421; India State Level Disease Burden Initiative Road Injury Collaborators, 2020, LANCET PUBLIC HLTH, V5, pe86; Kizer KW, 2000, MED CARE, V38, pS7; Koupenova M, 2017, EUR HEART J, V38, P785, DOI 10.1093/eurheartj/ehw550; Li YN, 2020, STROKE VASC NEUROL, V5, P279, DOI 10.1136/svn-2020-000431; Little P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1185; Mohamed-Hussein AAR, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.109975; Osborne TF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236554; Pickett KE, 2015, SOC SCI MED, V128, P316, DOI 10.1016/j.socscimed.2014.12.031; Wang JZ, 2019, MAIN RESULTS REPORT; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Yan YL, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001343	19	44	47	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246825	10.1371/journal.pone.0246825	http://dx.doi.org/10.1371/journal.pone.0246825			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH4VJ	33571280	Green Published, gold, Green Submitted			2023-01-03	WOS:000618274000020
J	Qaseem, A; Yost, J; Etxeandia-Ikobaltzeta, I; Abraham, GM; Jokela, JA; Forciea, MA; Miller, MC; Humphrey, LL				Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Abraham, George M.; Jokela, Janet A.; Forciea, Mary Ann; Miller, Matthew C.; Humphrey, Linda L.		Amer Coll Phys	Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)	ANNALS OF INTERNAL MEDICINE			English	Article									[Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar] Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA; [Yost, Jennifer] Villanova Univ, 800 Lancaster Ave, Villanova, PA 19085 USA; [Abraham, George M.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Abraham, George M.] St Vincent Hosp, 123 Summer St,Suite 370 North, Worcester, MA 01604 USA; [Jokela, Janet A.] Univ Illinois, Coll Med Urbana Champaign, Champaign, IL 61820 USA; [Forciea, Mary Ann; Miller, Matthew C.] Penn Med, 3615 Chestnut St, Philadelphia, PA 19104 USA; [Humphrey, Linda L.] Portland VA Med Ctr, Portland, OR USA; [Humphrey, Linda L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Etxeandia-Ikobaltzeta, Itziar] 1 Santa Margarita Hosp St,Ground Floor 2,Off 1, Irun 20303, Gipuzkoa, Spain; [Jokela, Janet A.] Carle Forum, 611 West Pk, Urbana, IL 61801 USA; [Miller, Matthew C.] Penn Med Radnor, 145 King Prussia Rd, Radnor, PA 19087 USA; [Humphrey, Linda L.] 12310 Northwest Tualatin Ave, Portland, OR 97229 USA	American College of Physicians; Villanova University; University of Massachusetts System; University of Massachusetts Worcester; University of Illinois System; University of Illinois Urbana-Champaign; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.	aqaseem@acponline.org	ETXEANDIA-IKOBALTZETA, ITZIAR/AFK-4845-2022; ETXEANDIA-IKOBALTZETA, ITZIAR/AAG-3519-2022	ETXEANDIA-IKOBALTZETA, ITZIAR/0000-0001-6606-649X; ETXEANDIA-IKOBALTZETA, ITZIAR/0000-0001-6606-649X; Abraham, George/0000-0003-4296-8362; Yost, Jennifer/0000-0002-3170-1956; Miller, Matthew/0000-0001-7267-4897; Qaseem, Amir/0000-0001-6866-7985; Forciea, Mary Ann/0000-0002-1999-1145				Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Kaka AS, 2021, ANN INTERN MED, V174, P663, DOI 10.7326/M20-8148; Lexicomp, REMD DRUG INF; ODay D., 2020, STORIES GILEAD; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; U.S. Food& Drug Administration, FDA APPR 1 TREATM CO; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wilt TJ, 2021, ANN INTERN MED, V174, P209, DOI 10.7326/M20-5752; Wilt TJ, 2020, 09009 VA ESP HLTH SE	12	14	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY	2021	174	5					673	+		10.7326/M20-8101	http://dx.doi.org/10.7326/M20-8101		FEB 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SF2QB	33560862	Green Published			2023-01-03	WOS:000652604800026
J	Ebinger, M; Siegerink, B; Kunz, A; Wendt, M; Weber, JE; Schwabauer, E; Geisler, F; Freitag, E; Lange, J; Behrens, J; Erdur, H; Ganeshan, R; Liman, T; Scheitz, JF; Schlemm, L; Harmel, P; Zieschang, K; Lorenz-Meyer, I; Napierkowski, I; Waldschmidt, C; Nolte, CH; Grittner, U; Wiener, E; Bohner, G; Nabavi, DG; Schmehl, I; Ekkernkamp, A; Jungehulsing, GJ; Mackert, BM; Hartmann, A; Rohmann, JL; Endres, M; Audebert, HJ				Ebinger, Martin; Siegerink, Bob; Kunz, Alexander; Wendt, Matthias; Weber, Joachim E.; Schwabauer, Eugen; Geisler, Frederik; Freitag, Erik; Lange, Julia; Behrens, Janina; Erdur, Hebun; Ganeshan, Ramanan; Liman, Thomas; Scheitz, Jan F.; Schlemm, Ludwig; Harmel, Peter; Zieschang, Katja; Lorenz-Meyer, Irina; Napierkowski, Ira; Waldschmidt, Carolin; Nolte, Christian H.; Grittner, Ulrike; Wiener, Edzard; Bohner, Georg; Nabavi, Darius G.; Schmehl, Ingo; Ekkernkamp, Axel; Jungehulsing, Gerhard J.; Mackert, Bruno-Marcel; Hartmann, Andreas; Rohmann, Jessica L.; Endres, Matthias; Audebert, Heinrich J.			Association Between Dispatch of Mobile Stroke Units and Functional Outcomes Among Patients With Acute Ischemic Stroke in Berlin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Importance Effects of thrombolysis in acute ischemic stroke are time-dependent. Ambulances that can administer thrombolysis (mobile stroke units [MSUs]) before arriving at the hospital have been shown to reduce time to treatment. Objective To determine whether dispatch of MSUs is associated with better clinical outcomes for patients with acute ischemic stroke. Design, Setting, and Participants This prospective, nonrandomized, controlled intervention study was conducted in Berlin, Germany, from February 1, 2017, to October 30, 2019. If an emergency call prompted suspicion of stroke, both a conventional ambulance and an MSU, when available, were dispatched. Functional outcomes of patients with final diagnosis of acute cerebral ischemia who were eligible for thrombolysis or thrombectomy were compared based on the initial dispatch (both MSU and conventional ambulance or conventional ambulance only). Exposure Simultaneous dispatch of an MSU (computed tomographic scanning with or without angiography, point-of-care laboratory testing, and thrombolysis capabilities on board) and a conventional ambulance (n = 749) vs conventional ambulance alone (n = 794). Main Outcomes and Measures The primary outcome was the distribution of modified Rankin Scale (mRS) scores (a disability score ranging from 0, no neurological deficits, to 6, death) at 3 months. The coprimary outcome was a 3-tier disability scale at 3 months (none to moderate disability; severe disability; death) with tier assignment based on mRS scores if available or place of residence if mRS scores were not available. Common odds ratios (ORs) were used to quantify the association between exposure and outcome; values less than 1.00 indicated a favorable shift in the mRS distribution and lower odds of higher levels of disability. Results Of the 1543 patients (mean age, 74 years; 723 women [47%]) included in the adjusted primary analysis, 1337 (87%) had available mRS scores (primary outcome) and 1506 patients (98%) had available the 3-tier disability scale assessment (coprimary outcome). Patients with an MSU dispatched had lower median mRS scores at month 3 (1; interquartile range [IQR], 0-3) than did patients without an MSU dispatched (2; IQR, 0-3; common OR for worse mRS, 0.71; 95% CI, 0.58-0.86; P < .001). Similarly, patients with an MSU dispatched had lower 3-month coprimary disability scores: 586 patients (80.3%) had none to moderate disability; 92 (12.6%) had severe disability; and 52 (7.1%) had died vs patients without an MSU dispatched: 605 (78.0%) had none to moderate disability; 103 (13.3%) had severe disability; and 68 (8.8%) had died (common OR for worse functional outcome, 0.73, 95% CI, 0.54-0.99; P = .04). Conclusions and Relevance In this prospective, nonrandomized, controlled intervention study of patients with acute ischemic stroke in Berlin, Germany, the dispatch of mobile stroke units, compared with conventional ambulances alone, was significantly associated with lower global disability at 3 months. Clinical trials in other regions are warranted. This cohort study compares global disability at 3 months among Berlin patients with out-of-hospital ischemic stroke brought to care via a mobile stroke unit ambulance (with prehospital CT scanning with or without angiography, point-of-care laboratory testing, prehospital thrombolysis) vs conventional ambulance alone. Question Is the dispatch of mobile stroke units in the out-of-hospital setting before arriving at the hospital associated with better functional outcomes among patients with acute ischemic stroke eligible for thrombolysis or thrombectomy? Findings In this prospective nonrandomized controlled intervention study involving 1543 patients in Berlin, Germany, the dispatch of mobile stroke units in addition to conventional ambulances vs conventional ambulances alone was significantly associated with lower levels of global disability at 3 months (common odds ratio for higher modified Rankin Scale scores [ie, worse outcome], 0.71). Meaning Among patients with acute ischemic stroke in Berlin, Germany, dispatch of a mobile stroke unit was associated with lower global disability at 3 months; further research in diverse settings is needed.	[Ebinger, Martin; Siegerink, Bob; Kunz, Alexander; Scheitz, Jan F.; Schlemm, Ludwig; Nolte, Christian H.; Rohmann, Jessica L.; Endres, Matthias; Audebert, Heinrich J.] Charite Univ Med Berlin, Ctr Stroke Res Berlin, Berlin, Germany; [Ebinger, Martin; Kunz, Alexander] Med Pk Berlin Humboldtmuhle, Neurol Klin, Berlin, Germany; [Wendt, Matthias; Zieschang, Katja; Schmehl, Ingo; Ekkernkamp, Axel] Unfallkrankenhaus Berlin, Klin Neurol Stroke Unit & Fruhrehabilitat, Berlin, Germany; [Weber, Joachim E.; Geisler, Frederik; Freitag, Erik; Lange, Julia; Behrens, Janina; Erdur, Hebun; Ganeshan, Ramanan; Liman, Thomas; Scheitz, Jan F.; Schlemm, Ludwig; Harmel, Peter; Lorenz-Meyer, Irina; Napierkowski, Ira; Waldschmidt, Carolin; Nolte, Christian H.; Endres, Matthias; Audebert, Heinrich J.] Charite Univ Med Berlin, Klin & Hochschulambulanz Neurol, Hindenburgdamm 30, D-12200 Berlin, Germany; [Schwabauer, Eugen; Nabavi, Darius G.] Vivantes Klinikum Neukolln, Klin Neurol Stroke Unit, Berlin, Germany; [Waldschmidt, Carolin] Zentrum Epilepsie, Klin Neurol Stroke Unit, Berlin, Germany; [Waldschmidt, Carolin] Vivantes Humboldt Klinikum, Berlin, Germany; [Nolte, Christian H.; Grittner, Ulrike; Endres, Matthias] Berlin Inst Hlth BIH, Berlin, Germany; [Weber, Joachim E.; Nolte, Christian H.; Endres, Matthias] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany; [Grittner, Ulrike] Charite Univ Med Berlin, Inst Biometry & Clin Epidemiol, Berlin, Germany; [Wiener, Edzard; Bohner, Georg] Charite Univ Med Berlin, Inst Neuroradiol, Universitatsmedizin Berlin, Berlin, Germany; [Jungehulsing, Gerhard J.] Jud Krankenhaus Berlin, Neurol Klin, Berlin, Germany; [Mackert, Bruno-Marcel] Vivantes Auguste Viktoria Klinikum, Klin Neurol Stroke Unit, Berlin, Germany; [Hartmann, Andreas] Klinikum Frankfurt Oder, Neurol Klin, Frankfurt, Germany; [Rohmann, Jessica L.] Charite Univ Med Berlin, Inst Publ Hlth, Berlin, Germany; [Endres, Matthias] NeuroCure Cluster Excellence, Berlin, Germany; [Endres, Matthias] German Ctr Neurodegenerat Dis DZNE, Partner Site Berlin, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; VIivantes Klinikum Neukolln; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; German Centre for Cardiovascular Research; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE)	Audebert, HJ (corresponding author), Charite Univ Med Berlin, Klin & Hochschulambulanz Neurol, Hindenburgdamm 30, D-12200 Berlin, Germany.	heinrich.audebert@charite.de	Nolte, Christian/AAA-2651-2022; Siegerink, Bob/K-1323-2012; Grittner, Ulrike/I-2026-2019	Nolte, Christian/0000-0001-5577-1775; Siegerink, Bob/0000-0002-8454-9142; Grittner, Ulrike/0000-0003-2595-0224; Scheitz, Jan/0000-0001-5835-4627; Weber, Joachim/0000-0002-1666-6021; Endres, Matthias/0000-0001-6520-3720; Schlemm, Ludwig/0000-0003-4165-2366; Ganeshan, Ramanan/0000-0003-4043-1115; Bohner, Georg/0000-0002-1919-092X; Rohmann, Jessica L./0000-0003-2420-5716; Audebert, Heinrich J./0000-0002-4785-0366; Rohrpasser-Napierkowski, Ira/0000-0003-0072-524X; Liman, Thomas/0000-0002-8471-8049; Erdur, Hebun/0000-0001-5383-9625				Audebert H, 2017, INT J STROKE, V12, P932, DOI 10.1177/1747493017729268; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BRANT R, 1990, BIOMETRICS, V46, P1171, DOI 10.2307/2532457; Dietrich M, 2014, CEREBROVASC DIS, V38, P457, DOI 10.1159/000371427; Ebinger M, 2017, INT J STROKE, V12, P653, DOI 10.1177/1747493017700152; Ebinger M, 2015, JAMA NEUROL, V72, P25, DOI 10.1001/jamaneurol.2014.3188; Ebinger M, 2014, JAMA-J AM MED ASSOC, V311, P1622, DOI 10.1001/jama.2014.2850; Fassbender K, 2003, STROKE, V34, pE44, DOI 10.1161/01.STR.0000075573.22885.3B; Fassbender K, 2017, LANCET NEUROL, V16, P227, DOI 10.1016/S1474-4422(17)30008-X; Gyrd-Hansen D, 2015, NEUROLOGY, V84, P1090, DOI 10.1212/WNL.0000000000001366; Helwig SA, 2019, JAMA NEUROL, V76, P1484, DOI 10.1001/jamaneurol.2019.2829; Kaplan Robert M, 2005, COPD, V2, P91; Kim JT, 2017, CIRCULATION, V135, P128, DOI 10.1161/CIRCULATIONAHA.116.023336; Kobayashi A, 2018, EUR J NEUROL, V25, P425, DOI 10.1111/ene.13539; Kunz A, 2017, CIRCULATION, V135, P1765, DOI 10.1161/CIRCULATIONAHA.117.027693; Kunz A, 2016, LANCET NEUROL, V15, P1035, DOI 10.1016/S1474-4422(16)30129-6; Nolte CH, 2018, STROKE, V49, P646, DOI 10.1161/STROKEAHA.117.019060; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Rahlfs VW, 2014, STROKE, V45, P627, DOI 10.1161/STROKEAHA.113.003151; Rajan S, 2015, JAMA NEUROL, V72, P229, DOI 10.1001/jamaneurol.2014.3618; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Walter S, 2012, LANCET NEUROL, V11, P397, DOI 10.1016/S1474-4422(12)70057-1; Wendt M, 2015, STROKE, V46, P740, DOI 10.1161/STROKEAHA.114.008159; Williams R, 2006, STATA J, V6, P58, DOI 10.1177/1536867X0600600104; Wilson JTL, 2005, STROKE, V36, P777, DOI 10.1161/01.STR.0000157596.13234.95; Yamal JM, 2018, INT J STROKE, V13, P321, DOI 10.1177/1747493017711950; Zhao H, 2020, STROKE, V51, P922, DOI 10.1161/STROKEAHA.119.027843; Zhao YD, 2008, STAT MED, V27, P462, DOI 10.1002/sim.2912	29	73	73	3	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2021	325	5					454	466		10.1001/jama.2020.26345	http://dx.doi.org/10.1001/jama.2020.26345			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC6JP	33528537	Green Published, Bronze			2023-01-03	WOS:000614941900018
J	Reid, PD; Cifu, AS; Bass, AR				Reid, Pankti D.; Cifu, Adam S.; Bass, Anne R.			Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Reid, Pankti D.; Cifu, Adam S.] Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA; [Bass, Anne R.] Weill Cornell Med, Hosp Special Surg, New York, NY USA	University of Chicago; Cornell University	Cifu, AS (corresponding author), Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA.	adamcifu@uchicago.edu	Reid, Pankti/AHA-0817-2022	Reid, Pankti/0000-0002-7645-0919				Abu-Sbeih H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0577-1; Bergqvist V, 2017, CANCER IMMUNOL IMMUN, V66, P581, DOI 10.1007/s00262-017-1962-6; Cappelli LC, 2017, IMMUNOTHERAPY-UK, V9, P5, DOI 10.2217/imt-2016-0117; Faje AT, 2018, CANCER-AM CANCER SOC, V124, P3706, DOI 10.1002/cncr.31629; Johnson DB, 2018, JAMA-J AM MED ASSOC, V320, P1702, DOI 10.1001/jama.2018.13995; Mahmood SS, 2018, J AM COLL CARDIOL, V71, P1755, DOI 10.1016/j.jacc.2018.02.037; National Institutes of Health, 2018, COMM TERM CRIT ADV E; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Wang YH, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0346-6	9	18	18	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2021	325	5					482	483		10.1001/jama.2020.17308	http://dx.doi.org/10.1001/jama.2020.17308			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC6JP	33528524				2023-01-03	WOS:000614941900021
J	Younus, M; Hasan, MM; Ali, S; Saddq, B; Sarwar, G; Ullah, MI; Maqsood, A; Ahmar, S; Mora-Poblete, F; Hassan, F; Chen, JT; Noureldeen, A; Darwish, H				Younus, Muhammad; Hasan, Muhammad Mohtasheemul; Ali, Sajjad; Saddq, Bushra; Sarwar, Gulam; Ullah, Muhammad Irfan; Maqsood, Ambreen; Ahmar, Sunny; Mora-Poblete, Freddy; Hassan, Farazia; Chen, Jen-Tsung; Noureldeen, Ahmed; Darwish, Hadeer			Extracts of Euphorbia nivulia Buch.-Ham. showed both phytotoxic and insecticidal capacities against Lemna minor L. and Oxycarenus hyalinipennis Costa	PLOS ONE			English	Article							CHEMICAL-COMPOSITION; ANTIOXIDANT ACTIVITY; ALLELOPATHY; LATEX; REQUIREMENTS; GERMINATION; GROWTH; OILS	Many phytochemicals can affect the growth and development of plants and insects which can be used as biological control agents. In this study, different concentrations of crude, hexane, chloroform, butanol, and aqueous extracts of Euphorbia nivulia Buch.-Ham., an endemic plant of the Cholistan desert in South Punjab of Pakistan, were analysed for their chemical constituents. Their various concentrations were also tested for their phytotoxic and insecticidal potential against duckweed, Lemna minor L., and the dusky cotton bug, Oxycarenus hyalinipennis Costa. various polyphenols, i.e., quercetin, gallic acid, caffeic acid, syringic acid, coumaric acid, ferulic acid, and cinnamic acid were detected in different concentrations with different solvents during the phytochemical screening of E. nivulia. In the phytotoxicity test, except for 100 mu g/mL of the butanol extract gave 4.5% growth regulation, no phytotoxic lethality could be found at 10 and 100 mu g/mL of all the extracts. The highest concentration, 1000 mu g/mL, of the chloroform, crude, and butanol extracts showed 100, 63.1, and 27.1% of growth inhibition in duckweed, respectively. In the insecticidal bioassay, the highest O. hyalinipennis mortalities (87 and 75%) were recorded at 15% concentration of the chloroform and butanol extracts of E. nivulia. In contrast, the lower concentrations of the E. nivulia extracts caused the lower mortalities. Altogether, these findings revealed that E. nivulia chloroform extracts showed significant phytotoxicity while all the extracts showed insecticidal potential. This potential can be, further, refined to be developed for bio-control agents.	[Younus, Muhammad] Islamia Univ Bahawalpur, Dept Pharmacognosy, Fac Pharm, Bahawalpur, Pakistan; [Younus, Muhammad; Hasan, Muhammad Mohtasheemul] Univ Karachi, Dept Pharmacognosy, Fac Pharm & Pharmaceut Sci, Karachi, Pakistan; [Ali, Sajjad; Saddq, Bushra] Islamia Univ Bahawalpur, UCA & ES, Dept Entomol, Bahawalpur, Pakistan; [Sarwar, Gulam] Islamia Univ Bahawalpur, Dept Bot, Fac Sci, Bahawalpur, Pakistan; [Ullah, Muhammad Irfan] Univ Sargodha, Dept Entomol, Coll Agr, Sargodha, Pakistan; [Maqsood, Ambreen] Islamia Univ Bahawalpur, Dept Plant Pathol, Bahawalpur, Pakistan; [Ahmar, Sunny; Mora-Poblete, Freddy] Univ Talca, Inst Biol Sci, Talca, Chile; [Hassan, Farazia] Virtual Univ Pakistan, Dept Biotechonolgy & Bioinformat, Bahawalpur, Pakistan; [Chen, Jen-Tsung] Natl Univ Kaohsiung, Dept Life Sci, Kaohsiung, Taiwan; [Noureldeen, Ahmed] Taif Univ, Dept Biol, Coll Sci, At Taif, Saudi Arabia; [Darwish, Hadeer] Taif Univ, Dept Biotechnol, Coll Sci, At Taif, Saudi Arabia	Islamia University of Bahawalpur; University of Karachi; Islamia University of Bahawalpur; Islamia University of Bahawalpur; University of Sargodha; Islamia University of Bahawalpur; Universidad de Talca; Virtual University of Pakistan; National University Kaohsiung; Taif University; Taif University	Younus, M (corresponding author), Islamia Univ Bahawalpur, Dept Pharmacognosy, Fac Pharm, Bahawalpur, Pakistan.; Younus, M (corresponding author), Univ Karachi, Dept Pharmacognosy, Fac Pharm & Pharmaceut Sci, Karachi, Pakistan.; Chen, JT (corresponding author), Natl Univ Kaohsiung, Dept Life Sci, Kaohsiung, Taiwan.	my0966@hotmail.com; jentsung@nuk.edu.tw	Ahmar, Sunny/HGS-2259-2022; Younus, Muhammad/GZL-1617-2022; Chen, Jen-Tsung/I-6733-2019; Noureldeen, Ahmed/GRS-9678-2022; Ullah, Muhammad Irfan/K-7750-2019; Mora-Poblete, Freddy/AAZ-1585-2020	Chen, Jen-Tsung/0000-0002-3540-4449; Ullah, Muhammad Irfan/0000-0002-2463-2665; 	Endowment Fund Secretariate (EFS), University of Agriculture, Faislabad, Pakistan	Endowment Fund Secretariate (EFS), University of Agriculture, Faislabad, Pakistan	The research is supported by the Endowment Fund Secretariate (EFS), University of Agriculture, Faislabad, Pakistan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas Muneer, 2015, Polish Journal of Entomology, V84, P127, DOI 10.1515/pjen-2015-0010; Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a; ABROSCA BD, 2005, PHYTOCHEMISTRY, V66, P2681; Ahmad H, 2012, J TRADIT CHIN MED, V32, P616, DOI 10.1016/S0254-6272(13)60080-1; Akkari H, 2015, IND CROP PROD, V74, P745, DOI 10.1016/j.indcrop.2015.06.008; Almeida V. T., 2017, African Journal of Biotechnology, V16, P615, DOI 10.5897/ajb2017.15972; Ayatollahi AM, 2010, IRAN J PHARM RES, V9, P429; Badgujar S.B., 2011, INT J PHYTOPHARMACOL, V2, P37; Batish DR, 2008, J PLANT PHYSIOL, V165, P297, DOI 10.1016/j.jplph.2007.05.003; Batish DR, 2007, CROP PROT, V26, P948, DOI 10.1016/j.cropro.2006.08.015; Birkett MA, 2001, PLANT SOIL, V232, P31, DOI 10.1023/A:1010325801256; Blum U, 1996, J NEMATOL, V28, P259; Callaway RM, 2004, FRONT ECOL ENVIRON, V2, P436, DOI 10.1890/1540-9295(2004)002[0436:NWISAT]2.0.CO;2; Cheng F, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.01020; Chlopicka J, 2012, LWT-FOOD SCI TECHNOL, V46, P548, DOI 10.1016/j.lwt.2011.11.009; de Jong Yde, 2014, Biodivers Data J, pe4034, DOI 10.3897/BDJ.2.e4034; de Silva WAPP, 2008, J NATL SCI FOUND SRI, V36, P15, DOI 10.4038/jnsfsr.v36i1.129; Duke SO, 2000, WEED RES, V40, P99, DOI 10.1046/j.1365-3180.2000.00161.x; Einhellig FA, 1996, AGRON J, V88, P886, DOI 10.2134/agronj1996.00021962003600060007x; Hasan, 2020, DOSE RESPONSE INTER, V2020, P1; Jabran K, 2015, CROP PROT, V72, P57, DOI 10.1016/j.cropro.2015.03.004; Jha P, 2010, WEED SCI, V58, P426, DOI 10.1614/WS-D-09-00038.1; KHAN AQ, 1990, J NAT PROD, V53, P728, DOI 10.1021/np50069a035; KHAN AQ, 1989, PLANTA MED, P290, DOI 10.1055/s-2006-962008; Khan M. F., 2000, ACTA BIOL CRACOV, V42, P14; Kumar K.P., 2014, EUR J PHARM TOXICOL, V4, P102; Lee DL, 1997, WEED SCI, V45, P601; Li ZH, 2010, MOLECULES, V15, P8933, DOI 10.3390/molecules15128933; Lin W.X., 2001, CHIN J APPL ECOL, V12, P871, DOI DOI 10.13287/J.1001-9332.2001.0207; Lungu L, 2011, ROM BIOTECH LETT, V16, P6089; Mancini E, 2014, CHEM BIODIVERS, V11, P639, DOI 10.1002/cbdv.201300326; Mediouni J., 2012, TUNIS J PLANT PROT, V7, P90; Mesquita RD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227811; Nenaah GE, 2015, J STORED PROD RES, V61, P9, DOI 10.1016/j.jspr.2014.12.007; Oudhia P., 1999, International Rice Research Notes, V24, P36; Pak-Dek MS, 2011, J MED PLANTS RES, V5, P5050; Radcliffe-Smith A., 2011, EUPHORBIACEAE FLORA; Rahuman AA, 2008, PARASITOL RES, V102, P867, DOI 10.1007/s00436-007-0839-6; Acosta-Motos JR, 2017, AGRONOMY-BASEL, V7, DOI 10.3390/agronomy7010018; RASOOL N, 1989, PHYTOCHEMISTRY, V28, P1193, DOI 10.1016/0031-9422(89)80207-9; Ravikanth V, 2003, CHEM PHARM BULL, V51, P431, DOI 10.1248/cpb.51.431; RIZK AFM, 1987, BOT J LINN SOC, V94, P293, DOI 10.1111/j.1095-8339.1987.tb01052.x; Romero-Romero T, 2002, J CHEM ECOL, V28, P617, DOI 10.1023/A:1014504531418; Schaefer C.W., 2000, HETEROPTERA EC IMPOR; Singh HP, 2005, ANN APPL BIOL, V146, P89, DOI 10.1111/j.1744-7348.2005.04018.x; Singh HP, 2003, AGR ECOSYST ENVIRON, V95, P537, DOI 10.1016/S0167-8809(02)00202-5; Smith TR, 2008, FLA ENTOMOL, V91, P479, DOI 10.1653/0015-4040(2008)91[479:AMPOCO]2.0.CO;2; Tawaha AM, 2003, J AGRON CROP SCI, V189, P298, DOI 10.1046/j.1439-037X.2003.00047.x; Uma M. S., 2009, Karnataka Journal of Agricultural Sciences, V22, P688; VIMAL JB, 2014, J ENTOMOL ZOOL STU E, V2, P267; Weir TL, 2004, CURR OPIN PLANT BIOL, V7, P472, DOI 10.1016/j.pbi.2004.05.007; Wolfe K, 2003, J AGR FOOD CHEM, V51, P609, DOI 10.1021/jf020782a; Younus M, 2019, PAK J PHARM SCI, V32, P1111; Yusuf Y., 2020, SYS REV PHARM, V11, P388, DOI [10.1016/j.jcot.2020.03.020, DOI 10.1016/J.JCOT.2020.03.020]	54	2	3	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2021	16	4							e0250118	10.1371/journal.pone.0250118	http://dx.doi.org/10.1371/journal.pone.0250118			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6EM	33930032	gold, Green Published			2023-01-03	WOS:000664607000009
J	Chaulagain, DR; Ashish, KC; Wrammert, J; Brunell, O; Basnet, O; Malqvist, M				Chaulagain, Dipak Raj; Ashish, K. C.; Wrammert, Johan; Brunell, Olivia; Basnet, Omkar; Malqvist, Mats			Effect of a scaled-up quality improvement intervention on health workers' competence on neonatal resuscitation in simulated settings in public hospitals: A pre-post study in Nepal	PLOS ONE			English	Article							HELPING BABIES BREATHE; MORTALITY	Background Helping Babies Breathe (HBB) training improves bag and mask ventilation and reduces neonatal mortality and fresh stillbirths. Quality improvement (QI) interventions can improve retention of neonatal resuscitation knowledge and skills. This study aimed to evaluate the effect of a scaled-up QI intervention package on uptake and retention of neonatal resuscitation knowledge and skills in simulated settings. Methods This was a pre-post study in 12 public hospitals of Nepal. Knowledge and skills of trainees on neonatal resuscitation were evaluated against the set standard before and after the introduction of QI interventions. Results Altogether 380 participants were included for knowledge evaluation and 286 for skill evaluation. The overall knowledge test score increased from 14.12 (pre-basic) to 15.91 (post-basic) during basic training (p < 0.001). The knowledge score decreased over time; 15.91 (post-basic) vs. 15.33 (pre-refresher) (p < 0.001). Overall skill score during basic training (16.98 1.79) deteriorated over time to 16.44 1.99 during refresher training (p < 0.001). The proportion of trainees passing the knowledge test increased to 91.1% (post-basic) from 67.9% (pre-basic) which decreased to 86.6% during refresher training after six months. The knowledge and skill scores were maintained above the set standard (>14.0) over time at all hospitals during refresher training. Conclusion HBB training together with QI tools improves health workers' knowledge and skills on neonatal resuscitation, irrespective of size and type of hospitals. The knowledge and skills deteriorate over time but do not fall below the standard. The HBB training together with QI interventions can be scaled up in other public hospitals. Trial registration This study was part of the larger Nepal Perinatal Quality Improvement Project (NePeriQIP) with International Standard Randomised Controlled Trial Number, ISRCTN30829654, registered 17(th) of May, 2017.	[Chaulagain, Dipak Raj; Ashish, K. C.; Wrammert, Johan; Brunell, Olivia; Malqvist, Mats] Uppsala Univ, Uppsala Global Hlth Res Implementat & Sustainabil, Dept Womens & Childrens Hlth, Uppsala, Sweden; [Ashish, K. C.] Soc Publ Hlth Phys Nepal SOPHPHYN, Kathmandu, Nepal; [Basnet, Omkar] Golden Commun, Lalitpur, Nepal	Uppsala University	Chaulagain, DR (corresponding author), Uppsala Univ, Uppsala Global Hlth Res Implementat & Sustainabil, Dept Womens & Childrens Hlth, Uppsala, Sweden.	dipak.chaulagain@kbh.uu.se	KC, Ashish/ABC-6651-2021; Målqvist, Mats/Q-1274-2019; KC, Ashish/AAH-3360-2021	Målqvist, Mats/0000-0002-8184-3530; KC, Ashish/0000-0002-0541-4486	Vetenskapsradet; Laerdal Foundation for Acute Medicine, Norway; Einhorn Family Foundation, Sweden; Swedish Research Council fund	Vetenskapsradet(Swedish Research Council); Laerdal Foundation for Acute Medicine, Norway; Einhorn Family Foundation, Sweden; Swedish Research Council fund	Funding was obtained from the Vetenskapsradet (SE), the Laerdal Foundation for Acute Medicine, Norway, and Einhorn Family Foundation, Sweden. AKC was the grantee of Vetenskapsradet (SE). MM was the grantee of Laerdal Foundation for Acute Medicine, Norway, and Einhorn Family Foundation, Sweden. Golden Community is not a commercial company but a national research agency and is the sub-grantee of the Swedish Research Council fund for data collection of Nepal Perinatal Quality Improvement Project (NePeriQIP). The funder provided support in form of salaries for OB, but did not have any additional role in the study design, data collection and analysis.	Ashish KC, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002900; Ashish KC, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0853-5; Ashish KC, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-0117; Bang A, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1141-3; Bellad RM, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0997-6; Boskabadi H, 2015, IRAN J PEDIATR, V25, DOI 10.5812/ijp.2006; Budhathoki SS, 2019, ACTA PAEDIATR, V108, P806, DOI 10.1111/apa.14706; Carlo WA, 2009, J PEDIATR-US, V154, P504, DOI 10.1016/j.jpeds.2008.10.005; Cordova E, 2018, INT J GYNECOL OBSTET, V142, P248, DOI 10.1002/ijgo.12512; Dol Justine, 2017, JBI Database System Rev Implement Rep, V15, P1528, DOI 10.11124/JBISRIR-2016-003243; Eblovi D, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1387985; Ersdal HL, 2013, RESUSCITATION, V84, P1422, DOI 10.1016/j.resuscitation.2013.04.005; Ersdal HL, 2012, RESUSCITATION, V83, P869, DOI 10.1016/j.resuscitation.2011.12.011; Governent of Nepal, 2016, NEP EV NEWB ACT PLAN, P90; Hoban R, 2013, J TROP PEDIATRICS, V59, P180, DOI 10.1093/tropej/fms077; Isangula KG, 2018, PAEDIATR INT CHILD H, V38, P46, DOI 10.1080/20469047.2016.1219119; Kamath-Rayne BD, 2018, GLOB HEALTH-SCI PRAC, V6, P538, DOI 10.9745/GHSP-D-18-00147; Leader A, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00061; Lee ACC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S12; Makene CL, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0381-3; Matterson HH, 2018, J PERINAT MED, V46, P934, DOI 10.1515/jpm-2017-0330; Mduma E, 2015, RESUSCITATION, V93, P1, DOI 10.1016/j.resuscitation.2015.04.019; Msemo G, 2013, PEDIATRICS, V131, pE353, DOI 10.1542/peds.2012-1795; Reisman J, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4490; Rule ARL, 2017, ACTA PAEDIATR, V106, P1666, DOI 10.1111/apa.13940; Singhal N, 2012, RESUSCITATION, V83, P90, DOI 10.1016/j.resuscitation.2011.07.010; Tabangin ME, 2018, INT HEALTH, V10, P163, DOI 10.1093/inthealth/ihy017; Wall SN, 2010, SEMIN PERINATOL, V34, P395, DOI 10.1053/j.semperi.2010.09.009; World Health Organization, 2016, STAND IMPR QUAL MAT	29	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2021	16	4							e0250762	10.1371/journal.pone.0250762	http://dx.doi.org/10.1371/journal.pone.0250762			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6DA	33914798	Green Published, gold			2023-01-03	WOS:000664603100065
J	Maxwell, CJ; Mondor, L; Kone, AJP; Hogan, DB; Wodchis, WP				Maxwell, Colleen J.; Mondor, Luke; Kone, Anna J. Pefoyo; Hogan, David B.; Wodchis, Walter P.			Sex differences in multimorbidity and polypharmacy trends: A repeated cross-sectional study of older adults in Ontario, Canada	PLOS ONE			English	Article							HEALTH OUTCOMES; COMPLEXITY; CARE; PREVALENCE; PATTERNS; DISEASES; PEOPLE	Background Multimorbidity is increasing among older adults, but the impact of these recent trends on the extent and complexity of polypharmacy and possible variation by sex remains unknown. We examined sex differences in multimorbidity, polypharmacy (5+ medications) and hyper-polypharmacy (10+ medications) in 2003 vs 2016, and the interactive associations between age, multimorbidity level, and time on polypharmacy measures. Methods and findings We employed a repeated cross-sectional study design with linked health administrative databases for all persons aged >= 66 years eligible for health insurance in Ontario, Canada at the two index dates. Descriptive analyses and multivariable logistic regression models were conducted; models included interaction terms between age, multimorbidity level, and time period to estimate polypharmacy and hyper-polypharmacy probabilities, risk differences and risk ratios for 2016 vs 2003. Multimorbidity, polypharmacy and hyper-polypharmacy increased significantly over the 13 years. At both index dates prevalence estimates for all three were higher in women, but a greater absolute increase in polypharmacy over time was observed in men (6.6% [from 55.7% to 62.3%] vs 0.9% [64.2%-65.1%] for women) though absolute increases in multimorbidity were similar for men and women (6.9% [72.5%-79.4%] vs 6.2% [75.9%-82.1%], respectively). Model findings showed that polypharmacy decreased over time among women aged < 90 years (especially for younger ages and those with fewer conditions), whereas it increased among men at all ages and multimorbidity levels (with larger absolute increases typically at older ages and among those with 4 or fewer conditions). Conclusions There are sex and age differences in the impact of increasing chronic disease burden on changes in measures of multiple medication use among older adults. Though the drivers and health consequences of these trends warrant further investigation, the findings support the heterogeneity and complexity in the evolving association between multimorbidity and polypharmacy measures in older populations.	[Maxwell, Colleen J.] Univ Waterloo, Sch Pharm & Publ Hlth & Hlth Syst, Waterloo, ON, Canada; [Maxwell, Colleen J.; Mondor, Luke; Wodchis, Walter P.] ICES, Toronto, ON, Canada; [Maxwell, Colleen J.; Mondor, Luke; Kone, Anna J. Pefoyo; Wodchis, Walter P.] Hlth Syst Performance Network HSPN, Toronto, ON, Canada; [Kone, Anna J. Pefoyo] Lakehead Univ, Dept Hlth Sci, Thunder Bay, ON, Canada; [Hogan, David B.] Univ Calgary, Cumming Sch Med, Dept Med, Div Geriatr Med, Calgary, AB, Canada; [Wodchis, Walter P.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Wodchis, Walter P.] Trillium Hlth Partners, Inst Better Hlth, Toronto, ON, Canada	University of Waterloo; University of Toronto; Lakehead University; University of Calgary; University of Toronto; University of Toronto; Trillium Health Partners	Maxwell, CJ (corresponding author), Univ Waterloo, Sch Pharm & Publ Hlth & Hlth Syst, Waterloo, ON, Canada.; Maxwell, CJ (corresponding author), ICES, Toronto, ON, Canada.; Maxwell, CJ (corresponding author), Hlth Syst Performance Network HSPN, Toronto, ON, Canada.	colleen.maxwell@uwaterloo.ca	Hogan, David Bryan/I-4360-2013	Hogan, David Bryan/0000-0002-9462-5460; Kone Pefoyo, Anna J/0000-0003-0231-2713	Ontario Ministry of Health (MOH); ICES - Ontario Ministry of Health (MOH); Ministry of Long-Term Care (MLTC)	Ontario Ministry of Health (MOH); ICES - Ontario Ministry of Health (MOH); Ministry of Long-Term Care (MLTC)	This research was supported by a grant from the Ontario Ministry of Health (MOH) to the Health System Performance Network (HSPN) and by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Agur K, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040391; Aoki T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21917-6; Bailey SC, 2020, J AM GERIATR SOC, V68, P569, DOI 10.1111/jgs.16255; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Bushnik T, 2018, HEALTH REP, V29, P14; Cadogan CA, 2016, DRUG SAFETY, V39, P109, DOI 10.1007/s40264-015-0378-5; Canadian Institute for Health Information [CIHI], 2018, DRUG US SEN CAN 2016; Canizares M, 2018, J GERONTOL B-PSYCHOL, V73, P1303, DOI 10.1093/geronb/gbx004; Charlesworth CJ, 2015, J GERONTOL A-BIOL, V70, P989, DOI 10.1093/gerona/glv013; Ellenbogen MI, 2020, DRUG AGING, V37, P57, DOI 10.1007/s40266-019-00726-0; Feng X, 2018, POPUL HEALTH MANAG, V21, P123, DOI 10.1089/pop.2017.0065; Franchi C, 2014, EUR J CLIN PHARMACOL, V70, P437, DOI 10.1007/s00228-013-1621-6; Fried TR, 2014, J AM GERIATR SOC, V62, P2261, DOI 10.1111/jgs.13153; Giovannini S, 2018, DRUG AGING, V35, P145, DOI 10.1007/s40266-018-0521-y; Goodman RA, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120239; Griffith LE, 2020, J CLIN EPIDEMIOL, V124, P163, DOI 10.1016/j.jclinepi.2020.04.019; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Hogan DB, 2020, CURR EPIDEMIOL REP, V7, P16, DOI 10.1007/s40471-020-00226-5; Hovstadius B, 2014, DRUG AGING, V31, P379, DOI 10.1007/s40266-014-0165-5; Kingston A, 2018, AGE AGEING, V47, P374, DOI 10.1093/ageing/afx201; Kristensen RU, 2019, J ALZHEIMERS DIS, V67, P949, DOI 10.3233/JAD-180427; Lebenbaum M, 2018, PREV MED, V116, P173, DOI 10.1016/j.ypmed.2018.08.025; Lochner Kimberly A, 2013, Medicare Medicaid Res Rev, V3, DOI 10.5600/mmrr.003.03.b02; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; Mauvais-Jarvis F, 2020, LANCET, V396, P565, DOI 10.1016/S0140-6736(20)31561-0; McGrail K, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1312; Mondor L, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002249; Morgan SG, 2016, AGE AGEING, V45, P535, DOI 10.1093/ageing/afw074; Muller CJ, 2014, INT J EPIDEMIOL, V43, P962, DOI 10.1093/ije/dyu029; National Institute for Health and Care Excellence, MULT POL; Nguyen TN, 2019, FAM PRACT, V36, P706, DOI 10.1093/fampra/cmz023; Nicholson K, 2019, BRIT J GEN PRACT, V69, pE647, DOI 10.3399/bjgp19X704657; Nishtala PS, 2015, GERONTOLOGY, V61, P195, DOI 10.1159/000368191; Nobili A, 2011, EUR J INTERN MED, V22, P597, DOI 10.1016/j.ejim.2011.08.029; Palladino R, 2019, HEALTH AFFAIR, V38, P613, DOI 10.1377/hlthaff.2018.05273; Pefoyo AJK, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1733-2; Public Health Agency of Canada, 2018, EC BURD ILLN CAN 201; Rieker P. P., 2005, Journals of Gerontology. Series B, Psychological Sciences and Social Sciences, V60, pS40; Rocca WA, 2014, MAYO CLIN PROC, V89, P1336, DOI 10.1016/j.mayocp.2014.07.010; Shehab N, 2016, JAMA-J AM MED ASSOC, V316, P2115, DOI 10.1001/jama.2016.16201; Stevenson JM, 2020, AGE AGEING, V49, P7, DOI 10.1093/ageing/afz121; Thavorn K, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017264; Thorell K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029477; van den Akker M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212046; van Oostrom SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160264; Wastesson JW, 2018, EXPERT OPIN DRUG SAF, V17, P1185, DOI 10.1080/14740338.2018.1546841; Wimmer BC, 2017, J AM GERIATR SOC, V65, P747, DOI 10.1111/jgs.14682	49	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2021	16	4							e0250567	10.1371/journal.pone.0250567	http://dx.doi.org/10.1371/journal.pone.0250567			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0VQ	33901232	Green Published, gold			2023-01-03	WOS:000662169700045
J	Chainitikun, S; Fernandez, JRE; Long, JP; Iwase, T; Kida, K; Wang, XP; Saleem, S; Lim, B; Valero, V; Ueno, NT				Chainitikun, Sudpreeda; Fernandez, Jose Rodrigo Espinosa; Long, James P.; Iwase, Toshiaki; Kida, Kumiko; Wang, Xiaoping; Saleem, Sadia; Lim, Bora; Valero, Vicente; Ueno, Naoto T.			Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review	PLOS ONE			English	Review							CONTROLLED SUPERIORITY TRIAL; STEM-CELL TRANSPLANTATION; OPEN-LABEL; MULTIMODALITY TREATMENT; ADJUVANT TRASTUZUMAB; SINGLE-ARM; BEVACIZUMAB; CYCLOPHOSPHAMIDE; PACLITAXEL; CARCINOMA	Background The current use of targeted therapy plus neoadjuvant chemotherapy for inflammatory breast cancer (IBC) is based on data extrapolated from studies in non-IBC. We conducted a systematic review to determine whether neoadjuvant chemotherapy plus targeted therapy results in a higher pathologic complete response (pCR) rate than neoadjuvant chemotherapy alone in patients with IBC. Method and findings This systematic review was registered in the PROSPERO register with registration number CRD42018089465. We searched MEDLINE & PubMed, EMBASE, and EBSCO from December 1998 through July 2020. All English-language clinical studies, both randomized and non-randomized, that evaluated neoadjuvant systemic treatment with or without targeted therapy before definitive surgery and reported the pCR results of IBC patients. First reviewer extracted data and assessed the risk of bias using the Risk of Bias In Non-randomized Studies of Interventions tool. Second reviewer confirmed the accuracy. Studies were divided into 3 groups according to systemic treatment: chemotherapy with targeted therapy, chemotherapy alone, and high-dose chemotherapy with hematopoietic stem cell support (HSCS). Of 995 screened studies, 23 with 1,269 IBC patients met the inclusion criteria. For each of the 3 groups of studies, we computed a weighted average of the pCR rates across all studies with confidence interval (CI). The weighted averages (95% CIs) were as follows: chemotherapy with targeted therapy, 31.6% (26.4%-37.3%), chemotherapy alone, 13.0% (10.3%-16.2%), and high-dose chemotherapy with HSCS, 23.0% (18.7%-27.7%). The high pCR by targeted therapy group came from anti-HER2 therapy, 54.4% (44.3%-64.0%). Key limitations of this study included no randomized clinical studies that included only IBC patients. Conclusion Neoadjuvant chemotherapy plus targeted therapy is more effective than neoadjuvant chemotherapy alone for IBC patients. These findings support current IBC standard practice in particular the use of anti-HER2 targeted therapy.	[Chainitikun, Sudpreeda; Fernandez, Jose Rodrigo Espinosa; Iwase, Toshiaki; Kida, Kumiko; Wang, Xiaoping; Saleem, Sadia; Lim, Bora; Valero, Vicente; Ueno, Naoto T.] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA; [Chainitikun, Sudpreeda; Fernandez, Jose Rodrigo Espinosa; Iwase, Toshiaki; Kida, Kumiko; Wang, Xiaoping; Saleem, Sadia; Lim, Bora; Valero, Vicente; Ueno, Naoto T.] Univ Texas MD Anderson Canc Ctr, Clin & Dept Breast Med Oncol, Houston, TX 77030 USA; [Long, James P.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Chainitikun, Sudpreeda] MedPk Hosp, Dept Med Oncol, Bangkok, Thailand; [Fernandez, Jose Rodrigo Espinosa] Inst Nacl Cancerol INCAN, Dept Med Oncol, Mexico City, DF, Mexico	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Instituto Nacional de Cancerologia (INCAN)	Ueno, NT (corresponding author), Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA.; Ueno, NT (corresponding author), Univ Texas MD Anderson Canc Ctr, Clin & Dept Breast Med Oncol, Houston, TX 77030 USA.	nueno@mdanderson.org	Iwase, Toshiaki/GPS-4381-2022; xiaoping, wang/GRX-3807-2022; , 0000-0002-4182-6058/F-9978-2014	, 0000-0002-4182-6058/0000-0002-4182-6058; Iwase, Toshiaki/0000-0002-5302-2292; Ueno, Naoto/0000-0002-0166-7275	Morgan Welch Inflammatory Breast Cancer Research Program; State of Texas Rare and Aggressive Breast Cancer Research Program Grant; National Institutes of Health/National Cancer Institute grant [P30 CA016672]; Center for Clinical and Translational Sciences [CCTS UL1TR000371]	Morgan Welch Inflammatory Breast Cancer Research Program; State of Texas Rare and Aggressive Breast Cancer Research Program Grant; National Institutes of Health/National Cancer Institute grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Clinical and Translational Sciences	This research was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, a State of Texas Rare and Aggressive Breast Cancer Research Program Grant, and National Institutes of Health/National Cancer Institute grant P30 CA016672 (Cancer Center Support Grant; used the Biostatistics Resource Group and the Clinical and Translational Research Center) and the Center for Clinical and Translational Sciences (CCTS UL1TR000371). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson William F, 2005, Breast Dis, V22, P9; Andreopoulou E, 2013, BREAST CANCER RES TR, V141, P429, DOI 10.1007/s10549-013-2704-x; [Anonymous], OV INFL BREAST CANC; Baldini Editta, 2004, Clin Breast Cancer, V5, P358, DOI 10.3816/CBC.2004.n.042; Bertucci F, 2016, LANCET ONCOL, V17, P600, DOI 10.1016/S1470-2045(16)00011-5; Boussen H, 2010, J CLIN ONCOL, V28, P3248, DOI 10.1200/JCO.2009.21.8594; Campbell JI, 2017, BREAST CANCER RES TR, V165, P181, DOI 10.1007/s10549-017-4303-8; Cardoso F, 2019, ANN ONCOL, V30, P1674, DOI 10.1093/annonc/mdz189; Costa R, 2017, CANCER TREAT REV, V53, P111, DOI 10.1016/j.ctrv.2016.12.010; Costa SD, 2010, J CLIN ONCOL, V28, P83, DOI 10.1200/JCO.2009.23.5101; Cristofanilli M, 2001, CANCER-AM CANCER SOC, V92, P1775, DOI 10.1002/1097-0142(20011001)92:7<1775::AID-CNCR1693>3.0.CO;2-E; Dawood S, 2011, ANN ONCOL, V22, P515, DOI 10.1093/annonc/mdq345; Dazzi C, 2001, HAEMATOLOGICA, V86, P523; de Matteis A, 2002, CANCER-AM CANCER SOC, V94, P895, DOI 10.1002/cncr.20335.abs; Ditsch N, 2012, ANTICANCER RES, V32, P3539; Earl HM, 2015, LANCET ONCOL, V16, P656, DOI 10.1016/S1470-2045(15)70137-3; Ellis GK, 2011, J CLIN ONCOL, V29, P1014, DOI 10.1200/JCO.2009.27.6543; Fouad TM, 2017, LANCET ONCOL, V18, pE228, DOI 10.1016/S1470-2045(17)30192-4; Gerber B, 2013, ANN ONCOL, V24, P2978, DOI 10.1093/annonc/mdt361; Gianni L, 2014, LANCET ONCOL, V15, P640, DOI 10.1016/S1470-2045(14)70080-4; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Giuliano AE, 2018, ANN SURG ONCOL, V25, P1783, DOI 10.1245/s10434-018-6486-6; Goncalves A, 2015, ANN ONCOL, V26, P1692, DOI 10.1093/annonc/mdv216; Hance KW, 2005, JNCI-J NATL CANCER I, V97, P966, DOI 10.1093/jnci/dji172; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Hurvitz SA, 2018, LANCET ONCOL, V19, P115, DOI 10.1016/S1470-2045(17)30716-7; Kim T, 2006, CLIN BREAST CANCER, V7, P386, DOI 10.3816/CBC.2006.n.055; Kummel S, 2005, ACTA ONCOL, V44, P248, DOI 10.1080/02841860510029725; Liberati A., 2009, ANN INTERN MED, V151, pW; Matsuda N, 2018, JAMA ONCOL, V4, P1207, DOI 10.1001/jamaoncol.2018.1436; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Nahleh ZA, 2016, BREAST CANCER RES TR, V158, P485, DOI 10.1007/s10549-016-3889-6; National Comprehensive Cancer Network, 2020, BREAST CANC VERSION3; Palazzo A, 2018, CLIN BREAST CANCER, V18, P328, DOI 10.1016/j.clbc.2018.01.010; Pierga JY, 2012, LANCET ONCOL, V13, P375, DOI 10.1016/S1470-2045(12)70049-9; Pizzuti L, 2016, J CELL PHYSIOL, V231, P2541, DOI 10.1002/jcp.25432; Rueth NM, 2014, J CLIN ONCOL, V32, P2018, DOI 10.1200/JCO.2014.55.1978; Rugo HS, 2004, ONCOLOGIST, V9, P43, DOI 10.1634/theoncologist.9-suppl_1-43; Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI 10.1056/NEJMoa1910549; Schwartzberg LS, 1999, BONE MARROW TRANSPL, V24, P981, DOI 10.1038/sj.bmt.1701965; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sportes C, 2009, BIOL BLOOD MARROW TR, V15, P963, DOI 10.1016/j.bbmt.2009.04.018; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Torrisi R, 2010, CLIN BREAST CANCER, V10, P483, DOI 10.3816/CBC.2010.n.064; U.S. Food and Drug Administration, PATH COMPL RESP NEOA; Ueno NT, 2018, J CANCER, V9, P1437, DOI 10.7150/jca.23969; Ueno NT, 1997, CANCER CHEMOTH PHARM, V40, P321, DOI 10.1007/s002800050664; Untch M, 2009, J CLIN ONCOL, V27, P2938, DOI 10.1200/JCO.2008.20.3133; van Uden DJP, 2019, BREAST CANCER RES TR, V176, P217, DOI 10.1007/s10549-019-05219-7; Veyret C, 2006, CANCER, V107, P2535, DOI 10.1002/cncr.22227; Viens P, 1998, BONE MARROW TRANSPL, V21, P249, DOI 10.1038/sj.bmt.1701074; Viens P, 1999, BRIT J CANCER, V81, P449, DOI 10.1038/sj.bjc.6690714	53	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2021	16	4							e0250057	10.1371/journal.pone.0250057	http://dx.doi.org/10.1371/journal.pone.0250057			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP1DH	33861773	gold, Green Published			2023-01-03	WOS:000641475400064
J	Hughes, CG; Mailloux, PT; Devlin, JW; Swan, JT; Sanders, RD; Anzueto, A; Jackson, JC; Hoskins, AS; Pun, BT; Orun, OM; Raman, R; Stollings, JL; Kiehl, AL; Duprey, MS; Bui, LN; O'Neal, HR; Snyder, A; Gropper, MA; Guntupalli, KK; Stashenko, GJ; Patel, MB; Brummel, NE; Girard, TD; Dittus, RS; Bernard, GR; Ely, EW; Pandharipande, PP				Hughes, C. G.; Mailloux, P. T.; Devlin, J. W.; Swan, J. T.; Sanders, R. D.; Anzueto, A.; Jackson, J. C.; Hoskins, A. S.; Pun, B. T.; Orun, O. M.; Raman, R.; Stollings, J. L.; Kiehl, A. L.; Duprey, M. S.; Bui, L. N.; O'Neal, H. R., Jr.; Snyder, A.; Gropper, M. A.; Guntupalli, K. K.; Stashenko, G. J.; Patel, M. B.; Brummel, N. E.; Girard, T. D.; Dittus, R. S.; Bernard, G. R.; Ely, E. W.; Pandharipande, P. P.		MENDS2 Study Investigators	Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; INTENSIVE-CARE; INFLAMMATORY RESPONSES; BRAIN-DYSFUNCTION; DELIRIUM; MORTALITY; MIDAZOLAM; GUIDELINES; RELIABILITY; VALIDATION	BACKGROUND Guidelines currently recommend targeting light sedation with dexmedetomidine or propofol for adults receiving mechanical ventilation. Differences exist between these sedatives in arousability, immunity, and inflammation. Whether they affect outcomes differentially in mechanically ventilated adults with sepsis undergoing light sedation is unknown. METHODS In a multicenter, double-blind trial, we randomly assigned mechanically ventilated adults with sepsis to receive dexmedetomidine (0.2 to 1.5 mu g per kilogram of body weight per hour) or propofol (5 to 50 mu g per kilogram per minute), with doses adjusted by bedside nurses to achieve target sedation goals set by clinicians according to the Richmond Agitation-Sedation Scale (RASS, on which scores range from -5 [unresponsive] to +4 [combative]). The primary end point was days alive without delirium or coma during the 14-day intervention period. Secondary end points were ventilator-free days at 28 days, death at 90 days, and age-adjusted total score on the Telephone Interview for Cognitive Status questionnaire (TICS-T; scores range from 0 to 100, with a mean of 50 +/- 10 and lower scores indicating worse cognition) at 6 months. RESULTS Of 432 patients who underwent randomization, 422 were assigned to receive a trial drug and were included in the analyses - 214 patients received dexmedetomidine at a median dose of 0.27 mu g per kilogram per hour, and 208 received propofol at a median dose of 10.21 mu g per kilogram per minute. The median duration of receipt of the trial drugs was 3.0 days (interquartile range, 2.0 to 6.0), and the median RASS score was -2.0 (interquartile range, -3.0 to -1.0). We found no difference between dexmedetomidine and propofol in the number of days alive without delirium or coma (adjusted median, 10.7 vs. 10.8 days; odds ratio, 0.96; 95% confidence interval [CI], 0.74 to 1.26), ventilator-free days (adjusted median, 23.7 vs. 24.0 days; odds ratio, 0.98; 95% CI, 0.63 to 1.51), death at 90 days (38% vs. 39%; hazard ratio, 1.06; 95% CI, 0.74 to 1.52), or TICS-T score at 6 months (adjusted median score, 40.9 vs. 41.4; odds ratio, 0.94; 95% CI, 0.66 to 1.33). Safety end points were similar in the two groups. CONCLUSIONS Among mechanically ventilated adults with sepsis who were being treated with recommended light-sedation approaches, outcomes in patients who received dexmedetomidine did not differ from outcomes in those who received propofol.	[Hughes, C. G.; Jackson, J. C.; Hoskins, A. S.; Pun, B. T.; Orun, O. M.; Raman, R.; Stollings, J. L.; Kiehl, A. L.; Patel, M. B.; Brummel, N. E.; Girard, T. D.; Dittus, R. S.; Bernard, G. R.; Ely, E. W.; Pandharipande, P. P.] Vanderbilt Univ, Med Ctr, Crit Illness Brain Dysfunct & Survivorship Ctr, Nashville, TN USA; [Hughes, C. G.; Jackson, J. C.; Raman, R.; Patel, M. B.; Girard, T. D.; Dittus, R. S.; Ely, E. W.; Pandharipande, P. P.] Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, Nashville, TN USA; [Hughes, C. G.; Pandharipande, P. P.] Vanderbilt Univ, Med Ctr, Div Anesthesiol Crit Care Med, Dept Anesthesiol, Nashville, TN USA; [Hughes, C. G.; Pun, B. T.; Bernard, G. R.; Ely, E. W.] Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN USA; [Dittus, R. S.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gen Internal Med & Publ Hlth, Nashville, TN USA; [Orun, O. M.; Raman, R.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Stollings, J. L.] Vanderbilt Univ, Med Ctr, Pharmaceut Serv, Nashville, TN USA; [Patel, M. B.] Vanderbilt Univ, Dept Surg, Med Ctr, Div Trauma & Surg Crit Care, Nashville, TN 37240 USA; [Hughes, C. G.; Pandharipande, P. P.] Tennessee Valley Healthcare Syst, Anesthesia Serv, Dept Vet Affairs Med Ctr, Nashville, TN USA; [Patel, M. B.] Tennessee Valley Healthcare Syst, Surg Serv, Dept Vet Affairs Med Ctr, Nashville, TN USA; [Dittus, R. S.; Ely, E. W.] Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs Med Ctr, Nashville, TN USA; [Mailloux, P. T.] Maine Med Ctr, Neurosci Inst, Portland, ME 04102 USA; [Mailloux, P. T.] Maine Med Ctr, Dept Crit Care Med, Portland, ME 04102 USA; [Devlin, J. W.; Duprey, M. S.] Northeastern Univ, Dept Pharm & Hlth Syst Sci, Bouve Coll Hlth Sci, Boston, MA 02115 USA; [Swan, J. T.; Bui, L. N.] Houston Methodist, Dept Pharm, Houston, TX USA; [Swan, J. T.] Houston Methodist, Dept Surg, Houston, TX USA; [Swan, J. T.] Houston Methodist, Ctr Outcomes Res, Houston, TX USA; [Guntupalli, K. K.] Baylor Coll Med, Pulm Crit Care & Sleep Med Sect, Ben Taub Hosp, Houston, TX 77030 USA; [Anzueto, A.] Univ Texas Hlth, Div Pulm Crit Care Med, San Antonio, TX USA; [Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA; [Snyder, A.] Texas Hlth Harris Methodist Hosp Ft Worth, Ft Worth, TX USA; [Sanders, R. D.] Univ Sydney, Sydney, NSW, Australia; [Sanders, R. D.] Royal Prince Alfred Hosp, Dept Anaesthet, Sydney, NSW, Australia; [Sanders, R. D.] Univ Wisconsin, Dept Anesthesiol, Madison, WI 53706 USA; [O'Neal, H. R., Jr.] Baton Rouge Gen Med Ctr, Pulm & Crit Care Med, Baton Rouge, LA USA; [O'Neal, H. R., Jr.] Our Lady Lake Reg Med Ctr, Baton Rouge, LA USA; [Gropper, M. A.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; [Stashenko, G. J.] Mission Hosp, Pulm & Crit Care, Asheville, NC USA; [Brummel, N. E.] Ohio State Univ, Div Pulm Crit Care & Sleep Med, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA; [Girard, T. D.] Univ Pittsburgh, Sch Med, Clin Res Invest & Syst Modeling Acute Illness Ctr, Dept Crit Care Med, Pittsburgh, PA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Maine Medical Center; Maine Medical Center; Northeastern University; The Methodist Hospital System; The Methodist Hospital - Houston; The Methodist Hospital System; The Methodist Hospital - Houston; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Sydney; University of Sydney; University of Wisconsin System; University of Wisconsin Madison; Our Lady Lake Regional Medical Center; University of California System; University of California San Francisco; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hughes, CG (corresponding author), 1211 21st Ave S,422 MAB, Nashville, TN 37212 USA.	christopher.hughes@vumc.org	Swan, Joshua/AAC-5754-2019	Swan, Joshua/0000-0002-6390-2322; Duprey, Matthew/0000-0002-2365-431X; Hughes, Christopher/0000-0002-9261-5875; Rizk, Elsie/0000-0003-1390-1409; Girard, Timothy/0000-0002-9833-4871	National Institutes of Health (NIH) [HL111111]; NIH [TR000445, 1F31AG066460, HL135144]; National Heart Lung and Blood Institute [HL14678-01]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a grant (HL111111) from the National Institutes of Health (NIH), a grant (TR000445) from the NIH for the use of REDCap, grants from the NIH to Dr. Duprey (1F31AG066460) and to Dr. Girard (HL135144), and a grant from the National Heart Lung and Blood Institute to Dr. Pun (HL14678-01). Dexmedetomidine was provided by Pfizer (previously by Hospira).	Barnes-Daly MA, 2017, CRIT CARE MED, V45, P171, DOI 10.1097/CCM.0000000000002149; Chandrasekhar R, 2020, CRIT CARE RESUSC, V22, P63; Christie JD, 2006, J CRIT CARE, V21, P125, DOI 10.1016/j.jcrc.2005.11.004; Devlin JW, 2018, CRIT CARE MED, V46, pE825, DOI 10.1097/CCM.0000000000003299; Dhital R, 2018, J COMMUNITY HOSP INT, V8, P49, DOI 10.1080/20009666.2018.1450592; Djaiani G, 2016, ANESTHESIOLOGY, V124, P362, DOI 10.1097/ALN.0000000000000951; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC; Gelinas C, 2006, AM J CRIT CARE, V15, P420; Helmy SAK, 2001, ANAESTHESIA, V56, P4, DOI 10.1046/j.1365-2044.2001.01713.x; Inouye SK, 2014, LANCET, V383, P911, DOI 10.1016/S0140-6736(13)60688-1; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kawazoe Y, 2017, JAMA-J AM MED ASSOC, V317, P1321, DOI 10.1001/jama.2017.2088; Kelbel I, 1999, ACTA ANAESTH SCAND, V43, P71, DOI 10.1034/j.1399-6576.1999.430115.x; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; Memis D, 2007, BRIT J ANAESTH, V98, P550, DOI 10.1093/bja/aem017; Nishina K, 1999, ANESTH ANALG, V88, P452, DOI 10.1097/00000539-199902000-00042; Olsen HT, 2020, NEW ENGL J MED, V382, P1103, DOI 10.1056/NEJMoa1906759; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Pandharipande PP, 2010, CRIT CARE, V14, DOI 10.1186/cc8916; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Pun BT, 2019, CRIT CARE MED, V47, P3, DOI 10.1097/CCM.0000000000003482; Qiao H, 2009, CRIT CARE, V13, DOI 10.1186/cc8012; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923; Schuler A, 2018, CRIT CARE MED, V46, P769, DOI 10.1097/01.ccm.0000529571.72014.b4; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2019, NEW ENGL J MED, V380, P2506, DOI 10.1056/NEJMoa1904710; Shehabi Y, 2010, CRIT CARE MED, V38, P2311, DOI 10.1097/CCM.0b013e3181f85759; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Venn RM, 2001, BRIT J ANAESTH, V86, P650, DOI 10.1093/bja/86.5.650; Vincent JL, 2014, LANCET RESP MED, V2, P380, DOI 10.1016/S2213-2600(14)70061-X; Wang XB, 2011, CRIT CARE MED, V39, P738, DOI 10.1097/CCM.0b013e318206bd86	40	57	62	14	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	2021	384	15					1424	1436		10.1056/NEJMoa2024922	http://dx.doi.org/10.1056/NEJMoa2024922			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN7TA	33528922	Bronze, Green Accepted			2023-01-03	WOS:000640554500009
J	Bula-Oyola, E; Belda-Lois, JM; Porcar-Seder, R; Page, A				Bula-Oyola, Ena; Belda-Lois, Juan-Manuel; Porcar-Seder, Rosa; Page, Alvaro			Effectiveness of electrophysical modalities in the sensorimotor rehabilitation of radial, ulnar, and median neuropathies: A meta-analysis	PLOS ONE			English	Article							CARPAL-TUNNEL-SYNDROME; LEVEL LASER THERAPY; SHOCK-WAVE THERAPY; CONSERVATIVE TREATMENT; NERVE INJURIES; IMPORTANT DIFFERENCE; TERM EFFECTIVENESS; MAGNETIC-FIELD; ULTRASOUND; PAIN	Introduction People with ulnar, radial or median nerve injuries can present significant impairment of their sensory and motor functions. The prescribed treatment for these conditions often includes electrophysical therapies, whose effectiveness in improving symptoms and function is a source of debate. Therefore, this systematic review aims to provide an integrative overview of the efficacy of these modalities in sensorimotor rehabilitation compared to placebo, manual therapy, or between them. Methods We conducted a systematic review according to PRISMA guidelines. We perform a literature review in the following databases: Biomed Central, Ebscohost, Lilacs, Ovid, PEDro, Sage, Scopus, Science Direct, Semantic Scholar, Taylor & Francis, and Web of Science, for the period 1980-2020. We include studies that discussed the sensorimotor rehabilitation of people with non-degenerative ulnar, radial, or median nerve injury. We assessed the quality of the included studies using the Risk of Bias Tool described in the Cochrane Handbook of Systematic Reviews of Interventions and the risk of bias across studies with the GRADE approach described in the GRADE Handbook. Results Thirty-eight studies were included in the systematic review and 34 in the meta-analysis. The overall quality of evidence was rated as low or very low according to GRADE criteria. Low-level laser therapy and ultrasound showed favourable results in improving symptom severity and functional status compared to manual therapy. In addition, the low level laser showed improvements in pinch strength compared to placebo and pain (VAS) compared to manual therapy. Splints showed superior results to electrophysical modalities. The clinical significance of the results was assessed by effect size estimation and comparison with the minimum clinically important difference (MCID). Conclusions We found favourable results in pain relief, improvement of symptoms, functional status, and neurophysiological parameters for some electrophysical modalities, mainly when applied with a splint. Our results coincide with those obtained in some meta-analyses. However, none of these can be considered clinically significant.	[Bula-Oyola, Ena] Univ Politecn Valencia, Valencia, Spain; [Bula-Oyola, Ena] Univ Norte, Dept Diseno, Barranquilla, Colombia; [Belda-Lois, Juan-Manuel; Porcar-Seder, Rosa; Page, Alvaro] Univ Politecn Valencia, Inst Univ Ingn Mecan & Biomecan, Valencia, Spain; [Belda-Lois, Juan-Manuel] CIBER Bioingn Biomat & Nanomed, Grp Tecnol Sanit IBV, Valencia, Spain; [Page, Alvaro] Univ Politecn Valencia, Dept Fis Aplicada, Valencia, Spain	Universitat Politecnica de Valencia; Universidad del Norte; Universitat Politecnica de Valencia; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Universitat Politecnica de Valencia	Bula-Oyola, E (corresponding author), Univ Politecn Valencia, Valencia, Spain.; Bula-Oyola, E (corresponding author), Univ Norte, Dept Diseno, Barranquilla, Colombia.	oyolae@uninorte.edu.co	Oyola, Ena Bula/AAP-1384-2021; Belda Lois, Juan Manuel/GXZ-8293-2022	Oyola, Ena Bula/0000-0001-9158-5830; Belda Lois, Juan Manuel/0000-0002-7648-799X	Colombian Ministry of Science: "Formacion de capital humano de alto nivel para las regiones-Atlantico	Colombian Ministry of Science: "Formacion de capital humano de alto nivel para las regiones-Atlantico	EBO: scholarship from the Colombian Ministry of Science: "Formacion de capital humano de alto nivel para las regiones-Atlantico 2018". URL: https://minciencias.gov.co/convocatorias/oportunidades-formacion/formacion-capitalhumano-alto-nivel-para-las-regiones The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abid Ali S., 2012, J FM BAGHDAD INTERNE, V54, P234; Armagan O, 2014, CLINICS, V69, P524, DOI 10.6061/clinics/2014(08)04; Atya AM, 2011, LIFE SCI J, V8, P413; Bakhtiary AH, 2004, AUST J PHYSIOTHER, V50, P147, DOI 10.1016/S0004-9514(14)60152-5; Barbour J, 2012, J HAND SURG-AM, V37A, P2150, DOI 10.1016/j.jhsa.2012.07.022; Baysal O, 2006, INT J CLIN PRACT, V60, P820, DOI 10.1111/j.1742-1241.2006.00867.x; Bekhet AH, 2017, LASER MED SCI, V32, P1439, DOI 10.1007/s10103-017-2234-6; Bergmeister KD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229530; Badur NB, 2020, CLIN REHABIL, V34, P1048, DOI 10.1177/0269215520930062; Boyaci A, 2014, ARCH RHEUMATOL, V29, P298, DOI 10.5606/ArchRheumatol.2014.4246; Burger M, 2017, PHYSIOTHER THEOR PR, V33, P184, DOI 10.1080/09593985.2017.1282999; Caliandro P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006839.pub3; Campbell WW, 2008, CLIN NEUROPHYSIOL, V119, P1951, DOI 10.1016/j.clinph.2008.03.018; Carter R, 2002, J FAM PRACTICE, V51, P38; Casale R, 2013, EUR J PHYS REHAB MED, V49, P205; Centro Cochrane Iberoamericano, 2012, MAN COCHR REV SIST I; Chang WD, 2008, PHOTOMED LASER SURG, V26, P551, DOI 10.1089/pho.2007.2234; Chen LC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129918; Cheung WKW, 2020, PHYSIOTHERAPY, V106, P24, DOI 10.1016/j.physio.2019.06.005; Colbert AP, 2010, ARCH PHYS MED REHAB, V91, P1098, DOI 10.1016/j.apmr.2010.02.013; Dahlin LB, 2008, CURR ORTHOPAED, V22, P9, DOI 10.1016/j.cuor.2008.01.002; Dakowicz A, 2011, ADV MED SCI-POLAND, V56, P270, DOI 10.2478/v10039-011-0041-z; Dincer U, 2009, PHOTOMED LASER SURG, V27, P119, DOI 10.1089/pho.2008.2211; Evcik D, 2007, PHOTOMED LASER SURG, V25, P34, DOI 10.1089/pho.2006.2032; Evers S, 2018, MUSCLE NERVE, V57, P25, DOI 10.1002/mus.25723; Federation of European Societies for Surgery of the Hand, 2013, CURRENT TREATMENT NE; Fusakul Y, 2014, LASER MED SCI, V29, P1279, DOI 10.1007/s10103-014-1527-2; Gibson W, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011976.pub2; Hentz VR, 2019, J HAND SURG-EUR VOL, V44, P775, DOI 10.1177/1753193419864838; Huisstede BM, 2018, ARCH PHYS MED REHAB, V99, P1623, DOI 10.1016/j.apmr.2017.08.482; Ichihara S, 2008, INJURY, V39, pS29, DOI 10.1016/j.injury.2008.08.029; Jiang JA, 2011, J PHYS THER SCI, V23, P661, DOI 10.1589/jpts.23.661; Ke MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep38344; Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205; Kim JK, 2013, J HAND SURG-EUR VOL, V38E, P75, DOI 10.1177/1753193412442137; Kim JC, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016870; Koca I, 2014, RHEUMATOL INT, V34, P1639, DOI 10.1007/s00296-014-3005-3; Lad SP, 2010, NEUROSURGERY, V66, P953, DOI 10.1227/01.NEU.0000368545.83463.91; Lazovic M, 2014, PHOTOMED LASER SURG, V32, P336, DOI 10.1089/pho.2013.3563; Lemieux J, 2007, J CLIN EPIDEMIOL, V60, P448, DOI 10.1016/j.jclinepi.2006.08.006; Li ZJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004424; Lim YH, 2017, J HAND THER, V30, P397, DOI 10.1016/j.jht.2017.06.019; Livani B, 2006, J BONE JOINT SURG BR, V88B, P1625, DOI 10.1302/0301-620X.88B12.17924; Milicin C, 2018, NEUROREHABILITATION, V42, P113, DOI 10.3233/NRE-172220; Muslumanoglu L., 2011, TURKISH J PHYS MED R, P1; O'Connor D, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003219, DOI 10.1002/14651858.CD003219]; Oshima Chikara, 2018, Laser Ther, V27, P56, DOI 10.5978/islsm.18-OR-06; Ozkan FU, 2015, ACTA NEUROL BELG, V115, P355, DOI 10.1007/s13760-014-0377-9; Oztas O, 1998, ARCH PHYS MED REHAB, V79, P1540, DOI 10.1016/S0003-9993(98)90416-6; Ozyurekoglu T, 2006, J HAND SURG-AM, V31A, P733, DOI 10.1016/j.jhsa.2006.01.012; Page MJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009601.pub2; Page P, 2014, INT J SPORTS PHYS TH, V9, P726; Paoloni M, 2015, EUR J PHYS REHAB MED, V51, P521; Patterson JMM, 2016, HAND CLIN, V32, P219, DOI 10.1016/j.hcl.2015.12.009; Peters S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004158.pub3; Piazzini D, 2007, CLIN REHABIL, V21, P299, DOI 10.1177/0269215507077294; Pratelli E, 2015, J BODYW MOV THER, V19, P113, DOI 10.1016/j.jbmt.2014.08.002; Raeissadat SA, 2014, J LASERS MED SCI, V5, P39; Raissi GR, 2017, ULTRASOUND MED BIOL, V43, P453, DOI 10.1016/j.ultrasmedbio.2016.08.022; Rasulic L, 2015, ACTA CLIN CROAT, V54, P19; Saeed FUR., 2012, PAKISTAN J MED HEAL, V6, P238; Sawyer ML, 1997, INT J HEAT MASS TRAN, V40, P2123, DOI 10.1016/S0017-9310(96)00267-0; Schunemann H, 2013, GRADE HDB; Scott Kevin R, 2013, Handb Clin Neurol, V110, P499, DOI 10.1016/B978-0-444-52901-5.00042-3; Shooshtari S M J, 2008, Electromyogr Clin Neurophysiol, V48, P229; Sim SE, 2019, J HAND THER, V32, P411, DOI 10.1016/j.jht.2018.01.004; Singh S., 2020, IP INT J AESTHETIC H, V3, P22; Soldado F, 2016, HAND CLIN, V32, P209, DOI 10.1016/j.hcl.2015.12.008; Tascioglu F, 2012, RHEUMATOL INT, V32, P409, DOI 10.1007/s00296-010-1652-6; Terzis JK, 2011, PLAST RECONSTR SURG, V127, P739, DOI 10.1097/PRS.0b013e3181fed7de; Verdugo RJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001552.pub2; Villafane JH, 2017, REHABIL NURS, V42, P139, DOI 10.1002/rnj.196; Wani A., 2020, INT J SURG MED, V6, P30; WASSERTHEIL S, 1970, BIOMETRICS, V26, P588, DOI 10.2307/2529115; Weintraub MI, 2008, PAIN MED, V9, P493, DOI 10.1111/j.1526-4637.2007.00324.x; Wipperman J, 2016, AM FAM PHYSICIAN, V94, P993; Wolny T, 2017, J MANIP PHYSIOL THER, V40, P263, DOI 10.1016/j.jmpt.2017.02.004; Wu YT, 2019, MUSCLE NERVE, V59, P174, DOI 10.1002/mus.26358; Wu YT, 2016, J ORTHOP RES, V34, P977, DOI 10.1002/jor.23113; Yagci I, 2009, CLIN RHEUMATOL, V28, P1059, DOI 10.1007/s10067-009-1213-0	80	1	1	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0248484	10.1371/journal.pone.0248484	http://dx.doi.org/10.1371/journal.pone.0248484			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QZ9HN	33735212	Green Published, gold			2023-01-03	WOS:000631029700090
J	Hodder, SL; Feinberg, J; Strathdee, SA; Shoptaw, S; Altice, FL; Ortenzio, L; Beyrer, C				Hodder, Sally L.; Feinberg, Judith; Strathdee, Steffanie A.; Shoptaw, Steven; Altice, Frederick L.; Ortenzio, Louis; Beyrer, Chris			The opioid crisis and HIV in the USA: deadly synergies	LANCET			English	Review							MEDICATION-ASSISTED TREATMENT; INJECT DRUGS; UNITED-STATES; PREEXPOSURE PROPHYLAXIS; SUBSTITUTION TREATMENT; METHADONE TREATMENT; VIRUS-INFECTION; RISK BEHAVIORS; RURAL-AREAS; PREVENTION	The opioid epidemic is one of the greatest public health problems that the USA faces. Opioid overdose death rates have increased steadily for more than a decade and doubled in 2013-17, as the highly potent synthetic opioid fentanyl entered the drug supply. Demographics of new HIV diagnoses among people who inject drugs are also changing, with more new HIV diagnoses occurring among White people, young people (aged 13-34 years), and people who reside outside large central metropolitan areas. Racial differences also exist in syringe sharing, which decreased among Black people and Hispanic people but remained unchanged among White people in 2005-15. Recent HIV outbreaks have occurred in rural areas of the USA, as well as among marginalised people in urban areas with robust HIV prevention and treatment services (eg, Seattle, WA). Multiple evidence-based interventions can effectively treat opioid use disorder and prevent HIV acquisition. However, considerable barriers exist precluding delivery of these solutions to many people who inject drugs. If the USA is serious about HIV prevention among this group, stigma must be eliminated, discriminatory policies must change, and comprehensive health care must be accessible to all. Finally, root causes of the opioid epidemic such as hopelessness need to be identified and addressed.	[Hodder, Sally L.; Feinberg, Judith] West Virginia Univ, Univ Hlth Sci Ctr, West Virginia Clin & Translat Sci Inst, Morgantown, WV 26506 USA; [Strathdee, Steffanie A.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Shoptaw, Steven] Univ Calif Los Angeles, Los Angeles, CA USA; [Altice, Frederick L.] Yale Univ, New Haven, CT USA; [Ortenzio, Louis] Clarksburg Mission, Clarksburg, WV USA; [Beyrer, Chris] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Baltimore, MD USA	West Virginia University; University of California System; University of California San Diego; University of California System; University of California Los Angeles; Yale University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Hodder, SL (corresponding author), West Virginia Univ, Univ Hlth Sci Ctr, West Virginia Clin & Translat Sci Inst, Morgantown, WV 26506 USA.	slhodder@hsc.wvu.edu		Shoptaw, Steven/0000-0002-3583-0026; feinberg, judith/0000-0003-4206-7214	Foundation for AIDS Research (amfAR); National Institute on Drug Abuse (NIDA) [R01-DA030768, U01 DA045384, R01 DA033679, R01 DA043125, R01 DA029910]; West Virginia Clinical and Translational Science Institute [NIGMS U54GM104942]; NIDA Merit Award [R37-DA019829]	Foundation for AIDS Research (amfAR); National Institute on Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); West Virginia Clinical and Translational Science Institute; NIDA Merit Award	This Series paper was supported by unrestricted grants from the Foundation for AIDS Research (amfAR), the National Institute on Drug Abuse (NIDA; R01-DA030768, U01 DA045384, R01 DA033679, R01 DA043125, R01 DA029910), and the West Virginia Clinical and Translational Science Institute NIGMS U54GM104942), and by a NIDA Merit Award (R37-DA019829).	Akbarzadeh V, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3887-y; Allen ST, 2020, AIDS BEHAV, V24, P1942, DOI 10.1007/s10461-019-02767-3; Alpren C, 2020, AM J PUBLIC HEALTH, V110, P37, DOI 10.2105/AJPH.2019.305366; Altice FL, 2010, LANCET, V376, P367, DOI 10.1016/S0140-6736(10)60829-X; Andrilla CHA, 2019, J RURAL HEALTH, V35, P108, DOI 10.1111/jrh.12307; Arias Elizabeth, 2019, Natl Vital Stat Rep, V68, P1; Aspinall EJ, 2014, INT J EPIDEMIOL, V43, P235, DOI 10.1093/ije/dyt243; Auty SG, 2020, J SUBST ABUSE TREAT, V115, DOI 10.1016/j.jsat.2020.108032; Baker DW, 2017, JAMA-J AM MED ASSOC, V317, P1117, DOI 10.1001/jama.2017.0935; Barnett ML, 2019, HEALTH AFFAIR, V38, P2048, DOI 10.1377/hlthaff.2019.00859; Bazzi AR, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6314-8; Bennett AS, 2011, J URBAN HEALTH, V88, P1020, DOI 10.1007/s11524-011-9600-7; Bernard CL, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002312; Bromberg DJ, 2020, CURR OPIN HIV AIDS, V15, P232, DOI 10.1097/COH.0000000000000631; Carroll Kathleen M, 2019, Focus (Am Psychiatr Publ), V17, P183, DOI 10.1176/appi.focus.17206; Case A, 2017, BROOKINGS PAP ECO AC, P397; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; Cicero TJ, 2015, JAMA PSYCHIAT, V72, P424, DOI 10.1001/jamapsychiatry.2014.3043; Cole ES, 2019, J GEN INTERN MED, V34, P936, DOI 10.1007/s11606-019-04943-6; Davies MC, ASSOCIATIONS NONMEDI; Degenhardt L, 2010, LANCET, V376, P285, DOI 10.1016/S0140-6736(10)60742-8; Dennis BB, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-105; Des Jarlais DC, 2015, MMWR-MORBID MORTAL W, V64, P1337, DOI 10.15585/mmwr.mm6448a3; Des Jarlais DC, 2012, DRUG ALCOHOL DEPEN, V124, P95, DOI 10.1016/j.drugalcdep.2011.12.020; Deweerdt S, 2019, NATURE, V573, pS10, DOI 10.1038/d41586-019-02686-2; Dowell D, 2016, HEALTH AFFAIR, V35, P1876, DOI 10.1377/hlthaff.2016.0448; Esmaeili A, 2017, J VIRAL HEPATITIS, V24, P117, DOI 10.1111/jvh.12628; Eyre E., 2016, DRUG FIRMS POURED 78; Feinberg J, 2019, NATURE, V573, P165, DOI 10.1038/d41586-019-02671-9; Figueroa C, 2015, AIDS BEHAV, V19, P1949, DOI 10.1007/s10461-015-1097-8; Fleischauer AT, 2017, MMWR-MORBID MORTAL W, V66, P569, DOI 10.15585/mmwr.mm6622a1; Gibson A, 2008, ADDICTION, V103, P462, DOI 10.1111/j.1360-0443.2007.02090.x; Gibson BA, 2017, J HEALTH CARE POOR U, V28, P643, DOI 10.1353/hpu.2017.0065; Golden MR, 2019, MMWR-MORBID MORTAL W, V68, P344, DOI 10.15585/mmwr.mm6815a2; Gonsalves GS, 2018, LANCET HIV, V5, pE569, DOI 10.1016/S2352-3018(18)30176-0; Green TC, 2020, SUBST ABUS, V41, P147, DOI 10.1080/08897077.2020.1752351; Guise A, 2017, ADDICTION, V112, P572, DOI 10.1111/add.13437; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Hagan H, 2000, J SUBST ABUSE TREAT, V19, P247, DOI 10.1016/S0740-5472(00)00104-5; Hansen H, 2016, DRUG ALCOHOL DEPEN, V164, P14, DOI 10.1016/j.drugalcdep.2016.03.028; Hedegaard Holly, 2020, NCHS Data Brief, P1; Institute of Medicine, 2007, PREV HIV INF DRUG US; International Network of People who Use Drugs, 2015, POSITION PAPER PREEX; Irwin A, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0153-2; Jalal H, 2018, SCIENCE, V361, P1218, DOI 10.1126/science.aau1184; Johnson RE, 2000, NEW ENGL J MED, V343, P1290, DOI 10.1056/NEJM200011023431802; Jones CM, 2019, ADDICTION, V114, P471, DOI 10.1111/add.14436; Jones CM, 2013, DRUG ALCOHOL DEPEN, V132, P95, DOI 10.1016/j.drugalcdep.2013.01.007; Joudrey PJ, 2019, JAMA-J AM MED ASSOC, V322, P1310, DOI 10.1001/jama.2019.12562; Kelly JF, 2019, TREATING OPIOID ADDI; Kennedy-Hendricks A, 2016, AM J PUBLIC HEALTH, V106, P291, DOI 10.2105/AJPH.2015.302953; Kerr Thomas, 2007, Curr HIV/AIDS Rep, V4, P158, DOI 10.1007/s11904-007-0023-8; Kishore S, 2019, NEW ENGL J MED, V380, P1988, DOI 10.1056/NEJMp1901276; Knudsen HK, 2019, INT J DRUG POLICY, V70, P8, DOI 10.1016/j.drugpo.2019.04.008; Lambdin BH, 2019, INT J DRUG POLICY, V74, P299, DOI 10.1016/j.drugpo.2019.10.004; Lee JD, 2018, LANCET, V391, P309, DOI 10.1016/S0140-6736(17)32812-X; Low AJ, 2016, CLIN INFECT DIS, V63, P1094, DOI 10.1093/cid/ciw416; MacArthur GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5945; MacDonald M., 2003, International Journal of Drug Policy, V14, P353, DOI 10.1016/S0955-3959(03)00133-6; Madden LM, 2018, ADDICTION, V113, P1450, DOI 10.1111/add.14198; Mahajan AP, 2008, AIDS, V22, pS67, DOI 10.1097/01.aids.0000327438.13291.62; Mancher M., 2019, MEDICATIONS OPIOID U; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; McFarland W, 2020, AIDS BEHAV, V24, P1290, DOI 10.1007/s10461-019-02682-7; Melvin SC, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.200256; Miller WC, 2018, LANCET, V392, P747, DOI 10.1016/S0140-6736(18)31487-9; MMWR, 2017, MMWR-MORBID MORTAL W, V66, P697; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; National Institute on Drug Abuse, 2021, OV DEATH RAT; Oster AM, 2018, C RETR OPP INF BOST; Owens DK, 2019, JAMA-J AM MED ASSOC, V321, P2203, DOI 10.1001/jama.2019.6390; Page K, 2015, JAIDS-J ACQ IMM DEF, V69, pS169, DOI 10.1097/QAI.0000000000000641; Peters PJ, 2016, NEW ENGL J MED, V375, P229, DOI 10.1056/NEJMoa1515195; Pitt AL, 2018, AM J PUBLIC HEALTH, V108, P1394, DOI 10.2105/AJPH.2018.304590; Ruiz MS, 2019, JAIDS-J ACQ IMM DEF, V82, pS148, DOI 10.1097/QAI.0000000000002176; Salmon AM, 2009, DRUG ALCOHOL DEPEN, V101, P132, DOI 10.1016/j.drugalcdep.2008.12.002; Schranz AJ, 2018, CURR HIV-AIDS REP, V15, P245, DOI 10.1007/s11904-018-0393-0; Sherman SG, 2019, DRUG ALCOHOL DEPEN, V195, P148, DOI 10.1016/j.drugalcdep.2018.08.014; Shrestha R, 2020, PATIENT PREFER ADHER, V14, P107, DOI 10.2147/PPA.S236794; Shrestha R, 2018, AIDS BEHAV, V22, P2640, DOI 10.1007/s10461-018-2099-0; Shrestha R, 2018, AIDS BEHAV, V22, P1228, DOI 10.1007/s10461-017-1851-1; Shrestha R, 2017, DRUG ALCOHOL DEPEN, V173, P107, DOI 10.1016/j.drugalcdep.2016.12.023; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Strathdee SA, 2020, AIDS, V34, P1997, DOI 10.1097/QAD.0000000000002673; Strathdee SA, 2015, NEW ENGL J MED, V373, P1380, DOI 10.1056/NEJMc1510396; Substance Abuse and Mental Health Services Administration, 2017, KEY SUBSTANCE USE ME; Substance Abuse and Mental Health Services Agency, 2020, MED ASS TREATM 2020; Suryaprasad AG, 2014, CLIN INFECT DIS, V59, P1411, DOI 10.1093/cid/ciu643; Swiss Health Service for Small Ruminants, 2020, TECHN INSTR FOOTR CO; Sypsa V, 2017, J INFECT DIS, V215, P1496, DOI 10.1093/infdis/jix100; Timko C, 2016, J ADDICT DIS, V35, P22, DOI 10.1080/10550887.2016.1100960; Twillman RK, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.18514; US Centers for Disease Control and Prevention, 2018, HIV SURVEILLANCE SPE; US Centers for Disease Control and Prevention, 2018, HIV SURV WOM; US Centers for Disease Control and Prevention, 2019, SYNTH OP OV DAT; US Centers for Disease Control and Prevention, 2018, HIV SURV PERS WHO IN; US Centers for Disease Control and Prevention, HIV SURVEILLANCE REP; US Department of Health and Human Services, 2019, WHAT IS END HIV EP P; US National Academies of Sciences Engineering and Medicine, 2020, OPPORTUNITIES IMPROV; US Public Health Service, 2018, PREXP PROPH PREV HIV; US Veterans Health Administration, 2000, PAIN 5 VITAL SIGN TO; Wegman MP, 2017, LANCET GLOB HEALTH, V5, pE198, DOI 10.1016/S2214-109X(16)30303-5; Wejnert C, 2016, MMWR-MORBID MORTAL W, V65, P1336, DOI 10.15585/mmwr.mm6547e1; Wood E, 2005, INT J DRUG POLICY, V16, P281, DOI 10.1016/j.drugpo.2005.07.004; Wood E, 2007, ADDICTION, V102, P916, DOI 10.1111/j.1360-0443.2007.01818.x; Zee AV, 2009, AM J PUBLIC HEALTH, V99, P221, DOI 10.2105/AJPH.2007.131714; Zhang C, 2019, AIDS PATIENT CARE ST, V33, P507, DOI 10.1089/apc.2019.0119; Zibbell JE, 2015, MMWR-MORBID MORTAL W, V64, P453	109	27	27	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2021	397	10279					1139	1150		10.1016/S0140-6736(21)00391-3	http://dx.doi.org/10.1016/S0140-6736(21)00391-3		MAR 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QZ0AN	33617769				2023-01-03	WOS:000630397800031
J	Pu, J; Mei, H; Lei, L; Li, DW; Zhao, JK; Li, B; Wang, HY; Ma, Y; Du, XB				Pu, Jing; Mei, He; Lei, Li; Li, Daiwen; Zhao, Jiekun; Li, Bin; Wang, Haiyan; Ma, Ying; Du, Xiao Bo			Knowledge of medical professionals, their practices, and their attitudes toward traditional Chinese medicine for the prevention and treatment of coronavirus disease 2019: A survey in Sichuan, China	PLOS ONE			English	Article							WECHAT	This study aimed to investigate the knowledge, practices, and attitudes of medical professionals toward Traditional Chinese Medicine (TCM) for the prevention and treatment of coronavirus disease 2019 (COVID-19). All 401 medical professionals were surveyed using an anonymous with an investigator using the Questionnaire star APP. The participants answered 14 questions; of the 401 participants, 55.2% agreed with the statement "TCM can be used for the prevention and treatment of COVID-19," 40.4% remained neutral, and 4.4% disagreed. Moreover, 75.3% agreed with the statement "There is no specific drug for COVID-19," 67% agreed with the statement "TCM can develop immunity to COVID-19" and 62.1% agreed with "TCM can alleviate the symptoms of patients with COVID-19." Meanwhile, 69.1% were aware that TCM has been recommended for COVID-19 by the National Health Commission of the People's Republic of China. Regarding the selection of sources of knowledge on whether "TCM can be used for the prevention and treatment of COVID-19," There were 277, 123, 82, 369, and 17 participants selected sources from "Hospital training," "Academic journals," "Academic Conferences," "Social media platforms (such as WeChat)" and "Others," respectively. Further, 358 participants will take TCM for the prevention of COVID-19. Multiple logistic regression analysis showed that age, major and received TCM treatment within the last five years were independent factors affecting the participants' attitudes. In the absence of specific drugs for COVID-19, more than half of the participants agreed that TCM could be used for the prevention and treatment of COVID-19 and most participants are willing to take TCM to prevent COVID-19, although unsure about its effectiveness. The main information sources on TCM for the treatment and prevention of COVID-19 were social platforms and hospital training.	[Pu, Jing; Lei, Li; Li, Daiwen; Zhao, Jiekun; Li, Bin] Mianyang Cent Hosp, Dept Tradit Chinese Med, Mianyang, Sichuan, Peoples R China; [Mei, He; Wang, Haiyan] Mianyang Cent Hosp, Dept Nursing, Mianyang, Sichuan, Peoples R China; [Ma, Ying] Mianyang Cent Hosp, Sci Res & Educ Dept, Mianyang, Sichuan, Peoples R China; [Du, Xiao Bo] Mianyang Cent Hosp, Dept Oncol, Mianyang, Sichuan, Peoples R China		Ma, Y (corresponding author), Mianyang Cent Hosp, Sci Res & Educ Dept, Mianyang, Sichuan, Peoples R China.; Du, XB (corresponding author), Mianyang Cent Hosp, Dept Oncol, Mianyang, Sichuan, Peoples R China.	1099435982@qq.com; duxiaobo2005@126.com		Du, Xiao-bo/0000-0001-6348-0636				Cao JL, 2020, CLIN INFECT DIS, V71, P748, DOI 10.1093/cid/ciaa243; Cao JL, 2020, INTENS CARE MED, V46, P851, DOI 10.1007/s00134-020-05987-7; Chinese Medical Association, NOT POSTP AC M CHIN; Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658; Fan LL, 2018, J INT MED RES, V46, P1709, DOI 10.1177/0300060518756244; Harmsworth K, 2001, SOC SCI MED, V52, P149, DOI 10.1016/S0277-9536(00)00124-6; Hon KLE, 2006, J NURS EDUC, V45, P182, DOI 10.3928/01484834-20060501-08; Hon KLE, 2005, AM J CHINESE MED, V33, P269, DOI 10.1142/S0192415X05002904; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Liu ZD, 2017, J TRADIT CHIN MED, V37, P261; Long XB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181895; Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6; Montag C, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02247; National Health Commission of the People's Republic of China, NOTICE PRINTING DIST; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; Shen LN, 2019, J MED INTERNET RES, V21, DOI 10.2196/13025; Wang J, 2017, BIOCHEM MOL BIOL EDU, V45, P421, DOI 10.1002/bmb.21065; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wang ZR, 2019, INT J NURS STUD, V98, P19, DOI 10.1016/j.ijnurstu.2019.06.001; Zhang W, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9607; Zhang XT, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0470-0; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	24	6	6	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2021	16	3							e0234855	10.1371/journal.pone.0234855	http://dx.doi.org/10.1371/journal.pone.0234855			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QY1VJ	33725021	Green Published, gold			2023-01-03	WOS:000629833700013
J	Wang, K; Yang, JC; Jang, YJ; Chen, GY; Zhang, YJ; Dai, YH; Zhang, DY; Wu, YC				Wang, Ke; Yang, Juan-Cheng; Jang, Yeong-Jiunn; Chen, Guan-Yu; Zhang, Ya-Jing; Dai, Yun-Hao; Zhang, Da-Yong; Wu, Yang-Chang			19-(Benzyloxy)-19-oxojolkinolide B (19-BJB), an ent-abietane diterpene diepoxide, inhibits the growth of bladder cancer T24 cells through DNA damage	PLOS ONE			English	Article							DOUBLE-STRAND BREAKS; JOLKINOLIDE-B; IN-VITRO; KAPPA-B; ACTIVATION; KINASE; REPAIR; CISPLATIN; APOPTOSIS; BINDING	Diterpenoids jolkinolide A and B, were first isolated from Euphorbia fischeriana. In our previous research, 19-(Benzyloxy)-19-oxojolkinolide B (19-BJB), a derivative of jolkinolides, was synthesized as a novel ent -abietane diterpene diepoxide. In this study, 19-BJB showed strong in vitro activity against bladder cancer cell lines. DNA damage which was observed through the interaction of 19-BJB with nucleotide chains and affected DNA repair resulted in the activation of checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) in bladder cancer cell lines. In vivo testing in nude mice also proved that 19-BJB revealed a potential inhibitory effect on tumor growth. Additionally, the 3D-QSAR models of jolkinolides were established. Briefly, we proved that 19-BJB could potentially be used as a drug to inhibit the growth of bladder tumor.	[Wang, Ke; Zhang, Ya-Jing; Zhang, Da-Yong] China Pharmaceut Univ, Dept Med Chem, Nanjing, Peoples R China; [Wang, Ke; Zhang, Ya-Jing; Zhang, Da-Yong] China Pharmaceut Univ, Ctr Drug Discovery, Nanjing, Peoples R China; [Wang, Ke; Wu, Yang-Chang] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Yang, Juan-Cheng; Jang, Yeong-Jiunn; Chen, Guan-Yu; Dai, Yun-Hao; Wu, Yang-Chang] China Med Univ Hosp, Chinese Med Res & Dev Ctr, Taichung, Taiwan; [Wu, Yang-Chang] Asia Univ, Coll Med & Hlth Sci, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan	China Pharmaceutical University; China Pharmaceutical University; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Zhang, DY (corresponding author), China Pharmaceut Univ, Dept Med Chem, Nanjing, Peoples R China.; Zhang, DY (corresponding author), China Pharmaceut Univ, Ctr Drug Discovery, Nanjing, Peoples R China.; Wu, YC (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.; Wu, YC (corresponding author), China Med Univ Hosp, Chinese Med Res & Dev Ctr, Taichung, Taiwan.; Wu, YC (corresponding author), Asia Univ, Coll Med & Hlth Sci, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan.	zhangdayong@cpu.edu.cn; yachwu@gmail.com		Chen, Guan-Yu/0000-0002-2773-8748	National Natural Science Foundation of China [30973607, 81172934]; Ministry of Science and Technology of Taiwan [MOST 103-2911-I-002-303, MOST 104-2911-I-002-302, MOST 107-2320-B-037-001]; National Health Research Institutes of Taiwan [NHRI-EX104-10241BI]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes of Taiwan(National Health Research Institutes - Taiwan)	This research was funded by the National Natural Science Foundation of China (No. 30973607; No. 81172934); Ministry of Science and Technology of Taiwan (MOST 103-2911-I-002-303; MOST 104-2911-I-002-302; MOST 107-2320-B-037-001), National Health Research Institutes of Taiwan (NHRI-EX104-10241BI).	Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Caffo O, 2011, CANCER-AM CANCER SOC, V117, P1190, DOI 10.1002/cncr.25667; Canals A, 2005, ACTA CRYSTALLOGR D, V61, P1009, DOI 10.1107/S0907444905015404; CHENG KC, 1992, J BIOL CHEM, V267, P166; Dean N, 1996, CANCER RES, V56, P3499; Dominici L., 2011, International Journal of Probiotics and Prebiotics, V6, P179; Freitas RF, 2009, BIOORGAN MED CHEM, V17, P2476, DOI 10.1016/j.bmc.2009.01.079; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; GOVARDHAN C, 1984, PHYTOCHEMISTRY, V23, P411, DOI 10.1016/S0031-9422(00)80342-8; GRAY GD, 1993, CANCER RES, V53, P577; Hanson JR, 2015, NAT PROD REP, V32, P76, DOI 10.1039/c4np00108g; Huang TY, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13122; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Ji XH, 1997, BIOCHEMISTRY-US, V36, P9690, DOI 10.1021/bi970805s; Kanvah S, 2010, ACCOUNTS CHEM RES, V43, P280, DOI 10.1021/ar900175a; Karsten R., 1997, BIF FUTURA, V12, P20; Lee HP, 2019, J FUNCT FOODS, V52, P537, DOI 10.1016/j.jff.2018.11.040; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lenis AT, 2020, JAMA-J AM MED ASSOC, V324, P1980, DOI [10.1001/jama.2020.17598, 10.1001/jama.2020.17601]; Liu SC, 2017, SCI REP-UK, V7, DOI 10.1038/srep43205; Liu WK, 2002, BIOCHEM PHARMACOL, V63, P951, DOI 10.1016/S0006-2952(01)00938-8; Luo HY, 2006, CAN J PHYSIOL PHARM, V84, P959, DOI 10.1139/Y06-045; Ma XJ, 2014, BIOCHEM BIOPH RES CO, V445, P282, DOI 10.1016/j.bbrc.2014.01.145; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Man SL, 2012, PHYTOTHER RES, V26, P1449, DOI 10.1002/ptr.4609; McNeely S, 2014, PHARMACOL THERAPEUT, V142, P1, DOI 10.1016/j.pharmthera.2013.10.005; Moretti M, 2013, FOOD CHEM, V140, P660, DOI 10.1016/j.foodchem.2012.10.022; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Pascal JM, 2018, DNA REPAIR, V71, P177, DOI 10.1016/j.dnarep.2018.08.022; Prevost Gregoire Pierre, 2003, Prog Cell Cycle Res, V5, P225; Pu YS, 2001, J UROLOGY, V165, P2082, DOI 10.1016/S0022-5347(05)66298-2; Richters A, 2020, WORLD J UROL, V38, P1895, DOI 10.1007/s00345-019-02984-4; Rothkamm K, 2015, ENVIRON MOL MUTAGEN, V56, P491, DOI 10.1002/em.21944; Samanta SK, 2013, J MED CHEM, V56, P5709, DOI 10.1021/jm400290q; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Scully R, 2013, MUTAT RES-FUND MOL M, V750, P5, DOI 10.1016/j.mrfmmm.2013.07.007; Shi HM, 2005, PLANTA MED, V71, P349, DOI 10.1055/s-2005-864102; Shi LY, 2011, SYNTHESIS-STUTTGART, P3807, DOI 10.1055/s-0031-1289293; Shi QW, 2008, CHEM REV, V108, P4295, DOI 10.1021/cr078350s; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Thoh M, 2011, J BIOL CHEM, V286, P4690, DOI 10.1074/jbc.M110.169334; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Tichy A., 2012, MIL MED SCI LETT, V81, P176, DOI [10.31482/mmsl.2012.025, DOI 10.31482/MMSL.2012.025]; Uto T, 2012, INT IMMUNOPHARMACOL, V12, P101, DOI 10.1016/j.intimp.2011.10.020; Wang JH, 2011, MOL CELLS, V32, P451, DOI 10.1007/s10059-011-0137-0; Wang K, 2016, SYNTHESIS-STUTTGART, V48, P2245, DOI 10.1055/s-0035-1561598; Wang Y, 2009, CANCER RES, V69, P7302, DOI 10.1158/0008-5472.CAN-09-0462; Wu QC, 2009, MOLECULES, V14, P4454, DOI 10.3390/molecules14114454; Yan SS, 2008, MOL CANCER THER, V7, P1523, DOI 10.1158/1535-7163.MCT-08-0263; Yang HL, 2015, INT IMMUNOPHARMACOL, V26, P119, DOI 10.1016/j.intimp.2015.03.021; Yu Hong-Jeng, 1992, Journal of the Formosan Medical Association, V91, P608; Zhu CZ, 2014, SYNTHESIS-STUTTGART, V46, P2574, DOI 10.1055/s-0034-1378317	56	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2021	16	3							e0248468	10.1371/journal.pone.0248468	http://dx.doi.org/10.1371/journal.pone.0248468			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY1VJ	33724994	Green Published, gold			2023-01-03	WOS:000629833700029
J	Zhong, YX; Yu, JS; Wang, XQ; Binas, B; Yoo, HH				Zhong, Yixiang; Yu, Jun Sang; Wang, Xiaoqiong; Binas, Bert; Yoo, Hye Hyun			Chemical-based primary human hepatocyte monolayer culture for the study of drug metabolism and hepatotoxicity: Comparison with the spheroid model	FASEB JOURNAL			English	Article						drug&#8208; induced liver injury; drug metabolism; hepatotoxicity; long&#8208; term cell culture; primary human hepatocyte		Traditionally cultured monolayers of primary human hepatocytes (PHHs) deteriorate within days and thereby become unsuitable for drug-related studies. PHH spheroids (3D PHHs) maintain liver functions for weeks, but are considerably more demanding. Recently, a chemical-based approach (5C PHHs) succeeded in long-term culture of hepatocyte monolayers, but it remains unclear whether the drug-related functions are preserved. To clarify this, we compared the 5C and 3D PHHs in terms of gene expression analysis, proteomic analysis, functionality (basal and induced activities of representative CYP450 enzymes and urea and albumin secretions), survival in culture, and sensitivity to representative drugs. In all comparisons, which spanned culture durations of up to 4 weeks, the 5C PHHs performed at least as well as the 3D PHHs. Hence, the novel 5C PHH monolayer format combines the convenience of the traditional monolayer format with the functionality and maintainability of the spheroid format. Our results suggest that 5C PHH monolayers can be used more conveniently and efficiently for high-throughput drug screening, preclinical drug safety evaluations, and mechanistic studies.	[Zhong, Yixiang; Yu, Jun Sang; Yoo, Hye Hyun] Hanyang Univ, Inst Pharmaceut Sci & Technol, Ansan, Gyeonggi Do, South Korea; [Zhong, Yixiang; Yu, Jun Sang; Yoo, Hye Hyun] Hanyang Univ, Coll Pharm, Ansan, Gyeonggi Do, South Korea; [Zhong, Yixiang; Wang, Xiaoqiong; Binas, Bert] Hanyang Univ, Dept Mol & Life Sci, Ansan, South Korea	Hanyang University; Hanyang University; Hanyang University	Yoo, HH (corresponding author), Hanyang Univ, Inst Pharmaceut Sci & Technol, Ansan, Gyeonggi Do, South Korea.; Yoo, HH (corresponding author), Hanyang Univ, Coll Pharm, Ansan, Gyeonggi Do, South Korea.	yoohh@hanyang.ac.kr			National Research Foundation of Korea (NRF) [2017R1A2B4001814]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea)	National Research Foundation of Korea (NRF), Grant/Award Number: 2017R1A2B4001814	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Baze A, 2018, TISSUE ENG PART C-ME, V24, P534, DOI [10.1089/ten.tec.2018.0134, 10.1089/ten.TEC.2018.0134]; Bell CC, 2018, TOXICOL SCI, V162, P655, DOI 10.1093/toxsci/kfx289; Bell CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep25187; Bjornsson ES, 2015, ARCH TOXICOL, V89, P327, DOI 10.1007/s00204-015-1456-2; Boteon YL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201419; Chapman KL, 2013, REGUL TOXICOL PHARM, V66, P88, DOI 10.1016/j.yrtph.2013.03.001; Esposti DD, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/387626; Gerets HHJ, 2012, CELL BIOL TOXICOL, V28, P69, DOI 10.1007/s10565-011-9208-4; Germano D, 2015, TOXICOL IN VITRO, V30, P79, DOI 10.1016/j.tiv.2014.05.009; Gu XL, 2018, ARCH TOXICOL, V92, P3505, DOI 10.1007/s00204-018-2302-0; HAUSSINGER D, 1990, KLIN WOCHENSCHR, V68, P1096, DOI 10.1007/BF01798059; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Jang KJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax5516; Gomez-Lechon MJ, 2014, EXPERT OPIN DRUG MET, V10, P1553, DOI 10.1517/17425255.2014.967680; Katsuda T, 2020, FEBS LETT, V594, P114, DOI 10.1002/1873-3468.13582; Lauschke VM, 2016, CHEM RES TOXICOL, V29, P1936, DOI 10.1021/acs.chemrestox.6b00150; LEE CH, 1993, J CELL PHYSIOL, V157, P392, DOI 10.1002/jcp.1041570223; Lewis DFV, 1998, ENVIRON HEALTH PERSP, V106, P633; Lushchak Volodymyr I, 2012, J Amino Acids, V2012, P736837, DOI 10.1155/2012/736837; Ma J, 2019, NUCLEIC ACIDS RES, V47, pD1211, DOI 10.1093/nar/gky869; MacParland SA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06318-7; Martignoni M, 2006, EXPERT OPIN DRUG MET, V2, P875, DOI 10.1517/17425255.2.6.875; McMillian MK, 2001, IN VITRO MOL TOXICOL, V14, P177, DOI 10.1089/109793301753407948; Oorts M, 2016, TOXICOL IN VITRO, V34, P179, DOI 10.1016/j.tiv.2016.03.008; Oorts M, 2015, J PHARMACOL TOX MET, V73, P63, DOI 10.1016/j.vascn.2015.03.002; Prieur X, 2005, J BIOL CHEM, V280, P27533, DOI 10.1074/jbc.M503139200; Regenthal R, 1999, J CLIN MONITOR COMP, V15, P529, DOI 10.1023/A:1009935116877; Shen T, 2019, GASTROENTEROLOGY, V156, P2230, DOI 10.1053/j.gastro.2019.02.002; Shiga T, 2011, HEART VESSELS, V26, P274, DOI 10.1007/s00380-010-0047-7; Suk KT, 2012, AM J GASTROENTEROL, V107, P1380, DOI 10.1038/ajg.2012.138; Swift B, 2010, DRUG METAB REV, V42, P446, DOI 10.3109/03602530903491881; Tang D, 2020, BIOCHEM BIOPH RES CO, V525, P238, DOI 10.1016/j.bbrc.2020.02.041; Tetsuka K, 2017, J PHARM SCI-US, V106, P2302, DOI 10.1016/j.xphs.2017.05.010; van Giersbergen PLM, 2005, J CLIN PHARMACOL, V45, P42, DOI 10.1177/0091270004270833; Vildhede A, 2015, J PROTEOME RES, V14, P3305, DOI 10.1021/acs.jproteome.5b00334; Vorrink SU, 2017, FASEB J, V31, P2696, DOI 10.1096/fj.201601375R; Xiang CG, 2019, SCIENCE, V364, P399, DOI 10.1126/science.aau7307; Xu JHJ, 2008, TOXICOL SCI, V105, P97, DOI 10.1093/toxsci/kfn109; Zanger UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/j.pharmthera.2012.12.007; Zeilinger K, 2016, EXP BIOL MED, V241, P1684, DOI 10.1177/1535370216657448; Zhong Y., 2021, FASEB J, V35; Zhong Y, 2019, GENES CELLS, V24, P324, DOI 10.1111/gtc.12678	43	1	1	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2021	35	3							e21379	10.1096/fj.202001629RR	http://dx.doi.org/10.1096/fj.202001629RR			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX8EV	33566373				2023-01-03	WOS:000629576700025
J	Suzuki, F; Morita, E; Miyagi, S; Tsujiguchi, H; Hara, A; Nguyen, TTT; Shimizu, Y; Hayashi, K; Suzuki, K; Kannon, T; Tajima, A; Matsumoto, S; Ishihara, A; Hori, D; Doki, S; Oi, Y; Sasahara, S; Satoh, M; Matsuzaki, I; Yanagisawa, M; Ikaga, T; Nakamura, H				Suzuki, Fumihiko; Morita, Emi; Miyagi, Sakae; Tsujiguchi, Hiromasa; Hara, Akinori; Thao Thi Thu Nguyen; Shimizu, Yukari; Hayashi, Koichiro; Suzuki, Keita; Kannon, Takayuki; Tajima, Atsushi; Matsumoto, Sumire; Ishihara, Asuka; Hori, Daisuke; Doki, Shotaro; Oi, Yuichi; Sasahara, Shinichiro; Satoh, Makoto; Matsuzaki, Ichiyo; Yanagisawa, Masashi; Ikaga, Toshiharu; Nakamura, Hiroyuki			Protein intake in inhabitants with regular exercise is associated with sleep quality: Results of the Shika study	PLOS ONE			English	Article							DIET HISTORY QUESTIONNAIRES; DURATION; POPULATION; TRYPTOPHAN; INDEX	Study objectives Although associations between sleep quality and environmental factors and nutrient intake have been reported, interactions between these factors have not been elucidated in detail. Therefore, this cross-sectional study examined the effects of regular exercise and nutrient intake on sleep quality using the Pittsburgh Sleep Quality Index (PSQI), which is the most frequently used index for sleep evaluation. Methods The participants included 378 individuals aged 40 years or older living in Shika Town, Ishikawa Prefecture. Of these individuals, 185 met the inclusion criteria. The participants completed a self-administered questionnaire assessing lifestyle habits and frequency and duration of exercise, the PSQI, and the brief-type self-administered diet history questionnaire (BDHQ) on nutrient intake. Results A two-way analysis of covariance on regular exercise and PSQI scores indicated that protein intake (17.13% of energy) was significantly higher in the regular exercise and PSQI <= 10 groups than in the non-regular exercise or PSQI >= 11 groups (p = 0.002). In a multiple logistic regression analysis with PSQI scores (<= 10 and >= 11), protein intake was a significant independent variable in any of the models adjusted for confounding factors such as age, sex, body mass index, current smoker, and current drinker (OR: 1.357, 95% CI: 1.081, 1.704, p = 0.009) in the regular exercise group but not in the non-regular exercise group. Conclusions We identified a positive relationship between sleep quality and protein intake in the regular exercise group. These findings suggest that regular exercise at least twice a week for 30 minutes or longer combined with high protein intake contributes to good sleep quality.	[Suzuki, Fumihiko; Tsujiguchi, Hiromasa; Hara, Akinori; Thao Thi Thu Nguyen; Shimizu, Yukari; Hayashi, Koichiro; Suzuki, Keita; Nakamura, Hiroyuki] Kanazawa Univ, Grad Sch Med Sci, Dept Environm & Prevent Med, Kanazawa, Ishikawa, Japan; [Morita, Emi; Matsumoto, Sumire; Ishihara, Asuka; Satoh, Makoto; Matsuzaki, Ichiyo; Yanagisawa, Masashi] Univ Tsukuba, Int Inst Integrat Sleep Med WPI IIIS, Tsukuba, Ibaraki, Japan; [Morita, Emi] Forestry & Forest Prod Res Inst, Forest Res & Management Org, Tsukuba, Ibaraki, Japan; [Miyagi, Sakae] Kanazawa Univ, Innovat Clin Res Ctr, Kanazawa, Ishikawa, Japan; [Tsujiguchi, Hiromasa; Hara, Akinori; Kannon, Takayuki; Tajima, Atsushi; Nakamura, Hiroyuki] Kanazawa Univ, Adv Prevent Med Sci Res Ctr, Kanazawa, Ishikawa, Japan; [Thao Thi Thu Nguyen] Haiphong Univ Med & Pharm, Fac Publ Hlth, Ngo Quyen, Hai Phong, Vietnam; [Shimizu, Yukari] Komatsu Univ, Fac Hlth Sci, Dept Nursing, Komatsu, Ishikawa, Japan; [Hayashi, Koichiro; Suzuki, Keita] Kanazawa Univ, Grad Sch Adv Prevent Med Sci, Dept Publ Hlth, Kanazawa, Ishikawa, Japan; [Kannon, Takayuki; Tajima, Atsushi] Kanazawa Univ, Grad Sch Adv Prevent Med Sci, Dept Bioinformat & Genom, Kanazawa, Ishikawa, Japan; [Matsumoto, Sumire; Ishihara, Asuka] Univ Tsukuba, PhD Program Human Biol, Tsukuba, Ibaraki, Japan; [Hori, Daisuke; Doki, Shotaro; Oi, Yuichi; Sasahara, Shinichiro; Matsuzaki, Ichiyo] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki, Japan; [Ikaga, Toshiharu] Keio Univ, Sch Sci Open & Environm Syst, Grad Sch Sci & Technol, Kohoku Ku, Yokohama, Kanagawa, Japan	Kanazawa University; University of Tsukuba; Forestry & Forest Products Research Institute - Japan; Kanazawa University; Kanazawa University; Hai Phong University Medicine & Pharmacy; Kanazawa University; Kanazawa University; University of Tsukuba; University of Tsukuba; Keio University	Suzuki, F (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Environm & Prevent Med, Kanazawa, Ishikawa, Japan.	f-suzuki@stu.kanazawa-u.ac.jp	Doki, Shotaro/AHA-5319-2022; Tajima, Atsushi/C-1053-2008; Suzuki, Fumihiko/AAI-8737-2021; IKAGA, Toshiharu/G-8095-2014	Tajima, Atsushi/0000-0001-6808-5491; Suzuki, Fumihiko/0000-0002-5156-9729; IKAGA, Toshiharu/0000-0002-3451-5614; Ishihara, Asuka/0000-0001-9701-6284	Ministry of Education, Culture, Sport, Science and Technology (MEXT) [15H04783, 16H03245]	Ministry of Education, Culture, Sport, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The present study was supported by a Grant-in-Aid for Scientific Research (B) by the Ministry of Education, Culture, Sport, Science and Technology (MEXT), number 15H04783 and 16H03245. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amagai Y, 2010, J EPIDEMIOL, V20, P106, DOI 10.2188/jea.JE20090053; Arent SM, 2000, J AGING PHYS ACTIV, V8, P407, DOI 10.1123/japa.8.4.407; Barakat Safa, 2019, J Clin Med Res, V11, P261, DOI 10.14740/jocmr2947w; Beydoun MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103490; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chiu HY, 2016, J PSYCHOSOM RES, V87, P85, DOI 10.1016/j.jpsychores.2016.06.010; Das S, 2020, J FAM MED PRIM CARE, V9, P1510, DOI 10.4103/jfmpc.jfmpc_1021_19; Doi Y, 2000, PSYCHIAT RES, V97, P165, DOI 10.1016/S0165-1781(00)00232-8; FERNSTROM JD, 1971, SCIENCE, V173, P149, DOI 10.1126/science.173.3992.149; Frank S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00393; Grandner MA, 2014, J SLEEP RES, V23, P22, DOI 10.1111/jsr.12084; Grandner MA, 2013, APPETITE, V64, P71, DOI 10.1016/j.appet.2013.01.004; HARTMANN E, 1979, J NERV MENT DIS, V167, P497, DOI 10.1097/00005053-197908000-00008; Hidaka T, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025730; Katagiri R, 2014, J OCCUP HEALTH, V56, P359, DOI 10.1539/joh.14-0051-OA; Kobayashi S, 2012, J EPIDEMIOL, V22, P151, DOI 10.2188/jea.JE20110075; Kobayashi S, 2011, PUBLIC HEALTH NUTR, V14, P1200, DOI 10.1017/S1368980011000504; Komada Y, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020134; Kovacevic A, 2018, SLEEP MED REV, V39, P52, DOI 10.1016/j.smrv.2017.07.002; Kripke DF, 2005, J CIRCADIAN RHYTHMS, V3, DOI [10.1186/1740-3391-3-3, DOI 10.1186/1740-3391-3-3]; Litleskare S, 2018, J SPORT MED PHYS FIT, V58, P1635, DOI 10.23736/S0022-4707.17.07878-1; Martin JL, 2013, J SLEEP RES, V22, P640, DOI [10.1111/jsr.12066, 10.1111/jsr.12078]; Mesas AE, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy114; Nakamura H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040911; Palagini L, 2013, CURR PHARM DESIGN, V19, P2409, DOI 10.2174/1381612811319130009; Passos GS, 2012, CLINICS, V67, P653, DOI 10.6061/clinics/2012(06)17; Res PT, 2012, MED SCI SPORT EXER, V44, P1560, DOI 10.1249/MSS.0b013e31824cc363; Sakamoto R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191771; Sharma Monika, 2014, Indian Heart J, V66, P565, DOI 10.1016/j.ihj.2014.10.412; Shi Z, 2008, INT J OBESITY, V32, P1835, DOI 10.1038/ijo.2008.191; Singh NA, 1997, SLEEP, V20, P95, DOI 10.1093/sleep/20.2.95; Smith K, 2020, HIGH GLYCAEMIC INDEX, DOI [10.1017/S0007114510005192, DOI 10.1017/S0007114510005192]; Stefan L, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15112512; Nguyen TTT, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121319; Tsujiguchi H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040775; Yamaguch M, 1992, J EPIDEMIOL, V2, P53, DOI [10.2188/jea.2.2sup_53, DOI 10.2188/JEA.2.2SUP_53]; Yoneyama S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105198; Zhang HQ, 2019, SLEEP MED, V58, P27, DOI 10.1016/j.sleep.2019.03.001; Zohal M, 2017, DIABETES METAB SYND, V11, pS377, DOI 10.1016/j.dsx.2017.03.020	39	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2021	16	2							e0247926	10.1371/journal.pone.0247926	http://dx.doi.org/10.1371/journal.pone.0247926			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QQ5BP	33635905	Green Published, gold			2023-01-03	WOS:000624538400044
J	Conrado, AB; Ierodiakonou, D; Gowland, MH; Boyle, RJ; Turner, PJ				Conrado, Alessia Baseggio; Ierodiakonou, Despo; Gowland, M. Hazel; Boyle, Robert J.; Turner, Paul J.			Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To describe time trends for hospital admissions due to food anaphylaxis in the United Kingdom over the past 20 years. DESIGN Analysis of national data, 1998-2018. SETTING Data relating to hospital admissions for anaphylaxis and deaths, and prescription data for adrenaline autoinjector devices. PARTICIPANTS UK population as a whole and devolved nations (England, Scotland, Wales, and Northern Ireland). MAIN OUTCOME MEASURES Time trends, age, and sex distributions for hospital admissions for anaphylaxis due to food and non-food triggers, and how these admission rates compare with the case fatality rate (number of fatalities as a proportion of hospital admissions). RESULTS Between 1998 and 2018, 101 891 people were admitted to hospital for anaphylaxis. Of these admissions, 30 700 (30.1%) were coded as due to a food trigger. Food anaphylaxis admissions increased from 1.23 to 4.04 per 100 000 population per year (from 1998 to 2018), an annual increase of 5.7% (95% confidence interval 5.5% to 5.9%, P<0.001). The largest increase in hospital admissions was observed in children younger than 15 years, with an increase from 2.1 to 9.2 admissions per 100 000 population per year (an annual increase of 6.6%, 95% confidence interval 6.3% to 7.0%). For comparison, the annual increase was 5.9% (5.6% to 6.2%) in people aged 15-59 years and 2.1% (1.8% to 3.1%) in those aged 60 years and older. 152 deaths were identified where the fatal event was probably caused by food induced anaphylaxis. The case fatality rate decreased from 0.7% to 0.19% for confirmed fatal food anaphylaxis (rate ratio 0.931, 95% confidence interval 0.904 to 0.959, P<0.001) and to 0.30% for suspected fatal food anaphylaxis (0.970, 0.945 to 0.996, P=0.024). At least 46% (86 of 187, which also includes 35 deaths in 1992-98) of deaths were triggered by peanut or tree nut. Cow's milk was responsible for 17 of 66 (26%) deaths in school aged children. Over the same time period, prescriptions for adrenaline autoinjectors increased by 336% (estimated rate ratio 1.113, 95% confidence interval 1.112 to 1.113; an increase of 11% per year). CONCLUSIONS Hospital admissions for food induced anaphylaxis have increased from 1998 to 2018, however the case fatality rate has decreased. In school aged children, cow's milk is now the most common single cause of fatal anaphylaxis.	[Conrado, Alessia Baseggio; Boyle, Robert J.; Turner, Paul J.] Imperial Coll London, Natl Heart & Lung Inst, Norfolk Pl, London W2 1PG, England; [Ierodiakonou, Despo] Univ Crete, Fac Med, Dept Social Med, Hlth Planning Unit, Iraklion, Greece; [Gowland, M. Hazel] Allergy Act, St Albans, England	Imperial College London; University of Crete	Turner, PJ (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Norfolk Pl, London W2 1PG, England.	p.turner@imperial.ac.uk	Baseggio Conrado, Alessia/P-8330-2019	Baseggio Conrado, Alessia/0000-0001-5775-424X; Gowland, M Hazel/0000-0002-5513-5979; Turner, Paul/0000-0001-9862-5161; Boyle, Robert/0000-0002-4913-7580; Ierodiakonou, Despo/0000-0002-7862-2016	UK Medical Research Council clinician scientist award [MR/K010468/1]; UK Food Standards Agency [FS101222]	UK Medical Research Council clinician scientist award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Food Standards Agency	This research was funded by a UK Medical Research Council clinician scientist award to PJT (reference MR/K010468/1) and by the UK Food Standards Agency (reference FS101222). The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.	[Anonymous], BBC; Barnett J, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6117-y; Brough HA, 2015, CLIN EXP ALLERGY, V45, P859, DOI 10.1111/cea.12466; Gonzalez-Perez A, 2010, J ALLERGY CLIN IMMUN, V125, P1098, DOI 10.1016/j.jaci.2010.02.009; Grabenhenrich LB, 2016, J ALLERGY CLIN IMMUN, V137, P1128, DOI 10.1016/j.jaci.2015.11.015; Hoffer V, 2011, PEDIAT ALLERG IMM-UK, V22, P172, DOI 10.1111/j.1399-3038.2010.00990.x; Jensen-Jarolim E, 2008, ALLERGY, V63, P610, DOI 10.1111/j.1398-9995.2008.01645.x; Levy MB, 2012, ISR MED ASSOC J, V14, P29; Marrs T, 2013, PEDIAT ALLERG IMM-UK, V24, P222, DOI 10.1111/pai.12013; National Institute for Health and Care Excellence, 2011, AN ASS CONF AN EP DE; Ramsey NB, 2019, J ALLER CL IMM-PRACT, V7, P2241, DOI 10.1016/j.jaip.2019.04.025; Tanno LK, 2020, ALLERGY, V75, P2206, DOI 10.1111/all.14468; Tanno LK, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0607-3; Turner PJ, 2020, J ALLER CL IMM-PRACT, V8, P1169, DOI 10.1016/j.jaip.2019.11.027; Turner PJ, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100066; Turner PJ, 2016, CURR OPIN ALLERGY CL, V16, P441, DOI 10.1097/ACI.0000000000000305; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Turner PJ, 2013, PEDIAT ALLERG IMM-UK, V24, P624, DOI 10.1111/pai.12148; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x	19	45	45	3	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2021	372								n251	10.1136/bmj.n251	http://dx.doi.org/10.1136/bmj.n251			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK7TO	33597169	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000620584600003
J	Kaka, AS; MacDonald, R; Greer, N; Vela, K; Duan-Porter, W; Obley, A; Wilt, TJ				Kaka, Anjum S.; MacDonald, Roderick; Greer, Nancy; Vela, Kathryn; Duan-Porter, Wei; Obley, Adam; Wilt, Timothy J.			Major Update: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points	ANNALS OF INTERNAL MEDICINE			English	Review								Background: Remdesivir is being studied and used for treatment of coronavirus disease 2019 (COVID-19). Purpose: To update a previous review of remdesivir for adults with COVID-19, including new meta-analyses of patients with COVID-19 of any severity compared with control. Data Sources: Several sources from 1 January 2020 through 7 December 2020. Study Selection: English-language, randomized controlled trials (RCTs) of remdesivir for COVID-19. New evidence is incorporated by using living review methods. Data Extraction: 1 reviewer abstracted data; a second reviewer verified the data. The Cochrane Risk of Bias Tool and GRADE (Grading of Recommendations Assessment, Development and Evaluation) method were used. Data Synthesis: The update includes 5 RCTs, incorporating data from a new large RCT and the final results of a previous RCT. Compared with control, a 10-day course of remdesivir probably results in little to no reduction in mortality (risk ratio [RR], 0.93 [95% CI, 0.82 to 1.06]; 4 RCTs) but may result in a small reduction in the proportion of patients receiving mechanical ventilation (RR, 0.71 [CI, 0.56 to 0.90]; 3 RCTs). Remdesivir probably results in a moderate increase in the percentage of patients who recovered and a moderate decrease in serious adverse events and may result in a large reduction in time to recovery. Effect on hospital length of stay or percentage remaining hospitalized is mixed. Compared with a 10-day course for those not requiring ventilation at baseline, a 5-day course may reduce mortality, the need for ventilation, and serious adverse events while increasing the percentage of patients who recovered or clinically improved. Limitation: Summarizing findings was challenging because of varying disease severity definitions and outcomes. Conclusion: In hospitalized adults with COVID-19, remdesivir probably results in little to no mortality difference but probably improves the percentage recovered and reduces serious harms and may result in a small reduction in the proportion receiving ventilation. For patients not receiving ventilation, a 5-day course may provide greater benefits and fewer harms with lower drug costs than a 10-day course.	[Kaka, Anjum S.] Minneapolis VA Hlth Care Syst, One Vet Dr 111-F, Minneapolis, MN 55417 USA; [MacDonald, Roderick; Greer, Nancy; Duan-Porter, Wei; Wilt, Timothy J.] Minneapolis VA Hlth Care Syst, One Vet Dr 111-0, Minneapolis, MN 55417 USA; [Kaka, Anjum S.; Duan-Porter, Wei; Wilt, Timothy J.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Greer, Nancy] VA Portland Hlth Care Syst, Portland, OR USA; [Vela, Kathryn] 5696 South Apsley Way, Boise, ID 83709 USA; [Obley, Adam] Portland VA Hlth Care Syst, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System	Wilt, TJ (corresponding author), Minneapolis VA Hlth Care Syst, One Vet Dr 111-0, Minneapolis, MN 55417 USA.	Tim.Wilt@va.gov		Kaka, Anjum/0000-0003-1817-8950; Vela, Kathryn/0000-0003-0221-2800				[Anonymous], 2020, ANN INTERN MED, DOI 10.7326/m20-5752; [Anonymous], STUDY EVALUATE EFFIC; [Anonymous], STUDY PARTICIPANTS E; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhimraj A, INFECT DIS SOC AM GU; Gilead Sciences, 2020, GIL RESP COVID 19; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Harrington DP, 2021, NEW ENGL J MED, V384, P576, DOI 10.1056/NEJMe2034294; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hsu J, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4457; Institute for Clinical and Economic Review, ICER 2 UPD PRIC MOD; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; MacDonald, 2020, RAPID RESPONSE COVID; McCreary EK, 2020, JAMA-J AM MED ASSOC, V324, P1041, DOI 10.1001/jama.2020.16337; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; National Institutes of Health, 2020, THER MAN PAT COVID 1; Qaseem A, 2021, ANN INTERN MED, V174, P673, DOI 10.7326/M20-8101; Schunemann H., 2020, GRADE HDB GRADING QU; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; U.S. Food and Drug Administration, 2020, FDA APPR 1 TREATM CO; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184	26	48	48	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY	2021	174	5					663	+		10.7326/M20-8148	http://dx.doi.org/10.7326/M20-8148		FEB 2021	14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SF2QB	33560863	Green Published			2023-01-03	WOS:000652604800025
J	Dewau, R; Muche, A; Fentaw, Z; Yalew, M; Bitew, G; Amsalu, ET; Arefaynie, M; Mekonen, AM				Dewau, Reta; Muche, Amare; Fentaw, Zinabu; Yalew, Melaku; Bitew, Gedamnesh; Amsalu, Erkihun Tadesse; Arefaynie, Mastewal; Mekonen, Asnakew Molla			Time to initiation of antenatal care and its predictors among pregnant women in Ethiopia: Cox-gamma shared frailty model	PLOS ONE			English	Article								Background Timely initiating antenatal care (ANC) is crucial in the countries that have high maternal morbidity and mortality. However, in developing countries including Ethiopia, pregnant mother's time to initiate antenatal care was not well-studied. Therefore, this study aimed to assess time to first ANC and its predictors among pregnant women in Ethiopia. Methods A community-based cross-sectional study was conducted among 7,543 pregnant women in Ethiopia using the Ethiopian Demographic Health Survey (EDHS), 2016 data. A two-stage stratified cluster sampling was employed. The Kaplan-Meier (KM) method was used to estimate time to first antenatal care visit. Cox-gamma shared frailty model was applied to determine predictors. Adjusted Hazard Ratio (AHR) with 95% confidence interval was reported as the effect size. Model adequacy was assessed by using the Cox-Snell residual plot. Statistical significance was considered at p value Results The median time to first ANC was 5 months with IQR (3,-). The independent predictors of time to first ANC visit were primary education [AHR: 1.24 (95%CI, 1.13-1.35)], secondary education [AHR: 1.28(95% CI, 1.11-1.47)], higher education [AHR: 1.43 (1.19-1.72)] as compared to women with no formal education. Having media exposure [AHR: 1.13 (95% CI, 1.03-1.24)], early initiation of ANC increases by 25% [AHR: 1.25 (95% CI, 1.12-1.40)] in poorer, 32% [AHR: 1.32 (95% CI, 1.17-1.49)] in middle, 37% [AHR: 1.37 (95% CI, 1.20-1.56)] in richer and 41% [AHR: 1.41 (95%CI, 1.1.19-1.67)] in richest households as compared to poorest household wealth index. Living in city administration, media exposure and community women literacy were also enabler factors, while, long distance from health facility and nomadic region residency were hindering factors of early ANC visit. Conclusions The current study revealed that women's time to first antenatal care visit was by far late in Ethiopia as compared to the world health organization recommendation (WHO). The predictors of time to first ANC visit were education status of women, having media exposure, level of household wealth index, community women literacy ad distance to health facility. It is vital that maternal and child health policies and strategies better to be directed at women development and also designing and applying interventions that intended to increase timely initiation ANC among pregnant-women. Researchers also recommended conducting studies using a stronger design like a cohort to establish temporality and reduce biases.	[Dewau, Reta; Muche, Amare; Fentaw, Zinabu; Bitew, Gedamnesh; Amsalu, Erkihun Tadesse] Wollo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Dessie, Ethiopia; [Yalew, Melaku; Arefaynie, Mastewal] Wollo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Reprod & Family Hlth, Dessie, Ethiopia; [Mekonen, Asnakew Molla] Wollo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Hlth Serv Management, Dessie, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Dewau, R (corresponding author), Wollo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Dessie, Ethiopia.	retadewau30@gmail.com	muche, amare/GNW-4693-2022; Mekonen, Asnakew Molla/ABA-7257-2020; Dewau, Reta/AAA-4202-2022; Fentaw, Zinabu/ABB-7298-2021; Arefaynie, Mastewal/AAZ-8374-2021; Tadesse, Erkihun/AAS-1819-2021	Mekonen, Asnakew Molla/0000-0001-7573-1594; Dewau, Reta/0000-0001-6531-2468; Arefaynie, Mastewal/0000-0001-9525-0552; Fentaw, Zinabu/0000-0002-4577-868X				Abejirinde IOO, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1853-7; Amato R, 2016, ELIFE, V5, DOI 10.7554/eLife.08714; [Anonymous], 2019, NAT METHODS, V16, P1, DOI 10.1038/s41592-018-0292-8; [Anonymous], 2014, LANCET INFECT DIS, V14, P1, DOI 10.1016/S1473-3099(13)70368-2; [Anonymous], 2019, PREV TREAT CARDIO CE, V19, P1; [Anonymous], 2017, NCCN PRACT GUIDEL, V2017, P1, DOI DOI 10.1155/2017/2683789; [Anonymous], 2017, EXPERT OPIN THER PAT, V27, P1, DOI DOI 10.1017/S0959270917000065; [Anonymous], 2017, DRUG SAF UPDATE, DOI DOI 10.1186/s13104-016-2345-3; [Anonymous], 2016, BIOMED RES INT, V3, P1; Atuhaire S., 2020, OBSTET GYNECOL INT J, V11, P77, DOI [DOI 10.15406/OGIJ.2020.11.00492, 10.15406/ogij.2020.11.00492]; Central Statistical Agency (CSA), 2016, ETH 2016 ICF ETH DEM; David Collett, 2015, FRANCESCA DOMINICI H, VThird; Dulla D., 2017, NURS HLTH CARE DIVER, V14, P76, DOI DOI 10.21767/2049-5471.10009626; Ejeta E, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.184.10926; Ewunetie AA, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1748-7; Fatema K, 2020, SSM-POPUL HLTH, V11, DOI 10.1016/j.ssmph.2020.100614; Fisseha G, 2017, INT J WOMENS HEALTH, V9, P749, DOI 10.2147/IJWH.S140366; Gebremeskel F, 2015, J ENVIRON PUBLIC HEA, V2015, DOI 10.1155/2015/971506; Grilli R, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000389, DOI 10.1002/14651858.CD000389]; Jordan RG, PRENATAL CARE POSTNA, V2nd, P1036; Lincetto O, ANTENATAL CARE; Makate M, 2017, J EPIDEMIOL GLOB HEA, V7, P255, DOI 10.1016/j.jegh.2017.08.005; Mezmur M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2298-9; Ministry of Health, 2019, ETHIOPIA NATL GUIDEL; Muniro Z, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2377-5; Nguyen KTQ, 2016, ELECTRON J STRUCT EN, V16, P69; Obiyan MO, 2015, SAGE OPEN, V5, DOI 10.1177/2158244015614070; Ogbo FA, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16173152; Paudel YR, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00242; Ponna Satyendra Nath, 2017, J Family Med Prim Care, V6, P231, DOI 10.4103/2249-4863.220024; Roy R., 2017, INT J REPROD CONTRAC, V6, P2846, DOI [10.18203/2320-1770.ijrcog20172562, DOI 10.18203/2320-1770.IJRCOG20172562]; SDGH Targets, 2016, ENSURE HLTH LIVES PR, DOI [10.18356/bd21ed60-en, DOI 10.18356/BD21ED60-EN]; Stacey T, 2012, AUST NZ J OBSTET GYN, V52, P242, DOI 10.1111/j.1479-828X.2011.01406.x; Tanou M, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7150-1; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214848; Tripathi V, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013408; Turyasiima M, 2015, E AFR MED J, V91, P317; Utuk N, 2017, INT J REPROD CONTRAC, V6, P3731, DOI 10.18203/2320-1770.ijrcog20174016; Wado YD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209602; Who/MSM/, 2015, ANT CAR MAT HLTH EFF; World Health Organization, 2019, WHO CONS GUID DRUG R	41	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2021	16	2							e0246349	10.1371/journal.pone.0246349	http://dx.doi.org/10.1371/journal.pone.0246349			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH0UN	33544714	gold, Green Published			2023-01-03	WOS:000617993300002
J	Przulj, D; Ladmore, D; Smith, KM; Phillips-Waller, A; Hajek, P				Przulj, Dunja; Ladmore, Daniella; Smith, Katie Myers; Phillips-Waller, Anna; Hajek, Peter			Time restricted eating as a weight loss intervention in adults with obesity	PLOS ONE			English	Article							BODY-WEIGHT; CALORIE RESTRICTION; CARDIO-PROTECTION; METABOLIC DISEASE; RISK; OVERWEIGHT; INTERMITTENT; MARKERS; DIET	Objectives Time-restricted eating (TRE) is a weight management approach in which food is consumed only within a specific period each day. The simplicity of this approach is appealing, but its efficacy is not known. The aim of this pilot cohort study was to assess adherence to TRE and its effects on weight and lipid profile. Methods Fifty participants with obesity attempted to follow TRE for 12 weeks. Surveys were conducted weekly over the phone to assess treatment adherence and ratings; and at 6 and 12 weeks, participants attended the clinic to be weighed, have their blood pressure taken and provide a blood sample for lipid profile. Treatment results were compared with data from previous comparable cohorts using other weight management methods. Results Mean age of the participants was 50 (SD = 12.0), mean weight 97kg (SD = 17.1), mean BMI = 35 (SD = 4.0) and most were female (74%). At weeks 6 and 12, 64% and 58% of participants continued to practice TRE on at least five days/week. Using the 'last observation carried forward' imputation, mean (SD) weight loss was 2.0 (1.7) kg and 2.6 (2.6) kg at 6 and 12 weeks. Among participants who provided follow-up data, those who adhered to the intervention for at least five days/week recorded greater weight loss than those with lower adherence (week 6: 2.5 (1.7) vs 1.0 (1.3), p = 0.003; week 12: 3.5 (2.7) vs 1.3 (2.0), p = 0.001). A total of 26% of the sample lost at least 5% of their body weight at 12 weeks. The intervention had no effect on blood pressure or lipid profile. Conclusions TRE results were modest, but at least on par with those achieved with more complex interventions, and weight loss did not decline at 12 weeks. A formal trial of the intervention is warranted.	[Przulj, Dunja; Ladmore, Daniella; Smith, Katie Myers; Phillips-Waller, Anna; Hajek, Peter] Queen Mary Univ London, Hlth & Lifestyle Res Unit, London, England	University of London; Queen Mary University London	Przulj, D (corresponding author), Queen Mary Univ London, Hlth & Lifestyle Res Unit, London, England.	d.przulj@qmul.ac.uk	Smith, Katie Elizabeth/GXH-2114-2022	Przulj, Dunja/0000-0003-1133-8835	British Heart Foundation [PG/17/41/33038]	British Heart Foundation(British Heart Foundation)	The study was funded by the British Heart Foundation, reference PG/17/41/33038 (https://www.bhf.org.uk/?gclid= CjwKCAjwxLH3BRApEiwAqX9arT51dMRT93ARz_ KcCGDIngXBHieYeS51wUVLEt4v3IQM90oRz-OTTRoCWDYQAvD_BwE&gclsrc=aw.ds) DP was the award recipient. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Antoni R, 2018, J NUTR SCI, V7, DOI 10.1017/jns.2018.13; Bhutani S, 2013, OBESITY, V21, P1370, DOI 10.1002/oby.20353; Catenacci VA, 2016, OBESITY, V24, P1874, DOI 10.1002/oby.21581; Chaix A, 2014, CELL METAB, V20, P991, DOI 10.1016/j.cmet.2014.11.001; Eshghinia S, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-4; Gabel Kelsey, 2018, Nutr Healthy Aging, V4, P345, DOI 10.3233/NHA-170036; Gill S, 2015, CELL METAB, V22, P789, DOI 10.1016/j.cmet.2015.09.005; Hajek P, PRAGMATIC RANDOMISED; Hajek P, 2012, J PUBLIC HEALTH-UK, V34, P377, DOI 10.1093/pubmed/fdr087; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; Harvie MN, 2011, INT J OBESITY, V35, P714, DOI 10.1038/ijo.2010.171; Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019; Health and Social Care Information Centre, 2020, STAT OB PHYS ACT DIE; Heilbronn LK, 2005, AM J CLIN NUTR, V81, P69; Herman CP, 1999, APPETITE, V33, P181, DOI 10.1006/appe.1999.0243; HILL AJ, 1984, APPETITE, V5, P361, DOI 10.1016/S0195-6663(84)80008-2; Hoddy KK, 2014, OBESITY, V22, P2524, DOI 10.1002/oby.20909; Hutchison AT, 2019, OBESITY, V27, P724, DOI 10.1002/oby.22449; Johnson JB, 2007, FREE RADICAL BIO MED, V42, P665, DOI 10.1016/j.freeradbiomed.2006.12.005; Klempel MC, 2013, METABOLISM, V62, P137, DOI 10.1016/j.metabol.2012.07.002; Klempel MC, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-98; Langsted A, 2019, PATHOLOGY, V51, P131, DOI 10.1016/j.pathol.2018.09.062; Marianna P, 2020, REV ENDOCR METAB DIS, V21, P17, DOI 10.1007/s11154-019-09524-w; Mattson MP, 2003, J NEUROCHEM, V84, P417, DOI 10.1046/j.1471-4159.2003.01586.x; Neter JE, 2003, HYPERTENSION, V42, P878, DOI 10.1161/01.HYP.0000094221.86888.AE; Ravussin E, 2019, OBESITY, V27, P1244, DOI 10.1002/oby.22518; Rayner M, 2005, J EPIDEMIOL COMMUN H, V59, P1054, DOI 10.1136/jech.2005.036491; Rothschild J, 2014, NUTR REV, V72, P308, DOI 10.1111/nure.12104; Sutton EF, 2018, CELL METAB, V27, P1212, DOI 10.1016/j.cmet.2018.04.010; Trepanowski JF, 2017, JAMA INTERN MED, V177, P930, DOI 10.1001/jamainternmed.2017.0936; Varady KA, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-146; Varady KA, 2009, AM J CLIN NUTR, V90, P1138, DOI 10.3945/ajcn.2009.28380; Wilkinson MJ, 2020, CELL METAB, V31, P92, DOI 10.1016/j.cmet.2019.11.004	33	13	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2021	16	1							e0246186	10.1371/journal.pone.0246186	http://dx.doi.org/10.1371/journal.pone.0246186			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF7LJ	33508009	gold, Green Published			2023-01-03	WOS:000635021400102
J	Yeh, YC; Cappelleri, JC; Marston, XL; Shelbaya, A				Yeh, Yu-Chen; Cappelleri, Joseph C.; Marston, Xiaocong L.; Shelbaya, Ahmed			Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: A MarketScan database study	PLOS ONE			English	Article							DIABETIC PERIPHERAL NEUROPATHY; HEALTH-CARE COSTS; MEDICATION ADHERENCE; PHARMACOLOGICAL-TREATMENT; EFNS GUIDELINES; TOLERABILITY; PERSISTENCE; DULOXETINE; EFFICACY; BURDEN	Objective To examine pregabalin dose titration and its impact on treatment adherence and duration in patients with neuropathic pain (NeP). Methods MarketScan database (2009-2014) was used to extract a cohort of incident adult pregabalin users with NeP who had at least 12 months of follow-up data. Any dose augmentation within 45 days following the first pregabalin claim was defined as dose titration. Adherence (measured by medication possession ratio/MPR) and persistence (measured as the duration of continuous treatment) were compared between the cohorts with and without dose titration. Logistic regressions and Cox proportional hazards models were used to identify the factors associated with adherence (MPR >= 0.8) and predictors of time to discontinuation. Results Among the 5,186 patients in the analysis, only 18% of patients had dose titration. Patients who had dose titration were approximately 2.6 times as likely to be adherent (MPR >= 0.8) (odds ratio = 2.59, P < 0.001) than those who did not have dose titration. Kaplan-Meier analysis shows that the time to discontinuation or switch was significantly longer among patients who had dose titration (4.99 vs. 4.04 months, P = 0.009). Conclusions Dose titration was associated with improved treatment adherence and persistence among NeP patients receiving pregabalin. The findings will provide valuable evidence to increase physician awareness of dose recommendations in the prescribing information and to educate patients on the importance of titration and adherence.	[Yeh, Yu-Chen] Pharmerit Int, Newton, MA 02458 USA; [Cappelleri, Joseph C.] Pfizer Inc, Dept Global Biometr & Data Management, New York, NY USA; [Marston, Xiaocong L.] Pharmerit Int, Shanghai, Peoples R China; [Shelbaya, Ahmed] Pfizer Inc, Dept Hlth Econ & Outcomes Res, New York, NY USA; [Shelbaya, Ahmed] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA	Pfizer; Pfizer; Columbia University	Yeh, YC (corresponding author), Pharmerit Int, Newton, MA 02458 USA.	ycyeh74@hotmail.com			Pfizer	Pfizer(Pfizer)	Yu-Chen Yeh and Xiaocong L. Marston are employees of Pharmerit International, who were paid consultants to Pfizer in connection with this study. Ahmed Shelbaya and Joseph C. Cappelleri are employees and stockholders of Pfizer Inc. This study was sponsored by Pfizer. All authors were involved in the study design, data collection, analysis, decision to publish, and preparation of the manuscript.	Alexander J, 2018, ADV THER, V35, P382, DOI 10.1007/s12325-018-0664-6; Attal N, 2010, EUR J NEUROL, V17, P1113, DOI 10.1111/j.1468-1331.2010.02999.x; Centre for Clinical Practice at NICE (UK)-National Institute for Health and Care Excellence: Clinical Guidelines, 2010, NEUR PAIN PHARM MAN; Cruccu G, 2007, EUR J NEUROL, V14, P952, DOI 10.1111/j.1468-1331.2007.01916.x; Dworkin RH, 2013, PAIN, V154, P2249, DOI 10.1016/j.pain.2013.06.004; Emir B, 2017, CLIN THER, V39, P98, DOI 10.1016/j.clinthera.2016.11.015; Farin E, 2013, J BEHAV MED, V36, P246, DOI 10.1007/s10865-012-9419-z; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Federal Drug Administration, 2004, HIGHL PRESCR INF LYR; Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Freeman R, 2008, DIABETES CARE, V31, P1448, DOI 10.2337/dc07-2105; Gharibian D, 2013, CLIN J PAIN, V29, P377, DOI 10.1097/AJP.0b013e31825e45d9; Gilron I, 2015, MAYO CLIN PROC, V90, P532, DOI 10.1016/j.mayocp.2015.01.018; Gustavsson A, 2013, PAIN MED, V14, P1072, DOI 10.1111/pme.12095; Haanpaa M, 2011, PAIN, V152, P14, DOI 10.1016/j.pain.2010.07.031; Iuga AO, 2014, RISK MANAG HEALTHC P, V7, P35, DOI 10.2147/RMHP.S19801; Jensen TS, 2011, PAIN, V152, P2204, DOI 10.1016/j.pain.2011.06.017; Kozma CM, 2013, PATIENT PREFER ADHER, V7, P509, DOI 10.2147/PPA.S40736; Langley Paul C, 2013, J Med Econ, V16, P85, DOI 10.3111/13696998.2012.729548; Lesser H, 2004, NEUROLOGY, V63, P2104, DOI 10.1212/01.WNL.0000145767.36287.A1; LIANG MH, 1989, ARTHRITIS RHEUM, V32, P1107, DOI 10.1002/anr.1780320909; Liu XC, 2011, CLINICOECONOMIC OUTC, V3, P63, DOI 10.2147/CEOR.S17846; Mailis A, 2012, PAIN RES MANAG, V17, P150, DOI 10.1155/2012/794325; Marlow NM, 2018, PAIN PRACT, V18, P154, DOI 10.1111/papr.12585; McCarberg B, 2006, AM J MANAG CARE, V12, pS263; Rini BI, 2013, LANCET ONCOL, V14, P1233, DOI 10.1016/S1470-2045(13)70464-9; Rosner B., 2015, FUNDAMENTALS BIOSTAT; Sansone Randy A, 2012, Innov Clin Neurosci, V9, P41; Schaefer C, 2014, CLINICOECONOMIC OUTC, V6, P483, DOI 10.2147/CEOR.S63323; Serpell M, 2017, J PAIN RES, V10, P1769, DOI 10.2147/JPR.S129832; Shneker BF, 2005, ANN PHARMACOTHER, V39, P2029, DOI 10.1345/aph.1G078; Smith BH, 2012, CURR PAIN HEADACHE R, V16, P191, DOI 10.1007/s11916-012-0256-0; van Hecke O, 2014, PAIN, V155, P654, DOI 10.1016/j.pain.2013.11.013; van Seventer R, 2006, CURR MED RES OPIN, V22, P375, DOI 10.1185/030079906X80404; Wu CH, 2012, DEPRESS ANXIETY, V29, P506, DOI 10.1002/da.21952; Zeber JE, 2013, VALUE HEALTH, V16, P891, DOI 10.1016/j.jval.2013.04.014; Zhao Y, 2011, PAIN PRACT, V11, P204, DOI 10.1111/j.1533-2500.2010.00412.x; Zhao Y, 2011, CURR MED RES OPIN, V27, P785, DOI 10.1185/03007995.2011.554807	38	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2021	16	1							e0242467	10.1371/journal.pone.0242467	http://dx.doi.org/10.1371/journal.pone.0242467			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM1OE	33471834	Green Published, gold			2023-01-03	WOS:000639428800028
J	Stone, PC; Kalpakidou, A; Todd, C; Griffiths, J; Keeley, V; Spencer, K; Buckle, P; Finlay, D; Vickerstaff, V; Omar, RZ				Stone, P. C.; Kalpakidou, A.; Todd, C.; Griffiths, J.; Keeley, V.; Spencer, K.; Buckle, P.; Finlay, D.; Vickerstaff, V.; Omar, R. Z.		PiPS2 Investigators Grp	The Prognosis in Palliative care Study II (PiPS2): A prospective observational validation study of a prognostic tool with an embedded qualitative evaluation	PLOS ONE			English	Article							PREDICTOR MODELS; LIFE; END	Background Prognosis in Palliative care Study (PiPS) models predict survival probabilities in advanced cancer. PiPS-A (clinical observations only) and PiPS-B (additionally requiring blood results) consist of 14- and 56-day models (PiPS-A14; PiPS-A56; PiPS-B14; PiPS-B56) to create survival risk categories: days, weeks, months. The primary aim was to compare PIPS-B risk categories against agreed multi-professional estimates of survival (AMPES) and to validate PiPS-A and PiPS-B. Secondary aims were to assess acceptability of PiPS to patients, caregivers and health professionals (HPs). Methods and findings A national, multi-centre, prospective, observational, cohort study with nested qualitative sub-study using interviews with patients, caregivers and HPs. Validation study participants were adults with incurable cancer; with or without capacity; recently referred to community, hospital and hospice palliative care services across England and Wales. Sub-study participants were patients, caregivers and HPs. 1833 participants were recruited. PiPS-B risk categories were as accurate as AMPES [PiPS-B accuracy (910/1484; 61%); AMPES (914/1484; 61%); p = 0.851]. PiPS-B14 discrimination (C-statistic 0.837) and PiPS-B56 (0.810) were excellent. PiPS-B14 predictions were too high in the 57-74% risk group (Calibration-in-the-large [CiL] -0.202; Calibration slope [CS] 0.840). PiPS-B56 was well-calibrated (CiL 0.152; CS 0.914). PiPS-A risk categories were less accurate than AMPES (p<0.001). PiPS-A14 (C-statistic 0.825; CiL -0.037; CS 0.981) and PiPS-A56 (C-statistic 0.776; CiL 0.109; CS 0.946) had excellent or reasonably good discrimination and calibration. Interviewed patients (n = 29) and caregivers (n = 20) wanted prognostic information and considered that PiPS may aid communication. HPs (n = 32) found PiPS user-friendly and considered risk categories potentially helpful for decision-making. The need for a blood test for PiPS-B was considered a limitation. Conclusions PiPS-B risk categories are as accurate as AMPES made by experienced doctors and nurses. PiPS-A categories are less accurate. Patients, carers and HPs regard PiPS as potentially helpful in clinical practice. Study registration ISRCTN13688211.	[Stone, P. C.; Kalpakidou, A.; Buckle, P.; Finlay, D.; Vickerstaff, V.] Univ Coll London UCL, Marie Curie Palliat Care Res Dept, Div Psychiat, London, England; [Todd, C.; Griffiths, J.; Spencer, K.] Univ Manchester, Sch Hlth Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Todd, C.; Griffiths, J.; Spencer, K.] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Todd, C.] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England; [Keeley, V.] Univ Hosp Derby & Burton NHS Fdn Trust, Palliat Med Dept, Derby, England; [Omar, R. Z.] Univ Coll London UCL, Dept Stat Sci, London, England	University of London; University College London; University of Manchester; University of Manchester; University of London; University College London	Stone, PC (corresponding author), Univ Coll London UCL, Marie Curie Palliat Care Res Dept, Div Psychiat, London, England.	p.stone@ucl.ac.uk	Todd, Chris/AAD-8661-2022; Todd, Chris/A-7904-2010	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Stone, Patrick/0000-0002-5765-9047; Vickerstaff, Victoria/0000-0002-3119-670X; Omar, Rumana/0000-0003-1483-1932	National Institute for Health Research, Health Technology Assessment (HTA) programme [NIHR-HTA 13/20/01]; Joint Research Office at UCL	National Institute for Health Research, Health Technology Assessment (HTA) programme; Joint Research Office at UCL	This paper presents independent research funded by the National Institute for Health Research, Health Technology Assessment (HTA) programme (NIHR-HTA 13/20/01). Awarded to PS, CT, JG, VK and RO. The Study Sponsor was the Joint Research Office at UCL (https://www.ucl.ac.uk/joint-research-office/) The funders and sponsor had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baba M, 2015, J PAIN SYMPTOM MANAG, V49, P853, DOI 10.1016/j.jpainsymman.2014.10.010; Chu C, 2019, CLIN MED, V19, P306, DOI 10.7861/clinmedicine.19-4-306; Gwilliam B, 2013, ANN ONCOL, V24, P482, DOI 10.1093/annonc/mds341; Gwilliam B, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4920; Harrell F, 2015, REGRESSION MODELLING, V1st, P92; Higginson IJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-111; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Kalpakidou AK, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0352-y; Kim ES, 2014, KOREAN J FAM MED, V35, P283, DOI 10.4082/kjfm.2014.35.6.283; Nicholson TRJ, 2008, BRIT MED J, V336, P322, DOI 10.1136/bmj.39457.485347.80; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pirovano M, 1999, J PAIN SYMPTOM MANAG, V17, P231, DOI 10.1016/S0885-3924(98)00145-6; Ravdin PM, 2001, J CLIN ONCOL, V19, P980, DOI 10.1200/JCO.2001.19.4.980; Ritchie J, 2003, QUALITATIVE RES PRAC, P77; StataCorp, 2015, STAT STAT SOFTW REL; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Steyerberg EW, 2009, CLIN PREDICTION MODE, DOI 10.1007/978-0-387-77244-8; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; White N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161407	19	5	5	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2021	16	4							e0249297	10.1371/journal.pone.0249297	http://dx.doi.org/10.1371/journal.pone.0249297			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XL	33909630	Green Published, gold			2023-01-03	WOS:000662174400015
J	Bamforth, RJ; Chhibba, R; Ferguson, TW; Sabourin, J; Pieroni, D; Askin, N; Tangri, N; Komenda, P; Rigatto, C				Bamforth, Ryan J.; Chhibba, Ruchi; Ferguson, Thomas W.; Sabourin, Jenna; Pieroni, Domenic; Askin, Nicole; Tangri, Navdeep; Komenda, Paul; Rigatto, Claudio			Strategies to prevent hospital readmission and death in patients with chronic heart failure, chronic obstructive pulmonary disease, and chronic kidney disease: A systematic review and meta-analysis	PLOS ONE			English	Review							RANDOMIZED-TRIAL; HIGH-RISK; MANAGEMENT PROGRAM; ELDERLY-PATIENTS; VIRTUAL WARD; CARE; HOME; MULTIDISCIPLINARY; MORTALITY; INTERVENTION	Background Readmission following hospital discharge is common and is a major financial burden on healthcare systems. Objectives Our objectives were to 1) identify studies describing post-discharge interventions and their efficacy with respect to reducing risk of mortality and rate of hospital readmission; and 2) identify intervention characteristics associated with efficacy. Methods A systematic review of the literature was performed. We searched MEDLINE, PubMed, Cochrane, EMBASE and CINAHL. Our selection criteria included randomized controlled trials comparing post-discharge interventions with usual care on rates of hospital readmission and mortality in high-risk chronic disease patient populations. We used random effects meta-analyses to estimate pooled risk ratios for all-cause and cause-specific mortality as well as all-cause and cause-specific hospitalization. Results We included 31 randomized controlled trials encompassing 9654 patients (24 studies in CHF, 4 in COPD, 1 in both CHF and COPD, 1 in CKD and 1 in an undifferentiated population). Meta-analysis showed post-discharge interventions reduced cause-specific (RR = 0.71, 95% CI = 0.63-0.80) and all cause (RR = 0.90, 95% CI = 0.81-0.99) hospitalization, all-cause (RR = 0.73, 95% CI = 0.65-0.83) and cause-specific mortality (RR = 0.68, 95% CI = 0.54-0.84) in CHF studies, and all-cause hospitalization (RR = 0.52, 95% CI = 0.32-0.83) in COPD studies. The inclusion of a cardiac nurse in the multidisciplinary team was associated with greater efficacy in reducing all-cause mortality among patients discharged after heart failure admission (HR = 0.64, 95% CI = 0.54-0.75 vs. HR = 0.87, 95% CI = 0.73-1.03). Conclusions Post-discharge interventions reduced all-cause mortality, cause-specific mortality, and cause-specific hospitalization in CHF patients and all-cause hospitalization in COPD patients. The presence of a cardiac nurse was associated with greater efficacy in included studies. Additional research is needed on the impact of post-discharge intervention strategies in COPD and CKD patients.	[Bamforth, Ryan J.; Chhibba, Ruchi; Ferguson, Thomas W.; Sabourin, Jenna; Pieroni, Domenic; Askin, Nicole; Tangri, Navdeep; Komenda, Paul; Rigatto, Claudio] Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada; [Bamforth, Ryan J.; Chhibba, Ruchi; Ferguson, Thomas W.; Sabourin, Jenna; Pieroni, Domenic; Tangri, Navdeep; Komenda, Paul; Rigatto, Claudio] Seven Oaks Hosp Chron Dis Innovat Ctr, Winnipeg, MB, Canada	University of Manitoba	Rigatto, C (corresponding author), Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada.; Rigatto, C (corresponding author), Seven Oaks Hosp Chron Dis Innovat Ctr, Winnipeg, MB, Canada.	crigatto@sbgh.mb.ca	; Askin, Nicole/P-5795-2015	Rigatto, Claudio/0000-0002-8306-8072; Askin, Nicole/0000-0001-9211-4694; Bamforth, Ryan/0000-0002-8316-2325; Komenda, Paul/0000-0001-7016-7146	University of Manitoba Max Rady College of Medicine	University of Manitoba Max Rady College of Medicine	We gratefully acknowledge the support of the University of Manitoba Max Rady College of Medicine.	Ambrosy AP, 2014, J AM COLL CARDIOL, V63, P1123, DOI 10.1016/j.jacc.2013.11.053; Angermann CE, 2012, CIRC-HEART FAIL, V5, P25, DOI 10.1161/CIRCHEARTFAILURE.111.962969; Antonicelli R, 2008, J TELEMED TELECARE, V14, P300, DOI 10.1258/jtt.2008.071213; Benady S., 2010, OTTAWA ONT; Canadian Institute for Health Information, 2012, ALL CAUS READM AC CA; Carbo A, 2018, TELEMED E-HEALTH, V24, P958, DOI 10.1089/tmj.2017.0269; Casas A, 2006, EUR RESPIR J, V28, P123, DOI 10.1183/09031936.06.00063205; Cleland JGF, 2005, J AM COLL CARDIOL, V45, P1654, DOI 10.1016/j.jacc.2005.01.050; Costantino ME, 2013, POPUL HEALTH MANAG, V16, P310, DOI 10.1089/pop.2012.0084; Dar O, 2009, EUR J HEART FAIL, V11, P319, DOI 10.1093/eurjhf/hfn050; Del Sindaco D, 2007, J CARDIOVASC MED, V8, P324, DOI 10.2459/JCM.0b013e32801164cb; Dendale P, 2012, EUR J HEART FAIL, V14, P333, DOI 10.1093/eurjhf/hfr144; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dhalla IA, 2014, JAMA-J AM MED ASSOC, V312, P1305, DOI 10.1001/jama.2014.11492; Dunagan WC, 2005, J CARD FAIL, V11, P358, DOI 10.1016/j.cardfail.2004.12.004; Giordano A, 2009, INT J CARDIOL, V131, P192, DOI 10.1016/j.ijcard.2007.10.027; Goldberg LR, 2003, AM HEART J, V146, P705, DOI 10.1016/S0002-8703(03)00393-4; Gwadry-Sridhar FH, 2004, ARCH INTERN MED, V164, P2315, DOI 10.1001/archinte.164.21.2315; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Ho TW, 2016, SCI REP-UK, V6, DOI 10.1038/srep23797; Jencks SF, 2011, NEW ENGL J MED, V364, P1582; Kasper EK, 2002, J AM COLL CARDIOL, V39, P471, DOI 10.1016/S0735-1097(01)01761-2; Ko FWS, 2017, THORAX, V72, P122, DOI 10.1136/thoraxjnl-2016-208396; Kotooka N, 2018, HEART VESSELS, V33, P866, DOI 10.1007/s00380-018-1133-5; Leppin AL, 2014, JAMA INTERN MED, V174, P1095, DOI 10.1001/jamainternmed.2014.1608; Leventhal ME, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13171; Lewis G, 2012, POPUL HEALTH MANAG, V15, P315, DOI 10.1089/pop.2011.0086; Li J, 2014, PERITON DIALYSIS INT, V34, P278, DOI 10.3747/pdi.2012.00268; Lin MH, 2017, J INVEST MED, V65, P899, DOI 10.1136/jim-2016-000199; Oscalices MIL, 2019, REV LAT-AM ENFERM, V27, DOI [10.1590/1518-8345.2484.3159, 10.1590/1518-8345.2484-3159]; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Medicare Payment Advisory Commission, 2008, REP C REF DEL SYST; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Negarandeh R, 2019, APPL CLIN INFORM, V10, P261, DOI 10.1055/s-0039-1685167; Olivari Z, 2018, INT J CARDIOL, V257, P137, DOI 10.1016/j.ijcard.2017.10.099; Ong MK, 2016, JAMA INTERN MED, V176, P310, DOI 10.1001/jamainternmed.2015.7712; Ritchie CS, 2016, TRANSL BEHAV MED, V6, P428, DOI 10.1007/s13142-016-0422-8; Safiri S, 2019, ANN RHEUM DIS, V78, P1463, DOI 10.1136/annrheumdis-2019-215920; Scherr D, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1252; Sorknaes AD, 2013, J TELEMED TELECARE, V19, P466, DOI 10.1177/1357633X13512067; Stewart S, 1999, LANCET, V354, P1077, DOI 10.1016/S0140-6736(99)03428-5; Stewart S, 1999, ARCH INTERN MED, V159, P257, DOI 10.1001/archinte.159.3.257; Swanson JO, 2018, HEALTH POLICY, V122, P737, DOI 10.1016/j.healthpol.2018.05.013; Tsuchihashi-Makaya M, 2013, CIRC J, V77, P926, DOI 10.1253/circj.CJ-13-0115; Uminski K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196114; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117; Villani A, 2014, J TELEMED TELECARE, V20, P468, DOI 10.1177/1357633X14555644; Wakefield BJ, 2008, TELEMED J E-HEALTH, V14, P753, DOI 10.1089/tmj.2007.0131; Wierzchowiecki Michal, 2006, Kardiol Pol, V64, P1063; Yam Carrie H. K., 2010, Hong Kong Medical Journal, V16, P383; Yu DSF, 2015, J AM GERIATR SOC, V63, P1583, DOI 10.1111/jgs.13533; Yun JE, 2018, J CARD FAIL, V24, P19, DOI 10.1016/j.cardfail.2017.09.006	52	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0249542	10.1371/journal.pone.0249542	http://dx.doi.org/10.1371/journal.pone.0249542			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0DC	33886582	Green Published, gold			2023-01-03	WOS:000644138300115
J	Mehta, N; Murphy, MF; Kaplan, L; Levinson, W				Mehta, Nishila; Murphy, Michael F.; Kaplan, Lawrie; Levinson, Wendy			Reducing unnecessary red blood cell transfusion in hospitalised patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							APPROPRIATENESS		[Mehta, Nishila; Levinson, Wendy] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada; [Mehta, Nishila] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Murphy, Michael F.] Oxford Univ Hosp NHS Fdn Trust, Oxford, England; [Murphy, Michael F.] John Radcliffe Hosp, NHS Blood & Transplant, Oxford, England; [Murphy, Michael F.] Univ Oxford, Radcliffe Dept Med, Oxford, England; [Kaplan, Lawrie; Levinson, Wendy] Choosing Wisely Canada, Toronto, ON, Canada	University of Toronto; University of Toronto; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford	Levinson, W (corresponding author), Univ Toronto, Temerty Fac Med, Toronto, ON, Canada.; Levinson, W (corresponding author), Choosing Wisely Canada, Toronto, ON, Canada.	wendy.levinson@utoronto.ca						American Association of Blood Banks, 2017, CHOOS WISELY; Baron DM, 2020, ANAESTHESIA, V75, P1105, DOI 10.1111/anae.15095; Barr PJ, 2011, TRANSFUSION, V51, P1684, DOI 10.1111/j.1537-2995.2011.03130.x; Bosboom JJ, 2018, TRANSFUSION, V58, P498, DOI 10.1111/trf.14432; Carson JL, 2018, AM HEART J, V200, P96, DOI 10.1016/j.ahj.2018.04.007; Choosing Wisely Canada, 2020, TRANSF MED CHOOS WIS; Docherty AB, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1351; Ducrocq G, 2021, JAMA-J AM MED ASSOC, V325, P552, DOI 10.1001/jama.2021.0135; Goodnough LT, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6897; Hibbs SP, 2015, TRANSFUS MED REV, V29, P14, DOI 10.1016/j.tmrv.2014.10.002; Holst LB, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1354; Islam R, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-93; Joy PJ, 2012, ANN ROY COLL SURG, V94, P201, DOI 10.1308/003588412X13171221501384; Kron AT, 2021, TRANSFUSION, V61, P410, DOI 10.1111/trf.16243; Leahy MF, 2017, TRANSFUSION, V57, P1347, DOI 10.1111/trf.14006; Mueller MM, 2019, JAMA-J AM MED ASSOC, V321, P983, DOI 10.1001/jama.2019.0554; Padhi S, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5832; Royal College of Obstetricians and Gynaecologists, 2015, GREEN TOP GUIDELINE, P47; Sadana D, 2018, JAMA INTERN MED, V178, P116, DOI 10.1001/jamainternmed.2017.6369; Shander A, 2010, TRANSFUSION, V50, P753, DOI 10.1111/j.1537-2995.2009.02518.x; Solh Z, 2018, TRANSFUSION, V58, P1835, DOI 10.1111/trf.14653; Soril Lesley J J, 2019, CMAJ Open, V7, pE252, DOI 10.9778/cmajo.20180209; Soril LJJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019912; Spradbrow J, 2016, TRANSFUSION, V56, P2466, DOI 10.1111/trf.13737; Staples S, 2020, TRANSFUSION, V60, P1658, DOI 10.1111/trf.15864; UK Department of Health and Social Care, 2020, GUID EXP ADV COMM SA	26	3	3	2	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	2021	373								n830	10.1136/bmj.n830	http://dx.doi.org/10.1136/bmj.n830			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK0PZ	33824140				2023-01-03	WOS:000638008700002
J	Butler, CC; Dorward, J; Yu, LM; Gbinigie, O; Hayward, G; Saville, BR; Van Hecke, O; Berry, N; Detry, M; Saunders, C; Fitzgerald, M; Harris, V; Patel, MG; de Lusignan, S; Ogburn, E; Evans, PH; Thomas, NPB; Hobbs, FDR; Allen, J; Andersson, M; Bongard, E; Borek, A; Butler, CC; Ferreira, F; Gbinigie, O; Grabey, J; Hobbs, FDR; Hopkins, S; Judge, D; Koshkouei, M; Llewelyn, MJ; Richards-Doran, D; Rutter, H; Swayze, H; Tripathy, M; Tonkin-Crine, S; Tonner, S				Butler, Christopher C.; Dorward, Jienchi; Yu, Ly-Mee; Gbinigie, Oghenekome; Hayward, Gail; Saville, Benjamin R.; Van Hecke, Oliver; Berry, Nick; Detry, Michelle; Saunders, Christina; Fitzgerald, Mark; Harris, Victoria; Patel, Mahendra G.; de Lusignan, Simon; Ogburn, Emma; Evans, Philip H.; Thomas, Nicholas P. B.; Hobbs, F. D. Richard; Allen, Julie; Andersson, Monique; Bongard, Emily; Borek, Aleksandra; Butler, Christopher C.; Ferreira, Filipa; Gbinigie, Oghenekome; Grabey, Jenna; Hobbs, F. D. Richard; Hopkins, Susan; Judge, David; Koshkouei, Mona; Llewelyn, Martin J.; Richards-Doran, Dan; Rutter, Heather; Swayze, Hannah; Tripathy, Manasa; Tonkin-Crine, Sarah; Tonner, Sharon		PRINCIPLE Trial Collaborative Grp	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial	LANCET			English	Article								Background Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking. We aimed to assess the effectiveness of azithromycin to treat suspected COVID-19 among people in the community who had an increased risk of complications. Methods In this UK-based, primary care, open-label, multi-arm, adaptive platform randomised trial of interventions against COVID-19 in people at increased risk of an adverse clinical course (PRINCIPLE), we randomly assigned people aged 65 years and older, or 50 years and older with at least one comorbidity, who had been unwell for 14 days or less with suspected COVID-19, to usual care plus azithromycin 500 mg daily for three days, usual care plus other interventions, or usual care alone. The trial had two coprimary endpoints measured within 28 days from randomisation: time to first self-reported recovery, analysed using a Bayesian piecewise exponential, and hospital admission or death related to COVID-19, analysed using a Bayesian logistic regression model. Eligible participants with outcome data were included in the primary analysis, and those who received the allocated treatment were included in the safety analysis. The trial is registered with ISRCTN, ISRCTN86534580. Findings The first participant was recruited to PRINCIPLE on April 2, 2020. The azithromycin group enrolled participants between May 22 and Nov 30, 2020, by which time 2265 participants had been randomly assigned, 540 to azithromycin plus usual care, 875 to usual care alone, and 850 to other interventions. 2120 (94%) of 2265 participants provided follow-up data and were included in the Bayesian primary analysis, 500 participants in the azithromycin plus usual care group, 823 in the usual care alone group, and 797 in other intervention groups. 402 (80%) of 500 participants in the azithromycin plus usual care group and 631 (77%) of 823 participants in the usual care alone group reported feeling recovered within 28 days. We found little evidence of a meaningful benefit in the azithromycin plus usual care group in time to first reported recovery versus usual care alone (hazard ratio 1.08, 95% Bayesian credibility interval [BCI] 0.95 to 1.23), equating to an estimated benefit in median time to first recovery of 0.94 days (95% BCI -0.56 to 2.43). The probability that there was a clinically meaningful benefit of at least 1.5 days in time to recovery was 0.23. 16 (3%) of 500 participants in the azithromycin plus usual care group and 28 (3%) of 823 participants in the usual care alone group were hospitalised (absolute benefit in percentage 0.3%, 95% BCI -1.7 to 2.2). There were no deaths in either study group. Safety outcomes were similar in both groups. Two (1%) of 455 participants in the azothromycin plus usual care group and four (1%) of 668 participants in the usual care alone group reported admission to hospital during the trial, not related to COVID-19. Interpretation Our findings do not justify the routine use of azithromycin for reducing time to recovery or risk of hospitalisation for people with suspected COVID-19 in the community. These findings have important antibiotic stewardship implications during this pandemic, as inappropriate use of antibiotics leads to increased antimicrobial resistance, and there is evidence that azithromycin use increased during the pandemic in the UK. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.	[Butler, Christopher C.; Dorward, Jienchi; Yu, Ly-Mee; Gbinigie, Oghenekome; Hayward, Gail; Van Hecke, Oliver; de Lusignan, Simon; Hobbs, F. D. Richard; Andersson, Monique; Butler, Christopher C.; Ferreira, Filipa; Grabey, Jenna; Hobbs, F. D. Richard; Judge, David; Koshkouei, Mona; Rutter, Heather; Swayze, Hannah; Tripathy, Manasa; Tonkin-Crine, Sarah; Tonner, Sharon; PRINCIPLE Trial Collaborative Grp] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England; [Dorward, Jienchi; Andersson, Monique] Oxford Univ Hosp NHS Trust, Dept Microbiol, Headley Way Headington, Oxford OX3 9DU, England; [Berry, Nick] Berry Consultants, 3345 Bee Cave Rd Suite 201, Austin, TX 78746 USA; [Dorward, Jienchi] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, ZA-3630 Durban, South Africa; [Evans, Philip H.] Univ Exeter, Coll Med & Hlth, B3183, Exeter EX1 2HZ, England; [Patel, Mahendra G.] Univ Bradford, Sch Pharm & Med Sci, Richmond Rd, Bradford BD7 1DP, England; [Llewelyn, Martin J.] Univ Sussex, Brighton & Sussex Med Sch, 94 N S Rd Falmer, Brighton BN1 9PX, England; [Hopkins, Susan] Publ Hlth England, London, England; [Saville, Benjamin R.] Vanderbilt Univ Sch Med, Dept Biostat, 2525 West End Ave Suite 1100, Nashville, TN 37203 USA	University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Kwazulu Natal; University of Exeter; University of Bradford; University of Brighton; University of Sussex; Public Health England; Vanderbilt University	Butler, CC; Hobbs, FDR (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England.	principle@phc.ox.ac.uk	Dorward, Jienchi/P-7100-2019; Llewelyn, Martin/A-7194-2011	Dorward, Jienchi/0000-0001-6072-1430; Llewelyn, Martin/0000-0002-6811-1124; Hayward, Gail/0000-0003-0852-627X; de Lusignan, Simon/0000-0002-8553-2641; Gbinigie, Oghenekome/0000-0002-2963-4491; Tonner, Sharon/0000-0002-7775-9926; Evans, Philip/0000-0002-5277-3545; Yu, Ly-Mee/0000-0003-0331-7364	UK Research and Innovation; UK Department of Health and Social Care; MRC [MC_PC_19079] Funding Source: UKRI	UK Research and Innovation(UK Research & Innovation (UKRI)); UK Department of Health and Social Care; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	UK Research and Innovation and UK Department of Health and Social Care.	[Anonymous], 2020, NAT MICROBIOL, V5, P779, DOI 10.1038/s41564-020-0739-4; Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236; Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742; de Lusignan S, PRINCIPLE TRIAL DEMO, V2021, DOI [10.1101/2021.02.02.21250902, DOI 10.1101/2021.02.02.21250902]; de Lusignan S, 2020, JMIR PUBLIC HLTH SUR, V6, P130, DOI 10.2196/19773; de Lusignan S, 2020, LANCET INFECT DIS, V20, P1034, DOI 10.1016/S1473-3099(20)30371-6; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Joy M, 2020, BRIT J GEN PRACT, V70, pE890, DOI 10.3399/bjgp20X713393; Kim PS, 2020, JAMA-J AM MED ASSOC, V324, P2149, DOI 10.1001/jama.2020.22813; Langford BJ, 2020, CLIN MICROBIOL INFEC, V26, P1622, DOI 10.1016/j.cmi.2020.07.016; Little P, 2013, LANCET INFECT DIS, V13, P123, DOI 10.1016/S1473-3099(12)70300-6; Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738; Min JY, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/649570; Moustgaard H, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6802; National Institute for Health and Care Excellence, 2020, COVID 19 RAPID GUIDE; NHS Digital, 2020, SEC US SERV SUS; Oliver ME, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2163; Poschet Jens F, 2020, bioRxiv, DOI 10.1101/2020.03.29.008631; Public Health England, 2020, COVID 19 INV IN CLIN; Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207; Sudre CH, 2020, ATTRIBUTES PREDICTOR, DOI [10.19.20214494, 10.1101/2020.10.19.20214494, DOI 10.1101/2020.10.19.20214494]; Topp CW, 2015, PSYCHOTHER PSYCHOSOM, V84, DOI 10.1159/000376585; Touret F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70143-6; UK National Health Service, 2021, SYMPT COR; UK Office for National Statistics, 2020, PREV LONG COVID SYMP; Woodcock J, 2017, NEW ENGL J MED, V377, P62, DOI 10.1056/NEJMra1510062	31	125	125	3	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2021	397	10279					1063	1074		10.1016/S0140-6736(21)00461-X	http://dx.doi.org/10.1016/S0140-6736(21)00461-X		MAR 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ0AN	33676597	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000630397800024
J	Koizumi, R; Kusama, Y; Muraki, Y; Ishikane, M; Yamasaki, D; Tanabe, M; Ohmagari, N				Koizumi, Ryuji; Kusama, Yoshiki; Muraki, Yuichi; Ishikane, Masahiro; Yamasaki, Daisuke; Tanabe, Masaki; Ohmagari, Norio			Effect of population inflow and outflow between rural and urban areas on regional antimicrobial use surveillance	PLOS ONE			English	Article								Purpose Regional-level measures can complement national antimicrobial stewardship programs. In Japan, sub-prefectural regions called secondary medical areas (SMAs) provide general inpatient care within their borders, and regional antimicrobial stewardship measures are frequently implemented at this level. There is therefore a need to conduct antimicrobial use (AMU) surveillance at this level to ascertain antimicrobial consumption. However, AMU estimates are generally standardized to residence-based nighttime populations, which do not account for population mobility across regional borders. We examined the impact of population in/outflow on SMA-level AMU estimates by comparing the differences between standardization using daytime and nighttime populations. Methods We obtained AMU information from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. AMU was quantified at the prefectural and SMA levels using the number of defined daily doses (DDDs) divided by (a) 1,000 nighttime population per day or (b) 1,000 daytime population per day. We identified and characterized the discrepancies between the two types of estimates at the prefectural and SMA levels. Results The national AMU was 17.21 DDDs per 1,000 population per day. The mean (95% confidence interval) prefectural-level DDDs per 1,000 nighttime and daytime population per day were 17.27 (14.10, 20.44) and 17.41 (14.30, 20.53), respectively. The mean (95% confidence interval) SMA-level DDDs per 1,000 nighttime and daytime population per day were 16.12 (9.84, 22.41) and 16.41 (10.57, 22.26), respectively. The nighttime population-standardized estimates were generally higher than the daytime population-standardized estimates in urban areas, but lower in the adjacent suburbs. Large differences were observed in the main metropolitan hubs in eastern and western Japan. Conclusion Regional-level AMU estimates, especially of smaller regions such as SMAs, are susceptible to the use of different populations for standardization. This finding indicates that AMU standardization based on population values is not suitable for AMU estimates in small regions.	[Koizumi, Ryuji; Kusama, Yoshiki; Ishikane, Masahiro; Ohmagari, Norio] Natl Ctr Global Hlth & Med, AMR Clin Reference Ctr, Tokyo, Japan; [Kusama, Yoshiki; Ohmagari, Norio] Tohoku Univ, Sch Med, Dept Emerging & Reemerging Infect Dis, Sendai, Miyagi, Japan; [Muraki, Yuichi] Kyoto Pharmaceut Univ, Dept Clin Pharmacoepidemiol, Kyoto, Japan; [Ishikane, Masahiro; Ohmagari, Norio] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan; [Yamasaki, Daisuke; Tanabe, Masaki] Mie Univ Hosp, Dept Infect Control & Prevent, Tsu, Mie, Japan	National Center for Global Health & Medicine - Japan; Tohoku University; Kyoto Pharmaceutical University; National Center for Global Health & Medicine - Japan; Mie University	Kusama, Y (corresponding author), Natl Ctr Global Hlth & Med, AMR Clin Reference Ctr, Tokyo, Japan.; Kusama, Y (corresponding author), Tohoku Univ, Sch Med, Dept Emerging & Reemerging Infect Dis, Sendai, Miyagi, Japan.	stone.bagle@gmail.com	Ohmagari, Norio/GLN-5290-2022	Ohmagari, Norio/0000-0002-4622-8970	Ministry of Health, Labor and Welfare (MHLW) research grant of Japan [20HA2003]	Ministry of Health, Labor and Welfare (MHLW) research grant of Japan	This work was supported by the Ministry of Health, Labor and Welfare (MHLW) research grant of Japan (20HA2003).	Avedissian SN, 2018, J ANTIMICROB CHEMOTH, V73, P2876, DOI 10.1093/jac/dky275; Benic MS, 2018, J ANTIMICROB CHEMOTH, V73, P50, DOI 10.1093/jac/dky118; Joint Programming Initiative on Antimicrobial Resistance, 2016, NATL ACTION PLAN ANT; Kusama Y, 2019, JPN J INFECT DIS, V72, P326, DOI 10.7883/yoken.JJID.2018.417; Kuster SP, 2008, INFECTION, V36, P549, DOI 10.1007/s15010-008-7462-z; Matsuda S., 2012, APJDM ASIAN PACIFIC, V6, P55; Ministry of Internal Affairs and Communications, PORT SIT OFF STAT JA; Park YM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17030908; Qi W, 2015, J GEOGR SCI, V25, P756, DOI 10.1007/s11442-015-1200-0; WHO, WHO METH GLOB PROGR; WHO Collaborating Centre for Drug Statistics Methodology, ATC DDD IND 2019 ATC DDD IND 2019; World Health Organization, 2015, GLOBAL ACTION PLAN A; Yu KC, 2018, CLIN INFECT DIS, V67, P1677, DOI 10.1093/cid/ciy354	13	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0248338	10.1371/journal.pone.0248338	http://dx.doi.org/10.1371/journal.pone.0248338			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QZ9HN	33735299	Green Published, gold			2023-01-03	WOS:000631029700101
J	Kesselheim, AS; Hwang, TJ; Avorn, J				Kesselheim, Aaron S.; Hwang, Thomas J.; Avorn, Jerry			Paying for Prescription Drugs in the New Administration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint discusses policies the Biden administration can enact to reduce costs, including benchmarking Medicare Part B drug payments to the lowest price paid in similar countries, preventing Part D plans from negotiating confidential rebates with manufacturers, and patent reform to promote generic drug use.	[Kesselheim, Aaron S.; Hwang, Thomas J.; Avorn, Jerry] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 75 Francis St, Boston, MA 02115 USA; [Kesselheim, Aaron S.; Hwang, Thomas J.; Avorn, Jerry] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kesselheim, AS (corresponding author), Brigham & Womens Hosp, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	akesselheim@bwh.harvard.edu			Arnold Ventures	Arnold Ventures	This work was supported by Arnold Ventures.	Congressional Budget Office, 2019, INC EFF PROP RUL SAF; Hwang TJ, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3434; Hwang TJ, 2020, REDUCING PRESCRIPTIO	3	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	2021	325	9					819	820		10.1001/jama.2021.0009	http://dx.doi.org/10.1001/jama.2021.0009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QS4AP	33651097				2023-01-03	WOS:000625843100005
J	Rosas, IO; Brau, N; Waters, M; Go, RC; Hunter, BD; Bhagani, S; Skiest, D; Aziz, MS; Cooper, N; Douglas, IS; Savic, S; Youngstein, T; Del Sorbo, L; Gracian, AC; De la Zerda, DJ; Ustianowski, A; Bao, M; Dimonaco, S; Graham, E; Matharu, B; Spotswood, H; Tsai, L; Malhotra, A				Rosas, I. O.; Brau, N.; Waters, M.; Go, R. C.; Hunter, B. D.; Bhagani, S.; Skiest, D.; Aziz, M. S.; Cooper, N.; Douglas, I. S.; Savic, S.; Youngstein, T.; Del Sorbo, L.; Gracian, A. Cubillo; De la Zerda, D. J.; Ustianowski, A.; Bao, M.; Dimonaco, S.; Graham, E.; Matharu, B.; Spotswood, H.; Tsai, L.; Malhotra, A.			Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort studies. Data are needed from randomized, placebo-controlled trials. METHODS In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab (at a dose of 8 mg per kilogram of body weight) or placebo. Approximately one quarter of the participants received a second dose of tocilizumab or placebo 8 to 24 hours after the first dose. The primary outcome was clinical status at day 28 on an ordinal scale ranging from 1 (discharged or ready for discharge) to 7 (death) in the modified intention-to-treat population, which included all the patients who had received at least one dose of tocilizumab or placebo. RESULTS Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses. The median value for clinical status on the ordinal scale at day 28 was 1.0 (95% confidence interval [CI], 1.0 to 1.0) in the tocilizumab group and 2.0 (non-ICU hospitalization without supplemental oxygen) (95% CI, 1.0 to 4.0) in the placebo group (between-group difference, -1.0; 95% CI, -2.5 to 0; P=0.31 by the van Elteren test). In the safety population, serious adverse events occurred in 103 of 295 patients (34.9%) in the tocilizumab group and in 55 of 143 patients (38.5%) in the placebo group. Mortality at day 28 was 19.7% in the tocilizumab group and 19.4% in the placebo group (weighted difference, 0.3 percentage points; 95% CI, -7.6 to 8.2; nominal P=0.94). CONCLUSIONS In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.	[Rosas, I. O.] Baylor Coll Med, Houston, TX 77030 USA; [Brau, N.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA; [Brau, N.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Waters, M.] eStudy Site, Chula Vista, CA USA; [Bao, M.; Tsai, L.] Genentech Inc, San Francisco, CA USA; [Malhotra, A.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Go, R. C.] Hackensack Meridian Sch Med, Hackensack, NJ USA; [Go, R. C.] Hacksensack Univ, Med Ctr, Hackensack, NJ USA; [Hunter, B. D.] Intermt Healthcare, Salt Lake City, UT USA; [Bhagani, S.] Royal Free Hosp, London, England; [Cooper, N.; Youngstein, T.] Imperial Coll London, London, England; [Savic, S.] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England; [Savic, S.] Natl Inst Hlth Res, Leeds Biomed Res Ctr, Leeds, W Yorkshire, England; [Ustianowski, A.] North Manchester Gen Hosp, Manchester, Lancs, England; [Dimonaco, S.; Graham, E.; Matharu, B.; Spotswood, H.] Roche Prod, Welwyn Garden City, Herts, England; [Skiest, D.] Univ Massachusetts, Med Sch Baystate, Springfield, MA USA; [Aziz, M. S.] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [Douglas, I. S.] Denver Hlth Med Ctr, Denver, CO USA; [Douglas, I. S.] Univ Colorado, Anschutz Sch Med, Aurora, CO USA; [Del Sorbo, L.] Univ Hlth Network, Toronto, ON, Canada; [Gracian, A. Cubillo] Univ CEU San Pablo, Hosp Univ HM Sanchinarro, Ctr Integral, Oncol Clara Campal, Madrid, Spain; [Gracian, A. Cubillo] Univ CEU San Pablo, Fac Med, Dept Ciencias Med Clin, Madrid, Spain; [De la Zerda, D. J.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Icahn School of Medicine at Mount Sinai; Roche Holding; Genentech; University of California System; University of California San Diego; Intermountain Healthcare; Intermountain Medical Center; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Imperial College London; University of Leeds; Leeds Biomedical Research Centre; Roche Holding; University of Massachusetts System; Rush University; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Toronto; University Toronto Affiliates; University Health Network Toronto; San Pablo CEU University; San Pablo CEU University; University of Miami	Rosas, IO (corresponding author), Baylor Coll Med, Sect Pulm Crit Care & Sleep Med, 7200 Cambridge St, Houston, TX 77030 USA.	ivan.rosas@bcm.edu	, Felipe/F-4242-2014	, Felipe/0000-0001-7658-5832; Savic, Sinisa/0000-0001-7910-0554; Douglas, Ivor/0000-0002-4541-1431; Ustianowski, Andrew/0000-0002-6134-7855; Bhagani, Sanjay/0000-0003-2557-4337	Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services [HHSO100201800036C]; Biomedical Research Centre of the United Kingdom National Institute for Health Research; National Institutes of Health; F. Hoffmann-La Roche	Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services; Biomedical Research Centre of the United Kingdom National Institute for Health Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); F. Hoffmann-La Roche(Hoffmann-La Roche)	Supported F. Hoffmann-La Roche and by a grant -(HHSO100201800036C) from the Biomedical Advanced Research and Development Authority of the Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services. Drs. Cooper and Youngstein were supported in part by the Biomedical Research Centre of the United Kingdom National Institute for Health Research. Dr. Malhotra is supported by the National Institutes of Health.	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Antwi-Amoabeng D, 2020, J MED VIROL, V92, P2516, DOI 10.1002/jmv.26038; Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cellina M, 2020, DIAGN INTERV IMAG, V101, P323, DOI 10.1016/j.diii.2020.03.010; Cevik M, 2021, LANCET MICROBE, V2, pE13, DOI 10.1016/S2666-5247(20)30172-5; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Kaye AG, 2020, PEERJ, V8, DOI 10.7717/peerj.10322; Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904; Lee K, 2009, GLOB INST, P1; Luo P, 2020, J MED VIROL, V92, P814, DOI 10.1002/jmv.25801; Mastroianni A, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100410; Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300; Pons S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03062-7; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Rubbert-Roth A, 2018, RHEUMATOL THER, V5, P21, DOI 10.1007/s40744-018-0102-x; Somers EC, 2021, CLIN INFECT DIS, V73, pE445, DOI [10.1093/cid/ciaa954, 10.1101/2020.05.29.20117358]; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP; Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907; Zhu JY, 2020, J MED VIROL, V92, P1902, DOI [10.1002/jmv.25884, 10.1002/jmv.26085]	29	455	465	5	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	2021	384	16					1503	1516		10.1056/NEJMoa2028700	http://dx.doi.org/10.1056/NEJMoa2028700		FEB 2021	14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ6OT	33631066	Green Published, Bronze			2023-01-03	WOS:000640379900001
J	Kim, SH; Ju, HM; Choi, CH; Park, HR; Shin, S				Kim, Seung Hyun; Ju, Hyang Mi; Choi, Chong-Hyuck; Park, Hae Ri; Shin, Seokyung			Inhalational versus intravenous maintenance of anesthesia for quality of recovery in patients undergoing corrective lower limb osteotomy: A randomized controlled trial	PLOS ONE			English	Article								Background Inhalational anesthesia and propofol-based total intravenous anesthesia (TIVA) are the two most popular methods of general anesthesia with distinct characteristics that may affect quality of recovery (QOR) differently. This study compared QOR after corrective lower limb osteotomy between desflurane-based inhalational anesthesia and propofol-based TIVA. Methods Sixty-eight patients, ASA class I or II who underwent corrective lower limb osteotomy were randomized to receive either desflurane anesthesia or propofol TIVA. The primary outcome was quality of recovery 40 (QoR-40) questionnaire scores on postoperative day (POD) 1 and 2. Postoperative nausea scores, antiemetic requirements, and amount of opioid consumption via intravenous patient-controlled analgesia (IV PCA) were assessed as secondary outcomes. Results Global QoR-40 scores on POD 1 (153.5 (140.3, 171.3) vs. 140.0 (120.0, 173.0), P = 0.056, 95% CI; -22.5, 0.2) and POD 2 (155.5 (146.8, 175.5) vs. 152.0 (134.0, 179.0), P = 0.209, 95% CI; -17.5, 3.9) were comparable between the two groups. Among the five dimensions of QoR-40, physical independence scores were significantly higher in the TIVA group compared to the Desflurane group on POD both 1 and 2. Nausea scores (0.0 (0.0, 0.0) vs. 1.0 (0.0, 3.5), P < 0.001) and number of patients requiring rescue antiemetics (0% vs. 15.2%, P = 0.017) were significantly lower in the TIVA group at the post anesthesia care unit (PACU). Although the number of bolus attempts between 0-24 h and the morphine equivalent dose of analgesics administered via IV PCA between 12-24 h were significantly less in the TIVA group compared to the Desflurane group, there was no significant difference between groups for the overall 48 h postoperative period. Conclusions Propofol-based TIVA did not improve global QoR-40 scores compared with desflurane-based inhalational anesthesia. However, considering the better QoR-40 scores in the domain of physical independence and less nausea in the early postoperative period, propofol TIVA should be considered as a useful option in patients undergoing corrective lower limb osteotomy.	[Kim, Seung Hyun; Shin, Seokyung] Yonsei Univ, Severance Hosp, Coll Med, Dept Anesthesiol & Pain Med,Anesthesia & Pain Res, Seoul, South Korea; [Ju, Hyang Mi] Yonsei Univ, Yongin Severance Hosp, Coll Med, Anesthesia & Pain Res Inst,Dept Anesthesiol & Pai, Seoul, South Korea; [Choi, Chong-Hyuck] Yonsei Univ, Dept Orthoped Surg, Coll Med, Seoul, South Korea; [Park, Hae Ri] Yonsei Univ, Severance Hosp, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Shin, S (corresponding author), Yonsei Univ, Severance Hosp, Coll Med, Dept Anesthesiol & Pain Med,Anesthesia & Pain Res, Seoul, South Korea.	skshin@yuhs.ac		Shin, Seokyung/0000-0002-2641-0070; Choi, Chong Hyuk/0000-0002-9080-4904; Kim, Seung Hyun/0000-0003-2127-6324	Department of Anesthesiology, Yonsei University College of Medicine, Seoul, Republic of Korea	Department of Anesthesiology, Yonsei University College of Medicine, Seoul, Republic of Korea	This work was supported by the Department of Anesthesiology, Yonsei University College of Medicine, Seoul, Republic of Korea.	Chen Y, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004769; COETZEE JF, 1995, ANESTHESIOLOGY, V82, P1328, DOI 10.1097/00000542-199506000-00003; Dahl MT, 2019, J BONE JOINT SURG AM, V101, P1435, DOI 10.2106/JBJS.19.00584; de Carli D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228805; De Oliveira GS, 2017, J CLIN ANESTH, V43, P70, DOI 10.1016/j.jclinane.2017.10.001; Gao L, 2019, J EXP ORTHOP, V6, DOI 10.1186/s40634-019-0177-5; Gauger PG, 2008, WORLD J SURG, V32, P1525, DOI 10.1007/s00268-008-9472-5; Gilliland HE, 1997, ANESTH ANALG, V85, P1394, DOI 10.1097/00000539-199712000-00039; Gornall BF, 2013, BRIT J ANAESTH, V111, P161, DOI 10.1093/bja/aet014; Herling SF, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011387.pub2; Hosny GA, 2020, J ORTHOP TRAUMATOL, V21, DOI 10.1186/s10195-019-0541-3; Hu ZC, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018-019-1116-y; Jaensson M, 2019, PERIOPER MED-LONDON, V8, DOI 10.1186/s13741-019-0115-1; Lee A, 1996, ANAESTH INTENS CARE, V24, P685, DOI 10.1177/0310057X9602400610; Lee WK, 2015, BRIT J ANAESTH, V114, P663, DOI 10.1093/bja/aeu405; Liu TJ, 2019, INT FORUM ALLERGY RH, V9, P248, DOI 10.1002/alr.22246; Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952; Mancuso CA, 2001, J BONE JOINT SURG AM, V83A, P1005, DOI 10.2106/00004623-200107000-00005; Marana E, 2010, J CLIN ANESTH, V22, P250, DOI 10.1016/j.jclinane.2009.07.011; Minto CF, 1997, ANESTHESIOLOGY, V86, P24, DOI 10.1097/00000542-199701000-00005; Moro ET, 2016, J CLIN ANESTH, V35, P369, DOI 10.1016/j.jclinane.2016.08.022; Myles PS, 2020, ANAESTHESIA, V75, pE143, DOI 10.1111/anae.14786; Myles PS, 2016, ANESTHESIOLOGY, V125, P39, DOI 10.1097/ALN.0000000000001158; Myles PS, 2000, ANAESTH INTENS CARE, V28, P276, DOI 10.1177/0310057X0002800304; Myles PS, 2001, ANESTHESIOLOGY, V95, P862, DOI 10.1097/00000542-200110000-00013; Myles PS, 2000, BRIT J ANAESTH, V84, P11, DOI 10.1093/oxfordjournals.bja.a013366; Na SH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012699; Powell R, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008646.pub2; Qiu Q, 2016, ANAESTHESIA, V71, P1222, DOI 10.1111/anae.13578; Schraag S, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0632-3; Soffin EM, 2016, BRIT J ANAESTH, V117, P62, DOI 10.1093/bja/aew362; Van Herck P, 2010, J EVAL CLIN PRACT, V16, P39, DOI 10.1111/j.1365-2753.2008.01111.x; Vishwanathan Karthik, 2017, Indian J Med Ethics, V2, P45; Visser K, 2001, ANESTHESIOLOGY, V95, P616, DOI 10.1097/00000542-200109000-00012; Wainwright TW, 2020, ACTA ORTHOP, V91, P3, DOI 10.1080/17453674.2019.1683790; Zaballos M, 2018, REV ESP ANEST REANIM, V65, P96, DOI 10.1016/j.redar.2017.09.010	36	0	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2021	16	2							e0247089	10.1371/journal.pone.0247089	http://dx.doi.org/10.1371/journal.pone.0247089			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8KQ	33606764	gold, Green Published			2023-01-03	WOS:000620629200135
J	Ali, S; Borin, TF; Piranlioglu, R; Ara, R; Lebedyeva, I; Angara, K; Achyut, BR; Arbab, AS; Rashid, MH				Ali, Sehar; Borin, Thaiz F.; Piranlioglu, Raziye; Ara, Roxan; Lebedyeva, Iryna; Angara, Kartik; Achyut, Bhagelu R.; Arbab, Ali Syed; Rashid, Mohammad H.			Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study	PLOS ONE			English	Article							STIMULATING FACTOR-1 RECEPTOR; INFILTRATING MYELOID CELLS; MARROW-DERIVED CELLS; RECURRENT GLIOBLASTOMA; SELECTIVE INHIBITOR; MDSC INFILTRATION; SUPPRESSOR-CELLS; VASCULAR MIMICRY; ANIMAL-MODEL; CANCER	Glioblastoma (GBM) is a hypervascular and aggressive primary malignant tumor of the central nervous system. Recent investigations showed that traditional therapies along with antiangiogenic therapies failed due to the development of post-therapy resistance and recurrence. Previous investigations showed that there were changes in the cellular and metabolic compositions in the tumor microenvironment (TME). It can be said that tumor cell-directed therapies are ineffective and rethinking is needed how to treat GBM. It is hypothesized that the composition of TME-associated cells will be different based on the therapy and therapeutic agents, and TME-targeting therapy will be better to decrease recurrence and improve survival. Therefore, the purpose of this study is to determine the changes in the TME in respect of T-cell population, M1 and M2 macrophage polarization status, and MDSC population following different treatments in a syngeneic model of GBM. In addition to these parameters, tumor growth and survival were also studied following different treatments. The results showed that changes in the TME-associated cells were dependent on the therapeutic agents, and the TME-targeting therapy improved the survival of the GBM bearing animals. The current GBM therapies should be revisited to add agents to prevent the accumulation of bone marrow-derived cells in the TME or to prevent the effect of immune-suppressive myeloid cells in causing alternative neovascularization, the revival of glioma stem cells, and recurrence. Instead of concurrent therapy, a sequential strategy would be better to target TME-associated cells.	[Ali, Sehar; Borin, Thaiz F.; Piranlioglu, Raziye; Ara, Roxan; Arbab, Ali Syed; Rashid, Mohammad H.] Augusta Univ, Georgia Canc Ctr, Lab Tumor Angiogenesis Initiat, Augusta, GA 30912 USA; [Lebedyeva, Iryna] Augusta Univ, Dept Chem & Phys, Augusta, GA USA; [Angara, Kartik] Michigan State Univ, Dept Pediat & Human Dev, Grand Rapids, MI USA; [Achyut, Bhagelu R.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Rashid, Mohammad H.] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Michigan State University; Emory University; Cedars Sinai Medical Center	Arbab, AS; Rashid, MH (corresponding author), Augusta Univ, Georgia Canc Ctr, Lab Tumor Angiogenesis Initiat, Augusta, GA 30912 USA.; Rashid, MH (corresponding author), Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA.	aarbab@augusta.edu; MohammadHarun.Rashid@cshs.org	Rashid, Mohammad Harun/E-3985-2019	Rashid, Mohammad Harun/0000-0003-1056-4910; Arbab, Ali/0000-0003-2902-3671	Georgia Cancer Center startup fund; Augusta University	Georgia Cancer Center startup fund; Augusta University	This study was supported by the Georgia Cancer Center startup fund and intramural grant program at Augusta University to Ali S. Arbab (ASA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achyut BR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14079-4; Achyut BR, 2016, CANCER BIOL THER, V17, P280, DOI 10.1080/15384047.2016.1139243; Achyut BR, 2015, CANCER LETT, V369, P416, DOI 10.1016/j.canlet.2015.09.004; Achyut BR, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-252; Achyut BR, 2016, ONCOTARGETS THER, V9, P1047, DOI 10.2147/OTT.S102907; Acker G, 2020, EUR J CANCER, V126, P106, DOI 10.1016/j.ejca.2019.12.005; Ali MM, 2013, TRANSL ONCOL, V6, P660, DOI 10.1593/tlo.13559; Angara K, 2018, NEOPLASIA, V20, P1070, DOI 10.1016/j.neo.2018.08.011; Angara Kartik, 2017, Histol Histopathol, V32, P917, DOI 10.14670/HH-11-856; [Anonymous], 2020, LANCET EDITORIAL, V2, pE268, DOI 10.1016/S2589-7500(20)30113-8; Arbab AS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122732; Arbab AS, 2012, HISTOL HISTOPATHOL, V27, P549, DOI 10.14670/HH-27.549; Borin TF, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-1043; Borin TF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178830; Borin TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116247; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; Cannarile MA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0257-y; Carter TC, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6204676; Caudill JS, 2011, AM J CLIN ONCOL-CANC, V34, P385, DOI 10.1097/COC.0b013e3181e8461a; Chen L, 2019, AM J PHYSIOL-HEART C, V316, pH1468, DOI 10.1152/ajpheart.00690.2018; Chen P, 2005, AM J PATHOL, V166, P615, DOI 10.1016/S0002-9440(10)62282-1; Cheng Y, 2019, BBA-REV CANCER, V1871, P289, DOI 10.1016/j.bbcan.2019.01.005; Choi J, 2018, HISTOL HISTOPATHOL, V33, P133, DOI 10.14670/HH-11-916; Dhermain F, 2005, B CANCER, V92, P333; Di Mitri D, 2019, CELL REP, V28, P2156, DOI 10.1016/j.celrep.2019.07.068; Diaz RJ, 2017, J NEURO-ONCOL, V133, P455, DOI 10.1007/s11060-017-2477-x; Dijkgraaf EM, 2013, CANCER RES, V73, P2480, DOI 10.1158/0008-5472.CAN-12-3542; Ding ZC, 2014, CANCER RES, V74, P3441, DOI 10.1158/0008-5472.CAN-13-3596; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Endo K, 2016, SCI REP-UK, V6, DOI 10.1038/srep21991; Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132; Finke J, 2011, INT IMMUNOPHARMACOL, V11, P856, DOI 10.1016/j.intimp.2011.01.030; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Gerstner ER, 2011, J NEURO-ONCOL, V103, P325, DOI 10.1007/s11060-010-0390-7; Ghose A, 2010, CURR ONCOL, V17, P52; Guo AM, 2007, J PHARMACOL EXP THER, V321, P18, DOI 10.1124/jpet.106.115360; Guo M, 2006, J PHARMACOL EXP THER, V317, P97, DOI 10.1124/jpet.105.097782; Gupta K, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00503; Gupta SK, 2014, CLIN CANCER RES, V20, P3730, DOI 10.1158/1078-0432.CCR-13-3446; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; Han YX, 2020, ADV EXP MED BIOL, V1248, P547, DOI 10.1007/978-981-15-3266-5_22; Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood-2011-09-379214; Jain M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41809; Janic B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037577; Johnson BW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092565; Kim MM, 2018, CANCER J, V24, P180, DOI 10.1097/PPO.0000000000000326; Kumar Sanath, 2013, Zhong Liu Za Zhi, V1, P16; Kumar S, 2012, J NEURO-ONCOL, V108, P411, DOI 10.1007/s11060-012-0846-z; Kumar V, 2017, CANCER CELL, V32, P654, DOI 10.1016/j.ccell.2017.10.005; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Labelle M, 2014, P NATL ACAD SCI USA, V111, pE3053, DOI 10.1073/pnas.1411082111; Lee YS, 2012, BRIT J CANCER, V106, P1833, DOI 10.1038/bjc.2012.177; Lesueur P, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5413-y; Lim M, 2018, NAT REV CLIN ONCOL, V15, P422, DOI 10.1038/s41571-018-0003-5; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Liu KH, 2015, ONCOTARGET, V6, P5088, DOI 10.18632/oncotarget.3243; MacDonald KPA, 2005, J IMMUNOL, V175, P1399, DOI 10.4049/jimmunol.175.3.1399; Mann J, 2018, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00748; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani Alberto, 2004, Novartis Found Symp, V256, P137; Mazaris P, 2014, CLIN NEUROL NEUROSUR, V120, P103, DOI 10.1016/j.clineuro.2014.03.001; Mehta M, 2014, SEMIN ONCOL, V41, pS1, DOI 10.1053/j.seminoncol.2014.09.007; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Nguyen MN, 2010, PLOS ONE, V5, pe9907; Noch EK, 2018, WORLD NEUROSURG, V116, P505, DOI 10.1016/j.wneu.2018.04.022; Ouzounova M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14979; Pasqualetti F, 2018, AM J CLIN ONCOL-CANC, V41, P1272, DOI 10.1097/COC.0000000000000464; Pawelek JM, 2008, FUTURE ONCOL, V4, P449, DOI 10.2217/14796694.4.4.449; Pesce J, 2006, J CLIN INVEST, V116, P2044, DOI 10.1172/JCI27727; Huong PT, 2019, CANCERS, V11, DOI 10.3390/cancers11020240; Piranlioglu R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09015-1; Plate KH, 2012, ACTA NEUROPATHOL, V124, P763, DOI 10.1007/s00401-012-1066-5; Priceman SJ, 2010, BLOOD, V115, P1461, DOI 10.1182/blood-2009-08-237412; Qiu SQ, 2018, CANCER TREAT REV, V70, P178, DOI 10.1016/j.ctrv.2018.08.010; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Remer Sandra, 2004, Clin J Oncol Nurs, V8, P368, DOI 10.1188/04.CJON.368-376; Restifo NP, 2016, NAT REV CANCER, V16, P121, DOI 10.1038/nrc.2016.2; Richardsen E, 2015, ANTICANCER RES, V35, P865; Rivera LB, 2015, CELL REP, V11, P577, DOI 10.1016/j.celrep.2015.03.055; Runa F, 2017, Curr Mol Biol Rep, V3, P218, DOI 10.1007/s40610-017-0073-7; Salminen A, 2018, AGEING RES REV, V48, P1, DOI 10.1016/j.arr.2018.09.001; Salminen A, 2018, BIOGERONTOLOGY, V19, P325, DOI 10.1007/s10522-018-9762-8; Sawanobori Y, 2008, BLOOD, V111, P5457, DOI 10.1182/blood-2008-01-136895; Schlesinger M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0669-2; Seki T, 2005, BIOL PHARM BULL, V28, P1651, DOI 10.1248/bpb.28.1651; Shaaban S, 2016, Int J Cancer Res, V12, P69; Shankar A, 2016, ONCOTARGETS THER, V9, P1205, DOI 10.2147/OTT.S93790; Shankar A, 2014, CHIN J CANCER, V33, P148, DOI 10.5732/cjc.013.10095; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Soda Y, 2013, J MOL MED, V91, P439, DOI 10.1007/s00109-013-1019-z; Stafford JH, 2016, NEURO-ONCOLOGY, V18, P797, DOI 10.1093/neuonc/nov272; Stanley ER, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a021857; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Tamura R, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.11; Tan SK, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00218; Tesi RJ, 2019, TRENDS PHARMACOL SCI, V40, P4, DOI 10.1016/j.tips.2018.10.008; Tipping M, 2017, J CLIN NEUROSCI, V44, P101, DOI 10.1016/j.jocn.2017.06.070; Tripathi C, 2014, ONCOTARGET, V5, P5350, DOI 10.18632/oncotarget.2110; Tsang DS, 2015, CLIN ONCOL-UK, V27, P176, DOI 10.1016/j.clon.2014.11.026; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; Umansky V, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040036; Uzuka T, 2014, J NEURO-ONCOL, V116, P299, DOI 10.1007/s11060-013-1291-3; van Linde ME, 2017, J NEURO-ONCOL, V135, P183, DOI 10.1007/s11060-017-2564-z; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Wang SL, 2019, AM J CANCER RES, V9, P1161; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Xu JY, 2013, CANCER RES, V73, P2782, DOI 10.1158/0008-5472.CAN-12-3981; Yan MJ, 2016, BBA-MOL CELL RES, V1863, P392, DOI 10.1016/j.bbamcr.2015.07.008; Zhang QW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050946; Zhou YD, 2019, FRONT ECOL EVOL, V7, DOI 10.3389/fevo.2019.00100; Zhu P, 2017, ONCOTARGET, V8, P44015, DOI 10.18632/oncotarget.17054; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723	118	14	14	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2021	16	2							e0246646	10.1371/journal.pone.0246646	http://dx.doi.org/10.1371/journal.pone.0246646			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH0TZ	33544755	gold, Green Published			2023-01-03	WOS:000617991900042
J	Nazaroff, J; Oyadomari, S; Brown, N; Wang, DA				Nazaroff, Jaron; Oyadomari, Sarah; Brown, Nolan; Wang, Dean			Reporting in clinical studies on platelet-rich plasma therapy among all medical specialties: A systematic review of Level I and II studies	PLOS ONE			English	Review							BIOLOGICS; INJECTION	Background The clinical practice of platelet-rich plasma (PRP) therapy has grown significantly in recent years in multiple medical specialties. However, comparisons of PRP studies across medical fields remain challenging because of inconsistent reporting of protocols and characterization of the PRP being administered. The purpose of this systematic review was to determine the quantity of level I/II studies within each medical specialty and compare the level of study reporting across medical fields. Methods The Cochrane Database, PubMed, and EMBASE databases were queried for level I/II clinical studies on PRP injections across all medical specialties. From these studies, data including condition treated, PRP processing and characterization, delivery, control group, and assessed outcomes were collected. Results A total of 132 studies met the inclusion and exclusion criteria and involved 28 different conditions across 8 specialties (cardiothoracic surgery, cosmetic, dermatology, musculoskeletal (MSK), neurology, oral maxillofacial surgery, ophthalmology, and plastic surgery). Studies on PRP for MSK injuries made up the majority of the studies (74%), with knee osteoarthritis and tendinopathy being most commonly studied. Of the 132 studies, only 44 (33%) characterized the composition of PRP used, and only 23 (17%) reported the leukocyte component. MSK studies were more likely to use patient-reported outcome measures to assess outcomes, while studies from other specialties were more likely to use clinician- or imaging-based objective outcomes. Overall, 61% of the studies found PRP to be favorable over control treatment, with no difference in favorable reporting between MSK and other medical specialties. Conclusions The majority of level I/II clinical studies investigating PRP therapy across all medical specialties have been conducted for MSK injuries with knee osteoarthritis and tendinopathy being the most commonly studied conditions. Inconsistent reporting of PRP composition exists among all studies in medicine. Rigorous reporting in human clinical studies across all medical specialties is crucial for evaluating the effects of PRP and moving towards disease-specific and individualized treatment.	[Nazaroff, Jaron; Oyadomari, Sarah; Brown, Nolan; Wang, Dean] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA; [Wang, Dean] Univ Calif Irvine Hlth, Dept Orthopaed Surg, Orange, CA 92868 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Wang, DA (corresponding author), Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA.; Wang, DA (corresponding author), Univ Calif Irvine Hlth, Dept Orthopaed Surg, Orange, CA 92868 USA.	deanwangmd@gmail.com		Wang, Dean/0000-0002-3005-1154				Abdul Ameer Lubaba A, 2018, Eur J Dent, V12, P528, DOI 10.4103/ejd.ejd_49_18; Albanese A, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-23; Anjayani S, 2014, INT J DERMATOL, V53, P109, DOI 10.1111/ijd.12162; Belk JW, 2021, AM J SPORT MED, V49, P249, DOI 10.1177/0363546520909397; Chahla J, 2017, J BONE JOINT SURG AM, V99, P1769, DOI 10.2106/JBJS.16.01374; Chu CR, 2019, J AM ACAD ORTHOP SUR, V27, pE50, DOI 10.5435/JAAOS-D-18-00305; Danilla S, 2016, AESTHET PLAST SURG, V40, P19, DOI 10.1007/s00266-015-0586-5; Dragoo JL, 2012, AM J SPORT MED, V40, P1274, DOI 10.1177/0363546512442334; Fitzpatrick J, 2018, AM J SPORT MED, V46, P933, DOI 10.1177/0363546517745525; Gupta AK, 2019, J CUTAN MED SURG, V23, P185, DOI 10.1177/1203475418818073; Hausauer AK, 2020, DERMATOL SURG, V46, P447, DOI 10.1097/DSS.0000000000002148; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Johal H, 2019, SPORTS HEALTH, V11, P355, DOI 10.1177/1941738119834972; Le ADK, 2018, CURR REV MUSCULOSKE, V11, P624, DOI 10.1007/s12178-018-9527-7; Marx RG, 2015, J BONE JOINT SURG AM, V97A, P1, DOI 10.2106/JBJS.N.01112; Mishra A, 2009, CLIN SPORT MED, V28, P113, DOI 10.1016/j.csm.2008.08.007; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Mori S, 2019, Int J Womens Dermatol, V5, P21, DOI 10.1016/j.ijwd.2018.08.001; Murray IR, 2017, J BONE JOINT SURG AM, V99, P809, DOI 10.2106/JBJS.16.00793; Pusic AL, 2011, PLAST RECONSTR SURG, V127, P1361, DOI 10.1097/PRS.0b013e3182063276; Rodeo S, 2019, AM J SPORT MED, V47, P2531, DOI 10.1177/0363546519872219; Samadi P, 2019, AESTHET PLAST SURG, V43, P803, DOI 10.1007/s00266-018-1293-9; Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x; Sundman EA, 2011, AM J SPORT MED, V39, P2135, DOI 10.1177/0363546511417792; Vaidya TS, 2019, PRS-GLOB OPEN, V7, DOI 10.1097/GOX.0000000000002423; Wang D, 2017, JBJS REV, V5, DOI 10.2106/JBJS.RVW.17.00024; Zhang ZX, 2016, ACTA ORTHOP TRAUMATO, V50, P191, DOI 10.3944/AOTT.2015.15.0113; Ziegler CG, 2019, AM J SPORT MED, V47, P2174, DOI 10.1177/0363546519832003	28	9	9	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	4							e0250007	10.1371/journal.pone.0250007	http://dx.doi.org/10.1371/journal.pone.0250007			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR0PU	33891618	gold, Green Published			2023-01-03	WOS:000642811900058
J	[Anonymous]				[Anonymous]			Summary for Patients: Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	2021	174	6					I22	I22		10.7326/P21-0003	http://dx.doi.org/10.7326/P21-0003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX0TN	33819058				2023-01-03	WOS:000682804400002
J	Williams, R; Alessi, C; Alexander, G; Allison, M; Aspinall, R; Batterham, RL; Bhala, N; Day, N; Dhawan, A; Drummond, C; Ferguson, J; Foster, G; Gilmore, I; Goldacre, R; Gordon, H; Henn, C; Kelly, D; MacGilchrist, A; McCorry, R; McDougall, N; Mirza, Z; Moriarty, K; Newsome, P; Pinder, R; Roberts, S; Rutter, H; Ryder, S; Samyn, M; Severi, K; Sheron, N; Thorburn, D; Verne, J; Williams, J; Yeoman, A				Williams, Roger; Alessi, Charles; Alexander, Graeme; Allison, Michael; Aspinall, Richard; Batterham, Rachel L.; Bhala, Neeraj; Day, Natalie; Dhawan, Anil; Drummond, Colin; Ferguson, James; Foster, Graham; Gilmore, Ian; Goldacre, Raphael; Gordon, Harriet; Henn, Clive; Kelly, Deirdre; MacGilchrist, Alastair; McCorry, Roger; McDougall, Neil; Mirza, Zulfiquar; Moriarty, Kieran; Newsome, Philip; Pinder, Richard; Roberts, Stephen; Rutter, Harry; Ryder, Stephen; Samyn, Marianne; Severi, Katherine; Sheron, Nick; Thorburn, Douglas; Verne, Julia; Williams, John; Yeoman, Andrew			New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK	LANCET			English	Review							BILIARY ATRESIA; ENGLAND	This Review, in addressing the unacceptably high mortality of patients with liver disease admitted to acute hospitals, reinforces the need for integrated clinical services. The masterplan described is based on regional, geographically sited liver centres, each linked to four to six surrounding district general hospitals-a pattern of care similar to that successfully introduced for stroke services. The plan includes the establishment of a lead and deputy lead clinician in each acute hospital, preferably a hepatologist or gastroenterologist with a special interest in liver disease, who will have prime responsibility for organising the care of admitted patients with liver disease on a 24/7 basis. Essential for the plan is greater access to intensive care units and high-dependency units, in line with the reconfiguration of emergency care due to the COVID-19 pandemic. This Review strongly recommends full implementation of alcohol care teams in hospitals and improved working links with acute medical services. We also endorse recommendations from paediatric liver services to improve overall survival figures by diagnosing biliary atresia earlier based on stool colour charts and better caring for patients with impaired cognitive ability and developmental mental health problems. Pilot studies of earlier diagnosis have shown encouraging progress, with 5-6% of previously undiagnosed cases of severe fibrosis or cirrhosis identified through use of a portable FibroScan in primary care. Similar approaches to the detection of early asymptomatic disease are described in accounts from the devolved nations, and the potential of digital technology in improving the value of clinical consultation and screening programmes in primary care is highlighted. The striking contribution of comorbidities, particularly obesity and diabetes (with excess alcohol consumption known to be a major factor in obesity), to mortality in COVID-19 reinforces the need for fiscal and other long delayed regulatory measures to reduce the prevalence of obesity. These measures include the food sugar levy and the introduction of the minimum unit price policy to reduce alcohol consumption. Improving public health, this Review emphasises, will not only mitigate the severity of further waves of COVID-19, but is crucial to reducing the unacceptable burden from liver disease in the UK.	[Williams, Roger; Day, Natalie; Sheron, Nick] Fdn Liver Res, Inst Hepatol, London, England; [Alessi, Charles; Henn, Clive; Verne, Julia] Publ Hlth England, Leeds, W Yorkshire, England; [Alexander, Graeme; Thorburn, Douglas] Royal Free Hosp, UCL Inst Liver & Digest Hlth, London, England; [Thorburn, Douglas] Royal Free Hosp, Sheila Sherlock Liver Ctr, London, England; [Allison, Michael] Cambridge Univ Hosp NHS Fdn Trust, Cambridge Biomed Res Ctr, Dept Med, Liver Unit, Cambridge, England; [Aspinall, Richard] Queen Alexandra Hosp, Portsmouth Hosp NHSTrust, Dept Gastroenterol & Hepatol, Portsmouth, Hants, England; [Batterham, Rachel L.] UCLH Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Bhala, Neeraj; Ferguson, James; Newsome, Philip] Univ Hosp Birmingham NHS Fdn Trust, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; [Bhala, Neeraj] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp Birmingham, Gastrointestinal & Liver Serv, Birmingham, W Midlands, England; [Dhawan, Anil; Samyn, Marianne] Kings Coll Hosp NHS Fdn Trust, Paediat Liver GI & Nutr Ctr, London, England; [Drummond, Colin] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England; [Drummond, Colin] South London & Maudsley NHS Fdn Trust, London, England; [Foster, Graham] Queen Mary Univ London, Barts Liver Ctr, London, England; [Gilmore, Ian] Univ Liverpool, Liverpool Ctr Alcohol Res, Liverpool, Merseyside, England; [Goldacre, Raphael] Univ Oxford, NIHR Oxford Biomed Res Ctr, Big Data Inst, Unit Hlth Care Epidemiol,Nuffield Dept Populat Hl, Oxford, England; [Gordon, Harriet] Hampshire Hosp Fdn Trust, Gastroenterol Dept, Winchester, Hants, England; [Kelly, Deirdre] Birmingham Womens & Childrens Hosp, Liver Unit, Birmingham, W Midlands, England; [MacGilchrist, Alastair] Royal Infirm Edinburgh NHS Trust, Dept Hepatol, Edinburgh, Midlothian, Scotland; [McCorry, Roger; McDougall, Neil] Royal Victoria Hosp, Liver Unit, Belfast, Antrim, North Ireland; [Mirza, Zulfiquar] West Middlesex Univ Hosp, Emergency Dept, London, England; [Moriarty, Kieran] British Soc Gastroenterol, London, England; [Pinder, Richard] Imperial Coll Sci & Technol, Sch Publ Hlth, London, England; [Roberts, Stephen; Williams, John] Swansea Univ, Med Sch, Swansea, W Glam, Wales; [Rutter, Harry] Univ Bath, Dept Social & Policy Sci, Bath, Avon, England; [Ryder, Stephen] Nottingham Univ Hosp NHS Trust, NIHR Biomed Res Ctr, Nottingham, England; [Ryder, Stephen] Univ Nottingham, Nottingham, England; [Severi, Katherine] Inst Alcohol Studies, London, England; [Yeoman, Andrew] Aneurin Bevan Univ Hlth Board, Newport, Gwent, Wales; [Gilmore, Ian] Alcohol Hlth Alliance, London, England	University of London; University College London; Public Health England; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Cambridge; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of London; University College London; University of Birmingham; University of Birmingham; King's College Hospital NHS Foundation Trust; University of London; King's College London; South London & Maudsley NHS Trust; University of London; Queen Mary University London; University of Liverpool; University of Oxford; Birmingham Women's Hospital; Royal Infirmary of Edinburgh; University of Edinburgh; Imperial College London; Swansea University; University of Bath; Nottingham University Hospital NHS Trust; University of Nottingham	Gilmore, I (corresponding author), Univ Liverpool, Liverpool Ctr Alcohol Res, Liverpool Hlth Partners, Liverpool L3 5TF, Merseyside, England.	igilmore@liverpool.ac.uk	Rutter, Harry/HCI-8765-2022; Newsome, Philip N/D-4495-2018; Drummond, Colin/H-5459-2011	Newsome, Philip N/0000-0001-6085-3652; Aspinall, Richard/0000-0002-5208-8185; Drummond, Colin/0000-0001-9379-5452; Rutter, Harry/0000-0002-9322-0656; Bhala, Neeraj/0000-0003-2502-1177; Batterham, Rachel/0000-0002-5477-8585; Pinder, Richard/0000-0002-7010-6009	NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK; NIHR Applied Research Collaboration South London; NIHR senior investigator award; Foundation for Liver Research (London, UK)	NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK; NIHR Applied Research Collaboration South London; NIHR senior investigator award; Foundation for Liver Research (London, UK)	We thank all those who attended meetings of the working groups of the Commission, including Mark Hudson (Freeman Hospital, Newcastle, UK); Camille Manceau and Mark Tyrell (Echosens, Paris, France); Jonny Greenberg, Riddhi Thakrar, and Thomas Stephens (Incisive Health, London, UK); John Wass (Department of Endocrinology, Churchill Hospital, Oxford, UK); Pamela Healy and Vanessa Hebditch (British Liver Trust, Bournemouth, UK); Jyotsna Vohra (Cancer Research UK, London, UK); Alison Taylor (Children's Liver Disease Foundation, Birmingham, UK); Ian Gee (Worcestershire Acute Hospital, Worcester, UK); Matthew Cramp (Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK); Mead Mathews (St Mary's Surgery, Southampton, UK); Helen Jarvis (Newcastle University, Newcastle, UK, and The Royal College of General Practitioners, London, UK); Annie McCloud (Kent and Medway NHS and Social Care Partnership, Gillingham, UK); Martin McKee (London School of Hygiene & Tropical Medicine, London, UK); Joanne Morling (Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK); Michael Goldacre (Unit of Health-Care Epidemiology, Nuffield Department of Population Health, University of Oxford, Oxford, UK); Peter Rice (Scottish Health Action on Alcohol Problems, Edinburgh, UK); Robyn Burton (Public Health England, Leeds, UK); Guruprasad Aithal (Nottingham Digestive Diseases Centre and the National Institute for Health Research [NIHR] Nottingham Biomedical Research Centre at the Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK); and Tamara Pinedo (Royal College of Emergency Medicine, London, UK). We thank Norgine for their unrestricted grant to the Foundation for Liver Research (London, UK), which has enabled the Commission to work with Incisive Health (London, UK) in bringing the work of the Commission to the attention of the UK Government. CD was partly funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK, and by the NIHR Collaboration for Leadership in Applied Health Research and Care South London, now recommissioned as the NIHR Applied Research Collaboration South London, and receives funding from an NIHR senior investigator award. The views expressed in this Review are those of the authors and not necessarily those of the Medical Research Council, the NHS, the NIHR, or the UK Government's Department of Health and Social Care.	Alcohol Health Alliance, ITS EV ALC PUBL FAC; Ananthapavan J, 2018, ASSESSING COST EFFEC; Angrisani L, 2021, OBES SURG, V31, P1937, DOI 10.1007/s11695-020-05207-7; [Anonymous], **DATA OBJECT**; Baker Colin, 2014, Qual Prim Care, V22, P232; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Barron E, 2020, LANCET DIABETES ENDO, V8, P813, DOI 10.1016/S2213-8587(20)30272-2; Blackwood R, 2021, ADDICTION, V116, P1700, DOI 10.1111/add.15354; Chalmers J, 2020, FRONTLINE GASTROENTE, V11, P86, DOI 10.1136/flgastro-2019-101177; Chen SM, 2006, PEDIATRICS, V117, P1147, DOI 10.1542/peds.2005-1267; Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2; Coomber K., 2020, INVESTIGATING INTRO; Davenport M, 2011, J PEDIATR SURG, V46, P1689, DOI 10.1016/j.jpedsurg.2011.04.013; Department of Health Northern Ireland, 2020, HLTH IN ANN REP 2020; Dillon JF, 2019, J HEPATOL, V71, P699, DOI 10.1016/j.jhep.2019.05.033; Drummond C, 2018, ASSERTIVE OUTREACH H; Fincham-Campbell S, 2018, ALCOHOL ALCOHOLISM, V53, P277, DOI 10.1093/alcalc/agx095; Finlay I, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1987; Fowell AJ, 2021, FRONTLINE GASTROENTE, V12, P102, DOI 10.1136/flgastro-2019-101304; Gaspar R, 2019, DIGEST LIVER DIS, V51, P1423, DOI 10.1016/j.dld.2019.03.016; Giles L, 2019, SALES BASED CONSUMPT; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Hazlehurst JM, 2020, CURR OBES REP, V9, P530, DOI 10.1007/s13679-020-00416-8; Intensive Care National Audit and Research Centre, 2020, COVID 19 REP; Intensive Care National Audit and Research Centre, 2020, ICNARC REPORT COVID; Jackson SE, 2021, ADDICTION, V116, P1233, DOI 10.1111/add.15295; Ji D, 2020, J HEPATOL, V73, P451, DOI 10.1016/j.jhep.2020.03.044; Joshi D, 2019, CLIN MED, V19, P425, DOI 10.7861/clinmed.2019-0172; Kallis C, 2020, ALIMENT PHARM THER, V52, P182, DOI 10.1111/apt.15781; Mao R, 2020, LANCET GASTROENTEROL, V5, P667, DOI 10.1016/S2468-1253(20)30126-6; Matthews K, 2019, J CLIN NURS, V28, P650, DOI 10.1111/jocn.14660; Morales BP, 2018, DIGEST LIVER DIS, V50, P76, DOI 10.1016/j.dld.2017.08.024; Moriarty KJ, 2020, FRONTLINE GASTROENTE, V11, P293, DOI 10.1136/flgastro-2019-101241; National Confidential Enquiry into Patient Outcome and Death, 2013, ALC REL LIV DIS MEAS; National Health Service Digital, 2020, STAT ALC; National Health Service England, 2019, ONL VERS NHS LONG TE; National Institute for Health and Care Excellence, 2020, FIBR ASS LIV FIBR CI; NHS England, 2015, CLIN MOD AMB SERV; Office for National Statistics, 2019, NAT POP PROJ MORT AS; Phillips T, 2020, ALCOHOL ALCOHOLISM, V55, P395, DOI 10.1093/alcalc/agaa024; Public Health England, 2019, AD SUBST MISS TREATM; Public Health England, LIV DIS APPL ALL OUR; Public Health England, 2019, ALC CAR TEAMS COR SE; Public Health England, ATL VAR; Public Health Scotland, 2019, ALC REL HOSP STAT; Rennie J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2409; Roberts E, 2020, ALCOHOL ALCOHOLISM, V55, P96, DOI 10.1093/alcalc/agz079; Roberts E, 2019, ADDICTION, V114, P1726, DOI 10.1111/add.14642; Roberts SE, 2019, ALIMENT PHARM THER, V49, P1334, DOI 10.1111/apt.15232; Robinson M, 2020, EVALUATING IMPACT MI; Rodijk LH, 2018, J PEDIATR GASTR NUTR, V67, P157, DOI 10.1097/MPG.0000000000001981; Royal College of Physicians, CENS CONS PHYS HIGH; Royal College of Physicians, 2019, FOC PHYS 2018 19 CEN; Royal College of Physicians, 2017, RCP LAUNCH IQ ACCR S; Royal College of Psychiatrists, 2020, TRAIN ADD PSYCH CURR; Rubino F, 2020, LANCET DIABETES ENDO, V8, P640, DOI 10.1016/S2213-8587(20)30157-1; Srivastava A, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1039-4; Talcott JB, 2019, J PEDIATR GASTR NUTR, V69, P145, DOI 10.1097/MPG.0000000000002380; The British Society of Gastroenterology and the Royal Bolton Hospital NHS Foundation Trust, 2016, QUAL PROD CAS STUD; UK Government, 2018, CHILDH OB PLAN ACT; UK Government, 2013, LOC AUTH PUBL HLTH F; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Williams R, 2020, LANCET, V395, P226, DOI 10.1016/S0140-6736(19)32908-3; Williams R, 2018, LANCET, V392, P2398, DOI 10.1016/S0140-6736(18)32561-3; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Yan HD, 2020, CLIN PHARMACOL THER, V108, P1185, DOI 10.1002/cpt.2047; Zhao JH, 2020, J STUD ALCOHOL DRUGS, V81, P225	68	3	3	8	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2021	397	10286					1770	1780		10.1016/S0140-6736(20)32396-5	http://dx.doi.org/10.1016/S0140-6736(20)32396-5		MAY 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY3KF	33714360	Green Submitted, Green Accepted, Green Published			2023-01-03	WOS:000647813600031
J	Garcheva, V; Akin, M; Adel, J; Martinez, CS; Bauersachs, J; Schafer, A				Garcheva, Vera; Akin, Muharrem; Adel, John; Martinez, Carolina Sanchez; Bauersachs, Johann; Schaefer, Andreas			High rate of critical coronary stenosis in comatose patients with Non-ST-elevation out-of-hospital cardiac arrest (NSTE-OHCA) undergoing therapeutic hypothermia-Experience from the HAnnover COoling REgistry (HACORE)	PLOS ONE			English	Article							SEGMENT ELEVATION; MYOCARDIAL-INFARCTION; ANGIOGRAPHY; INTERVENTION; ASSOCIATION; GUIDELINES; STRATEGIES; MANAGEMENT; SURVIVORS; OUTCOMES	Background Myocardial infarction is the most frequent cause for out-of-hospital cardiac arrest (OHCA) in adults. Patients with ST-segment elevations (STE) following return of spontaneous circulation (ROSC) are regularly admitted to the catheterisation laboratory for urgent coronary angiography. Whether patients without obvious STE (NSTE) should receive coronary angiography as part of a standardised diagnostic work-up following OHCA is still debated. Methods We analysed a cohort of 517 subsequent OHCA patients admitted at our institution who received a standardised diagnostic work-up including coronary angiography and therapeutic hypothermia. Patients were 6314 years old, 76% were male. Overall, 180 (35%) had ST-elevation in the post-ROSC ECG, 317 (61%) had shockable rhythm (ventricular fibrillation or tachycardia) at first ECG. ROSC was achieved after 2621 minutes. Results Critical coronary stenosis requiring PCI was present in 83% of shockable and 87% of non-shockable STE-OHCA and in 48% of shockable and 22% of non-shockable NSTE-OHCA patients. In-hospital survival was 61% in shockable and 55% in non-shockable STE-OHCA and 60% in shockable and 28% in non-shockable NSTE-OHCA. Conclusion Standardised admission diagnostics in OHCA patients undergoing therapeutic hypothermia with a strict admission protocol incorporating ECG and coronary catheterisation shows a high rate of relevant coronary stenosis in STE-OHCA irrespective of the initial rhythm and in NSTE-OHCA with initial shockable rhythm. Based on the unfavourable outcome and low PCI rate observed in NSTE-OHCA patients with a primary non-shockable ECG rhythm it might be reasonable to restrict routine early coronary angiography to patients with primary shockable rhythms and/or ST-segment elevations after ROSC.	[Garcheva, Vera; Akin, Muharrem; Adel, John; Martinez, Carolina Sanchez; Bauersachs, Johann; Schaefer, Andreas] Hannover Med Sch, Dept Cardiol & Angiol, Hannover, Germany	Hannover Medical School	Schafer, A (corresponding author), Hannover Med Sch, Dept Cardiol & Angiol, Hannover, Germany.	Schaefer.andreas@mh-hannover.de	Schäfer, Andreas/AAQ-9512-2021	Akin, Muharrem/0000-0002-0936-8755	Clinical Research Group (KFO) of the Deutsche Forschungsgemeinschaft [311]	Clinical Research Group (KFO) of the Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The study was partly supported by the Clinical Research Group (KFO) 311 of the Deutsche Forschungsgemeinschaft to JB. There was no additional external or internal funding received for this study.	Akin M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245210; Akin M, 2018, JACC-CARDIOVASC INTE, V11, P1811, DOI 10.1016/j.jcin.2018.06.022; Baldi E, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.32875; Collet JP., 2020, EUR HEART J, DOI [10.1093/eurheartj/ehaa624, DOI 10.1093/EURHEARTJ/EHAA624]; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; Dumas F, 2016, JACC-CARDIOVASC INTE, V9, P1011, DOI 10.1016/j.jcin.2016.02.001; Garcia S, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002670; Jentzer JC, 2018, RESUSCITATION, V123, P15, DOI 10.1016/j.resuscitation.2017.12.004; Kern KB, 2015, JACC-CARDIOVASC INTE, V8, P1031, DOI 10.1016/j.jcin.2015.02.021; Khan MS, 2017, RESUSCITATION, V121, P127, DOI 10.1016/j.resuscitation.2017.10.019; Lemkes JS, 2019, NEW ENGL J MED, V380, P1397, DOI 10.1056/NEJMoa1816897; Millin MG, 2016, RESUSCITATION, V108, P54, DOI 10.1016/j.resuscitation.2016.09.004; Napp LC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239777; Napp LC, 2016, CLIN RES CARDIOL, V105, P283, DOI 10.1007/s00392-015-0941-1; Neumann FJ, 2019, EUR HEART J, V40, P87, DOI 10.1093/eurheartj/ehy394; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Noc M, 2014, EUROINTERVENTION, V10, P31, DOI 10.4244/EIJV10I1A7; Panchal AR, 2020, CIRCULATION, V142, pS366, DOI 10.1161/CIR.0000000000000916; Priori SG, 2015, EUR HEART J, V36, P2793, DOI 10.1093/eurheartj/ehv316; Sieweke JT, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00925-2020; Sieweke JT, 2020, EUR HEART J-ACUTE CA, V9, P138, DOI 10.1177/2048872618757393; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; Staer-Jensen H, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.115.002784; Thiele H, 2017, NEW ENGL J MED, V377, P2419, DOI 10.1056/NEJMoa1710261; Thiele H, 2012, NEW ENGL J MED, V367, P1287, DOI 10.1056/NEJMoa1208410; Tongers J, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.118.005853	26	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2021	16	5							e0251178	10.1371/journal.pone.0251178	http://dx.doi.org/10.1371/journal.pone.0251178			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6FM	33945587	Green Published, gold			2023-01-03	WOS:000664609600052
J	Bienstock, JL; Eke, AC; Hueppchen, NA				Bienstock, Jessica L.; Eke, Ahizechukwu C.; Hueppchen, Nancy A.			Postpartum Hemorrhage	NEW ENGLAND JOURNAL OF MEDICINE			English	Review								Postpartum Hemorrhage The major causes of postpartum hemorrhage are uterine atony, lacerations, retained placenta or clots, and clotting factor deficiency. Uterine massage, oxytocin, and methylergonovine are the main treatments, along with blood transfusion and cardiovascular support.	[Bienstock, Jessica L.; Eke, Ahizechukwu C.; Hueppchen, Nancy A.] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Div Maternal Fetal Med, 600 N Wolfe St, Baltimore, MD 21287 USA	Johns Hopkins University	Bienstock, JL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Div Maternal Fetal Med, 600 N Wolfe St, Baltimore, MD 21287 USA.	jbienst@jhmi.edu		Eke, MD PhD, Ahizechukwu C./0000-0002-0070-9840				ALDERSON P, 2000, COCHRANE DB SYST REV, V2; Anderson JM, 2017, BJOG-INT J OBSTET GY, V124, P875, DOI [10.1111/1471-0528.14178, DOI 10.1111/1471-0528.14178]; [Anonymous], 2019, Obstet Gynecol, V134, pe150, DOI 10.1097/AOG.0000000000003564; [Anonymous], 2011, Obstet Gynecol, V117, P1472, DOI 10.1097/AOG.0b013e3182238c31; [Anonymous], 2009, WHO GUIDELINES MANAG; [Anonymous], 2007, MAK PREGN SAF; Antonelli E, 2006, BJOG-INT J OBSTET GY, V113, P846, DOI 10.1111/j.1471-0528.2006.00965.x; Bakri YN, 2001, INT J GYNECOL OBSTET, V74, P139, DOI 10.1016/S0020-7292(01)00395-2; Begley CM, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007412.pub5; BLynch C, 1997, BRIT J OBSTET GYNAEC, V104, P372, DOI 10.1111/j.1471-0528.1997.tb11471.x; Borovac-Pinheiro A, 2018, AM J OBSTET GYNECOL, V219, P162, DOI 10.1016/j.ajog.2018.04.013; Bose P, 2006, BJOG-INT J OBSTET GY, V113, P919, DOI 10.1111/j.1471-0528.2006.01018.x; Butwick AJ, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2015.01.008; Carlan SJ, 1997, J CLIN ULTRASOUND, V25, P301, DOI 10.1002/(SICI)1097-0096(199707)25:6<301::AID-JCU3>3.0.CO;2-G; Carrillo AP, 2019, WOMENS HEALTH, V15, DOI 10.1177/1745506519878081; Centers for Disease Control and Prevention, PREGN MORT SURV SYST; Centers for Disease Control and Prevention, POSTPARTUM HEMORRHAG; Cho HY, 2015, INT J QUAL HEALTH C, V27, P459, DOI 10.1093/intqhc/mzv068; Cho JH, 2000, OBSTET GYNECOL, V96, P129, DOI 10.1016/S0029-7844(00)00852-8; Collins SL, 2019, AM J OBSTET GYNECOL, V220, P511, DOI 10.1016/j.ajog.2019.02.054; Committee on Practice Bulletins-Obstetrics, 2017, Obstet Gynecol, V130, pe168, DOI 10.1097/AOG.0000000000002351; D'Antonio F, 2014, ULTRASOUND OBST GYN, V44, P8, DOI 10.1002/uog.13327; Dahlke JD, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.02.023; Diaz V, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010980.pub2; Dildy GA, 2002, CLIN OBSTET GYNECOL, V45, P330, DOI 10.1097/00003081-200206000-00005; Dilla AJ, 2013, OBSTET GYNECOL, V122, P120, DOI 10.1097/AOG.0b013e3182941c78; Dobiesz VA., 2017, ROSENS EMERGENCY MED, V9, P2314; Doomah Yussriya Hanaa, 2019, Acta Inform Med, V27, P318, DOI 10.5455/aim.2019.27.318-326; El-Hamamy E, 2005, BJOG-INT J OBSTET GY, V112, P126, DOI 10.1111/j.1471-0528.2004.00259.x; Esike COU, 2020, OBSTET GYNECOL, V136, P466, DOI 10.1097/AOG.0000000000003947; Gallos ID, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011689.pub2; Gerdessen L, 2021, J CLIN MONIT COMPUT, V35, P245, DOI 10.1007/s10877-020-00579-8; Gipson MG, 2013, SEMIN INTERVENT RAD, V30, P333, DOI 10.1055/s-0033-1359726; Haultain FWN, 1901, BRIT MED J, V1901, P974; Hayman RG, 2002, OBSTET GYNECOL, V99, P502, DOI 10.1016/S0029-7844(01)01643-X; Hofmeyr GJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008020.pub2; Hofmeyr GJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006431.pub3; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Hu K, 2020, J MED DEVICES, V14, DOI 10.1115/1.4045965; Hunt BJ, 2015, BRIT J HAEMATOL, V170, P788, DOI 10.1111/bjh.13580; Huntington JL, 1928, AM J OBSTET GYNECOL, V15, P34, DOI 10.1016/S0002-9378(15)32679-X; Hussain SA, 2019, CUREUS, V11, DOI 10.7759/cureus.6456; Jauniaux ERM, 2019, BJOG-INT J OBSTET GY, V126, pE1, DOI 10.1111/1471-0528.15306; Jauniaux E, 2018, INT J GYNECOL OBSTET, V140, P274, DOI 10.1002/ijgo.12408; Joshi VM, 2007, BJOG-INT J OBSTET GY, V114, P356, DOI 10.1111/j.1471-0528.2006.01235.x; Joshi VM, 2004, BJOG-INT J OBSTET GY, V111, P279, DOI 10.1111/j.1471-0528.2004.00056.x; Lester F, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.12.054; Likis FE, 2015, MANAGEMENT POSTPARTU; Lu MC, 2009, J PERINATOL, V29, P422, DOI 10.1038/jp.2009.2; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Marasinghe JP, 2011, ACTA OBSTET GYN SCAN, V90, P280, DOI 10.1111/j.1600-0412.2010.01048.x; Matsubara S, 2013, ACTA OBSTET GYN SCAN, V92, P378, DOI 10.1111/aogs.12077; McDonald SJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004074.pub3; McLucas B, 2016, MINIM INVASIV THER, V25, P1, DOI 10.3109/13645706.2015.1074082; Meher S, 2019, BEST PRACT RES CL OB, V61, P41, DOI 10.1016/j.bpobgyn.2019.04.003; Nyflot LT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175306; OLEARY JL, 1966, AM J OBSTET GYNECOL, V94, P920, DOI 10.1016/0002-9378(66)90026-3; Ouahba J, 2007, BJOG-INT J OBSTET GY, V114, P619, DOI 10.1111/j.1471-0528.2007.01272.x; Oyelese Y, 2007, OBSTET GYN CLIN N AM, V34, P421, DOI 10.1016/j.ogc.2007.06.007; Pacagnella RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057594; Pereira A, 2005, OBSTET GYNECOL, V106, P569, DOI 10.1097/01.AOG.0000168434.28222.d3; Porreco RP, 2010, CLIN OBSTET GYNECOL, V53, P182, DOI 10.1097/GRF.0b013e3181cc4139; Labarta FJR, 2016, EUR J OBSTET GYN R B, V206, P12, DOI 10.1016/j.ejogrb.2016.07.510; Saroja CSM, 2010, ARCH GYNECOL OBSTET, V281, P581, DOI 10.1007/s00404-009-1249-z; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Sebghati M, 2017, WOMENS HEALTH, V13, P34, DOI 10.1177/1745505717716860; Shields LE, 2015, AM J OBSTET GYNECOL, V212, P272, DOI 10.1016/j.ajog.2014.07.012; Suarez S, 2020, AM J OBSTET GYNECOL, V222, DOI 10.1016/j.ajog.2019.11.1287; Toffaletti JG, 2019, ANESTH ANALG, V128, P414, DOI 10.1213/ANE.0000000000003499; Tuncalp O, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000494.pub4; Turan J, 2011, J WOMENS HEALTH, V20, P91, DOI 10.1089/jwh.2010.2081; Vijayaraghavan R, 2006, BJOG-INT J OBSTET GY, V113, P1100, DOI 10.1111/j.1471-0528.2006.01052.x; Vintejoux E, 2015, AUST NZ J OBSTET GYN, V55, P572, DOI 10.1111/ajo.12376; WATERS EG, 1952, AM J OBSTET GYNECOL, V64, P1143, DOI 10.1016/0002-9378(52)90377-3; Young PP, 2011, TRANSFUS MED REV, V25, P293, DOI 10.1016/j.tmrv.2011.04.002; Zheng J, 2011, BJOG-INT J OBSTET GY, V118, P370, DOI 10.1111/j.1471-0528.2010.02809.x; Zuckerwise LC, 2020, AM J OBSTET GYNECOL, V222, DOI 10.1016/j.ajog.2019.08.035	77	31	34	10	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 29	2021	384	17					1635	1645		10.1056/NEJMra1513247	http://dx.doi.org/10.1056/NEJMra1513247			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV1ND	33913640				2023-01-03	WOS:000645605800014
J	Laher, AE; Paruk, F; Richards, GA; Venter, WDF				Laher, Abdullah E.; Paruk, Fathima; Richards, Guy A.; Venter, Willem D. F.			Predictors of prolonged hospital stay in HIV-positive patients presenting to the emergency department	PLOS ONE			English	Article							LENGTH-OF-STAY; INFECTED PATIENTS; MORTALITY; MENINGITIS; HIV/AIDS; PORTUGAL	Background Prolonged hospitalization places a significant burden on healthcare resources. Compared to the general population, hospital length of stay (LOS) is generally longer in HIV-positive patients. We identified predictors of prolonged hospital length of stay (LOS) in HIV-positive patients presenting to an emergency department (ED). Methods In this cross-sectional study, HIV-positive patients presenting to the Charlotte Maxeke Johannesburg Academic Hospital adult ED were prospectively enrolled between 07 July 2017 and 18 October 2018. Data was subjected to univariate and multivariate logistic regression to determine parameters associated with a higher likelihood of prolonged hospital LOS, defined as >= 7 days. Results Among the 1224 participants that were enrolled, the median (IQR) LOS was 4.6 (2.6-8.2) days, while the mean (SD) LOS was 6.9 (8.2) days. On multivariate analysis of the data, hemoglobin <11 g/dL (OR 1.37, p = 0.032), Glasgow coma scale (GCS) <15 (OR 1.80, p = 0.001), creatinine >120 mu mol/L (OR 1.85, p = 0.000), cryptococcal meningitis (OR 2.45, p = 0.015) and bacterial meningitis (OR 4.83, p = 0.002) were significantly associated with a higher likelihood of LOS >= 7 days, while bacterial pneumonia (OR 0.35, p = 0.000) and acute gastroenteritis (OR 0.40, p = 0.025) were significantly associated with a lower likelihood of LOS >= 7 days. Conclusion Various clinical and laboratory parameters are useful in predicting prolonged hospitalization among HIV-positive patients presenting to the ED. These parameters may be useful in guiding clinical decision making and directing the allocation of resources.	[Laher, Abdullah E.] Univ Witwatersrand, Fac Hlth Sci, Dept Emergency Med, Johannesburg, South Africa; [Paruk, Fathima] Univ Pretoria, Dept Crit Care, Pretoria, South Africa; [Richards, Guy A.] Univ Witwatersrand, Fac Hlth Sci, Dept Crit Care, Johannesburg, South Africa; [Venter, Willem D. F.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa	University of Witwatersrand; University of Pretoria; University of Witwatersrand; University of Witwatersrand	Laher, AE (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Dept Emergency Med, Johannesburg, South Africa.	abdullahlaher@msn.com	Laher, Abdullah/B-3391-2018; Paruk, Fathima/AAO-1864-2021	Laher, Abdullah/0000-0002-3306-7389; Paruk, Fathima/0000-0002-6549-0106				Barreneche MFA, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0186-3; Andersen L., 2015, CRIT CARE, V19, pP193, DOI [10.1053/j.jvca.2015.06.007, DOI 10.1053/J.JVCA.2015.06.007]; Augusto GF, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4131-0; Barbour KE, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-3; Bruijns SR, 2008, EMERG MED J, V25, P398, DOI 10.1136/emj.2007.051177; BURR RG, 1993, PARAPLEGIA, V31, P473, DOI 10.1038/sc.1993.76; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; Chua Jia Min, 2019, Endocrinol Diabetes Metab, V2, pe00062, DOI 10.1002/edm2.62; Coelho LE, 2017, BRAZ J INFECT DIS, V21, P190, DOI 10.1016/j.bjid.2016.10.007; Dias SS, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-125; Eghbalzadeh K, 2018, THER ADV CARDIO DIS, V12, P289, DOI 10.1177/1753944718798345; Faisst M, 2010, J CRIT CARE, V25, P105, DOI 10.1016/j.jcrc.2009.02.002; Goncalves MJF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060487; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Jones J, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002729; Krentz HB, 2006, HIV MED, V7, P457, DOI 10.1111/j.1468-1293.2006.00408.x; Laher AE, 2021, HIV MED, V22, P557, DOI 10.1111/hiv.13097; Laher AE, 2021, S AFR J HIV MED, V22, DOI 10.4102/sajhivmed.v22i1.1177; Laher AE., 2021, S AFRICAN MED J, DOI [10.7196/SAMJ.2021.v111i7.15604, DOI 10.7196/SAMJ.2021.V111I7.15604]; Maphula RW, 2020, HIV MED, V21, P334, DOI 10.1111/hiv.12834; Nathavitharana RL, 2012, INTERN MED J, V42, P683, DOI 10.1111/j.1445-5994.2011.02566.x; Okazaki Y, 2020, ACUTE MED SURG, V7, DOI 10.1002/ams2.482; Ritchwood TD, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0683-y; Sanoufa M, 2015, J Perioper Pract, V25, P267; Santella Anthony, 2010, J La State Med Soc, V162, P325; Toptas M, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9438046; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; Wu G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67031-4; Yerramilli A, 2017, NEUROL INDIA, V65, P1006, DOI 10.4103/neuroindia.NI_785_15	29	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2021	16	4							e0249706	10.1371/journal.pone.0249706	http://dx.doi.org/10.1371/journal.pone.0249706			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0BF	33882077	gold, Green Published			2023-01-03	WOS:000644133400039
J	Ortega, R; Nozari, A; Baker, W; Surani, S; Edwards, M				Ortega, Rafael; Nozari, Ala; Baker, William; Surani, Sannoor; Edwards, Melinda			Intranasal Naloxone Administration	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ortega, Rafael; Nozari, Ala; Surani, Sannoor; Edwards, Melinda] Boston Med Ctr, Dept Anesthesiol, 750 Albany St, Boston, MA 02118 USA; [Baker, William] Boston Med Ctr, Dept Emergency Med, Boston, MA USA	Boston Medical Center; Boston Medical Center	Ortega, R (corresponding author), Boston Med Ctr, Dept Anesthesiol, 750 Albany St, Boston, MA 02118 USA.	rafael.ortega@bmc.org		Baker, William/0000-0002-4915-2553; Nozari, Ala/0000-0002-5755-6347				Lynn RR, 2018, THER ADV DRUG SAF, V9, P63, DOI 10.1177/2042098617744161; Mundin G, 2017, ADDICTION, V112, P1647, DOI 10.1111/add.13849; Tippey KG, 2019, PAIN THER, V8, P89, DOI 10.1007/s40122-019-0118-0; Weiner SG, 2020, ANN EMERG MED, V75, P13, DOI 10.1016/j.annemergmed.2019.04.020	4	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2021	384	12							e44	10.1056/NEJMvcm2020745	http://dx.doi.org/10.1056/NEJMvcm2020745			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF4GG	33761209				2023-01-03	WOS:000634797200002
J	Egede, LE; Walker, RJ; Dismuke-Greer, CE; Pyzyk, S; Dawson, AZ; Williams, JS; Campbell, JA				Egede, Leonard E.; Walker, Rebekah J.; Dismuke-Greer, Clara E.; Pyzyk, Sarah; Dawson, Aprill Z.; Williams, Joni S.; Campbell, Jennifer A.			Cost-effectiveness of financial incentives to improve glycemic control in adults with diabetes: A pilot randomized controlled trial	PLOS ONE			English	Article							HEALTH-CARE; ACCEPTABILITY; INTERVENTIONS; BEHAVIOR	Purpose Determine the cost-effectiveness of three financial incentive structures in obtaining a 1% within group drop in HbA1c among adults with diabetes. Methods 60 African Americans with type 2 diabetes were randomized to one of three financial incentive structures and followed for 3-months. Group 1 (low frequency) received a single incentive for absolute HbA1c reduction, Group 2 (moderate frequency) received a two-part incentive for home testing of glucose and absolute HbA1c reduction and Group 3 (high frequency) received a multiple component incentive for home testing, attendance of weekly telephone education classes and absolute HbA1c reduction. The primary clinical outcome was HbA1c reduction within each arm at 3-months. Cost for each arm was calculated based on the cost of the intervention, cost of health care visits during the 3-month time frame, and cost of workdays missed from illness. Incremental cost effectiveness ratios (ICER) were calculated based on achieving a 1% within group drop in HbA1c and were bootstrapped with 1,000 replications. Results The ICER to decrease HbA1c by 1% was $1,100 for all three arms, however, bootstrapped standard errors differed with Group 1 having twice the variation around the ICER coefficient as Groups 2 and 3. ICERs were statistically significant for Groups 2 and 3 (p<0.001) indicating they are cost effective interventions. Conclusions Given ICERs of prior diabetes interventions range from $1,000-$4,000, a cost of $1,100 per 1% within group decrease in HbA1c is a promising intervention. Multi-component incentive structures seem to have the least variation in cost-effectiveness.	[Egede, Leonard E.; Walker, Rebekah J.; Pyzyk, Sarah; Dawson, Aprill Z.; Williams, Joni S.; Campbell, Jennifer A.] Med Coll Wisconsin, Dept Med, Div Gen Internal Med, Milwaukee, WI 53226 USA; [Egede, Leonard E.; Walker, Rebekah J.; Pyzyk, Sarah; Dawson, Aprill Z.; Williams, Joni S.; Campbell, Jennifer A.] Med Coll Wisconsin, Ctr Adv Populat Sci, Milwaukee, WI 53226 USA; [Dismuke-Greer, Clara E.] Palo Alto VA Hlth Care Syst, Hlth Econ Resource Ctr HERC, Palo Alto, CA USA	Medical College of Wisconsin; Medical College of Wisconsin	Egede, LE (corresponding author), Med Coll Wisconsin, Dept Med, Div Gen Internal Med, Milwaukee, WI 53226 USA.; Egede, LE (corresponding author), Med Coll Wisconsin, Ctr Adv Populat Sci, Milwaukee, WI 53226 USA.	legede@mcw.edu		Egede, Leonard/0000-0003-1546-1515	National Institute of Health (NIH) [K24DK093699]; National Institute of Diabetes and Digestive Kidney Disease [R01DK118038, R01DK120861]; National Institute for Minority Health and Health Disparities [R01MD013826]; American Diabetes Association [1-19-JDF-075]	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Diabetes and Digestive Kidney Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute for Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); American Diabetes Association(American Diabetes Association)	This study was funded through pilot funds from a National Institute of Health (NIH) K24 grant (K24DK093699, PI: Egede). In addition, effort for this study was partially supported by the National Institute of Diabetes and Digestive Kidney Disease (R01DK118038, R01DK120861, PI: Egede), the National Institute for Minority Health and Health Disparities (R01MD013826, PI: Egede/Walker), and the American Diabetes Association (1-19-JDF-075, PI: Walker). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blondon K, 2014, PSYCHOL HEALTH, V29, P552, DOI 10.1080/08870446.2013.867346; Breen RJ, 2020, ADDICT BEHAV, V110, DOI 10.1016/j.addbeh.2020.106513; Chapman GB, 2001, J EXP PSYCHOL-APPL, V7, P235, DOI 10.1037//1076-898X.7.3.235; Chin JY, 2020, CONTEMP CLIN TRIALS, V91, DOI 10.1016/j.cct.2020.105960; DeFulio A, 2012, PREV MED, V55, pS86, DOI 10.1016/j.ypmed.2012.04.017; Dieleman JL, 2016, JAMA-J AM MED ASSOC, V316, P2627, DOI 10.1001/jama.2016.16885; Egede LE, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-043760; Elliott RA, 2008, VALUE HEALTH, V11, P600, DOI 10.1111/j.1524-4733.2007.00304.x; Fernandes Ritabelle, 2019, Hawaii J Med Public Health, V78, P19; Giannini C, 2009, DIABETES-METAB RES, V25, pS34, DOI 10.1002/dmrr.986; Giles EL, 2015, PREV MED, V73, P145, DOI 10.1016/j.ypmed.2014.12.029; Giles EL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090347; Judah G., 2017, INCENTIVES DIABETIC; Kane RL, 2004, AM J PREV MED, V27, P327, DOI 10.1016/j.amepre.2004.07.002; Lee Y, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002761; Li R, 2010, DIABETES CARE, V33, P1872, DOI 10.2337/dc10-0843; Magliano DJ, 2018, DIABETES CARE, V41, P979, DOI 10.2337/dc17-2138; Mantzari E, 2015, HEALTH PSYCHOL, V34, P160, DOI 10.1037/hea0000088; Mitchell MS, 2013, AM J PREV MED, V45, P658, DOI 10.1016/j.amepre.2013.06.017; Mollenkamp M, 2019, HEALTH POLICY, V123, P1199, DOI 10.1016/j.healthpol.2019.09.008; Promberger M, 2012, SOC SCI MED, V75, P2509, DOI 10.1016/j.socscimed.2012.09.033; Purnell JQ, 2014, J ACAD NUTR DIET, V114, P1023, DOI 10.1016/j.jand.2014.03.011; Pyne JM, 2010, ARCH GEN PSYCHIAT, V67, P812, DOI 10.1001/archgenpsychiatry.2010.82; Siegel KR, 2020, DIABETES CARE, V43, P1557, DOI 10.2337/dci20-0017; Sutherland K, 2008, MED CARE RES REV, V65, p36S, DOI 10.1177/1077558708324235; Volpp KG, 2008, JAMA-J AM MED ASSOC, V300, P2631, DOI 10.1001/jama.2008.804; Wagner EH, 2001, JAMA-J AM MED ASSOC, V285, P182, DOI 10.1001/jama.285.2.182; Xu Jiaquan, 2020, NCHS Data Brief, P1; Yang WY, 2018, DIABETES CARE, V41, P917, DOI 10.2337/dci18-0007	29	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0248762	10.1371/journal.pone.0248762	http://dx.doi.org/10.1371/journal.pone.0248762			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QZ9HN	33735275	gold, Green Published			2023-01-03	WOS:000631029700089
J	Han, D; Kim, H; Kim, S; Park, Y; Cho, KJ				Han, Dongkyun; Kim, Hoon; Kim, Sehwan; Park, Yuli; Cho, Kyong Jin			Comparative study on the effect of hyperthermic massage and mechanical squeezing in the patients with mild and severe meibomian gland dysfunction: An interventional case series	PLOS ONE			English	Article							THERMAL PULSATION PROCEDURE; INTERNATIONAL WORKSHOP; THERMODYNAMIC TREATMENT; SUBCOMMITTEE; MANAGEMENT; SYSTEM; AGE	Background Meibomian glands exist beneath the palpebral conjunctiva; thus, it is invisible to the naked eye without infrared imaging. This study used meibography to group patients with meibomian gland dysfunction (MGD) and assessed the effects of hyperthermic massage and mechanical squeezing in both groups. Materials and methods Patients with MGD were divided into two groups, according to the degree of meibomian gland loss: group 1, in which the sum of eyelid scores ranged from 0 to 4 (mild to moderate gland loss) and group 2, in which the sum of eyelid scores ranged from 5 to 6 (severe gland loss). Hyperthermic massage and mechanical squeezing were given to both groups once a week for 4 weeks, and only non-preservative artificial tears were allowed. Ocular surface disease index (OSDI), Schirmer's test, meibography score, tear break-up time (TBUT), ocular surface staining, expressible meibomian gland, and quality before and after treatment were compared. Results Of the 49 patients who completed the 4 weeks of treatment and the evaluation at week 5, 29 were assigned to group 1 and 20 were assigned to group 2. Meibography scores, OSDI, TBUT, and expressibility of meibum had significant differences before and after treatments in both groups. However, there was no significant difference between the changes in clinical signs between group 1 and 2 after treatment. Without grouping, all patients showed significant decreases in meibography score, OSDI, cornea staining score, and increases in TBUT and expressibility of meibum after treatment. Conclusions Considering the results of the current study, hyperthermic massage and mechanical squeezing may be effective in patients with meibomian gland loss, regardless of the degree of severity.	[Han, Dongkyun; Kim, Hoon; Park, Yuli; Cho, Kyong Jin] Dankook Univ, Coll Med, Dept Ophthalmol, Cheonan, South Korea; [Kim, Hoon; Kim, Sehwan; Park, Yuli; Cho, Kyong Jin] Dankook Univ, Beckman Laser Inst Korea, Cheoan, South Korea; [Kim, Sehwan] Dankook Univ, Sch Med, Dept Biomed Engn, Cheoan, South Korea	Dankook University; Dankook University; Dankook University	Cho, KJ (corresponding author), Dankook Univ, Coll Med, Dept Ophthalmol, Cheonan, South Korea.; Cho, KJ (corresponding author), Dankook Univ, Beckman Laser Inst Korea, Cheoan, South Korea.	perfectcure@hanmail.net		Kim, Hoon/0000-0002-7932-1880	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI20C2088]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number: HI20C2088)	Arita R, 2015, OPHTHALMOLOGY, V122, P925, DOI 10.1016/j.ophtha.2014.12.018; Benitez-Del-Castillo JM, 2012, CLIN OPHTHALMOL, V6, P1689, DOI 10.2147/OPTH.S33133; Blackie CA, 2016, CLIN OPHTHALMOL, V10, P1385, DOI 10.2147/OPTH.S109663; Bron AJ, 2003, CORNEA, V22, P640, DOI 10.1097/00003226-200310000-00008; El Tumi H, 2017, EUR J PAIN, V21, P955, DOI 10.1002/ejp.1011; Eltumi H.G., 2017, OPEN PAIN J, V10, P44, DOI [https://doi.org/10.2174/1876386301710010044, DOI 10.2174/1876386301710010044]; Finis D, 2014, CORNEA, V33, P1265, DOI 10.1097/ICO.0000000000000273; Finis D, 2014, OCUL SURF, V12, P146, DOI 10.1016/j.jtos.2013.12.001; Geerling G, 2011, INVEST OPHTH VIS SCI, V52, P2050, DOI 10.1167/iovs.10-6997g; Gibbons A, 2017, CORNEA, V36, P679, DOI 10.1097/ICO.0000000000001196; Girotti G, 2019, EUR GERIATR MED, V10, P769, DOI 10.1007/s41999-019-00207-y; Greiner JV, 2016, EYE CONTACT LENS, V42, P99, DOI 10.1097/ICL.0000000000000166; Hura A, 2018, INVEST OPHTH VIS SCI, V59; Knop E, 2009, OPHTHALMOLOGE, V106, P980, DOI 10.1007/s00347-009-2044-8; Knop E, 2011, INVEST OPHTH VIS SCI, V52, P1938, DOI 10.1167/iovs.10-6997c; Korb DR, 2011, EYE CONTACT LENS, V37, P298, DOI 10.1097/ICL.0b013e31821bc7c5; Korb DR, 2010, CORNEA, V29, P930, DOI 10.1097/ICO.0b013e3181ca36d6; KORB DR, 1994, ADV EXP MED BIOL, V350, P293; Lee H, 2017, CLIN EXP OPTOM, V100, P598, DOI 10.1111/cxo.12532; Lee H, 2012, AM J OPHTHALMOL, V154, P949, DOI 10.1016/j.ajo.2012.06.009; Mand P, 2014, VISION PAN AM, V13; Maskin SL, 2010, CORNEA, V29, P1145, DOI 10.1097/ICO.0b013e3181d836f3; MATHERS WD, 1993, OPHTHALMOLOGY, V100, P347; Nelson JD, 2011, INVEST OPHTH VIS SCI, V52, P1930, DOI 10.1167/iovs.10-6997b; Nichols KK, 2011, INVEST OPHTH VIS SCI, V52, P1922, DOI 10.1167/iovs.10-6997a; Nien CJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P462, DOI 10.1001/archophthalmol.2011.69; Olson Mary Catherine, 2003, Eye Contact Lens, V29, P96, DOI 10.1097/01.ICL.0000060998.20142.8D; Schaumberg DA, 2011, INVEST OPHTH VIS SCI, V52, P1994, DOI 10.1167/iovs.10-6997e; Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615, DOI 10.1001/archopht.118.5.615; Shine WE, 2003, EXP EYE RES, V76, P417, DOI 10.1016/S0014-4835(03)00005-8; Souchier M, 2008, BRIT J OPHTHALMOL, V92, P819, DOI 10.1136/bjo.2007.133900; Thode AR, 2015, DRUGS, V75, P1177, DOI 10.1007/s40265-015-0432-8; Tsubota K, 2020, EYE CONTACT LENS, V46, pS2, DOI 10.1097/ICL.0000000000000643; 김주현, 2015, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V56, P13	34	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2021	16	3							e0247365	10.1371/journal.pone.0247365	http://dx.doi.org/10.1371/journal.pone.0247365			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU3OZ	33684150	Green Published, gold			2023-01-03	WOS:000627193500029
J	da Cruz, DG; de Magalhaes, RF; Padilha, GA; da Silva, MC; Braga, CL; Silva, AR; de Albuquerque, CFG; Capelozzi, VL; Samary, CS; Pelosi, P; Rocco, PRM; Silva, PL				da Cruz, Daniela G.; de Magalhaes, Raquel F.; Padilha, Gisele A.; da Silva, Mariana C.; Braga, Cassia L.; Silva, Adriana R.; Goncalves de Albuquerque, Cassiano F.; Capelozzi, Vera L.; Samary, Cynthia S.; Pelosi, Paolo; Rocco, Patricia R. M.; Silva, Pedro L.			Impact of positive biphasic pressure during low and high inspiratory efforts in Pseudomonas aeruginosa-induced pneumonia	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; PARTIAL VENTILATORY SUPPORT; END-EXPIRATORY PRESSURE; MECHANICAL VENTILATION; RAT MODEL; PROTECTIVE VENTILATION; TIDAL VOLUME; EXPRESSION; PULMONARY	Background During pneumonia, normal alveolar areas coexist adjacently with consolidated areas, and high inspiratory efforts may predispose to lung damage. To date, no study has evaluated different degrees of effort during Biphasic positive airway pressure (BIVENT) on lung and diaphragm damage in experimental pneumonia, though largely used in clinical setting. We aimed to evaluate lung damage, genes associated with ventilator-induced lung injury (VILI) and diaphragmatic injury, and blood bacteria in pressure-support ventilation (PSV), BIVENT with low and high inspiratory efforts in experimental pneumonia. Material and methods Twenty-eight male Wistar rats (mean +/- SD weight, 333 +/- 78g) were submitted Pseudomonas aeruginosa-induced pneumonia. After 24-h, animals were ventilated for 1h in: 1) PSV; 2) BIVENT with low (BIVENTLow-Effort); and 3) BIVENT with high inspiratory effort (BIVENTHigh-Effort). BIVENT was set at P-high to achieve V-T = 6 ml/kg and P-low at 5 cmH(2)O (n = 7/group). High- and low-effort conditions were obtained through anaesthetic infusion modulation based on neuromuscular drive (P-0.1). Lung mechanics, histological damage score, blood bacteria, and expression of genes related to VILI in lung tissue, and inflammation in diaphragm tissue. Results Transpulmonary peak pressure and histological damage score were higher in BIVENTHigh-Effort compared to BIVENTLow-Effort and PSV [16.1 +/- 1.9cmH(2)O vs 12.8 +/- 1.5cmH(2)O and 12.5 +/- 1.6cmH(2)O, p = 0.015, and p = 0.010; median (interquartile range) 11 (9-13) vs 7 (6-9) and 7 (6-9), p = 0.021, and p = 0.029, respectively]. BIVENTHigh-Effort increased interleukin-6 expression compared to BIVENTLow-Effort (p = 0.035) as well as expressions of cytokine-induced neutrophil chemoattractant-1, amphiregulin, and type III procollagen compared to PSV (p = 0.001, p = 0.001, p = 0.004, respectively). Tumour necrosis factor-alpha expression in diaphragm tissue and blood bacteria were higher in BIVENTHigh-Effort than BIVENTLow-Effort (p = 0.002, p = 0.009, respectively). Conclusion BIVENT requires careful control of inspiratory effort to avoid lung and diaphragm damage, as well as blood bacteria. P-0.1 might be considered a helpful parameter to optimize inspiratory effort.	[da Cruz, Daniela G.; de Magalhaes, Raquel F.; Padilha, Gisele A.; da Silva, Mariana C.; Braga, Cassia L.; Samary, Cynthia S.; Rocco, Patricia R. M.; Silva, Pedro L.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Inst Biophys, Lab Pulm Invest, Rio De Janeiro, RJ, Brazil; [Silva, Adriana R.; Goncalves de Albuquerque, Cassiano F.] Fundacao Oswaldo Cruz, Lab Immunopharmacol, Inst Oswaldo Cruz, Rio De Janeiro, Brazil; [Capelozzi, Vera L.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil; [Pelosi, Paolo] San Martino Policlin Hosp, IRCCS Oncol & Neurosci, Anesthesiol & Intens Care, Genoa, Italy; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, Genoa, Italy	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; University of Genoa	Silva, PL (corresponding author), Univ Fed Rio de Janeiro, Carlos Chagas Filho Inst Biophys, Lab Pulm Invest, Rio De Janeiro, RJ, Brazil.	pedroleme@biof.ufrj.br	Silva, Adriana/U-7811-2019; , Capelozzi/N-1737-2019; Gonçalves-de-Albuquerque, Cassiano Felippe/N-2815-2014; Rocco, Patricia/I-7460-2012; Silva, Pedro Leme/AAD-8236-2019; Gonçalves-de-Albuquerque, Cassiano Felippe/ABH-2409-2020	Silva, Adriana/0000-0002-5137-4251; , Capelozzi/0000-0001-9732-5853; Gonçalves-de-Albuquerque, Cassiano Felippe/0000-0002-4458-3055; Rocco, Patricia/0000-0003-1412-7136; Silva, Pedro Leme/0000-0001-5838-4949; Gonçalves-de-Albuquerque, Cassiano Felippe/0000-0002-4458-3055; samary, cynthia/0000-0002-1860-4166	Brazilian Council for Scientific and Technological Development (CNPq) [405686/2018-8]; Rio de Janeiro State Research Foundation (FAPERJ) [E-26/202.651/2018]; Coordination for the Improvement of Higher Education Personnel (CAPES); Department of Science and Technology -Brazilian Ministry of Health (DECIT/MS)	Brazilian Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Rio de Janeiro State Research Foundation (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Department of Science and Technology -Brazilian Ministry of Health (DECIT/MS)	This study was supported by the Brazilian Council for Scientific and Technological Development (CNPq, 405686/2018-8). http://www.cnpq.br/.PLS: Rio de Janeiro State Research Foundation (FAPERJ, E-26/202.651/2018), Coordination for the Improvement of Higher Education Personnel (CAPES) https://www.capes.gov.br/, and the Department of Science and Technology -Brazilian Ministry of Health (DECIT/MS) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akamine R, 2007, J BIOCHEM BIOPH METH, V70, P481, DOI 10.1016/j.jbbm.2006.11.008; BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788; Bertoni M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2777-y; Brochard L, 2017, INTENS CARE MED, V43, P250, DOI 10.1007/s00134-016-4645-4; Chiumello D, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1820-0; Curran CS, 2018, AM J RESP CRIT CARE, V197, P708, DOI 10.1164/rccm.201705-1043SO; de Magalhaes RF, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0476-7; Denning GM, 1998, INFECT IMMUN, V66, P5777, DOI 10.1128/IAI.66.12.5777-5784.1998; Dolinay T, 2006, PHYSIOL GENOMICS, V26, P68, DOI 10.1152/physiolgenomics.00110.2005; Doorduin J, 2017, AM J RESP CRIT CARE, V195, P1033, DOI 10.1164/rccm.201605-1016OC; Felix NS, 2019, ANESTHESIOLOGY, V130, P767, DOI 10.1097/ALN.0000000000002630; Ganesan SL, 2018, AM J RESP CRIT CARE, V198, P1199, DOI 10.1164/rccm.201705-0989OC; Henzler D, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0272-z; Kalil AC, 2016, CLIN INFECT DIS, V63, P575, DOI 10.1093/cid/ciw504; Kallet RH, 1999, CHEST, V116, P1826, DOI 10.1378/chest.116.6.1826; Khramtsova EA, 2019, NAT REV GENET, V20, P173, DOI 10.1038/s41576-018-0083-1; Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351; Lee SK, 2018, BMB REP, V51, P167, DOI 10.5483/BMBRep.2018.51.4.034; Li Bassi G, 2019, BRIT J ANAESTH, V122, P269, DOI 10.1016/j.bja.2018.07.039; Magalhaes PAF, 2018, EUR J ANAESTH, V35, P298, DOI 10.1097/EJA.0000000000000763; McMullen SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040190; Mizgerd JP, 2008, AM J PHYSIOL-LUNG C, V294, pL387, DOI 10.1152/ajplung.00330.2007; Moraes L, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0474-4; MORTOLA JP, 1983, J APPL PHYSIOL, V55, P250, DOI 10.1152/jappl.1983.55.1.250; Muller-Redetzky HC, 2014, CRIT CARE, V18, DOI 10.1186/cc13830; Nieman GF, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-019-0619-3; Orozco-Levi M, 2001, AM J RESP CRIT CARE, V164, P1734, DOI 10.1164/ajrccm.164.9.2011150; Parameswaran H, 2006, J APPL PHYSIOL, V100, P186, DOI 10.1152/japplphysiol.00424.2005; Penuelas O, 2020, INTENS CARE MED, V46, P444, DOI 10.1007/s00134-019-05867-9; Pinto EF, 2020, ANESTHESIOLOGY, V132, P307, DOI 10.1097/ALN.0000000000003060; Restrepo MI, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01190-2017; Saddy F, 2014, SEMIN RESP CRIT CARE, V35, P409, DOI 10.1055/s-0034-1382153; Saddy F, 2013, CRIT CARE, V17, DOI 10.1186/cc13051; Saddy F, 2010, INTENS CARE MED, V36, P1417, DOI 10.1007/s00134-010-1808-6; Silva PL, 2013, ANESTHESIOLOGY, V118, P395, DOI 10.1097/ALN.0b013e31827e554c; Sperber J, 2017, INTENS CARE MED EXP, V5, DOI 10.1186/s40635-017-0152-3; Suki B, 2011, J APPL PHYSIOL, V110, P1111, DOI 10.1152/japplphysiol.01244.2010; Telias I, 2020, AM J RESP CRIT CARE, V201, P1086, DOI 10.1164/rccm.201907-1425OC; Uhlig C, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-56; van Haren F, 2019, CRIT CARE MED, V47, P229, DOI 10.1097/CCM.0000000000003519; Vermillion MS, 2018, BIOL SEX DIFFER, V9, DOI 10.1186/s13293-018-0184-8; Wen J, 2014, INFLAMMATION, V37, P933, DOI 10.1007/s10753-014-9813-5; Wierzchon CGRS, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01071; Yoshida T, 2020, CURR OPIN CRIT CARE, V26, P59, DOI 10.1097/MCC.0000000000000691; Yoshida T, 2016, CRIT CARE MED, V44, pE678, DOI 10.1097/CCM.0000000000001649; Yoshida T, 2013, AM J RESP CRIT CARE, V188, P1420, DOI 10.1164/rccm.201303-0539OC; Yoshida T, 2012, CRIT CARE MED, V40, P1578, DOI 10.1097/CCM.0b013e3182451c40; Zhao T, 2014, RESP RES, V15, P1, DOI 10.1186/s12931-014-0158-2	48	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2021	16	2							e0246891	10.1371/journal.pone.0246891	http://dx.doi.org/10.1371/journal.pone.0246891			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK0KW	33577592	Green Published, gold			2023-01-03	WOS:000620071700009
J	Shimizu, K; Imamura, H; Tani, S; Adachi, H; Sakai, C; Ishii, A; Kataoka, H; Miyamoto, S; Aoki, T; Sakai, N				Shimizu, Kampei; Imamura, Hirotoshi; Tani, Shoichi; Adachi, Hidemitsu; Sakai, Chiaki; Ishii, Akira; Kataoka, Hiroharu; Miyamoto, Susumu; Aoki, Tomohiro; Sakai, Nobuyuki			Candidate drugs for preventive treatment of unruptured intracranial aneurysms: A cross-sectional study	PLOS ONE			English	Article							SUBARACHNOID HEMORRHAGE; CEREBRAL ANEURYSMS; RISK; ASPIRIN; RUPTURE; ROSUVASTATIN; PITAVASTATIN; SCORE	Background and purpose Establishment of drug therapy to prevent rupture of unruptured intracranial aneurysms (IAs) is needed. Previous human and animal studies have gradually clarified candidate drugs for preventive treatment of IA rupture. However, because most of these candidates belong to classes of drugs frequently co-administered to prevent cardiovascular diseases, epidemiological studies evaluating these drugs simultaneously should be performed. Furthermore, because drugs included in the same class may have different effects in terms of disease prevention, drug-by-drug assessments are important for planning intervention trials. Materials and methods We performed a cross-sectional study enrolling patients diagnosed with IAs between July 2011 and June 2019 at our institution. Patients were divided into ruptured or unruptured groups. The drugs investigated were selected according to evidence suggested by either human or animal studies. Univariate and multivariate logistic regression analyses were performed to assess the association of drug treatment with rupture status. We also performed drug-by-drug assessments of the association, including dose-response relationships, with rupture status. Results In total, 310 patients with ruptured and 887 patients with unruptured IAs were included. Multivariate analysis revealed an inverse association of statins (odds ratio (OR), 0.54; 95% confidence interval (CI) 0.38-0.77), calcium channel blockers (OR, 0.41; 95% CI 0.30-0.58), and angiotensin II receptor blockers (ARBs) (OR, 0.67; 95% CI 0.48-0.93) with ruptured IAs. Moreover, inverse dose-response relationships with rupture status were observed for pitavastatin and rosuvastatin among statins, benidipine, cilnidipine, and amlodipine among calcium channel blockers, and valsartan, azilsartan, candesartan, and olmesartan among ARBs. Only non-aspirin non-steroidal anti-inflammatory drugs were positively associated with ruptured IAs (OR, 3.24; 95% CI 1.71-6.13). Conclusions The present analysis suggests that several types of statins, calcium channel blockers, and ARBs are candidate drugs for preventive treatment of unruptured IAs.	[Shimizu, Kampei; Imamura, Hirotoshi; Tani, Shoichi; Adachi, Hidemitsu; Sakai, Chiaki; Sakai, Nobuyuki] Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Kobe, Hyogo, Japan; [Shimizu, Kampei; Ishii, Akira; Kataoka, Hiroharu; Miyamoto, Susumu] Kyoto Univ, Dept Neurosurg, Grad Sch Med, Kyoto, Japan; [Shimizu, Kampei; Aoki, Tomohiro] Natl Cerebral & Cardiovasc Ctr, Res Inst, Dept Mol Pharmacol, Osaka, Japan	Kobe City Medical Center General Hospital; Kyoto University; National Cerebral & Cardiovascular Center - Japan	Imamura, H (corresponding author), Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Kobe, Hyogo, Japan.	i-hiro@zg7.so-net.ne.jp	Kataoka, Hiroharu/GPT-3596-2022	Sakai, Nobuyuki/0000-0002-3289-1210; Shimizu, Kampei/0000-0003-4952-0608; Ishii, Akira/0000-0003-4234-2749				Abekura Y, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01802-8; Aoki T, 2009, NEUROSURGERY, V64, P357, DOI 10.1227/01.NEU.0000336764.92606.1D; Can A, 2018, NEUROLOGY, V91, pE1175, DOI 10.1212/WNL.0000000000006200; Can A, 2018, STROKE, V49, P1148, DOI 10.1161/STROKEAHA.117.019972; Can A, 2018, STROKE, V49, P34, DOI 10.1161/STROKEAHA.117.019249; Corman SL, 2005, ANN PHARMACOTHER, V39, P1073, DOI 10.1345/aph.1E514; Cortese F, 2016, PHARMACOL RES, V107, P1, DOI 10.1016/j.phrs.2016.02.012; Etminan N, 2015, NEUROLOGY, V85, P881, DOI 10.1212/WNL.0000000000001891; Fukuda M, 2021, J NEUROSURG, V134, P102, DOI 10.3171/2019.9.JNS19270; Furukawa T, 1999, J PHARMACOL EXP THER, V291, P464; Garbe E, 2013, STROKE, V44, P2422, DOI 10.1161/STROKEAHA.111.000811; Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1; Gross BA, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.03.072; Hasan DM, 2011, STROKE, V42, P3156, DOI 10.1161/STROKEAHA.111.619411; Huang WY, 2019, JAMA NEUROL, V76, P906, DOI 10.1001/jamaneurol.2019.1120; Ishii M, 2015, CIRC J, V79, P1115, DOI 10.1253/circj.CJ-14-0789; Li SJ, 2015, NEUROCHEM RES, V40, P1537, DOI 10.1007/s11064-015-1603-4; Lindbohm J, 2018, ATHEROSCLEROSIS, V274, P112, DOI 10.1016/j.atherosclerosis.2018.05.011; Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260; Phan K, 2017, STROKE, V48, P1210, DOI 10.1161/STROKEAHA.116.015674; Saku K, 2011, CIRC J, V75, P1493, DOI 10.1253/circj.CJ-10-1281; Shimizu K, 2016, AM J NEURORADIOL, V37, P679, DOI 10.3174/ajnr.A4577; Shimizu K, 2019, J NEUROPATH EXP NEUR, V78, P798, DOI 10.1093/jnen/nlz057; Shimizu K, 2019, NEUROL MED-CHIR, V59, P126, DOI 10.2176/nmc.st.2018-0326; Tada Y, 2014, STROKE, V45, P579, DOI 10.1161/STROKEAHA.113.003072; Ungprasert P, 2016, STROKE, V47, P356, DOI 10.1161/STROKEAHA.115.011678; Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1; Vergouwen MDI, 2018, INT J STROKE, V13, P992, DOI 10.1177/1747493018790033; Yoshimura Y, 2014, J STROKE CEREBROVASC, V23, P343, DOI 10.1016/j.jstrokecerebrovasdis.2013.04.022	29	4	4	7	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2021	16	2							e0246865	10.1371/journal.pone.0246865	http://dx.doi.org/10.1371/journal.pone.0246865			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK0KW	33577580	gold, Green Published			2023-01-03	WOS:000620071700021
J	Chang, R; Elhusseiny, KM; Yeh, YC; Sun, WZ				Chang, Raymond; Elhusseiny, Khaled Mossad; Yeh, Yu-Chang; Sun, Wei-Zen			COVID-19 ICU and mechanical ventilation patient characteristics and outcomes-A systematic review and meta-analysis	PLOS ONE			English	Article							DISEASE; MORTALITY; SEVERITY; CARE	Background Insight into COVID-19 intensive care unit (ICU) patient characteristics, rates and risks of invasive mechanical ventilation (IMV) and associated outcomes as well as any regional discrepancies is critical in this pandemic for individual case management and overall resource planning. Methods and findings Electronic searches were performed for reports through May 1 2020 and reports on COVID-19 ICU admissions and outcomes were included using predefined search terms. Relevant data was subsequently extracted and pooled using fixed or random effects meta-analysis depending on heterogeneity. Study quality was assessed by the NIH tool and heterogeneity was assessed by I-2 and Q tests. Baseline patient characteristics, ICU and IMV outcomes were pooled and meta-analyzed. Pooled odds ratios (pOR) were calculated for clinical features against ICU, IMV mortality. Subgroup analysis was carried out based on patient regions. A total of twenty-eight studies comprising 12,437 COVID-19 ICU admissions from seven countries were meta-analyzed. Pooled ICU admission rate was 21% [95% CI 0.12-0.34] and 69% of cases needed IMV [95% CI 0.61-0.75]. ICU and IMV mortality were 28.3% [95% CI 0.25-0.32], 43% [95% CI 0.29-0.58] and ICU, IMV duration was 7.78 [95% CI 6.99-8.63] and 10.12 [95% CI 7.08-13.16] days respectively. Besides confirming the significance of comorbidities and clinical findings of COVID-19 previously reported, we found the major correlates with ICU mortality were IMV [pOR 16.46, 95% CI 4.37-61.96], acute kidney injury (AKI) [pOR 12.47, 95% CI 1.52-102.7], and acute respiratory distress syndrome (ARDS) [pOR 6.52, 95% CI 2.66-16.01]. Subgroup analyses confirm significant regional discrepancies in outcomes. Conclusions This is a comprehensive systematic review and meta-analysis of COVID-19 ICU and IMV cases and associated outcomes. The significant association of AKI, ARDS and IMV with mortality has implications for ICU resource planning for AKI and ARDS as well as suggesting the need for further research into optimal ventilation strategies for COVID-19 patients in the ICU setting. Regional differences in outcome implies a need to develop region specific protocols for ventilatory support as well as overall treatment.	[Chang, Raymond; Sun, Wei-Zen] Inst East West Med, New York, NY 10016 USA; [Elhusseiny, Khaled Mossad] Al Azhar Univ, Fac Med, Cairo, Egypt; [Yeh, Yu-Chang; Sun, Wei-Zen] Natl Taiwan Univ Hosp, Dept Anesthesia, Taipei, Taiwan	Egyptian Knowledge Bank (EKB); Al Azhar University; National Taiwan University; National Taiwan University Hospital	Chang, R (corresponding author), Inst East West Med, New York, NY 10016 USA.	chang@meridianmedical.org		Chang, Raymond/0000-0001-9115-7799				A. C.Just, 2020, medRxiv, DOI 10.1101/2020.04.19.20062117; A.Hessami, 2020, medRxiv, DOI 10.1101/2020.04.12.20062869; A. S.Azman, 2020, medRxiv, DOI 10.1101/2020.04.22.20076190; Abate SM., 2020, B WHO UNPUB, V10, P6, DOI [10.2471/BLT.20.260737, DOI 10.2471/BLT.20.260737]; Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Argenziano Michael G, 2020, medRxiv, DOI 10.1101/2020.04.20.20072116; Armstrong RA, 2020, ANAESTHESIA, V75, P1340, DOI 10.1111/anae.15201; Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457; B.Riou, 2020, medRxiv, DOI 10.1101/2020.04.21.20073916; B.Zhang, 2020, medRxiv, DOI 10.1101/2020.03.17.20037572; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Borobia AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061733; Cao JL, 2020, CLIN INFECT DIS, V71, P748, DOI 10.1093/cid/ciaa243; Cao YH, 2020, J MED VIROL, V92, P1449, DOI 10.1002/jmv.25822; Chan L., 2020, MEDRXIV, DOI [10.1101/2020.05.04.20090944, DOI 10.1101/2020.05.04.20090944]; D.Liu, 2020, medRxiv, DOI 10.1101/2020.03.03.20030668; D.Parekh, 2020, medRxiv, DOI 10.1101/2020.06.04.20122069; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOCHERTY AB, 2020, FEATURES 16749 HOSPI, V16, P749, DOI [10.1136/bmj.m1985, DOI 10.1101/2020.04.23.20076042]; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Dondorp AM, 2020, AM J TROP MED HYG, V102, P1191, DOI 10.4269/ajtmh.20-0283; Du RH, 2020, ANN AM THORAC SOC, V17, P839, DOI 10.1513/AnnalsATS.202003-225OC; Feng XB, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00491; Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1; Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018; ICNARC, 2020, ICNARC REP COVID 19; Jain V, 2020, INT J PUBLIC HEALTH, V65, P533, DOI 10.1007/s00038-020-01390-7; Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331; Lindenauer PK, 2014, JAMA INTERN MED, V174, P1982, DOI 10.1001/jamainternmed.2014.5430; Liu H, 2020, AGING DIS, V11, P668, DOI 10.14336/AD.2020.0502; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202; NHLBI, STUD QUAL ASS TOOLS; Phua Jason, 2020, Lancet Respir Med, V8, P506, DOI 10.1016/S2213-2600(20)30161-2; Quah P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03006-1; Rees EM, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01726-3; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623; Santa Cruz R, 2019, RESP CARE, V64, P473, DOI 10.4187/respcare.06586; Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; Tian WJ, 2020, J MED VIROL, V92, P1875, DOI 10.1002/jmv.26050; Tsolaki V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03081-4; Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260; Valente-Acosta B, 2020, COVID 19 SEVERE PNEU, DOI [10.1101/2020.04.26.2008079, DOI 10.1101/2020.04.26.2008079]; Wan X, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/s12911-014-0111-9; Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471; Wang XH, 2020, RESEARCH-CHINA, V2020, DOI 10.34133/2020/2402961; Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Youssef M, 2020, J MED VIROL, V92, P1825, DOI 10.1002/jmv.26055; Zheng Y, 2020, J ZHEJIANG UNIV-SC B, V21, P378, DOI 10.1631/jzus.B2000174; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE	65	53	54	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246318	10.1371/journal.pone.0246318	http://dx.doi.org/10.1371/journal.pone.0246318			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH4VJ	33571301	Green Submitted, Green Published, gold			2023-01-03	WOS:000618274000090
J	Naftali, T; Schleider, LBL; Benjaminov, FS; Konikoff, FM; Matalon, ST; Ringel, Y				Naftali, Timna; Schleider, Lihi Bar-Lev; Benjaminov, Fabiana Scklerovsky; Konikoff, Fred Meir; Matalon, Shelly Tartakover; Ringel, Yehuda			Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; ENDOCANNABINOID SYSTEM; THERAPY	Background Cannabis is often used by patients with ulcerative colitis, but controlled studies are few. We aimed to assess the effect of cannabis in improving clinical and inflammatory outcomes in ulcerative colitis patients. Methods In a double-blind, randomized, placebo-controlled trial, patients received either cigarettes containing 0.5 g of dried cannabis flowers with80mgTetrahydrocannabinol (THC)or placebo cigarettes for 8 weeks. Parameters of disease including Lichtiger disease activity index, C reactive protein (CRP), calprotectin, Mayo endoscopic score and quality of life (QOL) were assessed before, during and after treatment. Results The study included 32 patients. Mean age was 30 years, 14 (43%) females. Lichtiger index improved in the cannabis group from 10.9 (IQR 9-14) to5 (IQR 1-7), (p<0.000), and in the placebo group from 11 (IQR 9-13) to 8 (IQR 7-10)(p = 0.15, p between groups 0.001). QOL improved in the cannabis group from 77 +/- 4 to 98 +/- 20 (p = 0.000) but not in the placebo group (78 +/- 3 at week 0 and 78 +/- 17 at week 8;p = 0.459; p between groups 0.007). Mayo endoscopic score changed in the cannabis group from 2.13 +/- 1 to 1.25 +/- 2 (p = 0.015) and in the placebo group from 2.15 +/- 1to 1.69 +/- 1 (p = 0.367, p between groups 0.17). Conclusion Short term treatment with THC rich cannabis induced clinical remission and improved quality of life in patients with mild to moderately active ulcerative colitis. However, these beneficial clinical effects were not associated with significant anti-inflammatory improvement in the Mayo endoscopic score or laboratory markers for inflammation.(clinicaltrials.gov NCT01040910).	[Naftali, Timna; Benjaminov, Fabiana Scklerovsky; Konikoff, Fred Meir; Matalon, Shelly Tartakover; Ringel, Yehuda] Meir Med Ctr, Inst Gastroenterol & Hepatol, Kefar Sava, Israel; [Naftali, Timna; Benjaminov, Fabiana Scklerovsky; Konikoff, Fred Meir; Matalon, Shelly Tartakover; Ringel, Yehuda] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Schleider, Lihi Bar-Lev] Tikun Olam Cannbit Pharmaceut, Res Dept, Tel Aviv, Israel; [Schleider, Lihi Bar-Lev] Ben Gurion Univ Negev, Soroka Med Ctr, Clin Res Ctr, Beer Sheva, Israel; [Schleider, Lihi Bar-Lev] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University; Soroka Medical Center; Ben Gurion University	Naftali, T (corresponding author), Meir Med Ctr, Inst Gastroenterol & Hepatol, Kefar Sava, Israel.; Naftali, T (corresponding author), Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.	timnanaftali@gmail.com	Naftali, Timna/AAQ-8257-2021	Naftali, Timna/0000-0002-8931-6524; Bar-Lev Schleider, Lihi/0000-0003-4349-3442	Tikun Olam, Israel	Tikun Olam, Israel	Funding: the cannabis used in the study was supplied by Tikun Olam, Israel. otherwise there was no funding.	Ahmed Waseem, 2016, Gastroenterol Hepatol (N Y), V12, P668; Altman DG, 1999, BRIT MED J, V319, P703, DOI 10.1136/bmj.319.7211.703; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P215; Asakura K, 2009, J GASTROENTEROL, V44, P659, DOI 10.1007/s00535-009-0057-3; Ashida T, 2011, TRANSFUS APHER SCI, V44, P113, DOI 10.1016/j.transci.2011.01.001; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cai RG, 2019, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2019/05/013; da Silva BC, 2014, WORLD J GASTROENTERO, V20, P9458, DOI 10.3748/wjg.v20.i28.9458; Gaston TE, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0882-y; Irving PM, 2018, INFLAMM BOWEL DIS, V24, P714, DOI 10.1093/ibd/izy002; Izzo AA, 2008, GUT, V57, P1140, DOI 10.1136/gut.2008.148791; Knowles SR, 2018, INFLAMM BOWEL DIS, V24, P742, DOI 10.1093/ibd/izx100; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; Lobaton T, 2015, J CROHNS COLITIS, V9, P846, DOI 10.1093/ecco-jcc/jjv111; Lohar V., 2013, PHYTOPHARMACOLOGY, V4, P41; Lucas CJ, 2018, BRIT J CLIN PHARMACO, V84, P2477, DOI 10.1111/bcp.13710; Ma C, 2015, J CLIN GASTROENTEROL, V49, P675, DOI 10.1097/MCG.0000000000000265; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; Massa F, 2005, J MOL MED, V83, P944, DOI 10.1007/s00109-005-0698-5; Matsuoka K, 2018, J GASTROENTEROL, V53, P305, DOI 10.1007/s00535-018-1439-1; Naftali T, 2017, DIGEST DIS SCI, V62, P1615, DOI 10.1007/s10620-017-4540-z; Naftali T, 2013, CLIN GASTROENTEROL H, V11, P1276, DOI 10.1016/j.cgh.2013.04.034; Naftali T, 2011, ISR MED ASSOC J, V13, P455; Newmeyer MN, 2016, CLIN CHEM, V62, P1579, DOI 10.1373/clinchem.2016.263475; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Pertwee RG, 2002, PROSTAG LEUKOTR ESS, V66, P101, DOI 10.1054/plef.2001.0341; Spindle TR, 2019, J ANAL TOXICOL, V43, P233, DOI 10.1093/jat/bky104; Stith SS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39462-1; Ungar B, 2016, ANN GASTROENTEROL, V29, P243, DOI 10.20524/aog.2016.0027; Vashist N, 2017, COCHRANE DB SYST REV, V25, P5; Weiss A, 2015, DRUG ALCOHOL DEPEN, V156, P84, DOI 10.1016/j.drugalcdep.2015.08.035	31	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246871	10.1371/journal.pone.0246871	http://dx.doi.org/10.1371/journal.pone.0246871			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH4VJ	33571293	Green Published, gold			2023-01-03	WOS:000618274000036
J	Maruyama, Y; Nakayama, M; Ueda, A; Miyazaki, M; Yokoo, T				Maruyama, Yukio; Nakayama, Masaaki; Ueda, Atsushi; Miyazaki, Mariko; Yokoo, Takashi			Comparisons of fatigue between dialysis modalities: A cross-sectional study	PLOS ONE			English	Article							QUALITY-OF-LIFE; PERITONEAL-DIALYSIS; COMBINED THERAPY; HEMODIALYSIS; DEPRESSION; MORTALITY; ASSOCIATION; RISK	Background Fatigue is one of the most frequent complications in dialyzed patients and is associated with poorer patient outcomes. Multiple factors are reported to be associated with fatigue development. Of them, the impacts of dialysis modalities remain unknown. Methods A total of 194 dialysis patients (mean age, 61 +/- 11 years; 134 males; modalities included hemodialysis (HD) in 26, online hemodiafiltration (HDF) in 74, peritoneal dialysis (PD) in 68, and combined therapy with PD and HD in 26 cases) were recruited for this cross-sectional study. Fatigue was assessed using the Profile of Mood States (POMS), a Visual Analogue Scale (VAS), and our original scale of fatigue, and depression was assessed by the Beck Depression Inventory-second edition (BDI-II). Our original scale of fatigue was administered both on dialysis and dialysis-free days to patients on HD and online HDF. Results The scores of the POMS, VAS, and our original scale were weakly but significantly inter-related (rho = 0.58, P<0.01; rho = 0.47, P<0.01, and rho = 0.42, P<0.01 between POMS and VAS, POMS and our original scale for fatigue, and VAS and our original scale for fatigue, respectively). The scores of these 3 tests showed no significant differences among the 4 modalities. On multivariate analysis, age, body mass index, creatinine, and employment status were associated with the presence or severity of fatigue, whereas dialysis modality was not. A similar result was obtained in 122 patients without depression. The prevalence of fatigue by our original scale was significantly lower on dialysis-free days than on dialysis days in patients on HD and online HDF. Conclusions The results suggest that there is no significant association between different dialysis modalities including HD, online HDF, PD and combined therapy with PD and HD and the prevalence or severity of fatigue.	[Maruyama, Yukio; Yokoo, Takashi] Jikei Univ, Dept Internal Med, Div Nephrol & Hypertens, Sch Med, Tokyo, Japan; [Nakayama, Masaaki] St Lukes Int Hosp, Kidney Ctr, Tokyo, Japan; [Ueda, Atsushi] Hitachi Gen Hosp, Dept Nephrol, Ibaraki, Japan; [Miyazaki, Mariko] Tohoku Univ Hosp, Res Div Chron Kidney Dis & Dialysis Treatment, Sendai, Miyagi, Japan	Jikei University; St. Luke's International Hospital; Tohoku University	Maruyama, Y (corresponding author), Jikei Univ, Dept Internal Med, Div Nephrol & Hypertens, Sch Med, Tokyo, Japan.	maruyama@td5.so-net.ne.jp		Maruyama, Yukio/0000-0002-5602-8104	Baxter International, Inc. [16CECPDAP0002]	Baxter International, Inc.	This study was supported in part by research grants M.N. has received from Baxter International, Inc. (number 16CECPDAP0002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Artom M, 2014, KIDNEY INT, V86, P497, DOI 10.1038/ki.2014.86; Bai YL, 2015, J CLIN NURS, V24, P2014, DOI 10.1111/jocn.12804; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Bossola M, 2015, NEPHRON, V130, P113, DOI 10.1159/000430827; Canaud B, 2006, KIDNEY INT, V69, P2087, DOI 10.1038/sj.ki.5000447; CARDENAS DD, 1982, NEPHRON, V30, P336, DOI 10.1159/000182512; Chaudhary K, 2011, CLIN J AM SOC NEPHRO, V6, P447, DOI 10.2215/CJN.07920910; Chilcot J, 2011, NEPHROL DIAL TRANSPL, V26, P1628, DOI 10.1093/ndt/gfq611; Davenport A, 2018, HEMODIAL INT, V22, P369, DOI 10.1111/hdi.12642; Farrokhi F, 2014, AM J KIDNEY DIS, V63, P623, DOI 10.1053/j.ajkd.2013.08.024; Jhamb M, 2008, AM J KIDNEY DIS, V52, P353, DOI 10.1053/j.ajkd.2008.05.005; Jhamb M, 2011, AM J NEPHROL, V33, P515, DOI 10.1159/000328004; Jhamb M, 2009, CLIN J AM SOC NEPHRO, V4, P1779, DOI 10.2215/CJN.00190109; Karakan S, 2011, CLIN NEPHROL, V76, P358, DOI 10.5414/CN106960; Kojima M, 2010, PSYCHOTHER PSYCHOSOM, V79, P303, DOI 10.1159/000319311; Lopes AA, 2004, KIDNEY INT, V66, P2047, DOI 10.1111/j.1523-1755.2004.00977.x; Maruyama Y, 2018, CONTRIB NEPHROL, V196, P64, DOI 10.1159/000485701; Maruyama Y, 2014, BLOOD PURIFICAT, V38, P149, DOI 10.1159/000368389; Nakayama M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18537-x; Nakayama M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184535; Nakayama M, 2010, THER APHER DIAL, V14, P489, DOI 10.1111/j.1744-9987.2010.00901.x; Nitta K, 2019, RENAL REPLACE THER, V5, DOI 10.1186/s41100-019-0248-1; Nowak Z, 2015, MED SCI MONITOR, V21, P1798, DOI 10.12659/MSM.893331; Nowak Z, 2014, INT J MED SCI, V11, P291, DOI 10.7150/ijms.5431; Suwabe T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205037; WOLCOTT DL, 1989, AM J KIDNEY DIS, V14, P478, DOI 10.1016/S0272-6386(89)80148-9; Zazzeroni L, 2017, KIDNEY BLOOD PRESS R, V42, P717, DOI 10.1159/000484115; Zuo MH, 2018, INT UROL NEPHROL, V50, P1329, DOI 10.1007/s11255-018-1871-4	28	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2021	16	2							e0246890	10.1371/journal.pone.0246890	http://dx.doi.org/10.1371/journal.pone.0246890			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH4UN	33566855	Green Published, gold			2023-01-03	WOS:000618271700006
J	Zhao, JH; Zhu, QS; Li, YW; Wang, LL				Zhao, Jian-Hui; Zhu, Qiu-Shuang; Li, Yi-Wen; Wang, Li-Li			Determinants of the intensity of uremic pruritus in patients receiving maintenance hemodialysis: A cross-sectional study	PLOS ONE			English	Article							5-D ITCH SCALE; PARATHYROIDECTOMY; INFLAMMATION	Background Uremic pruritus (UP) is a common and frustrating symptom in patients receiving hemodialysis (HD). The majority of patients have mild to moderate itching of the skin, and a small percentage have severe itching, which seriously affects their quality of life and survival rate. However, little is known about factors that influence the intensity of itching in patients. Methods A cross-sectional study on uremic pruritus in male and female patients receiving HD was conducted in September 2019. This study included 148 eligible patients who received HD at the Blood Purification Center of Xinchang County People's Hospital, Zhejiang Province, China from March 2019 to June 2019. We collected general data consisted of age, sex, body mass index (BMI), place of residence, educational level, diabetes mellitus status and duration of HD; as well as clinical, biochemical indicators, including serum calcium (Ca), serum phosphorus (P), serum albumin (ALB), haemoglobin (Hb), serum intact parathyroid hormone (iPTH), pre-dialysis serum urea nitrogen (BUN), normalized protein catabolic rate (nPCR), urea nitrogen clearance index (KT/V), ferritin (FER) and pre-dialysis serum creatinine (sCR). We also assayed the inflammatory cytokine serum high sensitivity C-reactive protein (hs-CRP). The Five-Dimensional Itching Scale (5DIS) was used to evaluate the degree of skin itching (none, mild, moderate, or severe). We used multiple logistic regression to analyze influencing factors on the degree of skin itching in patients with UP. Results Of the 148 patients, 60 had uremic pruritus (incidence rate, 40.54%). These included 22 cases of mild skin itching (14.86%), 30 of moderate skin itching (20.27%), and 8 of severe skin itching (5.41%). Compared with uremia patients without skin pruritus, patients with UP had higher levels of iPTH, Hb, BUN, nPCR, and hs-CRP. The composition ratio showed significant differences between urban and rural patients with different degrees of skin itching (P = 0.017); moreover, the difference of iPTH and hs-CRP levels were statistically significant (P = 0.009 and < 0.001, respectively). Using no itching as a reference, multiple logistic regression analysis showed that as hs-CRP level increased, the patient's risks of mild skin itching (odds ratio [OR] = 1.740; 95% confidence interval [CI], 1.061-2.854; P = 0.028), moderate skin itching (OR = 2.8838 95% CI, 1.744-4.718; P < 0.001), and severe skin itching (OR = 9.440; 95% CI, 3.547-25.124; P < 0.001) all increased as well. Compared with urban residents, rural residents have a higher risk of moderate itching (OR = 3.869; 95% CI, 1.099-13.622; P = 0.035). Conclusion Levels of hs-CRP were associated with the intensity of skin itching in patients with UP. Higher hs-CRP levels were closely related to severe skin itching. The relationship between the intensity of skin itching and the environment in maintenance hemodialysis patients needs further clarification.	[Zhao, Jian-Hui; Zhu, Qiu-Shuang] Xinchang Cty Peoples Hosp, Dept Nephrol, Shaoxing, Zhejiang, Peoples R China; [Zhao, Jian-Hui; Zhu, Qiu-Shuang; Wang, Li-Li] Xinchang Cty Peoples Hosp, Blood Purificat Ctr, Shaoxing, Zhejiang, Peoples R China; [Li, Yi-Wen] Zhejiang Peoples Hosp, Dept Nephrol, Hangzhou, Zhejiang, Peoples R China		Zhao, JH (corresponding author), Xinchang Cty Peoples Hosp, Dept Nephrol, Shaoxing, Zhejiang, Peoples R China.; Zhao, JH (corresponding author), Xinchang Cty Peoples Hosp, Blood Purificat Ctr, Shaoxing, Zhejiang, Peoples R China.	lyzhaojh@126.com		Zhao, Jianhui/0000-0002-6238-6776				Abdelsalam M, 2019, NEPHRON, V143, P120, DOI 10.1159/000501409; Aliasgharpour M, 2018, J NATL MED ASSOC, V110, P270, DOI 10.1016/j.jnma.2017.04.008; Combs SA, 2015, SEMIN NEPHROL, V35, P383, DOI 10.1016/j.semnephrol.2015.06.009; Depner TA, 1996, J AM SOC NEPHROL, V7, P780; DUO LJ, 1987, NEPHRON, V47, P179, DOI 10.1159/000184487; Elman S, 2010, BRIT J DERMATOL, V162, P587, DOI 10.1111/j.1365-2133.2009.09586.x; Grochulska K, 2019, ACTA DERM-VENEREOL, V99, P423, DOI 10.2340/00015555-3125; Huang WK, 2016, SCI REP-UK, V6, DOI 10.1038/srep23450; Jiang X, 2016, INT UROL NEPHROL, V48, P1533, DOI 10.1007/s11255-016-1364-2; Jing Y, 2015, INT J CLIN EXP MED, V8, P11188; Keithi-Reddy SR, 2007, KIDNEY INT, V72, P373, DOI 10.1038/sj.ki.5002197; Kfoury LW, 2012, J NEPHROL, V25, P644, DOI 10.5301/jn.5000039; Khan TM, 2013, J RENAL CARE, V39, P222, DOI 10.1111/j.1755-6686.2013.12038.x; Kimmel M, 2006, NEPHROL DIAL TRANSPL, V21, P749, DOI 10.1093/ndt/gfi204; Lai JW, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0475-z; Levy AR, 2020, AM J KIDNEY DIS, V75, P373, DOI [10.1053/j.ajkd.2019.07.013, 10.1053/j.ajkd.2019.07013]; Liu MH, 2017, THER CLIN RISK MANAG, V13, P255, DOI 10.2147/TCRM.S129133; Mahmudpour M, 2017, IRAN J KIDNEY DIS, V11, P50; Mettang T, 2015, KIDNEY INT, V87, P685, DOI 10.1038/ki.2013.454; Moldovan D, 2015, INT UROL NEPHROL, V47, P1871, DOI 10.1007/s11255-015-1106-x; Momose A, 2017, NEPHRON, V136, P103, DOI 10.1159/000458417; Nofal E, 2016, J DERMATOL TREAT, V27, P515, DOI 10.3109/09546634.2016.1161161; Pakfetrat M, 2018, HEMODIAL INT, V22, P103, DOI 10.1111/hdi.12540; Rayner HC, 2017, CLIN J AM SOC NEPHRO, V12, P2000, DOI 10.2215/CJN.03280317; Schricker S, 2019, ACTA DERM-VENEREOL, V99, P524, DOI 10.2340/00015555-3128; Shirazian S, 2013, J RENAL NUTR, V23, P428, DOI 10.1053/j.jrn.2013.08.002; Tseng CY, 2018, RENAL FAILURE, V40, P514, DOI 10.1080/0886022X.2018.1512871; Wieczorek A, 2020, J EUR ACAD DERMATOL, V34, P2368, DOI 10.1111/jdv.16360; Zhang Y, 2019, RENAL FAILURE, V41, P921, DOI 10.1080/0886022X.2019.1666724	29	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2021	16	1							e0245370	10.1371/journal.pone.0245370	http://dx.doi.org/10.1371/journal.pone.0245370			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM1OE	33471852	Green Published, gold			2023-01-03	WOS:000639428800034
J	Gryczynski, J; Nordeck, CD; Welsh, C; Mitchell, SG; O'Grady, KE; Schwartz, RP				Gryczynski, Jan; Nordeck, Courtney D.; Welsh, Christopher; Mitchell, Shannon G.; O'Grady, Kevin E.; Schwartz, Robert P.			Preventing Hospital Readmission for Patients With Comorbid Substance Use Disorder A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							ADDICTION CONSULTATION; CARE; METAANALYSIS; SERVICE	Background: Hospitalized patients with comorbid substance use disorders (SUDs) are at high risk for poor outcomes, including readmission and emergency department (ED) use. Objective: To determine whether patient navigation services reduce hospital readmissions. Design: Randomized controlled trial comparing Navigation Services to Avoid Rehospitalization (NavSTAR) versus treatment as usual (TAU). (ClinicalTrials.gov: NCT02599818) Setting: Urban academic hospital in Baltimore, Maryland, with an SUD consultation service. Participants: 400 hospitalized adults with comorbid SUD (opioid, cocaine, or alcohol). Intervention: NavSTAR used proactive case management, advocacy, service linkage, and motivational support to resolve internal and external barriers to care and address SUD, medical, and basic needs for 3 months after discharge. Measurements: Data on inpatient readmissions (primary outcome) and ED visits for 12 months were obtained for all participants via the regional health information exchange. Entry into SUD treatment, substance use, and related outcomes were assessed at 3-, 6-, and 12-month follow-up. Results: Participants had high levels of acute care use: 69% had an inpatient readmission and 79% visited the ED over the 12-month observation period. Event rates per 1000 person-days were 6.05 (NavSTAR) versus 8.13 (TAU) for inpatient admissions (hazard ratio, 0.74 [95% CI, 0.58 to 0.96]; P = 0.020) and 17.66 (NavSTAR) versus 27.85 (TAU) for ED visits (hazard ratio, 0.66 [CI, 0.49 to 0.89]; P = 0.006). Participants in the NavSTAR group were less likely to have an inpatient readmission within 30 days than those receiving TAU (15.5% vs. 30.0%; P < 0.001) and were more likely to enter community SUD treatment after discharge (P = 0.014; treatment entry within 3 months, 50.3% NavSTAR vs. 35.3% TAU). Limitation: Single-site trial, which limits generalizability. Conclusion: Patient navigation reduced inpatient readmissions and ED visits in this clinically challenging sample of hospitalized patients with comorbid SUDs.	[Gryczynski, Jan; Nordeck, Courtney D.; Mitchell, Shannon G.; Schwartz, Robert P.] Friends Res Inst, 1040 Pk Ave,Suite 103, Baltimore, MD 21201 USA; [Welsh, Christopher] Univ Maryland, Sch Med, 650 West Baltimore St, Baltimore, MD 21201 USA; [O'Grady, Kevin E.] Univ Maryland, Dept Psychol, 4904 Campus Dr, College Pk, MD 20742 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland College Park	Gryczynski, J (corresponding author), Friends Res Inst, 1040 Pk Ave,Suite 103, Baltimore, MD 21201 USA.			Nordeck, Courtney/0000-0002-3564-9139	National Institute on Drug Abuse of the National Institutes of Health [R01DA037942]	National Institute on Drug Abuse of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))	By award R01DA037942 from the National Institute on Drug Abuse of the National Institutes of Health.	Allison P. D., 2014, QUANTITATIVE APPL SO, V2nd; [Anonymous], 2017, HEALTHCARE COST UTIL; Bell J, 2017, BMC HEALTH SERV RES, DOI 10.1186/s12913-017-2209-0; Cleves M, 2016, INTRO SURVIVAL ANAL, P131; D'Amico MJ, 2019, J SUBST ABUSE TREAT, V106, P35, DOI 10.1016/j.jsat.2019.08.013; Englander H, 2020, J HOSP MED, V15, P184, DOI 10.12788/jhm.3311; Englander H, 2020, SUBST ABUS, V41, P419, DOI 10.1080/08897077.2019.1635968; Englander H, 2019, J GEN INTERN MED, V34, P2796, DOI 10.1007/s11606-019-05251-9; Englander H, 2019, J ADDICT MED, V13, P85, DOI 10.1097/ADM.0000000000000487; Englander H, 2017, J HOSP MED, V12, P339, DOI 10.12788/jhm.2736; Freeman HP, 2011, CANCER-AM CANCER SOC, V117, P3539, DOI 10.1002/cncr.26262; Gryczynski J, 2020, DRUG ALCOHOL DEPEN, V212, DOI 10.1016/j.drugalcdep.2020.107992; Gryczynski J, 2016, HEALTH AFFAIR, V35, P12, DOI 10.1377/hlthaff.2015.0618; Gupta A, 2018, ANESTHESIOLOGY, V128, P880, DOI 10.1097/ALN.0000000000002136; Kleinbaum DG, 2012, STAT BIOL HEALTH, P241, DOI 10.1007/978-1-4419-6646-9_6; Leppin AL, 2014, JAMA INTERN MED, V174, P1095, DOI 10.1001/jamainternmed.2014.1608; Lundahl B, 2013, PATIENT EDUC COUNS, V93, P157, DOI 10.1016/j.pec.2013.07.012; Marks LR, 2019, CLIN INFECT DIS, V68, P1935, DOI 10.1093/cid/ciy924; McDuff DR, 1997, AM J ADDICTION, V6, P256; McIlvennan CK, 2015, CIRCULATION, V131, P1796, DOI 10.1161/CIRCULATIONAHA.114.010270; Metzger DS, 2001, ENCY DRUGS ALCOHOL A, V2nd, P148; Monico LB, 2020, AM J EMERG MED, V38, P1466, DOI 10.1016/j.ajem.2020.03.005; Nordeck Courtney D, 2020, J Psychiatr Brain Sci, V5, DOI 10.20900/jpbs.20200013; Nordeck CD, 2018, DRUG ALCOHOL DEPEN, V186, P23, DOI 10.1016/j.drugalcdep.2017.12.043; Priest KC, 2019, J ADDICT MED, V13, P104, DOI 10.1097/ADM.0000000000000496; Ronan MV, 2016, HEALTH AFFAIR, V35, P832, DOI 10.1377/hlthaff.2015.1424; Rowell-Cunsolo TL, 2020, DRUG ALCOHOL DEPEN, V212, DOI 10.1016/j.drugalcdep.2020.107987; Schranz AJ, 2019, ANN INTERN MED, V170, P31, DOI 10.7326/M18-2124; Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00; Song ZR, 2017, HEALTH AFFAIR, V36, P2054, DOI 10.1377/hlthaff.2017.0689; Trowbridge P, 2017, J SUBST ABUSE TREAT, V79, P1, DOI 10.1016/j.jsat.2017.05.007; Vanderplasschen W, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00186; Wakeman SE, 2017, J GEN INTERN MED, V32, P909, DOI 10.1007/s11606-017-4077-z; Walley AY, 2012, J ADDICT MED, V6, P50, DOI 10.1097/ADM.0b013e318231de51; Weiner SG, 2020, ANN EMERG MED, V75, P13, DOI 10.1016/j.annemergmed.2019.04.020; Weinstein ZM, 2020, DRUG ALCOHOL DEPEN, V213, DOI 10.1016/j.drugalcdep.2020.108081; Weinstein ZM, 2018, MED CLIN N AM, V102, P587, DOI 10.1016/j.mcna.2018.03.001; Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4; Wu LT, 2018, DRUG ALCOHOL DEPEN, V192, P316, DOI 10.1016/j.drugalcdep.2018.08.013	39	15	15	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL	2021	174	7					899	+		10.7326/M20-5475	http://dx.doi.org/10.7326/M20-5475			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TM8QB	33819055				2023-01-03	WOS:000675809000016
J	Lee, RA; Centor, RM; Humphrey, LL; Jokela, JA; Andrews, R; Qaseem, A				Lee, Rachael A.; Centor, Robert M.; Humphrey, Linda L.; Jokela, Janet A.; Andrews, Rebecca; Qaseem, Amir		Amer Coll Phys	Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article						"Antibiotic Duration"; "short duration antibiotics" plus "acute bronchitis"; "community acquired pneumonia"; "pyelonephritis"; cystitis; "cellulitis"	ACUTE UNCOMPLICATED PYELONEPHRITIS; SKIN-STRUCTURE INFECTIONS; ACUTE BACTERIAL SKIN; DOUBLE-BLIND; CIPROFLOXACIN; METAANALYSIS; BRONCHITIS; DURATION; DISEASE; ADULTS	Description: Antimicrobial overuse is a major health care issue that contributes to antibiotic resistance. Such overuse includes unnecessarily long durations of antibiotic therapy in patients with common bacterial infections, such as acute bronchitis with chronic obstructive pulmonary disease (COPD) exacerbation, community-acquired pneumonia (CAP), urinary tract infections (UTIs), and cellulitis. This article describes best practices for prescribing appropriate and short-duration antibiotic therapy for patients presenting with these infections. Methods: The authors conducted a narrative literature review of published clinical guidelines, systematic reviews, and individual studies that addressed bronchitis with COPD exacerbations, CAP, UTIs, and cellulitis. This article is based on the best available evidence but was not a formal systematic review. Guidance was prioritized to the highest available level of synthesized evidence. Best Practice Advice 1: Clinicians should limit antibiotic treatment duration to 5 days when managing patients with COPD exacerbations and acute uncomplicated bronchitis who have clinical signs of a bacterial infection (presence of increased sputum purulence in addition to increased dyspnea, and/or increased sputum volume). Best Practice Advice 2: Clinicians should prescribe antibiotics for community-acquired pneumonia for a minimum of 5 days. Extension of therapy after 5 days of antibiotics should be guided by validated measures of clinical stability, which include resolution of vital sign abnormalities, ability to eat, and normal mentation. Best Practice Advice 3: In women with uncomplicated bacterial cystitis, clinicians should prescribe short-course antibiotics with either nitrofurantoin for 5 days, trimethoprim-sulfamethoxazole (TMP-SMZ) for 3 days, or fosfomycin as a single dose. In men and women with uncomplicated pyelonephritis, clinicians should prescribe short-course therapy either with fluoroquinolones (5 to 7 days) or TMP-SMZ (14 days) based on antibiotic susceptibility. Best Practice Advice 4: In patients with nonpurulent cellulitis, clinicians should use a 5- to 6-day course of antibiotics active against streptococci, particularly for patients able to self-monitor and who have close follow-up with primary care.	[Lee, Rachael A.] Univ Alabama Birmingham, 1900 Univ Blvd,THT 229, Birmingham, AL 35294 USA; [Centor, Robert M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA; [Centor, Robert M.] Univ Alabama Birmingham, FOT 720,1530 3rd Ave South, Birmingham, AL 35294 USA; [Humphrey, Linda L.] Portland VA Med Ctr, 3710 SW Us Vet Hosp Rd, Portland, OR 97201 USA; [Humphrey, Linda L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Jokela, Janet A.] Univ Illinois, Coll Med Urbana Champaign, 611 West Pk,207, Urbana, IL 61801 USA; [Andrews, Rebecca] Univ Connecticut, Hlth Ctr, 263 Farmington Ave,L-2104, Farmington, CT 06030 USA; [Qaseem, Amir] Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University; University of Illinois System; University of Illinois Urbana-Champaign; University of Connecticut; American College of Physicians	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.	aqaseem@acponline.org		Centor, Robert/0000-0002-9104-5137; Qaseem, Amir/0000-0001-6866-7985	ACP operating budget	ACP operating budget	Financial support for the development of this article comes exclusively fromthe ACP operating budget.	Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118; Burnham JP, 2019, INFECT CONT HOSP EP, V40, P112, DOI 10.1017/ice.2018.304; Centers for Disease Control and Prevention, 2019, CTR DIS CONTROL PREV; Centers for Disease Control and Prevention, 2019, ANT US US 2018 UPD P; Centers for Disease Control and Prevention, 2014, OUTP ANT PRESCR US; Cranendonk DR, 2020, CLIN MICROBIOL INFEC, V26, P606, DOI 10.1016/j.cmi.2019.09.019; Dinh A, 2017, EUR J CLIN MICROBIOL, V36, P1443, DOI 10.1007/s10096-017-2951-6; Drekonja DM, 2015, INFECT CONT HOSP EP, V36, P142, DOI 10.1017/ice.2014.41; El Moussaoui R, 2008, THORAX, V63, P415, DOI 10.1136/thx.2007.090613; Eliakim-Raz N, 2013, J ANTIMICROB CHEMOTH, V68, P2183, DOI 10.1093/jac/dkt177; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Fox MT, 2017, AM J MED, V130, P842, DOI 10.1016/j.amjmed.2017.01.025; goldcopd, 2022, GLOBAL STRATEGY DIAG; Gonzales R, 2001, ANN INTERN MED, V134, P521, DOI 10.7326/0003-4819-134-6-200103200-00021; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Hanretty AM, 2018, PHARMACOTHERAPY, V38, P674, DOI 10.1002/phar.2118; Harris AM, 2016, ANN INTERN MED, V164, P425, DOI 10.7326/M15-1840; Hepburn MJ, 2004, ARCH INTERN MED, V164, P1669, DOI 10.1001/archinte.164.15.1669; Kilburn SA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004299.pub2; King LM, 2021, CLIN INFECT DIS, V72, pE663, DOI 10.1093/cid/ciaa1404; Klausner HA, 2007, CURR MED RES OPIN, V23, P2637, DOI 10.1185/030079907X233340; Macheda G, 2018, J ANTIMICROB CHEMOTH, V73, P1084, DOI 10.1093/jac/dkx528; McCaig Linda E., 2011, Morbidity and Mortality Weekly Report, V60, P1153; Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST; Moran GJ, 2014, LANCET INFECT DIS, V14, P696, DOI 10.1016/S1473-3099(14)70737-6; NICE, 2019, CELL ER ANT PRESCR N; Peterson J, 2008, UROLOGY, V71, P17, DOI 10.1016/j.urology.2007.09.002; Prokocimer P, 2013, JAMA-J AM MED ASSOC, V309, P559, DOI 10.1001/jama.2013.241; Sethi S, 2001, CLIN MICROBIOL REV, V14, P336, DOI 10.1128/CMR.14.2.336-363.2001; Shapiro DJ, 2014, J ANTIMICROB CHEMOTH, V69, P234, DOI 10.1093/jac/dkt301; Spellberg B, 2018, J HOSP MED, V13, P361, DOI 10.12788/jhm.2904; Spellberg B, 2016, JAMA INTERN MED, V176, P1254, DOI 10.1001/jamainternmed.2016.3646; Stevens DL, 2014, CLIN INFECT DIS, V59, P147, DOI [10.1093/cid/ciu444, 10.1093/cid/ciu296]; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583; Tamma PD, 2017, JAMA INTERN MED, V177, P1308, DOI 10.1001/jamainternmed.2017.1938; Tansarli GS, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/aac.00635-18, 10.1128/AAC.00635-18]; Uranga A, 2016, JAMA INTERN MED, V176, P1257, DOI 10.1001/jamainternmed.2016.3633; Vaughn VM, 2019, ANN INTERN MED, V171, P153, DOI 10.7326/M18-3640	38	22	22	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	2021	174	6					822	+		10.7326/M20-7355	http://dx.doi.org/10.7326/M20-7355			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SS5IR	33819054				2023-01-03	WOS:000661788700022
J	Tan, LS; Chen, L; Jia, Y; Li, LY; Wang, JW; Huang, XY; Luo, Q; Yang, L; Xiong, ZY				Tan, Lishan; Chen, Li; Jia, Yan; Li, Lingyan; Wang, Jinwei; Huang, Xiaoyan; Luo, Qiong; Yang, Li; Xiong, Zuying		ISN AKF 0 25 China Consortium	Impact of diabetes mellitus on short-term prognosis, length of stay, and costs in patients with acute kidney injury: A nationwide survey in China	PLOS ONE			English	Article							AKI; COMPLICATIONS; MORTALITY	Background International data suggest that people with diabetes mellitus (DM) are at increased risk for worse acute kidney injury (AKI) outcomes; however, the data in China are limited. Therefore, this study aimed to describe the association of DM with short-term prognosis, length of stay, and expenditure in patients with AKI. Methods This study was based on the 2013 nationwide survey in China. According to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) and expanded criteria of AKI, 7604 patients with AKI were identified, and 1404 and 6200 patients were with and without DM, respectively. Clinical characteristics, outcomes, length of stay, and costs of these patients were compared. Multivariate regression analyses were conducted to evaluate the association of DM with mortality, failed renal recovery, length of stay, and costs. Results Patients with AKI and DM were older, had higher male preponderance (61.9%), presented with more comorbidities, and had higher serum creatinine levels compared with those without DM. An apparent increase in all-cause in-hospital mortality, length of stay, and costs was found in patients with DM. DM was not independently associated with failed renal recovery (adjusted OR (95%CI): 1.08 (0.94-1.25)) and in-hospital mortality (adjusted OR (95%): 1.16 (0.95-1.41)) in multivariate models. However, the diabetic status was positively associated with the length of stay (beta = 0.06, p<0.05) and hospital expenditure (beta = 0.10, p<0.01) in hospital after adjusting for possible confounders. Conclusion In hospitalized AKI patients, DM (vs. no DM) is independently associated with longer length of stay and greater costs, but is not associated with an increased risk for failed renal recovery and in-hospital mortality.	[Tan, Lishan; Chen, Li; Jia, Yan; Li, Lingyan; Huang, Xiaoyan; Luo, Qiong; Xiong, Zuying] Peking Univ, Shenzhen Peking Univ Hong Kong Univ Sci & Technol, Dept Nephrol, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China; [Wang, Jinwei; Yang, Li] Peking Univ, Peking Univ Hosp 1, Dept Med, Renal Div,Inst Nephrol,Key Lab Renal Dis,Minist H, Beijing, Peoples R China	Hong Kong University of Science & Technology; Peking University; Peking University	Xiong, ZY (corresponding author), Peking Univ, Shenzhen Peking Univ Hong Kong Univ Sci & Technol, Dept Nephrol, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China.; Yang, L (corresponding author), Peking Univ, Peking Univ Hosp 1, Dept Med, Renal Div,Inst Nephrol,Key Lab Renal Dis,Minist H, Beijing, Peoples R China.	li.yang@bjmu.edu.cn; xiongzy2005@163.com			China Postdoctoral Science Foundation [2018M643138]; fund of "San-ming" Project of Medicine in Shenzhen [SZSM201812097]; National Natural Science Foundation of China [91742205, 81625004]; Beijing Young Scientist Program [BJJWZYJH01201910001006]; Peking University Clinical Scientist Program by the Fundamental Research Funds for the Central Universities	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); fund of "San-ming" Project of Medicine in Shenzhen; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Young Scientist Program; Peking University Clinical Scientist Program by the Fundamental Research Funds for the Central Universities	Lishan Tan was supported by China Postdoctoral Science Foundation (No.2018M643138). Zuying Xiong was supported by the fund of "San-ming" Project of Medicine in Shenzhen (No.SZSM201812097). Li Yang was supported by the National Natural Science Foundation of China (No.91742205 and No.81625004), the Beijing Young Scientist Program (BJJWZYJH01201910001006), and Peking University Clinical Scientist Program by the Fundamental Research Funds for the Central Universities. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.	Arbel Y, 2019, INT J CARDIOL, V293, P197, DOI 10.1016/j.ijcard.2019.05.064; Bao XY, 2017, J DIABETES, V9, P405, DOI 10.1111/1753-0407.12428; Brown JR, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4278579; Chatterjee S, 2017, LANCET, V389, P2239, DOI 10.1016/S0140-6736(17)30058-2; Coca SG, 2010, KIDNEY INT, V78, P926, DOI 10.1038/ki.2010.259; Fang Y, 2010, BLOOD PURIFICAT, V30, P120, DOI 10.1159/000319972; Fortrie G, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2314-z; Gao GF, 2013, AM J PHYSIOL-RENAL, V304, pF515, DOI 10.1152/ajprenal.00533.2012; Gao NN, 2016, J DIABETES COMPLICAT, V30, P199, DOI 10.1016/j.jdiacomp.2015.11.018; Girling BJ, 2020, CLIN KIDNEY J, V13, P133, DOI 10.1093/ckj/sfz158; Hirsch IB, 2015, DIABETES CARE, V38, P1610, DOI 10.2337/dc14-2898; Hu HM, 2015, DIABETES THER, V6, P7, DOI 10.1007/s13300-015-0096-0; Iwagami M, 2018, NEPHROL DIAL TRANSPL, V33, P1354, DOI 10.1093/ndt/gfy011; Jager KJ, 2008, KIDNEY INT, V73, P256, DOI 10.1038/sj.ki.5002650; James MT, 2015, AM J KIDNEY DIS, V66, P602, DOI 10.1053/j.ajkd.2015.02.338; Johnson F, 2016, NEPHROLOGY, V21, P506, DOI 10.1111/nep.12649; Li YZ, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m997; Ma RCW, 2018, DIABETOLOGIA, V61, P1249, DOI 10.1007/s00125-018-4557-7; Mao WH, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6569-8; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; Mina GS, 2017, CLIN CARDIOL, V40, P726, DOI 10.1002/clc.22723; Muroya Y, 2018, AM J PHYSIOL-RENAL, V315, pF1843, DOI 10.1152/ajprenal.00184.2018; Naruse H, 2012, CIRC J, V76, P1848, DOI 10.1253/circj.CJ-11-1248; Nogami K, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013894; Ortega A, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/254529; Pavkov ME, 2018, MMWR-MORBID MORTAL W, V67, P289, DOI 10.15585/mmwr.mm6710a2; Pereira MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047746; Regassa LD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215967; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; Schwarze K, 2018, AM J PHYSIOL-RENAL, V315, pF1139, DOI 10.1152/ajprenal.00502.2017; Seuring T, 2015, PHARMACOECONOMICS, V33, P811, DOI 10.1007/s40273-015-0268-9; Silver SA, 2017, J HOSP MED, V12, P70, DOI 10.12788/jhm.2683; Szczech LA, 2009, J AM SOC NEPHROL, V20, P453, DOI 10.1681/ASN.2009010041; Trevelin SC, 2017, SHOCK, V47, P276, DOI 10.1097/SHK.0000000000000778; Vallon V, 2014, NEPHRON CLIN PRACT, V127, P133, DOI 10.1159/000363554; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Xie Xiwei, 2009, International Ophthalmology, V29, P485, DOI 10.1007/s10792-008-9272-9; Yang DZ, 2016, J DIABETES, V8, P847, DOI 10.1111/1753-0407.12366; Yang L, 2015, LANCET, V386, P1465, DOI 10.1016/S0140-6736(15)00344-X; Zeng XX, 2014, CLIN J AM SOC NEPHRO, V9, P12, DOI 10.2215/CJN.02730313; Zhang Luxia, 2019, Kidney Int Suppl (2011), V9, pe1, DOI 10.1016/j.kisu.2018.11.001	41	1	1	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2021	16	5							e0250934	10.1371/journal.pone.0250934	http://dx.doi.org/10.1371/journal.pone.0250934			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RW3BG	33939742	Green Published, gold			2023-01-03	WOS:000646400800037
J	Ezezika, O; Ragunathan, A; El-Bakri, Y; Barrett, K				Ezezika, Obidimma; Ragunathan, Apira; El-Bakri, Yasmine; Barrett, Kathryn			Barriers and facilitators to implementation of oral rehydration therapy in low- and middle-income countries: A systematic review	PLOS ONE			English	Review							SUGAR-SALT SOLUTION; SCALE-UP PROGRAM; CHILDHOOD DIARRHEA; RURAL COMMUNITIES; NATIONAL CONTROL; CASE-MANAGEMENT; UTTAR-PRADESH; DISEASE; ORS; MOTHERS	Background Oral rehydration therapy (ORT) is an effective and cheap treatment for diarrheal disease; globally, one of the leading causes of death in children under five. The World Health Organization launched a global campaign to improve ORT coverage in 1978, with activities such as educational campaigns, training health workers and the creation of designate programming. Despite these efforts, ORT coverage remains relatively low. The objective of this systematic review is to identify the barriers and facilitators to the implementation of oral rehydration therapy in low and middle-income countries. Methods A comprehensive search strategy comprised of relevant subject headings and keywords was executed in 5 databases including OVID Medline, OVID Embase, OVID HealthStar, Web of Science and Scopus. Eligible studies underwent quality assessment, and a directed content analysis approach to data extraction was conducted and aligned to the Consolidated Framework for Implementation Research (CFIR) to facilitate narrative synthesis. Results The search identified 1570 citations and following removal of duplicates as well as screening according to our inclusion/exclusion criteria, 55 articles were eligible for inclusion in the review. Twenty-three countries were represented in this review, with India, Bangladesh, Egypt, Nigeria, and South Africa having the most representation of available studies. Study dates ranged from 1981 to 2020. Overarching thematic areas spanning the barriers and facilitators that were identified included: availability and accessibility, knowledge, partnership engagement, and design and acceptability. Conclusion A systematic review of studies on implementation of ORT in low- and middle-income countries (LMICs) highlights key activities that facilitate the development of successful implementation that include: (1) availability and accessibility of ORT, (2) awareness and education among communities, (3) strong partnership engagement strategies, and (4) adaptable design to enhance acceptability. The barriers and facilitators identified under the CIFR domains can be used to build knowledge on how to adapt ORT to national and local settings and contribute to a better understanding on the implementation and use of ORT in LMICs. The prospects for scaling and sustaining ORT (after years of low use) will increase if implementation research informs local applications, and implementers engage appropriate stakeholders and test assumptions around localized theories of change from interventions to expected outcomes. Registration A protocol for this systematic review was developed and uploaded onto the PROSPERO international prospective register of systematic reviews database (Registration number: CRD420201695).	[Ezezika, Obidimma; Ragunathan, Apira; El-Bakri, Yasmine] Univ Toronto Scarborough, Dept Hlth & Soc, Toronto, ON, Canada; [Ezezika, Obidimma] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Ezezika, Obidimma] Ontario Tech Univ, Fac Hlth Sci, Oshawa, ON, Canada; [Ezezika, Obidimma] African Ctr Innovat & Leadership Dev, Abuja, Nigeria; [Barrett, Kathryn] Univ Toronto, Scarborough Lib, Toronto, ON, Canada	University of Toronto; University Toronto Scarborough; University of Toronto; University of Toronto; University Toronto Scarborough	Ezezika, O (corresponding author), Univ Toronto Scarborough, Dept Hlth & Soc, Toronto, ON, Canada.; Ezezika, O (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.; Ezezika, O (corresponding author), Ontario Tech Univ, Fac Hlth Sci, Oshawa, ON, Canada.; Ezezika, O (corresponding author), African Ctr Innovat & Leadership Dev, Abuja, Nigeria.	obidimma.ezezika@utoronto.ca	Barrett, Kathryn/AAP-4602-2021	Barrett, Kathryn/0000-0002-7940-2816				Abed F.H., 1988, MOTHERS LEARN SAVE L; Akpede GO, 1997, J DIARRHOEAL DIS RES, V15, P232; Ali F, 2017, ANN TROP MED PUBLIC, V10, P571, DOI 10.4103/ATMPH.ATMPH_68_17; Andrus A, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010503; [Anonymous], WHO OLD EN RET; [Anonymous], DEATH RAT DIARRH DIS; Aung T, 2014, J TROP PEDIATRICS, V60, P189, DOI 10.1093/tropej/fmt108; Baltazar JC, 2002, B WORLD HEALTH ORGAN, V80, P637; Barrett K., 2020, PROSPERO; BHAN MK, 1988, INDIAN J MED RES, V87, P197; Bhandari N, 2008, PEDIATRICS, V121, pE1279, DOI 10.1542/peds.2007-1939; Bhattacharya S K, 1994, Indian J Public Health, V38, P39; Bhutta ZA, 2013, LANCET, V381, P1417, DOI 10.1016/S0140-6736(13)60648-0; Billah SM, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020803; Boerma T, 2018, LANCET, V391, P1538, DOI 10.1016/S0140-6736(18)30104-1; Charyeva Z, 2015, J HEALTH POPUL NUTR, V34, DOI 10.1186/s41043-015-0005-1; Chowdhury AMR, 1997, HEALTH POLICY PLANN, V12, P58, DOI 10.1093/heapol/12.1.58; CHOWDHURY AMR, 1988, INT J EPIDEMIOL, V17, P655, DOI 10.1093/ije/17.3.655; CLOW DJ, 1985, BRIT MED J, V290, P691, DOI 10.1136/bmj.290.6469.691; Cooke ML, 2013, S AFR J CHILD HEALTH, V7, P84, DOI 10.7196/SAJCH.472; COREIL J, 1988, SOC SCI MED, V27, P87, DOI 10.1016/0277-9536(88)90166-9; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; de Sousa A, 2012, B WORLD HEALTH ORGAN, V90, P183, DOI 10.2471/BLT.11.093989; DEB B C, 1985, Indian Journal of Pediatrics, V52, P475, DOI 10.1007/BF02751021; Dippenaar H, 2005, S AFR FAM PRACT, V47, P51, DOI 10.1080/20786204.2005.10873188; El-Khoury M, 2016, GLOB HEALTH-SCI PRAC, V4, P264, DOI 10.9745/GHSP-D-16-00021; ELMOUGI M, 1986, J TROP PEDIATRICS, V32, P24, DOI 10.1093/tropej/32.1.24; ELRAFIE M, 1990, LANCET, V335, P334; FRANKEL SJ, 1984, J TROP MED HYG, V87, P137; GBD Compare, GBD COMP; Gebremedhin S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3126-6; GIBBONS E, 1994, PUBLIC HEALTH REP, V109, P428; Gill CJ, 2013, LANCET, V381, P1487, DOI 10.1016/S0140-6736(13)60314-1; GREENOUGH WB, 1991, J PEDIATR-US, V118, pS80, DOI 10.1016/S0022-3476(05)81431-3; GUTIERREZ G, 1994, MED CARE, V32, P436, DOI 10.1097/00005650-199405000-00003; Habib MA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-922; Hall-Clifford R, 2017, REV PANAM SALUD PUBL, V41; HEYMANN DL, 1990, B WORLD HEALTH ORGAN, V68, P193; HIRSCHHORN N, 1968, NEW ENGL J MED, V279, P176, DOI 10.1056/NEJM196807252790402; Howteerakul N, 2003, SOC SCI MED, V57, P1031, DOI 10.1016/S0277-9536(02)00478-1; KASSAYE M, 1994, ARCH PEDIAT ADOL MED, V148, P1288, DOI 10.1001/archpedi.1994.02170120050008; Kassegne S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-155; KENYA PR, 1990, SOC SCI MED, V31, P979, DOI 10.1016/0277-9536(90)90107-4; Khan AM, 2020, DIGEST DIS SCI, V65, P355, DOI 10.1007/s10620-019-05921-y; KIELMANN AA, 1986, TROP MED PARASITOL, V37, P15; KIELMANN AA, 1985, TROP MED PARASITOL, V36, P191; Kirk MA, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0437-z; Kumar S, 2015, J GLOB HEALTH, V5, P173, DOI 10.7189/jogh.05.020414; KUMAR V, 1987, Journal of Diarrhoeal Diseases Research, V5, P159; KUMAR V, 1989, Journal of Diarrhoeal Diseases Research, V7, P70; Kumate J., 1996, IMPACT ORAL REHYDRAT, V74, P9; Lam F, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010504; Lam F, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010502; Lam F, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010501; LANGSTEN R, 1995, SOC SCI MED, V40, P989, DOI 10.1016/0277-9536(94)00163-N; Lenters LM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S28; MacDonald SE, 2007, ASIA-PAC J PUBLIC HE, V19, P34, DOI 10.1177/10105395070190010701; Maken ZH, 2017, RAWAL MED J, V42, P408; Mathur A, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091646; Means AR, 2020, IMPLEMENT SCI, V15, DOI 10.1186/s13012-020-0977-0; MILLER P, 1995, SOC SCI MED, V40, pS1, DOI 10.1016/0277-9536(95)00001-N; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; MULL JD, 1988, SOC SCI MED, V27, P53, DOI 10.1016/0277-9536(88)90163-3; Munos MK, 2010, INT J EPIDEMIOL, V39, P75, DOI 10.1093/ije/dyq025; Nations M K, 1988, Bull Pan Am Health Organ, V22, P335; Nilsen P, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0242-0; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ogbo Patricia U., 2014, Pharmacy Pract (Granada), V12; Okeke TA, 1996, J DIARRHOEAL DIS RES, V14, P33; Pinker Steven, 2018, ENLIGHTENMENT NOW CA; Programme WHODDC Programme WHODDC, 1994, PROGR CONTR DIARRH D; Raghu M. B., 1995, Indian Journal of Pediatrics, V62, P439, DOI 10.1007/BF02755064; RAHMAN ASMM, 1985, LANCET, V2, P539; Reyes H, 1996, SALUD PUBLICA MEXICO, V38, P157; RONSMANS C, 1991, REV INFECT DIS, V13, pS351; Santosham M, 2010, LANCET, V376, P63, DOI 10.1016/S0140-6736(10)60356-X; Schroder K, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010503; SIRCAR BK, 1991, INDIAN J MED RES-A, V93, P297; Sood N, 2014, AM J TROP MED HYG, V90, P939, DOI 10.4269/ajtmh.13-0279; Sreeramareddy CT, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0836-6; Thiese MS, 2014, BIOCHEM MEDICA, V24, P199, DOI 10.11613/BM.2014.022; TOUCHETTE P, 1994, SOC SCI MED, V39, P425, DOI 10.1016/0277-9536(94)90140-6; Wagner Z, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002734; Wiens KE, 2020, LANCET GLOB HEALTH, V8, P1038, DOI 10.1016/S2214-109X(20)30230-8; Wilson SE, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010404; World Bank, 2021, LOW MIDDL INC DAT	86	3	3	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0249638	10.1371/journal.pone.0249638	http://dx.doi.org/10.1371/journal.pone.0249638			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RT0DC	33886584	Green Published, gold			2023-01-03	WOS:000644138300062
J	Joe, S; Totaro, M; Wang, HB; Beccai, L				Joe, Seonggun; Totaro, Massimo; Wang, Hongbo; Beccai, Lucia			Development of the Ultralight Hybrid Pneumatic Artificial Muscle: Modelling and optimization	PLOS ONE			English	Article							SOFT; ACTUATOR; ROBOT; PERFORMANCE; STIFFNESS	Pneumatic artificial muscles (PAMs) are one of the key technologies in soft robotics, and they enable actuation in mobile robots, in wearable devices and exoskeletons for assistive and rehabilitative purposes. While they recently showed relevant improvements, they still present quite low payload, limited bandwidth, and lack of repeatability, controllability and robustness. Vacuum-based actuation has been recently demonstrated as a very promising solution, and many challenges are still open, like generating at the same time a large contraction ratio, and a high blocking force with enhanced axial stiffness. In this paper, a novel Ultralight Hybrid PAM (UH-PAM), based on bellow-type elastomeric skin and vacuum actuation, is presented. In particular, open-cell foam is exploited as a structural backbone, together with plastic rings, all embedded in a thin skin. The design and optimization combine numerical, analytical, and experimental data. Both static and dynamic analysis are performed. The weight of the optimized actuator is only 20 g. Nevertheless, a contraction ratio up to 50% and a maximum payload of 3 kg can be achieved. From a dynamic point of view, a rise time of 0.5 s for the contraction phase is observed. Although hysteresis is significant when using the whole contraction span, it can be reduced (down to 11.5%) by tuning both the vacuum range and the operating frequency for cyclic movements. Finally, to demonstrate the potentiality of this soft actuation approach, a 3 DoFs Stewart platform is built. The feasibility of performing smooth movements by exploiting open-loop control is shown through simple and more complex handwriting figures projected on the XY plane.	[Joe, Seonggun; Totaro, Massimo; Wang, Hongbo; Beccai, Lucia] Ist Italiano Tecnol IIT, Soft BioRobot Percept, Genoa, Italy; [Joe, Seonggun] Scuola Super Sant Anna, BioRobot Inst, Pontedera, Italy	Istituto Italiano di Tecnologia - IIT; Scuola Superiore Sant'Anna	Joe, S; Beccai, L (corresponding author), Ist Italiano Tecnol IIT, Soft BioRobot Percept, Genoa, Italy.; Joe, S (corresponding author), Scuola Super Sant Anna, BioRobot Inst, Pontedera, Italy.	seonggun.joe@iit.it; lucia.beccai@iit.it	Joe, Seonggun/GWV-1404-2022; Totaro, Massimo/F-4746-2018	Joe, Seonggun/0000-0002-4290-7570; Totaro, Massimo/0000-0002-0630-7383; Beccai, Lucia/0000-0002-8754-5155	European Union's Horizon 2020 research and innovation programme [863212]; Marie Sklodowska-Curie Individual Fellowship from the European Union's Horizon 2020 research and innovation programme [799773]	European Union's Horizon 2020 research and innovation programme; Marie Sklodowska-Curie Individual Fellowship from the European Union's Horizon 2020 research and innovation programme	This work has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 863212 (PROBOSCIS project). Hongbo Wang would like to thank the financial support of his Marie Sklodowska-Curie Individual Fellowship from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 799773 (3D-SITS project).]	Akbari S, 2019, SENSOR ACTUAT A-PHYS, V290, P177, DOI 10.1016/j.sna.2019.03.015; Beccai L, 2020, 2020 3 IEEE INT C SO; Beccai L, 2018, 2018 IEEE INT C SOFT; Beccai L, 2020, 2020 3 IEEE INT C SO; Becht C, 2002, J PRESS VESS-T ASME, V124, P124, DOI 10.1115/1.1426405; Brancadoro M, 2019, FRONT ROBOT AI, V6, DOI 10.3389/frobt.2019.00012; Caldwell DG., 1993, IFAC P VOLUMES, V26, P522; Digumarti KM, 2017, IEEE ROBOT AUTOM LET, V2, P2302, DOI 10.1109/LRA.2017.2726113; Ding LW, 2019, MATER DESIGN, V182, DOI 10.1016/j.matdes.2019.108000; Donati M, 2013, SENSORS-BASEL, V13, P1021, DOI 10.3390/s130101021; Felt W, 2018, 2018 IEEE INTERNATIONAL CONFERENCE ON SOFT ROBOTICS (ROBOSOFT), P534; Galloway KC, 2013, 2013 16TH INTERNATIONAL CONFERENCE ON ADVANCED ROBOTICS (ICAR); Goulbourne NC., 2007, ELECTROACTIVE POLYM, V6524; Hao YF, 2017, CHIN CONTR CONF, P6781, DOI 10.23919/ChiCC.2017.8028427; Jiao ZD, 2019, ADV MATER TECHNOL-US, V4, DOI 10.1002/admt.201800429; Kalisky T, 2017, IEEE INT C INT ROBOT, P6207; Kang BB, 2019, SOFT ROBOT, V6, P214, DOI 10.1089/soro.2018.0006; Kellaris N, 2018, SCI ROBOT, V3, DOI 10.1126/scirobotics.aar3276; Khunt JB., 2014, IJIRST INT J INNOVAT, V1, P2349; Kim J, 2014, ACS NANO, V8, P2986, DOI 10.1021/nn500283q; Lee DY, 2017, SOFT ROBOT, V4, P163, DOI 10.1089/soro.2016.0038; Lee DY, 2014, PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATION IN ENGINEERING CONFERENCE, 2013, VOL 6B; Lee H, 2020, SCI ROBOT, V5, DOI 10.1126/scirobotics.aay9024; Lee JG, 2019, SOFT ROBOT, V6, P109, DOI 10.1089/soro.2018.0063; Li M, 2014, SMART MATER STRUCT, V23, DOI 10.1088/0964-1726/23/9/095007; Li SG, 2017, P NATL ACAD SCI USA, V114, P13132, DOI 10.1073/pnas.1713450114; Liu Q, 2017, FRONT NEUROROBOTICS, V11, DOI 10.3389/fnbot.2017.00064; Margheri L, 2012, BIOINSPIR BIOMIM, V7, DOI 10.1088/1748-3182/7/2/025004; Mazzolai B, 2012, BIOINSPIR BIOMIM, V7, DOI 10.1088/1748-3182/7/2/025005; Mirvakili SM, 2018, ADV MATER, V30, DOI 10.1002/adma.201704407; NEWLAND DE, 1964, J MECH ENG SCI, V6, P270, DOI 10.1243/JMES_JOUR_1964_006_040_02; Onal CD, 2013, IEEE-ASME T MECH, V18, P430, DOI 10.1109/TMECH.2012.2210239; Pabst O, 2014, ORG ELECTRON, V15, P3306, DOI 10.1016/j.orgel.2014.09.007; Pal A, 2020, ADV FUNCT MATER, V30, DOI [10.1002/adfm.201906603, 10.1002/adfm.201808713]; Robertson MA, 2017, SCI ROBOT, V2, DOI 10.1126/scirobotics.aan6357; Robertson MA, 2017, SOFT ROBOT, V4, P23, DOI 10.1089/soro.2016.0029; Schaffner M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03216-w; Situm Z, 2008, MED C CONTR AUTOMAT, P1011; Skorina EH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204637; SNEDDEN NW, 1985, THIN WALL STRUCT, V3, P145, DOI 10.1016/0263-8231(85)90030-8; Song DC, 2009, OPT ENG, V48, DOI 10.1117/1.3102073; Tawk C, 2019, IEEE-ASME T MECH, V24, P2118, DOI 10.1109/TMECH.2019.2933027; Tsukimori K., 1989, DESIGN ANAL, P663; Veale AJ, 2016, SMART MATER STRUCT, V25, DOI 10.1088/0964-1726/25/6/065013; Wakimoto S, 2016, SENSOR ACTUAT A-PHYS, V250, P48, DOI 10.1016/j.sna.2016.08.004; Wang HB, 2019, IEEE SENSOR; Wang HB, 2018, ADV SCI, V5, DOI 10.1002/advs.201800541; Wei SX, 2019, ANGEW CHEM INT EDIT, V58, P16243, DOI 10.1002/anie.201908437; Yang D, 2016, ADV MATER TECHNOL-US, V1, DOI 10.1002/admt.201600055; Yukisawa T, 2017, 2017 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND BIOMIMETICS (IEEE ROBIO 2017), P2303; Zhang GL, 2018, 2018 3RD INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION ENGINEERING (ICRAE), P14, DOI 10.1109/ICRAE.2018.8586677; Zhang YF, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201806698; Zhou FH, 2019, SENSOR ACTUAT A-PHYS, V292, P112, DOI 10.1016/j.sna.2019.02.017; Zolfagharian A, 2016, SENSOR ACTUAT A-PHYS, V250, P258, DOI 10.1016/j.sna.2016.09.028	54	4	4	6	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0250325	10.1371/journal.pone.0250325	http://dx.doi.org/10.1371/journal.pone.0250325			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0DC	33886654	Green Published, gold			2023-01-03	WOS:000644138300088
J	Dejene, H; Abera, M; Tadele, A				Dejene, Hiwot; Abera, Muluemebet; Tadele, Afework			Unmet need for family planning and associated factors among married women attending anti-retroviral treatment clinics in Dire Dawa City, Eastern Ethiopia	PLOS ONE			English	Article							HEALTH	Background Unmet need for family planning is a measure of the gap between women's contraceptive behavior and their fertility desires. It should be measured among different population groups to effectively implement public health interventions. Thus, this study aimed to determine the magnitude of unmet need for family planning and associated factors among HIV- positive women in Dire Dawa city Anti-retroviral treatment (ART) clinics, Eastern Ethiopia. Methods We carried out a facility-based cross-sectional study (March-June 2020) among 409 married women aged 15-49 on ART, using systematic random sampling. A face-to-face interview was done using a structured questionnaire. Bivariable and multivariable logistic regression was done to identify factors associated with unmet need for family planning. Results Overall, 33% [95% confidence interval (CI): 28.9-37.9] of the respondents had unmet need for family planning. Woman's residing in a rural area (adjusted odds ratio (AOR): 2.41 [95% CI: 1.24-4.67]), woman's not attained formal education (AOR: 4.14 [95% CI: 1.73-9.93]) and attaining primary education (AOR: 2.97 [95% CI: 1.54-5.74]), poor knowledge (AOR: 2.87 [95% CI: 1.52-5.40]), and unfavorable attitude towards family planning (AOR: 2.21 [95% CI: 1.12-4.34]), clients not satisfied with family planning service (AOR: 6.34 [95% CI: 3.31-12.15]), the woman not having decision making power on family planning (AOR:3.97 [95% CI: 2.14-7.38]) and not getting family planning counseling in ART clinics (AOR: 2.87 [95% CI: 1.54-5.35]) were positively associated with having unmet need for family planning. Conclusion This study indicates there a high unmet need for family planning among married HIV-positive women. Factors like a place of residence, educational status of women, knowledge and attitude towards family planning, client satisfaction with FP service, women decision-making power, and FP counseling service in ART. Therefore, we recommend that the concerned bodies should collaborate with ART clinics to design interventions that enhance access to family planning programs to combat the high unmet need for family planning among HIV-positive women.	[Dejene, Hiwot] Mettu Univ, Dept Publ Hlth, Mettu, Ethiopia; [Abera, Muluemebet; Tadele, Afework] Jimma Univ, Dept Populat & Family Hlth, Jimma, Ethiopia	Jimma University	Dejene, H (corresponding author), Mettu Univ, Dept Publ Hlth, Mettu, Ethiopia.	hiwotdejene74@gmail.com	Tadele, Afework/AAK-3071-2020	Tadele, Afework/0000-0001-5682-6117; Dejene, Hiwot/0000-0002-5110-4075	Jimma University	Jimma University	This research work is funded by Jimma University.	Abeje Gedefaw, 2016, BMC Res Notes, V9, P43, DOI 10.1186/s13104-016-1850-8; Abubeker Ferid A, 2019, Int J Reprod Med, V2019, P3276780, DOI 10.1155/2019/3276780; Asrat Woineshet, 2018, Contracept Reprod Med, V3, P25, DOI 10.1186/s40834-018-0079-4; Baschieri A, 2017, MATERN CHILD HLTH J, V21, P467, DOI 10.1007/s10995-016-2124-8; Berhane Yemane, 2013, ISRN AIDS, V2013, P319724, DOI 10.1155/2013/319724; Bogale B, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-342; Bradley SEK., 2012, REVISING UNMET NEED, V63 25; Central Statistical Agency (CSA) [Ethiopia] and ICF, 2016, ETHIOPIA DEMOGRAPHIC; Chakraborty NM, 2016, GLOB HEALTH-SCI PRAC, V4, P141, DOI 10.9745/GHSP-D-15-00384; Claridge AM, 2013, WOMEN HEALTH, V53, P777, DOI 10.1080/03630242.2013.831018; Endriyas M, 2017, CONTRACEP REPROD MED, V2, DOI 10.1186/s40834-016-0036-z; Fagbamigbe AF, 2018, SAGE OPEN, V8, DOI 10.1177/2158244017754023; Federal Democratic Republic of Ethiopia(FDRE), ETHIOPIA RH STRATEGI; Federal Democratic Republic of Ethiopia Ministry of Health, 2016, NATL REPROD HLTH STR, P102; Feyssa MD., 2015, J AIDS CLIN RES, V6; Fisheljoy D., 2012, DHS ANAL STUDIES, V25; Haile A, 2009, ETHIOP J HEALTH DEV, V20, DOI [10.4314/ejhd.v20i3.46824, DOI 10.4314/EJHD.V20I3.46824]; Kalolo A., 2018, INT J POPUL RES, V2018, P1; Koshewara P., 2019, J EVID BASED MED HEA, V6, P893; Laryea DO, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-126; MacQuarrie, 2015, DHS WORKING PAPERS, V122; Melaku YA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094682; Njuguna E., 2017, INT J REPROD CONTRAC, V6, P1746, DOI DOI 10.18203/2320-1770.IJRCOG20171935; Okigbo CC, 2014, AFR J REPROD HEALTH, V18, P134; Okunola TO, 2019, TROP DOCT, V49, P26, DOI 10.1177/0049475518809605; Rucinski KB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209114; Shafei MN., 2012, J COMMUNITY MED HLTH, V2, P180, DOI [10.4172/2161-0711.1000180, DOI 10.4172/2161-0711.1000180]; Sisay SelamwiytMKS., 2015, ADDIS ABABA U ELECT; Thindwa D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217330; Wanyenze RK, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-014-0158-x; World Health Organization (WHO) , 2019, UNMET NEED FAMILY PL; Yotebieng M, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.235.5859; Zewdu G, 2011, UNMET REPROD HLTH CA	33	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2021	16	4							e0250297	10.1371/journal.pone.0250297	http://dx.doi.org/10.1371/journal.pone.0250297			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP1DH	33861787	Green Published, gold			2023-01-03	WOS:000641475400062
J	Shimels, T; Kassu, RA; Bogale, G; Bekele, M; Getnet, M; Getachew, A; Shewamene, Z; Abraha, M				Shimels, Tariku; Kassu, Rodas Asrat; Bogale, Gelila; Bekele, Mahteme; Getnet, Melsew; Getachew, Abrham; Shewamene, Zewdneh; Abraha, Mebratu			Magnitude and associated factors of poor medication adherence among diabetic and hypertensive patients visiting public health facilities in Ethiopia during the COVID-19 pandemic	PLOS ONE			English	Article								Objective This study aims to assess the magnitude and associated factors of poor medication adherence among diabetic and hypertensive patients visiting public health facilities in Addis Ababa, Ethiopia during the COVID-19 pandemic. Methods A multi-site cross-sectional design was conducted from 1(st) through 30(th) of August 2020 at public health facilities of the study area. Adult outpatients with T2DM and hypertension visiting hospitals and health centers were included in the study. A proportion to size allocation method was used to determine the required sample size per facility. Data was collected using the 8-item Morisky medication adherence scale. Descriptive statistics and binary logistic regression were used to analyze data. A 95% confidence interval and p <= 0.05 statistical significance was considered to determine factors associated with poor medication adherence. Results A total of 409 patients were included in the present study. About 57% of the patients reported that the COVID-19 pandemic has posed negative impacts on either of their follow-up visits, availability of medications, or affordability of prices. And, 21% have reported that they have been affected in all aspects. The overall magnitude of poor medication adherence was 72%. Patients with extreme poverty were more likely to have good medication adherence (AOR: 0.59; 95%C.I: 0.36-0.97), whereas attendance to a health center (AOR: 1.71; 95%C.I: 1.02-2.85), presence of comorbidity (AOR: 2.05; 95%C.I: 1.13-3.71), and current substance use history (AOR: 11.57; 95%C.I: 1.52-88.05) predicted high odds of poor adherence. Conclusion Over a three-fourth of the patients, in the study setting, have poor adherence to their anti-diabetic and antihypertensive medications. Health facility type, income level, comorbidity, and current substance use history showed a statistically significant association with poor adherence to medication. Stakeholders should set alternative strategies as perceived impacts of the COVID-19 pandemic on medication adherence are high in the study area.	[Shimels, Tariku; Bekele, Mahteme; Getnet, Melsew; Getachew, Abrham; Abraha, Mebratu] St Pauls Hosp, Res Directorate, Millennium Med Coll, Addis Ababa, Ethiopia; [Kassu, Rodas Asrat] St Pauls Hosp, Dept Neurol, Millennium Med Coll, Addis Ababa, Ethiopia; [Bogale, Gelila] United Vis Med Serv, Addis Ababa, Ethiopia; [Shewamene, Zewdneh] Ethiopian Hlth Insurance Agcy, Addis Ababa, Ethiopia		Shimels, T (corresponding author), St Pauls Hosp, Res Directorate, Millennium Med Coll, Addis Ababa, Ethiopia.	tarphar2008@gmail.com	Mekonnon, Tariku Shimels/AAO-5298-2021	Mekonnon, Tariku Shimels/0000-0001-5212-7597; Tsegaw, Melsew Getnet/0000-0003-0889-9156; Getachew, Abrham/0000-0001-9725-1145; Sabe, Zewdneh Shewamene/0000-0003-1490-9672	Saint Paul's Hospital Millennium Medical College	Saint Paul's Hospital Millennium Medical College	Funding for the study was obtained from Saint Paul's Hospital Millennium Medical College. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abebe S, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4127-1; Ali Muhammed, 2017, BMC Res Notes, V10, P676, DOI 10.1186/s13104-017-3025-7; Amu H, 2020, PAN AFR MED J, V35, DOI 10.11604/pamj.supp.2020.35.24047; Asemahagn MA, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-431; Asgedom Solomon Weldegebreal, 2018, BMC Res Notes, V11, P27, DOI 10.1186/s13104-018-3139-6; Atinga RA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193995; Bekele EE., 2018, MOJ PUBLIC HLTH, V7, P280, DOI [10.15406/mojph.2018.07.00252, DOI 10.15406/MOJPH.2018.07.00252]; Biadgilign S, 2020, PAN AFR MED J, V35, DOI 10.11604/pamj.supp.2020.35.2.23906; Bovet P, 2002, B WORLD HEALTH ORGAN, V80, P33; Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575; Burkhart PV, 2003, J NURS SCHOLARSHIP, V35, P207; Chudasama YV, 2020, DIABETES METAB SYND, V14, P965, DOI 10.1016/j.dsx.2020.06.042; Danhieux K, 2020, BMC FAM PRACT, V21, DOI 10.1186/s12875-020-01326-3; Demoz GT, 2020, DIABETOL METAB SYNDR, V12, DOI 10.1186/s13098-020-00567-7; Demoz GT, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222985; Eticha T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120560; Getenet A, 2019, JRSM CARDIOVASC DIS, V8, DOI 10.1177/2048004019892758; Haynes RB, 2002, JAMA-J AM MED ASSOC, V288, P2880, DOI 10.1001/jama.288.22.2880; Kardas P., 2012, ABC PROJECT FINAL RE; Kassaw Chalachew, 2021, J Psychosoc Rehabil Ment Health, V8, P5, DOI 10.1007/s40737-020-00192-7; Kretchy IA, 2021, RES SOC ADMIN PHARM, V17, P2023, DOI 10.1016/j.sapharm.2020.04.007; Lee GKY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062775; Marmot M, 2002, HEALTH AFFAIR, V21, P31, DOI 10.1377/hlthaff.21.2.31; Martin Leslie R, 2005, Ther Clin Risk Manag, V1, P189; Mesfin Y., 2017, Epidemiology: Open Access, V7, P322, DOI 10.4172/2161-1165.1000322; Midao L, 2018, GERONTOLOGY, DOI [10.5772/intechopen.72070, DOI 10.5772/INTECHOPEN.72070]; Miller TA, 2013, DIABET METAB SYND OB, V6, P421, DOI 10.2147/DMSO.S36368; Misganaw A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1007; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Peacock E, 2017, MED CLIN N AM, V101, P229, DOI 10.1016/j.mcna.2016.08.005; Phillips J., 2008, EVALUATING PATIENT C; RAND CS, 1993, AM J CARDIOL, V72, pD68, DOI 10.1016/0002-9149(93)90014-4; Rathish D, 2019, J HEALTH POPUL NUTR, V38, DOI 10.1186/s41043-019-0161-9; Sabate E., 2001, NONCOMMUNICABLE DIS; Sahile AT, 2020, DIABETES METAB SYNDR, V13, P501, DOI 10.2147/DMSO.S237995; Saqib A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197482; STANTON AL, 1987, J BEHAV MED, V10, P377, DOI 10.1007/BF00846477; Stewart D, 2017, EXPERT OPIN DRUG SAF, V16, P203, DOI 10.1080/14740338.2017.1265503; Teshome DF, 2017, INTEGR BLOOD PRESS C, V10, P1, DOI 10.2147/IBPC.S128914; Tibebu A, 2017, INT J HEALTH SCI-IJH, V11; Uematsu H, 2016, POLICY RES WORKING P; van der Sande MAB, 2000, J HUM HYPERTENS, V14, P489, DOI 10.1038/sj.jhh.1001050; Viswanathan M, 2012, ANN INTERN MED, V157, P785, DOI 10.7326/0003-4819-157-11-201212040-00538; Vrijens B, 2008, BMJ-BRIT MED J, V336, P1114, DOI 10.1136/bmj.39553.670231.25; WHO, 2020, CONTR SIGN ROLL COVI; WHO, 2003, WORLD HLTH REP SHAP, P17; World Bank Group, 2015, ADDIS ABABA ETHIOPIA, P25	48	15	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2021	16	4							e0249222	10.1371/journal.pone.0249222	http://dx.doi.org/10.1371/journal.pone.0249222			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ8VV	33822807	gold, Green Published			2023-01-03	WOS:000637879100011
J	Khatiban, M; Amin, HM; Falahinia, G; Moghimbeigi, A; Yadollahi, M				Khatiban, Mahnaz; Moradi Amin, Hamid; Falahinia, Gholamhosein; Moghimbeigi, Abbas; Yadollahi, Mehran			Polyethylene eye-cover versus artificial teardrops in the prevention of ocular surface diseases in comatose patients: A prospective multicenter randomized triple-blinded three-arm clinical trial	PLOS ONE			English	Article							INTENSIVE-CARE; EXPOSURE KERATOPATHY; RISK-FACTORS; DISORDERS	Background Polyethylene covers are claimed to be useful in preventing ocular surface diseases (OSD); however, evidence of their clinical efficacy is limited. This clinical trial aimed to compare the use of polyethylene eye covers and artificial teardrops versus normal saline on the incidence and severity of OSD in comatose patients. Methods Of 90 eligible patients randomly assigned to three treatment groups, 79 patients completed the study, In group A, patients (n = 25) received artificial teardrops for left and normal saline for right eyes, in group B (n = 29) polyethylene covers for left and normal saline for right eyes, and in group C (n = 25) polyethylene covers for left and artificial teardrops for right eyes. As the patients were comatose, their blinding did not applicable, and a blinded observer evaluated the patients' eyes based on the Corneal Fluorescein Staining Pattern. The blinded analyzer analyzed collected data by SPSS-16 software at a 95% confidential level. Results The OSDs were observed in 65 (41.14%) out of 158 eyes examined. The artificial teardrop was more effective than the normal saline in group A, polyethylene eye cover was more useful than the normal saline in group B, and polyethylene eye cover was more effective than the artificial teardrop in group C in reducing the incidence of OSD (p< 0.01). Polyethylene eye covers had the most impact on reducing the severity of the OSD compared to the other interventions (p< .001). Conclusions Polyethylene eye covers significantly reduced the incidence and severity of OSD. Using polyethylene cover is suggested as a safe, effective, and accessible eye care intervention for preventing OSD in comatose patients.	[Khatiban, Mahnaz] Hamadan Univ Med Sci, Dept Med Surg Nursing, Dept Eth Educ Med Sci, Mother & Child Care Res Ctr,Sch Nursing & Midwife, Hamadan, Hamadan, Iran; [Moradi Amin, Hamid] Hamadan Univ Med Sci, Sch Nursing & Midwifery, Students Res Ctr, Hamadan, Hamadan, Iran; [Falahinia, Gholamhosein] Hamadan Univ Med Sci, Sch Nursing & Midwifery, Chron Dis Home Care Res Ctr, Dept Med Surg Nursing, Hamadan, Hamadan, Iran; [Moghimbeigi, Abbas] Hamadan Univ Med Sci, Dept Biostat & Epidemiol, Modeling Noncommunicable Dis Res Canter, Sch Publ Hlth, Hamadan, Hamadan, Iran; [Yadollahi, Mehran] Hamadan Univ Med Sci, Malayer Mehr Hosp, Hamadan, Hamadan, Iran		Falahinia, G (corresponding author), Hamadan Univ Med Sci, Sch Nursing & Midwifery, Chron Dis Home Care Res Ctr, Dept Med Surg Nursing, Hamadan, Hamadan, Iran.	h.falahinia@gmail.com		Khatiban, Mahnaz/0000-0002-7060-2205	Research and Technology Vice-chancellor of Hamadan University of Medical Sciences [IR.UMSHA.REC.1395.262]	Research and Technology Vice-chancellor of Hamadan University of Medical Sciences	This work was financially supported by the Research and Technology Vice-chancellor of Hamadan University of Medical Sciences (Approval Number: IR.UMSHA.REC.1395.262). The funding source had no role in the course of study, research or assembly of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmadi-Nejad M., 2013, ANN MILITARY HLTH SC, V10, P323; Al Dossary, 2012, J KING ABDULAZIZ U M, V19, P59, DOI [10.4197/Med.19-1S.4, DOI 10.4197/MED.19-1S.4]; Alansari MA, 2015, J INTENSIVE CARE MED, V30, P311, DOI 10.1177/0885066613510674; Ali F, 2015, PAK J OPHTHALMOL, V31, P131; Cosar CB, 2018, INDIAN J OPHTHALMOL, V66, P202, DOI 10.4103/ijo.IJO_716_17; Dawson Deborah, 2005, Intensive Crit Care Nurs, V21, P119, DOI 10.1016/j.iccn.2005.01.004; de Franca Caroline Fernandes Souza Macedo, 2016, Appl Nurs Res, V29, pe14, DOI 10.1016/j.apnr.2015.05.016; Demirel S, 2014, INTENS CRIT CARE NUR, V30, P38, DOI 10.1016/j.iccn.2013.08.001; Evans D., 2006, INT J EVID-BASED HEA, V106, p72A; Ezra DG, 2009, INTENS CARE MED, V35, P455, DOI 10.1007/s00134-008-1284-4; Ghanei M., 2016, J FUNDAM APPL SCI, V8, P16, DOI [10.4314/jfas.v8i2s.555, DOI 10.4314/JFAS.V8I2S.555]; Grealy B., 2019, CRITICAL CARE NURSIN, P103; Grixti A, 2012, OCUL SURF, V10, P26, DOI 10.1016/j.jtos.2011.10.001; Guler EK, 2017, CLIN NURS RES, V26, P504, DOI 10.1177/1054773816631471; Guler EK, 2011, J CLIN NURS, V20, P1916, DOI 10.1111/j.1365-2702.2010.03559.x; Hearne Benjamin J, 2018, J Intensive Care Soc, V19, P345, DOI 10.1177/1751143718764529; Hillier S, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-23; Koroloff N, 2004, INTENS CARE MED, V30, P1122, DOI 10.1007/s00134-004-2203-y; Logan, 2004, CLIN INTENSIVE CARE, V15, P23, DOI 10.5539/gjhs.v8n7p212; Marshall Andrea P, 2008, Aust Crit Care, V21, P97, DOI 10.1016/j.aucc.2007.10.002; McHugh J, 2008, EYE, V22, P1465, DOI 10.1038/sj.eye.6702930; Oh EG, 2009, J CLIN NURS, V18, P29, DOI 10.1111/j.1365-2702.2008.02388.x; Oliveira RS, 2016, REV PESQUI-CUID FUND, V8, P4423, DOI 10.9789/2175-5361.2016.v8i2.4423-4434; Pellegrini M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.34; Rezaei M., 2016, GLOB J HLTH SCI, V8, P212, DOI 10.5539/gjhs.v8n7p212; Rosenberg JB, 2008, CRIT CARE MED, V36, P3151, DOI 10.1097/CCM.0b013e31818f0ee7; Saritas TB, 2013, SCI WORLD J, DOI 10.1155/2013/182038; Schmidl D, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10080589; Shan H, 2010, INT J OPHTHALMOL-CHI, V3, P346, DOI 10.3980/j.issn.2222-3959.2010.04.16; Sivasankar S, 2006, INDIAN J CRIT CARE M, V10, P11, DOI 10.4103/0972-5229.24683; Taheri-Kharameh Z., 2017, BMJ OPEN, V7, DOI DOI 10.1136/BMJOPEN-2016-015415.177; van der Wekken RJ, 2013, NETH J MED, V71, P204; Werli-Alvarenga A, 2011, REV LAT-AM ENFERM, V19, P1088, DOI 10.1590/S0104-11692011000500005; Whitcher JP, 2010, AM J OPHTHALMOL, V149, P405, DOI 10.1016/j.ajo.2009.09.013; Yim W-y, 2009, EVIDENCE BASED EYE C, DOI [10.5353/th_b4325177, DOI 10.5353/TH_B4325177]	35	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2021	16	4							e0248830	10.1371/journal.pone.0248830	http://dx.doi.org/10.1371/journal.pone.0248830			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RH8NB	33793585	Green Published, gold			2023-01-03	WOS:000636467000006
J	Stegeman, I; Velde, HM; Robe, PAJT; Stokroos, RJ; Smit, AL				Stegeman, I; Velde, H. M.; Robe, P. A. J. T.; Stokroos, R. J.; Smit, A. L.			Tinnitus treatment by vagus nerve stimulation: A systematic review	PLOS ONE			English	Review							MODULATES CORTICAL SYNCHRONY; TONES; PLASTICITY; EFFICACY; SAFETY; SOUND	Background Tinnitus is a phantom sensation of sound, which can have a negative impact on quality of life of those affected. No curative treatments are currently known. Neuromodulation by vagus nerve stimulation has emerged as a new treatment option for tinnitus, though till date the effectiveness remains unclear. Therefore, we aim to review the effect of vagus nerve stimulation on tinnitus distress and tinnitus symptom severity in patients with chronic tinnitus. Methods We searched Pubmed, Embase and the Cochrane Library systematically for RCTs, observational studies and case studies on the effect of VNS treatment for tinnitus on October 29, 2019. Studies including adult patients with subjective tinnitus, comparing transcutaneous or implantable VNS to placebo or no treatment or before and after application of VNS treatment on tinnitus distress and tinnitus symptom severity measured with a validated questionnaire were eligible. The risk of bias was assessed with the appropriate tool for each type of study. Results Our search identified 9 primary studies of which 2 RCTs, 5 cohort studies and 2 case series or reports. 5 studies used transcutaneous VNS treatment and 4 used implanted VNS treatment. 6 studies combined VNS treatment with sound therapy. There was a serious risk of bias in all studies, especially on confounding. Most studies reported a small decrease in tinnitus distress or tinnitus symptom severity. Conclusion Due to methodological limitations and low reporting quality of the included studies, the effect of VNS on tinnitus remains unclear. To draw conclusions for which patient population and to what extent (t)VNS is beneficial in the treatment of tinnitus, a randomised controlled trial should be considered.	[Stegeman, I; Velde, H. M.; Stokroos, R. J.; Smit, A. L.] Univ Med Ctr Utrecht, Dept Otorhinolaryngol Head & Neck Surg, Utrecht, Netherlands; [Stegeman, I; Velde, H. M.; Robe, P. A. J. T.; Stokroos, R. J.; Smit, A. L.] Univ Med Ctr Utrecht Brain Ctr, Univ Med Ctr Utrecht, Utrecht, Netherlands; [Robe, P. A. J. T.] Univ Med Ctr Utrecht, Dept Neurol & Neurosurg, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Stegeman, I (corresponding author), Univ Med Ctr Utrecht, Dept Otorhinolaryngol Head & Neck Surg, Utrecht, Netherlands.; Stegeman, I (corresponding author), Univ Med Ctr Utrecht Brain Ctr, Univ Med Ctr Utrecht, Utrecht, Netherlands.	I.Stegeman@umcutrecht.nl	Stegeman, Inge/AAP-3949-2021	Smit, Adriana L/0000-0001-9126-9969; Stegeman, Inge/0000-0001-5154-7178; Velde, Hedwig/0000-0002-9408-5433				Bottomley JM, 2020, COMPR PSYCHIAT, V98, DOI 10.1016/j.comppsych.2019.152156; Cronlein T, 2016, J PSYCHOSOM RES, V83, P65, DOI 10.1016/j.jpsychores.2016.03.001; De Ridder D, 2015, OTOL NEUROTOL, V36, P575, DOI 10.1097/MAO.0000000000000704; De Ridder D, 2014, NEUROMODULATION, V17, P170, DOI 10.1111/ner.12127; Engineer ND, 2013, HEARING RES, V295, P58, DOI 10.1016/j.heares.2012.10.001; Henry James A, 2008, Trends Amplif, V12, P170, DOI 10.1177/1084713808319941; Hoare DJ., 2015, COCHRANE DB SYST REV, V2015; JJ E., 2017, HARV BUS REV, V2017; Kilgard MP, 2007, HEARING RES, V229, P171, DOI 10.1016/j.heares.2007.01.005; Kraus T, 2007, J NEURAL TRANSM, V114, P1485, DOI 10.1007/s00702-007-0755-z; Kreuzer PM, 2014, BRAIN STIMUL, V7, P740, DOI 10.1016/j.brs.2014.05.003; Langguth B, 2011, WORLD J BIOL PSYCHIA, V12, P489, DOI 10.3109/15622975.2011.575178; Leaver AM, 2011, NEURON, V69, P33, DOI 10.1016/j.neuron.2010.12.002; Lehtimaki J, 2013, ACTA OTO-LARYNGOL, V133, P378, DOI 10.3109/00016489.2012.750736; Mei ZG, 2014, WORLD J ACUPUNCT-MOX, V24, P30, DOI 10.1016/S1003-5257(14)60022-2; Moher D., 2009, PLOS MED PUBLIC LIB, V6, P1, DOI [10.1371/JOURNAL.PMED.1000097, DOI 10.1371/JOURNAL.PMED.1000097]; Moller AR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/608437; Nichols JA, 2011, NEUROSCIENCE, V189, P207, DOI 10.1016/j.neuroscience.2011.05.024; Shim HJ, 2015, J AUDIOL OTOL, V19, P159, DOI 10.7874/jao.2015.19.3.159; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Suk WC, 2018, J INT ADV OTOL, V14, P267, DOI 10.5152/iao.2018.3977; Tyler R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12178-w; Vanneste S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17750-y; Wichova H, 2018, AM J OTOLARYNG, V39, P599, DOI 10.1016/j.amjoto.2018.07.009	25	7	7	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2021	16	3							e0247221	10.1371/journal.pone.0247221	http://dx.doi.org/10.1371/journal.pone.0247221			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX8JZ	33705401	gold, Green Published			2023-01-03	WOS:000629590400002
J	Waldman, W; Kabata, PM; Dines, AM; Wood, DM; Yates, C; Heyerdahl, F; Hovda, KE; Giraudon, I; Dargan, PI; Anand, JS				Waldman, Wojciech; Kabata, Piotr M.; Dines, Alison M.; Wood, David M.; Yates, Christopher; Heyerdahl, Fridtjof; Hovda, Knut Erik; Giraudon, Isabelle; Dargan, Paul, I; Anand, Jacek Sein		Euro-DEN Res Grp	Rhabdomyolysis related to acute recreational drug toxicity-A Euro-DEN study	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; EMERGENCY-DEPARTMENT PATIENTS; SEVERITY; SPECTRUM	Background This study was conducted to retrospectively assess the relationships between: rhabdomyolysis (quantified by creatine kinase (CK) activity) and kidney injury (quantified by serum creatinine concentration), sex, age, body temperature on admission, presence of seizures, and agitation or aggression in patients presenting to the Emergency Department with acute recreational drug toxicity. We also investigated the association with the substances ingested. Methods All presentations to the 16 sentinel Euro-DEN centres in 10 European countries with acute recreational drug toxicity during the first year of the Euro-DEN study (October 2013 to September 2014) were considered. Cases that had abnormal CK activity recorded as part of routine clinical care were divided into 3 cohorts depending on peak CK activity. Cases with normal CK activity were included as a control group (4(th) cohort). Results Only 1,015 (18.4%) of the 5,529 Euro-DEN presentations had CK activity concentration recorded. Of this group 353 (34.8%) had also creatinine concentration measured. There were 375 (36.9%) with minor rhabdomyolysis, 69 (6.8%) with moderate rhabdomyolysis, and 24 (2.4%) with severe rhabdomyolysis; 547 (53.9%) were included in the control group. There was a positive correlation between CK activity and creatinine concentration (correlation coefficient r = 0.71, p<0.0001). There was no correlation between CK activity and body temperature at the time of presentation to the ED (correlation coefficient r = 0.07, p = 0.03). There was a positive correlation between CK activity and length of stay in the hospital (r = 0.31, p<0.001). There was no association between CK activity and the presence of seizures (p = 0.33) or agitation/aggression (p = 0.45), patients age (p = 0.4) or sex (p = 0.25). The 5 most common agents amongst patients presenting with rhabdomyolysis were: cocaine (n = 107; 22.9% presentations), amphetamine (76; 16.2%), cannabis (74; 15.8%), GHB/GBL (72; 15.4%) and heroin (67; 14.3%). The distribution of rhabdomyolysis in 5 most common drugs was (drug; patients with rhabdomyolysis, patients without rhabdomyolysis): cocaine (107, 122), cannabis (74, 117), GHB/GBL (72, 81), amphetamine (76, 66), heroin (67, 70). Conclusions Abnormal values of CK activity occurred in almost half (46.1%) of presentations to the Emergency Department with acute recreational drug toxicity in whom CK activity was measured; however, severe rhabdomyolysis is seen in only a small minority (2.4%). Those with rhabdomyolysis are at significantly higher risk of kidney injury and have a longer length of hospital stay.	[Waldman, Wojciech; Anand, Jacek Sein] Med Univ Gdansk, Dept Clin Toxicol, Gdansk, Poland; [Waldman, Wojciech; Kabata, Piotr M.; Anand, Jacek Sein] Pomeranian Ctr Toxicol, Gdansk, Poland; [Dines, Alison M.; Wood, David M.; Dargan, Paul, I] Guys & St Thomas NHS Fdn Trust, Clin Toxicol, London, England; [Dines, Alison M.; Wood, David M.; Dargan, Paul, I] Kings Hlth Partners, London, England; [Wood, David M.; Dargan, Paul, I] Kings Coll London, Fac Life Sci & Med, London, England; [Yates, Christopher] Hosp Univ Son Espases, Palma De Mallorca, Spain; [Heyerdahl, Fridtjof; Hovda, Knut Erik] Oslo Univ Hosp, Med Div, Oslo, Norway; [Giraudon, Isabelle] European Monitoring Ctr Drugs & Drug Addict EMCDD, Lisbon, Portugal	Fahrenheit Universities; Medical University Gdansk; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; Hospital Universitari Son Espases; University of Oslo	Waldman, W (corresponding author), Med Univ Gdansk, Dept Clin Toxicol, Gdansk, Poland.; Waldman, W (corresponding author), Pomeranian Ctr Toxicol, Gdansk, Poland.		Kabata, Piotr Maciej/AAU-6488-2020; Giraudon, Isabelle/AAS-9560-2021; Yates, Christopher/E-8718-2018	Kabata, Piotr Maciej/0000-0001-9711-348X; Sein Anand, Jacek/0000-0002-7258-8558; Hovda, Knut Erik/0000-0001-6341-8699; Yates, Christopher/0000-0003-0473-5445; Waldman, Wojciech/0000-0001-7986-8539	DPIP/ISEC Programme of the European Union; European Monitoring Centre for Drugs and Drug Addiction; European Commission; Swiss Centre for Applied Human Toxicology (SCAHT)	DPIP/ISEC Programme of the European Union; European Monitoring Centre for Drugs and Drug Addiction; European Commission(European CommissionEuropean Commission Joint Research Centre); Swiss Centre for Applied Human Toxicology (SCAHT)	With financial support from the DPIP/ISEC Programme of the European Union and the European Monitoring Centre for Drugs and Drug Addiction. All the authors had funding from the European Commission through the Euro-DEN project except ML and EL, whose costs were cofunded by the Swiss Centre for Applied Human Toxicology (SCAHT) and KP, IG and RS.	Allison RC, 2003, AM J MED SCI, V326, P79, DOI 10.1097/00000441-200308000-00005; Anand JS, 2011, CLIN TOXICOL, V49, P230; [Anonymous], 2015, FINAL REPORT EUROPEA; Auguie B, 2016, **DATA OBJECT**; Borek HA, 2012, ANN EMERG MED, V60, P103, DOI 10.1016/j.annemergmed.2012.01.005; BRODY SL, 1990, ANN EMERG MED, V19, P1137, DOI 10.1016/S0196-0644(05)81518-5; Brown CVR, 2004, J TRAUMA, V56, P1191, DOI 10.1097/01.TA.0000130761.78627.10; BUSH SP, 1995, ANN EMERG MED, V25, P845, DOI 10.1016/S0196-0644(95)70218-0; Bush SP, 1999, WILD ENVIRON MED, V10, P247, DOI 10.1580/1080-6032(1999)010[0247:NAWSSP]2.3.CO;2; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; Bywaters EGL., 1942, SURG GYNECOL OBS, V75, P612; Cohen J, 2005, ANN EMERG MED, V45, P414, DOI 10.1016/j.annemergmed.2004.06.018; Cunningham M, 1997, Intensive Crit Care Nurs, V13, P216, DOI 10.1016/S0964-3397(97)80056-0; de Meijer AR, 2003, INTENS CARE MED, V29, P1121, DOI 10.1007/s00134-003-1800-5; Delaney KA, 2012, J EMERG MED, V42, P521, DOI 10.1016/j.jemermed.2011.03.008; Dines AM, 2015, CLIN TOXICOL, V53, P893, DOI 10.3109/15563650.2015.1088157; Fernandez WG, 2005, AM J EMERG MED, V23, P1, DOI 10.1016/j.ajem.2004.09.025; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; Goldstein RA, 2009, DM-DIS MON, V55, P6, DOI 10.1016/j.disamonth.2008.10.002; Grunau BE, 2014, ACAD EMERG MED, V21, P631, DOI 10.1111/acem.12385; Jankovic SR, 2013, VOJNOSANIT PREGL, V70, P1039, DOI 10.2298/VSP1311039J; Larbi EB, 1998, ANN SAUDI MED, V18, P525, DOI 10.5144/0256-4947.1998.525; Liakoni E, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009784; Liechti ME, 2005, SWISS MED WKLY, V135, P206; Liechti ME, 2004, SWISS MED WKLY, V134, P534; Melli G, 2005, MEDICINE, V84, P377, DOI 10.1097/01.md.0000188565.48918.41; Persson HE, 1998, J TOXICOL-CLIN TOXIC, V36, P205, DOI 10.3109/15563659809028940; PRENDERGAST BD, 1993, POSTGRAD MED J, V69, P333, DOI 10.1136/pgmj.69.811.333; R-Core-Team, 2016, LANG ENV STAT COMP; Richards JR, 1999, AM J EMERG MED, V17, P681, DOI 10.1016/S0735-6757(99)90159-6; Richards JR, 2000, J EMERG MED, V19, P51, DOI 10.1016/S0736-4679(00)00180-3; ROTH D, 1988, NEW ENGL J MED, V319, P673, DOI 10.1056/NEJM198809153191103; SINGHAL PC, 1990, J TOXICOL-CLIN TOXIC, V28, P321, DOI 10.3109/15563659008994433; Supady A, 2009, DEUT MED WOCHENSCHR, V134, P935, DOI 10.1055/s-0029-1220252; Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681; Traub SJ, 2002, J URBAN HEALTH, V79, P549, DOI 10.1093/jurban/79.4.549; VEENSTRA J, 1994, NEPHROL DIAL TRANSPL, V9, P637, DOI 10.1093/ndt/9.6.637; WARD MM, 1988, ARCH INTERN MED, V148, P1553, DOI 10.1001/archinte.148.7.1553; Warren JD, 2002, MUSCLE NERVE, V25, P332, DOI 10.1002/mus.10053; WELCH RD, 1991, ANN EMERG MED, V20, P154, DOI 10.1016/S0196-0644(05)81215-6; Wickham H., 2016, P R USER C LOS ANG; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wickham H, 2007, J STAT SOFTW, V21, P1; WOODROW G, 1995, RENAL FAILURE, V17, P467, DOI 10.3109/08860229509037610; Zager RA, 1996, KIDNEY INT, V49, P314, DOI 10.1038/ki.1996.48; Zhou X, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071561	46	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2021	16	3							e0246297	10.1371/journal.pone.0246297	http://dx.doi.org/10.1371/journal.pone.0246297			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX8JZ	33705425	Green Published, gold			2023-01-03	WOS:000629590400061
J	Stewart, RAH; Jones, P; Dicker, B; Jiang, YN; Smith, T; Swain, A; Kerr, A; Scott, T; Smyth, D; Ranchord, A; Edmond, J; Than, M; Webster, M; White, HD; Devlin, G				Stewart, Ralph A. H.; Jones, Peter; Dicker, Bridget; Jiang, Yannan; Smith, Tony; Swain, Andrew; Kerr, Andrew; Scott, Tony; Smyth, David; Ranchord, Anil; Edmond, John; Than, Martin; Webster, Mark; White, Harvey D.; Devlin, Gerard			High flow oxygen and risk of mortality in patients with a -suspected acute coronary syndrome: pragmatic, cluster randomised, crossover trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT-ELEVATION; TASK-FORCE; THERAPY; MANAGEMENT	OBJECTIVE To determine the association between high flow supplementary oxygen and 30 day mortality in patients presenting with a suspected acute coronary syndrome (ACS). DESIGN Pragmatic, cluster randomised, crossover trial. SETTING Four geographical regions in New Zealand. PARTICIPANTS 40 872 patients with suspected or confirmed ACS included in the All New Zealand Acute Coronary Syndrome Quality Improvement registry or ambulance ACS pathway during the study periods. 20 304 patients were managed using the high oxygen protocol and 20 568 were managed using the low oxygen protocol. Final diagnosis of ST elevation myocardial infarction (STEMI) and non-STEMI were determined from the registry and ICD-10 discharge codes. INTERVENTIONS The four geographical regions were randomly allocated to each of two oxygen protocols in six month blocks over two years. The high oxygen protocol recommended oxygen at 6-8 L/min by face mask for ischaemic symptoms or electrocardiographic changes, irrespective of the transcapillary oxygen saturation (SpO(2)). The low oxygen protocol recommended oxygen only if SpO(2) was less than 90%, with a target SpO(2) of less than 95%. MAIN OUTCOME MEASURE 30 day all cause mortality determined from linkage to administrative data. RESULTS Personal and clinical characteristics of patients managed under both oxygen protocols were well matched. For patients with suspected ACS, 30 day mortality for the high and low oxygen groups was 613 (3.0%) and 642 (3.1%), respectively (odds ratio 0.97, 95% confidence interval 0.86 to 1.08). For 4159 (10%) patients with STEMI, 30 day mortality for the high and low oxygen groups was 8.8% (n=178) and 10.6% (n=225), respectively (0.81, 0.66 to 1.00) and for 10 218 (25%) patients with non-STEMI was 3.6% (n=187) and 3.5% (n=176), respectively (1.05, 0.85 to 1.29). CONCLUSION In a large patient cohort presenting with suspected ACS, high flow oxygen was not associated with an increase or decrease in 30 day mortality.	[Stewart, Ralph A. H.; Webster, Mark; White, Harvey D.] Auckland City Hosp, Green Lane Cardiovasc Serv, Private Bag 92024, Auckland 1030, New Zealand; [Stewart, Ralph A. H.; Webster, Mark; White, Harvey D.] Univ Auckland, Dept Med, Auckland, New Zealand; [Jones, Peter] Auckland City Hosp, Emergency Med Res, Auckland, New Zealand; [Jones, Peter] Univ Auckland, Dept Surg, Auckland, New Zealand; [Dicker, Bridget] St John Auckland, Auckland, New Zealand; [Dicker, Bridget] Auckland Univ Technol, Paramed Dept, Auckland, New Zealand; [Jiang, Yannan] Univ Auckland, Natl Inst Hlth Innovat, Auckland, New Zealand; [Smith, Tony] St John Ambulance, Auckland, New Zealand; [Swain, Andrew] Wellington Free Ambulance, Wellington, New Zealand; [Kerr, Andrew] Middlemore Hosp, Dept Cardiol, Otahuhu, Aukland, New Zealand; [Kerr, Andrew] Univ Auckland, Sect Epidemiol & Biostat, Auckland, New Zealand; [Scott, Tony] Northshore Hosp, Cardiol Dept, Auckland, New Zealand; [Smyth, David] Canterbury Dist Hlth Board, Christchurch, New Zealand; [Ranchord, Anil] Wellington Hosp, Cardiol Dept, Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Edmond, John] Southern Dist Hlth Board, Dunedin, New Zealand; [Edmond, John] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand; [Than, Martin] Christchurch Hosp, Dept Emergency Med, Christchurch, New Zealand; [Devlin, Gerard] Hauroa Tairawhiti Gisborne & Heart Fdn New Zealan, Gisborn, New Zealand	Auckland City Hospital; University of Auckland; Auckland City Hospital; University of Auckland; Auckland University of Technology; University of Auckland; University of Auckland; Dunedin Public Hospital; University of Otago; Christchurch Hospital New Zealand	Stewart, RAH (corresponding author), Auckland City Hosp, Green Lane Cardiovasc Serv, Private Bag 92024, Auckland 1030, New Zealand.; Stewart, RAH (corresponding author), Univ Auckland, Dept Med, Auckland, New Zealand.	rstewart@adhb.govt.nz	Dicker, Bridget/F-8770-2019	Dicker, Bridget/0000-0002-8151-7356	National Heart Foundation of New Zealand [1649]; Health Research Council of New Zealand (HRC); Ministry of Health [ANZACS-QI 41]; HRC	National Heart Foundation of New Zealand; Health Research Council of New Zealand (HRC)(Health Research Council of New Zealand); Ministry of Health; HRC	This work was supported by the National Heart Foundation of New Zealand (grant No 1649) and by the Health Research Council of New Zealand (HRC) clinical practitioner fellowships to RAHS and MT. The trial was undertaken as part of the All New Zealand Acute Coronary Syndrome Quality Improvement (ANZACS-QI), which is funded by the Ministry of Health (ANZACS-QI 41). Data linkage for mortality was obtained through the VIEW programme funded by the HRC. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.	Amsterdam, 2014, CIRCULATION, V130, pE433, DOI [10.1161/CIR.0000000000000151, 10.1161/CIR.0000000000000134]; Atkinson J., 2014, NZDEP2013 INDEX DEPR; Beasley R, 2007, J ROY SOC MED, V100, P130, DOI 10.1258/jrsm.100.3.130; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; Hofmann R, 2017, NEW ENGL J MED, V377, P1240, DOI 10.1056/NEJMoa1706222; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; James SK, 2020, JACC-CARDIOVASC INTE, V13, P502, DOI 10.1016/j.jcin.2019.09.016; Kerr AJ, 2016, NEW ZEAL MED J, V129, P23; Kerr AJ, 2019, NEW ZEAL MED J, V132, P19; Kohn MA, 2005, J EMERG MED, V29, P383, DOI 10.1016/j.jemermed.2005.04.010; McNulty PH, 2005, AM J PHYSIOL-HEART C, V288, pH1057, DOI 10.1152/ajpheart.00625.2004; O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729; O'Gara PT, 2013, J AM COLL CARDIOL, V61, P485, DOI [10.1016/j.jacc.2012.11.018, 10.1161/CIR.0b013e3182742c84]; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Sepehrvand N, 2018, HEART, V104, P1691, DOI 10.1136/heartjnl-2018-313089; Stub D, 2015, CIRCULATION, V131, P2143, DOI 10.1161/CIRCULATIONAHA.114.014494; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012	17	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	2021	372								n355	10.1136/bmj.n355	http://dx.doi.org/10.1136/bmj.n355			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR6QF	33653685	hybrid, Green Published			2023-01-03	WOS:000625340300013
J	Meganck, RM; Baric, RS				Meganck, Rita M.; Baric, Ralph S.			Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases	NATURE MEDICINE			English	Review							RESPIRATORY SYNDROME CORONAVIRUS; FULLY HUMAN-ANTIBODIES; OPEN-LABEL; FUNCTIONAL RECEPTOR; DOUBLE-BLIND; HUMAN-CELLS; VIRUS; REPLICATION; EFFICACY; INHIBITION	The twenty-first century has already recorded more than ten major epidemic or pandemic virus emergence events, including the ongoing and devastating coronavirus disease 2019 (COVID-19) pandemic. As viral disease emergence is expected to accelerate, these data dictate a need for proactive approaches to develop broadly active family-specific and cross-family therapeutics for use in future disease outbreaks. Emphasis should focus not only on the development of broad-spectrum small-molecule and antibody direct-acting antivirals, but also on host-factor therapeutics, including repurposing previously approved or in-pipeline drugs. Another new class of therapeutics with great antiviral therapeutic potential is RNA-based therapeutics. Rather than only focusing on known risks, dedicated efforts must be made toward pre-emptive research focused on outbreak-prone virus families, ultimately offering a strategy to shorten the gap between outbreak and response. Emphasis should also focus on orally available drugs for outpatient use, if possible, and on identifying combination therapies that combat viral and immune-mediated pathologies, extend the effectiveness of therapeutic windows and reduce drug resistance. While such an undertaking will require new vision, dedicated funding and private, federal and academic partnerships, this approach offers hope that global populations need never experience future pandemics such as COVID-19. As the emergence of viral diseases is expected to accelerate, proactive programs to develop broadly active family-specific and cross-family antiviral therapeutics will be key to prepare for future disease outbreaks.	[Meganck, Rita M.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill	Baric, RS (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.	rbaric@email.unc.edu		Meganck, Rita/0000-0003-2799-3754; Baric, Ralph/0000-0001-6827-8701				Abbott TR, 2020, CELL, V181, P865, DOI 10.1016/j.cell.2020.04.020; Ahmed AE, 2019, J INFECT PUBLIC HEAL, V12, P767, DOI 10.1016/j.jiph.2019.04.002; Ahn DG, 2011, ANTIVIR RES, V91, P1, DOI 10.1016/j.antiviral.2011.04.009; Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anderson KP, 1996, ANTIMICROB AGENTS CH, V40, P2004, DOI 10.1128/AAC.40.9.2004; Andreakos E, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012465; Arankalle VA, 2007, J GEN VIROL, V88, P1967, DOI 10.1099/vir.0.82714-0; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Balwani M, 2020, NEW ENGL J MED, V382, P2289, DOI 10.1056/NEJMoa1913147; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Benson MD, 2018, NEW ENGL J MED, V379, P22, DOI 10.1056/NEJMoa1716793; Bente DA, 2013, ANTIVIR RES, V100, P159, DOI 10.1016/j.antiviral.2013.07.006; Braun E, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1073; Burt Felicity J, 2017, Lancet Infect Dis, V17, pe107, DOI 10.1016/S1473-3099(16)30385-1; Cai QX, 2020, ENGINEERING-PRC, V6, P1192, DOI 10.1016/j.eng.2020.03.007; Carlsson L, 2018, MOL THER-METH CLIN D, V9, P330, DOI 10.1016/j.omtm.2018.04.003; Chen CC, 2021, FEBS J, V288, P5089, DOI 10.1111/febs.15696; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Cherry James D, 2004, Paediatr Respir Rev, V5, P262, DOI 10.1016/j.prrv.2004.07.009; Chhabra P, 2019, J GEN VIROL, V100, P1393, DOI 10.1099/jgv.0.001318; Chong HT, 2001, ANN NEUROL, V49, P810, DOI 10.1002/ana.1062; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; de Graaf M, 2016, NAT REV MICROBIOL, V14, P421, DOI 10.1038/nrmicro.2016.48; de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; Dijkman R, 2013, J VIROL, V87, P6081, DOI 10.1128/JVI.03368-12; Eberhardt KA, 2019, INT J INFECT DIS, V87, P15, DOI 10.1016/j.ijid.2019.07.015; Edwards CE, 2020, P NATL ACAD SCI USA, V117, P26915, DOI [10.1073/pnas.2001046117, 10.1073/pnas.2001046117/-/DCSupplemental]; Epstein JH, 2017, REV SCI TECH OIE, V36, P499, DOI 10.20506/rst.36.2.2669; Field HE, 2016, CURR OPIN VIROL, V16, P120, DOI 10.1016/j.coviro.2016.02.004; Flies EJ, 2015, VECTOR-BORNE ZOONOT, V15, P397, DOI 10.1089/vbz.2014.1759; Forrester NL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005693; Garnett LE, 2019, CURR OPIN VIROL, V37, P123, DOI 10.1016/j.coviro.2019.07.009; Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2; Glasgow Anum, 2020, bioRxiv, DOI 10.1101/2020.07.31.231746; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Gorbea C, 2017, NATURE, V550, P275, DOI 10.1038/nature24034; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0; Hampson L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147917; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641; Hashem H, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.598038; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Himeidan YE, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00169; Holmes EC, 2016, NATURE, V538, P193, DOI 10.1038/nature19790; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273, 10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.07.15.20151852]; Hou Yixuan J, 2020, bioRxiv, DOI 10.1101/2020.09.28.317685; Hua YM, 2010, GENE DEV, V24, P1634, DOI 10.1101/gad.1941310; Hung IFN, 2017, CHEST, V151, P1069, DOI 10.1016/j.chest.2016.11.012; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07; Ivanov Andrei I., 2008, V440, P15, DOI 10.1007/978-1-59745-178-9_2; Jan E, 2016, ANNU REV VIROL, V3, P283, DOI 10.1146/annurev-virology-100114-055014; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09; Kalenga OI, 2019, NEW ENGL J MED, V381, P373, DOI 10.1056/NEJMsr1904253; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Kauffman EB, 2017, J INFECT DIS, V216, pS976, DOI 10.1093/infdis/jix405; Kim JI, 2012, J MICROBIOL, V50, P359, DOI 10.1007/s12275-012-2163-9; Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3; Klemm T, 2020, EMBO J, V39, DOI 10.15252/embj.2020106275; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li Y, 2015, CELL RES, V25, P1237, DOI 10.1038/cr.2015.113; Lindsey NP, 2018, AM J TROP MED HYG, V98, P1472, DOI 10.4269/ajtmh.17-0927; Linsky TW, 2020, SCIENCE, V370, P1208, DOI 10.1126/science.abe0075; Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Luo CM, 2018, J VIROL, V92, DOI 10.1128/JVI.00116-18; Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113; Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985; Meng B, 2006, MOL BIOTECHNOL, V33, P141, DOI 10.1385/MB:33:2:141; Messer WB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001486; Middleton D, 2014, EMERG INFECT DIS, V20, P372, DOI 10.3201/eid2003.131159; Milewska A, 2018, J VIROL, V92, DOI 10.1128/JVI.01933-17; Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021; Neumann G, 2010, CELL RES, V20, P51, DOI 10.1038/cr.2009.124; Neumann G, 2009, NATURE, V459, P931, DOI 10.1038/nature08157; Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955; Osterholm MT, 2015, MBIO, V6, DOI 10.1128/mBio.00137-15; Pascal KE, 2015, P NATL ACAD SCI USA, V112, P8738, DOI 10.1073/pnas.1510830112; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Phelps KL, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030240; Pillai VS, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040465; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prakash TP, 2014, NUCLEIC ACIDS RES, V42, P8796, DOI 10.1093/nar/gku531; Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rappazzo CG, 2021, SCIENCE, V371, P823, DOI 10.1126/science.abf4830; Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1; Rossignol JF, 2006, LANCET, V368, P124, DOI 10.1016/S0140-6736(06)68852-1; Sarker D, 2020, CLIN CANCER RES, V26, P3936, DOI 10.1158/1078-0432.CCR-20-0414; Sharif-Yakan A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004457; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; Sissoko D, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001967; Stebbing J, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012697; Sugo T, 2016, J CONTROL RELEASE, V237, P1, DOI 10.1016/j.jconrel.2016.06.036; Sun D, 2020, ACTA PHARMACOL SIN, V41, P119, DOI 10.1038/s41401-019-0288-7; Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010; Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020; Szabat M, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9110925; Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458; Tang HQ, 2021, BIOTECHNOL BIOENG, V118, P1405, DOI 10.1002/bit.27636; The Complex Trait Consortium, 2018, NAT GENET, V36, P1133; Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503; Veiga N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06936-1; Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424; Wei J, 2021, CELL, V184, P76, DOI 10.1016/j.cell.2020.10.028; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163; Whitten-Bauer C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121555; Widagdo W, 2017, ONE HEALTH-AMSTERDAM, V3, P11, DOI 10.1016/j.onehlt.2016.12.001; Yang JW, 2020, CLIN MICROBIOL INFEC, V26, P1171, DOI 10.1016/j.cmi.2020.06.020; Yang LL, 2020, CELL STEM CELL, V27, P125, DOI 10.1016/j.stem.2020.06.015; Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100; Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x; Zhang M, 2021, ADV SCI, V8, DOI 10.1002/advs.202002928; Zhang WF, 2020, J PHYS CHEM LETT, V11, P4430, DOI 10.1021/acs.jpclett.0c00571; Zhou JH, 2018, THERANOSTICS, V8, P1575, DOI 10.7150/thno.23085; Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zou G, 2011, ANTIVIR RES, V91, P11, DOI 10.1016/j.antiviral.2011.05.001	128	49	49	9	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					401	410		10.1038/s41591-021-01282-0	http://dx.doi.org/10.1038/s41591-021-01282-0			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33723456	Green Submitted, Bronze			2023-01-03	WOS:000629708300018
J	Mahmood, MA; Hendarto, H; Laksana, MAC; Damayanti, HE; Suhargono, MH; Pranadyan, R; Santoso, KH; Redjeki, KS; Winard, B; Prasetyo, B; Vercruyssen, J; Moss, JR; Bi, P; Masitah, S; Warsiti; Pratama, AW; Dewi, ER; Listiyani, CH; Mufidah, I				Mahmood, Mohammad Afzal; Hendarto, Hendy; Laksana, Muhammad Ardian Cahya; Damayanti, Hanifa Erlin; Suhargono, Mohammad Hud; Pranadyan, Rizki; Santoso, Kohar Hari; Redjeki, Kartika Sri; Winard, Baksono; Prasetyo, Budi; Vercruyssen, Jorien; Moss, John Robert; Bi, Peng; Masitah, Syarifah; Warsiti; Pratama, Aldilia Wyasti; Dewi, Erni Rosita; Listiyani, Charity Hartika; Mufidah, Ismi			Health system and quality of care factors contributing to maternal deaths in East Java, Indonesia	PLOS ONE			English	Article								Despite most Indonesian women now receiving antenatal care on the nationally recommended four occasions and being delivered by skilled birth attendants, the nation's maternal mortality ratio (MMR) is estimated as 177 per 100,000 live births. Recent research in a rural district of Indonesia has indicated that poor service quality due to organizational and personnel factors is now a major determinant of this high MMR. The present research is an indepth analysis of possible health service organizational and quality of care related causes of death among 30 women admitted to a peak referral hospital in a major Indonesian city. Despite their condition being complex or deteriorating, most of these women arrived at the hospital in a state where it was feasible to prevent death with good quality care. Poor application of protocols, poor information flow from frontline hospitals to the peak referral hospital, delays in emergency care, and delays in management of deteriorating patients were the main contributing factors to these deaths. Pyramidal referrals also contributed, as many women were initially referred to hospitals where their condition could not be effectively managed. While generic quality improvement measures, particularly training and monitoring for rigorous application of clinical protocols (including forward planning for deteriorating patients) will help improve the situation, the districts and hospitals need to develop capacity to assess their local situation. Unless local organisational factors, staff knowledge and skill, blood and blood product availability, and local reasons for delays in providing care are identified, it may not be possible to effectively reduce the adverse pregnancy outcomes.	[Mahmood, Mohammad Afzal; Moss, John Robert; Bi, Peng] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia; [Mahmood, Mohammad Afzal] Univ Airlangga, Fac Med, Surabaya, Indonesia; [Hendarto, Hendy; Laksana, Muhammad Ardian Cahya; Damayanti, Hanifa Erlin; Pranadyan, Rizki; Winard, Baksono; Prasetyo, Budi] Univ Airlangga, Soetomo Teaching Hosp, Fac Med, Dept Obstet & Gynaecol, Surabaya, Indonesia; [Hendarto, Hendy; Laksana, Muhammad Ardian Cahya; Damayanti, Hanifa Erlin; Pranadyan, Rizki; Winard, Baksono; Prasetyo, Budi; Warsiti] Soetomo Teaching Hosp, Surabaya, East Java, Indonesia; [Suhargono, Mohammad Hud] Bangil Gen Hosp, Jawa Timur, Indonesia; [Santoso, Kohar Hari; Redjeki, Kartika Sri] Dept Hlth, Surabaya, Indonesia; [Vercruyssen, Jorien] Antwerp Univ Hosp, Obstet Dept, Edegem, Belgium; [Masitah, Syarifah] Wahab Syaharani Hosp, Samarinda, Indonesia; [Pratama, Aldilia Wyasti; Dewi, Erni Rosita; Listiyani, Charity Hartika] Univ Airlangga, Fac Med, Sch Midwifery, Surabaya, Indonesia; [Mufidah, Ismi] Dept Hlth, Kutai Kartanegara, Kalimantan Timu, Indonesia	University of Adelaide; Airlangga University; Airlangga University; University of Antwerp; Airlangga University	Mahmood, MA (corresponding author), Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia.; Mahmood, MA (corresponding author), Univ Airlangga, Fac Med, Surabaya, Indonesia.	afzal.mahmood@adelaide.edu.au		Rosita Dewi, Erni/0000-0002-1328-7800; Prasetyo, Budi/0000-0002-7237-9959				Badan Pusat Statistik, 2017, PROVINSI JAVA TIMUR; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Brenner S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123968; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Campbell OMR, 2016, LANCET, V388, P2193, DOI 10.1016/S0140-6736(16)31528-8; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; East Java Department of Health, 2018, E JAVA HLTH PROFILE; East Java Department of Health, 2017, E JAVA HLTH PROFILE; Farquhar C, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.07.044; Halim A, 2014, BJOG-INT J OBSTET GY, V121, P86, DOI 10.1111/1471-0528.13010; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Kruk ME, 2018, LANCET, V392, P2203, DOI [10.1016/S0140-6736(18)31668-4, 10.1016/s0140-6736(18)31668-4]; Mahmood MA, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3673265; Maternal Mortality Estimation Inter-agency Group, 2020, MATERNAL MORTALITY 2; Mboi N, 2018, LANCET, V392, P581, DOI 10.1016/S0140-6736(18)30595-6; Miller S, 2016, LANCET, V388, P2176, DOI 10.1016/S0140-6736(16)31472-6; Ministry of Health Republic of Indonesia., 2018, INDONESIA HLTH PROFI; NHS, 2010, CONTRIBUTORY FACTORS; Pedrana A, 2019, INT J GYNECOL OBSTET, V144, P42, DOI 10.1002/ijgo.12734; Renfrew MJ, 2014, LANCET, V384, P1129, DOI 10.1016/S0140-6736(14)60789-3; Singh S, 2016, PLOS, DOI [10.1371/journal.pone.0159793, DOI 10.1371/JOURNAL.PONE.0159793]; Souza JP, 2014, BJOG-INT J OBSTET GY, V121, P1, DOI 10.1111/1471-0528.12735; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Tholandi M, 2019, INT J GYNECOL OBSTET, V144, P21, DOI 10.1002/ijgo.12732; Tort J, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0669-y; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; World Health Organization, 2018, WHO RECOMMENDATIONS; World Health Organization, 2015, JAPAN TURNING CORNER	28	7	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2021	16	2							e0247911	10.1371/journal.pone.0247911	http://dx.doi.org/10.1371/journal.pone.0247911			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BP	33635928	Green Published, gold			2023-01-03	WOS:000624538400020
J	Sada, YH; Poursina, O; Zhou, H; Workeneh, BT; Maddali, SV; Najafi, B				Sada, Yvonne H.; Poursina, Olia; Zhou, He; Workeneh, Biruh T.; Maddali, Sandhya, V; Najafi, Bijan			Harnessing digital health to objectively assess cancer-related fatigue: The impact of fatigue on mobility performance	PLOS ONE			English	Article								Objective Cancer-related fatigue (CRF) is highly prevalent among cancer survivors, which may have long-term effects on physical activity and quality of life. CRF is assessed by self-report or clinical observation, which may limit timely diagnosis and management. In this study, we examined the effect of CRF on mobility performance measured by a wearable pendant sensor. Methods This is a secondary analysis of a clinical trial evaluating the benefit of exercise in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN). CRF status was classified based on a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score <= 33. Among 28 patients (age = 65.7 +/- 9.8 years old, BMI = 26.9 +/- 4.1 kg/m(2), sex = 32.9% female) with database variables of interest, twenty-one subjects (75.9%) were classified as non-CRF. Mobility performance, including behavior (sedentary, light, and moderate to vigorous activity (MtV)), postures (sitting, standing, lying, and walking), and locomotion (e.g., steps, postural transitions) were measured using a validated pendant-sensor over 24-hours. Baseline psychosocial, Functional Assessment of Cancer Therapy-General (FACT-G), Falls Efficacy Scale-International (FES-I), and motor-capacity assessments including gait (habitual speed, fast speed, and dual-task speed) and static balance were also performed. Results Both groups had similar baseline clinical and psychosocial characteristics, except for bodymass index (BMI), FACT-G, FACIT-F, and FES-I (p<0.050). The groups did not differ on motor-capacity. However, the majority of mobility performance parameters were different between groups with large to very large effect size, Cohen's d ranging from 0.91 to 1.59. Among assessed mobility performance, the largest effect sizes were observed for sedentary-behavior (d = 1.59, p = 0.006), light-activity (d = 1.48, p = 0.009), and duration of sitting +lying (d = 1.46, p = 0.016). The largest correlations between mobility performance and FACIT-F were observed for sitting+lying (rho = -0.67, p<0.001) and the number of steps per day (rho = 0.60, p = 0.001). Conclusion The results of this study suggest that sensor-based mobility performance monitoring could be considered as a potential digital biomarker for CRF assessment. Future studies warrant evaluating utilization of mobility performance to track changes in CRF over time, response to CRF-related interventions, and earlier detection of CRF.	[Sada, Yvonne H.] Baylor Coll Med, Dan L Duncan Canc Ctr, Sect Hematol & Oncol, Dept Med, Houston, TX 77030 USA; [Sada, Yvonne H.] Michael E DeBakey VA Med Ctr, Houston VA Ctr Innovat Qual Effectiveness & Safet, Houston, TX USA; [Poursina, Olia; Zhou, He; Maddali, Sandhya, V; Najafi, Bijan] Baylor Coll Med, Michael E DeBakey Dept Surg, Interdisciplinary Consortium Adv Mot Performance, Houston, TX 77030 USA; [Workeneh, Biruh T.] MD Anderson Canc Ctr, Dept Nephrol, Div Internal Med, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Najafi, B (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Interdisciplinary Consortium Adv Mot Performance, Houston, TX 77030 USA.	najafi.bijan@gmail.com	Najafi, Bijan/AAK-5650-2020	Najafi, Bijan/0000-0002-0320-8101	National Institutes of Health/National Cancer Institute [1R21CA190933-01A1]; National Institutes of Health/National Institute on Aging [1R42AG060853-01]; Baylor College of Medicine	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Baylor College of Medicine	This study was supported by the National Institutes of Health/National Cancer Institute (award number 1R21CA190933-01A1), the National Institutes of Health/National Institute on Aging (award number 1R42AG060853-01), and internal support from Baylor College of Medicine. There was no additional external funding received for this study. The content is solely the responsibility of the authors and does not necessarily represent the official views of sponsors.	Aminian K, 2002, J BIOMECH, V35, P689, DOI 10.1016/S0021-9290(02)00008-8; [Anonymous], STAT POWER ANAL BEHA; Berendsen BAJ, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-749; Bracewell N, 2012, DIABETIC MED, V29, P1553, DOI 10.1111/j.1464-5491.2012.03729.x; Brucker PS, 2005, EVAL HEALTH PROF, V28, P192, DOI 10.1177/0163278705275341; Butt Z, 2013, J PSYCHOSOM RES, V74, P64, DOI 10.1016/j.jpsychores.2012.10.011; Campbell PT, 2013, J CLIN ONCOL, V31, P876, DOI 10.1200/JCO.2012.45.9735; Cohen Adam B, 2018, Digit Biomark, V2, P94, DOI 10.1159/000492396; D'Silva A, 2018, LUNG CANCER, V119, P78, DOI 10.1016/j.lungcan.2018.03.010; Delbaere K, 2010, AGE AGEING, V39, P210, DOI 10.1093/ageing/afp225; Di Maio M, 2015, J CLIN ONCOL, V33, P910, DOI 10.1200/JCO.2014.57.9334; Ebede CC, 2017, MED CLIN N AM, V101, P1085, DOI 10.1016/j.mcna.2017.06.007; Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493; Ferriolli E, 2012, J PAIN SYMPTOM MANAG, V43, P1025, DOI 10.1016/j.jpainsymman.2011.06.013; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Gaskin CJ, 2016, CANCER CAUSE CONTROL, V27, P1093, DOI 10.1007/s10552-016-0787-5; George SM, 2013, J PHYS ACT HEALTH, V10, P350, DOI 10.1123/jpah.10.3.350; Giannouli E, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3261567; Gotze H, 2019, J GERIATR ONCOL, V10, P55, DOI 10.1016/j.jgo.2018.05.011; Gresham G, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0032-6; Gresham G, 2018, CONTEMP CLIN TRIALS, V64, P13, DOI 10.1016/j.cct.2017.11.002; Grewal G, 2012, GERONTOLOGY, V58, P463, DOI 10.1159/000338095; Gupta A, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.17.00152; Hilfiker R, 2018, BRIT J SPORT MED, V52, P651, DOI 10.1136/bjsports-2016-096422; Hillel I, 2019, EUR REV AGING PHYS A, V16, DOI 10.1186/s11556-019-0214-5; Hong JS, 2014, CURR ONCOL, V21, P174, DOI 10.3747/co.21.1984; Jansen CP, 2019, EUR REV AGING PHYS A, V16, DOI 10.1186/s11556-019-0223-4; Jones JM, 2016, J CANCER SURVIV, V10, P51, DOI 10.1007/s11764-015-0450-2; Kelly CM, 2016, J ONCOL, V2016, DOI 10.1155/2016/6186543; Kempen GIJM, 2008, AGE AGEING, V37, P45, DOI 10.1093/ageing/afm157; Lindberg CM, 2018, OCCUP ENVIRON MED, V75, P689, DOI 10.1136/oemed-2018-105077; Meneses-Echavez JF, 2015, J PHYSIOTHER, V61, P3, DOI 10.1016/j.jphys.2014.08.019; Minton O, 2009, ANN ONCOL, V20, P17, DOI 10.1093/annonc/mdn537; Najafi B, 2003, IEEE T BIO-MED ENG, V50, P711, DOI 10.1109/TBME.2003.812189; Najafi B, 2002, IEEE T BIO-MED ENG, V49, P843, DOI 10.1109/TBME.2002.800763; Najafi B., 2013, NOVEL WEARABLE TECHN; Najafi B, 2012, DIABETES MANAG, V2, P293, DOI [10.2217/dmt.12.38, DOI 10.2217/DMT.12.38]; Najafi B, 2011, IEEE ENG MED BIO, P6507, DOI 10.1109/IEMBS.2011.6091605; Najafi Bijan, 2010, J Diabetes Sci Technol, V4, P780; Nakagata T, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55030077; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Park J, 2019, SUPPORT CARE CANCER, V27, P1355, DOI 10.1007/s00520-018-4411-y; Phillips SM, 2015, CANCER-AM CANCER SOC, V121, P4044, DOI 10.1002/cncr.29620; Rapp K, 2012, AGING CLIN EXP RES, V24, P455, DOI 10.3275/8264; Razjouyan J, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18051336; Razjouyan J, 2017, J GERONTOL NURS, V43, DOI 10.3928/00989134-20170223-01; Rogers LQ, 2011, J CANCER SURVIV, V5, P54, DOI 10.1007/s11764-010-0160-8; Schwenk M, 2016, GERONTOLOGY, V62, P553, DOI 10.1159/000442253; Shaitelman SF, 2015, JAMA ONCOL, V1, P931, DOI 10.1001/jamaoncol.2015.2666; Stull DE, 2009, CURR MED RES OPIN, V25, P929, DOI [10.1185/03007990902774765, 10.1185/03007990902774765 ]; Swain CTV, 2020, CANCER-AM CANCER SOC, V126, P861, DOI 10.1002/cncr.32578; Ustun TB, 2003, DISABIL REHABIL, V25, P565, DOI 10.1080/0963828031000137063; Vallance JK, 2017, ANN HEMATOL, V96, P749, DOI 10.1007/s00277-017-2942-9; Vallance JK, 2014, CANCER-AM CANCER SOC, V120, P2919, DOI 10.1002/cncr.28779; van Roekel Eline H, 2016, Prev Med Rep, V4, P262, DOI 10.1016/j.pmedr.2016.06.022; van Roekel EH, 2016, CANCER CAUSE CONTROL, V27, P513, DOI 10.1007/s10552-016-0725-6; Wagner LI, 2015, CANCER-AM CANCER SOC, V121, P927, DOI 10.1002/cncr.29104; Wang XS, 2015, GYNECOL ONCOL, V136, P446, DOI 10.1016/j.ygyno.2014.10.013; Weiner LS, 2019, J CANCER SURVIV, V13, P468, DOI 10.1007/s11764-019-00768-8; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Wood TA, 2019, AM J PHYS MED REHAB, V98, P566, DOI 10.1097/PHM.0000000000001152; Yardley L, 2005, AGE AGEING, V34, P614, DOI 10.1093/ageing/afi196; Zahiri M, 2019, J GERIATR ONCOL, V10, P960, DOI 10.1016/j.jgo.2019.01.010; Zhou H, 2019, HARNESSING DIGITAL H; Zhou H, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18113939	65	1	1	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2021	16	2							e0246101	10.1371/journal.pone.0246101	http://dx.doi.org/10.1371/journal.pone.0246101			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QQ5BP	33636720	Green Published, gold			2023-01-03	WOS:000624538400029
J	Conserva, GAA; Quiros-Guerrero, LM; Costa-Silva, TA; Marcourt, L; Pinto, EG; Tempone, AG; Fernandes, JPS; Wolfender, JL; Queiroz, EF; Lago, JHG				Alves Conserva, Geanne A.; Quiros-Guerrero, Luis M.; Costa-Silva, Thais A.; Marcourt, Laurence; Pinto, Erika G.; Tempone, Andre G.; Fernandes, Joao Paulo S.; Wolfender, Jean-Luc; Queiroz, Emerson F.; Lago, Joao Henrique G.			Metabolite profile of Nectandra oppositifolia Nees & Mart. and assessment of antitrypanosomal activity of bioactive compounds through efficiency analyses	PLOS ONE			English	Article							MASS-SPECTROMETRY; NATURAL-PRODUCTS; TRYPANOSOMA-CRUZI; CONSTITUENTS; ACID	EtOH extracts from the leaves and twigs of Nectandra oppositifolia Nees & Mart. shown activity against amastigote forms of Trypanosoma cruzi. These extracts were subjected to successive liquid-liquid partitioning to afford bioactive CH2Cl2 fractions. UHPLC-TOF-HRMS/MS and molecular networking were used to obtain an overview of the phytochemical composition of these active fractions. Aiming to isolate the active compounds, both CH2Cl2 fractions were subjected to fractionation using medium pressure chromatography combined with semi-preparative HPLC-UV. Using this approach, twelve compounds (1-12) were isolated and identified by NMR and HRMS analysis. Several isolated compounds displayed activity against the amastigote forms of T. cruzi, especially ethyl protocatechuate (7) with EC50 value of 18.1 mu M, similar to positive control benznidazole (18.7 mu M). Considering the potential of compound 7, protocatechuic acid and its respective methyl (7a), n-propyl (7b), n-butyl (7c), n-pentyl (7d), and n-hexyl (7e) esters were tested. Regarding antitrypanosomal activity, protocatechuic acid and compound 7a were inactive, while 7b-7e exhibited EC50 values from 20.4 to 11.7 mu M, without cytotoxicity to mammalian cells. These results suggest that lipophilicity and molecular complexity play an important role in the activity while efficiency analysis indicates that the natural compound 7 is a promising prototype for further modifications to obtain compounds effective against the intracellular forms of T. cruzi.	[Alves Conserva, Geanne A.; Costa-Silva, Thais A.; Lago, Joao Henrique G.] Fed Univ ABC, Ctr Nat Sci & Humanities, Santo Andre, SP, Brazil; [Quiros-Guerrero, Luis M.; Marcourt, Laurence; Wolfender, Jean-Luc; Queiroz, Emerson F.] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland; [Quiros-Guerrero, Luis M.; Marcourt, Laurence; Wolfender, Jean-Luc; Queiroz, Emerson F.] Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland; [Pinto, Erika G.] Univ Dundee, Sch Life Sci, Drug Discovery Unit, Dundee, Scotland; [Tempone, Andre G.] Adolfo Lutz Inst, Ctr Parasitol & Mycol, Sao Paulo, Brazil; [Fernandes, Joao Paulo S.] Univ Fed Sao Paulo, Dept Pharmaceut Sci, Diadema, SP, Brazil	Universidade Federal do ABC (UFABC); University of Geneva; University of Geneva; University of Dundee; Instituto Adolfo Lutz; Universidade Federal de Sao Paulo (UNIFESP)	Lago, JHG (corresponding author), Fed Univ ABC, Ctr Nat Sci & Humanities, Santo Andre, SP, Brazil.; Wolfender, JL; Queiroz, EF (corresponding author), Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland.; Wolfender, JL; Queiroz, EF (corresponding author), Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland.	jean-luc.wolfender@unige.ch; emerson.ferreira@unige.ch; joao.lago@ufabc.edu.br	Fernandes, João Paulo/H-3617-2012	Fernandes, João Paulo/0000-0002-9089-273X; Lago, Joao Henrique G./0000-0002-1193-8374; Quiros-Guerrero, Luis/0000-0002-1630-8697	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo -FAPESP [2018/07885-1, 2018/10279-6, 2015/23403-9, 2016/20633-6, 2018/18975-1]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Ministerio de Ciencia, Tecnologia y Telecomunicaciones, MICITT from Costa Rica [214171-025]; Swiss National Science Foundation [316030_164095]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo -FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Ministerio de Ciencia, Tecnologia y Telecomunicaciones, MICITT from Costa Rica; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo -FAPESP, projects 2018/07885-1, 2018/10279-6, 2015/23403-9, 2016/20633-6, and 2018/18975-1. 2. Conselho Nacional de Desenvolvimento Cienti ' fico e Tecnologico (CNPq) for scientific research award to J.H.G.L and A.G.T. 3. Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior (CAPES) to fellow to T.A. C.S. L.M.Q.G 4. Ministerio de Ciencia, Tecnologi ' a y Telecomunicaciones, MICITT, from Costa Rica for the Scholarship provided (N 214171-025). 5. Swiss National Science Foundation for the support in the acquisition of the NMR 600 MHz (SNF R'Equip grant 316030_164095).	Al-Taweel AM, 2012, MOLECULES, V17, P2675, DOI 10.3390/molecules17032675; Allard PM, 2016, ANAL CHEM, V88, P3317, DOI 10.1021/acs.analchem.5b04804; Conserva GAA, 2019, PHYTOMEDICINE, V54, P302, DOI 10.1016/j.phymed.2018.09.236; Bern C, 2011, CLIN MICROBIOL REV, V24, P655, DOI 10.1128/CMR.00005-11; Challal S, 2015, PLANTA MED, V81, P1636, DOI 10.1055/s-0035-1545912; Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377; Costa-Silva TA, 2019, J VENOM ANIM TOXINS, V25, P1; Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717; Djoumbou Feunang Yannick, 2016, J Cheminform, V8, P61; Don R, 2014, PARASITOLOGY, V141, P140, DOI 10.1017/S003118201300142X; Durazzo A, 2020, FOODS, V9, DOI 10.3390/foods9030370; Durazzo A, 2019, PHYTOTHER RES, V33, P2221, DOI 10.1002/ptr.6419; Elliott MC, 2004, ORG BIOMOL CHEM, V2, P2003, DOI 10.1039/b404679j; Macias-Villamizar VE, 2015, B LATINOAM CARIBE PL, V14, P317; Gimenez BG, 2010, PHARMAZIE, V65, P148, DOI 10.1691/ph.2010.9733; Grecco SS, 2016, TETRAHEDRON-ASYMMETR, V27, P793, DOI 10.1016/j.tetasy.2016.07.009; HATTORI M, 1987, CHEM PHARM BULL, V35, P3315; Hopkins AL, 2014, NAT REV DRUG DISCOV, V13, P105, DOI 10.1038/nrd4163; Inoue Hiroaki, 2004, Biocontrol Science, V9, P39; Jansen AM, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00010; Leeson PD, 2007, NAT REV DRUG DISCOV, V6, P881, DOI 10.1038/nrd2445; Londero VS, 2020, BIOORG CHEM, V95, DOI 10.1016/j.bioorg.2019.103510; Lovering F, 2009, J MED CHEM, V52, P6752, DOI 10.1021/jm901241e; Mengarda AC, 2020, ACTA TROP, V205, DOI 10.1016/j.actatropica.2020.105350; Morais TR, 2020, SCI REP-UK, V10, P1, DOI [10.1038/s41598-019-56847-4, DOI 10.1038/S41598-019-56847-4]; Nguyen PH, 2010, BIOORG MED CHEM LETT, V20, P4128, DOI 10.1016/j.bmcl.2010.05.067; Oliveira EA, 2019, J NAT PROD, V82, P1177, DOI 10.1021/acs.jnatprod.8b00890; Perez-Molina JA, 2018, LANCET, V391, P82, DOI 10.1016/S0140-6736(17)31612-4; Pluskal T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-395; Queiroz EF, 2019, J CHROMATOGR A, V1598, P85, DOI 10.1016/j.chroma.2019.03.042; Rea A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002556; Rutz A, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.01329; Santini A., 2014, CURR BIOACT COMPD, V10, P1, DOI [10.2174/157340721001140724145924, DOI 10.2174/157340721001140724145924]; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Smith TR, 2006, ORG BIOMOL CHEM, V4, P4186, DOI 10.1039/b611880a; Syah, 2012, J APPL PHARM SCI, V2, P175, DOI DOI 10.7324/JAPS.2012.21231; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; Varela MT, 2019, BIOORG CHEM, V89, DOI 10.1016/j.bioorg.2019.102996; Varela MT, 2018, EUR J PHARM SCI, V122, P31, DOI 10.1016/j.ejps.2018.06.023; Velasco Alejandro, 2020, J Nucl Cardiol, V27, P445, DOI 10.1007/s12350-018-1361-1; Wang MX, 2016, NAT BIOTECHNOL, V34, P828, DOI 10.1038/nbt.3597; WU TS, 1995, PHYTOCHEMISTRY, V40, P121, DOI 10.1016/0031-9422(95)00248-6; Wu YB, 2014, CHEM NAT COMPD+, V50, P603, DOI 10.1007/s10600-014-1033-6; Yang T, 2010, PHARM BIOL, V48, P589, DOI 10.3109/13880200903214231; Zhang ZJ, 2009, FOOD CHEM, V113, P160, DOI 10.1016/j.foodchem.2008.07.061; Zimmermann FO, 2005, TETRAHEDRON LETT, V46, P3201, DOI 10.1016/j.tetlet.2005.03.052	46	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247334	10.1371/journal.pone.0247334	http://dx.doi.org/10.1371/journal.pone.0247334			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BB	33630860	Green Published, gold			2023-01-03	WOS:000624536800056
J	Kim, D; Shea, SM; Ku, DN				Kim, Dongjune; Shea, Susan M.; Ku, David N.			Lysis of arterial thrombi by perfusion of N,N'-Diacetyl-L-cystine (DiNAC)	PLOS ONE			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; VON-WILLEBRAND-FACTOR; THROMBOLYTIC THERAPY; ISCHEMIC-STROKE; CORONARY THROMBOLYSIS; MYOCARDIAL-INFARCTION; N-ACETYLCYSTEINE; ADAMTS13; ABCIXIMAB; ATHEROSCLEROSIS	The search persists for a safe and effective agent to lyse arterial thrombi in the event of acute heart attacks or strokes due to thrombotic occlusion. The culpable thrombi are composed either primarily of platelets and von Willebrand Factor (VWF), or polymerized fibrin, depending on the mechanism of formation. Current thrombolytics were designed to target red fibrin-rich clots, but may be not be efficacious on white VWF-platelet-rich arterial thrombi. We have developed an in vitro system to study the efficacy of known and proposed thrombolytic agents on white clots formed from whole blood in a stenosis with arterial conditions. The agents and adjuncts tested were tPA, ADAMTS-13, abciximab, N-acetyl cysteine, and N,N'-Diacetyl-L-cystine (DiNAC). Most of the agents, including tPA, had little thrombolytic effect on the white clots. In contrast, perfusion of DiNAC lysed thrombi as quickly as 1.5 min, which ranged up to 30 min at lower concentrations, and resulted in an average reduction in surface area of 71 +/- 20%. The clot burden was significantly reduced compared to both tPA and a saline control (p<0.0001). We also tested the efficacy of all agents on red fibrinous clots formed in stagnant conditions. DiNAC did not lyse red clots, whereas tPA significantly lysed red clot over 48 h (p<0.01). These results lead to a novel use for DiNAC as a possible thrombolytic agent against acute arterial occlusions that could mitigate the risk of hyper-fibrinolytic bleeding.	[Kim, Dongjune; Ku, David N.] Georgia Inst Technol, GW Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; [Shea, Susan M.] Washington Univ, Sch Med, St Louis, MO USA	University System of Georgia; Georgia Institute of Technology; Washington University (WUSTL)	Ku, DN (corresponding author), Georgia Inst Technol, GW Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.	david.ku@me.gatech.edu	Shea, Susan/AAJ-6109-2021	Shea, Susan/0000-0003-3756-2747; Kim, Dongjune/0000-0003-1181-7342	L.P. Huang Chair	L.P. Huang Chair	This study was funded by L.P. Huang Chair.	Adams HP, 2000, STROKE, V31, P601; Aponte-Santamaria C, 2015, BIOPHYS J, V108, P2312, DOI 10.1016/j.bpj.2015.03.041; ASTRUP T, 1947, NATURE, V159, P681, DOI 10.1038/159681b0; ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; Bannish BE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06383-w; BERGMANN SR, 1983, SCIENCE, V220, P1181; Bhatia R, 2010, STROKE, V41, P2254, DOI 10.1161/STROKEAHA.110.592535; Bivard A, 2013, J STROKE, V15, P90, DOI 10.5853/jos.2013.15.2.90; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Buszman PP, 2012, THROMB RES, V130, P265, DOI 10.1016/j.thromres.2011.10.020; CADROY Y, 1989, J LAB CLIN MED, V113, P436; Casa LDC, 2016, J HEMATOLOGY THROMBO, DOI 10.4172/2329-8790.1000249; Chapman SN, 2014, VASC HEALTH RISK MAN, V10, P75, DOI 10.2147/VHRM.S39213; Chen JM, 2011, J CLIN INVEST, V121, P593, DOI 10.1172/JCI41062; COLLEN D, 1984, CIRCULATION, V70, P1012, DOI 10.1161/01.CIR.70.6.1012; Coulter SA, 2000, CIRCULATION, V101, P2690, DOI 10.1161/01.CIR.101.23.2690; Crescente M, 2012, THROMB HAEMOSTASIS, V108, P527, DOI 10.1160/TH12-01-0046; Denorme F, 2016, BLOOD, V127, P2337, DOI 10.1182/blood-2015-08-662650; FRIEDMAN M, 1966, AM J PATHOL, V48, P19; Gogia S, 2015, BIORHEOLOGY, V52, P319, DOI 10.3233/BIR-15061; Griffin MT, 2019, BIOMICROFLUIDICS, V13, DOI 10.1063/1.5113508; Gurevitz O, 1998, ARTERIOSCL THROM VAS, V18, P200, DOI 10.1161/01.ATV.18.2.200; Hastings SM, 2017, RES PRACT THROMB HAE, V1, P1; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JORGENSEN L, 1964, ACTA PATHOL MIC SC, V62, P189, DOI 10.1111/apm.1964.62.2.189; Kim EY, 2006, NEUROLOGY, V67, P1846, DOI 10.1212/01.wnl.0000244492.99737.a8; Ku DN, 2007, BIORHEOLOGY, V44, P273; Kwon OK, 2002, AM J NEURORADIOL, V23, P447; Marder VJ, 2011, J THROMB HAEMOST, V9, P364, DOI 10.1111/j.1538-7836.2011.04370.x; Marder VJ, 2006, STROKE, V37, P2086, DOI 10.1161/01.STR.0000230307.03438.94; Martinez de Lizarrondo S., 2017, CIRCULATION, V136, P646, DOI DOI 10.1161/CIRCULATIONAHA.117.027290; MATSUO O, 1981, THROMB HAEMOSTASIS, V45, P225; MATSUO O, 1981, NATURE, V291, P590, DOI 10.1038/291590a0; Mehrabadi M, 2016, ANN BIOMED ENG, V44, P2339, DOI 10.1007/s10439-016-1550-5; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Muia J, 2014, P NATL ACAD SCI USA, V111, P18584, DOI 10.1073/pnas.1413282112; Para A, 2011, ANN BIOMED ENG, V39, P1961, DOI 10.1007/s10439-011-0296-3; Para AN, 2013, THROMB RES, V131, P418, DOI 10.1016/j.thromres.2013.02.018; Passam Freda J, 2019, Biophys Rev, V11, P419, DOI 10.1007/s12551-019-00543-0; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Pettersson K, 2003, CARDIOVASC DRUG REV, V21, P119; Piebalgs A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34082-7; Prabhakaran S, 2015, JAMA-J AM MED ASSOC, V313, P1451, DOI 10.1001/jama.2015.3058; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Soejima K, 2006, J BIOCHEM, V139, P147, DOI 10.1093/jb/mvj013; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; Tasci TO, 2017, SMALL, V13, DOI 10.1002/smll.201700954; Tersteeg C, 2017, BLOOD, V129, P1030, DOI 10.1182/blood-2016-09-738856; Tersteeg C, 2014, CIRCULATION, V129, P1320, DOI 10.1161/CIRCULATIONAHA.113.006727; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Wagberg M, 2001, J PHARMACOL EXP THER, V299, P76; Wechsler LR, 2011, NEW ENGL J MED, V364, P2138, DOI 10.1056/NEJMct1007370; Wellings PJ, 2012, CARDIOVASC ENG TECHN, V3, P161; Yago T, 2008, J CLIN INVEST, V118, P3195, DOI 10.1172/JCI35754; Zhang XH, 2009, SCIENCE, V324, P1330, DOI 10.1126/science.1170905	55	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247496	10.1371/journal.pone.0247496	http://dx.doi.org/10.1371/journal.pone.0247496			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BB	33630932	Green Published, gold			2023-01-03	WOS:000624536800114
J	van Wincoop, M; De Bijl-Marcus, K; Lilien, M; van den Hoogen, A; Groenendaal, F				van Wincoop, Maureen; De Bijl-Marcus, Karen; Lilien, Marc; van den Hoogen, Agnes; Groenendaal, Floris			Effect of therapeutic hypothermia on renal and myocardial function in asphyxiated (near) term neonates: A systematic review and meta-analysis	PLOS ONE			English	Review							ACUTE KIDNEY INJURY; CARDIAC TROPONIN-I; PERCUTANEOUS CORONARY INTERVENTION; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; PERINATAL ASPHYXIA; NEWBORN-INFANTS; DISEASE; OUTCOMES; FAILURE; TRIAL	Background Therapeutic hypothermia (TH) is a well-established neuroprotective therapy applied in (near) term asphyxiated infants. However, little is known regarding the effects of TH on renal and/or myocardial function. Objectives To describe the short- and long-term effects of TH on renal and myocardial function in asphyxiated (near) term neonates. Methods An electronic search strategy incorporating MeSH terms and keywords was performed in October 2019 and updated in June 2020 using PubMed and Cochrane databases. Inclusion criteria consisted of a RCT or observational cohort design, intervention with TH in a setting of perinatal asphyxia and available long-term results on renal and myocardial function. We performed a meta-analysis and heterogeneity and sensitivity analyses using a random effects model. Subgroup analysis was performed on the method of cooling. Results Of the 107 studies identified on renal function, 9 were included. None of the studies investigated the effects of TH on long-term renal function after perinatal asphyxia. The nine included studies described the effect of TH on the incidence of acute kidney injury (AKI) after perinatal asphyxia. Meta-analysis showed a significant difference between the incidence of AKI in neonates treated with TH compared to the control group (RR = 0.81; 95% CI 0.67-0.98; p = 0.03). No studies were found investigating the long-term effects of TH on myocardial function after neonatal asphyxia. Possible short-term beneficial effects were presented in 4 out of 5 identified studies, as observed by significant reductions in cardiac biomarkers and less findings of myocardial dysfunction on ECG and cardiac ultrasound. Conclusions TH in asphyxiated neonates reduces the incidence of AKI, an important risk factor for chronic kidney damage, and thus is potentially renoprotective. No studies were found on the long-term effects of TH on myocardial function. Short-term outcome studies suggest a cardioprotective effect.	[van Wincoop, Maureen; De Bijl-Marcus, Karen; van den Hoogen, Agnes; Groenendaal, Floris] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Neonatol, Utrecht, Netherlands; [van Wincoop, Maureen; De Bijl-Marcus, Karen; Lilien, Marc; van den Hoogen, Agnes; Groenendaal, Floris] Univ Utrecht, Utrecht, Netherlands; [Lilien, Marc] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Nephrol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	De Bijl-Marcus, K (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Neonatol, Utrecht, Netherlands.; De Bijl-Marcus, K (corresponding author), Univ Utrecht, Utrecht, Netherlands.	k.a.marcus@umcutrecht.nl		de Bijl-Marcus, Karen/0000-0001-5116-6092				Aggarwal A, 2005, J TROP PEDIATRICS, V51, P295, DOI 10.1093/tropej/fmi017; Akisu M, 2003, PROSTAG LEUKOTR ESS, V69, P45, DOI 10.1016/S0952-3278(03)00055-3; [Anonymous], 2014, REV MANAGER REVMAN C; Ashraf M, 2011, SAUDI J KIDNEY DIS T, V22, P1187; Azzopardi D, 2014, NEW ENGL J MED, V371, P140, DOI 10.1056/NEJMoa1315788; Basile DP, 2004, CURR OPIN NEPHROL HY, V13, P1, DOI 10.1097/00041552-200401000-00001; Basile DP, 2003, AM J PHYSIOL-RENAL, V284, pF338, DOI 10.1152/ajprenal.00169.2002; Bhatt GC, 2019, ARCH DIS CHILD, V104, P670, DOI 10.1136/archdischild-2018-315805; Bindroo S, 2022, STATPEARLS; Borenstein M., 2009, INTRO METAANALYSIS, DOI [10. 1002/9780470743386, DOI 10.1002/9780470743386]; Chaturvedi S, 2017, PEDIATR NEPHROL, V32, P227, DOI 10.1007/s00467-015-3298-9; Chou YH, 2017, J FORMOS MED ASSOC, V116, P652, DOI 10.1016/j.jfma.2017.04.026; Cornette L, 2012, FACTS VIEWS VIS OBGY, V4, P133; Diederen CMJ, 2018, THER HYPOTHERMIA TEM, V8, P211, DOI 10.1089/ther.2017.0046; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Erlinge D, 2014, J AM COLL CARDIOL, V63, P1857, DOI 10.1016/j.jacc.2013.12.027; Giannakis S, 2020, ACTA PAEDIATR, V109, P200, DOI 10.1111/apa.14979; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gotberg M, 2010, CIRC-CARDIOVASC INTE, V3, P400, DOI 10.1161/CIRCINTERVENTIONS.110.957902; Greenberg JH, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-184; Grines C., 2004, 16 ANN TRANSC CARD O; Groenendaal F, 2013, NEONATOLOGY, V104, P15, DOI 10.1159/000348823; Guillet R, 2012, PEDIATR RES, V71, P205, DOI 10.1038/pr.2011.30; Gulczynska EM, 2019, GINEKOL POL, V90, P403, DOI 10.5603/GP.2019.0069; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Gupta BD, 2005, INDIAN PEDIATR, V42, P928; Hankins GDV, 2002, OBSTET GYNECOL, V99, P688, DOI 10.1016/S0029-7844(02)01959-2; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Huang CH, 2009, ACAD EMERG MED, V16, P872, DOI 10.1111/j.1553-2712.2009.00495.x; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; JAYASHREE G, 1991, Indian Pediatrics, V28, P19; JEDEIKIN R, 1983, ARCH DIS CHILD, V58, P605, DOI 10.1136/adc.58.8.605; Jetton JG, 2017, LANCET CHILD ADOLESC, V1, P184, DOI 10.1016/S2352-4642(17)30069-X; Karlowicz MG, 1995, PEDIATR NEPHROL, V9, P718, DOI 10.1007/BF00868721; Kaur S, 2011, ANN TROP PAEDIATR, V31, P129, DOI 10.1179/146532811X12925735813922; Kicinski M, 2015, STAT MED, V34, P2781, DOI 10.1002/sim.6525; Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930; LaRosa DA, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00016; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Liu X, 2013, RESUSCITATION, V84, P1562, DOI 10.1016/j.resuscitation.2013.07.003; Liu X, 2011, PEDIATR RES, V70, P352, DOI 10.1203/PDR.0b013e31822941ee; MARTINANCEL A, 1995, J PEDIATR-US, V127, P786, DOI 10.1016/S0022-3476(95)70174-5; Mertens L, 2011, J AM SOC ECHOCARDIOG, V24, P1057, DOI 10.1016/j.echo.2011.07.014; National Heart Lung and Blood Institute, STUDY QUALITY ASSESS; Nestaas E, 2014, EARLY HUM DEV, V90, P247, DOI 10.1016/j.earlhumdev.2014.01.014; Nichol G, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.114.001965; Noc Marko, 2017, EuroIntervention, V13, pe531, DOI 10.4244/EIJ-D-17-00279; ONeill W, 2003, 15 ANN TRANSC CARD S; Peliowski-Davidovich A, 2012, PAED CHILD HEALT-CAN, V17, P41, DOI 10.1093/pch/17.1.41; Polglase GR, 2016, CLIN PERINATOL, V43, P469, DOI 10.1016/j.clp.2016.04.006; Rakesh K, 2018, J MATERN-FETAL NEO M, V31, P2418, DOI 10.1080/14767058.2017.1344633; Roka A, 2007, ACTA PAEDIATR, V96, P1118, DOI 10.1111/j.1651-2227.2007.00361.x; Sarkar S, 2014, PEDIATR RES, V75, P431, DOI 10.1038/pr.2013.230; Saw CL, 2019, J CHILD NEUROL, V34, P402, DOI 10.1177/0883073819828625; See EJ, 2019, KIDNEY INT, V95, P160, DOI 10.1016/j.kint.2018.08.036; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Shastri AT, 2012, ACTA PAEDIATR, V101, P26, DOI 10.1111/j.1651-2227.2011.02432.x; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Tanigasalam V, 2016, J MATERN-FETAL NEO M, V29, P2544, DOI 10.3109/14767058.2015.1094785; Teixeira RP, 2017, J PEDIATR NEONATAL I, V6, DOI 10.7363/060219; Testori C, 2019, HEART, V105, P531, DOI 10.1136/heartjnl-2018-313705; van den Belt SM, 2018, J AM SOC NEPHROL, V29, P2225, DOI 10.1681/ASN.2018010036; Vijlbrief DC, 2012, NEONATOLOGY, V102, P243, DOI 10.1159/000339117; Wang YS, 2018, CATHETER CARDIO INTE, V92, pE433, DOI 10.1002/ccd.27864; Yang L, 2010, NAT MED, V16, P535, DOI 10.1038/nm.2144; Zappitelli M, 2017, PEDIATR RES, V82, P569, DOI 10.1038/pr.2017.136; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030	71	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247403	10.1371/journal.pone.0247403	http://dx.doi.org/10.1371/journal.pone.0247403			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BB	33630895	gold, Green Published			2023-01-03	WOS:000624536800089
J	Kitsaras, G; Goodwin, M; Allan, J; Pretty, IA				Kitsaras, George; Goodwin, Michaela; Allan, Julia; Pretty, Iain A.			Defining and measuring bedtime routines in families with young children-A DELPHI process for reaching wider consensus	PLOS ONE			English	Article								Introduction Bedtime routines are one of the most common family activities. They affect children' wellbeing, development and health. Despite their importance, there is limited evidence and agreement on what constitutes an optimal bedtime routine. This study aims to reach expert consensus on a definition of optimal bedtime routines and to propose a measurement for bedtime routines. Method Four-step DELPHI process completed between February and March 2020 with 59 experts from different scientific, health and social care backgrounds. The DELPHI process started with an expert discussion group and then continued with 3 formal DELPHI rounds during which different elements of the definition and measurement of bedtime routines were iteratively refined. The proposed measurement of bedtime routines was then validated against existing data following the end of the DELPHI process. Results At the end of the four round DELPHI process and with a consistent 70% agreement level, a holistic definition of bedtime routines for families with young children between the ages of 2 and 8 years was achieved. Additionally, two approaches for measuring bedtime routines, one static (one-off) and one dynamic (over a 7-night period) are proposed following the end of the DELPHI process. A Bland-Altman difference plot was also calculated and visually examined showing agreement between the measurements that could allow them to be used interchangeably. Discussion Both the definition and the proposed measurements of bedtime routines are an important, initial step towards capturing a behavioural determinant of important health and developmental outcomes in children.	[Kitsaras, George; Goodwin, Michaela; Pretty, Iain A.] Univ Manchester, Div Dent, Dent Hlth Unit, Manchester, Lancs, England; [Allan, Julia] Univ Aberdeen, Inst Hlth Sci, Aberdeen, Scotland	University of Manchester; University of Aberdeen	Kitsaras, G (corresponding author), Univ Manchester, Div Dent, Dent Hlth Unit, Manchester, Lancs, England.	Georgios.kitsaras@manchester.ac.uk		Goodwin, Michaela/0000-0002-0375-3118; Kitsaras, George/0000-0002-1631-1730; Allan, Julia/0000-0001-7287-8363	Public Health Intervention Development Scheme of the Medical Research Council in the United Kingdom [MR/T002980/1]; MRC [MR/T002980/1] Funding Source: UKRI	Public Health Intervention Development Scheme of the Medical Research Council in the United Kingdom; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study forms part of a wider project funded by the Public Health Intervention Development Scheme of the Medical Research Council in the United Kingdom (ref.: MR/T002980/1).	Allen SL, 2016, SLEEP MED REV, V29, P1, DOI 10.1016/j.smrv.2015.08.006; Cain N, 2010, SLEEP MED, V11, P735, DOI 10.1016/j.sleep.2010.02.006; Eubank BH, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0165-8; Fischhoff B, 2014, P NATL ACAD SCI USA, V111, P13583, DOI 10.1073/pnas.1414635111; Giavarina D, 2015, BIOCHEM MEDICA, V25, P141, DOI 10.11613/BM.2015.015; Goodwin M, 2017, COMMUNITY DENT HLTH, V34, P8, DOI 10.1922/CDH_3926Goodwin06; Henderson JA, 2010, J PSYCHOPATHOL BEHAV, V32, P271, DOI 10.1007/s10862-009-9143-3; Kitsaras G, 2020, PILOT FEASIBILITY ST, V6, DOI 10.1186/s40814-020-0562-y; Kitsaras G, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5290-3; MacCoun RJ, 1998, ANNU REV PSYCHOL, V49, P259, DOI 10.1146/annurev.psych.49.1.259; Mindell JA, 2018, SLEEP MED REV, V40, P93, DOI 10.1016/j.smrv.2017.10.007; Mindell JA, 2010, SLEEP MED, V11, P274, DOI 10.1016/j.sleep.2009.04.012; Royal College of Surgeons Faculty of Dental Surgery, 2015, REPORT STATE CHILDRE; Sadeh A, 2010, SLEEP MED REV, V14, P89, DOI 10.1016/j.smrv.2009.05.003	14	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2021	16	2							e0247490	10.1371/journal.pone.0247490	http://dx.doi.org/10.1371/journal.pone.0247490			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP2HW	33626107	Green Published, gold			2023-01-03	WOS:000623658100069
J	Baldwin, GT; Seth, P; Noonan, RK				Baldwin, Grant T.; Seth, Puja; Noonan, Rita K.			Continued Increases in Overdose Deaths Related to Synthetic Opioids Implications for Clinical Practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							STATES	This Viewpoint summarizes a 2021 MMWR report documenting a concerning rise in illicit and synthetic opioid overdose deaths in the US between 2013 and 2019 and proposes strategies to connect clinicians and health systems with public health, public safety, and other community partners to share data, monitor trends, and better respond to the overdose epidemic.	[Baldwin, Grant T.; Seth, Puja; Noonan, Rita K.] Ctr Dis Control & Prevent, Div Overdose Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Baldwin, GT (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4700 Buford Hwy NE, Atlanta, GA 30341 USA.	gfb3@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		CDC Foundation, 2020, PUBL HLTH SAF TEAM P; Centers for Disease Control and Prevention, 2020, INCR FAT DRUG OV US; Hoots B, 2020, ADDICTION, V115, P946, DOI 10.1111/add.14878; Kariisa M, 2019, MMWR-MORBID MORTAL W, V68, P388, DOI 10.15585/mmwr.mm6817a3; Mattson CL, 2021, MMWR-MORBID MORTAL W, V70, P202, DOI 10.15585/mmwr.mm7006a4externalicon; National Academies of Science Engineering and Medicine, 2019, MED OP US DIS SAV LI; National Center for Injury Prevention and Control, OV DAT ACT OD2A; O'Donnell J, 2020, MMWR-MORBID MORTAL W, V69, P271, DOI 10.15585/mmwr.mm6910a4; Pardo B, 2019, FUTURE FENTANYL; Scholl Lawrence, 2018, MMWR Morb Mortal Wkly Rep, V67, P1419, DOI [10.15585/mmwr.mm6751521e1, 10.15585/mmwr.mm675152e1]	10	18	18	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2021	325	12					1151	1152		10.1001/jama.2021.1169	http://dx.doi.org/10.1001/jama.2021.1169		FEB 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ7PB	33571368	Green Accepted			2023-01-03	WOS:000617177800002
J	Horby, PW; Roddick, A; Spata, E; Staplin, N; Emberson, J; Pessoa-Amorim, G; Brightling, C; Prudon, B; Chadwick, D; Ustianowski, A; Ashish, A; Todd, S; Yates, B; Buttery, R; Scott, S; Maseda, D; Baillie, JK; Buch, M; Chappell, L; Day, J; Faust, SN; Jaki, T; Jeffery, K; Juszczak, E; Lim, WS; Montgomery, A; Mumford, A; Rowan, K; Thwaites, G; Mafham, M; Haynes, R; Landray, MJ; Horby, PW; Landray, MJ; Baillie, JK; Buch, M; Chappell, L; Day, J; Faust, SN; Haynes, R; Jaki, T; Jeffery, K; Juszczak, E; Lim, WS; Mafham, M; Montgomery, A; Mumford, A; Rowan, K; Thwaites, G; Sandercock, P; Darbyshire, J; DeMets, D; Fowler, R; Lalloo, D; Roberts, I; Wittes, J; Horby, P; Landray, MJ; Haynes, R; Fletcher, L; Barton, J; Basoglu, A; Brown, R; Brudlo, W; Denis, E; Howard, S; McChlery, G; Taylor, K; Cui, G; Goodenough, B; King, A; Lay, M; Murray, D; Stevens, W; Wallendszus, K; Welsh, R; Crichton, C; Davies, J; Goldacre, R; Harper, C; Knight, F; Latham-Mollart, J; Mafham, M; Nunn, M; Salih, H; Welch, J; Campbell, M; Pessoa-Amorim, G; Peto, L; Roddick, A; Knott, C; Wiles, J; Bell, JL; Emberson, J; Juszczak, E; Linsell, L; Spata, E; Staplin, N; Bagley, G; Cameron, S; Chamberlain, S; Farrell, B; Freeman, H; Kennedy, A; Whitehouse, A; Wilkinson, S; Wood, C; Reith, C; Davies, K; Halls, H; Holland, L; Wilson, K; Howie, L; Lunn, M; Rodgers, P; Barnard, A; Beety, J; Birch, C; Brend, M; Chambers, E; Chappell, L; Crawshaw, S; Drake, C; Duckles-Leech, H; Graham, J; Harman, T; Harper, H; Lock, S; Lomme, K; McMillan, N; Nickson, I; Ohia, U; Okell, E; Poustie, V; Sam, S; Sharratt, P; Sheffield, J; Slade, H; Hoff, WV; Walker, S; Williamson, J; De Soyza, A; Dimitri, P; Faust, SN; Lemoine, N; Minton, J; Gilmour, K; Pearson, K; Armah, C; Campbell, D; Cate, H; Priest, A; Thomas, E; Usher, R; Johnson, G; Logan, M; Pratt, S; Price, A; Shirley, K; Walton, E; Williams, P; Yelnoorkar, F; Hanson, J; Membrey, H; Gill, L; Oliver, A; Das, S; Murphy, S; Sutu, M; Collins, J; Monaghan, H; Unsworth, A; Beddows, S; Williams, KB; Dowling, S; Gibbons, K; Pine, K; Asghar, A; Aubrey, P; Jewell, DB; Donaldson, K; Skinner, T; Luo, J; Mguni, N; Muzengi, N; Pleass, R; Wayman, E; Coe, A; Hicks, J; Hough, M; Levett, C; Potter, A; Taylor, J; Dolman, M; Gerdes, L; Hall, C; Lockett, T; Wessex, DP; Bartholomew, J; Dowden, L; Rook, C; Walters, J; Denton, E; Tinkler, H; Alexander, A; Campbell, H; Chapman, K; Hall, A; Rodgers, A; Boyle, P; Brookes, M; Callens, C; Duffy, H; Green, C; Hampshire, K; Harrison, S; Kirk, J; Naz, M; Porter, L; Ryan, P; Shenton, J; Warmington, J; Amezaga, M; Dicks, P; Goodwin, J; Hodgson, H; Jackson, S; Odam, M; Williamson, D; Faust, SN; Bamford, A; Bandi, S; Bernatoniene, J; Cathie, K; Dmitri, P; Drysdale, S; Emonts, M; Evans, J; Finn, A; Fleming, P; Furness, J; Gale, C; Haynes, R; Jones, CE; Juszczak, E; Jyotish, D; Kelly, D; Murray, C; Pathan, N; Pollock, L; Ramanan, A; Riordan, A; Roehr, C; Wan, M; Whittaker, E; Chappell, L; Hodson, K; Knight, M; Pavord, S; Williamson, C; Odam, M; Black, P; Gallagher, B; MacInnes, L; O'Brien, R; Priestley, K; Saunderson, A; Bowman, L; Chen, F; Clarke, R; Goonasekara, M; Haynes, R; Herrington, W; Judge, P; Mafham, M; Ng, S; Preiss, D; Reith, C; Sammons, E; Zhu, D; Pinches, H; Bowker, P; Byrne-Watts, V; Chapman, G; Coleman, G; Gray, J; Rees, A; Landray, MJ; Mafham, M; Mather, N; Stephenson, C; Denwood, T; Harrison, D; Turner, G; Bruce, J; Arkley, C; Rees, S; Brightling, C; Brunskill, N; Wiselka, M; Adenwalla, S; Andreou, P; Bakoulas, P; Bandi, S; Batham, S; Beaver, T; Bhandal, K; Bourne, M; Boyles, L; Cannon, M; Charalambou, A; Cheung, CK; Cotter, R; Diver, S; Dunphy, A; Elneima, O; Fawke, J; Finch, J; Gardiner-Hill, C; Genato, G; Graham-Brown, M; Haines, C; Hargadon, B; Holdsworth, H; Ibrahim, W; Ingram, L; Silva, JAJ; Kaul, K; Joshi, M; Kapoor, S; Kim, JW; Kuverji, A; Kyriaki, K; Lea, A; Lee, T; Lewszuk, A; Lock, L; Macconaill, K; Major, R; McAuley, H; McCourt, P; Kutten, DM; Palfreeman, A; Parker, E; Patel, K; Patterson, M; Phillips, R; Plummer, L; Russell, R; Debbie, S; Selvaskandan, H; Southin, SM; Tsilimpari, KK; Wiesender, C; Yousuf, A; Ustianowski, A; Raw, J; Tully, R; Abdusamad, K; Antonina, Z; Ayaz, E; Blackledge, B; Bradley, P; Bray, F; Bruce, M; Carty, C; Charles, B; Connolly, G; Corbett, C; Dermody, S; Durrans, L; Falconer, E; Flaherty, J; Fox, C; Hadfield, D; Harris, J; Hoggett, L; Horsley, A; Hussain, S; Irving, R; Jacob, P; Johnstone, D; Joseph, R; Melville, JJ; Kamath, P; Khatun, T; Lamb, T; Law, H; Lazo, M; Lindergard, G; Lokanathan, S; Macfarlane, L; Mathen, S; McCullough, S; McMaster, P; McSorland, D; Mishra, B; Munt, S; Neal, A; Newport, R; O'Connor, G; O'Riordan, D; Page, I; Parambil, V; Philbin, J; Pinjala, MT; Rishton, C; Riste, M; Rothwell, J; Sam, M; Sarwar, Z; Scarratt, L; Sengupta, A; Sharaf, H; Prudon, B; Jagannathan, V; Adams, C; Aung, N; Barker, D; Campbell, B; Collins, V; Deane, J; Fenner, I; Gowans, S; Hartrey, W; Nafei, M; Poole, L; Purvi, S; Quigley, J; Ramshaw, A; Shepherd, L; Skelton, J; Srinivasan, R; Taylor, R; Walker, M; Weetman, M; Wetherall, B; Wild, S; Wilson, D; Lim, WS; Ali, M; Andrews, A; Anderson, L; Ashraf, S; Ashton, D; Babingto, G; Bartlett, G; Batra, D; Bendall, L; Benetti, N; Brear, T; Buck, A; Bugg, G; Butler, J; Butler, J; Cammack, RFD; Cantliff, J; Clark, L; Connor, E; Davies, P; Dent, M; Dobson, C; Fatemi, M; Fatemi, A; Fleming, L; Grundy, J; Hallas, J; Hodgen, L; Hodgson, S; Hodgkinson, S; Howard, L; Hutchinson, C; Jackson, B; Kaur, J; Keddie-Gray, E; Khurana, C; Langley, M; Looby, L; Meredith, M; Morris, L; Navarra, H; Nicol, R; Oliver, J; Peters, C; Petrova, B; Rose, Z; Ryan, L; Sampson, J; Squires, G; Squires, J; Taylor, R; Thomas, A; Thornton, J; Topham, K; Warburton, S; Wardle, S; Waterfall, H; Wei, S; Wildsmith, T; Wilson, L; Chadwick, D; Armstrong, S; Athorne, D; Branch, M; Brolly, J; Brown, S; Cheaveau, J; Chen, HM; Chua, Y; Cunningham, N; Dodds, J; Dorgan, S; Dunn, D; Harper, P; Harwood, H; Hebbron, K; Hunt, F; Bhushan, AK; Lambert, P; Leaning, D; Manders, T; McCarron, B; Miller-Biot, N; Milne, C; Mohammad, W; Mollet, M; Murad, A; Owston, M; Potts, J; Proctor, C; Rao, S; Seelarbokus, MA; Singh, P; Srirathan, V; Swithenbank, L; Thompson, L; Wardy, H; Wibli, L; Widdrington, J; Williams, J; Winder, P; Wroe, C; Elmahi, E; Zaman, M; Abdul, B; Abdulmumeen, A; Abdulshukkoor, N; Adnan, A; Nazeer, MHA; Bazli, A; Benesh, N; Chin, WJ; Cunningham, N; Daggett, H; Davies, E; Enyi, H; Fawohunre, S; Geoghegan, N; Glover, J; Hague, JW; Hall, K; Hallett, C; Haresh, K; Hassan, WU; Hewertson, J; Hosea, J; Htoon, NZ; Idrees, M; Igwe, C; Imtiaz, H; Irshad, M; Ismail, A; Jeffrey, R; Jith, J; Joshi, P; Periyasami, RK; Khalid, A; Khalid, MU; Kodituwakku, R; Lopez, P; Mahmood, A; Malanca, M; Mapfunde, IT; Maruthamuthu, VK; Masood, S; Masood, SSME; Matharu, M; Merchant, A; Merchant, F; Naqvi, S; Natarajan, R; Natarajan, N; Nawaz, K; Ndefo, O; Ogunkeye, O; Paranamana, S; Pugh, N; Raj, A; Rashid, K; Rogers, M; Saad, M; Selvadurai, G; Shah, A; Shahzeb, M; Shrestha, N; Singh, A; Smith, K; Sohail, B; Spinks, M; Stockham, L; Takyi, A; Teoh, YH; Ullah, S; Vayalaman, H; Wafa, SEI; Ward, T; Watson, R; White, D; Melly, LY; Zulaikha, R; Green, C; Whitehouse, T; Ahmed, I; Anderson, N; Armstrong, C; Bamford, A; Bancroft, H; Bates, M; Begum, S; Bellamy, M; Bergin, C; Bhandal, K; Brandl-Salutz, E; Buckingham, E; Burke, E; Carmody, M; Cooper, L; Daglish, J; Dasgin, J; Desai, A; Dhani, S; Dosanjh, D; Ellis, H; Gardiner, D; Forster, E; Grobovaite, E; Hopkin, B; Hull, D; Hussain, Y; Jones, J; Khan, L; Lenton, D; Lewis, M; Lovell, M; Lowe, F; Lynch, D; McGhee, C; McNeill, C; Moore, F; Nilsson, A; Nunnick, J; Prest, C; Price, V; Rhodes, J; Sale, J; Sangombe, M; Smith, H; Storey, I; Thrasyvoulou, L; Tsakiridou, K; Walsh, D; Welch, S; Willis, H; Wood, L; Woodford, J; Wooldridge, G; Zullo, C; Desai, P; Appleyard, D; Bromley, D; Chambers, N; Dale, S; Gledhill, L; Goddard, J; Greig, J; Haigh, A; Hallas, K; Hanson, K; Holroyd, K; Home, M; Kelly, D; Maharajh, A; Matapure, L; Mellor, S; Merwaha, E; Riley, H; Robinson, M; Sandhu, K; Schwarz, K; Shaw, L; Terrett, L; Usher, M; Wilson, A; Wood, T; Felton, T; Abbas, M; Rasheed, AA; Abraham, T; Aggarwal, S; Akili, S; Alexander, PDG; Allanson, A; Al-Sheklly, B; Arora, D; Avery, M; Avram, C; Aya, A; Banda, J; Banks, H; Baptist, M; Barrera, M; Bazaz, R; Behrouzi, R; Benson, V; Bentley, A; Bhadi, A; Biju, A; Bikov, A; Birchall, K; Blane, S; Bokhari, S; Bradley, P; Bradley-Potts, J; Dean, K; Dhillon, R; Dolan, D; Duggan, A; Duran, B; Durrington, H; Eades, C; Eatough, R; Clark, R; Clayton-Smith, J; Conway, R; Cook, E; Cummings-Fosong, G; Currie, S; Dalgleish, H; Davies, C; Dean, K; Dhillon, R; Dolan, D; Duggan, A; Duran, B; Durrington, H; Eades, C; Eatough, R; Elyoussfi, S; Evans, G; Fairclough, A; Faluyi, D; Ferguson, S; Fielding, J; Fiouniz, S; Fogarty, G; Fowler, S; Giannopoulou, S; Gillott, R; Gipson, A; Glasgow, S; Gorsuch, T; Grana, G; Gray, G; Grayson, A; Grey, G; Griffin, B; Hackney, P; Hameed, B; Hamid, I; Handrean, S; Henry, J; Higgins, L; Holt, L; Horsley, A; Howard, L; Hughes, S; Hulme, A; Hulme, P; Hyslop, M; Ingham, J; Ismail, O; Jafar, A; Jamal, S; James, L; John, A; Johnstone, E; Karunaratne, N; Kausar, Z; Kayappurathu, JN; Kelly, R; Khan, A; Khan, W; Knight, S; Kolakalurix, E; Kolakaluri, E; Kosmidis, C; Kothandaraman, E; Krizak, S; Kyi, NM; Lalloo, F; Logue, C; Lord, RW; Macfarlane, L; Madden, A; Mahaveer, A; Manderson, L; Margaritopoulos, G; Marsden, P; Mathews, J; McCarthy, E; McGrath, B; Mendonca, C; Metryka, A; Micallef, D; Mishra, A; Mistry, H; Mitra, S; Moss, S; Muazzam, A; Mudawi, D; Murray, C; Naguib, M; Naveed, S; Ninan, P; Nirmalan, M; Norton, R; Odell, N; Osborne, R; Padden, G; Palacios, A; Panes, A; Pantin, CT; Parker, B; Peacock, L; Peasley, A; Pomery, F; Power, N; Pursell, M; Ratcliffe, S; Reilly, M; Reynard, C; Rice, E; Rice, M; Riley, P; Rivera-Ortega, P; Rogers, J; Rogers, T; Santosh, R; Scott, A; Sellers, K; Sen, N; Shanahan, T; Shawcross, A; Shibly, S; Simpson, A; Sivanadarajah, S; Skehan, N; Smith, C; Smith, J; Smith, L; Soren, J; Spiller, W; Stratton, J; Stubbs, A; Swist-Szulik, K; Tallon, B; Thomas, S; Thorpe, S; Tohfa, M; Tousis, R; Trafford, MT; Turgut, T; Varghese, M; Varnier, G; Venables, I; Vinay, S; Wang, R; Ward, L; Warner, C; Watson, E; Watterson, D; Wentworth, L; Whitehead, C; Wilcock, D; Williams, JR; Willis, E; Woodhead, L; Worton, S; Xavier, B; Rege, K; Agbo, C; Akindolie, O; Al-Rabahi, A; Ambrogetti, R; Aung, KT; Shah, AA; Babs-Osibodu, AO; Bahadori, K; Bhayani, J; Bond, T; Boughton, H; Brooks, S; Butterworth-Cowin, N; Buttery, R; Carter, P; Catana, AM; Cave, L; Choi, S; Corogeanu, D; Croysdill, R; Davies, M; de Souza, J; Duff, N; Dufour, L; Ebigbola, O; Eddings, C; Faccenda, J; Feroz, A; Finch, L; Freer, C; Goodyear, P; Gooentilleke, R; Gosling, R; Halford, W; Havlik, S; Hoskins, T; Huson, C; Ishak, M; Javed, H; Jones, T; Kasianczuk, N; Kaur, D; Kerr, A; Khan, A; Koshy, G; Eskenazia, AK; Lahane, S; Lami, MKG; Marshall, J; McDevitt, K; Muru, N; Mustafa, AMM; Nazir, S; Okpala, I; Old, T; Oleszkiewicz, G; Orme, H; O'Sullivan, S; Paczko, P; Pandey, A; Patel, A; Pathak, S; Poon, S; Rather, MI; Vattekkat, RR; Rizvi, SHM; Samyraju, M; Sanyal, J; Shah, SH; Smith, E; Stacpoole, S; Tan, BTT; Temple, N; Thazhatheyil, K; Uddin, MS; Veale, N; Walter, D; Ashish, A; Cooper, J; Heaton, D; Hough, S; Parkinson, V; Robinson, E; Taylor, T; Tierney, C; Verma, A; Waddington, N; Williams, C; Zipitis, C; Tiberi, S; Aboaba, A; Adeyeye, E; Agwada-Akeru, J; Ali, FR; Allen, R; Ardley, C; Astin-Chamberlain, R; Bacon, G; Baillie, H; Batha, R; Bloom, B; Bolton, M; Borra, C; Boyapati, G; Buchanan, R; Chan, C; Chitsenga, C; Cipriano, B; Cofie, PF; DeLuna, M; Elia, S; El-Shakankery, K; Fikree, A; Ghosh, A; Goiriz, R; Goldsmith, P; Gouldbourne, M; Grant, A; Greenfield, L; Grigoriadou, S; Gritton, R; Gunganah, K; Hand, J; Harwood, C; Hemmila, U; Higgins, J; Hobden, D; Howaniec, L; Hsu, D; Iliodromiti, S; Issa, S; Jones, P; Juan, M; Kassam, J; Keith-Jopp, C; Khan, M; Khaw, CR; Kunst, H; Lai, J; Lee, I; Lieberman, D; Liebeschuetz, S; Magavern, E; Maniero, C; Maitland, J; Malcolm, H; Marshall, H; Matin, N; May, P; McDermott, R; Menacho, K; Millin, L; Mohammed, A; Moriarty, K; Naeem, S; Newman, T; Fhogartaigh, CN; Omar, M; Pakozdi, A; Parrott, M; Pfeffer, P; Pott, J; Powell, J; Ricketts, W; Riddell, A; Rughani, P; Sahdev, N; Sarodaya, V; Selvarajah, B; Skene, I; Smallshaw, KD; So, A; Stevenson, D; Suarez, C; Swaine, T; Thomas, S; Thomas, A; Thomson, J; Thorn, N; Tierney, C; Ullah, S; Vathenen, R; Velauthar, L; Ward, K; Wiles, K; Woodland, P; Youssouf, S; Zdanaviciene, A; Fegan, C; Balan, A; Basker, B; Bird, S; Boult, Z; Britten, V; Broad, L; Cendl, H; Chakraborty, M; Cole, J; Edgar, M; Evans, T; Evans, J; Evans, M; Forton, J; Frayling, S; Greaves, F; Harrhy, S; Haynes, M; Hill, H; Hilton, Z; Jones, L; Jorgensen, S; Kelly, A; Knibbs, L; Lau, D; Maureen, E; May, J; McGough, E; McQueen, A; Milner, J; Norman, R; Nyland, K; Oliver, C; Paradowski, K; Patal, M; Rahilly, K; Robinson, C; Scourfield, S; Starr, M; Struik, S; Thomas, E; Thomas-Turner, R; Williams, G; Williams, J; Williams, M; Zaher, S; Hine, P; Todd, S; Welters, I; Wootton, D; Ahmed, M; Ahmed, RA; Al Balushi, A; Barr, D; Bennett, A; Bond, H; Burston, C; Byrne, J; Chambers, L; Coey, D; Cross, T; Cruise, J; Fenlon, K; Gould, S; Haigh, K; Hall, C; Harrison, M; Hazenberg, P; Hicks, SR; Hope, S; Hunter, K; Islim, A; Iyer, S; Jackson, A; Jaime, F; Keogan, L; Knowles, K; Krasauskas, K; Lewis, J; Lopez, P; Lowe, C; Mediana, A; Middleton, M; Nugent, M; Pauls, L; Pringle, S; Quayle, I; Raghunath, S; Riley, M; Sedano, J; Shaw, D; Smith, C; Stevenson, S; Stockdale, A; Tangney, R; Tempany, J; Waugh, V; Williams, K; Yates, B; Ashbrook-Raby, C; Campbell, H; Charlton, D; Dodds, S; Ferguson, V; Hall, T; Hamoodi, I; Heslop, P; Luke, J; McLarty, N; Patterson, L; Pick, S; Reynolds, J; Robinson, S; Tanney, C; Taylor, L; Winder, L; Walker, C; Scott, S; Abouibrahim, M; Ahmad, M; Ahmed, SH; Ajibode, A; Alomari, L; Asrar, A; Austin, E; Bamford, P; Barclay, A; Barker, L; Barker-Williams, K; Barnsley, W; Batty, H; Benton, I; Billingham, S; Brearey, S; Brigham, S; Brooker, V; Burchett, C; Burgess, M; Cade, R; Cameron, F; Cannan, R; Cawley, K; Chavasse, N; Cheng, Z; Clarke, R; Cole, E; Cotton, C; Davidson, A; Doi, Y; Dragos, C; Ellerton, LN; Gamble, L; Grant, M; Grounds, J; Hodgkins, H; Irshad, MS; Iyer, M; Johari, A; Jones, C; Kearsley, N; Lim, B; Llanera, DK; Loh, SY; London, E; Martin, E; Maskell, P; McBurney, J; McCarthy, M; McEwen, R; Meeks, E; Metcalf-Cuenca, G; Middleton, S; Mihalca-Mason, L; Nayyar, M; Naz, F; Okpo, E; Parry, HC; Pearson, SA; Phillips, D; Pickering, C; Ponnuswamy, A; Prescott, V; Prince, J; Rahman, SU; Scott, S; Steele, C; Thorne, C; Tomlin, S; Trussell, T; Webster, T; Zammit, L; Zin, ET; Grahamx, C; Graham, C; Abdelaziz, A; Ali, O; Atkinson, J; Bell, G; Brewer, C; Clapham, M; Gregory, J; Hanif, S; Harper, R; Lane, M; McSkeane, A; Poultney, U; Poulton, K; Pritchard, S; Shah, S; Smit, C; Tzavaras, P; Vasadi, V; Wilson, A; Wilson, T; Zehnde, D; Shaw, D; Tariq, S; Ahmed, N; Ali, S; Allen, S; Alzetani, M; Ambrose, C; Aneke, K; Angel, T; Aung, ZM; Banerjee, R; Baqai, T; Batla, A; Bergstrom, M; Bhakta, S; Bibi, N; Chapman, T; David, A; Dirmantaite, L; Edmondson, M; Elfar, E; Elgamal, MM; El-Sbahi, H; Fishman, D; Fornolles, C; Forshall, T; Francioni, A; Gent, S; George, N; Ibrahim, A; Ingram, A; James, R; Dawa, KK; Khan, F; Khan, MA; Lee, S; Lingam, C; Luximon, CN; Marcus, N; Masood, M; Mejri, R; Moharram, A; Moss, C; Naik, G; Ng, AYKC; Nicholls, L; Nisar, M; Parmar, V; Raj, FP; Puisa, V; Quick, V; Ramabhadran, B; Reddy, A; Riaz, N; Rudran, B; Sabaretnam, S; Sagoo, H; Sarma, S; Savlani, K; Shah, P; Shaw, D; Soo, S; Sothirajah, P; Southern, I; Tate, ML; Travill, C; Uppal, VS; Wakeford, W; Brown, T; Andrews, J; Baker-Moffatt, M; Bamgboye, A; Barnes, D; Baryschpolec, S; Bell, L; Borbone, J; Broadway, M; Brogan, F; Bungue-Tuble, R; Burrows, K; Chauhan, A; Chauhan, M; Cowan, E; Darbyshire, A; Davey, M; David, M; Denham, J; Downe, H; Edwards, C; Fox, L; Garner, Z; Giles, B; Gribbin, A; Harrington-Davies, Y; Hawes, L; Hicks, A; Hossain, E; Howe, S; Jones, B; Lameirinhas, C; Longhurst, B; Mamman, M; McCready, S; Minnis, C; Moon, M; Mouland, J; Murray, L; Rose, S; Rupani, H; Rutgers, M; Scorrer, T; Scott, K; Thornton, R; Tiller, A; Turner, C; Wands, M; Watkins, L; White, M; Wiffen, L; Winter, J; Winn, S; Wake, R; Sadiq, SA; Aldana, A; Al-Hakim, B; Agyapong, KA; Azzopardi, G; Chicano, R; Chukwulobelu, I; Colbeck, N; Cole, N; Dogra, R; Doherty, E; Elradi, A; Emberton, J; Evans, TJ; Ganapathy, R; Haque, M; Hayre, R; Jain, S; Jian, K; Johnson, L; Johnson, A; Kotecha, J; Kundu, A; Langer, D; Mashhoudi, Y; Mathias, K; Maxan, ME; Mellor, F; Morgan, M; Nafees, S; Sai, VBP; Phanish, M; Rahimi, HR; Ramanna, S; Ratoff, J; Rozewicz, S; Samuel, TDL; Shah, B; Shahnazari, S; Shail, R; Sharif, A; Somalanka, S; Suckling, R; Swift, P; Tyagi, V; Vilimiene, N; Wells, C; Maseda, D; Ball, C; Best, K; Bridgwood, G; Broadhurst, R; Brockelsby, C; Brockley, T; Brown, J; Bujazia, R; Clarke, S; Cremona, J; Dixon, C; Dowson, S; Drogan, H; Duncan, F; Emmett, C; Emms, M; Farooq, H; Fullerton, D; Gabriel, C; Hammersley, S; Hum, R; Jones, T; Kay, S; Kelly, E; Kidd, M; Lees, D; Lowsby, R; Matovu, E; McIntyre, K; Moulton, H; Nourein, K; Nytianandan, G; O'Brian, M; Pagett, K; Ritchings, A; Smith, S; Taylor, J; Thomas, K; Turbitt, K; Yasmin, S; Spittle, N; Weatherly, N; Beavis, S; Beghini, S; Blundell, L; Bradder, J; Cort, J; Cresswell, J; Dale, K; Foo, A; Gardner, J; Gascoyne, R; Hall, E; Kelly-Baxter, M; Mackay, E; Moxham, K; Padmakumar, A; Pritchard, K; Salmon, J; Smith, A; Sorice, V; Stevenson, L; Whileman, A; Wolodimeroff, E; Meda, M; Democratis, J; Barnes, N; Brooks, N; Chapman, L; da Rocha, J; Dolman, R; Edwards, A; Foster, T; Fowe, F; Gaywood, E; Gee, S; Jaiswal, S; Molloholli, M; Raguro, A; Regan, F; Rowe-Leete, L; Smith, C; van de Venne, M; Weerasinghe, T; Jeffery, K; Ainsworth, M; Arnison-Newgass, C; Bashyal, A; Beer, S; Bloss, A; Buttress, D; Byrne, W; Capp, A; Carter, P; Cicconi, P; Corrigan, R; Coston, C; Cowen, L; Davidson, N; Downs, L; Edwards, J; Evans, R; Gardiner, S; Georgiou, D; Gillesen, A; Harin, A; Havinden-Williams, M; Haynes, R; Hird, C; Hudak, A; Hutton, P; Irons, R; Jastrzebska, P; Johnston, S; Kamfose, M; Lewis, K; Lockett, T; del Rocio, FMM; Garrido, JCM; Masih, S; Mentzer, A; Morris, S; O'Callaghan, C; Oliver, Z; Paulus, S; Perez, E; Periyasamy, L; Peto, L; Porter, D; Prasath, S; Purdue, C; Ramasamy, M; Roehr, CC; Rudenko, A; Sanchez, V; Sarfatti, A; Segovia, M; Sewdin, T; Seymour, J; Skinner, V; Smith, L; Diaz, AS; Taylor-Siddons, M; Thraves, H; Tsang, C; Vatish, M; Warren, Y; Wilcock, E; Khan, B; Ail, D; Aldouri, R; Awadzi, G; Bassoy, B; Bhalla, R; Billings, J; Bokhari, S; Boniface, G; Cernova, J; Chen, T; Chimbo, P; Chitalia, N; Bamfo, SD; Depala, D; Dhanoa, A; Edmunds, T; Fernandez, E; Ferrari, T; Fuller, B; Gherman, A; Heire, R; Ilves, L; Lacey, L; Lawrence, E; Lewis, M; Maric, A; Martin, W; Min, Z; Newman, C; Nicholas, R; Olufuwa, O; Pieniazek, N; Qadeer, T; Rathore, S; Sathianandan, S; Scott, C; Shonubi, A; Siddique, S; Sisson, G; Soan, M; Streit, D; Stuart, C; Szekely, M; Umeojiako, W; Urruela, S; Warner, B; Waterstone, M; White, S; Yip, K; Zafar, AM; Zaman, S; West, R; Abrams, J; Baldwin, A; Bannister, O; Barker, J; Beddall, H; Blamey, H; Chan, E; Chaplin, J; Chisnall, B; Cleaver, C; Crotty, S; Dey, P; Downs, L; Kononen, M; Kudsk-Iversen, S; Kudzinskas, A; Laurenson, M; Mandeville, J; McLure, S; Morgan-Smith, E; Ngumo, A; Oxlade, R; Parekh, A; Rahman, M; Robertson, C; Shah, S; Tebbutt, J; Vella, N; Veres, M; Watson, AJR; Wong, N; Zammit-Mangion, M; Zia, M; Gray, A; Baillie, K; Adam, M; Anand, A; Anderson, R; Baird, D; Balaskas, T; Balfour, J; Black, P; Blackstock, C; Brady, S; Campbell, R; Carter, J; Chapman, P; Cheyne, C; Christides, A; Christmas, D; Crisp, L; Cryans, D; Dear, J; Dhaliwal, K; Docherty, M; R, D; Donald, L; Dummer, S; Eddleston, M; Fethers, N; Foster, E; Frake, R; Gaughan, E; D, G; Godson, E; Grahamslaw, J; Grant, A; Grubb, N; Hainey, S; Harding, Z; Harris, M; Harvey, M; Henshall, D; Hobson, S; Hunter, N; Jaly, Y; Jameson, J; Japp, D; Khin, HHE; Kitto, L; Krupej, S; Langoya, C; Lawrie, R; Lloyd, A; Lyell, B; Lynch, D; Macfarlane, J; MacInnes, L; MacRaild, A; Marecka, M; Marshall, A; Martin, M; McCann, C; McCurrach, F; Moatt, E; Morley, W; Morrissey, M; Newby, D; Din, KNU; O'Brien, R; O'Sullivan, E; Odam, M; Peterson, A; Phelan, P; Pickering, G; Quinn, T; Robertson, N; Rooney, L; Rowan, N; Salman, R; Small, E; Stefanowska, P; Stevenson, A; Stock, S; Summers, A; Teasdale, J; Walker, I; Walker, K; Williams, A; Wight, A; Bailey, L; Bokhari, SO; Brownlee, S; Bull, A; Corless, J; Denmade, C; Ellard, N; Farrell, A; Hufton, A; Jacob, R; Jones, KE; Kerss, H; McEntee, J; Morris, N; Myagerimath, R; Newcombe, T; Parsonage, M; Peake, H; Pearson, D; Penfold, R; Rath, S; Saunders, R; Sharp, A; Spencer, B; Suliman, A; Sutton, S; Tan, H; Tarpey, D; Thompson, L; Thornton, T; Twohey, E; Wagstaff, D; Wahbi, Z; Williams, S; Phull, M; Umaipalan, A; Ah-Chuen, J; Ainsley, A; Baijiu, G; Basumatary, A; Calderwood, C; Dugh, P; Dunne, K; Greaves, P; Hunt, K; Islam, M; Katsande, V; Khan, MR; King, S; Loverdou, A; McGregor, A; Misbahuddin, A; Mohamed, A; Nagesh, N; Nicholls, D; O'Brien, N; Parker, L; Pogreban, T; Rosaro, L; Salciute, E; Sharma, M; Smith, H; Visentin, E; Walshaw, L; Saralaya, D; Akhtar, N; Beckett, V; Brear, L; Drew, V; Eedle, J; Hawes, N; Kmachia, S; Moss, S; Oddie, S; Paget, J; Regan, K; Ryan-Wakeling, D; Shenoy, A; Storton, K; Swingler, R; Syson, J; Todd, J; Wane, R; Wilson, A; Fuller, E; MacNair, A; Brown, C; Burns, A; Caroline, C; Davidson, R; Dickson, M; Duncan, B; Elkaram, N; Emmerson, I; Fairlie, L; Hashimm, M; Henderson, J; Hinshaw, K; Holden, J; Hovvels, R; Laybourne, S; Madgwick, P; Martin, K; Mckee, M; Moore, J; Mullen, N; Murphy, P; Palmer, L; Parish, G; Rangar, M; Shahrul, R; Smith, A; Smith, L; Smith, M; Stidolph, B; Terry, L; Trotter, A; Wakinshaw, F; Walton, E; Walton, M; Frise, M; Arimoto, R; Black, S; Camm, C; Coles, H; De Berker, H; Fries, A; Gabbitas, E; Hasan, N; Htet, Z; Jacques, N; Kashif, S; Keating, L; Leafe, S; Milne, Z; Mitchell, B; Okeke, T; Orchard, W; Parmar, A; Raffles, M; Shields, N; Thakker, M; Thomas, M; Wakefield, H; Walden, A; Moreno-Cuesta, J; Rokadiya, S; Govind, A; Haldeos, A; Leigh-Ellis, K; van Someren, C; Vincent, R; Walker, L; Thomas, K; George, T; Cannon, E; Ikomi, A; Jayasekera, L; Kittridge, L; Maloney, G; Manoharan, B; Mushabe, M; Nicholson, A; Pai, A; Riches, J; Samuel, J; Setty, N; Solesbury, A; Southam, D; Tisi, S; Vertue, M; Wadsworth, K; Yung, B; Limb, J; Atkinson, V; Birt, M; Brown, E; Cowton, A; Craig, V; Egginton, D; Fernandes, D; Ivy, A; Jayachandran, D; Jennings, J; Kay, A; Kent, M; McAuliffe, S; Naylor, S; Nyamugunduru, G; O'Brien, J; Postlethwaite, K; Potts, K; Ranka, P; Rogers, G; Sen, S; Temple, J; Wadd, S; Walters, H; Yorke, J; Whittington, A; Adamus, M; Barrett, J; Cawa, F; Chhabra, S; Chita, S; Dhillon, E; Filson, SA; Goodall, J; Gravell, R; Gupta-Wright, A; Gurram, S; Houston, H; Hulston, G; Isralls, S; Kukadiya, C; Lang, M; MaeLow, J; Macleod, C; Milburn, J; Muralidhara, K; Nayar, B; Ojo, O; Papineni, P; Parris, V; Patel, M; Quaid, S; Sethi, J; Sturdy, A; Tyagi, B; Vaccari, LC; van der Stelt, N; Wallis, G; Watson, E; Sarkar, R; Ahmed, I; Ahmed, S; Ambler, S; Babatunde, F; Banerjee, S; Bhatia, N; Brassington, L; Brokke, F; Bruce, D; Cassimon, B; Chauhan, RS; Chengappa, A; Divikar, N; Donnelly, C; Froneman, C; Gnanalingam, C; Gower, T; Harizaj, H; Hettiarachchi, G; Hollands, M; Jansz, S; Josiah, B; Kamara, M; Kidney, S; Kyere-Diabour, T; Lewiston, K; Miah, N; Millington, S; Mires, L; Mitchell, A; Mizzi, C; Naicker, K; Petrou, I; Phulpoto, MM; Ross-Parker, A; Ramadan, I; Roy, A; Ryan, A; Samuels, E; Sanctuary, T; Sharma, A; Singham, S; Sporrer, J; Ul Hassan, W; Vankayalapati, P; Velan, B; Smith, LV; Vyras, E; Wood, J; Zuhra, N; Clare, S; Ahmed, MC; Beuvink, Y; Blachford, K; Clamp, S; De,, JC; De, P; Fenton, M; Gammon, B; Hayes, A; Henry, L; Hussain, S; Joseph, S; Kinney, F; Knight, T; Kumar, R; Leong, W; Lim, T; Mahay, B; Nupa, Y; Orme, A; Osborne, W; Pilsworth, Z; Potter, S; Prew, S; Rajaiah, N; Rajasekaran, A; Senya, H; Shah, N; Shamim, N; Sivakumar, S; Smith, L; Thozthumparambil, P; Trudgill, N; Turner, A; Wagstaff, L; Willetts, S; Willis, H; Yan, M; Richardson, N; Alegria, A; Kapoor, R; Adegoke, K; Allen, L; Beranova, E; Boehmer, G; Crisp, N; Deery, J; Hansen, J; Elgohary, A; Elsefi, T; Hargreaves, C; Hazelton, T; Hulbert, R; Ionita, A; Knight, A; Linares, C; Loader, D; Matisa, E; McAndrew, J; Montasser, M; Moon, A; Oboh, C; Offord, P; Price, C; Rajasri, A; Rand, J; Schumacher, N; Stephensen, D; Stirrup, S; Tague, L; Tilbey, S; Turney, S; Vasu, V; Venditti, M; Weston, H; Woodward, Z; Kemp, T; Alexander, J; Al-Shamkhani, W; Bandla, N; Bland, A; Bodasing, N; Cadwgan, A; Chaudhary, MYN; Cheng, LY; Church, SR; Clark, F; Davies, M; Diwakar, L; Eaton, E; Evans, M; Farmer, A; Farook, F; Gellamucho, M; Glover, K; Haris, M; Humphries, J; Hussain, I; Khan, S; Korcierz, L; Lee, J; Machin, J; Marshall, J; McCreedy, H; Muddegowda, G; Mustapha, I; Nettleton, K; Noori, Z; Osman, W; Parker, H; Patel, N; Quinn, A; Ram, M; Remegoso, A; Scott, T; Sheikh, N; Swiftx, R; Thompson, C; Tomlinson, J; Turner, H; Walker, L; Weeratunga, J; White, C; White, J; Wu, P; Szakmany, T; Champanerkar, S; Griffiths, A; Ionescu, AA; Somashekar, C; Zalewska, K; Aitken, L; Baker, E; Barnett, D; Brouns, M; Cann, J; Cherian, S; Codd, R; Cutler, S; Davies, W; Dell, A; Edwards, M; Edwards, S; Fairbairn, S; Hawkins, N; Hodge, S; Hodkinson, G; Hughes, R; Ivenso, C; James, T; Jones, M; Jones, S; Lucey, A; MacCormac, J; Marshall, G; McKain, S; Nassa, H; Northfield, J; Palmer, S; Peter, L; Price, C; Pynn, M; Roynon-Reed, A; Shipp, L; Singh, J; Singh, M; Swarnkar, K; Torabi, P; Venkataramakrishnan, R; Wall, E; Waters, A; Wild, K; Winstanley, M; Wyness, K; Kushakovsky, V; Ramali, M; Alam, S; Bartholomew, S; Bataineh, A; Beeby, D; Bell, S; Broughton, N; Buckman, C; Calver, C; Campbell, J; Chabo, C; Chowdhury, M; Cooke, K; Deole, N; Driscoll, C; Elden, A; Eldew, H; Entwistle, N; Farnworth, F; Francis, R; Galloway, E; Garfield, M; Ghosh, A; Gray, G; Greenfield, P; Hadjiandreou, M; Hewer, H; Hossain, MS; Howard-Griffin, R; Islam, A; Jamieson, E; Jiao, Z; Johannessen, K; Lee, SH; Lewis, R; Lloyd, R; Mabelin, LA; Morris, D; Nallapareddy, S; Ooi, HC; Osagie, R; Parkinson, C; Patel, H; Prowse, H; Purewal, B; Ridley, P; Rivers, V; Rosier, J; Sharma, S; Sheik, A; Skelly, R; Smith, R; Sreenivasan, R; Taylor, A; Tovey, P; Turner, A; Turner, K; Vithian, K; Zhixin, J; Potton, E; Jain, N; Khadar, A; Morgan, P; Penny, J; Tatam, E; Abbasi, S; Acharya, D; Acosta, A; Ahmed, L; Ali, S; Alkhusheh, M; Amosun, V; Arter, A; Babi, M; Bacon, J; Bailey, K; Balachandran, N; Bandyopadhyam, S; Banks, L; Barla, J; Batty, T; Bax, S; Belgaumkar, A; Benison-Horner, G; Boles, A; Broomhead, N; Cetti, E; Chan, C; Chaudhry, I; Chudgar, D; Clark, J; Clueit, S; Collins, S; Combes, E; Conway, G; Curtis, O; Das, M; Daschel, M; Davies, S; Potton, E; Abbasi, S; Acharya, D; Acosta, A; Ahmed, L; Ali, S; Alkhusheh, M; Amosun, V; Arter, A; Babi, M; Bacon, J; Bailey, K; Balachandran, N; Bandyopadhyam, S; Banks, L; Barla, J; Batty, T; Bax, S; Belgaumkar, A; Benison-Horner, G; Boles, A; Broomhead, N; Cetti, E; Chan, C; Chaudhry, I; Chudgar, D; Clark, J; Clueit, S; Collins, S; Combes, E; Conway, G; Curtis, O; Das, M; Daschel, M; Davies, S; Day, A; Dhar, M; Diaz-Pratt, K; Dragan, C; Dube, H; Duraiswamy, V; Elias, J; Ellis, A; Ellis, TY; Emmanuel, J; Engden, A; Fahmay, Y; Field, B; Fishwick, K; Ganesh, U; Gilbert, C; Giokanini-Royal, T; Goudie, E; Griffith, S; Gurung, S; Habibi, R; Halevy, C; Haqiqi, A; Hartley, R; Hayman, A; Hives, J; Horsford, M; Hughes, S; Hui, C; Hussain, R; Iles, C; Jackson, L; James, A; Jayaram, D; Jessup-Dunton, E; Joefield, T; Khan, N; Kieffer, W; Knox, E; Kumar, V; Kumar, R; Kurmars, V; Lafferty, H; Lamb, F; Layug, R; Leitch, N; Lim, W; Limbu, U; Loveless, R; Mackenzie, M; Maghsoodi, N; Maher, S; Maljk, M; Man, I; McCarthy, N; Mearns, B; Mearns, C; Morgan-Jones, K; Mortem, G; Morton, G; Moya, B; Murphy, G; Mutton, S; Myers, A; Nasser, T; Navaratnam, J; Nazir, S; Nepal, S; Nimako, K; Nimako, L; O'Connor, C; Patel, A; Patel, K; Phongsathorn, V; Pillai, PA; Poole, M; Qureshi, N; Ranjan, S; Rehman, A; Samuels, T; Scott, E; Sekadde, G; Sharma, A; Sharp, G; Shotton, S; Simmons, O; Singh, P; Smith, S; Paranthamen, KS; Suresh, S; Thevarajah, K; Thomas, L; Timms, H; Tomasova, N; Tucker, S; Vara, S; Vaz, C; Weller, S; White, J; Wilde, M; Wilkinson, I; Williams, C; Win, M; Woosey, D; Wright, D; Roberts, M; Amsha, K; Cox, G; Downer, N; Hodgson, D; Hutchinson, J; Kalsoom, S; Molyneux, A; Noor, Z; Allsop, L; Brear, T; Buckley, P; Dunn, L; Gill, M; Goodwin, C; Heeley, C; Holmes, M; Holmes, R; Langthorne, E; Moulds, C; Nash, D; Rajeswary, J; Shelton, S; Slack, K; Smith, S; Valeria, B; Wynter, I; Yanney, M; Ynter, I; Azam, J; Chandler, KJ; Abdelfattah, M; Abung, A; Anderson, J; Antill, P; Appleby, S; Armtrong, P; Berriman, T; Bull, D; Clayton, O; Corlett, A; Crocombe, D; Davies, S; Elliott, K; Fahel, L; Ghosh, J; Gott, N; Greenwood, D; Holder, T; Inns, P; Lea, W; Lindsay, E; Mack, K; Marshall, N; McMeekin, S; Momoniat, T; Nikolaos, P; O'Kane, M; Patrick, G; Pearson, H; Ponnusamy, P; Poole, A; Price, N; Proudfoot, R; Purssord, G; Roche, S; Sefton, C; Shahi, S; Smith, D; Sohail, B; Thomas, R; Turnbull, A; Turner, L; Watchorn, HJ; Wiafe, E; Wilson, J; Yates, D; Bruce, MS; Baldwin, D; Clark, Z; Dale, M; Griffiths, D; Gunter, E; Horler, S; Joyce, T; Keltos, M; Kennard, S; Lakeman, N; Mallon, L; Miln, R; Nix, S; Orr, S; Pitts, S; Purandare, L; Rogers, L; Samways, J; Stride, E; Vamplew, L; Wallis, L; Willis, J; Blencowe, N; Singhal, P; Abraham, M; Al-Ramadhani, B; Archer, A; Aziz, G; Balcombe, A; Bateman, K; Baxter, M; Beacham, L; Belfield, K; Bell, N; Beresford, M; Bernatoniene, J; Bhojwani, D; Biggs, S; Blazeby, J; Bobruk, K; Brown, N; Buckley, L; Butler, P; Caws, C; Chakkarapani, E; Chatar, K; Chivima, B; de la Torre, CC; Cobain, K; Cotterill, D; Courtney, E; Cowman, S; Coy, K; Crosby, H; Curtis, K; Davis, P; Drewett, O; Dymond, H; Edgerley, K; Ekoi, M; Elokl, M; Evans, B; Farmery, T; Fineman, N; Finn, A; Gamble, L; Garty, F; Gibbison, B; Gourbault, L; Grant, D; Gregory, K; Griffin, M; Groome, R; Hamdollah-Zadeh, M; Hannington, A; Heywood, J; Hindmarsh, A; Holling, N; Houlihan, R; Hrycaiczuk, J; Hudson, H; Hurley, K; Jarvis, R; Jeffs, B; Jones, A; Jones, RE; King-Oakley, E; Kirkham, E; Kumar, R; Kurdy, M; Kyle, L; Lang, S; Leandro, L; Legge, H; Loro, F; Low, A; Martin, H; McCullagh, L; McMahon, G; Millett, L; Millington, K; Mok, J; Moon, JH; Morgan, L; Mulligan, S; O'Donovan, C; Payne, E; Penman, C; Pickard, J; Plumptre, C; Ramanan, A; Ramirez, J; Ratcliffe, S; Robinson, J; Roderick, M; Scattergood, S; Schadenberg, A; Sheppeard, R; Shioi, C; Simpson, D; Skorko, A; Squires, R; Stuttard, M; Sugden, P; Sundar, S; Swart, T; Swift, E; Thompson, K; Turner, K; Turner, S; Tyer, A; Vergnano, S; Vincent, R; Ward, R; Wilkinson, S; Williams, J; Williams, S; Willis, J; Winter, H; Woollen, L; Wright, R; Ibrahim, AY; Collini, P; Ang, A; Belcher, J; Chapman, L; Chin, K; Cohen, D; Cole, J; Colton, HE; Condliffe, R; Cribb, M; Curran, S; Darton, T; de Fonseka, D; de Silva, T; Dunn, A; Ferriman, E; Foster, RA; Greig, J; Hall, J; Haq, MU; Hardman, S; Headon, E; Holden, C; Hunt, L; Hurditch, E; Kibutu, F; Kitching, T; Lewis, L; Locke, T; Mair, L; May, P; Meiring, J; Middle, J; Middleton, JT; Morris, P; Newman, T; Passby, L; Payne, R; Rana, GF; Renshaw, S; Rothman, A; Sammut, D; Sherwin, S; Simpson, P; Sterrenburg, M; Stone, B; Surtees, M; Telfer, A; Thompson, R; Vethanayagam, N; West, R; Williams, T; Patel, K; Imray, C; Aldridge, N; Campbell, A; Evans, G; French, E; Grenfell, R; Hewins, S; Hewitt, D; Jones, J; Kumar, R; Mshengu, E; Quenby, S; Read, K; Satodia, P; Sear, E; Truslove, M; Kerry, A; Beale, A; Brooks, A; Browne, C; Butler, J; Callaghan, J; Chandrasekaran, B; Coombs, C; Davies, R; Davies, L; Elias, T; Fowler, E; Gowda, G; Gregory, J; Ipe, A; Jaffery, A; Jones, Q; Kyeremeh, L; Laing-Faiers, I; Langton, H; Lewis-Clarke, C; Mackinlay, C; Mappa, P; Maxwell, A; Mears, W; Mousley, E; Onyirioha, T; Pannell, L; Peglar, S; Pereira, A; Pointon, J; dos Reis, IPB; Price, E; Quayle, A; Qurratulain, Q; Small, S; Smith, H; Stratton, E; Tinkler, M; van der Meer, A; Wakefield, E; Waller, R; Walton, M; Watters, M; Whittam, L; Wiliams, T; Xia, Z; Yein, K; Zinyemba, V; Cupitt, J; Ahmed, N; Assaf, O; Barnett, A; Benham, L; Bradley, P; Bradshaw, Z; Brunton, M; Capstick, T; Caswell, M; Cunliffe, V; Downes, R; Latt, N; McDonald, R; Mulla, A; Mutema, E; Navin, J; Parker, A; Preston, S; Slawson, N; Stoddard, E; Traynor, S; Vasudevan, V; Ward, E; Warden, SA; Wilson, J; Zmierczak, A; Bari, S; Higham, A; Al-Jibury, M; Allison, K; Anu, V; Bartlett, C; Bhuiyan, S; Bishop, L; Burns, K; Davies, A; Fielding, A; Gorst, M; Hay, C; Keating, J; Khan, T; Mahmood, F; Mallinder, P; Peters, S; Power, D; Ritchie, J; Simpson, K; Spickett, H; Stokes, C; Thatcher, H; Varghese, A; Wan, T; Wood, F; Convery, R; Acheson, J; Brannigan, J; Cosgrove, D; McCullough, C; McFarland, D; McNulty, R; Sands, S; Thompson, O; Balasubramaniam, M; Subudhi, C; Acton, C; Ajmi, A; Ahmed, R; Ajmi, A; Al-Asadi, A; Amin, A; Bajandouh, A; Bhalme, M; Carrington, Z; Chadwick, J; Cocks, S; Dawe, C; Eusuf, A; Farzana, S; Hill, P; Holmes, R; Hughes, G; Hull, R; Ibrahim, K; Ijaz, M; Kalayi, RJ; Khurana, S; Latham, S; Lipscomb, K; Lomas, JP; Natarajan, N; Nethercott, D; Nicholas, P; Obeng, D; Priyash, V; Rhead, K; Saleh, M; Sharma, O; Shehata, Z; Shurmer, J; Sime, R; Singh, S; Smith, R; Tanton, E; Tewkesbury, D; Thet, P; Thornton, S; Wang, N; Watts, M; Webster, I; Easom, N; Adams, K; Baldwin, L; Barlow, G; Barton, R; Bexhell, H; Clark, D; Gunasekera, P; Harvey, A; Hayes, M; Ivan, M; James, A; Kassianides, X; Khan, S; Kolodziej, M; Lillie, P; Mathew, V; Mongolu, S; Muazzam, IA; O'Reilly, P; Perinpanathan, T; Philbey, C; Pickwell-Smith, B; Rollins, L; Samson, A; Sathyapalan, T; Sherris, L; Sivakumar, K; Taynton, T; Yates, H				Horby, P. W.; Roddick, A.; Spata, E.; Staplin, N.; Emberson, J.; Pessoa-Amorim, G.; Brightling, C.; Prudon, B.; Chadwick, D.; Ustianowski, A.; Ashish, A.; Todd, S.; Yates, B.; Buttery, R.; Scott, S.; Maseda, D.; Baillie, J. K.; Buch, M.; Chappell, L.; Day, J.; Faust, S. N.; Jaki, T.; Jeffery, K.; Juszczak, E.; Lim, W. S.; Montgomery, A.; Mumford, A.; Rowan, K.; Thwaites, G.; Mafham, M.; Haynes, R.; Landray, M. J.; Horby, P. W.; Landray, M. J.; Baillie, J. K.; Buch, M.; Chappell, L.; Day, J.; Faust, S. N.; Haynes, R.; Jaki, T.; Jeffery, K.; Juszczak, E.; Lim, W. S.; Mafham, M.; Montgomery, A.; Mumford, A.; Rowan, K.; Thwaites, G.; Sandercock, P.; Darbyshire, J.; DeMets, D.; Fowler, R.; Lalloo, D.; Roberts, I.; Wittes, J.; Horby, P.; Landray, M. J.; Haynes, R.; Fletcher, L.; Barton, J.; Basoglu, A.; Brown, R.; Brudlo, W.; Denis, E.; Howard, S.; McChlery, G.; Taylor, K.; Cui, G.; Goodenough, B.; King, A.; Lay, M.; Murray, D.; Stevens, W.; Wallendszus, K.; Welsh, R.; Crichton, C.; Davies, J.; Goldacre, R.; Harper, C.; Knight, F.; Latham-Mollart, J.; Mafham, M.; Nunn, M.; Salih, H.; Welch, J.; Campbell, M.; Pessoa-Amorim, G.; Peto, L.; Roddick, A.; Knott, C.; Wiles, J.; Bell, J. L.; Emberson, J.; Juszczak, E.; Linsell, L.; Spata, E.; Staplin, N.; Bagley, G.; Cameron, S.; Chamberlain, S.; Farrell, B.; Freeman, H.; Kennedy, A.; Whitehouse, A.; Wilkinson, S.; Wood, C.; Reith, C.; Davies, K.; Halls, H.; Holland, L.; Wilson, K.; Howie, L.; Lunn, M.; Rodgers, P.; Barnard, A.; Beety, J.; Birch, C.; Brend, M.; Chambers, E.; Chappell, L.; Crawshaw, S.; Drake, C.; Duckles-Leech, H.; Graham, J.; Harman, T.; Harper, H.; Lock, S.; Lomme, K.; McMillan, N.; Nickson, I.; Ohia, U.; OKell, E.; Poustie, V.; Sam, S.; Sharratt, P.; Sheffield, J.; Slade, H.; Hoff, W. Van't; Walker, S.; Williamson, J.; De Soyza, A.; Dimitri, P.; Faust, S. N.; Lemoine, N.; Minton, J.; Gilmour, K.; Pearson, K.; Armah, C.; Campbell, D.; Cate, H.; Priest, A.; Thomas, E.; Usher, R.; Johnson, G.; Logan, M.; Pratt, S.; Price, A.; Shirley, K.; Walton, E.; Williams, P.; Yelnoorkar, F.; Hanson, J.; Membrey, H.; Gill, L.; Oliver, A.; Das, S.; Murphy, S.; Sutu, M.; Collins, J.; Monaghan, H.; Unsworth, A.; Beddows, S.; Williams, K. Barker; Dowling, S.; Gibbons, K.; Pine, K.; Asghar, A.; Aubrey, P.; Jewell, D. Beaumont; Donaldson, K.; Skinner, T.; Luo, J.; Mguni, N.; Muzengi, N.; Pleass, R.; Wayman, E.; Coe, A.; Hicks, J.; Hough, M.; Levett, C.; Potter, A.; Taylor, J.; Dolman, M.; Gerdes, L.; Hall, C.; Lockett, T.; Wessex, D. Porter; Bartholomew, J.; Dowden, L.; Rook, C.; Walters, J.; Denton, E.; Tinkler, H.; Alexander, A.; Campbell, H.; Chapman, K.; Hall, A.; Rodgers, A.; Boyle, P.; Brookes, M.; Callens, C.; Duffy, H.; Green, C.; Hampshire, K.; Harrison, S.; Kirk, J.; Naz, M.; Porter, L.; Ryan, P.; Shenton, J.; Warmington, J.; Amezaga, M.; Dicks, P.; Goodwin, J.; Hodgson, H.; Jackson, S.; Odam, M.; Williamson, D.; Faust, S. N.; Bamford, A.; Bandi, S.; Bernatoniene, J.; Cathie, K.; Dmitri, P.; Drysdale, S.; Emonts, M.; Evans, J.; Finn, A.; Fleming, P.; Furness, J.; Gale, C.; Haynes, R.; Jones, C. E.; Juszczak, E.; Jyotish, D.; Kelly, D.; Murray, C.; Pathan, N.; Pollock, L.; Ramanan, A.; Riordan, A.; Roehr, C.; Wan, M.; Whittaker, E.; Chappell, L.; Hodson, K.; Knight, M.; Pavord, S.; Williamson, C.; Odam, M.; Black, P.; Gallagher, B.; MacInnes, L.; O'Brien, R.; Priestley, K.; Saunderson, A.; Bowman, L.; Chen, F.; Clarke, R.; Goonasekara, M.; Haynes, R.; Herrington, W.; Judge, P.; Mafham, M.; Ng, S.; Preiss, D.; Reith, C.; Sammons, E.; Zhu, D.; Pinches, H.; Bowker, P.; Byrne-Watts, V.; Chapman, G.; Coleman, G.; Gray, J.; Rees, A.; Landray, M. J.; Mafham, M.; Mather, N.; Stephenson, C.; Denwood, T.; Harrison, D.; Turner, G.; Bruce, J.; Arkley, C.; Rees, S.; Brightling, C.; Brunskill, N.; Wiselka, M.; Adenwalla, S.; Andreou, P.; Bakoulas, P.; Bandi, S.; Batham, S.; Beaver, T.; Bhandal, K.; Bourne, M.; Boyles, L.; Cannon, M.; Charalambou, A.; Cheung, C. Kay; Cotter, R.; Diver, S.; Dunphy, A.; Elneima, O.; Fawke, J.; Finch, J.; Gardiner-Hill, C.; Genato, G.; Graham-Brown, M.; Haines, C.; Hargadon, B.; Holdsworth, H.; Ibrahim, W.; Ingram, L.; Silva, J. Antonio Jesus; Kaul, K.; Joshi, M.; Kapoor, S.; Kim, J. Whang; Kuverji, A.; Kyriaki, K.; Lea, A.; Lee, T.; Lewszuk, A.; Lock, L.; Macconaill, K.; Major, R.; McAuley, H.; McCourt, P.; Kutten, D. Mullasseril; Palfreeman, A.; Parker, E.; Patel, K.; Patterson, M.; Phillips, R.; Plummer, L.; Russell, R.; Debbie, S.; Selvaskandan, H.; Southin, S. Michaela; Tsilimpari, K. Karali; Wiesender, C.; Yousuf, A.; Ustianowski, A.; Raw, J.; Tully, R.; Abdusamad, K.; Antonina, Z.; Ayaz, E.; Blackledge, B.; Bradley, P.; Bray, F.; Bruce, M.; Carty, C.; Charles, B.; Connolly, G.; Corbett, C.; Dermody, S.; Durrans, L.; Falconer, E.; Flaherty, J.; Fox, C.; Hadfield, D.; Harris, J.; Hoggett, L.; Horsley, A.; Hussain, S.; Irving, R.; Jacob, P.; Johnstone, D.; Joseph, R.; Melville, J. Julie; Kamath, P.; Khatun, T.; Lamb, T.; Law, H.; Lazo, M.; Lindergard, G.; Lokanathan, S.; Macfarlane, L.; Mathen, S.; McCullough, S.; McMaster, P.; McSorland, D.; Mishra, B.; Munt, S.; Neal, A.; Newport, R.; O'Connor, G.; O'Riordan, D.; Page, I.; Parambil, V.; Philbin, J.; Pinjala, M. Tejha; Rishton, C.; Riste, M.; Rothwell, J.; Sam, M.; Sarwar, Z.; Scarratt, L.; Sengupta, A.; Sharaf, H.; Prudon, B.; Jagannathan, V.; Adams, C.; Aung, N.; Barker, D.; Campbell, B.; Collins, V.; Deane, J.; Fenner, I.; Gowans, S.; Hartrey, W.; Nafei, M.; Poole, L.; Purvi, S.; Quigley, J.; Ramshaw, A.; Shepherd, L.; Skelton, J.; Srinivasan, R.; Taylor, R.; Walker, M.; Weetman, M.; Wetherall, B.; Wild, S.; Wilson, D.; Lim, W. S.; Ali, M.; Andrews, A.; Anderson, L.; Ashraf, S.; Ashton, D.; Babingto, G.; Bartlett, G.; Batra, D.; Bendall, L.; Benetti, N.; Brear, T.; Buck, A.; Bugg, G.; Butler, J.; Butler, J.; Cammack, R. F. D.; Cantliff, J.; Clark, L.; Connor, E.; Davies, P.; Dent, M.; Dobson, C.; Fatemi, M.; Fatemi, A.; Fleming, L.; Grundy, J.; Hallas, J.; Hodgen, L.; Hodgson, S.; Hodgkinson, S.; Howard, L.; Hutchinson, C.; Jackson, B.; Kaur, J.; Keddie-Gray, E.; Khurana, C.; Langley, M.; Looby, L.; Meredith, M.; Morris, L.; Navarra, H.; Nicol, R.; Oliver, J.; Peters, C.; Petrova, B.; Rose, Z.; Ryan, L.; Sampson, J.; Squires, G.; Squires, J.; Taylor, R.; Thomas, A.; Thornton, J.; Topham, K.; Warburton, S.; Wardle, S.; Waterfall, H.; Wei, S.; Wildsmith, T.; Wilson, L.; Chadwick, D.; Armstrong, S.; Athorne, D.; Branch, M.; Brolly, J.; Brown, S.; Cheaveau, J.; Chen, H. Min; Chua, Y.; Cunningham, N.; Dodds, J.; Dorgan, S.; Dunn, D.; Harper, P.; Harwood, H.; Hebbron, K.; Hunt, F.; Bhushan, A. Kala; Lambert, P.; Leaning, D.; Manders, T.; McCarron, B.; Miller-Biot, N.; Milne, C.; Mohammad, W.; Mollet, M.; Murad, A.; Owston, M.; Potts, J.; Proctor, C.; Rao, S.; Seelarbokus, M. A.; Singh, P.; Srirathan, V.; Swithenbank, L.; Thompson, L.; Wardy, H.; Wibli, L.; Widdrington, J.; Williams, J.; Winder, P.; Wroe, C.; Elmahi, E.; Zaman, M.; Abdul, B.; Abdulmumeen, A.; Abdulshukkoor, N.; Adnan, A.; Nazeer, M. H. Ahammed; Bazli, A.; Benesh, N.; Chin, W. Jie; Cunningham, N.; Daggett, H.; Davies, E.; Enyi, H.; Fawohunre, S.; Geoghegan, N.; Glover, J.; Hague, J. W.; Hall, K.; Hallett, C.; Haresh, K.; Hassan, W. Ul; Hewertson, J.; Hosea, J.; Htoon, N. Zaya; Idrees, M.; Igwe, C.; Imtiaz, H.; Irshad, M.; Ismail, A.; Jeffrey, R.; Jith, J.; Joshi, P.; Periyasami, R. Kaliannan; Khalid, A.; Khalid, M. Usman; Kodituwakku, R.; Lopez, P.; Mahmood, A.; Malanca, M.; Mapfunde, I. Tatenda; Maruthamuthu, V. Kumar; Masood, S.; Masood, S. S. M. E.; Matharu, M.; Merchant, A.; Merchant, F.; Naqvi, S.; Natarajan, R.; Natarajan, N.; Nawaz, K.; Ndefo, O.; Ogunkeye, O.; Paranamana, S.; Pugh, N.; Raj, A.; Rashid, K.; Rogers, M.; Saad, M.; Selvadurai, G.; Shah, A.; Shahzeb, M.; Shrestha, N.; Singh, A.; Smith, K.; Sohail, B.; Spinks, M.; Stockham, L.; Takyi, A.; Teoh, Y. He; Ullah, S.; Vayalaman, H.; Wafa, S. E. I.; Ward, T.; Watson, R.; White, D.; Melly, L. Ylquimiche; Zulaikha, R.; Green, C.; Whitehouse, T.; Ahmed, I.; Anderson, N.; Armstrong, C.; Bamford, A.; Bancroft, H.; Bates, M.; Begum, S.; Bellamy, M.; Bergin, C.; Bhandal, K.; Brandl-Salutz, E.; Buckingham, E.; Burke, E.; Carmody, M.; Cooper, L.; Daglish, J.; Dasgin, J.; Desai, A.; Dhani, S.; Dosanjh, D.; Ellis, H.; Gardiner, D.; Forster, E.; Grobovaite, E.; Hopkin, B.; Hull, D.; Hussain, Y.; Jones, J.; Khan, L.; Lenton, D.; Lewis, M.; Lovell, M.; Lowe, F.; Lynch, D.; McGhee, C.; McNeill, C.; Moore, F.; Nilsson, A.; Nunnick, J.; Prest, C.; Price, V.; Rhodes, J.; Sale, J.; Sangombe, M.; Smith, H.; Storey, I.; Thrasyvoulou, L.; Tsakiridou, K.; Walsh, D.; Welch, S.; Willis, H.; Wood, L.; Woodford, J.; Wooldridge, G.; Zullo, C.; Desai, P.; Appleyard, D.; Bromley, D.; Chambers, N.; Dale, S.; Gledhill, L.; Goddard, J.; Greig, J.; Haigh, A.; Hallas, K.; Hanson, K.; Holroyd, K.; Home, M.; Kelly, D.; Maharajh, A.; Matapure, L.; Mellor, S.; Merwaha, E.; Riley, H.; Robinson, M.; Sandhu, K.; Schwarz, K.; Shaw, L.; Terrett, L.; Usher, M.; Wilson, A.; Wood, T.; Felton, T.; Abbas, M.; Rasheed, A. Abdul; Abraham, T.; Aggarwal, S.; Akili, S.; Alexander, P. D. G.; Allanson, A.; Al-Sheklly, B.; Arora, D.; Avery, M.; Avram, C.; Aya, A.; Banda, J.; Banks, H.; Baptist, M.; Barrera, M.; Bazaz, R.; Behrouzi, R.; Benson, V.; Bentley, A.; Bhadi, A.; Biju, A.; Bikov, A.; Birchall, K.; Blane, S.; Bokhari, S.; Bradley, P.; Bradley-Potts, J.; Dean, K.; Dhillon, R.; Dolan, D.; Duggan, A.; Duran, B.; Durrington, H.; Eades, C.; Eatough, R.; Clark, R.; Clayton-Smith, J.; Conway, R.; Cook, E.; Cummings-Fosong, G.; Currie, S.; Dalgleish, H.; Davies, C.; Dean, K.; Dhillon, R.; Dolan, D.; Duggan, A.; Duran, B.; Durrington, H.; Eades, C.; Eatough, R.; Elyoussfi, S.; Evans, G.; Fairclough, A.; Faluyi, D.; Ferguson, S.; Fielding, J.; Fiouniz, S.; Fogarty, G.; Fowler, S.; Giannopoulou, S.; Gillott, R.; Gipson, A.; Glasgow, S.; Gorsuch, T.; Grana, G.; Gray, G.; Grayson, A.; Grey, G.; Griffin, B.; Hackney, P.; Hameed, B.; Hamid, I.; Handrean, S.; Henry, J.; Higgins, L.; Holt, L.; Horsley, A.; Howard, L.; Hughes, S.; Hulme, A.; Hulme, P.; Hyslop, M.; Ingham, J.; Ismail, O.; Jafar, A.; Jamal, S.; James, L.; John, A.; Johnstone, E.; Karunaratne, N.; Kausar, Z.; Kayappurathu, J. N.; Kelly, R.; Khan, A.; Khan, W.; Knight, S.; Kolakalurix, E.; Kolakaluri, E.; Kosmidis, C.; Kothandaraman, E.; Krizak, S.; Kyi, N. M.; Lalloo, F.; Logue, C.; Lord, R. W.; Macfarlane, L.; Madden, A.; Mahaveer, A.; Manderson, L.; Margaritopoulos, G.; Marsden, P.; Mathews, J.; McCarthy, E.; McGrath, B.; Mendonca, C.; Metryka, A.; Micallef, D.; Mishra, A.; Mistry, H.; Mitra, S.; Moss, S.; Muazzam, A.; Mudawi, D.; Murray, C.; Naguib, M.; Naveed, S.; Ninan, P.; Nirmalan, M.; Norton, R.; Odell, N.; Osborne, R.; Padden, G.; Palacios, A.; Panes, A.; Pantin, C. T.; Parker, B.; Peacock, L.; Peasley, A.; Pomery, F.; Power, N.; Pursell, M.; Ratcliffe, S.; Reilly, M.; Reynard, C.; Rice, E.; Rice, M.; Riley, P.; Rivera-Ortega, P.; Rogers, J.; Rogers, T.; Santosh, R.; Scott, A.; Sellers, K.; Sen, N.; Shanahan, T.; Shawcross, A.; Shibly, S.; Simpson, A.; Sivanadarajah, S.; Skehan, N.; Smith, C.; Smith, J.; Smith, L.; Soren, J.; Spiller, W.; Stratton, J.; Stubbs, A.; Swist-Szulik, K.; Tallon, B.; Thomas, S.; Thorpe, S.; Tohfa, M.; Tousis, R.; Trafford, M. T.; Turgut, T.; Varghese, M.; Varnier, G.; Venables, I.; Vinay, S.; Wang, R.; Ward, L.; Warner, C.; Watson, E.; Watterson, D.; Wentworth, L.; Whitehead, C.; Wilcock, D.; Williams, J. R.; Willis, E.; Woodhead, L.; Worton, S.; Xavier, B.; Rege, K.; Agbo, C.; Akindolie, O.; Al-Rabahi, A.; Ambrogetti, R.; Aung, K. Thu; Shah, A. Azman; Babs-Osibodu, A. Obaloluwa; Bahadori, K.; Bhayani, J.; Bond, T.; Boughton, H.; Brooks, S.; Butterworth-Cowin, N.; Buttery, R.; Carter, P.; Catana, A. Maria; Cave, L.; Choi, S.; Corogeanu, D.; Croysdill, R.; Davies, M.; de Souza, J.; Duff, N.; Dufour, L.; Ebigbola, O.; Eddings, C.; Faccenda, J.; Feroz, A.; Finch, L.; Freer, C.; Goodyear, P.; Gooentilleke, R.; Gosling, R.; Halford, W.; Havlik, S.; Hoskins, T.; Huson, C.; Ishak, M.; Javed, H.; Jones, T.; Kasianczuk, N.; Kaur, D.; Kerr, A.; Khan, A.; Koshy, G.; Eskenazia, A. Kozak; Lahane, S.; Lami, M. Kadhim Gulam; Marshall, J.; McDevitt, K.; Muru, N.; Mustafa, A. M. M.; Nazir, S.; Okpala, I.; Old, T.; Oleszkiewicz, G.; Orme, H.; O'Sullivan, S.; Paczko, P.; Pandey, A.; Patel, A.; Pathak, S.; Poon, S.; Rather, M. I.; Vattekkat, R. Renu; Rizvi, S. H. M.; Samyraju, M.; Sanyal, J.; Shah, S. H.; Smith, E.; Stacpoole, S.; Tan, B. Theng Tan; Temple, N.; Thazhatheyil, K.; Uddin, M. Saif; Veale, N.; Walter, D.; Ashish, A.; Cooper, J.; Heaton, D.; Hough, S.; Parkinson, V.; Robinson, E.; Taylor, T.; Tierney, C.; Verma, A.; Waddington, N.; Williams, C.; Zipitis, C.; Tiberi, S.; Aboaba, A.; Adeyeye, E.; Agwada-Akeru, J.; Ali, F. Runa; Allen, R.; Ardley, C.; Astin-Chamberlain, R.; Bacon, G.; Baillie, H.; Batha, R.; Bloom, B.; Bolton, M.; Borra, C.; Boyapati, G.; Buchanan, R.; Chan, C.; Chitsenga, C.; Cipriano, B.; Cofie, P. Foster; DeLuna, M.; Elia, S.; El-Shakankery, K.; Fikree, A.; Ghosh, A.; Goiriz, R.; Goldsmith, P.; Gouldbourne, M.; Grant, A.; Greenfield, L.; Grigoriadou, S.; Gritton, R.; Gunganah, K.; Hand, J.; Harwood, C.; Hemmila, U.; Higgins, J.; Hobden, D.; Howaniec, L.; Hsu, D.; Iliodromiti, S.; Issa, S.; Jones, P.; Juan, M.; Kassam, J.; Keith-Jopp, C.; Khan, M.; Khaw, C. Ryan; Kunst, H.; Lai, J.; Lee, I.; Lieberman, D.; Liebeschuetz, S.; Magavern, E.; Maniero, C.; Maitland, J.; Malcolm, H.; Marshall, H.; Matin, N.; May, P.; McDermott, R.; Menacho, K.; Millin, L.; Mohammed, A.; Moriarty, K.; Naeem, S.; Newman, T.; Fhogartaigh, C. Nic; Omar, M.; Pakozdi, A.; Parrott, M.; Pfeffer, P.; Pott, J.; Powell, J.; Ricketts, W.; Riddell, A.; Rughani, P.; Sahdev, N.; Sarodaya, V.; Selvarajah, B.; Skene, I.; Smallshaw, K. Denise; So, A.; Stevenson, D.; Suarez, C.; Swaine, T.; Thomas, S.; Thomas, A.; Thomson, J.; Thorn, N.; Tierney, C.; Ullah, S.; Vathenen, R.; Velauthar, L.; Ward, K.; Wiles, K.; Woodland, P.; Youssouf, S.; Zdanaviciene, A.; Fegan, C.; Balan, A.; Basker, B.; Bird, S.; Boult, Z.; Britten, V.; Broad, L.; Cendl, H.; Chakraborty, M.; Cole, J.; Edgar, M.; Evans, T.; Evans, J.; Evans, M.; Forton, J.; Frayling, S.; Greaves, F.; Harrhy, S.; Haynes, M.; Hill, H.; Hilton, Z.; Jones, L.; Jorgensen, S.; Kelly, A.; Knibbs, L.; Lau, D.; Maureen, E.; May, J.; McGough, E.; McQueen, A.; Milner, J.; Norman, R.; Nyland, K.; Oliver, C.; Paradowski, K.; Patal, M.; Rahilly, K.; Robinson, C.; Scourfield, S.; Starr, M.; Struik, S.; Thomas, E.; Thomas-Turner, R.; Williams, G.; Williams, J.; Williams, M.; Zaher, S.; Hine, P.; Todd, S.; Welters, I.; Wootton, D.; Ahmed, M.; Ahmed, R. A.; Al Balushi, A.; Barr, D.; Bennett, A.; Bond, H.; Burston, C.; Byrne, J.; Chambers, L.; Coey, D.; Cross, T.; Cruise, J.; Fenlon, K.; Gould, S.; Haigh, K.; Hall, C.; Harrison, M.; Hazenberg, P.; Hicks, S. R.; Hope, S.; Hunter, K.; Islim, A.; Iyer, S.; Jackson, A.; Jaime, F.; Keogan, L.; Knowles, K.; Krasauskas, K.; Lewis, J.; Lopez, P.; Lowe, C.; Mediana, A.; Middleton, M.; Nugent, M.; Pauls, L.; Pringle, S.; Quayle, I.; Raghunath, S.; Riley, M.; Sedano, J.; Shaw, D.; Smith, C.; Stevenson, S.; Stockdale, A.; Tangney, R.; Tempany, J.; Waugh, V.; Williams, K.; Yates, B.; Ashbrook-Raby, C.; Campbell, H.; Charlton, D.; Dodds, S.; Ferguson, V.; Hall, T.; Hamoodi, I.; Heslop, P.; Luke, J.; McLarty, N.; Patterson, L.; Pick, S.; Reynolds, J.; Robinson, S.; Tanney, C.; Taylor, L.; Winder, L.; Walker, C.; Scott, S.; Abouibrahim, M.; Ahmad, M.; Ahmed, S. Haris; Ajibode, A.; Alomari, L.; Asrar, A.; Austin, E.; Bamford, P.; Barclay, A.; Barker, L.; Barker-Williams, K.; Barnsley, W.; Batty, H.; Benton, I.; Billingham, S.; Brearey, S.; Brigham, S.; Brooker, V.; Burchett, C.; Burgess, M.; Cade, R.; Cameron, F.; Cannan, R.; Cawley, K.; Chavasse, N.; Cheng, Z.; Clarke, R.; Cole, E.; Cotton, C.; Davidson, A.; Doi, Y.; Dragos, C.; Ellerton, L. Nicola; Gamble, L.; Grant, M.; Grounds, J.; Hodgkins, H.; Irshad, M. Shoaib; Iyer, M.; Johari, A.; Jones, C.; Kearsley, N.; Lim, B.; Llanera, D. Kevin; Loh, S. Yin; London, E.; Martin, E.; Maskell, P.; McBurney, J.; McCarthy, M.; McEwen, R.; Meeks, E.; Metcalf-Cuenca, G.; Middleton, S.; Mihalca-Mason, L.; Nayyar, M.; Naz, F.; Okpo, E.; Parry, H. Claire; Pearson, S. Anthony; Phillips, D.; Pickering, C.; Ponnuswamy, A.; Prescott, V.; Prince, J.; Rahman, S. Ur; Scott, S.; Steele, C.; Thorne, C.; Tomlin, S.; Trussell, T.; Webster, T.; Zammit, L.; Zin, E. Thant; Grahamx, C.; Graham, C.; Abdelaziz, A.; Ali, O.; Atkinson, J.; Bell, G.; Brewer, C.; Clapham, M.; Gregory, J.; Hanif, S.; Harper, R.; Lane, M.; McSkeane, A.; Poultney, U.; Poulton, K.; Pritchard, S.; Shah, S.; Smit, C.; Tzavaras, P.; Vasadi, V.; Wilson, A.; Wilson, T.; Zehnde, D.; Shaw, D.; Tariq, S.; Ahmed, N.; Ali, S.; Allen, S.; Alzetani, M.; Ambrose, C.; Aneke, K.; Angel, T.; Aung, Z. Myo; Banerjee, R.; Baqai, T.; Batla, A.; Bergstrom, M.; Bhakta, S.; Bibi, N.; Chapman, T.; David, A.; Dirmantaite, L.; Edmondson, M.; Elfar, E.; Elgamal, M. Magdy; El-Sbahi, H.; Fishman, D.; Fornolles, C.; Forshall, T.; Francioni, A.; Gent, S.; George, N.; Ibrahim, A.; Ingram, A.; James, R.; Dawa, K. Kabiru; Khan, F.; Khan, M. Aamaz; Lee, S.; Lingam, C.; Luximon, C. Nisha; Marcus, N.; Masood, M.; Mejri, R.; Moharram, A.; Moss, C.; Naik, G.; Ng, A. Yong Kheng Cordero; Nicholls, L.; Nisar, M.; Parmar, V.; Raj, F. Prasanth; Puisa, V.; Quick, V.; Ramabhadran, B.; Reddy, A.; Riaz, N.; Rudran, B.; Sabaretnam, S.; Sagoo, H.; Sarma, S.; Savlani, K.; Shah, P.; Shaw, D.; Soo, S.; Sothirajah, P.; Southern, I.; Tate, M. Louise; Travill, C.; Uppal, V. Singh; Wakeford, W.; Brown, T.; Andrews, J.; Baker-Moffatt, M.; Bamgboye, A.; Barnes, D.; Baryschpolec, S.; Bell, L.; Borbone, J.; Broadway, M.; Brogan, F.; Bungue-Tuble, R.; Burrows, K.; Chauhan, A.; Chauhan, M.; Cowan, E.; Darbyshire, A.; Davey, M.; David, M.; Denham, J.; Downe, H.; Edwards, C.; Fox, L.; Garner, Z.; Giles, B.; Gribbin, A.; Harrington-Davies, Y.; Hawes, L.; Hicks, A.; Hossain, E.; Howe, S.; Jones, B.; Lameirinhas, C.; Longhurst, B.; Mamman, M.; McCready, S.; Minnis, C.; Moon, M.; Mouland, J.; Murray, L.; Rose, S.; Rupani, H.; Rutgers, M.; Scorrer, T.; Scott, K.; Thornton, R.; Tiller, A.; Turner, C.; Wands, M.; Watkins, L.; White, M.; Wiffen, L.; Winter, J.; Winn, S.; Wake, R.; Sadiq, S. Ahamed; Aldana, A.; Al-Hakim, B.; Agyapong, K. Ansu; Azzopardi, G.; Chicano, R.; Chukwulobelu, I.; Colbeck, N.; Cole, N.; Dogra, R.; Doherty, E.; Elradi, A.; Emberton, J.; Evans, T. J.; Ganapathy, R.; Haque, M.; Hayre, R.; Jain, S.; Jian, K.; Johnson, L.; Johnson, A.; Kotecha, J.; Kundu, A.; Langer, D.; Mashhoudi, Y.; Mathias, K.; Maxan, M. E.; Mellor, F.; Morgan, M.; Nafees, S.; Sai, V. Bharadwaj Palagiri; Phanish, M.; Rahimi, H. Rana; Ramanna, S.; Ratoff, J.; Rozewicz, S.; Samuel, T. D. L.; Shah, B.; Shahnazari, S.; Shail, R.; Sharif, A.; Somalanka, S.; Suckling, R.; Swift, P.; Tyagi, V.; Vilimiene, N.; Wells, C.; Maseda, D.; Ball, C.; Best, K.; Bridgwood, G.; Broadhurst, R.; Brockelsby, C.; Brockley, T.; Brown, J.; Bujazia, R.; Clarke, S.; Cremona, J.; Dixon, C.; Dowson, S.; Drogan, H.; Duncan, F.; Emmett, C.; Emms, M.; Farooq, H.; Fullerton, D.; Gabriel, C.; Hammersley, S.; Hum, R.; Jones, T.; Kay, S.; Kelly, E.; Kidd, M.; Lees, D.; Lowsby, R.; Matovu, E.; McIntyre, K.; Moulton, H.; Nourein, K.; Nytianandan, G.; O'Brian, M.; Pagett, K.; Ritchings, A.; Smith, S.; Taylor, J.; Thomas, K.; Turbitt, K.; Yasmin, S.; Spittle, N.; Weatherly, N.; Beavis, S.; Beghini, S.; Blundell, L.; Bradder, J.; Cort, J.; Cresswell, J.; Dale, K.; Foo, A.; Gardner, J.; Gascoyne, R.; Hall, E.; Kelly-Baxter, M.; Mackay, E.; Moxham, K.; Padmakumar, A.; Pritchard, K.; Salmon, J.; Smith, A.; Sorice, V.; Stevenson, L.; Whileman, A.; Wolodimeroff, E.; Meda, M.; Democratis, J.; Barnes, N.; Brooks, N.; Chapman, L.; da Rocha, J.; Dolman, R.; Edwards, A.; Foster, T.; Fowe, F.; Gaywood, E.; Gee, S.; Jaiswal, S.; Molloholli, M.; Raguro, A.; Regan, F.; Rowe-Leete, L.; Smith, C.; van de Venne, M.; Weerasinghe, T.; Jeffery, K.; Ainsworth, M.; Arnison-Newgass, C.; Bashyal, A.; Beer, S.; Bloss, A.; Buttress, D.; Byrne, W.; Capp, A.; Carter, P.; Cicconi, P.; Corrigan, R.; Coston, C.; Cowen, L.; Davidson, N.; Downs, L.; Edwards, J.; Evans, R.; Gardiner, S.; Georgiou, D.; Gillesen, A.; Harin, A.; Havinden-Williams, M.; Haynes, R.; Hird, C.; Hudak, A.; Hutton, P.; Irons, R.; Jastrzebska, P.; Johnston, S.; Kamfose, M.; Lewis, K.; Lockett, T.; del Rocio, F. Mendoza Maria; Garrido, J. Carlos Martinez; Masih, S.; Mentzer, A.; Morris, S.; O'Callaghan, C.; Oliver, Z.; Paulus, S.; Perez, E.; Periyasamy, L.; Peto, L.; Porter, D.; Prasath, S.; Purdue, C.; Ramasamy, M.; Roehr, C. C.; Rudenko, A.; Sanchez, V.; Sarfatti, A.; Segovia, M.; Sewdin, T.; Seymour, J.; Skinner, V.; Smith, L.; Diaz, A. Sobrino; Taylor-Siddons, M.; Thraves, H.; Tsang, C.; Vatish, M.; Warren, Y.; Wilcock, E.; Khan, B.; Ail, D.; Aldouri, R.; Awadzi, G.; Bassoy, B.; Bhalla, R.; Billings, J.; Bokhari, S.; Boniface, G.; Cernova, J.; Chen, T.; Chimbo, P.; Chitalia, N.; Bamfo, S. Danso; Depala, D.; Dhanoa, A.; Edmunds, T.; Fernandez, E.; Ferrari, T.; Fuller, B.; Gherman, A.; Heire, R.; Ilves, L.; Lacey, L.; Lawrence, E.; Lewis, M.; Maric, A.; Martin, W.; Min, Z.; Newman, C.; Nicholas, R.; Olufuwa, O.; Pieniazek, N.; Qadeer, T.; Rathore, S.; Sathianandan, S.; Scott, C.; Shonubi, A.; Siddique, S.; Sisson, G.; Soan, M.; Streit, D.; Stuart, C.; Szekely, M.; Umeojiako, W.; Urruela, S.; Warner, B.; Waterstone, M.; White, S.; Yip, K.; Zafar, A-M; Zaman, S.; West, R.; Abrams, J.; Baldwin, A.; Bannister, O.; Barker, J.; Beddall, H.; Blamey, H.; Chan, E.; Chaplin, J.; Chisnall, B.; Cleaver, C.; Crotty, S.; Dey, P.; Downs, L.; Kononen, M.; Kudsk-Iversen, S.; Kudzinskas, A.; Laurenson, M.; Mandeville, J.; McLure, S.; Morgan-Smith, E.; Ngumo, A.; Oxlade, R.; Parekh, A.; Rahman, M.; Robertson, C.; Shah, S.; Tebbutt, J.; Vella, N.; Veres, M.; Watson, A. J. R.; Wong, N.; Zammit-Mangion, M.; Zia, M.; Gray, A.; Baillie, K.; Adam, M.; Anand, A.; Anderson, R.; Baird, D.; Balaskas, T.; Balfour, J.; Black, P.; Blackstock, C.; Brady, S.; Campbell, R.; Carter, J.; Chapman, P.; Cheyne, C.; Christides, A.; Christmas, D.; Crisp, L.; Cryans, D.; Dear, J.; Dhaliwal, K.; Docherty, M.; R, Dodds; Donald, L.; Dummer, S.; Eddleston, M.; Fethers, N.; Foster, E.; Frake, R.; Gaughan, E.; D, Gilliland; Godson, E.; Grahamslaw, J.; Grant, A.; Grubb, N.; Hainey, S.; Harding, Z.; Harris, M.; Harvey, M.; Henshall, D.; Hobson, S.; Hunter, N.; Jaly, Y.; Jameson, J.; Japp, D.; Khin, H. Htet Ei; Kitto, L.; Krupej, S.; Langoya, C.; Lawrie, R.; Lloyd, A.; Lyell, B.; Lynch, D.; Macfarlane, J.; MacInnes, L.; MacRaild, A.; Marecka, M.; Marshall, A.; Martin, M.; McCann, C.; McCurrach, F.; Moatt, E.; Morley, W.; Morrissey, M.; Newby, D.; Din, K. Nizam Ud; O'Brien, R.; O'Sullivan, E.; Odam, M.; Peterson, A.; Phelan, P.; Pickering, G.; Quinn, T.; Robertson, N.; Rooney, L.; Rowan, N.; Salman, R.; Small, E.; Stefanowska, P.; Stevenson, A.; Stock, S.; Summers, A.; Teasdale, J.; Walker, I.; Walker, K.; Williams, A.; Wight, A.; Bailey, L.; Bokhari, S. Owais; Brownlee, S.; Bull, A.; Corless, J.; Denmade, C.; Ellard, N.; Farrell, A.; Hufton, A.; Jacob, R.; Jones, K. Elizabeth; Kerss, H.; McEntee, J.; Morris, N.; Myagerimath, R.; Newcombe, T.; Parsonage, M.; Peake, H.; Pearson, D.; Penfold, R.; Rath, S.; Saunders, R.; Sharp, A.; Spencer, B.; Suliman, A.; Sutton, S.; Tan, H.; Tarpey, D.; Thompson, L.; Thornton, T.; Twohey, E.; Wagstaff, D.; Wahbi, Z.; Williams, S.; Phull, M.; Umaipalan, A.; Ah-Chuen, J.; Ainsley, A.; Baijiu, G.; Basumatary, A.; Calderwood, C.; Dugh, P.; Dunne, K.; Greaves, P.; Hunt, K.; Islam, M.; Katsande, V.; Khan, M. R.; King, S.; Loverdou, A.; McGregor, A.; Misbahuddin, A.; Mohamed, A.; Nagesh, N.; Nicholls, D.; O'Brien, N.; Parker, L.; Pogreban, T.; Rosaro, L.; Salciute, E.; Sharma, M.; Smith, H.; Visentin, E.; Walshaw, L.; Saralaya, D.; Akhtar, N.; Beckett, V.; Brear, L.; Drew, V.; Eedle, J.; Hawes, N.; Kmachia, S.; Moss, S.; Oddie, S.; Paget, J.; Regan, K.; Ryan-Wakeling, D.; Shenoy, A.; Storton, K.; Swingler, R.; Syson, J.; Todd, J.; Wane, R.; Wilson, A.; Fuller, E.; MacNair, A.; Brown, C.; Burns, A.; Caroline, C.; Davidson, R.; Dickson, M.; Duncan, B.; Elkaram, N.; Emmerson, I.; Fairlie, L.; Hashimm, M.; Henderson, J.; Hinshaw, K.; Holden, J.; Hovvels, R.; Laybourne, S.; Madgwick, P.; Martin, K.; McKee, M.; Moore, J.; Mullen, N.; Murphy, P.; Palmer, L.; Parish, G.; Rangar, M.; Shahrul, R.; Smith, A.; Smith, L.; Smith, M.; Stidolph, B.; Terry, L.; Trotter, A.; Wakinshaw, F.; Walton, E.; Walton, M.; Frise, M.; Arimoto, R.; Black, S.; Camm, C.; Coles, H.; De Berker, H.; Fries, A.; Gabbitas, E.; Hasan, N.; Htet, Z.; Jacques, N.; Kashif, S.; Keating, L.; Leafe, S.; Milne, Z.; Mitchell, B.; Okeke, T.; Orchard, W.; Parmar, A.; Raffles, M.; Shields, N.; Thakker, M.; Thomas, M.; Wakefield, H.; Walden, A.; Moreno-Cuesta, J.; Rokadiya, S.; Govind, A.; Haldeos, A.; Leigh-Ellis, K.; van Someren, C.; Vincent, R.; Walker, L.; Thomas, K.; George, T.; Cannon, E.; Ikomi, A.; Jayasekera, L.; Kittridge, L.; Maloney, G.; Manoharan, B.; Mushabe, M.; Nicholson, A.; Pai, A.; Riches, J.; Samuel, J.; Setty, N.; Solesbury, A.; Southam, D.; Tisi, S.; Vertue, M.; Wadsworth, K.; Yung, B.; Limb, J.; Atkinson, V.; Birt, M.; Brown, E.; Cowton, A.; Craig, V.; Egginton, D.; Fernandes, D.; Ivy, A.; Jayachandran, D.; Jennings, J.; Kay, A.; Kent, M.; McAuliffe, S.; Naylor, S.; Nyamugunduru, G.; O'Brien, J.; Postlethwaite, K.; Potts, K.; Ranka, P.; Rogers, G.; Sen, S.; Temple, J.; Wadd, S.; Walters, H.; Yorke, J.; Whittington, A.; Adamus, M.; Barrett, J.; Cawa, F.; Chhabra, S.; Chita, S.; Dhillon, E.; Filson, S. Ann; Goodall, J.; Gravell, R.; Gupta-Wright, A.; Gurram, S.; Houston, H.; Hulston, G.; Isralls, S.; Kukadiya, C.; Lang, M.; MaeLow, J.; Macleod, C.; Milburn, J.; Muralidhara, K.; Nayar, B.; Ojo, O.; Papineni, P.; Parris, V.; Patel, M.; Quaid, S.; Sethi, J.; Sturdy, A.; Tyagi, B.; Vaccari, L. Cheyenne; van der Stelt, N.; Wallis, G.; Watson, E.; Sarkar, R.; Ahmed, I.; Ahmed, S.; Ambler, S.; Babatunde, F.; Banerjee, S.; Bhatia, N.; Brassington, L.; Brokke, F.; Bruce, D.; Cassimon, B.; Chauhan, R. Singh; Chengappa, A.; Divikar, N.; Donnelly, C.; Froneman, C.; Gnanalingam, C.; Gower, T.; Harizaj, H.; Hettiarachchi, G.; Hollands, M.; Jansz, S.; Josiah, B.; Kamara, M.; Kidney, S.; Kyere-Diabour, T.; Lewiston, K.; Miah, N.; Millington, S.; Mires, L.; Mitchell, A.; Mizzi, C.; Naicker, K.; Petrou, I.; Phulpoto, M. Mubeen; Ross-Parker, A.; Ramadan, I.; Roy, A.; Ryan, A.; Samuels, E.; Sanctuary, T.; Sharma, A.; Singham, S.; Sporrer, J.; Ul Hassan, W.; Vankayalapati, P.; Velan, B.; Smith, L. Vincent; Vyras, E.; Wood, J.; Zuhra, N.; Clare, S.; Ahmed, M. Cecilia; Beuvink, Y.; Blachford, K.; Clamp, S.; Colley, J.; De, P.; Fenton, M.; Gammon, B.; Hayes, A.; Henry, L.; Hussain, S.; Joseph, S.; Kinney, F.; Knight, T.; Kumar, R.; Leong, W.; Lim, T.; Mahay, B.; Nupa, Y.; Orme, A.; Osborne, W.; Pilsworth, Z.; Potter, S.; Prew, S.; Rajaiah, N.; Rajasekaran, A.; Senya, H.; Shah, N.; Shamim, N.; Sivakumar, S.; Smith, L.; Thozthumparambil, P.; Trudgill, N.; Turner, A.; Wagstaff, L.; Willetts, S.; Willis, H.; Yan, M.; Richardson, N.; Alegria, A.; Kapoor, R.; Adegoke, K.; Allen, L.; Beranova, E.; Boehmer, G.; Crisp, N.; Deery, J.; Hansen, J.; Elgohary, A.; Elsefi, T.; Hargreaves, C.; Hazelton, T.; Hulbert, R.; Ionita, A.; Knight, A.; Linares, C.; Loader, D.; Matisa, E.; McAndrew, J.; Montasser, M.; Moon, A.; Oboh, C.; Offord, P.; Price, C.; Rajasri, A.; Rand, J.; Schumacher, N.; Stephensen, D.; Stirrup, S.; Tague, L.; Tilbey, S.; Turney, S.; Vasu, V.; Venditti, M.; Weston, H.; Woodward, Z.; Kemp, T.; Alexander, J.; Al-Shamkhani, W.; Bandla, N.; Bland, A.; Bodasing, N.; Cadwgan, A.; Chaudhary, M. Yafaa Naveed; Cheng, L. Yin; Church, S. Rebecca; Clark, F.; Davies, M.; Diwakar, L.; Eaton, E.; Evans, M.; Farmer, A.; Farook, F.; Gellamucho, M.; Glover, K.; Haris, M.; Humphries, J.; Hussain, I.; Khan, S.; Korcierz, L.; Lee, J.; Machin, J.; Marshall, J.; McCreedy, H.; Muddegowda, G.; Mustapha, I.; Nettleton, K.; Noori, Z.; Osman, W.; Parker, H.; Patel, N.; Quinn, A.; Ram, M.; Remegoso, A.; Scott, T.; Sheikh, N.; Swiftx, R.; Thompson, C.; Tomlinson, J.; Turner, H.; Walker, L.; Weeratunga, J.; White, C.; White, J.; Wu, P.; Szakmany, T.; Champanerkar, S.; Griffiths, A.; Ionescu, A. Alina; Somashekar, C.; Zalewska, K.; Aitken, L.; Baker, E.; Barnett, D.; Brouns, M.; Cann, J.; Cherian, S.; Codd, R.; Cutler, S.; Davies, W.; Dell, A.; Edwards, M.; Edwards, S.; Fairbairn, S.; Hawkins, N.; Hodge, S.; Hodkinson, G.; Hughes, R.; Ivenso, C.; James, T.; Jones, M.; Jones, S.; Lucey, A.; MacCormac, J.; Marshall, G.; McKain, S.; Nassa, H.; Northfield, J.; Palmer, S.; Peter, L.; Price, C.; Pynn, M.; Roynon-Reed, A.; Shipp, L.; Singh, J.; Singh, M.; Swarnkar, K.; Torabi, P.; Venkataramakrishnan, R.; Wall, E.; Waters, A.; Wild, K.; Winstanley, M.; Wyness, K.; Kushakovsky, V.; Ramali, M.; Alam, S.; Bartholomew, S.; Bataineh, A.; Beeby, D.; Bell, S.; Broughton, N.; Buckman, C.; Calver, C.; Campbell, J.; Chabo, C.; Chowdhury, M.; Cooke, K.; Deole, N.; Driscoll, C.; Elden, A.; Eldew, H.; Entwistle, N.; Farnworth, F.; Francis, R.; Galloway, E.; Garfield, M.; Ghosh, A.; Gray, G.; Greenfield, P.; Hadjiandreou, M.; Hewer, H.; Hossain, M. S.; Howard-Griffin, R.; Islam, A.; Jamieson, E.; Jiao, Z.; Johannessen, K.; Lee, S. Han; Lewis, R.; Lloyd, R.; Mabelin, L. Andrew; Morris, D.; Nallapareddy, S.; Ooi, H. C.; Osagie, R.; Parkinson, C.; Patel, H.; Prowse, H.; Purewal, B.; Ridley, P.; Rivers, V.; Rosier, J.; Sharma, S.; Sheik, A.; Skelly, R.; Smith, R.; Sreenivasan, R.; Taylor, A.; Tovey, P.; Turner, A.; Turner, K.; Vithian, K.; Zhixin, J.; Potton, E.; Jain, N.; Khadar, A.; Morgan, P.; Penny, J.; Tatam, E.; Abbasi, S.; Acharya, D.; Acosta, A.; Ahmed, L.; Ali, S.; Alkhusheh, M.; Amosun, V.; Arter, A.; Babi, M.; Bacon, J.; Bailey, K.; Balachandran, N.; Bandyopadhyam, S.; Banks, L.; Barla, J.; Batty, T.; Bax, S.; Belgaumkar, A.; Benison-Horner, G.; Boles, A.; Broomhead, N.; Cetti, E.; Chan, C.; Chaudhry, I.; Chudgar, D.; Clark, J.; Clueit, S.; Collins, S.; Combes, E.; Conway, G.; Curtis, O.; Das, M.; Daschel, M.; Davies, S.; Potton, E.; Abbasi, S.; Acharya, D.; Acosta, A.; Ahmed, L.; Ali, S.; Alkhusheh, M.; Amosun, V.; Arter, A.; Babi, M.; Bacon, J.; Bailey, K.; Balachandran, N.; Bandyopadhyam, S.; Banks, L.; Barla, J.; Batty, T.; Bax, S.; Belgaumkar, A.; Benison-Horner, G.; Boles, A.; Broomhead, N.; Cetti, E.; Chan, C.; Chaudhry, I.; Chudgar, D.; Clark, J.; Clueit, S.; Collins, S.; Combes, E.; Conway, G.; Curtis, O.; Das, M.; Daschel, M.; Davies, S.; Day, A.; Dhar, M.; Diaz-Pratt, K.; Dragan, C.; Dube, H.; Duraiswamy, V.; Elias, J.; Ellis, A.; Ellis, T-Y; Emmanuel, J.; Engden, A.; Fahmay, Y.; Field, B.; Fishwick, K.; Ganesh, U.; Gilbert, C.; Giokanini-Royal, T.; Goudie, E.; Griffith, S.; Gurung, S.; Habibi, R.; Halevy, C.; Haqiqi, A.; Hartley, R.; Hayman, A.; Hives, J.; Horsford, M.; Hughes, S.; Hui, C.; Hussain, R.; Iles, C.; Jackson, L.; James, A.; Jayaram, D.; Jessup-Dunton, E.; Joefield, T.; Khan, N.; Kieffer, W.; Knox, E.; Kumar, V.; Kumar, R.; Kurmars, V.; Lafferty, H.; Lamb, F.; Layug, R.; Leitch, N.; Lim, W.; Limbu, U.; Loveless, R.; Mackenzie, M.; Maghsoodi, N.; Maher, S.; Maljk, M.; Man, I.; McCarthy, N.; Mearns, B.; Mearns, C.; Morgan-Jones, K.; Mortem, G.; Morton, G.; Moya, B.; Murphy, G.; Mutton, S.; Myers, A.; Nasser, T.; Navaratnam, J.; Nazir, S.; Nepal, S.; Nimako, K.; Nimako, L.; O'Connor, C.; Patel, A.; Patel, K.; Phongsathorn, V.; Pillai, P. A.; Poole, M.; Qureshi, N.; Ranjan, S.; Rehman, A.; Samuels, T.; Scott, E.; Sekadde, G.; Sharma, A.; Sharp, G.; Shotton, S.; Simmons, O.; Singh, P.; Smith, S.; Paranthamen, K. Sri; Suresh, S.; Thevarajah, K.; Thomas, L.; Timms, H.; Tomasova, N.; Tucker, S.; Vara, S.; Vaz, C.; Weller, S.; White, J.; Wilde, M.; Wilkinson, I.; Williams, C.; Win, M.; Woosey, D.; Wright, D.; Roberts, M.; Amsha, K.; Cox, G.; Downer, N.; Hodgson, D.; Hutchinson, J.; Kalsoom, S.; Molyneux, A.; Noor, Z.; Allsop, L.; Brear, T.; Buckley, P.; Dunn, L.; Gill, M.; Goodwin, C.; Heeley, C.; Holmes, M.; Holmes, R.; Langthorne, E.; Moulds, C.; Nash, D.; Rajeswary, J.; Shelton, S.; Slack, K.; Smith, S.; Valeria, B.; Wynter, I.; Yanney, M.; Ynter, I.; Azam, J.; Chandler, K. J.; Abdelfattah, M.; Abung, A.; Anderson, J.; Antill, P.; Appleby, S.; Armtrong, P.; Berriman, T.; Bull, D.; Clayton, O.; Corlett, A.; Crocombe, D.; Davies, S.; Elliott, K.; Fahel, L.; Ghosh, J.; Gott, N.; Greenwood, D.; Holder, T.; Inns, P.; Lea, W.; Lindsay, E.; Mack, K.; Marshall, N.; McMeekin, S.; Momoniat, T.; Nikolaos, P.; O'Kane, M.; Patrick, G.; Pearson, H.; Ponnusamy, P.; Poole, A.; Price, N.; Proudfoot, R.; Purssord, G.; Roche, S.; Sefton, C.; Shahi, S.; Smith, D.; Sohail, B.; Thomas, R.; Turnbull, A.; Turner, L.; Watchorn, H. J.; Wiafe, E.; Wilson, J.; Yates, D.; Bruce, M. Schuster; Baldwin, D.; Clark, Z.; Dale, M.; Griffiths, D.; Gunter, E.; Horler, S.; Joyce, T.; Keltos, M.; Kennard, S.; Lakeman, N.; Mallon, L.; Miln, R.; Nix, S.; Orr, S.; Pitts, S.; Purandare, L.; Rogers, L.; Samways, J.; Stride, E.; Vamplew, L.; Wallis, L.; Willis, J.; Blencowe, N.; Singhal, P.; Abraham, M.; Al-Ramadhani, B.; Archer, A.; Aziz, G.; Balcombe, A.; Bateman, K.; Baxter, M.; Beacham, L.; Belfield, K.; Bell, N.; Beresford, M.; Bernatoniene, J.; Bhojwani, D.; Biggs, S.; Blazeby, J.; Bobruk, K.; Brown, N.; Buckley, L.; Butler, P.; Caws, C.; Chakkarapani, E.; Chatar, K.; Chivima, B.; de la Torre, C. Clemente; Cobain, K.; Cotterill, D.; Courtney, E.; Cowman, S.; Coy, K.; Crosby, H.; Curtis, K.; Davis, P.; Drewett, O.; Dymond, H.; Edgerley, K.; Ekoi, M.; Elokl, M.; Evans, B.; Farmery, T.; Fineman, N.; Finn, A.; Gamble, L.; Garty, F.; Gibbison, B.; Gourbault, L.; Grant, D.; Gregory, K.; Griffin, M.; Groome, R.; Hamdollah-Zadeh, M.; Hannington, A.; Heywood, J.; Hindmarsh, A.; Holling, N.; Houlihan, R.; Hrycaiczuk, J.; Hudson, H.; Hurley, K.; Jarvis, R.; Jeffs, B.; Jones, A.; Jones, R. E.; King-Oakley, E.; Kirkham, E.; Kumar, R.; Kurdy, M.; Kyle, L.; Lang, S.; Leandro, L.; Legge, H.; Loro, F.; Low, A.; Martin, H.; McCullagh, L.; McMahon, G.; Millett, L.; Millington, K.; Mok, J.; Moon, J-H; Morgan, L.; Mulligan, S.; O'Donovan, C.; Payne, E.; Penman, C.; Pickard, J.; Plumptre, C.; Ramanan, A.; Ramirez, J.; Ratcliffe, S.; Robinson, J.; Roderick, M.; Scattergood, S.; Schadenberg, A.; Sheppeard, R.; Shioi, C.; Simpson, D.; Skorko, A.; Squires, R.; Stuttard, M.; Sugden, P.; Sundar, S.; Swart, T.; Swift, E.; Thompson, K.; Turner, K.; Turner, S.; Tyer, A.; Vergnano, S.; Vincent, R.; Ward, R.; Wilkinson, S.; Williams, J.; Williams, S.; Willis, J.; Winter, H.; Woollen, L.; Wright, R.; Ibrahim, A. Younes; Collini, P.; Ang, A.; Belcher, J.; Chapman, L.; Chin, K.; Cohen, D.; Cole, J.; Colton, H. E.; Condliffe, R.; Cribb, M.; Curran, S.; Darton, T.; de Fonseka, D.; de Silva, T.; Dunn, A.; Ferriman, E.; Foster, R. Anne; Greig, J.; Hall, J.; Haq, M. Ul; Hardman, S.; Headon, E.; Holden, C.; Hunt, L.; Hurditch, E.; Kibutu, F.; Kitching, T.; Lewis, L.; Locke, T.; Mair, L.; May, P.; Meiring, J.; Middle, J.; Middleton, J. T.; Morris, P.; Newman, T.; Passby, L.; Payne, R.; Rana, G. Farid; Renshaw, S.; Rothman, A.; Sammut, D.; Sherwin, S.; Simpson, P.; Sterrenburg, M.; Stone, B.; Surtees, M.; Telfer, A.; Thompson, R.; Vethanayagam, N.; West, R.; Williams, T.; Patel, K.; Imray, C.; Aldridge, N.; Campbell, A.; Evans, G.; French, E.; Grenfell, R.; Hewins, S.; Hewitt, D.; Jones, J.; Kumar, R.; Mshengu, E.; Quenby, S.; Read, K.; Satodia, P.; Sear, E.; Truslove, M.; Kerry, A.; Beale, A.; Brooks, A.; Browne, C.; Butler, J.; Callaghan, J.; Chandrasekaran, B.; Coombs, C.; Davies, R.; Davies, L.; Elias, T.; Fowler, E.; Gowda, G.; Gregory, J.; Ipe, A.; Jaffery, A.; Jones, Q.; Kyeremeh, L.; Laing-Faiers, I.; Langton, H.; Lewis-Clarke, C.; Mackinlay, C.; Mappa, P.; Maxwell, A.; Mears, W.; Mousley, E.; Onyirioha, T.; Pannell, L.; Peglar, S.; Pereira, A.; Pointon, J.; dos Reis, I. Ponte Bettencourt; Price, E.; Quayle, A.; Qurratulain, Q.; Small, S.; Smith, H.; Stratton, E.; Tinkler, M.; van der Meer, A.; Wakefield, E.; Waller, R.; Walton, M.; Watters, M.; Whittam, L.; Wiliams, T.; Xia, Z.; Yein, K.; Zinyemba, V.; Cupitt, J.; Ahmed, N.; Assaf, O.; Barnett, A.; Benham, L.; Bradley, P.; Bradshaw, Z.; Brunton, M.; Capstick, T.; Caswell, M.; Cunliffe, V.; Downes, R.; Latt, N.; McDonald, R.; Mulla, A.; Mutema, E.; Navin, J.; Parker, A.; Preston, S.; Slawson, N.; Stoddard, E.; Traynor, S.; Vasudevan, V.; Ward, E.; Warden, S. Andrew; Wilson, J.; Zmierczak, A.; Bari, S.; Higham, A.; Al-Jibury, M.; Allison, K.; Anu, V.; Bartlett, C.; Bhuiyan, S.; Bishop, L.; Burns, K.; Davies, A.; Fielding, A.; Gorst, M.; Hay, C.; Keating, J.; Khan, T.; Mahmood, F.; Mallinder, P.; Peters, S.; Power, D.; Ritchie, J.; Simpson, K.; Spickett, H.; Stokes, C.; Thatcher, H.; Varghese, A.; Wan, T.; Wood, F.; Convery, R.; Acheson, J.; Brannigan, J.; Cosgrove, D.; McCullough, C.; McFarland, D.; McNulty, R.; Sands, S.; Thompson, O.; Balasubramaniam, M.; Subudhi, C.; Acton, C.; Ajmi, A.; Ahmed, R.; Ajmi, A.; Al-Asadi, A.; Amin, A.; Bajandouh, A.; Bhalme, M.; Carrington, Z.; Chadwick, J.; Cocks, S.; Dawe, C.; Eusuf, A.; Farzana, S.; Hill, P.; Holmes, R.; Hughes, G.; Hull, R.; Ibrahim, K.; Ijaz, M.; Kalayi, R. J.; Khurana, S.; Latham, S.; Lipscomb, K.; Lomas, J. P.; Natarajan, N.; Nethercott, D.; Nicholas, P.; Obeng, D.; Priyash, V.; Rhead, K.; Saleh, M.; Sharma, O.; Shehata, Z.; Shurmer, J.; Sime, R.; Singh, S.; Smith, R.; Tanton, E.; Tewkesbury, D.; Thet, P.; Thornton, S.; Wang, N.; Watts, M.; Webster, I.; Easom, N.; Adams, K.; Baldwin, L.; Barlow, G.; Barton, R.; Bexhell, H.; Clark, D.; Gunasekera, P.; Harvey, A.; Hayes, M.; Ivan, M.; James, A.; Kassianides, X.; Khan, S.; Kolodziej, M.; Lillie, P.; Mathew, V.; Mongolu, S.; Muazzam, I. A.; O'Reilly, P.; Perinpanathan, T.; Philbey, C.; Pickwell-Smith, B.; Rollins, L.; Samson, A.; Sathyapalan, T.; Sherris, L.; Sivakumar, K.; Taynton, T.; Yates, H.		RECOVERY Collaborative Grp; Publ Heth England; Dept Hlth Social Care DHSC; DHSC Med Supply Contingency; NHS England; NHS Improvement; Movianto UK Ltd; Supply Chain Coordination Ltd	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	LANCET			English	Article								Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65.3 years (SD 15.7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0.97, 95% CI 0.87-1.07; p=0.50). No significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1.04, 95% CI 0.98-1.10; p=0.19). Among those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0.95, 95% CI 0.87-1.03; p=0.24). Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.	[Horby, P.; Landray, M. J.; Haynes, R.; Fletcher, L.; Barton, J.; Basoglu, A.; Brown, R.; Brudlo, W.; Denis, E.; Howard, S.; McChlery, G.; Taylor, K.; Cui, G.; Goodenough, B.; King, A.; Lay, M.; Murray, D.; Stevens, W.; Wallendszus, K.; Welsh, R.; Crichton, C.; Davies, J.; Goldacre, R.; Harper, C.; Knight, F.; Latham-Mollart, J.; Mafham, M.; Nunn, M.; Salih, H.; Welch, J.; Campbell, M.; Pessoa-Amorim, G.; Peto, L.; Roddick, A.; Knott, C.; Wiles, J.; Bell, J. L.; Emberson, J.; Juszczak, E.; Linsell, L.; Spata, E.; Staplin, N.; Bagley, G.; Cameron, S.; Chamberlain, S.; Farrell, B.; Freeman, H.; Kennedy, A.; Whitehouse, A.; Wilkinson, S.; Wood, C.; Reith, C.; Davies, K.; Halls, H.; Holland, L.; Wilson, K.; Howie, L.; Lunn, M.; Rodgers, P.] RECOVERY Cent Coordinating Off, Oxford OX3 7LF, England; [Barnard, A.; Beety, J.; Birch, C.; Brend, M.; Chambers, E.; Chappell, L.; Crawshaw, S.; Drake, C.; Duckles-Leech, H.; Graham, J.; Harman, T.; Harper, H.; Lock, S.; Lomme, K.; McMillan, N.; Nickson, I.; Ohia, U.; OKell, E.; Poustie, V.; Sam, S.; Sharratt, P.; Sheffield, J.; Slade, H.; Hoff, W. Van't; Walker, S.; Williamson, J.; De Soyza, A.; Dimitri, P.; Faust, S. N.; Lemoine, N.; Minton, J.; Gilmour, K.; Pearson, K.; Armah, C.; Campbell, D.; Cate, H.; Priest, A.; Thomas, E.; Usher, R.; Johnson, G.; Logan, M.; Pratt, S.; Price, A.; Shirley, K.; Walton, E.; Williams, P.; Yelnoorkar, F.; Hanson, J.; Membrey, H.; Gill, L.; Oliver, A.; Das, S.; Murphy, S.; Sutu, M.; Collins, J.; Monaghan, H.; Unsworth, A.; Beddows, S.; Williams, K. Barker; Dowling, S.; Gibbons, K.; Pine, K.; Asghar, A.; Aubrey, P.; Jewell, D. Beaumont; Donaldson, K.; Skinner, T.; Luo, J.; Mguni, N.; Muzengi, N.; Pleass, R.; Wayman, E.; Coe, A.; Hicks, J.; Hough, M.; Levett, C.; Potter, A.; Taylor, J.; Dolman, M.; Gerdes, L.; Hall, C.; Lockett, T.; Wessex, D. Porter; Bartholomew, J.; Dowden, L.; Rook, C.; Walters, J.; Denton, E.; Tinkler, H.; Alexander, A.; Campbell, H.; Chapman, K.; Hall, A.; Rodgers, A.; Boyle, P.; Brookes, M.; Callens, C.; Duffy, H.; Green, C.; Hampshire, K.; Harrison, S.; Kirk, J.; Naz, M.; Porter, L.; Ryan, P.; Shenton, J.; Warmington, J.; Amezaga, M.; Dicks, P.; Goodwin, J.; Hodgson, H.; Jackson, S.; Odam, M.; Williamson, D.] Natl Inst Hlth Res Clin Res Network, London, England; [Faust, S. N.; Bamford, A.; Bandi, S.; Bernatoniene, J.; Cathie, K.; Dmitri, P.; Drysdale, S.; Emonts, M.; Evans, J.; Finn, A.; Fleming, P.; Furness, J.; Gale, C.; Haynes, R.; Jones, C. E.; Juszczak, E.; Jyotish, D.; Kelly, D.; Murray, C.; Pathan, N.; Pollock, L.; Ramanan, A.; Riordan, A.; Roehr, C.; Wan, M.; Whittaker, E.] Paediat working Grp, London, England; [Chappell, L.; Hodson, K.; Knight, M.; Pavord, S.; Williamson, C.] Obstetr working Grp, London, England; [Brightling, C.; Brunskill, N.; Wiselka, M.; Adenwalla, S.; Andreou, P.; Bakoulas, P.; Bandi, S.; Batham, S.; Beaver, T.; Bhandal, K.; Bourne, M.; Boyles, L.; Cannon, M.; Charalambou, A.; Cheung, C. Kay; Cotter, R.; Diver, S.; Dunphy, A.; Elneima, O.; Fawke, J.; Finch, J.; Gardiner-Hill, C.; Genato, G.; Graham-Brown, M.; Haines, C.; Hargadon, B.; Holdsworth, H.; Ibrahim, W.; Ingram, L.; Silva, J. Antonio Jesus; Kaul, K.; Joshi, M.; Kapoor, S.; Kim, J. Whang; Kuverji, A.; Kyriaki, K.; Lea, A.; Lee, T.; Lewszuk, A.; Lock, L.; Macconaill, K.; Major, R.; McAuley, H.; McCourt, P.; Kutten, D. Mullasseril; Palfreeman, A.; Parker, E.; Patel, K.; Patterson, M.; Phillips, R.; Plummer, L.; Russell, R.; Debbie, S.; Selvaskandan, H.; Southin, S. Michaela; Tsilimpari, K. Karali; Wiesender, C.; Yousuf, A.] Univ Hosp Leicester NHS Trust, Leicester, Leics, England; [Ustianowski, A.; Raw, J.; Tully, R.; Abdusamad, K.; Antonina, Z.; Ayaz, E.; Blackledge, B.; Bradley, P.; Bray, F.; Bruce, M.; Carty, C.; Charles, B.; Connolly, G.; Corbett, C.; Dermody, S.; Durrans, L.; Falconer, E.; Flaherty, J.; Fox, C.; Hadfield, D.; Harris, J.; Hoggett, L.; Horsley, A.; Hussain, S.; Irving, R.; Jacob, P.; Johnstone, D.; Joseph, R.; Melville, J. Julie; Kamath, P.; Khatun, T.; Lamb, T.; Law, H.; Lazo, M.; Lindergard, G.; Lokanathan, S.; Macfarlane, L.; Mathen, S.; McCullough, S.; McMaster, P.; McSorland, D.; Mishra, B.; Munt, S.; Neal, A.; Newport, R.; O'Connor, G.; O'Riordan, D.; Page, I.; Parambil, V.; Philbin, J.; Pinjala, M. Tejha; Rishton, C.; Riste, M.; Rothwell, J.; Sam, M.; Sarwar, Z.; Scarratt, L.; Sengupta, A.; Sharaf, H.] Pennine Acute Hosp NHS Trust, Manchester, Lancs, England; [Prudon, B.; Jagannathan, V.; Adams, C.; Aung, N.; Barker, D.; Campbell, B.; Collins, V.; Deane, J.; Fenner, I.; Gowans, S.; Hartrey, W.; Nafei, M.; Poole, L.; Purvi, S.; Quigley, J.; Ramshaw, A.; Shepherd, L.; Skelton, J.; Srinivasan, R.; Taylor, R.; Walker, M.; Weetman, M.; Wetherall, B.; Wild, S.; Wilson, D.] North Tees & Hartlepool NHS Fdn Trust, Stockton On Tees, England; [Lim, W. S.; Ali, M.; Andrews, A.; Anderson, L.; Ashraf, S.; Ashton, D.; Babingto, G.; Bartlett, G.; Batra, D.; Bendall, L.; Benetti, N.; Brear, T.; Buck, A.; Bugg, G.; Butler, J.; Cammack, R. F. D.; Cantliff, J.; Clark, L.; Connor, E.; Davies, P.; Dent, M.; Dobson, C.; Fatemi, M.; Fatemi, A.; Fleming, L.; Grundy, J.; Hallas, J.; Hodgen, L.; Hodgson, S.; Hodgkinson, S.; Howard, L.; Hutchinson, C.; Jackson, B.; Kaur, J.; Keddie-Gray, E.; Khurana, C.; Langley, M.; Looby, L.; Meredith, M.; Morris, L.; Navarra, H.; Nicol, R.; Oliver, J.; Peters, C.; Petrova, B.; Rose, Z.; Ryan, L.; Sampson, J.; Squires, G.; Squires, J.; Taylor, R.; Thomas, A.; Thornton, J.; Topham, K.; Warburton, S.; Wardle, S.; Waterfall, H.; Wei, S.; Wildsmith, T.; Wilson, L.] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Chadwick, D.; Armstrong, S.; Athorne, D.; Branch, M.; Brolly, J.; Brown, S.; Cheaveau, J.; Chen, H. Min; Chua, Y.; Cunningham, N.; Dodds, J.; Dorgan, S.; Dunn, D.; Harper, P.; Harwood, H.; Hebbron, K.; Hunt, F.; Bhushan, A. Kala; Lambert, P.; Leaning, D.; Manders, T.; McCarron, B.; Miller-Biot, N.; Milne, C.; Mohammad, W.; Mollet, M.; Murad, A.; Owston, M.; Potts, J.; Proctor, C.; Rao, S.; Seelarbokus, M. A.; Singh, P.; Srirathan, V.; Swithenbank, L.; Thompson, L.; Wardy, H.; Wibli, L.; Widdrington, J.; Williams, J.; Winder, P.; Wroe, C.] South Tees Hosp NHS Fdn Trust, Middlesbrough, Cleveland, England; [Elmahi, E.; Zaman, M.; Abdul, B.; Abdulmumeen, A.; Abdulshukkoor, N.; Adnan, A.; Nazeer, M. H. Ahammed; Bazli, A.; Benesh, N.; Chin, W. Jie; Cunningham, N.; Daggett, H.; Davies, E.; Enyi, H.; Fawohunre, S.; Geoghegan, N.; Glover, J.; Hague, J. W.; Hall, K.; Hallett, C.; Haresh, K.; Hassan, W. Ul; Hewertson, J.; Hosea, J.; Htoon, N. Zaya; Idrees, M.; Igwe, C.; Imtiaz, H.; Irshad, M.; Ismail, A.; Jeffrey, R.; Jith, J.; Joshi, P.; Periyasami, R. Kaliannan; Khalid, A.; Khalid, M. Usman; Kodituwakku, R.; Lopez, P.; Mahmood, A.; Malanca, M.; Mapfunde, I. Tatenda; Maruthamuthu, V. Kumar; Masood, S.; Masood, S. S. M. E.; Matharu, M.; Merchant, A.; Merchant, F.; Naqvi, S.; Natarajan, R.; Natarajan, N.; Nawaz, K.; Ndefo, O.; Ogunkeye, O.; Paranamana, S.; Pugh, N.; Raj, A.; Rashid, K.; Rogers, M.; Saad, M.; Selvadurai, G.; Shah, A.; Shahzeb, M.; Shrestha, N.; Singh, A.; Smith, K.; Sohail, B.; Spinks, M.; Stockham, L.; Takyi, A.; Teoh, Y. He; Ullah, S.; Vayalaman, H.; Wafa, S. E. I.; Ward, T.; Watson, R.; White, D.; Melly, L. Ylquimiche; Zulaikha, R.] Northampton Gen Hosp NHS Trust, Northampton, England; [Green, C.; Whitehouse, T.; Ahmed, I.; Anderson, N.; Armstrong, C.; Bamford, A.; Bancroft, H.; Bates, M.; Begum, S.; Bellamy, M.; Bergin, C.; Bhandal, K.; Brandl-Salutz, E.; Buckingham, E.; Burke, E.; Carmody, M.; Cooper, L.; Daglish, J.; Dasgin, J.; Desai, A.; Dhani, S.; Dosanjh, D.; Ellis, H.; Gardiner, D.; Forster, E.; Grobovaite, E.; Hopkin, B.; Hull, D.; Hussain, Y.; Jones, J.; Khan, L.; Lenton, D.; Lewis, M.; Lovell, M.; Lowe, F.; Lynch, D.; McGhee, C.; McNeill, C.; Moore, F.; Nilsson, A.; Nunnick, J.; Prest, C.; Price, V.; Rhodes, J.; Sale, J.; Sangombe, M.; Smith, H.; Storey, I.; Thrasyvoulou, L.; Tsakiridou, K.; Walsh, D.; Welch, S.; Willis, H.; Wood, L.; Woodford, J.; Wooldridge, G.; Zullo, C.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Desai, P.; Appleyard, D.; Bromley, D.; Chambers, N.; Dale, S.; Gledhill, L.; Goddard, J.; Greig, J.; Haigh, A.; Hallas, K.; Hanson, K.; Holroyd, K.; Home, M.; Kelly, D.; Maharajh, A.; Matapure, L.; Mellor, S.; Merwaha, E.; Riley, H.; Robinson, M.; Sandhu, K.; Schwarz, K.; Shaw, L.; Terrett, L.; Usher, M.; Wilson, A.; Wood, T.] Calderdale & Huddersfield NHS Fdn Trust, Huddersfield, W Yorkshire, England; [Felton, T.; Abbas, M.; Rasheed, A. Abdul; Abraham, T.; Aggarwal, S.; Akili, S.; Alexander, P. D. G.; Allanson, A.; Al-Sheklly, B.; Arora, D.; Avery, M.; Avram, C.; Aya, A.; Banda, J.; Banks, H.; Baptist, M.; Barrera, M.; Bazaz, R.; Behrouzi, R.; Benson, V.; Bentley, A.; Bhadi, A.; Biju, A.; Bikov, A.; Birchall, K.; Blane, S.; Bokhari, S.; Bradley, P.; Bradley-Potts, J.; Dean, K.; Dhillon, R.; Dolan, D.; Duggan, A.; Duran, B.; Durrington, H.; Eades, C.; Eatough, R.; Clark, R.; Clayton-Smith, J.; Conway, R.; Cook, E.; Cummings-Fosong, G.; Currie, S.; Dalgleish, H.; Davies, C.; Dean, K.; Dhillon, R.; Duggan, A.; Duran, B.; Durrington, H.; Eades, C.; Eatough, R.; Elyoussfi, S.; Evans, G.; Fairclough, A.; Faluyi, D.; Ferguson, S.; Fielding, J.; Fiouniz, S.; Fogarty, G.; Fowler, S.; Giannopoulou, S.; Gillott, R.; Gipson, A.; Glasgow, S.; Gorsuch, T.; Grana, G.; Gray, G.; Grayson, A.; Grey, G.; Griffin, B.; Hackney, P.; Hameed, B.; Hamid, I.; Handrean, S.; Henry, J.; Higgins, L.; Holt, L.; Horsley, A.; Howard, L.; Hughes, S.; Hulme, A.; Hulme, P.; Hyslop, M.; Ingham, J.; Ismail, O.; Jafar, A.; Jamal, S.; James, L.; John, A.; Johnstone, E.; Karunaratne, N.; Kausar, Z.; Kayappurathu, J. N.; Kelly, R.; Khan, A.; Khan, W.; Knight, S.; Kolakalurix, E.; Kolakaluri, E.; Kosmidis, C.; Kothandaraman, E.; Krizak, S.; Kyi, N. M.; Lalloo, F.; Logue, C.; Lord, R. W.; Macfarlane, L.; Madden, A.; Mahaveer, A.; Manderson, L.; Margaritopoulos, G.; Marsden, P.; Mathews, J.; McCarthy, E.; McGrath, B.; Mendonca, C.; Metryka, A.; Micallef, D.; Mishra, A.; Mistry, H.; Mitra, S.; Moss, S.; Muazzam, A.; Mudawi, D.; Murray, C.; Naguib, M.; Naveed, S.; Ninan, P.; Nirmalan, M.; Norton, R.; Odell, N.; Osborne, R.; Padden, G.; Palacios, A.; Panes, A.; Pantin, C. T.; Parker, B.; Peacock, L.; Peasley, A.; Pomery, F.; Power, N.; Pursell, M.; Ratcliffe, S.; Reilly, M.; Reynard, C.; Rice, E.; Rice, M.; Riley, P.; Rivera-Ortega, P.; Rogers, J.; Rogers, T.; Santosh, R.; Scott, A.; Sellers, K.; Sen, N.; Shanahan, T.; Shawcross, A.; Shibly, S.; Simpson, A.; Sivanadarajah, S.; Skehan, N.; Smith, C.; Smith, J.; Smith, L.; Soren, J.; Spiller, W.; Stratton, J.; Stubbs, A.; Swist-Szulik, K.; Tallon, B.; Thomas, S.; Thorpe, S.; Tohfa, M.; Tousis, R.; Trafford, M. T.; Turgut, T.; Varghese, M.; Varnier, G.; Venables, I.; Vinay, S.; Wang, R.; Ward, L.; Warner, C.; Watson, E.; Watterson, D.; Wentworth, L.; Whitehead, C.; Wilcock, D.; Williams, J. R.; Willis, E.; Woodhead, L.; Worton, S.; Xavier, B.] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England; [Rege, K.; Agbo, C.; Akindolie, O.; Al-Rabahi, A.; Ambrogetti, R.; Aung, K. Thu; Shah, A. Azman; Babs-Osibodu, A. Obaloluwa; Bahadori, K.; Bhayani, J.; Bond, T.; Boughton, H.; Brooks, S.; Butterworth-Cowin, N.; Buttery, R.; Carter, P.; Catana, A. Maria; Cave, L.; Choi, S.; Corogeanu, D.; Croysdill, R.; Davies, M.; de Souza, J.; Duff, N.; Dufour, L.; Ebigbola, O.; Eddings, C.; Faccenda, J.; Feroz, A.; Finch, L.; Freer, C.; Goodyear, P.; Gooentilleke, R.; Gosling, R.; Halford, W.; Havlik, S.; Hoskins, T.; Huson, C.; Ishak, M.; Javed, H.; Jones, T.; Kasianczuk, N.; Kaur, D.; Kerr, A.; Khan, A.; Koshy, G.; Eskenazia, A. Kozak; Lahane, S.; Lami, M. Kadhim Gulam; Marshall, J.; McDevitt, K.; Muru, N.; Mustafa, A. M. M.; Nazir, S.; Okpala, I.; Old, T.; Oleszkiewicz, G.; Orme, H.; O'Sullivan, S.; Paczko, P.; Pandey, A.; Patel, A.; Pathak, S.; Poon, S.; Rather, M. I.; Vattekkat, R. Renu; Rizvi, S. H. M.; Samyraju, M.; Sanyal, J.; Shah, S. H.; Smith, E.; Stacpoole, S.; Tan, B. Theng Tan; Temple, N.; Thazhatheyil, K.; Uddin, M. Saif; Veale, N.; Walter, D.] North West Anglia NHS Fdn Trust, Peterborough, Cambs, England; [Ashish, A.; Cooper, J.; Heaton, D.; Hough, S.; Parkinson, V.; Robinson, E.; Taylor, T.; Tierney, C.; Verma, A.; Waddington, N.; Williams, C.; Zipitis, C.] Wrightington Wigan & Leigh NHS Fdn Trust, Wigan, England; [Tiberi, S.; Aboaba, A.; Adeyeye, E.; Agwada-Akeru, J.; Ali, F. Runa; Allen, R.; Ardley, C.; Astin-Chamberlain, R.; Bacon, G.; Baillie, H.; Batha, R.; Bloom, B.; Bolton, M.; Borra, C.; Boyapati, G.; Buchanan, R.; Chan, C.; Chitsenga, C.; Cipriano, B.; Cofie, P. Foster; DeLuna, M.; Elia, S.; El-Shakankery, K.; Fikree, A.; Ghosh, A.; Goiriz, R.; Goldsmith, P.; Gouldbourne, M.; Grant, A.; Greenfield, L.; Grigoriadou, S.; Gritton, R.; Gunganah, K.; Hand, J.; Harwood, C.; Hemmila, U.; Higgins, J.; Hobden, D.; Howaniec, L.; Hsu, D.; Iliodromiti, S.; Issa, S.; Jones, P.; Juan, M.; Kassam, J.; Keith-Jopp, C.; Khan, M.; Khaw, C. Ryan; Kunst, H.; Lai, J.; Lee, I.; Lieberman, D.; Liebeschuetz, S.; Magavern, E.; Maniero, C.; Maitland, J.; Malcolm, H.; Marshall, H.; Matin, N.; May, P.; McDermott, R.; Menacho, K.; Millin, L.; Mohammed, A.; Moriarty, K.; Naeem, S.; Newman, T.; Fhogartaigh, C. Nic; Omar, M.; Pakozdi, A.; Parrott, M.; Pfeffer, P.; Pott, J.; Powell, J.; Ricketts, W.; Riddell, A.; Rughani, P.; Sahdev, N.; Sarodaya, V.; Selvarajah, B.; Skene, I.; Smallshaw, K. Denise; So, A.; Stevenson, D.; Suarez, C.; Swaine, T.; Thomas, S.; Thomas, A.; Thomson, J.; Thorn, N.; Tierney, C.; Ullah, S.; Vathenen, R.; Velauthar, L.; Ward, K.; Wiles, K.; Woodland, P.; Youssouf, S.; Zdanaviciene, A.] Barts Hlth NHS Trust, London, England; [Fegan, C.; Balan, A.; Basker, B.; Bird, S.; Boult, Z.; Britten, V.; Broad, L.; Cendl, H.; Chakraborty, M.; Cole, J.; Edgar, M.; Evans, T.; Evans, J.; Evans, M.; Forton, J.; Frayling, S.; Greaves, F.; Harrhy, S.; Haynes, M.; Hill, H.; Hilton, Z.; Jones, L.; Jorgensen, S.; Kelly, A.; Knibbs, L.; Lau, D.; Maureen, E.; May, J.; McGough, E.; McQueen, A.; Milner, J.; Norman, R.; Nyland, K.; Oliver, C.; Paradowski, K.; Patal, M.; Rahilly, K.; Robinson, C.; Scourfield, S.; Starr, M.; Struik, S.; Thomas, E.; Thomas-Turner, R.; Williams, G.; Williams, J.; Williams, M.; Zaher, S.] Cardiff & Vale Univ LHB, Cardiff, S Glam, Wales; [Hine, P.; Todd, S.; Welters, I.; Wootton, D.; Ahmed, M.; Ahmed, R. A.; Al Balushi, A.; Barr, D.; Bennett, A.; Bond, H.; Burston, C.; Byrne, J.; Chambers, L.; Coey, D.; Cross, T.; Cruise, J.; Fenlon, K.; Gould, S.; Haigh, K.; Hall, C.; Harrison, M.; Hazenberg, P.; Hicks, S. R.; Hope, S.; Hunter, K.; Islim, A.; Iyer, S.; Jackson, A.; Jaime, F.; Keogan, L.; Knowles, K.; Krasauskas, K.; Lewis, J.; Lopez, P.; Lowe, C.; Mediana, A.; Middleton, M.; Nugent, M.; Pauls, L.; Pringle, S.; Quayle, I.; Raghunath, S.; Riley, M.; Sedano, J.; Shaw, D.; Smith, C.; Stevenson, S.; Stockdale, A.; Tangney, R.; Tempany, J.; Waugh, V.; Williams, K.] Liverpool Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England; [Yates, B.; Ashbrook-Raby, C.; Campbell, H.; Charlton, D.; Dodds, S.; Ferguson, V.; Hall, T.; Hamoodi, I.; Heslop, P.; Luke, J.; McLarty, N.; Patterson, L.; Pick, S.; Reynolds, J.; Robinson, S.; Tanney, C.; Taylor, L.; Winder, L.; Walker, C.] Northumbria Healthcare NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Scott, S.; Abouibrahim, M.; Ahmad, M.; Ahmed, S. Haris; Ajibode, A.; Alomari, L.; Asrar, A.; Austin, E.; Bamford, P.; Barclay, A.; Barker, L.; Barker-Williams, K.; Barnsley, W.; Batty, H.; Benton, I.; Billingham, S.; Brearey, S.; Brigham, S.; Brooker, V.; Burchett, C.; Burgess, M.; Cade, R.; Cameron, F.; Cannan, R.; Cawley, K.; Chavasse, N.; Cheng, Z.; Clarke, R.; Cole, E.; Cotton, C.; Davidson, A.; Doi, Y.; Dragos, C.; Ellerton, L. Nicola; Gamble, L.; Grant, M.; Grounds, J.; Hodgkins, H.; Irshad, M. Shoaib; Iyer, M.; Johari, A.; Jones, C.; Kearsley, N.; Lim, B.; Llanera, D. Kevin; Loh, S. Yin; London, E.; Martin, E.; Maskell, P.; McBurney, J.; McCarthy, M.; McEwen, R.; Meeks, E.; Metcalf-Cuenca, G.; Middleton, S.; Mihalca-Mason, L.; Nayyar, M.; Naz, F.; Okpo, E.; Parry, H. Claire; Pearson, S. Anthony; Phillips, D.; Pickering, C.; Ponnuswamy, A.; Prescott, V.; Prince, J.; Rahman, S. Ur; Steele, C.; Thorne, C.; Tomlin, S.; Trussell, T.; Webster, T.; Zammit, L.; Zin, E. Thant] Countess Chester Hosp NHS Fdn Trust, Chester, Cheshire, England; [Graham, C.; Abdelaziz, A.; Ali, O.; Atkinson, J.; Bell, G.; Brewer, C.; Clapham, M.; Gregory, J.; Hanif, S.; Harper, R.; Lane, M.; McSkeane, A.; Poultney, U.; Poulton, K.; Pritchard, S.; Shah, S.; Smit, C.; Tzavaras, P.; Vasadi, V.; Wilson, A.; Wilson, T.; Zehnde, D.] North Cumbria Integrated Care NHS Fdn Trust, Carlisle, England; [Shaw, D.; Tariq, S.; Ahmed, N.; Ali, S.; Allen, S.; Alzetani, M.; Ambrose, C.; Aneke, K.; Angel, T.; Aung, Z. Myo; Banerjee, R.; Baqai, T.; Batla, A.; Bergstrom, M.; Bhakta, S.; Bibi, N.; Chapman, T.; David, A.; Dirmantaite, L.; Edmondson, M.; Elfar, E.; Elgamal, M. Magdy; El-Sbahi, H.; Fishman, D.; Fornolles, C.; Forshall, T.; Francioni, A.; Gent, S.; George, N.; Ibrahim, A.; Ingram, A.; James, R.; Dawa, K. Kabiru; Khan, F.; Khan, M. Aamaz; Lee, S.; Lingam, C.; Luximon, C. Nisha; Marcus, N.; Masood, M.; Mejri, R.; Moharram, A.; Moss, C.; Naik, G.; Ng, A. Yong Kheng Cordero; Nicholls, L.; Nisar, M.; Parmar, V.; Raj, F. Prasanth; Puisa, V.; Quick, V.; Ramabhadran, B.; Reddy, A.; Riaz, N.; Rudran, B.; Sabaretnam, S.; Sagoo, H.; Sarma, S.; Savlani, K.; Shah, P.; Shaw, D.; Soo, S.; Sothirajah, P.; Southern, I.; Tate, M. Louise; Travill, C.; Uppal, V. Singh; Wakeford, W.] Luton & Dunstable Univ Hosp NHS Fdn Trust, Luton, Beds, England; [Brown, T.; Andrews, J.; Baker-Moffatt, M.; Bamgboye, A.; Barnes, D.; Baryschpolec, S.; Bell, L.; Borbone, J.; Broadway, M.; Brogan, F.; Bungue-Tuble, R.; Burrows, K.; Chauhan, A.; Chauhan, M.; Cowan, E.; Darbyshire, A.; Davey, M.; David, M.; Denham, J.; Downe, H.; Edwards, C.; Fox, L.; Garner, Z.; Giles, B.; Gribbin, A.; Harrington-Davies, Y.; Hawes, L.; Hicks, A.; Hossain, E.; Howe, S.; Jones, B.; Lameirinhas, C.; Longhurst, B.; Mamman, M.; McCready, S.; Minnis, C.; Moon, M.; Mouland, J.; Murray, L.; Rose, S.; Rupani, H.; Rutgers, M.; Scorrer, T.; Scott, K.; Thornton, R.; Tiller, A.; Turner, C.; Wands, M.; Watkins, L.; White, M.; Wiffen, L.; Winter, J.] Portsmouth Hosp NHS Trust, Portsmouth, Hants, England; [Winn, S.; Wake, R.; Sadiq, S. Ahamed; Aldana, A.; Al-Hakim, B.; Agyapong, K. Ansu; Azzopardi, G.; Chicano, R.; Chukwulobelu, I.; Colbeck, N.; Cole, N.; Dogra, R.; Doherty, E.; Elradi, A.; Emberton, J.; Evans, T. J.; Ganapathy, R.; Haque, M.; Hayre, R.; Jain, S.; Jian, K.; Johnson, L.; Johnson, A.; Kotecha, J.; Kundu, A.; Langer, D.; Mashhoudi, Y.; Mathias, K.; Maxan, M. E.; Mellor, F.; Morgan, M.; Nafees, S.; Sai, V. Bharadwaj Palagiri; Phanish, M.; Rahimi, H. Rana; Ramanna, S.; Ratoff, J.; Rozewicz, S.; Samuel, T. D. L.; Shah, B.; Shahnazari, S.; Shail, R.; Sharif, A.; Somalanka, S.; Suckling, R.; Swift, P.; Tyagi, V.; Vilimiene, N.; Wells, C.] Epsom & St Helier Univ Hosp NHS Trust, Epsom, Surrey, England; [Maseda, D.; Ball, C.; Best, K.; Bridgwood, G.; Broadhurst, R.; Brockelsby, C.; Brockley, T.; Brown, J.; Bujazia, R.; Clarke, S.; Cremona, J.; Dixon, C.; Dowson, S.; Drogan, H.; Duncan, F.; Emmett, C.; Emms, M.; Farooq, H.; Fullerton, D.; Gabriel, C.; Hammersley, S.; Hum, R.; Jones, T.; Kay, S.; Kelly, E.; Kidd, M.; Lees, D.; Lowsby, R.; Matovu, E.; McIntyre, K.; Moulton, H.; Nourein, K.; Nytianandan, G.; O'Brian, M.; Pagett, K.; Ritchings, A.; Smith, S.; Taylor, J.; Thomas, K.; Turbitt, K.; Yasmin, S.] Mid Cheshire Hosp NHS Fdn Trust, Crewe, Cheshire, England; [Spittle, N.; Weatherly, N.; Beavis, S.; Beghini, S.; Blundell, L.; Bradder, J.; Cort, J.; Cresswell, J.; Dale, K.; Foo, A.; Gardner, J.; Gascoyne, R.; Hall, E.; Kelly-Baxter, M.; Mackay, E.; Moxham, K.; Padmakumar, A.; Pritchard, K.; Salmon, J.; Smith, A.; Sorice, V.; Stevenson, L.; Whileman, A.; Wolodimeroff, E.] Chesterfield Royal Hosp NHS Fdn Trust, Calow, England; [Meda, M.; Democratis, J.; Barnes, N.; Brooks, N.; Chapman, L.; da Rocha, J.; Dolman, R.; Edwards, A.; Foster, T.; Fowe, F.; Gaywood, E.; Gee, S.; Jaiswal, S.; Molloholli, M.; Raguro, A.; Regan, F.; Rowe-Leete, L.; Smith, C.; van de Venne, M.; Weerasinghe, T.] Univ Hosp Derby & Burton NHS Fdn Trust, Derby, England; [Jeffery, K.; Ainsworth, M.; Arnison-Newgass, C.; Bashyal, A.; Beer, S.; Bloss, A.; Buttress, D.; Byrne, W.; Capp, A.; Carter, P.; Cicconi, P.; Corrigan, R.; Coston, C.; Cowen, L.; Davidson, N.; Downs, L.; Edwards, J.; Evans, R.; Gardiner, S.; Georgiou, D.; Gillesen, A.; Harin, A.; Havinden-Williams, M.; Haynes, R.; Hird, C.; Hudak, A.; Hutton, P.; Irons, R.; Jastrzebska, P.; Johnston, S.; Kamfose, M.; Lewis, K.; Lockett, T.; del Rocio, F. Mendoza Maria; Garrido, J. Carlos Martinez; Masih, S.; Mentzer, A.; Morris, S.; O'Callaghan, C.; Oliver, Z.; Paulus, S.; Perez, E.; Periyasamy, L.; Peto, L.; Porter, D.; Prasath, S.; Purdue, C.; Ramasamy, M.; Roehr, C. C.; Rudenko, A.; Sanchez, V.; Sarfatti, A.; Segovia, M.; Sewdin, T.; Seymour, J.; Skinner, V.; Smith, L.; Diaz, A. Sobrino; Taylor-Siddons, M.; Thraves, H.; Tsang, C.; Vatish, M.; Warren, Y.; Wilcock, E.] Oxford Univ Hosp NHS Fdn Trust, Oxford, England; [Khan, B.; Ail, D.; Aldouri, R.; Awadzi, G.; Bassoy, B.; Bhalla, R.; Billings, J.; Bokhari, S.; Boniface, G.; Cernova, J.; Chen, T.; Chimbo, P.; Chitalia, N.; Bamfo, S. Danso; Depala, D.; Dhanoa, A.; Edmunds, T.; Fernandez, E.; Ferrari, T.; Fuller, B.; Gherman, A.; Heire, R.; Ilves, L.; Lacey, L.; Lawrence, E.; Lewis, M.; Maric, A.; Martin, W.; Min, Z.; Newman, C.; Nicholas, R.; Olufuwa, O.; Pieniazek, N.; Qadeer, T.; Rathore, S.; Sathianandan, S.; Scott, C.; Shonubi, A.; Siddique, S.; Sisson, G.; Soan, M.; Streit, D.; Stuart, C.; Szekely, M.; Umeojiako, W.; Urruela, S.; Warner, B.; Waterstone, M.; White, S.; Yip, K.; Zafar, A-M; Zaman, S.] Dartford & Gravesham NHS Trust, Dartford, England; [West, R.; Abrams, J.; Baldwin, A.; Bannister, O.; Barker, J.; Beddall, H.; Blamey, H.; Chan, E.; Chaplin, J.; Chisnall, B.; Cleaver, C.; Crotty, S.; Dey, P.; Downs, L.; Kononen, M.; Kudsk-Iversen, S.; Kudzinskas, A.; Laurenson, M.; Mandeville, J.; McLure, S.; Morgan-Smith, E.; Ngumo, A.; Oxlade, R.; Parekh, A.; Rahman, M.; Robertson, C.; Shah, S.; Tebbutt, J.; Vella, N.; Veres, M.; Watson, A. J. R.; Wong, N.; Zammit-Mangion, M.; Zia, M.] Buckinghamshire Healthcare NHS Trust, Amersham, England; [Gray, A.; Baillie, K.; Adam, M.; Anand, A.; Anderson, R.; Baird, D.; Balaskas, T.; Balfour, J.; Black, P.; Blackstock, C.; Brady, S.; Campbell, R.; Carter, J.; Chapman, P.; Cheyne, C.; Christides, A.; Christmas, D.; Crisp, L.; Cryans, D.; Dear, J.; Dhaliwal, K.; Docherty, M.; R, Dodds; Donald, L.; Dummer, S.; Eddleston, M.; Fethers, N.; Foster, E.; Frake, R.; Gaughan, E.; D, Gilliland; Godson, E.; Grahamslaw, J.; Grant, A.; Grubb, N.; Hainey, S.; Harding, Z.; Harris, M.; Harvey, M.; Henshall, D.; Hobson, S.; Hunter, N.; Jaly, Y.; Jameson, J.; Japp, D.; Khin, H. Htet Ei; Kitto, L.; Krupej, S.; Langoya, C.; Lawrie, R.; Lloyd, A.; Lyell, B.; Lynch, D.; Macfarlane, J.; MacInnes, L.; MacRaild, A.; Marecka, M.; Marshall, A.; Martin, M.; McCann, C.; McCurrach, F.; Moatt, E.; Morley, W.; Morrissey, M.; Newby, D.; Din, K. Nizam Ud; O'Brien, R.; O'Sullivan, E.; Odam, M.; Peterson, A.; Phelan, P.; Pickering, G.; Quinn, T.; Robertson, N.; Rooney, L.; Rowan, N.; Salman, R.; Small, E.; Stefanowska, P.; Stevenson, A.; Stock, S.; Summers, A.; Teasdale, J.; Walker, I.; Walker, K.; Williams, A.] NHS Lothian Royal Infirm Edinburgh, Edinburgh, Midlothian, Scotland; [Wight, A.; Bailey, L.; Bokhari, S. Owais; Brownlee, S.; Bull, A.; Corless, J.; Denmade, C.; Ellard, N.; Farrell, A.; Hufton, A.; Jacob, R.; Jones, K. Elizabeth; Kerss, H.; McEntee, J.; Morris, N.; Myagerimath, R.; Newcombe, T.; Parsonage, M.; Peake, H.; Pearson, D.; Penfold, R.; Rath, S.; Saunders, R.; Sharp, A.; Spencer, B.; Suliman, A.; Sutton, S.; Tan, H.; Tarpey, D.; Thompson, L.; Thornton, T.; Twohey, E.; Wagstaff, D.; Wahbi, Z.; Williams, S.] Wirral Univ Teaching Hosp NHS Fdn Trust, Wirral, Merseyside, England; [Phull, M.; Umaipalan, A.; Ah-Chuen, J.; Ainsley, A.; Baijiu, G.; Basumatary, A.; Calderwood, C.; Dugh, P.; Dunne, K.; Greaves, P.; Hunt, K.; Islam, M.; Katsande, V.; Khan, M. R.; King, S.; Loverdou, A.; McGregor, A.; Misbahuddin, A.; Mohamed, A.; Nagesh, N.; Nicholls, D.; O'Brien, N.; Parker, L.; Pogreban, T.; Rosaro, L.; Salciute, E.; Sharma, M.; Smith, H.; Visentin, E.; Walshaw, L.] Barking Havering & Redbridge Univ Hosp NHS Trust, Romford, Essex, England; [Saralaya, D.; Akhtar, N.; Beckett, V.; Brear, L.; Drew, V.; Eedle, J.; Hawes, N.; Kmachia, S.; Moss, S.; Oddie, S.; Paget, J.; Regan, K.; Ryan-Wakeling, D.; Shenoy, A.; Storton, K.; Swingler, R.; Syson, J.; Todd, J.; Wane, R.; Wilson, A.] Bradford Teaching Hosp NHS Fdn Trust, Bradford, W Yorkshire, England; [Fuller, E.; MacNair, A.; Brown, C.; Burns, A.; Caroline, C.; Davidson, R.; Dickson, M.; Duncan, B.; Elkaram, N.; Emmerson, I.; Fairlie, L.; Hashimm, M.; Henderson, J.; Hinshaw, K.; Holden, J.; Hovvels, R.; Laybourne, S.; Madgwick, P.; Martin, K.; McKee, M.; Moore, J.; Mullen, N.; Murphy, P.; Palmer, L.; Parish, G.; Rangar, M.; Shahrul, R.; Smith, A.; Smith, L.; Smith, M.; Stidolph, B.; Terry, L.; Trotter, A.; Wakinshaw, F.; Walton, E.; Walton, M.] South Tyneside & Sunderland NHS Fdn Trust, Sunderland, Tyne & Wear, England; [Frise, M.; Arimoto, R.; Black, S.; Camm, C.; Coles, H.; De Berker, H.; Fries, A.; Gabbitas, E.; Hasan, N.; Htet, Z.; Jacques, N.; Kashif, S.; Keating, L.; Leafe, S.; Milne, Z.; Mitchell, B.; Okeke, T.; Orchard, W.; Parmar, A.; Raffles, M.; Shields, N.; Thakker, M.; Thomas, M.; Wakefield, H.; Walden, A.] Royal Berkshire NHS Fdn Trust, Reading, Berks, England; [Moreno-Cuesta, J.; Rokadiya, S.; Govind, A.; Haldeos, A.; Leigh-Ellis, K.; van Someren, C.; Vincent, R.; Walker, L.] North Middlesex Univ Hosp NHS Trust, London, England; [Thomas, K.; George, T.; Cannon, E.; Ikomi, A.; Jayasekera, L.; Kittridge, L.; Maloney, G.; Manoharan, B.; Mushabe, M.; Nicholson, A.; Pai, A.; Riches, J.; Samuel, J.; Setty, N.; Solesbury, A.; Southam, D.; Tisi, S.; Vertue, M.; Wadsworth, K.; Yung, B.] Basildon & Thurrock Univ Hosp NHS Fdn Trust, Basildon, England; [Limb, J.; Atkinson, V.; Birt, M.; Brown, E.; Cowton, A.; Craig, V.; Egginton, D.; Fernandes, D.; Ivy, A.; Jayachandran, D.; Jennings, J.; Kay, A.; Kent, M.; McAuliffe, S.; Naylor, S.; Nyamugunduru, G.; O'Brien, J.; Postlethwaite, K.; Potts, K.; Ranka, P.; Rogers, G.; Sen, S.; Temple, J.; Wadd, S.; Walters, H.; Yorke, J.] Cty Durham & Darlington NHS Fdn Trust, Darlington, Durham, England; [Whittington, A.; Adamus, M.; Barrett, J.; Cawa, F.; Chhabra, S.; Chita, S.; Dhillon, E.; Filson, S. Ann; Goodall, J.; Gravell, R.; Gupta-Wright, A.; Gurram, S.; Houston, H.; Hulston, G.; Isralls, S.; Kukadiya, C.; Lang, M.; MaeLow, J.; Macleod, C.; Milburn, J.; Muralidhara, K.; Nayar, B.; Ojo, O.; Papineni, P.; Parris, V.; Patel, M.; Quaid, S.; Sethi, J.; Sturdy, A.; Tyagi, B.; Vaccari, L. Cheyenne; van der Stelt, N.; Wallis, G.; Watson, E.] London North West Univ Healthcare NHS Trust, London, England; [Sarkar, R.; Ahmed, I.; Ahmed, S.; Ambler, S.; Babatunde, F.; Banerjee, S.; Bhatia, N.; Brassington, L.; Brokke, F.; Bruce, D.; Cassimon, B.; Chauhan, R. Singh; Chengappa, A.; Divikar, N.; Donnelly, C.; Froneman, C.; Gnanalingam, C.; Gower, T.; Harizaj, H.; Hettiarachchi, G.; Hollands, M.; Jansz, S.; Josiah, B.; Kamara, M.; Kidney, S.; Kyere-Diabour, T.; Lewiston, K.; Miah, N.; Millington, S.; Mires, L.; Mitchell, A.; Mizzi, C.; Naicker, K.; Petrou, I.; Phulpoto, M. Mubeen; Ross-Parker, A.; Ramadan, I.; Roy, A.; Ryan, A.; Samuels, E.; Sanctuary, T.; Sharma, A.; Singham, S.; Sporrer, J.; Ul Hassan, W.; Vankayalapati, P.; Velan, B.; Smith, L. Vincent; Vyras, E.; Wood, J.; Zuhra, N.] Medway NHS Fdn Trust, Gillingham, England; [Clare, S.; Ahmed, M. Cecilia; Beuvink, Y.; Blachford, K.; Clamp, S.; Colley, J.; De, P.; Fenton, M.; Gammon, B.; Hayes, A.; Henry, L.; Hussain, S.; Joseph, S.; Kinney, F.; Knight, T.; Kumar, R.; Leong, W.; Lim, T.; Mahay, B.; Nupa, Y.; Orme, A.; Osborne, W.; Pilsworth, Z.; Potter, S.; Prew, S.; Rajaiah, N.; Rajasekaran, A.; Senya, H.; Shah, N.; Shamim, N.; Sivakumar, S.; Smith, L.; Thozthumparambil, P.; Trudgill, N.; Turner, A.; Wagstaff, L.; Willetts, S.; Willis, H.; Yan, M.] Sandwell & West Birmingham Hosp NHS Trust, Birmingham, W Midlands, England; [Richardson, N.; Alegria, A.; Kapoor, R.; Adegoke, K.; Allen, L.; Beranova, E.; Boehmer, G.; Crisp, N.; Deery, J.; Hansen, J.; Elgohary, A.; Elsefi, T.; Hargreaves, C.; Hazelton, T.; Hulbert, R.; Ionita, A.; Knight, A.; Linares, C.; Loader, D.; Matisa, E.; McAndrew, J.; Montasser, M.; Moon, A.; Oboh, C.; Offord, P.; Price, C.; Rajasri, A.; Rand, J.; Schumacher, N.; Stephensen, D.; Stirrup, S.; Tague, L.; Tilbey, S.; Turney, S.; Vasu, V.; Venditti, M.; Weston, H.; Woodward, Z.] East Kent Hosp Univ NHS Fdn Trust, Canterbury, Kent, England; [Kemp, T.; Alexander, J.; Al-Shamkhani, W.; Bandla, N.; Bland, A.; Bodasing, N.; Cadwgan, A.; Chaudhary, M. Yafaa Naveed; Cheng, L. Yin; Church, S. Rebecca; Clark, F.; Davies, M.; Diwakar, L.; Eaton, E.; Evans, M.; Farmer, A.; Farook, F.; Gellamucho, M.; Glover, K.; Haris, M.; Humphries, J.; Hussain, I.; Khan, S.; Korcierz, L.; Lee, J.; Machin, J.; Marshall, J.; McCreedy, H.; Muddegowda, G.; Mustapha, I.; Nettleton, K.; Noori, Z.; Osman, W.; Parker, H.; Patel, N.; Quinn, A.; Ram, M.; Remegoso, A.; Scott, T.; Sheikh, N.; Swiftx, R.; Thompson, C.; Tomlinson, J.; Turner, H.; Walker, L.; Weeratunga, J.; White, C.; White, J.; Wu, P.] Univ Hosp North Midlands NHS Trust, Stoke On Trent, Staffs, England; [Szakmany, T.; Champanerkar, S.; Griffiths, A.; Ionescu, A. Alina; Somashekar, C.; Zalewska, K.; Aitken, L.; Baker, E.; Barnett, D.; Brouns, M.; Cann, J.; Cherian, S.; Codd, R.; Cutler, S.; Davies, W.; Dell, A.; Edwards, M.; Edwards, S.; Fairbairn, S.; Hawkins, N.; Hodge, S.; Hodkinson, G.; Hughes, R.; Ivenso, C.; James, T.; Jones, M.; Jones, S.; Lucey, A.; MacCormac, J.; Marshall, G.; McKain, S.; Nassa, H.; Northfield, J.; Palmer, S.; Peter, L.; Price, C.; Pynn, M.; Roynon-Reed, A.; Shipp, L.; Singh, J.; Singh, M.; Swarnkar, K.; Torabi, P.; Venkataramakrishnan, R.; Wall, E.; Waters, A.; Wild, K.; Winstanley, M.; Wyness, K.] Aneurin Bevan Univ LHB, Newport, Shrops, England; [Kushakovsky, V.; Ramali, M.; Alam, S.; Bartholomew, S.; Bataineh, A.; Beeby, D.; Bell, S.; Broughton, N.; Buckman, C.; Calver, C.; Campbell, J.; Chabo, C.; Chowdhury, M.; Cooke, K.; Deole, N.; Driscoll, C.; Elden, A.; Eldew, H.; Entwistle, N.; Farnworth, F.; Francis, R.; Galloway, E.; Garfield, M.; Ghosh, A.; Gray, G.; Greenfield, P.; Hadjiandreou, M.; Hewer, H.; Hossain, M. S.; Howard-Griffin, R.; Islam, A.; Jamieson, E.; Jiao, Z.; Johannessen, K.; Lee, S. Han; Lewis, R.; Lloyd, R.; Mabelin, L. Andrew; Morris, D.; Nallapareddy, S.; Ooi, H. C.; Osagie, R.; Parkinson, C.; Patel, H.; Prowse, H.; Purewal, B.; Ridley, P.; Rivers, V.; Rosier, J.; Sharma, S.; Sheik, A.; Skelly, R.; Smith, R.; Sreenivasan, R.; Taylor, A.; Tovey, P.; Turner, A.; Turner, K.; Vithian, K.; Zhixin, J.] East Suffolk & North Essex NHS Fdn Trust, Colchester, Essex, England; [Potton, E.; Jain, N.; Khadar, A.; Morgan, P.; Penny, J.; Tatam, E.; Abbasi, S.; Acharya, D.; Acosta, A.; Ahmed, L.; Ali, S.; Alkhusheh, M.; Arter, A.; Babi, M.; Bacon, J.; Bailey, K.; Balachandran, N.; Banks, L.; Barla, J.; Belgaumkar, A.; Benison-Horner, G.; Boles, A.; Broomhead, N.; Cetti, E.; Chan, C.; Chaudhry, I.; Chudgar, D.; Clark, J.; Clueit, S.; Combes, E.; Conway, G.; Curtis, O.; Das, M.; Daschel, M.; Potton, E.; Abbasi, S.; Acharya, D.; Ahmed, L.; Ali, S.; Alkhusheh, M.; Amosun, V.; Arter, A.; Babi, M.; Bacon, J.; Bailey, K.; Balachandran, N.; Bandyopadhyam, S.; Banks, L.; Barla, J.; Batty, T.; Bax, S.; Belgaumkar, A.; Benison-Horner, G.; Boles, A.; Broomhead, N.; Cetti, E.; Chan, C.; Chaudhry, I.; Chudgar, D.; Clark, J.; Clueit, S.; Collins, S.; Combes, E.; Conway, G.; Curtis, O.; Das, M.; Daschel, M.; Davies, S.; Day, A.; Dhar, M.; Diaz-Pratt, K.; Dragan, C.; Dube, H.; Duraiswamy, V.; Elias, J.; Ellis, A.; Ellis, T-Y; Emmanuel, J.; Engden, A.; Fahmay, Y.; Field, B.; Fishwick, K.; Ganesh, U.; Gilbert, C.; Giokanini-Royal, T.; Goudie, E.; Griffith, S.; Gurung, S.; Habibi, R.; Halevy, C.; Haqiqi, A.; Hartley, R.; Hayman, A.; Hives, J.; Horsford, M.; Hughes, S.; Hui, C.; Hussain, R.; Iles, C.; Jackson, L.; James, A.; Jayaram, D.; Jessup-Dunton, E.; Joefield, T.; Khan, N.; Kieffer, W.; Knox, E.; Kumar, V.; Kumar, R.; Kurmars, V.; Lafferty, H.; Lamb, F.; Layug, R.; Leitch, N.; Lim, W.; Limbu, U.; Loveless, R.; Mackenzie, M.; Maghsoodi, N.; Maher, S.; Maljk, M.; Man, I.; McCarthy, N.; Mearns, B.; Mearns, C.; Morgan-Jones, K.; Mortem, G.; Morton, G.; Moya, B.; Murphy, G.; Mutton, S.; Myers, A.; Nasser, T.; Navaratnam, J.; Nazir, S.; Nepal, S.; Nimako, K.; Nimako, L.; O'Connor, C.; Patel, A.; Patel, K.; Phongsathorn, V.; Pillai, P. A.; Poole, M.; Qureshi, N.; Ranjan, S.; Rehman, A.; Samuels, T.; Scott, E.; Sekadde, G.; Sharma, A.; Sharp, G.; Shotton, S.; Simmons, O.; Singh, P.; Smith, S.; Paranthamen, K. Sri; Suresh, S.; Thevarajah, K.; Thomas, L.; Timms, H.; Tomasova, N.; Tucker, S.; Vara, S.; Vaz, C.; Weller, S.; White, J.; Wilde, M.; Wilkinson, I.; Williams, C.; Win, M.; Woosey, D.; Wright, D.] Surrey & Sussex Healthcare NHS Trust, Surrey, England; [Roberts, M.; Amsha, K.; Cox, G.; Downer, N.; Hodgson, D.; Hutchinson, J.; Kalsoom, S.; Molyneux, A.; Noor, Z.; Allsop, L.; Brear, T.; Buckley, P.; Dunn, L.; Gill, M.; Goodwin, C.; Heeley, C.; Holmes, M.; Holmes, R.; Langthorne, E.; Moulds, C.; Nash, D.; Rajeswary, J.; Shelton, S.; Slack, K.; Smith, S.; Valeria, B.; Wynter, I.; Yanney, M.; Ynter, I.] Sherwood Forest Hosp NHS Fdn Trust, Sherwood, England; [Azam, J.; Chandler, K. J.; Abdelfattah, M.; Abung, A.; Anderson, J.; Antill, P.; Appleby, S.; Armtrong, P.; Berriman, T.; Bull, D.; Clayton, O.; Corlett, A.; Crocombe, D.; Davies, S.; Elliott, K.; Fahel, L.; Ghosh, J.; Gott, N.; Greenwood, D.; Holder, T.; Inns, P.; Lea, W.; Lindsay, E.; Mack, K.; Marshall, N.; McMeekin, S.; Momoniat, T.; Nikolaos, P.; O'Kane, M.; Patrick, G.; Pearson, H.; Ponnusamy, P.; Poole, A.; Price, N.; Proudfoot, R.; Purssord, G.; Roche, S.; Sefton, C.; Shahi, S.; Smith, D.; Sohail, B.; Thomas, R.; Turnbull, A.; Turner, L.; Watchorn, H. J.; Wiafe, E.; Wilson, J.; Yates, D.] York Teaching Hosp NHS Fdn Trust, York, N Yorkshire, England; [Bruce, M. Schuster; Baldwin, D.; Clark, Z.; Dale, M.; Griffiths, D.; Gunter, E.; Horler, S.; Joyce, T.; Keltos, M.; Kennard, S.; Lakeman, N.; Mallon, L.; Miln, R.; Nix, S.; Orr, S.; Pitts, S.; Purandare, L.; Rogers, L.; Samways, J.; Stride, E.; Vamplew, L.; Wallis, L.] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Bournemouth, Dorset, England; [Willis, J.; Blencowe, N.; Singhal, P.; Abraham, M.; Al-Ramadhani, B.; Archer, A.; Aziz, G.; Balcombe, A.; Bateman, K.; Baxter, M.; Beacham, L.; Belfield, K.; Bell, N.; Beresford, M.; Bernatoniene, J.; Bhojwani, D.; Biggs, S.; Blazeby, J.; Bobruk, K.; Brown, N.; Buckley, L.; Butler, P.; Caws, C.; Chakkarapani, E.; Chatar, K.; Chivima, B.; de la Torre, C. Clemente; Cobain, K.; Cotterill, D.; Courtney, E.; Cowman, S.; Coy, K.; Crosby, H.; Curtis, K.; Davis, P.; Drewett, O.; Dymond, H.; Edgerley, K.; Ekoi, M.; Elokl, M.; Evans, B.; Farmery, T.; Fineman, N.; Finn, A.; Gamble, L.; Garty, F.; Gibbison, B.; Gourbault, L.; Grant, D.; Gregory, K.; Griffin, M.; Groome, R.; Hamdollah-Zadeh, M.; Hannington, A.; Heywood, J.; Hindmarsh, A.; Holling, N.; Houlihan, R.; Hrycaiczuk, J.; Hudson, H.; Hurley, K.; Jarvis, R.; Jeffs, B.; Jones, A.; Jones, R. E.; King-Oakley, E.; Kirkham, E.; Kumar, R.; Kurdy, M.; Kyle, L.; Lang, S.; Leandro, L.; Legge, H.; Loro, F.; Low, A.; Martin, H.; McCullagh, L.; McMahon, G.; Millett, L.; Millington, K.; Mok, J.; Moon, J-H; Morgan, L.; Mulligan, S.; O'Donovan, C.; Payne, E.; Penman, C.; Pickard, J.; Plumptre, C.; Ramanan, A.; Ramirez, J.; Ratcliffe, S.; Robinson, J.; Roderick, M.; Scattergood, S.; Schadenberg, A.; Sheppeard, R.; Shioi, C.; Simpson, D.; Skorko, A.; Squires, R.; Stuttard, M.; Sugden, P.; Sundar, S.; Swart, T.; Swift, E.; Thompson, K.; Turner, K.; Turner, S.; Tyer, A.; Vergnano, S.; Vincent, R.; Ward, R.; Wilkinson, S.; Williams, J.; Williams, S.; Winter, H.; Woollen, L.; Wright, R.; Ibrahim, A. Younes] Univ Hosp Bristol & Weston NHS Fdn Trust, Bristol, Avon, England; [Aggarwal, S.; Collini, P.; Ang, A.; Belcher, J.; Chapman, L.; Chin, K.; Cohen, D.; Cole, J.; Colton, H. E.; Condliffe, R.; Cribb, M.; Curran, S.; Darton, T.; de Fonseka, D.; de Silva, T.; Dunn, A.; Ferriman, E.; Foster, R. Anne; Greig, J.; Hall, J.; Haq, M. Ul; Hardman, S.; Headon, E.; Holden, C.; Hunt, L.; Hurditch, E.; Kibutu, F.; Kitching, T.; Lewis, L.; Locke, T.; Mair, L.; May, P.; Meiring, J.; Middle, J.; Middleton, J. T.; Morris, P.; Newman, T.; Passby, L.; Payne, R.; Rana, G. Farid; Renshaw, S.; Rothman, A.; Sammut, D.; Sherwin, S.; Simpson, P.; Sterrenburg, M.; Stone, B.; Surtees, M.; Telfer, A.; Thompson, R.; Vethanayagam, N.; West, R.; Williams, T.] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England; [Patel, K.; Imray, C.; Aldridge, N.; Campbell, A.; Evans, G.; French, E.; Grenfell, R.; Hewins, S.; Hewitt, D.; Jones, J.; Kumar, R.; Mshengu, E.; Quenby, S.; Read, K.; Satodia, P.; Sear, E.; Truslove, M.] Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England; [Kerry, A.; Beale, A.; Brooks, A.; Browne, C.; Butler, J.; Callaghan, J.; Chandrasekaran, B.; Coombs, C.; Davies, R.; Davies, L.; Elias, T.; Fowler, E.; Gowda, G.; Gregory, J.; Ipe, A.; Jaffery, A.; Jones, Q.; Kyeremeh, L.; Laing-Faiers, I.; Langton, H.; Lewis-Clarke, C.; Mackinlay, C.; Mappa, P.; Maxwell, A.; Mears, W.; Mousley, E.; Onyirioha, T.; Pannell, L.; Peglar, S.; Pereira, A.; Pointon, J.; dos Reis, I. Ponte Bettencourt; Price, E.; Quayle, A.; Qurratulain, Q.; Small, S.; Smith, H.; Stratton, E.; Tinkler, M.; van der Meer, A.; Wakefield, E.; Waller, R.; Walton, M.; Watters, M.; Whittam, L.; Wiliams, T.; Xia, Z.; Yein, K.; Zinyemba, V.] Great Western Hosp NHS Fdn Trust, Swindon, Wilts, England; [Cupitt, J.; Ahmed, N.; Assaf, O.; Barnett, A.; Benham, L.; Bradley, P.; Bradshaw, Z.; Brunton, M.; Capstick, T.; Caswell, M.; Cunliffe, V.; Downes, R.; Latt, N.; McDonald, R.; Mulla, A.; Mutema, E.; Navin, J.; Parker, A.; Preston, S.; Slawson, N.; Stoddard, E.; Traynor, S.; Vasudevan, V.; Ward, E.; Warden, S. Andrew; Wilson, J.; Zmierczak, A.] Blackpool Teaching Hosp NHS Fdn Trust, Blackpool, England; [Bari, S.; Higham, A.; Al-Jibury, M.; Allison, K.; Anu, V.; Bartlett, C.; Bhuiyan, S.; Bishop, L.; Burns, K.; Davies, A.; Fielding, A.; Gorst, M.; Hay, C.; Keating, J.; Khan, T.; Mahmood, F.; Mallinder, P.; Peters, S.; Power, D.; Ritchie, J.; Simpson, K.; Spickett, H.; Stokes, C.; Thatcher, H.; Varghese, A.; Wan, T.; Wood, F.] Univ Hosp Morecambe Bay NHS Fdn Trust, Kendal, England; [Convery, R.; Acheson, J.; Brannigan, J.; Cosgrove, D.; McCullough, C.; McFarland, D.; McNulty, R.; Sands, S.; Thompson, O.] Southern HSC Trust, Portadown, England; [Balasubramaniam, M.; Subudhi, C.; Acton, C.; Ajmi, A.; Ahmed, R.; Ajmi, A.; Al-Asadi, A.; Amin, A.; Bajandouh, A.; Bhalme, M.; Carrington, Z.; Chadwick, J.; Cocks, S.; Dawe, C.; Eusuf, A.; Farzana, S.; Hill, P.; Holmes, R.; Hughes, G.; Hull, R.; Ibrahim, K.; Ijaz, M.; Kalayi, R. J.; Khurana, S.; Latham, S.; Lipscomb, K.; Lomas, J. P.; Natarajan, N.; Nethercott, D.; Nicholas, P.; Obeng, D.; Priyash, V.; Rhead, K.; Saleh, M.; Sharma, O.; Shehata, Z.; Shurmer, J.; Sime, R.; Singh, S.; Smith, R.; Tanton, E.; Tewkesbury, D.; Thet, P.; Thornton, S.; Wang, N.; Watts, M.; Webster, I.] Bolton NHS Fdn Trust, Bolton, England; [Easom, N.; Adams, K.; Baldwin, L.; Barlow, G.; Barton, R.; Bexhell, H.; Clark, D.; Gunasekera, P.; Harvey, A.; Hayes, M.; Ivan, M.; James, A.; Kassianides, X.; Khan, S.; Kolodziej, M.; Lillie, P.; Mathew, V.; Mongolu, S.; Muazzam, I. A.; O'Reilly, P.; Perinpanathan, T.; Philbey, C.; Pickwell-Smith, B.; Rollins, L.; Samson, A.; Sathyapalan, T.; Sherris, L.; Sivakumar, K.; Taynton, T.; Yates, H.] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England	University Hospitals of Leicester NHS Trust; University of Leicester; Nottingham University Hospital NHS Trust; University of Birmingham; Barts Health NHS Trust; Cardiff University; Portsmouth Hospitals NHS Trust; Oxford University Hospitals NHS Foundation Trust; Royal Berkshire Hospital; University of Sheffield; University of Warwick	Horby, PW; Landray, MJ (corresponding author), RECOVERY Cent Coordinating Off, Oxford OX3 7LF, England.	recoverytrial@ndph.ox.ac.uk; recoverytrial@ndph.ox.ac.uk	Chan, Xin Hui S/ABA-5004-2021; Rivera-Ortega, Pilar/X-7083-2019; Bunclark, Katherine/GLN-3109-2022; Ali, Omar/HHY-8838-2022; Skene, Imogen/D-6153-2018; chauhan, milan kumar/AAX-9583-2021; Evans, D Gareth/AAB-4308-2022; Chaudhuri, Nazia/J-4517-2019; Stockdale, Alexander/ADU-6666-2022; Tso, Simon/N-2422-2014; Darton, Thomas/H-2816-2017; Baillie, Kenneth/AEK-6650-2022; Gkrania-Klotsas, Effrossyni/AAT-8424-2021; Satodia, Prakash/ABF-4151-2021; Shanahan, Thomas/AAP-3822-2020; Ahmed, Naseer/C-8119-2019; Wu, Henry H.L./B-9400-2019; Baillie, John Kenneth/F-3124-2011; mcgrath, brendan a/D-7202-2013; Diwakar, Lavanya/G-7425-2016; Dhillon, Rubaid/GRF-0062-2022; Fawke, Joe/ABA-9407-2021; Tavoukjian, Vera/AAR-6922-2020; Kassianides, Xenophon/AAQ-1838-2020; hodgson, luke/AAG-1477-2019; Llewelyn, Martin/A-7194-2011; Langer, Daniel/B-7307-2014; Higgins, Julian PT/H-4008-2011; Dosanjh, Davinder/ABD-8895-2021; Caplin, Ben/AAH-1641-2019; Pessoa-Amorim, Guilherme/AAV-4151-2021; Faust, Saul/J-9779-2014; Durrington, Hannah/B-4564-2016; Payne, Brendan/I-1233-2016; Gibbison, Ben/J-6611-2014; Kudsk-Iversen, Soren/Y-9391-2018; moon, james/F-1031-2014	Chan, Xin Hui S/0000-0002-9941-6975; Rivera-Ortega, Pilar/0000-0002-7960-8822; Bunclark, Katherine/0000-0002-8785-0715; Skene, Imogen/0000-0001-5215-2899; chauhan, milan kumar/0000-0001-6120-2034; Evans, D Gareth/0000-0002-8482-5784; Chaudhuri, Nazia/0000-0003-3325-6996; Tso, Simon/0000-0001-9221-7618; Darton, Thomas/0000-0003-2209-9956; Baillie, Kenneth/0000-0001-5258-793X; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330; Satodia, Prakash/0000-0002-1796-5736; Shanahan, Thomas/0000-0001-5613-2545; Ahmed, Naseer/0000-0002-0960-1123; Wu, Henry H.L./0000-0002-4561-0844; Baillie, John Kenneth/0000-0001-5258-793X; mcgrath, brendan a/0000-0003-3048-3480; Diwakar, Lavanya/0000-0003-4369-6637; Fawke, Joe/0000-0002-5267-7107; Tavoukjian, Vera/0000-0002-5479-688X; hodgson, luke/0000-0002-8278-9513; Llewelyn, Martin/0000-0002-6811-1124; Langer, Daniel/0000-0001-8738-9482; Higgins, Julian PT/0000-0002-8323-2514; Dosanjh, Davinder/0000-0002-9169-5607; Caplin, Ben/0000-0001-9544-164X; Pessoa-Amorim, Guilherme/0000-0002-4050-6191; Scott, Alex/0000-0001-6719-0417; Rokadiya, Sakib/0000-0003-2955-4907; Barnett-Vanes, Ashton/0000-0002-8088-1068; Parker, Ben/0000-0001-7959-6529; Cathie, Katrina/0000-0001-5074-0769; Sarkar, Rahuldeb/0000-0002-4343-8526; Pastika, Libor/0000-0001-6892-6553; mumford, andrew/0000-0002-5523-511X; de Silva, Thushan/0000-0002-6498-9212; , Prof Dr Muhammad Shahid Iqbal/0000-0003-0245-5976; brightling, chris/0000-0002-9345-4903; Denis, Emmanuelle/0000-0001-8463-1341; Faust, Saul/0000-0003-3410-7642; Mishra, Eleanor/0000-0002-5903-3005; Sarodaya, Varun/0000-0003-4999-5144; Shelley, Ben/0000-0001-6771-9659; Iftikhar, Hina/0000-0003-2138-1415; Kelly, Dominic/0000-0002-6063-8896; Major, Rupert/0000-0003-4920-623X; Landray, Martin/0000-0001-6646-827X; Stewart, Grant D./0000-0003-3188-9140; Horsley, Alex/0000-0003-1828-0058; Ahmed, Muhammad Shamsher/0000-0001-6163-8102; Roddick, Alistair/0000-0002-4184-2541; Soiza, Roy/0000-0002-1397-4272; Collini, Paul/0000-0001-6696-6826; Durrington, Hannah/0000-0002-9990-9446; Brannigan, Jamie/0000-0003-1697-403X; Chapman, Laura/0000-0001-6174-9435; Vidler, Jennifer/0000-0003-2996-3014; Mutch, Callum/0000-0001-9788-0179; Drysdale, Simon/0000-0002-6350-6557; Torok, Mili Estee/0000-0001-9098-8590; Islim, Abdurrahman/0000-0001-9621-043X; Gregory, Katherine/0000-0002-0610-5386; Hoggett, Lee/0000-0003-1135-6232; Spears, Mark/0000-0003-4381-5819; Grandjean, Louis/0000-0002-1457-8327; Montgomery, Alan/0000-0003-0450-1606; Jha, Akhilesh/0000-0002-8413-7738; Hormis, Anil/0000-0001-5510-7639; Harwood, Catherine/0000-0002-1375-0965; Hodson, Kenneth/0000-0003-3091-6952; de Vere, Natasha/0000-0001-9593-6925; Burton, Ben/0000-0001-9579-9078; imray, chris/0000-0001-8451-4102; Dhaliwal, Kevin/0000-0002-3925-3174; Hinshaw, Kim/0000-0003-0468-4326; Peters, Mark/0000-0003-3653-4808; Whittaker, Elizabeth/0000-0002-7944-8793; Cooper, Jamie/0000-0003-3812-7026; Bibby, Anna/0000-0001-7386-7754; Lillie, Patrick/0000-0002-4811-4774; Daunt, Anna/0000-0001-6480-8867; Jethwa, Kishan/0000-0003-1715-9256; O'Sullivan, Eoin/0000-0002-7709-6595; maskell, nick/0000-0002-1276-6500; Hawcutt, Dan/0000-0002-8120-6507; Todd, Stacy/0000-0003-3215-9625; Staplin, Natalie/0000-0003-4482-4418; Christides, Alexander/0000-0002-9476-9827; Cole, Joby/0000-0002-5258-5835; Shah, Pallav/0000-0002-9052-4638; Lord, Robert/0000-0001-9008-2502; Bhagani, Sanjay/0000-0003-2557-4337; Al-Shahi Salman, Rustam/0000-0002-2108-9222; Graham-Brown, Matthew/0000-0002-6197-180X; Iliodromiti, Stamatina/0000-0001-6453-6654; Downey, Damian/0000-0002-6471-549X; Murray, Clare/0000-0002-8961-8055; Blunden, Susara/0000-0003-2328-3755; Bloom, Ben/0000-0002-3016-4925; Abu-Arafeh, Ahmad/0000-0003-2464-3871; Colton, Hayley/0000-0002-3287-4103; Esmail, Hanif/0000-0002-4278-9316; Ustianowski, Andrew/0000-0002-6134-7855; Lim, Wei Shen/0000-0002-7694-3051; So, Beng/0000-0003-4356-532X; Kametas, Nicholas/0000-0002-7992-6038; Ireland, Aidan Taeke/0000-0001-9513-2302; Elneima, Omer/0000-0003-2480-8840; Welters, Ingeborg/0000-0002-3408-8798; Forton, Julian/0000-0002-0580-0432; Leckie, Todd/0000-0003-4309-5225; Chalmers, James/0000-0001-5514-7868; Mentzer, Alexander/0000-0002-4502-2209; Payne, Brendan/0000-0002-3101-3512; Dey, Vishal/0000-0002-5108-4158; Gibani, Malick/0000-0003-1781-0053; King, Scott/0000-0001-6821-9234; Crocombe, Dominic/0000-0002-1401-6930; Pathan, Nazima/0000-0001-7656-9453; Taynton, Thomas/0000-0001-7771-9564; Haynes, Richard/0000-0002-1179-0023; Sahdev, Nikhil/0000-0003-2291-5044; Adamali, Huzaifa/0000-0002-8230-175X; vatish, manu/0000-0002-6012-2574; Parmar, Chetan/0000-0002-1238-6524; Willis, Joanna/0000-0003-3260-4311; Welch, Hugh/0000-0001-6906-2718; Jajbhay, Danyal/0000-0002-3475-9651; Dimitri, Paul/0000-0001-7625-6713; Gibbison, Ben/0000-0003-3635-6212; Puxty, Kathryn/0000-0002-5742-6171; Dark, Paul/0000-0003-3309-0164; Nigel, Brunskill/0000-0002-7109-7108; Newman, Tom/0000-0002-7987-9948; Quenby, Siobhan/0000-0003-3221-5471; Spata, Enti/0000-0002-7207-2076; Barker, Joseph/0000-0002-5483-9608; Rowan, Kathryn/0000-0001-8217-5602; Gorick, Hugh/0000-0003-3089-9830; Price, David/0000-0002-0562-7326; Lim, Ivy/0000-0001-9848-8769; Adams, Richard/0000-0003-3915-7243; Toshner, Mark/0000-0002-3969-6143; Ramasamy, Maheshi Nirmala/0000-0002-2119-951X; Linden, Dermot/0000-0003-0552-1115; Buch, Maya/0000-0002-8962-5642; Heyderman, Robert/0000-0003-4573-449X; Yanney, Michael/0000-0002-2543-4425; Bancroft, Elizabeth/0000-0002-5482-5660; Hum, Ryan Malcolm/0000-0003-0801-6974; Jhanji, Shaman/0000-0002-1116-628X; Pfeffer, Paul/0000-0003-0369-2885; Lowsby, Richard/0000-0001-9940-191X; Nadeem, Iftikhar/0000-0002-8644-925X; Fisk, Marie/0000-0002-1292-7642; Kudsk-Iversen, Soren/0000-0002-7112-3548; Stockdale, Alexander/0000-0002-5828-3328; Smith, Christopher/0000-0001-7369-2034; Haigh, Kathryn/0000-0003-1901-7315; Tridente, Ascanio/0000-0003-1500-447X; moon, james/0000-0001-8071-1491; Gupta-Wright, Ankur/0000-0002-5150-2970; Patel, Manish/0000-0003-3012-7507; Campbell, Mark/0000-0002-9759-0232; Behrouzi, Roya/0000-0002-1978-6539; Horby, Peter/0000-0002-9822-1586; Lai, James/0000-0002-0436-3795; Emberson, Jonathan/0000-0001-7792-9422; Burden, Christy/0000-0001-6409-5238; McKnight, Gerard/0000-0003-1546-7853; Ricketts, William/0000-0002-0475-0744	UK Research and Innovation (Medical Research Council); National Institute of Health Research	UK Research and Innovation (Medical Research Council); National Institute of Health Research(National Institute for Health Research (NIHR))	UK Research and Innovation (Medical Research Council) and National Institute of Health Research.	Addy C, 2020, BMJ OPEN RESPIR RES, V7; Carsana L., 2020, LANCET INFECT DIS, V20, P1135, DOI [10.1016/S1473-3099(20)30434-5, DOI 10.1016/S1473-3099(20)30434-5, DOI 10.1016/S2665-9913(20)30127-2]; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Echeverria-Esnal D, 2021, EXPERT REV ANTI-INFE, V19, P147, DOI 10.1080/14787210.2020.1813024; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Ginsburg AS, 2020, LANCET GLOB HEALTH, V8, pE1453, DOI 10.1016/S2214-109X(20)30444-7; Hall M, 2020, ISARIC CLIN DAT REP, DOI [10.1101/2020.07.17.20155218, DOI 10.1101/2020.07.17.20155218]; Horby P, 2020, NEW ENGL J MED, V383, P2030, DOI 10.1056/NEJMoa2022926; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Hui DS, 2018, ANTIVIR RES, V150, P202, DOI 10.1016/j.antiviral.2018.01.002; Hung IFN, 2017, CHEST, V151, P1069, DOI 10.1016/j.chest.2016.11.012; Kanoh S, 2010, CLIN MICROBIOL REV, V23, P590, DOI 10.1128/CMR.00078-09; Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046; Lee N, 2017, ANTIVIR RES, V144, P48, DOI 10.1016/j.antiviral.2017.05.008; Lim WS, 2011, THORAX, V66, P548, DOI 10.1136/thoraxjnl-2011-200081; Oliver ME, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2163; Omrani, 2020, ECLINICALMEDICINE, V29; Rawson TM, 2020, CLIN INFECT DIS, V71, P2459, DOI 10.1093/cid/ciaa530; Sekhavati E, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106143; SERMO, 2020, SERMO REP JUR IS STI; Shinkai M, 2008, PHARMACOL THERAPEUT, V117, P393, DOI 10.1016/j.pharmthera.2007.11.001; Spagnolo P, 2013, EUR RESPIR J, V42, P239, DOI 10.1183/09031936.00136712; Sterne JAC, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04641-3; Sultana J, 2020, DRUG SAFETY, V43, P691, DOI 10.1007/s40264-020-00976-7; Touret F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70143-6; WHO, DAT ACC WATCH RES AW; Zimmermann P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00302	30	76	79	5	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	2021	397	10274					605	612		10.1016/S0140-6736(21)00149-5	http://dx.doi.org/10.1016/S0140-6736(21)00149-5		FEB 2021	8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL2TN	33545096	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000620934000025
J	Bumpus, NN				Bumpus, Namandje N.			For better drugs, diversify clinical trials	SCIENCE			English	Editorial Material							AFRICAN-AMERICAN		[Bumpus, Namandje N.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Bumpus, NN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.	nbumpus1@jhmi.edu			Merck; Genentech; Amgen	Merck(Merck & Company); Genentech(Roche HoldingGenentech); Amgen(Amgen)	The author has received consulting fees, honoraria,or funding from Amgen, Merck, and Genentech.	Guengerich FP, 2016, TRENDS PHARMACOL SCI, V37, P625, DOI 10.1016/j.tips.2016.05.006; Hernandez W, 2020, PHARMACOGENOMICS J, V20, P126, DOI 10.1038/s41397-019-0095-z; Johnson JA, 2017, CLIN PHARMACOL THER, V102, P397, DOI 10.1002/cpt.668; Johnson JA, 1997, J PHARM SCI, V86, P1328, DOI 10.1021/js9702168; Johnson Vanessa A, 2011, ABNF J, V22, P84; Kimmel SE, 2013, NEW ENGL J MED, V369, P2283, DOI 10.1056/NEJMoa1310669; Lamba JK, 2002, ADV DRUG DELIVER REV, V54, P1271, DOI 10.1016/S0169-409X(02)00066-2; Lee CR, 2002, PHARMACOGENETICS, V12, P251, DOI 10.1097/00008571-200204000-00010; Limdi NA, 2017, PHARMACOGENET GENOM, V27, P347, DOI 10.1097/FPC.0000000000000298; Loree JM, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2019.1870; Miller DR, 2008, HYPERTENSION, V51, P1624, DOI 10.1161/HYPERTENSIONAHA.108.110270; Perera MA, 2014, CLIN PHARMACOL THER, V95, P242, DOI 10.1038/clpt.2013.209; Ramamoorthy A, 2015, CLIN PHARMACOL THER, V97, P263, DOI 10.1002/cpt.61; Scherr CL, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00548; Taber DJ, 2017, TRANSPLANTATION, V101, P2931, DOI 10.1097/TP.0000000000001840	15	0	1	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	2021	371	6529			SI		570	571		10.1126/science.abe2565	http://dx.doi.org/10.1126/science.abe2565			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QD7TF	33542124				2023-01-03	WOS:000615715300032
J	Marwa, KJ; Mcharo, G; Mwita, S; Katabalo, D; Ruganuza, D; Kapesa, A				Marwa, Karol Julius; Mcharo, Glory; Mwita, Stanley; Katabalo, Deogratias; Ruganuza, Deodatus; Kapesa, Anthony			Disposal practices of expired and unused medications among households in Mwanza, Tanzania	PLOS ONE			English	Article							DRUG DISPOSAL; PHARMACEUTICALS; ANTIBIOTICS; MEDICINES; KNOWLEDGE; BEHAVIOR; STORAGE; IMPACT	Background The community practice towards disposal of expired and unused medications in spite of its adverse impact have been widely neglected in many developing countries. The available guidelines in Tanzania focus on the disposal of expired medications and cosmetics in hospitals and community pharmacies only. Aim The aim of this study was to assess the disposal practice of expired and unused medications at household level in Mwanza city, north-western Tanzania. Methodology The household based cross-sectional study was conducted among 359 randomly selected household members. Semi-structured questionnaires were used for interview during data collection and while STATA(R) version 13 was used for analysis. Results Out 359 households visited, 252 (70.19%) had medications kept in their houses at the time of data collection. Among them, 10 (4.0%) households had kept medications at their houses because they were still continuing with treatment while 242 (96.0%) kept unused medications which were supposed to be discarded. The main reason for keeping unused or expired medications at home was uncompleted course of treatment (199 (82.20%) after feeling that they had recovered from illness. The main reason for discarding medications were recovering from illness (141(48.7%) and expiry (136 (46.9%). The major discarding practices for medications were disposing into domestic trashes (219 (75.5%) and pit latrines (45 (15.5%). Majority of respondents (273 (76%) were aware that improper disposal of expired medications are detrimental to human health and environment in general. Conclusion Improper disposal of unused and expired medications at household level was a common practice in the study area. Tailor-made interventions by the Food and Drugs Authority (FDA) and other national as well as local stake holders are urgently needed to address the situation.	[Marwa, Karol Julius] Catholic Univ Hlth & Allied Sci, Dept Pharmacol, Mwanza, Tanzania; [Mcharo, Glory; Mwita, Stanley; Katabalo, Deogratias] Catholic Univ Hlth & Allied Sci, Sch Pharm, Mwanza, Tanzania; [Ruganuza, Deodatus] Catholic Univ Hlth & Allied Sci, Dept Parasitol, Mwanza, Tanzania; [Kapesa, Anthony] Catholic Univ Hlth & Allied Sci, Dept Community Med, Mwanza, Tanzania		Marwa, KJ (corresponding author), Catholic Univ Hlth & Allied Sci, Dept Pharmacol, Mwanza, Tanzania.	carol_maro@yahoo.com		Marwa, Karol/0000-0001-5237-2904				Abahussain EA, 2007, PHARM WORLD SCI, V29, P368, DOI 10.1007/s11096-006-9082-y; Abahussain EA, 2006, MED PRIN PRACT, V15, P352, DOI 10.1159/000094268; Amod F, 2008, SA PHARM J, V75, P5; Angi'enda S.A., 2016, J ANTHROPOL ARCHAEOL, V4, P1, DOI [10.15640/jaa.v4n2a1, DOI 10.15640/JAA.V4N2A1]; [Anonymous], 2009, ENVIRON HEALTH PERSP, V117, pA244, DOI 10.1289/ehp.117-a244; [Anonymous], 2014, INT J PHARM SCI RES; [Anonymous], 2009, GUIDELINES SAFE DISP; Atinafu T, 2014, INT J PHARMA SCI RES, V5, P999; Baltazary G., 2013, E AFRICAN J PUBLIC H, V10, P246; Bates C, 2011, J UROLOGY, V185, P551, DOI 10.1016/j.juro.2010.09.088; Bellan N, 2012, BRAZ J PHARM SCI, V48, P507, DOI 10.1590/S1984-82502012000300018; Bound JP, 2005, ENVIRON HEALTH PERSP, V113, P1705, DOI 10.1289/ehp.8315; Boxall ABA, 2004, EMBO REP, V5, P1110, DOI 10.1038/sj.embor.7400307; Braund R, 2009, ENVIRON INT, V35, P952, DOI 10.1016/j.envint.2009.04.003; Burns W, 2006, B WORLD HEALTH ORGAN, V84, P689; Chartier Y., 2014, SAFE MANAGEMENT WAST; Chinwendu O., 2008, FIGHT FAKE DRUGS NAF; Daughton CG, 2003, ENVIRON HEALTH PERSP, V111, P775, DOI 10.1289/ehp.5948; Faurholt-Jepsen D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024215; Glassmeyer ST, 2009, ENVIRON INT, V35, P566, DOI 10.1016/j.envint.2008.10.007; Jones OAH, 2003, B WORLD HEALTH ORGAN, V81, P768; KISH L, 1949, J AM STAT ASSOC, V44, P380, DOI 10.2307/2280236; Kish L., 1965, SURVEY SAMPLING; Kotchen M, 2009, J ENVIRON MANAGE, V90, P1476, DOI 10.1016/j.jenvman.2008.10.002; Kuspis DA, 1996, VET HUM TOXICOL, V38, P48; Kusturica MP, 2012, INT J CLIN PHARM-NET, V34, P604, DOI 10.1007/s11096-012-9652-0; Matiko D., 2011, MANAGING DISPOSAL UN; McCullagh MC, 2012, J PAIN SYMPTOM MANAG, V43, P287, DOI 10.1016/j.jpainsymman.2011.03.024; Okeke IN, 1999, EMERG INFECT DIS, V5, P18, DOI 10.3201/eid0501.990103; Persson M, 2009, ENVIRON INT, V35, P771, DOI 10.1016/j.envint.2008.10.002; Redhwan Ahmed A. N., 2010, The Thai Journal of Pharmaceutical Sciences, V34, P117; Ruhoy IS, 2008, ENVIRON INT, V34, P1157, DOI 10.1016/j.envint.2008.05.002; Ruhoy IS, 2007, SCI TOTAL ENVIRON, V388, P137, DOI 10.1016/j.scitotenv.2007.08.013; Sahoo KC, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-629; Seehusen DA, 2006, J AM BOARD FAM MED, V19, P542, DOI 10.3122/jabfm.19.6.542; Smith CA, 2002, J PHARM SOC WIS, V5, P17; Ternes TA, 2004, ENVIRON SCI TECHNOL, V38, p392A, DOI 10.1021/es040639t; Tong AYC, 2011, ENVIRON INT, V37, P292, DOI 10.1016/j.envint.2010.10.002; Vollmer G., 2010, GREEN SUSTAIN PHARM, P165; Wieczorkiewicz SM, 2013, ANN PHARMACOTHER, V47, P482, DOI 10.1345/aph.1R706; Willis C, 2000, REV MED MICROBIOL, V11, P153; XFAM O, 1999, GUIDELINES SAFE DISP	42	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2021	16	2							e0246418	10.1371/journal.pone.0246418	http://dx.doi.org/10.1371/journal.pone.0246418			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF5UW	33539402	gold, Green Published			2023-01-03	WOS:000616960200005
J	Stubbs, RJ				Stubbs, R. James			Impact of carbohydrates, fat and energy density on energy intake	NATURE MEDICINE			English	Editorial Material							WEIGHT-LOSS; FEEDBACK-CONTROL; FOODS	People on low-fat, low-energy-density diets have lower ad libitum energy intake than that of those on high-fat, high-energy-density diets.	[Stubbs, R. James] Univ Leeds, Sch Psychol, Fac Med & Hlth, Leeds, W Yorkshire, England	University of Leeds	Stubbs, RJ (corresponding author), Univ Leeds, Sch Psychol, Fac Med & Hlth, Leeds, W Yorkshire, England.	R.J.Stubbs@leeds.ac.uk	Stubbs, R James/AAH-4739-2021	Stubbs, R James/0000-0002-0843-9064				Buckland NJ, 2015, PHYSIOL BEHAV, V152, P340, DOI 10.1016/j.physbeh.2015.07.001; Hall KD, 2021, NAT MED, V27, P344, DOI 10.1038/s41591-020-01209-1; Hall KD, 2017, OBESITY, V25, P2088, DOI 10.1002/oby.21978; MacLean PS, 2015, OBESITY, V23, P7, DOI 10.1002/oby.20967; O'Driscoll R, 2020, J SPORT SCI, V38, P1496, DOI 10.1080/02640414.2020.1746088; Polidori D, 2016, OBESITY, V24, P2289, DOI 10.1002/oby.21653; Ritz C, 2020, P NUTR SOC, V79, pE151, DOI 10.1017/S0029665120000993; Stubbs J, 2000, CRIT REV FOOD SCI, V40, P481, DOI 10.1080/10408690091189248; Stubbs R.J., OBES FACTS; Stubbs RJ, 2019, P NUTR SOC, V78, P576, DOI 10.1017/S0029665119001083; Stubbs RJ, 2018, EUR J CLIN NUTR, V72, P698, DOI 10.1038/s41430-018-0146-6; Stubbs RJ, 2006, BRIT J NUTR, V95, P657, DOI 10.1079/BJN20041361	12	2	2	2	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					200	201		10.1038/s41591-021-01241-9	http://dx.doi.org/10.1038/s41591-021-01241-9		FEB 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33526931				2023-01-03	WOS:000613582400003
J	Meneguci, CAG; Meneguci, J; Sasaki, JE; Tribess, S; Virtuoso, JS				Garcia Meneguci, Cintia Aparecida; Meneguci, Joilson; Sasaki, Jeffer Eidi; Tribess, Sheilla; Virtuoso Junior, Jair Sindra			Physical activity, sedentary behavior and functionality in older adults: A cross-sectional path analysis	PLOS ONE			English	Article							INSTRUMENTAL ACTIVITIES; SELF-ESTEEM; CARDIORESPIRATORY FITNESS; ACTIVITY INTERVENTION; COMBINED ASSOCIATIONS; DEPRESSIVE SYMPTOMS; ELDERLY POPULATION; NUTRITIONAL-STATUS; DISABILITY; RISK	Disability is negatively associated with the health of older adults, and it can be mediated by healthy lifestyles and behaviors throughout one's life. In this context, understanding the interrelationships between sedentary behavior, physical activity and functionality may assist in the implementation of effective public health actions. Thus, the aim of the present study was to investigate the relationships between both physical activity and sedentary behavior and functionality in older adults and the possible mediators. The variables analyzed were selected according to the content analysis of International Classification of Functioning, Disability and Health model, and included activity, participation, health conditions, body functions and structures, environmental factors and personal factors. 419 individuals participated in the study. Physical activity was directly associated with disability in instrumental activities of daily living (IADL), and the association was mediated by self-esteem, aerobic endurance, and agility/balance. Sedentary behavior was indirectly associated with IADL disability, and the association was mediated by aerobic resistance, nutritional status, and agility/balance. Regarding the basic activities of daily living (BADL), physical activity showed an indirect association mediated by aerobic resistance and IADL. The association of sedentary behavior with BADL was mediated by aerobic resistance and lower limb flexibility. These results reinforce the idea that functionality is multidimensional, and the mediating factors must be considered when strategies for promoting physical activity and reducing sedentary behavior are designed.	[Garcia Meneguci, Cintia Aparecida; Meneguci, Joilson; Virtuoso Junior, Jair Sindra] Fed Univ Triangulo Mineiro UFTM, Grad Program Hlth Care, Uberaba, MG, Brazil; [Sasaki, Jeffer Eidi; Tribess, Sheilla; Virtuoso Junior, Jair Sindra] Fed Univ Triangulo Mineiro UFTM, Grad Program Phys Educ, Uberaba, MG, Brazil	Universidade Federal do Triangulo Mineiro; Universidade Federal do Triangulo Mineiro	Meneguci, CAG (corresponding author), Fed Univ Triangulo Mineiro UFTM, Grad Program Hlth Care, Uberaba, MG, Brazil.	cintiaagar@hotmail.com		Garcia-Meneguci, Cintia Aparecida/0000-0002-5305-4024	Brazilian National Council for Scientific and Technological Development [448184/2014-1]	Brazilian National Council for Scientific and Technological Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by the Brazilian National Council for Scientific and Technological Development according to the MCTI/CNPQ/Universal 14/2014 Public Call, process n degrees 448184/2014-1, under the concession of researcher Jair Sindra Virtuoso Junior. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alves LC, 2008, CIENC SAUDE COLETIVA, V13, P1199, DOI 10.1590/S1413-81232008000400016; [Anonymous], 2005, BRAZ J PHYS THER IMP; Artaud F, 2015, J AM GERIATR SOC, V63, P1129, DOI 10.1111/jgs.13442; Auais M, 2016, ARCH GERONTOL GERIAT, V66, P147, DOI 10.1016/j.archger.2016.05.012; Awick EA, 2017, PSYCHOSOM MED, V79, P71, DOI 10.1097/PSY.0000000000000358; Brito LBB, 2013, AM J PHYS MED REHAB, V92, P241, DOI 10.1097/PHM.0b013e3182744203; Beissner KL, 2000, PHYS THER, V80, P556, DOI 10.1093/ptj/80.6.556; Benedetti Tânia R. Bertoldo, 2007, Rev Bras Med Esporte, V13, P11, DOI 10.1590/S1517-86922007000100004; Benedetti TB, 2004, REV BRAS CIENC MOV, V12, P25, DOI DOI 10.18511/RBCM.V12I1.538; Bertolazi AN, 2011, SLEEP MED, V12, P70, DOI 10.1016/j.sleep.2010.04.020; Boyle PA, 2002, INT J GERIATR PSYCH, V17, P164, DOI 10.1002/gps.539; Camilo BD, 2018, REV BRAS MED ESPORTE, V24, P310, DOI 10.1590/1517-869220182404183390; Carter S, 2017, EXERC SPORT SCI REV, V45, P80, DOI 10.1249/JES.0000000000000106; Cebolla EC, 2015, BRAZ J PHYS THER, V19, P146, DOI 10.1590/bjpt-rbf.2014.0085; Chakravarty EF, 2012, AM J MED, V125, P190, DOI 10.1016/j.amjmed.2011.08.006; Chase JAD, 2017, J AGING PHYS ACTIV, V25, P149, DOI 10.1123/japa.2016-0040; Chen T, 2016, J PHYS ACT HEALTH, V13, P303, DOI 10.1123/jpah.2015-0090; Chief Medical Officers (CMOs) of England Scotland, 2018, START ACT STAY ACT R; Cipriani Natália Cristina Santos, 2010, Rev. bras. cineantropom. desempenho hum., V12, P106, DOI 10.5007/1980-0037.2010v12n2p106; Cooper AJM, 2017, INT J EPIDEMIOL, V46, P141, DOI 10.1093/ije/dyw054; Cooper AJM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126465; Cooper R, 2011, AM J PREV MED, V41, P376, DOI 10.1016/j.amepre.2011.06.035; Corona LP, 2014, PUBLIC HEALTH NUTR, V17, P390, DOI 10.1017/S1368980012005319; Davis MG, 2014, J AGING PHYS ACTIV, V22, P474, DOI [10.1123/JAPA.2013-0042, 10.1123/japa.2013-0042]; de Menezes TN, 2014, CIENC SAUDE COLETIVA, V19, P3451, DOI 10.1590/1413-81232014198.15072013; Medeiros HBD, 2013, AGE, V35, P2399, DOI 10.1007/s11357-013-9525-z; Dodge HH, 2006, J GERONTOL A-BIOL, V61, P1330, DOI 10.1093/gerona/61.12.1330; dos Santos RL., 2008, REV BRAS PROMOC SAUD, V21, P290, DOI [DOI 10.5020/575, 10.5020/575]; Tavares DMD, 2016, CIENC SAUDE COLETIVA, V21, P3557, DOI 10.1590/1413-812320152111.03032016; Dunlop DD, 2015, J PHYS ACT HEALTH, V12, P93, DOI 10.1123/jpah.2013-0311; Dutra FCMS, 2016, BRAZ J PHYS THER, V20, P384, DOI 10.1590/bjpt-rbf.2014.0168; Eriksen L, 2016, SCAND J MED SCI SPOR, V26, P1435, DOI 10.1111/sms.12608; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gianoudis J, 2015, OSTEOPOROSIS INT, V26, P571, DOI 10.1007/s00198-014-2895-y; Goncalves DM, 2008, CAD SAUDE PUBLICA, V24, P380, DOI 10.1590/S0102-311X2008000200017; Gouveia ER, 2013, J AGING PHYS ACTIV, V21, P1, DOI 10.1123/japa.21.1.1; Guigoz Y, 2006, J NUTR HEALTH AGING, V10, P466; Hardy SE, 2011, J GEN INTERN MED, V26, P130, DOI 10.1007/s11606-010-1543-2; Heiland EG, 2016, AGE AGEING, V45, P812, DOI 10.1093/ageing/afw076; Hobbs M, 2015, BRIT J SPORT MED, V49, P1179, DOI 10.1136/bjsports-2014-093754; Houston DK, 2005, AM J CLIN NUTR, V81, P515; IBGE, 2018, PORT IBGE; Jin YC, 2019, J AGING HEALTH, V31, P1339, DOI 10.1177/0898264318778417; Jin YC, 2017, J GERONTOL A-BIOL, V72, P1710, DOI 10.1093/gerona/glw329; Jung HG, 2016, J PHYSIOL ANTHROPOL, V35, DOI 10.1186/s40101-016-0120-8; Kahraman T, 2021, PHYSIOTHER THEOR PR, V37, P527, DOI 10.1080/09593985.2019.1633715; Knaeps S, 2018, BRIT J SPORT MED, V52, P1063, DOI 10.1136/bjsports-2016-096083; Kohl HW, 2012, LANCET, V380, P294, DOI 10.1016/S0140-6736(12)60898-8; Kohler Renan, 2016, Rev. bras. geriatr. gerontol., V19, P603, DOI 10.1590/1809-98232016019.150092; Kulinski JP, 2014, MAYO CLIN PROC, V89, P1063, DOI 10.1016/j.mayocp.2014.04.019; Kulmala J, 2019, J AM GERIATR SOC, V67, P1138, DOI 10.1111/jgs.15837; Levy BR, 2012, JAMA-J AM MED ASSOC, V308, P1972, DOI 10.1001/jama.2012.14541; Liao Y, 2016, INT J BEHAV MED, V23, P402, DOI 10.1007/s12529-015-9484-0; Lin SI, 2017, J FORMOS MED ASSOC, V116, P72, DOI 10.1016/j.jfma.2016.01.011; Marinho F, 2016, EPIDEMIOL SERV SAUDE, V25, P713, DOI [10.5123/S1679-49742016000400005, 10.5123/s1679-49742016000400005]; Matos FS, 2018, CIENC SAUDE COLETIVA, V23, P3393, DOI 10.1590/1413-812320182310.23382016; McAuley Edward, 2005, J Gerontol B Psychol Sci Soc Sci, V60, pP268; McMullan II, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5265-4; Meneguci Joilson, 2015, Motri., V11, P160, DOI 10.6063/motricidade.3178; Mesa-Fernandez M, 2019, CIENC SAUDE COLETIVA, V24, P115, DOI 10.1590/1413-81232018241.35302016; Meurer ST., 2015, REV BRAS ATIV FISICA, V20, P57, DOI [10.12820/rbafs.v.20n1p57, DOI 10.12820/RBAFS.V.20N1P57]; Michele J, 2019, AGING MENT HEALTH, V23, P77, DOI 10.1080/13607863.2017.1394442; Milanovic Z, 2013, CLIN INTERV AGING, V8, DOI 10.2147/CIA.S44112; Miranda Gabriella Morais Duarte, 2016, Rev. bras. geriatr. gerontol., V19, P507, DOI 10.1590/1809-98232016019.150140; de Castro KCM, 2008, ARQ NEURO-PSIQUIAT, V66, P809, DOI 10.1590/S0004-282X2008000600006; Nonaka H, 2002, GAIT POSTURE, V15, P236, DOI 10.1016/S0966-6362(01)00191-6; Nourhashemi F, 2001, J GERONTOL A-BIOL, V56, pM448, DOI 10.1093/gerona/56.7.M448; O'Keeffe M, 2019, CLIN NUTR, V38, P2477, DOI 10.1016/j.clnu.2018.12.007; Opdenacker J, 2009, J SPORT EXERCISE PSY, V31, P743, DOI 10.1123/jsep.31.6.743; Oppewal A, 2015, RES DEV DISABIL, V41-42, P76, DOI 10.1016/j.ridd.2015.05.002; Oppewal A, 2014, RES DEV DISABIL, V35, P2299, DOI 10.1016/j.ridd.2014.05.027; Orr R, 2010, EUR J PHYS REHAB MED, V46, P183; Persson M, 2007, CLIN NUTR, V26, P216, DOI 10.1016/j.clnu.2006.12.002; Pollard B, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-97; Rabiee R, 2015, J EPIDEMIOL COMMUN H, V69, P266, DOI 10.1136/jech-2014-204851; Reid N, 2018, OSTEOPOROSIS INT, V29, P1341, DOI 10.1007/s00198-018-4428-6; Reynolds SL, 2003, SOC SCI MED, V57, P1875, DOI 10.1016/S0277-9536(03)00053-4; Rosenkranz RR, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1071; Sampaio RF, 2009, CAD SAUDE PUBLICA, V25, P475, DOI 10.1590/S0102-311X2009000300002; Sani SHZ, 2016, NEUROPSYCH DIS TREAT, V12, DOI 10.2147/NDT.S116811; Santos DA, 2012, EXP GERONTOL, V47, P908, DOI 10.1016/j.exger.2012.07.011; Santos DAT, 2017, ISSUES MENT HEALTH N, V38, P272, DOI 10.1080/01612840.2016.1263695; Lino VTS, 2008, CAD SAUDE PUBLICA, V24, P103, DOI 10.1590/S0102-311X2008000100010; Sardinha LB, 2015, J GERONTOL A-BIOL, V70, P119, DOI 10.1093/gerona/glu193; Sekaran NK, 2013, J AM GERIATR SOC, V61, P96, DOI 10.1111/jgs.12071; Shephard RJ, 2009, BRIT J SPORT MED, V43, P342, DOI 10.1136/bjsm.2007.044800; Sowa A, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1520-5; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; Stathokostas Liza, 2013, J Aging Res, V2013, P743843, DOI 10.1155/2013/743843; Storeng SH, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018942; Tak E, 2013, AGEING RES REV, V12, P329, DOI 10.1016/j.arr.2012.10.001; Toraman A, 2010, ARCH GERONTOL GERIAT, V51, P222, DOI 10.1016/j.archger.2009.10.012; Van der Horst K, 2007, MED SCI SPORT EXER, V39, P1241, DOI 10.1249/mss.0b013e318059bf35; van der Velde JHPM, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00242; Vaughan L, 2010, PSYCHOL AGING, V25, P343, DOI 10.1037/a0017729; Virtuoso JS, 2012, REV LAT-AM ENFERM, V20, P259, DOI 10.1590/S0104-11692012000200007; Volkert D, 2011, WIEN MED WOCHENSCHR, V161, P409, DOI 10.1007/s10354-011-0910-x; von Bonsdorff MB, 2011, EUR REV AGING PHYS A, V8, P23, DOI 10.1007/s11556-010-0070-9; Wang BWE, 2002, ARCH INTERN MED, V162, P2285, DOI 10.1001/archinte.162.20.2285; World Health Organisation, 2001, ICF INT CLASFUNCT	100	13	13	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2021	16	1							e0246275	10.1371/journal.pone.0246275	http://dx.doi.org/10.1371/journal.pone.0246275			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QB1HB	33513196	gold, Green Published			2023-01-03	WOS:000613891400035
J	Meyer, A; Fermaut, M; Drouin, J; Carbonnel, F; Weill, A				Meyer, Antoine; Fermaut, Marion; Drouin, Jerome; Carbonnel, Franck; Weill, Alain			Drug use for gastrointestinal symptoms during pregnancy: A French nationwide study 2010-2018	PLOS ONE			English	Article							PROTON PUMP INHIBITORS; SUDDEN CARDIAC DEATH; VENTRICULAR-ARRHYTHMIA; HYPEREMESIS GRAVIDARUM; PRESCRIPTION; MANAGEMENT; DOMPERIDONE; MEDICATION; DISEASES; DATABASE	Purpose To describe drug prescription for gastrointestinal symptoms during pregnancy. Methods Using the French national health database, we identified pregnancies ending with a birth between April 2010 and December 2018, in France. We studied prescription of antacids, antispasmodics, antinauseants, laxatives and antidiarrheals during pregnancy, between two trimesters before and two trimesters after delivery. We also assessed hospitalization for gastrointestinal symptoms during pregnancy. Results Among 6,365,471 pregnancies, 4,452,779 (74.0%) received at least one gastrointestinal drug during pregnancy; 2,228,275 (37.0%) received an antacid, 3,096,858 (51.5%) an antispasmodic, 1,861,731 (31.0%) an antinauseant, 919,116 (15.3%) a laxative and 617,808 (10.3%) an antidiarrheal. Prescription of proton pump inhibitors doubled from 12.2% in 2010 to 26.0% in 2018, while domperidone use decreased from 18.3% in 2010 to 2.2% in 2018. In addition, prescription of antacids increased from 7.0% during the trimester before pregnancy to 11.8% during the 1st trimester, 17.0% during the 2nd trimester and 23.4% during the 3rd trimester. Antispasmodic use was 10.6% during the trimester before pregnancy, 23.1% during the 1st trimester, 25.2% during the 2nd trimester and 24.0% during the 3rd trimester. Prescription of antinauseant drugs increased from 5.0% during the trimester before pregnancy to 25.7% during the 1st trimester, then decreased to 6.4% during the 2nd trimester and 3.2% during the 3rd trimester. Nausea/vomiting was the most common cause of hospitalization for gastrointestinal symptoms or diseases during pregnancy, although it accounted for only 1.0% of pregnancies. Conclusions Approximately three-quarters of women use drugs for gastrointestinal symptoms during pregnancy in France. Prescription of gastrointestinal drugs during pregnancy should be the subject of more detailed risk-benefit assessment and recommendations.	[Meyer, Antoine; Drouin, Jerome; Weill, Alain] ANSM CNAM, Epidemiol Produits Sante, GIS EPIPHARE, 42 Bd Liberat, St Denis, France; [Meyer, Antoine; Carbonnel, Franck] Hop Bicetre, AP HP, Le Kremlin Bicetre, France; [Meyer, Antoine; Carbonnel, Franck] Univ Paris Sud, Le Kremlin Bicetre, France; [Fermaut, Marion] Hop Jean Verdier, AP HP, Bondy, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP	Meyer, A (corresponding author), ANSM CNAM, Epidemiol Produits Sante, GIS EPIPHARE, 42 Bd Liberat, St Denis, France.; Meyer, A (corresponding author), Hop Bicetre, AP HP, Le Kremlin Bicetre, France.; Meyer, A (corresponding author), Univ Paris Sud, Le Kremlin Bicetre, France.	antoinemeyer@gmail.com	Meyer, Antoine/AAZ-6032-2021	Weill, Alain/0000-0001-8687-9092; Meyer, Antoine/0000-0003-1156-9289				Andrade SE, 2004, AM J OBSTET GYNECOL, V191, P398, DOI 10.1016/j.ajog.2004.04.025; [Anonymous], 2018, REC INT REL HEARTB P; ANSM: Agence nationale de securite du medicament et des produits de sante, RUPT STOCK VOGALENE; AstraZeneca, 2012, PRIL; Begaud B., DONNE VIE REELLE ENJ; Berard A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219095; Blotiere PO, 2019, NEUROLOGY, V93, pE167, DOI 10.1212/WNL.0000000000007696; Blotiere PO, 2018, PHARMACOEPIDEM DR S, V27, P763, DOI 10.1002/pds.4556; Body C, 2016, GASTROENTEROL CLIN N, V45, P267, DOI 10.1016/j.gtc.2016.02.005; Bottomley C, 2009, BEST PRACT RES CL OB, V23, P549, DOI 10.1016/j.bpobgyn.2008.12.012; Cleary BJ, 2010, PHARMACOEPIDEM DR S, V19, P408, DOI 10.1002/pds.1906; Coste J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74409-x; Damase-Michel C, 2014, THERAPIE, V69, P91, DOI 10.2515/therapie/2014005; Daw JR, 2012, CLIN THER, V34, P239, DOI 10.1016/j.clinthera.2011.11.025; Diav-Citrin O, 2005, ALIMENT PHARM THER, V21, P269, DOI 10.1111/j.1365-2036.2005.02306.x; Donati S, 2000, EUR J CLIN PHARMACOL, V56, P323, DOI 10.1007/s002280000149; French National Agency for Medicines and Health Products Safety, 2014, AN VENT MED FRANC 20; Gagne JJ, 2008, EUR J CLIN PHARMACOL, V64, P1125, DOI 10.1007/s00228-008-0546-y; Goueslard K, 2020, STUD HEALTH TECHNOL, V270, P213, DOI 10.3233/SHTI200153; Haas DM, 2018, OBSTET GYNECOL, V131, P789, DOI 10.1097/AOG.0000000000002579; Johannes CB, 2010, PHARMACOEPIDEM DR S, V19, P881, DOI 10.1002/pds.2016; Kallen BAJ, 2001, EUR J OBSTET GYN R B, V96, P63, DOI 10.1016/S0301-2115(00)00388-2; Kirchgesner J, 2017, ALIMENT PHARM THER, V45, P37, DOI 10.1111/apt.13835; Lacroix I, 2000, LANCET, V356, P1735, DOI 10.1016/S0140-6736(00)03209-8; Lassalle M, 2020, EUR J CLIN PHARMACOL, V76, P449, DOI 10.1007/s00228-019-02810-1; Li CM, 2020, ALIMENT PHARM THER, V51, P410, DOI 10.1111/apt.15610; Lupattelli A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004365; Matok I, 2012, DIGEST DIS SCI, V57, P699, DOI 10.1007/s10620-011-1940-3; MCBRIDE WG, 1961, LANCET, V2, P1358; McParlin C, 2016, JAMA-J AM MED ASSOC, V316, P1392, DOI 10.1001/jama.2016.14337; Meyer A, 2020, ALIMENT PHARM THER, V52, P1480, DOI 10.1111/apt.16074; Meyer A, 2019, ANN INTERN MED, V170, P99, DOI 10.7326/M18-1512; Mitchell AA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.02.029; National Health Service (NHS Digital), 2017, PRESCR COST AN ENGL; Olesen C, 2006, EUR J CLIN PHARMACOL, V62, P547, DOI 10.1007/s00228-006-0119-x; Phupong V, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011379.pub2; Quantin C, 2014, J GYNECOL OBST BIO R, V43, P680, DOI 10.1016/j.jgyn.2013.09.004; Rey G, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-33; Stephansson Olof, 2011, Clin Epidemiol, V3, P43, DOI 10.2147/CLEP.S16305; Stokholm J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082932; Tuppin P, 2017, REV EPIDEMIOL SANTE, V65, pS149, DOI 10.1016/j.respe.2017.05.004; Tuppin P, 2019, THER ADV GASTROENTER, V12, DOI 10.1177/1756284819853790; van der Woude CJ, 2014, GUT, V63, P1014, DOI 10.1136/gutjnl-2013-305418; van Noord C, 2010, DRUG SAFETY, V33, P1003, DOI 10.2165/11536840-000000000-00000; Weill A, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2002	45	8	9	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2021	16	1							e0245854	10.1371/journal.pone.0245854	http://dx.doi.org/10.1371/journal.pone.0245854			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ7OB	33481904	Green Published, gold			2023-01-03	WOS:000612929300020
J	Kitai, K; Kawaguchi, K; Tomohiro, T; Morita, M; So, T; Imanaka, T				Kitai, Katsuki; Kawaguchi, Kosuke; Tomohiro, Takenori; Morita, Masashi; So, Takanori; Imanaka, Tsuneo			The lysosomal protein ABCD4 can transport vitamin B-12 across liposomal membranes in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT HIPPOCAMPAL NEUROGENESIS; NEURONAL DIFFERENTIATION; EXPRESSION; MATURATION; PHENOTYPES; MODELS; BRAIN	Vitamin B-12 (cobalamin) is an essential micronutrient for human health, and mutation and dysregulation of cobalamin metabolism are associated with serious diseases, such as methylmalonic aciduria and homocystinuria. Mutations in ABCD4 or LMBRD1, which encode the ABC transporter ABCD4 and lysosomal membrane protein LMBD1, respectively, lead to errors in cobalamin metabolism, with the phenotype of a failure to release cobalamin from lysosomes. However, the mechanism of transport of cobalamin across the lysosomal membrane remains unknown. We previously demonstrated that LMBD1 is required for the translocation of ABCD4 from the endoplasmic reticulum to lysosomes. This suggests that ABCD4 performs an important function in lysosomal membrane cobalamin transport. In this study, we expressed human ABCD4 and LMBD1 in methylotrophic yeast and purified them. We prepared ABCD4 and/or LMBD1 containing liposomes loaded with cobalamin and then quantified the release of cobalamin from the liposomes by reverse-phase HPLC. We observed that ABCD4 was able to transport cobalamin from the inside to the outside of liposomes dependent on its ATPase activity and that LMBD1 exhibited no cobalamin transport activity. These results suggest that ABCD4 may be capable of transporting cobalamin from the lysosomal lumen to the cytosol. Furthermore, we examined a series of ABCD4 missense mutations to understand how these alterations impair cobalamin transport. Our findings give insight into the molecular mechanism of cobalamin transport by which ABCD4 involves and its importance in cobalamin deficiency.	[Kitai, Katsuki; Kawaguchi, Kosuke; Tomohiro, Takenori; Morita, Masashi; So, Takanori] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Toyama, Japan; [Imanaka, Tsuneo] Hiroshima Int Univ, Fac Pharmaceut Sci, Kure, Japan	University of Toyama	Kawaguchi, K (corresponding author), Univ Toyama, Grad Sch Med & Pharmaceut Sci, Toyama, Japan.	kkawa@pha.u-toyama.ac.jp	So, Takanori/R-6175-2019	So, Takanori/0000-0003-3004-8526; Kawaguchi, Kosuke/0000-0002-5115-7169; Imanaka, Tsuneo/0000-0003-4677-1356	Ministry of Education, Culture, Sports, Science and Technology of Japan [20K15990]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by Grant-in-aid for early-career scientists (20K15990 to Kosuke Kawaguchi) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Tamura Science and Technology Foundation (to Kosuke Kawaguchi).	Bonaguidi MA, 2011, CELL, V145, P1142, DOI 10.1016/j.cell.2011.05.024; Brandt MD, 2003, MOL CELL NEUROSCI, V24, P603, DOI 10.1016/S1044-7431(03)00207-0; CRAWLEY JN, 1985, NEUROSCI BIOBEHAV R, V9, P37, DOI 10.1016/0149-7634(85)90030-2; Etkin A, 2006, NEURON, V50, P127, DOI 10.1016/j.neuron.2006.03.013; Furutachi S, 2013, EMBO J, V32, P970, DOI 10.1038/emboj.2013.50; Goncalves JT, 2016, CELL, V167, P897, DOI 10.1016/j.cell.2016.10.021; Hagihara H, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0522-8; Hagihara Hideo, 2019, Neuropsychopharmacology Reports, V39, P78, DOI 10.1002/npr2.12048; Hagihara H, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/318596; Imoto Y, 2017, MOL BRAIN, V10, DOI 10.1186/s13041-017-0288-9; Iwasato T, 2004, GENESIS, V38, P130, DOI 10.1002/gene.20009; Kang EC, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019026; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Knoll B, 2006, NAT NEUROSCI, V9, P195, DOI 10.1038/nn1627; Kobayashi K, 2010, P NATL ACAD SCI USA, V107, P8434, DOI 10.1073/pnas.0912690107; Kobayashi M, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-12; Mairet-Coello G, 2012, DEVELOPMENT, V139, P475, DOI 10.1242/dev.067314; Nader K, 2019, BRAIN STRUCT FUNCT, V224, P2691, DOI 10.1007/s00429-019-01925-6; Nagashima S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56559-9; Nagashima S, 2011, J BIOL CHEM, V286, P33879, DOI 10.1074/jbc.M111.234997; Oku Y, 2013, J NEUROSCI, V33, P12586, DOI 10.1523/JNEUROSCI.0341-13.2013; Qin QY, 2006, J CELL BIOL, V172, P497, DOI 10.1083/jcb.200505079; Regad T, 2009, NAT NEUROSCI, V12, P132, DOI 10.1038/nn.2251; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shin R, 2013, BIPOLAR DISORD, V15, P405, DOI 10.1111/bdi.12064; Stritt C, 2010, MOL CELL BIOL, V30, P1828, DOI 10.1128/MCB.01434-09; Takao K, 2013, NEUROPSYCHOPHARMACOL, V38, P1409, DOI 10.1038/npp.2013.38; Terashima M, 2010, J NEUROSCI RES, V88, P1387, DOI 10.1002/jnr.22315; Torashima T, 2008, EMBO REP, V9, P393, DOI 10.1038/embor.2008.31; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Umemori, 2018, MOL BRAIN, V38; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Walton NM, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.56; Xu D, 2019, CELL RES, V29, P1039, DOI 10.1038/s41422-019-0222-z; Yamasaki N, 2008, MOL BRAIN, V1, DOI 10.1186/1756-6606-1-6; You JC, 2017, NAT MED, V23, P1377, DOI 10.1038/nm.4413; Zhang J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/727542	38	5	5	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN-JUN	2021	296								100654	10.1016/j.jbc.2021.100654	http://dx.doi.org/10.1016/j.jbc.2021.100654			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TI5TQ	33845046	gold, Green Published			2023-01-03	WOS:000672866400625
J	Lee, JS; Nair, NU; Dinstag, G; Chapman, L; Chung, YM; Wang, K; Sinha, S; Cha, H; Kim, D; Schperberg, AV; Srinivasan, A; Lazar, V; Rubin, E; Hwang, S; Berger, R; Beker, T; Ronai, ZE; Hannenhalli, S; Gilbert, MR; Kurzrock, R; Lee, SH; Aldape, K; Ruppin, E				Lee, Joo Sang; Nair, Nishanth Ulhas; Dinstag, Gal; Chapman, Lesley; Chung, Youngmin; Wang, Kun; Sinha, Sanju; Cha, Hongui; Kim, Dasol; Schperberg, Alexander, V; Srinivasan, Ajay; Lazar, Vladimir; Rubin, Eitan; Hwang, Sohyun; Berger, Raanan; Beker, Tuvik; Ronai, Ze'ev; Hannenhalli, Sridhar; Gilbert, Mark R.; Kurzrock, Razelle; Lee, Se-Hoon; Aldape, Kenneth; Ruppin, Eytan			Synthetic lethality-mediated precision oncology via the tumor transcriptome	CELL			English	Article							CELL LUNG-CANCER; PHASE-II; NEOADJUVANT CHEMOTHERAPY; METASTATIC MELANOMA; EXPRESSION ANALYSIS; MOLECULAR SUBTYPES; BIOMARKER ANALYSIS; BREAST-CANCER; RESISTANCE; CABOZANTINIB	Precision oncology has made significant advances, mainly by targeting actionable mutations in cancer driver genes. Aiming to expand treatment opportunities, recent studies have begun to explore the utility of tumor transcriptome to guide patient treatment. Here, we introduce SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a precision oncology framework harnessing genetic interactions to predict patient response to cancer therapy from the tumor transcriptome. SELECT is tested on a broad collection of 35 published targeted and immunotherapy clinical trials from 10 different cancer types. It is predictive of patients' response in 80% of these clinical trials and in the recent multi-arm WINTHER trial. The predictive signatures and the code are made publicly available for academic use, laying a basis for future prospective clinical studies.	[Lee, Joo Sang; Nair, Nishanth Ulhas; Chapman, Lesley; Wang, Kun; Sinha, Sanju; Hannenhalli, Sridhar; Ruppin, Eytan] NCI, Canc Data Sci Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Lee, Joo Sang; Chung, Youngmin; Kim, Dasol] Sungkyunkwan Univ, Sch Med, Next Generat Med Lab, Dept Artificial Intelligence, Suwon 16419, South Korea; [Lee, Joo Sang; Chung, Youngmin; Kim, Dasol] Sungkyunkwan Univ, Sch Med, Dept Precis Med, Suwon 16419, South Korea; [Lee, Joo Sang; Cha, Hongui; Lee, Se-Hoon] Sungkyunkwan Univ, Samsung Med Ctr, Samsung Adv Inst Hlth Sci & Technol, Dept Digital Hlth & Hlth Sci & Technol, Seoul 06351, South Korea; [Dinstag, Gal; Beker, Tuvik] Pangea Therapeut Ltd, IL-6971003 Tel Aviv, Israel; [Schperberg, Alexander, V] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA; [Srinivasan, Ajay] Datar Canc Genet Ltd, Res & Innovat Grp, Nasik 422010, Maharashtra, India; [Lazar, Vladimir; Kurzrock, Razelle] Worldwide Innovat Network WIN Assoc WIN Consortiu, F-94801 Villejuif, France; [Rubin, Eitan] Ben Gurion Univ Negev, Ctr Evolutionary Genom & Med, IL-8410501 Beer Sheva, Israel; [Hwang, Sohyun] CHA Univ, CHA Bundang Med Ctr, Dept Pathol, Seongnam 13497, South Korea; [Berger, Raanan] Chaim Sheba Med Ctr, Canc Ctr, IL-5262000 Tel Hashomer, Israel; [Ronai, Ze'ev] Sanford Burnham Prebys Med Discovery Inst, Canc Ctr, La Jolla, CA 92037 USA; [Gilbert, Mark R.] NCI, Neurooncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Kurzrock, Razelle] Univ Calif San Diego, Moore Canc Ctr, San Diego, CA 92037 USA; [Lee, Se-Hoon] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul 06351, South Korea; [Aldape, Kenneth] NCI, Lab Pathol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Samsung Medical Center; University of California System; University of California Los Angeles; Ben Gurion University; Pochon Cha University; Chaim Sheba Medical Center; Sanford Burnham Prebys Medical Discovery Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; Sungkyunkwan University (SKKU); Samsung Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lee, JS; Ruppin, E (corresponding author), NCI, Canc Data Sci Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.; Lee, JS (corresponding author), Sungkyunkwan Univ, Sch Med, Next Generat Med Lab, Dept Artificial Intelligence, Suwon 16419, South Korea.; Lee, JS (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Precis Med, Suwon 16419, South Korea.; Lee, JS (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Samsung Adv Inst Hlth Sci & Technol, Dept Digital Hlth & Hlth Sci & Technol, Seoul 06351, South Korea.	joosang.lee@skku.edu; eytan.ruppin@nih.go	Nair, Nishanth Ulhas/AFZ-7133-2022	Nair, Nishanth Ulhas/0000-0002-8832-0329; Schperberg, Alexander/0000-0002-3746-1105	Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR); National Research Foundation of Korea - Korean Government [NRF-2020R1A2C2007652]; Institute of Information & Communications Technology Planning & Evaluation (IITP) - Korean Government (MSIT) (AI Graduate School Support Program [Sungkyunkwan University]) [2019-0-00421]	Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR); National Research Foundation of Korea - Korean Government(National Research Foundation of KoreaKorean Government); Institute of Information & Communications Technology Planning & Evaluation (IITP) - Korean Government (MSIT) (AI Graduate School Support Program [Sungkyunkwan University])(Institute for Information & Communication Technology Planning & Evaluation (IITP), Republic of KoreaMinistry of Science & ICT (MSIT), Republic of Korea)	This research is supported in part by the Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR). This work utilized the computational resources of the NIH HPC Biowulf cluster. We thank E. Michael Gertz, Alejandro A. Schaffer, Sanna Madan, Peng Jiang, Tom Misteli, and Louis Staudt for providing many helpful comments. We thank all the patients and clinicians involved in the clinical trials analyzed in this study. Wethank Elizabeth Jaffe, Ignacio Melero, Robert Prins, Raul Rabadan, Antoni Ribas, Jeffrey Thompson, Nitin Roper, and Udayan Guha for sharing their data. This publication is partly based on research using data from Tempus Labs that has been made available through Vivli. Vivli has not contributed to or approved of and is not in any way responsible for the contents of this publication. J.S.L. is partly supported by a grant of the National Research Foundation of Korea funded by the Korean Government (NRF-2020R1A2C2007652) and Institute of Information & Communications Technology Planning & Evaluation (IITP) grant funded by the Korean Government (MSIT) (no. 2019-0-00421, AI Graduate School Support Program [Sungkyunkwan University]).	Aguirre AJ, 2016, CANCER DISCOV, V6, P914, DOI 10.1158/2159-8290.CD-16-0154; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003; Beaubier N, 2019, NAT BIOTECHNOL, V37, P1351, DOI 10.1038/s41587-019-0259-z; Belickova MM, 2016, INT J HEMATOL, V104, P566, DOI 10.1007/s12185-016-2058-3; Bolouri H, 2018, NAT MED, V24, P103, DOI 10.1038/nm.4439; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Braun DA, 2020, NAT MED, V26, P909, DOI 10.1038/s41591-020-0839-y; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Cho JW, 2020, EXP MOL MED, V52, P1550, DOI 10.1038/s12276-020-00493-8; Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7; Cowley GS, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.35; da Silva IP, 2019, CLIN CANCER RES, V25, P1272, DOI 10.1158/1078-0432.CCR-18-1680; Damotte D, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2100-3; Das Sahu A, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188323; Daud A, 2017, BRIT J CANCER, V116, P432, DOI 10.1038/bjc.2016.419; Decoster L., 2010, J CLIN ONCOL, V28, P8518; Del Rio M, 2017, EUR J CANCER, V76, P68, DOI 10.1016/j.ejca.2017.02.003; Desmedt C, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-40; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Feng XD, 2019, CANCER CELL, V35, P457, DOI 10.1016/j.ccell.2019.01.009; Fruehauf JP, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.9006; Gide TN, 2018, CLIN CANCER RES, V24, P1260, DOI 10.1158/1078-0432.CCR-17-2267; Graudens E, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-r19; Grimaldi AM, 2017, AM J CLIN DERMATOL, V18, P745, DOI 10.1007/s40257-017-0292-y; Guarneri V, 2015, ONCOLOGIST, V20, P1001, DOI 10.1634/theoncologist.2015-0138; Han JY, 2016, LUNG CANCER, V96, P108, DOI 10.1016/j.lungcan.2016.04.002; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Hayashi H, 2020, JAMA ONCOL, V6, P1931, DOI 10.1001/jamaoncol.2020.4643; Horak CE, 2013, CLIN CANCER RES, V19, P1587, DOI 10.1158/1078-0432.CCR-12-1359; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Hugo W, 2017, CELL, V168, P542, DOI 10.1016/j.cell.2017.01.010; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Hwang S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57218-9; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Iwamoto T, 2011, J NATL CANCER I, V103, P264, DOI 10.1093/jnci/djq524; Jansen MPHM, 2013, CANCER RES, V73, P6632, DOI 10.1158/0008-5472.CAN-13-0704; Julka PK, 2008, BRIT J CANCER, V98, P1327, DOI 10.1038/sj.bjc.6604322; Kakavand H, 2017, CLIN CANCER RES, V23, P6054, DOI 10.1158/1078-0432.CCR-16-1688; Katakami N, 2013, J CLIN ONCOL, V31, P3335, DOI 10.1200/JCO.2012.45.0981; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Kiura K, 2008, J THORAC ONCOL, V3, P386, DOI 10.1097/JTO.0b013e318168d228; Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068; Lee JS, 2019, JAMA ONCOL, V5, P1614, DOI 10.1001/jamaoncol.2019.2311; Lee JS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04647-1; Lisowska KM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00006; Liu D, 2019, NAT MED, V25, P1916, DOI 10.1038/s41591-019-0654-5; Lohrisch C, 2006, J CLIN ONCOL, V24, P4888, DOI 10.1200/JCO.2005.01.6089; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Magbanua MJM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0582-3; Manojlovic Z, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007087; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Nathanson T, 2017, CANCER IMMUNOL RES, V5, P84, DOI 10.1158/2326-6066.CIR-16-0019; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Novello S, 2009, BRIT J CANCER, V101, P1543, DOI 10.1038/sj.bjc.6605346; Pathria G, 2019, NAT CELL BIOL, V21, P1590, DOI 10.1038/s41556-019-0415-1; Pinyol R, 2019, GUT, V68, P1065, DOI 10.1136/gutjnl-2018-316408; Pleasance E, 2020, NAT CANCER, V1, P452, DOI 10.1038/s43018-020-0050-6; Prat A, 2017, CANCER RES, V77, P3540, DOI 10.1158/0008-5472.CAN-16-3556; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Rodon J, 2019, NAT MED, V25, P751, DOI 10.1038/s41591-019-0424-4; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Roper N, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100007; Sabine VS, 2010, BREAST CANCER RES TR, V122, P419, DOI 10.1007/s10549-010-0928-6; Sachdev P, 2013, J CLIN ONCOL, V31; Schalper KA, 2019, NAT MED, V25, P470, DOI 10.1038/s41591-018-0339-5; Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665; Shi YK, 2013, LANCET ONCOL, V14, P953, DOI 10.1016/S1470-2045(13)70355-3; Snyder A, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002309; Sorich MJ, 2008, PLOS MED, V5, P646, DOI 10.1371/journal.pmed.0050083; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Spentzos D, 2005, J CLIN ONCOL, V23, P7911, DOI 10.1200/JCO.2005.02.9363; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tanioka M, 2018, CLIN CANCER RES, V24, P5292, DOI 10.1158/1078-0432.CCR-17-3431; Terragna C, 2016, ONCOTARGET, V7, P9666, DOI 10.18632/oncotarget.5718; Thompson JC, 2020, LUNG CANCER, V139, P1, DOI 10.1016/j.lungcan.2019.10.012; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Vaske OM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.13968; Wakelee HA, 2017, CANCER CHEMOTH PHARM, V79, P923, DOI 10.1007/s00280-017-3283-z; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Wong M, 2020, NAT MED, V26, P1742, DOI 10.1038/s41591-020-1072-4; Wongchenko MJ, 2017, CLIN CANCER RES, V23, P5238, DOI 10.1158/1078-0432.CCR-17-0172; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zhao J, 2019, NAT MED, V25, P462, DOI 10.1038/s41591-019-0349-y	100	18	18	6	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 29	2021	184	9					2487	+		10.1016/j.cell.2021.03.030	http://dx.doi.org/10.1016/j.cell.2021.03.030		APR 2021	29	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RV7SH	33857424	Green Accepted, Bronze			2023-01-03	WOS:000646027900022
J	Zanetti, ACB; Dias, BM; Bernardes, A; Capucho, HC; Balsanelli, AP; de Moura, AA; Soato, R; Gabriel, CS				Barboza Zanetti, Ariane Cristina; Dias, Bruna Moreno; Bernardes, Andrea; Capucho, Helaine Carneiro; Balsanelli, Alexandre Pazetto; de Moura, Andre Almeida; Soato, Rodrigo; Gabriel, Carmen Silvia			Incidence and preventability of adverse events in adult patients admitted to a Brazilian teaching hospital	PLOS ONE			English	Article							HEALTH-CARE; CONSEQUENCES; SAFETY; QUALITY; RATES	Objective To analyze the incidence and preventability of adverse events related to health care in adult patients admitted to a Brazilian teaching hospital. Methods A retrospective cohort study, in which the incidence and preventability of adverse events related to health care were based on a two-stage retrospective review of 368 medical records (nurses and pharmacist review of medical records, followed by physicians review of triggered medical records) of adult patients whose hospitalizations occurred during 2015 in a high-complexity public teaching hospital located in Brazil. Data were collected from February 2018 to February 2019. Results A total of 266 adverse events were observed in 124 patients. The incidence of adverse events related to health care was 33.7% (95% CI 0.29-0.39), and the incidence density was 4.97 adverse events per 100 patient-days. Adverse events were responsible for 701 additional days of hospitalization, and the estimated length of additional hospital stay attributable to them was, on average, 6.8 days per event. The most common types of events were related to general care (60; 22.6%), medications (50; 18.8%), nosocomial infection (35; 13.2%), any other type (11; 4.1%), and diagnoses (2; 0.8%). Regarding the severity of adverse events, it was found that 168 (63.2%) were mild, 55 (20.7%) were moderate, and 43 (16.2%) were severe. In addition, it was estimated that 155 (58.3%) events were preventable. The length of a patient's hospital stay was identified as a risk factor for the occurrence of adverse events (RR 1.20; 95% CI 1.04-1.39). Conclusions Through knowledge of the incidence, nature, severity, preventability, and risk factors for the occurrence of adverse events, it is possible to create the opportunities to prioritize the implementation of strategies for mitigating specific events based on reliable data and concrete information.	[Barboza Zanetti, Ariane Cristina; Dias, Bruna Moreno; Bernardes, Andrea; de Moura, Andre Almeida; Soato, Rodrigo; Gabriel, Carmen Silvia] Univ Sao Paulo, Dept Gen & Specialized Nursing, Ribeirao Preto Coll Nursing, Sao Paulo, SP, Brazil; [Capucho, Helaine Carneiro] Univ Brasilia, Fac Hlth Sci, Dept Pharm, Brasilia, DF, Brazil; [Balsanelli, Alexandre Pazetto] Fed Univ Sao Paulo UNIFESP, Paulista Sch Nursing, Dept Adm Hlth & Nursing Serv, Sao Paulo, SP, Brazil	Universidade de Sao Paulo; Universidade de Brasilia; Universidade Federal de Sao Paulo (UNIFESP)	Zanetti, ACB (corresponding author), Univ Sao Paulo, Dept Gen & Specialized Nursing, Ribeirao Preto Coll Nursing, Sao Paulo, SP, Brazil.	arizanetti@gmail.com	Balsanelli, Alexandre Pazetto/AAC-9900-2019; Moura, André/H-2224-2019; Balsanelli, Alexandre Pazetto/J-5120-2015; Zanetti, Ariane Cristina Barboza/AAO-6642-2020; DIAS, BRUNA MORENO/D-9756-2018	Balsanelli, Alexandre Pazetto/0000-0003-3757-1061; Moura, André/0000-0003-2990-5375; Balsanelli, Alexandre Pazetto/0000-0003-3757-1061; Zanetti, Ariane Cristina Barboza/0000-0002-4458-3274; DIAS, BRUNA MORENO/0000-0002-7346-4848				Aranaz-Andres JM, 2008, J EPIDEMIOL COMMUN H, V62, P1022, DOI 10.1136/jech.2007.065227; Aranaz-Andres JM, 2011, BMJ QUAL SAF, V20, P1043, DOI 10.1136/bmjqs.2011.051284; Baines R, 2015, BMJ QUAL SAF, V24, P561, DOI 10.1136/bmjqs-2014-003702; Baines RJ, 2013, BMJ QUAL SAF, V22, P290, DOI 10.1136/bmjqs-2012-001126; Baker GR, 2004, CAN MED ASSOC J, V170, P1678, DOI 10.1503/cmaj.1040498; Baneres Joaquim, 2014, Med Clin (Barc), V143 Suppl 1, P3, DOI 10.1016/j.medcli.2014.07.005; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Davis Peter, 2003, N Z Med J, V116, pU624; Davis Peter, 2002, N Z Med J, V115, pU271; de Melo-Silva AM, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052000639, 10.11606/s1518-8787.2018052000639]; de Vries EN, 2008, QUAL SAF HEALTH CARE, V17, P216, DOI 10.1136/qshc.2007.023622; Dovey Susan M, 2017, JMIR Res Protoc, V6, pe10, DOI 10.2196/resprot.6696; Gaitán-Duarte Hernando, 2008, Rev. salud pública, V10, P215; Halfon P, 2017, INT J QUAL HEALTH C, V29, P527, DOI 10.1093/intqhc/mzx061; Hanskamp-Sebregts M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011078; Hoogervorst-Schilp J, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1205-5; Lancis-Sepulveda ML, 2014, REV CALID ASSIST, V29, P78, DOI 10.1016/j.cali.2013.10.003; Letaief M, 2010, INT J QUAL HEALTH C, V22, P380, DOI 10.1093/intqhc/mzq040; Lucas-Imbernon FJ, 2012, REV CALID ASSIST, V27, P189, DOI 10.1016/j.cali.2011.10.005; Aranaz-Andres JM, 2009, INT J QUAL HEALTH C, V21, P408, DOI 10.1093/intqhc/mzp047; Mendes W, 2009, INT J QUAL HEALTH C, V21, P279, DOI 10.1093/intqhc/mzp022; Michel P, 2004, BRIT MED J, V328, P199, DOI 10.1136/bmj.328.7433.199; Musavi SMH., 2016, J PATIENT SAF QUAL I, V4, P351, DOI [10.22038/PSJ.2016.6689, DOI 10.22038/PSJ.2016.6689]; Panagioti M, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4185; Rafter N, 2017, BMJ QUAL SAF, V26, P111, DOI 10.1136/bmjqs-2015-004828; Sari AA, 2015, ARCH IRAN MED, V18, P811, DOI 0151812/AIM.004; Schioler T, 2001, Ugeskr Laeger, V163, P5370; Sommella L, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-358; Soop M, 2009, INT J QUAL HEALTH C, V21, P285, DOI 10.1093/intqhc/mzp025; Sousa P, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-311; Tartaglia R, 2012, EPIDEMIOL PREV, V36, P151; Van den Heede K, 2006, INT J QUAL HEALTH C, V18, P211, DOI 10.1093/intqhc/mzl003; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; Vlayen Annemie, 2012, BMC Res Notes, V5, P468, DOI 10.1186/1756-0500-5-468; Vlayen A, 2012, J EVAL CLIN PRACT, V18, P485, DOI 10.1111/j.1365-2753.2010.01612.x; Waring J, 2016, SOCIOL HEALTH ILL, V38, P198, DOI 10.1111/1467-9566.12391; Wilson RM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e832; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; Zegers M, 2009, QUAL SAF HEALTH CARE, V18, P297, DOI 10.1136/qshc.2007.025924; Zhang EW, 2017, AM J EMERG MED, V35, P479, DOI 10.1016/j.ajem.2016.11.062	40	2	2	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2021	16	4							e0249531	10.1371/journal.pone.0249531	http://dx.doi.org/10.1371/journal.pone.0249531			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP1DC	33857137	Green Published, gold			2023-01-03	WOS:000641474900022
J	Nantha, YS; Chelliah, AAP; Haque, S; Zain, AZM				Nantha, Yogarabindranath Swarna; Chelliah, Azriel Abisheg Paul; Haque, Shamsul; Zain, Anuar Zaini Md			The internal realities of individuals with type 2 diabetes-Psychological disposition in self-management behaviour via grounded theory approach	PLOS ONE			English	Article							CARE; PEOPLE; ATTITUDES; WISHES; MODELS	Background A paradigm shift in the disease management of type 2 diabetes is urgently needed to stem the escalating trends seen worldwide. A "glucocentric" approach to diabetes management is no longer considered a viable option. Qualitative strategies have the potential to unearth the internal psychological attributes seen in people living with diabetes that are crucial to the sustenance of self-management behaviour. This study aims to identify and categorize the innate psychological dispositions seen in people with type 2 diabetes in relation to self-management behaviour. Methods We adopted a grounded theory approach to guide in-depth interviews of individuals with type 2 diabetes and healthcare professionals (HCP) at a regional primary care clinic in Malaysia. Twenty-four people with type 2 diabetes and 10 HCPs were recruited into the study to examine the inner narratives about disease management. Two focus group discussions (FGD) were also conducted for data triangulation. Results Participants' internal dialogue about the management of their disease is characterized by 2 major processes- 1) positive disposition and 2) negative disposition. Optimism, insight, and awareness are important positive values that influence T2D self-care practices. On the other hand, constructs such as stigma, worries, reservations, and pessimism connote negative dispositions that undermine the motivation to follow through disease management in individuals with type 2 diabetes. Conclusions We identified a contrasting spectrum of both constructive and undesirable behavioural factors that influence the 'internal environment' of people with type 2 diabetes. These results coincide with the constructs presented in other well-established health belief theories that could lead to novel behavioural change interventions. Furthermore, these findings allow the implementation of psychosocial changes that are in line with cultural sensitivities and societal norms seen in a specific community.	[Nantha, Yogarabindranath Swarna; Zain, Anuar Zaini Md] Monash Univ Malaysia, Clin Sch Johor Bahru, Jeffrey Cheah Sch Med & Hlth Sci, Subang Jaya, Malaysia; [Nantha, Yogarabindranath Swarna; Haque, Shamsul] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Dept Psychol, Subang Jaya, Malaysia; [Chelliah, Azriel Abisheg Paul] Hosp Sibu, Sarawak, Malaysia	Monash University; Monash University Sunway; Monash University; Monash University Sunway	Nantha, YS (corresponding author), Monash Univ Malaysia, Clin Sch Johor Bahru, Jeffrey Cheah Sch Med & Hlth Sci, Subang Jaya, Malaysia.; Nantha, YS (corresponding author), Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Dept Psychol, Subang Jaya, Malaysia.	Yoga.rabindranath@monash.edu		Haque, Shamsul/0000-0002-1561-6989	MOH-NIH grant [:91000440]; Ministry of Health Malaysia	MOH-NIH grant; Ministry of Health Malaysia	This study was funded by the MOH-NIH grant (Grant No.:91000440) received from the Ministry of Health Malaysia. YSN was the recipient of this grant. URL to grant website (http://www.nih.gov.my/web/grant-application/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beverly EA, 2012, J GEN INTERN MED, V27, P1180, DOI 10.1007/s11606-012-2070-0; Bootle S, 2015, DIABETES RES CLIN PR, V109, P6, DOI 10.1016/j.diabres.2015.04.004; Burns KK, 2016, DIABETIC MED, V33, P1184, DOI 10.1111/dme.13136; Charmaz K., 2006, CONSTRUCTING GROUNDE; Cho NH, 2018, DIABETES RES CLIN PR, V138, P271, DOI 10.1016/j.diabres.2018.02.023; Corbin J. M.., 2015, BASICS QUALITATIVE R; Harvey JN, 2009, DIABETIC MED, V26, P5, DOI 10.1111/j.1464-5491.2008.02628.x; Holt RIG, 2016, DIABETIC MED, V33, P1174, DOI 10.1111/dme.13109; Hussein Z, 2015, ANN GLOB HEALTH, V81, P851, DOI 10.1016/j.aogh.2015.12.016; International Diabetes Federation, 2017, IDF DIABETES ATLAS 8, V8th, P1; Low LL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147127; Low Lee Lan, 2014, Coll Antropol, V38, P11; Lu Y, 2016, EVAL HEALTH PROF, V39, P131, DOI 10.1177/0163278715588927; Monnier L, 2008, DIABETES METAB, V34, P207, DOI 10.1016/j.diabet.2008.01.011; Murray M., 2014, HLTH PSYCHOL THEORY, V4th; Nantha YS, 2019, FAM PRACT, V36, P581, DOI 10.1093/fampra/cmy119; Newton P, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/638205; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Ockleford E, 2008, CHRONIC ILLN, V4, P28, DOI 10.1177/1742395307086673; Ogden J., 2012, HLTH PSYCHOL TXB; Rubin RR., 2002, PRACTICAL PSYCHOL DI, V2nd, P1; Rushforth B, 2016, BRIT J GEN PRACT, V66, pE114, DOI 10.3399/bjgp16X683509; Serrano-Gil M, 2010, ADV THER, V27, P321, DOI 10.1007/s12325-010-0034-5; Shrivastava SR, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-14; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a; Zimmet Paul Z, 2017, Clin Diabetes Endocrinol, V3, P1, DOI 10.1186/s40842-016-0039-3	27	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2021	16	4							e0249620	10.1371/journal.pone.0249620	http://dx.doi.org/10.1371/journal.pone.0249620			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RN5ED	33848301	Green Published, gold			2023-01-03	WOS:000640373500007
J	Ostermann, M; Lumlertgul, N				Ostermann, Marlies; Lumlertgul, Nuttha			Wait and see for acute dialysis: but for how long?	LANCET			English	Editorial Material									[Ostermann, Marlies; Lumlertgul, Nuttha] Guys & St Thomas NHS Fdn Trust, Kings Coll London, Dept Crit Care, London SE1 7EH, England; [Lumlertgul, Nuttha] King Chulalongkorn Mem Hosp, Div Nephrol, Bangkok, Thailand; [Lumlertgul, Nuttha] King Chulalongkorn Mem Hosp, Excellence Ctr Crit Care Nephrol, Bangkok, Thailand; Chulalongkorn Univ, Crit Care Nephrol Res Unit, Bangkok, Thailand	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University	Ostermann, M (corresponding author), Guys & St Thomas NHS Fdn Trust, Kings Coll London, Dept Crit Care, London SE1 7EH, England.	marlies.ostermann@gstt.nhs.uk	Ostermann, Marlies/B-8777-2015	Ostermann, Marlies/0000-0001-9500-9080				Bagshaw SM, 2020, NEW ENGL J MED, V383, P240, DOI 10.1056/NEJMoa2000741; Barbar SD, 2018, NEW ENGL J MED, V379, P1431, DOI 10.1056/NEJMoa1803213; Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017; Hoste E, 2020, INTENS CARE MED, V46, P943, DOI 10.1007/s00134-019-05919-0; Klein SJ, 2018, INTENS CARE MED, V44, P323, DOI 10.1007/s00134-018-5126-8; Ostermann M, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19209; Ostermann M, 2020, KIDNEY INT, V98, P294, DOI 10.1016/j.kint.2020.04.020; Ostermann M, 2016, BLOOD PURIFICAT, V42, P224, DOI 10.1159/000448506; Rewa OG, 2019, J CRIT CARE, V52, P109, DOI 10.1016/j.jcrc.2019.04.011; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; Schneider AG, 2020, CURR OPIN CRIT CARE, V26, P549, DOI 10.1097/MCC.0000000000000770	11	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2021	397	10281					1241	1243						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RH2ZM	33812477				2023-01-03	WOS:000636093400005
J	Kaps, L; Ahlbrand, CJ; Gadban, R; Nagel, M; Labenz, C; Klimpke, P; Holtz, S; Boedecker, S; Michel, M; Kremer, WM; Hilscher, M; Galle, PR; Kraus, D; Schattenberg, JM; Weinmann-Menke, J				Kaps, L.; Ahlbrand, C. J.; Gadban, R.; Nagel, M.; Labenz, C.; Klimpke, P.; Holtz, S.; Boedecker, S.; Michel, M.; Kremer, W. M.; Hilscher, M.; Galle, P. R.; Kraus, D.; Schattenberg, J. M.; Weinmann-Menke, J.			Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care	PLOS ONE			English	Article							MANAGEMENT	Background ADVanced Organ Support (ADVOS) is a novel type of extracorporeal albumin dialysis and holds promise to sustain liver function and recovery of patients with acute-on-chronic liver failure (ACLF). Previously, ADVOS was tested as continuous treatment for intensive care patients with liver failure. Data related to the applicability and safety as discontinuous treatment outside of ICU is not available. Aim Evaluation of ADVOS as discontinuous treatment for patients with ACLF outside intensive care unit and comparison with a matched historic cohort. Methods and results In this retrospective study, 26 patients with ACLF and the indication for renal replacement therapy related to HRS-AKI were included. Majority of patients were male (65%) with alcoholic cirrhosis in 88% and infections as a trigger of ACLF in 96%. Liver function was severely compromised reflected by high median MELD and CLIF-C ACLF scores of 37 (IQR 32;40) and 56.5 (IQR 51;60), respectively. Patients were treated discontinuously with ADVOS over a median time of 12 days (IQR 8.25;17) and received 8 (IQR 4.25;9.75) treatment cycles on average. No treatment related adverse events were recorded, and safety laboratory parameters remained constant during the observation time. After 16 h cumulative dialysis therapy, ADVOS significantly reduced protein-bound bilirubin (14%), creatinine (11.8%) and blood urea nitrogen (BUN, 33%). Using a matched cohort with ACLF treated with hemodialysis, ADVOS achieved a stronger decrease in bilirubin (p = 0.01), while detoxification of water-soluble catabolites' including creatinine and BUN was comparable. The 28-days mortality in the ADVOS group was 56% (14/26) and was not inferior to predicted survival (predicted median 28-days mortality was 44%, IQR 30; 59). Conclusion Discontinuous ADVOS treatment was safe and effective in patients with ACLF outside intensive care and outperformed hemodialysis in reducing protein-bound metabolites.	[Kaps, L.; Ahlbrand, C. J.; Gadban, R.; Nagel, M.; Labenz, C.; Klimpke, P.; Holtz, S.; Boedecker, S.; Michel, M.; Kremer, W. M.; Hilscher, M.; Galle, P. R.; Kraus, D.; Schattenberg, J. M.; Weinmann-Menke, J.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Internal Med 1, Mainz, Germany; [Kaps, L.; Ahlbrand, C. J.; Nagel, M.; Labenz, C.; Michel, M.; Kremer, W. M.; Hilscher, M.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Cirrhosis Ctr Mainz CCM, Mainz, Germany; [Kaps, L.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Translat Immunol, Mainz, Germany; [Schattenberg, J. M.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, IMetabol Liver Res Program, Dept Med 1, Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Weinmann-Menke, J (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Internal Med 1, Mainz, Germany.	julia.weinmann-menke@unimedizin-mainz.de	Weinmann-Menke, Julia/ABC-3559-2021; Galle, Peter/ABE-2872-2021; Galle, Peter R/T-5292-2018; Schattenberg, Jörn M./C-1301-2013	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992; Schattenberg, Jörn M./0000-0002-4224-4703; Ghadban, Ruba/0000-0003-4147-1020; Kaps, Leonard/0000-0002-4782-8003				Angeli P, 2015, J HEPATOL, V62, P968, DOI 10.1016/j.jhep.2014.12.029; Engelmann C, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2156-0; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Fuhrmann V, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00714-3; Henschel B., 2015, CRIT CARE, V19, pP383; Hernaez R, 2017, GUT, V66, P541, DOI 10.1136/gutjnl-2016-312670; Huber W, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0569-x; Kribben A, 2012, GASTROENTEROLOGY, V142, P782, DOI 10.1053/j.gastro.2011.12.056; Man NK., 1995, LONG TERM HEMODIALYS, P11; Martinez JJG, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0453-z; Moreau R, 2016, CLIN MOL HEPATOL, V22, P1, DOI 10.3350/cmh.2016.22.1.1; Moreau R, 2013, GASTROENTEROLOGY, V144, P1426, DOI 10.1053/j.gastro.2013.02.042; Pawlotsky JM, 2020, J HEPATOL, V73, P1170, DOI 10.1016/j.jhep.2020.08.018; Score Calculators | EF Clif, EUR FDN STUD CHRON; Sponholz C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-015-1159-3; Tsipotis E, 2015, ADV CHRONIC KIDNEY D, V22, P382, DOI 10.1053/j.ackd.2015.05.004; Wehler M, 2001, HEPATOLOGY, V34, P255, DOI 10.1053/jhep.2001.26522; Wong F, 2017, J HEPATOL, V66, P860, DOI 10.1016/j.jhep.2016.10.024	18	2	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2021	16	4							e0249342	10.1371/journal.pone.0249342	http://dx.doi.org/10.1371/journal.pone.0249342			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH8NB	33793644	Green Published, gold			2023-01-03	WOS:000636467000035
J	Borelli, E; Bigi, S; Potenza, L; Artioli, F; Eliardo, S; Mucciarini, C; Cagossi, K; Razzini, G; Pasqualini, A; Lui, FS; Ferlazzo, F; Cruciani, M; Bruera, E; Efficace, F; Luppi, M; Cacciari, C; Porro, CA; Bandieri, E				Borelli, Eleonora; Bigi, Sarah; Potenza, Leonardo; Artioli, Fabrizio; Eliardo, Sonia; Mucciarini, Claudia; Cagossi, Katia; Razzini, Giorgia; Pasqualini, Antonella; Lui, Fausta; Ferlazzo, Fabio; Cruciani, Massimiliano; Bruera, Eduardo; Efficace, Fabio; Luppi, Mario; Cacciari, Cristina; Porro, Carlo Adolfo; Bandieri, Elena			Different semantic and affective meaning of the words associated to physical and social pain in cancer patients on early palliative/supportive care and in healthy, pain-free individuals	PLOS ONE			English	Article							EARLY PALLIATIVE CARE; QUALITY-OF-LIFE; PSYCHOLOGICAL PAIN; AMERICAN SOCIETY; LUNG; INTEGRATION; VALIDATION; ONCOLOGY; GOALS; QUESTIONNAIRE	Early palliative/supportive care (ePSC) is a medical intervention focused on patient's needs, that integrates standard oncological treatment, shortly after a diagnosis of advanced/metastatic cancer. ePSC improves the appropriate management of cancer pain. Understanding the semantic and emotional impact of the words used by patients to describe their pain may further improve its assessment in the ePSC setting. Psycholinguistics assumes that the semantic and affective properties of words affect the ease by which they are processed and comprehended. Therefore, in this cross-sectional survey study we collected normative data about the semantic and affective properties of words associated to physical and social pain, in order to investigate how patients with cancer pain on ePSC process them compared to healthy, pain-free individuals. One hundred ninety patients and 124 matched controls rated the Familiarity, Valence, Arousal, Pain-relatedness, Intensity, and Unpleasantness of 94 words expressing physical and social pain. Descriptive and inferential statistics were performed on ratings in order to unveil patients' semantic and affective representation of pain and compare it with those from controls. Possible effects of variables associated to the illness experience were also tested. Both groups perceived the words conveying social pain as more negative and pain-related than those expressing physical pain, confirming previous evidence of social pain described as worse than physical pain. Patients rated pain words as less negative, less pain-related, and conveying a lower intense and unpleasant pain than controls, suggesting either an adaptation to the pain experience or the role played by ePSC in improving patients' ability to cope with it. This exploratory study suggests that a chronic pain experience as the one experienced by cancer patients on ePSC affects the semantic and affective representation of pain words.	[Borelli, Eleonora; Lui, Fausta; Cacciari, Cristina; Porro, Carlo Adolfo] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Modena, Italy; [Borelli, Eleonora; Lui, Fausta; Cacciari, Cristina; Porro, Carlo Adolfo] Univ Modena & Reggio Emilia, Ctr Neurosci & Neurotechnol, Modena, Italy; [Bigi, Sarah] Univ Cattolica Sacro Cuore, Dept Linguist Sci & Foreign Literatures, Milan, Italy; [Potenza, Leonardo; Luppi, Mario] Azienda Osped Univ Modena, Hematol Unit & Chair, Modena, Italy; [Potenza, Leonardo; Luppi, Mario] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Modena, Italy; [Artioli, Fabrizio; Eliardo, Sonia; Mucciarini, Claudia; Cagossi, Katia; Razzini, Giorgia; Pasqualini, Antonella; Cruciani, Massimiliano; Bandieri, Elena] USL, Civil Hosp Carpi, Oncol & Palliat Care Units, Carpi, Italy; [Ferlazzo, Fabio] Sapienza Univ, Dept Psychol, Rome, Italy; [Bruera, Eduardo] UT MD Anderson Canc Ctr, Palliat Care & Rehabil Med, Houston, TX USA; [Efficace, Fabio] Italian Grp Adult Hematol Dis GIMEMA, Hlth Outcomes Res Unit, Rome, Italy	Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Catholic University of the Sacred Heart; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Universita di Modena e Reggio Emilia; Sapienza University Rome; University of Texas System; UTMD Anderson Cancer Center; Fondazione GIMEMA	Borelli, E (corresponding author), Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Modena, Italy.; Borelli, E (corresponding author), Univ Modena & Reggio Emilia, Ctr Neurosci & Neurotechnol, Modena, Italy.	eleonora.borelli@unimore.it	Lui, Fausta/P-3816-2015; Claudia, Mucciarini/AAY-8955-2021; Bruera, Eduardo/AAA-1550-2022; Borelli, Eleonora/AAU-9973-2021	Lui, Fausta/0000-0001-6577-059X; Claudia, Mucciarini/0000-0001-5439-6352; Efficace, Fabio/0000-0002-5065-5166; Borelli, Eleonora/0000-0002-3391-4437	FAR2016 grant from the University of Modena and Reggio Emilia	FAR2016 grant from the University of Modena and Reggio Emilia	This research was supported by the FAR2016 grant from the University of Modena and Reggio Emilia (https://www.unimore.it/).The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Back AL, 2007, ARCH INTERN MED, V167, P453, DOI 10.1001/archinte.167.5.453; Back AL, 2014, J PALLIAT MED, V17, P1244, DOI 10.1089/jpm.2014.0146; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Baliki MN, 2006, J NEUROSCI, V26, P12165, DOI 10.1523/JNEUROSCI.3576-06.2006; Bandieri E, 2012, ANN ONCOL, V23, P2016, DOI 10.1093/annonc/mds103; Bandieri E, 2020, BMJ SUPPORT PALLIAT, V10, DOI 10.1136/bmjspcare-2019-001794; Barrett LF, 1999, CURR DIR PSYCHOL SCI, V8, P10, DOI 10.1111/1467-8721.00003; Bernstein MJ, 2012, PERS SOC PSYCHOL B, V38, P185, DOI 10.1177/0146167211422449; Borelli E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199658; Bruera E, 1991, J Palliat Care, V7, P6; Bruera E, 2010, J CLIN ONCOL, V28, P4013, DOI 10.1200/JCO.2010.29.5618; Chen ZS, 2008, PSYCHOL SCI, V19, P789, DOI 10.1111/j.1467-9280.2008.02158.x; Citron FMM, 2016, BEHAV RES METHODS, V48, P91, DOI 10.3758/s13428-015-0581-4; Citron FMM, 2012, BRAIN LANG, V122, P211, DOI 10.1016/j.bandl.2011.12.007; Conejero I, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0893-z; Courtet P, 2019, ENCEPHALE, V45, pS7, DOI 10.1016/j.encep.2018.09.005; Cristofori I, 2013, CEREB CORTEX, V23, P2437, DOI 10.1093/cercor/bhs236; Dworkin RH, 2002, CLIN J PAIN, V18, P343, DOI 10.1097/00002508-200211000-00001; Efficace F, 2006, ANN ONCOL, V17, P1698, DOI 10.1093/annonc/mdl183; Eisenberger NI, 2006, PAIN, V126, P132, DOI 10.1016/j.pain.2006.06.024; Eisenberger NI, 2012, PSYCHOSOM MED, V74, P126, DOI 10.1097/PSY.0b013e3182464dd1; Eisenberger NI, 2010, BRAIN BEHAV IMMUN, V24, P558, DOI 10.1016/j.bbi.2009.12.009; El-Jawahri A, 2016, JAMA-J AM MED ASSOC, V316, P2094, DOI 10.1001/jama.2016.16786; Ferrell BR, 2017, J CLIN ONCOL, V35, P96, DOI 10.1200/JCO.2016.70.1474; Frumkin MR, 2021, J CLIN PSYCHOL, V77, P254, DOI 10.1002/jclp.23024; Galli G, 2019, J PAIN RES, V12, P1721, DOI 10.2147/JPR.S191548; GERNSBACHER MA, 1984, J EXP PSYCHOL GEN, V113, P256, DOI 10.1037/0096-3445.113.2.256; Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996; Hack TF, 2005, PSYCHO-ONCOLOGY, V14, P831, DOI 10.1002/pon.949; HERTH K, 1992, J ADV NURS, V17, P1251, DOI 10.1111/j.1365-2648.1992.tb01843.x; Holland JC, 1998, PSYCHO-ONCOL, V7, P460, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<460::AID-PON328>3.0.CO;2-R; Hui D, 2015, ANN ONCOL, V26, P1953, DOI 10.1093/annonc/mdv269; Jacobs AM, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00714; Jollant F, 2019, PROG NEURO-PSYCHOPH, V90, P55, DOI 10.1016/j.pnpbp.2018.10.018; Karayannis NV, 2019, ANN BEHAV MED, V53, P65, DOI 10.1093/abm/kay017; Karos K, 2018, J PAIN, V19, P787, DOI 10.1016/j.jpain.2018.02.011; Kelley AS, 2015, NEW ENGL J MED, V373, P747, DOI 10.1056/NEJMra1404684; KULIK JA, 1989, HEALTH PSYCHOL, V8, P221, DOI 10.1037/0278-6133.8.2.221; Levine EG., 2012, SPIRITUALITY BELIEF, P61; MacDonald G, 2005, PSYCHOL BULL, V131, P202, DOI 10.1037/0033-2909.131.2.202; Main CJ, 2016, PAIN, V157, P1387, DOI 10.1097/j.pain.0000000000000457; Maltoni M, 2016, EUR J CANCER, V65, P61, DOI 10.1016/j.ejca.2016.06.007; Manning-Walsh J, 2005, J HOLIST NURS, V23, P120, DOI 10.1177/0898010104272019; Masel EK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158830; Masten CL, 2012, SOC COGN AFFECT NEUR, V7, P106, DOI 10.1093/scan/nsq098; Master SL, 2009, PSYCHOL SCI, V20, P1316, DOI 10.1111/j.1467-9280.2009.02444.x; Mee S, 2006, J PSYCHIATR RES, V40, P680, DOI 10.1016/j.jpsychires.2006.03.003; Mehta A., 2008, J HOSP PALLIAT NURS, V10, P26, DOI [DOI 10.1097/01.NJH.0000306714.50539.1A, 10.1097/01.NJH.0000306714.50539.1a]; MELZACK R, 1968, P423; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Melzack R., 1983, OAIM MEAS; Moore PM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003751.pub3; Moro C, 2006, SUPPORT CARE CANCER, V14, P30, DOI 10.1007/s00520-005-0834-3; Paice Judith A, 2004, J Natl Cancer Inst Monogr, P98; Panksepp J., 1998, SCI MATH; Papini MR, 2015, NEUROSCI BIOBEHAV R, V48, P53, DOI 10.1016/j.neubiorev.2014.11.012; Ponnampalam A., 2016, BMJ SUPPORT PALLIAT, V6, pA87; Ripamonti C, 2010, TUMORI, V96, P1016; Ripamonti CI, 2012, TUMORI, V98, P385, DOI 10.1700/1125.12409; Riva P, 2011, EUR J SOC PSYCHOL, V41, P681, DOI 10.1002/ejsp.837; RUSSELL JA, 1980, J PERS SOC PSYCHOL, V39, P1161, DOI 10.1037/h0077714; Saunders C., 1964, NURS MIRROR, P7; Semino E., 2018, METAPHOR CANC END LI, DOI [10.4324/9781315629834, DOI 10.4324/9781315629834]; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Sontag S., 1979, ILLNESS METAPHOR; Tamburini M, 2000, ANN ONCOL, V11, P31, DOI 10.1023/A:1008396930832; Temel JS, 2017, J CLIN ONCOL, V35, P834, DOI 10.1200/JCO.2016.70.5046; Temel JS, 2011, J CLIN ONCOL, V29, P2319, DOI 10.1200/JCO.2010.32.4459; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Thornhill R., 1989, SOCIOBIOLOGY SOCIAL; Vanbutsele G, 2018, LANCET ONCOL, V19, P394, DOI 10.1016/S1470-2045(18)30060-3; Wierzbicka A, 2012, EMOT REV, V4, P307, DOI 10.1177/1754073912439761; World Health Organization National Cancer Control Programmes, 2011, POLICIES MANAGERIAL; Yao ML, 2020, J PAIN, V21, P677, DOI 10.1016/j.jpain.2019.10.007; Yoong J, 2013, JAMA INTERN MED, V173, P283, DOI 10.1001/jamainternmed.2013.1874; Zhang M., 2019, BRAIN SCI ADV, V5, P265, DOI [DOI 10.26599/BSA.2019.9050023, 10.26599/BSA.2019.9050023]; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	77	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2021	16	3							e0248755	10.1371/journal.pone.0248755	http://dx.doi.org/10.1371/journal.pone.0248755			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RH6VV	33788893	Green Published, gold			2023-01-03	WOS:000636354600009
J	Denny, JC; Collins, FS				Denny, Joshua C.; Collins, Francis S.			Precision medicine in 2030-seven ways to transform healthcare	CELL			English	Editorial Material							DIVERSITY	Precision medicine promises improved health by accounting for individual variability in genes, environment, and lifestyle. Precision medicine will continue to transform healthcare in the coming decade as it expands in key areas: huge cohorts, artificial intelligence (AI), routine clinical genomics, phenomics and environment, and returning value across diverse populations.	[Denny, Joshua C.] NIH, All Us Res Program, Bldg 10, Bethesda, MD 20892 USA; [Denny, Joshua C.; Collins, Francis S.] NIH, Bldg 10, Bethesda, MD 20892 USA; [Denny, Joshua C.] Bldg 1 Room 228,1 Ctr Dr, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Denny, JC (corresponding author), NIH, All Us Res Program, Bldg 10, Bethesda, MD 20892 USA.; Denny, JC (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.; Denny, JC (corresponding author), Bldg 1 Room 228,1 Ctr Dr, Bethesda, MD 20814 USA.	joshua.denny@nih.gov	Denny, Josh/AAL-3359-2021	Denny, Josh/0000-0002-3049-7332				Hofstra B, 2020, P NATL ACAD SCI USA, V117, P9284, DOI 10.1073/pnas.1915378117; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Knepper TC, 2018, NATURE, V557, P157, DOI 10.1038/d41586-018-05049-5; Manolio TA, 2020, LANCET DIGIT HEALTH, V2, pE567, DOI 10.1016/S2589-7500(20)30242-9; National Research Council (US) Committee on a Framework for Developing a New Taxonomy of Disease, 2011, PREC MED BUILD KNOWL; Robinson JR, 2018, ANNU REV BIOMED DA S, V1, P69, DOI 10.1146/annurev-biodatasci-080917-013335; Rodgers GP, 2020, JAMA-J AM MED ASSOC, V324, P735, DOI 10.1001/jama.2020.13601; Steinbrook R, 2009, NEW ENGL J MED, V361, P1321, DOI 10.1056/NEJMp0905046; Turro E, 2020, NATURE, V583, P96, DOI 10.1038/s41586-020-2434-2; Van Driest SL, 2014, CLIN PHARMACOL THER, V95, P423, DOI 10.1038/clpt.2013.229; Vujkovic M, 2020, NAT GENET, V52, P680, DOI 10.1038/s41588-020-0637-y; White KD, 2018, J ALLER CL IMM-PRACT, V6, P38, DOI 10.1016/j.jaip.2017.11.023; Wilkins CH, 2020, JAMA NEUROL, V77, P1063, DOI 10.1001/jamaneurol.2020.1614	15	65	67	12	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 18	2021	184	6					1415	1419		10.1016/j.cell.2021.01.015	http://dx.doi.org/10.1016/j.cell.2021.01.015		MAR 2021	5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QY9LN	33740447	Green Accepted, Bronze			2023-01-03	WOS:000630357400007
J	Forbes, H; Morton, CE; Bacon, S; McDonald, HI; Minassian, C; Brown, JP; Rentsch, CT; Mathur, R; Schultze, A; DeVito, NJ; MacKenna, B; Hulme, WJ; Croker, R; Walker, AJ; Williamson, EJ; Bates, C; Mehrkar, A; Curtis, HJ; Evans, D; Wing, K; Inglesby, P; Drysdale, H; Wong, AYS; Cockburn, J; McManus, R; Parry, J; Hester, F; Harper, S; Douglas, IJ; Smeeth, L; Evans, SJW; Bhaskaran, K; Eggo, RM; Goldacre, B; Tomlinson, LA				Forbes, Harriet; Morton, Caroline E.; Bacon, Seb; McDonald, Helen, I; Minassian, Caroline; Brown, Jeremy P.; Rentsch, Christopher T.; Mathur, Rohini; Schultze, Anna; DeVito, Nicholas J.; MacKenna, Brian; Hulme, William J.; Croker, Richard; Walker, Alex J.; Williamson, Elizabeth J.; Bates, Chris; Mehrkar, Amir; Curtis, Helen J.; Evans, David; Wing, Kevin; Inglesby, Peter; Drysdale, Henry; Wong, Angel Y. S.; Cockburn, Jonathan; McManus, Robert; Parry, John; Hester, Frank; Harper, Sam; Douglas, Ian J.; Smeeth, Liam; Evans, Stephen J. W.; Bhaskaran, Krishnan; Eggo, Rosalind M.; Goldacre, Ben; Tomlinson, Laurie A.			Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE RESPIRATORY ILLNESS; MORTALITY; COMMUNITY; HISTORY; FAMILY; MEN	OBJECTIVE To investigate whether risk of infection with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) and outcomes of coronavirus disease 2019 (covid-19) differed between adults living with and without children during the first two waves of the UK pandemic. DESIGN Population based cohort study, on behalf of NHS England. SETTING Primary care data and pseudonymously linked hospital and intensive care admissions and death records from England, during wave 1 (1 February to 31 August 2020) and wave 2 (1 September to 18 December 2020). PARTICIPANTS Two cohorts of adults (18 years and over) registered at a general practice on 1 February 2020 and 1 September 2020. MAIN OUTCOME MEASURES Adjusted hazard ratios for SARS-CoV-2 infection, covid-19 related admission to hospital or intensive care, or death from covid-19, by presence of children in the household. RESULTS Among 9 334 392adults aged 65 years and under, during wave 1, living with children was not associated with materially increased risks of recorded SARSCoV-2 infection, covid-19 related hospital or intensive care admission, or death from covid-19. In wave 2, among adults aged 65 years and under, living with children of any age was associated with an increased risk of recorded SARS-CoV-2 infection (hazard ratio 1.06 (95% confidence interval 1.05 to 1.08) for living with children aged 0-11 years; 1.22 (1.20 to 1.24) for living with children aged 12-18 years) and covid-19 related hospital admission (1.18 (1.06 to 1.31) for living with children aged 0-11; 1.26 (1.12 to 1.40) for living with children aged 12-18). Living with children aged 0-11 was associated with reduced risk of death from both covid-19 and non-covid-19 causes in both waves; living with children of any age was also associated with lower risk of dying from non-covid-19 causes. For adults 65 years and under during wave 2, living with children aged 0-11 years was associated with an increased absolute risk of having SARS-CoV-2 infection recorded of 40-60 per 10 000 people, from 810 to between 850 and 870, and an increase in the number of hospital admissions of 1-5 per 10 000 people, from 160 to between 161 and 165. Living with children aged 12-18 years was associated with an increase of 160-190 per 10 000 in the number of SARS-CoV-2 infections and an increase of 2-6 per 10 000 in the number of hospital admissions. CONCLUSIONS In contrast to wave 1, evidence existed of increased risk of reported SARS-CoV-2 infection and covid-19 outcomes among adults living with children during wave 2. However, this did not translate into a materially increased risk of covid-19 mortality, and absolute increases in risk were small.	[Forbes, Harriet; McDonald, Helen, I; Minassian, Caroline; Brown, Jeremy P.; Rentsch, Christopher T.; Mathur, Rohini; Schultze, Anna; Williamson, Elizabeth J.; Wing, Kevin; Wong, Angel Y. S.; Douglas, Ian J.; Smeeth, Liam; Evans, Stephen J. W.; Bhaskaran, Krishnan; Eggo, Rosalind M.; Tomlinson, Laurie A.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Elect Hlth Records Res Grp, London, England; [Morton, Caroline E.; Bacon, Seb; DeVito, Nicholas J.; MacKenna, Brian; Hulme, William J.; Croker, Richard; Walker, Alex J.; Mehrkar, Amir; Curtis, Helen J.; Evans, David; Inglesby, Peter; Drysdale, Henry; Goldacre, Ben] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, DataLab, Oxford OX2 6GG, England; [Bates, Chris; Cockburn, Jonathan; McManus, Robert; Parry, John; Hester, Frank; Harper, Sam] Phoenix Partnership, 129 Low Lane, Leeds, W Yorkshire, England; [Eggo, Rosalind M.] London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, London, England	University of London; London School of Hygiene & Tropical Medicine; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Goldacre, B (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, DataLab, Oxford OX2 6GG, England.	ben.goldacre@phc.ox.ac.uk	DeVito, Nicholas J./Q-5952-2017; Wing, Kevin/I-7807-2015; Smeeth, Liam/X-5862-2018	DeVito, Nicholas J./0000-0001-8286-1995; Minassian, Caroline/0000-0001-9406-1928; Bhaskaran, Krishnan/0000-0001-5364-8757; Hulme, William/0000-0002-9162-4999; Wing, Kevin/0000-0003-2335-9641; Forbes, Harriet/0000-0001-6888-2212; Smeeth, Liam/0000-0002-9168-6022; Evans, Stephen/0000-0002-1474-2596; Tomlinson, Laurie/0000-0001-8848-9493; McDonald, Helen/0000-0003-0576-2015	Medical Research Council (MRC) [MR/V015737/1]; Wellcome Trust; NIHR Oxford Biomedical Research Centre; NIHR Applied Research Collaboration Oxford and Thames Valley; Mohn Westlake Foundation; NHS England; Health Foundation; GlaxoSmithKline (GSK); Sir Henry Dale fellowship - Wellcome; Sir Henry Dale fellowship - Royal Society; Public Health England; British Heart Foundation; MRC; NIHR; GSK; UK Research and Innovation fellowship; Health Data Research UK; LSHTM; BG's grants	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Applied Research Collaboration Oxford and Thames Valley; Mohn Westlake Foundation; NHS England; Health Foundation; GlaxoSmithKline (GSK)(GlaxoSmithKline); Sir Henry Dale fellowship - Wellcome; Sir Henry Dale fellowship - Royal Society; Public Health England; British Heart Foundation(British Heart Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR(National Institute for Health Research (NIHR)); GSK(GlaxoSmithKline); UK Research and Innovation fellowship; Health Data Research UK; LSHTM; BG's grants	This work was supported by the Medical Research Council (MRC) MR/V015737/1. TPP provided technical expertise and infrastructure within its data centre pro bono in the context of a national emergency. RM holds a fellowship funded by the Wellcome Trust. BG's work on better use of data in healthcare more broadly is currently funded in part by NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn Westlake Foundation, NHS England, and the Health Foundation; all DataLab staff are supported by BG's grants on this work. AS is employed by the London School of Hygiene & Tropical Medicine (LSHTM) on a fellowship sponsored by GlaxoSmithKline (GSK). KB holds a Sir Henry Dale fellowship jointly funded by Wellcome and the Royal Society. HIM is funded by the National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation, a partnership between Public Health England and LSHTM. AYSW holds a fellowship from the British Heart Foundation. EW holds grants from MRC. IJD holds grants from NIHR and GSK. HF holds a UK Research and Innovation fellowship. RE is funded by Health Data Research UK and the MRC. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, Public Health England, or the Department of Health and Social Care. Funders had no role in the study design or the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.	Boast A., 2020, EVIDENCE SUMMARY PAE; Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; Department of Health and Social Care Public Health England, GUID SHIELD PROT PEO; Eales, 2020, HIGH PREVALENCE SARS, DOI [10.1101/2020.10.30.20223123, DOI 10.1101/2020.10.30.20223123]; Elliott J., 2021, SYMPTOM REPORTING 1; Farquharson C, 2020, DIFFERENCES KEY WORK; Github, 2020, ASS LIV CHILDR OUTC; Github, 2020, IS PRES CHILDR HOUS; GOV.UK, GET FREE NHS TEST CH; Grundy E, 2005, SOC SCI MED, V61, P217, DOI 10.1016/j.socscimed.2004.11.046; Grundy E, 2008, AM J EPIDEMIOL, V167, P271, DOI 10.1093/aje/kwm295; Heikkinen T, 2003, LANCET, V361, P51, DOI 10.1016/S0140-6736(03)12162-9; Intensive Care National Audit and Research Centre, 2020, COVID 19 REP; Iversen K, 2020, LANCET INFECT DIS, V20, P1401, DOI 10.1016/S1473-3099(20)30589-2; Jaffe DH, 2009, EUR J EPIDEMIOL, V24, P9, DOI 10.1007/s10654-008-9310-y; Lee J, 2020, LANCET CHILD ADOLESC, V4, P421, DOI 10.1016/S2352-4642(20)30109-7; Ministry of Housing Communities and Local Government, ENGLISH INDICES DEPR; Modig K, 2017, J EPIDEMIOL COMMUN H, V71, P424, DOI 10.1136/jech-2016-207857; MONTO AS, 1994, EPIDEMIOL REV, V16, P351, DOI 10.1093/oxfordjournals.epirev.a036158; MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164; Monto AS, 2003, DM-DIS MON, V49, P160, DOI 10.1067/mda.2003.17; MONTO AS, 1977, BRIT J PREV SOC MED, V31, P101; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; NHS Digital, 2018, DAT SEC PROT TOOLK; NHS Digital, 2020, BETA DAT SEC STAND; NHS Digital, 2019, ISB1523 NHS DIG; NHS England, 2021, PULS OX DET EARL DET; Office for National Statistics, 2020, COR COVID 19 REL DEA; Portela M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39124-2; Rajmil L, 2020, BMJ PAEDIATR OPEN, V4, DOI 10.1136/bmjpo-2020-000722; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Scientific Pandemic Influenza Group on Behaviours Department for Education, 2020, COVID 19 BEN REM ED; Secretary of State for Health and Social Care-UK Government, 2020, COR COVID 19 NOT ORG; Sette A, 2020, NAT REV IMMUNOL, V20, P457, DOI 10.1038/s41577-020-0389-z; Shah ASV, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3582; Swann OV, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3249; UK Office for National Statistics, 2020, COR COVID 19 INF SUR; UNESCO, ADV CONS SCH CLOS; VanderWeele TJ, 2013, EUR J EPIDEMIOL, V28, P113, DOI 10.1007/s10654-013-9770-6; Viner RM, 2021, JAMA PEDIATR, V175, P143, DOI 10.1001/jamapediatrics.2020.4573; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wood R, 2020, SHARING HOUSEHOLD CH, DOI [10.1101/2020.09.21.20196428v1., DOI 10.1101/2020.09.21.20196428V1]; Zeng Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep19351; Zimmermann P, 2021, ARCH DIS CHILD, V106, P429, DOI 10.1136/archdischild-2020-320338	45	40	41	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 17	2021	372								n628	10.1136/bmj.n628	http://dx.doi.org/10.1136/bmj.n628			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC4QT	33737413	hybrid, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000632788600007
J	Bitarakwate, E; Ashburn, K; Kazooba, P; Khamasi, R; Natumanya, E; Herrera, N; Owomugisha, B; Malkin, RA; Kisaakye, L				Bitarakwate, Edward; Ashburn, Kim; Kazooba, Patrick; Khamasi, Ronald; Natumanya, Eliab; Herrera, Nicole; Owomugisha, Boaz; Malkin, Robert A.; Kisaakye, Linda			Effects of the Pratt pouch model of dispensing nevirapine prophylaxis on HIV exposed infant completion of 6 weeks of prophylaxis in Uganda	PLOS ONE			English	Article								Introduction The innovative Pratt pouch could optimize dispensing nevirapine prophylaxis to HIV-exposed infants in pre-measured single dose pouches to increase completion of the full 6 week infant nevirapine regimen. Materials and methods Nineteen health facilities with highest HIV positivity rates among pregnant women across 9 districts in southwest and central Uganda were assigned to control and intervention groups. HIV-positive women enrolled at intervention facilities received pouches filled with premeasured single doses of nevirapine using Uganda national guidelines, which were integrated into the existing drug distribution system. During antenatal care (ANC) women received 14 pouches to cover time until the 6 day postpartum visit, with an additional 8 pouches if women were delayed in returning to the facility, and 28 pouches after delivery. Women enrolled at control facilities received standard nevirapine syrup following delivery for postnatal infant prophylaxis. In a select number of intervention facilities, during ANC, women received all 42 pouches needed to complete the 6 weeks regimen. Medical record data from enrolled women were extracted; interviews with HIV-positive women during postnatal care visits were conducted. Data were collected January to August 2018 (control sites) and October 2019 to February 2020 (intervention sites). Unadjusted and adjusted logistic regression models were used to identify factors associated with facility delivery, postnatal care follow-up visit, and completion of the full 6 weeks infant nevirapine regimen. Results Significantly more women in the intervention (n = 320) versus control (n = 340) group had facility delivery (292/316, 92.4% versus 169/340, 49.7%, p<0.0001), postnatal visits within 2 weeks postpartum (295/297, 99.3% versus 133/340, 39.1%, p<0.0001) and reported their infants completing the full 6 weeks infant prophylaxis regimen (299/313, 95.5% versus 210/242, 86.8%, p = 0.0002). Dispensing 42 versus 14 pouches during ANC did not have negative effects on these outcomes. Among out-of-facility deliveries, a higher proportion of infants received nevirapine within 72 hours of birth in the intervention versus control group, 95.8% versus 77.9%. In multivariate models, the intervention group was the only significant factor associated with facility delivery or completion of the full 6 weeks infant prophylaxis. Conclusions Use of the Pratt pouch resulted in an increase in HIV-exposed infants completing the full 6weeks prophylaxis regimen and associated benefits including increasing facility delivery and women's adherence to postnatal care services.	[Bitarakwate, Edward; Kazooba, Patrick; Khamasi, Ronald; Natumanya, Eliab; Owomugisha, Boaz] Elizabeth Glaser Pediat AIDS fdn EGPAF, Kampala, Uganda; [Ashburn, Kim; Herrera, Nicole] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC 20036 USA; [Malkin, Robert A.] Duke Univ, Biomed Engn, Durham, NC USA; [Kisaakye, Linda] Uganda Minist Hlth, Kampala, Uganda	Duke University	Ashburn, K (corresponding author), Elizabeth Glaser Pediat AIDS Fdn, Washington, DC 20036 USA.	kimberly.ashburn@gmail.com			United States Agency for International Development USAID [AID-OAA-A-16-00010]	United States Agency for International Development USAID(United States Agency for International Development (USAID)CGIAR)	This study was made possible by the generous support of the United States Agency for International Development USAID Cooperative Agreement AID-OAA-A-16-00010 (March 16, 2016 to March 15, 2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, HIV DRUG RESISTANCE; [Anonymous], 2020, **DROPPED REF**; [Anonymous], 2019, UG MIN HLTH DHIS2 DA; [Anonymous], SAS SOFTWARE VERSION; Choy A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001030; Dahinten AP, 2016, PEDIATR INFECT DIS J, V35, P987, DOI 10.1097/INF.0000000000001224; Dahinten Alexander P, 2016, Open Biomed Eng J, V10, P12, DOI 10.2174/1874120701610010012; Joint United Nations Programme for HIV/AIDS, 2019, START FREE STAY FREE; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2014, GAP REP; Malkin RA., 2013, J BIOMED ENG RES, V2, P66; Malkin Robert, 2012, Open Biomed Eng J, V6, P92, DOI 10.2174/1874120701206010092; Ministry of Health Uganda, UG AIDS COUNTR PROGR; Spiegel GJ, 2013, ANN BIOMED ENG, V41, P1860, DOI 10.1007/s10439-013-0780-z; Uganda Ministry of Health, 2016, SPECTR EST 2015 16	14	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2021	16	3							e0247507	10.1371/journal.pone.0247507	http://dx.doi.org/10.1371/journal.pone.0247507			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV3DA	33690610	gold, Green Published			2023-01-03	WOS:000627854700006
J	Choueiri, TK; Powles, T; Burotto, M; Escudier, B; Bourlon, MT; Zurawski, B; Juarez, VMO; Hsieh, JJ; Basso, U; Shah, AY; Suarez, C; Hamzaj, A; Goh, JC; Barrios, C; Richardet, M; Porta, C; Kowalyszyn, R; Feregrino, JP; Zolnierek, J; Pook, D; Kessler, ER; Tomita, Y; Mizuno, R; Bedke, J; Zhang, J; Maurer, MA; Simsek, B; Ejzykowicz, F; Schwab, GM; Apolo, AB; Motzer, RJ				Choueiri, T. K.; Powles, T.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Zurawski, B.; Juarez, V. M. Oyervides; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Hamzaj, A.; Goh, J. C.; Barrios, C.; Richardet, M.; Porta, C.; Kowalyszyn, R.; Feregrino, J. P.; Zolnierek, J.; Pook, D.; Kessler, E. R.; Tomita, Y.; Mizuno, R.; Bedke, J.; Zhang, J.; Maurer, M. A.; Simsek, B.; Ejzykowicz, F.; Schwab, G. M.; Apolo, A. B.; Motzer, R. J.		CheckMate 9ER Investigators	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTATIC UROTHELIAL CARCINOMA; FUNCTIONAL ASSESSMENT; OPEN-LABEL; THERAPY; CANCER; IMMUNOTHERAPY; COMBINATION; EVEROLIMUS	BACKGROUND The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known. METHODS In this phase 3, randomized, open-label trial, we randomly assigned adults with previously untreated clear-cell, advanced renal-cell carcinoma to receive either nivolumab (240 mg every 2 weeks) plus cabozantinib (40 mg once daily) or sunitinib (50 mg once daily for 4 weeks of each 6-week cycle). The primary end point was progression-free survival, as determined by blinded independent central review. Secondary end points included overall survival, objective response as determined by independent review, and safety. Health-related quality of life was an exploratory end point. RESULTS Overall, 651 patients were assigned to receive nivolumab plus cabozantinib (323 patients) or sunitinib (328 patients). At a median follow-up of 18.1 months for overall survival, the median progression-free survival was 16.6 months (95% confidence interval [CI], 12.5 to 24.9) with nivolumab plus cabozantinib and 8.3 months (95% CI, 7.0 to 9.7) with sunitinib (hazard ratio for disease progression or death, 0.51; 95% CI, 0.41 to 0.64; P<0.001). The probability of overall survival at 12 months was 85.7% (95% CI, 81.3 to 89.1) with nivolumab plus cabozantinib and 75.6% (95% CI, 70.5 to 80.0) with sunitinib (hazard ratio for death, 0.60; 98.89% CI, 0.40 to 0.89; P = 0.001). An objective response occurred in 55.7% of the patients receiving nivolumab plus cabozantinib and in 27.1% of those receiving sunitinib (P<0.001). Efficacy benefits with nivolumab plus cabozantinib were consistent across subgroups. Adverse events of any cause of grade 3 or higher occurred in 75.3% of the 320 patients receiving nivolumab plus cabozantinib and in 70.6% of the 320 patients receiving sunitinib. Overall, 19.7% of the patients in the combination group discontinued at least one of the trial drugs owing to adverse events, and 5.6% discontinued both. Patients reported better health-related quality of life with nivolumab plus cabozantinib than with sunitinib. CONCLUSIONS Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol Myers Squibb and others; CheckMate 9ER ClinicalTrials.gov number, NCT03141177.)	[Choueiri, T. K.] Brigham & Womens Hosp, Dept Med Oncol, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA; [Choueiri, T. K.] Harvard Med Sch, 450 Brookline Ave, Boston, MA 02215 USA; [Powles, T.] Queen Mary Univ London, Royal Free Natl Hlth Serv Trust, Canc Res UK Expt Canc Med Ctr, Dept Genitourinary Oncol,Barts Canc Inst, London, England; [Burotto, M.] Bradford Hill Clin Res Ctr, Santiago, Chile; [Escudier, B.] Gustave Roussy, Dept Med Oncol, Villejuif, France; [Bourlon, M. T.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Urol Oncol Clin, Dept Hematooncol, Mexico City, DF, Mexico; [Juarez, V. M. Oyervides] Univ Autonoma Nuevo Leon, Dept Med Oncol, Ctr Univ Canc, Hosp Univ Dr Jose Eleuterio Gonzalez, San Nicolas De Los Garza, Nuevo Leon, Mexico; [Feregrino, J. P.] Hosp H Queretaro, Dept Med Oncol, Queretaro, Mexico; [Zurawski, B.] Franciszek Lukaszczyk Oncol Ctr, Dept Outpatient Chemotherapy, Bydgoszcz, Poland; [Zolnierek, J.] Reg Specialist Hosp, Dept Clin Oncol & Hematol, Biala Podlaska, Poland; [Hsieh, J. J.] Washington Univ, Sch Med, Dept Med, Siteman Canc Ctr,Div Oncol, St Louis, MO 63110 USA; [Basso, U.] IRCCS, Ist Oncol Veneto, Dept Oncol, Oncol Unit 1, Padua, Italy; [Shah, A. Y.; Hamzaj, A.] Osped San Donato, Ist Toscano & Arezzo, Dept Med Oncol, Arezzo, Italy; [Porta, C.] Univ Pavia, Dept Internal Med, Pavia, Italy; [Porta, C.] Univ Bari A Moro, Bari, Italy; [Shah, A. Y.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Suarez, C.] Hosp Univ Vall Hebron, Vall Hebron Inst Oncol, Dept Med Oncol, Vall Hebron Barcelona Hosp Campus, Barcelona, Spain; [Goh, J. C.] Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld, Australia; [Pook, D.] Cabrini Monash Univ, Dept Med Oncol, Cabrini Hlth, Malvern, Vic, Australia; [Barrios, C.] Hosp Sao Lucas, Oncol Res Ctr, Porto Alegre, RS, Brazil; [Richardet, M.] Inst Oncol Cordoba, Fdn Richardet Longo, Cordoba, Argentina; [Kowalyszyn, R.] Clin Viedma, Inst Multidisciplinario Oncol, Viedma, Argentina; [Kessler, E. R.] Univ Colorado, Dept Internal Med, Div Med Oncol, Sch Med, Aurora, CO USA; [Tomita, Y.] Niigata Univ, Grad Sch Med & Dent Sci, Dept Urol, Niigata, Japan; [Tomita, Y.] Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Oncol, Niigata, Japan; [Mizuno, R.] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan; [Bedke, J.] Eberhard Karls Univ Tubingen, Dept Urol, Tubingen, Germany; [Zhang, J.] Bristol Myers Squibb, Dept Clin Res, Princeton, NJ USA; [Maurer, M. A.] Bristol Myers Squibb, Dept Clin Oncol, Princeton, NJ USA; [Simsek, B.] Bristol Myers Squibb, Dept Biostat, Princeton, NJ USA; [Ejzykowicz, F.] Bristol Myers Squibb, Dept Hlth Econ & Outcomes Res, Princeton, NJ USA; [Schwab, G. M.] Exelixis, Dept Clin Oncol, Alameda, CA USA; [Apolo, A. B.] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Motzer, R. J.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Cancer Research UK; University of London; Queen Mary University London; UNICANCER; Gustave Roussy; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Universidad Autonoma de Nuevo Leon; University Hospital Autonomous University of Nuevo Leon; Siteman Cancer Center; Washington University (WUSTL); IRCCS Istituto Oncologico Veneto (IOV); IRCCS Policlinico San Donato; University of Pavia; Universita degli Studi di Bari Aldo Moro; University of Texas System; UTMD Anderson Cancer Center; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Royal Brisbane & Women's Hospital; Cabrini Health; University of Colorado System; University of Colorado Anschutz Medical Campus; Niigata University; Niigata University; Keio University; Eberhard Karls University of Tubingen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis, Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center	Choueiri, TK (corresponding author), Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 450 Brookline Ave, Boston, MA 02215 USA.; Motzer, RJ (corresponding author), Mem Hosp, Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.; Choueiri, TK (corresponding author), Harvard Med Sch, 450 Brookline Ave, Boston, MA 02215 USA.	toni_choueiri@dfci.harvard.edu; motzerr@mskcc.org	Choueiri, Toni/K-5238-2019; Barrios, Carlos/HJG-7197-2022; Simsek, Burcin/M-2067-2019; Bedke, Jens/AAS-2837-2020; riccardi, ferdinando/K-7370-2016	Choueiri, Toni/0000-0002-9201-3217; Barrios, Carlos/0000-0001-6021-667X; Simsek, Burcin/0000-0003-2857-6629; Bedke, Jens/0000-0003-2778-3108; Apolo, Andrea/0000-0001-9409-1836; Suarez, Cristina/0000-0002-0502-5528; riccardi, ferdinando/0000-0002-2852-2770; Powles, Thomas/0000-0001-7760-4724	Bristol Myers Squibb; Ono Pharmaceutical; Exelixis; Ipsen Pharma; Takeda Pharmaceutical; Dana-Farber/Harvard Cancer Center Kidney Specialized Program of Research Excellence; Kohlberg Chair at Harvard Medical School; Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute; National Cancer Institute, Department of Defense; Cancer Center Support Grant-Core Grant [P30 CA008748]; National Institutes of Health Core Grant [P30 CA016672]; Trust Family	Bristol Myers Squibb(Bristol-Myers Squibb); Ono Pharmaceutical; Exelixis; Ipsen Pharma(Ipsen); Takeda Pharmaceutical(Takeda Pharmaceutical Company Ltd); Dana-Farber/Harvard Cancer Center Kidney Specialized Program of Research Excellence; Kohlberg Chair at Harvard Medical School; Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute; National Cancer Institute, Department of Defense(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)United States Department of Defense); Cancer Center Support Grant-Core Grant; National Institutes of Health Core Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Trust Family	Supported by Bristol Myers Squibb in collaboration with Ono Pharmaceutical and with Exelixis, Ipsen Pharma, and Takeda Pharmaceutical. The authors received no financial support or compensation for publication of this manuscript. Dr. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney Specialized Program of Research Excellence, the Kohlberg Chair at Harvard Medical School, the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute and by various grants from the National Cancer Institute, Department of Defense, and foundations. Patients treated at the Memorial Sloan Kettering Cancer Center were supported in part by a Cancer Center Support Grant-Core Grant (P30 CA008748). The University of Texas M.D. Anderson Cancer Center is supported by a National Institutes of Health Core Grant (P30 CA016672).	Agarwal N, 2020, J CLIN ONCOL, V29; Amin A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0420-0; Apolo AB, 2020, J CLIN ONCOL, V38, P3672, DOI 10.1200/JCO.20.01652; Apolo AB, 2020, LANCET ONCOL, V21, P1099, DOI 10.1016/S1470-2045(20)30202-3; Bedke J, 2020, VIRT ANN EUR ASS UR; Bergerot P, 2019, MOL CANCER THER, V18, P2185, DOI 10.1158/1535-7163.MCT-18-1399; Cella D, 2019, LANCET ONCOL, V20, P297, DOI 10.1016/S1470-2045(18)30778-2; Cella D, 2018, VALUE HEALTH, V21, P1413, DOI 10.1016/j.jval.2018.04.1371; Choueiri TK, 2017, J CLIN ONCOL, V35, P591, DOI 10.1200/JCO.2016.70.7398; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Glimm E, 2010, STAT MED, V29, P219, DOI 10.1002/sim.3748; Grimm MO, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020565; Heidegger I, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00490; Heng DYC, 2013, LANCET ONCOL, V14, P141, DOI 10.1016/S1470-2045(12)70559-4; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; Krigsfeld GS, 2020, J CLIN PATHOL, V73, P656, DOI 10.1136/jclinpath-2020-206466; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; McKay RR, 2018, J CLIN ONCOL, V36, P3615, DOI 10.1200/JCO.2018.79.0253; Mennitto A, 2016, THER ADV UROL, V8, P319, DOI 10.1177/1756287216656811; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; MOTZER RJ, 2020, J IMMUNOTHER CANCER, P8, DOI [DOI 10.1136/jitc-2020-000891, 10.1136/jitc-2020-000891]; Motzer R, 2019, LANCET ONCOL, V20, P1370, DOI 10.1016/S1470-2045(19)30413-9; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; National Cancer Institute, COMMON TERMINOLOGY C; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pal S, 2020, ANN ONCOL, V31, pS554, DOI 10.1016/j.annonc.2020.08.774; Rao D, 2009, J PAIN SYMPTOM MANAG, V38, P291, DOI 10.1016/j.jpainsymman.2008.08.013; Rini BI, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0813-8; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Saeed A, 2020, J CLIN ONCOL, V38; SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187; Schmidt E, 2018, TARGET ONCOL, V13, P205, DOI 10.1007/s11523-018-0559-0	35	445	448	11	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2021	384	9					829	841		10.1056/NEJMoa2026982	http://dx.doi.org/10.1056/NEJMoa2026982			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QS8DS	33657295	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000626124800018
J	Lopez-Medina, E; Lopez, P; Hurtado, IC; Davalos, DM; Ramirez, O; Martinez, E; Diazgranados, JA; Onate, JM; Chavarriaga, H; Herrera, S; Parra, B; Libreros, G; Jaramillo, R; Avendano, AC; Toro, DF; Torres, M; Lesmes, MC; Rios, CA; Caicedo, I				Lopez-Medina, Eduardo; Lopez, Pio; Hurtado, Isabel C.; Davalos, Diana M.; Ramirez, Oscar; Martinez, Ernesto; Diazgranados, Jesus A.; Onate, Jose M.; Chavarriaga, Hector; Herrera, Socrates; Parra, Beatriz; Libreros, Gerardo; Jaramillo, Roberto; Avendano, Ana C.; Toro, Dilian F.; Torres, Miyerlandi; Lesmes, Maria C.; Rios, Carlos A.; Caicedo, Isabella			Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INHIBITOR; REPLICATION	Importance: Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit. Objective: To determine whether ivermectin is an efficacious treatment for mild COVID-19. Design, Setting, and ParticipantsL Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state's health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020. Intervention: Patients were randomized to receive ivermectin, 300 mu g/kg of body weight per day for 5 days (n = 200) or placebo (n = 200). Main Outcomes and Measures: Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Solicited adverse events and serious adverse events were also collected. Results: Among 400 patients who were randomized in the primary analysis population (median age, 37 years [interquartile range {IQR}, 29-48]; 231 women [58%]), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P = .53 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each group). Conclusion and Relevance: Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.	[Lopez-Medina, Eduardo; Lopez, Pio] Ctr Estudios Infectol Pediat, Calle 5 B 5 37 BIS-28, Cali, Colombia; [Lopez-Medina, Eduardo; Lopez, Pio; Hurtado, Isabel C.] Univ Valle, Dept Pediat, Cali, Colombia; [Lopez-Medina, Eduardo; Ramirez, Oscar; Onate, Jose M.; Caicedo, Isabella] Clin Imbanaco, Cali, Colombia; [Hurtado, Isabel C.; Lesmes, Maria C.] State Hlth Dept, Valle Del Cauca, Colombia; [Davalos, Diana M.] Univ ICESI, Dept Publ Hlth, Cali, Colombia; [Ramirez, Oscar] POHEMA Pediat Oncol & Hematol Fdn, Cali, Colombia; [Ramirez, Oscar] Calis Canc Populat Based Registry, Cali, Colombia; [Martinez, Ernesto; Onate, Jose M.] Univ Valle, Dept Internal Med, Cali, Colombia; [Martinez, Ernesto] Christus Sinergia Salud, Cali, Colombia; [Diazgranados, Jesus A.] Neurol Occidente, Cali, Colombia; [Onate, Jose M.] Clin Occidente, Cali, Colombia; [Chavarriaga, Hector; Torres, Miyerlandi] Municipal Hlth Dept, Cali, Colombia; [Herrera, Socrates] Malaria Vaccine & Drug Dev Ctr, Caucaseco Sci Res Ctr, Cali, Colombia; [Parra, Beatriz; Libreros, Gerardo] Univ Valle, Dept Microbiol, Cali, Colombia; [Jaramillo, Roberto; Avendano, Ana C.] Hemato Oncologos, Cali, Colombia; [Toro, Dilian F.] Hlth Experts Comm, Valle Del Cauca, Colombia; [Rios, Carlos A.] Ctr Medico Santuario, Cali, Colombia	Universidad del Valle; Universidad ICESI; Universidad del Valle; Universidad del Valle	Lopez-Medina, E (corresponding author), Ctr Estudios Infectol Pediat, Calle 5 B 5 37 BIS-28, Cali, Colombia.	eduardo.lopez@ceiponline.org		Lopez Lopez, Pio/0000-0001-5230-6595; Hurtado Palacios, Isabel Cristina/0000-0002-3625-4892; Libreros-Zuniga, Gerardo Andres/0000-0003-0196-1957	Centro de Estudios en Infectologia Pediatrica [ScDi823]	Centro de Estudios en Infectologia Pediatrica	This study received an unrestricted grant from Centro de Estudios en Infectologia Pediatrica (grant ScDi823).	[Anonymous], CLIN TRIAL IVERMECTI; [Anonymous], FRONTLINE COVID 19 C; Arevalo A., 2020, LVERMECTIN REDUCE CO, DOI [10.1101/2020.11.02.363242, DOI 10.1101/2020.11.02.363242]; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Caly Leon, 2020, Antiviral Res, V178, P104787, DOI 10.1016/j.antiviral.2020.104787; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; de Melo GD, 2020, BIORXIV, V11, DOI 10.1101/2020.11.21.392639; Diazgranados-Sanchez JA, 2017, REV NEUROLOGIA, V65, P303, DOI 10.33588/rn.6507.2016574; Elgazzar A, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-100956/v1, DOI 10.21203/RS.3.RS-100956/V1]; Hashim HA., 2020, INFEC DIS EXCEPT HIV, DOI [10.1101/2020.10.26.20219345, DOI 10.1101/2020.10.26.20219345, 10.26.20219345]; Karaca-Mandic P, 2021, JAMA INTERN MED, V181, P131, DOI 10.1001/jamainternmed.2020.3857; Mahajan UV, 2020, J PUBLIC HEALTH-UK, V42, P445, DOI 10.1093/pubmed/fdaa070; Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147; Ministerio de Salud Gobierno del Estado de Bolivia, RES MIN NO 0259, DOI 10.1101/2020.10.26.20219345; Ministerio de Salud Republica del Peru, RES MIN NO 270 2020, DOI DOI 10.1093/cid/ciaa1009; Mitja O, 2021, CLIN INFECT DIS, V73, pE4073, DOI 10.1093/cid/ciaa1009; Molento MB, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100148; Momekov G, 2020, BIOTECHNOL BIOTEC EQ, V34, P469, DOI 10.1080/13102818.2020.1775118; Omura S, 2008, INT J ANTIMICROB AG, V31, P91, DOI 10.1016/j.ijantimicag.2007.08.023; Rajter JC, 2021, CHEST, V159, P85, DOI 10.1016/j.chest.2020.10.009; Rayner CR, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104805; Rodriguez Mega E., NATURE, DOI [10.21203/rs.3.rs-100956/v1, DOI 10.21203/RS.3.RS-100956/V3]; Schmith VD, 2020, CLIN PHARMACOL THER, V108, P762, DOI 10.1002/cpt.1889; Shakhsi Niaee M, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-109670/v1, DOI 10.21203/RS.3.RS-109670/V1]; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Smit MR, 2018, LANCET INFECT DIS, V18, P615, DOI 10.1016/S1473-3099(18)30163-4; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002; US Department of Health and Human Services, COMMON TERMINOLOGY C; US Senate Committee on Homeland Security & Governmental Affairs, EARL OUTP TREATM ESS; Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150; World Health Organization, WHO R D BLU NOV COR; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760	34	174	175	4	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2021	325	14					1426	1435		10.1001/jama.2021.3071	http://dx.doi.org/10.1001/jama.2021.3071		MAR 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN9GZ	33662102	Green Published, Bronze			2023-01-03	WOS:000625440200001
J	Kazi, AK; Rowther, AA; Atif, N; Nazir, H; Atiq, M; Zulfiqar, S; Malik, A; Surkan, PJ				Kazi, Asiya K.; Rowther, Armaan A.; Atif, Najia; Nazir, Huma; Atiq, Maria; Zulfiqar, Shaffaq; Malik, Abid; Surkan, Pamela J.			Intersections between patient-provider communication and antenatal anxiety in a public healthcare setting in Pakistan	PLOS ONE			English	Article							PHYSICIAN EMPATHY; CANCER; SATISFACTION; ASSOCIATIONS; PREVALENCE; OUTCOMES; QUALITY; WOMEN; TRUST	This study explores pregnant women's and healthcare providers' perspectives on the role of patient-provider communication in experiences of antenatal anxiety within a low-resource setting. In 2017-18, we consecutively sampled pregnant women (n = 19) with at least mild anxiety and purposively sampled antenatal care providers (n = 10) from a public hospital in Punjab Province, Pakistan. We then conducted in-depth interviews and thematically coded them with a combination of inductive and deductive coding methodologies. We found that patients expressed a desire for warm, empathetic communication from providers who demonstrate respect, attentiveness, and a shared lived experience. Providers revealed an awareness that their heavy caseloads, high stress levels, and discourteous tones adversely influenced communication with pregnant women and may exacerbate their anxieties, but also reported that compassionately addressing women's concerns, providing financial problem-solving and/or assistance, and moderating conflicting healthcare desires between patients and their families could alleviate anxiety in pregnant women. Patients reported feelings of anxiety stemming from a belief that they received lower quality communication from antenatal providers at public hospitals than patients received from antenatal providers at private hospitals, an experience that they partially attributed to their low socioeconomic status. Meanwhile, some providers disclosed potentially stigmatizing views of women from particular sociocultural backgrounds or low socioeconomic status, including perceptions that appeared to shape communication with these patients in antenatal care encounters. Our findings provide preliminary evidence that communication between pregnant women and antenatal providers that is warm, normalizes patient fears, and integrates patients' interpersonal and financial considerations can mitigate pregnant women's experiences of anxiety and reduce barriers to accessing antenatal care in Pakistan's public healthcare facilities.	[Kazi, Asiya K.; Rowther, Armaan A.; Surkan, Pamela J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Atif, Najia; Nazir, Huma; Atiq, Maria; Zulfiqar, Shaffaq; Malik, Abid] Human Dev Res Fdn, Islamabad, Pakistan; [Malik, Abid] Rawalpindi Med Univ, Rawalpindi, Pakistan	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kazi, AK (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	akazi5@alumin.jh.edu	Nazir, Huma/AAU-8995-2021	Kazi, Asiya K./0000-0001-9259-6726	National Institute of Mental Health (NIMH) at the United States National Institutes of Health (NIH) [RO1 MH111859-01]	National Institute of Mental Health (NIMH) at the United States National Institutes of Health (NIH)	This research was funded by the National Institute of Mental Health (NIMH) at the United States National Institutes of Health (NIH), grant number RO1 MH111859-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, DED VERS 8 2 14 WEB; Atif N, 2020, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00927; Bernstein M, 2004, CAN J NEUROL SCI, V31, P208, DOI 10.1017/S0317167100053841; Buss C, 2010, PSYCHONEUROENDOCRINO, V35, P141, DOI 10.1016/j.psyneuen.2009.07.010; Butow PN, 2002, SUPPORT CARE CANCER, V10, P161, DOI 10.1007/s005200100290; Chaitoff A, 2017, ACAD MED, V92, P1464, DOI 10.1097/ACM.0000000000001671; Dennis CL, 2017, BRIT J PSYCHIAT, V210, P315, DOI 10.1192/bjp.bp.116.187179; Dodani S, 2000, J Pak Med Assoc, V50, P138; Epstein RM, 2017, JAMA ONCOL, V3, P92, DOI 10.1001/jamaoncol.2016.4373; Fawcett EJ, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.18r12527; Feldman-Stewart D, 2005, PSYCHO-ONCOLOGY, V14, P801, DOI 10.1002/pon.950; Figueiredo B, 2011, ARCH WOMEN MENT HLTH, V14, P247, DOI 10.1007/s00737-011-0217-3; First M, 2016, AM PSYCHIATR ASSOC; Fogarty LA, 1999, J CLIN ONCOL, V17, P371, DOI 10.1200/JCO.1999.17.1.371; Girgis A, 2009, PATIENT EDUC COUNS, V77, P456, DOI 10.1016/j.pec.2009.09.018; Guba E.G., 1989, 4 GENERATION EVALUAT; Hassan R, 2011, PAK J MED RES; Hillen MA, 2011, PSYCHO-ONCOLOGY, V20, P227, DOI 10.1002/pon.1745; Jalil A, 2017, BMC HEALTH SERV RES, V17, P1, DOI 10.1186/s12913-017-2094-6; Kang YT, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13050468; Knight Kelly, 2015, ADDICTED PREGNANT PO; Knight Kelly R, 2017, Contemp Drug Probl, V44, P301, DOI 10.1177/0091450917740359; Knight KR., 2020, WOMENS REPROD HLTH, V7, P164, DOI [10.1080/23293691.2020.1780400, DOI 10.1080/23293691.2020.1780400]; Lee AM, 2007, OBSTET GYNECOL, V110, P1102, DOI 10.1097/01.AOG.0000287065.59491.70; LEVINSON W, 1995, J GEN INTERN MED, V10, P375, DOI 10.1007/BF02599834; Liang WC, 2006, PATIENT EDUC COUNS, V64, P387, DOI 10.1016/j.pec.2006.04.004; Matusitz J, 2015, J HUM BEHAV SOC ENVI, V25, P871, DOI 10.1080/10911359.2015.1035148; Mechanic D, 2000, SOC SCI MED, V51, P657, DOI 10.1016/S0277-9536(00)00014-9; Miles M., 1994, QUALITATIVE ANAL EXP; Mills J., 2006, INT J QUAL METH, V5, P1, DOI DOI 10.1177/160940690600500103; Misri S, 2015, J WOMENS HEALTH, V24, P762, DOI 10.1089/jwh.2014.5150; Moazam F, 2000, HASTINGS CENT REP, V30, P28, DOI 10.2307/3528451; Nadir M, 2018, INDIAN J PSYCHIAT, V60, P103, DOI 10.4103/psychiatry.IndianJPsychiatry_153_17; Nasreen HE, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1781-0; Nasreen HE, 2011, BMC WOMENS HEALTH, V11, DOI 10.1186/1472-6874-11-22; National Institute of Population Studies (NIPS) ICF International, PAK DEM HLTH SURV 20; Nicoloro-SantaBarbara J, 2017, SOC SCI MED, V190, P133, DOI 10.1016/j.socscimed.2017.08.011; O'Connor TG, 2013, BRAIN BEHAV IMMUN, V32, P21, DOI 10.1016/j.bbi.2013.02.002; O'Donnell KJ, 2014, DEV PSYCHOPATHOL, V26, P1255, DOI 10.1017/S095457941400100X; O'Donnell KJ, 2013, PSYCHONEUROENDOCRINO, V38, P1630, DOI 10.1016/j.psyneuen.2013.01.008; Oliffe J, 2007, QUAL HEALTH RES, V17, P149, DOI 10.1177/1049732306297695; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; Onyeajam DJ, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5285-0; Patel I, 2011, PATIENT-RELAT OUTCOM, V2, P21, DOI 10.2147/PROM.S15747; Qadir F, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1150; Raine R, 2010, MATERN CHILD HLTH J, V14, P590, DOI 10.1007/s10995-009-0489-7; Riedl D, 2017, Z PSYCHOSOM MED PSYC, V63, P131, DOI 10.13109/zptm.2017.63.2.131; Rowe Rachel E, 2002, Health Expect, V5, P63, DOI 10.1046/j.1369-6513.2002.00159.x; Saldana J, 2016, CODING MANUAL QUALIT, V3rd; Schetter CD, 2016, PAEDIATR PERINAT EP, V30, P421, DOI 10.1111/ppe.12300; Singh P., 2013, PARADIGM, V17, P37, DOI DOI 10.1177/0971890720130105; Stortenbeker IA, 2018, PATIENT EDUC COUNS, V101, P1577, DOI 10.1016/j.pec.2018.05.002; Sufrin C., 2017, JAILCARE JAILCARE, DOI [10.1525/california/9780520288669.001.0001, DOI 10.1525/CALIFORNIA/9780520288669.001.0001]; Surkan PJ, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037590; Travaline JM, 2005, J AM OSTEOPATH ASSOC, V105, P13; UNICEF, PAK DEM HLTH INF MOR; van Osch M, 2017, PATIENT EDUC COUNS, V100, P1482, DOI 10.1016/j.pec.2017.03.009; van Ryn M, 2003, AM J PUBLIC HEALTH, V93, P248, DOI 10.2105/AJPH.93.2.248; Verheul W, 2010, PATIENT EDUC COUNS, V80, P300, DOI 10.1016/j.pec.2010.06.017; Waqas A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116510; Weiss R, 2017, J HOSP MED, V12, P805, DOI 10.12788/jhm.2828; WHO, 2019, MAT MORT; WHO UNICEF UNFPA World Bank, 2019, TRENDS MAT MORT 2000; Wong ST, 2004, WOMEN HEALTH ISS, V14, P118, DOI 10.1016/j.whi.2004.04.003; Wright EB, 2004, BMJ-BRIT MED J, V328, P864, DOI 10.1136/bmj.38046.771308.7C; Young GJ, 2000, MED CARE, V38, P325, DOI 10.1097/00005650-200003000-00009; Zhang Shaoling, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P1070, DOI 10.3969/j.issn.1672-7347.2013.10.015; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	68	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2021	16	2							e0244671	10.1371/journal.pone.0244671	http://dx.doi.org/10.1371/journal.pone.0244671			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QH0TZ	33544747	gold, Green Published			2023-01-03	WOS:000617991900010
J	Kemp, SA; Collier, DA; Datir, RP; Ferreira, IATM; Gayed, S; Jahun, A; Hosmillo, M; Rees-Spear, C; Mlcochova, P; Lumb, IU; Roberts, DJ; Chandra, A; Temperton, N; Sharrocks, K; Blane, E; Modis, Y; Leigh, KE; Briggs, JAG; van Gils, MJ; Smith, KGC; Bradley, JR; Smith, C; Doffinger, R; Ceron-Gutierrez, L; Barcenas-Morales, G; Pollock, DD; Goldstein, RA; Smielewska, A; Skittrall, JP; Gouliouris, T; Goodfellow, IG; Gkrania-Klotsas, E; Illingworth, CJR; McCoy, LE; Gupta, RK				Kemp, Steven A.; Collier, Dami A.; Datir, Rawlings P.; Ferreira, Isabella A. T. M.; Gayed, Salma; Jahun, Aminu; Hosmillo, Myra; Rees-Spear, Chloe; Mlcochova, Petra; Lumb, Ines Ushiro; Roberts, David J.; Chandra, Anita; Temperton, Nigel; Sharrocks, Katherine; Blane, Elizabeth; Modis, Yorgo; Leigh, Kendra E.; Briggs, John A. G.; van Gils, Marit J.; Smith, Kenneth G. C.; Bradley, John R.; Smith, Chris; Doffinger, Rainer; Ceron-Gutierrez, Lourdes; Barcenas-Morales, Gabriela; Pollock, David D.; Goldstein, Richard A.; Smielewska, Anna; Skittrall, Jordan P.; Gouliouris, Theodore; Goodfellow, Ian G.; Gkrania-Klotsas, Effrossyni; Illingworth, Christopher J. R.; McCoy, Laura E.; Gupta, Ravindra K.		CITIID-NIHR BioResource COVID-19 C; COVID-19 Genomics UK COG-UK Consor	SARS-CoV-2 evolution during treatment of chronic infection	NATURE			English	Article							ACE2; RESISTANCE; MULTIPLE	The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for virus infection through the engagement of the human ACE2 protein(1) and is a major antibody target. Here we show that chronic infection with SARS-CoV-2 leads to viral evolution and reduced sensitivity to neutralizing antibodies in an immunosuppressed individual treated with convalescent plasma, by generating whole-genome ultra-deep sequences for 23 time points that span 101 days and using in vitro techniques to characterize the mutations revealed by sequencing. There was little change in the overall structure of the viral population after two courses of remdesivir during the first 57 days. However, after convalescent plasma therapy, we observed large, dynamic shifts in the viral population, with the emergence of a dominant viral strain that contained a substitution (D796H) in the S2 subunit and a deletion (Delta H69/Delta V70) in the S1 N-terminal domain of the spike protein. As passively transferred serum antibodies diminished, viruses with the escape genotype were reduced in frequency, before returning during a final, unsuccessful course of convalescent plasma treatment. In vitro, the spike double mutant bearing both Delta H69/Delta V70 and D796H conferred modestly decreased sensitivity to convalescent plasma, while maintaining infectivity levels that were similar to the wild-type virus.The spike substitution mutant D796H appeared to be the main contributor to the decreased susceptibility to neutralizing antibodies, but this mutation resulted in an infectivity defect. The spike deletion mutant Delta H69/Delta V70 had a twofold higher level of infectivity than wild-type SARS-CoV-2, possibly compensating for the reduced infectivity of the D796H mutation. These data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy, which is associated with the emergence of viral variants that show evidence of reduced susceptibility to neutralizing antibodies in immunosuppressed individuals.	[Kemp, Steven A.; Collier, Dami A.; Rees-Spear, Chloe; Goldstein, Richard A.; McCoy, Laura E.] UCL, Div Infect & Immun, London, England; [Collier, Dami A.; Datir, Rawlings P.; Ferreira, Isabella A. T. M.; Mlcochova, Petra; Chandra, Anita; Modis, Yorgo; Leigh, Kendra E.; Smith, Kenneth G. C.; Gupta, Ravindra K.] Cambridge Inst Therapeut Immunol & Infect Dis CIT, Cambridge, England; [Collier, Dami A.; Datir, Rawlings P.; Ferreira, Isabella A. T. M.; Mlcochova, Petra; Chandra, Anita; Blane, Elizabeth; Modis, Yorgo; Leigh, Kendra E.; Smith, Kenneth G. C.; Bradley, John R.; Gupta, Ravindra K.] Univ Cambridge, Dept Med, Cambridge, England; [Gayed, Salma; Sharrocks, Katherine; Skittrall, Jordan P.; Gouliouris, Theodore; Gkrania-Klotsas, Effrossyni] Cambridge Univ NHS Hosp Fdn Trust, Dept Infect Dis, Cambridge, England; [Jahun, Aminu; Hosmillo, Myra; Smielewska, Anna; Goodfellow, Ian G.] Univ Cambridge, Dept Pathol, Cambridge, England; [Lumb, Ines Ushiro; Roberts, David J.] NHS Blood & Transplant, Oxford, England; [Lumb, Ines Ushiro; Roberts, David J.] Univ Oxford, BRC Haematol Theme, Oxford, England; [Temperton, Nigel] Univ Kent, Medway Sch Pharm, Viral Pseudotype Unit, Canterbury, Kent, England; [Modis, Yorgo; Leigh, Kendra E.; Briggs, John A. G.] MRC, Lab Mol Biol, Cambridge, England; [van Gils, Marit J.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Amsterdam, Netherlands; [Bradley, John R.] NIHR Cambridge Bioresource, Cambridge, England; [Smith, Chris; Smielewska, Anna] Cambridge Univ NHS Hosp Fdn Trust, Dept Virol, Cambridge, England; [Doffinger, Rainer; Ceron-Gutierrez, Lourdes; Barcenas-Morales, Gabriela] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England; [Barcenas-Morales, Gabriela] UNAM, FES Cuautitlan, Cuautitlan, Mexico; [Pollock, David D.] Univ Colorado, Biochem & Mol Genet, Sch Med, Aurora, CO USA; [Skittrall, Jordan P.; Illingworth, Christopher J. R.] Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge, England; [Skittrall, Jordan P.] Addenbrookes Hosp, Clin Microbiol & Publ Hlth Lab, Cambridge, England; [Illingworth, Christopher J. R.] Univ Cambridge, MRC Biostat Unit, Cambridge, England; [Gupta, Ravindra K.] Africa Hlth Res Inst, Durban, South Africa	University of London; University College London; University of Cambridge; University of Cambridge; University of Oxford; University of Kent; MRC Laboratory Molecular Biology; University of Amsterdam; Academic Medical Center Amsterdam; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Universidad Nacional Autonoma de Mexico; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; Africa Health Research Institute	Gupta, RK (corresponding author), Cambridge Inst Therapeut Immunol & Infect Dis CIT, Cambridge, England.; Gupta, RK (corresponding author), Univ Cambridge, Dept Med, Cambridge, England.; Gupta, RK (corresponding author), Africa Hlth Res Inst, Durban, South Africa.	rkg20@cam.ac.uk	Gkrania-Klotsas, Effrossyni/AAT-8424-2021; Dorman, Matthew J/M-6603-2013; McClure, Patrick/J-4619-2019; Bunclark, Katherine/GLN-3109-2022; Betancor, Gilberto/AAB-5872-2021; Fraser, Christophe/A-8109-2008; Beggs, Andrew D/A-6912-2013; Coudert, Jerome D/B-2628-2008; van Gils, Marit J./H-4791-2019; Temperton, Nigel James/K-5158-2013; Temperton, Nigel James/M-1164-2019; Summers, Charlotte/A-6973-2012; Golubchik, Tanya/B-4226-2018; Payne, Brendan/I-1233-2016; O'Grady, Justin/I-2982-2012	Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330; Dorman, Matthew J/0000-0001-7064-6163; McClure, Patrick/0000-0002-1710-1049; Bunclark, Katherine/0000-0002-8785-0715; Betancor, Gilberto/0000-0003-0548-7690; Fraser, Christophe/0000-0003-2399-9657; Beggs, Andrew D/0000-0003-0784-2967; Coudert, Jerome D/0000-0001-6081-8494; van Gils, Marit J./0000-0003-3422-8161; Temperton, Nigel James/0000-0002-7978-3815; Temperton, Nigel James/0000-0002-7978-3815; Crook, Derrick/0000-0002-0590-2850; Flaviani, Flavia/0000-0002-4210-0451; Glaysher, Sharon/0000-0002-9584-0621; Gallis, Marta/0000-0003-0222-2398; Torok, Mili Estee/0000-0001-9098-8590; Summers, Charlotte/0000-0002-7269-2873; Allara, Elias/0000-0002-1634-8330; Pinckert, Malte/0000-0002-6072-5949; Rudder, Steven/0000-0003-0050-9037; Bewshea, Claire/0000-0002-0965-9587; Beckett, Angela/0000-0003-4948-1004; Datir, Rawlings/0000-0003-0521-2144; Golubchik, Tanya/0000-0003-2765-9828; Partridge, David/0000-0002-0417-2016; Bashton, Matthew/0000-0002-6847-1525; Collier, Dami Aderonke/0000-0001-5446-4423; Goldstein, Richard/0000-0001-5148-4672; Bayzid, Nadua/0000-0002-7209-9471; Moore, Catherine/0000-0001-8934-0930; Kingston, Nathalie/0000-0002-9190-2231; Blacow, Rachel/0000-0002-0946-5539; McNally, Alan/0000-0002-3099-630X; Breuer, Judith/0000-0001-8246-0534; Smith, Darren/0000-0003-4925-467X; Leigh, Kendra/0000-0002-6467-3330; Jahun, Aminu/0000-0002-4585-1701; Walker, Neil/0000-0001-9796-7688; Oszlanczi, Agnes/0000-0001-6148-6591; Payne, Brendan/0000-0002-3101-3512; Kemp, Steven/0000-0001-7077-6793; Nelson, Andrew/0000-0001-6665-4929; McCann, Clare M/0000-0003-3395-820X; Spencer Chapman, Michael/0000-0002-5320-8193; Signell, Adrian/0000-0003-4620-6891; Palmalux, Natasha/0000-0002-4246-6082; Ferreira, Isabella/0000-0001-5232-4670; O'Grady, Justin/0000-0001-5412-7152; Saeed, Kordo/0000-0003-0123-0302; Chappell, Joseph/0000-0002-8205-4242; Smith, Kenneth/0000-0003-3829-4326; Gouliouris, Theodore/0000-0002-2011-1205; de Silva, Thushan/0000-0002-6498-9212; Young, Gregory/0000-0001-5342-1421; Illingworth, Chris/0000-0002-0030-2784; Vancollie, Valerie/0000-0003-1547-1975; Ledesma, Juan/0000-0002-0871-5065; Wang, Dennis/0000-0003-0068-1005; Lackenby, Angie/0000-0002-1557-0415; Bradley, John/0000-0002-7774-8805; Prieto, Jacqui/0000-0002-5524-6775	Medical Research Council (MRC) part of UK Research & Innovation (UKRI); National Institute of Health Research (NIHR); Genome Research Limited; Wellcome Trust [WT108082AIA, 207498/Z/17/Z]; Medical Research Council Career Development Award [MR/R008698/1]; Bill and Melinda Gates Foundation via PANGEA grant [OPP1175094]; Wellcome Trust; MRC [MC_UU_00002/11]; National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre; Cambridge Clinical Trials Unit (CCTU); UCL Coronavirus Response Fund; Medical Research Council [MC_UP_1201/16]; NIH [GM083127]; BBSRC [BB/P007562/1, BBS/E/F/000PR10348] Funding Source: UKRI; MRC [MR/R008698/1, MC_PC_19027] Funding Source: UKRI	Medical Research Council (MRC) part of UK Research & Innovation (UKRI)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute of Health Research (NIHR)(National Institute for Health Research (NIHR)); Genome Research Limited; Wellcome Trust(Wellcome Trust); Medical Research Council Career Development Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Bill and Melinda Gates Foundation via PANGEA grant; Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Cambridge Clinical Trials Unit (CCTU); UCL Coronavirus Response Fund; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to the patient and his family. We thank the staff at CUH and the NIHR Cambridge Clinical Research Facility; R. Kugathasan and W. Barclay for discussions; M. Curran, W. Hamilton and D. Sparkes, A. Floto and F. Gallagher; J. Voss for the gift of HeLa cells stably expressing ACE2; and J. Nathan for the RBD protein and L. James for the nucleocapsid protein. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. R.K.G. is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). L.E.M. is supported by a Medical Research Council Career Development Award (MR/R008698/1). S.A.K. is supported by the Bill and Melinda Gates Foundation via PANGEA grant (OPP1175094). D.A.C. is supported by a Wellcome Trust Clinical PhD Research Fellowship. C.J.R.I. acknowledges MRC funding (MC_UU_00002/11). This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, the Cambridge Clinical Trials Unit (CCTU) and by the UCL Coronavirus Response Fund and made possible through generous donations from UCL's supporters, alumni, and friends (to L.E.M.). J.A.G.B. is supported by the Medical Research Council (MC_UP_1201/16). I.G.G. is a Wellcome Senior Fellow and supported by the Wellcome Trust (207498/Z/17/Z). D.D.P. is supported by NIH GM083127.	Avanzato VA, 2020, CELL, V183, P1901, DOI 10.1016/j.cell.2020.10.049; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Boshier F.A.T., 2020, PREPRINT, DOI [10.1101/2020.11.18.20230599, DOI 10.1101/2020.11.18.20230599]; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Minh BQ, 2013, MOL BIOL EVOL, V30, P1188, DOI 10.1093/molbev/mst024; Bull RA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20075-6; Cai YF, 2020, SCIENCE, V369, P1586, DOI [10.1101/2020.05.16.099317, 10.1126/science.abd4251]; CDC, 2020, DISCONTINUATION TRAN; Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364; Collier DA, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100062; Didelot X, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004041; Gregson J, 2020, J INFECT DIS, V222, P1108, DOI 10.1093/infdis/jiz631; Gupta RK, 2010, AIDS, V24, P1651, DOI 10.1097/QAD.0b013e3283398216; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Illingworth CJR, 2016, BIOINFORMATICS, V32, P2208, DOI 10.1093/bioinformatics/btw205; Jordan MR, 2010, J VIROL METHODS, V168, P114, DOI 10.1016/j.jviromet.2010.04.030; Kalyaanamoorthy S, 2017, NAT METHODS, V14, P587, DOI [10.1038/NMETH.4285, 10.1038/nmeth.4285]; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kemp S., 2020, SSRN ELECT J, V2020, P1, DOI [10.1101/2020.12.14.422555, DOI 10.2139/SSRN.3780277, 10.2139/ssrn.3780277, DOI 10.1101/2020.12.14.422555]; Kim, 2020, PREPRINT, DOI [10.21203/rs.3.rs-105996/v1, DOI 10.21203/RS.3.RS-105996/V1]; Leonard AS, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006203; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Loman N., 2020, NCOV 2019 NOVEL CORO; Lumby CK, 2020, ELIFE, V9, DOI 10.7554/eLife.56915; Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Meredith LW, 2020, LANCET INFECT DIS, V20, P1263, DOI 10.1016/S1473-3099(20)30562-4; Minh BQ, 2020, MOL BIOL EVOL, V37, P1530, DOI 10.1093/molbev/msaa015; Mlcochova P, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100099; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005; Quick J., 2020, PROTOCOLSIO, DOI [10.17504/protocols.io.bbmuik6w.https://doi.org/10.17504/protocols.io.bbmuik6w, DOI 10.17504/PROTOCOLS.IO.BBMUIK6W.HTTPS://DOI.ORG/10.17504/PROTOCOLS.IO.BBMUIK6W]; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Richard M, 2018, J VIROL, V92, DOI 10.1128/JVI.02063-17; Robbiani Davide F, 2020, Nature, V584, P437, DOI [10.1101/2020.05.13.092619, 10.1038/s41586-020-2456-9]; Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Simonovich VA, 2021, NEW ENGL J MED, V384, P619, DOI 10.1056/NEJMoa2031304; Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012; Vermeire J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050859; Wrobel AG, 2020, NAT STRUCT MOL BIOL, V27, P763, DOI 10.1038/s41594-020-0468-7; Xiong XL, 2020, NAT STRUCT MOL BIOL, V27, P934, DOI 10.1038/s41594-020-0478-5; Zhou TQ, 2020, CELL HOST MICROBE, V28, P867, DOI 10.1016/j.chom.2020.11.004; Zussman ME, 2012, PEDIATR RES, V71, P697, DOI 10.1038/pr.2012.16	48	339	343	9	99	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 8	2021	592	7853					277	+		10.1038/s41586-021-03291-y	http://dx.doi.org/10.1038/s41586-021-03291-y		FEB 2021	26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ8ZE	33545711	Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000625125600001
J	De Paep, DL; Van Hulle, F; Ling, ZD; Vanhoeij, M; Pirenne, J; Keymeulen, B; Pipeleers, D; Jacobs-Tulleneers-Thevissen, D				De Paep, Diedert L.; Van Hulle, Freya; Ling, Zhidong; Vanhoeij, Marian; Pirenne, Jacques; Keymeulen, Bart; Pipeleers, Daniel; Jacobs-Tulleneers-Thevissen, Daniel			Lower beta cell yield from donor pancreases after controlled circulatory death prevented by shortening acirculatory warm ischemia time and by using IGL-1 cold preservation solution	PLOS ONE			English	Article							CARDIAC DEATH; ISLET ISOLATION; POLYETHYLENE-GLYCOL; LIPID-PEROXIDATION; PHASE-3 TRIAL; TRANSPLANTATION; DONATION; OUTCOMES; GRAFT; MULTICENTER	Organs from donors after controlled circulatory death (DCD III) exhibit a higher risk for graft dysfunction due to an initial period of warm ischemia. This procurement condition can also affect the yield of beta cells in islet isolates from donor pancreases, and hence their use for transplantation. The present study uses data collected and generated by our Beta Cell Bank to compare the number of beta cells in isolates from DCD III (n = 141) with that from donors after brain death (DBD, n = 609), before and after culture, and examines the influence of donor and procurement variables. Beta cell number per DCD III-organ was significantly lower (58 x 10(6) versus 84 x 10(6) beta cells per DBD-organ; p < 0.001) but their purity (24% insulin positive cells) and insulin content (17 mu g / 10(6) beta cells in DCD III-organs versus 19 mu g / 10(6) beta cells in DBD-organs) were similar. Beta cell number correlated negatively with duration of acirculatory warm ischemia time above 10 min; for shorter acirculatory warm ischemia time, DCD III-organs did not exhibit a lower beta cell yield (74 x 10(6) beta cells). Use of Institut Georges Lopez-1 cold preservation solution instead of University of Wisconsin solution or histidine-tryptophan-ketoglutarate also protected against the loss in beta cell yield from DCD III-organs (86 x 10(6) for IGL-1 versus 54 x 10(6) and 65 x 10(6) beta cells respectively, p = 0.042). Multivariate analysis indicates that both limitation of acirculatory warm ischemia time and use of IGL-1 prevent the reduced beta cell yield in islet cell isolates from DCD III-organs.	[De Paep, Diedert L.; Van Hulle, Freya; Ling, Zhidong; Keymeulen, Bart; Pipeleers, Daniel; Jacobs-Tulleneers-Thevissen, Daniel] Vrije Univ Brussel VUB, Diabet Res Ctr, Brussels, Belgium; [De Paep, Diedert L.; Van Hulle, Freya; Ling, Zhidong; Keymeulen, Bart; Pipeleers, Daniel; Jacobs-Tulleneers-Thevissen, Daniel] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Diabet Clin, Brussels, Belgium; [De Paep, Diedert L.; Vanhoeij, Marian; Jacobs-Tulleneers-Thevissen, Daniel] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Dept Surg, Brussels, Belgium; [Pirenne, Jacques] Univ Hosp Leuven, Dept Abdominal Transplantat & Transplantat Coordi, Leuven, Belgium	Vrije Universiteit Brussel; University Hospital Brussels; Vrije Universiteit Brussel; University Hospital Brussels; Vrije Universiteit Brussel; KU Leuven; University Hospital Leuven	Jacobs-Tulleneers-Thevissen, D (corresponding author), Vrije Univ Brussel VUB, Diabet Res Ctr, Brussels, Belgium.; Jacobs-Tulleneers-Thevissen, D (corresponding author), Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Diabet Clin, Brussels, Belgium.; Jacobs-Tulleneers-Thevissen, D (corresponding author), Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Dept Surg, Brussels, Belgium.	Daniel.Jacobs-Tulleneers-Thevissen@uzbrussel.be	De Paep, Diedert Luc/AAM-7081-2020; Jacobs-Tulleneers-Thevissen, Daniel/AIE-5341-2022; Jacobs-Tulleneers-Thevissen, Daniel/GNH-4840-2022	De Paep, Diedert Luc/0000-0001-8969-6531; Jacobs-Tulleneers-Thevissen, Daniel/0000-0001-5758-9547; Jacobs-Tulleneers-Thevissen, Daniel/0000-0001-5758-9547; Vanhoeij, Marian/0000-0002-4806-2775; Keymeulen, Bart/0000-0002-8671-4527; Van Hulle, Freya/0000-0001-7079-4705; Pipeleers, Daniel/0000-0002-6440-2485	European Commission [512145, 241883, 681070]; Flemish Government (IWT TBM7) [IWT 130138]; Juvenile Diabetes Research Foundation [4-2005-1327, 17-2013-296]; "Wetenschappelijk Fonds Willy Gepts" of the UZ Brussel	European Commission(European CommissionEuropean Commission Joint Research Centre); Flemish Government (IWT TBM7); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); "Wetenschappelijk Fonds Willy Gepts" of the UZ Brussel	This work has benefitted from projects supported by the European Commission (FP6 512145, FP7 241883, H2020 681070, https://ec.europa.eu/programmes/horizon2020/en), the Flemish Government (IWT TBM7, IWT 130138, https://www.vlaio.be), the Juvenile Diabetes Research Foundation (4-2005-1327, 17-2013-296, https://www.jdrf.org) and the "Wetenschappelijk Fonds Willy Gepts" of the UZ Brussel (https://www.uzbrussel.be/web/onderzoek/fonds-willy-gepts).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam R, 2015, AM J TRANSPLANT, V15, P395, DOI 10.1111/ajt.13060; Anazawa T, 2014, TRANSPL P, V46, P1980, DOI 10.1016/j.transproceed.2014.06.006; Andres A, 2016, TRANSPL INT, V29, P34, DOI 10.1111/tri.12650; Badet Lionel, 2005, Transpl Int, V17, P815, DOI 10.1007/s00147-004-0789-1; Balamurugan AN, 2014, AM J TRANSPLANT, V14, P2595, DOI 10.1111/ajt.12872; Brandhorst H, 2017, CELL TRANSPLANT, V26, P1733, DOI 10.1177/0963689717727544; CASSIDY WM, 1994, J CLIN GASTROENTEROL, V19, P118, DOI 10.1097/00004836-199409000-00008; Clayton HA, 2000, TRANSPLANTATION, V69, P2094, DOI 10.1097/00007890-200005270-00021; CORLETT MP, 1988, J SURG RES, V45, P531, DOI 10.1016/0022-4804(88)90140-0; Detry O, 2012, TRANSPL P, V44, P1189, DOI 10.1016/j.transproceed.2012.05.001; Doppenberg JB, 2021, AM J TRANSPLANT, V21, P3077, DOI 10.1111/ajt.16533; Eurotransplant Foundation, EUROTRANSPLANT MANUA; Faure JP, 2002, J PHARMACOL EXP THER, V302, P861, DOI 10.1124/jpet.102.033688; Friberg AS, 2012, TRANSPLANTATION, V93, P632, DOI 10.1097/TP.0b013e3182455912; Habran M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231019; Hauet T, 1998, TRANSPLANT P, V30, P2798, DOI 10.1016/S0041-1345(98)00813-6; Hering BJ, 2016, DIABETES CARE, V39, P1230, DOI 10.2337/dc15-1988; Heylen L, 2018, AM J TRANSPLANT, V18, P881, DOI 10.1111/ajt.14526; Heylen L, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14031; HOLMES MA, 1995, TRANSPLANTATION, V60, P854, DOI 10.1097/00007890-199510270-00016; Ito T, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091430; Keymeulen B, 1998, DIABETOLOGIA, V41, P452, DOI 10.1007/s001250050929; Keymeulen B, 2006, P NATL ACAD SCI USA, V103, P17444, DOI 10.1073/pnas.0608141103; Komatsu H, 2019, TRANSPLANTATION, V103, P299, DOI 10.1097/TP.0000000000002280; Korsgren O, NORDIC NETWORK ISLET; Lee D, 2020, TRANSPLANTATION, V104, pE295, DOI 10.1097/TP.0000000000003321; Legeai C, 2020, AM J TRANSPLANT, V20, P3426, DOI 10.1111/ajt.15995; Ling ZD, 1996, J CLIN INVEST, V98, P2805, DOI 10.1172/JCI119108; MACK JE, 1991, CRYOBIOLOGY, V28, P1, DOI 10.1016/0011-2240(91)90002-6; Markmann JF, 2003, TRANSPLANTATION, V75, P1423, DOI 10.1097/01.TP.0000061119.32575.F4; Nano R, 2020, TRANSPLANTATION, V104, P190, DOI 10.1097/TP.0000000000002777; Niclauss N, 2012, TRANSPLANTATION, V93, P703, DOI 10.1097/TP.0b013e3182476cc8; O'Neill S, 2014, TRANSPL INT, V27, P1159, DOI 10.1111/tri.12403; Pipeleers D, 2008, DIABETES OBES METAB, V10, P54, DOI 10.1111/j.1463-1326.2008.00941.x; Reich DJ, 2009, AM J TRANSPLANT, V9, P2004, DOI 10.1111/j.1600-6143.2009.02739.x; RICORDI C, 1990, ACTA DIABETOL LAT, V27, P185, DOI 10.1007/BF02581331; Ricordi C, 2016, DIABETES, V65, P3418, DOI 10.2337/db16-0234; Saito T, 2010, TRANSPLANTATION, V90, P740, DOI 10.1097/TP.0b013e3181ecb044; Stewart ZA, 2009, AM J TRANSPLANT, V9, P286, DOI 10.1111/j.1600-6143.2008.02478.x; Summers DM, 2013, LANCET, V381, P727, DOI 10.1016/S0140-6736(12)61685-7; Summers DM, 2010, LANCET, V376, P1303, DOI 10.1016/S0140-6736(10)60827-6; Suntharalingam C, 2009, AM J TRANSPLANT, V9, P2157, DOI 10.1111/j.1600-6143.2009.02758.x; Thuong M, 2016, TRANSPL INT, V29, P749, DOI 10.1111/tri.12776; Wang LJ, 2016, CELL TRANSPLANT, V25, P1515, DOI 10.3727/096368916X691141; Zhao M, 2007, AM J TRANSPLANT, V7, P2318, DOI 10.1111/j.1600-6143.2007.01937.x	45	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2021	16	5							e0251055	10.1371/journal.pone.0251055	http://dx.doi.org/10.1371/journal.pone.0251055			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RW3BG	33939760	Green Published, gold			2023-01-03	WOS:000646400800013
J	Puentes, PR; Valderrama, N; Gonzalez, C; Daza, L; Munoz-Camargo, C; Cruz, JC; Arbelaez, P				Ruiz Puentes, Paola; Valderrama, Natalia; Gonzalez, Cristina; Daza, Laura; Munoz-Camargo, Carolina; Cruz, Juan C.; Arbelaez, Pablo			PharmaNet: Pharmaceutical discovery with deep recurrent neural networks	PLOS ONE			English	Article							DRUG DISCOVERY; HIGH-THROUGHPUT; ACTIVE-SITE; SOLUBILITY; EXPRESSION; PREDICTION; TOXICITY	The discovery and development of novel pharmaceuticals is an area of active research mainly due to the large investments required and long payback times. As of 2016, the development of a novel drug candidate required up to $ USD 2.6 billion in investment for only 10% rate of approval by the FDA. To help decreasing the costs associated with the process, a number of in silico approaches have been developed with relatively low success due to limited predicting performance. Here, we introduced a machine learning-based algorithm as an alternative for a more accurate search of new pharmacological candidates, which takes advantage of Recurrent Neural Networks (RNN) for active molecule prediction within large databases. Our approach, termed PharmaNet was implemented here to search for ligands against specific cell receptors within 102 targets of the DUD-E database, which contains 22886 active molecules. PharmaNet comprises three main phases. First, a SMILES representation of the molecule is converted into a raw molecular image. Second, a convolutional encoder processes the data to obtain a fingerprint molecular image that is finally analyzed by a Recurrent Neural Network (RNN). This approach enables precise predictions of the molecules' target on the basis of the feature extraction, the sequence analysis and the relevant information filtered out throughout the process. Molecule Target prediction is a highly unbalanced detection problem and therefore, we propose that an adequate evaluation metric of performance is the area under the Normalized Average Precision (NAP) curve. PharmaNet largely surpasses the previous state-of-the-art method with 97.7% in the Receiver Operating Characteristic curve (ROC-AUC) and 65.5% in the NAP curve. We obtained a perfect performance for human farnesyl pyrophosphate synthase (FPPS), which is a potential target for antimicrobial and anticancer treatments. We decided to test PharmaNet for activity prediction against FPPS by searching in the CHEMBL data set. We obtained three (3) potential inhibitors that were further validated through both molecular docking and in silico toxicity prediction. Most importantly, one of this candidates, CHEMBL2007613, was predicted as a potential antiviral due to its involvement on the PCDH17 pathway, which has been reported to be related to viral infections.	[Ruiz Puentes, Paola; Valderrama, Natalia; Gonzalez, Cristina; Daza, Laura; Arbelaez, Pablo] Univ Los Andes, Ctr Res & Format Artificial Intelligence, Bogota, Colombia; [Munoz-Camargo, Carolina; Cruz, Juan C.] Univ Los Andes, Dept Biomed Engn, Bogota, Colombia; [Cruz, Juan C.] Univ Adelaide, Sch Chem Engn & Adv Mat, Adelaide, SA, Australia	Universidad de los Andes (Colombia); Universidad de los Andes (Colombia); University of Adelaide	Arbelaez, P (corresponding author), Univ Los Andes, Ctr Res & Format Artificial Intelligence, Bogota, Colombia.	pa.arbelaez@uniandes.edu.co		Ruiz Puentes, Paola/0000-0003-4352-7999	Vice Presidency of Research & Creation's Publication Fund at Universidad de los Andes	Vice Presidency of Research & Creation's Publication Fund at Universidad de los Andes	The authors would also like to thank the Vice Presidency of Research & Creation's Publication Fund at Universidad de los Andes for its financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abate M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14495-6; Alsenz J, 2007, ADV DRUG DELIVER REV, V59, P546, DOI 10.1016/j.addr.2007.05.007; [Anonymous], 2020, BRUSSELS TIMES; [Anonymous], 2016, P 2016 IEEE C COMPUT, DOI [10.1109/CVPR.2016.90, DOI 10.1109/CVPR.2016.90]; [Anonymous], 2020, GUARDIAN 1026; [Anonymous], 2020, PHARM RES DAT; Avdeef A, 2020, MOL PHARMACEUT, V17, P3930, DOI 10.1021/acs.molpharmaceut.0c00689; Baker N, 2017, ARXIV PREPRINT ARXIV; ChEMBL, BRUSSELS TIMES; Chen LY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220113; Cho K., 2014, P C EMP METH NAT LAN, P1724, DOI DOI 10.3115/V1/D14-1179; Choubey J., 2013, IJCA P NATL SEM APPL, P66; Commission E, 2020, COR GLOB RESP 74 BIL; D'Costa VM, 2007, CURR OPIN MICROBIOL, V10, P481, DOI 10.1016/j.mib.2007.08.009; Everingham M, 2015, INT J COMPUT VISION, V111, P98, DOI 10.1007/s11263-014-0733-5; Gonczarek A., 2016, ARXIV PREPRINT ARXIV; Gonzalez C, 2020, ARXIV PREPRINT ARXIV; Goodfellow I, 2016, ADAPT COMPUT MACH LE, P1; Gritzalis D, 2015, BIOORG MED CHEM LETT, V25, P1117, DOI 10.1016/j.bmcl.2014.12.089; Hariharan B, 2015, PROC CVPR IEEE, P447, DOI 10.1109/CVPR.2015.7298642; Hasselgren C, 2019, REGUL TOXICOL PHARM, V107, DOI 10.1016/j.yrtph.2019.104403; Hershkovitz-Rokah O, 2015, CANCER LETT, V360, P245, DOI 10.1016/j.canlet.2015.02.031; Hessler G, 2018, MOLECULES, V23, DOI 10.3390/molecules23102520; Hoiem D, 2012, LECT NOTES COMPUT SC, V7574, P340, DOI 10.1007/978-3-642-33712-3_25; Hu PW, 2016, IEEE IJCNN, P1236, DOI 10.1109/IJCNN.2016.7727339; Kastl L, 2012, BREAST CANCER RES TR, V131, P445, DOI 10.1007/s10549-011-1424-3; Kim HY, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0166-2; Krizhevsky A., 2012, ADV NEURAL INFORM PR; Lagunin A, 2013, BIOINFORMATICS, V29, P2062, DOI 10.1093/bioinformatics/btt322; Lagunin A, 2011, MOL INFORM, V30, P241, DOI 10.1002/minf.201000151; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Leelananda SP, 2016, BEILSTEIN J ORG CHEM, V12, P2694, DOI 10.3762/bjoc.12.267; Lin TY, 2014, LECT NOTES COMPUT SC, V8693, P740, DOI 10.1007/978-3-319-10602-1_48; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Lopez MM, 2017, ARXIV PREPRINT ARXIV; Lovelace, 2020, CNBC; Maninis Kevis-Kokitsi, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P140, DOI 10.1007/978-3-319-46723-8_17; Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041; Martin D, 2001, EIGHTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOL II, PROCEEDINGS, P416, DOI 10.1109/ICCV.2001.937655; Martin DR, 2004, IEEE T PATTERN ANAL, V26, P530, DOI 10.1109/TPAMI.2004.1273918; Mayr A, 2016, FRONT ENV SCI-SWITZ, V3, DOI 10.3389/fenvs.2015.00080; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Nicolaou CA, 2019, ACS MED CHEM LETT, V10, P278, DOI 10.1021/acsmedchemlett.8b00488; Palca J., 2020, NPR; Park J, 2014, FRONT CHEM, V2, DOI [10.3389/fchem.2014.00050, 10.3389/fchem.2014.00077]; Petras G, 2020, USA TODAY; Phatak SS, 2009, EXPERT OPIN DRUG DIS, V4, P947, DOI 10.1517/17460440903190961; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Russell K, 2012, J BONE ONCOL, V1, P12, DOI 10.1016/j.jbo.2012.04.003; Santini D, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0634-8; Segler MHS, 2018, ACS CENTRAL SCI, V4, P120, DOI 10.1021/acscentsci.7b00512; Seshacharyulu P, 2019, ONCOGENE, V38, P5265, DOI 10.1038/s41388-019-0791-9; Sorrentino A, 2008, GYNECOL ONCOL, V111, P478, DOI 10.1016/j.ygyno.2008.08.017; Stokes JM, 2020, CELL, V180, P688, DOI 10.1016/j.cell.2020.01.021; Tolosana R, 2018, IEEE ACCESS, V6, P5128, DOI 10.1109/ACCESS.2018.2793966; Tsoumpra MK, 2015, BONE, V81, P478, DOI 10.1016/j.bone.2015.08.020; Ventola C Lee, 2015, P T, V40, P277; Wallach I., 2015, ARXIV PREPRINT ARXIV; Waller DD, 2019, CRIT REV BIOCHEM MOL, V54, P41, DOI 10.1080/10409238.2019.1568964; Wang XY, 2007, CELL HOST MICROBE, V2, P96, DOI 10.1016/j.chom.2007.06.009; Way2Drug, 2011, UND CHEM BIOL INT; WEININGER D, 1989, J CHEM INF COMP SCI, V29, P97, DOI 10.1021/ci00062a008; Xiao SH, 2016, ONCOTARGET, V7, P50229, DOI 10.18632/oncotarget.10357; Yang X, 2019, CHEM REV, V119, P10520, DOI 10.1021/acs.chemrev.8b00728; Yin W., 2017, ARXIV PREPRINT ARXIV; Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906; Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007	67	4	4	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2021	16	4							e0241728	10.1371/journal.pone.0241728	http://dx.doi.org/10.1371/journal.pone.0241728			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0VQ	33901196	Green Submitted, Green Published, gold			2023-01-03	WOS:000662169700002
J	Tobias, GC; Mandacaru, PMP; Guimaraes, RA; Morais, OL				Tobias, Gabriela Camargo; Pimenta Mandacaru, Polyana Maria; Guimaraes, Rafael Alves; Morais Neto, Otaliba Libanio			Use of prehospital, hospitalization and presence of sequelae and/or disability in road traffic injury victims in Brazil	PLOS ONE			English	Article							CRASH RATES; CARE; ACCIDENTS; SEVERITY; SYSTEM	Objective To estimate the prevalence and analyze the association between sociodemographic and behavioral variables with the use of prehospital care, hospitalization and sequelae and/or disability in victims of road traffic accidents victims in Brazil. Methods Data from the National Health Survey conducted in 2013 in Brazil were used. Data were collected through a direct household survey. The research sample consisted of 1,840 individuals who reported road traffic accidents in the previous 12 months. Poisson regression analysis was used to evaluate the factors associated with the use of prehospital care services, hospitalization, and the presence of sequelae and/or disability. Results The prevalence of road traffic accidents victims who received prehospital care was 13.0% (95% Confidence Interval [95% CI]: 10.3-16.3) and the factors associated with this outcome were: residing in the Northeast or North region of Brazil; residing in rural areas; and being a motorcycle occupant at the moment of the road traffic accident. The frequency of hospitalization was 7.7% (95% CI: 6.0-10.0) and the associated factors were: age between 40 and 59 years; being a motorcycle occupant or pedestrian and having received on-site care at the moment of the road traffic accident. The prevalence of sequelae and/or disability was 15.1% (95% CI: 12.5-18.2) and the associated factors were: age range between 30 and 39 years or 40 and 59 years; being a motorcycle occupant, being a pedestrian or belonging to other category of modes of transport and having received on-site care at the moment of the road traffic accident. Conclusion The study allowed to evaluate the factors associated with prehospital care, hospitalization and presence of sequelae and/or disability in the victims of road traffic accident and the results can guide the implementation of interventions that prioritize the population exposed to the highest risk of road traffic accident injuries and with less access to prehospital and hospital care services in Brazil.	[Tobias, Gabriela Camargo; Pimenta Mandacaru, Polyana Maria; Guimaraes, Rafael Alves; Morais Neto, Otaliba Libanio] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil; [Guimaraes, Rafael Alves] Univ Fed Goias, Fac Nursing, Goiania, Go, Brazil	Universidade Federal de Goias; Universidade Federal de Goias	Guimaraes, RA (corresponding author), Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.; Guimaraes, RA (corresponding author), Univ Fed Goias, Fac Nursing, Goiania, Go, Brazil.	rafaelalvesg5@gmail.com			Ministerio da Saude do Brasil	Ministerio da Saude do Brasil	Funding for Ministerio da Saude do Brasil.	Alfalahi E, 2018, PAN AFR MED J, V29, DOI 10.11604/pamj.2018.29.145.12974; Malvestio MAA, 2008, REV SAUDE PUBL, V42, P639, DOI 10.1590/S0034-89102008000400009; Andrade Silvânia Suely Caribé de Araújo, 2016, Rev. bras. epidemiol., V19, P100, DOI 10.1590/1980-5497201600010009; Balikuddembe JK, 2017, BMC EMERG MED, V17, DOI 10.1186/s12873-016-0112-3; Bhatti Junaid A, 2013, Ann Adv Automot Med, V57, P257; de Souza PRB, 2015, EPIDEMIOL SERV SAUDE, V24, P207, DOI 10.5123/S1679-49742015000200003; Brasil. Ministerio da Saude, SECR VIG SAUD DEP VI; Brasil. Ministerio da Saude. DATASUS, EST VIT; Cabral Amanda Priscila de Santana, 2008, Rev. bras. epidemiol., V11, P530, DOI 10.1590/S1415-790X2008000400002; Andrade SSCD, 2017, EPIDEMIOL SERV SAUDE, V26, P31, DOI [10.5123/s1679-49742017000100004, 10.5123/S1679-49742017000100004]; Carr BG, 2006, PREHOSP EMERG CARE, V10, P198, DOI 10.1080/10903120500541324; Chokotho L, 2017, PREHOSP DISASTER MED, V32, P14, DOI 10.1017/S1049023X16001175; Cleries Montse, 2015, Gac Sanit, V29 Suppl 1, P36, DOI 10.1016/j.gaceta.2015.03.011; Coutinho Leticia M S, 2008, Rev. Saúde Pública, V42, P992, DOI 10.1590/S0034-89102008000600003; Dandona R, 2006, J SAFETY RES, V37, P149, DOI 10.1016/j.jsr.2005.11.002; Vera-Lopez JD, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311x00144916, 10.1590/0102-311X00144916]; de Araujo GL, 2016, ACTA PAUL ENFERM, V29, P178, DOI 10.1590/1982-0194201600025; Minayo MCD, 2008, CAD SAUDE PUBLICA, V24, P1877, DOI 10.1590/S0102-311X2008000800016; Dhondt S, 2013, ACCIDENT ANAL PREV, V50, P659, DOI 10.1016/j.aap.2012.06.019; Hatamabadi HR, 2011, TRAFFIC INJ PREV, V12, P358, DOI 10.1080/15389588.2011.566656; Ibrahim NA, 2017, PREHOSP DISASTER MED, V32, P424, DOI 10.1017/S1049023X17006410; Institute for Health Metrics and Evaluation (IHME), DATA VISUALIZATION; Instituto de Pesquisa Economica Aplicada (IPEA). Instituto de Pesquisa Economica Aplicada, EST CUST AC TRANS BR; Ladeira RM, 2008, CAD SAUDE PUBLICA, V24, P287, DOI 10.1590/S0102-311X2008000200007; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Li Q, 2017, PUBLIC HEALTH, V144, pS57, DOI 10.1016/j.puhe.2016.11.012; Lin T, 2013, J PUBLIC HEALTH-UK, V35, P541, DOI 10.1093/pubmed/fdt003; Machado CV, 2011, REV SAUDE PUBL, V45, P519, DOI 10.1590/S0034-89102011005000022; Macinko J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134153; Mascarenhas MDM, 2016, CIENC SAUDE COLETIVA, V21, P3661, DOI 10.1590/1413-812320152112.24332016; Misra P, 2017, INDIAN J CRIT CARE M, V21, P678, DOI 10.4103/ijccm.IJCCM_197_17; Organizacao Mundial da Saude (OMS), ORG MUND SAUD INF SE; Palmera-Suarez R, 2016, ACCIDENT ANAL PREV, V91, P36, DOI 10.1016/j.aap.2016.02.024; Palmera-Suarez Rocio, 2015, Gac Sanit, V29 Suppl 1, P43, DOI 10.1016/j.gaceta.2015.01.009; Patey AM, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1517-z; Ray JJ, 2016, TRAFFIC INJ PREV, V17, P676, DOI 10.1080/15389588.2016.1149580; Rosado J., 2018, MED BUENOS AIRES, V78, P158; Sanchez-Mangas R, 2010, ACCIDENT ANAL PREV, V42, P1048, DOI 10.1016/j.aap.2009.12.012; Shavaleh Rasoul, 2018, Med J Islam Repub Iran, V32, P50, DOI 10.14196/mjiri.32.50; Shults RA, 2004, J SAFETY RES, V35, P447, DOI 10.1016/j.jsr.2004.06.001; Szwarcwald CL, 2014, CIENC SAUDE COLETIVA, V19, P333, DOI 10.1590/1413-81232014192.14072012; Tavares Fábio Lucio, 2014, Esc. Anna Nery, V18, P656, DOI 10.5935/1414-8145.20140093; Trowbridge MJ, 2009, AM J PREV MED, V37, P428, DOI 10.1016/j.amepre.2009.06.016; Vanderschuren M, 2015, INT J HEALTH GEOGR, V14, DOI 10.1186/1476-072X-14-5; World Health Organization, GLOBAL STATUS REPORT; World Health Organization (WHO) . World Health Organization, 2004, WORLD REPORT ROAD TR, DOI [10.1007/978-88-470-2131-0_11, DOI 10.1007/978-88-470-2131-0_11]; Yongchaitrakul T, 2012, SE ASIAN J TROP MED, V43, P785; Zafar SN, 2018, INT J SURG, V52, P245, DOI 10.1016/j.ijsu.2018.02.034; Zeng Q, 2019, TRANSPORTMETRICA A, V15, P1867, DOI 10.1080/23249935.2019.1652867; Zeng Q, 2020, J TRANSP SAF SECUR, V12, P566, DOI 10.1080/19439962.2018.1516259; Zeng Q, 2017, ACCIDENT ANAL PREV, V99, P184, DOI 10.1016/j.aap.2016.11.018	51	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2021	16	4							e0249895	10.1371/journal.pone.0249895	http://dx.doi.org/10.1371/journal.pone.0249895			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP1DH	33861788	Green Published, gold			2023-01-03	WOS:000641475400021
J	Kang, BH; Momin, N; Moynihan, KD; Silva, M; Li, YZ; Irvine, DJ; Wittrup, KD				Kang, Byong H.; Momin, Noor; Moynihan, Kelly D.; Silva, Murillo; Li, Yingzhong; Irvine, Darrell J.; Wittrup, K. Dane			Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice	PLOS ONE			English	Article							TERTIARY LYMPHOID STRUCTURES; B-CELLS; COMBINATION IMMUNOTHERAPY; HERV-K; CANCER; ANTIGEN; IMMUNITY; SEQUENCE; PROTEIN; INNATE	Following curative immunotherapy of B16F10 tumors, similar to 60% of mice develop a strong antibody response against cell-surface tumor antigens. Their antisera confer prophylactic protection against intravenous challenge with B16F10 cells, and also cross-react with syngeneic and allogeneic tumor cell lines MC38, EL.4, 4T1, and CT26. We identified the envelope glycoprotein (env) of a murine endogenous retrovirus (ERV) as the antigen accounting for the majority of this humoral response. A systemically administered anti-env monoclonal antibody cloned from such a response protects against tumor challenge, and prophylactic vaccination against the env protein protects a majority of naive mice from tumor establishment following subcutaneous inoculation with B16F10 cells. These results suggest the potential for effective prophylactic vaccination against analogous HERV-K env expressed in numerous human cancers.	[Kang, Byong H.; Momin, Noor; Moynihan, Kelly D.; Silva, Murillo; Li, Yingzhong; Irvine, Darrell J.; Wittrup, K. Dane] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Kang, Byong H.; Momin, Noor; Moynihan, Kelly D.; Li, Yingzhong; Irvine, Darrell J.; Wittrup, K. Dane] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Moynihan, Kelly D.; Irvine, Darrell J.] MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Moynihan, Kelly D.; Irvine, Darrell J.] Harvard Univ, Cambridge, MA 02138 USA; [Irvine, Darrell J.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Irvine, Darrell J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Wittrup, K. Dane] MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Wittrup, KD (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Wittrup, KD (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Wittrup, KD (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	wittrup@mit.edu		/0000-0003-2398-5896; /0000-0003-3145-6089; Moynihan, Kelly/0000-0001-6200-7863	Ragon Institute of MGH, MIT and Harvard; Koch Institute Frontier Research Program; Kathy and Curt Marble Cancer Research Fund; Mayo Clinic -Koch Institute Cancer Solutions Team Grant; National Cancer Institute [CA174795]	Ragon Institute of MGH, MIT and Harvard; Koch Institute Frontier Research Program; Kathy and Curt Marble Cancer Research Fund; Mayo Clinic -Koch Institute Cancer Solutions Team Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the Ragon Institute of MGH, MIT and Harvard, the Koch Institute Frontier Research Program, the Kathy and Curt Marble Cancer Research Fund, and the Mayo Clinic -Koch Institute Cancer Solutions Team Grant funding, and the National Cancer Institute, CA174795.	Affara NI, 2014, CANCER CELL, V25, P809, DOI 10.1016/j.ccr.2014.04.026; Angelini A, 2015, METHODS MOL BIOL, V1319, P3, DOI 10.1007/978-1-4939-2748-7_1; Carmi Y, 2015, NATURE, V521, P99, DOI 10.1038/nature14424; Cegolon L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-4; Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94; Chiaruttini G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1294296; Colbeck EJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01830; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; DeFalco J, 2018, CLIN IMMUNOL, V187, P37, DOI 10.1016/j.clim.2017.10.002; DiLillo DJ, 2010, J IMMUNOL, V184, P4006, DOI 10.4049/jimmunol.0903009; Escolano A, 2019, NATURE, V570, P468, DOI 10.1038/s41586-019-1250-z; Forte G, 2012, J IMMUNOL, V189, P2226, DOI 10.4049/jimmunol.1200744; Gilbert AE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019330; Hampton TA, 2000, CANCER GENE THER, V7, P446, DOI 10.1038/sj.cgt.7700124; HAYASHI H, 1992, J IMMUNOL, V149, P1223; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; Iglesia MD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw144; Kershaw MH, 2001, CANCER RES, V61, P7920; Kobayashi T, 2019, J INVEST DERMATOL, V139, P1535, DOI 10.1016/j.jid.2019.02.016; Kobayashi T, 2014, AM J PATHOL, V184, P3120, DOI 10.1016/j.ajpath.2014.07.003; Krishnamurthy J, 2015, CLIN CANCER RES, V21, P3241, DOI 10.1158/1078-0432.CCR-14-3197; LEONG SPL, 1988, CANCER RES, V48, P4954; Li MF, 1999, J VIROL, V73, P9178, DOI 10.1128/JVI.73.11.9178-9186.1999; Li M, 2017, CLIN CANCER RES, V23, P5892, DOI 10.1158/1078-0432.CCR-17-0001; Maksakova IA, 2008, CELL MOL LIFE SCI, V65, P3329, DOI 10.1007/s00018-008-8494-3; Momin N, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2614; Moynihan KD, 2016, NAT MED, V22, P1402, DOI 10.1038/nm.4200; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn F, 2010, P NATL ACAD SCI USA, V107, P19396, DOI 10.1073/pnas.1014515107; Ottina E, 2018, CANCER IMMUNOL RES, V6, P1292, DOI 10.1158/2326-6066.CIR-18-0038; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Ruddell A, 2011, NEOPLASIA, V13, P748, DOI 10.1593/neo.11756; Sarvaria A, 2017, CELL MOL IMMUNOL, V14, P662, DOI 10.1038/cmi.2017.35; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Smith CC, 2019, NAT REV CANCER, V19, P465, DOI 10.1038/s41568-019-0162-4; Song E, 2020, NATURE, V577, P689, DOI 10.1038/s41586-019-1912-x; Tiller T, 2009, J IMMUNOL METHODS, V350, P183, DOI 10.1016/j.jim.2009.08.009; Tokuyama M, 2018, P NATL ACAD SCI USA, V115, P12565, DOI 10.1073/pnas.1814589115; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Tzeng A, 2016, CELL REP, V17, P2503, DOI 10.1016/j.celrep.2016.11.020; Van Deventer JA, 2014, METHODS MOL BIOL, V1131, P151, DOI 10.1007/978-1-62703-992-5_10; Viswanathan S, 2006, NAT PROTOC, V1, P1351, DOI 10.1038/nprot.2006.234; Wang-Johanning F, 2012, JNCI-J NATL CANCER I, V104, P189, DOI 10.1093/jnci/djr540; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; WHITE HD, 1994, J VIROL, V68, P897, DOI 10.1128/JVI.68.2.897-904.1994; Wittrup KD, 2017, TRENDS CANCER, V3, P615, DOI 10.1016/j.trecan.2017.07.001; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001; Yang CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064159; Ye X, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1758602; Young GR, 2013, BIOESSAYS, V35, P794, DOI 10.1002/bies.201300049; Yuen GJ, 2016, TRENDS CANCER, V2, P747, DOI 10.1016/j.trecan.2016.10.010; Zhang X., NAT CANCER; Zhou FL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1047582; Zhou P, 2010, J IMMUNOTHER, V33, P789, DOI 10.1097/CJI.0b013e3181ee6ba9; Zhu EF, 2015, CANCER CELL, V27, P489, DOI 10.1016/j.ccell.2015.03.004	58	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2021	16	4							e0248903	10.1371/journal.pone.0248903	http://dx.doi.org/10.1371/journal.pone.0248903			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP1DC	33857179	gold, Green Published			2023-01-03	WOS:000641474900108
J	Yost, KE; Chang, HY; Satpathy, AT				Yost, Kathryn E.; Chang, Howard Y.; Satpathy, Ansuman T.			Recruiting T cells in cancer immunotherapy	SCIENCE			English	Editorial Material							IMMUNITY		[Yost, Kathryn E.; Chang, Howard Y.] Stanford Univ, Sch Med, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA; [Chang, Howard Y.] Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA; [Satpathy, Ansuman T.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Chang, HY (corresponding author), Stanford Univ, Sch Med, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA.; Chang, HY (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA.	howchang@sfanford.edu; satpathy@stanford.edu	Yost, Kathryn/X-2171-2019	Yost, Kathryn/0000-0001-6807-950X				Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Dammeijer F, 2020, CANCER CELL, V38, P685, DOI 10.1016/j.ccell.2020.09.001; Fairfax BP, 2020, NAT MED, V26, P193, DOI 10.1038/s41591-019-0734-6; Hammerich L, 2019, NAT MED, V25, P814, DOI 10.1038/s41591-019-0410-x; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Oh SA, 2020, NAT CANCER, V1, P681, DOI 10.1038/s43018-020-0075-x; Osorio JC, 2019, J CLIN ONCOL, V37, P3546, DOI 10.1200/JCO.19.00709; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Topalian SL, 2020, SCIENCE, V367, P525, DOI 10.1126/science.aax0182; Valpione S, 2020, NAT CANCER, V1, P210, DOI 10.1038/s43018-019-0022-x; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wu TD, 2020, NATURE, V579, P274, DOI 10.1038/s41586-020-2056-8; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zhang JJ, 2020, CLIN CANCER RES, V26, P1327, DOI 10.1158/1078-0432.CCR-19-2931	15	28	29	5	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	2021	372	6538					130	131		10.1126/science.abd1329	http://dx.doi.org/10.1126/science.abd1329			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RL8LG	33833111				2023-01-03	WOS:000639216800023
J	Bollmann, A; Hohenstein, S; Pellissier, V; Stengler, K; Reichardt, P; Ritz, JP; Thiele, H; Borger, MA; Hindricks, G; Meier-Hellmann, A; Kuhlen, R				Bollmann, Andreas; Hohenstein, Sven; Pellissier, Vincent; Stengler, Katharina; Reichardt, Peter; Ritz, Joerg-Peter; Thiele, Holger; Borger, Michael A.; Hindricks, Gerhard; Meier-Hellmann, Andreas; Kuhlen, Ralf			Utilization of in- and outpatient hospital care in Germany during the Covid-19 pandemic insights from the German-wide Helios hospital network	PLOS ONE			English	Article								Background During the early phase of the Covid-19 pandemic, reductions of hospital admissions with a focus on emergencies have been observed for several medical and surgical conditions, while trend data during later stages of the pandemic are scarce. Consequently, this study aims to provide up-to-date hospitalization trends for several conditions including cardiovascular, psychiatry, oncology and surgery cases in both the in- and outpatient setting. Methods and findings Using claims data of 86 Helios hospitals in Germany, consecutive cases with an in- or outpatient hospital admission between March 13, 2020 (the begin of the "protection" stage of the German pandemic plan) and December 10, 2020 (end of study period) were analyzed and compared to a corresponding period covering the same weeks in 2019. Cause-specific hospitalizations were defined based on the primary discharge diagnosis according to International Statistical Classification of Diseases and Related Health Problems (ICD-10) or German procedure classification codes for cardiovascular, oncology, psychiatry and surgery cases. Cumulative hospitalization deficit was computed as the difference between the expected and observed cumulative admission number for every week in the study period, expressed as a percentage of the cumulative expected number. The expected admission number was defined as the weekly average during the control period. A total of 1,493,915 hospital admissions (723,364 during the study and 770,551 during the control period) were included. At the end of the study period, total cumulative hospitalization deficit was -10% [95% confidence interval -10; -10] for cardiovascular and -9% [-10; -9] for surgical cases, higher than -4% [-4; -3] in psychiatry and 4% [4; 4] in oncology cases. The utilization of inpatient care and subsequent hospitalization deficit was similar in trend with some variation in magnitude between cardiovascular (-12% [-13; -12]), psychiatry (-18% [-19; -17]), oncology (-7% [-8; -7]) and surgery cases (-11% [-11; -11]). Similarly, cardiovascular and surgical outpatient cases had a deficit of -5% [-6; -5] and -3% [-4; -3], respectively. This was in contrast to psychiatry (2% [1; 2]) and oncology cases (21% [20; 21]) that had a surplus in the outpatient sector. While in-hospital mortality, was higher during the Covid-19 pandemic in cardiovascular (3.9 vs. 3.5%, OR 1.10 [95% CI 1.06-1.15], P<0.01) and in oncology cases (4.5 vs. 4.3%, OR 1.06 [95% CI 1.01-1.11], P<0.01), it was similar in surgical (0.9 vs. 0.8%, OR 1.06 [95% CI 1.00-1.13], P = 0.07) and in psychiatry cases (0.4 vs. 0.5%, OR 1.01 [95% CI 0.78-1.31], P<0.95). Conclusions There have been varying changes in care pathways and in-hospital mortality in different disciplines during the Covid-19 pandemic in Germany. Despite all the inherent and well-known limitations of claims data use, this data may be used for health care surveillance as the pandemic continues worldwide. While this study provides an up-to-date analysis of utilization of hospital care in the largest German hospital network, short- and long-term consequences are unknown and deserve further studies.	[Bollmann, Andreas; Hohenstein, Sven; Pellissier, Vincent; Thiele, Holger; Borger, Michael A.; Hindricks, Gerhard] Univ Leipzig, Heart Ctr Leipzig, Leipzig, Germany; [Bollmann, Andreas; Hohenstein, Sven; Pellissier, Vincent; Thiele, Holger; Borger, Michael A.; Hindricks, Gerhard] Leipzig Heart Inst, Leipzig, Germany; [Stengler, Katharina] Helios Pk Hosp, Dept Psychiat Psychotherapy & Psychosomat, Leipzig, Germany; [Reichardt, Peter] Helios Hosp Berlin Buch, Oncol Ctr Berlin Buch, Berlin, Germany; [Reichardt, Peter] Berlin Canc Inst, Berlin, Germany; [Ritz, Joerg-Peter] Helios Hosp Schwerin, Dept Surg, Schwerin, Germany; [Meier-Hellmann, Andreas] Helios Kliniken, Berlin, Germany; [Kuhlen, Ralf] Helios Hlth, Berlin, Germany	Heart Center Leipzig GMBH; Leipzig University; Heart Center Leipzig GMBH; Helios Kliniken	Bollmann, A (corresponding author), Univ Leipzig, Heart Ctr Leipzig, Leipzig, Germany.; Bollmann, A (corresponding author), Leipzig Heart Inst, Leipzig, Germany.	andreas.bollmann@helios-gesundheit.de	Borger, Michael/AAX-1514-2020	Borger, Michael/0000-0003-1046-1364; Bollmann, Andreas/0000-0002-5441-3906; Hohenstein, Sven/0000-0002-9708-1593				Anderson TS, 2020, J GEN INTERN MED, V35, P3129, DOI 10.1007/s11606-020-06027-2; Baum A, 2020, JAMA-J AM MED ASSOC, V324, P96, DOI 10.1001/jama.2020.9972; Bollmann A, 2020, EUR HEART J QUAL CAR, DOI [10.1093/ehjqcco/qcaa071, DOI 10.1093/EHJQCCO/QCAA071]; Bollmann A, 2020, EUR HEART J-QUAL CAR, V6, P221, DOI 10.1093/ehjqcco/qcaa049; Cozad M, 2019, AM J PUBLIC HEALTH, V109, P1584, DOI 10.2105/AJPH.2019.305317; Gluckman TJ, 2020, JAMA CARDIOL, V5, P1419, DOI 10.1001/jamacardio.2020.3629; Konig S, 2020, EUR J HEART FAIL, V22, P2190, DOI 10.1002/ejhf.2044; Konig S, 2018, EUR HEART J, V39, P3947, DOI 10.1093/eurheartj/ehy528; Mafham MM, 2020, LANCET, V396, P381, DOI 10.1016/S0140-6736(20)31356-8; Maringe C, 2020, LANCET ONCOL, V21, P1023, DOI 10.1016/S1470-2045(20)30388-0; Oseran AS, 2020, AM J MANAG CARE, V26, P327, DOI 10.37765/ajmc.2020.43837; Singh S, 2020, RESUSCITATION, V156, P164, DOI 10.1016/j.resuscitation.2020.08.133; Stang A, 2020, J INFECTION, V81, P797, DOI 10.1016/j.jinf.2020.09.012; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	14	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2021	16	3							e0249251	10.1371/journal.pone.0249251	http://dx.doi.org/10.1371/journal.pone.0249251			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF4TN	33765096	gold, Green Published			2023-01-03	WOS:000634832800030
J	Thapamagar, SB; Ellstrom, K; Anholm, JD; Fargo, RA; Dandamudi, N				Thapamagar, Suman B.; Ellstrom, Kathleen; Anholm, James D.; Fargo, Ramiz A.; Dandamudi, Nagamani			Impact of pulmonary rehabilitation in sleep in COPD patients measured by actigraphy	PLOS ONE			English	Article							QUALITY-OF-LIFE; OLDER-ADULTS; SUBJECTIVE SLEEP; EXERCISE; VALIDITY; MODERATE; INDEX; RELIABILITY; PREVALENCE; DISORDERS	Introduction Chronic obstructive pulmonary disease (COPD) patients have poor sleep quality, longer time to sleep onset and frequent nocturnal awakenings. Poor sleep quality in COPD is associated with poor quality of life (QoL), increased exacerbations and increased mortality. Pulmonary rehabilitation (PR) improves functional status and QoL in COPD but effects on sleep are unclear. PR improves subjective sleep quality but there is paucity of objective actigraphy data. We hypothesized that actigraphy would demonstrate subjective and objective improvement in sleep following PR. Paired comparisons (t-test or Wilcoxon-signed-rank test) were performed before and after PR data on all variables. Methods This retrospective study of COPD patients undergoing PR utilized actigraphy watch recordings before and after 8-weeks of PR to assess changes in sleep variables including total time in bed (TBT), total sleep time (TST), sleep onset latency (SOL), sleep efficiency (SE), wakefulness after sleep onset (WASO) and total nocturnal awakenings. A change in Pittsburg Sleep Quality Index (PSQI) was a secondary outcome. PSQI was performed before and after PR. Results Sixty-nine patients were included in the final analysis. Most participants were male (97%), non-obese (median BMI 27.5, IQR 24.3 to 32.4 kg/m(2)) with an average age of 69 +/- 8 years and 71% had severe COPD (GOLD stage 3 or 4). Prevalence of poor sleep quality (PSQI >= 5) was 86%. Paired comparisons did not show improvement in actigraphic sleep parameters following 8-weeks PR despite improvements in 6-min-walk distance (6MWD, mean improvement 54 m, 95% CI 34 m to 74 m, p<0.0001) and St. George's Respiratory Questionnaire scores (SGRQ, mean improvement 7.7 points, 95% CI 5.2 to 10.2, p<0.0001). Stratified analysis of all sleep variables by severity of COPD, BMI, mood, mental status, 6-MWD and SGRQ did not show significant improvement after PR. In Veterans with poor sleep quality (PSQI >= 5), PR improved subjective sleep quality (PSQI, mean difference 0.79, 95% CI 0.07 to 1.40, p = 0.03). Conclusions Pulmonary rehabilitation improved subjective sleep quality in Veterans who had poor sleep quality at the beginning of the PR but did not improve objective sleep parameters by actigraphy. Our findings highlight the complex interactions among COPD, sleep and exercise.	[Thapamagar, Suman B.; Anholm, James D.; Fargo, Ramiz A.; Dandamudi, Nagamani] Loma Linda Univ, Sch Med Loma Linda, Div Pulm Crit Care Sleep Allergy & Hyperbar Med, Loma Linda, CA 92350 USA; [Thapamagar, Suman B.; Ellstrom, Kathleen; Anholm, James D.; Fargo, Ramiz A.; Dandamudi, Nagamani] VA Loma Linda Healthcare Syst, Pulm & Crit Care Sect, Med Serv, Loma Linda, CA 92357 USA; [Thapamagar, Suman B.; Fargo, Ramiz A.] Riverside Univ Hlth Syst, Div Pulm Crit Care & Hyperbar Med, Moreno Valley, CA 92555 USA	Loma Linda University	Thapamagar, SB (corresponding author), Loma Linda Univ, Sch Med Loma Linda, Div Pulm Crit Care Sleep Allergy & Hyperbar Med, Loma Linda, CA 92350 USA.; Thapamagar, SB (corresponding author), VA Loma Linda Healthcare Syst, Pulm & Crit Care Sect, Med Serv, Loma Linda, CA 92357 USA.; Thapamagar, SB (corresponding author), Riverside Univ Hlth Syst, Div Pulm Crit Care & Hyperbar Med, Moreno Valley, CA 92555 USA.	suman.thapamagar@ruhealth.org	Anholm, James/GRF-6796-2022; Lista-Paz, Ana/I-1170-2016	Anholm, James/0000-0002-5699-3481; Lista-Paz, Ana/0000-0002-8458-6285				Aili K, 2017, J CLIN SLEEP MED, V13, P39, DOI 10.5664/jcsm.6384; Alexander M, 2016, SLEEP, V39, P1399, DOI 10.5665/sleep.5972; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Ancoli-Israel S, 2006, J CLIN SLEEP MED, V2, P333; Aydin H.T, 2014, COPD CLIN PERSPECTIV; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Bonardi JMT, 2016, SLEEP MED, V25, P122, DOI 10.1016/j.sleep.2016.06.025; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chennaoui M, 2015, SLEEP MED REV, V20, P59, DOI 10.1016/j.smrv.2014.06.008; CORMICK W, 1986, THORAX, V41, P846, DOI 10.1136/thx.41.11.846; Coventry PA, 2007, J PSYCHOSOM RES, V63, P551, DOI 10.1016/j.jpsychores.2007.08.002; Cox NS, 2019, COPD, V16, P25, DOI 10.1080/15412555.2019.1567701; Dodd JW, 2011, THORAX, V66, P425, DOI 10.1136/thx.2010.156372; Ellstrom K., 2018, AM J RESP CRIT CARE; Goel N, 2005, CHRONOBIOL INT, V22, P905, DOI 10.1080/07420520500263235; Gordon CS, 2019, CHEST, V156, P80, DOI 10.1016/j.chest.2019.04.009; Hajiro T, 1998, AM J RESP CRIT CARE, V158, P1185, DOI 10.1164/ajrccm.158.4.9802091; HOCH CC, 1987, PSYCHOPHYSIOLOGY, V24, P293, DOI 10.1111/j.1469-8986.1987.tb00298.x; Irwin MR, 2008, SLEEP, V31, P1001; Jakubowski KP, 2017, BEHAV SLEEP MED, V15, P257, DOI 10.1080/15402002.2015.1126595; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; KLINK M, 1987, CHEST, V91, P540, DOI 10.1378/chest.91.4.540; Lan CC, 2014, RESP CARE, V59, P1569, DOI 10.4187/respcare.02912; LAREAU SC, 1994, HEART LUNG, V23, P242; Lewis CA, 2009, THORAX, V64, P133, DOI 10.1136/thx.2007.088930; Majde JA, 2005, J ALLERGY CLIN IMMUN, V116, P1188, DOI 10.1016/j.jaci.2005.08.005; McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3; McDonnell LM, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.28; Mcsharry DG, 2012, RESPIROLOGY, V17, P1119, DOI 10.1111/j.1440-1843.2012.02217.x; Melancon MO, 2015, PHYSIOL BEHAV, V140, P203, DOI 10.1016/j.physbeh.2014.12.031; Middelkoop HAM, 1996, J GERONTOL A-BIOL, V51, pM108, DOI 10.1093/gerona/51A.3.M108; Mollayeva T, 2016, SLEEP MED REV, V25, P52, DOI 10.1016/j.smrv.2015.01.009; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; Nunes DM, 2009, LUNG, V187, P159, DOI 10.1007/s00408-009-9147-5; Omachi TA, 2012, SLEEP MED, V13, P476, DOI 10.1016/j.sleep.2011.12.007; Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418; Ryrso CK, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0718-1; Sadeh A, 2011, SLEEP MED REV, V15, P259, DOI 10.1016/j.smrv.2010.10.001; Singh SJ, 2014, EUR RESPIR J, V44, P1447, DOI 10.1183/09031936.00150414; Smith MT, 2018, J CLIN SLEEP MED, V14, P1231, DOI 10.5664/jcsm.7230; Soler X, 2013, COPD, V10, P156, DOI 10.3109/15412555.2012.729622; Spina G, 2017, THORAX, V72, P694, DOI 10.1136/thoraxjnl-2016-208900; Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST; STEVENSON JS, 1990, RES NURS HEALTH, V13, P209, DOI 10.1002/nur.4770130403; Tariq SH, 2006, AM J GERIAT PSYCHIAT, V14, P900, DOI 10.1097/01.JGP.0000221510.33817.86; Tryon WW, 2004, SLEEP, V27, P158, DOI 10.1093/sleep/27.1.158; Vardar-Yagli N, 2015, EXPERT REV RESP MED, V9, P233, DOI 10.1586/17476348.2015.1009041; Yang PY, 2012, J PHYSIOTHER, V58, P157, DOI 10.1016/S1836-9553(12)70106-6; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	51	1	1	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2021	16	3							e0248466	10.1371/journal.pone.0248466	http://dx.doi.org/10.1371/journal.pone.0248466			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QY1VJ	33724995	gold, Green Published			2023-01-03	WOS:000629833700033
J	Cox, JC; Leeds, IL; Sadiraj, V; Schnier, KE; Sweeney, JF				Cox, James C.; Leeds, Ira L.; Sadiraj, Vjollca; Schnier, Kurt E.; Sweeney, John F.			Effects of patients' hospital discharge preferences on uptake of clinical decision support	PLOS ONE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; LENGTH-OF-STAY; 30-DAY READMISSIONS; SURGERY; QUALITY; COST; PERFORMANCE; PREDICTION; OUTCOMES; SYSTEMS	The Centers for Medicare and Medicaid Services identified unplanned hospital readmissions as a critical healthcare quality and cost problem. Improvements in hospital discharge decision-making and post-discharge care are needed to address the problem. Utilization of clinical decision support (CDS) can improve discharge decision-making but little is known about the empirical significance of two opposing problems that can occur: (1) negligible uptake of CDS by providers or (2) over-reliance on CDS and underuse of other information. This paper reports an experiment where, in addition to electronic medical records (EMR), clinical decision-makers are provided subjective reports by standardized patients, or CDS information, or both. Subjective information, reports of being eager or reluctant for discharge, was obtained during examinations of standardized patients, who are regularly employed in medical education, and in our experiment had been given scripts for the experimental treatments. The CDS tool presents discharge recommendations obtained from econometric analysis of data from de-identified EMR of hospital patients. 38 clinical decision-makers in the experiment, who were third and fourth year medical students, discharged eight simulated patient encounters with an average length of stay 8.1 in the CDS supported group and 8.8 days in the control group. When the recommendation was "Discharge," CDS uptake of "Discharge" recommendation was 20% higher for eager than reluctant patients. Compared to discharge decisions in the absence of patient reports: (i) odds of discharging reluctant standardized patients were 67% lower in the CDS-assisted group and 40% lower in the control (no-CDS) group; whereas (ii) odds of discharging eager standardized patients were 75% higher in the control group and similar in CDS-assisted group. These findings indicate that participants were neither ignoring nor over-relying on CDS.	[Cox, James C.; Sadiraj, Vjollca] Georgia State Univ, Dept Econ, Atlanta, GA 30303 USA; [Cox, James C.; Sadiraj, Vjollca] Georgia State Univ, Expt Econ Ctr, Atlanta, GA 30303 USA; [Leeds, Ira L.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Schnier, Kurt E.] Univ Calif Merced, Dept Econ & Business Management, Merced, CA USA; [Sweeney, John F.] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA	University System of Georgia; Georgia State University; University System of Georgia; Georgia State University; Johns Hopkins University; University of California System; University of California Merced; Emory University	Cox, JC (corresponding author), Georgia State Univ, Dept Econ, Atlanta, GA 30303 USA.; Cox, JC (corresponding author), Georgia State Univ, Expt Econ Ctr, Atlanta, GA 30303 USA.	jccox@gsu.edu	Leeds, Ira L./H-5520-2019	Leeds, Ira L./0000-0001-6572-8658	National Institutes of Health, National Institute on Aging [1RC4AG039071]	National Institutes of Health, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded by the National Institutes of Health, National Institutes of Health, National Institute on Aging (grant number 1RC4AG039071): John F. Sweeney (PI); James C. Cox (PI); Vjollca Sadiraj (Co-investigator), Kurt E. Schnier (Co-investigator).	Abdelnoor M, 2017, VASC HEALTH RISK MAN, V13, P101, DOI 10.2147/VHRM.S122951; Bueno H, 2010, JAMA-J AM MED ASSOC, V303, P2141, DOI 10.1001/jama.2010.748; Carey K, 2014, MED CARE RES REV, V71, P99, DOI 10.1177/1077558713504998; Chau Anthony, 2011, Anesthesiol Clin, V29, P57, DOI 10.1016/j.anclin.2010.11.002; Chole RA, 2012, ARCH OTOLARYNGOL, V138, P707, DOI 10.1001/archoto.2012.1374; Comeau G, 2020, MUSIC MED; Cox JC, 2016, J ECON BEHAV ORGAN, V131, P24, DOI 10.1016/j.jebo.2015.03.014; Cox JC, 2016, J ECON BEHAV ORGAN, V131, P1, DOI 10.1016/j.jebo.2015.03.017; Croskerry Pat, 2009, Healthc Q, V12 Spec No Patient, pe171; Fiks AG, 2011, CURR PROB PEDIATR AD, V41, P60, DOI 10.1016/j.cppeds.2010.10.006; Fillmore CL, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-135; Fingar K.R., 2017, COMP ALL CAUSE 7 DAY; Hyslop B, 2021, AGE AGEING, V50, P358, DOI 10.1093/ageing/afaa238; Jaspers MWM, 2011, J AM MED INFORM ASSN, V18, P327, DOI 10.1136/amiajnl-2011-000094; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Kassin MT, 2012, J AM COLL SURGEONS, V215, P322, DOI 10.1016/j.jamcollsurg.2012.05.024; Khairat S, 2018, JMIR MED INF, V6, P25, DOI 10.2196/medinform.8912; Kim MO, 2017, J AM MED INFORM ASSN, V24, P246, DOI 10.1093/jamia/ocw154; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V310, P151, DOI 10.1001/jama.2013.7835; Kwok CS, 2018, JACC-CARDIOVASC INTE, V11, P665, DOI 10.1016/j.jcin.2018.01.248; Leeds IL, 2017, AM J SURG, V213, P112, DOI 10.1016/j.amjsurg.2016.03.010; Leeds IL, 2013, J SURG RES, V184, P42, DOI 10.1016/j.jss.2013.03.064; Mayr FB, 2017, JAMA-J AM MED ASSOC, V317, P530, DOI 10.1001/jama.2016.20468; McIlvennan CK, 2015, CIRCULATION, V131, P1796, DOI 10.1161/CIRCULATIONAHA.114.010270; Meunier A, 2017, ACTA ORTHOP, V88, P466, DOI 10.1080/17453674.2017.1298353; Roshanov PS, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f657; Sheetz KH, 2019, JAMA SURG, V154, P510, DOI 10.1001/jamasurg.2019.0090; Simon HA, 1955, Q J ECON, V69, P99, DOI 10.2307/1884852; Wallis CJD, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4366; Wiswell J, 2013, AM J EMERG MED, V31, P1448, DOI 10.1016/j.ajem.2013.07.018	30	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2021	16	3							e0247270	10.1371/journal.pone.0247270	http://dx.doi.org/10.1371/journal.pone.0247270			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QU3OZ	33684144	gold, Green Published			2023-01-03	WOS:000627193500027
J	Lugon, CC; Smit, M; Salamun, J; Abderrahmane, M; Braillard, O; Nehme, M; Bausch, FJ; Guessous, I; Spechbach, H				Lugon, Chloe Chevallier; Smit, Mikaela; Salamun, Julien; Abderrahmane, Meriem; Braillard, Olivia; Nehme, Mayssam; Bausch, Frederique Jacquerioz; Guessous, Idris; Spechbach, Herve			Novel outpatient management of mild to moderate COVID-19 spares hospital capacity and safeguards patient outcome: The Geneva PneumoCoV-Ambu study	PLOS ONE			English	Article								Background Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), the novel coronavirus that causes coronavirus disease (COVID-19), is creating an unprecedented burden on health care systems across the world due to its high rate of pneumonia-related hospitalizations. This study presents recommendations for the outpatient management of moderate SARS-CoV-2 pneumonia implemented at the Geneva University Hospital, Switzerland, from April 4 to June 30, 2020 and evaluated the impact of these recommendations on patient safety, patient satisfaction, and overall hospital capacity. Methods Recommendations for the outpatient management of moderate pneumonia implemented in the Geneva University Hospital (PneumoCoV-Ambu) between April 4 and June 30, 2020, were evaluated prospectively. The primary endpoint was hospitalization. Secondary endpoints were: severity of COVID-19 disease based on a 7-points ordinal scale assessed at 1 and 2 months following SARS-CoV-2 infection; patient satisfaction using a satisfaction survey and the analysis of number of beds and costs potentially averted. Results A total of 36 patients with COVID-19-related pneumonia were followed between April 4 and May 5, 2020. Five patients (14%) were hospitalized and none died over a median of 30 days follow-up. The majority of patients (n = 31; 86%) were satisfied with the ambulatory care they received. These novel recommendations for outpatient management resulted in sparing an estimated potential 124 hospital bed-nights and CHF 6'826 per capita averted hospitalization costs over the three months period. Conclusions Recommendations developed for the outpatient management of COVID-19-related pneumonia were able to spare hospital capacity without increasing adverse patient outcomes. Widely implementing such recommendations is crucial in preserving hospital capacity during this pandemic.	[Lugon, Chloe Chevallier; Salamun, Julien; Abderrahmane, Meriem; Braillard, Olivia; Nehme, Mayssam; Bausch, Frederique Jacquerioz; Guessous, Idris; Spechbach, Herve] Geneva Univ Hosp, Dept Community Med Primary Care & Emergency Med, Div Primary Care Med, Geneva, Switzerland; [Smit, Mikaela] Geneva Univ Hosp, Dept Med, Div Infect Dis, Geneva, Switzerland; [Smit, Mikaela] Univ Geneva, Fac Med, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva	Lugon, CC (corresponding author), Geneva Univ Hosp, Dept Community Med Primary Care & Emergency Med, Div Primary Care Med, Geneva, Switzerland.	chloe.lugon@hcuge.ch		Chevallier Lugon, Chloe/0000-0002-8386-3447; Smit, Mikaela/0000-0001-8530-748X				Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; CDC, COR DIS 2019 COVID 1; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Crooks CJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007974; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Dolgin M., 1994, NOMENCLATURE CRITERI; Jones BE, 2011, CHEST, V140, P156, DOI 10.1378/chest.10-1296; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; National Health Institute (NIH), WHATS NEW COR DIS CO; Nehme M, 2021, ANN INTERN MED, V174, P723, DOI 10.7326/M20-5926; Tan KS, 2020, US ICU RESOURCE AVAI; Tormey D, ECOG PERFORMANCE STA; Universite de Gen eve, UN INT GEN PED CRIT; World Health Organization, COR DIS COVID 19 DAS; Zillich AJ, 2014, HEALTH SERV RES, V49, P1537, DOI 10.1111/1475-6773.12176	16	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2021	16	3							e0247774	10.1371/journal.pone.0247774	http://dx.doi.org/10.1371/journal.pone.0247774			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT5BY	33662012	Green Published, gold			2023-01-03	WOS:000626604100128
J	Michigami, M; Takahashi, K; Yamashita, H; Ye, ZM; Nakase, I; Fujii, I				Michigami, Masataka; Takahashi, Kentaro; Yamashita, Haruna; Ye, Zhengmao; Nakase, Ikuhiko; Fujii, Ikuo			A "ligand-targeting" peptide-drug conjugate: Targeted intracellular drug delivery by VEGF-binding helix-loop-helix peptides via receptor-mediated endocytosis	PLOS ONE			English	Article								As a new alternative to antibody-drug conjugates, we generated "ligand-targeting" peptidedrug conjugates (PDCs), which utilize receptor-mediated endocytosis for targeted intracellular drug delivery. The PDC makes a complex with an extracellular ligand and then binds to the receptor on the cell surface to stimulate intracellular uptake via the endocytic pathway. A helix-loop-helix (HLH) peptide was designed as the drug carrier and randomized to give a conformationally constrained peptide library. The phage-displayed library was screened against vascular endothelial growth factor (VEGF) to yield the binding peptide M49, which exhibited strong binding affinity (K-D = 0.87 nM). The confocal fluorescence microscopy revealed that peptide M49 formed a ternary complex with VEGF and its receptor, which was then internalized into human umbilical vein endothelial cells (HUVECs) via VEGF receptormediated endocytosis. The backbone-cyclized peptide M49K was conjugated with a drug, monomethyl auristatin E, to afford a PDC, which inhibited VEGF-induced HUVEC proliferation. HLH peptides and their PDCs have great potential as a new modality for targeted molecular therapy.	[Michigami, Masataka; Takahashi, Kentaro; Yamashita, Haruna; Nakase, Ikuhiko; Fujii, Ikuo] Osaka Prefecture Univ, Dept Biol Sci, Sakai, Osaka, Japan; [Ye, Zhengmao] Interprot Corp, Osaka, Japan	Osaka Metropolitan University	Fujii, I (corresponding author), Osaka Prefecture Univ, Dept Biol Sci, Sakai, Osaka, Japan.	fujii@b.s.osakafu-u.ac.jp			Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from Japan Agency for Medical Research and Development (AMED) [JP19am0101097]; Interprotein Corporation	Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Interprotein Corporation	This research was supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from Japan Agency for Medical Research and Development (AMED) under Grant Number JP19am0101097. Interprotein Corporation provided support in the form of salaries for author ZY. The funders did not play any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the author are articulated in the `Author contributions' section.	BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Beck A, 2017, NAT REV DRUG DISCOV, V16, P315, DOI 10.1038/nrd.2016.268; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bhattacharya R, 2016, CANCER RES, V76, P3014, DOI 10.1158/0008-5472.CAN-15-1605; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Doronina SO, 2003, NAT BIOTECHNOL, V21, P778, DOI 10.1038/nbt832; Fedorova A, 2011, CHEM BIOL, V18, P839, DOI 10.1016/j.chembiol.2011.05.011; Fujii I, 2001, TETRAHEDRON LETT, V42, P3323, DOI 10.1016/S0040-4039(01)00382-3; Fujii I, 1998, NAT BIOTECHNOL, V16, P463, DOI 10.1038/nbt0598-463; Fujiwara D, 2016, ANGEW CHEM INT EDIT, V55, P10612, DOI 10.1002/anie.201603230; Gerber HP, 2009, BLOOD, V113, P4352, DOI 10.1182/blood-2008-09-179143; Goshima N, 2008, NAT METHODS, V5, P1011, DOI 10.1038/nmeth.1273; Hojo H, 2007, TETRAHEDRON LETT, V48, P25, DOI 10.1016/j.tetlet.2006.11.034; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Hoshino A, 2019, CLIN IMMUNOL, V203, P9, DOI 10.1016/j.clim.2019.03.011; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121; Jain N, 2015, PHARM RES-DORDR, V32, P3526, DOI 10.1007/s11095-015-1657-7; Johnson ECB, 2006, J AM CHEM SOC, V128, P6640, DOI 10.1021/ja058344i; Kabrun N, 1997, DEVELOPMENT, V124, P2039; Kaplon H, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2019.1703531; Kim MT, 2014, BIOCONJUGATE CHEM, V25, P1223, DOI 10.1021/bc5000109; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Mudiyanselage TMRR, 2020, ACS CHEM BIOL, V15, P360, DOI 10.1021/acschembio.9b00743; Perez HL, 2014, DRUG DISCOV TODAY, V19, P869, DOI 10.1016/j.drudis.2013.11.004; Podar K, 2006, P NATL ACAD SCI USA, V103, P19478, DOI 10.1073/pnas.0609329103; SAGA T, 1995, P NATL ACAD SCI USA, V92, P8999, DOI 10.1073/pnas.92.19.8999; Suzuki N, 1999, TETRAHEDRON LETT, V40, P6013, DOI 10.1016/S0040-4039(99)01095-3; Takahashi N, 2001, NAT BIOTECHNOL, V19, P563, DOI 10.1038/89320; Urquhart L, 2020, NAT REV DRUG DISCOV, V19, P228, DOI 10.1038/d41573-020-00047-7; Wan Q, 2007, ANGEW CHEM INT EDIT, V46, P9248, DOI 10.1002/anie.200704195; Wang LT, 2005, PROTEIN SCI, V14, P2436, DOI 10.1110/ps.051478705; Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Zhang LS, 2017, CELL PHYSIOL BIOCHEM, V44, P1251, DOI 10.1159/000485455; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhou Q, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5040064	38	4	4	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247045	10.1371/journal.pone.0247045	http://dx.doi.org/10.1371/journal.pone.0247045			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BB	33630870	gold, Green Published			2023-01-03	WOS:000624536800037
J	Dehghankar, M; Maleki-Ravasan, N; Tahghighi, A; Karimian, F; Karami, M				Dehghankar, Maryam; Maleki-Ravasan, Naseh; Tahghighi, Azar; Karimian, Fateh; Karami, Mohsen			Bioactivities of rose-scented geranium nanoemulsions against the larvae of Anopheles stephensi and their gut bacteria	PLOS ONE			English	Article							ESSENTIAL OIL; LARVICIDAL ACTIVITY; CULEX-PIPIENS; INSECTICIDAL ACTIVITY; DIPTERA-CULICIDAE; MALARIOUS AREAS; AROMATIC PLANTS; MOSQUITO; CITRONELLOL; RESISTANCE	Anopheles stephensi with three different biotypes is a major vector of malaria in Asia. It breeds in a wide range of habitats. Therefore, safer and more sustainable methods are needed to control its immature stages rather than chemical pesticides. The larvicidal and antibacterial properties of the Pelargonium roseum essential oil (PREO) formulations were investigated against mysorensis and intermediate forms of An. stephensi in laboratory conditions. A series of nanoemulsions containing different amounts of PREO, equivalent to the calculated LC50 values for each An. stephensi form, and various quantities of surfactants and co-surfactants were developed. The physical and morphological properties of the most lethal formulations were also determined. PREO and its major components, i.e. citronellol (21.34%), L-menthone (6.41%), linalool (4.214%), and geraniol (2.19%), showed potent larvicidal activity against the studied mosquitoes. The LC50/90 values for mysorensis and intermediate forms were computed as 11.44/42.42 ppm and 12.55/47.69 ppm, respectively. The F48/F44 nanoformulations with 94% and 88% lethality for the mysorensis and intermediate forms were designated as optimized formulations. The droplet size, polydispersity index, and zeta-potential for F48/F44 were determined as 172.8/90.95 nm, 0.123/0.183, and -1.08/-2.08 mV, respectively. These results were also confirmed by TEM analysis. Prepared formulations displayed antibacterial activity against larval gut bacteria in the following order of decreasing inhibitory: LC90, optimized nanoemulsions, and LC50. PREO-based formulations were more effective against mysorensis than intermediate. Compared to the crude PREO, the overall larvicidal activity of all nanoformulations boosted by 20% and the optimized formulations by 50%. The sensitivity of insect gut bacteria may be a crucial factor in determining the outcome of the effect of toxins on target insects. The formulations designed in the present study may be a good option as a potent and selective larvicide for An. stephensi.	[Dehghankar, Maryam] Islamic Azad Univ, Fac Basic Sci, Sci & Res Branch, Tehran, Iran; [Dehghankar, Maryam; Maleki-Ravasan, Naseh; Tahghighi, Azar] Pasteur Inst Iran, Biotechnol Res Ctr, Malaria & Vector Res Grp, Tehran, Iran; [Maleki-Ravasan, Naseh] Pasteur Inst Iran, Dept Parasitol, Tehran, Iran; [Tahghighi, Azar] Pasteur Inst Iran, Dept Clin Res, Lab Med Chem, Tehran, Iran; [Karimian, Fateh] Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Entomol & Vector Control, Tehran, Iran; [Karami, Mohsen] Babol Univ Med Sci, Dept Parasitol & Mycol, Babol, Iran	Islamic Azad University; Le Reseau International des Instituts Pasteur (RIIP); Pasteur Institute of Iran; Le Reseau International des Instituts Pasteur (RIIP); Pasteur Institute of Iran; Le Reseau International des Instituts Pasteur (RIIP); Pasteur Institute of Iran; Tehran University of Medical Sciences; Babol University of Medical Sciences	Maleki-Ravasan, N; Tahghighi, A (corresponding author), Pasteur Inst Iran, Biotechnol Res Ctr, Malaria & Vector Res Grp, Tehran, Iran.; Maleki-Ravasan, N (corresponding author), Pasteur Inst Iran, Dept Parasitol, Tehran, Iran.; Tahghighi, A (corresponding author), Pasteur Inst Iran, Dept Clin Res, Lab Med Chem, Tehran, Iran.	naseh_maleki@yahoo.com; atahghighi2009@gmail.com		Karimian, Fateh/0000-0002-2576-1215; Maleki-Ravasan, Naseh/0000-0001-7209-5908	Pasteur Institute of Iran [1080]	Pasteur Institute of Iran	This research was financially supported by the Pasteur Institute of Iran (grant no. 1080 to NMR and AT).	Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a; Abd El-Kareem MSM, 2020, PROCESSES, V8, DOI 10.3390/pr8020128; ACME Resistance, 2018, ACME, V17, P1; Adams J AC, 2006, PELARGONIUMS HERB SO; AHMED KS, 2001, PAKISTAN J BIOL SCI, V4, P1371; Aktar Md Wasim, 2009, Interdiscip Toxicol, V2, P1, DOI 10.2478/v10102-009-0001-7; Amer A, 2006, PARASITOL RES, V99, P466, DOI 10.1007/s00436-006-0182-3; Anderasen MH, 2006, EMERGING RESISTANCE, P1; [Anonymous], 2018, FARSOTTAFRETTIR, V11, P1, DOI DOI 10.1186/s13071-017-2573-y; [Anonymous], 2015, J ENTOMOL ZOOL STUD; ANYANWU GI, 1993, ANN TROP MED PARASIT, V87, P269, DOI 10.1080/00034983.1993.11812766; Aqil M, 2007, DRUG DISCOV TODAY, V12, P1061, DOI 10.1016/j.drudis.2007.09.001; Balasubramani S, 2018, MICROB PATHOGENESIS, V125, P475, DOI 10.1016/j.micpath.2018.10.017; Balasubramani S, 2017, ENVIRON SCI POLLUT R, V24, P15125, DOI 10.1007/s11356-017-9118-y; Benelli G, 2017, PARASITOL INT, V66, P166, DOI 10.1016/j.parint.2017.01.012; Benelli G, 2016, INSECTS, V7, DOI 10.3390/insects7040052; Bilia AR, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/651593; Bird S., 2014, UPTODATE, V14, P339; Botas GD, 2017, MOLECULES, V22, DOI 10.3390/molecules22111990; Brucker RM, 2012, TRENDS ECOL EVOL, V27, P443, DOI 10.1016/j.tree.2012.03.011; Campolo O, 2018, J FOOD QUALITY, DOI 10.1155/2018/6906105; Charlwood B., 1991, MED AROMATIC PLANTS, P339; Chavshin Ali Reza, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P47, DOI 10.1016/S2221-1691(14)60207-0; Chen W, 2010, S AFR J BOT, V76, P643, DOI 10.1016/j.sajb.2010.05.008; Chrustek A, 2018, MEDICINA-LITHUANIA, V54, DOI 10.3390/medicina54040061; Collotta M, 2013, TOXICOLOGY, V307, P35, DOI 10.1016/j.tox.2013.01.017; COLUZZI M, 1973, Parassitologia (Rome), V15, P129; Coutinho-Abreu IV, 2010, PARASITOL INT, V59, P1, DOI 10.1016/j.parint.2009.10.002; Dada N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20367-4; Dehghan H, 2017, J ARTHROPOD-BORNE DI, V11, P515; Dhifi Wissal, 2016, Medicines (Basel), V3, DOI 10.3390/medicines3040025; Douglas AE, 2009, FUNCT ECOL, V23, P38, DOI 10.1111/j.1365-2435.2008.01442.x; Douglas AE, 2015, ANNU REV ENTOMOL, V60, P17, DOI 10.1146/annurev-ento-010814-020822; Duarte JL, 2015, REV BRAS FARMACOGN, V25, P189, DOI [10.1016/j.bjp.2015.02.010, 10.1016/j.bjp.2015.02.2010]; Echeverria Javier, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6020042; El-Wakeil NE, 2013, GESUNDE PFLANZ, V65, P125, DOI 10.1007/s10343-013-0308-3; Essid R, 2017, APPL MICROBIOL BIOT, V101, P6993, DOI 10.1007/s00253-017-8442-y; Gallardo A, 2012, J MED ENTOMOL, V49, P332, DOI 10.1603/ME11142; Giunti G, 2019, IND CROP PROD, V142, DOI 10.1016/j.indcrop.2019.111869; Gopinath T., 2019, SCI REP, V9, P1; Grigoraki L, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003771; Grisales N, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002438; Guimaraes AC, 2019, MOLECULES, V24, DOI 10.3390/molecules24132471; Hanari-Bojd AA, 2012, J VECTOR DIS, V49, P91; Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000209; Hennemann Julia, 2007, LINX, V57, P79; Hikal WM, 2017, COGENT BIOL, V3, DOI 10.1080/23312025.2017.1404274; Hoosh-Deghati H, 2017, J ARTHROPOD-BORNE DI, V11, P354; Ignasiak K, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1133-0; Isman MB, 2011, PHYTOCHEM REV, V10, P197, DOI 10.1007/s11101-010-9170-4; Jesus FLM, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/6756793; Karami M, 2016, J ARTHROPOD-BORNE DI, V10, P349; Karimian F, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-018-3273-y; Karimian F, 2014, JPN J INFECT DIS, V67, P361, DOI 10.7883/yoken.67.361; Karunamoorthi K, 2013, HEALTH SCOPE, V2, DOI 10.17795/jhealthscope-9840; Kaur S, 2011, Z NATURFORSCH C, V66, P260, DOI 10.5560/ZNC.2011.66c0260; Kostyukovsky M, 2002, PEST MANAG SCI, V58, P1101, DOI 10.1002/ps.548; Krishnan KS, 1961, VECTORS MALARIA INDI; Kumar Y, 2018, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01081; Lee H, 2018, PRIMARY CARE, V45, P393, DOI 10.1016/j.pop.2018.05.001; Lei CF, 2018, BMC PHARMACOL TOXICO, V19, DOI 10.1186/s40360-018-0250-1; Lorenzi V, 2009, ANTIMICROB AGENTS CH, V53, P2209, DOI 10.1128/AAC.00919-08; Luna EC, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6587150; Maleki-Ravasan N, 2019, MICROBIOLOGYOPEN, V8, DOI 10.1002/mbo3.777; Maleki-Ravasan N, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-014-0517-3; MANOUCHEHRI AV, 1976, TROP GEOGR MED, V28, P228; Matsuoka H, 2002, PARASITOL INT, V51, P17, DOI 10.1016/S1383-5769(01)00095-2; Mossa A. T. H., 2016, Journal of Environmental Science and Technology, V9, P354; MR4, 2014, METH AN RES MAN; Muller GC, 2008, J AM MOSQUITO CONTR, V24, P150, DOI 10.2987/8756-971X(2008)24[150:IPAMAS]2.0.CO;2; MULLA MS, 1994, J AM MOSQUITO CONTR, V10, P574; Nagpal BN, 2003, J MED ENTOMOL, V40, P747, DOI 10.1603/0022-2585-40.6.747; Niang EA, 2018, J TROP MED-US, V2018, DOI 10.1155/2018/1470459; Nisha Sogan, 2018, International Journal of Mosquito Research, V5, P1; Nollet LMR, 2017, H S GREEN PESTICIDES; Noman A, 2020, SCI TOTAL ENVIRON, V699, DOI 10.1016/j.scitotenv.2019.134181; Odriozola-Serrano Isabel, 2014, Front Nutr, V1, P24, DOI 10.3389/fnut.2014.00024; Oliveira AEMFM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145835; Opender Koul, 2008, Biopesticides International, V4, P63; Osanloo M, 2018, ENVIRON SCI POLLUT R, V25, P6466, DOI 10.1007/s11356-017-0822-4; Osanloo M, 2017, IND CROP PROD, V109, P214, DOI 10.1016/j.indcrop.2017.08.037; Oshaghi M.A., 2006, Pakistan Journal of Biological Sciences, V9, P294, DOI 10.3923/pjbs.2006.294.298; Otti O, 2015, INSECT SCI, V22, P325, DOI 10.1111/1744-7917.12183; Ozkara A, 2016, ENVIRONMENTAL HLTH R; Pavela R, 2018, IND CROP PROD, V113, P46, DOI 10.1016/j.indcrop.2018.01.021; Pavela R, 2016, TRENDS PLANT SCI, V21, P1000, DOI 10.1016/j.tplants.2016.10.005; PEIRIS HTR, 1990, B ENTOMOL RES, V80, P49, DOI 10.1017/S0007485300045910; Pereira FD, 2015, PHARM BIOL, V53, P228, DOI 10.3109/13880209.2014.913299; Pietri JE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207985; Regnault-Roger C, 2012, ANNU REV ENTOMOL, V57, P405, DOI 10.1146/annurev-ento-120710-100554; Rodgers FH, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006391; Roubos CR, 2014, BIOL CONTROL, V75, P28, DOI 10.1016/j.biocontrol.2014.01.006; Russell RJ, 2011, EVOL APPL, V4, P225, DOI 10.1111/j.1752-4571.2010.00175.x; RYAN MF, 1988, J CHEM ECOL, V14, P1965, DOI 10.1007/BF01013489; Sant'Anna MRV, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-329; Sendi J.J., 2014, RECENT PROGR MED PLA, P129; Sinka ME, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-89; Soltani A, 2013, J ARTHROPOD-BORNE DI, V7, P56; Sougoufara S, 2017, J VECTOR DIS, V54, P4; Srivastava AK, 2016, HLTH EFFECTS PESTICI; SUBBARAO SK, 1987, MED VET ENTOMOL, V1, P265, DOI 10.1111/j.1365-2915.1987.tb00353.x; Sugumar S, 2014, B ENTOMOL RES, V104, P393, DOI 10.1017/S0007485313000710; SUGUNA SG, 1992, MED VET ENTOMOL, V6, P84, DOI 10.1111/j.1365-2915.1992.tb00040.x; Swamy MK, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/3012462; Sweet W. C., 1937, Indian Medical Gazette, V72, P665; Tabari MA, 2017, RES VET SCI, V114, P36, DOI 10.1016/j.rvsc.2017.03.001; Tabbabi A, 2019, AFR HEALTH SCI, V19, P1361, DOI 10.4314/ahs.v19i1.8; Tahghighi A, 2019, ASIAN PAC J TROP BIO, V9, P168, DOI 10.4103/2221-1691.256730; Tusting LS, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008923.pub2; Vatandoost H, 2006, ACTA TROP, V97, P196, DOI 10.1016/j.actatropica.2005.11.002; Vatandoost H, 2012, EXP PARASITOL, V132, P470, DOI 10.1016/j.exppara.2012.09.010; Weiss B, 2011, TRENDS PARASITOL, V27, P514, DOI 10.1016/j.pt.2011.05.001; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO, 2013, HDB INT VECT MAN; WHO, 1999, WHO SPEC EV PUBL HLT; World Health Organization, 2005, WHOCDSWHOPESGCDPP200, P1; World Health Organization (WHO), 2009, TEM DRINK WAT US VEC, P1; Xia XF, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00025; Zaim M, 2000, MED VET ENTOMOL, V14, P1, DOI 10.1046/j.1365-2915.2000.00211.x; Zaini A, 1975, IRAN J PUBLIC HLTH, P114	120	4	4	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2021	16	2							e0246470	10.1371/journal.pone.0246470	http://dx.doi.org/10.1371/journal.pone.0246470			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG1VY	33556110	Green Published, gold			2023-01-03	WOS:000617379900047
J	Sutton, EC; DeRose, VJ				Sutton, Emily C.; DeRose, Victoria J.			Early nucleolar responses differentiate mechanisms of cell death induced by oxaliplatin and cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE I; DNA-DAMAGE; TRANSCRIPTION; ACTIVATION; REDISTRIBUTION; COMPONENTS; ADDUCTS; CX-5461; CYCLE; P53	Recent reports provide evidence that the platinum chemotherapeutic oxaliplatin causes cell death via ribosome biogenesis stress, while cisplatin causes cell death via the DNA damage response (DDR). Underlying differences in mechanisms that might initiate disparate routes to cell death by these two broadly used platinum compounds have not yet been carefully explored. Additionally, prior studies had demonstrated that cisplatin can also inhibit ribosome biogenesis. Therefore, we sought to directly compare the initial influences of oxaliplatin and cisplatin on nucleolar processes and on the DDR. Using pulse-chase experiments, we found that at equivalent doses, oxaliplatin but not cisplatin significantly inhibited ribosomal RNA (rRNA) synthesis by Pol I, but neither compound affected rRNA processing. Inhibition of rRNA synthesis occurred as early as 90 min after oxaliplatin treatment in A549 cells, concurrent with the initial redistribution of the nucleolar protein nucleophosmin (NPM1). We observed that the nucleolar protein fibrillarin began to redistribute by 6 h after oxaliplatin treatment and formed canonical nucleolar caps by 24 h. In cisplatin-treated cells, DNA damage, as measured by gamma H2AX immunofluorescence, was more extensive, whereas nucleolar organization was unaffected. Taken together, our results demonstrate that oxaliplatin causes early nucleolar disruption via inhibition of rRNA synthesis accompanied by NPM1 relocalization and subsequently causes extensive nucleolar reorganization, while cisplatin causes early DNA damage without significant nucleolar disruption. These data support a model in which, at clinically relevant doses, cisplatin kills cells via the canonical DDR, and oxaliplatin kills cells via ribosome biogenesis stress, specifically via rapid inhibition of rRNA synthesis.	[Sutton, Emily C.] Univ Oregon, Dept Biol, Eugene, OR 97403 USA; [Sutton, Emily C.; DeRose, Victoria J.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; [DeRose, Victoria J.] Univ Oregon, Dept Chem & Biochem, Eugene, OR 97403 USA	University of Oregon; University of Oregon; University of Oregon	DeRose, VJ (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.; DeRose, VJ (corresponding author), Univ Oregon, Dept Chem & Biochem, Eugene, OR 97403 USA.	derose@uoregon.edu		Sutton, Emily/0000-0002-9607-3890	National Science Foundation [CHE1710721, CHE1531189]; National Institutes of Health [T32 GM007759-29]	National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Science Foundation [CHE1710721 to V. J. D. and CHE1531189 for microscopy] and the National Institutes of Health [T32 GM007759-29 to E. C. S.].	Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Brodska B, 2016, J CELL BIOCHEM, V117, P1319, DOI 10.1002/jcb.25420; Bruno PM, 2020, P NATL ACAD SCI USA, V117, P4053, DOI 10.1073/pnas.1921649117; Bruno PM, 2017, NAT MED, V23, P461, DOI 10.1038/nm.4291; Burger K, 2013, RNA BIOL, V10, P1623, DOI 10.4161/rna.26214; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Bursac S, 2014, BBA-MOL BASIS DIS, V1842, P817, DOI 10.1016/j.bbadis.2013.08.014; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chaney SG, 2005, CRIT REV ONCOL HEMAT, V53, P3, DOI 10.1016/j.critrevonc.2004.08.008; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Gilder AS, 2011, MOL BIOL CELL, V22, P1070, DOI 10.1091/mbc.E10-08-0731; Haddach M, 2012, ACS MED CHEM LETT, V3, P602, DOI 10.1021/ml300110s; Hamdane N, 2015, ONCOTARGET, V6, P27519, DOI 10.18632/oncotarget.4823; Horky M, 2001, J CELL SCI, V114, P663; Jordan P, 1998, NUCLEIC ACIDS RES, V26, P2831, DOI 10.1093/nar/26.12.2831; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Korsholm LM, 2020, NUCLEIC ACIDS RES, V48, P9449, DOI 10.1093/nar/gkaa713; Kruhlak M, 2007, NATURE, V447, P730, DOI 10.1038/nature05842; Larsen DH, 2014, NAT CELL BIOL, V16, P792, DOI 10.1038/ncb3007; Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759; McDevitt CE, 2019, J BIOL INORG CHEM, V24, P899, DOI 10.1007/s00775-019-01707-9; McKeage MJ, 2001, BRIT J CANCER, V85, P1219, DOI 10.1054/bjoc.2001.2024; Nicolas E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11390; Ozdian T, 2017, J PROTEOMICS, V162, P73, DOI 10.1016/j.jprot.2017.05.005; Peltonen K, 2014, CANCER CELL, V25, P77, DOI 10.1016/j.ccr.2013.12.009; Peltonen K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012996; Pickard AJ, 2013, CHEMMEDCHEM, V8, P1441, DOI 10.1002/cmdc.201300262; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z; Scott DD, 2016, BIOCHEM CELL BIOL, V94, P419, DOI 10.1139/bcb-2016-0068; Shav-Tal Y, 2005, MOL BIOL CELL, V16, P2395, DOI 10.1091/mbc.e04-11-0992; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Sutton EC, 2019, J AM CHEM SOC, V141, P18411, DOI 10.1021/jacs.9b10319; Terenzi A, 2016, J INORG BIOCHEM, V165, P71, DOI 10.1016/j.jinorgbio.2016.06.021; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; Tsai RYL, 2014, FASEB J, V28, P3290, DOI 10.1096/fj.14-254680; van der Walt S, 2014, PEERJ, V2, DOI 10.7717/peerj.453; van Sluis M, 2017, CURR OPIN CELL BIOL, V46, P81, DOI 10.1016/j.ceb.2017.03.004; van Sluis M, 2015, GENE DEV, V29, P1151, DOI 10.1101/gad.260703.115; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wei M, 2001, J BIOL CHEM, V276, P38774, DOI 10.1074/jbc.M106374200; Wei T, 2018, CELL REP, V23, P404, DOI 10.1016/j.celrep.2018.03.066; Woods SJ, 2015, BBA-GENE REGUL MECH, V1849, P821, DOI 10.1016/j.bbagrm.2014.10.007; Woynarowski JM, 2000, MOL PHARMACOL, V58, P920, DOI 10.1124/mol.58.5.920; Woynarowski JM, 1998, MOL PHARMACOL, V54, P770, DOI 10.1124/mol.54.5.770; Yang K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13599; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h	50	8	8	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN-JUN	2021	296								100633	10.1016/j.jbc.2021.100633	http://dx.doi.org/10.1016/j.jbc.2021.100633			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TI5TQ	33819479	Green Published, gold			2023-01-03	WOS:000672866400604
J	Brice, P; de Kerviler, E; Friedberg, JW				Brice, Pauline; de Kerviler, Eric; Friedberg, Jonathan W.			Classical Hodgkin lymphoma	LANCET			English	Review							STEM-CELL TRANSPLANTATION; POSITRON-EMISSION-TOMOGRAPHY; EVENT-FREE SURVIVAL; LONG-TERM SURVIVAL; BRENTUXIMAB VEDOTIN; EARLY-STAGE; FOLLOW-UP; PHASE-II; RESPONSE ASSESSMENT; 1ST-LINE TREATMENT	Classical Hodgkin lymphoma is one of the more frequent lymphomas and is generally considered a highly curable disease with standard first-line chemotherapy and radiotherapy in some cases. Despite these outstanding results, major problems remain unresolved. First, there are still patients who will not be cured with front-line regimens and, second, many patients who are cured of classical Hodgkin lymphoma continue to die prematurely due to the late toxic effects of their therapy. Because the median age of patients with classical Hodgkin lymphoma is in the mid-30s, the disease's impact on the number of years lost from productive life is remarkable. In recent years, the gold standard of chemotherapy (often combined with radiotherapy) has changed, with the approval of immunotherapy mostly in relapse settings.	[Brice, Pauline] Univ Paris, Hop St Louis, AP HP, Dept Oncohaematol, F-75475 Paris 7, France; [de Kerviler, Eric] Univ Paris, Hop St Louis, AP HP, Dept Radiol, Paris, France; [Friedberg, Jonathan W.] Univ Rochester, Wilmot Canc Inst, Rochester, NY USA	Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Rochester	Brice, P (corresponding author), Univ Paris, Hop St Louis, AP HP, Dept Oncohaematol, F-75475 Paris 7, France.	pauline.brice@sls.aphp.fr						Aleman BMP, 2007, BLOOD, V109, P1878, DOI 10.1182/blood-2006-07-034405; Andre MPE, 2017, J CLIN ONCOL, V35, P1786, DOI 10.1200/JCO.2016.68.6394; Armand P, 2018, J CLIN ONCOL, V36, P1428, DOI 10.1200/JCO.2017.76.0793; Barrington SF, 2019, J CLIN ONCOL, V37, P1732, DOI 10.1200/JCO.18.01799; Barrington SF, 2014, J CLIN ONCOL, V32, P3048, DOI 10.1200/JCO.2013.53.5229; Bartlett NL, 2007, ANN ONCOL, V18, P1071, DOI 10.1093/annonc/mdm090; Baxstrom K, 2018, SUPPORT CARE CANCER, V26, P2361, DOI 10.1007/s00520-018-4072-x; Behringer K, 2013, J CLIN ONCOL, V31, P231, DOI 10.1200/JCO.2012.44.3721; Borchmann P, 2017, LANCET, V390, P2790, DOI 10.1016/S0140-6736(17)32134-7; Brice P, 2008, BRIT J HAEMATOL, V141, P3, DOI 10.1111/j.1365-2141.2008.06998.x; Brockelmann PJ, 2018, BLOOD, V131, P1666, DOI 10.1182/blood-2017-10-772665; Casasnovas RO, 2019, LANCET ONCOL, V20, P202, DOI 10.1016/S1470-2045(18)30784-8; Chen R, 2017, J CLIN ONCOL, V35, P2125, DOI 10.1200/JCO.2016.72.1316; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Cohen JB, 2017, BLOOD, V129, P561, DOI 10.1182/blood-2016-08-685073; Connors JM, 2018, NEW ENGL J MED, V378, P331, DOI 10.1056/NEJMoa1708984; de Kerviler E, 2012, BEST PRACT RES CL HA, V25, P29, DOI 10.1016/j.beha.2012.01.006; Deau B, 2018, BRIT J HAEMATOL, V181, P341, DOI 10.1111/bjh.15184; DEVNEY RB, 1984, J PEDIATR-US, V105, P223, DOI 10.1016/S0022-3476(84)80117-1; Duggan DB, 2003, J CLIN ONCOL, V21, P607, DOI 10.1200/JCO.2003.12.086; Eichenauer DA, 2018, ANN ONCOL, V29, P19, DOI 10.1093/annonc/mdy080; Eichenauer DA, 2017, LANCET ONCOL, V18, P1680, DOI 10.1016/S1470-2045(17)30696-4; Evens AM, 2018, J CLIN ONCOL, V36, P3015, DOI 10.1200/JCO.2018.79.0139; Federico M, 2009, J CLIN ONCOL, V27, P805, DOI 10.1200/JCO.2008.17.0910; Forero-Torres A, 2015, BLOOD, V126, P2798, DOI 10.1182/blood-2015-06-644336; Friedberg JW, 2017, BLOOD, V130, P2829, DOI 10.1182/blood-2017-06-787200; Gallamini A, 2014, HAEMATOLOGICA, V99, P1107, DOI 10.3324/haematol.2013.103218; Garcia-Sanz R, 2019, ANN ONCOL, V30, P612, DOI 10.1093/annonc/mdz009; Greaves P, 2013, J CLIN ONCOL, V31, P256, DOI 10.1200/JCO.2011.39.9881; Hagenbeek A, 2016, HAEMATOLOGICA, V101, P44; Hapgood G, 2016, J CLIN ONCOL, V34, P2493, DOI 10.1200/JCO.2015.65.4194; Harel S, 2011, HAEMATOL-HEMATOL J, V96, P1692, DOI 10.3324/haematol.2011.045856; Harris NL, 2000, MODERN PATHOL, V13, P193, DOI 10.1038/modpathol.3880035; Hay AE, 2013, ANN ONCOL, V24, P3065, DOI 10.1093/annonc/mdt389; Herrera AF, 2020, BLOOD, V136, DOI 10.1182/blood-2020-137451; Herrera AF, 2018, BLOOD, V131, P1183, DOI 10.1182/blood-2017-10-811224; Howell SJ, 2009, BRIT J CANCER, V101, P582, DOI 10.1038/sj.bjc.6605215; Johnson P, 2016, NEW ENGL J MED, V374, P2419, DOI 10.1056/NEJMoa1510093; Josting A, 2002, ANN ONCOL, V13, P1628, DOI 10.1093/annonc/mdf221; KAPLAN HS, 1971, CANCER RES, V31, P1811; Klimm B, 2013, ANN ONCOL, V24, P3070, DOI 10.1093/annonc/mdt413; Kumar A, 2016, BLOOD, V128, P1458, DOI 10.1182/blood-2016-03-703470; Lazarovici J, 2015, HAEMATOLOGICA, V100, P1579, DOI 10.3324/haematol.2015.133025; Liu Y, 2014, LEUKEMIA, V28, P2248, DOI 10.1038/leu.2014.201; Maraldo MV, 2014, PEDIATR BLOOD CANCER, V61, P717, DOI 10.1002/pbc.24861; Maraldo MV, 2015, LANCET HAEMATOL, V2, pE492, DOI 10.1016/S2352-3026(15)00153-2; Meignan M, 2009, LEUKEMIA LYMPHOMA, V50, P1257, DOI 10.1080/10428190903040048; Merryman RW, 2017, BLOOD, V129, P1380, DOI 10.1182/blood-2016-09-738385; Meyer RM, 2017, J CLIN ONCOL, V35, P1760, DOI 10.1200/JCO.2017.72.2611; Morschhauser F, 2008, J CLIN ONCOL, V26, P5980, DOI 10.1200/JCO.2007.15.5887; Moskowitz Alison J, 2019, Am Soc Clin Oncol Educ Book, V39, P477, DOI 10.1200/EDBK_238799; Moskowitz AJ, 2015, LANCET ONCOL, V16, P284, DOI 10.1016/S1470-2045(15)70013-6; Moskowitz CH, 2015, LANCET, V385, P1853, DOI 10.1016/S0140-6736(15)60165-9; Moskowitz CH, 2012, BLOOD, V119, P1665, DOI 10.1182/blood-2011-10-388058; Nabhan C, 2016, JAMA-J AM MED ASSOC, V315, P2115, DOI 10.1001/jama.2016.4913; Ng AK, 2002, BLOOD, V100, P1989, DOI 10.1182/blood-2002-02-0634; Ng AK, 2002, J CLIN ONCOL, V20, P2101, DOI 10.1200/JCO.2002.08.021; Ng AK, 2014, BLOOD, V124, P3373, DOI 10.1182/blood-2014-05-579193; Ng AK, 2013, J CLIN ONCOL, V31, P2282, DOI 10.1200/JCO.2012.46.5732; Peggs KS, 2011, J CLIN ONCOL, V29, P971, DOI 10.1200/JCO.2010.32.1711; Press OW, 2016, J CLIN ONCOL, V34, P2020, DOI 10.1200/JCO.2015.63.1119; Radford J, 2015, NEW ENGL J MED, V372, P1598, DOI 10.1056/NEJMoa1408648; Ramchandren R, 2019, J CLIN ONCOL, V37, P1997, DOI 10.1200/JCO.19.00315; Ramchandren R, 2019, CLIN CANCER RES, V25, P1718, DOI 10.1158/1078-0432.CCR-18-2435; Reichel J, 2015, BLOOD, V125, P1061, DOI 10.1182/blood-2014-11-610436; Roemer MGM, 2018, J CLIN ONCOL, V36, P942, DOI 10.1200/JCO.2017.77.3994; Santoro A, 2007, HAEMATOL-HEMATOL J, V92, P35, DOI 10.3324/haematol.10661; Sarkozy C, 2019, AM J SURG PATHOL, V43, P341, DOI 10.1097/PAS.0000000000001198; Sasse S, 2017, J CLIN ONCOL, V35, P1999, DOI 10.1200/JCO.2016.70.9410; Schmitz N, 2002, LANCET, V359, P2065, DOI 10.1016/S0140-6736(02)08938-9; Stamatoullas A, 2015, BRIT J HAEMATOL, V170, P179, DOI 10.1111/bjh.13419; Stephens DM, 2019, BLOOD, V134, P1238, DOI 10.1182/blood.2019000719; Sureda A, 2008, J CLIN ONCOL, V26, P455, DOI 10.1200/JCO.2007.13.2415; Thomsen H, 2015, EUR J HUM GENET, V23, P824, DOI 10.1038/ejhg.2014.184; Urayama KY, 2012, JNCI-J NATL CANCER I, V104, P240, DOI 10.1093/jnci/djr516; Van Den Neste E, 2013, HAEMATOLOGICA, V98, P1185, DOI 10.3324/haematol.2012.072090; van Nimwegen FA, 2014, J CLIN ONCOL, V32, P3257, DOI 10.1200/JCO.2013.54.4379; Vijenthira A, 2020, LANCET HAEMATOL, V7, pE146, DOI 10.1016/S2352-3026(19)30218-2; Viviani S, 2011, NEW ENGL J MED, V365, P203, DOI 10.1056/NEJMoa1100340; von Tresckow B, 2018, LANCET HAEMATOL, V5, pE462, DOI 10.1016/S2352-3026(18)30140-6; Wattson DA, 2014, INT J RADIAT ONCOL, V90, P344, DOI 10.1016/j.ijrobp.2014.06.013; Younes A, 2012, J CLIN ONCOL, V30, P2183, DOI 10.1200/JCO.2011.38.0410; Yung L, 2003, LANCET, V361, P943, DOI 10.1016/S0140-6736(03)12777-8; Zaucha JM, 2019, CANCER TREAT REV, V77, P44, DOI 10.1016/j.ctrv.2019.06.002	84	16	16	2	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2021	398	10310					1518	1527		10.1016/S0140-6736(20)32207-8	http://dx.doi.org/10.1016/S0140-6736(20)32207-8		OCT 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL9OA	33493434				2023-01-03	WOS:000710725800026
J	Fungtammasan, S; Phupong, V				Fungtammasan, Siraphat; Phupong, Vorapong			The effect of Moringa oleifera capsule in increasing breastmilk volume in early postpartum patients: A double-blind, randomized controlled trial	PLOS ONE			English	Article								Moringa oleifera is an herbal galactagogue that has been used to increase the volume of breastmilk. Few studies have evaluated the effect of Moringa oleifera in breastfeeding. There are conflicting data whether it can increase the volume of breastmilk or not. Thus, the objective of this study is to evaluate the efficacy of Moringa oleifera leaves in increasing the volume of breastmilk in early postpartum mothers. A randomized, double-blind, placebo-controlled trial will be conducted. The outcomes of this study will provide the data of Moringa oleifera as an herbal medication to increase the volume of breastmilk. This information will be used to increase the rate of exclusive breastfeeding for the first 6 months as recommended by the World Health Organization.	[Fungtammasan, Siraphat; Phupong, Vorapong] Chulalongkorn Univ, Fac Med, Dept Obstet & Gynecol, Placental Related Dis Res Unit, Bangkok, Thailand	Chulalongkorn University	Phupong, V (corresponding author), Chulalongkorn Univ, Fac Med, Dept Obstet & Gynecol, Placental Related Dis Res Unit, Bangkok, Thailand.	vorapong.p@chula.ac.th		Fungtammasan, Siraphat/0000-0003-0379-7150; Phupong, Vorapong/0000-0003-0151-9595	Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University	Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University(Chulalongkorn University)	We plan to apply for Internal research grant: Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University.	Boss Melinda, 2018, F1000Res, V7, DOI 10.12688/f1000research.14452.1; BUTTE NF, 1988, AM J CLIN NUTR, V47, P815, DOI 10.1093/ajcn/47.5.815; Espinosa-Kuo C, 2005, FIL FAM PHYS, V43, P26; Estrella M.C.P., 2000, PHILIPP J PEDIAT, V49, P3; Foong SC, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011505.pub2; Kamalifard M, 2018, INT J WOMEN HEAL REP, V6, P84, DOI 10.15296/ijwhr.2018.15; Kent JC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091144; King J., 2013, PHILIPP J PEDIAT, V61, P34; Othman N, 2014, PROCD SOC BEHV, V153, P199, DOI 10.1016/j.sbspro.2014.10.054; Paritakul P, 2016, BREASTFEED MED, V11, P361, DOI 10.1089/bfm.2016.0073; Stohs SJ, 2015, PHYTOTHER RES, V29, P796, DOI 10.1002/ptr.5325; Sumarni, 2020, ENFERM CLIN, V30, P99, DOI 10.1016/j.enfcli.2019.10.050; World Health Organization, 2017, PROTECTING PROMOTING	13	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2021	16	4							e0248950	10.1371/journal.pone.0248950	http://dx.doi.org/10.1371/journal.pone.0248950			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ8VV	33822798	Green Published, gold			2023-01-03	WOS:000637879100017
J	Tang, TC; Tham, E; Liu, XY; Yehl, K; Rovner, AJ; Yuk, H; de la Fuente-Nunez, C; Isaacs, FJ; Zhao, XH; Lu, TK				Tang, Tzu-Chieh; Tham, Eleonore; Liu, Xinyue; Yehl, Kevin; Rovner, Alexis J.; Yuk, Hyunwoo; de la Fuente-Nunez, Cesar; Isaacs, Farren J.; Zhao, Xuanhe; Lu, Timothy K.			Hydrogel-based biocontainment of bacteria for continuous sensing and computation	NATURE CHEMICAL BIOLOGY			English	Article							MICROORGANISMS; SYSTEM; GROWTH	Genetically modified microorganisms (GMMs) can enable a wide range of important applications including environmental sensing and responsive engineered living materials. However, containment of GMMs to prevent environmental escape and satisfy regulatory requirements is a bottleneck for real-world use. While current biochemical strategies restrict unwanted growth of GMMs in the environment, there is a need for deployable physical containment technologies to achieve redundant, multi-layered and robust containment. We developed a hydrogel-based encapsulation system that incorporates a biocompatible multilayer tough shell and an alginate-based core. This deployable physical containment strategy (DEPCOS) allows no detectable GMM escape, bacteria to be protected against environmental insults including antibiotics and low pH, controllable lifespan and easy retrieval of genomically recoded bacteria. To highlight the versatility of DEPCOS, we demonstrated that robustly encapsulated cells can execute useful functions, including performing cell-cell communication with other encapsulated bacteria and sensing heavy metals in water samples from the Charles River. A dual-layer encapsulation approach provides physical containment of genetically modified bacteria (especially when combined with chemical containment) while also protecting them from environmental stressors and maintaining their sensing functions.	[Tang, Tzu-Chieh; Tham, Eleonore; Yehl, Kevin; Lu, Timothy K.] MIT, Elect Res Lab, Synthet Biol Grp, Cambridge, MA 02139 USA; [Tang, Tzu-Chieh; Yehl, Kevin; Lu, Timothy K.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Tang, Tzu-Chieh] MIT, Media Lab, Mediated Matter Grp, Cambridge, MA 02139 USA; [Tham, Eleonore] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Liu, Xinyue; Yuk, Hyunwoo; Zhao, Xuanhe] MIT, Dept Mech Engn, Cambridge, MA 02139 USA; [Rovner, Alexis J.] Wyss Inst Biol Inspired Engn, Boston, MA USA; [Rovner, Alexis J.] Harvard Univ, Dept Genet, Harvard Med Sch, Boston, MA 02115 USA; [Isaacs, Farren J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Isaacs, Farren J.] Yale Univ, Syst Biol Inst, West Haven, CT USA; [Isaacs, Farren J.] Yale Univ, Dept Biomed Engn, New Haven, CT USA; [Zhao, Xuanhe] MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Lu, Timothy K.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Yehl, Kevin] Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA; [de la Fuente-Nunez, Cesar] Univ Penn, Dept Psychiat, Machine Biol Grp,Perelman Sch Med, Inst Biomed Informat,Inst Translat Med & Therapeu, Philadelphia, PA 19104 USA; [de la Fuente-Nunez, Cesar] Univ Penn, Dept Microbiol, Machine Biol Grp,Perelman Sch Med, Inst Biomed Informat,Inst Translat Med & Therapeu, Philadelphia, PA 19104 USA; [de la Fuente-Nunez, Cesar] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [de la Fuente-Nunez, Cesar] Univ Penn, Sch Engn & Appl Sci, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA; [de la Fuente-Nunez, Cesar] Univ Penn, Penn Inst Computat Sci, Philadelphia, PA 19104 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Yale University; Yale University; Yale University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University System of Ohio; Miami University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Tang, TC; Lu, TK (corresponding author), MIT, Elect Res Lab, Synthet Biol Grp, Cambridge, MA 02139 USA.; Tang, TC; Lu, TK (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Tang, TC (corresponding author), MIT, Media Lab, Mediated Matter Grp, Cambridge, MA 02139 USA.; Zhao, XH (corresponding author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA.; Zhao, XH (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.	zijaytang@gmail.com; zhaox@mit.edu; timlu@mit.edu	Zhao, Xuanhe/B-1532-2008; de la Fuente, Cesar/ABE-2369-2021; /L-4329-2016	Zhao, Xuanhe/0000-0001-5387-6186; de la Fuente, Cesar/0000-0002-2005-5629; /0000-0003-1710-9750; /0000-0002-1187-493X; Tang, Tzu-Chieh/0000-0002-6215-8714	National Institutes of Health (NIH) New Innovator Award [1DP2OD008435]; NIH National Centers for Systems Biology [1P50GM098792]; US Office of Naval Research [N00014-13-1-0424]; Defense Advanced Research Projects Agency [HR0011-15-C-0091]; NIH [1R01HL153857-01]; National Science Foundation [EFMA-1935291]; US Army Research Office through the Institute for Soldier Nanotechnologies at MIT [W911NF-13-D-0001]; Institute for Diabetes, Obesity, and Metabolism; Penn Mental Health AIDS Research Center of the University of Pennsylvania; National Institute of General Medical Sciences of the NIH [R35GM138201]; Defense Threat Reduction Agency [HDTRA11810041, HDTRA1-21-1-0014]; Abdul Latif Jameel Water and Food Systems Laboratory (J-WAFS) Graduate Student Fellowship	National Institutes of Health (NIH) New Innovator Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Centers for Systems Biology; US Office of Naval Research(Office of Naval Research); Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); US Army Research Office through the Institute for Soldier Nanotechnologies at MIT; Institute for Diabetes, Obesity, and Metabolism; Penn Mental Health AIDS Research Center of the University of Pennsylvania; National Institute of General Medical Sciences of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Defense Threat Reduction Agency(United States Department of DefenseDefense Threat Reduction Agency); Abdul Latif Jameel Water and Food Systems Laboratory (J-WAFS) Graduate Student Fellowship	We thank F. Farzadfard for proving the SCRIBE strains and M. Mimee for providing the heme sensing strain. We thank S. Lin, N. Roquet, R. Citorik and S. Lemire for useful discussions. T.K.L. is grateful for funding received from the National Institutes of Health (NIH) New Innovator Award (no. 1DP2OD008435), NIH National Centers for Systems Biology (no. 1P50GM098792), the US Office of Naval Research (no. N00014-13-1-0424) and the Defense Advanced Research Projects Agency (no. HR0011-15-C-0091). X.Z. is grateful for funding received from the NIH (no. 1R01HL153857-01), the National Science Foundation (no. EFMA-1935291) and the US Army Research Office through the Institute for Soldier Nanotechnologies at MIT (no. W911NF-13-D-0001). C.F.-N. holds a Presidential Professorship at the University of Pennsylvania, is a recipient of the Langer Prize by the AIChE Foundation and acknowledges funding from the Institute for Diabetes, Obesity, and Metabolism, the Penn Mental Health AIDS Research Center of the University of Pennsylvania, the National Institute of General Medical Sciences of the NIH (no. R35GM138201), and the Defense Threat Reduction Agency (no. HDTRA11810041 and HDTRA1-21-1-0014). T.-C.T. gratefully acknowledge the support from The Abdul Latif Jameel Water and Food Systems Laboratory (J-WAFS) Graduate Student Fellowship.	Anselmo AC, 2016, ADV MATER, V28, P9486, DOI 10.1002/adma.201603270; Atkinson J., 2007, MECH SOILS FDN, V2nd ed., DOI [10.1201/9781315273549, DOI 10.1201/9781315273549]; Belkin S, 2017, NAT BIOTECHNOL, V35, P308, DOI 10.1038/nbt.3791; Billiet T, 2012, BIOMATERIALS, V33, P6020, DOI 10.1016/j.biomaterials.2012.04.050; Bjerketorp J, 2006, CURR OPIN BIOTECH, V17, P43, DOI 10.1016/j.copbio.2005.12.005; Brocklehurst KR, 1999, MOL MICROBIOL, V31, P893, DOI 10.1046/j.1365-2958.1999.01229.x; Cevenini L, 2016, SENSOR ACTUAT B-CHEM, V225, P249, DOI 10.1016/j.snb.2015.11.017; Chan CTY, 2016, NAT CHEM BIOL, V12, P82, DOI [10.1038/NCHEMBIO.1979, 10.1038/nchembio.1979]; Chen MT, 2005, NAT BIOTECHNOL, V23, P1551, DOI 10.1038/nbt1162; Choi M, 2013, NAT PHOTONICS, V7, P987, DOI [10.1038/NPHOTON.2013.278, 10.1038/nphoton.2013.278]; Dana GV, 2012, NATURE, V483, P29, DOI 10.1038/483029a; de las Heras A, 2008, ENVIRON MICROBIOL, V10, P3305, DOI 10.1111/j.1462-2920.2008.01722.x; Epstein MM, 2016, TRENDS BIOTECHNOL, V34, P601, DOI 10.1016/j.tibtech.2016.04.013; Eun YJ, 2011, ACS CHEM BIOL, V6, P260, DOI 10.1021/cb100336p; Farrar K, 2014, PLANT BIOTECHNOL J, V12, P1193, DOI 10.1111/pbi.12279; Farzadfard F., 2020, EFFICIENT RETROELEME, DOI [10.1101/2020.02.21.958983, DOI 10.1101/2020.02.21.958983]; Farzadfard F, 2014, SCIENCE, V346, P825, DOI 10.1126/science.1256272; Golmohamadi M, 2013, CARBOHYD POLYM, V94, P82, DOI 10.1016/j.carbpol.2013.01.046; Hoffman AS, 2002, ADV DRUG DELIVER REV, V54, P3, DOI 10.1016/j.addr.2012.09.010; HOUGHTON LA, 1988, GASTROENTEROLOGY, V94, P1276, DOI 10.1016/0016-5085(88)90664-6; Jarup L, 2009, TOXICOL APPL PHARM, V238, P201, DOI 10.1016/j.taap.2009.04.020; Kearney CJ, 2013, NAT MATER, V12, P1004, DOI [10.1038/NMAT3758, 10.1038/nmat3758]; Kim BC, 2003, BIOSENS BIOELECTRON, V18, P1015, DOI 10.1016/S0956-5663(02)00220-8; Kim BJ, 2014, ANGEW CHEM INT EDIT, V53, P14443, DOI 10.1002/anie.201408454; Knierim C, 2014, MACROMOL BIOSCI, V14, P537, DOI 10.1002/mabi.201300398; Kong HJ, 2008, PHARM RES, V25, P1230, DOI 10.1007/s11095-007-9526-7; Lee JW, 2018, NAT CHEM BIOL, V14, P530, DOI 10.1038/s41589-018-0056-x; Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003; Li P, 2017, ACS APPL MATER INTER, V9, P22321, DOI 10.1021/acsami.7b07166; Li ZH, 2018, ADV MATER, V30, DOI 10.1002/adma.201803925; Liu XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08355-2; Liu XY, 2017, P NATL ACAD SCI USA, V114, P2200, DOI 10.1073/pnas.1618307114; Mimee M, 2018, SCIENCE, V360, P915, DOI 10.1126/science.aas9315; Pedersen MW, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2013.0383; Roggo C, 2017, CURR OPIN BIOTECH, V45, P24, DOI 10.1016/j.copbio.2016.11.023; Rovner AJ, 2015, NATURE, V518, P89, DOI 10.1038/nature14095; Sheth RU, 2018, NAT REV GENET, V19, P718, DOI 10.1038/s41576-018-0052-8; Singh JS, 2011, GENE, V480, P1, DOI 10.1016/j.gene.2011.03.001; Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409; Tang TC, 2021, NAT REV MATER, V6, P332, DOI 10.1038/s41578-020-00265-w; Tomovic NS, 2015, CHEM IND CHEM ENG Q, V21, P411, DOI 10.2298/CICEQ140228043T; Torres L, 2016, ESSAYS BIOCHEM, V60, P393, DOI 10.1042/EBC20160013; Valade D, 2013, J POLYM SCI POL CHEM, V51, P129, DOI 10.1002/pola.26311; Weiss R, 2004, SER SYST BIOL, P120; Wright O, 2015, ACS SYNTH BIOL, V4, P307, DOI 10.1021/sb500234s; Wright O, 2013, MICROBIOL-SGM, V159, P1221, DOI 10.1099/mic.0.066308-0; Zarket BC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00077-7; Zhang BB, 2016, ACS APPL MATER INTER, V8, P8939, DOI 10.1021/acsami.6b00191	49	49	49	43	195	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2021	17	6					724	731		10.1038/s41589-021-00779-6	http://dx.doi.org/10.1038/s41589-021-00779-6		APR 2021	8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	SI9YY	33820990	Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000636963200001
J	Skipper, CP; Boulware, DR				Skipper, Caleb P.; Boulware, David R.			Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Letter									[Skipper, Caleb P.; Boulware, David R.] Univ Minnesota, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Skipper, CP (corresponding author), Univ Minnesota, Minneapolis, MN 55455 USA.		Boulware, David R/GRS-0999-2022; Boulware, David R/AAF-7124-2021	Boulware, David R/0000-0002-4715-0060; 				Acosta-Elias J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01062; [Бойко А.Н. Boyko A.N.], 2020, [Неврология, нейропсихиатрия, психосоматика, Neurology, Neuropsychiatry, Psychosomatics, Nevrologiya, neiropsikhiatriya, psikhosomatika], V12, P82, DOI 10.14412/2074-2711-2020-3-82-86; Lee Z, 2021, AM J TROP MED HYG, V104, P35, DOI 10.4269/ajtmh.20-1320; Lenze EJ, 2020, JAMA-J AM MED ASSOC, V324, P2292, DOI 10.1001/jama.2020.22760; Mitja O, 2021, CLIN INFECT DIS, V73, pE4073, DOI 10.1093/cid/ciaa1009; Omrani AS, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100645; Zambrano LD, 2020, MMWR-MORBID MORTAL W, V69, P1641, DOI 10.15585/mmwr.mm6944e3	7	2	2	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					434	+		10.7326/L20-1426	http://dx.doi.org/10.7326/L20-1426			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX4DA	33721539				2023-01-03	WOS:000629294000007
J	Murbe, D; Kriegel, M; Lange, J; Schumann, L; Hartmann, A; Fleischer, M				Muerbe, Dirk; Kriegel, Martin; Lange, Julia; Schumann, Lukas; Hartmann, Anne; Fleischer, Mario			Aerosol emission of adolescents voices during speaking, singing and shouting	PLOS ONE			English	Article							AIR-FLOW; DYNAMICS	Since the outbreak of the COVID-19 pandemic, singing activities for children and young people have been strictly regulated with far-reaching consequences for music education in schools and ensemble and choir singing in some places. This is also due to the fact, that there has been no reliable data available on aerosol emissions from adolescents speaking, singing, and shouting. By utilizing a laser particle counter in cleanroom conditions we show, that adolescents emit fewer aerosol particles during singing than what has been known so far for adults. In our data, the emission rates ranged from 16 P/s to 267 P/s for speaking, 141 P/s to 1240 P/s for singing, and 683 P/s to 4332 P/s for shouting. The data advocate an adaptation of existing risk management strategies and rules of conduct for groups of singing adolescents, like gatherings in an educational context, e.g. singing lessons or choir rehearsals.	[Muerbe, Dirk; Fleischer, Mario] Charite Univ Med Berlin, Dept Audiol & Phoniatr, Berlin, Germany; [Kriegel, Martin; Lange, Julia; Schumann, Lukas; Hartmann, Anne] Tech Univ Berlin, Hermann Rietschel Inst, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Berlin	Fleischer, M (corresponding author), Charite Univ Med Berlin, Dept Audiol & Phoniatr, Berlin, Germany.	mario.fleischer@charite.de		Fleischer, Mario/0000-0002-6186-8298				Abuhegazy M, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0029118; Adams, 1993, A033205 CAL ENV PROT; Alsved M, 2020, AEROSOL SCI TECH, V54, P1245, DOI 10.1080/02786826.2020.1812502; American Society of Heating Refrigerating and Air-Conditioning Engineers, 2015, ASHRAE POSITION DOCU; Amis TC, 1999, J PHYSIOL-LONDON, V515, P293, DOI 10.1111/j.1469-7793.1999.293ad.x; Asadi S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38808-z; Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001; Buonanno G, 2020, ENVIRON INT, V141, DOI 10.1016/j.envint.2020.105794; Chao CYH, 2009, J AEROSOL SCI, V40, P122, DOI 10.1016/j.jaerosci.2008.10.003; Fleischer M., 2020, RISK ASSESSMENT REHE, DOI [10.14279/depositonce-10388, DOI 10.14279/DEPOSITONCE-10388]; Gregson Watson, 2020, COMP RESPIRABLE AERO, DOI [10.26434/chemrxiv.12789221.v1, DOI 10.26434/CHEMRXIV.12789221.V1]; Gupta JK, 2010, INDOOR AIR, V20, P31, DOI 10.1111/j.1600-0668.2009.00623.x; Hamner L, 2020, MMWR-MORBID MORTAL W, V69, P606, DOI 10.15585/mmwr.mm6919e6; Howard DM, 2010, LOGOP PHONIATR VOCO, V35, P81, DOI 10.3109/14015439.2010.482863; Jiang JJ, 2016, J VOICE, V30, P641, DOI 10.1016/j.jvoice.2015.07.018; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; McAllister A, 1998, J VOICE, V12, P166, DOI 10.1016/S0892-1997(98)80036-2; Mittal R, 2013, ANNU REV FLUID MECH, V45, P437, DOI 10.1146/annurev-fluid-011212-140636; Morawska L, 2009, J AEROSOL SCI, V40, P256, DOI 10.1016/j.jaerosci.2008.11.002; Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730; Murbe D, 2020, AEROSOL EMISSION IS, P1, DOI DOI 10.31219/OSF.IO/ZNJEH; Papineni R S, 1997, J Aerosol Med, V10, P105, DOI 10.1089/jam.1997.10.105; Wei JJ, 2015, BUILD ENVIRON, V93, P86, DOI 10.1016/j.buildenv.2015.06.018; Yang CQ, 2015, BUILD SIMUL-CHINA, V8, P551, DOI 10.1007/s12273-014-0227-6	24	29	29	4	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2021	16	2							e0246819	10.1371/journal.pone.0246819	http://dx.doi.org/10.1371/journal.pone.0246819			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH4UN	33566852	Green Published, gold			2023-01-03	WOS:000618271700032
J	Graham-Clarke, E; Rushton, A; Marriott, J				Graham-Clarke, Emma; Rushton, Alison; Marriott, John			A Delphi study to explore and gain consensus regarding the most important barriers and facilitators affecting physiotherapist and pharmacist non-medical prescribing	PLOS ONE			English	Article							UK	Non-medical prescribing was introduced into the United Kingdom to improve patient care, but early research indicated a third of Allied Health Professionals may not use their prescribing qualification. A previous literature review, highlighting factors influencing prescribing, identified only papers with nursing and pharmacy participants. This investigation explored consensus on factors affecting physiotherapist and pharmacist non-medical prescribers. A three round Delphi study was conducted with pharmacist and physiotherapist prescribers. Round One comprised information gathering on facilitators and barriers to prescribing participants had experienced, and underwent content analysis. This was followed by two sequential consensus seeking rounds with participants asked to rate the importance of statements to themselves. Consensus criteria were determined a priori, including median, interquartile range, percentage agreement and Kendall's Coefficient of Concordance (W). Statements reaching consensus were ranked for importance in Round Three and analysed to produce top ten ranks for all participants and for each professional group. Participants, recruited October 2018, comprised 24 pharmacists and 18 physiotherapists. In Round One, content analysis of 172 statements regarding prescribing influences revealed 24 themes. 127 statements were included in Round Two for importance rating (barriers = 68, facilitators = 59). After Round Two, 29 statements reached consensus (barriers = 1, facilitators = 28), with no further statements reaching consensus following Round Three. The highest ranked statement in Round Three overall was: "Being able to prescribe to patients is more effective and really useful working [in my area]". Medical support and improved patient care factors appeared the most important. Differences were noted between physiotherapist and pharmacist prescribers regarding the top ten ranked statements, for example team working which pharmacists ranked higher than physiotherapists. Differences may be explained by the variety of practice areas and relative newness of physiotherapy prescribing. Barriers appear to be post or person specific, whereas facilitators appear universal.	[Graham-Clarke, Emma; Marriott, John] Univ Birmingham, Coll Med & Dent Sci, Sch Pharm, Inst Clin Sci, Birmingham, W Midlands, England; [Rushton, Alison] Western Univ, Sch Phys Therapy, London, ON, Canada; [Rushton, Alison] Univ Birmingham, Coll Life & Environm Sci, Ctr Precis Rehabil Spinal Pain, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England	University of Birmingham; Western University (University of Western Ontario); University of Birmingham	Graham-Clarke, E (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Pharm, Inst Clin Sci, Birmingham, W Midlands, England.	EMG315@bham.ac.uk	Graham-Clarke, Emma/GZG-8429-2022; Graham-Clarke, Emma/U-1559-2019; Rushton, Alison/V-1260-2017	Graham-Clarke, Emma/0000-0001-5657-778X; Rushton, Alison/0000-0001-8114-7669				[Anonymous], 1998, BEST PRACTICE EVIDEN, V2, P1; [Anonymous], 2016, PRESCR SURV REP, P54; Campbell SM, 2001, J CLIN PHARM THER, V26, P5, DOI 10.1046/j.1365-2710.2001.00331.x; Courtenay M, 2008, J ADV NURS, V61, P291, DOI 10.1111/j.1365-2648.2007.04512.x; Courtenay M, 2007, INT J NURS STUD, V44, P1093, DOI 10.1016/j.ijnurstu.2006.04.005; Courtenay M, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-138; Department of Health, 1999, REV PRESCR SUPPL ADM; Department of Health, 2006, CAR HOM IND PHARM PR; Department of Health, 2005, 4941 DEP HLTH; Dorer, 2010, EVALUATION NURSE PHA; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Graham-Clarke E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214630; Graham-Clarke E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196471; Hacking S, 2010, EVALUATION SCOPE PRA; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Hasson F, 2011, TECHNOL FORECAST SOC, V78, P1695, DOI 10.1016/j.techfore.2011.04.005; Health & Care Professions Council, PHYS 2015; Hicks C. M., 2009, RES METHODS CLIN THE; Holey EA, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-52; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Hung HL, 2008, EVAL PROGRAM PLANN, V31, P191, DOI 10.1016/j.evalprogplan.2008.02.005; Junger S, 2017, PALLIATIVE MED, V31, P684, DOI 10.1177/0269216317690685; Keeney S, 2006, J ADV NURS, V53, P205, DOI 10.1111/j.1365-2648.2006.03716.x; Keeney S, 2011, DELPHI TECHNIQUE NUR; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; McColl E, 2001, Health Technol Assess, V5, P1; McMillan SS, 2016, INT J CLIN PHARM-NET, V38, P655, DOI 10.1007/s11096-016-0257-x; Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y; Pope C., 2007, SYNTHESIZING QUALITA; Ritchie J, 2014, SOC JUSTICE, P111; Rushton AB, 2014, MANUAL THER, V19, P445, DOI 10.1016/j.math.2014.04.013; Schmidt RC, 1997, DECISION SCI, V28, P763, DOI 10.1111/j.1540-5915.1997.tb01330.x; Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048; von der Gracht HA, 2012, TECHNOL FORECAST SOC, V79, P1525, DOI 10.1016/j.techfore.2012.04.013; Weiss M.C., 2006, EXPLORING INNOVATION; Wiangkham T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011764; Zambaldi M, 2017, BRIT J SPORT MED, V51, P1221, DOI 10.1136/bjsports-2016-097131	37	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2021	16	2							e0246273	10.1371/journal.pone.0246273	http://dx.doi.org/10.1371/journal.pone.0246273			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QF2NJ	33529197	Green Published, gold			2023-01-03	WOS:000616736200038
J	Burke, D				Burke, David			Changing Hand Color after Carpal Tunnel Injection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Burke, David] Emory Univ, Sch Med, Atlanta, GA 30322 USA	Emory University	Burke, D (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30322 USA.	dburke2@emory.edu							0	0	0	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	2021	384	4					362	362		10.1056/NEJMicm2005527	http://dx.doi.org/10.1056/NEJMicm2005527			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QA8RR	33503691				2023-01-03	WOS:000613710400012
J	Veiga, VC; Prats, JAGG; Farias, DLC; Rosa, RG; Dourado, LK; Zampieri, FG; Machado, FR; Lopes, RD; Berwanger, O; Azevedo, LCP; Avezum, A; Lisboa, TC; Rojas, SSO; Coelho, JC; Leite, RT; Carvalho, JC; Andrade, LEC; Sandes, AF; Pintao, MCT; Castro, CG; Santos, SV; de Almeida, TML; Costa, AN; Gebara, OCE; de Freitas, FGR; Pacheco, ES; Machado, DJB; Martin, J; Conceicao, FG; Siqueira, SRR; Damiani, LP; Ishihara, LM; Schneider, D; de Souza, D; Cavalcanti, AB; Scheinberg, P				Veiga, Viviane C.; Prats, Joao A. G. G.; Farias, Danielle L. C.; Rosa, Regis G.; Dourado, Leticia K.; Zampieri, Fernando G.; Machado, Flavia R.; Lopes, Renato D.; Berwanger, Otavio; Azevedo, Luciano C. P.; Avezum, Alvaro; Lisboa, Thiago C.; Rojas, Salomon S. O.; Coelho, Juliana C.; Leite, Rodrigo T.; Carvalho, Julio C.; Andrade, Luis E. C.; Sandes, Alex F.; Pintao, Maria C. T.; Castro, Claudio G., Jr.; Santos, Sueli V.; de Almeida, Thiago M. L.; Costa, Andre N.; Gebara, Otavio C. E.; Rezende de Freitas, Flavio G.; Pacheco, Eduardo S.; Machado, David J. B.; Martin, Josiane; Conceicao, Fabio G.; Siqueira, Suellen R. R.; Damiani, Lucas P.; Ishihara, Luciana M.; Schneider, Daniel; de Souza, Denise; Cavalcanti, Alexandre B.; Scheinberg, Phillip		Coalition Covid-19 Brazil VI	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEVERE COVID-19; CYTOKINE STORM; IL-6	OBJECTIVE To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19). DESIGN Randomised, open label trial. SETTING Nine hospitals in Brazil, 8 May to 17 July 2020. PARTICIPANTS Adults with confirmed covid-19 who were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two serum biomarkers (C reactive protein, D dimer, lactate dehydrogenase, or ferritin). The data monitoring committee recommended stopping the trial early, after 129 patients had been enrolled, because of an increased number of deaths at 15 days in the tocilizumab group. INTERVENTIONS Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65) versus standard care alone (n=64). MAIN OUTCOME MEASURE The primary outcome, clinical status measured at 15 days using a seven level ordinal scale, was analysed as a composite of death or mechanical ventilation because the assumption of odds proportionality was not met. RESULTS A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed follow-up. All patients in the tocilizumab group and two in the standard care group received tocilizumab. 18 of 65 (28%) patients in the tocilizumab group and 13 of 64 (20%) in the standard care group were receiving mechanical ventilation or died at day 15 (odds ratio 1.54, 95% confidence interval 0.66 to 3.66; P=0.32). Death at 15 days occurred in 11 (17%) patients in the tocilizumab group compared with 2 (3%) in the standard care group (odds ratio 6.42, 95% confidence interval 1.59 to 43.2). Adverse events were reported in 29 of 67 (43%) patients who received tocilizumab and 21 of 62 (34%) who did not receive tocilizumab. CONCLUSIONS In patients with severe or critical covid-19, tocilizumab plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality	[Veiga, Viviane C.; Prats, Joao A. G. G.; Farias, Danielle L. C.; Rojas, Salomon S. O.; Coelho, Juliana C.; Leite, Rodrigo T.; Carvalho, Julio C.; Scheinberg, Phillip] BP A Beneficencia Portuguesa Sao Paulo, Rua Maestro Cardim 769-Bela Vista, BR-01323001 Sao Paulo, SP, Brazil; [Veiga, Viviane C.; Rosa, Regis G.; Zampieri, Fernando G.; Machado, Flavia R.; Azevedo, Luciano C. P.; Lisboa, Thiago C.; Cavalcanti, Alexandre B.] Brazilian Res Intens Care Network BRICNet, Sao Paulo, Brazil; [Rosa, Regis G.; Schneider, Daniel; de Souza, Denise] Hosp Moinhos Vento, Porto Alegre, RS, Brazil; [Dourado, Leticia K.; Zampieri, Fernando G.; Lisboa, Thiago C.; Santos, Sueli V.; Damiani, Lucas P.; Cavalcanti, Alexandre B.] HCor Res Inst, Sao Paulo, Brazil; [Machado, Flavia R.; Lisboa, Thiago C.; de Almeida, Thiago M. L.] Univ Fed Sao Paulo, Pain & Intens Care Dept, Anesthesiol, Sao Paulo, Brazil; [Lopes, Renato D.] Duke Univ, Duke Clin, Res Inst, Med Ctr, Durham, NC USA; [Lopes, Renato D.] Brazilian Clin Res Inst, Sao Paulo, Brazil; [Berwanger, Otavio; Castro, Claudio G., Jr.] Acad Res Org, Hosp Israelita Albert Einstein, Sao Paulo, Brazil; [Azevedo, Luciano C. P.] Hosp Sirio Libanes, Sao Paulo, Brazil; [Avezum, Alvaro] Internat Res Ctr Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil; [Andrade, Luis E. C.; Sandes, Alex F.; Pintao, Maria C. T.] Fleury Med & Hlth Labs, Grp Fleury, Sao Paulo, Brazil; [Castro, Claudio G., Jr.] Santa Casa Porto Alegre, Porto Alegre, RS, Brazil; [Gebara, Otavio C. E.] Hosp Santa Paula, Sao Paulo, Brazil; [Rezende de Freitas, Flavio G.; Pacheco, Eduardo S.] Hosp SEPACO, Sao Paulo, Brazil; [Machado, David J. B.; Martin, Josiane; Conceicao, Fabio G.; Siqueira, Suellen R. R.] Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil; [Damiani, Lucas P.; Ishihara, Luciana M.] Estatikos Consultoria Estatist, Sao Paulo, Brazil	Hospital do Coracao - HCor; Universidade Federal de Sao Paulo (UNIFESP); Duke University; Hospital Israelita Albert Einstein; Hospital Sirio Libanes; FLEURY GROUP	Veiga, VC (corresponding author), BP A Beneficencia Portuguesa Sao Paulo, Rua Maestro Cardim 769-Bela Vista, BR-01323001 Sao Paulo, SP, Brazil.	viviane.veiga@bp.org.br	Lisboa, Thiago/W-2973-2019; Azevedo, Luciano CP/H-2652-2012; Gebara, Otavio C. E./D-1542-2013; Chaves Coelho, Juliana/Q-2413-2016	Lisboa, Thiago/0000-0003-4306-2212; Azevedo, Luciano CP/0000-0001-6759-3910; Gebara, Otavio C. E./0000-0003-4089-3520; Prats, Joao/0000-0002-8084-0602; Veiga, Viviane/0000-0002-0287-3601; Chaves Coelho, Juliana/0000-0001-8781-7627	Fleury Laboratory in Sao Paulo, Brazil	Fleury Laboratory in Sao Paulo, Brazil	This trial was funded by the hospitals and research institutes participating in the Coalition covid-19 Brazil. The exploratory laboratory analysis was conducted and funded by Fleury Laboratory in Sao Paulo, Brazil. Instituto Votorantim provided a donation for the purchase of tocilizumab for this study. It had no role in the design of the trial, the conduct, the analysis, or the decision to submit the manuscript for publication.	Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021; Canziani LM, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102511; Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695; Farias Danielle Leao Cordeiro de, 2020, Rev Bras Ter Intensiva, V32, P337, DOI 10.5935/0103-507X.20200060; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2020, MEDRXIV, DOI [10.1101/2020.12.10.20245944, DOI 10.1101/2020.12.10.20245944]; Jones L, 2020, BBC NEWS; Kewan T, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100418; Klopfenstein T, 2020, MED MALADIES INFECT, V50, P397, DOI 10.1016/j.medmal.2020.05.001; Laguna-Goya R, 2020, J ALLERGY CLIN IMMUN, V146, P799, DOI 10.1016/j.jaci.2020.07.009; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Langer-Gould A, 2020, INT J INFECT DIS, V99, P291, DOI 10.1016/j.ijid.2020.07.081; Lee K, 2009, GLOB INST, P1; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Moreno-Perez O, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102523; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846; Petrak RM, 2020, EARLY TOCILIZUMAB DO, DOI [10.1101/2020.10.27.20211433, DOI 10.1101/2020.10.27.20211433]; Quartuccio L, 2020, J MED VIROL, V92, P2852, DOI 10.1002/jmv.26149; R Core Team, 2020, R LANG ENV STAT COMP; Rosas I., 2020, TOCILIZUMAB HOSP PAT, DOI [10.1101/2020.08.27.20183442, DOI 10.1101/2020.08.27.20183442]; Rose-John S, 2017, NAT REV RHEUMATOL, V13, P399, DOI 10.1038/nrrheum.2017.83; Rossotti R, 2020, J INFECTION, V81, pE11, DOI 10.1016/j.jinf.2020.07.008; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Scott LJ, 2017, DRUGS, V77, P1865, DOI 10.1007/s40265-017-0829-7; Somers EC, 2021, CLIN INFECT DIS, V73, pE445, DOI [10.1093/cid/ciaa954, 10.1101/2020.05.29.20117358]; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Tomasiewicz K, 2021, EXPERT REV ANTI-INFE, V19, P93, DOI 10.1080/14787210.2020.1800453; Vaninov Natalie, 2020, Nat Rev Immunol, V20, P277, DOI 10.1038/s41577-020-0305-6; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	41	210	214	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 20	2021	372								n84	10.1136/bmj.n84	http://dx.doi.org/10.1136/bmj.n84			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC0MY	33472855	Green Published, hybrid			2023-01-03	WOS:000721715800001
J	Chen, EM; Goold, S; Harrison, S; Ali, I; Makki, I; Kent, SS; Shuman, AG				Chen, Emily; Goold, Susan; Harrison, Sam; Ali, Iman; Makki, Ibtihal; Kent, Stanley S.; Shuman, Andrew G.			Drug shortage management: A qualitative assessment of a collaborative approach	PLOS ONE			English	Article							NATIONAL-SURVEY; CANCER; IMPACT	Drug shortages frequently and persistently affect healthcare institutions, posing formidable financial, logistical, and ethical challenges. Despite plentiful evidence characterizing the impact of drug shortages, there is a remarkable dearth of data describing current shortage management practices. Hospitals within the same state or region may not only take different approaches to shortages but may be unaware of shortages proximate facilities are facing. Our goal is to explore how hospitals in Michigan handle drug shortages to assess potential need for comprehensive drug shortage management resources. We conducted semi-structured interviews with diverse stakeholders throughout the state to describe experiences managing drug shortages, approaches to recent shortages, openness to inter-institutional engagement, ideas for a shared resource, and potential obstacles to implementation. To solicit additional feedback on ideas for a shared resource gathered from the interviews, we held focus groups with pharmacists, physicians, ethicists, and community representatives. Among participants representing a heterogeneous sample of institutions, three themes were consistent: (1) numerous drug shortage strategies occurring simultaneously; (2) inadequate resources and lead time to proactively manage shortages; and (3) interest in, but varied attitudes toward, a collaborative approach. These data provide insight to help develop and test a shared drug shortage management resource for enhancing fair allocation of scarce drugs. A shared resource may help institutions adopt accepted best practices and more efficiently access or share finite resources in times of shortage.	[Chen, Emily; Kent, Stanley S.] Michigan Med, Dept Pharm, Ann Arbor, MI USA; [Goold, Susan; Harrison, Sam; Ali, Iman; Shuman, Andrew G.] Univ Michigan, Med Sch, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA; [Makki, Ibtihal] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA; [Shuman, Andrew G.] Michigan Med, Dept Otolaryngol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Shuman, AG (corresponding author), Univ Michigan, Med Sch, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA.; Shuman, AG (corresponding author), Michigan Med, Dept Otolaryngol, Ann Arbor, MI 48109 USA.	shumana@med.umich.edu			Blue Cross Blue Shield of Michigan Foundation [002652.II]	Blue Cross Blue Shield of Michigan Foundation	This research was funded by the Blue Cross Blue Shield of Michigan Foundation (grant number: 002652.II): https://www.bcbsm.com/foundation/index.html.The sponsor had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2020, D444220 ASTM; [Anonymous], 2017, D250017A ASTM; [Anonymous], 2011, I SAFE MEDICATION PR; [Anonymous], 2013, PLANT LIST WORKING L; Beck JC, 2017, WORLD J CLIN ONCOL, V8, P336, DOI 10.5306/wjco.v8.i4.336; Bogaert P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125691; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Center for Drug Evaluation and Research, 2018, STAT REV BLA 761041; Croatian Dental Chamber, 2018, D66418E2 ASTM; Decamp Matthew, 2014, Pediatrics, V133, pe716, DOI 10.1542/peds.2013-2946; Fins JJ., 2012, ITS WHO YOU KNOW COM, V42, P12; Fox Erin R, 2018, Am J Health Syst Pharm, V75, P1742, DOI 10.2146/ajhp180441; Fox ER, 2014, MAYO CLIN PROC, V89, P361, DOI 10.1016/j.mayocp.2013.11.014; Goold S, 2016, PROG COMM HLTH PARTN, V10, P515, DOI 10.1353/cpr.2016.0059; Gray A, 2012, B WORLD HEALTH ORGAN, V90, P158, DOI 10.2471/BLT.11.101303; Hantel A, 2019, JAMA INTERN MED, V179, P710, DOI 10.1001/jamainternmed.2018.8251; McBride A, 2013, AM J HEALTH-SYST PH, V70, P609, DOI 10.2146/ajhp120563; McLaughlin M, 2013, J MANAGE CARE PHARM, V19, P783, DOI 10.18553/jmcp.2013.19.9.783; Metzger ML, 2012, NEW ENGL J MED, V367, P2461, DOI 10.1056/NEJMp1212468; Peters G., 2019, I THEORIES POLITICAL; Phuong JM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215837; Shuman A, 2020, ONCOLOGIST, V25, P274, DOI 10.1634/theoncologist.2019-1010; Shuman AG, 2020, ANN AM THORAC SOC, V17, P928, DOI 10.1513/AnnalsATS.202004-362VP; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Ventola C Lee, 2011, P T, V36, P740	25	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	4							e0243870	10.1371/journal.pone.0243870	http://dx.doi.org/10.1371/journal.pone.0243870			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR0PU	33891609	Green Published, gold			2023-01-03	WOS:000642811900028
J	Mathur, R; Rentsch, CT; Morton, CE; Hulme, WJ; Schultze, A; MacKenna, B; Eggo, RM; Bhaskaran, K; Wong, AYS; Williamson, EJ; Forbes, H; Wing, K; McDonald, HI; Bates, C; Bacon, S; Walker, AJ; Evans, D; Inglesby, P; Mehrkar, A; Curtis, HJ; DeVito, NJ; Croker, R; Drysdale, H; Cockburn, J; Parry, J; Hester, F; Harper, S; Douglas, IJ; Tomlinson, L; Evans, SJW; Grieve, R; Harrison, D; Rowan, K; Khunti, K; Chaturvedi, N; Smeeth, L; Ben Goldacre				Mathur, Rohini; Rentsch, Christopher T.; Morton, Caroline E.; Hulme, William J.; Schultze, Anna; MacKenna, Brian; Eggo, Rosalind M.; Bhaskaran, Krishnan; Wong, Angel Y. S.; Williamson, Elizabeth J.; Forbes, Harriet; Wing, Kevin; McDonald, Helen, I; Bates, Chris; Bacon, Seb; Walker, Alex J.; Evans, David; Inglesby, Peter; Mehrkar, Amir; Curtis, Helen J.; DeVito, Nicholas J.; Croker, Richard; Drysdale, Henry; Cockburn, Jonathan; Parry, John; Hester, Frank; Harper, Sam; Douglas, Ian J.; Tomlinson, Laurie; Evans, Stephen J. W.; Grieve, Richard; Harrison, David; Rowan, Kathy; Khunti, Kamlesh; Chaturvedi, Nishi; Smeeth, Liam; Ben Goldacre		OpenSAFELY Collaborative	Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform	LANCET			English	Article							RACE	Background COVID-19 has disproportionately affected minority ethnic populations in the UK. Our aim was to quantify ethnic differences in SARS-CoV-2 infection and COVID-19 outcomes during the first and second waves of the COVID-19 pandemic in England. Methods We conducted an observational cohort study of adults (aged >= 18 years) registered with primary care practices in England for whom electronic health records were available through the OpenSAFELY platform, and who had at least 1 year of continuous registration at the start of each study period (Feb 1 to Aug 3, 2020 [wave 1], and Sept 1 to Dec 31, 2020 [wave 2]). Individual-level primary care data were linked to data from other sources on the outcomes of interest: SARS-CoV-2 testing and positive test results and COVID-19-related hospital admissions, intensive care unit (ICU) admissions, and death. The exposure was self-reported ethnicity as captured on the primary care record, grouped into five high-level census categories (White, South Asian, Black, other, and mixed) and 16 subcategories across these five categories, as well as an unknown ethnicity category. We used multivariable Cox regression to examine ethnic differences in the outcomes of interest. Models were adjusted for age, sex, deprivation, clinical factors and comorbidities, and household size, with stratification by geographical region. Findings Of 17 288 532 adults included in the study (excluding care home residents), 10 877 978 (62.9%) were White, 1 025 319 (5.9%) were South Asian, 340 912 (2. 0%) were Black, 170 484 (1.0%) were of mixed ethnicity, 320 788 (1.9%) were of other ethnicity, and 4 553 051 (26.3%) were of unknown ethnicity. In wave 1, the likelihood of being tested for SARS-CoV-2 infection was slightly higher in the South Asian group (adjusted hazard ratio 1.08 [95% CI 1.07-1.09]), Black group (1.08 [1.06-1 .09]), and mixed ethnicity group (1. 04 [1. 02-1.05]) and was decreased in the other ethnicity group (0.77 [0.76-0.78]) relative to the White group. The risk of testing positive for SARS-CoV-2 infection was higher in the South Asian group (1.99 [1.94-2.04]), Black group (1.69 [1.62-1. 77]), mixed ethnicity group (1.49 [1.39-1. 59]), and other ethnicity group (1. 20 [1 .14-1.28]). Compared with the White group, the four remaining high-level ethnic groups had an increased risk of COVID-19-related hospitalisation (South Asian group 1.48 [1 .41-1.55], Black group 1.78 [1.67-1.90], mixed ethnicity group 1.63 [1. 45-1.83], other ethnicity group 1.54 [1.41-1.69]), COVID-19-related ICU admission (2.18 [1.92-2.48], 3.12 [2. 65-3.67], 2.96 [2. 26-3.87], 3.18 [2.58-3.93]), and death (1.26 [1.15-1 .37], 1.51 [1.31-1.71], 1.41 [1.11-1.81], 1.22 [1.00-1.48]). In wave 2, the risks of hospitalisation, ICU admission, and death relative to the White group were increased in the South Asian group but attenuated for the Black group compared with these risks in wave 1. Disaggregation into 16 ethnicity groups showed important heterogeneity within the five broader categories. Interpretation Some minority ethnic populations in England have excess risks of testing positive for SARS-CoV-2 and of adverse COVID-19 outcomes compared with the White population, even after accounting for differences in sociodemographic, clinical, and household characteristics. Causes are likely to be multifactorial, and delineating the exact mechanisms is crucial. Tackling ethnic inequalities will require action across many fronts, including reducing structural inequalities, addressing barriers to equitable care, and improving uptake of testing and vaccination. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.	[Mathur, Rohini; Rentsch, Christopher T.; Schultze, Anna; Bhaskaran, Krishnan; Wong, Angel Y. S.; Forbes, Harriet; Douglas, Ian J.; Tomlinson, Laurie; Smeeth, Liam] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1E 7HT, England; [Williamson, Elizabeth J.; Evans, Stephen J. W.] London Sch Hyg & Trop Med, Dept Med Stat, London, England; [Eggo, Rosalind M.; McDonald, Helen, I] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Grieve, Richard] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England; [Morton, Caroline E.; Hulme, William J.; MacKenna, Brian; Wing, Kevin; Bacon, Seb; Walker, Alex J.; Evans, David; Inglesby, Peter; Mehrkar, Amir; Curtis, Helen J.; DeVito, Nicholas J.; Croker, Richard; Drysdale, Henry; Ben Goldacre] Univ Oxford, DataLab, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [McDonald, Helen, I] Natl Inst Hlth Res, Hlth Protect Res Unit Immunisat, London, England; [Bates, Chris; Cockburn, Jonathan; Parry, John; Hester, Frank; Harper, Sam] TPP, Leeds, W Yorkshire, England; [Harrison, David; Rowan, Kathy] Intens Care Natl Audit & Res Ctr, London, England; [Khunti, Kamlesh] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England; [Chaturvedi, Nishi] UCL, Med Res Council Unit Lifelong Hlth & Ageing, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Oxford; Intensive Care National Audit & Research Centre; University of Leicester; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of London; University College London	Mathur, R (corresponding author), London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1E 7HT, England.	Rohini.mathur@lshtm.ac.uk	/ABC-9527-2021; DeVito, Nicholas J./Q-5952-2017; Harrison, David A/O-4355-2018; Smeeth, Liam/X-5862-2018; Wing, Kevin/I-7807-2015	DeVito, Nicholas J./0000-0001-8286-1995; Harrison, David A/0000-0002-9002-9098; Smeeth, Liam/0000-0002-9168-6022; Evans, Stephen/0000-0002-1474-2596; Bhaskaran, Krishnan/0000-0001-5364-8757; Forbes, Harriet/0000-0001-6888-2212; Grieve, Richard/0000-0001-8899-1301; Khunti, Kamlesh/0000-0003-2343-7099; Hulme, William/0000-0002-9162-4999; McDonald, Helen/0000-0003-0576-2015; Rowan, Kathryn/0000-0001-8217-5602; Wing, Kevin/0000-0003-2335-9641; Tomlinson, Laurie/0000-0001-8848-9493	UK Medical Research Council (MRC) [MR/V015737/1]; Wellcome Trust [201375/Z/16/Z]; NIHR Oxford Biomedical Research Centre; NIHR Applied Research Collaboration Oxford and Thames Valley; Mohn-Westlake Foundation; NHS England; Health Foundation; BG's grants; GlaxoSmithKline; Sir Henry Dale fellowship - Wellcome; Sir Henry Dale fellowship - Royal Society; Public Health England; LSHTM; British Heart Foundation; MRC; NIHR; Health Data Research UK; UK Research and Innovation fellowship	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Applied Research Collaboration Oxford and Thames Valley; Mohn-Westlake Foundation; NHS England; Health Foundation; BG's grants; GlaxoSmithKline(GlaxoSmithKline); Sir Henry Dale fellowship - Wellcome; Sir Henry Dale fellowship - Royal Society; Public Health England; LSHTM; British Heart Foundation(British Heart Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR(National Institute for Health Research (NIHR)); Health Data Research UK; UK Research and Innovation fellowship	This work was supported by the UK Medical Research Council (MRC; grant number MR/V015737/1). RM holds a fellowship funded by the Wellcome Trust (201375/Z/16/Z). BG's work on better use of data in health care more broadly is currently funded in part by the NIHR Oxford Biomedical Research Centre, the NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation, NHS England, and the Health Foundation; all DataLab staff are supported by BG's grants on this work. AS is employed by LSHTM on a fellowship sponsored by GlaxoSmithKline. KB holds a Sir Henry Dale fellowship jointly funded by Wellcome and the Royal Society. HIM is funded by the NIHR Health Protection Research Unit in Immunisation, a partnership between Public Health England and LSHTM. AYSW holds a fellowship from the British Heart Foundation. EJW holds grants from the MRC. IJD holds grants from the NIHR and GlaxoSmithKline. HF holds a UK Research and Innovation fellowship. RME is funded by Health Data Research UK and the MRC. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, Public Health England, or the Department of Health and Social Care. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency. The authors are very grateful for all the support received from the TPP Technical Operations team throughout this work, and for generous assistance from the information governance and database teams at NHS England and NHSX.	Aldridge Robert W, 2020, Wellcome Open Res, V5, P88, DOI [10.12688/wellcomeopenres.15922.1, 10.12688/wellcomeopenres.15922.2]; Aleta A, 2020, NAT HUM BEHAV, V4, P964, DOI 10.1038/s41562-020-0931-9; Apea V. J., 2020, ETHNICITY OUTCOMES P, DOI [10.1101/2020.06.10.20127621, DOI 10.1101/2020.06.10.20127621]; Asimakopoulou K, 2020, HEALTH EXPECT, V23, P1502, DOI 10.1111/hex.13134; Baqui P, 2020, LANCET GLOB HEALTH, V8, P1018, DOI 10.1016/S2214-109X(20)30285-0; Bear L, A RIGHT TO CARE THE; Bhala N, 2020, LANCET, V395, P1673, DOI 10.1016/S0140-6736(20)31102-8; Bhopal RS, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002515; Bhopal RS, 2013, MIGRATION ETHNICITY, P33; Cabinet Office, 2020, OV HOUS; Chen JT, 2021, J PUBLIC HEALTH MAN, V27, pS43, DOI 10.1097/PHH.0000000000001263; CHISHOLM J, 1990, BRIT MED J, V300, P1092, DOI 10.1136/bmj.300.6732.1092; Christie B, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e475; Griffith GJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19478-2; Harrison EM., 2020, PREPRINT, DOI [10.2139/ssrn.3618215, DOI 10.2139/SSRN.3618215]; Hawkins D, 2020, AM J IND MED, V63, P817, DOI 10.1002/ajim.23145; Iacobucci G, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2264; Kabarriti R, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19795; Kaur J., 2020, CORONAVIRUS COVID 19; Kenway P, 2020, ACCOUNTING FOR THE V; Khunti K, 2020, J PUBLIC HLTH OXF; Lassale C, 2020, MEDRXIV; Pirtle WNL, 2020, HEALTH EDUC BEHAV, V47, P504, DOI 10.1177/1090198120922942; Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107; Lee C, 2009, SOC SCI MED, V68, P1183, DOI 10.1016/j.socscimed.2008.12.036; London Health Observatory, 2003, MISS REC CAS REC ETH; Mahase E, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2506; Mathur R, 2013, NCRM WORKING PAPER S; Ministry of Housing Communities and Local Government, 2015, ENGLISH INDICES OF D; Morris S, 2020, CORONAVIRUS RECORD E; Munoz-Price LS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.21892; Nafilyan V, 2020, MEDRXIV, DOI [10.1101/2020.11.27.20238147, DOI 10.1101/2020.11.27.20238147]; Office for National Statistics, 2018, ETHNICITY FACTS AND; OpenSAFELY, COVID 19 TEST RESULT; Ortiz-Fernandez L, 2020, GENES IMMUN, V21, P269, DOI 10.1038/s41435-020-0107-7; Oshi M, 2020, CANCERS, V12, DOI 10.3390/cancers12020444; Pan D, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100404; Public Health England, 2020, BEYOND THE DATA UNDE; Raisi-Estabragh Z, 2020, J PUBLIC HEALTH-UK, V42, P451, DOI 10.1093/pubmed/fdaa095; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4921; Rentsch CT, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003379; Rubin-Miller L, 2020, COVID 19 RACIAL DISP; SAGE,, 2020, FACTORS INFLUENCING; SAGE publishing group (SAGE), 2020, DRIV HIGH COVID 19 I; Sapey E, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000644; Scientific Pandemic Influenza Group on Behaviours Environmental and Modelling Group, SPI B EMG MHCLG HOUS; Scott AP, 2013, J EPIDEMIOL COMMUN H, V67, P743, DOI 10.1136/jech-2012-202265; Smith CW., 2014, CENSUS ANALYSIS WHAT; Tapper J., 2021, LOW PAID SHUN COVID; Trades Union Congress, 2020, BME WORKERS HAVE BEE; UK Department of Health and Social Care, 2020, CORONAVIRUS COVID 19; Ward H., 2020, ANTIBODY PREVALENCE, DOI [10.1101/2020.08.12.20173690, DOI 10.1101/2020.08.12.20173690]; Warden J, 1999, BRIT MED J, V318, P625, DOI 10.1136/bmj.318.7184.625; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Yehia BR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18039	55	138	139	6	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2021	397	10286					1711	1724		10.1016/S0140-6736(21)00634-6	http://dx.doi.org/10.1016/S0140-6736(21)00634-6		MAY 2021	14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RY3KF	33939953	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000647813600026
J	Schadel, P; Troisi, F; Czapka, A; Gebert, N; Pace, S; Ori, A; Werz, O				Schaedel, Patrick; Troisi, Fabiana; Czapka, Anna; Gebert, Nadja; Pace, Simona; Ori, Alessandro; Werz, Oliver			Aging drives organ-specific alterations of the inflammatory microenvironment guided by immunomodulatory mediators in mice	FASEB JOURNAL			English	Article						aging; cytokines; inflammation; lipid mediators; resolution	HEPATIC STELLATE CELLS; EXTRACELLULAR VESICLES; LIVER FIBROSIS; SIGNAL TRANSDUCER; TRANSCRIPTION 3; EXOSOMES; DELIVERY; ACTIVATION; MECHANISMS; STAT3	Aging is accompanied by chronic, low-grade systemic inflammation, termed inflammaging, a main driver of age-associated diseases. Such sterile inflammation is typically characterized by elevated levels of pro-inflammatory mediators, such as cytokines, chemokines and reactive oxygen species causing organ damage. Lipid mediators play important roles in the fine-tuning of both the promotion and the resolution of inflammation. Yet, it remains unclear how lipid mediators fit within the concept of inflammaging and how their biosynthesis and function is affected by aging. Here, we provide comprehensive signature profiles of inflammatory markers in organs afflicted with inflammation of young and old C57BL/6 mice. We reveal an organ-specific footprint of inflammation-related cytokines, chemokines and lipid mediators, which are distinctively affected by aging. While some organs are characterized by a pronounced pro-inflammatory microenvironment and impaired resolution during aging, others display elevated levels of pro-resolving mediators or an overall decrease in inflammatory signaling. Our results demonstrate that it proves difficult to establish a unifying concept for alterations of immunomodulatory mediators as consequence of aging and that organ specificity needs to be considered. Moreover, our data imply that inclusion of lipid mediators into the concept of inflammaging provides a comprehensive tool to characterize the inflammatory microenvironment during aging on a broader and yet, more detailed scope.	[Schaedel, Patrick; Troisi, Fabiana; Czapka, Anna; Pace, Simona; Werz, Oliver] Friedrich Schiller Univ, Inst Pharm, Dept Pharmaceut Med Chem, Jena, Germany; [Troisi, Fabiana] Tech Univ Munich, Ctr Allergy & Environm ZAUM, Munich, Germany; [Troisi, Fabiana] Helmholtz Ctr Munich, Munich, Germany; [Gebert, Nadja; Ori, Alessandro] Fritz Lipmann Inst FLI, Leibniz Inst Aging, Jena, Germany	Friedrich Schiller University of Jena; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Werz, O (corresponding author), Friedrich Schiller Univ Jena, Inst Pharm, Dept Pharmaceut Med Chem, Philosophenweg 14, D-07743 Jena, Germany.	oliver.werz@uni-jena.de	Ori, Alessandro/M-8586-2019	Ori, Alessandro/0000-0002-3046-0871; Schadel, Patrick/0000-0002-9586-6653	Free State of Thuringia; ProExcellence Initiative 2 ("RegenerAging"); Deutsche Forschungsgemeinschaft; Europaischer Fonds fur regionale Entwicklung [2019FGR0095];  [SFB 1278/1 PolyTarget-316213987];  [C02];  [SFB 1127/2 ChemBioSys-239748522];  [A04]	Free State of Thuringia(European Commission); ProExcellence Initiative 2 ("RegenerAging"); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Europaischer Fonds fur regionale Entwicklung; ; ; ; 	Free State of Thuringia; ProExcellence Initiative 2 ("RegenerAging"); Deutsche Forschungsgemeinschaft; SFB 1278/1 PolyTarget-316213987, Grant/Award Number: C02; SFB 1127/2 ChemBioSys-239748522, Grant/Award Number: A04; Europaischer Fonds fur regionale Entwicklung, Grant/Award Number: 2019FGR0095	Al-Serri A, 2012, J HEPATOL, V56, P448, DOI 10.1016/j.jhep.2011.05.029; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Arriazu E, 2017, GUT, V66, P1123, DOI 10.1136/gutjnl-2015-310752; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Beebe JD, 2018, PHARMACOL THERAPEUT, V191, P74, DOI 10.1016/j.pharmthera.2018.06.006; Borges FT, 2013, J AM SOC NEPHROL, V24, P385, DOI 10.1681/ASN.2012101031; Breitkopf K, 2005, GUT, V54, P673, DOI 10.1136/gut.2004.042911; Busatto S, 2019, BIOMED MICRODEVICES, V21, DOI 10.1007/s10544-019-0396-7; Chakraborty D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01236-6; Choi S, 2019, BIOCHEM BIOPH RES CO, V513, P49, DOI 10.1016/j.bbrc.2019.03.156; Gong XH, 2014, CELL PHYSIOL BIOCHEM, V33, P97, DOI 10.1159/000356653; He WW, 2019, ONCOL LETT, V17, P5608, DOI 10.3892/ol.2019.10236; Hernandez-Gea V, 2011, ANNU REV PATHOL-MECH, V6, P425, DOI 10.1146/annurev-pathol-011110-130246; Johnsen KB, 2014, BBA-REV CANCER, V1846, P75, DOI 10.1016/j.bbcan.2014.04.005; Jung KH, 2017, CLIN CANCER RES, V23, P5537, DOI 10.1158/1078-0432.CCR-16-2253; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341; Kisseleva T, 2021, NAT REV GASTRO HEPAT, V18, P151, DOI 10.1038/s41575-020-00372-7; Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004; Krishna Murli, 2017, Clin Liver Dis (Hoboken), V10, P53, DOI 10.1002/cld.653; Lackner C, 2008, J HEPATOL, V48, P821, DOI 10.1016/j.jhep.2008.01.026; LeBleu VS, 2020, TRENDS CANCER, V6, P767, DOI 10.1016/j.trecan.2020.03.007; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Lou GH, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1512-5; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; Lu YJ, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00243; Mederacke I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3823; Mendt M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99263; Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48; Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641; O'Brien K, 2020, NAT REV MOL CELL BIO, V21, P585, DOI 10.1038/s41580-020-0251-y; Ogiso H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162183; Pechkovsky DV, 2012, AM J PATHOL, V180, P1398, DOI 10.1016/j.ajpath.2011.12.022; Qu Y, 2017, J CELL MOL MED, V21, P2491, DOI 10.1111/jcmm.13170; Schuppan D, 2018, MATRIX BIOL, V68-69, P435, DOI 10.1016/j.matbio.2018.04.006; Su TH, 2015, P NATL ACAD SCI USA, V112, P7243, DOI 10.1073/pnas.1507499112; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Vader P, 2016, ADV DRUG DELIVER REV, V106, P148, DOI 10.1016/j.addr.2016.02.006; van den Boorn JG, 2011, NAT BIOTECHNOL, V29, P325, DOI 10.1038/nbt.1830; Vinas O, 2003, HEPATOLOGY, V38, P919, DOI 10.1053/jhep.2003.50392; Wang H, 2011, AM J PATHOL, V179, P714, DOI 10.1016/j.ajpath.2011.05.005; Wang H, 2011, INT J BIOL SCI, V7, P536, DOI 10.7150/ijbs.7.536; WHITTAKER P, 1994, BASIC RES CARDIOL, V89, P397, DOI 10.1007/BF00788278; Xiang DM, 2018, GUT, V67, P1704, DOI 10.1136/gutjnl-2016-313392; Zeybel M, 2017, MOL THER, V25, P218, DOI 10.1016/j.ymthe.2016.10.004; Zhai XY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49287-7; Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240	47	3	3	3	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2021	35	5							e21558	10.1096/fj.202002684R	http://dx.doi.org/10.1096/fj.202002684R			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU6MM	33855766				2023-01-03	WOS:000645260100073
J	Cho, H; Heijnen, MJH; Craig, BA; Rietdyk, S				Cho, HyeYoung; Heijnen, Michel J. H.; Craig, Bruce A.; Rietdyk, Shirley			Falls in young adults: The effect of sex, physical activity, and prescription medications	PLOS ONE			English	Article							COMMUNITY-DWELLING ADULTS; GENDER-DIFFERENCES; COLLEGE-STUDENTS; OLDER-ADULTS; ENVIRONMENTAL-FACTORS; ALCOHOL; INJURIES; HEALTHY; RECALL; CIRCUMSTANCES	Falls are a major public health issue not only for older adults but also young adults, with fall-related injuries occurring more frequently in adult females than males. However, the sex differences in the frequency and circumstances of falls in young adults are understudied. This research quantified the frequency and circumstances of falls as a function of sex, physical activity, and prescription medications in young adults. For 16 weeks, young adult participants (N = 325; 89 males; 19.9 +/- 1.1 years) responded to a daily email asking if they had slipped, tripped, or fallen in the past 24 hours. Falls and fall-related injuries were not uncommon in young adults: 48% fell at least once, 25% fell more than once, and 10% reported an injury. The most common activities at the time of the fall for females were walking (44%) and sports (33%), and for males, sports (49%) and walking (37%). A zero-inflated Poisson model revealed that higher number of falls were associated with the following: higher levels of physical activity (p = 0.025), higher numbers of medications (p<0.0001), and being male (p = 0.008). Regarding circumstances of falling, females were more likely to be talking to a friend at the time of the fall (OR (95% CI): 0.35 (0.14-0.73); p = 0.01). For slips and trips without a fall, males and females reported the same number of slips (OR (95% CI): 0.885 (0.638-1.227) p = 0.46), but females reported more trips (OR (95% CI): 0.45 (0.30-0.67); p<0.01). Only females reported serious injuries such as concussion and fracture. In conclusion, the rate of falls in young adults was affected by physical activity levels, number of medications, and sex. Quantifying and understanding these differences leads to increased knowledge of falls across the lifespan and is instrumental in developing interventions to prevent falls.	[Cho, HyeYoung; Rietdyk, Shirley] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Cho, HyeYoung; Rietdyk, Shirley] Purdue Univ, Ctr Aging & Life Course, W Lafayette, IN 47907 USA; [Heijnen, Michel J. H.] Univ N Carolina, Sch Hlth & Appl Human Sci, Wilmington, NC USA; [Craig, Bruce A.] Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of North Carolina; University of North Carolina Wilmington; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Rietdyk, S (corresponding author), Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA.; Rietdyk, S (corresponding author), Purdue Univ, Ctr Aging & Life Course, W Lafayette, IN 47907 USA.	srietdyk@purdue.edu		Cho, HyeYoung/0000-0002-0722-8206	Purdue University Libraries Open Access Publishing Fund	Purdue University Libraries Open Access Publishing Fund	Publication of this article was funded in part by Purdue University Libraries Open Access Publishing Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Allin LJ, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01605-9; Berg WP, 1997, AGE AGEING, V26, P261, DOI 10.1093/ageing/26.4.261; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; Blazewick DH, 2018, AM J EMERG MED, V36, P608, DOI 10.1016/j.ajem.2017.09.034; CDC. Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Chen CM, 2017, SUBST USE MISUSE, V52, P1120, DOI 10.1080/10826084.2017.1293101; Cho H, 2019, GAIT POSTURE, V73, P273, DOI 10.1016/j.gaitpost.2019.07.380; Cho SH, 2004, CLIN BIOMECH, V19, P145, DOI 10.1016/j.clinbiomech.2003.10.003; Chou LS, 1998, J BIOMECH, V31, P685, DOI 10.1016/S0021-9290(98)00081-5; Compo NS, 2017, LAW HUMAN BEHAV, V41, P202, DOI 10.1037/lhb0000224; Court-Brown CM, 2017, INJURY, V48, P819, DOI 10.1016/j.injury.2017.02.021; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x; de Jong MR, 2013, THER ADV DRUG SAF, V4, P147, DOI 10.1177/2042098613486829; Den Otter AR, 2011, GAIT POSTURE, V34, P169, DOI 10.1016/j.gaitpost.2011.04.004; Der G, 2006, PSYCHOL AGING, V21, P62, DOI 10.1037/0882-7974.21.1.62; Duckham RL, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-133; Dufour AB, 2009, ARTHRIT CARE RES, V61, P1352, DOI 10.1002/art.24733; Foster RJ, 2014, EXP GERONTOL, V55, P152, DOI 10.1016/j.exger.2014.04.009; Freedman VA, 2006, MILBANK Q, V84, P493, DOI 10.1111/j.1468-0009.2006.00456.x; Ganz DA, 2005, J AM GERIATR SOC, V53, P2190, DOI 10.1111/j.1532-5415.2005.00509.x; Gebel K, 2015, JAMA INTERN MED, V175, P970, DOI 10.1001/jamainternmed.2015.0541; Gjoreski M, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16060800; GODIN G, 1985, Canadian Journal of Applied Sport Sciences, V10, P141; Hannan MT, 2010, AM J EPIDEMIOL, V171, P1031, DOI 10.1093/aje/kwq024; Heijnen MJH, 2012, EXP BRAIN RES, V223, P219, DOI 10.1007/s00221-012-3253-y; Heijnen MJH, 2016, HUM MOVEMENT SCI, V46, P86, DOI 10.1016/j.humov.2015.12.007; Hill K, 1999, AUST NZ J PUBL HEAL, V23, P41, DOI 10.1111/j.1467-842X.1999.tb01203.x; HINGSON R, 1987, J STUD ALCOHOL, V48, P212, DOI 10.15288/jsa.1987.48.212; Hingson RW, 2002, J STUD ALCOHOL, V63, P136, DOI 10.15288/jsa.2002.63.136; Jacobs JV, 2016, GAIT POSTURE, V49, P159, DOI 10.1016/j.gaitpost.2016.06.030; James MK, 2018, J SAFETY RES, V64, P83, DOI 10.1016/j.jsr.2017.12.010; Johnston L D., 2003, MONITORING FUTURE NA, VII; Kerrigan DC, 1998, AM J PHYS MED REHAB, V77, P2, DOI 10.1097/00002060-199801000-00002; Ko SU, 2011, J BIOMECH, V44, P1974, DOI 10.1016/j.jbiomech.2011.05.005; Kool B, 2009, INJURY PREV, V15, P341, DOI 10.1136/ip.2008.021303; Kool B, 2012, INJURY PREV, V18, P200, DOI 10.1136/injuryprev-2011-040202; Krems C, 2004, J SPORT MED PHYS FIT, V44, P71; Laflamme L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123390; Lee J, 2020, GERIATR NURS, V41, P747, DOI 10.1016/j.gerinurse.2020.05.005; LUNDEBERG MA, 1994, J EDUC PSYCHOL, V86, P114, DOI 10.1037/0022-0663.86.1.114; LundinOlsson L, 1997, LANCET, V349, P617, DOI 10.1016/S0140-6736(97)24009-2; Masse LC, 2012, J PHYS ACT HEALTH, V9, pS44, DOI 10.1123/jpah.9.s1.s44; McErlean DR, 2017, AUSTRALAS EMERG NURS, V20, P12, DOI 10.1016/j.aenj.2016.11.001; Miyasike-daSilva V, 2016, EXP BRAIN RES, V234, P3233, DOI 10.1007/s00221-016-4721-6; Morin L, 2019, CLIN EPIDEMIOL, V11, P483, DOI 10.2147/CLEP.S201614; Muir BC, 2020, GAIT POSTURE, V77, P100, DOI 10.1016/j.gaitpost.2020.01.020; Neder JA, 1999, EUR J APPL PHYSIOL O, V79, P522, DOI 10.1007/s004210050547; Nieves JW, 2005, J BONE MINER RES, V20, P529, DOI 10.1359/JBMR.041005; NISSAN M, 1990, J BIOMED ENG, V12, P165, DOI 10.1016/0141-5425(90)90139-E; Peel N, 2000, ACCIDENT ANAL PREV, V32, P371, DOI 10.1016/S0001-4575(99)00066-4; Peeters GMEE, 2010, J GERONTOL A-BIOL, V65, P743, DOI 10.1093/gerona/glq013; Pereira CLN, 2014, DISABIL REHABIL, V36, P117, DOI 10.3109/09638288.2013.782355; Persell SD, 2007, J GEN INTERN MED, V22, P1523, DOI 10.1007/s11606-007-0334-x; Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854; Raffegeau TE, 2018, GAIT POSTURE, V64, P59, DOI 10.1016/j.gaitpost.2018.05.029; Slutske WS, 2004, J ABNORM PSYCHOL, V113, P530, DOI 10.1037/0021-843X.113.4.530; Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835; Talbot LA, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-86; Telonio A, 2014, EXP GERONTOL, V50, P26, DOI 10.1016/j.exger.2013.11.007; Thomas NM, 2020, EXP GERONTOL, V132, DOI 10.1016/j.exger.2020.110839; Timsina LR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176561; Tom A, 2011, ACCIDENT ANAL PREV, V43, P1794, DOI 10.1016/j.aap.2011.04.012; Verma SK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150939; Verma SK, 2010, J OCCUP ENVIRON HYG, V7, P491, DOI 10.1080/15459624.2010.486693; Weerdesteyn V, 2006, GERONTOLOGY, V52, P131, DOI 10.1159/000091822; Westerterp KR, 2020, EUR J CLIN NUTR, V74, P135, DOI 10.1038/s41430-019-0408-y; Westerterp KR, 2001, J GERONTOL A-BIOL, V56, P7, DOI 10.1093/gerona/56.suppl_2.7; Winter D.A., 1991, BIOMECHANICS MOTOR C; Yagil D., 2000, TRANSP RES F, V3, P1, DOI DOI 10.1016/S1369-8478(00)00004-8; Yang YJ, 2015, J AM MED DIR ASSOC, V16, P388, DOI 10.1016/j.jamda.2014.12.003; Yoshimura E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17238713; Zietz D, 2009, J MOTOR BEHAV, V41, P357, DOI 10.3200/JMBR.41.4.357-366	72	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0250360	10.1371/journal.pone.0250360	http://dx.doi.org/10.1371/journal.pone.0250360			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RT0DC	33886646	gold, Green Published			2023-01-03	WOS:000644138300011
J	Takele, GM; Weharei, MA; Kidanu, HTM; Gebrekidan, KG; Gebregiorgis, BG				Takele, Goitom Molalign; Weharei, Medina Abdulkadir; Kidanu, Hiyab T. Michael; Gebrekidan, Kahsu Gebrekirstos; Gebregiorgis, Birhan Gebresillassie			Diabetes self-care practice and associated factors among type 2 diabetic patients in public hospitals of Tigray regional state, Ethiopia: A multicenter study	PLOS ONE			English	Article							GLYCEMIC CONTROL; KNOWLEDGE; MANAGEMENT	Background The prevalence of type 2 diabetes is increasing steadily at an alarming rate. Ethiopia is placed fourth among the top five countries of the African region members of the international diabetes federation. This study aimed to determine the level of diabetes self-care practice and associated factors among patients with type 2 diabetes mellitus attending public hospitals of the Tigray region. Methods An institution-based, cross-sectional study was conducted in six selected hospitals of Tigray region from January to February 2020. Study participants were recruited using a systematic random sampling method. Diabetes self-care practice was assessed using Summary Diabetes Self-Care Activities (SDSCA) assessment tool. The data were collected by trained nurses via face-to-face interview. Binary and multivariable logistic regression analyses were used to identify factors associated with self-care practices. Statistical significance was declared at p-value < 0.05. Results A total of 570 patients with type 2 diabetes were included in this study. The mean (SD) age of the participant was 46 (+/- 14.6) years. Less than half (46.7%) of the participants had good diabetes self-care practices. Surprisingly, only 68 (11.9%) of the participants had access to a personal glucometer. Urban residency (AOR = 1.9, 95% CI = 1.20-2.94), age group 48-63 years (AOR = 2.1, 95% CI = 1.19-3.98), not having a formal education (AOR = 2.6, 95% CI = 1.32-5.25), having family support (AOR = 1.9, 95% CI = 1.24-2.85), and having a personal glucometer at home (AOR = 6.1, 95% CI = 2.83-13.0) were the factors associated with good diabetes self-care practices. Conclusion The diabetes self-care practice in the region was found to be poor. Where factors like, being an urban resident, age group between 49-63 years, not having a formal education, and having a personal glucometer at home were associated with good self-care practices. Health care providers might have to consider actions to act on the identified factors and improve the level of self-care practices of the patients.	[Takele, Goitom Molalign; Weharei, Medina Abdulkadir; Kidanu, Hiyab T. Michael] Mekelle Univ, Coll Hlth Sci, Sch Nursing, Dept Emergency & Crit Care Nursing, Mekelle, Ethiopia; [Gebrekidan, Kahsu Gebrekirstos] Mekelle Univ, Coll Hlth Sci, Sch Nursing, Dept Pediat & Child Hlth Nursing, Mekelle, Ethiopia; [Gebregiorgis, Birhan Gebresillassie] Debre Berhan Univ, Coll Hlth Sci, Dept Nursing, Debre Berhan, Ethiopia	Mekelle University; Mekelle University	Takele, GM (corresponding author), Mekelle Univ, Coll Hlth Sci, Sch Nursing, Dept Emergency & Crit Care Nursing, Mekelle, Ethiopia.	goitommolalign49@gmail.com		molalign, goitom/0000-0002-9344-3390; Gebresillassie, Birhan/0000-0002-6886-5145				Abate Teshager Weldegiorgis, 2018, BMC Res Notes, V11, P800, DOI 10.1186/s13104-018-3874-8; Adem A.M., 2014, GLOBAL J MED RES, V14, P37; ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; Aschalew AY., 2019, BMC RES NOTES, V12, P1, DOI [10.1186/s13104-018-4038-6, DOI 10.1186/S13104-018-4038-6]; Ayele BH, 2019, SAGE OPEN MED, V7, DOI 10.1177/2050312119865646; Ballico E., 2014, INT J PURE APLLIED M, V97, P253, DOI [10.12732/ijpam.v97i2.14, DOI 10.12732/IJPAM.V97I2.14]; Bukhsh A, 2018, PATIENT PREFER ADHER, V12, P2377, DOI 10.2147/PPA.S177314; Dedefo MG., 2019, BMC RES NOTES, V12, P1, DOI [10.1186/s13104-018-4038-6, DOI 10.1186/S13104-018-4038-6]; Deepa M, 2014, Indian J Endocrinol Metab, V18, P379, DOI 10.4103/2230-8210.131191; Dinesh Peraje Vasu, 2016, J Family Med Prim Care, V5, P847, DOI 10.4103/2249-4863.201176; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; Fitzgerald JT, 1998, DIABETES CARE, V21, P706, DOI 10.2337/diacare.21.5.706; Goyal N, 2019, INT J COMMUNITY MED, V6, P1740; Ishak NH, 2017, J TAIBAH UNIV MED SC, V12, P504, DOI 10.1016/j.jtumed.2017.03.008; Kassahun T, 2016, BMC ENDOCR DISORD, V16, DOI 10.1186/s12902-016-0114-x; Khawaga G., 2015, EUROPEAN J RES MEDIC, P40; Mariye Teklewoini, 2018, BMC Res Notes, V11, P380, DOI 10.1186/s13104-018-3489-0; Mukherjee PS, 2020, INT J DIABETES DEV C, V40, P612, DOI 10.1007/s13410-020-00821-8; Niguse H, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4072-z; Nolan CJ, 2011, LANCET, V378, P169, DOI 10.1016/S0140-6736(11)60614-4; Shrivastava SR, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-14; Stephani V, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6050-0; Toobert DJ, 2000, DIABETES CARE, V23, P943, DOI 10.2337/diacare.23.7.943; West JD, 2002, AM J HEALTH-SYST PH, V59, P849, DOI 10.1093/ajhp/59.9.849; Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029; Wichit N, 2017, DIABETES RES CLIN PR, V123, P37, DOI 10.1016/j.diabres.2016.11.013; Williams R., 2019, IDF DIABETES ATLAS 9	27	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2021	16	4							e0250462	10.1371/journal.pone.0250462	http://dx.doi.org/10.1371/journal.pone.0250462			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0BF	33882117	gold, Green Published			2023-01-03	WOS:000644133400050
J	Mondala, PK; Vora, AA; Zhou, TY; Lazzari, E; Ladel, LS; Luo, XL; Kim, Y; Costello, C; MacLeod, AR; Jamieson, CHM; Crews, LA				Mondala, Phoebe K.; Vora, Ashni A.; Zhou, Tianyuan; Lazzari, Elisa; Ladel, Luisa; Luo, Xiaolin; Kim, Youngsoo; Costello, Caitlin; MacLeod, A. Robert; Jamieson, Catriona H. M.; Crews, Leslie A.			Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption	CELL STEM CELL			English	Article							MULTIPLE-MYELOMA; BONE-MARROW; STEM-CELLS; PLASMA-CELLS; TRANSCRIPTION; LENALIDOMIDE; RESISTANCE; EXPRESSION; PATHWAY; DIFFERENTIATION	In multiple myeloma, inflammatory and anti-viral pathways promote disease progression and cancer stem cell generation. Using diverse pre-clinical models, we investigated the role of interferon regulatory factor 4 (IRF4) in myeloma progenitor regeneration. In a patient-derived xenograft model that recapitulates IRF4 pathway activation in human myeloma, we test the effects of IRF4 antisense oligonucleotides (ASOs) and identify a lead agent for clinical development (ION251). IRF4 overexpression expands myeloma progenitors, while IRF4 ASOs impair myeloma cell survival and reduce IRF4 and c-MYC expression. IRF4 ASO monotherapy impedes tumor formation and myeloma dissemination in xenograft models, improving animal survival. Moreover, IRF4 ASOs eradicate myeloma progenitors and malignant plasma cells while sparing normal human hematopoietic stem cell development. Mechanistically, IRF4 inhibition disrupts cell cycle progression, downregulates stem cell and cell adhesion transcript expression, and promotes sensitivity to myeloma drugs. These findings will enable rapid clinical development of selective IRF4 inhibitors to prevent myeloma progenitor-driven relapse.	[Mondala, Phoebe K.; Vora, Ashni A.; Lazzari, Elisa; Ladel, Luisa; Jamieson, Catriona H. M.; Crews, Leslie A.] Univ Calif San Diego, Dept Med, Div Regenerat Med, La Jolla, CA 92093 USA; [Zhou, Tianyuan; Luo, Xiaolin; Kim, Youngsoo; MacLeod, A. Robert] Ionis Pharmaceut, Carlsbad, CA 92008 USA; [Costello, Caitlin; Jamieson, Catriona H. M.; Crews, Leslie A.] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA; [Costello, Caitlin] Univ Calif San Diego, Dept Med, Div Blood & Marrow Transplantat, San Diego, CA 92093 USA	University of California System; University of California San Diego; Ionis Pharmaceuticals, Inc.; University of California System; University of California San Diego; University of California System; University of California San Diego	Jamieson, CHM; Crews, LA (corresponding author), Univ Calif San Diego, Dept Med, Div Regenerat Med, La Jolla, CA 92093 USA.; MacLeod, AR (corresponding author), Ionis Pharmaceut, Carlsbad, CA 92008 USA.; Jamieson, CHM; Crews, LA (corresponding author), Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA.	rmacleod@ionisph.com; cjamieson@ucsd.edu; lcrews@ucsd.edu	Crews, Leslie/B-7584-2014	Crews, Leslie/0000-0003-0704-0067; Mondala, Phoebe/0000-0002-2758-1701; Zhou, Tianyuan/0000-0002-5496-4839	NIH [NCI 1R21CA194679, R01CA205944, NIDDK R01DK114468]; NIH (UCSD Specialized Cancer Center Support Grant) [2P30CA023100-33]; CIRM [TRAN110540]; LLS Blood Cancer Discoveries; NASA [NRA NNJ13ZBG001N]; UC San Diego Health Sciences Academic Senate; Altman Clinical and Translational Research Institute (UCSD NIH CTSA) [UL1TR001442]; Ionis Pharmaceuticals; Moores Family Foundation; Strauss Family Foundation; Koman Family Foundation; Sanford Stem Cell Clinical Center; UC San Diego Moores Cancer Center; San Diego Multiple Myeloma Support Group	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH (UCSD Specialized Cancer Center Support Grant)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CIRM(California Institute for Regenerative Medicine); LLS Blood Cancer Discoveries; NASA(National Aeronautics & Space Administration (NASA)); UC San Diego Health Sciences Academic Senate; Altman Clinical and Translational Research Institute (UCSD NIH CTSA); Ionis Pharmaceuticals; Moores Family Foundation; Strauss Family Foundation; Koman Family Foundation; Sanford Stem Cell Clinical Center; UC San Diego Moores Cancer Center; San Diego Multiple Myeloma Support Group	We thank Mark Minden (University of Toronto, Princess Margaret Cancer Center) for providing PCL patient material and Atsushi Miyawaki (Riken) for generously providing FUCCI lentiviral vectors. We also thank Cayla Mason, Ida Deichaite, Leisa Sutton, and the Tissue Technology and Microscopy Shared Resources at the Moores Cancer Center for technical assistance. We appreciate the vital support from funding agencies, including NIH (NCI 1R21CA194679, R01CA205944, and UCSD Specialized Cancer Center Support Grant 2P30CA023100-33; NIDDK R01DK114468), CIRM (TRAN110540), LLS Blood Cancer Discoveries, NASA (NRA NNJ13ZBG001N), and pilot grant funding from the UC San Diego Health Sciences Academic Senate and the Altman Clinical and Translational Research Institute (UCSD NIH CTSA Grant UL1TR001442). This work was also supported in part by Ionis Pharmaceuticals. Finally, we appreciate the generous support of the Moores Family Foundation, the Strauss Family Foundation, the Koman Family Foundation, the Sanford Stem Cell Clinical Center, the International Myeloma Foundation in collaboration with the San Diego Multiple Myeloma Support Group, and the UC San Diego Moores Cancer Center.	Abrahamsson AE, 2009, P NATL ACAD SCI USA, V106, P3925, DOI 10.1073/pnas.0900189106; Alexa A., 2019, GENE SET ENRICHMENT; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Andrews S., 2010, FASTQC QUALITY CONTR; Bai H, 2017, ONCOTARGET, V8, P85392, DOI 10.18632/oncotarget.19907; Ballance LT, 2006, PROG OCEANOGR, V69, P360, DOI 10.1016/j.pocean.2006.03.013; Bianchi G, 2014, CURR CANCER THER REV, V10, P70, DOI 10.2174/157339471002141124121404; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Calder A, 2013, STEM CELLS DEV, V22, P279, DOI 10.1089/scd.2012.0168; Chaidos A, 2013, BLOOD, V121, P318, DOI 10.1182/blood-2012-06-436220; Cheng WL, 2017, CIRCULATION, V136, P1412, DOI 10.1161/CIRCULATIONAHA.116.026046; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Colombo M, 2013, LEUKEMIA, V27, P1009, DOI 10.1038/leu.2013.6; Colombo M, 2016, ONCOTARGET, V7, P56013, DOI 10.18632/oncotarget.10820; Costello C, 2018, FUTURE ONCOL, V14, P95, DOI 10.2217/fon-2017-0493; Crews L.A., 2013, STEM CELLS HDB; Crews LA, 2016, CELL STEM CELL, V19, P599, DOI 10.1016/j.stem.2016.08.003; Crews LA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0370-3; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Crooke ST, 2019, NUCLEIC ACID THER, V29, P16, DOI 10.1089/nat.2018.0753; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Forsberg EC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008785; Fuhler GM, 2010, EXP CELL RES, V316, P1816, DOI 10.1016/j.yexcr.2010.03.013; Gandhi AK, 2014, BRIT J HAEMATOL, V164, P233, DOI 10.1111/bjh.12622; Geer LY, 2010, NUCLEIC ACIDS RES, V38, pD492, DOI 10.1093/nar/gkp858; Ghosh N, 2009, CANCER LETT, V277, P1, DOI 10.1016/j.canlet.2008.08.005; Goff D, 2010, CELL STEM CELL, V6, P296, DOI 10.1016/j.stem.2010.03.008; Goff DJ, 2013, CELL STEM CELL, V12, P316, DOI 10.1016/j.stem.2012.12.011; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hennig C., 2013, CRAN PACKAGE FPC; Herrmann K, 2015, J NUCL MED, V56, P410, DOI 10.2967/jnumed.114.151647; Hong D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5272; Huang XG, 2012, BLOOD, V120, P1095, DOI 10.1182/blood-2012-03-415984; Jiang QF, 2019, CANCER CELL, V35, P81, DOI 10.1016/j.ccell.2018.11.017; Jiang QF, 2017, NAT REV CANCER, V17, P381, DOI 10.1038/nrc.2017.23; Jiang QF, 2013, P NATL ACAD SCI USA, V110, P1041, DOI 10.1073/pnas.1213021110; Johnson K, 2008, IMMUNITY, V28, P335, DOI 10.1016/j.immuni.2007.12.019; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Klein U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357; Kortum KM, 2016, BLOOD, V128, P1226, DOI 10.1182/blood-2016-02-698092; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Kumar SK, 2019, J NATL COMPR CANC NE, V17, P1155, DOI 10.6004/jnccn.2019.0049; Lazzari E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01890-w; LEO R, 1992, ANN HEMATOL, V64, P132, DOI 10.1007/BF01697400; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lopez-Girona A, 2011, BRIT J HAEMATOL, V154, P325, DOI 10.1111/j.1365-2141.2011.08689.x; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Low MSY, 2019, CELL REP, V29, P2634, DOI 10.1016/j.celrep.2019.10.097; Mantovani A, 2006, LEUKEMIA, V20, P937, DOI 10.1038/sj.leu.2404229; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008-5472.CAN-07-3096; Mirandola L, 2013, LEUKEMIA, V27, P1558, DOI 10.1038/leu.2013.27; Mitchell AL, 2019, NUCLEIC ACIDS RES, V47, pD351, DOI 10.1093/nar/gky1100; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Nakamura-Ishizu A, 2014, DEVELOPMENT, V141, P4656, DOI 10.1242/dev.106575; Paner A, 2018, EXPERT REV HEMATOL, V11, P957, DOI 10.1080/17474086.2018.1538777; Pauklin S, 2013, CELL, V155, P135, DOI 10.1016/j.cell.2013.08.031; Pineda G, 2016, SCI REP-UK, V6, DOI 10.1038/srep23885; Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252; Ross SJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5253; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shaffer AL, 2009, CLIN CANCER RES, V15, P2954, DOI 10.1158/1078-0432.CCR-08-1845; Shastri A, 2018, J CLIN INVEST, V128, P5479, DOI 10.1172/JCI120156; Siegel DS, 2020, LEUKEMIA, V34, P3286, DOI 10.1038/s41375-020-0813-1; Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064; Stewart AK, 2015, NEW ENGL J MED, V372, P142, DOI 10.1056/NEJMoa1411321; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001; Van Valckenborgh E, 2012, LEUKEMIA, V26, P1436, DOI 10.1038/leu.2011.373; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Yaccoby S, 2005, CLIN CANCER RES, V11, P7599, DOI 10.1158/1078-0432.CCR-05-0523; Yaccoby S, 2018, CL LYMPH MYELOM LEUK, V18, P38, DOI 10.1016/j.clml.2017.09.020; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; Zhu YX, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0173-0; Zipeto MA, 2016, CELL STEM CELL, V19, P177, DOI 10.1016/j.stem.2016.05.004	77	12	12	3	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	APR 1	2021	28	4					623	+		10.1016/j.stem.2020.12.017	http://dx.doi.org/10.1016/j.stem.2020.12.017		APR 2021	23	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	RI3BH	33476575	Bronze, Green Accepted			2023-01-03	WOS:000636782400009
J	Servick, K; Couzin-Frankel, J; Matacic, C				Servick, Kelly; Couzin-Frankel, Jennifer; Matacic, Catherine			MEDICINE'S LONGEST YEAR	SCIENCE			English	Editorial Material																			0	1	2	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2021	371	6535					1195	1199		10.1126/science.371.6535.1195	http://dx.doi.org/10.1126/science.371.6535.1195			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RE3JJ	33737471				2023-01-03	WOS:000634054600017
J	Peake, D; Black, J; Kumbakumba, E; Bagayana, S; Barigye, C; Moschovis, P; Muhumuza, I; Kiwanuka, F; Semata, P; Rassool, K; Sobott, B; Rassool, R				Peake, David; Black, James; Kumbakumba, Elias; Bagayana, Sheillah; Barigye, Celestine; Moschovis, Peter; Muhumuza, Ivan; Kiwanuka, Frank; Semata, Patrick; Rassool, Kevin; Sobott, Bryn; Rassool, Roger			Technical results from a trial of the FREO2 Low-Pressure Oxygen Storage system, Mbarara Regional Referral Hospital, Uganda	PLOS ONE			English	Article								Increased access to reliable medical oxygen would reduce the global burden of pneumonia. Oxygen concentrators have been shown to be an effective solution, however they have significant drawbacks when used in low-resource environments where pneumonia burden is the heaviest. Low quality grid power can damage oxygen concentrators and blackouts can prevent at-risk patients from receiving continual oxygen therapy. Gaps in prescribed oxygen flow can result in acquired brain injuries, extended hypoxemia and death. The FREO2 Low-Pressure Oxygen Storage (LPOS) system consists of a suite of improvements to a standard oxygen concentrator which address these limitations. This study reports the technical results of a field trial of the system in Mbarara, Uganda. During this trial, oxygen supplied from the LPOS system was distributed to four beds in the paediatric ward of Mbarara Regional Referral Hospital. Over a three-month period, medical-grade oxygen was made available to patients 100% of the time. This period was sufficient to quantify the ability of the LPOS system to deal with blackouts, maintenance, and an unscheduled repair to the LPOS store.	[Peake, David; Black, James; Rassool, Kevin; Sobott, Bryn; Rassool, Roger] FREO2 Fdn Australia Ltd, Melbourne, Vic, Australia; [Peake, David; Sobott, Bryn; Rassool, Roger] Univ Melbourne, Fac Sci, Sch Phys, Parkville, Vic, Australia; [Kumbakumba, Elias; Bagayana, Sheillah; Barigye, Celestine; Muhumuza, Ivan; Kiwanuka, Frank; Semata, Patrick] Mbarara Reg Referral Hosp, Mbarara, Uganda; [Kumbakumba, Elias; Bagayana, Sheillah] Mbarara Univ Sci & Technol, Mbarara, Uganda; [Moschovis, Peter] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA	University of Melbourne; Mbarara University of Science & Technology; Harvard University; Harvard Medical School; Massachusetts General Hospital	Peake, D (corresponding author), FREO2 Fdn Australia Ltd, Melbourne, Vic, Australia.; Peake, D (corresponding author), Univ Melbourne, Fac Sci, Sch Phys, Parkville, Vic, Australia.	dpeake@unimelb.edu.au	Moschovis, Peter/GRY-7498-2022	Rassool, Kevin/0000-0002-8672-6704	Bill and Melinda Gates Foundation Grand Challenges Exploration Phase 1 grant	Bill and Melinda Gates Foundation Grand Challenges Exploration Phase 1 grant	FREO<INF>2</INF> Foundation Australia provided support in the form of salaries for authors JB and KR, and funding for the trial including registration costs and nursing support. FREO<INF>2</INF> provided input into the study and product design through their incountry expertise. FREO<INF>2</INF> Foundation assisted in clinical data collection. Data collection and analysis was performed by DP, RR and JB. FREO<INF>2</INF> Foundation operates on philanthropic donations and does not accept commercial funding. Early technical work on the LPOS system was made possible through a Bill and Melinda Gates Foundation Grand Challenges Exploration Phase 1 grant.	Adair-Rohani H, 2013, GLOB HEALTH-SCI PRAC, V1, P249, DOI 10.9745/GHSP-D-13-00037; [Anonymous], 2015, TECHNICAL SPECIFICAT; [Anonymous], Newlife Intensity 10 Elite Oxygen Concentrator Service Manual; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Catto AG, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S28; Chingwete A., 2019, AD334 PREREQUISITE P; Duke Trevor, 2010, Papua New Guinea Medical Journal, V53, P126; Howie SRC, 2009, B WORLD HEALTH ORGAN, V87, P763, DOI 10.2471/BLT.08.058370; Mbarara University of Science and Technology, 2018, PEDIAT CHILD HLTH; Mian Q, 2019, LANCET GLOB HEALTH, V7, pS10, DOI 10.1016/S2214-109X(19)30095-6; Nabwire J, 2018, J TROP PEDIATRICS, V64, P97, DOI 10.1093/tropej/fmx033; Peel D, 2013, ANAESTHESIA, V68, P706, DOI 10.1111/anae.12260; Rassool RP, 2017, RESP CARE, V62, P1582, DOI 10.4187/respcare.05532; Walsh BK, 2017, RESP CARE, V62, P645, DOI 10.4187/respcare.05245; World Health Organization, 2016, OXYG THER CHILDR MAN	15	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2021	16	3							e0248101	10.1371/journal.pone.0248101	http://dx.doi.org/10.1371/journal.pone.0248101			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV3DJ	33690713	gold, Green Published			2023-01-03	WOS:000627855600019
J	Anh, NTK; Yen, LM; Nguyen, NT; Nhat, PTH; Thuy, TTD; Phong, NT; Tuyen, PT; Yen, NH; Chambers, M; Hao, NV; Rollinson, T; Denehy, L; Thwaites, CL				Nguyen Thi Kim Anh; Lam Minh Yen; Nguyen Thanh Nguyen; Phung Tran Huy Nhat; Tran Thi Diem Thuy; Nguyen Thanh Phong; Pham Thi Tuyen; Nguyen Hoang Yen; Chambers, Mary; Nguyen Van Hao; Rollinson, Thomas; Denehy, Linda; Thwaites, C. Louise			Feasibility of establishing a rehabilitation programme in a Vietnamese intensive care unit	PLOS ONE			English	Article							LONG-TERM OUTCOMES; PHYSIOTHERAPISTS; EXPERIENCES; IMPROVE; AFRICA; DESIGN; ICU	Increasing numbers of people are surviving critical illness throughout the world, but survivorship is associated with long-term disability. In high-income settings physical rehabilitation is commonly employed to counter this and improve outcomes. These utilize highly-trained multidisciplinary teams and are unavailable and unaffordable in most low and middle income countries (LMICs). We aimed to design a sustainable intensive care unit (ICU) rehabilitation program and to evaluate its feasibility in a LMIC setting. In this project patients, care-givers and experts co-designed an innovative rehabilitation programme that can be delivered by non-expert ICU staff and family care-givers in a LMIC. We implemented this programme in adult patient with patients with tetanus at the Hospital for Tropical Diseases, Ho Chi Minh City over a 5-month period, evaluating the programme's acceptability, enablers and barriers. A 6-phase programme was designed, supported by written and video material. The programme was piloted in total of 30 patients. Rehabilitation was commenced a median 14 (inter quartile range (IQR) 10-18) days after admission. Each patient received a median of 25.5 (IQR 22.8-34.8) rehabilitation sessions out of a median 27 (22.8-35) intended (prescribed) sessions. There were no associated adverse events. Patients and staff found rehabilitation to be beneficial, enhanced relationships between carers, patients and staff and was deemed to be a positive step towards recovery and return to work. The main barrier was staff time. The programme was feasible for patients with tetanus and viewed positively by staff and participants. Staff time was identified as the major barrier to ongoing implementation.	[Nguyen Thi Kim Anh; Nguyen Thanh Nguyen; Tran Thi Diem Thuy; Nguyen Thanh Phong; Pham Thi Tuyen; Nguyen Van Hao] Hosp Trop Dis, Ho Chi Minh City, Vietnam; [Lam Minh Yen; Phung Tran Huy Nhat; Nguyen Hoang Yen; Chambers, Mary; Thwaites, C. Louise] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam; [Chambers, Mary; Thwaites, C. Louise] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England; [Nguyen Van Hao] Univ Med & Pharm, Ho Chi Minh City, Vietnam; [Rollinson, Thomas] Austin Hosp, Melbourne, Vic, Australia; [Denehy, Linda] Univ Melbourne, Melbourne, Vic, Australia	University of Oxford; University of Oxford; Hochiminh City University of Medicine & Pharmacy; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Thwaites, CL (corresponding author), Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam.; Thwaites, CL (corresponding author), Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England.	lthwaites@oucru.org	Rollinson, Thomas/AAH-7738-2021	Rollinson, Thomas/0000-0001-8973-661X; Nhat, Phung Tran Huy/0000-0003-2508-0900	Wellcome Trust [107367/Z/15/Z, MC 089276/B/09/7]	Wellcome Trust(Wellcome TrustEuropean Commission)	The study was funded by the Wellcome Trust. CLT received funding from 107367/Z/15/Z and LMY, MC 089276/B/09/7 The funder s had no role in study design, data collection and analysis,d ecision to publish or preparation of the manuscript.	Arain M, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-67; Blackwell RWN, 2017, INT J NURS STUD, V68, P83, DOI 10.1016/j.ijnurstu.2017.01.002; Calvo-Ayala E, 2013, CHEST, V144, P1469, DOI 10.1378/chest.13-0779; Crowley T, 2015, AFR J PRIM HEALTH CA, V7, DOI [10.4102/phcfm.v7i1.807, 10.4102/PHCFM.V7I1.807]; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Denehy L, 2013, CRIT CARE, V17, DOI 10.1186/cc12835; Denton M, 2015, HEALTH SOC CARE COMM, V23, P485, DOI 10.1111/hsc.12168; Diaz JV, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.2413; Donetto S., 2014, USING EXPERIENCE BAS; Feiring E, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3719-0; Fuhs AK, 2018, ARCH PHYS MED REHAB, V99, P1116, DOI 10.1016/j.apmr.2017.10.020; Greenhalgh T, 2016, MILBANK Q, V94, P392, DOI 10.1111/1468-0009.12197; Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8; Hill AD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1248-y; Hodgson CL, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0658-y; Jesus TS, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16060980; Kumar JA, 2007, INDIAN J CRIT CARE M, V11, P198, DOI 10.4103/0972-5229.37715; Kyu HH, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4111-4; Yen LM, 2019, LANCET, V393, P1657, DOI 10.1016/S0140-6736(18)33131-3; Lawton R, 2015, HEALTH PROMOT INT, V30, P38, DOI 10.1093/heapro/dau088; Levy R, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-019-2395-x; Mijovic H, 2016, J CLIN NURS, V25, P2083, DOI 10.1111/jocn.13349; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Parry SM, 2017, J CRIT CARE, V38, P137, DOI 10.1016/j.jcrc.2016.11.005; Roane H.S., 2015, CLIN ORG APPL APPL B, P321; Robert G, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7714; Schultz MJ, 2017, INTENS CARE MED, V43, P612, DOI 10.1007/s00134-017-4750-z; Sigera PC, 2016, PHYS THER, V96, P933, DOI 10.2522/ptj.20150363; Tipping CJ, 2017, INTENS CARE MED, V43, P171, DOI 10.1007/s00134-016-4612-0; Trischler J, 2018, J SERV RES-US, V21, P75, DOI 10.1177/1094670517714060; Trung TN, 2019, T ROY SOC TROP MED H, V113, P706, DOI 10.1093/trstmh/trz055; Tunpattu S, 2018, PHYSIOTHER THEOR PR, V34, P714, DOI 10.1080/09593985.2018.1423593; Phu VD, 2017, J INTENSIVE CARE, V5, DOI 10.1186/s40560-017-0266-4; World Health Organisation, 2001, ICF INT CLASFUNCT; World Health Organization (WHO), 2011, REP DIS	35	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2021	16	3							e0247406	10.1371/journal.pone.0247406	http://dx.doi.org/10.1371/journal.pone.0247406			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QS6AU	33657158	Green Published, gold			2023-01-03	WOS:000625981500044
J	Jiang, ZY; Shi, YX; Tan, GW; Wang, ZX				Jiang, Zhengye; Shi, Yanxi; Tan, Guowei; Wang, Zhanxiang			Computational screening of potential glioma-related genes and drugs based on analysis of GEO dataset and text mining	PLOS ONE			English	Article							CELL-BASED IMMUNOTHERAPY; KDA LAMININ RECEPTOR; SOFT-TISSUE SARCOMA; COMPLEX DISEASES; PHASE-II; MITOXANTRONE; DOXORUBICIN; CANCER; RADIOTHERAPY; PROGRESSION	Background Considering the high invasiveness and mortality of glioma as well as the unclear key genes and signaling pathways involved in the development of gliomas, there is a strong need to find potential gene biomarkers and available drugs. Methods Eight glioma samples and twelve control samples were analyzed on the GSE31095 datasets, and differentially expressed genes (DEGs) were obtained via the R software. The related glioma genes were further acquired from the text mining. Additionally, Venny program was used to screen out the common genes of the two gene sets and DAVID analysis was used to conduct the corresponding gene ontology analysis and cell signal pathway enrichment. We also constructed the protein interaction network of common genes through STRING, and selected the important modules for further drug-gene analysis. The existing antitumor drugs that targeted these module genes were screened to explore their efficacy in glioma treatment. Results The gene set obtained from text mining was intersected with the previously obtained DEGs, and 128 common genes were obtained. Through the functional enrichment analysis of the identified 128 DEGs, a hub gene module containing 25 genes was obtained. Combined with the functional terms in GSE109857 dataset, some overlap of the enriched function terms are both in GSE31095 and GSE109857. Finally, 4 antitumor drugs were identified through drug-gene interaction analysis. Conclusions In this study, we identified that two potential genes and their corresponding four antitumor agents could be used as targets and drugs for glioma exploration.	[Jiang, Zhengye; Tan, Guowei; Wang, Zhanxiang] Xiamen Univ, Xiamen Key Lab Brain Ctr, Dept Neurosurg, Affiliated Hosp 1, Xiamen, Peoples R China; [Jiang, Zhengye; Tan, Guowei; Wang, Zhanxiang] Xiamen Univ, Sch Med, Inst Neurosurg, Xiamen, Peoples R China; [Shi, Yanxi] Jiaxing Second Hosp, Dept Cardiol, Jiaxing, Peoples R China	Xiamen University; Xiamen University	Wang, ZX (corresponding author), Xiamen Univ, Xiamen Key Lab Brain Ctr, Dept Neurosurg, Affiliated Hosp 1, Xiamen, Peoples R China.; Wang, ZX (corresponding author), Xiamen Univ, Sch Med, Inst Neurosurg, Xiamen, Peoples R China.	wzx3819@163.com	Shi, Yanxi/GSD-8851-2022	Jiang, ZhengYe/0000-0001-5630-1476	National Natural Science Foundation of China [82072777]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was funded by the National Natural Science Foundation of China, grant number 82072777 to ZW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander DC, 2012, J CLIN MICROBIOL, V50, P3726, DOI 10.1128/JCM.00620-12; ANTMAN K, 1993, J CLIN ONCOL, V11, P1276, DOI 10.1200/JCO.1993.11.7.1276; ARSENEAU JC, 1986, INVEST NEW DRUG, V4, P53; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Batist G, 2009, CLIN CANCER RES, V15, P692, DOI 10.1158/1078-0432.CCR-08-0515; Berg EL, 2014, DRUG DISCOV TODAY, V19, P113, DOI 10.1016/j.drudis.2013.10.003; Bitz U, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.10094; BORDEN EC, 1987, J CLIN ONCOL, V5, P840, DOI 10.1200/JCO.1987.5.6.840; Canfield SM, 1999, J IMMUNOL, V163, P3430; Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108; Chen X, 2019, BRIEF BIOINFORM, V20, P515, DOI 10.1093/bib/bbx130; Chen X, 2017, BRIEF BIOINFORM, V18, P558, DOI 10.1093/bib/bbw060; Chen X, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006418; Chen X, 2018, BIOINFORMATICS, V34, P4256, DOI 10.1093/bioinformatics/bty503; Cheng M, 2013, CELL MOL IMMUNOL, V10, P230, DOI 10.1038/cmi.2013.10; Chetty CJ, 2017, EXP CELL RES, V360, P264, DOI 10.1016/j.yexcr.2017.09.016; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Dolecek, 2013, NEURO-ONCOLOGY, V15, P646, DOI 10.1093/neuonc/nos389; Duong HHP, 2013, INT J PHARMACEUT, V454, P486, DOI 10.1016/j.ijpharm.2013.06.017; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fang F, 2018, FRONT MED-PRC, V12, P440, DOI 10.1007/s11684-018-0653-9; Feldman EJ, 2011, J CLIN ONCOL, V29, P979, DOI 10.1200/JCO.2010.30.5961; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Gao JM, 2020, BRAIN RES, P1739; Giege R, 1998, CURR OPIN STRUC BIOL, V8, P286, DOI 10.1016/S0959-440X(98)80060-2; Griffith M, 2013, NAT METHODS, V10, P1209, DOI [10.1038/nmeth.2689, 10.1038/NMETH.2689]; Guo YC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040722; Hale ML, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2960-9; Hooper CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112909; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jansen M, 2010, LANCET NEUROL, V9, P717, DOI 10.1016/S1474-4422(10)70105-8; Judson I, 2014, LANCET ONCOL, V15, P415, DOI 10.1016/S1470-2045(14)70063-4; Jung JH, 2019, CANCERS, V11; Jung JH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/879746; Khumalo T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139584; Larriba Y, 1986, MICROARRAY BIOINFORM, V19862019, P207; Le Deley MC, 2007, J CLIN ONCOL, V25, P292, DOI 10.1200/JCO.2006.05.9048; Lim O, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00286; Link KH, 2001, CANCER-AM CANCER SOC, V92, P2746, DOI 10.1002/1097-0142(20011201)92:11<2746::AID-CNCR10098>3.0.CO;2-Q; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Meyer MA, 2008, NEW ENGL J MED, V359, P1850, DOI 10.1056/NEJMc086380; Mosca E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S12-S8; Nelson J, 2008, BIOSCIENCE REP, V28, P33, DOI 10.1042/BSR20070004; Racine JS, 2012, J APPL ECONOMET, V27, P167, DOI 10.1002/jae.1278; Rock K, 2012, BRIT J RADIOL, V85, pE729, DOI 10.1259/bjr/83796755; SAIKI JH, 1986, CANCER, V58, P2196, DOI 10.1002/1097-0142(19861115)58:10<2196::AID-CNCR2820581005>3.0.CO;2-J; Sanjuan X, 1996, J PATHOL, V179, P376, DOI 10.1002/(SICI)1096-9896(199608)179:4<376::AID-PATH591>3.0.CO;2-V; Schrappe M, 2010, LANCET, V376, P1968, DOI 10.1016/S0140-6736(10)62194-0; Shi WL, 2011, SCIENCE, V333, P1630, DOI 10.1126/science.1208813; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Soderlund G, 2004, NEOPLASMA, V51, P1; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun L, 2015, MOL MED REP, V12, P4266, DOI 10.3892/mmr.2015.3958; Sung PS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113648; Swoboda RK, 2007, CANCER RES, V67, P3555, DOI 10.1158/0008-5472.CAN-06-2763; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Vilas-Boas F, 2016, FREE RADICAL BIO MED, V90, P145, DOI 10.1016/j.freeradbiomed.2015.11.019; von Mehren M, 2018, J NATL COMPR CANC NE, V16, P536, DOI 10.6004/jnccn.2018.0025; Wang JH, 2020, BIOINFORMATICS, V36, P1973, DOI 10.1093/bioinformatics/btz807; Wang QH, 2018, CANCER CELL, V33, P152, DOI 10.1016/j.ccell.2017.12.012; Wu MS, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-44; Wu YH, 2019, EXP CELL RES, V379, P30, DOI 10.1016/j.yexcr.2019.03.022; Yang ZD, 2015, SPINE, V40, pE745, DOI 10.1097/BRS.0000000000000939; Yu S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-28; ZALUPSKI M, 1991, JNCI-J NATL CANCER I, V83, P926, DOI 10.1093/jnci/83.13.926; Zhang YW, 2009, ARCH IMMUNOL THER EX, V57, P435, DOI 10.1007/s00005-009-0051-8; Zhao WY, 2016, J BIOMED NANOTECHNOL, V12, P1404, DOI 10.1166/jbn.2016.2266; Zhou YX, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-138; Zhou Z, 2018, INT J BIOL SCI, V14, P124, DOI 10.7150/ijbs.22619; Zinzani PL, 2008, LANCET ONCOL, V9, P352, DOI 10.1016/S1470-2045(08)70039-1	72	2	2	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2021	16	2							e0247612	10.1371/journal.pone.0247612	http://dx.doi.org/10.1371/journal.pone.0247612			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BP	33635875	Green Published, gold			2023-01-03	WOS:000624538400054
J	Kim, J; Kim, HS; Bae, YJ; Lee, HC; Lee, JW; Kang, HT				Kim, Joungyoun; Kim, Hyeong-Seop; Bae, Yun-Jong; Lee, Hyeong-Chul; Lee, Jae-woo; Kang, Hee-Taik			Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study	PLOS ONE			English	Article								Statins have been recommended for use in atherosclerotic cardio-cerebrovascular disease (CCVD). The purpose of this study was to investigate the efficacy of five different types of statin in the secondary prevention of CCVD in patients. This study retrospectively designed and analyzed data from the National Health Insurance Service-National Health in Korea. Participants aged 40 to 69 years were categorized into five statin groups (atorvastatin, rosuvastatin, pitavastatin, simvastatin, and pravastatin). The primary composite outcome was defined as recurrence of CCVD or all causes of death. Cox proportional hazard regression models were adopted after stepwise adjustments for confounders to investigate the difference in efficacy among the different statins. Of the 755 final participants, 48 patients experienced primary composite outcomes. After adjustments, the hazard ratios (95% confidence intervals) for primary composite outcomes of atorvastatin, pitavastatin, and rosuvastatin groups were 0.956 (0.456-2.005), 1.347 (0.354-5.116), and 0.943 (0.317-2.803), respectively, when compared with the simvastatin group. There were no significant differences between the statins in efficacy for preventing recurrence of CCVD events and/or death in CCVD patients.	[Kim, Joungyoun] Yonsei Univ, Mo Im Kim Nursing Res Inst, Coll Nursing, Seoul, South Korea; [Kim, Hyeong-Seop; Bae, Yun-Jong] Chungbuk Natl Univ, Dept Informat & Stat, Cheongju, Chungbuk, South Korea; [Lee, Hyeong-Chul; Lee, Jae-woo; Kang, Hee-Taik] Chungbuk Natl Univ Hosp, Dept Family Med, Cheongju, Chungbuk, South Korea; [Kang, Hee-Taik] Chungbuk Natl Univ, Coll Med, Dept Family Med, Cheongju, Chungbuk, South Korea	Yonsei University; Yonsei University Health System; Chungbuk National University; Chungbuk National University; Chungbuk National University Hospital; Chungbuk National University	Lee, JW (corresponding author), Chungbuk Natl Univ Hosp, Dept Family Med, Cheongju, Chungbuk, South Korea.	shrimp0611@gmail.com	Lee, Jae-woo/F-2959-2016	Lee, Jae-woo/0000-0003-1784-6494; Kang, Hee-Taik/0000-0001-8048-6247	JW Pharmaceutical [CBNUH 2019-07-013]	JW Pharmaceutical	This research was supported by a grant from JW Pharmaceutical. (CBNUH 2019-07-013) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Barter PJ, 2010, J LIPID RES, V51, P1546, DOI 10.1194/jlr.P002816; Chan KKW, 2003, CLIN CANCER RES, V9, P10; Collins R, 2016, LANCET, V388, P2532, DOI 10.1016/S0140-6736(16)31357-5; Endres M, 2006, ATHEROSCLEROSIS SUPP, V7, P31, DOI 10.1016/j.atherosclerosissup.2006.01.005; Grundy SM, 2019, J AM COLL CARDIOL, V73, pE285, DOI 10.1016/j.jacc.2018.11.003; Jakobisiak M, 2003, INT J ONCOL, V23, P1055; Kip KE, 2008, J AM COLL CARDIOL, V51, P701, DOI 10.1016/j.jacc.2007.10.034; Law M, 2006, AM J CARDIOL, V97, p52C, DOI 10.1016/j.amjcard.2005.12.010; Liao JK, 2007, AM J CARDIOL, V99, P410, DOI 10.1016/j.amjcard.2006.08.051; Libby P, 2004, AM J MED, V116, P9, DOI 10.1016/j.amjmed.2004.02.006; Masana L, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-S1-S2; Pignone M, 2000, BRIT MED J, V321, P983, DOI 10.1136/bmj.321.7267.983; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Seong SC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016640; Shin HY, 2018, J KOREAN MED ASSOC, V61, P573, DOI 10.5124/jkma.2018.61.9.573; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Teramoto T, 2010, EXPERT OPIN PHARMACO, V11, P817, DOI 10.1517/14656561003641990; World Health Organization, 2017, CARDIOVASCULAR DIS C; Zhou Z, 2006, AM HEART J, V151, P273, DOI 10.1016/j.ahj.2005.04.003	21	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247419	10.1371/journal.pone.0247419	http://dx.doi.org/10.1371/journal.pone.0247419			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BB	33630898	Green Published, Green Submitted, gold			2023-01-03	WOS:000624536800113
J	Lima, RDL; Bocker, U; McDougall, GJ; Allwood, JW; Afseth, NK; Wubshet, SG				Lima, Rita de Cassia Lemos; Bocker, Ulrike; McDougall, Gordon J.; Allwood, J. William; Afseth, Nils Kristian; Wubshet, Sileshi Gizachew			Magnetic ligand fishing using immobilized DPP-IV for identification of antidiabetic ligands in lingonberry extract	PLOS ONE			English	Article								In this work, a new magnetic ligand fishing probe for discovery of DPP-IV inhibitory ligands was developed and it was tested as a proof of concept on the fruit extract of Vaccinium vitis-idaea (lingonberry). The ligands were shown to have appreciable dipeptidyl peptidase IV (DPP-IV) inhibitory activity (IC50: 31.8 mu g mL-1).) Inhibition of DPP-IV is a well-known therapeutic approach for management of type 2 diabetes (T2D). DPP-IV was successfully immobilized onto magnetic beads and was shown to retain its catalytic activity and selectivity over a model mixture. A total of four ligands were successfully fished out and identified as cyanidin-3-galactoside (2), cyanidin-3-arabinoside (3), proanthocynidin A (4), and 10-carboxyl-pyranopeonidin 3-O-(6 ''-O-p-coumaroyl)-glucoside (5) using HPLC/HRMS.	[Lima, Rita de Cassia Lemos; Bocker, Ulrike; Afseth, Nils Kristian; Wubshet, Sileshi Gizachew] NOFIMA AS, As, Norway; [McDougall, Gordon J.; Allwood, J. William] James Hutton Inst, Environm & Biochem Sci Dept, Plant Biochem & Food Qual Grp, Invergowrie, Dundee, Scotland	Nofima; James Hutton Institute	Lima, RDL; Wubshet, SG (corresponding author), NOFIMA AS, As, Norway.	ritalemosrm@gmail.com; sileshi.wubshet@nofima.no			Research Council of Norway [261849/F20, 262300/F40]; Rural Affairs Food and Environment Strategic Research Group of the Scottish Government	Research Council of Norway(Research Council of Norway); Rural Affairs Food and Environment Strategic Research Group of the Scottish Government	The Research Council of Norway is greatly acknowledged for the financial support for R.C.L.L. and S.G.W. (Project no. 261849/F20) and U.B. and N.K.A. (Project no.262300/F40). The Hutton authors gratefully acknowledge support for G.J.M. and J.W.A. through Strategic Research Portfolio funding from the Rural Affairs Food and Environment Strategic Research Group of the Scottish Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-masri IM, 2009, J ENZYM INHIB MED CH, V24, P1061, DOI 10.1080/14756360802610761; Barbosa O, 2014, RSC ADV, V4, P1583, DOI 10.1039/c3ra45991h; Berger Joel P, 2018, Endocrinol Diabetes Metab, V1, pe00002, DOI 10.1002/edm2.2; Boath AS, 2012, FOOD CHEM, V135, P929, DOI 10.1016/j.foodchem.2012.06.065; Capeletti LB, 2012, FOURIER TRANSFORM IN, V1st, P13; Casedas G, 2019, S AFR J BOT, V120, P241, DOI 10.1016/j.sajb.2018.07.001; Ciesla L, 2016, NAT PROD REP, V33, P1131, DOI 10.1039/c6np00016a; Cornell S, 2020, J CLIN PHARM THER, V45, P17, DOI 10.1111/jcpt.13230; Denny PW, 2018, EXPERT OPIN DRUG DIS, V13, P1153, DOI 10.1080/17460441.2018.1534826; Edirisinghe I, 2016, J BERRY RES, V6, P237, DOI 10.3233/JBR-160137; Ek S, 2006, J AGR FOOD CHEM, V54, P9834, DOI 10.1021/jf0623687; Fan JF, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/479505; Hansen KB, 2005, ORG PROCESS RES DEV, V9, P634, DOI 10.1021/op0500786; Hsu K-C, 2013, BIOACTIVE FOOD PEPTI, V3rd, P13; Hussain H., 2019, EXPERT OPIN THER PAT, V29, P7, DOI [10.1080/13543776.2019.1549230, DOI 10.1080/13543776.2019.1549230]; Jain MR, 2017, BRIT J PHARMACOL, V174, P2346, DOI 10.1111/bph.13842; Jiang JB, 2019, TALANTA, V195, P127, DOI 10.1016/j.talanta.2018.11.009; Johnson MH, 2013, MOL NUTR FOOD RES, V57, P1182, DOI 10.1002/mnfr.201200678; Kylli P, 2011, J AGR FOOD CHEM, V59, P3373, DOI 10.1021/jf104621e; Liu DM, 2017, TALANTA, V164, P548, DOI 10.1016/j.talanta.2016.12.028; Liu R, 2017, MOLECULES, V22, DOI 10.3390/molecules22101714; McDougall GJ, 2008, J AGR FOOD CHEM, V56, P3016, DOI 10.1021/jf073469n; McDougall GJ, 2009, FOOD CHEM, V115, P193, DOI 10.1016/j.foodchem.2008.11.093; Patil PD, 2017, DRUG DES DEV THER, V11, P1567, DOI 10.2147/DDDT.S133453; Petersen MJ, 2019, PHYTOCHEMISTRY, V164, P94, DOI 10.1016/j.phytochem.2019.04.016; Rodrigues T, 2016, NAT CHEM, V8, P531, DOI [10.1038/nchem.2479, 10.1038/NCHEM.2479]; ShibuyaSaruta H, 1996, J CLIN LAB ANAL, V10, P435, DOI 10.1002/(SICI)1098-2825(1996)10:6<435::AID-JCLA21>3.0.CO;2-X; Tao Y, 2013, J PHARMACEUT BIOMED, V78-79, P190, DOI 10.1016/j.jpba.2013.02.024; Tella H, 2015, THER ADV ENDOCRINOL, V6, P109, DOI 10.1177/2042018815580257; Torronen R, 2012, BRIT J NUTR, V107, P1445, DOI 10.1017/S0007114511004557; Virtanen JK, 2015, AM J CLIN NUTR, V101, P1088, DOI 10.3945/ajcn.114.104109; Wang HB, 2015, J CHROMATOGR A, V1392, P20, DOI 10.1016/j.chroma.2015.03.002; Wubshet SG, 2019, TALANTA, V200, P279, DOI 10.1016/j.talanta.2019.03.047; Wubshet SG, 2015, J NAT PROD, V78, P2657, DOI 10.1021/acs.jnatprod.5b00603; Zheng YX, 2021, FOOD CHEM, V335, DOI 10.1016/j.foodchem.2020.127666; Zhu WJ, 2018, J FOOD SCI, V83, P1131, DOI 10.1111/1750-3841.14087; Zhuo RJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21111516	37	2	2	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2021	16	2							e0247329	10.1371/journal.pone.0247329	http://dx.doi.org/10.1371/journal.pone.0247329			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QO3ZL	33617581	Green Published, gold			2023-01-03	WOS:000623082400034
J	Allada, R; Bass, J				Allada, Ravi; Bass, Joseph			Circadian Mechanisms in Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							REV-ERB-ALPHA; GENE-EXPRESSION; CELL-FUNCTION; CLOCK; RHYTHMS; SLEEP; TIME; LIGHT; CANCER; TRANSCRIPTION	Molecular insights into diurnal variations in human physiology and behavior are extending our understanding of a wide range of disease processes. Chronobiology is also providing testable hypotheses regarding the timing of treatments.	[Allada, Ravi] Northwestern Univ, Dept Neurobiol, Evanston, IL USA; [Bass, Joseph] Northwestern Univ, Dept Med, Div Endocrinol Metab & Mol Med, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Feinberg School of Medicine	Bass, J (corresponding author), Northwestern Univ, Dept Med, 303 E Super St,Lurie 7-107, Chicago, IL 60611 USA.	j-bass@northwestern.edu						Altman BJ, 2015, CELL METAB, V22, P1009, DOI 10.1016/j.cmet.2015.09.003; Arble DM, 2009, OBESITY, V17, P2100, DOI 10.1038/oby.2009.264; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bass J, 2016, SCIENCE, V354, P994, DOI 10.1126/science.aah4965; Braun R, 2018, P NATL ACAD SCI USA, V115, pE9247, DOI 10.1073/pnas.1800314115; BRIDGES AB, 1991, BLOOD COAGUL FIBRIN, V2, P447, DOI 10.1097/00001721-199106000-00007; Carr O, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19888-9; Chang AM, 2015, P NATL ACAD SCI USA, V112, P1232, DOI 10.1073/pnas.1418490112; Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048; CZEISLER CA, 1995, NEW ENGL J MED, V332, P6, DOI 10.1056/NEJM199501053320102; Duffy JF, 2011, P NATL ACAD SCI USA, V108, P15602, DOI 10.1073/pnas.1010666108; Fang B, 2014, CELL, V159, P1140, DOI 10.1016/j.cell.2014.10.022; Flourakis M, 2015, CELL, V162, P836, DOI 10.1016/j.cell.2015.07.036; Fultz NE, 2019, SCIENCE, V366, P628, DOI 10.1126/science.aax5440; Gaddameedhi S, 2011, P NATL ACAD SCI USA, V108, P18790, DOI 10.1073/pnas.1115249108; Gehring W, 2003, J MOL EVOL, V57, pS286, DOI 10.1007/s00239-003-0038-8; Gibbs J, 2014, NAT MED, V20, P919, DOI 10.1038/nm.3599; Hablitz LM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18115-2; Hand LE, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-018-1770-1; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019; Izumo M, 2014, ELIFE, V3, DOI 10.7554/eLife.04617; Jeyaraj D, 2012, NATURE, V483, P96, DOI 10.1038/nature10852; Jiddou MR, 2013, AM J CARDIOL, V111, P631, DOI 10.1016/j.amjcard.2012.11.010; Kemp DM, 2002, MOL CELL ENDOCRINOL, V191, P157, DOI 10.1016/S0303-7207(02)00064-3; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kohsaka A, 2007, CELL METAB, V6, P414, DOI 10.1016/j.cmet.2007.09.006; Koike N, 2012, SCIENCE, V338, P349, DOI 10.1126/science.1226339; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Kriebs A, 2017, P NATL ACAD SCI USA, V114, P8776, DOI 10.1073/pnas.1704955114; Laing EE, 2017, ELIFE, V6, DOI 10.7554/eLife.20214; Lam MTY, 2013, NATURE, V498, P511, DOI 10.1038/nature12209; Lamia KA, 2011, NATURE, V480, P552, DOI 10.1038/nature10700; LeGates TA, 2014, NAT REV NEUROSCI, V15, P443, DOI 10.1038/nrn3743; LeGates TA, 2012, NATURE, V491, P594, DOI 10.1038/nature11673; Leng Y, 2019, LANCET NEUROL, V18, P307, DOI 10.1016/S1474-4422(18)30461-7; Levi F, 1997, LANCET, V350, P681, DOI 10.1016/S0140-6736(97)03358-8; Li JZ, 2013, P NATL ACAD SCI USA, V110, P9950, DOI 10.1073/pnas.1305814110; Manfredini R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030404; Martin-Olalla JM, 2020, CURR BIOL, V30, pR298, DOI 10.1016/j.cub.2020.03.007; McKee CA, 2020, CELL MOL LIFE SCI, V77, P1049, DOI 10.1007/s00018-019-03314-y; Meredith AL, 2006, NAT NEUROSCI, V9, P1041, DOI 10.1038/nn1740; Mersch PPA, 1999, J AFFECT DISORDERS, V53, P35, DOI 10.1016/S0165-0327(98)00097-4; Montaigne D, 2018, LANCET, V391, P59, DOI 10.1016/S0140-6736(17)32132-3; MULLER JE, 1987, J CARDIOVASC PHARM, V10, pS104, DOI 10.1097/00005344-198710011-00020; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Papagiannakopoulos T, 2016, CELL METAB, V24, P324, DOI 10.1016/j.cmet.2016.07.001; Patke A, 2020, NAT REV MOL CELL BIO, V21, P67, DOI 10.1038/s41580-019-0179-2; Patke A, 2017, CELL, V169, P203, DOI 10.1016/j.cell.2017.03.027; Paul JR, 2020, EUR J NEUROSCI, V51, P109, DOI 10.1111/ejn.14343; Peek CB, 2017, CELL METAB, V25, P86, DOI 10.1016/j.cmet.2016.09.010; Perelis M, 2015, SCIENCE, V350, DOI 10.1126/science.aac4250; Petrenko V, 2017, GENE DEV, V31, P383, DOI 10.1101/gad.290379.116; Poteser M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051611; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Salem AH, 2014, CLIN PHARMACOKINET, V53, P347, DOI 10.1007/s40262-013-0121-2; Scheer FAJL, 2014, BLOOD, V123, P590, DOI 10.1182/blood-2013-07-517060; Skene DJ, 2007, SLEEP MED, V8, P651, DOI 10.1016/j.sleep.2006.11.013; Taylor D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1888; Thosar SS, 2018, J CLIN INVEST, V128, P2157, DOI 10.1172/JCI80590; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; TWIDALE N, 1989, AM J CARDIOL, V64, P1204, DOI 10.1016/0002-9149(89)90881-3; VANCAUTER E, 1991, J CLIN INVEST, V88, P934, DOI 10.1172/JCI115396; Vitale J, 2015, CHRONOBIOL INT, V32, P385, DOI 10.3109/07420528.2014.983604; Wegrzyn LR, 2017, AM J EPIDEMIOL, V186, P532, DOI 10.1093/aje/kwx140; Wehrens SMT, 2017, CURR BIOL, V27, P1768, DOI 10.1016/j.cub.2017.04.059; Wilkinson MJ, 2020, CELL METAB, V31, P92, DOI 10.1016/j.cmet.2019.11.004; Xu FK, 2019, CELL REP, V27, P59, DOI 10.1016/j.celrep.2019.03.015; Yates NJ, 2016, REV NEUROSCIENCE, V27, P669, DOI 10.1515/revneuro-2016-0030; Yin L, 2007, SCIENCE, V318, P1786, DOI 10.1126/science.1150179; Yu XF, 2013, SCIENCE, V342, P727, DOI 10.1126/science.1243884; Zhang HX, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007927; Zhang R, 2014, P NATL ACAD SCI USA, V111, P16219, DOI 10.1073/pnas.1408886111	75	112	114	29	95	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	2021	384	6					550	561		10.1056/NEJMra1802337	http://dx.doi.org/10.1056/NEJMra1802337			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG5JQ	33567194	Green Accepted			2023-01-03	WOS:000617621800012
J	Dhanani, S; Hornby, L; van Beinum, A; Scales, NB; Hogue, M; Baker, A; Beed, S; Boyd, JG; Chandler, JA; Chasse, M; D'Aragon, F; Dezfulian, C; Doig, CJ; Duska, F; Friedrich, JO; Gardiner, D; Gofton, T; Harvey, D; Herry, C; Isac, G; Kramer, AH; Kutsogiannis, DJ; Maslove, DM; Meade, M; Mehta, S; Munshi, L; Norton, L; Pagliarello, G; Ramsay, T; Rusinova, K; Scales, D; Schmidt, M; Seely, A; Shahin, J; Slessarev, M; So, D; Talbot, H; van Mook, WNKA; Waldauf, P; Weiss, M; Wind, JT; Shemie, SD				Dhanani, S.; Hornby, L.; van Beinum, A.; Scales, N. B.; Hogue, M.; Baker, A.; Beed, S.; Boyd, J. G.; Chandler, J. A.; Chasse, M.; D'Aragon, F.; Dezfulian, C.; Doig, C. J.; Duska, F.; Friedrich, J. O.; Gardiner, D.; Gofton, T.; Harvey, D.; Herry, C.; Isac, G.; Kramer, A. H.; Kutsogiannis, D. J.; Maslove, D. M.; Meade, M.; Mehta, S.; Munshi, L.; Norton, L.; Pagliarello, G.; Ramsay, T.; Rusinova, K.; Scales, D.; Schmidt, M.; Seely, A.; Shahin, J.; Slessarev, M.; So, D.; Talbot, H.; van Mook, W. N. K. A.; Waldauf, P.; Weiss, M.; Wind, J. T.; Shemie, S. D.		Canadian Critical Care Trials Grp; Canadian Donation Transplantation	Resumption of Cardiac Activity after Withdrawal of Life-Sustaining Measures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DONATION; AUTORESUSCITATION; TRANSPLANTATION; DEATH	BACKGROUND The minimum duration of pulselessness required before organ donation after circulatory determination of death has not been well studied. METHODS We conducted a prospective observational study of the incidence and timing of resumption of cardiac electrical and pulsatile activity in adults who died after planned withdrawal of life-sustaining measures in 20 intensive care units in three countries. Patients were intended to be monitored for 30 minutes after determination of death. Clinicians at the bedside reported resumption of cardiac activity prospectively. Continuous blood-pressure and electrocardiographic (ECG) wave-forms were recorded and reviewed retrospectively to confirm bedside observations and to determine whether there were additional instances of resumption of cardiac activity. RESULTS A total of 1999 patients were screened, and 631 were included in the study. Clinically reported resumption of cardiac activity, respiratory movement, or both that was confirmed by waveform analysis occurred in 5 patients (1%). Retrospective analysis of ECG and blood-pressure waveforms from 480 patients identified 67 instances (14%) with resumption of cardiac activity after a period of pulselessness, including the 5 reported by bedside clinicians. The longest duration after pulselessness before resumption of cardiac activity was 4 minutes 20 seconds. The last QRS complex coincided with the last arterial pulse in 19% of the patients. CONCLUSIONS After withdrawal of life-sustaining measures, transient resumption of at least one cycle of cardiac activity after pulselessness occurred in 14% of patients according to retrospective analysis of waveforms; only 1% of such resumptions were identified at the bedside. These events occurred within 4 minutes 20 seconds after a period of pulselessness. (Funded by the Canadian Institutes for Health Research and others.)	[Dhanani, S.] Univ Ottawa, Childrens Hosp Eastern Ontario, Ottawa, ON, Canada; [Dhanani, S.; Hornby, L.; van Beinum, A.; Hogue, M.; Talbot, H.] Univ Ottawa, Childrens Hosp Eastern Ontario Res Inst, Ottawa, ON, Canada; [Dhanani, S.] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Chandler, J. A.] Univ Ottawa, Ctr Hlth Law Policy & Eth, Ottawa, ON, Canada; [Hornby, L.; Shemie, S. D.] Canadian Blood Serv, Ottawa, ON, Canada; [van Beinum, A.] Carleton Univ, Ottawa, ON, Canada; [Scales, N. B.; Herry, C.; Seely, A.] Ottawa Hosp Res Inst, Dynam Anal Lab, Ottawa, ON, Canada; [Scales, N. B.; Herry, C.; Seely, A.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Ramsay, T.] Ottawa Hosp Res Inst, Clin Epidemiol Program Methods Ctr, Ottawa, ON, Canada; [Pagliarello, G.] Ottawa Hosp, Dept Crit Care & Gen Surg, Ottawa, ON, Canada; [Seely, A.] Ottawa Hosp, Dept Surg, Ottawa, ON, Canada; [Seely, A.] Ottawa Hosp, Div Thorac Surg, Ottawa, ON, Canada; [So, D.] Univ Ottawa Heart Inst, Intervent Cardiol Program, Ottawa, ON, Canada; [Baker, A.] St Michaels Hosp, Dept Crit Care Trauma & Neurosurg Program, Toronto, ON, Canada; [Friedrich, J. O.; Scales, D.] Unity Hlth St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Friedrich, J. O.] Univ Toronto, Toronto, ON, Canada; [Mehta, S.] Univ Toronto, Mt Sinai Hosp, Toronto, ON, Canada; [Mehta, S.; Munshi, L.; Scales, D.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Talbot, H.] Canadian Donat & Transplantat Res Program, Toronto, ON, Canada; [Beed, S.] Dalhousie Univ, Dept Crit Care, Halifax, NS, Canada; [Beed, S.] Dalhousie Univ, Dept Anesthesia, Halifax, NS, Canada; [Boyd, J. G.; Maslove, D. M.] Queens Univ, Dept Med, Kingston, ON, Canada; [Boyd, J. G.; Maslove, D. M.] Queens Univ, Dept Crit Care Med, Kingston, ON, Canada; [Chasse, M.] Univ Montreal Hosp, Res Ctr, Dept Med Crit Care, Montreal, PQ, Canada; [Shahin, J.] McGill Univ, Div Pulm Med, Dept Crit Care, Montreal, PQ, Canada; [Shahin, J.; Shemie, S. D.] McGill Univ Hlth Ctr & Res Inst, Montreal, PQ, Canada; [Weiss, M.] Transplant Quebec, Montreal, PQ, Canada; [Shemie, S. D.] Montreal Childrens Hosp, Div Crit Care, Montreal, PQ, Canada; [D'Aragon, F.] Univ Sherbrooke, Dept Anesthesiol, Sherbrooke, PQ, Canada; [D'Aragon, F.] Ctr Hosp Univ CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada; [Doig, C. J.] Univ Calgary, Cumming Sch Med, Dept Crit Care Med, Calgary, AB, Canada; [Doig, C. J.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Doig, C. J.] Univ Calgary, Cumming Sch Med, Dept Med, Calgary, AB, Canada; [Kramer, A. H.] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Kramer, A. H.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Doig, C. J.] Alberta Hlth Serv, Calgary Zone, Calgary, AB, Canada; [Gofton, T.] Western Univ, Dept Clin Neurol Sci, London Hlth Sci Ctr, London, ON, Canada; [Gofton, T.] Western Univ, Schulich Sch Med & Dent, London, ON, Canada; [Norton, L.] Western Univ, Kings Univ Coll, Dept Psychol, London, ON, Canada; [Slessarev, M.] Western Univ, Dept Med, London, ON, Canada; [Slessarev, M.] Western Univ, Brain & Mind Inst, London, ON, Canada; [Isac, G.] Univ British Columbia, Dept Med, Div Crit Care, Vancouver, BC, Canada; [Isac, G.] Univ British Columbia, Dept Anesthesia, Div Crit Care, Vancouver, BC, Canada; [Kutsogiannis, D. J.] Univ Alberta, Fac Med & Dent, Dept Crit Care Med, Edmonton, AB, Canada; [Meade, M.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Meade, M.] Hamilton Hlth Sci Ctr, Hamilton, ON, Canada; [Weiss, M.] CHU Quebec, Ctr Mere Enfant Soleil, Div Pediat Intens Care, Quebec City, PQ, Canada; [Weiss, M.] Univ Laval, Fac Med, Dept Pediat, Quebec City, PQ, Canada; [Dezfulian, C.] Univ Pittsburgh, Sch Med, Crit Care Med Dept, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Duska, F.; Schmidt, M.; Waldauf, P.] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Duska, F.; Schmidt, M.; Waldauf, P.] Charles Univ Prague, FNKV Univ Hosp, Prague, Czech Republic; [Rusinova, K.] Charles Univ Prague, Fac Med 1, Dept Palliat Med, Prague, Czech Republic; [Rusinova, K.] Gen Univ Hosp, Prague, Czech Republic; [Gardiner, D.; Harvey, D.] NHS Blood & Transplant, Bristol, Avon, England; [Gardiner, D.; Harvey, D.] Nottingham Univ Hosp NHS Trust, Adult Crit Care, Nottingham, England; [van Mook, W. N. K. A.] Maastricht Univ Med Ctr, Dept Intens Care Med, Maastricht, Netherlands; [Wind, J. T.] Maastricht Univ Med Ctr, Heart & Vasc Ctr, Maastricht, Netherlands	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; Canadian Blood Services; Carleton University; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa Heart Institute; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; Dalhousie University; Dalhousie University; Queens University - Canada; Queens University - Canada; Universite de Montreal; McGill University; McGill University; McGill University; University of Sherbrooke; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; Alberta Health Services (AHS); University of Calgary; London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of British Columbia; University of British Columbia; University of Alberta; McMaster University; McMaster University; Laval University; Laval University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Charles University Prague; Charles University Prague; University Hospital Vinohrady; Charles University Prague; General University Hospital Prague; Nottingham University Hospital NHS Trust; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Dhanani, S (corresponding author), Childrens Hosp Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1M 1N8, Canada.	sdhanani@cheo.on.ca	Waldauf, Petr/K-6785-2017; Schmidt, Matous/CAJ-5116-2022; Weiss, Matthew/S-7084-2019	Waldauf, Petr/0000-0003-4668-5837; Weiss, Matthew/0000-0002-1052-0128; Harvey, Daniel/0000-0002-5165-3277; Scales, Nathan/0000-0002-9535-7138; Norton, Loretta/0000-0002-6651-1837; van Beinum, Amanda/0000-0003-0594-496X; Chasse, Michael/0000-0001-7075-1924	Canadian Institutes for Health Research as part of the Canadian Donation and Transplantation Research Program; Karel Pavlik Foundation; CHEO Research Institute	Canadian Institutes for Health Research as part of the Canadian Donation and Transplantation Research Program(Canadian Institutes of Health Research (CIHR)); Karel Pavlik Foundation; CHEO Research Institute	Supported by the Canadian Institutes for Health Research as part of the Canadian Donation and Transplantation Research Program, CHEO Research Institute, and Karel Pavlik Foundation.	Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Altman DG, 2005, STAT CONFIDENCE CONF, V2nd, P45; Bernat JL, 2008, NEW ENGL J MED, V359, P669, DOI 10.1056/NEJMp0804161; Boucek MM, 2008, NEW ENGL J MED, V359, P709, DOI 10.1056/NEJMoa0800660; Bravi A, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-90; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Cook DA, 2018, ANAESTH INTENS CARE, V46, P400, DOI 10.1177/0310057X1804600409; Curfman GD, 2008, NEW ENGL J MED, V359, P749, DOI 10.1056/NEJMe0805480; Dhanani S, 2014, CRIT CARE MED, V42, P2358, DOI 10.1097/CCM.0000000000000417; Dhanani Sonny, 2012, J Intensive Care Med, V27, P238, DOI 10.1177/0885066610396993; Greer DM, 2020, JAMA; Hornby K, 2010, CRIT CARE MED, V38, P1246, DOI 10.1097/CCM.0b013e3181d8caaa; Hornby L, 2018, CRIT CARE MED, V46, pe268, DOI 10.1097/CCM.0000000000002920; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; R Core Team, 2021, R LANG ENV STAT COMP; Seely AJE, 2014, CRIT CARE, V18, DOI 10.1186/cc13822; Sheth KN, 2012, CRIT CARE MED, V40, P158, DOI 10.1097/CCM.0b013e31822f0b2a; Smith M, 2019, INTENS CARE MED, V45, P310, DOI 10.1007/s00134-019-05533-0; van Beinum A, 2019, CAN J ANESTH, V66, P406, DOI 10.1007/s12630-018-01287-3; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Weiss MJ, 2016, PEDIATR CRIT CARE ME, V17, pe87, DOI 10.1097/PCC.0000000000000602; YOUNGNER SJ, 1993, JAMA-J AM MED ASSOC, V269, P2769, DOI 10.1001/jama.269.21.2769	22	30	29	1	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	2021	384	4					345	352		10.1056/NEJMoa2022713	http://dx.doi.org/10.1056/NEJMoa2022713			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA8RR	33503343	Bronze			2023-01-03	WOS:000613710400010
J	Besen, BAMP; Park, M; Ranzani, OT				Besen, Bruno A. M. P.; Park, Marcelo; Ranzani, Otavio T.			Noninvasive ventilation in critically ill very old patients with pneumonia: A multicenter retrospective cohort study	PLOS ONE			English	Article								Background Very old patients (>= 80 years-old, VOP) are increasingly admitted to intensive care units (ICUs). Community-acquired pneumonia (CAP) is a common reason for admission and the best strategy of support for respiratory failure in this scenario is not fully known. We evaluated whether noninvasive ventilation (NIV) would be beneficial compared to invasive mechanical ventilation (IMV) regarding hospital mortality. Methods Multicenter cohort study of VOPs admitted with CAP in need of IMV or NIV to 11 Brazilian ICUs from 2009 through 2012. We used logistic regression models to evaluate the association between the initial ventilatory strategy (NIV vs. IMV) and hospital mortality adjusting for confounding factors. We evaluated effect modification with interaction terms in pre-specified sub-groups. Results Of 369 VOPs admitted for CAP with respiratory failure, 232 (63%) received NIV and 137 (37%) received IMV as initial ventilatory strategy. IMV patients were sicker at baseline (median SOFA 8 vs. 4). Hospital mortality was 114/232 (49%) for NIV and 90/137 (66%) for IMV. For the comparison NIV vs. IMV (reference), the crude odds ratio (OR) was 0.50 (95% CI, 0.33-0.78, p = 0.002). This association was largely confounded by antecedent characteristics and non-respiratory SOFA (adjOR = 0.70, 95% CI, 0.41-1.20, p = 0.196). The fully adjusted model, additionally including P(a)o(2)/F(i)o(2) ratio, pH and P(a)co(2), yielded an adjOR of 0.81 (95% CI, 0.46-1.41, p = 0.452). There was no strong evidence of effect modification among relevant subgroups, such as P(a)o(2)/F(i)o(2) ratio <= 150 (p = 0.30), acute respiratory acidosis (p = 0.42) and non-respiratory SOFA >= 4 (p = 0.53). Conclusions NIV was not associated with lower hospital mortality when compared to IMV in critically ill VOP admitted with CAP, but there was no strong signal of harm from its use. The main confounders of this association were both the severity of respiratory dysfunction and of extrarespiratory organ failures.	[Besen, Bruno A. M. P.] Hosp Luz, Intens Care Unit, AMIL, United Hlth Grp UHG, Sao Paulo, SP, Brazil; [Besen, Bruno A. M. P.; Park, Marcelo] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med,Dept Clin Med, Med Intens Care Unit,Discipline Emergencies Clin, Sao Paulo, SP, Brazil; [Ranzani, Otavio T.] Barcelona Inst Global Hlth, ISGlobal, Barcelona, Spain; [Ranzani, Otavio T.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Pulm Div,Heart Inst InCor, Sao Paulo, Brazil	Universidade de Sao Paulo; ISGlobal; Universidade de Sao Paulo	Besen, BAMP (corresponding author), Hosp Luz, Intens Care Unit, AMIL, United Hlth Grp UHG, Sao Paulo, SP, Brazil.; Besen, BAMP (corresponding author), Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med,Dept Clin Med, Med Intens Care Unit,Discipline Emergencies Clin, Sao Paulo, SP, Brazil.	brunobesen@yahoo.com.br	Ranzani, Otavio T./K-1196-2012; Besen, Bruno Adler Maccagnan Pinheiro/I-2241-2019	Ranzani, Otavio T./0000-0002-4677-6862; Besen, Bruno Adler Maccagnan Pinheiro/0000-0002-3516-9696				Al-Rajhi A, 2018, AM J EMERG MED, V36, P347, DOI 10.1016/j.ajem.2017.08.016; Antonelli M, 2001, INTENS CARE MED, V27, P1718, DOI 10.1007/s00134-001-1114-4; Berbenetz N, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005351.pub4; Carrillo A, 2012, INTENS CARE MED, V38, P458, DOI 10.1007/s00134-012-2475-6; Carteaux G, 2016, CRIT CARE MED, V44, P282, DOI 10.1097/CCM.0000000000001379; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cilloniz C, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0126-2019; Cilloniz C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200504; Daniel P, 2017, THORAX, V72, P376, DOI 10.1136/thoraxjnl-2016-209405; Ferreyro BL, 2020, JAMA-J AM MED ASSOC, V324, P57, DOI 10.1001/jama.2020.9524; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Garrouste-Orgeas M, 2013, INTENS CARE MED, V39, P1574, DOI 10.1007/s00134-013-2977-x; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Heyland D, 2015, CRIT CARE MED, V43, P1352, DOI 10.1097/CCM.0000000000001024; Heyland DK, 2015, INTENS CARE MED, V41, P1911, DOI 10.1007/s00134-015-4028-2; Klouwenberg PMCK, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1035-1; Laporte L, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0430-6; Lederer DJ, 2019, ANN AM THORAC SOC, V16, P22, DOI 10.1513/AnnalsATS.201808-564PS; Besen BAMP, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0204-y; Mark PE, 2006, CRIT CARE MED, V34, pS176, DOI 10.1097/01.CCM.0000232624.14883.9A; Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5; Norton EC, 2019, JAMA-J AM MED ASSOC, V321, P1304, DOI 10.1001/jama.2019.1954; Osadnik CR, 2017, COCHRANE DATABASE SY, V7, pHTTPS; Philippart F, 2013, INTENS CARE MED, V39, P1565, DOI 10.1007/s00134-013-2976-y; Ranzani OT, 2020, INTENS CARE MED, V46, P1030, DOI 10.1007/s00134-020-05963-1; Schortgen F, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-5; Shahin J, 2015, J CRIT CARE, V30, P649, DOI [10.1016/j.jcrc.2015.03.003, 10.1016/j.jcrc.2014.09.021]; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Stefan MS, 2018, J CRIT CARE, V43, P190, DOI 10.1016/j.jcrc.2017.05.023; Valley TS, 2017, CRIT CARE MED, V45, pE466, DOI [10.1097/CCM.0000000000002272, 10.1097/CCM.0000000000002076]; Valley TS, 2015, JAMA-J AM MED ASSOC, V314, P1272, DOI 10.1001/jama.2015.11068; van Haren F, 2019, CRIT CARE MED, V47, P229, DOI 10.1097/CCM.0000000000003519; Vesin A, 2013, INTENS CARE MED, V39, P1396, DOI 10.1007/s00134-013-2949-1; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vink EE, 2018, INTENS CARE MED, V44, P1369, DOI 10.1007/s00134-018-5339-x; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Wilson ME, 2018, CRIT CARE MED, V46, P1209, DOI 10.1097/CCM.0000000000003082; Wood Kelly A, 2003, Curr Opin Crit Care, V9, P316, DOI 10.1097/00075198-200308000-00011; Yoshida T, 2017, AM J RESP CRIT CARE, V195, P985, DOI 10.1164/rccm.201604-0748CP; Zampieri FG, 2018, INTENS CARE MED, V44, P1512, DOI 10.1007/s00134-018-5342-2; Zampieri FG, 2017, INTENS CARE MED, V43, P39, DOI 10.1007/s00134-016-4563-5; Zampieri FG, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-59; Zampieri Fernando Godinho, 2017, Rev. bras. ter. intensiva, V29, P418, DOI [10.5935/0103-507X.20170062, 10.5935/0103-507x.20170062]	43	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2021	16	1							e0246072	10.1371/journal.pone.0246072	http://dx.doi.org/10.1371/journal.pone.0246072			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA9GX	33503042	gold, Green Published			2023-01-03	WOS:000613751800041
J	Vilimovsky, T; Chen, P; Hoidekrova, K; Petioky, J; Harsa, P				Vilimovsky, Tomas; Chen, Peii; Hoidekrova, Kristyna; Petioky, Jakub; Harsa, Pavel			Prism adaptation treatment to address spatial neglect in an intensive rehabilitation program: A randomized pilot and feasibility trial	PLOS ONE			English	Article							UNILATERAL NEGLECT; STROKE PATIENTS; SELF-CARE; HEMISPATIAL NEGLECT; RECOVERY; GUIDELINES; THERAPY; MOTOR	Spatial neglect (SN) is a common cognitive disorder after brain injury. Prism adaptation treatment (PAT) is one of the promising interventions for SN albeit inconsistent results from previous studies. We carried out a comparison intervention (PAT vs. Sham) and aimed to evaluate the efficacy of PAT on visuospatial symptoms of SN in an inpatient rehabilitation setting that offered a highly intensive comprehensive brain injury rehabilitation program. A total of 34 patients with moderate-to-severe SN secondary to stroke or traumatic brain injury were randomized to the PAT group and the Sham group (an active control group). Both groups received 10 sessions of treatment, over two weeks, in addition to the rehabilitation therapies provided by their rehabilitation care teams. Outcomes were measured using an ecological instrument (the Catherine Bergego Scale) and paper-and-pencil tests (the Bells Test, the Line Bisection Test and the Scene Copying Test). Patients were assessed at baseline, immediately after treatment, two weeks after treatment, and four weeks after treatment. 23 (67.6%) patients completed treatment and all the assessment sessions and were included in the final analyses using mixed linear modeling. While SN symptoms reduced in both groups, we found no difference between the two groups in the degree of improvement. In addition, the average SN recovery rates were 39.1% and 28.6% in the PAT and Sham groups, respectively, but this discrepancy did not reach statistical significance. Thus, the present study suggests that PAT may contribute little to SN care in the context of a highly intensive inpatient rehabilitation program. Further large-scale investigation is required to uncover the mechanisms underlying PAT and Sham in order to refine the treatment or create new interventions.	[Vilimovsky, Tomas; Harsa, Pavel] Charles Univ Prague, Fac Med 1, Dept Psychiat, Prague, Czech Republic; [Chen, Peii] Kessler Fdn, W Orange, NJ USA; [Chen, Peii] Rutgers State Univ, Dept Phys Med & Rehabil, Newark, NJ USA; [Hoidekrova, Kristyna] Charles Univ Prague, Fac Med 1, Dept Rehabil Med, Prague, Czech Republic; [Hoidekrova, Kristyna; Petioky, Jakub] Rehabil Ctr Kladruby, Kladruby, Czech Republic; [Hoidekrova, Kristyna] Charles Univ Prague, Fac Phys Educ & Sport, Dept Kinanthropol, Prague, Czech Republic; [Petioky, Jakub] Charles Univ Prague, Fac Med 3, Prague, Czech Republic	Charles University Prague; General University Hospital Prague; Kessler Institute for Rehabilitation; Rutgers State University Newark; Rutgers State University New Brunswick; Charles University Prague; Charles University Prague; Charles University Prague	Vilimovsky, T (corresponding author), Charles Univ Prague, Fac Med 1, Dept Psychiat, Prague, Czech Republic.	tomas.vilimovsky@gmail.com		Hoidekrova, Kristyna/0000-0002-6981-5844	program PROGRES [Progres = C4 = 8D.Q 06/LF1 = 20]	program PROGRES	TV: This study was supported by the program PROGRES (Progres = C4 = 8D.Q 06/LF1 = 20). The program had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrade K, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-68; Azouvi P, 2002, J NEUROL NEUROSUR PS, V73, P160, DOI 10.1136/jnnp.73.2.160; Azouvi P, 1996, NEUROPSYCHOL REHABIL, V6, P133, DOI 10.1080/713755501; Azouvi P, 2017, ANN PHYS REHABIL MED, V60, P191, DOI 10.1016/j.rehab.2016.10.006; Barrett AM, 2019, BRAIN COGNITION, V129, P16, DOI 10.1016/j.bandc.2018.11.013; Billingsley RL, 2002, DEV MED CHILD NEUROL, V44, P191, DOI 10.1017/S001216220100192X; Bowen A, 2016, ROYAL COLL PHYS 2016; Buxbaum LJ, 2004, NEUROLOGY, V62, P749, DOI 10.1212/01.WNL.0000113730.73031.F4; Carter AR, 2017, CORTEX, V88, P81, DOI 10.1016/j.cortex.2016.12.009; Champod AS, 2018, NEUROPSYCHOL REHABIL, V28, P491, DOI 10.1080/09602011.2016.1182032; Chapman HL, 2010, NEUROPSYCHOLOGIA, V48, P2595, DOI 10.1016/j.neuropsychologia.2010.05.006; Chen P, 2014, KESSLER FDN NEGLECT; Chen P, 2020, HONG KONG J OCCUP TH, V33, P25, DOI 10.1177/1569186120921472; Chen P, 2018, DISABIL REHABIL, V40, P2677, DOI 10.1080/09638288.2017.1347720; Chen PI, 2014, BRAIN IMAGING BEHAV, V8, P346, DOI 10.1007/s11682-012-9200-5; Chen P, 2017, TOP STROKE REHABIL, V24, P24, DOI 10.1080/10749357.2016.1186373; Chen PI, 2015, ARCH PHYS MED REHAB, V96, P869, DOI 10.1016/j.apmr.2014.10.023; Chen P, 2012, TOP STROKE REHABIL, V19, P423, DOI 10.1310/tsr1905-423; Corbetta M, 2011, ANNU REV NEUROSCI, V34, P569, DOI 10.1146/annurev-neuro-061010-113731; DENES G, 1982, BRAIN, V105, P543, DOI 10.1093/brain/105.3.543; Eldridge Sandra M, 2016, BMJ, V355, pi5239, DOI 10.1136/bmj.i5239; Fortis P, 2011, NEUROREPORT, V22, P700, DOI 10.1097/WNR.0b013e32834a3e20; Fortis P, 2010, NEUROPSYCHOLOGY, V24, P681, DOI 10.1037/a0019476; Frassinetti F, 2001, NEUROPSYCHOLOGIA, V39, P725, DOI 10.1016/S0028-3932(00)00156-1; GAINOTTI G, 1972, J NEUROL NEUROSUR PS, V35, P545, DOI 10.1136/jnnp.35.4.545; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Gillen G, 2015, AM J OCCUP THER, V69, P23, DOI 10.5014/ajot.2015.013409; Gillen R, 2005, ARCH PHYS MED REHAB, V86, P763, DOI 10.1016/j.apmr.2004.10.029; Goedert KM, 2020, NEUROPSYCHOL REHABIL, V30, P32, DOI 10.1080/09602011.2018.1448287; Goedert KM, 2014, NEUROREHAB NEURAL RE, V28, P483, DOI 10.1177/1545968313516872; Goedert KM, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00211; Gossmann A, 2013, NEUROREHAB NEURAL RE, V27, P534, DOI 10.1177/1545968313478489; Gutierrez-Herrera M, 2020, NEUROPSYCHOL REHABIL, V30, P187, DOI 10.1080/09602011.2018.1454329; Hammerbeck U, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9120374; HARRIS CS, 1963, SCIENCE, V140, P812, DOI 10.1126/science.140.3568.812; Hebert D, 2016, INT J STROKE, V11, P459, DOI 10.1177/1747493016643553; Heilman KM, 2000, SEMIN NEUROL, V20, P463, DOI 10.1055/s-2000-13179; Jehkonen M, 2006, RESTOR NEUROL NEUROS, V24, P209; Karnath HO, 2012, NEUROPSYCHOLOGIA, V50, P1010, DOI 10.1016/j.neuropsychologia.2011.06.027; Katz N, 1999, ARCH PHYS MED REHAB, V80, P379, DOI 10.1016/S0003-9993(99)90273-3; Kerkhoff G, 2012, NEUROPSYCHOLOGIA, V50, P1072, DOI 10.1016/j.neuropsychologia.2012.01.024; Mancuso M, 2012, EUR J PHYS REHAB MED, V48, P197; Mizuno K, 2011, NEUROREHAB NEURAL RE, V25, P711, DOI 10.1177/1545968311407516; Muth ER, 1996, J PSYCHOSOM RES, V40, P511, DOI 10.1016/0022-3999(95)00638-9; Nguyen J, 2013, NEUROLOGY, V80; Nijboer TCW, 2014, NEUROREPORT, V25, P307, DOI 10.1097/WNR.0000000000000088; Pandian JD, 2014, NEUROLOGY, V83, P1012, DOI 10.1212/WNL.0000000000000773; Panico F, 2020, CORTEX, V123, P57, DOI 10.1016/j.cortex.2019.10.003; Paolucci S, 2001, ARCH PHYS MED REHAB, V82, P743, DOI 10.1053/apmr.2001.23191; Parton A, 2004, J NEUROL NEUROSUR PS, V75, P13; Riestra Alonso R, 2013, Handb Clin Neurol, V110, P347, DOI 10.1016/B978-0-444-52901-5.00029-0; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; Rode G, 2001, NEUROPSYCHOLOGIA, V39, P1250, DOI 10.1016/S0028-3932(01)00064-1; Rossetti Y, 1998, NATURE, V395, P166, DOI 10.1038/25988; Rundek T, 2000, NEUROLOGY, V55, P1180, DOI 10.1212/WNL.55.8.1180; Saevarsson S, 2011, APPL NEUROPSYCHOL, V18, P95, DOI 10.1080/09084282.2010.547774; Saj A, 2019, CORTEX, V119, P301, DOI 10.1016/j.cortex.2019.04.022; Sarri M, 2008, NEUROPSYCHOLOGIA, V46, P1069, DOI 10.1016/j.neuropsychologia.2007.11.005; Serino A, 2006, NEUROPSYCHOLOGIA, V44, P1068, DOI 10.1016/j.neuropsychologia.2005.10.024; Serino A, 2009, STROKE, V40, P1392, DOI 10.1161/STROKEAHA.108.530485; Shiraishi H, 2010, NEUROREHABILITATION, V27, P165, DOI 10.3233/NRE-2010-0593; Striemer CL, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00334; Stroke Foundation, 2022, CLIN GUID STROK MAN; Ten Brink AF, 2017, NEUROREHAB NEURAL RE, V31, P1017, DOI 10.1177/1545968317744277; Turner-Stokes L, 2009, CLIN REHABIL, V23, P362, DOI 10.1177/0269215508101742; Turton AJ, 2010, NEUROPSYCHOL REHABIL, V20, P180, DOI 10.1080/09602010903040683; Vaes N, 2018, NEUROPSYCHOL REHABIL, V28, P899, DOI 10.1080/09602011.2016.1208617; Wee JYM, 2008, AM J PHYS MED REHAB, V87, P910, DOI 10.1097/PHM.0b013e31818a58bd; Welfringer A, 2013, J INT NEUROPSYCH SS1, V19, P34, DOI DOI 10.1017/S1355617712000884; Wilson FC, 2003, NEUROPSYCHOL REHABIL, V13, P537, DOI 10.1080/09602010343000200; Wilson FC, 2000, RESTOR NEUROL NEUROS, V16, P1; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098; Yang NYH, 2013, FRONT HUM NEUROSCI, V7, P1, DOI 10.3389/fnhum.2013.00187	73	9	9	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2021	16	1							e0245425	10.1371/journal.pone.0245425	http://dx.doi.org/10.1371/journal.pone.0245425			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PZ7OB	33481828	Green Published, gold			2023-01-03	WOS:000612929300107
J	Rayment-Jones, H; Dalrymple, K; Harris, J; Harden, A; Parslow, E; Georgi, T; Sandall, J				Rayment-Jones, Hannah; Dalrymple, Kathryn; Harris, James; Harden, Angela; Parslow, Elidh; Georgi, Thomas; Sandall, Jane			Project20: Does continuity of care and community-based antenatal care improve maternal and neonatal birth outcomes for women with social risk factors? A prospective, observational study	PLOS ONE			English	Article								Background Social factors associated with poor childbirth outcomes and experiences of maternity care include minority ethnicity, poverty, young motherhood, homelessness, difficulty speaking or understanding English, migrant or refugee status, domestic violence, mental illness and substance abuse. It is not known what specific aspects of maternity care work to improve the maternal and neonatal outcomes for these under-served, complex populations. Methods This study aimed to compare maternal and neonatal clinical birth outcomes for women with social risk factors accessing different models of maternity care. Quantitative data on pregnancy and birth outcome measures for 1000 women accessing standard care, group practice and specialist models of care at two large, inner-city maternity services were prospectively collected and analysed using multinominal regression. The level of continuity of care and place of antenatal care were used as independent variables to explore these potentially influential aspects of care. Outcomes adjusted for women's social and medical risk factors and the service attended. Results Women who received standard maternity care were significantly less likely to use water for pain relief in labour (RR 0.11, CI 0.02-0.62) and have skin to skin contact with their baby shortly after birth (RR 0.34, CI 0.14-0.80) compared to the specialist model of care. Antenatal care based in the hospital setting was associated with a significant increase in preterm birth (RR 2.38, CI 1.32-4.27) and low birth weight (RR 2.31, CI 1.24-4.32), and a decrease in induction of labour (RR 0.65, CI 0.45-0.95) compared to community-based antenatal care, this was despite women's medical risk factors. A subgroup analysis found that preterm birth was increased further for women with the highest level of social risk accessing hospital-based antenatal care (RR 3.11, CI1.49-6.50), demonstrating the protective nature of community-based antenatal care. Conclusions This research highlights how community-based antenatal care, with a focus on continuity of carer reduced health inequalities and improved maternal and neonatal clinical outcomes for women with social risk factors. The findings support the current policy drive to increase continuity of midwife-led care, whilst adding that community-based care may further improve outcomes for women at increased risk of health inequalities. The relationship between community-based models of care and neonatal outcomes require further testing in future research. The identification of specific mechanisms such as help-seeking and reduced anxiety, to explain these findings are explored in a wider evaluation.	[Rayment-Jones, Hannah; Dalrymple, Kathryn; Sandall, Jane] Kings Coll London, Fac Life Sci & Med, Dept Women & Childrens Hlth, London, England; [Harris, James] Chelsea & Westminster NHS Fdn Trust, Clin Res Facil, London, England; [Harden, Angela] City Univ London, Sch Hlth Sci, London, England; [Parslow, Elidh] Imperial Coll NHS Trust, St Marys Hosp, London, England; [Georgi, Thomas] Kings Coll London, Fac Life Sci & Med, Sch Populat Hlth & Environm Sci, London, England	University of London; King's College London; Imperial College London; City University London; Imperial College London; University of London; King's College London	Rayment-Jones, H (corresponding author), Kings Coll London, Fac Life Sci & Med, Dept Women & Childrens Hlth, London, England.	Hannah.Rayment-Jones@kcl.ac.uk	Rayment-Jones, Hannah/I-9364-2019; Sandall, Jane/D-4146-2009	Rayment-Jones, Hannah/0000-0002-3027-8025; Dalrymple, Kathryn/0000-0003-0958-6725; Georgi, Tom/0000-0001-5735-9784; Harris, James/0000-0001-7631-3757; Sandall, Jane/0000-0003-2000-743X	National Institute for Health Research (NIHR Doctoral Research Fellowship) [DRF-2017-10-033]; NIHR Applied Research Collaboration North Thames; NIHR Applied Research Collaboration South London [NIHR ARC South London]; Wellbeing of Women [PRF006]; MRC [MR/V005839/1]	National Institute for Health Research (NIHR Doctoral Research Fellowship)(National Institute for Health Research (NIHR)); NIHR Applied Research Collaboration North Thames; NIHR Applied Research Collaboration South London [NIHR ARC South London]; Wellbeing of Women(Wellbeing of Women (WoW)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This report is independent research supported by the National Institute for Health Research (NIHR Doctoral Research Fellowship, HRJ, DRF-2017-10-033). AH is supported by the NIHR Applied Research Collaboration North Thames. JS (King's College London) is supported by the NIHR Applied Research Collaboration South London [NIHR ARC South London]. JS is also an NIHR Senior Investigator. JH is supported by a Post-doctoral Fellowship from Wellbeing of Women (Award Ref PRF006). KD is funded by the MRC (grant number: MR/V005839/1).	Amjad S, 2019, J OBSTET GYNAECOL CA, V41, P1752, DOI 10.1016/j.jogc.2019.02.126; Anandaciva, 2017, WHAT IS HAPPENING WA; Andersson E, 2012, MIDWIFERY, V28, P502, DOI 10.1016/j.midw.2011.07.006; Andrade CC, 2015, J ENVIRON PSYCHOL, V41, P125, DOI 10.1016/j.jenvp.2014.12.001; [Anonymous], 2019, NHS LONG TERM PLAN; Attanasio L, 2015, MED CARE, V53, P863, DOI 10.1097/MLR.0000000000000411; Austrailian Institute of Health and Welfare (AIHW), 2018, MAT DEATHS AUSTR 201; Billner-Garcia R, 2018, MCN-AM J MATERN-CHIL, V43, P158, DOI 10.1097/NMC.0000000000000430; Blencowe H, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-S1-S2; Blumenshine P, 2010, AM J PREV MED, V39, P263, DOI 10.1016/j.amepre.2010.05.012; Braveman P, 2010, MATERN CHILD HLTH J, V14, P20, DOI 10.1007/s10995-008-0427-0; Center for Disease Control & Prevention, 2019, MAT INF HLTH; Charles A., 2019, NHS LONG TERM PLAN E; Choe SA, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2620-8; Cluett ER, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000111.pub4; Ribeiro MRC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170469; Cumberlege J, 2016, NATL MATERN REV; D'Onofrio BM, 2013, JAMA PSYCHIAT, V70, P1231, DOI 10.1001/jamapsychiatry.2013.2107; Declercq Eugene, 2017, MAT MORT; Dehlendorf C, 2013, AM J PUBLIC HEALTH, V103, P1772, DOI 10.2105/AJPH.2013.301339; Demakakos P, 2008, SOC SCI MED, V67, P330, DOI 10.1016/j.socscimed.2008.03.038; Draper ES., 2020, MBRRACE UK PERINATAL; du Prel JB, 2009, DTSCH ARZTEBL INT, V106, P335, DOI 10.3238/arztebl.2009.0335; Duru OK, 2012, J NATL MED ASSOC, V104, P89, DOI 10.1016/S0027-9684(15)30120-6; Easter A, 2021, BRIT J PSYCHIAT, V219, P494, DOI 10.1192/bjp.2020.250; Ebert L, 2014, WOMEN BIRTH, V27, P132, DOI 10.1016/j.wombi.2013.11.003; Essex HN, 2013, BJOG-INT J OBSTET GY, V120, P732, DOI 10.1111/1471-0528.12177; Turienzo CF, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003350; Fleischer NL, 2014, ENVIRON HEALTH PERSP, V122, P425, DOI 10.1289/ehp.1306837; Flenady V, 2011, LANCET, V377, P1703, DOI 10.1016/S0140-6736(11)60064-0; Garcia R, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0657-2; Geronimus Arline T., 1992, Ethnicity and Disease, V2, P207; Geronimus AT, 2006, AM J PUBLIC HEALTH, V96, P826, DOI 10.2105/AJPH.2004.060749; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Grimes D.A., 2002, LANCET, DOI [10.1016/S0140-6736%2802%2907500-1, DOI 10.1016/S0140-6736%2802%2907500-1]; Harden A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4254; Healthcare Financial Management Association, 2019, VAL COMM SERV COMP A; Hollowell J., 2012, INCREASING EARLY INI; Homer C.S.E, 2014, LANCET, DOI [10.1016/S0140-6736%2814%2960790-X, DOI 10.1016/S0140-6736%2814%2960790-X]; Homer CSE, 2017, MIDWIFERY, V48, P1, DOI 10.1016/j.midw.2017.02.009; Howell EA, 2018, CLIN OBSTET GYNECOL, V61, P387, DOI 10.1097/GRF.0000000000000349; Jomeen J, 2013, ETHNIC HEALTH, V18, P280, DOI 10.1080/13557858.2012.730608; Karriker-Jaffe KJ, 2011, DRUG ALCOHOL REV, V30, P84, DOI 10.1111/j.1465-3362.2010.00191.x; Kennedy H.P, 2016, LANCET GLOB HEALTH, DOI [10.1016/S2214-109X%2816%2930183-8, DOI 10.1016/S2214-109X%2816%2930183-8]; Khalifeh H, 2013, AM J PUBLIC HEALTH, V103, P462, DOI 10.2105/AJPH.2012.300723; Kildea S, 2019, WOMEN BIRTH, V32, P466, DOI 10.1016/j.wombi.2019.06.013; Kim MK, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-017-0715-7; Klima C.S, 2003, J MIDWIFERY WOMENS H, DOI [10.1016/S1526-9523%2803%2900062-X, DOI 10.1016/S1526-9523%2803%2900062-X]; Knight M, 2018, MIDWIFERY; Knight M, 2019, SAVING LIVES IMPROVI; Knight M, 2020, PAEDIATR PERINAT EP, V34, P392, DOI 10.1111/ppe.12640; Knight M, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b542; Koh K.S, 2017, AM J OBSTET GYNECOL; Lilliecreutz C, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-015-0775-x; Lindquist A, 2015, BJOG-INT J OBSTET GY, V122, P1610, DOI 10.1111/1471-0528.13059; Lipsky M., 1969, ANN M AM POLIT SCI A; Liu Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6307-7; Lukasse M, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-60; Luthra R, 2020, J ETHN MIGR STUD, V46, P980, DOI 10.1080/1369183X.2018.1539287; Manuck TA, 2017, SEMIN PERINATOL, V41, P511, DOI 10.1053/j.semperi.2017.08.010; Maruthappu M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6518; McAuliffe M., 2017, WORLD MIGRATION REPO; McCall SJ, 2015, J EPIDEMIOL COMMUN H, V69, P49, DOI 10.1136/jech-2014-204214; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Medley N, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012505.pub2; Messer LC, 2008, SOC SCI MED, V67, P1247, DOI 10.1016/j.socscimed.2008.06.009; Miller R, 2006, ENCY STAT SCI; Ministry of Housing C. & L. G., 2019, ENGLISH INDICES DEPR; Moore ER, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub4; Murray SF, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2008.032136; Nair M, 2016, BJOG-INT J OBSTET GY, V123, P1654, DOI 10.1111/1471-0528.13978; National Maternity Review, 2016, BETTER BIRTHS IMPROV; Nazroo J.Y., 2009, SOCIAL DETERMINANTS; Nazroo J, 2007, SOCIOL HEALTH ILL, V29, P811, DOI 10.1111/j.1467-9566.2007.01043.x; NHS England and NHS Improvement, 2017, IMPL BETT BIRTHS CON; NHS England and NHS Improvement, 2019, LOND MAT MORT THEM R; Norsker FN, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001077; Office for National Statistics, 2017, UK DROPS EUR CHILD M; Organization W. H, 2018, HLTH REF MIGR PRACT; Pattenden S, 1999, J EPIDEMIOL COMMUN H, V53, P355, DOI 10.1136/jech.53.6.355; Phillips R, 2013, NEWBORN INFANT NURS, V13, P67, DOI 10.1053/j.nainr.2013.04.001; Public Health England, 2018, LOCAL ACTION HLTH IN; Race Disparity Unit C. O., 2017, RAC DISP AUD SUMM FI; Rayment-Jones H, 2020, MIDWIFERY, V84, DOI 10.1016/j.midw.2020.102654; Rayment-Jones H, 2019, BIRTH-ISS PERINAT C, V46, P461, DOI 10.1111/birt.12446; Rayment-Jones H, 2015, MIDWIFERY, V31, P409, DOI 10.1016/j.midw.2015.01.003; Renfrew M.J, 2014, LANCET, DOI [10.1016/S0140-6736%2814%2960789-3, DOI 10.1016/S0140-6736%2814%2960789-3]; Robertson B, 2009, MATERN CHILD HLTH J, V13, P407, DOI 10.1007/s10995-008-0353-1; Roe Yvette., 2020, J INDIG WELLBEING, V5; Rotundo Genie, 2011, Nurs Womens Health, V15, P508, DOI 10.1111/j.1751-486X.2011.01678.x; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Sandall J., 2016, SHEIL KITZ S; Sandall J, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004667.pub5, 10.1002/14651858.CD004667.pub3]; Savitz D.A, 2004, ETHNIC DIS; Scott RH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186412; Seaton SE, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001100; Singh Gopal K, 2019, Int J MCH AIDS, V8, P19, DOI 10.21106/ijma.271; Sorbye IK, 2016, BEST PRACT RES CL OB, V32, P60, DOI 10.1016/j.bpobgyn.2015.08.017; Staneva A, 2015, WOMEN BIRTH, V28, P179, DOI 10.1016/j.wombi.2015.02.003; Stevens J, 2014, MATERN CHILD NUTR, V10, P456, DOI 10.1111/mcn.12128; Thomas J., 2001, ROYAL COLL OBSTETRIC; Turienzo CF, 2019, MIDWIFERY, V69, P110, DOI 10.1016/j.midw.2018.11.005; Turienzo CF, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009044; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; WADDINGTON CH, 1956, NATURE, V177, P1241, DOI 10.1038/1771241a0; WHO UNICEF UNFPA W. B. G. and the U. N. P. D, 2019, TRENDS MAT MORT 200; Wiggins Meg, 2018, Pilot Feasibility Stud, V4, P169, DOI 10.1186/s40814-018-0361-x; Zheng DN, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0297-2	108	5	5	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2021	16	5							e0250947	10.1371/journal.pone.0250947	http://dx.doi.org/10.1371/journal.pone.0250947			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6FM	33945565	Green Accepted, gold, Green Published			2023-01-03	WOS:000664609600030
J	Vann, CG; Morton, RW; Mobley, CB; Vechetti, IJ; Ferguson, BK; Haun, CT; Osburn, SC; Sexton, CL; Fox, CD; Romero, MA; Roberson, PA; Oikawa, SY; McGlory, C; Young, KC; McCarthy, JJ; Phillips, SM; Roberts, MD				Vann, Christopher G.; Morton, Robert W.; Mobley, Christopher B.; Vechetti, Ivan J.; Ferguson, Brian K.; Haun, Cody T.; Osburn, Shelby C.; Sexton, Casey L.; Fox, Carlton D.; Romero, Matthew A.; Roberson, Paul A.; Oikawa, Sara Y.; McGlory, Chris; Young, Kaelin C.; McCarthy, John J.; Phillips, Stuart M.; Roberts, Michael D.			An intron variant of the GLI family zinc finger 3 (GLI3) gene differentiates resistance training-induced muscle fiber hypertrophy in younger men	FASEB JOURNAL			English	Article						GLI3; hypertrophy; polymorphisms; skeletal muscle	MAXIMAL O-2 UPTAKE; SKELETAL-MUSCLE; PHYSICAL-ACTIVITY; BODY-COMPOSITION; STRENGTH RESPONSE; POLYMORPHISMS; EXERCISE; GENOTYPE; ACTN3; PHENOTYPES	We examined the association between genotype and resistance training-induced changes (12 wk) in dual x--ray energy absorptiometry (DXA)-derived lean soft tissue mass (LSTM) as well as muscle fiber cross-sectional area (fCSA; vastus lateralis; n = 109; age = 22 +/- 2 y, BMI = 24.7 +/- 3.1 kg/m(2)). Over 315 000 genetic polymorphisms were interrogated from muscle using DNA microarrays. First, a targeted investigation was performed where single nucleotide polymorphisms (SNP) identified from a systematic literature review were related to changes in LSTM and fCSA. Next, genome-wide association (GWA) studies were performed to reveal associations between novel SNP targets with pre-to post-training change scores in mean fCSA and LSTM. Our targeted investigation revealed no genotype-by-time interactions for 12 common polymorphisms regarding the change in mean fCSA or change in LSTM. Our first GWA study indicated no SNP were associated with the change in LSTM. However, the second GWA study indicated two SNP exceeded the significance level with the change in mean fCSA (P = 6.9 x 10(-7) for rs4675569, 1.7 x 10(-6) for rs10263647). While the former target is not annotated (chr2:205936846 (GRCh38.p12)), the latter target (chr7:41971865 (GRCh38.p12)) is an intron variant of the GLI Family Zinc Finger 3 (GLI3) gene. Follow-up analyses indicated fCSA increases were greater in the T/C and C/C GLI3 genotypes than the T/T GLI3 genotype (P < .05). Data from the Auburn cohort also revealed participants with the T/C and C/C genotypes exhibited increases in satellite cell number with training (P < .05), whereas T/T participants did not. Additionally, those with the T/C and C/C genotypes achieved myonuclear addition in response to training (P < .05), whereas the T/T participants did not. In summary, this is the first GWA study to examine how polymorphisms associate with the change in hypertrophy measures following resistance training. Future studies are needed to determine if the GLI3 variant differentiates hypertrophic responses to resistance training given the potential link between this gene and satellite cell physiology.	[Vann, Christopher G.; Ferguson, Brian K.; Osburn, Shelby C.; Sexton, Casey L.; Fox, Carlton D.; Romero, Matthew A.; Roberson, Paul A.; Young, Kaelin C.; Roberts, Michael D.] Auburn Univ, Sch Kinesiol, 301 Wire Rd,Off 260, Auburn, AL 36849 USA; [Vann, Christopher G.] Duke Univ, Sch Med, Duke Mol Physiol Inst, Durham, NC USA; [Morton, Robert W.; Oikawa, Sara Y.; McGlory, Chris; Phillips, Stuart M.] McMaster Univ, Dept Kinesiol, Hamilton, ON, Canada; [Mobley, Christopher B.; McCarthy, John J.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY USA; [Mobley, Christopher B.; McCarthy, John J.] Univ Kentucky, Ctr Muscle Biol, Lexington, KY USA; [Vechetti, Ivan J.] Univ Nebraska, Dept Nutr & Hlth Sci, Lincoln, NE USA; [Haun, Cody T.] Fitomics LLC, Birmingham, AL USA; [Young, Kaelin C.; Roberts, Michael D.] Edward Via Coll Osteopath Med, Dept Cell Biol & Physiol, Auburn, AL USA	Auburn University System; Auburn University; Duke University; McMaster University; University of Kentucky; University of Kentucky; University of Nebraska System; University of Nebraska Lincoln	Roberts, MD (corresponding author), Auburn Univ, Sch Kinesiol, 301 Wire Rd,Off 260, Auburn, AL 36849 USA.; Roberts, MD (corresponding author), Auburn Univ, Mol & Appl Sci Lab, 301 Wire Rd,Off 260, Auburn, AL 36849 USA.; Roberts, MD (corresponding author), Auburn Univ, Appl Physiol Lab, 301 Wire Rd,Off 260, Auburn, AL 36849 USA.	mdr0024@auburn.edu	Vechetti, Ivan/C-5406-2012; Morton, Robert/J-8906-2018; Phillips, Stuart/B-2343-2009	Vechetti, Ivan/0000-0003-1024-1011; Morton, Robert/0000-0003-0099-4167; Phillips, Stuart/0000-0002-1956-4098	Auburn University (AU); Natural Science and Engineering Research Council of Canada; Office of Extramural Research, National Institutes of Health (OER) [R01AG054840, F32DK126312]	Auburn University (AU); Natural Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Office of Extramural Research, National Institutes of Health (OER)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Auburn University (AU); Natural Science and Engineering Research Council of Canada; Office of Extramural Research, National Institutes of Health (OER), Grant/Award Number: R01AG054840 and F32DK126312	Antonio J, 2019, J INT SOC SPORT NUTR, V16, DOI 10.1186/s12970-019-0307-6; Ash GI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148112; Bea JW, 2010, BEHAV GENET, V40, P649, DOI 10.1007/s10519-010-9361-1; Bouchard C, 2001, MED SCI SPORT EXER, V33, pS446, DOI 10.1097/00005768-200106001-00013; Bouchard C, 2011, J APPL PHYSIOL, V110, P1160, DOI 10.1152/japplphysiol.00973.2010; Chaillou T, 2013, J APPL PHYSIOL, V115, P1065, DOI 10.1152/japplphysiol.00611.2013; Clarkson PM, 2005, J APPL PHYSIOL, V99, P154, DOI 10.1152/japplphysiol.01139.2004; Damas F, 2018, EUR J APPL PHYSIOL, V118, P2607, DOI 10.1007/s00421-018-3984-y; Delmonico MJ, 2007, J GERONTOL A-BIOL, V62, P206, DOI 10.1093/gerona/62.2.206; Devaney JM, 2009, J CELL BIOCHEM, V107, P1073, DOI 10.1002/jcb.22209; Erskine RM, 2014, SCAND J MED SCI SPOR, V24, P642, DOI 10.1111/sms.12055; Erskine RM, 2012, J APPL PHYSIOL, V112, P1329, DOI 10.1152/japplphysiol.01137.2011; Fu L, 2016, ELIFE, V5, DOI 10.7554/eLife.15690; Gacesa JZP, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-217; Gineviciene V, 2016, BIOL SPORT, V33, P199, DOI 10.5604/20831862.1201051; Goodman CA, 2014, REV PHYSIOL BIOCH P, V166, P43, DOI 10.1007/112_2013_17; Hand BD, 2007, J APPL PHYSIOL, V103, P1678, DOI 10.1152/japplphysiol.00420.2007; Harmon BT, 2010, J APPL PHYSIOL, V109, P1779, DOI 10.1152/japplphysiol.00633.2010; Haun CT, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00247; Haun CT, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00084; He LX, 2019, MENOPAUSE, V26, P899, DOI 10.1097/GME.0000000000001364; Hoffman EP, 2013, MED SCI SPORT EXER, V45, P1060, DOI 10.1249/MSS.0b013e31828093c1; Hong AR, 2014, J SPORT SCI MED, V13, P680; Ivey FM, 2000, J GERONTOL A-BIOL, V55, pM641, DOI 10.1093/gerona/55.11.M641; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Keogh Justin W L, 2015, PeerJ, V3, pe980, DOI 10.7717/peerj.980; Kephart WC, 2016, AMINO ACIDS, V48, P779, DOI 10.1007/s00726-015-2125-8; Klimentidis YC, 2015, INT J OBESITY, V39, P1371, DOI 10.1038/ijo.2015.78; Kostek MA, 2009, MED SCI SPORT EXER, V41, P1063, DOI 10.1249/MSS.0b013e3181930337; Kostek MC, 2005, J APPL PHYSIOL, V98, P2147, DOI 10.1152/japplphysiol.00817.2004; Krauss S, 2008, CANCER RES, V68, P4658, DOI 10.1158/0008-5472.CAN-07-6174; Lavin KM, 2019, PHYSIOLOGY, V34, P112, DOI 10.1152/physiol.00044.2018; Li X, 2014, J SPORT SCI, V32, P883, DOI 10.1080/02640414.2013.865252; Ma F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054685; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; Mobley CB, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090972; Mobley CB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195203; Morton RW, 2016, J APPL PHYSIOL, V121, P129, DOI 10.1152/japplphysiol.00154.2016; Murakami SI, 2009, INT J MOL MED, V23, P81, DOI 10.3892/ijmm_00000104; Nader GA, 2005, AM J PHYSIOL-CELL PH, V289, pC1457, DOI 10.1152/ajpcell.00165.2005; Norman B, 2009, J APPL PHYSIOL, V106, P959, DOI 10.1152/japplphysiol.91435.2008; Orkunoglu-Suer FE, 2011, OBESITY, V19, P662, DOI 10.1038/oby.2010.180; Orkunoglu-Suer FE, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-117; Pereira A, 2013, AGE, V35, P1949, DOI 10.1007/s11357-012-9461-3; Pescatello LS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/643575; Pescatello LS, 2006, MED SCI SPORT EXER, V38, P1074, DOI 10.1249/01.mss.0000222835.28273.80; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rankinen T, 2010, OBESITY, V18, P322, DOI 10.1038/oby.2009.205; Renault MA, 2013, CIRC RES, V113, P1148, DOI 10.1161/CIRCRESAHA.113.301546; Riechman SE, 2004, J APPL PHYSIOL, V97, P2214, DOI 10.1152/japplphysiol.00491.2004; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952; Roberts MD, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00834; Schalk A, 2018, EUR J HUM GENET, V26, P527, DOI 10.1038/s41431-017-0009-y; Sprouse C, 2014, DIABETES, V63, P363, DOI 10.2337/db13-1150; Thomis MAI, 2004, EUR J APPL PHYSIOL, V92, P267, DOI 10.1007/s00421-004-1093-6; Thompson PD, 2004, MED SCI SPORT EXER, V36, P1132, DOI 10.1249/01.MSS.0000132274.26612.23; Van Deveire KN, 2012, J STRENGTH COND RES, V26, P1740, DOI 10.1519/JSC.0b013e31825c2bef; Walsh S, 2012, GENE, V510, P66, DOI 10.1016/j.gene.2012.08.020; Walsh S, 2009, J APPL PHYSIOL, V107, P1235, DOI 10.1152/japplphysiol.90835.2008; Yoo J, 2016, EUR J APPL PHYSIOL, V116, P947, DOI 10.1007/s00421-016-3353-7	62	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2021	35	5							e21587	10.1096/fj.202100113RR	http://dx.doi.org/10.1096/fj.202100113RR			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU6MM	33891350	hybrid, Green Published			2023-01-03	WOS:000645260100038
J	Eckardt, KU; Agarwal, R; Aswad, A; Awad, A; Block, GA; Bacci, MR; Farag, YMK; Fishbane, S; Hubert, H; Jardine, A; Khawaja, Z; Koury, MJ; Maroni, BJ; Matsushita, K; McCullough, PA; Lewis, EF; Luo, WL; Parfrey, PS; Pergola, P; Sarnak, MJ; Spinowitz, B; Tumlin, J; Vargo, DL; Walters, KA; Winkelmayer, WC; Wittes, J; Zwiech, R; Chertow, GM				Eckardt, Kai-Uwe; Agarwal, Rajiv; Aswad, Ahmad; Awad, Ahmed; Block, Geoffrey A.; Bacci, Marcelo R.; Farag, Youssef M. K.; Fishbane, Steven; Hubert, Harold; Jardine, Alan; Khawaja, Zeeshan; Koury, Mark J.; Maroni, Bradley J.; Matsushita, Kunihiro; McCullough, Peter A.; Lewis, Eldrin F.; Luo, Wenli; Parfrey, Patrick S.; Pergola, Pablo; Sarnak, Mark J.; Spinowitz, Bruce; Tumlin, James; Vargo, Dennis L.; Walters, Kimberly A.; Winkelmayer, Wolfgang C.; Wittes, Janet; Zwiech, Rafal; Chertow, Glenn M.			Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of compounds that stimulate endogenous erythropoietin production. Methods We conducted two randomized, open-label, noninferiority phase 3 trials to evaluate the safety and efficacy of vadadustat, as compared with darbepoetin alfa, in patients with anemia and incident or prevalent dialysis-dependent chronic kidney disease (DD-CKD). The primary safety end point, assessed in a time-to-event analysis, was the first occurrence of a major adverse cardiovascular event (MACE, a composite of death from any cause, a nonfatal myocardial infarction, or a nonfatal stroke), pooled across the trials (noninferiority margin, 1.25). A key secondary safety end point was the first occurrence of a MACE plus hospitalization for either heart failure or a thromboembolic event. The primary and key secondary efficacy end points were the mean change in hemoglobin from baseline to weeks 24 to 36 and from baseline to weeks 40 to 52, respectively, in each trial (noninferiority margin, -0.75 g per deciliter). Results A total of 3923 patients were randomly assigned in a 1:1 ratio to receive vadadustat or darbepoetin alfa: 369 in the incident DD-CKD trial and 3554 in the prevalent DD-CKD trial. In the pooled analysis, a first MACE occurred in 355 patients (18.2%) in the vadadustat group and in 377 patients (19.3%) in the darbepoetin alfa group (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.11). The mean differences between the groups in the change in hemoglobin concentration were -0.31 g per deciliter (95% CI, -0.53 to -0.10) at weeks 24 to 36 and -0.07 g per deciliter (95% CI, -0.34 to 0.19) at weeks 40 to 52 in the incident DD-CKD trial and -0.17 g per deciliter (95% CI, -0.23 to -0.10) and -0.18 g per deciliter (95% CI, -0.25 to -0.12), respectively, in the prevalent DD-CKD trial. The incidence of serious adverse events in the vadadustat group was 49.7% in the incident DD-CKD trial and 55.0% in the prevalent DD-CKD trial, and the incidences in the darbepoetin alfa group were 56.5% and 58.3%, respectively. Conclusions Among patients with anemia and CKD who were undergoing dialysis, vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; INNO(2)VATE ClinicalTrials.gov numbers, NCT02865850 and NCT02892149.) Vadadustat for Anemia in Patients Undergoing Dialysis Two randomized, open-label, noninferiority phase 3 trials compared the prolyl hydroxylase inhibitor vadadustat with darbepoetin alfa in patients with incident or prevalent chronic kidney disease who were undergoing dialysis. Vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations.	[Eckardt, Kai-Uwe] Charite, Dept Nephrol & Med Intens Care, Charitepl 1, D-10117 Berlin, Germany; [Agarwal, Rajiv] Indiana Univ Sch Med, Dept Med, Div Nephrol, Indianapolis, IN 46202 USA; [Aswad, Ahmad] Gonzalez MD & Aswad MD Hlth Care Serv, Miami, FL USA; [Awad, Ahmed] Clin Res Consultants, Kansas City, MO USA; [Block, Geoffrey A.] US Renal Care, Plano, TX USA; [McCullough, Peter A.] Baylor Univ, Med Ctr, Baylor Heart & Vasc Hosp, Baylor Heart & Vasc Inst, Dallas, TX USA; [Pergola, Pablo] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Renal Associates, San Antonio, TX 78229 USA; [Winkelmayer, Wolfgang C.] Baylor Coll Med, Sect Nephrol, Houston, TX 77030 USA; [Bacci, Marcelo R.] Praxis Med Res, Sao Paulo, Brazil; [Bacci, Marcelo R.] Fac Med ABC, Div Gen Practice, Dept Med, Sao Paulo, Brazil; [Farag, Youssef M. K.; Khawaja, Zeeshan; Maroni, Bradley J.; Luo, Wenli; Vargo, Dennis L.] Akebia Therapeut, Cambridge, MA USA; [Sarnak, Mark J.] Tufts Univ, Sch Med, Div Nephrol, Tufts Med Ctr, Boston, MA 02111 USA; [Fishbane, Steven] Hofstra Northwell Sch Med, Div Nephrol, Dept Med, Great Neck, NY USA; [Spinowitz, Bruce] New York Presbyterian, Div Nephrol, Queens, NY USA; [Hubert, Harold] Nephrol Associates, Augusta, GA USA; [Tumlin, James] Emory Univ, Sch Med, Atlanta, GA USA; [Jardine, Alan] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Koury, Mark J.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Matsushita, Kunihiro] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Lewis, Eldrin F.; Chertow, Glenn M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Parfrey, Patrick S.] Mem Univ, Dept Med, St John, NF, Canada; [Walters, Kimberly A.; Wittes, Janet] Stat Collaborat, Washington, DC USA; [Zwiech, Rafal] Med Univ Lodz, Barlicki Mem Teaching Hosp 1, Dialysis Dept, Dept Kidney Transplantat, Lodz, Poland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Indiana University System; Indiana University Bloomington; Baylor University; Baylor University Medical Center; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine; Faculdade de Medicina do ABC; Tufts Medical Center; Tufts University; Northwell Health; Emory University; University of Glasgow; Vanderbilt University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Stanford University; Memorial University Newfoundland; Medical University Lodz	Eckardt, KU (corresponding author), Charite, Dept Nephrol & Med Intens Care, Charitepl 1, D-10117 Berlin, Germany.	nephro-intensiv@charite.de	Block, Geoffrey/AAV-8070-2021; Bacci, Marcelo R/K-8728-2012; Matsushita, Kunihiro/AAJ-5817-2020	Block, Geoffrey/0000-0002-4646-7074; Bacci, Marcelo R/0000-0001-8578-8404; Matsushita, Kunihiro/0000-0002-7179-718X; Chertow, Glenn/0000-0002-7599-0534; Jardine, Alan/0000-0001-5815-9370				Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; Babitt JL, 2012, J AM SOC NEPHROL, V23, P1631, DOI 10.1681/ASN.2011111078; Bernhardt WM, 2010, J AM SOC NEPHROL, V21, P2151, DOI 10.1681/ASN.2010010116; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Chen N, 2019, NEW ENGL J MED, V381, P1011, DOI 10.1056/NEJMoa1901713; Chertow GM, 2021, NEW ENGL J MED, V384, P1589, DOI 10.1056/NEJMoa2035938; Eckardt K-U., 2020, NEPHROL DIAL TRANSPL; Haase VH, 2019, NEPHROL DIAL TRANSPL, V34, P90, DOI 10.1093/ndt/gfy055; Haase VH, 2013, BLOOD REV, V27, P41, DOI 10.1016/j.blre.2012.12.003; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Koury MJ, 2015, NAT REV NEPHROL, V11, P394, DOI 10.1038/nrneph.2015.82; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P121, DOI 10.1093/ndt/gfg458; Luo W., 2020, NEPHROL DIAL TRANSPL; Macdougall IC, 2007, NEPHROL DIAL TRANSPL, V22, P2, DOI 10.1093/ndt/gfm160; Martin ER, 2017, AM J NEPHROL, V45, P380, DOI 10.1159/000464476; Maxwell PH, 2016, NAT REV NEPHROL, V12, P157, DOI 10.1038/nrneph.2015.193; Mix TCH, 2005, AM HEART J, V149, P408, DOI 10.1016/j.ahj.2004.09.047; Pergola PE, 2016, KIDNEY INT, V90, P1115, DOI 10.1016/j.kint.2016.07.019; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Schodel J, 2019, NAT REV NEPHROL, V15, P641, DOI 10.1038/s41581-019-0182-z; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Sugahara M, 2017, KIDNEY INT, V92, DOI 10.1016/j.kint.2017.02.035	23	53	57	5	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 29	2021	384	17					1601	1612		10.1056/NEJMoa2025956	http://dx.doi.org/10.1056/NEJMoa2025956			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV1ND	33913638	Bronze			2023-01-03	WOS:000645605800011
J	Mason, M; Arukumar, P; Feinglass, J				Mason, Maryann; Arukumar, Ponni; Feinglass, Joe			The Pandemic Stay-at-Home Order and Opioid-Involved Overdose Fatalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Mason, Maryann] Northwestern Univ, Buehler Ctr Hlth Policy & Econ, Feinberg Sch Med, 420 E Super St,Ninth Floor, Chicago, IL 60611 USA; [Arukumar, Ponni] Cook Cty Med Examiners Off, Chicago, IL USA; [Feinglass, Joe] Northwestern Univ, Div Gen Internal Med & Geriatr, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Mason, M (corresponding author), Northwestern Univ, Buehler Ctr Hlth Policy & Econ, Feinberg Sch Med, 420 E Super St,Ninth Floor, Chicago, IL 60611 USA.	maryann-mason@northwestern.edu						Alegria M, 2021, HEALTH AFFAIR, V40, P226, DOI 10.1377/hlthaff.2020.01472; [Anonymous], 2020, OP DAT DASHB; Centers for Disease Control and Prevention (CDC), 2020, INCR FAT DRUG OV US; Cook County Government, 2020, MED EX CAS ARCH; Englander H, 2020, J HOSP MED, V15, P628, DOI 10.12788/jhm.3485; Feinglass J, 2022, PUBLIC HEALTH REP, V137, P291, DOI 10.1177/0033354921994901; Larochelle MR, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.06.039; Mason M, 2021, MMWR-MORBID MORTAL W, V70, P362, DOI [10.15585/mmwr.mm7010a3, 10.15585/mmwr.mm7010a3externalicon]; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012	9	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	2021	325	24					2495	2496		10.1001/jama.2021.6700	http://dx.doi.org/10.1001/jama.2021.6700		APR 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD7ZK	33890982	Bronze			2023-01-03	WOS:000642581800001
J	Cuchet, P; Valette, X				Cuchet, Pierre; Valette, Xavier			Radiation pneumonitis and chemotherapy in a patient with multiple myeloma	LANCET			English	Editorial Material									[Valette, Xavier] Ctr Hosp Univ Caen Normandie, Serv Reanimat Med, Caen, France; [Cuchet, Pierre] Ctr Hosp Univ Caen Normandie, Serv Pneumol, F-14000 Caen, France	CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU de Caen NORMANDIE; Universite de Caen Normandie	Cuchet, P (corresponding author), Ctr Hosp Univ Caen Normandie, Serv Pneumol, F-14000 Caen, France.	pierrecuchet91@gmail.com							0	1	1	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 17	2021	397	10283					1484	1484						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RN5FX	33865496				2023-01-03	WOS:000640378100025
J	Fujimoto, K; Kawasaki, M; Abe, R; Yokoyama, T; Haga, T; Sugiura, K				Fujimoto, Kyoko; Kawasaki, Mai; Abe, Reiko; Yokoyama, Takashi; Haga, Takeshi; Sugiura, Katsuaki			Establishing defined daily doses (DDDs) for antimicrobial agents used in pigs, cattle and poultry in Japan and comparing them with European DDD values	PLOS ONE			English	Article							ANIMALS; USAGE	Monitoring of antimicrobial use is essential in the management of the development and selection of antimicrobial resistance. A variety of indicators has become available to monitor antimicrobial use in human and animal medicine. One of them is an indicator based on defined daily dose (DDD). By using the number of DDDs administered and normalising it by the population at risk of being treated over a defined period, one can estimate the number of treatment days with antimicrobial agents in a population. For veterinary medicine, the European Medicines Agency (EMA) has published the European values of DDD (DDDvet) for food-producing animals. In this study, we defined Japanese defined daily doses for antimicrobial agents (DDDjp) using DDD values that we previously assigned for antimicrobial products approved for use in pigs, cattle and poultry in Japan and compared them with DDDvet values. For the comparison, the quotient of Japanese and European values (QDDD) was calculated and the effect of the administration route and the number of active substances contained in the preparation was investigated. A total of 59 DDDjp values were defined for 43 antimicrobial agents using the data of 276 products approved for use in pigs. Likewise, a total of 55 DDDjp values were defined for 32 antimicrobial agents using the data of 196 products for use in cattle, and a total of 27 DDDjps values were defined for 25 antimicrobial agents using the data of 131 products approved for use in poultry. A comparison was made for 42, 28 and 17 pairs of DDDjp and DDDvet values for antimicrobial agents used for pigs, cattle and poultry respectively. The comparison showed median QDDD value of 0.61 and 0.66 for antimicrobial agents used for pigs and cattle respectively (p<0.01), indicating that the Japanese daily doses are significantly lower than the corresponding EMA values in these species. For the antimicrobial agents used for poultry, no significant difference was observed between DDDjp and DDDvet values with a median QDDD value of 1.15. The difference between DDDvet and DDDjp values and absence of DDDvet values for some antimicrobial agents marketed in Japan indicate that DDDjp rather than DDDvet should be used as the basis for the calculation of antimicrobial use monitoring in farm animals in Japan.	[Fujimoto, Kyoko; Kawasaki, Mai; Abe, Reiko; Yokoyama, Takashi; Sugiura, Katsuaki] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Global Agr Sci, Tokyo, Japan; [Haga, Takeshi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Med Sci, Tokyo, Japan	University of Tokyo; University of Tokyo	Sugiura, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Global Agr Sci, Tokyo, Japan.	aksugiur@mail.ecc.u-tokyo.ac.jp		Sugiura, Katsuaki/0000-0002-8807-7584	Ministry of Agriculture, Forestry and Fisheries of Japan [JPJ008617.17935699]	Ministry of Agriculture, Forestry and Fisheries of Japan(Ministry of Agriculture Forestry & Fisheries - Japan)	KS JPJ008617.17935699 Ministry of Agriculture, Forestry and Fisheries of Japan https://www.maff.go.jp/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241644; Bosman AL, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00220; Echtermann T, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00240; EMA, PRINC ASS DEF DAIL D; EMA, DEF DAIL DOS AN DDDV; European Medicines Agency (EMA), 2012, REV ESVAC REFL PAP C; Food and Agricultural Materials Inspection Center (FAMIC), RES OFF TEST SPEC FE; Fujimoto K., J JAPANESE VET MEDIC; Grave K, 2014, J ANTIMICROB CHEMOTH, V69, P2284, DOI 10.1093/jac/dku106; Hardefeldt LY, 2018, AUST VET J, V96, P151, DOI 10.1111/avj.12677; Hardefeldt LY, 2018, EQUINE VET J, V50, P65, DOI 10.1111/evj.12709; Holmes AH, 2016, LANCET, V387, P176, DOI 10.1016/S0140-6736(15)00473-0; Hosoi Y, 2014, REV SCI TECH OIE, V33, P1007, DOI 10.20506/rst.33.3.2337; Jensen VF, 2004, PREV VET MED, V64, P201, DOI 10.1016/j.prevetmed.2004.04.001; Larde H, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00010; Livestock Improvement Association of Japan, 2016, SUMM DAIR COW HERD A; Matsuda M, 2017, J ANIMAL HYG, V42, P191; Ministry of Agriculture,, 2018, REP JAP VET ANT RES; National Agriculture and Food Research Organization (NARO), 2013, JAP FEED STAND SWIN; Netherlands Veterinary Institute (SDa), USG ANT AGR LIV NETH; O'Neill L, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.558793; Sanders P, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00540; Sugiura K, 2009, VET ITAL, V45, P305; Takagi H., 2017, JAPANESE J ANIMAL HY, V45, P155; Takagi H., 2020, NIPPON JUISHIKAI ZAS, V73, P352; WHO, 2018, DDD DEF GEN CONS CIT; WHO, 2020, ATCV IND 2020; World Organisation for Animal Health (OIE), 4 OIE ANN REPORT ANT	28	5	5	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2021	16	4							e0245105	10.1371/journal.pone.0245105	http://dx.doi.org/10.1371/journal.pone.0245105			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP1DH	33861745	gold, Green Published, Green Submitted			2023-01-03	WOS:000641475400028
J	Komolafe, AO; Olowokere, AE; Irinoye, OO				Komolafe, Abiola Olubusola; Olowokere, Adekemi Eunice; Irinoye, Omolola Oladunni			Assessment of integration of emergency obstetric and newborn care in maternal and newborn care in healthcare facilities in Osun State, Nigeria	PLOS ONE			English	Article							IMPLEMENTATION; MORTALITY; DELIVERY	The integration of emergency obstetric and newborn care (EmONC) into maternal and newborn care is essential for its effectiveness to avert preventable maternal and newborn deaths in healthcare facilities. This study used a theory-oriented quantitative approach to document the reported extent of EmONC integration, and its relationship with EmONC training, guidelines availability and level of healthcare facility. A descriptive cross-sectional study was conducted among five hundred and five (505) healthcare providers and facility managers across the three levels of healthcare delivery. An adapted questionnaire from NoMad instrument was used to collect data on the integration of EmONC from the study participants. Ethical approval was obtained and informed consents taken from the participants. Both descriptive (frequency, percentage, mean and median) and inferential analyses (Kruskal Wallis and Mann Whitney tests) were done with statistical significance level of p<0.05 using STATA 14. The mean age of respondents was 38.68 +/- 8.27. The results showed that the EmONC integration median score at the three levels of healthcare delivery was high (77 (IQR = 83-71)). The EmONC integration median score were 76 (IQR = 84-70), 76 (IQR = 80-68) and 78 (IQR = 84-74) in the primary, secondary and tertiary healthcare facilities respectively. Integration of EmONC was highest (83 (IQR = 87-78)) among healthcare providers who had EmONC training and also had EmONC guidelines made available to them. There were significant differences in EmONC integration at the three levels of healthcare delivery (p = 0.046), among healthcare providers who had EmONC training and those with EmONC guidelines available in their maternity units (p = 0.001). EmONC integration was reportedly high and significantly associated with EmONC training and availability of guidelines. However, the congruence of reported and actual extent of integration of EmONC at the three levels of healthcare delivery still need validation as such would account for the implementation success and maternal-neonatal outcomes.	[Komolafe, Abiola Olubusola; Olowokere, Adekemi Eunice; Irinoye, Omolola Oladunni] Obafemi Awolowo Univ, Dept Nursing Sci, Ife, Osun State, Nigeria	Obafemi Awolowo University	Komolafe, AO (corresponding author), Obafemi Awolowo Univ, Dept Nursing Sci, Ife, Osun State, Nigeria.	abiolakomolafe2016@gmail.com		Komolafe, Abiola/0000-0002-2123-7782; OLOWOKERE, Adekemi/0000-0002-0499-6015; Irinoye, Omolola/0000-0001-6806-1000	Consortium for Advanced Research Training in Africa (CARTA); Carnegie Corporation of New York [B 8606.R02]; Sida [54100113]; DELTAS Africa Initiative [107768/Z/15/Z]; Deutscher Akademischer Austauschdienst (DAAD); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust (UK); UK government	Consortium for Advanced Research Training in Africa (CARTA); Carnegie Corporation of New York; Sida; DELTAS Africa Initiative; Deutscher Akademischer Austauschdienst (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust (UK)(Wellcome Trust); UK government	This research was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No-B 8606.R02), Sida (Grant No:54100113), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z) and Deutscher Akademischer Austauschdienst (DAAD). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. The statements made and views expressed are solely the responsibility of the Fellow. A.O. received fellowship grant for PhD from the Consortium for Advanced Research Training in Africa (CARTA). The funders have no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Aluko JO, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-018-3819-x; Ameh CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167270; Ameh CA, 2015, BEST PRACT RES CL OB, V29, P1077, DOI 10.1016/j.bpobgyn.2015.03.019; Banke-Thomas A., 2017, BMC PREGNANCY CHILDB, V17, P1, DOI [10.1186/s12884-016-1183-6, DOI 10.1186/S12884-016-1183-6]; Banke-Thomas A, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.31880; Bohren MA, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-71; Calvello EJ, 2015, B WORLD HEALTH ORGAN, V93, P417, DOI 10.2471/BLT.14.146571; Diffin J, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0382-5; Ebuehi OM., 2013, CLIN MED DIAGN, V3, P29, DOI DOI 10.5923/J.CMD.20130302.03; Fatiregun A., 2015, ANN COMMUNITY MED PR, V1, P1; Finch TL, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0591-x; Ijadunola KT, 2010, BMC WOMENS HEALTH, V10, DOI 10.1186/1472-6874-10-6; Johnson MJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017727; Koce F, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4046-9; Mahato P.K., 2017, J ASIAN MIDWIVES, V4, P25; May CR, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-29; Mirkuzie AH, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-354; National Population Commission (NPC) [Nigeria] and ICF International, 2014, NIG DEM HLTH SURV 20, P1; National Population Commission (NPC) [Nigeria] and ICF International, 2019, NIG DEM HLTH SURV 20, P1; National Primary Health Care Development Agency (NPHCDA), NAT PRIM HLTH CAR DE, P1; Ntambue AM, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1224-9; Ntoimo OF, 2018, INT J WOMENS HEALTH, V10, P69, DOI 10.2147/IJWH.S151784; Nyamtema AS, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-30; Obembe TA, 2014, AM J SOC MANAG SCI, V5, P84; Okoli Henry, 2017, Pan Afr Med J, V26, P105, DOI 10.11604/pamj.2017.26.105.11483; Okonafua F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188392; Okonofua F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213719; Olsen S, 2010, VET CLIN N AM-FOOD A, V26, P15, DOI 10.1016/j.cvfa.2009.10.006; Otolorin E, 2015, INT J GYNECOL OBSTET, V130, pS46, DOI 10.1016/j.ijgo.2015.03.007; Pattinson RC, 2015, SAMJ S AFR MED J, V105, P256, DOI [10.7196/samj.9181, 10.7196/SAMJ.9181]; Proctor E, 2011, ADM POLICY MENT HLTH, V38, P65, DOI 10.1007/s10488-010-0319-7; Rasanathan K, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0493-7; Roos N, 2016, BEST PRACT RES CL OB, V36, P30, DOI 10.1016/j.bpobgyn.2016.06.002; Smith JD, 2017, FAM SYST HEALTH, V35, P125, DOI 10.1037/fsh0000252; WHO UNICEF UNFPA World_Bank_Group UNPD, 2015, TRENDS MAT MORT 1990, P14; Wolfenden L, 2016, AUST NZ J PUBL HEAL, V40, P209, DOI 10.1111/1753-6405.12518; Wong KLM, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3225-4	37	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2021	16	4							e0249334	10.1371/journal.pone.0249334	http://dx.doi.org/10.1371/journal.pone.0249334			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP1DC	33857184	Green Published, gold			2023-01-03	WOS:000641474900088
J	Schjorring, OL; Klitgaard, TL; Perner, A; Wetterslev, J; Lange, T; Siegemund, M; Backlund, M; Keus, F; Laake, JH; Morgan, M; Thormar, KM; Rosborg, SA; Bisgaard, J; Erntgaard, AES; Lynnerup, ASH; Pedersen, RL; Crescioli, E; Gielstrup, TC; Behzadi, MT; Poulsen, LM; Estrup, S; Laigaard, JP; Andersen, C; Mortensen, CB; Brand, BA; White, J; Jarnvig, IL; Moller, MH; Quist, L; Bestle, MH; Schonemann-Lund, M; Kamper, MK; Hindborg, M; Hollinger, A; Gebhard, CE; Zellweger, N; Meyhoff, CS; Hjort, M; Bech, LK; Grofte, T; Bundgaard, H; Ostergaard, LHM; Thyo, MA; Hildebrandt, T; Uslu, B; Solling, CG; Moller-Nielsen, N; Brochner, AC; Borup, M; Okkonen, M; Dieperink, W; Pedersen, UG; Andreasen, AS; Buus, L; Aslam, TN; Winding, RR; Schefold, JC; Thorup, SB; Iversen, SA; Engstrom, J; Kjaer, MBN; Rasmussen, BS				Schjorring, Olav L.; Klitgaard, Thomas L.; Perner, Anders; Wetterslev, Jorn; Lange, Theis; Siegemund, Martin; Backlund, Minna; Keus, Frederik; Laake, Jon H.; Morgan, Matthew; Thormar, Katrin M.; Rosborg, Soren A.; Bisgaard, Jannie; Erntgaard, Annette E. S.; Lynnerup, Anne-Sofie H.; Pedersen, Rasmus L.; Crescioli, Elena; Gielstrup, Theis C.; Behzadi, Meike T.; Poulsen, Lone M.; Estrup, Stine; Laigaard, Jens P.; Andersen, Cheme; Mortensen, Camilla B.; Brand, Bjorn A.; White, Jonathan; Jarnvig, Inge-Lise; Moller, Morten H.; Quist, Lars; Bestle, Morten H.; Schonemann-Lund, Martin; Kamper, Maj K.; Hindborg, Mathias; Hollinger, Alexa; Gebhard, Caroline E.; Zellweger, Nuria; Meyhoff, Christian S.; Hjort, Mathias; Bech, Laura K.; Grofte, Thorbjorn; Bundgaard, Helle; Ostergaard, Lars H. M.; Thyo, Maria A.; Hildebrandt, Thomas; Uslu, Bulent; Solling, Christoffer G.; Moller-Nielsen, Nette; Brochner, Anne C.; Borup, Morten; Okkonen, Marjatta; Dieperink, Willem; Pedersen, Ulf G.; Andreasen, Anne S.; Buus, Lone; Aslam, Tayyba N.; Winding, Robert R.; Schefold, Joerg C.; Thorup, Stine B.; Iversen, Susanne A.; Engstrom, Janus; Kjaer, Maj-Brit N.; Rasmussen, Bodil S.		HOT-ICU Investigators	Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND Patients with acute hypoxemic respiratory failure in the intensive care unit (ICU) are treated with supplemental oxygen, but the benefits and harms of different oxygenation targets are unclear. We hypothesized that using a lower target for partial pressure of arterial oxygen (Pao(2)) would result in lower mortality than using a higher target. METHODS In this multicenter trial, we randomly assigned 2928 adult patients who had recently been admitted to the ICU (<= 12 hours before randomization) and who were receiving at least 10 liters of oxygen per minute in an open system or had a fraction of inspired oxygen of at least 0.50 in a closed system to receive oxygen therapy targeting a Pao(2) of either 60 mm Hg (lower-oxygenation group) or 90 mm Hg (higher-oxygenation group) for a maximum of 90 days. The primary outcome was death within 90 days. RESULTS At 90 days, 618 of 1441 patients (42.9%) in the lower-oxygenation group and 613 of 1447 patients (42.4%) in the higher-oxygenation group had died (adjusted risk ratio, 1.02; 95% confidence interval, 0.94 to 1.11; P=0.64). At 90 days, there was no significant between-group difference in the percentage of days that patients were alive without life support or in the percentage of days they were alive after hospital discharge. The percentages of patients who had new episodes of shock, myocardial ischemia, ischemic stroke, or intestinal ischemia were similar in the two groups (P=0.24). CONCLUSIONS Among adult patients with acute hypoxemic respiratory failure in the ICU, a lower oxygenation target did not result in lower mortality than a higher target at 90 days.	[Schjorring, Olav L.; Klitgaard, Thomas L.; Rosborg, Soren A.; Bisgaard, Jannie; Erntgaard, Annette E. S.; Lynnerup, Anne-Sofie H.; Pedersen, Rasmus L.; Crescioli, Elena; Gielstrup, Theis C.; Behzadi, Meike T.; Rasmussen, Bodil S.] Aalborg Univ, Aalborg Univ Hosp, Dept Anesthesia & Intens Care, Aalborg, Denmark; [Poulsen, Lone M.; Estrup, Stine; Laigaard, Jens P.; Andersen, Cheme; Mortensen, Camilla B.] Zealand Univ Hosp, Koge, Denmark; [Perner, Anders; Wetterslev, Jorn; Brand, Bjorn A.; Jarnvig, Inge-Lise; Moller, Morten H.; Quist, Lars; Kjaer, Maj-Brit N.] Rigshosp, Bispebjerg, Denmark; [Lange, Theis] Univ Copenhagen, Sect Biostat, Dept Publ Hlth, Bispebjerg, Denmark; [Meyhoff, Christian S.; Hjort, Mathias; Bech, Laura K.] Frederiksberg Univ Hosp, Copenhagen, Denmark; [White, Jonathan; Engstrom, Janus] Copenhagen Trial Unit, Copenhagen, Denmark; [Bestle, Morten H.; Schonemann-Lund, Martin; Kamper, Maj K.; Hindborg, Mathias] Nordsjaellands Hosp, Hillerod, Denmark; [Grofte, Thorbjorn; Bundgaard, Helle] Randers Cent Hosp, Randers, Denmark; [Ostergaard, Lars H. M.; Thyo, Maria A.] Aarhus Univ Hosp, Aarhus, Denmark; [Hildebrandt, Thomas; Uslu, Bulent] Zealand Univ Hosp, Roskilde, Denmark; [Solling, Christoffer G.; Moller-Nielsen, Nette] Viborg Hosp, Viborg, Denmark; [Backlund, Minna; Brochner, Anne C.] Kolding Cty Hosp, Kolding, Denmark; [Pedersen, Ulf G.] Hvidovre Univ Hosp, Hvidovre, Denmark; [Andreasen, Anne S.] Herlev Hosp, Herlev, Denmark; [Buus, Lone] Horsens Hosp, Horsens, Denmark; [Winding, Robert R.] Herning Hosp, Herning, Denmark; [Thorup, Stine B.] Holbaek Cent Hosp, Holbaek, Denmark; [Iversen, Susanne A.] Slagelse Hosp, Slagelse, Denmark; [Siegemund, Martin; Hollinger, Alexa; Gebhard, Caroline E.; Zellweger, Nuria] Univ Basel, Dept Intens Care, Basel, Switzerland; [Siegemund, Martin; Hollinger, Alexa; Gebhard, Caroline E.; Zellweger, Nuria] Univ Basel, Dept Clin Res, Basel, Switzerland; [Schefold, Joerg C.] Univ Bern, Inselspital, Dept Intens Care, Bern, Switzerland; [Borup, Morten; Okkonen, Marjatta] Helsinki Univ Hosp, Dept Perioperat Intens Care & Pain Med, Helsinki, Finland; [Keus, Frederik; Dieperink, Willem] Univ Med Ctr Groningen, Dept Crit Care, Groningen, Netherlands; [Laake, Jon H.; Aslam, Tayyba N.] Oslo Univ Hosp, Rikshosp, Dept Anesthesia & Intens Care, Oslo, Norway; [Laake, Jon H.; Aslam, Tayyba N.] Oslo Univ Hosp, Rikshosp, Dept Clin Res, Oslo, Norway; [Morgan, Matthew] Cardiff Univ Hosp Wales, Dept Intens Care, Cardiff, Wales; [Thormar, Katrin M.] Landspitali Univ Hosp, Dept Anesthesia & Intens Care, Reykjavik, Iceland	Aalborg University; Aalborg University Hospital; Rigshospitalet; University of Copenhagen; Aarhus University; Aarhus University; Aarhus University; Kolding Hospital; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; Aarhus University; Aarhus University; Holbaek Hospital; University of Basel; University of Basel; University of Bern; University Hospital of Bern; University of Helsinki; Helsinki University Central Hospital; University of Groningen; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Cardiff University; Landspitali National University Hospital	Rasmussen, BS (corresponding author), Aalborg Univ Hosp, Dept Anesthesia & Intens Care, Hobrovej 18-21, DK-9000 Aalborg, Denmark.	bodil.steen.rasmussen@rn.dk	Lass Klitgaard, Thomas/AAZ-1656-2021; Laake, Jon Henrik/L-3224-2019; Hjort, Mathias/AAN-2240-2021; Laigaard, Jens/GOH-3351-2022; Wetterslev, Jørn/ABF-1251-2020	Lass Klitgaard, Thomas/0000-0002-8781-1206; Laake, Jon Henrik/0000-0001-6157-5359; Laigaard, Jens/0000-0001-5297-3769; Wetterslev, Jørn/0000-0001-7778-1771; Dieperink, Willem/0000-0003-2738-7471; Lange, Theis/0000-0001-6807-8347; Andreasen, Anne Sofie/0000-0002-8759-3405; Perner, Anders/0000-0002-4668-0123; Zellweger, Nuria Manuela/0000-0002-3202-2365; Schefold, Joerg C./0000-0001-9162-5724; Mortensen, Camilla Bekker/0000-0001-5202-3552; Bannard-Smith, Jonathan/0000-0001-7120-480X; Bestle, Morten/0000-0001-6585-2659; Morgan, Matt/0000-0002-2357-7190; Poulsen, Lone Musaeus/0000-0002-7030-3395; Rasmussen, Bodil Steen/0000-0003-2190-145X; Hildebrandt, Thomas/0000-0001-7845-9899; Bisgaard, Jannie/0000-0001-6499-9691; Meyhoff, Christian/0000-0002-4885-4609; Solling, Christoffer/0000-0003-0721-926X	Innovation Fund Denmark [4108-00011A]; Aalborg University Hospital; Regions of Denmark [EMN2017-00901, EMN-2019-01055]; Obel Family Foundation [25457]; Danish Society of Anesthesiology and Intensive Care Medicine; Intensive Care Symposium Hindsgavl	Innovation Fund Denmark; Aalborg University Hospital; Regions of Denmark; Obel Family Foundation; Danish Society of Anesthesiology and Intensive Care Medicine; Intensive Care Symposium Hindsgavl	Supported by a grant (4108-00011A) from Innovation Fund Denmark, by the Aalborg University Hospital, by grants (EMN2017-00901 and EMN-2019-01055) from the Regions of Denmark, by a grant (25457) from the Obel Family Foundation, by the Danish Society of Anesthesiology and Intensive Care Medicine, and by the Intensive Care Symposium Hindsgavl.	Aggarwal NR, 2018, CRIT CARE MED, V46, P517, DOI 10.1097/CCM.0000000000002886; Barbateskovic M, 2021, CHEST, V159, P154, DOI 10.1016/j.chest.2020.07.015; Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431; Beasley R, 2015, RESPIROLOGY, V20, P1182, DOI 10.1111/resp.12620; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; Claesson J, 2015, ACTA ANAESTH SCAND, V59, P286, DOI 10.1111/aas.12449; Ebmeier SJ, 2018, ANAESTH INTENS CARE, V46, P297, DOI 10.1177/0310057X1804600307; Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Goodman SN, 1999, ANN INTERN MED, V130, P1005, DOI 10.7326/0003-4819-130-12-199906150-00019; Helmerhorst HJF, 2017, CRIT CARE MED, V45, P187, DOI 10.1097/CCM.0000000000002084; Jakobsen JC, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0442-1; Mackle D, 2020, NEW ENGL J MED, V382, P989, DOI 10.1056/NEJMoa1903297; O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729; Panwar R, 2016, AM J RESP CRIT CARE, V193, P43, DOI 10.1164/rccm.201505-1019OC; Schjorring OL, 2018, ACTA ANAESTH SCAND, V62, P1443, DOI 10.1111/aas.13171; Schjorring OL, 2020, ACTA ANAESTH SCAND, V64, P847, DOI 10.1111/aas.13569; Schjorring OL, 2020, BRIT J ANAESTH, V124, P420, DOI 10.1016/j.bja.2019.12.039; Schjorring OL, 2019, ACTA ANAESTH SCAND, V63, P956, DOI 10.1111/aas.13356; Schjorring OL, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2257-9; Sjoding MW, 2020, NEW ENGL J MED, V383, P2477, DOI 10.1056/NEJMc2029240; Tamborrino M JJC., 2015, J BIOM BIOSTAT, V06, P1, DOI [10.4172/2155-6180.1000227, DOI 10.4172/2155-6180.1000227]	27	91	92	4	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	2021	384	14					1301	1311		10.1056/NEJMoa2032510	http://dx.doi.org/10.1056/NEJMoa2032510			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ7RN	33471452	Green Published, Bronze			2023-01-03	WOS:000637799800008
J	Prost, DM; Merenzon, MA; Gomez-Escalante, JI; Primavera, A; Benitez, MV; Gil, AS; Marenco, PM; Califano, MM; Cueto, CM; Dakoff, JMZ; Colonna, M; Mazzon, A; Zaninovich, RS; De Cristofaro, OR				Prost, Diego M.; Merenzon, Martin A.; Gomez-Escalante, Jose, I; Primavera, Andres; Vargas Benitez, Mara; Gil, Andres S.; Marenco, Pablo M.; Califano, Maria M.; Moughty Cueto, Carolina; Zaloff Dakoff, Juan M.; Colonna, Mario; Mazzon, Alejandro; Zaninovich, Roberto S.; De Cristofaro, Oscar R.			Effects of time to chemoradiation on high-grade gliomas from the Buenos Aires Metropolitan Area	PLOS ONE			English	Article							ARGENTINA; CARE	High-Grade Gliomas (HGG) are the most frequent brain tumor in adults. The gold standard of clinical care recommends beginning chemoradiation within 6 weeks of surgery. Disparities in access to healthcare in Argentina are notorious, often leading to treatment delays. We conducted this retrospective study to evaluate if time to chemoradiation after surgery is correlated with progression-free survival (PFS). Our study included clinical cases with a histological diagnosis of Glioblastoma (GBM), Anaplastic Astrocytoma (AA) or High-Grade Glioma (HGG) in patients over 18 years of age from 2014 to 2020. We collected data on clinical presentation, type of resection, time to surgery, time to chemoradiation, location within the Buenos Aires Metropolitan Area (BAMA) and type of health insurance. We found 63 patients that fit our inclusion criteria, including 26 (41.3%) females and 37 (58.7%) males. Their median age was 54 years old (19-86). Maximal safe resection was achieved in 49.2% (n = 31) of the patients, incomplete resection in 34.9% (n = 22) and the other 15.9% (n = 10) received a biopsy, but no resection. The type of health care insurance was almost evenly divided, with 55.6% (n = 35) of the patients having public vs. 44.4% (n = 28) having private health insurance. Median time to chemoradiation after surgery was 8 (CI 6.68-9.9) weeks for the global population. When we ordered the patients PFS by time to chemoradiation we found that there was a statistically significant effect of time to chemoradiation on patient PFS. Patients had a PFS of 10 months (p = 0.014) (CI 6.89-13.10) when they received chemoradiation <5 weeks vs a PFS of 7 months (CI 4.93-9.06) when they received chemoradiation between 5 to 8 weeks and a PFS of 4 months (CI 3.76-4.26 HR 2.18 p = 0.006) when they received chemoradiation >8 weeks after surgery. Also, our univariate and multivariate analysis found that temporal lobe location (p = 0.03), GMB histology (p = 0.02) and biopsy as surgical intervention (p = 0.02) all had a statistically significant effect on patient PFS. Thus, time to chemoradiation is an important factor in patient PFS. Our data show that although an increase in HGG severity contributes to a decrease in patient PFS, there is also a large effect of time to chemoradiation. Our results suggest that we can improve patient PFS by making access to healthcare in Buenos Aires more equitable by reducing the average time to chemoradiation following tumor resection.	[Prost, Diego M.; De Cristofaro, Oscar R.] Univ Buenos Aires, Inst Oncol Angel H Roffo, Med Oncol Dept, Neurooncol Unit, Buenos Aires, DF, Argentina; [Merenzon, Martin A.; Califano, Maria M.; Moughty Cueto, Carolina; Zaloff Dakoff, Juan M.; Colonna, Mario; Mazzon, Alejandro] Univ Buenos Aires, Inst Oncol Angel H Roffo, Surg Oncol Dept, Neurooncol Unit, Buenos Aires, DF, Argentina; [Gomez-Escalante, Jose, I] Univ Buenos Aires, Inst Oncol Angel H Roffo, Pathol Dept, Buenos Aires, DF, Argentina; [Primavera, Andres] Univ Buenos Aires, Inst Oncol Angel H Roffo, Med Imaging Dept, Buenos Aires, DF, Argentina; [Vargas Benitez, Mara] Ctr Privado Radioterapia, Radiat Oncol, Cordoba, Argentina; [Gil, Andres S.] Univ Buenos Aires, Inst Oncol Angel H Roffo, Radiat Oncol Dept, Buenos Aires, DF, Argentina; [Marenco, Pablo M.] Univ Buenos Aires, Inst Oncol Angel H Roffo, Psicooncol Dept, Buenos Aires, DF, Argentina; [Zaninovich, Roberto S.] Univ Buenos Aires, Hosp Clin Jose de San Martin, Neurosurg Dept, Buenos Aires, DF, Argentina; [De Cristofaro, Oscar R.] Univ Buenos Aires, Inst Oncol Angel H Roffo, Clin Oncol Dept, Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires; University of Buenos Aires; University of Buenos Aires; University of Buenos Aires; University of Buenos Aires; University of Buenos Aires; University of Buenos Aires	Prost, DM (corresponding author), Univ Buenos Aires, Inst Oncol Angel H Roffo, Med Oncol Dept, Neurooncol Unit, Buenos Aires, DF, Argentina.	dieprost@gmail.com		Prost, Diego/0000-0002-4962-8611; Merenzon, Martin/0000-0002-2181-9029				Brat DJ, 2020, ACTA NEUROPATHOL, V139, P603, DOI 10.1007/s00401-020-02127-9; Brat DJ, 2018, ACTA NEUROPATHOL, V136, P805, DOI 10.1007/s00401-018-1913-0; Chang S., 2016, NEURO ONCOL, P1; D'Amico RS, 2017, WORLD NEUROSURG, V103, P538, DOI 10.1016/j.wneu.2017.04.041; Geurts M, 2019, CANCER-AM CANCER SOC, V125, P174, DOI 10.1002/cncr.31834; Hervey-Jumper SL, 2016, J NEURO-ONCOL, V130, P269, DOI 10.1007/s11060-016-2110-4; Instituto Nacional de Estadistica, 2022, ESTIMACIONES PROYECC; Iriart C, 2006, INT J HEALTH SERV, V36, P177, DOI 10.2190/2DYU-E8ME-DG87-4JTH; Irwin C, 2007, J NEURO-ONCOL, V85, P339, DOI 10.1007/s11060-007-9426-z; Machado CV, 2018, CIENC SAUDE COLETIVA, V23, P2197, DOI 10.1590/1413-81232018237.08362018; Nam JY, 2017, J ONCOL PRACT, V13, P629, DOI 10.1200/JOP.2017.025536; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Pontes L, 2017, J GLOB ONCOL, V3, P157, DOI 10.1200/JGO.2016.004911; Rabadan AT., 2017, SURG NEUROL INT, V13, P1417, DOI [10.4103/sni.sni_497_16 28680737, DOI 10.4103/SNI.SNI_497_1628680737]; Rubinstein A, 2018, HEALTH SYST REFORM, V4, P203, DOI 10.1080/23288604.2018.1477537; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sulman EP, 2017, J CLIN ONCOL, V35, P361, DOI 10.1200/JCO.2016.70.7562; Warren KT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00186; Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273; Wen PY, 2017, J CLIN ONCOL, V35, P2439, DOI 10.1200/JCO.2017.72.7511	20	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2021	16	4							e0249486	10.1371/journal.pone.0249486	http://dx.doi.org/10.1371/journal.pone.0249486			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RI2KE	33798233	gold, Green Published			2023-01-03	WOS:000636737700008
J	Prang, P; Schuld, C; Rupp, R; Hensel, C; Weidner, N				Prang, Peter; Schuld, Christian; Rupp, Ruediger; Hensel, Cornelia; Weidner, Norbert			Influence of patient isolation due to colonization with multidrug-resistant organisms on functional recovery after spinal cord injury	PLOS ONE			English	Article								Study design Chart reviews were combined with neurological and functional outcome data obtained from the prospective European Multicenter Study on Spinal Cord Injury (EMSCI, www.emsci.org). Objectives To determine if strict physical isolation of multidrug-resistant organisms (MDRO)-positive patients negatively affects neurological recovery and functional outcome in the first year after acute spinal cord injury (SCI). Setting SCI Center Heidelberg University Hospital. Methods Individuals with acute (< 6 weeks) traumatic or ischemic SCI were included. During primary comprehensive care, isolated MDRO-positive patients (n = 13) were compared with a MDRO-negative control group (n = 13) matched for functional (Spinal Cord Independence Measure-SCIM) and neurological impairment (motor scores based on the International Standards for Neurological Classification of Spinal Cord Injury-ISNCSCI) at an early stage up to 40 days after SCI. SCIM scores and motor scores were obtained at 12 weeks (intermediate stage) and 24 or 48 weeks (late stage) after SCI. Results Isolated MDRO-positive (median duration of hospitalization: 175 days, 39% of inpatient stay under isolation measures) and non-isolated MDRO-negative (median duration of hospitalization: 161 days) patients showed functional and neurological improvements, which were not statistically different between groups at the intermediate and late stage. Conclusion Prolonged isolation due to MDRO colonization for over a third of the inpatient comprehensive care period does not appear to impair neurological recovery and functional outcome within the first year after SCI.	[Prang, Peter; Schuld, Christian; Rupp, Ruediger; Hensel, Cornelia; Weidner, Norbert] Heidelberg Univ Hosp, Spinal Cord Injury Ctr, Heidelberg, Germany	Ruprecht Karls University Heidelberg	Weidner, N (corresponding author), Heidelberg Univ Hosp, Spinal Cord Injury Ctr, Heidelberg, Germany.	Norbert.weidner@med.uni-heidelberg.de						Alexander MS, 2009, SPINAL CORD, V47, P582, DOI 10.1038/sc.2009.18; [Anonymous], 2012, BUNDESGESUNDHEITSBLA, V55, P1311, DOI 10.1007/s00103-012-1549-5; Balbale SN, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0318-x; Catalano G, 2003, SOUTH MED J, V96, P141, DOI 10.1097/01.SMJ.0000050683.36014.2E; Catz A, 2001, DISABIL REHABIL, V23, P263; Catz A, 2007, J REHABIL RES DEV, V44, P65, DOI 10.1682/JRRD.2005.07.0123; Chittick P, 2016, AM J INFECT CONTROL, V44, P657, DOI 10.1016/j.ajic.2015.12.033; Curt A, 2004, SPINAL CORD, V42, P1, DOI 10.1038/sj.sc.3101558; Evans HL, 2003, SURGERY, V134, P180, DOI 10.1067/msy.2003.222; Evans ME, 2013, AM J INFECT CONTROL, V41, P422, DOI 10.1016/j.ajic.2012.06.006; Fitzpatrick MA, 2016, INFECT CONT HOSP EP, V37, P768, DOI 10.1017/ice.2016.60; Franz M, 2018, SPINAL CORD, V56, P158, DOI 10.1038/s41393-017-0007-5; Gasink LB, 2008, INFECT CONT HOSP EP, V29, P275, DOI 10.1086/527508; Hassouna H, 2008, ACTA ORTHOP BELG, V74, P528; Hogardt M, 2015, EUROSURVEILLANCE, V20, P23, DOI 10.2807/1560-7917.ES2015.20.26.21171; Itzkovich M, 2007, DISABIL REHABIL, V29, P1926, DOI 10.1080/09638280601046302; Jakob W, 2009, J NEUROTRAUM, V26, P2037, DOI 10.1089/neu.2008.0824; Karam G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1320-7; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P535, DOI 10.1179/204577211X13207446293695; Kommission fur Krankenhaushygiene und Infektionspravention (KRINKO), 2014, BUNDESGESUNDHEITSBLA, V57, P695, DOI [10.1007/s00103-014-1980-x, DOI 10.1007/s00103-014-1980-x, DOI 10.1007/S00103-014-1980-X]; Manian FA, 2002, INFECT CONT HOSP EP, V23, P516, DOI 10.1086/502099; Maurer-Burkhard B, 2016, SPINAL CORD, V54, P619, DOI 10.1038/sc.2015.223; Minary-Dohen Patrica, 2003, BMC Geriatr, V3, P5, DOI 10.1186/1471-2318-3-5; Mylotte JM, 2000, AM J INFECT CONTROL, V28, P291, DOI 10.1067/mic.2000.107424; Nair R, 2020, CLIN MICROBIOL INFEC, V26, P684, DOI 10.1016/j.cmi.2020.01.022; Pike JH, 2002, ARCH PHYS MED REHAB, V83, P1028, DOI 10.1053/apmr.2002.33108; Rollnik JD, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0833-2; Rollnik JD, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-34; Schuld C, 2013, SPINAL CORD, V51, P282, DOI 10.1038/sc.2012.149; Schuld C, 2012, J NEUROTRAUM, V29, P453, DOI 10.1089/neu.2011.2085; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; Tarzi S, 2001, J HOSP INFECT, V49, P250, DOI 10.1053/jhin.2001.1098; Torres K, 2013, AM J INFECT CONTROL, V41, P1043, DOI 10.1016/j.ajic.2013.02.013; van Hedel HJ, 2005, ARCH PHYS MED REHAB, V86, P190, DOI 10.1016/j.apmr.2004.02.010; van Langeveld SA, 2009, ARCH PHYS MED REHAB, V90, P1229, DOI 10.1016/j.apmr.2008.12.026; Wirz M, 2015, J NEUROTRAUM, V32, P194, DOI 10.1089/neu.2014.3335	36	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2021	16	3							e0249295	10.1371/journal.pone.0249295	http://dx.doi.org/10.1371/journal.pone.0249295			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RF4TU	33770131	Green Published, Green Accepted, gold			2023-01-03	WOS:000634833500035
J	Doughty, H; Milner-Gulland, EJ; Lee, JSH; Oliver, K; Carrasco, LR; Verissimo, D				Doughty, Hunter; Milner-Gulland, E. J.; Lee, Janice Ser Huay; Oliver, Kathryn; Carrasco, L. Roman; Verissimo, Diogo			Evaluating a large-scale online behaviour change intervention aimed at wildlife product consumers in Singapore	PLOS ONE			English	Article							METAANALYSIS; PERCEPTIONS; MEDICINE; MEDIA; NEWS	Interventions to shift the behaviour of consumers using unsustainable wildlife products are key to threatened species conservation. Whether these interventions are effective is largely unknown due to a dearth of detailed evaluations. We previously conducted a country-level online behaviour change intervention targeting consumers of the Critically Endangered saiga antelope (Saiga tatarica) horn in Singapore. To evaluate intervention impact, we carried out in-person consumer surveys with >2,000 individuals pre- and post-intervention (2017 and 2019), and 93 in-person post-intervention surveys with traditional Chinese medicine (TCM) shopkeepers (2019). The proportion of self-reported high-usage saiga horn consumers in the target audience (Chinese Singaporean women aged 35-59) did not change significantly from pre- to post-intervention (24.4% versus 22.6%). However, post-intervention the target audience was significantly more likely than the non-target audience to accurately recall the intervention message and to report a decrease in saiga horn usage (4% versus 1% reported a behaviour change). Within the target audience, high-usage consumers were significantly more likely than lower-usage consumers to recall the message and report a behaviour change. Across respondents who reported a decrease in saiga horn usage, they cited the intervention message as a specific reason for their behaviour change significantly more than other reasons. Additionally, across all respondents, the belief that saiga is a common species in the wild decreased significantly from pre- to post-intervention. TCM shopkeepers, however, cited factors such as price and availability as the strongest influences on saiga horn sales. In sum, the intervention did significantly influence some consumers but the reduction of high-usage consumer frequency was not significant at the population level. We explore reasons for these findings, including competing consumer influences, characteristics of the intervention, and evaluation timing. This work suggests our intervention approach has potential, and exemplifies a multi-pronged in-person evaluation of an online wildlife trade consumer intervention.	[Doughty, Hunter; Milner-Gulland, E. J.; Verissimo, Diogo] Univ Oxford, Dept Zool, Oxford, England; [Doughty, Hunter; Milner-Gulland, E. J.; Verissimo, Diogo] Univ Oxford, Oxford Martin Programme Illegal Wildlife Trade, Oxford, England; [Lee, Janice Ser Huay] Nanyang Technol Univ Singapore, Asian Sch Environm, Singapore, Singapore; [Oliver, Kathryn] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London, England; [Carrasco, L. Roman] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore; [Verissimo, Diogo] San Diego Zoo, Inst Conservat Res, Escondido, CA USA	University of Oxford; University of Oxford; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; University of London; London School of Hygiene & Tropical Medicine; National University of Singapore; Zoological Society of San Diego	Doughty, H (corresponding author), Univ Oxford, Dept Zool, Oxford, England.; Doughty, H (corresponding author), Univ Oxford, Oxford Martin Programme Illegal Wildlife Trade, Oxford, England.	hunterldoughty@gmail.com	Oliver, Kathryn/I-9905-2019; Carrasco, Luis R/H-8017-2012	Oliver, Kathryn/0000-0002-4326-5258; Carrasco, Luis R/0000-0002-2894-1473; Doughty, Hunter/0000-0001-5203-5115	Oxford University through the Oxford Martin Programme on the Illegal Wildlife Trade	Oxford University through the Oxford Martin Programme on the Illegal Wildlife Trade	This research was funded by Oxford University through the Oxford Martin Programme on the Illegal Wildlife Trade (grant held by author EJMG). The funder provided support in the form of salaries for authors (EJMG, DV) and fieldwork costs but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section of the manuscript.	Allcott H, 2014, AM ECON REV, V104, P3003, DOI 10.1257/aer.104.10.3003; Althubaiti A, 2016, J MULTIDISCIP HEALTH, V9, P211, DOI 10.2147/JMDH.S104807; [Anonymous], 2019, WORLD BANK ANAL INT; Baylis K, 2016, CONSERV LETT, V9, P58, DOI 10.1111/conl.12180; Burke HM, 2019, EVAL PROGRAM PLANN, V77, DOI 10.1016/j.evalprogplan.2019.101721; Byrne D, 2013, EVALUATION-US, V19, P217, DOI 10.1177/1356389013495617; Capurro D., 2014, J MED INTERNET RES, V16, P79, DOI [10.2196/jmir.267924642014, DOI 10.2196/JMIR.267924642014]; Cavatorta E., 2017, COMPLEMENTS ALTERNAT; Ceballos G, 2017, P NATL ACAD SCI USA, V114, pE6089, DOI 10.1073/pnas.1704949114; Chang L, 2015, QUAL HEALTH RES, V25, P241, DOI 10.1177/1049732314551991; Chung VCH, 2014, HEALTH EXPECT, V17, P622, DOI 10.1111/j.1369-7625.2012.00794.x; CITES (Convention on International Trade in Endangered Species of Wild Fauna and Flora),, 2018, 17 M STAND COMM 2018; CMS (Convention on the Conservation of Migratory Species of Wild Animals), MEMORANDUM UNDERSTAN; DEFLEUR ML, 1991, SOCIOL INQ, V61, P148, DOI 10.1111/j.1475-682X.1991.tb00273.x; Doughty H., 2021, USING THEORY EVIDENC, DOI [10.1002/pan3.10189, DOI 10.1002/PAN3.10189]; Doughty H, 2020, CONSERV SCI PRACT, V2, DOI 10.1111/csp2.272; Doughty H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222038; Fox J, 2002, COX PROPORTIONAL HAZ; Greenfield S., 2018, SOC MARK Q; Haustein S, 2013, CURR OPIN ENV SUST, V5, P197, DOI 10.1016/j.cosust.2013.04.009; Ho D., 2018, WHITWORTH PACKAGE MA; Israel G. D., 1992, FLORIDA COOPERATIVE; John FAVS, 2014, J APPL ECOL, V51, P1479, DOI 10.1111/1365-2664.12352; LaCroix JM, 2014, JAIDS-J ACQ IMM DEF, V66, pS329, DOI 10.1097/QAI.0000000000000230; Lanthorn H., 2016, WORKING PAPER EXTERN; Lenzner T, 2010, APPL COGNITIVE PSYCH, V24, P1003, DOI 10.1002/acp.1602; Lim MK, 2005, COMPLEMENT THER MED, V13, P16, DOI 10.1016/j.ctim.2004.11.002; Liu XB, 2012, SUSTAIN DEV, V20, P293, DOI 10.1002/sd.484; Loebnitz N, 2016, FOOD QUAL PREFER, V50, P102, DOI 10.1016/j.foodqual.2016.02.003; Molden DC, 2014, SOC COGNITION, V32, P1; MRC NIHR. (UK Medical Research Council UK National Institute for Health Research), 2019, DEVELOPING EVALUATIN; Olmedo A, 2018, CONSERV LETT, V11, DOI 10.1111/conl.12365; Park T, 2020, MENU CHANGE; R Core Team, LANG ENV STAT COMP; Rafferty A., 2015, KING HELE S ANALYSIN; Schmidt S, 2015, J ADVERTISING, V44, P415, DOI 10.1080/00913367.2015.1018460; Sherry JL., 1997, J INT COMMUNICATION, V4, P75; Snyder LB, 2004, J HEALTH COMMUN, V9, P71, DOI 10.1080/10810730490271548; Spence W, 2013, COMPLEMENT THER CLIN, V19, P63, DOI 10.1016/j.ctcp.2013.02.003; 't Sas-Rolfes M, 2019, ANNU REV ENV RESOUR, V44, P201, DOI 10.1146/annurev-environ-101718-033253; Thomas-Walters L, 2020, CONSERV SCI PRACT, V2, DOI 10.1111/csp2.248; Tonkin-Crine S, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0436-0; UNEP (United Nations Environment Programme), WILD LIFE CAMPAIGN 2; URA (Urban Redevelopment Authority), 2019, MASTER PLAN 2014; Verissimo D, 2019, CONSERV BIOL, V33, P623, DOI 10.1111/cobi.13227; WCS Peru (Wildlife Conservation Society), SI COMPRAS ERES C MP; Weeks BE, 2012, HEALTH COMMUN, V27, P158, DOI 10.1080/10410236.2011.571757; White H, 2018, J DEV EFFECT, V10, P17, DOI 10.1080/19439342.2018.1439078; Wojnicka K, 2016, EVAL PROGRAM PLANN, V57, P39, DOI 10.1016/j.evalprogplan.2016.04.001; Wu Tim, 2016, ATTENTION MERCHANTS, V1st; Wynes S, 2018, ENVIRON RES LETT, V13, DOI 10.1088/1748-9326/aae5d7; Young W, 2017, RESOUR CONSERV RECY, V117, P195, DOI 10.1016/j.resconrec.2016.10.016; Zheng MH, 2013, PHYS REV E, V88, DOI 10.1103/PhysRevE.88.012818; Zhou CQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140556	54	5	5	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2021	16	3							e0248144	10.1371/journal.pone.0248144	http://dx.doi.org/10.1371/journal.pone.0248144			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RC8FS	33760837	Green Published, gold			2023-01-03	WOS:000633030400068
J	van den Broek, AG; Kloek, CJJ; Pisters, MF; Veenhof, C				van den Broek, Anke G.; Kloek, Corelien J. J.; Pisters, Martijn F.; Veenhof, Cindy			Validity and reliability of the Dutch STarT MSK tool in patients with musculoskeletal pain in primary care physiotherapy	PLOS ONE			English	Article							LOW-BACK-PAIN; CROSS-CULTURAL ADAPTATION; STRATIFIED PRIMARY-CARE; METHODOLOGICAL QUALITY; BIG DATA; PSYCHOMETRIC PROPERTIES; COSMIN CHECKLIST; CHRONIC DISEASE; SCREENING TOOL; HEALTH	Objective To evaluate the validity and reliability of the Dutch STarT MSK tool in patients with musculoskeletal pain in primary care physiotherapy. Methods Physiotherapists included patients with musculoskeletal pain, aged 18 years or older. Patients completed a questionnaire at baseline and follow-up at 5 days and 3 months, respectively. Construct validity was assessed by comparing scores of STarT MSK items with reference questionnaires. Pearson's correlation coefficients were calculated to test predefined hypotheses. Test-retest reliability was evaluated by calculating quadratic-weighted kappa coefficients for overall STarT MSK tool scores (range 0-12) and prognostic subgroups (low, medium and high risk). Predictive validity was assessed by calculating relative risk ratios for moderate risk and high risk, both compared with low risk, in their ability to predict persisting disability at 3 months. Results In total, 142 patients were included in the analysis. At baseline, 74 patients (52.1%) were categorised as low risk, 64 (45.1%) as medium risk and 4 (2.8%) as high risk. For construct validity, nine of the eleven predefined hypotheses were confirmed. For test-retest reliability, kappa coefficients for the overall tool scores and prognostic subgroups were 0.71 and 0.65, respectively. For predictive validity, relative risk ratios for persisting disability were 2.19 (95% CI: 1.10-4.38) for the medium-risk group and 7.30 (95% CI: 4.11-12.98) for the high-risk group. Conclusion The Dutch STarT MSK tool showed a sufficient to good validity and reliability in patients with musculoskeletal pain in primary care physiotherapy. The sample size for high-risk patients was small (n = 4), which may limit the generalisability of findings for this group. An external validation study with a larger sample of high-risk patients (>= 50) is recommended.	[van den Broek, Anke G.; Pisters, Martijn F.; Veenhof, Cindy] Univ Utrecht, Dept Rehabil Phys Therapy Sci & Sports, Rudolf Magnus Inst Neurosci, Univ Med Ctr Utrecht, Utrecht, Netherlands; [van den Broek, Anke G.; Kloek, Corelien J. J.; Veenhof, Cindy] Univ Appl Sci Utrecht, Expertise Ctr Hlth Urban Living, Res Grp Innovat Human Movement Care, Utrecht, Netherlands; [van den Broek, Anke G.; Kloek, Corelien J. J.; Pisters, Martijn F.; Veenhof, Cindy] Julius Hlth Care Ctr, Ctr Phys Therapy Res & Innovat Primary Care, Utrecht, Netherlands; [Pisters, Martijn F.] Fontys Univ Appl Sci, Res Grp Empowering Hlth Behav, Eindhoven, Netherlands	Utrecht University; Utrecht University Medical Center	van den Broek, AG (corresponding author), Univ Utrecht, Dept Rehabil Phys Therapy Sci & Sports, Rudolf Magnus Inst Neurosci, Univ Med Ctr Utrecht, Utrecht, Netherlands.; van den Broek, AG (corresponding author), Univ Appl Sci Utrecht, Expertise Ctr Hlth Urban Living, Res Grp Innovat Human Movement Care, Utrecht, Netherlands.; van den Broek, AG (corresponding author), Julius Hlth Care Ctr, Ctr Phys Therapy Res & Innovat Primary Care, Utrecht, Netherlands.	Anke.vandenBroek@han.nl		Veenhof, Cindy/0000-0003-0970-2896				Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Alyass A, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0108-y; Babatunde OO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178621; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; Beneciuk JM, 2014, J ORTHOP SPORT PHYS, V44, P656, DOI 10.2519/jospt.2014.5178; Bier JD, 2017, MUSCULOSKEL SCI PRAC, V31, P22, DOI 10.1016/j.msksp.2017.06.006; Bier JD, 2017, PHYS THER, V97, P561, DOI 10.1093/ptj/pzx023; Bujang MA, 2016, J CLIN DIAGN RES, V10, pYE1, DOI 10.7860/JCDR/2016/18129.8744; Campbell P, 2016, J PAIN RES, V9, P807, DOI 10.2147/JPR.S116614; Cohen J., 2013, STAT POWER ANAL BEHA; Croft P, 2003, PAIN, V105, P309, DOI 10.1016/S0304-3959(03)00246-X; de Raaij EJ, 2012, MANUAL THER, V17, P330, DOI 10.1016/j.math.2012.03.001; De Vet H.C., 2011, MEASUREMENT MED PRAC; de Vries HJ, 2013, J OCCUP REHABIL, V23, P1, DOI 10.1007/s10926-012-9373-1; de Vroome EMM, 2015, J OCCUP REHABIL, V25, P675, DOI 10.1007/s10926-015-9575-4; Dunn KM, 2005, SPINE, V30, P1887, DOI 10.1097/01.brs.0000173900.46863.02; Dunn KM., 2017, RHEUMATOLOGY S2, V56, pK, DOI [10.1093/rheumatology/kex062.177, DOI 10.1093/RHEUMATOLOGY/KEX062.177]; Foster NE, 2014, ANN FAM MED, V12, P102, DOI 10.1370/afm.1625; Foster NE, 2013, BEST PRACT RES CL RH, V27, P649, DOI 10.1016/j.berh.2013.10.005; Hay EM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-58; Henschke N, 2012, ARTHRIT CARE RES, V64, P1217, DOI 10.1002/acr.21665; Hill JC, 2020, BMC FAM PRACT, V21, DOI 10.1186/s12875-019-1074-9; Hill JC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012445; Hill JC, 2008, ARTHRIT RHEUM-ARTHR, V59, P632, DOI 10.1002/art.23563; Hill JC, 2011, LANCET, V378, P1560, DOI 10.1016/S0140-6736(11)60937-9; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; Jellema P, 2006, SPINE, V31, P1699, DOI 10.1097/01.brs.0000224179.04964.aa; Kamper SJ, 2010, J CLIN EPIDEMIOL, V63, P760, DOI 10.1016/j.jclinepi.2009.09.009; Keele University, KEEL START MSK TOOL; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lin I, 2020, BRIT J SPORT MED, V54, P79, DOI 10.1136/bjsports-2018-099878; Mallen CD, 2007, BRIT J GEN PRACT, V57, P655; Mallen CD, 2013, JAMA INTERN MED, V173, P1119, DOI 10.1001/jamainternmed.2013.962; March L, 2014, BEST PRACT RES CL RH, V28, P353, DOI 10.1016/j.berh.2014.08.002; Meerding WJ, 1998, BRIT MED J, V317, P111, DOI 10.1136/bmj.317.7151.111; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Mokkink LB, 2010, QUAL LIFE RES, V19, P539, DOI 10.1007/s11136-010-9606-8; Mokkink LB, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-22; Morso L, 2013, EUR SPINE J, V22, P1859, DOI 10.1007/s00586-013-2690-z; Newell D, 2015, MANUAL THER, V20, P533, DOI 10.1016/j.math.2014.08.001; Ngiam KY, 2019, LANCET ONCOL, V20, pE262, DOI 10.1016/S1470-2045(19)30149-4; Picavet HSJ, 2004, ANN RHEUM DIS, V63, P723, DOI 10.1136/ard.2003.010769; Picavet HSJ, 2003, PAIN, V102, P167, DOI 10.1016/S0304-3959(02)00372-X; Portney LG., 2014, FDN CLIN RES APPL PR; Prosperi M, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/s12911-018-0719-2; Protheroe J, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2587-z; Schober P, 2018, ANESTH ANALG, V126, P1763, DOI 10.1213/ANE.0000000000002864; Sim J, 2005, PHYS THER, V85, P257; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Tack C, 2019, MUSCULOSKEL SCI PRAC, V39, P164, DOI 10.1016/j.msksp.2018.11.012; Taft C, 2001, QUAL LIFE RES, V10, P395, DOI 10.1023/A:1012552211996; Terwee CB, 2012, QUAL LIFE RES, V21, P651, DOI 10.1007/s11136-011-9960-1; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; van der Maas LCC, 2012, EUR J PSYCHOL ASSESS, V28, P68, DOI 10.1027/1015-5759/a000092; van der Zee-Neuen A, 2016, ARTHRIT CARE RES, V68, P1823, DOI 10.1002/acr.22913; Woby SR, 2005, PAIN, V117, P137, DOI 10.1016/j.pain.2005.05.029; Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646	57	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0248616	10.1371/journal.pone.0248616	http://dx.doi.org/10.1371/journal.pone.0248616			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QZ9HN	33735303	Green Published, gold			2023-01-03	WOS:000631029700100
J	Stewart, M; Rodriguez-Watson, C; Albayrak, A; Asubonteng, J; Belli, A; Brown, T; Cho, K; Das, R; Eldridge, E; Gatto, N; Gelman, A; Gerlovin, H; Goldberg, SL; Hansen, E; Hirsch, J; Ho, YL; Ip, A; Izano, M; Jones, J; Justice, AC; Klesh, R; Kuranz, S; Lam, C; Mao, QQ; Mataraso, S; Mera, R; Posner, DC; Rassen, JA; Siefkas, A; Schrag, A; Tourassi, G; Weckstein, A; Wolf, F; Bhat, A; Winckler, S; Sigal, EV; Allen, J				Stewart, Mark; Rodriguez-Watson, Carla; Albayrak, Adem; Asubonteng, Julius; Belli, Andrew; Brown, Thomas; Cho, Kelly; Das, Ritankar; Eldridge, Elizabeth; Gatto, Nicolle; Gelman, Alice; Gerlovin, Hanna; Goldberg, Stuart L.; Hansen, Eric; Hirsch, Jonathan; Ho, Yuk-Lam; Ip, Andrew; Izano, Monika; Jones, Jason; Justice, Amy C.; Klesh, Reyna; Kuranz, Seth; Lam, Carson; Mao, Qingqing; Mataraso, Samson; Mera, Robertino; Posner, Daniel C.; Rassen, Jeremy A.; Siefkas, Anna; Schrag, Andrew; Tourassi, Georgia; Weckstein, Andrew; Wolf, Frank; Bhat, Amar; Winckler, Susan; Sigal, Ellen, V; Allen, Jeff			COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients	PLOS ONE			English	Article								Background The COVID-19 pandemic remains a significant global threat. However, despite urgent need, there remains uncertainty surrounding best practices for pharmaceutical interventions to treat COVID-19. In particular, conflicting evidence has emerged surrounding the use of hydroxychloroquine and azithromycin, alone or in combination, for COVID-19. The COVID-19 Evidence Accelerator convened by the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research, assembled experts from the health systems research, regulatory science, data science, and epidemiology to participate in a large parallel analysis of different data sets to further explore the effectiveness of these treatments. Methods Electronic health record (EHR) and claims data were extracted from seven separate databases. Parallel analyses were undertaken on data extracted from each source. Each analysis examined time to mortality in hospitalized patients treated with hydroxychloroquine, azithromycin, and the two in combination as compared to patients not treated with either drug. Cox proportional hazards models were used, and propensity score methods were undertaken to adjust for confounding. Frequencies of adverse events in each treatment group were also examined. Results Neither hydroxychloroquine nor azithromycin, alone or in combination, were significantly associated with time to mortality among hospitalized COVID-19 patients. No treatment groups appeared to have an elevated risk of adverse events. Conclusion Administration of hydroxychloroquine, azithromycin, and their combination appeared to have no effect on time to mortality in hospitalized COVID-19 patients. Continued research is needed to clarify best practices surrounding treatment of COVID-19.	[Stewart, Mark; Sigal, Ellen, V; Allen, Jeff] Friends Canc Res, Washington, DC 20036 USA; [Rodriguez-Watson, Carla; Bhat, Amar; Winckler, Susan; Sigal, Ellen, V] US FDA, Reagan Udall Fdn, Washington, DC 20204 USA; [Albayrak, Adem; Eldridge, Elizabeth; Gelman, Alice; Jones, Jason] Hlth Catalyst, Salt Lake City, UT USA; [Asubonteng, Julius; Mera, Robertino] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA; [Belli, Andrew; Hansen, Eric] COTA Inc, Boston, MA USA; [Brown, Thomas; Hirsch, Jonathan; Izano, Monika; Schrag, Andrew; Wolf, Frank] Syapse, San Francisco, CA USA; [Cho, Kelly; Gerlovin, Hanna; Ho, Yuk-Lam; Posner, Daniel C.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr MA, Boston, MA USA; [Cho, Kelly] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Das, Ritankar; Lam, Carson; Mao, Qingqing; Mataraso, Samson; Siefkas, Anna] Dascena, Oakland, CA USA; [Gatto, Nicolle; Rassen, Jeremy A.; Weckstein, Andrew] Aetion, New York, NY USA; [Goldberg, Stuart L.; Ip, Andrew] Hackensack Univ, Div Outcomes & Value Res, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA; [Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA; [Justice, Amy C.] Yale Univ, Sch Med & Publ Hlth, New Haven, CT USA; [Klesh, Reyna] HealthVerity, Philadelphia, PA USA; [Kuranz, Seth] TriNetX, Cambridge, MA USA; [Tourassi, Georgia] Oak Ridge Natl Lab, Natl Ctr Computat Sci, Oak Ridge, TN USA	US Food & Drug Administration (FDA); Gilead Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Hackensack University Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; United States Department of Energy (DOE); Oak Ridge National Laboratory	Allen, J (corresponding author), Friends Canc Res, Washington, DC 20036 USA.	jallen@focr.org	Goldberg, Stuart/GXG-1919-2022	Gerlovin, Hanna/0000-0002-6700-2129; Albayrak, Adem/0000-0002-6436-3164; Siefkas, Anna/0000-0001-8379-6523; Asubonteng, Julius/0000-0001-8991-3276; Allen, Jeffrey/0000-0001-9957-6664; Posner, Daniel C/0000-0002-3056-6924				[Anonymous], 2020, CORONAVIRUS DIS 2019; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Chief Investigators of the RECOVERY Trial, 2020, NO CLIN BENEFIT USE; Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005; Fiolet T, 2021, CLIN MICROBIOL INFEC, V27, P19, DOI 10.1016/j.cmi.2020.08.022; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Greenwell B., 2019, GBM GEN BOOSTED REGR; Greifer N., 2020, WEIGHTIT WEIGHTING C; Ip A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237693; Jones M., 2020, NATURAL LANGUAGE PRO; Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793; Ridgeway G.J.U., 2007, GEN BOOSTED MODELS G, V1; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Singh AK, 2020, DIABETES METAB SYND, V14, P589, DOI 10.1016/j.dsx.2020.05.017; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237	15	5	5	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2021	16	3							e0248128	10.1371/journal.pone.0248128	http://dx.doi.org/10.1371/journal.pone.0248128			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY9GW	33730088	Green Submitted, Green Published, gold			2023-01-03	WOS:000630345000029
J	Bauer, C; Champagne-Langabeer, T; Bakos-Block, C; Zhang, KH; Persse, D; Langabeer, JR				Bauer, Cici; Champagne-Langabeer, Tiffany; Bakos-Block, Christine; Zhang, Kehe; Persse, David; Langabeer, James R.			Patterns and risk factors of opioid-suspected EMS overdose in Houston metropolitan area, 2015-2019: A Bayesian spatiotemporal analysis	PLOS ONE			English	Article								Background Opioid-related overdose deaths are the top accidental cause of death in the United States, and development of regional strategies to address this epidemic should begin with a better understanding of where and when overdoses are occurring. Methods and findings In this study, we relied on emergency medical services data to investigate the geographical and temporal patterns in opioid-suspected overdose incidents in one of the largest and most ethnically diverse metropolitan areas (Houston Texas). Using a cross sectional design and Bayesian spatiotemporal models, we identified zip code areas with excessive opioid-suspected incidents, and assessed how the incidence risks were associated with zip code level socioeconomic characteristics. Our analysis suggested that opioid-suspected overdose incidents were particularly high in multiple zip codes, primarily south and central within the city. Zip codes with high percentage of renters had higher overdose relative risk (RR = 1.03; 95% CI: [1.01, 1.04]), while crowded housing and larger proportion of white citizens had lower relative risks (RR = 0.9; 95% CI: [0.84, 0.96], RR = 0.97, 95% CI: [0.95, 0.99], respectively). Conclusions Our analysis illustrated the utility of Bayesian spatiotemporal models in assisting the development of targeted community strategies for local prevention and harm reduction efforts.	[Bauer, Cici; Zhang, Kehe] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Biostat & Data Sci, Houston, TX 77030 USA; [Champagne-Langabeer, Tiffany; Bakos-Block, Christine; Langabeer, James R.] Univ Texas Hlth Sci Ctr Houston, ACE Res Lab, Sch Biomed Informat, Houston, TX 77030 USA; [Persse, David] City Houston Fire Dept, Off Emergency Med Serv, Houston, TX USA; [Langabeer, James R.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Emergency Med, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Bauer, C (corresponding author), Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Biostat & Data Sci, Houston, TX 77030 USA.	cici.x.bauer@uth.tmc.edu		Bakos-Block, Christine/0000-0001-9201-962X; Bauer, Cici/0000-0002-2337-7965				BESAG J, 1974, J ROY STAT SOC B MET, V36, P192; BESAG J, 1991, ANN I STAT MATH, V43, P1, DOI 10.1007/BF00116466; Buchanich JM, 2018, PUBLIC HEALTH REP, V133, P423, DOI 10.1177/0033354918774330; Darke S, 2003, ADDICTION, V98, P1169, DOI 10.1046/j.1360-0443.2003.00474.x; Gelman A., BAYESIAN DATA ANAL, VThird; Gielen AC, 2013, J BURN CARE RES, V34, pE250, DOI 10.1097/BCR.0b013e3182685b3a; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Kashani S, 2018, CARDIOL CLIN, V36, P343, DOI 10.1016/j.ccl.2018.03.001; Keseg DP, 2019, J EMERG MED, V57, P187, DOI 10.1016/j.jemermed.2019.04.017; Knowlton A, 2013, PREHOSP EMERG CARE, V17, P317, DOI 10.3109/10903127.2013.792888; Koester S, 2017, INT J DRUG POLICY, V48, P115, DOI 10.1016/j.drugpo.2017.06.008; Langabeer J, 2020, J SUBST ABUSE TREAT, V111, P11, DOI 10.1016/j.jsat.2019.12.008; Leroux B.G., 2000, STAT MODELS EPIDEMIO, V116, P179, DOI DOI 10.1007/978-1-4612-1284-3_4; Li ZR, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002956; Ludwig G., 2013, FIREHOUSE, V38, P46; NEMSIS, NAT EMS DAT US MAN V, V34; NIH, 2019, TEX OP SUMM; Ofstedal MB, 2011, GERONTOLOGIST, V51, pS8, DOI 10.1093/geront/gnq100; Ross EM, 2018, PREHOSP DISASTER MED, V33, P127, DOI 10.1017/S1049023X18000055; Rowe C, 2019, J URBAN HEALTH, V96, P6, DOI 10.1007/s11524-018-0250-x; Rue H, 2009, J R STAT SOC B, V71, P319, DOI 10.1111/j.1467-9868.2008.00700.x; SAMHSA, 2014, NAT SURV DRUG US MEN; SAMHSA, 2008, RES UN WORLD POP PRO; Slavova S, 2015, PUBLIC HEALTH REP, V130, P339, DOI 10.1177/003335491513000411; Stewart K, 2017, J URBAN HEALTH, V94, P572, DOI 10.1007/s11524-017-0177-7; Togia A, 2008, PREHOSPITAL DISASTER, V23, P36, DOI 10.1017/S1049023X00005537; Tracy M, 2005, DRUG ALCOHOL DEPEN, V79, P181, DOI 10.1016/j.drugalcdep.2005.01.010; US CB, 2019, QUICK FACTS; Wagner KD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223823; Wampler DA, 2011, PREHOSP EMERG CARE, V15, P320, DOI 10.3109/10903127.2011.569854; Watson DP, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0226-x; Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4	32	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2021	16	3							e0247050	10.1371/journal.pone.0247050	http://dx.doi.org/10.1371/journal.pone.0247050			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QX8JZ	33705402	gold, Green Published			2023-01-03	WOS:000629590400053
J	Ackley, SF; Elahi, F; Glymour, MM				Ackley, Sarah F.; Elahi, Fanny; Glymour, M. Maria			Instrumental variable meta-analysis of aggregated randomized drug trial data for evaluating proposed target mechanisms	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Clinical trials provide an opportunity to understand not only drug efficacy but also disease biology. Instrumental variable meta-analysis provides an approach to combining results from multiple trials into a single estimate of the effect of modifying a biological target on an outcome of interest.	[Ackley, Sarah F.; Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St, San Francisco, CA 94143 USA; [Elahi, Fanny] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Glymour, MM (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St, San Francisco, CA 94143 USA.	maria.glymour@ucsf.edu		Elahi, Fanny/0000-0003-4663-4992	National Institutes of Health National Institute on Aging	National Institutes of Health National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from the National Institutes of Health National Institute on Aging for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	Ackley SF, 2021, BMJ-BRIT MED J, V372	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2021	372								n346	10.1136/bmj.n346	http://dx.doi.org/10.1136/bmj.n346			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ1PF	33632740	Bronze			2023-01-03	WOS:000624298000010
J	Baba, Y; Ooyama, C; Tazawa, Y; Kohzuki, M				Baba, Yoshihiko; Ooyama, Chika; Tazawa, Yasushi; Kohzuki, Masahiro			Effects of Adachi Rehabilitation Programme on older adults under long-term care: A multi-centre controlled trial	PLOS ONE			English	Article								Objectives We developed the Adachi Rehabilitation Programme (ARP), a community rehabilitation program. Under the supervision of professional caregivers, older adults cleaned and planted flowers in the park and they walked and shopped in the community. We examined the effects of ARP on individuals receiving small-group multifunctional at-home care at community facilities. Methods This was a multi-centre controlled trial at thirteen small multifunctional at-home care facilities in Adachi, Tokyo. The primary outcomes of the study were daily step counts and timed up & go (TUG). Secondary outcomes included gait speed, step length, Barthel Index for Activities of Daily Living, Functional Independence Measure, Mini-Mental State Examination (MMSE) and EuroQOL 5 Dimension. Results Ninety-six individuals at thirteen small multifunctional at-home care facilities were recruited for participation in December 2017. They were allocated to intervention (38) and control (40) groups. The average daily step count of the control group decreased from 852 to 727, but it increased by approximately 650 steps, from 990 to 1635, for the intervention group. Average TUG decreased from 16.1 s to 14.0 s and MMSE score increased from 15.9 to 16.3 for the intervention group, but a significant interaction was not found. On non-intervention home days, the daily step counts of the intervention group increased significantly from 908 steps to 1485 steps, while those of the control group decreased from 865 steps to 722 steps. Conclusions ARP may have effectively increased the physical activity of older adults under long-term care by increasing motivation and changing behaviour.	[Baba, Yoshihiko] Kyorin Univ, Sch Med, Fac Med, Mitaka, Tokyo, Japan; [Ooyama, Chika] Tohoku Med & Pharmaceut Univ Hosp, Sendai, Miyagi, Japan; [Tazawa, Yasushi] Sendai Orthopaed Hosp, Sendai, Miyagi, Japan; [Kohzuki, Masahiro] Tohoku Univ, Grad Sch Med, Dept Internal Med & Rehabil Sci, Sendai, Miyagi, Japan	Kyorin University; Tohoku Medical & Pharmaceutical University; Tohoku University	Kohzuki, M (corresponding author), Tohoku Univ, Grad Sch Med, Dept Internal Med & Rehabil Sci, Sendai, Miyagi, Japan.	kohzuki@med.tohoku.ac.jp	Baba, Yoshihiko/AAW-5394-2021	Baba, Yoshihiko/0000-0001-7034-9724				Aoyagi Y, 2009, GERONTOLOGY, V55, P523, DOI 10.1159/000236326; Picorelli AMA, 2014, J PHYSIOTHER, V60, P151, DOI 10.1016/j.jphys.2014.06.012; Barreto PD, 2015, J SPORT SCI, V33, P116, DOI 10.1080/02640414.2014.928828; Baum Elizabeth E, 2003, J Am Med Dir Assoc, V4, P74, DOI 10.1016/S1525-8610(04)70279-0; Bravo G, 1999, J GERONTOL B-PSYCHOL, V54, pP180, DOI 10.1093/geronb/54B.3.P180; Burton E, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-419; Chou CH, 2012, ARCH PHYS MED REHAB, V93, P237, DOI 10.1016/j.apmr.2011.08.042; Culos-Reed SN, 2008, CAN J AGING, V27, P81, DOI [10.3138/cja.27.1.81, 10.3138/cja.27.1.081]; Dean CM, 2012, NEUROREHAB NEURAL RE, V26, P1046, DOI 10.1177/1545968312441711; Demeyer H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154587; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; DUNCAN HH, 1995, J APPL GERONTOL, V14, P64, DOI 10.1177/073346489501400105; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Frost R, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0547-8; Guo Y, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-100; Hauer K, 2003, ARCH PHYS MED REHAB, V84, P1426, DOI 10.1016/S0003-9993(03)00267-3; Hauer K, 2012, J AM GERIATR SOC, V60, P8, DOI 10.1111/j.1532-5415.2011.03778.x; Kamioka H, 2014, COMPLEMENT THER MED, V22, P930, DOI 10.1016/j.ctim.2014.08.009; Kasser G., 2015, J AM MED DIR ASSOC, V15, P1, DOI [10.1111/j.1360-0443.2004.00785.x, DOI 10.1111/J.1360-0443.2004.00785.X]; Kim MJ, 2016, DEMENT GER COGN D EX, V6, P222, DOI 10.1159/000446508; Lamb SE, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1675; Motl RW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073247; Mudge S, 2009, ARCH PHYS MED REHAB, V90, P296, DOI 10.1016/j.apmr.2008.07.025; Nagai K, 2018, ARCH GERONTOL GERIAT, V76, P41, DOI 10.1016/j.archger.2018.02.005; Nakanishi M, 2018, INT J GERIATR PSYCH, V33, P495, DOI 10.1002/gps.4784; Nemoto M, 2012, ARCH GERONTOL GERIAT, V55, P385, DOI 10.1016/j.archger.2011.10.004; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Samus QM, 2006, J GERONTOL B-PSYCHOL, V61, pP311, DOI 10.1093/geronb/61.5.P311; Shimada H, 2018, J AM MED DIR ASSOC, V19, P584, DOI 10.1016/j.jamda.2017.09.019; Talbot LA, 2003, J AM GERIATR SOC, V51, P387, DOI 10.1046/j.1532-5415.2003.51113.x; Tamiya N, 2011, LANCET, V378, P1183, DOI 10.1016/S0140-6736(11)61176-8; Tsutsui T, 2005, J AM GERIATR SOC, V53, P522, DOI 10.1111/j.1532-5415.2005.53175.x; Tudor-Locke C, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-80; UN, 2015, BRIEFING PAPER GROWI; United Nations, 2017, WORLD POP AG 2017 HI; Wang D, 2013, ACT ADAPT AGING, V37, P153, DOI 10.1080/01924788.2013.784942; Weening-Dijksterhuis E, 2011, AM J PHYS MED REHAB, V90, P156, DOI 10.1097/PHM.0b013e3181f703ef	37	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2021	16	2							e0245646	10.1371/journal.pone.0245646	http://dx.doi.org/10.1371/journal.pone.0245646			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QK0KW	33577618	Green Published, gold			2023-01-03	WOS:000620071700002
J	Beom, JH; Kim, JH; Seo, J; Lee, JH; Chung, YE; Chung, HS; Chung, SP; Kim, CH; You, JS				Beom, Jin Ho; Kim, Ju Hee; Seo, Jeho; Lee, Jung Ho; Chung, Yong Eun; Chung, Hyun Soo; Chung, Sung Phil; Kim, Chul Hoon; You, Je Sung			Targeted temperature management at 33 degrees C or 36 degrees C induces equivalent myocardial protection by inhibiting HMGB1 release in myocardial ischemia/reperfusion injury	PLOS ONE			English	Article								Acute myocardial infarction (AMI) is lethal and causes myocardial necrosis via time-dependent ischemia due to prolonged occlusion of the infarct-related artery. No effective therapy or potential therapeutic targets can prevent myocardial ischemia/reperfusion (I/R) injury. Targeted temperature management (TTM) may reduce peri-infarct regions by inhibiting the extracellular release of high mobility group box-1 (HMGB1) as a primary mediator of the innate immune response. We used a rat left anterior descending (LAD) coronary artery ligation model to determine if TTM at 33 degrees C and 36 degrees C had similar myocardial protective effects. Rats were divided into sham, LAD I/R+37 degrees C normothermia, LAD I/R+33 degrees C TTM, and LAD I/R+36 degrees C TTM groups (n = 5 per group). To verify the cardioprotective effect of TTM by specifically inhibiting HMGB1, rats were assigned to sham, LAD I/R, and LAD I/R after pre-treatment with glycyrrhizin (known as a pharmacological inhibitor of HMGB1) groups (n = 5 per group). Different target temperatures of 33 degrees C and 36 degrees C caused equivalent reductions in infarct volume after myocardial I/R, inhibited the extracellular release of HMGB1 from infarct tissue, and suppressed the expression of inflammatory cytokines from peri-infarct regions. TTM at 33 degrees C and 36 degrees C significantly attenuated the elevation of cardiac troponin, a sensitive and specific marker of heart muscle damage, after injury. Similarly, glycyrrhizin alleviated myocardial damage by suppressing the extracellular release of HMGB1. TTM at 33 degrees C and 36 degrees C had equivalent myocardial protective effects by similar inhibiting HMGB1 release against myocardial I/R injury. This is the first study to suggest that a target core temperature of 36 degrees C is applicable for cardioprotection.	[Beom, Jin Ho; Kim, Ju Hee; Seo, Jeho; Chung, Hyun Soo; Chung, Sung Phil; You, Je Sung] Yonsei Univ, Dept Emergency Med, Coll Med, Seoul, South Korea; [Lee, Jung Ho; Kim, Chul Hoon] Yonsei Univ, Brain Res Inst, Coll Med, Dept Pharmacol,BK21 PLUS Project Med Sci, Seoul, South Korea; [Lee, Jung Ho] Eulji Univ, Dept Pharmacol, Sch Med, Daejeon, South Korea; [Chung, Yong Eun] Yonsei Univ, Dept Radiol, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Eulji University; Yonsei University; Yonsei University Health System	You, JS (corresponding author), Yonsei Univ, Dept Emergency Med, Coll Med, Seoul, South Korea.; Kim, CH (corresponding author), Yonsei Univ, Brain Res Inst, Coll Med, Dept Pharmacol,BK21 PLUS Project Med Sci, Seoul, South Korea.	kimhoon@yuhs.ac; youjsmd@yuhs.ac	; Chung, Sung Phil/F-8344-2016	You, Je Sung/0000-0002-2074-6745; Kim, Chul Hoon/0000-0002-7360-429X; Chung, Sung Phil/0000-0002-3074-011X; Chung, Yong Eun/0000-0003-0811-9578; Chung, Hyun Soo/0000-0001-6110-1495	Basic Science Research Program of the National Research Foundation of Korea (NRF) - Ministry of Science and ICT [NRF-2015R1C1A1A01054641, NRF-2018R1C1B6006159, NRF-2019R1A2C3002354, NRF-2019R1C1C1006332]; Yonsei University College of Medicine [6-2017-0092, 6-2019-0188]	Basic Science Research Program of the National Research Foundation of Korea (NRF) - Ministry of Science and ICT; Yonsei University College of Medicine(General Electric)	This work was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT (grant numbers NRF-2015R1C1A1A01054641 and NRF-2018R1C1B6006159 to J.S.Y; NRF-2019R1A2C3002354 to C.H.K; and NRF-2019R1C1C1006332 to J.B.) and a faculty research grant from the Yonsei University College of Medicine (grant number 6-2017-0092 to J.B. and 6-2019-0188 to J.S.Y.). The funding bodies had no role in the design, collection, analysis, or interpretation of this study.	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Andrassy M, 2011, J INTERN MED, V270, P245, DOI 10.1111/j.1365-2796.2011.02369.x; Andrassy M, 2008, CIRCULATION, V117, P3216, DOI 10.1161/CIRCULATIONAHA.108.769331; Arvidsson L, 2017, ACTA ANAESTH SCAND, V61, P1176, DOI 10.1111/aas.12957; Boersma E, 2006, EUR HEART J, V27, P779, DOI 10.1093/eurheartj/ehi810; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Dai WD, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002265; Dash R, 2018, JACC-CARDIOVASC INTE, V11, P195, DOI 10.1016/j.jcin.2017.08.056; Ding HS, 2013, GENE, V527, P389, DOI 10.1016/j.gene.2013.05.041; Frohlich GM, 2013, EUR HEART J, V34, P1714, DOI 10.1093/eurheartj/eht090; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089450; Greulich S, 2019, J AM HEART ASSOC, V8, DOI [10.1161/JAHA.119.012429, DOI 10.1161/JAHA.119.012429]; Hausenloy DJ, 2015, NEW ENGL J MED, V373, P1073, DOI 10.1056/NEJMe1509718; Hausenloy DJ, 2013, J CLIN INVEST, V123, P92, DOI 10.1172/JCI62874; Herring MJ, 2015, J CARDIOVASC PHARM T, V20, P193, DOI 10.1177/1074248414535664; Herring MJ, 2014, THER HYPOTHERMIA TEM, V4, P159, DOI 10.1089/ther.2014.0016; Heusch G, 2017, EUR HEART J, V38, P774, DOI 10.1093/eurheartj/ehw224; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kelly FE, 2010, ANAESTHESIA, V65, P505, DOI 10.1111/j.1365-2044.2009.06237.x; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Kirkegaard H, 2019, ANESTHESIOLOGY, V131, P186, DOI 10.1097/ALN.0000000000002700; Kohlhauer M, 2016, ARCH CARDIOVASC DIS, V109, P716, DOI 10.1016/j.acvd.2016.05.005; Kushner FG, 2009, CIRCULATION, V120, P2271, DOI 10.1161/CIRCULATIONAHA.109.192663; Lee JH, 2018, SHOCK, V50, P714, DOI 10.1097/SHK.0000000000001106; Lee JH, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0260-0; Li L, 2018, PATHOL RES PRACT, V214, P174, DOI 10.1016/j.prp.2017.11.016; Lin YL, 2015, EXP THER MED, V9, P1537, DOI 10.3892/etm.2015.2290; Liu P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14848-1; Loukili N, 2011, CARDIOVASC RES, V89, P586, DOI 10.1093/cvr/cvq373; Lu HX, 2019, CYTOKINE GROWTH F R, V47, P74, DOI 10.1016/j.cytogfr.2019.05.009; Menees DS, 2013, NEW ENGL J MED, V369, P901, DOI 10.1056/NEJMoa1208200; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Mu SW, 2018, BIOMED REP, V9, P191, DOI 10.3892/br.2018.1127; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Reid E, 2012, J CEREBR BLOOD F MET, V32, P1765, DOI 10.1038/jcbfm.2012.69; Rochitte CE, 2012, HEART, V98, P348, DOI 10.1136/heartjnl-2011-301332; Schwartz BG, 2012, AM J CARDIOL, V110, P461, DOI 10.1016/j.amjcard.2012.03.048; Sorensen MV, 2011, JACC-CARDIOVASC INTE, V4, P281, DOI 10.1016/j.jcin.2010.10.015; Takahashi M, 2008, CARDIOVASC RES, V80, P5, DOI 10.1093/cvr/cvn212; Takahashi M, 2015, J ATHEROSCLER THROMB, V22, P553, DOI 10.5551/jat.ED008; Tian Ming, 2015, Chronic Dis Transl Med, V1, P18, DOI 10.1016/j.cdtm.2015.02.002; Tissier R, 2009, CARDIOVASC RES, V83, P345, DOI 10.1093/cvr/cvp046; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Wang WE, 2013, CIRC RES, V113, P288, DOI 10.1161/CIRCRESAHA.113.300929; Wang XW, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008024; Xu H, 2011, AM J PHYSIOL-HEART C, V300, pH913, DOI 10.1152/ajpheart.00703.2010; Yan W, 2019, AM J PHYSIOL-HEART C, DOI [10.1152/ajpheart.00065.20192019, DOI 10.1152/AJPHEART.00065.20192019]; Yellon D.M., 2007, NEW ENGL J MED, V357, P1121, DOI [DOI 10.1056/NEJMRA071667, 10.1056/NEJMra071667]; Zhai CL, 2012, ACTA PHARMACOL SIN, V33, P1477, DOI 10.1038/aps.2012.112	51	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2021	16	1							e0246066	10.1371/journal.pone.0246066	http://dx.doi.org/10.1371/journal.pone.0246066			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA9GX	33503060	Green Published, gold			2023-01-03	WOS:000613751800022
J	Luyckx, VA; Harris, DCH; Varghese, C; Jha, V				Luyckx, Valerie A.; Harris, David C. H.; Varghese, Cherian; Jha, Vivekanand			Bringing equity in access to quality dialysis	LANCET			English	Editorial Material							KIDNEY-DISEASE; CARE		[Luyckx, Valerie A.] Harvard Med Sch, Div Renal, Brigham & Womens Hosp, Boston, MA 02115 USA; [Luyckx, Valerie A.] Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South Africa; [Harris, David C. H.] Univ Sydney, Westmead Inst Med Res, Ctr Transplantat & Renal Res, Sydney, NSW, Australia; [Varghese, Cherian] WHO, Geneva, Switzerland; [Jha, Vivekanand] George Inst Global Hlth, New Delhi, India; [Jha, Vivekanand] Univ New South Wales, Fac Med, Sydney, NSW, Australia; [Jha, Vivekanand] Imperial Coll London, Sch Publ Hlth, London, England; [Jha, Vivekanand] Manipal Acad Higher Educ, Prasanna Sch Publ Hlth, Manipal, India	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Cape Town; University of Sydney; Westmead Institute for Medical Research; World Health Organization; University of New South Wales Sydney; Imperial College London; Manipal Academy of Higher Education (MAHE)	Jha, V (corresponding author), George Inst Global Hlth, New Delhi, India.; Jha, V (corresponding author), Univ New South Wales, Fac Med, Sydney, NSW, Australia.; Jha, V (corresponding author), Imperial Coll London, Sch Publ Hlth, London, England.; Jha, V (corresponding author), Manipal Acad Higher Educ, Prasanna Sch Publ Hlth, Manipal, India.	vjha@georgeinstitute.org.in	Luyckx, Valerie/J-9747-2019	Luyckx, Valerie/0000-0001-7066-8135; Jha, Vivekanand/0000-0002-8015-9470				Afiatin, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177436; Bikbov B, 2020, LANCET, V395, P709, DOI 10.1016/S0140-6736(20)30045-3; Harris DCH, 2020, KIDNEY INT, V98, P1062, DOI 10.1016/j.kint.2020.07.022; International Society of Nephrology, 2021, ISN FRAM DEV DIAL PR; International Society of Nephrology, 2019, GLOBAL KIDNEY HLTH A; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Manyazewal T, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0221-9; Pike Eva, 2017, J Clin Med Res, V9, P104, DOI 10.14740/jocmr2817w; Ramachandran R, 2020, KIDNEY INT, V98, P238, DOI 10.1016/j.kint.2020.04.019; Shroff R, 2021, PERITON DIALYSIS INT, V41, P137, DOI 10.1177/0896860821995385; Tonelli M, 2020, KIDNEY INT SUPPL, V10, pE19, DOI 10.1016/j.kisu.2019.11.002; Vanholder R, 2017, NAT REV NEPHROL, V13, P393, DOI 10.1038/nrneph.2017.63; Voorhoeve A, 2017, HEALTH SYST REFORM, V3, P301, DOI 10.1080/23288604.2017.1324938; World Health Organization (WHO), 2014, MAK FAIR CHOIC PATH	14	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2021	398	10294					10	11		10.1016/S0140-6736(21)00732-7	http://dx.doi.org/10.1016/S0140-6736(21)00732-7		JUL 2021	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC9PM	33865498				2023-01-03	WOS:000668969500009
J	Gaber, CE; Kinlaw, AC; Edwards, JK; Lund, JL; Sturmer, T; Hinton, SP; Pate, V; Bartelt, LA; Sandler, RS; Peery, AF				Gaber, Charles E.; Kinlaw, Alan C.; Edwards, Jessie K.; Lund, Jennifer L.; Sturmer, Til; Hinton, Sharon Peacock; Pate, Virginia; Bartelt, Luther A.; Sandler, Robert S.; Peery, Anne F.			Comparative Effectiveness and Harms of Antibiotics for Outpatient Diverticulitis Two Nationwide Cohort Studies	ANNALS OF INTERNAL MEDICINE			English	Article							ASSOCIATION; GUIDELINES; SELECTION; SOCIETY; RISK	Background: Outpatient diverticulitis is commonly treated with either a combination of metronidazole and a fluoroquinolone (metronidazole-with-fluoroquinolone) or amoxicillin-clavulanate alone. The U.S. Food and Drug Administration advised that fluoroquinolones be reserved for conditions with no alternative treatment options. The comparative effectiveness of metronidazole-with-fluoroquinolone versus amoxicillin-clavulanate for diverticulitis is uncertain. Objective: To determine the effectiveness and harms of metronidazole-with-fluoroquinolone versus amoxicillin-clavulanate for outpatient diverticulitis. Design: Active-comparator, new-user, retrospective cohort studies. Setting: Nationwide population-based claims data on U.S. residents aged 18 to 64 years with private employer-sponsored insurance (2000 to 2018) or those aged 65 years or older with Medicare (2006 to 2015). Participants: Immunocompetent adults with diverticulitis in the outpatient setting. Intervention: Metronidazole-with-fluoroquinolone or amoxicillin-clavulanate. Measurements: 1-year risks for inpatient admission, urgent surgery, and Clostridioides difficile infection (CDI) and 3-year risk for elective surgery. Results: In MarketScan (IBM Watson Health), new users of metronidazole-with-fluoroquinolone (n = 106 361) and amoxicillin-clavulanate (n = 13 160) were identified. There were no differences in 1-year admission risk (risk difference, 0.1 percentage points [95% CI, -0.3 to 0.6]), 1-year urgent surgery risk (risk difference, 0.0 percentage points [CI, -0.1 to 0.11), 3-year elective surgery risk (risk difference, 0.2 percentage points [CI, -0.3 to 0.7]), or 1-year CDI risk (risk difference, 0.0 percentage points [CI, -0.1 to 0.1]) between groups. In Medicare, new users of metronidazole-with-fluoroquinolone (n = 17639) and amoxicillin-clavulanate (n = 2709) were identified. There were no differences in 1-year admission risk (risk difference, 0.1 percentage points [CI, -0.7 to 0.9]), 1-year urgent surgery risk (risk difference, -0.2 percentage points [CI, -0.6 to 0.11), or 3-year elective surgery risk (risk difference, -0.3 percentage points [CI, -1.1 to 0.4]) between groups. The 1-year CDI risk was higher for metronidazole-with-fluoroquinolone than for amoxicillin-clavulanate (risk difference, 0.6 percentage points [CI, 0.2 to 1.0]). Limitation: Residual confounding is possible, and not all harms associated with these antibiotics, most notably drug-induced liver injury, could be assessed. Conclusion: Treating diverticulitis in the outpatient setting with amoxicillin-clavulanate may reduce the risk for fluoroquinolone-related harms without adversely affecting diverticulitis-specific outcomes.	[Gaber, Charles E.; Bartelt, Luther A.; Sandler, Robert S.; Peery, Anne F.] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Sch Med, Chapel Hill, NC 27599 USA; [Gaber, Charles E.; Edwards, Jessie K.; Lund, Jennifer L.; Sturmer, Til; Hinton, Sharon Peacock; Pate, Virginia] Univ N Carolina, Sch Publ Hlth, 135 Dauer Dr, Chapel Hill, NC 27599 USA; [Kinlaw, Alan C.] Univ N Carolina, Sch Pharm, 301 Pharm Lane, Chapel Hill, NC 27599 USA; [Kinlaw, Alan C.; Sturmer, Til] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA; [Bartelt, Luther A.; Sandler, Robert S.; Peery, Anne F.] Univ N Carolina, Sch Med, Bioinformat Bldg CB 7080,130 Mason Farm Rd, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Peery, AF (corresponding author), Univ N Carolina, Sch Med, Bioinformat Bldg CB 7080,130 Mason Farm Rd, Chapel Hill, NC 27599 USA.	cgaber@unc.edu; Anne_Peery@med.unc.edu	Stürmer, Til/AAB-5459-2022	Gaber, Charles/0000-0002-6752-2968; Edwards, Jessie/0000-0002-1741-335X; Kinlaw, Alan/0000-0002-4279-8685	National Institutes of Health	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	National Institutes of Health.	Alves C, 2019, EUR J CLIN PHARMACOL, V75, P1431, DOI 10.1007/s00228-019-02713-1; Au S, 2019, DIS COLON RECTUM, V62, P1533, DOI 10.1097/DCR.0000000000001330; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118; Bharucha AE, 2015, AM J GASTROENTEROL, V110, P1588, DOI 10.1038/ajg.2015.302; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Brunelli SM, 2013, PHARMACOEPIDEM DR S, V22, P542, DOI 10.1002/pds.3434; Chabok A, 2012, BRIT J SURG, V99, P532, DOI 10.1002/bjs.8688; Chalasani N, 2015, GASTROENTEROLOGY, V148, P1340, DOI 10.1053/j.gastro.2015.03.006; Chubak J, 2012, J CLIN EPIDEMIOL, V65, P343, DOI 10.1016/j.jclinepi.2011.09.002; D'Arcy M, 2018, CURR EPIDEMIOL REP, V5, P272, DOI 10.1007/s40471-018-0155-y; Daniels L, 2017, BRIT J SURG, V104, P52, DOI 10.1002/bjs.10309; Danielson Group, 2014, DAN GROUP; Dong HR, 2015, AM J EPIDEMIOL, V181, P532, DOI 10.1093/aje/kwu289; Edwards Jessie K, 2016, Curr Epidemiol Rep, V3, P285, DOI 10.1007/s40471-016-0089-1; Etzioni DA, 2010, DIS COLON RECTUM, V53, P861, DOI 10.1007/DCR.0b013e3181cdb243; Feuerstadt P, 2020, J MED ECON, V23, P603, DOI 10.1080/13696998.2020.1724117; Francis NK, 2019, SURG ENDOSC, V33, P2726, DOI 10.1007/s00464-019-06882-z; Hall J, 2020, DIS COLON RECTUM, V63, P728, DOI 10.1097/DCR.0000000000001679; IBM Watson Health, IBM MARKETSCAN RES D; Kawatkar A, 2015, PHARMACOEPIDEM DR S, V24, P27, DOI 10.1002/pds.3708; KELLUM JM, 1992, CLIN THER, V14, P376; Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107; Lee CC, 2015, JAMA INTERN MED, V175, P1839, DOI 10.1001/jamainternmed.2015.5389; Lo Re V, 2013, PHARMACOEPIDEM DR S, V22, P861, DOI 10.1002/pds.3470; Lund Jennifer L, 2015, Curr Epidemiol Rep, V2, P221; McCusker ME, 2003, EMERG INFECT DIS, V9, P730; Morales D, 2019, JAMA NEUROL, V76, P827, DOI 10.1001/jamaneurol.2019.0887; Murphy CC, 2019, GASTROENTEROLOGY, V156, P958, DOI [10.1053/j.gastro.2018.11.060, 10.1053/j.gastro.2018.08.063]; Orman ES, 2011, CLIN GASTROENTEROL H, V9, P517, DOI 10.1016/j.cgh.2011.02.019; Pant C, 2012, TRANSPL INFECT DIS, V14, P540, DOI 10.1111/j.1399-3062.2012.00761.x; Parekh TM, 2014, JAMA INTERN MED, V174, P1605, DOI 10.1001/jamainternmed.2014.3293; Peery AF, 2021, GASTROENTEROLOGY, V160, P906, DOI 10.1053/j.gastro.2020.09.059; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Sartelli M, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00313-4; Sellick J, 2018, PSYCHOSOMATICS, V59, P259, DOI 10.1016/j.psym.2017.11.001; Simianu VV, 2016, ANN SURG, V263, P123, DOI 10.1097/SLA.0000000000001053; Stollman N, 2015, GASTROENTEROLOGY, V149, P1944, DOI 10.1053/j.gastro.2015.10.003; Strate LL, 2012, AM J GASTROENTEROL, V107, P1486, DOI 10.1038/ajg.2012.194; Sturmer T, 2010, AM J EPIDEMIOL, V172, P843, DOI 10.1093/aje/kwq198; Swanson SM, 2018, ANN INTERN MED, V168, pITC65, DOI 10.7326/AITC201805010; U.S. Food and Drug Administration, FDA REINF SAF INF SE; U.S. Food and Drug Administration, DRUG IND LIV INJ RAN; Westreich D, 2017, EPIDEMIOLOGY, V28, P525, DOI 10.1097/EDE.0000000000000648; Westreich D, 2014, AM J EPIDEMIOL, V179, P797, DOI 10.1093/aje/kwt328; Yang D., SAS GLOBAL FORUM 201; Young-Fadok TM, 2018, NEW ENGL J MED, V379, P1635, DOI 10.1056/NEJMcp1800468	47	5	5	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	2021	174	6					737	+		10.7326/M20-6315	http://dx.doi.org/10.7326/M20-6315			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SS5IR	33617725	Green Accepted			2023-01-03	WOS:000661788700013
J	Haidl, H; Gaugler, J; Cvirn, G; Jasser-Nitsche, H; Schwinger, W; Pohl, S; Bisping, E; Gallistl, S; Schlagenhauf, A				Haidl, Harald; Gaugler, Johanna; Cvirn, Gerhard; Jasser-Nitsche, Hildegard; Schwinger, Wolfgang; Pohl, Sina; Bisping, Egbert; Gallistl, Siegfried; Schlagenhauf, Axel			Impact of electric cardioversion on platelet activation	PLOS ONE			English	Article							ATRIAL-FIBRILLATION; THROMBOSIS; FIELDS	Introduction Atrial fibrillation (AF) comes along with high risk of stroke. This risk continues even after re-establishing sinus rhythm with cardioversion. Aim of this study is to evaluate the contribution of electric cardioversion (EC) to platelet activation and procoagulatory tendency. Methods Extent of platelet activation before and after electric cardioversion was quantified using flow cytometry, impedance aggregation measurements with Multiplate (R), and quantification of serum levels of platelet factor 4 (PF4) and ss-thromboglobulin (ss-TG) in patients with AF (N = 10). Results No significant differences were observed in any of the measured parameters comparing the values from before and after cardioversion. Geometric means of P-selectin expression and integrin alpha IIb beta 3 activation were 0.27 (+/- 0.07) and 2.30 (+/- 2.61) before EC and 0.28 (+/- 0.17) and 1.67 (+/- 1.82) after EC. Levels of ss-TG were 110.11 ng/ml (+/- 3.78) before and 110.51 ng/ml (+/- 2.56) after EC, levels of PF4 were 35.64 ng/ml (+/- 12.94) before and 32.40 ng/ml (+/- 4.95) after EC. Platelet aggregation triggered with adenosine diphosphate (ADP), arachidonic acid, collagen, Ristocetin, or thrombin receptor activating peptide (TRAP) revealed results within the normally expected ranges without significant changes before and after EC. Discussion Electric cardioversion has no influence on platelet activation markers which is in agreement with other studies reporting electrical cardioversion to be safe.	[Haidl, Harald; Gaugler, Johanna; Jasser-Nitsche, Hildegard; Pohl, Sina; Gallistl, Siegfried; Schlagenhauf, Axel] Med Univ Graz, Dept Paediat & Adolescent Med, Div Gen Paediat, Graz, Austria; [Cvirn, Gerhard] Med Univ Graz, Otto Loewi Res Ctr, Div Physiol Chem, Graz, Austria; [Schwinger, Wolfgang] Med Univ Graz, Dept Paediat & Adolescent Med, Div Paediat Haematol Oncol, Graz, Austria; [Bisping, Egbert] Med Univ Graz, Dept Internal Med, Div Cardiol, Graz, Austria	Medical University of Graz; Medical University of Graz; Medical University of Graz; Medical University of Graz	Schlagenhauf, A (corresponding author), Med Univ Graz, Dept Paediat & Adolescent Med, Div Gen Paediat, Graz, Austria.	axel.schlagenhauf@medunigraz.at	Schlagenhauf, Axel/AAK-9598-2021	Schlagenhauf, Axel/0000-0003-3408-6415; Haidl, Harald/0000-0003-4026-1507				Agbani EO, 2017, BLOOD, V130, P2171, DOI 10.1182/blood-2017-05-787259; Airaksinen KEJ, 2013, J AM COLL CARDIOL, V62, P1187, DOI 10.1016/j.jacc.2013.04.089; Bahm J, 1996, MICROSURG, V17, P286; BONGARD O, 1989, VASA-J VASCULAR DIS, V18, P162; Crijns HJGM, 2014, INT J CARDIOL, V172, P588, DOI 10.1016/j.ijcard.2014.01.099; Frelinger AL, 2016, PLATELETS, V27, P128, DOI 10.3109/09537104.2015.1048214; Hardy ET, 2018, LAB CHIP, V18, P2985, DOI 10.1039/c8lc00573g; Khan IA, 2003, INT J CARDIOL, V92, P113, DOI 10.1016/S0167-5273(03)00107-4; Khan IA, 2003, INT J CARDIOL, V89, P239, DOI 10.1016/S0167-5273(02)00477-1; Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210; PATEL A, 1993, STROKE, V24, P903, DOI 10.1161/01.STR.24.6.903; Ulrich D, 2004, THROMB HAEMOSTASIS, V91, P1000, DOI 10.1160/TH03-08-0523; Zamani P, 2015, J INTENSIVE CARE MED, V30, P484, DOI 10.1177/0885066614534603	13	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0250353	10.1371/journal.pone.0250353	http://dx.doi.org/10.1371/journal.pone.0250353			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0DC	33886660	Green Published, gold			2023-01-03	WOS:000644138300036
J	Iftimie, S; Lopez-Azcona, AF; Vallverdu, I; Hernandez-Flix, S; de Febrer, G; Parra, S; Hernandez-Aguilera, A; Riu, F; Joven, J; Andreychuk, N; Baiges-Gaya, G; Ballester, F; Benavent, M; Burdeos, J; Catala, A; Castane, E; Castane, H; Colom, J; Feliu, M; Gabaldo, X; Garrido, D; Garrido, P; Gil, J; Guelbenzu, P; Lozano, C; Marimon, F; Pardo, P; Pujol, I; Rabassa, A; Revuelta, L; Rios, M; Rius-Gordillo, N; Rodriguez-Tomas, E; Rojewski, W; Roquer-Fanlo, E; Sabate, N; Teixido, A; Vasco, C; Camps, J; Castro, A				Iftimie, Simona; Lopez-Azcona, Ana F.; Vallverdu, Immaculada; Hernandez-Flix, Salvador; de Febrer, Gabriel; Parra, Sandra; Hernandez-Aguilera, Anna; Riu, Francesc; Joven, Jorge; Andreychuk, Natalia; Baiges-Gaya, Gerard; Ballester, Frederic; Benavent, Marc; Burdeos, Jose; Catala, Alba; Castane, Eric; Castane, Helena; Colom, Josep; Feliu, Mireia; Gabaldo, Xavier; Garrido, Diana; Garrido, Pedro; Gil, Joan; Guelbenzu, Paloma; Lozano, Carolina; Marimon, Francesc; Pardo, Pedro; Pujol, Isabel; Rabassa, Antoni; Revuelta, Laia; Rios, Marta; Rius-Gordillo, Neus; Rodriguez-Tomas, Elisabet; Rojewski, Wojciech; Roquer-Fanlo, Esther; Sabate, Noelia; Teixido, Anna; Vasco, Carlos; Camps, Jordi; Castro, Antoni			First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain	PLOS ONE			English	Article							COVID-19	Many countries have seen a two-wave pattern in reported cases of coronavirus disease-19 during the 2020 pandemic, with a first wave during spring followed by the current second wave in late summer and autumn. Empirical data show that the characteristics of the effects of the virus do vary between the two periods. Differences in age range and severity of the disease have been reported, although the comparative characteristics of the two waves still remain largely unknown. Those characteristics are compared in this study using data from two equal periods of 3 and a half months. The first period, between 15(th) March and 30(th) June, corresponding to the entire first wave, and the second, between 1(st) July and 15(th) October, corresponding to part of the second wave, still present at the time of writing this article. Two hundred and four patients were hospitalized during the first period, and 264 during the second period. Patients in the second wave were younger and the duration of hospitalization and case fatality rate were lower than those in the first wave. In the second wave, there were more children, and pregnant and post-partum women. The most frequent signs and symptoms in both waves were fever, dyspnea, pneumonia, and cough, and the most relevant comorbidities were cardiovascular diseases, type 2 diabetes mellitus, and chronic neurological diseases. Patients from the second wave more frequently presented renal and gastrointestinal symptoms, were more often treated with non-invasive mechanical ventilation and corticoids, and less often with invasive mechanical ventilation, conventional oxygen therapy and anticoagulants. Several differences in mortality risk factors were also observed. These results might help to understand the characteristics of the second wave and the behaviour and danger of SARS-CoV-2 in the Mediterranean area and in Western Europe. Further studies are needed to confirm our findings.	[Iftimie, Simona; Lopez-Azcona, Ana F.; Parra, Sandra; Andreychuk, Natalia; Benavent, Marc; Burdeos, Jose; Catala, Alba; Castane, Eric; Colom, Josep; Feliu, Mireia; Garrido, Diana; Gil, Joan; Guelbenzu, Paloma; Lozano, Carolina; Marimon, Francesc; Pardo, Pedro; Rabassa, Antoni; Revuelta, Laia; Rios, Marta; Sabate, Noelia; Castro, Antoni] Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, Hosp Univ St Joan, Dept Internal Med, Reus, Spain; [Vallverdu, Immaculada; Garrido, Pedro] Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, Hosp Univ St Joan, Intens Care Unit, Reus, Spain; [Hernandez-Flix, Salvador; Teixido, Anna] Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, Hosp Univ St Joan, Sect Pneumol, Reus, Spain; [de Febrer, Gabriel; Roquer-Fanlo, Esther; Vasco, Carlos] Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, Hosp Univ St Joan, Intermediate Care Unit, Reus, Spain; [Hernandez-Aguilera, Anna; Riu, Francesc] Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, Hosp Univ St Joan, Dept Pathol, Reus, Spain; [Hernandez-Aguilera, Anna; Joven, Jorge; Baiges-Gaya, Gerard; Castane, Helena; Rodriguez-Tomas, Elisabet; Camps, Jordi] Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, Hosp Univ St Joan, Unitat Recerca Biomed, Reus, Spain; [Ballester, Frederic; Gabaldo, Xavier; Pujol, Isabel] Lab Referencia Camp Tarragona & Terres Ebre, Reus, Spain; Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, Hosp Univ St Joan, Dept Pediat, Reus, Spain; [Rojewski, Wojciech] Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, Hosp Univ St Joan, Dept Emergency, Reus, Spain	Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV)	Camps, J (corresponding author), Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, Hosp Univ St Joan, Unitat Recerca Biomed, Reus, Spain.	jcamps@grupsagessa.com	Iftimie, Simona/GLU-5446-2022; Castañé, Helena/AFO-7722-2022; Gabaldó-Barrios, Xavier/AHA-0633-2022	Iftimie, Simona/0000-0003-0714-8414; Parra, Sandra/0000-0001-9363-6574; Pujol Bajador, Isabel/0000-0002-0521-0483; Andreychuk, Natalia/0000-0001-6219-7820	AHA - Fundacio La Marato de TV3, Barcelona, Spain [20180710]	AHA - Fundacio La Marato de TV3, Barcelona, Spain	SI, AHA, JJ, JC, and AC were funded by a grant from Fundacio La Marato de TV3 (20180710), Barcelona, Spain. Funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleta A., 2020, AGE DIFFERENTIAL ANA, V11; [Anonymous], 2020, ARCH PATHOL LAB MED, DOI 10.5858/arpa.2020-0901-SA; [Anonymous], [No title captured]; Ballester-Arnal R, 2020, AIDS BEHAV, V24, P2253, DOI 10.1007/s10461-020-02877-3; Buonanno P, 2020, SPATIAL DYNAMICS SAR, V11; Costanzo M, 2020, CURR MED CHEM, V27, P4536, DOI 10.2174/0929867327666200416131117; COVID-19 RISK and Treatments (CORIST) Collaboration, 2020, Eur J Intern Med, V82, P38, DOI 10.1016/j.ejim.2020.08.019; Di Castelnuovo A, 2020, VASC PHARMACOL, V135, DOI 10.1016/j.vph.2020.106805; Di Castelnuovo A, 2020, NUTR METAB CARDIOVAS, V30, P1899, DOI 10.1016/j.numecd.2020.07.031; Di Gennaro F, 2020, MEDITERR J HEMATOL I, V12, DOI 10.4084/MJHID.2020.063; Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702; Fan GH, 2021, TRANSBOUND EMERG DIS, V68, P213, DOI 10.1111/tbed.13819; Hodcroft EB, 2020, EMERGENCE SPREAD SAR, V10; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Iftimie S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234452; Ip A, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05773-w; Lam S, 2020, EUR J PHARMACOL, V886, DOI 10.1016/j.ejphar.2020.173451; Long SW, 2020, MBIO, V11, DOI 10.1128/mBio.02707-20; Looi MK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4113; Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2; Ran JJ, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa133; Ran JJ, 2020, J INFECTION, V81, pE9, DOI 10.1016/j.jinf.2020.07.011; Ran JJ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01253-2020; Renardy M, 2020, J THEOR BIOL, V507, DOI 10.1016/j.jtbi.2020.110461; Saito S, 2021, J INFECTION, V82, P116, DOI 10.1016/j.jinf.2020.10.033; Shen KL, 2020, WORLD J PEDIATR, V16, P232, DOI 10.1007/s12519-020-00362-4; Vahidy FS, 2020, JAMA-J AM MED ASSOC, V324, P998, DOI 10.1001/jama.2020.15301; Win A, 2020, QJM-INT J MED, V113, P856, DOI 10.1093/qjmed/hcaa290; Yang J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19238-2	30	123	126	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2021	16	3							e0248029	10.1371/journal.pone.0248029	http://dx.doi.org/10.1371/journal.pone.0248029			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH6VV	33788866	Green Published, gold, Green Submitted			2023-01-03	WOS:000636354600045
J	DiDiodato, G; Hassan, S; Cooley, K				DiDiodato, Giulio; Hassan, Samah; Cooley, Kieran			Elicitation of stakeholder viewpoints about medical cannabis research for pain management in critically ill ventilated patients: A Q-methodology study	PLOS ONE			English	Article								Objectives To determine acceptability of medical cannabis research in critically ill patients. Design Q-methodology survey. Setting Convenience sample of healthcare providers and the general public were recruited at an acute care community hospital in Ontario, Canada. Participants In the first phase, 63 respondents provided 197 unique viewpoints in response to a topic statement about medical cannabis use in critically ill patients. Twenty-five viewpoints were selected for the q-sample. In the second phase, 99 respondents ranked these viewpoints according to an a priori quasi normal distribution ranging from +4 (most agree) to -4 (least agree). Factor analysis was combined with comments provided by survey respondents to label and describe the extracted factors. Results The factor labels were hoping and caring (factor 1), pragmatic progress (factor 2), and cautious/conservative and protectionist (factor 3). Factor 1 describes a viewpoint of unequivocal support for medical cannabis research in this population with few caveats. Factor 2 describes a viewpoint of cautious support with a need to monitor for unintended adverse effects. Factor 3 describes a viewpoint of ensuring that current analgosedation techniques are optimized before exposing patients to another potentially harmful drug. Conclusions Using a q-methodology design, we were able to sample and describe the viewpoints that exist about medical cannabis research in critically ill patients. Three factors emerged that seemed to adequately describe the relative ranking of q-statements by the majority of respondents. Combining the distinguishing statements along with respondent comments allowed us to determine that the majority support medical cannabis research in critically ill patients.	[DiDiodato, Giulio] McMaster Univ, Med Ctr, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [DiDiodato, Giulio] Royal Victoria Reg Hlth Ctr, Ctr Educ & Res, Barrie, ON, Canada; [Hassan, Samah; Cooley, Kieran] Canadian Coll Naturopath Med, Toronto, ON, Canada; [Cooley, Kieran] Univ Technol Sydney, Australian Res Ctr Complementary & Integrat Med, Fac Hlth, Ultimo, Australia; [Cooley, Kieran] Pacific Coll Oriental Med, Chicago, IL USA	McMaster University; University of Technology Sydney	DiDiodato, G (corresponding author), McMaster Univ, Med Ctr, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.; DiDiodato, G (corresponding author), Royal Victoria Reg Hlth Ctr, Ctr Educ & Res, Barrie, ON, Canada.	didiodatog@rvh.on.ca		DiDiodato, Giulio/0000-0003-2836-8037; Cooley, Kieran/0000-0001-7960-6504	Canopy Health Innovation; Royal Victoria Regional Health Centre Foundation	Canopy Health Innovation; Royal Victoria Regional Health Centre Foundation	This study was funded by Canopy Health Innovation in the form of an unrestricted educational grant awarded to GD, KC, and SH. In addition, the Royal Victoria Regional Health Centre Foundation provided funding to cover the publication costs associated with this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank the Royal Victoria Regional Health Centre Foundation for their support of the publication costs.	Akhtar-Danesh N, 2018, STATA J, V18, P432, DOI 10.1177/1536867X1801800209; Barnes MP, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3230; Brown S.R., 1993, OPERANT SUBJECTIVITY, V16, P91, DOI DOI 10.15133/J.OS.1993.002; Di Forti M, 2019, LANCET PSYCHIAT, V6, P427, DOI 10.1016/S2215-0366(19)30048-3; Dolgin E, 2018, NATURE, V555, P300, DOI 10.1038/d41586-018-03070-2; Freeman TP., 2019, BMJ-BRIT MED J, V1141, pL1141, DOI [10.1136/bmj.l1141, DOI 10.1136/BMJ.L1141]; Ibanez Borja, 2018, Eur Heart J, V39, P119, DOI 10.1093/eurheartj/ehx393; Karanges EA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022101; Keyhani S, 2018, ANN INTERN MED, V169, P282, DOI 10.7326/M18-0810; Ko GD, 2016, J PAIN RES, V9, P735, DOI 10.2147/JPR.S98182; Kross EK, 2019, JAMA-J AM MED ASSOC, V321, P649, DOI 10.1001/jama.2019.0072; Lotsch J, 2018, EUR J PAIN, V22, P471, DOI 10.1002/ejp.1148; Manuzak JA, 2018, CLIN INFECT DIS, V66, P1872, DOI 10.1093/cid/cix1116; Martyn JAJ, 2019, NEW ENGL J MED, V380, P365, DOI 10.1056/NEJMra1800222; Mayor S., 2019, BMJ-BRIT MED J, DOI [10.1136/bmj.l574, DOI 10.1136/BMJ.L574, DOI 10.1136/BMJ.1574]; Mouhamed Y, 2018, DRUG HEALTHC PATIENT, V10, P45, DOI 10.2147/DHPS.S158592; Pun BT, 2019, CRIT CARE MED, V47, P3, DOI 10.1097/CCM.0000000000003482; Ramlo S, 2015, SAGE HDB MIX METHODS, V2010, P505; ROOTMAN I, 1979, DRUG ALCOHOL DEPEN, V4, P425, DOI 10.1016/0376-8716(79)90075-9; Schmid AB, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025530; Stenner P., 2016, DOING Q METHODOLOGY, V0887; Sznitman SR, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0082-x; Woodhams SG, 2017, NEUROPHARMACOLOGY, V124, P105, DOI 10.1016/j.neuropharm.2017.06.015	23	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0248475	10.1371/journal.pone.0248475	http://dx.doi.org/10.1371/journal.pone.0248475			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QZ9HN	33735318	Green Published, gold			2023-01-03	WOS:000631029700067
J	Pouzol, L; Baumlin, N; Sassi, A; Tunis, M; Marrie, J; Vezzali, E; Farine, H; Mentzel, U; Martinic, MM				Pouzol, Laetitia; Baumlin, Nadege; Sassi, Anna; Tunis, Melanie; Marrie, Julia; Vezzali, Enrico; Farine, Herve; Mentzel, Ulrich; Martinic, Marianne M.			ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases	FASEB JOURNAL			English	Article						CXCR7; experimental autoimmune encephalomyelitis; immunomodulation; myelin repair; demyelinating diseases	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CHEMOKINE RECEPTOR; REMYELINATION FAILURE; PROGENITOR CELLS; AXONAL INJURY; VIRAL MODEL; CXCL12; PROMOTES; EXPRESSION; MIGRATION	Current strategies for the treatment of demyelinating diseases such as multiple sclerosis (MS) are based on anti-inflammatory or immunomodulatory drugs. Those drugs have the potential to reduce the frequency of new lesions but do not directly promote remyelination in the damaged central nervous system (CNS). Targeting CXCR7 (ACKR3) has been postulated as a potential therapeutic approach in demyelinating diseases, leading to both immunomodulation by reducing leukocyte infiltrates and promyelination by enhancing myelin repair. ACT-1004-1239 is a potent, selective, insurmountable, and orally available first-in-class CXCR7 receptor antagonist. The effect of ACT-1004-1239 was evaluated in the myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) and the cuprizone-induced demyelination mouse models. In addition, ACT-1004-1239 was assessed in a rat oligodendrocyte precursor cell (OPC) differentiation assay in vitro. In the MOG-induced EAE model, ACT-1004-1239 treatment (10-100 mg/kg, twice daily, orally) showed a significant dose-dependent reduction in disease clinical scores, resulting in increased survival. At the highest dose tested (100 mg/kg, twice daily), ACT-1004-1239 delayed disease onset and significantly reduced immune cell infiltrates into the CNS and plasma neurofilament light chain concentration. Treatment with ACT-1004-1239 dose-dependently increased plasma CXCL12 concentration, which correlated with a reduction of the cumulative disease score. Furthermore, in the cuprizone model, ACT-1004-1239 treatment significantly increased the number of mature myelinating oligodendrocytes and enhanced myelination in vivo. In vitro, ACT-1004-1239 promoted the maturation of OPCs into myelinating oligodendrocytes. These results provide evidence that ACT-1004-1239 both reduces neuroinflammation and enhances myelin repair substantiating the rationale to explore its therapeutic potential in a clinical setting.	[Pouzol, Laetitia; Baumlin, Nadege; Sassi, Anna; Tunis, Melanie; Marrie, Julia; Vezzali, Enrico; Farine, Herve; Mentzel, Ulrich; Martinic, Marianne M.] Idorsia Pharmaceut Ltd, Allschwil, Switzerland	Idorsia Pharmaceuticals Ltd	Pouzol, L (corresponding author), Idorsia Pharmaceut Ltd, Hegenheimermattweg 91, CH-4123 Basel, Switzerland.	laetitia.pouzol@idorsia.com		Martinic, Marianne/0000-0003-4407-3423; Pouzol, Laetitia/0000-0001-8727-1142; Vezzali, Enrico/0000-0002-5550-9387				Sanchez-Alcaniz JA, 2011, NEURON, V69, P77, DOI 10.1016/j.neuron.2010.12.006; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Banisadr G, 2016, J NEUROIMMUNE PHARM, V11, P26, DOI 10.1007/s11481-015-9616-y; Bao JH, 2016, BIOCHEM BIOPH RES CO, V469, P1, DOI 10.1016/j.bbrc.2015.11.059; Berahovich RD, 2014, IMMUNOLOGY, V141, P111, DOI 10.1111/imm.12176; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Carbajal KS, 2011, GLIA, V59, P1813, DOI 10.1002/glia.21225; Carbajal KS, 2010, P NATL ACAD SCI USA, V107, P11068, DOI 10.1073/pnas.1006375107; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Cheng WJ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/659206; Chu TC, 2017, NEUROSCIENTIST, V23, P627, DOI 10.1177/1073858416685690; Cruz-Orengo L, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-170; Cruz-Orengo L, 2011, J EXP MED, V208, P327, DOI 10.1084/jem.20102010; Doan V, 2013, J NEUROSCI RES, V91, P363, DOI 10.1002/jnr.23174; Fricker SP, 2006, BIOCHEM PHARMACOL, V72, P588, DOI 10.1016/j.bcp.2006.05.010; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Galli E, 2019, NAT MED, V25, P1290, DOI 10.1038/s41591-019-0521-4; Gottle P, 2010, ANN NEUROL, V68, P915, DOI 10.1002/ana.22214; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Gudi V, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00073; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Hauser J, 2020, NUTR NEUROSCI, V23, P931, DOI 10.1080/1028415X.2019.1580918; Herrero-Herranz E, 2008, NEUROBIOL DIS, V30, P162, DOI 10.1016/j.nbd.2008.01.001; Huynh C, 2021, CLIN PHARMACOL THER, V109, P1648, DOI 10.1002/cpt.2154; Jakimovski D, 2020, MULT SCLER J, V26, P1670, DOI 10.1177/1352458519881428; Kadi L, 2006, J NEUROIMMUNOL, V174, P133, DOI 10.1016/j.jneuroim.2006.01.011; Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Kipp M, 2012, CNS NEUROL DISORD-DR, V11, P598, DOI 10.2174/187152712801661257; Kremer D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146503; Kuhle J, 2019, NEUROLOGY, V92, pE1007, DOI 10.1212/WNL.0000000000007032; Kuhlmann T, 2008, BRAIN, V131, P1749, DOI 10.1093/brain/awn096; Lewellis SW, 2012, SEMIN CELL DEV BIOL, V23, P333, DOI 10.1016/j.semcdb.2012.03.009; Li YN, 2015, STEM CELL TRANSL MED, V4, P1122, DOI 10.5966/sctm.2015-0074; Lounsbury N, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13020033; Luker KE, 2012, ONCOGENE, V31, P4750, DOI 10.1038/onc.2011.633; Magalon K, 2012, ANN NEUROL, V71, P213, DOI 10.1002/ana.22593; Martin R, 2016, EUR J IMMUNOL, V46, P2078, DOI 10.1002/eji.201646485; Mason JL, 2004, AM J PATHOL, V164, P1673, DOI 10.1016/S0002-9440(10)63726-1; Maysami S, 2006, NEUROREPORT, V17, P1187, DOI 10.1097/01.wnr.0000227985.92551.9a; McCandless EE, 2008, AM J PATHOL, V172, P799, DOI 10.2353/ajpath.2008.070918; McCandless EE, 2006, J IMMUNOL, V177, P8053, DOI 10.4049/jimmunol.177.11.8053; Meiron M, 2008, J EXP MED, V205, P2643, DOI 10.1084/jem.20080730; Menhaji-Klotz E., 2020, ACS MED CHEM LETT; Meyrath M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16664-0; Moll NM, 2009, ARCH NEUROL-CHICAGO, V66, P44, DOI 10.1001/archneurol.2008.512; Motavaf M, 2017, CELL MOL NEUROBIOL, V37, P1335, DOI 10.1007/s10571-017-0472-6; Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175; O'Boyle G, 2009, FASEB J, V23, P3906, DOI 10.1096/fj.09-134643; Odemis V, 2012, GLIA, V60, P372, DOI 10.1002/glia.22271; Odemis V, 2010, J CELL SCI, V123, P1081, DOI 10.1242/jcs.062810; Oh J, 2014, THER ADV NEUROL DISO, V7, P239, DOI 10.1177/1756285614546855; Patel JR, 2010, P NATL ACAD SCI USA, V107, P11062, DOI 10.1073/pnas.1006301107; Pouzol L, 2021, FASEB J, V35; Puchert M, 2017, MOL CELL NEUROSCI, V85, P105, DOI 10.1016/j.mcn.2017.09.001; Quinn KE, 2018, CYTOKINE, V109, P17, DOI 10.1016/j.cyto.2018.02.024; Richard-Bildstein S, 2020, J MED CHEM, V63, P15864, DOI 10.1021/acs.jmedchem.0c01588; Robinson AP, 2014, HAND CLINIC, V122, P173, DOI 10.1016/B978-0-444-52001-2.00008-X; Sadeghian-Rizi T, 2018, CNS NEUROL DISORD-DR, V17, P496, DOI 10.2174/1871527317666180713111100; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Stritt M, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007313; Wang C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00641; Williams JL, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00154; Williams JL, 2014, J EXP MED, V211, P791, DOI 10.1084/jem.20131224; Zabel BA, 2009, J IMMUNOL, V183, P3204, DOI 10.4049/jimmunol.0900269; Zilkha-Falb R, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0468-4	67	10	11	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2021	35	3							e21431	10.1096/fj.202002465R	http://dx.doi.org/10.1096/fj.202002465R			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX8EV	33595155				2023-01-03	WOS:000629576700049
J	Garcia-Lorenzo, B; Fernandez-Barcelo, C; Maduell, F; Sampietro-Colom, L				Garcia-Lorenzo, Borja; Fernandez-Barcelo, Carla; Maduell, Francisco; Sampietro-Colom, Laura			Health Technology Assessment of a new water quality monitoring technology: Impact of automation, digitalization and remoteness in dialysis units	PLOS ONE			English	Article								Background Water quality monitoring at the dialysis units (DU) is essential to ensure an appropriate dialysis fluid quality and guarantee an optimal and safe dialysis treatment to patients. This paper aims to evaluate the effectiveness, economic and organizational impact of automation, digitalization and remote water quality monitoring, through a New Water Technology (NWT) at a hospital DU to produce dialysis water, compared to a Conventional Water Technology (CWT). Methods A before-and-after study was carried out at the Hospital Clinic Barcelona. Data on CWT was collected during 1-year (control) and 7-month for the NWT (case). Data on water quality, resource use and unit cost were retrospective and prospectively collected. A comparative effectiveness analysis on the compliance rate of quality water parameters with the international guidelines between the NWT and the CWT was conducted. This was followed by a cost-minimization analysis and an organizational impact from the hospital perspective. An extensive deterministic sensitivity analysis was also performed. Results The NWT compared to the CWT showed no differences on effectiveness measured as the compliance rate on international requirements on water quality (100% vs. 100%), but the NWT yielded savings of 3,599 EUR/year compared to the CWT. The NWT offered more data accuracy (daily measures: 6 vs. 1 and missing data: 0 vs. 20 days/year), optimization of the DU employees' workload (attendance to DU: 4 vs. 19 days/month) and workflow, through the remote and continuous monitoring, reliability of data and process regarding audits for quality control. Conclusions While the compliance of international recommendations on continuous monitoring was performed with the CWT, the NWT was efficient compared to the CWT, mainly due to the travel time needed by the technical operator to attend the DU. These results were scalable to other economic contexts. Nonetheless, they should be taken with caution either when the NWT equipment/maintenance cost are largely increased, or the workforce involvement is diminished.	[Garcia-Lorenzo, Borja; Fernandez-Barcelo, Carla; Sampietro-Colom, Laura] Univ Barcelona, Hosp Clin Barcelona, Assessment Innovat & New Technol Unit, Barcelona, Catalonia, Spain; [Maduell, Francisco] Univ Barcelona, Hosp Clin Barcelona, Dept Nephrol & Renal Transplantat, Barcelona, Catalonia, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Garcia-Lorenzo, B (corresponding author), Univ Barcelona, Hosp Clin Barcelona, Assessment Innovat & New Technol Unit, Barcelona, Catalonia, Spain.	bogarcia@clinic.cat	Fernández-Barceló, Carla/AAI-1518-2021	Fernández-Barceló, Carla/0000-0001-5495-879X; Maduell, Francisco/0000-0002-1673-0353; Sampietro-Colom, Laura/0000-0001-7182-0231	Fresenius Medical Care (FMC); FMC	Fresenius Medical Care (FMC); FMC	Fresenius Medical Care (FMC) has cofinanced the present study. No authors have directly received the project grant; the institution which the authors work for (Hospital Cli ' nic Barcelona) is the one that received the project grant instead. BGL, CFB, FM, LSC reports grants from FMC during the conduct of the study. BGL reports conferences fees and expenses from FMC during the conduct of the study. FM reports personal fees from FMC during the conduct of the study. The funders had no role in study design, analysis or decision to publish. FMC had role in the data collection and reviewing the final version of the manuscript.	Agar JWM, 2020, NAT REV NEPHROL, V16, P556, DOI 10.1038/s41581-020-0296-3; [Anonymous], 2002, NEPHROL DIAL TRANSPL, V17, P45; Canaud B, 1998, NEPHROL DIAL TRANSPL, V13, P3, DOI 10.1093/ndt/13.suppl_5.3; Canaud B, 2000, NEPHROL DIAL TRANSPL, V15, P21, DOI 10.1093/ndt/15.suppl_1.21; Drummond MF, 2015, METHODS EC EVALUATIO, V4th; Elshahat S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230512; Federacion de Empresas de Tecnologias Sanitarias, 2018, IMPACTO TECNOLOGIAS; Haller MC, 2014, NEPHROL DIAL TRANSPL, V29, P1994, DOI 10.1093/ndt/gft369; International Standard Organization, 23500 ISO; Kramer A, 2018, CLIN KIDNEY J, V11, P108, DOI 10.1093/ckj/sfx149; Ledebo I, 1999, ARTIF ORGANS, V23, P37, DOI 10.1046/j.1525-1594.1999.06275.x; Ledebo I, 2007, NEPHROL DIAL TRANSPL, V22, P20, DOI 10.1093/ndt/gfl574; Lucena R., 2015, WATER DIALYSIS FLUID; Masakane I, 2006, THER APHER DIAL, V10, P348, DOI 10.1111/j.1744-9987.2006.00388.x; Palmer AJ, 2005, NEPHROL DIAL TRANSPL, V20, P1038, DOI 10.1093/ndt/gfh824; Pizzarelli F, 1998, NEPHROL DIAL TRANSPL, V13, P363, DOI 10.1093/oxfordjournals.ndt.a027831; Robinson BM, 2014, KIDNEY INT, V85, P158, DOI 10.1038/ki.2013.252; van der Tol A, 2020, NEPHROL DIAL TRANSPL, V35, P979, DOI 10.1093/ndt/gfaa035; Weber C, 2000, ARTIF ORGANS, V24, P323, DOI 10.1046/j.1525-1594.2000.06494.x	19	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247450	10.1371/journal.pone.0247450	http://dx.doi.org/10.1371/journal.pone.0247450			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BB	33630930	gold, Green Published			2023-01-03	WOS:000624536800051
J	Kardani, K; Bolhassani, A				Kardani, Kimia; Bolhassani, Azam			Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches	PLOS ONE			English	Article							IN-VIVO DELIVERY; THERAPEUTIC PROTEINS; FUSION PROTEIN; VACCINE; PREDICTION; NANOPARTICLES; LOCALIZATION; MOLECULES; MECHANISM; POLYMERS	Among various delivery systems for vaccine and drug delivery, cell-penetrating peptides (CPPs) have been known as a potent delivery system because of their capability to penetrate cell membranes and deliver some types of cargoes into cells. Several CPPs were found in the proteome of viruses such as Tat originated from human immunodeficiency virus-1 (HIV-1), and VP22 derived from herpes simplex virus-1 (HSV-1). In the current study, a wide-range of CPPs was identified in the proteome of SARS-CoV-2, a new member of coronaviruses family, using in silico analyses. These CPPs may play a main role for high penetration of virus into cells and infection of host. At first, we submitted the proteome of SARS-CoV-2 to CellPPD web server that resulted in a huge number of CPPs with ten residues in length. Afterward, we submitted the predicted CPPs to C2Pred web server for evaluation of the probability of each peptide. Then, the uptake efficiency of each peptide was investigated using CPPred-RF and MLCPP web servers. Next, the physicochemical properties of the predicted CPPs including net charge, theoretical isoelectric point (pI), amphipathicity, molecular weight, and water solubility were calculated using protparam and pepcalc tools. In addition, the probability of membrane binding potential and cellular localization of each CPP were estimated by Boman index using APD3 web server, D factor, and TMHMM web server. On the other hand, the immunogenicity, toxicity, allergenicity, hemolytic potency, and half-life of CPPs were predicted using various web servers. Finally, the tertiary structure and the helical wheel projection of some CPPs were predicted by PEP-FOLD3 and Heliquest web servers, respectively. These CPPs were divided into: a) CPP containing tumor homing motif (RGD) and/or tumor penetrating motif (RXXR); b) CPP with the highest Boman index; c) CPP with high half-life (similar to 100 hour) in mammalian cells, and d) CPP with +5.00 net charge. Based on the results, we found a large number of novel CPPs with various features. Some of these CPPs possess tumor-specific motifs which can be evaluated in cancer therapy. Furthermore, the novel and potent CPPs derived from SARS-CoV-2 may be used alone or conjugated to some sequences such as nuclear localization sequence (NLS) for vaccine and drug delivery.	[Kardani, Kimia; Bolhassani, Azam] Pasteur Inst Iran, Dept Hepatitis & AIDS, Tehran, Iran	Le Reseau International des Instituts Pasteur (RIIP); Pasteur Institute of Iran	Bolhassani, A (corresponding author), Pasteur Inst Iran, Dept Hepatitis & AIDS, Tehran, Iran.	azam.bolhassani@yahoo.co	Bolhassani, Azam/HDN-7200-2022	Bolhassani, Azam/0000-0001-7363-7406; kardani, kimia/0000-0003-0357-6331				Bolhassani A, 2017, PEPTIDES, V87, P50, DOI 10.1016/j.peptides.2016.11.011; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Caesar CEB, 2006, BIOCHEMISTRY-US, V45, P7682, DOI 10.1021/bi052095t; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Chakraborty H, 2020, BIOPHYS CHEM, V265, DOI 10.1016/j.bpc.2020.106438; Chaudhary K, 2016, SCI REP-UK, V6, DOI 10.1038/srep22843; Chen L, 2015, AMINO ACIDS, V47, P1485, DOI 10.1007/s00726-015-1974-5; Dhakal S, 2019, VET RES, V50, DOI 10.1186/s13567-019-0712-5; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Du XF, 2018, DRUG DELIV, V25, P1516, DOI 10.1080/10717544.2018.1480674; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Florindo HF, 2020, NAT NANOTECHNOL, V15, P630, DOI 10.1038/s41565-020-0732-3; Freire JM, 2014, FEBS J, V281, P191, DOI 10.1111/febs.12587; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Garg A, 2020, CRIT REV THER DRUG, V37, P183, DOI 10.1615/CritRevTherDrugCarrierSyst.2020033273; Gautam A., 2015, CELL PENETRATING PEP, P59; Gautam A, 2015, EUR J PHARM BIOPHARM, V89, P93, DOI 10.1016/j.ejpb.2014.11.020; Gautam A, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-74; Gautier R, 2008, BIOINFORMATICS, V24, P2101, DOI 10.1093/bioinformatics/btn392; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Habault J, 2019, MOLECULES, V24, DOI 10.3390/molecules24050927; Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4; Hoffmann K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30790-2; Kadkhodayan S, 2017, CURR DRUG DELIV, V14, P536, DOI 10.2174/1567201813666161006114448; Kajiwara N., 2020, SCI REP-UK, V10, P1, DOI [10.1038/s41598-019-56847-4, DOI 10.1038/S41598-019-56847-4]; Kardani K., 2020, CORONAVIRUSES, V1, P1; Kardani K, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2020.11.002; Kardani K, 2020, EXPERT REV CLIN PHAR, V13, P1001, DOI 10.1080/17512433.2020.1814743; Kardani K, 2019, EXPERT OPIN DRUG DEL, V16, P1227, DOI 10.1080/17425247.2019.1676720; Kumar Swatantra, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00571-5; Kuriakose A, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1298473; Kwon SJ, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-73; Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329; Li YJ, 2019, J PROTEOME RES, V18, P1392, DOI 10.1021/acs.jproteome.9b00012; Liu B, 2019, IEEE ACM T COMPUT BI, V16, P292, DOI 10.1109/TCBB.2017.2765331; Liu ZH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37214-1; Madani Fatemeh, 2011, J Biophys, V2011, P414729, DOI 10.1155/2011/414729; Mahajan M, 2018, BBA-BIOMEMBRANES, V1860, P407, DOI 10.1016/j.bbamem.2017.10.002; Mahajan M, 2015, BBA-BIOMEMBRANES, V1848, P721, DOI 10.1016/j.bbamem.2014.11.025; Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010; Manayalan B, 2018, J PROTEOME RES, V17, P2715, DOI 10.1021/acs.jproteome.8b00148; Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nabel GJ, 2013, NEW ENGL J MED, V368, P551, DOI 10.1056/NEJMra1204186; Nevagi RJ, 2019, EUR POLYM J, V114, P397, DOI 10.1016/j.eurpolymj.2019.03.009; Qi XP, 2011, MOL PLANT MICROBE IN, V24, P25, DOI 10.1094/MPMI-07-10-0147; Raagel H, 2011, PEPTIDE AND PROTEIN DELIVERY, P221, DOI 10.1016/B978-0-12-384935-9.10010-0; Rhee M, 2006, J BIOL CHEM, V281, P1233, DOI 10.1074/jbc.M509813200; Rydberg HA, 2012, BIOCHEMISTRY-US, V51, P5531, DOI 10.1021/bi300454k; Senel S, 2020, DRUG DELIV TRANSL RE, V10, P1644, DOI 10.1007/s13346-020-00806-4; Shahbazi S, 2018, INT IMMUNOPHARMACOL, V62, P170, DOI 10.1016/j.intimp.2018.07.006; Shankar G, 2014, AAPS J, V16, P658, DOI 10.1208/s12248-014-9599-2; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tang H, 2016, BIOCHEM BIOPH RES CO, V477, P150, DOI 10.1016/j.bbrc.2016.06.035; Tang J, 2020, BRIEF BIOINFORM, V21, P621, DOI 10.1093/bib/bby127; Wabalo EK., 2020, BIOL PHARM SCI, V12, P117; Wallis J, 2020, EUR J PHARM SCI, V152, DOI 10.1016/j.ejps.2020.105456; Wei LY, 2017, J PROTEOME RES, V16, P2044, DOI 10.1021/acs.jproteome.7b00019; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Xia HM, 2012, INT J PHARMACEUT, V436, P840, DOI 10.1016/j.ijpharm.2012.07.029; Yang JR, 2019, CURR DRUG DELIV, V16, P430, DOI 10.2174/1567201816666190123120915; Yin JY, 2020, NUCLEIC ACIDS RES, V48, pD1042, DOI 10.1093/nar/gkz779; Yu R, 2019, J DRUG TARGET, V27, P780, DOI 10.1080/1061186X.2018.1547734; Zareba G, 2006, DRUG TODAY, V42, P321, DOI 10.1358/dot.2006.42.5.973586; Zhang MM, 2017, ACS BIOMATER SCI ENG, V3, P108, DOI 10.1021/acsbiomaterials.6b00418	68	9	9	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2021	16	2							e0247396	10.1371/journal.pone.0247396	http://dx.doi.org/10.1371/journal.pone.0247396			54	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8KQ	33606823	Green Published, gold			2023-01-03	WOS:000620629200119
J	Mandic, MR; Oalde, MM; Lunic, TM; Sabovljevic, AD; Sabovljevic, MS; Gasic, UM; Duletic-Lausevic, SN; Bozic, BD; Nedeljkovic, BDB				Mandic, Marija R.; Oalde, Mariana M.; Lunic, Tanja M.; Sabovljevic, Aneta D.; Sabovljevic, Marko S.; Gasic, Uros M.; Duletic-Lausevic, Sonja N.; Bozic, Bojan Dj; Nedeljkovic, Biljana Dj Bozic			Chemical characterization and in vitro immunomodulatory effects of different extracts of moss Hedwigia ciliata (Hedw.) P. Beauv. from the Vrsacke Planine Mts., Serbia	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; NITRIC-OXIDE; INHIBITORY-ACTIVITIES; PROTOCATECHUIC ACID; SIGNALING PATHWAY; ETHANOL EXTRACT; PHENOLIC-ACIDS; HUMAN BREAST; CANCER; BRYOPHYTES	Bioactive compounds from natural sources are of great importance because of their potential pharmacological activity and tremendous structural diversity. In this study, the chemical composition of different moss extracts of Hedwigia ciliata P. Beauv. have been examined, as well as their antioxidant, antineurodegenerative/anti-neuroinflammatory, antidiabetic, and antiproliferative potential. The extracts were prepared by Soxhlet extractor using solvents of different polarity. Chemical characterization of the extracts revealed the presence of phenolics and flavonoid compounds, together with triterpenoids as secondary metabolites of high biological activity. Significant antioxidant properties of all the extracts were exhibited using the beta-carotene assay. The highest activities were found for water:ethanol extract (with the highest inhibition rate of 96%), but also significant inhibition was measured for ethanol and ethyl acetate extracts (80% and 70%, respectively). Confirmation of biocompatibility of investigated moss extracts has been performed using normal human fibroblast cell line, MRC-5. The H. ciliata extracts exhibited significant antiproliferative activity (similar to 50%) against the MDA-MB-231 (human breast adenocarcinoma cell line), which has not previously been reported elsewhere. The Griess assay confirmed the potential anti-neuroinflammatory activity of the extracts, as significant effects in reducing NO production by LPS-stimulated BV2 (normal murine microglia cell line) was observed. This data is in line with noted antineurodegenerative potential measured by the inhibition of acetylcholinesterase (with the highest inhibition rate of 60% for ethyl acetate extract) and tyrosinase (with the highest inhibition rate of 70% for ethanol extract). Additionally, the H. ciliata extracts exhibited significant antidiabetic effect mediated by alpha-glucosidase inhibition (with the highest inhibition rate of 80% for ethyl acetate extract). The obtained data suggest the presence of immunomodulatory effects of the moss extracts in vitro, which allows the design of new experiments aimed at detecting and characterizing bioactive compounds of the extracts and additionally elucidate detailed mechanisms of their effects.	[Mandic, Marija R.; Lunic, Tanja M.; Bozic, Bojan Dj; Nedeljkovic, Biljana Dj Bozic] Univ Belgrade, Fac Biol, Inst Physiol & Biochem Ivan Djaja, Belgrade, Serbia; [Oalde, Mariana M.; Sabovljevic, Aneta D.; Sabovljevic, Marko S.; Duletic-Lausevic, Sonja N.] Univ Belgrade, Fac Biol, Inst Bot & Bot Garden Jevremovac, Belgrade, Serbia; [Gasic, Uros M.] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Natl Inst Republ Serbia, Dept Plant Physiol, Belgrade, Serbia	University of Belgrade; University of Belgrade; University of Belgrade	Bozic, BD; Nedeljkovic, BDB (corresponding author), Univ Belgrade, Fac Biol, Inst Physiol & Biochem Ivan Djaja, Belgrade, Serbia.	bbozic@bio.bg.ac.rs; biljana@bio.bg.ac.rs	Bozic, Bojan/ABA-3278-2020; Sabovljevic, Marko/ABC-8637-2020; Gašić, Uroš/P-2239-2016	Sabovljevic, Marko/0000-0001-5809-0406; Gašić, Uroš/0000-0001-5384-8396; Bozic, Bojan/0000-0001-9910-2741; Oalde Pavlovic, Mariana/0000-0001-9338-7811; Sabovljevic, Aneta/0000-0003-3092-9972; Bozic Nedeljkovic, Biljana/0000-0002-1238-1731	Ministry of Education and Science of the Republic of Serbia [451-03-68/2020-14/200178, 451-03-68/2020-14/200007]	Ministry of Education and Science of the Republic of Serbia(Ministry of Education, Science & Technological Development, Serbia)	This work was supported by the grant of the Ministry of Education and Science of the Republic of Serbia (Contract numbers: 451-03-68/2020-14/200178 and 451-03-68/2020-14/200007).	Aminudin Nurul Iman, 2015, Journal of Coastal Life Medicine, V3, P126, DOI 10.12980/JCLM.3.2015JCLM-2014-0115; [Anonymous], 2019, CANC DISCOV, V10, pOF5; Asakawa Y, 1998, J HATTORI BOT LAB, V84, P91; Asakawa Y, 2018, J NAT PROD, V81, P641, DOI 10.1021/acs.jnatprod.6b01046; Basile A, 1999, PHYTOCHEMISTRY, V52, P1479, DOI 10.1016/S0031-9422(99)00286-1; Basli A, 2017, PHENOLIC COMPOUNDS B, P193; Bendary E., 2013, Annals of Agricultural Science (Cairo), V58, P173, DOI 10.1016/j.aoas.2013.07.002; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199a0; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Brusselmans K, 2005, J BIOL CHEM, V280, P5636, DOI 10.1074/jbc.M408177200; Canli K, 2014, J PURE APPL MICROBIO, V8, P2987; Carocho M, 2013, ANTI-CANCER AGENT ME, V13, P1236, DOI 10.2174/18715206113139990301; Chobot V, 2008, Z NATURFORSCH C, V63, P476; Choi BM, 2002, J BIOCHEM MOL BIOL, V35, P116; Chou TH, 2010, J NAT PROD, V73, P1767, DOI 10.1021/np100281g; Dai J, 2010, MOLECULES, V15, P7313, DOI 10.3390/molecules15107313; Dapkevicius A, 1998, J SCI FOOD AGR, V77, P140, DOI 10.1002/(SICI)1097-0010(199805)77:1&lt;140::AID-JSFA18&gt;3.0.CO;2-K; Garcia-Molina MD, 2012, J AGR FOOD CHEM, V60, P6447, DOI 10.1021/jf301238q; Dey A, 2015, J ACUTE DIS, V4, P236, DOI 10.1016/j.joad.2015.04.011; Dhama K, 2015, INT J PHARMACOL, V11, P253, DOI 10.3923/ijp.2015.253.290; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Fettes N., 2019, MINIATURE WORLD DECL, DOI [DOI 10.2305/IUCN.CH.2019.ERL.2.EN, 10.2305/IUCN.CH.2019.ERL.2.en]; Gonzalez Mancebo J, 2019, IUCN RED LIST THREAT; Gotoh T, 1999, J CELL BIOL, V144, P427, DOI 10.1083/jcb.144.3.427; Heim KE, 2002, J NUTR BIOCHEM, V13, P572, DOI 10.1016/S0955-2863(02)00208-5; Huang M, 2012, EXPERT OPIN INV DRUG, V21, P1801, DOI 10.1517/13543784.2012.727395; Jeong JW, 2014, CHEM-BIOL INTERACT, V212, P30, DOI 10.1016/j.cbi.2014.01.012; Kazeem MI, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/527570; Kim JS, 2005, IMMUNOLOGY, V115, P375, DOI 10.1111/j.1365-2567.2005.02156.x; Kim MY, 2018, NUTR RES PRACT, V12, P41, DOI 10.4162/nrp.2018.12.2.129; Kim YJ, 2005, CELL MOL LIFE SCI, V62, P1707, DOI 10.1007/s00018-005-5054-y; Klavina L, 2018, COMPOSITION MOSSES T; Klavina L, 2015, MOLECULES, V20, P17221, DOI 10.3390/molecules200917221; Kocak MS, 2016, IND CROP PROD, V85, P204, DOI 10.1016/j.indcrop.2016.03.015; Kuo KC, 2012, 2012 IEEE ASIA PACIFIC CONFERENCE ON CIRCUITS AND SYSTEMS (APCCAS), P120, DOI 10.1109/APCCAS.2012.6418986; Li K, 2018, CHEM CENT J, V12, DOI 10.1186/s13065-018-0445-y; Li L, 2007, BRAIN RES, V1159, P8, DOI 10.1016/j.brainres.2007.04.066; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Ludwiczuk A, 2019, FOOD CHEM TOXICOL, V132, DOI 10.1016/j.fct.2019.110649; Lunic TM, 2020, MOLECULES, V25, DOI 10.3390/molecules25153343; Masaki H, 1997, BIOL PHARM BULL, V20, P304; Masuda T, 2005, BIOSCI BIOTECH BIOCH, V69, P197, DOI 10.1271/bbb.69.197; Merkl R, 2010, CZECH J FOOD SCI, V28, P275, DOI 10.17221/132/2010-CJFS; Mihailovic V, 2016, IND CROP PROD, V89, P141, DOI 10.1016/j.indcrop.2016.04.075; Misic D, 2015, PHYTOCHEM ANALYSIS, V26, P72, DOI 10.1002/pca.2538; Miyazawa M, 2003, J AGR FOOD CHEM, V51, P6953, DOI 10.1021/jf030388s; Murad H, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0315-4; Nahas R, 2013, LIPID OXIDATION, P243; Nair S.S., 2013, EUR J EXP BIOL, V3, P128; Neagu E, 2015, J TAIWAN INST CHEM E, V52, P1, DOI 10.1016/j.jtice.2015.01.026; Olajide OA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/459723; Opeyemi RF, 2019, PERTANIKA J TROP AGR, V42, P139; Osterdahl B, 1976, ACTA CHEM SCAND; OSTERDAHL BG, 1978, ACTA CHEM SCAND B, V32, P93, DOI 10.3891/acta.chem.scand.32b-0093; OSTERDAHL BG, 1977, ACTA CHEM SCAND B, V31, P293, DOI 10.3891/acta.chem.scand.31b-0293; OYAIZU M, 1986, Japanese Journal of Nutrition, V44, P307; Oyedemi Sunday O, 2017, ScientificWorldJournal, V2017, P3592491, DOI 10.1155/2017/3592491; Park SE, 2014, ONCOL REP, V32, P2461, DOI 10.3892/or.2014.3507; Park YK, 1997, ARQ BIOL TECNOL, V40, P97; Peixoto Sobrinho TJS., 2012, LATEST RES QUALITY C, V1, P47, DOI [https://doi.org/10.5772/45955, DOI 10.5772/45955]; Pereira DM, 2009, MOLECULES; Rabi T, 2009, BREAST CANCER RES TR, V115, P223, DOI 10.1007/s10549-008-0118-y; Rahimifard M, 2017, AGEING RES REV, V36, P11, DOI 10.1016/j.arr.2017.02.004; Sabovljevic A, 2009, METHODS MOL BIOL, V547, P117, DOI 10.1007/978-1-60327-287-2_10; SANTOS-SANCHEZ N. F., 2019, ANTIOXIDANTS-BASEL; Savelev S, 2003, PHARMACOL BIOCHEM BE, V75, P661, DOI 10.1016/S0091-3057(03)00125-4; Sawai S, 2011, FRONT PLANT SCI, V2, DOI 10.3389/fpls.2011.00025; Scherrmann JM, 2002, VASC PHARMACOL, V38, P349, DOI 10.1016/S1537-1891(02)00202-1; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Tungmunnithum Duangjai, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030093; Tusevski O, 2014, CENT EUR J BIOL, V9, P888, DOI 10.2478/s11535-014-0322-1; Wan LS, 2013, J NAT PROD, V76, P1248, DOI 10.1021/np400082g; Wang XN, 2018, BIOCHEM BIOPH RES CO, V504, P812, DOI 10.1016/j.bbrc.2018.08.043; Whitehead James, 2018, LINDBERGIA, V41, DOI 10.25227/linbg.01097; Winter AN, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6297080; Xie CF, 2009, CHEM BIODIVERS, V6, P303, DOI 10.1002/cbdv.200700450; Yang HJ, 2010, CURR DRUG TARGETS, V11, P733, DOI 10.2174/138945010791170842; Yao H, 2011, J ENVIRON SCI HEAL C, V29, P1, DOI 10.1080/10590501.2011.551317; Yaynta OT, 2019, DETERMINATION ANTIOX; Yin MC, 2009, J AGR FOOD CHEM, V57, P6468, DOI 10.1021/jf9004466; Ying YM, 2014, PHYTOCHEMISTRY, V108, P171, DOI 10.1016/j.phytochem.2014.09.022; Zengin G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113527	83	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246810	10.1371/journal.pone.0246810	http://dx.doi.org/10.1371/journal.pone.0246810			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH4VJ	33571277	Green Published, gold			2023-01-03	WOS:000618274000001
J	Mederos, MA; Reber, HA; Girgis, MD				Mederos, Michael A.; Reber, Howard A.; Girgis, Mark D.			Acute Pancreatitis: A Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review								ImportanceIn the United States, acute pancreatitis is one of the leading causes of hospital admission from gastrointestinal diseases, with approximately 300000 emergency department visits each year. Outcomes from acute pancreatitis are influenced by risk stratification, fluid and nutritional management, and follow-up care and risk-reduction strategies, which are the subject of this review. ObservationsMEDLINE was searched via PubMed as was the Cochrane databases for English-language studies published between January 2009 and August 2020 for current recommendations for predictive scoring tools, fluid management and nutrition, and follow-up and risk-reduction strategies for acute pancreatitis. Several scoring systems, such as the Bedside Index of Severity in Acute Pancreatitis (BISAP) and the Acute Physiology and Chronic Health Evaluation (APACHE) II tools, have good predictive capabilities for disease severity (mild, moderately severe, and severe per the revised Atlanta classification) and mortality, but no one tool works well for all forms of acute pancreatitis. Early and aggressive fluid resuscitation and early enteral nutrition are associated with lower rates of mortality and infectious complications, yet the optimal type and rate of fluid resuscitation have yet to be determined. The underlying etiology of acute pancreatitis should be sought in all patients, and risk-reduction strategies, such as cholecystectomy and alcohol cessation counseling, should be used during and after hospitalization for acute pancreatitis. Conclusions and RelevanceAcute pancreatitis is a complex disease that varies in severity and course. Prompt diagnosis and stratification of severity influence proper management. Scoring systems are useful adjuncts but should not supersede clinical judgment. Fluid management and nutrition are very important aspects of care for acute pancreatitis. This narrative review summarizes the pathogenesis, diagnosis, and management of acute pancreatitis, including advances in risk stratification, fluid and nutritional management, and follow-up care and risk-reduction strategies.	[Mederos, Michael A.; Reber, Howard A.; Girgis, Mark D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Girgis, MD (corresponding author), Univ Calif Los Angeles, 10833 Le Conte Ave,14-174 CHS, Los Angeles, CA 90095 USA.	mdgirgis@mednet.ucla.edu						Aboulian A, 2010, ANN SURG, V251, P615, DOI 10.1097/SLA.0b013e3181c38f1f; Al-Omran M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002837.pub2; Ali UA, 2016, CLIN GASTROENTEROL H, V14, P738, DOI 10.1016/j.cgh.2015.12.040; Arvanitakis M, 2020, CLIN NUTR, V39, P612, DOI 10.1016/j.clnu.2020.01.004; Bakker OJ, 2014, NEW ENGL J MED, V371, P1983, DOI 10.1056/NEJMoa1404393; Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Besselink M, 2013, PANCREATOLOGY, V13, pE1, DOI 10.1016/j.pan.2013.07.063; BLAMEY SL, 1984, GUT, V25, P1340, DOI 10.1136/gut.25.12.1340; Brindise E, 2019, PANCREAS, V48, P169, DOI 10.1097/MPA.0000000000001228; Busireddy Kiran K, 2014, World J Gastrointest Pathophysiol, V5, P252, DOI 10.4291/wjgp.v5.i3.252; Choosakul S., 2018, PANCREATOLOGY; Crockett SD, 2018, GASTROENTEROLOGY, V154, P1096, DOI 10.1053/j.gastro.2018.01.032; Dubina ED, 2018, JAMA SURG, V153, P1057, DOI 10.1001/jamasurg.2018.2614; Dutta AK, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010582.pub2; Falor AE, 2012, ARCH SURG-CHICAGO, V147, P1031, DOI 10.1001/archsurg.2012.1473; Forsmark CE, 2016, NEW ENGL J MED, V375, P1972, DOI 10.1056/NEJMra1505202; Foster BR, 2016, RADIOGRAPHICS, V36, P675, DOI 10.1148/rg.2016150097; Gao W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130412; Gapp J, 2019, PANCREAS, V48, P548, DOI [10.1097/MPA.0000000000001275, 10.1097/mpa.0000000000001275]; Garg SK, 2019, J CLIN GASTROENTEROL, V53, P220, DOI 10.1097/MCG.0000000000001030; HARVEY MH, 1989, BRIT J SURG, V76, P859, DOI 10.1002/bjs.1800760832; Hollemans RA, 2018, PANCREATOLOGY, V18, P253, DOI 10.1016/j.pan.2018.02.009; Huang W, 2019, DIGEST DIS SCI, V64, P1985, DOI 10.1007/s10620-019-05568-9; Hwang SS, 2013, JAMA SURG, V148, P867, DOI 10.1001/jamasurg.2013.3033; IMRIE CW, 1978, BRIT J SURG, V65, P337, DOI 10.1002/bjs.1800650514; Iqbal U, 2018, J DIGEST DIS, V19, P335, DOI 10.1111/1751-2980.12606; Ketwaroo G, 2019, DIGEST DIS SCI, V64, P2514, DOI 10.1007/s10620-019-05674-8; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kochar B, 2015, GASTROINTEST ENDOSC, V81, P143, DOI 10.1016/j.gie.2014.06.045; Krishna SG, 2017, PANCREAS, V46, P482, DOI [10.1097/MPA.0000000000000783, 10.1097/mpa.0000000000000783]; Kruger B, 2000, AM J PATHOL, V157, P43, DOI 10.1016/S0002-9440(10)64515-4; Lankisch PG, 2015, LANCET, V386, P85, DOI 10.1016/S0140-6736(14)60649-8; Li J, 2014, WORLD J GASTROENTERO, V20, P16146, DOI 10.3748/wjg.v20.i43.16146; Loveday BPT, 2010, AM J GASTROENTEROL, V105, P1466, DOI 10.1038/ajg.2010.137; Magnusdottir BA, 2019, SCAND J GASTROENTERO, V54, P87, DOI 10.1080/00365521.2018.1550670; Mao EQ, 2010, CHINESE MED J-PEKING, V123, P1639, DOI 10.3760/cmaj.issn.0366-6999.2010.13.005; Meng WB, 2011, WORLD J GASTROENTERO, V17, P4235, DOI 10.3748/wjg.v17.i37.4235; Mueck KM, 2019, ANN SURG, V270, P519, DOI 10.1097/SLA.0000000000003424; Nealon WH, 2004, ANN SURG, V239, P741, DOI 10.1097/01.sla.0000128688.97556.94; Nitsche Claudia, 2012, Curr Gastroenterol Rep, V14, P131, DOI 10.1007/s11894-012-0245-9; Nordback I, 2009, GASTROENTEROLOGY, V136, P848, DOI 10.1053/j.gastro.2008.11.044; Papachristou GI, 2017, ANN GASTROENTEROL, V30, P106, DOI 10.20524/aog.2016.0109; Parniczky A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165309; Poropat G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010605.pub2; Qi DS, 2018, JPEN-PARENTER ENTER, V42, P1139, DOI 10.1002/jpen.1139; RANSON JHC, 1977, J SURG RES, V22, P79, DOI 10.1016/0022-4804(77)90045-2; RANSON JHC, 1974, AM J GASTROENTEROL, V61, P443; ROXVALL L, 1991, BIOL CHEM H-S, V372, P273, DOI 10.1515/bchm3.1991.372.1.273; Sahu Biswanath, 2017, Indian J Radiol Imaging, V27, P152, DOI 10.4103/ijri.IJRI_300_16; Sarr MG, 2013, POL ARCH MED WEWN, V123, P118, DOI 10.20452/pamw.1627; Sellers ZM, 2018, GASTROENTEROLOGY, V155, P469, DOI 10.1053/j.gastro.2018.04.013; Simons-Linares CR, 2019, PANCREAS, V48, P1263, DOI 10.1097/MPA.0000000000001428; Singh VK, 2009, AM J GASTROENTEROL, V104, P966, DOI 10.1038/ajg.2009.28; Stirling AD, 2017, HPB, V19, P874, DOI 10.1016/j.hpb.2017.06.001; Taydas O, 2018, JPN J RADIOL, V36, P151, DOI 10.1007/s11604-017-0709-9; Thoeni RF, 2012, RADIOLOGY, V262, P751, DOI 10.1148/radiol.11110947; Uehara S, 1989, Adv Exp Med Biol, V247B, P643; van Baal MC, 2012, ANN SURG, V255, P860, DOI 10.1097/SLA.0b013e3182507646; Vivian E, 2019, AM J GASTROENTEROL, V114, P1322, DOI 10.14309/ajg.0000000000000264; Wang KX, 2011, GASTROINTEST ENDOSC, V73, P283, DOI 10.1016/j.gie.2010.10.045; Wu BU, 2008, GUT, V57, P1698, DOI 10.1136/gut.2008.152702; Wu BU, 2011, ARCH INTERN MED, V171, P669, DOI 10.1001/archinternmed.2011.126; Wu BU, 2009, GASTROENTEROLOGY, V137, P129, DOI 10.1053/j.gastro.2009.03.056; Wu LM, 2014, BRIT J SURG, V101, P1644, DOI 10.1002/bjs.9665; Zhi MM, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00637; Zilio MB, 2019, HPB, V21, P259, DOI 10.1016/j.hpb.2018.08.003	66	97	107	30	113	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2021	325	4					382	390		10.1001/jama.2020.20317	http://dx.doi.org/10.1001/jama.2020.20317			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ6GI	33496779				2023-01-03	WOS:000612836900028
J	Zoeller, JJ; Press, MF; Selfors, LM; Dering, J; Slamon, DJ; Hurvitz, SA; Brugge, JS				Zoeller, Jason J.; Press, Michael F.; Selfors, Laura M.; Dering, Judy; Slamon, Dennis J.; Hurvitz, Sara A.; Brugge, Joan S.			Clinical evaluation of BCL-2/X-L levels pre- and post-HER2-targeted therapy	PLOS ONE			English	Article							BREAST-CANCER CELLS; ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR; LAPATINIB RESISTANCE; ADAPTIVE RESISTANCE; APOPTOSIS INDUCTION; TAMOXIFEN THERAPY; ALPHA EXPRESSION; TARGETING BCL-2; UP-REGULATION	Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gene expression within tumor biopsies, collected before and after lapatinib or trastuzumab treatment, from the TRIO-B-07 clinical trial (NCT#00769470). We detected BCL2 mRNA upregulation in both HER2+/ER- as well as HER2+/ER+ patient tumors treated with lapatinib or trastuzumab. To address whether mRNA expression correlated with protein expression, we evaluated pre- and post-treatment tumors for BCL-2 via immunohistochemistry. Despite BCL2 mRNA upregulation within HER2+/ER- tumors, BCL-2 protein levels were undetectable in most of the lapatinib- or trastuzumab-treated HER2+/ER- tumors. BCL-2 upregulation was evident within the majority of lapatinib-treated HER2+/ER+ tumors and was often coupled with increased ER expression and decreased proliferation. Comparable BCL-2 upregulation was not observed within the trastuzumab-treated HER2+/ER+ tumors. Together, these results provide clinical validation of the BCL-2 induction associated with the adaptive response to lapatinib and support evaluation of BCL-2 inhibitors within the context of lapatinib and other HER2-targeted receptor tyrosine kinase inhibitors.	[Zoeller, Jason J.; Selfors, Laura M.; Brugge, Joan S.] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA; [Zoeller, Jason J.; Selfors, Laura M.; Brugge, Joan S.] Harvard Med Sch, Ludwig Ctr Harvard, Boston, MA 02115 USA; [Press, Michael F.] Univ Southern Calif, Pathol, Los Angeles, CA 90007 USA; [Dering, Judy; Slamon, Dennis J.; Hurvitz, Sara A.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Dept Med,Div Hematol Oncol, Los Angeles, CA 90095 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Southern California; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Brugge, JS (corresponding author), Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA.; Brugge, JS (corresponding author), Harvard Med Sch, Ludwig Ctr Harvard, Boston, MA 02115 USA.	joan_brugge@hms.harvard.edu		SELFORS, LAURA/0000-0002-1317-7353	Department of Defense Breast Cancer Research Fellowship Award [W81XWH-11-1-0572]; Breast Cancer Research Foundation; Stand Up To Cancer-American Association for Cancer Research Dream Team Translational Cancer Research Grant [SU2C-AACR-DT0409]	Department of Defense Breast Cancer Research Fellowship Award(United States Department of Defense); Breast Cancer Research Foundation; Stand Up To Cancer-American Association for Cancer Research Dream Team Translational Cancer Research Grant	Our work was supported by a Department of Defense Breast Cancer Research Fellowship Award [https://cdmrp.army.mil/bcrp/], Award Number W81XWH-11-1-0572 (to J.J. Zoeller), a Breast Cancer Research Foundation Grant [https://www.bcrf.org] (to M.F. Press) and a Stand Up To Cancer-American Association for Cancer Research Dream Team Translational Cancer Research Grant [https://standuptocancer. org], Grant Number SU2C-AACR-DT0409 (to J.S. Brugge and D.J. Slamon). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587; BHARGAVA V, 1994, AM J PATHOL, V145, P535; Cameron DA, 2000, EUR J CANCER, V36, P845, DOI 10.1016/S0959-8049(00)00013-7; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Crawford Anatasha, 2011, Current Pharmacogenomics & Personalized Medicine, V9, P184; Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; de Laval VR, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau013; Diermeier-Daucher S, 2011, CYTOM PART A, V79A, P684, DOI 10.1002/cyto.a.21107; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Eustace AJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4852-1; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Giuliano M, 2015, CLIN CANCER RES, V21, P3995, DOI 10.1158/1078-0432.CCR-14-2728; GOULDING H, 1995, HUM PATHOL, V26, P291, DOI 10.1016/0046-8177(95)90060-8; Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Holloway JN, 2004, MOL ENDOCRINOL, V18, P1396, DOI 10.1210/me.2004-0048; Hurvitz SA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19494-2; Hurvitz SA, 2013, CANCER TREAT REV, V39, P219, DOI 10.1016/j.ctrv.2012.04.008; JOHNSTON SRD, 1994, EUR J CANCER, V30A, P1663, DOI 10.1016/0959-8049(94)00327-2; Keen JC, 1997, BREAST CANCER RES TR, V44, P123, DOI 10.1023/A:1005796915388; Kenny FS, 2001, BREAST CANCER RES TR, V65, P135, DOI 10.1023/A:1006469627067; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; Lok SW, 2019, CANCER DISCOV, V9, P354, DOI 10.1158/2159-8290.CD-18-1151; Martin AP, 2008, MOL PHARMACOL, V74, P807, DOI 10.1124/mol.108.047365; Martin AP, 2009, CANCER BIOL THER, V8, P2084; Merino D, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7049; Milella M, 2004, CLIN CANCER RES, V10, P7747, DOI 10.1158/1078-0432.CCR-04-0908; Mitchell C, 2010, CANCER BIOL THER, V10, P907, DOI 10.4161/cbt.10.9.13273; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pazarentzos E, 2015, ONCOGENE, V34, P5599, DOI 10.1038/onc.2015.26; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Plotkin A, 2014, BREAST CANCER RES TR, V147, P249, DOI 10.1007/s10549-014-3093-5; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; Wang YC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3067; Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103; Zoeller JJ, 2019, MOL CANCER THER, V18, P1115, DOI 10.1158/1535-7163.MCT-18-0743; Zoeller JJ, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0020-z	49	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2021	16	5							e0251163	10.1371/journal.pone.0251163	http://dx.doi.org/10.1371/journal.pone.0251163			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6FV	33951110	Green Submitted, Green Published, gold			2023-01-03	WOS:000664610500067
J	Horby, PW; Landray, MJ				Horby, Peter W.; Landray, Martin J.		Recovery Collaborative Grp	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	LANCET			English	Article							CORONAVIRUS DISEASE 2019; OUTCOMES	Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein >= 75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg-800 mg (depending on weight) given intravenously. A second dose could be given 12-24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0.85; 95% CI 0.76-0.94; p=0.0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1.22; 1.12-1.33; p<0.0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0.84; 95% CI 0.77-0.92; p<0.0001). Interpretation In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Copyright (C) 2021 Published by Elsevier Ltd. All rights reserved.	[Horby, Peter W.; Landray, Martin J.] RECOVERY Cent Coordinating Off, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England	University of Oxford	Horby, PW; Landray, MJ (corresponding author), RECOVERY Cent Coordinating Off, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England.		Chan, Xin Hui S/ABA-5004-2021; Tageldin, Amr/CAF-8726-2022; Darton, Thomas/H-2816-2017; Caplin, Ben/AAH-1641-2019; Evans, D Gareth/AAB-4308-2022; mcgrath, brendan a/D-7202-2013; Dosanjh, Davinder/ABD-8895-2021; Gkrania-Klotsas, Effrossyni/AAT-8424-2021; Rivera-Ortega, Pilar/X-7083-2019; Shanahan, Thomas/AAP-3822-2020; Pessoa-Amorim, Guilherme/AAV-4151-2021; Tso, Simon/N-2422-2014; Wu, Henry H.L./B-9400-2019; Ahmed, Naseer/C-8119-2019; Fawke, Joe/ABA-9407-2021; Payne, Brendan/I-1233-2016; Pearse, Rupert/H-5426-2011; Montgomery, Hugh/C-2592-2008; Faust, Saul/J-9779-2014; Skene, Imogen/D-6153-2018; Porter, Joanna/C-7162-2009; Llewelyn, Martin/A-7194-2011; moon, james/F-1031-2014; Kudsk-Iversen, Soren/Y-9391-2018; Gibbison, Ben/J-6611-2014	Chan, Xin Hui S/0000-0002-9941-6975; Darton, Thomas/0000-0003-2209-9956; Caplin, Ben/0000-0001-9544-164X; Evans, D Gareth/0000-0002-8482-5784; mcgrath, brendan a/0000-0003-3048-3480; Dosanjh, Davinder/0000-0002-9169-5607; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330; Rivera-Ortega, Pilar/0000-0002-7960-8822; Shanahan, Thomas/0000-0001-5613-2545; Pessoa-Amorim, Guilherme/0000-0002-4050-6191; Tso, Simon/0000-0001-9221-7618; Wu, Henry H.L./0000-0002-4561-0844; Ahmed, Naseer/0000-0002-0960-1123; Fawke, Joe/0000-0002-5267-7107; Pastika, Libor/0000-0001-6892-6553; Sarkar, Rahuldeb/0000-0002-4343-8526; Barnacle, James/0000-0003-1316-6205; Mentzer, Alexander/0000-0002-4502-2209; Campbell, Mark/0000-0002-9759-0232; Spears, Mark/0000-0003-4381-5819; Ali, Mohammad/0000-0002-4765-615X; Islim, Abdurrahman/0000-0001-9621-043X; kumar, vimal/0000-0002-3801-995X; Dark, Paul/0000-0003-3309-0164; So, Beng/0000-0003-4356-532X; Welch, Hugh/0000-0001-6906-2718; Brankin-Frisby, Thomas/0000-0003-2184-8580; maskell, nick/0000-0002-1276-6500; Gorick, Hugh/0000-0003-3089-9830; Noba, Lyrics/0000-0002-5389-7937; Scott, Alex/0000-0001-6719-0417; Gupta-Wright, Ankur/0000-0002-5150-2970; King, Scott/0000-0001-6821-9234; Abu-Arafeh, Ahmad/0000-0003-2464-3871; Rokadiya, Sakib/0000-0003-2955-4907; Downey, Damian/0000-0002-6471-549X; Al-Shahi Salman, Rustam/0000-0002-2108-9222; Ustianowski, Andrew/0000-0002-6134-7855; Esmail, Hanif/0000-0002-4278-9316; Drysdale, Simon/0000-0002-6350-6557; Gorog, Diana/0000-0002-9286-1451; Dixon, Giles/0000-0001-9787-0739; Hawcutt, Dan/0000-0002-8120-6507; de Vere, Natasha/0000-0001-9593-6925; Bancroft, Elizabeth/0000-0002-5482-5660; Peto, Leon/0000-0002-4100-2163; Brannigan, Jamie/0000-0003-1697-403X; Kametas, Nicholas/0000-0002-7992-6038; Montgomery, Alan/0000-0003-0450-1606; Kapil, Vikas/0000-0001-5778-6188; Jajbhay, Danyal/0000-0002-3475-9651; Barker, Joseph/0000-0002-5483-9608; Hodson, Kenneth/0000-0003-3091-6952; Payne, Brendan/0000-0002-3101-3512; vatish, manu/0000-0002-6012-2574; Forton, Julian/0000-0002-0580-0432; Barnett-Vanes, Ashton/0000-0002-8088-1068; Mazzella, Andrea/0000-0003-1560-7465; Foley, Paul/0000-0002-4856-832X; Dhaliwal, Kevin/0000-0002-3925-3174; Lord, Robert/0000-0001-9008-2502; brightling, chris/0000-0002-9345-4903; Mutch, Callum/0000-0001-9788-0179; mumford, andrew/0000-0002-5523-511X; Puxty, Kathryn/0000-0002-5742-6171; Dobbie, Laurence J./0000-0003-1908-848X; Cole, Joby/0000-0002-5258-5835; Rowan, Kathryn/0000-0001-8217-5602; Chaudhuri, Nazia/0000-0003-3325-6996; Gibani, Malick/0000-0003-1781-0053; Jethwa, Kishan/0000-0003-1715-9256; Willis, Joanna/0000-0003-3260-4311; Pearse, Rupert/0000-0002-4373-5934; Mahaveer, Ajit/0000-0001-9786-6860; Soiza, Roy/0000-0002-1397-4272; Merrick, Blair/0000-0002-6061-6064; Montgomery, Hugh/0000-0001-8797-5019; Parmar, Chetan/0000-0002-1238-6524; Last, Anna/0000-0001-8730-9323; Murray, Eleanor/0000-0002-4837-4840; Jhanji, Shaman/0000-0002-1116-628X; Faust, Saul/0000-0003-3410-7642; Colton, Hayley/0000-0002-3287-4103; Vallabhaneni, Pramodh/0000-0002-4887-8651; Chapman, Laura/0000-0001-6174-9435; Naisbitt, Michael/0000-0003-1560-6235; Welters, Ingeborg/0000-0002-3408-8798; Bachar, Roudi/0000-0001-8113-7110; Rickman, Hannah/0000-0002-3502-0744; Burton, Ben/0000-0001-9579-9078; Taynton, Thomas/0000-0001-7771-9564; Nadeem, Iftikhar/0000-0002-8644-925X; Bibby, Anna/0000-0001-7386-7754; Green, Christopher/0000-0002-1984-4014; Skene, Imogen/0000-0001-5215-2899; Lim, Ivy/0000-0001-9848-8769; McKnight, Gerard/0000-0003-1546-7853; imray, chris/0000-0001-8451-4102; Aujayeb, Avinash/0000-0002-0859-5550; Iliodromiti, Stamatina/0000-0001-6453-6654; O'Sullivan, Eoin/0000-0002-7709-6595; Quenby, Siobhan/0000-0003-3221-5471; Orton, Christopher/0000-0002-9167-5462; Bhagani, Sanjay/0000-0003-2557-4337; Tridente, Ascanio/0000-0003-1500-447X; Iftikhar, Hina/0000-0003-2138-1415; Crocombe, Dominic/0000-0002-1401-6930; Pathan, Nazima/0000-0001-7656-9453; Cooper, Jamie/0000-0003-3812-7026; Peters, Mark/0000-0003-3653-4808; Kelly, Dominic/0000-0002-6063-8896; Cavazza, Anna/0000-0003-3720-0463; Porter, Joanna/0000-0002-7307-169X; Pfeffer, Paul/0000-0003-0369-2885; Newman, Tom/0000-0002-7987-9948; Ripley, David/0000-0001-8460-9873; Buch, Maya/0000-0002-8962-5642; Shah, Pallav/0000-0002-9052-4638; Bukhari, Marwan/0000-0003-4311-5222; Graham, Jonathan/0000-0002-3227-5928; Llewelyn, Martin/0000-0002-6811-1124; Hormis, Anil/0000-0001-5510-7639; Hoggett, Lee/0000-0003-1135-6232; Murray, Clare/0000-0002-8961-8055; Linares, Christian Alexander/0000-0002-2473-8873; Burden, Christy/0000-0001-6409-5238; Gregory, Katherine/0000-0002-0610-5386; Adamali, Huzaifa/0000-0002-8230-175X; Lillie, Patrick/0000-0002-4811-4774; Hodgson, Luke/0000-0002-8278-9513; Adams, Richard/0000-0003-3915-7243; Archer, Ann/0000-0002-4185-4454; CARTER, Michael/0000-0003-3403-4746; Lewis, Joseph/0000-0002-3837-5188; Bassett, John/0000-0002-8815-6012; Hum, Ryan Malcolm/0000-0003-0801-6974; Cathie, Katrina/0000-0001-5074-0769; Linden, Dermot/0000-0003-0552-1115; Hartshorn, Stuart/0000-0003-0419-1564; Haynes, Richard/0000-0002-1179-0023; Mishra, Eleanor/0000-0002-5903-3005; Ricketts, William/0000-0002-0475-0744; Underwood, Jonathan/0000-0001-6963-2821; Hannah, Jennifer/0000-0002-3491-6653; Behrouzi, Roya/0000-0002-1978-6539; Emberson, Jonathan/0000-0001-7792-9422; Macleod, Mary Joan/0000-0003-2115-8184; Shelley, Ben/0000-0001-6771-9659; Smith, Christopher/0000-0001-7369-2034; Roehr, Charles Christoph/0000-0001-7965-4637; Christides, Alexander/0000-0002-9476-9827; Ramasamy, Maheshi Nirmala/0000-0002-2119-951X; Milligan, Iain D/0000-0002-6501-5524; Baillie, John Kenneth/0000-0001-5258-793X; Harwood, Catherine/0000-0002-1375-0965; de Silva, Thushan/0000-0002-6498-9212; moon, james/0000-0001-8071-1491; Denis, Emmanuelle/0000-0001-8463-1341; Landray, Martin/0000-0001-6646-827X; Barrett, Amy/0000-0001-8671-8803; Lim, Wei Shen/0000-0002-7694-3051; Kudsk-Iversen, Soren/0000-0002-7112-3548; De Sousa, Paulo/0000-0003-3011-4116; Sahdev, Nikhil/0000-0003-2291-5044; Collini, Paul/0000-0001-6696-6826; Dey, Vishal/0000-0002-5108-4158; Razvi, Salman/0000-0002-9047-1556; Nigel, Brunskill/0000-0002-7109-7108; Whittaker, Elizabeth/0000-0002-7944-8793; Vidler, Jennifer/0000-0003-2996-3014; Glaysher, Sharon/0000-0002-9584-0621; Lowsby, Richard/0000-0001-9940-191X; Gibbison, Ben/0000-0003-3635-6212; Graham-Brown, Matthew/0000-0002-6197-180X; Hinshaw, Kim/0000-0003-0468-4326; Ireland, Aidan Taeke/0000-0001-9513-2302; Patel, Manish/0000-0003-3012-7507; Parekh, Dhruv/0000-0002-1508-8362	UK Research and Innovation (Medical Research Council); National Institute of Health Research	UK Research and Innovation (Medical Research Council); National Institute of Health Research(National Institute for Health Research (NIHR))	UK Research and Innovation (Medical Research Council) and National Institute of Health Research.	Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2; Del Valle D.M., 2020, NAT MED, V26, P1636, DOI DOI 10.1038/s41591-020-1051-9; Dorward DA, 2021, AM J RESP CRIT CARE, V203, P192, DOI 10.1164/rccm.202008-3265OC; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA; Escadafal C, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002396; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Kassambara A, 2020, INFECT DIS-NOR, DOI [DOI 10.1093/CID/CIAA344, DOI 10.1093/cid/ciaa344]; Lescure FX, 2021, LANCET RESP MED, V9, P522, DOI 10.1016/S2213-2600(21)00099-0; Murthy S, 2021, LANCET RESP MED, V9, P438, DOI 10.1016/S2213-2600(21)00127-2; National Institutes of Health, 2021, TREATM GUID PAN COR; Oberhoffer M, 1999, CRIT CARE MED, V27, P1814, DOI 10.1097/00003246-199909000-00018; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Rosas I., 2020, TOCILIZUMAB HOSP PAT, DOI [10.1101/2020.08.27.20183442, DOI 10.1101/2020.08.27.20183442]; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Soin AS, 2021, LANCET RESP MED, V9, P511, DOI 10.1016/S2213-2600(21)00081-3; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019; Zhou L, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032, 10.1097/CM90000000000000824.]	28	890	900	5	45	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	2021	397	10285					1637	1645						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV0EH	33933206	hybrid, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000645510600024
J	Svege, S; Nkosi-Gondwe, T; Lange, S				Svege, Sarah; Nkosi-Gondwe, Thandile; Lange, Siri			"Satanism is witchcraft's younger sibling": Changing perceptions of natural and supernatural anaemia causality in Malawian children	PLOS ONE			English	Article							MEDICINE; HEALTH; DIARRHEA; MALARIA; DOCTORS	In countries of sub-Saharan Africa, many children are admitted to hospital with severe forms of anaemia. The late hospital admissions of anaemic children contribute significantly to child morbidity and mortality in these countries. This qualitative study explores local health beliefs and traditional treatment practices that may hinder timely seeking of hospital care for anaemic children. In January of 2019, nine focus group discussions were conducted with 90 participants in rural communities of Malawi. The participants represented four groups of caregivers; mothers, fathers, grandmothers and grandfathers of children under the age of five. The Malawian medical landscape is comprised of formal and informal therapeutic alternatives-and this myriad of modalities is likely to complicate the healthcare choices of caregivers. When dealing with child illness, many participants reported how they would follow a step-by-step, 'multi-try' therapeutic pathway where a combination of biomedical and traditional treatment options were sought at varying time points depending on the perceived cause and severity of symptoms. The participants linked anaemia to naturalistic (malaria, poor nutrition and the local illnesses kakozi and kapamba), societal (the local illness msempho) and supernatural or personalistic (witchcraft and Satanism) causes. Most participants agreed that anaemia due to malaria and poor nutrition should be treated at hospital. As for local illnesses, many grandparents suggested herbal treatment offered by traditional healers, while the majority of parents would opt for hospital care. However, participants across all age groups claimed that anaemia caused by witchcraft and Satanism could only be dealt with by traditional healers or prayer, respectively. The multiple theories of anaemia causality combined with extensive use of and trust in traditional and complementary medicine may explain the frequent delay in admittance of anaemic children to hospital.	[Svege, Sarah; Nkosi-Gondwe, Thandile] Univ Bergen, Dept Global Publ Hlth & Primary Care, Ctr Int Hlth, Bergen, Norway; [Nkosi-Gondwe, Thandile] Univ Malawi, Coll Med, Sch Publ Hlth & Family Med, Blantyre, Malawi; [Lange, Siri] Univ Bergen, Dept Hlth Promot & Dev, Bergen, Norway; [Lange, Siri] Chr Michelsen Inst, Bergen, Norway	University of Bergen; University of Malawi; University of Bergen	Svege, S (corresponding author), Univ Bergen, Dept Global Publ Hlth & Primary Care, Ctr Int Hlth, Bergen, Norway.	sarah.svege@icloud.com	Lange, Siri/AAZ-1788-2021	Lange, Siri/0000-0002-5906-4485	Research Council of Norway through the Global Health and Vaccination Programme (GLOBVAC) [234487]; European Union	Research Council of Norway through the Global Health and Vaccination Programme (GLOBVAC); European Union(European Commission)	The study was funded by the Research Council of Norway through the Global Health and Vaccination Programme (GLOBVAC), project number 234487. GLOBVAC is part of the EDCTP2 programme supported by the European Union. The Council had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, BRIT J HAEMATOL; Calis JCJ, 2016, MALAWI MED J, V28, P99; Colvin CJ, 2013, SOC SCI MED, V86, P66, DOI 10.1016/j.socscimed.2013.02.031; Comoro C, 2003, ACTA TROP, V87, P305, DOI 10.1016/S0001-706X(03)00113-X; Cross J, 2010, SOC SCI MED, V71, P1593, DOI 10.1016/j.socscimed.2010.07.040; Danielsen L, 2017, DEV CHANGE, V48, P429, DOI 10.1111/dech.12307; Dhabangi A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209476; Diaz T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-157; Ellis AA, 2007, SOC SCI MED, V64, P701, DOI 10.1016/j.socscimed.2006.10.011; FOSTER GM, 1976, AM ANTHROPOL, V78, P773, DOI 10.1525/aa.1976.78.4.02a00030; Friend-du Preez N, 2009, SOC SCI MED, V68, P343, DOI 10.1016/j.socscimed.2008.10.027; Gondwe T, 2018, BMC PEDIATR, V18, P1, DOI [10.1186/s12887-017-0974-x, DOI 10.1186/S12887-017-0974-X]; Government of Malawi, 2017, HLTH SECT STRAT PLAN, P122; Haskins L, 2017, AFR J PRIM HEALTH CA, V9, DOI 10.4102/phcfm.v9i1.1378; Hsu E, 2008, INT ENCY PUBLIC HLTH; Kahissay MH, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4052-y; Kerr RB, 2008, SOC SCI MED, V66, P1095, DOI 10.1016/j.socscimed.2007.11.019; Kouadio M'Bra Kd, 2013, BMC Hematol, V13, P5, DOI 10.1186/2052-1839-13-5; Krueger R. A., 2015, FOCUS GROUPS PRACTIC; Lambert H, 2012, SOC SCI MED, V74, P1029, DOI 10.1016/j.socscimed.2011.12.024; Langwick SA, 2011, BODIES POLITICS AFRI, P320; Langwick SA, 2008, AM ETHNOL, V35, P428, DOI 10.1111/j.1548-1425.2008.00044.x; Malawi DHS, 2015, MAL 2015 16 DEM HLTH; Morgan D. L., 1997, QUALITATIVE RES METH, DOI 10.9781412984287; Murdock G, 1980, THEORY ILLNESS WORLD; Ngimbudzi EB., 2016, OPEN J NURS, V6, P342, DOI [10.4236/ojn.2016.64036, DOI 10.4236/OJN.2016.64036]; Penkala-Gawecka D, 2016, ANTHROPOL MED, V23, P135, DOI 10.1080/13648470.2016.1180582; Pilkington H, 2004, J EPIDEMIOL COMMUN H, V58, P826, DOI 10.1136/jech.2003.016089; Sandberg J, 2019, SOC SCI MED, V226, P87, DOI 10.1016/j.socscimed.2019.02.028; SCHEPER-HUGHES N, 1987, Medical Anthropology Quarterly, V1, P6, DOI 10.1525/maq.1987.1.1.02a00020; Svege S, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3327-z; Thornton R, 2015, MED ANTHROPOL, V34, P353, DOI 10.1080/01459740.2015.1031225; Townsend AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088006; UNDP, HUM DEV REP; Wendland C, 2012, CURR ANTHROPOL, V53, P755, DOI 10.1086/668467; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Whyte Susan Reynolds, 1997, QUESTIONING MISFORTU, V4; World Health Organization U.S. Department of Health and Human Services National Institute on Aging National Institutes of Health, 2011, GLOBAL HLTH AGING, P1	38	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2021	16	4							e0250661	10.1371/journal.pone.0250661	http://dx.doi.org/10.1371/journal.pone.0250661			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6EM	33930023	gold, Green Published			2023-01-03	WOS:000664607000021
J	Saintrain, MVD; Saintrain, SV; Branco, JGD; Caldas, JMP; Lourenco, CB; Vieira-Meyer, APGF				de Lima Saintrain, Maria Vieira; Saintrain, Suzanne Vieira; de Oliveira Branco, July Grassiely; Peixoto Caldas, Jose Manuel; Lourenco, Caroline Barbosa; Fernandes Vieira-Meyer, Anya Pimentel Gomes			Dependence in instrumental activities of daily living and its implications for older adults' oral health	PLOS ONE			English	Article							DISABILITY; IMPROVEMENT; DISEASES	We aimed to assess the association between dependence in instrumental activities of daily living (IADL) and oral health in older adults. We conducted a cross-sectional study of 280 people aged >= 60 years served at public primary health care centers in Northeastern Brazil. Sociodemographic, oral discomfort and general health data were collected. The Lawton and Brody scale were used to assess IADL. This research adheres to the STROBE checklist. Most participants were married (n = 139; 49.6%), women (n = 182; 65.0%) and retired (n = 212; 75.7%). A total of 37 (13.2%) older adults had some degree of dependence in IADL. Dependence in IADL was associated with: retirement (p<0.040), poor general health (p = 0.002), speech problems (p = 0.014), use of medications (p = 0.021), difficulty chewing and swallowing food (p = 0.011), voice changes (p = 0.044), edentulism (p = 0.011), use of toothbrush (p<0.001), use of toothpaste (p<0.001), and visit to the dentist in the previous year (p = 0.020). Functional disability was associated with older age, cardiovascular diseases, speech problems, chewing and swallowing difficulties, use of medication and brushing deficiency. The functional dependence in IADL can be considered an indicator of oral health status in older adults.	[de Lima Saintrain, Maria Vieira; Saintrain, Suzanne Vieira; de Oliveira Branco, July Grassiely; Lourenco, Caroline Barbosa] Univ Fortaleza UNIFOR, Publ Hlth Grad Program, Fortaleza, Ceara, Brazil; [Peixoto Caldas, Jose Manuel] Univ Porto, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal; [Fernandes Vieira-Meyer, Anya Pimentel Gomes] Fundacao Oswaldo Cruz, Family Hlth Masters Program, Eusebio, Ceara, Brazil; [Fernandes Vieira-Meyer, Anya Pimentel Gomes] Ctr Univ Christus, Fac Dent, Fortaleza, Ceara, Brazil	Universidade Fortaleza; Universidade do Porto; Fundacao Oswaldo Cruz	Saintrain, MVD (corresponding author), Univ Fortaleza UNIFOR, Publ Hlth Grad Program, Fortaleza, Ceara, Brazil.	mvlsaintrain@yahoo.com.br	; Peixoto Caldas, Jose Manuel/K-5410-2013	Saintrain, Maria/0000-0003-1514-3218; Peixoto Caldas, Jose Manuel/0000-0003-0796-1595				Alexandre TD, 2014, REV SAUDE PUBL, V48, P378, DOI 10.1590/S0034-8910.2014048004754; Atchison K A, 1990, J Dent Educ, V54, P680; Benjamin RM, 2010, PUBLIC HEALTH REP, V125, P158, DOI 10.1177/003335491012500202; DATASUS, 2012, POP RES EST CEAR; de Andrade FB, 2013, J AM GERIATR SOC, V61, P809, DOI 10.1111/jgs.12221; Saintrain MVD, 2018, PUBLIC HEALTH NURS, V35, P473, DOI 10.1111/phn.12529; Saintrain MVD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039733; Del Duca GF, 2009, REV SAUDE PUBL, V43, P796, DOI 10.1590/S0034-89102009005000057; Freitas RS, 2012, ACTA PAUL ENFERM, V25, P933, DOI 10.1590/S0103-21002012000600017; Fukai K., 2015, CURRENT EVIDENCE DEN; Gavasso William César, 2017, Rev. bras. geriatr. gerontol., V20, P398, DOI 10.1590/1981-22562017020.160080; Gontijo Cristina Franco, 2016, Rev. bras. epidemiol., V19, P471, DOI 10.1590/1980-5497201600030001; Hesseberg K, 2013, DEMENT GERIATR COGN, V36, P146, DOI 10.1159/000351010; Hobdell M, 2003, INT DENT J, V53, P285, DOI 10.1111/j.1875-595X.2003.tb00761.x; Hoogendijk EO, 2019, J AM MED DIR ASSOC, V20, P1105, DOI 10.1016/j.jamda.2019.01.129; IBGE, 2010, CENS FORT; INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATISTICA (IBGE), 2011, CENS DEM 2010; Kassebaum NJ, 2017, J DENT RES, V96, P380, DOI 10.1177/0022034517693566; LAGO Jéssica Damares, 2017, Rev. odontol. UNESP, V46, P284, DOI 10.1590/1807-2577.23916; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lewis A, 2015, AUST DENT J, V60, P95, DOI 10.1111/adj.12288; Lodha N, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00243; Marino R, 2015, J AGING HEALTH, V27, P3, DOI 10.1177/0898264314533723; Ribeiro LHM, 2012, CIENC SAUDE COLETIVA, V17, P2169, DOI 10.1590/S1413-81232012000800027; Niemi CA, 2018, PUBLIC HEALTH NURS, V35, P581, DOI 10.1111/phn.12532; Pengpid S, 2018, BMC ORAL HEALTH, V18, DOI 10.1186/s12903-018-0582-7; Peres MA, 2019, LANCET, V394, P249, DOI 10.1016/S0140-6736(19)31146-8; Petersen PE, 2003, COMMUNITY DENT ORAL, V31, P3, DOI 10.1046/j..2003.com122.x; Petersen PE, 2005, COMMUNITY DENT HLTH, V22, P71; Petersen PE, 2008, INT DENT J, V58, P115, DOI 10.1922/IDJ_1930Petersen07; Richardson, 2005, CUMMINGS OTOLARYNGOL, V3, P2128; Tribess S., 2015, TEXTO CONTEXTO ENFER, V24, P521, DOI [10.1590/0104-07072015001652014, DOI 10.1590/0104-07072015001652014]; Trize Débora de Melo, 2014, Fisioter. Pesqui., V21, P378, DOI 10.590/1809-2950/13223421042014; Viveiro Larissa Alamino Pereira de, 2014, Rev. bras. geriatr. gerontol., V17, P235, DOI 10.1590/S1809-98232014000200002; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; WHO, 2015, WORLD REP AG HLTH; WHO, 2017, WHONMHPND182; WHO. World Health Organization, 2006, OR HLTH AG SOC INT O; World Health Organisation, 1992, WHO TECHN REP SER, V826, P16; World Health Organization (2003), 2003, WORLD OR HLTH REP 20	40	4	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2021	16	4							e0249275	10.1371/journal.pone.0249275	http://dx.doi.org/10.1371/journal.pone.0249275			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6DA	33914779	Green Published, gold			2023-01-03	WOS:000664603100017
J	Conan, N; Paye, CP; Ortuno, R; Chijuwa, A; Chiwandira, B; Goemaere, E; Garone, DB; Coulborn, RM; Chihana, M; Maman, D				Conan, Nolwenn; Paye, Cyrus P.; Ortuno, Reinaldo; Chijuwa, Alexander; Chiwandira, Brown; Goemaere, Eric; Garone, Daniela Belen; Coulborn, Rebecca M.; Chihana, Menard; Maman, David			What gaps remain in the HIV cascade of care? Results of a population-based survey in Nsanje District, Malawi	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; VIRAL LOAD; AFRICA	Introduction The Malawi Ministry of Health (MoH) has been in collaboration with Medecins sans Frontieres (MSF) to increase access to quality HIV care through decentralization of antiretroviral therapy (ART) diagnosis and treatment from hospital to clinics in Nsanje District since 2011. A population-based household survey was implemented to provide information on HIV prevalence and cascade of care to inform and prioritize community-based HIV interventions in the district. Methods A cross-sectional survey was conducted between September 2016 and January 2017. Using two-stage cluster sampling, eligible adult individuals aged >= 15 years living in the selected households were asked to participate. Participants were interviewed and tested for HIV at home. Those tested HIV-positive had their HIV-RNA viral load (VL) measured, regardless of their ART status. All participants tested HIV-positive at the time of the survey were advised to report their HIV test result to the health facility of their choice that MSF was supported in the district. HIV-RNA VL results were made available in this health facility. Results Among 5,315 eligible individuals, 91.1% were included in the survey and accepted an HIV test. The overall prevalence was 12.1% (95% Confidence Interval (CI): 11.2-13.0) and was higher in women than in men: 14.0% versus 9.5%, P<0.001. Overall HIV-positive status awareness was 80.0% (95%CI: 76.4-83.1) and was associated with sex (P<0.05). Linkage to care was 78.0% (95%CI: 74.3-81.2) and participants in care 76.2% (95%CI: 72.4-79.5). ART coverage among participants aware of their HIV-positive status was 95.3% (95%CI: 92.9-96.9) and was not associated with sex (P = 0.55). Viral load suppression among participants on ART was 89.9% (95%CI: 86.6-92.4) and was not statistically different by sex (p = 0.40). Conclusions Despite encouraging results in HIV testing coverage, cascade of care, and UNAIDS targets in Nsanje District, some gap remains in the first 90, specifically among men and young adults. Enhanced community engagement and new strategies of testing, such as index testing, could be implemented to identify those who are still undiagnosed, particularly men and young adults.	[Conan, Nolwenn; Paye, Cyrus P.; Coulborn, Rebecca M.; Chihana, Menard; Maman, David] Epicentre, Paris, France; [Ortuno, Reinaldo; Garone, Daniela Belen] Medecins Sans Frontieres, Blantyre, Malawi; [Chijuwa, Alexander] Minist Hlth, Nsanje, Malawi; [Chiwandira, Brown] Minist Hlth, Dept HIV & AIDS, HIV Care Treatment & Support Programme, Lilongwe, Malawi; [Goemaere, Eric] Southern Africa Med Unit, Cape Town, South Africa		Conan, N (corresponding author), Epicentre, Paris, France.	nolwenn.conan@epicentre.msf.org	Conan, Nolwenn/GXV-2604-2022	Conan, Nolwenn/0000-0002-7182-4934	Medecins sans Frontieres	Medecins sans Frontieres	This study was funded in full by Medecins sans Frontieres, including equipment, materials, logistics, and human resources.	Abu-Raddad LJ, 2014, AIDS, V28, P927, DOI 10.1097/QAD.0000000000000211; [Anonymous], Government of Malawi Malawi AIDS Response Progress Report 2015; [Anonymous], Malawi | UNAIDS; [Anonymous], Government of Malawi Global AIDS Response Progress Report (GARPR) Malawi Progress Report for 2013 31 st; [Anonymous], National Statistical Office- Malawi; [Anonymous], DHS PROGRAM DEMOGRAP; [Anonymous], NATL STRATEGIC PLAN; [Anonymous], MALAWI POPULATION BA; [Anonymous], Malawi Guidelines for HIV Clinical Management in Children & Adults; [Anonymous], 2016, MAL HIV TEST SERV GU; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Bemelmans M, 2010, TROP MED INT HEALTH, V15, P1413, DOI 10.1111/j.1365-3156.2010.02649.x; Bicego GT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077101; Bilinski A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185699; Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/aid.2012.0089, 10.1089/AID.2012.0089]; Chihana ML, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207656; Chirwa Z, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00069; Choko AT, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001102; Conan N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25613; Eisinger RW, 2018, JAMA-J AM MED ASSOC, V190; Furtado J, 2014, SAO PAULO MED J, V132, P383, DOI 10.1590/1516-3180.20141326T2; Ganguli Ishani, 2009, Curr HIV/AIDS Rep, V6, P217, DOI 10.1007/s11904-009-0029-5; Grabowski MK, 2018, AIDS, V32, P363, DOI 10.1097/QAD.0000000000001706; Harrington BJ., 2019, RISK SCORE PREDICTIN, V46, P416, DOI [10.1097/OLQ.0000000000000989, DOI 10.1097/OLQ.0000000000000989]; Huerga H, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5208-0; Huerga H, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2740-y; Huerga H, 2016, JAIDS-J ACQ IMM DEF, V73, P411, DOI 10.1097/QAI.0000000000001081; Kim AA, 2016, AIDS, V30, P2685, DOI 10.1097/QAD.0000000000001227; Kuwane B, 2009, LANCET, V374, P1329, DOI 10.1016/S0140-6736(09)61823-7; Makusha T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122783; Maman D, 2016, TROP MED INT HEALTH, V21, P1442, DOI 10.1111/tmi.12772; Maman D, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20673; Maman D, 2015, AIDS, V29, P1557, DOI 10.1097/QAD.0000000000000741; Merson MH, 1997, LANCET, V349, P352, DOI 10.1016/S0140-6736(96)08260-8; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Novitsky V., 2015, ESTIMATED AGE GENDER, P1; Peltzer K, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-174; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Sharma M, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002262; Staveteig S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186316; Sweat, 2012, LANCET INFECT DIISEA, V11, P525; UNAIDS, 2014, UND FAST TRACK ACC A; van RH., AIDS BEHAV, V17; WHO, PREQ DIAGN PROGR PUB; WHO, 2015, CONSOLIDATED GUIDELI; WHO, 2012, M FRAM METR SUPP EFF; World Health Organization, 2016, CONSOLIDATED GUIDELI, V2nd ed; World Health Organization, 2010, DEL HIV TEST RES MES, P21; Wright AA, 2006, NEW ENGL J MED, V354, P437, DOI 10.1056/NEJMp058302; MALAWI DEMOGRAPHIC H	50	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0248410	10.1371/journal.pone.0248410	http://dx.doi.org/10.1371/journal.pone.0248410			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0DC	33886575	Green Published, gold			2023-01-03	WOS:000644138300044
J	Owusu, M; Sylverken, AA; El-Duah, P; Ayisi-Boateng, NK; Yeboah, R; Adu, E; Asamoah, J; Frimpong, M; Senyo, J; Acheampong, G; Mutocheluh, M; Amuasi, J; Owusu-Dabo, E; Adu-Sarkodie, Y; Phillips, RO				Owusu, Michael; Sylverken, Augustina Angelina; El-Duah, Philip; Ayisi-Boateng, Nana Kwame; Yeboah, Richmond; Adu, Eric; Asamoah, Jesse; Frimpong, Michael; Senyo, Japhet; Acheampong, Godfred; Mutocheluh, Mohamed; Amuasi, John; Owusu-Dabo, Ellis; Adu-Sarkodie, Yaw; Phillips, Richard Odame			Low risk of SARS-CoV-2 in blood transfusion	PLOS ONE			English	Article							CORONAVIRUS	Background The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), continues to remain a global challenge. There is emerging evidence of SARS-CoV-2 virus found in the blood of patients from China and some developed countries. However, there is inadequate data reported in Ghana and other parts of Africa, where blood transfusion service heavily relies on voluntary and replacement blood donors. This study aimed to investigate whether plasma of infected individuals could pose significant transfusion transmitted risk of COVID-19 in Ghanaian populations. Methods This cross-sectional retrospective study was conducted at the Kumasi Centre for Collaborative Research into Tropical Medicine (KCCR), KNUST, Ghana. Study subjects comprised contacts of COVID-19 individuals, those with classical symptoms of COVID-19 and individuals who had recovered based on the new Ghana discharge criteria. Whole blood, sputum or deep coughed saliva samples were collected and transported to KCCR for SARS-CoV-2 testing. Viral nucleic acid was extracted from sputum/nasopharyngeal samples using Da An Gene column based kit and from plasma using LBP nucleic acid extraction kit. Real-Time PCR was performed specifically targeting the ORF1ab and Nucleocapsid (N) genomic regions of the virus. Results A total of 97 individuals were recruited into the study, with more than half being males (58; 59.7%). The mean age of all subjects was 33 years (SD = 7.7) with minimum being 22 years and maximum 56 years. Majority (76; 78.4%) of all the subjects were asymptomatic, and among the few symptomatic subjects, cough (10; 10.3%) was the most predominant symptom. Of the 97 sputum samples tested, 79 (81.4%) were positive for SARS-CoV-2. We identified SARS-CoV-2 viral RNA in the plasma of 1 (1.03%) subject who had clinically recovered. Conclusion This study reports the identification of SARS-CoV-2 viral RNA in a convalescent individual in Ghana. Due to the low prevalence observed and the marginal cycling thresholds associated, the risk of transfusion transmission of SARS-CoV-2 is negligible. Well-powered studies and advanced diagnostics to determine infectious viremia is recommended to further evaluate the potential risk of hematogenous transmission among recovered patients.	[Owusu, Michael] Kwame Nkrumah Univ Sci & Technol, Dept Med Diagnost, Kumasi, Ghana; [Owusu, Michael; Sylverken, Augustina Angelina; Yeboah, Richmond; Adu, Eric; Asamoah, Jesse; Frimpong, Michael; Phillips, Richard Odame] Kwame Nkrumah Univ Sci & Technol, Kumasi Ctr Collaborat Res Trop Med, Kumasi, Ghana; [Owusu, Michael; Acheampong, Godfred] Ctr Hlth Syst Strengthening, Kumasi, Ghana; [Sylverken, Augustina Angelina] Kwame Nkrumah Univ Sci & Technol, Dept Theoret & Appl Biol, Kumasi, Ghana; [El-Duah, Philip] Charite Univ Med Berlin, Inst Virol, Berlin, Germany; [Ayisi-Boateng, Nana Kwame; Phillips, Richard Odame] Kwame Nkrumah Univ Sci & Technol, Dept Med, Kumasi, Ghana; [Frimpong, Michael] Kwame Nkrumah Univ Sci & Technol, Dept Mol Med, Kumasi, Ghana; [Senyo, Japhet; Mutocheluh, Mohamed; Adu-Sarkodie, Yaw] Kwame Nkrumah Univ Sci & Technol, Dept Clin Microbiol, Kumasi, Ghana; [Amuasi, John; Owusu-Dabo, Ellis] Kwame Nkrumah Univ Sci & Technol, Dept Global & Int Hlth, Kumasi, Ghana	Kwame Nkrumah University Science & Technology; Kumasi Center for Collaborative Research; Kwame Nkrumah University Science & Technology; Kwame Nkrumah University Science & Technology; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Kwame Nkrumah University Science & Technology; Kwame Nkrumah University Science & Technology; Kwame Nkrumah University Science & Technology; Kwame Nkrumah University Science & Technology	Owusu, M (corresponding author), Kwame Nkrumah Univ Sci & Technol, Dept Med Diagnost, Kumasi, Ghana.; Owusu, M (corresponding author), Kwame Nkrumah Univ Sci & Technol, Kumasi Ctr Collaborat Res Trop Med, Kumasi, Ghana.; Owusu, M (corresponding author), Ctr Hlth Syst Strengthening, Kumasi, Ghana.	michaelowusu80@gmail.com	El-Duah, Philip/AAN-7425-2021; Phillips, Richard Odame/ABD-5394-2021	El-Duah, Philip/0000-0003-1671-0755; Phillips, Richard Odame/0000-0001-8992-0222; Acheampong, Godfred/0000-0003-2495-9235; SYLVERKEN, AUGUSTINA/0000-0002-7691-914X; YEBOAH, RICHMOND/0000-0002-2765-6179; Kamasah, Japhet Senyo/0000-0003-0369-555X				Corman VM, 2020, TRANSFUSION, V60, P1119, DOI 10.1111/trf.15841; Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Ghana Health Service, 2020, GHANA NATL STRATEGY; Ghana-Health-Service, 2020, DE ISOLATION DISCHAR; Ghana-Health-Service, 2020, UPDATES CORONAVIRUS; Hopkins C, 2020, CORONAVIRUS RESOURCE; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Tho DP., 2020, ANN INTERN MED, V173; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786; Wang WK, 2005, J CLIN MICROBIOL, V43, P962, DOI 10.1128/JCM.43.2.962-965.2005; Zhang W, 2020, EMERG MICROBES INFEC, V9, DOI 10.1080/22221751.2020.1729071	12	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2021	16	4							e0249069	10.1371/journal.pone.0249069	http://dx.doi.org/10.1371/journal.pone.0249069			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN5ED	33848293	Green Published, gold			2023-01-03	WOS:000640373500008
J	Powles, T; Rosenberg, JE; Sonpavde, GP; Loriot, Y; Duran, I; Lee, JL; Matsubara, N; Vulsteke, C; Castellano, D; Wu, CZ; Campbell, M; Matsangou, M; Petrylak, DP				Powles, Thomas; Rosenberg, Jonathan E.; Sonpavde, Guru P.; Loriot, Yohann; Duran, Ignacio; Lee, Jae-Lyun; Matsubara, Nobuaki; Vulsteke, Christof; Castellano, Daniel; Wu, Chunzhang; Campbell, Mary; Matsangou, Maria; Petrylak, Daniel P.			Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; VINFLUNINE PLUS; SUPPORTIVE CARE; CELL CARCINOMA; DOCETAXEL; IMMUNOTHERAPY; PEMBROLIZUMAB; NECTIN-4; THERAPY; AGENT	Background Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment. Methods We conducted a global, open-label, phase 3 trial of enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-containing chemotherapy and had had disease progression during or after treatment with a PD-1 or PD-L1 inhibitor. Patients were randomly assigned in a 1:1 ratio to receive enfortumab vedotin (at a dose of 1.25 mg per kilogram of body weight on days 1, 8, and 15 of a 28-day cycle) or investigator-chosen chemotherapy (standard docetaxel, paclitaxel, or vinflunine), administered on day 1 of a 21-day cycle. The primary end point was overall survival. Results A total of 608 patients underwent randomization; 301 were assigned to receive enfortumab vedotin and 307 to receive chemotherapy. As of July 15, 2020, a total of 301 deaths had occurred (134 in the enfortumab vedotin group and 167 in the chemotherapy group). At the prespecified interim analysis, the median follow-up was 11.1 months. Overall survival was longer in the enfortumab vedotin group than in the chemotherapy group (median overall survival, 12.88 vs. 8.97 months; hazard ratio for death, 0.70; 95% confidence interval [CI], 0.56 to 0.89; P=0.001). Progression-free survival was also longer in the enfortumab vedotin group than in the chemotherapy group (median progression-free survival, 5.55 vs. 3.71 months; hazard ratio for progression or death, 0.62; 95% CI, 0.51 to 0.75; P<0.001). The incidence of treatment-related adverse events was similar in the two groups (93.9% in the enfortumab vedotin group and 91.8% in the chemotherapy group); the incidence of events of grade 3 or higher was also similar in the two groups (51.4% and 49.8%, respectively). Conclusions Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor.	[Powles, Thomas] Queen Mary Univ London, Barts Canc Ctr, London, England; [Rosenberg, Jonathan E.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Sonpavde, Guru P.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Loriot, Yohann] Univ Paris Saclay, Gustave Roussy, Villejuif, France; [Duran, Ignacio] Hosp Univ Marques Valdecilla, Inst Invest Sanitaria Valdecilla, Cantabria, Spain; [Castellano, Daniel] Hosp Univ 12 Octubre, Madrid, Spain; [Lee, Jae-Lyun] Asan Med Ctr, Seoul, South Korea; [Lee, Jae-Lyun] Univ Ulsan, Coll Med, Seoul, South Korea; [Matsubara, Nobuaki] Natl Canc Ctr Hosp East, Chiba, Japan; [Vulsteke, Christof] Univ Antwerp, Integrated Canc Ctr Ghent, Ctr Oncol Res, Ghent, Belgium; [Wu, Chunzhang; Matsangou, Maria] Astellas Pharma, Northbrook, IL USA; [Campbell, Mary] Seagen, Bothell, WA USA; [Petrylak, Daniel P.] Yale Sch Med, Smilow Canc Ctr, New Haven, CT USA	University of London; Queen Mary University London; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario 12 de Octubre; University of Ulsan; National Cancer Center - Japan; University of Antwerp; Astellas Pharmaceuticals; Yale University	Powles, T (corresponding author), Yale Sch Med, Yale Canc Ctr, 333 Cedar St,POB 208032, New Haven, CT 06902 USA.	daniel.petrylak@yale.edu	Vulsteke, Christof/AAO-5115-2021; Loriot, Yohann/W-5572-2019	Vulsteke, Christof/0000-0002-4607-5660; Powles, Thomas/0000-0001-7760-4724	Astellas Pharma US; Seagen	Astellas Pharma US(Astellas Pharmaceuticals); Seagen	Supported by Astellas Pharma US and Seagen.; We thank Stephanie Phan, Pharm.D., Regina Switzer, Ph.D., and Elizabeth Hermans, Ph.D. (OPEN Health Medical Communications), for writing and editorial assistance with an earlier version of the manuscript (funded by Astellas Pharma US and Seagen).	[Anonymous], 2020, ASTELLAS SEATTLE GEN; Bambury RM, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00003; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bellmunt J, 2014, ANN ONCOL, V25, P40, DOI 10.1093/annonc/mdu223; Bellmunt J, 2013, ANN ONCOL, V24, P1466, DOI 10.1093/annonc/mdt007; Bellmunt J, 2009, J CLIN ONCOL, V27, P4454, DOI 10.1200/JCO.2008.20.5534; Black Peter C, 2020, Can Urol Assoc J, V14, pE373, DOI 10.5489/cuaj.6458; Challita-Eid PM, 2016, CANCER RES, V76, P3003, DOI 10.1158/0008-5472.CAN-15-1313; Dreicer R, 2003, CANCER, V97, P2743, DOI 10.1002/cncr.11413; Fradet Y, 2019, ANN ONCOL, V30, P970, DOI 10.1093/annonc/mdz127; Kamat AM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0271-0; Kersten K, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00516; McCaffrey JA, 1997, J CLIN ONCOL, V15, P1853, DOI 10.1200/JCO.1997.15.5.1853; Nadal R, 2019, CANCER TREAT REV, V76, P10, DOI 10.1016/j.ctrv.2019.04.002; National Comprehensive Cancer Network, 2020, BLADDER CANC VERSION; Petrylak DP, 2020, LANCET ONCOL, V21, P105, DOI 10.1016/S1470-2045(19)30668-0; Petrylak DP, 2017, LANCET, V390, P2266, DOI 10.1016/S0140-6736(17)32365-6; Powles T, 2020, NEW ENGL J MED, V383, P1218, DOI 10.1056/NEJMoa2002788; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Rosenberg J, 2020, J CLIN ONCOL, V38, P1041, DOI 10.1200/JCO.19.02044; Rosenberg JE, 2020, J CLIN ONCOL, V38; Rosenberg JE, 2019, J CLIN ONCOL, V37, P2592, DOI 10.1200/JCO.19.01140; Sridhar SS, 2020, JAMA ONCOL, V6, P1751, DOI 10.1001/jamaoncol.2020.3927; van Dijk N, 2019, EUR UROL, V75, P435, DOI 10.1016/j.eururo.2018.09.022; Vaughn DJ, 2002, J CLIN ONCOL, V20, P937, DOI 10.1200/JCO.20.4.937; Warren M., 2019, CAN UROL ASS J; Zhang Y, 2018, ONCOL LETT, V15, P8789, DOI 10.3892/ol.2018.8365; Zhang YJ, 2016, CANCER LETT, V375, P179, DOI 10.1016/j.canlet.2016.02.049; Zhu J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0314-1	29	183	185	3	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2021	384	12					1125	1135		10.1056/NEJMoa2035807	http://dx.doi.org/10.1056/NEJMoa2035807			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF4GG	33577729	Green Accepted, Bronze			2023-01-03	WOS:000634797200012
J	Puwanant, S; Sinphurmsukskul, S; Krailak, L; Nakaviroj, P; Boonbumrong, N; Siwamogsatham, S; Chettakulanurak, K; Ariyachaipanich, A; Boonyaratavej, S				Puwanant, Sarinya; Sinphurmsukskul, Supanee; Krailak, Laddawan; Nakaviroj, Pavinee; Boonbumrong, Noppawan; Siwamogsatham, Sarawut; Chettakulanurak, Krailerk; Ariyachaipanich, Aekarach; Boonyaratavej, Smonporn			The impact of the coronavirus disease and Tele-Heart Failure Clinic on cardiovascular mortality and heart failure hospitalization in ambulatory patients with heart failure	PLOS ONE			English	Article								Background We sought to investigate the impact of the COVID-19 pandemic and the Tele-HF Clinic (Tele-HFC) program on cardiovascular death, heart failure (HF) rehospitalization, and heart transplantation rates in a cohort of ambulatory HF patients during and after the peak of the pandemic. Methods Using the HF clinic database, we compared data of patients with HF before, during, and after the peak of the pandemic (January 1 to March 17 [pre-COVID], March 17 to May 31 [peak-COVID], and June 1 to October 1 [post-COVID]). During peak-COVID, all patients were managed by Tele-HFC or hospitalization. After June 1, patients chose either a face-to-face clinic visit or a continuous tele-clinic visit. Results Cardiovascular death and medical titration rates were similar in peak-COVID compared with all other periods. HF readmission rates were significantly lower in peak-COVID (8.7% vs. 2.5%, p<0.001) and slightly increased (3.5%) post-COVID. Heart transplant rates were substantially increased in post-COVID (4.5% vs. peak-COVID [0%], p = 0.002). After June 1, 38% of patients continued with the Tele-HFC program. Patients managed by the Tele-HFC program for <6 months were less likely to have HF with reduced ejection fraction (73% vs. 54%, p = 0.005) and stage-D HF (33% vs. 14%, p = 0.001), and more likely to achieve the target neurohormonal blockade dose (p<0.01), compared with the >= 6-month Tele-HFC group. Conclusions HF rehospitalization and transplant rates significantly declined during the pandemic in ambulatory care of HF. However, reduction in these rates did not affect subsequent 5-month hospitalization and cardiovascular mortality in the setting of Tele-HFC program and continuum of advanced HF therapies.	[Puwanant, Sarinya; Sinphurmsukskul, Supanee; Krailak, Laddawan; Nakaviroj, Pavinee; Boonbumrong, Noppawan; Siwamogsatham, Sarawut; Chettakulanurak, Krailerk; Ariyachaipanich, Aekarach; Boonyaratavej, Smonporn] Chulalongkorn Univ, Div Cardiol, Dept Med, Fac Med, Bangkok, Thailand; [Puwanant, Sarinya; Sinphurmsukskul, Supanee; Krailak, Laddawan; Nakaviroj, Pavinee; Boonbumrong, Noppawan; Siwamogsatham, Sarawut; Chettakulanurak, Krailerk; Ariyachaipanich, Aekarach; Boonyaratavej, Smonporn] King Chulalongkorn Mem Hosp, Cardiac Ctr, Thai Red Cross Soc, Bangkok, Thailand	Chulalongkorn University; Chulalongkorn University; Thai Red Cross Society	Puwanant, S (corresponding author), Chulalongkorn Univ, Div Cardiol, Dept Med, Fac Med, Bangkok, Thailand.; Puwanant, S (corresponding author), King Chulalongkorn Mem Hosp, Cardiac Ctr, Thai Red Cross Soc, Bangkok, Thailand.	spuwanant@gmail.com						Andersson C, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.120.007274; Ansari M, 2003, CIRCULATION, V107, P2799, DOI 10.1161/01.CIR.0000070952.08969.5B; Boyne JJJ, 2012, EUR J HEART FAIL, V14, P791, DOI 10.1093/eurjhf/hfs058; Bromage DI, 2020, EUR J HEART FAIL, V22, P978, DOI 10.1002/ejhf.1925; Chaudhry SI, 2007, J CARD FAIL, V13, P56, DOI 10.1016/j.cardfail.2006.09.001; Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Cleland JGF, 2005, J AM COLL CARDIOL, V45, P1654, DOI 10.1016/j.jacc.2005.01.050; Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941; Dendale P, 2012, EUR J HEART FAIL, V14, P333, DOI 10.1093/eurjhf/hfr144; Dickinson MG, 2018, J CARD FAIL, V24, P682, DOI 10.1016/j.cardfail.2018.08.011; Dunagan WC, 2005, J CARD FAIL, V11, P358, DOI 10.1016/j.cardfail.2004.12.004; Gallagher BD, 2017, J CARD FAIL, V23, P345, DOI 10.1016/j.cardfail.2016.11.001; Giordano A, 2009, INT J CARDIOL, V131, P192, DOI 10.1016/j.ijcard.2007.10.027; Gorodeski EZ, 2020, J CARD FAIL, V26, P448, DOI 10.1016/j.cardfail.2020.04.008; Koehler F, 2011, CIRCULATION, V123, P1873, DOI 10.1161/CIRCULATIONAHA.111.018473; Moyer-Knox D, 2004, J CARD FAIL, V10, P219, DOI 10.1016/j.cardfail.2003.09.009; Nishiga M, 2020, NAT REV CARDIOL, V17, P543, DOI 10.1038/s41569-020-0413-9; Wilcox JE, 2020, J AM COLL CARDIOL, V76, P719, DOI 10.1016/j.jacc.2020.05.075; Yancy CW, 2013, CIRCULATION, V128, P1810, DOI 10.1161/CIR.0b013e31829e8807	19	4	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2021	16	3							e0249043	10.1371/journal.pone.0249043	http://dx.doi.org/10.1371/journal.pone.0249043			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC6NY	33755715	gold, Green Published			2023-01-03	WOS:000632916600012
J	Byrne, AL; Baldwin, A; Harvey, C; Brown, J; Willis, E; Hegney, D; Ferguson, B; Judd, J; Kynaston, D; Forrest, R; Heritage, B; Heard, D; Mclellan, S; Thompson, S; Palmer, J				Byrne, Amy-Louise; Baldwin, Adele; Harvey, Clare; Brown, Janie; Willis, Eileen; Hegney, Desley; Ferguson, Bridget; Judd, Jenni; Kynaston, Doug; Forrest, Rachel; Heritage, Brody; Heard, David; Mclellan, Sandy; Thompson, Shona; Palmer, Janine			Understanding the impact and causes of 'failure to attend' on continuity of care for patients with chronic conditions	PLOS ONE			English	Article							SUPPORT	Aim To understand the impact and causes of 'Failure to Attend' (FTA) labelling, of patients with chronic conditions. Background Nurse navigators are registered nurses employed by public hospitals in Queensland, Australia, to coordinate the care of patients with multiple chronic conditions, who frequently miss hospital appointments. The role of the nurse navigator is to improve care management of these patients. Evidence for this is measured through improvement in patient self-management of their conditions, a reduction in preventable hospital admissions and compliance with attendance at outpatient clinics. Failure to attend (FTA) is one measure of hospital utilisation, identifying outpatient appointments that are cancelled or not attended. Method The cohort for this study was patients with multiple chronic conditions, and nurse navigators coordinating their care. Data describing the concept of FTA were thematically analysed twelve months into this three year evaluation. Results Although the patient is blamed for failing to attend appointments, the reasons appear to be a mixture of systems error/miscommunication between the patient and the health services or social reasons impacting on patient's capacity to attend. Themes emerging from the data were: access barriers; failure to recognise personal stigma of FTA; and bridging the gap. Conclusion The nurse navigators demonstrate their pivotal role in engaging with outpatient services to reduce FTAs whilst helping patients to become confident in dealing with multiple appointments. There are many reasons why a patient is unable to attend a scheduled appointment. The phrase 'Failure to Attend' has distinctly negative connotations and can lead to a sense of blame and shame for those with complex chronic needs. We propose the use of the neutral phrase "appointment did not proceed" to replace FTA. Implications for Nursing management This article advocates for further consideration of collaborative models that engage the patient in their care journey and for consideration of the language used within the outpatient acute hospital setting, proposing the term 'appointment did not proceed.'	[Byrne, Amy-Louise; Baldwin, Adele; Harvey, Clare; Brown, Janie; Willis, Eileen; Heard, David] Cent Queensland Univ, Sch Nursing Midwifery & Social Sci, Townsville, Qld, Australia; [Brown, Janie] Curtin Univ, Sch Nursing Midwifery & Paramed, Perth, WA, Australia; [Brown, Janie] St John God Midland Publ & Private Hosp, Midland, WA, Australia; [Willis, Eileen] Flinders Univ S Australia, Coll Nursing & Hlth Sci, Adelaide, SA, Australia; [Hegney, Desley] Univ Adelaide, Sch Nursing, Adelaide, SA, Australia; [Hegney, Desley; Ferguson, Bridget] Cent Queensland Univ, Sch Nursing Midwifery & Social Sci, North Rockhampton, Australia; [Judd, Jenni] Cent Queensland Univ, Sch Hlth Med & Appl Sci, Bundaberg, Qld, Australia; [Kynaston, Doug] Sunshine Coast Hosp & Hlth Serv, Birtinya, Australia; [Forrest, Rachel] Eastern Inst Technol, Sch Nursing, Napier, New Zealand; [Heritage, Brody] Murdoch Univ, Discipline Psychol, Coll Sci Hlth Engn & Educ, Perth, WA, Australia; [Mclellan, Sandy] Cent Queensland Univ, Sch Nursing Midwifery & Social Sci, Mackay, Qld, Australia; [Thompson, Shona] Eastern Inst Technol, Napier, New Zealand; [Palmer, Janine] Hawkes Bay Dist Hlth Board, Hastings, New Zealand	Central Queensland University; Curtin University; St John of God Health Care; Flinders University South Australia; University of Adelaide; Central Queensland University; Central Queensland University; Murdoch University; Central Queensland University	Byrne, AL (corresponding author), Cent Queensland Univ, Sch Nursing Midwifery & Social Sci, Townsville, Qld, Australia.	a.byrne@cqu.edu.au	Forrest, Rachel/D-1184-2010; Heritage, Brody/AAY-5111-2021; Heritage, Brody/AAZ-3501-2021; Brown, Janie/T-7861-2019; Judd, Jenni/K-2521-2012	Forrest, Rachel/0000-0002-5086-0493; Heritage, Brody/0000-0002-6437-7232; Heritage, Brody/0000-0002-6437-7232; Brown, Janie/0000-0001-8502-4252; Heard, David/0000-0003-4157-3000; Willis, Eileen/0000-0001-7576-971X; Byrne, Amy-Louise/0000-0002-8679-8310; Judd, Jenni/0000-0001-8441-5008	Queensland Health	Queensland Health	Funding (financial support) for this project was provided by Queensland Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No other funding was received for the project. No authors have received a salary from the funders.	Allen W, 2017, ENVIRON MANAGE, V59, P956, DOI 10.1007/s00267-017-0839-y; Archibald T, 2016, EVAL PROGRAM PLANN, V59, P119, DOI 10.1016/j.evalprogplan.2016.05.015; Australian Commission on Safety and Quality in Health Care, 2017, NATL SAFETY QUALITY, V2nd; Australian Health Ministers Advisory Council, 2017, NATL STRATEGIC FRAME; Australian Institute of Health and Welfare, 2019, RUR REM HLTH; Borgonovi E, 2013, VALUE HEALTH, V16, pS34, DOI 10.1016/j.jval.2012.10.006; Burckhardt Carol S, 2003, Health Qual Life Outcomes, V1, P60, DOI 10.1186/1477-7525-1-60; Collins Jacinta, 2003, Aust Health Rev, V26, P52; Cooper A, 2018, DIABETIC MED, V35, P1630, DOI 10.1111/dme.13705; Fairclough N., Critical discourse analysis and critical policy studies; Forrest RH., 2019, NEW ZEAL J EDUC STUD; Fry D, 2020, HEALTH PROMOT INT, V35, P624, DOI 10.1093/heapro/daz039; Fullbright-Anderson K., 1998, NEW APPROACHES EVALU; Furber CM, 2010, MIDWIFERY, V26, P232, DOI 10.1016/j.midw.2008.05.003; Goddu AP, 2018, J GEN INTERN MED, V33, P685, DOI 10.1007/s11606-017-4289-2; Hannan-Jones C, 2019, AUST J PRIM HEALTH, V25, P339, DOI 10.1071/PY19042; Legal Aid Queensland, 2015, WARRANTS; Morales-Asencio JM, 2016, J EVAL CLIN PRACT, V22, P122, DOI 10.1111/jep.12300; Queensland Health, 2017, STANDARD DOH; Queensland Health, 2019, QUEENSLAND HLTH SYST; Queensland Health, 2018, OFFICE CHIEF NURSING; Randall S, 2016, AUST J PRIM HEALTH, V22, P181, DOI 10.1071/PY15140; Rist, 2009, ROAD ATLAS RESULTS; Roberts K, 2011, INT J HEALTH CARE Q, V24, P406, DOI 10.1108/09526861111139214; Saldana J, 2016, CODING MANUAL QUALIT, V3rd; Sheridan NF, 2015, HEALTH EXPECT, V18, P32, DOI 10.1111/hex.12006; Waring T., 2008, ELECT J BUSINESS RES, V6, P85	27	3	3	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2021	16	3							e0247914	10.1371/journal.pone.0247914	http://dx.doi.org/10.1371/journal.pone.0247914			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QR6XN	33651826	gold, Green Published			2023-01-03	WOS:000625359500033
J	Bhattacharyya, A; Sarma, P; Kaur, H; Medhi, B				Bhattacharyya, Anusuya; Sarma, Phulen; Kaur, Hardeep; Medhi, Bikash			Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19	ANNALS OF INTERNAL MEDICINE			English	Letter									[Bhattacharyya, Anusuya] Govt Med Coll & Hosp, Chandigarh, India; [Sarma, Phulen; Kaur, Hardeep; Medhi, Bikash] Postgrad Inst Med Educ & Res, Chandigarh, India	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Bhattacharyya, A (corresponding author), Govt Med Coll & Hosp, Chandigarh, India.			Medhi, Bikash/0000-0002-4017-641X				Acosta-Elias J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01062; [Бойко А.Н. Boyko A.N.], 2020, [Неврология, нейропсихиатрия, психосоматика, Neurology, Neuropsychiatry, Psychosomatics, Nevrologiya, neiropsikhiatriya, psikhosomatika], V12, P82, DOI 10.14412/2074-2711-2020-3-82-86; Itelman Edward, 2020, Isr Med Assoc J, V22, P271; Sheybani Z., 2020, ROLE FOLIC ACID MANA, P1, DOI [10.26434/chemrxiv.12034980.v1, DOI 10.26434/CHEMRXIV.12034980.V1]; Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207	5	5	5	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					434	434		10.7326/L21-0001	http://dx.doi.org/10.7326/L21-0001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX4DA	33721533				2023-01-03	WOS:000629294000006
J	Peos, JJ; Helms, ER; Fournier, PA; Krieger, J; Sainsbury, A				Peos, Jackson J.; Helms, Eric R.; Fournier, Paul A.; Krieger, James; Sainsbury, Amanda			A 1-week diet break improves muscle endurance during an intermittent dieting regime in adult athletes: A pre-specified secondary analysis of the ICECAP trial	PLOS ONE			English	Article								Athletes undergoing energy restriction for weight/fat reduction sometimes apply 'diet breaks' involving increased energy intake, but there is little empirical evidence of effects on out-comes. Twenty-six resistance-trained athletes (11/26 or 42% female) who had completed 12 weeks of intermittent energy restriction participated in this study. Participants had a mean (SD) age of 29.3 (6.4) years, a weight of 72.7 (15.9) kg, and a body fat percentage of 21.3 (7.5) %. During the 1-week diet break, energy intake was increased (by means of increased carbohydrate intake) to predicted weight maintenance requirements. While the 1-week diet break had no significant effect on fat mass, it led to small but significant increases in mean body weight (0.6 kg, P< 0.001), fat-free mass (0.7 kg, P< 0.001) and in resting energy expenditure, from a mean (and 95% confidence interval) of 7000 (6420 to 7580) kJ/day to 7200 (6620 to 7780) kJ/day (P = 0.026). Overall, muscle endurance in the legs (but not arms) improved after the diet break, including significant increases in the work completed by the quadriceps and hamstrings in a maximum-effort 25-repetition set, with values increasing from 2530 (2170 to 2890) J to 2660 (2310 to 3010) J (P = 0.018) and from 1280 (1130 to 1430) J to 1380 (1220 to 1540) J (P = 0.018) following the diet break, respectively. However, muscle strength did not change. Participants reported significantly lower sensations of hunger (P = 0.017), prospective consumption (P = 0.020) and irritability (P = 0.041) after the diet break, and significantly higher sensations of fullness (P = 0.002), satisfaction (P = 0.002), and alertness (P = 0.003). In summary, a 1-week diet break improved muscle endurance in the legs and increased mental alertness, and reduced appetite and irritability. With this considered, it may be wise for athletes to coordinate diet breaks with training sessions that require muscle endurance of the legs and/or mental focus, as well as in the latter parts of a weight loss phase when increases in appetite might threaten dietary adherence.	[Peos, Jackson J.; Fournier, Paul A.; Sainsbury, Amanda] Univ Western Australia, Fac Sci, Sch Human Sci Exercise & Sports Sci, Crawley, WA, Australia; [Helms, Eric R.] Auckland Univ Technol, Sports Performance Inst New Zealand SPRINZ, Auckland, New Zealand; [Krieger, James] Weightology LLC, Issaquah, WA, Australia	University of Western Australia; Auckland University of Technology	Peos, JJ (corresponding author), Univ Western Australia, Fac Sci, Sch Human Sci Exercise & Sports Sci, Crawley, WA, Australia.	jackson.peos@research.uwa.edu.au	Salis, Amanda/A-3187-2011	Salis, Amanda/0000-0001-9176-1574; Peos, Jackson/0000-0002-1006-2147; Fournier, Paul/0000-0002-9963-9685	Australian Department of Education and Training; National Health and Medical Research Council (NHMRC) of Australia [1042555, 1135897]; Renaissance Periodisation	Australian Department of Education and Training(Australian GovernmentDepartment of Industry, Innovation and Science); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Renaissance Periodisation	This work was supported in part by Renaissance Periodisation and by the Australian Department of Education and Training via a Research Training Program Scholarship awarded to JJP, as well as by the National Health and Medical Research Council (NHMRC) of Australia via Senior Research Fellowships (1042555 and 1135897) to AS. The funders provided support in the form of salaries for authors AS and JP but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these 'authors are articulated in the author contributions' section.	ACHESON KJ, 1988, AM J CLIN NUTR, V48, P240, DOI 10.1093/ajcn/48.2.240; Andrade A, 2016, J SPORT SCI MED, V15, P601; [Anonymous], [No title captured]; Appleton KM, 2015, J HEALTH PSYCHOL, V20, P702, DOI 10.1177/1359105315573430; Baker JS, 2010, J NUTR METAB, V2010, DOI 10.1155/2010/905612; Blundell J, 2010, OBES REV, V11, P251, DOI 10.1111/j.1467-789X.2010.00714.x; Brito CJ, 2012, INT J SPORT NUTR EXE, V22, P89, DOI 10.1123/ijsnem.22.2.89; Burke L., PRACTICAL SPORTS NUT; Burke LM, 2017, J PHYSIOL-LONDON, V595, P2785, DOI 10.1113/JP273230; Burke LM, 2011, J SPORT SCI, V29, pS17, DOI 10.1080/02640414.2011.585473; Calbet JAL, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00483; Cicatiello AG, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00474; Davis J, 2018, BRAIN RES, V1693, P154, DOI 10.1016/j.brainres.2018.01.024; Escobar Kurt A, 2016, Int J Exerc Sci, V9, P460; Haff GG, 2003, J STRENGTH COND RES, V17, P187; Harris RBS, 2014, BBA-MOL BASIS DIS, V1842, P414, DOI 10.1016/j.bbadis.2013.05.009; Hickey A, 2019, EDUC SCI, V9, DOI 10.3390/educsci9030242; Holmberg H, 2008, DEPLETION RESYNTHESI, P660; Horman T, 2018, PSYCHOPHARMACOLOGY, V235, P3055, DOI 10.1007/s00213-018-4998-1; Langan-Evans C, 2011, STRENGTH COND J, V33, P25, DOI 10.1519/SSC.0b013e318231bb64; Leveritt M, 1999, SPORTS MED, V28, P413, DOI 10.2165/00007256-199928060-00004; Maestu J, 2010, J STRENGTH COND RES, V24, P1074, DOI 10.1519/JSC.0b013e3181cb6fd3; Maestu J, 2008, METABOLISM, V57, P221, DOI 10.1016/j.metabol.2007.09.004; Marcora SM, 2009, J APPL PHYSIOL, V106, P857, DOI 10.1152/japplphysiol.91324.2008; Marriott B.M., 1995, NOT EATING ENOUGH OV; Martin K, 2018, SPORTS MED, V48, P2041, DOI 10.1007/s40279-018-0946-9; Murray B, 2018, NUTR REV, V76, P243, DOI 10.1093/nutrit/nuy001; Pageaux B, 2018, PROG BRAIN RES, V240, P291, DOI 10.1016/bs.pbr.2018.10.004; Peos JJ, 2018, BMJ OPEN SPORT EXERC, V4, DOI 10.1136/bmjsem-2018-000423; Peos JJ, 2019, SPORTS, V7, DOI 10.3390/sports7010022; Pilegaard H, 1999, AM J PHYSIOL-ENDOC M, V276, pE255, DOI 10.1152/ajpendo.1999.276.2.E255; Rogol AD, 2000, CURR OPIN PEDIATR, V12, P382, DOI 10.1097/00008480-200008000-00018; Russell S, 2019, EUR J SPORT SCI, V19, P1367, DOI 10.1080/17461391.2019.1618397; Spiotta AM, 2018, WORLD NEUROSURG, V120, pE188, DOI 10.1016/j.wneu.2018.08.013; Thomas DT, 2016, J ACAD NUTR DIET, V116, P501, DOI 10.1016/j.jand.2015.12.006; Trexler ET, 2014, J INT SOC SPORT NUTR, V11, DOI 10.1186/1550-2783-11-7; Walter G, 1997, AM J PHYSIOL-CELL PH, V272, pC525, DOI 10.1152/ajpcell.1997.272.2.C525; Weinberg R. S., 1981, QUEST, P195; Westerterp KR, 2017, EUR J CLIN NUTR, V71, P340, DOI 10.1038/ejcn.2016.237; Zanchi D, 2017, NEUROSCI BIOBEHAV R, V80, P457, DOI 10.1016/j.neubiorev.2017.06.013	40	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247292	10.1371/journal.pone.0247292	http://dx.doi.org/10.1371/journal.pone.0247292			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BB	33630880	Green Published, gold			2023-01-03	WOS:000624536800057
J	Weimer, MB; Wakeman, SE; Saitz, R				Weimer, Melissa B.; Wakeman, Sarah E.; Saitz, Richard			Removing One Barrier to Opioid Use Disorder Treatment Is It Enough?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Weimer, Melissa B.] Yale Sch Med, Dept Med, Program Addict Med, New Haven, CT USA; [Wakeman, Sarah E.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA; [Saitz, Richard] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA USA; [Saitz, Richard] Boston Univ, Sect Gen Internal Med, Clin Addict Res & Educ Unit, Grayken Ctr Addict,Boston Med Ctr,Sch Med, Boston, MA 02118 USA	Yale University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Boston University; Boston Medical Center; Boston University	Weimer, MB (corresponding author), Yale Sch Med, 367 Cedar St,Harkness Hall A,Ste 417A, New Haven, CT 06510 USA.	Melissa.weimer@yale.edu		Weimer, Melissa/0000-0002-5624-2434				Ahmad F., 2021, NATL HLTH STAT REPOR; Department of Health and Human Services, ANN PRACT GUID ADM B; Fatseas M, 2007, Curr Psychiatry Rep, V9, P358, DOI 10.1007/s11920-007-0046-2; Haffajee RL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6373; Lin LK, 2019, J GEN INTERN MED, V34, P2313, DOI 10.1007/s11606-019-05165-6; Sigmon SC, 2016, NEW ENGL J MED, V375, P2504, DOI 10.1056/NEJMc1610047; Substance Abuse and Mental Health Services Administration, 2019, 2019 NAT SURV DRUG U	7	11	11	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2021	325	12					1147	1148		10.1001/jama.2021.0958	http://dx.doi.org/10.1001/jama.2021.0958		FEB 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ7PB	33630020				2023-01-03	WOS:000621911900003
J	Hamooya, BM; Musonda, P; Mutale, W; Masenga, SK; Halwiindi, H; Mutengo, KH; Chiyenu, KOR; Chongwe, G; Koethe, JR; Lipworth, L; Heimburger, DC				Hamooya, Benson M.; Musonda, Patrick; Mutale, Wilbroad; Masenga, Sepiso K.; Halwiindi, Hikabasa; Mutengo, Katongo H.; Chiyenu, Kaseya O. R.; Chongwe, Gershom; Koethe, John R.; Lipworth, Loren; Heimburger, Douglas C.			Prevalence of low high-density lipoprotein among young adults receiving antiretroviral therapy in Zambia: An opportunity to consider non-communicable diseases in resource-limited settings	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; HDL-CHOLESTEROL; LIPID-LEVELS; RISK-FACTORS; ASSOCIATION; DYSLIPIDEMIA; AIDS; MORTALITY; PROFILE; GENDER	Background With the introduction of effective antiretroviral therapy (ART), people living with HIV (PLWH) are surviving longer and are at risk for developing metabolic abnormalities that contribute to cardiovascular disease (CVD). In Sub-Saharan Africa (SSA), there is a paucity of epidemiological data on lipid profiles among young adults receiving ART. This study aimed to estimate the prevalence of low high-density lipoprotein cholesterol (HDL-c), a cardioprotective lipid class, and whether it differed by age among adults on ART in Livingstone, Zambia. Methods From April to December 2019, we conducted a cross-sectional study of 597 PLWH [n = 58 aged 18-24 years (young adults); n = 539 aged >= 25 years (adults)] on ART for >= 6 months. Data collected included demographic and lifestyle information, anthropometrics, viral load (VL), CD4 count, blood pressure, lipid profiles and fasting/random blood glucose. Clinical measures were defined as: low HDL-c [<1.0 mmol/L for men, <1.3 for women], increased waist circumference (WC) [>= 94 cm for men, >= 80 cm for women], high triglycerides (TG) [>= 1.7 mmol/l], and virological failure (VF) [VL >= 1000 copies/mu l]. We used logistic regression to examine the association between age and low HDL-c after adjusting for multiple variables. Results Among the young adults, 60% (35/58) were women, median (25(th), 75(th) percentile) age 21 years (18, 23), and median time on ART 116 months (60, 144). Among adults, 63% (342/539) were women, median age 46 years (40, 53) and median time on ART 108 months (60, 144). Young adults had a lower CD4 count compared to adults (median, 492 vs. 568 cells/mu L, p = 0.010) and higher prevalence of VF (29% vs. 17%, p = 0.016). In young adults, prevalence of low HDL-c was significantly higher than in adults (63 vs. 38%, p<0.001). A high proportion of young adults (75%) and adults (58%) with low HDL-c were on dolutegravir (DTG)-based ART regimens. After adjusting for sex, duration on ART, WC, body mass index, ART regimen, VF, CD4 count, low density lipoprotein cholesterol, blood pressure and smoking, young adults were significantly more likely than adults to have low HDL-c (odds ratio 2.93; 95% confidence interval 1.46-5.86). Conclusion Low HDL-c is highly prevalent among young adult with HIV in SSA independent of other risk factors for metabolic derangements. Lipid abnormalities among young PLWH may contribute to the early development of cardiovascular diseases in this population. This highlights the need to consider low HDL-c in the quest to reduce CVD risk among young adults on ART in SSA.	[Hamooya, Benson M.; Musonda, Patrick; Mutale, Wilbroad; Halwiindi, Hikabasa; Chongwe, Gershom] Univ Zambia, Sch Publ Hlth, Lusaka, Zambia; [Hamooya, Benson M.; Masenga, Sepiso K.] Mulungushi Univ, Sch Med & Hlth Sci, Livingstone, Zambia; [Hamooya, Benson M.; Koethe, John R.; Heimburger, Douglas C.] Vanderbilt Inst Global Hlth, Nashville, TN 37232 USA; [Masenga, Sepiso K.] Univ Zambia, Sch Hlth Sci, Dept Biomed Sci, Lusaka, Zambia; [Masenga, Sepiso K.; Koethe, John R.; Lipworth, Loren; Heimburger, Douglas C.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Mutengo, Katongo H.; Chiyenu, Kaseya O. R.] Livingstone Cent Hosp, Livingstone, Zambia; [Mutengo, Katongo H.; Chiyenu, Kaseya O. R.] Minist Hlth, Lusaka, Zambia; [Koethe, John R.; Lipworth, Loren; Heimburger, Douglas C.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Heimburger, Douglas C.] Univ Zambia, Sch Med, Lusaka, Zambia	University of Zambia; Vanderbilt University; University of Zambia; Vanderbilt University; Vanderbilt University; University of Zambia	Hamooya, BM (corresponding author), Univ Zambia, Sch Publ Hlth, Lusaka, Zambia.; Hamooya, BM (corresponding author), Mulungushi Univ, Sch Med & Hlth Sci, Livingstone, Zambia.; Hamooya, BM (corresponding author), Vanderbilt Inst Global Hlth, Nashville, TN 37232 USA.	benmalambo@gmail.com		Hamooya, Benson/0000-0003-1385-0998	Fogarty International Center of the US National Institutes of Health [D43 TW009744]	Fogarty International Center of the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	Research reported in this publication was supported by the Fogarty International Center of the US National Institutes of Health under Award Number D43 TW009744. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Abebe Molla, 2014, BMC Res Notes, V7, P380, DOI 10.1186/1756-0500-7-380; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Amberbir A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197728; Anastos K, 2007, JAIDS-J ACQ IMM DEF, V45, P34, DOI 10.1097/QAI.0b013e318042d5fe; Asiki G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126166; Asztalos BF, 2006, ATHEROSCLEROSIS, V184, P72, DOI 10.1016/j.atherosclerosis.2005.04.013; Bagella P, 2019, INFECT DRUG RESIST, V12, P1385, DOI 10.2147/IDR.S203813; Barter P, 2007, NEW ENGL J MED, V357, P1301, DOI 10.1056/NEJMoa064278; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Bernal E, 2008, AIDS PATIENT CARE ST, V22, P569, DOI 10.1089/apc.2007.0186; Buchacz K, 2008, JAIDS-J ACQ IMM DEF, V47, P304, DOI 10.1097/QAI.0b013e31815e7453; CASTELLI WP, 1988, CAN J CARDIOL, V4, pA5; Ching T, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0387; Chyu KY, 2011, CURR ATHEROSCLER REP, V13, P405, DOI 10.1007/s11883-011-0189-9; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cohan GR, 2000, POSTGRAD MED, V107, P141, DOI 10.3810/pgm.2000.04.986; da Cunha Joel, 2015, World J Virol, V4, P56, DOI 10.5501/wjv.v4.i2.56; Dave JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151911; Dixon P, 2020, J HEALTH ECON, V70, DOI 10.1016/j.jhealeco.2020.102300; Eren Esin, 2012, Open Biochem J, V6, P78, DOI 10.2174/1874091X01206010078; Feeney Eoin R, 2011, Open Cardiovasc Med J, V5, P49, DOI 10.2174/1874192401105010049; Ghehi C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177440; Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283; Grundy SM, 2019, J AM COLL CARDIOL, V73, pE285, DOI 10.1016/j.jacc.2018.11.003; Guaraldi G, 2019, J FRALITY AGING, V8, P88, DOI 10.14283/jfa.2019.6; Guira Oumar, 2016, J Int Assoc Provid AIDS Care, V15, P159, DOI 10.1177/2325957415601503; Hanley TM, 2011, J VIROL, V85, P10834, DOI 10.1128/JVI.00789-11; Hanley TM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000981; Hirigo Agete Tadewos, 2016, BMC Res Notes, V9, P145, DOI 10.1186/s13104-016-1953-2; Hou L, 2020, MOL MED, V26, DOI 10.1186/s10020-019-0133-y; Iwuala SO, 2015, NIGER J CLIN PRACT, V18, P626, DOI 10.4103/1119-3077.154208; Kagaruki GB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-904; Kotani K, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-147; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Liu E, 2013, CLIN INFECT DIS, V56, P1820, DOI 10.1093/cid/cit120; Liu MH, 2020, NEUROIMAGE, V208, DOI 10.1016/j.neuroimage.2019.116459; Lobo RA, 2019, CLIMACTERIC, V22, P610, DOI 10.1080/13697137.2019.1640197; Mocroft A, 2010, JAIDS-J ACQ IMM DEF, V55, P262, DOI 10.1097/QAI.0b013e3181e9be6b; Nery MW, 2011, BRAZ J INFECT DIS, V15, P151, DOI 10.1590/S1413-86702011000200010; Neuhaus J, 2010, AIDS, V24, P697, DOI 10.1097/QAD.0b013e3283365356; Njoroge A, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0503-9; Ombeni Walter, 2016, J Int Assoc Provid AIDS Care, V15, P164, DOI 10.1177/2325957415614642; Ortblad KF, 2013, LANCET, V381, P105; Padmapriyadarsini C, 2017, INDIAN J MED RES, V145, P640, DOI 10.4103/ijmr.IJMR_1611_15; Patel P, 2018, AIDS, V32, pS5, DOI 10.1097/QAD.0000000000001888; Qiao Q, 2007, ANN CLIN BIOCHEM, V44, P232, DOI 10.1258/000456307780480963; Quercia R, 2015, CLIN DRUG INVEST, V35, P211, DOI 10.1007/s40261-014-0266-2; Rossouw JE, 2002, CARDIOVASC RES, V53, P550, DOI 10.1016/S0008-6363(01)00478-3; SCHAEFER EJ, 1994, J LIPID RES, V35, P871; Shah ASV, 2018, CIRCULATION, V138, P1100, DOI 10.1161/CIRCULATIONAHA.117.033369; Sprinz E, 2010, BRAZ J INFECT DIS, V14, P575, DOI 10.1016/S1413-8670(10)70115-X; Vos AG, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0460-z; WHO, 2012, WHO GLOB STRAT SURV; WHO, NCDS STEPWISE APPR S; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; Wohl DA, 2006, CLIN INFECT DIS, V43, P645, DOI 10.1086/507333; World Health Organization, 2020, LECHASCHI VRACH; Yu H, 2020, EXP MOL PATHOL, V116, DOI 10.1016/j.yexmp.2020.104493; Zhou DT, 2016, BIOCHEM RES INT, V2016, DOI 10.1155/2016/3204818; Zhou JM, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.2949	60	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2021	16	2							e0247004	10.1371/journal.pone.0247004	http://dx.doi.org/10.1371/journal.pone.0247004			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8MA	33592027	Green Published, gold			2023-01-03	WOS:000620632800075
J	Ho, JSY; Mok, BWY; Campisi, L; Jordan, T; Yildiz, S; Parameswaran, S; Wayman, JA; Gaudreault, NN; Meekins, DA; Indran, SV; Morozov, I; Trujillo, JD; Fstkchyan, YS; Rathnasinghe, R; Zhu, ZY; Zheng, SM; Zhao, N; White, K; Ray-Jones, H; Malysheva, V; Thiecke, MJ; Lau, SY; Liu, HL; Zhang, ANJX; Lee, ACY; Liu, WC; Jangra, S; Escalera, A; Aydillo, T; Melo, BS; Guccione, E; Sebra, R; Shum, E; Bakker, J; Kaufman, DA; Moreira, AL; Carossino, M; Balasuriya, UBR; Byun, M; Albrecht, RA; Schotsaert, M; Garcia-Sastre, A; Chanda, SK; Miraldi, ER; Jeyasekharan, AD; TenOever, BR; Spivakov, M; Weirauch, MT; Heinz, S; Chen, HL; Benner, C; Richt, JA; Marazzi, I				Ho, Jessica Sook Yuin; Mok, Bobo Wing-Yee; Campisi, Laura; Jordan, Tristan; Yildiz, Soner; Parameswaran, Sreeja; Wayman, Joseph A.; Gaudreault, Natasha N.; Meekins, David A.; Indran, Sabarish, V; Morozov, Igor; Trujillo, Jessie D.; Fstkchyan, Yesai S.; Rathnasinghe, Raveen; Zhu, Zeyu; Zheng, Simin; Zhao, Nan; White, Kris; Ray-Jones, Helen; Malysheva, Valeriya; Thiecke, Michiel J.; Lau, Siu-Ying; Liu, Honglian; Zhang, Anna Junxia; Lee, Andrew Chak-Yiu; Liu, Wen-Chun; Jangra, Sonia; Escalera, Alba; Aydillo, Teresa; Melo, Betsaida Salom; Guccione, Ernesto; Sebra, Robert; Shum, Elaine; Bakker, Jan; Kaufman, David A.; Moreira, Andre L.; Carossino, Mariano; Balasuriya, Udeni B. R.; Byun, Minji; Albrecht, Randy A.; Schotsaert, Michael; Garcia-Sastre, Adolfo; Chanda, Sumit K.; Miraldi, Emily R.; Jeyasekharan, Anand D.; TenOever, Benjamin R.; Spivakov, Mikhail; Weirauch, Matthew T.; Heinz, Sven; Chen, Honglin; Benner, Christopher; Richt, Juergen A.; Marazzi, Ivan			TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation	CELL			English	Article							READ ALIGNMENT; TOPOTECAN; RESPONSES; ORGANIZATION; XENOGRAFTS; INTERFERON; MACROPHAGE; IRINOTECAN; RELEVANCE; DYNAMICS	The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently affecting millions of lives worldwide. Large retrospective studies indicate that an elevated level of inflammatory cytokines and pro-inflammatory factors are associated with both increased disease severity and mortality. Here, using multidimensional epigenetic, transcriptional, in vitro, and in vivo analyses, we report that topoisomerase 1 (TOP1) inhibition suppresses lethal inflammation induced by SARS-CoV-2. Therapeutic treatment with two doses of topotecan (TPT), an FDA-approved TOP1 inhibitor, suppresses infection-induced inflammation in hamsters. TPT treatment as late as 4 days post-infection reduces morbidity and rescues mortality in a transgenic mouse model. These results support the potential of TOP1 inhibition as an effective host-directed therapy against severe SARS-CoV-2 infection. TPT and its derivatives are inexpensive clinical-grade inhibitors available in most countries. Clinical trials are needed to evaluate the efficacy of repurposing TOP1 inhibitors for severe coronavirus disease 2019 (COVID-19) in humans.	[Ho, Jessica Sook Yuin; Campisi, Laura; Jordan, Tristan; Yildiz, Soner; Fstkchyan, Yesai S.; Rathnasinghe, Raveen; Zhu, Zeyu; Zheng, Simin; Zhao, Nan; White, Kris; Liu, Wen-Chun; Jangra, Sonia; Escalera, Alba; Aydillo, Teresa; Albrecht, Randy A.; Schotsaert, Michael; Garcia-Sastre, Adolfo; TenOever, Benjamin R.; Marazzi, Ivan] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Mok, Bobo Wing-Yee; Lau, Siu-Ying; Liu, Honglian; Zhang, Anna Junxia; Lee, Andrew Chak-Yiu; Chen, Honglin] Univ Hong Kong, Li Ka Shing Fac Med HKUMed, Dept Microbiol, Hong Kong, Peoples R China; [Mok, Bobo Wing-Yee; Lau, Siu-Ying; Liu, Honglian; Zhang, Anna Junxia; Lee, Andrew Chak-Yiu; Chen, Honglin] Univ Hong Kong, Li Ka Shing Fac Med HKUMed, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China; [Ray-Jones, Helen; Malysheva, Valeriya; Spivakov, Mikhail] MRC London Inst Med Sci, London W12 0NN, England; [Parameswaran, Sreeja; Weirauch, Matthew T.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA; [Shum, Elaine] NYU, Div Med Oncol & Hematol, Langone Perlmutter Canc Ctr, New York, NY 10016 USA; [Jeyasekharan, Anand D.] Natl Univ Singapore, Natl Univ Hosp, Dept Haematol Oncol, Singapore 117599, Singapore; [Jeyasekharan, Anand D.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Heinz, Sven; Benner, Christopher] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92092 USA; [Richt, Juergen A.] Kansas State Univ, Ctr Excellence Emerging & Zoonot Anim Dis CEEZAD, Manhattan, KS 66506 USA; [Wayman, Joseph A.; Miraldi, Emily R.] Cincinnati Childrens Hosp, Div Immunobiol, Cincinnati, OH 45229 USA; [Wayman, Joseph A.; Miraldi, Emily R.] Cincinnati Childrens Hosp, Div Biomed Informat, Cincinnati, OH 45229 USA; [Gaudreault, Natasha N.; Meekins, David A.; Indran, Sabarish, V; Morozov, Igor; Trujillo, Jessie D.; Richt, Juergen A.] Kansas State Univ, Coll Vet Med, Diagnost Med & Pathobiol, 1800 Denison Ave, Manhattan, KS 66506 USA; [Guccione, Ernesto; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA; [Guccione, Ernesto; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY USA; [Melo, Betsaida Salom; Sebra, Robert] Icahn Sch Med Mt Sinai, Dept Genet & Genom, New York, NY 10029 USA; [Melo, Betsaida Salom; Sebra, Robert] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Bakker, Jan] Pontificia Univ Catolica Chile, Santiago, Chile; [Bakker, Jan] Erasmus MC Univ, Med Ctr Rotterdam, Rotterdam, Netherlands; [Bakker, Jan] NYU, Sch Med, Journal Crit Care, New York, NY USA; [Bakker, Jan] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Kaufman, David A.] NYU, Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY USA; [Moreira, Andre L.] NYU, Sch Med, Dept Pathol, New York, NY USA; [Carossino, Mariano; Balasuriya, Udeni B. R.] Louisiana State Univ, Sch Vet Med, Louisiana Anim Dis Diagnost Lab, Baton Rouge, LA 70803 USA; [Carossino, Mariano; Balasuriya, Udeni B. R.] Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA USA; [Byun, Minji] Icahn Sch Med Mt Sinai, Dept Med, Clin Immunol, New York, NY USA; [Albrecht, Randy A.; Schotsaert, Michael; Garcia-Sastre, Adolfo; TenOever, Benjamin R.; Marazzi, Ivan] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, One Gustave L Levy Pl,Box 1124, New York, NY 10029 USA; [Chanda, Sumit K.] Sanford Burnham Prebys Med Discovery Inst, Infect & Inflammatory Dis Ctr, Immun & Pathogenesis Program, La Jolla, CA 92037 USA; [TenOever, Benjamin R.] Icahn Sch Med Mt Sinai, Virus Engn Ctr Therapeut & Res, New York, NY 10029 USA; [Wayman, Joseph A.; Miraldi, Emily R.; Weirauch, Matthew T.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA; [Thiecke, Michiel J.] Enhanc3D Genom Ltd, Cambridge CB22 0AT, England; [Weirauch, Matthew T.] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA; [Weirauch, Matthew T.] Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; [Sebra, Robert] Sema4, Mt Sinai Venture, Stamford, CT USA; [Sebra, Robert] Icahn Sch Med Mt Sinai, Black Family Stem Cell Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; University of Hong Kong; University of Hong Kong; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; New York University; National University of Singapore; National University of Singapore; University of California System; University of California San Diego; Kansas State University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Kansas State University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Pontificia Universidad Catolica de Chile; Erasmus University Rotterdam; Erasmus MC; New York University; Columbia University; New York University; New York University; Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University; Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Sanford Burnham Prebys Medical Discovery Institute; Icahn School of Medicine at Mount Sinai; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Icahn School of Medicine at Mount Sinai	Marazzi, I (corresponding author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; Marazzi, I (corresponding author), Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.	ivan.marazzi@mssm.edu	Carossino, Mariano/AAV-1586-2020; Liu, Wen-Chun/AAU-3193-2021; Aydillo Gomez, Teresa Allende/W-4439-2019; LIU, WEN-CHUN/ABC-8722-2020; Bakker, Jan/A-4011-2009	Carossino, Mariano/0000-0003-3864-5915; Liu, Wen-Chun/0000-0003-0344-4371; Aydillo Gomez, Teresa Allende/0000-0003-3086-1058; Bakker, Jan/0000-0003-2236-7391; Albrecht, Randy/0000-0003-4008-503X; Shum, Elaine/0000-0002-0390-5716; Byun, Minji/0000-0002-2830-4079; Yildiz, Soner/0000-0002-7235-6108; Mok, Bobo/0000-0003-3187-2736; tenOever, Benjamin/0000-0003-0324-3078; Malysheva, Valeriya/0000-0002-0919-7845; Jordan, Tristan/0000-0002-0602-2871; Ho, Jessica Sook Yuin/0000-0003-2234-2602; Rathnasinghe, Raveen/0000-0002-1260-2493	NBAF Transition Funds [HHSN 272201400006C]; NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN 272201400006C]; Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases [HSHQDC-16-A-B0006]; NIAID [U19AI135972]; DOD grant [W81XWH-20-1-0270]; Defense Advanced Research Projects Agency [HR0011-19-2-0020]; JPB Foundation; Open Philanthropy Project [2020-215611 [5384]]; Swiss National Foundation (SNF) [P2GEP3_184202]; Burroughs Wellcome Fund (United States) [1017892]; Chan Zuckerberg Initiative (United States) [2018-191895]; Hirschl Young Investigator fellowship; NIH grants [U01AI150748, R01AI143840]; AMP Core of the Center of Emerging and Zoonotic Infectious Diseases of the National Institutes of Health [P20GM130448]	NBAF Transition Funds; NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS); Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases(United States Department of Homeland Security (DHS)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DOD grant; Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); JPB Foundation; Open Philanthropy Project; Swiss National Foundation (SNF)(Swiss National Science Foundation (SNSF)); Burroughs Wellcome Fund (United States); Chan Zuckerberg Initiative (United States); Hirschl Young Investigator fellowship; NIH grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AMP Core of the Center of Emerging and Zoonotic Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the staff of KSU Biosecurity Research Institute; the histological laboratory at the Kansas State Veterinary Diagnostic Laboratory (KSVDL); members of the Histology and Immunohistochemistry sections at the Louisiana Animal Disease Diagnostic Laboratory (LADDL); the CMG staff; and Bianca Artiaga, Dashzeveg Bold, Konner Cool, Emily Gilbert-Esparza, Chester McDowell, and Yonghai Li. We thank the teams at the Icahn School of Medicine at Mount Sinai, the Genomics and Mouse facilities, and Alan Soto from the Biorepository and Pathology Dean's CoRE. We thank Cindy Beharry, Nanyi Julia Zhao, Nancy Francoeur, Nataly Fishman, Marion Dejosez, Thomas Zwaka, and Carles Martinez-Romero for their help and advice. Luis Martinez (Texas Biomedical Research Institute) and the Center for Therapeutic Antibody Development (CTAD) (Thomas Moran, Andy Duty, and Thomas Kraus) kindly provided the NP1C7C7 antibody. This work was partially supported through grants from NBAF Transition Funds and the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) under contract number HHSN 272201400006C to A.G.-S.; the Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases under grant HSHQDC-16-A-B0006 to J.A.R.; CRIP (Center for Research for Influenza Pathogenesis CEIRS, contract HHSN272201400008C); supplements to NIAID grant U19AI135972 and DOD grant W81XWH-20-1-0270; the Defense Advanced Research Projects Agency (HR0011-19-2-0020); and the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 [5384]), and anonymous donors. S.Y. received funding from a Swiss National Foundation (SNF) Early Postdoc.Mobility fellowship (P2GEP3_184202). This work was partially supported by funding to I. Marazzi., specifically the Burroughs Wellcome Fund (United States; 1017892), the Chan Zuckerberg Initiative (United States; 2018-191895), the Hirschl Young Investigator fellowship, and NIH grants U01AI150748 and R01AI143840. Partial support by the AMP Core of the Center of Emerging and Zoonotic Infectious Diseases of the National Institutes of Health under award number P20GM130448 to J.R.	Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1038/s41591-020-0913-5, 10.1101/2020.03.17.20037713]; Anderson EL, 2008, P NATL ACAD SCI USA, V105, P14976, DOI 10.1038/s41598-019-45839-z; Ballance LT, 2006, PROG OCEANOGR, V69, P360, DOI 10.1016/j.pocean.2006.03.013; Banerjee AK, 2020, CELL, V183, P1325, DOI 10.1016/j.cell.2020.10.004; Banerjee A, 2020, EMERG INFECT DIS, V26, P2054, DOI 10.3201/eid2609.201495; Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Bost P, 2020, CELL, V181, P1475, DOI 10.1016/j.cell.2020.05.006; Cairns J, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0992-2; Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363; Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Chen LF, 2019, CELL REP, V26, P1174, DOI 10.1016/j.celrep.2019.01.032; Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005; Daniloski Z, 2021, CELL, V184, P92, DOI 10.1016/j.cell.2020.10.030; Del Valle D.M., 2020, NAT MED, V26, P1636, DOI DOI 10.1038/s41591-020-1051-9; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fukaya T, 2016, CELL, V166, P358, DOI 10.1016/j.cell.2016.05.025; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; Grajales-Reyes GE, 2020, SCIENCE, V369, P626, DOI 10.1126/science.abd2208; Guichard S, 2001, CLIN CANCER RES, V7, P3222; Heinz S, 2018, CELL, V174, P1522, DOI 10.1016/j.cell.2018.07.047; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; HOUGHTON PJ, 1995, CANCER CHEMOTH PHARM, V36, P393; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI 10.1073/pnas.2009799117; Kollmannsberger C, 1999, ONCOLOGY-BASEL, V56, P1, DOI 10.1159/000011923; Korotkevich G., 2021, BIORXIV, DOI [10.1101/060012v3, DOI 10.1101/060012, 10.1101/060012]; Lambert SA, 2019, NAT GENET, V51, P981, DOI 10.1038/s41588-019-0411-1; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lee S, 2020, TRENDS IMMUNOL, V41, P1083, DOI 10.1016/j.it.2020.10.005; Lei XB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17665-9; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lin YC, 2012, NAT IMMUNOL, V13, P1196, DOI 10.1038/ni.2432; Liu X, 2020, CELL, V182, P24, DOI 10.1016/j.cell.2020.06.023; Marazzi I, 2018, NAT REV MOL CELL BIO, V19, P245, DOI 10.1038/nrm.2017.113; Marazzi I, 2012, NATURE, V483, P428, DOI 10.1038/nature10892; Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182; McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Miller MS, 2015, NAT IMMUNOL, V16, P485, DOI 10.1038/ni.3132; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; Nagano T, 2017, NATURE, V547, P61, DOI 10.1038/nature23001; Nemati F, 2010, ANTI-CANCER DRUG, V21, P25, DOI 10.1097/CAD.0b013e3283300a29; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rao SSP, 2017, CELL, V171, P305, DOI 10.1016/j.cell.2017.09.026; Rialdi A, 2016, SCIENCE, V352, DOI 10.1126/science.aad7993; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; ROWINSKY EK, 1992, J CLIN ONCOL, V10, P647, DOI 10.1200/JCO.1992.10.4.647; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Schoenfelder S, 2015, GENOME RES, V25, P582, DOI 10.1101/gr.185272.114; Schwarzer W, 2017, NATURE, V551, P51, DOI 10.1038/nature24281; Senecal A, 2014, CELL REP, V8, P75, DOI 10.1016/j.celrep.2014.05.053; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01708; von Pawel J, 1999, J CLIN ONCOL, V17, P658, DOI 10.1200/JCO.1999.17.2.658; Wingett Steven, 2015, F1000Res, V4, P1310, DOI 10.12688/f1000research.7334.1; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zabidi MA, 2015, NATURE, V518, P556, DOI 10.1038/nature13994; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041	77	27	27	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 13	2021	184	10					2618	+	e17	10.1016/j.cell.2021.03.051	http://dx.doi.org/10.1016/j.cell.2021.03.051		MAY 2021	32	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	SF5YM	33836156	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000652830800009
J	Kolosenko, I; Goroshchuk, O; Vidarsdottir, L; Bjorklund, AC; Dowdy, SF; Palm-Apergi, C				Kolosenko, Iryna; Goroshchuk, Oksana; Vidarsdottir, Linda; Bjorklund, Ann-Charlotte; Dowdy, Steven F.; Palm-Apergi, Caroline			RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients	FASEB JOURNAL			English	Article						cytarabine; pediatric acute myeloid leukemia; Polo-like kinase; Prodrugs; RNA interference	TARGETING PLK1; VOLASERTIB; DELIVERY; NANOPARTICLES; CYTARABINE; INHIBITOR; TRIAL; SIRNA	Polo-like kinase 1 (Plk1) is an important regulator of the cell cycle and it is frequently overexpressed in cancer cells. Several small molecule inhibitors have been developed to target Plk1 and some of them have reached clinical trials in adults with acute myeloid leukemia (AML). Pediatric AML patients have a poor prognosis and survivors suffer from long-term side effects. As adult AML cells have an elevated expression of Plk1, AML is a disease candidate for Plk1 inhibition. However, the relative success of clinical trials have been hampered by adverse reactions. Herein, PLK1-targeting RNA interference (RNAi) prodrugs that enter cells without a trans-fection reagent are used to target PLK1 selectively in primary cells from pediatric AML patients. We show that PLK1 and PLK4 mRNA expression are significantly higher in pediatric AML patients when compared to healthy donors and that PLK1 is downregulated by on average 50% using RNAi prodrugs without a significant effect on other PLK family members. In addition, the RNAi prodrug-induced decrease in PLK1 can be used to potentiate the effect of cytarabine. In summary, PLK1-targeting RNAi prodrugs can decrease the elevated levels of PLK1 in primary cells from pediatric AML patients and sensitize pediatric AML cells to chemotherapeutics.	[Kolosenko, Iryna; Goroshchuk, Oksana; Vidarsdottir, Linda; Bjorklund, Ann-Charlotte; Palm-Apergi, Caroline] Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med Biomol & Cellular Med, 5th Floor,Halsovagen 7, S-14157 Stockholm, Sweden; [Dowdy, Steven F.] UCSD Sch Med, Dept Cellular & Mol Med, La Jolla, CA USA	Karolinska Institutet; Karolinska University Hospital; University of California System; University of California San Diego	Palm-Apergi, C (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med Biomol & Cellular Med, 5th Floor,Halsovagen 7, S-14157 Stockholm, Sweden.	caroline.palm.apergi@ki.se		Vidarsdottir, Linda/0000-0003-3082-1320; Goroshchuk, Oksana/0000-0002-1585-1962; Palm Apergi, Caroline/0000-0003-2236-2099	Swedish Childhood Cancer Foundation; Gunvor and Josef Aner Foundation; Ake Wiberg Foundation; Magnus Bergvall Foundation; Karolinska Institutets Forskningsstiftelser; Stiftelsen Clas Groschinskys Minnesfond	Swedish Childhood Cancer Foundation(European Commission); Gunvor and Josef Aner Foundation; Ake Wiberg Foundation; Magnus Bergvall Foundation; Karolinska Institutets Forskningsstiftelser; Stiftelsen Clas Groschinskys Minnesfond	Swedish Childhood Cancer Foundation; Gunvor and Josef Aner Foundation; Ake Wiberg Foundation; Magnus Bergvall Foundation; Karolinska Institutets Forskningsstiftelser; Stiftelsen Clas Groschinskys Minnesfond	Alexander S, 2015, LANCET ONCOL, V16, pE604, DOI 10.1016/S1470-2045(15)00197-7; [Anonymous], 2018, TECHNIQUES; Blum WG, 2020, CANCER-AM CANCER SOC, V126, P4668, DOI 10.1002/cncr.32904; Brandwein JM, 2015, THER ADV HEMATOL, V6, P80, DOI 10.1177/2040620715571077; Chevallier P, 2011, LEUKEMIA, V25, P939, DOI 10.1038/leu.2011.25; De Braud FG, 2013, J CLIN ONCOL, V31; Debacker AJ, 2020, MOL THER, V28, P1759, DOI 10.1016/j.ymthe.2020.06.015; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; Driscoll DL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111060; Megias-Vericat JE, 2018, ANN HEMATOL, V97, P1115, DOI 10.1007/s00277-018-3304-y; Ellis PM., 2013, J THORAC ONCOL, V8, pS2; Goroshchuk O, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59653-5; Goroshchuk O, 2019, ONCOGENE, V38, P1, DOI 10.1038/s41388-018-0443-5; Guo JF, 2017, MOL PHARMACEUT, V14, P940, DOI 10.1021/acs.molpharmaceut.6b01150; Hao ZL, 2015, ONCOTARGETS THER, V8, P1761, DOI 10.2147/OTT.S60762; Hou HA, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00674-7; Ikezoe T, 2009, LEUKEMIA, V23, P1564, DOI 10.1038/leu.2009.94; Jarfelt M, 2016, BRIT J HAEMATOL, V175, P577, DOI 10.1111/bjh.14374; Kassim Adetola A, 2017, Hematol Oncol Stem Cell Ther, V10, P245, DOI 10.1016/j.hemonc.2017.05.021; Kolosenko I, 2017, J CONTROL RELEASE, V261, P199, DOI 10.1016/j.jconrel.2017.07.002; Kristen AV, 2019, NEURODEGENER DIS MAN, V9, P5, DOI 10.2217/nmt-2018-0033; Landry B, 2016, J CONTROL RELEASE, V224, P8, DOI 10.1016/j.jconrel.2015.12.052; Lee KS, 2015, TRENDS PHARMACOL SCI, V36, P858, DOI 10.1016/j.tips.2015.08.013; Liu ZX, 2017, TRANSL ONCOL, V10, P22, DOI 10.1016/j.tranon.2016.10.003; McCarroll JA, 2015, ONCOTARGET, V6, P12020, DOI 10.18632/oncotarget.2664; Meade BR, 2014, NAT BIOTECHNOL, V32, P1256, DOI 10.1038/nbt.3078; Medinger Michael, 2016, Leuk Res Rep, V6, P39; Molgaard-Hansen L, 2011, PEDIATR BLOOD CANCER, V57, P1222, DOI 10.1002/pbc.22931; Molgaard-Hansen L, 2010, BRIT J HAEMATOL, V151, P447, DOI 10.1111/j.1365-2141.2010.08389.x; Ottmann OG, 2019, BRIT J HAEMATOL, V184, P1017, DOI 10.1111/bjh.15204; Peeters M, 2013, J CLIN ONCOL, V31; Pujade-Lauraine E, 2013, J CLIN ONCOL, V31; Raab M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1395; Renner AG, 2009, BLOOD, V114, P659, DOI 10.1182/blood-2008-12-195867; Richardson DR, 2019, SEMIN ONCOL NURS, V35, DOI 10.1016/j.soncn.2019.150957; Rudolph D, 2015, J PHARMACOL EXP THER, V352, P579, DOI 10.1124/jpet.114.221150; Setten RL, 2019, NAT REV DRUG DISCOV, V18, P421, DOI 10.1038/s41573-019-0017-4; Solans BP, 2018, CLIN PHARMACOKINET, V57, P379, DOI 10.1007/s40262-017-0566-9; Talati C, 2016, CRIT REV ONCOL HEMAT, V98, P200, DOI 10.1016/j.critrevonc.2015.10.013; Tsvetkov L, 2005, J BIOL CHEM, V280, P11943, DOI 10.1074/jbc.M413514200; Turcotte LM, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123477; van Ens D, 2020, BONE MARROW TRANSPL, V55, P2308, DOI 10.1038/s41409-020-0966-6; Wang NN, 2015, INT J MOL SCI, V16, P1266, DOI 10.3390/ijms16011266; Wang YQ, 2020, CANCER GENE THER, V27, P45, DOI 10.1038/s41417-019-0095-9; Wilhelmsson M, 2019, BONE MARROW TRANSPL, V54, P726, DOI 10.1038/s41409-018-0337-8; Yang ZG, 2014, NANOSCALE, V6, P9742, DOI 10.1039/c4nr01510j; Yim HS, 2009, MOL CELL BIOL, V29, P2609, DOI 10.1128/MCB.01277-08; Zeidan AM, 2020, CLIN CANCER RES, V26, P6132, DOI 10.1158/1078-0432.CCR-20-2586	48	1	1	2	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2021	35	5							e21476	10.1096/fj.202002454RR	http://dx.doi.org/10.1096/fj.202002454RR			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU6MM	33788972	hybrid			2023-01-03	WOS:000645260100019
J	Zhang, JX; Lyu, T; Cao, YM; Feng, H				Zhang, Jiaxue; Lyu, Tong; Cao, Yaming; Feng, Hui			Role of TCF-1 in differentiation, exhaustion, and memory of CD8(+) T cells: A review	FASEB JOURNAL			English	Review						cancer; CD8(+) T cells; exhaustion; immune memory; TCF-1; viral Infection	ALLERGIC RHINITIS MODEL; AIRWAY INFLAMMATION; MURINE MODEL; SUBSTANCE-P; CHANNEL TRPA1; GUINEA-PIG; ASTHMA; CHALLENGE; EXPRESSION; RESPONSIVENESS	T cell factor-1 (TCF-1) (encoded by the TCF7 gene) is a transcription factor that plays important role during the T cell development and differentiation for T cell to exercise its functions including producing memory T cells. Not only TCF-1 can modulate the T cell development but also exerts various effects on the differentiation and function of mature CD8(+) T cells. In addition, it drives the production and maintenance of the immune response of CD8(+) T cells after PD-1 checkpoint blockade therapy. TCF-1 can serve as a potential target of immunotherapy and may provide promising novel treatment strategies for patients with cancer and infections. Moreover, TCF-1 is a potential biomarker of CD8(+) T cell functionality to predict the efficacy of immunotherapy in fighting against cancer and infections. Herein, we summarize the role of TCF-1 in T cell development and its applications in the treatment of cancer and infectious diseases.	[Zhang, Jiaxue] China Med Univ, Clin Med Fac 1, Shenyang, Liaoning, Peoples R China; [Lyu, Tong; Cao, Yaming; Feng, Hui] China Med Univ, Coll Basic Med Sci, Dept Immunol, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China	China Medical University; China Medical University	Feng, H (corresponding author), China Med Univ, Coll Basic Med Sci, Dept Immunol, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China.	hfeng@cmu.edu.cn						Andre E, 2008, J CLIN INVEST, V118, P2574, DOI 10.1172/JCI34886; Bautista DM, 2013, ANNU REV PHYSIOL, V75, P181, DOI 10.1146/annurev-physiol-030212-183811; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Bessac BF, 2008, J CLIN INVEST, V118, P1899, DOI 10.1172/JCI34192; Bonay M, 2006, ALLERGY, V61, P111, DOI 10.1111/j.1398-9995.2006.00967.x; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Buch TRH, 2013, CHEM-BIOL INTERACT, V206, P462, DOI 10.1016/j.cbi.2013.08.012; Caceres AI, 2009, P NATL ACAD SCI USA, V106, P9099, DOI 10.1073/pnas.0900591106; Compalati E, 2010, EXPERT REV CLIN IMMU, V6, P413, DOI [10.1586/ECI.10.15, 10.1586/eci.10.15]; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; Deng HY, 2019, ALLERGY, V74, P731, DOI 10.1111/all.13647; Eid SR, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-48; Fang ZF, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.OA3541; Hens G, 2011, AM J RESP CELL MOL, V44, P517, DOI 10.1165/rcmb.2009-0425OC; Hirano A, 2006, AM J RESP CELL MOL, V35, P366, DOI 10.1165/rcmb.2005-0452OC; Ikeda RK, 2003, J IMMUNOL, V171, P4860, DOI 10.4049/jimmunol.171.9.4860; Inui K, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.13098; Kaelberer MM, 2016, JOVE-J VIS EXP, DOI 10.3791/53917; KleinJan A, 2010, CLIN EXP ALLERGY, V40, P494, DOI 10.1111/j.1365-2222.2009.03417.x; Leynaert N, 2004, J ALLERGY CLIN IMMUN, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Liu ZY, 2015, AM J PHYSIOL-GASTR L, V308, pG482, DOI 10.1152/ajpgi.00374.2014; McCusker C, 2002, J ALLERGY CLIN IMMUN, V110, P891, DOI 10.1067/mai.2002.130048; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; Mukaida N, 2003, AM J PHYSIOL-LUNG C, V284, pL566, DOI 10.1152/ajplung.00233.2002; Mukhopadhyay I, 2011, J RECEPT SIG TRANSD, V31, P350, DOI 10.3109/10799893.2011.602413; Nassenstein C, 2008, J PHYSIOL-LONDON, V586, P1595, DOI 10.1113/jphysiol.2007.148379; Nassini R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042454; OKAMOTO Y, 1993, J IMMUNOL, V151, P4391; Passalacqua G, 2001, CURR OPIN ALLERGY CL, V1, P7; Reznikov LR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166089; Samitas K, 2018, ALLERGY, V73, P993, DOI 10.1111/all.13373; Saranz RJ, 2017, CLIN EXP ALLERGY, V47, P988, DOI 10.1111/cea.12938; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007; Taylor-Clark TE, 2009, AM J RESP CELL MOL, V40, P756, DOI 10.1165/rcmb.2008-0292OC; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Togias A, 1999, ALLERGY, V54, P94, DOI 10.1111/j.1398-9995.1999.tb04410.x; Tourangeau LM, 2011, J ALLERGY CLIN IMMUN, V127, pAB52, DOI 10.1016/j.jaci.2010.12.218; Tsunematsu M, 2007, LIFE SCI, V80, P1388, DOI 10.1016/j.lfs.2006.12.038; Underwood S, 1995, EUR RESPIR J, V8, P2104, DOI 10.1183/109031936.95.08122104; Van Gerven L, 2012, RHINOLOGY, V50, P227, DOI [10.4193/Rhino11.152, 10.4193/Rhino.11.152]; Wang W, 2016, ALLERGY, V71, P378, DOI 10.1111/all.12808; Wang Y, 2005, CLIN EXP ALLERGY, V35, P1104, DOI 10.1111/j.1365-2222.2005.02301.x; Xie JX, 2015, ALLERGY ASTHMA IMMUN, V7, P76, DOI 10.4168/aair.2015.7.1.76; Yarova PL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0282; Yorgancioglu A, 2008, TUBERK TORAK, V56, P224; Zhang QL, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-61	50	7	7	3	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2021	35	5							e21549	10.1096/fj.202002566R	http://dx.doi.org/10.1096/fj.202002566R			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU6MM	33913198				2023-01-03	WOS:000645260100083
J	De Blasi, RA; Campagna, G; Finazzi, S				De Blasi, Roberto Alberto; Campagna, Giuseppe; Finazzi, Stefano			A dynamic Bayesian network model for predicting organ failure associations without predefining outcomes	PLOS ONE			English	Article							SOFA SCORE; SEPSIS; TIME	Critical care medicine has been a field for Bayesian networks (BNs) application for investigating relationships among failing organs. Criticisms have been raised on using mortality as the only outcome to determine the treatment efficacy. We aimed to develop a dynamic BN model for detecting interrelationships among failing organs and their progression, not predefining outcomes and omitting hierarchization of organ interactions. We collected data from 850 critically ill patients from the national database used in many intensive care units. We considered as nodes the organ failure assessed by a score as recorded daily. We tested several possible DBNs and used the best bootstrapping results for calculating the strength of arcs and directions. The network structure was learned using a hill climbing method. The parameters of the local distributions were fitted with a maximum of the likelihood algorithm. The network that best satisfied the accuracy requirements included 15 nodes, corresponding to 5 variables measured at three times: ICU admission, second and seventh day of ICU stay. From our findings some organ associations had probabilities higher than 50% to arise at ICU admittance or in the following days persisting over time. Our study provided a network model predicting organ failure associations and their evolution over time. This approach has the potential advantage of detecting and comparing the effects of treatments on organ function.	[De Blasi, Roberto Alberto; Campagna, Giuseppe] Univ Roma Sapienza, Dipartimento Sci Med Chirurg & Med Traslaz, Osped St Adrea, Rome, Italy; [Finazzi, Stefano] Ist Ric Farmacol Mario Negri IRCCS, Lab Clin Data Sci, Dipartimento Salute Pubbl, Ranica, BG, Italy	Sapienza University Rome	De Blasi, RA (corresponding author), Univ Roma Sapienza, Dipartimento Sci Med Chirurg & Med Traslaz, Osped St Adrea, Rome, Italy.	radbl@libero.it		De Blasi, Roberto/0000-0002-1069-2544	Dipartimento di Scienze Medico-Chirurgiche e Medicina Traslazionale of University of Rome "La Sapienza" [000323_19]	Dipartimento di Scienze Medico-Chirurgiche e Medicina Traslazionale of University of Rome "La Sapienza"	Giuseppe Campagna received a fund for data analysis from the research funds of the Dipartimento di Scienze Medico-Chirurgiche e Medicina Traslazionale of University of Rome "La Sapienza" for the analysis of data (n. 000323_19 master del.04.03.020; PI: GC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armstrong PW, 2017, CIRCULATION, V135, P2299, DOI 10.1161/CIRCULATIONAHA.117.026229; Bueno MLP, 2016, J BIOMED INFORM, V61, P283, DOI 10.1016/j.jbi.2016.05.003; Chickering D, 1997, P 13 C UNC ART INT P; COOPER GF, 1992, MACH LEARN, V9, P309, DOI 10.1023/A:1022649401552; Daly R, 2011, KNOWL ENG REV, V26, P99, DOI 10.1017/S0269888910000251; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Ghahramani Z, 1998, LECT NOTES ARTIF INT, V1387, P168, DOI 10.1007/BFb0053999; Imoto S., 2002, GENOME INFORM, V13, P369; Jeschke MG, 2016, CRIT CARE MED, V44, P1950, DOI 10.1097/CCM.0000000000001930; KJAERULFF U, 1995, INT J FORECASTING, V11, P89, DOI 10.1016/0169-2070(94)02003-8; Korb KB, 2010, COM SCI DAT; Lucas PJF, 2004, ARTIF INTELL MED, V30, P201, DOI 10.1016/j.artmed.2003.11.001; Mania S., 2004, CAUSAL DISCOVERY USI; Nagarajan R, 2013, BAYESIAN NETWORKS R; Oda S, 2000, INTENS CARE MED, V26, P1786, DOI 10.1007/s001340000710; Peelen L, 2010, J BIOMED INFORM, V43, P273, DOI 10.1016/j.jbi.2009.10.002; Sandri M, 2014, J BIOMED INFORM, V48, P106, DOI 10.1016/j.jbi.2013.12.008; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; SHORT RD, 1981, IEEE T INFORM THEORY, V27, P622, DOI 10.1109/TIT.1981.1056403; Sucar LE, 2015, ADV COMPUT VIS PATT, P1, DOI 10.1007/978-1-4471-6699-3; Thachil J, 2017, BRIT J HAEMATOL, V177, P27, DOI 10.1111/bjh.14482; van der Heijden M, 2014, J BIOMED INFORM, V48, P94, DOI 10.1016/j.jbi.2013.12.007; VanderWeele TJ, 2017, EPIDEMIOLOGY, V28, P399, DOI 10.1097/EDE.0000000000000641; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	25	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2021	16	4							e0250787	10.1371/journal.pone.0250787	http://dx.doi.org/10.1371/journal.pone.0250787			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XL	33909682	Green Published, gold			2023-01-03	WOS:000662174400077
J	Pompeu, DD; de Paula, BLF; Barros, APO; Nunes, SC; Carneiro, AMP; Araujo, JLN; Silva, CM				Pompeu, Danielle da Silva; Freitas de Paula, Brennda Lucy; Oliveira Barros, Antonia Patricia; Nunes, Samir Costa; Pingarilho Carneiro, Alexandra Melo; Nogueira Araujo, Jesuina Lamartine; Silva, Cecy Martins			Combination of strontium chloride and photobiomodulation in the control of tooth sensitivity post-bleaching: A split-mouth randomized clinical trial	PLOS ONE			English	Article							LEVEL LASER THERAPY; HUMAN DENTAL-PULP; HYDROGEN-PEROXIDE; DESENSITIZING AGENT; DOUBLE-BLIND; IRRADIATION; EFFICACY; ENAMEL; HYPERSENSITIVITY; MITOCHONDRIAL	Objective This split-mouth randomized controlled clinical trial assessed the effect of 10% strontium chloride in combination with photobiomodulation (PBM) for the control of tooth sensitivity (TS) post-bleaching. Methods The upper/lower, right and left quadrants of fifty volunteers were randomized and allocated to four groups (n = 25): PLACEBO-placebo gel + simulation of PBM; Placebo + PBM; STRONTIUM-10% strontium chloride + simulation of PBM; and PBM + STRONTIUM-10% strontium chloride + PBM. All groups received tooth bleaching treatment with 35% hydrogen peroxide. For the PBM treatment, the laser tip was positioned in the apical and cervical regions of the teeth bleached in the respective hemi-arch. The laser system was operated in continuous mode, using 1.7 J of energy. A dose of 60 J/cm(2) was applied to each point for 16 seconds under 808 nm near-infrared light (100mW of power), with a point area of 0.028 cm(2). TS was assessed during a 21-day follow-up, using the modified visual analogue scale. Results In the intragroup assessment, the Friedman test indicated that PBM + STRONTIUM promoted the greatest reduction in TS after the second week of treatment (p <= 0.05). The Wilcoxon-Mann-Whitney test indicated that the groups Placebo + PBM, STRONTIUM, and STRONTIUM + PBM did not differ statistically (p >= 0.05) in the first and third weeks of treatment The group PLACEBO exhibited the greatest TS in the first three days after each bleaching session. Conclusion The combination of 10% strontium chloride with PBM was effective in reducing post-bleaching TS; however, the combination of 10% strontium chloride with PBM was effective in reducing post-bleaching TS; however, it did not differ from the individual use of Placebo + PBM or STRONTIUM groups assessed after 21 days of follow-up.	[Pompeu, Danielle da Silva; Oliveira Barros, Antonia Patricia; Nunes, Samir Costa] Fed Univ Para, Sch Dent, Belem, Para, Brazil; [Freitas de Paula, Brennda Lucy; Pingarilho Carneiro, Alexandra Melo; Nogueira Araujo, Jesuina Lamartine; Silva, Cecy Martins] Fed Univ Para, Postgrad Program Dent, Belem, Para, Brazil	Universidade Federal do Para; Universidade Federal do Para	Silva, CM (corresponding author), Fed Univ Para, Postgrad Program Dent, Belem, Para, Brazil.	cecymsilva@gmail.com	Silva, Cecy/ABC-8878-2020; Barros, Antonia Patrícia Oliveira/GQH-4452-2022	Silva, Cecy/0000-0002-7870-8848; Nunes, Samir/0000-0001-5651-7058	National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq) [161846/2018-1]; National Council for Scientific andTechnological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq) [130961/2019-1]; Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES) [88882.445619/2019-01]	National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); National Council for Scientific andTechnological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	APOB received scholarship support from National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -CNPq) [161846/2018-1]. AMPC received scholarship support from National Council for Scientific andTechnological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -CNPq) [130961/2019-1]. BLFP received scholarship support from Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior CAPES) [88882.445619/2019-01].	Alencar CD, 2018, J ESTHET RESTOR DENT, V30, P352, DOI 10.1111/jerd.12386; Alencar CD, 2017, AM J DENT, V30, P267; Anders JJ, 2015, PHOTOMED LASER SURG, V33, P183, DOI 10.1089/pho.2015.9848; Pierote JJA, 2020, J APPL ORAL SCI, V28, DOI 10.1590/1678-7757-2019-0755; Bagis S, 2002, LASER SURG MED, V30, P376, DOI 10.1002/lsm.10057; Bender IB, 2000, J ENDODONT, V26, P175, DOI 10.1097/00004770-200003000-00012; Bistey T, 2007, J DENT, V35, P325, DOI 10.1016/j.jdent.2006.10.004; Bortolatto J F, 2014, J Dent Res, V93, p66S, DOI 10.1177/0022034514537466; BYERS MR, 1983, ANAT REC, V205, P441, DOI 10.1002/ar.1092050409; Cavalli V, 2004, J ORAL REHABIL, V31, P155, DOI 10.1111/j.1365-2842.2004.01138.x; Calheiros APC, 2017, PHOTOMED LASER SURG, V35, P415, DOI 10.1089/pho.2017.4282; Poubel LAD, 2019, CLIN ORAL INVEST, V23, P435, DOI 10.1007/s00784-018-2452-8; de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201; Duque CCD, 2017, CLIN ORAL INVEST, V21, P2509, DOI 10.1007/s00784-017-2049-7; de Paula B, 2019, CLIN ORAL INVEST, V23, P2723, DOI 10.1007/s00784-018-2715-4; Costa CAD, 2010, ORAL SURG ORAL MED O, V109, pE59, DOI 10.1016/j.tripleo.2009.12.002; DEDHIYA MG, 1973, J DENT RES, V52, P1097, DOI 10.1177/00220345730520051901; Diniz ACS, 2018, OPER DENT, V43, P472, DOI 10.2341/17-020-C; Durgalakshmi D, 2018, BIOMATER SCI-UK, V6, P1764, DOI 10.1039/c8bm00362a; ESPÍNDOLA-CASTRO Luís Felipe, 2020, Rev. odontol. UNESP, V49, pe20200023, DOI 10.1590/1807-2577.02320; Esposito P, 2003, EUR J ORAL SCI, V111, P454, DOI 10.1034/j.1600-0722.2003.00062.x; Favaro-Pipi E, 2011, PHOTOMED LASER SURG, V29, P311, DOI 10.1089/pho.2010.2841; Fonseca AS, 2010, LASER SURG MED, V42, P481, DOI 10.1002/lsm.20921; Frozanfar A, 2013, IRAN J BASIC MED SCI, V16, P1071; Gerritsen AE, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-126; Gibson M, 2013, J DENT, V41, P668, DOI 10.1016/j.jdent.2013.06.003; GORDON MW, 1960, ARCH BIOCHEM BIOPHYS, V91, P75, DOI 10.1016/0003-9861(60)90457-4; Hamblin MR, 2017, AIMS BIOPHYS, V4, P337, DOI 10.3934/biophy.2017.3.337; Huang M, 2016, ACTA BIOMATER, V38, P201, DOI 10.1016/j.actbio.2016.04.037; Keshri GK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166705; Kielbassa AM, 2015, QUINTESSENCE INT, V46, P881, DOI 10.3290/j.qi.a34700; Kimura Y, 2000, J CLIN PERIODONTOL, V27, P715, DOI 10.1034/j.1600-051x.2000.027010715.x; Kobler A, 2008, QUINTESSENCE INT, V39, P321; Kothari S, 2019, J DENT, V84, P22, DOI 10.1016/j.jdent.2019.03.007; Kwon SR, 2015, J ESTHET RESTOR DENT, V27, P240, DOI 10.1111/jerd.12152; Lesaffre E, 2009, STAT MED, V28, P3470, DOI 10.1002/sim.3634; Lin KY, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903-018-0694-0; Silveira PCL, 2011, LASER MED SCI, V26, P125, DOI 10.1007/s10103-010-0839-0; Low SB, 2015, OPEN DENT J, V9, P92, DOI 10.2174/1874364101509010092; Machado LS, 2013, INT J PERIODONT REST, V33, P209, DOI 10.11607/prd.1410; Maghaireh GA, 2014, OPER DENT, V39, P239, DOI 10.2341/12-527-C; Majji Priyanka, 2016, Indian J Dent Res, V27, P477, DOI 10.4103/0970-9290.195618; Markowitz K, 1992, Proc Finn Dent Soc, V88 Suppl 1, P39; Martini EC, 2020, CLIN ORAL INVEST, V24, P385, DOI 10.1007/s00784-019-02942-9; Martins LM, 2020, OPER DENT, V45, pE1, DOI 10.2341/18-149-C; Matsumoto K, 2007, J ORAL LASER APPL, V7, P7; Mehta D, 2018, J ESTHET RESTOR DENT, V30, P254, DOI 10.1111/jerd.12374; Mehta D, 2013, EUR J ORAL SCI, V121, P477, DOI 10.1111/eos.12067; Cardenas AFM, 2019, CLIN ORAL INVEST, V23, P3673, DOI 10.1007/s00784-019-03042-4; Moosavi H, 2016, LASER MED SCI, V31, P713, DOI 10.1007/s10103-016-1913-z; Mushashe Amanda-Mahammad, 2018, J Clin Exp Dent, V10, pe772, DOI 10.4317/jced.54967; Mussttaf RA, 2019, INT J RADIAT BIOL, V95, P120, DOI 10.1080/09553002.2019.1524944; Nammour S, 2017, PHOTOMED LASER SURG, V35, P629, DOI 10.1089/pho.2016.4256; Nanjundasetty Jyothi Kashi, 2016, J Conserv Dent, V19, P207, DOI 10.4103/0972-0707.181927; Park HJ, 2004, DENT MATER J, V23, P517, DOI 10.4012/dmj.23.517; Parreiras SO, 2018, J AM DENT ASSOC, V149, P281, DOI 10.1016/j.adaj.2017.10.025; Passarella S, 2014, J PHOTOCH PHOTOBIO B, V140, P344, DOI 10.1016/j.jphotobiol.2014.07.021; De Freitas ACP, 2011, MICROSC RES TECHNIQ, V74, P1069, DOI 10.1002/jemt.20996; Pesevska S, 2010, LASER MED SCI, V25, P647, DOI 10.1007/s10103-009-0685-0; Pihlstrom BL, 2010, J DENT RES, V89, P759, DOI 10.1177/0022034510374737; Reed MD, 2014, J CLIN PHARMACOL, V54, P241, DOI 10.1002/jcph.250; Reis A, 2011, OPER DENT, V36, P590, DOI 10.2341/10-173-C; Rezazadeh F, 2019, J LASERS MED SCI, V10, P1, DOI 10.15171/jlms.2019.01; Rezende M, 2016, OPER DENT, V41, P578, DOI 10.2341/15-207-C; Rezende M, 2016, J DENT, V45, P1, DOI 10.1016/j.jdent.2015.11.003; ROSS MR, 1961, J PERIODONTOL, V32, P49, DOI 10.1902/jop.1961.32.1.49; Saeki K, 2016, DENT MATER, V32, P240, DOI 10.1016/j.dental.2015.11.020; Sato C, 2013, J DENT RES, V92, P187, DOI 10.1177/0022034512470831; Sfondrini MF, 2018, EUR J PAEDIATR DENT, V19, P61, DOI 10.23804/ejpd.2018.19.01.11; Silva RC., 2018, J CLIN DIAGN RES, V12, pZC01, DOI [10.7860/JCDR/2018/37325.12340, DOI 10.7860/JCDR/2018/37325.12340]; Soares DG, 2014, J DENT, V42, P185, DOI 10.1016/j.jdent.2013.10.021; Soares Diana Gabriela, 2013, Braz. Dent. J., V24, P121, DOI 10.1590/0103-6440201302161; Sommer AP, 2019, PHOTOBIOMODULATION P, V37, P336, DOI 10.1089/photob.2018.4606; Tay LY, 2009, J AM DENT ASSOC, V140, P1245, DOI 10.14219/jada.archive.2009.0047; Turner L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000030.pub2; Vitale MC, 2018, CASE REP DENT, V2018, DOI 10.1155/2018/3048429; WAKABAYASHI H, 1993, LASER SURG MED, V13, P605, DOI 10.1002/lsm.1900130603; Wang YN, 2015, J DENT, V43, P913, DOI 10.1016/j.jdent.2015.03.015; White M, 1999, J ALLERGY CLIN IMMUN, V103, pS378, DOI 10.1016/S0091-6749(99)70215-0; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yang ZY, 2009, AM J DENT, V22, P283; Younger J, 2009, CURR PAIN HEADACHE R, V13, P39, DOI 10.1007/s11916-009-0009-x	82	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2021	16	4							e0250501	10.1371/journal.pone.0250501	http://dx.doi.org/10.1371/journal.pone.0250501			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XL	33909659	gold, Green Published			2023-01-03	WOS:000662174400052
J	Schwandt, HM; Boulware, A; Corey, J; Herrera, A; Hudler, E; Imbabazi, C; King, I; Linus, J; Manzi, I; Merrit, M; Mezier, L; Miller, A; Morris, H; Musemakweli, D; Musekura, U; Mutuyimana, D; Ntakarutimana, C; Patel, N; Scanteianu, A; Shemeza, BE; Sterling-Donaldson, G; Umutoni, C; Uwera, L; Zeiler, M; Feinberg, S				Schwandt, Hilary M.; Boulware, Angel; Corey, Julia; Herrera, Ana; Hudler, Ethan; Imbabazi, Claudette; King, Ilia; Linus, Jessica; Manzi, Innocent; Merrit, Madelyn; Mezier, Lyn; Miller, Abigail; Morris, Haley; Musemakweli, Dieudonne; Musekura, Uwase; Mutuyimana, Divine; Ntakarutimana, Chimene; Patel, Nirali; Scanteianu, Adriana; Shemeza, Biganette-Evidente; Sterling-Donaldson, Gi'anna; Umutoni, Chantal; Uwera, Lyse; Zeiler, Madeleine; Feinberg, Seth			" horizontal ellipsis we have to think first what we are going to feed our children before we have them horizontal ellipsis ": Rwandan women use family planning to provide a better life for their children	PLOS ONE			English	Article							CONTRACEPTION; QUANTITY; QUALITY; MEN	Use of modern contraception in Rwanda has risen dramatically over a short time period. To better understand contraceptive users' motivations for family planning services in Rwanda, 32 in-depth interviews with contraceptive users and eight focus groups with 88 family planning providers were conducted in Rwanda's Musanze and Nyamasheke districts. Study participants noted how family planning is critical for providing a better life for children. Family planning gives mothers independence from childcare to work in order to provide for their children's wellbeing. Family planning presented an opportunity for generational upward mobility and was perceived as a way to contribute positively to society.	[Schwandt, Hilary M.; Miller, Abigail; Zeiler, Madeleine] Western Washington Univ, Fairhaven Coll, Bellingham, WA 98225 USA; [Boulware, Angel] Spelman Coll, Atlanta, GA 30314 USA; [Corey, Julia] Wheaton Coll, Norton, MA 02766 USA; [Herrera, Ana] Northwest Vista Community Coll, San Antonio, TX USA; [Hudler, Ethan] Whatcom Community Coll, Bellingham, WA USA; [Imbabazi, Claudette; Manzi, Innocent; Musemakweli, Dieudonne; Mutuyimana, Divine; Shemeza, Biganette-Evidente; Umutoni, Chantal; Uwera, Lyse] INES, Ruhengeri, Ruhengeri, Musanze, Rwanda; [King, Ilia] Xavier Univ, New Orleans, LA 70125 USA; [Linus, Jessica] UMBC, Baltimore, MD USA; [Merrit, Madelyn; Feinberg, Seth] Western Washington Univ, Dept Sociol, Bellingham, WA 98225 USA; [Mezier, Lyn] SUNY Coll Oswego, Oswego, NY USA; [Morris, Haley] Western Oregon Univ, Monmouth, OR USA; [Musekura, Uwase] Eastern Oregon Univ, La Grande, OR USA; [Ntakarutimana, Chimene] Univ Kentucky, Lexington, KY USA; [Patel, Nirali] Arcadia Univ, Glenside, PA USA; [Sterling-Donaldson, Gi'anna] Drexel Univ, Philadelphia, PA 19104 USA	Western Washington University; Spelman College; Xavier University of Louisiana; University System of Maryland; University of Maryland Baltimore County; Western Washington University; State University of New York (SUNY) System; State University of New York (SUNY) - Oswego; Western Oregon University; Eastern Oregon University; University of Kentucky; Drexel University	Schwandt, HM (corresponding author), Western Washington Univ, Fairhaven Coll, Bellingham, WA 98225 USA.	hilary.schwandt@wwu.edu	Corey, Julia/AGQ-7115-2022	Corey, Julia/0000-0002-4296-2975; Scanteianu, Adriana/0000-0001-5491-0227; Schwandt, Hilary/0000-0003-3959-9594	National Science Foundation (NSF) under the Research for Undergraduates (REU) funding stream [1852411]; NSF grant	National Science Foundation (NSF) under the Research for Undergraduates (REU) funding stream; NSF grant(National Science Foundation (NSF))	The funding for this research came from the National Science Foundation (NSF) under the Research for Undergraduates (REU) funding stream, grant number 1852411. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Two of the authors received two weeks of their salary from this NSF grant, they are: Hilary Schwandt and Seth Feinberg.	Alano A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203432; [Anonymous], 1993, BERL SCI SOFTW DEV; BECKER GS, 1976, J POLIT ECON, V84, pS143, DOI 10.1086/260536; BECKER GS, 1973, J POLIT ECON, V81, pS279, DOI 10.1086/260166; Brunie Aurelie, 2013, Int J Gynaecol Obstet, V123 Suppl 1, pe11, DOI 10.1016/j.ijgo.2013.07.005; Bucagu M, 2012, REPROD HEALTH MATTER, V20, P50, DOI 10.1016/S0968-8080(12)39611-0; Frost JJ, 2013, CONTRACEPTION, V87, P465, DOI 10.1016/j.contraception.2012.08.012; Green J., 2004, QUALITATIVE METHODS; Koffi TB, 2018, GLOB HEALTH-SCI PRAC, V6, P316, DOI 10.9745/GHSP-D-17-00471; Ministry of Health Rwanda, 2015, NAT COMM HLTH POL; Muhoza DN, 2016, J POPUL RES, V33, P361, DOI 10.1007/s12546-016-9177-9; National Institute of Statistics of Rwanda Ministry of Finance and Economic Planning Ministry of Health The DHS Program ICF International, 2016, DHS PROGR ICF INT RW; Repubic of Rwanda Ministry of Finance and Economic Planning, 2000, RWAND VIS 2020; Republic of Rwanda Ministry of Health, 2012, FAM PLANN POL; Schwandt HM, 2018, CONTRACEP REPROD MED, V3, DOI 10.1186/s40834-018-0072-y; Shattuck D, 2011, AM J PUBLIC HEALTH, V101, P1089, DOI 10.2105/AJPH.2010.300091; Singh S, 2009, ADDING IT COSTS BENE; Solo J, 2008, FAMILY PLANNING RWAN; Stephenson R, 2012, GLOB PUBLIC HEALTH, V7, P618, DOI 10.1080/17441692.2012.672581; Ulin PR, 2005, QUALITATIVE RES METH; Westoff CF, 2013, POPUL DEV REV, V38, P169, DOI 10.1111/j.1728-4457.2013.00558.x; Withers M, 2015, CULT HEALTH SEX, V17, P1132, DOI 10.1080/13691058.2015.1043144; Wolff B, 2000, STUD FAMILY PLANN, V31, P124, DOI 10.1111/j.1728-4465.2000.00124.x; Zulu EM, 2012, ASSESSMENT DRIVERS P	24	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0246132	10.1371/journal.pone.0246132	http://dx.doi.org/10.1371/journal.pone.0246132			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RT0DC	33886566	gold, Green Published			2023-01-03	WOS:000644138300005
J	Szabo, L; Molnar, R; Tomesz, A; Deutsch, A; Darago, R; Nowrasteh, G; Varjas, T; Nemeth, B; Budan, F; Kiss, I				Szabo, Laszlo; Molnar, Richard; Tomesz, Andras; Deutsch, Arpad; Darago, Richard; Nowrasteh, Ghodratollah; Varjas, Timea; Nemeth, Balazs; Budan, Ferenc; Kiss, Istvan			The effects of flavonoids, green tea polyphenols and coffee on DMBA induced LINE-1 DNA hypomethylation	PLOS ONE			English	Article							OXIDATIVE STRESS; DIETARY FLAVONOIDS; DOWN-REGULATION; CANCER; METHYLATION; GLUTATHIONE; CELLS; MECHANISMS; PREVENTION; PROLIFERATION	The intake of carcinogenic and chemopreventive compounds are important nutritional factors related to the development of malignant tumorous diseases. Repetitive long interspersed element-1 (LINE-1) DNA methylation pattern plays a key role in both carcinogenesis and chemoprevention. In our present in vivo animal model, we examined LINE-1 DNA methylation pattern as potential biomarker in the liver, spleen and kidney of mice consuming green tea (Camellia sinensis) extract (catechins 80%), a chinese bayberry (Morella rubra) extract (myricetin 80%), a flavonoid extract (with added resveratrol) and coffee (Coffee arabica) extract. In the organs examined, carcinogen 7,12-dimethylbenz(a)anthracene (DMBA)-induced hypomethylation was prevented by all test materials except chinese bayberry extract in the kidneys. Moreover, the flavonoid extract caused significant hypermethylation in the liver compared to untreated controls and to other test materials. The tested chemopreventive substances have antioxidant, anti-inflammatory properties and regulate molecular biological signaling pathways. They increase glutathione levels, induce antioxidant enzymes, which decrease free radical damage caused by DMBA, and ultimately, they are able to increase the activity of DNA methyltransferase enzymes. Furthermore, flavonoids in the liver may inhibit the procarcinogen to carcinogen activation of DMBA through the inhibition of CYP1A1 enzyme. At the same time, paradoxically, myricetin can act as a prooxidant as a result of free radical damage, which can explain that it did not prevent hypomethylation in the kidneys. Our results demonstrated that LINE-1 DNA methylation pattern is a useful potential biomarker for detecting and monitoring carcinogenic and chemopreventive effects of dietary compounds.	[Szabo, Laszlo; Molnar, Richard; Tomesz, Andras; Deutsch, Arpad; Darago, Richard; Nowrasteh, Ghodratollah; Varjas, Timea; Nemeth, Balazs; Budan, Ferenc; Kiss, Istvan] Univ Pecs, Med Sch, Dept Publ Hlth Med, Pecs, Hungary; [Budan, Ferenc] Univ Pecs, Med Sch, Inst Physiol, Pecs, Hungary; [Budan, Ferenc] Univ Pannonia, Inst Environm Engn, Fac Engn, Veszprem, Hungary; [Budan, Ferenc] Univ Pecs, Szentagothai Res Ctr, Pecs, Hungary	University of Pecs; University of Pecs; University of Pannonia; University of Pecs	Szabo, L (corresponding author), Univ Pecs, Med Sch, Dept Publ Hlth Med, Pecs, Hungary.	laszlo.szabo.pte@gmail.com	Nemeth, Balazs/AAP-1660-2021; Budán, Ferenc/AAW-1481-2020	Nemeth, Balazs/0000-0002-4914-9872; Kiss, Istvan/0000-0002-7558-1300; Budan, Ferenc/0000-0003-1562-9496; Varjas, Timea/0000-0002-4950-0669; Molnar, Richard/0000-0001-8600-0842	Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology in Hungary	Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology in Hungary	This work was supported by the Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology in Hungary, within the framework of the "Innovation for the sustainable life and environment" thematic programme of the University of Pecs. The authors received no specific funding for this work.	Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Andrea SK, 2018, ORVOSI HETILAP, V159, P3, DOI 10.1556/650.2018.30927; Aslan B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8351; Baba Y, 2018, DIGESTION, V97, P26, DOI 10.1159/000484104; Baba Y, 2014, CLIN CANCER RES, V20, P1114, DOI 10.1158/1078-0432.CCR-13-1645; Bag Arundhati, 2018, J Nat Sci Biol Med, V9, P2, DOI 10.4103/jnsbm.JNSBM_46_17; Beetch M., HDB NUTR DIET AND EP, P1819, DOI [10.1007/978-3-319-55530-0_104, DOI 10.1007/978-3-319-55530-0_104]; Bohn SK, 2014, MOL NUTR FOOD RES, V58, P915, DOI 10.1002/mnfr.201300526; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burin VM, 2014, MICROCHEM J, V114, P155, DOI 10.1016/j.microc.2013.12.014; Busch C, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0095-z; Capek P, 2014, CARBOHYD POLYM, V103, P418, DOI 10.1016/j.carbpol.2013.12.068; Cui Y, 2008, CANCER-AM CANCER SOC, V112, P2241, DOI 10.1002/cncr.23398; Dickinson Douglas, 2014, Inflammation & Allergy Drug Targets, V13, P15; Ferenc B, 2009, IN VIVO, V23, P591; Fiander H, 2000, CANCER LETT, V156, P117, DOI 10.1016/S0304-3835(00)00368-2; Furlan D, 2017, BRIT J CANCER, V116, P793, DOI 10.1038/bjc.2017.9; Gerszon J., MEDICAL J CELL BIOL, V4, DOI [10.1038/ncb750, DOI 10.1038/NCB750]; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jiao Y, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-201; Kloypan C, 2015, CELL BIOCHEM FUNCT, V33, P375, DOI 10.1002/cbf.3124; Kretzschmar M, 1996, EXP TOXICOL PATHOL, V48, P439; Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8; LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P2859, DOI 10.1016/0006-2952(89)90442-5; Liang N, 2016, NUTRIENTS, V8, DOI 10.3390/nu8010016; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Lubecka K, 2016, CARCINOGENESIS, V37, P656, DOI 10.1093/carcin/bgw048; Garcia-Gimenez JL, 2017, FREE RADICAL BIO MED, V112, P36, DOI 10.1016/j.freeradbiomed.2017.07.008; Ma X., ENZYME INHIBITORS AC; Machado ACD, 2015, BRIEF FUNCT GENOMICS, V14, P61, DOI 10.1093/bfgp/elu040; Maugeri A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072118; Narayanan BA, 2006, CURR CANCER DRUG TAR, V6, P711, DOI 10.2174/156800906779010218; Narvaez DM, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00400; Newman MR, 2012, EPIGENETICS-US, V7, P92, DOI 10.4161/epi.7.1.18815; Park LK, 2012, P NUTR SOC, V71, P75, DOI 10.1017/S0029665111003302; Pastore RL, 2006, EXPLORE-NY, V2, P531, DOI 10.1016/j.explore.2006.08.008; Ponnaluri VKC, 2018, J MOL BIOL, V430, P2051, DOI 10.1016/j.jmb.2018.05.014; Quintana RM, 2013, J INVEST DERMATOL, V133, P239, DOI 10.1038/jid.2012.245; Ramadass P, 2003, TOXICOL SCI, V76, P212, DOI 10.1093/toxsci/kfg227; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Santes-Palacios R, 2020, TOXICOL IN VITRO, V62, DOI 10.1016/j.tiv.2019.104681; Serrano Antonio, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030076; STEVENS B, 1968, J PHYS CHEM-US, V72, P3468, DOI 10.1021/j100856a019; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Struhl K, 2014, ELIFE, V3, DOI 10.7554/eLife.02475; Sweeney BP, 2006, ANAESTHESIA, V61, P159, DOI 10.1111/j.1365-2044.2005.04462.x; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Diaz-Gerevini GT, 2016, NUTRITION, V32, P174, DOI 10.1016/j.nut.2015.08.017; Valcic S, 1999, CHEM RES TOXICOL, V12, P382, DOI 10.1021/tx990003t; Vanden Berghe W, 2012, PHARMACOL RES, V65, P565, DOI 10.1016/j.phrs.2012.03.007; Vandiver AR, 2015, SCI REP-UK, V5, DOI 10.1038/srep17911; Wang LH, 2018, MOL MED REP, V17, P2113, DOI 10.3892/mmr.2017.8145; Wang SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159102; Watson RE, 2003, TOXICOL SCI, V75, P289, DOI 10.1093/toxsci/kfg190; White MC, 2013, J ADOLESCENT HEALTH, V52, pS1, DOI 10.1016/j.jadohealth.2013.02.016; Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007; Xu YY, 2019, J BIOMED RES, V33, P181, DOI 10.7555/JBR.31.20170016; Yiannakopoulou EC, 2015, PHARMACOLOGY, V95, P111, DOI 10.1159/000375503; Zhang Y, 2018, FOOD FUNCT, V9, P525, DOI [10.1039/c7fo01453h, 10.1039/C7FO01453H]; Zhu Y, 2019, EXP THER MED, V17, P1742, DOI 10.3892/etm.2018.7131; Zia-Ul-Haq M, 2014, MOLECULES, V19, P10998, DOI 10.3390/molecules190810998	64	5	5	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2021	16	4							e0250157	10.1371/journal.pone.0250157	http://dx.doi.org/10.1371/journal.pone.0250157			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ1EM	33878138	gold, Green Published			2023-01-03	WOS:000642162200028
J	Ashina, M; Katsarava, Z; Do, TP; Buse, DC; Pozo-Rosich, P; Ozge, A; Krymchantowski, AV; Lebedeva, ER; Ravishankar, K; Yu, SY; Sacco, S; Ashina, S; Younis, S; Steiner, TJ; Lipton, RB				Ashina, Messoud; Katsarava, Zaza; Thien Phu Do; Buse, Dawn C.; Pozo-Rosich, Patricia; Ozge, Aynur; Krymchantowski, Abouch, V; Lebedeva, Elena R.; Ravishankar, Krishnamurthy; Yu, Shengyuan; Sacco, Simona; Ashina, Sait; Younis, Samaira; Steiner, Timothy J.; Lipton, Richard B.			Migraine: epidemiology and systems of care	LANCET			English	Review							TENSION-TYPE HEADACHE; GLOBAL BURDEN; HEALTH-CARE; EPISODIC MIGRAINE; COST BURDEN; PREVALENCE; POPULATION; MANAGEMENT; DISORDERS; RISK	Migraine is a neurovascular disorder that affects over 1 billion people worldwide. Its widespread prevalence, and associated disability, have a range of negative and substantial effects not only on those immediately affected but also on their families, colleagues, employers, and society. To reduce this global burden, concerted efforts are needed to implement and improve migraine care that is supported by informed health-care policies. In this Series paper, we summarise the data on migraine epidemiology, including estimates of its very considerable burden on the global economy. First, we present the challenges that continue to obstruct provision of adequate care worldwide. Second, we outline the advantages of integrated and coordinated systems of care, in which primary and specialist care complement and support each other; the use of comprehensive referral and linkage protocols should enable continuity of care between these systems levels. Finally, we describe challenges in low and middle-income countries, including countries with poor public health education, inadequate access to medication, and insufficient formal education and training of health-care professionals resulting in misdiagnosis, mismanagement, and wastage of resources.	[Ashina, Messoud; Thien Phu Do; Younis, Samaira] Univ Copenhagen, Danish Headache Ctr, Dept Neurol, Rigshosp Glostrup,Fac Hlth & Med Sci, Copenhagen, Denmark; [Ashina, Messoud] Danish Knowledge Ctr Headache Disorders, Glostrup, Denmark; [Ashina, Messoud] Azerbaijan Med Univ, Dept Neurol, Baku, Azerbaijan; [Katsarava, Zaza] Evangelical Hosp Unna, Dept Neurol, Unna, Germany; [Katsarava, Zaza] Univ Duisburg Essen, Dept Neurol, Essen, Germany; [Katsarava, Zaza] EVEX Med Corp, Tbilisi, GA USA; [Ashina, Messoud; Katsarava, Zaza] IM Sechenov First Moscow State Med Univ, Dept Neurol, Moscow, Russia; [Buse, Dawn C.; Lipton, Richard B.] Albert Einstein Coll Med, Dept Neurol, Bronx, NY USA; [Pozo-Rosich, Patricia] Hosp Univ Vall dHebron, Neurol Dept, Headache Unit, 5, Barcelona, Spain; [Pozo-Rosich, Patricia] Univ Autbnoma Barcelona, Vail dHebron Res Inst, Dept Med, Headache & Neurol Pain Res Grp, Barcelona, Spain; [Ozge, Aynur] Mersin Univ, Sch Med, Dept Neurol, Mersin, Turkey; [Krymchantowski, Abouch, V] Headache Ctr Rio, Rio De Janeiro, Brazil; [Lebedeva, Elena R.] Ural State Med Univ, Int Headache Ctr Europe Asia, Dept Neurol, Ekaterinburg, Russia; [Ravishankar, Krishnamurthy] Jaslok Hosp & Res Ctr, Lilavati Hosp & Res Ctr, Headache & Migraine Clin, Mumbai, Maharashtra, India; [Yu, Shengyuan] Peoples Liberat Army Gen Hosp, Dept Neurol, Beijing, Peoples R China; [Sacco, Simona] Univ Aquila, Dept Appl Clin Sci & Biotechnol, Neurosci Sect, Laquila, Italy; [Ashina, Sait] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Comprehens Headache Ctr, Dept Neurol & Anesthesia, Boston, MA USA; [Steiner, Timothy J.] Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Trondheim, Norway; [Steiner, Timothy J.] Imperial Coll London, Div Brain Sci, London, England; [Lipton, Richard B.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA	University of Copenhagen; Ministry of Education of Azerbaijan Republic; Azerbaijan Medical University; University of Duisburg Essen; Sechenov First Moscow State Medical University; Yeshiva University; Albert Einstein College of Medicine; Hospital Universitari Vall d'Hebron; Mersin University; Ural State Medical University; Chinese People's Liberation Army General Hospital; University of L'Aquila; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Norwegian University of Science & Technology (NTNU); Imperial College London; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Ashina, M (corresponding author), Univ Copenhagen, Danish Headache Ctr, Dept Neurol, Rigshosp Glostrup, DK-2600 Copenhagen, Denmark.	ashina@dadlnet.dk	Ashina, Messoud/AFU-1246-2022; Lipton, Richard Bruce/AAY-2818-2021; Ashina, Sait/I-1766-2019; Sacco, Simona/I-5253-2012	Ashina, Messoud/0000-0003-0951-5804; Ashina, Sait/0000-0003-3973-6640; Sacco, Simona/0000-0003-0651-1939				American Headache Society, 2016, HEAD ED TRAIN; Ashina M., 2019, COMMUNICATION    NOV; Ashina M, 2020, NEW ENGL J MED, V383, P1866, DOI 10.1056/NEJMra1915327; Ashina S, 2018, EUR J PAIN, V22, P904, DOI 10.1002/ejp.1176; Ashina S, 2017, ACTA NEUROL SCAND, V136, P470, DOI 10.1111/ane.12751; Ashina S, NATURE REV DIS PRIME; Ashina S, 2015, CEPHALALGIA, V35, P211, DOI 10.1177/0333102414535110; Ashina S, 2012, J HEADACHE PAIN, V13, P615, DOI 10.1007/s10194-012-0479-9; Ayzenberg I, 2012, CEPHALALGIA, V32, P373, DOI 10.1177/0333102412438977; Baykan B, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0589-2; Bigal ME, 2007, NEUROLOGY, V69, P16, DOI 10.1212/01.wnl.0000265212.90735.64; Bigal ME, 2006, NEUROLOGY, V67, P252, DOI 10.1212/01.wnl.0000225052.35019.f9; Bonafede M, 2018, HEADACHE, V58, P700, DOI 10.1111/head.13275; Booth S, 2019, PEERJ, V7, DOI 10.7717/peerj.8134; Braschinsky M, 2018, EUR J NEUROL, V25, P497, DOI 10.1111/ene.13524; Braschinsky M, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0613-1; Breslau N, 2003, NEUROLOGY, V60, P1308, DOI 10.1212/01.WNL.0000058907.41080.54; Bsner S, 2014, BRIT J GEN PRACT, V64, pE532, DOI 10.3399/bjgp14X681325; Buse DC, 2010, J NEUROL NEUROSUR PS, V81, P428, DOI 10.1136/jnnp.2009.192492; Buse DC, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-1084-y; Buse DC, 2019, HEADACHE, V59, P1286, DOI 10.1111/head.13613; Buse DC, 2018, HEADACHE, V58, P512, DOI 10.1111/head.13254; Buse DC, 2016, MAYO CLIN PROC, V91, P596, DOI 10.1016/j.mayocp.2016.02.013; Buse DC, 2012, HEADACHE, V52, P1456, DOI 10.1111/j.1526-4610.2012.02223.x; Diener HC, 2015, CLIN MED, V15, P344, DOI 10.7861/clinmedicine.15-4-344; Gelaye B, 2017, NEUROLOGY, V88, P1795, DOI [10.1212/WNL.0000000000003919, 10.1212/wnl.0000000000003919]; Hawkins K, 2008, HEADACHE, V48, P553, DOI 10.1111/j.1526-4610.2007.00990.x; Hawkins K, 2007, J OCCUP ENVIRON MED, V49, P368, DOI 10.1097/JOM.0b013e31803b9510; Hu XH, 1999, ARCH INTERN MED, V159, P813, DOI 10.1001/archinte.159.8.813; Hu XM, 2017, NEUROL SCI, V38, P33, DOI 10.1007/s10072-016-2746-z; Jette N, 2008, HEADACHE, V48, P501, DOI 10.1111/j.1526-4610.2007.00993.x; Katsarava Z, 2009, NEUROLOGY, V73, P1796, DOI 10.1212/WNL.0b013e3181c34abb; Katsarava Z, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0839-1; Katsarava Z, 2012, CEPHALALGIA, V32, P1019, DOI 10.1177/0333102412459478; Krymchantowski AV, 2015, HEADACHE, V55, P51, DOI 10.1111/head.12513; Krymchantowski Abouch Valenty, 2007, MedGenMed, V9, P21; Kulkarni GB, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0549-x; Lampl C, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0649-2; Lampl C, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0599-8; Lampl C, 2012, J HEADACHE PAIN, V13, P67, DOI 10.1007/s10194-011-0398-1; Latinovic R, 2006, J NEUROL NEUROSUR PS, V77, P385, DOI 10.1136/jnnp.2005.073221; Launer LJ, 1999, NEUROLOGY, V53, P537, DOI 10.1212/WNL.53.3.537; Lebedeva ER, 2017, CEPHALALGIA, V37, P225, DOI 10.1177/0333102416642603; Linde M, 2012, EUR J NEUROL, V19, P703, DOI 10.1111/j.1468-1331.2011.03612.x; Linde M, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0496-6; Lipton RB, 2007, NEUROLOGY, V68, P343, DOI 10.1212/01.wnl.0000252808.97649.21; Lipton RB, 2000, NEUROLOGY, V55, P629, DOI 10.1212/WNL.55.5.629; Liu RZ, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-47; Lyngberg AC, 2005, AM J EPIDEMIOL, V161, P1066, DOI 10.1093/aje/kwi139; Manandhar K, 2015, J HEADACHE PAIN, V16, P1, DOI [10.1186/s10194-015-0580-y, 10.1186/s10194-016-0594-0]; Mbewe E, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0513-9; Mbewe E, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0515-7; OBRIEN B, 1994, INT J EPIDEMIOL, V23, P1020, DOI 10.1093/ije/23.5.1020; OTTMAN R, 1994, NEUROLOGY, V44, P2105, DOI 10.1212/WNL.44.11.2105; Peres MFP, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1036-6; Rao GN, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0574-9; RASMUSSEN BK, 1992, INT J EPIDEMIOL, V21, P1138, DOI 10.1093/ije/21.6.1138; Ravishankar K, 2004, LANCET NEUROL, V3, P564, DOI 10.1016/S1474-4422(04)00855-5; Ravishankar K, 2003, CEPHALALGIA, V23, P577; RUSSELL MB, 1992, CEPHALALGIA, V12, P369, DOI 10.1111/j.1468-2982.1992.00369.x; Sacco S, 2015, EUR J NEUROL, V22, P1001, DOI 10.1111/ene.12701; Saylor D, 2018, SEMIN NEUROL, V38, P182, DOI 10.1055/s-0038-1646946; Scher AI, 2017, NEUROLOGY, V89, P461, DOI 10.1212/WNL.0000000000004177; Selekler MH, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-88; Starling AJ, 2015, MAYO CLIN PROC, V90, P408, DOI 10.1016/j.mayocp.2015.01.010; Steiner TJ, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-018-0899-2; Steiner TJ, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-0970-7; Steiner TJ, 2011, J HEADACHE PAIN, V12, P419, DOI 10.1007/s10194-011-0320-x; Steiner TJ, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-31; Steiner TJ, 2004, LANCET NEUROL, V3, P204, DOI 10.1016/S1474-4422(04)00703-3; Steiner TJ, 2000, FUNCT NEUROL, V15, P219; Stewart WF, 2008, CEPHALALGIA, V28, P1170, DOI 10.1111/j.1468-2982.2008.01666.x; Stokes M, 2011, HEADACHE, V51, P1058, DOI 10.1111/j.1526-4610.2011.01945.x; Stovner LJ, 2007, CEPHALALGIA, V27, P193, DOI 10.1111/j.1468-2982.2007.01288.x; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Stovner LJ, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-5; Tfelt-Hansen P, 2000, BRAIN, V123, P9, DOI 10.1093/brain/123.1.9; Tfelt-Hansen P, 2007, CNS DRUGS, V21, P877, DOI 10.2165/00023210-200721110-00001; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; van den Berg JSP, 2017, HEADACHE, V57, P1252, DOI 10.1111/head.13098; Veenstra P, 2016, CEPHALALGIA, V36, P772, DOI 10.1177/0333102415612767; Viana M, 2020, EUR J NEUROL, V27, P536, DOI 10.1111/ene.14098; Viticchi G, 2011, HEADACHE, V51, P232, DOI 10.1111/j.1526-4610.2010.01778.x; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Wober C, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0847-1; World Health Organization, 2011, ATLAS HEADACHE DISOR; Yao CY, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1048-2; Yu SY, 2019, CEPHALALGIA, V39, P42; Yu SY, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0790-6; Yu SY, 2012, HEADACHE, V52, P582, DOI 10.1111/j.1526-4610.2011.02061.x; Zebenigus M, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0765-7; Zebenigus M, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0704-z; Zeeberg P, 2005, CEPHALALGIA, V25, P1159, DOI 10.1111/j.1468-2982.2005.00980.x	93	109	111	13	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 17	2021	397	10283					1485	1495		10.1016/S0140-6736(20)32160-7	http://dx.doi.org/10.1016/S0140-6736(20)32160-7		APR 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN5FX	33773613				2023-01-03	WOS:000640378100026
J	Qiu, X; Gao, YC; Zhang, ZX; Cheng, SJ; Zhang, SM				Qiu, Xuan; Gao, Yicheng; Zhang, Zhaoxu; Cheng, Sijia; Zhang, Shuangmei			Fire Acupuncture versus conventional acupuncture to treat spasticity after stroke: A systematic review and meta-analysis	PLOS ONE			English	Review							UPPER-LIMB SPASTICITY; CEREBRAL-ISCHEMIA; SHOULDER PAIN; BLOOD-FLOW; REHABILITATION; EFFICACY; THERAPY; INJURY; SAFETY; RATS	Background Post-stroke spasm is currently a complex clinical problem that remains to be resolved. Due to its excellent efficacy and few side effects, clinicians have used fire acupuncture to treat post-stroke spasticity in China. Objectives The purpose of this study was to evaluate the clinical efficacy of fire acupuncture compared with conventional acupuncture to treat post-stroke spasms and provide a detailed summary of the commonly used acupoints. Methods Eight databases (MEDLINE/PubMed, Web of Science, the Cochrane database, EMBASE, CBM, CNKI, WanFang, and VIP) were searched for randomized controlled trials (RCTs) published from database inception through August 30, 2020. RCTs that compared fire acupuncture with conventional acupuncture as a treatment intervention for patients with spasticity after stroke were included. Revman 5.3 software was used to calculate risk ratios (RR) and standard mean differences (SMD) with 95% confidence intervals (CI). Methodological evaluation or critical appraisal of the included articles was assessed using RoB-2. Results Sixteen studies with a total of 1,118 patients were included. Although according to the standards of the Rob 2.0 tool, most studies are considered to have some problems. Comprehensive analysis of the results revealed a consistent trend indicating several advantages of using fire needles compared to conventional acupuncture in treating post-stroke spasms, including the effective rate, recovery rate, and improvement of multiple scales represented by MAS. Concerning secondary outcomes, using the scales of FMA, BI, or NDS in this random model meta-analysis, fire acupuncture exhibited better performance compared to acupuncture [SMD = 2.27, 95%CI [1.40,3.13 (random-effects model) ], [SMD = 1.46,95% CI [1.03,1.90 (random-effects model)], and [SMD = 0.90, 95%CI [0.44,1.35 (random-effects model)], respectively, with moderately high heterogeneity. When the effective rate was used as an outcome in the subgroup analysis, fire needles performed better than conventional acupuncture with respect to damage to the upper or lower limbs, and the thickness and depth of acupuncture. When the modified Ashworth scale (MAS) was used as the outcome, and the damage occurred in the lower extremity, the acupuncture depth exceeded 15mm, or the duration of stroke was longer than six months, the fire needles did not perform better than conventional acupuncture, [SMD = 0.01, 95%CI [-0.47,0.48 (fix-effects model)], [SMD = 0.21 [-0.51,0.93(random-effects model)], and [SMD = 0.76, 95%CI [-0.08,1.60 (random-effects model)], respectively. The acupoints identified with the highest frequencies in this study were Yang-meridian, including LI11-Quchi (nine times), LI4-Hegu (seven times), and ST36-Zusanli (five times). Moreover, no serious adverse effects were reported in any of the studies included in this analysis. Conclusions Despite several limitations, this was the first meta-analysis to focus on the treatment of post-stroke spasticity using fire needle acupuncture compared with conventional acupuncture. Our results confirmed that fire needles could provide a better clinical effect than conventional acupuncture, which will help standardize fire needle treatment strategies for post-stroke spasms.	[Qiu, Xuan; Gao, Yicheng] Guangzhou Univ Chinese Med, Clin Med Coll Acupuncture Moxibust & Rehabil, Guangzhou, Peoples R China; [Qiu, Xuan; Gao, Yicheng; Cheng, Sijia] Guangzhou Univ Tradit Chinese Med, Guangzhou, Peoples R China; [Zhang, Zhaoxu] Peking Univ Peoples Hosp, Dept Neurol, Beijing, Peoples R China; [Zhang, Shuangmei] Univ Chinese Acad Sci, Dept Rehabil, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China; [Zhang, Shuangmei] Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Peking University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Chinese Academy of Sciences	Qiu, X (corresponding author), Guangzhou Univ Chinese Med, Clin Med Coll Acupuncture Moxibust & Rehabil, Guangzhou, Peoples R China.; Qiu, X (corresponding author), Guangzhou Univ Tradit Chinese Med, Guangzhou, Peoples R China.	qiuxuan20202020@163.com			Zhuweifeng Guangdong Provincial Famous Chinese Medicine Studio Construction Project [2018(5)]; 2020 Major Project of Science and Technology Project of Guangdong Province Traditional Chinese Medicine Bureau Grant [20203015]; Science and technology development plan of Shandong Province [2017G006021]	Zhuweifeng Guangdong Provincial Famous Chinese Medicine Studio Construction Project; 2020 Major Project of Science and Technology Project of Guangdong Province Traditional Chinese Medicine Bureau Grant; Science and technology development plan of Shandong Province	(1) Zhuweifeng full name:Zhuweifeng Guangdong Provincial Famous Chinese Medicine Studio Construction Project Grant numbers: Guangdong Chinese Medicine Office 2018(5) (2) Zhaoxu Zhang full name:2020 Major Project of Science and Technology Project of Guangdong Province Traditional Chinese Medicine Bureau Grant numbers:(20203015) the funder play an role in the preparation of the manuscript (3) Zhaoxu Zhang full name:Science and technology development plan of Shandong Province Grant numbers:(2017G006021) the funder play an role in the preparation of the manuscript.	Bohland JW, 2006, NEUROIMAGE, V32, P821, DOI 10.1016/j.neuroimage.2006.04.173; Brown D, 2020, HEALTH PROMOT PRACT, V21, P496, DOI 10.1177/1524839919893361; Burke JF, 2012, STROKE, V43, P2207, DOI 10.1161/STROKEAHA.112.656967; Chai FC., 2017, SHANXI J TRADITIONAL; Chau JPC, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00030; Chavez LM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112270; Chen JZ., 2005, J GUANGZHOU U TRADIT; Chen LY, 2019, J AFFECT DISORDERS, V250, P298, DOI 10.1016/j.jad.2019.03.020; Chen LF, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1193-y; Chen SQ, 2020, CHIN J INTEGR MED, V26, P20, DOI 10.1007/s11655-019-3079-6; Deng Y., 2019, J SICHUAN TRADITIONA, V35, P186; Do KH, 2017, CLIN REHABIL, V31, P1179, DOI 10.1177/0269215516689331; Dong Y, 2017, EUR J PHYS REHAB MED, V53, P256, DOI 10.23736/S1973-9087.16.04329-X; Gao TY., 2004, NEI MONGOL J TRADITI, V5, P7, DOI [10.13359/j.cnki.gzxbtcm.2013.02.010, DOI 10.13359/J.CNKI.GZXBTCM.2013.02.010]; Hara T, 2018, TOXINS, V10, DOI 10.3390/toxins10090349; Harrison RA, 2015, CEREBROVASC DIS, V39, P190, DOI 10.1159/000375397; Iskra D A, 2019, Zh Nevrol Psikhiatr Im S S Korsakova, V119, P51, DOI 10.17116/jnevro201911912251; Kamalakannan S, 2017, INDIAN J MED RES, V146, P175, DOI 10.4103/ijmr.IJMR_516_15; Li J, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-441; Li WH, 2016, J ACUPUNCT MERIDIAN, V9, P128, DOI 10.1016/j.jams.2015.08.005; Li Z, 2015, J NEUROSCI NURS, V47, P10, DOI 10.1097/JNN.0000000000000109; Liu CM, 2014, J TRADIT CHIN MED, V34, P566, DOI 10.1016/S0254-6272(15)30064-9; Liu J, 2017, BIOMED PHARMACOTHER, V89, P1125, DOI 10.1016/j.biopha.2017.02.077; Liu Q., 2018, J GUANGZHOU U TRADIT, V35, P430, DOI [10.13359/j.cnki.gzxbtccm.2018.03.011, DOI 10.13359/J.CNKI.GZXBTCCM.2018.03.011]; Liu Y., 2014, J FUJIAN U TRADITION; Lozano R., 2010, TREATMENT PATIENTS A; Lozano R, 2013, LANCET, V381, P991, DOI 10.1016/S0140-6736(13)60704-7; Lundstrom E, 2010, STROKE, V41, P319, DOI 10.1161/STROKEAHA.109.558619; MacPherson Hugh, 2010, J Evid Based Med, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x; Marcheschi E, 2018, HEALTH SOC CARE COMM, V26, pE451, DOI 10.1111/hsc.12518; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nelson KP, 2018, STAT METHODS MED RES, V27, P812, DOI 10.1177/0962280216643347; Page MJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019703; Peng FY., 2017, CHINESE J INTEGRATED, V5, P160, DOI [10.16282/j.cnki.cn11-9336/r.2017.30.130, DOI 10.16282/J.CNKI.CN11-9336/R.2017.30.130]; Peng FY., 2017, CHINESE J INTEGRATED, V5, P84, DOI [10.16282/j.cnki.cn11-9336/r.2017.12.065, DOI 10.16282/J.CNKI.CN11-9336/R.2017.12.065]; Rajsic S, 2019, EUR J HEALTH ECON, V20, P107, DOI 10.1007/s10198-018-0984-0; Sang P., 2017, CHINA CONTINUING MED, V9, P108; Schaechter JD, 2007, J ALTERN COMPLEM MED, V13, P527, DOI 10.1089/acm.2007.6316; Sheng GY., 2017, NEI MONGOL J TRADITI, V36, P115, DOI [10.16040/j.cnki.cn15-1101.2017.14.115, DOI 10.16040/J.CNKI.CN15-1101.2017.14.115]; Shi LH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017124; Sommerfeld DK, 2004, STROKE, V35, P134, DOI 10.1161/01.STR.0000105386.05173.5E; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Tang EYH, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.006443; Wang J, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/9245186; Wang Ning, 2015, Zhongguo Zhen Jiu, V35, P1105; Wang Ning, 2015, Zhen Ci Yan Jiu, V40, P304; Wang SH, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1337-0; Wang YH., 2018, HEILONGJIANG J TRADI; Wu P, 2010, STROKE, V41, pE171, DOI 10.1161/STROKEAHA.109.573576; Wu SM, 2019, LANCET NEUROL, V18, P394, DOI 10.1016/S1474-4422(18)30500-3; Wu ZY, 2012, ACUPUNCT MED, V30, P331, DOI 10.1136/acupmed-2012-010172; Xie GL, 2013, EXP THER MED, V5, P1593, DOI 10.3892/etm.2013.1030; Xu JC, 2019, CNS NEUROL DISORD-DR, V18, P245, DOI 10.2174/1871527318666190204111701; Xu YY., 2015, JIANGSU J TRADIT CHI, V47, P63; Yang ZQ., 2017, SHENZHEN J INTEGR TR, V27, P60, DOI 10.16458/j.cnki.1007-0893.2017.20.027; Yuan BG., 2015, J GUANGZHOU U TRADIT; Yuan Ying, 2020, Zhongguo Zhen Jiu, V40, P347, DOI 10.13703/j.0255-2930.20190502-0003; Yue XY, 2019, J INTEGR MED-JIM, V17, P167, DOI 10.1016/j.joim.2019.03.002; Zhao MH., 2013, J GUANGZHOU U TRADIT, V30, P175, DOI [10.13359/j.cnnki.gzxbtcm.2013.02.010, DOI 10.13359/J.CNNKI.GZXBTCM.2013.02.010]; Zhu W, 2017, J NEUROIMMUNE PHARM, V12, P575, DOI 10.1007/s11481-017-9747-4; Zhu Y, 2019, ANN PHYS REHABIL MED, V62, P297, DOI 10.1016/j.rehab.2018.09.010	61	4	4	15	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2021	16	4							e0249313	10.1371/journal.pone.0249313	http://dx.doi.org/10.1371/journal.pone.0249313			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM0OE	33836008	gold, Green Published			2023-01-03	WOS:000639361000031
J	Hut-Mossel, L; Ahaus, K; Welker, G; Gans, R				Hut-Mossel, Lisanne; Ahaus, Kees; Welker, Gera; Gans, Rijk			Understanding how and why audits work in improving the quality of hospital care: A systematic realist review	PLOS ONE			English	Review							HEALTH-CARE; CLINICAL AUDIT; OPERATING-ROOM; FEEDBACK INTERVENTIONS; IMPROVEMENT PROJECT; MULTICENTER AUDIT; OF-CARE; ACCREDITATION; IMPLEMENTATION; SAFETY	Background Several types of audits have been used to promote quality improvement (QI) in hospital care. However, in-depth studies into the mechanisms responsible for the effectiveness of audits in a given context is scarce. We sought to understand the mechanisms and contextual factors that determine why audits might, or might not, lead to improved quality of hospital care. Methods A realist review was conducted to systematically search and synthesise the literature on audits. Data from individual papers were synthesised by coding, iteratively testing and supplementing initial programme theories, and refining these theories into a set of context-mechanism-outcome configurations (CMOcs). Results From our synthesis of 85 papers, seven CMOcs were identified that explain how audits work: (1) externally initiated audits create QI awareness although their impact on improvement diminishes over time; (2) a sense of urgency felt by healthcare professionals triggers engagement with an audit; (3) champions are vital for an audit to be perceived by healthcare professionals as worth the effort; (4) bottom-up initiated audits are more likely to bring about sustained change; (5) knowledge-sharing within externally mandated audits triggers participation by healthcare professionals; (6) audit data support healthcare professionals in raising issues in their dialogues with those in leadership positions; and (7) audits legitimise the provision of feedback to colleagues, which flattens the perceived hierarchy and encourages constructive collaboration. Conclusions This realist review has identified seven CMOcs that should be taken into account when seeking to optimise the design and usage of audits. These CMOcs can provide policy makers and practice leaders with an adequate conceptual grounding to design contextually sensitive audits in diverse settings and advance the audit research agenda for various contexts. PROSPERO registration CRD42016039882.	[Hut-Mossel, Lisanne] Univ Groningen, Univ Med Ctr Groningen, Ctr Expertise Qual & Safety, Groningen, Netherlands; [Ahaus, Kees] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Dept Hlth Serv Management & Org, Rotterdam, Netherlands; [Welker, Gera] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Gans, Rijk] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands	University of Groningen; Erasmus University Rotterdam; University of Groningen; University of Groningen	Hut-Mossel, L (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Ctr Expertise Qual & Safety, Groningen, Netherlands.	p.a.mossel@umcg.nl		Welker, Gera/0000-0002-9202-192X; Gans, Reinold/0000-0001-5481-2387				Albornos-Munoz Laura, 2018, JBI Database System Rev Implement Rep, V16, P247, DOI 10.11124/JBISRIR-2017-003349; Aldridge P, 2018, J PAEDIATR CHILD H, V54, P416, DOI 10.1111/jpc.13770; Alomari A, 2020, J CLIN NURS, V29, P3403, DOI 10.1111/jocn.15374; Anderson P, 2012, BRIT J HOSP MED, V73, P526, DOI 10.12968/hmed.2012.73.9.526; Benitez-Rosario MA, 2012, J PAIN SYMPTOM MANAG, V44, P532, DOI 10.1016/j.jpainsymman.2011.10.029; Astbury B, 2010, AM J EVAL, V31, P363, DOI 10.1177/1098214010371972; Bodenheimer Thomas, 2007, Qual Manag Health Care, V16, P10; Bogh SB, 2016, INT J QUAL HEALTH C, V28, P715, DOI 10.1093/intqhc/mzw099; Bohigas L, 2000, INT J QUAL HEALTH C, V12, P231, DOI 10.1093/intqhc/12.3.231; Botje D, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1826-3; Braithwaite J, 2009, QUAL SAF HEALTH CARE, V18, P37, DOI 10.1136/qshc.2007.023317; Braithwaite J, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1057-z; Braithwaite J, 2010, QUAL SAF HEALTH CARE, V19, P14, DOI 10.1136/qshc.2009.033928; Brown B, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-019-0883-5; Brubakk K, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0933-x; Canitano S, 2015, TUMORI, V101, pS51, DOI 10.5301/tj.5000461; Chua CC, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3009-x; Clarke J V, 2009, J Wound Care, V18, P5; Cohen MM, 2005, QUAL SAF HEALTH CARE, V14, P169, DOI 10.1136/qshc.2004.010942; Colquhoun H, 2017, BMJ QUAL SAF, V26, P54, DOI 10.1136/bmjqs-2015-005004; Colquhoun HL, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-66; Conaty O, 2018, INT J HEALTH CARE Q, V31, P162, DOI 10.1108/IJHCQA-05-2017-0078; Cosgrove JF, 2008, ANAESTHESIA, V63, P599, DOI 10.1111/j.1365-2044.2008.05441.x; Counihan T, 2016, AM J MED QUAL, V31, P31, DOI 10.1177/1062860614549761; Currie K, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-00767-w; Dafoe S, 2015, ANAESTH INTENS CARE, V43, P719, DOI 10.1177/0310057X1504300609; Dalkin SM, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0237-x; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Desveaux L, 2017, INT J QUAL HEALTH C, V29, P941, DOI 10.1093/intqhc/mzx136; Dinescu A, 2011, J HOSP MED, V6, P28, DOI 10.1002/jhm.831; Dixon N., 2007, GETTING CLIN AUDIT R; Dixon N., 2011, FACULTY DENT J, V2, P79; Dixon-Woods Mary, 2019, Wellcome Open Res, V4, P203, DOI 10.12688/wellcomeopenres.14993.1; Dixon-Woods M, 2011, MILBANK Q, V89, P167, DOI 10.1111/j.1468-0009.2011.00625.x; Dunne D, 2018, INT J HEALTH CARE Q, V31, P966, DOI 10.1108/IJHCQA-06-2017-0109; Dupont C, 2011, INT J QUAL HEALTH C, V23, P583, DOI 10.1093/intqhc/mzr042; Easterlow D, 2010, J CLIN NURS, V19, P721, DOI 10.1111/j.1365-2702.2009.03098.x; Edmondson AC, 2001, ADMIN SCI QUART, V46, P685, DOI 10.2307/3094828; Elli L, 2020, BMC GASTROENTEROL, V20, DOI 10.1186/s12876-020-01524-4; Emmel N., 2018, DOING REALIST RES, DOI 10.4135/9781526451729; Esposito P, 2013, INT J ARTIF ORGANS, V36, P305, DOI 10.5301/ijao.5000202; Flodgren G, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008992.pub3; Foy R, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-50; Gallagher-Swann M, 2011, TRANSFUSION MED, V21, P51, DOI 10.1111/j.1365-3148.2010.01041.x; Gazarin M, 2019, CAN J RURAL MED, V24, P44, DOI 10.4103/CJRM.CJRM_27_18; Gommans J, 2008, INTERN MED J, V38, P243, DOI 10.1111/j.1445-5994.2007.01518.x; Greenfield D, 2008, INT J QUAL HEALTH C, V20, P172, DOI 10.1093/intqhc/mzn005; Greenfield D, 2015, HEALTH EXPECT, V18, P3110, DOI 10.1111/hex.12300; Greenfield D, 2011, INT J QUAL HEALTH C, V23, P8, DOI 10.1093/intqhc/mzq069; Greenhalgh J, 2017, HLTH SERV DELIV RES, V5, P1, DOI DOI 10.3310/HSDR05020; Greenhalgh J, 2018, J PATIENT-REP OUTCOM, V2, DOI 10.1186/s41687-018-0061-6; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; Gude WT, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-019-0937-8; Gunningberg L, 2008, INT J QUAL HEALTH C, V20, P246, DOI 10.1093/intqhc/mzn009; Hall AC, 2015, J LARYNGOL OTOL, V129, P454, DOI 10.1017/S0022215115000596; Halpape Katelyn, 2014, Can J Hosp Pharm, V67, P17; Hanskamp-Sebregts M., 2018, INT J QUAL HLTH C; Hawe P, 2009, AM J COMMUN PSYCHOL, V43, P267, DOI 10.1007/s10464-009-9229-9; Hayes AF, 2007, COMMUN METHODS MEAS, V1, P77, DOI 10.1080/19312450709336664; Healy Kathy, 2019, J Perioper Pract, V29, P54, DOI 10.1177/1750458918793295; Hempel S, 2015, BMJ QUAL SAF, V24, P796, DOI 10.1136/bmjqs-2014-003151; Hovlid E, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05475-0; Hunter M, 2014, CONTEMP NURSE, V49, P75, DOI [10.5172/conu.2014.49.75, 10.1080/10376178.2014.11081956]; Hut-Mossel L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015121; Ingen-Housz-Oro S, 2012, DERMATOLOGY, V225, P204, DOI 10.1159/000343288; International Organization for Standardization, 2015, 9000 ISO; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Ivers NM, 2014, IMPLEMENT SCI, V9, DOI [10.1186/1748-5908-9-14, 10.1186/1748-5908-9-51]; Iyer RS, 2013, AM J ROENTGENOL, V200, P132, DOI 10.2214/AJR.12.9580; Jagosh J, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1949-1; Jain N, 2008, ANN ROY COLL SURG, V90, P483, DOI 10.1308/003588408X301145; Johnson AM, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000423; Johnson S, 2018, J NURS CARE QUAL, V33, P67, DOI 10.1097/NCQ.0000000000000269; Johnston G, 2000, QUAL HEALTH CARE, V9, P23, DOI 10.1136/qhc.9.1.23; Kalanithi L, 2013, AM J MED QUAL, V28, P472, DOI 10.1177/1062860613478976; Kampstra NA, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3828-9; Kaplan HC, 2010, MILBANK Q, V88, P500, DOI 10.1111/j.1468-0009.2010.00611.x; Kennedy NA, 2013, INTERN MED J, V43, P772, DOI 10.1111/imj.12166; Kilsdonk MJ, 2014, BRIT J CANCER, V110, P850, DOI 10.1038/bjc.2013.814; Kilsdonk MJ, 2016, CANCER MED-US, V5, P478, DOI 10.1002/cam4.612; Klazinga N, 2000, INT J QUAL HEALTH C, V12, P183, DOI 10.1093/intqhc/12.3.183; Krippendorff K, 2004, HUM COMMUN RES, V30, P411, DOI 10.1093/hcr/30.3.411; Kurmis R, 2015, J BURN CARE RES, V36, P471, DOI 10.1097/BCR.0000000000000125; Lacouture A, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0345-7; Langston M, 2011, J NURS CARE QUAL, V26, P49, DOI 10.1097/NCQ.0b013e3181ea75b8; Lanteigne G, 2016, INT J HEALTH PLAN M, V31, DOI 10.1002/hpm.2314; Leung S, 2016, J OBSTET GYNAECOL CA, V38, P351, DOI 10.1016/j.jogc.2016.01.004; Lewis CM, 2015, CANCER-AM CANCER SOC, V121, P1581, DOI 10.1002/cncr.29238; Li C, 2008, CAN J HOSP PHARM, V61, P203; Lingard L, 2012, ACAD MED, V87, P1762, DOI 10.1097/ACM.0b013e318271fc82; Looper K, 2016, J PEDIATR ONCOL NURS, V33, P165, DOI 10.1177/1043454215610490; Marchal B, 2012, EVALUATION-US, V18, P192, DOI 10.1177/1356389012442444; Mazzini E, 2015, TUMORI J, V101, pS42, DOI 10.5301/tj.5000466; McDonald KM., 2013, CLOSING QUALITY GAP; McLiesh P, 2009, INT J EVID-BASED HEA, V7, P173, DOI 10.1111/j.1744-1609.2009.00138.x; Mills JKA, 2014, DEMENTIA-LONDON, V13, P697, DOI 10.1177/1471301213519894; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Mughal Z, 2019, J EVAL CLIN PRACT, V25, P456, DOI 10.1111/jep.13063; Munn Zachary, 2015, JBI Database System Rev Implement Rep, V13, P338, DOI 10.11124/jbisrir-2015-2315; Myers MK, 2018, J MULTIDISCIP HEALTH, V11, P467, DOI 10.2147/JMDH.S171745; Nardini S, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-40; National Institute for Clinical Excellence (Great Britain), 2002, PRINC BEST PRAC CLIN; Nicolaisen A., 2018, INT J QUAL HEALTH C; Nugus P, 2010, SOC SCI MED, V71, P898, DOI 10.1016/j.socscimed.2010.05.029; Numan RC, 2012, LUNG CANCER, V78, P270, DOI 10.1016/j.lungcan.2012.08.006; Oliveri A, 2016, EUR RADIOL, V26, P2663, DOI 10.1007/s00330-015-4100-x; Owen C, 2011, AUST HEALTH REV, V35, P430, DOI 10.1071/AH10925; Pawson R., 2006, EVIDENCE BASED POLIC, DOI DOI 10.4135/9781849209120; Pawson Ray, 2005, J Health Serv Res Policy, V10 Suppl 1, P21, DOI 10.1258/1355819054308530; Pawson R, 2012, EVALUATION-US, V18, P176, DOI 10.1177/1356389012440912; Pearson M, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0321-2; Perkins JN, 2014, INT J PEDIATR OTORHI, V78, P782, DOI 10.1016/j.ijporl.2014.02.010; Pomey MP, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-31; Power D, 2007, J OPER MANAG, V25, P126, DOI 10.1016/j.jom.2006.02.005; Radford A, 2007, J EVAL CLIN PRACT, V13, P130, DOI 10.1111/j.1365-2753.2007.00679.x; Reznek MA, 2014, INT J QUAL HEALTH C, V26, P278, DOI 10.1093/intqhc/mzu045; Roberts CM, 2012, J EVAL CLIN PRACT, V18, P599, DOI 10.1111/j.1365-2753.2011.01639.x; Rohweder C, 2019, PREV MED, V129, DOI 10.1016/j.ypmed.2019.105859; Rycroft-Malone J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-33; Shadman KA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4441; Sheena Y, 2012, J LARYNGOL OTOL, V126, P1049, DOI 10.1017/S002221511200165X; Sinuff T, 2015, BMJ QUAL SAF, V24, P393, DOI 10.1136/bmjqs-2015-003978; Smiddy Maura P, 2019, J Infect Prev, V20, P164, DOI 10.1177/1757177419833165; Smith Louise, 2018, JBI Database System Rev Implement Rep, V16, P233, DOI 10.11124/JBISRIR-2016-003071; Snelling I, 2019, LEADERSH HEALTH SERV, V33, P85, DOI 10.1108/LHS-12-2018-0064; Spencer E, 2009, QUAL SAF HEALTH CARE, V18, pI22, DOI 10.1136/qshc.2008.029355; Spurgeon P., 2000, CLIN GOVERNANCE POLI; Spurgeon P, 2011, HEALTH SERV MANAG RE, V24, P114, DOI 10.1258/hsmr.2011.011006; Staines A, 2015, QUAL MANAG HEALTH CA, V24, P21, DOI 10.1097/QMH.0000000000000048; Stephenson M, 2016, INT J QUAL HEALTH C, V28, P92, DOI 10.1093/intqhc/mzv113; Stewart C, 2018, NURS CRIT CARE, V23, P172, DOI 10.1111/nicc.12354; Thor Johan, 2004, Qual Manag Health Care, V13, P130; Thornlow DK, 2009, HEALTH CARE MANAGE R, V34, P262, DOI 10.1097/HMR.0b013e3181a16bce; Tiscar-Gonzalez Veronica, 2019, JBI Database System Rev Implement Rep, V17, P614, DOI 10.11124/JBISRIR-2017-003749; Tucker AL, 2003, CALIF MANAGE REV, V45, P55, DOI 10.2307/41166165; Ursprung R, 2005, QUAL SAF HEALTH CARE, V14, P284, DOI 10.1136/qshc.2004.012542; van Gelderen SC., 2017, J HOSP ADM, V6, P15; Vanoli M, 2012, INTERN EMERG MED, V7, P27, DOI 10.1007/s11739-011-0684-6; Veenstra GL, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012591; Wallenburg I, 2019, J HEALTH ORGAN MANAG, V33, P869, DOI 10.1108/JHOM-10-2018-0305; Walshe K, 2007, INT J QUAL HEALTH C, V19, P57, DOI 10.1093/intqhc/mzm004; Weske U, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2865-8; Wong G, 2013, BMC MED, V11, DOI [10.1186/1741-7015-11-21, 10.1186/1741-7015-11-20]; Wood SD, 2015, INTENS CRIT CARE NUR, V31, P106, DOI 10.1016/j.iccn.2014.11.006; Wooller KR, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3421-2; Wright KM., 2014, JBI LIB SYST REV, V12, P199	146	6	6	4	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2021	16	3							e0248677	10.1371/journal.pone.0248677	http://dx.doi.org/10.1371/journal.pone.0248677			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RH6VV	33788894	Green Published, gold			2023-01-03	WOS:000636354600008
J	Deng, K; Xiao, HT; Liu, XX; Ogawa, R; Xu, XW; Liu, Y				Deng, Ke; Xiao, Haitao; Liu, Xiaoxue; Ogawa, Rei; Xu, Xuewen; Liu, Yong			Strontium-90 brachytherapy following intralesional triamcinolone and 5-fluorouracil injections for keloid treatment: A randomized controlled trial	PLOS ONE			English	Article							HYPERTROPHIC SCARS; ADJUVANT IRRADIATION; SURGICAL EXCISION; ACETONIDE; STANDARD	Background Keloid disease is hard to fully eradicate. Recurrence and other unsatisfactory results were found in many patients. No current therapeutic modality has been determined to be most effective for treating keloid scars. Intralesional corticosteroid injections is most commonly recommended for primary management of small and young keloids as well as hypertrophic scars. However, it's difficult for patients to adhere to long-term triamcinolone acetonide injection therapy because of the pain, inconvenience or complications including hormonal imbalance or irregular menstruation. Objective We aimed to determine whether and how Strontium-90 brachytherapy as an adjuvant radiation could affect keloid recurrence after intralesional triamcinolone and 5-fluorouracil injections. Methods We included keloid patients from March 2019 to September 2019 and randomly allocated them to two groups after 3 intralesional triamcinolone and 5-fluorouracil injections at 3 weeks interval. The experimental group received Strontium-90 brachytherapy at a total dose of 15-20Gy, while the control group didn't receive any adjuvant treatment. We performed both Vancouver Scar Scale scoring and Color Doppler ultrasound examination to monitor and evaluate lesions regularly. A one-year follow-up was completed for each patient. Results 31 patients who had 42 keloids in total were recruited. We found intralesional triamcinolone and 5-fluorouracil injections could effectively reduce the thickness and modify the hardness of small and young keloids. Strontium-90 brachytherapy reduced the one-year recurrence rate from 85.7 percent to 44.4 percent after 3 intralesional triamcinolone and 5-fluorouracil injections. The lesions' thickness or elasticity was not affected by Strontium-90 brachytherapy. Conclusion Strontium-90 brachytherapy as an adjuvant radiation could effectively reduce small sized keloids recurrence after intralesional triamcinolone and 5-fluorouracil injections. It worked by enhancing the lesions' stability post-injection.	[Deng, Ke; Xiao, Haitao; Liu, Xiaoxue; Xu, Xuewen; Liu, Yong] Sichuan Univ, West China Hosp, Dept Plast & Burn Surg, Chengdu, Sichuan, Peoples R China; [Ogawa, Rei] Nippon Med Sch, Dept Plast Reconstruct & Aesthet Surg, Tokyo, Japan	Sichuan University; Nippon Medical School	Liu, Y (corresponding author), Sichuan Univ, West China Hosp, Dept Plast & Burn Surg, Chengdu, Sichuan, Peoples R China.	liu.yong7088@163.com		Liu, Yong/0000-0003-4574-7880; Deng, Ke/0000-0002-6454-9129; Xu, Xuewen/0000-0003-0567-2749				Betarbet Udayan, 2020, J Clin Aesthet Dermatol, V13, P33; Coppola MM, 2018, CLIN COSMET INV DERM, V11, P387, DOI 10.2147/CCID.S133672; DEKA B C, 1987, Indian Journal of Cancer, V24, P15; ESCARMANT P, 1993, INT J RADIAT ONCOL, V26, P245, DOI 10.1016/0360-3016(93)90204-9; Gauglitz GG, 2013, CLIN COSMET INV DERM, V6, P103, DOI 10.2147/CCID.S35252; Gauglitz GG, 2011, MOL MED, V17, P113, DOI 10.2119/molmed.2009.00153; Goutos Ioannis, 2017, Scars Burn Heal, V3, p2059513117735483, DOI 10.1177/2059513117735483; Gupta S, 2011, INDIAN J DERMATOL VE, V77, P94, DOI 10.4103/0378-6323.74968; Hietanen KE, 2019, J PLAST RECONSTR AES, V72, P4, DOI 10.1016/j.bjps.2018.05.052; Khalid FA, 2019, BURNS, V45, P69, DOI 10.1016/j.burns.2018.08.011; Lv KY, 2018, BURNS TRAUMA, V6, DOI 10.1186/s41038-018-0129-9; Muneuchi G, 2006, SCAND J PLAST RECONS, V40, P111, DOI 10.1080/02844310500430003; Mustoe TA, 2002, PLAST RECONSTR SURG, V110, P560, DOI 10.1097/00006534-200208000-00031; Nangole Ferdinand W, 2019, JPRAS Open, V22, P44, DOI 10.1016/j.jpra.2019.09.004; Ogawa R, 2007, ANN PLAS SURG, V59, P688, DOI 10.1097/SAP.0b013e3180423b32; Ogawa R, 2019, BURNS TRAUMA, V7, DOI 10.1186/s41038-019-0175-y; Perdanasari AT, 2014, ARCH PLAST SURG-APS, V41, P620, DOI 10.5999/aps.2014.41.6.620; Ragoowansi R, 2003, PLAST RECONSTR SURG, V111, P1853, DOI 10.1097/01.PRS.0000056869.31142.DE; Ramirez-Fort MK, 2017, BRIT J DERMATOL, V177, pE327, DOI 10.1111/bjd.15667; Reissis D, 2017, ANN ROY COLL SURG, V99, pE233, DOI 10.1308/rcsann.2017.0156; Ren YM, 2017, INT WOUND J, V14, P480, DOI 10.1111/iwj.12629; Shah VV, 2016, DERMATOLOGY THER, V6, P169, DOI 10.1007/s13555-016-0118-5; Sobec Raluca, 2013, Clujul Med, V86, P313; van Leeuwen MCE, 2015, PRS-GLOB OPEN, V3, DOI 10.1097/GOX.0000000000000357; Wolfram D, 2009, DERMATOL SURG, V35, P171, DOI 10.1111/j.1524-4725.2008.34406.x; Xu J, 2017, CHINESE MED J-PEKING, V130, P1715, DOI 10.4103/0366-6999.209896; Zainib M., 2020, RAD THERAPY TREATMEN	27	2	2	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2021	16	3							e0248799	10.1371/journal.pone.0248799	http://dx.doi.org/10.1371/journal.pone.0248799			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC6NY	33755674	Green Published, gold			2023-01-03	WOS:000632916600009
J	Wang, S; Yang, XX; Wang, W; Zhang, YK; Li, TJ; Zhao, L; Bao, YR; Meng, XS				Wang, Shuai; Yang, Xinxin; Wang, Wei; Zhang, Yunkun; Li, Tianjiao; Zhao, Lin; Bao, Yongrui; Meng, Xiansheng			Interpretation of the absorbed constituents and pharmacological effect of Spica Schizonepetae extract on non-small cell lung cancer	PLOS ONE			English	Article								As a traditional Chinese medicine (TCM) with a usage history of over 2,000 years in China, Spica Schizonepetae possesses definite clinical activity in the treatment of non-small cell lung cancer (NSCLC). However, its active ingredients and mechanism of action remain unclear at present. The further exploration of its active components and underlying mechanism will provide a basis for the development of candidate anti-tumor drugs. Our previous study explored the chemical constituents of Spica Schizonepetae extract (SSE). On this basis, molecular networking technology was applied in analyzing the QTOF-MS/MS data of rat plasma after intragastric administration of SSE using the GNPS database platform. A total of 26 components were found, including 9 proterotype components and 17 metabolites, which revealed the potential active ingredients of SSE. Later, the Lewis lung cancer mouse model was established, and the inhibition rate and histopathological sections were used as the indicators to investigate the anti-tumor effect of SSE, whereas the body weight, survival rate, thymus index and spleen index served as the indicators to explore the pharmacological effects of SSE on improving mouse immunity. The results showed that SSE had comparable anti-tumor efficacy to cisplatin, which enhanced the immunity, improved the quality of life, and extended the survival time of lung cancer mice. Furthermore, human A549 lung tumor cells were selected to explore the mechanism of SSE in treating NSCLC based on cell metabonomics. After data mining by the MPP software, 23 differential endogenous metabolites were identified between SSE and tumor groups. Moreover, results of pathway enrichment analysis using the MetaboAnalyst 4.0 software indicated that these metabolites were mainly enriched in four metabolic pathways (p < 0.1). By adopting the network pharmacology method, the metabolic pathways discovered by cell metabolomics were verified against the ChEMBL, STITCH, UniProt and TCGA databases, and differences in the underlying mechanism between cells and humans were found. It was proved that SSE affected the metabolism of purine, arachidonic acid and histidine to exert the anti-tumor efficacy. Furthermore, the multi-target, multi-pathway, and immunoenhancement mechanism of SSE in anti-tumor treatment was revealed, which provided a scientific basis for new drug development and the rational application of Spica Schizonepetae in clinic.	[Wang, Shuai; Yang, Xinxin; Wang, Wei; Li, Tianjiao; Zhao, Lin; Bao, Yongrui; Meng, Xiansheng] Liaoning Univ Tradit Chinese Med, Coll Pharm, Dalian, Peoples R China; [Wang, Shuai; Yang, Xinxin; Li, Tianjiao; Bao, Yongrui; Meng, Xiansheng] Liaoning Multidimens Anal Tradit Chinese Med Tech, Dalian, Peoples R China; [Zhang, Yunkun] Dalian Med Univ, Affiliated Hosp 2, Dalian, Peoples R China	Liaoning University of Traditional Chinese Medicine; Dalian Medical University	Bao, YR; Meng, XS (corresponding author), Liaoning Univ Tradit Chinese Med, Coll Pharm, Dalian, Peoples R China.; Bao, YR; Meng, XS (corresponding author), Liaoning Multidimens Anal Tradit Chinese Med Tech, Dalian, Peoples R China.	byr1026@163.com; mxsvvv@163.com	yang, xin/HGU-9981-2022	Bao, Yongrui/0000-0003-0588-2113; Wang, Shuai/0000-0002-8895-5199	Liaoning Key Research and Development Project [2020JH2/10300088]; Natural Science Foundation of Liaoning Province [2019-ZD-0946]; Liaoning Provincial TCM Modernization Research and Innovation Team Project [LT2017015]; National Key Research and Development Project [2018YFC1704805]; Youth Program of Education Department of Liaoning Province [L201725]; Liaoning Province Distinguished Professor Support Program, China [187]	Liaoning Key Research and Development Project; Natural Science Foundation of Liaoning Province(Natural Science Foundation of Liaoning Province); Liaoning Provincial TCM Modernization Research and Innovation Team Project; National Key Research and Development Project; Youth Program of Education Department of Liaoning Province; Liaoning Province Distinguished Professor Support Program, China	Xiansheng Meng, the Liaoning Key Research and Development Project (2020JH2/10300088); Shuai Wang, the Natural Science Foundation of Liaoning Province (2019-ZD-0946); Xiansheng Meng, the Liaoning Provincial TCM Modernization Research and Innovation Team Project (LT2017015); Xinxin Yang, the National Key Research and Development Project (2018YFC1704805); Wei Wang, the Youth Program of Education Department of Liaoning Province (L201725).; This work received the support of the Liaoning Province Distinguished Professor Support Program (Liao Jiao Fa [2014] No.187), China.	Anwar J, 2013, FOOD CHEM TOXICOL, V56, P459, DOI 10.1016/j.fct.2013.02.030; Boudreau LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031833; Brandao RD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3409; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen SG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01110-x; Chung TW, 2004, FASEB J, V18, P1670, DOI 10.1096/fj.04-2126com; Ferraz-Filha ZS, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/2712108; Flesner BK, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0290-8; Huang CY, 2011, TOXICOL IN VITRO, V25, P1274, DOI 10.1016/j.tiv.2011.04.014; Jiang ZQ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020447; Kang OH, 2010, MOLECULES, V15, P385, DOI 10.3390/molecules15010385; Li Yaoyuan, 2011, Zhongguo Zhong Yao Za Zhi, V36, P3375; Li YC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/383608; Li ZH, 2018, TALANTA, V189, P606, DOI 10.1016/j.talanta.2018.07.020; Lin YH, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/6514705; Liu WT, 2014, J ANTIBIOT, V67, P99, DOI 10.1038/ja.2013.99; Luo LK, 2019, J CHROMATOGR B, V1129, DOI 10.1016/j.jchromb.2019.121791; Mahboubi-Rabbani M, 2021, CURR MED CHEM, V28, P1143, DOI 10.2174/0929867326666191210104820; Pauff JM, 2009, J NAT PROD, V72, P725, DOI 10.1021/np8007123; Quinn RA, 2017, TRENDS PHARMACOL SCI, V38, P143, DOI 10.1016/j.tips.2016.10.011; Radhika R, 2018, J BIOMOL STRUCT DYN, V36, P1369, DOI 10.1080/07391102.2017.1323013; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Wang BS, 2012, FOOD CHEM TOXICOL, V50, P526, DOI 10.1016/j.fct.2011.12.010; Wang S, 2019, J LIQ CHROMATOGR R T, V42, P605, DOI 10.1080/10826076.2019.1646274; Wang XJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep18997; Yarla NS, 2016, SEMIN CANCER BIOL, V40-41, P48, DOI 10.1016/j.semcancer.2016.02.001; Yin J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01697; Yu ST, 2019, J PHARMACEUT BIOMED, V166, P281, DOI 10.1016/j.jpba.2019.01.020	28	3	3	9	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2021	16	3							e0248700	10.1371/journal.pone.0248700	http://dx.doi.org/10.1371/journal.pone.0248700			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY9GW	33730076	gold, Green Published			2023-01-03	WOS:000630345000073
J	Anttila, MR; Soderlund, A; Sjogren, T				Anttila, Marjo-Riitta; Soderlund, Anne; Sjogren, Tuulikki			Patients' experiences of the complex trust-building process within digital cardiac rehabilitation	PLOS ONE			English	Article							LIFE; SUPPORT; DISEASE; CARE	The development of digital solutions is becoming increasingly important in facing global challenges. Therefore, research on this topic is important in taking into account cardiac patients' experiences of the rehabilitation process for the design of digital counseling solutions. The aim of the present qualitative study was to explore the different meanings that patients give to the rehabilitation process using a Glaserian grounded theory (GT) approach. Qualitative interviews were conducted with 30 participants from a rehabilitation center in Finland. The findings indicated a "complex trust-building process" core category comprising five categories of trust-building in rehabilitation: feeling that one has hit rock bottom, facing and coping in a crosscurrent, understanding together as a peer group, moving toward a healthier lifestyle with technology, and finding self-awareness. The complex process of trust-building involved interactions among emotion, cognition, and acceptance and support processes. Therefore, digital rehabilitation should be incorporated into counseling based on patients' psychosocial, physical and emotional needs to help patients become aware of their own feelings and thoughts during the rehabilitation process.	[Anttila, Marjo-Riitta; Sjogren, Tuulikki] Univ Jyvaskyla, Fac Sport & Hlth Sci, Jyvaskyla, Finland; [Soderlund, Anne] Malardalen Univ, Sch Hlth Care & Social Welf, Vasteras, Sweden	University of Jyvaskyla; Malardalen University	Anttila, MR (corresponding author), Univ Jyvaskyla, Fac Sport & Hlth Sci, Jyvaskyla, Finland.	marjo-riitta.m-r.anttila@jyu.fi		Anttila, Marjo-Riitta/0000-0002-6950-4261; Soderlund, Anne/0000-0002-4537-030X	University of Jyvaskyla; Social insurance institution of Finland (Kela)	University of Jyvaskyla; Social insurance institution of Finland (Kela)	University of Jyvaskyla and Social insurance institution of Finland (Kela) The University of Jyvaskyla is employer by researchers, Tuulikki Sjogren and Marjo-Riitta Anttila (salary). The authors received no specific funding for this work (article). The funders (Kela) had no role (no salary) in decision to publish, or preparation of the manuscript by any authors.	Anttila MR, 2019, J MED INTERNET RES, V21, DOI 10.2196/10985; BANDURA A, 1989, AM PSYCHOL, V44, P1175, DOI 10.1037/0003-066X.44.9.1175; Banner D, 2015, STUD HEALTH TECHNOL, V209, P9, DOI 10.3233/978-1-61499-505-0-9; BECK AT, 1970, BEHAV THER, V1, P184, DOI 10.1016/S0005-7894(70)80030-2; Buys R, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0329-9; Clark RA, 2015, EUR J PREV CARDIOL, V22, P35, DOI 10.1177/2047487313501093; Comer J. S., 2013, BERGIN GARFIELDS HDB, Vsixth, P21; Devi R, 2014, INT J THER REHABIL, V21, P434, DOI 10.12968/ijtr.2014.21.9.434; Ellis JM, 2019, J CARDIOPULM REHABIL, V39, pE13, DOI 10.1097/HCR.0000000000000429; Embuldeniya G, 2013, PATIENT EDUC COUNS, V92, P3, DOI 10.1016/j.pec.2013.02.002; Folkman S., 1984, STRESS APPRAISAL COP; Gallo LC, 2005, J BEHAV MED, V28, P433, DOI 10.1007/s10865-005-9010-y; Glaser B., 1992, BASICS GROUNDED THEO; Glaster B. G., 1967, THEORETICAL SENSITIV; Hamalainen H, 2000, SCAND J PUBLIC HEALT, V28, P62, DOI 10.1177/140349480002800111; Hansen TB, 2018, EUR J CARDIOVASC NUR, V17, P45, DOI 10.1177/1474515117716245; Hare DL, 2014, EUR HEART J, V35, P1365, DOI 10.1093/eurheartj/eht462; Hellem E, 2020, PHYSIOTHER THEOR PR, V36, P1107, DOI 10.1080/09593985.2018.1550829; Jbilou J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029560; Jokar F, 2017, J NURS RES, V25, P344, DOI [10.1097/jnr.0000000000000220, 10.1097/JNR.0000000000000220]; Kazantzis N, 2018, COGNITIVE THER RES, V42, P349, DOI 10.1007/s10608-018-9920-y; Knudsen MV, 2020, EUR J CARDIOVASC NUR, V19, P376, DOI 10.1177/1474515119885325; Livneh H, 2005, J COUNS DEV, V83, P12, DOI 10.1002/j.1556-6678.2005.tb00575.x; Melholt C, 2018, PATIENT EDUC COUNS, V101, P854, DOI 10.1016/j.pec.2017.12.017; Moos RH, 2003, J CLIN PSYCHOL, V59, P1387, DOI 10.1002/jclp.10229; Park C.L., 1997, REV GEN PSYCHOL, V1, P115, DOI [10.1037/1089-2680.1.2.115, DOI 10.1037/1089-2680.1.2.115, https://doi.org/10.1037/1089-2680.1.2.115, 10.1037//1089-2680.1.2.115, DOI 10.1037//1089-2680.1.2.115]; Partridge SR, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.8081; Pfaeffli L., 2013, HEART LUNG CIRC, V22, P567, DOI [10.1016/j.hlc.2013.04.048, DOI 10.1016/J.HLC.2013.04.048]; Rawstorn JC, 2018, ARCH PHYS MED REHAB, V99, P2373, DOI 10.1016/j.apmr.2018.06.027; Richards SH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002902.pub4; Roy S.C., 1999, ROY ADAPTATION MODEL; Schaufel MA, 2011, INT J QUAL STUD HEAL, V6, DOI 10.3402/qhw.v6i1.5917; Schweier R, 2018, PATIENT EDUC COUNS, V101, P1283, DOI 10.1016/j.pec.2018.02.015; Smart JF, 2009, J REHABIL, V75, P3; Steinhubl SR, 2015, J AM COLL CARDIOL, V66, P1489, DOI 10.1016/j.jacc.2015.08.006; STRUTZEL E, 1968, NURS RES, V17, P364; Webb TL, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1376; Wentzer HS, 2013, INT J MED INFORM, V82, pE386, DOI 10.1016/j.ijmedinf.2013.01.008; Yates BC, 2018, J CARDIOPULM REHABIL, V38, pE6, DOI 10.1097/HCR.0000000000000317; Yehle KS, 2012, J CARDIOPULM REHABIL, V32, P203, DOI 10.1097/HCR.0b013e31825b4e6a	40	3	3	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2021	16	3							e0247982	10.1371/journal.pone.0247982	http://dx.doi.org/10.1371/journal.pone.0247982			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QV3DJ	33690681	Green Published, gold			2023-01-03	WOS:000627855600009
J	Emmanouilidis, L; Esteban-Hofer, L; Damberger, FF; de Vries, T; Nguyen, CKX; Ibanez, LF; Mergenthal, S; Klotzsch, E; Yulikov, M; Jeschke, G; Allain, FHT				Emmanouilidis, Leonidas; Esteban-Hofer, Laura; Damberger, Fred F.; de Vries, Tebbe; Nguyen, Cristina K. X.; Ibanez, Luis Fabregas; Mergenthal, Simon; Klotzsch, Enrico; Yulikov, Maxim; Jeschke, Gunnar; Allain, Frederic H. -T.			NMR and EPR reveal a compaction of the RNA-binding protein FUS upon droplet formation	NATURE CHEMICAL BIOLOGY			English	Article							PHASE-SEPARATION; DISTANCE MEASUREMENTS; LIQUID DROPLETS; TRANSITION; GRANULES	Many RNA-binding proteins undergo liquid-liquid phase separation, which underlies the formation of membraneless organelles, such as stress granules and P-bodies. Studies of the molecular mechanism of phase separation in vitro are hampered by the coalescence and sedimentation of organelle-sized droplets interacting with glass surfaces. Here, we demonstrate that liquid droplets of fused in sarcoma (FUS)-a protein found in cytoplasmic aggregates of amyotrophic lateral sclerosis and frontotemporal dementia patients-can be stabilized in vitro using an agarose hydrogel that acts as a cytoskeleton mimic. This allows their spectroscopic characterization by liquid-phase NMR and electron paramagnetic resonance spectroscopy. Protein signals from both dispersed and condensed phases can be observed simultaneously, and their respective proportions can be quantified precisely. Furthermore, the agarose hydrogel acts as a cryoprotectant during shock-freezing, which facilitates pulsed electron paramagnetic resonance measurements at cryogenic temperatures. Surprisingly, double electron-electron resonance measurements revealed a compaction of FUS in the condensed phase.	[Emmanouilidis, Leonidas; Damberger, Fred F.; de Vries, Tebbe; Nguyen, Cristina K. X.; Allain, Frederic H. -T.] Swiss Fed Inst Technol, Inst Biochem, Dept Biol, Zurich, Switzerland; [Esteban-Hofer, Laura; Ibanez, Luis Fabregas; Yulikov, Maxim; Jeschke, Gunnar] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Lab Phys Chem, Zurich, Switzerland; [Mergenthal, Simon; Klotzsch, Enrico] Humboldt Univ, Inst Biol Expt Biophys Mechanobiol, Berlin, Germany; [Klotzsch, Enrico] Swiss Fed Inst Technol, Dept Hlth Sci & Technol, Lab Appl Mechanobiol, Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Humboldt University of Berlin; Swiss Federal Institutes of Technology Domain; ETH Zurich	Emmanouilidis, L; Allain, FHT (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Dept Biol, Zurich, Switzerland.; Jeschke, G (corresponding author), Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Lab Phys Chem, Zurich, Switzerland.	leonidas@bc.biol.ethz.ch; gjeschke@ethz.ch; allain@bc.biol.ethz.ch	Damberger, Fred F/A-8938-2011	Damberger, Fred F/0000-0002-8457-3409; Esteban Hofer, Laura/0000-0002-5793-116X; Fabregas Ibanez, Luis/0000-0002-8085-1256; Emmanouilidis, Leonidas/0000-0001-8931-8901; Jeschke, Gunnar/0000-0001-6853-8585; Mergenthal, Simon/0000-0002-6795-1084; de Vries, Tebbe/0000-0001-8851-3537	Swiss National Science Foundation; Sinergia [CR-SII5_170976]; NCCR RNA Disease; EMBO long-term postdoctoral fellowship; Volkswagen Foundation Experiment! grant [95664]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Sinergia; NCCR RNA Disease; EMBO long-term postdoctoral fellowship(European Molecular Biology Organization (EMBO)); Volkswagen Foundation Experiment! grant	This work was supported by the Swiss National Science Foundation with Sinergia grant no. CR-SII5_170976, NCCR RNA & Disease and an EMBO long-term postdoctoral fellowship. E.K. acknowledges support from Volkswagen Foundation Experiment! grant no. 95664. We thank K. Weis and M. Hondele for sharing microscope instruments and expertise, and A. Gossert and I. Ritsch for valuable discussions.	Abbondanzieri EA, 2019, CURR GENET, V65, P691, DOI 10.1007/s00294-018-00927-x; Alberti S, 2018, J MOL BIOL, V430, P4806, DOI 10.1016/j.jmb.2018.06.038; Baust J, 2006, ADV BIOPRESERVATION, DOI [10.1201/9781420004229.ch1, DOI 10.1201/9781420004229.CH1]; Bentmann E, 2012, J BIOL CHEM, V287, P23079, DOI 10.1074/jbc.M111.328757; Boeynaems S, 2018, TRENDS CELL BIOL, V28, P420, DOI 10.1016/j.tcb.2018.02.004; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Borbat PP, 2013, J PHYS CHEM LETT, V4, P170, DOI 10.1021/jz301788n; Bosco DA, 2010, HUM MOL GENET, V19, P4160, DOI 10.1093/hmg/ddq335; Brady JP, 2017, P NATL ACAD SCI USA, V114, pE8194, DOI 10.1073/pnas.1706197114; Breitgoff FD, 2017, PHYS CHEM CHEM PHYS, V19, P15766, DOI 10.1039/c7cp01488k; Burke KA, 2015, MOL CELL, V60, P231, DOI 10.1016/j.molcel.2015.09.006; Dorn G, 2017, NAT METHODS, V14, P487, DOI [10.1038/NMETH.4235, 10.1038/nmeth.4235]; Elbaum-Garfinkle S, 2015, P NATL ACAD SCI USA, V112, P7189, DOI 10.1073/pnas.1504822112; Fabregas Ibanez Luis, 2020, Magn Reson (Gott), V1, P209, DOI 10.5194/mr-1-209-2020; Feric M, 2013, NAT CELL BIOL, V15, P1253, DOI 10.1038/ncb2830; Gomes E, 2019, J BIOL CHEM, V294, P7115, DOI 10.1074/jbc.TM118.001192; Gromov I, 2001, J MAGN RESON, V149, P196, DOI 10.1006/jmre.2001.2298; Guo M, 2017, P NATL ACAD SCI USA, V114, pE8618, DOI 10.1073/pnas.1705179114; Hughes MP, 2018, SCIENCE, V359, P698, DOI 10.1126/science.aan6398; Jeschke G, 2012, ANNU REV PHYS CHEM, V63, P419, DOI 10.1146/annurev-physchem-032511-143716; Jeschke G, 2009, PHYS CHEM CHEM PHYS, V11, P6580, DOI 10.1039/b905724b; Kato M, 2012, CELL, V149, P753, DOI 10.1016/j.cell.2012.04.017; Klare JP, 2009, PHOTOSYNTH RES, V102, P377, DOI 10.1007/s11120-009-9490-7; Lameiras P, 2019, FARADAY DISCUSS, V218, P233, DOI 10.1039/c8fd00226f; Li PL, 2012, NATURE, V483, P336, DOI 10.1038/nature10879; Lin Y, 2017, J BIOL CHEM, V292, P19110, DOI 10.1074/jbc.M117.800466; Lin Y, 2015, MOL CELL, V60, P208, DOI 10.1016/j.molcel.2015.08.018; Lucas LH, 2004, CONCEPT MAGN RESON A, V20A, P24, DOI 10.1002/cmr.a.10094; Luo F, 2018, NAT STRUCT MOL BIOL, V25, P341, DOI 10.1038/s41594-018-0050-8; McSwiggen DT, 2019, GENE DEV, V33, P1619, DOI 10.1101/gad.331520.119; Milo R, 2013, BIOESSAYS, V35, P1050, DOI 10.1002/bies.201300066; Mitrea DM, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-015-0125-7; Mitrev Y, 2016, CHEM COMMUN, V52, P5418, DOI 10.1039/c6cc01853j; Murakami T, 2015, NEURON, V88, P678, DOI 10.1016/j.neuron.2015.10.030; Murray DT, 2017, CELL, V171, P615, DOI 10.1016/j.cell.2017.08.048; Murthy AC, 2020, J BIOL CHEM, V295, P2375, DOI 10.1074/jbc.REV119.009847; Murthy AC, 2019, NAT STRUCT MOL BIOL, V26, P637, DOI 10.1038/s41594-019-0250-x; Nott TJ, 2015, MOL CELL, V57, P936, DOI 10.1016/j.molcel.2015.01.013; Pastore A, 2007, J PEPT SCI, V13, P342, DOI 10.1002/psc.848; Patel A, 2015, CELL, V162, P1066, DOI 10.1016/j.cell.2015.07.047; Protter DSW, 2016, TRENDS CELL BIOL, V26, P668, DOI 10.1016/j.tcb.2016.05.004; Reichheld SE, 2017, P NATL ACAD SCI USA, V114, pE4408, DOI 10.1073/pnas.1701877114; Shang YL, 2016, BRAIN RES, V1647, P65, DOI 10.1016/j.brainres.2016.03.036; Souquere S, 2009, J CELL SCI, V122, P3619, DOI 10.1242/jcs.054437; Tripathi V, 2012, MOL BIOL CELL, V23, P3694, DOI 10.1091/mbc.E12-03-0206; Tsang B, 2019, P NATL ACAD SCI USA, V116, P4218, DOI 10.1073/pnas.1814385116; Tschaggelar R, 2009, J MAGN RESON, V200, P81, DOI 10.1016/j.jmr.2009.06.007; Wang J, 2018, CELL, V174, P688, DOI 10.1016/j.cell.2018.06.006; Wheeler JR, 2017, METHODS, V126, P12, DOI 10.1016/j.ymeth.2017.04.020	50	23	23	6	44	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAY	2021	17	5					608	614		10.1038/s41589-021-00752-3	http://dx.doi.org/10.1038/s41589-021-00752-3		MAR 2021	7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RS6YG	33686294				2023-01-03	WOS:000626376100002
J	Silva, TACC; Quigley, SP; Kidd, LJ; Anderson, ST; McLennan, SR; Poppi, DP				Silva, Tiago A. C. C.; Quigley, Simon P.; Kidd, Lisa J.; Anderson, Stephen T.; McLennan, Stuart R.; Poppi, Dennis P.			Effect of a high crude protein content diet during energy restriction and re-alimentation on animal performance, skeletal growth and metabolism of bone tissue in two genotypes of cattle	PLOS ONE			English	Article							CATCH-UP GROWTH; CASTRATE MALE CATTLE; COMPENSATORY GROWTH; FOOD RESTRICTION; PHOSPHATASE-ACTIVITY; TRENBOLONE ACETATE; FEED RESTRICTION; BODY-COMPOSITION; BOS-INDICUS; DAIRY-COWS	The objective of this study was to investigate the effect of diet crude protein (CP) content and metabolisable energy (ME) intake on skeletal growth and associated parameters of growing steers prior to and during compensatory growth in weight and catch-up growth in skeletal elongation. The experiment was a factorial design with two cattle genotypes [Brahman crossbred (BX, 178 +/- 6 kg) and Holstein-Friesian (HF, 230 +/- 34 kg)] and three nutritional treatments; high CP content and high ME intake (HCP-HME), high CP content and low ME intake (HCP-LME) and low CP content and low ME intake (LCP-LME) with the ME intake of HCP-LME matched to that of LCP-LME. Nutritional treatments were imposed over a 103 d period (Phase 1), and after this, all steers were offered ad libitum access to the HCP-HME nutritional treatment for 100 d (Phase 2). Steers fed the high CP content treatment with a low ME intake, showed higher hip height gain (P = 0.04), larger terminal hypertrophic chondrocytes (P = 0.02) and a higher concentration of total triiodothyronine in plasma (P = 0.01) than steers with the same ME intake of the low CP content treatment. In addition, the low CP treatment resulted in significant decreases in bone volume (P = 0.03), bone surface area (P = 0.03) and the concentration of bone-specific alkaline phosphatase in plasma (P < 0.001) compared to steers fed the HCP-HME treatment. A significant interaction between genotype and nutritional treatment existed for the concentration of thyroxine (T4) in plasma where HF steers fed LCP-LME had a lower T4 concentration in plasma (P = 0.05) than BX steers. All steers with a restricted ME intake during Phase 1 demonstrated compensatory growth during Phase 2. However, HF steers fed the LCP treatment during Phase 1 showed a tendency (P = 0.07) for a greater LWG during Phase 2 without any increase in dry matter intake. Results observed at the growth plate and hip height growth suggest that catch-up growth in cattle may also be explained by the growth plate senescence hypothesis. Contrary to our initial hypothesis, the results demonstrate that greater CP intake during ME restriction does not increase compensatory gain in cattle during re-alimentation.	[Silva, Tiago A. C. C.] Univ New England, Sch Environm & Rural Sci, Armidale, NSW, Australia; [Silva, Tiago A. C. C.; Quigley, Simon P.; Poppi, Dennis P.] Univ Queensland, Sch Agr & Food Sci, Gatton, Australia; [Kidd, Lisa J.] Univ Queensland, Sch Vet Sci, Gatton, Australia; [Anderson, Stephen T.] Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia; [McLennan, Stuart R.] Univ Queensland, Ctr Anim Sci, Queensland Alliance Agr & Food Innovat, Dutton Pk, Australia	University of New England; University of Queensland; University of Queensland; University of Queensland; University of Queensland	Silva, TACC (corresponding author), Univ New England, Sch Environm & Rural Sci, Armidale, NSW, Australia.; Silva, TACC (corresponding author), Univ Queensland, Sch Agr & Food Sci, Gatton, Australia.	tiago.silva@une.edu.au	da Silva, Tiago Alves Corrêa Carvalho/AAW-5060-2020	da Silva, Tiago Alves Corrêa Carvalho/0000-0001-6138-9863	Meat and Livestock Australia (MLA); Coordination of Improvement of Higher Education Personnel (CAPES)	Meat and Livestock Australia (MLA)(Meat and Livestock Australia); Coordination of Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This study was funded by Meat and Livestock Australia (MLA) and the first author received financial support from Coordination of Improvement of Higher Education Personnel (CAPES). The funders had no role in study design,data collection and analysis, decision to publish, or preparation of the manuscript.	ALWAY SE, 1990, AM J PHYSIOL, V259, pC92, DOI 10.1152/ajpcell.1990.259.1.C92; Anderson ST, 2017, ANIM PROD SCI, V57, P2291, DOI 10.1071/AN17363; ASHWORTH A, 1969, BRIT J NUTR, V23, P835, DOI 10.1079/BJN19690094; BALCELLS J, 1992, J CHROMATOGR-BIOMED, V575, P153, DOI 10.1016/0378-4347(92)80517-T; BARON J, 1994, ENDOCRINOLOGY, V135, P1367, DOI 10.1210/en.135.4.1367; Bassett JHD, 2016, ENDOCR REV, V37, P135, DOI 10.1210/er.2015-1106; BLUM JW, 1985, J NUTR, V115, P417, DOI 10.1093/jn/115.4.417; Bourrin S, 2000, ENDOCRINOLOGY, V141, P3149, DOI 10.1210/en.141.9.3149; Bourrin S, 2000, J BONE MINER RES, V15, P1555, DOI 10.1359/jbmr.2000.15.8.1555; Bowen MK, 2006, AUST J AGR RES, V57, P173, DOI 10.1071/AR05182; BREUR GJ, 1991, J ORTHOPAED RES, V9, P348, DOI 10.1002/jor.1100090306; Butler WR, 2000, ANIM REPROD SCI, V60, P449, DOI 10.1016/S0378-4320(00)00076-2; Callis G, 1998, J HISTOTECHNOL, V21, P49; Chen X.B, 1995, ESTIMATION MICROBIAL; COOPER SDB, 1994, LIVEST PROD SCI, V40, P263, DOI 10.1016/0301-6226(94)90094-9; Coutinho EL, 2004, BRAZ J MED BIOL RES, V37, P1853, DOI 10.1590/S0100-879X2004001200011; DAMEN GM, 1994, J PEDIATR GASTR NUTR, V19, P394, DOI 10.1097/00005176-199411000-00005; Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS2, DOI 10.1007/s001980070002; DELMAS PD, 1991, J BONE MINER RES, V6, P639; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; Devlin MJ, 2010, J BONE MINER RES, V25, P2078, DOI 10.1002/jbmr.82; Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023; DROUILLARD JS, 1991, J ANIM SCI, V69, P3357; ELLENBERGER MA, 1989, J ANIM SCI, V67, P1446; Elsasser TH, 1989, J ANIM SCI, V67, P128, DOI [10.2527/jas1989.671128x, DOI 10.2527/JAS1989.671128X]; Ferrell C.L., 1988, J ANIM SCI, V66, P23, DOI [DOI 10.1093/ANSCI/66.SUPPLEMENT_3.23, 10.1093/ansci/66.Supplement_3.23]; FRANDSEN AM, 1954, ANAT REC, V119, P247, DOI 10.1002/ar.1091190208; Freer M., 2007, NUTR REQUIREMENTS DO; Gafni RI, 2001, PEDIATR RES, V50, P618, DOI 10.1203/00006450-200111000-00014; Gat-Yablonski G, 2008, J PEDIATR ENDOCR MET, V21, P879; GLASS AR, 1978, ENDOCRINOLOGY, V102, P1925, DOI 10.1210/endo-102-6-1925; Gonzalez-Bulnes A, 2012, REPRODUCTION, V144, P269, DOI 10.1530/REP-12-0105; Govoni KE, 2007, PHYSIOL GENOMICS, V30, P354, DOI 10.1152/physiolgenomics.00022.2007; HAYDEN JM, 1993, J ANIM SCI, V71, P3327, DOI 10.2527/1993.71123327x; Holly R. G., 1980, American Journal of Physiology, V238, pC63; Hornick JL, 1998, J ANIM SCI, V76, P260, DOI [10.2527/1998.761260x, DOI 10.2527/1998.761260X]; Hunt DW, 1991, J ANIM SCI, V69, P2452, DOI [10.2527/1991.6962452x, DOI 10.2527/1991.6962452X]; Hunter R, 1985, BRIT J NUTR, V53, P637; Huxley J. S., 1936, Nature London, V137, P780, DOI 10.1038/137780b0; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; Istasse L., 2000, Domestic Animal Endocrinology, V19, P121, DOI 10.1016/S0739-7240(00)00072-2; Jobling M, 2010, AQUACULT INT, V18, P501, DOI 10.1007/s10499-009-9260-8; Keogh K, 2015, J ANIM SCI, V93, P3578, DOI 10.2527/jas.2014-8470; Kim D, 2010, J VET MED SCI, V72, P773, DOI 10.1292/jvms.09-0409; Kurosaki N, 2007, J VET MED SCI, V69, P265, DOI 10.1292/jvms.69.265; KYRIAZAKIS I, 1993, BRIT J NUTR, V69, P617, DOI 10.1079/BJN19930064; Lee CY, 1990, J ANIM SCI, V68, P2682; Liesegang A, 1998, J DAIRY SCI, V81, P2614, DOI 10.3168/jds.S0022-0302(98)75819-9; Lui JC, 2011, ENDOCR REV, V32, P422, DOI 10.1210/er.2011-0001; Mardon J, 2009, PEDIATR RES, V66, P513, DOI 10.1203/PDR.0b013e3181b9b4bb; Mohan S, 2012, CURR OSTEOPOROS REP, V10, P178, DOI 10.1007/s11914-012-0100-9; Moreira VR, 2009, J DAIRY SCI, V92, P5189, DOI 10.3168/jds.2009-2289; Naranjo WM, 2002, ENDOCRINOLOGY, V143, P2233, DOI 10.1210/en.143.6.2233; Nilsson O, 2005, HORM RES, V64, P157, DOI 10.1159/000088791; Osborne J., 2010, PRACTICAL ASSESSMENT, V15, P12, DOI [10.7275/qbpc-gk17, DOI 10.7275/QBPC-GK17]; Pando R, 2014, J ENDOCRINOL, V223, P227, DOI 10.1530/JOE-14-0486; Passos MCF, 2001, NUTR RES, V21, P917, DOI 10.1016/S0271-5317(01)00294-9; Pinheiro J., 2018, NLME LINEAR NONLINEA; R.C. Team, 2013, R LANGUAGE ENV STAT; RADCLIFFE JD, 1979, BRIT J NUTR, V41, P111, DOI 10.1079/BJN19790018; RADCLIFFE JD, 1976, BRIT J NUTR, V36, P457, DOI 10.1079/BJN19760100; Ramos CF, 2000, P SOC EXP BIOL MED, V224, P256, DOI 10.1046/j.1525-1373.2000.22429.x; Ryan W. J., 1990, Nutrition Abstracts and Reviews. Series B, Livestock Feeds and Feeding, V60, P653; RYAN WJ, 1993, AUST J AGR RES, V44, P1623, DOI 10.1071/AR9931623; RYAN WJ, 1993, AUST J AGR RES, V44, P1609, DOI 10.1071/AR9931609; Salazar JAE, 2013, J ANIM PHYSIOL AN N, V97, P502, DOI 10.1111/j.1439-0396.2012.01291.x; Sato R, 2013, VET J, V197, P358, DOI 10.1016/j.tvjl.2013.01.013; SAWAYA AL, 1985, BRIT J NUTR, V53, P175, DOI 10.1079/BJN19850021; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shao YY, 2007, REV ENDOCR METAB DIS, V7, P265, DOI [10.1359/jbmr.070806, DOI 10.1359/JBMR.070806]; Sheng MHC, 2013, BONE, V52, P133, DOI 10.1016/j.bone.2012.09.027; Silva JE, 2006, PHYSIOL REV, V86, P435, DOI 10.1152/physrev.00009.2005; Sliwa E, 2010, J ANIM PHYSIOL AN N, V94, P293, DOI 10.1111/j.1439-0396.2008.00909.x; SMALLRIDGE RC, 1982, METABOLISM, V31, P538, DOI 10.1016/0026-0495(82)90091-9; van der Spek AH, 2017, MOL CELL ENDOCRINOL, V458, P29, DOI 10.1016/j.mce.2017.01.025; VANHOOF VO, 1990, CLIN CHEM, V36, P875; VANSOEST PJ, 1991, J DAIRY SCI, V74, P3583, DOI 10.3168/jds.S0022-0302(91)78551-2; WEBSTER AJF, 1993, P NUTR SOC, V52, P69, DOI 10.1079/PNS19930038; WILLIAMS PE, 1973, J ANAT, V116, P45; Wilsman NJ, 2008, J ORTHOP RES, V26, P1457, DOI 10.1002/jor.20547; WILSON PN, 1960, BIOL REV, V35, P324, DOI 10.1111/j.1469-185X.1960.tb01327.x; Yambayamba ESK, 1996, LIVEST PROD SCI, V46, P19, DOI 10.1016/0301-6226(96)00014-0; Yambayamba ESK, 1996, J ANIM SCI, V74, P57; YAYHA ZAH, 1994, CLIN SCI, V87, P213, DOI 10.1042/cs0870213; YOUNG M J, 1987, Proceedings of the New Zealand Society of Animal Production, V47, P73	85	1	1	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247718	10.1371/journal.pone.0247718	http://dx.doi.org/10.1371/journal.pone.0247718			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BB	33630953	gold, Green Published			2023-01-03	WOS:000624536800075
J	Shobiye, HO; Bolarinwa, OA; Fasiku, MM; Akande, TM; Janssens, W				Shobiye, Hezekiah Olayinka; Bolarinwa, Oladimeji Akeem; Fasiku, Mojirola Martina; Akande, Tanimola Makanjuola; Janssens, Wendy			What medicines do households keep in their cabinets? Understanding the possession and use of medicines at home and the role of health insurance in Nigeria	PLOS ONE			English	Article							SELF-MEDICATION; CARE; VENDORS; IMPACT	Background Globally, the possession of medicines stored at home is increasing. However, little is known about the determinants of possessing medicines, their usage according to clinical purpose, which we term 'correct drug match', and the role of health insurance. Methods This study uses data from a 2013 survey evaluating a health insurance program in Kwara State, Nigeria, which upgraded health facilities and subsidized insurance premiums. The final dataset includes 1,090 households and 4,641 individuals. Multilevel mixed-effects logistic regressions were conducted at both the individual level and at the level of the medicines kept in respondents' homes to understand the determinants of medicine possession and correct drug match, respectively, and to investigate the effect of health insurance on both. Results A total of 9,266 medicines were classified with 61.2% correct match according to self-reported use, 11.9% incorrect match and 26.9% indeterminate. Most medicines (73.0%) were obtained from patent proprietary medicine vendors (PPMVs). At 36.6%, analgesics were the most common medicine held at home, while anti-malarial use had the highest correct match at 96.1%. Antihistamines, vitamins and minerals, expectorants, and antibiotics were most likely to have an incorrect match at respectively 35.8%, 33.6%, 31.9%, and 26.6%. Medicines were less likely to have a correct match when found with the uneducated and obtained from public facilities. Enrolment in the insurance program increased correct matches for specific medicines, notably antihypertensives and antibiotics (odds ratio: 25.15 and 3.60, respectively). Conclusion Since PPMVs serve as both the most popular and better channel compared to the public sector to obtain medicines, we recommend that policymakers strengthen their focus on these vendors to educate communities on medicine types and their correct use. Health insurance programs that provide affordable access to improved-quality health facilities represent another important avenue for reducing the burden of incorrect drug use. This appears increasingly important in view of the global rise in antimicrobial resistance.	[Shobiye, Hezekiah Olayinka] Harvard Univ, John F Kennedy Sch Govt, Boston, MA 02115 USA; [Shobiye, Hezekiah Olayinka] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02118 USA; [Bolarinwa, Oladimeji Akeem; Akande, Tanimola Makanjuola] Univ Ilorin, Teaching Hosp, Dept Epidemiol & Community Hlth, Ilorin, Nigeria; [Fasiku, Mojirola Martina] Fed Med Ctr, Dept Community Med & Primary Care, Abeokuta, Ogun, Nigeria; [Janssens, Wendy] Amsterdam Inst Global Hlth & Dev AIGHD, Amsterdam, Netherlands; [Janssens, Wendy] Vrije Univ Amsterdam, Sch Business & Econ, Amsterdam, Netherlands	Harvard University; Boston University; University of Ilorin; Vrije Universiteit Amsterdam	Shobiye, HO (corresponding author), Harvard Univ, John F Kennedy Sch Govt, Boston, MA 02115 USA.; Shobiye, HO (corresponding author), Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02118 USA.	hoshobiye@gmail.com		Akande, Tanimola Makanjuola/0000-0002-5220-8669; Janssens, Wendy/0000-0002-2085-8608; Shobiye, Hezekiah/0000-0003-1395-0729	Stichting Health Insurance Fund - Netherlands Ministry of Foreign Affairs	Stichting Health Insurance Fund - Netherlands Ministry of Foreign Affairs	Stichting Health Insurance Fund (www.pharmaccess.org/health-insurance-fund) financed by the Netherlands Ministry of Foreign Affairs provided funding for research time of HOS, OAB, MMF, TMA and WJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afolabi AO, 2008, ANN AFR MED, V7, P120, DOI 10.4103/1596-3519.55666; Aina BA, 2008, J INFECT DEV COUNTR, V2, P68, DOI 10.3855/jidc.325; Akande TM, 2020, LONG TERM IMPACT VOL; Akinyandenu O, 2014, J SCI INNOV RES, V3, P251; [Anonymous], 2018, J COMMUNITY MED PRIM; Auta A, 2011, J PHARMACOL PHARMACO, V2, P195, DOI 10.4103/0976-500X.83290; Awad A. I., 2007, Eastern Mediterranean Health Journal, V13, P1202; Bennadi Darshana, 2013, J Basic Clin Pharm, V5, P19, DOI 10.4103/0976-0105.128253; Beyeler N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117165; Byarugaba DK, 2004, INT J ANTIMICROB AG, V24, P105, DOI 10.1016/j.ijantimicag.2004.02.015; Nguyen CV, 2012, HEALTH ECON, V21, P946, DOI 10.1002/hec.1768; Das J, 2012, J DEV ECON, V98, P76, DOI 10.1016/j.jdeveco.2011.07.001; De Bolle L, 2008, ANN PHARMACOTHER, V42, P572, DOI 10.1345/aph.1K533; Dupas P, 2011, ANNU REV ECON, V3, P425, DOI 10.1146/annurev-economics-111809-125029; Ekor M, 2014, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00177; El-Nimr NA, 2015, E MEDITERR HEALTH J, V21, P256, DOI 10.26719/2015.21.4.256; Fadare J, 2014, S AFR FAM PRACT, V56, P253, DOI 10.1080/20786190.2014.980155; Founou RC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189621; Gustafsson-Wright E., 2013, ACHIEVING UNIVERSAL, P28; Gustafsson-Wright E, 2018, INT J HEALTH ECON MA, V18, P221, DOI 10.1007/s10754-017-9231-y; Haque SMR., 2015, AM J MED MED SERVICE, V5, P31; Hendriks ME, 2014, JAMA INTERN MED, V174, P555, DOI 10.1001/jamainternmed.2013.14458; Holloway KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152020; Hu B, 2006, STAT SINICA, V16, P847; Janssens W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166121; Kamsu-Foguem B, 2014, INTEGR MED RES, V3, P126, DOI 10.1016/j.imr.2014.05.001; Kandasami S, 2019, JAIDS-J ACQ IMM DEF, V81, P533, DOI 10.1097/QAI.0000000000002064; Kheir N, 2011, DRUG HEALTHC PATIENT, V3, P99, DOI 10.2147/DHPS.S25372; Kumar YS., 2013, INT J PHARM THERAPEU, V4, P59; Leroy AM, 1987, RROD, DOI [10.1002/0471725382, DOI 10.1002/0471725382]; Makki M, 2019, PHARMACY-BASEL, V7, DOI 10.3390/pharmacy7020061; National Population Commission-NPC and ICF, 2019, NIG DEM HLTH SURV 20; Nelissen HE, 2020, HEALTH POLICY PLANN, V35, P354, DOI 10.1093/heapol/czz172; Ocan M, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-650; Ofori-Asenso R, 2016, PHARMACY-BASEL, V4, DOI 10.3390/pharmacy4040035; Ofori-Asenso R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3428-8; OSHINAME FO, 1992, SOC SCI MED, V35, P1477, DOI 10.1016/0277-9536(92)90050-Z; Ozioma E, 2019, HERBAL MED AFRICAN T, DOI [10.5772/intechopen.80348, DOI 10.5772/INTECHOPEN.80348]; Robyn PJ, 2012, HEALTH POLICY PLANN, V27, P156, DOI 10.1093/heapol/czr019; Tabi MM, 2006, INT NURS REV, V53, P52, DOI 10.1111/j.1466-7657.2006.00444.x; Teni FS, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4152-8; Uzochukwu BSC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091667; Vialle-Valentin CE, 2015, HEALTH POLICY PLANN, V30, P1044, DOI 10.1093/heapol/czu107; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Health Organization, 2010, PROBL IRR DRUG US SE; World Health Organization, 2004, RAT US MED; Yousif M A, 2002, East Mediterr Health J, V8, P422	48	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2021	16	2							e0247591	10.1371/journal.pone.0247591	http://dx.doi.org/10.1371/journal.pone.0247591			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QP2HW	33626095	gold, Green Published			2023-01-03	WOS:000623658100028
J	Miyashiro, S; Yamada, Y; Muta, T; Ishikawa, H; Abe, T; Hori, M; Oka, K; Koshikawa, F; Ito, E				Miyashiro, Shun; Yamada, Yurika; Muta, Toshizumi; Ishikawa, Haruyuki; Abe, Tetsuri; Hori, Masashi; Oka, Kotaro; Koshikawa, Fusako; Ito, Etsuro			Activation of the orbitofrontal cortex by both meditation and exercise: A near-infrared spectroscopy study	PLOS ONE			English	Article							PREFRONTAL CORTEX; INSULAR CORTEX; NITRIC-OXIDE; MINDFULNESS; BRAIN; STRESS; ATTENTION; RESPONSES; SYSTEM; STIMULATION	In some types of meditation, such as mindfulness and Zen, breathing is the focus of attention, whereas during an excessive, short-period of anaerobic exercise, the muscles become the focus of attention. Thus, during both efforts, one's attention is focused on a certain feature of the body. Both meditation and exercise generally provide mental refreshment to humans. We hypothesized that the same brain regions are activated by both efforts in humans. To examine this hypothesis, we engaged participants in 3 tasks: meditation, exercise, and a control task. After each task, the participants underwent a 2-back test to concentrate their thoughts, while changes in their blood hemoglobin levels were simultaneously monitored using near-infrared spectroscopy (NIRS). Seventeen participants (20-24 years of age; 11 men, 6 women) were enrolled. We applied a fast-Fourier transform (FFT) analysis to the NIRS wave data and calculated the correlation coefficients of the FFT data between (1) meditation and control, (2) exercise and control, and (3) meditation and exercise, at the orbitofrontal cortex (OFC) and dorsolateral prefrontal cortex (DLPFC), brain areas that are generally involved in mental refreshment. A significant difference in the correlation coefficients between the OFC and DLPFC was detected in the meditation and exercise analysis, and signal source analysis confirmed that the NIRS waves spread from the right and left OFC edges (i.e., right and left temples) toward the center. Our results suggest that both meditation and exercise activate the OFC, which is involved in emotional reactions and motivation behavior, resulting in mental refreshment.	[Miyashiro, Shun; Yamada, Yurika; Ito, Etsuro] Waseda Univ, Dept Biol, Tokyo, Japan; [Muta, Toshizumi; Ishikawa, Haruyuki; Abe, Tetsuri; Koshikawa, Fusako] Waseda Univ, Dept Psychol, Tokyo, Japan; [Hori, Masashi] Waseda Univ, Dept Educ Psychol, Tokyo, Japan; [Oka, Kotaro] Keio Univ, Dept Biosci & Informat, Yokohama, Kanagawa, Japan; [Oka, Kotaro; Ito, Etsuro] Waseda Univ, Waseda Res Inst Sci & Engn, Tokyo, Japan; [Oka, Kotaro; Ito, Etsuro] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung, Taiwan	Waseda University; Waseda University; Waseda University; Keio University; Waseda University; Kaohsiung Medical University	Ito, E (corresponding author), Waseda Univ, Dept Biol, Tokyo, Japan.; Ito, E (corresponding author), Waseda Univ, Waseda Res Inst Sci & Engn, Tokyo, Japan.; Ito, E (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Kaohsiung, Taiwan.	eito@waseda.jp		Ito, Etsuro/0000-0002-1877-6566	Japan Society for the Promotion of Science [19H00633]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by a Grant-in-Aid (19H00633) for Scientific Research (A) from the Japan Society for the Promotion of Science to F.K. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Alderman BL, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2015.225; Arnsten AFT, 2015, NAT NEUROSCI, V18, P1376, DOI 10.1038/nn.4087; Ashdown-Franks G, 2019, CURR OPIN PSYCHIATR, V32, P375, DOI 10.1097/YCO.0000000000000526; Basso Julia C, 2017, Brain Plast, V2, P127, DOI 10.3233/BPL-160040; Blagden JC, 1996, J ANXIETY DISORD, V10, P243, DOI 10.1016/0887-6185(96)00009-6; Braboszcz C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170647; Buhlmayer L, 2017, SPORTS MED, V47, P2309, DOI 10.1007/s40279-017-0752-9; Byun KH, 2014, NEUROIMAGE, V98, P336, DOI 10.1016/j.neuroimage.2014.04.067; Cumming G, 2007, J CELL BIOL, V177, P7, DOI 10.1083/jcb.200611141; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; Dentico D, 2018, EUR J NEUROSCI, V48, P2310, DOI 10.1111/ejn.14131; DEUTCH AY, 1990, PROG BRAIN RES, V85, P367; Doll A, 2016, NEUROIMAGE, V134, P305, DOI 10.1016/j.neuroimage.2016.03.041; Edwards MK, 2018, POSTGRAD MED, V130, P222, DOI 10.1080/00325481.2018.1409049; Eliot R S, 1976, Adv Cardiol, V18, P231; Esch T, 2005, NEUROENDOCRINOL LETT, V26, P175; Feng K, 2019, PSYCHIAT RES, V275, P86, DOI 10.1016/j.psychres.2019.03.015; Gallegos AM, 2017, CLIN PSYCHOL REV, V58, P115, DOI 10.1016/j.cpr.2017.10.004; Goldstein LE, 1996, J NEUROSCI, V16, P4787; Grant JA, 2013, BIOL PSYCHOL, V92, P275, DOI 10.1016/j.biopsycho.2012.09.007; Hamedinia M., 2017, BIOSCI BIOTECHNOL RE, V14, P1201, DOI [10.13005/bbra/2562, DOI 10.13005/bbra/2562]; Hegberg NJ, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00133; Hoshi Y, 2001, J APPL PHYSIOL, V90, P1657, DOI 10.1152/jappl.2001.90.5.1657; Ishikawa H, 2018, MINDFULNESS, V9, P556, DOI 10.1007/s12671-017-0797-8; Ito E, 2019, BIOPHYS PHYSICOBIOL, V16, P132, DOI 10.2142/biophysico.16.0_132; Kahlaoui K, 2012, BRAIN LANG, V121, P164, DOI 10.1016/j.bandl.2011.11.002; Kerr CE, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00012; Kida T, 2013, NEUROSCI RES, V76, P76, DOI 10.1016/j.neures.2013.03.006; Kitaura H, 2007, NEUROSCI RES, V59, P160, DOI 10.1016/j.neures.2007.06.1469; Krimer LS, 1998, NAT NEUROSCI, V1, P286, DOI 10.1038/1099; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Kwak S, 2020, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.03073; Le Roux-Mallouf T, 2020, MED SCI SPORT EXER, V52, P2437, DOI 10.1249/MSS.0000000000002387; Lee CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075360; Ludwig DS, 2008, JAMA-J AM MED ASSOC, V300, P1350, DOI 10.1001/jama.300.11.1350; LYUBOMIRSKY S, 1995, J PERS SOC PSYCHOL, V69, P176, DOI 10.1037/0022-3514.69.1.176; Maharjan A, 2019, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00533; Manna A, 2010, BRAIN RES BULL, V82, P46, DOI 10.1016/j.brainresbull.2010.03.001; MCLAUGHLIN LJ, 1978, PAVLOVIAN J BIOL SCI, V13, P29; MORROW J, 1990, J PERS SOC PSYCHOL, V58, P519, DOI 10.1037/0022-3514.58.3.519; Motomura K, 2019, BRAIN STRUCT FUNCT, V224, P2167, DOI 10.1007/s00429-019-01895-9; Murphy BL, 1996, P NATL ACAD SCI USA, V93, P1325, DOI 10.1073/pnas.93.3.1325; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; Pan C, 2001, IEEE T SIGNAL PROCES, V49, P444, DOI 10.1109/78.902128; Pascoe MC, 2017, PSYCHONEUROENDOCRINO, V86, P152, DOI 10.1016/j.psyneuen.2017.08.008; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rogers-Carter MM, 2018, NAT NEUROSCI, V21, P404, DOI 10.1038/s41593-018-0071-y; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Saito N, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/1260285; Shin J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196359; Simkin DR, 2014, CHILD ADOL PSYCH CL, V23, P487, DOI 10.1016/j.chc.2014.03.002; Sirgy MJ, 2019, QUAL LIFE RES, V28, P1921, DOI 10.1007/s11136-019-02145-5; STONE AA, 1984, J PERS SOC PSYCHOL, V46, P892, DOI 10.1037/0022-3514.46.4.892; Strangman G, 2002, NEUROIMAGE, V17, P719, DOI 10.1006/nimg.2002.1227; Sun H, 2016, NEUROGASTROENT MOTIL, V28, P1104, DOI 10.1111/nmo.12815; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; Takahashi T., 2018, INT J NEUROLOGY RES, V4, P364; Takizawa R, 2014, NEUROIMAGE, V85, P498, DOI 10.1016/j.neuroimage.2013.05.126; Tang YY, 2015, NAT REV NEUROSCI, V16, P213, DOI 10.1038/nrn3916; Tsuzuki D, 2007, NEUROIMAGE, V34, P1506, DOI 10.1016/j.neuroimage.2006.10.043; Van Cappellen P, 2016, SOC COGN AFFECT NEUR, V11, P1579, DOI 10.1093/scan/nsw078; Vilagut G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155431; Wallis JD, 2007, ANNU REV NEUROSCI, V30, P31, DOI 10.1146/annurev.neuro.30.051606.094334; Williams N, 2017, OCCUP MED-OXFORD, V67, P404, DOI 10.1093/occmed/kqx063; Williamson JW, 1999, J APPL PHYSIOL, V87, P1213; Williamson JW, 1997, J PHYSIOL-LONDON, V503, P277, DOI 10.1111/j.1469-7793.1997.277bh.x; Yu XJ, 2011, INT J PSYCHOPHYSIOL, V80, P103, DOI 10.1016/j.ijpsycho.2011.02.004	69	3	3	4	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2021	16	2							e0247685	10.1371/journal.pone.0247685	http://dx.doi.org/10.1371/journal.pone.0247685			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QO8DE	33621250	gold, Green Published			2023-01-03	WOS:000623367700015
J	Combes, G; Owen, G; Damery, S; Flanagan, S; Brown, C; Currie, G				Combes, Gill; Owen, Gareth; Damery, Sarah; Flanagan, Sarah; Brown, Celia; Currie, Graeme			Implementing a new clinical pathway in a non-receptive context: Mixed methods evaluation of a new fracture pathway for older people in a hospital Trust in the West Midlands, UK	PLOS ONE			English	Article								Objectives This paper reports a mixed methods evaluation of a new pathway to improve clinical outcomes for older people with fractures treated at a hospital Trust in the West Midlands, UK. The paper focuses specifically on the context surrounding the translation of the new pathway into practice and the way that external and internal factors influenced its adaptation and implementation. Methods Quantitative analysis used a controlled Interrupted Time Series (ITS) to estimate the effect of the new pathway on patient complication rate, median length of hospital stay and 30-day mortality by comparing the pre- and post-intervention periods. ITS data were extracted from the UK Trauma Audit and Research Network (TARN) database and a patient-level control group identified using propensity score matching. Parallel qualitative analysis aimed to examine the context surrounding the new pathway and how external and internal factors might influence its adaption and implementation into clinical practice. Data were collected via semi-structured interviews (n = 16) undertaken with staff and clinical stakeholders within the Trust and were analysed using the COM-B (Capability, Opportunity, Motivation) model of behaviour. Results No statistically significant effects were found for any of the patient outcomes studied in the controlled ITS analysis. Qualitative data suggest that the lack of effectiveness of the new initiative can be explained with reference to the capability, opportunity and motivation of internal Trust stakeholders to engage with the pathway, which created a non-receptive environment within the Trust. Conclusions Successfully implementing new care pathways in environments that may be non-receptive to change requires efforts to be put into winning 'hearts and minds' within the organisation to ensure engagement from key stakeholders during intervention development. Evidence must be provided internally of the way that a given intervention will alleviate the problematic issues being experienced within the organisation, and external dissemination of results should be avoided until there is evidence of a positive effect within the organisation where the new care pathway is first implemented.	[Combes, Gill; Damery, Sarah; Flanagan, Sarah] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Owen, Gareth; Currie, Graeme] Univ Warwick, Warwick Business Sch, Coventry, W Midlands, England; [Brown, Celia] Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England	University of Birmingham; University of Warwick; University of Warwick	Damery, S (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.	s.l.damery@bham.ac.uk	Damery, Sarah/ABA-8641-2021	Damery, Sarah/0000-0003-3681-8608	National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM)	National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM)	All authors were funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM), now recommissioned as NIHR Applied Research Collaboration West Midlands (https://warwick.ac.uk/fac/sci/med/about/centres/arc-wm/).This is an infrastructure grant and has no specific grant number. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	British Geriatrics Society, 2012, QUAL CAR OLD PEOPL U; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; Clement ND, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-26; Creswell J. W., 2013, QUAL INQ, V3rd; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Ferrera PC, 2000, AM J EMERG MED, V18, P575, DOI 10.1053/ajem.2000.9266; French SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-38; Greenhalgh T, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.8775; HINDS P, 1995, ORGAN SCI, V6, P373, DOI 10.1287/orsc.6.4.373; Huy QN, 1999, ACAD MANAGE REV, V24, P325, DOI 10.2307/259085; JICK TD, 1979, ADMIN SCI QUART, V24, P602, DOI 10.2307/2392366; Kroll T., 2009, MIXED METHODS RES NU; Leech, 2005, INT J SOC RES METHOD, V8, P375, DOI DOI 10.1080/13645570500402447; Linden A, 2015, STATA J, V15, P480, DOI 10.1177/1536867X1501500208; McNulty T, 2004, ORGAN STUD, V25, P1389, DOI 10.1177/0170840604046349; McNulty T, 2003, BRIT J MANAGE, V14, pS31, DOI 10.1111/j.1467-8551.2003.00391.x; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Morgan DL, 2007, J MIX METHOD RES, V1, P48, DOI 10.1177/2345678906292462; National Institute for Health and Care Excellence (NICE), 2012, CG103 DEL; NUTT PC, 1993, J MANAGE, V19, P299, DOI 10.1177/014920639301900206; Onwuegbuzie Anthony, 2003, HDB MIXED METHODS SO, P351; Pettigrew A., 1992, PUBLIC MONEY MANAGE, V12, P27, DOI [DOI 10.1080/09540969209387719, 10.1080/09540969209387719]; Pope C, 2006, QUALITATIVE RES HLTH; Robert G, 2014, PERSPECTIVES CONTEXT; Tasselli S, 2015, ORGAN STUD, V36, P841, DOI 10.1177/0170840614556917; Tonkin-Crine S, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0436-0; Walsh IJ, 2011, ACAD MANAGE J, V54, P1017, DOI 10.5465/amj.2008.0658; Williams I, 2011, HEALTH SERV MANAG RE, V24, P213, DOI 10.1258/hsmr.2011.011014	29	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2021	16	2							e0247455	10.1371/journal.pone.0247455	http://dx.doi.org/10.1371/journal.pone.0247455			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QO3ZL	33617583	Green Published, gold			2023-01-03	WOS:000623082400056
J	Kutal, D; Kunwar, RM; Baral, K; Sapkota, P; Sharma, HP; Rimal, B				Kutal, Durga; Kunwar, Ripu M.; Baral, Kedar; Sapkota, Prabhat; Sharma, Hari P.; Rimal, Bhagawat			Factors that influence the plant use knowledge in the middle mountains of Nepal	PLOS ONE			English	Article							MEDICINAL-PLANTS; SPECIES RICHNESS; PEOPLE; ETHNOBOTANY; HYPOTHESIS; VEGETATION; TAMBOPATA; DISTRICT; AREA; PERU	An account of total of 58 plant species including 57 genera and 43 families was reported as useful in ethnomedicine from semi-structured questionnaire survey to the 76 participants of Kaski and Baitadi districts, Nepal. Fieldwork and participatory meetings were carried out between September 2017 and January 2018. A total of 419 emic use reports including 150 from Kaski and 269 from Baitadi were reported from 58 ethnomedicinal plant species. Each species was reported for 2-43 use reports and each participant recorded 1-12 use reports. About 25% (n = 104) use reports were associated with the treatment of digestive system disorders followed by 83 for general complaints. Of the species assessed, 53 species had IASc value < 0.25 and only five species had > 0.25. Species Swertia chirayita, Paris polyphylla, Bergenia ciliata, Valeriana jatamansi and Centella asiatica with > 0.25 IASc were found to be highly consented; however they were incongruent between the sample groups and sites. Divergent plant use knowledge specific to each sample district and group was corresponding to the heterogeneity of socio-economy and culture of the sites. Gender, ethnicity, household economy and food availability of the respondents were leading factors affecting the plant use knowledge. Despite the sites were relatively homogenous in eco-physiography, they possessed the distinct plant use knowledge, hinted that the socio-economic factors are more explanatory in plant use knowledge.	[Kutal, Durga] Univ Wisconsin, Whitewater, WI 53190 USA; [Kunwar, Ripu M.] Ethnobot Soc Nepal, Kathmandu, Nepal; [Baral, Kedar] Massey Univ, Palmerston North, New Zealand; [Baral, Kedar; Sapkota, Prabhat] Dept Forest & Soil Conservat, Kathmandu, Nepal; [Sharma, Hari P.] Tribhuvan Univ, Inst Sci & Technol, Cent Dept Zool, Kathmandu, Nepal; [Rimal, Bhagawat] Tribhuvan Univ, Coll Appl Sci CAS Nepal, Kathmandu, Nepal	University of Wisconsin System; Massey University; Tribhuvan University; Institute of Science & Technology (IoST) - Nepal; Tribhuvan University	Kunwar, RM (corresponding author), Ethnobot Soc Nepal, Kathmandu, Nepal.	ripukunwar@gmail.com	Sharma, Hari Prasad/AFM-2895-2022; Sharma, Hari Prasad/AAT-6094-2021; Sharma, Hari Prasad/GOJ-7665-2022; Kunwar, Ripu/AAR-8887-2021	Sharma, Hari Prasad/0000-0002-0708-1769; Sharma, Hari Prasad/0000-0002-0708-1769; Kunwar, Ripu/0000-0002-9303-0932	National Geographic Society (USA) [EC-212R-18]	National Geographic Society (USA)(National Geographic Society)	Ripu Kunwar received an Early Career Grant (EC-212R-18) from National Geographic Society (USA) for field travel in Baitadi. Kedar Baral and Prabhat Sapkota received grants from divisional forest offices for field visits. But the grants did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are given in the `author contributions'.	ADB, 2017, COUNTRY POVERTY ANAL; Adhikari Mahendra, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6020069; Albuquerque UP., 2014, METHODS TECHNIQUES E, V1, DOI [10.1007/978-1-4614-8636-7, DOI 10.1007/978-1-4614-8636-7]; Alencar NL, 2010, ECON BOT, V64, P68, DOI 10.1007/s12231-009-9104-5; Amouei A, 2015, FUTUR MED ED J; [Anonymous], 2013, GASTROENTEROL HEP S3, P1, DOI DOI 10.1017/S1743923X12000670; Atreya K, 2018, ENVIRON MANAGE, V61, P741, DOI 10.1007/s00267-018-1009-6; Baral S., 2017, Banko Janakari, V27, P31, DOI 10.3126/banko.v27i1.18547; beda A., 2015, PLOS ONE, V10, P1, DOI DOI 10.1371/J0URNAL.P0NE.0127296; Bhandari P., 2018, J NAT HIST MUS, V30, P55, DOI [10.3126/jnhm.v30i0.27538, DOI 10.3126/JNHM.V30I0.27538]; Bhatt V., 2002, ZOOS PRINT J, P17; Bhatta D., 2003, COMMUNITY APPROACHES; Bhattarai K. R., 2018, Our Nature, V16, P55, DOI 10.3126/on.v16i1.22123; Bhattarai K. R., 2011, Banko Janakari, V21, P31; Bhuju U.R., 2007, NEPAL BIODIVERSITY R; Buchanan Hamilton F., 1971, ACCOUNT KINGDOM NEPA; Cameron MM, 1996, HUM ORGAN, V55, P84, DOI 10.17730/humo.55.1.g206551211750h58; Charmakar S, 2020, PEERJ; Chhetri Ram B., 1992, USER GROUP FORESTRY; Coburn B., 1984, KAILASH, V11, P55; Devkota R, 2003, BOT ORIENT, V1, P135; DFO, 2017, SIG PROT FOR SIG BAI; Dixit A, 2014, VULNERABILITY IMPACT; Giday M, 2003, J ETHNOPHARMACOL, V85, P43, DOI 10.1016/S0378-8741(02)00359-8; GoN, 2001, FLOW PLANTS NEP PHAN; Grau O, 2007, J BIOGEOGR, V34, P1907, DOI 10.1111/j.1365-2699.2007.01745.x; Gurung LJ., 2017, MED PLANTS NEPAL ANT, P152; Hagen T., 1969, DENCKSCHRIFT DESSCHW, V86, P1; Hasan M. K., 2013, International Journal of Medicinal and Aromatic Plants, V3, P102; ICIMOD, 2010, LAND COV NEP; IOM, 2019, MIGR NEP COUNTR PROF, P155; Koirala R., 1998, BOT DIVERSITY PROJEC; Kunwar RM, 2020, GLOB ECOL CONSERV, V23, DOI 10.1016/j.gecco.2020.e01081; Kunwar RM, 2020, ECOL INDIC, V108, DOI 10.1016/j.ecolind.2019.105679; Kunwar RM, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0242-7; Kunwar RM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167812; Kunwar RM, 2015, J ETHNOPHARMACOL, V163, P210, DOI 10.1016/j.jep.2015.01.035; Kunwar RM, 2020, J FORESTRY RES, V31, P1625, DOI 10.1007/s11676-019-00987-w; LRMP, 1986, LAND SYST REP; Mahwasane ST, 2013, S AFR J BOT, V88, P69, DOI 10.1016/j.sajb.2013.05.004; Mainali J, 2019, CLIM DEV, V11, P607, DOI 10.1080/17565529.2018.1521329; Malla B, 2015, J ETHNOPHARMACOL, V165, P103, DOI 10.1016/j.jep.2014.12.057; Manzardo A E, 1976, Contrib Nepalese Stud, V3, P83; Manzardo AE., 1977, CONTRIB NEPALESE STU, V4, P63; Martin G, 1995, ETHNOBOTANY METHOD M, DOI [10.4324/9781849775854, DOI 10.4324/9781849775854]; MESSERSCHMIDT DA, 1976, HUM ECOL, V4, P167, DOI 10.1007/BF01531219; Miller G.C., 2009, M WHO COLL CTR FAM I; Muller JG, 2015, AMBIO, V44, P67, DOI 10.1007/s13280-014-0517-8; Nunes AT, 2016, J ARID ENVIRON, V135, P96, DOI 10.1016/j.jaridenv.2016.08.015; Paniagua-Zambrana NY, 2014, ECOL SOC, V19, DOI 10.5751/ES-06934-190409; Pfeiffer Jeanine M., 2005, Journal of Ethnobiology, V25, P240, DOI 10.2993/0278-0771(2005)25[240:ACAEVI]2.0.CO;2; PHILLIPS O, 1993, ECON BOT, V47, P33, DOI 10.1007/BF02862204; Pokhrel G, 2019, FOR J I FOR NEPAL, V16, P14, DOI [10.3126/forestry.v16i0.28351, DOI 10.3126/FORESTRY.V16I0.28351]; Program WWF, 2005, OV GLAC GLAC RETR SU; Rasul G, 2012, MT RES DEV, V32, P137, DOI 10.1659/MRD-JOURNAL-D-11-00112.1; Reyes-Garcia V, 2006, ECON BOT, V60, P62, DOI 10.1663/0013-0001(2006)60[62:CPAEVO]2.0.CO;2; Rimal B, 2019, ECOSYST SERV, V38, DOI 10.1016/j.ecoser.2019.100963; Rivera D, 2007, ECON BOT, V61, P269, DOI 10.1663/0013-0001(2007)61[269:GFPITM]2.0.CO;2; Salick J, 2014, J ETHNOBIOL, V34, P276, DOI 10.2993/0278-0771-34.3.276; Saslis-Lagoudakis CH, 2011, J ETHNOPHARMACOL, V135, P476, DOI 10.1016/j.jep.2011.03.044; Sati B., 2014, SUSTAINABLE LIVELIHO; Singh V, 2017, J RES PRACT, V13; Skeldon R, 2011, CRIT ASIAN STUD, V43, P310, DOI 10.1080/14672715.2011.570572; Soldati G. T., 2017, Environment, Development and Sustainability, V19, P2143, DOI 10.1007/s10668-016-9844-1; Sousa RD, 2019, ACTA BOT BRAS, V33, P283, DOI 10.1590/0102-33062018abb0320; Staub PO, 2015, J ETHNOPHARMACOL, V174, P514, DOI 10.1016/j.jep.2015.08.051; Subedi A, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-64; Subedi R., 2017, ETHNOBOTANICAL STUDY; Thomas E, 2009, J ARID ENVIRON, V73, P854, DOI 10.1016/j.jaridenv.2009.03.010; Trotter RT., 1986, PLANTS INDIGENOUS ME, P91, DOI [10.4324/9781315060385-6, DOI 10.4324/9781315060385-6]; Turner NJ, 2009, GLOBAL ENVIRON CHANG, V19, P180, DOI 10.1016/j.gloenvcha.2009.01.005; Vandebroek I, 2010, ECON BOT, V64, P303, DOI 10.1007/s12231-010-9135-y; Vetaas OR, 2002, GLOBAL ECOL BIOGEOGR, V11, P291, DOI 10.1046/j.1466-822X.2002.00297.x; Voeks RA, 2007, SINGAPORE J TROP GEO, V28, P7, DOI 10.1111/j.1467-9493.2006.00273.x; Weckerle CS, 2006, ECON BOT, V60, P3, DOI 10.1663/0013-0001(2006)60[3:PKOTSI]2.0.CO;2; World Bank, 2020, LAND NEP	76	10	11	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246390	10.1371/journal.pone.0246390	http://dx.doi.org/10.1371/journal.pone.0246390			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QH4VJ	33571303	Green Published, gold			2023-01-03	WOS:000618274000099
J	Stirton, H; Meek, BP; Edel, AL; Solati, Z; Surendran, A; Aukema, H; Modirrousta, M; Ravandi, A				Stirton, Hannah; Meek, Benjamin P.; Edel, Andrea L.; Solati, Zahra; Surendran, Arun; Aukema, Harold; Modirrousta, Mandana; Ravandi, Amir			Oxolipidomics profile in major depressive disorder: Comparing remitters and non-remitters to repetitive transcranial magnetic stimulation treatment	PLOS ONE			English	Article							OXIDATIVE STRESS; INFLAMMATION; BRAIN; METAANALYSIS; MATTER	Background Repetitive Transcranial Magnetic Stimulation [rTMS] is increasingly being used to treat Major Depressive Disorder [MDD]. Given that not all patients respond to rTMS, it would be clinically useful to have reliable biomarkers that predict treatment response. Oxidized phosphatidylcholine [OxPC] and some oxylipins are important plasma biomarkers of oxidative stress and inflammation. Not only is depression associated with oxidative stress, but rTMS has been shown to have anti-oxidative effects. Objectives To investigate whether plasma oxolipidomics profiles could predict treatment response in patients with treatment resistant MDD. Methods Fourty-eight patients undergoing rTMS treatment for MDD were recruited along with nine healthy control subjects. Plasma OxPCs and oxylipins were extracted and analyzed through high performance liquid chromatography coupled with mass spectrometry. Patients with a Hamilton Depression Rating Scale score [Ham-D] <= 7 post-treatment were defined as having entered remission. Results Fifty-seven OxPC and 32 oxylipin species were identified in our subjects. MDD patients who entered remission following rTMS had significantly higher pre-rTMS levels of total and fragmented OxPCs compared to non-remitters and controls [one-way ANOVA, p<0.05]. However, no significant changes in OxPC levels were found as a result of rTMS, regardless of treatment response [p>0.05]. No differences in plasma oxylipins were found between remitters and non-remitters at baseline. Conclusion Certain categories of OxPCs may be useful predictive biomarkers for response to rTMS treatment in MDD. Given that elevated oxidized lipids may indicate higher levels of oxidative stress and inflammation in the brain, patients with this phenotype of depression may be more receptive to rTMS treatment.	[Stirton, Hannah; Edel, Andrea L.; Solati, Zahra; Surendran, Arun; Aukema, Harold; Ravandi, Amir] St Boniface Hosp Albrechtsen Res Ctr, Cardiovasc Lipid Lab, Winnipeg, MB, Canada; [Stirton, Hannah; Solati, Zahra; Surendran, Arun; Modirrousta, Mandana; Ravandi, Amir] Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada; [Meek, Benjamin P.; Modirrousta, Mandana] Univ Manitoba, Dept Psychiat, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Ravandi, A (corresponding author), St Boniface Hosp Albrechtsen Res Ctr, Cardiovasc Lipid Lab, Winnipeg, MB, Canada.; Modirrousta, M; Ravandi, A (corresponding author), Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada.; Modirrousta, M (corresponding author), Univ Manitoba, Dept Psychiat, Winnipeg, MB, Canada.	mmodirrousta@sbgh.mb.ca; aravandi@sbgh.mb.ca		/0000-0001-6663-1225; Meek, Benjamin P/0000-0001-8075-1290; Stirton, Hannah/0000-0001-5592-0240; Aukema, Harold/0000-0002-6982-7239	Research Manitoba	Research Manitoba	Funding for this work was provided from Research Manitoba. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Aftanas LI, 2018, B EXP BIOL MED+, V165, P195, DOI 10.1007/s10517-018-4128-4; Al-Orf SM, 2011, INDIAN J CLIN BIOCHE, V26, P154, DOI 10.1007/s12291-010-0064-4; Black CN, 2015, PSYCHONEUROENDOCRINO, V51, P164, DOI 10.1016/j.psyneuen.2014.09.025; Bochkov VN, 2010, ANTIOXID REDOX SIGN, V12, P1009, DOI 10.1089/ars.2009.2597; Chervyakov AV, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00303; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Durmaz O, 2018, J ECT, V34, P127, DOI 10.1097/YCT.0000000000000467; Faria R, 2014, NEUROSCIENCE, V273, P1, DOI 10.1016/j.neuroscience.2014.04.042; FOLCH J, 1957, J BIOL CHEM, V226, P497; George MS, 2013, CURR OPIN PSYCHIATR, V26, P13, DOI 10.1097/YCO.0b013e32835ab46d; Grieve SM, 2013, NEUROIMAGE-CLIN, V3, P332, DOI 10.1016/j.nicl.2013.08.016; Guest J, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-79; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hasin DS, 2018, JAMA PSYCHIAT, V75, P336, DOI 10.1001/jamapsychiatry.2017.4602; Ihara Y, 2005, NEUROL RES, V27, P310, DOI 10.1179/016164105X39897; Kar SK, 2019, CLIN PSYCHOPHARM NEU, V17, P25, DOI 10.9758/cpn.2019.17.1.25; Kelly MS, 2017, J NEUROPSYCH CLIN N, V29, P179, DOI 10.1176/appi.neuropsych.16100181; Kohler O, 2014, JAMA PSYCHIAT, V71, P1381, DOI 10.1001/jamapsychiatry.2014.1611; Lamers F, 2013, MOL PSYCHIATR, V18, P692, DOI 10.1038/mp.2012.144; Lindqvist D, 2017, PSYCHONEUROENDOCRINO, V76, P197, DOI 10.1016/j.psyneuen.2016.11.031; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P287; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P676, DOI 10.1016/j.pnpbp.2010.05.004; Maher P, 2000, CELL MOL LIFE SCI, V57, P1287, DOI 10.1007/PL00000766; Maia A, 2019, ACTA PSYCHIAT SCAND, V139, P420, DOI 10.1111/acps.13026; Marcourakis Tania, 2008, Dement. neuropsychol., V2, P2, DOI 10.1590/S1980-57642009DN20100002; Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5; Modirrousta M, 2018, NEUROPSYCH DIS TREAT, V14, P309, DOI 10.2147/NDT.S151841; Monirujjaman M, 2017, BBA-MOL CELL BIOL L, V1862, P1562, DOI 10.1016/j.bbalip.2017.08.005; Myint AM, 2009, METAB BRAIN DIS, V24, P55, DOI 10.1007/s11011-008-9114-5; Noda Y, 2015, PSYCHOL MED, V45, P3411, DOI 10.1017/S0033291715001609; OBRIEN JS, 1965, J LIPID RES, V6, P537; Post A, 1999, EUR J NEUROSCI, V11, P3247, DOI 10.1046/j.1460-9568.1999.00747.x; Sawamura J, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0838-6; Solati Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051051; Tunez I, 2006, NEUROSCI RES, V56, P91, DOI 10.1016/j.neures.2006.05.012; Wang JF, 2007, CAN J PSYCHIAT, V52, P753; Weismann D, 2012, BBA-BIOMEMBRANES, V1818, P2465, DOI 10.1016/j.bbamem.2012.01.018; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Whooley MA, 2013, ANNU REV CLIN PSYCHO, V9, P327, DOI 10.1146/annurev-clinpsy-050212-185526; World Health Organization, 2018, DEPRESSION	41	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246592	10.1371/journal.pone.0246592	http://dx.doi.org/10.1371/journal.pone.0246592			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH4VJ	33571313	gold, Green Published			2023-01-03	WOS:000618274000033
J	Pandurangi, RS; Tomasetti, M; Verapazham, ST; Paulmurugan, R; Ma, C; Rajput, S; Anjanappa, M; Nakshatri, H				Pandurangi, Raghu S.; Tomasetti, Marco; Verapazham, Sekar T.; Paulmurugan, Ramasamy; Ma, Cynthia; Rajput, Sandeep; Anjanappa, Manjushree; Nakshatri, Harikrishna			A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment	PLOS ONE			English	Article							NEGATIVE BREAST-CANCER; ALPHA-TOCOPHERYL SUCCINATE; NF-KAPPA-B; CATHEPSIN-B; DEFICIENT ACTIVATION; MULTIDRUG-RESISTANCE; CELLS; DOXORUBICIN; EXPRESSION; CD95	Cancer cells develop tactics to circumvent the interventions by desensitizing themselves to interventions. Amongst many, the principle routes of desensitization include a) activation of survival pathways (e.g. NF-kB, PARP) and b) downregulation of cell death pathways (e.g. CD95/CD95L). As a result, it requires high therapeutic dose to achieve tumor regression which, in turn damages normal cells through the collateral effects. Methods are needed to sensitize the low and non-responsive resistant tumor cells including cancer stem cells (CSCs) in order to evoke a better response from the current treatments. Current treatments including chemotherapy can induce cell death only in bulk cancer cells sparing CSCs and cancer resistant cells (CRCs) which are shown to be responsible for high recurrence of disease and low patient survival. Here, we report several novel tumor targeted sensitizers derived from the natural Vitamin E analogue (AMP-001-003). The drug design is based on a novel concept "A priori activation of apoptosis pathways of tumor technology (AAAPT) which is designed to activate specific cell death pathways and inhibit survival pathways simultaneously and selectively in cancer cells sparing normal cells. Our results indicate that AMP-001-003 sensitize various types of cancer cells including MDA-MB-231 (triple negative breast cancer), PC3 (prostate cancer) and A543 (lung cancer) cells resulting in reducing the IC-50 of doxorubicin in vitro when used as a combination. At higher doses, AMP-001 acts as an anti-tumor agent on its own. The synergy between AMP-001 and doxorubicin could pave a new pathway to use AAAPT leading molecules as neoadjuvant to chemotherapy to achieve better efficacy and reduced off-target toxicity compared to the current treatments.	[Pandurangi, Raghu S.] Sci Engi Medco Solut Inc, St Charles, MO 63303 USA; [Tomasetti, Marco] Polytech Univ Marche, Dept Clin & Mol Sci, Sect Expt & Occupat Med, Ancona, Italy; [Verapazham, Sekar T.; Paulmurugan, Ramasamy] Stanford Univ, Sch Med, Canary Ctr Canc Early Detect, Mol Imaging Program Stanford MIPS,Dept Radiol, Palo Alto, CA 94304 USA; [Ma, Cynthia; Rajput, Sandeep] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA; [Anjanappa, Manjushree; Nakshatri, Harikrishna] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Marche Polytechnic University; Stanford University; Siteman Cancer Center; Washington University (WUSTL); Indiana University System; Indiana University Bloomington	Pandurangi, RS (corresponding author), Sci Engi Medco Solut Inc, St Charles, MO 63303 USA.	raghuaa66@yahoo.com		Paulmurugan, Ramasamy/0000-0001-7155-4738	NIH [R43CA183353]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	All the funding or sources of support received during this study was from NIH R43CA183353 only. There was no additional external funding received for this study. Funding organization did not play any roles in designing experiments, data collection, analysis or any decision to publish the data. NIH has provided only financial support to Sci-Engi-Medco Solutions Inc SEMCO through salary (RP, PI) and research cost.	Alexandre J, 2007, CANCER RES, V67, P3512, DOI 10.1158/0008-5472.CAN-06-3914; Ali M, 2011, MOL CANCER THER, V10, P2320, DOI 10.1158/1535-7163.MCT-11-0356; Yau Meng-Choy Arthur Charles, 2011, J Orthop Surg (Hong Kong), V19, P1; [Anonymous], 2014, REG ANESTH PAIN MED; Benzer F, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22030; Bloomgarden ZT, 2016, J DIABETES, V8, P4, DOI 10.1111/1753-0407.12345; Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chung EJ, 1999, ACTA ONCOL, V38, P449; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dubowchik GM, 2002, BIOCONJUGATE CHEM, V13, P855, DOI 10.1021/bc025536j; Ebert MPA, 2005, PROTEOMICS, V5, P1693, DOI 10.1002/pmic.200401030; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Hainaut P, 2013, CURR OPIN ONCOL, V25, P50, DOI 10.1097/CCO.0b013e32835b651e; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; IC-50 of chemo drugs: Kline, 2011, BREAST CANCER RES, P13, DOI [10.1186/bcr2801 21214929, DOI 10.1186/BCR2801 21214929]; Ireland DJ, 2008, FOOD CHEM TOXICOL, V46, P508, DOI 10.1016/j.fct.2007.08.030; Joseph I, 2004, EJC S, V2-8, P473; Kaltschmidt C, 2019, CANCERS, V11, DOI 10.3390/cancers11050655; Kawada A, 1996, BRIT J DERMATOL, V135, P905, DOI 10.1046/j.1365-2133.1996.d01-1093.x; Krammer PH, 1997, CELL DEATH DIFFER, V4, P362, DOI 10.1038/sj.cdd.4400252; Kruszewski WJ, 2004, NEOPLASMA, V51, P38; Kuriyama H, 2002, NEURO-ONCOLOGY, V4, P179, DOI 10.1093/neuonc/4.3.179; Lebert JM, 2018, CURR ONCOL, V25, pS142, DOI 10.3747/co.25.3954; Liang L, 2012, J CONTROL RELEASE, V160, P618, DOI 10.1016/j.jconrel.2012.02.020; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Lory Santarelli, COMBINED CIRCULATING, V90, P457; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; May S.K S, 2007, BIOLOGICAL CHEMISTRY, V281, P10540; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; MIRSKI SEL, 1987, CANCER RES, V47, P2594; Moon DO, 2009, ARCH PHARM RES, V32, P1351, DOI 10.1007/s12272-009-2002-7; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nogueira V, 2013, CLIN CANCER RES, V19, P4309, DOI 10.1158/1078-0432.CCR-12-1424; Olivera A, 2012, INT IMMUNOPHARMACOL, V12, P368, DOI 10.1016/j.intimp.2011.12.009; Pandurangi Raghu, COMPOSITIONS METHODS, Patent No. WO/2017/131911; Pathan RA, 2010, INDIAN J PHARMACOL, V42, P44, DOI 10.4103/0253-7613.62411; Peter ME, 2015, CELL DEATH DIFFER, V22, P549, DOI 10.1038/cdd.2015.3; Pratt MR, 2009, CHEM BIOL, V16, P1001, DOI 10.1016/j.chembiol.2009.07.011; Raghu Pandurangi, 2019, J MED CHEM; Ramp U, 2000, BRIT J CANCER, V82, P1851, DOI 10.1054/bjoc.2000.1155; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Ruan Hang, 2015, Horiz Cancer Res, V56, P23; Sekar TV, 2014, THERANOSTICS, V4, P460, DOI 10.7150/thno.8077; Shao LJ, 2012, TRANSL CANCER RES, V1, P100, DOI 10.3978/j.issn.2218-676X.2012.05.04; SMETS LA, 1994, ANTI-CANCER DRUG, V5, P3, DOI 10.1097/00001813-199402000-00001; Srinivasarao M, 2015, NAT REV DRUG DISCOV, V14, P203, DOI 10.1038/nrd4519; Stepan Koudelka, J PHARM SCI, V99, P2434, DOI [10.1002/jps.22002 20039382, DOI 10.1002/JPS.22002 20039382]; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tomasetti M, 2004, BRIT J CANCER, V90, P1644, DOI 10.1038/sj.bjc.6601707; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wedam SB, 2006, J CLIN ONCOL, V24, P769, DOI 10.1200/JCO.2005.03.4645; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Wuchter C, 1999, LEUKEMIA, V13, P1943, DOI 10.1038/sj.leu.2401605; Yamasaki F, 2007, MOL CANCER THER, V6, P2168, DOI 10.1158/1535-7163.MCT-06-0514; Young-EE Kwon, 2007, ANTICANCER RES, V27, P321	59	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2021	16	2							e0225869	10.1371/journal.pone.0225869	http://dx.doi.org/10.1371/journal.pone.0225869			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG4AY	33556062	Green Published, gold, Green Submitted			2023-01-03	WOS:000617531400004
J	Kluge, MG; Maltby, S; Walker, N; Bennett, N; Aidman, E; Nalivaiko, E; Walker, FR				Kluge, Murielle G.; Maltby, Steven; Walker, Nicole; Bennett, Neanne; Aidman, Eugene; Nalivaiko, Eugene; Walker, Frederick Rohan			Development of a modular stress management platform (Performance Edge VR) and a pilot efficacy trial of a bio-feedback enhanced training module for controlled breathing	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; VIRTUAL-REALITY; COGNITIVE PERFORMANCE; COMMITMENT THERAPY; PACED RESPIRATION; BIOFEEDBACK; ACCEPTANCE; MEMORY	This paper describes the conceptual design of a virtual reality-based stress management training tool and evaluation of the initial prototype in a pilot efficacy study. Performance Edge virtual-reality (VR) was co-developed with the Australian Defence Force (ADF) to address the need for practical stress management training for ADF personnel. The VR application is biofeedback-enabled and contains key stress management techniques derived from acceptance and commitment and cognitive behavioural therapy in a modular framework. End-user-provided feedback on usability, design, and user experience was positive, and particularly complimentary of the respiratory biofeedback functionality. Training of controlled breathing delivered across 3 sessions increased participants' self-reported use of breath control in everyday life and progressively improved controlled breathing skills (objectively assessed as a reduction in breathing rate and variability). Thus the data show that a biofeedback-enabled controlled breathing protocol delivered through Performance Edge VR can produce both behaviour change and objective improvement in breathing metrics. These results confirm the validity of Performance Edge VR platform, and its Controlled Breathing module, as a novel approach to tailoring VR-based applications to train stress management skills in a workplace setting.	[Kluge, Murielle G.; Maltby, Steven; Nalivaiko, Eugene; Walker, Frederick Rohan] Univ Newcastle, Fac Hlth & Med, Ctr Adv Training Syst, Callaghan, NSW, Australia; [Kluge, Murielle G.; Maltby, Steven; Aidman, Eugene; Nalivaiko, Eugene; Walker, Frederick Rohan] Univ Newcastle, Fac Hlth & Med, Sch Biomed Sci & Pharm, Callaghan, NSW, Australia; [Walker, Nicole] Army Sch Hlth, Bonegilla, Vic, Australia; [Bennett, Neanne] Dept Def, Canberra, ACT, Australia; [Aidman, Eugene] Def Sci & Technol Grp, Land Div, Edinburgh, SA, Australia; [Aidman, Eugene] Univ Sydney, Sch Psychol, Sydney, NSW, Australia	University of Newcastle; University of Newcastle; Defence Science & Technology; Defence Science & Technology; University of Sydney	Walker, FR (corresponding author), Univ Newcastle, Fac Hlth & Med, Ctr Adv Training Syst, Callaghan, NSW, Australia.; Walker, FR (corresponding author), Univ Newcastle, Fac Hlth & Med, Sch Biomed Sci & Pharm, Callaghan, NSW, Australia.	rohan.walker@newcastle.edu.au	Bennett, Neanne/GWM-6383-2022	Maltby, Steven/0000-0003-1240-5964; AIDMAN, Eugene/0000-0002-7711-794X	Australian Defence Innovation Hub [CTD 2017-5]	Australian Defence Innovation Hub	Funding for this project was provided by the Australian Defence Innovation Hub (https://www.innovationhub.defence.gov.au/; Contract CTD 2017-5; authors EN & FRW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aidman E, 2020, FRONT HUM NEUROSCI, V13, DOI 10.3389/fnhum.2019.00466; Andersen JP, 2016, SAGE OPEN, V6, DOI 10.1177/2158244016638708; Andersen JP, 2015, SAGE OPEN, V5, DOI 10.1177/2158244015590446; [Anonymous], 2010, J OBSTET GYNAECOLOGY; Baars M, 2018, LEARN INDIVID DIFFER, V64, P125, DOI 10.1016/j.lindif.2018.05.007; Botella C, 2015, NEUROPSYCH DIS TREAT, V11, P2533, DOI 10.2147/NDT.S89542; Brady M, 2020, ETR&D-EDUC TECH RES, V68, P2853, DOI 10.1007/s11423-020-09800-6; CLARK ME, 1990, BIOFEEDBACK SELF-REG, V15, P273, DOI 10.1007/BF01011109; Crawford C, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/747694; de Bruin EI, 2016, MINDFULNESS, V7, P1182, DOI 10.1007/s12671-016-0561-5; Dessy E, 2018, J COGN ENHANCE, V2, P12, DOI 10.1007/s41465-017-0039-y; Engert V, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700495; Girotti M, 2018, PROG NEURO-PSYCHOPH, V85, P161, DOI 10.1016/j.pnpbp.2017.07.004; Grossman E, 2001, J HUM HYPERTENS, V15, P263, DOI 10.1038/sj.jhh.1001147; Heilman KJ, 2008, APPL PSYCHOPHYS BIOF, V33, P83, DOI 10.1007/s10484-008-9054-1; Jester DJ, 2019, AGING MENT HEALTH, V23, P574, DOI 10.1080/13607863.2018.1432031; Kaplan JB, 2017, MINDFULNESS, V8, P1373, DOI 10.1007/s12671-017-0713-2; Kennedy L, 2019, COGN TECHNOL WORK, V21, P161, DOI 10.1007/s10111-018-0487-x; Kiselev A. B., 2012, Vestnik Otorinolaringologii, P44; Koolhaas JM, 2011, NEUROSCI BIOBEHAV R, V35, P1291, DOI 10.1016/j.neubiorev.2011.02.003; Lerner D, 2020, JMIR SERIOUS GAMES, V8, DOI 10.2196/18822; Ley R, 1999, BEHAV MODIF, V23, P441, DOI 10.1177/0145445599233006; Liston C, 2009, P NATL ACAD SCI USA, V106, P912, DOI 10.1073/pnas.0807041106; Lupien SJ, 2007, BRAIN COGNITION, V65, P209, DOI 10.1016/j.bandc.2007.02.007; Maarsingh BM, 2019, GAMES HEALTH J, V8, P326, DOI 10.1089/g4h.2018.0145; Makransky G, 2018, ETR&D-EDUC TECH RES, V66, P1141, DOI 10.1007/s11423-018-9581-2; Mattingly V, 2019, HUM RESOUR MANAGE R, V29, P140, DOI 10.1016/j.hrmr.2018.03.002; MCCAUL KD, 1979, J PERS SOC PSYCHOL, V37, P564, DOI 10.1037/0022-3514.37.4.564; Meredith Lisa S, 2011, Rand Health Q, V1, P2; Ost LG, 2014, BEHAV RES THER, V61, P105, DOI 10.1016/j.brat.2014.07.018; Pallavicini F, 2016, AEROSP MED HUM PERF, V87, P1021, DOI 10.3357/AMHP.4596.2016; Pizzoli SFM, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00479; Powers MB, 2009, PSYCHOTHER PSYCHOSOM, V78, P73, DOI 10.1159/000190790; Prinsloo GE, 2013, APPL PSYCHOPHYS BIOF, V38, P81, DOI 10.1007/s10484-013-9210-0; Prinsloo GE, 2011, APPL COGNITIVE PSYCH, V25, P792, DOI 10.1002/acp.1750; Rizzo A, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1414560; Rockstroh C, 2019, INT J HUM-COMPUT ST, V130, P209, DOI 10.1016/j.ijhcs.2019.06.011; Roozendaal B, 2009, NAT REV NEUROSCI, V10, P423, DOI 10.1038/nrn2651; Russo MA, 2017, BREATHE, V13, P298, DOI 10.1183/20734735.009817; Schein MH, 2001, J HUM HYPERTENS, V15, P271, DOI 10.1038/sj.jhh.1001148; Schwabe L, 2012, NEUROSCI BIOBEHAV R, V36, P1740, DOI 10.1016/j.neubiorev.2011.07.002; Silverman WK, 2008, J CLIN CHILD ADOLESC, V37, P105, DOI 10.1080/15374410701817907; SISTO SA, 1995, CLIN AUTON RES, V5, P139, DOI 10.1007/BF01826195; Steptoe A, 2007, BRAIN BEHAV IMMUN, V21, P901, DOI 10.1016/j.bbi.2007.03.011; Stetz MC, 2011, MIL MED, V176, P1065, DOI 10.7205/MILMED-D-10-00393; Sutarto AP, 2013, WORK, V44, P231, DOI 10.3233/WOR-121499; van den Hout MA, 2011, J BEHAV THER EXP PSY, V42, P423, DOI 10.1016/j.jbtep.2011.03.004; van Dixhoorn Jan, 2015, ERJ Open Res, V1; Vaschillo EG, 2006, APPL PSYCHOPHYS BIOF, V31, P129, DOI 10.1007/s10484-006-9009-3; Wood KH, 2015, NEUROIMAGE, V119, P371, DOI 10.1016/j.neuroimage.2015.06.086; Yackle K, 2017, SCIENCE, V355, P1411, DOI 10.1126/science.aai7984; Zaccaro A, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00353	52	1	1	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2021	16	2							e0245068	10.1371/journal.pone.0245068	http://dx.doi.org/10.1371/journal.pone.0245068			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QF2NJ	33529187	gold, Green Published			2023-01-03	WOS:000616736200043
J	Bogale, B; Morkrid, K; Abbas, E; Abu Ward, I; Anaya, F; Ghanem, B; Hijaz, T; Isbeih, M; Issawi, S; Nazzal, ZAS; Qaddomi, SE; Froen, JF				Bogale, Binyam; Morkrid, Kjersti; Abbas, Eatimad; Abu Ward, Itimad; Anaya, Firas; Ghanem, Buthaina; Hijaz, Taghreed; Isbeih, Mervett; Issawi, Sally; Nazzal, Zaher A. S.; Qaddomi, Sharif E.; Froen, J. Frederik			The effect of a digital targeted client communication intervention on pregnant women's worries and satisfaction with antenatal care in Palestine-A cluster randomized controlled trial	PLOS ONE			English	Article							MIDDLE-INCOME COUNTRIES; HEALTH REGISTRY; BEHAVIOR-CHANGE; CHILD HEALTH; MOBILE PHONE; RELIABILITY; VALIDITY; VERSION; SCALE; QUALITY	Background The eRegCom cluster randomized controlled trial assesses the effectiveness of targeted client communication (TCC) via short message service (SMS) to pregnant women, from a digital maternal and child health registry (eRegistry) in Palestine, on improving attendance and quality of care. In this paper, we assess whether this TCC intervention could also have unintended consequences on pregnant women's worries, and their satisfaction with antenatal care (ANC). Methods We interviewed a sub-sample of Arabic-speaking women attending ANC at public primary healthcare clinics, randomized to either the TCC intervention or no TCC (control) in the eRegCom trial, who were in 38 weeks of gestation and had a phone number registered in the eRegistry. Trained female data collectors interviewed women by phone from 67 intervention and 64 control clusters, after securing informed oral consent. The Arabic interview guide, pilot-tested prior to the data collection, included close-ended questions to capture the woman's socio-demographic status, agreement questions about their satisfaction with ANC services, and the 13-item Cambridge Worry Scale (CWS). We employed a non-inferiority study design and an intention-to-treat analysis approach. Results A total of 454 women, 239 from the TCC intervention and 215 from the control arm participated in this sub-study. The mean and standard deviation of the CWS were 1.8 (1.9) for the intervention and 2.0 (1.9) for the control arm. The difference in mean between the intervention and control arms was -0.16 (95% CI: -0.31 to -0.01) after adjusting for clustering, which was below the predefined non-inferiority margin of 0.3. Women in both groups were equally satisfied with the ANC services they received. Conclusion The TCC intervention via SMS did not increase pregnancy-related worries among recipients. There was no difference in women's satisfaction with the ANC services between intervention and control arms.	[Bogale, Binyam; Morkrid, Kjersti; Froen, J. Frederik] Norwegian Inst Publ Hlth, Div Hlth Serv, Global Hlth Cluster, Oslo, Norway; [Bogale, Binyam; Froen, J. Frederik] Univ Bergen, Ctr Intervent Sci Maternal & Child Hlth, Bergen, Norway; [Abbas, Eatimad; Abu Ward, Itimad; Ghanem, Buthaina; Isbeih, Mervett; Issawi, Sally; Qaddomi, Sharif E.] Palestinian Natl Inst Publ Hlth, Irbid, Palestine; [Anaya, Firas; Nazzal, Zaher A. S.] An Najah Natl Univ, Fac Med & Hlth Sci, Nablus, Palestine; [Hijaz, Taghreed] Palestinian Minist Hlth, Ramallah, Palestine	Norwegian Institute of Public Health (NIPH); University of Bergen; An Najah National University	Froen, JF (corresponding author), Norwegian Inst Publ Hlth, Div Hlth Serv, Global Hlth Cluster, Oslo, Norway.; Froen, JF (corresponding author), Univ Bergen, Ctr Intervent Sci Maternal & Child Hlth, Bergen, Norway.	frederik.froen@fhi.no	Nazzal, Zaher Ahmad/AAW-3875-2020	Nazzal, Zaher Ahmad/0000-0002-2655-6109; Anaya, Firas/0000-0003-3033-1532	European Research Council [617639]; Research Council of Norway [234376, 223269]	European Research Council(European Research Council (ERC)European Commission); Research Council of Norway(Research Council of Norway)	This study and the eRegistry research project are funded by the European Research Council [https://erc.europa.eu/] (grant agreement number: 617639, project title: A New Paradigm for Public Health Surveillance: Unlocking the Potential of Data to Empower Woman and Health Systems; project acronym, HEALTHMPOWR) and the Research Council of Norway [https://www.forskningsradet.no/en/] (grant agreement number: 234376, project title: Harmonized Reproductive Health Registry Communication Strategies: Using Health Data to Empower Women and Health Systems; and grant agreement number: 223269, project title: Center for Intervention Science in Maternal and Child health (CISMAC) [https://www.uib.no/en/cismac], University of Bergen, Norway). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdi F, 2018, IRAN J PSYCHIATR BEH, V12, DOI 10.5812/ijpbs.14581; Allen-Scott LK, 2014, INT J PUBLIC HEALTH, V59, P3, DOI 10.1007/s00038-013-0526-6; Ames HMR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013447; [Anonymous], 2019, PASS 2019 POW AN SAM; Biaggi A, 2016, J AFFECT DISORDERS, V191, P62, DOI 10.1016/j.jad.2015.11.014; Bogale B, 2020, BMC MED INFORM DECIS, V20, DOI 10.1186/s12911-019-1002-x; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Monge FJC, 2012, MIDWIFERY, V28, P112, DOI 10.1016/j.midw.2010.11.006; Cho YM, 2018, TELEMED E-HEALTH, V24, P727, DOI 10.1089/tmj.2017.0249; Dauletyarova MA, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15020325; de Labrusse C, 2016, WOMEN HEALTH ISS, V26, P100, DOI 10.1016/j.whi.2015.09.003; Dennis CL, 2017, BRIT J PSYCHIAT, V210, P315, DOI 10.1192/bjp.bp.116.187179; Feroz A, 2017, BMC HEALTH SERV RES, V17, P1, DOI 10.1186/s12913-017-2664-7; Fjeldsoe BS, 2009, AM J PREV MED, V36, P165, DOI 10.1016/j.amepre.2008.09.040; Froen JF, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0801-7; Gourounti K, 2012, MIDWIFERY, V28, P746, DOI 10.1016/j.midw.2011.09.004; Green JM, 2003, J HEALTH PSYCHOL, V8, P753, DOI 10.1177/13591053030086008; Gugglberger L, 2018, HEALTH PROMOT INT, V33, P557, DOI 10.1093/heapro/day060; Gunay EY, 2015, MIDWIFERY, V31, P359, DOI 10.1016/j.midw.2014.10.003; Jareethum Rossathum, 2008, Journal of the Medical Association of Thailand, V91, P458; Lee SH, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.010401; Marcolino MS, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.8873; Mbuagbaw L, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-014-0654-6; Morkrid K, 2021, TRIALS, V22, DOI 10.1186/s13063-020-04980-1; Mortazavi F, 2016, SCIENTIFICA, V2016, DOI 10.1155/2016/5791560; Muench Frederick, 2017, J Med Internet Res, V19, pe147, DOI 10.2196/jmir.7463; Ohman SG, 2003, SCAND J CARING SCI, V17, P148, DOI 10.1046/j.1471-6712.2003.00095.x; Petersen JJ, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-490; Raine R, 2010, MATERN CHILD HLTH J, V14, P590, DOI 10.1007/s10995-009-0489-7; Rathbone AL, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7740; Sinesi A, 2019, BJPSYCH OPEN, V5, DOI 10.1192/bjo.2018.75; Sondaal SFV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154664; Stevens WJM, 2019, J MED INTERNET RES, V21, DOI 10.2196/10736; van den Heuvel JFM, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9262; Venkateswaran M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212635; Venkateswaran M, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2386-5; Vodopivec-Jamsek V, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007457.pub2; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO, 2022, WHO RECOMMENDATIONS; World Health Organization, 2019, WHO GUIDELINE RECOMM	40	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	4							e0249713	10.1371/journal.pone.0249713	http://dx.doi.org/10.1371/journal.pone.0249713			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RR0PU	33891597	Green Published, gold			2023-01-03	WOS:000642811900052
J	Kim, HR; Bae, HJ; Jeon, JW; Ham, YR; Na, KR; Lee, KW; Hyon, YK; Choi, DE				Kim, Hae Ri; Bae, Hong Jin; Jeon, Jae Wan; Ham, Young Rok; Na, Ki Ryang; Lee, Kang Wook; Hyon, Yun Kyong; Choi, Dae Eun			A novel approach to dry weight adjustments for dialysis patients using machine learning	PLOS ONE			English	Article							HEMODIALYSIS-PATIENTS; BIOIMPEDANCE SPECTROSCOPY; SERUM CREATININE; HYDRATION STATUS; MORTALITY; MARKER; MASS; OVERHYDRATION; DISEASE	Background and aims Knowledge of the proper dry weight plays a critical role in the efficiency of dialysis and the survival of hemodialysis patients. Recently, bioimpedance spectroscopy(BIS) has been widely used for set dry weight in hemodialysis patients. However, BIS is often misrepresented in clinical healthy weight. In this study, we tried to predict the clinically proper dry weight (DWCP) using machine learning for patient's clinical information including BIS. We then analyze the factors that influence the prediction of the clinical dry weight. Methods As a retrospective, single center study, data of 1672 hemodialysis patients were reviewed. DWCP data were collected when the dry weight was measured using the BIS (DWBIS). The gap between the two (Gap(DW)) was calculated and then grouped and analyzed based on gaps of 1 kg and 2 kg. Results Based on the gap between DWBIS and DWCP, 972, 303, and 384 patients were placed in groups with gaps of <1 kg, >= 1kg and <2 kg, and >= 2 kg, respectively. For less than 1 kg and 2 kg of GapDW, It can be seen that the average accuracies for the two groups are 83% and 72%, respectively, in usign XGBoost machine learning. As Gap(DW) increases, it is more difficult to predict the target property. As Gap(DW) increase, the mean values of hemoglobin, total protein, serum albumin, creatinine, phosphorus, potassium, and the fat tissue index tended to decrease. However, the height, total body water, extracellular water (ECW), and ECW to intracellular water ratio tended to increase. Conclusions Machine learning made it slightly easier to predict DWCP based on DWBIS under limited conditions and gave better insights into predicting DWCP. Malnutrition-related factors and ECW were important in reflecting the differences between DWBIS and DWCP.	[Kim, Hae Ri; Jeon, Jae Wan] Chungnam Natl Univ, Dept Internal Med, Div Nephrol, Sejong Hosp, Sejong, South Korea; [Kim, Hae Ri; Ham, Young Rok; Na, Ki Ryang; Lee, Kang Wook; Choi, Dae Eun] Chungnam Natl Univ, Med Sch, Dept Nephrol, Daejeon, South Korea; [Bae, Hong Jin] Cheongju St Marys Hosp, Div Nephrol, Dept Internal Med, Cheongju, South Korea; [Ham, Young Rok; Na, Ki Ryang; Lee, Kang Wook; Choi, Dae Eun] Chungnam Natl Univ, Med Sch, Dept Med Sci, Daejeon, South Korea; [Hyon, Yun Kyong] Natl Inst Math Sci, Med Math Div, Daejeon, South Korea	Chungnam National University; Chungnam National University; Chungnam National University; National Institute for Mathematical Sciences (NIMS), Republic of Korea	Choi, DE (corresponding author), Chungnam Natl Univ, Med Sch, Dept Nephrol, Daejeon, South Korea.; Choi, DE (corresponding author), Chungnam Natl Univ, Med Sch, Dept Med Sci, Daejeon, South Korea.; Hyon, YK (corresponding author), Natl Inst Math Sci, Med Math Div, Daejeon, South Korea.	hyon@nims.re.kr; daenii@cnu.ac.kr	Choi, Dae Eun/B-5996-2014	Choi, Dae Eun/0000-0003-2870-3958	National Institute for Mathematical Sciences (NIMS) - Korea government [NIMS-B21910000]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2017R1D1AB03035061]	National Institute for Mathematical Sciences (NIMS) - Korea government(National Institute for Mathematical Sciences (NIMS), Republic of Korea); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education(National Research Foundation of KoreaMinistry of Education (MOE), Republic of KoreaNational Research Council for Economics, Humanities & Social Sciences, Republic of Korea)	This research was supported by National Institute for Mathematical Sciences (NIMS) grant funded by the Korea government, 2021 (No. NIMSB21910000) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF2017R1D1AB03035061). However, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2011, CLIN J AM SOC NEPHRO, V6, P1066, DOI 10.2215/CJN.09321010; Amato R., 2008, ANNA CORE CURRICULUM, P692; Ando Y, 1995, ARTIF ORGANS, V19, P1237, DOI 10.1111/j.1525-1594.1995.tb02292.x; Androne AS, 2003, CIRCULATION, V107, P226, DOI 10.1161/01.CIR.0000052623.16194.80; Arefan D, 2020, MED PHYS, V47, P110, DOI 10.1002/mp.13886; Calvert J., 2017, BIORXIV, P223289; Chamney PW, 2002, KIDNEY INT, V61, P2250, DOI 10.1046/j.1523-1755.2002.00377.x; Chang ST, 2004, BLOOD PURIFICAT, V22, P351, DOI 10.1159/000080031; Charra B., 1993, ASAIO J; Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785; Cox-Reijven PL, 2001, AM J KIDNEY DIS, V38, P832, DOI 10.1053/ajkd.2001.27703; Daugirdas J.T., 2012, HDB DIALYSIS; Dumler F, 2003, ASAIO J, V49, P282, DOI 10.1097/01.MAT.0000065465.52748.BB; Fishbane S, 1996, AM J KIDNEY DIS, V28, P257, DOI 10.1016/S0272-6386(96)90309-1; Garagarza C, 2017, INT UROL NEPHROL, V49, P1243, DOI 10.1007/s11255-017-1558-2; Gupta A, 2018, HEALTHC INFORM RES, V24, P250, DOI 10.4258/hir.2018.24.3.250; Ho T.K., 1995, P 3 INT C DOC AN REC; Hung SC, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001480; Jaeger JQ, 1999, J AM SOC NEPHROL, V10, P392; Jones CH, 2002, J RENAL NUTR, V12, P209, DOI 10.1053/jren.2002.35295; Ke GL, 2017, ADV NEUR IN, V30; Lee SW, 2003, AM J KIDNEY DIS, V41, P1257, DOI 10.1016/S0272-6386(03)00358-5; Molnar MZ, 2011, AM J TRANSPLANT, V11, P725, DOI 10.1111/j.1600-6143.2011.03468.x; Nakhoul GN, 2015, AM J NEPHROL, V41, P456, DOI 10.1159/000437151; Onofriescu M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135691; Passauer J, 2010, NEPHROL DIAL TRANSPL, V25, P545, DOI 10.1093/ndt/gfp517; Patel SS, 2013, J CACHEXIA SARCOPENI, V4, P19, DOI 10.1007/s13539-012-0079-1; POGGI A, 1980, INT J ARTIF ORGANS, V3, P332, DOI 10.1177/039139888000300607; San Miguel S, 2010, REN SOC AUSTRALAS J, V6, P19; Sands JJ, 2014, HEMODIAL INT, V18, P415, DOI 10.1111/hdi.12138; Sinha AD, 2009, SEMIN DIALYSIS, V22, P480, DOI 10.1111/j.1525-139X.2009.00641.x; VERTES V, 1969, NEW ENGL J MED, V280, P978, DOI 10.1056/NEJM196905012801802; Vinge E, 1999, SCAND J CLIN LAB INV, V59, P587, DOI 10.1080/00365519950185076; Vitturi N, 2014, INT UROL NEPHROL, V46, P169, DOI 10.1007/s11255-013-0500-5; Wizemann V, 2009, NEPHROL DIAL TRANSPL, V24, P1574, DOI 10.1093/ndt/gfn707; Zaki DS., 2019, CLIN MED DIAGNOSTICS, V1	36	3	3	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	4							e0250467	10.1371/journal.pone.0250467	http://dx.doi.org/10.1371/journal.pone.0250467			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR0PU	33891656	Green Published, gold			2023-01-03	WOS:000642811900045
J	Wang, JN; Yang, WX; Chen, PW; Guo, JB; Liu, R; Wen, PF; Li, K; Lu, Y; Ma, T; Li, XL; Qin, SQ; Zhang, YM; Wang, YK				Wang, Junning; Yang, Weixia; Chen, Puwen; Guo, Jianbin; Liu, Rui; Wen, Pengfei; Li, Kun; Lu, Yao; Ma, Tao; Li, Xiaoli; Qin, Siqing; Zhang, Yumin; Wang, Yakang			The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis	PLOS ONE			English	Article							CLINICAL CHARACTERISTICS; WUHAN	Objectives Coronavirus disease 2019 (COVID-19) remains a global challenge. Corticosteroids constitute a group of anti-inflammatory and immunosuppressive drugs that are widely used in the treatment of COVID-19. Comprehensive reviews investigating the comparative proportion and efficacy of corticosteroid use are scarce. Therefore, we conducted a systematic review and meta-analysis of clinical trials to evaluate the proportion and efficacy of corticosteroid use for the treatment of COVID-19. Methods We conducted a comprehensive literature review and meta-analysis of research articles, including observational studies and clinical trials, by searching the PubMed, EMBASE, Cochrane Controlled Trials Registry, and China Academic Journal Network Publishing databases. Patients treated between December 1, 2019, and January 1, 2021, were included. The outcome measures were the proportion of patients treated with corticosteroids, viral clearance and mortality. The effect size with the associated 95% confidence interval is reported as the weighted mean difference for continuous outcomes and the odds ratio for dichotomous outcomes. Results Fifty-two trials involving 15710 patients were included. The meta-analysis demonstrated that the proportion of COVID-19 patients who received corticosteroids was significantly lower than that of patients who did not receive corticosteroids (35.19% vs. 64.49%). In addition, our meta-analysis demonstrated no significant difference in the proportions of severe and nonsevere cases treated with corticosteroids (27.91% vs. 20.91%). We also performed subgroup analyses stratified by whether patients stayed in the intensive care unit (ICU) and found that the proportion of patients who received corticosteroids was significantly higher among those who stayed in the ICU than among those who did not. The results of our meta-analysis indicate that corticosteroid treatment significantly delayed the viral clearance time. Finally, our meta-analysis demonstrated no significant difference in the use of corticosteroids for COVID-19 between patients who died and those who survived. This result indicates that mortality is not correlated with corticosteroid therapy. Conclusion The proportion of COVID-19 patients who received corticosteroids was significantly lower than that of patients who did not receive corticosteroids. Corticosteroid use in subjects with severe acute respiratory syndrome coronavirus 2 infections delayed viral clearance and did not convincingly improve survival; therefore, corticosteroids should be used with extreme caution in the treatment of COVID-19.	[Wang, Junning; Li, Xiaoli] Xi An Jiao Tong Univ, Honghui Hosp, Dept Resp, Xian, Peoples R China; [Yang, Weixia] Genertec Universal Xihang Hosp Xian Co Ltd, Dept Pathol, Xian, Peoples R China; [Chen, Puwen] Southern Med Univ, Affiliated Foshan Hosp, Peoples Hosp Foshan 2, Dept Cardiol, Foshan, Peoples R China; [Guo, Jianbin; Liu, Rui; Wen, Pengfei; Li, Kun; Lu, Yao; Ma, Tao; Qin, Siqing; Zhang, Yumin; Wang, Yakang] XianJiaotong Univ, Honghui Hosp, Dept Orthoped, Xian, Peoples R China	Xi'an Jiaotong University; Southern Medical University - China	Wang, YK (corresponding author), XianJiaotong Univ, Honghui Hosp, Dept Orthoped, Xian, Peoples R China.	wangyakangde@163.com			Shaanxi Natural Science Foundation of China [2019JQ-536]	Shaanxi Natural Science Foundation of China	This work was supported by the Shaanxi Natural Science Foundation of China (Number 2019JQ-536). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; [Anonymous], 2020, NEW ENGL J MED, DOI [DOI 10.1056/NEJMOA2002032, DOI 10.1056/NEJMC2005203]; Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC; [白澎 Bai Peng], 2020, [中华急诊医学杂志, Chinese Journal of Emergency Medicine], V29, P483; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Chen N, 2020, LANCET, V395, P507, DOI DOI 10.1016/S0140-6736(20)30211-7; Chen N, 2020, LANCET, V395, P507, DOI [10.1016/S0140-6736(20)30211-7, DOI 10.1016/S0140-6736(20)30183-5]; Cruz-Topete D, 2015, NEUROIMMUNOMODULAT, V22, P20, DOI 10.1159/000362724; Deng L., 2020, CLIN INFECT DIS, DOI [DOI 10.1093/CID/CIAA270, 10.1093/cid/ciaa270]; Deng YT, 2020, CAMB CHINA LIBR, P1; Dequin PF, 2020, JAMA-J AM MED ASSOC, V324, P1298, DOI 10.1001/jama.2020.16761; Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20; Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781; Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC; Emmi G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102575; Fang XW, 2020, J INFECTION, V81, P147, DOI 10.1016/j.jinf.2020.03.039; Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041; [高亭 Gao Ting], 2020, [中国呼吸与危重监护杂志, Chinese Journal of Respiratory and Critical Care Medicine], V19, P148; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Han YY, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108413; Hong KS, 2020, YONSEI MED J, V61, P431, DOI 10.3349/ymj.2020.61.5.431; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huang Q., 2020, INT J CLIN PHARM-NET, P1; Jacobs JP, 2020, ASAIO J, V66, P722, DOI 10.1097/MAT.0000000000001185; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jeronimo CMP, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1177.ciaa1177, DOI 10.1093/CID/CIAA1177, 10.1093/cid/ciaa1177]; Lee Kyung-Yil, 2020, Clin Exp Pediatr, V63, P117, DOI 10.3345/cep.2020.00290; Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006; Li H, 2020, LEUKEMIA, V34, P1503, DOI [10.1038/s41375-020-0848-3, 10.1007/s11263-020-01364-5]; Li Q, 2020, INFECT DIS THER, V9, P823, DOI 10.1007/s40121-020-00332-3; Li RQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104363; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Lian JS, 2020, INFLUENZA OTHER RESP, V14, P564, DOI 10.1111/irv.12758; Lian JS, 2020, CLIN INFECT DIS, V71, P740, DOI 10.1093/cid/ciaa242; Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774; Liu J, 2020, J CLIN INVEST, V130, P6417, DOI 10.1172/JCI140617; Luo DH, 2018, STAT METHODS MED RES, V27, P1785, DOI 10.1177/0962280216669183; Luo P., 2020, J MED VIROL, V92, P814, DOI [10.1002/jmv.25801, DOI 10.1002/jmv.25801]; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Mattiuzzi C, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.06; Monton C, 1999, EUR RESPIR J, V14, P218, DOI 10.1034/j.1399-3003.1999.14a37.x; Ni Q., 2020, CHINESE J CLIN INFEC, pE009; Organization WH. World Health Organization, COR DIS 2019 COVID 1; Petersen MW, 2020, ACTA ANAESTH SCAND, V64, P1365, DOI 10.1111/aas.13673; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Qiu CF, 2020, J MED VIROL, V92, P2027, DOI 10.1002/jmv.25975; Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022; Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Shen QX, 2020, PEDIATR PULM, V55, P1424, DOI 10.1002/ppul.24762; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Sun LJ, 2020, J MED VIROL, V92, P2055, DOI 10.1002/jmv.25966; Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; Wang LZ, 2020, CLIN EPIDEMIOL, V12, P387, DOI 10.2147/CLEP.S249903; Wang Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0158-2; Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351; Xu Zhe, 2020, Lancet Respir Med, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016; Yang X, 2020, LANCET RESP MED, V8, P475; Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062; Yuzhong W, 2020, CHINESE PHARMACOL B, P453; Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577; Zhang J, 2020, J COASTAL RES, V323, P1061, DOI DOI 10.2112/JCR-SI109-001.1; Zhang Y, 2020, DIABETES OBES METAB, V22, P1443, DOI 10.1111/dom.14086; Zhao XY, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05010-w; Zheng F, 2020, CURR MED SCI, V40, P275, DOI 10.1007/s11596-020-2172-6; Zhong H, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104872; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	75	14	14	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2021	16	4							e0249481	10.1371/journal.pone.0249481	http://dx.doi.org/10.1371/journal.pone.0249481			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0BF	33882090	gold, Green Submitted, Green Published			2023-01-03	WOS:000644133400010
J	Gasperini, B; Pelusi, G; Frascati, A; Sarti, D; Dolcini, F; Espinosa, E; Prospero, E				Gasperini, Beatrice; Pelusi, Gilda; Frascati, Annamaria; Sarti, Donatella; Dolcini, Franco; Espinosa, Emma; Prospero, Emilia			Predictors of adverse outcomes using a multidimensional nursing assessment in an Italian community hospital	PLOS ONE			English	Article							FRAILTY; CARE; PHENOTYPE; MORTALITY	Background There is growing evidence about the role of nurses in patient outcomes in several healthcare settings. However, there is still a lack of evidence about the transitional care setting. We aimed to assess the association between patient characteristics identified in a multidimensional nursing assessment and outcomes of mortality and acute hospitalization during community hospital stay. Methods A retrospective observational study was performed on patients consecutively admitted to a community hospital (CH) in Loreto (Ancona, Italy) between January 1(st), 2018 and May 31st, 2019. The nursing assessment included sociodemographic characteristics, functional status, risk of falls (Conley Score) and pressure damage (Norton scale), nursing diagnoses, presence of pressure sores, feeding tubes, urinary catheters or vascular access devices and comorbidities. Two logistic regression models were developed to assess the association between patient characteristics identified in a multidimensional nursing assessment and outcomes of mortality and acute hospitalization during CH stay. Results We analyzed data from 298 patients. The mean age was 83 +/- 9.9 years; 60.4% (n = 180) were female. The overall mean length of stay was 42.8 +/- 36 days (32 +/- 32 days for patients who died and 33.9 +/- 35 days for patients who had an acute hospitalization, respectively). An acute hospitalization was reported for 13.4% (n = 40) of patients and 21.8% (n = 65) died. An increased risk of death was related to female sex (OR 2.25, 95% CI 1.10-4.62), higher Conley Score (OR 1.19; 95% CI 1.03-1.37) and having a vascular access device (OR 3.64, 95% CI 1.82-7.27). A higher Norton score was associated with a decreased risk of death (OR 0.71, 95% CI 0.62-0.81). The risk for acute hospitalization was correlated with younger age (OR 0.94, 95% CI 0.91-0.97), having a vascular access device (OR 2.33, 95% CI 1.02-5.36), impaired walking (OR 2.50, 95% CI 1.03-6.06) and it is inversely correlated with a higher Conley score (OR 0.84, 95% CI 0.77-0.98). Conclusion Using a multidimensional nursing assessment enables identification of risk of nearness of end of life and acute hospitalization to target care and treatment. The present study adds further knowledge on this topic and confirms the importance of nursing assessment to evaluate the risk of patients' adverse outcome development.	[Gasperini, Beatrice; Sarti, Donatella; Prospero, Emilia] Univ Politecn Marche, Sect Hyg & Publ Hlth, Ancona, Italy; [Gasperini, Beatrice; Espinosa, Emma] Azienda Osped Osped Riuniti Marche Nord, Geriatr, Fano, PU, Italy; [Pelusi, Gilda] Univ Politecn Marche, Sch Nursing, Ancona, Italy; [Frascati, Annamaria] Intermediate Care Community Hosp, Loreto, AN, Italy; [Dolcini, Franco] ASUR Marche, Ancona, Italy	Marche Polytechnic University; Marche Polytechnic University	Gasperini, B (corresponding author), Univ Politecn Marche, Sect Hyg & Publ Hlth, Ancona, Italy.; Gasperini, B (corresponding author), Azienda Osped Osped Riuniti Marche Nord, Geriatr, Fano, PU, Italy.	b.gasperini@univpm.it	GASPERINI, BEATRICE/AAE-7339-2022	GASPERINI, BEATRICE/0000-0002-9981-3460; Prospero, Emilia/0000-0002-2387-8639				Allen J, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-346; American Nurses Association (ANA), 2010, NURS SOC POL STAT ES, V3rd; Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262; Burston S, 2014, J CLIN NURS, V23, P1785, DOI 10.1111/jocn.12337; Chang SF, 2015, INT J NURS STUD, V52, P1362, DOI 10.1016/j.ijnurstu.2015.04.005; Conley D, 1999, Medsurg Nurs, V8, P348; Coster S, 2018, INT J NURS STUD, V78, P76, DOI 10.1016/j.ijnurstu.2017.10.009; Dwyer R, 2014, AGE AGEING, V43, P759, DOI 10.1093/ageing/afu117; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Garasen H, 2008, SCAND J PUBLIC HEALT, V36, P197, DOI 10.1177/1403494808089685; Heslop L, 2014, J ADV NURS, V70, P2469, DOI 10.1111/jan.12503; Infusion Nurses Society (INS), 2021, J INFUS NURS S1, V44, pS1, DOI [DOI 10.1097/NAN.0000000000000396, 10.1097/NAN.0000000000000396, DOI 10.1097/NHH.0000000000000481]; Ingersoll GL, 2000, J ADV NURS, V32, P1272, DOI 10.1046/j.1365-2648.2000.01598.x; Kane Robert L, 2007, Evid Rep Technol Assess (Full Rep), P1; Kane RL, 2007, MED CARE, V45, P1195, DOI 10.1097/MLR.0b013e3181468ca3; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; Kojima G, 2018, AGE AGEING, V47, P193, DOI 10.1093/ageing/afx162; Kunaviktikul Wipada, 2005, Nurs Health Sci, V7, P273, DOI 10.1111/j.1442-2018.2005.00247.x; NANDA International, 2008, NURS DIAGN 2009 2011; National Institute for Health and Care Excellence, 2018, EM AC MED CAR 16 SER; Needleman J, 2011, NEW ENGL J MED, V364, P1037, DOI 10.1056/NEJMsa1001025; Norton D., 1962, INVESTIGATION GERIAT, V238, P12; Pilotto A, 2017, J AM MED DIR ASSOC, V18, DOI 10.1016/j.jamda.2016.11.004; Pitchforth E., 2017, HEALTH SERV DELIVERY, V5, DOI DOI 10.3310/HSDR05190; Rothman MJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000849; Sezgin D, 2020, EUR GERIATR MED, V11, P961, DOI 10.1007/s41999-020-00365-4; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Winpenny EM, 2016, INT J INTEGR CARE, V16, DOI 10.5334/ijic.2463	29	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2021	16	4							e0249630	10.1371/journal.pone.0249630	http://dx.doi.org/10.1371/journal.pone.0249630			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP1DC	33857183	Green Published, gold			2023-01-03	WOS:000641474900063
J	Friedman, GK; Johnston, JM; Bag, AK; Bernstock, JD; Li, R; Aban, I; Kachurak, K; Nan, L; Kang, KD; Totsch, S; Schlappi, C; Martin, AM; Pastakia, D; McNall-Knapp, R; Sait, SF; Khakoo, Y; Karajannis, MA; Woodling, K; Palmer, JD; Osorio, DS; Leonard, J; Abdelbaki, MS; Madan-Swain, A; Atkinson, TP; Whitley, RJ; Fiveash, JB; Markert, JM; Gillespie, GY				Friedman, G. K.; Johnston, J. M.; Bag, A. K.; Bernstock, J. D.; Li, R.; Aban, I; Kachurak, K.; Nan, L.; Kang, K. D.; Totsch, S.; Schlappi, C.; Martin, A. M.; Pastakia, D.; McNall-Knapp, R.; Sait, S. Farouk; Khakoo, Y.; Karajannis, M. A.; Woodling, K.; Palmer, J. D.; Osorio, D. S.; Leonard, J.; Abdelbaki, M. S.; Madan-Swain, A.; Atkinson, T. P.; Whitley, R. J.; Fiveash, J. B.; Markert, J. M.; Gillespie, G. Y.			Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND Outcomes in children and adolescents with recurrent or progressive high-grade glioma are poor, with a historical median overall survival of 5.6 months. Pediatric high-grade gliomas are largely immunologically silent or "cold," with few tumor-infiltrating lymphocytes. Preclinically, pediatric brain tumors are highly sensitive to oncolytic virotherapy with genetically engineered herpes simplex virus type 1 (HSV-1) G207, which lacks genes essential for replication in normal brain tissue. METHODS We conducted a phase 1 trial of G207, which used a 3+3 design with four dose cohorts of children and adolescents with biopsy-confirmed recurrent or progressive supratentorial brain tumors. Patients underwent stereotactic placement of up to four intratumoral catheters. The following day, they received G207 (10(7) or 10(8) plaque-forming units) by controlled-rate infusion over a period of 6 hours. Cohorts 3 and 4 received radiation (5 Gy) to the gross tumor volume within 24 hours after G207 administration. Viral shedding from saliva, conjunctiva, and blood was assessed by culture and polymerase-chain-reaction assay. Matched pre- and post-treatment tissue samples were examined for tumor-infiltrating lymphocytes by immunohistologic analysis. RESULTS Twelve patients 7 to 18 years of age with high-grade glioma received G207. No dose-limiting toxic effects or serious adverse events were attributed to G207 by the investigators. Twenty grade 1 adverse events were possibly related to G207. No virus shedding was detected. Radiographic, neuropathological, or clinical responses were seen in 11 patients. The median overall survival was 12.2 months (95% confidence interval, 8.0 to 16.4); as of June 5, 2020, a total of 4 of 11 patients were still alive 18 months after G207 treatment. G207 markedly increased the number of tumor-infiltrating lymphocytes. CONCLUSIONS Intratumoral G207 alone and with radiation had an acceptable adverse-event profile with evidence of responses in patients with recurrent or progressive pediatric high-grade glioma. G207 converted immunologically "cold" tumors to "hot."	[Friedman, G. K.; Kachurak, K.; Nan, L.; Kang, K. D.; Totsch, S.; Schlappi, C.; Madan-Swain, A.] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol Oncol, Birmingham, AL 35233 USA; [Atkinson, T. P.] Univ Alabama Birmingham, Div Pediat Allergy & Immunol, Birmingham, AL 35233 USA; [Whitley, R. J.] Univ Alabama Birmingham, Div Pediat Infect Dis, Birmingham, AL 35233 USA; [Friedman, G. K.; Johnston, J. M.; Markert, J. M.; Gillespie, G. Y.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35233 USA; [Li, R.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35233 USA; [Aban, I] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35233 USA; [Fiveash, J. B.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35233 USA; [Friedman, G. K.; Johnston, J. M.; Li, R.; Kachurak, K.; Madan-Swain, A.; Atkinson, T. P.; Whitley, R. J.] Childrens Alabama, Birmingham, AL USA; [Bag, A. K.] St Jude Childrens Res Hosp, Dept Diagnost Imaging, 332 N Lauderdale St, Memphis, TN 38105 USA; [Pastakia, D.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Bernstock, J. D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Bernstock, J. D.] Harvard Med Sch, Boston Childrens Hosp, Boston, MA 02115 USA; [Martin, A. M.] Albert Einstein Coll Med, Dept Pediat, New York, NY USA; [Sait, S. Farouk; Khakoo, Y.; Karajannis, M. A.] Mem Sloan Kettering Canc Ctr, Dept Pediat, 1275 York Ave, New York, NY 10021 USA; [Khakoo, Y.] Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA; [McNall-Knapp, R.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73190 USA; [Woodling, K.; Osorio, D. S.; Abdelbaki, M. S.] Nationwide Childrens Hosp, Div Pediat Hematol Oncol & Bone Marrow Transplant, Columbus, OH USA; [Leonard, J.] Nationwide Childrens Hosp, Dept Pediat Neurosurg, Columbus, OH USA; [Palmer, J. D.] Ohio State Univ, Dept Radiat Oncol, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Abdelbaki, M. S.] Washington Univ, Sch Med, Div Pediat Hematol Oncol & Bone Marrow Transplant, St Louis, MO 14263 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; St Jude Children's Research Hospital; Vanderbilt University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Yeshiva University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Washington University (WUSTL)	Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Pediat, 1600 7th Ave S,Lowder 512, Birmingham, AL 35233 USA.	gfriedman@peds.uab.edu	Bag, Asim/G-8308-2019; Martin, Allison/GPX-3158-2022; nan, li li/HHM-7022-2022	Bag, Asim/0000-0001-6164-5863; Martin, Allison/0000-0002-5984-4684; Bernstock, Joshua/0000-0002-7814-3867; Gillespie, George/0000-0001-6436-9542; Friedman, Gregory/0000-0002-6653-7420	Food and Drug Administration [R01FD005379]; National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) [UL1TR003096]; Cannonball Kids' Cancer Foundation; Rally Foundation for Childhood Cancer Research; Department of Defense [W81XWH-15-1-0108]; Andrew McDonough B+ Foundation; Kaul Pediatric Research Institute; NIH/National Cancer Institute Cancer Center Support Grants [P30CA013148, P30CA008748]; Kelsie's Crew, Eli's Block Party Childhood Cancer Foundation; Eli Jackson Foundation; Jaxon's F.R.O.G. Foundation; Battle for a Cure Foundation; Sandcastle Kids; Hyundai Hope on Wheels; St. Baldrick's Foundation	Food and Drug Administration(United States Department of Health & Human Services); National Center for Advancing Translational Sciences of the National Institutes of Health (NIH); Cannonball Kids' Cancer Foundation; Rally Foundation for Childhood Cancer Research; Department of Defense(United States Department of Defense); Andrew McDonough B+ Foundation; Kaul Pediatric Research Institute; NIH/National Cancer Institute Cancer Center Support Grants; Kelsie's Crew, Eli's Block Party Childhood Cancer Foundation; Eli Jackson Foundation; Jaxon's F.R.O.G. Foundation; Battle for a Cure Foundation; Sandcastle Kids; Hyundai Hope on Wheels; St. Baldrick's Foundation	Supported by grants from the Food and Drug Administration (R01FD005379), the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) (UL1TR003096), Cannonball Kids' Cancer Foundation, the Rally Foundation for Childhood Cancer Research, Hyundai Hope on Wheels, St. Baldrick's Foundation, the Department of Defense (W81XWH-15-1-0108), Andrew McDonough B+ Foundation, Kaul Pediatric Research Institute, and NIH/National Cancer Institute Cancer Center Support Grants to the University of Alabama at Birmingham (P30CA013148) and to Memorial Sloan Kettering Cancer Center (P30CA008748), and by Kelsie's Crew, Eli's Block Party Childhood Cancer Foundation, the Eli Jackson Foundation, Jaxon's F.R.O.G. Foundation, Battle for a Cure Foundation, and Sandcastle Kids.	Advani SJ, 2011, GENE THER, V18, P1098, DOI 10.1038/gt.2011.61; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Benencia F, 2008, CANCER BIOL THER, V7, P1194, DOI 10.4161/cbt.7.8.6216; Bernstock JD, 2020, CANCER GENE THER, V27, P246, DOI 10.1038/s41417-019-0091-0; Carceller F, 2016, J NEURO-ONCOL, V129, P109, DOI 10.1007/s11060-016-2151-8; Chiocca EA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw5680; Cohen KJ, 2011, NEURO-ONCOLOGY, V13, P317, DOI 10.1093/neuonc/noq191; Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435; Foreman PM, 2017, NEUROTHERAPEUTICS, V14, P333, DOI 10.1007/s13311-017-0516-0; Friedman GK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32353-x; Friedman GK, 2016, NEURO-ONCOLOGY, V18, P227, DOI 10.1093/neuonc/nov123; Friedman GK, 2009, J NEURO-ONCOL, V95, P199, DOI 10.1007/s11060-009-9926-0; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Jakacki RI, 2016, NEURO-ONCOLOGY, V18, P1442, DOI 10.1093/neuonc/now038; Jones C, 2017, NEURO-ONCOLOGY, V19, P153, DOI 10.1093/neuonc/now101; Kaufman HL, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0116-2; Kieran MW, 2019, NEURO-ONCOLOGY, V21, P537, DOI 10.1093/neuonc/noy202; Kline C, 2018, J NEURO-ONCOL, V137, P103, DOI 10.1007/s11060-017-2701-8; Lang A, 2005, J IMMUNOL, V174, P2919, DOI 10.4049/jimmunol.174.5.2919; Lang FF, 2018, J CLIN ONCOL, V36, P1419, DOI 10.1200/JCO.2017.75.8219; Leddon JL, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2014.10; Mackay A, 2018, CANCER CELL, V33, P829, DOI 10.1016/j.ccell.2018.04.004; Mackay A, 2017, CANCER CELL, V32, P520, DOI 10.1016/j.ccell.2017.08.017; Markert JM, 2014, MOL THER, V22, P1048, DOI 10.1038/mt.2014.22; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Marotel M, 2020, CYTOKINE GROWTH F R, V56, P59, DOI 10.1016/j.cytogfr.2020.06.005; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Okada Hideho, 2015, Lancet Oncol, V16, pe534, DOI 10.1016/S1470-2045(15)00088-1; Taipale K, 2016, MOL THER, V24, P1323, DOI 10.1038/mt.2016.67; Toda M, 1999, HUM GENE THER, V10, P385, DOI 10.1089/10430349950018832; Todo T, 1999, HUM GENE THER, V10, P2741, DOI 10.1089/10430349950016483; WHITLEY RJ, 1993, J CLIN INVEST, V91, P2837, DOI 10.1172/JCI116527; Xu FJ, 2007, J PEDIATR-US, V151, P374, DOI 10.1016/j.jpeds.2007.04.065	35	80	82	13	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 29	2021	384	17					1613	1622		10.1056/NEJMoa2024947	http://dx.doi.org/10.1056/NEJMoa2024947		APR 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV1ND	33838625	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000640368200001
J	Meyerhardt, JA; Shi, Q; Fuchs, CS; Meyer, J; Niedzwiecki, D; Zemla, T; Kumthekar, P; Guthrie, KA; Couture, F; Kuebler, P; Bendell, JC; Kumar, P; Lewis, D; Tan, B; Bertagnolli, M; Grothey, A; Hochster, HS; Goldberg, RM; Venook, A; Blanke, C; O'Reilly, EM; Shields, AF				Meyerhardt, Jeffrey A.; Shi, Qian; Fuchs, Charles S.; Meyer, Jeffrey; Niedzwiecki, Donna; Zemla, Tyler; Kumthekar, Priya; Guthrie, Katherine A.; Couture, Felix; Kuebler, Philip; Bendell, Johanna C.; Kumar, Pankaj; Lewis, Dequincy; Tan, Benjamin; Bertagnolli, Monica; Grothey, Axel; Hochster, Howard S.; Goldberg, Richard M.; Venook, Alan; Blanke, Charles; O'Reilly, Eileen M.; Shields, Anthony F.			Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Question Does the cyclooxygenase 2 inhibitor celecoxib, when added to standard adjuvant chemotherapy, improve disease-free survival among patients with stage III colon cancer? Findings In this randomized clinical trial that involved 2526 patients, the addition of celecoxib for 3 years, compared with placebo, to standard adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) did not significantly improve disease-free survival (76.3% vs 73.4% at 3 years; hazard ratio for disease recurrence or death, 0.89). Meaning Among patients with stage III colon cancer, the addition of celecoxib, compared with placebo, to standard adjuvant chemotherapy did not significantly improve disease-free survival. Importance Aspirin and cyclooxygenase 2 (COX-2) inhibitors have been associated with a reduced risk of colorectal polyps and cancer in observational and randomized studies. The effect of celecoxib, a COX-2 inhibitor, as treatment for nonmetastatic colon cancer is unknown. Objective To determine if the addition of celecoxib to adjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) improves disease-free survival in patients with stage III colon cancer. Design, Setting, and Participants Cancer and Leukemia Group B (Alliance)/Southwest Oncology Group 80702 was a 2 x 2 factorial design, phase 3 trial conducted at 654 community and academic centers throughout the United States and Canada. A total of 2526 patients with stage III colon cancer were enrolled between June 2010 and November 2015 and were followed up through August 10, 2020. Interventions Patients were randomized to receive adjuvant FOLFOX (every 2 weeks) for 3 vs 6 months with or without 3 years of celecoxib (400 mg orally daily; n = 1263) vs placebo (n = 1261). This report focuses on the results of the celecoxib randomization. Main Outcomes and Measures The primary end point was disease-free survival, measured from the time of randomization until documented recurrence or death from any cause. Secondary end points included overall survival, adverse events, and cardiovascular-specific events. Results Of the 2526 patients who were randomized (mean [SD] age, 61.0 years [11 years]; 1134 women [44.9%]), 2524 were included in the primary analysis. Adherence with protocol treatment, defined as receiving celecoxib or placebo for more than 2.75 years or continuing treatment until recurrence, death, or unacceptable adverse events, was 70.8% for patients treated with celecoxib and 69.9% for patients treated with placebo. A total of 337 patients randomized to celecoxib and 363 to placebo experienced disease recurrence or died, and with 6 years' median follow-up, the 3-year disease-free survival was 76.3% for celecoxib-treated patients vs 73.4% for placebo-treated patients (hazard ratio [HR] for disease recurrence or death, 0.89; 95% CI, 0.76-1.03; P = .12). The effect of celecoxib treatment on disease-free survival did not vary significantly according to assigned duration of adjuvant chemotherapy (P for interaction = .61). Five-year overall survival was 84.3% for celecoxib vs 81.6% for placebo (HR for death, 0.86; 95% CI, 0.72-1.04; P = .13). Hypertension (any grade) occurred while treated with FOLFOX in 14.6% of patients in the celecoxib group vs 10.9% of patients in the placebo group, and a grade 2 or higher increase in creatinine levels occurred after completion of FOLFOX in 1.7% vs 0.5% of patients, respectively. Conclusions and Relevance Among patients with stage III colon cancer, the addition of celecoxib for 3 years, compared with placebo, to standard adjuvant chemotherapy did not significantly improve disease-free survival. This randomized trial compares the effect of adding celecoxib to standard adjuvant chemotherapy in improving disease-free survival among patients treated for stage III colon cancer.	[Meyerhardt, Jeffrey A.] Dana Farber Partners CancerCare, Dept Med Oncol, Boston, MA USA; [Shi, Qian; Meyer, Jeffrey; Zemla, Tyler] Mayo Clin, Alliance Stat & Data Management Ctr, Rochester, MN USA; [Fuchs, Charles S.] Smilow Canc Hosp, Yale Sch Med, Yale Canc Ctr, New Haven, CT USA; [Niedzwiecki, Donna] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA; [Kumthekar, Priya] Northwestern Med, Feinberg Sch Med, Chicago, IL USA; [Guthrie, Katherine A.] Fred Hutchinson Canc Res Ctr, SWOG Stat & Data Management Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Couture, Felix] Hotel Dieu Quebec, Quebec City, PQ, Canada; [Kuebler, Philip] Columbus NCI Community Oncol Res Program, Columbus, OH USA; [Bendell, Johanna C.] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA; [Kumar, Pankaj] Illinois CancerCare PC, Peoria, IL USA; [Lewis, Dequincy] Cone Hlth Med Grp, Asheboro, NC USA; [Tan, Benjamin] Washington Univ, Sch Med St Louis, Siteman Canc Ctr, St Louis, MO 63110 USA; [Bertagnolli, Monica] Brigham & Womens Hosp, Off Alliance Grp Chair, 75 Francis St, Boston, MA 02115 USA; [Grothey, Axel] West Canc Ctr & Res Inst, Germantown, TN USA; [Hochster, Howard S.] Rutgers Canc Inst, New Brunswick, NJ USA; [Goldberg, Richard M.] West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA; [Venook, Alan] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Blanke, Charles] Oregon Hlth & Sci Univ, Knight Canc Inst, SWOG Canc Res Network Grp, Chairs Off, Portland, OR 97201 USA; [O'Reilly, Eileen M.] Weill Cornell Med Ctr, Mem Sloan Kettering Canc Ctr, New York, NY USA; [Shields, Anthony F.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA	Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; Yale University; Duke University; Northwestern University; Feinberg School of Medicine; Fred Hutchinson Cancer Center; Southwest Oncology Group; Laval University; Sarah Cannon Research Institute; Tennessee Oncology; Saint Louis University; Siteman Cancer Center; Washington University (WUSTL); Harvard University; Brigham & Women's Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; West Virginia University; University of California System; University of California San Francisco; Oregon Health & Science University; Cornell University; Memorial Sloan Kettering Cancer Center; Barbara Ann Karmanos Cancer Institute; Wayne State University	Meyerhardt, JA (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.	meyerhardt@dfci.harvard.edu		Niedzwiecki, Donna/0000-0002-3566-0450				Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2; Ali R, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-261; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Bertagnolli Monica M., 2007, V174, P73; Chan AT, 2012, CANCER PREV RES, V5, P164, DOI 10.1158/1940-6207.CAPR-11-0391; Chan AT, 2009, JAMA-J AM MED ASSOC, V302, P649, DOI 10.1001/jama.2009.1112; Chan AT, 2003, CANCER CAUSE CONTROL, V14, P413, DOI 10.1023/A:1024986220526; Coghill AE, 2011, GUT, V60, P491, DOI 10.1136/gut.2010.221143; Cross JT, 2008, PHARMACOGENOMICS J, V8, P237, DOI 10.1038/sj.tpj.6500487; Din FVN, 2010, GUT, V59, P1670, DOI 10.1136/gut.2009.203000; Domingo E, 2013, J CLIN ONCOL, V31, P4297, DOI 10.1200/JCO.2013.50.0322; Drew DA, 2016, NAT REV CANCER, V16, P173, DOI 10.1038/nrc.2016.4; Goh HH, 2014, ANTICANCER RES, V34, P7407; Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Joharatnam-Hogan N, 2019, LANCET GASTROENTEROL, V4, P854, DOI 10.1016/S2468-1253(19)30289-4; Kerr DJ, 2007, NEW ENGL J MED, V357, P360, DOI 10.1056/NEJMoa071841; Li PW, 2015, GUT, V64, P1419, DOI 10.1136/gutjnl-2014-308260; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Michel P, 2018, DIGEST LIVER DIS, V50, P305, DOI 10.1016/j.dld.2017.12.023; Midgley RS, 2010, J CLIN ONCOL, V28, P4575, DOI 10.1200/JCO.2010.29.6244; Ng K, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju345; Nishihara R, 2013, JAMA-J AM MED ASSOC, V309, P2563, DOI 10.1001/jama.2013.6599; Petrera M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5126-7; Proschan MA, 2006, STAT BIOL HEALTH, P1, DOI 10.1007/978-0-387-44970-8; Reimers MS, 2014, JAMA INTERN MED, V174, P732, DOI 10.1001/jamainternmed.2014.511; Salem ME, 2020, ANN ONCOL, V31, P480, DOI 10.1016/j.annonc.2019.12.007; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Therneau TM., 2000, MODELING SURVIVAL DA	35	20	20	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2021	325	13					1277	1285		10.1001/jama.2021.2454	http://dx.doi.org/10.1001/jama.2021.2454			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK4TM	33821899	Green Published, Bronze			2023-01-03	WOS:000638289800017
J	Garrelfs, SF; Frishberg, Y; Hulton, SA; Koren, MJ; O'Riordan, WD; Cochat, P; Deschenes, G; Shasha-Lavsky, H; Saland, JM; van't Hoff, WG; Fuster, DG; Magen, D; Moochhala, SH; Schalk, G; Simkova, E; Groothoff, JW; Sas, DJ; Meliambro, KA; Lu, J; Sweetser, MT; Garg, PP; Vaishnaw, AK; Gansner, JM; McGregor, TL; Lieske, JC				Garrelfs, Sander F.; Frishberg, Yaacov; Hulton, Sally A.; Koren, Michael J.; O'Riordan, William D.; Cochat, Pierre; Deschenes, Georges; Shasha-Lavsky, Hadas; Saland, Jeffrey M.; van't Hoff, William G.; Fuster, Daniel G.; Magen, Daniella; Moochhala, Shabbir H.; Schalk, Gesa; Simkova, Eva; Groothoff, Jaap W.; Sas, David J.; Meliambro, Kristin A.; Lu, Jiandong; Sweetser, Marianne T.; Garg, Pushkal P.; Vaishnaw, Akshay K.; Gansner, John M.; McGregor, Tracy L.; Lieske, John C.		ILLUMINATE-A Collaborators	Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BackgroundPrimary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. MethodsIn this double-blind, phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with PH1 who were 6 years of age or older to receive subcutaneous lumasiran or placebo for 6 months (with doses given at baseline and at months 1, 2, 3, and 6). The primary end point was the percent change in 24-hour urinary oxalate excretion from baseline to month 6 (mean percent change across months 3 through 6). Secondary end points included the percent change in the plasma oxalate level from baseline to month 6 (mean percent change across months 3 through 6) and the percentage of patients with 24-hour urinary oxalate excretion no higher than 1.5 times the upper limit of the normal range at month 6. ResultsA total of 39 patients underwent randomization; 26 were assigned to the lumasiran group and 13 to the placebo group. The least-squares mean difference in the change in 24-hour urinary oxalate excretion (lumasiran minus placebo) was -53.5 percentage points (P<0.001), with a reduction in the lumasiran group of 65.4% and an effect seen as early as month 1. The between-group differences for all hierarchically tested secondary end points were significant. The difference in the percent change in the plasma oxalate level (lumasiran minus placebo) was -39.5 percentage points (P<0.001). In the lumasiran group, 84% of patients had 24-hour urinary oxalate excretion no higher than 1.5 times the upper limit of the normal range at month 6, as compared with 0% in the placebo group (P<0.001). Mild, transient injection-site reactions were reported in 38% of lumasiran-treated patients. ConclusionsLumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1. The majority of patients who received lumasiran had normal or near-normal levels after 6 months of treatment. (Funded by Alnylam Pharmaceuticals; ILLUMINATE-A ClinicalTrials.gov number, NCT03681184.) Primary hyperoxaluria type 1 is caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. This trial tested whether an oligonucleotide drug can reduce the production of hepatic oxalate.	[Garrelfs, Sander F.; Groothoff, Jaap W.] Univ Amsterdam, Amsterdam UMC, Emma Childrens Hosp, Dept Pediat Nephrol, Amsterdam, Netherlands; [Frishberg, Yaacov] Shaare Zedek Med Ctr, Div Pediat Nephrol, Jerusalem, Israel; [Hulton, Sally A.] Birmingham Womens & Childrens Hosp, Dept Nephrol, Birmingham, W Midlands, England; [van't Hoff, William G.] Great Ormond St Hosp Sick Children, Dept Paediat Nephrol, London, England; [Moochhala, Shabbir H.] UCL Dept Renal Med, Royal Free Hosp, London, England; [Koren, Michael J.] Jacksonville Ctr Clin Res, Jacksonville, FL USA; [O'Riordan, William D.] EStudySite, San Diego, CA USA; [Cochat, Pierre] Univ Lyon, Lyon, France; [Cochat, Pierre] Ctr Rare Renal Dis, Lyon, France; [Cochat, Pierre] INSERM Pediat Clin Invest Ctr, Hosp Civils Lyon, Lyon, France; [Deschenes, Georges] Hop Robert Debre, Dept Pediat Nephrol, Paris, France; [Shasha-Lavsky, Hadas] Galilee Med Ctr, Pediat Nephrol Unit, Nahariyya, Israel; [Magen, Daniella] Rambam Hlth Care Campus, Pediat Nephrol Inst, Haifa, Israel; [Saland, Jeffrey M.; Meliambro, Kristin A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Fuster, Daniel G.] Univ Bern, Univ Hosp Bern, Inselspital, Dept Nephrol & Hypertens, Bern, Switzerland; [Schalk, Gesa] Univ Bonn, Bonn, Germany; [Simkova, Eva] Al Jalila Childrens Hosp, Dubai, U Arab Emirates; [Sas, David J.] Mayo Clin, Div Pediat Nephrol & Hypertens, Rochester, MN USA; [Lieske, John C.] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA; [Lu, Jiandong; Sweetser, Marianne T.; Garg, Pushkal P.; Vaishnaw, Akshay K.; Gansner, John M.; McGregor, Tracy L.] Alnylam Pharmaceut, Cambridge, MA USA	Emma Children's Hospital; University of Amsterdam; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Birmingham Women's Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Western Galilee Hospital; Rambam Health Care Campus; Icahn School of Medicine at Mount Sinai; University of Bern; University Hospital of Bern; University of Bonn; Mayo Clinic; Mayo Clinic	Garrelfs, SF (corresponding author), Univ Amsterdam, Amsterdam UMC, Emma Childrens Hosp, Dept Pediat Nephrol,Locat AMC, Rm H8-253,Meibergdreef 9, NL-1105 AZ Amsterdam, Noord Holland, Netherlands.	s.f.garrelfs@amsterdamumc.nl	Fuster, Daniel G/AAA-7079-2021	Fuster, Daniel G/0000-0001-7220-1803; Vogt, Bruno/0000-0002-1548-6387; Hayes, Wesley Nathan/0000-0002-8091-6945; Gupta, Mantu/0000-0001-8448-285X	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	Supported by Alnylam Pharmaceuticals.	Clifford-Mobley O, 2017, PEDIATR NEPHROL, V32, P2159, DOI 10.1007/s00467-017-3741-1; Clifford-Mobley O, 2015, ANN CLIN BIOCHEM, V52, P113, DOI 10.1177/0004563214529937; COCHAT P, 1989, LANCET, V1, P1142; Cochat P, 2013, PEDIATR NEPHROL, V28, P2273, DOI 10.1007/s00467-013-2444-5; Cochat P, 2013, NEW ENGL J MED, V369, P649, DOI 10.1056/NEJMra1301564; COULTHARD MG, 1993, PEDIATR NEPHROL, V7, P774, DOI 10.1007/BF01213354; Craigen WJ, 1996, J INHERIT METAB DIS, V19, P793, DOI 10.1007/BF01799176; DANPURE CJ, 1986, FEBS LETT, V201, P20, DOI 10.1016/0014-5793(86)80563-4; Danpure CJ, 2019, PRIMARY HYPEROXALURI; Dick PT, 1999, PEDIATR RADIOL, V29, P68, DOI 10.1007/s002470050539; Frishberg Y, 2014, J MED GENET, V51, P526, DOI 10.1136/jmedgenet-2014-102529; Galanti M, 2010, PEDIATR NEPHROL, V25, P2359, DOI 10.1007/s00467-010-1593-z; GIBBS DA, 1969, J LAB CLIN MED, V73, P901; Gruessner RW, 1998, NEW ENGL J MED, V338, P1924, DOI 10.1056/NEJM199806253382615; HAFFNER D, 1995, NEPHROL DIAL TRANSPL, V10, P47, DOI 10.1093/ndt/10.supp8.47; Hopp K, 2015, J AM SOC NEPHROL, V26, P2559, DOI 10.1681/ASN.2014070698; Hoppe B, 2010, KIDNEY INT, V77, P383, DOI 10.1038/ki.2009.471; Hoyer-Kuhn H, 2014, CLIN J AM SOC NEPHRO, V9, P468, DOI 10.2215/CJN.06820613; Jamieson NV, 2005, AM J NEPHROL, V25, P282, DOI 10.1159/000086359; Khorsandi SE, 2016, PEDIATR TRANSPLANT, V20, P523, DOI 10.1111/petr.12705; Leflot M, 2018, NEPHROL THER, V14, P148, DOI 10.1016/j.nephro.2017.06.004; Lieske JC, 2005, AM J NEPHROL, V25, P290, DOI 10.1159/000086360; Mandrile G, 2014, KIDNEY INT, V86, P1197, DOI 10.1038/ki.2014.222; MARANGELLA M, 1992, J UROLOGY, V148, P986, DOI 10.1016/S0022-5347(17)36796-4; McGregor TL, 2020, ELIFE, V9, DOI 10.7554/eLife.54363; Nolkemper D, 2000, Pediatr Transplant, V4, P177, DOI 10.1034/j.1399-3046.2000.00107.x; Perinpam M, 2017, CLIN BIOCHEM, V50, P1014, DOI 10.1016/j.clinbiochem.2017.07.017; Petrarulo M, 1998, J NEPHROL, V11, P23; Salido EC, 2006, P NATL ACAD SCI USA, V103, P18249, DOI 10.1073/pnas.0607218103; Shapiro R, 2001, TRANSPLANTATION, V72, P428, DOI 10.1097/00007890-200108150-00012; Tang XJ, 2015, KIDNEY INT, V87, P623, DOI 10.1038/ki.2014.298; van Woerden CS, 2003, NEPHROL DIAL TRANSPL, V18, P273, DOI 10.1093/ndt/18.2.273; Zhao F, 2016, CLIN J AM SOC NEPHRO, V11, P119, DOI 10.2215/CJN.02810315	33	120	120	12	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 1	2021	384	13					1216	1226		10.1056/NEJMoa2021712	http://dx.doi.org/10.1056/NEJMoa2021712			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ8KV	33789010	Bronze, Green Published			2023-01-03	WOS:000637850100008
J	[Anonymous]				[Anonymous]			Update to living systematic review on drug treatments for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 31	2021	372								n858	10.1136/bmj.n858	http://dx.doi.org/10.1136/bmj.n858			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH3WJ	33789885	Bronze			2023-01-03	WOS:000636152900018
J	Qiao, JX; Li, YS; Zeng, R; Liu, FL; Luo, RH; Huang, C; Wang, YF; Zhang, J; Quan, BX; Shen, CJ; Mao, X; Liu, XL; Sun, WN; Yang, W; Ni, XC; Wang, K; Xu, L; Duan, ZL; Zou, QC; Zhang, HL; Qu, W; Long, YHP; Li, MH; Yang, RC; Liu, XL; You, J; Zhou, YL; Yao, R; Li, WP; Liu, JM; Chen, P; Liu, Y; Lin, GF; Yang, X; Zou, J; Li, LL; Hu, YG; Lu, GW; Li, WM; Wei, YQ; Zheng, YT; Lei, J; Yang, SY				Qiao, Jingxin; Li, Yue-Shan; Zeng, Rui; Liu, Feng-Liang; Luo, Rong-Hua; Huang, Chong; Wang, Yi-Fei; Zhang, Jie; Quan, Baoxue; Shen, Chenjian; Mao, Xin; Liu, Xinlei; Sun, Weining; Yang, Wei; Ni, Xincheng; Wang, Kai; Xu, Ling; Duan, Zi-Lei; Zou, Qing-Cui; Zhang, Hai-Lin; Qu, Wang; Long, Yang-Hao-Peng; Li, Ming-Hua; Yang, Rui-Cheng; Liu, Xiaolong; You, Jing; Zhou, Yangli; Yao, Rui; Li, Wen-Pei; Liu, Jing-Ming; Chen, Pei; Liu, Yang; Lin, Gui-Feng; Yang, Xin; Zou, Jun; Li, Linli; Hu, Yiguo; Lu, Guang-Wen; Li, Wei-Min; Wei, Yu-Quan; Zheng, Yong-Tang; Lei, Jian; Yang, Shengyong			SARS-CoV-2 M-pro inhibitors with antiviral activity in a transgenic mouse model	SCIENCE			English	Article							3CL PROTEASE INHIBITORS; SARS; DISCOVERY; DESIGN	The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (M-pro) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing M-pro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 M-pro activity in vitro, with 50% inhibitory concentration values ranging from 7.6 to 748.5 nM. The cocrystal structure of M-pro in complex with MI-23, one of themost potent compounds, revealed its interactionmode. Two compounds (MI-09 and MI-30) showed excellent antiviral activity in cell-based assays. In a transgenic mouse model of SARS-CoV-2 infection, oral or intraperitoneal treatment withMI-09 or MI-30 significantly reduced lung viral loads and lung lesions. Both also displayed good pharmacokinetic properties and safety in rats.	[Qiao, Jingxin; Li, Yue-Shan; Zeng, Rui; Huang, Chong; Zhang, Jie; Quan, Baoxue; Shen, Chenjian; Mao, Xin; Liu, Xinlei; Sun, Weining; Yang, Wei; Ni, Xincheng; Wang, Kai; Yang, Rui-Cheng; Liu, Xiaolong; You, Jing; Zhou, Yangli; Yao, Rui; Li, Wen-Pei; Liu, Jing-Ming; Liu, Yang; Lin, Gui-Feng; Yang, Xin; Zou, Jun; Hu, Yiguo; Lu, Guang-Wen; Li, Wei-Min; Wei, Yu-Quan; Lei, Jian; Yang, Shengyong] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Liu, Feng-Liang; Luo, Rong-Hua; Xu, Ling; Duan, Zi-Lei; Zheng, Yong-Tang] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China; [Liu, Feng-Liang; Luo, Rong-Hua; Xu, Ling; Duan, Zi-Lei; Zou, Qing-Cui; Zhang, Hai-Lin; Qu, Wang; Long, Yang-Hao-Peng; Li, Ming-Hua; Zheng, Yong-Tang] Chinese Acad Sci, Ctr Biosafety Megasci, Kunming Inst Zool, Kunming Natl High Level Biosafety Res Ctr Nonhuma, Kunming 650107, Yunnan, Peoples R China; [Wang, Yi-Fei; Chen, Pei; Li, Linli] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Hai-Lin] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China; [Lei, Jian] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; Kunming Institute of Zoology; Sichuan University; Chinese Academy of Sciences; Kunming Institute of Zoology; Sichuan University	Lei, J; Yang, SY (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Zheng, YT (corresponding author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.; Zheng, YT (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Kunming Inst Zool, Kunming Natl High Level Biosafety Res Ctr Nonhuma, Kunming 650107, Yunnan, Peoples R China.; Lei, J (corresponding author), Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Chengdu 610041, Sichuan, Peoples R China.	zhengyt@mail.kiz.ac.cn; leijian@scu.edu.cn; yangsy@scu.edu.cn	Liu, Jingming/GPG-2366-2022; Zhang, Jiujun/M-5668-2017; Lu, Guangwen/HCH-9193-2022; ronghua, luo/AHE-19098-2022; Liu, Yang/AHH-3577-2022; Zeng, Rui/GRY-0646-2022	Liu, Yang/0000-0002-5071-3928; Zeng, Rui/0000-0003-1188-3198; Zhang, Jie/0000-0002-0249-6674; Zou, Jun/0000-0002-5395-6052; qiao, jingxin/0000-0002-8617-5148; Liu, Feng-Liang/0000-0002-5038-5012; Chong, Huang/0000-0003-0951-3411; Wang, Yifei/0000-0002-8873-613X; Wei, Yu-quan/0000-0002-6211-3217; Li, Yueshan/0000-0003-2343-1252; Lei, Jian/0000-0001-9326-0554	fast-track research fund on COVID-19 of Sichuan Province [2020YFS0006, 2020YFS0010]; fast-track grants of SARS-CoV-2 research from West China Hospital, Sichuan University [HX-2019-nCoV-053, HX-2019-nCoV039]; National Natural Science Foundation of China [81930125, 00402354A1028]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University; Fundamental Research Funds for the Central Universities [20822041D4060]; National Key R&D Program of China [2020YFC0842000]	fast-track research fund on COVID-19 of Sichuan Province; fast-track grants of SARS-CoV-2 research from West China Hospital, Sichuan University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Key R&D Program of China	Supported by the fast-track research fund on COVID-19 of Sichuan Province (2020YFS0006, 2020YFS0010), the fast-track grants of SARS-CoV-2 research from West China Hospital, Sichuan University (HX-2019-nCoV-053, HX-2019-nCoV039), the National Natural Science Foundation of China (81930125 and 00402354A1028), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University, the Fundamental Research Funds for the Central Universities (20822041D4060), and the National Key R&D Program of China (2020YFC0842000 to Y.-T.Z.).	Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; [Anonymous], 2020, TRANSL PEDIATR, DOI DOI 10.21037/TP.2020.02.06; Boras B., 2020, 293498 BIORXIV; Boras Britton, 2021, bioRxiv, DOI 10.1101/2020.09.12.293498; Bricogne G., 2017, BUSTER VERSION 2104; Cannalire R., 2020, **DROPPED REF**; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681; Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489; Dragovich PS, 1999, J MED CHEM, V42, P1213, DOI 10.1021/jm9805384; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061; Gampe C, 2020, J MED CHEM, V63, P14357, DOI 10.1021/acs.jmedchem.0c01177; Ganguly Himal Kanti, 2020, Biophys Rev, V12, P25, DOI 10.1007/s12551-020-00621-8; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936; Hoffman RL, 2020, J MED CHEM, V63, P12725, DOI 10.1021/acs.jmedchem.0c01063; Jain RP, 2004, J MED CHEM, V47, P6113, DOI 10.1021/jm0494873; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]; Kovalevskiy O, 2018, ACTA CRYSTALLOGR D, V74, P215, DOI 10.1107/S2059798318000979; Liu YY, 1999, ANAL BIOCHEM, V267, P331, DOI 10.1006/abio.1998.3014; Looi MK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4113; Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z; Martin YC, 2005, J MED CHEM, V48, P3164, DOI 10.1021/jm0492002; Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461; Rathnayake AD, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc5332; Rognan D, 2015, **DROPPED REF**, V4, P319; Sacco MD, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abe0751; Smith P, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3350; Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020; Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589; Weiss MS, 1997, J APPL CRYSTALLOGR, V30, P203, DOI 10.1107/S0021889897003907; Westberg M., 2020, 275891 BIORXIV; Wu F, 2020, NATURE, V580, pE7; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Yang K. S, 2020, CHEMMEDCHEM, V15, P1; Yang KS, 2021, CHEMMEDCHEM, V16, P942, DOI 10.1002/cmdc.202000924; Yip Y, 2004, BIOORG MED CHEM LETT, V14, P251, DOI 10.1016/j.bmcl.2003.09.074; Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405; Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828; Zhou P., 2020, NATURE, V579, P270; Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001; Zhu W, 2020, ACS PHARMACOL TRANSL, V3, P1008, DOI 10.1021/acsptsci.0c00108	45	166	170	38	233	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2021	371	6536					1374	+		10.1126/science.abf1611	http://dx.doi.org/10.1126/science.abf1611			89	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH2GI	33602867	Green Published			2023-01-03	WOS:000636043400052
J	Manenti, L; Maggiore, U; Fiaccadori, E; Meschi, T; Antoni, AD; Nouvenne, A; Ticinesi, A; Cerundolo, N; Prati, B; Delsante, M; Gandoflini, I; Donghi, L; Gentile, M; Farina, MT; Oliva, V; Zambrano, C; Regolisti, G; Palmisano, A; Caminiti, C; Cocchi, E; Ferrari, C; Riella, LV; Cravedi, P; Peruzzi, L				Manenti, Lucio; Maggiore, Umberto; Fiaccadori, Enrico; Meschi, Tiziana; Antoni, Anna Degli; Nouvenne, Antonio; Ticinesi, Andrea; Cerundolo, Nicoletta; Prati, Beatrice; Delsante, Marco; Gandoflini, Ilaria; Donghi, Lorenzo; Gentile, Micaela; Farina, Maria Teresa; Oliva, Vincenzo; Zambrano, Cristina; Regolisti, Giuseppe; Palmisano, Alessandra; Caminiti, Caterina; Cocchi, Enrico; Ferrari, Carlo; Riella, Leonardo, V; Cravedi, Paolo; Peruzzi, Licia			Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study	PLOS ONE			English	Article								Objectives Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed. We hypothesized that colchicine, by counteracting proinflammatory pathways implicated in the uncontrolled inflammatory response of COVID-19 patients, reduces pulmonary complications, and improves survival. Methods This retrospective study included 71 consecutive COVID-19 patients (hospitalized with pneumonia on CT scan or outpatients) who received colchicine and compared with 70 control patients who did not receive colchicine in two serial time periods at the same institution. We used inverse probability of treatment propensity-score weighting to examine differences in mortality, clinical improvement (using a 7-point ordinary scale), and inflammatory markers between the two groups. Results Amongst the 141 COVID-19 patients (118 [83.7%] hospitalized), 70 (50%) received colchicine. The 21-day crude cumulative mortality was 7.5% in the colchicine group and 28.5% in the control group (P = 0.006; adjusted hazard ratio: 0.24 [95%CI: 0.09 to 0.67]); 21-day clinical improvement occurred in 40.0% of the patients on colchicine and in 26.6% of control patients (adjusted relative improvement rate: 1.80 [95%CI: 1.00 to 3.22]). The strong association between the use of colchicine and reduced mortality was further supported by the diverging linear trends of percent daily change in lymphocyte count (P = 0.018), neutrophil-to-lymphocyte ratio (P = 0.003), and in C-reactive protein levels (P = 0.009). Colchicine was stopped because of transient side effects (diarrhea or skin rashes) in 7% of patients. Conclusion In this retrospective cohort study colchicine was associated with reduced mortality and accelerated recovery in COVID-19 patients. This support the rationale for current larger randomized controlled trials testing the safety/efficacy profile of colchicine in COVID-19 patients.	[Manenti, Lucio; Maggiore, Umberto; Fiaccadori, Enrico; Delsante, Marco; Gandoflini, Ilaria; Gentile, Micaela; Farina, Maria Teresa; Oliva, Vincenzo; Zambrano, Cristina; Regolisti, Giuseppe; Palmisano, Alessandra] Univ Parma, Dipartimento Med & Chirurg, Parma, Italy; [Manenti, Lucio; Maggiore, Umberto; Fiaccadori, Enrico; Delsante, Marco; Gandoflini, Ilaria; Gentile, Micaela; Farina, Maria Teresa; Oliva, Vincenzo; Zambrano, Cristina; Palmisano, Alessandra] Azienda Osped Univ Parma, UO Nefrol, Parma, Italy; [Meschi, Tiziana; Nouvenne, Antonio; Ticinesi, Andrea; Cerundolo, Nicoletta; Prati, Beatrice] Azienda Osped Univ Parma, Dipartimento Geriatr Riabilitat, Parma, Italy; [Antoni, Anna Degli; Donghi, Lorenzo; Ferrari, Carlo] Azienda Osped Univ Parma, UO Malattie Infett & Epatol, Parma, Italy; [Regolisti, Giuseppe] Azienda Osped Univ Parma, UO Clin & Immunol Med, Parma, Italy; [Caminiti, Caterina] Azienda Osped Univ Parma, UO Ric & Innovaz, Parma, Italy; [Cocchi, Enrico; Peruzzi, Licia] Regina Margherita Childrens Hosp, Pediat Nephrol Unit, Citta Salute & Sci Torino, Turin, Italy; [Riella, Leonardo, V] Harvard Med Sch, Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02115 USA; [Cravedi, Paolo] Icahn Sch Med Mt Sinai, Dept Med, Renal Div, New York, NY 10029 USA	University of Parma; University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; A.O.U. Citta della Salute e della Scienza di Torino; Harvard University; Harvard Medical School; Massachusetts General Hospital; Icahn School of Medicine at Mount Sinai	Maggiore, U (corresponding author), Univ Parma, Dipartimento Med & Chirurg, Parma, Italy.; Maggiore, U (corresponding author), Azienda Osped Univ Parma, UO Nefrol, Parma, Italy.	umberto.maggiore@unipr.it	Delsante, Marco/ABE-3185-2021; Caminiti, Caterina/AAE-3130-2022; Caminiti, Caterina/K-4532-2016; Cocchi, Enrico/Q-8112-2018; Ticinesi, Andrea/K-5017-2016	Delsante, Marco/0000-0003-0715-6764; Caminiti, Caterina/0000-0002-3196-2435; Caminiti, Caterina/0000-0002-3196-2435; Cocchi, Enrico/0000-0002-7532-956X; Ticinesi, Andrea/0000-0001-9171-8592; Peruzzi, Licia/0000-0002-5704-3867	NIH NIAID [3U01AI063594-17S1]	NIH NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	PC is supported by NIH NIAID grant 3U01AI063594-17S1. No external funding was received for this study.	Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2019.02.033, 10.1016/j.jiph.2020.02.033]; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Castano-Rodriguez C, 2018, MBIO, V9, DOI 10.1128/mBio.02325-17; Cocchi E, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-2820; Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136; Della-Torre E, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108490; Dupuis J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242318; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Imazio M, 2013, NEW ENGL J MED, V369, P1522, DOI 10.1056/NEJMoa1208536; Karamanou M, 2018, CURR PHARM DESIGN, V24, P654, DOI 10.2174/1381612824666180115105850; Martinez GJ, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002128; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Montealegre-Gomez G, 2021, REUMATOL CLIN, V17, P371, DOI 10.1016/j.reuma.2020.05.001; Nidorf SM, 2019, CLIN THER, V41, P41, DOI 10.1016/j.clinthera.2018.11.016; Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010; Nonaka D, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019814; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Scarsi M, 2020, ANN RHEUM DIS, V79, P1286, DOI 10.1136/annrheumdis-2020-217712	18	22	23	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2021	16	3							e0248276	10.1371/journal.pone.0248276	http://dx.doi.org/10.1371/journal.pone.0248276			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC8FS	33760858	Green Published, gold			2023-01-03	WOS:000633030400011
J	Paiva, CN; Tausk, DV				Paiva, Claudia N.; Tausk, Daniel V.			Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19	ANNALS OF INTERNAL MEDICINE			English	Letter									[Paiva, Claudia N.; Tausk, Daniel V.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Paiva, CN (corresponding author), Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.			Tausk, Daniel/0000-0001-5489-3770				Dodd S, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-84; Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207	2	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					432	433		10.7326/L20-1424	http://dx.doi.org/10.7326/L20-1424			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX4DA	33721541				2023-01-03	WOS:000629294000004
J	Nabwera, HM; Shah, V; Neville, R; Sosseh, F; Saidykhan, M; Faal, F; Sonko, B; Keita, O; Schmidt, WP; Torondel, B				Nabwera, Helen M.; Shah, Vishna; Neville, Rowena; Sosseh, Fatou; Saidykhan, Mariama; Faal, Fatou; Sonko, Bakery; Keita, Omar; Schmidt, Wolf-Peter; Torondel, Belen			Menstrual hygiene management practices and associated health outcomes among school-going adolescents in rural Gambia	PLOS ONE			English	Article								Inadequate menstrual hygiene management (MHM) practices have been associated with adverse health outcomes. This study aimed to describe MHM practices among schoolgirls from rural Gambia and assess risk factors associated with urogenital infections and depressive symptoms. A cross-sectional study was conducted among adolescent schoolgirls in thirteen schools in rural Gambia. A questionnaire was used to collect information on sociodemographics, MHM practices and clinical symptoms of reproductive and urinary tract infections (UTIs). A modified Beck Depression Inventory-II was used to screen for depressive symptoms. Mid-stream urine samples were collected to assess for UTIs. Modified Poisson regression analysis was used to determine risk factors for symptoms of urogenital infections and depression among adolescent girls. Three hundred and fifty-eight girls were recruited. Although, 63% of the girls attended schools providing free disposable pads, reusable cloths/towels were the commonest absorbent materials used. Heavy menstrual bleeding was associated with depressive symptoms (adjusted prevalence ratio, aPR 1.4 [95% CI 1.0, 1.9]), while extreme menstrual pain (aPR 1.3 [95% CI 1.2, 1,4]), accessing sanitary pads in school (aPR 1.4 [95% CI 1.2, 1.5]) and less access to functional water source at school (aPR 1.4 [95% CI 1.3, 1.6]) were associated with UTI symptoms. Conversely, privacy in school toilets (aPR 0.6 [95% CI 0.5, 0.7]) was protective for UTI symptoms. Heavy menstrual bleeding (aPR 1.4 [95% CI 1.1, 2.0]) and taking <30 minutes to collect water at home were associated with RTI symptoms (aPR 1.2 [95% CI 1.0, 1.5]) while availability of soap in school toilets (aPR 0.6 [95% CI 0.5, 0.8] was protective for RTI symptoms. Interventions to ensure that schoolgirls have access to private sanitation facilities with water and soap both at school and at home could reduce UTI and RTI symptoms. More attention is also needed to support girls with heavy menstrual bleeding and pain symptoms.	[Nabwera, Helen M.; Shah, Vishna; Torondel, Belen] London Sch Hyg & Trop Med, Dept Infect Dis, Environm Hlth Grp, London, England; [Nabwera, Helen M.] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England; [Shah, Vishna; Neville, Rowena; Sosseh, Fatou; Saidykhan, Mariama; Faal, Fatou; Sonko, Bakery] MRC Unit, MRCG Keneba, Nutr Theme, Banjul, Gambia; [Keita, Omar] Minist Basic & Secondary Educ, Reg Educ Directorate 4, Mansakonko Lower River R, Gambia; [Schmidt, Wolf-Peter] London Sch Hyg & Trop Med, Dept Dis Control, London, England	University of London; London School of Hygiene & Tropical Medicine; Liverpool School of Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Torondel, B (corresponding author), London Sch Hyg & Trop Med, Dept Infect Dis, Environm Hlth Grp, London, England.	Belen.Torondel@lshtm.ac.uk	Nabwera, Helen/GRJ-3507-2022	Sonko, Bakary/0000-0003-3822-2680; Shah, Vishna/0000-0003-0472-4287; Nabwera, Helen/0000-0003-1056-729X; Schmidt, Wolf-Peter/0000-0001-7449-4152	Medical Research Council [MR/N027744/1]; MRC [MR/N027744/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	BT awarded funding from the Medical Research Council (https://mrc.ukri.org/funding/), Grant number (MR/N027744/1). The funder and sponsor had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams J, 2009, WATER SANITATION HYG; Alexander KT, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081682; Baker KK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188234; Baker KK, 2015, PLOS ONE, V10; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; Brown J, 2013, ARCH DIS CHILD, V98, P629, DOI 10.1136/archdischild-2011-301528; Caruso BA, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000414; CATES W, 1985, LANCET, V2, P596; Chinyama J, 2018, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6360-2; Coleman R, 2006, SOC PSYCH PSYCH EPID, V41, P720, DOI 10.1007/s00127-006-0085-8; Council WSaSC, 2013, CEL WOM BETT MENSTR; Crichton J, 2013, HEALTH CARE WOMEN IN, V34, P891, DOI 10.1080/07399332.2012.740112; Davis J, 2018, TROP MED INT HEALTH, V23, P1350, DOI 10.1111/tmi.13159; Garcia-Batista ZE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199750; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Garber J, 2006, AM J PREV MED, V31, pS104, DOI 10.1016/j.amepre.2006.07.007; Girod C, 2017, J URBAN HEALTH, V94, P835, DOI 10.1007/s11524-017-0189-3; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Hennegan J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012596; Hennig BJ, 2017, INT J EPIDEMIOL, V46, DOI 10.1093/ije/dyv206; Kaplan A, 2013, INT J WOMENS HEALTH, V5, P323, DOI 10.2147/IJWH.S42064; Kea P, 2007, CAN J AFR STUDIES, V41, P258, DOI 10.1080/00083968.2007.11434726; Kerubo E, 2016, SEX TRANSM INFECT, V92, P251, DOI 10.1136/sextrans-2015-052371; Kim MH, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18965; Kuringe E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221053; Marsh V, 2019, BMC MED ETHICS, V20, DOI 10.1186/s12910-019-0375-9; Mascarenhas MN, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001356; Miiro G, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-017-0502-z; Montgomery P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048274; Morison L, 2005, SEX TRANSM INFECT, V81, P242, DOI 10.1136/sti.2004.011684; Nalugya-Sserunjogi J, 2016, CHILD ADOL PSYCH MEN, V10, DOI 10.1186/s13034-016-0133-4; Patkar, 2004, MENSTRUAL HYGIENE MA; Phillips-Howard PA, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.33032; Phillips-Howard PA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013229; Phillips-Howard PA, 2015, J WOMENS HEALTH, V24, P801, DOI 10.1089/jwh.2014.5031; Saadeh SA, 2011, PEDIATR NEPHROL, V26, P1967, DOI 10.1007/s00467-011-1801-5; Shah V, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6599-2; Sommer M, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000405; Sommer M, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001962; Sommer M, 2015, AM J PUBLIC HEALTH, V105, P1302, DOI 10.2105/AJPH.2014.302525; Statistics GBo, 2019, GAMBIA MULTIPLE INDI; Thapar A, 2012, LANCET, V379, P1056, DOI 10.1016/S0140-6736(11)60871-4; The Gambia Bureau of Statistics (GBOS), 2011, UNICEF GAMBIAMULTIPL; Torondel B, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3384-2; Tsai JD, 2016, UROL SCI, V27, P131, DOI 10.1016/j.urols.2016.10.001; UN Systems, 2012, GAMBIA GAMBIA RESPON; UNICEF, 2013, P MENSTR HYG MAN SCH; UNICEF, 2013, SNAPSHOT WASH SCH E; Van Biljon G, 2012, S AFR FAM PRACT, V54, P392, DOI 10.1080/20786204.2012.10874257; van Eijk AM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010290; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6; WHO U, 2015, WASH POST2015 PROPOS; Wilson E, 2018, LANCET CHILD ADOLESC, V2, pE17, DOI 10.1016/S2352-4642(18)30209-8; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	55	8	8	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247554	10.1371/journal.pone.0247554	http://dx.doi.org/10.1371/journal.pone.0247554			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QQ5BB	33630924	Green Accepted, Green Published, gold			2023-01-03	WOS:000624536800082
J	Cascone, T; William, WN; Weissferdt, A; Leung, CH; Lin, HY; Pataer, A; Godoy, MCB; Carter, BW; Federico, L; Reuben, A; Khan, MAW; Dejima, H; Francisco-Cruz, A; Parra, ER; Solis, LM; Fujimoto, J; Tran, HT; Kalhor, N; Fossella, FV; Mott, FE; Tsao, AS; Blumenschein, G; Le, XN; Zhang, JJ; Skoulidis, F; Kurie, JM; Altan, M; Lu, C; Glisson, BS; Byers, LA; Elamin, YY; Mehran, RJ; Rice, DC; Walsh, GL; Hofstetter, WL; Roth, JA; Antonoff, MB; Kadara, H; Haymaker, C; Bernatchez, C; Ajami, NJ; Jenq, RR; Sharma, P; Allison, JP; Futreal, A; Wargo, JA; Wistuba, II; Swisher, SG; Lee, JJ; Gibbons, DL; Vaporciyan, AA; Heymach, JV; Sepesi, B				Cascone, Tina; William, William N., Jr.; Weissferdt, Annikka; Leung, Cheuk H.; Lin, Heather Y.; Pataer, Apar; Godoy, Myrna C. B.; Carter, Brett W.; Federico, Lorenzo; Reuben, Alexandre; Khan, Md Abdul Wadud; Dejima, Hitoshi; Francisco-Cruz, Alejandro; Parra, Edwin R.; Solis, Luisa M.; Fujimoto, Junya; Tran, Hai T.; Kalhor, Neda; Fossella, Frank V.; Mott, Frank E.; Tsao, Anne S.; Blumenschein, George, Jr.; Le, Xiuning; Zhang, Jianjun; Skoulidis, Ferdinandos; Kurie, Jonathan M.; Altan, Mehmet; Lu, Charles; Glisson, Bonnie S.; Byers, Lauren Averett; Elamin, Yasir Y.; Mehran, Reza J.; Rice, David C.; Walsh, Garrett L.; Hofstetter, Wayne L.; Roth, Jack A.; Antonoff, Mara B.; Kadara, Humam; Haymaker, Cara; Bernatchez, Chantale; Ajami, Nadim J.; Jenq, Robert R.; Sharma, Padmanee; Allison, James P.; Futreal, Andrew; Wargo, Jennifer A.; Wistuba, Ignacio I.; Swisher, Stephen G.; Lee, J. Jack; Gibbons, Don L.; Vaporciyan, Ara A.; Heymach, John V.; Sepesi, Boris			Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	NATURE MEDICINE			English	Article							OPEN-LABEL; SINGLE-ARM; CHEMOTHERAPY; MULTICENTER; ATEZOLIZUMAB; ANTI-CTLA-4; ANTI-PD-1; SURVIVAL; THERAPY	Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment in operable NSCLC remain unclear. We report the results of the phase 2 randomized NEOSTAR trial (NCT03158129) of neoadjuvant nivolumab or nivolumab + ipilimumab followed by surgery in 44 patients with operable NSCLC, using major pathologic response (MPR) as the primary endpoint. The MPR rate for each treatment arm was tested against historical controls of neoadjuvant chemotherapy. The nivolumab + ipilimumab arm met the prespecified primary endpoint threshold of 6 MPRs in 21 patients, achieving a 38% MPR rate (8/21). We observed a 22% MPR rate (5/23) in the nivolumab arm. In 37 patients resected on trial, nivolumab and nivolumab + ipilimumab produced MPR rates of 24% (5/21) and 50% (8/16), respectively. Compared with nivolumab, nivolumab + ipilimumab resulted in higher pathologic complete response rates (10% versus 38%), less viable tumor (median 50% versus 9%), and greater frequencies of effector, tissue-resident memory and effector memory T cells. Increased abundance of gut Ruminococcus and Akkermansia spp. was associated with MPR to dual therapy. Our data indicate that neoadjuvant nivolumab + ipilimumab-based therapy enhances pathologic responses, tumor immune infiltrates and immunologic memory, and merits further investigation in operable NSCLC. Neoadjuvant treatment with nivolumab plus ipilimumab is well tolerated and demonstrates clinical efficacy in patients with early stage lung cancer.	[Cascone, Tina; William, William N., Jr.; Reuben, Alexandre; Tran, Hai T.; Fossella, Frank V.; Mott, Frank E.; Tsao, Anne S.; Blumenschein, George, Jr.; Le, Xiuning; Zhang, Jianjun; Skoulidis, Ferdinandos; Kurie, Jonathan M.; Altan, Mehmet; Lu, Charles; Glisson, Bonnie S.; Byers, Lauren Averett; Elamin, Yasir Y.; Wistuba, Ignacio I.; Gibbons, Don L.; Heymach, John V.] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Weissferdt, Annikka; Kalhor, Neda] Univ Texas MD Anderson Canc Ctr, Pathol, Houston, TX 77030 USA; [Weissferdt, Annikka; Pataer, Apar; Mehran, Reza J.; Rice, David C.; Walsh, Garrett L.; Hofstetter, Wayne L.; Roth, Jack A.; Antonoff, Mara B.; Swisher, Stephen G.; Vaporciyan, Ara A.; Sepesi, Boris] Univ Texas MD Anderson Canc Ctr, Thorac & Cardiovasc Surg, Houston, TX 77030 USA; [Leung, Cheuk H.; Lin, Heather Y.; Lee, J. Jack] Univ Texas MD Anderson Canc Ctr, Biostat, Houston, TX 77030 USA; [Godoy, Myrna C. B.; Carter, Brett W.] Univ Texas MD Anderson Canc Ctr, Thorac Imaging, Houston, TX 77030 USA; [Federico, Lorenzo; Bernatchez, Chantale] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA; [Khan, Md Abdul Wadud; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Surg Oncol, Houston, TX 77030 USA; [Dejima, Hitoshi; Francisco-Cruz, Alejandro; Parra, Edwin R.; Solis, Luisa M.; Fujimoto, Junya; Kadara, Humam; Haymaker, Cara; Bernatchez, Chantale; Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Translat Mol Pathol, Houston, TX 77030 USA; [Ajami, Nadim J.; Jenq, Robert R.; Futreal, Andrew] Univ Texas MD Anderson Canc Ctr, Genom Med, Houston, TX 77030 USA; [Jenq, Robert R.] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Jenq, Robert R.] CPRIT Scholar Canc Res, Houston, TX USA; [Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA; [Sharma, Padmanee; Allison, James P.] Univ Texas MD Anderson Canc Ctr, Immunol, Houston, TX 77030 USA; [Heymach, John V.] Univ Texas MD Anderson Canc Ctr, Canc Biol, Houston, TX 77030 USA; [William, William N., Jr.] Hosp BP, Oncol Ctr, Sao Paulo, Brazil; [Dejima, Hitoshi] Teikyo Univ, Sch Med, Itabashi Ku, Tokyo, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Teikyo University	Cascone, T (corresponding author), Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.	tcascone@mdanderson.org	Altan, Orhan/AAD-4550-2022; Lee, Jack/P-7331-2019; William, William/GRX-5352-2022; Francisco-Cruz, Alejandro/AIC-9273-2022	Lee, Jack/0000-0002-4584-929X; Tran, Hai/0000-0003-4065-9355; Lee, J. Jack/0000-0001-5469-9214; Haymaker, Cara/0000-0002-1317-9287; Reuben, Alexandre/0000-0003-4510-0382	Bristol Myers Squibb; National Institutes of Health (NIH)/National Cancer Institute (NCI) through the University of Texas Lung Specialized Program of Research Excellence (SPORE) [5P50CA070907]; NIH/NCI [P30 CA016672]; Cancer Center Support Grant; Conquer Cancer Foundation of the American Society of Clinical Oncology Career Development Award 2018 [12895]; Connie Rasor Endowment for Cancer Research; Bruton Endowed Chair in Tumor Biology; TMP-IL at the Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center; T. J. Martell Foundation	Bristol Myers Squibb(Bristol-Myers Squibb); National Institutes of Health (NIH)/National Cancer Institute (NCI) through the University of Texas Lung Specialized Program of Research Excellence (SPORE); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant; Conquer Cancer Foundation of the American Society of Clinical Oncology Career Development Award 2018; Connie Rasor Endowment for Cancer Research; Bruton Endowed Chair in Tumor Biology; TMP-IL at the Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center; T. J. Martell Foundation	We thank the patients and their families for participating in this study. We thank all the members of our regulatory, clinical, data coordination and translational research teams in the Departments of Thoracic/Head and Neck Medical Oncology and Thoracic Surgery at the MD Anderson Cancer Center for their support on this trial. We thank the members of the strategic alliance teams at Bristol Myers Squibb and the MD Anderson Cancer Center (E. B. Roarty and A. Spelman) for their support. We thank the members of the Translational Molecular Pathology Immune-Profiling Laboratory (TMP-IL) B. Sanchez Espiridon, S. Wijeratne, for their assistance with sample procurement and inventory, C.-W. B. Chow, W. Lu, L. Kakarala, M. Jiang, A. Tamegnon, and J. Zhou for their technical assistance, and D. Lorenzini for pathology assistance in imaging analysis. We thank L. Little and C. Gumbs from the Department of Genomic Medicine for assistance with TCR sequencing. We thank the MD Anderson's Program for Innovative Microbiome and Translational Research (PRIME-TR) for supporting the analysis and interpretation of the microbiome results presented herein (Drs. J. A. Wargo and N. J. Ajami are the program director and executive scientific director for PRIME-TR, respectively). We thank Mr. D. Aten, Sr. Medical Illustrator in Creative Communications at MD Anderson Cancer Center, for his assistance with figure formatting. Funding support for the clinical trial was provided by Bristol Myers Squibb. Support for the study was also partially provided by the National Institutes of Health (NIH)/National Cancer Institute (NCI) through the University of Texas Lung Specialized Program of Research Excellence (SPORE; grant no. 5P50CA070907 to T.C., L.A.B., F.S., J.M.K., J.A.R., I.I.W., D.L.G. and J.V.H.), the NIH/NCI P30 CA016672 Cancer Center Support Grant, the Conquer Cancer Foundation of the American Society of Clinical Oncology Career Development Award 2018 Project ID 12895 (to T.C.), the Connie Rasor Endowment for Cancer Research (to D.L.G.), the Bruton Endowed Chair in Tumor Biology (to J.V.H.), and the TMP-IL at the Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center. The study was also partially supported by the generous philanthropic contributions to the University of Texas MD Anderson Cancer Center Lung Cancer Moon Shot Program, the University of Texas MD Anderson Cancer Center Physician Scientist Program (from the T. J. Martell Foundation, to T.C). the Khalifa Bin Zayed Al Nahyan Foundation (to T.C.), the Ford Petrin Donation (to J.V.H.), the Rexanna's Foundation for Fighting Lung Cancer (to T.C., D.L.G., J.V.H. and B.S.) and the Bob Mayberry Foundation (to T.C.).	Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Bentebibel SE, 2019, CANCER DISCOV, V9, P711, DOI 10.1158/2159-8290.CD-18-1495; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5; Cascone T, 2020, CLIN CANCER RES, V26, P3525, DOI 10.1158/1078-0432.CCR-19-4180; Cascone T, 2018, ANN THORAC SURG, V105, P418, DOI 10.1016/j.athoracsur.2017.08.052; Chaft JE, 2013, J THORAC ONCOL, V8, P1084, DOI 10.1097/JTO.0b013e31829923ec; Djenidi F, 2015, J IMMUNOL, V194, P3475, DOI 10.4049/jimmunol.1402711; Duhen T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05072-0; Edgar RC, 2016, UNOISE2 IMPROVED ERR, V81257, DOI 10.1101/081257; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Gao SG, 2020, J THORAC ONCOL, V15, P816, DOI 10.1016/j.jtho.2020.01.017; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Hellmann MD, 2014, LANCET ONCOL, V15, pE42, DOI 10.1016/S1470-2045(13)70334-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kwiatkowski DJ, 2019, J CLIN ONCOL, V37; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Martin J, 2002, J CLIN ONCOL, V20, P1989, DOI 10.1200/JCO.2002.08.092; Parra ER, 2018, APPL IMMUNOHISTO M M, V26, P83, DOI 10.1097/PAI.0000000000000531; Parra ER, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13942-8; Parra ER, 2020, CANCERS, V12, DOI 10.3390/cancers12020255; Parra ER, 2019, CANCERS, V11, DOI 10.3390/cancers11020247; Pataer A, 2012, J THORAC ONCOL, V7, P825, DOI 10.1097/JTO.0b013e318247504a; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Provencio M, 2020, LANCET ONCOL, V21, P1413, DOI 10.1016/S1470-2045(20)30453-8; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Ramalingam SS, 2020, J CLIN ONCOL, V38; Reck M, 2020, J CLIN ONCOL, V38; Reuben A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14273-0; Reuben A, 2017, CANCER DISCOV, V7, P1088, DOI 10.1158/2159-8290.CD-17-0256; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sepesi B, 2019, J THORAC ONCOL, V14, pS745, DOI 10.1016/j.jtho.2019.08.1595; Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9; Thall PF, 1996, J CLIN ONCOL, V14, P296, DOI 10.1200/JCO.1996.14.1.296; Tsao MS, 2018, J THORAC ONCOL, V13, P1302, DOI 10.1016/j.jtho.2018.05.013; Wei SC, 2019, P NATL ACAD SCI USA, V116, P22699, DOI 10.1073/pnas.1821218116; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Weissferdt A, 2020, CLIN LUNG CANCER, V21, P341, DOI 10.1016/j.cllc.2019.11.003; William WN, 2013, J THORAC ONCOL, V8, P222, DOI 10.1097/JTO.0b013e3182774108; Woolson RFC., 2002, STAT METHODS ANAL BI, Ved 2; Wu TD, 2020, NATURE, V579, P274, DOI 10.1038/s41586-020-2056-8	45	146	152	15	52	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					504	+		10.1038/s41591-020-01224-2	http://dx.doi.org/10.1038/s41591-020-01224-2		FEB 2021	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33603241	Green Accepted			2023-01-03	WOS:000619508200002
J	Schmidt, MM; Griffin, JM; McCabe, P; Stuart-Mullen, L; Branda, M; OByrne, TJ; Bowers, M; Trotter, K; McLeod, C				Schmidt, Monika M.; Griffin, Joan M.; McCabe, Pamela; Stuart-Mullen, Lynette; Branda, Megan; OByrne, Thomas J.; Bowers, Margaret; Trotter, Kathryn; McLeod, Christopher			Shared medical appointments: Translating research into practice for patients treated with ablation therapy for atrial fibrillation	PLOS ONE			English	Article								Background People with atrial fibrillation (AF) have lower reported quality of life and increased risk of heart attack, death, and stroke. Lifestyle modifications can improve arrhythmia-free survival/symptom severity. Shared medical appointments (SMAs) have been effective at targeting lifestyle change in other chronic diseases and may be beneficial for patients with AF. Objective To determine if perceived self-management and satisfaction with provider communication differed between patients who participated in SMAs compared to patients in standard care. Secondary objectives were to examine differences between groups for knowledge about AF, symptom severity, and healthcare utilization. Methods We conducted a retrospective analysis of data collected where patients were assigned to either standard care (n = 62) or a SMA (n = 59). Surveys were administered at pre-procedure, 3, and 6 months. Results Perceived self-management was not significantly different at baseline (p = 0.95) or 6 months (p = 0.21). Patients in SMAs reported more knowledge gain at baseline (p = 0.01), and higher goal setting at 6 months (p = 0.0045). Symptom severity for both groups followed similar trends. Conclusion Patients with AF who participated in SMAs had similar perceived self-management, patient satisfaction with provider communication, symptom severity, and healthcare utilization with their counterparts, but had a statistically significant improvement in knowledge about their disease.	[Schmidt, Monika M.] US Dept Vet Affairs, Nashville, TN 37203 USA; [Griffin, Joan M.; McCabe, Pamela; Stuart-Mullen, Lynette; OByrne, Thomas J.] Mayo Clin, Rochester, MN USA; [Branda, Megan] Univ Colorado Denver, Dept Biostat & Informat, Colorado Sch Publ Hlth, Anschutz Med Campus, Aurora, CO USA; [Bowers, Margaret; Trotter, Kathryn] Duke Univ, Durham, NC USA; [McLeod, Christopher] Mayo Clin, Jacksonville, FL 32224 USA	US Department of Veterans Affairs; Mayo Clinic; Children's Hospital Colorado; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; Duke University; Mayo Clinic	Schmidt, MM (corresponding author), US Dept Vet Affairs, Nashville, TN 37203 USA.	monika.schmidt@va.gov		Schmidt, Monika/0000-0001-6414-7974				[Anonymous], 1998, ABSTRACT SESSION 1 T, V21, P790; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bodenheimer T, 2014, ANN FAM MED, V12, P573, DOI 10.1370/afm.1713; Bos-Touwen I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126400; Calkins H, 2018, EUROPACE, V20, P157, DOI [10.1093/europace/eux275, 10.1093/europace/eux274, 10.1016/j.hrthm.2017.05.012]; Colilla S, 2013, AM J CARDIOL, V112, P1142, DOI 10.1016/j.amjcard.2013.05.063; Dimitrov Dimiter M, 2003, Work, V20, P159; Edelman D., 2012, VA EVIDENCE BASED SY; Edelman D, 2015, J GEN INTERN MED, V30, P99, DOI 10.1007/s11606-014-2978-7; Glasgow RE, 2005, MED CARE, V43, P436, DOI 10.1097/01.mlr.0000160375.47920.8c; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Greene J, 2012, J GEN INTERN MED, V27, P520, DOI 10.1007/s11606-011-1931-2; Haslam SA, 2009, APPL PSYCHOL-INT REV, V58, P1, DOI 10.1111/j.1464-0597.2008.00379.x; Heyworth L, 2014, ANN FAM MED, V12, P324, DOI 10.1370/afm.1660; Hibbard JH, 2004, HEALTH SERV RES, V39, P1005, DOI 10.1111/j.1475-6773.2004.00269.x; Hibbard JH, 2007, HEALTH SERV RES, V42, P1443, DOI 10.1111/j.1475-6773.2006.00669.x; January CT, 2014, J AM COLL CARDIOL, V64, P2304, DOI 10.1016/j.jacc.2014.04.004; Jhagroo RA, 2013, J UROLOGY, V190, P1778, DOI 10.1016/j.juro.2013.05.037; Kim MH, 2011, CIRC-CARDIOVASC QUAL, V4, P313, DOI 10.1161/CIRCOUTCOMES.110.958165; Koponen L, 2008, J ADV NURS, V61, P51, DOI 10.1111/j.1365-2648.2007.04465.x; Lane DA., 2015, REV ESP CARDIOL, DOI DOI 10.1093/EUROPACE/EUV233; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Mark DB, 2019, JAMA-J AM MED ASSOC, V321, P1275, DOI 10.1001/jama.2019.0692; McCabe PJ, 2018, PATIENT PREFER ADHER, V12, P1907, DOI 10.2147/PPA.S172970; Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140; Palaniappan LP, 2011, J AM BOARD FAM MED, V24, P326, DOI 10.3122/jabfm.2011.03.100220; Pathak RK, 2015, J AM COLL CARDIOL, V65, P2159, DOI 10.1016/j.jacc.2015.03.002; Pathak RK, 2014, J AM COLL CARDIOL, V64, P2222, DOI 10.1016/j.jacc.2014.09.028; Paul S, 2013, HEART LUNG, V42, P456, DOI 10.1016/j.hrtlng.2013.08.006; Rahaghi FF, 2014, PULM CIRC, V4, P53, DOI 10.1086/674883; Riley SB, 2013, J AM ASSOC NURSE PRA, V25, P466, DOI 10.1111/j.1745-7599.2012.00796.x; Seesing FM, 2014, NEUROLOGY, V83, P240, DOI 10.1212/WNL.0000000000000588; Smith Carol E, 2015, J Cardiovasc Nurs, V30, pS25, DOI 10.1097/JCN.0000000000000255; Trotter Kathryn J, 2013, Nurse Pract, V38, P48, DOI 10.1097/01.NPR.0000428816.72503.49	34	0	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2021	16	2							e0246861	10.1371/journal.pone.0246861	http://dx.doi.org/10.1371/journal.pone.0246861			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QK0KW	33577612	gold, Green Published			2023-01-03	WOS:000620071700032
J	Whisler, A; Dosani, N; To, MJ; O'Brien, K; Young, S; Hwang, SW				Whisler, Adam; Dosani, Naheed; To, Matthew J.; O'Brien, Kristen; Young, Samantha; Hwang, Stephen W.			The effect of a Housing First intervention on primary care retention among homeless individuals with mental illness	PLOS ONE			English	Article							HIV; SERVICES; HEALTH; ADULTS; VETERANS; OUTCOMES; SUPPORT; CHOICE; ACCESS	Background Primary care retention, defined as ongoing periodic contact with a consistent primary care provider, is beneficial for people with serious chronic illnesses. This study examined the effect of a Housing First intervention on primary care retention among homeless individuals with mental illness. Methods Two hundred individuals enrolled in the Toronto site of the At Home Project and randomized to Housing First or Treatment As Usual were studied. Medical records were reviewed to determine if participants were retained in primary care, defined as having at least one visit with the same primary care provider in each of two consecutive six-month periods during the 12 month period preceding and following randomization. Results Medical records were obtained for 47 individuals randomized to Housing First and 40 individuals randomized to Treatment As Usual. During the one year period following randomization, the proportion of Housing First and Treatment As Usual participants retained in primary care was not significantly different (38.3% vs. 47.5%, p = 0.39). The change in primary care retention rates from the year preceding randomization to the year following randomization was +10.6% in the Housing First group and -5.0% in the Treatment As Usual group. Conclusion Among homeless individuals with mental illness, Housing First did not significantly affect primary care retention over the follow-up period. These findings suggest Housing First interventions may need to place greater emphasis on connecting clients with primary care providers.	[Whisler, Adam; To, Matthew J.; O'Brien, Kristen; Young, Samantha; Hwang, Stephen W.] St Michaels Hosp, Li Ka Shing Knowledge Inst, MAP Ctr Urban Hlth Solut, Toronto, ON, Canada; [Dosani, Naheed] Inner City Hlth Associates, Toronto, ON, Canada; [Dosani, Naheed] St Michaels Hosp, Dept Family & Community Med, Toronto, ON, Canada; [Dosani, Naheed] McMaster Univ, Fac Hlth Sci, Div Palliat Care, Hamilton, ON, Canada; [Dosani, Naheed] William Osler Hlth Syst, Div Palliat Care, Brampton, ON, Canada; [Hwang, Stephen W.] Univ Toronto, Dept Med, Div Gen Internal Med, Toronto, ON, Canada	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster University; University of Toronto	Dosani, N (corresponding author), Inner City Hlth Associates, Toronto, ON, Canada.; Dosani, N (corresponding author), St Michaels Hosp, Dept Family & Community Med, Toronto, ON, Canada.; Dosani, N (corresponding author), McMaster Univ, Fac Hlth Sci, Div Palliat Care, Hamilton, ON, Canada.; Dosani, N (corresponding author), William Osler Hlth Syst, Div Palliat Care, Brampton, ON, Canada.	dosanin@smh.ca	Hwang, Stephen W./GVR-7773-2022		Health Canada	Health Canada	This research has been made possible through a financial contribution from Health Canada (https://www.canada.ca/en/health-canada. html). The views expressed herein solely represent the authors. The Mental Health Commission of Canada (https://www.mentalhealthcommission.ca/English) oversaw the conduct of the study and provided training and technical support to the service teams and research staff throughout the project. However, the funder had no role in the analysis and interpretation of the data, preparation, review or approval of the manuscript.	Appel PW, 2012, J ADDICT DIS, V31, P270, DOI 10.1080/10550887.2012.694602; Argintaru N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-577; Cabral HJ, 2007, AIDS PATIENT CARE ST, V21, pS59, DOI 10.1089/apc.2007.9986; Chrystal JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117395; Ciaranello AL, 2006, J HEALTH CARE POOR U, V17, P441, DOI 10.1353/hpu.2006.0056; City of Toronto, 2018, STREET NEEDS ASS RES; Fareed A, 2009, J PSYCHIATR PRACT, V15, P227, DOI 10.1097/01.pra.0000351884.83377.e2; Fekadu A, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0138-x; Frankish CJ, 2005, CAN J PUBLIC HEALTH, V96, pS23, DOI 10.1007/BF03403700; Gardner LI, 2005, AIDS, V19, P423, DOI 10.1097/01.aids.0000161772.51900.eb; Goering P, 2002, PSYCHIAT SERV, V53, P1472, DOI 10.1176/appi.ps.53.11.1472; Goering PN, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000323; Greenwood RM, 2005, AM J COMMUN PSYCHOL, V36, P223, DOI 10.1007/s10464-005-8617-z; Havens JR, 2009, J SUBST ABUSE TREAT, V36, P306, DOI 10.1016/j.jsat.2008.07.002; Health Quality Ontario, 2016, Ont Health Technol Assess Ser, V16, P1; Hwang SW, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-787; Hwang SW, 2001, CAN MED ASSOC J, V164, P229; Khandor Erika, 2011, Open Med, V5, pe94; Kresky-Wolff M, 2010, J BEHAV HEALTH SER R, V37, P213, DOI 10.1007/s11414-009-9206-y; Kushel MB, 2002, AM J PUBLIC HEALTH, V92, P778, DOI 10.2105/AJPH.92.5.778; Mares AS, 2011, ADM POLICY MENT HLTH, V38, P459, DOI 10.1007/s10488-011-0333-4; Marx KA, 2011, AIDS CARE, V23, P1298, DOI 10.1080/09540121.2011.555942; McCarthy JF, 2007, HEALTH SERV RES, V42, P1042, DOI 10.1111/j.1475-6773.2006.00642.x; McGuire J, 2009, ADM POLICY MENT HLTH, V36, P255, DOI 10.1007/s10488-009-0210-6; Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V61, P574, DOI 10.1097/QAI.0b013e318273762f; Mugavero MJ, 2009, CLIN INFECT DIS, V48, P248, DOI 10.1086/595705; Naar-King S, 2007, AIDS PATIENT CARE ST, V21, pS40, DOI 10.1089/apc.2007.9988; Nelson G, 2007, AM J ORTHOPSYCHIAT, V77, P350, DOI 10.1037/0002-9432.77.3.350; Padgett DK, 2006, RES SOCIAL WORK PRAC, V16, P74, DOI 10.1177/1049731505282593; Sherer R, 2002, AIDS CARE, V14, pS31, DOI 10.1080/09540120220149975; Smartt C, 2019, BJPSYCH OPEN, V5, DOI 10.1192/bjo.2019.32; Tsemberis S, 2004, AM J PUBLIC HEALTH, V94, P651, DOI 10.2105/AJPH.94.4.651; Tsemberis S, 1999, New Dir Ment Health Serv, P9, DOI 10.1002/yd.23319998204; Tsemberis S, 2000, PSYCHIATR SERV, V51, P487, DOI 10.1176/appi.ps.51.4.487; Ulett KB, 2009, AIDS PATIENT CARE ST, V23, P41, DOI 10.1089/apc.2008.0132; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Yehia BR, 2012, AIDS, V26, P1131, DOI 10.1097/QAD.0b013e3283528afa	37	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246859	10.1371/journal.pone.0246859	http://dx.doi.org/10.1371/journal.pone.0246859			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QH4VJ	33571302	gold, Green Published			2023-01-03	WOS:000618274000060
J	Srisurapanont, K; Samakarn, Y; Kamklong, B; Siratrairat, P; Bumiputra, A; Jaikwang, M; Srisurapanont, M				Srisurapanont, Karan; Samakarn, Yanisa; Kamklong, Boonyasit; Siratrairat, Phichayakan; Bumiputra, Arina; Jaikwang, Montita; Srisurapanont, Manit			Blue-wavelength light therapy for post-traumatic brain injury sleepiness, sleep disturbance, depression, and fatigue: A systematic review and network meta-analysis	PLOS ONE			English	Review							DISORDERS; QUALITY; PREVALENCE; INTERVENTIONS; SUPPRESSION; MANAGEMENT; MELATONIN; IMPACT; SCALE; MOOD	Objective This review aimed to determine the efficacy of blue-wavelength light therapy (BWLT) for post-traumatic brain injury (TBI) sleepiness, sleep disturbance, depression, and fatigue. Methods Pubmed, Scopus, Web of Science, Cochrane Library, Academic Search Complete, and CINAHL. Included trials were randomized controlled trials (RCTs) of BWLT in adults with a history of TBI. Outcomes of interest included sleepiness, sleep disturbance, depression, or fatigue. Two reviewers independently screened the searched items, selected the trials, extracted the data, and rating the quality of trials. We aggregated the data using a random-effect, frequentist network meta-analysis (NMA). Results We searched the databases on July 4, 2020. This review included four RCTs of 117 patients with a history of TBI who were randomized to received BWLT, amber light therapy (ALT), or no light therapy (NLT). Moderate-quality evidence revealed that: i) BWLT was significantly superior to NLT in reducing depression (SMD = 0.81, 95% CI = 0.20 to 1.43) ii) BWLT reduced fatigue at a significantly greater extent than NLT (SMD = 1.09, 95% CI = 0.41 to 1.76) and ALT (SMD = 1.00, 95% CI = 0.14 to 1.86). Low-quality evidence suggested that BWLT reduced depression at a greater extent than ALT (SMD = 0.57, 95% CI = 0.04 to 1.10). Low-quality evidence found that the dropout rates of those receiving BWLT and ALT were not significantly different (RR = 3.72, 95% CI = 0.65 to 21.34). Conclusion Moderate-quality evidence suggests that BWLT may be useful for post-TBI depression and fatigue.	[Srisurapanont, Karan; Samakarn, Yanisa; Kamklong, Boonyasit; Siratrairat, Phichayakan; Bumiputra, Arina; Jaikwang, Montita] Chiang Mai Univ, Fac Med, Chiang Mai, Thailand; [Srisurapanont, Manit] Chiang Mai Univ, Fac Med, Dept Psychiat, Chiang Mai, Thailand	Chiang Mai University; Chiang Mai University	Srisurapanont, M (corresponding author), Chiang Mai Univ, Fac Med, Dept Psychiat, Chiang Mai, Thailand.	manit.s@cmu.ac.th	Srisurapanont, Karan/ABA-7567-2021; Srisurapanont, Manit/R-9997-2017	Srisurapanont, Karan/0000-0001-9296-6344; Srisurapanont, Manit/0000-0001-6203-1206	Chiang Mai University, Chiang Mai, Thailand [16/2563]	Chiang Mai University, Chiang Mai, Thailand	This work was supported by a grant from Chiang Mai University, Chiang Mai, Thailand (grant no. 16/2563 for M.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, BMJ, V2015, ph1887; [Anonymous], 2020, J KOREAN MED SCI, V35, pe112; Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117; Beck A.T., 1996, MANUAL BECK DEPRESSI; Boutron I, 2019, COCHRANE HDB SYSTEMA, P177; Buysse D J, 1989, Psychiatry Res, V28, P193; Cajochen C, 2000, BEHAV BRAIN RES, V115, P75, DOI 10.1016/S0166-4328(00)00236-9; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Center for Environmental Therapeutics, 2017, LIGHT BOX SEL CRIT; Chellappa SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016429; Choi K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36791-5; Cohen J., 2013, STAT POWER ANAL BEHA; Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500; Ferentinos P, 2009, J PSYCHOSOM RES, V66, P37, DOI 10.1016/j.jpsychores.2008.07.009; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Imbach LL, 2016, NEUROLOGY, V86, P1945, DOI 10.1212/WNL.0000000000002697; James SL, 2019, LANCET NEUROL, V18, P56, DOI 10.1016/S1474-4422(18)30415-0; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Juengst SB, 2017, PSYCHOL RES BEHAV MA, V10, P175, DOI 10.2147/PRBM.S113264; Killgore WDS, 2020, NEUROBIOL DIS, V134, DOI 10.1016/j.nbd.2019.104679; Kozaki T, 2016, NEUROSCI LETT, V616, P1, DOI 10.1016/j.neulet.2015.12.063; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Martensson B, 2015, J AFFECT DISORDERS, V182, P1, DOI 10.1016/j.jad.2015.04.013; Maruani J, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00085; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McGuinness LA, 2021, RES SYNTH METHODS, V12, P55, DOI 10.1002/jrsm.1411; Mitolo M, 2018, DEMENT GERIATR COGN, V46, P371, DOI 10.1159/000494921; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; R Core Team, 2021, R LANG ENV STAT COMP; R Core Team, 2019, RSTUDIO INTEGRATED D; Raikes AC, 2020, J HEAD TRAUMA REHAB, V35, pE405, DOI 10.1097/HTR.0000000000000579; Raymackers JM, 2019, ACTA NEUROL BELG, V119, P607, DOI 10.1007/s13760-019-01214-3; Ruger M, 2005, J SLEEP RES, V14, P221, DOI 10.1111/j.1365-2869.2005.00452.x; Scholten AC, 2016, J NEUROTRAUM, V33, P1969, DOI 10.1089/neu.2015.4252; Shang BH, 2019, GERIATR NURS, V40, P405, DOI 10.1016/j.gerinurse.2019.01.001; Sinclair KL, 2014, NEUROREHAB NEURAL RE, V28, P303, DOI 10.1177/1545968313508472; van Maanen A, 2016, SLEEP MED REV, V29, P52, DOI 10.1016/j.smrv.2015.08.009; Viola-Saltzman M, 2016, NEUROPSYCH DIS TREAT, V12, P339, DOI 10.2147/NDT.S69105; Wu CX, 2019, WORLDV EVID-BASED NU, V16, P102, DOI 10.1111/wvn.12352; Xu GZ, 2017, THER ADV NEUROL DISO, V10, P229, DOI 10.1177/1756285616682675	46	8	8	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2021	16	2							e0246172	10.1371/journal.pone.0246172	http://dx.doi.org/10.1371/journal.pone.0246172			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QF5UW	33539446	Green Published, gold			2023-01-03	WOS:000616960200076
J	Ehlers, J; Grimmer, J; Strack, V; Huckauf, A				Ehlers, Jan; Grimmer, Janine; Strack, Veronika; Huckauf, Anke			The influence of sham feedback on physiological processing during fear-driven stimulation	PLOS ONE			English	Article							CONDUCTANCE RECOVERY-TIME; HEART-RATE FEEDBACK; PUPIL SIZE; DESENSITIZATION; BIOFEEDBACK; PHOBIAS; EMOTION; ANXIETY	Biofeedback constitutes a well-established, non-invasive method to voluntary interfere in emotional processing by means of cognitive strategies. However, treatment durations exhibit strong inter-individual variations and first successes can often be achieved only after a large number of sessions. Sham feedback constitutes a rather untapped approach by providing feedback that does not correspond to the participant's actual state. The current study aims to gain insights into mechanisms of sham feedback processing in order to support new techniques in biofeedback therapy. We carried out two experiments and applied different types of sham feedback on skin conductance responses and pupil size changes during affective processing. Results indicate that standardized but context-sensitive sham signals based on skin conductance responses exert a stronger influence on emotional regulation compared to individual sham feedback from ongoing pupil dynamics. Also, sham feedback should forego unnatural signal behavior to avoid irritation and skepticism among participants. Altogether, a reasonable combination of stimulus features and sham feedback characteristics enables to considerably reduce the actual bodily responsiveness already within a single session.	[Ehlers, Jan; Grimmer, Janine] Bauhaus Univ Weimar, Dept Comp Sci, Weimar, Germany; [Strack, Veronika; Huckauf, Anke] Ulm Univ, Dept Gen Psychol, Ulm, Germany	Bauhaus-Universitat Weimar; Ulm University	Ehlers, J (corresponding author), Bauhaus Univ Weimar, Dept Comp Sci, Weimar, Germany.	jan.ehlers@uni-weimar.de		Ehlers, Jan/0000-0002-4475-2349	German Research Foundation (DFG)	German Research Foundation (DFG)(German Research Foundation (DFG))	We acknowledge support from the German Research Foundation (DFG) and BauhausUniversitat Weimar within the program of Open Access Publishing.	Al-Omar D., 2013, UNIVERSAL ACCESS HUM, V8010, P253, DOI DOI 10.1007/978-3-642-39191-0_28; Barlow D.H., 2004, ANXIETY ITS DISORDER; Bradley M.M., 2007, INT AFFECTIVE DIGITI, V2nd; Bradley MM, 2001, EMOTION, V1, P276, DOI 10.1037//1528-3542.1.3.276; Bradley MM, 2000, PSYCHOPHYSIOLOGY, V37, P204, DOI 10.1111/1469-8986.3720204; Brauer A., 1999, PSYCHIAT TIMES, V16, P1; Bremner FD, 2012, INVEST OPHTH VIS SCI, V53, P7343, DOI 10.1167/iovs.12-10881; Cook-Vienot R, 2016, J EMDR PRACT RES, V10, pE133, DOI 10.1891/1933-3196.10.3.E133; EHLERS A, 1988, BEHAV RES THER, V26, P1, DOI 10.1016/0005-7967(88)90028-9; Ehlers J, 2020, ETRA 2020 SHORT PAPERS: ACM SYMPOSIUM ON EYE TRACKING RESEARCH & APPLICATIONS, DOI 10.1145/3379156.3391358; Ehlers J, 2018, INT J HUM-COMPUT ST, V119, P28, DOI 10.1016/j.ijhcs.2018.06.003; Garfinkel SN, 2015, BIOL PSYCHOL, V104, P65, DOI 10.1016/j.biopsycho.2014.11.004; Garfinkel SN, 2013, SOC COGN AFFECT NEUR, V8, P231, DOI 10.1093/scan/nss140; Georgi J., 2014, COMMUNICATIONS COMPU, P104; Heuser J., 2010, WIE WIRKSAM IST BIOF, P29; Huckauf A, 2014, P 8 INT C PERV COMP, P343; JANISSE MP, 1974, SOC BEHAV PERSONAL, V2, P125, DOI 10.2224/sbp.1974.2.2.125; KENT RN, 1972, BEHAV THER, V3, P1, DOI 10.1016/S0005-7894(72)80046-7; Khalfa S, 2002, INT J PSYCHOPHYSIOL, V45, P155; Kotov R. I., 2004, MULTIDIMENSIONAL IOW; Laux L, 1981, STATE TRAIT ANGSTINV; LEVANDER SE, 1980, PSYCHOPHYSIOLOGY, V17, P105, DOI 10.1111/j.1469-8986.1980.tb00119.x; Love J, 2019, J STAT SOFTW, V88, P1, DOI 10.18637/jss.v088.i02; Martin A., 2010, WIE WIRKSAM IST BIOF, P17; MCNALLY RJ, 1982, BEHAV RES THER, V20, P153, DOI 10.1016/0005-7967(82)90114-0; Mehling WE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048230; Micoulaud-Franchi JA, 2014, EPILEPSY BEHAV, V41, P244, DOI 10.1016/j.yebeh.2014.10.017; Partala T, 2003, INT J HUM-COMPUT ST, V59, P185, DOI 10.1016/S1071-5819(03)00017-X; Peirce JW., 2015, PSYCHOPY; Reutemann M.., 2006, SUGGESTIBILITAT SITU; Schmitz C., 2017, LIMESURVEY; SELIGMAN ME, 1971, BEHAV THER, V2, P307, DOI 10.1016/S0005-7894(71)80064-3; Tabachnik L., 2015, CONCEPT, V38; VALINS S, 1967, J PERS SOC PSYCHOL, V7, P345, DOI 10.1037/h0025239; VALINS S, 1966, J PERS SOC PSYCHOL, V4, P400, DOI 10.1037/h0023791; VENABLES PH, 1981, PSYCHOPHYSIOLOGY, V18, P10, DOI 10.1111/j.1469-8986.1981.tb01533.x; Windthorst P, 2015, PSYCHOTHER PSYCH MED, V65, P146, DOI 10.1055/s-0034-1387320	37	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2021	16	5							e0251211	10.1371/journal.pone.0251211	http://dx.doi.org/10.1371/journal.pone.0251211			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6FV	33951095	Green Published, gold			2023-01-03	WOS:000664610500075
J	Coomarasamy, A; Gallos, ID; Papadopoulou, A; Dhillon-Smith, RK; Al-Memar, M; Brewin, J; Christiansen, OB; Stephenson, MD; Oladapo, OT; Wijeyaratne, CN; Small, R; Bennett, PR; Regan, L; Goddijn, M; Devall, AJ; Bourne, T; Brosens, JJ; Quenby, S				Coomarasamy, Arri; Gallos, Ioannis D.; Papadopoulou, Argyro; Dhillon-Smith, Rima K.; Al-Memar, Maya; Brewin, Jane; Christiansen, Ole B.; Stephenson, Mary D.; Oladapo, Olufemi T.; Wijeyaratne, Chandrika N.; Small, Rachel; Bennett, Phillip R.; Regan, Lesley; Goddijn, Mariette; Devall, Adam J.; Bourne, Tom; Brosens, Jan J.; Quenby, Siobhan			Sporadic miscarriage: evidence to provide effective care	LANCET			English	Review							PREGNANCY ASSESSMENT UNIT; EMERGENCY-DEPARTMENT; RANDOMIZED-TRIAL; VAGINAL PROGESTERONE; MANAGEMENT; WOMEN; ULTRASOUND; IMPACT; ABORTION; DYDROGESTERONE	The physical and psychological effect of miscarriage is commonly underappreciated. The journey from diagnosis of miscarriage, through clinical management, to supportive aftercare can be challenging for women, their partners, and caregivers. Diagnostic challenges can lead to delayed or ineffective care and increased anxiety. Inaccurate diagnosis of a miscarriage can result in the unintended termination of a wanted pregnancy. Uncertainty about the therapeutic effects of interventions can lead to suboptimal care, with variations across facilities and countries. For this Series paper, we have developed recommendations for practice from a literature review, appraisal of guidelines, and expert group discussions. The recommendations are grouped into three categories: (1) diagnosis of miscarriage, (2) prevention of miscarriage in women with early pregnancy bleeding, and (3) management of miscarriage. We recommend that every country reports annual aggregate miscarriage data, similarly to the reporting of stillbirth. Early pregnancy services need to focus on providing an effective ultrasound service, as it is central to the diagnosis of miscarriage, and be able to provide expectant management of miscarriage, medical management with mifepristone and misoprostol, and surgical management with manual vacuum aspiration. Women with the dual risk factors of early pregnancy bleeding and a history of previous miscarriage can be recommended vaginal micronised progesterone to improve the prospects of livebirth. We urge health-care funders and providers to invest in early pregnancy care, with specific focus on training for clinical nurse specialists and doctors to provide comprehensive miscarriage care within the setting of dedicated early pregnancy units.	[Coomarasamy, Arri; Gallos, Ioannis D.; Papadopoulou, Argyro; Dhillon-Smith, Rima K.; Devall, Adam J.] Univ Birmingham, Inst Metab & Syst Res, Tommys Natl Ctr Miscarriage Res, Birmingham, W Midlands, England; [Al-Memar, Maya; Bennett, Phillip R.; Regan, Lesley; Bourne, Tom] Imperial Coll London, Tommys Natl Ctr Miscarriage Res, London, England; [Brewin, Jane] Tommys Char, Laurence Pountney Hill, London, England; [Christiansen, Ole B.] Aalborg Univ Hosp, Dept Obstet & Gynaecol, Ctr Recurrent Pregnancy Loss Western Denmark, Aalborg, Denmark; [Stephenson, Mary D.] Univ Illinois, Dept Obstet & Gynecol, Recurrent Pregnancy Loss Program, Chicago, IL 60612 USA; [Oladapo, Olufemi T.] WHO, Dept Sexual & Reprod Hlth & Res, UNDP UNFPA UNICEF WHO World Bank Special Programm, Geneva, Switzerland; [Wijeyaratne, Chandrika N.] Univ Colombo, Dept Reprod Med, Colombo, Sri Lanka; [Small, Rachel] Univ Hosp Birmingham NHS Fdn Trust, Birmingham Heartlands Hosp, Birmingham, W Midlands, England; [Goddijn, Mariette] Univ Amsterdam, Amsterdam UMC, Ctr Reprod Med, Amsterdam, Netherlands; [Bourne, Tom] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium; [Brosens, Jan J.; Quenby, Siobhan] Univ Warwick, Warwick Med Sch, Div Biomed Sci, Warwick, England; [Brosens, Jan J.; Quenby, Siobhan] Univ Hosp Coventry & Warwickshire NHS Trust, Tommys Natl Ctr Miscarriage Res, Coventry, W Midlands, England	University of Birmingham; Imperial College London; Aalborg University; Aalborg University Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; The World Bank; United Nations Population Fund; World Health Organization; University of Colombo; Heart of England NHS Foundation Trust; University of Birmingham; University of Amsterdam; KU Leuven; University of Warwick; University of Warwick	Gallos, ID (corresponding author), Univ Birmingham, Inst Metab & Syst Res, Birmingham B15 2TT, W Midlands, England.	i.d.gallos@bham.ac.uk	Bourne, Tom/I-6478-2012; Papadopoulou, Argyro/AAR-1380-2020; Devall, Adam/AAC-9646-2022	Bourne, Tom/0000-0003-1421-6059; Papadopoulou, Argyro/0000-0001-9409-8608; Quenby, Siobhan/0000-0003-3221-5471; Gallos, Ioannis/0000-0002-2766-358X; Bennett, Phillip/0000-0002-6253-4919; Goddijn, Mariette/0000-0001-9928-9673	Tommy's Charity; Wellcome Trust Investigator Award [212233/Z/18/Z]	Tommy's Charity; Wellcome Trust Investigator Award(Wellcome Trust)	The Tommy's Charity funds the Tommy's National Centre for Miscarriage Research. JJB holds a Wellcome Trust Investigator Award (212233/Z/18/Z). The funders had no role in the writing of the Series paper, or in the decision to submit the paper for publication.	Akhter P, 2007, IRISH J MED SCI, V176, P23, DOI 10.1007/s11845-007-0013-2; Aleman A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003576.pub2; Axelsen SM, 1995, EUR J OBSTET GYN R B, V63, P131, DOI 10.1016/0301-2115(95)02236-8; BATZOFIN JH, 1984, OBSTET GYNECOL, V63, P515; Bignardi T, 2010, ULTRASOUND OBST GYN, V35, P344, DOI 10.1002/uog.7523; BIGRIGG MA, 1991, BRIT MED J, V302, P577, DOI 10.1136/bmj.302.6776.577; Bottomley C, 2009, BEST PRACT RES CL OB, V23, P463, DOI 10.1016/j.bpobgyn.2009.02.004; Brownlea S, 2005, AUST NZ J OBSTET GYN, V45, P108, DOI 10.1111/j.1479-828X.2005.00351.x; Carp H, 2012, GYNECOL ENDOCRINOL, V28, P983, DOI 10.3109/09513590.2012.702875; CATES W, 1985, LANCET, V2, P596; Chen JL, 2016, INT IMMUNOPHARMACOL, V40, P347, DOI 10.1016/j.intimp.2016.09.018; Cleeve A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149172; Coomarasamy A, 2019, NEW ENGL J MED, V380, P1815, DOI 10.1056/NEJMoa1813730; Coomarasamy A, 2015, NEW ENGL J MED, V373, P2141, DOI 10.1056/NEJMoa1504927; Coomarasamy A, 2020, AM J OBSTET GYNECOL, V223, P167, DOI 10.1016/j.ajog.2019.12.006; Coomarasamy Arri, 2011, BMJ, V342, pd1914, DOI 10.1136/bmj.d1914; Devaseelan P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007422.pub2; Di Renzo GC, 2012, GYNECOL ENDOCRINOL, V28, P925, DOI 10.3109/09513590.2012.730576; Doubilet PM, 2013, NEW ENGL J MED, V369, P1443, DOI 10.1056/NEJMra1302417; Duley L, 2005, COCHRANE DATABASE SY, V3; El-Zibdeh MY, 2009, MATURITAS, V65, pS43, DOI 10.1016/j.maturitas.2009.11.013; Elson J, 2004, CURR OPIN OBSTET GYN, V16, P339, DOI 10.1097/01.gco.0000136501.81614.05; French JI, 1999, OBSTET GYNECOL, V93, P715, DOI 10.1016/S0029-7844(98)00557-2; Gallos ID, 2017, COCHRANE DB SYST REV, V3, DOI [DOI 10.1002/14651858.CD012602, 10.1002/14651858.CD012602]; Guha S, 2013, HUM REPROD, V28, P2905, DOI 10.1093/humrep/det342; Iyoke CA, 2014, NIGER J CLIN PRACT, V17, P419, DOI 10.4103/1119-3077.134003; Jackson E, 2011, REPROD HEALTH MATTER, V19, P133, DOI 10.1016/S0968-8080(11)37563-5; Jeve Y, 2011, ULTRASOUND OBST GYN, V38, P489, DOI 10.1002/uog.10108; Kiemtore S, 2017, INT J GYNECOL OBSTET, V136, P215, DOI 10.1002/ijgo.12031; Kongnyuy EJ, 2007, TROP DOCT, V37, P70, DOI 10.1258/004947507780609310; Lane BF, 2013, ULTRASOUND Q, V29, P91, DOI 10.1097/RUQ.0b013e31829158c2; Ledger WL, 2016, FERTIL STERIL, V105, P417, DOI 10.1016/j.fertnstert.2015.11.002; Lee HJ, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3616875; Lissauer D, 2019, NEW ENGL J MED, V380, P1012, DOI 10.1056/NEJMoa1808817; May W, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001779.pub2; Melese T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0166287; Morin L, 2016, J OBSTET GYNAECOL CA, V38, P982, DOI 10.1016/j.jogc.2016.06.001; National Collaborating Centre for Women's and Children's Health (UK), 2012, ECTOPIC PREGNANCY MI; O'Rourke D, 2009, AUST NZ J OBSTET GYN, V49, P110, DOI 10.1111/j.1479-828X.2009.00954.x; Ogwulu CBO, 2020, BJOG-INT J OBSTET GY, V127, P757, DOI 10.1111/1471-0528.16068; Palagiano A, 2004, ANN NY ACAD SCI, V1034, P200, DOI 10.1196/annals.1335.022; Pandian RU, 2009, MATURITAS, V65, pS47, DOI 10.1016/j.maturitas.2009.11.016; Pexsters A, 2011, ULTRASOUND OBST GYN, V38, P510, DOI 10.1002/uog.8884; Ramin K D, 1995, Infect Dis Obstet Gynecol, V2, P213, DOI 10.1155/S1064744995000044; Rhone SA, 2012, J OBSTET GYNAECOL CA, V34, P243, DOI 10.1016/S1701-2163(16)35184-2; Rovner P, 2018, J ULTRAS MED, V37, P1533, DOI 10.1002/jum.14474; Sayasneh A, 2012, ULTRASOUND OBST GYN, V40, P145, DOI 10.1002/uog.11184; Schouwink M H, 2000, Early Pregnancy, V4, P203; SEERAS R, 1989, East African Medical Journal, V66, P607; SIPILA P, 1992, BRIT J OBSTET GYNAEC, V99, P959, DOI 10.1111/j.1471-0528.1992.tb13697.x; Smith LFP, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3827; Titapant Vitaya, 2012, Journal of the Medical Association of Thailand, V95, P1372; Tomic V, 2011, GYNECOL ENDOCRINOL, V27, P1010, DOI 10.3109/09513590.2011.569791; Tunde-Byass M, 2009, J OBSTET GYNAECOL CA, V31, P841, DOI 10.1016/S1701-2163(16)34302-X; van den Berg MMJ, 2015, REPROD BIOMED ONLINE, V31, P192, DOI 10.1016/j.rbmo.2015.04.008; Volgsten H, 2018, ACTA OBSTET GYN SCAN, V97, P1491, DOI 10.1111/aogs.13432; Wahabi HA, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005943.pub5; Wendt K, 2014, EMERG MED J, V31, pE50, DOI 10.1136/emermed-2013-202887; World Health Organization, 2012, SAF AB TECHN POL GUI, V2nd ed.; Yang J, 2005, PAEDIATR PERINAT EP, V19, P276, DOI 10.1111/j.1365-3016.2005.00655.x; Zaqout M, 2015, PEDIATR CARDIOL, V36, P1483, DOI 10.1007/s00246-015-1190-9	61	12	12	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	2021	397	10285					1668	1674		10.1016/S0140-6736(21)00683-8	http://dx.doi.org/10.1016/S0140-6736(21)00683-8		APR 2021	7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV0EH	33915095	Green Published, Green Submitted			2023-01-03	WOS:000645510600027
J	Gal, A; Barko, PC; Biggs, PJ; Gedye, KR; Midwinter, AC; Williams, DA; Burchell, RK; Pazzi, P				Gal, Arnon; Barko, Patrick C.; Biggs, Patrick J.; Gedye, Kristene R.; Midwinter, Anne C.; Williams, David A.; Burchell, Richard K.; Pazzi, Paolo			One dog's waste is another dog's wealth: A pilot study of fecal microbiota transplantation in dogs with acute hemorrhagic diarrhea syndrome	PLOS ONE			English	Article							GUT MICROBIOME; BUTYRATE; HEALTH; DIVERSITY; RESOLUTION; FROZEN	Canine acute hemorrhagic diarrhea syndrome (AHDS) has been associated in some studies with Clostridioides perfringens overgrowth and toxin-mediated necrosis of the intestinal mucosa. We aimed to determine the effect of a single fecal microbiota transplantation (FMT) on clinical scores and fecal microbiomes of 1 and 7 dogs with AHDS from New Zealand and South Africa. We hypothesized that FMT would improve AHDS clinical scores and increase microbiota alpha-diversity and short-chain fatty acid (SCFA)-producing microbial communities' abundances in dogs with AHDS after FMT. We sequenced the V3-V4 region of the 16S-rRNA gene in the feces of AHDS FMT-recipients and sham-treated control dogs, and their healthy donors at admission, discharge, and 30 days post-discharge. There were no significant differences in median AHDS clinical scores between FMT-recipients and sham-treated controls at admission or discharge (P = 0.22, P = 0.41). At admission, the Shannon diversity index (SDI) was lower in AHDS dogs than healthy donors (P = 0.002). The SDI did not change from admission to 30 days in sham-treated dogs yet increased in FMT-recipients from admission to discharge (P = 0.04) to levels not different than donors (P = 0.33) but significantly higher than sham-treated controls (P = 0.002). At 30 days, the SDI did not differ between FMT recipients, sham-treated controls, and donors (P = 0.88). Principal coordinate analysis of the Bray-Curtis index separated post-FMT and donor dogs from pre-FMT and sham-treated dogs (P = 0.009) because of increased SCFA-producing genera's abundances after FMT. A single co-abundance subnetwork contained many of the same OTUs found to be differentially abundant in FMT-recipients, and the abundance of this module was increased in FMT-recipients at discharge and 30 days, compared to sham-treated controls. We conclude in this small pilot study FMT did not have any clinical benefit. A single FMT procedure has the potential to increase bacterial communities of SCFA-producing genera important for intestinal health up to 30 days post-FMT.	[Gal, Arnon; Barko, Patrick C.; Williams, David A.] Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA; [Biggs, Patrick J.; Gedye, Kristene R.; Midwinter, Anne C.] Massey Univ, Infect Dis Res Ctr, Sch Vet Sci, Mol Epidemiol & Publ Hlth Lab, Palmerston North, New Zealand; [Biggs, Patrick J.] Massey Univ, Sch Fundamental Sci, Bioinformat & Stat Grp, Palmerston North, New Zealand; [Burchell, Richard K.] North Coast Vet & Referral Ctr, Sunshine Coast, Qld, Australia; [Pazzi, Paolo] Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, Pretoria, South Africa	University of Illinois System; University of Illinois Urbana-Champaign; Massey University; Massey University; University of Pretoria	Gal, A (corresponding author), Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA.	agal2@illions.edu	Burchell, Richard/Q-9453-2019; Biggs, Patrick Jon/H-3355-2014	Burchell, Richard/0000-0002-8527-9308; Biggs, Patrick Jon/0000-0002-0285-4101; Gal`, Arnon/0000-0002-6449-2812; Pazzi, Paolo/0000-0002-5331-1422; Midwinter, Anne/0000-0001-5731-3233				Aguirre M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113864; Aroniadis OC, 2013, CURR OPIN GASTROEN, V29, P79, DOI 10.1097/MOG.0b013e32835a4b3e; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Baxter NT, 2019, MBIO, V10, DOI [10.1128/mBio.02566-18, 10.1128/mbio.02566-18]; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bokulich NA, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0470-z; Bolyen E, 2019, NAT BIOTECHNOL, V37, P1091, DOI 10.1038/s41587-019-0252-6; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Borody TJ, 2012, NAT REV GASTRO HEPAT, V9, P88, DOI 10.1038/nrgastro.2011.244; Bottero E., 2017, Veterinaria (Cremona), V31; BURROWS CF, 1977, J AM ANIM HOSP ASSOC, V13, P451; Busch K, 2015, VET REC, V176, P253, DOI 10.1136/vr.102738; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Cave NJ, 2002, J AM VET MED ASSOC, V221, P52, DOI 10.2460/javma.2002.221.52; Chaitman J, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00192; Chaitman J, 2016, VET MED-RES REP, V7, P71, DOI 10.2147/VMRR.S105238; Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047; Cotran RS, 2010, ROBBINS COTRAN PATHO, P763, DOI DOI 10.1016/B978-1-4377-0792-2.50022-5; De Vadder F, 2016, CELL METAB, V24, P151, DOI 10.1016/j.cmet.2016.06.013; Ferreira-Halder CV, 2017, BEST PRACT RES CL GA, V31, P643, DOI 10.1016/j.bpg.2017.09.011; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gao ZG, 2009, DIABETES, V58, P1509, DOI 10.2337/db08-1637; Geirnaert A, 2014, ANAEROBE, V30, P70, DOI 10.1016/j.anaerobe.2014.08.010; Gohari IM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122684; Gough E, 2011, CLIN INFECT DIS, V53, P994, DOI 10.1093/cid/cir632; Haegeman B, 2013, ISME J, V7, P1092, DOI 10.1038/ismej.2013.10; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Heilmann RM, 2017, J VET EMERG CRIT CAR, V27, P586, DOI 10.1111/vec.12636; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Kelly TN, 2016, CIRC RES, V119, P956, DOI 10.1161/CIRCRESAHA.116.309219; Kieler IN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41195-0; Lau WL, 2019, NAT REV NEPHROL, V15, P389, DOI 10.1038/s41581-019-0142-7; Lawley TD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002995; Lee CH, 2016, JAMA-J AM MED ASSOC, V315, P142, DOI 10.1001/jama.2015.18098; Leipig-Rudolph M, 2018, J VET DIAGN INVEST, V30, P495, DOI 10.1177/1040638718766983; Louis P, 2017, ENVIRON MICROBIOL, V19, P29, DOI 10.1111/1462-2920.13589; Markel ME, 2012, J VET INTERN MED, V26, P765; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Mortier F, 2015, VET REC, V176, P627, DOI 10.1136/vr.103090; Negata N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40182-9; Niina A, 2019, VET MED-RES REP, V10, P197, DOI 10.2147/VMRR.S230862; Peng LY, 2009, J NUTR, V139, P1619, DOI 10.3945/jn.109.104638; Pereira GQ, 2018, J VET INTERN MED, V32, P707, DOI 10.1111/jvim.15072; Pilla R, 2020, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00498; Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490; R Core Team, 2020, R LANG ENV STAT COMP; Redfern A, 2017, VET REC, V181, DOI 10.1136/vr.103826; Ricotta C, 2017, ECOL COMPLEX, V31, P201, DOI 10.1016/j.ecocom.2017.07.003; Rossi G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094699; Schlegel BJ, 2012, CAN VET J, V53, P555; Scott KP, 2006, J BACTERIOL, V188, P4340, DOI 10.1128/JB.00137-06; Seekatz AM, 2014, MBIO, V5, DOI 10.1128/mBio.00893-14; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Shin H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075729, 10.1371/journal.pone.0081330]; Sindern N, 2019, J VET INTERN MED, V33, P100, DOI 10.1111/jvim.15361; Sofi AA, 2013, SCAND J GASTROENTERO, V48, P266, DOI 10.3109/00365521.2012.743585; Su S, 2017, BIOINFORMATICS, V33, P2050, DOI 10.1093/bioinformatics/btx094; Suchodolski JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051907; Sugita K, 2019, BMC VET RES, V15, DOI 10.1186/s12917-018-1754-z; Tamanai-Shacoori Z, 2017, FUTURE MICROBIOL, V12, P157, DOI 10.2217/fmb-2016-0130; Tan J, 2014, ADV IMMUNOL, V121, P91, DOI 10.1016/B978-0-12-800100-4.00003-9; Terveer EM, 2017, CLIN MICROBIOL INFEC, V23, P924, DOI 10.1016/j.cmi.2017.05.015; Unterer S, 2015, Vet Rec, V176, P309, DOI 10.1136/vr.102521; Unterer S, 2014, J VET INTERN MED, V28, P52, DOI 10.1111/jvim.12236; Unterer S, 2011, J VET INTERN MED, V25, P973, DOI 10.1111/j.1939-1676.2011.00765.x; Vincent C, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0156-3; Zhang XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071108; Zhong YD, 2015, MOL NUTR FOOD RES, V59, P2066, DOI 10.1002/mnfr.201500187; Ziese AL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204691	70	5	5	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2021	16	4							e0250344	10.1371/journal.pone.0250344	http://dx.doi.org/10.1371/journal.pone.0250344			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP4TZ	33872339	Green Published, gold			2023-01-03	WOS:000641723300017
J	[Anonymous]				[Anonymous]			Update to living WHO guideline on drugs for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	9	9	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 31	2021	372								n860	10.1136/bmj.n860	http://dx.doi.org/10.1136/bmj.n860			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH3WJ	33789884	Bronze			2023-01-03	WOS:000636152900001
J	Alshogran, OY; Al-Eitan, LN; Altawalbeh, SM; Aman, HA				Alshogran, Osama Y.; Al-Eitan, Laith N.; Altawalbeh, Shoroq M.; Aman, Hatem A.			Association of DRD4 exon III and 5-HTTLPR VNTR genetic polymorphisms with psychiatric symptoms in hemodialysis patients	PLOS ONE			English	Article							SEROTONIN TRANSPORTER GENE; ANXIETY-RELATED TRAITS; DEPRESSION; DISORDERS; CHILDREN; ALLELE; ADHD; TPH	Mental illness is prevalent among hemodialysis (HD) patients. Given that the dopaminergic and serotonergic pathways are involved in the etiology of psychiatric disease, this study evaluated the genetic association of dopamine D4 receptor (DRD4) and serotonin transporter (SLC6A4) genes with psychiatric symptom susceptibility among HD patients. Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety and depressive symptoms among patients (n = 265). Genetic polymorphisms of DRD4 (48 bp VNTR) and SLC6A4 (5-HTTLPR VNTR and rs25531) were examined using a conventional polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique, as appropriate. Significant differences were observed in the distribution of 5-HTTLPR genotypes, SLC6A4 tri-allelic-phased genotype, and DRD4-Exon III VNTR genotypes/alleles between patients with anxiety symptoms versus those with normal/borderline conditions (p<0.05). Binary logistic regression analyses showed that the heterozygous 4,5 VNTR genotype of DRD4 was associated with a higher risk of anxiety symptoms after adjusting for other covariates (odds ratio = 4.25, p = 0.028). None of the studied polymorphisms was linked to depression in HD patients. Collectively, the current findings provide genetic clues to psychopathology in HD patients and suggest that the DRD4 exon III VNTR polymorphism is involved in the etiology of anxiety in this patient population.	[Alshogran, Osama Y.; Altawalbeh, Shoroq M.] Jordan Univ Sci & Technol, Dept Clin Pharm, Fac Pharm, Irbid, Jordan; [Al-Eitan, Laith N.; Aman, Hatem A.] Jordan Univ Sci & Technol, Dept Appl Biol Sci, Irbid, Jordan; [Al-Eitan, Laith N.] Jordan Univ Sci & Technol, Dept Biotechnol & Genet Engn, Irbid, Jordan	Jordan University of Science & Technology; Jordan University of Science & Technology; Jordan University of Science & Technology	Alshogran, OY (corresponding author), Jordan Univ Sci & Technol, Dept Clin Pharm, Fac Pharm, Irbid, Jordan.	oyalshogran@just.edu.jo		Alshogran, Osama/0000-0002-2466-4763; Al-Eitan, Laith/0000-0003-0064-0190	Deanship of Scientific Research at Jordan University of Science and Technology [16/2017]	Deanship of Scientific Research at Jordan University of Science and Technology	Osama Y. Alshogran has received funding from the Deanship of Scientific Research at Jordan University of Science and Technology (grant number 16/2017). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adkins DE, 2012, DEV PSYCHOPATHOL, V24, P267, DOI 10.1017/S0954579411000824; Al-Eitan LN, 2020, GENE, V733, DOI 10.1016/j.gene.2019.144267; Al-Eitan LN, 2014, TOXICOL IND HEALTH, V30, P598, DOI 10.1177/0748233712462446; Alshogran OY, 2019, PROG NEURO-PSYCHOPH, V94, DOI 10.1016/j.pnpbp.2019.109657; Alshogran OY, 2018, GEN HOSP PSYCHIAT, V53, P25, DOI 10.1016/j.genhosppsych.2018.04.003; ASGHARI V, 1995, J NEUROCHEM, V65, P1157, DOI 10.1046/j.1471-4159.1995.65031157.x; Bonvicini C, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0755-4; Border R, 2019, AM J PSYCHIAT, V176, P376, DOI 10.1176/appi.ajp.2018.18070881; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Cheng PF, 2021, ACTA NEUROL BELG, V121, P933, DOI 10.1007/s13760-020-01342-1; Cheon KA, 2007, NEUROPSYCHOPHARMACOL, V32, P1377, DOI 10.1038/sj.npp.1301244; Chilcot J, 2018, ANN BEHAV MED, V52, P1, DOI 10.1007/s12160-017-9918-9; Cukor D, 2007, CLIN J AM SOC NEPHRO, V2, P484, DOI 10.2215/CJN.00040107; Culverhouse RC, 2018, MOL PSYCHIATR, V23, P133, DOI 10.1038/mp.2017.44; Dell'Osso L, 2016, CURR PHARM DESIGN, V22, P949, DOI 10.2174/1381612822666151214104826; Gervasini G, 2018, GENE, V654, P43, DOI 10.1016/j.gene.2018.02.035; Guenzani D, 2019, J PSYCHOSOM RES, V124, DOI 10.1016/j.jpsychores.2019.109783; Hamarman S, 2004, J CHILD ADOL PSYCHOP, V14, P564, DOI 10.1089/cap.2004.14.564; Hu JJ, 2019, PSYCHIAT GENET, V29, P97, DOI 10.1097/YPG.0000000000000222; Januar V, 2015, INT J EPIDEMIOL, V44, P1364, DOI 10.1093/ije/dyu273; Jia PL, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S3-S12; Koks G, 2020, EXP BIOL MED, V245, P733, DOI 10.1177/1535370220916888; Koks G, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01398; Lesch KP, 2005, PROG NEURO-PSYCHOPH, V29, P1062, DOI 10.1016/j.pnpbp.2005.03.012; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Leung PWL, 2005, AM J MED GENET B, V133B, P54, DOI 10.1002/ajmg.b.30129; Lopez LS, 2005, BIOL PSYCHIAT, V57, P999, DOI 10.1016/j.biopsych.2005.01.030; Minelli A, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-50; Osher Y, 2000, MOL PSYCHIATR, V5, P216, DOI 10.1038/sj.mp.4000660; Ptacek R, 2011, MED SCI MONITOR, V17, pRA215, DOI 10.12659/MSM.881925; Risch N, 2009, JAMA-J AM MED ASSOC, V301, P2462, DOI 10.1001/jama.2009.878; Ryan J, 2019, J GERIATR PSYCH NEUR, V32, P175, DOI 10.1177/0891988719841725; Schoots O, 2003, PHARMACOGENOMICS J, V3, P343, DOI 10.1038/sj.tpj.6500208; Schouten RW, 2020, J PSYCHOSOM RES, V133, DOI 10.1016/j.jpsychores.2020.109995; Serretti A, 2002, AM J MED GENET, V114, P361, DOI 10.1002/ajmg.10356; Tamminga CA, 2002, BIOL PSYCHIAT, V52, P589, DOI 10.1016/S0006-3223(02)01470-1; Tochigi M, 2006, NEUROSCI LETT, V398, P333, DOI 10.1016/j.neulet.2006.01.020; Vandenbergh DJ, 2000, AM J MED GENET, V96, P678, DOI 10.1002/1096-8628(20001009)96:5<678::AID-AJMG15>3.0.CO;2-8; Wang LJ, 2014, NEUROPSYCH DIS TREAT, V10, P1235, DOI 10.2147/NDT.S54277; Xiang LB, 2008, BRAIN RES, V1207, P214, DOI 10.1016/j.brainres.2008.02.009; Yin L, 2015, PHARMACOPSYCHIATRY, V48, P95, DOI 10.1055/s-0034-1398508; Zhang LJ, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-020-01424-1	43	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2021	16	3							e0249284	10.1371/journal.pone.0249284	http://dx.doi.org/10.1371/journal.pone.0249284			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RH6XT	33784353	gold, Green Published			2023-01-03	WOS:000636359600020
J	Weng, CL; Wang, XC; Huang, L; Lin, XS; Liu, QH				Weng, Cuilian; Wang, Xincai; Huang, Long; Lin, Xingsheng; Liu, Qinghua			Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study	PLOS ONE			English	Article							ANTICOAGULATION; THROMBOSIS	Introduction Patients at intermediate-high risk of developing a pulmonary embolism (PE) are very likely to experience adverse outcomes, such as cardiovascular instability and death. The role of thrombolytic therapy in intermediate-high-risk PE remains controversial. Objectives This study aimed to determine the efficacy and safety of low-dose urokinase (UK) thrombolytic therapy for intermediate-high-risk PE. Patients and methods This retrospective study included 81 consecutive patients with intermediate-high-risk PE from two centers. Patients received low-dose UK or low-molecular-weight heparin (anticoagulant therapy group). The efficacy outcomes were mortality, computed tomography pulmonary angiography (CTPA)-confirmed absorption, and dyspnea. Safety was assessed as the incidence of bleedings. Results The in-hospital mortality, 9-month mortality, and long-term mortality at the last follow-up were comparable for the low-dose UK group and the anticoagulant therapy group (6.45% vs. 0%, p = 0.144, 9.68% vs. 8.16%, p = 0.815, and 12.90% vs. 12.24%, p = 0.931, respectively). CTPA-confirmed absorption at one month after admission was higher in the low-dose UK group than in the anticoagulant therapy group (p = 0.016). The incidences of short-term dyspnea at discharge and long-term dyspnea at the last follow-up were lower in the low-dose UK group than in the anticoagulant therapy group (27.59% vs. 52%, p = 0.035, 33.33% vs. 58.14%, p = 0.043, respectively). No major bleeding occurred. The incidence of minor bleeding was not significantly different between the two groups (3.23% vs. 6%, p = 0.974). Conclusion In intermediate-high-risk PE, a low-dose UK might increase CTPA-confirmed absorption and improve short-term and long-term dyspnea without affecting mortality or increasing the bleeding risk.	[Weng, Cuilian; Wang, Xincai; Huang, Long; Lin, Xingsheng] Fujian Med Univ, Fujian Prov Hosp, Shengli Clin Med Coll, Dept Intens Care Unit,South Branch, Fuzhou, Fujian, Peoples R China; [Liu, Qinghua] Fujian Med Univ, Fujian Prov Hosp, Shengli Clin Med Coll, Dept Otorhinolaryngol, Fuzhou, Fujian, Peoples R China; [Weng, Cuilian; Wang, Xincai; Huang, Long; Lin, Xingsheng] Fujian Prov Hosp, South Branch, Dept Intens Care Unit, Fuzhou, Fujian, Peoples R China; [Liu, Qinghua] Fujian Prov Hosp, Dept Otorhinolaryngol, Fuzhou, Fujian, Peoples R China	Fujian Medical University; Fujian Provincial Hospital; Fujian Medical University; Fujian Provincial Hospital; Fujian Provincial Hospital; Fujian Provincial Hospital	Liu, QH (corresponding author), Fujian Med Univ, Fujian Prov Hosp, Shengli Clin Med Coll, Dept Otorhinolaryngol, Fuzhou, Fujian, Peoples R China.; Liu, QH (corresponding author), Fujian Prov Hosp, Dept Otorhinolaryngol, Fuzhou, Fujian, Peoples R China.	15280096007@163.com		Wang, Xincai/0000-0001-7098-770X	National Science Foundation of China [81301995]; Fujian Provincial Department of Science and Technology [2020J011095, 2018ZQN-6]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fujian Provincial Department of Science and Technology	This study was supported by: the National Science Foundation of China (grant 81301995); the Fujian Provincial Department of Science and Technology (2020J011095 and 2018ZQN-6). The funding institutions were not involved in the design of the study; in the collection, management, analysis, or interpretation of data; in the preparation, review, or approval of the manuscript; or in the decision to submit for publication.	Barco S, 2019, CLIN RES CARDIOL, V108, P772, DOI 10.1007/s00392-018-1405-1; Becattini C, 2016, EUR RESPIR J, V48, P780, DOI 10.1183/13993003.00024-2016; Bhamani Amyn, 2019, F1000Res, V8, DOI 10.12688/f1000research.17861.1; Bulpa P, 2009, CHEST, V136, P1141, DOI 10.1378/chest.08-2583; Eberle H, 2018, AM J HEALTH-SYST PH, V75, P1275, DOI 10.2146/ajhp170357; Jaff MR, 2011, CIRCULATION, V123, P1788, DOI 10.1161/CIR.0b013e318214914f; Kahn SR, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2017.03.033; Kline JA, 2014, J THROMB HAEMOST, V12, P459, DOI 10.1111/jth.12521; Konstantinides S, 2002, NEW ENGL J MED, V347, P1143, DOI 10.1056/NEJMoa021274; Konstantinides SV, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01647-2019; Konstantinides SV, 2017, J AM COLL CARDIOL, V69, P1536, DOI 10.1016/j.jacc.2016.12.039; Konstantinides SV, 2014, EUR HEART J, V35, P3033, DOI 10.1093/eurheartj/ehu283; Kuo WT, 2015, CHEST, V148, P667, DOI 10.1378/chest.15-0119; Meyer G, 2014, NEW ENGL J MED, V370, P1402, DOI 10.1056/NEJMoa1302097; Mirambeaux Rosa, 2019, TH Open, V3, pe356, DOI 10.1055/s-0039-3401003; Schissler AJ, 2018, PULM CIRC, V8, DOI 10.1177/2045894018800265; Sharifi M, 2013, AM J CARDIOL, V111, P273, DOI 10.1016/j.amjcard.2012.09.027; Sista AK, 2017, VASC MED, V22, P37, DOI 10.1177/1358863X16670250; Stevinson BG, 2007, EUR HEART J, V28, P2517, DOI 10.1093/eurheartj/ehm295; Tapson VF, 2018, JACC-CARDIOVASC INTE, V11, P1401, DOI 10.1016/j.jcin.2018.04.008; Wendelboe AM, 2016, CIRC RES, V118, P1340, DOI 10.1161/CIRCRESAHA.115.306841; Xu QX, 2015, J THORAC DIS, V7, P810, DOI 10.3978/j.issn.2072-1439.2015.04.51; Zhao TM, 2018, CLIN APPL THROMB-HEM, V24, P1067, DOI 10.1177/1076029618758953	23	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2021	16	3							e0248603	10.1371/journal.pone.0248603	http://dx.doi.org/10.1371/journal.pone.0248603			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF4TU	33770113	Green Published, gold			2023-01-03	WOS:000634833500016
J	Karagianni, F; Piperi, C; Mpakou, V; Spathis, A; Foukas, PG; Dalamaga, M; Pappa, V; Papadavid, E				Karagianni, Fani; Piperi, Christina; Mpakou, Vassiliki; Spathis, Aris; Foukas, Periklis G.; Dalamaga, Maria; Pappa, Vasiliki; Papadavid, Evangelia			Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma	PLOS ONE			English	Article								Background The combination of JAK/STAT and HDAC inhibitors exerted beneficial effects in haematological malignancies, presenting promising therapeutic CTCL targets. We aim to investigate the efficacy of JAK1/2i ruxolitinib in combination with HDACi resminostat in CTCL in vitro. Material & methods Non-toxic concentrations of ruxolitinib and/or resminostat were administered to MyLa (MF) and SeAx (SS) cells for 24h. Cytotoxicity, cell proliferation and apoptosis were estimated through MTT, BrdU/7AAD and Annexin V/PI assay. Multi-pathway analysis was performed to investigate the effect of JAK1/2i and/or HDACi on JAK/STAT, Akt/mTOR and MAPK signalling pathways. Results Both drugs and their combination were cytotoxic in MyLa (p<0.05) and in SeAx cell line (p<0.001), inhibited proliferation of MyLa (p<0.001) and SeAx (p<0.001) at 24h, compared to untreated cells. Moreover, combined drug treatment induced apoptosis after 24h (p<0.001) in MyLa, and SeAx (p<0.001). The combination of drugs had a strong synergistic effect with a CI<1. Importantly, the drugs' combination inhibited phosphorylation of STAT3 (p<0.001), Akt (p<0.05), ERK1/2 (p<0.001) and JNK (p<0.001) in MyLa, while it reduced activation of Akt (p<0.05) and JNK (p<0.001) in SeAx. Conclusion The JAKi/HDACi combination exhibited substantial anti-tumor effects in CTCL cell lines, and may represent a promising novel therapeutic modality for CTCL patients.	[Karagianni, Fani; Dalamaga, Maria; Papadavid, Evangelia] NKUA, Dept Dermatol & Venereal Dis 2, Athens, Greece; [Piperi, Christina; Dalamaga, Maria] NKUA, Dept Biol Chem, Athens, Greece; [Mpakou, Vassiliki; Pappa, Vasiliki] Attikon Univ Gen Hosp, Dept Internal Med 2, NKUA, Athens, Greece; [Mpakou, Vassiliki; Pappa, Vasiliki] Attikon Univ Gen Hosp, Res Inst, NKUA, Athens, Greece; [Spathis, Aris; Foukas, Periklis G.] Natl & Kapodistrian Univ Athens, Dept Pathol 2, Athens, Greece	University Hospital Attikon; University Hospital Attikon; National & Kapodistrian University of Athens	Karagianni, F (corresponding author), NKUA, Dept Dermatol & Venereal Dis 2, Athens, Greece.	karagiannifani@gmail.com		Karagianni, Fani/0000-0001-9514-2199; Dalamaga, Maria/0000-0002-7008-388X; Piperi, Christina/0000-0002-2701-0618				Barrio S, 2013, BRIT J HAEMATOL, V161, P667, DOI 10.1111/bjh.12308; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Benedetti R, 2015, ANTIOXID REDOX SIGN, V23, P99, DOI 10.1089/ars.2013.5776; Bradford PT, 2009, BLOOD, V113, P5064, DOI 10.1182/blood-2008-10-184168; Bretz AC, 2018, EUR J CANCER, V101, pS2, DOI 10.1016/j.ejca.2018.07.144; Campbell JJ, 2010, BLOOD, V116, P767, DOI 10.1182/blood-2009-11-251926; Cardoso BA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143897; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Civallero M, 2017, ONCOTARGET, V8, P103797, DOI 10.18632/oncotarget.21951; Clark JD, 2014, J MED CHEM, V57, P5023, DOI 10.1021/jm401490p; Cristofoletti C, 2019, LEUKEMIA, V33, P1231, DOI 10.1038/s41375-018-0305-8; de Masson A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar5894; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Devata S, 2016, AM J CLIN DERMATOL, V17, P225, DOI 10.1007/s40257-016-0177-5; Dulmage BO, 2013, BRIT J DERMATOL, V169, P1188, DOI 10.1111/bjd.12578; Dulmage BO, 2018, CURR DERMATOL REP, V7, P91, DOI 10.1007/s13671-018-0214-0; Haery Leila, 2015, Genes Cancer, V6, P184; Hull EE, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8797206; Kim YH, 2003, ARCH DERMATOL, V139, P857, DOI 10.1001/archderm.139.7.857; Klemke CD, 2009, CANCER RES, V69, P4175, DOI 10.1158/0008-5472.CAN-08-4631; Koboldt DC, 2013, CELL, V155, P27, DOI 10.1016/j.cell.2013.09.006; Krejsgaard T, 2006, LEUKEMIA, V20, P1759, DOI 10.1038/sj.leu.2404350; Kremer M, 2010, EXP DERMATOL, V19, P800, DOI 10.1111/j.1600-0625.2010.01102.x; Levidou G, 2013, J AM ACAD DERMATOL, V69, P375, DOI 10.1016/j.jaad.2013.04.027; Li Janet Y, 2012, Cancer Manag Res, V4, P75, DOI 10.2147/CMAR.S9660; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marquard L, 2009, HISTOPATHOLOGY, V54, P688, DOI 10.1111/j.1365-2559.2009.03290.x; Meyer SC, 2015, CANCER CELL, V28, P15, DOI 10.1016/j.ccell.2015.06.006; Mishra A, 2016, CANCER DISCOV, V6, P986, DOI 10.1158/2159-8290.CD-15-1297; Mullally A, 2012, J CLIN ONCOL, V30, P4168, DOI 10.1200/JCO.2012.44.0347; Nebbioso A, 2010, J MOL ENDOCRINOL, V45, P219, DOI 10.1677/JME-10-0043; Netchiporouk E, 2014, CELL CYCLE, V13, P3331, DOI 10.4161/15384101.2014.965061; Papadavid E, 2014, EXP DERMATOL, V23, P931, DOI 10.1111/exd.12547; Perez C, 2015, HAEMATOLOGICA, V100, pE450, DOI 10.3324/haematol.2015.132837; Ramelyte E, 2019, EXPERT OPIN INV DRUG, V28, P799, DOI 10.1080/13543784.2019.1654995; Scarisbrick JJ, 2014, BRIT J DERMATOL, V170, P1226, DOI 10.1111/bjd.12909; Schade AE, 2006, BLOOD, V107, P4834, DOI 10.1182/blood-2005-08-3076; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Torres ANB, 2018, SEMIN CUTAN MED SURG, V37, P81, DOI 10.12788/j.sder.2018.007; Trung LQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055183; van Doorn R, 2009, BLOOD, V113, P127, DOI 10.1182/blood-2008-04-153031; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302; Wernham AG, 2015, BRIT J DERMATOL, V173, P1295, DOI 10.1111/bjd.13939; Wilcox RA, 2017, AM J HEMATOL, V92, P1085, DOI 10.1002/ajh.24876; Yumeen S, 2020, YALE J BIOL MED, V93, P111	45	8	8	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2021	16	3							e0248298	10.1371/journal.pone.0248298	http://dx.doi.org/10.1371/journal.pone.0248298			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX8JZ	33705488	gold, Green Published			2023-01-03	WOS:000629590400081
J	Barbosa, JMC; Nicoletti, CD; da Silva, PB; Melo, TG; Futuro, DO; Ferreira, VF; Salomao, K				Barbosa, Juliana M. C.; Nicoletti, Caroline D.; da Silva, Patricia B.; Melo, Tatiana G.; Futuro, Debora O.; Ferreira, Vitor F.; Salomao, Kelly			Characterization and trypanocidal activity of a beta-lapachone-containing drug carrier	PLOS ONE			English	Article							TRYPANOSOMA-CRUZI ACTIVITY; IN-VITRO; NAPHTHOQUINONES; BENZNIDAZOLE; BIOAVAILABILITY; VIVO; CYCLODEXTRINS; SOLUBILITY; STRATEGIES; COMPLEXES	The treatment of Chagas disease (CD), a neglected parasitic condition caused by Trypanosoma cruzi, is still based on only two drugs, nifurtimox (Nif) and benznidazole (Bz), both of which have limited efficacy in the late chronic phase and induce severe side effects. This scenario justifies the continuous search for alternative drugs, and in this context, the natural naphthoquinone beta-lapachone (beta-Lap) and its derivatives have demonstrated important trypanocidal activities. Unfortunately, the decrease in trypanocidal activity in the blood, high toxicity to mammalian cells and low water solubility of beta-Lap limit its systemic administration and, consequently, clinical applications. For this reason, carriers as drug delivery systems can strategically maximize the therapeutic effects of this drug, overcoming the above mentioned restrictions. Accordingly, the aim of this study is to investigate the in vitro anti-T. cruzi effects of beta-Lap encapsulated in2-hydroxypropyl-beta-cyclodextrin (2HP-beta-CD) and its potential toxicity to mammalian cells.	[Barbosa, Juliana M. C.; da Silva, Patricia B.; Salomao, Kelly] Fundacao Oswaldo Cruz, Lab Biol Celular Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil; [Nicoletti, Caroline D.; Futuro, Debora O.; Ferreira, Vitor F.] Univ Fed Fluminense, Inst Quim, Lab Sintese Organ Aplicada, Niteroi, RJ, Brazil; [Nicoletti, Caroline D.; Ferreira, Vitor F.] Univ Fed Fluminense, Fac Farm, Niteroi, RJ, Brazil; [Melo, Tatiana G.] Fundacao Oswaldo Cruz, Lab Ultraestrutura Celular, Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil	Fundacao Oswaldo Cruz; Universidade Federal Fluminense; Universidade Federal Fluminense; Fundacao Oswaldo Cruz	Salomao, K (corresponding author), Fundacao Oswaldo Cruz, Lab Biol Celular Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.	ks@ioc.fiocruz.br		Salomao, Kelly/0000-0001-5397-718X	Coordenacao de Aperfeicoamento de Pessoal de Nivel superior Conselho Nacional de Desenvolvimento Cientifico e Tecnologico Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Rio de Janeiro Instituto Oswaldo Cruz (IOC/FIOCRUZ) Print Fiocruz-Capes	Coordenacao de Aperfeicoamento de Pessoal de Nivel superior Conselho Nacional de Desenvolvimento Cientifico e Tecnologico Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Rio de Janeiro Instituto Oswaldo Cruz (IOC/FIOCRUZ) Print Fiocruz-Capes	Coordenacao de Aperfeicoamento de Pessoal de Nivel superior Conselho Nacional de Desenvolvimento Cientifico e Tecnologico Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Rio de Janeiro Instituto Oswaldo Cruz (IOC/FIOCRUZ) Print Fiocruz-Capes The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alves-Silva I, 2014, THERMOCHIM ACTA, V575, P29, DOI 10.1016/j.tca.2013.10.007; Aminin D, 2020, CHEM PHARM BULL, V68, P46, DOI 10.1248/cpb.c19-00911; [Anonymous], 2015, Wkly Epidemiol Rec, V90, P33; Buckner FS, 1996, ANTIMICROB AGENTS CH, V40, P2592, DOI 10.1128/AAC.40.11.2592; CARVALHO LH, 1988, BRAZ J MED BIOL RES, V21, P485; Cascabulho CM, 2020, MEM I OSWALDO CRUZ, V115, DOI 10.1590/0074-02760190389; Correa G, 2009, PARASITOL INT, V58, P424, DOI 10.1016/j.parint.2009.08.006; Costantino L, 2006, CURR MED CHEM, V13, P65, DOI 10.2174/092986706775197944; Coura JR, 2012, REV SOC BRAS MED TRO, V45, P286, DOI 10.1590/S0037-86822012000300002; Coura JR, 2002, MEM I OSWALDO CRUZ, V97, P3, DOI 10.1590/S0074-02762002000100001; Silva EN, 2008, EUR J MED CHEM, V43, P1774, DOI 10.1016/j.ejmech.2007.10.015; da Silva EN, 2019, EUR J MED CHEM, V179, P863, DOI 10.1016/j.ejmech.2019.06.056; Cardoso MFD, 2015, BIOORGAN MED CHEM, V23, P4763, DOI 10.1016/j.bmc.2015.05.039; DOCAMPO R, 1977, EXP PARASITOL, V42, P142, DOI 10.1016/0014-4894(77)90071-6; Eloy JO, 2014, COLLOID SURFACE B, V123, P345, DOI 10.1016/j.colsurfb.2014.09.029; da Costa DCF, 2020, MOLECULES, V25, DOI 10.3390/molecules25040893; Ferreira SB, 2011, EUR J MED CHEM, V46, P3071, DOI 10.1016/j.ejmech.2011.03.012; Ferreira VF, 2016, CURR PHARM DESIGN, V22, P5899, DOI 10.2174/1381612822666160611012532; Ferreira VF, 2010, ORG BIOMOL CHEM, V8, P4793, DOI 10.1039/c0ob00277a; FILARDI LS, 1987, T ROY SOC TROP MED H, V81, P755, DOI 10.1016/0035-9203(87)90020-4; Freitas RHCN, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110162; Futuro DO, 2018, AN ACAD BRAS CIENC, V90, P1187, DOI 10.1590/0001-3765201820170815; Gharib R, 2015, CARBOHYD POLYM, V129, P175, DOI 10.1016/j.carbpol.2015.04.048; Grillo R, 2007, J BIOL PHYS, V33, P445, DOI 10.1007/s10867-008-9054-7; Guimaraes TT, 2013, EUR J MED CHEM, V63, P523, DOI 10.1016/j.ejmech.2013.02.038; Jardim GAM, 2017, EUR J MED CHEM, V136, P406, DOI 10.1016/j.ejmech.2017.05.011; Kohli AG, 2014, J CONTROL RELEASE, V190, P274, DOI 10.1016/j.jconrel.2014.04.047; LACH JL, 1964, J PHARM SCI-US, V53, P69, DOI 10.1002/jps.2600530112; Leonardi D, 2013, INT J BIOL MACROMOL, V62, P543, DOI 10.1016/j.ijbiomac.2013.10.007; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; LOPES JN, 1978, ANN TROP MED PARASIT, V72, P523, DOI 10.1080/00034983.1978.11719356; Maximiano FP, 2011, J PHARM PHARMACOL, V63, P786, DOI 10.1111/j.2042-7158.2011.01284.x; MEIRELLES MNL, 1984, J SUBMICR CYTOL PATH, V16, P533; MEIRELLES MNL, 1986, EUR J CELL BIOL, V41, P198; Moraes DC, 2018, J MYCOL MED, V28, P314, DOI 10.1016/j.mycmed.2018.03.004; Nasongkla N, 2003, PHARMACEUT RES, V20, P1626, DOI 10.1023/A:1026143519395; Nicoletti CD, 2020, J DRUG DELIV SCI TEC, V58, DOI 10.1016/j.jddst.2020.101777; Nicoletti CD, 2020, J BIOENERG BIOMEMBR, V52, P185, DOI 10.1007/s10863-020-09826-8; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; Pereyra CE, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0925-8; Pinto AV, 2009, MOLECULES, V14, P4570, DOI 10.3390/molecules14114570; PINTO AV, 1987, T ROY SOC TROP MED H, V81, P609, DOI 10.1016/0035-9203(87)90427-5; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X; Ribeiro V, 2020, INT J PARASITOL-DRUG, V12, P7, DOI 10.1016/j.ijpddr.2019.11.004; Romanha AJ, 2010, MEM I OSWALDO CRUZ, V105, P233, DOI 10.1590/S0074-02762010000200022; Salomao K, 2010, ANTIMICROB AGENTS CH, V54, P2023, DOI 10.1128/AAC.01241-09; Salomao K, 2016, CURR TOP MED CHEM, V16, P2266, DOI 10.2174/1568026616666160413125049; Scalise ML, 2016, AM J TROP MED HYG, V95, P388, DOI 10.4269/ajtmh.15-0889; Simoes-Silva MR, 2017, BIOCHEM PHARMACOL, V145, P46, DOI 10.1016/j.bcp.2017.08.025; Stella VJ, 2008, TOXICOL PATHOL, V36, P30, DOI 10.1177/0192623307310945; Stella VJ, 1997, PHARMACEUT RES, V14, P556, DOI 10.1023/A:1012136608249; Szente L, 2018, MOLECULES, V23, DOI 10.3390/molecules23051228; Vinuesa T, 2017, AM J TROP MED HYG, V97, P1469, DOI 10.4269/ajtmh.17-0044; WHO, 2020, CHAG DIS; Ying HZ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2460565; Zingales B, 2012, INFECT GENET EVOL, V12, P240, DOI 10.1016/j.meegid.2011.12.009	58	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2021	16	3							e0246811	10.1371/journal.pone.0246811	http://dx.doi.org/10.1371/journal.pone.0246811			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT5BY	33661933	gold, Green Published			2023-01-03	WOS:000626604100002
J	Hahn, WC; Bader, JS; Braun, TP; Califano, A; Clemons, PA; Druker, BJ; Ewald, AJ; Fu, HA; Jagu, S; Kemp, CJ; Kim, W; Kuo, CJ; McManus, M; Mills, GB; Mo, XL; Sahni, N; Schreiber, SL; Talamas, JA; Tamayo, P; Tyner, JW; Wagner, BK; Weiss, WA; Gerhard, DS				Hahn, William C.; Bader, Joel S.; Braun, Theodore P.; Califano, Andrea; Clemons, Paul A.; Druker, Brian J.; Ewald, Andrew J.; Fu, Haian; Jagu, Subhashini; Kemp, Christopher J.; Kim, William; Kuo, Calvin J.; McManus, Michael; Mills, Gordon B.; Mo, Xiulei; Sahni, Nidhi; Schreiber, Stuart L.; Talamas, Jessica A.; Tamayo, Pablo; Tyner, Jeffrey W.; Wagner, Bridget K.; Weiss, William A.; Gerhard, Daniela S.		Canc Target Discovery Dev Network	An expanded universe of cancer targets	CELL			English	Review							PROTEIN-PROTEIN INTERACTIONS; GENOME-WIDE; IMMUNE CELLS; TUMOR-CELLS; IMMUNOTHERAPY; DEPENDENCY; DISCOVERY; BLOCKADE; THERAPY; SCREENS	The characterization of cancer genomes has provided insight into somatically altered genes across tumors, transformed our understanding of cancer biology, and enabled tailoring of therapeutic strategies. However, the function of most cancer alleles remains mysterious, and many cancer features transcend their genomes. Consequently, tumor genomic characterization does not influence therapy for most patients. Approaches to understand the function and circuitry of cancer genes provide complementary approaches to elucidate both oncogene and non-oncogene dependencies. Emerging work indicates that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes. Here we describe a framework for this expanded list of cancer targets, providing novel opportunities for clinical translation.	[Hahn, William C.; Talamas, Jessica A.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA; [Bader, Joel S.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Bader, Joel S.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Califano, Andrea] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Syst Biol Biomed Informat Biochem & Mol Biop, New York, NY USA; [Braun, Theodore P.; Druker, Brian J.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Braun, Theodore P.; Druker, Brian J.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Fu, Haian; Mo, Xiulei] Emory Univ, Emory Chem Biol Discovery Ctr, Dept Pharmacol & Chem Biol, Atlanta, GA 30322 USA; [Fu, Haian; Mo, Xiulei] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Kemp, Christopher J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA; [Kuo, Calvin J.] Stanford Univ, Hematol Div, Sch Med, Stanford, CA USA; [McManus, Michael] Univ Calif San Francisco, Dept Microbiol & Immunol, UCSF Diabet Ctr, San Francisco, CA 94143 USA; [McManus, Michael; Weiss, William A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Mills, Gordon B.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Knight Canc Inst, Portland, OR 97201 USA; [Clemons, Paul A.; Schreiber, Stuart L.; Wagner, Bridget K.] Broad Inst, 415 Main St, Cambridge, MA USA; [Kim, William; Tamayo, Pablo] Univ Calif San Diego, Ctr Novel Therapeut, Moores Canc Ctr, La Jolla, CA USA; [Kim, William; Tamayo, Pablo] Univ Calif San Diego, Dept Med, La Jolla, CA USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Weiss, William A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Jagu, Subhashini; Gerhard, Daniela S.] NCI, Off Canc Genom, Ctr Canc Genom, NIH, Bethesda, MD 20892 USA; [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Sahni, Nidhi] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Smithville, TX USA; [Ewald, Andrew J.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Cell Biol, Baltimore, MD USA	Harvard University; Dana-Farber Cancer Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Columbia University; Oregon Health & Science University; Oregon Health & Science University; Emory University; Emory University; Fred Hutchinson Cancer Center; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Oregon Health & Science University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Center for Cancer Genomics (CCG); Oregon Health & Science University; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins Medicine	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA.	william_hahn@dfci.harvard.edu	Moreno, Carlos S/B-3863-2009; Stockwell, Brent R/AAE-7200-2019; Chen, Ken/AAU-1432-2021; Bhattacharya, Asmita/GQR-2455-2022	Moreno, Carlos S/0000-0002-5582-0028; Stockwell, Brent R/0000-0002-3532-3868; Chen, Ken/0000-0003-4013-5279; Bhattacharya, Asmita/0000-0002-5669-8036; Kaufman, Dan/0000-0002-2003-2494; Grasset, Eloise/0000-0001-9857-582X; Bollam, Saumya/0000-0002-6903-4618; Lind, Evan/0000-0001-7026-2012; Kuo, Calvin/0000-0002-7427-5985; Serwas, Nina/0000-0003-2243-5446; Perrone, Matthew/0000-0002-3720-212X; Padmanaban, Veena/0000-0002-4810-2597; Nakano, Michitaka/0000-0003-1049-5791; Bader, Joel/0000-0002-6020-4625; Tay, Neil/0000-0001-5643-050X; Dunworth, Matthew/0000-0002-8852-169X	NCI [U01 CA217846, U01 CA217858, U01 CA217862, U01 CA217875, U01 CA176058, U01 CA217883, U01 CA217851, U01 CA217882, U01 CA217842, U01 CA217848, U01 CA21788, U01 CA217864]	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Data generated by the CTD<SUP>2</SUP> Network can be found in the Data Portal and Dashboard. More information about the centers can be found on the Network web site. CTD2 Centers are funded in part by NCI grants U01 CA217846, U01 CA217858, U01 CA217862, U01 CA217875, U01 CA176058, U01 CA217883, U01 CA217851, U01 CA217882, U01 CA217842, U01 CA217848, U01 CA21788, and U01 CA217864.	Alvarez MJ, 2018, NAT GENET, V50, P979, DOI 10.1038/s41588-018-0138-4; Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Arbour KC, 2019, JAMA-J AM MED ASSOC, V322, P764, DOI 10.1001/jama.2019.11058; Arendt D, 2016, NAT REV GENET, V17, P744, DOI 10.1038/nrg.2016.127; Ashiru O, 2010, CANCER RES, V70, P481, DOI 10.1158/0008-5472.CAN-09-1688; Bannon AE, 2017, EXPERT REV MOL DIAGN, V17, P445, DOI 10.1080/14737159.2017.1308826; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Biffi G, 2021, PHYSIOL REV, V101, P147, DOI 10.1152/physrev.00048.2019; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Braun TP, 2020, CANCER CELL, V37, P530, DOI 10.1016/j.ccell.2020.03.006; Brown JS, 2017, CANCER DISCOV, V7, P20, DOI 10.1158/2159-8290.CD-16-0860; Califano A, 2017, NAT REV CANCER, V17, P116, DOI 10.1038/nrc.2016.124; Cancer Target Discovery and Development Network, 2016, Mol Cancer Res, V14, P675, DOI 10.1158/1541-7786.MCR-16-0090; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chan EM, 2019, NATURE, V568, P551, DOI 10.1038/s41586-019-1102-x; Chan IS, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202001134; Chari A, 2019, NEW ENGL J MED, V381, P727, DOI 10.1056/NEJMoa1903455; Chen JC, 2014, CELL, V159, P402, DOI 10.1016/j.cell.2014.09.021; Clayton A, 2008, J IMMUNOL, V180, P7249, DOI 10.4049/jimmunol.180.11.7249; Cortes-Cros M, 2013, P NATL ACAD SCI USA, V110, P489, DOI 10.1073/pnas.1212780110; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; de Andrade LF, 2018, SCIENCE, V359, P1537, DOI 10.1126/science.aao0505; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421; Dijkstra KK, 2018, CELL, V174, P1586, DOI 10.1016/j.cell.2018.07.009; Dong MB, 2019, CELL, V178, P1189, DOI 10.1016/j.cell.2019.07.044; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Findlay GM, 2018, NATURE, V562, P217, DOI 10.1038/s41586-018-0461-z; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Grosse-Wilde A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126522; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Hammerl D, 2018, SEMIN CANCER BIOL, V52, P178, DOI 10.1016/j.semcancer.2017.11.003; Hangauer MJ, 2017, NATURE, V551, P247, DOI 10.1038/nature24297; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hedlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016899; Hekman RM, 2020, MOL CELL, V80, P1104, DOI 10.1016/j.molcel.2020.11.028; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Huttlin EL, 2017, NATURE, V545, P505, DOI 10.1038/nature22366; Ilic N, 2017, P NATL ACAD SCI USA, V114, pE3434, DOI 10.1073/pnas.1617922114; Ishizuka JJ, 2019, NATURE, V565, P43, DOI 10.1038/s41586-018-0768-9; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Janes KA, 2016, CURR OPIN BIOTECH, V39, P120, DOI 10.1016/j.copbio.2016.03.015; Jang C, 2018, CELL, V173, P822, DOI 10.1016/j.cell.2018.03.055; Jenkins RW, 2018, CANCER DISCOV, V8, P196, DOI 10.1158/2159-8290.CD-17-0833; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Kim JW, 2017, CELL SYST, V5, P105, DOI 10.1016/j.cels.2017.08.002; Kryukov GV, 2016, SCIENCE, V351, P1214, DOI 10.1126/science.aad5214; Kupiec J, 1997, MOL GEN GENET, V255, P201, DOI 10.1007/s004380050490; Lane-Reticker SK, 2018, IMMUNOTHERAPY-UK, V10, P167, DOI 10.2217/imt-2017-0164; Lanier LL, 2019, J EXP MED, V216, P1726, DOI 10.1084/jem.20191183; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; LeBleu VS, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.029447; Levine AJ, 2019, J MOL CELL BIOL, V11, P524, DOI 10.1093/jmcb/mjz026; Li HX, 2019, NAT MED, V25, P850, DOI 10.1038/s41591-019-0404-8; Li JJ, 2017, CELL STEM CELL, V20, P303, DOI 10.1016/j.stem.2016.11.004; Li ZG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14356; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Lui GYL, 2020, EBIOMEDICINE, V60, DOI 10.1016/j.ebiom.2020.102988; Lundholm M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108925; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; MacLean Adam L, 2018, Curr Opin Syst Biol, V9, P32, DOI 10.1016/j.coisb.2018.02.009; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Mavrakis KJ, 2016, SCIENCE, V351, P1208, DOI 10.1126/science.aad5944; Menendez JA, 2006, CURR OPIN CLIN NUTR, V9, P346, DOI 10.1097/01.mco.0000232893.21050.15; Miller JS, 2019, ANNU REV CANC BIOL, V3, P77, DOI 10.1146/annurev-cancerbio-030518-055653; Mo XL, 2019, CELL CHEM BIOL, V26, P331, DOI 10.1016/j.chembiol.2018.11.011; Monje M, 2020, CANCER RES, V80, P2979, DOI 10.1158/0008-5472.CAN-20-0646; Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Neal JT, 2016, ANNU REV PATHOL-MECH, V11, P199, DOI 10.1146/annurev-pathol-012615-044249; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Niedermaier B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54757-z; Nijhawan D, 2012, CELL, V150, P842, DOI 10.1016/j.cell.2012.07.023; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Palucka AK, 2016, CELL, V164, P1233, DOI 10.1016/j.cell.2016.01.049; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parnas O, 2015, CELL, V162, P675, DOI 10.1016/j.cell.2015.06.059; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Patel SJ, 2017, NATURE, V548, P537, DOI 10.1038/nature23477; Paul P, 2019, MUTAT RES-REV MUTAT, V781, P88, DOI 10.1016/j.mrrev.2019.04.004; Pettitt SJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03917-2; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Prior IA, 2020, CANCER RES, V80, P2969, DOI 10.1158/0008-5472.CAN-19-3682; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Raez LE, 2013, CANCER CHEMOTH PHARM, V71, P523, DOI 10.1007/s00280-012-2045-1; Raj A, 2008, CELL, V135, P216, DOI 10.1016/j.cell.2008.09.050; Roerink SF, 2018, NATURE, V556, P457, DOI 10.1038/s41586-018-0024-3; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Samanta D, 2016, CANCER RES, V76, P4430, DOI 10.1158/0008-5472.CAN-16-0530; Schaub FX, 2018, CELL SYST, V6, P282, DOI 10.1016/j.cels.2018.03.003; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Shifrut E, 2018, CELL, V175, P1958, DOI 10.1016/j.cell.2018.10.024; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Stadhouders R, 2019, NATURE, V569, P345, DOI 10.1038/s41586-019-1182-7; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Sullivan LB, 2018, NAT CELL BIOL, V20, P782, DOI 10.1038/s41556-018-0125-0; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Talos F, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14662; Thompson TW, 2017, ELIFE, V6, DOI 10.7554/eLife.30881; Tommasini-Ghelfi S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw4543; Tran HC, 2017, CLIN CANCER RES, V23, P804, DOI 10.1158/1078-0432.CCR-16-1743; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Venkatesh HS, 2019, NATURE, V573, P539, DOI 10.1038/s41586-019-1563-y; Viswanathan VS, 2017, NATURE, V547, P453, DOI 10.1038/nature23007; Wagner AD, 2007, ANN ONCOL, V18, P82, DOI 10.1093/annonc/mdl340; Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wong KM, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0608-3; Ye LP, 2019, NAT BIOTECHNOL, V37, P1302, DOI 10.1038/s41587-019-0246-4; Yuki K, 2020, TRENDS IMMUNOL, V41, P652, DOI 10.1016/j.it.2020.06.010; Zhang QC, 2012, NATURE, V490, P556, DOI 10.1038/nature11503; Zhu GW, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-119	123	51	51	6	67	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 4	2021	184	5					1142	1155		10.1016/j.cell.2021.02.020	http://dx.doi.org/10.1016/j.cell.2021.02.020		MAR 2021	14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QX9AZ	33667368	Green Accepted, Bronze			2023-01-03	WOS:000629635700007
J	Topoll, A; Arnold, R				Topoll, Alicia; Arnold, Robert			In chronic noncancer illness, palliative care reduces symptoms and health care use but does not improve QoL	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Topoll, Alicia; Arnold, Robert] UPMC Hlth Syst, Pittsburgh, PA 15206 USA		Topoll, A (corresponding author), UPMC Hlth Syst, Pittsburgh, PA 15206 USA.							Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Traue DC, 2005, J ROY SOC MED, V98, P503, DOI 10.1258/jrsm.98.11.503; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					JC31	JC31		10.7326/ACPJ202103160-031	http://dx.doi.org/10.7326/ACPJ202103160-031			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD9VR	33646840				2023-01-03	WOS:000669667000006
J	Serrano-Lomelin, J; Hicks, A; Kumar, M; Johnson, DW; Chari, R; Osornio-Vargas, A; Crawford, S; Bakal, J; Ospina, MB				Serrano-Lomelin, Jesus; Hicks, Anne; Kumar, Manoj; Johnson, David W.; Chari, Radha; Osornio-Vargas, Alvaro; Crawford, Susan; Bakal, Jeffrey; Ospina, Maria B.			Patterns of respiratory health services utilization from birth to 5 years of children who experienced adverse birth outcomes	PLOS ONE			English	Article							GESTATIONAL-AGE STATUS; ADULT LUNG-FUNCTION; PRETERM BIRTH; PERINATAL FACTORS; DEPRIVATION INDEX; THORACIC SOCIETY; ASTHMA; CHILDHOOD; WEIGHT; RISK	Introduction Adverse birth outcomes have important consequences for future lung health. We evaluated patterns of respiratory health services utilization in early childhood among children born preterm (PTB), small and large for gestational age at term (SGA and LGA, respectively), and appropriate-for-gestational age at term. Materials and methods We conducted a population-based retrospective cohort study using administrative health data of all singleton live births in Alberta, Canada between 2005-2010. Data on hospitalizations and emergency department (ED) visits from birth to 5 years were collected for asthma, bronchitis, bronchiolitis, croup, influenza, pneumonia, and other acute upper and lower respiratory tract infections (other URTI and other LRTI, respectively). Adjusted rate ratios were estimated for respiratory ED visits and hospitalizations for adverse birth outcomes using the appropriate-for-gestational age at term group as reference. Age-specific trajectories of total respiratory health services utilization rates for each group were estimated in Poisson models. Results A total of 293,764 episodes of respiratory care from 206,994 children were analyzed. Very PTB children had the highest rates of health services use for all respiratory conditions, particularly for asthma, pneumonia, and bronchiolitis hospitalizations. Moderate/late PTB children also had elevated ED visits and hospitalizations for all respiratory conditions. Children born SGA showed high rates of ED visits for other LRTI, and of hospitalizations for bronchitis, bronchiolitis, and other URTI. Children born LGA had high rates of croup and other URTI ED visits, and of bronchiolitis and bronchiolitis hospitalizations. Age-specific trajectories showed a decreasing trend in the rates of total respiratory health service utilization from birth to five years of age for all groups studied. Children born PTB and LGA at term significantly required more respiratory health services over time compared to the reference group. Conclusion Patterns of paediatric respiratory health services utilization vary according to gestational age and fetal growth.	[Serrano-Lomelin, Jesus; Chari, Radha; Ospina, Maria B.] Univ Alberta, Fac Med & Dent, Dept Obstet & Gynecol, Edmonton, AB, Canada; [Hicks, Anne; Kumar, Manoj; Osornio-Vargas, Alvaro] Univ Alberta, Fac Med & Dent, Dept Pediat, Edmonton, AB, Canada; [Johnson, David W.] Univ Calgary, Cumming Sch Med, Dept Pediat Emergency Med & Physiol & Pharmacol, Calgary, AB, Canada; [Crawford, Susan; Bakal, Jeffrey] Alberta Hlth Serv, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of Calgary; Alberta Health Services (AHS)	Ospina, MB (corresponding author), Univ Alberta, Fac Med & Dent, Dept Obstet & Gynecol, Edmonton, AB, Canada.	mospina@ualberta.ca	Bakal, Jeff/ABE-4051-2021; Osornio Vargas, Alvaro Roman/B-4645-2010	Osornio Vargas, Alvaro Roman/0000-0001-8287-7102; Ospina, Maria/0000-0001-9305-7521; Bakal, Jeffrey/0000-0002-3658-2554; SERRANO-LOMELIN, JESUS/0000-0003-1627-3647	Lois Hole Hospital for Women through a Women and Children's Health Research Institute Recruitment Award (MBO); Lung Association Alberta & NWT through the 2017-2018 National Grant Review program; Canada Research Chair Program (Government of Canada; Ottawa, Canada)	Lois Hole Hospital for Women through a Women and Children's Health Research Institute Recruitment Award (MBO); Lung Association Alberta & NWT through the 2017-2018 National Grant Review program; Canada Research Chair Program (Government of Canada; Ottawa, Canada)	This research was funded by the Lois Hole Hospital for Women through a Women and Children's Health Research Institute Recruitment Award (MBO) (https://www.wchri.org), and the Lung Association Alberta & NWT through the 2017-2018 National Grant Review program (https://www.ab.lung.ca/what-we-do/research/grant-opportunities/national-grant-review).MBO's research is supported by the Canada Research Chair Program (Government of Canada; Ottawa, Canada). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberta Perinatal Health Program, 2016, ALBERTA PERINATAL HL; Algert CS, 2011, PEDIAT ALLERG IMM-UK, V22, P836, DOI 10.1111/j.1399-3038.2011.01206.x; [Anonymous], 2015, Obstet Gynecol, V126, pe52, DOI 10.1097/AOG.0000000000001108; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; Baxter D, 2010, HUM VACCINES, V6, P494, DOI 10.4161/hv.6.6.12008; Been JV, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001596; Belon AP, 2020, PAEDIATR PERINAT EP, V34, P150, DOI 10.1111/ppe.12639; Bjornson CL, 2013, CAN MED ASSOC J, V185, P1317, DOI 10.1503/cmaj.121645; Boonyaratanakornkit J, 2020, J PEDIAT INF DIS SOC, V9, P21, DOI 10.1093/jpids/piy107; Brew BK, 2012, CLIN EXP ALLERGY, V42, P1621, DOI 10.1111/j.1365-2222.2012.04056.x; Britt RD, 2013, EXPERT REV RESP MED, V7, P515, DOI 10.1586/17476348.2013.838020; Canadian Institute for Health Information, 2015, ICD 10 CA INT STAT C; Canadian Institute for Health Information, 2018, ASTHMA HOSPITALIZATI; Carraro S, 2014, EUR RESPIR J, V44, P1682, DOI 10.1183/09031936.00084114; Cosmi E, 2011, J PREGNANCY, V2011, DOI 10.1155/2011/364381; Davidson R, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-14; den Dekker HT, 2016, J ALLERGY CLIN IMMUN, V137, P1026, DOI 10.1016/j.jaci.2015.08.050; Douros K, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00218; Ducharme FM, 2015, CAN RESPIR J, V22, P135, DOI 10.1155/2015/101572; Duijts L, 2012, EUR J EPIDEMIOL, V27, P5, DOI 10.1007/s10654-012-9657-y; Edwards CA, 2003, THORAX, V58, P1061, DOI 10.1136/thorax.58.12.1061; Fiorino EK, 2009, CLIN CHEST MED, V30, P601, DOI 10.1016/j.ccm.2009.05.010; Gessner BD, 2007, THORAX, V62, P231, DOI 10.1136/thx.2005.053363; Government of Alberta, 2009, INT MIGRATION ALBERT; Government of Alberta, 2020, ALBERTA POPULATION E; Haataja P, 2018, PEDIATR PULM, V53, P209, DOI 10.1002/ppul.23908; Heaman M, 2013, PAEDIATR PERINAT EP, V27, P54, DOI 10.1111/ppe.12016; Henderson AJ, 2012, SEMIN FETAL NEONAT M, V17, P82, DOI 10.1016/j.siny.2012.01.006; Hinds A, 2016, CAN J PUBLIC HEALTH, V107, pE56, DOI [10.17269/cjph.107.5244, 10.17269/CJPH.107.5244]; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Johnson J, 2015, J PERINATOL, V35, P72, DOI 10.1038/jp.2014.142; Johnston KM, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-93; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Liu XQ, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-13; Mitanchez D, 2015, WORLD J DIABETES, V6, P734, DOI 10.4239/wjd.v6.i5.734; Mu M, 2014, HEART LUNG CIRC, V23, P511, DOI 10.1016/j.hlc.2013.11.018; Nissen F, 2017, CLIN EPIDEMIOL, V9, P643, DOI 10.2147/CLEP.S143718; Pampalon R, 2009, CHRONIC DIS CAN, V29, P178; Pampalon R, 2012, CAN J PUBLIC HEALTH, V103, pS17, DOI 10.1007/BF03403824; Paranjothy S, 2013, PEDIATRICS, V132, pE1562, DOI 10.1542/peds.2013-1737; Patelarou E, 2009, INT J ENV RES PUB HE, V6, P2752, DOI 10.3390/ijerph6112752; Pike KC, 2015, PAEDIATR RESPIR REV, V16, P182, DOI 10.1016/j.prrv.2014.12.001; Quinn JA, 2016, VACCINE, V34, P6047, DOI 10.1016/j.vaccine.2016.03.045; Rao DP, 2016, HEALTH PROMOT CHRON, V36, P194, DOI 10.24095/hpcdp.36.9.03; Ren CL, 2016, AM J RESP CRIT CARE, V194, P356, DOI 10.1164/rccm.201604-0694ST; Serrano-Lomelin J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17238973; Sharma D, 2016, CLIN MED INSIGHTS-PE, V10, P67, DOI 10.4137/CMPed.S40070; StataCorp, 2017, STATA STAT SOFTWARE, DOI DOI 10.2307/2234838; Statistics Canada, TABLE 13 10 0745 01; Townsi N, 2018, EUR CLIN RESPIR J, V5, DOI 10.1080/20018525.2018.1487214; Turner S, 2011, AM J RESP CRIT CARE, V184, P407, DOI 10.1164/rccm.201012-2075OC; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Voort AMMSVD, 2014, J ALLERGY CLIN IMMUN, V133, P1317, DOI 10.1016/j.jaci.2013.12.1082; Weschenfelder F, 2019, GEBURTSH FRAUENHEILK, V79, P1183, DOI 10.1055/a-0891-0919; Yoshimoto J, 2019, ACTA PAEDIATR, V108, P473, DOI 10.1111/apa.14507; Zar HJ, 2014, PEDIATR PULM, V49, P430, DOI 10.1002/ppul.23030	56	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2021	16	2							e0247527	10.1371/journal.pone.0247527	http://dx.doi.org/10.1371/journal.pone.0247527			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8KQ	33606848	gold, Green Published			2023-01-03	WOS:000620629200129
J	Jermy, MC; Spence, CJT; Kirton, R; O'Donnell, JF; Kabaliuk, N; Gaw, S; Hockey, H; Jiang, Y; Abidin, ZZ; Dougherty, RL; Rowe, P; Mahaliyana, AS; Gibbs, A; Roberts, SA				Jermy, M. C.; Spence, C. J. T.; Kirton, R.; O'Donnell, J. F.; Kabaliuk, N.; Gaw, S.; Hockey, H.; Jiang, Y.; Abidin, Z. Zulkhairi; Dougherty, R. L.; Rowe, P.; Mahaliyana, A. S.; Gibbs, A.; Roberts, S. A.			Assessment of dispersion of airborne particles of oral/nasal fluid by high flow nasal cannula therapy	PLOS ONE			English	Article								Background Nasal High Flow (NHF) therapy delivers flows of heated humidified gases up to 60 LPM (litres per minute) via a nasal cannula. Particles of oral/nasal fluid released by patients undergoing NHF therapy may pose a cross-infection risk, which is a potential concern for treating COVID-19 patients. Methods Liquid particles within the exhaled breath of healthy participants were measured with two protocols: (1) high speed camera imaging and counting exhaled particles under high magnification (6 participants) and (2) measuring the deposition of a chemical marker (riboflavin-5-monophosphate) at a distance of 100 and 500 mm on filter papers through which air was drawn (10 participants). The filter papers were assayed with HPLC. Breathing conditions tested included quiet (resting) breathing and vigorous breathing (which here means nasal snorting, voluntary coughing and voluntary sneezing). Unsupported (natural) breathing and NHF at 30 and 60 LPM were compared. Results Imaging: During quiet breathing, no particles were recorded with unsupported breathing or 30 LPM NHF (detection limit for single particles 33 mu m). Particles were detected from 2 of 6 participants at 60 LPM quiet breathing at approximately 10% of the rate caused by unsupported vigorous breathing. Unsupported vigorous breathing released the greatest numbers of particles. Vigorous breathing with NHF at 60 LPM, released half the number of particles compared to vigorous breathing without NHF. Chemical marker tests: No oral/nasal fluid was detected in quiet breathing without NHF (detection limit 0.28 mu L/m3). In quiet breathing with NHF at 60 LPM, small quantities were detected in 4 out of 29 quiet breathing tests, not exceeding 17 mu L/m3. Vigorous breathing released 200-1000 times more fluid than the quiet breathing with NHF. The quantities detected in vigorous breathing were similar whether using NHF or not. Conclusion During quiet breathing, 60 LPM NHF therapy may cause oral/nasal fluid to be released as particles, at levels of tens of mu L per cubic metre of air. Vigorous breathing (snort, cough or sneeze) releases 200 to 1000 times more oral/nasal fluid than quiet breathing (p < 0.001 with both imaging and chemical marker methods). During vigorous breathing, 60 LPM NHF therapy caused no statistically significant difference in the quantity of oral/nasal fluid released compared to unsupported breathing. NHF use does not increase the risk of dispersing infectious aerosols above the risk of unsupported vigorous breathing. Standard infection prevention and control measures should apply when dealing with a patient who has an acute respiratory infection, independent of which, if any, respiratory support is being used.	[Jermy, M. C.; Kabaliuk, N.; Abidin, Z. Zulkhairi] Univ Canterbury, Dept Mech Engn, Christchurch, New Zealand; [Spence, C. J. T.; Kirton, R.; O'Donnell, J. F.; Rowe, P.] Fisher & Paykel Healthcare, Auckland, New Zealand; [O'Donnell, J. F.] Massey Univ, Sch Nursing, Coll Hlth, Auckland, New Zealand; [Gaw, S.; Mahaliyana, A. S.; Gibbs, A.] Univ Canterbury, Sch Phys & Chem Sci, Christchurch, New Zealand; [Hockey, H.] Biometr Matters Ltd, Hamilton, New Zealand; [Jiang, Y.] Univ Auckland, Dept Stat, Auckland, New Zealand; [Dougherty, R. L.] Univ Kansas, Dept Mech Engn, Lawrence, KS 66045 USA; [Roberts, S. A.] Auckland Dist Hlth Board, Dept Microbiol Lab Plus, Auckland, New Zealand	University of Canterbury; Haier; Massey University; University of Canterbury; University of Auckland; University of Kansas; Auckland District Health Board	Jermy, MC (corresponding author), Univ Canterbury, Dept Mech Engn, Christchurch, New Zealand.	mark.jermy@canterbury.ac.nz	ODonnell, Jane/GEX-9181-2022	ODonnell, Jane/0000-0002-9554-5497	Fisher & Paykel Healthcare Ltd; NHF cannulae (Optiflow); NHF source (Airvo/Airvo2); Malaysian Ministry of Higher Education; University of Canterbury Erskine Fellowship	Fisher & Paykel Healthcare Ltd; NHF cannulae (Optiflow); NHF source (Airvo/Airvo2); Malaysian Ministry of Higher Education; University of Canterbury Erskine Fellowship	This study was partially funded by Fisher & Paykel Healthcare Ltd, who also provided the NHF cannulae (Optiflow) and the NHF source (Airvo/Airvo2). The funder provided support in the form of salaries for authors CJS, JFO, RK and PR, but did not take part in the data collection or reduction. None of the data obtained was excluded from the manuscript. The specific roles of these authors are articulated in the `author contributions' section. YJ and HH carried out statistical analyses under consulting service agreements with Fisher & Paykel Healthcare Ltd; ZZA was supported by a scholarship from the Malaysian Ministry of Higher Education; RD was on sabbatical from the University of Kansas and was partly supported by a University of Canterbury Erskine Fellowship.	Anfinrud P, 2020, NEW ENGL J MED, V382, P2061, DOI 10.1056/NEJMc2007800; Bahl P, 2022, J INFECT DIS, V225, P1561, DOI 10.1093/infdis/jiaa189; Chia PY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16670-2; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Gaeckle NT, 2020, AM J RESP CRIT CARE, V202, P1115, DOI 10.1164/rccm.202006-2309OC; Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885; Hui D S C, 2014, Hong Kong Med J, V20 Suppl 4, P9; Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018; Johnson GR, 2011, J AEROSOL SCI, V42, P839, DOI 10.1016/j.jaerosci.2011.07.009; Kotoda M, 2020, J HOSP INFECT, V104, P534, DOI 10.1016/j.jhin.2019.11.010; Lauc G, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010344; Lefebvre Arthur H., 1989, ATOMIZATION SPRAY; Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007; Leung NHL, 2020, NAT MED, V26, P676, DOI 10.1038/s41591-020-0843-2; Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3; Loh NHW, 2020, CAN J ANESTH, V67, P893, DOI 10.1007/s12630-020-01634-3; Mittal R, 2020, J FLUID MECH, V894, DOI 10.1017/jfm.2020.330; Mundel T, 2013, J APPL PHYSIOL, V114, P1058, DOI 10.1152/japplphysiol.01308.2012; Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717; Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5; Spence CJT, 2011, EXP FLUIDS, V50, P1005, DOI 10.1007/s00348-010-0984-z; Spence CJT, 2012, EXP FLUIDS, V52, P569, DOI 10.1007/s00348-011-1044-z; Tellier R, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3707-y; TOBIN MJ, 1983, CHEST, V84, P202, DOI 10.1378/chest.84.2.202; Tran K, 2013, CADTH Technol Overv, V3, pe3201; Wang K, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00653-z; Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093; Xie X, 2007, INDOOR AIR, V17, P211, DOI 10.1111/j.1600-0668.2007.00469.x	28	12	12	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2021	16	2							e0246123	10.1371/journal.pone.0246123	http://dx.doi.org/10.1371/journal.pone.0246123			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK0KW	33577565	Green Published, Green Submitted, gold			2023-01-03	WOS:000620071700052
J	Holt, DC; Harris, TM; Hughes, JT; Lilliebridge, R; Croker, D; Graham, S; Hall, H; Wilson, J; Tong, SYC; Giffard, PM				Holt, Deborah C.; Harris, Tegan M.; Hughes, Jaquelyne T.; Lilliebridge, Rachael; Croker, David; Graham, Sian; Hall, Heather; Wilson, Judith; Tong, Steven Y. C.; Giffard, Phillip M.			Longitudinal whole-genome based comparison of carriage and infection associated Staphylococcus aureus in northern Australian dialysis clinics	PLOS ONE			English	Article							HEMODIALYSIS; EPIDEMIOLOGY; PREVENTION; COMPLEX; DECOLONIZATION; COLONIZATION; STRATEGY; STRAINS	Background The study objective was to reveal reservoirs potentially leading to Staphylococcus aureus infections in haemodialysis clinic clients in the tropical north of the Australian Northern Territory (NT). This client population are primarily Aboriginal Australians who have a greater burden of ill health than other Australians. Reservoir identification will enhance infection control in this client group, including informing potential S. aureus decolonisation strategies. Methods and findings The study participants were 83 clients of four haemodialysis clinics in the Darwin region of the NT, and 46 clinical staff and researchers who had contact with the clinic clients. The study design was longitudinal, encompassing swabbing of anatomical sites at two month intervals to yield carriage isolates, and also progressive collection of infection isolates. Swab sampling was performed for all participants, and infection isolates collected for dialysis clients only. Analysis was based on the comparison of 139 carriage isolates and 27 infection isolates using whole genome sequencing. Genome comparisons were based on of 20,651 genome-wide orthologous SNPs, presence/absence of the mecA and pvl genes, and inferred multilocus sequence type and clonal complex. Pairs of genomes meeting the definition of "not discriminated" were classed as defining potential transmission events. The primary outcome was instances of potential transmission between a carriage site other than a skin lesion and an infection site, in the same individual. Three such instances were identified. Two involved ST762 (CC1) PVL- MRSA, and one instance ST121 PVL+ MSSA. Three additional instances were identified where the carriage strains were derived from skin lesions. Also identified were six instances of potential transmission of a carriage strains between participants, including transmission of strains between dialysis clients and staff/researchers, and one potential transmission of a clinical strain between participants. There were frequent occurrences of longitudinal persistence of carriage strains in individual participants, and two examples of the same strain causing infection in the same participants at different times. Strains associated with infections and skin lesions were enriched for PVL and mecA in comparison to strains associated with long term carriage. Conclusions This study indicated that strains differ with respect to propensity to stably colonise sites such as the nose, and cause skin infections. PVL+ strains were associated with infection and skin lesions and were almost absent from the carriage sites. PVL- MRSA (mainly CC1) strains were associated with infection and also with potential transmission events involving carriage sites, while PVL- MSSA were frequently observed to stably colonise individuals without causing infection, and to be rarely transmitted. Current clinical guidelines for dialysis patients suggest MRSA decolonisation. Implementation in this client group may impact infections by PVL- MRSA, but may have little effect on infection by PVL+ strains. In this study, the PVL+ strains were predominant causes of infection but rarely colonised typical carriage sites such as the nose, and in the case of ST121, were MSSA. The important reservoirs for infection by PVL+ strains appeared to be prior infections.	[Holt, Deborah C.; Harris, Tegan M.; Lilliebridge, Rachael; Croker, David; Graham, Sian; Wilson, Judith; Tong, Steven Y. C.; Giffard, Phillip M.] Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia; [Holt, Deborah C.; Giffard, Phillip M.] Charles Darwin Univ, Coll Hlth & Human Sci, Darwin, NT, Australia; [Hughes, Jaquelyne T.] Charles Darwin Univ, Menzies Sch Hlth Res, Wellbeing & Preventable Chron Dis Div, Darwin, NT, Australia; [Hughes, Jaquelyne T.] Royal Darwin Hosp, Dept Nephrol, Div Med, Darwin, NT, Australia; [Hall, Heather] Northern Terr Dept Hlth, Renal Serv, Darwin, NT, Australia; [Tong, Steven Y. C.] Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia; [Tong, Steven Y. C.] Univ Melbourne, Doherty Dept, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia	Charles Darwin University; Menzies School of Health Research; Charles Darwin University; Charles Darwin University; Menzies School of Health Research; Royal Melbourne Hospital; University of Melbourne	Giffard, PM (corresponding author), Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia.; Giffard, PM (corresponding author), Charles Darwin Univ, Coll Hlth & Human Sci, Darwin, NT, Australia.	phil.giffard@menzies.edu.au	Tong, Steven/N-2353-2013	Tong, Steven/0000-0002-1368-8356; Giffard, Phil/0000-0002-3030-9127	National Health and Medical Research Council of Australia (NHMRC) [1022782]; Jacquot Research Establishment Award from the Royal Australian College of Physicians; NHMRC Early Career Fellowship [1092576, 1145033]	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Jacquot Research Establishment Award from the Royal Australian College of Physicians; NHMRC Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This research was funded by the National Health and Medical Research Council of Australia (NHMRC) https://www.nhmrc.gov.au/(Project Grant 1022782). JTH was supported by a Jacquot Research Establishment Award from the Royal Australian College of Physicians (https://www.racp.edu.au/about/foundation/research-awards-andcareer-grants/research-establishment-awards) and an NHMRC Early Career Fellowship (#1092576). ST is a NHMRC Career Development Fellow (#1145033) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aktas E, 2011, AM J INFECT CONTROL, V39, P421, DOI 10.1016/j.ajic.2010.06.012; (ANZDATA) AaNZDaTR, 2018, 41 ANZDATA AANZDATR; Bagge K, 2019, EUR J CLIN MICROBIOL, V38, P683, DOI 10.1007/s10096-019-03474-6; Barcudi D, 2020, J INFECTION, V80, P24, DOI 10.1016/j.jinf.2019.10.001; Cameron JK, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0485-7; Cho SY, 2017, CLIN INFECT DIS, V64, pS82, DOI 10.1093/cid/cix133; Coombs GW, 2014, COMMUN DIS INTELL, V38, pE59; Coombs GW, 2004, J CLIN MICROBIOL, V42, P4735, DOI 10.1128/JCM.42.10.4735-4743.2004; Davey RX, 2019, PATHOLOGY, V51, P308, DOI 10.1016/j.pathol.2018.11.010; Deurenberg RH, 2008, INFECT GENET EVOL, V8, P747, DOI 10.1016/j.meegid.2008.07.007; Gagnaire J, 2019, EUR J CLIN MICROBIOL, V38, P1811, DOI 10.1007/s10096-019-03613-z; Hadfield J, 2018, BIOINFORMATICS, V34, P292, DOI 10.1093/bioinformatics/btx610; Hall MD, 2019, ELIFE, V8, DOI 10.7554/eLife.46402; Harris TM, 2018, CLIN MICROBIOL INFEC, V24, P1027, DOI 10.1016/j.cmi.2018.04.020; Henderson A, 2018, BRIT MED BULL, V125, P25, DOI 10.1093/bmb/ldx046; Holt DC, 2011, GENOME BIOL EVOL, V3, P881, DOI 10.1093/gbe/evr078; Hughes JT, 2020, AUST HEALTH REV, V44, P234, DOI 10.1071/AH18230; Hunt M, 2017, MICROB GENOMICS, V3, DOI 10.1099/mgen.0.000131; Jardine M, 2019, NEPHROLOGY, V24, P951, DOI 10.1111/nep.13511; Jauneikaite E, 2019, CLIN MICROBIOLOGY IN, DOI [10.1016/j.cmi.2019.07.014 31357012, DOI 10.1016/J.CMI.2019.07.014 31357012]; Kallen AJ, 2011, SEMIN DIALYSIS, V24, P533, DOI 10.1111/j.1525-139X.2011.00959.x; Kang YC, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-284; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lilliebridge RA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019749; Lim WH, 2019, MED J AUSTRALIA, V211, P374, DOI 10.5694/mja2.50354; McDonald M, 2006, J CLIN MICROBIOL, V44, P3720, DOI 10.1128/JCM.00836-06; Miller LG, 2012, CLIN INFECT DIS, V54, P1523, DOI 10.1093/cid/cis213; Moschou A, 2019, J INFECT CHEMOTHER, DOI [10.1016/j.jiac.2019.08.008 31501027, DOI 10.1016/J.JIAC.2019.08.008 31501027]; Nguyen DB, 2017, CLIN J AM SOC NEPHRO, V12, P1139, DOI 10.2215/CJN.11411116; Parker MG, 2012, SEMIN DIALYSIS, V25, P42, DOI 10.1111/j.1525-139X.2011.00999.x; Price A, 2015, J HOSP INFECT, V90, P22, DOI 10.1016/j.jhin.2015.01.001; Rao Q, 2015, J MED MICROBIOL, V64, P1462, DOI 10.1099/jmm.0.000185; Ritchie SR, 2019, NEPHROLOGY, V24, P744, DOI 10.1111/nep.13474; Sarovich Derek S, 2014, BMC Res Notes, V7, P618, DOI 10.1186/1756-0500-7-618; Simor AE, 2011, LANCET INFECT DIS, V11, P952, DOI 10.1016/S1473-3099(11)70281-X; Tong SYC, 2015, EPIDEMIOL INFECT, V143, P1519, DOI 10.1017/S0950268814002611; Tong SYC, 2015, INT J SYST EVOL MICR, V65, P15, DOI 10.1099/ijs.0.062752-0; Tong SYC, 2015, GENOME RES, V25, P111, DOI 10.1101/gr.174730.114; Tong SYC, 2012, SEMIN IMMUNOPATHOL, V34, P185, DOI 10.1007/s00281-011-0300-x; Tong SYC, 2010, J INFECT DIS, V202, P760, DOI 10.1086/655396; Tong SYC, 2009, J INFECT DIS, V199, P1461, DOI 10.1086/598218; van Hal SJ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01453; Vandecasteele SJ, 2009, CLIN J AM SOC NEPHRO, V4, P1388, DOI 10.2215/CJN.01590309; Vandenesch F, 2003, EMERG INFECT DIS, V9, P978; Verhoeven PO, 2014, EXPERT REV ANTI-INFE, V12, P75, DOI 10.1586/14787210.2014.859985; Vlack S, 2006, MED J AUSTRALIA, V184, P556, DOI 10.5694/j.1326-5377.2006.tb00379.x; Wilgenbusch James C, 2003, Curr Protoc Bioinformatics, VChapter 6, DOI 10.1002/0471250953.bi0604s00; Williamson DA, 2014, CLIN MICROBIOL INFEC, V20, P597, DOI 10.1111/1469-0691.12702	48	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2021	16	2							e0245790	10.1371/journal.pone.0245790	http://dx.doi.org/10.1371/journal.pone.0245790			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH0TZ	33544742	gold, Green Published			2023-01-03	WOS:000617991900047
J	Becerril, S; Fruhbeck, G				Becerril, Sara; Fruehbeck, Gema			Cagrilintide plus semaglutide for obesity management	LANCET			English	Editorial Material									[Becerril, Sara; Fruehbeck, Gema] Univ Navarra, Univ Navarra Clin, Metab Res Lab, Dept Endocrinol & Nutr,IdiSNA,CIBEROBN, Pamplona 31008, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; University of Navarra	Fruhbeck, G (corresponding author), Univ Navarra, Univ Navarra Clin, Metab Res Lab, Dept Endocrinol & Nutr,IdiSNA,CIBEROBN, Pamplona 31008, Spain.	gfruhbeck@unav.es						Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS111, DOI 10.2337/dc21-S009; Bray GA, 2016, LANCET, V387, P1947, DOI 10.1016/S0140-6736(16)00271-3; Enebo LB, 2021, LANCET, V397, P1736, DOI 10.1016/S0140-6736(21)00845-X; Fletcher MM, 2021, J PHARMACOL EXP THER, V377, DOI 10.1124/jpet.121.000567; Kalyani RR, 2021, NEW ENGL J MED, V384, P1248, DOI 10.1056/NEJMcp2000280; Mathiesen DS, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.617400; Ryan D, 2021, LANCET DIABETES ENDO, V9, P252, DOI 10.1016/S2213-8587(21)00081-4; Tak YJ, 2021, CURR OBES REP, V10, P14, DOI 10.1007/s13679-020-00422-w; Zhang ZY, 2021, HYPERTENSION, V77, P788, DOI 10.1161/HYPERTENSIONAHA.120.12858	9	8	8	2	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	2021	397	10286					1687	1689		10.1016/S0140-6736(21)00944-2	http://dx.doi.org/10.1016/S0140-6736(21)00944-2		MAY 2021	4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RY3KF	33894837				2023-01-03	WOS:000647813600004
J	Baye, AM; Ababu, A; Bayisa, R; Abdella, M; Diriba, E; Wale, M; Selam, MN				Baye, Assefa Mulu; Ababu, Andualem; Bayisa, Regasa; Abdella, Mahdi; Diriba, Edessa; Wale, Minyechel; Selam, Muluken Nigatu			Perspectives of compounding pharmacists on alcohol-based hand sanitizer production and utilization for COVID-19 prevention in Addis Ababa, Ethiopia: A descriptive phenomenology study	PLOS ONE			English	Article							HEALTH; HYGIENE; FEASIBILITY; INFECTION	Background Globally, the safety of patients and healthcare providers is at risk due to health care-associated infections (HCAIs). World Health Organization and the Centers for Disease Control and Prevention recommend using alcohol-based hand rub (ABHR) for hand hygiene in healthcare settings to prevent HCAIs. Irrational use of ABHR will have undesirable consequences including wastage of products, exposure of healthcare providers to infections and emergence of microbial resistance to the alcohol in hand sanitizers. This study aimed to explore the perspective and experiences of compounding pharmacists on production and utilization of ABHR solution for coronavirus disease in 2019 (COVID-19) prevention in public hospitals of Addis Ababa, Ethiopia. Methods A descriptive qualitative study using in-depth interview of 13 key-informants serving as compounding pharmacists in public hospitals of Addis Ababa, Ethiopia, was conducted. The study participants were identified and selected by purposive sampling. All transcribed interviews were subjected to thematic analysis and transcripts were analyzed manually. Findings The compounding pharmacists in this study had a mean age of 30.6 (3.1) years and nine of the thirteen participants were men. Ten participants believed that the compounding practice in their respective sites followed the principles of good compounding practice. More than half of the participants did not believe that ABHR products were used rationally in health facilities. They argued that users did not have enough awareness when and how to use sanitizers. Most of the interviewees reported that compounding personnel had no formal training on ABHR solution production. Study participants suggested incentive mechanisms and reimbursements for experts involved in the compounding of ABHR solutions. Conclusion Three of the compounding pharmacists indicated that ABHR production in their setting lack compliance to good compounding practice due to inadequate compounding room, quality control tests, manpower and equipment. Despite this, most study participants preferred the in-house ABHR products than the commercially available ones. Thus, training, regular monitoring and follow-up of the hospital compounding services can further build staff confidence.	[Baye, Assefa Mulu] Addis Ababa Univ, Sch Pharm, Dept Pharmacol & Clin Pharm, Addis Ababa, Ethiopia; [Ababu, Andualem; Bayisa, Regasa; Abdella, Mahdi; Diriba, Edessa] Minist Hlth, Pharmaceut & Med Equipment Directorate PMED, Addis Ababa, Ethiopia; [Wale, Minyechel] All African Lepros TB Rehabil & Training Ctr ALER, Addis Ababa, Ethiopia; [Selam, Muluken Nigatu] Addis Ababa Univ, Sch Pharm, Dept Pharmaceut & Social Pharm, Addis Ababa, Ethiopia	Addis Ababa University; Addis Ababa University	Baye, AM (corresponding author), Addis Ababa Univ, Sch Pharm, Dept Pharmacol & Clin Pharm, Addis Ababa, Ethiopia.	assefa.mulu@aau.edu.et	Selam, Muluken Nigatu/ABC-8323-2021	Baye, Assefa Mulu/0000-0002-6657-7828; Nigatu, Muluken/0000-0002-3539-536X; Aynalem, Minychel/0000-0003-2062-0322				Administration Drug. and Authority Control. ( DACA) of Ethiopia., 2002, STAND EST PRACT PHAR; Al-Quteimat OM, 2021, RES SOC ADMIN PHARM, V17, P480, DOI 10.1016/j.sapharm.2020.03.018; Allegranzi B, 2007, INFECT CONT HOSP EP, V28, P1323, DOI 10.1086/521656; Allegranzi B, 2013, LANCET INFECT DIS, V13, P843, DOI 10.1016/S1473-3099(13)70163-4; Bauer-Savage J, 2013, B WORLD HEALTH ORGAN, V91, P963, DOI 10.2471/BLT.12.117085; Boyce JM, 2002, INFECT CONT HOSP EP, V23, pS3, DOI 10.1086/503164; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Budd A., 2016, Journal of Service Science and Management, V9, P150, DOI 10.4236/jssm.2016.92019; Central Statistical Agency A.A, PROJ POP ETH 2019; Ellingson K, 2014, INFECT CONT HOSP EP, V35, P937, DOI [10.1086/677145, 10.1017/S0899823X00193900]; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Ethiopian Standards Agency, 2020, SAMPL SAN TEST WER S; Food and Drug Administration (FDA), POL TEMP COMP CERT A; Hand Hygiene Australia, 2019, NAT HAND HYG IN MAN; Infection Control Today, 2003, INFECTION CONTROL TO; International Pharmaceutical Federation, 2020, COR SARS COV 2 OUTBR; Kama-Kieghe S, LOCAL PRODUCTION ALC; Kramer A, 2002, LANCET, V359, P1489, DOI 10.1016/S0140-6736(02)08426-X; Li Y, 2015, J HOSP INFECT, V90, P338, DOI 10.1016/j.jhin.2015.04.006; Merks P, 2021, RES SOC ADMIN PHARM, V17, P1807, DOI 10.1016/j.sapharm.2020.05.033; Ministry of health-Ethiopia, 2020, NAT GUID COMP DERM P; Ministry of Health-Ethiopia, 2019, HLTH FAC ALC BAS HAN; NAPRA, 2016, MOD STAND PHARM COMP; Organization WH, 2009, WHO GUID HAND HYG HL; Pharmaceutical Group of European Union, NTR; Pidot SJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar6115; Pittet D, 2008, J HOSP INFECT, V68, P285, DOI 10.1016/j.jhin.2007.12.013; Rutter V, 2018, J PHARM POLICY PRACT, V11, DOI 10.1186/s40545-018-0140-3; Starks H, 2007, QUAL HEALTH RES, V17, P1372, DOI 10.1177/1049732307307031; Statista Mexico, 2022, DIST AG BAS BEV PROD; Sydney Children's Hospital Network, 2020, COVID 19 STAND OP PR; USP, COMP ALC BAS HAND SA; USP. &LANGBRAC, 2019, PHARM COMP NON STER; World Health Organization, 2019, MENT HOLIST HLTH SOM; World Health Organization (WHO), 2010, GUID LOC PROD WHO RE; World Health Organization (WHO), 2002, ANN 9 GUID PACK PHAR, V902; World Health Organization (WHO), 2012, ALC BAS HDB PROC APP	37	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2021	16	4							e0250020	10.1371/journal.pone.0250020	http://dx.doi.org/10.1371/journal.pone.0250020			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6DA	33914768	Green Published, gold			2023-01-03	WOS:000664603100029
J	Chacon, AM; Nguyen, DD; McCabe, P; Madill, C				Chacon, Antonia Margarita; Duy Duong Nguyen; McCabe, Patricia; Madill, Catherine			Aerosol-generating behaviours in speech pathology clinical practice: A systematic literature review	PLOS ONE			English	Review							HEALTH-CARE; SIZE DISTRIBUTION; INFLUENZA; DROPLETS; GRADE; TRANSMISSION; GUIDELINES; INFECTION; CONSENSUS; TABLES	Objective To evaluate the evidence of aerosol generation across tasks involved in voice and speech assessment and intervention, to inform better management and to reduce transmission risk of such diseases as COVID-19 in healthcare settings and the wider community. Design Systematic literature review. Data sources and eligibility Medline, Embase, Scopus, Web of Science, CINAHL, PubMed Central and grey literature through ProQuest, The Centre for Evidence-Based Medicine, COVID-Evidence and speech pathology national bodies were searched up until August 13(th), 2020 for articles examining the aerosol-generating activities in clinical voice and speech assessment and intervention within speech pathology. Results Of the 8288 results found, 39 studies were included for data extraction and analysis. Included articles were classified into one of three categories: research studies, review articles or clinical guidelines. Data extraction followed appropriate protocols depending on the classification of each article (e.g. PRISMA for review articles). Articles were assessed for risk of bias and certainty of evidence using the GRADE system. Six behaviours were identified as aerosol generating. These were classified into three categories: vegetative acts (coughing, breathing), verbal communication activities of daily living (speaking, loud voicing), and performance-based tasks (singing, sustained phonation). Certainty of evidence ranged from very low to moderate with variation in research design and variables. Conclusions This body of literature helped to both identify and categorise the aerosol-generating behaviours involved in speech pathology clinical practice and confirm the low level of evidence throughout the speech pathology literature pertaining to aerosol generation. As many aerosol-generating behaviours are common human behaviours, these findings can be applied across healthcare and community settings. Systematic review registration Registration number CRD42020186902 with PROSPERO International Prospective Register for Systematic Reviews.	[Chacon, Antonia Margarita; Duy Duong Nguyen; McCabe, Patricia; Madill, Catherine] Univ Sydney, Sydney Sch Hlth Sci, Fac Med & Hlth, Discipline Speech Pathol, Sydney, NSW, Australia; [Chacon, Antonia Margarita; Duy Duong Nguyen; Madill, Catherine] Univ Sydney, Sydney Sch Hlth Sci, Fac Med & Hlth, Doctor Liang Voice Program, Sydney, NSW, Australia	University of Sydney; University of Sydney	Chacon, AM (corresponding author), Univ Sydney, Sydney Sch Hlth Sci, Fac Med & Hlth, Discipline Speech Pathol, Sydney, NSW, Australia.; Chacon, AM (corresponding author), Univ Sydney, Sydney Sch Hlth Sci, Fac Med & Hlth, Doctor Liang Voice Program, Sydney, NSW, Australia.	antonia.chacon@sydney.edu.au	Madill, Catherine/J-6156-2017	Madill, Catherine/0000-0001-8114-1427; Chacon, Antonia/0000-0003-2902-659X; Nguyen, Duy Duong/0000-0001-8097-8938				Adhikari U, 2019, RISK ANAL, V39, P2608, DOI 10.1111/risa.13389; Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2019.02.033, 10.1016/j.jiph.2020.02.033]; Asadi S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227699; Asadi S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38808-z; Bagg JCJ., 2020, MITIGATION AEROSOL G; Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X; Bolton L, 2020, INT J LANG COMM DIS, V55, P629, DOI 10.1111/1460-6984.12544; Campbell M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6890; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Carlson AL, 2010, CURR OPIN INFECT DIS, V23, P293, DOI 10.1097/QCO.0b013e32833bb804; Chen YL, 2017, ANN INTERN MED, V166, P128, DOI 10.7326/M16-1565; Cook TM, 2020, ANAESTHESIA, V75, P920, DOI 10.1111/anae.15071; DUGUID JP, 1946, J HYG-CAMBRIDGE, V44, P471, DOI 10.1017/S0022172400019288; El Sharkawi A, 2002, J NEUROL NEUROSUR PS, V72, P31; Fairbanks G., 1960, VOICE ARTICULATION D; Georgiou GP, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.109937; Giovanni A, 2021, EUR ARCH OTO-RHINO-L, V278, P1687, DOI 10.1007/s00405-020-06200-7; Gralton J, 2011, J INFECTION, V62, P1, DOI 10.1016/j.jinf.2010.11.010; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P173, DOI 10.1016/j.jclinepi.2012.08.001; Holmgren H, 2010, J AEROSOL SCI, V41, P439, DOI 10.1016/j.jaerosci.2010.02.011; Hui DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050845; Johnson GR, 2011, J AEROSOL SCI, V42, P839, DOI 10.1016/j.jaerosci.2011.07.009; Johnson GR, 2009, J AEROSOL MED PULM D, V22, P229, DOI 10.1089/jamp.2008.0720; Kempster GB, 2009, AM J SPEECH-LANG PAT, V18, P124, DOI 10.1044/1058-0360(2008/08-0017); Kinross P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.11.2000285; Knottnerus A, 2008, J CLIN EPIDEMIOL, V61, P323, DOI 10.1016/j.jclinepi.2007.11.006; Kohanski MA, 2020, INT FORUM ALLERGY RH, V10, P1173, DOI 10.1002/alr.22661; Lee J, 2019, AEROSOL AIR QUAL RES, V19, P840, DOI 10.4209/aaqr.2018.01.0031; Lindsley WG, 2016, INFLUENZA OTHER RESP, V10, P404, DOI 10.1111/irv.12390; Lindsley WG, 2012, J OCCUP ENVIRON HYG, V9, P443, DOI 10.1080/15459624.2012.684582; Mattei A, 2020, EUR ANN OTORHINOLARY, V137, P173, DOI 10.1016/j.anorl.2020.04.011; Mick P, 2020, J OTOLARYNGOL-HEAD N, V49, DOI 10.1186/s40463-020-00424-7; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Morawska L, 2009, J AEROSOL SCI, V40, P256, DOI 10.1016/j.jaerosci.2008.11.002; Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730; Naunheim MR, 2021, J VOICE, V35, P765, DOI 10.1016/j.jvoice.2020.06.028; Nicas M, 2009, RISK ANAL, V29, P1292, DOI 10.1111/j.1539-6924.2009.01253.x; Papineni RS, 1996, J AEROSOL MED, V10, P105, DOI 10.1089/jam.1997.10.105; Pasnick Susan, 2020, Am J Respir Crit Care Med, DOI 10.1164/rccm.2020C11; Qureshi Z, 2020, WHAT IS EVIDENCE SUP; RCSLT, GUID RED RISK TRANSM; Santesso N, 2016, J CLIN EPIDEMIOL, V74, P28, DOI 10.1016/j.jclinepi.2015.12.006; Schunemann HJ, 2020, ANN INTERN MED, V173, P204, DOI 10.7326/M20-2306; SPA, 2020, GUID SERV DEL CLIN P; Stelzer-Braid S, 2009, J MED VIROL, V81, P1674, DOI 10.1002/jmv.21556; Tang JW, 2006, J HOSP INFECT, V64, P100, DOI 10.1016/j.jhin.2006.05.022; Tang JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034818; Tang JW, 2009, J R SOC INTERFACE, V6, pS727, DOI 10.1098/rsif.2009.0295.focus; Vergara J, 2020, AM J SPEECH-LANG PAT, V29, P2242, DOI 10.1044/2020_AJSLP-20-00163; Viswanath Aparna, 2020, J Clin Orthop Trauma, V11, P500, DOI 10.1016/j.jcot.2020.03.014; Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093; Wilson N, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3206; Wolfel R, 2020, NATURE, V581, P465, DOI 10.1038/s41586-020-2196-x; Xie XJ, 2009, J R SOC INTERFACE, V6, pS703, DOI 10.1098/rsif.2009.0388.focus; Xu RB, 2020, IEEE PHOTONICS J, V12, DOI [10.1109/JPHOT.2020.2979564, 10.1038/s41368-020-0080-z]; Yang SH, 2007, J AEROSOL MED, V20, P484, DOI 10.1089/jam.2007.0610; You SH, 2013, J EPIDEMIOL, V23, P251, DOI 10.2188/jea.JE20120031; Yu FT, 2020, CLIN INFECT DIS, V71, P793, DOI 10.1093/cid/ciaa345; Zayas G, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-11; Zemouri C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178007; Zhu SW, 2006, BUILD ENVIRON, V41, P1691, DOI 10.1016/j.buildenv.2005.06.024	63	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2021	16	4							e0250308	10.1371/journal.pone.0250308	http://dx.doi.org/10.1371/journal.pone.0250308			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ST0XL	33909654	Green Published, gold			2023-01-03	WOS:000662174400045
J	Stone, P; Vickerstaff, V; Kalpakidou, A; Todd, C; Griffiths, J; Keeley, V; Spencer, K; Buckle, P; Finlay, D; Omar, RZ				Stone, P.; Vickerstaff, V.; Kalpakidou, A.; Todd, C.; Griffiths, J.; Keeley, V.; Spencer, K.; Buckle, P.; Finlay, D.; Omar, R. Z.			Prognostic tools or clinical predictions: Which are better in palliative care?	PLOS ONE			English	Article							ADVANCED CANCER-PATIENTS; SURVIVAL PREDICTION; SCORE; VALIDATION; ACCURACY; INDEX; PERFORMANCE	Purpose The Palliative Prognostic (PaP) score; Palliative Prognostic Index (PPI); Feliu Prognostic Nomogram (FPN) and Palliative Performance Scale (PPS) have all been proposed as prognostic tools for palliative cancer care. However, clinical judgement remains the principal way by which palliative care professionals determine prognoses and it is important that the performance of prognostic tools is compared against clinical predictions of survival (CPS). Methods This was a multi-centre, cohort validation study of prognostic tools. Study participants were adults with advanced cancer receiving palliative care, with or without capacity to consent. Key prognostic data were collected at baseline, shortly after referral to palliative care services. CPS were obtained independently from a doctor and a nurse. Results Prognostic data were collected on 1833 participants. All prognostic tools showed acceptable discrimination and calibration, but none showed superiority to CPS. Both PaP and CPS were equally able to accurately categorise patients according to their risk of dying within 30 days. There was no difference in performance between CPS and FPN at stratifying patients according to their risk of dying at 15, 30 or 60 days. PPI was significantly (p<0.001) worse than CPS at predicting which patients would survive for 3 or 6 weeks. PPS and CPS were both able to discriminate palliative care patients into multiple iso-prognostic groups. Conclusions Although four commonly used prognostic algorithms for palliative care generally showed good discrimination and calibration, none of them demonstrated superiority to CPS. Prognostic tools which are less accurate than CPS are of no clinical use. However, prognostic tools which perform similarly to CPS may have other advantages to recommend them for use in clinical practice (e.g. being more objective, more reproducible, acting as a second opinion or as an educational tool). Future studies should therefore assess the impact of prognostic tools on clinical practice and decision-making.	[Stone, P.; Vickerstaff, V.; Kalpakidou, A.; Buckle, P.; Finlay, D.] Univ Coll London UCL, Div Psychiat, Marie Curie Palliat Care Res Dept, London, England; [Todd, C.; Griffiths, J.; Spencer, K.] Univ Manchester, Sch Hlth Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Todd, C.; Griffiths, J.; Spencer, K.] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Todd, C.] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England; [Keeley, V.] Univ Hosp Derby & Burton NHS Fdn Trust, Palliat Med Dept, Derby, England; [Omar, R. Z.] Univ Coll London UCL, Dept Stat Sci, London, England	University of London; University College London; University of Manchester; University of Manchester; University of London; University College London	Stone, P (corresponding author), Univ Coll London UCL, Div Psychiat, Marie Curie Palliat Care Res Dept, London, England.	p.stone@ucl.ac.uk	Todd, Chris/AAD-8661-2022; Todd, Chris/A-7904-2010	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Vickerstaff, Victoria/0000-0002-3119-670X; Stone, Patrick/0000-0002-5765-9047; Omar, Rumana/0000-0003-1483-1932	National Institute for Health Research, Health Technology Assessment (HTA) programme (NIHR-HTA) [13/20/01]; Joint Research Office at UCL	National Institute for Health Research, Health Technology Assessment (HTA) programme (NIHR-HTA); Joint Research Office at UCL	This paper presents independent research funded by the National Institute for Health Research, Health Technology Assessment (HTA) programme (NIHR-HTA 13/20/01). Awarded to PS, CT, JG, VK and RO. The Study Sponsor was the Joint Research Office at UCL https://www.ucl.ac.uk/joint-research-office/).The funders and sponsor had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson F, 1996, J PALLIAT CARE, V12, P5, DOI 10.1177/082585979601200102; Baba M, 2015, EUR J CANCER, V51, P1618, DOI 10.1016/j.ejca.2015.04.025; Chen CH, 2017, PALLIATIVE MED, V31, P406, DOI 10.1177/0269216316663976; Cheng WH, 2012, ASIAN PAC J CANCER P, V13, P2861, DOI 10.7314/APJCP.2012.13.6.2861; Chu CT, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-019-0698-2; Ermacora P., 2015, SUPPORT CARE CANCER, V1, pS77; Ermacora P, 2019, SUPPORT CARE CANCER, V27, P2095, DOI 10.1007/s00520-018-4463-z; Farinholt P, 2018, J PAIN SYMPTOM MANAG, V55, P792, DOI 10.1016/j.jpainsymman.2017.11.028; Feliu J, 2011, JNCI-J NATL CANCER I, V103, P1613, DOI 10.1093/jnci/djr388; Glare PA, 2004, J CLIN ONCOL, V22, P4823, DOI 10.1200/JCO.2004.12.056; Gwilliam B, 2013, ANN ONCOL, V24, P482, DOI 10.1093/annonc/mds341; Gwilliam B, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4920; Hagerty RG, 2005, ANN ONCOL, V16, P1005, DOI 10.1093/annonc/mdi211; Harrell F, 2015, LOGISTIC ORDINAL REG, V1st, P92; Hui D, 2020, PALLIATIVE MED, V34, P126, DOI 10.1177/0269216319873261; Hui D, 2019, SUPPORT CARE CANCER, V27, P1973, DOI 10.1007/s00520-019-04727-y; Hui D, 2016, EUR J CANCER, V64, P89, DOI 10.1016/j.ejca.2016.05.009; Innes S, 2009, PALLIATIVE MED, V23, P29, DOI 10.1177/0269216308098799; Kaasa S, 2018, LANCET ONCOL, V19, pE588, DOI 10.1016/S1470-2045(18)30415-7; Kalpakidou AK, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0352-y; Kaplowitz SA, 2002, HEALTH COMMUN, V14, P221, DOI 10.1207/S15327027HC1402_4; Kirk P, 2004, BMJ-BRIT MED J, V328, P1343, DOI 10.1136/bmj.38103.423576.55; Lau F, 2009, J PAIN SYMPTOM MANAG, V38, P134, DOI 10.1016/j.jpainsymman.2008.05.017; Maltoni M, 1999, J PAIN SYMPTOM MANAG, V17, P240, DOI 10.1016/S0885-3924(98)00146-8; Maltoni M, 2005, J CLIN ONCOL, V23, P6240, DOI 10.1200/JCO.2005.06.866; Maltoni M, 2012, ONCOLOGIST, V17, P446, DOI 10.1634/theoncologist.2011-0397; Morita T, 1999, SUPPORT CARE CANCER, V7, P128, DOI 10.1007/s005200050242; Morita T, 2001, PALLIATIVE MED, V15, P419, DOI 10.1191/026921601680419474; Nicholson TRJ, 2008, BRIT MED J, V336, P322, DOI 10.1136/bmj.39457.485347.80; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pirovano M, 1999, J PAIN SYMPTOM MANAG, V17, P231, DOI 10.1016/S0885-3924(98)00145-6; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Stiel S, 2010, SUPPORT CARE CANCER, V18, P43, DOI 10.1007/s00520-009-0628-0; Stone CA, 2008, J PAIN SYMPTOM MANAG, V35, P617, DOI 10.1016/j.jpainsymman.2007.07.006; Stone P., 2021, HEALTH TECHNOL ASSES, V25, P1, DOI [10.3310/hta25280, DOI 10.3310/HTA25280]; Tavares T, 2018, PALLIATIVE MED, V32, P413, DOI 10.1177/0269216317705788; Temel JS, 2011, J CLIN ONCOL, V29, P2319, DOI 10.1200/JCO.2010.32.4459; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; White N, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0907-4; White N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161407	41	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2021	16	4							e0249763	10.1371/journal.pone.0249763	http://dx.doi.org/10.1371/journal.pone.0249763			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XL	33909658	gold, Green Published			2023-01-03	WOS:000662174400021
J	Anand, S; Montez-Rath, ME; Han, JL; Garcia, P; Bozeman, J; Kerschmann, R; Beyer, P; Parsonnet, J; Chertow, GM				Anand, Shuchi; Montez-Rath, Maria E.; Han, Jialin; Garcia, Pablo; Bozeman, Julie; Kerschmann, Russell; Beyer, Paul; Parsonnet, Julie; Chertow, Glenn M.			Laboratory correlates of SARS-CoV-2 seropositivity in a nationwide sample of patients on dialysis in the US	PLOS ONE			English	Article							HEPATITIS-B VACCINE; SERUM-ALBUMIN; PERITONEAL-DIALYSIS; PARATHYROID-HORMONE; HEMODIALYSIS; MORTALITY; PREDICTOR; SURVIVAL; DISEASE; RISK	Patients on dialysis are at high risk for death due to COVID-19, yet a significant proportion do survive as evidenced by presence of SARS-CoV-2 antibodies in 8% of patients in the U.S. in July 2020. It is unclear whether patients with seropositivity represent the subgroup with robust health status, who would be more likely to mount a durable antibody response. Using data from a July 2020 sample of 28,503 patients receiving dialysis, we evaluated the cross-sectional association of SARS-CoV-2 seropositivity with laboratory surrogates of patient health. In separate logistic regression models, we assessed the association of SARS-CoV-2 seropositivity with seven laboratory-based covariates (albumin, creatinine, hemoglobin, sodium, potassium, phosphate, and parathyroid hormone), across the entire range of the laboratory and in comparison to a referent value. Models accounted for age, sex, region, race and ethnicity, and county-level COVID-19 deaths per 100,000. Odds of seropositivity for albumin 3 and 3.5 g/dL were 2.1 (95% CI 1.9-2.3) and 1.3 (1.2-1.4) respectively, compared with 4 g/dL. Odds of seropositivity for serum creatinine 5 and 8 mg/dL were 1.8 (1.6-2.0) and 1.3 (1.2-1.4) respectively, compared with 12.5 mg/dL. Lower values of hemoglobin, sodium, potassium, phosphate, and parathyroid hormone were associated with higher odds of seropositivity. Laboratory values associated with poorer health status and higher risk for mortality were also associated with higher likelihood of SARS-CoV-2 antibodies in patients receiving dialysis.	[Anand, Shuchi; Montez-Rath, Maria E.; Han, Jialin; Garcia, Pablo; Chertow, Glenn M.] Stanford Univ, Dept Med, Div Nephrol, Sch Med, Palo Alto, CA 94304 USA; [Bozeman, Julie; Kerschmann, Russell; Beyer, Paul] Ascend Clin Lab, Redwood City, CA USA; [Parsonnet, Julie] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Sch Med, Palo Alto, CA 94304 USA; [Parsonnet, Julie; Chertow, Glenn M.] Stanford Univ, Dept Epidemiol & Populat Hlth, Sch Med, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University	Anand, S (corresponding author), Stanford Univ, Dept Med, Div Nephrol, Sch Med, Palo Alto, CA 94304 USA.	sanand2@stanford.edu	Han, Jialin/AFQ-6523-2022	Chertow, Glenn/0000-0002-7599-0534; Parsonnet, Julie/0000-0001-7342-5366; han, Jialin/0000-0001-5731-8974; Garcia, Pablo/0000-0002-8482-8192	National Institutes of Diabetes, and Digestive and Kidney Diseases [5K23DK101826]	National Institutes of Diabetes, and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported in the form of a career development grant from the National Institutes of Diabetes, and Digestive and Kidney Diseases (Grant No. 5K23DK101826) awarded to SA. Ascend Clinical Laboratories provided support in the form of salaries for authors JK, RK, and PB. The specific roles of these authors are articulated in the `author contributions' section. Ascend Clinical Laboratories supported the remainder plasma testing for SARS-CoV2 antibodies. The funders had no additional role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Abelson R., 2020, NY TIMES; Aburawi EH, 2006, ANN MED, V38, P154, DOI 10.1080/07853890500358343; Alberici F, 2020, KIDNEY INT, V98, P20, DOI 10.1016/j.kint.2020.04.030; Anand S, 2020, LANCET, V396, P1335, DOI 10.1016/S0140-6736(20)32009-2; Avram MM, 1996, AM J KIDNEY DIS, V28, P924, DOI 10.1016/S0272-6386(96)90396-0; Avram MM, 2001, AM J KIDNEY DIS, V37, pS77, DOI 10.1053/ajkd.2001.20754; Avram MM, 2001, AM J KIDNEY DIS, V38, P1351, DOI 10.1053/ajkd.2001.29254; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Broeders NE, 2011, CLIN J AM SOC NEPHRO, V6, P2573, DOI 10.2215/CJN.04670511; BUTI M, 1992, AM J NEPHROL, V12, P144, DOI 10.1159/000168436; Center for Medicare and Medicaid Services, 2020, PRELIMINARY MEDICARE; Centers for Disease Control and Prevention, 2020, NATIONWIDE COMMERICA; Clarke C, 2020, J AM SOC NEPHROL, V31, P1969, DOI 10.1681/ASN.2020060827; Couchoud C, 2020, KIDNEY INT, V98, P1519, DOI 10.1016/j.kint.2020.07.042; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Edey M, 2010, NEPHROLOGY, V15, P137, DOI 10.1111/j.1440-1797.2009.01268.x; Flythe JE, 2021, AM J KIDNEY DIS, V77, P190, DOI 10.1053/j.ajkd.2020.09.003; Fu Y, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01190-2020; Gauthier J, 2020, BONE MARROW TRANSPL, V55, P675, DOI 10.1038/s41409-019-0679-x; Gelman A., 2007, DATA ANAL USING REGR; Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031; Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; ISEKI K, 1993, KIDNEY INT, V44, P115, DOI 10.1038/ki.1993.220; Jager KJ, 2020, RESULTS ERA EDTA REG; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Kato H, 2020, J INFECT CHEMOTHER, V26, P865, DOI 10.1016/j.jiac.2020.05.005; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Leavey SF, 1998, AM J KIDNEY DIS, V31, P997, DOI 10.1053/ajkd.1998.v31.pm9631845; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Ng JH, 2020, KIDNEY INT, V98, P1530, DOI 10.1016/j.kint.2020.07.030; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Peces R, 1997, AM J KIDNEY DIS, V29, P239, DOI 10.1016/S0272-6386(97)90036-6; Rocco MV, 1996, J AM SOC NEPHROL, V7, P889; Roltgen Katharina, 2020, medRxiv, DOI 10.1101/2020.08.15.20175794; Sanchez E, 2020, MANAGEMENT HEMODIALY; Sosa R, 2021, KIDNEY INT REP, V6, P1110, DOI 10.1016/j.ekir.2021.01.028; Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0; Sun LG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16242-3; Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213; U.S. Food & Drug Administration, 2020, EUA AUTHORIZED SEROL; Wang Y, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23412; Wi YM, 2014, INT J CLIN PRACT, V68, P222, DOI [10.1111/ijcp.12249, 10.1111/ijcp.12368]; Xia H, 1999, J AM SOC NEPHROL, V10, P1309	45	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2021	16	4							e0249466	10.1371/journal.pone.0249466	http://dx.doi.org/10.1371/journal.pone.0249466			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP1DC	33857168	Green Published, gold			2023-01-03	WOS:000641474900044
J	Li, Y; Gao, YZ; Liu, XG; Shi, J; Xia, JW; Yang, JC; Mao, LJ				Li, Yue; Gao, Yunzhe; Liu, Xinguo; Shi, Jian; Xia, Jiawen; Yang, Jiancheng; Mao, Lijun			The influence of beam delivery uncertainty on dose uniformity and penumbra for pencil beam scanning in carbon-ion radiotherapy	PLOS ONE			English	Article							FLUKA CODE; PROTON; SYSTEM; MODEL; IRRADIATION; PERFORMANCE; THERAPY; DESIGN	The dose uniformity and penumbra in the treatment field are important factors in radiotherapy, which affects the outcomes of radiotherapy. In this study, the integrated depth-dose-distributions (IDDDs) of 190 MeV/u and 260 MeV/u carbon beams in the active spot-scanning delivery system were measured and calculated by FLUKA Monte Carlo simulation based on the Heavy Ion Medical Machine (HIMM). Considering the dose distributions caused by secondary particles and scattering, we also used different types of pencil beam (PB) models to fit and compare the spatial distributions of PB. We superposed a bunch of PB to form a 20x20 cm(2) treatment field with the double Gaussian and double Gaussian logistic beam models and calculated the influence of beam delivery error on the field flatness and penumbra, respectively. The simulated IDDDs showed good agreement with the measured values. The triple Gaussian and double Gaussian logistic beam models have good fitness to the simulated dose distributions. There are different influences on dose uniformity and penumbra resulting from beam uncertainties. These results would be helpful for understanding carbon ion therapy, and physical therapists are more familiar with beam characteristics for active scanning therapy, which provides a reference for commissioning and optimization of treatment plans in radiotherapy.	[Li, Yue; Gao, Yunzhe; Liu, Xinguo; Shi, Jian; Xia, Jiawen; Yang, Jiancheng; Mao, Lijun] Chinese Acad Sci, Inst Modern Phys, Lanzhou, Peoples R China; [Li, Yue; Gao, Yunzhe; Xia, Jiawen] Univ Chinese Acad Sci, Beijing, Peoples R China; [Gao, Yunzhe; Xia, Jiawen] Huizhou Res Ctr Ion Sci, Huizhou, Peoples R China	Chinese Academy of Sciences; Institute of Modern Physics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Mao, LJ (corresponding author), Chinese Acad Sci, Inst Modern Phys, Lanzhou, Peoples R China.	maolijun@impcas.ac.cn		Mao, Lijun/0000-0002-0023-8217	Guangdong Innovative and Entrepreneurial Research Team Program [2016ZT06G373]	Guangdong Innovative and Entrepreneurial Research Team Program	Guangdong Innovative and Entrepreneurial Research Team Program (No. 2016ZT06G373).	Almhagen E, 2018, PHYS MEDICA, V52, P27, DOI 10.1016/j.ejmp.2018.06.007; [Anonymous], 2016, NUCL TECHNIQUES, DOI [DOI 10.11889/J.0253-3219.2016.HJS.39.090202, 10.11889/j.0253-3219.2016.hjs.39.090202]; Battistoni G, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00116; Battistoni G, 2015, ANN NUCL ENERGY, V82, P10, DOI 10.1016/j.anucene.2014.11.007; Bohlen TT, 2014, NUCL DATA SHEETS, V120, P211, DOI 10.1016/j.nds.2014.07.049; Chun-Hui Miao, 2017, Nuclear Science and Techniques, V28, DOI 10.1007/s41365-017-0324-6; Dai ZY, 2012, CHINESE PHYS C, V36, P784, DOI 10.1088/1674-1137/36/8/018; Durante M, 2010, NAT REV CLIN ONCOL, V7, P37, DOI 10.1038/nrclinonc.2009.183; Dvorak P, 2018, CLIN RADIOTHERAPY PH; Furukawa T, 2007, MED PHYS, V34, P1085, DOI 10.1118/1.2558213; Furukawa T, 2010, MED PHYS, V37, P5672, DOI 10.1118/1.3501313; Grevillot L, 2015, PHYS MED BIOL, V60, P7985, DOI 10.1088/0031-9155/60/20/7985; Gudowska I, 2004, PHYS MED BIOL, V49, P1933, DOI 10.1088/0031-9155/49/10/008; HABERER T, 1993, NUCL INSTRUM METH A, V330, P296, DOI 10.1016/0168-9002(93)91335-K; Hara Y, 2014, MED PHYS, V41, DOI 10.1118/1.4860256; Lanca L, 2014, RADIOGRAPHY, V20, P333, DOI 10.1016/j.radi.2014.04.007; Liu HD, 2017, EPJ WEB CONF, V153, DOI 10.1051/epjconf/201715304018; Matsumoto S, 2019, MED PHYS, V46, P5824, DOI 10.1002/mp.13864; Mirandola A, 2018, MED PHYS, V45, P2266, DOI 10.1002/mp.12866; Mirandola A, 2015, MED PHYS, V42, P5287, DOI 10.1118/1.4928397; Parodi K, 2012, PHYS MED BIOL, V57, P3759, DOI 10.1088/0031-9155/57/12/3759; Parodi K, 2013, J RADIAT RES, V54, P91, DOI 10.1093/jrr/rrt051; Saini J, 2018, TRANSL LUNG CANCER R, V7, P171, DOI 10.21037/tlcr.2018.04.05; Schwaab J, 2011, PHYS MED BIOL, V56, P7813, DOI 10.1088/0031-9155/56/24/009; Titt U, 2010, PHYS MED BIOL, V55, P7097, DOI 10.1088/0031-9155/55/23/S10; Torikoshi M, 2007, J RADIAT RES, V48, pA15, DOI 10.1269/jrr.48.A15; Vlachoudis V., FLAIR POWERFUL USER; Xing Y, 2017, MED PHYS, V44, P6047, DOI 10.1002/mp.12569; Yan YL, 2017, CHINESE PHYS C, V41, DOI 10.1088/1674-1137/41/9/098201; Yonai S, 2012, MED PHYS, V39, P5028, DOI 10.1118/1.4736823; Yu J, 2014, MED PHYS, V41, P96, DOI 10.1118/1.4885956; Zhang H, 2018, PHYS MEDICA, V55, P15, DOI 10.1016/j.ejmp.2018.10.014; Zhou J, 2020, PHYS MED BIOL, V65, DOI 10.1088/1361-6560/ab81ca	33	1	1	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2021	16	4							e0249452	10.1371/journal.pone.0249452	http://dx.doi.org/10.1371/journal.pone.0249452			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH8NB	33793680	gold, Green Published			2023-01-03	WOS:000636467000077
J	Huang, CY; Chang, YJ; Wei, PL; Hung, CS; Wang, W				Huang, Chien-Yu; Chang, Yu-Jia; Wei, Po-Li; Hung, Chin-Sheng; Wang, Weu			Methyl gallate, gallic acid-derived compound, inhibit cell proliferation through increasing ROS production and apoptosis in hepatocellular carcinoma cells	PLOS ONE			English	Article							INDUCED OXIDATIVE STRESS; ENDOPLASMIC-RETICULUM STRESS; KILKA FISH-OIL; METHYL-3-O-METHYL GALLATE; CANCER STATISTICS; NITRIC-OXIDE; AUTOPHAGY; DEATH; ANTIOXIDANT; INDUCTION	Hepatocellular carcinoma (HCC) is a global health problem. Currently, there is no effective therapeutic strategy for HCC. Methyl gallate (MG), from plant-derived phenolic gallic acid, has exhibited antitumor efficacy. However, the effect of MG on HCC is unclear. In vitro growth activity was detected by a sulforhodamine assay. A zebrafish xenotransplantation was applied to evaluate the inhibitory effect of MG. Reactive oxygen species (ROS) production, autophagy, and lysosome formation were detected by specific dyes. Finally, apoptosis was examined using annexin V-FITC/PI staining and western blot was performed to determine the molecular mechanism. It was demonstrated that MG treatment inhibited the proliferation of Hep3B, Mahlavu, and HepJ5 cells. Xenotransplantation also showed that MG inhibited the growth of Hep3B and HepJ5 cells. MG treatment increased cellular levels of superoxide and oxidative stress. Increases in autophagy and lysosome formation were found after MG treatment. The western blot analysis showed that MG activated cleavage of caspase-3 and poly (SDP ribose) polymerase (PARP), modulated levels of the Bcl2, Bax, and Bad ligands, and induced apoptosis. MG induced autophagy with notable activation of beclin-1, autophagy related 5+12 (ATG5+12), and conversion of light chain 3-I (LC3-I) to II. Our study showed that MG exposure inhibited HCC proliferation both in vitro and in vivo. And blocking autophagy enhanced MG-induced cytotoxicity in HCC cells. These findings suggested MG might serve as a powerful therapeutic supplement for human HCC patients.	[Huang, Chien-Yu; Wei, Po-Li; Hung, Chin-Sheng; Wang, Weu] Taipei Med Univ, Coll Med, Sch Med, Dept Surg, Taipei, Taiwan; [Huang, Chien-Yu; Hung, Chin-Sheng] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Huang, Chien-Yu] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Colorectal Surg, Taipei, Taiwan; [Huang, Chien-Yu] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan; [Chang, Yu-Jia] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Chang, Yu-Jia] Taipei Med Univ, Wan Fang Hosp, Cell Physiol & Mol Image Res Ctr, Taipei, Taiwan; [Wei, Po-Li] Taipei Med Univ, Taipei Med Univ Hosp, Dept Surg, Div Colorectal Surg, Taipei, Taiwan; [Wei, Po-Li] Taipei Med Univ, Taipei Med Univ Hosp, Canc Res Ctr, Taipei, Taiwan; [Wei, Po-Li] Taipei Med Univ, Taipei Med Univ Hosp, Translat Lab, Taipei, Taiwan; [Wei, Po-Li] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan	Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University	Wang, W (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Surg, Taipei, Taiwan.; Chang, YJ (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.; Chang, YJ (corresponding author), Taipei Med Univ, Wan Fang Hosp, Cell Physiol & Mol Image Res Ctr, Taipei, Taiwan.	r5424012@tmu.edu.tw; wangweu@tmu.edu.tw			PL WEI MOST [108MOST-00-1223-1]	PL WEI MOST	PL WEI MOST grants (108MOST-00-1223-1).	Anwanwan D, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2019.188314; Asnaashari M, 2016, J SCI FOOD AGR, V96, P4594, DOI 10.1002/jsfa.7677; Asnaashari M, 2014, FOOD CHEM, V159, P439, DOI 10.1016/j.foodchem.2014.03.038; Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32; Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049; Cabrera R, 2010, ALIMENT PHARM THER, V31, P461, DOI 10.1111/j.1365-2036.2009.04200.x; Chan AWH, 2018, J HEPATOL, V69, P1284, DOI 10.1016/j.jhep.2018.08.027; Chang YJ, 2011, ANN SURG ONCOL, V18, P2395, DOI 10.1245/s10434-011-1597-3; Chen C, 2017, NITRIC OXIDE-BIOL CH, V70, P31, DOI 10.1016/j.niox.2017.07.005; Chen CH, 2011, FOOD CHEM TOXICOL, V49, P494, DOI 10.1016/j.fct.2010.11.031; Chen XP, 2012, NEURAL REGEN RES, V7, P376, DOI 10.3969/j.issn.1673-5374.2012.05.009; Cheng P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.17; Choi JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102697; Choi JG, 2009, MOLECULES, V14, P1773, DOI 10.3390/molecules14051773; Crispo JAG, 2010, BIOCHEM BIOPH RES CO, V393, P773, DOI 10.1016/j.bbrc.2010.02.079; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; El-Serag HB, 2008, GASTROENTEROLOGY, V134, P1752, DOI 10.1053/j.gastro.2008.02.090; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fan HJ, 2014, TARGET ONCOL, V9, P279, DOI 10.1007/s11523-013-0286-5; Fang JP, 2012, GLYCOCONJUGATE J, V29, P365, DOI 10.1007/s10719-012-9416-z; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Habtemariam S, 2011, J MED FOOD, V14, P1412, DOI 10.1089/jmf.2010.0257; Hsieh TJ, 2004, FOOD CHEM TOXICOL, V42, P843, DOI 10.1016/j.fct.2004.01.008; Jacobi H, 1998, FREE RADICAL BIO MED, V24, P972, DOI 10.1016/S0891-5849(97)00400-0; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kamatham S, 2015, TOXICOL REP, V2, P520, DOI 10.1016/j.toxrep.2015.03.001; Kang MS, 2009, J MICROBIOL, V47, P760, DOI 10.1007/s12275-009-0097-7; Kang MS, 2008, J MICROBIOL, V46, P744, DOI 10.1007/s12275-008-0235-7; Khurana S, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/657512; Kim H, 2016, KOREAN J PHYSIOL PHA, V20, P261, DOI 10.4196/kjpp.2016.20.3.261; Kim SH, 2017, ONCOTARGET, V8, P111581, DOI 10.18632/oncotarget.22875; Lee H, 2010, J IMMUNOL, V185, P6698, DOI 10.4049/jimmunol.1001373; Lee SH, 2013, BBA-GEN SUBJECTS, V1830, P4017, DOI 10.1016/j.bbagen.2013.03.030; Liang HH, 2013, TUMOR BIOL, V34, P3209, DOI 10.1007/s13277-013-0891-z; Liu WL, 2018, INT J MOL MED, V41, P2028, DOI 10.3892/ijmm.2018.3412; Liu YX, 2018, BIOCHEM BIOPH RES CO, V498, P246, DOI 10.1016/j.bbrc.2018.01.091; Liu ZK, 2017, CELL PHYSIOL BIOCHEM, V44, P1856, DOI 10.1159/000485821; Luo KW, 2011, CHEMOTHERAPY, V57, P449, DOI 10.1159/000331641; Maheswari U, 2018, APOPTOSIS, V23, P210, DOI 10.1007/s10495-018-1449-8; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Makhov P, 2014, BRIT J CANCER, V110, P899, DOI 10.1038/bjc.2013.810; Marchi Saverio, 2012, J Signal Transduct, V2012, P329635, DOI 10.1155/2012/329635; Markkanen E, 2017, DNA REPAIR, V59, P82, DOI 10.1016/j.dnarep.2017.09.007; Monteiro HP, 2019, NITRIC OXIDE-BIOL CH, V89, P1, DOI 10.1016/j.niox.2019.04.009; Nabavi SF, 2013, CELL MOL NEUROBIOL, V33, P261, DOI 10.1007/s10571-012-9893-4; Nabavi SM, 2013, J PHARM PHARMACOL, V65, P868, DOI 10.1111/jphp.12048; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Poetsch AR, 2020, COMPUT STRUCT BIOTEC, V18, P207, DOI 10.1016/j.csbj.2019.12.013; Rahman N, 2016, BIOFACTORS, V42, P716, DOI 10.1002/biof.1310; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Reddy DB, 2009, J ETHNOPHARMACOL, V124, P506, DOI 10.1016/j.jep.2009.05.022; Shehta A, 2016, SURG ONCOL, V25, P364, DOI 10.1016/j.suronc.2016.08.002; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Stauffer JK, 2012, HEPATOLOGY, V56, P1567, DOI 10.1002/hep.25674; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Trevisani F, 2008, CARCINOGENESIS, V29, P1299, DOI 10.1093/carcin/bgn113; Wang RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139232; Wang WL, 2015, CANCER LETT, V358, P47, DOI 10.1016/j.canlet.2014.12.025; Wang YB, 2017, EBIOMEDICINE, V17, P45, DOI 10.1016/j.ebiom.2017.02.019; Whang WK, 2005, EXP MOL MED, V37, P343, DOI 10.1038/emm.2005.44; Winter E, 2014, TOXICOL IN VITRO, V28, P769, DOI 10.1016/j.tiv.2014.02.002; Yamashita Tatsuya, 2016, Rinsho Byori, V64, P787; Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013	64	13	13	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2021	16	3							e0248521	10.1371/journal.pone.0248521	http://dx.doi.org/10.1371/journal.pone.0248521			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY1VJ	33725002	gold, Green Published			2023-01-03	WOS:000629833700032
J	Daunys, G; Sukiene, L; Vaitkevicius, L; Valiulis, G; Sofiev, M; Sauliene, I				Daunys, Gintautas; Sukiene, Laura; Vaitkevicius, Lukas; Valiulis, Gediminas; Sofiev, Mikhail; Sauliene, Ingrida			Clustering approach for the analysis of the fluorescent bioaerosol collected by an automatic detector	PLOS ONE			English	Article							AIRBORNE POLLEN; PINACEAE POLLEN; IDENTIFICATION; DISPERSION; SITES	Automatically operating particle detection devices generate valuable data, but their use in routine aerobiology needs to be harmonized. The growing network of researchers using automatic pollen detectors has the challenge to develop new data processing systems, best suited for identification of pollen or spore from bioaerosol data obtained near-real-time. It is challenging to recognise all the particles in the atmospheric bioaerosol due to their diversity. In this study, we aimed to find the natural groupings of pollen data by using cluster analysis, with the intent to use these groupings for further interpretation of real-time bioaerosol measurements. The scattering and fluorescence data belonging to 29 types of pollen and spores were first acquired in the laboratory using Rapid-E automatic particle detector. Neural networks were used for primary data processing, and the resulting feature vectors were clustered for scattering and fluorescence modality. Scattering clusters results showed that pollen of the same plant taxa associates with the different clusters corresponding to particle shape and size properties. According to fluorescence clusters, pollen grouping highlighted the possibility to differentiate Dactylis and Secale genera in the Poaceae family. Fluorescent clusters played a more important role than scattering for separating unidentified fluorescent particles from tested pollen. The proposed clustering method aids in reducing the number of false-positive errors.	[Daunys, Gintautas; Sukiene, Laura; Vaitkevicius, Lukas; Valiulis, Gediminas; Sofiev, Mikhail; Sauliene, Ingrida] Vilnius Univ, Siauliai Acad, Shiauliai, Lithuania; [Sofiev, Mikhail] Finish Meteorol Inst, Helsinki, Finland	Vilnius University	Sauliene, I (corresponding author), Vilnius Univ, Siauliai Acad, Shiauliai, Lithuania.	ingrida.sauliene@sa.vu.lt	Sauliene, Ingrida/J-9320-2019; Šukienė, Laura/AAJ-1261-2021; Daunys, Gintautas/F-6870-2014	Sauliene, Ingrida/0000-0003-0250-1127; Šukienė, Laura/0000-0002-8273-7182; Daunys, Gintautas/0000-0003-2295-2881	European Social Fund [09.3.3-LMT-K712-01-0066]; Research Council of Lithuania (LMTLT)	European Social Fund(European Social Fund (ESF)); Research Council of Lithuania (LMTLT)(Research Council of Lithuania (LMTLT))	This research has been supported by the European Social Fund (project no. 09.3.3-LMT-K712-01-0066) under grant agreement with the Research Council of Lithuania (LMTLT).	Alcazar P, 2019, AEROBIOLOGIA, V35, P269, DOI 10.1007/s10453-019-09558-2; Bagcioglu M, 2017, METHODS ECOL EVOL, V8, P870, DOI 10.1111/2041-210X.12697; Bogawski P, 2019, SCI TOTAL ENVIRON, V689, P109, DOI 10.1016/j.scitotenv.2019.06.348; Buters JTM, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0197-8; Chappuis C, 2020, AEROBIOLOGIA, V36, P159, DOI 10.1007/s10453-019-09619-6; Clot B, 2020, AEROBIOLOGIA, DOI 10.1007/s10453-020-09666-4; Core Team, R LANG ENV STAT COMP; Crouzy B, 2016, ATMOS ENVIRON, V140, P202, DOI 10.1016/j.atmosenv.2016.05.062; Galan C, 2014, AEROBIOLOGIA, V30, P385, DOI 10.1007/s10453-014-9335-5; Garcia-Mozo H, 2017, ALLERGY, V72, P1849, DOI 10.1111/all.13210; Gehrig R, 2019, AEROBIOLOGIA, V35, P577, DOI 10.1007/s10453-019-09593-z; Halbritter H, 2018, ILLUSTRATED POLLEN TERMINOLOGY, 2ND EDITION, P429, DOI 10.1007/978-3-319-71365-6_12; Hernandez-Ceballos MA, 2015, INT J BIOMETEOROL, V59, P971, DOI 10.1007/s00484-014-0910-9; Huffman JA, 2020, AEROSOL SCI TECH, V54, P465, DOI 10.1080/02786826.2019.1664724; International Diabetes Federation, 2019, IDF DIABETES ATLAS, V9th ed; Karatzas K.D., 2013, ALLERGENIC POLLEN, P217; Kawashima S, 2007, ATMOS ENVIRON, V41, P7987, DOI 10.1016/j.atmosenv.2007.09.019; Kiselev D, 2011, OPT EXPRESS, V19, P24516, DOI 10.1364/OE.19.024516; Lind T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166887; Makra L, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2010JD014743; Murtagh F, 2012, WIRES DATA MIN KNOWL, V2, P86, DOI 10.1002/widm.53; O'Connor DJ, 2014, AEROSOL SCI TECH, V48, P341, DOI 10.1080/02786826.2013.872768; O'Connor DJ, 2011, ATMOS ENVIRON, V45, P6451, DOI 10.1016/j.atmosenv.2011.07.044; Oh JW, 2009, J KOREAN MED ASSOC, V52, P579, DOI 10.5124/jkma.2009.52.6.579; Oteros J, 2019, SCI TOTAL ENVIRON, V688, P1263, DOI 10.1016/j.scitotenv.2019.06.131; Oteros J, 2015, INT ARCH ALLERGY IMM, V167, P158, DOI 10.1159/000436968; Pfaar O, 2020, ALLERGY, V75, P1099, DOI 10.1111/all.14111; R Studio Team, R STUDIO INTEGRATED; Sauliene I., 2007, Acta Biologica Universitatis Daugavpiliensis, P61; Sauliene I, 2019, FORESTS, V10, DOI 10.3390/f10110959; Sauliene I, 2019, ATMOS MEAS TECH, V12, P3435, DOI 10.5194/amt-12-3435-2019; Sauliene Ingrida, 2015, Acta Agrobotanica, V68, P391, DOI 10.5586/aa.2015.036; Sauliene I, 2016, AEROBIOLOGIA, V32, P157, DOI 10.1007/s10453-015-9387-1; Sauvageat E, 2020, ATMOS MEAS TECH, V13, P1539, DOI 10.5194/amt-13-1539-2020; Scheifinger H., 2013, ALLERGENIC POLLEN, P71, DOI DOI 10.1007/978-94-007-4881-1_4; Siauliai municipality, GEN PLAN CITY; Slowikowski Kamil., 2020, GGREPEL AUTOMATICALL; Smith M, 2005, AEROBIOLOGIA, V21, P85, DOI 10.1007/s10453-005-4178-8; Sofiev M, 2019, AEROBIOLOGIA, V35, P523, DOI 10.1007/s10453-019-09583-1; Statistics Lithuania, GEOGR DAT; Swanson BE, 2020, AEROSOL SCI TECH, V54, P426, DOI 10.1080/02786826.2019.1711357; Szczepanek K, 2017, AEROBIOLOGIA, V33, P109, DOI 10.1007/s10453-016-9454-2; Tesendic D, 2022, ENTERP INF SYST-UK, V16, DOI 10.1080/17517575.2020.1793391; Valiulis G., 2020, **DATA OBJECT**, DOI [10.5281/zenodo.3873205, DOI 10.5281/ZENODO.3873205]; Valiulis G., 2020, **DATA OBJECT**, DOI [10.5281/zenodo.3873204, DOI 10.5281/ZENODO.3873204]; Veriankaite L, 2010, J ENVIRON ENG LANDSC, V18, P137, DOI 10.3846/jeelm.2010.16; Voukantsis D, 2013, AEROBIOLOGIA, V29, P175, DOI 10.1007/s10453-012-9271-1; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Zimmermann B, 2018, PLANTA, V247, P171, DOI 10.1007/s00425-017-2774-9	49	6	6	7	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2021	16	3							e0247284	10.1371/journal.pone.0247284	http://dx.doi.org/10.1371/journal.pone.0247284			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX8JZ	33705418	Green Published, gold			2023-01-03	WOS:000629590400041
J	You, JHS; Cho, WCS; Ming, WK; Li, YC; Kwan, CK; Au, KH; Au, JSK				You, Joyce H. S.; Cho, William C. S.; Ming, Wai-Kit; Li, Yu-Chung; Kwan, Chung-Kong; Au, Kwok-Hung; Au, Joseph Siu-Kie			EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis	PLOS ONE			English	Article							1ST-LINE TREATMENT; ASIAN PATIENTS; OPEN-LABEL; CHEMOTHERAPY; ADENOCARCINOMA; CISPLATIN; GEMCITABINE; SURVIVAL; THERAPY; NSCLC	Introduction Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to compare the EGFR mutation-guided target therapy versus empirical chemotherapy for first-line treatment of advanced NSCLC in the public healthcare setting of Hong Kong. Methods A Markov model was designed to simulate outcomes of a hypothetical cohort of advanced (stage IIIB/IV) NSCLC adult patients with un-tested EGFR-sensitizing mutation status. Four treatment strategies were evaluated: Empirical first-line chemotherapy with cisplatin-pemetrexed (empirical chemotherapy group), and EGFR mutation-guided use of a TKI (afatinib, erlotinib, and gefitinib). Model outcome measures were direct medical cost, progression-free survival, overall survival, and quality-adjusted life-years (QALYs). Incremental cost per QALY gained (ICER) was estimated. Sensitivity analyses were performed to examine robustness of model results. Results Empirical chemotherapy and EGFR mutation-guided gefitinib gained lower QALYs at higher costs than the erlotinib group. Comparing with EGFR mutation-guided erlotinib, the afatinib strategy gained additional QALYs with ICER (540,633 USD/QALY). In 10,000 Monte Carlo simulations for probabilistic sensitivity analysis, EGFR mutation-guided afatinib, erlotinib, gefitinib and empirical chemotherapy were preferred strategy in 0%, 98%, 0% and 2% of time at willingness-to-pay (WTP) 47,812 USD/QALY (1x gross domestic product (GDP) per capita), and in 30%, 68%, 2% and 0% of time at WTP 143,436 USD/QALY (3x GDP per capita), respectively. Conclusions EGFR mutation-guided erlotinib appears to be the cost-effective strategy from the perspective of Hong Kong public healthcare provider over a broad range of WTP.	[You, Joyce H. S.; Ming, Wai-Kit] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Hong Kong, Peoples R China; [Cho, William C. S.; Au, Kwok-Hung] Queen Elizabeth Hosp, Hosp Author, Dept Clin Oncol, Hong Kong, Peoples R China; [Li, Yu-Chung] Hong Kong United Oncol Ctr, Hong Kong, Peoples R China; [Kwan, Chung-Kong] United Christian Hosp, Hosp Author, Dept Oncol, Hong Kong, Peoples R China; [Au, Joseph Siu-Kie] Hong Kong Adventist Hosp, Oncol Ctr, Hong Kong, Peoples R China	Chinese University of Hong Kong; United Christian Hospital	You, JHS (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Pharm, Hong Kong, Peoples R China.	joyceyou@cuhk.edu.hk	You, Joyce H. S./C-2984-2008; Ming, Wai-kit/AAH-5989-2019	You, Joyce H. S./0000-0002-5763-7403; Ming, Wai-kit/0000-0002-8846-7515	Health and Medical Research Fund, Food and Health Bureau, The Government of the Hong Kong SAR, China [15160531]	Health and Medical Research Fund, Food and Health Bureau, The Government of the Hong Kong SAR, China	JHSY received support from Health and Medical Research Fund (project number 15160531), Food and Health Bureau, The Government of the Hong Kong SAR, China. URL: https://rfs1.fhb.gov.hk/english/welcome/welcome.html The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arrieta O, 2016, EUR J HEALTH ECON, V17, P855, DOI 10.1007/s10198-015-0726-5; Briggs A, 2006, DECISION MODELLING H; Census and Statistics Department, GOVT HONG KONG SAR N; Chouaid C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-301; Dickson R, 2011, PHARMACOECONOMICS, V29, P1051, DOI 10.2165/11591600-000000000-00000; Ezeife DA, 2018, LUNG CANCER, V125, P1, DOI 10.1016/j.lungcan.2018.08.024; Gu XH, 2019, LUNG CANCER, V127, P84, DOI 10.1016/j.lungcan.2018.11.029; Hong SD, 2014, SCI REP-UK, V4, DOI 10.1038/srep07268; Hospital Authority, OVERVIEW HONG KONG C; Lee CK, 2013, JNCI-J NATL CANCER I, V105, P595, DOI 10.1093/jnci/djt072; Liang WH, 2019, TRANSL LUNG CANCER R, V8, P1163, DOI 10.21037/tlcr.2019.12.14; Lim EA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160155; Lopes GD, 2012, CANCER-AM CANCER SOC, V118, P1032, DOI 10.1002/cncr.26372; Lu S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205827; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Nafees B, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-84; Narita Y, 2015, LUNG CANCER, V90, P71, DOI 10.1016/j.lungcan.2015.07.006; Romanus D, 2015, J THORAC ONCOL, V10, P586, DOI 10.1097/JTO.0000000000000474; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Shi Y, 2014, J THORAC ONCOL, V9, P154, DOI 10.1097/JTO.0000000000000033; Wang H, 2019, FUTURE ONCOL, V15, P181, DOI 10.2217/fon-2018-0692; WHO, 2002, REDUCING RISKS PROMO; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; You RX, 2019, CANCER MANAG RES, V11, P10239, DOI 10.2147/CMAR.S219722; Zhang YX, 2016, ONCOTARGET, V7, P20093, DOI 10.18632/oncotarget.7713; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	27	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2021	16	3							e0247860	10.1371/journal.pone.0247860	http://dx.doi.org/10.1371/journal.pone.0247860			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR6LP	33647045	gold, Green Published			2023-01-03	WOS:000625328100012
J	Olsen, Y; Fitzgerald, RM; Wakeman, SE				Olsen, Yngvild; Fitzgerald, Ruchi M.; Wakeman, Sarah E.			Overcoming Barriers to Treatment of Opioid Use Disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Olsen, Yngvild] Inst Behav Resources Inc, 2104 Maryland Ave, Baltimore, MD 21218 USA; [Fitzgerald, Ruchi M.] Rush Univ, Chicago, IL 60612 USA; [Wakeman, Sarah E.] Massachusetts Gen Hosp, Med, Charlestown, MA USA	Rush University; Harvard University; Massachusetts General Hospital	Olsen, Y (corresponding author), Inst Behav Resources Inc, 2104 Maryland Ave, Baltimore, MD 21218 USA.	yngvild.olsen@gmail.com						Department of Health and Human Services, HHS EXP ACC TREATM O; Duncan A, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.14045; Ghertner R, 2020, PSYCHIAT SERV, V71, P971, DOI 10.1176/appi.ps.201900635; Huhn AS, 2017, J SUBST ABUSE TREAT, V78, P1, DOI 10.1016/j.jsat.2017.04.005; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Substance Abuse and Mental Health Services Administration, STAT REG X WAIV	6	11	11	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2021	325	12					1149	1150		10.1001/jama.2021.1741	http://dx.doi.org/10.1001/jama.2021.1741		FEB 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ7PB	33630021				2023-01-03	WOS:000621911900001
J	Sevransky, JE; Rothman, RE; Hager, DN; Bernard, GR; Brown, SM; Buchman, TG; Busse, LW; Coopersmith, CM; DeWilde, C; Ely, W; Eyzaguirre, LM; Fowler, AA; Gaieski, DF; Gong, MN; Hall, A; Hinson, JS; Hooper, MH; Kelen, GD; Khan, A; Levine, MA; Lewis, RJ; Lindsell, CJ; Marlin, JS; McGlothlin, A; Moore, BL; Nugent, KL; Nwosu, S; Polito, CC; Rice, TW; Ricketts, EP; Rudolph, CC; Sanfilippo, F; Viele, K; Martin, GS; Wright, DW				Sevransky, Jonathan E.; Rothman, Richard E.; Hager, David N.; Bernard, Gordon R.; Brown, Samuel M.; Buchman, Timothy G.; Busse, Laurence W.; Coopersmith, Craig M.; DeWilde, Christine; Ely, Wesley; Eyzaguirre, Lindsay M.; Fowler, Alpha A.; Gaieski, David F.; Gong, Michelle N.; Hall, Alex; Hinson, Jeremiah S.; Hooper, Michael H.; Kelen, Gabor D.; Khan, Akram; Levine, Mark A.; Lewis, Roger J.; Lindsell, Chris J.; Marlin, Jessica S.; McGlothlin, Anna; Moore, Brooks L.; Nugent, Katherine L.; Nwosu, Samuel; Polito, Carmen C.; Rice, Todd W.; Ricketts, Erin P.; Rudolph, Caroline C.; Sanfilippo, Fred; Viele, Kert; Martin, Greg S.; Wright, David W.		VICTAS Investigators	Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis The VICTAS Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RESPIRATORY-FAILURE; SEPTIC SHOCK; ASCORBIC-ACID; ORGAN FAILURE; INJURY	IMPORTANCE Sepsis is a common syndrome with substantial morbidity and mortality. A combination of vitamin C, thiamine, and corticosteroids has been proposed as a potential treatment for patients with sepsis. OBJECTIVE To determine whether a combination of vitamin C, thiamine, and hydrocortisone every 6 hours increases ventilator- and vasopressor-free days compared with placebo in patients with sepsis. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, double-blind, adaptive-sample-size, placebo-controlled trial conducted in adult patients with sepsis-induced respiratory and/or cardiovascular dysfunction. Participants were enrolled in the emergency departments or intensive care units at 43 hospitals in the United States between August 2018 and July 2019. After enrollment of 501 participants, funding was withheld, leading to an administrative termination of the trial. All study-related follow-up was completed by January 2020. INTERVENTIONS Participants were randomized to receive intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 hours (n = 252) or matching placebo (n = 249) for 96 hours or until discharge from the intensive care unit or death. Participants could be treated with open-label corticosteroids by the clinical team, with study hydrocortisone or matching placebo withheld if the total daily dose was greater or equal to the equivalent of 200 mg of hydrocortisone. MAIN OUTCOMES AND MEASURES The primary outcome was the number of consecutive ventilator- and vasopressor-free days in the first 30 days following the day of randomization. The key secondary outcome was 30-day mortality. RESULTS Among 501 participants randomized (median age, 62 [interquartile range {IQR}, 50-70] years; 46% female; 30% Black; median Acute Physiology and Chronic Health Evaluation II score, 27 [IQR, 20.8-33.0]; median Sequential Organ Failure Assessment score, 9 [IQR, 7-12]), all completed the trial. Open-label corticosteroids were prescribed to 33% and 32% of the intervention and control groups, respectively. Ventilator- and vasopressor-free days were a median of 25 days (IQR, 0-29 days) in the intervention group and 26 days (IQR, 0-28 days) in the placebo group, with a median difference of -1 day (95% CI, -4 to 2 days; P =.85). Thirty-day mortality was 22% in the intervention group and 24% in the placebo group. CONCLUSIONS AND RELEVANCE Among critically ill patients with sepsis, treatment with vitamin C, thiamine, and hydrocortisone, compared with placebo, did not significantly increase ventilator- and vasopressor-free days within 30 days. However, the trial was terminated early for administrative reasons and may have been underpowered to detect a clinically important difference.	[Sevransky, Jonathan E.; Busse, Laurence W.; Polito, Carmen C.; Martin, Greg S.] Emory Univ, Sch Med, Div Pulm Allergy Crit Care & Sleep, Atlanta, GA USA; [Sevransky, Jonathan E.; Buchman, Timothy G.; Busse, Laurence W.; Coopersmith, Craig M.; Polito, Carmen C.; Martin, Greg S.] Emory Healthcare, Emory Crit Care Ctr, Atlanta, GA USA; [Rothman, Richard E.; Hinson, Jeremiah S.; Kelen, Gabor D.; Ricketts, Erin P.] Johns Hopkins Univ, Dept Emergency Med, Baltimore, MD USA; [Hager, David N.] Johns Hopkins Univ, Div Pulm Crit Care, Baltimore, MD 21205 USA; [Bernard, Gordon R.; Ely, Wesley; Rice, Todd W.] Vanderbilt Univ, Med Ctr, Div Pulm Crit Care, Nashville, TN 37235 USA; [Brown, Samuel M.] Intermt Med Ctr, Div Pulm Crit Care, Salt Lake City, UT USA; [Brown, Samuel M.] Univ Utah, Salt Lake City, UT USA; [Buchman, Timothy G.; Coopersmith, Craig M.] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA; [DeWilde, Christine; Fowler, Alpha A.] Virginia Commonwealth Univ, Div Pulm Crit Care, Med Coll Virginia Campus, Richmond, VA USA; [Ely, Wesley] Johns Hopkins Crit Illness, Brain Dysfunct & Survivorship CIBS Ctr, Baltimore, MD USA; [Ely, Wesley] Vet Affairs Tennessee Valley Geriatr Res Educ Cli, Nashville, TN USA; [Eyzaguirre, Lindsay M.] Johns Hopkins Univ, Div Brain Injury Outcomes, Baltimore, MD USA; [Gaieski, David F.] Thomas Jefferson Univ Hosp, Dept Emergency Med, Philadelphia, PA 19107 USA; [Gong, Michelle N.] Montefiore Med Ctr, Dept Crit Care, 111 E 210th St, Bronx, NY 10467 USA; [Hall, Alex; Moore, Brooks L.; Nugent, Katherine L.; Rudolph, Caroline C.; Wright, David W.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; [Hooper, Michael H.] Sentara Healthcare, Div Pulm Crit Care, Norfolk, VA USA; [Khan, Akram] Oregon Hlth & Sci Univ, Div Pulm Crit Care, Portland, OR 97201 USA; [Levine, Mark A.] NIH, Mol & Clin Nutr Sect, Bldg 10, Bethesda, MD 20892 USA; [Lewis, Roger J.] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA; [Lewis, Roger J.; McGlothlin, Anna; Viele, Kert] Berry Consultants LLC, Austin, TX USA; [Lewis, Roger J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Emergency Med, Los Angeles, CA 90095 USA; [Lewis, Roger J.] Lundquist Inst Biomed Innovat, Torrance, CA USA; [Lindsell, Chris J.; Nwosu, Samuel] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Marlin, Jessica S.] Vanderbilt Univ, Med Ctr, Vanderbilt Coordinating Ctr, Nashville, TN USA; [Sanfilippo, Fred] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Viele, Kert] Univ Kentucky, Dept Biostat, Lexington, KY USA	Emory University; Emory University; Johns Hopkins University; Johns Hopkins University; Vanderbilt University; Intermountain Healthcare; Intermountain Medical Center; Utah System of Higher Education; University of Utah; Emory University; Virginia Commonwealth University; Geriatric Research Education & Clinical Center; Johns Hopkins University; Jefferson University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Emory University; Sentara Healthcare; Oregon Health & Science University; National Institutes of Health (NIH) - USA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Vanderbilt University; Vanderbilt University; Emory University; University of Kentucky	Sevransky, JE (corresponding author), Emory Univ Hosp, Room D226, Atlanta, GA 30322 USA.	jsevran@emory.edu	Levine, Mark/HIZ-8652-2022; Khan, Akram/AAB-6446-2022; Moore, Brooks/GRJ-5636-2022; Martin, Greg/B-4085-2009; Gill, Jasreen/AAU-8351-2021; Hall, Alex/AAR-9495-2021; Puskarich, Michael/N-7849-2014; Brown, Samuel/E-6846-2015	Levine, Mark/0000-0001-6297-4650; Khan, Akram/0000-0003-3091-632X; Moore, Brooks/0000-0002-8835-0296; Martin, Greg/0000-0002-9684-7593; Gill, Jasreen/0000-0002-1703-5379; Hall, Alex/0000-0001-8532-524X; Douglas, Ivor/0000-0002-4541-1431; Belsky, Justin/0000-0002-3711-0954; Gibbs, Kevin/0000-0002-5272-2289; Puskarich, Michael/0000-0001-6358-4670; Brown, Samuel/0000-0003-1206-6261; McGlothlin, Anna/0000-0002-9079-6166; Files, Daniel Clark/0000-0002-1595-4080; Quinn, James/0000-0002-3694-2118; Greenwood, John/0000-0003-2337-557X	Marcus Foundation; Nova Biomedical Inc	Marcus Foundation; Nova Biomedical Inc	Funding for the trial was provided by the Marcus Foundation to Emory University, which supervised the distribution of resources to clinical sites. Johns Hopkins served as the clinical coordinating center and Vanderbilt University as the data coordinating center. Nova Biomedical Inc provided support to 6 sites with point-of-care glucometers. Vitamin C, thiamine, and hydrocortisone were purchased from McGuff Pharmaceuticals Inc. SCCM Discovery, a critical care research infrastructure program, facilitated the design and conduct of the study, provided administrative support to conducting the study, and was involved in critical manuscript revision. SCCM Discovery reviewed and critiqued the study, which met criteria for SCCM Discovery endorsement.	Barabutis N, 2017, CHEST, V152, P954, DOI 10.1016/j.chest.2017.07.014; Buchman TG, 2020, CRIT CARE MED, V48, P276, DOI 10.1097/CCM.0000000000004224; de Grooth HJ, 2020, JAMA-J AM MED ASSOC, V323, P792, DOI 10.1001/jama.2019.21981; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Fowler AA, 2020, JAMA-J AM MED ASSOC, V323, P792, DOI 10.1001/jama.2019.21987; Fowler AA, 2019, JAMA-J AM MED ASSOC, V322, P1261, DOI 10.1001/jama.2019.11825; Fujii T, 2020, JAMA-J AM MED ASSOC, V323, P423, DOI 10.1001/jama.2019.22176; Hager DN, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3254-2; Hager DN, 2018, CHEST, V154, P228, DOI 10.1016/j.chest.2018.03.018; Lindsell CJ, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3775-8; Marik PE, 2017, CHEST, V151, P1229, DOI 10.1016/j.chest.2016.11.036; Marshall JC, 2014, TRENDS MOL MED, V20, P195, DOI 10.1016/j.molmed.2014.01.007; Moskowitz A, 2020, JAMA-J AM MED ASSOC, V324, P642, DOI 10.1001/jama.2020.11946; Putzu A, 2019, CRIT CARE MED, V47, P774, DOI 10.1097/CCM.0000000000003700; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Spoelstra-de Man AME, 2018, CURR OPIN CRIT CARE, V24, P248, DOI 10.1097/MCC.0000000000000510; Torio CM, 2016, HCUP STAT BRIEFS; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wilson JX, 2013, ANTIOXID REDOX SIGN, V19, P2129, DOI 10.1089/ars.2013.5401; Yende S, 2016, CRIT CARE MED, V44, P1461, DOI 10.1097/CCM.0000000000001658	22	81	82	8	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2021	325	8					742	751		10.1001/jama.2020.24505	http://dx.doi.org/10.1001/jama.2020.24505			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM7LT	33620405	Green Published, Bronze			2023-01-03	WOS:000621957400022
J	Miller, JE; Carter, KW; de Klerk, N; Burgner, DP				Miller, Jessica E.; Carter, Kim W.; de Klerk, Nicholas; Burgner, David P.			The familial risk of infection-related hospitalization in children: A population-based sibling study	PLOS ONE			English	Article							DISEASE; HERITABILITY; TWIN	Objective To assess the risk of severe childhood infections within families, we conducted a sibling analysis in a population-based cohort study with genealogical linkage. We investigated the sibling risk of hospitalization with common infections, a marker of severity. We hypothesized that having siblings hospitalized for infection would increase the proband's risk of admission with infection. Study design We used population data on Western Australian live-born singletons and their siblings between 1980 and 2014. Measures of infection were infection-related hospitalizations from discharge diagnostic codes. Exposure was having a sibling who had an infection-related hospitalization. Outcomes were infection-related hospitalizations in the child/proband. Probands were followed until an infection-related hospitalization admission (up to the first three), death, 18th birthday, or end of 2014, whichever occurred first. Infection risks were estimated by adjusted Cox proportional hazard models for multiple events. Results Of 512,279 probands, 142,915 (27.9%) had infection-related hospitalizations; 133,322 (26.0%) had a sibling with a previous infection-related hospitalization (i.e. exposed). Median interval between sibling and proband infection-related hospitalizations was 1.4 years (inter-quartile range 0.5-3.7). Probands had a dose-dependent increase in risk if sibling/s had 1, 2, or 3+ infection-related hospitalizations (adjusted hazard ratio, aHR 1.41, 95% CI 1.39-1.43; aHR 1.65, 1.61-1.69; aHR 1.83, 1.77-1.90, respectively). Among siblings with the same clinical infection type, highest sibling risks were for genitourinary (aHR 2.06, 1.68-2.53), gastrointestinal (aHR 2.07, 1.94-2.19), and skin/soft tissue infections (aHR 2.34, 2.15-2.54). Overall risk of infection-related hospitalization was higher in children with more siblings and with older siblings. Conclusion In this population-based study, we observed an increased risk of infection-related hospitalization in children whose siblings were previously hospitalized for infection. Public health interventions may be particularly relevant in families of children hospitalized with infection.	[Miller, Jessica E.; Burgner, David P.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Miller, Jessica E.; Burgner, David P.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Carter, Kim W.; de Klerk, Nicholas] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Burgner, David P.] Monash Univ, Dept Paediat, Clayton, Vic, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Telethon Kids Institute; University of Western Australia; Monash University	Miller, JE (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic, Australia.; Miller, JE (corresponding author), Univ Melbourne, Dept Paediat, Parkville, Vic, Australia.	jessica.miller@mcri.edu.au	; de Klerk, Nicholas/D-8388-2016	Miller, Jessica/0000-0002-1806-1894; de Klerk, Nicholas/0000-0001-9223-0767	Australian National Health and Medical Research Council [GTN572742, GTN106594, GTN1064829, GTN1175744]; Victorian Government's Operational Infrastructure Support Program	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational Infrastructure Support Program	This work is supported by the Australian National Health and Medical Research Council GTN572742, GTN106594, and GTN1064829 and GTN1175744. Research at Murdoch Children's Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Australia P, POP W AUSTR 2020; Burgner D, 2006, LANCET INFECT DIS, V6, P653, DOI 10.1016/S1473-3099(06)70601-6; Carville KS, 2007, PEDIATR INFECT DIS J, V26, P210, DOI 10.1097/01.inf.0000254148.09831.7f; Casselbrant ML, 1999, JAMA-J AM MED ASSOC, V282, P2125, DOI 10.1001/jama.282.22.2125; Gee V HQ., 2007, PERINATAL STAT W AUS; Glasson EJ, 2008, INT J EPIDEMIOL, V37, P30, DOI 10.1093/ije/dym136; Goto T, 2016, PEDIATR INFECT DIS J, V35, pE158, DOI 10.1097/INF.0000000000001134; Haralambous E, 2003, EPIDEMIOL INFECT, V130, P413, DOI 10.1017/S0950268803008513; Holman CDJ, 2008, AUST HEALTH REV, V32, P766, DOI 10.1071/AH080766; Hughes AM, 2013, CLIN EXP IMMUNOL, V172, P466, DOI 10.1111/cei.12077; Jepson A, 1998, B I PASTEUR, V96, P71, DOI 10.1016/S0020-2452(98)80001-8; Kamper-Jorgensen M, 2006, PEDIATRICS, V118, P1439, DOI 10.1542/peds.2006-0373; Laursen MF, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0477-6; Miller JE., 2016, LANCET INFECT DIS, DOI [10.1016/S1473-3099%2816%2900150-X, DOI 10.1016/S1473-3099%2816%2900150-X]; Petersen L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010603; Pink B., 2006, STATISTICS-ABINGDON; PRENTICE RL, 1981, BIOMETRIKA, V68, P373, DOI 10.1093/biomet/68.2.373; Rostgaard K, 2014, INT J EPIDEMIOL, V43, P1607, DOI 10.1093/ije/dyu118; Saxena S, 1999, BRIT MED J, V318, P642, DOI 10.1136/bmj.318.7184.642; Song H, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5784; STANLEY FJ, 1994, PAEDIATR PERINAT EP, V8, P433, DOI 10.1111/j.1365-3016.1994.tb00482.x; StataCorp, 2019, STATA STAT SOFTWARE; Statistics ABo, 2008, CHILDH ED CAR; Statistics ABo, 2015, MIGR AUSTR 2013 14 2; Tielemans SMAJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3862; van der Eijk EA, 2007, AM J RESP CRIT CARE, V176, P1281, DOI 10.1164/rccm.200703-435OC; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Watson RL, 1999, PEDIATRICS, V104, P1251, DOI 10.1542/peds.104.6.1251; Yorita KL, 2008, PEDIATRICS, V121, P244, DOI 10.1542/peds.2007-1392	30	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2021	16	4							e0250181	10.1371/journal.pone.0250181	http://dx.doi.org/10.1371/journal.pone.0250181			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XL	33909680	gold, Green Published			2023-01-03	WOS:000662174400040
J	Walker, KF; Plumb, J; Gray, J; Thornton, JG; Avery, AJ; Daniels, JP				Walker, Kate F.; Plumb, Jane; Gray, Jim; Thornton, Jim G.; Avery, Anthony J.; Daniels, Jane P.			Should all pregnant women be offered testing for group B streptococcus?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PREVENTION; DISEASE; STRATEGIES		[Walker, Kate F.; Thornton, Jim G.; Avery, Anthony J.; Daniels, Jane P.] Univ Nottingham, Nottingham, England; [Plumb, Jane] Grp B Strep Support, Haywards Heath, England; [Gray, Jim] Birmingham Womens & Childrens NHS Fdn Trust, Birmingham, W Midlands, England	University of Nottingham	Walker, KF (corresponding author), Univ Nottingham, Nottingham, England.	kate.walker@nottingham.ac.uk		Walker, Kate F./0000-0001-5794-7324				[Anonymous], 2020, OBSTET GYNECOL, V135, pE51, DOI [10.1097/AOG.0000000000003668, 10.1097/AOG.0000000000003335]; Australian Government Depart of Health, 2019, PREGN CAR GUID GROUP PREGN CAR GUID GROUP, V394; Bevan D, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024324; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; da Silva HD, 2019, J INFECT PUBLIC HEAL, V12, P479, DOI 10.1016/j.jiph.2019.03.004; Hasperhoven GF, 2020, BJOG-INT J OBSTET GY, V127, P680, DOI 10.1111/1471-0528.16085; Heath PGT, 2004, LANCET, V363, P292, DOI 10.1016/S0140-6736(03)15389-5; Huang J, 2019, PEDIATR NEONATOL, V60, P487, DOI 10.1016/j.pedneo.2019.07.001; Hughes RG, 2017, BJOG-INT J OBSTET GY, V124, pE280, DOI 10.1111/1471-0528.14821; Kaambwa B, 2010, BJOG-INT J OBSTET GY, V117, P1616, DOI 10.1111/j.1471-0528.2010.02752.x; Le Doare K, 2017, CLIN INFECT DIS, V65, pS143, DOI 10.1093/cid/cix654; Li QY, 2020, PEDIATR INFECT DIS J, V39, P740, DOI 10.1097/INF.0000000000002674; Money D, 2016, J OBSTET GYNAECOL CA, V38, pS326, DOI 10.1016/j.jogc.2016.09.042; O'Sullivan C, 2016, ARCH DIS CHILD, V101, pA2, DOI DOI 10.1136/ARCHDISCHILD-2016-310863.3; O'Sullivan CP, 2019, LANCET INFECT DIS, V19, P83, DOI 10.1016/S1473-3099(18)30555-3; Ohlsson A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007467.pub4; Schrag SJ, 2002, NEW ENGL J MED, V347, P233, DOI 10.1056/NEJMoa020205; Schrag SJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2013; Seedat F, 2016, UNIVERSAL ANTENATAL; Seedat F, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1432-3; World Health Organization (WHO), 2015, WHO REC PREV TRE MAT	21	1	1	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2021	373								n882	10.1136/bmj.n882	http://dx.doi.org/10.1136/bmj.n882			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ8OY	33903125	Green Accepted			2023-01-03	WOS:000678538700009
J	Yimam, Y; Nateghpour, M; Mohebali, M; Afshar, MJA				Yimam, Yonas; Nateghpour, Mehdi; Mohebali, Mehdi; Abbaszadeh Afshar, Mohammad Javad			A systematic review and meta-analysis of asymptomatic malaria infection in pregnant women in Sub-Saharan Africa: A challenge for malaria elimination efforts	PLOS ONE			English	Review							PLASMODIUM-FALCIPARUM INFECTIONS; ASSESSING RISK; ANEMIA; BIAS; PARASITEMIA; PREVALENCE; HEPCIDIN; BURDEN; IRON; TOOL	Background In Sub-Saharan Africa (SSA), where malaria transmission is stable, malaria infection in pregnancy adversely affects pregnant women, fetuses, and newborns and is often asymptomatic. So far, a plethora of primary studies have been carried out on asymptomatic malaria infection in pregnant women in SSA. Nevertheless, no meta-analysis estimated the burden of asymptomatic malaria infection in pregnant women in SSA, so this meta-analysis was carried out to bridge this gap. Methods PubMed, Web of Science, Scopus, Embase, and ProQuest were systematically searched for relevant studies published until 4 August 2020, and also the expansion of the search was performed by October 24, 2020. We assessed heterogeneity among included studies using I-squared statistics (I-2). Publication bias was assessed by visual inspection of the funnel plot and further quantitatively validated by Egger's and Begg's tests. The pooled prevalence and pooled odds ratio (OR) and their corresponding 95% Confidence Interval (CI) were estimated using the random-effects model in Stata 15 software. Results For this meta-analysis, we included 35 eligible studies. The overall prevalence estimate of asymptomatic Plasmodium infection prevalence was 26.1%% (95%CI: 21-31.2%, I-2 = 99.0%). According to species-specific pooled prevalence estimate, Plasmodium falciparum was dominant species (22.1%, 95%CI: 17.1-27.2%, I-2 = 98.6%), followed by Plasmodium vivax, Plasmodium malariae and Plasmodium ovale, respectively, found to be 3% (95%CI: 0-5%, I-2 = 88.3%), 0.8% (95%CI: 0.3-0.13%, I-2 = 60.5%), and 0.2% (95%CI: -0.01-0.5%, I-2 = 31.5%). Asymptomatic malaria-infected pregnant women were 2.28 times more likely anemic (OR = 2.28, 95%CI: 1.66-3.13, I-2 = 56.3%) than in non-infected pregnant women. Asymptomatic malaria infection was 1.54 times higher (OR = 1.54, 95%CI: 1.28-1.85, I-2 = 11.5%) in primigravida women compared to multigravida women. Conclusion In SSA, asymptomatic malaria infection in pregnant women is prevalent, and it is associated with an increased likelihood of anemia compared to non-infected pregnant women. Thus, screening of asymptomatic pregnant women for malaria and anemia should be included as part of antenatal care.	[Yimam, Yonas; Nateghpour, Mehdi; Mohebali, Mehdi; Abbaszadeh Afshar, Mohammad Javad] Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Parasitol & Mycol, Tehran, Iran; [Yimam, Yonas] Woldia Univ, Fac Nat & Computat Sci, Dept Biol, Woldia, Ethiopia; [Mohebali, Mehdi] Univ Tehran Med Sci, Ctr Res Endem Parasites Iran CREPI, Tehran, Iran; [Abbaszadeh Afshar, Mohammad Javad] Jiroft Univ Med Sci, Dept Med Parasitol & Mycol, Sch Med, Jiroft, Iran	Tehran University of Medical Sciences; Tehran University of Medical Sciences	Mohebali, M (corresponding author), Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Parasitol & Mycol, Tehran, Iran.; Mohebali, M (corresponding author), Univ Tehran Med Sci, Ctr Res Endem Parasites Iran CREPI, Tehran, Iran.	mohebali@tums.ac.ir	Abbaszadeh Afshar, Mohammad Javad/ABF-7357-2021; mohebali, mehdi/ABF-3606-2021	Abbaszadeh Afshar, Mohammad Javad/0000-0002-8723-6432; Yimam, Yonas/0000-0002-5873-0239				ABELIN I, 1948, HELV PHYSIOL PHARM A, V6, P1; Aitken EH, 2010, J INFECT DIS, V201, P1316, DOI 10.1086/651578; [Anonymous], 2018, WORLD MALARIA REPORT; [Anonymous], 2019, LIC CC BY NC SA 3 0; Baum E, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0611-9; Bediako Y, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0683-6; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BOEVER F, 1948, ARCH INT PHARMACOD T, V77, P1; Britton S, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1158-0; Cottrell G, 2015, CLIN INFECT DIS, V60, P1481, DOI 10.1093/cid/civ122; de Mast Q, 2010, HAEMATOL-HEMATOL J, V95, P1068, DOI 10.3324/haematol.2009.019331; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Desai M, 2018, LANCET INFECT DIS, V18, pE119, DOI 10.1016/S1473-3099(18)30064-1; Douamba Z, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/198317; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FAQUIN W C, 1992, Blood, V79, P1987; Feleke DG, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-3152-9; FONSECA JC, 2017, J VECTOR DIS, V54, P201, DOI DOI 10.4103/0972-9062.217610; Galatas B, 2016, TRENDS PARASITOL, V32, P296, DOI 10.1016/j.pt.2015.11.015; Gamble C, 2007, PLOS MED, V4, P506, DOI 10.1371/journal.pmed.0040107; Haldar Kasturi, 2009, Hematology Am Soc Hematol Educ Program, P87, DOI 10.1182/asheducation-2009.1.87; Hassanpour G, 2019, TRAVEL MED INFECT DI, V31, DOI 10.1016/j.tmaid.2019.05.012; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Isah AY, 2011, ANN AFR MED, V10, P171, DOI 10.4103/1596-3519.82070; Laishram DD, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-29; Leopardi O, 1996, PATHOL RES PRACT, V192, P892, DOI 10.1016/S0344-0338(96)80068-9; Lindblade KA, 2013, EXPERT REV ANTI-INFE, V11, P623, DOI [10.1586/eri.13.45, 10.1586/ERI.13.45]; Males S, 2008, CLIN INFECT DIS, V46, P516, DOI 10.1086/526529; Maryrose AU., 2014, J BASIC CLIN REPROD, V3, P44, DOI [DOI 10.4103/2278-960X.129279, 10.4103/2278-960X.129279]; Matangila JR, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-132; Mathison BA, 2017, J CLIN MICROBIOL, V55, P2009, DOI [10.1128/JCM.02562-16, 10.1128/jcm.02562-16]; Mayengue PI, 2004, TROP MED INT HEALTH, V9, P949, DOI 10.1111/j.1365-3156.2004.01294.x; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Mlugu EM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093123; Naidoo I, 2011, PARASITOLOGY, V138, P1469, DOI 10.1017/S0031182011000746; Ndam NT, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/43785; Nega Desalegn, 2015, BMC Res Notes, V8, P110, DOI 10.1186/s13104-015-1081-4; Nega D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123630; Nosten F, 2004, TRENDS PARASITOL, V20, P425, DOI 10.1016/j.pt.2004.06.007; NOSTEN F, 1991, T ROY SOC TROP MED H, V85, P424, DOI 10.1016/0035-9203(91)90205-D; Ofori Mf, 2009, Ghana Med J, V43, P13; Ogbodo S O, 2009, Niger J Physiol Sci, V24, P95; Sifakis S, 2000, ANN NY ACAD SCI, V900, P125, DOI 10.1111/j.1749-6632.2000.tb06223.x; Spottiswoode N, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00125; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28	46	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2021	16	4							e0248245	10.1371/journal.pone.0248245	http://dx.doi.org/10.1371/journal.pone.0248245			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH8NB	33793584	Green Published, gold			2023-01-03	WOS:000636467000072
J	Bianchi, F; Sommariva, M; Le Noci, V; Camelliti, S; Gagliano, N; Giussani, M; Balsari, A; Tagliabue, E; Sfondrini, L				Bianchi, Francesca; Sommariva, Michele; Le Noci, Valentino; Camelliti, Simone; Gagliano, Nicoletta; Giussani, Marta; Balsari, Andrea; Tagliabue, Elda; Sfondrini, Lucia			Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity	PLOS ONE			English	Article							VITAMIN-D SUPPLEMENTATION; NATURAL-KILLER-CELLS; ALVEOLAR MACROPHAGES; 25-HYDROXYVITAMIN D; LUNG-CANCER; RISK; CYTOTOXICITY; ACTIVATION; EXPRESSION; PROTEIN	Background 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] plays a role in calcium homeostasis but can also exert immunomodulatory effects. In lungs, characterized by a particular immunosuppressive environment primarily due to the presence of alveolar macrophages (AM), 1,25(OH)2D3 has been shown to favor the immune response against pathogens. Here, we explored the ability of aerosolized 1,25(OH)2D3 to locally promote an anti-tumor phenotype in alveolar macrophages (AM) in the treatment of lung metastases. Methods Cytotoxicity assay has been used to assess the capability of AM, in vitro treated of not with 1,25(OH)2D3, to stimulate NK cells. Sulforhodamine B (SRB) assay has been used to assess the effect of 1,25(OH)2D3 on MC-38 and B16 tumor cells in vitro growth. 1,25(OH)2D3 was aerosolized in immunocompetent mouse models to evaluate the effect of local administration of 1,25(OH)2D3 on in vivo growth of MC-38 and B16 tumor cells within lungs and on infiltrating immune cells. Results In vitro incubation of naive AM with 1,25(OH)2D3 improved their ability to stimulate NK cell cytotoxicity. In vivo aerosolized 1,25(OH)2D3 significantly reduced the metastatic growth of MC-38 colon carcinoma, a tumor histotype that frequently metastasizes to lung in human. Immune infiltrate obtained from digested lungs of 1,25(OH)2D3-treated mice bearing MC-38 metastases revealed an increased expression of MHCII and CD80 on AM and an up-modulation of CD69 expression on effector cells that paralleled a strong increased ability of these cells to kill MC-38 tumor in vitro. Conclusions Together, these data show that aerosol delivery can represent a feasible and novel approach to supplement 1,25(OH)2D3 directly to the lungs promoting the activation of local immunity against cancer.	[Bianchi, Francesca; Sommariva, Michele; Le Noci, Valentino; Camelliti, Simone; Gagliano, Nicoletta; Balsari, Andrea; Sfondrini, Lucia] Univ Milan, Dipartimento Sci Biomed Salute, Milan, Italy; [Bianchi, Francesca; Balsari, Andrea; Tagliabue, Elda] Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Targeting Unit, Milan, Italy; [Giussani, Marta] Fdn IRCCS Ist Nazl Tumori, Dept Diagnost Pathol & Lab, Lab Med Unit, Milan, Italy	University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Sfondrini, L (corresponding author), Univ Milan, Dipartimento Sci Biomed Salute, Milan, Italy.	lucia.sfondrini@unimi.it	Bianchi, Francesca/ABD-5518-2020; LE NOCI, VALENTINO MARIO/C-9504-2017	Bianchi, Francesca/0000-0001-5197-5279; LE NOCI, VALENTINO MARIO/0000-0002-7470-6909; Camelliti, Simone/0000-0001-5072-2798	AIRC (Associazione Italiana per la Ricerca sul Cancro) [12162, 24718]; Fondazione Umberto Veronesi; Piano di Sostegno alla Ricerca 2017 Universita degli Studi di Milano	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi(Fondazione Umberto Veronesi); Piano di Sostegno alla Ricerca 2017 Universita degli Studi di Milano	This work was supported by AIRC (Associazione Italiana per la Ricerca sul Cancro; No 12162 to E. T. and No 24718 to L. S.), by Fondazione Umberto Veronesi (Fellowship 2018 and 2019 to F.B.) and Piano di Sostegno alla Ricerca 2017 Universita degli Studi di Milano. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu el Maaty MA, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0183-6; Abu el Maaty MA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102184; ADAMS JS, 1983, J CLIN INVEST, V72, P1856, DOI 10.1172/JCI111147; Allard B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01777; Artaza JN, 2009, J ENDOCRINOL, V200, P207, DOI 10.1677/JOE-08-0241; Balogh G, 1999, EXP MOL PATHOL, V67, P63, DOI 10.1006/exmp.1999.2264; BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; Bianchi F, 2015, J CELL PHYSIOL, V230, P2661, DOI 10.1002/jcp.24968; Bittenbring JT, 2014, J CLIN ONCOL, V32, P3242, DOI 10.1200/JCO.2013.53.4537; Bjelakovic G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007469.pub2; Bochen F, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1476817; Bozzetto S, 2012, ALLERGY, V67, P10, DOI 10.1111/j.1398-9995.2011.02711.x; Bruns H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3230; Chen GC, 2015, CANCER CAUSE CONTROL, V26, P1719, DOI 10.1007/s10552-015-0665-6; Chishimba L, 2010, THORAX, V65, P456, DOI 10.1136/thx.2009.128793; COHEN MS, 1986, J IMMUNOL, V136, P1049; Divangahi M, 2015, TRENDS IMMUNOL, V36, P307, DOI 10.1016/j.it.2015.03.005; El-Shazly AE, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/373589; Feng QQ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008613; Gerke AK, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-18; Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; Greiller CL, 2015, NUTRIENTS, V7, P4240, DOI 10.3390/nu7064240; Hansdottir S, 2008, J IMMUNOL, V181, P7090, DOI 10.4049/jimmunol.181.10.7090; Hansdottir S, 2011, VITAM HORM, V86, P217, DOI 10.1016/B978-0-12-386960-9.00009-5; Hansdottir S, 2010, J IMMUNOL, V184, P965, DOI 10.4049/jimmunol.0902840; Hernandez Jose L., 2021, Journal of Clinical Endocrinology & Metabolism, V106, pE1343, DOI 10.1210/clinem/dgaa733; Hidaka M, 2013, EUR J PHARMACOL, V721, P305, DOI 10.1016/j.ejphar.2013.09.014; Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8; Jeon SM, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0038-9; Jiang X, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80655-w; Kaneno R, 2002, IMMUNOL LETT, V81, P183, DOI 10.1016/S0165-2478(02)00037-8; Kelly JL, 2015, J CLIN ONCOL, V33, P1482, DOI 10.1200/JCO.2014.57.5092; Le Noci V, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2015892; Le Noci V, 2018, CELL REP, V24, P3528, DOI 10.1016/j.celrep.2018.08.090; Le Noci V, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1040214; Lee GY, 2018, J NUTR BIOCHEM, V55, P178, DOI 10.1016/j.jnutbio.2018.01.004; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Liu W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092736; Mann EH, 2014, ANN NY ACAD SCI, V1317, P57, DOI 10.1111/nyas.12410; Manson JE, 2019, NEW ENGL J MED, V380, P33, DOI [10.1056/NEJMoa1809944, 10.1056/nejmoa1809944]; Martens PJ, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051248; Mattiola I, 2015, J IMMUNOL, V195, P2818, DOI 10.4049/jimmunol.1500325; McCullough ML, 2010, AM J EPIDEMIOL, V172, P21, DOI 10.1093/aje/kwq113; MERINO F, 1989, CELL IMMUNOL, V118, P328, DOI 10.1016/0008-8749(89)90381-X; Mitchell F, 2020, LANCET DIABETES ENDO, V8, P570, DOI 10.1016/S2213-8587(20)30183-2; Mohan M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008874; Mondul AM, 2017, EPIDEMIOL REV, V39, P28, DOI 10.1093/epirev/mxx005; Mortara L, 2018, TARGET ONCOL, V13, P657, DOI 10.1007/s11523-018-0586-x; Najafi M, 2019, J CELL BIOCHEM, V120, P2756, DOI 10.1002/jcb.27646; Nica-Badea D, 2021, ANTI-CANCER AGENT ME, V21, P1942, DOI 10.2174/1871520621666210112115846; Nonn L, 2006, CANCER RES, V66, P4516, DOI 10.1158/0008-5472.CAN-05-3796; Ota K, 2015, EUR J IMMUNOL, V45, P3188, DOI 10.1002/eji.201545541; Powe CE, 2013, NEW ENGL J MED, V369, P1991, DOI 10.1056/NEJMoa1306357; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; QUESADA JM, 1995, CALCIFIED TISSUE INT, V56, P113, DOI 10.1007/BF00296341; Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446; Sommariva M, 2017, CELL IMMUNOL, V313, P52, DOI 10.1016/j.cellimm.2017.01.004; Taylor SK, 2016, LUNG, V194, P931, DOI 10.1007/s00408-016-9939-3; Turdo F, 2016, ONCOTARGET, V7, P69649, DOI 10.18632/oncotarget.11935; Vogiatzi MG, 2014, J CLIN ENDOCR METAB, V99, P1132, DOI 10.1210/jc.2013-3655; Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0; Welsh J, 2007, ACTA PHARMACOL SIN, V28, P1373, DOI 10.1111/j.1745-7254.2007.00700.x; Wierzbicka JM, 2015, INT J ONCOL, V47, P1084, DOI 10.3892/ijo.2015.3088; Wobke TK, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00244; Wu X, 2019, ACTA PHARM SIN B, V9, P203, DOI 10.1016/j.apsb.2018.09.002; XU H, 1993, SCAND J IMMUNOL, V38, P535, DOI 10.1111/j.1365-3083.1993.tb03237.x; Yakoob MY, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008824.pub2; Zhang LQ, 2015, CELL PHYSIOL BIOCHEM, V36, P299, DOI 10.1159/000374072; Zittermann A, 2016, EUR J MED RES, V21, DOI 10.1186/s40001-016-0208-y	70	0	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2021	16	3							e0248789	10.1371/journal.pone.0248789	http://dx.doi.org/10.1371/journal.pone.0248789			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH6OZ	33780475	Green Published, gold			2023-01-03	WOS:000636336800040
J	van Egmond, S; de Vries, E; Hollestein, L; Bastiaens, M; de Roos, KP; Kuijpers, D; Steyerberg, E; Wakkee, M; Mosterd, K; Nijsten, T; de Bekker-Grob, EW				van Egmond, Sven; de Vries, Esther; Hollestein, Loes; Bastiaens, Maarten; de Roos, Kees-Peter; Kuijpers, Danielle; Steyerberg, Ewout; Wakkee, Marlies; Mosterd, Klara; Nijsten, Tamar; de Bekker-Grob, Esther W.			What do patients and dermatologists prefer regarding low-risk basal cell carcinoma follow-up care? A discrete choice experiment	PLOS ONE			English	Article								Background Follow-up after low-risk basal cell carcinoma (BCC) is being provided more frequently than recommended by guidelines. To design an acceptable strategy to successfully reduce this 'low-value' care, it is important to obtain insights into the preferences of patients and dermatologists. Objective To determine the preferences and needs of patients and dermatologists to reduce low-risk BCC follow-up care, and the trade-offs they are willing to make. Methods A questionnaire including a discrete choice experiment was created, containing attributes regarding amount of follow-up, continuity of care, method of providing addition information, type of healthcare provider, duration of follow-up visits and skin examination. In total, 371 BCC patients and all Dutch dermatologists and dermatology residents (n = 620) were invited to complete the questionnaire. A panel latent class model was used for analysis. Results Eighty-four dermatologists and 266 BCC patients (21% and 72% response rates respectively) completed the discrete choice experiment. If the post-treatment visit was performed by the same person as treatment provider and a hand-out was provided to patients containing personalised information, the acceptance of having no additional follow-up visits (i.e. following the guidelines) would increase from 55% to 77% by patients. Female patients and older dermatologists, however, are less willing to accept the guidelines and prefer additional follow-up visits. Limitations The low response rate of dermatologists. Conclusion This discrete choice experiment revealed a feasible strategy to substantially reduce costs, while maintaining quality of care, based on the preferences and needs of BCC patients, which is supported by dermatologists.	[van Egmond, Sven; Hollestein, Loes; Wakkee, Marlies; Nijsten, Tamar] Erasmus MC Canc Inst, Dept Dermatol, Rotterdam, Netherlands; [de Vries, Esther] Pontificia Univ Javeriana, Hosp San Ignacio, Dept Clin Epidemiol & Biostat, Bogota, Colombia; [de Vries, Esther; Steyerberg, Ewout] Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Bastiaens, Maarten] TweeSteden Ziekenhuis, Dept Dermatol, Tilburg, Netherlands; [de Roos, Kees-Peter] DermaPark, Dept Dermatol, Uden, Netherlands; [Kuijpers, Danielle] Amphia Ziekenhuis, Dept Dermatol, Breda, Netherlands; [Steyerberg, Ewout] Leiden Univ Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands; [Mosterd, Klara] Maastricht Univ Med Ctr, Dept Dermatol, Maastricht, Netherlands; [de Bekker-Grob, Esther W.] Erasmus Univ, Sect Hlth Technol Assessment, Rotterdam, Netherlands; [de Bekker-Grob, Esther W.] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Erasmus Choice Modelling Ctr, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Hospital Universitario San Ignacio; Pontificia Universidad Javeriana; Erasmus University Rotterdam; Erasmus MC; Elisabeth-TweeSteden Ziekenhuis (ETZ); Amphia Hospital; Leiden University; Leiden University Medical Center (LUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Erasmus University Rotterdam; Erasmus University Rotterdam	van Egmond, S (corresponding author), Erasmus MC Canc Inst, Dept Dermatol, Rotterdam, Netherlands.	s.vanegmond@erasmusmc.nl	Hollestein, Loes/AFL-0006-2022; de Vries, Esther/A-6603-2009; de Roos, Kees-Peter/B-4364-2014; Steyerberg, Ewout/C-1509-2018	Hollestein, Loes/0000-0001-8922-6791; de Vries, Esther/0000-0002-5560-2258; de Roos, Kees-Peter/0000-0002-2970-8649; van Egmond, Sven/0000-0002-1323-4928; Steyerberg, Ewout/0000-0002-7787-0122	Citrienfonds (Dutch Ministry of Health, Welfare and Sport); health insurance company VGZ	Citrienfonds (Dutch Ministry of Health, Welfare and Sport); health insurance company VGZ	This study was sponsored by Citrienfonds (Dutch Ministry of Health, Welfare and Sport) and the health insurance company VGZ (https://www.vgz.nl/). The funders had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report nor in the decision to submit the article for publication.	[Anonymous], 1999, MEDISCHE PROFIELEN B; Bech M, 2005, HEALTH ECON, V14, P1079, DOI 10.1002/hec.984; Cabana MD, 2004, J FAM PRACTICE, V53, P974; Clark MD, 2014, PHARMACOECONOMICS, V32, P883, DOI 10.1007/s40273-014-0170-x; Cull WL, 2005, HEALTH SERV RES, V40, P213, DOI 10.1111/j.1475-6773.2005.00350.x; Cummings SM, 2001, HEALTH SERV RES, V35, P1347; Cunningham CT, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0016-z; Damery S, 2014, EJSO-EUR J SURG ONC, V40, P1655, DOI 10.1016/j.ejso.2014.04.020; de Bekker-Grob EW, 2015, PATIENT, V8, P373, DOI 10.1007/s40271-015-0118-z; de Bock GH, 2004, BRIT J CANCER, V90, P1144, DOI 10.1038/sj.bjc.6601655; Essers BAB, 2010, PHARMACOECONOMICS, V28, P507, DOI 10.2165/11532240-000000000-00000; Feiten S, 2014, DTSCH ARZTEBL INT, V111, P537, DOI 10.3238/arztebl.2014.0537; Flohil SC, 2011, BRIT J DERMATOL, V165, P874, DOI 10.1111/j.1365-2133.2011.10488.x; Gordon LG, 2015, EUR J CANCER PREV, V24, P141, DOI 10.1097/CEJ.0000000000000056; Greene W.H, 2016, NLOGIT VERSION 5 REF; Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223; Jones R, 1999, BRIT MED J, V319, P1241, DOI 10.1136/bmj.319.7219.1241; Kimman ML, 2010, ACTA ONCOL, V49, P328, DOI 10.3109/02841860903536002; LANCASTER KJ, 1966, J POLIT ECON, V74, P132, DOI 10.1086/259131; Leavitt M, 2001, MedGenMed, V3, P2; Marzuka Alexander G., 2015, Yale Journal of Biology and Medicine, V88, P167; Montgomery DA, 2008, BREAST, V17, P347, DOI 10.1016/j.breast.2008.02.004; Murchie P, 2010, BRIT J CANCER, V102, P1447, DOI 10.1038/sj.bjc.6605638; Murchie P, 2010, SUPPORT CARE CANCER, V18, P225, DOI 10.1007/s00520-009-0648-9; Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV), 2014, EV BAS RICHTL BAS; Saunders CL, 2016, MED CARE, V54, P45, DOI 10.1097/MLR.0000000000000457; Soekhai V, 2019, PHARMACOECONOMICS, V37, P201, DOI 10.1007/s40273-018-0734-2; Street DJ, 2005, INT J RES MARK, V22, P459, DOI 10.1016/j.ijresmar.2005.09.003; Swait J., 1994, J RETAIL CONSUM SERV, V1, P77, DOI [10.1016/0969-6989(94)90002-7, DOI 10.1016/0969-6989(94)90002-7]; Trakatelli M, 2014, EUR J DERMATOL, V24, P312, DOI 10.1684/ejd.2014.2271; van Egmond S, 2019, BRIT J DERMATOL, V180, P122, DOI 10.1111/bjd.16900; van Egmond S., 2018, BRIT J DERMATOL; Verkouteren JAC, 2017, BRIT J DERMATOL, V177, P359, DOI 10.1111/bjd.15321; Wakkee M, 2019, EUR J CANCER, V117, P32, DOI 10.1016/j.ejca.2019.05.010; Watson V, 2017, HEALTH ECON, V26, P810, DOI 10.1002/hec.3354	35	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2021	16	3							e0249298	10.1371/journal.pone.0249298	http://dx.doi.org/10.1371/journal.pone.0249298			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RH6OZ	33780499	gold, Green Published			2023-01-03	WOS:000636336800011
J	Miki, A; Kusuhara, S; Otsuji, T; Kawashima, Y; Miki, K; Imai, H; Nakamura, M; Tsujikawa, A				Miki, Akiko; Kusuhara, Sentaro; Otsuji, Tsuyoshi; Kawashima, Yu; Miki, Katsuaki; Imai, Hisanori; Nakamura, Makoto; Tsujikawa, Akitaka			Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy	PLOS ONE			English	Article								This multicenter retrospective study was conducted to evaluate the 1-year treatment outcome of photodynamic therapy (PDT) combined with anti-vascular endothelial growth factor (VEGF) therapy for pachychoroid neovasculopathy (PNV). A total of 42 eyes of 42 patients with treatment-naive PNV who were treated with PDT combined with intravitreal injections of an anti-VEGF agent (ranibizumab or aflibercept) for 1 year. All eyes showed exudative and/or hemorrhagic changes that affected the fovea at baseline. After the initial combination therapy, subfoveal choroidal thickness (SCT) and central retinal thickness (CRT) were significantly reduced and were maintained as such for 12 months (P < 0.01 in SCT and CRT). The best-corrected visual acuity (BCVA) (0.19 +/- 0.30 at baseline) significantly improved at 3 months (0.15 +/- 0.29, P < 0.05) and further improved at 12 months (0.10 +/- 0.30, P < 0.01) when compared to that at baseline. After the initial combination therapy, 32 eyes (76.2%) required no additional treatments for 12 months. The mean number of additional PDT and intravitreal injections of anti-VEGF agents was 0.1 +/- 0.3 and 0.9 +/- 1.9, respectively. Of the 42 eyes included in this study, 22 eyes (52.4%) had polypoidal lesions at baseline. No significant differences in SCT, CRT, or BCVA were observed at any time points between eyes with and without polypoidal lesions. Of 20 eyes without polypoidal lesions, only 1 eye (5.0%) needed additional treatments. PNV, especially without polypoidal lesions, can be treated effectively with PDT combined with anti-VEGF therapy with few sessions.	[Miki, Akiko; Kusuhara, Sentaro; Imai, Hisanori; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan; [Otsuji, Tsuyoshi; Miki, Katsuaki] Kansai Med Univ, Med Ctr, Dept Ophthalmol, Osaka, Japan; [Kawashima, Yu; Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan	Kobe University; Kansai Medical University; Kyoto University	Miki, A (corresponding author), Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan.	acacyey@med.kobe-u.ac.jp						Arf S, 2020, JPN J OPHTHALMOL, V64, P257, DOI 10.1007/s10384-020-00730-7; Chan WM, 2008, RETINA-J RET VIT DIS, V28, P85, DOI 10.1097/IAE.0b013e318156777f; Chan WM, 2003, AM J OPHTHALMOL, V136, P836, DOI 10.1016/S0002-9394(03)00462-8; Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4; Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008; Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275; Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013; Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967; Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417; Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y; Kitajima Y, 2020, GRAEF ARCH CLIN EXP, V258, P1279, DOI 10.1007/s00417-020-04661-4; Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030; Lee JH, 2016, RETINA-J RET VIT DIS, V36, P889, DOI 10.1097/IAE.0000000000000809; Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1921, DOI 10.1097/IAE.0b013e31822bf6b1; Matsumoto H, 2020, JPN J OPHTHALMOL, V64, P203, DOI 10.1007/s10384-020-00722-7; Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204; Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331; Roy R, 2019, INDIAN J OPHTHALMOL, V67, P1678, DOI 10.4103/ijo.IJO_1481_18; Sartini F, 2020, INT OPHTHALMOL, V40, P3577, DOI 10.1007/s10792-020-01522-1; Schworm B, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65370-w; Smretschnig E, 2016, EYE, V30, P805, DOI 10.1038/eye.2016.41; Yamashiro K, 2020, JPN J OPHTHALMOL, V64, P555, DOI 10.1007/s10384-020-00773-w; Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5; Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758	24	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2021	16	3							e0248760	10.1371/journal.pone.0248760	http://dx.doi.org/10.1371/journal.pone.0248760			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC6NY	33755678	Green Published, gold			2023-01-03	WOS:000632916600018
J	Gerardin, M; Rousselet, M; Couec, ML; Masseau, A; Guerlais, M; Authier, N; Deheul, S; Roussin, A; Micallef, J; Djezzar, S; Feuillet, F; Jolliet, P; Victorri-Vigneau, C				Gerardin, Marie; Rousselet, Morgane; Couec, Marie-Laure; Masseau, Agathe; Guerlais, Marylene; Authier, Nicolas; Deheul, Sylvie; Roussin, Anne; Micallef, Joelle; Djezzar, Samira; Feuillet, Fanny; Jolliet, Pascale; Victorri-Vigneau, Caroline		FAN	Descriptive analysis of sickle cell patients living in France: The PHEDRE cross-sectional study	PLOS ONE			English	Article							QUALITY-OF-LIFE; DISEASE PATIENTS; PAIN; ADOLESCENTS; HEMOGLOBIN; ADULTS; RISK	Background Sickle cell disease (SCD) induces chronic haemolytic anaemia and intermittent vaso-occlusion that results in tissue ischaemia causing acute, severe pain episodes that can lead to frequent hospitalizations. These consequences can have repercussions on family, social, school and/or professional life. Here, we present some of the results of the PHEDRE study (Pharmacodependance Et DREpanocytose-drug dependence and sickle-cell disease), which is the largest study of patients with SCD in France. This paper intends to describe characteristics of the French SCD population. We also aimed to assess the impact of the disease on the lives of patients using objective and subjective variables. Methods The PHEDRE study was a national multicentric observational study. Adults, adolescents and children with a confirmed SCD diagnosis were included in the study by their referring doctor. Then, they were interviewed by phone about their socioeconomic status, about the impact of the disease on their lives and about their analgesic and psychoactive drug use. Results The study population consisted of 872 patients (28% were minors). Seventy-two percent of adults were active, and all minors were in school. Many patients presented criteria of severe SCD. Seventy-five percent were homozygous SS, 15% were double heterozygotes SC and 8% were heterozygotes S beta thal, 87% received specific treatment, 58% were hospitalized at least once for vaso-occlusive crisis in the past 12 months, and the number of analgesic drugs taken averaged 3.8. Seventy-five percent of patients reported academic or professional consequences related to their SCD, and 52% reported social consequences. Conclusions The impact of SCD on patients' lives can be significant, nevertheless their social integration seems to be maintained. We highlighted respect of recommendations regarding analgesic treatments and only a few patients used tobacco, alcohol or cannabis.	[Gerardin, Marie; Rousselet, Morgane; Guerlais, Marylene; Jolliet, Pascale; Victorri-Vigneau, Caroline] CHU Nantes, Serv Pharmacol Clin, Nantes, France; [Rousselet, Morgane] CHU Nantes, Serv Addictol & Psychiat, Nantes, France; [Rousselet, Morgane; Feuillet, Fanny; Jolliet, Pascale; Victorri-Vigneau, Caroline] Univ Nantes & Tours, INSERM, U1246 SPHERE Methods Patient Ctr Outcomes & Hlth, Nantes, France; [Couec, Marie-Laure] CHU Nantes, Serv Pediat & Oncol Pediat, Nantes, France; [Masseau, Agathe] CHU Nantes, Serv Med Interne, Nantes, France; [Authier, Nicolas] CHU Clermont Ferrand, Serv Pharmacol Med, Clermont Ferrand, France; [Deheul, Sylvie] CHU Lille, Serv Pharmacol, Lille, France; [Roussin, Anne] CHU Toulouse, Serv Pharmacol Med & Clin, Toulouse, France; [Micallef, Joelle] Hop La Timone, AP HM, Serv Pharmacol Clin, Marseille, France; [Djezzar, Samira] Hop Fernand Widal, AP HP, Ctr Evaluat & Informat Pharmacodependence Addicto, Paris, France; [Feuillet, Fanny] CHU Nantes, Plateforme Biometrie, Nantes, France	Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; CHU Clermont Ferrand; Universite de Lille - ISITE; CHU Lille; CHU de Toulouse; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Nantes Universite; CHU de Nantes	Victorri-Vigneau, C (corresponding author), CHU Nantes, Serv Pharmacol Clin, Nantes, France.; Victorri-Vigneau, C (corresponding author), Univ Nantes & Tours, INSERM, U1246 SPHERE Methods Patient Ctr Outcomes & Hlth, Nantes, France.	pharmacodependance@chu-nantes.fr	Roussin, Anne/E-3557-2018	Djezzar, Samira/0000-0003-2413-230X; Rousselet, Morgane/0000-0003-4027-7963	French health products agency (Agence Nationale de Securite du Medicament et des produits de sante - ANSM) [AAP-2014-009]	French health products agency (Agence Nationale de Securite du Medicament et des produits de sante - ANSM)(French National Research Agency (ANR))	For this project (AAP-2014-009), the University Hospital of Nantes has received funding only from the French health products agency (Agence Nationale de Securite du Medicament et des produits de sante - ANSM) (www.ansm.sante.fr).The ANSM had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Zahrani OS, 2019, SAUDI MED J, V40, P59, DOI 10.15537/smj.2019.1.22919; Alrayyes Sahar, 2018, Dis Mon, V64, P283, DOI 10.1016/j.disamonth.2017.12.003; Anie KA, 2005, BRIT J HAEMATOL, V129, P723, DOI 10.1111/j.1365-2141.2005.05500.x; [Anonymous], ORPHANET PROPOS MALA; [Anonymous], 1 TRIM 2019 TAUX CHO; [Anonymous], PRIS CHARG DREP CHEZ; [Anonymous], INS SCI SANT; [Anonymous], MEN SEL STRUCT FAM 2; [Anonymous], ALD 10 SYNDR DREP MA; [Anonymous], RET SCOL ENTR 6 PLUS; ANSM: Agence nationale de securite du medicament et des produits de sante, 2017, ET LIEUX CONS BENZ P; Atoui M, 2015, J PEDIATR HEALTH CAR, V29, P424, DOI 10.1016/j.pedhc.2015.01.012; Brown SE, 2015, J PAIN SYMPTOM MANAG, V49, P539, DOI 10.1016/j.jpainsymman.2014.06.007; Chakravorty S, 2018, ARCH DIS CHILD, V103, P1104, DOI 10.1136/archdischild-2018-314955; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Cooper O, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1136-7; Cronin RM, 2019, HEMATOLOGY, V24, P189, DOI 10.1080/16078454.2018.1549801; Dampier C, 2017, J PAIN, V18, P490, DOI 10.1016/j.jpain.2016.12.016; Depistage neonatal de la drepanocytose en France, HAUT AUT SANT; Di Maggio R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030681; Eiser C, 2001, QUAL LIFE RES, V10, P347, DOI 10.1023/A:1012253723272; de Freitas SLF, 2018, REV BRAS ENFERM, V71, P195, DOI 10.1590/0034-7167-2016-0409; Fitzpatrick P, 2019, IRISH J MED SCI, V188, P921, DOI 10.1007/s11845-018-1949-0; Fosdal MB, 2015, J PEDIATR ONCOL NURS, V32, P5, DOI 10.1177/1043454214555193; Gerardin M, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0677-5; Gil KM, 2004, HEALTH PSYCHOL, V23, P267, DOI 10.1037/0278-6133.23.3.267; Goldstein-Leever A, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27027; Graves J Kelly, 2016, Pediatr Nurs, V42, P113; Habibi A, 2015, REV MED INTERNE, V36, p5S3, DOI 10.1016/S0248-8663(15)60002-9; Hijmans CT, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-121; Howard J, 2005, BRIT J HAEMATOL, V131, P123, DOI 10.1111/j.1365-2141.2005.05723.x; Jesus Amanda Cristina da Silva de, 2018, Rev. paul. pediatr., V36, P491, DOI 10.1590/1984-0462/;2018;36;4;00010; John-Olabode Sarah, 2015, Niger Med J, V56, P204, DOI 10.4103/0300-1652.160397; Little I, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012665; Madani BM, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-1009-5; Mangla A., 2020, STATPEARLS; Mastandrea EB, 2015, SAO PAULO MED J, V133, P421, DOI 10.1590/1516-3180.2015.00171105; Piel FB, 2013, LANCET, V381, P142, DOI 10.1016/S0140-6736(12)61229-X; Po' C, 2013, CLIN J PAIN, V29, P60, DOI 10.1097/AJP.0b013e318245764b; Poku BA, 2017, INT J NURS STUD, V80, P20, DOI 10.1016/j.ijnurstu.2017.12.008; Rees DC, 2010, LANCET, V376, P2018, DOI 10.1016/S0140-6736(10)61029-X; Russo G, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1099-0; Saraf SL, 2014, PAEDIATR RESPIR REV, V15, P4, DOI 10.1016/j.prrv.2013.11.003; Serjeant GR, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011783; Souza RC, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091638; Thomas VJ, 2002, BRIT J HEALTH PSYCH, V7, P345, DOI 10.1348/135910702760213724; Toumi ML, 2018, LIFE SCI, V210, P96, DOI 10.1016/j.lfs.2018.08.066; Valrie CR, 2018, J PEDIAT HEMATOL ONC, V40, P116, DOI 10.1097/MPH.0000000000001067; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Wallen GR, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-207; Weatherall DJ, 2010, BLOOD, V115, P4331, DOI 10.1182/blood-2010-01-251348; Williams H, 2018, J HEALTH CARE POOR U, V29, P814, DOI 10.1353/hpu.2018.0060	52	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0248649	10.1371/journal.pone.0248649	http://dx.doi.org/10.1371/journal.pone.0248649			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QZ9HN	33735176	gold, Green Published			2023-01-03	WOS:000631029700079
J	Zhao, MM; Hoti, K; Wang, H; Raghu, A; Katabi, D				Zhao, Mingmin; Hoti, Kreshnik; Wang, Hao; Raghu, Aniruddh; Katabi, Dina			Assessment of medication self-administration using artificial intelligence	NATURE MEDICINE			English	Article							INHALER TECHNIQUE; ADHERENCE; BARRIERS; ASTHMA; ERRORS	Artificial intelligence coupled with wireless home sensors can monitor the use of insulin pens and inhalers by patients and alert of errors in self-medication in an unobtrusive manner. Errors in medication self-administration (MSA) lead to poor treatment adherence, increased hospitalizations and higher healthcare costs. These errors are particularly common when medication delivery involves devices such as inhalers or insulin pens. We present a contactless and unobtrusive artificial intelligence (AI) framework that can detect and monitor MSA errors by analyzing the wireless signals in the patient's home, without the need for physical contact. The system was developed by observing self-administration conducted by volunteers and evaluated by comparing its prediction with human annotations. Findings from this study demonstrate that our approach can automatically detect when patients use their inhalers (area under the curve (AUC) = 0.992) or insulin pens (AUC = 0.967), and assess whether patients follow the appropriate steps for using these devices (AUC = 0.952). The work shows the potential of leveraging AI-based solutions to improve medication safety with minimal overhead for patients and health professionals.	[Zhao, Mingmin; Hoti, Kreshnik; Wang, Hao; Raghu, Aniruddh; Katabi, Dina] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Hoti, Kreshnik] Univ Prishtina, Fac Med, Div Pharm, Prishtina, Kosovo	Massachusetts Institute of Technology (MIT)	Zhao, MM; Hoti, K (corresponding author), MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Hoti, K (corresponding author), Univ Prishtina, Fac Med, Div Pharm, Prishtina, Kosovo.	mingmin@mit.edu; kreshnik@mit.edu		Hoti, Kreshnik/0000-0001-7652-6074; Zhao, Mingmin/0000-0001-5226-9085	Fulbright scholarship; Delta Electronics [6934407]	Fulbright scholarship; Delta Electronics	We thank the editor and the reviewers for their insightful comments and feedback. We are grateful to S. Desselle, L. Celi, L. Xing, X. Li, H. Hsu, J. Stokes, Z. Hussain, U. Munir, D. Vasisht, C.-Y. Hsu, G. Zhang, S. Yue, H. He, L. Fan, Y. Yang, T. Li, Y. Liu, H. Rahul, Z. Kabelac and R. Hristov for their comments on our manuscript. We also thank all the individuals who participated in our study. D.K., M.Z., H.W. and A.R. are funded by Delta Electronics (6934407). K.H. is funded by a Fulbright scholarship.	Adib F., 2014, P 11 USENIX C NETW S, P317, DOI DOI 10.5555/2616448.2616478; Adib F, 2015, CHI 2015: PROCEEDINGS OF THE 33RD ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, P837, DOI 10.1145/2702123.2702200; Aldeer M, 2018, APPL SYST INNOV, V1, DOI 10.3390/asi1020014; [Anonymous], 2016, INT C LEARN REPR; Cohen JL, 2009, ANN ALLERG ASTHMA IM, V103, P325, DOI 10.1016/S1081-1206(10)60532-7; Cooke CE, 2010, CURR MED RES OPIN, V26, P231, DOI 10.1185/03007990903421994; Fan L, 2020, P IEEE CVF C COMP VI, P10699; Frid AH, 2016, MAYO CLIN PROC, V91, P1231, DOI 10.1016/j.mayocp.2016.06.010; Giraud V, 2011, RESP MED, V105, P1815, DOI 10.1016/j.rmed.2011.07.004; Goris S, 2013, J AEROSOL MED PULM D, V26, P336, DOI 10.1089/jamp.2012.1017; Graves A., 2006, P 23 INT C MACH LEAR, P369; Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319; Hochreiter S, 1997, NEURAL COMPUT, V9, P1735, DOI [10.1162/neco.1997.9.1.1, 10.1007/978-3-642-24797-2]; Hsu C.-Y., 2019, P 2019 CHI C HUM FAC, P1, DOI DOI 10.13031/AIM.201901464; Hsu CY, 2017, PROCEEDINGS OF THE 2017 ACM SIGCHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI'17), P2116, DOI 10.1145/3025453.3025937; Iuga AO, 2014, RISK MANAG HEALTHC P, V7, P35, DOI 10.2147/RMHP.S19801; Kabelac Zachary, 2019, Digit Biomark, V3, P22, DOI 10.1159/000498922; Kelly P, 2013, AM J PREV MED, V44, P314, DOI 10.1016/j.amepre.2012.11.006; Lam WY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/217047; Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410; Lavorini F, 2008, RESP MED, V102, P593, DOI 10.1016/j.rmed.2007.11.003; Lavorini F, 2019, THER ADV RESPIR DIS, V13, DOI 10.1177/1753466619884532; Lippi G, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105941; Melani AS, 2011, RESP MED, V105, P930, DOI 10.1016/j.rmed.2011.01.005; Molimard M, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01794-2016; Murphy A, 2020, EVALUATION-US, V14, P19; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Peyrot M, 2012, DIABETIC MED, V29, P682, DOI 10.1111/j.1464-5491.2012.03605.x; Price D, 2013, RESP MED, V107, P37, DOI 10.1016/j.rmed.2012.09.017; Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28; Ruud KW, 2018, PATIENT EDUC COUNS, V101, P1828, DOI 10.1016/j.pec.2018.05.018; Samaranayake NR., 2013, ADV PHARMACOEPIDEMIO, V2, P1; Selvin E, 2016, DIABETES CARE, V39, pE33, DOI 10.2337/dc15-2229; Spain CV, 2016, CLIN THER, V38, P1653, DOI 10.1016/j.clinthera.2016.05.009; Spollett G, 2016, DIABETES EDUCATOR, V42, P379, DOI 10.1177/0145721716648017; Stegemann S, 2012, EUR GERIATR MED, V3, P254, DOI 10.1016/j.eurger.2012.05.004; Trief Paula M, 2016, Clin Diabetes, V34, P25, DOI 10.2337/diaclin.34.1.25; Truong TH, 2017, DIABETES THER, V8, P221, DOI 10.1007/s13300-017-0242-y; URQUHART J, 1994, CLIN PHARMACOKINET, V27, P202, DOI 10.2165/00003088-199427030-00004; Viswanathan M, 2012, ANN INTERN MED, V157, P785, DOI 10.7326/0003-4819-157-11-201212040-00538; Wang W, 2016, UBICOMP'16: PROCEEDINGS OF THE 2016 ACM INTERNATIONAL JOINT CONFERENCE ON PERVASIVE AND UBIQUITOUS COMPUTING, P363, DOI 10.1145/2971648.2971670; Wu YX, 2018, LECT NOTES COMPUT SC, V11217, P3, DOI 10.1007/978-3-030-01261-8_1; Yonglong Tian, 2018, Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies, V2, DOI 10.1145/3264947; Zhao MM, 2018, PROC CVPR IEEE, P7356, DOI 10.1109/CVPR.2018.00768; Zhao MM, 2018, PROCEEDINGS OF THE 2018 CONFERENCE OF THE ACM SPECIAL INTEREST GROUP ON DATA COMMUNICATION (SIGCOMM '18), P267, DOI 10.1145/3230543.3230579; Zhao MM, 2017, PR MACH LEARN RES, V70; Zhao MM, 2016, MOBICOM'16: PROCEEDINGS OF THE 22ND ANNUAL INTERNATIONAL CONFERENCE ON MOBILE COMPUTING AND NETWORKING, P95, DOI 10.1145/2973750.2973762; Zullig Leah L, 2015, Patient Prefer Adherence, V9, P139, DOI 10.2147/PPA.S69651	48	3	3	3	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01273-1	http://dx.doi.org/10.1038/s41591-021-01273-1		MAR 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33737750	Bronze			2023-01-03	WOS:000630281500003
J	West, HM; Milliren, CE; Vragovic, O; Kohler, JR; Yarrington, C				West, Helen Mahoney; Milliren, Carly E.; Vragovic, Olivera; Kohler, Julia R.; Yarrington, Christina			Perceived barriers to Chagas disease screening among a diverse group of prenatal care providers	PLOS ONE			English	Article								Background Chagas disease is a vector borne infection of poverty endemic to Latin America which affects an estimated 40,000 women of child-bearing age in the United States (US). In the US Chagas disease is concentrated among individuals who have lived in endemic areas. Prenatal diagnosis and treatment are needed to prevent congenital transmission. The objective of this study was to assess perceived barriers to Chagas disease screening among prenatal care providers in Obstetrics/Gynecology and Family Medicine Departments of a tertiary care safety-net hospital caring for a significant at-risk population. Methodology/Principal findings An anonymous survey was distributed to 178 Obstetrics/Gynecology and Family Medicine practitioners. Of the 66 respondents, 39% thought Chagas screening was very important, and 48% somewhat important as a public health initiative. One third judged screening patients during clinic visits as very important. Most respondents (64%) reported being familiar with Chagas disease. However, only 32% knew how to order a test and only 22% reported knowing what to do if a test was positive. Conclusions/Significance These findings will be incorporated into measures to facilitate full implementation of Chagas screening, and can inform initiatives at other centers who wish to address this deeply neglected infection among their patient families. Greater integration of information on Chagas disease screening and treatment in medical and nursing education curricula can contribute to addressing this disease with the focus that its potentially fatal sequelae merit.	[West, Helen Mahoney; Kohler, Julia R.] Boston Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA; [West, Helen Mahoney] Simmons Univ, Sch Nursing, Boston, MA 02115 USA; [Milliren, Carly E.] Boston Childrens Hosp, Inst Ctr Clin & Translat Res, Boston, MA USA; [Vragovic, Olivera; Yarrington, Christina] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kohler, Julia R.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Yarrington, Christina] Boston Med Ctr, Dept Obstet Gynecol, Boston, MA USA	Harvard University; Boston Children's Hospital; Simmons University; Harvard University; Boston Children's Hospital; Boston University; Harvard University; Harvard Medical School; Boston Medical Center	West, HM (corresponding author), Boston Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA.; West, HM (corresponding author), Simmons Univ, Sch Nursing, Boston, MA 02115 USA.	helen.mahoney-west@childrens.harvard.edu		Yarrington, Christina/0000-0001-6380-8400; Milliren, Carly/0000-0001-6280-8417	National Library of Medicine [1G08LM013191-01]	National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This work was supported in the form of funding from the National Library of Medicine (nlm. nih.gov) (Grant No. 1G08LM013191-01) awarded to JRK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, Wkly Epidemiol Rec, V90, P33; Bennett C, 2018, MMWR-MORBID MORTAL W, V67, P738, DOI 10.15585/mmwr.mm6726a2; Bern C, 2015, NEW ENGL J MED, V373, P1882, DOI [10.1056/NEJMra1410150, 10.1056/NEJMc1510996]; Carlier Y, 2019, PLOS NEGL TROP DIS, V13, P1; Center for Disease Control and Prevention, 2020, CHAG DIS; Edwards MS, 2019, J PEDIAT INF DIS SOC, V8, P461, DOI 10.1093/jpids/piz018; Edwards MS, 2018, PEDIATR INFECT DIS J, V37, pE24, DOI 10.1097/INF.0000000000001733; Fabbro DL., 2014, PLOS NEGL TROP DIS, V8, P1; Forsyth C, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007447; Gascon J, 2007, REV ESP CARDIOL, V60, P285, DOI 10.1157/13100280; Lee BY, 2013, LANCET INFECT DIS, V13, P342, DOI 10.1016/S1473-3099(13)70002-1; Manne-Goehler J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005033; Manne-Goehler J, 2015, AM J TROP MED HYG, V93, P108, DOI 10.4269/ajtmh.14-0826; Messenger LA, 2018, CURR OPIN INFECT DIS, V31, P415, DOI [10.1097/QCO.0000000000000478, 10.1097/qco.0000000000000478]; Pan American Health Organization, 2019, GUID DIAGN TREATM CG; Patterson NM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006841; Ribeiro I., 2016, PLOS NEGL TROP DIS, V10, P1; Ribeiro I, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000484; Sosa-Estani S, 2009, REV SOC BRAS MED TRO, V42, P484, DOI 10.1590/S0037-86822009000500002; Stimpert KK, 2010, EMERG INFECT DIS, V16, P871, DOI 10.3201/eid1605.091440; Verani JR, 2010, AM J TROP MED HYG, V83, P891, DOI 10.4269/ajtmh.2010.09-0543	21	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2021	16	2							e0246783	10.1371/journal.pone.0246783	http://dx.doi.org/10.1371/journal.pone.0246783			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BP	33635887	Green Published, gold			2023-01-03	WOS:000624538400030
J	Mussini, C; Cozzi-Lepri, A; Menozzi, M; Meschiari, M; Franceschini, E; Milic, J; Brugioni, L; Pietrangelo, A; Girardis, M; Cossarizza, A; Tonelli, R; Clini, E; Massari, M; Bartoletti, M; Ferrari, A; Cattelan, AM; Zuccala, P; Lichtner, M; Rossotti, R; Girardi, E; Nicastri, E; Puoti, M; Antinori, A; Viale, P; Guaraldi, G				Mussini, Cristina; Cozzi-Lepri, Alessandro; Menozzi, Marianna; Meschiari, Marianna; Franceschini, Erica; Milic, Jovana; Brugioni, Lucio; Pietrangelo, Antonello; Girardis, Massimo; Cossarizza, Andrea; Tonelli, Roberto; Clini, Enrico; Massari, Marco; Bartoletti, Michele; Ferrari, Anna; Cattelan, Anna Maria; Zuccala, Paola; Lichtner, Miriam; Rossotti, Roberto; Girardi, Enrico; Nicastri, Emanuele; Puoti, Massimo; Antinori, Andrea; Viale, Pierluigi; Guaraldi, Giovanni			Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection	PLOS ONE			English	Article							COVID-19	Background The aim of this secondary analysis of the TESEO cohort is to identify, early in the course of treatment with tocilizumab, factors associated with the risk of progressing to mechanical ventilation and death and develop a risk score to estimate the risk of this outcome according to patients' profile. Methods Patients with COVID-19 severe pneumonia receiving standard of care + tocilizumab who were alive and free from mechanical ventilation at day 6 after treatment initiation were included in this retrospective, multicenter cohort study. Multivariable logistic regression models were built to identify predictors of mechanical ventilation or death by day-28 from treatment initiation and beta-coefficients were used to develop a risk score. Secondary outcome was mortality. Patients with the same inclusion criteria as the derivation cohort from 3 independent hospitals were used as validation cohort. Results 266 patients treated with tocilizumab were included. By day 28 of hospital follow-up post treatment initiation, 40 (15%) underwent mechanical ventilation or died [26 (10%)]. At multivariable analysis, sex, day-4 PaO2/FiO(2) ratio, platelets and CRP were independently associated with the risk of developing the study outcomes and were used to generate the proposed risk score. The accuracy of the score in AUC was 0.80 and 0.70 in internal validation and test for the composite endpoint and 0.92 and 0.69 for death, respectively. Conclusions Our score could assist clinicians in identifying, early after tocilizumab administration, patients who are likely to progress to mechanical ventilation or death, so that they could be selected for eventual rescue therapies.	[Mussini, Cristina; Menozzi, Marianna; Meschiari, Marianna; Franceschini, Erica; Guaraldi, Giovanni] Policlin Modena, Azienda Osped Univ, Dept Infect Dis, Modena, Italy; [Mussini, Cristina; Milic, Jovana; Girardis, Massimo; Guaraldi, Giovanni] Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, Modena, Italy; [Cozzi-Lepri, Alessandro] UCL, UCL Populat Hlth Sci, Inst Global Hlth, Ctr Clin Res Epidemiol Modelling & Evaluat CREME, London, England; [Brugioni, Lucio] Policlin Modena, Azienda Osped Univ, Internal Med Dept, Modena, Italy; [Pietrangelo, Antonello; Cossarizza, Andrea; Clini, Enrico] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy; [Girardis, Massimo] Policlin Modena, Azienda Osped Univ, Dept Anaesthesia & Intens Care Unit, Modena, Italy; [Tonelli, Roberto; Clini, Enrico] Policlin Modena, Azienda Osped Univ, Resp Dis Unit, Modena, Italy; [Massari, Marco] Azienda USL IRCCS Reggio Emilia, Infect Dis Unit, Reggio Emilia, Italy; [Bartoletti, Michele; Viale, Pierluigi] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy; [Ferrari, Anna; Cattelan, Anna Maria] Univ Padua, Azienda Osped, Infect Dis Unit, Padua, Italy; [Zuccala, Paola; Lichtner, Miriam] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Polo Pontino, Rome, Italy; [Rossotti, Roberto] Niguarda Hosp Milan, Milan, Italy; [Girardi, Enrico; Nicastri, Emanuele; Puoti, Massimo; Antinori, Andrea] Natl Inst Infect Dis L Spallanzani INMI, Rome, Italy; [Puoti, Massimo] Univ Milano Bicocca, Sch Med, Milan, Italy	Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Universita di Modena e Reggio Emilia; University of London; University College London; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; University of Bologna; University of Padua; Azienda Ospedaliera - Universita di Padova; Sapienza University Rome; IRCCS Lazzaro Spallanzani; University of Milano-Bicocca	Mussini, C (corresponding author), Policlin Modena, Azienda Osped Univ, Dept Infect Dis, Modena, Italy.; Mussini, C (corresponding author), Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, Modena, Italy.	cristina.mussini@unimore.it	Meschiari, Marianna/AAC-1916-2022; Tonelli, Roberto/AAB-7569-2022; franceschini, erica/AAC-4025-2022; Pietrangelo, Antonello/K-1517-2016; Mussini, Cristina/K-8672-2016; Clini, Enrico/A-4496-2017; GIRARDIS, Massimo/K-8974-2016	Meschiari, Marianna/0000-0002-1254-9995; Tonelli, Roberto/0000-0002-6202-0758; Pietrangelo, Antonello/0000-0002-7411-935X; Mussini, Cristina/0000-0002-6615-4198; Antinori, Andrea/0000-0003-2121-4684; Clini, Enrico/0000-0002-1515-5094; GIRARDIS, Massimo/0000-0002-2453-0829; Ferrari, Anna/0000-0001-6924-6306; Franceschini, Erica/0000-0001-6922-5759	Italian Ministry of Health [202012371675]	Italian Ministry of Health(Ministry of Health, Italy)	This work was supported by Progetto Covid 202012371675 funded by Italian Ministry of Health.	Bartoletti M, 2020, CLIN MICROBIOL INFEC, V26, P1545, DOI 10.1016/j.cmi.2020.08.003; Berardicurti O, 2020, CLIN EXP RHEUMATOL, V38, P1247; Biran N, 2020, LANCET RHEUMATOL, V2, pE603, DOI 10.1016/S2665-9913(20)30277-0; Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2; Cozzi-Lepri A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025665; Ferrari D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239172; Gordon Anthony C., INTERLEUKIN 6 RECEPT, DOI [10.1101/2021.01.07.21249390v1, DOI 10.1101/2021.01.07.21249390V1]; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Hariyanto TI, 2021, J MED VIROL, V93, P1832, DOI 10.1002/jmv.26698; Hennigan Stephanie, 2008, Ther Clin Risk Manag, V4, P767; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273, 10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.07.15.20151852]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0; Malgie J, 2021, CLIN INFECT DIS, V72, pE742, DOI 10.1093/cid/ciaa1445; Monforte AD, 2020, INT J INFECT DIS, V100, P67, DOI 10.1016/j.ijid.2020.09.037; Navarro-Millan I, 2020, ARTHRITIS RHEUMATOL, V72, P1990, DOI 10.1002/art.41422; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Tleyjeh IM, 2021, CLIN MICROBIOL INFEC, V27, P215, DOI 10.1016/j.cmi.2020.10.036	22	4	4	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2021	16	2							e0247275	10.1371/journal.pone.0247275	http://dx.doi.org/10.1371/journal.pone.0247275			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QO8DE	33621264	Green Published, gold			2023-01-03	WOS:000623367700028
J	Tuohy, JF; Bloomfield, FH; Crowther, CA; Harding, JE				Tuohy, Jeremy F.; Bloomfield, Frank H.; Crowther, Caroline A.; Harding, Jane E.			Maternal and neonatal glycaemic control after antenatal corticosteroid administration in women with diabetes in pregnancy: A retrospective cohort study	PLOS ONE			English	Article							GLUCOSE; INSULIN; HYPOGLYCEMIA; BABIES; BETAMETHASONE; MELLITUS; OUTCOMES; TRENDS	Objective To describe maternal and neonatal glycaemic control following antenatal corticosteroid administration to women with diabetes in pregnancy. Design Retrospective cohort study Setting A tertiary hospital in Auckland, New Zealand Population Women with diabetes in pregnancy who received antenatal corticosteroids from 2006-2016. Methods Corticosteroid administration, maternal and neonatal glycaemia data were retrieved from electronic patient records. Demographic data were downloaded from the hospital database. Relationships between variables were analysed using multivariate analysis. Main outcome measures Maternal hyperglycaemia and neonatal hypoglycaemia Results Corticosteroids were administered to 647 of 7317 of women with diabetes (8.8%) who gave birth to 715 babies. After an initial course of corticosteroids, 92% and 52% of women had blood glucose concentrations > 7 and > 10 mmol/L respectively. Median peak blood glucose concentration of approximately 10 mmol/L occurred 9 hours after corticosteroid administration and hyperglycaemia lasted approximately 72 hours. Thirty percent of women gave birth within 72 hours of the last dose of corticosteroids. Babies of women who were hyperglycaemic within 24 hours of birth were more likely to develop hypoglycaemia (< 2.6 mmol/L, OR 1.51 [95% CI 1.10-2.07], p = 0.01) and severe hypoglycaemia (<= 2.0 mmol/L, OR 2.00 [95% CI 1.41-2.85], p < 0.0001) than babies of non-hyperglycaemic mothers. There was no association between maternal glycaemia within 7 days of the last dose of corticosteroids and neonatal hypoglycaemia. Conclusions Hyperglycaemia is common in women with diabetes in pregnancy following antenatal corticosteroid administration. Maternal hyperglycaemia in the 24 hours prior to birth is associated with increased risk of neonatal hypoglycaemia. Limitations included the retrospective study design, so that not all data were available for all women and babies and the glucose testing schedule was variable.	[Tuohy, Jeremy F.; Bloomfield, Frank H.; Crowther, Caroline A.; Harding, Jane E.] Univ Auckland, Liggins Inst, Auckland, New Zealand	University of Auckland	Harding, JE (corresponding author), Univ Auckland, Liggins Inst, Auckland, New Zealand.	j.harding@auckland.ac.nz			Lotteries Health Research Grant [190606-002467]	Lotteries Health Research Grant	JT received 190606-002467 Lotteries Health Research Grant. https://www.communitymatters.govt.nz/lottery-grants-board/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alsweiler JM, 2012, PEDIATRICS, V129, P639, DOI 10.1542/peds.2011-2470; Antenatal Corticosteroids Clinical Practice Guidelines Panel, 2015, ANT CORT GIV WOM PRI; Auckland District Health Board, 2017, NEWB CLIN GUID HYP M; Auckland District Health Board, 2017, DIABETES PREGNANCY; Brownfoot FC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006764.pub3; Dalfra MG, 2016, J MATERN-FETAL NEO M, V29, P2889, DOI 10.3109/14767058.2015.1107903; Fadl HE, 2010, DIABETIC MED, V27, P436, DOI 10.1111/j.1464-5491.2010.02978.x; Feig DS, 2017, LANCET, V390, P2347, DOI 10.1016/S0140-6736(17)32400-5; Gyamfi-Bannerman C, 2016, NEW ENGL J MED, V374, P1311, DOI 10.1056/NEJMoa1516783; Harris DL, 2013, LANCET, V382, P2077, DOI 10.1016/S0140-6736(13)61645-1; Harris DL, 2012, J PEDIATR-US, V161, P787, DOI 10.1016/j.jpeds.2012.05.022; Iafusco Dario, 2008, BMC Pregnancy Childbirth, V8, P23, DOI 10.1186/1471-2393-8-23; Itoh A, 2016, ENDOCR J, V63, P101, DOI 10.1507/endocrj.EJ15-0482; Jolley JA, 2016, DIABETES RES CLIN PR, V118, P98, DOI 10.1016/j.diabres.2016.06.005; KENEPP NB, 1982, LANCET, V1, P1150; KUHL C, 1982, ACTA PAEDIATR SCAND, V71, P19, DOI 10.1111/j.1651-2227.1982.tb09366.x; Mathiesen ER, 2002, ACTA OBSTET GYN SCAN, V81, P835, DOI 10.1034/j.1600-0412.2002.810906.x; National Institute for Health and Care Excellence, 2015, DIAB PREGN MAN PREC; Paul R, 2019, AUST NZ J OBSTET GYN, V59, P463, DOI 10.1111/ajo.12963; Pettit KE, 2014, J MATERN-FETAL NEO M, V27, P683, DOI 10.3109/14767058.2013.832750; Polyakov A, 2007, AUST NZ J OBSTET GYN, V47, P42, DOI 10.1111/j.1479-828X.2006.00677.x; Razaz N, 2015, OBSTET GYNECOL, V125, P288, DOI 10.1097/AOG.0000000000000629; Roberts D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub3; Rowe CW, 2019, DIABETIC MED, V36, P228, DOI 10.1111/dme.13864; Shah R, 2019, NEONATOLOGY, V115, P116, DOI 10.1159/000492859; Star J, 2000, J Matern Fetal Med, V9, P273; Tuohy JF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229014; Tuohy JF, 2019, AUST NZ J OBSTET GYN, V59, P416, DOI 10.1111/ajo.12890; Yamamoto JM, 2018, DIABETIC MED, V35, P173, DOI 10.1111/dme.13546; Yu F, 2014, J CLIN ENDOCR METAB, V99, P4674, DOI 10.1210/jc.2013-4332	30	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2021	16	2							e0246175	10.1371/journal.pone.0246175	http://dx.doi.org/10.1371/journal.pone.0246175			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8JB	33600450	Green Published, gold			2023-01-03	WOS:000620625100006
J	Chin, CH; Tseng, LM; Chao, TC; Wang, TJ; Wu, SF; Liang, SY				Chin, Chia-Hui; Tseng, Ling-Ming; Chao, Ta-Chung; Wang, Tsae-Jyy; Wu, Shu-Fang; Liang, Shu-Yuan			Self-care as a mediator between symptom-management self-efficacy and quality of life in women with breast cancer	PLOS ONE			English	Article							EORTC QLQ-C30; VALIDATION; DISTRESS; QUESTIONNAIRE; CHEMOTHERAPY; TRANSLATION; OUTPATIENTS; EDUCATION; PROGRAM; PAIN	Background The important role of self-efficacy in facilitating health behavior and, in turn, promoting health outcomes has been widely presumed in the theoretical literature. However, little research has focused on the mechanism by which self-care mediates the relationship between symptom-management self-efficacy and quality of life (QOL) in breast cancer patients. Objective The purpose of this study was to examine the relationship between symptom-management self-efficacy and quality of life in Taiwanese oncology outpatients with breast cancer and then proposes self-care as a mediator between these two factors. Methods This cross-sectional study enrolled 201 oncology outpatients at one teaching hospital in metropolitan Taipei City, Taiwan. The research instruments included the Symptom-Management Self-Efficacy Scale-Cancer (SMSES-Breast Ca.), the Self-Care Scale, and the European Organization for Research & Treatment of Cancer Quality of Life Group Questionnaire (EORTC-QLQ-C30). Results Symptom-management self-efficacy (SMSE) was directly associated with the QOL of the participants (beta = 5.94, p < .001). Moreover, SMSE was indirectly associated with QOL through self-care. Self-care was found to mediate the relationship between symptom-management self-efficacy and global QOL (indirect effect = 0.54, 95% CI 0.12 to 1.18). The level of 95% CI was significant. Conclusions The present study supports that self-efficacy beliefs and self-care both significantly and positively influence the quality of life of patients.	[Chin, Chia-Hui] Shin Kong Wu Ho Mem Hosp, Dept Nursing, Taipei, Taiwan; [Tseng, Ling-Ming; Chao, Ta-Chung] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan; [Wang, Tsae-Jyy; Wu, Shu-Fang; Liang, Shu-Yuan] Natl Taipei Univ Nursing & Hlth Sci, Coll Nursing, Taipei, Taiwan	Shin Kong Wu Ho Su Memorial Hospital; Taipei Veterans General Hospital; National Taipei University of Nursing & Health Science (NTUNHS)	Liang, SY (corresponding author), Natl Taipei Univ Nursing & Hlth Sci, Coll Nursing, Taipei, Taiwan.	shuyuan@ntunhs.edu.tw			Shin Kong Wu Ho-Su Memorial Hospital in Taiwan [DN-PC-107-002]	Shin Kong Wu Ho-Su Memorial Hospital in Taiwan	The research was supported by the Shin Kong Wu Ho-Su Memorial Hospital in Taiwan (DN-PC-107-002). Initials of the authors who received each award: Shu-Yuan Liang & Chia-Hui Chin Grant numbers awarded to each author:DN-PC-107-002 ~The full name of each funder:Shin Kong Wu Ho-Su Memorial Hospital in Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Adamowicz K, 2020, HEALTH QUAL LIFE OUT, V18, DOI 10.1186/s12955-020-01389-x; Arraras JI, 2002, PSYCHO-ONCOL, V11, P249, DOI 10.1002/pon.555; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; Bandura A, 1986, SOCIAL FDN THOUGHT A; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Becker MH, 1974, HLTH BELIEF MODEL PE; Byar Katherine L, 2006, Oncol Nurs Forum, V33, pE18, DOI 10.1188/06.ONF.E18-E26; Chen AMH, 2014, RES SOC ADMIN PHARM, V10, P378, DOI 10.1016/j.sapharm.2013.07.001; Heckman JE, 2011, J UROLOGY, V186, P1855, DOI 10.1016/j.juro.2011.06.059; HILL RJ, 1977, CONTEMP SOCIOL, V6, P244, DOI 10.2307/2065853; Hoopman R, 2006, EUR J CANCER, V42, P1839, DOI 10.1016/j.ejca.2005.08.047; Huang FF, 2018, PSYCHOL HEALTH MED, V23, P804, DOI 10.1080/13548506.2018.1434216; Kim HJ, 2009, J NURS SCHOLARSHIP, V41, P158, DOI 10.1111/j.1547-5069.2009.01267.x; Krikorian S, 2019, J ONCOL PHARM PRACT, V25, P1590, DOI 10.1177/1078155218800384; Lehto US, 2019, QUAL LIFE RES, V28, P677, DOI 10.1007/s11136-018-2069-z; Liang SY, 2015, ASIAN NURS RES, V9, P312, DOI 10.1016/j.anr.2015.09.001; Liang SY, 2016, CANCER NURS, V39, P67, DOI 10.1097/NCC.0000000000000244; Liang SY, 2008, PSYCHO-ONCOLOGY, V17, P1100, DOI 10.1002/pon.1326; Park KU, 2008, ONCOLOGY-BASEL, V74, P7, DOI 10.1159/000143212; Pool MK, 2012, GASTROENTEROL NURS, V35, P332, DOI 10.1097/SGA.0b013e3182605f86; Porter LS, 2008, PAIN, V137, P306, DOI 10.1016/j.pain.2007.09.010; Richardson LC, 2007, BREAST J, V13, P581, DOI 10.1111/j.1524-4741.2007.00512.x; Royer HR, 2009, ONCOL NURS FORUM, V36, P463, DOI 10.1188/09.ONF.463-470; Sarkar U, 2006, DIABETES CARE, V29, P823, DOI 10.2337/diacare.29.04.06.dc05-1615; Sharma A, 2013, INT J SURG ONCOL, V2013, DOI 10.1155/2013/269510; Shrout PE, 2002, PSYCHOL METHODS, V7, P422, DOI 10.1037//1082-989X.7.4.422; Wang SP, 2011, J NURS RES, V19, P257, DOI 10.1097/JNR.0b013e318237f08d; Wang ZX, 2019, COMPLEMENT THER MED, V43, P165, DOI 10.1016/j.ctim.2019.01.027; Weber BA, 2004, PSYCHO-ONCOL, V13, P47, DOI 10.1002/pon.718; White LL, 2019, ONCOL NURS FORUM, V46, P113, DOI 10.1188/19.ONF.113-128; Wood LJ, 2006, ONCOL NURS FORUM, V33, P535, DOI 10.1188/06.ONF.535-542; Yang W., 1996, THESIS; Zhao H, 2000, QUAL LIFE RES, V9, P129, DOI 10.1023/A:1008981520920	34	7	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2021	16	2							e0246430	10.1371/journal.pone.0246430	http://dx.doi.org/10.1371/journal.pone.0246430			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QF5UW	33539460	Green Published, gold			2023-01-03	WOS:000616960200100
J	Stenzinger, A; Kazdal, D; Peters, S				Stenzinger, Albrecht; Kazdal, Daniel; Peters, Solange			Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets	CELL			English	Editorial Material							TUMOR	The advent of immune checkpoint blockers for cancer therapy has spawned great interest in identifying molecular features reflecting the complexity of tumor immunity, which can subsequently be leveraged as predictive biomarkers. In a thorough big-data approach analyzing the largest series of homogenized molecular and clinical datasets, Litchfield et al. identified a set of genomic biomarkers that identifies immunotherapy responders across cancer types.	[Stenzinger, Albrecht; Kazdal, Daniel] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Stenzinger, Albrecht] German Canc Consortium DKTK, Heidelberg Partner Site, Heidelberg, Germany; [Stenzinger, Albrecht; Kazdal, Daniel] German Ctr Lung Res DZL, Heidelberg Partner Site, Heidelberg, Germany; [Peters, Solange] Lausanne Univ Hosp, Dept Oncol, Lausanne, Switzerland	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Peters, S (corresponding author), Lausanne Univ Hosp, Dept Oncol, Lausanne, Switzerland.	solange.peters@chuv.ch	Kazdal, Daniel/ABG-7629-2020	Kazdal, Daniel/0000-0001-8187-3281				Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Braun DA, 2020, NAT MED, V26, P909, DOI 10.1038/s41591-020-0839-y; Budczies J, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2020.1860586; Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; Goswami S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc4220; Kazdal D, 2019, J THORAC ONCOL, V14, P1935, DOI 10.1016/j.jtho.2019.07.006; Litchfield K, 2021, CELL, V184, P596, DOI 10.1016/j.cell.2021.01.002; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Sha D, 2020, CANCER DISCOV, V10, P1808, DOI 10.1158/2159-8290.CD-20-0522; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; U.S. Food and Drug Administration, 2020, FDA APPR PEMBR AD CH	11	2	2	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2021	184	3					571	573		10.1016/j.cell.2021.01.008	http://dx.doi.org/10.1016/j.cell.2021.01.008		FEB 2021	3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QX8ZJ	33508231	Bronze			2023-01-03	WOS:000629631400003
J	Nagano, T; Kakuma, T; Umezu, Y; Yanagawa, T				Nagano, Tomohiko; Kakuma, Tatsuyuki; Umezu, Yuichi; Yanagawa, Takashi			Nutritional status and activities of daily living in patients with Parkinson's disease	PLOS ONE			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; MALNUTRITION; RELIABILITY; STROKE	Patients with Parkinson's disease are often frail and likely to be malnourished. Several studies have reported the adverse effects of malnutrition on functional outcomes; however, the association between nutritional status and activities of daily living is unclear among patients with Parkinson's disease. This study aimed to investigate the relationship between nutritional status and activities of daily living in patients with Parkinson's disease. We conducted a retrospective cohort study with the data of 124 patients who were consecutively admitted to a rehabilitation hospital in Japan, among whom the data of 61 patients were included in the analyses. The Controlling Nutritional Status score was used to measure the nutritional status of the participants, and the motor subdomain of the Functional Independence Measure was used to assess the activities of daily living. Piecewise linear mixed-effects models were fitted to the data after adjusting for confounding factors. A poor nutritional status (i.e., Controlling Nutritional Status score >3) was significantly associated with a poor Functional Independence Measure gain, which was defined as difference in the score values of the Functional Independence Measures between discharge and admission. Our findings could aid in developing nutritional intervention programs for patients with Parkinson's disease by employing the Controlling Nutritional Status score to improve their activities of daily living.	[Nagano, Tomohiko; Umezu, Yuichi] Kokura Rehabil Hosp, Kitakyushu, Fukuoka, Japan; [Kakuma, Tatsuyuki; Yanagawa, Takashi] Kurume Univ, Biostat Ctr, Kurume, Fukuoka, Japan	Kurume University	Nagano, T (corresponding author), Kokura Rehabil Hosp, Kitakyushu, Fukuoka, Japan.	nagano838@gmail.com		Nagano, Tomohiko/0000-0001-6313-0097				Barichella M, 2008, NUTR NEUROSCI, V11, P128, DOI 10.1179/147683008X301441; BEYER PL, 1995, J AM DIET ASSOC, V95, P979, DOI 10.1016/S0002-8223(95)00269-3; Davalos A, 1996, STROKE, V27, P1028, DOI 10.1161/01.STR.27.6.1028; Earley W, 2019, AM J PSYCHIAT, V176, P439, DOI 10.1176/appi.ajp.2018.18070824; Harimoto N, 2018, ANN SURG ONCOL, V25, P3316, DOI 10.1245/s10434-018-6672-6; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Ignacio de Ulíbarri J., 2005, Nutr. Hosp., V20, P38; Jaafar AF, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-124; Kishimoto H, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2655; Kokura Y, 2016, J STROKE CEREBROVASC, V25, P1335, DOI 10.1016/j.jstrokecerebrovasdis.2016.01.048; Kunieda K, 2013, J PAIN SYMPTOM MANAG, V46, P201, DOI 10.1016/j.jpainsymman.2012.07.020; Kuroda D, 2018, GASTRIC CANCER, V21, P204, DOI 10.1007/s10120-017-0744-3; Lin TK, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165727; Lombard K, 2014, J NUTR HEALTH AGING, V18, P649, DOI 10.1007/s12603-014-0490-8; Ma K, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00001; Narumi T, 2013, J CARDIOL, V62, P307, DOI 10.1016/j.jjcc.2013.05.007; Nishioka S, 2018, J ACAD NUTR DIET, V118, P1270, DOI 10.1016/j.jand.2018.02.012; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Sheard JM, 2011, NUTR REV, V69, P520, DOI 10.1111/j.1753-4887.2011.00413.x; Shidfar Farzad, 2016, Med J Islam Repub Iran, V30, P454; Thomas DR, 2002, AM J CLIN NUTR, V75, P308, DOI 10.1093/ajcn/75.2.308; Uc EY, 2006, MOVEMENT DISORD, V21, P930, DOI 10.1002/mds.20837; van der Marck MA, 2012, PARKINSONISM RELAT D, V18, P263, DOI 10.1016/j.parkreldis.2011.10.016; Visvanathan R, 2004, AGE AGEING, V33, P260, DOI 10.1093/ageing/afh078	24	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2021	16	2							e0246329	10.1371/journal.pone.0246329	http://dx.doi.org/10.1371/journal.pone.0246329			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF2NJ	33529255	Green Published, gold			2023-01-03	WOS:000616736200059
J	Belfort, MB; Qureshi, F; Litt, J; Enlow, MB; De Vivo, I; Gregory, K; Tiemeier, H				Belfort, Mandy Brown; Qureshi, Farah; Litt, Jonathan; Enlow, Michelle Bosquet; De Vivo, Immaculata; Gregory, Katherine; Tiemeier, Henning			Telomere length shortening in hospitalized preterm infants: A pilot study	PLOS ONE			English	Article							YOUNG-ADULTS; BORN PRETERM; BIRTH; OUTCOMES; RISK; CHILDREN; DISEASE; AGE; METAANALYSIS; PREMATURITY	Leukocyte telomere length is a biomarker of aging-related health risks. Hospitalized preterm infants frequently experience elevated oxidative stress and inflammation, both of which contribute to telomere shortening. Our aim was to examine changes in telomere length during neonatal intensive care unit (NICU) hospitalization in a cohort of preterm infants <32 weeks' gestation. We conducted a longitudinal study of 10 infants (mean gestational age 27 weeks, range 23.5 to 29, at birth). We isolated DNA from dried blood spots and used Real Time Quantitative PCR to measure relative leukocyte telomere length in triplicate at three time points for each participant. From birth to discharge, infants experienced an average decline in relative telomere length of 0.021 units per week (95% CI -0.040, -0.0020; p = 0.03), after adjustment for gestational age at birth. Our results suggest a measurable decline in telomere length during NICU hospitalization. We speculate that telomere length change may convey information about NICU exposures that carry short- and long-term health risks.	[Belfort, Mandy Brown; Gregory, Katherine] Brigham & Womens Hosp, Dept Pediat Newborn Med, 75 Francis St, Boston, MA 02115 USA; [Belfort, Mandy Brown; Litt, Jonathan; Enlow, Michelle Bosquet; Gregory, Katherine] Harvard Med Sch, Boston, MA 02115 USA; [Qureshi, Farah; Litt, Jonathan; Tiemeier, Henning] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA; [Litt, Jonathan] Beth Israel Deaconess Med Ctr, Dept Neonatol, Boston, MA 02215 USA; [Enlow, Michelle Bosquet] Boston Childrens Hosp, Dept Psychiat, Boston, MA USA; [De Vivo, Immaculata] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Belfort, MB (corresponding author), Brigham & Womens Hosp, Dept Pediat Newborn Med, 75 Francis St, Boston, MA 02115 USA.; Belfort, MB (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	mbelfort@bwh.harvard.edu	Tiemeier, Henning/H-6534-2019	Tiemeier, Henning/0000-0002-4395-1397; Gregory, Katherine/0000-0002-0610-5386; Qureshi, Farah/0000-0002-9092-8085; De Vivo, Immaculata/0000-0002-7185-7402; Belfort, Mandy/0000-0001-8799-3313				Aarnoudse-Moens CSH, 2009, PEDIATRICS, V124, P717, DOI 10.1542/peds.2008-2816; Akkad A, 2006, BJOG-INT J OBSTET GY, V113, P318, DOI 10.1111/j.1471-0528.2005.00839.x; Aviv A, 2009, AM J EPIDEMIOL, V169, P323, DOI 10.1093/aje/kwn338; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; Blackburn EH, 2015, SCIENCE, V350, P1193, DOI 10.1126/science.aab3389; Brydges CR, 2018, DEV MED CHILD NEUROL, V60, P452, DOI 10.1111/dmcn.13685; Casavant SG, 2019, EARLY HUM DEV, V131, P63, DOI 10.1016/j.earlhumdev.2019.03.003; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Cheong JL, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2016.4805; Crump C, 2019, JAMA PEDIATR, V173, P736, DOI 10.1001/jamapediatrics.2019.1327; de Jong F, 2012, HYPERTENSION, V59, P226, DOI 10.1161/HYPERTENSIONAHA.111.181784; De Vivo I, 2009, CANCER EPIDEM BIOMAR, V18, P1152, DOI 10.1158/1055-9965.EPI-08-0998; DeJong F, 2011, AM HEART ASS JOINT C; Delgado DA, 2019, HUM GENET, V138, P49, DOI 10.1007/s00439-018-1964-2; Eidelman AI, 2012, PEDIATRICS, V129, pE827, DOI 10.1542/peds.2011-3552; Elizabeth CL, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0547-4; Enlow MB, 2020, PSYCHONEUROENDOCRINO, V115, DOI 10.1016/j.psyneuen.2020.104602; Factor-Litvak P, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3927; Fyhrquist F, 2013, NAT REV CARDIOL, V10, P274, DOI 10.1038/nrcardio.2013.30; Gu BW, 2011, AGING CELL, V10, P338, DOI 10.1111/j.1474-9726.2011.00674.x; Hadchouel A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136123; He H, 2015, AM J RESP CRIT CARE, V192, P520, DOI 10.1164/rccm.201503-0522LE; Horbar JD, 2016, 2015 MANUAL OPERAT 2; Hovi P, 2016, HYPERTENSION, V68, P880, DOI 10.1161/HYPERTENSIONAHA.116.08167; Kuban KCK, 2015, PEDIATR NEUROL, V52, P42, DOI 10.1016/j.pediatrneurol.2014.10.005; Li S, 2014, OBES REV, V15, P804, DOI 10.1111/obr.12214; Moore TA, 2018, BIOL RES NURS, V20, P497, DOI 10.1177/1099800418791028; Moreira RS, 2014, J PEDIAT-BRAZIL, V90, P119, DOI 10.1016/j.jped.2013.05.010; Niu ZZ, 2019, J PEDIATR-US, V215, P64, DOI 10.1016/j.jpeds.2019.08.040; Olsen IE, 2010, PEDIATRICS, V125, pE214, DOI 10.1542/peds.2009-0913; Pascal A, 2018, DEV MED CHILD NEUROL, V60, P342, DOI 10.1111/dmcn.13675; Pettker CM, 2017, OBSTET GYNECOL, V129, pE150, DOI 10.1097/AOG.0000000000002046; Prescott J, 2012, HUM REPROD, V27, P3622, DOI 10.1093/humrep/des314; Provenzi L, 2019, EARLY HUM DEV, V129, P1, DOI 10.1016/j.earlhumdev.2018.12.002; Provenzi L, 2018, PSYCHONEUROENDOCRINO, V89, P113, DOI 10.1016/j.psyneuen.2018.01.009; Provenzi L, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00295; Richardosn DK, 2001, J PEDIATR-US, V138, P92, DOI 10.1067/mpd.2001.109608; Ridout KK, 2018, MOL PSYCHIATR, V23, P858, DOI 10.1038/mp.2017.26; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Savran O, 2018, INT J CHRONIC OBSTR, V13, P683, DOI 10.2147/COPD.S153555; Scarabino D, 2017, EXP GERONTOL, V98, P143, DOI 10.1016/j.exger.2017.08.025; Sipola-Leppanen M, 2015, AM J EPIDEMIOL, V181, P861, DOI 10.1093/aje/kwu443; Smeets CCJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143951; Song LL, 2019, ENVIRON HEALTH PERSP, V127, DOI [10.1289/EHP4492, 10.1289/ehp4492]; Sperling MA, 2004, NEW ENGL J MED, V351, P2229, DOI 10.1056/NEJMe048274; Stroustrup A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193835; Turner KJ, 2014, BIOMARK MED, V8, P485, DOI 10.2217/bmm.14.13; Vasu V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180082; Vohr BR, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0269; vom Hove M, 2014, J PEDIATR-US, V164, P40, DOI 10.1016/j.jpeds.2013.07.045; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Wang H, 2008, MOVEMENT DISORD, V23, P302, DOI 10.1002/mds.21867; Wang Q, 2018, AGEING RES REV, V48, P11, DOI 10.1016/j.arr.2018.09.002; Wong JYY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087348; Yeh JK, 2016, GENES-BASEL, V7, DOI 10.3390/genes7090058	55	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2021	16	1							e0243468	10.1371/journal.pone.0243468	http://dx.doi.org/10.1371/journal.pone.0243468			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM1OE	33471805	Green Published, gold			2023-01-03	WOS:000639428800004
J	Khan, SMR; Akhter, T; Hussain, M				Rafique Khan, Sardar Muhammad; Akhter, Tanveer; Hussain, Mumtaz			Ethno-veterinary practice for the treatment of animal diseases in Neelum Valley, Kashmir Himalaya, Pakistan	PLOS ONE			English	Article							MALLOTUS-PHILIPPINENSIS FRUIT; MEDICINAL-PLANTS; ETHNOVETERINARY PRACTICES; DISTRICT; ANTHELMINTICS; INVENTORY; LIVESTOCK; KAMALA; AGENCY	Plant species are not only used as fodder or forage but also contribute substantially in the treatment of various health disorders, particularly in livestock. This study is the first quantitative ethnobotanical effort on ethnoveterinary uses of medicinal plants conducted in the Upper Neelum Valley of Azad Jammu & Kashmir, Pakistan. Information pertaining to cure different ailments of animals were collected from 126 informants through semi-structured interviews, group discussion and field walks. In order to identify the plant species used and their preferred habitats, elderly and experienced members of the tribes, locally known 'Budhair' (aged), were interviewed and sometimes accompanied in the field. The data was further analyzed through ethnobotanical indices. In all, 39 plant species, belonging to 31 genera and 21 families were documented which were used by the indigenous communities of Kashmir Himalaya for curing 21 different diseases of 7 different types of livestock. The highest number of ethno-medicinal plants were contributed by the Polygonaceae family, followed by Crassulaceae, Asteraceae and other families. Roots were the most used part of the plant for preparing ethnoveterinary medicines, followed by the aerial parts. The highest frequency of citation (41) and relative frequency of citation (7.32) was recorded for Saussurea lappa, followed by Rumex acetosa (37/6.61), Rumex nepalensis (36/6.43), Thymus linearis (28/5.0) and Angelica cyclocarpa (28/5.0). The highest use value was recorded for Saussurea lappa (0.33), followed by Rumex acetosa (0.29), Rumex nepalensis (0.29), Thymus linearis and Angelica cyclocarpa (0.22 each). The current study has made an important contribution towards the preservation of indigenous plants-based knowledge from extinction. The phytochemical and pharmacological investigations of the plants with high use value can be a potential source of novel drugs to treat health problems of animals and humans.	[Rafique Khan, Sardar Muhammad; Akhter, Tanveer] Univ Azad Jammu & Kashmir, Dept Bot, Muzaffarabad, Pakistan; [Hussain, Mumtaz] Hazara Univ, Dept Bot, Mansehra, Pakistan	University of Azad Jammu & Kashmir; Hazara University	Khan, SMR (corresponding author), Univ Azad Jammu & Kashmir, Dept Bot, Muzaffarabad, Pakistan.	ddcccajk@gmail.com		sarwar, rafique/0000-0002-1921-2252				Abbasi AM, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-84; Ahmad H., 1996, P 1 TRAIN WORKSH ETH, P202; Ahmad KS, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0196-1; Akhtar M S, 1988, FINAL RES REPORT 198; Akhtar MS, 2000, SMALL RUMINANT RES, V38, P99, DOI 10.1016/S0921-4488(00)00163-2; AKHTAR MS, 1992, SMALL RUMINANT RES, V8, P121, DOI 10.1016/0921-4488(92)90013-T; Alexiades M.N, 1996, SELECTED GUIDELINES; [Anonymous], 1992, J EC TAX BOT; [Anonymous], 2014, AJK GLANCE; Ayeni EA., 2018, WORLD NEWS NATURAL S, V16, P53; Aziz MA, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0212-0; Barboza RRD, 2007, J ETHNOBIOL ETHNOMED, V3, DOI 10.1186/1746-4269-3-32; Bharati KA., 2012, ETHNOBOTANY RES APPL, V10, P339; Bhatti RC., 2017, ANN PLANT SCI, V6, P1898, DOI DOI 10.21746/APS.2017.6.12.17; BSI, 1996, FLORA INDIA; Bullitta S, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0250-7; CROOM EM, 1983, ECON BOT, V37, P13, DOI 10.1007/BF02859302; Dar E.I., 2003, J PLANT SCI, V2, P680; DAR G H, 1984, Journal of Economic and Taxonomic Botany, V5, P668; Dar GH., 2001, BIODIVERSITY KASHMIR, P120; Dastagir G., 2001, Hamdard Medicus, V44, P29; Dhar U, 2000, BIOL CONSERV, V95, P57, DOI 10.1016/S0006-3207(00)00010-0; Dilshad SMR, 2008, J ETHNOPHARMACOL, V117, P393, DOI 10.1016/j.jep.2008.02.011; Eswaran S., 2013, International Journal of Botany, V9, P37, DOI 10.3923/ijb.2013.37.43; Farooq Z, 2008, J ETHNOPHARMACOL, V118, P213, DOI 10.1016/j.jep.2008.03.015; Ganesan S, 2008, INDIAN J TRADIT KNOW, V7, P347; Gorsi MS., 2002, ASIAN J PLANT SCI, V1, P222; GORSI MS, 2002, ASIAN J PLANT SCI, V1, P604, DOI DOI 10.3923/ajps.2002.604.615; Hammond JA, 1997, VET RES COMMUN, V21, P213, DOI 10.1023/A:1005884429253; Haq I, 1993, MED PLANTS MANSEHRA, P63; Hassan HU, 2014, IRISH VET J, V67, DOI 10.1186/2046-0481-67-6; Heinrich M, 2009, J ETHNOPHARMACOL, V124, P1, DOI 10.1016/j.jep.2009.03.043; Hoareau L., 1999, ELECT J BIOTECHNOL, V2; Hocking GM., 1958, VEGETATION, V9, P103; Husain M., 2001, GEOGRAPHY JAMMU KASH, P15; Hussain F, 1996, P 1 TRAIN WORKSH ETH, P207; Ishtiaq Ch. Muhammad, 2006, Asian Journal of Plant Sciences, V5, P390; Jabbar A, 2006, J ETHNOPHARMACOL, V108, P152, DOI 10.1016/j.jep.2006.04.015; Jost CC, 1996, SMALL RUMINANT RES, V20, P147, DOI 10.1016/0921-4488(95)00791-1; Kachroo P., 1987, FOREST FLORA SRINAGA; Kaul M. K., 1997, Medicinal plants of Kashmir and Ladakh: temperate and cold arid Himalaya.; Khan M. A., 2012, Pakistan Journal of Weed Science Research, V18, P495; Khan Z.S., 2004, INDIAN J TRADIT KNOW, V3, P351; Khattak NS, 2015, J ETHNOPHARMACOL, V171, P273, DOI 10.1016/j.jep.2015.05.048; Khuroo Anzar A., 2007, Asian Journal of Plant Sciences, V6, P148; Lans C, 2007, J ETHNOBIOL ETHNOMED, V3, DOI 10.1186/1746-4269-3-11; Lawrence WR., 1992, VALLEY KASHMIR 1895; Liu YC, 2009, J ETHNOBIOL ETHNOMED, V5, DOI 10.1186/1746-4269-5-15; Majeed M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241705; Martin G.A., 2004, ETHNOBOTANY METHODS; Marwat S. K., 2008, Sarhad Journal of Agriculture, V24, P305; Nasir E, FLORA PAKISTAN NO 1; Ocvirk S, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-43; Ole-Miaron JO, 2003, J ETHNOPHARMACOL, V84, P79, DOI 10.1016/S0378-8741(02)00283-0; Pie SJ., 1987, HIMALAYAN ECOSYST, P97; Saghir IA., 2001, J BIOL SCI, V1, P1165; Shehzad Kh. Rizwan, 1999, Pakistan Journal of Forestry, V49, P91; Shinwari ZK, 1996, P 1 TRAINING WORKSHO, P124; Stewart RR., 1972, ANNOTATED CATALOGUE; Sullivan K., 1997, COMPLETE NATURAL HOM, P3; Tariq A, 2014, SCI WORLD J, DOI [10.1155/2014/748490, 10.1155/2014/127526]; Ullah M, 2013, J ETHNOPHARMACOL, V150, P918, DOI 10.1016/j.jep.2013.09.032; Utkarsh G, 1999, CURR SCI INDIA, V77, P1418; Utkarsh G., 2001, RESONANCE, V2, P51; Zaman MB., 1970, FOR I PAK, V38, P34	70	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2021	16	4							e0250114	10.1371/journal.pone.0250114	http://dx.doi.org/10.1371/journal.pone.0250114			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6EM	33930052	Green Published, gold			2023-01-03	WOS:000664607000008
J	Mello, MM; Riley, T				Mello, Michelle M.; Riley, Trish			To Address Drug Affordability, Grab the Low-hanging Fruit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									[Mello, Michelle M.] Stanford Law Sch, 559 Nathan Abbott Way, Stanford, CA 94305 USA; [Mello, Michelle M.] Stanford Univ, Dept Med, Stanford Hlth Policy, Stanford, CA 94305 USA; [Mello, Michelle M.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Riley, Trish] Natl Acad State Hlth Policy, Portland, ME USA	Stanford University; Stanford University; Stanford University	Mello, MM (corresponding author), Stanford Law Sch, 559 Nathan Abbott Way, Stanford, CA 94305 USA.; Mello, MM (corresponding author), Stanford Sch Med, Dept Hlth Res & Policy, 559 Nathan Abbott Way, Stanford, CA 94305 USA.	mmello@law.stanford.edu		Mello, Michelle/0000-0003-2877-4270				Alpern JD, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13595; Anderson-Cook A, 2020, MEDICARE D, DOI DOI 10.1377/HBLOG20200204.864372/FULL/; Conti RM, 2018, J PHARM POLICY PRACT, V11, DOI 10.1186/s40545-018-0156-8; Deb C, 2020, JAMA-J AM MED ASSOC, V323, P826, DOI 10.1001/jama.2020.0359; Gavulic KA, 2021, J HEALTH POLIT POLIC, V46, P599, DOI 10.1215/03616878-8970810; Hernandez I, 2020, JAMA-J AM MED ASSOC, V323, P854, DOI 10.1001/jama.2020.1012; Hernandez I, 2019, HEALTH AFFAIR, V38, P76, DOI 10.1377/hlthaff.2018.05147	7	2	2	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	2021	325	16					1599	1600		10.1001/jama.2021.4619	http://dx.doi.org/10.1001/jama.2021.4619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV1RL	33904881	Bronze			2023-01-03	WOS:000645617800002
J	Feyisa, T; Kiya, GT; Maleko, WA				Feyisa, Tufa; Kiya, Girum Tesfaye; Maleko, Wondimagegn Adissu			Assessment of recipients' characteristics, transfusion appropriateness, and utilization pattern of blood and blood products in Jimma Medical Center, Jimma, Ethiopia	PLOS ONE			English	Article							CELL TRANSFUSION; REQUEST	Background As blood transfusion remains life-saving and is being frequently prescribed, a greater number of its practice is unnecessary or inappropriate. This important clinical intervention is reported as one of the five overused medical treatments, with gross over-ordering and whole blood transfusions as the sole component being common in developing countries. Study of recipient's demographics, clinical conditions, appropriate blood utilization, and continuous clinical audits for quality assurance and service improvement plan are important factors to this practice. This study was designed to assess the recipient's characteristics, blood type distributions, appropriateness of blood transfusion, and utilization practice of the big medical center. Methods Institution based cross-sectional study was conducted from February 1 to June 30, 2018. Data were collected using a structured data collection format prepared for this study. All transfusion prescriptions were followed from requisition up to completion. Patient's age, sex, requesting departments, hemodynamics, number and component of units requested and issued, and units transfused were collected. Transfusion appropriateness was assessed by a criterion-based method while blood utilization was calculated. Results A total of 545 units of blood for 425 patients were cross-matched of the 809 units of total blood prescribed. The mean and median age of transfused individuals was found to be 27.47 15.28 years and 26 years respectively, and 65.4% females most in reproductive age groups. O and A Rhesus-positive blood types were the two major blood groups observed. Overall 82.1% of transfusions were appropriate; while only 27.8% of patients received appropriate components as 96.5% of individuals received a whole blood transfusion. Significant blood utilization was recorded with a C/T ratio of 1.05, TP% of 100%, and TI of 1.23. Conclusion Much of the transfusion recipients were relatively young aged and females, most in the reproductive age group. Although whole blood was used as a sole component, significant blood transfusion utilization and appropriateness were recorded; while appropriate component transfusion was recorded to be significantly low. Local transfusion guidelines and appropriate component preparation and utilization are required to improve the sub-optimal blood component transfusion practice.	[Feyisa, Tufa] Jimma Univ, Hematol Lab Unit, Jimma Med Ctr, Jimma, Ethiopia; [Kiya, Girum Tesfaye; Maleko, Wondimagegn Adissu] Jimma Univ, Sch Med Lab Sci, Jimma, Ethiopia; [Maleko, Wondimagegn Adissu] Jimma Univ, Clin Trial Unit, Jimma, Ethiopia	Jimma University; Jimma University; Jimma University	Maleko, WA (corresponding author), Jimma Univ, Sch Med Lab Sci, Jimma, Ethiopia.; Maleko, WA (corresponding author), Jimma Univ, Clin Trial Unit, Jimma, Ethiopia.	wondeade@gmail.com	Tesfaye, Girum/AAB-3547-2022; Adissu, Wondimagegn/AAY-2236-2021	Tesfaye, Girum/0000-0001-7858-3793; Adissu, Wondimagegn/0000-0003-1624-3114	Jimma University	Jimma University	The study was supported by Jimma University for data collection, analysis and resource; and no any authors received special or specific funding for this study.	[Anonymous], 2006, HDB BLOOD BANKING TR; Belayneh Tadesse, 2013, J Blood Transfus, V2013, P758910, DOI 10.1155/2013/758910; Britten AFH., 1994, BLOOD TRANSFUSION BA; Bugge HF, 2013, VOX SANG, V104, P37, DOI 10.1111/j.1423-0410.2012.01628.x; Butler EK, 2015, TRANSFUSION, V55, P1058, DOI 10.1111/trf.13010; Chawla T., 2001, JPMA (Journal of the Pakistan Medical Association), V51, P251; Contreras M., 2009, ABC TRANSFUSION; Efraim K., 2001, BLOODLESS MED SURG, V43; Erhabor O, 2011, TRANSFUS CLIN BIOL, V18, P516, DOI 10.1016/j.tracli.2011.06.001; Erhabor O., 2012, TRANSFUSION MED MADE; Federal Ministry of Health, 2005, NAT BLOOD TRANSF SER; Federal Ministry of Health, NAT BLOOD BANK SERV, V1st; Federal Ministry of Health, 2016, NAT GUID APPR US BLO; Field SP, 2007, J CLIN PATHOL, V60, P1073, DOI 10.1136/jcp.2006.043505; Franchini M, 2017, BLOOD TRANSFUS-ITALY, V15, P307, DOI 10.2450/2017.0059-17; FRIEDMAN BA, 1976, TRANSFUSION, V16, P380; Fung MK., 2005, TECHNICAL MANUAL, V15th; Fung MK, 2014, TECHNICAL MANUAL, V18th; Golassa Lemu, 2017, BMC Res Notes, V10, P330, DOI 10.1186/s13104-017-2644-3; Goodnough LT, 2013, LANCET, V381, P1791, DOI 10.1016/S0140-6736(13)60673-X; Grazzini G, 2008, BLOOD TRANSFUS-ITALY, V6, P186, DOI 10.2450/2008.0049-07; Harvey GK., 2008, MOLLISONS BLOOD TRAN, V11th; Haynes SL, 2004, TRANSFUS MED REV, V18, P93, DOI 10.1016/j.tmrv.2003.12.005; Hillyer CD, 2007, BLOOD BANKING TRANSF; Jeffrey JM., 2012, TRANSFUSION MED, V3rd; Joubert S, 2013, TRANSFUS APHER SCI, V49, P522, DOI 10.1016/j.transci.2013.04.037; Kipkulei JC, 2019, OPEN J BLOOD DIS, V9, P30; Kohli N, 2019, TROP MED INT HEALTH, V24, P11, DOI 10.1111/tmi.13173; Laher M, 2019, TRANSFUS APHER SCI, V58, P43, DOI 10.1016/j.transci.2018.11.002; Mafirakureva N, 2015, BLOOD TRANSFUS-ITALY, V13, P600, DOI 10.2450/2015.0019-15; Mahfouz MF., 2019, GEN SURG, V2, P4; Mama M., 2016, MALARIA RES TREATMEN, V2016, P1, DOI [10.1155/2016/8043768, DOI 10.1155/2016/8043768]; Mitlyng BL, 2006, AM J HEMATOL, V81, P432, DOI 10.1002/ajh.20644; Murphy MF., 2013, PRACTICAL TRANSFUSIO; Natukunda B, 2010, TRANSFUSION MED, V20, P134, DOI 10.1111/j.1365-3148.2010.00992.x; Norfolk D., 2013, TRANSFUSION HDB, V5th; Okoroiwu Henshaw Uchechi, 2018, BMC Hematol, V18, P16, DOI 10.1186/s12878-018-0112-5; Olatunji PO., 2004, AFR J TRAUMA, V2, P16; Olawumi HO, 2006, TROP J HLTH SCI, V13, P15; Diaz MQ, 2017, BLOOD TRANSFUS-ITALY, V15, P199, DOI 10.2450/2016.0324-15; RB SV., 2009, POSTGRAD MED J NAMS, V9; Richa S, 2015, INT J MED SCI ED, V2; Salaudeen AG, 2011, NIGER J CLIN PRACT, V14, P303, DOI 10.4103/1119-3077.86773; Schneider WS, 2013, HIST BLOOD TRANSFUSI; Shander A, 2011, TRANSFUS MED REV, V25, P232, DOI 10.1016/j.tmrv.2011.02.001; Szczepiorkowski ZM, 2013, HEMATOL-AM SOC HEMAT, P638, DOI 10.1182/asheducation-2013.1.638; Tapko JB, 2009, STATUS BLOOD SAFETY; Tapko JB, 2014, STATUS BLOOD SAFETY; Tegu GA., 2020, HEMATOL TRANSFUS INT, V8, P42; Tesfaye K, 2015, EGYPT J MED HUM GENE, V16, P71, DOI [10.1016/j.ejmhg.2014.09.002, DOI 10.1016/J.EJMHG.2014.09.002]; Thakkar RN, 2016, TRANSFUSION, V56, P2212, DOI 10.1111/trf.13718; Tiwari AK, 2017, GLOB JOURN TRANS MED, V2, P109; Toby LS., 2016, ROSSIS PRINCIPLES TR, V5th; Tuckfield A, 1997, MED J AUSTRALIA, V167, P473, DOI 10.5694/j.1326-5377.1997.tb126674.x; Vibhute M, 2000, J Postgrad Med, V46, P13; Waheed U., 2017, GLOB JOURN TRANS MED, V2, P113; Weimer A, 2019, TRANSFUSION, V59, P412, DOI 10.1111/trf.14949; WHO,, 2009, SAF BLOOD BLOOD PROD; WHO (World Health Organization), 2020, BLOOD SAF AV; Wicinski M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061784; World Health Organization, 2010, AID MEM CLIN TRANSF; World Health Organization, 2000, APPR CLIN US BLOOD B; World Health Organization, 2001, CLIN USE BLOOD HDB; World Health Organization, 2011, GLOB DAT BLOOD SAF S; World Health Organization, 2017, GLOBAL STATUS REPORT; World Health Organization (WHO), 2011, HEM CONC DIAGN AN AS; Yaddanapudi S, 2014, INDIAN J ANAESTH, V58, P538, DOI 10.4103/0019-5049.144648; Yazdi AP, 2016, ARCH BONE JT SURG-AB, V4, P75; Zerihun T., 2016, J HLTH ED RES DEV, V4; Zewdie K, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4584-1; Zhu CT, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002164	71	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2021	16	4							e0250623	10.1371/journal.pone.0250623	http://dx.doi.org/10.1371/journal.pone.0250623			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0VQ	33901253	gold, Green Published			2023-01-03	WOS:000662169700051
J	Karim, SI; Irfan, F; Saad, H; Alqhtani, M; Alsharhan, A; Alzhrani, A; Alhawas, F; Alatawi, S; Alassiri, M; Ahmed, AMA				Karim, Syed Irfan; Irfan, Farhana; Saad, Hussain; Alqhtani, Mohammed; Alsharhan, Abdulmalik; Alzhrani, Ahmed; Alhawas, Feras; Alatawi, Saud; Alassiri, Mohammed; Ahmed, Abdullah M. A.			Men's knowledge, attitude, and barriers towards emergency contraception: A facility based cross-sectional study at King Saud University Medical City	PLOS ONE			English	Article							REPRODUCTIVE HEALTH; AWARENESS; PERCEPTIONS; MALES; WOMEN; PERSPECTIVE; COUNTRIES; STUDENTS; PILL	Background Male partners have a considerable role in influencing women's contraceptive decision making to reduce the chance of unintended pregnancy. Most studies are focused on women's knowledge and barriers for emergency contraception (EC) use. There is limited research on this topic from the male perspective. This study aimed to gather baseline data on men's knowledge, attitudes and barriers about EC. Methods Descriptive analytic cross-sectional study was conducted from Dec 2019 -May 2020 at the King Khalid University Hospital (KKUH); a teaching facility with general and subspecialty medical services in King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia. Data were collected using a structured pretested questionnaire and analyzed using SPSS version 23.0. Descriptive statistics and Chi square tests were used. Multivariate logistic regression analysis was used to find significant predictors for EC awareness and use. A p value < 0.05 was considered statistically significant. Results A total of 461 participants completed the questionnaire (response rate 86%). The majority (82%) of the participants were unaware of EC; with only 18% having some knowledge. Knowledgeable men had positive attitudes (73.5%) about EC as compared to non- knowledgeable ones (55.0%). Factors found to be associated with less knowledge of EC were cultural [0.46, 95%CI 0.22. 0.96] and religious unacceptability [OR 0.51, 95%CI 0.29, 0.89)]. Higher level of education [OR 1.83, 95%CI 0.94, 3.53] was associated with more knowledge regarding EC. The study showed that correct information about using contraceptives within 3 days of unprotected sex [OR 4.96, 95%CI 1.81, 13.60]; availability without prescription [OR 5.06, 95%CI 1.68, 15.30], EC advertisement [OR 4.84, 95%CI 0.96, 24.27] and receipt of information from family/friends [OR 18.50, 95%CI 5.19, 65.93] were factors that contributed to men using EC. Conclusion The current knowledge of EC among men is limited. Social determinants affect these levels of knowledge, as well as the usage of EC. Factors that were associated with the use of ECPs were correct knowledge, advertisement, availability and receipt of information from family/friends. The findings highlight the need to educate men on this important topic to avoid unintended pregnancy, keeping in view cultural and social values. Future qualitative studies are needed to understand the male perspective.	[Karim, Syed Irfan; Saad, Hussain] King Saud Univ, Dept Family & Community Med, Coll Med, Riyadh, Saudi Arabia; [Karim, Syed Irfan; Irfan, Farhana; Ahmed, Abdullah M. A.] King Saud Univ, Coll Med, Dept Family & Community Med, Chair Med Educ Res & Dev, Riyadh, Saudi Arabia; [Alqhtani, Mohammed; Alsharhan, Abdulmalik; Alzhrani, Ahmed; Alhawas, Feras; Alatawi, Saud; Alassiri, Mohammed] King Saud Univ, Coll Med, Riyadh, Saudi Arabia	King Saud University; King Saud University; King Saud University	Karim, SI (corresponding author), King Saud Univ, Dept Family & Community Med, Coll Med, Riyadh, Saudi Arabia.; Karim, SI (corresponding author), King Saud Univ, Coll Med, Dept Family & Community Med, Chair Med Educ Res & Dev, Riyadh, Saudi Arabia.	irfankarim1969@gmail.com	ahmed, abdullah M. A/GXH-6661-2022	ahmed, abdullah M. A/0000-0003-0266-7215; Karim, Syed Irfan/0000-0001-5188-3091; Alsharhan, Abdulmalik/0000-0002-4209-707X	Deanship of Scientific Research, King Saud University	Deanship of Scientific Research, King Saud University(King Saud University)	The source of funding was financial support for our study. The research was not funded by a specific project grant, but we are grateful to the Deanship of Scientific Research, King Saud University for funding through Vice Deanship of Scientific Research Chairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors did not receive any salary from any of the funders.	Abdulghani HM, 2009, J HEALTH POPUL NUTR, V27, P339; Ajzen I, 2011, BASIC APPL SOC PSYCH, V33, P101, DOI 10.1080/01973533.2011.568834; Al-Matary A, 2014, BMC MED ETHICS, V15, DOI 10.1186/1472-6939-15-10; Alhusain F, 2018, SAUDI J HLTH SCI, V7, P121, DOI [10.4103/sjhs.sjhs_8_18, DOI 10.4103/SJHS.SJHS_8_18]; [Anonymous], 2018, EMERGENCY CONTRACEPT; Bearak J, 2018, LANCET GLOB HEALTH, V6, pE380, DOI 10.1016/S2214-109X(18)30029-9; CHIPFAKACHA VG, 1993, E AFR MED J, V70, P82; CHNG CL, 1983, J SCHOOL HEALTH, V53, P197, DOI 10.1111/j.1746-1561.1983.tb07820.x; Ciochetto S., 1995, AM STAT ASS; El Hamri N, 2010, J FAM PLAN REPROD H, V36, P27, DOI 10.1783/147118910790291019; Elgharabawy R, 2015, INT ARCH MED, V8, pe34; Emergency contraception, 2015, OBSTET GYNECOL, V126, pE1; Foster AM, 2005, CONTRACEPTION, V72, P130, DOI 10.1016/j.contraception.2005.03.003; Ghazal-Aswad S, 2002, J FAM PLAN REPROD H, V28, P196, DOI 10.1783/147118902101196559; Goodcalculators.com, SAMPL SIZ CALC; Habibzadekh F., 2012, LANCET, V380; Kabagenyi A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-21; Kara WSK, 2019, CUREUS, V11, DOI 10.7759/cureus.4362; Karim SI, 2015, PAK J MED SCI, V31, P1500, DOI 10.12669/pjms.316.8127; Kathpalia S K, 2016, Med J Armed Forces India, V72, P116, DOI 10.1016/j.mjafi.2015.09.012; Kwasnik BH, 1999, LIBR TRENDS, V48, P22; Lawrence RE, 2010, CONTRACEPTION, V82, P324, DOI 10.1016/j.contraception.2010.04.151; Little P, 1998, BMJ-BRIT MED J, V316, P1948, DOI 10.1136/bmj.316.7149.1948; Lys C, 2019, J SEX RES, V56, P999, DOI 10.1080/00224499.2018.1544604; Marafie N, 2007, EUR J OBSTET GYN R B, V130, P216, DOI 10.1016/j.ejogrb.2006.05.023; Marcell AV, 2012, PERSPECT SEX REPRO H, V44, P184, DOI 10.1363/4418412; Matoskova J, 2016, J COMPETITIVENESS, V8, P5, DOI 10.7441/joc.2016.04.01; Mosha I, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-523; Mutumba M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5331-y; Myer Landon, 2007, BMC Womens Health, V7, P14, DOI 10.1186/1472-6874-7-14; Najafi-Sharjabad Fatemeh, 2013, Glob J Health Sci, V5, P181, DOI 10.5539/gjhs.v5n5p181; Nguyen BT, 2009, WOMEN HEALTH ISS, V19, P365, DOI 10.1016/j.whi.2009.07.003; Oyediran KA, 2002, J BIOSOC SCI, V34, P497, DOI 10.1017/S0021932002004972; Pazol K, 2018, AM J PREV MED, V55, P703, DOI 10.1016/j.amepre.2018.07.012; Richards MJ, 2016, J ADOLESCENT HEALTH, V58, P366, DOI 10.1016/j.jadohealth.2015.10.011; Ridgeway CL, 2004, GENDER SOC, V18, P510, DOI 10.1177/0891243204265269; Sahin NH, 2008, J OBSTET GYNAECOL RE, V34, P392, DOI 10.1111/j.1447-0756.2007.00698.x; Scholmerich VLN, 2016, HEALTH EDUC BEHAV, V43, P246, DOI 10.1177/1090198116629442; Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x; Seetharaman S, 2016, OPEN ACCESS J CONTR, V7, P161, DOI 10.2147/OAJC.S97075; Shapiro GK, 2014, HEALTH POLICY PLANN, V29, P483, DOI 10.1093/heapol/czt040; Shelat PR., 2012, INT J BASIC CLIN PHA, V1, P77, DOI [10.5455/2319-2003.ijbcp001912, DOI 10.5455/2319-2003.IJBCP001912]; Srikanthan A, 2008, J OBSTET GYNAECOL CA, V30, P129, DOI 10.1016/S1701-2163(16)32736-0; Sweileh Waleed M, 2015, Fertil Res Pract, V1, P6, DOI 10.1186/2054-7099-1-6; von Rosen FT, 2017, EUR J CONTRACEP REPR, V22, P45, DOI 10.1080/13625187.2016.1269162; Wright RL, 2017, AM J MENS HEALTH, V11, P469, DOI 10.1177/1557988315595857; Yapici G, 2010, J OBSTET GYNAECOL RE, V36, P1087, DOI 10.1111/j.1447-0756.2010.01276.x; Yen S, 2015, J PEDIATR ADOL GYNEC, V28, P337, DOI 10.1016/j.jpag.2014.09.018	48	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2021	16	4							e0249292	10.1371/journal.pone.0249292	http://dx.doi.org/10.1371/journal.pone.0249292			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0VQ	33901184	Green Published, gold			2023-01-03	WOS:000662169700008
J	Zeigelboim, BS; Jose, MR; dos Santos, GJB; Severiano, MIR; Teive, HAG; Stechman-Neto, J; Santos, RS; de Araujo, CM; Cavalcante-Leao, BL				Zeigelboim, Bianca Simone; Jose, Maria Renata; Santos, Geslaine Janaina Bueno dos; Severiano, Maria Izabel Rodrigues; Teive, Helio Afonso Ghizoni; Stechman-Neto, Jose; Santos, Rosane Sampaio; de Araujo, Cristiano Miranda; Cavalcante-Leao, Bianca Lopes			Balance rehabilitation with a virtual reality protocol for patients with hereditary spastic paraplegia: Protocol for a clinical trial	PLOS ONE			English	Article							MINI-MENTAL-STATE; VESTIBULAR DISORDERS ACTIVITIES; QUALITY-OF-LIFE; BRAZILIAN VERSION; FALLS; DISEASE; SCALE; FEATURES	Background Neurodegenerative diseases are sporadic hereditary conditions characterized by progressive dysfunction of the nervous system. Among the symptoms, vestibulopathy is one of the causes of discomfort and a decrease in quality of life. Hereditary spastic paraplegia is a heterogeneous group of hereditary degenerative diseases involving the disorder of a single gene and is characterized by the progressive retrograde degeneration of fibers in the spinal cord. Objective To determine the benefits of vestibular rehabilitation involving virtual reality by comparing pre intervention and post intervention assessments in individuals with hereditary spastic paraplegia. Methods In this randomized controlled clinical trial from the Rebec platform RBR-3jmx67 in which allocation concealment was performed and the evaluators be blinded will be included. The participants will include 40 patients diagnosed with hereditary spastic paraplegia. The interventions will include vestibular rehabilitation with virtual reality using the Wii(R) console, Wii-Remote and Wii Balance Board (Nintendo), and the studies will include pre- and post intervention assessments. Group I will include twenty volunteers who performed balance games. Group II will include twenty volunteers who performed balance games and muscle strength games. The games lasted from 30 minutes to an hour, and the sessions were performed twice a week for 10 weeks (total: 20 sessions). Results This study provides a definitive assessment of the effectiveness of a virtual reality vestibular rehabilitation program in halting the progression of hereditary spastic paraplegia, and this treatment can be personalized and affordable. Conclusion The study will determine whether a vestibular rehabilitation program with the Nintendo Wii(R) involving virtual reality can reduce the progressive effect of hereditary spastic paraplegia and serve as an alternative treatment option that is accessible and inexpensive. Rebec platform trial: RBR-3JMX67.	[Zeigelboim, Bianca Simone; Jose, Maria Renata; Stechman-Neto, Jose; Santos, Rosane Sampaio; de Araujo, Cristiano Miranda; Cavalcante-Leao, Bianca Lopes] UTP Univ Tuiuti Parana, Curitiba, Parana, Brazil; [Santos, Geslaine Janaina Bueno dos; Severiano, Maria Izabel Rodrigues] IFPR Inst Fed Parana, Curitiba, Parana, Brazil; [Teive, Helio Afonso Ghizoni] UFPR Univ Fed Parana, Curitiba, Parana, Brazil	Instituto Federal do Parana; Universidade Federal do Parana	Cavalcante-Leao, BL (corresponding author), UTP Univ Tuiuti Parana, Curitiba, Parana, Brazil.	blcleao@gmail.com	Cavalcante-Leao, Bianca/T-4727-2019; Zeigelboim, Bianca Simone/E-2438-2018; STECHMAN-NETO, JOSE/V-5941-2017; Araujo, Cristiano/V-4958-2019; Sampaio Santos, Rosane/A-1597-2017; Jose, Maria Renata/V-1941-2018	Cavalcante-Leao, Bianca/0000-0002-6170-1914; Zeigelboim, Bianca Simone/0000-0003-4871-2683; Araujo, Cristiano/0000-0003-1325-4248; Sampaio Santos, Rosane/0000-0001-6400-5706; Rodrigues Severiano, Maria Izabel/0000-0002-7230-7744; Jose, Maria Renata/0000-0001-8442-1838	Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES)	Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	Thanks to the service of neurology at the hospital of the Federal University of Parana for giving permission for the accomplishment of the research and the Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES).	[Anonymous], 2009, REV PSIQUIATR RIO GD; Aratani MC, 2013, BRAZ J OTORHINOLAR, V79, P203, DOI 10.5935/1808-8694.20130036; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; BERTOLUCCI PHF, 1994, ARQ NEURO-PSIQUIAT, V52, P1, DOI 10.1590/S0004-282X1994000100001; Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014; Camargos FFO, 2010, BRAZ J PHYS THER, V14, P237, DOI 10.1590/S1413-35552010000300010; Caovilla HH., 2009, REV EQUILIBR CORPORA, V1, P9; Carvalho DS, 2006, MIGRANEAS CEFALEIAS, V9, P164; Cohen HS, 2000, ARCH OTOLARYNGOL, V126, P881, DOI 10.1001/archotol.126.7.881; Cohen HS, 2000, LARYNGOSCOPE, V110, P1204, DOI 10.1097/00005537-200007000-00026; de Bruin ED, 2010, Z GERONTOL GERIATR, V43, P229, DOI 10.1007/s00391-010-0124-7; Faber I, 2014, ARQ NEURO-PSIQUIAT, V72, P219, DOI 10.1590/0004-282X20130248; Fink JK, 2013, ACTA NEUROPATHOL, V126, P307, DOI 10.1007/s00401-013-1115-8; Finsterer J, 2012, J NEUROL SCI, V318, P1, DOI 10.1016/j.jns.2012.03.025; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Guimaraes LHCT., 2004, REV NEUROCIENC, V12, P68; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Kim M, 2009, J BONE JOINT SURG AM, V91A, P289, DOI 10.2106/JBJS.H.00219; Klimpe S, 2012, EUR J NEUROL, V19, P168, DOI 10.1111/j.1468-1331.2011.03443.x; Lajoie Y, 2004, ARCH GERONTOL GERIAT, V38, P11, DOI 10.1016/S0167-4943(03)00082-7; Lee G., 2020, NEUROREHABILITATION; Li RC, 2006, ARCH PHYS MED REHAB, V87, P411, DOI 10.1016/j.apmr.2005.11.011; Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237; Mangabeira-Albernaz P., 1981, OTORRINOLARINGOLOGIA, V10a edicao, DOI [10.1159/000275534, DOI 10.1159/000275534]; Marques AP, 2013, BRAZ J PHYS THER, V17, P170, DOI 10.1590/S1413-35552012005000072; Matos VSB., 2010, REV EQUILIB CORPORAL, V2, P76; Mitolo M, 2014, J ALZHEIMERS DIS, V39, P823, DOI 10.3233/JAD-131403; Miyamoto ST, 2004, BRAZ J MED BIOL RES, V37, P1411, DOI 10.1590/S0100-879X2004000900017; Parry SW, 2001, POSTGRAD MED J, V77, P103, DOI 10.1136/pmj.77.904.103; Paula FL., 2007, FISIOTER, V20, P143; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Severiano MIR, 2018, ARQ NEURO-PSIQUIAT, V76, P78, DOI [10.1590/0004-282X20170195, 10.1590/0004-282x20170195]; Santos G, 2017, HEARING BALANC COMMU, V15, P244, DOI 10.1080/21695717.2017.1381490; Sisto SA, 2007, J REHABIL RES DEV, V44, P123, DOI 10.1682/JRRD.2005.11.0172; Smits M, 2020, BMJ OPEN SPORT EXERC, V6, DOI 10.1136/bmjsem-2020-000943; THAL LJ, 1986, NEUROLOGY, V36, P262, DOI 10.1212/WNL.36.2.262; Yardley L, 2005, AGE AGEING, V34, P614, DOI 10.1093/ageing/afi196; Zanoni A., 2010, REV BRAS MED, V67, P113; Zeigelboim BS, 2021, INT ARCH OTORHINOLAR, V25, P64, DOI 10.1055/s-0040-1702973; Zeigelboim Bianca Simone, 2013, Audiol., Commun. Res., V18, P143; Zeigelboim BS, 2011, ARQ NEURO-PSIQUIAT, V69, P760, DOI 10.1590/S0004-282X2011000600007; Zeigelboim BS., 2013, MULTIDISCIPLINARITY, V1ed, P429	42	0	0	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2021	16	4							e0249095	10.1371/journal.pone.0249095	http://dx.doi.org/10.1371/journal.pone.0249095			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RH8NB	33793609	Green Published, gold			2023-01-03	WOS:000636467000024
J	Tang, CY; Wang, VX; Lun, MY; Mincer, JS; Ng, JC; Brallier, JW; Schwartz, AE; Ahn, H; McCormick, PJ; Nir, T; Delman, B; Sano, M; Deiner, SG; Baxter, MG				Tang, Cheuk Y.; Wang, Victoria X.; Lun, Min Yin; Mincer, Joshua S.; Ng, Johnny C.; Brallier, Jess W.; Schwartz, Arthur E.; Ahn, Helen; McCormick, Patrick J.; Nir, Tommer; Delman, Bradley; Sano, Mary; Deiner, Stacie G.; Baxter, Mark G.			Transient changes in white matter microstructure during general anesthesia	PLOS ONE			English	Article							AGE-RELATED DIFFERENCES; INTRACRANIAL-PRESSURE; TAU PHOSPHORYLATION; WATER DIFFUSION; VOLUME CHANGES; BRAIN WATER; SEVOFLURANE; ISOFLURANE; CLEARANCE; SYSTEM	Cognitive dysfunction after surgery under general anesthesia is a well-recognized clinical phenomenon in the elderly. Physiological effects of various anesthetic agents have been studied at length. Very little is known about potential effects of anesthesia on brain structure. In this study we used Diffusion Tensor Imaging to compare the white matter microstructure of healthy control subjects under sevoflurane anesthesia with their awake state. Fractional Anisotropy, a white mater integrity index, transiently decreases throughout the brain during sevoflurane anesthesia and then returns back to baseline. Other DTI metrics such as mean diffusivity, axial diffusivity and radial diffusivity were increased under sevoflurane anesthesia. Although DTI metrics are age dependent, the transient changes due to sevoflurane were independent of age and sex. Volumetric analysis shows various white matter volumes decreased whereas some gray matter volumes increased during sevoflurane anesthesia. These results suggest that sevoflurane anesthesia has a significant, but transient, effect on white matter microstructure. In spite of the transient effects of sevoflurane anesthesia there were no measurable effects on brain white matter as determined by the DTI metrics at 2 days and 7 days following anesthesia. The role of white matter in the loss of consciousness under anesthesia will need to be studied and MRI studies with subjects under anesthesia will need to take these results into account.	[Tang, Cheuk Y.; Wang, Victoria X.; Lun, Min Yin; Ng, Johnny C.; Delman, Bradley] Icahn Sch Med Mt Sinai, BioMed Engn Imaging Inst, New York, NY 10029 USA; [Tang, Cheuk Y.; Baxter, Mark G.] Icahn Sch Med Mt Sinai, Nash Family Dept Neurosci, New York, NY 10029 USA; [Tang, Cheuk Y.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Mincer, Joshua S.; Brallier, Jess W.; McCormick, Patrick J.; Sano, Mary] Mem Sloan Kettering Canc, Dept Anesthesiol & Crit Care Med, New York, NY USA; [Schwartz, Arthur E.; Ahn, Helen; Nir, Tommer] Icahn Sch Med Mt Sinai, Dept Anesthesiol Perioperat & Pain Med, New York, NY 10029 USA; [Deiner, Stacie G.] Dartmouth Hitchcock, Dept Anesthesiol, Lebanon, NH USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; Dartmouth College	Tang, CY (corresponding author), Icahn Sch Med Mt Sinai, BioMed Engn Imaging Inst, New York, NY 10029 USA.; Tang, CY (corresponding author), Icahn Sch Med Mt Sinai, Nash Family Dept Neurosci, New York, NY 10029 USA.; Tang, CY (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.	Cheuk.Tang1@gmail.com			NIH [5R01AG046634]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was funded by: NIH 5R01AG046634, Trajectory of Recovery in the Elderly, PI: Mark Baxter (MB) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson AW, 1996, MAGN RESON MED, V35, P162, DOI 10.1002/mrm.1910350206; Araque A, 2010, PHILOS T R SOC B, V365, P2375, DOI 10.1098/rstb.2009.0313; Artuso R, 2010, BRAIN DEV-JPN, V32, P17, DOI 10.1016/j.braindev.2009.02.004; Assaf Y, 2006, AM J NEURORADIOL, V27, P1717; BAYLOR DA, 1969, J PHYSIOL-LONDON, V203, P555, DOI 10.1113/jphysiol.1969.sp008879; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; Benveniste H, 2019, ANESTH ANALG, V128, P747, DOI 10.1213/ANE.0000000000004069; Benveniste H, 2017, ANESTHESIOLOGY, V127, P976, DOI 10.1097/ALN.0000000000001888; Casaca-Carreira J, 2018, MOL NEUROBIOL, V55, P2780, DOI 10.1007/s12035-017-0501-y; Clark CA, 2000, MAGN RESON MED, V44, P852, DOI 10.1002/1522-2594(200012)44:6<852::AID-MRM5>3.0.CO;2-A; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; DIETZEL I, 1986, ANN NY ACAD SCI, V481, P72, DOI 10.1111/j.1749-6632.1986.tb27140.x; DIETZEL I, 1989, GLIA, V2, P25, DOI 10.1002/glia.440020104; DiNuzzo M, 2017, CURR OPIN NEUROBIOL, V47, P65, DOI 10.1016/j.conb.2017.09.010; Dorenbeck U, 2005, ROFO-FORTSCHR RONTG, V177, P99, DOI 10.1055/s-2004-813728; Filippi M, 2000, ARCH NEUROL-CHICAGO, V57, P1017, DOI 10.1001/archneur.57.7.1017; Fjell AM, 2008, NEUROIMAGE, V42, P1654, DOI 10.1016/j.neuroimage.2008.06.005; Gao X, 2019, LIFE SCI, V221, P143, DOI 10.1016/j.lfs.2019.02.024; GIDEON P, 1995, AM J NEURORADIOL, V16, P381; Goren S, 2001, J NEUROSURG ANESTH, V13, P113, DOI 10.1097/00008506-200104000-00008; Hoffmann J, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1004-1; Iida H, 1998, ANESTHESIOLOGY, V89, P954, DOI 10.1097/00000542-199810000-00020; Iliff JJ, 2013, STROKE, V44, pS93, DOI 10.1161/STROKEAHA.112.678698; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Jesse S, 2020, ANN CLIN TRANSL NEUR, V7, P46, DOI 10.1002/acn3.50959; Jevtovic-Todorovic V, 2013, BRIT J ANAESTH, V111, P143, DOI 10.1093/bja/aet177; Jiang J, 2015, MOL MED REP, V12, P3, DOI 10.3892/mmr.2015.3424; Kohtala S, 2016, ACS CHEM NEUROSCI, V7, P749, DOI 10.1021/acschemneuro.6b00002; KOTANI J, 1992, J NEUROSURG ANESTH, V4, P194, DOI 10.1097/00008506-199207000-00008; LARACH DR, 1991, ANESTHESIOLOGY, V75, P268, DOI 10.1097/00000542-199108000-00015; Lasser M, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00165; Le Freche H, 2012, ANESTHESIOLOGY, V116, P779, DOI 10.1097/ALN.0b013e31824be8c7; MacVicar BA, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020388; Mandl RCW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003631; Mason SE, 2010, J ALZHEIMERS DIS, V22, pS67, DOI 10.3233/JAD-2010-101086; Mincer JS, 2018, ANESTH ANALG, V126, P1675, DOI 10.1213/ANE.0000000000002427; ML R, 2013, FRONT HUM NEUROSCI, V7, P817, DOI DOI 10.3389/fnhum.2013.00817; MURR R, 1995, ANESTH ANALG, V80, P1108, DOI 10.1097/00000539-199506000-00007; Newman S, 2007, ANESTHESIOLOGY, V106, P572, DOI 10.1097/00000542-200703000-00023; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Ostby I, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000272; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Planel E, 2009, FASEB J, V23, P2595, DOI 10.1096/fj.08-122424; Rasmussen R, 2019, CELL REP, V28, P1182, DOI 10.1016/j.celrep.2019.06.082; Rathee R, 2016, MAGN RESON INSIGHTS, V9, P9, DOI 10.4137/MRI.S39666; Sarica A, 2019, ANN CLIN TRANSL NEUR, V6, P233, DOI 10.1002/acn3.685; SCHELLER MS, 1988, ANESTHESIOLOGY, V68, P548, DOI 10.1097/00000542-198804000-00012; SCHETTINI A, 1979, BRIT J ANAESTH, V51, P1117, DOI 10.1093/bja/51.12.1117; Schroeck H, 2019, J CLIN ANESTH, V54, P89, DOI 10.1016/j.jclinane.2018.10.022; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; TAKAHASHI H, 1993, BRIT J ANAESTH, V71, P551, DOI 10.1093/bja/71.4.551; Tamnes CK, 2010, CEREB CORTEX, V20, P534, DOI 10.1093/cercor/bhp118; Tao GR, 2014, ANESTHESIOLOGY, V121, P510, DOI 10.1097/ALN.0000000000000278; Thrane VR, 2013, SCI REP-UK, V3, DOI 10.1038/srep02582; Ulug AM, 2003, AM J NEURORADIOL, V24, P1171; Veenith T, 2011, CURR OPIN ANESTHESIO, V24, P451, DOI 10.1097/ACO.0b013e328347e373; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Yokota Hajime, 2019, Curr Gerontol Geriatr Res, V2019, P5675014, DOI 10.1155/2019/5675014; Yoon B, 2008, ARCH GERONTOL GERIAT, V47, P129, DOI 10.1016/j.archger.2007.07.004; Zhao CL, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005063	64	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2021	16	3							e0247678	10.1371/journal.pone.0247678	http://dx.doi.org/10.1371/journal.pone.0247678			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF4TU	33770816	Green Published, gold			2023-01-03	WOS:000634833500014
J	Lee, EJ; Kim, SJ; Bae, J; Lee, EJ; Kwon, OD; Jeong, HY; Kim, Y; Jeong, HB				Lee, Eung-Joon; Kim, Seung Jae; Bae, Jeonghoon; Lee, Eun Ji; Kwon, Oh Deog; Jeong, Han-Yeong; Kim, Yongsung; Jeong, Hae-Bong			Impact of onset-to-door time on outcomes and factors associated with late hospital arrival in patients with acute ischemic stroke	PLOS ONE			English	Article								Background and purpose Previous studies have reported that early hospital arrival improves clinical outcomes in patients with acute ischemic stroke; however, whether early arrival is associated with favorable outcomes regardless of reperfusion therapy and the type of stroke onset time is unclear. Thus, we investigated the impact of onset-to-door time on outcomes and evaluated the predictors of pre-hospital delay after ischemic stroke. Methods Consecutive acute ischemic stroke patients who arrived at the hospital within five days of onset from September 2019 to May 2020 were selected from the prospective stroke registries of Seoul National University Hospital and Chung-Ang University Hospital of Seoul, Korea. Patients were divided into early (onset-to-door time, <= 4.5 h) and late (>4.5 h) arrivers. Multivariate analyses were performed to assess the effect of early arrival on clinical outcomes and predictors of late arrival. Results Among the 539 patients, 28.4% arrived early and 71.6% arrived late. Early hospital arrival was significantly associated with favorable outcomes (three-month modified Rankin Scale [mRS]: 0-2, adjusted odds ratio [aOR]: 2.03, 95% confidence interval: [CI] 1.04-3.96) regardless of various confounders, including receiving reperfusion therapy and type of stroke onset time. Furthermore, a lower initial National Institute of Health Stroke Scale (NIHSS) score (aOR: 0.94, 95% CI: 0.90-0.97), greater pre-stroke mRS score (aOR: 1.58, 95% CI: 1.18-2.13), female sex (aOR: 1.71, 95% CI: 1.14-2.58), unclear onset time, and <= 6 years of schooling (aOR: 1.76, 95% CI: 1.03-3.00 compared to >12 years of schooling) were independent predictors of late arrival. Conclusions Thus, the onset-to-door time of <= 4.5 h is crucial for better clinical outcome, and lower NIHSS score, greater pre-stroke mRS score, female sex, unclear onset times, and <= 6 years of schooling were independent predictors of late arrival. Therefore, educating about the importance of early hospital arrival after acute ischemic stroke should be emphasized. More strategic efforts are needed to reduce the prehospital delay by understanding the predictors of late arrival.	[Lee, Eung-Joon; Bae, Jeonghoon; Jeong, Han-Yeong] Seoul Natl Univ Hosp, Dept Neurol, Seoul, South Korea; [Kim, Seung Jae] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Family Med, Seoul, South Korea; [Kim, Seung Jae] Catholic Univ Korea, Seoul St Marys Hosp, Int Healthcare Ctr, Coll Med, Seoul, South Korea; [Lee, Eun Ji] Soonchunhyang Univ, Seoul Hosp, Dept Radiol, Seoul, South Korea; [Kwon, Oh Deog] Republic Korea Navy 2nd Fleet Med Corps, Pyeongtaek Si, Gyeonggi Do, South Korea; [Kim, Yongsung; Jeong, Hae-Bong] Chung Ang Univ Hosp, Dept Neurol, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Soonchunhyang University; Chung Ang University; Chung Ang University Hospital	Jeong, HB (corresponding author), Chung Ang Univ Hosp, Dept Neurol, Seoul, South Korea.	hbjeong315@gmail.com		Kim, Yongsung/0000-0001-6347-763X; Jeong, HaeBong/0000-0002-4937-288X; Kim, Seung Jae/0000-0001-8885-7137	Korea Centers for Disease Control & Prevention, Republic of Korea [2020ER620200]	Korea Centers for Disease Control & Prevention, Republic of Korea	This research was supported by a fund (#2020ER620200) by the Korea Centers for Disease Control & Prevention, Republic of Korea (http://www.kdca.go.kr).	Adeoye O, 2009, AM J EMERG MED, V27, P141, DOI 10.1016/j.ajem.2008.02.004; Berglund A, 2017, MATURITAS, V99, P47, DOI 10.1016/j.maturitas.2017.02.007; Berglund A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007661; Copeland LA., 2020, ENEUROLOGICALSCI, V21, P100285, DOI [10.1016/j.ensci.2020.100285, DOI 10.1016/J.ENSCI.2020.100285]; Demaerschalk BM, 2016, STROKE, V47, P581, DOI 10.1161/STR.0000000000000086; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Evenson KR, 2009, INT J STROKE, V4, P187, DOI 10.1111/j.1747-4949.2009.00276.x; Faiz KW, 2014, J STROKE CEREBROVASC, V23, P534, DOI 10.1016/j.jstrokecerebrovasdis.2013.05.007; Faiz KW, 2013, EMERG MED J, V30, P669, DOI 10.1136/emermed-2012-201543; Fang J, 2011, CLIN NEUROL NEUROSUR, V113, P85, DOI 10.1016/j.clineuro.2010.09.004; Fassbender K, 2013, LANCET NEUROL, V12, P585, DOI 10.1016/S1474-4422(13)70100-5; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Gibler WB, 2002, ANN EMERG MED, V39, P123, DOI 10.1067/mem.2002.121402; Gorelick PB, 2013, J STROKE, V15, P78, DOI 10.5853/jos.2013.15.2.78; Jin HQ, 2012, STROKE, V43, P362, DOI 10.1161/STROKEAHA.111.623512; Jorgensen HS, 1996, NEUROLOGY, V47, P383, DOI 10.1212/WNL.47.2.383; Kang DW, 2012, STROKE, V43, P3278, DOI 10.1161/STROKEAHA.112.675926; Khatri P, 2014, LANCET NEUROL, V13, P567, DOI 10.1016/S1474-4422(14)70066-3; Kim J, 2019, GERIATR GERONTOL INT, V19, P352, DOI 10.1111/ggi.13615; Kim YJ, 2016, INT J STROKE, V11, P212, DOI 10.1177/1747493015616513; Kothari R, 1999, ANN EMERG MED, V33, P3, DOI 10.1016/S0196-0644(99)70431-2; Kwon YD, 2010, EUR NEUROL, V64, P207, DOI 10.1159/000319176; la Rosa FD, 2012, STROKE, V43, P1591, DOI 10.1161/STROKEAHA.111.645986; Lees KR, 2002, LANCET NEUROL, V1, P41, DOI 10.1016/S1474-4422(02)00005-4; Leon-Jimenez C, 2014, NEUROLOGIA, V29, P200, DOI 10.1016/j.nrl.2013.05.003; Madsen TE, 2016, J STROKE CEREBROVASC, V25, P504, DOI 10.1016/j.jstrokecerebrovasdis.2015.10.026; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Matsuo R, 2017, STROKE, V48, P3049, DOI 10.1161/STROKEAHA.117.018132; Naganuma M, 2009, CEREBROVASC DIS, V28, P33, DOI 10.1159/000215941; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Rosamond WD, 1998, ACAD EMERG MED, V5, P45, DOI 10.1111/j.1553-2712.1998.tb02574.x; Rossnagel K, 2004, ANN EMERG MED, V44, P476, DOI 10.1016/j.annemergmed.2004.06.019; Smith MA, 1998, ANN INTERN MED, V129, P190, DOI 10.7326/0003-4819-129-3-199808010-00005; Smith MA, 2010, STROKE, V41, P905, DOI 10.1161/STROKEAHA.110.578112; Song D, 2015, J STROKE, V17, P159, DOI 10.5853/jos.2015.17.2.159; Tong D, 2012, STROKE, V43, P1912, DOI 10.1161/STROKEAHA.111.644963; Turan Tanya N, 2005, J Stroke Cerebrovasc Dis, V14, P272, DOI 10.1016/j.jstrokecerebrovasdis.2005.07.002; Wouters A, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00153	38	4	4	4	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2021	16	3							e0247829	10.1371/journal.pone.0247829	http://dx.doi.org/10.1371/journal.pone.0247829			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF4TN	33765030	gold, Green Published			2023-01-03	WOS:000634832800086
J	Manze, MG; Romero, DR; De, P; Hartnett, J; Roberts, L				Manze, Meredith G.; Romero, Diana R.; De, Prabal; Hartnett, Josette; Roberts, Lynn			The association of pregnancy control, emotions, and beliefs with pregnancy desires: A new perspective on pregnancy intentions	PLOS ONE			English	Article							UNINTENDED PREGNANCY; REPRODUCTIVE HEALTH; PRIMARY-CARE; BLACK-WOMEN; AMBIVALENCE; PROTECTION; CONSTRUCT; HAPPINESS; RISK	Context Standard pregnancy intentions measures do not always align with how people approach pregnancy. Studies that have investigated beyond a binary framework found that those with "ambivalent" feelings towards pregnancy are less likely to use contraception consistently, but the reasons for this are unclear. We sought to gain a nuanced understanding of pregnancy desires, and how perceptions about pregnancy are associated with contraceptive use. Methods We used non-probability quota sampling based on sex, age, and geographic region for a web-based survey of heterosexual men and women, aged 21-44 years, who could become pregnant/impregnate and were not currently pregnant (n = 1,477; 51% female). The survey was created using unique items informed by recent literature. Bivariate and multivariable analyses explored relationships between various perceptions about pregnancy with pregnancy desires categorized as: wanting a pregnancy, not wanting a pregnancy, and not trying but would be okay with a pregnancy. We conducted a sub-group analysis of those who were not trying but would be okay with a pregnancy (n = 460), using descriptive statistics to examine how consistent contraceptive use was associated with emotions and beliefs about avoiding pregnancy. Results After adjustment, those who felt that pregnancy may not always be avoidable, but instead determined by fate/higher power, or a natural process that happens when it is meant to, were significantly more likely (aOR: 1.83, 95% CI: 1.05-3.36; aOR: 2.21, 95% CI: 1.29-3.76, respectively) to report not trying but being okay with pregnancy, whereas those with negative feelings about a pregnancy were less likely to feel okay about a pregnancy (aOR: 0.11, 95% CI: 0.08-0.15), versus not wanting a pregnancy. In the sub-group analysis, those who felt pregnancy was determined by fate/higher power or a natural process were more likely to report not using contraception consistently (70%, 68%, respectively). Conclusions Those who state they are not trying but would be okay with pregnancy may not use contraception consistently because of beliefs that pregnancy is predetermined. Our findings support less categorical and more multidimensional approaches to measuring fertility intentions, with important implications for reproductive health service provision.	[Manze, Meredith G.; Romero, Diana R.; Roberts, Lynn] CUNY, Grad Sch Publ Hlth & Hlth Policy, Dept Community Hlth & Social Sci, New York, NY 10021 USA; [De, Prabal] CUNY, Grad Ctr, Econ Program, New York, NY USA; [De, Prabal] CUNY City Coll, Dept Econ & Business, New York, NY USA; [Hartnett, Josette] Stamford Hosp, Off Res & Clin Trials, Stamford, CT USA	City University of New York (CUNY) System; City University of New York (CUNY) System; City University of New York (CUNY) System; City College of New York (CUNY); Stamford Hospital	Manze, MG (corresponding author), CUNY, Grad Sch Publ Hlth & Hlth Policy, Dept Community Hlth & Social Sci, New York, NY 10021 USA.	Meredith.manze@sph.cuny.edu	Hartnett, Josette/ADT-6095-2022	Hartnett, Josette/0000-0002-7475-4265; Manze, Meredith/0000-0002-0768-9467; De, Prabal/0000-0002-0043-3207	City University of New York (CUNY) Graduate School of Public Health and Health Policy	City University of New York (CUNY) Graduate School of Public Health and Health Policy	Author: MGM Grant Number: N/A Mechanism: Dean's Mentored Research Award grant Funder: City University of New York (CUNY) Graduate School of Public Health and Health Policy The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiken ARA, 2016, PERSPECT SEX REPRO H, V48, P147, DOI 10.1363/48e10316; Aiken ARA, 2015, SOC SCI MED, V132, P149, DOI 10.1016/j.socscimed.2015.03.038; Barrett G, 2002, SOC SCI MED, V55, P545, DOI 10.1016/S0277-9536(01)00187-3; Bellanca HK, 2013, CONTRACEPTION, V88, P3, DOI 10.1016/j.contraception.2013.05.003; Blake SM, 2007, PERSPECT SEX REPRO H, V39, P194, DOI 10.1363/3919407; Borrero S, 2015, CONTRACEPTION, V91, P150, DOI 10.1016/j.contraception.2014.09.014; Campbell A A, 2000, Matern Child Health J, V4, P163, DOI 10.1023/A:1009519329226; Carter MW, 2012, AM J PUBLIC HEALTH, V102, P449, DOI 10.2105/AJPH.2011.300461; Daniels Kimberly, 2014, NCHS Data Brief, P1; Ewing AC, 2017, CONTEMP CLIN TRIALS, V54, P1, DOI 10.1016/j.cct.2016.12.014; Finer LB, 2016, NEW ENGL J MED, V374, P843, DOI 10.1056/NEJMsa1506575; Gilliam ML, 2009, J PEDIATR ADOL GYNEC, V22, P97, DOI 10.1016/j.jpag.2008.05.008; Gomez AM, 2019, PERSPECT SEX REPRO H, V51, P7, DOI 10.1363/psrh.12088; Gomez AM, 2018, WOMEN HEALTH ISS, V28, P408, DOI 10.1016/j.whi.2018.07.001; Higgins JA, 2012, PERSPECT SEX REPRO H, V44, P236, DOI 10.1363/4423612; Jones HE, 2020, CONTRACEPTION, V101, P226, DOI 10.1016/j.contraception.2019.12.003; Jones J, 2012, 55 NAT HLTH STAT; Kottke M, 2015, J PEDIATR ADOL GYNEC, V28, P543, DOI 10.1016/j.jpag.2015.04.008; Lopez Iris, 2008, MATTERS CHOICE PUERT; Luker KC, 1999, FAM PLANN PERSPECT, V31, P248, DOI 10.2307/2991574; Macleod CI, 2016, J PUBLIC HEALTH-UK, V38, pE384, DOI 10.1093/pubmed/fdv123; Manze MG, 2020, ETHNIC DIS, V30, P525, DOI 10.18865/ed.30.4.525; Manze MG, 2020, CONTRACEPTION, V101, P91, DOI 10.1016/j.contraception.2019.11.004; Manze MG, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0793-7; McQuillan J, 2011, MATERN CHILD HLTH J, V15, P178, DOI 10.1007/s10995-010-0604-9; Morof D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035381; Mumford SL, 2016, FERTIL STERIL, V106, P1453, DOI 10.1016/j.fertnstert.2016.07.1067; Novak NL, 2018, AM J PUBLIC HEALTH, V108, P611, DOI 10.2105/AJPH.2018.304369; Orr ST, 2008, ANN EPIDEMIOL, V18, P545, DOI 10.1016/j.annepidem.2008.03.005; Paterno MT, 2017, J RACIAL ETHN HEALTH, V4, P184, DOI 10.1007/s40615-016-0217-0; Potter JE, 2019, CONTRACEPTION, V100, P1, DOI 10.1016/j.contraception.2019.02.005; Roberts Dorothy., 1998, KILLING BLACK BODY; Rocca CH, 2019, MED CARE, V57, P152, DOI 10.1097/MLR.0000000000001048; Sable M R, 2000, Matern Child Health J, V4, P191, DOI 10.1023/A:1009527631043; Santelli J, 2003, PERSPECT SEX REPRO H, V35, P94, DOI 10.1363/3509403; Schwarz EB, 2007, CONTRACEPTION, V75, P305, DOI 10.1016/j.contraception.2006.12.002; Schwarz EB, 2012, ANN FAM MED, V10, P516, DOI 10.1370/afm.1404; Tone A, 2008, CONTROLLING REPROD A; Whaley AL, 2003, J NATL MED ASSOC, V95, P702	39	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2021	16	3							e0249032	10.1371/journal.pone.0249032	http://dx.doi.org/10.1371/journal.pone.0249032			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RC6NY	33755705	Green Published, gold			2023-01-03	WOS:000632916600049
J	Gruessner, BM; Weathers, PJ				Gruessner, Brian M.; Weathers, Pamela J.			In vitro analyses of Artemisia extracts on Plasmodium falciparum suggest a complex antimalarial effect	PLOS ONE			English	Article							ANNUA-L. INFUSION; ORAL CONSUMPTION; LEAF TABLETS; MALARIA; RESISTANCE; ANTIBODIES; PARASITE; PHARMACOKINETICS; SUSCEPTIBILITY; MUTATIONS	Dried-leaf Artemisia annua L. (DLA) antimalarial therapy was shown effective in prior animal and human studies, but little is known about its mechanism of action. Here IC50s and ring-stage assays (RSAs) were used to compare extracts of A. annua (DLAe) to artemisinin (ART) and its derivatives in their ability to inhibit and kill Plasmodium falciparum strains 3D7, MRA1252, MRA1240, Cam3.11 and Cam3.11rev in vitro. Strains were sorbitol and Percoll synchronized to enrich for ring-stage parasites that were treated with hot water, methanol and dichloromethane extracts of DLA, artemisinin, CoArtem (TM), and dihydroartemisinin. Extracts of A. afra SEN were also tested. There was a correlation between ART concentration and inhibition of parasite growth. Although at 6 hr drug incubation, the RSAs for Cam3.11rev showed DLA and ART were less effective than high dose CoArtem (TM), 8 and 24 hr incubations yielded equivalent antiparasitic results. For Cam3.11, drug incubation time had no effect. DLAe was more effective on resistant MRA-1240 than on the sensitive MRA-1252 strain. Because results were not as robust as observed in animal and human studies, a host interaction was suspected, so sera collected from adult and pediatric Kenyan malaria patients was used in RSA inhibition experiments and compared to sera from adults naive to the disease. The sera from both age groups of malaria patients inhibited parasite growth >= 70% after treatment with DLAe and compared to malaria naive subjects suggesting some host interaction with DLA. The discrepancy between these data and in-vivo reports suggested that DLA's effects require an interaction with the host to unlock their potential as an antimalarial therapy. Although we showed there are serum-based host effects that can kill up to 95% of parasites in vitro, it remains unclear how or if they play a role in vivo. These results further our understanding of how DLAe works against the malaria parasite in vitro.	[Gruessner, Brian M.; Weathers, Pamela J.] Worcester Polytech Inst, Dept Biol & Biotechnol, Worcester, MA 01609 USA	Worcester Polytechnic Institute	Weathers, PJ (corresponding author), Worcester Polytech Inst, Dept Biol & Biotechnol, Worcester, MA 01609 USA.	weathers@wpi.edu		Weathers, Pamela/0000-0001-5138-3839	WPI Ararat Fund for Artemisinin Research [NIH-2R15AT008277-02]; National Center for Complementary and Integrative Health	WPI Ararat Fund for Artemisinin Research; National Center for Complementary and Integrative Health	The WPI Ararat Fund for Artemisinin Research, and for Award Number NIH-2R15AT008277-02 from the National Center for Complementary and Integrative Health that enabled funding phytochemical analyses of the plant material used in this study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Complementary and Integrative Health or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adderley JD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17829-7; Amaratunga C, 2016, LANCET INFECT DIS, V16, P357, DOI 10.1016/S1473-3099(15)00487-9; Arvouet-Grand A, 1994, J Pharm Belg, V49, P462; Ashton M, 1998, CLIN PHARMACOL THER, V63, P482, DOI 10.1016/S0009-9236(98)90044-3; Birgersson S, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1134-8; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; Czechowski T, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00984; Daddy NB, 2017, PHYTOMEDICINE, V32, P37, DOI 10.1016/j.phymed.2017.04.006; De Donno A, 2012, T ROY SOC TROP MED H, V106, P696, DOI 10.1016/j.trstmh.2012.07.008; DESOWITZ RS, 1993, INFECT IMMUN, V61, P988, DOI 10.1128/IAI.61.3.988-993.1993; Desrosiers MR, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020254; Desrosiers MR, 2018, J ETHNOPHARMACOL, V210, P254, DOI 10.1016/j.jep.2017.08.038; Desrosiers MR, 2016, J ETHNOPHARMACOL, V190, P313, DOI 10.1016/j.jep.2016.06.041; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Egan AF, 1999, PARASITE IMMUNOL, V21, P133, DOI 10.1046/j.1365-3024.1999.00209.x; Elfawal MA, 2015, P NATL ACAD SCI USA, V112, P821, DOI 10.1073/pnas.1413127112; Elfawal MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052746; Ganesh D, 2012, PARASITOL RES, V110, P2289, DOI 10.1007/s00436-011-2763-z; Gomes LR, 2014, LUPUS, V23, P1295, DOI 10.1177/0961203314546021; Hollman PCH, 1997, FEBS LETT, V418, P152, DOI 10.1016/S0014-5793(97)01367-7; Islamuddin M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003321; Johnson JD, 2007, ANTIMICROB AGENTS CH, V51, P1926, DOI 10.1128/AAC.01607-06; Kim WS, 2015, KOREAN J PHYSIOL PHA, V19, P21, DOI 10.4196/kjpp.2015.19.1.21; Lagarce Laurence, 2016, J Travel Med, V23, DOI 10.1093/jtm/taw049; LIU KCSC, 1992, PLANT CELL REP, V11, P637, DOI 10.1007/BF00236389; Lubell Y, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-452; Malik S, 2019, ESSENTIAL OIL RES TR, P197; Martini MC, 2020, J ETHNOPHARMACOL, V262, DOI 10.1016/j.jep.2020.113191; Menard D, 2016, NEW ENGL J MED, V374, P2453, DOI 10.1056/NEJMoa1513137; Mensah-Brown HE, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz254; Mouton J, 2013, PLANTA MED, V79, P468, DOI 10.1055/s-0032-1328324; Mwai L, 2009, ANTIMICROB AGENTS CH, V53, P5069, DOI 10.1128/AAC.00638-09; Nass J, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104275; Ogwang PE, 2012, TROP J PHARM RES, V11, P445, DOI 10.4314/tjpr.v11i3.14; Ogwang PE, 2011, BRIT J PHARM RES, V1, P124, DOI 10.9734/BJPR/2011/392; Padmavathy J, 2017, BANGL J PHARMACOL, V12, P151, DOI 10.3329/bjp.v12i2.31020; Phyo AP, 2012, LANCET, V379, P1960, DOI 10.1016/S0140-6736(12)60484-X; Plewes K, 2019, INFECT DIS CLIN N AM, V33, P39, DOI 10.1016/j.idc.2018.10.002; Rath K, 2004, AM J TROP MED HYG, V70, P128, DOI 10.4269/ajtmh.2004.70.128; Silva LFRE, 2012, MEM I OSWALDO CRUZ, V107, P859, DOI 10.1590/S0074-02762012000700004; Sanz LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030949; Saunders DL, 2014, NEW ENGL J MED, V371, P484, DOI 10.1056/NEJMc1403007; Siriwardana A, 2016, ANTIMICROB AGENTS CH, V60, P6952, DOI 10.1128/AAC.00857-16; Snider D, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113638; Srivastava K, 2017, PARASITOL RES, V116, P1849, DOI 10.1007/s00436-017-5455-5; Straimer J, 2015, SCIENCE, V347, P428, DOI 10.1126/science.1260867; Suberu JO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080790; Hien TT, 2011, CLIN THER, V33, P644, DOI 10.1016/j.clinthera.2011.04.017; Tu YY, 2016, ANGEW CHEM INT EDIT, V55, P10210, DOI 10.1002/anie.201601967; Vreden SGS, 2013, MEM I OSWALDO CRUZ, V108, P968, DOI 10.1590/0074-0276130167; Wahlgren M., 2013, IIC THAWING GLYCEROL, V6th, P20; Warsame M, 2017, TROP MED INT HEALTH, V22, P415, DOI 10.1111/tmi.12847; Weathers Pamela J, 2014, World J Pharmacol, V3, P39; Weathers PJ, 2014, IND CROP PROD, V62, P173, DOI 10.1016/j.indcrop.2014.08.033; Weathers PJ, 2014, J ETHNOPHARMACOL, V153, P732, DOI 10.1016/j.jep.2014.03.037; Wei SJ, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0929-3; WHO, 2017, WORLD MALARIA REPORT; Witkowski B, 2013, ANTIMICROB AGENTS CH, V57, P914, DOI 10.1128/AAC.01868-12; Witkowski B, 2010, ANTIMICROB AGENTS CH, V54, P1872, DOI 10.1128/AAC.01636-09; World Health Organization, 2019, USE NONPHARMACEUTICA; World Health Organization, 2017, WHOHTMGMP20179	61	2	2	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2021	16	3							e0240874	10.1371/journal.pone.0240874	http://dx.doi.org/10.1371/journal.pone.0240874			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR6XN	33651845	gold, Green Published			2023-01-03	WOS:000625359500019
J	Hoertel, N; Sanchez-Rico, M; Vernet, R; Jannot, AS; Neuraz, A; Blanco, C; Lemogne, C; Airagnes, G; Paris, N; Daniel, C; Gramfort, A; Lemaitre, G; Bernaux, M; Bellamine, A; Beeker, N; Limosin, F				Hoertel, Nicolas; Sanchez-Rico, Marina; Vernet, Raphael; Jannot, Anne-Sophie; Neuraz, Antoine; Blanco, Carlos; Lemogne, Cedric; Airagnes, Guillaume; Paris, Nicolas; Daniel, Christel; Gramfort, Alexandre; Lemaitre, Guillaume; Bernaux, Melodie; Bellamine, Ali; Beeker, Nathanael; Limosin, Frederic		AP-HP Univ INSERM Covid-19 Res Col; AP-HP Covid CDR Initiative	Observational study of haloperidol in hospitalized patients with COVID-19	PLOS ONE			English	Article								Background Haloperidol, a widely used antipsychotic, has been suggested as potentially useful for patients with COVID-19 on the grounds of its in-vitro antiviral effects against SARS-CoV-2, possibly through sigma-1 receptor antagonist effect. Methods We examined the associations of haloperidol use with intubation or death and time to discharge home among adult patients hospitalized for COVID-19 at Assistance Publique-Hopitaux de Paris (AP-HP) Greater Paris University hospitals. Study baseline was defined as the date of hospital admission. The primary endpoint was a composite of intubation or death and the secondary endpoint was discharge home among survivors in time-to-event analyses. In the primary analyses, we compared these two outcomes between patients receiving and not receiving haloperidol using univariate Cox regression models in matched analytic samples based on patient characteristics and other psychotropic medications. Sensitivity analyses included propensity score analyses with inverse probability weighting and multivariable Cox regression models. Results Of 15,121 adult inpatients with a positive COVID-19 PT-PCR test, 39 patients (0.03%) received haloperidol within the first 48 hours of admission. Over a mean follow-up of 13.8 days (SD = 17.9), 2,024 patients (13.4%) had a primary end-point event and 10,179 patients (77.6%) were discharged home at the time of study end on May 1(st). The primary endpoint occurred in 9 patients (23.1%) who received haloperidol and 2,015 patients (13.4%) who did not. The secondary endpoint of discharge home occurred in 16 patients (61.5%) who received haloperidol and 9,907 patients (85.8%) who did not. There were no significant associations between haloperidol use and the primary (HR, 0.80; 95% CI, 0.39 to 1.62, p = 0.531) and secondary (HR, 1.30; 95% CI, 0.74 to 2.28, p = 0.355) endpoints. Results were similar in multiple sensitivity analyses. Conclusion Findings from this multicenter observational study suggest that haloperidol use prescribed at a mean dose of 4.5 mg per day (SD = 5.2) for a mean duration of 8.4 days (SD = 7.2) may not be associated with risk of intubation or death, or with time to discharge home, among adult patients hospitalized for COVID-19.	[Hoertel, Nicolas; Sanchez-Rico, Marina; Lemogne, Cedric; Airagnes, Guillaume; Limosin, Frederic] Ctr Univ Paris, Hop Corentin Celton, AP HP, Dept Psychiat, Issy Les Moulineaux, France; [Hoertel, Nicolas; Lemogne, Cedric; Airagnes, Guillaume; Limosin, Frederic] Inst Psychiat & Neurosci Paris, INSERM, Paris, France; [Hoertel, Nicolas; Jannot, Anne-Sophie; Lemogne, Cedric; Airagnes, Guillaume; Limosin, Frederic] Univ Paris, Fac Sante, UFR Med, Paris, France; [Sanchez-Rico, Marina] Univ Complutense Madrid, Fac Psychol, Dept Psychobiol & Behav Sci Methods, Madrid, Spain; [Vernet, Raphael; Jannot, Anne-Sophie] Ctr Univ Paris, Biostat & Publ Hlth Dept, Hop Europeen Georges Pompidou, AP HP,Med Informat, Paris, France; [Jannot, Anne-Sophie; Neuraz, Antoine] Univ Paris, Cordeliers Res Ctr, INSERM, UMR S 1138, Paris, France; [Neuraz, Antoine] Ctr Univ Paris, Necker Enfants Malad Hosp, AP HP, Dept Med Informat, Paris, France; [Blanco, Carlos] NIDA, Bethesda, MD 20892 USA; [Paris, Nicolas; Daniel, Christel] AP HP, DSI WIND, Paris, France; [Paris, Nicolas] Univ Paris Saclay, Univ Paris Sud, CNRS, LIMSI, Orsay, France; [Daniel, Christel] Univ Paris 13, Sorbonne Paris Cite, UMR S 1142, Sorbonne Univ,INSERM, Paris, France; [Gramfort, Alexandre; Lemaitre, Guillaume] Univ Paris Saclay, CEA, INRIA, Palaiseau, France; [Bernaux, Melodie] AP HP, Direct Strategie & Transformat, Paris, France; [Bellamine, Ali; Beeker, Nathanael] Ctr Univ Paris, Hop Cochin, AP HP, Unite Rech Clin, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Corentin-Celton - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Complutense University of Madrid; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Assistance Publique Hopitaux Paris (APHP); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris 13; CEA; Inria; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Sanchez-Rico, M (corresponding author), Ctr Univ Paris, Hop Corentin Celton, AP HP, Dept Psychiat, Issy Les Moulineaux, France.; Sanchez-Rico, M (corresponding author), Univ Complutense Madrid, Fac Psychol, Dept Psychobiol & Behav Sci Methods, Madrid, Spain.	marinals@ucm.es	Neuraz, Antoine/ABI-6442-2020; Airagnes, Guillaume/M-8309-2017; , Hoertel/H-9457-2015	Neuraz, Antoine/0000-0001-7142-6728; Airagnes, Guillaume/0000-0002-3494-5083; , Hoertel/0000-0002-7890-1349; LEBLANC, Judith/0000-0002-0323-6671; Sanchez-Rico, Marina/0000-0002-1121-8641; Lemogne, Cedric/0000-0002-3487-4721				Alvarado, 2020, DEXAMETHASONE USE MO, DOI [10.1101/2020.10.23.20218172, DOI 10.1101/2020.10.23.20218172]; Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5; Blanco, 2020, MEDRXIV, DOI [10.1101/2020.07.15.20154310, DOI 10.1101/2020.07.15.20154310]; Chevance A, 2020, ENCEPHALE, V46, P193, DOI 10.1016/j.encep.2020.04.005; Dalwadi DA, 2017, NEUROCHEM INT, V105, P21, DOI 10.1016/j.neuint.2017.02.003; Devlin Jacob, 2019, P 2019 C N AM CHAPT, Patent No. [ArXiv181004805Cs, 181004805]; Dunkler D, 2018, J STAT SOFTW, V84, P1, DOI 10.18637/jss.v084.i02; Efron B., 1981, CANADIAN J STATISTIC, V9, P139, DOI [DOI 10.2307/3314608, 10.1093/jtm/taab016, DOI 10.1093/jtm/taab016]; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hansen BB, 2006, J COMPUT GRAPH STAT, V15, P609, DOI 10.1198/106186006X137047; Hoertel N., 2020, ASS HYDROXYZINE USE, DOI [10.1101/2020.10.23.20154302, DOI 10.1101/2020.10.23.20154302]; Hoertel N, 2021, MOL PSYCHIATR, V26, P5199, DOI 10.1038/s41380-021-01021-4; Hoertel N, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1001-6; Hoertel Nicolas, 2020, medRxiv, DOI 10.1101/2020.04.23.20076885; Hur K, 2020, OTOLARYNG HEAD NECK, V163, P170, DOI 10.1177/0194599820929640; Jouffroy Jordan, 2020, MEDEXT COMBINING EXP; Le Strat Y, 2011, ADDICTION, V106, P1871, DOI 10.1111/j.1360-0443.2011.03547.x; Mitsuda T, 2011, BIOCHEM BIOPH RES CO, V415, P519, DOI 10.1016/j.bbrc.2011.10.113; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517; Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597; Stuart EA, 2013, J CLIN EPIDEMIOL, V66, pS84, DOI 10.1016/j.jclinepi.2013.01.013; Therneau TM., 2000, MODELING SURVIVAL DA; von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010; Williamson E., 2020, MEDRXIV, P1, DOI [10.1101/2020.05.06.20092999, 10.1101/2020.05.06.20092999v1]; Xiong GL, 2020, J PSYCHOSOM RES, V135, DOI 10.1016/j.jpsychores.2020.110138; Zayed Y, 2019, J CRIT CARE, V50, P280, DOI 10.1016/j.jcrc.2019.01.009; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	31	23	24	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2021	16	2							e0247122	10.1371/journal.pone.0247122	http://dx.doi.org/10.1371/journal.pone.0247122			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8KQ	33606790	Green Published, gold, Green Submitted			2023-01-03	WOS:000620629200136
J	Murai, IH; Fernandes, AL; Sales, LP; Pinto, AJ; Goessler, KF; Duran, CSC; Silva, CBR; Franco, AS; Macedo, MB; Dalmolin, HHH; Baggio, J; Balbi, GGM; Reis, BZ; Antonangelo, L; Caparbo, VF; Gualano, B; Pereira, RMR				Murai, Igor H.; Fernandes, Alan L.; Sales, Lucas P.; Pinto, Ana J.; Goessler, Karla F.; Duran, Camila S. C.; Silva, Carla B. R.; Franco, Andre S.; Macedo, Marina B.; Dalmolin, Henrique H. H.; Baggio, Janaina; Balbi, Guilherme G. M.; Reis, Bruna Z.; Antonangelo, Leila; Caparbo, Valeria F.; Gualano, Bruno; Pereira, Rosa M. R.			Effect of a Single High Dose of Vitamin D-3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							D SUPPLEMENTATION	IMPORTANCE The efficacy of vitamin D-3 supplementation in coronavirus disease 2019 (COVID-19) remains unclear. OBJECTIVE To investigate the effect of a single high dose of vitamin D-3 on hospital length of stay in patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS This was a multicenter, double-blind, randomized, placebo-controlled trial conducted in 2 sites in Sao Paulo, Brazil. The study included 240 hospitalized patients with COVID-19 who were moderately to severely ill at the time of enrollment from June 2, 2020, to August 27, 2020. The final follow-up was on October 7, 2020. INTERVENTIONS Patients were randomly assigned to receive a single oral dose of 200 000 IU of vitamin D-3 (n = 120) or placebo (n = 120). MAIN OUTCOMES AND MEASURES The primary outcome was length of stay, defined as the time from the date of randomization to hospital discharge. Prespecified secondary outcomes included mortality during hospitalization; the number of patients admitted to the intensive care unit; the number of patients who required mechanical ventilation and the duration of mechanical ventilation; and serum levels of 25-hydroxyvitamin D, total calcium, creatinine, and C-reactive protein. RESULTS Of 240 randomized patients, 237 were included in the primary analysis (mean [SD] age, 56.2 [14.4] years; 104 [43.9%] women; mean [SD] baseline 25-hydroxyvitamin D level, 20.9 [9.2] ng/mL). Median (interquartile range) length of stay was not significantly different between the vitamin D-3 (7.0 [4.0-10.0] days) and placebo groups (7.0 [5.0-13.0] days) (log-rank P = .59; unadjusted hazard ratio for hospital discharge, 1.07 [95% CI, 0.82-1.39]; P = .62). The difference between the vitamin D-3 group and the placebo group was not significant for in-hospital mortality (7.6% vs 5.1%; difference, 2.5% [95% CI, -4.1% to 9.2%]; P = .43), admission to the intensive care unit (16.0% vs 21.2%; difference, -5.2% [95% CI, -15.1% to 4.7%]; P = .30), or need for mechanical ventilation (7.6% vs 14.4%; difference, -6.8% [95% CI, -15.1% to 1.2%]; P = .09). Mean serum levels of 25-hydroxyvitamin D significantly increased after a single dose of vitamin D-3 vs placebo (44.4 ng/mL vs 19.8 ng/mL; difference, 24.1 ng/mL [95% CI, 19.5-28.7]; P < .001). There were no adverse events, but an episode of vomiting was associated with the intervention. CONCLUSIONS AND RELEVANCE Among hospitalized patients with COVID-19, a single high dose of vitamin D-3, compared with placebo, did not significantly reduce hospital length of stay. The findings do not support the use of a high dose of vitamin D-3 for treatment of moderate to severe COVID-19.	[Murai, Igor H.; Fernandes, Alan L.; Sales, Lucas P.; Duran, Camila S. C.; Silva, Carla B. R.; Franco, Andre S.; Macedo, Marina B.; Dalmolin, Henrique H. H.; Baggio, Janaina; Balbi, Guilherme G. M.; Reis, Bruna Z.; Caparbo, Valeria F.; Pereira, Rosa M. R.] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Rheumatol Div, Sao Paulo, Brazil; [Pinto, Ana J.; Goessler, Karla F.; Gualano, Bruno] Univ Sao Paulo, Fac Med, Appl Physiol & Nutr Res Grp, Sao Paulo, Brazil; [Antonangelo, Leila] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Clin Pathol Div, Sao Paulo, Brazil; [Gualano, Bruno] Univ Sao Paulo, Food Res Ctr, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Pereira, RMR (corresponding author), Univ Sao Paulo, Fac Med FMUSP, Rheumatol Div, 3 Andar,Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.	rosamariarp@yahoo.com	Pinto, Ana Jessica/E-9869-2018; Reis, Bruna Zavarize/F-3102-2014; Pinto, Ana Jessica/Y-6637-2019; Fernandes, Alan Lins/R-7248-2019; Pereira, Rosa M R/C-5192-2012; Gualano, Bruno/ABA-9571-2020; Antonangelo, Leila/H-9998-2012; Caparbo, Valéria/ABF-1198-2021; Sales, Lucas Peixoto/AAV-2301-2020; Macêdo, Marina Barguil/AID-8278-2022	Pinto, Ana Jessica/0000-0002-1363-7233; Reis, Bruna Zavarize/0000-0001-8726-8699; Pinto, Ana Jessica/0000-0002-1363-7233; Fernandes, Alan Lins/0000-0002-6786-3922; Pereira, Rosa M R/0000-0002-3723-5028; Gualano, Bruno/0000-0001-7100-8681; Antonangelo, Leila/0000-0002-8634-5100; Sales, Lucas Peixoto/0000-0003-2439-2240; Macêdo, Marina Barguil/0000-0002-8927-5566; de Falco Caparbo, Valeria/0000-0002-6606-8628; Franco, Andre/0000-0002-6526-0140	FAPESP [20/05752-4, 19/24782-4, 20/11102-2, 16/00006-7, 17/13552-2, 15/26937-4, 19/18039-7]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [305556/2017-7]	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study was supported by FAPESP (grants 20/05752-4; 19/24782-4; 20/11102-2; 16/00006-7; 17/13552-2; 15/26937-4; 19/18039-7) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (305556/2017-7).	Aglipay M, 2017, JAMA-J AM MED ASSOC, V318, P245, DOI 10.1001/jama.2017.8708; Aibana O, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002907; Annweiler G, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113377; Autier P, 2014, LANCET DIABETES ENDO, V2, P76, DOI 10.1016/S2213-8587(13)70165-7; Bacchetti P, 2008, BIOMETRICS, V64, P577, DOI [10.1111/j.1541-0420.2008.01004.x, 10.1111/j.1541-0420.2008.01004_1.x]; Bacchetti P, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-17; Bilezikian JP, 2020, EUR J ENDOCRINOL, V183, pR133, DOI 10.1530/EJE-20-0665; Campbell GR, 2012, AUTOPHAGY, V8, P1523, DOI 10.4161/auto.21154; Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175; Carpagnano GE, 2021, J ENDOCRINOL INVEST, V44, P765, DOI 10.1007/s40618-020-01370-x; Franco AS, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000007024, 10.1097/md.0000000000007024]; Hernandez Jose L., 2021, Journal of Clinical Endocrinology & Metabolism, V106, pE1343, DOI 10.1210/clinem/dgaa733; Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8; Kaufman HW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239252; Kearns MD, 2014, ENDOCR PRACT, V20, P341, DOI 10.4158/EP13265.RA; Laplana M, 2018, GENE, V678, P384, DOI 10.1016/j.gene.2018.08.017; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Martineau AR, 2020, LANCET DIABETES ENDO, V8, P735, DOI 10.1016/S2213-8587(20)30268-0; Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583; Meltzer DO, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19722; Mitchell F, 2020, LANCET DIABETES ENDO, V8, P570, DOI 10.1016/S2213-8587(20)30183-2; Sabetta JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011088; van Etten E, 2005, J STEROID BIOCHEM, V97, P93, DOI 10.1016/j.jsbmb.2005.06.002	23	236	242	14	56	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	2021	325	11					1053	1060		10.1001/jama.2020.26848	http://dx.doi.org/10.1001/jama.2020.26848		FEB 2021	8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ1BV	33595634	Green Published, Bronze			2023-01-03	WOS:000619613600003
J	Ducrocq, G; Gonzalez-Juanatey, JR; Puymirat, E; Lemesle, G; Cachanado, M; Durand-Zaleski, I; Arnaiz, JA; Martinez-Selles, M; Silvain, J; Ariza-Sole, A; Ferrari, E; Calvo, G; Danchin, N; Avendano-Sola, C; Frenkiel, J; Rousseau, A; Vicaut, E; Simon, T; Steg, PG				Ducrocq, Gregory; Gonzalez-Juanatey, Jose R.; Puymirat, Etienne; Lemesle, Gilles; Cachanado, Marine; Durand-Zaleski, Isabelle; Albert Arnaiz, Joan; Martinez-Selles, Manuel; Silvain, Johanne; Ariza-Sole, Albert; Ferrari, Emile; Calvo, Gonzalo; Danchin, Nicolas; Avendano-Sola, Cristina; Frenkiel, Jerome; Rousseau, Alexandra; Vicaut, Eric; Simon, Tabassome; Steg, Philippe Gabriel		REALITY Investigators	Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia The REALITY Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This noninferiority trial compares the effects of a restrictive (hemoglobin <= 8 g/dL) vs liberal (hemoglobin <= 10 g/dL) transfusion strategy on 30-day cardiovascular events among adults with acute myocardial infarction (AMI) and anemia (hemoglobin 7-10 g/dL). Question Is a restrictive strategy of blood transfusion noninferior to a liberal strategy among patients with acute myocardial infarction and anemia? Findings In this randomized clinical trial that included 668 patients with acute myocardial infarction and hemoglobin level between 7 and 10 g/dL who were treated with a restrictive transfusion strategy (triggered by hemoglobin <= 8 g/dL) vs a liberal strategy (triggered by hemoglobin <= 10 g/dL), the composite outcome (all-cause death, stroke, recurrent myocardial infarction, or emergency revascularization) at 30 days occurred in 11% vs 14% of patients, a difference that met the noninferiority criterion of relative risk less than 1.25. Meaning A restrictive transfusion strategy compared with a liberal strategy resulted in a noninferior rate of major cardiovascular events among patients with acute myocardial infarction and anemia, but the CI included what may be a clinically important harm. Importance The optimal transfusion strategy in patients with acute myocardial infarction and anemia is unclear. Objective To determine whether a restrictive transfusion strategy would be clinically noninferior to a liberal strategy. Design, Setting, and Participants Open-label, noninferiority, randomized trial conducted in 35 hospitals in France and Spain including 668 patients with myocardial infarction and hemoglobin level between 7 and 10 g/dL. Enrollment could be considered at any time during the index admission for myocardial infarction. The first participant was enrolled in March 2016 and the last was enrolled in September 2019. The final 30-day follow-up was accrued in November 2019. Interventions Patients were randomly assigned to undergo a restrictive (transfusion triggered by hemoglobin <= 8; n = 342) or a liberal (transfusion triggered by hemoglobin <= 10 g/dL; n = 324) transfusion strategy. Main Outcomes and Measures The primary clinical outcome was major adverse cardiovascular events (MACE; composite of all-cause death, stroke, recurrent myocardial infarction, or emergency revascularization prompted by ischemia) at 30 days. Noninferiority required that the upper bound of the 1-sided 97.5% CI for the relative risk of the primary outcome be less than 1.25. The secondary outcomes included the individual components of the primary outcome. Results Among 668 patients who were randomized, 666 patients (median [interquartile range] age, 77 [69-84] years; 281 [42.2%] women) completed the 30-day follow-up, including 342 in the restrictive transfusion group (122 [35.7%] received transfusion; 342 total units of packed red blood cells transfused) and 324 in the liberal transfusion group (323 [99.7%] received transfusion; 758 total units transfused). At 30 days, MACE occurred in 36 patients (11.0% [95% CI, 7.5%-14.6%]) in the restrictive group and in 45 patients (14.0% [95% CI, 10.0%-17.9%]) in the liberal group (difference, -3.0% [95% CI, -8.4% to 2.4%]). The relative risk of the primary outcome was 0.79 (1-sided 97.5% CI, 0.00-1.19), meeting the prespecified noninferiority criterion. In the restrictive vs liberal group, all-cause death occurred in 5.6% vs 7.7% of patients, recurrent myocardial infarction occurred in 2.1% vs 3.1%, emergency revascularization prompted by ischemia occurred in 1.5% vs 1.9%, and nonfatal ischemic stroke occurred in 0.6% of patients in both groups. Conclusions and Relevance Among patients with acute myocardial infarction and anemia, a restrictive compared with a liberal transfusion strategy resulted in a noninferior rate of MACE after 30 days. However, the CI included what may be a clinically important harm.	[Ducrocq, Gregory; Steg, Philippe Gabriel] Univ Paris, INSERM, French Alliance Cardiovasc Trials FACT, AP HP,U1148, Paris, France; [Gonzalez-Juanatey, Jose R.] Univ Santiago de Compostela, Univ Hosp, Cardiol Dept, IDIS,CIBERCV, Santiago De Compostela, Spain; [Puymirat, Etienne; Danchin, Nicolas] Univ Paris, French Alliance Cardiovasc Trials FACT, Hop Europeen Georges Pompidou, AP HP, Paris, France; [Lemesle, Gilles] Univ Lille, CHU Lille, Fac Med Lille, Inst Pasteur Lille,Inserm,U1011,Inst Coeur Poumon, Lille, France; [Lemesle, Gilles] French Alliance Cardiovasc Trials FACT, Paris, France; [Cachanado, Marine; Rousseau, Alexandra; Simon, Tabassome] Hop St Antoine, AP HP, Dept Clin Pharmacol, Paris, France; [Cachanado, Marine; Rousseau, Alexandra; Simon, Tabassome] Hop St Antoine, AP HP, Clin Res Platform East Paris URC CRC CRB, Paris, France; [Durand-Zaleski, Isabelle; Frenkiel, Jerome] Hop Hotel Dieu, AP HP, Hlth Econ Res Unit, INSERM,UMR CRESS 1153, Paris, France; [Albert Arnaiz, Joan; Martinez-Selles, Manuel] Hosp Clin Barcelona, Clin Pharmacol Dept, Clin Trials Unit, Barcelona, Spain; [Albert Arnaiz, Joan; Martinez-Selles, Manuel] Univ Complutense, Univ Europea, Hosp Univ Gregorio Maranon, CIBERCV,Serv Cardiol, Madrid, Spain; [Silvain, Johanne] Sorbonne Univ, Inst Cardiol, Hop Pitie Salpetriere, AP HP,ACTION Study Grp,INSERM,UMRS1166, Paris, France; [Ariza-Sole, Albert] Univ Hosp Bellvitge, Heart Dis Inst, Barcelona, Spain; [Ferrari, Emile] Univ Cote dAzur, Serv Cardiol, CHU Nice, Hop Pasteur 1, Nice, France; [Calvo, Gonzalo] Univ Barcelona, Hosp Clin Barcelona, Area Medicament, Barcelona, Spain; [Avendano-Sola, Cristina] Hosp Univ Puerta Hierro Majadahonda, Clin Pharmacol Serv, Madrid, Spain; [Vicaut, Eric] Univ Paris Diderot, Fernand Widal Hosp, AP HP, Sorbonne Paris Cite,Dept Biostat, Paris, France; [Simon, Tabassome] Sorbonne Univ, Dept Clin Pharmacol, French Alliance Cardiovasc Trials FACT, Hop St Antoine,AP HP,Clin Res Platform URCEST CRB, Paris, France; [Steg, Philippe Gabriel] Imperial Coll, Royal Brompton Hosp, London, England	Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CIBER - Centro de Investigacion Biomedica en Red; CIBERCV; Universidade de Santiago de Compostela; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERCV; Complutense University of Madrid; European University of Madrid; General University Gregorio Maranon Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; University of Barcelona; Hospital Clinic de Barcelona; Hospital Puerta de Hierro-Majadahonda; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Imperial College London; Royal Brompton Hospital	Steg, PG (corresponding author), Hop Bichat Claude Bernard, AP HP, 46 Rue Henri Huchard, F-75018 Paris, France.	gabriel.steg@aphp.fr	Puymirat, Etienne/AAP-8895-2021; Garcia-Garcia, Cosme/E-2406-2016	Garcia-Garcia, Cosme/0000-0001-6330-1677; Puymirat, Etienne/0000-0002-0533-9682; Avendano Sola, Cristina/0000-0001-5437-7215; Gonzalez Juanatey, Jose Ramon/0000-0001-9681-3388; FERRARI, Emile/0000-0002-8233-6039				Alexander KP, 2008, AM HEART J, V155, P1047, DOI 10.1016/j.ahj.2008.01.009; [Anonymous], 2016, NON CLIN TRIALS EST; [Anonymous], 1998, STAT PRINC CLIN TRIA; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Carson JL, 2013, JAMA-J AM MED ASSOC, V309, P83, DOI 10.1001/jama.2012.50429; Chatterjee S, 2013, JAMA INTERN MED, V173, P132, DOI 10.1001/2013.jamainternmed.1001; Cooper HA, 2011, AM J CARDIOL, V108, P1108, DOI 10.1016/j.amjcard.2011.06.014; Docherty AB, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1351; Ducrocq G, 2021, CLIN CARDIOL, V44, P143, DOI 10.1002/clc.23453; Ducrocq G, 2015, AM HEART J, V170, P726, DOI 10.1016/j.ahj.2015.07.004; Farhan S, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.004908; Hahn JY, 2018, LANCET, V391, P1274, DOI 10.1016/S0140-6736(18)30493-8; Hanssen M, 2012, HEART, V98, P699, DOI 10.1136/heartjnl-2012-301700; Jabre P, 2018, JAMA-J AM MED ASSOC, V319, P779, DOI 10.1001/jama.2018.0156; Kedhi E, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k3793; Kim HS, 2020, LANCET, V396, P1079, DOI 10.1016/S0140-6736(20)31791-8; Mazer CD, 2018, NEW ENGL J MED, V379, P1224, DOI 10.1056/NEJMoa1808561; Mulla SM, 2012, JAMA-J AM MED ASSOC, V308, P2605, DOI 10.1001/2012.jama.11235; Murphy GJ, 2015, NEW ENGL J MED, V372, P997, DOI 10.1056/NEJMoa1403612; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Pocock SJ, 2015, J AM COLL CARDIOL, V66, P2886, DOI 10.1016/j.jacc.2015.10.051; Puymirat E, 2012, JAMA-J AM MED ASSOC, V308, P998, DOI 10.1001/2012.jama.11348; Rao SV, 2014, J AM COLL CARDIOL, V63, P1297, DOI 10.1016/j.jacc.2013.11.028; Rao SV, 2004, JAMA-J AM MED ASSOC, V292, P1555, DOI 10.1001/jama.292.13.1555; Sabatine MS, 2005, CIRCULATION, V111, P2042, DOI 10.1161/01.CIR.0000162477.70955.5F; Silvain J, 2014, J AM COLL CARDIOL, V63, P1289, DOI 10.1016/j.jacc.2013.11.029; Silvain J, 2010, EUR HEART J, V31, P2816, DOI 10.1093/eurheartj/ehq209; Steg PG, 2017, EUR HEART J, V38, P1044, DOI 10.1093/eurheartj/ehx110; Thygesen K, 2012, CIRCULATION, V126, P2020, DOI 10.1161/CIR.0b013e31826e1058; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Watanabe H, 2019, JAMA-J AM MED ASSOC, V321, P2414, DOI 10.1001/jama.2019.8145; Williamson LM, 2013, LANCET, V381, P1866, DOI 10.1016/S0140-6736(13)60631-5; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615; Yeh RW, 2014, J AM COLL CARDIOL, V64, P820, DOI 10.1016/j.jacc.2014.05.041	34	59	60	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2021	325	6					552	560		10.1001/jama.2021.0135	http://dx.doi.org/10.1001/jama.2021.0135			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG0MD	33560322	Bronze, Green Published			2023-01-03	WOS:000617279600018
J	Davar, D; Dzutsev, AK; McCulloch, JA; Rodrigues, RR; Chauvin, JM; Morrison, RM; Deblasio, RN; Menna, C; Ding, QQ; Pagliano, O; Zidi, B; Zhang, SW; Badger, JH; Vetizou, M; Cole, AM; Fernandes, MR; Prescott, S; Costa, RGF; Balaji, AK; Morgun, A; Vujkovic-Cvijin, I; Wang, H; Borhani, AA; Schwartz, MB; Dubner, HM; Ernst, SJ; Rose, A; Najjar, YG; Belkaid, Y; Kirkwood, JM; Trinchieri, G; Zarour, HM				Davar, Diwakar; Dzutsev, Amiran K.; McCulloch, John A.; Rodrigues, Richard R.; Chauvin, Joe-Marc; Morrison, Robert M.; Deblasio, Richelle N.; Menna, Carmine; Ding, Quanquan; Pagliano, Ornella; Zidi, Bochra; Zhang, Shuowen; Badger, Jonathan H.; Vetizou, Marie; Cole, Alicia M.; Fernandes, Miriam R.; Prescott, Stephanie; Costa, Raquel G. F.; Balaji, Ascharya K.; Morgun, Andrey; Vujkovic-Cvijin, Ivan; Wang, Hong; Borhani, Amir A.; Schwartz, Marc B.; Dubner, Howard M.; Ernst, Scarlett J.; Rose, Amy; Najjar, Yana G.; Belkaid, Yasmine; Kirkwood, John M.; Trinchieri, Giorgio; Zarour, Hassane M.			Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients	SCIENCE			English	Article							CD8(+) T-CELLS; NATURAL-KILLER; GUT MICROBIOTA; EFFICACY; PEMBROLIZUMAB; SUPPRESSION; NIVOLUMAB; REVEAL	Anti-programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to patients with advanced melanoma. The composition of the gut microbiota correlates with anti-PD-1 efficacy in preclinical models and cancer patients. To investigate whether resistance to anti-PD-1 can be overcome by changing the gut microbiota, this clinical trial evaluated the safety and efficacy of responder-derived fecal microbiota transplantation (FMT) together with anti-PD-1 in patients with PD-1-refractory melanoma. This combination was well tolerated, provided clinical benefit in 6 of 15 patients, and induced rapid and durable microbiota perturbation. Responders exhibited increased abundance of taxa that were previously shown to be associated with response to anti-PD-1, increased CD8(+) T cell activation, and decreased frequency of interleukin-8-expressing myeloid cells. Responders had distinct proteomic and metabolomic signatures, and transkingdom network analyses confirmed that the gut microbiome regulated these changes. Collectively, our findings show that FMT and anti-PD-1 changed the gut microbiome and reprogrammed the tumor microenvironment to overcome resistance to anti-PD-1 in a subset of PD-1 advanced melanoma.	[Davar, Diwakar; Chauvin, Joe-Marc; Morrison, Robert M.; Deblasio, Richelle N.; Menna, Carmine; Ding, Quanquan; Pagliano, Ornella; Zidi, Bochra; Zhang, Shuowen; Ernst, Scarlett J.; Rose, Amy; Najjar, Yana G.; Kirkwood, John M.; Zarour, Hassane M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; [Davar, Diwakar; Chauvin, Joe-Marc; Morrison, Robert M.; Deblasio, Richelle N.; Menna, Carmine; Ding, Quanquan; Pagliano, Ornella; Zidi, Bochra; Zhang, Shuowen; Ernst, Scarlett J.; Rose, Amy; Najjar, Yana G.; Kirkwood, John M.; Zarour, Hassane M.] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Dzutsev, Amiran K.; McCulloch, John A.; Rodrigues, Richard R.; Badger, Jonathan H.; Vetizou, Marie; Cole, Alicia M.; Fernandes, Miriam R.; Prescott, Stephanie; Costa, Raquel G. F.; Balaji, Ascharya K.; Trinchieri, Giorgio] NCI, Lab Integrat Canc Immunol, Ctr Canc Res, Bethesda, MD 20892 USA; [Rodrigues, Richard R.] Frederick Natl Lab Canc Res, Basic Sci Program, Genet & Microbiome Core, Frederick, MD 21702 USA; [Morgun, Andrey] Oregon State Univ, Coll Pharm, Corvallis, OR 97331 USA; [Vujkovic-Cvijin, Ivan; Belkaid, Yasmine] NIAID, Lab Immune Syst Biol, NIH, Bethesda, MD 20892 USA; [Wang, Hong] Univ Pittsburgh, UPMC Hillman Canc Ctr, Biostat Facil, Pittsburgh, PA 15213 USA; [Borhani, Amir A.] Univ Pittsburgh, Dept Radiol, Div Abdominal Imaging, Pittsburgh, PA 15213 USA; [Schwartz, Marc B.; Dubner, Howard M.] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA; [Zarour, Hassane M.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15213 USA; [Zhang, Shuowen] Tsinghua Univ, Sch Med, 1 Tsinghua Yuan, Beijing 100084, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oregon State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tsinghua University	Zarour, HM (corresponding author), Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA.; Trinchieri, G (corresponding author), NCI, Lab Integrat Canc Immunol, Ctr Canc Res, Bethesda, MD 20892 USA.; Zarour, HM (corresponding author), Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15213 USA.	trinchig@mail.nih.gov; zarourhm@upmc.edu	Fernandes, Miriam Rodriguez/AAB-5493-2022; zidi, Bochra/GQZ-1473-2022; Davar, Diwakar/AAL-9592-2021	McCulloch, John/0000-0001-7107-6561; Rodrigues, Richard/0000-0003-3985-3003; Chauvin, Joe-Marc/0000-0002-5294-8632; Cole, Alicia/0000-0002-7792-2543; Davar, Diwakar/0000-0002-7846-8055; Vujkovic-Cvijin, Ivan/0000-0002-8611-4900; Kirkwood, John/0000-0002-3570-4476; Morrison, Robert/0000-0002-8421-8183; Balaji, Ascharya/0000-0003-1382-5864; Prescott, Stephanie/0000-0002-0469-5255; Wang, Hong/0000-0003-0477-2908	Merck MSD; Melanoma Breakthrough Foundation Breakthrough Consortium; National Cancer Institute (NCI) of the National Institutes of Health (NIH) [R01 CA228181, R01 CA222203]; James W. and Frances G. McGlothlin Chair in Melanoma Immunotherapy Research; UPMC Hillman Cancer Center Microbiome Shared Facility; NIH NCI Comprehensive Cancer Center Support CORE grant [P30 CA047904]; University of Pittsburgh Center for Research Computing and Unified Flow Cytometry Core of the University of Pittsburgh's Department of Immunology; Intramural Research Program of the NIH, NIAID, and NCI Center for Cancer Research	Merck MSD(Merck & Company); Melanoma Breakthrough Foundation Breakthrough Consortium; National Cancer Institute (NCI) of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); James W. and Frances G. McGlothlin Chair in Melanoma Immunotherapy Research; UPMC Hillman Cancer Center Microbiome Shared Facility; NIH NCI Comprehensive Cancer Center Support CORE grant; University of Pittsburgh Center for Research Computing and Unified Flow Cytometry Core of the University of Pittsburgh's Department of Immunology; Intramural Research Program of the NIH, NIAID, and NCI Center for Cancer Research	The clinical trial (NCT03341143) was supported by a research contract from Merck MSD to D.D. D.D. is supported by the Melanoma Breakthrough Foundation Breakthrough Consortium. H.M.Z. is supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) (award numbers R01 CA228181 and R01 CA222203) and the James W. and Frances G. McGlothlin Chair in Melanoma Immunotherapy Research. Work of the UPMC Hillman Cancer Center Microbiome Shared Facility and Cytometry Facility is supported by the NIH NCI Comprehensive Cancer Center Support CORE grant (P30 CA047904). This research was supported in part by the University of Pittsburgh Center for Research Computing and Unified Flow Cytometry Core of the University of Pittsburgh's Department of Immunology through the resources provided. This work was supported in part by the Intramural Research Program of the NIH, NIAID, and NCI Center for Cancer Research.	Alshetaiwi H, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay6017; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Cao Y, 2014, BIOINFORMATICS, V30, P1674, DOI 10.1093/bioinformatics/btu104; Danilo M, 2018, CELL REP, V22, P2107, DOI 10.1016/j.celrep.2018.01.072; Dzutsev A, 2015, EUR J IMMUNOL, V45, P17, DOI 10.1002/eji.201444972; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Finlay BB, 2020, NAT REV IMMUNOL, V20, P522, DOI 10.1038/s41577-020-0374-6; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Gokyavuz B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39553-z; Goldszmid RS, 2015, CANCER IMMUNOL RES, V3, P103, DOI 10.1158/2326-6066.CIR-14-0225; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Guia S, 2008, BLOOD, V111, P5008, DOI 10.1182/blood-2007-11-122259; Hasumi K, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26381; Kamphorst AO, 2017, P NATL ACAD SCI USA, V114, P4993, DOI 10.1073/pnas.1705327114; Kluger HM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000398; Koblish HK, 1998, J EXP MED, V188, P1603, DOI 10.1084/jem.188.9.1603; Krieg C, 2018, NAT MED, V24, P144, DOI 10.1038/nm.4466; Kunert A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0608-y; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Larkin J, 2015, JAMA ONCOL, V1, P433, DOI 10.1001/jamaoncol.2015.1184; Martinez-Guryn K, 2018, CELL HOST MICROBE, V23, P458, DOI 10.1016/j.chom.2018.03.011; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Menni C, 2017, SCI REP-UK, V7, DOI [10.1038/s41598-017-10382-2, 10.1038/s41598-017-13722-4]; Nowicka Malgorzata, 2017, F1000Res, V6, P748, DOI 10.12688/f1000research.11622.3; Ohkawa T, 2001, IMMUNOLOGY, V103, P281, DOI 10.1046/j.1365-2567.2001.01248.x; Peters BA, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0672-4; Pinato DJ, 2019, JAMA ONCOL, V5, P1774, DOI 10.1001/jamaoncol.2019.2785; Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148; Ribas A, 2018, LANCET ONCOL, V19, pE219, DOI 10.1016/S1470-2045(18)30202-X; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Ribas A, 2016, CANCER IMMUNOL RES, V4, P194, DOI 10.1158/2326-6066.CIR-15-0210; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rodrigues RR, 2018, METHODS MOL BIOL, V1849, P227, DOI 10.1007/978-1-4939-8728-3_15; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sanmamed MF, 2017, ANN ONCOL, V28, P1988, DOI 10.1093/annonc/mdx190; Schalper KA, 2020, NAT MED, V26, P688, DOI 10.1038/s41591-020-0856-x; Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Terme M, 2011, CANCER RES, V71, P5393, DOI 10.1158/0008-5472.CAN-11-0993; Vernocchi P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01144; Wood DE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1891-0; Yambartsev A, 2016, BIOL DIRECT, V11, DOI 10.1186/s13062-016-0155-0; Zarour HM, 2016, CLIN CANCER RES, V22, P1856, DOI 10.1158/1078-0432.CCR-15-1849; Zeng MY, 2016, IMMUNITY, V44, P647, DOI 10.1016/j.immuni.2016.02.006	51	309	318	54	226	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	2021	371	6529			SI		595	+		10.1126/science.abf3363	http://dx.doi.org/10.1126/science.abf3363			51	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD7TF	33542131	Green Accepted			2023-01-03	WOS:000615715300047
J	Li, Y; Song, QP; Li, L; Sun, W; Zhang, C				Li, Yang; Song, Qipeng; Li, Li; Sun, Wei; Zhang, Cui			Tai Chi practitioners have lower fall risks under dual-task conditions during stair descending	PLOS ONE			English	Article							CENTER-OF-MASS; GROUND REACTION FORCES; OLDER-ADULTS; DYNAMIC STABILITY; BALANCE CONTROL; POSTURAL CONTROL; BODY STABILITY; FOOT CLEARANCE; COGNITIVE TASK; GAIT	Stairs are among the most hazardous locations, and stair descending contributes to a high risk of falls among the elderly under dual-task (DT) conditions. The purpose of this study was to determine whether the practitioners of Tai Chi (TC), one type of mind-body exercise, have lower fall risks under DT conditions during stair descending, compared with their no-exercise (NE) counterparts. Fifteen TC practitioners with at least 10 years of experience in TC and fifteen NE participants were recruited in this study. They were asked to descend a six-step staircase under single-task (ST) and DT conditions. An eight-camera motion analysis system and two force plates were used for data collection. Results showed group by DT interactions in walking velocity (p = 0.016) and center of mass-center of pressure inclination angle (COM-COP IA) in the anteroposterior directions (p = 0.026). Group effects observed with foot clearance (p = 0.031), trunk (p = 0.041) and head (p = 0.002) tilt angles, and COM-COP IA in the mediolateral (p = 0.006) directions. Significant DT effects only detected in foot clearance (p = 0.004). Although both groups of participants adopted a more cautious gait strategy under the dual-task condition, the TC practitioners were less influenced by the DT paradigm than their NE counterparts. Our observations indicated that TC practitioners have lower fall risks under DT conditions during stair descending.	[Li, Yang] Nanjing Forestry Univ, Dept Phys Educ, Nanjing, Jiangsu, Peoples R China; [Song, Qipeng; Sun, Wei] Shandong Sport Univ, Coll Sports & Hlth, Jinan, Shandong, Peoples R China; [Li, Li] Georgia Southern Univ, Dept Hlth Sci & Kinesiol, Statesboro, GA USA; [Zhang, Cui] Shandong Inst Sport Sci, Lab Biomech, Jinan, Shandong, Peoples R China	Nanjing Forestry University; Shandong Sport University; University System of Georgia; Georgia Southern University	Song, QP (corresponding author), Shandong Sport Univ, Coll Sports & Hlth, Jinan, Shandong, Peoples R China.	songqipeng@sdpei.edu.cn		Song, Qipeng/0000-0002-4103-9193; Song, Qipeng/0000-0002-7073-3643; /0000-0001-5902-9762	China Shandong Key Research and Development Plan [2017G006043]; China Scholarship Council [201809370020]; Natural Science Foundation of China [31700815]	China Shandong Key Research and Development Plan; China Scholarship Council(China Scholarship Council); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Q.S.:China Shandong Key Research and Development Plan (2017G006043), and China Scholarship Council (201809370020). W.S.:Natural Science Foundation of China (31700815)	Barrett RS, 2010, GAIT POSTURE, V32, P429, DOI 10.1016/j.gaitpost.2010.07.010; Beauchet O, 2008, J AM GERIATR SOC, V56, P181, DOI 10.1111/j.1532-5415.2007.01464.x; Blazewick DH, 2018, AM J EMERG MED, V36, P608, DOI 10.1016/j.ajem.2017.09.034; Bosse I, 2012, HUM MOVEMENT SCI, V31, P1560, DOI 10.1016/j.humov.2012.05.003; Buckley JG, 2005, GAIT POSTURE, V22, P146, DOI 10.1016/j.gaitpost.2004.08.006; Burgener SC, 2008, AM J ALZHEIMERS DIS, V23, P382, DOI 10.1177/1533317508317527; Cayless SM, 2001, APPL ERGON, V32, P155, DOI 10.1016/S0003-6870(00)00052-1; Chalmers GR, 2002, J GERONTOL A-BIOL, V57, pB321, DOI 10.1093/gerona/57.8.B321; Chien HL, 2014, GAIT POSTURE, V39, P1045, DOI 10.1016/j.gaitpost.2014.01.007; Chien HL, 2013, GAIT POSTURE, V38, P391, DOI 10.1016/j.gaitpost.2012.12.015; COHEN HH, 1985, J SAFETY RES, V16, P171, DOI 10.1016/0022-4375(85)90004-0; Cohen J., 2013, STAT POWER ANAL BEHA; Dault MC, 2003, COGNITIVE BRAIN RES, V16, P434, DOI 10.1016/S0926-6410(03)00058-2; Delafontaine A, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20185059; Hamel KA, 2005, GAIT POSTURE, V21, P135, DOI 10.1016/j.gaitpost.2004.01.006; Hsue BJ, 2014, ARCH PHYS MED REHAB, V95, P1860, DOI 10.1016/j.apmr.2014.05.001; Hsue BJ, 2009, GAIT POSTURE, V29, P465, DOI 10.1016/j.gaitpost.2008.11.007; Kelly VE, 2010, EXP BRAIN RES, V207, P65, DOI 10.1007/s00221-010-2429-6; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; Lam L C W, 2014, Hong Kong Med J, V20, P20; Lee HJ, 2006, ARCH PHYS MED REHAB, V87, P569, DOI 10.1016/j.apmr.2005.11.033; Li FZ, 2007, J AGING PHYS ACTIV, V15, P139, DOI 10.1123/japa.15.2.139; Li FZ, 2014, ARCH GERONTOL GERIAT, V58, P434, DOI 10.1016/j.archger.2013.12.003; Li FZ, 2005, J GERONTOL A-BIOL, V60, P187, DOI 10.1093/gerona/60.2.187; Li L, 2019, J SPORT HEALTH SCI, V8, P218, DOI 10.1016/j.jshs.2018.09.010; Li L, 2010, AM J CHINESE MED, V38, P449, DOI 10.1142/S0192415X1000797X; Lu HL, 2017, HUM MOVEMENT SCI, V54, P354, DOI 10.1016/j.humov.2017.06.004; Lu HL, 2017, GAIT POSTURE, V51, P109, DOI 10.1016/j.gaitpost.2016.09.030; Madehkhaksar F, 2016, GAIT POSTURE, V43, P114, DOI 10.1016/j.gaitpost.2015.09.009; McCrory JL, 2014, CLIN BIOMECH, V29, P143, DOI 10.1016/j.clinbiomech.2013.11.020; Mian OS, 2007, GAIT POSTURE, V26, P463, DOI 10.1016/j.gaitpost.2006.11.202; Novak AC, 2016, APPL ERGON, V52, P275, DOI 10.1016/j.apergo.2015.07.027; Ojha HA, 2009, PHYS THER, V89, P1080, DOI 10.2522/ptj.20080187; Peterka RJ, 2002, J NEUROPHYSIOL, V88, P1097, DOI 10.1152/jn.2002.88.3.1097; Pierce CA, 2004, EDUC PSYCHOL MEAS, V64, P916, DOI 10.1177/0013164404264848; Pijnappels M, 2008, EUR J APPL PHYSIOL, V102, P585, DOI 10.1007/s00421-007-0613-6; Qu XD, 2015, J BIOMECH, V48, P4059, DOI 10.1016/j.jbiomech.2015.10.004; Roys MS, 2001, APPL ERGON, V32, P135, DOI 10.1016/S0003-6870(00)00049-1; Sheehan RC, 2012, APPL ERGON, V43, P473, DOI 10.1016/j.apergo.2011.07.004; Silsupadol P, 2009, ARCH PHYS MED REHAB, V90, P381, DOI 10.1016/j.apmr.2008.09.559; Simoni D, 2013, CLIN BIOMECH, V28, P692, DOI 10.1016/j.clinbiomech.2013.05.011; Song QP, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10061979; Song QP, 2018, SPORT BIOMECH, V17, P402, DOI 10.1080/14763141.2017.1358761; Song QP, 2017, RES SPORTS MED, V25, P197, DOI 10.1080/15438627.2017.1282363; Song QP, 2014, RES SPORTS MED, V22, P172, DOI 10.1080/15438627.2014.881823; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; Vallabhajosula S, 2015, J BIOMECH, V48, P921, DOI 10.1016/j.jbiomech.2015.02.024; Wayne PM, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00332; Wiesmeier IK, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00097; Woollacott MH, 1997, PHYS THER, V77, P646, DOI 10.1093/ptj/77.6.646; Yao J, 2019, RES SPORTS MED, V27, P121, DOI 10.1080/15438627.2018.1502184; Yiou E, 2017, WORLD J ORTHOP, V8, P815, DOI 10.5312/wjo.v8.i11.815; Zhang C, 2015, RES SPORTS MED, V23, P102, DOI 10.1080/15438627.2014.915835; Zhang C, 2011, GAIT POSTURE, V34, P191, DOI 10.1016/j.gaitpost.2011.04.008; Zhou JH, 2014, EUR J NEUROSCI, V39, P1343, DOI 10.1111/ejn.12492; Zietz D, 2011, GAIT POSTURE, V34, P279, DOI 10.1016/j.gaitpost.2011.05.017	56	1	1	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2021	16	2							e0246292	10.1371/journal.pone.0246292	http://dx.doi.org/10.1371/journal.pone.0246292			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QF5UW	33539403	gold, Green Published			2023-01-03	WOS:000616960200073
J	Aschale, A; Adane, M; Getachew, M; Faris, K; Gebretsadik, D; Sisay, T; Dewau, R; Chanie, MG; Muche, A; Zerga, AA; Lingerew, M; Gebrehiwot, M; Berhanu, L; Ademas, A; Abebe, M; Ketema, G; Yirsaw, M; Bogale, K; Ayele, FY; Melaku, MS; Amsalu, ET; Bitew, G; Keleb, A; Berihun, G; Natnael, T; Hassen, S; Yenuss, M; Dagne, M; Feleke, A; Kloos, H				Aschale, Awoke; Adane, Metadel; Getachew, Melaku; Faris, Kebede; Gebretsadik, Daniel; Sisay, Tadesse; Dewau, Reta; Chanie, Muluken Genetu; Muche, Amare; Zerga, Aregash Abebayehu; Lingerew, Mistir; Gebrehiwot, Mesfin; Berhanu, Leykun; Ademas, Ayechew; Abebe, Masresha; Ketema, Gebremariam; Yirsaw, Mengistie; Bogale, Kassahun; Ayele, Fanos Yeshanew; Melaku, Mequannent Sharew; Amsalu, Erkihun Tadesse; Bitew, Gedamnesh; Keleb, Awoke; Berihun, Gete; Natnael, Tarikuwa; Hassen, Seada; Yenuss, Mohammed; Dagne, Mengesha; Feleke, Alelgne; Kloos, Helmut			Water, sanitation, and hygiene conditions and prevalence of intestinal parasitosis among primary school children in Dessie City, Ethiopia	PLOS ONE			English	Article							SCHOOLCHILDREN; EPIDEMIOLOGY; INFECTIONS; TOWN	Background Intestinal parasitosis is a major public health problem that affects the health of primary school children in low- and middle-income countries where water, sanitation, and hygiene (WASH) conditions are deficient. Since there is a paucity of information on the prevalence and associated factors of this problem among primary school children in Dessie City in Ethiopia, this study was designed to address these gaps. Methods A school-based cross-sectional study was conducted among 407 stratified-sampled primary school children in five primary schools at Dessie City from April to June 2018. Data were collected using a pretested structured questionnaire, an observation checklist and laboratory analysis of stool samples. Stool specimen from each study participant was collected using clean, properly labeled and leak-proof stool cup. A portion of stool from each study participant collected sample was processed using saline wet mount technique and examined by microscope. The remaining specimens were preserved with 10% formalin and transported to Dessie Comprehensive Specialized Hospital laboratory to be processed by using formol-ether concentration technique. Then, slide smears were prepared from each processed stool specimen and finally, it was microscopically examined with 10x as well as 40x objectives for the presence or absence of intestinal parasites. Factors significantly associated with intestinal parasitosis were determined using binary logistic regression model at 95% CI (confidence interval). Thus, bivariate (COR [crude odds ratio]) and multivariable (AOR [adjusted odds ratio]) logistic regression analyses were carried out. From the multivariable analysis, variables having a p-value of less than 0.05 were declared as factors significantly associated with intestinal parasitosis among primary school children. Main findings The overall prevalence of intestinal parasitosis was found to be 16.0% (95% CI: 12.5-19.4%), of these, 50.8% were positive for protozoa, 32.2% for helminth infections and 16.9% for double co-infections. Entamoeba histolytica was the most prevalent parasite (29.2%), followed by Giardia lamblia (21.5%), Ascaris lumbricoides (18.5%), Hymenolepis nana (9.2%) and Enterobius vermicularis (4.6%). Prevalence rates were similar among government (16.3%) and private (15.7%) school children. Water consumption was less than 5 liters per capita per day in 4 of the 5 schools. Thirty-eight (9.3%) of primary school students reported that they practiced open defecation. About two-thirds (285, 70.0%) said they always washed their hands after defecation. Mother's education (illiterate) (AOR = 3.3; 95% CI: 1.20-9.37), father's education (illiterate) (AOR = 3.9; 95% CI: 1.40-10.82), fathers who could read and write (AOR = 3.3; 95% CI: 1.25-7.86), handwashing before meal (sometimes) (AOR = 2.2; 95% CI: 1.11-4.17) and poor knowledge of WASH (AOR = 9.3; 95% CI: 2.17-16.70) were statistically associated with presence of intestinal parasitic infections. Conclusion We concluded that the prevalence of intestinal parasitosis in the study area among Grades 4-8 primary school children had public health significance. Factors significantly associated with intestinal parasitosis among primary school children's were illiterate mothers and fathers, irregular handwashing of children before meals, and poor knowledge of WASH. Health education to improve students' WASH knowledge and mass deworming for parasites are recommended as preventive measures; and improvements to the quality of WASH facilities in primary schools are strongly recommended to support these measures.	[Aschale, Awoke] Dessie Comprehens Specialized Hosp, Hyg & Environm Hlth Infect Prevent & Control Unit, Dessie, Ethiopia; [Adane, Metadel; Getachew, Melaku; Faris, Kebede; Sisay, Tadesse; Lingerew, Mistir; Gebrehiwot, Mesfin; Berhanu, Leykun; Ademas, Ayechew; Abebe, Masresha; Keleb, Awoke; Berihun, Gete; Natnael, Tarikuwa; Hassen, Seada; Yenuss, Mohammed; Dagne, Mengesha; Feleke, Alelgne] Wollo Univ, Coll Med & Hlth Sci, Dept Environm Hlth, Dessie, Ethiopia; [Gebretsadik, Daniel] Wollo Univ, Coll Med & Hlth Sci, Dept Med Lab Sci, Dessie, Ethiopia; [Dewau, Reta; Muche, Amare; Amsalu, Erkihun Tadesse; Bitew, Gedamnesh] Wollo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Dessie, Ethiopia; [Chanie, Muluken Genetu] Wollo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Hlth Syst & Policy, Dessie, Ethiopia; [Zerga, Aregash Abebayehu; Ayele, Fanos Yeshanew] Wollo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Nutr, Dessie, Ethiopia; [Ketema, Gebremariam; Yirsaw, Mengistie; Bogale, Kassahun] Wollo Univ, Coll Med & Hlth Sci, Dept Pharm, Dessie, Ethiopia; [Melaku, Mequannent Sharew] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Hlth Informat, Gondar, Ethiopia; [Kloos, Helmut] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	University of Gondar; University of California System; University of California San Francisco	Adane, M (corresponding author), Wollo Univ, Coll Med & Hlth Sci, Dept Environm Hlth, Dessie, Ethiopia.	metadel.adane2@gmail.com	ayele, fanos/AAA-5299-2022; Hassen, Seada/GOH-0623-2022; muche, amare/GNW-4693-2022; Tadesse, Erkihun/AAS-1819-2021; Keleb, Awoke/AGX-2940-2022; Dewau, Reta/AAA-4202-2022; Ademas, Ayechew/AAO-4212-2021; Ademas, Ayechew/AAG-5984-2021; Berhanu, Leykun/AAC-6695-2022; Damtew, Mesfin Gebrehiwot/W-2543-2019; Weldehanna, Daniel/ABA-8617-2020; Adane, Metadel/AFQ-9478-2022	Keleb, Awoke/0000-0002-7510-3448; Dewau, Reta/0000-0001-6531-2468; Ademas, Ayechew/0000-0003-2602-162X; Ademas, Ayechew/0000-0003-2602-162X; Berhanu, Leykun/0000-0002-2998-0917; Damtew, Mesfin Gebrehiwot/0000-0002-8124-5151; Weldehanna, Daniel/0000-0001-5032-5143; Adane, Metadel/0000-0002-7039-4768; Genetu Chanie, MULUKEN/0000-0001-7059-1449; Bogale, Kassahun/0000-0001-7358-6741				Abossie A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-166; Alamir M., 2013, Health, V5, P1697, DOI 10.4236/health.2013.510228; Alemu M, 2019, ETHIOP J HEALTH SCI, V29, P923, DOI 10.4314/ejhs.v29i1.14; Andualem MA., 2014, J PUBL HLTH RES, V2, P248, DOI DOI 10.12691/AJPHR-2-6-6; [Anonymous], 2017, JLSRF, V3, pA104; [Anonymous], 2019, INT J BIOMEDICAL MAT; Ansha MG, 2020, J TROP MED-US, V2020, DOI 10.1155/2020/9813743; Barreto SM, 2012, INT J EPIDEMIOL, V41, P557, DOI 10.1093/ije/dys017; Cheesbrough M, 2006, DISTRICT LAB PRACTIC, V1st, DOI [10.1017/cbo9780511543470, DOI 10.1017/CBO9780511543470]; Chelkeba L, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8222-y; Debalke S, 2013, ETHIOP J HEALTH SCI, V23, P237, DOI 10.4314/ejhs.v23i3.6; Dessie City Adminstration (DCA), 2017, DESS TOWN ED DEP 201; Eleni Kidane, 2014, International Journal of Current Microbiology and Applied Sciences, V3, P11; En WL, 2011, SE ASIAN J TROP MED, V42, P1022; Fentie T, 2013, T ROY SOC TROP MED H, V107, P480, DOI 10.1093/trstmh/trt056; Fewtrell L, 2007, WATER SANITATION HYG, V15; Gebretsadik D, 2020, PEDIATR HEALTH MED T, V11, P179, DOI 10.2147/PHMT.S252061; Gebretsadik Daniel, 2018, BMC Res Notes, V11, P771, DOI 10.1186/s13104-018-3888-2; Gebreyohanns A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204259; Global Health Council, 2013, WAT SAN HYG GLOB HLT; Hailegebriel T, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2466-x; Hernandez PC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218681; Hosmer JD, 2013, APPL LOGISTIC REGRES; Jejaw A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1952-6; Liao CW, 2016, AFR HEALTH SCI, V16, P690, DOI 10.4314/ahs.v16i3.8; Mahmud MA, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-019-4871-2; Montgomery MA, 2007, ENVIRON SCI TECHNOL, V41, P17, DOI 10.1021/es072435t; Okyay P, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-64; Pruss-Ustun A., 2008, SAFER WATER BETTER H; Ryan E., 2017, BASELINE ASSESSMENT, P1; Salem DAB, 2013, INT J INFECT DIS, V17, pE343, DOI 10.1016/j.ijid.2012.11.022; Sejdini A, 2011, ANN TROP MED PARASIT, V105, P241, DOI 10.1179/136485911X12987676649584; Sitotaw B, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3971-x; SS V et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, 2020, CIRCULATION, V2020, pe1; Vedachalam S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176272; Vivas A P, 2010, J Prev Med Hyg, V51, P73; Workneh T, 2014, J BACTERIOL PARASITO, V15, P1, DOI DOI 10.4172/2155-9597.1000181	37	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2021	16	2							e0245463	10.1371/journal.pone.0245463	http://dx.doi.org/10.1371/journal.pone.0245463			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF2OR	33534792	gold, Green Published			2023-01-03	WOS:000616739700040
J	Lelijveld, N; Musyoki, E; Adongo, SW; Mayberry, A; Wells, JC; Opondo, C; Kerac, M; Bailey, J				Lelijveld, Natasha; Musyoki, Eunice; Adongo, Susan Were; Mayberry, Amy; Wells, Jonathan C.; Opondo, Charles; Kerac, Marko; Bailey, Jeanette			Relapse and post-discharge body composition of children treated for acute malnutrition using a simplified, combined protocol: A nested cohort from the ComPAS RCT	PLOS ONE			English	Article							MODERATE ACUTE MALNUTRITION; EXPERIENCE	Introduction Severe and moderate acute malnutrition (SAM and MAM) affect more than 50 million children worldwide yet 80% of these children do not access care. The Combined Protocol for Acute Malnutrition Study (ComPAS) trial assessed the effectiveness of a simplified, combined SAM/MAM protocol for children aged 6-59 months and found non-inferior recovery compared to standard care. To further inform policy, this study assessed post-discharge outcomes of children treated with this novel protocol in Kenya. Methods Six 'combined' protocol clinics treated SAM and MAM children using an optimised mid-upper arm circumference (MUAC)-based dose of ready-to-use therapeutic food (RUTF). Six 'standard care' clinics treated SAM with weight-based RUTF rations; MAM with ready-to-use supplementary food (RUSF). Four months post-discharge, we assessed anthropometry, recent history of illness, and body composition by bioelectrical impedance analysis. Data was analysed using multivariable linear regression, adjusted for age, sex and allowing for clustering by clinic. Results We sampled 850 children (median age 18 months, IQR 15-23); 44% of the original trial sample in Kenya. Children treated with the combined protocol had similar anthropometry, fat-free mass, fat mass, skinfold thickness z-scores, and frequency of common illnesses 4 months post-discharge compared the standard protocol. Mean subscapular skinfold z-scores were close to the global norm (standard care: 0.24; combined 0.27). There was no significant difference in odds of relapse between protocols (SAM, 3% vs 3%, OR = 1.0 p = 0.75; MAM, 10% vs 12%, OR = 0.90 p = 0.34). Conclusions Despite the lower dosage of RUTF for most SAM children in the combined protocol, their anthropometry and relapse rates at 4 months post-discharge were similar to standard care. MAM children treated with RUTF had similar body composition to those treated with RUSF and neither group exhibited excess adiposity. These results add further evidence that a combined protocol is as effective as standard care with no evidence of adverse effects post-discharge. A simplified, combined approach could treat more children, stretch existing resources further, and contribute to achieving Sustainable Development Goal Two.	[Lelijveld, Natasha; Mayberry, Amy] Act Hunger, Wasted Lives, London, England; [Lelijveld, Natasha] Emergency Nutr Network, Oxford, England; [Musyoki, Eunice; Adongo, Susan Were] Int Rescue Comm, Nairobi, Kenya; [Wells, Jonathan C.] UCL, Childhood Nutr Res Ctr, Inst Child Hlth, UCL Great Ormond St, London, England; [Opondo, Charles] London Sch Hyg & Trop Med, Dept Med Stat, London, England; [Kerac, Marko; Bailey, Jeanette] London Sch Hyg & Trop Med, Ctr Maternal Adolescent & Child Hlth MARCH, Dept Populat Hlth, London, England; [Bailey, Jeanette] Int Rescue Comm, New York, NY USA	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Lelijveld, N (corresponding author), Act Hunger, Wasted Lives, London, England.; Lelijveld, N (corresponding author), Emergency Nutr Network, Oxford, England.	Natasha.lelijveld.11@ucl.ac.uk	Kerac, Marko/GQR-1136-2022	Kerac, Marko/0000-0002-3745-7317; Lelijveld, Natasha/0000-0002-8452-0198; Mayberry, Amy/0000-0003-1113-2706; Bailey, Jeanette/0000-0002-4343-4939	ACF Foundation; Office of U.S. Foreign Disaster Assistance; Children's Investment Fund Foundation	ACF Foundation; Office of U.S. Foreign Disaster Assistance; Children's Investment Fund Foundation	Funded by the ACF Foundation (granted to NL); and the Office of U.S. Foreign Disaster Assistance (granted to JB); and the Children's Investment Fund Foundation (granted to JB). The funders play no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.	Ashraf H, 2012, J TROP PEDIATRICS, V58, P253, DOI 10.1093/tropej/fmr083; Bailey J, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003192; Bailey J, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2643-2; Bartz S, 2014, J CLIN ENDOCR METAB, V99, P2128, DOI 10.1210/jc.2013-4018; Binns PJ, 2016, ARCH PUBLIC HEALTH, V74, DOI 10.1186/s13690-016-0136-x; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; de Onis Mercedes, 2004, Food Nutr Bull, V25, pS15; Girma T, 2016, CLIN NUTR, V35, P713, DOI 10.1016/j.clnu.2015.05.002; Initiatives D, 2018, 2018 GLOB NUTR REP S; Kangas ST, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002887; Lelijveld N, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2594-7; Lelijveld N, 2016, LANCET GLOB HEALTH, V4, pE654, DOI 10.1016/S2214-109X(16)30133-4; Lives NW, STATE ACUTE MALNUTRI; Maust A, 2015, J NUTR, V145, P2604, DOI 10.3945/jn.115.214957; Nikiema L, 2014, AM J CLIN NUTR, V100, P241, DOI 10.3945/ajcn.113.072538; Njunge JM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42436-y; Norman K, 2012, CLIN NUTR, V31, P854, DOI 10.1016/j.clnu.2012.05.008; O'Sullivan NP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202053; PICCOLI A, 1994, KIDNEY INT, V46, P534, DOI 10.1038/ki.1994.305; Schaefer R, 2021, MATERN CHILD NUTR, V17, DOI 10.1111/mcn.13107; Shrimpton R., 2012, DOUBLE BURDEN MALNUT; Singhal A, 2014, GLOBAL EPIDEMIC NONC; Smith MD, 2017, WORLD DEV, V93, P402, DOI 10.1016/j.worlddev.2017.01.006; Stobaugh HC, 2019, MATERN CHILD NUTR, V15, DOI 10.1111/mcn.12702; van der Kam S, 2017, THESIS; Wells JCK, 2009, BRIT J NUTR, V102, P1776, DOI 10.1017/S0007114509991255; WHO, 2006, GROWTH REF DAT 5 19	27	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2021	16	2							e0245477	10.1371/journal.pone.0245477	http://dx.doi.org/10.1371/journal.pone.0245477			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF2OR	33534818	Green Published, gold			2023-01-03	WOS:000616739700065
J	Pinto, PR; Yoshinaga, MY; Del Bianco, V; Bochi, AP; Ferreira, GS; Pinto, IFD; Rodrigues, LG; Nakandakare, ER; Okamoto, MM; Machado, UF; Miyamoto, S; Catanozi, S; Passarelli, M				Pinto, Paula Ramos; Yoshinaga, Marcos Y.; Del Bianco, Vanessa; Bochi, Ana Paula; Ferreira, Guilherme S.; Pinto, Isabella F. D.; Rodrigues, Leticia G.; Nakandakare, Edna R.; Okamoto, Maristela M.; Machado, Ubiratan F.; Miyamoto, Sayuri; Catanozi, Sergio; Passarelli, Marisa			Dietary sodium restriction alters muscle lipidomics that relates to insulin resistance in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-SALT DIET; SKELETAL-MUSCLE; ANGIOTENSIN-II; CHLORIDE RESTRICTION; GLUCOSE-TRANSPORT; GENE-EXPRESSION; FATTY-ACIDS; ACCUMULATION; SENSITIVITY; LIPOPROTEIN	A low-sodium (LS) diet has been shown to reduce blood pressure (BP) and the incidence of cardiovascular diseases. However, severe dietary sodium restriction promotes insulin resistance (IR) and dyslipidemia in animal models and humans. Thus, further clarification of the long-term consequences of LS is needed. Here, we investigated the effects of chronic LS on gastrocnemius gene and protein expression and lipidomics and its association with IR and plasma lipids in LDL receptor knockout mice. Three-month-old male mice were fed a normal sodium diet (NS; 0.5% Na; n = 12-19) or LS (0.06% Na; n = 14-20) over 90 days. Body mass (BM), BP, plasma total cholesterol, triacylglycerol (TG), glucose, hematocrit, and IR were evaluated. LS increased BM (9%), plasma TG (51%), blood glucose (19%), and IR (46%) when compared with the NS. RT-qPCR analysis revealed that genes involved in lipid uptake and oxidation were increased by the LS: Fabp3 (106%), Prkaa1 (46%), and Cpt1 (74%). Genes and proteins (assessed by Western blotting) involved in insulin signaling were not changed by the LS. Similarly, lipid species classically involved in muscle IR, such as diacylglycerols and ceramides detected by ultra-high-performance liquid chromatography coupled to mass spectrometry, were also unchanged by LS. Species of phosphatidylcholines (68%), phosphatidylinositol (90%), and free fatty acids (59%) increased while cardiolipins (41%) and acylcarnitines (9%) decreased in gastrocnemius in response to LS and were associated with glucose disposal rate. Together these results suggest that chronic LS alters glycerophospholipid and fatty acids species in gastrocnemius that may contribute to glucose and lipid homeostasis derangements in mice.	[Pinto, Paula Ramos; Del Bianco, Vanessa; Bochi, Ana Paula; Ferreira, Guilherme S.; Rodrigues, Leticia G.; Nakandakare, Edna R.; Catanozi, Sergio; Passarelli, Marisa] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Lab Lipides LIM 10, Sao Paulo, Brazil; [Yoshinaga, Marcos Y.; Pinto, Isabella F. D.; Miyamoto, Sayuri] Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, Brazil; [Okamoto, Maristela M.; Machado, Ubiratan F.] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo, Brazil; [Passarelli, Marisa] Univ Nove Julho, Programa Posgrad Med, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Nove de Julho	Passarelli, M (corresponding author), Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Lab Lipides LIM 10, Sao Paulo, Brazil.; Passarelli, M (corresponding author), Univ Nove Julho, Programa Posgrad Med, Sao Paulo, Brazil.	m.passarelli@fm.usp.br	Nakandakare, Edna R/D-6625-2012; Passarelli, Marisa/C-8129-2012; Miyamoto, Sayuri/A-2144-2008; Yoshinaga, Marcos Y/J-4715-2012; Ferreira, Guilherme da Silva/I-6532-2015	Miyamoto, Sayuri/0000-0002-5714-8984; Yoshinaga, Marcos Y/0000-0002-5533-5348; Ferreira, Guilherme da Silva/0000-0001-7125-441X	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, FAPESP [15/21072-5, 2016/15603-0, 2013/07937-8]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES) [001]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq, Brazil	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq, Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The authors would like to thank the financial support from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, FAPESP (grants #15/21072-5 toM. P. and 2016/15603-0 toM. P. and U. F. M. and 2013/07937-8 to S. M.), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES)Finance Code 001 to P. R. P. and G. S. F. M. P., U. F. M., and S. M. are recipients of a research award from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq, Brazil.	Aguer C., 2008, CELL METAB, V7, P45; Amati F, 2011, DIABETES, V60, P2588, DOI 10.2337/db10-1221; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; Brink M, 2001, ENDOCRINOLOGY, V142, P1489, DOI 10.1210/en.142.4.1489; Catanozi S, 2003, J LIPID RES, V44, P727, DOI 10.1194/jlr.M200330-JLR200; Catanozi S, 2001, ATHEROSCLEROSIS, V158, P81, DOI 10.1016/S0021-9150(01)00415-4; Chaves AB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48059-7; Chicco AJ, 2007, AM J PHYSIOL-CELL PH, V292, pC33, DOI 10.1152/ajpcell.00243.2006; Coelho MS, 2006, NUTR METAB CARDIOVAS, V16, P148, DOI 10.1016/j.numecd.2005.09.001; Cogliati S, 2016, TRENDS BIOCHEM SCI, V41, P261, DOI 10.1016/j.tibs.2016.01.001; Csibi A., 2013, AM J PHYSIOL-RENAL, V304, pF505; Daniele G, 2014, DIABETES, V63, P2812, DOI 10.2337/db13-1130; Das S., 2016, TRENDS BIOCHEM SCI, V41, P261; Daum G, 1997, PROG LIPID RES, V36, P103, DOI 10.1016/S0163-7827(97)00006-4; Dean DJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE957, DOI 10.1152/ajpendo.1998.275.6.E957; Diamond-Stanic Maggie K., 2010, Archives of Physiology and Biochemistry, V116, P88, DOI 10.3109/13813451003758703; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Eum JY, 2020, J CHROMATOGR B, V1141, DOI 10.1016/j.jchromb.2020.122022; Fusco FB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177086; Garg R., 2010, PLOS ONE, V5; Goto-Inoue N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03267; Graudal NA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004022.pub4; He FJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1325; He JA, 1999, JAMA-J AM MED ASSOC, V282, P2027, DOI 10.1001/jama.282.21.2027; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Katayama IA, 2014, J NUTR, V144, P1571, DOI 10.3945/jn.114.192054; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Lee JS, 2006, J APPL PHYSIOL, V100, P1467, DOI 10.1152/japplphysiol.01438.2005; Lee S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24976-x; Levin MC, 2007, AM J PHYSIOL-ENDOC M, V293, pE1772, DOI 10.1152/ajpendo.00158.2007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Mejia E. M., 2015, CELL METAB, V21, P868; Nagata S., 2017, J ENDOCRINOL, V232, P547; Nakandakare ER, 2008, ATHEROSCLEROSIS, V200, P410, DOI 10.1016/j.atherosclerosis.2007.12.034; Newsom SA, 2016, J APPL PHYSIOL, V120, P1355, DOI 10.1152/japplphysiol.00664.2015; Okamoto MM, 2004, AM J PHYSIOL-REG I, V286, pR779, DOI 10.1152/ajpregu.00396.2003; Paran C. W., 2018, NAT REV MOL CELL BIO, V19, P654; Prada PD, 2000, HYPERTENSION, V35, P424, DOI 10.1161/01.HYP.35.1.424; Prada PO, 2005, J ENDOCRINOL, V185, P429, DOI 10.1677/joe.1.06028; Sabio G, 2010, MOL CELL BIOL, V30, P106, DOI 10.1128/MCB.01162-09; Sanders PW, 2009, AM J PHYSIOL-RENAL, V297, pF237, DOI 10.1152/ajprenal.00027.2009; Shaikh SR, 2014, BIOCHEMISTRY-US, V53, P5589, DOI 10.1021/bi500868g; Shao W., 2010, PEPTIDES, V31, P889; Song YH, 2005, J CLIN INVEST, V115, P451, DOI 10.1172/JCI200522324; STAMLER J, 1991, HYPERTENSION, V17, pI9, DOI 10.1161/01.HYP.17.1_Suppl.I9; van der Veen JN, 2017, BBA-BIOMEMBRANES, V1859, P1558, DOI 10.1016/j.bbamem.2017.04.006; Wei YZ, 2006, J BIOL CHEM, V281, P35137, DOI 10.1074/jbc.M601320200; Yang Q, 2018, NAT REV MOL CELL BIO, V19, P654, DOI 10.1038/s41580-018-0044-8; Zabielski P, 2014, AM J PHYSIOL-ENDOC M, V306, pE529, DOI 10.1152/ajpendo.00610.2012	51	3	3	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN-JUN	2021	296								100344	10.1016/j.jbc.2021.100344	http://dx.doi.org/10.1016/j.jbc.2021.100344			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TI5TQ	33524391	Green Published, gold			2023-01-03	WOS:000672866400318
J	Xie, HF; Zhao, JF; Wang, KL; Peng, HW				Xie, Hongfei; Zhao, Junfang; Wang, Kaili; Peng, Huiwen			Long-term variations in solar radiation, diffuse radiation, and diffuse radiation fraction caused by aerosols in China during 1961-2016	PLOS ONE			English	Article							LIGHT USE EFFICIENCY; VARIABILITY; POLLUTION; TREND; INDIA; WHEAT; COOL	The effects of atmospheric aerosols on the terrestrial climate system are more regional than those of greenhouse gases, which are more global. Thus, it is necessary to examine the typical regional effects of how aerosols affect solar radiation in order to develop a more comprehensive understanding. In this study, we used global AErosol RObotic NETwork (AERONET) data and robust radiation observational evidence to investigate the impact of aerosols on total radiation, diffuse radiation, and the diffuse radiation fraction in China from 1961 to 2016. Our results showed that there were different temporal changes in the aerosol optical depth (AOD), total solar radiation, diffuse radiation and diffuse radiation fraction over the past 56 years. Specifically, the 550 nm AOD from 2005 to 2016 decreased significantly, with annual average AOD of 0.51. Meanwhile, the average total solar radiation reduced by 2.48%, while there was a slight increase in average diffuse radiation at a rate of 3.10 MJ center dot m(-2)center dot yr(-1). Moreover, the spatial heterogeneities of AOD, total radiation, diffuse radiation, and the diffuse radiation fraction in China were significant. Aerosol particle emissions in the developed eastern and southern regions of China were more severe than those in the western regions, resulting in higher total radiation and diffuse radiation in the western plateau than in the eastern plain. In addition, aerosols were found to have negative effects on total radiation and sunshine hours, and positive effects on diffuse radiation and diffuse radiation fraction. Further, the diffuse radiation fraction was negatively correlated with sunshine hours. However, there was a positive correlation between AOD and sunshine hours. These results could be used to assess the impacts of climate change on terrestrial ecosystem productivity and carbon budgets.	[Xie, Hongfei; Zhao, Junfang; Wang, Kaili; Peng, Huiwen] Chinese Acad Meteorol Sci, State Key Lab Severe Weather, Beijing, Peoples R China; [Wang, Kaili] Sichuan Agr Univ, Resources Coll, Chengdu, Peoples R China	Chinese Academy of Meteorological Sciences (CAMS); Chinese Academy of Sciences; Sichuan Agricultural University	Zhao, JF (corresponding author), Chinese Acad Meteorol Sci, State Key Lab Severe Weather, Beijing, Peoples R China.	zhaojfcams@163.com			National Key Research and Development Program of China [2017YFA0603004]	National Key Research and Development Program of China	This work was supported by the National Key Research and Development Program of China (2017YFA0603004).	Barros V, 2014, CLIMATE CHANGE 2014: IMPACTS, ADAPTATION, AND VULNERABILITY, PT A: GLOBAL AND SECTORAL ASPECTS, pIX; Chan CK, 2008, ATMOS ENVIRON, V42, P1, DOI 10.1016/j.atmosenv.2007.09.003; Cheng Z, 2016, ENVIRON INT, V89-90, P212, DOI 10.1016/j.envint.2016.02.003; [符传博 Fu Chuanbo], 2018, [科学通报, Chinese Science Bulletin], V63, P2655; Gao M, 2018, ATMOS ENVIRON, V190, P35, DOI 10.1016/j.atmosenv.2018.07.011; Giles DM, 2017, AGU FALL; Guo JP, 2017, ENVIRON POLLUT, V230, P1030, DOI 10.1016/j.envpol.2017.07.062; Han X, 2011, ATMOS ENVIRON, V45, P6576, DOI 10.1016/j.atmosenv.2011.08.006; Kanniah KD, 2016, ATMOS RES, V182, P302, DOI 10.1016/j.atmosres.2016.08.002; Latha R, 2018, J ENVIRON MANAGE, V206, P1224, DOI 10.1016/j.jenvman.2017.09.047; Liang F, 2005, ANN GEOPHYS-GERMANY, V23, P2425, DOI 10.5194/angeo-23-2425-2005; Reddy KRO, 2019, ATMOS RES, V218, P117, DOI 10.1016/j.atmosres.2018.11.011; Ren XL, 2013, ANN GEOPHYS-GERMANY, V31, P277, DOI 10.5194/angeo-31-277-2013; Roderick ML, 2012, NAT CLIM CHANGE, V2, P76, DOI 10.1038/nclimate1395; Satheesh SK, 2000, NATURE, V405, P60, DOI 10.1038/35011039; Schiermeier Q, 2006, NATURE, V442, P854, DOI 10.1038/442854a; Sharma D, 2017, ENVIRON POLLUT, V231, P1030, DOI 10.1016/j.envpol.2017.08.052; Shi ChunE, 2018, China Environmental Science, V38, P1231; Sorribas M, 2019, ATMOS ENVIRON, V205, P52, DOI 10.1016/j.atmosenv.2019.02.017; Stocker TF, 2014, CLIMATE CHANGE 2013: THE PHYSICAL SCIENCE BASIS, P1, DOI 10.1017/cbo9781107415324; Tang WJ, 2011, ATMOS CHEM PHYS, V11, P393, DOI 10.5194/acp-11-393-2011; Tie XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep29612; Wang S, 2018, AGR FOREST METEOROL, V248, P479, DOI 10.1016/j.agrformet.2017.10.023; Wang YW, 2016, GEOPHYS RES LETT, V43, P11777, DOI 10.1002/2016GL071009; Wang Y, 2019, ATMOS ENVIRON, V200, P280, DOI 10.1016/j.atmosenv.2018.12.023; Xu H, 2017, ATMOS ENVIRON, V166, P393, DOI 10.1016/j.atmosenv.2017.07.036; Xue WH, 2020, SCI TOTAL ENVIRON, V741, DOI 10.1016/j.scitotenv.2020.140324; Yang XY, 2019, AGR FOREST METEOROL, V275, P233, DOI 10.1016/j.agrformet.2019.05.028; Zhang J, 2020, ECOL INDIC, V108, DOI 10.1016/j.ecolind.2019.105761; Zhang TY, 2018, ENVIRON RES LETT, V13, DOI 10.1088/1748-9326/aaea09; Zhang X, 2015, INT J CLIMATOL, V35, P452, DOI 10.1002/joc.3994; Zhou X., 1998, CHIN J ATMOS SCI, V4, P418; Zhou ZG, 2018, RENEW ENERG, V119, P675, DOI 10.1016/j.renene.2017.12.052; Zou L, 2016, METEOROL ATMOS PHYS, V128, P155, DOI 10.1007/s00703-015-0410-4	34	3	3	5	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2021	16	5							e0250376	10.1371/journal.pone.0250376	http://dx.doi.org/10.1371/journal.pone.0250376			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RW3BG	33939718	Green Published, gold			2023-01-03	WOS:000646400800065
J	Costantino, G; Solbiati, M; Elli, S; Paganuzzi, M; Massabo, D; Montano, N; Mancarella, M; Cortellaro, F; Cataudella, E; Bellone, A; Capsoni, N; Bertolini, G; Nattino, G; Casazza, G				Costantino, Giorgio; Solbiati, Monica; Elli, Silvia; Paganuzzi, Marco; Massabo, Didi; Montano, Nicola; Mancarella, Marta; Cortellaro, Francesca; Cataudella, Emanuela; Bellone, Andrea; Capsoni, Nicolo; Bertolini, Guido; Nattino, Giovanni; Casazza, Giovanni			Utility of hospitalization for elderly individuals affected by COVID-19	PLOS ONE			English	Article							TOCILIZUMAB; ADMISSION; RISK	Background During the COVID-19 pandemic, the number of individuals needing hospital admission has sometimes exceeded the availability of hospital beds. Since hospitalization can have detrimental effects on older individuals, preference has been given to younger patients. The aim of this study was to assess the utility of hospitalization for elderly affected by COVID-19. We hypothesized that their mortality decreases when there is greater access to hospitals. Methods This study examined 1902 COVID-19 patients consecutively admitted to three large hospitals in Milan, Italy. Overall mortality data for Milan from the same period was retrieved. Based on emergency department (ED) data, both peak and off-peak phases were identified. The percentage of elderly patients admitted to EDs during these two phases were compared by calculating the standardized mortality ratio (SMR) of the individuals younger than, versus older than, 80 years. Results The median age of the patients hospitalized during the peak phase was lower than the median age during the off-peak phase (64 vs. 75 years, respectively; p <0.001). However, while the SMR for the younger patients was lower during the off-peak phase (1.98, 95% CI: 1.72-2.29 versus 1.40, 95% CI: 1.25-1.58, respectively), the SMR was similar between both phases for the elderly patients (2.28, 95% CI: 2.07-2.52 versus 2.48, 95% CI: 2.32-2.65, respectively). Conclusions Greater access to hospitals during an off-peak phase did not affect the mortality rate of COVID-19-positive elderly patients in Milan. This finding, if confirmed in other settings, should influence future decisions regarding resource management of health care organizations.	[Costantino, Giorgio; Solbiati, Monica; Montano, Nicola; Mancarella, Marta] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; [Costantino, Giorgio; Solbiati, Monica; Montano, Nicola] Univ Milan, Dipartimento Sci Clin & Comunita, Milan, Italy; [Elli, Silvia; Paganuzzi, Marco; Massabo, Didi] Univ Milan, Milan, Italy; [Cortellaro, Francesca; Cataudella, Emanuela] ASST Santi Paolo & Carlo, Pronto Soccorso & Degenza Breve San Carlo, Milan, Italy; [Bellone, Andrea; Capsoni, Nicolo] ASST Grande Osped Metropolitano Niguarda, Med Urgenza & Pronto Soccorso, Milan, Italy; [Bertolini, Guido; Nattino, Giovanni] Ist Ric Farmacol Mario Negri IRCCS, Dipartimento Salute Pubbl, Lab Epidemiol Clin, Bergamo, Italy; [Casazza, Giovanni] Univ Milan, Dipartimento Sci Biomed & Clin L Sacco, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan	Solbiati, M (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.; Solbiati, M (corresponding author), Univ Milan, Dipartimento Sci Clin & Comunita, Milan, Italy.	monica.solbiati@gmail.com	Solbiati, Monica/K-4755-2016; Casazza, Giovanni/G-3661-2012; costantino, giorgio/AAC-6441-2022; Paganuzzi, Marco Maria/HHS-6951-2022; Nattino, Giovanni/T-7306-2019	Solbiati, Monica/0000-0003-1964-3770; Casazza, Giovanni/0000-0003-3718-1784; costantino, giorgio/0000-0002-6391-3849; Paganuzzi, Marco Maria/0000-0002-0857-539X; Nattino, Giovanni/0000-0002-3034-6251; Bertolini, Guido/0000-0002-3101-4259	Tsunami project of the Lombardy region	Tsunami project of the Lombardy region	This research was funded from the Tsunami project of the Lombardy region. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236; Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021; Costantino G, 2014, CARDIOL J, V21, P606, DOI 10.5603/CJ.a2014.0071; Di Castelnuovo A, 2021, THROMB HAEMOSTASIS, V121, P1054, DOI 10.1055/a-1347-6070; Di Castelnuovo A, 2020, NUTR METAB CARDIOVAS, V30, P1899, DOI 10.1016/j.numecd.2020.07.031; Di Gennaro F, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9080489; EDERER F, 1974, AM J EPIDEMIOL, V100, P165, DOI 10.1093/oxfordjournals.aje.a112024; Evans SJ, 2014, AGE AGEING, V43, P127, DOI 10.1093/ageing/aft156; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Jaffe E, 2020, AM J EMERG MED, V38, P1526, DOI 10.1016/j.ajem.2020.04.023; Kherad O, 2020, EUR J INTERN MED, V76, P1, DOI 10.1016/j.ejim.2020.04.014; Kruse RL, 2004, MED CARE, V42, P860, DOI 10.1097/01.mlr.0000135828.95415.b1; Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044; Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011; Odone A, 2020, LANCET PUBLIC HEALTH, V5, pE310, DOI 10.1016/S2468-2667(20)30099-2; Rizzo M, 2020, JAMA INTERN MED, V180, P1250, DOI 10.1001/jamainternmed.2020.2543; Sbrojavacca R, 2015, EUR J INTERN MED, V26, P476, DOI 10.1016/j.ejim.2015.06.003; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Theoharides TC, 2020, J BIOL REG HOMEOS AG, V34, P1241, DOI 10.23812/20-EDITORIAL_1-5; Volpp KG, 2012, JAMA-J AM MED ASSOC, V308, P1635, DOI 10.1001/jama.2012.13616; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Xie JF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5619	23	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2021	16	4							e0250730	10.1371/journal.pone.0250730	http://dx.doi.org/10.1371/journal.pone.0250730			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0VQ	33901228	Green Published, gold			2023-01-03	WOS:000662169700062
J	Wang, ZH; Zhang, Y; Wei, WR				Wang, Zhenghao; Zhang, Yu; Wei, Wuran			Effect of dietary treatment and fluid intake on the prevention of recurrent calcium stones and changes in urine composition: A meta-analysis and systematic review	PLOS ONE			English	Article							INCIDENT KIDNEY-STONES; LOW ANIMAL PROTEIN; RISK-FACTORS; FIBER; NEPHROLITHIASIS; PREVALENCE; MANAGEMENT; HEALTH; MEN	To perform a systematic review and meta-analysis of randomized controlled trials (RCTs) for investigating the effect of dietary treatment and fluid intake on the prevention of recurrent calcium stones and changes in urine composition. PubMed, Web of Science, Embase, EBSCO, and Cochrane Library databases (updated November 2020) were searched for studies with the following keywords: diet, fluid, recurrent, prevention, randomized controlled trials, and nephrolithiasis. The search strategy and study selection process was conducted by following the PRISMA statement. Six RCTs were identified for satisfying the inclusion criteria and enrolled in this meta-analysis. Our result showed that low protein with or without high fiber diet intervention does not decrease the recurrence of stone upon comparing with control groups (RR = 2.32, 95% CI = 0.42-12.85; P = 0.34) with significant heterogeneity among the studies (I-2 = 81%, P = 0.02). But normal-calcium, low protein, low-salt diet had recurrences did reduced the recurrence compared to normal-calcium diet. And the fluid intake has a positive effect on prevention of recurrent stone formation (RR = 0.39, 95% CI = 0.19-0.80; P = 0.01) with insignificant heterogeneity among the studies (I-2 = 9%, P = 0.30). The different components of urine at baseline were reported in four studies. Upon reviewing the low protein with or without high fiber dietary therapy groups, it was found that there were no obvious changes in the 24-hour urine sodium, calcium, citrate, urea, and sulfate. In conclusion, our study shows that the only low protein with or without fiber does not affect recurrence, but low Na, normal Ca diet has a marked effect on reducing recurrence of calcium stone. And fluid intake shows a significant reduction in the recurrence of calcium stone.	[Wang, Zhenghao; Zhang, Yu; Wei, Wuran] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China	Sichuan University	Wei, WR (corresponding author), Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China.	wzh2019kb@163.com	Wang, Zhenghao/HGB-9714-2022; Wang, Zhenghao/HGB-9731-2022	, Wuran/0000-0002-1380-5065				Antonelli JA, 2014, EUR UROL, V66, P724, DOI 10.1016/j.eururo.2014.06.036; Borghi L, 1996, J UROLOGY, V155, P839, DOI 10.1016/S0022-5347(01)66321-3; Borghi L, 2002, NEW ENGL J MED, V346, P77, DOI 10.1056/NEJMoa010369; Bouatia M, 2015, AFR J UROL, V21, P194, DOI 10.1016/j.afju.2015.02.006; BRESLAU NA, 1988, J CLIN ENDOCR METAB, V66, P140, DOI 10.1210/jcem-66-1-140; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Curhan GC, 2004, ARCH INTERN MED, V164, P885, DOI 10.1001/archinte.164.8.885; Curhan GC, 1998, ANN INTERN MED, V128, P534, DOI 10.7326/0003-4819-128-7-199804010-00003; Dussol B, 2008, NEPHRON CLIN PRACT, V110, pC185, DOI 10.1159/000167271; EBISUNO S, 1991, BRIT J UROL, V67, P237, DOI 10.1111/j.1464-410X.1991.tb15125.x; Escribano J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004754.pub2; Ferraro PM, 2017, J UROLOGY, V198, P858, DOI 10.1016/j.juro.2017.03.124; Hiatt RA, 1996, AM J EPIDEMIOL, V144, P25, DOI 10.1093/oxfordjournals.aje.a008851; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hirvonen T, 1999, AM J EPIDEMIOL, V150, P187, DOI 10.1093/oxfordjournals.aje.a009979; JAHNEN A, 1992, UROL RES, V20, P3, DOI 10.1007/BF00294326; Kocvara R, 1999, BJU INT, V84, P393; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Liu Y, 2018, ASIAN J UROL, V5, P205, DOI 10.1016/j.ajur.2018.08.007; LJUNGHALL S, 1984, BRIT J UROL, V56, P122, DOI 10.1111/j.1464-410X.1984.tb05346.x; Nguyen QV, 2001, KIDNEY INT, V59, P2273, DOI 10.1046/j.1523-1755.2001.00744.x; Parivar F, 1996, J UROLOGY, V155, P432, DOI 10.1016/S0022-5347(01)66411-5; Prezioso D, 2015, ARCH ITAL UROL ANDRO, V87, P105, DOI 10.4081/aiua.2015.2.105; Qaseem A, 2014, ANN INTERN MED, V161, P659, DOI 10.7326/M13-2908; Romero Victoriano, 2010, Rev Urol, V12, pe86; Rotily M, 2000, KIDNEY INT, V57, P1115, DOI 10.1046/j.1523-1755.2000.00939.x; Sarica K, 2006, UROL RES, V34, P184, DOI 10.1007/s00240-006-0040-x; Scales CD, 2012, EUR UROL, V62, P160, DOI 10.1016/j.eururo.2012.03.052; SHAH PJR, 1980, BRIT J UROL, V52, P426, DOI 10.1111/j.1464-410X.1980.tb03082.x; Stoller ML, 2009, J UROLOGY, V181, P1140, DOI 10.1016/j.juro.2008.11.020; Taylor EN, 2004, J AM SOC NEPHROL, V15, P3225, DOI 10.1097/01.ASN.0000146012.44570.20; Taylor EN, 2009, J AM SOC NEPHROL, V20, P2253, DOI 10.1681/ASN.2009030276; Torricelli FCM, 2020, INT BRAZ J UROL, V46, P927, DOI [10.1590/s1677-5538.ibju.2020.99.07, 10.1590/S1677-5538.IBJU.2020.99.07]; Turk C, 2016, EUR UROL, V69, P468, DOI 10.1016/j.eururo.2015.07.040; WASSERSTEIN AG, 1987, MINER ELECTROL METAB, V13, P85	35	3	3	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2021	16	4							e0250257	10.1371/journal.pone.0250257	http://dx.doi.org/10.1371/journal.pone.0250257			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP4TZ	33872340	gold, Green Published			2023-01-03	WOS:000641723300014
J	Gebrehiwot, AN; Kato, T; Nakazawa, K				Gebrehiwot, Adonay N.; Kato, Tatsuya; Nakazawa, Kimitaka			Inducing lateralized phosphenes over the occipital lobe using transcranial magnetic stimulation to navigate a virtual environment	PLOS ONE			English	Article							INTRACORTICAL MICROSTIMULATION; ELECTRICAL-STIMULATION; RETINAL PROSTHESIS; ARTIFICIAL VISION; BLIND; SYSTEM	Electrical stimulation involving visual areas of the brain produces artificial light percepts called phosphenes. These visual percepts have been extensively investigated in previous studies involving intracortical microsimulation (ICMS) and serve as the basis for developing a visual prosthesis for the blind. Although advances have been achieved, many challenges still remain with implementing a functional ICMS for visual rehabilitation purposes. Transcranial magnetic stimulation (TMS) over the primary occipital lobe offers an alternative method to produce phosphenes non-invasively. A main challenge facing blind individuals involves navigation. Within the scientific community, methods to evaluate the ability of a visual prosthesis to facilitate in navigation has been neglected. In this study, we investigate the effectiveness of evoking lateralized phosphenes to navigate a computer simulated virtual environment. More importantly, we demonstrate how virtual environments along with the development of a visual prosthesis share a mutual relationship benefiting both patients and researchers. Using two TMS devices, a pair of 40mm figure-of-eight coils were placed over each occipital hemisphere resulting in lateralized phosphene perception. Participants were tasked with making a series of left and right turns using peripheral devices depending on the visual hemifield in which a phosphene is present. If a participant was able to accurately perceive all ten phosphenes, the simulated target is able to advance and fully exit the virtual environment. Our findings demonstrate that participants can interpret lateralized phosphenes while highlighting the integration of computer based virtual environments to evaluate the capability of a visual prosthesis during navigation.	[Gebrehiwot, Adonay N.; Kato, Tatsuya; Nakazawa, Kimitaka] Univ Tokyo, Dept Life Sci, Tokyo, Japan; [Kato, Tatsuya] Japan Soc Promot Sci, Tokyo, Japan	University of Tokyo; Japan Society for the Promotion of Science	Nakazawa, K (corresponding author), Univ Tokyo, Dept Life Sci, Tokyo, Japan.	nakazawa@idaten.c.u-tokyo.ac.jp		Nakazawa, Kimitaka/0000-0001-5483-8659; Kato, Tatsuya/0000-0002-4493-2200	Japan Society for the Promotion of Science Kakenhi [18H04082]; Uehara Memorial Foundation; Core Research for Evolutional Science and Technology program by the Japan Science and Technology Agency	Japan Society for the Promotion of Science Kakenhi(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Uehara Memorial Foundation(Uehara Memorial Foundation); Core Research for Evolutional Science and Technology program by the Japan Science and Technology Agency	This research was funded by the Japan Society for the Promotion of Science Kakenhi grant number 18H04082, research grant by the Uehara Memorial Foundation, and the Core Research for Evolutional Science and Technology program by the Japan Science and Technology Agency.	BAK M, 1990, MED BIOL ENG COMPUT, V28, P257, DOI 10.1007/BF02442682; Bakondi B, 2016, MOL THER, V24, P556, DOI 10.1038/mt.2015.220; Barnes N, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/3/036013; Bonmassar G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1914; BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519; Chader GJ, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.16-19125; Chen SC, 2009, VISION RES, V49, P1493, DOI 10.1016/j.visres.2009.02.003; Christie BP, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/2/025003; Cogan SF, 2008, ANNU REV BIOMED ENG, V10, P275, DOI 10.1146/annurev.bioeng.10.061807.160518; Cover T.M., 2006, ELEMENTS INFORM THEO, Vsecond; da Cruz L, 2016, OPHTHALMOLOGY, V123, P2248, DOI 10.1016/j.ophtha.2016.06.049; Dagnelie G, 2008, ANNU REV BIOMED ENG, V10, P339, DOI 10.1146/annurev.bioeng.10.061807.160529; DOBELLE WH, 1974, SCIENCE, V183, P440, DOI 10.1126/science.183.4123.440; Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002; Elkin-Frankston Seth, 2010, J Vis Exp, DOI 10.3791/1762; Farnum A, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00036; Fernandez Eduardo, 2018, Bioelectron Med, V4, P12, DOI 10.1186/s42234-018-0013-8; Gaub BM, 2015, MOL THER, V23, P1562, DOI 10.1038/mt.2015.121; Gothe J, 2002, BRAIN, V125, P479, DOI 10.1093/brain/awf045; Gulino M, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00689; Kammer T, 2005, EXP BRAIN RES, V160, P129, DOI 10.1007/s00221-004-1992-0; Kuder GF, 1937, PSYCHOMETRIKA, V2, P151, DOI 10.1007/BF02288391; Lee SW, 2017, IEEE T NEUR SYS REH, V25, P1375, DOI 10.1109/TNSRE.2016.2631446; Lewis PM, 2015, BRAIN RES, V1595, P51, DOI 10.1016/j.brainres.2014.11.020; Losey DM, 2016, FRONT ROBOT AI, V3, DOI 10.3389/frobt.2016.00072; MARG E, 1994, OPTOMETRY VISION SCI, V71, P301, DOI 10.1097/00006324-199405000-00001; Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9; Minusa S, 2018, IEEE T BIO-MED ENG, V65, P1301, DOI 10.1109/TBME.2017.2748136; Park HJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3463; Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270; Rao RPN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111332; Real S, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19153404; Rizou ME, 2018, BIOMED PHYS ENG EXPR, V4, DOI 10.1088/2057-1976/aaa0dd; Romei V, 2008, CEREB CORTEX, V18, P2010, DOI 10.1093/cercor/bhm229; Salminen-Vaparanta N, 2014, CEREB CORTEX, V24, P2751, DOI 10.1093/cercor/bht131; Schiller PH, 2008, PERCEPTION, V37, P1529, DOI 10.1068/p6100; Schmidt EM, 1996, BRAIN, V119, P507, DOI 10.1093/brain/119.2.507; Shepherd RK, 2013, TRENDS BIOTECHNOL, V31, P562, DOI 10.1016/j.tibtech.2013.07.001; Stocco A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137303; Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565; Terhune DB, 2015, CEREB CORTEX, V25, P4341, DOI 10.1093/cercor/bhv015	41	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2021	16	4							e0249996	10.1371/journal.pone.0249996	http://dx.doi.org/10.1371/journal.pone.0249996			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN8MG	33852643	Green Published, gold			2023-01-03	WOS:000640604500071
J	Farooq, N; Chuan, B; Mahmud, H; El Khoudary, SR; Nouraie, SM; Evankovich, J; Yang, LB; Dunlap, D; Bain, W; Kitsios, G; Zhang, YZ; O'Donnell, CP; McVerry, BJ; Shah, FA				Farooq, Nauman; Chuan, Byron; Mahmud, Hussain; El Khoudary, Samar R.; Nouraie, Seyed Mehdi; Evankovich, John; Yang, Libing; Dunlap, Daniel; Bain, William; Kitsios, Georgios; Zhang, Yingze; O'Donnell, Christopher P.; McVerry, Bryan J.; Shah, Faraaz Ali			Association of the systemic host immune response with acute hyperglycemia in mechanically ventilated septic patients	PLOS ONE			English	Article							INSULIN-RESISTANCE; HOSPITAL MORTALITY; SEVERE SEPSIS; SOLUBLE ST2; TNF-ALPHA; PENTRAXIN 3; PROCALCITONIN; CYTOKINE; RECEPTOR; GLUCOSE	Hyperglycemia during sepsis is associated with increased organ dysfunction and higher mortality. The role of the host immune response in development of hyperglycemia during sepsis remains unclear. We performed a retrospective analysis of critically ill adult septic patients requiring mechanical ventilation (n = 153) to study the relationship between hyperglycemia and ten markers of the host injury and immune response measured on the first day of ICU admission (baseline). We determined associations between each biomarker and: (1) glucose, insulin, and c-peptide levels at the time of biomarker collection by Pearson correlation; (2) average glucose and glycemic variability in the first two days of ICU admission by linear regression; and (3) occurrence of hyperglycemia (blood glucose>180mg/dL) by logistic regression. Results were adjusted for age, pre-existing diabetes mellitus, severity of illness, and total insulin and glucocorticoid dose. Baseline plasma levels of ST2 and procalcitonin were positively correlated with average blood glucose and glycemic variability in the first two days of ICU admission in unadjusted and adjusted analyses. Additionally, higher baseline ST2, IL-1ra, procalcitonin, and pentraxin-3 levels were associated with increased risk of hyperglycemia. Our results suggest associations between the host immune response and hyperglycemia in critically ill septic patients particularly implicating the interleukin-1 axis (IL-1ra), the interleukin-33 axis (ST2), and the host response to bacterial infections (procalcitonin, pentraxin-3).	[Farooq, Nauman] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA; [Chuan, Byron; Nouraie, Seyed Mehdi; Evankovich, John; Dunlap, Daniel; Bain, William; Kitsios, Georgios; Zhang, Yingze; O'Donnell, Christopher P.; McVerry, Bryan J.; Shah, Faraaz Ali] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA; [Mahmud, Hussain] Univ Pittsburgh, Div Endocrinol & Metab, Pittsburgh, PA USA; [El Khoudary, Samar R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Yang, Libing] Tsinghua Univ, Sch Med, Beijing, Peoples R China; [Bain, William; Shah, Faraaz Ali] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA; [Kitsios, Georgios; McVerry, Bryan J.] Univ Pittsburgh, Ctr Med & Microbiome, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tsinghua University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Shah, FA (corresponding author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA.; Shah, FA (corresponding author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.	shahfa@upmc.edu	McVerry, Bryan/AAS-7790-2021; Nouraie, Seyed Mehdi/O-4071-2018	McVerry, Bryan/0000-0002-1175-4874; Nouraie, Seyed Mehdi/0000-0001-7465-0581; El Khoudary, Samar/0000-0003-2913-0821; Bain, William/0000-0001-8506-0552	National Institutes of Health [5K23GM122069, 5K23HL139987, 5K08HL144820, 5P01HL114453]; Veterans Health Administration [IK2BX004886]; Clinical and Translational Science Institute at the University of Pittsburgh through the National Institutes of Health [UL1-TR-000005]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Health Administration(US Department of Veterans Affairs); Clinical and Translational Science Institute at the University of Pittsburgh through the National Institutes of Health	FAS received funding for this work by National Institutes of Health (https://www.nih.gov/) (5K23GM122069). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. GK received funding for this work by National Institutes of Health (https://www.nih.gov/) (5K23HL139987). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. JE received funding for this work by National Institutes of Health (https://www.nih.gov/) (5K08HL144820). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. BJM received funding for this work by National Institutes of Health (https://www.nih.gov/) (5P01HL114453). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. WB received funding for this work by Veterans Health Administration (https://www.va.gov/health/) (IK2BX004886). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Statistical support was provided by the Clinical and Translational Science Institute at the University of Pittsburgh through the National Institutes of Health Grant UL1-TR-000005 (https://www.nih.gov/).	Abbasi A, 2010, J CLIN ENDOCR METAB, V95, pE26, DOI 10.1210/jc.2010-0305; Borst SE, 2004, ENDOCRINE, V23, P177, DOI 10.1385/ENDO:23:2-3:177; Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783; Brunkhorst FM, 2000, INTENS CARE MED, V26, pS148, DOI 10.1007/BF02900728; Caironi P, 2017, EUR J CLIN INVEST, V47, P73, DOI 10.1111/eci.12704; Castelli GP, 2004, CRIT CARE, V8, pR234, DOI 10.1186/cc2877; Cekmez F, 2016, CLIN LAB, V62, P751, DOI 10.7754/Clin.Lab.2014.141013; Chao HY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170408; Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8; Coglianese EE, 2012, CLIN CHEM, V58, P1673, DOI 10.1373/clinchem.2012.192153; Delamaire M, 1997, DIABETIC MED, V14, P29, DOI 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V; Duncan BB, 2003, DIABETES, V52, P1799, DOI 10.2337/diabetes.52.7.1799; Ehses JA, 2008, BIOCHEM SOC T, V36, P340, DOI 10.1042/BST0360340; Fan J, 1996, SHOCK, V6, P164, DOI 10.1097/00024382-199609010-00002; Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756; Hasan A, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/7901062; Hoogerwerf JJ, 2010, INTENS CARE MED, V36, P630, DOI 10.1007/s00134-010-1773-0; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Hur M, 2015, ANN LAB MED, V35, P570, DOI 10.3343/alm.2015.35.6.570; Jager J, 2007, ENDOCRINOLOGY, V148, P241, DOI 10.1210/en.2006-0692; Karzai W, 1997, INFECTION, V25, P329, DOI 10.1007/BF01740811; Kitsios GD, 2019, CRIT CARE MED, V47, P1724, DOI 10.1097/CCM.0000000000004018; Krinsley JS, 2008, CRIT CARE MED, V36, P3008, DOI 10.1097/CCM.0b013e31818b38d2; Krinsley JS, 2003, MAYO CLIN PROC, V78, P1471, DOI 10.4065/78.12.1471; Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213; Lee YT, 2018, J INFECTION, V76, P1, DOI 10.1016/j.jinf.2017.10.016; Leonidou L, 2007, J INFECTION, V55, P340, DOI 10.1016/j.jinf.2007.05.177; Leonidou L, 2008, AM J MED SCI, V336, P467, DOI 10.1097/MAJ.0b013e318176abb4; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lin YH, 2016, DIABETES RES CLIN PR, V118, P140, DOI 10.1016/j.diabres.2016.06.006; Lu JL, 2019, INT IMMUNOPHARMACOL, V70, P9, DOI 10.1016/j.intimp.2019.02.018; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Marik PE, 2004, INTENS CARE MED, V30, P748, DOI 10.1007/s00134-004-2167-y; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; MEHTA VK, 1994, EUR J ENDOCRINOL, V130, P208, DOI 10.1530/eje.0.1300208; MEIKLE AW, 1977, AM J MED, V63, P200, DOI 10.1016/0002-9343(77)90233-9; Miller AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047830; Milovanovic M, 2012, IMMUNOL RES, V52, P89, DOI 10.1007/s12026-012-8283-9; Muller B, 2001, SWISS MED WKLY, V131, P595; Nakamura M, 2012, CRIT CARE, V16, DOI 10.1186/cc11301; Oshikawa K, 2002, CLIN EXP ALLERGY, V32, P1520, DOI 10.1046/j.1365-2745.2002.01494.x; Qu W, 2018, J ENDOCRINOL INVEST, V41, P455, DOI 10.1007/s40618-017-0742-7; Saberi F, 2008, JPEN-PARENTER ENTER, V32, P227, DOI 10.1177/0148607108316195; SANDLER S, 1990, ENDOCRINOLOGY, V126, P1288, DOI 10.1210/endo-126-2-1288; Sarkar SK, 1997, J AM STAT ASSOC, V92, P1601, DOI 10.2307/2965431; Sechterberger MK, 2013, CRIT CARE, V17, DOI 10.1186/cc12572; Shanmugam N, 2003, DIABETES, V52, P1256, DOI 10.2337/diabetes.52.5.1256; Singamsetty S, 2016, APPL PHYSIOL NUTR ME, V41, P12, DOI 10.1139/apnm-2015-0213; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Takashi Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196526; Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978; van Asseldonk EJP, 2015, CLIN IMMUNOL, V160, P155, DOI 10.1016/j.clim.2015.06.003; van Vught LA, 2016, CRIT CARE MED, V44, P1338, DOI 10.1097/CCM.0000000000001650; Wang R, 2016, J INVEST MED, V64, P1124, DOI 10.1136/jim-2016-000082; Wang XS, 2019, EXP THER MED, V18, P722, DOI 10.3892/etm.2019.7611; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1; Xu H, 2017, MILITARY MED RES, V4, P1, DOI 10.1186/s40779-017-0115-8; Yu WK, 2003, WORLD J GASTROENTERO, V9, P1824, DOI 10.3748/wjg.v9.i8.1824; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	62	0	0	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2021	16	3							e0248853	10.1371/journal.pone.0248853	http://dx.doi.org/10.1371/journal.pone.0248853			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC6NY	33755703	Green Published, gold			2023-01-03	WOS:000632916600033
J	Pillon, NJ; Loos, RJF; Marshall, SM; Zierath, JR				Pillon, Nicolas J.; Loos, Ruth J. F.; Marshall, Sally M.; Zierath, Juleen R.			Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care	CELL			English	Review							CIRCADIAN CLOCK; SKELETAL-MUSCLE; INSULIN-RESISTANCE; BODY-WEIGHT; SHIFT-WORK; EXERCISE; TIME; ASSOCIATION; COVID-19; EXPOSURE	The prevalence of type 2 diabetes and obesity has risen dramatically for decades and is expected to rise further, secondary to the growing aging, sedentary population. The strain on global health care is projected to be colossal. This review explores the latest work and emerging ideas related to genetic and environmental factors influencing metabolism. Translational research and clinical applications, including the impact of the COVID-19 pandemic, are highlighted. Looking forward, strategies to personalize all aspects of prevention, management and care are necessary to improve health outcomes and reduce the impact of these metabolic diseases.	[Pillon, Nicolas J.; Zierath, Juleen R.] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; [Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY USA; [Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY USA; [Marshall, Sally M.] Newcastle Univ, Fac Clin Med Sci, Translat & Clin Res Inst, Diabet Res Grp, 4th Floor William Leech Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Zierath, Juleen R.] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Zierath, Juleen R.] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark	Karolinska Institutet; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Newcastle University - UK; Karolinska Institutet; Novo Nordisk Foundation; University of Copenhagen	Zierath, JR (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.; Zierath, JR (corresponding author), Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.	juleen.zierath@ki.se	Loos, Ruth/GON-5877-2022; Pillon, Nicolas J/M-4170-2019; Loos, Ruth/Q-2862-2016	Pillon, Nicolas J/0000-0003-1107-9490; Loos, Ruth/0000-0002-8532-5087; Marshall, Sally/0000-0001-5735-713X	Marie Sklodowska-Curie Actions (European Commission) [704978]; Swedish Research Council (Vetenskapsradet) [2015-00165]; Novo Nordisk Foundation Challenge Grant [NNF14OC0011493]; Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen [NNF18CC0034900, 190503]; National Institutes of Health [R01DK110113, R01DK107786, R01HL142302, R01 DK124097]	Marie Sklodowska-Curie Actions (European Commission); Swedish Research Council (Vetenskapsradet)(Swedish Research Council); Novo Nordisk Foundation Challenge Grant; Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	N.J.P. was supported by an Individual Fellowship from the Marie Sklodowska-Curie Actions (European Commission, 704978). J.R.Z. was supported from the Swedish Research Council (Vetenskapsradet) (2015-00165), a Novo Nordisk Foundation Challenge Grant (NNF14OC0011493), and the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen (NNF18CC0034900). R.J.F.L. was supported by the National Institutes of Health (R01DK110113; R01DK107786; R01HL142302; R01 DK124097) and the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen (Alliance 190503).	Achebak H, 2019, LANCET PLANET HEALTH, V3, pE297, DOI 10.1016/S2542-5196(19)30090-7; Ahlqvist E, 2018, LANCET DIABETES ENDO, V6, P361, DOI 10.1016/S2213-8587(18)30051-2; Al-Mrabeh A, 2020, CELL METAB, V31, P233, DOI 10.1016/j.cmet.2019.11.018; Ameln H, 2005, FASEB J, V19, P1009, DOI 10.1096/fj.04-2304fje; American Diabetes Association, 2020, Diabetes Care, V43, pS14, DOI 10.2337/dc20-S002; Apicella M, 2020, LANCET DIABETES ENDO, V8, P782, DOI 10.1016/S2213-8587(20)30238-2; Archer AE, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0529; Areta JL, 2013, J PHYSIOL-LONDON, V591, P2319, DOI 10.1113/jphysiol.2012.244897; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Barbosa TD, 2016, MOL METAB, V5, P184, DOI 10.1016/j.molmet.2015.12.002; Barres R, 2016, NAT REV ENDOCRINOL, V12, P441, DOI 10.1038/nrendo.2016.87; Barres R, 2013, CELL REP, V3, P1020, DOI 10.1016/j.celrep.2013.03.018; Barres R, 2012, CELL METAB, V15, P405, DOI 10.1016/j.cmet.2012.01.001; Barron E, 2020, LANCET DIABETES ENDO, V8, P813, DOI 10.1016/S2213-8587(20)30272-2; Barroso I, 2019, CELL, V177, P146, DOI 10.1016/j.cell.2019.02.024; Bluher M, 2019, NAT REV ENDOCRINOL, V15, P288, DOI 10.1038/s41574-019-0176-8; Boskovic A, 2018, ANNU REV GENET, V52, P21, DOI 10.1146/annurev-genet-120417-031404; Bray GA, 2017, OBES REV, V18, P715, DOI 10.1111/obr.12551; Bruun JM, 2006, AM J PHYSIOL-ENDOC M, V290, pE961, DOI 10.1152/ajpendo.00506.2005; Cai DS, 2013, TRENDS ENDOCRIN MET, V24, P40, DOI 10.1016/j.tem.2012.11.003; Catalano PM, 2017, BMJ-BRIT MED J, V356, DOI [10.1136/bmj.j1, 10.1136/bmj.j1631]; Chaix A, 2014, CELL METAB, V20, P991, DOI 10.1016/j.cmet.2014.11.001; Chan JCN, 2020, LANCET, V396, P2019, DOI 10.1016/S0140-6736(20)32374-6; Charlot K, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060592; Chouchani ET, 2019, CELL METAB, V29, P27, DOI 10.1016/j.cmet.2018.11.002; Chung J, 2008, P NATL ACAD SCI USA, V105, P1739, DOI 10.1073/pnas.0705799105; Chung WK, 2020, DIABETOLOGIA, V63, P1671, DOI [10.2337/dci20-0022, 10.1007/s00125-020-05181-w]; Cienfuegos S, 2020, CELL METAB, V32, P366, DOI 10.1016/j.cmet.2020.06.018; Crameri Giovanni Andrea Gerardo, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.36.2001542; Crosby P, 2019, CELL, V177, P896, DOI 10.1016/j.cell.2019.02.017; da Silveira MP, 2021, CLIN EXP MED, V21, P15, DOI 10.1007/s10238-020-00650-3; Dennis JM, 2018, CLIN EPIDEMIOL, V10, P1869, DOI 10.2147/CLEP.S179555; Elks Cathy E, 2012, Front Endocrinol (Lausanne), V3, P29, DOI 10.3389/fendo.2012.00029; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Feehan KT, 2019, TRENDS MOL MED, V25, P198, DOI 10.1016/j.molmed.2019.01.006; Forouhi NG, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2234; Freese Jens, 2017, F1000Res, V6, P1787, DOI 10.12688/f1000research.12724.2; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; Gabriel BM, 2019, NAT REV ENDOCRINOL, V15, P197, DOI 10.1038/s41574-018-0150-x; Gamble KL, 2014, NAT REV ENDOCRINOL, V10, P466, DOI 10.1038/nrendo.2014.78; Gasparrini A, 2015, LANCET, V386, P369, DOI 10.1016/S0140-6736(14)62114-0; Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041; Guisado-Vasco P, 2020, TRENDS ENDOCRIN MET, V31, P802, DOI 10.1016/j.tem.2020.08.004; Hajat S, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0284-7; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019; Hattersley AT, 2017, DIABETOLOGIA, V60, P769, DOI 10.1007/s00125-017-4226-2; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; Holman N, 2020, LANCET DIABETES ENDO, V8, P823, DOI 10.1016/S2213-8587(20)30271-0; Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363; Huang CR, 2012, CIRC-CARDIOVASC QUAL, V5, P609, DOI 10.1161/CIRCOUTCOMES.112.965707; Ji YJ, 2019, DIABETES, V68, P207, DOI 10.2337/db18-0708; Johnston BC, 2014, JAMA-J AM MED ASSOC, V312, P923, DOI 10.1001/jama.2014.10397; Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859; Kassir R, 2020, OBES REV, V21, DOI 10.1111/obr.13034; KELLEY DE, 1992, DIABETES, V41, P698, DOI 10.2337/diabetes.41.6.698; Kenny Glen P, 2016, Temperature (Austin), V3, P119, DOI 10.1080/23328940.2015.1131506; Kettner NM, 2015, CELL METAB, V22, P448, DOI 10.1016/j.cmet.2015.06.005; Khera AV, 2019, CELL, V177, P587, DOI 10.1016/j.cell.2019.03.028; Kim YH, 2020, ENDOCR REV, V41, DOI 10.1210/endrev/bnaa014; Kohner EM, 1998, ARCH OPHTHALMOL-CHIC, V116, P297, DOI 10.1001/archopht.116.3.297; Kondo T, 2014, EBIOMEDICINE, V1, P80, DOI 10.1016/j.ebiom.2014.11.001; Koopman ADM, 2017, J BIOL RHYTHM, V32, P359, DOI 10.1177/0748730417713572; Krause M, 2020, DIABETOL METAB SYNDR, V12, DOI 10.1186/s13098-020-00572-w; Lamia KA, 2009, SCIENCE, V326, P437, DOI 10.1126/science.1172156; Lancaster GI, 2014, TRENDS IMMUNOL, V35, P262, DOI 10.1016/j.it.2014.02.008; Larder R, 2017, P NATL ACAD SCI USA, V114, P9421, DOI 10.1073/pnas.1707310114; Lee YS, 2018, CELL, V172, P22, DOI 10.1016/j.cell.2017.12.025; Li YP, 2010, DIABETES, V59, P2400, DOI 10.2337/db10-0385; Lim EL, 2011, DIABETOLOGIA, V54, P2506, DOI 10.1007/s00125-011-2204-7; Lin YC, 2009, CHRONOBIOL INT, V26, P740, DOI 10.1080/07420520902929029; Lo KB, 2020, CARDIORENAL MED, V10, P1, DOI 10.1159/000503919; Locke AE, 2015, NATURE, V518, P197, DOI 10.1038/nature14177; Lowe DA, 2020, JAMA INTERN MED, V180, P1491, DOI 10.1001/jamainternmed.2020.4153; Lundell LS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18412-w; Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6; Meade RD, 2020, ENVIRON INT, V144, DOI 10.1016/j.envint.2020.105909; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Morley JE, 2020, J CACHEXIA SARCOPENI, V11, P863, DOI 10.1002/jcsm.12589; Multhaup ML, 2015, CELL METAB, V21, P138, DOI 10.1016/j.cmet.2014.12.014; Murashov AK, 2016, FASEB J, V30, P775, DOI 10.1096/fj.15-274274; Murray CJL, 2020, LANCET, V396, P1223, DOI 10.1016/S0140-6736(20)30752-2; Nanayakkara N, 2021, DIABETOLOGIA, V64, P275, DOI 10.1007/s00125-020-05319-w; Newman AC, 2017, BRIT J CANCER, V116, P1499, DOI 10.1038/bjc.2017.118; Nitert MD, 2012, DIABETES, V61, P3322, DOI 10.2337/db11-1653; Palsson-McDermott EM, 2020, CELL RES, V30, P300, DOI 10.1038/s41422-020-0291-z; Pan A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001141; Pearson ER, 2006, NEW ENGL J MED, V355, P467, DOI 10.1056/NEJMoa061759; Peek CB, 2017, CELL METAB, V25, P86, DOI 10.1016/j.cmet.2016.09.010; Periard JD, 2015, SCAND J MED SCI SPOR, V25, P20, DOI 10.1111/sms.12408; Pillon NJ, 2016, AM J PHYSIOL-ENDOC M, V311, pE825, DOI 10.1152/ajpendo.00296.2016; Ranheim T, 1997, ARTERIOSCL THROM VAS, V17, P3286, DOI 10.1161/01.ATV.17.11.3286; Rathjen T, 2017, NAT NEUROSCI, V20, P1096, DOI 10.1038/nn.4590; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; Reidy PT, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041514; Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]; Rudic RD, 2004, PLOS BIOL, V2, P1893, DOI 10.1371/journal.pbio.0020377; Ryder JW, 2000, DIABETES, V49, P647, DOI 10.2337/diabetes.49.4.647; Rynders CA, 2018, J PHYSIOL-LONDON, V596, P1319, DOI 10.1113/JP273282; Sanchez-Sanchez E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092826; Sato S, 2019, CELL METAB, V30, P92, DOI 10.1016/j.cmet.2019.03.013; Savikj M, 2020, DIABETOLOGIA, V63, P1491, DOI 10.1007/s00125-020-05166-9; Savikj M, 2019, DIABETOLOGIA, V62, P233, DOI 10.1007/s00125-018-4767-z; Song JD, 2020, CELL METAB, V32, P726, DOI 10.1016/j.cmet.2020.09.008; Stanford KI, 2015, DIABETES, V64, P427, DOI 10.2337/db13-1848; Taylor R, 2015, CLIN SCI, V128, P405, DOI 10.1042/CS20140553; Tiffon C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113425; Timpel P, 2019, DIABETOLOGIA, V62, P1842, DOI 10.1007/s00125-019-4941-y; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Udler MS, 2019, ENDOCR REV, V40, P1500, DOI 10.1210/er.2019-00088; Udler MS, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002654; van der Klaauw AA, 2015, CELL, V161, P119, DOI 10.1016/j.cell.2015.03.008; Vimalananda VG, 2015, DIABETOLOGIA, V58, P699, DOI 10.1007/s00125-014-3480-9; VROMAN NB, 1983, J APPL PHYSIOL, V55, P69, DOI 10.1152/jappl.1983.55.1.69; Wang SF, 2020, DIABETOLOGIA, V63, P2102, DOI 10.1007/s00125-020-05209-1; Wang X, 2020, TRENDS ENDOCRIN MET, V31, P712, DOI 10.1016/j.tem.2020.07.001; West MA, 2016, BRIT J SURG, V103, P744, DOI 10.1002/bjs.10112; Wilkinson MJ, 2020, CELL METAB, V31, P92, DOI 10.1016/j.cmet.2019.11.004; Willemsen G, 2015, TWIN RES HUM GENET, V18, P762, DOI 10.1017/thg.2015.83; Xin YQ, 2020, DIABETOLOGIA, V63, P2112, DOI 10.1007/s00125-020-05224-2; Yengo L, 2018, HUM MOL GENET, V27, P3641, DOI 10.1093/hmg/ddy271; Young MW, 2018, ANGEW CHEM INT EDIT, V57, P11532, DOI 10.1002/anie.201803337; Yuan S, 2020, DIABETOLOGIA, V63, P2359, DOI 10.1007/s00125-020-05253-x	123	54	54	11	59	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 18	2021	184	6					1530	1544		10.1016/j.cell.2021.02.012	http://dx.doi.org/10.1016/j.cell.2021.02.012		MAR 2021	15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QY9LN	33675692	hybrid, Green Published			2023-01-03	WOS:000630357400017
J	Morin, L; Savale, L; Pham, T; Colle, R; Figueiredo, S; Harrois, A; Gasnier, M; Lecoq, AL; Meyrignac, O; Noel, N; Baudry, E; Bellin, MF; Beurnier, A; Choucha, W; Corruble, E; Dortet, L; Hardy-Leger, I; Radiguer, F; Sportouch, S; Verny, C; Wyplosz, B; Zaidan, MH; Becquemont, L; Montani, D; Monnet, X				Morin, Luc; Savale, Laurent; Pham, Tai; Colle, Romain; Figueiredo, Samy; Harrois, Anatole; Gasnier, Matthieu; Lecoq, Anne-Lise; Meyrignac, Olivier; Noel, Nicolas; Baudry, Elodie; Bellin, Marie-France; Beurnier, Antoine; Choucha, Walid; Corruble, Emmanuelle; Dortet, Laurent; Hardy-Leger, Isabelle; Radiguer, Francois; Sportouch, Sabine; Verny, Christiane; Wyplosz, Benjamin; Zaidan, Mohamad; Becquemont, Laurent; Montani, David; Monnet, Xavier		COMEBAC Study Grp	Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; DEPRESSION; SURVIVORS; VALIDATION; ANXIETY	IMPORTANCE Little is known about long-term sequelae of COVID-19. OBJECTIVE To describe the consequences at 4 months in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In a prospective uncontrolled cohort study, survivors of COVID-19 who had been hospitalized in a university hospital in France between March 1 and May 29, 2020, underwent a telephone assessment 4 months after discharge, between July 15 and September 18, 2020. Patients with relevant symptoms and all patients hospitalized in an intensive care unit (ICU) were invited for further assessment at an ambulatory care visit. EXPOSURES Survival of hospitalization for COVID-19. MAIN OUTCOMES AND MEASURES Respiratory, cognitive, and functional symptoms were assessed by telephone with the Q3PC cognitive screening questionnaire and a checklist of symptoms. At the ambulatory care visit, patients underwent pulmonary function tests, lung computed tomographic scan, psychometric and cognitive tests (including the 36-Item Short-Form Health Survey and 20-item Multidimensional Fatigue Inventory), and, for patients who had been hospitalized in the ICU or reported ongoing symptoms, echocardiography. RESULTS Among 834 eligible patients, 478 were evaluated by telephone (mean age, 61 years [SD, 16 years]; 201 men, 277 women). During the telephone interview, 244 patients (51%) declared at least 1 symptom that did not exist before COVID-19: fatigue in 31%, cognitive symptoms in 21%, and new-onset dyspnea in 16%. There was further evaluation in 177 patients (37%), including 97 of 142 former ICU patients. The median 20-item Multidimensional Fatigue Inventory score (n = 130) was 4.5 (interquartile range, 3.0-5.0) for reduced motivation and 3.7 (interquartile range, 3.0-4.5) for mental fatigue (possible range, 1 [best] to 5 [worst]). The median 36-Item Short-Form Health Survey score (n = 145) was 25 (interquartile range, 25.0-75.0) for the subscale "role limited owing to physical problems" (possible range, 0 [best] to 100 [worst]). Computed tomographic lung-scan abnormalities were found in 108 of 171 patients (63%), mainly subtle ground-glass opacities. Fibrotic lesions were observed in 33 of 171 patients (19%), involving less than 25% of parenchyma in all but 1 patient. Fibrotic lesions were observed in 19 of 49 survivors (39%) with acute respiratory distress syndrome. Among 94 former ICU patients, anxiety, depression, and posttraumatic symptoms were observed in 23%, 18%, and 7%, respectively. The left ventricular ejection fraction was less than 50% in 8 of 83 ICU patients (10%). New-onset chronic kidney disease was observed in 2 ICU patients. Serology was positive in 172 of 177 outpatients (97%). CONCLUSIONS AND RELEVANCE Four months after hospitalization for COVID-19, a cohort of patients frequently reported symptoms not previously present, and lung-scan abnormalities were common among those who were tested. These findings are limited by the absence of a control group and of pre-COVID assessments in this cohort. Further research is needed to understand longer-term outcomes and whether these findings reflect associations with the disease.	[Morin, Luc] Univ Paris Saclay, Hop Bicetre, Serv Reanimat Pediatr & Med Neonatale, AP HP,Sante Enfant & Adolescent, Le Kremlin Bicetre, France; [Savale, Laurent] Univ Paris Saclay, Serv Pneumol & Soins Intensifs Resp, Hop Bicetre, AP HP,DMU 5,Thorinno,INSERM,UMR S999, Le Kremlin Bicetre, France; [Pham, Tai; Sportouch, Sabine; Monnet, Xavier] Univ Paris Saclay, Serv Med Intens Reanimat, CORREVE Malad Coeur & Vaisseaux, AP HP,DMU 4,FHU Sepsis,Hop Bicetre, Le Kremlin Bicetre, France; [Colle, Romain; Gasnier, Matthieu; Choucha, Walid; Corruble, Emmanuelle] Univ Paris Saclay, DMU 11 Psychiat Sante Mentale Addictol & Nutr, CESP Ctr Rech Epidemiol & Sante Populat,INSERM, AP HP,Serv Psychiat,Hop Bicetre,Equipe MOODS,U117, Le Kremlin Bicetre, France; [Figueiredo, Samy; Harrois, Anatole; Radiguer, Francois] Univ Paris Saclay, Hop Bicetre, Serv Reanimat Chirurg, DMU 12 Anesthesie,Reanimat,AP HP,Douleur, Le Kremlin Bicetre, France; [Lecoq, Anne-Lise; Becquemont, Laurent] Univ Paris Saclay, Ctr Rech Clin Paris Saclay, DMU 13 Sante Publ,U1018, AP HP,Informat Med,Appui Rech Clin,INSERM,CESP, Le Kremlin Bicetre, France; [Meyrignac, Olivier; Bellin, Marie-France] Univ Paris Saclay, Hop Bicetre, AP HP, Serv Radiol Diagnost & Intervent, Le Kremlin Bicetre, France; [Noel, Nicolas; Hardy-Leger, Isabelle] Univ Paris Saclay, Hop Bicetre, DMU 7 Endocrinol Immunites Inflammat Canc Urgence, AP HP,Serv Med Interne & Immunol Clin, Le Kremlin Bicetre, France; [Baudry, Elodie; Verny, Christiane] Univ Paris Saclay, Hop Bicetre, AP HP, Serv Geriatr Aigue,DMU 1 Med Terr Geriatr, Le Kremlin Bicetre, France; [Beurnier, Antoine] Univ Paris Saclay, Hop Bicetre, Serv Physiol & Explorat Fonct Resp, DMU 5 Thorinno,AP HP,INSERM,UMR S999, Le Kremlin Bicetre, France; [Dortet, Laurent] Univ Paris Saclay, Hop Bicetre, DMU 15 Biol Genet PUI, AP HP,Serv Microbiol,INSERM 1193, Le Kremlin Bicetre, France; [Wyplosz, Benjamin] Univ Paris Saclay, DMU 7 Endocrinol Immunites Inflammat Canc Urgence, Serv Malad Infect & Trop, AP HP,Hop Bicetre,INSERM,U1018,CESP, Le Kremlin Bicetre, France; [Zaidan, Mohamad] Univ Paris Saclay, Hop Bicetre, DMU 4 CORREVE Malad Coeur & Vaisseaux, AP HP,Serv Nephrol Transplantat, Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Monnet, X (corresponding author), Hop Bicetre, Serv Med Intens Reanimat, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France.	xavier.monnet@aphp.fr	Noel, Nicolas/AAK-3911-2021; DORTET, Laurent/D-5159-2014; Lai, Chistopher/ADS-7951-2022; Meyrignac, Olivier/AAT-2856-2020; Morin, Luc/AAU-1979-2021	DORTET, Laurent/0000-0001-6596-7384; Lai, Chistopher/0000-0001-5088-3364; Meyrignac, Olivier/0000-0002-9744-9095; Morin, Luc/0000-0001-6721-4677; Montani, David/0000-0002-9358-6922; MONNET, Xavier/0000-0001-6820-2678; Harrois, Anatole/0000-0002-5098-4656; Noel, Nicolas/0000-0003-4055-617X; Gasnier, Matthieu/0000-0003-4887-4025	Assistance Publique-Hopitaux de Paris	Assistance Publique-Hopitaux de Paris	This study was funded by Assistance Publique-Hopitaux de Paris.	BARCZAK P, 1988, BRIT J PSYCHIAT, V152, P698, DOI 10.1192/bjp.152.5.698; Beck A T, 1974, Mod Probl Pharmacopsychiatry, V7, P151; Blevins CA, 2015, J TRAUMA STRESS, V28, P489, DOI 10.1002/jts.22059; Boulding R, 2016, EUR RESPIR REV, V25, P287, DOI 10.1183/16000617.0088-2015; Couzin-Frankel J, 2020, SCIENCE, V368, P455, DOI 10.1126/science.368.6490.455; De Lorenzo R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239570; Dhont S, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01462-5; Dortet L, 2020, EMERG MICROBES INFEC, V9, P2212, DOI 10.1080/22221751.2020.1826892; Gentile S, 2003, EUR J CANCER CARE, V12, P58, DOI 10.1046/j.1365-2354.2003.00295.x; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Holland AE, 2014, EUR RESPIR J, V44, P1428, DOI 10.1183/09031936.00150314; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Jackson JC, 2014, LANCET RESP MED, V2, P369, DOI 10.1016/S2213-2600(14)70051-7; Levey AS, 2020, KIDNEY INT, V97, P1117, DOI 10.1016/j.kint.2020.02.010; Liepmann D., 2010, AUFMERKSAMKEITS KONZ; Mazza MG, 2020, BRAIN BEHAV IMMUN, V89, P594, DOI 10.1016/j.bbi.2020.07.037; Metral M, 2020, HIV MED, V21, P342, DOI 10.1111/hiv.12828; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Parker C., 2020, PSYCHOSOMATICS, DOI [10.1016/j.psym.2020.1010.1001, DOI 10.1016/J.PSYM.2020.1010.1001]; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Roussel M., 2016, BATTERIE GRECOGVASC; Shah AS, 2021, THORAX, V76, P402, DOI 10.1136/thoraxjnl-2020-216308; van den Borst B, 2021, CLIN INFECT DIS, V73, pE1089, DOI 10.1093/cid/ciaa1750; van Gassel RJJ, 2021, AM J RESP CRIT CARE, V203, P371, DOI 10.1164/rccm.202010-3823LE; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wei JP, 2020, J X-RAY SCI TECHNOL, V28, P383, DOI 10.3233/XST-200685; White PD, 1998, J PSYCHOSOM RES, V44, P269, DOI 10.1016/S0022-3999(97)00186-4; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhao YM, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100463	31	217	222	1	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	2021	325	15					1525	1534		10.1001/jama.2021.3331	http://dx.doi.org/10.1001/jama.2021.3331		MAR 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RQ8AS	33729425	Green Published, Bronze			2023-01-03	WOS:000630486200003
J	McDougal, L; Singh, A; Kumar, K; Dehingia, N; Barros, AJD; Ewerling, F; Atmavilas, Y; Raj, A				McDougal, Lotus; Singh, Abhishek; Kumar, Kaushalendra; Dehingia, Nabamallika; Barros, Aluisio J. D.; Ewerling, Fernanda; Atmavilas, Yamini; Raj, Anita			Planning for work: Exploring the relationship between contraceptive use and women's sector-specific employment in India	PLOS ONE			English	Article							LABOR-FORCE PARTICIPATION; DIRECTED ACYCLIC GRAPHS; QUALITATIVE FINDINGS; CHILD MARRIAGE; FERTILITY; HEALTH; IMPACT; EDUCATION; ETHIOPIA; STERILIZATION	While the health-related benefits of contraceptive use for women are well documented, potential social benefits, including enabling women's employment, have not been well researched. We examine the relationship between contraceptive use and women's employment in India, a country where both factors have remained relatively static over the past ten years. We use data from India's 2015-16 National Family Health Survey to test the association between current contraceptive use (none, sterilization, IUD, condom, pill, rhythm method or withdrawal) and current employment status (none, professional, clerical or sales, agricultural, services or production) with multivariable, multinomial regression; variable selection was guided by a directed acyclic graph. More than three-quarters of women in this sample were currently using contraception; sterilization was most common. Women who were sterilized or chose traditional contraception, relative to those not using contraception, were more likely to be employed in the agricultural and production sectors, versus not being employed (sterilization adjusted relative risk ratio [aRRR] = 1.5, p<0.001 for both agricultural and production sectors; rhythm aRRR = 1.5, p = 0.01 for agriculture; withdrawal aRRR = 1.5, p = 0.02 for production). In contrast, women with IUDs, compared to those who not using contraception, were more likely to be employed in the professional sector versus not being employed (aRRR = 1.9, p = 0.01). The associations between current contraceptive use and employment were heterogeneous across methods and sectors, though in no case was contraceptive use significantly associated with lower relative probabilities of employment. Policies designed to support women's access to contraception should consider the sector-specific employment of the populations they target.	[McDougal, Lotus; Dehingia, Nabamallika; Raj, Anita] Univ Calif San Diego, Sch Med, Ctr Gender Equ & Hlth, La Jolla, CA 92093 USA; [Singh, Abhishek; Kumar, Kaushalendra] Int Inst Populat Sci, Mumbai, Maharashtra, India; [Barros, Aluisio J. D.; Ewerling, Fernanda] Univ Fed Pelotas, Int Ctr Equ Hlth, Pelotas, RS, Brazil; [Atmavilas, Yamini] Bill & Melinda Gates Fdn, Delhi, India	University of California System; University of California San Diego; International Institute for Population Sciences; Universidade Federal de Pelotas	McDougal, L (corresponding author), Univ Calif San Diego, Sch Med, Ctr Gender Equ & Hlth, La Jolla, CA 92093 USA.	lmcdouga@ucsd.edu	Dehingia, Nabamallika/AAY-5588-2021	Dehingia, Nabamallika/0000-0003-1787-9050; Singh, Abhishek/0000-0001-6263-4410	Bill & Melinda Gates Foundation [OPP1179208]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	This work was supported by the Bill & Melinda Gates Foundation [OPP1179208] (PI: AR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Riyami Asya, 2004, Reprod Health Matters, V12, P144, DOI 10.1016/S0968-8080(04)23113-5; Almanza CH, 2018, DEMOGRAPHY, V55, P643, DOI 10.1007/s13524-018-0664-9; An P., 2019, REPROD HEALTH, V16, P1, DOI [10.1186/s12978-018-0662-9, DOI 10.1186/S12978-018-0662-9]; Arendal G, GENDER DIVISION LABO; Austin AE, 2019, CHILD ABUSE NEGLECT, V91, P78, DOI 10.1016/j.chiabu.2019.02.011; Bailey MJ, 2006, Q J ECON, V121, P289; Bhan N, 2019, J ADOLESCENT HEALTH, V65, P498, DOI 10.1016/j.jadohealth.2019.05.002; Black RE, 2016, LANCET, V388, P2811, DOI 10.1016/S0140-6736(16)00738-8; Blackstone SR, 2017, J BIOSOC SCI, V49, P423, DOI 10.1017/S0021932016000377; Bloom D., 2003, DEMOGRAPHIC DIVIDEND; Bloom DE, 2009, J ECON GROWTH, V14, P79, DOI 10.1007/s10887-009-9039-9; Blumenthal PD, 2018, CONTRACEPTION, V98, P215, DOI 10.1016/j.contraception.2018.04.019; Boyce SC, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1577-0; Bradley SEK, 2012, REVISING UNMET NEED; Chola L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130077; Chun H, 2002, APPL ECON LETT, V9, P631, DOI 10.1080/13504850110117850; Cleland J, 2012, LANCET, V380, P149, DOI 10.1016/S0140-6736(12)60609-6; Cohen SA., 2010, GUTTMACHER POLICY RE, V13, P12; Das S, 2015, 2015 14TH INTERNATIONAL CONFERENCE ON INFORMATION TECHNOLOGY (ICIT 2015), P221, DOI 10.1109/ICIT.2015.34; DaVanzo J, 2007, BJOG-INT J OBSTET GY, V114, P1079, DOI 10.1111/j.1471-0528.2007.01338.x; de Jong E, 2017, WORLD DEV, V90, P360, DOI 10.1016/j.worlddev.2016.10.012; de Oliveira IT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086654; Dehingia N, 2019, SSM-POPUL HLTH, V9, DOI 10.1016/j.ssmph.2019.100467; Department of Statistics ILO., 2018, DECENT WORK SUSTAINA; Directorate General of Employment Minstry of Labour and Employment., 2015, NATL CLASSIFICATION; Ewerling F, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.020434; Ferrant G., 2014, UNPAID CARE WORK MIS; Field E, 2017, CONTRACT NO WORKING; Finlay J, 2013, BIOGAS CHALLENGES EX; Finlay JE, 2021, WORLD DEV, V139, DOI 10.1016/j.worlddev.2020.105313; Finlay JE, 2018, MILBANK Q, V96, P300, DOI 10.1111/1468-0009.12326; Fletcher E, 2017, WOMEN WORK INDIA DES; Frost JJ, 2008, PERSPECT SEX REPRO H, V40, P94, DOI 10.1363/4009408; Galor O, 1996, AM ECON REV, V86, P374, DOI 10.3386/w4550; Ghule Mohan, 2015, Asian J Res Soc Sci Humanit, V5, P18, DOI 10.5958/2249-7315.2015.00132.X; Glassman A, 2016, CTR GLOBAL DEV; Government of Tamil Nadu , 2018, HLTH FAMILY WELFARE; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Gross T., 2017, ORG INVISIBLE STRATE; Hirway I, 2011, FEM ECON, V17, P67, DOI 10.1080/13545701.2011.622289; International Institute for Population Sciences,, 2017, NATL FAMILY HLTH SUR; International Institute for Population Sciences (IIPS) and Macro International, 2007, NATL FAMILY HLTH SUR, VI; International Labour Office, 2015, INSIGHTS WORKING CON; International Labour Organization, 2016, WORKPL STRESS COLL C; International Labour Organization Department of Statistics, 2013, CONTRACT NO ICLS1920; International Labour Organization (ILO), 2018, CAR WORK CAR JOBS FU; Irani L, 2021, ASIAN POPUL STUD, V17, P94, DOI 10.1080/17441730.2020.1778854; Islam Ahmed Zohirul, 2016, Int J MCH AIDS, V5, P92; James KS, 2011, SCIENCE, V333, P576, DOI 10.1126/science.1207969; Jha P, 2011, LANCET, V377, P1921, DOI 10.1016/S0140-6736(11)60649-1; John NA, 2020, FEM ECON, V26, P23, DOI 10.1080/13545701.2019.1632471; Jutting JP, 2008, J HUM DEV CAPABIL, V9, P65, DOI DOI 10.1080/14649880701811401; Khan ME, 1980, FERTILITY CONTROL IN, pXIV; Klasen S, 2015, WORLD BANK ECON REV, V29, P449, DOI 10.1093/wber/lhv003; Lahoti R, 2016, FEM ECON, V22, P168, DOI 10.1080/13545701.2015.1066022; Liu L, 2008, POP STUD-J DEMOG, V62, P191, DOI 10.1080/00324720801897796; Mammen K, 2000, J ECON PERSPECT, V14, P141, DOI 10.1257/jep.14.4.141; McClendon KA, 2018, CULT HEALTH SEX, V20, P799, DOI 10.1080/13691058.2017.1383513; McDougal L, 2020, SSM-POPUL HLTH, V12, DOI 10.1016/j.ssmph.2020.100688; McDougal L, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100414; McDougal L, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0631-z; McDougal L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171002; McDougal L, 2016, ASIA-PAC J PUBLIC HE, V28, P423, DOI 10.1177/1010539516654539; McIntosh C, 2016, 7901 WORLD BANK GROU; Ministry of Statistics and Programme Implementation Government of India., 2020, TIME USE INDIA 2019; Mwaikambo L, 2011, STUD FAMILY PLANN, V42, P67, DOI 10.1111/j.1728-4465.2011.00267.x; National Health Mission MoHFW Government of India, JAN SUR YOJ; National Statistics Office Government of India., 2019, ANN REPORT PERIODIC; OCONNOR JS, 1993, BRIT J SOCIOL, V44, P501, DOI 10.2307/591814; Office IL, 2018, WOM MEN INF EC STAT; Oxfam India, 2019, MIND GAP STATE EMPLO; Pallikadavath S, 2015, J BIOSOC SCI, V47, P75, DOI 10.1017/S002193201300059X; Poduval Jayita, 2009, Mens Sana Monogr, V7, P63, DOI 10.4103/0973-1229.41799; Prakash N, 2020, J ECON BEHAV ORGAN, V180, P494, DOI 10.1016/j.jebo.2020.10.017; Raj A, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6340-6; Raj Anita, 2015, Int J Gynaecol Obstet, V130 Suppl 3, pE56, DOI 10.1016/j.ijgo.2015.03.013; Raj A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106210; Raj A, 2013, INT J GYNECOL OBSTET, V121, P162, DOI 10.1016/j.ijgo.2012.12.011; Raj A, 2010, ARCH DIS CHILD, V95, P931, DOI 10.1136/adc.2009.178707; Reed E, 2016, MATERN CHILD HLTH J, V20, P1203, DOI 10.1007/s10995-016-1921-4; Rowland D., 2003, DEMOGRAPHIC METHODS; Rutstein SO, 2004, DHS COMP REPORTS NO; Saavala M, 1999, STUD FAMILY PLANN, V30, P288, DOI 10.1111/j.1728-4465.1999.t01-1-.x; Shakya HB, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08759-6; SHAPIRO D, 1994, STUD FAMILY PLANN, V25, P96, DOI 10.2307/2138087; Shrier I, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-70; Sundari S, 2020, INDIAN J LABOUR ECON, V63, P689, DOI 10.1007/s41027-020-00245-2; Textor J, 2016, INT J EPIDEMIOL, V45, P1887, DOI 10.1093/ije/dyw341; Thomas JJ, 2014, ECON POLIT WEEKLY, V49; Tsui AO, 2010, EPIDEMIOL REV, V32, P152, DOI 10.1093/epirev/mxq012; UN General Assembly, 2015, RESOLUTION ADOPTED G; World Bank, 2012, INCLUSIVE GREEN GROW; World Health Organization Department of Reproductive Health and Research Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs Knowledge for Health Project, 2018, FAMILY PLANNING GLOB; Wu XG, 2014, CHINESE SOCIOL REV, V46, P3, DOI 10.2753/CSA2162-0555460301; Yeakey MP, 2009, STUD FAMILY PLANN, V40, P205, DOI 10.1111/j.1728-4465.2009.00203.x; Zimmerman LA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218157	96	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2021	16	3							e0248391	10.1371/journal.pone.0248391	http://dx.doi.org/10.1371/journal.pone.0248391			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QX8JZ	33705471	gold, Green Published			2023-01-03	WOS:000629590400010
J	Quynh, HL; Bich, TNT; Hoang, LT; Erickson, VI; Padungtod, P				Huong Luu Quynh; Thuy Nguyen Thi Bich; Long Ta Hoang; Erickson, Vera Irene; Padungtod, Pawin			Quality testing of veterinary antimicrobial products used for livestock in Vietnam, 2018-2019	PLOS ONE			English	Article								Access to quality veterinary antimicrobial products contributes to efficient treatment of diseases in Vietnamese livestock and to reducing antimicrobial resistance (AMR). Poor quality antimicrobial drugs can lead to treatment failure, potentially influencing the inappropriate use of antimicrobials products, including increasing the dose, combining drugs, or changing to a broader spectrum antimicrobial. The objective of the study was to determine the actual concentration of antimicrobial active ingredient (AAI) in commercially available veterinary antimicrobial products as an indicator of their quality. A total of 144 veterinary antimicrobial products were purchased from randomly selected veterinary drug stores in 34 districts in eight provinces. For the qualitative analysis, we observed criteria linked to form, colour, and labelling information according to the Department of Animal Health regulations. For the quantitative analysis, high-performance liquid chromatography was used to determine the actual concentration of AAI in each sample. Of the 144 samples, 131 (91%) met the national standard of quality of being within +/- 10% of the labelled concentration. Ten antimicrobials (6.9%) contained less than half of the labelled content concentrations. Veterinary antimicrobial product quality control is an important part of addressing AMR. To support the national action plan to lower AMR, a veterinary drug quality control program should be implemented at all stages of the supply chain to assure high quality drugs and effective treatment of sick animals.	[Huong Luu Quynh; Thuy Nguyen Thi Bich] Natl Inst Vet Res, Hanoi, Vietnam; [Long Ta Hoang] Natl Ctr Vet Drugs Testing 1, Dept Anim Hlth, Hanoi, Vietnam; [Erickson, Vera Irene; Padungtod, Pawin] Vietnam Country Off, Food & Agr Org United Nat, Hanoi, Vietnam	Food & Agriculture Organization of the United Nations (FAO)	Quynh, HL (corresponding author), Natl Inst Vet Res, Hanoi, Vietnam.	lqhuongvet@gmail.com		Luu, Huongq/0000-0003-0426-6132; Erickson, Vera Irene/0000-0001-7443-2330	Fleming Fund through the Food and Agriculture Organization of the United Nations [LOA-FAVIE.2018.34-GCP. GLO.710.UK]	Fleming Fund through the Food and Agriculture Organization of the United Nations	This is a work done under Letter of Agreement (LOA2), funded the Fleming Fund through the Food and Agriculture Organization of the United Nations (LOA-FAVIE.2018.34-GCP. GLO.710.UK).	Clifford K, 2018, B WORLD HEALTH ORGAN, V96, P662, DOI 10.2471/BLT.18.209585; Coyne L, 2019, ANTIBIOTICS-BASEL, V8, DOI 10.3390/antibiotics8010033; Tran KC, 2018, AQUACULTURE, V482, P167, DOI 10.1016/j.aquaculture.2017.09.038; Ministry of Agriculture and Rural Development, 2003, NG K C PH P L U H NH; Yen NTP, 2019, VET MED SCI, V5, P512, DOI 10.1002/vms3.189; Nhung NT, 2016, ANTIBIOTICS-BASEL, V5, DOI 10.3390/antibiotics5040037; Takele Beyene, 2016, Journal of Veterinary Science and Technology, V7, P285; Tran MP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124267	8	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2021	16	3							e0247337	10.1371/journal.pone.0247337	http://dx.doi.org/10.1371/journal.pone.0247337			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QS6AU	33657144	gold, Green Published			2023-01-03	WOS:000625981500063
J	Vourc'h, M; Garret, C; Gacouin, A; Lacherade, JC; Jonas, M; Klouche, K; Ferrandiere, M; Jaber, S; Flet, L; Dailly, E; Pouplet, C; Maamar, A; Reignier, J; Roquilly, A; Feuillet, F; Mahe, PJ; Asehnoune, K				Vourc'h, Mickael; Garret, Charlotte; Gacouin, Arnaud; Lacherade, Jean-Claude; Jonas, Maud; Klouche, Kada; Ferrandiere, Martine; Jaber, Samir; Flet, Laurent; Dailly, Eric; Pouplet, Caroline; Maamar, Adel; Reignier, Jean; Roquilly, Antoine; Feuillet, Fanny; Mahe, Pierre-Joachim; Asehnoune, Karim		BACLOREA Study Grp	Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SAMPLE-SIZE RECALCULATION; CRITICALLY-ILL; PRACTICE GUIDELINES; DELIRIUM; MANAGEMENT; ICU; PREVENTION; WITHDRAWAL; SCORE; MODEL	IMPORTANCE Unhealthy alcohol use can lead to agitation in the intensive care unit (ICU). OBJECTIVE To assess whether high-dose baclofen reduces agitation-related events compared with placebo in patients with unhealthy alcohol use receiving mechanical ventilation. DESIGN, SETTINGS, AND PARTICIPANTS This phase 3, double-blind, placebo-controlled, randomized clinical trial conducted in 18 ICUs in France recruited adults receiving mechanical ventilation who met criteria for unhealthy alcohol use. Patients were enrolled from June 2016 to February 2018; the last follow-up was in May 2019. INTERVENTIONS Baclofen (n = 159), adjusted from 50 to 150 mg per day based on estimated glomerular filtration rate, or placebo (n = 155) during mechanical ventilation up to a maximum of 15 days before gradual dose reduction over 3 to 6 days. MAIN OUTCOMES AND MEASURES The primary end point was the percentage of patients with at least 1 agitation-related event over the treatment period. Secondary outcomes included duration of mechanical ventilation, length of ICU stay, and 28-day mortality. RESULTS Among 314 patients who were randomized (mean age, 57 years; 60 [17.2%] women), 313 (99.7%) completed the trial. There was a statistically significant decrease in the percentage of patients who experienced at least 1 agitation-related event in the baclofen group vs the placebo group (31 [19.7%] vs 46 [29.7%]; difference, -9.93%[95% CI, -19.45% to -0.42%]; adjusted odds ratio, 0.59 [95% CI, 0.35-0.99]). Of 18 prespecified secondary end points, 14 were not significantly different. Compared with the placebo group, the baclofen group had a significantly longer median length of mechanical ventilation (9 vs 8 days; difference, 2.00 [95% CI, 0.00-3.00]; hazard ratio [HR] for extubation, 0.76 [95% CI, 0.60-0.97]) and stay in the ICU (14 vs 11 days; difference, 2.00 [95% CI, 0.00-4.00]; HR for discharge, 0.70 [95% CI, 0.54-0.90]). At 28 days, there was no significant difference in mortality in the baclofen vs placebo group (25.3% vs 21.6%; adjusted odds ratio, 1.24 [95% CI, 0.72-2.13]). Delayed awakening (no eye opening at 72 hours after cessation of sedatives and analgesics) occurred in 14 patients (8.9%) in the baclofen group vs 3 (1.9%) in the placebo group. CONCLUSIONS AND RELEVANCE Among patients with unhealthy alcohol use receiving mechanical ventilation, treatment with high-dose baclofen, compared with placebo, resulted in a statistically significant reduction in agitation-related events. However, considering the modest effect and the totality of findings for the secondary end points and adverse events, further research is needed to determine the possible role of baclofen in this setting and to potentially optimize dosing.	[Vourc'h, Mickael; Roquilly, Antoine; Mahe, Pierre-Joachim; Asehnoune, Karim] Ctr Hosp Univ Nantes, Serv Anesthesie Reanimat Chirurg, Nantes, France; [Garret, Charlotte; Gacouin, Arnaud; Maamar, Adel; Reignier, Jean] Ctr Hosp Univ Nantes, Serv Med Intens Reanimat, Nantes, France; [Lacherade, Jean-Claude; Pouplet, Caroline] Ctr Hosp Dept Vendee, Serv Med Intens Reanimat, La Roche Sur Yon, France; [Jonas, Maud] Ctr Hosp Gen St Nazaire, Serv Med Intens Reanimat, St Nazaire, France; [Klouche, Kada] Ctr Hosp Univ Montpellier, Serv Med Intens Reanimat, Montpellier, France; [Ferrandiere, Martine] Ctr Hosp Univ Tours, Serv Anesthesie Reanimat, Tours, France; [Jaber, Samir] Ctr Hosp Univ Montpellier, Serv Anesthesie Reanimat, Montpellier, France; [Flet, Laurent] Ctr Hosp Univ Nantes, Serv Pharm, Nantes, France; [Dailly, Eric] Ctr Hosp Univ Nantes, Serv Pharmacol Clin, Nantes, France; [Feuillet, Fanny] Ctr Hosp Univ Nantes, Plateforme Methodol & Biostat, Nantes, France; [Feuillet, Fanny] Univ Nantes, INSERM, SPHERE U1246, Nantes, France	Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; CHD Vendee; Universite de Montpellier; CHU de Montpellier; CHU Tours; Universite de Montpellier; CHU de Montpellier; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Asehnoune, K (corresponding author), CHU Nantes, Serv Anesthesie Reanimat, 1 Pl Alexis Ricordeau, F-44093 Nantes 1, France.	karim.asehnoune@chu-nantes.fr	FLET, Laurent/X-1192-2019	FLET, Laurent/0000-0001-8305-7085; Roquilly, Antoine/0000-0002-1029-6242; Maamar, Adel/0000-0001-8352-3613	French Ministry of Health (Interregion French Clinical Hospital Research Program) [PHRCI 2014-API14/N/096]; Nantes University Hospital	French Ministry of Health (Interregion French Clinical Hospital Research Program); Nantes University Hospital	The BACLOREA study was supported by the French Ministry of Health (Interregion French Clinical Hospital Research Program, PHRCI 2014-API14/N/096). Nantes University Hospital sponsored the study.	[Anonymous], 2020, NAT SURV DRUG US HLT; [Anonymous], 2014, TEMP REC US BACL ALC; Awissi DK, 2013, INTENS CARE MED, V39, P16, DOI 10.1007/s00134-012-2758-y; Boulain T, 1998, AM J RESP CRIT CARE, V157, P1131, DOI 10.1164/ajrccm.157.4.9702083; Curry SJ, 2018, JAMA-J AM MED ASSOC, V320, P1899, DOI 10.1001/jama.2018.16789; de Beaurepaire Renaud, 2012, Front Psychiatry, V3, P103, DOI 10.3389/fpsyt.2012.00103; Devlin JW, 2018, CRIT CARE MED, V46, pE825, DOI 10.1097/CCM.0000000000003299; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Friede T, 2004, PHARM STAT, V3, P269, DOI 10.1002/pst.140; Friede T, 2006, BIOMETRICAL J, V48, P537, DOI 10.1002/bimj.200510238; Gacouin A, 2014, CRIT CARE MED, V42, P860, DOI 10.1097/CCM.0000000000000041; Girard TD, 2018, NEW ENGL J MED, V379, P2506, DOI 10.1056/NEJMoa1808217; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Griswold MG, 2018, LANCET, V392, P1015, DOI [10.1016/s0140-6736(18)31310-2, 10.1016/S0140-6736(18)31310-2, 10.1136/bmj.l94]; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kuan Y, 2005, NEPHROL DIAL TRANSPL, V20, P2394, DOI 10.1093/ndt/gfi076; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Long AC, 2014, INTENS CARE MED, V40, P820, DOI 10.1007/s00134-014-3306-8; Mackenbach JP, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001909; Naudet F, 2018, LANCET PSYCHIAT, V5, P961, DOI 10.1016/S2215-0366(18)30419-X; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Riker RR, 2013, AM J CRIT CARE, V22, P153, DOI 10.4037/ajcc2013480; Saitz R, 2005, NEW ENGL J MED, V352, P596, DOI 10.1056/NEJMcp042262; Schuckit MA, 2014, NEW ENGL J MED, V371, P2109, DOI 10.1056/NEJMra1407298; Schulz M, 2012, CRIT CARE, V16, DOI 10.1186/cc11441; Siegel MD, 2003, CLIN CHEST MED, V24, P713, DOI 10.1016/S0272-5231(03)00104-7; Spillane S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.21451; Stewart Donald, 2019, J Intensive Care Soc, V20, P208, DOI 10.1177/1751143718787748; Thibault, 2020, ANAESTH CRIT CARE ME, V5, DOI [10.23880/accmj-16000170, DOI 10.23880/ACCMJ-16000170]; van den Boogaard M, 2018, JAMA-J AM MED ASSOC, V319, P680, DOI 10.1001/jama.2018.0160; Vourc'h M, 2019, DATA BRIEF, V25, DOI 10.1016/j.dib.2019.104231; Vourc'h M, 2019, PROG NEURO-PSYCHOPH, V92, P450, DOI 10.1016/j.pnpbp.2019.02.016; Vourc'h M, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1539-2; Wan SZ, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/5193028; Wassenaar A, 2015, INTENS CARE MED, V41, P1048, DOI 10.1007/s00134-015-3777-2	35	3	3	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2021	325	8					732	741		10.1001/jama.2021.0658	http://dx.doi.org/10.1001/jama.2021.0658			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM7LT	33620407	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000621957400021
J	Fatur, K; Kreft, S				Fatur, Karsten; Kreft, Samo			Nixing the nightshades: Traditional knowledge of intoxicating members of the Solanaceae among hallucinogenic plant and mushroom users in Slovenia	PLOS ONE			English	Article								Anticholinergic plants of the family Solanaceae have a long history of use as medicines, poisons, and recreational drugs. Though they were the intoxicating substances of choice throughout Europe for centuries, their use for these purposes has declined with the globalisation of other recreational drugs. The present study sought to examine the level of knowledge surrounding these plants among individuals who had used other hallucinogenic plants or mushrooms in Slovenia. Participants were questioned in regards to the anticholinergic Solanaceae that are known to grow wild in Slovenia: Atropa belladonna L., Datura stramonium L., Hyoscyamus niger L., and Scopolia carniolica L. As expected, only a small number of individuals had any substantial knowledge of these plants, and fewer still had used them; some were even unfamiliar with any of these plants. Knowledge of toxicity generally arose from family members, while books and the internet played prominent roles in regards to use knowledge. Knowledge of the plants was vastly varied, with many individuals confusing the plants for others, especially other members of the Solanaceae. Ultimately, a small group of individuals had the largest body of knowledge of these plants, though this was linked with university studies rather than traditional uses. Knowledge of the intoxicating Solanaceae has been largely lost in Slovenia among users of other botanical hallucinogens, likely due to the various dangers their use poses and the undesirable effects they often cause.	[Fatur, Karsten; Kreft, Samo] Univ Ljubljani, Fak Farmacijo, Ljubljana, Slovenia	University of Ljubljana	Fatur, K (corresponding author), Univ Ljubljani, Fak Farmacijo, Ljubljana, Slovenia.	karsten.fatur@gmail.com		Fatur, Karsten/0000-0002-4557-2999				Aikman J, 1827, HIST SCOTLAND TRANSL, VI; Arroo RRJ., 2007, TRANSGENIC CROPS 6, V61, P2; Baraniecka-Olszewska K, 2016, ANTHROPOL J EUR CULT, V25, P118, DOI 10.3167/ajec.2016.250108; Carruthers DMJ, 2015, MOSAIC, V48, P119, DOI 10.1353/mos.2015.0025; Cilensek M, 1892, NA E KODLJIVE RASTLI; Daunay MC, 2007, ACTA HORTIC, P59, DOI 10.17660/ActaHortic.2007.745.3; Dioscorides, 2000, MATERIA MED; Falkowska U., 2018, Polish Journal of Public Health, V128, P19; Fatur K, 2018, POMEGRANATE; Fatur K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245022; Fatur K, 2020, ECON BOT, V74, P140, DOI 10.1007/s12231-020-09498-w; Fatur K, 2019, J ETHNOPHARMACOL, V244, DOI 10.1016/j.jep.2019.112151; Geeta R, 2007, J BIOSCIENCES, V32, P1227, DOI 10.1007/s12038-007-0132-y; Gunda B, 1967, KROEBER ANTHR SOC SP, V1, P1; HOCKING G. M., 1947, Economic Botany, V1, P306, DOI 10.1007/BF02858575; Lenclud G, 1987, TERRAIN, V9, P1; Leonti M, 2011, J ETHNOPHARMACOL, V134, P542, DOI 10.1016/j.jep.2011.01.017; Leporatti ML, 2007, ETHNOBIOLOGICA, V64, P51; Diaz JL, 2010, PHENOMENOL COGN SCI, V9, P159, DOI 10.1007/s11097-010-9157-z; Maheshwari N. O., 2013, Journal of Medicinal Plants Research, V7, P2885; Merlin MD, 2003, ECON BOT, V57, P295, DOI 10.1663/0013-0001(2003)057[0295:AEFTTO]2.0.CO;2; Ostling M, 2016, MAGIC RITUAL WITCHCR, V11, P30, DOI 10.1353/mrw.2016.0008; Penicka S, 2008, DARK SIDE PROC SEVEN, P181; Piccillo GA, 2006, INT J CLIN PRACT, V60, P492, DOI 10.1111/j.1368-5031.2006.00864.x; Pliny the Elder, 1855, NAT HIST; Porta G, 1658, NATURAL MAGICK; Ruck CAP, 2015, HISTORY OF TOXICOLOGY AND ENVIRONMENTAL HEALTH: TOXICOLOGY IN ANTIQUITY, VOL II, P116, DOI 10.1016/B978-0-12-801506-3.00012-1; Sanz C, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00007; Slaughter RJ, 2012, NEW ZEAL MED J, V125, P87; Stevanovic ZD., 2014, ETHNOBOTANY BIOCULTU, P229; Stika HP, 1996, VEG HIST ARCHAEOBOT, V5, P81, DOI 10.1007/BF00189437; Tareau MA, 2017, J ETHNOPHARMACOL, V203, P200, DOI 10.1016/j.jep.2017.03.031; Van Bingen H, 2001, PHYS VARIOUS NATURAL; Waniakowa J., 2007, MANDRAGORA BELLADONN, P124	34	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2021	16	2							e0247688	10.1371/journal.pone.0247688	http://dx.doi.org/10.1371/journal.pone.0247688			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QO3ZL	33617573	Green Published, gold			2023-01-03	WOS:000623082400042
J	Wachterman, MW; Sommers, BD				Wachterman, Melissa W.; Sommers, Benjamin D.			Dying Poor in the US - Disparities in End-of-Life Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									[Wachterman, Melissa W.] VA Boston Healthcare Syst, 150 South Huntington Ave, Boston, MA 02130 USA; [Wachterman, Melissa W.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Sommers, Benjamin D.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Sommers, Benjamin D.] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Wachterman, MW (corresponding author), VA Boston Healthcare Syst, 150 South Huntington Ave, Boston, MA 02130 USA.	melissa.wachterman@alumni.tufts.edu							0	7	7	3	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2021	325	5					423	424		10.1001/jama.2020.26162	http://dx.doi.org/10.1001/jama.2020.26162			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC6JP	33528526	Bronze			2023-01-03	WOS:000614941900003
J	Skender, K; Singh, V; Stalsby-Lundborg, C; Sharma, M				Skender, Kristina; Singh, Vivek; Stalsby-Lundborg, Cecilia; Sharma, Megha			Trends and patterns of antibiotic prescribing at orthopedic inpatient departments of two private-sector hospitals in Central India: A 10-year observational study	PLOS ONE			English	Article								Background Frequent antibiotic prescribing in departments with high infection risk like orthopedics prominently contributes to the global increase of antibiotic resistance. However, few studies present antibiotic prescribing patterns and trends among orthopedic inpatients. Aim To compare and present the patterns and trends of antibiotic prescription over 10 years for orthopedic inpatients in a teaching (TH) and a non-teaching hospital (NTH) in Central India. Methods Data from orthopedic inpatients (TH-6446; NTH-4397) were collected using a prospective cross-sectional study design. Patterns were compared based on the indications and corresponding antibiotic treatments, mean Defined Daily Doses (DDD)/1000 patient-days, adherence to the National List of Essential Medicines India (NLEMI) and the World Health Organization Model List of Essential Medicines (WHOMLEM). Antibiotic prescriptions were analyzed separately for the operated and the non-operated inpatients. Linear regression was used to analyze the time trends of antibiotic prescribing; in total through DDD/1000 patient-days and by antibiotic groups. Results Third generation cephalosporins were the most prescribed antibiotic class (TH-39%; NTH-65%) and fractures were the most common indications (TH-48%; NTH-48%). Majority of the operated inpatients (TH-99%; NTH-97%) were prescribed pre-operative prophylactic antibiotics. The non-operated inpatients were also prescribed antibiotics (TH-40%; NTH-75%), although few of them had infectious diagnoses (TH-8%; NTH-14%). Adherence to the NLEMI was lower (TH-31%; NTH-34%) than adherence to the WHOMLEM (TH-65%; NTH-62%) in both hospitals. Mean DDD/1000 patient-days was 16 times higher in the TH (2658) compared to the NTH (162). Total antibiotic prescribing increased over 10 years (TH-beta= 3.23; NTH-beta = 1.02). Conclusion Substantial number of inpatients were prescribed antibiotics without clear infectious indications. Adherence to the NLEMI and the WHOMLEM was low in both hospitals. Antibiotic use increased in both hospitals over 10 years and was higher in the TH than in the NTH. The need for developing and implementing local antibiotic prescribing guidelines is emphasized.	[Skender, Kristina; Stalsby-Lundborg, Cecilia; Sharma, Megha] Karolinska Inst, Dept Global Publ Hlth Hlth Syst & Policy, Stockholm, Sweden; [Singh, Vivek] Ruxmaniben Deepchand Med Coll, Dept Orthoped, Ujjain, Madhya Pradesh, India; [Sharma, Megha] Ruxmaniben Deepchand Gardi Med Coll, Dept Pharmacol, Ujjain, Madhya Pradesh, India	Karolinska Institutet	Sharma, M (corresponding author), Karolinska Inst, Dept Global Publ Hlth Hlth Syst & Policy, Stockholm, Sweden.; Sharma, M (corresponding author), Ruxmaniben Deepchand Gardi Med Coll, Dept Pharmacol, Ujjain, Madhya Pradesh, India.	meghasharma27@rediffmail.com	Sharma, Megha/AAJ-1119-2021	Sharma, Megha/0000-0001-9165-9393; Stalsby Lundborg, Cecilia/0000-0001-6525-1861; Skender, Kristina/0000-0003-3511-0202	Swedish Research Council (Vetenskapsradet) [K2007-70X-20514-01-3, K2010-396-70X-20514-04-3, 201701327]; Asia Link [348-2006-6633]; Karolinska Institutet Foundation [2019-01843]; Elisabeth and Alfred Ahlqvist's Foundation 2019 from Apotekarsocieteten, Sweden	Swedish Research Council (Vetenskapsradet)(Swedish Research Council); Asia Link; Karolinska Institutet Foundation(Karolinska Institutet); Elisabeth and Alfred Ahlqvist's Foundation 2019 from Apotekarsocieteten, Sweden	The study was funded by the Swedish Research Council (Vetenskapsradet; K2007-70X-20514-01-3, K2010-396-70X-20514-04-3, 201701327) and Asia Link (348-2006-6633). KS is the recipient of scholarships by Karolinska Institutet Foundation 2019-01843 and Elisabeth and Alfred Ahlqvist's Foundation 2019 from Apotekarsocieteten, Sweden. MS is the recipient of Erasmus Mundus Lot-15. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azar FM., 2017, CAMPBELLS OPERATIVE, P3526; Bryson DJ, 2016, BONE JOINT J, V98B, P1014, DOI 10.1302/0301-620X.98B8.37359; Chandy SJ, 2014, J INFECT DEV COUNTR, V8, P1096, DOI 10.3855/jidc.4745; Cohen ME, 2017, J AM COLL SURGEONS, V225, P631, DOI 10.1016/j.jamcollsurg.2017.08.010; Dhammi IK, 2015, INDIAN J ORTHOP, V49, P373, DOI 10.4103/0019-5413.159556; Dixit A, 2019, INDIAN J COMMUN MED, V44, P4, DOI 10.4103/ijcm.IJCM_217_18; Gandra S, 2019, CLIN INFECT DIS, V69, P563, DOI 10.1093/cid/ciy955; Hickson CJ, 2015, BONE JOINT RES, V4, P181, DOI 10.1302/2046-3758.411.2000432; Holloway Kathleen Anne, 2011, Expert Rev Clin Pharmacol, V4, P335, DOI 10.1586/ecp.11.14; Hyndman RJ, 2019, OTEXTS, V3rd; Juno AA, 2019, LAT AM J PHARM, V38, P1366; Kim B, 2020, KOREAN J INTERN MED, V35, P703, DOI 10.3904/kjim.2017.332; Klein EY, 2018, P NATL ACAD SCI USA, V115, pE3463, DOI 10.1073/pnas.1717295115; Li BY, 2018, J ORTHOP RES, V36, P22, DOI 10.1002/jor.23656; Lundborg CS, 2017, BMJ-BRIT MED J, V358, P42, DOI 10.1136/bmj.j2440; Rodriguez-Merchan E-C, COMPLEX FRACTURES LI; Shallcross LJ, 2014, BRIT J GEN PRACT, V64, P604, DOI 10.3399/bjgp14X682561; Sharma M, PLOS ONE; Sharma M, 2015, INFECT DIS-NOR, V47, P302, DOI 10.3109/00365548.2014.988747; Sharma M, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-155; Solanki N, 2019, ARCH PHARM PRACT, V10, P114; The Core-Committee, 2015, NAT LIST ESS MED 201; Uckay I, 2013, J HOSP INFECT, V84, P5, DOI 10.1016/j.jhin.2012.12.014; World Health Organization, 2018, WHO REP SURV ANT CON; World Health Organization, 2019, MENT HOLIST HLTH SOM; World Health Organization, 2003, INTRO DRUG UTILIZATI; World Health Organization Collaborating Centre for Drug Statistics Methodology, 2020, ATC CLASS IND DDDS	27	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2021	16	1							e0245902	10.1371/journal.pone.0245902	http://dx.doi.org/10.1371/journal.pone.0245902			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA9GX	33503028	Green Published, gold			2023-01-03	WOS:000613751800034
J	Ni, YN; Wang, T; Liang, BM; Liang, ZA				Ni, Yue-Nan; Wang, Ting; Liang, Bin-miao; Liang, Zong-An			The independent factors associated with oxygen therapy in COVID-19 patients under 65 years old	PLOS ONE			English	Article							OUTCOMES	Background The number of hospitalized young coronavirus disease 2019 (COVID-19) patients has increased significantly. However, specific data about COVID-19 patients under 65 years old who are admitted to the hospital are scarce. Methods The COVID-19 patients under 65 years old who were admitted to the hospital in Sichuan Province, Renmin Hospital of Wuhan University, and Wuhan Red Cross Hospital were included in this study. Demographic information, laboratory data and clinical treatment courses were extracted from electronic medical records. Risk factors associated with oxygen therapy were explored. Results Eight hundred thirty-three COVID-19 patients under 65 years old were included. Of the included patients, 29.4% had one or more comorbidities. Oxygen therapy was required in 63.1% of these patients, and the mortality was 2.9% among the oxygen therapy patients. Fever (odds ratio [OR] 2.072, 95% confidence interval [CI] 1.312-3.271, p = 0.002), dys-pnea (OR 2.522, 95% CI 1.213-5.243, p = 0.013), chest distress (OR 2.278, 95% CI 1.160-4.473, p = 0.017), elevated respiratory rate (OR 1.114, 95% CI 1.010-1.228, p = 0.031), and decreased albumin (OR 0.932, 95% CI 0.880-0.987, p = 0.016) and globulin levels (OR 0.929, 95% 0.881-0.980, p = 0.007) were independent factors related to oxygen therapy. Conclusions Oxygen therapy is highly required in COVID-19 patients under 65 years old who are admitted to the hospital, but the success rate is high. Respiratory failure-related symptoms, elevated respiratory rate, low albumin and globulin levels, and fever at admission are independent risk factors related to the requirement of oxygen.	[Ni, Yue-Nan; Wang, Ting; Liang, Bin-miao; Liang, Zong-An] Sichuan Univ, Dept Resp & Crit Care, West China Sch Med, Chengdu, Peoples R China; [Ni, Yue-Nan; Wang, Ting; Liang, Bin-miao; Liang, Zong-An] Sichuan Univ, West China Hosp, Chengdu, Peoples R China	Sichuan University; Sichuan University	Liang, BM; Liang, ZA (corresponding author), Sichuan Univ, Dept Resp & Crit Care, West China Sch Med, Chengdu, Peoples R China.	liangbinmiao@163.com; liangzatg@126.com			National Key Research and Development Program of China [2016YFC1304303]; Sichuan Science and Technology Agency Grant [2019YFS0033]; Sichuan Science and Technology Project [2020YFS0005]	National Key Research and Development Program of China; Sichuan Science and Technology Agency Grant; Sichuan Science and Technology Project	This study was partly supported by the National Key Research and Development Program of China (2016YFC1304303), awarded to Zong-An Liang, and the Sichuan Science and Technology Agency Grant (2019YFS0033), awarded to BinMiao Liang and Sichuan Science and Technology Project (2020YFS0005), awarded to Ting Wang. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alwarawrah Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01055; [Anonymous], 2020, RECENT INCREASE COVI; Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398; Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X; Catteau L, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106144; Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004; Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951; De Vito A, 2020, EUR REV MED PHARMACO, V24, P7861, DOI 10.26355/eurrev_202007_22291; Duan K, 2020, P NATL ACAD SCI USA, V117, P9490, DOI 10.1073/pnas.2004168117; Edalatifard M, 2020, INTRAVENOUS METHYLPR; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Griffin DE, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100282; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020; Guarneri C, 2021, LANCET INFECT DIS, V21, P24, DOI 10.1016/S1473-3099(20)30402-3; Hasday JD, 2000, CELL STRESS CHAPERON, V5, P471, DOI 10.1379/1466-1268(2000)005<0471:FATHSR>2.0.CO;2; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Kassambara A, 2020, INFECT DIS-NOR, DOI [DOI 10.1093/CID/CIAA344, DOI 10.1093/cid/ciaa344]; Kim S, 2017, AM SURGEON, V83, P1220; Li Y, 2021, HISTOPATHOLOGY, V78, P542, DOI 10.1111/his.14249; Lu GG, 2020, CLIN CHIM ACTA, V508, P98, DOI 10.1016/j.cca.2020.04.034; Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202; Neuraz A, 2015, CRIT CARE MED, V43, P1587, DOI 10.1097/CCM.0000000000001015; Paliogiannis P, 2020, J INFECT DEV COUNTR, V14, P685, DOI 10.3855/jidc.12879; Richardson S, 2020, JAMA; Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003; Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3; Vaira LA, 2020, HEAD NECK-J SCI SPEC, V42, P1560, DOI 10.1002/hed.26269; Vaira LA, 2020, HEAD NECK-J SCI SPEC, V42, P1252, DOI 10.1002/hed.26204; Wang C, 2018, LANCET, V391, P1706, DOI [10.1016/S0140-6736(18)30841-9, 10.1016/s0140-6736(18)30841-9]; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xie J, 2020, MAYO CLIN PROC, V95, P1138, DOI 10.1016/j.mayocp.2020.04.006; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zinellu A, 2020, RITIS RATIO PROGNOST	35	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2021	16	1							e0245690	10.1371/journal.pone.0245690	http://dx.doi.org/10.1371/journal.pone.0245690			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ7OB	33481912	gold, Green Published			2023-01-03	WOS:000612929300100
J	Fernandes, LDM; Lansky, S; Passos, HR; Bozlak, CT; Shaw, BA				Fernandes, Luisa da Matta Machado; Lansky, Sonia; Passos, Hozana Reis; Bozlak, Christine T.; Shaw, Benjamin A.			Brazilian women's use of evidence-based practices in childbirth after participating in the Senses of Birth intervention: A mixed-methods study	PLOS ONE			English	Article							PLANNED BEHAVIOR; SELF-EFFICACY; HEALTH-CARE; MATERNITY CARE; DELIVERY; IMPLEMENTATION; CHALLENGES; ADOPTION; LABOR; EDUCATION	Brazil has a cesarean rate of 56% and low use of Intrapartum Evidence-based Practices (IEBP) of 3.4%, reflecting a medically centered and highly interventionist maternal health care model. The Senses of Birth (SoB) is a health education intervention created to promote normal birth, use of EBP, and reduce unnecessary c-sections. This study aimed to understand the use of intrapartum EBP by Brazilian women who participated in the SoB intervention. 555 women answered the questionnaire between 2015 and 2016. Bivariate analysis and ANOVA test were used to identify if social-demographic factors, childbirth information, and perceived knowledge were associated with the use of EBP. A qualitative analysis was performed to explore women's experiences. Research participants used the following EBP: birth plan (55.2%), companionship during childbirth (81.6%), midwife care (54.2%), freedom of mobility during labor (57.7%), choice of position during delivery (57.2%), and non-pharmacological pain relief methods (74.2%). Doula support was low (26.9%). Being a black woman was associated with not using a birth plan or having doula support. Women who gave birth in private hospitals were more likely not to use the EBP. Barriers to the use of EBP identified by women were an absence of individualized care, non-respect for their choices or provision of EBP by health care providers, inadequate structure and ambiance in hospitals to use EBP, and rigid protocols not centered on women's needs. The SoB intervention was identified as a potential facilitator. Women who used EBP described a sense of control over their bodies and perceived self-efficacy to advocate for their chosen practices. Women saw the strategies to overcome barriers as a path to become their childbirth protagonist. Health education is essential to increase the use of EBP; however, it should be implemented combined with changes in the maternal care system, promoting woman-centered and evidence-based models.	[Fernandes, Luisa da Matta Machado] Fundacao Oswaldo Cruz FIOCRUZ, Inst Rene Rachou, Belo Horizonte, MG, Brazil; [Lansky, Sonia; Passos, Hozana Reis] Dept Hlth, Belo Horizonte, MG, Brazil; [Bozlak, Christine T.; Shaw, Benjamin A.] SUNY Albany, Sch Publ Hlth, Dept Hlth Policy Management & Behav, Albany, NY USA	Fundacao Oswaldo Cruz; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Fernandes, LDM (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Rene Rachou, Belo Horizonte, MG, Brazil.	luisa@mattamachado.org	da Matta Machado Fernandes, Luisa/ABG-9429-2021	da Matta Machado Fernandes, Luisa/0000-0002-5440-7928; Reis Passos, Hozana/0000-0002-9845-593X	National Council of Technological and Scientific Development (CNPq) [05/2013]; Ministry of Health [05/2013]; Bill and Melinda Gates Foundation [05/2013]; Pan-American Health Organization [05/2013]; Funding Agency of the State of Minas Gerais (FAPEMIG) [05/2013]	National Council of Technological and Scientific Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Ministry of Health; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Pan-American Health Organization; Funding Agency of the State of Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG))	This work was supported by funding from a group of organizations list bellow, part of the call MCTI/CNPq/MS/SCTIE/Decit/Fundacao Bill e Melinda Gates N o 05/2013 Organizations: National Council of Technological and Scientific Development (CNPq)-http://www.cnpq.br/web/guest/fomento-tecnologico, -Ministry of Health https://www.saude.gov.br/trabalho-educacao-e-qualificacao/gestao-e-regulacao-do-trabalho-emsaude/premio-inovasus, -Bill and Melinda Gates Foundation -https://www.gatesfoundation.org/, Pan-American Health Organization -https://www.paho.org/bra/, -Funding Agency of the State of Minas Gerais (FAPEMIG) -https://fapemig.br/pt/. The funding was directed to implement the health education intervention and data collection. Authors did not receive personal funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agencia Nacional de Saude Suplementar (ANS),, 2017, BR SET SUPL 2019 TAX; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ajzen I., 2012, DEMOGR RES, V29; Ajzen I, 2011, PSYCHOL HEALTH, V26, P1113, DOI 10.1080/08870446.2011.613995; [Anonymous], 1985, LANCET, V2, P436; Benoit C., 2007, J MENT HEALTH, V16, P719, DOI [10.1080/09638230701506846, DOI 10.1080/09638230701506846]; Berghella V, 2008, AM J OBSTET GYNECOL, V199, P445, DOI 10.1016/j.ajog.2008.06.093; Boatin AA, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k55; BRASIL, 2017, MINISTERIO SAUDE SEC; BRASIL, 2011, PORTARIA N 1459 24 J, P1; BRASIL Lei., 1990, DISPOE CONDICOES PRO, P1; BRASIL "Ministerio da Saude, 2019, SVS INFORMA O AN LIS; BRASIL Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia de Doencas e Agravos Nao Transmissiveis e Promocao da Saude, 2015, SAUDE BRASIL 2014 AN; Brixval CS, 2016, SEX REPROD HEALTHC, V10, P32, DOI 10.1016/j.srhc.2016.03.003; Cabral FB, 2013, REV ESC ENFERM USP, V47, P281, DOI 10.1590/S0080-62342013000200002; Carlsson IM, 2015, MIDWIFERY, V31, P1000, DOI 10.1016/j.midw.2015.05.005; Castro Jamile Claro de, 2005, Rev. Latino-Am. Enfermagem, V13, P960; Cavalcanti Pauline Cristine da Silva, 2013, Physis, V23, P1297, DOI 10.1590/S0103-73312013000400014; Cortes CT, 2015, REV ESC ENFERM USP, V49, P716, DOI 10.1590/S0080-623420150000500002; da Costa PB, 2013, REV PESQUI-CUID FUND, V5, P671, DOI 10.9789/2175-5361.2013v5n4p671; de Carvalho VF, 2014, SAUDE SOC-SAO PAULO, V23, P572, DOI 10.1590/S0104-12902014000200017; de Castro M.R., 2014, RESSIGNIFICANDO SE C; Santos FSD, 2019, CAD SAUDE PUBLICA, V35, DOI [10.1590/0102-311X00143718, 10.1590/0102-311x00143718]; DeSisto CL, 2018, ANN EPIDEMIOL, V28, P225, DOI 10.1016/j.annepidem.2018.01.012; Dias Marcos Augusto Bastos, 2005, Ciênc. saúde coletiva, V10, P699, DOI 10.1590/S1413-81232005000300026; Diniz Carmen Simone Grilo, 2005, Ciênc. saúde coletiva, V10, P627; Ebrahimipour S, 2016, J INT SOC PREV COMMU, V6, P584, DOI 10.4103/2231-0762.195514; Fernandes L.daM.M., 2019, PREGNANT WOMENS KNOW; Fernandes LMM, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-02874-3; Fertonani HP, 2015, CIENC SAUDE COLETIVA, V20, P1869, DOI 10.1590/1413-81232015206.13272014; Diniz CSG, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00127013; Gruber KJ, 2013, J PERINAT EDUC, V22, P49, DOI 10.1891/1058-1243.22.1.49; Hardeman RR, 2016, J MIDWIFERY WOM HEAL, V61, P773, DOI 10.1111/jmwh.12497; Hussein SAAA, 2016, WOMEN BIRTH, V29, P321, DOI 10.1016/j.wombi.2015.12.006; Instituto Brasileiro de Geografia e Estatistica (IBGE), 2018, ESTATISTICAS GENERO; Ip WY, 2009, J CLIN NURS, V18, P2125, DOI 10.1111/j.1365-2702.2008.02720.x; Isbir GG, 2016, APPL NURS RES, V32, P227, DOI 10.1016/j.apnr.2016.07.013; Nagahama EEI, 2008, CAD SAUDE PUBLICA, V24, P1859, DOI 10.1590/S0102-311X2008000800014; Kara N, 2017, GLOB HEALTH-SCI PRAC, V5, P232, DOI 10.9745/GHSP-D-16-00411; KENNELL J, 1991, JAMA-J AM MED ASSOC, V265, P2197, DOI 10.1001/jama.265.17.2197; Lansky S., 2010, REV TEMPUS ACTAS SAU, V4, P191; Lansky S, 2019, CIENC SAUDE COLETIVA, V24, P2811, DOI 10.1590/1413-81232018248.30102017; Lansky S, 2019, INT J GYNECOL OBSTET, V145, P91, DOI 10.1002/ijgo.12765; Lansky S, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00133213; Leal MD, 2019, CAD SAUDE PUBLICA, V35, DOI [10.1590/0102-311X00223018, 10.1590/0102-311x00223018]; Leal MD, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00151513; Leal MD, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-15; Leal MD, 2005, REV SAUDE PUBL, V39, P100, DOI 10.1590/S0034-89102005000100013; Lu Michael C, 2003, Matern Child Health J, V7, P13, DOI 10.1023/A:1022537516969; Lu MC, 2010, ETHNIC DIS, V20, P62; Macinko James, 2015, N Engl J Med, V372, P2177, DOI 10.1056/NEJMp1501140; McLemore MR, 2018, SOC SCI MED, V201, P127, DOI 10.1016/j.socscimed.2018.02.013; Merighi Miriam Aparecida Barbosa, 2007, Acta paul. enferm., V20, P434, DOI 10.1590/S0103-21002007000400008; Miller S, 2016, LANCET, V388, P2176, DOI 10.1016/S0140-6736(16)31472-6; Nakamura-Pereira M, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0228-7; da Gama SGN, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0236-7; Occhi GM, 2018, LANCET, V392, P1290, DOI 10.1016/S0140-6736(18)32407-3; Pereira Rui Pedro Gomes, 2012, Rev. Enf. Ref., VserIII, P55, DOI 10.12707/RIII11146; Rebelo F, 2010, ACTA OBSTET GYN SCAN, V89, P903, DOI 10.3109/00016349.2010.484044; Rogelberg S.G., 2007, ENCY IND ORG PSYCHOL, P1168; Sakala C., 2008, EVIDENCED BASED MATE; Fernandes RZS, 2014, CIENC SAUDE COLETIVA, V19, P4457, DOI 10.1590/1413-812320141911.21662013; Scaffidi RM, 2014, J MIDWIFERY WOM HEAL, V59, P246, DOI 10.1111/jmwh.12173; Souza S.R.R.K., 2016, TEXTO CONTEXTO ENFER, V25, P1, DOI [10.1590/0104-0707201600004080014, DOI 10.1590/0104-0707201600004080014]; Spitz R., 2018, J SEMEST DEP DISEN U, V1, P126; Suarez-Cortes M, 2015, REV LAT-AM ENFERM, V23, P520, DOI 10.1590/0104-1169.0067.2583; Torloni MR, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0247-4; Turan JM, 2006, SOC SCI MED, V62, P2196, DOI 10.1016/j.socscimed.2005.10.005; UN General Assembly, 2015, RESOLUTION ADOPTED G; Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X; Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4; Whitaker KM, 2016, J BEHAV MED, V39, P41, DOI 10.1007/s10865-015-9672-z; Windau-Melmer T., 2013, GUIDE ADVOCATING RES; World Health Organization,, 1996, CAR NORM BIRTH PRACT, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]; World Health Organization, 2018, RECOMMENDATIONS INTR; Yazlle MEHD, 2001, REV SAUDE PUBL, V35, P202, DOI 10.1590/S0034-89102001000200015	76	1	1	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2021	16	4							e0248740	10.1371/journal.pone.0248740	http://dx.doi.org/10.1371/journal.pone.0248740			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP1DH	33861756	Green Published, gold			2023-01-03	WOS:000641475400046
J	Mehta, M; Purpura, LJ; McConville, TH; Neidell, MJ; Anderson, MR; Bernstein, EJ; Dietz, DE; Laracy, J; Gunaratne, SH; Miller, EH; Cheng, J; Zucker, J; Shah, SS; Chaudhuri, S; Gordillo, CA; Patel, SR; Guo, TW; Karaaslan, LE; Reshef, R; Miko, BA; Bathon, JM; Pereira, MR; Uhlemann, AC; Yin, MT; Sobieszczyk, ME				Mehta, Monica; Purpura, Lawrence J.; McConville, Thomas H.; Neidell, Matthew J.; Anderson, Michaela R.; Bernstein, Elana J.; Dietz, Donald E.; Laracy, Justin; Gunaratne, Shauna H.; Miller, Emily Happy; Cheng, Jennifer; Zucker, Jason; Shah, Shivang S.; Chaudhuri, Shaoli; Gordillo, Christian A.; Patel, Shreena R.; Guo, Tai Wei; Karaaslan, Lara E.; Reshef, Ran; Miko, Benjamin A.; Bathon, Joan M.; Pereira, Marcus R.; Uhlemann, Anne-Catrin; Yin, Michael T.; Sobieszczyk, Magdalena E.			What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak	PLOS ONE			English	Article							SINGLE-CENTER	Background Tocilizumab, an interleukin-6 receptor blocker, has been used in the inflammatory phase of COVID-19, but its impact independent of corticosteroids remains unclear in patients with severe disease. Methods In this retrospective analysis of patients with COVID-19 admitted between March 2 and April 14, 2020 to a large academic medical center in New York City, we describe outcomes associated with tocilizumab 400 mg (without methylprednisolone) compared to a propensity-matched control. The primary endpoints were change in a 7-point ordinal scale of oxygenation and ventilator free survival, both at days 14 and 28. Secondary endpoints include incidence of bacterial superinfections and gastrointestinal perforation. Primary outcomes were evaluated using t-test. Results We identified 33 patients who received tocilizumab and matched 74 controls based on demographics and health measures upon admission. After adjusting for illness severity and baseline ordinal scale, we failed to find evidence of an improvement in hypoxemia based on an ordinal scale at hospital day 14 in the tocilizumab group (OR 2.2; 95% CI, 0.7-6.5; p = 0.157) or day 28 (OR 1.1; 95% CI, 0.4-3.6; p = 0.82). There also was no evidence of an improvement in ventilator-free survival at day 14 (OR 0.8; 95% CI, 0.18-3.5; p = 0.75) or day 28 (OR 1.1; 95% CI, 0.1-1.8; p = 0.23). There was no increase in secondary bacterial infection rates in the tocilizumab group compared to controls (OR 0.37; 95% CI, 0.09-1.53; p = 0.168). Conclusions There was no evidence to support an improvement in hypoxemia or ventilator-free survival with use of tocilizumab 400 mg in the absence of corticosteroids. No increase in secondary bacterial infections was observed in the group receiving tocilizumab.	[Mehta, Monica; Cheng, Jennifer] Columbia Univ, Dept Pharm, NewYork Presbyterian Hosp, Irving Med Ctr, New York, NY 10027 USA; [Purpura, Lawrence J.; McConville, Thomas H.; Dietz, Donald E.; Laracy, Justin; Gunaratne, Shauna H.; Miller, Emily Happy; Zucker, Jason; Miko, Benjamin A.; Pereira, Marcus R.; Uhlemann, Anne-Catrin; Yin, Michael T.; Sobieszczyk, Magdalena E.] Columbia Univ, Dept Med, Irving Med Ctr, Div Infect Dis, New York, NY USA; [Purpura, Lawrence J.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA; [Neidell, Matthew J.] Columbia Univ, Mailman Sch Publ Hlth, Dept Hlth Policy & Management, New York, NY USA; [Anderson, Michaela R.; Patel, Shreena R.] Columbia Univ, Dept Med, Div Pulm Crit Care, Irving Med Ctr, New York, NY USA; [Bernstein, Elana J.; Bathon, Joan M.] Columbia Univ, NewYork Presbyterian Hosp, Dept Med, Div Rheumatol,Irving Med Ctr, New York, NY USA; [Shah, Shivang S.] Columbia Univ, Dept Pediat, Div Infect Dis, Irving Med Ctr, New York, NY 10027 USA; [Chaudhuri, Shaoli] Columbia Univ, Dept Med, Irving Med Ctr, New York, NY USA; [Gordillo, Christian A.; Reshef, Ran] Columbia Univ, Blood & Marrow Transplantat Program, Irving Med Ctr, New York, NY USA; [Guo, Tai Wei; Karaaslan, Lara E.] Columbia Univ, Vagelos Coll Phys & Surg, Irving Med Ctr, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Mehta, M (corresponding author), Columbia Univ, Dept Pharm, NewYork Presbyterian Hosp, Irving Med Ctr, New York, NY 10027 USA.	mem9059@nyp.org	Purpura, Lawrence/AAX-7394-2021	Yin, Michael T/0000-0002-9346-9056; Miller, Emily/0000-0002-0640-5653; Purpura, Lawrence/0000-0002-2900-6022; Mehta, Monica/0000-0002-0472-6912	National institute of Allergy and Infectious Diseases of the NIH [T32AI114398]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [T32AI114398]	National institute of Allergy and Infectious Diseases of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Anne-Catrin Uhlemann, MD, PhD has previously received NIH grant support from Allergan, GSK and Merck unrelated to this project. Joan Bathon, MD has participated in, and been reimbursed for, a grant review panel for Gilead Sciences, unrelated to this project. Lawrence J Purpura, MD was supported by the National institute of Allergy and Infectious Diseases of the NIH under Award T32AI114398. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Justin Laracy, MD was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number T32AI114398. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The specific roles of these authors are articulated in the `author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhimraj A, INFECT DIS SOC AM GU; Brown SM, 2016, CHEST, V150, P307, DOI 10.1016/j.chest.2016.01.003; Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9; Somers E, 2020, CLIN INFECT DIS, V382, P1708, DOI [10.1093/cid/ciaa954., DOI 10.1093/CID/CIAA954]; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	15	5	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2021	16	4							e0249349	10.1371/journal.pone.0249349	http://dx.doi.org/10.1371/journal.pone.0249349			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM0NQ	33831046	Green Published, gold			2023-01-03	WOS:000639359600041
J	Tkacik, PT; Dahlberg, JL; Johnson, JE; Hoth, JJ; Szer, RA; Hellman, SE				Tkacik, Peter T.; Dahlberg, Jerry L.; Johnson, James E.; Hoth, James J.; Szer, Rebecca A.; Hellman, Samuel E.			Sizing of airborne particles in an operating room	PLOS ONE			English	Article								Medical procedures that produce aerosolized particles are under great scrutiny due to the recent concerns surrounding the COVID-19 virus and increased risk for nosocomial infections. For example, thoracostomies, tracheotomies and intubations/extubations produce aerosols that can linger in the air. The lingering time is dependent on particle size where, e.g., 500 mu m (0.5 mm) particles may quickly fall to the floor, while 1 mu m particles may float for extended lengths of time. Here, a method is presented to characterize the size of 600 mu m particles resulting from surgery in an operating room (OR). The particles are measured in-situ (next to a patient on an operating table) through a 75mm aperture in a similar to 400 mm rectangular enclosure with minimal flow restriction. The particles and gasses exiting a patient are vented through an enclosed laser sheet while a camera captures images of the side-scattered light from the entrained particles. A similar optical configuration was described by Anfinrud et al.; however, we present here an extended method which provides a calibration method for determining particle size. The use of a laser sheet with side-scattered light provides a large FOV and bright image of the particles; however, the particle image dilation caused by scattering does not allow direct measurement of particle size. The calibration routine presented here is accomplished by measuring fixed particle distribution ranges with a calibrated shadow imaging system and mapping these measurements to the in-situ imaging system. The technique used for generating and measuring these particles is described. The result is a three-part process where 1) particles of varying sizes are produced and measured using a calibrated, high-resolution shadow imaging method, 2) the same particle generators are measured with the in-situ imaging system, and 3) a correlation mapping is made between the (dilated) laser image size and the measured particle size. Additionally, experimental and operational details of the imaging system are described such as requirements for the enclosure volume, light management, air filtration and control of various laser reflections. Details related to the OR environment and requirements for achieving close proximity to a patient are discussed as well.	[Tkacik, Peter T.; Dahlberg, Jerry L.] Univ N Carolina, Dept Mech Engn, Charlotte, NC 28223 USA; [Johnson, James E.; Hoth, James J.] Wake Forest Sch Med, Dept Gen Surg, Winston Salem, NC 27101 USA; [Szer, Rebecca A.] West Virginia Sch Osteopath Med, Lewisburg, WV USA; [Hellman, Samuel E.] Mem Sloan Kettering Canc Ctr, Dept Med Phys, 1275 York Ave, New York, NY 10021 USA	University of North Carolina; University of North Carolina Charlotte; Wake Forest University; Memorial Sloan Kettering Cancer Center	Tkacik, PT (corresponding author), Univ N Carolina, Dept Mech Engn, Charlotte, NC 28223 USA.	ptkacik@uncc.edu		Dahlberg, Jerry/0000-0003-2778-5349; Hellman, Samuel/0000-0002-5519-870X	Wake Forest School of Medicine; U.S. Office of Naval Research [N00014-18-1-2754]	Wake Forest School of Medicine; U.S. Office of Naval Research(Office of Naval Research)	This material is based upon research supported by, or in part by, a grant from Wake Forest School of Medicine (no award number) and the U.S. Office of Naval Research under award number N00014-18-1-2754. Other than CoAuthors, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. https://school.wakehealth.edu/https://www.onr.navy.mil/.	Anfinrud P, 2020, NEW ENGL J MED, V382, P2061, DOI 10.1056/NEJMc2007800; [Anonymous], 2020, REDLAKE MOTIONXTRA H; [Anonymous], 2020, DANTEC DYNAMICS MEAS; [Anonymous], 2020, DMS500 CAMBUSTION; [Anonymous], 2020, RAYPOWER 5000 5000MW; [Anonymous], 2020, ARRI EB400575D HIGH; [Anonymous], 2020, MOTION STUDIO 64BIT; [Anonymous], 2020, V3528 MPY 11 35MM F2; [Anonymous], 2020, ARRILUX 400 LAMP; [Anonymous], 2020, AEROSOL; [Anonymous], 2020, 610N 6 SPRING TEMPER; [Anonymous], 2020, BROOKHAVEN INSTRUMEN; [Anonymous], 2020, IPAD PRO11 SPECIFICA; Artium, 2020, PDI PHASED DOPPLER I; Asadi S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38808-z; Baron P., GENERATION BEHAV AIR; Berne B.J., 2000, DYNAMIC LIGHT SCATTE; Chao CYH, 2009, J AEROSOL SCI, V40, P122, DOI 10.1016/j.jaerosci.2008.10.003; Dantec Dynamics, 2020, LASER DOPPLER ANEMOM; DUGUID JP, 1946, J HYG-CAMBRIDGE, V44, P471, DOI 10.1017/S0022172400019288; Fischer EP, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd3083; Hinds W.C., 2011, AEROSOL MEASUREMENT, P31; JACKSON TA, 1987, APPL OPTICS, V26, P2137, DOI 10.1364/AO.26.002137; Jankovic L, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12125204; LaVision, 2020, LASER IMAGING DENSE; TSI, 2020, PHASE DOPPLER PARTIC; TSI, 2020, VIBRATING ORIFICE GE; TSI, 2017, SCANN MOB PART SIZ 3; Wells W.F., 1955, AIRBORNE CONTAGION A; World Health Organization, 2005, JOINT ILO WHO GUID H, P79; Xie X, 2007, INDOOR AIR, V17, P211, DOI 10.1111/j.1600-0668.2007.00469.x	31	0	0	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2021	16	4							e0249586	10.1371/journal.pone.0249586	http://dx.doi.org/10.1371/journal.pone.0249586			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ5NA	33819294	gold, Green Published			2023-01-03	WOS:000637647200015
J	Cousins, MM; Jannausch, M; Jagsi, R; Ilgen, M				Cousins, Matthew M.; Jannausch, Mary; Jagsi, Reshma; Ilgen, Mark			Differences between cancer patients and others who use medicinal Cannabis	PLOS ONE			English	Article								Background Cancer patients have been at the forefront of policy discussions leading to legalization of medical Cannabis (marijuana). Unfortunately, Cannabis use among those with cancer is poorly understood. Methods A diverse group of patients seeking certification for medical Cannabis in the state of Michigan were surveyed at the time of their presentation to medical dispensaries. The survey assessed demographics, employment/disability, pain, physical functioning, mental health, mode of Cannabis use, and frequency/amount of Cannabis use. Chi-square and t-tests were performed to compare those who did and did not endorse cancer diagnosis. Results Analysis of data from 1485 adults pursuing medical Cannabis certification, including 72 (4.8%) reporting a cancer diagnosis, indicated that those with cancer were older [mean age 53.4 years (SD = 10.5) vs. 44.7 years (SD = 13.0); p<0.001] than those without cancer. They also differed regarding employment status (p<0.001; working: 20.8% vs. 46.2%; disabled: 44.4% vs. 26.5% for those with vs. those without cancer, respectively). Those with cancer used less Cannabis (p = 0.033 for quantity used) and used Cannabis less often (p = 0.032 for frequency of use); they less frequently endorsed smoking Cannabis (80% vs 91%; p = 0.015). There was a non-significant trend to increased edible use in those with cancer (57% vs. 44%; p = 0.052). Conclusions Patients with cancer who are seeking medical Cannabis are different from those seeking medical Cannabis without cancer, and they report using Cannabis differently. Further research to characterize the patterns and consequences of Cannabis use in cancer patients is needed.	[Cousins, Matthew M.; Jagsi, Reshma] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Jannausch, Mary; Ilgen, Mark] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Ilgen, Mark] VA Ctr Clin Management Res CCMR, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Cousins, MM (corresponding author), Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.	cousinma@med.umich.edu		Cousins, Matthew/0000-0003-0067-9087	National Institutes of Health [4R01DA033397]; VA Health Services Research Development [RCS 19-333]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Health Services Research Development(US Department of Veterans Affairs)	This work was supported by funding from the National Institutes of Health (https://www.nih.gov) via 4R01DA033397 to MI, which supported the overall study design, conduct and data collection. MI's time was supported by Grant RCS 19-333 from VA Health Services Research & Development. The funders did not play a role in the present analysis, decision to publish, or preparation of the manuscript.	Abdel-Rahman O, 2021, EXPERT REV PHARM OUT, V21, P1025, DOI 10.1080/14737167.2021.1854735; Adler NE, 2008, CANC CARE WHOLE PATI; ( ALA) ALA, 2020, MARIJUANA LUNG HLTH; Braun IM, 2021, CANCER-AM CANCER SOC, V127, P67, DOI 10.1002/cncr.33202; Campbell G, 2018, LANCET PUBLIC HEALTH, V3, pE341, DOI 10.1016/S2468-2667(18)30110-5; Caruso R, 2017, INT REV PSYCHIATR, V29, P389, DOI 10.1080/09540261.2017.1288090; Chawla D, 2018, DRUG ALCOHOL DEPEN, V193, P177, DOI 10.1016/j.drugalcdep.2018.05.035; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Ilgen MA, 2013, DRUG ALCOHOL DEPEN, V132, P654, DOI 10.1016/j.drugalcdep.2013.04.019; Kim A, 2019, J PALLIAT MED, V22, P1196, DOI 10.1089/jpm.2018.0529; Macari DM, 2020, AM J CLIN ONCOL-CANC, V43, P636, DOI 10.1097/COC.0000000000000718; Martell K, 2018, CURR ONCOL, V25, P219, DOI 10.3747/co.25.3983; Natl Acad Sci Engn Med, 2017, HEALTH EFFECTS OF CANNABIS AND CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH, P1, DOI 10.17226/24625; Pergam SA, 2017, CANCER-AM CANCER SOC, V123, P4488, DOI 10.1002/cncr.30879; Shi SY, 2019, CUREUS, V11, DOI 10.7759/cureus.3918; Substance Abuse and Mental Health Services Administration, 2020, HHS PUBL NSDUH, VH-55; Ware J.E., 1995, SF 12 SCORE SF 12 PH; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weinberger MI, 2011, INT J GERIATR PSYCH, V26, P21, DOI 10.1002/gps.2497; Zhang H, 2018, JAMA OTOLARYNGOL, V144, P1017, DOI 10.1001/jamaoto.2018.0486	20	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2021	16	3							e0248227	10.1371/journal.pone.0248227	http://dx.doi.org/10.1371/journal.pone.0248227			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY1VJ	33725004	Green Published, gold			2023-01-03	WOS:000629833700031
J	Okuno, T; Kunisawa, S; Fushimi, K; Imanaka, Y				Okuno, Takuya; Kunisawa, Susumu; Fushimi, Kiyohide; Imanaka, Yuichi			Intra-operative autologous blood donation for cardiovascular surgeries in Japan: A retrospective cohort study	PLOS ONE			English	Article								Intra-operative autologous blood donation is a blood conservation technique with limited evidence. We evaluated the association between intra-operative autologous blood donation and decrease in peri-operative transfusion in cardiovascular surgery based on evidence from a Japanese administrative database. We extracted the data of patients who had undergone cardiovascular surgery from the Diagnosis Procedure Combination database in Japan (2016-2019). Based on the surgery type, we examined the association of intra-operative autologous blood donation with the transfusion rate and amount of blood used in cardiac and aortic surgeries using multilevel propensity score matching. We enrolled 32,433 and 4,267 patients who underwent cardiac and aortic surgeries and received 5.0% and 6.7% intra-operative autologous blood donation with mean volumes of 557.68 mL and 616.96 mL, respectively. The red blood cell transfusion rates of the control and intra-operative autologous blood donation groups were 60.6% and 38.4%, respectively, in the cardiac surgery cohort (p < .001) and 91.4%, and 83.8%, respectively, in the aortic surgery cohort (p = .037). The transfusion amounts for the control and intra-operative autologous blood donation groups were 5.9 and 3.5 units of red blood cells, respectively, for cardiac surgery patients (p < .001) and 11.9 and 7.9 units, respectively, for aortic surgery patients (p < .001). Intra-operative autologous blood donation could reduce the transfusion rate or amount of red blood cells and fresh frozen plasma for patients undergoing index cardiovascular surgery and could be an effective blood transfusion strategy in cardiovascular surgery for Japanese patients.	[Okuno, Takuya; Kunisawa, Susumu; Imanaka, Yuichi] Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Kyoto, Japan; [Fushimi, Kiyohide] Tokyo Med & Dent Univ, Hlth Policy & Informat Sect, Grad Sch, Tokyo, Japan	Kyoto University; Tokyo Medical & Dental University (TMDU)	Imanaka, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Kyoto, Japan.	imanaka-y@umin.net	Yuichi, Imanaka/GYR-2098-2022; KUNISAWA, Susumu/HCH-1094-2022	Yuichi, Imanaka/0000-0003-4613-2159; Okuno, Takuya/0000-0003-2990-759X	Ministry of Health, Labour and Welfare of Japan [20AA2005]; Japan Society [19H01075]	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japan Society(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Yuichi Imanaka received Health Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (20AA2005) and a Grant-in-Aid for Scientific Research from the Japan Society (19H01075).	Arpino B, 2011, COMPUT STAT DATA AN, V55, P1770, DOI 10.1016/j.csda.2010.11.008; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Balachandran S, 2002, ANN THORAC SURG, V73, P1912, DOI 10.1016/S0003-4975(02)03513-0; Barile L, 2017, ANESTH ANALG, V124, P743, DOI 10.1213/ANE.0000000000001609; Casati V, 2002, ANESTHESIOLOGY, V97, P367, DOI 10.1097/00000542-200208000-00013; Crawford TC, 2018, ANN THORAC SURG, V105, P129, DOI 10.1016/j.athoracsur.2017.06.062; Curley GF, 2014, CRIT CARE MED, V42, P2611, DOI 10.1097/CCM.0000000000000548; Ferraris VA, 2011, ANN THORAC SURG, V91, P944, DOI 10.1016/j.athoracsur.2010.11.078; Flom-Halvorsen HI, 2003, ANN THORAC SURG, V76, P744, DOI 10.1016/S0003-4975(03)00349-7; Goldberg J, 2015, ANN THORAC SURG, V100, P1581, DOI 10.1016/j.athoracsur.2015.04.135; Hayashida K, 2021, J EPIDEMIOL, V31, P1, DOI 10.2188/jea.JE20200288; Henderson RA, 2019, TRANSFUSION, V59, P2023, DOI 10.1111/trf.15253; Isogai T, 2017, HEART VESSELS, V32, P1271, DOI 10.1007/s00380-017-1007-2; Isogai T, 2017, HEART VESSELS, V32, P944, DOI 10.1007/s00380-017-0958-7; Koch CG, 2006, CRIT CARE MED, V34, P1608, DOI 10.1097/01.CCM.0000217920.48559.D8; Krieger KH, 2012, BLOOD CONSERVATION C; McGill N, 2002, BMJ-BRIT MED J, V324, P1299, DOI 10.1136/bmj.324.7349.1299; Ministry of Health Labour and Welfare in Japan., ANN SURV US BLOOD PR; Oswald E, 2010, TRANSFUSION, V50, P400, DOI 10.1111/j.1537-2995.2009.02393.x; Paone G, 2014, ANN THORAC SURG, V97, P87, DOI 10.1016/j.athoracsur.2013.07.020; Rottman G, 1998, TRANSFUSION, V38, P477, DOI 10.1046/j.1537-2995.1998.38598297218.x; Salis S, 2008, J CARDIOTHOR VASC AN, V22, P814, DOI 10.1053/j.jvca.2008.08.004; Shander A, 2020, ANESTH ANALG, V131, P74, DOI 10.1213/ANE.0000000000004844; Stover EP, 1998, ANESTHESIOLOGY, V88, P327, DOI 10.1097/00000542-199802000-00009; WHO, 2020, MAINT SAF AD BLOOD S; Zimmermann E, 2019, ANN THORAC SURG, V108, P1738, DOI 10.1016/j.athoracsur.2019.06.091	26	2	2	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2021	16	3							e0247282	10.1371/journal.pone.0247282	http://dx.doi.org/10.1371/journal.pone.0247282			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV3DA	33690678	Green Published, gold			2023-01-03	WOS:000627854700056
J	Maust, DT; Strominger, J; Kim, HM; Langa, KM; Bynum, JPW; Chang, CH; Kales, HC; Zivin, K; Solway, E; Marcus, SC				Maust, Donovan T.; Strominger, Julie; Kim, H. Myra; Langa, Kenneth M.; Bynum, Julie P. W.; Chang, Chiang-Hua; Kales, Helen C.; Zivin, Kara; Solway, Erica; Marcus, Steven C.			Prevalence of Central Nervous System-Active Polypharmacy Among Older Adults With Dementia in the US	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC SYMPTOMS; MEDICARE CLAIMS; MEDICATIONS; HEALTH; TRENDS; IMPACT; FALLS; CARE	Question What is the prevalence of polypharmacy with central nervous system (CNS)-active medications among community-dwelling older adults with dementia in the US? Findings In this cross-sectional analysis of 1 159 968 older adults with dementia, traditional Medicare, and prescription coverage in 2018, 13.9% were prescribed CNS-active polypharmacy, defined as overlapping prescription fills for 3 or more medications from the following drug classes: antidepressants, antipsychotics, antiepileptics, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonist hypnotics, and opioids. Meaning In 2018, 13.9% of older adults with dementia in the US had filled prescriptions consistent with CNS-active polypharmacy. Importance Community-dwelling older adults with dementia have a high prevalence of psychotropic and opioid use. In these patients, central nervous system (CNS)-active polypharmacy may increase the risk for impaired cognition, fall-related injury, and death. Objective To determine the extent of CNS-active polypharmacy among community-dwelling older adults with dementia in the US. Design, Setting, and Participants Cross-sectional analysis of all community-dwelling older adults with dementia (identified by International Classification of Diseases, Ninth Revision, Clinical Modification or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis codes; N = 1 159 968) and traditional Medicare coverage from 2015 to 2017. Medication exposure was estimated using prescription fills between October 1, 2017, and December 31, 2018. Exposures Part D coverage during the observation year (January 1-December 31, 2018). Main Outcomes and Measures The primary outcome was the prevalence of CNS-active polypharmacy in 2018, defined as exposure to 3 or more medications for longer than 30 days consecutively from the following classes: antidepressants, antipsychotics, antiepileptics, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonist hypnotics, and opioids. Among those who met the criterion for polypharmacy, duration of exposure, number of distinct medications and classes prescribed, common class combinations, and the most commonly used CNS-active medications also were determined. Results The study included 1 159 968 older adults with dementia (median age, 83.0 years [interquartile range {IQR}, 77.0-88.6 years]; 65.2% were female), of whom 13.9% (n = 161 412) met the criterion for CNS-active polypharmacy (32 139 610 polypharmacy-days of exposure). Those with CNS-active polypharmacy had a median age of 79.4 years (IQR, 74.0-85.5 years) and 71.2% were female. Among those who met the criterion for CNS-active polypharmacy, the median number of polypharmacy-days was 193 (IQR, 88-315 polypharmacy-days). Of those with CNS-active polypharmacy, 57.8% were exposed for longer than 180 days and 6.8% for 365 days; 29.4% were exposed to 5 or more medications and 5.2% were exposed to 5 or more medication classes. Ninety-two percent of polypharmacy-days included an antidepressant, 47.1% included an antipsychotic, and 40.7% included a benzodiazepine. The most common medication class combination included an antidepressant, an antiepileptic, and an antipsychotic (12.9% of polypharmacy-days). Gabapentin was the most common medication and was associated with 33.0% of polypharmacy-days. Conclusions and Relevance In this cross-sectional analysis of Medicare claims data, 13.9% of older adults with dementia in 2018 filled prescriptions consistent with CNS-active polypharmacy. The lack of information on prescribing indications limits judgments about clinical appropriateness of medication combinations for individual patients. This pharmacoepidemiology study uses Medicare claims data to describe the prevalence of central nervous system-active polypharmacy among community-dwelling older adults with dementia in the US, including durations of exposure and number of drugs and drug classes.	[Maust, Donovan T.; Zivin, Kara] Univ Michigan, Dept Psychiat, 2800 Plymouth Rd,NCRC 016-226W, Ann Arbor, MI 48109 USA; [Maust, Donovan T.; Strominger, Julie; Kim, H. Myra; Langa, Kenneth M.; Zivin, Kara] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA; [Maust, Donovan T.; Kim, H. Myra; Langa, Kenneth M.; Bynum, Julie P. W.; Chang, Chiang-Hua; Zivin, Kara; Solway, Erica] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA; [Langa, Kenneth M.; Bynum, Julie P. W.; Chang, Chiang-Hua] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Langa, Kenneth M.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA; [Kales, Helen C.] Univ Calif Davis, Dept Psychiat, Sacramento, CA 95817 USA; [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California Davis; University of Pennsylvania	Maust, DT (corresponding author), Univ Michigan, Dept Psychiat, 2800 Plymouth Rd,NCRC 016-226W, Ann Arbor, MI 48109 USA.	maustd@umich.edu		Langa, Kenneth/0000-0002-2798-1836; Zivin, Kara/0000-0001-8246-6864				2019 American Geriatrics Society, 2019, BEERS CRIT UPD EXP P; Abrahamson K, 2021, J APPL GERONTOL, V40, P1071, DOI 10.1177/0733464820948328; Bain Kevin T, 2006, Am J Geriatr Pharmacother, V4, P168, DOI 10.1016/j.amjopharm.2006.06.006; Breining A, 2017, INT J GERIATR PSYCH, V32, P750, DOI 10.1002/gps.4517; Bynum JPW, 2014, HEALTH AFFAIR, V33, P534, DOI 10.1377/hlthaff.2013.1247; Deshpande LS, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00011; Dudas R, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003944.pub2; Eicheldinger C, 2008, HEALTH CARE FINANC R, V29, P27; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; Gray SL, 2020, J GERONTOL A-BIOL, V75, P1003, DOI 10.1093/gerona/glz270; Gustafsson M, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-56; Hanlon JT, 2009, J GERONTOL A-BIOL, V64, P492, DOI 10.1093/gerona/gln043; Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5; Iaboni A, 2016, DRUG AGING, V33, P523, DOI 10.1007/s40266-016-0380-3; KALES HC, 2015, BMJ-BRIT MED J, V5, P350, DOI DOI 10.1136/BMJJ369; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; Kesselheim AS, 2011, HEALTH AFFAIR, V30, P2318, DOI 10.1377/hlthaff.2011.0370; Lambiase PD, 2019, ARRHYTH ELECTROPHYSI, V8, P161, DOI 10.15420/aer.2019.8.3.G1; Landes AM, 2001, J AM GERIATR SOC, V49, P1700, DOI 10.1046/j.1532-5415.2001.49282.x; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Maust DT, 2020, JAMA-J AM MED ASSOC, V324, P706, DOI 10.1001/jama.2020.8519; Maust DT, 2017, JAMA INTERN MED, V177, P583, DOI 10.1001/jamainternmed.2016.9225; Maust DT, 2017, INT J GERIATR PSYCH, V32, P164, DOI 10.1002/gps.4452; McKean A, 2012, CNS DRUGS, V26, P383, DOI 10.2165/11632030-000000000-00000; Moore TJ, 2017, JAMA INTERN MED, V177, P274, DOI 10.1001/jamainternmed.2016.7507; Norgaard A, 2017, J ALZHEIMERS DIS, V56, P707, DOI 10.3233/JAD-160828; Orsel K, 2018, EUR NEUROPSYCHOPHARM, V28, P1260, DOI 10.1016/j.euroneuro.2018.04.005; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Porsteinsson AP, 2014, JAMA-J AM MED ASSOC, V311, P682, DOI 10.1001/jama.2014.93; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Tannenbaum C, 2012, DRUG AGING, V29, P639, DOI 10.2165/11633250-000000000-00000; Taylor DH, 2002, J CLIN EPIDEMIOL, V55, P929, DOI 10.1016/S0895-4356(02)00452-3; US Food Drug Administration, 2016, FDA WARNS SER RISKS; Vasudev A, 2015, AM J GERIAT PSYCHIAT, V23, P1259, DOI 10.1016/j.jagp.2015.07.001; Vigen CLP, 2011, AM J PSYCHIAT, V168, P831, DOI 10.1176/appi.ajp.2011.08121844; Walsh KA, 2016, INT PSYCHOGERIATR, V28, P1807, DOI 10.1017/S1041610216001307; Wei YJ, 2016, MED CARE, V54, pE73; Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357; Wright RM, 2009, J AM GERIATR SOC, V57, P243, DOI 10.1111/j.1532-5415.2008.02127.x	39	23	23	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	2021	325	10					952	961		10.1001/jama.2021.1195	http://dx.doi.org/10.1001/jama.2021.1195			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV3UE	33687462	Green Published, Bronze			2023-01-03	WOS:000627899400017
J	Patel, R; Marbaniang, SP; Srivastava, S; Kumar, P; Chauhan, S; Simon, DJ				Patel, Ratna; Marbaniang, Strong P.; Srivastava, Shobhit; Kumar, Pradeep; Chauhan, Shekhar; Simon, David J.			Gender differential in low psychological health and low subjective well-being among older adults in India: With special focus on childless older adults	PLOS ONE			English	Article							LIFE; WOMEN; DETERMINANTS; RETIREMENT; DISPARITY; MORTALITY; SUPPORT; CASTE; MOOD; MEN	Background Gender and health are two factors that shape the quality of life in old age. Previous available literature established an associaton between various demographic and socio-economic factors with the health and well-being of older adults in India; however, the influence of childless aged is neglected. Therefore, the study examined the gender differential in psychological health and subjective well-being among older adults, focusing on childless older adults. Methodology This study utilized data from Building a Knowledge Base on Population Aging in India (BKPAI). Psychological health and subjective well-being were examined for 9541 older adults aged 60 years & above. Descriptive statistics and bivariate analysis were used to find the preliminary results. Further, multivariate analysis has been done to fulfill the objective of the study. Results Around one-fifth (21.2%) of the men reported low psychological health, whereas around one-fourth (25.5%) of the women reported low psychological health. Further, around 24 per cent of men and 29 per cent of women reported low subjective well-being. Results found that low psychological well-being (OR = 1.87, C.I. = 1.16-3.01), as well as low subjective well-being (OR = 1.78, C.I. = 1.15-2.76), was higher in childless older women than in childless older men. Higher education, community involvement, good self-rated health, richest wealth quintile, and residing in urban areas significantly decrease the odds of low subjective well-being and low psychological well-being among older adults. Conclusion There is a need to improve older adults' psychological health and subjective well-being through expanded welfare provisions, especially for childless older adults. Moreover, there is an immediate requirement to cater to the needs of poor and uneducated older adults.	[Patel, Ratna] Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Mumbai, Maharashtra, India; [Marbaniang, Strong P.; Srivastava, Shobhit; Kumar, Pradeep] Int Inst Populat Sci, Dept Math Demog & Stat, Mumbai, Maharashtra, India; [Chauhan, Shekhar] Int Inst Populat Sci, Dept Populat Policies & Programmes, Mumbai, Maharashtra, India; [Simon, David J.] Paris 1 Pantheon Sorbonne Univ, Paris, France	International Institute for Population Sciences; International Institute for Population Sciences; International Institute for Population Sciences	Chauhan, S (corresponding author), Int Inst Populat Sci, Dept Populat Policies & Programmes, Mumbai, Maharashtra, India.	shekhariips2486@gmail.com	Kumar, Pradeep/AAN-9128-2021; CHAUHAN, SHEKHAR/AAH-7233-2020; Kumar, Pradeep/GQV-5790-2022; Marbaniang, Strong P/AAN-9493-2021; Srivastava, Shobhit/AAI-1811-2021	Kumar, Pradeep/0000-0003-4259-820X; CHAUHAN, SHEKHAR/0000-0002-6926-7649; Marbaniang, Strong P/0000-0001-5347-1867; Srivastava, Shobhit/0000-0002-7138-4916				Agrawal J, 2011, SOC INDIC RES, V101, P419, DOI 10.1007/s11205-010-9669-5; Bahl N.K.H., 2017, OPEN J SOCIAL SCI, V5, P321, DOI [10.4236/jss.2017.57020, DOI 10.4236/JSS.2017.57020]; Barford A, 2006, BMJ-BRIT MED J, V332, P808, DOI 10.1136/bmj.332.7545.808; Bhaswati Das, 2018, Journal of Population and Social Studies, V26, P219; BKPAI, 2011, REP STAT ELD SEL STA; Bloom DE, 2011, CURR HIST, V110, P143; Carmel S, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00218; Chaurasia H, 2018, AGEING INT, V43, P207, DOI 10.1007/s12126-017-9317-3; Chou KL, 2004, INT J GERIATR PSYCH, V19, P449, DOI 10.1002/gps.1111; Das M, 2020, INDIAN J GERONTOLOGY, V34; Denton M, 2004, SOC SCI MED, V58, P2585, DOI 10.1016/j.socscimed.2003.09.008; Deshpande A, 2000, AM ECON REV, V90, P322, DOI 10.1257/aer.90.2.322; Gibney S, 2017, SOC INDIC RES, V130, P305, DOI 10.1007/s11205-015-1177-1; Gildner TE, 2019, J GERONTOL B-PSYCHOL, V74, P516, DOI 10.1093/geronb/gbw145; Hadley R.A., 2018, AGEING CHILDREN GEND, P66, DOI 10.4324/9781315226835; Hashmi JF, 2018, J PSYCHIAT NURSING, V7, P91, DOI [10.21088/jpn.2277.9035.7318.4, DOI 10.21088/JPN.2277.9035.7318.4]; Jacob K S, 1997, Indian J Psychiatry, V39, P196; Kirchengast S, 2008, ANTHROPOL ANZ, V66, P237, DOI 10.1127/aa/66/2008/237; Ko H, 2019, ARCH GERONTOL GERIAT, V83, P239, DOI 10.1016/j.archger.2019.05.009; Kumar A, 2017, INDIAN J GERONTOLOGY, V31; Kumar J., 2010, BLOCKED CASTE EC DIS; Lamb S., 2020, CARING OLD AGE PERSP, P321; Lee J, 2014, J GERONTOL B-PSYCHOL, V69, P603, DOI 10.1093/geronb/gbu017; Lieber J, 2020, SSM-POPUL HLTH, V11, DOI 10.1016/j.ssmph.2020.100572; Lukaschek K, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0513-5; Lv QC, 2017, ASIA PAC J TOUR RES, V22, P951, DOI 10.1080/10941665.2017.1345772; Meisenberg G, 2015, J HAPPINESS STUD, V16, P1539, DOI 10.1007/s10902-014-9577-5; Mhaske R., 2017, J PSYCHOSOC RES, V12, P71; Oksuzyan A, 2008, AGING CLIN EXP RES, V20, P91; Oksuzyan A, 2018, GERONTOLOGIST, V58, P1156, DOI 10.1093/geront/gnx111; Osman U. A. N., 2018, MANAGEMENT RES J, V7, P146; Patel R., 2019, INDIAN J SOC RES, V60, P279; Perkins JM, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3682-9; Pinquart M, 2001, J GERONTOL B-PSYCHOL, V56, pP195, DOI 10.1093/geronb/56.4.P195; Population Reference Bureau, 2012, IND AG POP TOD RES A, V25, P1; Quashie NT, 2018, ASIAN SOC WORK POLIC, V12, P130, DOI 10.1111/aswp.12145; Rajan S.I., 2017, CROSS CULTURAL CROSS, P143, DOI [10.1007/978-981-10-1654-7_8, DOI 10.1007/978-981-10-1654-7_8]; REMPEL J, 1985, J MARRIAGE FAM, V47, P343, DOI 10.2307/352134; Rowland DT, 2007, J FAM ISSUES, V28, P1311, DOI 10.1177/0192513X07303823; Ryan RM, 2001, ANNU REV PSYCHOL, V52, P141, DOI 10.1146/annurev.psych.52.1.141; Schmid T, 2012, EUR J AGEING, V9, P39, DOI 10.1007/s10433-011-0197-1; Sharma R., 2016, INT J AGEING DEV COU, V1, P68; Shidhaye R, 2010, INT J EPIDEMIOL, V39, P1510, DOI 10.1093/ije/dyq179; Singh L, 2016, J CROSS-CULT GERONTO, V31, P173, DOI 10.1007/s10823-016-9286-0; Singh L, 2013, SAGE OPEN, V3, DOI 10.1177/2158244013487914; Singh PK, 2018, SSM-POPUL HLTH, V5, P180, DOI 10.1016/j.ssmph.2018.06.008; Singh PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031666; Singh P, 2020, PALGR COMMUN, V6, DOI 10.1057/s41599-020-0488-2; Srivastava S, 2021, AGEING INT, V46, P182, DOI 10.1007/s12126-020-09385-8; Subramanian SV, 2006, AM J PUBLIC HEALTH, V96, P818, DOI 10.2105/AJPH.2004.060103; United Nations Department of Economic and Social Affairs Population Division, 2019, WORLD POP AG 2019 WO, DOI [10.1007/978-94-007-5204-7_6, DOI 10.1007/978-94-007-5204-7_6]; Vozikaki M, 2018, J PUBLIC HEALTH-HEID, V26, P613, DOI 10.1007/s10389-018-0916-6; World Health Organization, 1992, ASS SUBJ WELLB SUBJ	53	8	9	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2021	16	3							e0247943	10.1371/journal.pone.0247943	http://dx.doi.org/10.1371/journal.pone.0247943			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QU3OZ	33684164	gold, Green Published			2023-01-03	WOS:000627193500001
J	Yarnell, CJ; Jewell, LM; Astell, A; Pinto, R; Devine, LA; Detsky, ME; Downar, J; Ilan, R; Rawal, S; Wong, N; You, JJ; Fowler, RA				Yarnell, Christopher J.; Jewell, Laura M.; Astell, Alex; Pinto, Ruxandra; Devine, Luke A.; Detsky, Michael E.; Downar, James; Ilan, Roy; Rawal, Shail; Wong, Natalie; You, John J.; Fowler, Rob A.			Observational study of agreement between attending and trainee physicians on the surprise question: "Would you be surprised if this patient died in the next 12 months?"	PLOS ONE			English	Article								Background Optimal end-of-life care requires identifying patients that are near the end of life. The extent to which attending physicians and trainee physicians agree on the prognoses of their patients is unknown. We investigated agreement between attending and trainee physician on the surprise question: "Would you be surprised if this patient died in the next 12 months?", a question intended to assess mortality risk and unmet palliative care needs. Methods This was a multicentre prospective cohort study of general internal medicine patients at 7 tertiary academic hospitals in Ontario, Canada. General internal medicine attending and senior trainee physician dyads were asked the surprise question for each of the patients for whom they were responsible. Surprise question response agreement was quantified by Cohen's kappa using Bayesian multilevel modeling to account for clustering by physician dyad. Mortality was recorded at 12 months. Results Surprise question responses encompassed 546 patients from 30 attending-trainee physician dyads on academic general internal medicine teams at 7 tertiary academic hospitals in Ontario, Canada. Patients had median age 75 years (IQR 60-85), 260 (48%) were female, and 138 (25%) were dependent for some or all activities of daily living. Trainee and attending physician responses agreed in 406 (75%) patients with adjusted Cohen's kappa of 0.54 (95% credible interval 0.41 to 0.66). Vital status was confirmed for 417 (76%) patients of whom 160 (38% of 417) had died. Using a response of "No" to predict 12-month mortality had positive likelihood ratios of 1.84 (95% CrI 1.55 to 2.22, trainee physicians) and 1.51 (95% CrI 1.30 to 1.72, attending physicians), and negative likelihood ratios of 0.31 (95% CrI 0.17 to 0.48, trainee physicians) and 0.25 (95% CrI 0.10 to 0.46, attending physicians). Conclusion Trainee and attending physician responses to the surprise question agreed in 54% of cases after correcting for chance agreement. Physicians had similar discriminative accuracy; both groups had better accuracy predicting which patients would survive as opposed to which patients would die. Different opinions of a patient's prognosis may contribute to confusion for patients and missed opportunities for engagement with palliative care services.	[Yarnell, Christopher J.; Fowler, Rob A.] Univ Toronto, Inst Hlth Management Policy & Evaluat, Toronto, ON, Canada; [Yarnell, Christopher J.; Devine, Luke A.; Detsky, Michael E.] Sinai Hlth Syst, Dept Med, Toronto, ON, Canada; [Yarnell, Christopher J.; Detsky, Michael E.; Wong, Natalie; Fowler, Rob A.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Jewell, Laura M.] Mem Univ Newfoundland, Discipline Family Med, Happy Valley Goose Bay, NF, Canada; [Astell, Alex] Univ Manitoba, Sect Crit Care Med, Fac Med, Winnipeg, MB, Canada; [Pinto, Ruxandra; Fowler, Rob A.] Sunnybrook Hlth Sci Ctr, Dept Crit Care, Toronto, ON, Canada; [Devine, Luke A.; Rawal, Shail; Wong, Natalie] Univ Toronto, Div Gen Internal Med, Temerty Fac Med, Toronto, ON, Canada; [Downar, James] Ottawa Hosp, Ottawa, ON, Canada; [Downar, James] Univ Ottawa, Div Palliat Care, Fac Med, Ottawa, ON, Canada; [Ilan, Roy] Technion, Dept Crit Care Med, Israel Inst Technol, Rambam Hlth Care Campus, Haifa, Israel; [Rawal, Shail] Univ Hlth Network, Gen Internal Med, Toronto, ON, Canada; [Wong, Natalie] St Michaels Hosp, Dept Gen Internal Med, Toronto, ON, Canada; [Wong, Natalie] St Michaels Hosp, Dept Crit Care Med, Toronto, ON, Canada; [You, John J.] Trillium Hlth Partners, Dept Med, Div Gen Internal & Hospitalist Med, Mississauga, ON, Canada; [Fowler, Rob A.] Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Memorial University Newfoundland; University of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Rambam Health Care Campus; Technion Israel Institute of Technology; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Trillium Health Partners; University of Toronto	Yarnell, CJ (corresponding author), Univ Toronto, Inst Hlth Management Policy & Evaluat, Toronto, ON, Canada.; Yarnell, CJ (corresponding author), Sinai Hlth Syst, Dept Med, Toronto, ON, Canada.; Yarnell, CJ (corresponding author), Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.	christopher.yarnell@sinaihealth.ca		Yarnell, Christopher/0000-0001-5657-9398	Resident Research Grant from the Physician Services Incorporated Foundation [R15-40]; Canadian Institutes for Health Research CGS-M at the University of Toronto; Clinician Investigator Program at the University of Toronto; Eliot Phillipson Clinician Scientist Training Program at the University of Toronto; PSI Foundation	Resident Research Grant from the Physician Services Incorporated Foundation; Canadian Institutes for Health Research CGS-M at the University of Toronto; Clinician Investigator Program at the University of Toronto; Eliot Phillipson Clinician Scientist Training Program at the University of Toronto; PSI Foundation	The study was funded by a Resident Research Grant from the Physician Services Incorporated Foundation (Dr Yarnell, R15-40). Dr Yarnell is also funded by the Canadian Institutes for Health Research CGS-M, the Clinician Investigator Program, and the Eliot Phillipson Clinician Scientist Training Program at the University of Toronto. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources including the PSI Foundation. No endorsement by any of the funding agencies is intended or should be inferred. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barrera R, 2001, J CRIT CARE, V16, P32, DOI 10.1053/jcrc.2001.21794; Bekelman JE, 2016, JAMA-J AM MED ASSOC, V315, P272, DOI 10.1001/jama.2015.18603; Burkner PC, 2017, J STAT SOFTW, V80, P1, DOI 10.18637/jss.v080.i01; Carpenter B, 2017, J STAT SOFTW, V76, P1, DOI 10.18637/jss.v076.i01; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Courtright KR, 2019, J GEN INTERN MED, V34, P1841, DOI 10.1007/s11606-019-05169-2; Detsky ME, 2017, JAMA-J AM MED ASSOC, V317, P2187, DOI 10.1001/jama.2017.4078; Downar J, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.11146; Downar J, 2017, CAN MED ASSOC J, V189, pE484, DOI 10.1503/cmaj.160775; Dy S, 2007, BMJ-BRIT MED J, V334, P511, DOI 10.1136/bmj.39127.653704.80; Elliott M, 2017, BMJ SUPPORT PALLIAT, V7, P32, DOI 10.1136/bmjspcare-2014-000679; Fitzmaurice Garrett M., 2004, APPL LONGITUDINAL AN, Vxvii; Frick S, 2003, CRIT CARE MED, V31, P456, DOI 10.1097/01.CCM.0000049945.69373.7C; Gane MD, 2013, NEPHRON CLIN PRACT, V123, P185, DOI 10.1159/000353735; Glare PA, 2008, J PALLIAT MED, V11, P84, DOI 10.1089/jpm.2008.9992; Goettler CE, 2010, J TRAUMA, V68, P1279, DOI 10.1097/TA.0b013e3181de3b99; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Heyland DK, 2013, JAMA INTERN MED, V173, P778, DOI 10.1001/jamainternmed.2013.180; Hill Andrea D, 2019, CMAJ Open, V7, pE306, DOI 10.9778/cmajo.20180097; Hsiao CK, 2011, J CLIN EPIDEMIOL, V64, P808, DOI 10.1016/j.jclinepi.2010.10.015; Hsu AT, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013666; Hudson KE, 2018, J PALLIAT MED, V21, P789, DOI 10.1089/jpm.2017.0509; Hui D, 2011, ONCOLOGIST, V16, P1642, DOI 10.1634/theoncologist.2011-0173; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Koffman J, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3612-0; Koffman J, 2009, J MED ETHICS, V35, P440, DOI 10.1136/jme.2008.027839; Kurahashi A, 41 ANN M SOC MED DEC, P1; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Moss AH, 2008, CLIN J AM SOC NEPHRO, V3, P1379, DOI 10.2215/CJN.00940208; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Pang WF, 2013, PERITON DIALYSIS INT, V33, P60, DOI 10.3747/pdi.2011.00204; POSES RM, 1990, ARCH INTERN MED, V150, P1874, DOI 10.1001/archinte.150.9.1874; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; POSES RM, 1991, CRIT CARE MED, V19, P1533, DOI 10.1097/00003246-199112000-00016; Quinn KL, 2019, CAN MED ASSOC J, V191, pE1369, DOI 10.1503/cmaj.190770; R Development Core Team, BOOK R LANG ENV STAT, P2021; Romo RD, 2017, CAN MED ASSOC J, V189, pE1072, DOI 10.1503/cmaj.733231; Royal College of Physicians and Surgeons Canada, 2015, OBJ TRAIN SPEC INT M; Stone P, 2012, BMJ SUPPORT PALLIAT, V2, P219, DOI 10.1136/bmjspcare-2012-000216; Thomas K., 2011, GOLD STANDARDS FRAME; van Walraven C, 2015, CAN MED ASSOC J, V187, P725, DOI 10.1503/cmaj.150209; Vincent JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8204; Vincent JL, 2010, CRIT CARE MED, V38, P283, DOI 10.1097/CCM.0b013e3181b785a2; Wegier P, 2019, BMJ QUAL SAF, V28, P971, DOI 10.1136/bmjqs-2018-009285; White N, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0907-4; You JJ, 2015, JAMA INTERN MED, V175, P549, DOI 10.1001/jamainternmed.2014.7732; Yourman LC, 2012, JAMA-J AM MED ASSOC, V307, P182, DOI 10.1001/jama.2011.1966	49	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247571	10.1371/journal.pone.0247571	http://dx.doi.org/10.1371/journal.pone.0247571			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QQ5BB	33630939	gold, Green Published			2023-01-03	WOS:000624536800050
J	Sampaziotis, F; Muraro, D; Tysoe, OC; Sawiak, S; Beach, TE; Godfrey, EM; Upponi, SS; Brevini, T; Wesley, BT; Garcia-Bernardo, J; Mahbubani, K; Canu, G; Gieseck, R; Berntsen, NL; Mulcahy, VL; Crick, K; Fear, C; Robinson, S; Swift, L; Gambardella, L; Bargehr, J; Ortmann, D; Brown, SE; Osnato, A; Murphy, MP; Corbett, G; Gelson, WTH; Mells, GF; Humphreys, P; Davies, SE; Amin, I; Gibbs, P; Sinha, S; Teichmann, SA; Butler, AJ; See, TC; Melum, E; Watson, CJE; Saeb-Parsy, K; Vallier, L				Sampaziotis, Fotios; Muraro, Daniele; Tysoe, Olivia C.; Sawiak, Stephen; Beach, Timothy E.; Godfrey, Edmund M.; Upponi, Sara S.; Brevini, Teresa; Wesley, Brandon T.; Garcia-Bernardo, Jose; Mahbubani, Krishnaa; Canu, Giovanni; Gieseck, Richard, III; Berntsen, Natalie L.; Mulcahy, Victoria L.; Crick, Keziah; Fear, Corrina; Robinson, Sharayne; Swift, Lisa; Gambardella, Laure; Bargehr, Johannes; Ortmann, Daniel; Brown, Stephanie E.; Osnato, Anna; Murphy, Michael P.; Corbett, Gareth; Gelson, William T. H.; Mells, George F.; Humphreys, Peter; Davies, Susan E.; Amin, Irum; Gibbs, Paul; Sinha, Sanjay; Teichmann, Sarah A.; Butler, Andrew J.; See, Teik Choon; Melum, Espen; Watson, Christopher J. E.; Saeb-Parsy, Kourosh; Vallier, Ludovic			Cholangiocyte organoids can repair bile ducts after transplantation in the human liver	SCIENCE			English	Article								Organoid technology holds great promise for regenerative medicine but has not yet been applied to humans. We address this challenge using cholangiocyte organoids in the context of cholangiopathies, which represent a key reason for liver transplantation. Using single-cell RNA sequencing, we show that primary human cholangiocytes display transcriptional diversity that is lost in organoid culture. However, cholangiocyte organoids remain plastic and resume their in vivo signatures when transplanted back in the biliary tree. We then utilize a model of cell engraftment in human livers undergoing ex vivo normothermic perfusion to demonstrate that this property allows extrahepatic organoids to repair human intrahepatic ducts after transplantation. Our results provide proof of principle that cholangiocyte organoids can be used to repair human biliary epithelium.	[Sampaziotis, Fotios; Muraro, Daniele; Tysoe, Olivia C.; Brevini, Teresa; Wesley, Brandon T.; Canu, Giovanni; Gambardella, Laure; Bargehr, Johannes; Ortmann, Daniel; Brown, Stephanie E.; Osnato, Anna; Humphreys, Peter; Sinha, Sanjay; Vallier, Ludovic] Wellcome MRC Cambridge Stem Cell Inst, Cambridge, Cambs, England; [Sampaziotis, Fotios; Mulcahy, Victoria L.; Gambardella, Laure; Bargehr, Johannes; Gelson, William T. H.; Mells, George F.; Sinha, Sanjay] Univ Cambridge, Dept Med, Cambridge, Cambs, England; [Sampaziotis, Fotios; Gelson, William T. H.; Mells, George F.] Cambridge Univ Hosp NHS Fdn Trust, Cambridge Liver Unit, Cambridge, Cambs, England; [Tysoe, Olivia C.; Beach, Timothy E.; Mahbubani, Krishnaa; Amin, Irum; Gibbs, Paul; Butler, Andrew J.; Watson, Christopher J. E.; Saeb-Parsy, Kourosh; Vallier, Ludovic] Univ Cambridge, Dept Surg, Cambridge, Cambs, England; [Tysoe, Olivia C.; Beach, Timothy E.; Mahbubani, Krishnaa; Amin, Irum; Gibbs, Paul; Butler, Andrew J.; Watson, Christopher J. E.; Saeb-Parsy, Kourosh; Vallier, Ludovic] NIHR Cambridge Biomed Res Ctr, Cambridge, Cambs, England; [Sawiak, Stephen] Univ Cambridge, Dept Clin Neurosci, Cambridge, Cambs, England; [Godfrey, Edmund M.; Upponi, Sara S.; See, Teik Choon] Cambridge Univ Hosp NHS Fdn Trust, Dept Radiol, Cambridge, Cambs, England; [Garcia-Bernardo, Jose; Teichmann, Sarah A.] Wellcome Sanger Inst, Wellcome Genome Campus, Hinxton, Cambs, England; [Gieseck, Richard, III] NIAID, Immunopathogenesis Sect, Lab Parasit Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Berntsen, Natalie L.; Melum, Espen] Oslo Univ Hosp, Rikshosp, Norwegian PSC Res Ctr, Dept Transplantat Med,Div Surg Inflammatory Dis &, Oslo, Norway; [Berntsen, Natalie L.; Melum, Espen] Oslo Univ Hosp, Res Inst Internal Med, Div Surg Inflammatory Dis & Transplantat, Oslo, Norway; [Berntsen, Natalie L.; Melum, Espen] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Mulcahy, Victoria L.; Mells, George F.] Univ Cambridge, Acad Dept Med Genet, Cambridge, Cambs, England; [Crick, Keziah; Fear, Corrina; Robinson, Sharayne; Swift, Lisa; Amin, Irum; Gibbs, Paul; Butler, Andrew J.; Watson, Christopher J. E.; Saeb-Parsy, Kourosh] Cambridge Univ Hosp NHS Fdn Trust, Dept Surg, Cambridge, Cambs, England; [Bargehr, Johannes] Univ Cambridge, Div Cardiovasc Med, Cambridge, Cambs, England; [Murphy, Michael P.] Univ Cambridge, MRC Mitochondrial Biol Unit, Cambridge, Cambs, England; [Corbett, Gareth] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, Cambs, England; [Davies, Susan E.] Cambridge Univ Hosp NHS Fdn Trust, Dept Histopathol, Cambridge, Cambs, England; [Teichmann, Sarah A.] Univ Cambridge, Dept Phys, Cavendish Lab, Cambridge, Cambs, England; [Melum, Espen] Oslo Univ Hosp, Rikshosp, Div Surg Inflammatory Dis & Transplantat, Sect Gastroenterol,Dept Transplantat Med, Oslo, Norway; [Melum, Espen] Univ Oslo, Fac Med, Hybrid Technol Hub Ctr Excellence, Inst Basic Med Sci, Oslo, Norway; [Watson, Christopher J. E.] Natl Inst Hlth Res NIHR, Cambridge Biomed Res Ctr, Cambridge, Cambs, England; [Watson, Christopher J. E.] NIHR Blood & Transplant Res Unit BTRU, Cambridge, Cambs, England; [Watson, Christopher J. E.] Univ Cambridge Collaborat Newcastle Univ & Partne, Cambridge, Cambs, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Wellcome Trust Sanger Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Oslo; National Hospital Norway; University of Oslo; University of Cambridge	Sampaziotis, F; Vallier, L (corresponding author), Wellcome MRC Cambridge Stem Cell Inst, Cambridge, Cambs, England.; Sampaziotis, F (corresponding author), Univ Cambridge, Dept Med, Cambridge, Cambs, England.; Sampaziotis, F (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Cambridge Liver Unit, Cambridge, Cambs, England.	fs347@cam.ac.uk; lv225@cam.ac.uk	Canu, Giovanni/AAN-8515-2021; Corbett, Gareth/GOK-1289-2022; Sawiak, Stephen/I-8944-2012	Canu, Giovanni/0000-0002-3349-4479; Saeb-Parsy, Kourosh/0000-0002-0633-3696; Vallier, Ludovic/0000-0002-3848-2602; Wesley, Brandon/0000-0003-0530-329X; Bargehr, Johannes/0000-0002-9304-3573; Sawiak, Stephen/0000-0003-4210-9816; Garcia-Bernardo, Jose/0000-0003-3626-5433	NIHR Clinical Lectureship; Academy of Medical Sciences Starter Grant for Clinical Lecturers; Addenbrooke's Charitable Trust; Rosetrees Trust; EASL Juan Rodes fellowship; Cambridge University Hospitals NIHR Biomedical Research Centre; Medical Research Council of the Wellcome-MRC Cambridge Stem Cell Institute; BHF Senior Research Fellowship [FS/18/46/33663]; NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]; ERC advanced grant New-Chol; Wellcome Trust; EPSRC [TS/H001220/1] Funding Source: UKRI; MRC [G0701448] Funding Source: UKRI	NIHR Clinical Lectureship; Academy of Medical Sciences Starter Grant for Clinical Lecturers; Addenbrooke's Charitable Trust; Rosetrees Trust(Rosetrees Trust); EASL Juan Rodes fellowship; Cambridge University Hospitals NIHR Biomedical Research Centre; Medical Research Council of the Wellcome-MRC Cambridge Stem Cell Institute; BHF Senior Research Fellowship; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); ERC advanced grant New-Chol; Wellcome Trust(Wellcome TrustEuropean Commission); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	F.S. was supported by an NIHR Clinical Lectureship, the Academy of Medical Sciences Starter Grant for Clinical Lecturers, the Addenbrooke's Charitable Trust, and the Rosetrees Trust. T.B. was supported an EASL Juan Rodes fellowship. The L.V. laboratory is funded by the ERC advanced grant New-Chol, the Cambridge University Hospitals NIHR Biomedical Research Centre, and the core support grant from the Wellcome Trust and Medical Research Council of the Wellcome-MRC Cambridge Stem Cell Institute. L.G. and S.Si. were supported by a BHF Senior Research Fellowship (FS/18/46/33663). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.	Aizarani N, 2019, NATURE, V572, P199, DOI 10.1038/s41586-019-1373-2; Arber C, 2013, SEMIN HEMATOL, V50, P131, DOI 10.1053/j.seminhematol.2013.03.026; Berntsen NL, 2018, AM J PHYSIOL-GASTR L, V314, pG349, DOI 10.1152/ajpgi.00124.2017; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Caballero B., 2003, **DROPPED REF**, V2, P471; Drost J, 2017, DEVELOPMENT, V144, P968, DOI 10.1242/dev.140566; Enestvedt CK, 2013, LIVER TRANSPLANT, V19, P965, DOI 10.1002/lt.23696; FARMER RG, 1975, GASTROENTEROLOGY, V68, P627; Haghverdi L, 2018, NAT BIOTECHNOL, V36, P421, DOI 10.1038/nbt.4091; Haghverdi L, 2016, NAT METHODS, V13, P845, DOI 10.1038/nmeth.3971; Kiselev VY, 2017, NAT METHODS, V14, P483, DOI [10.1038/NMETH.4236, 10.1038/nmeth.4236]; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kwon SB, 2008, TOXICOL PATHOL, V36, P660, DOI 10.1177/0192623308320272; MacParland SA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06318-7; Masyuk AI, 2006, HEPATOLOGY, V43, pS75, DOI 10.1002/hep.20996; McCarthy DJ, 2017, BIOINFORMATICS, V33, P1179, DOI 10.1093/bioinformatics/btw777; Nasralla D, 2018, NATURE, V557, P50, DOI 10.1038/s41586-018-0047-9; Parikh K, 2019, NATURE, V567, P49, DOI 10.1038/s41586-019-0992-y; Pepe-Mooney B. J., CELL STEM CELL, V25; Pepe-Mooney BJ, 2019, CELL STEM CELL, V25, P23, DOI 10.1016/j.stem.2019.04.004; Planas-Paz L, 2019, CELL STEM CELL, V25, P39, DOI 10.1016/j.stem.2019.04.005; Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]; Ravikumar R, 2016, AM J TRANSPLANT, V16, P1779, DOI 10.1111/ajt.13708; Rimland CA, 2021, HEPATOLOGY, V73, P247, DOI 10.1002/hep.31252; Sampaziotis F, 2017, NAT MED, V23, P954, DOI 10.1038/nm.4360; Sampaziotis F, 2017, NAT PROTOC, V12, P814, DOI 10.1038/nprot.2017.011; Sampaziotis F, 2015, NAT BIOTECHNOL, V33, P845, DOI 10.1038/nbt.3275; Si-Tayeb K, 2010, DEV CELL, V18, P175, DOI 10.1016/j.devcel.2010.01.011; Skaro AI, 2009, SURGERY, V146, P543, DOI 10.1016/j.surg.2009.06.052; Squires RH, 2014, HEPATOLOGY, V60, P362, DOI 10.1002/hep.27191; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tabibian JH, 2013, COMPR PHYSIOL, V3, P541, DOI 10.1002/cphy.c120019; Tysoe OC, 2019, NAT PROTOC, V14, P1884, DOI 10.1038/s41596-019-0168-0; Watson CJE, 2018, AM J TRANSPLANT, V18, P2005, DOI 10.1111/ajt.14687; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; Yoo KS, 2016, GUT LIVER, V10, P851, DOI 10.5009/gnl15600; Zappia L, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy083; Zong YW, 2011, INT J BIOCHEM CELL B, V43, P257, DOI 10.1016/j.biocel.2010.06.020; Zweers SJLB, 2012, HEPATOLOGY, V55, P575, DOI 10.1002/hep.24702	39	71	77	31	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	2021	371	6531					839	+		10.1126/science.aaz6964	http://dx.doi.org/10.1126/science.aaz6964			52	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ4MB	33602855	Green Submitted, Green Accepted			2023-01-03	WOS:000619664700055
J	Diress, M; Yeshaw, Y; Bantihun, M; Dagnew, B; Ambelu, A; Seid, MA; Akalu, Y				Diress, Mengistie; Yeshaw, Yigizie; Bantihun, Minychil; Dagnew, Baye; Ambelu, Adugnaw; Seid, Mohammed Abdu; Akalu, Yonas			Refractive error and its associated factors among pregnant women attending antenatal care unit at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia	PLOS ONE			English	Article							RISK-FACTORS; VISUAL IMPAIRMENT; VISION IMPAIRMENT; OCULAR CHANGES; PREVALENCE; BLINDNESS; EYE; POPULATION; MAGNITUDE; ADULTS	Background Refractive error is one of the commonly encountered problems during pregnancy and being the cause of deleterious effects on health. Despite its impacts, there is no evidence on the magnitude and associated factors of refractive error among pregnant women in Ethiopia. This study aimed to determine the prevalence of refractive error and its associated factors among pregnant women attending antenatal care unit at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2020. Methods An institution-based cross-sectional study was employed. An ocular examination was performed using Retinoscope and Snellen's illiterate "E" chart. The required data were collected using an interviewer-administered questionnaire which comprised socio-demographic, clinical and pregnancy-related variables. EpiData 3.02 and STATA 14 were used for data entry and analysis respectively. Both bivariable and multivariable binary logistic regression analyses were executed to identify factors associated with refractive error. Variables with a p-value <= 0.05 in the multivariable logistic regression analysis were declared as significantly associated factors with refractive error. Results A total of 401 pregnant women with a median age of 27 (IQR = 24-31) years participated in this study. The overall prevalence of refractive error among the study participants was 35.66% (95% CI: 30.95-40.37). Of the total study participants, ninety-two (22.90%) of them were myopic, forty-five (11.22%) were hyperopic and the rest were antimetropic. Increased maternal age (AOR = 1.31; 95% CI: 1.16-1.48)), increased parity (AOR = 3.17, 95% CI: 1.92-5.25), increased gestational age (AOR = 1.15, 95% CI: 1.08-1.22), and regular use of computers/ watching television (AOR = 6.19, 95% CI: 2.46-15.59) were significantly associated with refractive error. Conclusion The prevalence of refractive error among pregnant women was high where myopia was the most common variety. Advanced maternal age, increased gestational age, increased parity and regular use of computer or watching television were significantly associated with refractive error among pregnant women. Therefore, apart from providing other maternal health services, routine screening and evaluation of pregnant women for refractive error during antenatal care visit is recommended to avoid its negative impacts.	[Diress, Mengistie; Yeshaw, Yigizie; Dagnew, Baye; Ambelu, Adugnaw; Akalu, Yonas] Univ Gondar, Sch Med, Dept Human Physiol, Gondar, Ethiopia; [Yeshaw, Yigizie] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia; [Bantihun, Minychil] Univ Gondar, Sch Med, Dept Optometry, Gondar, Ethiopia; [Seid, Mohammed Abdu] Debre Tabor Univ, Sch Med, Dept Human Physiol, Debre Tabor, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Diress, M (corresponding author), Univ Gondar, Sch Med, Dept Human Physiol, Gondar, Ethiopia.	mengistiediress@gmail.com	Dagnew, Baye/AAL-9572-2020; Dagnew, Baye/AAS-3964-2021; Yeshaw, Yigizie/L-6336-2019	Dagnew, Baye/0000-0002-2397-5930; Dagnew, Baye/0000-0002-2397-5930; Diress, Mengistie/0000-0003-4186-4991; Yeshaw, Yigizie/0000-0003-4587-7925; Abdu Seid, Mohammed/0000-0002-3197-5332				Agrawal N, 2018, NEPAL J OPHTHALMOL, V10, P16, DOI 10.3126/nepjoph.v10i1.21685; Alemayehu AM AM., 2019, WORLD J OPHTHALMOL V, V2, P1; Andualem HB, 2017, CLIN OPTOM, V9, P85, DOI 10.2147/OPTO.S129326; [Anonymous], 2010, World Health Statistics 2010; Ari Budi Himawan, 2018, INT C PUBL HLTH, P288; ASTM, 2010, D4318 ASTM ASTM INT; Balasubramanian K, 2017, INT J SCI STUDY, V5, P89, DOI 10.17354/ijss/2017/342; Cappellini MD, 2015, SEMIN HEMATOL, V52, P261, DOI 10.1053/j.seminhematol.2015.07.006; Corbu Catalina., 2013, GINECO EU, V9; Dey A, 2013, KERALA J OPHTHALMOL, V25, P383; DO A., 2017, M J OPHT, V2; Ebeigbe JA, 2012, NIGER J CLIN PRACT, V15, P298, DOI 10.4103/1119-3077.100624; Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5; Gilbert C, 2018, CEYLON MED J, V63, pS33, DOI 10.4038/cmj.v63i5.8740; Gotovac M, 2013, COLLEGIUM ANTROPOL, V37, P189; Guan HY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215827; Hashemi H, 2018, J CURR OPHTHALMOL, V30, P3, DOI 10.1016/j.joco.2017.08.009; Ilhan C., 2018, EC OPHTHALMOLOGY, V9, P308; Irving EL, 2019, J OPTOM, V12, P55, DOI 10.1016/j.optom.2018.02.002; Jee D, 2016, ACTA OPHTHALMOL, V94, pE204, DOI 10.1111/aos.12776; Kaimbo DKW., 2014, SAJ CASE REP, V1, P105; Kalaiselvi B., 2019, INDIAN J CLIN EXPT O, V5, P219; Kalogeropoulos D, 2019, J OBSTET GYNAECOL, V39, P1037, DOI 10.1080/01443615.2019.1584891; Khalaj M., 2010, Journal of Mazandaran University of Medical Sciences, V20, P25; Kim Seung-Hyun, 2015, Korean J Ophthalmol, V29, P53, DOI 10.3341/kjo.2015.29.1.53; Kokab S, 2012, J EVOL MED DENT SCI-, V1, P1223, DOI 10.14260/jemds/199; Krishnaiah S, 2009, CLIN OPHTHALMOL, V3, P17; Kumar KSAB., 2016, INT J MED SCI PUBLIC, V5, P1364; Lee LK, 2007, SEMIN NEUROL, V27, P405, DOI 10.1055/s-2007-991124; Mehdizadehkashi K, 2018, J PREGNANCY, V2018, pCO, DOI 10.1155/2018/5280697; Mountjoy E, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2022; Naidoo K, 2014, BRIT J OPHTHALMOL, V98, P612, DOI 10.1136/bjophthalmol-2013-304081; Nkiru Z Nwachukwu, 2018, J Family Med Prim Care, V7, P1037, DOI 10.4103/jfmpc.jfmpc_335_17; Ofir D, 2015, ARCH GYNECOL OBSTET, V291, P519, DOI 10.1007/s00404-014-3412-4; Parrey MUR, 2019, PAK J MED SCI, V35, P394, DOI 10.12669/pjms.35.2.648; Peltzer K, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070811; Rai BB, 2021, GRAEF ARCH CLIN EXP, V259, P613, DOI 10.1007/s00417-020-04891-6; Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210; Rezai S., 2016, OBSTET GYNECOL INT J, V4; Richdale K, 2016, OPTOMETRY VISION SCI, V93, P3, DOI 10.1097/OPX.0000000000000757; Richdale K, 2013, INVEST OPHTH VIS SCI, V54, P1095, DOI 10.1167/iovs.12-10619; Roos NM, 2012, OBSTET GYNECOL SURV, V67, P242, DOI 10.1097/OGX.0b013e318250a457; Saad A., 2007, Eastern Mediterranean Health Journal, V13, P819; Sabel BA, 2018, EPMA J, V9, P133, DOI 10.1007/s13167-018-0136-8; Samra Khawla Abu, 2013, Oman J Ophthalmol, V6, P87, DOI 10.4103/0974-620X.116626; Sanghavi M, 2014, CIRCULATION, V130, P1003, DOI 10.1161/CIRCULATIONAHA.114.009029; Semanyenzi S., 2015, RWANDA MED J, V72, P8; Sewunet SA, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-95; Shaaban YM, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1263-2; Sharma S, 2006, AUST NZ J OBSTET GYN, V46, P186, DOI 10.1111/j.1479-828X.2006.00569.x; Skalicky SE, 2016, OCULAR VISUAL PHYSL; Stadler Tanja, 2014, PLoS Curr, V6, DOI 10.1371/currents.outbreaks.02bc6d927ecee7bbd33532ec8ba6a25f; Stambolian D, 2013, CLIN GENET, V84, P102, DOI 10.1111/cge.12180; Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025; Tan CSH, 2011, EYE, V25, P1294, DOI 10.1038/eye.2011.144; Toygar O, 2015, TURK J MED SCI, V45, P651, DOI 10.3906/sag-1404-153; Vidusha KSS., 2018, INT J COMMUNITY MED, V5, P1471, DOI 10.18203/2394-6040.ijcmph20181219; Wang M, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1042-0; World Health Organization, 2007, PREV CARD DIS GUID A; Wu FC, 2020, GRAEF ARCH CLIN EXP, V258, P663, DOI 10.1007/s00417-019-04552-3; Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035; Yarbag A, 2015, PAK J MED SCI, V31, P1481, DOI 10.12669/pjms.316.8204; Yemane Berhane, 2007, Ethiopian Journal of Health Development, V21, P204	63	2	2	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2021	16	2							e0246174	10.1371/journal.pone.0246174	http://dx.doi.org/10.1371/journal.pone.0246174			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK0KW	33577552	Green Published, gold			2023-01-03	WOS:000620071700007
J	Tome, R; Rangel, MA; Gibson-Davis, CM; Bellows, L				Tome, Romina; Rangel, Marcos A.; Gibson-Davis, Christina M.; Bellows, Laura			Heightened immigration enforcement impacts US citizens' birth outcomes: Evidence from early ICE interventions in North Carolina	PLOS ONE			English	Article							CORTICOTROPIN-RELEASING HORMONE; PREGNANCY; STRESS; HEALTH; DEPORTATION; ASSOCIATION; CHILDREN; ANXIETY; INDEX	We examine how increased Immigration and Customs Enforcement (ICE) activities impacted newborn health and prenatal care utilization in North Carolina around the time Section 287(g) of the Immigration and Nationality Act was first being implemented within the state. Focusing on administrative data between 2004 and 2006, we conduct difference-in-differences and triple-difference case-control regression analysis. Pregnancies were classified by levels of potential exposure to immigration enforcement depending on parental nativity and educational attainment. Contrast groups were foreign-born parents residing in nonadopting counties and all US-born non-Hispanic parents. The introduction of the program was estimated to decrease birth weight by 58.54 grams (95% confidence interval [CI], -83.52 to -33.54) with effects likely following from reduced intrauterine growth. These results are shown to coexist with a worsening in the timing of initiation and frequency of prenatal care received. Since birth outcomes influence health, education, and earnings trajectories, our findings suggest that the uptick in ICE activities can have large socioeconomic costs over US-born citizens.	[Tome, Romina; Rangel, Marcos A.; Gibson-Davis, Christina M.; Bellows, Laura] Duke Univ, Sanford Sch Publ Policy, Durham, NC 27708 USA; [Tome, Romina] Amer Inst Res, Washington, DC USA; [Bellows, Laura] Univ Virginia, Curry Sch Educ & Human Dev, Charlottesville, VA USA	Duke University; American Institutes for Research; University of Virginia	Gibson-Davis, CM (corresponding author), Duke Univ, Sanford Sch Publ Policy, Durham, NC 27708 USA.	cgibson@duke.edu	Bellows, Laura/AAS-6882-2021	Bellows, Laura/0000-0003-4388-0696; De Almeida Rangel, Marcos/0000-0001-9527-5127	NICHD NIH HHS [P2C HD065563] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abraham S, 2018, SSRN ELECT J; Aizer A, 2014, SCIENCE, V344, P856, DOI 10.1126/science.1251872; Almond D, 2011, REV ECON STAT, V93, P387, DOI 10.1162/REST_a_00089; Arbona C, 2010, HISPANIC J BEHAV SCI, V32, P362, DOI 10.1177/0739986310373210; Arriaga F, 2017, SOCIOL RACE ETHNIC, V3, P417, DOI 10.1177/2332649217700923; Athey S., 2018, W24963 NBER; Barbazanges A, 1996, J NEUROSCI, V16, P3943; BARKER DJP, 1990, BRIT MED J, V301, P1111, DOI 10.1136/bmj.301.6761.1111; Black SE, 2007, Q J ECON, V122, P409, DOI 10.1162/qjec.122.1.409; Brabeck KM, 2014, AM J ORTHOPSYCHIAT, V84, P496, DOI 10.1037/ort0000011; Capps R., 2011, DELEGATION DIVERGENC; Capps R., 2018, REVVING DEPORTATION; Case A, 2005, J HEALTH ECON, V24, P365, DOI 10.1016/j.jhealeco.2004.09.008; Castaneda H, 2015, ANNU REV PUBL HEALTH, V36, P375, DOI 10.1146/annurev-publhealth-032013-182419; Chaudry A., 2010, INT MIGR REV, DOI DOI 10.1111/IMRE.12106.16; Dee TS, 2020, AM EDUC RES J, V57, P694, DOI 10.3102/0002831219860816; Dreby J, 2012, J MARRIAGE FAM, V74, P829, DOI 10.1111/j.1741-3737.2012.00989.x; East C.N., 2018, 11486 IZA DP; Eika L, 2019, J POLIT ECON, V127, P2795, DOI 10.1086/702018; Ellis M, 2016, ANN AM ASSOC GEOGR, V106, P891, DOI 10.1080/24694452.2015.1135725; Gemmill A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7084; Golash-Boza T, 2013, LAT STUD, V11, P271, DOI 10.1057/lst.2013.14; Gonzalez-Barrera A., 2016, US IMMIGRANT DEPORTA; Goodman-Bacon, 2018, W25018 NBER; Governor's Office of Hispanic/Latino Affairs, 2011, DEMOGRAPHIC TRENDS H; Hagan J, 2003, INT MIGR REV, V37, P444; Hobel CJ, 1999, AM J OBSTET GYNECOL, V180, pS257, DOI 10.1016/S0002-9378(99)70712-X; Hoffman S, 1996, PAEDIATR PERINAT EP, V10, P380, DOI 10.1111/j.1365-3016.1996.tb00063.x; Hoynes H, 2011, J PUBLIC ECON, V95, P813, DOI 10.1016/j.jpubeco.2010.12.006; Huizink AC, 2003, J CHILD PSYCHOL PSYC, V44, P810, DOI 10.1111/1469-7610.00166; Koball H., 2015, HLTH SOCIAL SERVICE; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1486, DOI 10.2105/AJPH.84.9.1486; Lobel M, 2008, HEALTH PSYCHOL, V27, P604, DOI 10.1037/a0013242; Nguyen MT, 2016, URBAN STUD, V53, P302, DOI 10.1177/0042098014563029; Majzoub JA, 1999, AM J OBSTET GYNECOL, V180, pS242, DOI 10.1016/S0002-9378(99)70708-8; McLean M, 1999, TRENDS ENDOCRIN MET, V10, P174, DOI 10.1016/S1043-2760(98)00146-5; Meaney MJ, 1996, DEV NEUROSCI-BASEL, V18, P49, DOI 10.1159/000111395; Mulder EJH, 2002, EARLY HUM DEV, V70, P3, DOI 10.1016/S0378-3782(02)00075-0; Nguyen M. T., 2010, 287 G PROGRAM COSTS; Novak NL, 2017, INT J EPIDEMIOL, V46, P839, DOI 10.1093/ije/dyw346; O'Connor TG, 2002, BRIT J PSYCHIAT, V180, P502, DOI 10.1192/bjp.180.6.502; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; Passel J.S., 2019, US UNAUTHORIZED IMMI; Passel J.S., 2019, MEXICANS DECLINE LES; Pham H., 2018, WASH LEE L REV, V75, P1253; Potochnick S, 2017, J IMMIGR MINOR HEALT, V19, P1042, DOI 10.1007/s10903-016-0464-5; Rhodes SD, 2015, AM J PUBLIC HEALTH, V105, P329, DOI 10.2105/AJPH.2014.302218; Shonkoff JP, 2009, JAMA-J AM MED ASSOC, V301, P2252, DOI 10.1001/jama.2009.754; Strauss RS, 2000, JAMA-J AM MED ASSOC, V283, P625, DOI 10.1001/jama.283.5.625; Teixeira JMA, 1999, BRIT MED J, V318, P153, DOI 10.1136/bmj.318.7177.153; Torche F, 2019, AM J EPIDEMIOL, V188, P24, DOI 10.1093/aje/kwy218; US President, 2017, EXECUTIVE ORDER ENHA; Wallace SP, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.10.016; Watson T, 2014, AM ECON J-ECON POLIC, V6, P313, DOI 10.1257/pol.6.3.313; Woods SM, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.07.041; Yang SM, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-104; Young MED, 2019, AM J PUBLIC HEALTH, V109, P1171, DOI [10.2105/ajph.2019.305171, 10.2105/AJPH.2019.305171]; Young MED, 2019, ETHNIC HEALTH, V24, P960, DOI 10.1080/13557858.2017.1390074; Yu B, 2018, ACTA PAEDIATR, V107, P86, DOI 10.1111/apa.13993	59	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2021	16	2							e0245020	10.1371/journal.pone.0245020	http://dx.doi.org/10.1371/journal.pone.0245020			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QF2OR	33534807	Green Published, gold			2023-01-03	WOS:000616739700037
J	Raynor, PC; Adesina, A; Aboubakr, HA; Yang, M; Torremorell, M; Goyal, SM				Raynor, Peter C.; Adesina, Adepeju; Aboubakr, Hamada A.; Yang, My; Torremorell, Montserrat; Goyal, Sagar M.			Comparison of samplers collecting airborne influenza viruses: 1. Primarily impingers and cyclones	PLOS ONE			English	Article							PARTICLE BOUNCE; A VIRUSES; SWINE; INFECTIONS; IMPACTOR; SURVIVAL; TRANSMISSION; PATHOGENESIS; SUBSTRATE; OUTBREAKS	Researchers must be able to measure concentrations, sizes, and infectivity of virus-containing particles in animal agriculture facilities to know how far infectious virus-containing particles may travel through air, where they may deposit in the human or animal respiratory tract, and the most effective ways to limit exposures to them. The objective of this study was to evaluate a variety of impinger and cyclone aerosol or bioaerosol samplers to determine approaches most suitable for detecting and measuring concentrations of virus-containing particles in air. Six impinger/cyclone air samplers, a filter-based sampler, and a cascade impactor were used in separate tests to collect artificially generated aerosols of MS2 bacteriophage and swine and avian influenza viruses. Quantification of infectious MS2 coliphage was carried out using a double agar layer procedure. The influenza viruses were titrated in cell cultures to determine quantities of infectious virus. Viral RNA was extracted and used for quantitative real time RT-PCR, to provide total virus concentrations for all three viruses. The amounts of virus recovered and the measured airborne virus concentrations were calculated and compared among the samplers. Not surprisingly, high flow rate samplers generally collected greater quantities of virus than low flow samplers. However, low flow rate samplers generally measured higher, and likely more accurate, airborne concentrations of Infectious virus and viral RNA than high flow samplers. To assess airborne viruses in the field, a two-sampler approach may work well. A suitable high flow sampler may provide low limits of detection to determine if any virus is present in the air. If virus is detected, a suitable lower flow sampler may measure airborne virus concentrations accurately.	[Raynor, Peter C.; Adesina, Adepeju] Univ Minnesota, Sch Publ Hlth, Div Environm Hlth Sci, Minneapolis, MN 55455 USA; [Aboubakr, Hamada A.; Yang, My; Torremorell, Montserrat; Goyal, Sagar M.] Univ Minnesota, Coll Vet Med, Vet Populat Med Dept, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Raynor, PC (corresponding author), Univ Minnesota, Sch Publ Hlth, Div Environm Hlth Sci, Minneapolis, MN 55455 USA.	praynor@umn.edu	Aboubakr, Hamada/I-7604-2016	Aboubakr, Hamada/0000-0002-8233-2353; goyal, sagar/0000-0002-7781-3080	National Institute of Occupational Safety and Health [U54 OH010170]	National Institute of Occupational Safety and Health(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))	PCR: This research was conducted through the Upper Midwest Agricultural Safety and Health (UMASH) Center, which is funded by cooperative agreement U54 OH010170 from the National Institute of Occupational Safety and Health, http://www.cdc.gov/niosh.The funders had no role in study design, data collection and analysis,	Agranovski IE, 2005, AEROSOL SCI TECH, V39, P912, DOI 10.1080/02786820500297012; Alonso C, 2017, J VET DIAGN INVEST, V29, P298, DOI 10.1177/1040638717700221; Alonso C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135675; Appert J, 2012, AEROSOL SCI TECH, V46, P249, DOI 10.1080/02786826.2011.619224; Arriola CS, 2015, EMERG INFECT DIS, V21, P2135, DOI 10.3201/eid2112.150904; BENBOUGH JE, 1971, J GEN VIROL, V10, P209, DOI 10.1099/0022-1317-10-3-209; Blachere FM, 2009, CLIN INFECT DIS, V48, P438, DOI 10.1086/596478; Bridges CB, 2002, J INFECT DIS, V185, P1005, DOI 10.1086/340044; Chang MC, 1999, ATMOS ENVIRON, V33, P2313, DOI 10.1016/S1352-2310(99)00082-5; Chen PS, 2009, AEROSOL SCI TECH, V43, P290, DOI 10.1080/02786820802621232; Chen Y, 2013, LANCET, V381, P1916, DOI 10.1016/S0140-6736(13)60903-4; Choi MJ, 2015, CLIN INFECT DIS, V61, P1355, DOI 10.1093/cid/civ618; Corzo CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071444; Corzo CA, 2013, VET J, V196, P171, DOI 10.1016/j.tvjl.2012.09.024; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; DZUBAY TG, 1976, ATMOS ENVIRON, V10, P229, DOI 10.1016/0004-6981(76)90095-0; Fabian P, 2009, INDOOR AIR, V19, P433, DOI 10.1111/j.1600-0668.2009.00609.x; Fabian P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002691; Ge S, 2014, AEROSOL SCI TECH, V48, P1360, DOI 10.1080/02786826.2014.984800; Gray GC, 2007, EMERG INFECT DIS, V13, P1871, DOI 10.3201/eid1312.061323; Herfst S, 2014, CURR TOP MICROBIOL, V385, P137, DOI 10.1007/82_2014_387; Hogan CJ, 2005, J APPL MICROBIOL, V99, P1422, DOI 10.1111/j.1365-2672.2005.02720.x; IJAZ MK, 1987, J VIROL METHODS, V18, P87, DOI 10.1016/0166-0934(87)90114-5; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Khalili SF, 2018, RES PHARM SCI, V13, P283, DOI 10.4103/1735-5362.228958; Kormuth KA, 2018, J INFECT DIS, V218, P739, DOI 10.1093/infdis/jiy221; Lednicky J, 2016, AEROSOL SCI TECH, V50, pI, DOI 10.1080/02786826.2016.1179254; Lee DH, 2015, J VIROL, V89, P6521, DOI 10.1128/JVI.00728-15; Leith D, 1996, AM IND HYG ASSOC J, V57, P1137, DOI 10.1202/0002-8894(1996)057<1137:LMOOMC>2.0.CO;2; Lindsley WG, 2006, J ENVIRON MONITOR, V8, P1136, DOI 10.1039/b609083d; Lindsley WG, 2010, CLIN INFECT DIS, V50, P693, DOI 10.1086/650457; Ma W, 2009, ZOONOSES PUBLIC HLTH, V56, P326, DOI 10.1111/j.1863-2378.2008.01217.x; Maines TR, 2009, SCIENCE, V325, P484, DOI 10.1126/science.1177238; Marple VA, 2020, AEROSOL MEASUREMENT, P129; Mitchell JP, 2009, AAPS PHARMSCITECH, V10, P243, DOI 10.1208/s12249-009-9202-9; Mitchell J.P., 2003, DRUG DELIV LUNG, V14, P75; Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730; Musher DM, 2003, NEW ENGL J MED, V348, P1256, DOI 10.1056/NEJMra021771; Neira V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146616; O'Connell KP, 2006, APPL ENVIRON MICROB, V72, P478, DOI 10.1128/AEM.72.1.478-483.2006; Occupational Safety and Health Administration, 2010, OSHA FACT SHEET INFL; Occupational Safety and Health Administration, 2006, OSHA GUID UPD PROT E; PAK SS, 1992, AEROSOL SCI TECH, V16, P141, DOI 10.1080/02786829208959544; Pearce MB, 2012, P NATL ACAD SCI USA, V109, P3944, DOI 10.1073/pnas.1119945109; SATTAR SA, 1987, CRIT REV ENV CONTR, V17, P89, DOI 10.1080/10643388709388331; Slomka MJ, 2010, INFLUENZA OTHER RESP, V4, P277, DOI 10.1111/j.1750-2659.2010.00149.x; Tellier R, 2009, J R SOC INTERFACE, V6, pS783, DOI 10.1098/rsif.2009.0302.focus; Torremorell M, 2016, AVIAN DIS, V60, P637, DOI 10.1637/11395-021816-Reg.1; Uhrbrand K, 2018, J APPL MICROBIOL, V124, P990, DOI 10.1111/jam.13588; Verreault D, 2008, MICROBIOL MOL BIOL R, V72, P413, DOI 10.1128/MMBR.00002-08; Willeke K, 1998, AEROSOL SCI TECH, V28, P439, DOI 10.1080/02786829808965536; Wong KK, 2012, EMERG INFECT DIS, V18, P1937, DOI 10.3201/eid1812.121097; Yang W, 2011, J R SOC INTERFACE, V8, P1176, DOI 10.1098/rsif.2010.0686; Zuo ZL, 2014, APPL ENVIRON MICROB, V80, P2796, DOI 10.1128/AEM.00056-14	55	6	6	4	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2021	16	1							e0244977	10.1371/journal.pone.0244977	http://dx.doi.org/10.1371/journal.pone.0244977			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF7LJ	33507951	Green Published, gold			2023-01-03	WOS:000635021400027
J	Lalani, S; Dosani, A; Forcheh, N; Premji, SS; Siddiqui, S; Shaikh, K; Mian, A; Yim, IS				Lalani, Sharifa; Dosani, Aliyah; Forcheh, Ntonghanwah; Premji, Shahirose Sadrudin; Siddiqui, Sana; Shaikh, Kiran; Mian, Ayesha; Yim, Ilona S.		Maternal-infant Global Hlth Team M	Perceived stress may mediate the relationship between antenatal depressive symptoms and preterm birth: A pilot observational cohort study	PLOS ONE			English	Article							PREGNANCY-RELATED ANXIETY; MIDDLE-INCOME COUNTRIES; GESTATIONAL-AGE; MATERNAL STRESS; RISK-FACTORS; PSYCHOLOGICAL DISTRESS; PRENATAL STRESS; WOMEN; OUTCOMES; PREVALENCE	Background Screening for changes in pregnancy-related anxiety and depressive symptoms during pregnancy may further our understanding of the relationship between these two variables and preterm birth. Objectives To determine whether changes in pregnancy-related anxiety and depressive symptoms during pregnancy influence the risk of preterm birth among Pakistani women; explore whether perceived stress moderates or mediates this relationship, and examine the relationship between the various components of pregnancy-related anxiety and preterm birth. Methods A prospective cohort study design was used to recruit a diverse sample of 300 low-risk pregnant women from four centers of Aga Khan Hospital for Women and Children in Karachi, Pakistan. Changes in pregnancy-related anxiety and depressive symptoms during pregnancy were tested. Multiple logistic regression analysis was used to determine a predictive model for preterm birth. We then determined if the influence of perceived stress could moderate or mediate the effect of depressive symptoms on preterm birth. Results Changes in pregnancy-related anxiety (OR = 1.1, CI 0.97-1.17, p = 0.167) and depressive symptoms (OR = 0.9, CI 0.85-1.03, p = 0.179) were insignificant as predictors of preterm birth after adjusting for the effects of maternal education and family type. When perceived stress was added into the model, we found that changes in depressive symptoms became marginally significant after adjusting for covariates (OR = 0.9, CI 0.82-1.01, p = 0.082). After adjusting for the mediation effect of change in perceived stress, the effect of change in depressive symptoms on preterm birth were marginally significant after adjusting for covariates. Among six different dimensions of pregnancy-related anxiety, mother's concerns about fetal health showed a trend towards being predictive of preterm birth (OR = 1.3, CI 0.97-1.72, p = 0.078). Conclusions There may be a relationship between perceived stress and antenatal depressive symptoms and preterm birth. This is the first study of its kind to be conducted in Pakistan. Further research is required to validate these results.	[Lalani, Sharifa; Shaikh, Kiran] Aga Khan Univ, Sch Nursing & Midwifery, Karachi, Pakistan; [Dosani, Aliyah] Mt Royal Univ, Sch Nursing & Midwifery, Calgary, AB, Canada; [Dosani, Aliyah] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Forcheh, Ntonghanwah; Premji, Shahirose Sadrudin] Univ Toronto, Sch Nursing York, Toronto, ON, Canada; [Siddiqui, Sana; Mian, Ayesha] Aga Khan Univ, Dept Psychiat, Karachi, Pakistan; [Yim, Ilona S.] Univ Calif Irvine, Dept Psychol Sci, Irvine, CA USA	Aga Khan University; Mount Royal University; University of Calgary; University of Toronto; Aga Khan University; University of California System; University of California Irvine	Dosani, A (corresponding author), Mt Royal Univ, Sch Nursing & Midwifery, Calgary, AB, Canada.; Dosani, A (corresponding author), Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada.	adosani@mtroyal.ca		Sadrudin Premji, Shahirose/0000-0003-0323-8009; Forcheh, Ntonghanwah/0000-0003-3734-5072	Canadian Institutes of Health Research [264531, 376731-PJT]; Aga Khan University, University Research Council Multi-Disciplinary Project [144005SONAM]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Aga Khan University, University Research Council Multi-Disciplinary Project	Canadian Institutes of Health Research (Planning Grant Number 264531; Project Grant Number 376731-PJT. SSP received the funding) and Aga Khan University, University Research Council Multi-Disciplinary Project (Grant Number 144005SONAM. SK received the funding). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adrian JA, 2020, CHILD NEUROPSYCHOL, V26, P834, DOI 10.1080/09297049.2020.1761313; Astone NM, 2007, PAEDIATR PERINAT EP, V21, P310, DOI 10.1111/j.1365-3016.2007.00821.x; Batra K, 2020, ASIAN J PSYCHIATR, V54, DOI 10.1016/j.ajp.2020.102436; Bayrampour H, 2016, INT J NURS STUD, V55, P115, DOI 10.1016/j.ijnurstu.2015.10.023; Bergink V, 2011, J PSYCHOSOM RES, V70, P385, DOI 10.1016/j.jpsychores.2010.07.008; Biaggi A, 2016, J AFFECT DISORDERS, V191, P62, DOI 10.1016/j.jad.2015.11.014; Blackmore ER, 2016, J AFFECT DISORDERS, V197, P251, DOI 10.1016/j.jad.2016.03.008; Boyd RC, 2005, ARCH WOMEN MENT HLTH, V8, P141, DOI 10.1007/s00737-005-0096-6; Bright KS, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00467; Brunton RJ, 2019, WOMEN BIRTH, V32, pE118, DOI 10.1016/j.wombi.2018.05.004; Bushnik T, 2017, HEALTH REP, V28, P3; Buss C, 2011, STRESS, V14, P665, DOI 10.3109/10253890.2011.623250; Bussieres EL, 2015, DEV REV, V36, P179, DOI 10.1016/j.dr.2015.04.001; Canady RB, 2009, EGYPT J PSYCHIAT, V17, P91, DOI DOI 10.4103/1110-1105.158117; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cohen S, 2012, J APPL SOC PSYCHOL, V42, P1320, DOI 10.1111/j.1559-1816.2012.00900.x; Corbani IE, 2017, INT J SOC PSYCHIATR, V63, P622, DOI 10.1177/0020764017725543; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Dadi AF, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8293-9; Dadi AF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227323; Devi T., 2020, AUTHOREA, DOI [10.22541/au.158758076.65534162, DOI 10.22541/AU.158758076.65534162]; Doktorchik C, 2018, J AFFECT DISORDERS, V227, P71, DOI 10.1016/j.jad.2017.10.001; Dole N, 2003, AM J EPIDEMIOL, V157, P14, DOI 10.1093/aje/kwf176; Fisher J, 2012, B WORLD HEALTH ORGAN, V90, P139, DOI 10.2471/BLT.11.091850; Fransson E, 2011, BIRTH-ISS PERINAT C, V38, P10, DOI 10.1111/j.1523-536X.2010.00441.x; Gavin AR, 2009, WOMEN HEALTH ISS, V19, P325, DOI 10.1016/j.whi.2009.05.004; Gelaye B, 2016, LANCET PSYCHIAT, V3, P973, DOI 10.1016/S2215-0366(16)30284-X; Ghimire U, 2021, EARLY HUM DEV, V152, DOI 10.1016/j.earlhumdev.2020.105243; Ghosh JKC, 2010, ARCH WOMEN MENT HLTH, V13, P327, DOI 10.1007/s00737-009-0135-9; Giurgescu C, 2012, JOGNN-J OBST GYN NEO, V41, pE51, DOI 10.1111/j.1552-6909.2012.01409.x; Glynn LM, 2008, HEALTH PSYCHOL, V27, P43, DOI 10.1037/0278-6133.27.1.43; Grote NK, 2010, ARCH GEN PSYCHIAT, V67, P1012, DOI 10.1001/archgenpsychiatry.2010.111; Guardino CM., 2014, ZERO 3, V34, P12; Hanif A, 2017, ANN KING EDWARD MED, V23, P229; Hayes A. F., 2013, MODEL TEMPLATES PROC; Hayes A. F., 2013, MEDIATION MODERATION; Hobel CJ, 2008, CLIN OBSTET GYNECOL, V51, P333, DOI 10.1097/GRF.0b013e31816f2709; Hoffman S, 2000, HEALTH PSYCHOL, V19, P535, DOI 10.1037/0278-6133.19.6.535; Huizink AC, 2004, EARLY HUM DEV, V79, P81, DOI 10.1016/j.earlhumdev.2004.04.014; Huizink AC, 2003, J CHILD PSYCHOL PSYC, V44, P810, DOI 10.1111/1469-7610.00166; Huizink AC, 2002, J AM ACAD CHILD PSY, V41, P1078, DOI 10.1097/00004583-200209000-00008; Hung HY, 2021, J AFFECT DISORDERS, V280, P156, DOI 10.1016/j.jad.2020.10.062; Kane HS, 2014, BIOL PSYCHOL, V100, P13, DOI 10.1016/j.biopsycho.2014.04.003; Krabbendam L, 2005, PAEDIATR PERINAT EP, V19, P421, DOI 10.1111/j.1365-3016.2005.00679.x; Kramer MS, 2009, AM J EPIDEMIOL, V169, P1319, DOI 10.1093/aje/kwp061; Li D, 2009, HUM REPROD, V24, P146, DOI 10.1093/humrep/den342; Liu C, 2016, BJOG-INT J OBSTET GY, V123, P1973, DOI 10.1111/1471-0528.13891; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; Mancuso RA, 2004, PSYCHOSOM MED, V66, P762, DOI 10.1097/01.psy.0000138284.70670.d5; McEwen B, 2012, ALLOSTATIC LOAD REV; McEwen Bruce S, 2006, Dialogues Clin Neurosci, V8, P367; McEwen BS, 2003, HORM BEHAV, V43, P2, DOI 10.1016/S0018-506X(02)00024-7; Murphy DJ, 2007, BEST PRACT RES CL OB, V21, P773, DOI 10.1016/j.bpobgyn.2007.03.001; Murray D., 1990, J REPROD INFANT PSYC, V8, P99, DOI [DOI 10.1080/02646839008403615, 10.1080/02646839008403615]; Navarro P, 2007, GEN HOSP PSYCHIAT, V29, P1, DOI 10.1016/j.genhosppsych.2006.10.004; Neggers Y, 2006, ACTA OBSTET GYN SCAN, V85, P277, DOI 10.1080/00016340600566121; Nordeng H, 2012, J CLIN PSYCHOPHARM, V32, P186, DOI 10.1097/JCP.0b013e3182490eaf; Orr ST, 1997, WOMEN HEALTH ISS, V7, P38, DOI 10.1016/S1049-3867(96)00017-5; Orr ST, 2002, AM J EPIDEMIOL, V156, P797, DOI 10.1093/aje/kwf131; Orr ST, 2007, PSYCHOSOM MED, V69, P566, DOI 10.1097/PSY.0b013e3180cac25d; Parker Jennifer D., 1994, Annals of Epidemiology, V4, P271; Premji S, 2014, MATERN CHILD HLTH J, V18, P2393, DOI 10.1007/s10995-014-1479-y; Premji SS, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/450309; Purisch SE, 2017, SEMIN PERINATOL, V41, P387, DOI 10.1053/j.semperi.2017.07.009; Quinn JA, 2016, VACCINE, V34, P6047, DOI 10.1016/j.vaccine.2016.03.045; Rahman A, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001462; Rauchfuss M, 2011, J PERINAT MED, V39, P515, DOI [10.1515/JPM.2011.067, 10.1515/jpm.2011.067]; Rini CK, 1999, HEALTH PSYCHOL, V18, P333, DOI 10.1037/0278-6133.18.4.333; Rosario MK, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016072; Sandman CA, 2011, PRETERM BIRTH - MOTHER AND CHILD, P95; Sealy-Jefferson S, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2019.100362; Seravalli L, 2014, J MIDWIFERY WOM HEAL, V59, P374, DOI 10.1111/jmwh.12088; Shaikh K, 2020, J AFFECT DISORDERS, V267, P49, DOI 10.1016/j.jad.2020.01.180; Sinesi A, 2019, BJPSYCH OPEN, V5, DOI 10.1192/bjo.2018.75; Smith MV, 2011, MATERN CHILD HLTH J, V15, P401, DOI 10.1007/s10995-010-0595-6; Speilberger CD., 2010, STATE TRAIT ANXIETY, DOI [10.1016/j.jopan.2010.03.006, DOI 10.1016/J.JOPAN.2010.03.006]; Staneva A, 2015, WOMEN BIRTH, V28, P179, DOI 10.1016/j.wombi.2015.02.003; Straub H, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.06.033; Sungkar A, 2017, MED J INDONES, V26, P198, DOI 10.13181/mji.v26i3.1454; Suri R, 2007, AM J PSYCHIAT, V164, P1206, DOI 10.1176/appi.ajp.2007.06071172; Surkan PJ, 2019, J PSYCHOSOM OBST GYN, V40, P48, DOI 10.1080/0167482X.2017.1398725; Tomfohr-Madsen L, 2019, HEALTH PSYCHOL, V38, P1025, DOI 10.1037/hea0000792; Wadhwa PD, 2011, CLIN PERINATOL, V38, P351, DOI 10.1016/j.clp.2011.06.007; Wall V, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020056; Wegman HL, 2009, PSYCHOSOM MED, V71, P805, DOI 10.1097/PSY.0b013e3181bb2b46; Weis KL, 2020, MIL MED, V185, pE678, DOI 10.1093/milmed/usz399; Whitehead N, 2010, ETHNIC DIS, V20, P261; World Health Organization, 2008, MAT MENT HLTH CHILD; Yonkers KA, 2012, EPIDEMIOLOGY, V23, P677, DOI 10.1097/EDE.0b013e31825838e9	90	1	1	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2021	16	5							e0250982	10.1371/journal.pone.0250982	http://dx.doi.org/10.1371/journal.pone.0250982			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6FM	33945579	Green Published, gold			2023-01-03	WOS:000664609600033
J	Da Mesquita, S; Papadopoulos, Z; Dykstra, T; Brase, L; Farias, FG; Wall, M; Jiang, H; Kodira, CD; de Lima, KA; Herz, J; Louveau, A; Goldman, DH; Salvador, AF; Onengut-Gumuscu, S; Farber, E; Dabhi, N; Kennedy, T; Milam, MG; Baker, W; Smirnov, I; Rich, SS; Benitez, BA; Karch, CM; Perrin, RJ; Farlow, M; Chhatwal, JP; Holtzman, DM; Cruchaga, C; Harari, O; Kipnis, J				Da Mesquita, Sandro; Papadopoulos, Zachary; Dykstra, Taitea; Brase, Logan; Farias, Fabiana Geraldo; Wall, Morgan; Jiang, Hong; Kodira, Chinnappa Dilip; de Lima, Kalil Alves; Herz, Jasmin; Louveau, Antoine; Goldman, Dylan H.; Salvador, Andrea Francesca; Onengut-Gumuscu, Suna; Farber, Emily; Dabhi, Nisha; Kennedy, Tatiana; Milam, Mary Grace; Baker, Wendy; Smirnov, Igor; Rich, Stephen S.; Benitez, Bruno A.; Karch, Celeste M.; Perrin, Richard J.; Farlow, Martin; Chhatwal, Jasmeer P.; Holtzman, David M.; Cruchaga, Carlos; Harari, Oscar; Kipnis, Jonathan		Dominantly Inherited Alzheimer Net	Meningeal lymphatics affect microglia responses and anti-A beta immunotherapy	NATURE			English	Article							ALZHEIMERS-DISEASE; R/BIOCONDUCTOR PACKAGE; BRAIN; ONSET; RISK; NORMALIZATION; BIOCONDUCTOR; ASSOCIATION; EXPRESSION; SYSTEM	Alzheimer's disease (AD) is the most prevalent cause of dementia(1). Although there is no effective treatment for AD, passive immunotherapy with monoclonal antibodies against amyloid beta (A beta) is a promising therapeutic strategy(2,3). Meningeal lymphatic drainage has an important role in the accumulation of A beta in the brain(4), but it is not known whether modulation of meningeal lymphatic function can influence the outcome of immunotherapy in AD. Here we show that ablation of meningeal lymphatic vessels in 5xFAD mice (a mouse model of amyloid deposition that expresses five mutations found in familial AD) worsened the outcome of mice treated with anti-A beta passive immunotherapy by exacerbating the deposition of A beta, microgliosis, neurovascular dysfunction, and behavioural deficits. By contrast, therapeutic delivery of vascular endothelial growth factor C improved clearance of A beta by monoclonal antibodies. Notably, there was a substantial overlap between the gene signature of microglia from 5xFAD mice with impaired meningeal lymphatic function and the transcriptional profile of activated microglia from the brains of individuals with AD. Overall, our data demonstrate that impaired meningeal lymphatic drainage exacerbates the microglial inflammatory response in AD and that enhancement of meningeal lymphatic function combined with immunotherapies could lead to better clinical outcomes.	[Da Mesquita, Sandro; Wall, Morgan; Louveau, Antoine; Goldman, Dylan H.; Salvador, Andrea Francesca; Dabhi, Nisha; Kennedy, Tatiana; Milam, Mary Grace; Baker, Wendy; Smirnov, Igor; Kipnis, Jonathan] Univ Virginia, Dept Neurosci, Charlottesville, VA 22903 USA; [Da Mesquita, Sandro] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Papadopoulos, Zachary; Dykstra, Taitea; de Lima, Kalil Alves; Herz, Jasmin; Goldman, Dylan H.; Salvador, Andrea Francesca; Smirnov, Igor; Kipnis, Jonathan] Washington Univ, Ctr Brain Immunol & Glia BIG, St Louis, MO 63110 USA; [Papadopoulos, Zachary; Dykstra, Taitea; de Lima, Kalil Alves; Herz, Jasmin; Goldman, Dylan H.; Salvador, Andrea Francesca; Smirnov, Igor; Perrin, Richard J.; Kipnis, Jonathan] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Papadopoulos, Zachary; Kipnis, Jonathan] Washington Univ, Neurosci Grad Program, St Louis, MO 63110 USA; [Brase, Logan; Farias, Fabiana Geraldo; Benitez, Bruno A.; Karch, Celeste M.; Cruchaga, Carlos; Harari, Oscar] Washington Univ, Dept Psychiat, St Louis, MO 63110 USA; [Jiang, Hong; Karch, Celeste M.; Perrin, Richard J.; Holtzman, David M.; Cruchaga, Carlos] Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, Dept Neurol,Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Kodira, Chinnappa Dilip] PureTech Hlth, Boston, MA USA; [Louveau, Antoine] Cleveland Clin, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44106 USA; [Goldman, Dylan H.; Salvador, Andrea Francesca; Kipnis, Jonathan] Univ Virginia, Neurosci Grad Program, Charlottesville, VA 22903 USA; [Onengut-Gumuscu, Suna; Farber, Emily; Rich, Stephen S.] Univ Virginia, Ctr Publ Hearth Genom, Charlottesville, VA USA; [Benitez, Bruno A.; Cruchaga, Carlos] Washington Univ, Sch Med, NeuroGen & Informat Ctr, St Louis, MO USA; [Farlow, Martin] Indiana Sch Med, Indianapolis, IN USA; [Chhatwal, Jasmeer P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA	University of Virginia; Mayo Clinic; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Cleveland Clinic Foundation; University of Virginia; University of Virginia; Washington University (WUSTL); Indiana University System; Indiana University Bloomington; Harvard University; Harvard Medical School; Massachusetts General Hospital	Da Mesquita, S; Kipnis, J (corresponding author), Univ Virginia, Dept Neurosci, Charlottesville, VA 22903 USA.; Da Mesquita, S (corresponding author), Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA.; Kipnis, J (corresponding author), Washington Univ, Ctr Brain Immunol & Glia BIG, St Louis, MO 63110 USA.; Kipnis, J (corresponding author), Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA.; Kipnis, J (corresponding author), Washington Univ, Neurosci Grad Program, St Louis, MO 63110 USA.; Kipnis, J (corresponding author), Univ Virginia, Neurosci Grad Program, Charlottesville, VA 22903 USA.	damesquita@mayo.edu; kipnis@wustl.edu	Kipnis, Jonathan/AGG-9735-2022; Cruchaga, Carlos/ABF-4065-2020; Da Mesquita, Sandro/A-7365-2010; Benitez, Bruno A./E-7116-2014	Kipnis, Jonathan/0000-0002-3714-517X; Cruchaga, Carlos/0000-0002-0276-2899; Da Mesquita, Sandro/0000-0002-0786-5010; Benitez, Bruno A./0000-0002-2699-3878; Rich, Stephen/0000-0003-3872-7793; Salvador, Andrea Francesca/0000-0002-9197-7575	National Institutes of Health/National Institute on Aging [AG034113, AG057496]; PureTech Health; Cure Alzheimer's Fund; Ed Owens Family Foundation [RF1AG053303, RF1AG058501, AG057777, AG067764, AG062734]; Dominantly Inherited Alzheimer's Network (DIAN) - National Institute on Aging (NIA) [UF1AG032438]; German Center for Neurodegenerative Diseases (DZNE); Raul Carrea Institute for Neurological Research (FLENI); Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)	National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PureTech Health; Cure Alzheimer's Fund; Ed Owens Family Foundation; Dominantly Inherited Alzheimer's Network (DIAN) - National Institute on Aging (NIA); German Center for Neurodegenerative Diseases (DZNE)(Helmholtz Association); Raul Carrea Institute for Neurological Research (FLENI); Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)(Korea Health Industry Development Institute (KHIDI))	We thank S. Smith for editing the manuscript and S. Blackburn and N. Al-Hamadani for animal colony maintenance. This work was supported by grants from the National Institutes of Health/National Institute on Aging (AG034113 and AG057496), PureTech Health, the Cure Alzheimer's Fund and the Ed Owens Family Foundation to J.K.; RF1AG053303 and RF1AG058501 to C.C.; AG057777 and AG067764 to O.H.; and AG062734 to C.M.K. O.H. is an Archer Foundation Research Scientist. We thank all members of the Kipnis laboratory for their comments during discussions of this work. We acknowledge the staff of the Neuropathology Cores and other personnel of the Charles F. and Joanne Knight Alzheimer Disease Research Center (P30 AG066444, P01AG026276, P01AG03991). Data collection and sharing for this project were supported by The Dominantly Inherited Alzheimer's Network (DIAN, UF1AG032438) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), with partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI). This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and contributions of the Knight ADRC and DIAN (see full list of DIAN consortium members in Supplementary Notes) research and support staff at each of the participating sites for their contributions to this study.	Abbasi J, 2018, JAMA-J AM MED ASSOC, V320, P965, DOI 10.1001/jama.2018.13027; Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cruchaga C, 2014, NATURE, V505, P550, DOI 10.1038/nature12825; Da Mesquita S, 2018, NEURON, V100, P375, DOI 10.1016/j.neuron.2018.09.022; Da Mesquita S, 2018, NATURE, V560, P185, DOI 10.1038/s41586-018-0368-8; Darnell G, 2012, BIOINFORMATICS, V28, pI147, DOI 10.1093/bioinformatics/bts235; Del-Aguila JL, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0524-x; Del-Aguila JL, 2018, J ALZHEIMERS DIS, V62, P745, DOI 10.3233/JAD-170834; Deming Y, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau2291; Deming Y, 2017, ACTA NEUROPATHOL, V133, P839, DOI 10.1007/s00401-017-1685-y; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Duong D, 2016, BIOINFORMATICS, V32, P156, DOI 10.1093/bioinformatics/btw272; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Eskin E, 2008, GENOME RES, V18, P653, DOI 10.1101/gr.072785.107; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Hafemeister C, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1874-1; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hong GN, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0950; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Howard R, 2020, NAT REV NEUROL, V16, P63, DOI 10.1038/s41582-019-0295-9; Huang KL, 2017, NAT NEUROSCI, V20, P1052, DOI 10.1038/nn.4587; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Kastanenka KV, 2016, J NEUROSCI, V36, P12549, DOI 10.1523/JNEUROSCI.2080-16.2016; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008; Kunkle BW, 2019, NAT GENET, V51, P414, DOI 10.1038/s41588-019-0358-2; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Logovinsky V, 2016, ALZHEIMERS RES THER, V8, DOI [10.1186/s13195-016-0181-2, 10.1016/j.trci.2016.01.001]; Louveau A, 2018, NAT NEUROSCI, V21, P1380, DOI 10.1038/s41593-018-0227-9; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lun ATL, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0947-7; Mathys H, 2019, NATURE, V570, P332, DOI 10.1038/s41586-019-1195-2; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; McCarthy DJ, 2017, BIOINFORMATICS, V33, P1179, DOI 10.1093/bioinformatics/btw777; McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003; Merlini M, 2019, NEURON, V101, P1099, DOI 10.1016/j.neuron.2019.01.014; Montagne A, 2020, NATURE, V581, P70, DOI 10.1038/s41586-020-2247-3; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Nettleton D, 2000, BIOMETRICS, V56, P52, DOI 10.1111/j.0006-341X.2000.00052.x; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pliner HA, 2019, NAT METHODS, V16, P983, DOI 10.1038/s41592-019-0535-3; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rustenhoven J, 2021, CELL, V184, P1000, DOI 10.1016/j.cell.2020.12.040; Ryu JK, 2018, NAT IMMUNOL, V19, P1212, DOI 10.1038/s41590-018-0232-x; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Shi Y, 2019, J EXP MED, V216, P2546, DOI 10.1084/jem.20190980; Soneson Charlotte, 2015, F1000Res, V4, P1521, DOI 10.12688/f1000research.7563.1; Spangenberg EE, 2016, BRAIN, V139, P1265, DOI 10.1093/brain/aww016; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Sul JH, 2015, AM J HUM GENET, V96, P857, DOI 10.1016/j.ajhg.2015.04.012; Sweeney MD, 2018, NAT REV NEUROL, V14, P133, DOI 10.1038/nrneurol.2017.188; Tarasoff-Conway JM, 2016, NAT REV NEUROL, V12, P248, DOI 10.1038/nrneurol.2016.36; Tinevez JY, 2017, METHODS, V115, P80, DOI 10.1016/j.ymeth.2016.09.016; Tucker S, 2015, J ALZHEIMERS DIS, V43, P575, DOI 10.3233/JAD-140741; Uhlmann RE, 2020, NAT NEUROSCI, V23, P1580, DOI 10.1038/s41593-020-00737-w; Van den Berge K, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1406-4; Vanlandewijck M, 2018, NATURE, V554, P475, DOI 10.1038/nature25739; Wang LM, 2019, BRAIN PATHOL, V29, P176, DOI 10.1111/bpa.12656; Won, 2020, PREPRINT, DOI 10.1101/2020.09.25.310722; Xiong M, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd7522; Yamazaki Y, 2019, NAT REV NEUROL, V15, P501, DOI 10.1038/s41582-019-0228-7; Yan Q, 2021, MOL PSYCHIATR, V26, P309, DOI 10.1038/s41380-018-0246-7; Yu GC, 2015, BIOINFORMATICS, V31, P608, DOI 10.1093/bioinformatics/btu684; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067; Zhou YY, 2020, NAT MED, V26, P131, DOI 10.1038/s41591-019-0695-9	70	60	60	13	123	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 13	2021	593	7858					255	+		10.1038/s41586-021-03489-0	http://dx.doi.org/10.1038/s41586-021-03489-0		APR 2021	35	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SB2RT	33911285	Green Accepted			2023-01-03	WOS:000645224800002
J	Meyer, S; Nourkami-Tutdibi, N; Poryo, M; Casper, M; Geipel, M; Zemlin, M				Meyer, Sascha; Nourkami-Tutdibi, Nasenien; Poryo, Martin; Casper, Markus; Geipel, Martina; Zemlin, Michael			Pericardial effusion, cardiomegaly, oedema, and IgA deficiency in a child: coeliac disease	LANCET			English	Editorial Material									[Meyer, Sascha; Nourkami-Tutdibi, Nasenien; Geipel, Martina; Zemlin, Michael] Univ Childrens Hosp Saarland, Dept Paediat & Neonatol, D-66421 Homburg, Germany; [Poryo, Martin] Univ Childrens Hosp Saarland, Dept Paediat Cardiol, Homburg, Germany; [Casper, Markus] Saarland Univ, Med Ctr, Dept Med 2, Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Meyer, S (corresponding author), Univ Childrens Hosp Saarland, Dept Paediat & Neonatol, D-66421 Homburg, Germany.	sascha.meyer@uks.eu							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	2021	397	10284					1576	1576						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR7QA	33894835				2023-01-03	WOS:000643286900023
J	Sanchez, X; Orrico, M; Morillo, T; Manzano, A; Jimbo, R; Armijos, L				Sanchez, Xavier; Orrico, Maria; Morillo, Toa; Manzano, Andrea; Jimbo, Ruth; Armijos, Luciana			Reducing unnecessary antibiotic prescription through implementation of a clinical guideline on self-limiting respiratory tract infections	PLOS ONE			English	Article							PRIMARY-CARE; POPULATION; STRATEGIES; SETTINGS	Background Clinical guidelines (CG) are used to reduce variability in practice when the scientific evidence is sparse or when multiple therapies are available. The development and implementation of evidence-based CG is intended to organize and provide the best available evidence to support clinical decision making in order to improve quality of care. Upper respiratory tract infections (URTI) are the leading cause of misuse of antibiotics and a CG may reduce the unnecessary antibiotic prescription. Methods The aim of this quasi-experimental, before-after study was to analyze the short- and long-term effects of the implementation of a CG to decrease the rate of antibiotic prescription in URTI cases in the emergency department of a third level private hospital in Quito, Ecuador. The study included 444 patients with a main diagnosis of URTI. They were distributed in three groups: a baseline cohort 2011 (n = 114), a first post-implementation cohort 2011 (n = 114), and a later post-implementation cohort 2018 (n = 216). The implementation strategy consisted of five key steps: acceptance of the need for implementation of the CG, dissemination of the CG, an educational campaign, constant feedback, and sustainability of the strategy through continuous training. Results The results of this study show a 42.90% of antibiotic prescription rate before the CG implementation. After the implementation of the CG, the prescription rate of antibiotics was significantly reduced by 24.5% (42.9% vs 18.4%, p<0.0001) and the appropriate antibiotic prescription rate was significantly increased by 44.2% (22.4% vs 66.6%, p<0.0001) in the first post-implementation cohort 2011. There was not a significant difference in antibiotic prescription rate and appropriate antibiotic prescription rate between two post-implementation cohorts: 18.4% vs 25.9% (p = 0.125) and 66.6% vs 50% (p = 0.191), respectively. Conclusions The implementation of CGs decreases the rate of antibiotic prescription in URTI cases. The results are remarkable after early implementation, but the effect persists over time. The emphasis must shift from guideline development to strategy implementation.	[Sanchez, Xavier; Jimbo, Ruth] Pontificia Univ Catolica Ecuador, Ctr Invest Salud Amer Latina CISeAL, Quito, Ecuador; [Sanchez, Xavier; Orrico, Maria; Morillo, Toa; Manzano, Andrea; Jimbo, Ruth; Armijos, Luciana] Pontificia Univ Catolica Ecuador, Postgrad Med Familiar & Comunitaria, Fac Med, Quito, Ecuador; [Sanchez, Xavier; Jimbo, Ruth] Univ Alcala Henares, Madrid, Spain; [Sanchez, Xavier] Pontificia Univ Catolica Ecuador, Fac Med, Quito, Ecuador; [Jimbo, Ruth] Pontificia Univ Catolica Ecuador, Ctr Invest Salud Amer Latina CISeAL, Quito, Ecuador	Pontificia Universidad Catolica del Ecuador; Pontificia Universidad Catolica del Ecuador; Universidad de Alcala; Pontificia Universidad Catolica del Ecuador; Pontificia Universidad Catolica del Ecuador	Sanchez, X (corresponding author), Pontificia Univ Catolica Ecuador, Ctr Invest Salud Amer Latina CISeAL, Quito, Ecuador.; Sanchez, X (corresponding author), Pontificia Univ Catolica Ecuador, Postgrad Med Familiar & Comunitaria, Fac Med, Quito, Ecuador.; Sanchez, X (corresponding author), Univ Alcala Henares, Madrid, Spain.; Sanchez, X (corresponding author), Pontificia Univ Catolica Ecuador, Fac Med, Quito, Ecuador.	xavier.sanchez.c@gmail.com	Jimbo Sotomayor, Ruth/AHA-5476-2022	Jimbo Sotomayor, Ruth/0000-0001-5016-3834; Sanchez, Xavier/0000-0002-8258-8746				[Anonymous], 2002, PROMOTING RATIONAL U; Arnold SR, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003539.pub2; Bagger K, 2015, EUR J GEN PRACT, V21, P118, DOI 10.3109/13814788.2014.1001361; Blumenthal KG, 2015, ANN ALLERG ASTHMA IM, V115, P294, DOI 10.1016/j.anai.2015.05.011; Boonacker CWB, 2010, INT J PEDIATR OTORHI, V74, P1113, DOI 10.1016/j.ijporl.2010.07.008; Butt AA, 2017, INT J INFECT DIS, V55, P20, DOI 10.1016/j.ijid.2016.12.004; Cordoba G, 2017, J ANTIMICROB CHEMOTH, V72, P305, DOI 10.1093/jac/dkw370; Dekker ARJ, 2015, FAM PRACT, V32, P401, DOI 10.1093/fampra/cmv019; DeVries TPG, 1994, FRESLE DAAP EDHOED M; Doubova SV, 2015, B MED HOSP INFANT M, V72, P235, DOI 10.1016/j.bmhimx.2015.07.003; Durkin MJ, 2018, INFECT CONT HOSP EP, V39, P584, DOI 10.1017/ice.2018.26; Fischer F, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/healthcare4030036; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Gill JM, 2006, FAM MED, V38, P349; Greenhalgh T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3725; Grimshaw Jeremy M, 2012, Proc Am Thorac Soc, V9, P298, DOI 10.1513/pats.201208-066ST; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Grol R, 2001, MED CARE, V39, pII46; Heikkinen T, 2003, LANCET, V361, P51, DOI 10.1016/S0140-6736(03)12162-9; Holloway KA, 2015, PAEDIATR INT CHILD H, V35, P5, DOI 10.1179/2046905514Y.0000000115; Johnson DP, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-1630; Juzych NS, 2005, J GEN INTERN MED, V20, P901, DOI 10.1111/j.1525-1497.2005.0198.x; Kotwani A, 2014, TROP MED INT HEALTH, V19, P761, DOI 10.1111/tmi.12327; Kourlaba G, 2016, EUROSURVEILLANCE, V21, P20, DOI 10.2807/1560-7917.ES.2016.21.26.30266; Le JV, 2015, FAM PRACT, V32, P681, DOI 10.1093/fampra/cmv061; Le JV, 2017, DAN MED J, V64; Lee TH, 2017, BRIT J GEN PRACT, V67, pE168, DOI 10.3399/bjgp17X688885; Little P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1606; Lopez-Vazquez P, 2012, J EVAL CLIN PRACT, V18, P473, DOI 10.1111/j.1365-2753.2010.01610.x; Malesker MA, 2017, CHEST, V152, P1021, DOI 10.1016/j.chest.2017.08.009; McKay R, 2016, ANTIMICROB AGENTS CH, V60, P4106, DOI 10.1128/AAC.00209-16; Monto AS, 2002, AM J MED, V112, p4S; Morgan SG, 2016, AGE AGEING, V45, P535, DOI 10.1093/ageing/afw074; Mortazhejri S, 2020, SYST REV-LONDON, V9, DOI 10.1186/s13643-020-01359-w; National Institute for Health and Care Excellence (NICE), 2008, SELF LIM RESP TRACT; O'Connor MN, 2012, DRUG AGING, V29, P437, DOI 10.2165/11632610-000000000-00000; Parikh K, 2014, PEDIATRICS, V133, pE1, DOI 10.1542/peds.2013-2005; Pollock M, 2007, AM FAM PHYSICIAN, V75, P231; Rodrigues AT, 2013, INT J ANTIMICROB AG, V41, P203, DOI 10.1016/j.ijantimicag.2012.09.003; Rossignoli A, 2007, EUR J CLIN PHARMACOL, V63, P1099, DOI 10.1007/s00228-007-0376-3; Choez XS, 2018, BMC PHARMACOL TOXICO, V19, DOI 10.1186/s40360-018-0237-y; Shamsuddin S, 2016, INT J INFECT DIS, V52, P16, DOI 10.1016/j.ijid.2016.09.013; Shapiro DJ, 2014, J ANTIMICROB CHEMOTH, V69, P234, DOI 10.1093/jac/dkt301; Spurling GKP, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004417.pub5; Thamlikitkul V, 2004, INT J INFECT DIS, V8, P47, DOI 10.1016/j.ijid.2003.09.001; van der Velden AW, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659268; Vodicka TA, 2013, BRIT J GEN PRACT, V63, pE445, DOI 10.3399/bjgp13X669167; Wang ZC, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0763-4	48	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2021	16	4							e0249475	10.1371/journal.pone.0249475	http://dx.doi.org/10.1371/journal.pone.0249475			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH8NB	33793627	Green Published, gold			2023-01-03	WOS:000636467000045
J	Prakash, MD; Stojanovska, L; Feehan, J; Nurgali, K; Donald, EL; Plebanski, M; Flavel, M; Kitchen, B; Apostolopoulos, V				Prakash, Monica D.; Stojanovska, Lily; Feehan, Jack; Nurgali, Kulmira; Donald, Elizabeth L.; Plebanski, Magdalena; Flavel, Matthew; Kitchen, Barry; Apostolopoulos, Vasso			Anti-cancer effects of polyphenol-rich sugarcane extract	PLOS ONE			English	Article							BREAST-CANCER; EXERCISE; MECHANISMS; L.; IMMUNOMODULATION; PROLIFERATION; MODULATION; EXPRESSION; SURVIVAL; INSULIN	Plant polyphenols have an array of health benefits primarily thought to be related to their high content of anti-oxidants. These are commonly undervalued and knowledge of their biological properties have grown exponentially in the last decade. Polyphenol-rich sugarcane extract (PRSE), a natural extract from sugar cane, is marketed as high in anti-oxidants and polyphenols, but its anti-cancer activity has not been reported previously. We show that, PRSE exerts anti-cancer properties on a range of cancer cells including human (LIM2045) and mouse (MC38, CT26) colon cancer cells lines; human lung cancer (A549), human ovarian cancer (SKOV-3), pro-monocytic human leukemia (U937) and to mouse melanoma (B16) cell lines; whereas no effects were noted on human breast (ZR-75-1) and human colon (HT29) cancer cell lines, as well as to human normal colon epithelial cell line (T4056). Anti-proliferative effects were shown to be mediated via alteration in cytokines, VEGF-1 and NF-kappa B expression.	[Prakash, Monica D.; Feehan, Jack; Nurgali, Kulmira; Donald, Elizabeth L.; Apostolopoulos, Vasso] Victoria Univ, Inst Hlth & Sport, Melbourne, Vic, Australia; [Prakash, Monica D.; Plebanski, Magdalena] RMIT Univ, Sch Hlth & Biomed Sci, Melbourne, Vic, Australia; [Stojanovska, Lily] United Arab Emirates Univ, Coll Food & Agr, Dept Nutr & Hlth, Al Ain, U Arab Emirates; [Feehan, Jack] Univ Melbourne, Dept Med Western Hlth, Melbourne, Vic, Australia; [Flavel, Matthew; Kitchen, Barry] Prod Makers, Bioact Div, Melbourne, Vic, Australia	Victoria University; Royal Melbourne Institute of Technology (RMIT); United Arab Emirates University; University of Melbourne	Apostolopoulos, V (corresponding author), Victoria Univ, Inst Hlth & Sport, Melbourne, Vic, Australia.	Vasso.Apostolopoulos@vu.edu.au	Plebanski, Magdalena/AAU-3144-2021	Feehan, Jack/0000-0002-9627-1299; Prakash, Monica/0000-0002-2814-7560; , Magdalena/0000-0001-6889-3667; Stojanovska, Lily/0000-0001-7186-4461; Nurgali, Kulmira/0000-0002-2597-6929; Flavel, Matthew/0000-0001-7455-5162	Product Makers (TPM) (Australia) Pty Ltd; Innovation Connections Grant, Department of Industry, Innovation and Science, VIC Australia	Product Makers (TPM) (Australia) Pty Ltd; Innovation Connections Grant, Department of Industry, Innovation and Science, VIC Australia	The study was supported by The Product Makers (TPM) (Australia) Pty Ltd (http://www.tpm.com.au/) and the Innovation Connections Grant, Department of Industry, Innovation and Science, VIC Australia (https://www.industry.gov.au/).The funder (TPM) provided support in the form of salaries for authors M.F and B.K but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. VA was the recipient of all funding for this study.	Ali SE, 2019, MOLECULES, V24, DOI 10.3390/molecules24050934; Alves VG, 2016, AN ACAD BRAS CIENC, V88, P1201, DOI 10.1590/0001-3765201620150349; Apostolopoulos V, 2016, MOL NUTR FOOD RES, V60, P43, DOI 10.1002/mnfr.201500272; Apostolopoulos V, 2014, IMMUNOTHERAPY-UK, V6, P1145, DOI [10.2217/IMT.14.76, 10.2217/imt.14.76]; Araujo JR, 2011, NUTR RES, V31, P77, DOI 10.1016/j.nutres.2011.01.006; Bendardaf R, 2017, LIBYAN J MED, V12, DOI 10.1080/19932820.2017.1290741; Bennani H, 2007, CANCER DETECT PREV, V31, P64, DOI 10.1016/j.cdp.2006.09.006; Bucio-Noble D, 2018, J PROTEOMICS, V177, P1, DOI 10.1016/j.jprot.2018.02.009; Chalopin M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110080; CUMMINGS JH, 1992, GASTROENTEROLOGY, V103, P1783, DOI 10.1016/0016-5085(92)91435-7; Del Rio D, 2013, ANTIOXID REDOX SIGN, V18, P1818, DOI 10.1089/ars.2012.4581; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Deseo MA, 2020, FOOD CHEM, V314, DOI 10.1016/j.foodchem.2020.126180; Ehrke MJ, 2003, INT IMMUNOPHARMACOL, V3, P1105, DOI 10.1016/S1567-5769(03)00021-3; Ellis TP, 2016, EUR J NUTR, V55, P2365, DOI 10.1007/s00394-015-1043-6; Feng SM, 2014, FOOD CHEM, V151, P452, DOI 10.1016/j.foodchem.2013.11.057; Ghiringhelli F, 2012, ANTI-CANCER AGENT ME, V12, P852, DOI 10.2174/187152012802650048; Han DH, 2009, ANTICANCER RES, V29, P1417; Jaganathan SK, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/830616; Ji J, 2019, J AM COLL NUTR, V38, P670, DOI 10.1080/07315724.2019.1587323; Khazali AS, 2018, BRIT J CANCER, V118, P566, DOI 10.1038/bjc.2017.414; Kune S, 1987, Nutr Cancer, V9, P21; Li ZG, 2009, CELL MOL IMMUNOL, V6, P415, DOI 10.1038/cmi.2009.53; Liu LP, 2008, MOL NUTR FOOD RES, V52, P1182, DOI 10.1002/mnfr.200700499; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; McTiernan A, 2008, NAT REV CANCER, V8, P205, DOI 10.1038/nrc2325; Mikkelsen K, 2017, MATURITAS, V106, P48, DOI 10.1016/j.maturitas.2017.09.003; MOBUS VJ, 1993, J CANCER RES CLIN, V120, P27, DOI 10.1007/BF01200721; Moyle CWA, 2015, MOL NUTR FOOD RES, V59, P401, DOI 10.1002/mnfr.201400478; Pallavi R., 2012, International Journal of Research in Pharmacy and Chemistry, V2, P338; Prokopchuk O, 2005, BRIT J CANCER, V92, P921, DOI 10.1038/sj.bjc.6602416; Pudkasam S, 2017, MATURITAS, V105, P16, DOI 10.1016/j.maturitas.2017.04.022; Queen Brannon L, 2010, Curr Aging Sci, V3, P34; Sayin N, 2013, TURK J IMMUNOL, V1, P42, DOI 10.5606/tji.2013.213; Scalbert A, 2005, AM J CLIN NUTR, V81, p215S, DOI 10.1093/ajcn/81.1.215S; Shin KJ, 2016, CURR PHARM DESIGN, V22, P2389, DOI 10.2174/1381612822666160226144025; Stojanovska L, 2014, MATURITAS, V77, P318, DOI 10.1016/j.maturitas.2014.01.006; Stover MG, 2013, POLYPHENOLS HUMAN HL, V1, P3, DOI [10.1016/B978-0-12-398456-2.00001%26%23x2013%3B3, DOI 10.1016/B978-0-12-398456-2.00001%26%23X2013%3B3]; Wahyudi Sianne, 2007, Acta Med Indones, V39, P66; WCRF. AICR, 2018, NUTR PHYS ACT CANC G; Wright AG, 2014, PLANT FOOD HUM NUTR, V69, P310, DOI 10.1007/s11130-014-0446-5; Wu S, 2016, NATURE, V529, P43, DOI 10.1038/nature16166; Xu H, 2018, NUTR RES, V57, P1, DOI 10.1016/j.nutres.2018.04.011; Yahfoufi N, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111618; Yu MX, 2013, CANCER RES, V73, P4061, DOI 10.1158/0008-5472.CAN-12-3946; Zhao Y, 2015, FOOD CHEM, V185, P112, DOI 10.1016/j.foodchem.2015.03.120; Zhou BH, 2015, PHYTOTHER RES, V29, P415, DOI 10.1002/ptr.5267	47	6	6	7	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2021	16	3							e0247492	10.1371/journal.pone.0247492	http://dx.doi.org/10.1371/journal.pone.0247492			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV3DA	33690618	gold, Green Published			2023-01-03	WOS:000627854700071
J	Atiba, FA; Fatokun, AA; Imosemi, IO; Malomo, AO				Atiba, Foluso A.; Fatokun, Amos A.; Imosemi, Innocent O.; Malomo, Adefolarin O.			Kola nut from Cola nitida vent. Schott administered to pregnant rats induces histological alterations in pups' cerebellum	PLOS ONE			English	Article							EXTERNAL GRANULAR LAYER; MIGRATION DEFECTS; CELL-MIGRATION; NERVOUS-SYSTEM; DEGENERATION; EXPOSURE; TOXICITY; MOUSE; OVEREXPRESSION; ACTIVATION	Kola nut (from Cola nitida) is popular in Nigeria and West Africa and is commonly consumed by pregnant women during the first trimester to alleviate morning sickness and dizziness. There is, however, a dearth of information on its effects on the developing brain. This study, therefore, investigated the potential effects of kola nut on the structure of the developing neonatal and juvenile cerebellum in the rat. Pregnant Wistar rats were administered water (as control) or crude (aqueous) kola nut extract at 400, 600, and 800 mg/kg body weight orally, from pregnancy to day 21 after birth. On postnatal days 1, 7, 14, 21 and 28, the pups were weighed, anaesthetised, sacrificed and perfused with neutral buffered formalin. Their brains were dissected out, weighed and the cerebellum preserved in 10% buffered formalin. Paraffin sections of the cerebellum were stained with haematoxylin and eosin for cerebellar cytoarchitecture, cresyl violet stain for Purkinje cell count, Glial Fibrillary Acidic Protein (GFAP) immunohistochemistry (IHC) for estimation of gliosis, and B-cell lymphoma 2 (Bcl-2) IHC for apoptosis induction. The kola nut-treated rats exhibited initial reduction in body and brain weights, persistent external granular layer, increased molecular layer thickness, and loss of Bergmann glia. Their Purkinje cells showed reduction in density, loss of dendrites and multiple layering, and their white matter showed neurodegeneration (spongiosis) and GFAP and Bcl-2 over-expression, with evidence of reactive astrogliosis. This study, therefore, demonstrates that kola nut, administered repeatedly at certain doses to pregnant dams, could disrupt normal postnatal cerebellar development in their pups. The findings suggest potential deleterious effects of excessive kola nut consumption on human brain and thus warrant further studies to understand the wider implications for human brain development.	[Atiba, Foluso A.; Imosemi, Innocent O.; Malomo, Adefolarin O.] Univ Ibadan, Coll Med, Dept Anat, Ibadan, Nigeria; [Fatokun, Amos A.] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Liverpool, Merseyside, England; [Malomo, Adefolarin O.] Univ Ibadan, Coll Med, Dept Surg, Ibadan, Nigeria	University of Ibadan; Liverpool John Moores University; University of Ibadan	Atiba, FA; Malomo, AO (corresponding author), Univ Ibadan, Coll Med, Dept Anat, Ibadan, Nigeria.; Malomo, AO (corresponding author), Univ Ibadan, Coll Med, Dept Surg, Ibadan, Nigeria.	folusoatiba@gmail.com; ademalomo@yahoo.com	; Fatokun, Amos/T-7918-2017	Atiba, Foluso/0000-0003-4780-7840; Fatokun, Amos/0000-0001-5183-7589				AJAREM JS, 1994, J KING SAUD U SCIENC, V6, P41; ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; Archibong V.B., 2017, SAUDI J MED PHARM SC, V3, P849; Atiba F. A., 2016, African Journal of Biomedical Research, V19, P65; Baloui H, 2004, EUR J NEUROSCI, V20, P2605, DOI 10.1111/j.1460-9568.2004.03728.x; Bouet V, 2005, NEUROSCI LETT, V382, P10, DOI 10.1016/j.neulet.2005.02.051; Bufalo MC, 2013, J ETHNOPHARMACOL, V149, P84, DOI 10.1016/j.jep.2013.06.004; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Burdock GA, 2005, BOCA RATON, P993; Calatrava-Ferreras L, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/135187; Casoni F, 2017, CONTEMP CLIN NEUROSC, V21, P67, DOI 10.1007/978-3-319-59749-2_4; Celec P, 2010, J PSYCHOPHARMACOL, V24, P1569, DOI 10.1177/0269881109105401; DEBLAS AL, 1984, J NEUROSCI, V4, P265; Dethy S, 1997, NEUROSCI LETT, V224, P25, DOI 10.1016/S0304-3940(97)13461-9; Ettarh RR, 2000, PHARM BIOL, V38, P281, DOI 10.1076/1388-0209(200009)3841-AFT281; Harborne JB, 1999, GEN INTRO PHYTOCHEMI; Haskell CF, 2013, NUTR RES REV, V26, P49, DOI 10.1017/S0954422413000036; Ifesanya J.U., 2013, J DENT ORAL HYGIENE, V5, P13; Ikegwuonu F I, 1981, J Appl Toxicol, V1, P292, DOI 10.1002/jat.2550010603; Imosemi IO, 2011, INT J MORPHOL, V29, P331, DOI 10.4067/S0717-95022011000200004; JENKINS T, 1978, FUNCTIONAL MAMMALIAN; Kern JK, 2006, J TOXICOL ENV HEAL B, V9, P485, DOI 10.1080/10937400600882079; Komuro H, 2003, CELL MOL LIFE SCI, V60, P1084, DOI 10.1007/s00018-003-2248-z; KOPPEL H, 1982, J ANAT, V134, P73; Kumar K, 2013, CELL MOL NEUROBIOL, V33, P731, DOI 10.1007/s10571-013-9942-7; Legradi J, 2015, ENVIRON SCI POLLUT R, V22, P16277, DOI 10.1007/s11356-014-3805-8; Liang CC, 2010, J BIOL CHEM, V285, P3499, DOI 10.1074/jbc.M109.072389; Martinez S, 2000, RES PRO CEL, V30, P91; Marzban H, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00450; McIlroy RJ., 1963, INTRO TROPICAL CASH; Miller RA, 2002, MAGICAL RITUAL USE H; National Research Council (US). National Research Council (US) Committee for the Update of the Guide for Care and Use of Laboratory Animals, 2011, NAT RES COUNC US COM; Nicolas O, 2007, FASEB J, V21, P3107, DOI 10.1096/fj.06-7827com; Nowakowska-Kotas M, 2014, CEREBELLUM, V13, P541, DOI 10.1007/s12311-014-0566-3; Nyaruhucha C N M, 2009, Tanzan J Health Res, V11, P29; Obidike I. R., 2011, Comparative Clinical Pathology, V20, P625, DOI 10.1007/s00580-010-1045-y; Obochi G O, 2007, Niger J Physiol Sci, V22, P99; Ogunwole Eunice, 2015, Niger J Physiol Sci, V30, P51; Ojo GB, 2010, REV ELECT BIOMED ELE, V2, P18; Ologe FE, 2008, J LARYNGOL OTOL, V122, P786, DOI 10.1017/S0022215107000242; Olopade Funmilayo Eniola, 2018, Journal of Caffeine and Adenosine Research, V8, P27, DOI 10.1089/caff.2017.0010; Onyiapat JLE, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-19; Opanashuk LA, 2001, EUR J NEUROSCI, V13, P48, DOI 10.1046/j.1460-9568.2001.01359.x; Priyanka S, 2012, TOXICOL ENVIRON CHEM, V94, P1422, DOI 10.1080/02772248.2012.695002; Qu Q, 2005, CEREBELLUM, V4, P261, DOI 10.1080/14734220500358351; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; SMEYNE RJ, 1989, J NEUROSCI, V9, P1608; Snell RS, 2005, CLIN NEUROANATOMY; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; SPYKER JM, 1975, FED PROC, V34, P1835; Steele AD, 2007, J NEUROSCI, V27, P13022, DOI 10.1523/JNEUROSCI.3290-07.2007; Tende J. A., 2011, British Journal of Pharmacology and Toxicology, V2, P132; Tindall R, 1998, ETHNOBO LEAF, V2, P1; Umoren E. B., 2011, International Research Journal of Pharmacy and Pharmacology, V1, P93; Umoren E B, 2009, Niger J Physiol Sci, V24, P73; VanderLugt JJ, 1996, VET PATHOL, V33, P495, DOI 10.1177/030098589603300503; Wang VY, 2001, NAT REV NEUROSCI, V2, P484, DOI 10.1038/35081558; Weller M, 2006, DEV NEUROSCI-BASEL, V28, P70, DOI 10.1159/000090754; Wolansky MJ, 2005, NEUROTOXICOL TERATOL, V27, P299, DOI 10.1016/j.ntt.2004.12.006; Xu HW, 2013, MOL NEUROBIOL, V47, P833, DOI 10.1007/s12035-013-8405-y	61	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2021	16	3							e0247573	10.1371/journal.pone.0247573	http://dx.doi.org/10.1371/journal.pone.0247573			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU3OZ	33684143	gold, Green Published, Green Accepted			2023-01-03	WOS:000627193500040
J	Lemieux, S; Buies, A; Turgeon, AF; Hallet, J; Daigle, G; Cote, F; Provencher, S				Lemieux, Simon; Buies, Alex; Turgeon, Alexis F.; Hallet, Julie; Daigle, Gaetan; Cote, Francois; Provencher, Steeve			Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis	PLOS ONE			English	Review							INTERNAL RADIATION-THERAPY; CHEMOEMBOLIZATION; SORAFENIB; SAFETY; TRIAL	Background Recently, the use of Yttrium-90 transarterial radioembolization in non-surgical hepatocellular carcinoma was suggested but the evidence supporting its use is unclear. Methods We searched Medline, Embase, Web of Science and Cochrane CENTRAL from inception up to April 14, 2020 for randomized controlled trials comparing Y90-TARE to standard of care in non-surgical HCC patients. Our primary outcome was overall survival (OS). Our secondary outcomes were progression-free survival, time to progression, disease control rate, grade >= 3 adverse events and rates of gastro-intestinal ulcers. Hazard ratios (HR) and risk ratios (RR) with random-effects model were used for our analyses. The risk of bias of the included studies was assessed using Cochrane's RoB 2 tool. Results Of 1,604 citations identified, eight studies (1,439 patients) were included in our analysis. No improvement in overall survival were noted when Yttrium-90 transarterial radioembolization was compared to standard treatments (HR 0.99 [95% CI 0.81-1.21], 6 studies, I-2 = 77.6%). However, Yttrium-90 transarterial radioembolization was associated with fewer grade >= 3 adverse events (RR 0.64 [95% CI 0.45-0.92], 7 studies, I-2 = 66%). No difference was observed on other secondary outcomes. Discussion In non-surgical HCC patients, Yttrium-90 transarterial radioembolization was not associated with significant effect on survival, progression-free survival, time to progression, disease control rate and the incidence of gastro-intestinal ulcers but was however associated with significantly lower rates of grade >= 3 adverse events. Further randomized controlled trials are warranted to better delineate optimal treatment.	[Lemieux, Simon; Buies, Alex; Cote, Francois] Univ Laval, Dept Radiol & Nucl Med, Quebec City, PQ, Canada; [Lemieux, Simon; Provencher, Steeve] Univ Laval, Quebec Hearth & Lung Inst, Res Ctr, Quebec City, PQ, Canada; [Turgeon, Alexis F.] Univ Laval, Dept Anesthesiol & Crit Care Med, Div Crit Care Med, Quebec City, PQ, Canada; [Turgeon, Alexis F.] Univ Laval, CHU Quebec, Res Ctr, Trauma Emergency Crit Care Med,Populat Hlth & Opt, Quebec City, PQ, Canada; [Hallet, Julie] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Div Gen Surg, Toronto, ON, Canada; [Hallet, Julie] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Daigle, Gaetan] Univ Laval, Fac Engn Sci, Dept Math & Stat, Quebec City, PQ, Canada; [Provencher, Steeve] Univ Laval, Dept Med, Div Respirol, Quebec City, PQ, Canada	Laval University; Laval University; Laval University; Laval University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Laval University; Laval University	Lemieux, S (corresponding author), Univ Laval, Dept Radiol & Nucl Med, Quebec City, PQ, Canada.; Lemieux, S (corresponding author), Univ Laval, Quebec Hearth & Lung Inst, Res Ctr, Quebec City, PQ, Canada.	simon.lemieux.9@ulaval.ca	Lemieux, Simon/GSI-7715-2022	Cote, Francois/0000-0001-7077-1490; Lemieux, Simon/0000-0003-0924-1225; Turgeon, Alexis/0000-0001-5675-8791				Abdel-Rahman O, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011313.pub3; Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Biederman DM, 2016, J VASC INTERV RADIOL, V27, P812, DOI 10.1016/j.jvir.2016.01.147; Chandler J., 2013, COCHRANE UNIT; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chow PKH, 2018, J CLIN ONCOL, V36, P1913, DOI 10.1200/JCO.2017.76.0892; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dhondt E, 2020, J VASC INTERV RADIOL, V31, pS140, DOI [10.1016/j.jvir.2019.12.360, DOI 10.1016/J.JVIR.2019.12.360]; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, 2019, J Hepatol, V70, P817, DOI 10.1016/j.jhep.2019.01.020; Facciorusso A, 2016, WORLD J HEPATOL, V8, P770, DOI 10.4254/wjh.v8.i18.770; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gabr A, 2018, J VASC INTERV RADIOL, V29, P1502, DOI 10.1016/j.jvir.2018.06.027; Gates VL, 2014, J VASC INTERV RADIOL, V25, P266, DOI 10.1016/j.jvir.2013.11.005; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; GUYOT P, 2012, TRIALS, V12, P9, DOI DOI 10.1186/1471-2288-12-9; Julian Higgins JT, 2022, COCHRANE HDB SYSTEMA; Katsanos K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184597; Kim PH, 2019, KOREAN J RADIOL, V20, DOI 10.3348/kjr.2018.0496; Kolligs FT, 2015, LIVER INT, V35, P1715, DOI 10.1111/liv.12750; KRAMER MS, 1981, ANN INTERN MED, V29, P111, DOI DOI 10.1038/CLPT.1981.18; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lobo L, 2016, CARDIOVASC INTER RAD, V39, P1580, DOI 10.1007/s00270-016-1426-y; Manghisi G, 1998, HEPATOLOGY, V28, P751; Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913; Mathoulin-Pelissier S, 2008, J CLIN ONCOL, V26, P3721, DOI 10.1200/JCO.2007.14.1192; Mazzaferro V, 2019, EFFICACY EVALUATION; MICHIELS S, 2005, J NUCL MED, V21, P119, DOI DOI 10.1017/S0266462305050154PMID; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; National Cancer Institute NIoH, 2017, COMMON TERMINOLOGY C; Pitton MB, 2015, CARDIOVASC INTER RAD, V38, P352, DOI 10.1007/s00270-014-1012-0; Ricke J, 2019, J HEPATOL, V71, P1164, DOI 10.1016/j.jhep.2019.08.006; Salem R, 2018, HEPATOLOGY, V68, P1429, DOI 10.1002/hep.29691; Salem R, 2016, GASTROENTEROLOGY, V151, P1155, DOI 10.1053/j.gastro.2016.08.029; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Van Der Gucht A, 2017, J NUCL MED, V58, P1334, DOI 10.2967/jnumed.116.184713; Venerito M, 2020, J NUCL MED, V61, DOI 10.2967/jnumed.120.242933; Vilgrain V, 2017, J HEPATOL, V66, pS85, DOI 10.1016/S0168-8278(17)30436-1; Vogel A, 2018, ANN ONCOL, V29, P238, DOI 10.1093/annonc/mdy308; Yang Y, 2018, CANCER BIOL MED, V15, P299, DOI 10.20892/j.issn.2095-3941.2017.0177; Zhang YF, 2015, BIOSCI TRENDS, V9, P289, DOI 10.5582/bst.2015.01089	41	3	3	6	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2021	16	3							e0247958	10.1371/journal.pone.0247958	http://dx.doi.org/10.1371/journal.pone.0247958			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT5BY	33662011	gold, Green Published			2023-01-03	WOS:000626604100089
J	Hassan, EM; Mahmoud, HN				Hassan, Emad M.; Mahmoud, Hussam N.			Impact of multiple waves of COVID-19 on healthcare networks in the United States	PLOS ONE			English	Article								The risk of overwhelming hospitals from multiple waves of COVID-19 is yet to be quantified. Here, we investigate the impact of different scenarios of releasing strong measures implemented around the U.S. on COVID-19 hospitalized cases and the risk of overwhelming the hospitals while considering resources at the county level. We show that multiple waves might cause an unprecedented impact on the hospitals if an increasing number of the population becomes susceptible and/or if the various protective measures are discontinued. Furthermore, we explore the ability of different mitigation strategies in providing considerable relief to hospitals. The results can help planners, policymakers, and state officials decide on additional resources required and when to return to normalcy.	[Hassan, Emad M.; Mahmoud, Hussam N.] Colorado State Univ, Dept Civil & Environm Engn, Ft Collins, CO 80523 USA	Colorado State University	Mahmoud, HN (corresponding author), Colorado State Univ, Dept Civil & Environm Engn, Ft Collins, CO 80523 USA.	Hussam.Mahmoud@colostate.edu		Hassan, Emad/0000-0003-0634-2397; Mahmoud, Hussam/0000-0002-3106-6067	National Institute of Standards and Technology (NIST) [70NANB15H044]; Colorado State University [70NANB15H044]	National Institute of Standards and Technology (NIST)(National Institute of Standards & Technology (NIST) - USA); Colorado State University	This study was funded by the cooperative agreement 70NANB15H044 between the National Institute of Standards and Technology (NIST) and Colorado State University. The content expressed in this paper are the views of the authors and do not necessarily represent the opinions or views of NIST or the U.S Department of Commerce. The George T. Abell Professorship discretionary funding provided support in the form of salary for author HNM.	[Anonymous], 2020, HOSPITALS; [Anonymous], 2020, USATODAY; Branas CC., 2020, FLATTENING CURVE IT, DOI [10.1101/2020.04.01.20049759, DOI 10.1101/2020.04.01.20049759]; Bureau UC, 2018, CARTOGRAPHIC BOUNDAR; Carenzo L, 2020, ANAESTHESIA, V75, P928, DOI 10.1111/anae.15072; CDC, 2020, IMPL MIT STRAT COMM; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Centers for Disease Control and Prevention, 2020, COVID 19 MOD DAT DAS; Chen SM, 2020, LANCET, V395, P1305, DOI 10.1016/S0140-6736(20)30744-3; Definitive Healthcare, 2020, US HOSP BEDS; Denver Health, 2005, AHRQ PUBLICATION, V05; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Gilbert M, 2020, NAT MED, V26, P643, DOI 10.1038/s41591-020-0871-y; Gopinath G., 2020, IMFBLOG; Grassly NC, 2008, NAT REV MICROBIOL, V6, P477, DOI 10.1038/nrmicro1845; Guan DB, 2020, NAT HUM BEHAV, V4, P577, DOI 10.1038/s41562-020-0896-8; Hartnett KP, 2020, MMWR-MORBID MORTAL W, V69, P699, DOI 10.15585/mmwr.mm6923e1; Hassan EM, 2020, RELIAB ENG SYST SAFE, V201, DOI 10.1016/j.ress.2020.106953; Hsiang S, 2020, NATURE, V585, pE7, DOI [10.1038/s41586-020-2691-0, 10.1038/s41586-020-2404-8]; Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Lopez G, 2020, VOX, DOI 1497089/police-prosecutions-black-lives-matter-breonna-taylor-george-floyd; Matrajt L, 2020, EMERG INFECT DIS, V26, P1740, DOI 10.3201/eid2608.201093; Miller IF, 2020, NAT MED, V26, P1212, DOI 10.1038/s41591-020-0952-y; National Healthcare Safety Network (NHSN), 2020, COVID 19 MOD DAT OV; Panchal N., 2020, IMPLICATIONS COVID 1; Peng L, 2020, ENVIRON SCI POLLUT R, V27, P13524, DOI 10.1007/s11356-020-07903-4; Pereira-Sanchez V, 2020, LANCET PSYCHIAT, V7, pE29, DOI 10.1016/S2215-0366(20)30153-X; Rosenbaum L., 2020, NEW ENGL J MED, P1969, DOI [10.1056/NEJMp2009027, DOI 10.1056/NEJMP2009027]; Society of Critical Care Medicine, 2020, SHORT ICU PROV WHO O; Swift EK., 2002, GUIDANCE NATL HEALTH, DOI [10.17226/10512 25057628, DOI 10.17226/1051225057628]; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; Toy S, 2020, WALL STR J; U.S. Census Bureau, 2019, ACS DEM HOUS EST; USAFacts, 2020, COR LOC COVID 19 MAP; Week Education, 2020, MAP AR SCH CLOS, DOI DOI 10.1002/14651858.CD013812; Weissman GE, 2020, ANN INTERN MED, V173, P21, DOI 10.7326/M20-1260; Worldometers, 2020, COVID 19 COR PAND, DOI DOI 10.2307/J.CTV16T6N4G; Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9; Zhang ZQ, 2020, J INFECTION, V81, P170, DOI 10.1016/j.jinf.2020.03.018; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	41	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2021	16	3							e0247463	10.1371/journal.pone.0247463	http://dx.doi.org/10.1371/journal.pone.0247463			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QS6AU	33657621	gold, Green Published			2023-01-03	WOS:000625981500010
J	Wong, JP; Damania, B				Wong, Jason P.; Damania, Blossom			SARS-CoV-2 dependence on host pathways	SCIENCE			English	Editorial Material							TRANSLATION		[Wong, Jason P.; Damania, Blossom] Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Wong, Jason P.; Damania, Blossom] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Damania, B (corresponding author), Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.; Damania, B (corresponding author), Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	damania@med.unc.edu		Wong, Jason/0000-0002-0710-3112	National Institutes of Health [CA096500, CA254564, CA019014, CA163217, DE028211]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	J.P.W. and B.D. are supported by National Institutes of Health grants CA096500, CA254564,CA019014, CA163217, and DE028211.	Banerjee AK, 2020, CELL, V183, P1325, DOI 10.1016/j.cell.2020.10.004; Basta N., MCGILL COVID19 VACCI, V2021; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Jaafar ZA, 2019, NAT REV MICROBIOL, V17, P110, DOI 10.1038/s41579-018-0117-x; Laham-Karam N, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00276; Nakagawa K, 2016, ADV VIRUS RES, V96, P165, DOI 10.1016/bs.aivir.2016.08.001; Pruijssers Andrea J, 2020, bioRxiv, DOI 10.1101/2020.04.27.064279; Reuschl A-K., 2021, BIORXIV; Schubert K, 2020, NAT STRUCT MOL BIOL, V27, P959, DOI 10.1038/s41594-020-0511-8; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; Thoms M, 2020, SCIENCE, V369, P1249, DOI 10.1126/science.abc8665; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; White KM, 2021, SCIENCE, V371, P926, DOI 10.1126/science.abf4058	13	16	16	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	2021	371	6532					884	885		10.1126/science.abg6837	http://dx.doi.org/10.1126/science.abg6837			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QM5IR	33632832				2023-01-03	WOS:000621813400022
J	Delzer, ME; Kkonde, A; McAdams, RM				Delzer, Mackenzie E.; Kkonde, Anthony; McAdams, Ryan M.			Viewpoints of pregnant mothers and community health workers on antenatal care in Lweza village, Uganda	PLOS ONE			English	Article								Background Uganda is a low-income country with high fertility, adolescent birth, and maternal mortality rates. How Ugandan Ministry of Health antenatal education guidelines have been implemented into standardized health education and how pregnant women utilize health facilities remains unclear. Objective We aimed to determine how women obtain education during pregnancy, what guidelines health educators follow, and what barriers exist to receiving antenatal care in Lweza Village, Uganda. Methods Household surveys were conducted with women in Lweza who were or had previously been pregnant. Focus group discussions were conducted with community members and Lweza Primary School teachers. Interviews were conducted with key informants, including midwives, a traditional birth attendant, a community leader, and a Village Health Team member. Data collection was done in English along with a Luganda translator. Results Of the 100 household surveys conducted, 86% of women did not meet the WHO recommendation of 8 antenatal appointments during their pregnancies. Reasons cited for inadequate visits included facing long wait times (>7 h) at health facilities, getting education from family or traditional healers, or being told to delay antenatal care until 6 months pregnant. Informant interviews revealed that no standardized antenatal education program exists. Respondents felt least educated on family planning and postpartum depression, despite 37% of them reporting symptoms consistent with postpartum depression. Education was also lacking on the use of traditional herbs, although most women (60%) reported using them during pregnancy. Conclusions Most women in Lweza do not receive 8 antenatal appointments during their pregnancies or any standardized antenatal education. Educational opportunities on family planning, postpartum depression, and the safety of traditional herbs during pregnancy exist. Future studies should focus on ways to overcome barriers to antenatal care, which could include implementing community-based education programs to improve health outcomes for women in Lweza Village.	[Delzer, Mackenzie E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Kkonde, Anthony] Mukono Dist Municipal, Mukono, Uganda; [McAdams, Ryan M.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Delzer, ME (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.	mecarlson3@wisc.edu		Delzer, Mackenzie/0000-0002-8237-0122; McAdams, Ryan/0000-0002-9579-1698	University of Wisconsin School of Medicine and Public Health; Herman and Gwendolyn Shapiro Foundation	University of Wisconsin School of Medicine and Public Health; Herman and Gwendolyn Shapiro Foundation	Research support was provided by an award from the University of Wisconsin School of Medicine and Public Health and the Herman and Gwendolyn Shapiro Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, HUMAN DEV INDICATORS; [Anonymous], 2019, MUKONO MUNICIPALITY; Bank TW., FERTILITY RATE TOTAL; Banke-Thomas OE, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1246-3; Bariagaber H., 2016, Studies on Ethno-Medicine, V10, P411; Benova L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3546-3; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brummelte S, 2016, HORM BEHAV, V77, P153, DOI 10.1016/j.yhbeh.2015.08.008; Committee GR.  Maternal N. Organization TWH, 2016, HUMAN REPROD PROGRAM; Gajaria A, 2018, ASIAN J PSYCHIATR, V37, P112, DOI 10.1016/j.ajp.2018.08.014; Huebl L, 2016, AM J TROP MED HYG, V95, P1440, DOI 10.4269/ajtmh.15-0579; Kyaddondo D, 2017, INT J GYNECOL OBSTET, V139, P38, DOI 10.1002/ijgo.12405; Mbonye MK, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-165; Mengist Hylemariam Mihiretie, 2017, BMC Res Notes, V10, P440, DOI 10.1186/s13104-017-2770-y; Munabi-Babigumira S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213511; Organization TWH (RHR) RHaR (NHD) NfHaD Maternal N Child and Adolescent Health (MCA)., WHO GUIDANCE ANTENAT; Seward N, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002467; Unicef, 2018, LEV TRENDS INESTIMAT; United Nations Population Fund (UNFPA), 2019, TRENDS MAT MORT 2000; Viguera MDA., 2018, POSTPARTUM UNIPOLAR; Waiswa Peter, 2008, BMC Pregnancy Childbirth, V8, P21, DOI 10.1186/1471-2393-8-21; World Health Organization, 2014, WHO REC COMM MOB FAC; Young SL., PICA PREGNANCY	23	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2021	16	2							e0246926	10.1371/journal.pone.0246926	http://dx.doi.org/10.1371/journal.pone.0246926			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8MA	33592036	Green Published, gold			2023-01-03	WOS:000620632800044
J	Saliba-Gustafsson, EA; Nyberg, A; Borg, MA; Rosales-Klintz, S; Lundborg, CS				Saliba-Gustafsson, Erika A.; Nyberg, Anna; Borg, Michael A.; Rosales-Klintz, Senia; Lundborg, Cecilia Stalsby			Barriers and facilitators to prudent antibiotic prescribing for acute respiratory tract infections: A qualitative study with general practitioners in Malta	PLOS ONE			English	Article							RANDOMIZED CONTROLLED TRIAL; CROSS-SECTIONAL ANALYSIS; PRIMARY-CARE PHYSICIANS; PATIENTS EXPECTATIONS; COST-EFFECTIVENESS; PRESCRIPTION; PERCEPTIONS; BEHAVIOR; GPS; STRATEGIES	Background Antibiotic resistance is a leading global public health concern and antibiotic use is a key driver. Effective interventions are needed to target key stakeholders, including general practitioners (GPs). In Malta, little is known about factors that influence GPs' antibiotic prescribing, making it challenging to implement targeted interventions. We therefore aimed to explore GPs' understanding of antibiotic use and resistance, and describe their perceived barriers and facilitators to prudent antibiotic prescribing for acute respiratory tract infections in Malta. Methods Face-to-face individual semi-structured interviews were held with a quota sample of 20 GPs in 2014. Interviews were audio recorded and transcribed verbatim, and later analysed iteratively using manifest and latent content analysis. Findings were collated in a socioecological model to depict how GPs as individuals are embedded within larger social systems and contexts, and how each component within this system impacts their prescribing behaviour. Findings We found that GPs' antibiotic prescribing decisions are complex and impacted by numerous barriers and facilitators at the individual, interpersonal, organisational, community, and public policy level. Predominant factors found to impact GPs' antibiotic prescribing included not only intrinsic GP factors such as knowledge, awareness, experience, and misconceptions, but also several external factors. At the interpersonal level, GPs' perceived patient demand and behaviour to be a persistent issue that impacts their prescribing decisions. Similarly, some GPs found pressure from drug reps to be concerning despite being considered an important source of information. Organisational and public policy-level issues such as lack of access to relevant antibiotic prescribing guidelines and current antibiotic resistance data from the community, were also considered major barriers to appropriate antibiotic prescribing. Utilisation of diagnostic testing was found to be low and GPs' perceptions on the introduction of rapid point-of-care tests to support antibiotic prescription decisions, were mixed. Conclusion This study revealed the complexity of the antibiotic prescribing decision and the numerous barriers and facilitators that impact it, visualised through a socioecological model. Addressing GPs' antibiotic prescribing practices will require targeted and coordinated implementation activities at all levels to change behaviour and address misconceptions, whilst also improving the physical and social environment.	[Saliba-Gustafsson, Erika A.; Rosales-Klintz, Senia; Lundborg, Cecilia Stalsby] Karolinska Inst, Dept Global Publ Hlth Hlth Syst & Policy HSP Impr, Stockholm, Sweden; [Saliba-Gustafsson, Erika A.] Stanford Univ, Div Primary Care & Populat Hlth, Sch Med, Stanford, CA 94305 USA; [Nyberg, Anna] Stockholm Univ, Fac Social Sci, Stockholm, Sweden; [Borg, Michael A.] Mater Dei Hosp, Dept Infect Prevent & Control, Msida, Malta; [Borg, Michael A.] Univ Malta, Fac Med & Surg, Msida, Malta; [Rosales-Klintz, Senia] European Ctr Dis Prevent & Control, Unit Surveillance & Response Support SRS, Solna, Sweden	Karolinska Institutet; Stanford University; Stockholm University; University of Malta; European Centre for Disease Prevention & Control	Saliba-Gustafsson, EA (corresponding author), Karolinska Inst, Dept Global Publ Hlth Hlth Syst & Policy HSP Impr, Stockholm, Sweden.; Saliba-Gustafsson, EA (corresponding author), Stanford Univ, Div Primary Care & Populat Hlth, Sch Med, Stanford, CA 94305 USA.	erika.saliba@gmail.com	Gustafsson, Erika Saliba/AAR-7256-2021	Saliba-Gustafsson, Erika A/0000-0003-1587-9591; Stalsby Lundborg, Cecilia/0000-0001-6525-1861; Rosales Klintz, Senia/0000-0002-2897-6123	Karolinska Institutet [3-1233/2013]	Karolinska Institutet(Karolinska Institutet)	This work was supported by Karolinska Institutet funding for doctoral education (KIDfunding 3-1233/2013). It was also supported by funding available to CSL at Karolinska Institutet. This study received no other specific grant from any public, commercial or not-for-profit funding agencies. Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akkerman AE, 2005, J ANTIMICROB CHEMOTH, V56, P930, DOI 10.1093/jac/dki283; Akkerman AE, 2004, J ANTIMICROB CHEMOTH, V54, P1116, DOI 10.1093/jac/dkh480; Anthierens S, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-101; Arroll B, 2002, J FAM PRACTICE, V51, P954; Ashworth M, 2016, BRIT J GEN PRACT, V66, pE40, DOI 10.3399/bjgp15X688105; Azzopardi-Muscat N., 2017, HLTH SYSTEMS TRANSIT, V19, P1; Bell BG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-13; Bernier A, 2014, ANTIMICROB AGENTS CH, V58, P71, DOI 10.1128/AAC.01813-13; Biezen R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028329; Bjorkman I, 2013, SCAND J PRIM HEALTH, V31, P50, DOI 10.3109/02813432.2012.751695; Borg MA, 2002, INT J ANTIMICROB AG, V20, P253, DOI 10.1016/S0924-8579(02)00194-2; Borg MA, 2019, J ANTIMICROB CHEMOTH, V74, P3379, DOI 10.1093/jac/dkz312; Borg MA, 2012, J ANTIMICROB CHEMOTH, V67, P763, DOI 10.1093/jac/dkr541; Butler CC, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2242; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; Butler CC, 2008, SCAND J PRIM HEALTH, V26, P17, DOI 10.1080/02813430701726285; Carlsen B, 2007, BRIT J GEN PRACT, V57, P971, DOI 10.3399/096016407782604820; Cassini A, 2019, LANCET INFECT DIS, V19, P56, DOI 10.1016/S1473-3099(18)30605-4; Cates C, 1999, BRIT MED J, V318, P715, DOI 10.1136/bmj.318.7185.715; Chahwakilian P, 2011, J ANTIMICROB CHEMOTH, V66, P2872, DOI 10.1093/jac/dkr387; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; Coenen S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076691; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Dallas A, 2015, FAM PRACT, V32, P49, DOI 10.1093/fampra/cmu069; Abad MD, 2016, JAMA INTERN MED, V176, P21, DOI 10.1001/jamainternmed.2015.7088; Dekker ARJ, 2015, FAM PRACT, V32, P401, DOI 10.1093/fampra/cmv019; Dempsey PP, 2014, BMC FAM PRACT, V15, DOI 10.1186/s12875-014-0194-5; Deschepper R, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-123; Dowell J, 2001, BRIT J GEN PRACT, V51, P200; Dyrkorn R, 2016, SCAND J PRIM HEALTH, V34, P180, DOI 10.3109/02813432.2016.1163035; ECDC, 2018, SURV ANT CONS EUR 20; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Fernandez-Alvarez I, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221326; Fickweiler F, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016408; Formoso G, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5391; Francis NA, 2012, BRIT J GEN PRACT, V62, DOI [10.3399/bjgp12X653561, 10.3399/bjgp12X654614]; Frich JC, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-12; Gaygisiz U, 2017, J INFECT PUBLIC HEAL, V10, P755, DOI 10.1016/j.jiph.2016.11.011; Germeni E, 2018, BRIT J GEN PRACT, V68, pE633, DOI 10.3399/bjgp18X697889; Golden SD, 2012, HEALTH EDUC BEHAV, V39, P364, DOI 10.1177/1090198111418634; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Gulliford MC, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l236; Gulliford MC, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3410; Haeseker MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051860; Hendaus MA, 2015, THER CLIN RISK MANAG, V11, P1265, DOI 10.2147/TCRM.S87789; Hoftede G., 2010, CULTURES ORG SOFTWAR; Howick J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005611; Hoye S, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-34; Huttner B, 2010, LANCET INFECT DIS, V10, P17, DOI 10.1016/S1473-3099(09)70305-6; Ilett KF, 2000, BRIT J CLIN PHARMACO, V49, P168, DOI 10.1046/j.1365-2125.2000.00123.x; Klepser DG, 2012, AM J MANAG CARE, V18, pE145; Kumar S, 2003, BMJ-BRIT MED J, V326, P138, DOI 10.1136/bmj.326.7381.138; Little P, 2001, BMJ-BRIT MED J, V322, P336, DOI 10.1136/bmj.322.7282.336; Little P, 2005, JAMA-J AM MED ASSOC, V293, P3029, DOI 10.1001/jama.293.24.3029; Little P, 2004, BMJ-BRIT MED J, V328, P444, DOI 10.1136/bmj.38013.644086.7C; Little P, 2002, BRIT J GEN PRACT, V52, P187; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Little P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1606; Llor C, 2014, RESP CARE, V59, P1918, DOI 10.4187/respcare.03275; Mack N., 2005, QUALITATIVE RES METH; Mangione-Smith R, 1999, PEDIATRICS, V103, P711, DOI 10.1542/peds.103.4.711; Manne M, 2018, SOUTH MED J, V111, P235, DOI 10.14423/SMJ.0000000000000795; McDermott L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016903; McDonagh MS, 2018, J INT MED RES, V46, P3337, DOI 10.1177/0300060518782519; McKay R, 2016, ANTIMICROB AGENTS CH, V60, P4106, DOI 10.1128/AAC.00209-16; MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401; Meropol SB, 2013, ANN FAM MED, V11, P165, DOI 10.1370/afm.1449; Muijrers PEM, 2005, FAM PRACT, V22, P624, DOI 10.1093/fampra/cmi074; Murphy M, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X593820; National Institute for Health and Care Excellence, 2008, RESP TRACT INF SELF; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; O'Connor R, 2018, IRISH J MED SCI, V187, P969, DOI 10.1007/s11845-018-1774-5; O'Neill J., 2016, Tackling drug-resistant infections globally: final report and recommendations; Oppong R, 2013, BRIT J GEN PRACT, V63, pE465, DOI 10.3399/bjgp13X669185; Peters S, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X593866; PricewaterhouseCoopers, 2012, HEALTHC DEL MALT; Prosser H, 2003, FAM PRACT, V20, P61, DOI 10.1093/fampra/20.1.61; Raft CF, 2017, EUR J GEN PRACT, V23, P191, DOI 10.1080/13814788.2017.1347628; Rosman S, 2008, EUR J PUBLIC HEALTH, V18, P312, DOI 10.1093/eurpub/ckm118; Saliba-Gustafsson EA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-032704; Saliba-Gustafsson EA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225506; Saliba-Gustafsson EA, 2019, J ANTIMICROB CHEMOTH, V74, P1116, DOI 10.1093/jac/dky544; Saliba-Gustafsson EA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017992; Shallcross L, 2017, J ANTIMICROB CHEMOTH, V72, P1818, DOI 10.1093/jac/dkx048; Simpson SA, 2007, J ANTIMICROB CHEMOTH, V59, P292, DOI [10.1093/jac/dk1467, 10.1093/jac/dkl467]; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352; Stanton N, 2010, EUR RESPIR J, V35, P761, DOI 10.1183/09031936.00168409; Thoolen B, 2012, HEALTH PSYCHOL REV, V6, P92, DOI 10.1080/17437199.2011.552061; TNS Opinion & Social, 2016, SPEC EUR 445 ANT RES; TNS Opinion & Social, 2013, SPEC EUR 407 ANT RES; TNS Opinion & Social, 2018, SPEC EUR 478 ANT RES; Tonkin-Crine Sarah Kg, 2017, Cochrane Database Syst Rev, V9, pCD012252, DOI 10.1002/14651858.CD012252.pub2; van Duijn HJ, 2007, BRIT J GEN PRACT, V57, P561; Wald ER, 2013, PEDIATRICS, V132, pE262, DOI 10.1542/peds.2013-1071; Watkins C, 2003, QUAL SAF HEALTH CARE, V12, P29, DOI 10.1136/qhc.12.1.29; Welschen I, 2004, FAM PRACT, V21, P234, DOI 10.1093/fampra/cmh303; WHO, 2012, EVOLVING THREAT OF ANTIMICROBIAL RESISTANCE: OPTIONS FOR ACTION, P1; World Health Organization, 2015, GLOBAL ACTION PLAN A; Zarb P., 2011, Malta Medical Journal, V23, P13; Zoorob R, 2012, AM FAM PHYSICIAN, V86, P817	101	4	4	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246782	10.1371/journal.pone.0246782	http://dx.doi.org/10.1371/journal.pone.0246782			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QH4VJ	33571265	Green Published, gold			2023-01-03	WOS:000618274000023
J	Mueller, S; Winzer, EB; Duvinage, A; Gevaert, AB; Edelmann, F; Haller, B; Pieske-Kraigher, E; Beckers, P; Bobenko, A; Hommel, J; Van de Heyning, CM; Esefeld, K; von Korn, P; Christle, JW; Haykowsky, MJ; Linke, A; Wisloff, U; Adams, V; Pieske, B; van Craenenbroeck, EM; Halle, M				Mueller, Stephan; Winzer, Ephraim B.; Duvinage, Andre; Gevaert, Andreas B.; Edelmann, Frank; Haller, Bernhard; Pieske-Kraigher, Elisabeth; Beckers, Paul; Bobenko, Anna; Hommel, Jennifer; Van de Heyning, Caroline M.; Esefeld, Katrin; von Korn, Pia; Christle, Jeffrey W.; Haykowsky, Mark J.; Linke, Axel; Wisloff, Ulrik; Adams, Volker; Pieske, Burkert; van Craenenbroeck, Emeline M.; Halle, Martin		OptimEx-Clin Study Grp	Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This randomized trial compares the effects of high-intensity interval training, moderate continuous training, and guideline-based physical activity on change in peak oxygen consumption (V?o2) in patients with heart failure with preserved ejection fraction (HFpEF). Question Is there a difference in change in peak oxygen consumption (V?o(2)) among patients with heart failure with preserved ejection fraction (HFpEF) treated with differing modes of exercise? Findings This randomized clinical trial included 180 patients with HFpEF assigned to high-intensity interval training, moderate continuous training, or a control of guideline-based physical activity advice. At 3 months, the changes in peak V?o(2) were 1.1, 1.6, and -0.6 mL/kg/min, respectively. There was no statistically significant difference between high-intensity interval and moderate continuous training, and neither group met the a priori-defined minimal clinically important difference of 2.5 mL/kg/min compared with the guideline control. Meaning These findings do not support either high-intensity interval training or moderate continuous training compared with guideline-based physical activity for patients with HFpEF. Importance Endurance exercise is effective in improving peak oxygen consumption (peak V?o(2)) in patients with heart failure with preserved ejection fraction (HFpEF). However, it remains unknown whether differing modes of exercise have different effects. Objective To determine whether high-intensity interval training, moderate continuous training, and guideline-based advice on physical activity have different effects on change in peak V?o(2) in patients with HFpEF. Design, Setting, and Participants Randomized clinical trial at 5 sites (Berlin, Leipzig, and Munich, Germany; Antwerp, Belgium; and Trondheim, Norway) from July 2014 to September 2018. From 532 screened patients, 180 sedentary patients with chronic, stable HFpEF were enrolled. Outcomes were analyzed by core laboratories blinded to treatment groups; however, the patients and staff conducting the evaluations were not blinded. Interventions Patients were randomly assigned (1:1:1; n = 60 per group) to high-intensity interval training (3 x 38 minutes/week), moderate continuous training (5 x 40 minutes/week), or guideline control (1-time advice on physical activity according to guidelines) for 12 months (3 months in clinic followed by 9 months telemedically supervised home-based exercise). Main Outcomes and Measures Primary end point was change in peak V?o(2) after 3 months, with the minimal clinically important difference set at 2.5 mL/kg/min. Secondary end points included changes in metrics of cardiorespiratory fitness, diastolic function, and natriuretic peptides after 3 and 12 months. Results Among 180 patients who were randomized (mean age, 70 years; 120 women [67%]), 166 (92%) and 154 (86%) completed evaluation at 3 and 12 months, respectively. Change in peak V?o(2) over 3 months for high-intensity interval training vs guideline control was 1.1 vs -0.6 mL/kg/min (difference, 1.5 [95% CI, 0.4 to 2.7]); for moderate continuous training vs guideline control, 1.6 vs -0.6 mL/kg/min (difference, 2.0 [95% CI, 0.9 to 3.1]); and for high-intensity interval training vs moderate continuous training, 1.1 vs 1.6 mL/kg/min (difference, -0.4 [95% CI, -1.4 to 0.6]). No comparisons were statistically significant after 12 months. There were no significant changes in diastolic function or natriuretic peptides. Acute coronary syndrome was recorded in 4 high-intensity interval training patients (7%), 3 moderate continuous training patients (5%), and 5 guideline control patients (8%). Conclusions and Relevance Among patients with HFpEF, there was no statistically significant difference in change in peak V?o(2) at 3 months between those assigned to high-intensity interval vs moderate continuous training, and neither group met the prespecified minimal clinically important difference compared with the guideline control. These findings do not support either high-intensity interval training or moderate continuous training compared with guideline-based physical activity for patients with HFpEF.	[Mueller, Stephan; Duvinage, Andre; Esefeld, Katrin; von Korn, Pia; Christle, Jeffrey W.; Halle, Martin] Tech Univ Munich, Univ Hosp Klinikum Rechts Isar, Dept Prevent & Sports Med, Munich, Germany; [Mueller, Stephan; Duvinage, Andre; Esefeld, Katrin; von Korn, Pia; Christle, Jeffrey W.] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany; [Winzer, Ephraim B.; Hommel, Jennifer; Linke, Axel; Adams, Volker] Tech Univ Dresden, Heart Ctr Dresden, Dept Internal Med & Cardiol, Univ Hosp, Dresden, Germany; [Gevaert, Andreas B.; Beckers, Paul; Van de Heyning, Caroline M.; van Craenenbroeck, Emeline M.] Univ Antwerp, GENCOR Dept, Res Grp Cardiovasc Dis, Antwerp, Belgium; [Gevaert, Andreas B.; Beckers, Paul; Van de Heyning, Caroline M.; van Craenenbroeck, Emeline M.] Antwerp Univ Hosp, Dept Cardiol, Edegem, Belgium; [Edelmann, Frank; Pieske-Kraigher, Elisabeth; Bobenko, Anna; Pieske, Burkert] Charite Univ Med Berlin, Dept Internal Med & Cardiol, Campus Virchow Klinikum, Berlin, Germany; [Edelmann, Frank; Pieske-Kraigher, Elisabeth; Bobenko, Anna; Pieske, Burkert] DZHK German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany; [Haller, Bernhard] Tech Univ Munich, Inst Med Informat Stat & Epidemiol, Munich, Germany; [Christle, Jeffrey W.] Stanford Univ, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA; [Haykowsky, Mark J.] Univ Alberta, Fac Nursing, Edmonton, AB, Canada; [Wisloff, Ulrik] Norwegian Univ Sci & Technol, Cardiac Exercise Res Grp, Dept Circulat & Med Imaging, Trondheim, Norway	Technical University of Munich; German Centre for Cardiovascular Research; Munich Heart Alliance; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Antwerp; University of Antwerp; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Centre for Cardiovascular Research; Technical University of Munich; Stanford University; University of Alberta; Norwegian University of Science & Technology (NTNU)	Halle, M (corresponding author), Tech Univ Munich, Dept Prevent & Sports Med, Accredited Ctr Sports Cardiol EAPC, Sch Med,Univ Hosp Klinikum Rechts Isar, Georg Brauchle Ring 56, D-80992 Munich, Germany.	martin.halle@mri.tum.de	Van Craenenbroeck, Emeline/AAG-4540-2020; Haller, Bernhard/I-1943-2019; Van De Heyning, Caroline M./H-6320-2016; Winzer, Ephraim/GYQ-8644-2022; Gevaert, Andreas B./B-2484-2017; Mueller, Stephan/AAM-9760-2021; Pieske, Burkert/M-8089-2016	Van Craenenbroeck, Emeline/0000-0001-7686-2668; Haller, Bernhard/0000-0002-9723-393X; Van De Heyning, Caroline M./0000-0002-4661-4732; Gevaert, Andreas B./0000-0002-1338-4133; Mueller, Stephan/0000-0003-4890-3981; von Korn, Pia/0000-0003-4528-2681; Haykowsky, Mark/0000-0002-7217-2747; Pieske, Burkert/0000-0002-6466-5306; Edelmann, Frank/0000-0003-4401-5936				Alves AJ, 2012, MED SCI SPORT EXER, V44, P776, DOI 10.1249/MSS.0b013e31823cd16a; Angadi SS, 2015, J APPL PHYSIOL, V119, P753, DOI 10.1152/japplphysiol.00518.2014; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020, DOI 10.1152/jappl.1986.60.6.2020; Bobenko A, 2018, ESC HEART FAIL, V5, P53, DOI 10.1002/ehf2.12227; Bonsu KO, 2018, HEART FAIL REV, V23, P147, DOI 10.1007/s10741-018-9679-y; Bowen TS, 2015, EUR J HEART FAIL, V17, P263, DOI 10.1002/ejhf.239; Chang PP, 2014, AM J CARDIOL, V113, P504, DOI 10.1016/j.amjcard.2013.10.032; da Silveira AD, 2020, EUR J PREV CARDIOL, V27, P1733, DOI 10.1177/2047487319901206; Edelmann F, 2013, JAMA-J AM MED ASSOC, V309, P781, DOI 10.1001/jama.2013.905; Edelmann F, 2011, J AM COLL CARDIOL, V58, P1780, DOI 10.1016/j.jacc.2011.06.054; Ellingsen O, 2017, CIRCULATION, V135, P839, DOI 10.1161/CIRCULATIONAHA.116.022924; Fleg JL, 2015, CIRC-HEART FAIL, V8, P209, DOI 10.1161/CIRCHEARTFAILURE.113.001420; Fujimoto N, 2012, AM HEART J, V164, P869, DOI 10.1016/j.ahj.2012.06.028; Fukuta H, 2019, HEART FAIL REV, V24, P535, DOI 10.1007/s10741-019-09774-5; Gary RA, 2004, HEART LUNG, V33, P210, DOI 10.1016/j.hrtlng.2004.01.004; Gevaert AB, 2019, EUR J HEART FAIL, V21, P125, DOI 10.1002/ejhf.1339; Guazzi M, 2016, CIRCULATION, V133, pE694, DOI 10.1161/CIR.0000000000000406; Haykowsky MJ, 2012, J AM COLL CARDIOL, V60, P120, DOI 10.1016/j.jacc.2012.02.055; Ho JE, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.003116; Kitzman DW, 2016, JAMA-J AM MED ASSOC, V315, P36, DOI 10.1001/jama.2015.17346; Kitzman DW, 2013, J AM COLL CARDIOL, V62, P584, DOI 10.1016/j.jacc.2013.04.033; Kitzman DW, 2010, CIRC-HEART FAIL, V3, P659, DOI 10.1161/CIRCHEARTFAILURE.110.958785; Kitzman DW, 2002, JAMA-J AM MED ASSOC, V288, P2144, DOI 10.1001/jama.288.17.2144; Mezzani A, 2009, EUR J CARDIOV PREV R, V16, P249, DOI 10.1097/HJR.0b013e32832914c8; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Pandey A, 2017, J AM COLL CARDIOL, V69, P1129, DOI 10.1016/j.jacc.2016.11.081; Paulus WJ, 2007, EUR HEART J, V28, P2539, DOI 10.1093/eurheartj/ehm037; Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106; Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854; Schmederer Z, 2018, INT J CARDIOL, V273, P147, DOI 10.1016/j.ijcard.2018.08.087; Solomon SD, 2019, NEW ENGL J MED, V381, P1609, DOI 10.1056/NEJMoa1908655; Spertus J, 2005, AM HEART J, V150, P707, DOI 10.1016/j.ahj.2004.12.010; Suchy C, 2014, EUR J PREV CARDIOL, V21, P18, DOI 10.1177/2047487314552764; Tucker WJ, 2018, HEART LUNG CIRC, V27, P9, DOI 10.1016/j.hlc.2017.07.002; Tucker Wesley J, 2016, Card Fail Rev, V2, P95, DOI 10.15420/cfr.2016:16:2; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Yelland LN, 2015, CLIN TRIALS, V12, P418, DOI 10.1177/1740774515588097	37	69	71	24	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2021	325	6					542	551		10.1001/jama.2020.26812	http://dx.doi.org/10.1001/jama.2020.26812			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG0MD	33560320	Green Published, Bronze			2023-01-03	WOS:000617279600017
J	Leeming, J; Brown, P				Leeming, Jack; Brown, Patrick			Meet the food pioneer whose meat replacements are rocking the gravy boat	NATURE			English	Editorial Material						Careers; Lab life; Industry		Pat Brown explains how he's slicing into the market with plant-based steaks that are eco-friendly and good to eat. Pat Brown explains how he's slicing into the market with plant-based steaks that are eco-friendly and good to eat.	[Brown, Patrick] Impossible Foods, Redwood City, CA USA										0	1	1	6	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 4	2021	590	7844					176	176		10.1038/d41586-021-00264-z	http://dx.doi.org/10.1038/d41586-021-00264-z			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QA9GL	33526940	Bronze			2023-01-03	WOS:000613750500006
J	Qaseem, A; Etxeandia-Ikobaltzeta, I; Fitterman, N; Williams, JW; Kansagara, D				Qaseem, Amir; Etxeandia-Ikobaltzeta, Itziar; Fitterman, Nick; Williams, John W., Jr.; Kansagara, Devan			Appropriate Use of High-Flow Nasal Oxygen in Hospitalized Patients for Initial or Postextubation Management of Acute Respiratory Failure: A Clinical Guideline From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; NONINVASIVE VENTILATION; CANNULA OXYGEN; EMERGENCY-DEPARTMENT; THERAPY; EXTUBATION; EXACERBATIONS; DYSPNEA	Description: The American College of Physicians (ACP) developed this guideline to provide clinical recommendations on the appropriate use of high-flow nasal oxygen (HFNO) in hospitalized patients for initial or postextubation management of acute respiratory failure. It is based on the best available evidence on the benefits and harms of HFNO, taken in the context of costs and patient values and preferences. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review on the efficacy and safety of HFNO. The patient-centered health outcomes evaluated included all-cause mortality, hospital length of stay, 30-day hospital readmissions, hospital-acquired pneumonia, days of intubation or reintubation, intensive care unit (ICU) admission and ICU transfers, patient comfort, dyspnea, delirium, barotrauma, compromised nutrition, gastric dysfunction, functional independence at discharge, discharge disposition, and skin breakdown. This guideline was developed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) method. Target Audience and Patient Population: The target audience is all clinicians, and the target patient population is adult patients with acute respiratory failure treated in a hospital setting (including emergency departments, hospital wards, intermediate or step-down units, and ICUs). Recommendation 1a: ACP suggests that clinicians use high-flow nasal oxygen rather than noninvasive ventilation in hospitalized adults for the management of acute hypoxemic respiratory failure (conditional recommendation; low-certainty evidence). Recommendation 1b: ACP suggests that clinicians use highflow nasal oxygen rather than conventional oxygen therapy for hospitalized adults with postextubation acute hypoxemic respiratory failure (conditional recommendation; low-certainty evidence).	[Qaseem, Amir; Etxeandia-Ikobaltzeta, Itziar] Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA; [Fitterman, Nick] Northwell Hlth, 270 Pk Ave, Huntington, WV 11743 USA; [Williams, John W., Jr.] Duke Univ, Durham Vet Affairs Med Ctr, Sch Med, 200 Morris St,3rd Floor, Durham, NC 27701 USA; [Kansagara, Devan] Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA; [Etxeandia-Ikobaltzeta, Itziar] 1 Santa Margarita Hosp St,Ground Floor 2,Off 1, Irun 20303, Gipuzkoa, Spain	American College of Physicians; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.	aqaseem@acponline.org	ETXEANDIA-IKOBALTZETA, ITZIAR/AAG-3519-2022; ETXEANDIA-IKOBALTZETA, ITZIAR/AFK-4845-2022; Williams, Jr., John/A-3696-2008	ETXEANDIA-IKOBALTZETA, ITZIAR/0000-0001-6606-649X; ETXEANDIA-IKOBALTZETA, ITZIAR/0000-0001-6606-649X; Williams, Jr., John/0000-0002-5267-5558; Qaseem, Amir/0000-0001-6866-7985	ACP	ACP	Financial support for the development of this guideline comes exclusively fromthe ACP operating budget.	Azoulay E, 2018, JAMA-J AM MED ASSOC, V320, P2099, DOI 10.1001/jama.2018.14282; Baldomero AK, 2021, ANN INTERN MED, V174, P952, DOI 10.7326/M20-4675; Bell N, 2015, EMERG MED AUSTRALAS, V27, P537, DOI 10.1111/1742-6723.12490; Cho JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e194; Cong L, 2019, INT J CLIN EXP MED, V12, P10863; Corley A, 2015, INTENS CARE MED, V41, P887, DOI 10.1007/s00134-015-3765-6; Cuquemelle E, 2012, RESP CARE, V57, P1571, DOI 10.4187/respcare.01681; Delorme M, 2017, CRIT CARE MED, V45, P1981, DOI 10.1097/CCM.0000000000002693; Doshi P, 2018, ANN EMERG MED, V72, P73, DOI 10.1016/j.annemergmed.2017.12.006; Ferreyro BL, 2020, JAMA-J AM MED ASSOC, V324, P57, DOI 10.1001/jama.2020.9524; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; GRADEpro GDT, 2015, GRADEPRO GUID DEV TO; Grieco DL, 2020, AM J RESP CRIT CARE, V201, P303, DOI 10.1164/rccm.201904-0841OC; Hernandez G, 2016, JAMA-J AM MED ASSOC, V316, P1565, DOI 10.1001/jama.2016.14194; Hernandez G, 2016, JAMA-J AM MED ASSOC, V315, P1354, DOI 10.1001/jama.2016.2711; Jackson T, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000730; Jing GQ, 2019, RES NURS HEALTH, V42, P217, DOI 10.1002/nur.21942; Jones PG, 2016, RESP CARE, V61, P291, DOI 10.4187/respcare.04252; Lemiale V, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1097-0; Maggiore SM, 2014, AM J RESP CRIT CARE, V190, P282, DOI 10.1164/rccm.201402-0364OC; Makdee O, 2017, ANN EMERG MED, V70, P465, DOI 10.1016/j.annemergmed.2017.03.028; Matsuda W, 2020, RESP CARE, V65, P610, DOI 10.4187/respcare.07095; Moller W, 2017, J APPL PHYSIOL, V122, P191, DOI 10.1152/japplphysiol.00584.2016; Nishimura M, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0084-5; Papazian L, 2016, INTENS CARE MED, V42, P1336, DOI 10.1007/s00134-016-4277-8; Parke RL, 2013, RESP CARE, V58, P1621, DOI 10.4187/respcare.02358; Parke RL, 2011, RESP CARE, V56, P265, DOI 10.4187/respcare.00801; Pilcher J, 2017, RESPIROLOGY, V22, P1149, DOI 10.1111/resp.13050; Qaseem A, 2019, ANN INTERN MED, V171, P354, DOI 10.7326/M18-3279; Qaseem A, 2019, ANN INTERN MED, V170, P863, DOI 10.7326/M18-3290; Rittayamai N, 2015, RESP CARE, V60, P1377, DOI 10.4187/respcare.03837; Rittayamai N, 2014, RESP CARE, V59, P485, DOI 10.4187/respcare.02397; Ruangsomboon O, 2020, ANN EMERG MED, V75, P615, DOI 10.1016/j.annemergmed.2019.09.009; Saksitthichok B, 2019, J THORAC DIS, V11, P1929, DOI 10.21037/jtd.2019.05.02; Santesso N, 2020, J CLIN EPIDEMIOL, V119, P126, DOI 10.1016/j.jclinepi.2019.10.014; Schunemann H, GRADE HDB; Schwabbauer N, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-66; Sklar MC, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0432-4; Song HZ, 2017, CLINICS, V72, P562, DOI 10.6061/clinics/2017(09)07; Spoletini G, 2018, J CRIT CARE, V48, P418, DOI 10.1016/j.jcrc.2018.10.004; Stephan F, 2015, JAMA-J AM MED ASSOC, V313, P2331, DOI 10.1001/jama.2015.5213; Vargas F, 2015, RESP CARE, V60, P1369, DOI 10.4187/respcare.03814; Vourc'h M, 2020, J CARDIOTHOR VASC AN, V34, P157, DOI 10.1053/j.jvca.2019.05.039	43	7	7	2	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL	2021	174	7					977	+		10.7326/M20-7533	http://dx.doi.org/10.7326/M20-7533			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM8QB	33900796				2023-01-03	WOS:000675809000024
J	Gebremichael, SG; Yismaw, E; Tsegaw, BD; Shibeshi, AD				Gebremichael, Shewayiref Geremew; Yismaw, Emebet; Tsegaw, Belete Dejen; Shibeshi, Adeladilew Dires			Determinants of water source use, quality of water, sanitation and hygiene perceptions among urban households in North-West Ethiopia: A cross-sectional study	PLOS ONE			English	Article							BEHAVIOR	Background Clean water is an essential part of human healthy life and wellbeing. More recently, rapid population growth, high illiteracy rate, lack of sustainable development, and climate change; faces a global challenge in developing countries. The discontinuity of drinking water supply forces households either to use unsafe water storage materials or to use water from unsafe sources. The present study aimed to identify the determinants of water source types, use, quality of water, and sanitation perception of physical parameters among urban households in North-West Ethiopia. Methods A community-based cross-sectional study was conducted among households from February to March 2019. An interview-based a pre-tested and structured questionnaire was used to collect the data. Data collection samples were selected randomly and proportional to each of the kebeles' households. MS Excel and R Version 3.6.2 were used to enter and analyze the data; respectively. Descriptive statistics using frequencies and percentages were used to explain the sample data concerning the predictor variable. Both bivariate and multivariate logistic regressions were used to assess the association between independent and response variables. Results Four hundred eighteen (418) households have participated. Based on the study undertaken,78.95% of households used improved and 21.05% of households used unimproved drinking water sources. Households drinking water sources were significantly associated with the age of the participant (x(2) = 20.392, df = 3), educational status (x(2) = 19.358, df = 4), source of income (x(2) = 21.777, df = 3), monthly income (x(2) = 13.322, df = 3), availability of additional facilities (x(2) = 98.144, df = 7), cleanness status (x(2) = 42.979, df = 4), scarcity of water (x(2) = 5.1388, df = 1) and family size (x(2) = 9.934, df = 2). The logistic regression analysis also indicated that those factors are significantly determining the water source types used by the households. Factors such as availability of toilet facility, household member type, and sex of the head of the household were not significantly associated with drinking water sources. Conclusion The uses of drinking water from improved sources were determined by different demographic, socio-economic, sanitation, and hygiene-related factors. Therefore; the local, regional, and national governments and other supporting organizations shall improve the accessibility and adequacy of drinking water from improved sources in the area.	[Gebremichael, Shewayiref Geremew; Yismaw, Emebet; Tsegaw, Belete Dejen] Debre Tabor Univ, Dept Stat, Debre Tabor, Ethiopia; [Shibeshi, Adeladilew Dires] Debre Tabor Univ, Dept Math, Debre Tabor, Ethiopia		Gebremichael, SG (corresponding author), Debre Tabor Univ, Dept Stat, Debre Tabor, Ethiopia.	Shewayirefg@gmail.com	Dejen, Belete/AAS-8716-2021	Geremew, Shewayiref/0000-0002-7053-9402				Abebaw D, 2010, IFPRI DISCUSSION PAP; Andualem TG, 2019, J HYDROL-REG STUD, V24, DOI 10.1016/j.ejrh.2019.100610; [Anonymous], 1997, WORLD HEALTH FORUM, V18, P248; [Anonymous], 2017, DRINKING WATER QUALI; [Anonymous], 2016, DRINKING WATER QUALI; [Anonymous], 2015, WATER SANITATION HYG; [Anonymous], 2014, PROGR DRINKING WATER; [Anonymous], [No title captured]; Arouna A, 2010, WATER RESOUR MANAG, V24, P1381, DOI 10.1007/s11269-009-9504-4; Baba S.A, 2017, **DROPPED REF**; Beyene A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1804-4; Bosch C., 2001, WATER SANITATION POV; Brick T, 2004, INT J HYG ENVIR HEAL, V207, P473, DOI 10.1078/1438-4639-00318; Christine M, 2013, GRADUATE THESES DISS; Cochran, 1977, SAMPLING TECHNIQUES; De Troyer N, 2016, WATER-SUI, V8, DOI 10.3390/w8040123; Derara Chalchisa, 2017, Environmental Systems Research, V6, DOI 10.1186/s40068-017-0089-2; Edgar Morgenroth, 2014, FINAL REPORT HOUSEHO; Ethiopia, 2016, DEM HLTH SURV 2016; Fotue L. A. T., 2012, Journal of Sustainable Development in Africa, V14, P86; Froukh ML, 2001, WATER RESOUR MANAG, V15, P363, DOI 10.1023/A:1015527117823; Gebremichael SG, 2020, MOJ PUBLIC HLTH, V9, DOI [10.15406/mojph.2020.09.0032, DOI 10.15406/MOJPH.2020.09.0032]; Gizachew M, 2020, INT J MICROBIOL, V2020, DOI 10.1155/2020/5340202; Grafton RQ, 2011, WATER RESOUR RES, V47, DOI 10.1029/2010WR009685; Gualie YT, 2019, INT J SCI REP, V5, P240; HEADLEY JC, 1963, LAND ECON, V39, P440; Hussien WA, 2016, WATER RESOUR MANAG, V30, P2931, DOI 10.1007/s11269-016-1314-x; Ifabiyi I.P, 2010, GLOBAL J HUMAN SOCIA, V10, P45; Jain S.K., 2010, J COMP SOCIAL WELFAR, V26, P215; Joachim V. B, 2016, ZEF DISCUSSION PAPER, V221; Keshavarzi AR, 2006, WATER RES, V40, P1173, DOI 10.1016/j.watres.2006.01.021; Koskei E. C., 2013, Research Journal of Environmental and Earth Sciences, V5, P714; Madanat S, 1993, MODELING HOUSEHOLD C; Marinoski AK, 2014, WATER-SUI, V6, P1985, DOI 10.3390/w6071985; Ministry of Finance and Economic Development, 2010, GROWTH TRANSF PLAN; MU X, 1990, WATER RESOUR RES, V26, P521, DOI 10.1029/WR026i004p00521; Onundi F.T, 2014, J ENV EARTH SCI, V4; Oyekale AS, 2012, LIFE SCI J, V9, P2488; Raimi M. O., 2019, PUBLIC HLTH OPEN ACC, V3, DOI [10.23880/phoa-16000134, DOI 10.23880/PHOA-16000134]; Rewata J, 2000, WATER RESOURCE DEV, V16, P407; Roy A, 2014, FEBS OPEN BIO, V4, P105, DOI 10.1016/j.fob.2013.12.004; SANDIFORD P, 1990, J TROP MED HYG, V93, P383; Simelane M. S., 2020, Advances in Public Health, V2020, DOI 10.1155/2020/6758513; Thomas MLH, 2020, WATER-SUI, V12, DOI 10.3390/w12092603; Totouom F, 2013, INT J EC PRACTICES T, V3; Unicef WHO, 2012, PROGR DRINKING WATER; WHO, 2013, PREVENTING DIS HLTH; WHO, 2004, WHO GUIDELINES DRINK; WHO and UNICEF definitions of improved drinking-water source on the JMP, 2012, **DROPPED REF**; WHO/UNICEF, 2017, PROGR DRINKING WATER; WHO/UNICEF, JOINT MON PROGR WAT; WHO/UNICEF, 2017, PROGR DRINKING WATER; WHO/UNICEF, 2011, PROGR SAN DRINK WAT; World Health Organization and United Nations Children's Fund, US AM 2002 WORLD BAN; World Health Organization and United Nations Children's Fund. United States of America, WORLD BANK DOC FED D; Zizza CA, 2009, J GERONTOL A-BIOL, V64, P481, DOI 10.1093/gerona/gln045	56	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0239502	10.1371/journal.pone.0239502	http://dx.doi.org/10.1371/journal.pone.0239502			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0DC	33886565	Green Submitted, Green Published, gold			2023-01-03	WOS:000644138300120
J	Alkhateeb, H; El Fathi, A; Ghanbari, M; Haidar, A				Alkhateeb, Haneen; El Fathi, Anas; Ghanbari, Milad; Haidar, Ahmad			Modelling glucose dynamics during moderate exercise in individuals with type 1 diabetes	PLOS ONE			English	Article							INDUCED TRANSLOCATION; INSULIN SENSITIVITY; ARTIFICIAL PANCREAS; PHYSICAL-ACTIVITY; GLYCEMIC CONTROL; SKELETAL-MUSCLE; TRANSPORT; INTENSITY; RESISTANCE; CHILDREN	The artificial pancreas is a closed-loop insulin delivery system that automatically regulates glucose levels in individuals with type 1 diabetes. In-silico testing using simulation environments accelerates the development of better artificial pancreas systems. Simulation environments need an accurate model that captures glucose dynamics during exercise to simulate real-life scenarios. We proposed six variations of the Bergman Minimal Model to capture the physiological effects of moderate exercise on glucose dynamics in individuals with type 1 diabetes. We estimated the parameters of each model with clinical data using a Bayesian approach and Markov chain Monte Carlo methods. The data consisted of measurements of plasma glucose, plasma insulin, and oxygen consumption collected from a study of 17 adults with type 1 diabetes undergoing aerobic exercise sessions. We compared the models based on the physiological plausibility of their parameters estimates and the deviance information criterion. The best model features (i) an increase in glucose effectiveness proportional to exercise intensity, and (ii) an increase in insulin action proportional to exercise intensity and duration. We validated the selected model by reproducing results from two previous clinical studies. The selected model accurately simulates the physiological effects of moderate exercise on glucose dynamics in individuals with type 1 diabetes. This work offers an important tool to develop strategies for exercise management with the artificial pancreas.	[Alkhateeb, Haneen; Ghanbari, Milad] McGill Univ, Dept Biomed Engn, Montreal, PQ, Canada; [El Fathi, Anas] McGill Univ, Dept Elect & Comp Engn, Montreal, PQ, Canada; [Haidar, Ahmad] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Haidar, A (corresponding author), McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada.	ahmad.haidar@mcgill.ca	El Fathi, Anas/AAW-7415-2020; El Fathi, Anas/GYD-9666-2022	El Fathi, Anas/0000-0001-7837-1555; 				Al Khalifah RA, 2016, DIABETIC MED, V33, P1686, DOI 10.1111/dme.13070; [Anonymous], USERS MANUAL YSI 230; Ben Brahim Najib, 2015, J Diabetes Sci Technol, V9, P1185, DOI 10.1177/1932296815607864; BERGMAN RN, 1979, AM J PHYSIOL, V236, pE667, DOI 10.1152/ajpendo.1979.236.6.E667; Bohn B, 2015, DIABETES CARE, V38, P1536, DOI 10.2337/dc15-0030; Brazeau AS, 2008, DIABETES CARE, V31, P2108, DOI 10.2337/dc08-0720; Breton MD, 2014, DIABETES TECHNOL THE, V16, P506, DOI 10.1089/dia.2013.0333; Breton Marc D, 2008, J Diabetes Sci Technol, V2, P169; Chimen M, 2012, DIABETOLOGIA, V55, P542, DOI 10.1007/s00125-011-2403-2; Cobelli C, 2006, P DIAB TECHN M ATL G; Colberg SR, 2016, DIABETES CARE, V39, P2065, DOI 10.2337/dc16-1728; Craig E. Taplin, 2018, TYPE 1 DIABETES MELL; Dalla Man Chiara, 2007, J Diabetes Sci Technol, V1, P323; Derouich M, 2002, J BIOMECH, V35, P911, DOI 10.1016/S0021-9290(02)00055-6; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; Ewings SM, 2015, STAT METHODS MED RES, V24, P342, DOI 10.1177/0962280214520732; Foster NC, 2019, DIABETES TECHNOL THE, V21, P66, DOI 10.1089/dia.2018.0384; Funai K, 2009, AM J PHYSIOL-ENDOC M, V297, pE242, DOI 10.1152/ajpendo.00194.2009; FUSHIKI T, 1989, AM J PHYSIOL, V256, pE580, DOI 10.1152/ajpendo.1989.256.5.E580; Galassetti PR, 2006, PEDIATR DIABETES, V7, P16, DOI 10.1111/j.1399-543X.2006.00140.x; Gilks WR, 1995, MARKOV CHAIN MONTE C; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE556, DOI 10.1152/ajpendo.1991.261.5.E556; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE795, DOI 10.1152/ajpendo.1991.261.6.E795; GOODYEAR LJ, 1990, AM J PHYSIOL, V258, pE667, DOI 10.1152/ajpendo.1990.258.4.E667; Guelfi KJ, 2007, AM J PHYSIOL-ENDOC M, V292, pE865, DOI 10.1152/ajpendo.00533.2006; Haidar A, 2016, IEEE CONTR SYST MAG, V36, P28, DOI 10.1109/MCS.2016.2584318; Haidar A, 2015, LANCET DIABETES ENDO, V3, P17, DOI 10.1016/S2213-8587(14)70226-8; HANSEN I, 1986, AM J PHYSIOL, V250, pE269, DOI 10.1152/ajpendo.1986.250.3.E269; Harmer AR, 2007, DIABETES CARE, V30, P1269, DOI 10.2337/dc06-1790; Hernandez-Ordonez M, 2008, J BIOMECH, V41, P744, DOI 10.1016/j.jbiomech.2007.11.028; Hobbs Nicole, 2019, J Diabetes Sci Technol, V13, P718, DOI 10.1177/1932296818820550; Hovorka R, 2002, AM J PHYSIOL-ENDOC M, V282, pE992, DOI 10.1152/ajpendo.00304.2001; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Kanderian Sami S, 2009, J Diabetes Sci Technol, V3, P1047; Kim J, 2007, ANN BIOMED ENG, V35, P69, DOI [10.1007/s10439-006-9210-x, 10.1007/s10439-006-9201-x]; Lenart PJ, 2002, IFAC P VOLUMES, V35, P247, DOI [10.3182/20020721-6-ES-1901.01350, DOI 10.3182/20020721-6-ES-1901.01350]; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Mallad A, 2015, AM J PHYSIOL-ENDOC M, V308, pE1106, DOI 10.1152/ajpendo.00014.2015; Man CD, 2007, IEEE T BIO-MED ENG, V54, P1740, DOI 10.1109/TBME.2007.893506; Man Chiara Dalla, 2009, J Diabetes Sci Technol, V3, P56; McMahon SK, 2007, J CLIN ENDOCR METAB, V92, P963, DOI 10.1210/jc.2006-2263; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; Nguyen TTP, 2019, DIABETES, V68, DOI 10.2337/db19-62-LB; Palumbo MC, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006073; PLOUG T, 1984, AM J PHYSIOL, V247, pE726, DOI 10.1152/ajpendo.1984.247.6.E726; Rabasa-Lhoret R, 2001, DIABETES CARE, V24, P625, DOI 10.2337/diacare.24.4.625; Resalat N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217301; RICHTER EA, 1989, J APPL PHYSIOL, V66, P876; Riddell MC, 2017, LANCET DIABETES ENDO, V5, P377, DOI 10.1016/S2213-8587(17)30014-1; Riddell Michael C, 2015, J Diabetes Sci Technol, V9, P1217, DOI 10.1177/1932296815609370; RIZZA RA, 1982, DIABETES, V31, P663, DOI 10.2337/diabetes.31.8.663; ROMERES D., 2019, AM DIABETES ASS; Roy Anirban, 2007, J Diabetes Sci Technol, V1, P338; Schneider K., 2020, THESIS ETH ZURICH; Shetty VB, 2016, J CLIN ENDOCR METAB, V101, P972, DOI 10.1210/jc.2015-4026; Spiegelhalter D., 2003, WINBUGS USER MANUAL; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; STORER TW, 1990, MED SCI SPORT EXER, V22, P704, DOI 10.1249/00005768-199010000-00024; Szadkowska A, 2008, DIABETIC MED, V25, P282, DOI 10.1111/j.1464-5491.2007.02357.x; Taleb N, 2016, DIABETOLOGIA, V59, P2561, DOI 10.1007/s00125-016-4107-0; Thabit H, 2015, NEW ENGL J MED, V373, P2129, DOI 10.1056/NEJMoa1509351; Todd JA, 2010, IMMUNITY, V32, P457, DOI 10.1016/j.immuni.2010.04.001; Visentin Roberto, 2018, J Diabetes Sci Technol, V12, P273, DOI 10.1177/1932296818757747; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; Wilinska Malgorzata E, 2010, J Diabetes Sci Technol, V4, P132; Xie JY, 2019, J BIOMECH ENG-T ASME, V141, DOI 10.1115/1.4041522; Zaharieva DP, 2019, DIABETES CARE, V42, P824, DOI 10.2337/dc18-2204; ZORZANO A, 1986, AM J PHYSIOL, V251, pE21, DOI 10.1152/ajpendo.1986.251.1.E21	69	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2021	16	3							e0248280	10.1371/journal.pone.0248280	http://dx.doi.org/10.1371/journal.pone.0248280			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF4TU	33770092	gold, Green Published			2023-01-03	WOS:000634833500030
J	Galan-Vasquez, E; Perez-Rueda, E				Galan-Vasquez, Edgardo; Perez-Rueda, Ernesto			A landscape for drug-target interactions based on network analysis	PLOS ONE			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; NITRIC-OXIDE; INTERACTION PREDICTION; COMMUNITY STRUCTURE; COPPER; FOSTAMATINIB; DISCOVERY; VITAMIN; OPINION; BIOLOGY	In this work, we performed an analysis of the networks of interactions between drugs and their targets to assess how connected the compounds are. For our purpose, the interactions were downloaded from the DrugBank database, and we considered all drugs approved by the FDA. Based on topological analysis of this interaction network, we obtained information on degree, clustering coefficient, connected components, and centrality of these interactions. We identified that this drug-target interaction network cannot be divided into two disjoint and independent sets, i.e., it is not bipartite. In addition, the connectivity or associations between every pair of nodes identified that the drug-target network is constituted of 165 connected components, where one giant component contains 4376 interactions that represent 89.99% of all the elements. In this regard, the histamine H1 receptor, which belongs to the family of rhodopsin-like G-protein-coupled receptors and is activated by the biogenic amine histamine, was found to be the most important node in the centrality of input-degrees. In the case of centrality of output-degrees, fostamatinib was found to be the most important node, as this drug interacts with 300 different targets, including arachidonate 5-lipoxygenase or ALOX5, expressed on cells primarily involved in regulation of immune responses. The top 10 hubs interacted with 33% of the target genes. Fostamatinib stands out because it is used for the treatment of chronic immune thrombocytopenia in adults. Finally, 187 highly connected sets of nodes, structured in communities, were also identified. Indeed, the largest communities have more than 400 elements and are related to metabolic diseases, psychiatric disorders and cancer. Our results demonstrate the possibilities to explore these compounds and their targets to improve drug repositioning and contend against emergent diseases.	[Galan-Vasquez, Edgardo] Univ Nacl Autonoma Mexico, Inst Invest Matemat Aplicadas & Sistemas, Dept Ingn Sistemas Comp & Automatizac, Ciudad Univ, Mexico City, DF, Mexico; [Perez-Rueda, Ernesto] Univ Nacl Autonoma Mexico, Inst Invest Matemat Aplicadas & Sistemas, Unidad Acad Yucatan, Merida, Yucatan, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Galan-Vasquez, E (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Matemat Aplicadas & Sistemas, Dept Ingn Sistemas Comp & Automatizac, Ciudad Univ, Mexico City, DF, Mexico.; Perez-Rueda, E (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Matemat Aplicadas & Sistemas, Unidad Acad Yucatan, Merida, Yucatan, Mexico.	edgardo.galan@iimas.unam.mx; ernesto.perez@iimas.unam.mx	Galán-Vásquez, Edgardo/AFP-3050-2022; Perez-Rueda, Ernesto/D-7468-2016	Galán-Vásquez, Edgardo/0000-0002-9165-1241; Perez-Rueda, Ernesto/0000-0002-6879-0673	Direccion General de Asuntos del Personal Academico-Universidad Nacional Autonoma de Me'xico [IA201221, IN-209620]; CYTED [P918PTE0261]	Direccion General de Asuntos del Personal Academico-Universidad Nacional Autonoma de Me'xico(Universidad Nacional Autonoma de Mexico); CYTED	Direccion General de Asuntos del Personal Academico-Universidad Nacional Autonoma de Me ' xico (IA201221 and IN-209620) and CYTED (P918PTE0261). There was no additional external funding received for this study. The funders did not have additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali MA, 2017, NAT REV DRUG DISCOV, V16, P309, DOI 10.1038/nrd.2016.262; Anighoro A, 2014, J MED CHEM, V57, P7874, DOI 10.1021/jm5006463; [Anonymous], 2009, ENCY NEUROSCIENCE; Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; Arrell DK, 2010, CLIN PHARMACOL THER, V88, P120, DOI 10.1038/clpt.2010.91; Bansal M, 2014, NAT BIOTECHNOL, V32, P1213, DOI 10.1038/nbt.3052; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Bost M, 2016, J TRACE ELEM MED BIO, V35, P107, DOI 10.1016/j.jtemb.2016.02.006; Braselmann S, 2006, J PHARMACOL EXP THER, V319, P998, DOI 10.1124/jpet.106.109058; Bussel J, 2018, AM J HEMATOL, V93, P921, DOI 10.1002/ajh.25125; Chen HL, 2015, COMPUT MATH METHOD M, V2015, DOI 10.1155/2015/130620; Chen HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062975; Chen X, 2020, BRIEF BIOINFORM, V21, P47, DOI 10.1093/bib/bby098; Chen X, 2016, BRIEF BIOINFORM, V17, P696, DOI 10.1093/bib/bbv066; Chen X, 2012, MOL BIOSYST, V8, P1970, DOI 10.1039/c2mb00002d; Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16; Colson P, 2016, INT J ANTIMICROB AG, V48, P349, DOI 10.1016/j.ijantimicag.2016.07.004; Cook CCH, 1998, ALCOHOL ALCOHOLISM, V33, P317; Cui YZ, 2014, PHYSICA A, V416, P198, DOI 10.1016/j.physa.2014.08.050; Currie KS, 2014, J MED CHEM, V57, P3856, DOI 10.1021/jm500228a; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Eustace J, 2015, PHYSICA A, V421, P510, DOI 10.1016/j.physa.2014.11.039; Harmar AJ, 2009, NUCLEIC ACIDS RES, V37, pD680, DOI 10.1093/nar/gkn728; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hunter S, 2009, NUCLEIC ACIDS RES, V37, pD211, DOI 10.1093/nar/gkn785; Imming P, 2006, NAT REV DRUG DISCOV, V5, P821, DOI 10.1038/nrd2132; Institute of Medicine, 2014, DRUG REP REP WORKSHS, DOI [10.17226/18731.https://doi.org/10.17226/18731, DOI 10.17226/18731.HTTPS://DOI.ORG/10.17226/18731]; Iovanovici A, 2014, INT CONF SYST THEO, P815, DOI 10.1109/ICSTCC.2014.6982519; Ishima Y, 2009, DRUG METAB PHARMACOK, V24, P308, DOI 10.2133/dmpk.24.308; Janga SC, 2009, MOL BIOSYST, V5, P1536, DOI [10.1039/b908147j, 10.1039/B908147j]; Junker B.H., 2008, WILEY SERIES BIOINFO; Khan JA, 2007, EXPERT OPIN THER TAR, V11, P695, DOI 10.1517/14728222.11.5.695; Klein AB, 2010, NEUROSCIENCE, V169, P1007, DOI 10.1016/j.neuroscience.2010.05.054; Klingerman CM, 2014, SCHIZOPHRENIA BULL, V40, P327, DOI 10.1093/schbul/sbs196; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; LAMBIOTTE R, 2008, ARXIV08121770; Lavecchia A, 2015, DRUG DISCOV TODAY, V20, P318, DOI 10.1016/j.drudis.2014.10.012; Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5; Lima AN, 2016, EXPERT OPIN DRUG DIS, V11, P225, DOI 10.1517/17460441.2016.1146250; Lin SJ, 2003, CURR OPIN CELL BIOL, V15, P241, DOI 10.1016/S0955-0674(03)00006-1; Liu C, 2020, PHYS REP, V846, P1, DOI 10.1016/j.physrep.2019.12.004; Lu JY, 2019, NEUROPSYCHOPHARMACOL, V44, P1123, DOI 10.1038/s41386-019-0332-9; Mahabadi N., 2020, RIBOFLAVIN DEFICIENC; Mancuso C, 2010, J NEUROCHEM, V113, P563, DOI 10.1111/j.1471-4159.2010.06606.x; Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601; Mendez-Lucio O, 2016, J MEX CHEM SOC, V60, P168; Meng FL, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.1057; Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004; Mollison PL, 2000, BRIT J HAEMATOL, V108, P13; Newland A, 2018, IMMUNOTHERAPY-UK, V10, P9, DOI 10.2217/imt-2017-0097; Newman MEJ, 2004, PHYS REV E, V70, DOI [10.1103/PhysRevE.70.056131, 10.1103/PhysRevE.69.026113]; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078; Pons P, 2005, LECT NOTES COMPUT SC, V3733, P284; Prakash A, 2015, FUND CLIN PHARMACOL, V29, P131, DOI 10.1111/fcp.12110; Radicchi F, 2004, P NATL ACAD SCI USA, V101, P2658, DOI 10.1073/pnas.0400054101; Raghavan UN, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.036106; Read SA, 2019, ADV NUTR, V10, P696, DOI 10.1093/advances/nmz013; Reichardt J, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.016110; Riccaboni M, 2010, DRUG DISCOV TODAY, V15, P517, DOI 10.1016/j.drudis.2010.05.001; Rossetti G, 2019, APPL NETW SCI, V4, DOI 10.1007/s41109-019-0165-9; Rosvall M, 2008, P NATL ACAD SCI USA, V105, P1118, DOI 10.1073/pnas.0706851105; Ryall KA, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0055-9; Samelson-Jones BJ, 2006, BIOCHEMISTRY-US, V45, P8527, DOI 10.1021/bi060143j; Sharma HS., 2003, BLOOD SPINAL CORD BR; Sharma MC, 2005, RES VET SCI, V79, P113, DOI 10.1016/j.rvsc.2004.11.015; Skinner M, 2014, BRIT J PHARMACOL, V171, P2308, DOI 10.1111/bph.12559; Strating JRPM, 2015, CELL REP, V10, P600, DOI 10.1016/j.celrep.2014.12.054; Tan X, 2012, NAT BIOTECHNOL, V30, P1125, DOI 10.1038/nbt.2391; van den Berghe PVE, 2009, NUTR REV, V67, P658, DOI 10.1111/j.1753-4887.2009.00250.x; Vogt I, 2010, MOL INFORM, V29, P10, DOI 10.1002/minf.200900069; Wacker D, 2017, CELL, V168, P377, DOI 10.1016/j.cell.2016.12.033; Wang R, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3283-6; Wang XY, 2016, PHYSICA A, V462, P569, DOI 10.1016/j.physa.2016.06.096; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Wu ZR, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01134; Wu ZK, 2013, MOL BIOSYST, V9, P1268, DOI 10.1039/c3mb25382a; Yang Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep30750; Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338; Zhuang QX, 2018, MOL NEUROBIOL, V55, P8059, DOI 10.1007/s12035-018-0976-1	84	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2021	16	3							e0247018	10.1371/journal.pone.0247018	http://dx.doi.org/10.1371/journal.pone.0247018			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY9GW	33730052	Green Published, gold			2023-01-03	WOS:000630345000064
J	Belludi, A; McFall, AM; Solomon, SS; Celentano, DD; Mehta, SH; Srikrishnan, AK; Kumar, MS; Solomon, S; Lucas, GM				Belludi, Ashwin; McFall, Allison M.; Solomon, Sunil Suhas; Celentano, David D.; Mehta, Shruti H.; Srikrishnan, A. K.; Kumar, M. Suresh; Solomon, Suniti; Lucas, Gregory M.			Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: Results from a multi-city crosssectional survey	PLOS ONE			English	Article								Introduction Pre-exposure prophylaxis (PrEP) is effective in reducing HIV transmission among key populations. In India, where PrEP is not currently part of the national HIV program, little is known about PrEP awareness, willingness to use PrEP, and barriers to uptake among people who inject drugs (PWID) and men who have sex with men (MSM). Methods We used respondent-driven sampling to accrue PWID and MSM in 22 sites from August 2016 to May 2017. Participants were asked about awareness of PrEP, willingness to use PrEP (following a brief description) and reasons why they might not be willing to use PrEP. Participants were also queried on preferences for PrEP delivery modality (oral vs. injectable). Multi-level logistic regression models were used to determine participant correlates of willingness to use PrEP. Estimates were weighted for the sampling method. Results A total of 10,538 PWID and 8,621 MSM who self-reported being HIV-negative were included in the analysis. Only 6.1% (95% confidence interval [CI]: 5.9, 6.3) of PWID and 8.0% of MSM (95% CI: 7.7, 8.4) were aware of PrEP. However, willingness to use PrEP was substantially higher in both groups: 52.4% of PWID and 67.6% of MSM. Participants commonly cited a perceived low risk for acquiring HIV infection, being perceived by others as being HIV-positive, and side effects as reasons why they would be unwilling to use PrEP. Among PWID, sharing needles and hazardous alcohol use were associated with increased willingness to use PrEP. Among MSM, having a main male partner and injection drug use were associated with increased willingness to use PrEP. Preference for daily oral or monthly injectable PrEP was similar among MSM (39.6%% vs. 41.7%,), while PWID were more likely to prefer oral to injectable administration routes (56.3% vs. 31.1%). Conclusions As India plans to roll-out of PrEP in the public sector, our multi-city survey of PWID and MSM highlights the need for key population-focused education campaigns about PrEP and self-assessment of risk.	[Belludi, Ashwin; McFall, Allison M.; Solomon, Sunil Suhas; Celentano, David D.; Mehta, Shruti H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Solomon, Sunil Suhas; Celentano, David D.; Lucas, Gregory M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Solomon, Sunil Suhas; Srikrishnan, A. K.; Kumar, M. Suresh; Solomon, Suniti] YR Gaitonde Ctr AIDS Res & Educ, Chennai, Tamil Nadu, India	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Lucas, GM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	glucas@jhmi.edu		Lucas, Gregory/0000-0002-3013-4339	National Institute on Drug Abuse [R01DA032059, R01DA041034, K24DA035684]; National Institute of Mental Health [R01MH89266]; Johns Hopkins Center for AIDS Research [P30 AI094189]	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Johns Hopkins Center for AIDS Research	This project was funded by the National Institute on Drug Abuse (R01DA032059 [GML, SHM], R01DA041034 [GML, SHM], K24DA035684 [GML]) and the National Institute of Mental Health (R01MH89266 [DDC]). Other support was provided by the Elton John AIDS Foundation and Johns Hopkins Center for AIDS Research (P30 AI094189). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. National Institute on Drug Abuse: https://www.drugabuse.gov/National Institute of Mental Health: https://www.nimh.nih.gov/index.shtml Elton John AIDS Foundation: https://ejaf.org/Johns Hopkins Center for AIDS Research: http://www.hopkinscfar.org/.	[Anonymous], 2020, LONG ACTING INJECTAB; Banik S, 2019, ARCH SEX BEHAV, V48, P305, DOI 10.1007/s10508-018-1361-x; Chakrapani V, 2015, AIDS PATIENT CARE ST, V29, P569, DOI 10.1089/apc.2015.0143; Chandhiok N, 2014, SEX HEALTH, V11, P171, DOI 10.1071/SH13067; Clement ME, 2020, CURR OPIN HIV AIDS, V15, P19, DOI 10.1097/COH.0000000000000597; Ganapathi L, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25287; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Heckathorn DD, 2002, SOC PROBL, V49, P11, DOI 10.1525/sp.2002.49.1.11; HIV NACOI-NIoMS, 2018, HIV NACOI NIOMS ESTI; Hodges-Mameletzis I, 2018, SEX HEALTH, V15, P489, DOI 10.1071/SH18125; Kazemian P, 2020, CLIN INFECT DIS, V70, P633, DOI 10.1093/cid/ciz249; Lim SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182838; Lucas GM, 2016, AIDS, V30, P619, DOI [10.1097/QAD.0000000000000949, 10.1097/QAD.0000000000000592]; Marfatia YS, 2017, INDIAN J SEX TRANSM, V38, P1, DOI 10.4103/ijstd.IJSTD_26_17; Mehta SH, 2015, CLIN INFECT DIS, V61, P1732, DOI 10.1093/cid/civ669; NACO, 2017, HIV SENT SURV TECHN; National AIDS Control Organisation, 2017, NAT STRAT PLAN HIV A; Oldenburg CE, 2016, AIDS BEHAV, V20, pS365, DOI 10.1007/s10461-016-1483-x; Palchaudhuri R, 2016, INDIAN J MED RES, V144, P789, DOI 10.4103/ijmr.IJMR_1902_16; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Sidebottom D, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3463-4; Siegler AJ, 2018, ANN EPIDEMIOL, V28, P841, DOI 10.1016/j.annepidem.2018.06.005; Sineath R Craig, 2013, J Int Assoc Provid AIDS Care, V12, P227, DOI 10.1177/2325957413488184; Solomon SS, 2019, LANCET HIV, V6, pE283, DOI 10.1016/S2352-3018(19)30034-7; Solomon SS, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1905-5; Solomon SS, 2015, AIDS, V29, P723, DOI 10.1097/QAD.0000000000000602; Steward WT, 2008, SOC SCI MED, V67, P1225, DOI 10.1016/j.socscimed.2008.05.032; To KW, 2018, INT J INFECT DIS, V77, P113, DOI 10.1016/j.ijid.2018.10.027; Traeger MW, 2019, JAMA-J AM MED ASSOC, V321, P1380, DOI 10.1001/jama.2019.2947; Uthappa CK, 2018, HIV MED, V19, P243, DOI 10.1111/hiv.12572; Volz E, 2008, J OFF STAT, V24, P79; Wheelock A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054288; White RG, 2015, J CLIN EPIDEMIOL, V68, P1463, DOI 10.1016/j.jclinepi.2015.04.002; Yang D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076650	34	3	3	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247352	10.1371/journal.pone.0247352	http://dx.doi.org/10.1371/journal.pone.0247352			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QQ5BB	33630909	gold, Green Published			2023-01-03	WOS:000624536800026
J	Merianos, AL; Jandarov, RA; Gordon, JS; Lyons, MS; Mahabee-Gittens, EM				Merianos, Ashley L.; Jandarov, Roman A.; Gordon, Judith S.; Lyons, Michael S.; Mahabee-Gittens, E. Melinda			Healthcare resources attributable to child tobacco smoke exposure	PLOS ONE			English	Article							SECONDHAND SMOKE; EMERGENCY-DEPARTMENT; RETAIL CLINICS; UNITED-STATES; VISITS; INTERVENTION; IMPACT; COSTS; HOME	Background Tobacco smoke exposure (TSE) places an economic toll on the U.S. healthcare system. There is a gap in the literature on pediatric emergency department (ED) and urgent care related healthcare costs and utilization specific to tobacco smoke-exposed patients. The objectives were to assess pediatric ED visits, urgent care visits and hospital admissions longitudinally, and baseline visit costs among tobacco smoke-exposed children (TSE group) relative to unexposed children (non-TSE group). Methods and findings We conducted a retrospective study using electronic medical records of 380 children ages 0-17 years in the TSE group compared to 1,140 in the non-TSE group propensity score matched via nearest neighbor search by child age, sex, race, and ethnicity. Linear and Poisson regression models were used. Overall, children had a mean of 0.19 (SE = 0.01) repeat visits within 30-days, and 0.69 (SE = 0.04) pediatric ED visits and 0.87 (SE = 0.03) urgent care visits over 12-months following their baseline visit. The percent of children with >= 1 urgent care visit was higher among the TSE group (52.4%) than the non-TSE group (45.1%, p = 0.01). Children in the TSE group (M = $1,136.97, SE = 76.44) had higher baseline pediatric ED visit costs than the non-TSE group (M = $1,018.96, SE = 125.51, p = 0.01). Overall, children had 0.08 (SE = 0.01) hospital admissions over 12-months, and the TSE group (M = 0.12, SE = 0.02) had higher mean admissions than the non-TSE group (M = 0.06, SE = 0.01, p = 0.02). The child TSE group was at 1.85 times increased risk of having hospital admissions (95% CI = 1.23, 2.79, p = 0.003) than the non-TSE group. Conclusions Tobacco smoke-exposed children had higher urgent care utilization and hospital admissions over 12-months, and higher pediatric ED costs at baseline. Pediatric ED visits, urgent care visits, and hospitalizations may be opportune times for initiating tobacco control interventions, which may result in reductions of preventable acute care visits.	[Merianos, Ashley L.] Univ Cincinnati, Sch Human Serv, Cincinnati, OH 45221 USA; [Merianos, Ashley L.; Lyons, Michael S.] Univ Cincinnati, Coll Med, Ctr Addict Res, Cincinnati, OH 45221 USA; [Jandarov, Roman A.] Univ Cincinnati, Coll Med, Dept Environm & Publ Hlth Sci, Div Biostat & Bioinformat, Cincinnati, OH USA; [Gordon, Judith S.] Univ Arizona, Coll Nursing, Tucson, AZ 85721 USA; [Lyons, Michael S.] Univ Cincinnati, Dept Emergency Med, Coll Med, Cincinnati, OH USA; [Mahabee-Gittens, E. Melinda] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Arizona; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Merianos, AL (corresponding author), Univ Cincinnati, Sch Human Serv, Cincinnati, OH 45221 USA.; Merianos, AL (corresponding author), Univ Cincinnati, Coll Med, Ctr Addict Res, Cincinnati, OH 45221 USA.	ashley.merianos@uc.edu		Merianos, Ashley/0000-0002-5640-7227	National Institute on Drug Abuse [K01DA044313]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01HD083354]; National Cancer Institute [R21CA184337]	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institute on Drug Abuse (Grant Number K01DA044313 to ALM); Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant Number R01HD083354 to EMMG); and National Cancer Institute (Grant Number R21CA184337 to EMMG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alpern ER, 2014, ACAD EMERG MED, V21, P365, DOI 10.1111/acem.12347; Bernstein SL, 2016, J SUBST ABUSE TREAT, V71, P58, DOI 10.1016/j.jsat.2016.08.014; Burns RR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.4185; Casey JA, 2016, ANNU REV PUBL HEALTH, V37, P61, DOI 10.1146/annurev-publhealth-032315-021353; Creamer MR, 2019, MMWR-MORBID MORTAL W, V68, P1013, DOI 10.15585/mmwr.mm6845a2; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; Hill SC, 2008, TOB CONTROL, V17, P32, DOI 10.1136/tc.2007.020990; Jacob P, 2017, CHEM RES TOXICOL, V30, P270, DOI 10.1021/acs.chemrestox.6b00343; King BA, 2016, PREV MED, V82, P51, DOI 10.1016/j.ypmed.2015.11.010; Lemhoefer C, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160434; Levy DE, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-125; Mahabee-Gittens EM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218151; Mahabee-Gittens EM, 2018, AM J PREV MED, V54, P64, DOI 10.1016/j.amepre.2017.08.011; Mahabee-Gittens EM, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4278-8; Mahabee-Gittens EM, 2016, CIN-COMPUT INFORM NU, V34, P560, DOI 10.1097/CIN.0000000000000267; Mahabee-Gittens EM, 2016, JMIR RES PROTOC, V5, DOI 10.2196/resprot.4453; Mahabee-Gittens EM, 2020, PEDIATR EMERG CARE, V36, P527, DOI 10.1097/PEC.0000000000001646; Mason J, 2015, PUBLIC HEALTH REP, V130, P230, DOI 10.1177/003335491513000310; Max W, 2015, TOB CONTROL, V24, P205, DOI 10.1136/tobaccocontrol-2013-051253; Max W, 2012, AM J PUBLIC HEALTH, V102, P2173, DOI 10.2105/AJPH.2012.300805; Mehrotra A, 2009, ANN INTERN MED, V151, P321, DOI 10.7326/0003-4819-151-5-200909010-00006; Merianos AL, 2019, PREV MED, V123, P138, DOI 10.1016/j.ypmed.2019.03.028; Merianos AL, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0266; Merianos AL, 2017, J ASTHMA, V54, P798, DOI 10.1080/02770903.2016.1265127; Merianos AL, 2017, AM J PREV MED, V53, P441, DOI 10.1016/j.amepre.2017.03.020; Montalbano A, 2017, J PEDIATR-US, V191, P238, DOI 10.1016/j.jpeds.2017.08.035; Montalbano A, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3100; National Center for Chronic Disease P, 2014, HLTH CONSMOK 50 YE; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2010, REP SURG GEN TOB SMO; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2006, HLTH CONS INV EXP TO; Phelan MP, 2019, TOB PREV CESS, V5, DOI 10.18332/tpc/107116; Plescia Marcus, 2011, N C Med J, V72, P7; R Core Team, 2021, R LANG ENV STAT COMP; Saywell RM, 2013, J PUBLIC HEALTH MAN, V19, pE10, DOI 10.1097/PHH.0b013e3182893df9; Schlichting LE, 2017, ACAD EMERG MED, V24, P1483, DOI 10.1111/acem.13281; Spanier AJ, 2015, PEDIATRICS, V135, pE416, DOI 10.1542/peds.2014-1748; Sweeney L, 2020, RESP CARE, V65, P407, DOI 10.4187/respcare.06810; Thygeson M, 2008, HEALTH AFFAIR, V27, P1283, DOI 10.1377/hlthaff.27.5.1283; Tsai J., 2019, NCHS DATA BRIEF, V348, P1; Wang Z, 2015, ANN ALLERG ASTHMA IM, V115, P396, DOI 10.1016/j.anai.2015.08.005; Weinick RM, 2010, HEALTH AFFAIR, V29, P1630, DOI 10.1377/hlthaff.2009.0748; World Health Organization, 2011, WHO SUMM PRINC EV HL; Yao TT, 2019, AM J PREV MED, V56, P281, DOI 10.1016/j.amepre.2018.08.013	43	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2021	16	2							e0247179	10.1371/journal.pone.0247179	http://dx.doi.org/10.1371/journal.pone.0247179			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QO8DE	33621228	Green Published, gold			2023-01-03	WOS:000623367700036
J	Janakiraman, B; Gebreyesus, T; Yihunie, M; Genet, MG				Janakiraman, Balamurugan; Gebreyesus, Tsiwaye; Yihunie, Mulualem; Genet, Moges Gashaw			Knowledge, attitude, and practice of antenatal exercises among pregnant women in Ethiopia: A cross-sectional study	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; CARE; BELIEFS; LEVEL	Background "Is pregnancy opportunity or a barrier for engaging in exercise". Maternal health still is a top priority in sub-Saharan Africa including Ethiopia. Participation in exercises during pregnancy in low-middle income countries is constrained. The objective of this study was to evaluate the knowledge, attitude, and practice of antenatal exercises among Ethiopian women during pregnancy, and also to examine the barriers to prenatal physical activity. Methods A descriptive hospital-based cross-sectional study was conducted and 349 pregnant women receiving prenatal care at the ante-natal care clinic, University of Gondar comprehensive specialized hospital were recruited. Data were obtained on maternal characteristics, knowledge, attitude, practice, and barriers towards antenatal exercise (ANEx) by interview method. Results Among 349 pregnant women, 138 (39.5%) and 193 (55.3%) had adequate knowledge, a positive attitude, and good practice respectively. Overall, 108 (30.9) of the respondents practiced antenatal exercise, while only 41 (37.9%) of those pregnant women had a good practice. Brisk walking (90.7%), relaxation (38.9%), and breathing exercise (36.1%) were most practice ANEx, while pelvic floor 6 (5.6%) and 3 (2.8%) yoga were the least practiced. Enhancing post-natal recovery (71%) and vaginal bleeding (64.5) were perceived as benefits and contraindication of ANEx. More than half of the pregnant women (53.6) reported that ANEx is not appropriate for Ethiopian culture. Knowledge, attitude, and practice of ANEx among pregnant women are significantly associated with higher education, government employees, pre-pregnancy exercise, and being advised on ANEx before. Women with adequate knowledge are more likely to have a good practice (AOR 4.53, 95%CI: 1.64, 15.3). Conclusion The findings of this study suggest that knowledge concerning antenatal exercise is low and their attitude is reasonably favorable. However, very few Ethiopian pregnant practices ANEx according to recommended guidelines during pregnancy.	[Janakiraman, Balamurugan; Gebreyesus, Tsiwaye] Mekelle Univ, Coll Hlth Sci & Ayder Comprehens Specialized Hosp, Sch Med, Dept Physiotherapy, Mekelle, Ethiopia; [Yihunie, Mulualem; Genet, Moges Gashaw] Univ Gondar Comprehens Specialized Hosp, Coll Med & Hlth Sci, Sch Med, Dept Physiotherapy, Gondar, Ethiopia	Mekelle University	Janakiraman, B (corresponding author), Mekelle Univ, Coll Hlth Sci & Ayder Comprehens Specialized Hosp, Sch Med, Dept Physiotherapy, Mekelle, Ethiopia.	bala77@physio@gmail.com	Janakiraman, Balamurugan/AAG-9563-2020	Janakiraman, Balamurugan/0000-0003-3866-9351; Gashaw, Moges/0000-0002-4532-1786	University of Gondar [SOM112/7/2019]	University of Gondar	This study was fully resourced and partly funded by the University of Gondar (Grant no: SOM112/7/2019). The views presented in the article are the authors and not necessarily express the views of the funding organization. University of Gondar did not involve in the design of the study, data collection, analysis, and interpretation. There was no additional external funding received for this study.	Ababa A., 2014, FEDERAL DEMOCRATIC R; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; American Pregnancy Association, 2016, EX PREGN, V12, P2017; American Pregnancy Association, 2010, KEG EX; [Anonymous], SEXUAL REPROD HLTH; [Anonymous], PHYS ACTIVITY EXERCI; Asefa F, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0225-x; Awusi V. O., 2009, Benin Journal of Postgraduate Medicine, V11, P21; Chuma Bekalu Thomas, 2020, Depress Res Treat, V2020, P6718342, DOI 10.1155/2020/6718342; Coll CVN, 2017, J SCI MED SPORT, V20, P17, DOI 10.1016/j.jsams.2016.06.007; Comm Obstet Practice, 2015, OBSTET GYNECOL, V126, pe135, DOI 10.1097/AOG.0000000000001214; Downs DS, 2004, J MIDWIFERY WOM HEAL, V49, P138, DOI 10.1016/j.jmwh.2003.11.009; Duncombe D, 2009, MIDWIFERY, V25, P430, DOI 10.1016/j.midw.2007.03.002; Ethiopia C., 2016, DEMOGRAPHIC HLTH SUR; Garland M, 2017, JNP-J NURSE PRACT, V13, P54, DOI 10.1016/j.nurpra.2016.07.005; Gashaw M, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03184-4; Gebregziabher D, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4496-5; Gibson JL, 2020, ACTA OBSTET GYN SCAN, V99, P147, DOI 10.1111/aogs.13785; Hailemariam TT, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-2777-6; Hayman M, 2020, WOMEN BIRTH, V33, pE357, DOI 10.1016/j.wombi.2019.07.302; Hjorth MF, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-154; Janakiraman B, 2020, DIABETES METAB SYNDR, V13, P343, DOI 10.2147/DMSO.S235981; Mbada Chidozie E, 2014, ISRN Obstet Gynecol, V2014, P260539, DOI 10.1155/2014/260539; Muche AA, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2492-3; NICE antenatal care guideline, GUIDELINES; Nkhata LA., 2014, J SCI RES REPORTS, P1986; Ojukwu CP., 2018, INT J REPROD CONTRAC, V7, P2541; Regassa N, 2011, AFR HEALTH SCI, V11, P390; Ribeiro CP, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-31; Sujindra E., 2015, INT J ED PSYCHOL RES, V1, P234, DOI [10.4103/2395-2296.158347, DOI 10.4103/2395-2296.158347]; Tafere TE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192428; Tuncalp O, 2017, BJOG-INT J OBSTET GY, V124, P860, DOI 10.1111/1471-0528.14599; UNICEF, 2006, STATE WORLDS CHILDRE, V7; Watson ED, 2018, MATERN CHILD HLTH J, V22, P1190, DOI 10.1007/s10995-018-2504-3; Whitford HM, 2007, MIDWIFERY, V23, P204, DOI 10.1016/j.midw.2006.06.006; Wolfe LA, 2003, CLIN OBSTET GYNECOL, V46, P488, DOI 10.1097/00003081-200306000-00027; Yeneneh A, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1874-2	37	6	6	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2021	16	2							e0247533	10.1371/journal.pone.0247533	http://dx.doi.org/10.1371/journal.pone.0247533			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8KQ	33606844	Green Published, gold			2023-01-03	WOS:000620629200165
J	Habte, A; Gebiremeskel, F; Shewangizaw, M; Dessu, S; Glagn, M				Habte, Aklilu; Gebiremeskel, Feleke; Shewangizaw, Misgun; Dessu, Samuel; Glagn, Mustefa			Uptake of complete postnatal care services and its determinants among rural women in Southern Ethiopia: Community-based cross-sectional study based on the current WHO recommendation	PLOS ONE			English	Article								Background Postnatal care services are a constellation of preventive care, practices, and assessments designed to identify and manage maternal and newborn complications during the first six weeks after birth. Recognizing the role of the appropriate PNC at this critical time, the World Health Organization recommended four visits as a complete PNC for all post-partum mothers and newborns to ensure their survival. Although there have been numerous studies on the factors affecting the general PNC service in Ethiopia, there is a shortage of evidence on the use of complete postnatal care services and its determinants. Therefore, the objective of this study was to assess the uptake of full postnatal care service and its determinants among women who recently gave birth in the Ezha district of southern Ethiopia. Methods A community-based cross-sectional study was conducted in Ezha district. A two-stage sampling technique was applied. A total of 568 mothers who stayed for at least 6 weeks after childbirth from selected Kebeles were included in the study using computer-generated random numbers. Data collected through pre-established, structured, and interviewer-administered questionnaires were entered into EpiData3.1 and exported to SPPS version 23 for analysis. The Principal Components Analysis (PCA) was carried out to assess the wealth status of participants. The Multivariable logistic regression model has been fitted to identify the determinants of complete post-natal care service uptake. Results The overall uptake of complete postnatal care services in the study area was 23.9% [95% CI: (19.9, 27.5)]. The factors namely; maternal education of secondary and above [AOR: 4.31, 95%CI: 2.15, 8.05], having four and more antenatal visits [AOR: 4.03, 95%CI: 1.83, 8.85], Caesarean delivery [AOR: 3.75, 95%CI: 1.78, 7.92], having good knowledge on PNC [AOR: 4.31, 95%CI: 2.34, 9.04], and being a model household [AOR: 3.61, 95%CI: 1.97, 6.64] were recognized as determinants complete postnatal care uptake. Conclusion and recommendation Complete post-natal care services uptake in the study area was low. Thus, a due emphasis should be given to behavioral change communication activities to improve maternal knowledge on PNC and enhancing adequate ANC uptake by health workers in the district. Besides, health extension workers in the district need to work on creating a model household through continuing education, support, and follow-up.	[Habte, Aklilu] Wachemo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Reprod Hlth, Hosanna, Ethiopia; [Gebiremeskel, Feleke; Glagn, Mustefa] Arba Minch Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Arba Minch, Ethiopia; [Shewangizaw, Misgun] Arba Minch Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Hlth Educ & Promot Unit, Arba Minch, Southern Ethiop, Ethiopia; [Dessu, Samuel] Wolkite Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Wolkite, Southern Ethiop, Ethiopia	Arba Minch University; Arba Minch University	Habte, A (corresponding author), Wachemo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Reprod Hlth, Hosanna, Ethiopia.	akliluhabte57@gmail.com	Habte, Aklilu/ABB-7649-2020; hailegebireal, aklilu habte/ABD-1527-2020	hailegebireal, aklilu habte/0000-0002-5719-4294				Abebo TA, 2018, ARCH PUBLIC HEALTH, V76, DOI 10.1186/s13690-018-0256-6; Aboubaker S, 2014, J GLOB HEALTH, V4, P32, DOI 10.7189/jogh.04.020302; ACOG, 2018, PRES TASK FORC RED P; Agha S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0979-8; Akibu M, 2018, J PREGNANCY, V2018, DOI 10.1155/2018/8625437; Amato R, 2016, ELIFE, V5, DOI 10.7554/eLife.08714; Angore BN, 2018, J HEALTH POPUL NUTR, V37, DOI 10.1186/s41043-018-0140-6; [Anonymous], 2016, US ENERGY INF ADM, V2016, P7; [Anonymous], 2014, CANC DISCOV, V4, pOF1; [Anonymous], 2015, TRANSPLANTATION DIRE, V1, pe2, DOI 10.1097/TXD.0000000000000509; [Anonymous], 2014, REC POSTN CAR MOTH N; CSAE, 2016, CENTR STAT AG ETH ET; Darega B, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0940-x; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Desta SH., 2017, INT J SOC SCI MANAG, V4, P248; Gogia S, 2016, J PERINATOL, V36, pS54, DOI 10.1038/jp.2016.33; Hodgins S., 2017, POSTNATAL CARE FOCUS; James L, 2015, CURR RES J SOC SCI, V7, P106; Jolivet RR, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1763-8; Kante AM, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0769-8; Karim AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065160; Li C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-31; Medhanyie A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-352; Mon A.S., 2018, WOMEN ITS DETERMINAN; NCCN Clinical Practice, 2018, ACUTE MYELOID LEUKEM, VV2, pMS28; Organization WH, 2015, HLTH 2015 MDGS MILL; rajesh B, 2017, EFFECT WOMENS EMPOWE, V46, P95; Sado L, 2014, SOC SCI MED, V114, P169, DOI 10.1016/j.socscimed.2014.05.047; Sakeah E, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1926-7; Sarbjit G, 2018, WILEY INTERDISCIPL R, V7, pe286, DOI 10.1002/WENE.286; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Stenberg K, 2014, LANCET, V383, P1333, DOI 10.1016/S0140-6736(13)62231-X; Tesfahun F, 2014, MATERN CHILD HLTH J, V18, P2341, DOI 10.1007/s10995-014-1474-3; UN-DESA, 2017, SUST DEV GOAL 3 ENS; UNICEF, 2016, OP FRAM GLOB STRAT W; UNICEF, 2017, MAT NEWB HLTH DISP E; UNICEF World Health Organization World Bank Group United Nations, 2017, LEV TRENDS CHILD MOR; United Nations, 2018, SUST DEV GOALS REP 2; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WHO, 2017, ALL EYES MAT HLTH; WHO, 2013, WORLD HLTH STAT 2013; WHO/UNICEF, 2010, HOM VIS NEWB CHILD S; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; World Health Organization, 2010, WHO TECHN CONS POSTP; World Health Organization, 2015, PREGN CHILDB POSTP N; 2018, CURR OPIN TOXICOL, V10	46	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2021	16	2							e0246243	10.1371/journal.pone.0246243	http://dx.doi.org/10.1371/journal.pone.0246243			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF2OR	33534844	Green Published, gold			2023-01-03	WOS:000616739700059
J	Fan, YL; To, MKT; Yeung, EHK; Wu, JB; He, R; Xu, ZM; Zhang, RW; Li, GS; Cheung, KMC; Cheung, JPY				Fan, Yunli; To, Michael K. T.; Yeung, Eric H. K.; Wu, Jianbin; He, Rong; Xu, Zhuoman; Zhang, Ruiwen; Li, Guangshuo; Cheung, Kenneth M. C.; Cheung, Jason P. Y.			Does curve pattern impact on the effects of physiotherapeutic scoliosis specific exercises on Cobb angles of participants with adolescent idiopathic scoliosis: A prospective clinical trial with two years follow-up	PLOS ONE			English	Article							MODEL; BIOMECHANICS; BRACE	Background Current clinical evidence suggests that a well-planned physiotherapeutic scoliosis specific exercise (PSSE) program is effective for scoliosis regression. Objectives We investigated the effect of curve patterns on Cobb angles with PSSE. Methods This was a non-randomized prospective clinical trial that recruited participants with adolescent idiopathic scoliosis between January and June 2017. Participants were grouped by curve pattern into major thoracic and major lumbar groups. An outpatient-based PSSE program was conducted with the following schedule of intensive exercise: >= 1 session of supervised PSSE per month and > 30min of home exercise 5 days/week in the first 6 months, after which exercise frequency was reduced to 1 session of supervised PSSE every three months and > 30min of home exercise 5 days/week until 2 years after study initiation. Radiographic Cobb angle progressions were identified at the 1, 1.5 and 2-year follow-ups. A mixed model analysis of variance (ANOVA) was performed to examine the differences in Cobb angles between groups at four testing time points. The two-tailed significance level was set to 0.05. Results In total, 40 participants were recruited, including 22 with major thoracic curves (5 males and 17 females; mean age 13.5 +/- 1.8 years; Cobb angle 18-45 degrees) and 18 with major lumbar curves (7 males and 11 females; mean age 12.7 +/- 1.7 years; Cobb angle 15-48 degrees). Curve regressions, namely the reduction of Cobb angles between 7 to 10 degrees were noted in 9.1% of participants in the major thoracic group; reductions of 6 to 13 degrees were noted in 33.3% of participants in the major lumbar group at the 2-year follow-up. Repeated measurements revealed a significant time effect (F-2.2,F-79.8 = 4.1, p = 0.02), but no group (F-2.2,F-79.8 = 2.3, p = 0.1) or time x group (F-1,F-37 = 0.97, p = 0.3) effects in reducing Cobb angles after 2 years of PSSE. A logistic regression analysis revealed that no correlation was observed between curve pattern and curve regression or stabilization (OR: 0.2, 95% CI: 0.31-1.1, p = 0.068) at the 2-year follow-up. Conclusion This was the first study to investigate the long-term effects of PSSE in reducing Cobb angles on the basis of major curve location. No significant differences in correction were observed between major thoracic and major lumbar curves. A regression effect and no curve deterioration were noted in both groups at the 2-year follow-up.	[Fan, Yunli; To, Michael K. T.; Wu, Jianbin; Cheung, Kenneth M. C.; Cheung, Jason P. Y.] Univ Hong Kong, Shenzhen Hosp, Dept Orthopaed, Shenzhen, Guangdong, Peoples R China; [Fan, Yunli; To, Michael K. T.; Cheung, Kenneth M. C.; Cheung, Jason P. Y.] Univ Hong Kong, Dept Orthpaed & Traumatol, Hong Kong, Peoples R China; [Fan, Yunli; Yeung, Eric H. K.; He, Rong; Xu, Zhuoman; Zhang, Ruiwen; Li, Guangshuo] Univ Hong Kong, Dept Physiotherapy, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Cheung, JPY (corresponding author), Univ Hong Kong, Shenzhen Hosp, Dept Orthopaed, Shenzhen, Guangdong, Peoples R China.; Cheung, JPY (corresponding author), Univ Hong Kong, Dept Orthpaed & Traumatol, Hong Kong, Peoples R China.	cheungjp@hku.hk	Cheung, Jason Pui Yin/J-2214-2012; Cheung, Jason Pui Yin/AAJ-2016-2020	Cheung, Jason Pui Yin/0000-0002-7052-0875; Fan, Yunli/0000-0001-9936-8857; Zhang, Ruiwen/0000-0001-5482-8899	Sanming Project of Medicine "Team of Excellence in Spinal Deformities and Spinal Degeneration Diseases" in Shenzhen, Guangdong province, China [SZSM201612055]; University of Hong Kong - Shenzhen Hospital Seeding Project [HKUSZH201902042]	Sanming Project of Medicine "Team of Excellence in Spinal Deformities and Spinal Degeneration Diseases" in Shenzhen, Guangdong province, China; University of Hong Kong - Shenzhen Hospital Seeding Project	Funding Project: Sanming Project of Medicine (SZSM201612055) "Team of Excellence in Spinal Deformities and Spinal Degeneration Diseases" in Shenzhen, Guangdong province, China. The University of Hong Kong - Shenzhen Hospital Seeding Project, HKUSZH201902042, Jason PY Cheung Receiver: Kenneth MC Cheung, Jason PY Cheung.	Almansour H, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111804; [Anonymous], 1984, NUREG, V3, P1061; [Anonymous], 2016, WHO DRUG INFO, V30, P181; BARNES PD, 1993, RADIOLOGY, V186, P247, DOI 10.1148/radiology.186.1.8416573; Berdishevsky H, 2016, SCOLIOSIS SPINAL DIS, V11, DOI 10.1186/s13013-016-0076-9; Burger M, 2019, SOUTH AFR J PHYSIOTH, V75, DOI 10.4102/sajp.v75i1.904; Chan SL, 2014, SCOLIOSIS SPINAL DIS, V9, DOI 10.1186/1748-7161-9-1; COBB JR, 1958, J BONE JOINT SURG AM, V40, P507, DOI 10.2106/00004623-195840030-00002; Coe JD, 2006, SPINE, V31, P345, DOI 10.1097/01.brs.0000197188.76369.13; Czaprowski D, 2011, SCOLIOSIS SPINAL DIS, V6, DOI 10.1186/1748-7161-6-22; Davids JR, 2004, J BONE JOINT SURG AM, V86A, P2187, DOI 10.2106/00004623-200410000-00009; De Giorgi S, 2013, EUR SPINE J, V22, pS815, DOI 10.1007/s00586-013-3020-1; Dolan LA, 2019, SPINE DEFORM, V7, P890, DOI 10.1016/j.jspd.2019.01.011; Dolgin E, 2019, CANCER DISCOV, V9, P8, DOI 10.1158/2159-8290.CD-NB2018-163; Eskandari AH, 2017, J BIOMECH, V57, P18, DOI 10.1016/j.jbiomech.2017.03.011; Fan YL, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891-020-03517-6; Fitzmaurice G.M., 2012, APPL LONGITUDINAL AN; Gstoettner M, 2007, EUR SPINE J, V16, P1587, DOI 10.1007/s00586-007-0401-3; Hajihosseinali M, 2014, MED ENG PHYS, V36, P1296, DOI 10.1016/j.medengphy.2014.07.009; Kim S, 2017, STAT METHODS MED RES, V26, P1237, DOI 10.1177/0962280215572407; Korbel Krzysztof, 2014, Pol Orthop Traumatol, V79, P118; Lehnert-Schroth C, 1981, ZFA (Stuttgart), V57, P2227; Lehnert-Schroth C, 1979, ZFA (Stuttgart), V55, P1969; Li M, 2014, SPINE, V39, P1408, DOI 10.1097/BRS.0000000000000423; LITTLE DG, 1994, J PEDIATR ORTHOPED, V14, P569, DOI 10.1097/01241398-199409000-00003; Liu DL, 2020, SPINE, V45, P1039, DOI 10.1097/BRS.0000000000003451; Malfair D, 2010, AM J ROENTGENOL, V194, pS8, DOI 10.2214/AJR.07.7145; Mishra P, 2019, ANN CARD ANAESTH, V22, P67, DOI 10.4103/aca.ACA_157_18; Monticone M, 2014, EUR SPINE J, V23, P1204, DOI 10.1007/s00586-014-3241-y; Negrini S, 2006, SCOLIOSIS SPINAL DIS, V1, DOI 10.1186/1748-7161-1-14; Negrini S, 2009, SCOLIOSIS SPINAL DIS, V4, DOI 10.1186/1748-7161-4-19; Oxland TR, 2016, J BIOMECH, V49, P817, DOI 10.1016/j.jbiomech.2015.10.035; PANJABI MM, 1980, NEUROSURGERY, V7, P76, DOI 10.1227/00006123-198007000-00014; Rigo MD, 2010, SCOLIOSIS SPINAL DIS, V5, DOI 10.1186/1748-7161-5-1; Schreiber S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168746; Smits-Engelsman B, 2011, J PEDIATR-US, V158, P130, DOI 10.1016/j.jpeds.2010.07.021; Thompson JY, 2019, PHYSIOTHERAPY, V105, P214, DOI 10.1016/j.physio.2018.10.004; Thompson RM, 2017, J BONE JOINT SURG AM, V99, P923, DOI 10.2106/JBJS.16.01050; van Ginkel JR, 2014, MULTIVAR BEHAV RES, V49, P78, DOI 10.1080/00273171.2013.855890; Wang WJ, 2012, SPINE, V37, P1586, DOI 10.1097/BRS.0b013e3182511d0c; Weinstein SL, 2008, LANCET, V371, P1527, DOI 10.1016/S0140-6736(08)60658-3; Weinstein SL, 2019, J PEDIATR ORTHOPED, V39, pS44, DOI 10.1097/BPO.0000000000001350; Weiss H R, 1997, Pediatr Rehabil, V1, P35; Weiss Hans-Rudolf, 2002, Stud Health Technol Inform, V91, P352; Weiss Hans-Rudolf, 2003, Pediatr Rehabil, V6, P23, DOI 10.1080/1363849031000095288; Yagci G, 2019, PROSTHET ORTHOT INT, V43, P301, DOI 10.1177/0309364618820144; Yagci G, 2018, J BACK MUSCULOSKELET, V31, P693, DOI 10.3233/BMR-170868	47	2	2	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2021	16	1							e0245829	10.1371/journal.pone.0245829	http://dx.doi.org/10.1371/journal.pone.0245829			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ9QF	33493172	gold, Green Published			2023-01-03	WOS:000613081500068
J	Susic, AP; Klemenc-Ketis, Z; Blagus, R; Gorenjec, NR				Susic, Antonija Poplas; Klemenc-Ketis, Zalika; Blagus, Rok; Gorenjec, Nina Ruzic			Factors that determine dependence in daily activities: A cross-sectional study of family practice non-attenders from Slovenia	PLOS ONE			English	Article							UNITED-STATES; OLDER-ADULTS; HEALTH-CARE; DISABILITY; RISK; COMMUNITY; PREVALENCE; VALIDITY; MALNUTRITION; RELIABILITY	Background Independence in daily activities is defined as the ability to perform functions related to daily living, i.e. the capacity of living independently in the community with little or no help from others. Objective We focused on non-attenders as a subgroup of patients whose health status is not well known to family practice teams. Our goal was to estimate the prevalence of dependence and its severity level in the daily activities of patients, and to determine the factors that are associated with the occurrence of dependence. Design Cross-sectional observational study. Settings and participants Data was obtained in family medicine settings. Participants in the study were adults living in the community (aged 18 or over) who had not visited their chosen family physician in the last 5 years (non-attenders) and who were able to participate in the study. Through the electronic system, we identified 2,025 non-attenders. Community nurses collected data in the participants' homes. The outcome measure was dependence in daily activities, assessed through eight items: personal hygiene; eating and drinking; mobility; dressing and undressing; urination and defecation; continence; avoiding hazards in the environment; and communication. Results The final sample consisted of 1,999 patients (98.7% response rate). The mean age was 59.9 (range 20 to 99). Dependence in daily activities was determined in 466 or 23.3% (95% CI: [21.5, 25.2]) of the patients. Older patients (over 60 years), with at least one chronic disease, increased risk of falling, moderate feelings of loneliness and a lower self-assessment of health were statistically significantly more likely to be dependent in their daily activities, according to our multivariate model. Conclusions A considerable proportion of family practice non-attenders were found to be dependent in daily activities, though at a low level. We identified several factors associated with this dependence. This could help to identify people at risk of being dependent in daily activities in the general adult population, and enable specific interventions that would improve their health status.	[Susic, Antonija Poplas; Klemenc-Ketis, Zalika; Gorenjec, Nina Ruzic] Ljubljana Community Hlth Ctr, Ljubljana, Slovenia; [Susic, Antonija Poplas; Klemenc-Ketis, Zalika] Univ Ljubljana, Fac Med, Dept Family Med, Ljubljana, Slovenia; [Klemenc-Ketis, Zalika] Univ Maribor, Fac Med, Dept Family Med, Maribor, Slovenia; [Blagus, Rok; Gorenjec, Nina Ruzic] Univ Ljubljana, Fac Med, Inst Biostat & Med Informat, Ljubljana, Slovenia	University of Ljubljana; University of Maribor; University of Ljubljana	Klemenc-Ketis, Z (corresponding author), Ljubljana Community Hlth Ctr, Ljubljana, Slovenia.; Klemenc-Ketis, Z (corresponding author), Univ Ljubljana, Fac Med, Dept Family Med, Ljubljana, Slovenia.; Klemenc-Ketis, Z (corresponding author), Univ Maribor, Fac Med, Dept Family Med, Maribor, Slovenia.	zalika.klemenc@um.si		Klemenc-Ketis, Zalika/0000-0002-0270-1754; Ruzic Gorenjec, Nina/0000-0001-8505-1437; Poplas Susic, Antonija/0000-0002-4328-3333	Norway Grants; Government Office for Development and European Cohesian Policy in Slovenia [4300-367/2014]; Slovenian Research Agency (Methodology for Data Analysis in Medical Sciences) [P3-0154]; Slovenian Research Agency [P3-0339]	Norway Grants; Government Office for Development and European Cohesian Policy in Slovenia; Slovenian Research Agency (Methodology for Data Analysis in Medical Sciences); Slovenian Research Agency(Slovenian Research Agency - Slovenia)	This work was supported by the Norway Grants and the Government Office for Development and European Cohesian Policy in Slovenia (No. 4300-367/2014). RB was partly supported by the Slovenian Research Agency (Methodology for Data Analysis in Medical Sciences, P3-0154). ZKK was partly supported by the Slovenian Research Agency (Research in the field of Public Health, P3-0339).	[Anonymous], 2002, ACTIVE AGEING POLICY; Beach SR, 2017, J AM GERIATR SOC, V65, P560, DOI 10.1111/jgs.14547; Buchman AS, 2014, ARCH GERONTOL GERIAT, V58, P74, DOI 10.1016/j.archger.2013.08.001; Buchman AS, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-77; Cinarli T, 2017, NURS RES, V66, P330, DOI 10.1097/NNR.0000000000000227; Courtney-Long EA, 2015, MMWR-MORBID MORTAL W, V64, P777, DOI 10.15585/mmwr.MM6429a2; Daniels R, 2010, EUR J AGEING, V7, P37, DOI 10.1007/s10433-010-0141-9; Dryden R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-723; Durovich CJ, 2018, POPUL HEALTH MANAG, V21, P13, DOI 10.1089/pop.2017.0015; Feinglass J, 2018, POPUL HEALTH MANAG, V21, P96, DOI 10.1089/pop.2017.0026; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Gierach Marcin, 2014, ISRN Endocrinol, V2014, P514589, DOI 10.1155/2014/514589; Graf Carla, 2009, Medsurg Nurs, V18, P315; Hardy S. E., 2014, CURRENT DIAGNOSIS TR, P3; Holmgren M, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-381; Holst KK, 2014, GOF PACKAGE MODEL DI; Klemenc-Ketis Z, 2020, NUTRITION, V72, DOI 10.1016/j.nut.2019.110657; Klemenc-Ketis Z, 2019, J COMMUN HEALTH NURS, V36, P139, DOI 10.1080/07370016.2019.1630996; Laan W, 2013, MATURITAS, V75, P276, DOI 10.1016/j.maturitas.2013.04.005; Leikauf J, 2009, J AM GERIATR SOC, V57, P1219, DOI 10.1111/j.1532-5415.2009.02313.x; Li XJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019901; Litwin H, 2009, EUR J AGEING, V6, P167, DOI 10.1007/s10433-009-0126-8; Mlinac ME, 2016, ARCH CLIN NEUROPSYCH, V31, P506, DOI 10.1093/arclin/acw049; Morse J. M., 1997, PREVENTING PATIENT F; Nagarkar A, 2017, ARCH GERONTOL GERIAT, V69, P151, DOI 10.1016/j.archger.2016.11.015; Okoro CA, 2018, MMWR-MORBID MORTAL W, V67, P882, DOI 10.15585/mmwr.mm6732a3; Perenboom RJM, 2012, DISABIL REHABIL, V34, P1556, DOI 10.3109/09638288.2011.647233; Pharr Jennifer R, 2012, Glob J Health Sci, V4, P99, DOI 10.5539/gjhs.v4n6p99; R Core Team, 2020, R LANG ENV STAT COMP; Ramadass S, 2018, J Family Med Prim Care, V7, P1177, DOI 10.4103/jfmpc.jfmpc_10_18; REBOUCAS M, 2017, REV SAUDE PUBL, V51, P65220, DOI DOI 10.11606/51518-8787.2017051006959; Reboucas M, 2017, REV SAUDE PUBL, V51, DOI [10.11606/S1518-8787.2017051006959, 10.11606/s1518-8787.2017051006959]; Rubio Encarnacion, 2009, BMC Geriatr, V9, P26, DOI 10.1186/1471-2318-9-26; Sekaran NK, 2013, J AM GERIATR SOC, V61, P96, DOI 10.1111/jgs.12071; SMILKSTEIN G, 1982, J FAM PRACTICE, V15, P303; Stevens AC, 2016, MMWR-MORBID MORTAL W, V65, P1021, DOI 10.15585/mmwr.mm6538a1; Stratton RJ, 2004, BRIT J NUTR, V92, P799, DOI 10.1079/BJN20041258; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; TUSEKBUNC K, 2018, ACTA MEDICOBIOTECHNI, V11, P45; Van der Heyden J, 2014, J PUBLIC HEALTH-HEID, V22, P371, DOI 10.1007/s10389-014-0624-9; van der Vorst A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165127; Wang YF, 2005, AM J CLIN NUTR, V81, P555; World Health Organization, 2000, WHO TECHN REP SER, V894	43	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2021	16	1							e0245465	10.1371/journal.pone.0245465	http://dx.doi.org/10.1371/journal.pone.0245465			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PZ7OB	33481824	gold, Green Published			2023-01-03	WOS:000612929300164
J	Carenzo, L; Cena, T; Carfagna, F; Rondi, V; Ingrassia, PL; Cecconi, M; Violato, C; Della Corte, F; Vaschetto, R				Carenzo, Luca; Cena, Tiziana; Carfagna, Fabio; Rondi, Valentina; Ingrassia, Pier Luigi; Cecconi, Maurizio; Violato, Claudio; Della Corte, Francesco; Vaschetto, Rosanna			Assessing anaesthesiology and intensive care specialty physicians: An Italian language multisource feedback system	PLOS ONE			English	Article							MEDICAL-EDUCATION; PERFORMANCE; COMPETENCE; PATIENT; FEASIBILITY; VALIDITY; DOCTORS; SKILLS	Background Physician professionalism, including anaesthesiologists and intensive care doctors, should be continuously assessed during training and subsequent clinical practice. Multi-source feedback (MSF) is an assessment system in which healthcare professionals are assessed on several constructs (e.g., communication, professionalism, etc.) by multiple people (medical colleagues, coworkers, patients, self) in their sphere of influence. MSF has gained widespread acceptance for both formative and summative assessment of professionalism for reflecting on how to improve clinical practice. Methods Instrument development and psychometric analysis (feasibility, reliability, construct validity via exploratory factor analysis) for MSF questionnaires in a postgraduate specialty training in Anaesthesiology and intensive care in Italy. Sixty-four residents at the Universita del Piemonte Orientale (Italy) Anesthesiology Residency Program. Main outcomes assessed were: development and psychometric testing of 4 questionnaires: self, medical colleague, coworker and patient assessment. Results Overall 605 medical colleague questionnaires (mean of 9.3 +/- 1.9) and 543 coworker surveys (mean 8.4 +/- 1.4) were collected providing high mean ratings for all items (> 4.0 /5.0). The self-assessment item mean score ranged from 3.1 to 4.3. Patient questionnaires (n = 308) were returned from 31 residents (40%; mean 9.9 +/- 6.2). Three items had high percentages of "unable to assess" (> 15%) in coworker questionnaires. Factor analyses resulted in a two-factor solution: clinical management with leadership and accountability accounting for at least 75% of the total variance for the medical colleague and coworker's survey with high internal consistency reliability (Cronbach's alpha > 0.9). Patient's questionnaires had a low return rate, a limited exploratory analysis was performed. Conclusions We provide a feasible and reliable Italian language MSF instrument with evidence of construct validity for the self, coworkers and medical colleague. Patient feedback was difficult to collect in our setting.	[Carenzo, Luca; Cecconi, Maurizio] Humanitas Clin & Res Ctr IRCCS, Dept Anesthesia & Intens Care Med, Rozzano, MI, Italy; [Cena, Tiziana; Della Corte, Francesco; Vaschetto, Rosanna] Azienda Osped Univ Maggiore Carita, Dept Anaesthesia & Intens Care Med, Novara, Italy; [Carfagna, Fabio; Cecconi, Maurizio] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele Milan, Italy; [Rondi, Valentina; Della Corte, Francesco; Vaschetto, Rosanna] Univ Piemonte Orientale, Dipartimento Med Traslaz, Novara, Italy; [Ingrassia, Pier Luigi] Ctr Profess Sociosanitario, Ctr Simulaz, Lugano, Switzerland; [Ingrassia, Pier Luigi] Univ Piemonte Orientale, Ctr Interdipartimentale Didatt Innovat & Simulaz, SIMNOVA, Novara, Italy; [Violato, Claudio] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Violato, Claudio] Univ Minnesota, Sch Med, Dept Med Educ, Minneapolis, MN 55455 USA	Azienda Ospedaliera Maggiore della Carita di Novara; University of Eastern Piedmont Amedeo Avogadro; Humanitas University; University of Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo Avogadro; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Carenzo, L (corresponding author), Humanitas Clin & Res Ctr IRCCS, Dept Anesthesia & Intens Care Med, Rozzano, MI, Italy.	luca.carenzo@humanitas.it	Cecconi, Maurizio/HDN-8785-2022; Cecconi, Maurizio/A-6241-2012; Carfagna, Fabio/I-2811-2019	Cecconi, Maurizio/0000-0002-4376-6538; Cecconi, Maurizio/0000-0002-4376-6538; Carfagna, Fabio/0000-0002-1378-1649; Violato, Claudio/0000-0001-7551-5621; Carenzo, Luca/0000-0002-4646-2660; Cena, Tiziana/0000-0001-7127-4146				Al Ansari A, 2014, ADV MED EDUC PRACT, V5, P39, DOI 10.2147/AMEP.S57236; Amore M., 2020, EXCELLENCE POSTGRADU; Anderson MB, 1999, ACAD MED, V74, P13; [Anonymous], 2010, R LANG ENV STAT COMP; [Anonymous], 2019, EUROPEAN TRAINING RE; Archer JC, 2005, BMJ-BRIT MED J, V330, P1251, DOI 10.1136/bmj.38447.610451.8F; Bracken DW, 2001, HUM RESOURCE MANAGE, V40, P3, DOI 10.1002/hrm.4012; Brown JD., 2009, JALT TEST EVAL SIG N, V13, P20; Campbell JL, 2008, QUAL SAF HEALTH CARE, V17, P187, DOI 10.1136/qshc.2007.024679; Caretta-Weyer Holly A, 2017, J Grad Med Educ, V9, P367, DOI 10.4300/JGME-D-17-00200.1; Crossley J, 2012, MED EDUC, V46, P28, DOI 10.1111/j.1365-2923.2011.04166.x; Cyna AM, 2009, ANAESTHESIA, V64, P658, DOI 10.1111/j.1365-2044.2009.05887.x; Donnon T, 2014, ACAD MED, V89, P511, DOI 10.1097/ACM.0000000000000147; Ferguson J, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-76; Flierler WJ, 2013, ANAESTHESIA, V68, P713, DOI 10.1111/anae.12196; Hall W, 1999, CAN MED ASSOC J, V161, P52; Lipner RS, 2002, ACAD MED, V77, pS64, DOI 10.1097/00001888-200210001-00021; Lockyer JM, 2006, CAN J ANAESTH, V53, P33, DOI 10.1007/BF03021525; Lockyer Jocelyn, 2003, J Contin Educ Health Prof, V23, P4, DOI 10.1002/chp.1340230103; Lockyer JM, 2006, ACAD EMERG MED, V13, P1296, DOI 10.1197/j.aem.2006.07.030; Mahoney D, 2019, ACAD PEDIATR, V19, P555, DOI 10.1016/j.acap.2018.12.002; Marturano A., 2017, MED MORALE, V66, P633, DOI [10.4081/mem.2017.511, DOI 10.4081/MEM.2017.511]; Mazzucco Walter, 2019, Acta Biomed, V90, P15, DOI 10.23750/abm.v90i9-S.8696; McGrady E, 2013, ANAESTHESIA, V68, P1095, DOI 10.1111/anae.12421; Mianda S, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3561-4; Miller A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5064; MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045; Mueller Paul S., 2009, Keio Journal of Medicine, V58, P133; Ogrinc Greg, 2016, BMJ Qual Saf, V25, P986, DOI 10.1136/bmjqs-2015-004411; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; Rethans JJ, 2002, MED EDUC, V36, P901, DOI 10.1046/j.1365-2923.2002.01316.x; Ricciardi W., 2016, MED CHIRURGIA, V71, P3219, DOI [10.4487/medchir2016-71-1, DOI 10.4487/MEDCHIR2016-71-1]; Sala F., 2002, CONSULT PSYCH J, V54, P166, DOI [10.1037/1061-4087.54.3.166, DOI 10.1037/1061-4087.54.3.166]; Scemama PH, 2012, ANESTHESIOLOGY, V117, P651, DOI 10.1097/ALN.0b013e3182632358; Scheele F, 2008, MED TEACH, V30, P248, DOI 10.1080/01421590801993022; Shorten GD, 2020, EUR J ANAESTH, V37, P421, DOI 10.1097/EJA.0000000000001201; Stevens S, 2018, J CONTIN EDUC HEALTH, V38, P262, DOI 10.1097/CEH.0000000000000219; Swanwick T, 2005, BRIT J GEN PRACT, V55, P461; Van der Vleuten CPM, 1996, ADV HEALTH SCI EDUC, V1, P41, DOI 10.1007/BF00596229; Violato C, 2003, BMJ-BRIT MED J, V326, P546, DOI 10.1136/bmj.326.7388.546; Violato C, 1997, ACAD MED, V72, pS82, DOI 10.1097/00001888-199710001-00028; Violato C, 2008, MED EDUC, V42, P1007, DOI 10.1111/j.1365-2923.2008.03127.x; Wisman-Zwarter N, 2016, EUR J ANAESTH, V33, P559, DOI 10.1097/EJA.0000000000000474; Wood Laurence, 2006, Med Teach, V28, pe185, DOI 10.1080/01421590600834286; Yamamoto S, 2017, CUREUS, V9, DOI 10.7759/cureus.1060	45	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	4							e0250404	10.1371/journal.pone.0250404	http://dx.doi.org/10.1371/journal.pone.0250404			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR0PU	33891626	Green Published, gold			2023-01-03	WOS:000642811900054
J	Baldomero, AK; Melzer, AC; Greer, N; Majeski, BN; MacDonald, R; Linskens, EJ; Wilt, TJ				Baldomero, Arianne K.; Melzer, Anne C.; Greer, Nancy; Majeski, Brittany N.; MacDonald, Roderick; Linskens, Eric J.; Wilt, Timothy J.			Effectiveness and Harms of High-Flow Nasal Oxygen for Acute Respiratory Failure: An Evidence Report for a Clinical Guideline From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Review							POSITIVE-PRESSURE VENTILATION; OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; CANNULA OXYGEN; NONINVASIVE VENTILATION; IMMUNOCOMPROMISED PATIENTS; EMERGENCY-DEPARTMENT; ENDOTRACHEAL INTUBATION; THERAPY; EXTUBATION	Background: Use of high-flow nasal oxygen (HFNO) for treatment of adults with acute respiratory failure (ARF) has increased. Purpose: To assess HFNO versus noninvasive ventilation (NIV) or conventional oxygen therapy (COT) for ARF in hospitalized adults. Data Sources: English-language searches of MEDLINE, Embase, CINAHL, and Cochrane Library from January 2000 to July 2020; systematic review reference lists. Study Selection: 29 randomized controlled trials evaluated HFNO versus NIV (k=11) or COT (k=21). Data Extraction: Data extraction by a single investigator was verified by a second, 2 investigators assessed risk of bias, and evidence certainty was determined by consensus. Data Synthesis: Results are reported separately for HFNO versus NIV, for HFNO versus COT, and by initial or postextubation management. Compared with NIV, HFNO may reduce all-cause mortality, intubation, and hospital-acquired pneumonia and improve patient comfort in initial ARF management (low-certainty evidence) but not in postextubation management. Compared with COT, HFNO may reduce reintubation and improve patient comfort in postextubation ARF management (low-certainty evidence). Limitations: Trials varied in populations enrolled, ARF causes, and treatment protocols. Trial design, sample size, duration of treatment and follow-up, and results reporting were often insufficient to adequately assess many outcomes. Protocols, clinician and health system training, cost, and resource use were poorly characterized. Conclusion: Compared with NIV, HFNO as initial ARF management may improve several clinical outcomes. Compared with COT, HFNO as postextubation management may reduce reintubations and improve patient comfort; HFNO resulted in fewer harms than NIV or COT. Broad applicability, including required clinician and health system experience and resource use, is not well known.	[Baldomero, Arianne K.; Melzer, Anne C.] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN USA; [Baldomero, Arianne K.; Melzer, Anne C.] Univ Minnesota, Minneapolis, MN USA; [Greer, Nancy; Majeski, Brittany N.; MacDonald, Roderick; Linskens, Eric J.; Wilt, Timothy J.] Minneapolis Vet Affairs Hlth Care Syst, Ctr Care Delivery & Outcomes Res, Minneapolis, MN USA; [Baldomero, Arianne K.; Melzer, Anne C.] 1 Vet Dr,Pulm 111-N, Minneapolis, MN 55417 USA; [Greer, Nancy; Majeski, Brittany N.; MacDonald, Roderick; Linskens, Eric J.; Wilt, Timothy J.] 1 Vet Dr,111-0, Minneapolis, MN 55417 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Baldomero, AK (corresponding author), 1 Vet Dr,Pulm 111-N, Minneapolis, MN 55417 USA.	baldo004@umn.edu	Melzer, Anne/AFS-2490-2022; Baldomero, Arianne K/L-6555-2019	Baldomero, Arianne K/0000-0002-8309-0747	National Institutes of Health National Center for Advancing Translational Sciences [KL2TR002492, UL1TR002494]	National Institutes of Health National Center for Advancing Translational Sciences	The evidence review was commissioned by ACP. The material is the result of work supported by and conducted at the Minneapolis VA Health Care System. Dr. Baldomero was also supported, in part, by grants KL2TR002492 and UL1TR002494 from the National Institutes of Health National Center for Advancing Translational Sciences.	Andino R, 2020, THER ADV RESPIR DIS, V14, DOI 10.1177/1753466620956459; [Anonymous], 2015, GRADEPRO GDT GRADEPR; Apltekinoglu Mendil N, 2021, TURK J MED SCI, V51, P1756, DOI 10.3906/sag-2007-228; Azoulay E, 2018, JAMA-J AM MED ASSOC, V320, P2099, DOI 10.1001/jama.2018.14282; Baldomero AK, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034956; Bell N, 2015, EMERG MED AUSTRALAS, V27, P537, DOI 10.1111/1742-6723.12490; Cheng LC, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55100693; Cho JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e194; Cong L, 2019, INT J CLIN EXP MED, V12, P10863; Corley A, 2011, BRIT J ANAESTH, V107, P998, DOI 10.1093/bja/aer265; Corley A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010172.pub2; Corley A, 2015, INTENS CARE MED, V41, P887, DOI 10.1007/s00134-015-3765-6; Cortegiani A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03409-0; Cortegiani A, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2473-y; Cortegiani A, 2019, J CRIT CARE, V50, P250, DOI 10.1016/j.jcrc.2018.12.015; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Delorme M, 2017, CRIT CARE MED, V45, P1981, DOI 10.1097/CCM.0000000000002693; Doshi P, 2018, ANN EMERG MED, V72, P73, DOI 10.1016/j.annemergmed.2017.12.006; Doshi PB, 2020, HEART LUNG, V49, P610, DOI 10.1016/j.hrtlng.2020.03.008; Drake MG, 2018, ANN AM THORAC SOC, V15, P145, DOI 10.1513/AnnalsATS.201707-548FR; Frat JP, 2016, LANCET RESP MED, V4, P646, DOI 10.1016/S2213-2600(16)30093-5; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756; Geng WR, 2020, CAN RESPIR J, V2020, DOI 10.1155/2020/2301712; Grieco DL, 2020, AM J RESP CRIT CARE, V201, P303, DOI 10.1164/rccm.201904-0841OC; Groves Nicole, 2007, Aust Crit Care, V20, P126; Hasani A, 2008, Chron Respir Dis, V5, P81, DOI 10.1177/1479972307087190; Haywood ST, 2019, AM J EMERG MED, V37, P2084, DOI 10.1016/j.ajem.2019.03.002; Helviz Y, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1990-4; Hernandez G, 2016, JAMA-J AM MED ASSOC, V316, P1565, DOI 10.1001/jama.2016.14194; Hernandez G, 2016, JAMA-J AM MED ASSOC, V315, P1354, DOI 10.1001/jama.2016.2711; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Huang CC, 2019, EMERG MED INT, V2019, DOI 10.1155/2019/2130935; Huang HB, 2018, J CRIT CARE, V43, P300, DOI 10.1016/j.jcrc.2017.09.176; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Jing GQ, 2019, RES NURS HEALTH, V42, P217, DOI 10.1002/nur.21942; Jones PG, 2016, RESP CARE, V61, P291, DOI 10.4187/respcare.04252; Kang HYJ, 2020, RESP CARE, V65, P369, DOI 10.4187/respcare.07205; Leeies M, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0593-5; Lemiale V, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1097-0; Lenglet H, 2012, RESP CARE, V57, P1873, DOI 10.4187/respcare.01575; Li XY, 2020, INT J CHRONIC OBSTR, V15, P3051, DOI 10.2147/COPD.S283020; Liesching TN, 2019, J INTENSIVE CARE MED, V34, P140, DOI 10.1177/0885066616689043; Lin SM, 2017, RESP MED, V131, P58, DOI 10.1016/j.rmed.2017.08.005; Maggiore SM, 2014, AM J RESP CRIT CARE, V190, P282, DOI 10.1164/rccm.201402-0364OC; Makdee O, 2017, ANN EMERG MED, V70, P465, DOI 10.1016/j.annemergmed.2017.03.028; Matsuda W, 2020, RESP CARE, V65, P610, DOI 10.4187/respcare.07095; Mehta AB, 2017, ANN AM THORAC SOC, V14, P1667, DOI 10.1513/AnnalsATS.201703-208OC; Moller W, 2017, J APPL PHYSIOL, V122, P191, DOI 10.1152/japplphysiol.00584.2016; Monro-Somerville T, 2017, CRIT CARE MED, V45, pE449, DOI 10.1097/CCM.0000000000002091; Ni YN, 2017, CHEST, V151, P764, DOI 10.1016/j.chest.2017.01.004; Ou XF, 2017, CAN MED ASSOC J, V189, pE260, DOI 10.1503/cmaj.160570; Papachatzakis Y, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165994; Parke R, 2009, BRIT J ANAESTH, V103, P886, DOI 10.1093/bja/aep280; Parke RL, 2013, RESP CARE, V58, P1621, DOI 10.4187/respcare.02358; Parke RL, 2011, RESP CARE, V56, P1151, DOI 10.4187/respcare.01106; Parke RL, 2011, RESP CARE, V56, P265, DOI 10.4187/respcare.00801; Pilcher J, 2017, RESPIROLOGY, V22, P1149, DOI 10.1111/resp.13050; Rezaei A, 2021, CLIN RESPIR J, V15, P420, DOI 10.1111/crj.13315; Ritchie JE, 2011, ANAESTH INTENS CARE, V39, P1103, DOI 10.1177/0310057X1103900620; Rittayamai N, 2015, RESP CARE, V60, P1377, DOI 10.4187/respcare.03837; Rittayamai N, 2014, RESP CARE, V59, P485, DOI 10.4187/respcare.02397; Roca O, 2010, RESP CARE, V55, P408; Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5; Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016; Ruangsomboon O, 2020, ANN EMERG MED, V75, P615, DOI 10.1016/j.annemergmed.2019.09.009; Saksitthichok B, 2019, J THORAC DIS, V11, P1929, DOI 10.21037/jtd.2019.05.02; Schunemann H, 2019, GRADE HDB; Schwabbauer N, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-66; Sim MAB, 2008, ANAESTHESIA, V63, P938, DOI 10.1111/j.1365-2044.2008.05536.x; Sklar MC, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0432-4; Song HZ, 2017, CLINICS, V72, P562, DOI 10.6061/clinics/2017(09)07; Spoletini G, 2018, J CRIT CARE, V48, P418, DOI 10.1016/j.jcrc.2018.10.004; Stephan F, 2015, JAMA-J AM MED ASSOC, V313, P2331, DOI 10.1001/jama.2015.5213; Sztrymf B, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.07.075; Sztrymf B, 2011, INTENS CARE MED, V37, P1780, DOI 10.1007/s00134-011-2354-6; Tan DY, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03214-9; Theerawit P, 2021, J CRIT CARE, V63, P117, DOI 10.1016/j.jcrc.2020.09.031; Thille AW, 2011, CRIT CARE MED, V39, P2612, DOI 10.1097/CCM.0b013e3182282a5a; Tinelli V, 2019, J EMERG MED, V57, P322, DOI 10.1016/j.jemermed.2019.06.033; Tiruvoipati R, 2010, J CRIT CARE, V25, P463, DOI 10.1016/j.jcrc.2009.06.050; Vargas F, 2015, RESP CARE, V60, P1369, DOI 10.4187/respcare.03814; Veroniki AA, 2019, RES SYNTH METHODS, V10, P23, DOI 10.1002/jrsm.1319; Vourc'h M, 2020, J CARDIOTHOR VASC AN, V34, P157, DOI 10.1053/j.jvca.2019.05.039; Walkey Allan J, 2013, Ann Am Thorac Soc, V10, P10, DOI 10.1513/AnnalsATS.201206-034OC; Williams R, 1996, CRIT CARE MED, V24, P1920, DOI 10.1097/00003246-199611000-00025; Xu ZH, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0908-7; Zhu YF, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2465-y	88	11	11	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL	2021	174	7					952	+		10.7326/M20-4675	http://dx.doi.org/10.7326/M20-4675			23	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM8QB	33900793	Green Accepted			2023-01-03	WOS:000675809000022
J	Maki, S; Nagai, K; Ando, S; Tamakoshi, K				Maki, Shigeyoshi; Nagai, Kuniyoshi; Ando, Shoko; Tamakoshi, Koji			Structure and predictors of in-hospital nursing care leading to reduction in early readmission among patients with schizophrenia in Japan: A cross-sectional study	PLOS ONE			English	Article							EVALUATION SCHEMA ESSENCES; QUALITY-OF-CARE; PSYCHIATRIC-INPATIENTS; PSYCHOMETRIC PROPERTIES; AFTER-DISCHARGE; RISK; INTERVENTIONS; INDICATOR; PEOPLE; FACILITIES	Schizophrenia is a disorder characterized by psychotic relapses. Globally, about 15%-30% of patients with schizophrenia discharged from inpatient psychiatric admissions are readmitted within 90 days due to exacerbation of symptoms that leads to self-harm, harm to others, or self-neglect. The purpose of this study was to investigate the structure and predictors of in-hospital nursing care leading to reduction in early readmission among patients with schizophrenia. A new questionnaire was developed to assess the extent to which respondents delivered in-hospital nursing care leading to reduction in early readmission among patients with schizophrenia. This study adopted a cross-sectional research design. The survey was conducted with the new questionnaires. The participants were registered nurses working in psychiatric wards. Item analyses and exploratory factor analyses were performed using the new questionnaires to investigate the structure of in-hospital nursing care leading to reduction in early readmission. Stepwise regression analyses were conducted to examine the factors predicting in-hospital nursing care leading to reduction in early readmission. Data were collected from 724 registered nurses in Japan. In-hospital nursing care leading to reduction in early readmission was found to consist of five factors: promoting cognitive functioning and self-care, identifying reasons for readmission, establishing cooperative systems within the community, sharing goals about community life, and creating restful spaces. In-hospital nursing care leading to reduction in early readmission was predicted by the following variables: the score on the nursing excellence scale in clinical practice, the score on therapeutic hold, and the participation of community care providers in pre-discharge conferences. Japanese psychiatric nurses provide nursing care based on these five factors leading to reduction in early readmission. Such nursing care would be facilitated by not only nurses' excellence but also nurses' environmental factors, especially the therapeutic climate of the ward and the participation of community care providers in pre-discharge conferences.				s-maki@sugiyama-u.ac.jp		Maki, Shigeyoshi/0000-0003-0847-0042	Japan Society for the Promotion of Science KAKENHI [JP17K17523]; KAKENHI [17K17523]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	SM was funded by Japan Society for the Promotion of Science KAKENHI Grant#JP17K17523. URL: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17K17523/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews CE, 2017, PSYCHIAT SERV, V68, P847, DOI 10.1176/appi.ps.201600334; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Campbell K, 2019, INT J MENT HEALTH NU, V28, P407, DOI 10.1111/inm.12553; Cha CY, 2020, INT J NURS PRACT, V26, DOI 10.1111/ijn.12874; Chen FP, 2014, COMMUNITY MENT HLT J, V50, P520, DOI 10.1007/s10597-013-9641-3; Chen SC, 2018, J NURS RES, V26, P72, DOI 10.1097/jnr.0000000000000230; Chi MH, 2016, SCHIZOPHR RES, V170, P184, DOI 10.1016/j.schres.2015.11.025; Chien WT, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0744-6; Cho H, 2018, J NURS SCHOLARSHIP, V50, P403, DOI 10.1111/jnu.12390; Department of Mental Health Policy National Institute of Mental Health Japan, 2018, NEW MENTAL HLTH WELF; Donisi V, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1114-0; Donisi V, 2016, GEN HOSP PSYCHIAT, V39, P53, DOI 10.1016/j.genhosppsych.2015.10.009; Forchuk C, 2005, J Psychiatr Ment Health Nurs, V12, P556, DOI 10.1111/j.1365-2850.2005.00873.x; Han KT, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0804-y; Han KT, 2015, PSYCHIAT RES, V229, P880, DOI 10.1016/j.psychres.2015.07.051; Hosie L, 2018, J PSYCHIATR MENT HLT, V25, P531, DOI 10.1111/jpm.12498; Howells K, 2009, CRIM BEHAV MENT HEAL, V19, P308, DOI 10.1002/cbm.745; Hung YY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186768; Joseph F., 2019, MULTIVARIATE DATA AN, V8th; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Kameoka T., 2015, MEASURING TOOL FILE, V3, P64; Kameoka T., 2015, J NURSING STUDIES NA, V14, P1; Kasai K, 2017, LANCET PSYCHIAT, V4, P268, DOI 10.1016/S2215-0366(16)30373-X; Khaleghparast S, 2014, J CLIN NURS, V23, P2215, DOI 10.1111/jocn.12499; Killaspy H, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0799-4; Killaspy H, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0737-5; Killaspy H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038070; Killaspy H, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-35; Lay B, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00120; Long CG, 2011, CRIM BEHAV MENT HEAL, V21, P202, DOI 10.1002/cbm.791; Lorine K, 2015, J NERV MENT DIS, V203, P425, DOI 10.1097/NMD.0000000000000305; Lundqvist L-O., 2014, OPEN J NURS, V04, P878, DOI [10.4236/ojn.2014.412093, DOI 10.4236/OJN.2014.412093]; Lundqvist LO, 2019, ASIAN J PSYCHIATR, V46, P29, DOI 10.1016/j.ajp.2019.09.027; Lundqvist LO, 2018, ASIAN J PSYCHIATR, V34, P1, DOI 10.1016/j.ajp.2018.03.006; Maki S., 2018, J JAPAN SOC NURSING, V41, P713, DOI [10.15065/jjsnr.20180308015, DOI 10.15065/JJSNR.20180308015]; Marder SR, 2019, NEW ENGL J MED, V381, P1753, DOI 10.1056/NEJMra1808803; Meehan J, 2006, BRIT J PSYCHIAT, V188, P129, DOI 10.1192/bjp.188.2.129; Ministry of Health  Labour and Welfare, 2020, MATTERS MEDICAL TREA; Moos R. H., 1987, PSYCHOL HEALTH, V1, P97, DOI [10.1080/08870448708400318, DOI 10.1080/08870448708400318]; Nation Health Commission, 2020, CHIN HLTH STAT YB 20; Noda S., 2012, CLIN PSYCHIAT, V54, P211; Noda S., 2014, CLIN PSYCHIAT, V56, P715; Okumura Y, 2019, J EPIDEMIOL, V29, P288, DOI 10.2188/jea.JE20180096; Pett M., 2003, MAKING SENCE FACTOR; Pillai A, 2018, SCHIZOPHR RES, V193, P263, DOI 10.1016/j.schres.2017.06.059; Rozental A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157503; Sariah AE, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0240-9; Schalast N., 2016, ESSEN CLIMATE EVALUA, DOI [10.1055/s-0035-1552766 26765091, DOI 10.1055/S-0035-155276626765091]; Schalast Norbert, 2008, Crim Behav Ment Health, V18, P49, DOI 10.1002/cbm.677; Sfetcu R, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1386-z; Shaffer SL, 2015, PSYCHIAT SERV, V66, P1155, DOI 10.1176/appi.ps.201400362; Siess J, 2017, ARCH PSYCHIAT NURS, V31, P582, DOI 10.1016/j.apnu.2017.08.001; Takano A, 2015, ARCH PSYCHIAT NURS, V29, P302, DOI 10.1016/j.apnu.2015.05.002; Tonkin M, 2012, PSYCHOL ASSESSMENT, V24, P573, DOI 10.1037/a0026267; Tyler N, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4658-0; Vigod SN, 2015, J PSYCHIATR RES, V61, P205, DOI 10.1016/j.jpsychires.2014.12.003; Vigod SN, 2013, CAN J PSYCHIAT, V58, P476, DOI 10.1177/070674371305800806; Vigod SN, 2013, BRIT J PSYCHIAT, V202, P187, DOI 10.1192/bjp.bp.112.115030; Walter F, 2019, LANCET PSYCHIAT, V6, P582, DOI 10.1016/S2215-0366(19)30180-4; Word Health Organization, 2018, MENTAL HLTH ATLAS 20; Yamaguchi S, 2019, INT J MENT HEALTH SY, V13, DOI 10.1186/s13033-019-0298-3; Zou HO, 2013, INT J MENT HEALTH NU, V22, P256, DOI 10.1111/j.1447-0349.2012.00863.x	62	0	0	3	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2021	16	4							e0250771	10.1371/journal.pone.0250771	http://dx.doi.org/10.1371/journal.pone.0250771			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6EM	33930056	Green Published, gold			2023-01-03	WOS:000664607000032
J	Navarro-Guillen, C; Pereira, GD; Lopes, A; Colen, R; Engrola, S				Navarro-Guillen, Carmen; Pereira, Gabriella do Vale; Lopes, Andre; Colen, Rita; Engrola, Sofia			Egg nutritional modulation with amino acids improved performance in zebrafish larvae	PLOS ONE			English	Article							DIETARY ARGININE; GROWTH-PERFORMANCE; ENZYME-ACTIVITIES; DIGESTIVE ENZYME; JUVENILE JIAN; GLUTAMINE; FISH; ULTRASOUND; CHOLECYSTOKININ; MICROINJECTION	New and more efficient methods to sustainably intensify Aquaculture production are essential to attain the seafood demand for direct human consumption in the near future. Nutrition has been identified as one strategy of early exposure that might affect animal early development and later phenotype. This strategy may have positive consequences in the modulation of fish digestive physiology, which will correlate with higher performance outputs. Thus, improving fish digestive efficiency will lead to higher productivity and lower biogenic emission from aquaculture facilities, minimising the impact on the environment while increasing the biological efficiency. An innovative in ovo nutritional modulation technique based on low-frequency ultrasounds was used to enhance the transport of amino acids across the embryo membranes. An early stimulus with either arginine or glutamine, both involved in gut maturation, was applied in zebrafish (Danio rerio) embryos at 3.5 hours post-fertilization (hpf). At 22 days post-fertilization (dpf), growth performance, digestive enzyme activities and gut microbiota composition were analysed to evaluate the larval nutrition-induced metabolic plasticity and the effects on fish digestive efficiency. Results showed that fish survival was not affected either by the sonophoresis technique or amino acid supplementation. Final dry weight at 22 dpf was statistically higher in larvae from glutamine treatment when compared to the control even with lower trypsin activity, suggesting a higher nutrient digestion capacity, due to a slightly modulation of gut microbiota. Higher arginine supplementation levels should be tested as strategy to enhance growth at later developmental stages. In conclusion, this study demonstrated the efficiency of sonophoresis technique for in ovo nutritional modulation and suggests that in ovo glutamine supplementation might promote growth at later developmental stage through a positive microbiota modulation.	[Navarro-Guillen, Carmen; Lopes, Andre; Colen, Rita; Engrola, Sofia] Ctr Ciencias Mar Algarve CCMAR, Aquaculture Res Grp, Faro, Portugal; [Pereira, Gabriella do Vale] SPAROS Lda, Olhao, Portugal; [Navarro-Guillen, Carmen] CSIC, Inst Ciencias Marinas Andalucia ICMAN, Dept Marine Biol & Aquaculture, Cadiz, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencias Marinas de Andalucia (ICMAN)	Engrola, S (corresponding author), Ctr Ciencias Mar Algarve CCMAR, Aquaculture Res Grp, Faro, Portugal.	sengrola@ualg.pt	Colen, Rita I. P. B./D-7999-2016; Navarro, Carmen/GON-7706-2022; Engrola, Sofia/A-2485-2012	Colen, Rita I. P. B./0000-0001-7104-1844; Engrola, Sofia/0000-0002-5244-5541	FCT -Foundation for Science and Technology [ALG-01-0145-FEDER029151, UIDB/04326/2020]; European Social Fund [IF/00482/2014/CP1217/CT0005]; Operational Programme Human Potential; FCT	FCT -Foundation for Science and Technology(Portuguese Foundation for Science and Technology); European Social Fund(European Social Fund (ESF)); Operational Programme Human Potential; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This study received Portuguese national funds from FCT -Foundation for Science and Technology through project ALG-01-0145-FEDER029151 "PROLAR -Early metabolic programming in fish through nutritional modulation", and UIDB/04326/2020. The funder provided support in the form of salaries for author CNG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. SE acknowledges a FCT investigator grant (IF/00482/2014/CP1217/CT0005) funded by the European Social Fund, the Operational Programme Human Potential and FCT. The specific roles of all authors are articulated in the `author contributions' section. The commercial affiliation participating in the present study (SPAROS Lda.) did not participate in the research funding, the author GVP contributed to microbiota data analysis.	Allon G, 2016, AQUACULTURE, V451, P93, DOI 10.1016/j.aquaculture.2015.08.040; Bart AN, 2001, AQUACULTURE, V196, P189, DOI 10.1016/S0044-8486(00)00579-2; Beirao J, 2006, AQUACULTURE, V261, P897, DOI 10.1016/j.aquaculture.2006.07.039; Buentello JA, 2007, J AQUAT ANIM HEALTH, V19, P195, DOI 10.1577/H07-004.1; Butt RL, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00009; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Carvalho AP, 2006, AQUAC RES, V37, P1107, DOI 10.1111/j.1365-2109.2006.01534.x; Chen GF, 2012, BRIT J NUTR, V108, P195, DOI 10.1017/S0007114511005459; Cheng ZY, 2011, AQUACULTURE, V319, P247, DOI 10.1016/j.aquaculture.2011.06.025; Conceicao LEC, 1998, FISH PHYSIOL BIOCHEM, V19, P43, DOI 10.1023/A:1007738228055; Conceicao LEC, 2003, AQUACULTURE, V227, P221, DOI 10.1016/S0044-8486(03)00505-2; Costas B, 2012, AMINO ACIDS, V43, P327, DOI 10.1007/s00726-011-1082-0; Egerton S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00873; Engrola S, 2014, AQUACULTUE EUROPE, V14; Engrola S, 2014, 16 INT S FISH NUTR F; Engrola S, 2016, AQ EUR 16 EAS 2016 2; Farias M., 2016, INT J MARINE BIOL RE, V1, P1, DOI DOI 10.15226/24754706/1/1/00101; Fernandez-Alonso M, 2001, VACCINE, V19, P3067, DOI 10.1016/S0264-410X(01)00046-9; Fjellheim AJ, 2012, AQUAC RES, V43, P1499, DOI 10.1111/j.1365-2109.2011.02952.x; Frenkel V, 2000, J CONTROL RELEASE, V68, P251, DOI 10.1016/S0168-3659(00)00264-9; Fuiman LA, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.1414; HALVER JE, 1957, J NUTR, V63, P95, DOI 10.1093/jn/63.1.95; Hara H, 2000, J NUTR BIOCHEM, V11, P52, DOI 10.1016/S0955-2863(99)00071-6; HARA H, 1995, J NUTR, V125, P1143; Hou ZX, 2020, REV FISH BIOL FISHER, V30, P67, DOI 10.1007/s11160-019-09590-y; Karau A, 2014, ADV BIOCHEM ENG BIOT, V143, P189, DOI 10.1007/10_2014_269; Larque E, 2007, NUTRITION, V23, P87, DOI 10.1016/j.nut.2006.09.006; Lauzon HL, 2010, J APPL MICROBIOL, V108, P624, DOI 10.1111/j.1365-2672.2009.04454.x; Lin Y, 2006, AQUACULTURE, V256, P389, DOI 10.1016/j.aquaculture.2006.02.011; Liu JW, 2015, AQUACULTURE, V446, P48, DOI 10.1016/j.aquaculture.2015.04.012; Liu Y, 2008, BRIT J NUTR, V100, P552, DOI 10.1017/S0007114508911612; Lopes A, 2016, EFFECTS GROWTH NUTRI; Nadal AL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00114; Loser C, 1999, GUT, V44, P12, DOI 10.1136/gut.44.1.12; Lucas A, 1998, J NUTR, V128, p401S, DOI 10.1093/jn/128.2.401S; Ma N, 2019, COMPR REV FOOD SCI F, V18, P221, DOI 10.1111/1541-4337.12401; Martins G, 2019, ZEBRAFISH, V16, P300, DOI 10.1089/zeb.2018.1691; McBride M.J., 2014, PROKARYOTES OTHER MA, P577; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; Morais S, 2014, AQUACULTURE, V432, P374, DOI 10.1016/j.aquaculture.2014.04.033; Navarro-Guillen C., 2021, **DATA OBJECT**, DOI [10.5281/zenodo.4537443, DOI 10.5281/ZENODO.4537443]; Navarro-Guillen C, 2019, COMP BIOCHEM PHYS A, V228, P1, DOI 10.1016/j.cbpa.2018.10.019; Otani S, 2008, FISHERIES SCI, V74, P208, DOI 10.1111/j.1444-2906.2007.01512.x; Peres A, 1997, FISH PHYSIOL BIOCHEM, V16, P479, DOI 10.1023/A:1007786128254; Popovic PJ, 2007, J NUTR, V137, p1681S, DOI 10.1093/jn/137.6.1681S; Qiyou X, 2011, J APPL ICHTHYOL, V27, P721, DOI 10.1111/j.1439-0426.2011.01710.x; Rahardja DP, 2018, IOP C SER EARTH ENV, V157, DOI 10.1088/1755-1315/157/1/012071; Rocha F, 2014, J EXP BIOL, V217, P1139, DOI 10.1242/jeb.095463; Roeselers G, 2011, ISME J, V5, P1595, DOI 10.1038/ismej.2011.38; Ronnestad I., 2005, PHYSL ECOLOGICAL ADA, P434; Rotllant G, 2008, AQUACULTURE, V282, P90, DOI 10.1016/j.aquaculture.2008.06.004; Salmanzadeh M, 2016, ARCH ANIM BREED, V59, P235, DOI 10.5194/aab-59-235-2016; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shirakashi R, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4936573; Singh K, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00066; Song ZD, 2016, CHIN J OCEANOL LIMN, V34, P1013, DOI 10.1007/s00343-016-5031-3; Stagaman K, 2020, LAB ANIMAL, V49, P201, DOI 10.1038/s41684-020-0573-6; TACHIBANA K, 1991, J PHARM PHARMACOL, V43, P270, DOI 10.1111/j.2042-7158.1991.tb06681.x; Vadstein O, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01820; Valente LMP, 2013, REV AQUACULT, V5, pS168, DOI 10.1111/raq.12020; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th; Wu Q, 2019, BRAZ J POULTRY SCI, V21, DOI 10.1590/1806-9061-2019-1123; Yang ZY, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00169; Young J. Z., 1933, Pubblicazioni della Stazione Zoologica di Napoli, V12, P425; Zhou YC, 2002, AQUACULTURE, V203, P229, DOI 10.1016/S0044-8486(01)00634-2	66	0	0	3	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2021	16	4							e0248356	10.1371/journal.pone.0248356	http://dx.doi.org/10.1371/journal.pone.0248356			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM0OE	33835997	gold, Green Published			2023-01-03	WOS:000639361000014
J	Motzer, R; Alekseev, B; Rha, SY; Porta, C; Eto, M; Powles, T; Grunwald, V; Hutson, TE; Kopyltsov, E; Mendez-Vidal, MJ; Kozlov, V; Alyasova, A; Hong, SH; Kapoor, A; Gordoa, TA; Merchan, JR; Winquist, E; Maroto, P; Goh, JC; Kim, M; Gurney, H; Patel, V; Peer, A; Procopio, G; Takagi, T; Melichar, B; Rolland, F; De Giorgi, U; Wong, S; Bedke, J; Schmidinger, M; Dutcus, CE; Smith, AD; Dutta, L; Mody, K; Perini, RF; Xing, DY; Choueiri, TK				Motzer, Robert; Alekseev, Boris; Rha, Sun-Young; Porta, Camillo; Eto, Masatoshi; Powles, Thomas; Gruenwald, Viktor; Hutson, Thomas E.; Kopyltsov, Evgeny; Mendez-Vidal, Maria J.; Kozlov, Vadim; Alyasova, Anna; Hong, Sung-Hoo; Kapoor, Anil; Alonso Gordoa, Teresa; Merchan, Jaime R.; Winquist, Eric; Maroto, Pablo; Goh, Jeffrey C.; Kim, Miso; Gurney, Howard; Patel, Vijay; Peer, Avivit; Procopio, Giuseppe; Takagi, Toshio; Melichar, Bohuslav; Rolland, Frederic; De Giorgi, Ugo; Wong, Shirley; Bedke, Jens; Schmidinger, Manuela; Dutcus, Corina E.; Smith, Alan D.; Dutta, Lea; Mody, Kalgi; Perini, Rodolfo F.; Xing, Dongyuan; Choueiri, Toni K.		CLEAR Trial Investigators	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							1ST-LINE TREATMENT; FOLLOW-UP; SUNITINIB; CABOZANTINIB; MONOTHERAPY; THERAPY; CANCER; TRIAL	BACKGROUND Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. METHODS In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously once every 3 weeks), lenvatinib (18 mg orally once daily) plus everolimus (5 mg orally once daily), or sunitinib (50 mg orally once daily, alternating 4 weeks receiving treatment and 2 weeks without treatment). The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated. RESULTS A total of 1069 patients were randomly assigned to receive lenvatinib plus pembrolizumab (355 patients), lenvatinib plus everolimus (357), or sunitinib (357). Progression-free survival was longer with lenvatinib plus pembrolizumab than with sunitinib (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P<0.001) and was longer with lenvatinib plus everolimus than with sunitinib (median, 14.7 vs. 9.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.80; P<0.001). Overall survival was longer with lenvatinib plus pembrolizumab than with sunitinib (hazard ratio for death, 0.66; 95% CI, 0.49 to 0.88; P=0.005) but was not longer with lenvatinib plus everolimus than with sunitinib (hazard ratio, 1.15; 95% CI, 0.88 to 1.50; P = 0.30). Grade 3 or higher adverse events emerged or worsened during treatment in 82.4% of the patients who received lenvatinib plus pembrolizumab, 83.1% of those who received lenvatinib plus everolimus, and 71.8% of those who received sunitinib. Grade 3 or higher adverse events occurring in at least 10% of the patients in any group included hypertension, diarrhea, and elevated lipase levels. CONCLUSIONS Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib.	[Motzer, Robert] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA; [Alekseev, Boris] P Hertsen Moscow Oncol Res Inst, Moscow, Russia; [Kopyltsov, Evgeny] State Inst Hlth Care Reg Clin Oncol Dispensary, Omsk, Russia; [Kozlov, Vadim] State Budgetary Hlth Care Inst Novosibirsk Reg Cl, Novosibirsk, Russia; [Alyasova, Anna] Prevoljskiy Reg Med Ctr, Novgorod, Russia; [Rha, Sun-Young] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea; [Hong, Sung-Hoo] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea; [Kim, Miso] Seoul Natl Univ Hosp, Seoul, South Korea; [Porta, Camillo] San Matteo Univ Hosp Fdn, Pavia, Italy; [Procopio, Giuseppe] Ist Nazl Tumori IRCCS, Milan, Italy; [De Giorgi, Ugo] Ist Sci Romagnolo Studio & Cura Tumori IRCCS, Meldola, Italy; [Eto, Masatoshi] Kyushu Univ, Fukuoka, Japan; [Takagi, Toshio] Tokyo Womens Med Univ, Tokyo, Japan; [Powles, Thomas] Royal Free NHS Trust, London, England; [Smith, Alan D.] Eisai, Hatfield, Herts, England; [Gruenwald, Viktor] Univ Hosp Essen, Essen, Germany; [Bedke, Jens] Univ Tubingen, Tubingen, Germany; [Hutson, Thomas E.] Texas Oncol, Dallas, TX USA; [Mendez-Vidal, Maria J.] Univ Reina Sofia, Cordoba Hosp, Maimonides Inst Biomed Res, Dept Med Oncol, Cordoba, Spain; [Alonso Gordoa, Teresa] Hosp Univ Ramon y Cajal, Madrid, Spain; [Maroto, Pablo] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Kapoor, Anil] McMaster Univ, Hamilton, ON, Canada; [Winquist, Eric] Western Univ, London, ON, Canada; [Merchan, Jaime R.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA; [Patel, Vijay] Florida Canc Specialists, Gainesville, FL USA; [Goh, Jeffrey C.] ICON Res, South Brisbane, Qld, Australia; [Goh, Jeffrey C.] Univ Queensland, St Lucia, Qld, Australia; [Gurney, Howard] Macquarie Univ, Sydney, NSW, Australia; [Wong, Shirley] Western Hlth, Melbourne, Vic, Australia; [Peer, Avivit] Rambam Hlth Care Campus, Haifa, Israel; [Melichar, Bohuslav] Palacky Univ, Olomouc, Czech Republic; [Melichar, Bohuslav] Univ Hosp Olomouc, Olomouc, Czech Republic; [Rolland, Frederic] Ctr Rene Gauducheau, St Herblain, France; [Schmidinger, Manuela] Med Univ Vienna, Dept Urol, Vienna, Austria; [Dutcus, Corina E.; Dutta, Lea; Mody, Kalgi; Xing, Dongyuan] Eisai, Woodcliff Lake, NJ USA; [Perini, Rodolfo F.] Merck, Kenilworth, NJ USA; [Choueiri, Toni K.] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA	Memorial Sloan Kettering Cancer Center; Yonsei University; Yonsei University Health System; Catholic University of Korea; Seoul St. Mary's Hospital; Seoul National University (SNU); Seoul National University Hospital; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Meldola (IRST); Kyushu University; Tokyo Women's Medical University; University of London; University College London; Eisai Co Ltd; University of Duisburg Essen; Eberhard Karls University of Tubingen; Texas Oncology; Hospital Universitario Ramon y Cajal; Hospital of Santa Creu i Sant Pau; McMaster University; Western University (University of Western Ontario); University of Miami; Florida Cancer Specialists; ICON plc; University of Queensland; Macquarie University; Rambam Health Care Campus; Palacky University Olomouc; University Hospital Olomouc; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Medical University of Vienna; Eisai Co Ltd; Merck & Company; Harvard University; Dana-Farber Cancer Institute	Motzer, R (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.; Choueiri, TK (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.	motzerr@mskcc.org; toni_choueiri@dfci.harvard.edu	Choueiri, Toni/K-5238-2019; Kapoor, Anil/AAQ-7184-2021; Bedke, Jens/AAS-2837-2020; Massari, Francesco/K-7239-2016; KIMURA, GO/Y-7843-2018; Alekseev, Boris/O-1008-2017; riccardi, ferdinando/K-7370-2016	Choueiri, Toni/0000-0002-9201-3217; Kapoor, Anil/0000-0001-9180-8029; Bedke, Jens/0000-0003-2778-3108; Massari, Francesco/0000-0001-6476-6871; Gurney, Howard/0000-0003-0217-5261; KIMURA, GO/0000-0003-0088-9324; Powles, Thomas/0000-0001-7760-4724; Alekseev, Boris/0000-0002-3398-4128; Bambury, Richard/0000-0002-2189-6972; Calabro', Fabio/0000-0002-7863-3540; OUDARD, Stephane/0000-0003-0893-285X; riccardi, ferdinando/0000-0002-2852-2770; Rha, Sun Young/0000-0002-2512-4531	Eisai; Merck Sharp and Dohme; Memorial Sloan Kettering Cancer Center Support Grant/Core Grant [P30 CA008748]	Eisai(Eisai Co Ltd); Merck Sharp and Dohme(Merck & Company); Memorial Sloan Kettering Cancer Center Support Grant/Core Grant	Supported by Eisai and Merck Sharp and Dohme. The conduct of the trial at the Memorial Sloan Kettering Cancer Center was supported in part by a Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748).	[Anonymous], 2020, AFINITOR EVEROLIMUS; [Anonymous], 2020, LENVIMA LENVATINIB; Bedke J., 2020, EUR UROL; Choueiri TK, 2020, ANN ONCOL, V31, pS1159, DOI 10.1016/j.annonc.2020.08.2257; Choueiri TK., 2018, J CLIN ONCOL; Choueiri TK, 2020, NAT MED, V26, P1519, DOI 10.1038/s41591-020-1093-z; Choueiri TK, 2017, J CLIN ONCOL, V35, P591, DOI 10.1200/JCO.2016.70.7398; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Lee JL, 2020, J CLIN ONCOL, V38; Makker V, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.02627; Maurer W, 2013, STAT BIOPHARM RES, V5, P311, DOI 10.1080/19466315.2013.807748; Molina AM, 2014, CANCER CHEMOTH PHARM, V73, P181, DOI 10.1007/s00280-013-2339-y; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289; Motzer RJ, 2020, J NATL COMPR CANC NE, V18, P1161, DOI 10.6004/jnccn.2020.0043; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Powles T, 2020, LANCET ONCOL, V21, P1563, DOI 10.1016/S1470-2045(20)30436-8; Rassy E, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920907504; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; RxList, 2020, KEYTRUDA PEMBROLIZUM; SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187; Taylor MH, 2020, J CLIN ONCOL, V38, P1154, DOI 10.1200/JCO.19.01598	22	431	434	13	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	2021	384	14					1289	1300		10.1056/NEJMoa2035716	http://dx.doi.org/10.1056/NEJMoa2035716			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ7RN	33616314	Bronze			2023-01-03	WOS:000637799800007
J	McDermott, MM; Spring, B; Tian, L; Treat-Jacobson, D; Ferrucci, L; Lloyd-Jones, D; Zhao, LH; Polonsky, T; Kibbe, MR; Bazzano, L; Guralnik, JM; Forman, DE; Rego, A; Zhang, DX; Domanchuk, K; Leeuwenburgh, C; Sufit, R; Smith, B; Manini, T; Criqui, MH; Rejeski, WJ				McDermott, Mary M.; Spring, Bonnie; Tian, Lu; Treat-Jacobson, Diane; Ferrucci, Luigi; Lloyd-Jones, Donald; Zhao, Lihui; Polonsky, Tamar; Kibbe, Melina R.; Bazzano, Lydia; Guralnik, Jack M.; Forman, Daniel E.; Rego, Al; Zhang, Dongxue; Domanchuk, Kathryn; Leeuwenburgh, Christiaan; Sufit, Robert; Smith, Brittany; Manini, Todd; Criqui, Michael H.; Rejeski, W. Jack			Effect of Low-Intensity vs High-Intensity Home-Based Walking Exercise on Walk Distance in Patients With Peripheral Artery Disease The LITE Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Question Does a low-intensity (does not induce ischemic leg symptoms) home-based walking exercise intervention improve 6-minute walk distance more than a high-intensity (induces ischemic leg symptoms) home-based walking exercise intervention and does the low-intensity intervention improve 6-minute walk distance more than a nonexercise control (weekly health educational sessions only) among patients with lower-extremity peripheral artery disease (PAD)? Findings In this multicenter randomized clinical trial that included 305 participants with PAD, low-intensity exercise, high-intensity exercise, and nonexercise control resulted in a mean 12-month change in 6-minute walk distance of -6.4 m, 34.5 m, and -15.1 m, respectively. Low-intensity exercise was significantly less effective than high-intensity exercise and was not significantly different from the nonexercise control. Meaning These findings do not support the use of low-intensity walking exercise for patients with PAD. This randomized trial compares the effects of comfortable low-intensity home-based walking exercise vs high-intensity exercise sufficient to elicit ischemic symptoms vs nonexercise control on 6-minute walk distance among patients with peripheral arterial disease (PAD). Importance Supervised high-intensity walking exercise that induces ischemic leg symptoms is the first-line therapy for people with lower-extremity peripheral artery disease (PAD), but adherence is poor. Objective To determine whether low-intensity home-based walking exercise at a comfortable pace significantly improves walking ability in people with PAD vs high-intensity home-based walking exercise that induces ischemic leg symptoms and vs a nonexercise control. Design, Setting, and Participants Multicenter randomized clinical trial conducted at 4 US centers and including 305 participants. Enrollment occurred between September 25, 2015, and December 11, 2019; final follow-up was October 7, 2020. Interventions Participants with PAD were randomized to low-intensity walking exercise (n = 116), high-intensity walking exercise (n = 124), or nonexercise control (n = 65) for 12 months. Both exercise groups were asked to walk for exercise in an unsupervised setting 5 times per week for up to 50 minutes per session wearing an accelerometer to document exercise intensity and time. The low-intensity group walked at a pace without ischemic leg symptoms. The high-intensity group walked at a pace eliciting moderate to severe ischemic leg symptoms. Accelerometer data were viewable to a coach who telephoned participants weekly for 12 months and helped them adhere to their prescribed exercise. The nonexercise control group received weekly educational telephone calls for 12 months. Main Outcomes and Measures The primary outcome was mean change in 6-minute walk distance at 12 months (minimum clinically important difference, 8-20 m). Results Among 305 randomized patients (mean age, 69.3 [SD, 9.5] years, 146 [47.9%] women, 181 [59.3%] Black patients), 250 (82%) completed 12-month follow-up. The 6-minute walk distance changed from 332.1 m at baseline to 327.5 m at 12-month follow-up in the low-intensity exercise group (within-group mean change, -6.4 m [95% CI, -21.5 to 8.8 m]; P = .34) and from 338.1 m to 371.2 m in the high-intensity exercise group (within-group mean change, 34.5 m [95% CI, 20.1 to 48.9 m]; P < .001) and the mean change for the between-group comparison was -40.9 m (97.5% CI, -61.7 to -20.0 m; P < .001). The 6-minute walk distance changed from 328.1 m at baseline to 317.5 m at 12-month follow-up in the nonexercise control group (within-group mean change, -15.1 m [95% CI, -35.8 to 5.7 m]; P = .10), which was not significantly different from the change in the low-intensity exercise group (between-group mean change, 8.7 m [97.5% CI, -17.0 to 34.4 m]; P = .44). Of 184 serious adverse events, the event rate per participant was 0.64 in the low-intensity group, 0.65 in the high-intensity group, and 0.46 in the nonexercise control group. One serious adverse event in each exercise group was related to study participation. Conclusions and Relevance Among patients with PAD, low-intensity home-based exercise was significantly less effective than high-intensity home-based exercise and was not significantly different from the nonexercise control for improving 6-minute walk distance. These results do not support the use of low-intensity home-based walking exercise for improving objectively measured walking performance in patients with PAD.	[McDermott, Mary M.; Spring, Bonnie; Lloyd-Jones, Donald; Zhao, Lihui; Rego, Al; Zhang, Dongxue; Domanchuk, Kathryn; Sufit, Robert; Smith, Brittany] Northwestern Univ, Feinberg Sch Med, 750 N Rubloff, Chicago, IL 60611 USA; [Tian, Lu] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA; [Treat-Jacobson, Diane] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA; [Ferrucci, Luigi] NIA, Div Intramural Res, Bethesda, MD 20892 USA; [Polonsky, Tamar] Univ Chicago, Dept Med, Med Sch, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Kibbe, Melina R.] Univ N Carolina, Sch Med, Dept Surg, Chapel Hill, NC 27515 USA; [Bazzano, Lydia] Tulane Univ, New Orleans, LA 70118 USA; [Guralnik, Jack M.] Univ Maryland, Dept Epidemiol, College Pk, MD 20742 USA; [Forman, Daniel E.] Univ Pittsburgh, Pittsburgh, PA USA; [Leeuwenburgh, Christiaan; Manini, Todd] Univ Florida, Gainesville, FL USA; [Criqui, Michael H.] Univ Calif San Diego, San Diego, CA 92103 USA; [Rejeski, W. Jack] Wake Forest Univ, Winston Salem, NC 27101 USA	Northwestern University; Feinberg School of Medicine; Stanford University; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Chicago; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Tulane University; University System of Maryland; University of Maryland College Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of Florida; University of California System; University of California San Diego; Wake Forest University	McDermott, MM (corresponding author), Northwestern Univ, Feinberg Sch Med, 750 N Rubloff, Chicago, IL 60611 USA.	mdm608@northwestern.edu		Treat-Jacobson, Diane/0000-0003-3296-8764; tian, lu/0000-0002-5893-0169; Lloyd-Jones, Donald/0000-0003-0847-6110				Aboyans V, 2012, CIRCULATION, V126, P2890, DOI 10.1161/CIR.0b013e318276fbcb; Amirhamzeh MMR, 1997, EUR J VASC ENDOVASC, V13, P301, DOI 10.1016/S1078-5884(97)80102-5; Collins TC, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7959; Conte MS, 2015, J VASC SURG, V61, p2S, DOI 10.1016/j.jvs.2014.12.009; Criqui MH, 2015, CIRC RES, V116, P1509, DOI 10.1161/CIRCRESAHA.116.303849; Dua A, 2020, J VASC SURG, V71, P1702, DOI 10.1016/j.jvs.2019.08.238; Fakhry F, 2012, J VASC SURG, V56, P1132, DOI 10.1016/j.jvs.2012.04.046; Frank L, 2014, JAMA-J AM MED ASSOC, V312, P1513, DOI 10.1001/jama.2014.11100; Gardner AW, 2018, VASC MED, V23, P349, DOI 10.1177/1358863X18762599; Gardner AW, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001107; Gardner AW, 2011, CIRCULATION, V123, P491, DOI 10.1161/CIRCULATIONAHA.110.963066; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; Gerhard-Herman MD, 2017, CIRCULATION, V135, pE686, DOI 10.1161/CIR.0000000000000470; Harwood AE, 2016, ANN VASC SURG, V34, P280, DOI 10.1016/j.avsg.2016.02.009; Heun R, 1998, INT J GERIATR PSYCH, V13, P368, DOI 10.1002/(SICI)1099-1166(199806)13:6<368::AID-GPS775>3.3.CO;2-0; McDermott MM, 2020, ARTERIOSCL THROM VAS, V40, P2577, DOI 10.1161/ATVBAHA.120.313831; McDermott MM, 2021, J VASC SURG, V73, P267, DOI 10.1016/j.jvs.2020.03.052; McDermott MM, 2020, CIRC RES, V126, P589, DOI 10.1161/CIRCRESAHA.119.315600; McDermott MM, 2018, JAMA-J AM MED ASSOC, V319, P1665, DOI 10.1001/jama.2018.3275; McDermott MM, 2014, CIRCULATION, V130, P61, DOI 10.1161/CIRCULATIONAHA.114.007002; McDermott MM, 2013, JAMA-J AM MED ASSOC, V310, P57, DOI 10.1001/jama.2013.7231; McDermott M, 2017, JAMA-J AM MED ASSOC, V318, P2089, DOI 10.1001/jama.2017.17437; McDermott MM, 2000, J VASC SURG, V32, P1164, DOI 10.1067/mva.2000.108640; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; Mika P, 2005, AM J PHYS MED REHAB, V84, P756, DOI 10.1097/01.phm.0000176346.94747.49; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Regensteiner JG, 1990, J VASC MED BIOL, V2, P142; Treat-Jacobson D, 2019, CIRCULATION, V139, pE10, DOI 10.1161/CIR.0000000000000623; Vun SV, 2016, J VASC SURG, V64, P1763, DOI 10.1016/j.jvs.2016.06.099; Ward MM, 2014, ARTHRIT CARE RES, V66, P1783, DOI 10.1002/acr.22392; Ware J.E., 1993, SF 36 HLTH SURVEY MA	31	45	44	6	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2021	325	13					1266	1276		10.1001/jama.2021.2536	http://dx.doi.org/10.1001/jama.2021.2536			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK4TM	33821898	Bronze, Green Published			2023-01-03	WOS:000638289800016
J	Chan, EYL; Smullin, C; Clavijo, S; Papp-Green, M; Park, E; Nelson, M; Giarratano, G; Wagman, JA				Chan, Elaine Y. L.; Smullin, Carolyn; Clavijo, Stephanie; Papp-Green, Melissa; Park, Eunhee; Nelson, Marlene; Giarratano, Gloria; Wagman, Jennifer A.			A qualitative assessment of structural barriers to prenatal care and congenital syphilis prevention in Kern County, California	PLOS ONE			English	Article								Congenital syphilis is the result of placental transmission from mother to fetus of Treponema pallidum. Although congenital syphilis is preventable through timely treatment, the rate of new infections in the United States (US) has increased each year since 2013, and is increasing at a noticeably greater pace in California (CA). Most research into congenital syphilis has focused on individual psychosocial and behavioral factors that contribute to maternal vulnerability for syphilis. The aim of this study was to evaluate structural barriers to prenatal care access and utilization and congenital syphilis prevention in Kern County, CA. Transcripts from 8 in-depth interviews with prenatal care providers and 5 focus group discussions with 42 pregnant and postpartum persons were examined using thematic analysis. Structural barriers experienced by pregnant and postpartum persons to prenatal care access and utilization included (1) burdens of poverty; (2) stigma around substance use in pregnancy; (3) citizenship status; (4) lack of healthcare coverage; (5) low sexual health literacy; and (6) gender inequality Structural barriers experienced by prenatal care providers in congenital syphilis prevention included (1) limited guidance on clinical management of syphilis in pregnancy; (2) decay in public health infrastructure; and (3) inadequate support for managing patients' social comorbidities. The response to congenital syphilis prevention will require an examination of the complex context of social determinants of health in which persons diagnosed with syphilis live in.	[Chan, Elaine Y. L.; Smullin, Carolyn; Clavijo, Stephanie] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Clavijo, Stephanie; Park, Eunhee; Wagman, Jennifer A.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90095 USA; [Clavijo, Stephanie] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA; [Papp-Green, Melissa] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA; [Nelson, Marlene] Calif State Univ Bakersfield, Sch Social Sci & Educ, Bakersfield, CA USA; [Giarratano, Gloria] Louisiana State Univ, Sch Nursing, Baton Rouge, LA 70803 USA; [Wagman, Jennifer A.] Univ Calif Los Angeles, Dept Community Hlth Sci, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Charles R. Drew University of Medicine & Science; Los Angeles County Department of Public Health; California State University System; California State University Bakersfield; Louisiana State University System; Louisiana State University; University of California System; University of California Los Angeles	Wagman, JA (corresponding author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90095 USA.; Wagman, JA (corresponding author), Univ Calif Los Angeles, Dept Community Hlth Sci, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.	jennwagman@ucla.edu	Park, Eunee/CAF-4882-2022; Chan, Elaine/GRR-5490-2022	Smullin, Carolyn/0000-0002-0794-5790; Park, Eunhee/0000-0001-6442-8119	March of Dimes; Centers for Disease Control and Prevention [U380T000199-05-00]	March of Dimes(March of Dimes); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	JW received funding by March of Dimes (https://www.marchofdimes.org/) and the Centers for Disease Control and Prevention (https://www.cdc.gov/) (U380T000199-05-00). The views expressed in the report do not necessarily reflect the official policies of the Department of Health and Human Services; nor do they mention trade names, commercial practices, or organizations imply endorsement by the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bernstein Kyle T, 2018, Sex Transm Dis, V45, pS1, DOI 10.1097/OLQ.0000000000000817; Biswas HH, 2018, SEX TRANSM DIS, V45, P435, DOI [10.1097/OLQ.0000000000000782, 10.1097/olq.0000000000000782]; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Bryant A., AMA J ETHICS, V20, P269; ( CDC) CfDC, 2015, MMWR RECOMM REP, V64; Centers for Disease Control and Prevention (CDC), 2019, SEXUALLY TRANSMITTED; DiOrio D, 2018, SEX TRANSM DIS, V45, P447, DOI [10.1097/OLQ.0000000000000783, 10.1097/olq.0000000000000783]; Health CDoP, 2018, CAL SEX TRANSM DIS S; Hollier LM, 2003, AM J OBSTET GYNECOL, V189, P1178, DOI 10.1067/S0002-9378(03)00547-7; Knight KR, 2019, NEW ENGL J MED, V381, P593, DOI 10.1056/NEJMp1907437; Kroeger KA, 2018, SEX TRANSM DIS, V45, P442, DOI [10.1097/OLQ.0000000000000787, 10.1097/olq.0000000000000787]; Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3; Metzl JM, 2014, SOC SCI MED, V103, P126, DOI 10.1016/j.socscimed.2013.06.032; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Papp-Green M, 2018, SOLUTIONS SYPHILLS T, DOI [10.1080/10410236.2018.1431020, DOI 10.1080/10410236.2018.1431020]; Santis M. de, 2012, Infectious Diseases in Obstetrics and Gynecology, V2012, P430585, DOI 10.1155/2012/430585; Smullin C, 2020, SEX TRANS DIS; U.S. Census Bureau, 2018, 2018 NAT STAT POP ES	18	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2021	16	4							e0249419	10.1371/journal.pone.0249419	http://dx.doi.org/10.1371/journal.pone.0249419			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH8NB	33793630	Green Published, gold			2023-01-03	WOS:000636467000009
J	Clement, J; Jacobi, M; Greenwood, BN				Clement, Jeffrey; Jacobi, Maura; Greenwood, Brad N.			Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims	PLOS ONE			English	Article							ADHERENCE; THERAPY	Patient access and adherence to chronic medications is critical. In this work, we evaluate whether disruptions related to Covid-19 have affected new and existing patients' access to pharmacological therapies without interruption. We do so by performing a retrospective analysis on a dataset of 9.4 billion US prescription drug claims from 252 million patients from May, 2019 through August, 2020 (about 93% of prescriptions dispensed within those months). Using fixed effect (conditional likelihood) linear models, we evaluate continuity of care, how many days of supply patients received, and the likelihood of discontinuing therapy for drugs from classes with significant population health impacts. Findings indicate that more prescriptions were filled in March 2020 than in any prior month, followed by a significant drop in monthly dispensing. Compared to the pre-Covid era, a patient's likelihood of discontinuing some medications increased after the spread of Covid: norgestrel-ethinyl estradiol (hormonal contraceptive) discontinuation increased 0.62% (95% CI: 0.59% to 0.65%, p<0.001); dexmethylphenidate HCL (ADHD stimulant treatment) discontinuation increased 2.84% (95% CI: 2.79% to 2.89%, p<0.001); escitalopram oxalate (SSRI antidepressant) discontinuation increased 0.57% (95% CI: 0.561% to 0.578%, p<0.001); and haloperidol (antipsychotic) discontinuation increased 1.49% (95% CI: 1.41% to 1.57%, p<0.001). In contrast, the likelihood of discontinuing tacrolimus (immunosuppressant) decreased 0.15% (95% CI: 0.12% to 0.19%, p<0.001). The likelihood of discontinuing buprenorphine/naloxone (opioid addiction therapy) decreased 0.59% (95% CI: 0.55% to 0.62% decrease, p<0.001). We also observe a notable decline in new patients accessing these latter two therapies. Most US patients were able to access chronic medications during the early months of Covid-19, but still were more likely to discontinue their therapies than in previous months. Further, fewer than normal new patients started taking medications that may be vital to their care. Providers would do well to inquire about adherence and provide prompt, nonjudgmental, re-initiation of medications. From a policy perspective, opioid management programs seem to demonstrate a robust ability to manage existing patients in spite of disruption.	[Clement, Jeffrey] Univ Minnesota, Carlson Sch Management, Informat & Decis Sci, Minneapolis, MN 55455 USA; [Jacobi, Maura] Allina Hlth, United Family Med Residency, St Paul, MN USA; [Greenwood, Brad N.] George Mason Univ, Sch Business, Informat Syst & Operat Management, Arlington, VA USA	University of Minnesota System; University of Minnesota Twin Cities; Allina Health System; George Mason University	Clement, J (corresponding author), Univ Minnesota, Carlson Sch Management, Informat & Decis Sci, Minneapolis, MN 55455 USA.	cleme514@umn.edu	Clement, Jeffrey/J-6883-2019	Clement, Jeffrey/0000-0002-4500-7260				Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; [Anonymous], 2020, SYMPHONY HEALTHCARE; Brancu M, 2016, PSYCHOL TRAUMA-US, V8, P222, DOI 10.1037/tra0000078; Chan SS, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003072; Commission C of MHP, 2018, PRESCR DRUG COUP STU; Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P1049, DOI [10.1101/2020.04.22.20076141v1, 10.15585/mmwr.mm6932a1]; Degli Esposti L, 2020, RISK MANAG HEALTHC P, V13, P3179, DOI 10.2147/RMHP.S265264; Deke J., 2014, MATH POLICY RES REPO, V6, P1; Erin Fox, 2020, AM SOC HLTH SYSTEM P; Felt BT, 2014, AM FAM PHYSICIAN, V90, P456; Giavoli C, 2020, EUR J ENDOCRINOL, V183, pL13, DOI 10.1530/EJE-20-0481; Haley DF, 2020, JAMA-J AM MED ASSOC, V324, P1615, DOI 10.1001/jama.2020.18543; Kaye L, 2020, J ALLER CL IMM-PRACT, V8, P2384, DOI 10.1016/j.jaip.2020.04.053; Mahal SK, 2014, AM J GERIAT PSYCHIAT, V22, pS75, DOI 10.1016/j.jagp.2013.12.083; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Rader R, 2009, AM FAM PHYSICIAN, V79, P657; Rosenbaum J, 2021, AM J EMERG MED, V41, P51, DOI 10.1016/j.ajem.2020.12.047; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Woolhandler S, 2020, ANN INTERN MED, V173, P63, DOI 10.7326/M20-1491; Yang PK, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.190440; Zhang JP, 2013, INT J NEUROPSYCHOPH, V16, P1205, DOI 10.1017/S1461145712001277; Ziedan E., 2020, 27621 NBER	22	25	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2021	16	4							e0249453	10.1371/journal.pone.0249453	http://dx.doi.org/10.1371/journal.pone.0249453			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH8NB	33793663	Green Published, gold			2023-01-03	WOS:000636467000075
J	Pillai, A; Keyes, KM; Susser, E				Pillai, Aravind; Keyes, Katherine M.; Susser, Ezra			Antidepressant prescriptions and adherence in primary care in India: Insights from a cluster randomized control trial	PLOS ONE			English	Article								Background The World Health Organization recommends that treatment of depression in low and middle-income countries with a scarcity of psychiatrists could be done in primary care and should include prescription of antidepressant medications for moderate and severe depression. Little is known, however, about the actual practices of antidepressant prescription by primary care physicians in low and middle-income countries, nor about adherence by people receiving such prescriptions. In a large study of primary care clinics in Goa, India, we examined the relationship of actual to recommended prescribing practices for depression, among all patients who screened positive for common mental disorder. We also examined other patient and clinic characteristics associated with antidepressant prescription, and self-reported adherence over a one-month period. Methods Patients attending 24 primary care clinics were screened for common mental disorders. Those who screened positive were eligible to enroll in a trial to assess the effectiveness of a collaborative stepped care (CSC) intervention for mental disorders. Physicians in the 12 intervention and 12 control clinics (usual care) were free to prescribe antidepressants and follow-up interviews were conducted at 2, 6 and 12 months. Screening results were shared with the physician, but they were blinded to the diagnosis generated later using a standardized diagnostic interview administered by a health counsellor. We categorized these later diagnoses as "moderate/severe depression", "mild depression or non-depression diagnosis", and "no diagnosis". We used a two-level hierarchical logistic regression model to examine diagnostic and other factors associated with antidepressant prescription and one-month adherence. Results Overall, about 47% of screened positive patients (n = 1320) received an antidepressant prescription: 60% of those with moderate/severe depression, 48% of those with mild depression or non-depression diagnosis, and 31% with no diagnosis. Women (OR 1.29; 95%CI 1.04-1.60) and older adults (OR 1.80; 95%CI 1.32-2.47) were more likely to receive an antidepressant prescription. While the overall rate of antidepressant prescription was similar in clinics with and without CSC, patients without any diagnosis were more likely to receive a prescription (OR 2.20 95% CI 1.03-4.70) in the usual care clinics. About 47% of patients adhered to antidepressant treatment for one month or more and adherence was significantly better among older adults (OR 3.92; 95% CI 1.70-8.93) and those who received antidepressant as part of the CSC treatment model (OR 6.10 95% CI 3.67-10.14) compared with those attending the usual care clinic. Conclusion Antidepressants were widely prescribed following screening in primary care, but prescription patterns were in poor accord with WHO recommendations. The data suggest under-prescription for people with moderate/severe depression; over-prescription for people with mild depression or non-depression diagnoses; and over-prescription for people with no disorders. For all diagnoses adherence was low, especially in usual care clinics. To address these concerns, there is an urgent need to study and develop strategies in primary care practices to limit unnecessary antidepressant prescriptions, target prescription for those patients who clearly benefit, and to improve adherence to antidepressant treatment.	[Pillai, Aravind; Keyes, Katherine M.; Susser, Ezra] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10027 USA; [Susser, Ezra] New York State Psychiat Inst & Hosp, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute	Pillai, A (corresponding author), Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10027 USA.	apillai@caa.columbia.edu	Pillai, Aravind/I-7344-2013	Pillai, Aravind/0000-0001-6997-2607	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	The MANAS trial was funded by the Wellcome Trust. However, the authors received no funding for the specific research reported in this article.	Abbing-Karahagopian V, 2014, EUR J CLIN PHARMACOL, V70, P849, DOI 10.1007/s00228-014-1676-z; Andrew Gracy, 2012, BMC Res Notes, V5, P499, DOI 10.1186/1756-0500-5-499; [Anonymous], 2019, POSITION STATEMENT A; Araya R, 2003, LANCET, V361, P995, DOI 10.1016/S0140-6736(03)12825-5; Arroll B, 2016, J PRIM HEALTH CARE, V8, P325, DOI 10.1071/HC16008; Baumeister H, 2012, J AFFECT DISORDERS, V139, P240, DOI 10.1016/j.jad.2011.05.025; Bolton P, 2003, JAMA-J AM MED ASSOC, V289, P3117, DOI 10.1001/jama.289.23.3117; Chatterjee S, 2008, WORLD PSYCHIATRY, V7, P39; Davidson JRT, 1999, J CLIN PSYCHIAT, V60, P4; Dowrick C., 2016, BJPSYCH ADV, V22, P99; Gers L, 2018, THER ADV DRUG SAF, V9, P373, DOI 10.1177/2042098618778974; Goldberg D Williams P., 1988, USERS GUIDE GHQ; Heath I, 1999, BRIT MED J, V318, P439; Hung CI, 2014, CURR OPIN PSYCHIATR, V27, P344, DOI 10.1097/YCO.0000000000000086; Hyde J, 2005, BRIT J GEN PRACT, V55, P755; Jacob K S, 2011, Indian J Psychiatry, V53, P195, DOI 10.4103/0019-5545.86798; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; Maust DT, 2017, PSYCHIAT SERV, V68, P449, DOI 10.1176/appi.ps.201600197; Ministry of Health and Family Welfare Government of India, 2018, NAT MENT HLTH PROGR; National Collaborating Centre for Mental, 2010, DEPR TREATM MAN DEPR; Ngo VK, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001443; Olfson M, 2016, JAMA INTERN MED, V176, P1482, DOI 10.1001/jamainternmed.2016.5057; Organization WH, 2009, MENT HLTH SYST SEL L; Padmanathan P, 2016, EPIDEMIOL PSYCH SCI, V25, P4, DOI 10.1017/S2045796015000803; Patel V, 2008, PSYCHOL MED, V38, P221, DOI 10.1017/S0033291707002334; Patel V., 2012, BRIT J PSYCHIAT, V200, P166; Patel V, 2017, LANCET, V389, P176, DOI 10.1016/S0140-6736(16)31589-6; Patel V, 2010, LANCET, V376, P2086, DOI 10.1016/S0140-6736(10)61508-5; Pereira J, 1999, Indian J Psychiatry, V41, P358; Petrovic M., 2005, PHARMACOTHERAPY DEPR; Rao TSS, 2017, INDIAN J PSYCHIAT, V59, P157, DOI 10.4103/psychiatry.IndianJPsychiatry_202_17; Raykov T, 2015, EDUC PSYCHOL MEAS, V75, P1063, DOI 10.1177/0013164414564052; Reynolds CF, 2017, WORLD PSYCHIATRY, V16, P316, DOI 10.1002/wps.20459; Rivero-Santana A, 2013, PATIENT PREFER ADHER, V7, P151, DOI 10.2147/PPA.S39382; Samples H, 2015, PSYCHIAT SERV, V66, P455, DOI 10.1176/appi.ps.201400021; Sansone Randy A, 2012, Innov Clin Neurosci, V9, P41; Schwenk TL, 1996, GEN HOSP PSYCHIAT, V18, P407, DOI 10.1016/S0163-8343(96)00062-X; WHO, 2016, MHGAP INT GUID VERS; Wong J, 2016, JAMA-J AM MED ASSOC, V315, P2230, DOI 10.1001/jama.2016.3445; World Health Organization, 2017, DEPRESSION OTHER COM; World Health Organization and Calouste Gulbenkian Foundation, 2014, INT RESP MENT DIS OT	41	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2021	16	3							e0248641	10.1371/journal.pone.0248641	http://dx.doi.org/10.1371/journal.pone.0248641			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QZ9HS	33739982	Green Published, gold			2023-01-03	WOS:000631030200024
J	Dougan, M; Luoma, AM; Dougan, SK; Wucherpfennig, KW				Dougan, Michael; Luoma, Adrienne M.; Dougan, Stephanie K.; Wucherpfennig, Kai W.			Understanding and treating the inflammatory adverse events of cancer immunotherapy	CELL			English	Review								During the past decade, immunotherapies have made a major impact on the treatment of diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and Drug Administration (FDA)-approved checkpoint blockade and chimeric antigen receptor (CAR) T cell therapies, but also limit the development and use of combination therapies. Fundamentally, these adverse events highlight the intricate balance of pro- and anti-inflammatory pathways that regulate protective immune responses. Here, we discuss the cellular and molecular mechanisms of inflammatory adverse events, current approaches to treatment, as well as opportunities for the design of immunotherapies that limit such inflammatory toxicities while preserving anti-tumor efficacy.	[Dougan, Michael] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; [Dougan, Michael] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Dougan, Michael] Harvard Med Sch, Boston, MA 02114 USA; [Luoma, Adrienne M.; Dougan, Stephanie K.; Wucherpfennig, Kai W.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, 450 Brookline Ave, Boston, MA 02215 USA; [Luoma, Adrienne M.; Dougan, Stephanie K.; Wucherpfennig, Kai W.] Harvard Med Sch, Dept Immunol, 25 Shattuck St, Boston, MA 02115 USA; [Wucherpfennig, Kai W.] Brigham & Womens Hosp, Dept Neurol, 25 Shattuck St, Boston, MA 02115 USA; [Wucherpfennig, Kai W.] Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Dougan, M (corresponding author), Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.; Dougan, M (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Dougan, M (corresponding author), Harvard Med Sch, Boston, MA 02114 USA.; Wucherpfennig, KW (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & Virol, 450 Brookline Ave, Boston, MA 02215 USA.; Wucherpfennig, KW (corresponding author), Harvard Med Sch, Dept Immunol, 25 Shattuck St, Boston, MA 02115 USA.; Wucherpfennig, KW (corresponding author), Brigham & Womens Hosp, Dept Neurol, 25 Shattuck St, Boston, MA 02115 USA.; Wucherpfennig, KW (corresponding author), Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA.	mldougan@partners.org; kai_wucherpfennig@dfci.harvard.edu			American Cancer Society [MRAT-18-113-01]; Melanoma Research Alliance [597698]; NIH [R01 CA238039, R01CA251599, P01 CA163222, T32CA207021]; NIH Mentored Clinical Scientist Development Award [1K08DK114563-01]; American Gastroenterological Association Research Scholars Award	American Cancer Society(American Cancer Society); Melanoma Research Alliance; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Mentored Clinical Scientist Development Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Gastroenterological Association Research Scholars Award	This work was supported by a Team Award from the American Cancer Society (MRAT-18-113-01), the Melanoma Research Alliance (597698 to K.W.W., S.K.D., and M.D.), NIH (R01 CA238039, R01CA251599, and P01 CA163222 to K.W.W. and T32CA207021 to A.M.L. and K.W.W.), a NIH Mentored Clinical Scientist Development Award (1K08DK114563-01 to M.D.), and the American Gastroenterological Association Research Scholars Award (to M.D.).	Abu-Sbeih H, 2020, J CLIN ONCOL, V38, P576, DOI 10.1200/JCO.19.01674; Abu-Sbeih H, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0461-4; Acharya N, 2020, IMMUNITY, V53, P658, DOI 10.1016/j.immuni.2020.08.005; Alspach E, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a028480; Arbour KC, 2018, J CLIN ONCOL, V36, P2872, DOI 10.1200/JCO.2018.79.0006; Badran YR, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0711-0; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Bertrand F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02358-7; Brudno JN, 2019, BLOOD REV, V34, P45, DOI 10.1016/j.blre.2018.11.002; Cappelli LC, 2017, ARTHRIT CARE RES, V69, P1751, DOI 10.1002/acr.23177; Cavalli G, 2015, RHEUMATOLOGY, V54, P2134, DOI 10.1093/rheumatology/kev269; Charych DH, 2016, CLIN CANCER RES, V22, P680, DOI 10.1158/1078-0432.CCR-15-1631; Cohen JV, 2021, MODERN PATHOL, V34, P426, DOI 10.1038/s41379-020-00653-1; Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119; de Filette J, 2019, HORM METAB RES, V51, P145, DOI 10.1055/a-0843-3366; Deya-Martinez A, 2021, BONE MARROW TRANSPL, V56, P376, DOI 10.1038/s41409-020-01027-6; Dolladille C, 2020, JAMA ONCOL, V6, P865, DOI 10.1001/jamaoncol.2020.0726; Dougan M, 2021, GASTROENTEROLOGY, V160, P1384, DOI 10.1053/j.gastro.2020.08.063; Dougan M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01547; Dougan M, 2017, J CELL BIOCHEM, V118, P3049, DOI 10.1002/jcb.26005; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Esfahani K, 2020, NAT REV CLIN ONCOL, V17, P504, DOI 10.1038/s41571-020-0352-8; Eshhar Z, 2014, CANCER J, V20, P123, DOI 10.1097/PPO.0000000000000027; Faje AT, 2018, CANCER-AM CANCER SOC, V124, P3706, DOI 10.1002/cncr.31629; Fedorov VD, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006597; Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7; Gust J, 2018, CNS DRUGS, V32, P1091, DOI 10.1007/s40263-018-0582-9; Horvat TZ, 2015, J CLIN ONCOL, V33, P3193, DOI 10.1200/JCO.2015.60.8448; Hughes MS, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0756-0; Hui EF, 2017, SCIENCE, V355, P1428, DOI 10.1126/science.aaf1292; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Kalos M, 2013, IMMUNITY, V39, P49, DOI 10.1016/j.immuni.2013.07.002; Keegan A, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000678; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Leonard WJ, 2019, IMMUNITY, V50, P832, DOI 10.1016/j.immuni.2019.03.028; Leonardi GC, 2018, J CLIN ONCOL, V36, P1905, DOI 10.1200/JCO.2017.77.0305; Letourneau S, 2010, P NATL ACAD SCI USA, V107, P2171, DOI 10.1073/pnas.0909384107; Levin AM, 2012, NATURE, V484, P529, DOI 10.1038/nature10975; Linette GP, 2013, BLOOD, V122, P863, DOI 10.1182/blood-2013-03-490565; Luoma AM, 2020, CELL, V182, P655, DOI 10.1016/j.cell.2020.06.001; Marthey L, 2016, J CROHNS COLITIS, V10, P395, DOI 10.1093/ecco-jcc/jjv227; Martins F, 2019, NAT REV CLIN ONCOL, V16, P563, DOI 10.1038/s41571-019-0218-0; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035; Menzies AM, 2017, ANN ONCOL, V28, P368, DOI 10.1093/annonc/mdw443; Mooradian MJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000451; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Morsut L, 2016, CELL, V164, P780, DOI 10.1016/j.cell.2016.01.012; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neurath MF, 2019, CYTOKINE GROWTH F R, V45, P1, DOI 10.1016/j.cytogfr.2018.12.002; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Parker KR, 2020, CELL, V183, P126, DOI 10.1016/j.cell.2020.08.022; Pauken KE, 2019, TRENDS IMMUNOL, V40, P511, DOI 10.1016/j.it.2019.04.002; Phillips GS, 2019, J CLIN ONCOL, V37, P2746, DOI 10.1200/JCO.18.02141; Pollack MH, 2018, ANN ONCOL, V29, P250, DOI 10.1093/annonc/mdx642; Pugliese A, 2017, J CLIN INVEST, V127, P2881, DOI 10.1172/JCI94549; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226; Reynolds K, 2018, ONCOLOGIST, V23, P991, DOI 10.1634/theoncologist.2018-0174; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X; Rosato PC, 2020, CURR OPIN IMMUNOL, V63, P35, DOI 10.1016/j.coi.2020.01.001; Roybal KT, 2016, CELL, V167, P419, DOI 10.1016/j.cell.2016.09.011; Sadelain M, 2013, CANCER DISCOV, V3, P388, DOI 10.1158/2159-8290.CD-12-0548; Safa H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0774-y; Salem JE, 2019, NEW ENGL J MED, V380, P2377, DOI 10.1056/NEJMc1901677; Shiuan E, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0210-0; Silva DA, 2019, NATURE, V565, P186, DOI 10.1038/s41586-018-0830-7; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Smillie CS, 2019, CELL, V178, P714, DOI 10.1016/j.cell.2019.06.029; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Stamatouli A, 2018, DIABETES, V67, P1471, DOI 10.2337/dbi18-0002; Tahir SA, 2019, P NATL ACAD SCI USA, V116, P22246, DOI 10.1073/pnas.1908079116; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Tsang VHM, 2019, J CLIN ENDOCR METAB, V104, P5499, DOI 10.1210/jc.2019-00423; U.S. Food and Drug Administration, 2017, YESCARTA PACKAGE INS; U.S. Food and Drug Administration, 2017, KYMRIAH PRODUCT INFO; Van Belle TL, 2011, PHYSIOL REV, V91, P79, DOI 10.1152/physrev.00003.2010; Verheijden RJ, 2020, CLIN CANCER RES, V26, P2268, DOI 10.1158/1078-0432.CCR-19-3322; Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923; Wucherpfennig KW, 2011, SEMIN IMMUNOL, V23, P84, DOI 10.1016/j.smim.2011.01.007; Zhao YL, 2019, IMMUNITY, V51, P1059, DOI 10.1016/j.immuni.2019.11.003; Zhu EF, 2015, CANCER CELL, V27, P489, DOI 10.1016/j.ccell.2015.03.004	86	28	30	22	89	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 18	2021	184	6					1575	1588		10.1016/j.cell.2021.02.011	http://dx.doi.org/10.1016/j.cell.2021.02.011		MAR 2021	14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QY9LN	33675691	Green Accepted, Bronze			2023-01-03	WOS:000630357400020
J	Lo-Ciganic, WH; Donohue, JM; Hulsey, EG; Barnes, S; Li, Y; Kuza, CC; Yang, QN; Buchanich, J; Huang, JL; Mair, C; Wilson, DL; Gellad, WF				Lo-Ciganic, Wei-Hsuan; Donohue, Julie M.; Hulsey, Eric G.; Barnes, Susan; Li, Yuan; Kuza, Courtney C.; Yang, Qingnan; Buchanich, Jeanine; Huang, James L.; Mair, Christina; Wilson, Debbie L.; Gellad, Walid F.			Integrating human services and criminal justice data with claims data to predict risk of opioid overdose among Medicaid beneficiaries: A machine-learning approach	PLOS ONE			English	Article								Health system data incompletely capture the social risk factors for drug overdose. This study aimed to improve the accuracy of a machine-learning algorithm to predict opioid overdose risk by integrating human services and criminal justice data with health claims data to capture the social determinants of overdose risk. This prognostic study included Medicaid beneficiaries (n = 237,259) in Allegheny County, Pennsylvania enrolled between 2015 and 2018, randomly divided into training, testing, and validation samples. We measured 290 potential predictors (239 derived from Medicaid claims data) in 30-day periods, beginning with the first observed Medicaid enrollment date during the study period. Using a gradient boosting machine, we predicted a composite outcome (i.e., fatal or nonfatal opioid overdose constructed using medical examiner and claims data) in the subsequent month. We compared prediction performance between a Medicaid claims only model to one integrating human services and criminal justice data with Medicaid claims (i.e., integrated model) using several metrics (e.g., C-statistic, number needed to evaluate [NNE] to identify one overdose). Beneficiaries were stratified into risk-score decile subgroups. The samples (training = 79,087, testing = 79,086, validation = 79,086) had similar characteristics (age = 38 +/- 18 years, female = 56%, white = 48%, having at least one overdose = 1.7% during study period). Using the validation sample, the integrated model slightly improved on the Medicaid claims only model (C-statistic = 0.885; 95%CI = 0.877-0.892 vs. C-statistic = 0.871; 95%CI = 0.863-0.878), with small corresponding improvements in the NNE and positive predictive value. Nine of the top 30 most important predictors in the integrated model were human services and criminal justice variables. Using the integrated model, approximately 70% of individuals with overdoses were members of the top risk decile (overdose rates in the subsequent month = 47/10,000 beneficiaries). Few individuals in the bottom 9 deciles had overdose episodes (0-12/10,000). Machine-learning algorithms integrating claims and social service and criminal justice data modestly improved opioid overdose prediction among Medicaid beneficiaries for a large U.S. county heavily affected by the opioid crisis.	[Lo-Ciganic, Wei-Hsuan; Huang, James L.; Wilson, Debbie L.] Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, Gainesville, FL USA; [Lo-Ciganic, Wei-Hsuan; Huang, James L.] Univ Florida, Ctr Drug Evaluat & Safety CoDES, Gainesville, FL USA; [Donohue, Julie M.; Barnes, Susan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA; [Donohue, Julie M.; Barnes, Susan; Kuza, Courtney C.; Yang, Qingnan; Gellad, Walid F.] Univ Pittsburgh, Hlth Policy Inst, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15261 USA; [Hulsey, Eric G.] Vital Strategies, Overdose Prevent Program, Pittsburgh, PA USA; [Hulsey, Eric G.; Li, Yuan] Allegheny Cty Dept Human Serv, Off Analyt Technol & Planning, Pittsburgh, PA USA; [Hulsey, Eric G.; Mair, Christina] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA; [Buchanich, Jeanine] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Buchanich, Jeanine] Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Occupat Biostat & Epidemiol, Pittsburgh, PA USA; [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA; [Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res Promot, Pittsburgh, PA USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Donohue, JM (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA.; Donohue, JM (corresponding author), Univ Pittsburgh, Hlth Policy Inst, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15261 USA.	jdonohue@pitt.edu		Mair, Christina/0000-0003-3841-3313; Wilson, Debbie/0000-0002-1640-5497; Lo-Ciganic, Wei-Hsuan/0000-0001-6590-4770	NIH/NIDA [R01DA044985]; R.K Mellon Foundation [9111]; Graduate School of Public Health at the University of Pittsburgh	NIH/NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); R.K Mellon Foundation; Graduate School of Public Health at the University of Pittsburgh	This study was funded by NIH/NIDA R01DA044985 (W-H L-C, JMD, JLH, CCK, QY, JLH, WFG) https://urldefense.proofpoint.com/v2/url?u=https-3A__www.drugabuse.gov&d= DwIGaQ&c=sJ6xIWYx-zLMB3EPkvcnVg&r= pDlPdDBMHMsG2D-njUbaUVX-AZD70Bprw 27QJ6CMgdc&m=TfH5r-yM8eL7mLF0NSA57GxXwbZ5f-EfhQSCEEacIU&s=lQighfy2qTCJV KgUQsF9JRUuKBK-JFtPa_xgZXqR2vo & e=; R.K Mellon Foundation 9111 (W-H L-C, JMD, SB, CCK, QY, JB, CM, WFG) https://urldefense.proofpoint.com/v2/url?u=https-3A__www.rkmf.org&d= DwIGaQ&c=sJ6xIWYx-zLMB3EPkvcnVg&r= pDlPdDBMHMsG2D-njUbaUVX-AZD70Bprw27 QJ6CMgdc&m=TfH5r-yM8eL7mLF0NSA57GxXwbZ5f-EfhQSCEEacIU&s=2cQQH5XIfqGCk2 rwLOyeoOTlD_gM6vY6_NyEsn1A3YM & e=; and pilot funding from the Dean of the Graduate School of Public Health at the University of Pittsburgh (#N/A) (N/A) https://urldefense.proofpoint.com/v2/url? u=https-3A__publichealth.pitt.edu_home_about_ history-2Dmission-2Dvision_welcome-2Dfrom2Dthe-2Ddean&d=DwIGaQ&c=sJ6xIWYx-zLMB3E PkvcnVg&r=pDlPdDBMHMsG2D-njUbaUVX-AZ D70Bprw27QJ6CMgdc&m=TfH5r-yM8eL7 mLF0NSA57-GxXwbZ5f-EfhQSCEEacIU&s= oRB9UKQ1Ocz910qLtbPLZC6ieBLXM8tBiBHN Wt6caAg&e=. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altekruse SF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227966; Amalakuhan B, 2012, J COMMUNITY HOSP INT, V2, DOI 10.3402/jchimp.v2i1.9915; [Anonymous], 2017, FINAL REPORT DRAFT; Baumblatt JAG, 2014, JAMA INTERN MED, V174, P796, DOI 10.1001/jamainternmed.2013.12711; Becker WC, 2008, DRUG ALCOHOL DEPEN, V94, P38, DOI 10.1016/j.drugalcdep.2007.09.018; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1136/bmj.h5527, 10.1148/radiol.2015151516, 10.1373/clinchem.2015.246280]; Bouskill KE, 2018, US DEP HLTH HUMAN SE; Canan C, 2017, J AM MED INFORM ASSN, V24, P1204, DOI 10.1093/jamia/ocx066; Carey CM, 2018, ANN INTERN MED, V168, P837, DOI 10.7326/M17-3065; Cepeda MS, 2012, DRUG SAFETY, V35, P325, DOI 10.2165/11596600-000000000-00000; Chirikov VV, 2017, MED CARE, V55, pE104, DOI 10.1097/MLR.0000000000000405; Cochran G, 2017, MED CARE, V55, P291, DOI 10.1097/MLR.0000000000000676; Cochran G, 2015, SUBST ABUS, V36, P192, DOI 10.1080/08897077.2014.993491; Coolen P., 2009, Morbidity and Mortality Weekly Report, V58, P1171; Cotto JH, 2010, GENDER MED, V7, P402, DOI 10.1016/j.genm.2010.09.004; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Edlund MJ, 2010, CLIN J PAIN, V26, P1, DOI 10.1097/AJP.0b013e3181b99f35; Fernandes JC, 2015, DRUG ALCOHOL DEPEN, V153, P346, DOI 10.1016/j.drugalcdep.2015.05.032; Ferris LM, 2019, AM J PREV MED, V57, pE211, DOI 10.1016/j.amepre.2019.07.026; Florence CS, 2016, MED CARE, V54, P901, DOI 10.1097/MLR.0000000000000625; Glanz JM, 2018, J GEN INTERN MED, V33, P1646, DOI 10.1007/s11606-017-4288-3; Goyal H, 2017, AM J MED, V130, pE113, DOI 10.1016/j.amjmed.2016.09.022; Green CA, 2017, PHARMACOEPIDEM DR S, V26, P509, DOI 10.1002/pds.4157; Hacker K, 2018, PUBLIC HEALTH REP, V133, P658, DOI 10.1177/0033354918803938; Haffajee RL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6373; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Harle Christopher A, 2018, AMIA Annu Symp Proc, V2018, P527; Hastie T., 2013, ELEMENTS STAT LEARNI, DOI DOI 10.1007/978-0-387-84858-7_16; Hedegaard Holly, 2015, NCHS Data Brief, P1; Hylan TR, 2015, J PAIN, V16, P380, DOI 10.1016/j.jpain.2015.01.011; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Krawczyk N, 2020, DRUG ALCOHOL DEPEN, V213, DOI 10.1016/j.drugalcdep.2020.107997; Liang YY, 2016, PAIN MED, V17, P2268, DOI 10.1093/pm/pnw071; Lo-Ciganic WH, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0968; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Oliva EM, 2017, PSYCHOL SERV, V14, P34, DOI 10.1037/ser0000099; Peirce GL, 2012, MED CARE, V50, P494, DOI 10.1097/MLR.0b013e31824ebd81; Rice JB, 2012, PAIN MED, V13, P1162, DOI 10.1111/j.1526-4637.2012.01450.x; Romero-Brufau S, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0999-1; Rose AJ, 2018, J GEN INTERN MED, V33, P1512, DOI 10.1007/s11606-018-4532-5; Rough K, 2019, PHARMACOEPIDEM DR S, V28, P62, DOI 10.1002/pds.4443; Saito T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118432; Saloner B, 2018, PUBLIC HEALTH REP, V133, p24S, DOI 10.1177/0033354918793627; SAMHSA, 2015, RES 2014 NAT SURV DR; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Smart R, 2018, US DEP HLTH HUMAN SE; Smith SM, 2013, PAIN, V154, P2287, DOI 10.1016/j.pain.2013.05.053; Stopka TJ, 2019, INT J DRUG POLICY, V68, P37, DOI 10.1016/j.drugpo.2019.03.024; Sullivan MD, 2010, PAIN, V150, P332, DOI 10.1016/j.pain.2010.05.020; Thottakkara P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155705; Tuffery S., 2011, DATA MINING STAT DEC; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401; Wachino V., 2016, BEST PRACTICES ADDRE; Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526-4637.2005.00072.x; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x; Wei YJJ, 2019, JAMA-J AM MED ASSOC, V321, P609, DOI 10.1001/jama.2018.20404; White AG, 2009, AM J MANAG CARE, V15, P897; Wood E, 2019, JAMA-J AM MED ASSOC, V322, P1912, DOI 10.1001/jama.2019.15802; Xing J, 2015, OVERDOSE DEATHS MEDI; Yang Z, 2015, J PAIN, V16, P445, DOI 10.1016/j.jpain.2015.01.475; Zedler B, 2015, PAIN MED, V16, P1566, DOI 10.1111/pme.12777; Zedler BK, 2018, PAIN MED, V19, P68, DOI 10.1093/pm/pnx009	64	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0248360	10.1371/journal.pone.0248360	http://dx.doi.org/10.1371/journal.pone.0248360			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QZ9HN	33735222	gold, Green Published			2023-01-03	WOS:000631029700099
J	Donnelly, S; Wilson, AG; Mannan, H; Dix, C; Whitehill, L; Kroll, T				Donnelly, Susie; Wilson, Anthony G.; Mannan, Hasheem; Dix, Claire; Whitehill, Laura; Kroll, Thilo			(In)Visible illness: A photovoice study of the lived experience of self-managing rheumatoid arthritis	PLOS ONE			English	Article							PARTICIPATORY ACTION RESEARCH; QUALITY-OF-LIFE; MANAGEMENT PROGRAM; CHRONIC DISEASE; DISABILITY; IDENTITY; HEALTH; PAIN; OPPORTUNITIES; PERSPECTIVES	Background Chronic illnesses, such as Rheumatoid Arthritis (RA), are a growing burden on health care systems worldwide. Self-management emphasises the patient's central role in managing their illness. This is pertinent given the majority of care is provided by the individual themselves; yet how individuals make sense of self-management in everyday life is largely unseen. Objective The purpose of this study was to capture the strengths and concerns of individuals with RA in self-managing their illness, raise awareness of their lived experience and spark a dialogue among stakeholders. Methods A community-based participatory approach, Photovoice, was adopted. A purposive sample of participants were tasked with taking photographs to represent the challenges and solutions to living with RA. Group workshops and semi-structured interviews were conducted to facilitate reflection, dialogue and analysis. Data analysis followed Braun and Clarke's thematic analysis. Public exhibitions were held throughout the Autumn of 2019. Results Eight women and three men (n = 11) across suburban and urban regions of Ireland were recruited (mean age 57 years, disease duration 4-21 years). Participants identified four main themes which reflected the lived experience of self-managing RA: (i) I'm Here but I'm Not, (ii) Visible Illness, (iii) Medicine in All its Forms, (iv) Mind Yourself. These themes captured the challenge of reduced agency, limited contribution and participation, and a complex relationship between visible and invisible illness. Solutions focused on improving psychological and emotional resilience, particularly through personal reflection and increased agency. Conclusions Our findings suggest that RA is experienced as a fluid relationship between states of masking and surfacing of illness shaped by contextual and situational factors. Photovoice was a highly effective tool to capture and communicate this complexity. Supporting increased agency among individuals with RA to control the (in)visibility of illness and disability can inform the development of future self-management support.	[Donnelly, Susie; Mannan, Hasheem; Kroll, Thilo] Univ Coll Dublin, Ctr Interdisciplinary Res Educ & Innovat Hlth Sys, Sch Nursing Midwifery & Hlth Syst, Dublin, Ireland; [Donnelly, Susie; Wilson, Anthony G.; Whitehill, Laura] Univ Coll Dublin, Sch Med & Med Sci, Conway Inst, Dublin, Ireland; [Mannan, Hasheem] FLAME Univ, Pune, Maharashtra, India	University College Dublin; University College Dublin	Donnelly, S (corresponding author), Univ Coll Dublin, Ctr Interdisciplinary Res Educ & Innovat Hlth Sys, Sch Nursing Midwifery & Hlth Syst, Dublin, Ireland.; Donnelly, S (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Conway Inst, Dublin, Ireland.	susie.donnelly@ucd.ie		Wilson, Anthony Gerard/0000-0003-4855-3926; Donnelly, Susie/0000-0002-0352-3232; Kroll, Thilo/0000-0003-2082-5117	Wellcome Trust Institutional Strategic Support Fund (ISSF); University College Dublin; SFI-HRB-Wellcome Trust Biomedical Research Partnership as part of a Medical Humanities and Social Science Collaboration Scheme [204844/Z/16/Z]	Wellcome Trust Institutional Strategic Support Fund (ISSF)(Wellcome Trust); University College Dublin; SFI-HRB-Wellcome Trust Biomedical Research Partnership as part of a Medical Humanities and Social Science Collaboration Scheme	Funding for this research was awarded to SD under a Wellcome Trust Institutional Strategic Support Fund (ISSF) which was financed jointly by University College Dublin and the SFI-HRB-Wellcome Trust Biomedical Research Partnership as part of a Medical Humanities and Social Science Collaboration Scheme (Grant number 204844/Z/16/Z). This fund provided support in the form of salaries for authors CD and SD, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Alamanos Y, 2005, AUTOIMMUN REV, V4, P130, DOI 10.1016/j.autrev.2004.09.002; Allegrante JP, 2018, HEALTH EDUC BEHAV, V45, P6, DOI 10.1177/1090198117749010; [Anonymous], 2020, BUDGETING INVOLVEMEN; [Anonymous], 2012, ADV VISUAL METHODOLO; [Anonymous], 2006, CONVENTION RIGHTS PE; [Anonymous], 2010, MED ANTROPOLOGIE, P22; [Anonymous], 2008, NORD REV, DOI [DOI 10.1515/nor-2017-0181, DOI 10.1177/0022146510383495]; Armstrong D, 2014, SOCIOL HEALTH ILL, V36, P163, DOI 10.1111/1467-9566.12100; Asbring P, 2003, SOC SCI MED, V57, P711, DOI 10.1016/S0277-9536(02)00420-3; Baker TA, 2006, QUAL HEALTH RES, V16, P1405, DOI 10.1177/1049732306294118; Banks Sarah, 2012, COMMUNITY BASED PART; Barlow JH, 2002, HLTH ED J, V61, P365, DOI DOI 10.1177/001789690206100408; Barsky AJ, 1999, ANN INTERN MED, V130, P910, DOI 10.7326/0003-4819-130-11-199906010-00016; Berger Peter L., 1966, SOCIAL CONSTRUCTION; Birt L, 2016, QUAL HEALTH RES, V26, P1802, DOI 10.1177/1049732316654870; Bodur H, 2006, RHEUMATOL INT, V26, P541, DOI 10.1007/s00296-005-0023-1; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Budig K, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5335-7; Carlson ED, 2006, QUAL HEALTH RES, V16, P836, DOI 10.1177/1049732306287525; Catalani C, 2010, HEALTH EDUC BEHAV, V37, P424, DOI 10.1177/1090198109342084; Caughlin JP, 2009, HEALTH COMMUN, V24, P270, DOI 10.1080/10410230902806070; Central Statistics Office, 2011, CENSUS 2011 POPULATI; Charmaz K, 1995, SOCIOL QUART, V36, P657, DOI 10.1111/j.1533-8525.1995.tb00459.x; Charmaz K. C., 1991, GOOD DAYS BAD DAYS S; Charmaz K, 2010, J INT EDUC BUS, V3, P6, DOI 10.1108/18363261011106858; Chiou AF, 2009, J CLIN NURS, V18, P2206, DOI 10.1111/j.1365-2702.2008.02759.x; Collier J., 1986, VISUAL ANTHR PHOTOGR; Cook JE, 2017, J SOC ISSUES, V73, P359, DOI 10.1111/josi.12221; Daker-White G, 2014, DISABIL REHABIL, V36, P1061, DOI 10.3109/09638288.2013.829531; Dam RF, 2020, AFFINITY DIAGRAMS LE; Dassah E, 2017, QUAL HEALTH RES, V27, P1412, DOI 10.1177/1049732316687731; Defenbaugh NL, 2013, HEALTH COMMUN, V28, P159, DOI 10.1080/10410236.2012.666712; Donnelly S., 2020, SELF MANAGING RHEUMA, DOI [10.7486/DRI.8c980c55x, DOI 10.7486/DRI.8C980C55X]; Donnelly S, 2020, HEALTH EXPECT, V23, P1388, DOI 10.1111/hex.13122; Elzen H, 2007, SOC SCI MED, V64, P1832, DOI 10.1016/j.socscimed.2007.02.008; Evans-Agnew RA, 2016, QUAL HEALTH RES, V26, P1019, DOI 10.1177/1049732315624223; Ewald W., 2000, SECRET GAMES COLLABO; Flanagan EH, 2009, PSYCHIATR REHABIL J, V33, P18, DOI 10.2975/33.1.2009.18.25; Foster-Fishman P, 2005, AM J COMMUN PSYCHOL, V36, P275, DOI 10.1007/s10464-005-8626-y; Fowler FJ, 2011, HEALTH AFFAIR, V30, P699, DOI 10.1377/hlthaff.2011.0003; Fulford J, 2014, PHOTOGRAPHERS PLAYBO; Fusch PI, 2015, QUAL REP, V20, P1408; Goffman Erving, 1963, BEHAV PUBLIC PLACES; Golden T, 2020, QUAL HEALTH RES, V30, P960, DOI 10.1177/1049732320905564; Griffiths C, 2005, BRIT J GEN PRACT, V55, P831; Guba E.G., 1989, 4 GENERATION EVALUAT; Han CS, 2016, HEALTH-LONDON, V20, P110, DOI 10.1177/1363459314567790; HAYS RB, 1993, AIDS, V7, P425, DOI 10.1097/00002030-199303000-00019; Horrell Lindsey N, 2017, Health Mark Q, V34, P268, DOI 10.1080/07359683.2017.1375240; Hoving JL, 2013, RHEUMATOLOGY, V52, P1254, DOI 10.1093/rheumatology/ket111; Hudon C, 2016, FAM PRACT, V33, P167, DOI 10.1093/fampra/cmw007; Hwang EJ, 2004, INT J NURS STUD, V41, P239, DOI 10.1016/S0020-7489(03)00132-9; Hynes G., 2019, CASE 34 RES BECOMES; Meo AI, 2010, INT J QUAL METH, V9, P149, DOI 10.1177/160940691000900203; Jennings H, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1794-8; Joachim G, 2000, J ADV NURS, V32, P243, DOI 10.1046/j.1365-2648.2000.01466.x; Johnston G, 2016, GLOB PUBLIC HEALTH, V11, P799, DOI 10.1080/17441692.2016.1170176; Jones E.E., 1984, SOCIAL STIGMA PSYCHO; Jones MC, 2011, J NURS HEALTHC CHOIN, V3, P174, DOI [DOI 10.1111/J.1752-9824.2011.01096.X, 10.1111/j.1752-9824.2011]; Klocker N, 2015, EMOT SPACE SOC, V17, P37, DOI 10.1016/j.emospa.2015.06.006; Kool MB, 2010, ANN RHEUM DIS, V69, P1990, DOI 10.1136/ard.2009.123224; Kristiansen TM, 2012, MUSCULOSKELET CARE, V10, P29, DOI 10.1002/msc.224; Lal S, 2012, CAN J OCCUP THER, V79, P181, DOI 10.2182/cjot.2012.79.3.8; Lempp H, 2006, CHRONIC ILLN, V2, P109, DOI 10.1179/174592006X110987; Liebenberg L, 2018, INT J QUAL METH, V17, DOI 10.1177/1609406918757631; Lorig K R, 2001, Eff Clin Pract, V4, P256; Lorig K, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00253; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Lucero A, 2015, HUMAN COMPUTER INTER; Maguire, 2000, DOING PARTICIPATORY; Maher C, 2018, INT J QUAL METH, V17, DOI 10.1177/1609406918786362; McIntyre A., 2003, GENDER PLACE CULT, V10, P47, DOI 10.1080/0966369032000052658; Meetoo Danny, 2008, Br J Nurs, V17, P1320; Nault Connors JD, 2019, RES INVOLV ENGAGEM, V5, P39, DOI DOI 10.1186/S40900-019-0166-Y; Ovayolu OU, 2012, J CLIN NURS, V21, P101, DOI 10.1111/j.1365-2702.2011.03710.x; Parameswaran UD, 2020, QUAL SOC WORK, V19, P630, DOI 10.1177/1473325019840394; Petronio S., 2002, BOUNDARIES PRIVACY D; Pollard L, 2005, CLIN EXP RHEUMATOL, V23, pS43; Reason Peter, 2008, SAGE HDB ACTION RES, V2nd; Reavey P., 2011, VISUAL METHODS PSYCH; Ronzi S, 2016, SSM-POPUL HLTH, V2, P732, DOI 10.1016/j.ssmph.2016.09.004; Rose G., 2016, VISUAL METHODOLOGIES; Scheibelhofer E, 2008, INT J SOC RES METHOD, V11, P403, DOI 10.1080/13645570701401370; Scott DL, 2000, RHEUMATOLOGY, V39, P122, DOI 10.1093/rheumatology/39.2.122; Shapira Y, 2010, NAT REV RHEUMATOL, V6, P468, DOI 10.1038/nrrheum.2010.86; She EN, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093294; SHERRER YS, 1986, ARTHRITIS RHEUM, V29, P494, DOI 10.1002/art.1780290406; Sitvast J., 2017, SCI FEDERATION NURSI, V1; Sitvast JE, 2012, HEALTH CARE ANAL, V20, P177, DOI 10.1007/s10728-011-0176-x; Skoy E, 2019, CLIN MED INSIGHTS PS, V10, DOI 10.1177/1179557318821095; Stack RJ, 2012, ANN RHEUM DIS, V71, P493, DOI 10.1136/ard.2011.155416; Strauss AL, 1984, CHRONIC ILLNESS QUAL, Vsecond; Thorne S, 1998, Image J Nurs Sch, V30, P173, DOI 10.1111/j.1547-5069.1998.tb01275.x; Thorne S, 2002, QUAL HEALTH RES, V12, P437, DOI 10.1177/104973202129120007; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Toye F, 2019, BMC RHEUMATOL, V3, DOI 10.1186/s41927-018-0049-0; Turner B., 2008, BODY SOC EXPLORATION, V3rd; Uhm DC, 2012, J KOREAN ACAD NURS, V42, P434, DOI 10.4040/jkan.2012.42.3.434; van den Hoek J, 2017, RHEUMATOL INT, V37, P487, DOI 10.1007/s00296-016-3638-5; Wang C, 1997, HEALTH EDUC BEHAV, V24, P369, DOI 10.1177/109019819702400309; Wang CC, 1999, J WOMENS HEALTH, V8, P185, DOI 10.1089/jwh.1999.8.185; Wang CC, 2001, HEALTH EDUC BEHAV, V28, P560, DOI 10.1177/109019810102800504; Werremeyer A, 2017, QUAL HEALTH RES, V27, P1959, DOI 10.1177/1049732317693221; Wilde L, 2020, PSYCHOL MEN MASCULIN, V21, P309, DOI 10.1037/men0000220; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616; Yi J, 2016, QUAL HEALTH RES, V26, P1044, DOI 10.1177/1049732315599374; Zhao SP, 2015, CLIN RHEUMATOL, V34, P845, DOI 10.1007/s10067-015-2896-z	107	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2021	16	3							e0248151	10.1371/journal.pone.0248151	http://dx.doi.org/10.1371/journal.pone.0248151			32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QU3OZ	33684123	Green Published, gold			2023-01-03	WOS:000627193500016
J	Kantorova, V; Wheldon, MC; Dasgupta, ANZ; Ueffing, P; Castanheira, HC				Kantorova, Vladimira; Wheldon, Mark C.; Dasgupta, Aisha N. Z.; Ueffing, Philipp; Castanheira, Helena Cruz			Contraceptive use and needs among adolescent women aged 15-19: Regional and global estimates and projections from 1990 to 2030 from a Bayesian hierarchical modelling study	PLOS ONE			English	Article							INTERVENTIONS; BEHAVIOR	Expanding access to contraception and ensuring that need for family planning is satisfied are essential for achieving universal access to reproductive healthcare services, as called for in the 2030 Agenda for Sustainable Development. To quantify the gaps that remain in meeting needs among adolescents, this study provides a harmonised data set and global estimates and projections of family planning indicators for adolescents aged 15-19 years. We compiled a comprehensive dataset of family-planning indicators among women aged 15-19 from 754 nationally representative surveys. We used a Bayesian hierarchical model with country-specific annual trends to estimate contraceptive prevalence and unmet need for family planning, with 95% uncertainty intervals (UIs), for 185 countries, taking into account changes in proportions married or in a union and differences in sexual activity among unmarried women across countries. Among 300 million women aged 15-19 years in 2019, 29.8 million (95% UI 24.6-41.7) use any contraception, and 15.0 million (95% UI 12.1-29.2) have unmet need for family planning. Population growth and the postponement of marriage influence trends in the absolute number of adolescents using contraception or experiencing unmet need. Large gaps remain in meeting family-planning needs among adolescents. The proportion of the need satisfied by modern methods, Sustainable Development Goals (SDG) indicator 3.7.1, was 59.2% (95% UI 44.8-67.2) globally among adolescents, lower compared to 75.7% (95% UI 73.2%-78.0%) among all women age 15-49 years. It was less than one half of adolescents in need in Western Asia and Northern Africa (38.7%, 95%UI = 20.9-56.5), Central and Southern Asia (43.5%, 95%UI = 36.6-52.3), and sub-Saharan Africa (45.6%, 95%UI = 42.2-49.0). The main limitations of the study are: (i) the uncertainty surrounding estimates for countries with limited or biased data is large; and (ii) underreporting of contraceptive use and needs is likely, especially among unmarried adolescents.	[Kantorova, Vladimira; Wheldon, Mark C.; Dasgupta, Aisha N. Z.; Ueffing, Philipp] United Nations, Populat Div, Dept Econ & Social Affairs, New York, NY 10017 USA; [Castanheira, Helena Cruz] United Nations, Econ Commiss Latin Amer & Caribbean, Santiago, Chile		Kantorova, V (corresponding author), United Nations, Populat Div, Dept Econ & Social Affairs, New York, NY 10017 USA.	kantorova@un.org	Wheldon, Mark/O-5019-2019	Wheldon, Mark/0000-0002-6897-9644; Kantorova, Vladimira/0000-0002-2960-5930; Dasgupta, Aisha/0000-0003-0945-137X	Bill and Melinda Gates Foundation [OPP1183453, OPP1110679]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	VK, MCW, PU, and ANZD received funding from the Bill and Melinda Gates Foundation at https://www.gatesfoundation.org/(Grants Nos. OPP1183453 and OPP1110679). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AITCHISON J, 1982, J ROY STAT SOC B MET, V44, P139; Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1; Behrman JA, 2018, STUD FAMILY PLANN, V49, P319, DOI 10.1111/sifp.12075; Biddlecom Ann E, 2007, Afr J Reprod Health, V11, P99, DOI 10.2307/25549734; Chandra-Mouli V, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0347-9; Chandra-Mouli V, 2015, GLOB HEALTH-SCI PRAC, V3, P333, DOI 10.9745/GHSP-D-15-00126; Darroch JE, 2016, COSTS BEN M CONTR NE; Darroch JE, 2016, RES GAPS ADOLESCENT, DOI [10.1186/s12978-016-0162-8, DOI 10.1186/S12978-016-0162-8]; Digitale J, 2017, ANN AM ACAD POLIT SS, V669, P93, DOI 10.1177/0002716216678591; FP2030, 2018, MIND GAP COMM DAT GA; GELFAND AE, 1990, J AM STAT ASSOC, V85, P398, DOI 10.2307/2289776; Gelman A., 2013, BAYESIAN DATA ANAL M; Gottschalk LB, 2014, CONTRACEPTION, V90, P211, DOI 10.1016/j.contraception.2014.04.017; Guttmacher Institute, 2018, FACT SHEET; Kantorova V, 2018, 20182 DEP EC SOC AFF; Kantorova V, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003026; Liang MJ, 2019, J ADOLESCENT HEALTH, V65, pS3, DOI 10.1016/j.jadohealth.2019.09.015; MacQuarrie KL., 2017, SEXUAL REPROD HLTH E; MacQuarrieK, 2014, DHS COMP REPORTS; Mensch BS, 2008, STUD FAMILY PLANN, V39, P321, DOI 10.1111/j.1728-4465.2008.00178.x; Mensch BS, 2003, DEMOGRAPHY, V40, P247, DOI 10.1353/dem.2003.0017; Coll CDN, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0686-9; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pawlowsky-Glahn V, 2015, MODELING ANAL COMPOS, P272, DOI [10.1002/9781119003144, DOI 10.1002/9781119003144]; Plummer M., JAGS VERSION 4 2 0; R Core Team, 2021, R LANG ENV STAT COMP; Radovich E, 2018, J ADOLESCENT HEALTH, V62, P273, DOI 10.1016/j.jadohealth.2017.09.013; Scholey J, 2017, DEMOGR RES, V36, P627, DOI 10.4054/DemRes.2017.36.21; Sully E, 2018, FUTURE SCENARIOS ADO; Ueffing P, 2020, J BIOSOC SCI, V52, P860, DOI 10.1017/S002193201900083X; UN, 2015, ARES701 UN, DOI 10.1163/157180910X12665776638740; UN (United Nations), 2019, DEP EC SOC AFF WORLD; United Nations Children's Fund, 2021, PAR AD PROGR GUID PA; United Nations Department of Economic and Social Affairs Population Division, 2017, WORLD MARR DAT 2017; United Nations. Department of Economic and Social Affairs. Population Division, 2019, EST PROJ FAM PLANN I; United Nations Department of Economic and Social Affairs Population Division, 2019, WORLD CONTR US 2019; United Nations Department of Economic and Social Affairs Population Division, 2018, EST PROJ WOM REPR AG	37	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2021	16	3							e0247479	10.1371/journal.pone.0247479	http://dx.doi.org/10.1371/journal.pone.0247479			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QT5BY	33661965	Green Published, gold			2023-01-03	WOS:000626604100028
J	Araujo, BLD				de Castro Araujo, Bruno Luis			Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19	ANNALS OF INTERNAL MEDICINE			English	Letter									[de Castro Araujo, Bruno Luis] Hosp Canc II, Rio De Janeiro, Brazil; [de Castro Araujo, Bruno Luis] Natl Canc Inst Brazil, Rio De Janeiro, Brazil	National Cancer Institute (Inca)	Araujo, BLD (corresponding author), Hosp Canc II, Rio De Janeiro, Brazil.; Araujo, BLD (corresponding author), Natl Canc Inst Brazil, Rio De Janeiro, Brazil.		Araujo, Bruno/U-1267-2018	Araujo, Bruno/0000-0002-9035-136X				Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; Schluger NW, 2020, ANN INTERN MED, V173, P662, DOI 10.7326/M20-5041; Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					433	434		10.7326/L20-1425	http://dx.doi.org/10.7326/L20-1425			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX4DA	33721540				2023-01-03	WOS:000629294000005
J	Marendic, M; Polic, N; Matek, H; Orsulic, L; Polasek, O; Kolcic, I				Marendic, Mario; Polic, Nikolina; Matek, Helena; Orsulic, Lucija; Polasek, Ozren; Kolcic, Ivana			Mediterranean diet assessment challenges: Validation of the Croatian Version of the 14-item Mediterranean Diet Serving Score (MDSS) Questionnaire	PLOS ONE			English	Article								Mediterranean diet (MD) is among the most commonly investigated diets and recognized as one of the healthiest dietary patterns. Due to its complexity, geographical and cultural variations, it also represents a challenge for quantification. The aim of this cross-sectional study was to assess reliability and validity of the Croatian version of the 14-item Mediterranean Diet Serving Score (MDSS), using the Mediterranean Diet Adherence Screener (MEDAS) as the referent test. We included the exploratory sample of 360 medical students, and a confirmatory sample of 299 health studies students from the University of Split, Croatia. Test-retest reliability and validity of the MDSS were tested using intra-class correlation coefficients (ICC), while Cohen's kappa statistic was used to test correct classification of subjects into MD adherent/non-adherent category. A very good reliability was shown for the overall MDSS score (ICC = 0.881 [95% CI 0.843-0.909]), and a moderate reliability for the binary adherence (kappa = 0.584). Concurrent validity of the MDSS was also better when expressed as a total score (ICC = 0.544 [0.439-0.629]) as opposed to the adherence (kappa = 0.223), with similar result in the confirmatory sample (ICC = 0.510 [0.384-0.610]; kappa = 0.216). Disappointingly, only 13.6% of medical students were adherent to the MD according to MDSS, and 19.7% according to the MEDAS questionnaire. Nevertheless, MDSS score was positively correlated with age (rho = 0.179: P = 0.003), self-assessed health perception (rho = 0.123; P = 0.047), and mental well-being (rho = 0.139: P = 0.022). MDSS questionnaire is a short, reliable and reasonably valid instrument, and thus useful for assessing the MD adherence, with better results when used as a numeric score, even in the population with low MD adherence.	[Marendic, Mario] Univ Split, Univ Dept Hlth Studies, Split, Croatia; [Marendic, Mario] Univ Split, Sch Med, Univ Postgrad Doctoral Study Program Evidence Bas, Split, Croatia; [Polic, Nikolina] Inst Emergency Med Split Dalmatia Cty, Split, Croatia; [Matek, Helena] Gen Hosp Sibenik, Shibenik, Croatia; [Orsulic, Lucija] Univ Split, Sch Med, Split, Croatia; [Polasek, Ozren; Kolcic, Ivana] Univ Split, Sch Med, Dept Publ Hlth, Split, Croatia	University of Split; University of Split; University of Split; University of Split	Kolcic, I (corresponding author), Univ Split, Sch Med, Dept Publ Hlth, Split, Croatia.	ikolcic@mefst.hr	Marendić, Mario/AAA-2867-2021; Marendić, Mario/X-5987-2019; Polasek, Ozren/B-6002-2011; Kolcic, Ivana/E-2713-2017	Marendić, Mario/0000-0002-2968-1175; Marendić, Mario/0000-0002-2968-1175; Polasek, Ozren/0000-0002-5765-1862; Kolcic, Ivana/0000-0001-7918-6052				Afshin A, 2019, LANCET, V393, P1958, DOI 10.1016/S0140-6736(19)30041-8; Aidoud A, 2019, NUTR CLIN DIET HOSP, V39, P26, DOI 10.12873/392carrasco; Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; ALTMAN DG, 1994, J NATL CANCER I, V86, P829, DOI 10.1093/jnci/86.11.829; Martinez-Gonzalez MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043134; Antonopoulou M, 2020, INT J HEALTH PLAN M, V35, P5, DOI 10.1002/hpm.2881; Aoun C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218541; Assaf-Balut C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185873; Bach A, 2006, PUBLIC HEALTH NUTR, V9, P132, DOI 10.1079/PHN2005936; Bach-Faig A, 2011, PUBLIC HEALTH NUTR, V14, P2274, DOI 10.1017/S1368980011002515; Bamia C, 2017, CURR DEV NUTR, V1, DOI 10.3945/cdn.116.000075; Baydemir C, 2018, J INT MED RES, V46, P1585, DOI 10.1177/0300060518757158; Boden S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214551; Corella D, 2018, ANNU REV FOOD SCI T, V9, P227, DOI 10.1146/annurev-food-032217-020802; D'Alessandro A, 2018, INT J FOOD SCI NUTR, V69, P647, DOI 10.1080/09637486.2017.1417978; D'Alessandro A, 2015, NUTRIENTS, V7, P7863, DOI 10.3390/nu7095367; Davis C, 2015, NUTRIENTS, V7, P9139, DOI 10.3390/nu7115459; de-Mateo-Silleras B, 2019, J COMMUN HEALTH, V44, P74, DOI 10.1007/s10900-018-0555-4; Dinu M, 2018, EUR J CLIN NUTR, V72, P30, DOI 10.1038/ejcn.2017.58; England CY, 2015, EUR J CLIN NUTR, V69, P977, DOI 10.1038/ejcn.2015.6; Esposito K, 2017, ENDOCRINE, V56, P27, DOI 10.1007/s12020-016-1018-2; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; Fiore M, 2015, EUR J PUBLIC HEALTH, V25, P1019, DOI 10.1093/eurpub/ckv127; Galilea-Zabalza I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198974; Gianfredi V, 2018, ANN IG MED PREV COMU, V30, P470, DOI 10.7416/ai.2018.2258; Gil A, 2015, NUTR HOSP, V31, P128, DOI 10.3305/nh.2015.31.sup3.8761; Gregorio MJ, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051511; Hebestreit K, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3337-y; Ruiz AH, 2015, NUTR HOSP, V32, P1872, DOI 10.3305/nh.2015.32.5.9629; Hren D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017406; Jacka FN, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0791-y; Garcia-Meseguer MJ, 2014, APPETITE, V78, P156, DOI 10.1016/j.appet.2014.03.020; Kline R. B, 2011, PRINCIPLES PRACTICE; Kolcic I, 2016, CROAT MED J, V57, P415, DOI 10.3325/cmj.2016.57.415; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; La Torre G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193360; Liyanage T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159252; Mahdavi-Roshan M, 2018, MEDITERR J NUTR META, V11, P323, DOI 10.3233/MNM-18205; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Mila-Villarroel R, 2011, PUBLIC HEALTH NUTR, V14, P2338, DOI 10.1017/S1368980011002606; Monteagudo C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128594; Navarro-Gonzalez I, 2014, NUTR HOSP, V30, P165, DOI 10.3305/nh.2014.30.1.7413; Olmedo-Requena R, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030488; Panagiotakos DB, 2006, NUTR METAB CARDIOVAS, V16, P559, DOI 10.1016/j.numecd.2005.08.006; Papadaki A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020138; Park MS, 2018, INT J NURS STUD, V79, P58, DOI 10.1016/j.ijnurstu.2017.11.003; Paviic eelj S., 2019, PAEDIATR CROAT, V63, P24, DOI [10.13112/PC.2019.5, DOI 10.13112/PC.2019.5]; Real H, 2020, INT J FOOD SCI NUTR, V71, P1, DOI 10.1080/09637486.2019.1617838; Rees K, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009825.pub3; Ros E, 2014, ADV NUTR, V5, p330S, DOI 10.3945/an.113.005389; Saez-Almendros S, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-118; Salvatore FP, 2019, BRIT FOOD J, V121, P1314, DOI 10.1108/BFJ-06-2018-0339; Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566; Schwingshackl L, 2015, CANCER MED-US, V4, P1933, DOI 10.1002/cam4.539; Stefan L, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040419; Tennant R, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-63; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Veronese N, 2020, NUTR METAB CARDIOVAS, V30, P410, DOI 10.1016/j.numecd.2019.11.003; Wild D, 2005, VALUE HEALTH, V8, P94, DOI 10.1111/j.1524-4733.2005.04054.x; Willett W, 2019, LANCET, V393, P447, DOI 10.1016/S0140-6736(18)31788-4; Zaragoza-Marti A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019033; Zurita-Ortega F, 2018, NUTRIENTS, V10, DOI 10.3390/nu10080966	62	7	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2021	16	3							e0247269	10.1371/journal.pone.0247269	http://dx.doi.org/10.1371/journal.pone.0247269			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QR6LP	33647026	gold, Green Published			2023-01-03	WOS:000625328100017
J	Manyau, PMC; Mabeka, M; Mudzviti, T; Kadzatsa, W; Nyamhunga, A				Manyau, Pinky M. C.; Mabeka, Mensil; Mudzviti, Tinashe; Kadzatsa, Webster; Nyamhunga, Albert			Renal function impairment in cervical cancer patients treated with cisplatin-based chemoradiation: A review of medical records in a Zimbabwean outpatient department	PLOS ONE			English	Review								Background There is a potential increase in risk of renal function impairment among patients with invasive cervical cancer (ICC) who are HIV-positive and treated with cisplatin-based concurrent chemoradiation (CCRT). This concern is due to overlapping nephrotoxicity of the drugs, and nephropathy from the diseases themselves. There is limited literature available for the short-term renal outcomes for HIV-positive patients with ICC during routine clinical management. This study aimed to assess if HIV-infection increased the risk of renal impairment in ICC patients treated with CCRT, and explore the respective risk factors. Materials and methods This was a retrospective review of records of ICC patients treated with at least one cycle of weekly cisplatin during CCRT at the Parirenyatwa Radiotherapy Center from January 2017-December 2018. The RIFLE criteria were used to classify renal impairment. Analyses were performed with Fisher's Exact tests, Wilcoxon rank sum tests. Odds ratios (OR) were generated using logistic regression. All statistical tests were 2-sided at a 5% level of significance. Results Seventy-two eligible patients were identified, 32 (44.44%) were HIV-positive. HIV-positive patients were younger (p = 0.002), had lower albumin levels (p = 0.014) and received lower cisplatin doses (p = 0.044). The mean percent reduction in estimated glomerular filtration rate (eGFR) from baseline was -19% (95% CI: -25.9% to -13.2%) for all patients. Thirty-one (43.1%) patients experienced renal impairment, 50% and 37.5% of HIV-positive and -negative patients respectively (p = 0.287). HIV-infection was associated with an adjusted OR of 1.16 (95% CI 0.35-3.43, p = 0.769). Baseline eGFR< 60ml/min was the only independent predictor of renal impairment, OR 0.25 (95% CI: 0.07-0.85). Baseline eGFR<60ml/min was also associated with receipt of lower cisplatin doses (p = 0.044). Conclusion HIV-infection was not associated with elevated risk of renal impairment. Patients with an eGFR<60ml/min appear to be managed more cautiously reducing their risk for renal impairment during cisplatin therapy. The high prevalence of renal impairment in this population suggests the need for optimization of pre-treatment protocols.	[Manyau, Pinky M. C.; Mabeka, Mensil; Mudzviti, Tinashe] Univ Zimbabwe, Sch Pharm, Harare, Zimbabwe; [Mudzviti, Tinashe] Newlands Clin, Harare, Zimbabwe; [Kadzatsa, Webster; Nyamhunga, Albert] Radiotherapy Ctr, Parirenyatwa Grp Hosp, Harare, Zimbabwe; [Kadzatsa, Webster; Nyamhunga, Albert] Univ Zimbabwe, Dept Radiol, Harare, Zimbabwe	University of Zimbabwe; University of Zimbabwe	Manyau, PMC (corresponding author), Univ Zimbabwe, Sch Pharm, Harare, Zimbabwe.	pinky.manyau@gmail.com		Manyau, Pinky/0000-0002-3772-1018				Andrajati R., 2014, ASIAN PAC J CANCER P, V15; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681; de Jongh FE, 2003, BRIT J CANCER, V88, P1199, DOI 10.1038/sj.bjc.6600884; Einstein MH, 2019, GYNECOL ONCOL, V153, P20, DOI 10.1016/j.ygyno.2019.01.023; Etsebeth M, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw374.40; Fabian J, 2009, NAT REV NEPHROL, V5, P591, DOI 10.1038/nrneph.2009.141; Faig J, 2018, AM J CLIN ONCOL-CANC, V41, P432, DOI 10.1097/COC.0000000000000301; Greystoke AP, 2010, EUR J CANCER CARE, V19, P80, DOI 10.1111/j.1365-2354.2007.00908.x; Hawes SE, 2003, J INFECT DIS, V188, P555, DOI 10.1086/376996; Kurz M, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14135; Lam MSH, 2003, J ONCOL PHARM PRACT, V9, P45, DOI DOI 10.1191/1078155203JP1070A; Liu G, 2018, AIDS, V32, P795, DOI [10.1097/QAD.0000000000001765, 10.1097/qad.0000000000001765]; Loh JM, 2018, CLIN GENITOURIN CANC, V16, P90, DOI 10.1016/j.clgc.2017.08.016; Lopes JA, 2013, CLIN KIDNEY J, V6, P8, DOI 10.1093/ckj/sfs160; Maiman M, 1997, OBSTET GYNECOL, V89, P76, DOI 10.1016/S0029-7844(96)00378-X; Mathew G, 2006, J GEN INTERN MED, V21, pC3, DOI 10.1111/j.1525-1497.2006.00518.x; Mtisi TJ, 2019, AIDS RES THER, V16, DOI 10.1186/s12981-019-0227-1; National Comprehensive Cancer Network, 2019, NCCN GUIDELINES VERS; Ndlovu N, 2003, Cent Afr J Med, V49, P107; Ntekim A, 2015, CANCER MED-US, V4, P1381, DOI 10.1002/cam4.485; Reese MJ, 2013, DRUG METAB DISPOS, V41, P353, DOI 10.1124/dmd.112.048918; T.L.P Chiwanga, 2016, HIV PROFILE PATIENTS; Tharavichitkul E, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2558-9; WHO, 2019, UPD REC 1 2 LIN ANT; Yamamoto Y, 2017, J OBSTET GYNAECOL RE, V43, P1880, DOI 10.1111/jog.13457	26	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2021	16	2							e0245383	10.1371/journal.pone.0245383	http://dx.doi.org/10.1371/journal.pone.0245383			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP2HW	33626044	gold, Green Published			2023-01-03	WOS:000623658100040
J	Naravane, AV; Mundae, R; Zhou, YJ; Santilli, C; van Kuijk, FJGM; Nazari, H; Yamanuha, J; Emerson, GG; Koozekanani, DD; Montezuma, SR				Naravane, Ameay, V; Mundae, Rusdeep; Zhou, Yujia; Santilli, Christopher; van Kuijk, Frederik J. G. M.; Nazari, Hossein; Yamanuha, Justin; Emerson, Geoffrey G.; Koozekanani, Dara D.; Montezuma, Sandra R.			Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study	PLOS ONE			English	Article								Regularly scheduled intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are essential to maintaining and/or improving many ocular conditions including: neovascular age-related macular degeneration (nAMD), diabetic retinopathy, and retinal vein occlusions with macular edema (RVO). This study aims to assess the effect of unintended delays in anti-VEGF treatment during the first wave of the COVID-19 pandemic. This retrospective case series identified patients receiving regularly scheduled anti-VEGF intravitreal injections based on current procedural terminology (CPT) code at two practices in Minnesota. Diagnoses were limited to nAMD, diabetic macular edema (DME), proliferative diabetic retinopathy, and RVO. Patients were divided into two groups based on whether they maintained or delayed their follow-up visit by more than two weeks beyond the recommended treatment interval during the COVID-19 lockdown. The 'COVID-19 lockdown' was defined as the period after March, 28(th), 2020, when a lockdown was declared in Minnesota. We then compared the visual acuity and structural changes to the retina using ocular coherence tomography (OCT) to assess whether delayed treatment resulted in worse visual outcomes. A total of 167 eyes from 117 patients met criteria for inclusion in this study. In the delayed group, the average BCVA at the pre- and post-lockdown visits were 0.614 and 0.715 (logMAR) respectively (p = 0.007). Central subfield thickness (CST) increased from 341 to 447 in the DME delayed group (p = 0.03) while the CST increased from 301 to 314 (p = 0.4) in the nAMD delayed group. The results of this pilot study suggests that treatment delays may have a negative impact on the visual and anatomic outcomes of patients with nAMD and DME. Future studies with larger sample sizes are required for further investigation.	[Naravane, Ameay, V; Mundae, Rusdeep; Zhou, Yujia; van Kuijk, Frederik J. G. M.; Nazari, Hossein; Yamanuha, Justin; Koozekanani, Dara D.; Montezuma, Sandra R.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA; [Santilli, Christopher] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Emerson, Geoffrey G.] Retina Ctr, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Montezuma, SR (corresponding author), Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.	smontezu@umn.edu	Nazari, Hossein/GOK-8161-2022	Nazari, Hossein/0000-0002-8945-9680; Naravane, Ameay/0000-0003-2570-7857	Minnesota Lions Foundation; Knobloch Chair Professorship; VitreoRetinal Surgery 2020 Research Award	Minnesota Lions Foundation; Knobloch Chair Professorship; VitreoRetinal Surgery 2020 Research Award	Funding was provided by the Minnesota Lions Foundation, the Knobloch Chair Professorship (SRM), and VitreoRetinal Surgery 2020 Research Award (AN). The funding organizations had no role in the design or conduct of this research.	Agarwal D, 2020, INDIAN J OPHTHALMOL, V68, P1216, DOI 10.4103/ijo.IJO_1391_20; American Academy of Ophthalmology, LIST URG EM OPHTH PR; American Society of Retina Specialists, 2020, MEMB SURV PREF TREND; [Anonymous], COVID 19 HOSP DEATH; Baek SK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49749-y; Bierschbach Briana, 2020, STAR TRIBUNE; Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018; Centers for Disease Control and Prevention, COVID DAT TRACK; Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9; Greenlee TE, 2021, RETINA-J RET VIT DIS, V41, P581, DOI 10.1097/IAE.0000000000002888; Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032; Huemer J, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2020-000560; Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x; Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055; Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053; Minnesota Department of Public Health, SIT UPD COVID 19; Payne JF, 2017, OPHTHALMOLOGY, V124, P74, DOI 10.1016/j.ophtha.2016.09.021; Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039; Rahimzadeh M, 2020, PHYS, V6, P1; Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Shmeuli O., 2020, EYE, V4, P1; Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4; Williams G., 2014, REV OPHTHALMOL; Yalamanchili SP, 2020, AM J OPHTHALMOL, V219, P215, DOI 10.1016/j.ajo.2020.06.040; Ziemssen F, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0401-y	26	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2021	16	2							e0247161	10.1371/journal.pone.0247161	http://dx.doi.org/10.1371/journal.pone.0247161			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8ME	33596257	Green Published, gold			2023-01-03	WOS:000620633200052
J	Abate, TW; Dessie, G; Workineh, Y; Gedamu, H; Birhanu, M; Ayalew, E; Tirfie, M; Endalamaw, A				Abate, Teshager Weldegiorgis; Dessie, Getenet; Workineh, Yinager; Gedamu, Haileyesus; Birhanu, Minyichil; Ayalew, Emiru; Tirfie, Mulat; Endalamaw, Aklilu			Non-adherence to self-care and associated factors among diabetes adult population in Ethiopian: A systemic review with meta-analysis	PLOS ONE			English	Review							SUB-SAHARAN AFRICA; FOLLOW-UP; MANAGEMENT EDUCATION; NATIONAL STANDARDS; PHYSICAL-ACTIVITY; PUBLIC HOSPITALS; ECONOMIC BURDEN; REGIONAL STATE; BEHAVIORS; ADHERENCE	Background Self-care practice among people with diabetes is not well-implemented in Ethiopia. So far, in Ethiopia, several observational studies have been done on self-care practice and its determinants in people with diabetes. However, a comprehensive review that would have a lot of strong evidence for designing intervention is lacking. So, this review with a meta-analysis was conducted to bridge this gap. Methods A systematic review of an observational study is conducted following the PRISMA checklist. Three reviewers have been searched and extracted from the World Health Organization's Hinari portal (SCOPUS, African Index Medicus, and African Journals Online databases), PubMed, Google Scholar and EMBASE. Articles' quality was assessed using the Newcastle-Ottawa Scale by two independent reviewers, and only studies with low and moderate risk were included in the final analysis. The review presented the pooled proportion of non-adherence to self-care practice in people with diabetes and the odds ratios of risk factors hindering to self-care practice after checking for heterogeneity and publication bias. The review has been registered in PROSPERO with protocol number CRD 42020149478. Results We included 21 primary studies (with 7,134 participants) in this meta-analysis. The pooled proportion of non-adherence to self-care in the diabetes population was 49.91 (95% CI: 44.73-55.08, I-2 = 89.8%). Male (Pooled Odds Ratio (POR): 1.84 95%CI; 1.04-2.64, I-2 = 15.0%), having private glucometer (POR: 2.71; 95%CI: 1.46-3.95, I-2 = 0.0%), short-term Diabetes Mellitus (DM) duration (POR: 3.69; 95%CI: 1.86-5.52, I-2 = 0.0%), DM complication (POR: 2.22; 95%CI: 1.48-2.95, I-2 = 0.0%), treatment satisfaction (POR: 1.8; 95% CI: 1.15-2.44, I-2 = 0.0%), received diabetes self-management education (POR: 2.71; 95% CI: 1.46-3.95, I-2 = 0.0%) and poor self-efficacy (POR: 3.09; 95% CI: 1.70-4.48, I-2 = 0.0%) were statistically significant factors of non-adherence to self-care practice. Conclusions The overall pooled proportion of non-adherence to self-care among adult diabetes in Ethiopia was high. Further works would be needed to improve self-care practice in the diabetes population. So, factors that were identified might help to revise the plan set by the country, and further research might be required to health facility fidelity and each domain of self-care practice according to diabetes self-management guideline.	[Abate, Teshager Weldegiorgis; Dessie, Getenet; Gedamu, Haileyesus; Ayalew, Emiru] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Hlth Sci, Dept Adult Hlth Nursing, Bahir Dar, Ethiopia; [Workineh, Yinager; Birhanu, Minyichil; Endalamaw, Aklilu] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Hlth Sci, Dept Pediat & Child Hlth Nursing, Bahir Dar, Ethiopia; [Tirfie, Mulat] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Nutr & Dietet, Bahir Dar, Ethiopia	Bahir Dar University; Bahir Dar University; Bahir Dar University	Abate, TW (corresponding author), Bahir Dar Univ, Coll Med & Hlth Sci, Sch Hlth Sci, Dept Adult Hlth Nursing, Bahir Dar, Ethiopia.	teshagerhylemarriam@gmail.com	Dessie, Getenet/AHC-4372-2022; Dessie, Getenet/Y-7728-2018; Workineh, Yinager/GZK-4021-2022; Endalamaw, Aklilu/P-3617-2019	Workineh, Yinager/0000-0002-5175-1045; Endalamaw, Aklilu/0000-0002-9121-6549; Bayih, Mulat Tirfie/0000-0003-3735-4892; Abate, Teshager/0000-0003-1742-5403				Abate Teshager Weldegiorgis, 2018, BMC Res Notes, V11, P800, DOI 10.1186/s13104-018-3874-8; ADA Diabetes JC, 2019, STAND MED CAR DIAB 2, V37, P11, DOI DOI 10.2337/CD18-0105; Addisu Y, 2014, ASSESSMENT DIABETIC, V3; Addisu Y, 2014, J METABOLIC SYND, V3; Adu MD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217771; AFCICERO FF, 2020, NUTR METAB CARDIOVAS, DOI DOI 10.1016/J.NUMECD.2020.03.005; Ahern MM, 2007, DIS MANAGE, V10, P347, DOI 10.1089/dis.2007.106709; Al-Amer R, 2016, ISSUES MENT HEALTH N, V37, P744, DOI 10.1080/01612840.2016.1208692; Alemayhu T, 2018, SELF CARE PRACTICES; Alemu S, 1998, DIABETIC MED, V15, P791, DOI 10.1002/(SICI)1096-9136(199809)15:9<791::AID-DIA676>3.3.CO;2-S; Alyaarubi Saif, 2011, Sultan Qaboos Univ Med J, V11, P343; Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS38, DOI 10.2337/dc18-S004; [Anonymous], 2014, WORLD J MED MED SCI, DOI DOI 10.21203/RS.3.RS-104748/V1; [Anonymous], 2006, DETECTING PUBLICATIO; Ansari RM, 2019, CLIN EPIDEMIOL GLOB, V7, P177, DOI 10.1016/j.cegh.2018.04.003; Aschalew AY, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4630-4; Aschalew AY, 2019, SELF CARE PRACTICE A, V12, P1, DOI DOI 10.1186/S13104-019-4630-4; Atun R, 2017, LANCET DIABETES ENDO, V5, P622, DOI 10.1016/S2213-8587(17)30181-X; Austin M, 2005, US ENDOCRINE REV, V2005, P16; Ayele BH, 2019, SAGE OPEN MED, V7, DOI 10.1177/2050312119865646; Ayele K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035515; Beck J, 2018, DIABETES EDUCATOR, V44, P35, DOI 10.1177/0145721718754797; Berhe KK, 2013, ADHERENCE DIABETES S, V3, P211; Berhe KK, 2017, ASSESSMENT SELF CARE; Berhe KK, 2017, GLOBAL J MED RES; Berhe KK, 2013, GREEN J MED SCI, V3, P211, DOI DOI 10.15580/GJMS.2013.6.071813739; Birabwa C, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4535-x; Bommer C, 2018, DIABETES CARE, V41, P963, DOI 10.2337/dc17-1962; Bonger Z, 2018, PATIENT PREFER ADHER, V12, P963, DOI 10.2147/PPA.S156043; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Bosworth H, 2010, IMPROVING PATIENT TREATMENT ADHERENCE: A CLINICIAN'S GUIDE, P1, DOI 10.1007/978-1-4419-5866-2; Chali Segni Wanna, 2018, BMC Res Notes, V11, P833, DOI 10.1186/s13104-018-3939-8; Chaudri NA, 2004, ADHERENCE LONG TERM; Cho NH, 2018, DIABETES RES CLIN PR, V138, P271, DOI 10.1016/j.diabres.2018.02.023; CLARKE S, 2012, DIABETES EDUCATOR, V69, P83; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Dedefo MG, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4258-4; DSouza MS, 2015, GSTF J NURS HLTH CAR, V2; Dube L, 2015, DIABETES EDUCATOR, V41, P69, DOI 10.1177/0145721714558305; Dunachie S, 2019, T ROY SOC TROP MED H, V113, P56, DOI 10.1093/trstmh/try124; Federation ID, 2017, IDF DIABETES ATLAS; Fransen MP, 2012, PATIENT EDUC COUNS, V88, P44, DOI 10.1016/j.pec.2011.11.015; Funnell MM, 2007, DIABETES CARE, V30, P1630, DOI 10.2337/dc07-9923; Getie Mihret A, 2018, THESIS HARAMAYA U; Glasgow RE, 2000, AM J PREV MED, V19, P9, DOI 10.1016/S0749-3797(00)00157-4; Gouda HN, 2019, LANCET GLOB HEALTH, V7, pE1375, DOI 10.1016/S2214-109X(19)30374-2; Gurmu Y, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3448-4; Hagstromer M, 2010, AM J EPIDEMIOL, V171, P1055, DOI 10.1093/aje/kwq069; Hapsari, 2018, J KEPERAWATAN SOEDIR, V13, P71; HARRIS MI, 1993, BRIT J BIOMED SCI, V16, P1116, DOI DOI 10.2337/DIACARE.16.8.1116; Hartweg D, 1991, DOROTHEA OREM SELF C; Health AGDo, 2015, AUSTR NATL DIABETES; Herman W.H., 2017, DIABETES MELLITUS DE, P1; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Islam SMS, 2015, VALUE HEALTH, V18, pA619, DOI 10.1016/j.jval.2015.09.2166; Islam SMS, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000033; Kassahun T, 2016, BMC ENDOCR DISORD, V16, DOI 10.1186/s12902-016-0114-x; Ketema DB, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8425-2; Kirigia JM, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-6; Lemessa F., 2014, THESIS ADDIS ABABA U; Levitt NS, 2008, HEART, V94, P1376, DOI 10.1136/hrt.2008.147306; Luo XP, 2015, INT J ENV RES PUB HE, V12, P11304, DOI 10.3390/ijerph120911304; Mamo M, 2016, DIABETES CHOLEST MET, V1, P101; Mamo M, 2016, CROSS SECTIONAL STUD, V1, P2; Mamo M, 2016, J DIABETES CHOLESTER, V1, P2, DOI [10.1016/j.susc.2004.07.054, DOI 10.1016/J.SUSC.2004.07.054]; Mariye Teklewoini, 2018, BMC Res Notes, V11, P380, DOI 10.1186/s13104-018-3489-0; Mogre V, 2019, J CLIN NURSIG, V28; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Motala AA, 2008, EPIDEMIOLOGY DIABETE, P133; Moucheraud C, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001258; Nagelkerk J, 2006, J ADV NURS, V54, P151, DOI 10.1111/j.1365-2648.2006.03799.x; Nam S, 2011, DIABETES RES CLIN PR, V93, P1, DOI 10.1016/j.diabres.2011.02.002; Ng SW, 2012, OBES REV, V13, P659, DOI 10.1111/j.1467-789X.2011.00982.x; Niguse H, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4072-z; Noshad S, 2015, ANN GLOB HEALTH, V81, P839, DOI 10.1016/j.aogh.2015.10.003; NUCHEBERENGUER B, 2018, J DIABETES RES, V2018, P1, DOI DOI 10.1155/2018/9262395; Nyomba BLG, 2004, DIABETIC MED, V21, P129, DOI 10.1046/j.1464-5491.2003.01070.x; Organization WH, 2003, ADHERENCE LONG TERM; Ovbiagele B, 2015, J NEUROL SCI, V348, P136, DOI 10.1016/j.jns.2014.11.023; Pastakia SD, 2017, DIABETES METAB SYNDR, V10, P247, DOI 10.2147/DMSO.S126314; Rafferty AP, 2019, J PUBLIC HLTH MANAGE; Rajasekhar A, 2011, J THROMB THROMBOLYS, V32, P40, DOI 10.1007/s11239-010-0544-7; RobatSarpooshi D, 2020, PATIENT-RELAT OUTCOM, V11, P129, DOI 10.2147/PROM.S243678; Rubens M, 2018, DIABETES CARE, V41, pE72, DOI 10.2337/dc17-1942; Rustveld LO, 2009, PATIENT PREFER ADHER, V3, P123; Sabat E, 2003, ADHERENCE LONG TERM; Saleh Farzana, 2014, BMC Public Health, V14, P431, DOI 10.1186/1471-2458-14-431; Shrivastava SR, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-14; Smeltzer SC, TXB MED SURG NURSING; Smith M.C., 2015, NURSING THEORIES NUR; Sorato MM, 2016, J DIABETES METAB, V7, DOI 10.4172/2155-6156.1000684; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Stephani V, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6050-0; Tadesse E, 2014, GLOBAL J MED RES, V14, P14; Tadesse E, 2015, ASSESSMENT KNOWLEDGE; Tassew B., 2015, THESIS ADDIS ABABA; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Tiruneh SA, 2019, J DIABETES METAB DIS, V18, P199, DOI 10.1007/s40200-019-00408-z; Whittemore R, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-1035-x; Workneh MH, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1378-6; World Health Organization, 2016, GLOB REP PSOR; World Health Organization, 2018, WORLD HLTH STAT MON; Yeweyenhareg Feleke, 2005, Ethiopian Journal of Health Development, V19, P203	106	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2021	16	2							e0245862	10.1371/journal.pone.0245862	http://dx.doi.org/10.1371/journal.pone.0245862			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH4UN	33566861	gold, Green Published			2023-01-03	WOS:000618271700041
J	Sahni, PS; Singh, K; Sharma, N; Garg, R				Sahni, Pooja Swami; Singh, Kamlesh; Sharma, Nitesh; Garg, Rahul			Yoga an effective strategy for self-management of stress-related problems and wellbeing during COVID19 lockdown: A cross-sectional study	PLOS ONE			English	Article								This cross-sectional research aims to study the effect of yoga practice on the illness perception, and wellbeing of healthy adults during 4-10 weeks of lockdown due to COVID19 outbreak. A total of 668 adults (64.7% males, M = 28.12 years, SD = 9.09 years) participated in the online survey. The participants were grouped as; yoga practitioners, other spiritual practitioners, and non-practitioners based on their responses to daily practices that they follow. Yoga practitioners were further examined based on the duration of practice as; long-term, mid-term and beginners. Multivariate analysis indicates that yoga practitioners had significantly lower depression, anxiety, & stress (DASS), and higher general wellbeing (SWGB) as well as higher peace of mind (POMS) than the other two groups. The results further revealed that the yoga practitioners significantly differed in the perception of personal control, illness concern and emotional impact of COVID19. However, there was no significant difference found for the measure of resilience (BRS) in this study. Yoga practitioners also significantly differed in the cognitive reappraisal strategy for regulating their emotions than the other two groups. Interestingly, it was found that beginners -those who had started practicing yoga only during the lockdown period reported no significant difference for general wellbeing and peace of mind when compared to the mid-term practitioner. Evidence supports that yoga was found as an effective self- management strategy to cope with stress, anxiety and depression, and maintain wellbeing during COVID19 lockdown.	[Sahni, Pooja Swami; Singh, Kamlesh; Sharma, Nitesh; Garg, Rahul] Indian Inst Technol Delhi, Natl Resource Ctr Value Educ Engn, Noida, India; [Singh, Kamlesh] Indian Inst Technol Delhi, Dept Humanities & Social Sci, New Delhi, India; [Garg, Rahul] Indian Inst Technol Delhi, Dept Comp Sci & Engn, New Delhi, India; [Garg, Rahul] Indian Inst Technol Delhi, Amar Nath & Shahsi Khosla Sch Informat Technol, New Delhi, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi	Sahni, PS (corresponding author), Indian Inst Technol Delhi, Natl Resource Ctr Value Educ Engn, Noida, India.	pooja.sahni@nrcvee.iitd.ac.in		Sahni, Pooja/0000-0003-0592-0503; SINGH, KAMLESH/0000-0002-2306-4459				Atkinson NL, 2009, AM J HEALTH BEHAV, V33, P3; Bhatia T, 2020, INT YOGA DAY 2020 WH; Boyraz G, 2020, J LOSS TRAUMA, V25, P503, DOI 10.1080/15325024.2020.1763556; Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020; Bussing A, EVIDENCE BASED COMPL; Cowen VS, 2005, J BODYW MOV THER, V9, P211, DOI 10.1016/j.jbmt.2004.08.001; Davis TJ, 2016, PERS INDIV DIFFER, V96, P115, DOI 10.1016/j.paid.2016.02.080; Desikachar K, 2005, INT J YOGA THER, V15, P17, DOI [10.17761/ijyt.15.1.p501l33535230737, DOI 10.17761/IJYT.15.1.P501L33535230737]; Geuens M, 2002, PSYCHOL REP, V91, P657, DOI 10.2466/PR0.91.6.657-670; Goyal Rajni, 2014, Int J Appl Basic Med Res, V4, P67, DOI 10.4103/2229-516X.136776; Grant AM, 2009, J POSIT PSYCHOL, V4, P396, DOI 10.1080/17439760902992456; Gross J, 2003, NEUROIMAGE, V48, P9, DOI [10.1037/t06463-000, DOI 10.1037/T06463-000, DOI 10.1037/0022-3514.85.2.348]; Gross JJ, 2003, J PERS SOC PSYCHOL, V85, P348, DOI 10.1037/0022-3514.85.2.348; Grossi E, 2019, CULT MED PSYCHIAT, V43, P4, DOI 10.1007/s11013-018-9593-8; Grover S, 2020, INDIAN J PSYCHIAT, V62, P354, DOI 10.4103/psychiatry.IndianJPsychiatry_427_20; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; IGLEWICZ B, 1987, J QUAL TECHNOL, V19, P180, DOI 10.1080/00224065.1987.11979063; Kirkwood G, 2005, BRIT J SPORT MED, V39, P884, DOI 10.1136/bjsm.2005.018069; Lamiani G, 2015, HAEMOPHILIA, V21, P598, DOI 10.1111/hae.12654; Lau R. R., 1983, HEALTH PSYCHOL, V2, P167, DOI [10.1037/0278-6133.2.2.167, DOI 10.1037/0278-6133.2.2.167]; Lee Y-C, 2014, PSYCTESTS DATASET, DOI [10.1037/t32371-000, DOI 10.1037/T32371-000]; Lepherd L, 2020, J RELIG SPIRITUAL A, V32, P306; Leventhal H., 2020, HDB PSYCHOL HLTH, VIV, P219, DOI DOI 10.1201/9781003044307-9; Longo Y, 2017, PERS INDIV DIFFER, V109, P148, DOI 10.1016/j.paid.2017.01.005; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Meyers L. S., 2013, PERFORMING DATA ANAL; Miceli J, 2019, PSYCHO-ONCOLOGY, V28, P1513, DOI 10.1002/pon.5108; Moreira-Almeida A, 2006, REV BRAS PSIQUIATR, V28, P242, DOI 10.1590/S1516-44462006000300018; Nagendra HR, 2020, INT J YOGA, V13, P87, DOI 10.4103/ijoy.IJOY_27_20; Petrie KJ, 2002, PSYCHOSOM MED, V64, P580, DOI 10.1097/00006842-200207000-00007; Rehman U, 2021, COMMUNITY MENT HLT J, V57, P42, DOI 10.1007/s10597-020-00664-x; Segal DL, 2007, AGING MENT HEALTH, V11, P415, DOI 10.1080/13607860600963588; Selamu M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2370-5; Shaikh S, 2013, INDIAN J PHYSIOTHERA, P207, DOI [10.5958/j.0973-5674.7.2.042, DOI 10.5958/J.0973-5674.7.2.042]; Singh K, 2016, INT J INDIAN PSYCHOL, V4, P5, DOI [10.4103/0972-2327.194419, DOI 10.4103/0972-2327.194419]; Singh K., 2014, POSITIVE NATIONS COM; Singh K., 2016, INDIAN J CLIN PSYCHO, V43, P58; Smith BW, 2008, INT J BEHAV MED, V15, P194, DOI 10.1080/10705500802222972; Smith C, 2007, COMPLEMENT THER MED, V15, P77, DOI 10.1016/j.ctim.2006.05.001; Stickley A, 2015, J AFFECT DISORDERS, V178, P142, DOI 10.1016/j.jad.2015.02.020; Tabachnick B., 2007, USING MULTIVARIATE S, V3, P402; Tabachnick B. G., 2007, USING MULTIVARIATE S, V5, P481; Van Hoof E, 2020, WORLD EC FORUM, V9; Vos RC, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0720-y; Williams L, 2011, J PSYCHOSOM RES, V70, P141, DOI 10.1016/j.jpsychores.2010.07.015; Woodyard Catherine, 2011, Int J Yoga, V4, P49, DOI 10.4103/0973-6131.85485; Yusoff MSB, 2013, ASIAN J PSYCHIATR, V6, P60, DOI 10.1016/j.ajp.2012.09.001; Zammuner VL, 2005, INT REV PSYCHIATR, V17, P355, DOI 10.1080/09540260500238348	49	19	19	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2021	16	2							e0245214	10.1371/journal.pone.0245214	http://dx.doi.org/10.1371/journal.pone.0245214			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QH4UN	33566848	Green Published, gold			2023-01-03	WOS:000618271700017
J	Sene, LD; Scarano, WR; Zapparoli, A; Gontijo, JAR; Boer, PA				Sene, Leticia de Barros; Scarano, Wellerson Rodrigo; Zapparoli, Adriana; Rocha Gontijo, Jose Antonio; Boer, Patricia Aline			Impact of gestational low-protein intake on embryonic kidney microRNA expression and in nephron progenitor cells of the male fetus	PLOS ONE			English	Article							INTRAUTERINE GROWTH RESTRICTION; GENE-EXPRESSION; BETA-CATENIN; MESENCHYMAL TRANSITION; METANEPHRIC MESENCHYME; MYC; FETAL; PROLIFERATION; PODOCYTE; LET-7	Background Here, we have demonstrated that gestational low-protein (LP) intake offspring present lower birth weight, reduced nephron numbers, renal salt excretion, arterial hypertension, and renal failure development compared to regular protein (NP) intake rats in adulthood. We evaluated the expression of various miRNAs and predicted target genes in the kidney in gestational 17-days LP (DG-17) fetal metanephros to identify molecular pathways involved in the proliferation and differentiation of renal embryonic or fetal cells. Methods Pregnant Wistar rats were classified into two groups based on protein supply during pregnancy: NP (regular protein diet, 17%) or LP diet (6%). Renal miRNA sequencing (miRNA-Seq) performed on the MiSeq platform, RT-qPCR of predicted target genes, immunohistochemistry, and morphological analysis of 17-DG NP and LP offspring were performed using previously described methods. Results A total of 44 miRNAs, of which 19 were up and 25 downregulated, were identified in 17-DG LP fetuses compared to age-matched NP offspring. We selected 7 miRNAs involved in proliferation, differentiation, and cellular apoptosis. Our findings revealed reduced cell number and Six-2 and c-Myc immunoreactivity in metanephros cap (CM) and ureter bud (UB) in 17-DG LP fetuses. Ki-67 immunoreactivity in CM was 48% lesser in LP compared to age-matched NP fetuses. Conversely, in LP CM and UB, beta-catenin was 154%, and 85% increased, respectively. Furthermore, mTOR immunoreactivity was higher in LP CM (139%) and UB (104%) compared to that in NP offspring. TGF beta-1 positive cells in the UB increased by approximately 30% in the LP offspring. Moreover, ZEB1 metanephros-stained cells increased by 30% in the LP offspring. ZEB2 immunofluorescence, although present in the entire metanephros, was similar in both experimental groups. Conclusions Maternal protein restriction changes the expression of miRNAs, mRNAs, and proteins involved in proliferation, differentiation, and apoptosis during renal development. Renal ontogenic dysfunction, caused by maternal protein restriction, promotes reduced reciprocal interaction between CM and UB; consequently, a programmed and expressive decrease in nephron number occurs in the fetus.	[Sene, Leticia de Barros; Zapparoli, Adriana; Rocha Gontijo, Jose Antonio; Boer, Patricia Aline] Univ Estadual Campinas, Fetal Programming & Hydroelectrolyte Metab Lab, Nucleus Med & Expt Surg, Dept Internal Med,Fac Med Sci, Campinas, SP, Brazil; [Scarano, Wellerson Rodrigo] Sao Paulo State Univ, Biosci Inst, Dept Struct & Funct Biol, Botucatu, SP, Brazil	Universidade Estadual de Campinas; Universidade Estadual Paulista	Boer, PA (corresponding author), Univ Estadual Campinas, Fetal Programming & Hydroelectrolyte Metab Lab, Nucleus Med & Expt Surg, Dept Internal Med,Fac Med Sci, Campinas, SP, Brazil.	boer@fcm.unicamp.br	Boer, Patrícia A/P-4435-2014; Gontijo, José/AAW-2644-2021; Zapparoli, Adriana/ABE-4385-2021	Gontijo, Jose/0000-0002-4658-385X; Scarano, Wellerson Rodrigo/0000-0002-6682-2934	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/12486-5, 2014/50938-8]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [465699/2014-6]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, 2013/12486-5 and 2014/50938-8), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, 465699/2014-6).	Agrogiannis GD, 2014, MOL MED REP, V10, P579, DOI 10.3892/mmr.2014.2258; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ambros V, 2011, CURR OPIN GENET DEV, V21, P511, DOI 10.1016/j.gde.2011.04.003; [Anonymous], 2016, IEEE-ASME T MECH, VPP, P1, DOI DOI 10.1109/IEEESTD.2016.7460875; Bao MH, 2013, INT J MOL SCI, V14, P23086, DOI 10.3390/ijms141123086; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boivin FJ, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00081; Bridgewater D, 2008, DEV BIOL, V317, P83, DOI 10.1016/j.ydbio.2008.02.010; Bridgewater D, 2011, J AM SOC NEPHROL, V22, P718, DOI 10.1681/ASN.2010050562; Brodbeck S, 2004, MECH DEVELOP, V121, P1211, DOI 10.1016/j.mod.2004.05.019; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Cerqueira DM, 2017, FASEB J, V31, P3540, DOI 10.1096/fj.201700010R; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, ANNU REV GENOM HUM G, V8, P215, DOI 10.1146/annurev.genom.8.080706.092351; Chen G, 2010, ONCOL REP, V23, P997, DOI 10.3892/or_00000725; Chen JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080266; Cheng HT, 2003, DEVELOPMENT, V130, P5031, DOI 10.1242/dev.00697; Cheng HT, 2007, DEVELOPMENT, V134, P801, DOI 10.1242/dev.02773; Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83; Chu CY, 2007, J CELL PHYSIOL, V213, P412, DOI 10.1002/jcp.21230; Chu JYS, 2014, AM J PHYSIOL-RENAL, V306, pF764, DOI 10.1152/ajprenal.00426.2013; Copley MR, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.98; Costantini F, 2010, DEV CELL, V18, P698, DOI 10.1016/j.devcel.2010.04.008; Couillard M, 2009, DEV DYNAM, V238, P405, DOI 10.1002/dvdy.21841; Davis EM, 2014, MATERN CHILD HLTH J, V18, P554, DOI 10.1007/s10995-013-1272-3; Ding W, 2010, HEPATOLOGY, V52, P945, DOI 10.1002/hep.23748; Fogelgren B, 2009, AM J PHYSIOL-RENAL, V296, pF1166, DOI 10.1152/ajprenal.90550.2008; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; Guerke J, 2016, REPRODUCTION, V151, P465, DOI 10.1530/REP-15-0523; Harvey SJ, 2008, J AM SOC NEPHROL, V19, P2150, DOI 10.1681/ASN.2008020233; Hendry C, 2011, PEDIATR NEPHROL, V26, P1395, DOI 10.1007/s00467-010-1750-4; Ho J, 2012, J AM SOC NEPHROL, V23, P400, DOI 10.1681/ASN.2011080797; Ho J, 2011, J AM SOC NEPHROL, V22, P1053, DOI 10.1681/ASN.2010080841; Hu MC, 2005, DEVELOPMENT, V132, P215, DOI 10.1242/dev.01573; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Karner CM, 2011, DEVELOPMENT, V138, P1247, DOI 10.1242/dev.057646; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kopan R, 2014, CURR TOP DEV BIOL, V107, P293, DOI 10.1016/B978-0-12-416022-4.00011-1; Langley-Evans SC, 2006, P NUTR SOC, V65, P97, DOI 10.1079/PNS2005478; Li JYZ, 2010, NEPHROLOGY, V15, P599, DOI 10.1111/j.1440-1797.2010.01363.x; Little MH, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008300; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lucas A, 1998, J NUTR, V128, p401S, DOI 10.1093/jn/128.2.401S; Lv XY, 2014, CELL BIOCHEM FUNCT, V32, P571, DOI 10.1002/cbf.3052; Marose TD, 2008, DEV BIOL, V314, P112, DOI 10.1016/j.ydbio.2007.11.016; Marrone AK, 2014, J AM SOC NEPHROL, V25, P1440, DOI 10.1681/ASN.2013040390; Marrone AK, 2014, PEDIATR NEPHROL, V29, P565, DOI 10.1007/s00467-013-2599-0; Menendez-Castro C, 2014, PEDIATR RES, V75, P697, DOI 10.1038/pr.2014.27; Menendez-Castro C, 2013, NEPHROL DIAL TRANSPL, V28, P1407, DOI 10.1093/ndt/gfs517; Mesquita FF, 2010, BRAZ J MED BIOL RES, V43, P1010, DOI [10.1590/S0100-879X2010007500113, 10.1590/S0100-879X2010001100001]; Mesquita FF, 2010, NEPHROL DIAL TRANSPL, V25, P380, DOI 10.1093/ndt/gfp505; Meza-Sosa KF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00175; Monk C, 2012, DEV PSYCHOPATHOL, V24, P1361, DOI 10.1017/S0954579412000764; Mugford JW, 2009, DEV BIOL, V333, P312, DOI 10.1016/j.ydbio.2009.06.043; Nagalakshmi VK, 2015, DEV DYNAM, V244, P444, DOI 10.1002/dvdy.24221; Nagalakshmi VK, 2011, KIDNEY INT, V79, P317, DOI 10.1038/ki.2010.385; Nijland MJ, 2007, J PHYSIOL-LONDON, V579, P643, DOI 10.1113/jphysiol.2006.122101; Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011; Pan CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039151; Pan XC, 2017, DEVELOPMENT, V144, P4173, DOI 10.1242/dev.153700; Phua YL, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12537; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385, DOI 10.1007/BF00849241; Schreuder M, 2006, KIDNEY BLOOD PRESS R, V29, P108, DOI 10.1159/000094538; Schulman BRM, 2005, DEV DYNAM, V234, P1046, DOI 10.1002/dvdy.20599; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sene LB, 2018, J EXP BIOL, V221, DOI 10.1242/jeb.171694; Sene LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071310; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.e07-03-0249; Sun LJ, 2015, MED SCI MONITOR, V21, P195, DOI 10.12659/MSM.892141; Wang P, 2018, CELL REP, V24, P3554, DOI 10.1016/j.celrep.2018.08.056; Wei J, 2014, FREE RADICAL BIO MED, V67, P91, DOI 10.1016/j.freeradbiomed.2013.10.811; Wulczyn FG, 2007, FASEB J, V21, P415, DOI 10.1096/fj.06-6130com; Xiang C, 2016, J HUAZHONG U SCI-MED, V36, P186, DOI 10.1007/s11596-016-1564-0; Yermalovich AV, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08127-4	77	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2021	16	2							e0246289	10.1371/journal.pone.0246289	http://dx.doi.org/10.1371/journal.pone.0246289			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH0TZ	33544723	gold, Green Published, Green Submitted			2023-01-03	WOS:000617991900051
J	Agrafiotis, DK; Yang, E; Littman, GS; Byttebier, G; Dipietro, L; DiBernardo, A; Chavez, JC; Rykman, A; McArthur, K; Hajjar, K; Lees, KR; Volpe, BT; Krams, M; Krebs, HI				Agrafiotis, Dimitris K.; Yang, Eric; Littman, Gary S.; Byttebier, Geert; Dipietro, Laura; DiBernardo, Allitia; Chavez, Juan C.; Rykman, Avrielle; McArthur, Kate; Hajjar, Karim; Lees, Kennedy R.; Volpe, Bruce T.; Krams, Michael; Krebs, Hermano, I			Accurate prediction of clinical stroke scales and improved biomarkers of motor impairment from robotic measurements	PLOS ONE			English	Article							ARM MOVEMENTS; QSAR; TRIALS	Objective One of the greatest challenges in clinical trial design is dealing with the subjectivity and variability introduced by human raters when measuring clinical end-points. We hypothesized that robotic measures that capture the kinematics of human movements collected longitudinally in patients after stroke would bear a significant relationship to the ordinal clinical scales and potentially lead to the development of more sensitive motor biomarkers that could improve the efficiency and cost of clinical trials. Materials and methods We used clinical scales and a robotic assay to measure arm movement in 208 patients 7, 14, 21, 30 and 90 days after acute ischemic stroke at two separate clinical sites. The robots are low impedance and low friction interactive devices that precisely measure speed, position and force, so that even a hemiparetic patient can generate a complete measurement profile. These profiles were used to develop predictive models of the clinical assessments employing a combination of artificial ant colonies and neural network ensembles. Results The resulting models replicated commonly used clinical scales to a cross-validated R-2 of 0.73, 0.75, 0.63 and 0.60 for the Fugl-Meyer, Motor Power, NIH stroke and modified Rankin scales, respectively. Moreover, when suitably scaled and combined, the robotic measures demonstrated a significant increase in effect size from day 7 to 90 over historical data (1.47 versus 0.67). Discussion and conclusion These results suggest that it is possible to derive surrogate biomarkers that can significantly reduce the sample size required to power future stroke clinical trials.	[Agrafiotis, Dimitris K.; Yang, Eric; DiBernardo, Allitia; Krams, Michael] Janssen Res & Dev, Titusville, NJ 08560 USA; [Agrafiotis, Dimitris K.; Yang, Eric] Novartis Inst BioMed Res, Cambridge, MA 02139 USA; [Littman, Gary S.] GSL Stat Consulting, Ardmore, PA USA; [Byttebier, Geert] Bioconstat Bvba, Ghent, Belgium; [Dipietro, Laura; Krebs, Hermano, I] MIT, Dept Mech Engn, Cambridge, MA 02139 USA; [Chavez, Juan C.] Biogen Idec Inc, Cambridge, MA USA; [Rykman, Avrielle] Burke Med Res Inst, New York, NY USA; [McArthur, Kate; Hajjar, Karim; Lees, Kennedy R.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Hajjar, Karim] Univ Duisburg Essen, Dept Neurol, Essen, Germany; [Volpe, Bruce T.] Feinstein Inst Med Res, Manhasset, NY USA	Johnson & Johnson; Janssen Pharmaceuticals; Novartis; Massachusetts Institute of Technology (MIT); Biogen; University of Glasgow; University of Duisburg Essen; Northwell Health	Agrafiotis, DK (corresponding author), Janssen Res & Dev, Titusville, NJ 08560 USA.; Agrafiotis, DK (corresponding author), Novartis Inst BioMed Res, Cambridge, MA 02139 USA.; Krebs, HI (corresponding author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA.	dimitris.agrafiotis@gmail.com; hikrebs@mit.edu		Agrafiotis, Dimitris/0000-0002-5604-5692	Wyeth [6917860]	Wyeth(Wyeth)	This study was funded by a grant from Wyeth to HIK (Grant No. 6917860). Support for this study in the form of salaries was provided by the following: Janssen Research & Development (DA, EY, AD and MK), GSL Statistical Consulting (GL), Bioconstat Bvba (GB), and Biogen-Idec (JC). The specific roles of these authors are articulated in the `author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrafiotis DK, 2007, J CHEM INF MODEL, V47, P1999, DOI 10.1021/ci700267w; Agrafiotis DK, 2002, NAT REV DRUG DISCOV, V1, P337, DOI 10.1038/nrd791; Agrafiotis DK, 2002, P NATL ACAD SCI USA, V99, P15869, DOI 10.1073/pnas.242424399; Agrafiotis DK, 2003, J COMPUT CHEM, V24, P1215, DOI 10.1002/jcc.10234; Agrafiotis DK, 2003, J CHEM INF COMP SCI, V43, P475, DOI 10.1021/ci025631m; Agrafiotis DK, 2002, J CHEM INF COMP SCI, V42, P903, DOI 10.1021/ci0203702; Ali M, 2007, STROKE, V38, P1905, DOI 10.1161/STROKEAHA.106.473579; Alt Murphy M, 2011, NEUROREHAB NEURAL RE, V25, P71, DOI 10.1177/1545968310370748; [Anonymous], 2014, AIDS EX PER NERV SYS; Balasubramanian Sivakumar, 2012, Am J Phys Med Rehabil, V91, pS255, DOI 10.1097/PHM.0b013e31826bcdc1; Bosecker C, 2010, NEUROREHAB NEURAL RE, V24, P62, DOI 10.1177/1545968309343214; Breiman L, 1996, MACH LEARN, V24, P49; Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1007/bf00058655; Colombo R, 2005, IEEE T NEUR SYS REH, V13, P311, DOI 10.1109/TNSRE.2005.848352; Dipietro L, 2007, J NEUROPHYSIOL, V98, P757, DOI 10.1152/jn.01295.2006; Dorigo M., 1997, IEEE Transactions on Evolutionary Computation, V1, P53, DOI 10.1109/4235.585892; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Ferraro M, 2003, NEUROLOGY, V61, P1604, DOI 10.1212/01.WNL.0000095963.00970.68; Ferraro M, 2002, NEUROREHAB NEURAL RE, V16, P283, DOI 10.1177/154596830201600306; FLASH T, 1985, J NEUROSCI, V5, P1688, DOI 10.1523/jneurosci.05-07-01688.1985; Freund Y, 1997, J COMPUT SYST SCI, V55, P119, DOI 10.1006/jcss.1997.1504; Gassert R, 2018, J NEUROENG REHABIL, V15, DOI 10.1186/s12984-018-0383-x; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Glantz SA, 2012, PRIMER BIOSTATISTICS; Goffredo M, 2019, APPL BIONICS BIOMECH, V2019, DOI 10.1155/2019/4251089; Gregson JM, 2000, AGE AGEING, V29, P223, DOI 10.1093/ageing/29.3.223; Haykin S, 1999, NEURAL NETWORKS COMP; Health NI of others. National Institute of Neurological Disorders and Stroke, 2010, STROK SCAL; Hogan N, 2007, EXP BRAIN RES, V181, P13, DOI 10.1007/s00221-007-0899-y; Hogan N, 2011, PROG BRAIN RES, V192, P59, DOI 10.1016/B978-0-444-53355-5.00004-X; Izrailev S, 2002, SAR QSAR ENVIRON RES, V13, P417, DOI 10.1080/10629360290014296; Izrailev S, 2001, J CHEM INF COMP SCI, V41, P176, DOI 10.1021/ci000036s; John G., 1994, P 11 INT C MACH LEAR, P121, DOI [DOI 10.1016/B978-1-55860-335-6.50023-4, 10.1016/B978-1-55860-335-6.50023-4]; Kanzler CM, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0286-7; Kerr DM, 2012, STROKE, V43, P1401, DOI 10.1161/STROKEAHA.111.644484; Kohavi R, 1997, ARTIF INTELL, V97, P273, DOI 10.1016/S0004-3702(97)00043-X; Krabben T, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-15; Krebs H I, 2002, Top Stroke Rehabil, V8, P54; Krebs HI, 2014, STROKE, V45, P200, DOI 10.1161/STROKEAHA.113.002296; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Marsh EB, 2016, NEUROHOSPITALIST, V6, P97, DOI 10.1177/1941874415619964; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; Novak KE, 2002, EXP BRAIN RES, V144, P351, DOI 10.1007/s00221-002-1060-6; Ona ED, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/9758939; RANKIN J, 1957, Scott Med J, V2, P200; Rohrer B, 2002, J NEUROSCI, V22, P8297; Roweis ST, 2000, SCIENCE, V290, P2323, DOI 10.1126/science.290.5500.2323; Team R. C, 2018, R LANG ENV STAT COMP; Tenenbaum JB, 2000, SCIENCE, V290, P2319, DOI 10.1126/science.290.5500.2319; Tikhonov A. N, 1977, SCRIPTA SERIES MATH; WOLPERT DH, 1992, NEURAL NETWORKS, V5, P241, DOI 10.1016/S0893-6080(05)80023-1	52	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2021	16	1							e0245874	10.1371/journal.pone.0245874	http://dx.doi.org/10.1371/journal.pone.0245874			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB1HB	33513170	Green Published, Green Accepted, gold			2023-01-03	WOS:000613891400044
J	Kamath, DY; Bhuvana, KB; Salazar, LJ; Varghese, K; Kamath, A; Idiculla, J; Pais, P; Kulkarni, S; Granger, BB; Xavier, D				Kamath, Deepak Y.; Bhuvana, K. B.; Salazar, Luke Joshua; Varghese, Kiron; Kamath, Anant; Idiculla, Jyoti; Pais, Prem; Kulkarni, Shruthi; Granger, Bradi B.; Xavier, Denis			A qualitative, grounded theory exploration of the determinants of self-care behavior among Indian patients with a lived experience of chronic heart failure	PLOS ONE			English	Article								Background Prior reports have documented extremely poor adherence to evidence-based medications among South Asian patients with established chronic cardiovascular diseases. Treatment adherence is now considered a part of the 'self-care' process, the determinants of which have not been adequately explored or explained among South Asian patients with chronic heart failure (CHF). Our objective was to qualitatively ascertain the determinants of the self-care process among Indian patients with a lived experience of heart failure. Methods We conducted in-depth interviews (audio-recorded) among 22 purposively sampled patients living with chronic heart failure, diagnosed at least 4 weeks prior to the interview and 17 caregivers (n = 39) in a tertiary care teaching hospital in Southern India. We employed an inductive analytical approach using Charmaz's constructivist grounded theory. Initial lineby-line coding and categorization was followed by memo writing, reflexive analysis after interviewing and analyzing four, eight and twelve patients, and at each stage further theoretical sampling was carried out until we reached thematic saturation. We used NVivo ver. 12 to analyze and organize data. Results The mean age of our patients was 61 years and they represented 5 Indian states and spoke seven languages, distributed across socio-economic strata and literacy levels. We classified self-care determinants into 3 broad, simple categories and defined underlying themes namely, negative determinants (passivity, entrenched beliefs, negative affect, lack of knowledge, financial difficulties, and fatalism), intermediate factors (patient expectations, provider/hospital hopping) and facilitators or positive self-care determinants (intrinsic and extrinsic facilitators). Gender and the cultural background of patients' upbringing appear to shape these determinants, thereby affecting self-care decision making in chronic heart failure. Conclusion We have empirically described a unique set of self-care determinants among Indian chronic heart failure patients, which in turn are shaped by economic and socio-cultural factors. Assessing for and addressing these determinants during clinical interactions through multifactorial approaches may help improve self-care among Indian CHF patients, thus improving treatment adherence and clinical outcomes.	[Kamath, Deepak Y.; Bhuvana, K. B.; Xavier, Denis] St Johns Med Coll, Dept Pharmacol, Bengaluru, Karnataka, India; [Kamath, Deepak Y.; Pais, Prem; Xavier, Denis] St Johns Res Inst, Div Clin Res & Training, Koramangala, Bengaluru, India; [Salazar, Luke Joshua] St Johns Med Coll Bengaluru, Dept Psychiat, Bengaluru, Karnataka, India; [Varghese, Kiron] St Johns Med Coll, Dept Cardiol, Bengaluru, Karnataka, India; [Kamath, Anant] Azim Premji Univ, Sch Dev, Bengaluru, Karnataka, India; [Idiculla, Jyoti; Kulkarni, Shruthi] St Johns Med Coll, Dept Internal Med, Bengaluru, Karnataka, India; [Granger, Bradi B.] Duke Univ, Sch Nursing, Durham, NC USA	St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Research Institute; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Medical College; Duke University	Bhuvana, KB (corresponding author), St Johns Med Coll, Dept Pharmacol, Bengaluru, Karnataka, India.	bhuvana.bvn@gmail.com		kamath, deepak/0000-0002-8044-7747; Salazar, Luke Joshua/0000-0002-5164-6771	India Alliance - Department of Biotechnology (DBT)/Wellcome Trust [IA/CPHE/15/1/502053]	India Alliance - Department of Biotechnology (DBT)/Wellcome Trust	This study was funded by the India Alliance - Department of Biotechnology (DBT)/Wellcome Trust as an early career fellowship to Dr. Deepak Y. Kamath (KDY), ref.no. IA/CPHE/15/1/502053. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand S, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1480-9; ANNANDALE E, 1990, SOCIOL HEALTH ILL, V12, P24, DOI 10.1111/1467-9566.ep10844865; Burr V., 1995, INTRO SOCIAL CONSTRU; CHARMAZ K, 1990, SOC SCI MED, V30, P1161, DOI 10.1016/0277-9536(90)90256-R; Chew LD, 2008, J GEN INTERN MED, V23, P561, DOI 10.1007/s11606-008-0520-5; Chiaranai C, 2014, J CARDIOVASC NURS, V29, pE9, DOI 10.1097/JCN.0000000000000105; Dokainish H, 2016, INT J CARDIOL, V204, P133, DOI 10.1016/j.ijcard.2015.11.183; Dressler WW, 2001, MED ANTHROPOL Q, V15, P455, DOI 10.1525/maq.2001.15.4.455; Gadhave S, 2015, INDIAN J PEDIATR, V82, P1175, DOI 10.1007/s12098-015-1753-z; Gautam S, 2010, INDIAN J PSYCHIAT, V52, pS309, DOI 10.4103/0019-5545.69259; Gerstel N, 2001, GENDER SOC, V15, P197, DOI 10.1177/089124301015002003; Huffman MD, 2010, NATL MED J INDIA, V23, P283; Jaarsma Tiny, 2017, Curr Heart Fail Rep, V14, P71, DOI 10.1007/s11897-017-0324-1; Jonkman NH, 2016, CIRCULATION, V133, P1189, DOI 10.1161/CIRCULATIONAHA.115.018006; Kamath D Y, 2020, Wellcome Open Res, V5, P10, DOI 10.12688/wellcomeopenres.15485.1; Kamath DY, 2019, INTERVIEW GUIDE PANA, DOI [10.6084/m9.figshare.11176187.v1, DOI 10.6084/M9.FIGSHARE.11176187.V1]; Kolandaivelu K, 2014, EUR HEART J, V35, P3267, DOI 10.1093/eurheartj/ehu364; Littlejohn S, 2012, ENCY COMMUNICATION T; Lorber J., 2002, GENDER SOCIAL CONSTR; Matlock DD, 2010, J CARD FAIL, V16, P823, DOI 10.1016/j.cardfail.2010.06.003; MILLER B, 1990, J MARRIAGE FAM, V52, P311, DOI 10.2307/353028; RAMANUJAN AK, 1989, CONTRIB INDIAN SOC, V23, P41, DOI 10.1177/006996689023001004; Riegel B, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006997; Riegel B, 2016, J CARDIOVASC NURS, V31, P226, DOI 10.1097/JCN.0000000000000244; Riegel B, 2012, ADV NURS SCI, V35, P194, DOI 10.1097/ANS.0b013e318261b1ba; Sedlar N, 2017, EUR J CARDIOVASC NUR, V16, P272, DOI 10.1177/1474515117691644; Srinivas MN., 2012, REMEMBERED VILLAGE; Stacey M, 2003, SOCIOLOGY HLTH HEALI; Yusuf S, 2011, LANCET, V378, P1231, DOI 10.1016/S0140-6736(11)61215-4	29	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2021	16	1							e0245659	10.1371/journal.pone.0245659	http://dx.doi.org/10.1371/journal.pone.0245659			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QA9GX	33503044	gold, Green Published			2023-01-03	WOS:000613751800018
J	Jerby-Arnon, L; Neftel, C; Shore, ME; Weisman, HR; Mathewson, ND; McBride, MJ; Haas, B; Izar, B; Volorio, A; Boulay, G; Cironi, L; Richman, AR; Broye, LC; Gurski, JM; Luo, CC; Mylvaganam, R; Nguyen, L; Mei, SL; Melms, JC; Georgescu, C; Cohen, O; Buendia-Buendia, JE; Segerstolpe, A; Sud, M; Cuoco, MS; Labes, D; Gritsch, S; Zollinger, DR; Ortogero, N; Beechem, JM; Nielsen, GP; Chebib, I; Nguyen-Ngoc, T; Montemurro, M; Cote, GM; Choy, E; Letovanec, I; Cherix, S; Wagle, N; Sorger, PK; Haynes, AB; Mullen, JT; Stamenkovic, I; Rivera, MN; Kadoch, C; Wucherpfennig, KW; Rozenblatt-Rosen, O; Suva, ML; Riggi, N; Regev, A				Jerby-Arnon, Livnat; Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Mathewson, Nathan D.; McBride, Matthew J.; Haas, Brian; Izar, Benjamin; Volorio, Angela; Boulay, Gaylor; Cironi, Luisa; Richman, Alyssa R.; Broye, Liliane C.; Gurski, Joseph M.; Luo, Christina C.; Mylvaganam, Ravindra; Nguyen, Lan; Mei, Shaolin; Melms, Johannes C.; Georgescu, Christophe; Cohen, Ofir; Buendia-Buendia, Jorge E.; Segerstolpe, Asa; Sud, Malika; Cuoco, Michael S.; Labes, Danny; Gritsch, Simon; Zollinger, Daniel R.; Ortogero, Nicole; Beechem, Joseph M.; Petur Nielsen, G.; Chebib, Ivan; Nguyen-Ngoc, Tu; Montemurro, Michael; Cote, Gregory M.; Choy, Edwin; Letovanec, Igor; Cherix, Stephane; Wagle, Nikhil; Sorger, Peter K.; Haynes, Alex B.; Mullen, John T.; Stamenkovic, Ivan; Rivera, Miguel N.; Kadoch, Cigall; Wucherpfennig, Kai W.; Rozenblatt-Rosen, Orit; Suva, Mario L.; Riggi, Nicolo; Regev, Aviv			Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma	NATURE MEDICINE			English	Article							RNA-SEQ; WHOLE-EXOME; T-CELLS; SINGLE; EXPRESSION; DISCOVERY; MELANOMA; INSIGHTS; TUMORS; FUSION	Single-cell transcriptional profiling of primary human synovial sarcoma tumors suggests that combinatorial treatment with HDAC and CDK4/CDK6 inhibitors could enhance tumor immunogenicity. Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18-SSX fusion, and is characterized by low T cell infiltration. Here, we studied the cancer-immune interplay in SyS using an integrative approach that combines single-cell RNA sequencing (scRNA-seq), spatial profiling and genetic and pharmacological perturbations. scRNA-seq of 16,872 cells from 12 human SyS tumors uncovered a malignant subpopulation that marks immune-deprived niches in situ and is predictive of poor clinical outcomes in two independent cohorts. Functional analyses revealed that this malignant cell state is controlled by the SS18-SSX fusion, is repressed by cytokines secreted by macrophages and T cells, and can be synergistically targeted with a combination of HDAC and CDK4/CDK6 inhibitors. This drug combination enhanced malignant-cell immunogenicity in SyS models, leading to induced T cell reactivity and T cell-mediated killing. Our study provides a blueprint for investigating heterogeneity in fusion-driven malignancies and demonstrates an interplay between immune evasion and oncogenic processes that can be co-targeted in SyS and potentially in other malignancies.	[Jerby-Arnon, Livnat] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Jerby-Arnon, Livnat] Chan Zuckerberg Biohub, San Francisco, CA USA; [Jerby-Arnon, Livnat; Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Haas, Brian; Izar, Benjamin; Volorio, Angela; Boulay, Gaylor; Richman, Alyssa R.; Nguyen, Lan; Georgescu, Christophe; Cohen, Ofir; Segerstolpe, Asa; Sud, Malika; Cuoco, Michael S.; Gritsch, Simon; Wagle, Nikhil; Rivera, Miguel N.; Kadoch, Cigall; Wucherpfennig, Kai W.; Rozenblatt-Rosen, Orit; Suva, Mario L.; Regev, Aviv] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA; [Jerby-Arnon, Livnat; Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Haas, Brian; Richman, Alyssa R.; Cohen, Ofir; Gritsch, Simon; Rozenblatt-Rosen, Orit; Suva, Mario L.; Regev, Aviv] Broad Inst Harvard & MIT, Klarman Cell Observ, Cambridge, MA 02142 USA; [Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Volorio, Angela; Boulay, Gaylor; Richman, Alyssa R.; Luo, Christina C.; Mylvaganam, Ravindra; Gritsch, Simon; Petur Nielsen, G.; Rivera, Miguel N.; Suva, Mario L.; Riggi, Nicolo] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Volorio, Angela; Boulay, Gaylor; Richman, Alyssa R.; Luo, Christina C.; Mylvaganam, Ravindra; Gritsch, Simon; Petur Nielsen, G.; Rivera, Miguel N.; Suva, Mario L.; Riggi, Nicolo] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA; [Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; McBride, Matthew J.; Volorio, Angela; Boulay, Gaylor; Richman, Alyssa R.; Luo, Christina C.; Mylvaganam, Ravindra; Cohen, Ofir; Buendia-Buendia, Jorge E.; Gritsch, Simon; Petur Nielsen, G.; Rivera, Miguel N.; Suva, Mario L.; Riggi, Nicolo] Harvard Med Sch, Boston, MA 02115 USA; [Neftel, Cyril; Cironi, Luisa; Broye, Liliane C.; Letovanec, Igor; Stamenkovic, Ivan; Riggi, Nicolo] CHU Vaudois, Inst Pathol, Fac Biol & Med, Lausanne, Switzerland; [Mathewson, Nathan D.; Wucherpfennig, Kai W.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA; [Mathewson, Nathan D.; Wucherpfennig, Kai W.] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA; [Mathewson, Nathan D.] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA; [McBride, Matthew J.; Kadoch, Cigall] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Izar, Benjamin; Melms, Johannes C.] Columbia Ctr Translat Immunol, New York, NY USA; [Izar, Benjamin; Melms, Johannes C.] Columbia Univ, Med Ctr, Div Hematol & Oncol, New York, NY USA; [Gurski, Joseph M.; Chebib, Ivan] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Mei, Shaolin; Sorger, Peter K.] Harvard Med Sch, Lab Syst Pharmacol, Boston, MA 02115 USA; [Cohen, Ofir; Buendia-Buendia, Jorge E.; Wagle, Nikhil] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Cuoco, Michael S.] Univ Calif San Diego, Bioinformat & Syst Biol Grad Program, La Jolla, CA 92093 USA; [Labes, Danny] Univ Lausanne, Flow Cytometry Facil, Dept Biol & Med, Lausanne, Switzerland; [Zollinger, Daniel R.; Ortogero, Nicole; Beechem, Joseph M.] NanoString Technol, Seattle, WA USA; [Nguyen-Ngoc, Tu; Montemurro, Michael] Univ Lausanne, Dept Oncol, Ctr Hosp Univ Vaudois, Lausanne, Switzerland; [Cote, Gregory M.; Choy, Edwin] Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA; [Cherix, Stephane] CHU Vaudois, Fac Biol & Med, Dept Orthoped, Lausanne, Switzerland; [Haynes, Alex B.; Mullen, John T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Regev, Aviv] MIT, Howard Hughes Med Inst, Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA 02139 USA; [Rozenblatt-Rosen, Orit; Regev, Aviv] Genentech Inc, San Francisco, CA 94080 USA	Stanford University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Columbia University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of California System; University of California San Diego; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Harvard University; Massachusetts General Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Roche Holding; Genentech	Suva, ML; Regev, A (corresponding author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.; Suva, ML; Regev, A (corresponding author), Broad Inst Harvard & MIT, Klarman Cell Observ, Cambridge, MA 02142 USA.; Suva, ML; Riggi, N (corresponding author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.; Suva, ML; Riggi, N (corresponding author), Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.; Suva, ML; Riggi, N (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Riggi, N (corresponding author), CHU Vaudois, Inst Pathol, Fac Biol & Med, Lausanne, Switzerland.; Regev, A (corresponding author), MIT, Howard Hughes Med Inst, Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA 02139 USA.; Regev, A (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.	Suva.Mario@mgh.harvard.edu; nicolo.riggi@chuv.ch; aregev@broadinstitute.org	Montemurro, Michael/GQH-8271-2022; Rozenblatt-Rosen, Orit/HDN-4182-2022	Mathewson, Nathan/0000-0002-8895-2609; Melms, Johannes/0000-0002-5410-6586; Nguyen-Ngoc, Tu/0000-0001-7574-2947; Mei, Shaolin/0000-0002-2193-764X	CRI; NCI [1U24CA180922, R33-CA202820]; Koch Institute NCI Support (core) grant [P30-CA14051]; Ludwig Centers at Harvard and MIT; AMRF; Broad Institute; Howard Goodman Fellowship at MGH; Merkin Institute Fellowship at the Broad Institute of MIT and Harvard; Swiss National Science Foundation Sinergia grant [CRSII5_177266]; Center for Cancer Systems Pharmacology at Harvard Medical School [CA225088]; Burroughs Wellcome Fund Career Award for Medical Scientists; Louis V. Gerstner, Jr. Scholars Program; Velocity Fellow Program; Swiss National Science Foundation Professorship grant [PP00P3-157468/1, PP00P3_183724]; Swiss Cancer League [KFS-3973-08-2016]; Fond'Action Contre le Cancer grant; FORCE grant; American Cancer Society [PF-17-042-01-LIB]; NIH - NCI [L30 CA231679-01]; Thomas and Diana Ryan MGH Research Scholar Award; Klarman Cell Observatory; STARR cancer consortium; Scientific Interface from BWF;  [K08CA222663];  [R37CA245523]	CRI; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Koch Institute NCI Support (core) grant; Ludwig Centers at Harvard and MIT; AMRF; Broad Institute; Howard Goodman Fellowship at MGH; Merkin Institute Fellowship at the Broad Institute of MIT and Harvard; Swiss National Science Foundation Sinergia grant(Swiss National Science Foundation (SNSF)); Center for Cancer Systems Pharmacology at Harvard Medical School; Burroughs Wellcome Fund Career Award for Medical Scientists(Burroughs Wellcome Fund); Louis V. Gerstner, Jr. Scholars Program; Velocity Fellow Program; Swiss National Science Foundation Professorship grant; Swiss Cancer League; Fond'Action Contre le Cancer grant; FORCE grant; American Cancer Society(American Cancer Society); NIH - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Thomas and Diana Ryan MGH Research Scholar Award; Klarman Cell Observatory; STARR cancer consortium; Scientific Interface from BWF; ; 	We thank L. Gaffney and A. Hupalowska for help with artwork and L. Gaffney for help in figure preparation. We thank K. Itoh, N. Naka and S. Takenaka (Osaka University, Japan) for providing the Aska cell lines, and Akira Kawai (National Cancer Center Hospital, Japan) for providing the SYO1 cell line. We thank M. Brown for help with CNA visualization. L.J.-A. is a Chan Zuckerberg Biohub investigator and holds a Career Award at the Scientific Interface from BWF. L.J.-A. was a fellow of the Eric and Wendy Schmidt postdoctoral program and a CRI Irvington Fellow supported by the CRI. A.R. is an HHMI Investigator. Work was supported by the Klarman Cell Observatory, STARR cancer consortium, NCI grants 1U24CA180922, R33-CA202820, the Koch Institute NCI Support (core) grant P30-CA14051, Ludwig Centers at Harvard and MIT, AMRF and the Broad Institute (A.R.). Work was also supported by grants from the Howard Goodman Fellowship at MGH (M.L.S.), the Merkin Institute Fellowship at the Broad Institute of MIT and Harvard (M.L.S.), R37CA245523 (M.L.S.), the Swiss National Science Foundation Sinergia grant CRSII5_177266 (M.L.S. and I.S.). Imaging CyCIF work was supported by a grant (CA225088) from the Center for Cancer Systems Pharmacology at Harvard Medical School (P.K.S.), K08CA222663 (B.I.), Burroughs Wellcome Fund Career Award for Medical Scientists (B.I.), Louis V. Gerstner, Jr. Scholars Program (B.I.) and the Velocity Fellow Program (B.I.). N.R. is supported by the Swiss National Science Foundation Professorship grant (PP00P3-157468/1 and PP00P3_183724), the Swiss Cancer League grant KFS-3973-08-2016, the Fond'Action Contre le Cancer grant and the FORCE grant. N.D.M. was supported by a postdoctoral fellowship from the American Cancer Society (PF-17-042-01-LIB) and the NIH education loan repayment program funded by the NCI (L30 CA231679-01). M.N.R. is supported by the Thomas and Diana Ryan MGH Research Scholar Award. Processed scRNA-seq data are available at https://portals.broadinstitute.org/single_cell/study/synovial-sarcoma and GEO GSE131309. Raw scRNA-seq data is deposited in the controlled access repository DUOS (https://duos.broadinstitute.org/#/hom) accession: DUOS-000123 (via the data catalog https://duos.broadinstitute.org/dataset_catalog).	Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/nmeth.4463, 10.1038/NMETH.4463]; [Anonymous], 2004, PHYS REV E, DOI DOI 10.1103/PhysRevE.69.026113; Ayyoub M, 2005, J IMMUNOL, V174, P5092, DOI 10.4049/jimmunol.174.8.5092; Ayyoub M, 2003, CANCER RES, V63, P5601; Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; Balogh KN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197702; Banito A, 2018, CANCER CELL, V33, P527, DOI [10.1016/j.ccell.2018.01.018, 10.1016/j.ccell.2018.07.006]; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bottcher JP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9306; Bovolenta LA, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-405; Brin S., 1998, 7 INT WORLD WID WEB; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446; Cohen O, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.SABCS16-S1-01; Costello M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1443; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Fan J, 2016, NAT METHODS, V13, P241, DOI [10.1038/nmeth.3734, 10.1038/NMETH.3734]; Filbin MG, 2018, SCIENCE, V360, P331, DOI 10.1126/science.aao4750; Fisher S, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r1; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Groger CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051136; Haas BJ, 2017, STAR FUSION FAST ACC, DOI [DOI 10.1101/120295, 10.1101/120295]; Haghverdi L, 2015, BIOINFORMATICS, V31, P2989, DOI 10.1093/bioinformatics/btv325; Han H, 2015, SCI REP-UK, V5, DOI 10.1038/srep11432; Herrmann C, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks543; Iura K, 2017, HUM PATHOL, V61, P130, DOI 10.1016/j.humpath.2016.12.006; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Jones KB, 2011, CANCER CONTROL, V18, P196, DOI 10.1177/107327481101800307; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD1284, DOI 10.1093/nar/gkx1188; Lagarde P, 2013, J CLIN ONCOL, V31, P608, DOI 10.1200/JCO.2012.46.0147; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; Martin-Broto J, 2020, CLIN CANCER RES, V26, P5801, DOI 10.1158/1078-0432.CCR-19-3335; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; McBride MJ, 2018, CANCER CELL, V33, P1128, DOI 10.1016/j.ccell.2018.05.002; McDavid A, 2013, BIOINFORMATICS, V29, P461, DOI 10.1093/bioinformatics/bts714; Merritt CR, 2020, NAT BIOTECHNOL, V38, P586, DOI 10.1038/s41587-020-0472-9; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Nakayama R, 2010, AM J SURG PATHOL, V34, P1599, DOI 10.1097/PAS.0b013e3181f7ce2c; Nielsen TO, 2015, CANCER DISCOV, V5, P124, DOI 10.1158/2159-8290.CD-14-1246; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Pollack SM, 2018, EXPERT REV VACCINES, V17, P107, DOI 10.1080/14760584.2018.1419068; Pollack SM, 2017, CANCER-AM CANCER SOC, V123, P3291, DOI 10.1002/cncr.30726; Przybyl J, 2014, INT J BIOCHEM CELL B, V53, P505, DOI 10.1016/j.biocel.2014.05.006; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Ramilowski JA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8866; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Robbins PF, 2008, J IMMUNOL, V180, P6116, DOI 10.4049/jimmunol.180.9.6116; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Smith HA, 2011, J IMMUNOTHER, V34, P569, DOI 10.1097/CJI.0b013e31822b5b1d; Smith HA, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/150591; Stubbington MJT, 2016, NAT METHODS, V13, P329, DOI [10.1038/NMETH.3800, 10.1038/nmeth.3800]; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tirosh I, 2016, NATURE, V539, P309, DOI 10.1038/nature20123; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Trujillo JA, 2018, CANCER IMMUNOL RES, V6, P990, DOI 10.1158/2326-6066.CIR-18-0277; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; Venteicher AS, 2017, SCIENCE, V355, DOI 10.1126/science.aai8478; Waltman L, 2013, EUR PHYS J B, V86, DOI 10.1140/epjb/e2013-40829-0; Welch JD, 2019, CELL, V177, P1873, DOI 10.1016/j.cell.2019.05.006; Yang Z, 2016, BIOINFORMATICS, V32, P1, DOI 10.1093/bioinformatics/btv544; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zhou Y, 2017, ONCOL REP, V37, P3351, DOI 10.3892/or.2017.5617	80	31	31	4	26	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					289	+		10.1038/s41591-020-01212-6	http://dx.doi.org/10.1038/s41591-020-01212-6		JAN 2021	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33495604	Green Accepted, Green Submitted			2023-01-03	WOS:000611467500003
J	Buser, JM; Munro-Kramer, ML; Veliz, PT; Zhang, XY; Lockhart, N; Biemba, G; Ngoma, T; Scott, N; Lori, JR				Buser, Julie M.; Munro-Kramer, Michelle L.; Veliz, Philip T.; Zhang, Xingyu; Lockhart, Nancy; Biemba, Godfrey; Ngoma, Thandiwe; Scott, Nancy; Lori, Jody R.			How maternity waiting home use influences attendance of antenatal and postnatal care	PLOS ONE			English	Article							MORTALITY	As highlighted in the International Year of the Nurse and the Midwife, access to quality nursing and midwifery care is essential to promote maternal-newborn health and improve survival. One intervention aimed at improving maternal-newborn health and reducing underutilization of pregnancy services is the construction of maternity waiting homes (MWHs). The purpose of this study was to assess whether there was a significant change in antenatal care (ANC) and postnatal care (PNC) attendance, family planning use, and vaccination rates before and after implementation of the Core MWH Model in rural Zambia. A quasi-experimental controlled before-and-after design was used to evaluate the impact of the Core MWH Model by assessing associations between ANC and PNC attendance, family planning use, and vaccination rates for mothers who gave birth to a child in the past 13 months. Twenty health care facilities received the Core MWH Model and 20 were identified as comparison facilities. Before-and-after community surveys were carried out. Multivariable logistic regression were used to assess the association between Core MWH Model use and ANC and PNC attendance. The total sample includes 4711 mothers. Mothers who used the Core MWH Model had better ANC and PNC attendance, family planning use, and vaccination rates than mothers who did not use a MWH. All mothers appeared to fare better across these outcomes at endline. We found an association between Core MWH Model use and better ANC and PNC attendance, family planning use, and newborn vaccination outcomes. Maternity waiting homes may serve as a catalyst to improve use of facility services for vulnerable mothers.	[Buser, Julie M.] Univ Michigan, Michigan Med, Ann Arbor, MI 48109 USA; [Munro-Kramer, Michelle L.; Lockhart, Nancy; Lori, Jody R.] Univ Michigan, Sch Nursing, Dept Hlth Behav & Biol Sci, Ann Arbor, MI 48109 USA; [Veliz, Philip T.; Zhang, Xingyu] Univ Michigan, Sch Nursing, Dept Syst Populat & Leadership, Appl Biostat Lab, Ann Arbor, MI 48109 USA; [Biemba, Godfrey] Natl Hlth Res Author, Lusaka, Zambia; [Biemba, Godfrey; Scott, Nancy] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA USA; [Biemba, Godfrey; Ngoma, Thandiwe] Zambian Ctr Appl Hlth Res & Dev ZCAHRD Ltd, Lusaka, Zambia; [Ngoma, Thandiwe] Right Care Zambia, Lusaka, Zambia	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Boston University	Buser, JM (corresponding author), Univ Michigan, Michigan Med, Ann Arbor, MI 48109 USA.	jbuser@umich.edu		Scott, Nancy/0000-0002-4713-4642; Zhang, Xingyu/0000-0001-8108-1997	Bill & Melinda Gates Foundation [OPP1130334]; ELMA Foundation [ELMA-15-F0010]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); ELMA Foundation	The study program was developed and is being implemented in collaboration with Merck for Mothers, Merck's 10-year, $500 million initiative to help create a world where no woman dies giving life. Merck for Mothers is known as MSD for Mothers outside the United States and Canada (MRK 1846-06500.COL). The development of the study article was additionally supported in part by the Bill & Melinda Gates Foundation (OPP1130334) https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2015/06/OPP1130334 and The ELMA Foundation (ELMA-15-F0010) http://www.elmaphilanthropies.org/the-elma-foundation/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily reflect positions or policies of Merck, the Bill & Melinda Gates Foundation, or The ELMA Foundation.	Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Bekele BB, MATERNITY WAITING HO; Bonawitz R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225523; Chama-Chiliba CM, 2015, HEALTH POLICY PLANN, V30, P78, DOI 10.1093/heapol/czt099; Chungu C, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00094; Conlon CM, 2019, GLOB HEALTH-SCI PRAC, V7, pS6, DOI 10.9745/GHSP-D-18-00427; DHS, ZAMBIA DHS 2013 14 F; DHS, 2018, ZAMB STAND DHS; FigaTalamanca I, 1996, SOC SCI MED, V42, P1381, DOI 10.1016/0277-9536(95)00286-3; Fogliati P, 2017, HEALTH POLICY PLANN, V32, P1354, DOI 10.1093/heapol/czx100; Henry EG, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-4989-x; Henry EG, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0328-z; Jacobs C, 2018, BMC HEALTH SERV RES, V18, P1, DOI [10.1186/s12913-017-2770-6, DOI 10.1186/S12913-017-2770-6]; Jacobs C, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00011; Lori JR, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2384-6; Lori JR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209815; Lori JR, 2016, MIDWIFERY, V41, P89, DOI 10.1016/j.midw.2016.08.005; Lori JR, 2013, INT J GYNECOL OBSTET, V123, P114, DOI 10.1016/j.ijgo.2013.05.024; Lori JR, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-134; Mutale W, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4187-x; Nganjo Phiri S, RURAL URBAN INEQUITY; Nuamah GB, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-018-2159-5; Okedo-Alex IN, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031890; Renfrew MJ, 2019, BIRTH-ISS PERINAT C, V46, P396, DOI 10.1111/birt.12442; Scott NA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022224; Sialubanje C, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1317-5; SMGL, ZAMB OUR PROGR; UN IGME, ZAMB; van Lonkhuijzen L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006759.pub3; WHO, 1996, MAT WAIT HOM REV EXP; WHO, WHO REC ANT CAR SCH; WHO, ZAMB COUNTR PROF; World Health Organization, WHO REC POSTN CAR MO; World Health Organization, OPPORTUNITIES AFRICA; World Health Organization, YEAR NURS MIDW 2020	35	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2021	16	1							e0245893	10.1371/journal.pone.0245893	http://dx.doi.org/10.1371/journal.pone.0245893			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PZ7OB	33481942	gold, Green Published			2023-01-03	WOS:000612929300059
J	Barbash, IJ; Davis, BS; Yabes, JG; Seymour, CW; Angus, DC; Kahn, JM				Barbash, Ian J.; Davis, Billie S.; Yabes, Jonathan G.; Seymour, Chris W.; Angus, Derek C.; Kahn, Jeremy M.			Treatment Patterns and Clinical Outcomes After the Introduction of the Medicare Sepsis Performance Measure (SEP-1)	ANNALS OF INTERNAL MEDICINE			English	Article							INTERNATIONAL CONSENSUS DEFINITIONS; HOSPITAL MORTALITY; CARE; PAY	Background: Medicare requires that hospitals report on their adherence to the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1). Objective: To evaluate the effect of SEP-1 on treatment patterns and patient outcomes. Design: Longitudinal study of hospitals using repeated cross-sectional cohorts of patients. Setting: 11 hospitals within an integrated health system. Patients: 54 225 encounters between January 2013 and December 2017 for adults with sepsis who were hospitalized through the emergency department. Intervention: Onset of the SEP-1 reporting requirement in October 2015. Measurements: Changes in SEP-1-targeted processes, including antibiotic administration, lactate measurement, and fluid administration at 3 hours from sepsis onset; repeated lactate and vasopressor administration for hypotension within 6 hours of sepsis onset; and sepsis outcomes, including risk-adjusted intensive care unit (ICU) admission, in-hospital mortality, and home discharge among survivors. Results: Two years after its implementation, SEP-1 was associated with variable changes in process measures, with the greatest effect being an increase in lactate measurement within 3 hours of sepsis onset (absolute increase, 23.7 percentage points [95% CI, 20.7 to 26.7 percentage points]; P < 0.001). There were small increases in antibiotic administration (absolute increase, 4.7 percentage points [CI, 1.9 to 7.6 percentage points]; P = 0.001) and fluid administration of 30 mL/kg of body weight within 3 hours of sepsis onset (absolute increase, 3.4 percentage points [CI, 1.5 to 5.2 percentage points]; P < 0.001). There was no change in vasopressor administration. There was a small increase in ICU admissions (absolute increase, 2.0 percentage points [CI, 0 to 4.0 percentage points]; P = 0.055) and no changes in mortality (absolute change, 0.1 percentage points [CI, -0.9 to 1.1 percentage points]; P = 0.87) or discharge to home. Limitation: Data are from a single health system. Conclusion: Implementation of the SEP-1 mandatory reporting program was associated with variable changes in process measures, without improvements in clinical outcomes. Revising the measure may optimize its future effect.	[Barbash, Ian J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; [Barbash, Ian J.; Angus, Derek C.; Kahn, Jeremy M.] UPMC Hlth Syst, Pittsburgh, PA USA; [Davis, Billie S.] Univ Pittsburgh, Sch Med, 602A Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA; [Yabes, Jonathan G.] Ctr Res Hlth Care, 200 Meyran Ave,Suite 300, Pittsburgh, PA 15213 USA; [Seymour, Chris W.] Univ Pittsburgh, Sch Med, 3520 Fifth Ave,Suite 100, Pittsburgh, PA 15261 USA; [Angus, Derek C.] Univ Pittsburgh, Sch Med, 614 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA; [Kahn, Jeremy M.] Univ Pittsburgh, Sch Med, 602B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA; [Barbash, Ian J.] Univ Pittsburgh, Montefiore Hosp 628 NW,3459 Fifth Ave, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Barbash, IJ (corresponding author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.; Barbash, IJ (corresponding author), Univ Pittsburgh, Montefiore Hosp 628 NW,3459 Fifth Ave, Pittsburgh, PA 15213 USA.	barbashij@upmc.edu		Barbash, Ian/0000-0002-9840-0576; Angus, Derek/0000-0002-7026-5181; Yabes, Jonathan/0000-0002-9406-2362	Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality.	Afshar M, 2019, CRIT CARE MED, V47, P1371, DOI 10.1097/CCM.0000000000003919; Angus DC, 2016, AM J RESP CRIT CARE, V194, P14, DOI 10.1164/rccm.201604-0879ED; Barbash IJ, 2019, CRIT CARE MED, V47, P1026, DOI 10.1097/CCM.0000000000003613; Barbash IJ, 2017, J HOSP MED, V12, P963, DOI 10.12788/jhm.2929; Barbash IJ, 2016, AM J RESP CRIT CARE, V194, P139, DOI 10.1164/rccm.201604-0723ED; Buchman TG, 2020, CRIT CARE MED, V48, P276, DOI 10.1097/CCM.0000000000004224; Centers for Medicare & Medicaid Services, TECHN EXP PAN COMP M TECHN EXP PAN COMP M; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Kahn JM, 2019, JAMA-J AM MED ASSOC, V322, P240, DOI 10.1001/jama.2019.9021; Kempker JA, 2020, CRIT CARE MED, V48, P1881, DOI 10.1097/CCM.0000000000004577; Klompas M, 2016, ANN INTERN MED, V165, P517, DOI 10.7326/M16-0588; Levy MM, 2018, AM J RESP CRIT CARE, V198, P1406, DOI [10.1164/rccm.201712-2545OC, 10.1164/rccm.201712-2545oc]; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Liu V, 2014, JAMA-J AM MED ASSOC, V312, P90, DOI 10.1001/jama.2014.5804; Liu VX, 2017, AM J RESP CRIT CARE, V196, P856, DOI 10.1164/rccm.201609-1848OC; Mendelson A, 2017, ANN INTERN MED, V166, P341, DOI 10.7326/M16-1881; Pepper DJ, 2018, ANN INTERN MED, V168, P558, DOI 10.7326/M17-2947; Rhee C, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa05, DOI 10.1093/CID/CIAA05]; Rhee C, 2020, CRIT CARE MED, V48, P779, DOI 10.1097/CCM.0000000000004305; Rhee C, 2019, CRIT CARE MED, V47, P1169, DOI 10.1097/CCM.0000000000003817; Rhee C, 2018, CRIT CARE MED, V46, P1585, DOI 10.1097/CCM.0000000000003261; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; Seymour CW, 2017, NEW ENGL J MED, V376, P2235, DOI 10.1056/NEJMoa1703058; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287	26	18	18	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL	2021	174	7					927	+		10.7326/M20-5043	http://dx.doi.org/10.7326/M20-5043			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM8QB	33872042	Green Accepted			2023-01-03	WOS:000675809000019
J	Cainap, C; Ungur, RA; Bochis, OV; Achimas, P; Vlad, C; Havasi, A; Vidrean, A; Farcas, A; Tat, T; Gherman, A; Piciu, A; Bota, M; Constantin, AM; Pop, LA; Maniu, D; Crisan, O; Cioban, CV; Balacescu, O; Coza, O; Balacescu, L; Marta, MM; Dronca, E; Cainap, S				Cainap, Calin; Ungur, Rodica Ana; Bochis, Ovidiu-Vasile; Achimas, Patriciu; Vlad, Catalin; Havasi, Andrei; Vidrean, Andreea; Farcas, Anca; Tat, Tiberiu; Gherman, Alexandra; Piciu, Andra; Bota, Madalina; Constantin, Anne-Marie; Pop, Laura Ancuta; Maniu, Dana; Crisan, Ovidiu; Cioban, Cosmin Vasile; Balacescu, Ovidiu; Coza, Ovidiu; Balacescu, Loredana; Marta, Monica Mihaela; Dronca, Eleonora; Cainap, Simona			Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis	PLOS ONE			English	Article							1ST-LINE TREATMENT; PLUS BEVACIZUMAB; OXALIPLATIN; CHEMOTHERAPY; EFFICACY; SAFETY; MAINTENANCE; COMBINATION; STRATEGY; FOLFIRI	Colorectal cancer remains one of the most frequent malignancies (third place at both genders) worldwide in the last decade, owing to significant changes in modern dietary habits. Approximately half of the patients develop metastases during the course of their disease. The available therapeutic armamentarium is constantly evolving, raising questions regarding the best approach for improving survival. Bevacizumab remains one of the most widely used therapies for treating metastatic colorectal cancer and can be used after progression. This study aimed to identify the best chemotherapy partner for bevacizumab after progression. We performed a retrospective analysis of patients with metastatic colorectal cancer who were treated with bevacizumab as first- and second-line chemotherapy. Data were collected for 151 patients, 40 of whom were treated with double-dose bevacizumab after the first progression. The two standard chemotherapy regimens combined with bevacizumab were FOLFIRI/CAPIRI and FOLFOX4/CAPEOX. The initiation of first-line treatment with irinotecan-based chemotherapy improved progression-free survival and time to treatment failure but not overall survival. After the first progression, retreatment with the same regimen as that used in the induction phase was the best approach for improving overall survival (median overall survival: 46.5 vs. 27.0 months for the same vs. switched strategy, respectively). No correlations were observed between the dose intensity of irinotecan, oxaliplatin, 5-fluorouracil, or bevacizumab and the overall survival, progression-free survival in the first-/second-line treatment, and time to treatment failure. Interaction between an irinotecan-based regimen as a second-line treatment and double-dose bevacizumab after progression was associated with an improved overall survival (p = 0.06). Initiating systemic treatment with an irinotecan-based regimen in combination with bevacizumab improved the progression-free survival in the first-line treatment and time to treatment failure. In terms of overall survival, bevacizumab treatment after the first progression is better partnered with the same regimen as that used in the induction phase.	[Cainap, Calin; Bochis, Ovidiu-Vasile; Achimas, Patriciu; Vlad, Catalin; Havasi, Andrei; Vidrean, Andreea; Tat, Tiberiu; Gherman, Alexandra; Piciu, Andra; Balacescu, Ovidiu; Coza, Ovidiu; Balacescu, Loredana] Ion Chiricuta Inst Oncol, Cluj Napoca, Romania; [Cainap, Calin; Achimas, Patriciu; Vlad, Catalin; Piciu, Andra; Coza, Ovidiu] Iuliu Hatieganu Univ Med & Pharm, Dept Oncol, Cluj Napoca, Romania; [Ungur, Rodica Ana; Farcas, Anca] Iuliu Hatieganu Univ Med & Pharm, Dept Med Specialties, Cluj Napoca, Romania; [Bota, Madalina; Cainap, Simona] Iuliu Hatieganu Univ Med & Pharm, Dept Mother & Child, Cluj Napoca, Romania; [Constantin, Anne-Marie] Iuliu Hatieganu Univ Med & Pharm, Dept Morphol Sci, Cluj Napoca, Romania; [Pop, Laura Ancuta; Dronca, Eleonora] Iuliu Hatieganu Univ Med & Pharm, Dept Mol Sci, Cluj Napoca, Romania; [Maniu, Dana] Babes Bolyai Univ, Fac Phys, Cluj Napoca, Romania; [Crisan, Ovidiu] Iuliu Hatieganu Univ Med & Pharm, Fac Pharm, Cluj Napoca, Romania; [Cioban, Cosmin Vasile] Iuliu Hatieganu Univ Med & Pharm, Fac Med Dent, Cluj Napoca, Romania; [Marta, Monica Mihaela] Iuliu Hatieganu Univ Med & Pharm, Fac Med Dent, Cluj Napoca, Romania	Oncology Institute Prof. Dr. Ion Chiricuta; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Babes Bolyai University from Cluj; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy	Ungur, RA (corresponding author), Iuliu Hatieganu Univ Med & Pharm, Dept Med Specialties, Cluj Napoca, Romania.	ungurmed@yahoo.com	Maniu, Dana/GQP-1378-2022; Cainap, Calin/AAU-5665-2020; Coza, Ovidiu/HCG-8546-2022; Ungur, Rodica Ana/GRR-2412-2022; Marta, Monica Mihaela/Z-6036-2019; Cainap, Simona/AAZ-7975-2020	Maniu, Dana/0000-0002-3759-6544; Cainap, Calin/0000-0002-7535-8766; Marta, Monica Mihaela/0000-0003-2153-4493; Balacescu, Ovidiu/0000-0003-0253-7103	 [105774];  [10/01.09.2016]	; 	Knowledge transfer of biogenomics in oncology and related domains in clinical applications -BIOGENONCO, MySMIS Code: 105774, Financing contract No: 10/01.09.2016. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4; Botrel TEA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2734-y; Bendell JC, 2012, ONCOLOGIST, V17, P1486, DOI 10.1634/theoncologist.2012-0190; Bochis OV, 2020, J BUON, V25, P875; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buccafusca G, 2019, CRIT REV ONCOL HEMAT, V136, P20, DOI 10.1016/j.critrevonc.2019.01.023; Cabart M, 2016, B CANCER, V103, P541, DOI 10.1016/j.bulcan.2016.03.007; Chan DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135599; Chibaudel B, 2012, THER ADV MED ONCOL, V4, P75, DOI 10.1177/1758834011431592; Chibaudel B, 2011, J CLIN ONCOL, V29, P4199, DOI 10.1200/JCO.2011.35.5867; Chibaudel B, 2009, J CLIN ONCOL, V27, P5727, DOI 10.1200/JCO.2009.23.4344; Comella P, 2008, DRUGS, V68, P949, DOI 10.2165/00003495-200868070-00005; Esin E, 2016, CANCER TREAT REV, V42, P82, DOI 10.1016/j.ctrv.2015.10.012; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Gheorghe-Cetean S, 2017, J BUON, V22, P568; Hegewisch-Becker S, 2015, LANCET ONCOL, V16, P1355, DOI 10.1016/S1470-2045(15)00042-X; Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107; Jang HJ, 2017, ONCOTARGET, V8, P73009, DOI 10.18632/oncotarget.20314; Labianca R, 2013, ANN ONCOL, V24, P64, DOI 10.1093/annonc/mdt354; Landre T, 2018, INT J COLORECTAL DIS, V33, P1125, DOI 10.1007/s00384-018-3053-3; Loree JM, 2018, CLIN COLORECTAL CANC, V17, P65, DOI 10.1016/j.clcc.2017.10.011; Macedo LT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-89; Maniu DR, 2018, J BUON, V23, pS122; Nakayama G, 2014, CANCER CHEMOTH PHARM, V73, P847, DOI 10.1007/s00280-014-2416-x; Robinson SM, 2012, ANN SURG ONCOL, V19, P4287, DOI 10.1245/s10434-012-2438-8; Rubbia-Brandt L, 2010, HISTOPATHOLOGY, V56, P430, DOI 10.1111/j.1365-2559.2010.03511.x; Seicean A, 2016, J GASTROINTEST LIVER, V25, P213, DOI 10.15403/jgld.2014.1121.252.ugg; Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3; Tournigand C, 2006, J CLIN ONCOL, V24, P394, DOI 10.1200/JCO.2005.03.0106; Van Cutsem E, 2009, ANN ONCOL, V20, P1842, DOI 10.1093/annonc/mdp233; Venook A., 2014, ANN ONCOL, V25, pII112, DOI [10.1093/annonc/mdu193.19, DOI 10.1093/ANNONC/MDU193.19]; Xu R, 2018, ONCOTARGETS THER, V11, P8605, DOI 10.2147/OTT.S171724; Yamazaki K, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3534	33	0	0	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2021	16	4							e0248922	10.1371/journal.pone.0248922	http://dx.doi.org/10.1371/journal.pone.0248922			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XL	33909622	gold, Green Published			2023-01-03	WOS:000662174400011
J	Jensen, BR; Malling, ASB; Schmidt, SI; Meyer, M; Morberg, BM; Wermuth, L				Jensen, Bente Rona; Malling, Anne Sofie Bogh; Schmidt, Sissel Ida; Meyer, Morten; Morberg, Bo Mohr; Wermuth, Lene			Long-term treatment with transcranial pulsed electromagnetic fields improves movement speed and elevates cerebrospinal erythropoietin in Parkinson's disease	PLOS ONE			English	Article							TYROSINE-HYDROXYLASE; DOPAMINERGIC-NEURONS; FORCE DEVELOPMENT; RAT MODEL; SYMPTOMS; RECOVERY; SYSTEM; TREMOR; MOTOR; AGE	Background Parkinson's disease is characterized by motor dysfunctions including bradykinesia. In a recent study, eight weeks of daily transcranial stimulation with bipolar pulsed electromagnetic fields improved functional rate of force development and decreased inter-hand tremor coherence in patients with mild Parkinson's disease. Objective To investigate the effect of long-term treatment with transcranial bipolar pulsed electromagnetic fields on motor performance in terms of movement speed and on neurotrophic and angiogenic factors. Methods Patients diagnosed with idiopathic Parkinson's disease had either daily 30-min treatment with bipolar (50 V) transcranial pulsed electromagnetic stimulation (squared pulses, 3ms duration) for three eight-week periods separated by one-week pauses (T-PEMF group) (n = 16) or were included in a PD-control group (n = 8). Movement speed was assessed in a six-cycle sit-to-stand task performed on a force plate. Cerebrospinal fluid and venous blood were collected and analyzed for erythropoietin and vascular endothelial growth factor. Results Major significant improvement of movement speed compared to the natural development of the disease was found (p = 0.001). Thus, task completion time decreased gradually during the treatment period from 10.10s to 8.23s (p<0.001). The untreated PD-control group did not change (p = 0.458). The treated group did not differ statistically from that of a healthy age matched reference group at completion of treatment. Erythropoietin concentration in the cerebrospinal fluid also increased significantly in the treated group (p = 0.012). Conclusion Long-term treatment with transcranial bipolar pulsed electromagnetic fields increased movement speed markedly and elevated erythropoietin levels. We hypothesize that treatment with transcranial bipolar pulsed electromagnetic fields improved functional performance by increasing dopamine levels in the brain, possibly through erythropoietin induced neural repair and/or protection of dopaminergic neurons.	[Jensen, Bente Rona; Malling, Anne Sofie Bogh; Meyer, Morten; Morberg, Bo Mohr; Wermuth, Lene] Univ Southern Denmark, Odense Univ Hosp, Dept Neurol, Odense, Denmark; [Jensen, Bente Rona; Malling, Anne Sofie Bogh; Meyer, Morten; Wermuth, Lene] Univ Southern Denmark, Dept Clin Re BRIDGE, Odense, Denmark; [Schmidt, Sissel Ida; Meyer, Morten] Univ Southern Denmark, Inst Mol Med, Dept Neurobiol Res, Odense, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Southern Denmark	Jensen, BR (corresponding author), Univ Southern Denmark, Odense Univ Hosp, Dept Neurol, Odense, Denmark.; Jensen, BR (corresponding author), Univ Southern Denmark, Dept Clin Re BRIDGE, Odense, Denmark.	bente.r.jensen@rsyd.dk	Wermuth, Lene/O-9464-2014; Schmidt, Sissel Ida/AAE-5230-2019	Wermuth, Lene/0000-0001-6930-8562; Schmidt, Sissel Ida/0000-0003-4939-8155	Jascha Foundation, Denmark; Den A.P. Mollerske Stottefond, Copenhagen, Denmark; Grosserer L.F. Foghts Foundation, Charlottenlund, Denmark	Jascha Foundation, Denmark; Den A.P. Mollerske Stottefond, Copenhagen, Denmark; Grosserer L.F. Foghts Foundation, Charlottenlund, Denmark	The research group received funding from The Jascha Foundation, Denmark; Den A.P. Mollerske Stottefond, Copenhagen, Denmark; and Grosserer L.F. Foghts Foundation, Charlottenlund, Denmark. The authors report no competing interest. Thus, the funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bragin DE, 2015, J NEUROSURG, V122, P1239, DOI 10.3171/2014.8.JNS132083; Byts Nadiya, 2009, Exp Transl Stroke Med, V1, P4, DOI 10.1186/2040-7378-1-4; Caligiore D, 2016, NPJ PARKINSONS DIS, V2, DOI 10.1038/npjparkd.2016.25; Carelli S, 2017, RESTOR NEUROL NEUROS, V35, P583, DOI 10.3233/RNN-170750; Carelli S, 2017, NEUROPHARMACOLOGY, V119, P76, DOI 10.1016/j.neuropharm.2017.03.035; Carmeliet P, 2002, SEMIN CELL DEV BIOL, V13, P39, DOI 10.1006/scdb.2001.0290; CONTRERASVIDAL JL, 1995, LIFE SCI, V58, P165, DOI 10.1016/0024-3205(95)02237-6; Crouse JJ, 2016, REV NEUROSCIENCE, V27, P549, DOI 10.1515/revneuro-2016-0002; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; Hamidi Gholamali, 2013, Pathophysiology, V20, P153, DOI 10.1016/j.pathophys.2013.01.001; Hammond KG, 2017, CLIN BIOMECH, V45, P14, DOI 10.1016/j.clinbiomech.2017.04.003; Hei WH, 2016, INT J NEUROSCI, V126, P739, DOI 10.3109/00207454.2015.1054032; Hinkle DE., 2003, APPL SATISTICS BEHAV, V5th; Jang W, 2014, J NEUROL SCI, V337, P47, DOI 10.1016/j.jns.2013.11.015; Jensen BR, 2018, CASE REP NEUROL, V10, P242, DOI 10.1159/000492486; Lange KW, 2006, HUM MOVEMENT SCI, V25, P492, DOI 10.1016/j.humov.2006.05.006; Lei T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061414; Lim J, 2015, NEUROREPORT, V26, P380, DOI 10.1097/WNR.0000000000000356; Malling ASB, 2016, GAIT POSTURE, V43, P141, DOI 10.1016/j.gaitpost.2015.09.013; Malling ASB, 2019, J NEUROENG REHABIL, V16, DOI 10.1186/s12984-019-0491-2; Malling ASB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204478; Morberg BM, 2018, EUR J NEUROL, V25, P963, DOI 10.1111/ene.13637; Morberg BM, 2017, MOVEMENT DISORD, V32, P625, DOI 10.1002/mds.26927; Movafagh S, 2015, J CELL BIOCHEM, V116, P696, DOI 10.1002/jcb.25074; Nagatsu T, 2016, J NEURAL TRANSM, V123, P1255, DOI 10.1007/s00702-016-1596-4; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Pan YH, 2013, BIOELECTROMAGNETICS, V34, P180, DOI 10.1002/bem.21755; Petzinger G M, 2015, Brain Plast, V1, P29; Politis M, 2010, MOVEMENT DISORD, V25, P1646, DOI 10.1002/mds.23135; Qi C, 2014, INT J MOL MED, V34, P440, DOI 10.3892/ijmm.2014.1810; Rahbek U. L., 2005, ORAL BIOSCI MED, V2, P1; Rose M, 2013, THESIS; Rose MH, 2013, MOTOR CONTROL, V17, P203, DOI 10.1123/mcj.17.2.203; Rose MH., 2012, ARCHPHYSMEDREHABIL, DOI [10.1016/j.apmr.2012.11.025, DOI 10.1016/J.APMR.2012.11.025]; Shim JW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010275; Spedden ME, 2017, DEV NEUROPSYCHOL, V42, P495, DOI 10.1080/87565641.2017.1399129; Swinnen SP, 1997, MOVEMENT DISORD, V12, P958, DOI 10.1002/mds.870120619; Urnukhsaikhan E, 2016, LIFE SCI, V151, P130, DOI 10.1016/j.lfs.2016.02.066; Widl K, 2007, NEUROCHEM RES, V32, P1163, DOI 10.1007/s11064-007-9286-0; Xue YQ, 2007, NEUROSCIENCE, V146, P1245, DOI 10.1016/j.neuroscience.2007.02.004; Xue YQ, 2010, GENE THER, V17, P83, DOI 10.1038/gt.2009.113; Yang LZ., 2017, J ALZHEIMERS DIS PAR, V7, P1, DOI [10.4172/2161-0460.1000320, DOI 10.4172/2161-0460.1000320]	42	1	1	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2021	16	4							e0248800	10.1371/journal.pone.0248800	http://dx.doi.org/10.1371/journal.pone.0248800			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XL	33909634	Green Published, gold			2023-01-03	WOS:000662174400010
J	Koutoukidis, DA; Morris, E; Henry, JA; Shammoon, Y; Zimmerman, M; Michalopoulou, M; Jebb, SA; Aveyard, P				Koutoukidis, Dimitrios A.; Morris, Elizabeth; Henry, John A.; Shammoon, Yusra; Zimmerman, Matthew; Michalopoulou, Moscho; Jebb, Susan A.; Aveyard, Paul			What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis	PLOS ONE			English	Article							FATTY LIVER-DISEASE; INSULIN-SENSITIZING AGENTS; PLACEBO-CONTROLLED TRIAL; URSODEOXYCHOLIC ACID; HISTOLOGICAL ACTIVITY; OBETICHOLIC ACID; DOUBLE-BLIND; VITAMIN-E; FIBROSIS; PENTOXIFYLLINE	Background and aim Trials of treatments for non-alcoholic steatohepatitis require endpoint assessment with liver biopsies. Previous large-scale trials have calculated their sample size expecting high retention but on average did not achieve this. We aimed to quantify the proportion of participants with a valid follow-up biopsy. Methods We conducted a systematic review of MEDLINE and Embase until May 2020 and included randomized clinical trials of any intervention in non-alcoholic steatohepatitis with at least 1-year follow-up. We were guided by Cochrane methods to run a meta-analysis with generalized linear mixed models with random effects. Results Forty-one trials (n = 6,695) were included. The proportion of participants with a valid follow-up biopsy was 82% (95%CI: 78%-86%, I-2 = 92%). There was no evidence of a difference by location, trial length, or by allocated treatment group. Reasons for missing follow-up biopsies were, in ranked order, related to participants (95 per 1,000 participants (95%CI: 69-129, I-2 = 92%), medical factors, protocol, trial conduct, and other/unclear. Biopsy-related serious adverse events occurred in 16 per 1,000 participants (95% CI: 8-33, I-2 = 54%). No biopsy-related deaths were reported. Conclusions The proportion of participants with a valid follow-up biopsy in therapeutic trials in non-alcoholic steatohepatitis is on average 82%, with around 1 in 10 participants declining a follow-up biopsy. These findings can inform adequately-powered trials.	[Koutoukidis, Dimitrios A.; Morris, Elizabeth; Henry, John A.; Shammoon, Yusra; Zimmerman, Matthew; Michalopoulou, Moscho; Jebb, Susan A.; Aveyard, Paul] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Koutoukidis, Dimitrios A.; Michalopoulou, Moscho; Jebb, Susan A.; Aveyard, Paul] NHS Fdn Trust, Oxford Univ Hosp, NIHR Oxford Biomed Res Ctr, Oxford, England	University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford	Koutoukidis, DA (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England.; Koutoukidis, DA (corresponding author), NHS Fdn Trust, Oxford Univ Hosp, NIHR Oxford Biomed Res Ctr, Oxford, England.	dimitrios.koutoukidis@phc.ox.ac.uk	; Koutoukidis, Dimitrios/I-4800-2017	Henry, Aaron/0000-0002-7650-0963; Aveyard, Paul/0000-0002-1802-4217; Zimmerman, Matthew/0000-0002-6884-722X; Koutoukidis, Dimitrios/0000-0002-1955-7234; Jebb, Susan/0000-0001-9190-2920	National Institute for Health Research (NIHR) Oxford Biomedical Research Centre [ISBRC-1215-20008]; NIHR Applied Research Collaboration Oxford and Thames Valley; Wellcome Trust	National Institute for Health Research (NIHR) Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Applied Research Collaboration Oxford and Thames Valley; Wellcome Trust(Wellcome Trust)	This study was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (grant number: ISBRC-1215-20008). S.A.J. and P.A. are NIHR Senior Investigators and also funded by the NIHR Applied Research Collaboration Oxford and Thames Valley. EM is funded by a Wellcome Trust Clinical Doctoral Research Fellowship. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.	Abdelmalek MF, 2009, HEPATOLOGY, V50, P1818, DOI 10.1002/hep.23239; Aithal GP, 2008, GASTROENTEROLOGY, V135, P1176, DOI 10.1053/j.gastro.2008.06.047; Ajmera VH, 2020, HEPATOLOGY, V71, P849, DOI 10.1002/hep.30974; Alam S, 2020, JGH OPEN, V4, P663, DOI 10.1002/jgh3.12315; Alam S, 2018, HEPATIC MED-EVID RES, V10, P23, DOI 10.2147/HMER.S158053; Alam S, 2017, J TRANSL INTERN MED, V5, P155, DOI 10.1515/jtim-2017-0021; Argo CK, 2015, J HEPATOL, V62, P190, DOI 10.1016/j.jhep.2014.08.036; Armstrong MJ, 2016, LANCET, V387, P679, DOI 10.1016/S0140-6736(15)00803-X; Bril F, 2019, DIABETES CARE, V42, P1481, DOI 10.2337/dc19-0167; Cadranel JF, 2000, HEPATOLOGY, V32, P477, DOI 10.1053/jhep.2000.16602; Chalasani N, 2020, GASTROENTEROLOGY, V158, P1334, DOI 10.1053/j.gastro.2019.11.296; Cusi K, 2016, ANN INTERN MED, V165, P305, DOI 10.7326/M15-1774; Dasarathy S, 2015, J CLIN GASTROENTEROL, V49, P137, DOI 10.1097/MCG.0000000000000099; Dufour JF, 2006, CLIN GASTROENTEROL H, V4, P1537, DOI 10.1016/j.cgh.2006.09.025; Dulai PS, 2017, HEPATOLOGY, V65, P1557, DOI 10.1002/hep.29085; EMA, 2018, DRAFT REFLECTION PAP; Eslam M, 2020, J HEPATOL, V73, P202, DOI 10.1016/j.jhep.2020.03.039; FDA, 2018, NONCIRRHOTIC NONALCO; Friedman SL, 2018, HEPATOLOGY, V67, P1754, DOI 10.1002/hep.29477; Geier A, 2018, SCAND J GASTROENTERO, V53, P1114, DOI 10.1080/00365521.2018.1501091; Georgescu EF, 2009, WORLD J GASTROENTERO, V15, P942, DOI 10.3748/wjg.15.942; Harrison SA, 2020, J HEPATOL, V73, P26, DOI 10.1016/j.jhep.2020.02.027; Harrison Stephen A, 2020, J Hepatol, V72, P816, DOI 10.1016/j.jhep.2019.11.024; Harrison SA, 2020, J HEPATOL, V72, P613, DOI 10.1016/j.jhep.2019.10.023; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Hunter JP, 2014, J CLIN EPIDEMIOL, V67, P897, DOI 10.1016/j.jclinepi.2014.03.003; Idilman R, 2008, ALIMENT PHARM THER, V28, P200, DOI 10.1111/j.1365-2036.2008.03723.x; Jayakumar S, 2019, J HEPATOL, V70, P133, DOI 10.1016/j.jhep.2018.09.024; Kheong CW, 2017, CLIN GASTROENTEROL H, V15, P1940, DOI 10.1016/j.cgh.2017.04.016; Leuschner UFH, 2010, HEPATOLOGY, V52, P472, DOI 10.1002/hep.23727; Lindor KD, 2004, HEPATOLOGY, V39, P770, DOI 10.1002/hep.20092; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; McPherson S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175717; Navarro VJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221683; Nelson A, 2009, J CLIN GASTROENTEROL, V43, P990, DOI 10.1097/MCG.0b013e31819c392e; Neuschwander-Tetri BA, 2015, LANCET, V385, P956, DOI 10.1016/S0140-6736(14)61933-4; Newsome PN, 2020, J HEPATOL, V73, P231, DOI 10.1016/j.jhep.2020.03.024; OLIVEIRA Claudia P, 2019, Arq. Gastroenterol., V56, P184, DOI [10.1590/S0004-2803.201900000-36, 10.1590/s0004-2803.201900000-36]; Omer Z, 2010, EUR J GASTROEN HEPAT, V22, P18, DOI 10.1097/MEG.0b013e32832e2baf; Promrat K, 2010, HEPATOLOGY, V51, P121, DOI 10.1002/hep.23276; Ratziu V, 2008, GASTROENTEROLOGY, V135, P100, DOI 10.1053/j.gastro.2008.03.078; Ratziu V, 2020, HEPATOLOGY, V72, P892, DOI 10.1002/hep.31108; Ratziu V, 2016, GASTROENTEROLOGY, V150, P1147, DOI 10.1053/j.gastro.2016.01.038; Sanyal AJ, 2014, GASTROENTEROLOGY, V147, P377, DOI 10.1053/j.gastro.2014.04.046; Sanyal Arun J, 2011, Hepatology, V54, P344, DOI 10.1002/hep.24376; Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929; Shields William W, 2009, Therap Adv Gastroenterol, V2, P157, DOI 10.1177/1756283X09105462; Stijnen T, 2010, STAT MED, V29, P3046, DOI 10.1002/sim.4040; Sturm N, 2009, GASTROEN CLIN BIOL, V33, P984, DOI 10.1016/j.gcb.2009.05.010; Sumida Y, 2014, WORLD J GASTROENTERO, V20, P475, DOI 10.3748/wjg.v20.i2.475; Targher G, 2016, J HEPATOL, V65, P589, DOI 10.1016/j.jhep.2016.05.013; Torres DM, 2011, HEPATOLOGY, V54, P1631, DOI 10.1002/hep.24558; van der Poorten D, 2006, INTERN MED J, V36, P692, DOI 10.1111/j.1445-5994.2006.01216.x; Van Wagner LB, 2011, ANN HEPATOL, V10, P277, DOI 10.1016/S1665-2681(19)31539-X; Wong RJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.20294; Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109; Younossi ZM, 2021, HEPATOLOGY, V73, P1194, DOI 10.1002/hep.31420; Younossi ZM, 2019, LANCET, V394, P2184, DOI 10.1016/S0140-6736(19)33041-7; Younossi ZM, 2016, HEPATOLOGY, V64, P1577, DOI 10.1002/hep.28785; Zein CO, 2011, HEPATOLOGY, V54, P1610, DOI 10.1002/hep.24544	60	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2021	16	4							e0250385	10.1371/journal.pone.0250385	http://dx.doi.org/10.1371/journal.pone.0250385			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0BF	33882107	Green Published, gold			2023-01-03	WOS:000644133400049
J	Alves, L				Alves, Lise			Brazilian ICUs short of drugs and beds amid COVID-19 surge	LANCET			English	Editorial Material																			0	8	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 17	2021	397	10283					1431	1432						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RN5FX	33865483	Green Published, Bronze			2023-01-03	WOS:000640378100008
J	Karatzas, E; Kakouri, AC; Kolios, G; Delis, A; Spyrou, GM				Karatzas, Evangelos; Kakouri, Andrea C.; Kolios, George; Delis, Alex; Spyrou, George M.			Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action	PLOS ONE			English	Article							ORAL SUBMUCOUS FIBROSIS; EXTRACELLULAR-MATRIX; LIVER FIBROSIS; NETWORK INTEGRATION; ATRIAL-FIBRILLATION; PULMONARY-FIBROSIS; GENE-EXPRESSION; CAPTOPRIL; CELECOXIB; INHIBITOR	Fibrotic diseases cover a spectrum of systemic and organ-specific maladies that affect a large portion of the population, currently without cure. The shared characteristic these diseases feature is their uncontrollable fibrogenesis deemed responsible for the accumulated damage in the susceptible tissues. Idiopathic Pulmonary Fibrosis, an interstitial lung disease, is one of the most common and studied fibrotic diseases and still remains an active research target. In this study we highlight unique and common (i) genes, (ii) biological pathways and (iii) candidate repurposed drugs among 9 fibrotic diseases. We identify 7 biological pathways involved in all 9 fibrotic diseases as well as pathways unique to some of these diseases. Based on our Drug Repurposing results, we suggest captopril and ibuprofen that both appear to slow the progression of fibrotic diseases according to existing bibliography. We also recommend nafcillin and memantine, which haven't been studied against fibrosis yet, for further wet-lab experimentation. We also observe a group of cardiomyopathy-related pathways that are exclusively highlighted for Oral Submucous Fibrosis. We suggest digoxin to be tested against Oral Submucous Fibrosis, since we observe cardiomyopathy-related pathways implicated in Oral Submucous Fibrosis and there is bibliographic evidence that digoxin may potentially clear myocardial fibrosis. Finally, we establish that Idiopathic Pulmonary Fibrosis shares several involved genes, biological pathways and candidate inhibiting-drugs with Dupuytren's Disease, IgG4-related Disease, Systemic Sclerosis and Cystic Fibrosis. We propose that treatments for these fibrotic diseases should be jointly pursued.	[Karatzas, Evangelos; Delis, Alex] Univ Athens, Dept Informat & Telecommun, Athens, Greece; [Kakouri, Andrea C.; Spyrou, George M.] Cyprus Inst Neurol & Genet, Dept Bioinformat, Nicosia, Cyprus; [Kakouri, Andrea C.] Cyprus Inst Neurol & Genet, Dept Neurogenet, Nicosia, Cyprus; [Kakouri, Andrea C.; Spyrou, George M.] Cyprus Sch Mol Med, Nicosia, Cyprus; [Kolios, George] Democritus Univ Thrace, Dept Med, Alexandroupolis, Greece	National & Kapodistrian University of Athens; Democritus University of Thrace	Spyrou, GM (corresponding author), Cyprus Inst Neurol & Genet, Dept Bioinformat, Nicosia, Cyprus.; Spyrou, GM (corresponding author), Cyprus Sch Mol Med, Nicosia, Cyprus.	georges@cing.ac.cy	Kolios, George/N-6641-2013	Kolios, George/0000-0002-2066-4782; Kakouri, Andrea/0000-0003-2982-679X	IKY (State Scholarships Foundation) scholarship under the Action "Strengthening Human Resources, Education and Lifelong Learning", 2014-2020; European Social Fund (ESF); European Commission Research Executive Agency Grant BIORISE [669026]; European Commission Research Executive Agency (REA) Grant BIORISE [669026];  [MIS 5000432]	IKY (State Scholarships Foundation) scholarship under the Action "Strengthening Human Resources, Education and Lifelong Learning", 2014-2020; European Social Fund (ESF)(European Social Fund (ESF)); European Commission Research Executive Agency Grant BIORISE; European Commission Research Executive Agency (REA) Grant BIORISE; 	Evangelos Karatzas is a PhD student in the National and Kapodistrian University of Athens. His doctoral thesis is being funded by the IKY (State Scholarships Foundation) scholarship under the Action "Strengthening Human Resources, Education and Lifelong Learning", 2014-2020, cofunded by the European Social Fund (ESF) and the Greek State (MIS 5000432). Andrea Kakouri holds a PhD Student fellow position funded by the European Commission Research Executive Agency Grant BIORISE (No. 669026), under the Spreading Excellence, Widening Participation, Science with and for Society Framework. George M. Spyrou holds the Bioinformatics ERA Chair Position funded by the European Commission Research Executive Agency (REA) Grant BIORISE (Num. 669026), under the Spreading Excellence, Widening Participation, Science with and for Society Framework.	Abbaszadeh S, 2018, BIOMED PHARMACOTHER, V108, P1237, DOI 10.1016/j.biopha.2018.09.153; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; Bajusz D, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0069-3; Baybutt RC, 2007, CURR PHARM DESIGN, V13, P1327, DOI 10.2174/138161207780618803; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bodenhofer U, 2011, BIOINFORMATICS, V27, P2463, DOI 10.1093/bioinformatics/btr406; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Borkham-Kamphorst E, 2011, LIVER INT, V31, P656, DOI 10.1111/j.1478-3231.2011.02495.x; Brown AS, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.29; Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140; Carlile GW, 2015, J CYST FIBROS, V14, P16, DOI 10.1016/j.jcf.2014.06.001; Chavez E, 2010, LIVER INT, V30, P969, DOI 10.1111/j.1478-3231.2010.02256.x; Chen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065544; [陈悦 Chen Yue], 2016, [玻璃钢/复合材料, Fiber Reinforced Plastics/Composites], P5; COATES AL, 1982, CHEST, V82, P543, DOI 10.1378/chest.82.5.543; Cohen EP, 1996, LAB INVEST, V75, P349; Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143; DESA J V, 1957, Ann Otol Rhinol Laryngol, V66, P1143; Duan QN, 2016, NPJ SYST BIOL APPL, V2, DOI 10.1038/npjsba.2016.15; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Ftahy MM., 2013, COMP CLIN PATHOL, V22, P425, DOI DOI 10.1007/s00580-012-1427-4; Gao JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069309; Ge Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep09496; Ghazi-Khansari M, 2007, J APPL TOXICOL, V27, P342, DOI 10.1002/jat.1212; Hallberg P, 2007, EUR J CLIN PHARMACOL, V63, P959, DOI 10.1007/s00228-007-0346-9; Haller ST, 2012, AM J HYPERTENS, V25, P690, DOI 10.1038/ajh.2012.17; Hansen ML, 2013, CARDIOLOGY, V126, P202, DOI 10.1159/000354217; Harris TR, 2018, MOL PHARMACOL, V94, P834, DOI 10.1124/mol.118.111831; Herrera J, 2018, J CLIN INVEST, V128, P45, DOI 10.1172/JCI93557; Hui AY, 2006, LIVER INT, V26, P125, DOI 10.1111/j.1478-3231.2005.01202.x; Hutchinson J, 2015, EUR RESPIR J, V46, P795, DOI 10.1183/09031936.00185114; Jaffar J., 2012, C103 PATHOGENESIS BI, pA5173; Jaffer J, 2014, CHEST, V146, P1055, DOI 10.1378/chest.13-2688; JALIL JE, 1991, AM J HYPERTENS, V4, P51, DOI 10.1093/ajh/4.1.51; Jiang XW, 2009, J ORAL MAXIL SURG, V67, P1510, DOI 10.1016/j.joms.2008.12.056; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Karatzas E., 2020, PATHWALKS IDENTIFYIN, DOI [10.1093/bioinformatics/btaa291, DOI 10.1093/BIOINFORMATICS/BTAA291]; Karatzas E, 2020, BIOINFORMATICS, V36, P4070, DOI 10.1093/bioinformatics/btaa291; Karatzas E, 2020, BIOINFORMATICS, V36, P2602, DOI 10.1093/bioinformatics/btz976; Karatzas E, 2019, COMPUT STRUCT BIOTEC, V17, P939, DOI 10.1016/j.csbj.2019.05.010; Kim JW, 2010, TOHOKU J EXP MED, V222, P319, DOI 10.1620/tjem.222.319; Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Konstan MW, 2007, AM J RESP CRIT CARE, V176, P1084, DOI 10.1164/rccm.200702-181OC; KONSTAN MW, 1995, NEW ENGL J MED, V332, P848, DOI 10.1056/NEJM199503303321303; LAI DR, 1995, J ORAL PATHOL MED, V24, P402, DOI 10.1111/j.1600-0714.1995.tb01209.x; Lands LC, 2007, J PEDIATR-US, V151, P249, DOI 10.1016/j.jpeds.2007.04.009; Lau JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013360; Lex A, 2014, IEEE T VIS COMPUT GR, V20, P1983, DOI 10.1109/TVCG.2014.2346248; Li X, 1998, Hua Xi Kou Qiang Yi Xue Za Zhi, V16, P50; Li Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125873; Lindroos PM, 2001, AM J PHYSIOL-LUNG C, V280, pL354, DOI 10.1152/ajplung.2001.280.2.L354; Lindstrom DR, 2007, J OTOLARYNGOL, V36, P309, DOI 10.2310/7070.2007.0049; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Liu G, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86380; Liu H, 2009, PROSTAG OTH LIPID M, V88, P63, DOI 10.1016/j.prostaglandins.2008.10.002; Lussier YA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001512; Milner KL, 2009, HEPATOLOGY, V49, P1926, DOI 10.1002/hep.22896; Mitani H, 1999, PHOTOCHEM PHOTOBIOL, V69, P41, DOI 10.1562/0031-8655(1999)069<0041:AOHMSE>2.3.CO;2; Montojo J, 2010, BIOINFORMATICS, V26, P2927, DOI 10.1093/bioinformatics/btq562; MOSS AJ, 1975, WESTERN J MED, V122, P471; Mostafavi S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-s1-s4; Nakagawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136994; Okada M, 2010, BIOL PHARM BULL, V33, P1517, DOI 10.1248/bpb.33.1517; Paik YH, 2009, GUT, V58, P1517, DOI 10.1136/gut.2008.157420; Parapuram SK, 2011, J INVEST DERMATOL, V131, P1996, DOI 10.1038/jid.2011.156; Pavlopoulos GA., 2020, ARENA3DWEB INTERACTI; Pearson K, 1900, PHILOS MAG, V50, P157, DOI 10.1080/14786440009463897; PECKHAM DG, 1995, CLIN SCI, V89, P277, DOI 10.1042/cs0890277; POWIS G, 1994, CANCER RES, V54, P2419; Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST; Rajendran R, 2006, Indian J Dent Res, V17, P190; RAMOS SG, 1994, PATHOL INT, V44, P655; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosenbloom J, 2017, METHODS MOL BIOL, V1627, P1, DOI 10.1007/978-1-4939-7113-8_1; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; SHARMA JK, 1987, INT J ORAL MAX SURG, V16, P695, DOI 10.1016/S0901-5027(87)80055-3; Shi-wen X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007438; Singh M, 2010, INDIAN J MED RES, V131, P665; Spyrou G, 2019, 2019 IEEE 19 INT C B; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Takahashi T, 2015, BRIT J DERMATOL, V173, P681, DOI 10.1111/bjd.13779; Tanabe T, 2006, INTERNAL MED, V45, P1243, DOI 10.2169/internalmedicine.45.1759; Tanramluk D, 2009, CHEM BIOL DRUG DES, V74, P16, DOI 10.1111/j.1747-0285.2009.00832.x; Tepper RS, 1997, PEDIATR PULM, V24, P48, DOI 10.1002/(SICI)1099-0496(199707)24:1<48::AID-PPUL8>3.3.CO;2-8; Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001; Tuncer I, 2003, EXP TOXICOL PATHOL, V55, P159, DOI 10.1078/0940-2993-00309; Ursu O, 2019, NUCLEIC ACIDS RES, V47, pD963, DOI 10.1093/nar/gky963; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Verrecchia F, 2007, WORLD J GASTROENTERO, V13, P3056, DOI 10.3748/wjg.v13.i22.3056; VIDT DG, 1982, NEW ENGL J MED, V306, P214; Wang YB, 2014, SCI CHINA LIFE SCI, V57, P201, DOI 10.1007/s11427-013-4604-z; Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537; Wen SL, 2014, J GASTROEN HEPATOL, V29, P1932, DOI 10.1111/jgh.12641; Wengrower D, 2004, INFLAMM BOWEL DIS, V10, P536, DOI 10.1097/00054725-200409000-00007; Wernig G, 2017, P NATL ACAD SCI USA, V114, P4757, DOI 10.1073/pnas.1621375114; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; WOODRUFF HB, 1975, ANAL CHEM, V47, P2027, DOI 10.1021/ac60362a002; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Xu M, 2007, J ETHNOPHARMACOL, V112, P292, DOI 10.1016/j.jep.2007.03.011; Xu SW, 2004, MOL BIOL CELL, V15, P2707, DOI 10.1091/mbc.E03-12-0902; Yu J, 2009, LIVER INT, V29, P25, DOI 10.1111/j.1478-3231.2008.01760.x; Zacharia L., 1957, ACTA RHEUMATOLOGICA, V3, P76; Zhang C, 2016, J CELL MOL MED, V20, P116, DOI 10.1111/jcmm.12709; Zhang XL, 2016, BIOL TRACE ELEM RES, V173, P372, DOI 10.1007/s12011-016-0661-z; Zhi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081612; Zuberi K, 2013, NUCLEIC ACIDS RES, V41, pW115, DOI 10.1093/nar/gkt533	110	2	2	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2021	16	4							e0249687	10.1371/journal.pone.0249687	http://dx.doi.org/10.1371/journal.pone.0249687			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK2GO	33826640	Green Published, gold			2023-01-03	WOS:000638119900010
J	Dorjdagva, J; Batbaatar, E; Svensson, M; Dorjsuren, B; Togtmol, M; Kauhanen, J				Dorjdagva, Javkhlanbayar; Batbaatar, Enkhjargal; Svensson, Mikael; Dorjsuren, Bayarsaikhan; Togtmol, Munkhsaikhan; Kauhanen, Jussi			Does social health insurance prevent financial hardship in Mongolia? Inpatient care: A case in point	PLOS ONE			English	Article							CHALLENGES	Background Protecting people from financial hardship and impoverishment due to health care costs is one of the fundamental purposes of the Mongolian health system. However, the inefficient, oversized hospital sector is considered one of the main shortcomings of the system. The aim of this study is to contribute to policy discussions by estimating the extent of catastrophic health expenditure and impoverishment due to inpatient care at secondary-level and tertiary-level public hospitals and private hospitals. Methods Data were derived from a nationally representative survey, the Household Socio-Economic Survey 2012, conducted by the National Statistical Office of Mongolia. A total of 12,685 households were involved in the study. "Catastrophic health expenditure" is defined as out-of-pocket payments for inpatient care that exceed a threshold of 40% of households' non-discretionary expenditure. The "impoverishment" effect of out-of-pocket payments for inpatient care was estimated as the difference between the poverty level before health care payments and the poverty level after these payments. Results At the threshold of 40% of capacity to pay, 0.31%, 0.07%, and 0.02% of Mongolian households suffered financially as a result of their member(s) staying in tertiary-level and secondary-level public hospitals and private hospitals respectively. About 0.13% of the total Mongolian population was impoverished owing to out-of-pocket payments for inpatient care at tertiary-level hospitals. Out-of-pocket payments for inpatient care at secondary-level hospitals and private hospitals were responsible for 0.10% and 0.09% respectively of the total population being pushed into poverty. Conclusions Although most inpatient care at public hospitals is covered by the social health insurance benefit package, patients who utilized inpatient care at tertiary-level public hospitals were more likely to push their households into financial hardship and poverty than the inpatients at private hospitals. Improving the hospital sector's efficiency and financial protection for inpatients would be a crucial means of attaining universal health coverage in Mongolia.	[Dorjdagva, Javkhlanbayar; Kauhanen, Jussi] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Fac Hlth Sci, Kuopio, Finland; [Batbaatar, Enkhjargal] Univ Eastern Finland, Fac Social Sci & Business Studies, Dept Social Sci, Kuopio, Finland; [Svensson, Mikael] Univ Gothenburg, Inst Med, Sch Publ Hlth & Community Med, Gothenburg, Sweden; [Dorjsuren, Bayarsaikhan] WHO, Dept Hlth Syst Governance & Financing, Geneva, Switzerland; [Togtmol, Munkhsaikhan] Minist Hlth, Ulaanbaatar, Mongolia	University of Eastern Finland; University of Eastern Finland; University of Gothenburg; World Health Organization; Ministry of Health Mongolia	Dorjdagva, J (corresponding author), Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Fac Hlth Sci, Kuopio, Finland.	javkhlanbayar.dorjdagva@uef.fi	Kauhanen, Jussi/ABC-4064-2021	Batbaatar, Enkhjargal/0000-0002-8806-2841				Asian Development Bank, 2008, MONG HLTH SOCI PROT; Bayarsaikhan D, 2015, INT SOC SECUR REV, V68, P93, DOI 10.1111/issr.12089; Bayarsaikhan D, 2005, INT SOC SECUR REV, V58, P27, DOI 10.1111/j.1468-246X.2005.00224.x; Bredenkamp C, 2012, HLTH EQUITY FINANCIA; Center for Global Development Hospitals for Health Working Group, 2015, BETT HOSP BETT HLTH; Center for Health Development, 2017, HLTH IND 2016; Center for Health Development, 2018, HLTH IND 2017; Customer Rights Association of Gobi-Altai Province, 2010, REP EV MON SOC HLTH; Daramragchaa A., 2011, HOSP SERVICES COSTIN; Dorjdagva J, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0572-4; Dorjdagva J, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0395-8; Dorjdagva J, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0281-9; Dorjdagva J, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0185-8; Dorjsuren B., 2017, DEV NATL HLTH FINANC; Jigjidsuren A., 2019, FREE UNIVERSAL ACCES, V19; Limwattananon S, 2007, B WORLD HEALTH ORGAN, V85, P600, DOI 10.2471/BLT.06.033720; Ministry of Health and Sports and Ministry of Finance, 2015, 498345 MIN HLTH SPOR; National Statistical Office of Mongolia, 2013, HOUS SOC SURV 2012; O'Donnell O, 2007, ANAL HLTH EQUITY USI, DOI [10.1596/978-0-8213-6933-3, DOI 10.1596/978-0-8213-6933-3]; Qingyue M, 2011, ALLIANCE HLTH POLICY, P1; Somanathan A, 2015, ASSESSMENT SYSTEMS P; Tandon A., 2000, MEASURING OVERALL HL; The State Great Hural (Parliament) of Mongolia, LAW SOCIAL HLTH INSU; The World Bank, HOSP BEDS 1000 PEOPL; The World Bank HD sector, 2007, MONG HLTH SYST CROSS; Tsevelvaanchig U, 2017, HEALTH POLICY PLANN, V32, P476, DOI 10.1093/heapol/czw157; Tsilaajav T, 2013, MONGOLIA HLTH SYSTEM, V3; United Nations, 2015, AG SUST DEV; Wagstaff A, 2003, HEALTH ECON, V12, P921, DOI 10.1002/hec.776; WHO, 2010, WOR HEALT REP, P1; World Bank, INT COMP PROGR DAT; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5	32	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2021	16	3							e0248518	10.1371/journal.pone.0248518	http://dx.doi.org/10.1371/journal.pone.0248518			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH6VV	33788865	Green Published, gold			2023-01-03	WOS:000636354600004
J	Moller, JK; Sorensen, M; Hardahl, C				Moller, Jens Kjolseth; Sorensen, Martin; Hardahl, Christian			Prediction of risk of acquiring urinary tract infection during hospital stay based on machine-learning: A retrospective cohort study	PLOS ONE			English	Article							CARE-ASSOCIATED INFECTIONS; ELECTRONIC HEALTH RECORDS; SURVEILLANCE	Background Healthcare associated infections (HAI) are a major burden for the healthcare system and associated with prolonged hospital stay, increased morbidity, mortality and costs. Healthcare associated urinary tract infections (HA-UTI) accounts for about 20-30% of all HAI's, and with the emergence of multi-resistant urinary tract pathogens, the total burden of HA-UTI will most likely increase. Objective The aim of the current study was to develop two predictive models, using data from the index admission as well as historic data on a patient, to predict the development of UTI at the time of entry to the hospital and after 48 hours of admission (HA-UTI). The ultimate goal is to predict the individual patient risk of acquiring HA-UTI before it occurs so that health care professionals may take proper actions to prevent it. Methods Retrospective cohort analysis of approx. 300 000 adult admissions in a Danish region was performed. We developed models for UTI prediction with five machine-learning algorithms using demographic information, laboratory results, data on antibiotic treatment, past medical history (ICD10 codes), and clinical data by transformation of unstructured narrative text in Electronic Medical Records to structured data by Natural Language Processing. Results The five machine-learning algorithms have been evaluated by the performance measures average squared error, cumulative lift, and area under the curve (ROC-index). The algorithms had an area under the curve (ROC-index) ranging from 0.82 to 0.84 for the entry model (T = 0 hours after admission) and from 0.71 to 0.77 for the HA-UTI model (T = 48 hours after admission). Conclusion The study is proof of concept that it is possible to create machine-learning models that can serve as early warning systems to predict patients at risk of acquiring urinary tract infections during admission. The entry model and the HA-UTI models perform with a high ROC-index indicating a sufficient sensitivity and specificity, which may make both models instrumental in individualized prevention of UTI in hospitalized patients. The favored machine-learning methodology is Decision Trees to ensure the most transparent results and to increase clinical understanding and implementation of the models.	[Moller, Jens Kjolseth] Univ Hosp Southern Denmark, Lillebaelt Hosp, Dept Clin Microbiol, Vejle, Denmark; [Sorensen, Martin] SAS Inst AS, Copenhagen, Denmark; [Hardahl, Christian] SAS Inst AS, Aarhus, Denmark	University of Southern Denmark; Lillebaelt Hospital; SAS Institute Inc; SAS Institute Inc	Moller, JK (corresponding author), Univ Hosp Southern Denmark, Lillebaelt Hosp, Dept Clin Microbiol, Vejle, Denmark.	jens.kjoelseth.moeller@rsyd.dk		Sorensen, Martin/0000-0001-6928-4521; Moller, Jens Kjolseth/0000-0002-5547-5498	Region of Southern Denmark Research Foundation [17/15659]	Region of Southern Denmark Research Foundation	This study received funding from the Region of Southern Denmark Research Foundation, 17/15659, awarded to JKM.	Centers for Disease Control and Prevention, 2017, NATL HEALTHCARE SAFE; Chakraborty G., 2013, TEXT MINING ANAL PRA; Chang YJ, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0023137, 10.1371/journal.pone.0020029]; Corey KM, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002701; Eriksson R, 2013, J AM MED INFORM ASSN, V20, P947, DOI 10.1136/amiajnl-2013-001708; Freeman R, 2013, J HOSP INFECT, V84, P106, DOI 10.1016/j.jhin.2012.11.031; Gerdes LU, 2013, STUD HEALTH TECHNOL, V192, P1145, DOI 10.3233/978-1-61499-289-9-1145; Girard R, 2017, J HOSP INFECT, V97, P74, DOI 10.1016/j.jhin.2017.05.007; GLENISTER HM, 1993, J HOSP INFECT, V23, P229, DOI 10.1016/0195-6701(93)90028-X; Goldstein BA, 2017, J AM MED INFORM ASSN, V24, P198, DOI 10.1093/jamia/ocw042; Hsu HE, 2015, AM J INFECT CONTROL, V43, P592, DOI 10.1016/j.ajic.2015.02.019; Hur EY, 2019, CIN-COMPUT INFORM NU, V37, P463, DOI 10.1097/CIN.0000000000000506; Jin SJ, 2013, SCAND J INFECT DIS, V45, P672, DOI 10.3109/00365548.2013.799287; King C, 2012, J HOSP INFECT, V82, P219, DOI 10.1016/j.jhin.2012.05.004; Leth RA, 2006, J HOSP INFECT, V62, P71, DOI 10.1016/j.jhin.2005.04.002; Luo L, 2019, INT J HEALTH PLAN M, V34, pE1236, DOI 10.1002/hpm.2769; Mevik K, 2019, INT J QUAL HEALTH C, V31, P535, DOI 10.1093/intqhc/mzy210; Obermeyer Z, 2016, NEW ENGL J MED, V375, P1216, DOI 10.1056/NEJMp1606181; Redder J., 2016, THESIS; Redder JD, 2016, J HOSP INFECT, V92, P397, DOI 10.1016/j.jhin.2015.12.009; Redder JD, 2015, J HOSP INFECT, V91, P231, DOI 10.1016/j.jhin.2015.05.011; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Taylor G, 2016, ANTIMICROB RESIST IN, V5, DOI 10.1186/s13756-016-0118-3; Taylor RA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194085; Ye CY, 2019, J MED INTERNET RES, V21, DOI 10.2196/13719; Zarb P, 2012, EUROSURVEILLANCE, V17, P4	26	0	0	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2021	16	3							e0248636	10.1371/journal.pone.0248636	http://dx.doi.org/10.1371/journal.pone.0248636			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RH6VV	33788888	Green Published, gold			2023-01-03	WOS:000636354600003
J	Varpio, L; Bader-Larsen, K; Hamwey, M; Durning, S; Meyer, H; Cruthirds, D; Artino, A				Varpio, Lara; Bader-Larsen, Karlen; Hamwey, Meghan; Durning, Steven; Meyer, Holly; Cruthirds, Danette; Artino, Anthony			Delivering patient care during large-scale emergency situations: Lessons from military care providers	PLOS ONE			English	Article							MASS CASUALTY	Background Today, physicians are at the front lines of a pandemic response. Military physicians are uniquely trained to excel in such large-scale emergency situations. Civilian physicians can harness military know-how, but it will require research into military healthcare responses-specifically, we need to learn lessons from military interprofessional healthcare teams (MIHTs). Methods This research answers two questions: What are the characteristics of successful MIHTs? Why are those characteristics important to MIHT success in large-scale emergency situations? Using a Grounded Theory approach, 30 interviews were conducted soliciting perspectives from the broadest range of healthcare professionals who had experiences working in and leading MIHTs. Purposive sampling was used to recruit participants broadly across: contexts where MIHTs work; military branches; ranks; genders; and healthcare professions. Data were iteratively collected and analyzed. Results 30 participants were interviewed (18 male (60%); 21 officers (70%); 9 enlisted (30%)) who held various healthcare occupations (medic/tech/corpsman (9); nurse (7); physician (7); dentist (2); occupational therapist (2); chaplain (1); physician's assistant (1); and psychiatrist (1)). Six characteristics of successful MIHTs that are directly applicable to large-scale emergency situations were identified thatthat clustered into two themes: own your purposes and responsibilities (through mission focus and ethical bearing) and get it done, safely (via situational awareness, adaptability, and leadership with followership). Conclusions This study provides insights, informed by decades of military service and training, to help civilian physicians succeed in large-scale emergency situations. These experiences from the war front can support today's pandemic responses on the home front.	[Varpio, Lara; Durning, Steven] Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA; [Bader-Larsen, Karlen; Hamwey, Meghan; Meyer, Holly] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA; [Cruthirds, Danette] Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, Bethesda, MD 20814 USA; [Artino, Anthony] George Washington Univ, Sch Med & Hlth Sci, Dept Hlth Human Funct & Rehabil Sci, Washington, DC 20052 USA	Uniformed Services University of the Health Sciences - USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Uniformed Services University of the Health Sciences - USA; George Washington University	Bader-Larsen, K (corresponding author), Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA.	karlen.bader.ctr@usuhs.edu		Bader Larsen, Karlen/0000-0003-3233-8703	Uniformed Services University	Uniformed Services University	This study was funded to LV by the Uniformed Services University (www.usuhs.edu).	[Anonymous], 2019, ACTIVE SHOOTER INCID; Cornett E, 2016, BOARD HLTH SCI POLIC; Crawford Juanita, 2014, Nurs Manage, V45, P30, DOI 10.1097/01.NUMA.0000451999.41720.30; Elster EA, 2013, JAMA-J AM MED ASSOC, V310, P475, DOI 10.1001/jama.2013.167481; Hunt R, 2015, WHITE HOUSE INITIATI; King DR, 2015, J TRAUMA ACUTE CARE, V78, P594, DOI 10.1097/TA.0000000000000561; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Leung C, 2018, J CRIT CARE, V46, P99, DOI 10.1016/j.jcrc.2018.05.001; Lozada MJ, 2019, J TRAUMA ACUTE CARE, V86, P128, DOI 10.1097/TA.0000000000002089; Patton M. Q., 2002, QUALITATIVE RES EVAL, V3rd; Pereira BMT, 2010, J CRANIOFAC SURG, V21, P982, DOI 10.1097/SCS.0b013e3181e1e791; RAND Corporation, 2019, DOMESTIC TERRORISM; Raux M, 2019, INTENS CARE MED, V45, P1231, DOI 10.1007/s00134-019-05724-9; Ries J, 2020, THERE ISNT ENOUGH ME; Sohn VY, 2007, J SURG RES, V138, P25, DOI 10.1016/j.jss.2006.09.006; STRUTZEL E, 1968, NURS RES, V17, P364; The Defense Health Agency, MEDICAL ED TRAINING; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Tschannen D, 2018, INT J MED EDUC, V9, P182, DOI 10.5116/ijme.5b30.9a84; Varpio L., 2018, MIL MED, V183, P448, DOI [10.1093/milmed/usy08729741728, DOI 10.1093/MILMED/USY08729741728]; Varpio L, 2021, MED TEACH, V43, P32, DOI 10.1080/0142159X.2020.1791318; Varpio L, 2021, J INTERPROF CARE, V35, P55, DOI 10.1080/13561820.2020.1711718	22	1	1	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2021	16	3							e0248286	10.1371/journal.pone.0248286	http://dx.doi.org/10.1371/journal.pone.0248286			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH6VV	33788854	gold, Green Published			2023-01-03	WOS:000636354600024
J	Gill, PS; Poduval, S; Thakur, JS; Iqbal, R				Gill, Paramjit S.; Poduval, Shoba; Thakur, Jarnail S.; Iqbal, Romaina			COVID-19, community trials, and inclusion	LANCET			English	Editorial Material							MINORITY ETHNIC-GROUPS; UNDER-REPRESENTATION		[Gill, Paramjit S.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; [Poduval, Shoba] UCL, Dept Primary Care & Populat Hlth, UCL eHlth Unit, London, England; [Thakur, Jarnail S.] Post Grad Inst Med Educ & Res, Dept Community Med, Chandigarh, India; [Thakur, Jarnail S.] Post Grad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh, India; [Iqbal, Romaina] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan	University of Warwick; University of London; University College London; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Aga Khan University	Gill, PS (corresponding author), Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.	p.gill.1@warwick.ac.uk						Berry SM, 2015, JAMA-J AM MED ASSOC, V313, P1619, DOI 10.1001/jama.2015.2316; Blundell R, 2020, FISC STUD, V41, P291, DOI 10.1111/1475-5890.12232; Butler CC, 2021, LANCET, V397, P1063, DOI 10.1016/S0140-6736(21)00461-X; Chastain DB, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2021971; Ekezie W, 2021, J PUBLIC HEALTH-UK, V43, pE258, DOI 10.1093/pubmed/fdaa196; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Gill PS, 2013, BRIT J GEN PRACT, V63, P342, DOI 10.3399/bjgp13X668456; Gill PS, 2013, FAM PRACT, V30, P233, DOI 10.1093/fampra/cms054; He JZ, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4139-0; Horby PW, 2021, LANCET, V397, P605, DOI 10.1016/S0140-6736(21)00149-5; Institute of Health Equity, 2020, HLTH EQ ENGL MARM RE; National Institute for Health Research, 2020, INCLUDE ROADM CAN HE; Public Health England, 2020, NFDA NEWS 0401; Treweek S, 2020, LANCET, V395, P1955, DOI 10.1016/S0140-6736(20)31380-5; WHO, 2008, PHARMAFORUM 0121; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4	16	4	4	2	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2021	397	10279					1036	1037						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QZ0AN	33743853	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000630397800003
J	Silva, RCD; de Souza, MA; da Silva, JYP; Ponciano, CD; Viera, VB; Bertozzo, CCDS; Guerra, GC; Araujo, DFD; da Conceicao, MM; Dias, CDQ; Oliveira, ME; Soares, JKB				de Franca Silva, Roberta Cristina; Albuquerque de Souza, Mikaelle; Pereira da Silva, Jaielison Yandro; Ponciano, Carolina da Silva; Viera, Vanessa Bordin; de Menezes Santos Bertozzo, Camila Carolina; Guerra, Gerlane Coelho; de Souza Araujo, Daline Fernandes; da Conceicao, Marta Maria; Querino Dias, Celina de Castro; Oliveira, Maria Elieidy; Barbosa Soares, Juliana Kessia			Evaluation of the effectiveness of macaiba palm seed kernel (Acrocomia intumescens drude) on anxiolytic activity, memory preservation and oxidative stress in the brain of dyslipidemic rats	PLOS ONE			English	Article							POLYUNSATURATED FATTY-ACIDS; ANXIETY-RELATED BEHAVIOR; FISH-OIL; DIETARY SUPPLEMENTATION; NEUROTROPHIC FACTOR; MEMBRANE-LIPIDS; AXIS FUNCTION; ANTIOXIDANTS; GLUTATHIONE; DEFICITS	Macaiba palm seed kernel is a source of lipids and phenolic compounds. The objective of this study was to evaluate the effects of macaiba palm seed kernel on anxiety, memory, and oxidative stress in the brain of health and dyslipidemic rats. Forty rats were used, divided into 4 groups (n = 10 each): control (CONT), dyslipidemic (DG), kernel (KG), and Dyslipidemic kernel (DKG). Dyslipidemia was induced using a high fat emulsion for 14 days before treatment. KG and DKG received 1000 mg/kg of macaiba palm seed kernel per gavage for 28 days. After treatment, anxiety tests were carried out using the Open Field Test (OFT), Elevated Plus Maze (EPM), and the Object Recognition Test (ORT) to assess memory. In the animals' brain tissue, levels of malondialdehyde (MDA) and total glutathione (GSH) were quantified to determine oxidative stress. The data were treated with Two Way ANOVA followed by Tukey (p <0.05). Results demonstrated that the animals treated with kernel realized more rearing. DG and KG groomed less compared with CONT and DKG compared with all groups in OFT. KG spent more time in aversive open arms compared with CONT and DKG compared with all groups in EPM. Only DKG spent more time in the central area in EMP. KG and DKG showed a reduction in the exploration rate and MDA values (p <0.05). Data showed that macaiba palm seed kernel consumption induced anxiolytic-like behaviour and decreased lipids peroxidation in rats' brains. On the other hand, this consumption by healthy and dyslipidemic animals compromises memory.	[de Franca Silva, Roberta Cristina; Pereira da Silva, Jaielison Yandro; Ponciano, Carolina da Silva; Viera, Vanessa Bordin; de Menezes Santos Bertozzo, Camila Carolina; Barbosa Soares, Juliana Kessia] Univ Fed Campina Grande, Cuite, PB, Brazil; [Albuquerque de Souza, Mikaelle; da Conceicao, Marta Maria; Querino Dias, Celina de Castro; Oliveira, Maria Elieidy; Barbosa Soares, Juliana Kessia] Univ Fed Paraiba, Joao Pessoa, Paraiba, Brazil; [Guerra, Gerlane Coelho; de Souza Araujo, Daline Fernandes] Univ Fed Rio Grande do Norte, Natal, RN, Brazil	Universidade Federal de Campina Grande; Universidade Federal da Paraiba; Universidade Federal do Rio Grande do Norte	Silva, RCD (corresponding author), Univ Fed Campina Grande, Cuite, PB, Brazil.	robertasaron@gmail.com		Silva, Jaielison Yandro/0000-0002-9297-654X	CNPQ (National Council for Scientific and Technological Development) Brazil [Universal 423166/2018-2]	CNPQ (National Council for Scientific and Technological Development) Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study was supported by CNPQ (National Council for Scientific and Technological Development) Brazil -Universal 423166/2018-2. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. JKBS is the researcher responsible for using the funding. There was no additional external funding received for this study.	Alrefaie Z, 2015, INT J VITAM NUTR RES, V85, P282, DOI 10.1024/0300-9831/a000286; Alzoubi KH, 2013, PHYSIOL BEHAV, V119, P72, DOI 10.1016/j.physbeh.2013.06.011; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Andrich DE, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00372; Atreya I, 2008, J INTERN MED, V263, P591, DOI 10.1111/j.1365-2796.2008.01953.x; Bahaeddin Z, 2017, NUTR NEUROSCI, V20, P317, DOI [10.1080/1028415X.2015.1126954, 10.1080/1028415x.2015.1126954]; Barbosa MQ, 2018, FOOD FUNCT, V9, P2891, DOI [10.1039/c7fo01764b, 10.1039/C7FO01764B]; Batool Z, 2018, PLANT FOOD HUM NUTR, V73, P7, DOI 10.1007/s11130-018-0655-4; Batool Z, 2016, BRAIN RES BULL, V120, P63, DOI 10.1016/j.brainresbull.2015.11.001; Bayraktar K, 2012, TURK J FISH AQUAT SC, V12, P661, DOI 10.4194/1303-2712-v12_3_14; Beilharz JE, 2015, NUTRIENTS, V7, P6719, DOI 10.3390/nu7085307; Benzie IFF, 1999, METHOD ENZYMOL, V299, P15; Bora P.S., 2004, 101 NCIA TECNOLOGIA, V4, P158, DOI [10.1080/11358120409487755, DOI 10.1080/11358120409487755]; Budzynska B, 2015, PSYCHOPHARMACOLOGY, V232, P931, DOI 10.1007/s00213-014-3728-6; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Cavaliere G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00818; Czysz AH, 2013, CNS NEUROL DISORD-DR, V12, P466, DOI 10.2174/1871527311312040005; Das UN, 2003, BRAIN DEV-JPN, V25, P251, DOI 10.1016/S0387-7604(02)00221-8; Siqueira EMD, 2012, FOOD RES INT, V45, P427, DOI 10.1016/j.foodres.2011.11.005; Dias LS, 2013, IND CROP PROD, V49, P610, DOI 10.1016/j.indcrop.2013.06.005; Divneet Kaur, 2017, Pharmacognosy Journal, V9, P638, DOI 10.5530/pj.2017.5.101; Dominguez-Avila JA, 2015, FOOD CHEM, V168, P529, DOI 10.1016/j.foodchem.2014.07.092; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Egawa J, 2016, J PHYSIOL-LONDON, V594, P4565, DOI 10.1113/JP270590; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Fernandes FS, 2011, NUTRITION, V27, P1040, DOI 10.1016/j.nut.2010.11.001; FOLCH J, 1957, J BIOL CHEM, V226, P497; de Melo MFFT, 2017, INT J DEV NEUROSCI, V61, P58, DOI 10.1016/j.ijdevneu.2017.06.006; Gadkari PV, 2015, FOOD BIOPROD PROCESS, V93, P122, DOI 10.1016/j.fbp.2013.12.004; Ganji A, 2017, METAB BRAIN DIS, V32, P503, DOI 10.1007/s11011-016-9940-9; Gustavsson M, 2010, NUTR RES, V30, P279, DOI 10.1016/j.nutres.2010.04.005; HANDLEY SL, 1984, N-S ARCH PHARMACOL, V327, P1, DOI 10.1007/BF00504983; HIGBY WK, 1962, J FOOD SCI, V27, P42, DOI 10.1111/j.1365-2621.1962.tb00055.x; Hovatta I, 2010, NEUROSCI RES, V68, P261, DOI 10.1016/j.neures.2010.08.007; Hryhorczuk C, 2017, PSYCHONEUROENDOCRINO, V83, P142, DOI 10.1016/j.psyneuen.2017.06.002; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Komaki A., 2015, AVICENNA J NEURO PSY, V2, P2015, DOI [10.17795/ajnpp-27189, DOI 10.17795/AJNPP-27189]; Krolow R, 2014, CURR NEUROPHARMACOL, V12, P193, DOI 10.2174/1570159X11666131120223530; Kumar V, 2014, ROBBINS COTRAN PATHO; Lalanza JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085049; Leffa DD, 2015, FOOD RES INT, V77, P649, DOI 10.1016/j.foodres.2015.10.006; Lescano CH, 2015, J MED FOOD, V18, P656, DOI 10.1089/jmf.2014.0077; Lindqvist A, 2006, EUR J NEUROL, V13, P1385, DOI 10.1111/j.1468-1331.2006.01500.x; Liu LX, 2009, FOOD CHEM, V112, P35, DOI 10.1016/j.foodchem.2008.05.038; Mangge H, 2014, WORLD J CARDIOL, V6, P462, DOI 10.4330/wjc.v6.i6.462; Markakis P., 1982, ANTHOCYANINS FOOD CO, P263; Martins S, 2011, BIOTECHNOL ADV, V29, P365, DOI 10.1016/j.biotechadv.2011.01.008; Matrisciano F, 2020, NEUROBIOL STRESS, V12, DOI 10.1016/j.ynstr.2020.100222; Mizrahi M, 2014, NANOMED-NANOTECHNOL, V10, P1353, DOI 10.1016/j.nano.2014.03.015; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Moon ML, 2014, METABOLISM, V63, P1131, DOI 10.1016/j.metabol.2014.06.002; Muller CP, 2015, BBA-MOL CELL BIOL L, V1851, P1052, DOI 10.1016/j.bbalip.2014.12.014; Muthaiyah B, 2014, J ALZHEIMERS DIS, V42, P1397, DOI 10.3233/JAD-140675; Oliveira VB, 2012, FOOD RES INT, V48, P170, DOI 10.1016/j.foodres.2012.03.011; Pase CS, 2015, J NUTR BIOCHEM, V26, P1200, DOI 10.1016/j.jnutbio.2015.05.013; Patrick RP, 2015, FASEB J, V29, P2207, DOI 10.1096/fj.14-268342; do Nascimento ADP, 2016, J SUPERCRIT FLUID, V111, P1, DOI 10.1016/j.supflu.2016.01.013; PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24, P525, DOI 10.1016/0091-3057(86)90552-6; Perveen T., 2016, J BIOCH MOL BIOL, V49, P69; Pudell C, 2014, EUR J NEUROSCI, V39, P266, DOI 10.1111/ejn.12406; Pulido R, 2000, J AGR FOOD CHEM, V48, P3396, DOI 10.1021/jf9913458; Rachetti ALF, 2013, BEHAV BRAIN RES, V237, P283, DOI 10.1016/j.bbr.2012.09.048; Sharma S, 2013, INT J OBESITY, V37, P382, DOI 10.1038/ijo.2012.48; Shin AC, 2010, INT J OBESITY, V34, P1218, DOI 10.1038/ijo.2010.34; Silva-Junior E.V., 2020, J OURNAL AGRONOMY CR, P1, DOI [10.1111/jac.12435, DOI 10.1111/JAC.12435]; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; Stutz B, 2016, EMBO MOL MED, V8, P3, DOI 10.15252/emmm.201505749; Surveswaran S, 2007, FOOD CHEM, V102, P938, DOI 10.1016/j.foodchem.2006.06.033; Tang MM, 2018, PROSTAG LEUKOTR ESS, V128, P11, DOI 10.1016/j.plefa.2017.11.001; Upadhyay P, 2018, BIOMED PHARMACOTHER, V97, P1046, DOI 10.1016/j.biopha.2017.11.008; Voigt JP, 2005, BRAIN RES, V1046, P145, DOI 10.1016/j.brainres.2005.03.048; Warneke W, 2014, PHARMACOL BIOCHEM BE, V116, P45, DOI 10.1016/j.pbb.2013.11.016; Xu DY, 2012, LIFE SCI, V90, P30, DOI 10.1016/j.lfs.2011.10.010; YAMAMURO Y, 1995, BRAIN RES, V684, P1, DOI 10.1016/0006-8993(95)00290-7; Yang XL, 2010, FOOD CHEM TOXICOL, V48, P2374, DOI 10.1016/j.fct.2010.05.074; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015	78	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2021	16	3							e0246184	10.1371/journal.pone.0246184	http://dx.doi.org/10.1371/journal.pone.0246184			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY9GW	33730037	gold, Green Published			2023-01-03	WOS:000630345000033
J	Romani, A; Simone, G; Campo, M; Moncini, L; Bernini, R				Romani, Annalisa; Simone, Gabriele; Campo, Margherita; Moncini, Lorenzo; Bernini, Roberta			Sweet chestnut standardized fractions from sustainable circular process and green tea extract: In vitro inhibitory activity against phytopathogenic fungi for innovative applications in green agriculture	PLOS ONE			English	Article							HYDROLYZABLE TANNINS; PLANT-EXTRACTS; ANTIOXIDANT; MECHANISM; OIL	In the present study, the antifungal activities of two commercial tannins-rich dry fractions towards different filamentous fungi of agronomical and food interest were evaluated. In particular, a standardized fraction from sweet chestnut (Castanea sativa Mill.) wood by-products and a commercial green tea (Camellia sinensis L.) leaf extract were tested at different concentrations (0.1-5.0% and 0.2% w/v respectively). The Sweet Chestnut Wood fraction was produced in an industrial plant through an environmentally and economically sustainable process, involving hot-water extraction and a sequence of membrane filtration steps with different molecular cut-offs for fractionation and concentration of the active principles. The Sweet Chestnut Wood and Green Tea Leaf extracts were characterised via HPLC/DAD/MS quali-quantitative analysis. The first extract showed a polyphenolic content of 20.5% w/w, 100% hydrolysable tannins; the second one showed a polyphenolic content of 87.5% w/w, of which 96.2% epigallocatechin gallate and 3.8% epicatechin gallate. The antifungal activity of the Sweet Chestnut fraction in aqueous solutions was evaluated towards different filamentous fungi, in particular telluric phytopathogens (Fusarium oxysporum f. sp. radicis-lycopersici; Fusarium solani; Rhizoctonia solani; Sclerotium rolfsii) and post harvest pathogens (Botrytis cinerea, that can also attack field plants; Penicillium digitatum; Penicillium italicum), and compared to the activity of Green Tea Leaf extract solutions. The experimental results evidenced, for almost all tested fungi, inhibition of the mycelial growth rate in presence of tannins. The lowest inhibitions were observed for B. cinerea (7.5%, to 28.9%) and P. italicum (53.8% in 5.0% w/v Sweet Chestnut extract substrate). A proportional inhibitory effect to tannin concentration was observed for F. oxysporum f. sp. radicis-lycopersici and F. solani (from 33.7% to 56.6%), R. solani (from 29.7% to 68.8%) and P. digitatum (64.7% to 87.0%). The highest effect resulted for S. rolfsii, (5.0% to 100%).	[Romani, Annalisa; Campo, Margherita] Univ Florence, PHYTOLAB Pharmaceut Cosmet Food supplement Techno, Dept Stat, Comp,Applicat,Giuseppe Parenti DiSIA, Florence, Italy; [Romani, Annalisa; Simone, Gabriele] Univ Florence, City Prato Univ Ctr Educ & Sci Serv, PIN Scrl, Prato, Italy; [Simone, Gabriele; Moncini, Lorenzo] ISIS Leopoldo II di Lorena, Ctr Ric Strumenti Biotecnici Settore Agricolofore, Grosseto, Italy; [Campo, Margherita] Consortium INSTM, Florence, Italy; [Bernini, Roberta] Univ Tuscia, Dept Agr & Forest Sci DAFNE, Viterbo, Italy	University of Florence; University of Florence; Tuscia University	Campo, M (corresponding author), Univ Florence, PHYTOLAB Pharmaceut Cosmet Food supplement Techno, Dept Stat, Comp,Applicat,Giuseppe Parenti DiSIA, Florence, Italy.; Campo, M (corresponding author), Consortium INSTM, Florence, Italy.	margherita.campo@unifi.it		BERNINI, Roberta/0000-0002-2548-3876	Tuscany Region, POR CREO FESR 2014-2020 "Formulation of new sustainable products for agriculture based on natural extracts", Plants for Plants: "Boost conventional agriculture's confidence: new organic bio-stimulants to reduce water, nutrients and pesticid [LIFE18 ENV/NL/000043]	Tuscany Region, POR CREO FESR 2014-2020 "Formulation of new sustainable products for agriculture based on natural extracts", Plants for Plants: "Boost conventional agriculture's confidence: new organic bio-stimulants to reduce water, nutrients and pesticid	This research is part of the following projects: Tuscany Region, POR FESR 2014/2020. Nat-BackeryInnov "Innovative production of a bakery line based on natural functional extracts for wellness and sports"; Tuscany Region, POR CREO FESR 2014-2020 "Formulation of new sustainable products for agriculture based on natural extracts", LIFE18 ENV/NL/000043 Plants for Plants: "Boost conventional agriculture's confidence: new organic bio-stimulants to reduce water, nutrients and pesticide demand".	Agnolucci M, 2020, FOOD MICROBIOL, V92, DOI 10.1016/j.fm.2020.103598; Al-Samarrai G, 2012, ANN AGR ENV MED, V19, P673; Bargiacchi E, 2013, ACTA HORTIC, V1009, P111, DOI 10.17660/ActaHortic.2013.1009.13; Basirico L, 2019, ANIMAL, V13, P2847, DOI 10.1017/S1751731119001356; Biancalani C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163357; Bule M, 2020, RECENT ADVANCES IN NATURAL PRODUCTS ANALYSIS, P132; Buzzini P, 2008, MINI-REV MED CHEM, V8, P1179, DOI 10.2174/138955708786140990; Campo M, 2016, NAT PROD COMMUN, V11, P409; de Albuquerque CC, 2006, BRAZ ARCH BIOL TECHN, V49, P527, DOI 10.1590/S1516-89132006000500001; Chan EWC, 2011, PHARMACOGN RES, V3, P266, DOI 10.4103/0974-8490.89748; Chiarini A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/471790; Funatogawa K, 2004, MICROBIOL IMMUNOL, V48, P251, DOI 10.1111/j.1348-0421.2004.tb03521.x; Hoque MZ., 2016, PROGRESSIVE AGR, V27, P154; Imperatori F, 2019, NAT PROD RES, V33, P3465, DOI 10.1080/14786419.2018.1481841; Jigisha A., 2012, INT RES J PHARM, V3, P139; Kinay P, 2007, CROP PROT, V26, P647, DOI 10.1016/j.cropro.2006.06.002; Korge K, 2020, INT J FOOD SCI TECH, V55, P3043, DOI 10.1111/ijfs.14569; Li YL, 2017, EUR J PLANT PATHOL, V149, P299, DOI 10.1007/s10658-017-1177-x; Liu HM, 2010, LETT APPL MICROBIOL, V51, P258, DOI 10.1111/j.1472-765X.2010.02888.x; Lizarraga D, 2007, FEBS J, V274, P4802, DOI 10.1111/j.1742-4658.2007.06010.x; Lucarini M, 2018, MOLECULES, V23, DOI 10.3390/molecules23081888; Lupini C, 2009, RES VET SCI, V87, P482, DOI 10.1016/j.rvsc.2009.04.007; Mastrogiovanni F, 2021, NAT PROD RES, V35, P1696, DOI 10.1080/14786419.2019.1627350; Mastrogiovanni F, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030548; Mastrogiovanni F, 2020, NAT PROD RES, V34, P1465, DOI 10.1080/14786419.2018.1508149; Messini A, 2017, INT DAIRY J, V66, P6, DOI 10.1016/j.idairyj.2016.10.012; Oerke EC, 2006, J AGR SCI, V144, P31, DOI 10.1017/S0021859605005708; Okuda T, 2005, PHYTOCHEMISTRY, V66, P2012, DOI 10.1016/j.phytochem.2005.04.023; ONG KC, 1995, EXPERIENTIA, V51, P577, DOI 10.1007/BF02128747; Osorio E, 2010, IND CROP PROD, V31, P153, DOI 10.1016/j.indcrop.2009.09.017; Reygaert WC, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00434; Romani A, 2006, J PHARMACEUT BIOMED, V41, P415, DOI 10.1016/j.jpba.2005.11.031; Romani A, 2014, USE SWEET CHESTNUT T; Romani A, 2012, FOOD CHEM, V130, P214, DOI 10.1016/j.foodchem.2011.07.009; Sharma A, 2012, FOOD CHEM, V135, P672, DOI 10.1016/j.foodchem.2012.04.143; Singh P, 2008, J SCI FOOD AGR, V88, P2421, DOI 10.1002/jsfa.3342; Tao Shutian, 2010, Archives of Phytopathology and Plant Protection, V43, P1564, DOI 10.1080/03235400802583834; Tian J, 2011, INT J FOOD MICROBIOL, V145, P464, DOI 10.1016/j.ijfoodmicro.2011.01.023; Turchetti B, 2005, PHYTOTHER RES, V19, P44, DOI 10.1002/ptr.1622; Wu HS, 2009, BIOL RES, V42, P297, DOI [10.4067/S0716-97602009000300004, /S0716-97602009000300004]; YUGARANI T, 1993, PLANTA MED, V59, P28, DOI 10.1055/s-2006-959598	41	6	6	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2021	16	2							e0247298	10.1371/journal.pone.0247298	http://dx.doi.org/10.1371/journal.pone.0247298			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QO3ZL	33617600	Green Published, gold			2023-01-03	WOS:000623082400048
J	Wahl, A; Gralinski, LE; Johnson, CE; Yao, WB; Kovarova, M; Dinnon, KH; Liu, HW; Madden, VJ; Krzystek, HM; De, C; White, KK; Gully, K; Schafer, A; Zaman, T; Leist, SR; Grant, PO; Bluemling, GR; Kolykhalov, AA; Natchus, MG; Askin, FB; Painter, G; Browne, EP; Jones, CD; Pickles, RJ; Baric, RS; Garcia, JV				Wahl, Angela; Gralinski, Lisa E.; Johnson, Claire E.; Yao, Wenbo; Kovarova, Martina; Dinnon, Kenneth H., III; Liu, Hongwei; Madden, Victoria J.; Krzystek, Halina M.; De, Chandrav; White, Kristen K.; Gully, Kendra; Schafer, Alexandra; Zaman, Tanzila; Leist, Sarah R.; Grant, Paul O.; Bluemling, Gregory R.; Kolykhalov, Alexander A.; Natchus, Michael G.; Askin, Frederic B.; Painter, George; Browne, Edward P.; Jones, Corbin D.; Pickles, Raymond J.; Baric, Ralph S.; Garcia, J. Victor			SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801	NATURE			English	Article							REVERSE GENETICS; SARS; KNOWLEDGE; COVID-19; CDNA	All coronaviruses known to have recently emerged as human pathogens probably originatedin bats(1). Here we use a single experimental platform based on immunodeficient mice implanted with human lung tissue (hereafter, human lung-only mice (LoM)) to demonstrate the efficient in vivo replication of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as two endogenous SARS-like bat coronaviruses that show potential for emergence as human pathogens. Virus replication in this model occurs in bona fide human lung tissue and does not require any type of adaptation of the virus or the host. Our results indicate that bats contain endogenous coronaviruses that are capable of direct transmission to humans. Our detailed analysis of in vivo infection with SARS-CoV-2 in human lung tissue from LoM showed a predominant infection of human lung epithelial cells, including type-2 pneumocytes that are present in alveoli and ciliated airway cells. Acute infection with SARS-CoV-2 was highly cytopathic and induced a robust and sustained type-I interferon and inflammatory cytokine and chemokine response. Finally, we evaluated a therapeutic and pre-exposure prophylaxis strategy for SARS-CoV-2 infection. Our results show that therapeutic and prophylactic administration of EIDD-2801-an oral broad-spectrum antiviral agent that is currently in phase II/III clinical trials-markedly inhibited SARS-CoV-2 replication in vivo, and thus has considerable potential for the prevention and treatment of COVID-19.	[Wahl, Angela; Johnson, Claire E.; Yao, Wenbo; Kovarova, Martina; De, Chandrav; Garcia, J. Victor] Univ North Carolina Chapel Hill, Int Ctr Adv Translat Sci, Chapel Hill, NC 27599 USA; [Wahl, Angela; Johnson, Claire E.; Yao, Wenbo; Kovarova, Martina; De, Chandrav; Browne, Edward P.; Garcia, J. Victor] Univ North Carolina Chapel Hill, Div Infect Dis, Dept Med, Chapel Hill, NC 27599 USA; [Wahl, Angela; Johnson, Claire E.; Yao, Wenbo; Kovarova, Martina; De, Chandrav; Browne, Edward P.; Garcia, J. Victor] Univ North Carolina Chapel Hill, Ctr AIDS Res, Chapel Hill, NC 27599 USA; [Gralinski, Lisa E.; Dinnon, Kenneth H., III; Gully, Kendra; Schafer, Alexandra; Leist, Sarah R.; Baric, Ralph S.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA; [Dinnon, Kenneth H., III; Browne, Edward P.; Pickles, Raymond J.; Baric, Ralph S.] Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC USA; [Liu, Hongwei; Krzystek, Halina M.; Zaman, Tanzila; Grant, Paul O.; Jones, Corbin D.] Univ North Carolina Chapel Hill, Dept Biol, Chapel Hill, NC USA; [Liu, Hongwei; Krzystek, Halina M.; Zaman, Tanzila; Grant, Paul O.; Jones, Corbin D.] Univ North Carolina Chapel Hill, Dept Genet, Chapel Hill, NC USA; [Madden, Victoria J.; White, Kristen K.] Univ North Carolina Chapel Hill, Microscopy Serv Lab, Chapel Hill, NC USA; [Bluemling, Gregory R.; Kolykhalov, Alexander A.; Painter, George] Emory Univ, Emory Inst Drug Dev EIDD, Atlanta, GA 30322 USA; [Bluemling, Gregory R.; Kolykhalov, Alexander A.; Natchus, Michael G.; Painter, George] Emory DRIVE, Drug Innovat Ventures, Atlanta, GA USA; [Askin, Frederic B.] Univ North Carolina Chapel Hill, Dept Pathol, Chapel Hill, NC USA; [Painter, George] Emory Univ, Dept Pharmacol & Chem Biol, Atlanta, GA 30322 USA; [Browne, Edward P.] Univ North Carolina Chapel Hill, UNC HIV Cure Ctr, Chapel Hill, NC USA; [Pickles, Raymond J.] Univ North Carolina Chapel, Marsico Lung Inst, Chapel Hill, NC USA; [Baric, Ralph S.] Univ North Carolina Chapel Hill, Rapid Emerging Antiviral Drug Discovery Initiat, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Emory University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Emory University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Garcia, JV (corresponding author), Univ North Carolina Chapel Hill, Int Ctr Adv Translat Sci, Chapel Hill, NC 27599 USA.; Garcia, JV (corresponding author), Univ North Carolina Chapel Hill, Div Infect Dis, Dept Med, Chapel Hill, NC 27599 USA.; Garcia, JV (corresponding author), Univ North Carolina Chapel Hill, Ctr AIDS Res, Chapel Hill, NC 27599 USA.	victor_garcia@med.unc.edu	, Pathology Services Core/CEZ-2246-2022; Ariel, Pablo/AGJ-4118-2022	Dinnon, Kenneth/0000-0002-8942-1551; Kovarova, Martina/0000-0001-7152-1709; Madden, Victoria/0000-0002-7909-7743	National Institutes of Health [R21AI113736, U19AI100625, R01 AI108197, R01AI123010, R01AI111899, R01AI140799, R01MH108179]; North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill; North Carolina Coronavirus Relief Fund; Cancer Center Support Grant [P30 CA016086]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill; North Carolina Coronavirus Relief Fund; Cancer Center Support Grant	We thank current and past members of the laboratory of J.V.G. for technical assistance; technicians at the UNC Animal Histopathology and Laboratory Medicine Core and Division of Comparative Medicine; the UNC School of Medicine Bioinformatics and Analytics Research Collaborative (BARC) for providing technical support; and K. Mollan and B. Shook-Sa of the UNC CFAR Biostatistics Core for providing statistical support. This work was supported by funding from National Institutes of Health grants R21AI113736 (R.J.P.), U19AI100625 and R01 AI108197 (R.S.B.), Fast Grants (L.E.G.), R01AI123010 (A.W.), R01AI111899 (J.V.G.), R01AI140799 (J.V.G.) and R01MH108179 (J.V.G.). This project was also supported by the North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill with funding from the North Carolina Coronavirus Relief Fund established and appropriated by the North Carolina General Assembly. The Microscopy Services Laboratory, Department of Pathology and Laboratory Medicine, is supported in part by P30 CA016086 Cancer Center Support Grant to the UNC Lineberger Comprehensive Cancer Center.	[Anonymous], 2017, MSPHERE, DOI DOI https://doi.org/10.1128/mSphere.00346-17; Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4; Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Cockrell AS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.226; Cox RM, 2021, NAT MICROBIOL, V6, P11, DOI 10.1038/s41564-020-00835-2; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; Dinnon Kenneth H, 2020, bioRxiv, DOI 10.1101/2020.05.06.081497; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Franks Teri J, 2008, Proc Am Thorac Soc, V5, P763, DOI 10.1513/pats.200803-025HR; Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027; Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011; Kim PS, 2020, JAMA-J AM MED ASSOC, V324, P2149, DOI 10.1001/jama.2020.22813; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06; Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113; Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985; Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134; Merck Sharp & Dohme Corp, 2020, EFFICACY SAFETY MOLN; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Regeneron Pharmaceuticals Inc, 2020, REGENERONS COVID 19; Rockx Barry, 2020, Science, V368, P1012, DOI 10.1126/science.abb7314; Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; Siu KL, 2009, J BIOL CHEM, V284, P16202, DOI 10.1074/jbc.M109.008227; Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005; Sticher ZM, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01719-19; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010; TOOTS M, 2019, SCI, V11; VERHEIDEN A, 2020, J VIROL, V94; Wahl A, 2019, NAT BIOTECHNOL, V37, P1163, DOI 10.1038/s41587-019-0225-9; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100; Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533; Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	52	152	154	18	79	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 18	2021	591	7850					451	+		10.1038/s41586-021-03312-w	http://dx.doi.org/10.1038/s41586-021-03312-w		FEB 2021	20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY6JL	33561864	Green Accepted, Bronze, Green Published, Green Submitted			2023-01-03	WOS:000627311500001
J	Sharif, S; Rochwerg, B				Sharif, Sameer; Rochwerg, Bram			Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Sharif, Sameer; Rochwerg, Bram] McMaster Univ, Hamilton, ON, Canada	McMaster University	Sharif, S (corresponding author), McMaster Univ, Hamilton, ON, Canada.							Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028; Pierrakos C, 2010, CRIT CARE, V14, DOI 10.1186/cc8872; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; WISE J, 2020, BMJ-BRIT MED J, V371, DOI DOI 10.1136/BMJ.M4530	4	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB	2021	174	2					JC16	JC16		10.7326/ACPJ202102160-016	http://dx.doi.org/10.7326/ACPJ202102160-016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ2CK	33524280				2023-01-03	WOS:000619497100006
J	Yan, SM; Wu, G				Yan, Shaomin; Wu, Guang			Is lymphopenia different between SARS and COVID-19 patients?	FASEB JOURNAL			English	Article						COVID-19; lymphopenia; glucocorticoids; apoptosis; SARS-CoV; SARS-CoV-2	ACUTE RESPIRATORY SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; HUMAN CORONAVIRUS NL63; SPIKE PROTEIN; CLINICAL CHARACTERISTICS; MONOCYTE DEACTIVATION; FUNCTIONAL RECEPTOR; IMMUNE-RESPONSE; CATHEPSIN-L; APOPTOSIS	Lymphopenia is commonly observed in SARS and COVID-19 patients although the lymphocyte count is not always below 0.8 x 10(9)/L in all the patients. It is suggested that lymphopenia serves as a useful predictor for prognosis in the patients. It is also hypothesized that lymphopenia is related to glucocorticoids and apoptosis. However, the ordering between lymphopenia and apoptosis appears different between SARS and COVID-19 patients, ie, lymphopenia is prior to apoptosis in SARS patients whereas apoptosis is prior to lymphopenia in COVID-19 patients. This paper attempts to figure out this contradiction through three players, lymphopenia, glucocorticoids, and apoptosis. Although the literature does not provide a solid explanation, the level of glucocorticoids could determine the ordering between lymphopenia and apoptosis because the administration of high doses of glucocorticoids could lead to lymphopenia whereas low doses of glucocorticoids could benefit patients. In the meantime, this paper raises several questions, which need to be answered in order to better understand the whole course of COVID-19.	[Yan, Shaomin; Wu, Guang] Guangxi Acad Sci, Natl Engn Res Ctr Nonfood Biorefinery, State Key Lab Nonfood Biomass & Enzyme Technol, Guangxi Biomass Engn Technol Res Ctr,Guangxi Key, 98 Daling Rd, Nanning 530007, Guangxi, Peoples R China		Wu, G (corresponding author), Guangxi Acad Sci, Natl Engn Res Ctr Nonfood Biorefinery, State Key Lab Nonfood Biomass & Enzyme Technol, Guangxi Biomass Engn Technol Res Ctr,Guangxi Key, 98 Daling Rd, Nanning 530007, Guangxi, Peoples R China.	hongguanglishibahao@gxas.cn		Yan, Shaomin/0000-0001-7642-3972; Wu, Guang/0000-0003-0775-5759				Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Baraniuk JN, 1997, AM J RESP CRIT CARE, V155, P704, DOI 10.1164/ajrccm.155.2.9032216; Barnes Peter J, 2011, Br J Pharmacol, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Cui W, 2003, CLIN INFECT DIS, V37, P857, DOI 10.1086/378587; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; Dharel N, 2008, HEPATOLOGY, V47, P1136, DOI 10.1002/hep.22176; Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560; Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Du LY, 2007, BIOCHEM BIOPH RES CO, V359, P174, DOI 10.1016/j.bbrc.2007.05.092; Fathi N, 2020, CELL BIOL INT, V44, P1792, DOI 10.1002/cbin.11403; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; FAUCI AS, 1975, IMMUNOLOGY, V28, P669; Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152; Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8; Girardot T, 2017, APOPTOSIS, V22, P295, DOI 10.1007/s10495-016-1325-3; Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10; Goodman S, 2002, CRIT CARE, V6, P381; Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828; Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3; Herold MJ, 2006, CELL MOL LIFE SCI, V63, P60, DOI 10.1007/s00018-005-5390-y; Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC; Ho T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010013; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102; Hofmann H, 2006, J VIROL, V80, P8639, DOI 10.1128/JVI.00560-06; Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8; Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943; Hotchkiss RS, 2005, CLIN INFECT DIS, V41, pS465, DOI 10.1086/431998; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18; Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12; Kleine-Weber H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34859-w; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Lang ZW, 2003, CHINESE MED J-PEKING, V116, P976; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; Lu HY, 2005, WORLD J GASTROENTERO, V11, P2971, DOI 10.3748/wjg.v11.i19.2971; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Ma-Lauer Y, 2016, P NATL ACAD SCI USA, V113, pE5192, DOI 10.1073/pnas.1603435113; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; Maneechotesuwan K, 2008, J ALLERGY CLIN IMMUN, V121, P43, DOI 10.1016/j.jaci.2007.10.011; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10; Mukerjee R, 2010, CELL CYCLE, V9, P4569, DOI 10.4161/cc.9.22.13836; Munoz-Fontela C, 2011, J IMMUNOL, V187, P6428, DOI 10.4049/jimmunol.1101459; Nelemans T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100961; Newton AH, 2016, SEMIN IMMUNOPATHOL, V38, P471, DOI 10.1007/s00281-016-0558-0; Pampin M, 2006, J VIROL, V80, P8582, DOI 10.1128/JVI.00031-06; Panesar NS, 2008, MED HYPOTHESES, V71, P298, DOI 10.1016/j.mehy.2008.03.019; Panesar NS, 2004, EUR J CLIN INVEST, V34, P382, DOI 10.1111/j.1365-2362.2004.01347.x; Panesar NS, 2003, LANCET, V361, P1985, DOI 10.1016/S0140-6736(03)13557-X; Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Petrovsky N, 1998, CYTOKINE, V10, P307, DOI 10.1006/cyto.1997.0289; Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331; Shieh WJ, 2005, HUM PATHOL, V36, P303, DOI 10.1016/j.humpath.2004.11.006; Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10; Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076; Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4; Tang PS, 2008, AM J PHYSIOL-LUNG C, V294, pL632, DOI 10.1152/ajplung.00262.2007; Thompson BT, 2003, CRIT CARE MED, V31, pS253, DOI 10.1097/01.CCM.0000057900.19201.55; Volk HD, 1996, INTENS CARE MED, V22, pS474, DOI 10.1007/BF01743727; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Weber SU, 2008, CRIT CARE, V12, DOI 10.1186/cc7088; Wheeler DS, 2009, CRIT CARE, V13, DOI 10.1186/cc8162; Wu XD, 2004, CELL RES, V14, P400, DOI 10.1038/sj.cr.7290240; Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363; Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; Zheng F, 2020, EUR REV MED PHARMACO, V24, P3404, DOI 10.26355/eurrev_202003_20711; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011	87	8	8	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2021	35	2							e21245	10.1096/fj.202002512	http://dx.doi.org/10.1096/fj.202002512			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RY3BC	33495994	Green Published			2023-01-03	WOS:000647789600106
J	Hao, Z; Li, Z; Huo, JJ; Li, JD; Liu, FH; Yin, P				Hao, Zhuang; Li, Zhen; Huo, Jinjin; Li, Jiandong; Liu, Fenghua; Yin, Peng			Effects of Chinese wolfberry and Astragalus extract on the antioxidant capacity of Tibetan pig liver	PLOS ONE			English	Article							PEROXISOMES	The objective of this study is to determine the effect of Chinese wolfberry (Lycium barbarum) and Astragalus (Astragalus membranaceus) extract (WAE) on the antioxidant capacity of Tibetan pig liver, and discussed the regulatory effect of WAE on the liver antioxidant mechanism. Twelve healthy 120-day-old Tibetan black pigs (35 +/- 2 kg) were divided randomly into two groups. The WAE group was fed a basal diet supplemented with 1% WAE for 90 days. The control group was fed the same diet, but without the WAE. We found that liver superoxide dismutase 1 (SOD1) activity (P<0.05), total antioxidative capacity (T-AOC) (P<0.05), and catalase (CAT) activity (P<0.01) significantly increased in the WAE group compared with the control group; malondialdehyde (MDA) content decreased, but this was not significant (P >0.05). Transcriptome sequencing analysis detected 106 differentially expressed genes (DEGs) related to oxidative stress. GO enrichment analysis showed these DEGs were involved in the positive regulation of reactive oxygen metabolism and biosynthesis, process regulation, and regulation of the oxidative stress response. KEGG Pathway enrichment analysis showed they were enriched in the PI3K-Akt, AMPK, Rap1, and peroxisome signaling pathways. The expression levels of key peroxisome biosynthesis genes (e.g., PEX3 and PEX11B) and key antioxidant genes (e.g., CAT and SOD1) were significantly higher in the WAE group than in the control group. The PRDX1 and PRDX5 content also was significantly higher in the WAE group. This study showed that the WAE regulated the antioxidant and anti-stress ability of Tibetan pig liver through a "peroxisome antioxidant-oxidant stress" signaling pathway.	[Hao, Zhuang; Li, Zhen; Huo, Jinjin; Li, Jiandong; Liu, Fenghua] Beijing Univ Agr, Coll Anim Sci & Technol, Beijing, Peoples R China; [Yin, Peng] Chinese Acad Sci, Inst Microbiol, Beijing, Peoples R China	Beijing University of Agriculture; Chinese Academy of Sciences; Institute of Microbiology, CAS	Liu, FH (corresponding author), Beijing Univ Agr, Coll Anim Sci & Technol, Beijing, Peoples R China.; Yin, P (corresponding author), Chinese Acad Sci, Inst Microbiol, Beijing, Peoples R China.	liufenghua1209@126.com; leilaileila@126.com			Beijing Municipal Science and Technology Project [D171100002117002]	Beijing Municipal Science and Technology Project	This work was supported by a grant from Beijing Municipal Science and Technology Project (No. D171100002117002).	Abdelaziz AR, 2019, J INVEST DERMATOL, V139, pB3, DOI 10.1016/j.jid.2019.06.012; Alagawany M, 2018, POULTRY SCI; Amagase H, 2011, FOOD RES INT, V44, P1702, DOI 10.1016/j.foodres.2011.03.027; Aranovich A, 2014, J CELL SCI, V127, P3675, DOI 10.1242/jcs.146282; Bajor M, 2018, BRIT J CANCER, V119, P873, DOI 10.1038/s41416-018-0263-y; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bonekamp NA, 2010, BIOFACTORS OXFORD EN, V35, P345; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Chen JS, 2020, J ANIM PHYSIOL AN N, V104, P1106, DOI 10.1111/jpn.13247; Delille HK, 2009, HISTOCHEM CELL BIOL, V131, P441, DOI 10.1007/s00418-009-0561-9; DHAUNSI GS, 1992, J BIOL CHEM, V267, P6870; Ding CB, 2017, J CELL MOL MED, V21, P193, DOI 10.1111/jcmm.12955; ECONOMOU KD, 1991, J AM OIL CHEM SOC, V68, P109, DOI 10.1007/BF02662329; Ellah MRA, 2010, COMP CLIN PATHOL, V19, P615; Esteve-Codina A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-552; Fagarasanu A, 2007, ANNU REV CELL DEV BI, V23, P321, DOI 10.1146/annurev.cellbio.23.090506.123456; Farag MR, 2018, ECOTOX ENVIRON SAFE, V156, P311, DOI 10.1016/j.ecoenv.2018.03.010; Feng Y, 2018, J FORESTRY RES, V29, P851, DOI 10.1007/s11676-017-0472-x; Fransen M, 2012, BBA-MOL BASIS DIS, V1822, P1363, DOI 10.1016/j.bbadis.2011.12.001; Gueant JL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03054-w; Gulcin I, 2004, FOOD CHEM, V87, P393, DOI 10.1016/j.foodchem.2003.12.008; Gunawan A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072298; Guo WW, 2018, INT J BIOL MACROMOL, V112, P608, DOI 10.1016/j.ijbiomac.2018.02.009; Hagen S., 2019, INT J MOL SCI; Han R, 2017, MOL MED REP, V15; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Huang YF, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9573291; Jia L, 2016, SCI REP-UK, V6, DOI 10.1038/srep36209; Jia N, 2019, INT J BIOL MACROMOL, V132, P213, DOI 10.1016/j.ijbiomac.2019.03.196; Jiang JB, 2010, INT J RHEUM DIS, V13, P396, DOI 10.1111/j.1756-185X.2010.01555.x; Kim W, 2015, J TRADITIONAL COMPLE, V6, P294, DOI [10.1016/j.jtcme.2015.10.002PMID:27419096, DOI 10.1016/J.JTCME.2015.10.002PMID:27419096]; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Knoops B, 2011, ANTIOXID REDOX SIGN, V15, P817, DOI 10.1089/ars.2010.3584; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Li MH, 2011, LWT-FOOD SCI TECHNOL, V44, P1745, DOI 10.1016/j.lwt.2011.02.017; Li XM, 2007, INT J BIOL MACROMOL, V40, P461, DOI 10.1016/j.ijbiomac.2006.11.002; Liu YH, 2018, ANIM NUTR, V4, P113, DOI 10.1016/j.aninu.2018.01.007; Lopez-Lluch G, 2008, EXP GERONTOL, V43, P813, DOI 10.1016/j.exger.2008.06.014; Matsuzaki T, 2008, J CELL BIOL, V183, P1275, DOI 10.1083/jcb.200806062; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Oboh G, 2007, FOOD CHEM, V102, P178, DOI 10.1016/j.foodchem.2006.05.048; Ramayo-Caldas Y, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-547; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005; Samborski A, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.113.107870; Sanchez-Valle V, 2012, CURR MED CHEM, V19, P4850, DOI 10.2174/092986712803341520; Schrader M, 2007, BIOESSAYS, V29, P1105, DOI 10.1002/bies.20659; Schrader M, 2006, BBA-MOL CELL RES, V1763, P1755, DOI 10.1016/j.bbamcr.2006.09.006; Sies H, 2015, REDOX BIOL, V4, P180, DOI 10.1016/j.redox.2015.01.002; Slamenova D, 2008, NEOPLASMA, V55, P394; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Stolz DB, 2002, HEPATOLOGY, V36, P81, DOI 10.1053/jhep.2002.33716; Tiippana E, 2016, SCAND J PAIN, V12, P19, DOI 10.1016/j.sjpain.2016.02.008; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Turner-Ivey B, 2013, ONCOGENE, V32, P5302, DOI 10.1038/onc.2012.624; Wanders RJA, 2006, ANNU REV BIOCHEM, V75, P295, DOI 10.1146/annurev.biochem.74.082803.133329; Wu JD, 2010, J HEPATOL, V53, P73, DOI 10.1016/j.jhep.2010.01.032; Xiao J, 2012, J ETHNOPHARMACOL, V139, P462, DOI 10.1016/j.jep.2011.11.033; Yang RF, 2015, J FUNCT FOODS, V17, P903, DOI 10.1016/j.jff.2015.06.045; Yang WJ, 2009, BIOL PHARM BULL, V32, P1021, DOI 10.1248/bpb.32.1021; Yong JW, 2012, PLOS ONE, V7; Zhang Q, 2015, FOOD NUTR RES, V59, DOI 10.3402/fnr.v59.28696; Zhou Y, 2015, J MOL NEUROSCI, V55, P941, DOI 10.1007/s12031-014-0449-6; Zhu J, 2013, CARBOHYD POLYM, V98, P8, DOI 10.1016/j.carbpol.2013.04.057	67	4	4	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2021	16	1							e0245749	10.1371/journal.pone.0245749	http://dx.doi.org/10.1371/journal.pone.0245749			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA9GX	33503027	gold, Green Published			2023-01-03	WOS:000613751800033
J	Hsu, G; Kovacs, B				Hsu, Greta; Kovacs, Balazs			Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To examine county level associations between the prevalence of medical and recreational cannabis stores (referred to as dispensaries) and opioid related mortality rates. DESIGN Panel regression methods. SETTING 812 counties in the United States in the 23 states that allowed legal forms of cannabis dispensaries to operate by the end of 2017. PARTICIPANTS The study used US mortality data from the Centers for Disease Control and Prevention combined with US census data and data from Weedmaps.com on storefront dispensary operations. Data were analyzed at the county level by using panel regression methods. MAIN OUTCOME MEASURE The main outcome measures were the log transformed, age adjusted mortality rates associated with all opioid types combined, and with subcategories of prescription opioids, heroin, and synthetic opioids other than methadone. The associations of medical dispensary and recreational dispensary counts with age adjusted mortality rates were also analyzed. RESULTS County level dispensary count (natural logarithm) is negatively related to the log transformed, age adjusted mortality rate associated with all opioid types (3=-0.17, 95% confidence interval-0.23 to-0.11). According to this estimate, an increase from one to two storefront dispensaries in a county is associated with an estimated 17% reduction in all opioid related mortality rates. Dispensary count has a particularly strong negative association with deaths caused by synthetic opioids other than methadone (3=-0.21, 95% confidence interval-0.27 to-0.14), with an estimated 21% reduction in mortality rates associated with an increase from one to two dispensaries. Similar associations were found for medical versus recreational storefront dispensary counts on synthetic (non-methadone) opioid related mortality rates. CONCLUSIONS Higher medical and recreational storefront dispensary counts are associated with reduced opioid related death rates, particularly deaths associated with synthetic opioids such as fentanyl. While the associations documented cannot be assumed to be causal, they suggest a potential association between increased prevalence of medical and recreational cannabis dispensaries and reduced opioid related mortality rates. This study highlights the importance of considering the complex supply side of related drug markets and how this shapes opioid use and misuse.	[Hsu, Greta] Univ Calif Davis, Grad Sch Management, Davis, CA 95616 USA; [Kovacs, Balazs] Yale Univ, Sch Management, 165 Whitney Ave, New Haven, CT 06520 USA	University of California System; University of California Davis; Yale University	Kovacs, B (corresponding author), Yale Univ, Sch Management, 165 Whitney Ave, New Haven, CT 06520 USA.	balazs.kovacs@yale.edu						[Anonymous], 2017, AM J PUBLIC HLTH, V107, P1827, DOI [10.2105/ AJPH.2017.304059, DOI 10.2105/AJPH.2017.304059]; [Anonymous], 2019, PRESCRIPTION DRUG AB; Aviram J, 2017, PAIN PHYSICIAN, V20, pE755; Bachhuber MA, 2014, JAMA INTERN MED, V174, P1668, DOI 10.1001/jamainternmed.2014.4005; CDC Injury Center, 2020, DRUG OVERDOSE DEATHS; Chan NW, 2020, ECON INQ, V58, P589, DOI 10.1111/ecin.12819; Freisthler B, 2016, ADDICTION, V111, P1027, DOI 10.1111/add.13301; Freisthler B, 2014, DRUG ALCOHOL DEPEN, V143, P244, DOI 10.1016/j.drugalcdep.2014.07.036; Gladden RM, 2019, MMWR-MORBID MORTAL W, V68, P737, DOI 10.15585/mmwr.mm6834a2; Gujarati D.N., 2008, MCGRAW HILL ED, V5th; Hsu G, 2019, STRATEGIC MANAGE J, V40, P2214, DOI 10.1002/smj.3078; Hsu G, 2018, ORGAN SCI, V29, P172, DOI 10.1287/orsc.2017.1167; Jalal H, 2018, SCIENCE, V361, P1218, DOI 10.1126/science.aau1184; Liang D, 2019, SUBST USE MISUSE, V54, P2387, DOI 10.1080/10826084.2019.1650775; Liang D, 2019, DRUG ALCOHOL REV, V38, P597, DOI 10.1111/dar.12964; Livingston MD, 2000, RECREATIONAL CANNABI; Lucas P, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-019-0278-6; Meier MH, 2012, P NATL ACAD SCI USA, V109, pE2657, DOI 10.1073/pnas.1206820109; Monnat SM, 2019, AM J PUBLIC HEALTH, V109, P1084, DOI 10.2105/AJPH.2019.305136; Pacula RL, 2014, J POLICY ANAL MANAG, V33, P212, DOI 10.1002/pam.21726; Powell D, 2018, J HEALTH ECON, V58, P29, DOI 10.1016/j.jhealeco.2017.12.007; Prescription Drug Overdose Data & Statistics, 2013, GUID ICD 9 CM ICD 10; Romano JP, 2005, ECONOMETRICA, V73, P1237, DOI 10.1111/j.1468-0262.2005.00615.x; Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265; Shi YY, 2019, DRUG ALCOHOL DEPEN, V194, P13, DOI 10.1016/j.drugalcdep.2018.09.016; Shi YY, 2016, PREV MED, V91, P1, DOI 10.1016/j.ypmed.2016.07.015; Shover CL, 2019, P NATL ACAD SCI USA, V116, P12624, DOI 10.1073/pnas.1903434116; Smart R, 2019, AM J DRUG ALCOHOL AB, V45, P644, DOI 10.1080/00952990.2019.1669626; Smith RA, 2020, ECON INQ, V58, P569, DOI 10.1111/ecin.12825; Staggs B, 2020, ORANGE CTY REGIST; Walsh Z, 2017, CLIN PSYCHOL REV, V51, P15, DOI 10.1016/j.cpr.2016.10.002; Wen HF, 2018, JAMA INTERN MED, V178, P673, DOI 10.1001/jamainternmed.2018.1007; Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4; Wooldridge J, 2012, INTRO ECONOMETRICS M	34	9	9	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2021	372								m4957	10.1136/bmj.m4957	http://dx.doi.org/10.1136/bmj.m4957			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE0QS	33504472	hybrid, Green Published			2023-01-03	WOS:000615912900008
J	Ben Lagha, A; Pellerin, G; Vaillancourt, K; Grenier, D				Ben Lagha, Amel; Pellerin, Genevieve; Vaillancourt, Katy; Grenier, Daniel			Effects of a tart cherry (Prunus cerasus L.) phenolic extract on Porphyromonas gingivalis and its ability to impair the oral epithelial barrier	PLOS ONE			English	Article							POLYPHENOLS; IRON; PATHOGENESIS; PERIODONTITIS; GINGIPAINS; MECHANISMS; EXPRESSION; CLAUDIN-4; VIRULENCE; OCCLUDIN	Periodontal diseases, including gingivitis and periodontitis, are a global oral health problem. Porphyromonas gingivalis, a key pathogen involved in the onset of periodontitis, is able to colonize the subgingival epithelium and invade the underlying connective tissue due to the contribution of cysteine proteases known as gingipains. In this study, we investigated the effects of a phenolic extract prepared from tart cherry (Prunus cerasus L.) juice on the growth, adherence, and protease activity of P. gingivalis. We also assessed the protective effect of the tart cherry extract on the disruption of the oral epithelial barrier induced by P. gingivalis. The tart cherry extract that contains procyanidins and quercetin and its derivatives (rutinoside, glucoside) as the most important phenolic compounds attenuated P. gingivalis growth, reduced adherence to an experimental basement membrane matrix model, and decreased the protease activities of P. gingivalis. The tart cherry extract also exerted a protective effect on the integrity of the oral epithelial barrier in an in vitro model infected with P. gingivalis. More specifically, the extract prevented a decrease in transepithelial electrical resistance as well as the destruction of tight junction proteins (zonula occludens-1 and occludin). These results suggest that the tart cherry phenolic extract may be a promising natural product for the treatment of periodontitis through its ability to attenuate the virulence properties of P. gingivalis and curtail the ability of this pathogen to impair the oral epithelial barrier.	[Ben Lagha, Amel; Pellerin, Genevieve; Vaillancourt, Katy; Grenier, Daniel] Univ Laval, Oral Ecol Res Grp, Fac Dent, Quebec City, PQ, Canada	Laval University	Grenier, D (corresponding author), Univ Laval, Oral Ecol Res Grp, Fac Dent, Quebec City, PQ, Canada.	Daniel.Grenier@greb.ulaval.ca	Grenier, Daniel/E-5557-2015	Grenier, Daniel/0000-0003-0878-4674	Laboratoire de Contro le Microbiologique de l'Universite Laval [2020-11]	Laboratoire de Contro le Microbiologique de l'Universite Laval	DG; 2020-11; Laboratoire de Contro le Microbiologique de l'Universite Laval; The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alba CMA, 2019, CRIT REV FOOD SCI, V59, P626, DOI 10.1080/10408398.2017.1384918; Allaker RP, 2015, VIRULENCE, V6, P196, DOI 10.4161/21505594.2014.983783; Amano A, 2003, J PERIODONTOL, V74, P90, DOI 10.1902/jop.2003.74.1.90; Amasheh M, 2008, J NUTR, V138, P1067, DOI 10.1093/jn/138.6.1067; Andrian E, 2004, INFECT IMMUN, V72, P4689, DOI 10.1128/IAI.72.8.4689-4698.2004; [Anonymous], 2018, AM J TRANSPLANT S1, V18, P10, DOI DOI 10.1109/JSEN.2018.2870228; Ben Lagha A, 2020, ANAEROBE, V65, DOI 10.1016/j.anaerobe.2020.102266; Ben Lagha A, 2020, PHYTOTHER RES, V34, P886, DOI 10.1002/ptr.6574; Ben Lagha A, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty030; Ben Lagha A, 2015, J AGR FOOD CHEM, V63, P6999, DOI 10.1021/acs.jafc.5b01525; Bodet C, 2006, J DENT RES, V85, P235, DOI 10.1177/154405910608500306; Carrasco-Pozo C, 2013, J AGR FOOD CHEM, V61, P5291, DOI 10.1021/jf400150p; Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002; Chai SC, 2018, FOOD FUNCT, V9, P3185, DOI [10.1039/c8fo00468d, 10.1039/C8FO00468D]; Checchi V, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144923; Daglia M, 2012, CURR OPIN BIOTECH, V23, P174, DOI 10.1016/j.copbio.2011.08.007; Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333; Feghali K, 2012, J AGR FOOD CHEM, V60, P5728, DOI 10.1021/jf203304v; Fitzpatrick RE, 2009, FUTURE MICROBIOL, V4, P471, DOI 10.2217/FMB.09.18; Frencken JE, 2017, J CLIN PERIODONTOL, V44, pS94, DOI 10.1111/jcpe.12677; Grenier D, 2003, INFECT IMMUN, V71, P4742, DOI 10.1128/IAI.71.8.4742-4748.2003; Grenier D, 2011, CURR DRUG TARGETS, V12, P322, DOI 10.2174/138945011794815310; Groger S, 2008, J PERIODONTAL RES, V43, P604, DOI 10.1111/j.1600-0765.2007.01019.x; Groeger S, 2010, EUR J ORAL SCI, V118, P582, DOI 10.1111/j.1600-0722.2010.00782.x; Hajishengallis G, 2014, TRENDS IMMUNOL, V35, P3, DOI 10.1016/j.it.2013.09.001; Hajishengallis G, 2012, ADV EXP MED BIOL, V946, P69, DOI 10.1007/978-1-4614-0106-3_5; Jain S, 2010, PERIODONTOL 2000, V54, P53, DOI 10.1111/j.1600-0757.2009.00333.x; Katz J, 2000, INFECT IMMUN, V68, P1441, DOI 10.1128/IAI.68.3.1441-1449.2000; Kelley DS, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030368; Khokhar S, 2003, FOOD CHEM, V81, P133, DOI 10.1016/S0308-8146(02)00394-1; Kirakosyan A, 2018, FOOD CHEM, V252, P142, DOI 10.1016/j.foodchem.2018.01.084; Konkel JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01403; Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579-018-0089-x; Lemanceau P, 2009, ADV BOT RES, V51, P491, DOI 10.1016/S0065-2296(09)51012-9; Lopez NJ, 2000, J PERIODONTOL, V71, P948, DOI 10.1902/jop.2000.71.6.948; McCune LM, 2011, CRIT REV FOOD SCI, V51, P1, DOI 10.1080/10408390903001719; Mila I, 1996, PHYTOCHEMISTRY, V42, P1551, DOI 10.1016/0031-9422(96)00174-4; Mysak J, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/476068; Nakayama M, 2017, JPN DENT SCI REV, V53, P134, DOI 10.1016/j.jdsr.2017.06.001; Nigri F, 2016, SURG NEUROL INT S31, V7, pS785; Ohya M, 2016, MICROB PATHOGENESIS, V94, P54, DOI 10.1016/j.micpath.2015.10.016; Pan WY, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368-019-0064-z; Popadiak K, 2007, J IMMUNOL, V178, P7242, DOI 10.4049/jimmunol.178.11.7242; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; Suzuki T, 2009, J NUTR, V139, P965, DOI 10.3945/jn.108.100867; Vitale KC, 2017, CURR SPORT MED REP, V16, P230, DOI 10.1249/JSR.0000000000000385; Wang SS, 2019, LIFE SCI, V227, P129, DOI 10.1016/j.lfs.2019.04.029; Wilensky A, 2015, J INNATE IMMUN, V7, P127, DOI 10.1159/000365970; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W	49	4	4	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2021	16	1							e0246194	10.1371/journal.pone.0246194	http://dx.doi.org/10.1371/journal.pone.0246194			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA8QK	33497417	Green Published, gold			2023-01-03	WOS:000613707100027
J	Jabar, A; Madni, A; Bashir, S; Tahir, N; Usman, F; Rahim, MA; Jan, N; Shah, H; Khan, A; Khan, S				Jabar, Abdul; Madni, Asadullah; Bashir, Sajid; Tahir, Nayab; Usman, Faisal; Rahim, Muhammad Abdur; Jan, Nasrullah; Shah, Hassan; Khan, Arshad; Khan, Safiullah			Statistically optimized pentazocine loaded microsphere for the sustained delivery application: Formulation and characterization	PLOS ONE			English	Article							ETHYL CELLULOSE MICROSPHERES; PARTICLE-SIZE DISTRIBUTION; DISPERSION STIRRING SPEED; IN-VITRO EVALUATION; RHEOLOGICAL PROPERTIES; PLGA NANOPARTICLES; RELEASE; PAIN; ETHYLCELLULOSE; MICROPARTICLES	Pentazocine (PTZ) is a narcotic analgesic used to manage moderate to severe, acute and chronic pains. In this study, PTZ loaded Ethyl cellulose microsphere has been formulated for sustained release and improved bioavailability of PTZ. These microspheres were fabricated by oil in water emulsion solvent evaporation technique. A three factorial, three levels Box-Behnken design was applied to investigate the influence of different formulation components and process variables on the formulation response using the numeric approach through the design expert((R)) software. All the formulations were characterized for the morphology, different physicochemical properties and the results were supported with the ANOVA analysis, three dimensional contour graphs and regression equations. The maximum percentage yield was 98.67% with 98% entrapment of PTZ. The mean particle size of the formulations ranges from 50-148 mu m, which directly relates to the concentration of polymer and inversely proportional to the stirring speed. SEM revealed the spherical shape of PTZ microspheres with porous structures. These are physically, chemically and thermally stable as confirmed through Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction (PXRD) and thermal gravimetric (TG) analysis respectively. The microspheres provided a sustained release of the PTZ for more than 12 hours, following zero order with fickian and non fickian diffusion. The results indicate that prepared microspheres can be a potential drug delivery system (DDS) for the delivery of PTZ in the management of pains.	[Jabar, Abdul; Madni, Asadullah; Rahim, Muhammad Abdur; Jan, Nasrullah; Shah, Hassan; Khan, Arshad; Khan, Safiullah] Islamia Univ Bahawalpur, Dept Pharm, Bahawalpur, Pakistan; [Bashir, Sajid; Tahir, Nayab] Univ Sargodha, Coll Pharm, Sargodha, Pakistan; [Usman, Faisal] BZ Univ, Dept Pharmaceut, Multan, Pakistan	Islamia University of Bahawalpur; University of Sargodha; Bahauddin Zakariya University	Madni, A (corresponding author), Islamia Univ Bahawalpur, Dept Pharm, Bahawalpur, Pakistan.	asadpharmacist@hotmail.com	Tahir, Nayab/AFT-6470-2022; Jan, Nasrullah/GPP-6186-2022	Jan, Nasrullah/0000-0002-1279-2397; Madni, Prof. Dr. M. Asadullah/0000-0002-0388-9867				Al Malyan M, 2006, J CRANIOFAC SURG, V17, P302, DOI 10.1097/00001665-200603000-00018; Alnaief M, 2018, CARBOHYD POLYM, V180, P264, DOI 10.1016/j.carbpol.2017.10.038; Baudonnet L, 2004, J DISPER SCI TECHNOL, V25, P183, DOI 10.1081/DIS-120030665; Baudonnet L, 2002, J DISPER SCI TECHNOL, V23, P499, DOI 10.1081/DIS-120014018; Boni FI, 2016, DRUG DEV IND PHARM, V42, P1283, DOI 10.3109/03639045.2015.1125915; Bonnie RJ, 2019, AM J PUBLIC HEALTH, V109, P31, DOI 10.2105/AJPH.2018.304881; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Budhian A, 2007, INT J PHARM, V336, P367, DOI 10.1016/j.ijpharm.2006.11.061; Chandak AR, 2010, PHARM DEV TECHNOL, V15, P296, DOI 10.3109/10837450903188501; Chapman C Richard, 2017, J Pain, V18, DOI 10.1016/j.jpain.2016.11.004; Choudhury A., 2019, J APPL PHARM RES, V7, P1; Dhakar RC., 2012, J DRUG DELIVERY THER, V2; Elbahri Z, 2005, POLYM BULL, V54, P353, DOI 10.1007/s00289-005-0385-2; Fang X, 2016, THER CLIN RISK MANAG, V12, P535, DOI 10.2147/TCRM.S103853; Furuishi T, 2008, BIOL PHARM BULL, V31, P1439, DOI 10.1248/bpb.31.1439; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gaur PK, 2014, J FOOD DRUG ANAL, V22, P542, DOI 10.1016/j.jfda.2014.05.001; Gupta Rishikesh, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P729; Hacene YC, 2016, INT J PHARMACEUT, V506, P138, DOI 10.1016/j.ijpharm.2016.04.047; Haznedar S, 2004, INT J PHARMACEUT, V269, P131, DOI 10.1016/j.ijpharm.2003.09.015; Hernandez RM, 2010, ADV DRUG DELIVER REV, V62, P711, DOI 10.1016/j.addr.2010.02.004; Homs M, 2018, COLLOID SURFACE A, V536, P204, DOI 10.1016/j.colsurfa.2017.06.009; Hou CD, 2012, DRUG DEV IND PHARM, V38, P848, DOI 10.3109/03639045.2011.630394; Jamekhorshid A, 2014, RENEW SUST ENERG REV, V31, P531, DOI 10.1016/j.rser.2013.12.033; Jyothi NVN, 2010, J MICROENCAPSUL, V27, P187, DOI 10.3109/02652040903131301; Kang H, 2006, POLYMER, V47, P7927, DOI 10.1016/j.polymer.2006.09.017; Kar M, 2007, PHARMAZIE, V62, P122, DOI 10.1691/ph.2007.2.6062; Kashif PM, 2017, AAPS PHARMSCITECH, V18, P1810, DOI 10.1208/s12249-016-0653-5; Kawai K, 2017, FAM PRACT, V34, P656, DOI 10.1093/fampra/cmx034; Khairnar Gokul, 2014, Journal of Pharmaceutical Investigation, V44, P411, DOI 10.1007/s40005-014-0118-3; King CD, 2013, PAIN, V154, P476, DOI 10.1016/j.pain.2012.12.009; Koban L, 2016, EMOTION, V16, P24, DOI 10.1037/emo0000087; Li JL, 2013, J NUCL MATER, V440, P283, DOI 10.1016/j.jnucmat.2013.05.020; Li Y, 2020, MATER LETT, V264, DOI 10.1016/j.matlet.2020.127345; LJ JJ., 2011, INT J RES PHARM CHEM, V1, P519; Lu YQ, 2017, ACS APPL MATER INTER, V9, P29167, DOI 10.1021/acsami.7b09160; Madni A, 2018, AAPS PHARMSCITECH, V19, P1544, DOI 10.1208/s12249-018-0967-6; Mao SR, 2007, INT J PHARM, V334, P137, DOI 10.1016/j.ijpharm.2006.10.036; Parida P, 2016, J PHARM ANAL, V6, P341, DOI 10.1016/j.jpha.2014.02.001; Portenoy RK, 2014, J CLIN ONCOL, V32, P1662, DOI 10.1200/JCO.2013.52.5188; Quinten T, 2009, EUR J PHARM SCI, V37, P207, DOI 10.1016/j.ejps.2009.02.006; Rao KR, 2005, J MICROENCAPSUL, V22, P863, DOI 10.1080/02652040500273498; Sahil K., 2011, INT J RES PHARM CHEM, V1, P1184; Sharma M., 2019, J DRUG DELIVERY THER, V9, P311; Shi K, 2013, ASIAN J PHARM SCI, V8, P58, DOI 10.1016/j.ajps.2013.07.007; Sonawane SH., ENCAPSULATION ACTIVE, V2020, P1; Song XR, 2008, INT J PHARMACEUT, V350, P320, DOI 10.1016/j.ijpharm.2007.08.034; Srivastava Anand Kumar, 2005, Acta Pharmaceutica (Zagreb), V55, P277; Tahir N, 2017, INT J PHARMACEUT, V533, P156, DOI 10.1016/j.ijpharm.2017.09.061; Varshosaz J, 2007, J MICROENCAPSUL, V24, P253, DOI 10.1080/02652040601162723; Verma PRP, 2009, ACTA PHARMACEUT, V59, P171, DOI 10.2478/v10007-009-0014-y; Yamada T, 2001, J CONTROL RELEASE, V75, P271, DOI 10.1016/S0168-3659(01)00399-6; Yu DG, 2013, ACTA BIOMATER, V9, P5665, DOI 10.1016/j.actbio.2012.10.021; ZINUTTI C, 1994, J MICROENCAPSUL, V11, P555, DOI 10.3109/02652049409034994; Zirak MB., 2015, INT J CURR MICROBIOL, V4, P924, DOI 10.20964/2016.10.30; Zugic A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020156	56	5	5	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2021	16	4							e0250876	10.1371/journal.pone.0250876	http://dx.doi.org/10.1371/journal.pone.0250876			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6EM	33930049	Green Published, gold			2023-01-03	WOS:000664607000043
J	Tan, TXZ; Nadkarni, NV; Chua, WC; Loo, LM; Iau, PTC; Ang, ASH; Goo, JTT; Chan, KC; Malhotra, R; Ong, MEH; Matchar, DB; Seow, DCC; Nguyen, HV; Ng, YS; Chan, A; Wong, TH				Tan, Timothy Xin Zhong; Nadkarni, Nivedita V.; Chua, Wei Chong; Loo, Lynette Ma; Iau, Philip Tsau Choong; Ang, Arron Seng Hock; Goo, Jerry Tiong Thye; Chan, Kim Chai; Malhotra, Rahul; Ong, Marcus Eng Hock; Matchar, David Bruce; Seow, Dennis Chuen Chai; Nguyen, Hai V.; Ng, Yee Sien; Chan, Angelique; Wong, Ting-Hway			Frailty and length of stay in older adults with blunt injury in a national multicentre prospective cohort study	PLOS ONE			English	Article							MAJOR TRAUMA; MORTALITY; DEFINITION; PREDICTOR; MORBIDITY; INDEX; FALLS; RISK	Background Patients suffering moderate or severe injury after low falls have higher readmission and long-term mortality rates compared to patients injured by high-velocity mechanisms such as motor vehicle accidents. We hypothesize that this is due to higher pre-injury frailty in low-fall patients, and present baseline patient and frailty demographics of a prospective cohort of moderate and severely injured older patients. Our second hypothesis was that frailty was associated with longer length of stay (LOS) at index admission. Methods This is a prospective, nation-wide, multi-center cohort study of Singaporean residents aged >= 55 years admitted for >= 48 hours after blunt injury with an injury severity score or new injury severity score >= 10, or an Organ Injury Scale >= 3, in public hospitals from 2016-2018. Demographics, mechanism of injury and frailty were recorded and analysed by Chi-square, or Kruskal-Wallis as appropriate. Results 218 participants met criteria and survived the index admission. Low fall patients had the highest proportion of frailty (44, 27.3%), followed by higher level fallers (3, 21.4%) and motor vehicle accidents (1, 2.3%) (p < .01). Injury severity, extreme age, and surgery were independently associated with longer LOS. Frail patients were paradoxically noted to have shorter LOS (p < .05). Conclusion Patients sustaining moderate or severe injury after low falls are more likely to be frail compared to patients injured after higher-velocity mechanisms. However, this did not translate into longer adjusted LOS in hospital at index admission.	[Tan, Timothy Xin Zhong] SingHlth Serv, Emergency Med Residency Program, Singapore, Singapore; [Nadkarni, Nivedita V.] Duke NUS Grad Med Sch, Ctr Quantitat Med, Singapore, Singapore; [Chua, Wei Chong] Tan Tock Seng Hosp, Trauma Serv, Singapore, Singapore; [Loo, Lynette Ma; Iau, Philip Tsau Choong] Natl Univ Singapore Hosp, Dept Gen Surg, Singapore, Singapore; [Ang, Arron Seng Hock] Changi Gen Hosp, Accid & Emergency, Singapore, Singapore; [Goo, Jerry Tiong Thye] Khoo Teck Puat Hosp, Dept Gen Surg, Singapore, Singapore; [Chan, Kim Chai] Ng Teng Fong Gen Hosp, Emergency Med Dept, Singapore, Singapore; [Malhotra, Rahul; Ong, Marcus Eng Hock; Matchar, David Bruce; Wong, Ting-Hway] Duke NUS Grad Med Sch, Hlth Serv & Syst Res, Singapore, Singapore; [Ong, Marcus Eng Hock] Singapore Gen Hosp, Dept Emergency Med, Singapore, Singapore; [Seow, Dennis Chuen Chai] Singapore Gen Hosp, Dept Geriatr Med, Singapore, Singapore; [Nguyen, Hai V.] Mem Univ Newfoundland, Sch Pharm, St John, NF, Canada; [Ng, Yee Sien] Singapore Gen Hosp, Dept Rehabil Med, Singapore, Singapore; [Chan, Angelique] Duke NUS Grad Med Sch, Ctr Ageing Res & Educ, Singapore, Singapore; [Wong, Ting-Hway] Singapore Gen Hosp, Dept Gen Surg, Singapore, Singapore	National University of Singapore; Tan Tock Seng Hospital; National University of Singapore; Changi General Hospital; National University of Singapore; Singapore General Hospital; Singapore General Hospital; Memorial University Newfoundland; Singapore General Hospital; National University of Singapore; Singapore General Hospital	Tan, TXZ (corresponding author), SingHlth Serv, Emergency Med Residency Program, Singapore, Singapore.	timothy.tbj13@gmail.com		Tan, Timothy Xin Zhong/0000-0001-5938-2304; Malhotra, Rahul/0000-0002-9978-4276; Matchar, David/0000-0003-3020-2108	National Medical Research Council Health NMRC HSRG [NMRC/HSRG/0054/2016]; Duke-NUS Khoo Pilot Award; SingHealth Medical Student Talent Development Awards - Project, Singapore	National Medical Research Council Health NMRC HSRG; Duke-NUS Khoo Pilot Award; SingHealth Medical Student Talent Development Awards - Project, Singapore	This work was supported by the National Medical Research Council Health NMRC HSRG (NMRC/HSRG/0054/2016), the Duke-NUS Khoo Pilot Award 2015, and the 2016 SingHealth Medical Student Talent Development Awards -Project, Singapore. One or more of the authors are employed by SingHealth Services. The funders provided support in the form of salaries for authors TXZT, NVN, ASHA, RM, MEHO, DBM, DCCS, YSN, AC, THW, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Beck B, 2018, BJS OPEN, V2, P310, DOI 10.1002/bjs5.80; Butcher N, 2012, INJURY, V43, P196, DOI 10.1016/j.injury.2011.06.029; Butcher NE, 2014, J TRAUMA ACUTE CARE, V77, P620, DOI 10.1097/TA.0000000000000404; Chan A, 2011, J AGING HEALTH, V23, P1285, DOI 10.1177/0898264311408417; Chu AHY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136944; Fang X, 2012, J NUTR HEALTH AGING, V16, P903, DOI 10.1007/s12603-012-0368-6; Farhat JS, 2012, J TRAUMA ACUTE CARE, V72, P1526, DOI 10.1097/TA.0b013e3182542fab; Fawcett VJ, 2015, J AM COLL SURGEONS, V220, P330, DOI 10.1016/j.jamcollsurg.2014.11.012; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Hewitt J, 2015, AM J SURG, V209, P254, DOI 10.1016/j.amjsurg.2014.05.022; Ho AFW, 2015, PREHOSP EMERG CARE, V19, P409, DOI 10.3109/10903127.2014.980477; Joseph B, 2014, J AM COLL SURGEONS, V219, P10, DOI 10.1016/j.jamcollsurg.2014.03.020; Koizia L, 2019, TRAUMA, V21, P21, DOI 10.1177/1460408618783221; MAHONEY F I, 1965, Md State Med J, V14, P61; Makary MA, 2010, J AM COLL SURGEONS, V210, P901, DOI 10.1016/j.jamcollsurg.2010.01.028; Malhotra R, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2016.06.013; Pape HC, 2014, J TRAUMA ACUTE CARE, V77, P780, DOI 10.1097/TA.0000000000000453; Ringdal KG, 2008, SCAND J TRAUMA RESUS, V16, DOI 10.1186/1757-7241-16-7; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Spaniolas K, 2010, J TRAUMA, V69, P821, DOI 10.1097/TA.0b013e3181efc6c6; Tan HL, 2019, WORLD J EMERG SURG, V14, DOI 10.1186/s13017-019-0280-z; Velanovich V, 2013, J SURG RES, V183, P104, DOI 10.1016/j.jss.2013.01.021; Wong T.H., 2018, CAN J SURG, V61, pS104; Wong TH, 2019, J AM MED DIR ASSOC, V20, P201, DOI 10.1016/j.jamda.2018.08.006; Wong TH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137127	25	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2021	16	4							e0250803	10.1371/journal.pone.0250803	http://dx.doi.org/10.1371/journal.pone.0250803			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6EM	33930058	gold, Green Published			2023-01-03	WOS:000664607000036
J	Yoshioka, Y; Kamata, Y; Tominaga, M; Umehara, Y; Yoshida, I; Matsuoka, N; Takamori, K				Yoshioka, Yasuko; Kamata, Yayoi; Tominaga, Mitsutoshi; Umehara, Yoshie; Yoshida, Ikuyo; Matsuoka, Nobuya; Takamori, Kenji			Extract of Scutellaria baicalensis induces semaphorin 3A production in human epidermal keratinocytes	PLOS ONE			English	Article							NERVE GROWTH-FACTOR; SCRATCHING BEHAVIOR; OXIDATIVE STRESS; NC/NGA MICE; SKIN; EXPRESSION; PHARMACOKINETICS; COMPONENTS; WOGONIN; ITCH	In a disease-state-dependent manner, the histamine-resistant itch in dry skin-based skin diseases such as atopic dermatitis (AD) and xerosis is mainly due to hyperinnervation in the epidermis. Semaphorin 3A (Sema3A) is a nerve repulsion factor expressed in keratinocytes and it suppresses nerve fiber elongation in the epidermis. Our previous studies have shown that Sema3A ointment inhibits epidermal hyperinnervation and scratching behavior and improves dermatitis scores in AD model mice. Therefore, we consider Sema3A as a key therapeutic target for improving histamine-resistant itch in AD and xerosis. This study was designed to screen a library of herbal plant extracts to discover compounds with potential to induce Sema3A in normal human epidermal keratinocytes (NHEKs) using a reporter gene assay, so that positive samples were found. Among the positive samples, only the extract of S. baicalensis was found to consistently increase Sema3A levels in cultured NHEKs in assays using quantitative real-time PCR and ELISA. In evaluation of reconstituted human epidermis models, the level of Sema3A protein in culture supernatants significantly increased by application of the extract of S. baicalensis. In addition, we investigated which components in the extract of S. baicalensis contributed to Sema3A induction and found that baicalin and baicalein markedly increased the relative luciferase activity, and that baicalein had higher induction activity than baicalin. Thus, these findings suggest that S. baicalensis extract and its compounds, baicalin and baicalein, may be promising candidates for improving histamine-resistant itch via the induction of Sema3A expression in epidermal keratinocytes.	[Yoshioka, Yasuko; Yoshida, Ikuyo; Matsuoka, Nobuya] Kobayashi Pharmaceut Co Ltd, Cent R&D Lab, Ibaraki, Osaka, Japan; [Yoshioka, Yasuko; Kamata, Yayoi; Tominaga, Mitsutoshi; Umehara, Yoshie; Takamori, Kenji] Juntendo Univ, Inst Environm & Gender Specif Med, Juntendo Itch Res Ctr JIRC, Grad Sch Med, Chiba, Japan; [Takamori, Kenji] Juntendo Univ Urayasu Hosp, Dept Dermatol, Chiba, Japan	Kobayashi Pharmaceutical Co Ltd; Juntendo University; Juntendo University	Takamori, K (corresponding author), Juntendo Univ, Inst Environm & Gender Specif Med, Juntendo Itch Res Ctr JIRC, Grad Sch Med, Chiba, Japan.; Takamori, K (corresponding author), Juntendo Univ Urayasu Hosp, Dept Dermatol, Chiba, Japan.	ktakamor@juntendo.ac.jp	Tominaga, Mitsutoshi/F-1267-2018	Tominaga, Mitsutoshi/0000-0002-1254-1803	Strategic Research Foundation from the Ministry of Education, Culture, Sports, Science and Technology [S1311011]; Kobayashi Pharmaceutical Co., Ltd.	Strategic Research Foundation from the Ministry of Education, Culture, Sports, Science and Technology; Kobayashi Pharmaceutical Co., Ltd.	This work was supported by a grant from the Strategic Research Foundation Grant-aided Project for Private Universities from the Ministry of Education, Culture, Sports, Science and Technology (Grant number: S1311011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This research was also funded by Kobayashi Pharmaceutical Co., Ltd. (URL: KOBAYASHI Pharmaceutical Co.,Ltd.). Three of the authors (YY, IY, NM), who are employees of Kobayashi Pharmaceutical Co., Ltd, had a partial role in data collection and analysis, and preparation of the manuscript.	Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; Dontchev VD, 2002, J NEUROSCI, V22, P6659; Gaire BP, 2014, CHIN J INTEGR MED, V20, P712, DOI 10.1007/s11655-014-1347-9; Hidaka T, 2017, NAT IMMUNOL, V18, P64, DOI 10.1038/ni.3614; Huang KF, 2016, EXP DERMATOL, V25, P623, DOI 10.1111/exd.13024; Hui KM, 2002, BIOCHEM PHARMACOL, V64, P1415, DOI 10.1016/S0006-2952(02)01347-3; Ikoma A, 2006, NAT REV NEUROSCI, V7, P535, DOI 10.1038/nrn1950; Islam MN, 2012, NAT PROD RES, V26, P1957, DOI 10.1080/14786419.2011.631134; Kamata Y, 2020, J INVEST DERMATOL, V140, P1346, DOI 10.1016/j.jid.2020.01.001; Kim KC, 2012, BIOMOL THER, V20, P57, DOI 10.4062/biomolther.2012.20.1.057; Li CR, 2011, BIOPHARM DRUG DISPOS, V32, P427, DOI 10.1002/bdd.771; Li-Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005; Makino T, 2008, J NAT MED, V62, P294, DOI 10.1007/s11418-008-0230-7; Negi O, 2012, J DERMATOL SCI, V66, P37, DOI 10.1016/j.jdermsci.2012.01.007; Paus R, 2006, J CLIN INVEST, V116, P1174, DOI 10.1172/JCI28553; Poumay Y, 2004, ARCH DERMATOL RES, V296, P203, DOI 10.1007/s00403-004-0507-y; Seo ON, 2013, J FUNCT FOODS, V5, P1741, DOI 10.1016/j.jff.2013.07.020; Shukla S, 2010, PHARM RES-DORDR, V27, P962, DOI 10.1007/s11095-010-0089-7; Srinivas NR, 2010, XENOBIOTICA, V40, P357, DOI 10.3109/00498251003663724; Sun CH, 2016, MOLECULES, V21, DOI 10.3390/molecules21081067; Tang XQ, 2004, J NEUROSCI, V24, P819, DOI 10.1523/JNEUROSCI.1263-03.2004; Tominaga M, 2008, BRIT J DERMATOL, V158, P842, DOI 10.1111/j.1365-2133.2007.08410.x; Tominaga M., 2014, ITCH MECH TREATMENT; Tominaga M, 2014, J DERMATOL, V41, P205, DOI 10.1111/1346-8138.12317; Yamada Y, 2016, EXP DERMATOL, V25, P611, DOI 10.1111/exd.12999; Yamaguchi J, 2008, J INVEST DERMATOL, V128, P2842, DOI 10.1038/jid.2008.150; Yao Y, 2014, INT J MOL SCI, V15, P20913, DOI 10.3390/ijms151120913; Yosipovitch G., 2004, International Journal of Cosmetic Science, V26, P1, DOI 10.1111/j.0142-5463.2004.00199.x	28	0	0	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2021	16	4							e0250663	10.1371/journal.pone.0250663	http://dx.doi.org/10.1371/journal.pone.0250663			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SX8OK	33905439	gold, Green Published			2023-01-03	WOS:000665456800032
J	Chau, E; Rosella, LC; Mondor, L; Wodchis, WP				Chau, Edward; Rosella, Laura C.; Mondor, Luke; Wodchis, Walter P.			Association between continuity of care and subsequent diagnosis of multimorbidity in Ontario, Canada from 2001-2015: A retrospective cohort study	PLOS ONE			English	Article							ADMINISTRATIVE DATA; HEART-FAILURE; HEALTH-CARE; MEDICATION ADHERENCE; DISEASE; ADULTS; POPULATION; MANAGEMENT; EDUCATION; ACCURACY	Background Continuity of care is a well-recognized principle of the primary care discipline owing to its medical, interpersonal, and cost-saving benefits. Relationship continuity or the ongoing therapeutic relationship between a patient and their physician is a particularly desirable goal, but its role in preventing the accumulation of chronic conditions diagnoses in individuals is unknown. The objective of this study was to investigate the effect of continuity of care with physicians on the rate of incident multimorbidity diagnoses in patients with existing conditions. Methods This was a population-based, retrospective cohort study from 2001 to 2015 that focused on patients aged 18 to 105 years with at least one chronic condition (n = 166,665). Our primary exposure was relationship continuity of care with general practitioners and specialists measured using the Bice-Boxerman Continuity of Care Index (COCI). COCI was specified as a time-dependent exposure prior to the observation period. Our outcomes of interest were the time to diagnosis of a second, third, and fourth chronic condition estimated using cause-specific hazard regressions accounting for death as a competing risk. Findings We observed that patients with a single chronic condition and high continuity of care (>0.50) were diagnosed with a second chronic condition or multimorbidity at an 8% lower rate compared to individuals with low continuity (cause-specific hazard ratio (HR) 0.92 (95% Confidence Interval 0.90-0.93; p<0.0001) after adjusting for age, sex, income, place of residence, primary care enrolment, and the annual number of physician visits. Continuity remained protective as the degree of multimorbidity increased. Among patients with two conditions, the risk of diagnosis of a third chronic condition was also 8% lower for individuals with high continuity (HR 0.92; CI 0.90-0.94; p<0.0001). Patients with three conditions and high continuity had a 9% lower risk of diagnosis with a fourth condition (HR 0.91; CI 0.89-0.93; p<0.0001). Conclusions Continuity of care is a potentially modifiable health system factor that reduces the rate at which diagnoses of chronic conditions are made over time in patients with multimorbidity. Additional research is needed to explain the underlying mechanisms through which continuity is related to a protective effect and the clinical sequalae.	[Chau, Edward; Rosella, Laura C.; Wodchis, Walter P.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Rosella, Laura C.; Wodchis, Walter P.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Rosella, Laura C.; Wodchis, Walter P.] Trillium Hlth Partners, Inst Better Hlth, Mississauga, ON, Canada; [Rosella, Laura C.; Mondor, Luke; Wodchis, Walter P.] ICES, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; Trillium Health Partners; University of Toronto	Wodchis, WP (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.; Wodchis, WP (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.; Wodchis, WP (corresponding author), Trillium Hlth Partners, Inst Better Hlth, Mississauga, ON, Canada.; Wodchis, WP (corresponding author), ICES, Toronto, ON, Canada.	walter.wodchis@utoronto.ca		wodchis, walter/0000-0003-2494-7031	Health System Performance Research Network - Ministry of Health and Long-Term Care [06034]; Ontario SPOR Support Unit; Ontario Ministry of Health; Canada Research Chair in Population Health Analytics; Trillium Health Partners Foundation	Health System Performance Research Network - Ministry of Health and Long-Term Care; Ontario SPOR Support Unit; Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario); Canada Research Chair in Population Health Analytics; Trillium Health Partners Foundation(University of Toronto)	The funding for this manuscript was obtained through the Health System Performance Research Network funded by a grant from the Ministry of Health and Long-Term Care (#06034) and from the Ontario SPOR Support Unit. Any views expressed in this manuscript belong solely to the authors and not the funding agency. ICES receives funding from the Ontario Ministry of Health. LCR is supported by a Canada Research Chair in Population Health Analytics. LCR and WPW are supported by Research Chairs funded by the Trillium Health Partners Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alazri Mohammed, 2007, Sultan Qaboos Univ Med J, V7, P197; Allen SM, 2009, DISABIL HEALTH J, V2, P180, DOI 10.1016/j.dhjo.2009.06.004; Andersen P. K., 2012, STAT MODELS BASED CO; Austin PC, 2002, AM HEART J, V144, P290, DOI 10.1067/mhj.2002.123839; Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719; Barker I, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j84; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bayliss EA, 2008, FAM PRACT, V25, P287, DOI 10.1093/fampra/cmn040; Bayliss EA, 2015, ANN FAM MED, V13, P123, DOI 10.1370/afm.1739; Betancourt MT, 2014, CHRON DIS INJ CAN, V34, P1; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; Boyd CM, 2014, CURR OPIN HIV AIDS, V9, P419, DOI 10.1097/COH.0000000000000073; BRESLAU N, 1975, J MED EDUC, V50, P965; Calderon-Larranaga A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659295; Canadian Institute for Health Information, 2015, CONT CAR FAM MED PHY; Canadian Institute for Health Information, 2011, SEN HLTH CAR SYST WH, P23; Chen CC, 2016, AM J MANAG CARE, V22, P136; Chen CC, 2013, MED CARE, V51, P231, DOI 10.1097/MLR.0b013e31827da5b9; Chen LM, 2014, JAMA INTERN MED, V174, P749, DOI 10.1001/jamainternmed.2013.14331; Cheng SH, 2014, MED CARE, V52, P149, DOI 10.1097/MLR.0000000000000042; Cowie L, 2009, J HEALTH SERV RES PO, V14, P82, DOI 10.1258/jhsrp.2009.008111; Delva D, 2011, CAN FAM PHYSICIAN, V57, P915; Dhalwani NN, 2017, J GERONTOL A-BIOL, V72, P528, DOI 10.1093/gerona/glw146; DuGoff Eva H, 2016, J Comorb, V6, P65, DOI 10.15256/joc.2016.6.76; DuGoff EH, 2014, MED CARE, V52, P688, DOI 10.1097/MLR.0000000000000166; Dumbreck S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h949; Gershon AS, 2009, COPD, V6, P388, DOI 10.1080/15412550903140865; Gershon AS., 2009, COPD J CHRONIC OBSTR, V5, P388, DOI [10.1155/2009/963098, DOI 10.1155/2009/963098]; Gilbert AL, 2011, AUSTRALAS J AGEING, V30, P32, DOI 10.1111/j.1741-6612.2011.00530.x; Glazier RH, 2012, COMP PRIMARY CARE MO; Gray DJP, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021161; Gruneir A, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1415-5; Gulliford M, 2011, J HEALTH SERV RES PO, V16, P67, DOI 10.1258/jhsrp.2010.010015; Guo JY, 2017, MED CARE, V55, P744, DOI 10.1097/MLR.0000000000000758; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Health System Performance Research Network, 2013, CAR PEOPL MULT CHRON, V2, P1; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Information CI for H, 2016, TRENDS INC REL HLTH, DOI [10.1080/17441692.2014.931448, DOI 10.1080/17441692.2014.931448]; Jaakkimainen RL, 2016, J ALZHEIMERS DIS, V54, P337, DOI 10.3233/JAD-160105; Johnson-Lawrence V, 2017, SSM-POPUL HLTH, V3, P366, DOI 10.1016/j.ssmph.2017.03.007; Krali B., 2008, MEASURING RURALITY R; Lane NE, 2015, EBIOMEDICINE, V2, P2094, DOI 10.1016/j.ebiom.2015.11.018; Leijten FRM, 2018, HEALTH POLICY, V122, P12, DOI 10.1016/j.healthpol.2017.06.002; Liang HL, 2017, INQUIRY-J HEALTH CAR, V54, DOI 10.1177/0046958017724003; Melis R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103120; Mondor L, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002249; Mondor L, 2016, QUAL LIFE RES, V25, P2619, DOI 10.1007/s11136-016-1281-y; Muth C, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0223-1; Nunes BP, 2016, ARCH GERONTOL GERIAT, V67, P130, DOI 10.1016/j.archger.2016.07.008; Page RL, 2016, CIRCULATION, V134, pE32, DOI 10.1161/CIR.0000000000000426; Pefoyo AJK, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1733-2; Public Health Agency of Canada, 2015, REP CAN CHRON DIS SU; Public Health Agency of Canada, 2014, EC BURD ILLN CAN; Reid R., 2002, DEFINING CONFUSION C; Roberts KC, 2015, HEALTH PROMOT CHRON, V35, DOI 10.24095/hpcdp.35.6.01; Ruel G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096291; Ryan A, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0355-9; Salisbury C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X548929; Schultz SE, 2013, CHRON DIS INJ CAN, V33, P160; Slordal L, 2006, DRUG SAFETY, V29, P567; St Sauver JL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006413; Thavorn K, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017264; Tu Karen, 2007, Open Med, V1, pe18; Tucker-Seeley RD, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-313; van Oostrom SH, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-61; van Walraven C, 2004, J CLIN EPIDEMIOL, V57, P672, DOI 10.1016/j.jclinepi.2003.12.008; van Walraven C, 2010, J CLIN EPIDEMIOL, V63, P1000, DOI 10.1016/j.jclinepi.2010.01.023; Widdifield J, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-216; Worrall G, 2011, CAN FAM PHYSICIAN, V57, pE16	70	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2021	16	3							e0245193	10.1371/journal.pone.0245193	http://dx.doi.org/10.1371/journal.pone.0245193			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX8JZ	33705429	Green Published, gold			2023-01-03	WOS:000629590400095
J	Al-Saleh, K; Salah, T; Arafah, M; Husain, S; Al-Rikabi, A; Abd El-Aziz, N				Al-Saleh, Khalid; Salah, Tareq; Arafah, Maria; Husain, Sufia; Al-Rikabi, Ammar; Abd El-Aziz, Nashwa			Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia	PLOS ONE			English	Article								Background The prognostic impact of neoadjuvant chemotherapy (NAC) on the receptor expression status in patients with locally advanced breast cancer (LABC) is still not fully understood. We aimed to evaluate the changes in hormone (estrogen and progesterone) receptor (HR) and human epidermal growth factor receptor 2 (HER2) status post-NAC and their correlation with survival. Methods Patients with LABC who have received NAC between 2008 and 2015 and have been followed up till December 2019 at the Oncology Center, King Saud University, KSA were analyzed retrospectively. biomarker analysis of ER, PR & HER2 were done using immunohistochemistry (IHC) and Fluorescent in situ hybridization. Results Ninety-one patients fulfilled the inclusion criteria. HR status changed in 21(23.1%) patients, with a significant difference between patients with stable receptors and those with any receptor conversion; p = 0.000. Five (5.5%) initially HER2 negative tumors became HER2 positive and 10 (11%) initially HER2 positive tumors became HER2 negative after NAC. The difference in HER2 expression level before and after NAC was not statistically significant (p = 0.302). Univariate analysis relating patients' characteristics and 10-years disease-free survival (DFS) showed only significant correlations with the expressions of ER, PR, and any receptor conversion, (ER and/or PR) p< 0.001, p< 0.001, and p = 0.001; respectively. In the univariate analysis, none of the clinicopathological features showed a significant correlation with the OS except for the molecular subtypes PConclusions Patients with LABC have significant changes in the ER and PR receptor status following NAC. Post-NAC expressions change of ER and PR (ER and/or PR) are correlated to DFS. Retesting of the hormone receptors should be considered after NAC in Saudi patients with LABC.	[Al-Saleh, Khalid; Abd El-Aziz, Nashwa] King Saud Univ, Coll Med, Dept Med, Div Hematol Oncol, Riyadh, Saudi Arabia; [Salah, Tareq] King Saud Univ, Oncol Ctr, Div Radiat Oncol, Riyadh, Saudi Arabia; [Salah, Tareq] Assiut Univ, Fac Med, Dept Clin Oncol & Nucl Med, Assiut, Egypt; [Arafah, Maria; Husain, Sufia; Al-Rikabi, Ammar] King Saud Univ, Coll Med, Dept Pathol, Riyadh, Saudi Arabia; [Abd El-Aziz, Nashwa] Assiut Univ, South Egypt Canc Inst, Dept Med Oncol, Assiut, Egypt	King Saud University; King Saud University; Egyptian Knowledge Bank (EKB); Assiut University; King Saud University; Egyptian Knowledge Bank (EKB); Assiut University	Abd El-Aziz, N (corresponding author), King Saud Univ, Coll Med, Dept Med, Div Hematol Oncol, Riyadh, Saudi Arabia.; Abd El-Aziz, N (corresponding author), Assiut Univ, South Egypt Canc Inst, Dept Med Oncol, Assiut, Egypt.	nashwa.abdelaziz888@gmail.com	Husain, Sufia/GZM-5798-2022	ABDELAZIZ, NASHWA/0000-0002-1701-9248; Arafah, Maria/0000-0002-6847-5884	College of Medicine Research Center, Deanship of Scientific Research, King Saud University	College of Medicine Research Center, Deanship of Scientific Research, King Saud University	The authors would like to acknowledge the support they received from the College of Medicine Research Center, Deanship of Scientific Research, King Saud University, as well as the technician team of the Department of Pathology, College of Medicine, King Saud University.	Adams AL, 2008, BREAST J, V14, P141, DOI 10.1111/j.1524-4741.2007.00544.x; Al-Rikabi A, 2012, CROAT MED J, V53, P239, DOI 10.3325/cmj.2012.53.239; Al-Saleh K, 2017, ONCOL LETT, V14, P337, DOI 10.3892/ol.2017.6144; Alghamdi IG, 2013, BREAST CANCER-TARGET, V5, P103, DOI 10.2147/BCTT.S50750; Allison KH, 2020, ARCH PATHOL LAB MED, V144, P545, DOI 10.5858/arpa.2019-0904-SA; Arens N, 2005, VIRCHOWS ARCH, V446, P489, DOI 10.1007/s00428-005-1244-0; Bartlett JMS, 2011, J CLIN ONCOL, V29, P1531, DOI 10.1200/JCO.2010.30.3677; Bertos NR, 2011, J CLIN INVEST, V121, P3789, DOI 10.1172/JCI57100; Bines J, 1996, J CLIN ONCOL, V14, P1718, DOI 10.1200/JCO.1996.14.5.1718; Buchholz TA, 2002, CANCER J, V8, P461, DOI 10.1097/00130404-200211000-00010; Burcombe RJ, 2005, BRIT J CANCER, V92, P147, DOI 10.1038/sj.bjc.6602256; Caudle AS, 2010, J CLIN ONCOL, V28, P1821, DOI 10.1200/JCO.2009.25.3286; Chang J, 2003, CANCER-AM CANCER SOC, V97, P545, DOI 10.1002/cncr.11083; Chen S, 2012, ANN SURG ONCOL, V19, P3002, DOI 10.1245/s10434-012-2318-2; Chollet P, 2002, BRIT J CANCER, V86, P1041, DOI 10.1038/sj/bjc/6600210; Jin X, 2015, ONCOTARGET, V6, P9600, DOI 10.18632/oncotarget.3292; Kasami M, 2008, BREAST, V17, P523, DOI 10.1016/j.breast.2008.04.002; Mauri D, 2005, JNCI-J NATL CANCER I, V97, P188, DOI 10.1093/jnci/dji021; Ozmen V., 2015, CANC TREATMENT COMMU, V4, P89, DOI [10.1016/j.ctrc.2015.07.001, DOI 10.1016/J.CTRC.2015.07.001]; Parinyanitikul N, 2015, CLIN BREAST CANCER, V15, P153, DOI 10.1016/j.clbc.2014.09.006; Quddus Ruhul M, 2005, Breast Cancer, V12, P294; Razavi P, 2018, CANCER CELL, V34, P427, DOI 10.1016/j.ccell.2018.08.008; ROSE DP, 1980, CANCER RES, V40, P4043; Tacca O, 2007, ONCOLOGIST, V12, P636, DOI 10.1634/theoncologist.12-6-636; Tan MC, 2009, AM J SURG, V198, P520, DOI 10.1016/j.amjsurg.2009.06.004; Tan QX, 2014, INT J CLIN EXP PATHO, V7, P4086; van de Ven S, 2011, CANCER TREAT REV, V37, P422, DOI 10.1016/j.ctrv.2010.11.006; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yang LB, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1332-7; Yoshida A, 2017, J SURG ONCOL, V116, P1021, DOI 10.1002/jso.24762; Zattarin E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122644; Zhang N, 2011, CANCER INVEST, V29, P594, DOI 10.3109/07357907.2011.621913	32	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2021	16	3							e0247802	10.1371/journal.pone.0247802	http://dx.doi.org/10.1371/journal.pone.0247802			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT5CA	33667252	gold, Green Published			2023-01-03	WOS:000626604300033
J	Alemanno, F; Houdayer, E; Parma, A; Spina, A; Del Forno, A; Scatolini, A; Angelone, S; Brugliera, L; Tettamanti, A; Beretta, L; Iannaccone, S				Alemanno, Federica; Houdayer, Elise; Parma, Anna; Spina, Alfio; Del Forno, Alessandra; Scatolini, Alessandra; Angelone, Sara; Brugliera, Luigia; Tettamanti, Andrea; Beretta, Luigi; Iannaccone, Sandro			COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience	PLOS ONE			English	Article							RATING SCALE; SURVIVORS; IMPAIRMENT; VALIDITY; OUTCOMES; RISK; MOCA	Introduction COVID-19 complications can include neurological, psychiatric, psychological, and psychosocial impairments. Little is known on the consequences of SARS-COV-2 on cognitive functions of patients in the sub-acute phase of the disease. We aimed to investigate the impact of COVID-19 on cognitive functions of patients admitted to the COVID-19 Rehabilitation Unit of the San Raffaele Hospital (Milan, Italy). Material and methods 87 patients admitted to the COVID-19 Rehabilitation Unit from March 27(th) to June 20(th) 2020 were included. Patients underwent Mini Mental State Evaluation (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton Rating Scale for Depression, and Functional Independence Measure (FIM). Data were divided in 4 groups according to the respiratory assistance in the acute phase: Group1 (orotracheal intubation), Group2 (non-invasive ventilation using Biphasic Positive Airway Pressure), Group3 (Venturi Masks), Group4 (no oxygen therapy). Follow-ups were performed at one month after home-discharge. Results Out of the 87 patients (62 Male, mean age 67.23 +/- 12.89 years), 80% had neuropsychological deficits (MoCA and MMSE) and 40% showed mild-to-moderate depression. Group1 had higher scores than Group3 for visuospatial/executive functions (p = 0.016), naming (p = 0.024), short- and long-term memory (p = 0.010, p = 0.005), abstraction (p = 0.024), and orientation (p = 0.034). Group1 was younger than Groups2 and 3. Cognitive impairments correlated with patients' age. Only 18 patients presented with anosmia. Their data did not differ from the other patients. FIM (<100) did not differ between groups. Patients partly recovered at one-month follow-up and 43% showed signs of post-traumatic stress disorder. Conclusion Patients with severe functional impairments had important cognitive and emotional deficits which might have been influenced by the choice of ventilatory therapy, but mostly appeared to be related to aging, independently of FIM scores. These findings should be integrated for correct neuropsychiatric assistance of COVID-19 patients in the subacute phase of the disease, and show the need for long-term psychological support and treatment of post-COVID-19 patients.	[Alemanno, Federica; Houdayer, Elise; Parma, Anna; Del Forno, Alessandra; Scatolini, Alessandra; Angelone, Sara; Brugliera, Luigia; Tettamanti, Andrea; Iannaccone, Sandro] IRCCS San Raffaele Sci Inst, Dept Rehabil & Funct Recovery, Milan, Italy; [Spina, Alfio] IRCCS San Raffaele Sci Inst, Dept Neurosurg & Gamma Knife Radiosurg, Milan, Italy; [Beretta, Luigi] IRCCS San Raffaele Sci Inst, Dept Gen Anesthesia & Intens Care, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Houdayer, E (corresponding author), IRCCS San Raffaele Sci Inst, Dept Rehabil & Funct Recovery, Milan, Italy.	houdayer.elise@hsr.it						Al-Janabi OM, 2018, J NEUROIMAGING, V28, P301, DOI 10.1111/jon.12494; Azim D, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.8790; Brugliera L, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2714; Brugliera L, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2678; Carda S, 2020, ANN PHYS REHABIL MED, V63, P554, DOI 10.1016/j.rehab.2020.04.001; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; Di Castelnuovo A, 2020, NUTR METAB CARDIOVAS, V30, P1899, DOI 10.1016/j.numecd.2020.07.031; Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Garrigues E, 2020, J INFECTION, V81, pE4, DOI 10.1016/j.jinf.2020.08.029; Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8; Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1; Hoops S, 2009, NEUROLOGY, V73, P1738, DOI 10.1212/WNL.0b013e3181c34b47; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Iannaccone S, 2020, ARCH PHYS MED REHAB, V101, P1656, DOI 10.1016/j.apmr.2020.05.015; Inoue S, 2019, ACUTE MED SURG, V6, P233, DOI 10.1002/ams2.415; Inzitari D, 2007, ARCH INTERN MED, V167, P81, DOI 10.1001/archinte.167.1.81; Inzitari D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2477; Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3981; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Mariotto S, 2020, J NEUROL NEUROSUR PS, V91, P1010, DOI 10.1136/jnnp-2020-323881; Maydych V, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00384; Meng XM, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102581; Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC; Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062; Murray H, 2020, COGN BEH THER, V13, DOI 10.1017/S1754470X2000015X; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nelliot A, 2019, ANN AM THORAC SOC, V16, P731, DOI 10.1513/AnnalsATS.201812-851OC; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Parker AM, 2015, CRIT CARE MED, V43, P1121, DOI 10.1097/CCM.0000000000000882; Pasqua F, 2009, RESP MED, V103, P471, DOI 10.1016/j.rmed.2008.09.007; Pasquier F, 1996, EUR NEUROL, V36, P268, DOI 10.1159/000117270; Pfoh ER, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0934-5; Pisani MA, 2003, J AM GERIATR SOC, V51, P689, DOI 10.1034/j.1600-0579.2003.00215.x; Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187; Rawal G, 2017, J TRANSL INTERN MED, V5, P90, DOI 10.1515/jtim-2016-0016; Sasannejad C, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2626-z; Varatharaj Aravinthan, 2020, Lancet Psychiatry, V7, P875, DOI 10.1016/S2215-0366(20)30287-X; Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729; Wilcox ME, 2013, CRIT CARE MED, V41, pS81, DOI 10.1097/CCM.0b013e3182a16946	45	60	66	6	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2021	16	2							e0246590	10.1371/journal.pone.0246590	http://dx.doi.org/10.1371/journal.pone.0246590			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG1VY	33556127	gold, Green Published, Green Submitted			2023-01-03	WOS:000617379900048
J	Chen, BW; Chiu, GW; He, YC; Huang, CY; Huang, HT; Sung, SY; Hsieh, CL; Chang, WC; Hsu, MS; Wei, ZH; Yao, DJ				Chen, Bo-Wei; Chiu, Guo-Wei; He, Yun-Chi; Huang, Chih-Yu; Huang, Hao-Ting; Sung, Shian-Ying; Hsieh, Chia-Ling; Chang, Wei-Chieh; Hsu, Ming-Shinn; Wei, Zung-Hang; Yao, Da-Jeng			Extracellular and intracellular intermittent magnetic-fluid hyperthermia treatment of SK-Hep1 hepatocellular carcinoma cells based on magnetic nanoparticles coated with polystyrene sulfonic acid	PLOS ONE			English	Article							CONTRAST AGENTS; APOPTOSIS; FIELDS	The use of magnetic nanoparticles (MNPs) magnetized on applying an alternating magnetic field (AMF) to stimulate the thermal characteristics and to induce tumor apoptosis is a currently active area of research in cancer treatment. In previous work, we developed biocompatible and superparamagnetic polystyrene-sulfonic-acid-coated magnetic nanoparticles (PSS-MNPs) as applications for magnetically labeled cell trapping, but without assessment of treatment effects on tumor diseases. In the present work, we examined PSS-MNP-induced magnetic fluid hyperthermia (MFH) on SK-Hep1 hepatocellular carcinoma (HCC) cells for lethal thermal effects with a self-made AMF system; an adjustable AMF frequency generated a variable intensity of magnetic field and induced MNP relaxation. The extracellular and intracellular MFH treatments on a SK-Hep1 cell line were implemented in vitro; the result indicates that the lethal effects were efficient and caused a significantly decreased cell viability of SK-Hep1 cells. As the PSS-MNP concentration decreased, especially in intracellular MFH treatments, the MFH effects on cells, however, largely decreased through heat spreading to the culture medium. On controlling and decreasing the volume of culture medium, the problem of heat spreading was solved. It can be consequently expected that PSS-MNPs would be a prospective agent for intracellular cancer magnetotherapy.	[Chen, Bo-Wei; Wei, Zung-Hang; Yao, Da-Jeng] Natl Tsing Hua Univ, Inst NanoEngn & MicroSyst, Hsinchu, Taiwan; [Chiu, Guo-Wei; He, Yun-Chi; Huang, Chih-Yu; Huang, Hao-Ting; Wei, Zung-Hang; Yao, Da-Jeng] Natl Tsing Hua Univ, Dept Power Mech Engn, Hsinchu, Taiwan; [Sung, Shian-Ying; Hsieh, Chia-Ling] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, Taipei, Taiwan; [Sung, Shian-Ying; Hsieh, Chia-Ling] Taipei Med Univ, TMU Res Ctr Canc Translat Med, Taipei, Taiwan; [Chang, Wei-Chieh] Chang Bing Show Chwan Mem Hosp, Dept Neurosurg, Changhua, Taiwan; [Hsu, Ming-Shinn] Min Sheng Hosp, Dept Obstet & Gynecol, Ching Kuo Campus, Taoyuan, Taiwan	National Tsing Hua University; National Tsing Hua University; Taipei Medical University; Taipei Medical University; Chang Bing Show Chwan Memorial Hospital	Yao, DJ (corresponding author), Natl Tsing Hua Univ, Inst NanoEngn & MicroSyst, Hsinchu, Taiwan.; Yao, DJ (corresponding author), Natl Tsing Hua Univ, Dept Power Mech Engn, Hsinchu, Taiwan.	djyao@mx.nthu.edu.tw	Huang, Chih-Yu/AAS-3695-2021	Huang, Chih-Yu/0000-0003-4243-4707	Ministry of Science and Technology (MOST), Taiwan [MOST 105-2628-M-007-002MY3, MOST 104-2221-E-007-015-MY4]	Ministry of Science and Technology (MOST), Taiwan(Ministry of Science and Technology, Taiwan)	The Ministry of Science and Technology (MOST), Taiwan, provided support for this study in the form of grants (MOST 105-2628-M-007-002MY3 and MOST 104-2221-E-007-015-MY4) awarded to the following authors: BWC; GWC; YCH; CYH; HTH; ZHW; and DJY.	Carter T, 2016, IMMUNOTHERAPY-UK, V8, P941, DOI 10.2217/imt.16.11; Chen BW, 2020, SCI TECHNOL ADV MAT, V21, P471, DOI 10.1080/14686996.2020.1790032; Cheng DF, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-195; Cheng KK, 2015, BIOMATERIALS, V44, P155, DOI 10.1016/j.biomaterials.2014.12.005; Eun JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110744; Forman HJ, 2009, MOL ASPECTS MED, V30, P1, DOI 10.1016/j.mam.2008.08.006; Gallo J, 2013, CHEM SOC REV, V42, P7816, DOI 10.1039/c3cs60149h; Gneveckow U, 2004, MED PHYS, V31, P1444, DOI 10.1118/1.1748629; Guardia P, 2012, ACS NANO, V6, P3080, DOI 10.1021/nn2048137; Herea DD, 2018, INT J NANOMED, V13, P5743, DOI 10.2147/IJN.S174853; Hu SH, 2012, ADV MATER, V24, P3627, DOI 10.1002/adma.201201251; Huang CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135299; Huang XH, 2008, LASER MED SCI, V23, P217, DOI 10.1007/s10103-007-0470-x; Hwang ES, 2006, EXP BIOL MED, V231, P322; Jose J, 2020, ENVIRON SCI POLLUT R, V27, P19214, DOI 10.1007/s11356-019-07231-2; Kim DH, 2010, NAT MATER, V9, P165, DOI [10.1038/nmat2591, 10.1038/NMAT2591]; Kobayashi T, 2011, BIOTECHNOL J, V6, P1342, DOI 10.1002/biot.201100045; Latorre M, 2009, P R HEALTH SCI J, V28, P227; Laurent S, 2011, ADV COLLOID INTERFAC, V166, P8, DOI 10.1016/j.cis.2011.04.003; Lee CW, 2018, ONCOL LETT, V15, P559, DOI 10.3892/ol.2017.7320; Leulmi S, 2015, NANOSCALE, V7, P15904, DOI 10.1039/c5nr03518j; Maier-Hauff K, 2011, J NEURO-ONCOL, V103, P317, DOI 10.1007/s11060-010-0389-0; Mansell R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04154-1; Na HB, 2009, ADV MATER, V21, P2133, DOI 10.1002/adma.200802366; Piazza RD, 2020, MATER RES EXPRESS, V7, DOI 10.1088/2053-1591/ab6700; Sanz B, 2017, BIOMATERIALS, V114, P62, DOI 10.1016/j.biomaterials.2016.11.008; Sengupta S, 2018, J ADV RES, V14, P97, DOI 10.1016/j.jare.2018.06.003; Tai Y, 2018, INT J CLIN EXP PATHO, V11, P2931; Wang HL, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014498; Wang YXJ, 2011, QUANT IMAGING MED SU, V1, P35, DOI 10.3978/j.issn.2223-4292.2011.08.03; Wu K, 2017, AIP ADV, V7, DOI 10.1063/1.4978458; Yagawa Y., 2017, J CANCER METAS TREAT, V3, P218, DOI [10.20517/2394-4722.2017.35, DOI 10.20517/2394-4722.2017.35]; Zhang EM, 2014, ACS NANO, V8, P3192, DOI 10.1021/nn406302j	33	4	4	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2021	16	2							e0245286	10.1371/journal.pone.0245286	http://dx.doi.org/10.1371/journal.pone.0245286			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH0TZ	33544751	Green Published, gold			2023-01-03	WOS:000617991900008
J	Ciapponi, A; Donato, M; Gulmezoglu, AM; Alconada, T; Bardach, A				Ciapponi, Agustin; Donato, Manuel; Gulmezoglu, A. Metin; Alconada, Tomas; Bardach, Ariel			Mobile apps for detecting falsified and substandard drugs: A systematic review	PLOS ONE			English	Review							INTERVENTIONS; COMBAT	The use of substandard and counterfeit medicines (SCM) leads to significant health and economic consequences, like treatment failure, rise of antimicrobial resistance, extra expenditures of individuals or households and serious adverse drug reactions including death. Our objective was to systematically search, identify and compare relevant available mobile applications (apps) for smartphones and tablets, which use could potentially affect clinical and public health outcomes. We carried out a systematic review of the literature in January 2020, including major medical databases, and app stores. We used the validated Mobile App Rating Scale (MARS) to assess the quality of apps, (1 worst score, 3 acceptable score, and 5 best score). We planned to evaluate the accuracy of the mobile apps to detect SCM. We retrieved 335 references through medical databases and 42 from Apple, Google stores and Google Scholar. We finally included two studies of the medical database, 25 apps (eight from the App Store, eight from Google Play, eight from both stores, and one from Google Scholar), and 16 websites. We only found one report on the accuracy of a mobile apps detecting SCMs. Most apps use the imprint, color or shape for pill identification, and only a few offer pill detection through photographs or bar code. The MARS mean score for the apps was 3.17 (acceptable), with a maximum of 4.9 and a minimum of 1.1. The 'functionality' dimension resulted in the highest mean score (3.4), while the 'engagement' and 'information' dimensions showed the lowest one (3.0). In conclusion, we found a remarkable evidence gap about the accuracy of mobile apps in detecting SCMs. However, mobile apps could potentially be useful to screen for SCM by assessing the physical characteristics of pills, although this should still be assessed in properly designed research studies.	[Ciapponi, Agustin; Donato, Manuel; Alconada, Tomas] Consejo Nacl Invest Cient & Tecn, Inst Efectividad Clin & Sanitaria IECS, Buenos Aires, DF, Argentina; [Ciapponi, Agustin; Donato, Manuel; Alconada, Tomas; Bardach, Ariel] Consejo Nacl Invest Cient & Tecn, IECS, Ctr & Invest Epidemiol & Salud Publ CIESP, Buenos Aires, DF, Argentina; [Gulmezoglu, A. Metin] WHO, Dept Reprod Hlth & Res, UNDP UNFPA UNICEF WHO World Bank Special Programm, Geneva, Switzerland	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); The World Bank; United Nations Population Fund; World Health Organization	Ciapponi, A (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Efectividad Clin & Sanitaria IECS, Buenos Aires, DF, Argentina.; Ciapponi, A (corresponding author), Consejo Nacl Invest Cient & Tecn, IECS, Ctr & Invest Epidemiol & Salud Publ CIESP, Buenos Aires, DF, Argentina.	aciapponi@iecs.org.ar	Bardach, Ariel/H-9566-2019	Bardach, Ariel/0000-0003-4437-0073; Ciapponi, Agustin/0000-0001-5142-6122; Donato, Manuel/0000-0002-5949-3845	HRP (the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction)	HRP (the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction)	This work was funded by an independent grant from HRP (the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction https://wwww.who.int/reproductivehealth/hrp/en/).The funder's role was limited to developing the terms of references and reviewing the drafts. The funders had no role in the final content or decision to publish the manuscript.	Adam A, 2018, WORLD J UROL, V36, P565, DOI 10.1007/s00345-017-2150-1; [Anonymous], 2019, COVID SYST REV SOFTW; [Anonymous], 2020, CHECKFAKE DLT SG APP; Bardus M, 2016, INT J BEHAV NUTR PHY, V13, DOI 10.1186/s12966-016-0359-9; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Cuomo RE, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006657; Fadlallah R, 2016, PHARM MED, V30, P263, DOI 10.1007/s40290-016-0156-4; Fernandez FM, 2011, ANALYST, V136, P3073, DOI 10.1039/c0an00627k; Guo YQ, 2020, JMIR AGING, V3, DOI 10.2196/15290; Hall PE, 2016, WHO DRUG INF, V30, P35; Hamilton WL, 2016, HEALTH POLICY PLANN, V31, P1448, DOI 10.1093/heapol/czw062; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Hymel PA, 2020, EVALUATION MEDSNAP M, DOI [10.1101/2020.05.06.20093427, DOI 10.1101/2020.05.06.20093427]; Khalifian S, 2013, APPL CLIN INFORM, V4, P53, DOI 10.4338/ACI-2012-10-CR-0047; Kim BYB, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.8613; Kovacs S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090601; Lefaucheur JP, 2014, BMJ, V125, P2150, DOI DOI 10.1136/BMJ.B2700; Mackey TK, 2017, EXPERT OPIN DRUG SAF, V16, P587, DOI 10.1080/14740338.2017.1313227; National Heart Lung and Blood Institute, 2013, STUD QUAL ASS TOOLS; Ozawa S, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.1662; Rasheed H, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00995; Roth L, 2018, GLOBALIZATION HEALTH, V14, DOI 10.1186/s12992-018-0360-y; Santo K, 2016, JMIR MHEALTH UHEALTH, V4, DOI 10.2196/mhealth.6742; Stoyanov SR, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.3422; Vickers S, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000725; WHO, 2017, WHO GLOB SURV MON SY; Woods Leanna Sarah, 2019, JMIR Hum Factors, V6, pe13009, DOI 10.2196/13009; World Health Organization, 2017, STUD PUBL HTH SOC IM; World Health Organization, 2017, DEF SUBST FALS SF ME; World Health Organization (WHO), 2015, HLTH 2015 MDGS MILL, DOI 10.1007/BF01918387	30	3	3	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2021	16	2							e0246061	10.1371/journal.pone.0246061	http://dx.doi.org/10.1371/journal.pone.0246061			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF5UW	33539433	Green Published, gold			2023-01-03	WOS:000616960200092
J	Sayinzoga, F; Lundeen, T; Musange, SF; Butrick, E; Nzeyimana, D; Murindahabi, N; Azman-Firdaus, H; Sloan, NL; Benitez, A; Phillips, B; Ghosh, R; Walker, D				Sayinzoga, Felix; Lundeen, Tiffany; Musange, Sabine F.; Butrick, Elizabeth; Nzeyimana, David; Murindahabi, Nathalie; Azman-Firdaus, Hana; Sloan, Nancy L.; Benitez, Alejandra; Phillips, Beth; Ghosh, Rakesh; Walker, Dilys			Assessing the impact of group antenatal care on gestational length in Rwanda: A cluster-randomized trial	PLOS ONE			English	Article							GROUP PRENATAL-CARE; PERINATAL OUTCOMES; MODEL	Background Research on group antenatal care in low- and middle-income contexts suggests high acceptability and preliminary implementation success. Methods We studied the effect of group antenatal care on gestational age at birth among women in Rwanda, hypothesizing that participation would increase mean gestational length. For this unblinded cluster randomized trial, 36 health centers were pair-matched and randomized; half continued individual antenatal care (control), half implemented group antenatal care (intervention). Women who initiated antenatal care between May 2017 and December 2018 were invited to participate, and included in analyses if they presented before 24 weeks gestation, attended at least two visits, and their birth outcome was obtained. We used a generalized estimating equations model for analysis. Findings In total, 4091 women in 18 control clusters and 4752 women in 18 intervention clusters were included in the analysis. On average, women attended three total antenatal care visits. Gestational length was equivalent in the intervention and control groups (39.3 weeks (SD 1.6) and 39.3 weeks (SD 1.5)). There were no significant differences between groups in secondary outcomes except that more women in control sites attended postnatal care visits (40.1% versus 29.7%, p = 0.003) and more women in intervention sites attended at least three total antenatal care visits (80.7% versus 71.7%, p = 0.003). No harms were observed. Interpretation Group antenatal care did not result in a difference in gestational length between groups. This may be due to the low intervention dose. We suggest studies of both the effectiveness and costs of higher doses of group antenatal care among women at higher risk of preterm birth. We observed threats to group care due to facility staff shortages; we recommend studies in which antenatal care providers are exclusively allocated to group antenatal care during visits.	[Sayinzoga, Felix] Rwanda Biomed Ctr, Maternal Child & Community Hlth Div, Kigali, Rwanda; [Lundeen, Tiffany; Butrick, Elizabeth; Azman-Firdaus, Hana; Sloan, Nancy L.; Phillips, Beth; Ghosh, Rakesh; Walker, Dilys] Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94143 USA; [Musange, Sabine F.; Nzeyimana, David; Murindahabi, Nathalie] Univ Rwanda, Sch Publ Hlth, Kigali, Rwanda; [Benitez, Alejandra] Univ Calif Berkeley, Dept Biostat, Berkeley, CA 94720 USA; [Walker, Dilys] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA	Rwanda Biomedical Center; University of California System; University of California San Francisco; University of Rwanda; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Lundeen, T (corresponding author), Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94143 USA.	tiffany.lundeen@gmail.com		Nzeyimana, David/0000-0002-1389-7107	East Africa Preterm Birth initiative - Bill and Melinda Gates Foundation [OPP1107312]	East Africa Preterm Birth initiative - Bill and Melinda Gates Foundation	This trial is supported by the East Africa Preterm Birth initiative, a multi-year, multi-country effort generously funded by the Bill and Melinda Gates Foundation (OPP1107312). The Foundation's website is www.gatesfoundation.org.The funder reviewed the study design but did not have input on analysis or interpretation of results.	Butrick Elizabeth, 2020, Gates Open Res, V4, P7, DOI 10.12688/gatesopenres.13090.1; Catling CJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007622.pub3; Chawanpaiboon S, 2019, LANCET GLOB HEALTH, V7, pE37, DOI 10.1016/S2214-109X(18)30451-0; Grenier L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222177; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hayes G, 2017, STUD CAN MIL HIST, P1; IBM Corp, 2017, REL IBM SPSS STAT VE; Ickovics JR, 2007, OBSTET GYNECOL, V110, P330, DOI 10.1097/01.AOG.0000275284.24298.23; Ickovics JR, 2016, AM J PUBLIC HEALTH, V106, P359, DOI 10.2105/AJPH.2015.302960; Lori JR, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1414-5; Lu B, 2011, AM STAT, V65, P21, DOI 10.1198/tast.2011.08294; Lundeen T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219471; Manant A, 2011, J MIDWIFERY WOM HEAL, V56, P94, DOI 10.1111/j.1542-2011.2010.00021.x; Mazzoni SE, 2017, AM J OBSTET GYNECOL, V216, P552, DOI 10.1016/j.ajog.2017.02.006; Musabyimana A, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0750-5; Musange Sabine Furere, 2019, Gates Open Res, V3, P1548, DOI 10.12688/gatesopenres.13053.1; National Institute of Statistics of Rwanda Ministry of Finance and Economic Planning Ministry of Health TDPII, 2016, RWAND DEM HLTH SURV; Nizeyimana Pacifique, 2018, [Journal of the Korean Data And Information Science Sociaty, 한국데이터정보과학회지], V29, P547, DOI 10.7465/jkdi.2018.29.2.547; Patil CL, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1493-3; Patil CL, 2017, INT J GYNECOL OBSTET, V139, P290, DOI 10.1002/ijgo.12324; Press S, 2019, STAT STAT SOFTW REL; R Core Team, 2019, R LANG ENV STAT COMP; Rising SS, 1998, J NURSE-MIDWIFERY, V43, P46, DOI 10.1016/S0091-2182(97)00117-1; Sayinzoga F, 2018, J MIDWIFERY WOM HEAL, V63, P593, DOI 10.1111/jmwh.12871; Thielen K, 2012, J PERINAT EDUC, V21, P209, DOI 10.1891/1058-1243.21.4.209; Villar J, 2014, LANCET; WHO, REC ANT CAR POS PREG	27	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2021	16	2							e0246442	10.1371/journal.pone.0246442	http://dx.doi.org/10.1371/journal.pone.0246442			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF2NJ	33529256	Green Published, gold			2023-01-03	WOS:000616736200066
J	Velingkaar, N; Mezhnina, V; Poe, A; Kondratov, RV				Velingkaar, Nikkhil; Mezhnina, Volha; Poe, Allan; Kondratov, Roman, V			Two-meal caloric restriction induces 12-hour rhythms and improves glucose homeostasis	FASEB JOURNAL			English	Article						aging; metabolism; diet; circadian rhythms; gene expression; glucose homeostasis; 12&#8208; hour rhythms	PERIPHERAL CIRCADIAN CLOCKS; MTOR SIGNALING PATHWAY; DIETARY RESTRICTION; FOOD-INTAKE; LIFE-SPAN; METABOLISM; LIVER; TIME; GROWTH; MICE	Glucose metabolism is tightly regulated and disrupting glucose homeostasis is a hallmark of many diseases. Caloric restriction (CR), periodic fasting, and circadian rhythms are interlinked with glucose metabolism. Here, we directly investigated if CR depends on periodic fasting and circadian rhythms to improve glucose metabolism. CR was implemented as two-meals per day (2M-CR), provided at 12-hour intervals, and compared with one meal per day CR, mealtime (MT), and ad libitum (AL) feeding. The 2M-CR impacted the circadian rhythms in blood glucose, metabolic signaling, circadian clock, and glucose metabolism gene expression. 2M-CR significantly reduced around the clock blood glucose and improved glucose tolerance. Twenty-four-hour rhythms in mTOR signaling and gene expression observed under AL, MT, and CR, became 12-hour rhythms in 2M-CR. The 12-hour rhythms in behavior, gene expression, and signaling persisted in fasted mice, implicating some internal regulation. The study highlights that the reduction in caloric intake rather than meal frequency and duration of fasting is essential for metabolic reprograming and improvement in glucose metabolism and provides evidence on food-entrained molecular pacemaker, which can be uncoupled from the light-entrained circadian clock and rhythms.	[Velingkaar, Nikkhil; Mezhnina, Volha; Poe, Allan; Kondratov, Roman, V] Cleveland State Univ, Ctr Gene Regulat Hlth & Dis, Cleveland, OH 44115 USA; [Velingkaar, Nikkhil; Mezhnina, Volha; Poe, Allan; Kondratov, Roman, V] Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA	University System of Ohio; Cleveland State University; University System of Ohio; Cleveland State University	Velingkaar, N; Kondratov, RV (corresponding author), Cleveland State Univ, Ctr Gene Regulat Hlth & Dis, Cleveland, OH 44115 USA.; Velingkaar, N; Kondratov, RV (corresponding author), Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA.	n.velingkaar@vikes.csuohio.edu; r.kondratov@csuohio.edu	Velingkaar, Nikkhil/ABC-8132-2020	Velingkaar, Nikkhil/0000-0003-1571-0833; Mezhnina, Volha/0000-0001-9634-0410	NIA NIH HHS [R01 AG039547] Funding Source: Medline; NIH HHS [S10 OD025252] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Acosta-Rodriguez VA, 2017, CELL METAB, V26, P267, DOI 10.1016/j.cmet.2017.06.007; Aguilar-Arnal L, 2015, P NATL ACAD SCI USA, V112, P6863, DOI 10.1073/pnas.1411264111; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Asher G, 2015, CELL, V161, P84, DOI 10.1016/j.cell.2015.03.015; Astafev AA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09289-9; Atger F, 2015, P NATL ACAD SCI USA, V112, pE6579, DOI 10.1073/pnas.1515308112; Bass J, 2012, NATURE, V491, P348, DOI 10.1038/nature11704; Bruss MD, 2010, AM J PHYSIOL-ENDOC M, V298, pE108, DOI 10.1152/ajpendo.00524.2009; Cao R, 2011, NEUROSCIENCE, V181, P79, DOI 10.1016/j.neuroscience.2011.03.005; Cao RF, 2008, MOL CELL NEUROSCI, V38, P312, DOI 10.1016/j.mcn.2008.03.005; Cao R, 2013, NEURON, V79, P712, DOI 10.1016/j.neuron.2013.06.026; Chaix A, 2019, CELL METAB, V29, P303, DOI 10.1016/j.cmet.2018.08.004; Chaix A, 2014, CELL METAB, V20, P991, DOI 10.1016/j.cmet.2014.11.001; Chavan R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10580; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Eckel-Mahan KL, 2013, CELL, V155, P1464, DOI 10.1016/j.cell.2013.11.034; Greenwell BJ, 2019, CELL REP, V27, P649, DOI 10.1016/j.celrep.2019.03.064; Hagopian K, 2003, EXP GERONTOL, V38, P253, DOI 10.1016/S0531-5565(02)00203-6; Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019; Jouffe C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001455; Katewa SD, 2016, CELL METAB, V23, P143, DOI 10.1016/j.cmet.2015.10.014; Kennedy BK, 2016, CELL METAB, V23, P990, DOI 10.1016/j.cmet.2016.05.009; Khapre RV, 2014, AGING-US, V6, P675, DOI 10.18632/aging.100686; Khapre RV, 2014, AGING-US, V6, P48, DOI 10.18632/aging.100633; Kohsaka A, 2007, CELL METAB, V6, P414, DOI 10.1016/j.cmet.2007.09.006; Lamming DW, 2011, CELL METAB, V13, P617, DOI 10.1016/j.cmet.2011.05.006; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lipton JO, 2015, CELL, V161, P1138, DOI 10.1016/j.cell.2015.04.002; Longo VD, 2015, AGING CELL, V14, P497, DOI 10.1111/acel.12338; Mattson MP, 2014, P NATL ACAD SCI USA, V111, P16647, DOI 10.1073/pnas.1413965111; Mistlberger RE, 2011, PHYSIOL BEHAV, V104, P535, DOI 10.1016/j.physbeh.2011.04.015; Mitchell SJ, 2019, CELL METAB, V29, P221, DOI 10.1016/j.cmet.2018.08.011; Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128; Mukherji A, 2015, P NATL ACAD SCI USA, V112, pE6683, DOI 10.1073/pnas.1519735112; Nakahata Y, 2007, CURR OPIN CELL BIOL, V19, P230, DOI 10.1016/j.ceb.2007.02.016; Nohara K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11926-y; O'Neill JS, 2011, NATURE, V469, P498, DOI 10.1038/nature09702; Patel SA, 2016, FASEB J, V30, P1634, DOI 10.1096/fj.15-282475; Patton DF, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00185; Piper MDW, 2008, CELL METAB, V8, P99, DOI 10.1016/j.cmet.2008.06.012; Ray S, 2020, SCIENCE, V367, P800, DOI 10.1126/science.aaw7365; Sato S, 2017, CELL, V170, P664, DOI 10.1016/j.cell.2017.07.042; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Sherman H, 2012, FASEB J, V26, P3493, DOI 10.1096/fj.12-208868; Solanas G, 2017, CELL, V170, P678, DOI 10.1016/j.cell.2017.07.035; Solovev I, 2019, BIOGERONTOLOGY, V20, P159, DOI 10.1007/s10522-018-9784-2; Sutton EF, 2018, CELL METAB, V27, P1212, DOI 10.1016/j.cmet.2018.04.010; Taormina G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/308690; Tognini P, 2017, CELL METAB, V26, P523, DOI 10.1016/j.cmet.2017.08.015; Tulsian R, 2018, AGING-US, V10, P1640, DOI 10.18632/aging.101498; Ulgherait M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15617-x; Velingkaar N, 2020, AGING CELL, V19, DOI 10.1111/acel.13138; Wu R, 2019, CELL METAB, V29, P653, DOI 10.1016/j.cmet.2018.11.006; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	54	1	1	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2021	35	2							e21342	10.1096/fj.202002470R	http://dx.doi.org/10.1096/fj.202002470R			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RY3BC	33543540	hybrid, Green Published			2023-01-03	WOS:000647789600033
J	Boehm, JS; Garnett, MJ; Adams, DJ; Francies, HE; Golub, TR; Hahn, WC; Iorio, F; McFarland, JM; Parts, L; Vazquez, F				Boehm, Jesse S.; Garnett, Mathew J.; Adams, David J.; Francies, Hayley E.; Golub, Todd R.; Hahn, William C.; Iorio, Francesco; McFarland, James M.; Parts, Leopold; Vazquez, Francisca			Cancer research needs a better map	NATURE			English	Editorial Material						Cancer; Medical research	LANDSCAPE; ONCOGENE		[Boehm, Jesse S.; Golub, Todd R.; Hahn, William C.; McFarland, James M.; Vazquez, Francisca] Broad Inst, Canc Dependency Map Project, Cambridge, MA 02142 USA; [Hahn, William C.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Garnett, Mathew J.; Adams, David J.; Francies, Hayley E.; Iorio, Francesco; Parts, Leopold] Wellcome Sanger Inst, Canc Dependency Map Project, Hinxton, England; [Iorio, Francesco] Human Technopole, Milan, Italy	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Wellcome Trust Sanger Institute; Human Technopole	Boehm, JS (corresponding author), Broad Inst, Canc Dependency Map Project, Cambridge, MA 02142 USA.	boehm@broadinstitute.org; mathew.garnett@sanger.ac.uk	Adams, David/GMW-8541-2022; Iorio, Francesco/H-3284-2019	Adams, David/0000-0001-9490-0306; Iorio, Francesco/0000-0001-7063-8913				Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Corsello SM, 2020, NAT CANCER, V1, P235, DOI 10.1038/s43018-019-0018-6; Dempster JM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13805-y; Feldman D, 2019, CELL, V179, P787, DOI 10.1016/j.cell.2019.09.016; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831; Haverty PM, 2016, NATURE, V533, P333, DOI 10.1038/nature17987; Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Rozenblatt-Rosen O, 2017, NATURE, V550, P451, DOI 10.1038/550451a; Stockley TL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0364-2; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	16	25	26	3	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 28	2021	589	7843					514	516		10.1038/d41586-021-00182-0	http://dx.doi.org/10.1038/d41586-021-00182-0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PY4CS	33500573				2023-01-03	WOS:000611994100015
J	Alderfer, L; Russo, E; Archilla, A; Coe, B; Hanjaya-Putra, D				Alderfer, Laura; Russo, Elizabeth; Archilla, Adriana; Coe, Brian; Hanjaya-Putra, Donny			Matrix stiffness primes lymphatic tube formation directed by vascular endothelial growth factor-C	FASEB JOURNAL			English	Article						hyaluronic acid; lymphatic networks; matrix stiffness; mechanoregulation; VEGF-C	NUCLEOTIDE EXCISION-REPAIR; MITOCHONDRIAL PERMEABILITY TRANSITION; NECROTIC CELL-DEATH; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE; MOLECULAR-MECHANISMS; PROGRAMMED NECROSIS; ESSENTIAL KINASE; ATR KINASE; S PHASE	Dysfunction of the lymphatic system is associated with a wide range of disease phenotypes. The restoration of dysfunctional lymphatic vessels has been hypothesized as an innovative method to rescue healthy phenotypes in diseased states including neurological conditions, metabolic syndromes, and cardiovascular disease. Compared to the vascular system, little is known about the molecular regulation that controls lymphatic tube morphogenesis. Using synthetic hyaluronic acid (HA) hydrogels as a chemically and mechanically tunable system to preserve lymphatic endothelial cell (LECs) phenotypes, we demonstrate that low matrix elasticity primes lymphatic cord-like structure (CLS) formation directed by a high concentration of vascular endothelial growth factor-C (VEGF-C). Decreasing the substrate stiffness results in the upregulation of key lymphatic markers, including PROX-1, lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), and VEGFR-3. Consequently, higher levels of VEGFR-3 enable stimulation of LECs with VEGF-C which is required to both activate matrix metalloproteinases (MMPs) and facilitate LEC migration. Both of these steps are critical in establishing CLS formation in vitro. With decreases in substrate elasticity, we observe increased MMP expression and increased cellular elongation, as well as formation of intracellular vacuoles, which can further merge into coalescent vacuoles. RNAi studies demonstrate that MMP-14 is required to enable CLS formation and that LECs sense matrix stiffness through YAP/TAZ mechanosensors leading to the activation of their downstream target genes. Collectively, we show that by tuning both the matrix stiffness and VEGF-C concentration, the signaling pathways of CLS formation can be regulated in a synthetic matrix, resulting in lymphatic networks which will be useful for the study of lymphatic biology and future approaches in tissue regeneration.	[Alderfer, Laura; Hanjaya-Putra, Donny] Univ Notre Dame, Bioengn Grad Program, Notre Dame, IN USA; [Russo, Elizabeth; Coe, Brian; Hanjaya-Putra, Donny] Univ Notre Dame, Aerosp & Mech Engn, 141 Multidisciplinary Res Bldg, Notre Dame, IN 46556 USA; [Archilla, Adriana; Hanjaya-Putra, Donny] Univ Notre Dame, Notre Dame Nanosci & Technol NDnano, Notre Dame, IN USA; [Hanjaya-Putra, Donny] Univ Notre Dame, Chem & Biomol Engn, Notre Dame, IN USA	University of Notre Dame; University of Notre Dame; University of Notre Dame; University of Notre Dame	Hanjaya-Putra, D (corresponding author), Univ Notre Dame, Aerosp & Mech Engn, 141 Multidisciplinary Res Bldg, Notre Dame, IN 46556 USA.	dputra1@nd.edu		HanjayaPutra, Donny/0000-0002-5403-544X	American Heart Association (AHA) [19-CDA-34630012]; American Cancer Society (ACS) [IRG-17-182-04]; Walther Cancer Foundation (WCF) [0180.01]; HHS \ NIH \ National Center for Advancing Translational Sciences (NCATS) [ULITR001108]	American Heart Association (AHA)(American Heart Association); American Cancer Society (ACS)(American Cancer Society); Walther Cancer Foundation (WCF); HHS \ NIH \ National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	American Heart Association (AHA), Grant/Award Number: 19-CDA-34630012; American Cancer Society (ACS), Grant/Award Number: IRG-17-182-04; Walther Cancer Foundation (WCF): 0180.01; HHS | NIH | National Center for Advancing Translational Sciences (NCATS), Grant/Award Number: ULITR001108	Alcock RF, 2012, HEART, V98, P792, DOI 10.1136/heartjnl-2011-301577; Andrabi SA, 2014, P NATL ACAD SCI USA, V111, P10209, DOI 10.1073/pnas.1405158111; Andrabi SA, 2011, NAT MED, V17, P692, DOI 10.1038/nm.2387; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Auclair Y, 2009, CELL CYCLE, V8, P1865, DOI 10.4161/cc.8.12.8800; Auclair Y, 2008, P NATL ACAD SCI USA, V105, P17896, DOI 10.1073/pnas.0801585105; Bai P, 2015, TRENDS ENDOCRIN MET, V26, P75, DOI 10.1016/j.tem.2014.11.003; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; Bentle MS, 2006, J BIOL CHEM, V281, P33684, DOI 10.1074/jbc.M603678200; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Budker V, 2006, BIOPOLYMERS, V83, P646, DOI 10.1002/bip.20602; Burgess RC, 2014, CELL REP, V9, P1703, DOI 10.1016/j.celrep.2014.10.060; Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x; Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53; Cho YS, 2010, MOL CELLS, V29, P327, DOI 10.1007/s10059-010-0066-3; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 2006, METHOD ENZYMOL, V409, P493, DOI 10.1016/S0076-6879(05)09029-4; Douglas DL, 2014, J CELL SCI, V127, P4134, DOI 10.1242/jcs.128009; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Fischer JMF, 2014, FEBS J, V281, P3625, DOI 10.1111/febs.12885; Francis RJ, 2013, J LEUKOCYTE BIOL, V93, P95, DOI 10.1189/jlb.0412212; Gagne JP, 2012, SCIENCE, V336, P678, DOI 10.1126/science.1221870; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Han SI, 2008, BMB REP, V41, P1; Harris HE, 2004, EUR J IMMUNOL, V34, P1503, DOI 10.1002/eji.200424916; Heffernan TP, 2009, J INVEST DERMATOL, V129, P1805, DOI 10.1038/jid.2008.435; Hilton BA, 2015, MOL CELL, V60, P35, DOI 10.1016/j.molcel.2015.08.008; Hsu PC, 2019, ONCOGENE, V38, P1166, DOI 10.1038/s41388-018-0506-7; Kalogeris T, 2012, INT REV CEL MOL BIO, V298, P229, DOI 10.1016/B978-0-12-394309-5.00006-7; Kedar PS, 2008, DNA REPAIR, V7, P1787, DOI 10.1016/j.dnarep.2008.07.006; Kennedy CL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000516; Kim D, 2018, NUCLEIC ACIDS RES, V46, P8311, DOI 10.1093/nar/gky625; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kitsis RN, 2010, P NATL ACAD SCI USA, V107, P9031, DOI 10.1073/pnas.1003827107; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Krysko DV, 2008, METHOD ENZYMOL, V442, P307, DOI [10.1016/S0070-6879(08)01416-X, 10.1016/S0076-6879(08)01416-X]; Kumar A, 2014, CELL, V158, P633, DOI 10.1016/j.cell.2014.05.046; Kung G, 2011, CIRC RES, V108, P1017, DOI 10.1161/CIRCRESAHA.110.225730; LaRocque JR, 2007, GENETICS, V175, P1023, DOI 10.1534/genetics.106.067330; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Lee TH, 2014, ONCOGENE, V33, P19, DOI 10.1038/onc.2012.539; Li GY, 2010, BIOMED ENVIRON SCI, V23, P371, DOI 10.1016/S0895-3988(10)60078-5; Li ZK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068297; Linkermann A, 2013, AM J TRANSPLANT, V13, P2797, DOI 10.1111/ajt.12448; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; Liu C, 2017, NUCLEIC ACIDS RES, V45, P8129, DOI 10.1093/nar/gkx565; Liu QH, 2000, GENE DEV, V14, P1448; Liu SZ, 2011, MOL CELL, V43, P192, DOI 10.1016/j.molcel.2011.06.019; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Luo M, 2013, CIRC RES, V113, P690, DOI 10.1161/CIRCRESAHA.113.301651; Marechal Alexandre, 2013, Cold Spring Harb Perspect Biol, V5, DOI 10.1101/cshperspect.a012716; Mastrocola AS, 2013, J BIOL CHEM, V288, P24731, DOI 10.1074/jbc.M113.497974; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; Monassier JP, 2008, ARCH CARDIOVASC DIS, V101, P491, DOI 10.1016/j.acvd.2008.06.014; Muller GJ, 2004, BRAIN PATHOL, V14, P415; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakayama H, 2007, J CLIN INVEST, V117, P2431, DOI 10.1172/JCI31060; Nam EA, 2011, J BIOL CHEM, V286, P28707, DOI 10.1074/jbc.M111.248914; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Park S, 2015, ANAT CELL BIOL, V48, P66, DOI 10.5115/acb.2015.48.1.66; Pascal JM, 2018, DNA REPAIR, V71, P177, DOI 10.1016/j.dnarep.2018.08.022; PATEL R, 1989, J CELL SCI, P129; Phengchat R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38281; Prabhakaran S, 2015, JAMA-J AM MED ASSOC, V313, P1451, DOI 10.1001/jama.2015.3058; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Radak D, 2017, CURR VASC PHARMACOL, V15, P115, DOI 10.2174/1570161115666161104095522; Saldivar JC, 2018, SCIENCE, V361, P806, DOI 10.1126/science.aap9346; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P622, DOI 10.1038/nrm.2017.67; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shell SM, 2009, J BIOL CHEM, V284, P24213, DOI 10.1074/jbc.M109.000745; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Strom CE, 2012, BIOMOLECULES, V2, P635, DOI 10.3390/biom2040635; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Toledo LI, 2011, MOL ONCOL, V5, P368, DOI 10.1016/j.molonc.2011.07.002; Traven A, 2005, BIOESSAYS, V27, P397, DOI 10.1002/bies.20204; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Visvanathan A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067689; Wang YF, 2016, SCIENCE, V354, DOI 10.1126/science.aad6872; Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902; Wu X, 2007, ONCOGENE, V26, P757, DOI 10.1038/sj.onc.1209828; Wu XM, 2006, CANCER RES, V66, P2997, DOI 10.1158/0008-5472.CAN-05-3403; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yang PM, 2007, CHEM RES TOXICOL, V20, P406, DOI 10.1021/tx060144c; Yelamos J, 2011, AM J CANCER RES, V1, P328; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuan JY, 2009, APOPTOSIS, V14, P469, DOI 10.1007/s10495-008-0304-8; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang FJ, 2014, TOXICOL SCI, V140, P118, DOI 10.1093/toxsci/kfu073; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	101	9	9	2	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2021	35	5							e21498	10.1096/fj.202002426RR	http://dx.doi.org/10.1096/fj.202002426RR			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU6MM	33774872	Green Accepted			2023-01-03	WOS:000645260100098
J	Delbaere, K; Valenzuela, T; Lord, SR; Clemson, L; Zijlstra, GAR; Close, JCT; Lung, T; Woodbury, A; Chow, J; McInerney, G; Miles, L; Toson, B; Briggs, N; van Schooten, KS				Delbaere, Kim; Valenzuela, Trinidad; Lord, Stephen R.; Clemson, Lindy; Zijlstra, G. A. Rixt; Close, Jacqueline C. T.; Lung, Thomas; Woodbury, Ashley; Chow, Jessica; McInerney, Garth; Miles, Lillian; Toson, Barbara; Briggs, Nancy; van Schooten, Kimberley S.			E-health StandingTall balance exercise for fall prevention in older people: results of a two year randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBjECTIVE To test whether StandingTall, a home based, e-health balance exercise programme delivered through an app, could provide an effective, self-managed fall prevention programme for community dwelling older people. DESIGN Assessor blinded, randomised controlled trial. SETTING Older people living independently in the community in Sydney, Australia. PARTICIPANTS 503 people aged 70 years and older who were independent in activities of daily living, without cognitive impairment, progressive neurological disease, or any other unstable or acute medical condition precluding exercise. INTERVENTIONS Participants were block randomised to an intervention group (two hours of StandingTall per week and health education; n=254) or a control group (health education; n=249) for two years. MAIN OUTCOME MEASURES The primary outcomes were the rate of falls (number of falls per person year) and the proportion of people who had a fall over 12 months. Secondary outcomes were the number of people who had a fall and the number who had an injurious fall (resulting in any injury or requiring medical care), adherence, mood, health related quality of life, and activity levels over 24 months; and balance and mobility outcomes over 12 months. RESULTS The fall rates were not statistically different in the two groups after the first 12 months (0.60 falls per year (standard deviation 1.05) in the intervention group; 0.76 (1.25) in the control group; incidence rate ratio 0.84, 95% confidence interval 0.62 to 1.13, P=0.071). Additionally, the proportion of people who fell was not statistically different at 12 months (34.6% in intervention group, 40.2% in control group; relative risk 0.90, 95% confidence interval 0.67 to 1.20, P=0.461). However, the intervention group had a 16% lower rate of falls over 24 months compared with the control group (incidence rate ratio 0.84, 95% confidence interval 0.72 to 0.98, P=0.027). Both groups had a similar proportion of people who fell over 24 months (relative risk 0.87, 95% confidence interval 0.68 to 1.10, P=0.239), but the proportion of people who had an injurious fall over 24 months was 20% lower in the intervention group compared with the control group (relative risk 0.80, 95% confidence interval 0.66 to 0.98, P=0.031). In the intervention group, 68.1% and 52.0% of participants exercised for a median of 114.0 min/week (interquartile range 53.5) after 12 months and 120.4 min/week (38.6) after 24 months, respectively. Groups remained similar in mood and activity levels. The intervention group had a 0.03 (95% confidence interval 0.01 to 0.06) improvement on the EQ-5D-5L (EuroQol five dimension five level) utility score at six months, and an improvement in standing balance of 11 s (95% confidence interval 2 to 19 s) at six months and 10 s (1 to 19 s) at 12 months. No serious training related adverse events occurred. CONCLUSIONS The StandingTall balance exercise programme did not significantly affect the primary outcomes of this study. However, the programme significantly reduced the rate of falls and the number of injurious falls over two years, with similar but not statistically significant effects at 12 months. E-health exercise programmes could provide promising scalable fall prevention strategies. TRIAL REGISTRATION ACTRN12615000138583	[Delbaere, Kim; Lord, Stephen R.; Close, Jacqueline C. T.; Woodbury, Ashley; Chow, Jessica; McInerney, Garth; Miles, Lillian; Toson, Barbara; van Schooten, Kimberley S.] Neurosci Res Australia, Falls Balance & Injury Res Ctr, Randwick, NSW, Australia; [Delbaere, Kim; Lord, Stephen R.; van Schooten, Kimberley S.] Univ New South Wales, Sch Populat Hlth, Kensington, NSW, Australia; [Valenzuela, Trinidad; Clemson, Lindy; Lung, Thomas] Univ Sydney, Sch Publ Hlth, Fac Med & Hlth, Sydney, NSW, Australia; [Valenzuela, Trinidad] Univ Finis Terrae, Sch Kinesiol, Exercise Sci Lab, Fac Med, Santiago, Chile; [Zijlstra, G. A. Rixt] Maastricht Univ, Care & Publ Hlth Res Inst, Dept Hlth Serv Res, Maastricht, Netherlands; [Close, Jacqueline C. T.] Univ New South Wales, Prince Wales Hosp Clin Sch, Kensington, NSW, Australia; [Lung, Thomas] Univ New South Wales, George Inst Global Hlth, Newtown, NSW, Australia; [Toson, Barbara] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia; [Briggs, Nancy] Univ New South Wales, Stats Cent, Mark Wainwright Analyt Ctr, Kensington, NSW, Australia	Neuroscience Research Australia; University of New South Wales Sydney; University of Sydney; Universidad Finis Terrae; Maastricht University; Maastricht University Medical Centre (MUMC); University of New South Wales Sydney; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; Flinders University South Australia; University of New South Wales Sydney	Delbaere, K (corresponding author), Neurosci Res Australia, Margarete Ainsworth Bldg,Barker St, Randwick, NSW 2031, Australia.	k.delbaere@neura.edu.au	Valenzuela, Trinidad/AAE-7451-2022; Toson, Barbara/M-4534-2019; Clemson, Lindy/B-7736-2014; van Schooten, Kimberley/A-5844-2012; Lung, Tom/J-9686-2017	Toson, Barbara/0000-0001-6661-9971; Lord, Stephen R/0000-0002-7111-8802; Clemson, Lindy/0000-0003-2687-1114; van Schooten, Kimberley/0000-0003-0902-8440; Zijlstra, Rixt/0000-0001-7377-5745; Close, Jacqueline/0000-0003-2908-9507; Valenzuela, Trinidad/0000-0001-7764-0223; Delbaere, Kim/0000-0002-5655-0234; Lung, Tom/0000-0001-9978-6311	Australian National Health and Medical Research Council [APP1105106, APP1117171, APP1084739]; NeuRA Foundation; NHMRC Early Career Fellowship [APP1141392]; National Heart Foundation Postdoctoral Fellowship [101956]; Human Frontier Science Program Fellowship [LT001080/2017]; Gandel Philaptropy	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); NeuRA Foundation; NHMRC Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation Postdoctoral Fellowship(National Heart Foundation of Australia); Human Frontier Science Program Fellowship(Human Frontier Science Program); Gandel Philaptropy	This study was funded by Australian National Health and Medical Research Council grant APP1084739, Gandel Philaptropy, and NeuRA Foundation. KD and SRL were supported by the Australian National Health and Medical Research Council (APP1105106, APP1117171). TL is currently supported by a NHMRC Early Career Fellowship (APP1141392) and National Heart Foundation Postdoctoral Fellowship (award ID 101956). KSvS was supported by a Human Frontier Science Program Fellowship (LT001080/2017). The funders did not have a role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	[Anonymous], 2018, GLOBAL ACTION PLAN P; Bangor A, 2009, J USABILITY STUD, V4, P114; Bhasin S, 2020, NEW ENGL J MED, V383, P129, DOI 10.1056/NEJMoa2002183; Bohannon RW, 1997, AGE AGEING, V26, P15, DOI 10.1093/ageing/26.1.15; Brandler TC, 2012, GAIT POSTURE, V35, P164, DOI 10.1016/j.gaitpost.2011.08.003; CSUKA M, 1985, AM J MED, V78, P77, DOI 10.1016/0002-9343(85)90465-6; Delbaere K, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009173; Delbaere K, 2010, BRIT J SPORT MED, V44, P1029, DOI 10.1136/bjsm.2009.060350; Delbaere K, 2011, J GERONTOL A-BIOL, V66, P674, DOI 10.1093/gerona/glr019; Everett B, 2009, INT J NURS STUD, V46, P824, DOI 10.1016/j.ijnurstu.2009.01.016; Finnegan S, 2019, PHYSIOTHERAPY, V105, P187, DOI 10.1016/j.physio.2018.09.002; Gatt JM, 2014, PSYCHIAT RES, V219, P204, DOI 10.1016/j.psychres.2014.04.033; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Howe TE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004963.pub3; Huque MH, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0615-6; James SL, 2020, INJURY PREV, V26, P3, DOI 10.1136/injuryprev-2019-043286; KENDZIERSKI D, 1991, J SPORT EXERCISE PSY, V13, P50, DOI 10.1123/jsep.13.1.50; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x; Langhammer B, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7856823; Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237; McClure NS, 2017, VALUE HEALTH, V20, P644, DOI 10.1016/j.jval.2016.11.015; McGarrigle L, 2020, PHYS MED REHABILITAT, DOI [10.21203/ rs.3.rs-63743/v1, DOI 10.21203/RS.3.RS-63743/V1]; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nyman SR, 2012, AGE AGEING, V41, P16, DOI 10.1093/ageing/afr103; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Reitan R. M., 1985, HALSTEAD REITAN NEUR, V4; Richardson JRJ, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-38; Schoene D, 2017, J AM MED DIR ASSOC, V18, P719, DOI 10.1016/j.jamda.2017.03.010; Schoene D, 2014, AGE AGEING, V43, P285, DOI 10.1093/ageing/aft157; Sherrington C, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012424.pub2; Simek EM, 2012, PREV MED, V55, P262, DOI 10.1016/j.ypmed.2012.07.007; Trenerry MR, 1989, PSYCHOL ASSESSMENT R; Ustun TB, 2010, B WORLD HEALTH ORGAN, V88, P815, DOI 10.2471/BLT.09.067231; Valenzuela T, 2018, J GERIATR PHYS THER, V41, P49, DOI 10.1519/JPT.0000000000000095; van Schooten KS, 2015, J AGING PHYS ACTIV, V23, P9, DOI [10.1123/japa.2013-0103, 10.1123/JAPA.2013-0103]; Viney R, 2011, VALUE HEALTH, V14, P928, DOI 10.1016/j.jval.2011.04.009; Yardley L, 2007, J GERONTOL B-PSYCHOL, V62, pP119, DOI 10.1093/geronb/62.2.P119; Zhao RQ, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1359-9	40	24	24	4	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	2021	373								n740	10.1136/bmj.n740	http://dx.doi.org/10.1136/bmj.n740			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RK0PZ	33824131	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000638008700007
J	Puri, MC; Huber-Krum, S; Canning, D; Guo, MQ; Shah, IH				Puri, Mahesh Chandra; Huber-Krum, Sarah; Canning, David; Guo, Muqi; Shah, Iqbal H.			Does family planning counseling reduce unmet need for modern contraception among postpartum women: Evidence from a stepped-wedge cluster randomized trial in Nepal	PLOS ONE			English	Article								Background Postpartum women have high rates of unmet need for modern contraception in the two years following birth in Nepal. We assessed whether providing contraceptive counseling during pregnancy and/or prior to discharge from the hospital for birth or after discharge from the hospital for birth was associated with reduced postpartum unmet need in Nepal. Methods We used data from a larger a stepped-wedge, cluster randomized trial, including contraceptive counselling in six tertiary hospitals. Group 1 hospitals (three hospitals) initiated the intervention after three months of baseline data collection, while Group 2 hospitals (three hospitals) initiated the same intervention after nine months. We have enrolled 21,280 women in the baseline interviews and conducted two follow-up interviews with them, one and two years after they had delivered in one of our study hospitals. We estimated the effect of counseling and its timing (pre-discharge, post- discharge, both, or neither) on unmet need for modern contraception in the postpartum period, using random-effects logistic regressions. Results Unmet need for modern contraception was high (54% at one year and 50% at two years). Women counseled in either the pre-discharge period (Odds ratio [OR] 0.86; 95% CI: 0.80, 0.93) or in the post-discharge period (OR 0.86; 95% CI: 0.79, 0.93) were less likely to have an unmet need in the postpartum period compared to women with no counseling. However, women who received counseling in both the pre- and post-discharge period were 27% less likely than women who had not received counseling to have unmet need (OR 0.73; 95% CI: 0.67, 0.80). Conclusions Counseling women either before or after discharge reduces unmet need for postpartum contraception but counseling in both periods is most effective.	[Puri, Mahesh Chandra] Ctr Res Environm Hlth & Populat Act CREHPA, Kathmandu, Nepal; [Huber-Krum, Sarah; Canning, David; Guo, Muqi; Shah, Iqbal H.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health	Puri, MC (corresponding author), Ctr Res Environm Hlth & Populat Act CREHPA, Kathmandu, Nepal.	mahesh@crehpa.org.np		Puri, Mahesh/0000-0002-2913-1480; Huber-Krum, Sarah/0000-0003-0938-252X	Susan Thompson Buffett Foundation	Susan Thompson Buffett Foundation	The main study was funded by Susan Thompson Buffett Foundation. The funder of the study had no role in study design, data collection, data analysis, decision to publish, or preparation of the manuscript. In addition, no funding support had received to prepare this manuscript.	Abdel-Tawab NG, 2008, FRONTIERS FINAL REPO; Achyut P, 2016, J FAM PLAN REPROD H, V42, P107, DOI 10.1136/jfprhc-2015-101271; Adeyemi AB, 2005, EUR J CONTRACEP REPR, V10, P229, DOI 10.1080/13625180500279763; Akman M, 2010, J INT MED RES, V38, P1243, DOI 10.1177/147323001003800405; Barber SL, 2007, INT FAM PLAN PERSPEC, V33, P6, DOI 10.1363/3300607; Canning D, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1160-0; Canning D, 2012, LANCET, V380, P165, DOI 10.1016/S0140-6736(12)60827-7; CBS, 2012, STAT NCBO; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; de Caestecker L, 2018, INT J GYNECOL OBSTET, V143, P4, DOI 10.1002/ijgo.12598; Dockalova B, 2016, USTAINABLE DEV GOALS, P1; FishelJoy D, 2012, DHS ANAL STUDIES, V25; Foreit KG, 1993, INT FAMILY PLANNING, V19, P19, DOI DOI 10.2307/2133378; Furuta M, 2006, INT FAM PLAN PERSPEC, V32, P17, DOI 10.1363/3201706; Hubacher D, 2015, CONTRACEPTION, V92, P420, DOI 10.1016/j.contraception.2015.08.008; Mehata S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/649567; Ministry of Health and Population (MoHP) Nepal., 2015, NATL FAMILY PLANNING; MoH Nepal New ERA ICF, 2017, NEPAL DEMOGRAPHIC HL; Morel RS., 2006, ACHIEVING MILLENNIUM; Pandey J.P., 2013, MATERNAL CHILD HLTH; Pasha O, 2015, REPROD HEALTH, V12, DOI 10.1186/1742-4755-12-S2-S11; Pfitzer A, 2015, INT J GYNECOL OBSTET, V130, pS54, DOI 10.1016/j.ijgo.2015.03.008; Puri MC, 2020, BMC WOMENS HEALTH, V20, DOI 10.1186/s12905-020-00904-y; Puri MC, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3777-3; Rajan S, 2016, INT PERSPECT SEX R H, V42, P167, DOI 10.1363/42e2816; Ross JA, 2001, INT FAM PLAN PERSPEC, V27, P20, DOI 10.2307/2673801; Rutstein SO., 2011, TRENDS BIRTH SPACING, V28; Shattuck D, 2019, SEX REPROD HLTH MATT, V27, P248, DOI 10.1080/26410397.2019.1647398; Shrestha D R, 2012, J Nepal Health Res Counc, V10, P108; Singh S, 2009, ADDING IT COSTS BENE; Singh S., 2014, ADD COSTS BEN INV SE; Smith KB, 2002, CONTRACEPTION, V65, P237, DOI 10.1016/S0010-7824(01)00308-0; Sully E, 2020, ADDING IT INVESTING; Vernon R, 2009, STUD FAMILY PLANN, V40, P235, DOI 10.1111/j.1728-4465.2009.00206.x; WHO/USAID, 2012, STAT COLL ACT POSTP; World Health Organization (WHO, 2013, PROGR STRAT POSTP FA; Zerai A, 2001, Afr J Reprod Health, V5, P68, DOI 10.2307/3583432	37	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2021	16	3							e0249106	10.1371/journal.pone.0249106	http://dx.doi.org/10.1371/journal.pone.0249106			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RF4TU	33770114	gold, Green Published			2023-01-03	WOS:000634833500046
J	Li, R; Tang, ZY; Liu, F; Yang, M				Li, Rui; Tang, Zhiyong; Liu, Fu; Yang, Ming			Efficacy and safety of trimethoprim-sulfamethoxazole for the prevention of pneumocystis pneumonia in human immunodeficiency virus-negative immunodeficient patients: A systematic review and meta-analysis	PLOS ONE			English	Article								Background Pneumocystis pneumonia (PCP) has a significant impact on the mortality of immunocompromised patients. It is not known whether the prophylactic application of trimethoprim-sulfamethoxazole (TMP-SMZ) can reduce the incidence of PCP and mortality in the human immunodeficiency virus (HIV)-negative immunodeficient population. The safety profile is also unknown. There have been few reports on this topic. The aim of this study was to systematically evaluate the efficacy and safety of the use of TMP-SMZ for the prevention of PCP in this population of patients from the perspective of evidence-based medicine. Methods A comprehensive search without restrictions on publication status or other parameters was conducted. Clinical randomized controlled trials (RCTs) or case-control trials (CCSs) of TMP-SMZ used for the prevention of PCP in HIV-negative immunocompromised populations were considered eligible. A meta-analysis was performed using the Mantel-Haenszel fixed-effects model or Mantel-Haenszel random-effects model, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated and reported. Results Of the 2392 records identified, 19 studies (n = 4135 patients) were included. The efficacy analysis results indicated that the PCP incidence was lower in the TMP-SMZ group than in the control group (OR = 0.27, 95% CI (0.10, 0.77), p = 0.01); however, the rate of drug discontinuation was higher in the TMP-SMZ group than in the control group (OR = 14.31, 95% CI (4.78, 42.91), p<0.00001). In addition, there was no statistically significant difference in the rate of mortality between the two groups (OR = 0.54, 95% CI (0.21, 1.37), p = 0.19). The safety analysis results showed that the rate of adverse events (AEs) was higher in the TMP-SMZ group than in the control group (OR = 1.92, 95% CI (1.06, 3.47), p = 0.03). Conclusions TMP-SMZ has a better effect than other drugs or the placebo with regard to preventing PCP in HIV-negative immunocompromised individuals, but it may not necessarily reduce the rate of mortality, the rate of drug discontinuation or AEs. Due to the limitations of the research methodologies used, additional large-scale clinical trials and well-designed research studies are needed to identify more effective therapies for the prevention of PCP.	[Li, Rui; Liu, Fu; Yang, Ming] North Sichuan Med Coll, Affiliated Hosp, Dept Pharm, Nanchong, Sichuan, Peoples R China; [Tang, Zhiyong] North Sichuan Med Coll, Affiliated Clin Med Coll 2, Nanchong Cent Hosp, Dept Pharm, Nanchong, Sichuan, Peoples R China; [Tang, Zhiyong] Nanchong Key Lab Individualized Drug Therapy, Nanchong, Sichuan, Peoples R China	North Sichuan Medical University; North Sichuan Medical University	Yang, M (corresponding author), North Sichuan Med Coll, Affiliated Hosp, Dept Pharm, Nanchong, Sichuan, Peoples R China.	yangming1211@163.com		yang, ming/0000-0001-8350-6506	Sichuan science and technology project [2018JY0415]; affiliated hospital of north sichuan medical college project [2019JC038]	Sichuan science and technology project; affiliated hospital of north sichuan medical college project	Prof. Ming Yang is funded by Sichuan science and technology project (No.2018JY0415; http://kjt.sc.gov.cn/) and Mrs. Rui Li is funded by affiliated hospital of north sichuan medical college project (No.2019JC038; https://www.nsmc.edu.cn/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cilloniz C, 2019, EXPERT REV ANTI-INFE, V17, P787, DOI 10.1080/14787210.2019.1671823; Colby C, 1999, BONE MARROW TRANSPL, V24, P897, DOI 10.1038/sj.bmt.1702004; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Evans RA, 2015, TRANSPL INFECT DIS, V17, P816, DOI 10.1111/tid.12457; Friedrich JO, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-5; Gabardi S, 2012, CLIN TRANSPLANT, V26, pE184, DOI 10.1111/j.1399-0012.2012.01624.x; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Huang Laurence, 2011, Proc Am Thorac Soc, V8, P294, DOI 10.1513/pats.201009-062WR; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1975, CANCER, V36, P2004, DOI 10.1002/cncr.2820360912; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Katsuyama T, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4472; Kimura M, 2008, RHEUMATOL INT, V28, P673, DOI 10.1007/s00296-007-0505-4; Kitazawa T, 2019, J INFECT CHEMOTHER, V25, P351, DOI 10.1016/j.jiac.2019.01.005; Levinsen M, 2012, EUR J HAEMATOL, V88, P78, DOI 10.1111/j.1600-0609.2011.01695.x; Li R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137252; Molina A, 2018, BIOL BLOOD MARROW TR, V24, P1715, DOI 10.1016/j.bbmt.2018.03.010; Nazir HF, 2017, J PEDIAT HEMATOL ONC, V39, P203, DOI 10.1097/MPH.0000000000000804; Neofytos D, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12984; Ogawa Jun, 2005, Mod Rheumatol, V15, P91; Okada J, 1999, Kansenshogaku Zasshi, V73, P1123; Park JW, 2018, ANN RHEUM DIS, V77, P644, DOI 10.1136/annrheumdis-2017-211796; Redjoul R, 2019, BONE MARROW TRANSPL, V54, P1082, DOI 10.1038/s41409-018-0391-2; Salzer HJF, 2018, RESPIRATION, V96, P52, DOI 10.1159/000487713; Sangiolo D, 2005, BIOL BLOOD MARROW TR, V11, P521, DOI 10.1016/j.bbmt.2005.04.011; Schmajuk G, 2019, SEMIN ARTHRITIS RHEU, V48, P1087, DOI 10.1016/j.semarthrit.2018.10.018; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Stringer JR, 1996, CLIN MICROBIOL REV, V9, P489, DOI 10.1128/CMR.9.4.489; Thomas CF, 2004, NEW ENGL J MED, V350, P2487, DOI 10.1056/NEJMra032588; Vananuvat P, 2011, SEMIN ARTHRITIS RHEU, V41, P497, DOI 10.1016/j.semarthrit.2011.05.004; Vesole DH, 2012, LEUKEMIA, V26, P2517, DOI 10.1038/leu.2012.124; WARD TT, 1993, CLIN INFECT DIS, V17, P323, DOI 10.1093/clinids/17.3.323; Wynd S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129991; Zmarlicka M, 2015, PROG TRANSPLANT, V25, P210, DOI 10.7182/pit2015153	34	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2021	16	3							e0248524	10.1371/journal.pone.0248524	http://dx.doi.org/10.1371/journal.pone.0248524			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF4TN	33765022	Green Published, gold			2023-01-03	WOS:000634832800081
J	Ballard, HK; Eakin, SM; Maldonado, T; Bernard, JA				Ballard, Hannah K.; Eakin, Sydney M.; Maldonado, Ted; Bernard, Jessica A.			Using high-definition transcranial direct current stimulation to investigate the role of the dorsolateral prefrontal cortex in explicit sequence learning	PLOS ONE			English	Article							SPATIAL WORKING-MEMORY; BRAIN ACTIVATION; BASAL GANGLIA; FUNCTIONAL CONNECTIVITY; CONVENTIONAL TDCS; SINGLE-SESSION; MOTOR CORTEX; IMPLICIT; SENSORIMOTOR; CEREBELLUM	Though we have a general understanding of the brain areas involved in motor sequence learning, there is more to discover about the neural mechanisms underlying skill acquisition. Skill acquisition may be subserved, in part, by interactions between the cerebellum and prefrontal cortex through a cerebello-thalamo-prefrontal network. In prior work, we investigated this network by targeting the cerebellum; here, we explored the consequence of stimulating the dorsolateral prefrontal cortex using high-definition transcranial direct current stimulation (HD-tDCS) before administering an explicit motor sequence learning paradigm. Using a mixed within- and between- subjects design, we employed anodal (n = 24) and cathodal (n = 25) HD-tDCS (relative to sham) to temporarily alter brain function and examine effects on skill acquisition. The results indicate that both anodal and cathodal prefrontal stimulation impedes motor sequence learning, relative to sham. These findings suggest an overall negative influence of active prefrontal stimulation on the acquisition of a sequential pattern of finger movements. Collectively, this provides novel insight on the role of the dorsolateral prefrontal cortex in initial skill acquisition, when cognitive processes such as working memory are used. Exploring methods that may improve motor learning is important in developing therapeutic strategies for motor-related diseases and rehabilitation.	[Ballard, Hannah K.; Bernard, Jessica A.] Texas A&M Univ, Texas A&M Inst Neurosci, College Stn, TX 77843 USA; [Eakin, Sydney M.; Maldonado, Ted; Bernard, Jessica A.] Texas A&M Univ, Dept Psychol & Brain Sci, College Stn, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Ballard, HK (corresponding author), Texas A&M Univ, Texas A&M Inst Neurosci, College Stn, TX 77843 USA.	hannah_ballard@tamu.edu		Ballard, Hannah/0000-0003-1892-3949				Aizenstein HJ, 2004, CEREB CORTEX, V14, P199, DOI 10.1093/cercor/bhg119; Albouy G, 2012, NEUROIMAGE, V60, P324, DOI 10.1016/j.neuroimage.2011.12.049; Anguera JA, 2012, BEHAV BRAIN RES, V228, P107, DOI 10.1016/j.bbr.2011.11.040; Anguera JA, 2010, J COGNITIVE NEUROSCI, V22, P1917, DOI 10.1162/jocn.2009.21351; Ballard HK, 2019, J NEUROPHYSIOL, V122, P490, DOI 10.1152/jn.00036.2019; Bernard JA, 2013, CEREBELLUM, V12, P721, DOI 10.1007/s12311-013-0481-z; Bernard JA, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00031; Berner MP, 2008, PSYCHOL RES-PSYCH FO, V72, P138, DOI 10.1007/s00426-006-0097-8; Bhakuni R, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00076; Bo J, 2009, J NEUROPHYSIOL, V101, P3116, DOI 10.1152/jn.00006.2009; Buch ER, 2017, CLIN NEUROPHYSIOL, V128, P589, DOI 10.1016/j.clinph.2017.01.004; Cole L, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00787; DaSilva AF, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00089; Datta A, 2016, IEEE ENG MED BIO, P1774, DOI 10.1109/EMBC.2016.7591061; Denis G, 2019, HUM MOVEMENT SCI, V67, DOI 10.1016/j.humov.2019.102507; Doyon J, 1997, BRAIN COGNITION, V34, P218, DOI 10.1006/brcg.1997.0899; Doyon J, 2018, CURR OPIN BEHAV SCI, V20, P89, DOI 10.1016/j.cobeha.2017.11.012; Doyon J, 2002, P NATL ACAD SCI USA, V99, P1017, DOI 10.1073/pnas.022615199; Doyon J, 2009, BEHAV BRAIN RES, V199, P61, DOI 10.1016/j.bbr.2008.11.012; Eliassen JC, 2001, EXP BRAIN RES, V141, P269, DOI 10.1007/s002210100822; Exner C, 2002, LEARN MEMORY, V9, P376, DOI 10.1101/lm.48402; Foerster A, 2013, EUR J NEUROSCI, V37, P786, DOI 10.1111/ejn.12079; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Gbadeyan O, 2016, J NEUROSCI, V36, P12530, DOI 10.1523/JNEUROSCI.2450-16.2016; GRAFTON ST, 1995, J COGNITIVE NEUROSCI, V7, P497, DOI 10.1162/jocn.1995.7.4.497; Greeley B, 2019, J NEUROPHYSIOL, V121, P1906, DOI 10.1152/jn.00795.2018; Hasan A, 2013, J COGNITIVE NEUROSCI, V25, P558, DOI 10.1162/jocn_a_00338; Hashemirad F, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00153; Hikosaka O, 1999, TRENDS NEUROSCI, V22, P464, DOI 10.1016/S0166-2236(99)01439-3; Hill AT, 2018, BRAIN STIMUL, V11, P1033, DOI 10.1016/j.brs.2018.06.005; Hill AT, 2016, BRAIN STIMUL, V9, P197, DOI 10.1016/j.brs.2015.10.006; Honda M, 1998, BRAIN, V121, P2159, DOI 10.1093/brain/121.11.2159; Horvath JC, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00002; Huang Y, 2017, ELIFE, V6, DOI 10.7554/eLife.18834; Imburgio MJ, 2018, NEUROPSYCHOLOGIA, V117, P156, DOI 10.1016/j.neuropsychologia.2018.04.022; Israely S, 2019, REV NEUROSCIENCE, V30, P821, DOI 10.1515/revneuro-2019-0008; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; JENKINS IH, 1994, J NEUROSCI, V14, P3775; Karni A, 1998, P NATL ACAD SCI USA, V95, P861, DOI 10.1073/pnas.95.3.861; Ke YF, 2019, FRONT HUM NEUROSCI, V13, DOI 10.3389/fnhum.2019.00019; Kelly RM, 2003, J NEUROSCI, V23, P8432; Krienen FM, 2009, CEREB CORTEX, V19, P2485, DOI 10.1093/cercor/bhp135; Kwak Y, 2012, BEHAV BRAIN RES, V230, P116, DOI 10.1016/j.bbr.2012.02.006; Kwak Y, 2010, J NEUROPHYSIOL, V103, P942, DOI 10.1152/jn.00197.2009; Leite J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024140; Mancuso LE, 2016, J COGNITIVE NEUROSCI, V28, P1063, DOI 10.1162/jocn_a_00956; Nikolin S, 2019, FRONT INTEGR NEUROSC, V12, DOI 10.3389/fnint.2018.00064; Nikolin S, 2015, NEUROIMAGE, V117, P11, DOI 10.1016/j.neuroimage.2015.05.019; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Nozari N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084338; O'Reilly JX, 2010, CEREB CORTEX, V20, P953, DOI 10.1093/cercor/bhp157; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pope PA, 2015, CEREB CORTEX, V25, P4551, DOI 10.1093/cercor/bhv094; Rauch SL, 1995, HUM BRAIN MAPP, V3, P271, DOI 10.1002/hbm.460030403; Sakai K, 1998, J NEUROSCI, V18, P1827; Salmi J, 2010, J COGNITIVE NEUROSCI, V22, P2663, DOI 10.1162/jocn.2009.21382; Savic B, 2019, NEUROSCIENCE, V414, P77, DOI 10.1016/j.neuroscience.2019.06.034; Savic B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10128-0; Savic B, 2017, BRAIN STIMUL, V10, P567, DOI 10.1016/j.brs.2017.01.001; Schendan HE, 2003, NEURON, V37, P1013, DOI 10.1016/S0896-6273(03)00123-5; Seidler RD, 2006, BRAIN RES BULL, V70, P337, DOI 10.1016/j.brainresbull.2006.06.008; Shilo G, 2019, EXP BRAIN RES, V237, P919, DOI 10.1007/s00221-019-05477-3; Strick PL, 2009, ANNU REV NEUROSCI, V32, P413, DOI 10.1146/annurev.neuro.31.060407.125606; Sun FT, 2007, CEREB CORTEX, V17, P1227, DOI 10.1093/cercor/bhl033; Takano Y, 2011, NEUROSCI LETT, V491, P40, DOI 10.1016/j.neulet.2011.01.004; Talimkhani A, 2019, BASIC CLIN NEUROSCI, V10, P59, DOI 10.32598/bcn.9.10.350; Talsma LJ, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00481; Taubert M, 2011, NEUROIMAGE, V57, P1492, DOI 10.1016/j.neuroimage.2011.05.078; Ungerleider LG, 2002, NEUROBIOL LEARN MEM, V78, P553, DOI 10.1006/nlme.2002.4091; Vakil E, 2000, NEUROPSYCHOLOGIA, V38, P1, DOI 10.1016/S0028-3932(99)00058-5; Wu YJ, 2014, BRAIN COGNITION, V91, P87, DOI 10.1016/j.bandc.2014.09.002; Zhu FF, 2015, BRAIN STIMUL, V8, P784, DOI 10.1016/j.brs.2015.02.005	73	1	1	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0246849	10.1371/journal.pone.0246849	http://dx.doi.org/10.1371/journal.pone.0246849			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QZ9HN	33735211	gold, Green Submitted, Green Published			2023-01-03	WOS:000631029700115
J	Lu, L; Su, S; Yang, HT; Jiang, SB				Lu, Lu; Su, Shan; Yang, Haitao; Jiang, Shibo			Antivirals with common targets against highly pathogenic viruses	CELL			English	Review							RESPIRATORY SYNDROME-CORONAVIRUS; DEPENDENT RNA-POLYMERASES; EBOLA-VIRUS; PROTEASE INHIBITORS; STRUCTURAL BASIS; CRYSTAL-STRUCTURES; VIRAL-INFECTIONS; CORE STRUCTURE; HIV ENVELOPE; CELL ENTRY	Historically, emerging viruses appear constantly and have cost millions of human lives. Currently, climate change and intense globalization have created favorable conditions for viral transmission. Therefore, effective antivirals, especially those targeting the conserved protein in multiple unrelated viruses, such as the compounds targeting RNA-dependent RNA polymerase, are urgently needed to combat more emerging and re-emerging viruses in the future, Here we reviewed the development of antivirals with common targets, including those against the same protein across viruses, or the same viral function, to provide clues for development of antivirals for future epidemics.	[Lu, Lu; Su, Shan; Jiang, Shibo] Fudan Univ, Sch Basic Med Sci, Shanghai Inst Infect Dis & Biosecur, Key Lab Med Mol Virol,MOE,NHC,CAMS, Shanghai 200032, Peoples R China; [Yang, Haitao] Shanghai Tech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China; [Yang, Haitao] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Fudan University; ShanghaiTech University; ShanghaiTech University	Jiang, SB (corresponding author), Fudan Univ, Sch Basic Med Sci, Shanghai Inst Infect Dis & Biosecur, Key Lab Med Mol Virol,MOE,NHC,CAMS, Shanghai 200032, Peoples R China.; Yang, HT (corresponding author), Shanghai Tech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China.; Yang, HT (corresponding author), Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.	yanght@shanghaitech.edu.cn; shibojiang@fudan.edu.cn	Lu, Lu/K-7070-2014; Jiang, Shibo/L-4500-2014; Su, Shan/AAS-9659-2021; lu, lu/HGA-0894-2022; lu, lu/HII-7530-2022	Lu, Lu/0000-0002-2255-0391; Jiang, Shibo/0000-0001-8283-7135; Su, Shan/0000-0003-0593-9968; 	National Natural Science Foundation of China [82041025, 81822045, 82041036]; National Major Science and Technology Projects of China [2018ZX10301403]; National Key R&D Program of China [2020YFA0707500]; Natural Science Foundation of Tianjin [18JCJQJC48000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Major Science and Technology Projects of China; National Key R&D Program of China; Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin)	We thank the staff of Sagene Biotechnology Co., LTD who drew the mechanism diagrams for us. We thank Dr. Wen Cui from Shanghai Tech University who helped analyze crystal structures. As we downloaded the crystal structures of the related proteins from PDB database, we thank all the authors for sharing these crystal structures. All crystal structures were analyzed by the PyMOL Molecular Graphics System, Version 2.0 (Schrodinger, LLC). This study was supported by grants from the National Natural Science Foundation of China(82041025 to S.J.; 81822045 and 82041036 to L.L.), the National Major Science and Technology Projects of China (2018ZX10301403 to L.L.), the National Key R&D Program of China (2020YFA0707500 to H.Y.), and the Natural Science Foundation of Tianjin (18JCJQJC48000 to H.Y.).	Al-Obaidi MMJ, 2018, ACTA VIROL, V62, P16, DOI 10.4149/av_2018_102; Anantpadma M, 2016, ANTIMICROB AGENTS CH, V60, P4471, DOI 10.1128/AAC.00543-16; Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Beaucourt S, 2014, CURR OPIN VIROL, V8, P10, DOI 10.1016/j.coviro.2014.04.011; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bestle D, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000786; Boldescu V, 2017, NAT REV DRUG DISCOV, V16, P565, DOI 10.1038/nrd.2017.33; Caskey M, 2019, NAT MED, V25, P547, DOI 10.1038/s41591-019-0412-8; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Cohn LB, 2020, CELL HOST MICROBE, V27, P519, DOI 10.1016/j.chom.2020.03.014; Curreli F, 2020, MBIO, V11, DOI 10.1128/mBio.02451-20; Curreli F, 2020, J MED CHEM, V63, P1724, DOI 10.1021/acs.jmedchem.9b02149; Das K, 2013, CURR OPIN VIROL, V3, P111, DOI 10.1016/j.coviro.2013.03.012; Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330; De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15; de Wispelaere M, 2018, CELL CHEM BIOL, V25, P1006, DOI 10.1016/j.chembiol.2018.05.011; Debnath AK, 1999, J MED CHEM, V42, P3203, DOI 10.1021/jm990154t; Eltahla AA, 2015, VIRUSES-BASEL, V7, P5206, DOI 10.3390/v7102868; Emu B, 2018, NEW ENGL J MED, V379, P645, DOI 10.1056/NEJMoa1711460; Engelman A, 2012, NAT REV MICROBIOL, V10, P279, DOI 10.1038/nrmicro2747; Erbel P, 2006, NAT STRUCT MOL BIOL, V13, P372, DOI 10.1038/nsmb1073; Forssmann WG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001697; Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027; Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498; Garten W., 2018, ACTIVATION VIRUSES H, P205, DOI 10.1007/978-3-319-75474-1_9; Gaudinski MR, 2019, LANCET, V393, P889, DOI 10.1016/S0140-6736(19)30036-4; Ghosh AK, 2016, J MED CHEM, V59, P5172, DOI 10.1021/acs.jmedchem.5b01697; Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8; Hoenen T, 2019, NAT REV MICROBIOL, V17, P593, DOI 10.1038/s41579-019-0233-2; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Holthausen DJ, 2017, IMMUNITY, V46, P587, DOI 10.1016/j.immuni.2017.03.018; Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544; Ikematsu H, 2011, EXPERT REV ANTI-INFE, V9, P851, DOI [10.1586/ERI.11.112, 10.1586/eri.11.112]; Jacobson JM, 2004, ANTIMICROB AGENTS CH, V48, P423, DOI 10.1128/AAC.48.2.423-429.2004; Jacome R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66440-9; Jia HX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01945; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jiang SB, 2011, J MED CHEM, V54, P572, DOI 10.1021/jm101014v; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114; Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x; Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3; Kong R, 2016, SCIENCE, V352, P828, DOI 10.1126/science.aae0474; Koszalka P, 2017, INFLUENZA OTHER RESP, V11, P240, DOI 10.1111/irv.12446; Lamb YN, 2020, DRUGS, V80, P1355, DOI 10.1007/s40265-020-01378-w; Lee JE, 2008, NATURE, V454, P177, DOI 10.1038/nature07082; Lei J, 2016, SCIENCE, V353, P503, DOI 10.1126/science.aag2419; Liang CY, 2020, EUR J MED CHEM, V201, DOI 10.1016/j.ejmech.2020.112527; Lip KM, 2006, J VIROL, V80, P941, DOI 10.1128/JVI.80.2.941-950.2006; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067; Malet H, 2008, ANTIVIR RES, V80, P23, DOI 10.1016/j.antiviral.2008.06.007; Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923; McCauley JA, 2016, CURR OPIN PHARMACOL, V30, P84, DOI 10.1016/j.coph.2016.07.015; Mercer J, 2020, CELL, V182, P786, DOI 10.1016/j.cell.2020.06.033; Miller EH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207084; Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111; Mirsaeidi M, 2016, ANN AM THORAC SOC, V13, P1223, DOI 10.1513/AnnalsATS.201511-729PS; Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004; Montoya MC, 2018, MBIO, V9, DOI 10.1128/mBio.02272-18; Morens DM, 2020, CELL, V182, P1077, DOI 10.1016/j.cell.2020.08.021; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Nishimura Y, 2020, P NATL ACAD SCI USA, V117, P22436, DOI 10.1073/pnas.2009700117; Njoroge FG, 2008, ACCOUNTS CHEM RES, V41, P50, DOI 10.1021/ar700109k; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Pancera M, 2017, NAT CHEM BIOL, V13, P1115, DOI [10.1038/NCHEMBIO.2460, 10.1038/nchembio.2460]; Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461; Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3; Renn A, 2020, TRENDS PHARMACOL SCI, V41, P815, DOI 10.1016/j.tips.2020.07.004; Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024; Ruiz FX, 2020, CURR OPIN STRUC BIOL, V61, P113, DOI 10.1016/j.sbi.2019.11.011; Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5; Shi Y, 2017, TRENDS BIOCHEM SCI, V42, P443, DOI 10.1016/j.tibs.2017.02.009; Si LL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau8408; Sok D, 2018, NAT IMMUNOL, V19, P1179, DOI 10.1038/s41590-018-0235-7; Su XJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01063; Sun XL, 2007, CURR MED CHEM, V14, P2304, DOI 10.2174/092986707781696582; Szabo B.G., 2020, MEDRXIV2020201120262; Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076; Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148; Wang CY, 2019, NEW ENGL J MED, V380, P1535, DOI 10.1056/NEJMoa1802264; Wang C, 2018, J MED CHEM, V61, P8734, DOI 10.1021/acs.jmedchem.8b00890; Wang Q, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz2254; Wang Q, 2020, CELL, V182, P417, DOI 10.1016/j.cell.2020.05.034; Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180; Wec AZ, 2017, CELL, V169, P878, DOI 10.1016/j.cell.2017.04.037; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Williamson BN, 2020, NATURE, V585, P273, DOI 10.1038/s41586-020-2423-5; World-Health-Organization, 2020, PRIOR DIS RES DEV EM; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Xia S, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0184-0; Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x; Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580; Xiao TS, 2020, NAT CHEM BIOL, V16, P529, DOI 10.1038/s41589-020-0496-y; Xie D, 2010, ANTIMICROB AGENTS CH, V54, P191, DOI 10.1128/AAC.00976-09; Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100; Yilmaz NK, 2016, TRENDS MICROBIOL, V24, P547, DOI 10.1016/j.tim.2016.03.010; Young B, 2021, LANCET INFECT DIS, V21, P20, DOI 10.1016/S1473-3099(20)30911-7; Yu YF, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15672; Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035; Zhao XL, 2017, CELL, V169, P891, DOI 10.1016/j.cell.2017.04.038; Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100; Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	108	37	40	12	83	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 18	2021	184	6					1604	1620		10.1016/j.cell.2021.02.013	http://dx.doi.org/10.1016/j.cell.2021.02.013		MAR 2021	17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QY9LN	33740455	Bronze			2023-01-03	WOS:000630357400022
J	Tessema, ZT; Teshale, AB; Tesema, GA; Yeshaw, Y; Worku, MG				Tessema, Zemenu Tadesse; Teshale, Achamyeleh Birhanu; Tesema, Getayeneh Antehunegn; Yeshaw, Yigizie; Worku, Misganaw Gebrie			Pooled prevalence and determinants of modern contraceptive utilization in East Africa: A Multi-country Analysis of recent Demographic and Health Surveys	PLOS ONE			English	Article							TRENDS; WOMEN; ETHIOPIA; NIGERIA	Background According to the 2017 estimate, around 214 million reproductive-age women in developing regions who want to avoid pregnancy do not use a modern contraceptive method. Although there are studies done on factors associated with modern contraceptive utilization in individual East African countries, as to our search of the literature, there is limited evidence on the pooled prevalence and determinants of modern contraceptive utilization in the East African region. Therefore, this study aimed to estimate the pooled prevalence and determinants of modern contraceptive utilization in the East African region. Methods The pooled prevalence of modern contraceptive utilization and the strength of determinants were estimated using STATA version 14. Intra-class Correlation Coefficient (ICC), Median Odds Ratio (MOR), Proportional Change in Variance (PCV), and deviance were used for model fitness and comparison. The multilevel logistic regression model was fitted to identify determinants of modern contraceptive use in the region. Adjusted Odds Ratio with its 95% Confidence Interval was presented, and variables with a p-value <= of 0.05 were declared significant determinants of modern contraceptive utilization. Results Overall, about 20.68% (95%CI:-20.46.,20.91)of women used modern contraceptive, ranging from 9.08% in Mozambique to 61.49% in Comoros. In the multilevel logistic regression model; maternal age group 25-34 (AOR: 0.79, 95%CI:0.76,0.82) and 35-49 (AOR:0.49, 95%CI:0.46,0.51). Being married (AOR:0.85, 95%CI:0.82,0.88), mothers with primary education (AOR:1.48, 95%CI:1.43,1.54) and secondary and above education level (AOR:1.60, 95%CI:1.52,1.69), husbands with primary education (AOR:2.43, 95%CI:2.35,2.51) and secondary and above education level (AOR:2.92, 95%CI:2.76,3.05). The mothers who had occupation (AOR:2.11, 95%CI:1.23,1.33), mothers from households with middle wealth index (AOR:1.23, 95%CI:1.19,1.28) and rich wealth index (AOR:1.28, 95%CI:1.23,1.33) were found to be significant determinants of modern contraceptive use. Conclusion We found that modern contraceptive utilization in the 12 East Africa countries was low compared to SDG target 2030(75%). The governmental and non-governmental organizations should scale up their public health programs to the poor and marginalized communities to scale up modern contraceptive utilization uptake in the region. In addition, reforming the health system and reproductive health education through mass media to create awareness of modern contraceptive use benefits are effective strategies to improve modern contraceptive use among East Africa women.	[Tessema, Zemenu Tadesse; Teshale, Achamyeleh Birhanu; Tesema, Getayeneh Antehunegn; Yeshaw, Yigizie] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia; [Yeshaw, Yigizie] Univ Gondar, Dept Human Physiol, Coll Med & Hlth Sci, Gondar, Ethiopia; [Worku, Misganaw Gebrie] Univ Gondar, Dept Human Anat, Coll Med & Hlth Sci, Gondar, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Tessema, ZT (corresponding author), Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia.	zemenut1979@gmail.com	Tadesse, Zemenu/ABG-1690-2021; Teshale, Achamyeleh/HHN-8416-2022; Yeshaw, Yigizie/L-6336-2019	Tadesse, Zemenu/0000-0003-3878-7956; Yeshaw, Yigizie/0000-0003-4587-7925				Abate MG, 2019, ARCH PUBLIC HEALTH, V77, DOI 10.1186/s13690-019-0371-z; Abraha TH, 2017, EPIDEMIOL HEALTH, V39, DOI 10.4178/epih.e2017012; Alemayehu GA, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0611-3; Ametepi P, 2012, DHS ANAL STUD; [Anonymous], 2020, WORLD HLTH ORG, DOI DOI 10.1080/09639284.2021.1971095; Apanga PA, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.10.5301; Aviisah PA, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0634-9; Behrman JA, 2018, STUD FAMILY PLANN, V49, P319, DOI 10.1111/sifp.12075; Beson P, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0649-2; Beyene GA, 2019, AFR J REPROD HEALTH, V23, P101, DOI 10.29063/ajrh2019/v23i2.10; Biratu A, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0092-x; Bongaarts J, 2019, AFR J REPROD HEALTH, V23, P96, DOI 10.29063/ajrh2019/v23i3.9; Cahill N, 2018, LANCET, V391, P870, DOI 10.1016/S0140-6736(17)33104-5; Demographic T., GUIDE DHS STAT; Department of Economic and Social Affairs PDUN, 2019, FAMILY PLANNING 2030; Ejembi C. L., 2015, DHS Working Papers; Eliason S, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-261; Endriyas M, 2017, CONTRACEP REPROD MED, V2, DOI 10.1186/s40834-016-0036-z; FAUVEAU V, 1990, BRIT MED J, V301, P103, DOI 10.1136/bmj.301.6743.103; Gebeyehu A., 2014, TRENDS DETERMINANTS; Hounton S, 2015, GLOBAL HEALTH ACTION, V8, P53, DOI 10.3402/gha.v8.29737; Humera H, 2013, J OBSTET GYN INDIA, V63, P410, DOI 10.1007/s13224-013-0447-6; Izugbara CO., 2018, AFRICAN POPUL HEAL R; Jacobs J, 2017, EUR J CONTRACEP REPR, V22, P439, DOI 10.1080/13625187.2017.1409889; Katz M. H, 2011, MULTIVARIABLE ANAL P, VThird; Mohammed A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-13; Coll CDN, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0686-9; Ochako R, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1483-1; Okigbo CC, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0664-3; Palamuleni Martin E, 2013, Afr J Reprod Health, V17, P91; Rebecca Winter., 2013, DHS ANALYTICAL STUDI; Tawiah EO, 1997, J BIOSOC SCI, V29, P141, DOI 10.1017/S0021932097001417; Tomkins A, 2001, BRIT J NUTR, V85, pS93, DOI 10.1079/BJN2001358; UNDESA, 2017, WORLD FAMILY PLANNIN, P43, DOI [10.1186/s12875-017-0618-0 28327096, DOI 10.1186/S12875-017-0618-028327096]; Wang CT, 2012, CONTRACEPTION, V85, P570, DOI 10.1016/j.contraception.2011.10.014; Wang W., 2017, ARXIV170500648; WHO. Organization WH, 2010, WORLD HLTH STAT 2010; Yaya S, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0658-5	38	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0247992	10.1371/journal.pone.0247992	http://dx.doi.org/10.1371/journal.pone.0247992			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QZ9HN	33735305	gold, Green Published			2023-01-03	WOS:000631029700025
J	Thammavaranucupt, K; Spanuchart, I				Thammavaranucupt, Kanin; Spanuchart, Ittikorn			Sulfonamide Crystals	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Thammavaranucupt, Kanin; Spanuchart, Ittikorn] Mahidol Univ, Bangkok, Thailand	Mahidol University	Thammavaranucupt, K (corresponding author), Mahidol Univ, Bangkok, Thailand.	geng103@hotmail.com		Thammavaranucupt, Kanin/0000-0002-9873-3848					0	0	0	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2021	384	11					1053	1053		10.1056/NEJMicm2028020	http://dx.doi.org/10.1056/NEJMicm2028020			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QY5HJ	33734650				2023-01-03	WOS:000630070600017
J	Bekele, F; Tsegaye, T; Negash, E; Fekadu, G				Bekele, Firomsa; Tsegaye, Tesfaye; Negash, Efrem; Fekadu, Ginenus			Magnitude and determinants of drug-related problems among patients admitted to medical wards of southwestern Ethiopian hospitals: A multicenter prospective observational study	PLOS ONE			English	Article								Background Drug-related problem (DRP) is an event involving drugs that can impact the patient's desired goal of therapy. In hospitalized patients, DRPs happen during the whole process of drug use such as during prescription, dispensing, administration, and follow-up of their treatment. Unrecognized and unresolved DRPs lead to significant drug-related morbidity and mortality. Several studies conducted in different hospitals and countries showed a high incidence of DRPs among hospitalized patients. Despite the available gaps, there were scanties of studies conducted on DRPs among patients admitted to medical wards in Ethiopia. Therefore, this study assessed the magnitude of drug-related problems and associated factors among patients admitted to the medical wards of selected Southwestern Ethiopian hospitals. Patients and methods A multicenter prospective observational study was conducted at medical wards of Mettu Karl Hospital, Bedele General Hospital and Darimu General Hospital. Adult patients greater than 18 years who were admitted to the non-intensive care unit (ICU) of medical wards and with more than 48 h of length of stay were included. Identified DRPs were recorded and classified using the pharmaceutical care network Europe foundation classification system and adverse drug reaction was assessed using the Naranjo algorithm of adverse drug reaction probability scale. Hill-Bone Compliance to High Blood Pressure Therapy Scale was used to measure medication adherence. Multivariable logistic regression was used to analyze the associations between the dependent variable and independent variables. Result Of the 313 study participants, 178 (56.9%) were males. The prevalence of actual or potential DRPs among study participants taking at least a single drug was 212 (67.7%). About 125 (36.63%) patients had one or more co-morbid disease and the average duration of hospital stay of 7.14 +/- 4.731 days. A total of 331 DRPs were identified with an average 1.06 DRP per patient. The three-leading categories of DRPs were unnecessary prescription of drugs 92 (27.79%), non-adherence (17.22%) and dose too high (16.92%). The most common drugs associated with DRPs were ceftriaxone (28.37%), cimetidine (14.88%), and diclofenac (14.42%). The area of residence (AOR = 2.550, 95CI%: 1.238-5.253, p = 0.011), hospital stay more than 7 days (AOR = 9.785, 95CI%: 4.668-20.511, p <= 0.001), poly pharmacy (AOR = 3.229, 95CI%: 1.433-7.278, p = 0.005) were predictors of drug-related problem in multivariable logistic regression analysis. Conclusion The magnitude of drug therapy problems among patients admitted to the medical wards of study settings was found to be high. Therefore, the clinical pharmacy services should be established in hospitals to tackle the DTPs in this area. Additionally, healthcare providers of hospitals also should create awareness for patients seeking care from health facilities of the importance of rational drug usage.	[Bekele, Firomsa; Tsegaye, Tesfaye] Mettu Univ, Coll Hlth Sci, Dept Pharm, Mettu, Ethiopia; [Negash, Efrem] Mettu Univ, Coll Hlth Sci, Dept Publ Hlth, Mettu, Ethiopia; [Fekadu, Ginenus] Wollega Univ, Inst Hlth Sci, Dept Pharm, Nekemte, Ethiopia; [Fekadu, Ginenus] Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Bekele, F (corresponding author), Mettu Univ, Coll Hlth Sci, Dept Pharm, Mettu, Ethiopia.	firomsabekele21@gmail.com	Fekadu, Ginenus/AAH-1203-2019	Fekadu, Ginenus/0000-0002-4926-0685				Ayalew MB, 2015, J RES PHARM PRACT, V4, P216, DOI 10.4103/2279-042X.167048; Ayele Yohanes, 2018, BMC Res Notes, V11, P728, DOI 10.1186/s13104-018-3838-z; Bekele F, 2021, SAGE OPEN MED, V9, DOI 10.1177/2050312121989625; Bekele NA, 2020, INFECT DRUG RESIST, V13, P1743, DOI 10.2147/IDR.S247587; Belayneh YM, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3612-x; Bhagavathula SA, 2017, J BASIC CLIN PHARM, V8, pS016; Bichave A., 2015, INDIAN J PHARMACOL, V47, P57; Birarra MK, 2017, INT J CLIN PHARM-NET, V39, P1039, DOI 10.1007/s11096-017-0504-9; Bosma L, 2008, PHARM WORLD SCI, V30, P31, DOI 10.1007/s11096-007-9136-9; Cipolle RJ, 2012, PHARM CAR PRACT PAT, Vthird; Degu Amsalu, 2017, Gynecol Oncol Res Pract, V4, P15, DOI 10.1186/s40661-017-0054-9; Donaldson MS, 2000, ERR IS HUMAN BUILDIN, DOI DOI 10.1001/jama.2010.1506; Easton KL, 2004, BRIT J CLIN PHARMACO, V57, P611, DOI 10.1111/j.1365-2125.2003.02052.x; Flaherty JH, 2000, J GERONTOL A-BIOL, V55, pM554, DOI 10.1093/gerona/55.10.M554; Hussein M., 2014, CLIN PHARM BIOPHARMA, V3, P2; Kim M T, 2000, Prog Cardiovasc Nurs, V15, P90, DOI 10.1111/j.1751-7117.2000.tb00211.x; Koh Yvonne, 2005, Ther Clin Risk Manag, V1, P39, DOI 10.2147/tcrm.1.1.39.53597; Mohammed S., 2017, ASIAN J PHARM CLIN R, V10, P310, DOI [10.22159/ajpcr.2017.v10i4.16595, DOI 10.22159/AJPCR.2017.V10I4.16595]; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Niriayo YL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206120; Peterson Cecilia, 2017, Drugs Real World Outcomes, V4, P97, DOI 10.1007/s40801-017-0108-7; Pharmaceutical Care Network Europe Foundation, 2010, PCNE CLASS SCHEM DRU, V62; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P460, DOI 10.1136/bmj.329.7463.460-a; Rashed AN, 2014, BRIT J CLIN PHARMACO, V77, P873, DOI 10.1111/bcp.12270; Saavedra PA, 2016, REV SOC BRAS MED TRO, V49, P763, DOI 10.1590/0037-8682-0238-2016; Schatz S., 2015, PHARM PRAC, V1; Song Y, 2011, ASIAN NURS RES, V5, P183, DOI 10.1016/j.anr.2011.09.007; Tigabu BM, 2014, J RES PHARM PRACT, V3, P1, DOI 10.4103/2279-042X.132702; Tumwikirize WA, 2011, AFR HEALTH SCI, V11, P72; Urbina O, 2015, THER CLIN RISK MANAG, V11, P9, DOI 10.2147/TCRM.S71749	30	6	6	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2021	16	3							e0248575	10.1371/journal.pone.0248575	http://dx.doi.org/10.1371/journal.pone.0248575			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY1VJ	33725022	Green Published, gold			2023-01-03	WOS:000629833700005
J	Mohammed, SA; Yitafr, MG; Workneh, BD; Hailu, AD				Mohammed, Solomon Ahmed; Yitafr, Minilu Girma; Workneh, Birhanu Demeke; Hailu, Abel Demerew			Health-related quality of life and associated factors among people living with human immunodeficiency virus on highly active antiretroviral therapy in North East Ethiopia: Cross-sectional study	PLOS ONE			English	Article							HIV-INFECTED ADULTS; HIV/AIDS PATIENTS; DISCRIMINATION	Introduction HIV/AIDS remains a public health concern affecting millions of people across the world. Although the health-related quality of life (HRQoL) of patients living with HIV has significantly improved after treatment, its chronicity makes the HRQoL uncertain. This study assessed factors associated with the health-related quality of life among people living with HIV/AIDS on HAART in North-East Ethiopia. Methods An institutional-based cross-sectional study was conducted from March to April 2018, and systematic random sampling was used to select 235 participants who were on HAART. HRQoL was assessed using the Medical Outcomes Study HIV Health Survey. Descriptive and multiple linear regression analysis were computed using the statistical package for social sciences version 20. Results The study revealed one-factor structure and had good overall internal consistency (78.5). Over one-third (42.6%; 95% CI; 36.2%, 48.9%) of participants had good HRQoL. The least HRQoL mean score was found for cognitive functioning 32.21(+/- 19.78), followed by social functioning 40.58(+/- 29.8). Factors associated with the overall HRQoL were 25-45 years of age (beta = - 3.55, 95% CI;-6.54, -0.55), working in private sector (beta = -5.66, 95% CI;-9.43, -1.88), government (beta = -4.29, 95% CI;-7.83, -0.75) and self-employment (beta = -8.86, 95% CI;-13.50, -4.21), 100-200 (beta = - 4.84, 95% CI;-9.04, -0.63) and 201-350 CD4 at the time of diagnosis (beta = - 7.45, 95% CI;-11.73, -3.16), 351-500 current CD4 level (beta = 8.34, 95% CI;5.55, 11.41), 6-10 years of disease duration (beta = -8.28, 95% CI;-12.51, -4.04), WHO stage II (beta = -4.78, 95% CI;-8.52, -1.04) and III (beta = 3.42, 95% CI;0.06, 6.79) during treatment initiation and not taking of Cotrimoxazole prophylaxis (beta = -5.79, 95% CI;-8.34, -3.25). Conclusions High proportion of participants had a poor HRQoL. Routine assessment and appropriate interventions at each visit is recommended to improve HRQoL.	[Mohammed, Solomon Ahmed; Workneh, Birhanu Demeke] Wollo Univ, Coll Med & Hlth Sci, Dept Pharm, Dessie, Ethiopia; [Yitafr, Minilu Girma] Debre Berhan Univ, Coll Med & Hlth Sci, Dept Pharm, Debre Berhan, Ethiopia; [Hailu, Abel Demerew] Dessie Hlth Sci Coll, Dept Pharm, Dessie, Ethiopia	University of Gondar; University of Gondar	Mohammed, SA (corresponding author), Wollo Univ, Coll Med & Hlth Sci, Dept Pharm, Dessie, Ethiopia.	ahmedsolomon21@gmail.com		Mohammed, Solomon Ahmed/0000-0002-6498-8455				Abebe Weldsilase Y., 2018, ADV PUBLIC HLTH, V2018, DOI [10.1155/2018/1893562, DOI 10.1155/2018/1893562]; Alemayehu M, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0636-6; Arrey AE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159488; Ayalew M. B., 2018, Journal of Basic and Clinical Pharmacy (JBCP), V9, P302; Ayele Mega T., 2019, OPEN PUBLIC HLTH J, V12; Tran BX, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-27; Basavaraj K H, 2010, Indian J Sex Transm Dis AIDS, V31, P75, DOI 10.4103/0253-7184.74971; Biraguma J, 2018, SAHARA J-J SOC ASP H, V15, P110, DOI 10.1080/17290376.2018.1520144; Briongos-Figuero LS, 2011, EUR REV MED PHARMACO, V15, P855; Burki TK, 2011, LANCET, V377, P286, DOI 10.1016/S0140-6736(11)60079-2; Campsmith Michael L, 2003, Health Qual Life Outcomes, V1, P12, DOI 10.1186/1477-7525-1-12; da Costa TL, 2014, REV LAT-AM ENFERM, V22, P582, DOI 10.1590/0104-1169.3350.2455; Degroote S, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-40; den Daas C, 2019, QUAL LIFE RES, V28, P2685, DOI 10.1007/s11136-019-02203-y; Deribew A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-408; Dutra BS, 2019, BRAZ J INFECT DIS, V23, P211, DOI 10.1016/j.bjid.2019.06.005; Emuren L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178953; Gakhar H, 2013, DRUGS, V73, P651, DOI 10.1007/s40265-013-0040-4; George S, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0517-4; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hidru TH, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0204-z; Imam M H, 2011, Bangladesh Med Res Counc Bull, V37, P1; Jha Nisha, 2018, J Nepal Health Res Counc, V16, P313; Kaplan B H, 1977, Med Care, V15, P47, DOI 10.1097/00005650-197705001-00006; Liu J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201177; Marashi T., 2009, Journal of Communicable Diseases, V41, P101; Mb A., 2018, J BASIC CLIN PHARM, V9; Mekuria LA, 2015, AIDS CARE, V27, P934, DOI 10.1080/09540121.2015.1020748; Melaku T, 2020, PATIENT-RELAT OUTCOM, V11, P73, DOI [10.2147/PROM.S239429, 10.17816/PED11273-84]; Miners A, 2014, LANCET HIV, V1, pE32, DOI 10.1016/S2352-3018(14)70018-9; Ndubuka NO, 2017, PALLIAT SUPPORT CARE, V15, P214, DOI 10.1017/S1478951516000638; Pascoe EA, 2009, PSYCHOL BULL, V135, P531, DOI 10.1037/a0016059; Rand Health Care, 12 IT SHORT FORM SUR; Razavi P, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/849406; Rourke SB, 2012, AIDS BEHAV, V16, P2361, DOI 10.1007/s10461-012-0284-0; Sun W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064562; Surur AS, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2714-1; Suthar AB, 2012, B WORLD HEALTH ORGAN, V90, P128, DOI 10.2471/BLT.11.093260; UNAIDS, 2019, UNAIDS DAT 2019 UNAI, DOI [10.1371/journal.pone.0158767, DOI 10.1371/JOURNAL.PONE.0158767]; UNAIDS, 2019, GLOBAL HIV AIDS EPID; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; WHO, 2014, EXECUTIVE SUMMARY; Wu AW., 1999, MOS HIV HLTH SURVEY; Yahaya SS, 2016, INT J INFECT DIS, V45, P271, DOI 10.1016/j.ijid.2016.02.603; Yaya I, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4171-x	45	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2021	16	3							e0247777	10.1371/journal.pone.0247777	http://dx.doi.org/10.1371/journal.pone.0247777			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QT5CA	33667245	Green Published, gold			2023-01-03	WOS:000626604300052
J	Okuda, N; Kyogoku, M; Inata, Y; Isaka, K; Moon, K; Hatachi, T; Shimizu, Y; Takeuchi, M				Okuda, Nao; Kyogoku, Miyako; Inata, Yu; Isaka, Kanako; Moon, Kazue; Hatachi, Takeshi; Shimizu, Yoshiyuki; Takeuchi, Muneyuki			Estimation of change in pleural pressure in assisted and unassisted spontaneous breathing pediatric patients using fluctuation of central venous pressure: A preliminary study	PLOS ONE			English	Article								Background It is important to evaluate the size of respiratory effort to prevent patient self-inflicted lung injury and ventilator-induced diaphragmatic dysfunction. Esophageal pressure (Pes) measurement is the gold standard for estimating respiratory effort, but it is complicated by technical issues. We previously reported that a change in pleural pressure (Delta Ppl) could be estimated without measuring Pes using change in CVP (Delta CVP) that has been adjusted with a simple correction among mechanically ventilated, paralyzed pediatric patients. This study aimed to determine whether our method can be used to estimate Delta Ppl in assisted and unassisted spontaneous breathing patients during mechanical ventilation. Methods The study included hemodynamically stable children (aged <18 years) who were mechanically ventilated, had spontaneous breathing, and had a central venous catheter and esophageal balloon catheter in place. We measured the change in Pes (Delta Pes), Delta CVP, and Delta Ppl that was calculated using a corrected Delta CVP (c Delta CVP-derived Delta Ppl) under three pressure support levels (10, 5, and 0 cmH(2)O). The c Delta CVP-derived Delta Ppl value was calculated as follows: c Delta CVP-derived Delta Ppl = k x Delta CVP, where k was the ratio of the change in airway pressure (Delta Paw) to the Delta CVP during airway occlusion test. Results Of the 14 patients enrolled in the study, 6 were excluded because correct positioning of the esophageal balloon could not be confirmed, leaving eight patients for analysis (mean age, 4.8 months). Three variables that reflected Delta Ppl (Delta Pes, Delta CVP, and c Delta CVP-derived Delta Ppl) were measured and yielded the following results: -6.7 +/- 4.8, - -2.6 +/- 1.4, and - -7.3 +/- 4.5 cmH2O, respectively. The repeated measures correlation between c Delta CVP-derived Delta Ppl and Delta Pes showed that c Delta CVP-derived Delta Ppl had good correlation with Delta Pes (r = 0.84, p< 0.0001). Conclusions Delta Ppl can be estimated reasonably accurately by Delta CVP using our method in assisted and unassisted spontaneous breathing children during mechanical ventilation.	[Okuda, Nao] Nara Med Univ Hosp, Ctr Infect Dis, Kashihara, Nara, Japan; [Okuda, Nao; Kyogoku, Miyako; Inata, Yu; Isaka, Kanako; Moon, Kazue; Hatachi, Takeshi; Shimizu, Yoshiyuki; Takeuchi, Muneyuki] Osaka Womens & Childrens Hosp, Dept Intens Care Med, Osaka, Japan	Nara Medical University	Takeuchi, M (corresponding author), Osaka Womens & Childrens Hosp, Dept Intens Care Med, Osaka, Japan.	mutake1017@gmail.com	Inata, Yu/H-7572-2019	Inata, Yu/0000-0002-2180-9517	JSPS KAKENHI [JP18K08904]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI Grant Number JP18K08904.	ASHER MI, 1982, J APPL PHYSIOL, V52, P491, DOI 10.1152/jappl.1982.52.2.491; Bakdash JZ, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00456; BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788; BAYDUR A, 1987, J APPL PHYSIOL, V62, P315, DOI 10.1152/jappl.1987.62.1.315; BEARDSMORE CS, 1980, J APPL PHYSIOL, V49, P735, DOI 10.1152/jappl.1980.49.4.735; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Bellemare P, 2007, INTENS CARE MED, V33, P2004, DOI 10.1007/s00134-007-0842-5; Bertoni M, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2617-0; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Cates A., 1996, INFANT RESP FUNCTION, P241; Chieveley-Williams S, 2002, CHEST, V121, P533, DOI 10.1378/chest.121.2.533; Colombo J, 2020, MINERVA ANESTESIOL, V86, P1296, DOI 10.23736/S0375-9393.20.14323-2; DECHMAN G, 1992, J APPL PHYSIOL, V72, P383, DOI 10.1152/jappl.1992.72.1.383; FLEMALE A, 1988, EUR RESPIR J, V1, P51; Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2; Goligher EC, 2018, AM J RESP CRIT CARE, V197, P204, DOI 10.1164/rccm.201703-0536OC; Hedenstierna G, 2012, MINERVA ANESTESIOL, V78, P959; HEDSTRAND U, 1976, UPSALA J MED SCI, V81, P49, DOI 10.3109/03009737609179021; HYLKEMA BS, 1983, CRIT CARE MED, V11, P271, DOI 10.1097/00003246-198304000-00004; Kyogoku M, 2020, J CLIN MONIT COMPUT, V34, P725, DOI 10.1007/s10877-019-00368-y; LESOUEF PN, 1983, J APPL PHYSIOL, V55, P353, DOI 10.1152/jappl.1983.55.2.353; Mauri T, 2016, INTENS CARE MED, V42, P1360, DOI 10.1007/s00134-016-4400-x; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; Mojoli F, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.08.37; OSTRANDER LE, 1977, RESP PHYSIOL, V31, P63, DOI 10.1016/0034-5687(77)90065-2; Schepens T, 2019, ANESTHESIOLOGY, V130, P620, DOI 10.1097/ALN.0000000000002605; Vaporidi K, 2020, AM J RESP CRIT CARE, V201, P20, DOI 10.1164/rccm.201903-0596SO; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP; Verscheure S, 2017, J CRIT CARE, V37, P65, DOI 10.1016/j.jcrc.2016.08.024; WALLING PT, 1976, BRIT J ANAESTH, V48, P475, DOI 10.1093/bja/48.5.475; Yoshida T, 2019, CURR OPIN CRIT CARE, V25, P192, DOI 10.1097/MCC.0000000000000597; Zin WA., 1998, PRINCIPLES PRACTICE, P545	32	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2021	16	3							e0247360	10.1371/journal.pone.0247360	http://dx.doi.org/10.1371/journal.pone.0247360			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR6LP	33647041	Green Published, gold			2023-01-03	WOS:000625328100024
J	Messier, SP; Mihalko, SL; Beavers, DP; Nicklas, BJ; DeVita, P; Carr, JJ; Hunter, DJ; Lyles, M; Guermazi, A; Bennell, KL; Loeser, RF				Messier, Stephen P.; Mihalko, Shannon L.; Beavers, Daniel P.; Nicklas, Barbara J.; DeVita, Paul; Carr, J. Jeffery; Hunter, David J.; Lyles, Mary; Guermazi, Ali; Bennell, Kim L.; Loeser, Richard F.			Effect of High-Intensity Strength Training on Knee Pain and Knee Joint Compressive Forces Among Adults With Knee Osteoarthritis: The START Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER-ADULTS; WEIGHT-LOSS; RESISTANCE; EXERCISE; PROGRESSION; ARTHRITIS; HIP; IMPROVEMENT; DISABILITY; OVERWEIGHT	Key PointsQuestionIs high-intensity strength training more effective than low-intensity strength training and attention control for the outcomes of knee pain and knee joint compressive forces in participants with knee osteoarthritis? FindingsIn this randomized clinical trial involving 377 participants with knee osteoarthritis, high-intensity strength training, compared with low-intensity strength training and an attention control, did not significantly improve knee pain or knee joint compressive forces at 18 months. MeaningThese findings do not support the use of high-intensity strength training over low-intensity strength training or attention control in adults with knee osteoarthritis. ImportanceThigh muscle weakness is associated with knee discomfort and osteoarthritis disease progression. Little is known about the efficacy of high-intensity strength training in patients with knee osteoarthritis or whether it may worsen knee symptoms. ObjectiveTo determine whether high-intensity strength training reduces knee pain and knee joint compressive forces more than low-intensity strength training and more than attention control in patients with knee osteoarthritis. Design, Setting, and ParticipantsAssessor-blinded randomized clinical trial conducted at a university research center in North Carolina that included 377 community-dwelling adults (>= 50 years) with body mass index (BMI) ranging from 20 to 45 and with knee pain and radiographic knee osteoarthritis. Enrollment occurred between July 2012 and February 2016, and follow-up was completed September 2017. InterventionsParticipants were randomized to high-intensity strength training (n=127), low-intensity strength training (n=126), or attention control (n=124). Main Outcomes and MeasuresPrimary outcomes at the 18-month follow-up were Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) knee pain (0 best-20 worst; minimally clinically important difference [MCID, 2]) and knee joint compressive force, defined as the maximal tibiofemoral contact force exerted along the long axis of the tibia during walking (MCID, unknown). ResultsAmong 377 randomized participants (mean age, 65 years; 151 women [40%]), 320 (85%) completed the trial. Mean adjusted (sex, baseline BMI, baseline outcome values) WOMAC pain scores at the 18-month follow-up were not statistically significantly different between the high-intensity group and the control group (5.1 vs 4.9; adjusted difference, 0.2; 95% CI, -0.6 to 1.1; P=.61) or between the high-intensity and low-intensity groups (5.1 vs 4.4; adjusted difference, 0.7; 95% CI, -0.1 to 1.6; P=.08). Mean knee joint compressive forces were not statistically significantly different between the high-intensity group and the control group (2453 N vs 2512 N; adjusted difference, -58; 95% CI, -282 to 165 N; P=.61), or between the high-intensity and low-intensity groups (2453 N vs 2475 N; adjusted difference, -21; 95% CI, -235 to 193 N; P=.85). There were 87 nonserious adverse events (high-intensity, 53; low-intensity, 30; control, 4) and 13 serious adverse events unrelated to the study (high-intensity, 5; low-intensity, 3; control, 5). Conclusions and RelevanceAmong patients with knee osteoarthritis, high-intensity strength training compared with low-intensity strength training or an attention control did not significantly reduce knee pain or knee joint compressive forces at 18 months. The findings do not support the use of high-intensity strength training over low-intensity strength training or an attention control in adults with knee osteoarthritis. Trial RegistrationClinicalTrials.gov Identifier: NCT01489462 This randomized trial compares the effects of high- vs low-intensity strength training vs control on 18-mo knee pain and knee joint compressive force among adults with knee pain and radiographic evidence of osteoarthritis.	[Messier, Stephen P.] Wake Forest Univ, Dept Hlth & Exercise Sci, JB Snow Biomech Lab, Winston Salem, NC 27109 USA; [Messier, Stephen P.; Nicklas, Barbara J.; Lyles, Mary] Wake Forest Sch Med, Sect Gerontol & Geriatr Med, Winston Salem, NC 27101 USA; [Mihalko, Shannon L.; Nicklas, Barbara J.] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27109 USA; [Beavers, Daniel P.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC 27101 USA; [DeVita, Paul] East Carolina Univ, Dept Kinesiol, Greenville, NC 27858 USA; [Carr, J. Jeffery] Vanderbilt Univ, Dept Radiol & Radiol Sci, 221 Kirkland Hall, Nashville, TN 37235 USA; [Hunter, David J.] Univ Sydney, Royal North Shore Hosp, Rheumatol Dept, Sydney, NSW, Australia; [Hunter, David J.] Univ Sydney, Inst Bone & Joint Res, Kolling Inst, Sydney, NSW, Australia; [Guermazi, Ali] Boston Univ, Dept Radiol, VA Boston Healthcare Syst, Sch Med, Boston, MA 02215 USA; [Bennell, Kim L.] Univ Melbourne, Dept Physiotherapy, Parkville, Vic, Australia; [Loeser, Richard F.] Univ N Carolina, Div Rheumatol Allergy & Immunol, Sch Med, Chapel Hill, NC 27515 USA; [Loeser, Richard F.] Univ N Carolina, Thurston Arthrit Res Ctr, Sch Med, Chapel Hill, NC 27515 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; University of North Carolina; East Carolina University; Vanderbilt University; Royal North Shore Hospital; University of Sydney; University of Sydney; Kolling Institute of Medical Research; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; University of Melbourne; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Messier, SP (corresponding author), Wake Forest Univ, JB Snow Biornechan Lab, Dept Hlth & Exercise Sci, Worrell Profess Ctr, 1834 Wake Forest Rd, Winston Salem, NC 27109 USA.	messier@wfu.edu	Carr, John/A-1938-2012	Carr, John/0000-0002-4398-8237				Altman RD, 2007, OSTEOARTHR CARTILAGE, V15, pA1, DOI 10.1016/j.joca.2006.11.009; Baker KR, 2001, J RHEUMATOL, V28, P1655; Bandura A., 1997, SELF EFFICACY EXERCI; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bliddal H, 2011, ANN RHEUM DIS, V70, P1798, DOI 10.1136/ard.2010.142018; Dougados M, 2000, OSTEOARTHR CARTILAGE, V8, P395, DOI 10.1053/joca.2000.0361; Englund M, 2018, ANN RHEUM DIS, V77, P159, DOI 10.1136/annrheumdis-2017-211664; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FELSON DT, 1995, ARTHRITIS RHEUM-US, V38, P1500, DOI 10.1002/art.1780381017; Ferenczi MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085739; Griffin TM, 2005, EXERC SPORT SCI REV, V33, P195, DOI 10.1097/00003677-200510000-00008; Griffiths G, 1993, INFLAMMOPHARMACOLOGY, V2, P85, DOI DOI 10.1007/BF02663745; Hall M, 2018, OSTEOARTHR CARTILAGE, V26, P495, DOI 10.1016/j.joca.2018.01.018; Hurley MV, 1998, BRIT J RHEUMATOL, V37, P1181; Jan MH, 2008, PHYS THER, V88, P427, DOI 10.2522/ptj.20060300; Kapstad H, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-55; King LK, 2008, MED SCI SPORT EXER, V40, P1376, DOI 10.1249/MSS.0b013e31816f1c4a; Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI [10.1002/art.41142, 10.1002/acr.24131]; Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027; Mazzuca SA, 2008, OSTEOARTHR CARTILAGE, V16, P1555, DOI 10.1016/j.joca.2008.04.010; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Messier SP, 2013, JAMA-J AM MED ASSOC, V310, P1263, DOI 10.1001/jama.2013.277669; Messier SP, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-208; Mikesky AE, 2006, ARTHRIT RHEUM-ARTHR, V55, P690, DOI 10.1002/art.22245; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Naylor JM, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1249-7; Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018; Otterness IG, 1998, ARTHRITIS RHEUM-US, V41, P2068, DOI 10.1002/1529-0131(199811)41:11<2068::AID-ART23>3.0.CO;2-L; Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001; Sharma L, 2003, ANN INTERN MED, V138, P613, DOI 10.7326/0003-4819-138-8-200304150-00006; Sharma L, 2000, ARTHRITIS RHEUM, V43, P568, DOI 10.1002/1529-0131(200003)43:3<568::AID-ANR13>3.0.CO;2-E; Singh NA, 1997, J GERONTOL A-BIOL, V52, pM27, DOI 10.1093/gerona/52A.1.M27; Siviero P, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2593-1; Tuttle AH, 2015, PAIN, V156, P2616, DOI 10.1097/j.pain.0000000000000333; Van Den Hoogen BM, 1998, BRIT J RHEUMATOL, V37, P671; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Wilson DR, 2008, RHEUM DIS CLIN N AM, V34, P605, DOI 10.1016/j.rdc.2008.05.002	38	20	21	12	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2021	325	7					646	657		10.1001/jama.2021.0411	http://dx.doi.org/10.1001/jama.2021.0411			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ3QZ	33591346	Green Published, Bronze			2023-01-03	WOS:000619608000017
J	de Lucas, B; Perez, LM; Bernal, A; Galvez, BG				de Lucas, Beatriz; Perez, Laura M.; Bernal, Aurora; Galvez, Beatriz G.			Application of low-intensity pulsed therapeutic ultrasound on mesenchymal precursors does not affect their cell properties	PLOS ONE			English	Article							STEM-CELLS; FRACTURE; STIMULATION; APOPTOSIS; MECHANOTRANSDUCTION; ACTIVATION; EXPRESSION; MIGRATION; EXPOSURE; CHANNELS	Ultrasound is considered a safe and non-invasive tool in regenerative medicine and has been used in the clinic for more than twenty years for applications in bone healing after the approval of the Exogen device, also known as low-intensity pulsed ultrasound (LIPUS). Beyond its effects on bone health, LIPUS has also been investigated for wound healing of soft tissues, with positive results for various cell processes including cell proliferation, migration and angiogenesis. As LIPUS has the potential to treat chronic skin wounds, we sought to evaluate the effects produced by a conventional therapeutic ultrasound device at low intensities (also considered LIPUS) on the migration capacity of mouse and human skin mesenchymal precursors (s-MPs). Cells were stimulated for 3 days (20 minutes per day) using a traditional ultrasound device with the following parameters: 100 mW/cm(2) with 20% duty cycle and frequency of 3 MHz. At the parameters used, ultrasound failed to affect s-MP proliferation, with no evident changes in morphology or cell groupings, and no changes at the cytoskeletal level. Further, the migration and invasion ability of s-MPs were unaffected by the ultrasound protocol, and no major changes were detected in the gene/protein expression of ROCK1, integrin beta 1, laminin beta 1, type I collagen and transforming growth factor beta 1. Finally, RNA-seq analysis revealed that only 10 genes were differentially expressed after ultrasound stimulation. Among them, 5 encode for small nuclear RNAs and 2 encode for proteins belonging to the nuclear pore complex. Considering the results overall, while the viability of s-MPs was not affected by ultrasound stimulation and no changes were detected in proliferation/migration, RNA-seq analysis would suggest that s-MPs do respond to ultrasound. The use of 100 mW/cm(2) intensity or conventional therapeutic ultrasound devices might not be optimal for the stimulation the properties of cell populations. Future studies should investigate the potential application of ultrasound using variations of the tested parameters.	[de Lucas, Beatriz; Perez, Laura M.; Galvez, Beatriz G.] Univ Europea Madrid, Fac Biomed & Hlth Sci, Madrid, Spain; [Bernal, Aurora] Ctr Nacl Invest Cardiovasc CNIC, Madrid, Spain	European University of Madrid; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Galvez, BG (corresponding author), Univ Europea Madrid, Fac Biomed & Hlth Sci, Madrid, Spain.	beatriz.ggalvez@ufv.es	Bernal, Aurora/AAG-1926-2019; de Lucas Moreno, Beatriz/P-1378-2019; Gálvez, Beatriz G./H-1644-2015	Bernal, Aurora/0000-0002-5741-7865; de Lucas Moreno, Beatriz/0000-0002-2852-0118; Gálvez, Beatriz G./0000-0002-8082-9323	Spanish Ministry of Science and Innovation [SAF 2015-67911-R]; FPU fellowship from the Spanish Ministry	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); FPU fellowship from the Spanish Ministry	This study was supported by grants from the Spanish Ministry of Science and Innovation (SAF 2015-67911-R) to BGG. BdL is supported by FPU fellowship from the Spanish Ministry.	Angle SR, 2011, ULTRASONICS, V51, P281, DOI 10.1016/j.ultras.2010.09.004; Atherton P, 2017, J CELL SCI, V130, P2277, DOI 10.1242/jcs.192781; Bernal A, 2012, CELL DEATH DIFFER, V19, P345, DOI 10.1038/cdd.2011.110; Bernal A, 2015, STEM CELL REV REP, V11, P852, DOI 10.1007/s12015-015-9608-6; Bernal A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053215; Bohari SPM, 2015, J TISSUE ENG, V6, DOI 10.1177/2041731415615777; Boyle Sarah T, 2016, Small GTPases, V7, P139, DOI 10.1080/21541248.2016.1173771; Carovac Aladin, 2011, Acta Inform Med, V19, P168, DOI 10.5455/aim.2011.19.168-171; Chan CW, 2006, J ORTHOP RES, V24, P2072, DOI 10.1002/jor.20258; Chen Y, 2010, J CELL MOL MED, V14, P1494, DOI 10.1111/j.1582-4934.2009.00912.x; Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932; de Lucas B, 2020, GENES-BASEL, V11, DOI 10.3390/genes11091086; de Lucas B, 2018, J CELL MOL MED, V22, P746, DOI 10.1111/jcmm.13422; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; European Food Safety Authority (EFSA), 2015, EFSA J, V13, pe4138, DOI 10.2903/j.efsa.2015.4138; Feril LB, 2005, CANCER LETT, V221, P145, DOI 10.1016/j.canlet.2004.08.034; Fung CH, 2012, ULTRASOUND MED BIOL, V38, P745, DOI 10.1016/j.ultrasmedbio.2012.01.022; Gallo M, 2018, FOODS, V7, DOI 10.3390/foods7100164; Gao QH, 2017, J ENDODONT, V43, P1130, DOI 10.1016/j.joen.2017.02.022; Harrison A, 2016, ULTRASONICS, V70, P45, DOI 10.1016/j.ultras.2016.03.016; Hebert MD, 2013, INT J BIOCHEM CELL B, V45, P1314, DOI 10.1016/j.biocel.2013.03.019; HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623-199401000-00004; Huang JJ, 2015, AM J TRANSL RES, V7, P1106; Ikeda T, 2016, ADV EXP MED BIOL, V880, P113, DOI 10.1007/978-3-319-22536-4_7; Iwanabe Y, 2016, J PROSTHODONT RES, V60, P308, DOI 10.1016/j.jpor.2016.03.002; Karijolich J, 2010, RNA BIOL, V7, P192, DOI 10.4161/rna.7.2.11207; KC A., 2017, J TOUR HOSP ED, V7, P25, DOI [10.3126/jthe.v7i0.17688, DOI 10.3126/JTHE.V7I0.17688]; Kosters A, 2017, INT ORTHOP, V41, P2067, DOI 10.1007/s00264-017-3574-3; Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623-199707000-00002; Lafarga M, 2017, RNA BIOL, V14, P712, DOI 10.1080/15476286.2016.1231360; Lagneaux L, 2002, EXP HEMATOL, V30, P1293, DOI 10.1016/S0301-472X(02)00920-7; Lemaster JE, 2018, ACS APPL NANO MATER, V1, P1321, DOI 10.1021/acsanm.8b00063; Leskinen JJ, 2012, ULTRASOUND MED BIOL, V38, P777, DOI 10.1016/j.ultrasmedbio.2012.01.019; Lv YG, 2013, BIOTECHNOL LETT, V35, P2201, DOI 10.1007/s10529-013-1313-4; Man J, 2012, J BONE MINER METAB, V30, P602, DOI 10.1007/s00774-012-0368-y; Monden K, 2015, J HARD TISSUE BIOL, V24, P189, DOI 10.2485/jhtb.24.189; Nagao M, 2017, J CELL PHYSIOL, V232, P3337, DOI 10.1002/jcp.25777; Padilla F, 2014, ULTRASONICS, V54, P1125, DOI 10.1016/j.ultras.2014.01.004; Poh YC, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1873; Prieto ML, 2018, ULTRASOUND MED BIOL, V44, P1217, DOI 10.1016/j.ultrasmedbio.2017.12.020; Qiu ZH, 2019, ISCIENCE, V21, P448, DOI 10.1016/j.isci.2019.10.037; Robey Pamela, 2017, F1000Res, V6, DOI 10.12688/f1000research.10955.1; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roper JA, 2015, J INVEST DERMATOL, V135, P2842, DOI 10.1038/jid.2015.224; Rubin C, 2001, J BONE JOINT SURG AM, V83A, P259, DOI 10.2106/00004623-200102000-00015; Saito M, 2004, BONE, V35, P644, DOI 10.1016/j.bone.2004.04.024; Samandari M, 2017, J BIOMECH, V60, P39, DOI 10.1016/j.jbiomech.2017.06.003; Santana LD, 2013, ULTRASONICS, V53, P870, DOI 10.1016/j.ultras.2012.12.009; Shi MF, 2016, ULTRASONICS, V64, P43, DOI 10.1016/j.ultras.2015.07.011; Tsai WC, 2006, J ORTHOP RES, V24, P1310, DOI 10.1002/jor.20130; Vogel V, 2006, ANNU REV BIOPH BIOM, V35, P459, DOI 10.1146/annurev.biophys.35.040405.102013; Wang N, 2009, NAT REV MOL CELL BIO, V10, P75, DOI 10.1038/nrm2594; Warden SJ, 2006, PHYS THER, V86, P1118, DOI 10.1093/ptj/86.8.1118; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Yilmaz V, 2017, EUR J RHEUMATOL, V4, P104, DOI 10.5152/eurjrheum.2017.160089; Zhang L, 2015, INT J HYPERTHER, V31, P280, DOI 10.3109/02656736.2014.996790; Zhao L, 2017, ULTRASOUND MED BIOL, V43, P1986, DOI 10.1016/j.ultrasmedbio.2017.04.020; Zhao XY, 2017, SCI REP-UK, V7, DOI 10.1038/srep40512; Zhou SX, 2004, J BIOL CHEM, V279, P54463, DOI 10.1074/jbc.M404786200; Zura R, 2017, J ORTHOP TRAUMA, V31, P248, DOI 10.1097/BOT.0000000000000778; Zura R, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0498-1; 2019, J CROHNS COLITIS S1, V13	62	1	1	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2021	16	2							e0246261	10.1371/journal.pone.0246261	http://dx.doi.org/10.1371/journal.pone.0246261			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH4VJ	33571276	Green Published, gold			2023-01-03	WOS:000618274000028
J	Shinozaki, E; Makiyama, A; Kagawa, Y; Satake, H; Tanizawa, Y; Cai, ZH; Piao, YZ				Shinozaki, Eiji; Makiyama, Akitaka; Kagawa, Yoshinori; Satake, Hironaga; Tanizawa, Yoshinori; Cai, Zhihong; Piao, Yongzhe			Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database	PLOS ONE			English	Article							POST-PROGRESSION SURVIVAL; 1ST PROGRESSION; BEVACIZUMAB; OXALIPLATIN; COMBINATION; TRIAL; COLON; FLUOROURACIL; HYPERTENSION; MULTICENTER	The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan. This retrospective observational study was conducted using a Japanese hospital-based administrative database. Patients were enrolled if they started adjuvant therapy (and presumably experienced early recurrence) or first-line treatment for advanced CRC between May 2016 and July 2019, and were analysed until September 2019. Factors associated with overall treatment duration from second-line treatment with FOLFIRI plus antiangiogenic drugs were explored with multivariate Cox regression analysis. The most common first-line treatments were FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) or CAPOX (capecitabine, oxaliplatin) with bevacizumab (presumed RAS-mutant CRC) and FOLFOX with panitumumab (presumed RAS-wild type CRC). The most common second-line treatments were FOLFIRI-based. Many patients did not transition to subsequent lines of therapy. For second-line treatment, antiangiogenic drugs were prescribed more often for patients with presumed RAS-mutant CRC, right-sided CRC, and independent activities of daily living (ADL). The median duration of second-line FOLFIRI plus antiangiogenic drug treatment was 4.5 months; 66.2% of patients transitioned to third-line therapy. Low body mass index and not fully independent ADL were significantly associated with shorter overall duration of antitumor drug treatment from second-line therapy. Left-sided CRC, presumed RAS-wild type CRC, previous use of oral fluoropyrimidines and use of proteinuria qualitative tests, antihypertensives, or anticholinergics during second-line therapy were significantly associated with longer treatment. Treatment of advanced CRC in Japan is consistent with both international and Japanese guidelines, but transition rates to subsequent therapies need improvement. In addition to antitumor drug treatment, better ADL, higher body mass index, management of hypertension, and proteinuria tests were associated with continuation of sequential therapy that included antiangiogenic drugs.	[Shinozaki, Eiji] Japanese Fdn Canc Res, Canc Inst Hosp, Gastroenterol Ctr, Tokyo, Japan; [Makiyama, Akitaka] Gifu Univ Hosp, Canc Ctr, Gifu, Japan; [Kagawa, Yoshinori] Osaka Gen Med Ctr, Dept Gastroenterol Surg, Osaka, Japan; [Satake, Hironaga] Kansai Med Univ Hosp, Canc Treatment Ctr, Osaka, Japan; [Tanizawa, Yoshinori; Cai, Zhihong; Piao, Yongzhe] Eli Lilly Japan KK, Med Dev Unit Japan, Kobe, Hyogo, Japan	Japanese Foundation for Cancer Research; Gifu University; Kansai Medical University; Eli Lilly	Tanizawa, Y (corresponding author), Eli Lilly Japan KK, Med Dev Unit Japan, Kobe, Hyogo, Japan.	tanizawa_yoshinori@lilly.com	Satake, Hironaga/G-6243-2013	Satake, Hironaga/0000-0001-7629-6803; Tanizawa, Yoshinori/0000-0002-5014-2483; cai, zhihong/0000-0002-3431-197X	Eli Lilly Japan K.K. - Eli Lilly Japan K.K	Eli Lilly Japan K.K. - Eli Lilly Japan K.K	This study was sponsored by Eli Lilly Japan K.K., manufacturer/licensee of ramucirumab. Medical writing assistance provided by Serina Stretton, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe - Envision Pharma Group was funded by Eli Lilly Japan K.K. The funder provided support in the form of salaries for authors (YT, ZC, and YP) and was involved in the study design, data collection, data analysis, preparation of the manuscript, and in the decision to publish.	Amna M. T. Abdullah, 2015, INT J COMPUT NETWORK, V7, P19; Baba H, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2016-000135; Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1; Benson AB, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036; Boyko EJ, 2013, J DIABETES COMPLICAT, V27, P642, DOI 10.1016/j.jdiacomp.2013.07.007; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Ciombor KK, 2018, ONCOLOGIST, V23, P25, DOI 10.1634/theoncologist.2017-0203; Denda T, 2019, CANCER SCI, V110, P1032, DOI 10.1111/cas.13943; Dotan E, 2012, J NATL COMPR CANC NE, V10, P213, DOI 10.6004/jnccn.2012.0020; Fessele KL, 2018, SEMIN ONCOL NURS, V34, P168, DOI 10.1016/j.soncn.2018.03.008; Fukuda Naoki, 2018, Oncotarget, V9, P15219, DOI 10.18632/oncotarget.24635; Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305; Hamnvik OPR, 2015, CANCER-AM CANCER SOC, V121, P311, DOI 10.1002/cncr.28972; Hashiguchi Y, 2020, INT J CLIN ONCOL, V25, P1, DOI 10.1007/s10147-019-01485-z; Holch JW, 2017, EUR J CANCER, V70, P87, DOI 10.1016/j.ejca.2016.10.007; Iizumi S, 2018, CANCER CHEMOTH PHARM, V81, P981, DOI 10.1007/s00280-018-3569-9; Imai H, 2017, THORAC CANCER, V8, P379, DOI 10.1111/1759-7714.12463; Izzedine H, 2010, EUR J CANCER, V46, P439, DOI 10.1016/j.ejca.2009.11.001; Kubicka S, 2013, ANN ONCOL, V24, P2342, DOI 10.1093/annonc/mdt231; Lafayette RA, 2014, AM J NEPHROL, V40, P75, DOI 10.1159/000365156; Lee MKC, 2019, CURR ONCOL, V26, pS7, DOI 10.3747/co.26.5719; Lim HH, 2019, TARGET ONCOL, V14, P743, DOI 10.1007/s11523-019-00683-z; Maiello E, 2017, ANN ONCOL, V28, P16; Matsuda S, 2010, ASIAN PACIFIC J DIS, V4, P55, DOI DOI 10.7223/APJDM.4.55; McMahon AD, 2000, BRIT J CLIN PHARMACO, V50, P419, DOI 10.1046/j.1365-2125.2000.00289.x; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; Ministry of Health Labour and Welfare, 2016, OV NAT CANC REG 2016; Ministry of Health Labour and Welfare. Cancer Information Service National Cancer Center Japan., CANC REG STAT VIT ST; Nakamura M., 2016, JAP J PHARMACOEPIDEM, V21, P23, DOI [10.3820/jjpe.21.23, DOI 10.3820/JJPE.21.23]; Nakayama G, 2012, CANCER CHEMOTH PHARM, V70, P575, DOI 10.1007/s00280-012-1948-1; Petrelli F, 2013, ANN ONCOL, V24, P186, DOI 10.1093/annonc/mds289; PETRI H, 1991, STAT MED, V10, P577, DOI 10.1002/sim.4780100409; Price TJ, 2013, EXPERT REV ANTICANC, V13, P597, DOI [10.1586/ERA.13.37, 10.1586/era.13.37]; Roviello Giandomenico, 2018, Oncotarget, V9, P22332, DOI 10.18632/oncotarget.24900; Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201; Wade D T, 1988, Int Disabil Stud, V10, P64; Yamada Y, 2018, ANN ONCOL, V29, P624, DOI 10.1093/annonc/mdx816; Yoshihiro T, 2019, INT J CLIN ONCOL, V24, P508, DOI 10.1007/s10147-018-01391-w; Zhang CJ, 2018, AGING-US, V10, P1424, DOI 10.18632/aging.101478	41	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2021	16	2							e0246160	10.1371/journal.pone.0246160	http://dx.doi.org/10.1371/journal.pone.0246160			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG1VY	33556095	gold, Green Published			2023-01-03	WOS:000617379900071
J	Hwang, JP; Ferrajoli, A; Lok, AS				Hwang, Jessica P.; Ferrajoli, Alessandra; Lok, Anna S.			Hepatitis B reactivation after chemoimmunotherapy: screen before treatment	LANCET			English	Editorial Material									[Hwang, Jessica P.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med, Houston, TX 77030 USA; [Ferrajoli, Alessandra] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Lok, Anna S.] Univ Michigan, Dept Internal Med, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan	Lok, AS (corresponding author), Univ Michigan, Dept Internal Med, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA.	aslok@umich.edu		Hwang, Jessica/0000-0002-5896-4182	NIDDK NIH HHS [P30 DK034933, U01 DK082863] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))			0	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	2021	397	10273					510	510						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF1LZ	33549195	Green Accepted			2023-01-03	WOS:000616661900026
J	Dirnena-Fusini, I; Am, MK; Fougner, AL; Carlsen, SM; Christiansen, SC				Dirnena-Fusini, Ilze; Am, Marte Kierulf; Fougner, Anders Lyngvi; Carlsen, Sven Magnus; Christiansen, Sverre Christian			Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A systematic review and meta-analysis	PLOS ONE			English	Review							ACCU-CHEK(R) DIAPORT; PORT SYSTEM; ARTIFICIAL PANCREAS; PROGRAMMABLE PUMPS; DELIVERY; PERITONEAL; GLUCAGON; HYPOGLYCEMIA; METABOLISM; ABSORPTION	The intraperitoneal route of administration accounts for less than 1% of insulin treatment regimes in patients with diabetes mellitus type 1 (DM1). Despite being used for decades, a systematic review of various physiological effects of this route of insulin administration is lacking. Thus, the aim of this systematic review was to identify the physiological effects of continuous intraperitoneal insulin infusion (CIPII) compared to those of continuous subcutaneous insulin infusion (CSII) in patients with DM1. Four databases (EMBASE, PubMed, Scopus and CENTRAL) were searched beginning from the inception date of each database to 10(th) of July 2020, using search terms related to intraperitoneal and subcutaneous insulin administration. Only studies comparing CIPII treatment (>= 1 month) with CSII treatment were included. Primary outcomes were long-term glycaemic control (after >= 3 months of CIPII inferred from glycated haemoglobin (HbA1c) levels) and short-term (>= 1 day for each intervention) measurements of insulin dynamics in the systematic circulation. Secondary outcomes included all reported parameters other than the primary outcomes. The search identified a total of 2242 records; 39 reports from 32 studies met the eligibility criteria. This meta-analysis focused on the most relevant clinical end points; the mean difference (MD) in HbA1c levels during CIPII was significantly lower than during CSII (MD = -6.7 mmol/mol, [95% CI: -10.3 --3.1]; in percentage: MD = -0.61%, [95% CI: -0.94 -- 0.28], p = 0.0002), whereas fasting blood glucose levels were similar (MD = 0.20 mmol/L, [95% CI: -0.34-0.74], p = 0.47; in mg/dL: MD = 3.6 mg/dL, [95% CI: -6.1-13.3], p = 0.47). The frequencies of severe hypo- and hyper-glycaemia were reduced. The fasting insulin levels were significantly lower during CIPII than during CSII (MD = 16.70 pmol/L, [95% CI: -23.62 --9.77], p < 0.0001). Compared to CSII treatment, CIPII treatment improved overall glucose control and reduced fasting insulin levels in patients with DM1.	[Dirnena-Fusini, Ilze; Am, Marte Kierulf; Carlsen, Sven Magnus; Christiansen, Sverre Christian] Norwegian Univ Sci, Dept Clin & Mol Med, Fac Med & Hlth Sci, Trondheim, Norway; [Am, Marte Kierulf; Carlsen, Sven Magnus; Christiansen, Sverre Christian] St Olavs Univ Hosp, Dept Endocrinol, Trondheim, Norway; [Fougner, Anders Lyngvi] Norwegian Univ Sci, Fac Informat Technol & Elect Engn, Dept Engn Cybernet, Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Dirnena-Fusini, I (corresponding author), Norwegian Univ Sci, Dept Clin & Mol Med, Fac Med & Hlth Sci, Trondheim, Norway.	ilze.dirnena-fusini@ntnu.no	Fougner, Anders Lyngvi/J-3284-2013; St Olav Hospital, Medisinsk Klinikk -/AAD-6414-2022	Fougner, Anders Lyngvi/0000-0001-7583-5027; Christiansen, Sverre Christian/0000-0002-0378-0474	Norwegian Research Council (NRC) as part of Centre for Digital Life Norway [248872]; Central Norway Regional Health Authority (CNRHA) [2014/23166]	Norwegian Research Council (NRC) as part of Centre for Digital Life Norway; Central Norway Regional Health Authority (CNRHA)	The Norwegian Research Council (NRC) is funding the Double Intraperitoneal Artificial Pancreas project (project number 248872) (all authors) as part of Centre for Digital Life Norway (digitallifenorway.org). The study is also supported by a scholarship from the Central Norway Regional Health Authority (CNRHA) (grant no 2014/23166) (MKA). These grants support the development to create a safe and robust artificial pancreas for patients with diabetes. The funding bodies are not involved in any other aspect of this systematic review, such as the design of the review's protocol and analysis plan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almalki MH, 2012, CLIN INVEST MED, V35, pE132; Arnqvist H., 2010, GROWTH HORM IGF RES, V20, pS24; BEYLOT M, 1987, DIABETES METAB, V13, P450; Calculator O, 2019, CHOLESTEROL UNITS CO; Catargi B, 2000, DIABETES METAB, V26, P210; Catargi B, 2002, DIABETES METAB, V28, P133; Christiansen SC, 2017, DIABETES THER, V8, P489, DOI 10.1007/s13300-017-0263-6; COLETTE C, 1989, HORM METAB RES, V21, P37, DOI 10.1055/s-2007-1009144; Conway B, 2009, DIABETES VASC DIS RE, V6, P223, DOI 10.1177/1479164109336041; Dassau E, 2017, DIABETES OBES METAB, V19, P1698, DOI 10.1111/dom.12999; Diabetes.co.uk, 2019, BLOOD SUGAR CONV; Duvillard L, 2005, J CLIN ENDOCR METAB, V90, P5761, DOI 10.1210/jc.2005-0989; Duvillard L, 2007, ATHEROSCLEROSIS, V194, P342, DOI 10.1016/j.atherosclerosis.2006.10.034; Edgerton DS, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126974; endmemo.com, 2016, INS UN CONV; FELIG P, 1974, P SOC EXP BIOL MED, V147, P88; GEORGOPOULOS A, 1992, DIABETES CARE, V15, P19, DOI 10.2337/diacare.15.1.19; GEORGOPOULOS A, 1994, DIABETES CARE, V17, P1295, DOI 10.2337/diacare.17.11.1295; GIACCA A, 1993, J CLIN ENDOCR METAB, V77, P738, DOI 10.1210/jcem.77.3.8370695; Goldstein DE, 2004, DIABETES CARE, V27, P1761, DOI 10.2337/diacare.27.7.1761; GRECO AV, 1979, DIABETOLOGIA, V17, P23, DOI 10.1007/BF01222973; Guerci B, 1996, METABOLISM, V45, P430, DOI 10.1016/S0026-0495(96)90215-2; Guo B, 2016, J CLIN EPIDEMIOL, V69, P199, DOI 10.1016/j.jclinepi.2015.07.010; HanaireBroutin H, 1996, DIABETOLOGIA, V39, P1498, DOI 10.1007/s001250050604; Hedman CA, 2009, DIABETOLOGIA, V52, pS376; Hedman CA, 2014, CLIN ENDOCRINOL, V81, P58, DOI 10.1111/cen.12296; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Home PD, 2015, DIABETES OBES METAB, V17, P1011, DOI 10.1111/dom.12501; Husband D J, 1984, Diabet Med, V1, P99; Jeandidier N, 2002, DIABETES CARE, V25, P84, DOI 10.2337/diacare.25.1.84; JEANDIDIER N, 1992, TRANSPLANT P, V24, P948; Laing SP, 2003, DIABETOLOGIA, V46, P760, DOI 10.1007/s00125-003-1116-6; Lassmann-Vague V, 1998, DIABETES CARE, V21, P2041, DOI 10.2337/diacare.21.11.2041; LassmannVague V, 1996, DIABETIC MED, V13, P1051, DOI 10.1002/(SICI)1096-9136(199612)13:12<1051::AID-DIA286>3.0.CO;2-Y; LASSMANNVAGUE V, 1995, DIABETES CARE, V18, P498, DOI 10.2337/diacare.18.4.498; LASSMANNVAGUE V, 1994, HORM METAB RES, V26, P436, DOI 10.1055/s-2007-1001725; Liebl A, 2013, DIABETES TECHNOL THE, V15, pA13; Liebl A, 2009, DIABETES OBES METAB, V11, P1001, DOI 10.1111/j.1463-1326.2009.01059.x; Liebl A, 2013, EVALUTION NEW ACCU C; Liebl A, 2013, DIABETES, V62, pA247; Liebl A, 2014, DIABETES, V63, pA241; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; MICOSSI P, 1986, ACTA DIABETOL LAT, V23, P155, DOI 10.1007/BF02624675; Oskarsson PR, 2000, DIABETES METAB, V26, P118; Oskarsson PR, 1999, DIABETES METAB, V25, P491; Pacifico A, 1997, GIORNALE ITALIANO DI, V17, P21; PITT HA, 1992, ANN SURG, V216, P483, DOI 10.1097/00000658-199210000-00011; Project E.P.H.P, 2008, QUAL ASS TOOL QUANT; RACCAH D, 1994, DIABETES CARE, V17, P941, DOI 10.2337/diacare.17.8.941b; RENARD E, 1993, DIABETES METAB, V19, P364; SCHADE DS, 1981, METABOLISM, V30, P149, DOI 10.1016/0026-0495(81)90164-5; SCHADE DS, 1979, DIABETES, V28, P1069, DOI 10.2337/diab.28.12.1069; Schnell O, 1994, DIABETES STOFFWECHSE, P51; SELAM JL, 1989, METABOLISM, V38, P908, DOI 10.1016/0026-0495(89)90240-0; SELAM JL, 1990, DIABETES, V39, P1361, DOI 10.2337/diabetes.39.11.1361; Spaan N, 2014, ACTA DIABETOL, V51, P339, DOI 10.1007/s00592-014-0557-3; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; van Dijk PR, 2020, THER ADV ENDOCRINOL, V11, DOI 10.1177/2042018820908456; van Dijk PR, 2016, J CLIN ENDOCR METAB, V101, P2493, DOI 10.1210/jc.2016-1473; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Walter H, 1989, AKTUELLE ENDOKRINOLO, V10, P224; Wan CKN, 2000, METABOLISM, V49, P984, DOI 10.1053/meta.2000.7727; WREDLING R, 1991, DIABETES METAB, V17, P456; WREDLING R, 1991, DIABETIC MED, V8, P597, DOI 10.1111/j.1464-5491.1991.tb01663.x	65	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2021	16	4							e0249611	10.1371/journal.pone.0249611	http://dx.doi.org/10.1371/journal.pone.0249611			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN5ED	33848314	Green Published, gold			2023-01-03	WOS:000640373500025
J	Eythorsson, E; Asgeirsdottir, TL; Erlendsdottir, H; Hrafnkelsson, B; Kristinsson, KG; Haraldsson, A				Eythorsson, Elias; Asgeirsdottir, Tinna L.; Erlendsdottir, Helga; Hrafnkelsson, Birgir; Kristinsson, Karl G.; Haraldsson, Asgeir			The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland-A population-based time series analysis	PLOS ONE			English	Article							OTITIS-MEDIA; PNEUMONIA HOSPITALIZATIONS; CHILDHOOD IMMUNIZATION; ADMISSIONS; EFFICACY; CHILDREN; DISEASE; USA	Introduction Streptococcus pneumoniae is a cause of infections that range in severity from acute otitis media (AOM) to pneumonia and invasive pneumococcal disease (IPD). The 10-valent pneumococcal conjugate vaccine (PHiD-CV10) was introduced into the Icelandic paediatric immunisation programme in 2011. The aim was to estimate the population impact and cost-effectiveness of PHiD-CV10 introduction. Methods Data on primary care visits from 2005-2015 and hospitalisations from 2005-2017 were obtained from population-based registries. A Bayesian time series analysis with synthetic controls was employed to estimate the number of cases of AOM, pneumonia and IPD that would have occurred between 2013-2017, had PHiD-CV10 not been introduced. Prevented cases were calculated by subtracting the observed number of cases from this estimate. The cost of the programme was calculated accounting for cost-savings due to prevented cases. Results The introduction of PHiD-CV10 prevented 13,767 (95% credible interval [CI] 2,511-29,410) visits for AOM from 2013-2015, and prevented 1,814 (95%CI -523-4,512) hospitalisations for pneumonia and 53 (95%CI -17-177) admissions for IPD from 2013-2017. Visits for AOM decreased both among young children and among children 4-19 years of age, with rate ratios between 0.72-0.89. Decreases were observed in both pneumonia hospitalisations (rate ratios between 0.67-0.92) and IPD (rate ratios between 0.27-0.94). The total cost of implementing PHiD-CV10 in Iceland was -7,463,176 United States Dollars (USD) (95%CI -16,159,551-582,135) with 2.1 USD (95%CI 0.2-4.7) saved for every 1 USD spent. Conclusions The introduction of PHiD-CV10 was associated with large decreases in visits and hospitalisations for infections commonly caused by pneumococcus and was cost-saving during the first five years of the immunisation programme.	[Eythorsson, Elias; Erlendsdottir, Helga; Kristinsson, Karl G.; Haraldsson, Asgeir] Univ Iceland, Fac Med, Reykjavik, Iceland; [Asgeirsdottir, Tinna L.] Univ Iceland, Fac Econ, Reykjavik, Iceland; [Erlendsdottir, Helga; Kristinsson, Karl G.] Landspitali Natl Univ Hosp Iceland, Dept Clin Microbiol, Reykjavik, Iceland; [Hrafnkelsson, Birgir] Univ Iceland, Dept Math, Reykjavik, Iceland; [Haraldsson, Asgeir] Landspitali Natl Univ Hosp Iceland, Childrens Hosp Iceland, Reykjavik, Iceland	University of Iceland; University of Iceland; University of Iceland	Haraldsson, A (corresponding author), Univ Iceland, Fac Med, Reykjavik, Iceland.; Haraldsson, A (corresponding author), Landspitali Natl Univ Hosp Iceland, Childrens Hosp Iceland, Reykjavik, Iceland.	asgeir@landspitali.is		Haraldsson, Asgeir/0000-0001-5364-7877	GlaxoSmithKline Biologicals SA; Landspitali University Hospital Research Fund	GlaxoSmithKline Biologicals SA(GlaxoSmithKline); Landspitali University Hospital Research Fund	An investigator-initiated study funded by GlaxoSmithKline Biologicals SA. The protocol was written and the study planned before any funding was requested. Additionally, a grant was received from the Landspitali University Hospital Research Fund. GlaxoSmithKline Biologicals SA was provided the opportunity to review a draft version of this manuscript, but the authors are solely responsible for final content and interpretation. The authors received no financial support or other form of compensation related to the development of the manuscript.	Alicino C, 2017, VACCINE, V35, P5776, DOI 10.1016/j.vaccine.2017.09.005; Andrade AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184204; Ben-Shimol S, 2014, CLIN INFECT DIS, V59, P1724, DOI 10.1093/cid/ciu683; Berglund A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112211; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Bruhn CAW, 2017, P NATL ACAD SCI USA, V114, P1524, DOI 10.1073/pnas.1612833114; Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6; Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005; de Oliveira LH, 2021, CLIN INFECT DIS, V73, P306, DOI 10.1093/cid/ciaa614; Eythorsson E., 2017, PEDIAT INFECT DIS J, V1; Gray A., 2011, APPL METHODS COST EF; Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165; Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9; Grijalva CG, 2006, PEDIATRICS, V118, P865, DOI 10.1542/peds.2006-0492; Holubar M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172414; Jardine A, 2010, PEDIATR INFECT DIS J, V29, P607, DOI 10.1097/INF.0b013e3181d7d09c; Lau WCY, 2015, VACCINE, V33, P5072, DOI 10.1016/j.vaccine.2015.08.022; Marom T, 2014, JAMA PEDIATR, V168, P68, DOI 10.1001/jamapediatrics.2013.3924; Nair H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1693-x; Newall AT, 2016, VACCINE, V34, P320, DOI 10.1016/j.vaccine.2015.11.053; Prymula R, 2011, VACCINE, V29, P1959, DOI 10.1016/j.vaccine.2010.12.086; Ray GT, 2009, VACCINE, V27, P6483, DOI 10.1016/j.vaccine.2009.08.045; Reyburn R, 2021, LANCET GLOB HEALTH, V9, pE91, DOI 10.1016/S2214-109X(20)30421-6; Saokaew S, 2016, PHARMACOECONOMICS, V34, P1211, DOI 10.1007/s40273-016-0439-3; Saxena S, 2015, J INFECTION, V71, P428, DOI 10.1016/j.jinf.2015.06.011; Shioda K., 2018, EPIDEMIOLOGY INTERNE, V4, P1; Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0; Sigurdsson S, 2020, VACCINE, V38, P2707, DOI 10.1016/j.vaccine.2020.01.094; Sigurdsson S, 2018, CLIN INFECT DIS, V67, P1213, DOI 10.1093/cid/ciy233; Simonsen L, 2014, LANCET RESP MED, V2, P387, DOI 10.1016/S2213-2600(14)70032-3; Simonsen L, 2011, MBIO, V2, DOI 10.1128/mBio.00309-10; Taylor S, 2012, CLIN INFECT DIS, V54, P1765, DOI 10.1093/cid/cis292; Tregnaghi MW, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001657; Tsaban G, 2017, VACCINE, V35, P2882, DOI 10.1016/j.vaccine.2017.04.032; van de Vooren K, 2014, PHARMACOECONOMICS, V32, P29, DOI 10.1007/s40273-013-0113-y; Vehtari A, 2017, STAT COMPUT, V27, P1413, DOI 10.1007/s11222-016-9696-4; Vojtek I, 2017, INT J PEDIATR OTORHI, V100, P174, DOI 10.1016/j.ijporl.2017.07.009; Warren JL, 2017, CLIN INFECT DIS, V65, P1813, DOI 10.1093/cid/cix638; Wu DBC, 2015, VACCINE, V33, P1633, DOI 10.1016/j.vaccine.2015.01.081	39	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2021	16	4							e0249497	10.1371/journal.pone.0249497	http://dx.doi.org/10.1371/journal.pone.0249497			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM0NQ	33831049	Green Published, gold			2023-01-03	WOS:000639359600025
J	Gilliam, EA; Cheung, T; Kraemer, K; Litrownik, D; Wayne, PM; Moy, ML; Yeh, GY				Gilliam, Elizabeth A.; Cheung, Tina; Kraemer, Kristen; Litrownik, Daniel; Wayne, Peter M.; Moy, Marilyn L.; Yeh, Gloria Y.			The impact of Tai Chi and mind-body breathing in COPD: Insights from a qualitative sub-study of a randomized controlled trial	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC HEART-FAILURE; SELF-EFFICACY; OF-LIFE; CHALLENGES INHERENT; EXERCISE CAPACITY; PHYSICAL-ACTIVITY; BEHAVIOR-CHANGE; HEALTH; REHABILITATION	Purpose Chronic obstructive pulmonary disease (COPD) is associated with multiple psychosocial and behavioral factors. Prior research suggests that mind-body interventions may support the development and maintenance of healthy behaviors and improve health-related quality-of-life in such patients. We sought to qualitatively explore cognitive, psychosocial, and behavioral changes in patients with COPD who participated in two different mind-body interventions compared to an education control. Methods We analyzed semi-structured qualitative exit interviews from a prospective, randomized pilot trial (N = 123) investigating 12-weeks of Tai Chi (TC) vs. mind-body breathing (MBB) vs. education (EDU) control in patients with moderate-severe COPD. TC involved traditional movements, that integrate meditative breathing, while MBB focused mainly on meditative breathing techniques alone. Interviews were audio-recorded and transcribed verbatim. Qualitative analysis of randomly selected transcripts was performed by two independent reviewers using an iterative process to identify emergent themes informed by grounded theory methods until thematic saturation was reached. Results A total of 66 transcripts were reviewed (N = 22 TC, N = 22 MBB, N = 22 EDU). Participants were mean age = 68.1 years, GOLD Stage = 2.3, baseline FEV1(1) percent predicted mean (SD): 58% (13.4), 42.4% female. We identified six frequently mentioned themes: 1) overall awareness and understanding, 2) self-care knowledge, skills and behaviors, 3) behavior-related neurocognitive concepts, 4) physical function, 5) psychological well-being, and 6) social support/social function. Compared to EDU, more participants in TC and MBB noted improvements in awareness of self and the mind-body connection (e.g., body and breath awareness), knowledge of breathing techniques and integration of self-care skills with daily activities, self-efficacy for symptom management (particularly managing anxiety and dyspnea), acceptance of disease, physical function improvements (e.g., endurance, dyspnea, fatigue), and psychological well-being (particularly relaxation, emotion regulation and decreased reactivity). Compared to MBB, those in TC shared more intention to continue with self-care behaviors, physical activity self-efficacy, and improved flexibility. All three groups, including EDU, noted increased social support and knowledge of disease. Those in EDU, however, had fewer mentions of processes related to behavior change, and less concrete changes in neurocognitive, psychological, and physical function domains. Conclusions Mind-body interventions including meditative breathing may impact behavior-related neurocognitive and emotional factors that improve self-care management and support positive behavioral changes in patients with COPD.	[Gilliam, Elizabeth A.; Cheung, Tina; Kraemer, Kristen; Litrownik, Daniel; Yeh, Gloria Y.] Beth Israel Deaconess Med Ctr, Div Gen Med, Dept Med, Brookline, MA 02215 USA; [Kraemer, Kristen; Moy, Marilyn L.] Harvard Med Sch, Boston, MA 02115 USA; [Wayne, Peter M.; Yeh, Gloria Y.] Harvard Med Sch, Osher Ctr Integrat Med, Boston, MA 02115 USA; [Wayne, Peter M.; Yeh, Gloria Y.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Moy, Marilyn L.] Vet Adm Boston Healthcare Syst, Dept Med, Pulm & Crit Care Med Sect, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Gilliam, EA (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med, Dept Med, Brookline, MA 02215 USA.	egilliam@bidmc.harvard.edu		Kraemer, Kristen/0000-0002-5532-0111; Gilliam, Elizabeth/0000-0003-4265-0979; Litrownik, Daniel/0000-0002-5352-0224	National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) [R01AT005436, K24AT009465, K24AT009282]	National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by an award (R01AT005436) from the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) (https://www.nccih.nih.gov/).Dr.Yeh was supported by K24AT009465 from the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) (https://www.nccih.nih.gov/).Dr.Wayne was supported by K24AT009282 from the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) (https://www.nccih.nih.gov/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beauchamp MK, 2013, CHEST, V144, P1124, DOI 10.1378/chest.12-2421; Behera D, 1998, J Assoc Physicians India, V46, P207; Bishop FL, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55100632; Chatzisarantis NLD, 2007, PERS SOC PSYCHOL B, V33, P663, DOI 10.1177/0146167206297401; Cheng M., 1985, MASTER CHENGS 13 CHA; Corhay JL, 2014, INT J CHRONIC OBSTR, V9, P27, DOI 10.2147/COPD.S52012; Curry LA, 2009, CIRCULATION, V119, P1442, DOI 10.1161/CIRCULATIONAHA.107.742775; DeSteno D, 2013, HEALTH PSYCHOL, V32, P474, DOI 10.1037/a0030259; Ding M, 2014, J ALTERN COMPLEM MED, V20, P79, DOI 10.1089/acm.2013.0087; Donesky-Cuenco D, 2009, J ALTERN COMPLEM MED, V15, P225, DOI 10.1089/acm.2008.0389; Emery CF, 1992, J CARDIOPULM REHABIL, V12, P65; Farb N., 2015, FRONT PSYCHOL, P6, DOI [10.3389/fpsyg.2015.00006, DOI 10.3389/FPSYG.2015.00006]; Farver-Vestergaard I, 2015, PSYCHOTHER PSYCHOSOM, V84, P37, DOI 10.1159/000367635; Foley G, 2015, HEALTH SERV RES, V50, P1195, DOI 10.1111/1475-6773.12275; Frantzis B, 2006, OPENING ENERGY GATES; Gardiner C, 2010, RESP MED, V104, P159, DOI 10.1016/j.rmed.2009.09.007; George J, 2005, CHEST, V128, P3198, DOI 10.1378/chest.128.5.3198; Giardino ND, 2004, APPL PSYCHOPHYS BIOF, V29, P121, DOI 10.1023/B:APBI.0000026638.64386.89; Guell MR, 2017, AM J RESP CRIT CARE, V195, P622, DOI 10.1164/rccm.201603-0602OC; Helm B, 2002, TAIJIQUAN J, V2002, P8; Hill K, 2008, EUR RESPIR J, V31, P667, DOI 10.1183/09031936.00125707; Jankowska-Polanska Beata, 2016, Pneumonol Alergol Pol, V84, P3, DOI 10.5603/PiAP.a2015.0079; Jerath R, 2006, MED HYPOTHESES, V67, P566, DOI 10.1016/j.mehy.2006.02.042; Jones P, 2012, INT J CHRONIC OBSTR, V7, P697, DOI 10.2147/COPD.S32675; Kimura H, 2005, J ALTERN COMPLEM MED, V11, P285, DOI 10.1089/acm.2005.11.285; Korpershoek YJG, 2016, INT J CHRONIC OBSTR, V11, P2977, DOI 10.2147/COPD.S116196; Kunik ME, 2001, PSYCHOL MED, V31, P717, DOI 10.1017/S0033291701003890; Lacasse Y, 1996, LANCET, V348, P1115, DOI 10.1016/S0140-6736(96)04201-8; Lacasse Y, 2001, J Cardiopulm Rehabil, V21, P80, DOI 10.1097/00008483-200103000-00004; Li FZ, 2001, J AGING PHYS ACTIV, V9, P161, DOI 10.1123/japa.9.2.161; Lolak S, 2008, PSYCHOTHER PSYCHOSOM, V77, P119, DOI 10.1159/000112889; Louie Stephanie Wai-Shan, 2004, Occup Ther Int, V11, P145, DOI 10.1002/oti.203; Mehling Wolf E, 2011, Philos Ethics Humanit Med, V6, P6, DOI 10.1186/1747-5341-6-6; Meis JJM, 2014, RESP MED, V108, P500, DOI 10.1016/j.rmed.2013.11.001; Nielsen L, 2018, BEHAV RES THER, V101, P3, DOI 10.1016/j.brat.2017.07.002; Osypiuk K., 2020, J ALTERN COMPLEM MED, P1; Osypiuk K, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00174; Pal GK., 2004, INDIAN J MED RES, V7; Peng CK, 1999, INT J CARDIOL, V70, P101, DOI 10.1016/S0167-5273(99)00066-2; Rebar AL, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/s12966-019-0829-y; Ries AL, 2008, RESP CARE, V53, P1203; Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418; Ringbaek T, 2010, J CARDIOPULM REHABIL, V30, P47, DOI 10.1097/HCR.0b013e3181c9c985; Robins CJ, 2012, J CLIN PSYCHOL, V68, P117, DOI 10.1002/jclp.20857; Rydlewska A, 2013, PATIENT PREFER ADHER, V7, P337, DOI 10.2147/PPA.S41863; Salmoirago-Blotcher E, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006603; Schneider J, 2019, OBES REV, V20, P448, DOI 10.1111/obr.12795; Sutherl ER, 2004, NEW ENGL J MED, P9, DOI [10.1056/NEJMp038224, DOI 10.1056/NEJMP038224]; TANDON MK, 1978, THORAX, V33, P514, DOI 10.1136/thx.33.4.514; Tsukino M, 1996, CHEST, V110, P896, DOI 10.1378/chest.110.4.896; Uchmanowicz I, 2016, INT J CHRONIC OBSTR, V11, P963, DOI 10.2147/COPD.S102754; Verhoef MJ, 2002, J ALTERN COMPLEM MED, V8, P275, DOI 10.1089/10755530260127961; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P191, DOI 10.1089/acm.2007.7170B; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P95, DOI 10.1089/acm.2007.7170A; Wayne PM, 2014, J AM GERIATR SOC, V62, P25, DOI 10.1111/jgs.12611; Wu WB, 2014, INT J CHRONIC OBSTR, V9, P1253, DOI 10.2147/COPD.S70862; Yeh G.Y., 2003, J CARD FAIL, V9, pS1, DOI 10.1016/S1071-9164(03)00141-6; Yeh GY, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000697; Yeh GY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154678; Yeh GY, 2016, J CARDIOPULM REHABIL, V36, P186, DOI 10.1097/HCR.0000000000000170; Yeh GY, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-337; Yeh GY, 2011, ARCH INTERN MED, V171, P750, DOI 10.1001/archinternmed.2011.150; Yeh GY, 2004, AM J MED, V117, P541, DOI 10.1016/j.amjmed.2004.04.016; Zhang CQ, 2018, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.02350; Zhang M, 2016, J ALTERN COMPLEM MED, V22, P810, DOI 10.1089/acm.2015.0224	65	4	4	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2021	16	4							e0249263	10.1371/journal.pone.0249263	http://dx.doi.org/10.1371/journal.pone.0249263			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RM0NQ	33831022	gold, Green Published			2023-01-03	WOS:000639359600118
J	Kidwell, K; Albo, C; Pope, M; Bowman, L; Xu, HY; Wells, L; Barrett, N; Patel, N; Allison, A; Kutlar, A				Kidwell, Kyle; Albo, Camila; Pope, Michael; Bowman, Latanya; Xu, Hongyan; Wells, Leigh; Barrett, Nadine; Patel, Niren; Allison, Amy; Kutlar, Abdullah			Characteristics of sickle cell patients with frequent emergency department visits and hospitalizations	PLOS ONE			English	Article								Vaso-occlusive episodes (VOEs) are a hallmark of sickle cell disease (SCD), and account for >90% of health care encounters for this patient population. The Cooperative Study of Sickle Cell Disease, a large study enrolling >3000 patients, showed that the majority of SCD patients (80%) experienced 0-3 major pain crises/year. Only a small minority (similar to 5%) experienced >= 6 VOEs/year. Our study sought to further understand this difference in VOE frequency between SCD patients. We analyzed 25 patients (13M/12F, mean age of 28.8) with >= 6 ED visits or hospitalizations/year (high utilizers), and compared these with 9 patients (6M/3F, mean age of 37.6) who had <= 2 ED visits or hospitalizations/year (low utilizers). All subjects were given a demographic survey along with questionnaires for depression, anxiety, and Health Locus of Control. Each subject then underwent quantitative sensory testing (QST) with three different modalities: pressure pain sensitivity, heat and cold sensitivity, and Von Frey monofilament testing. Laboratory and clinical data were collected through subjects' medical records. CBC and chemistry analysis showed high utilizers had higher WBC (p<0.01), ANC (p<0.01), total bilirubin (p = 0.02), and lower MCV (p = 0.03). Opioid use (morphine equivalents) over the past 6 months was significantly higher in the high utilizer group (12125.7 mg vs 2423.1 mg, p = 0.005). QST results showed lower pressure pain threshold at the ulna (224.4 KPa vs 338.9 KPa, p = 0.04) in the high utilizer group. High utilizers also had higher anxiety (9.0 vs 4.6, p = 0.04) and depression scores (10.0 vs 6.0, p = 0.051). While the low utilizer group had higher education levels with more associate and bachelor degrees (p = 0.009), there was no difference in income or employment. These data show that many biological and psychosocial factors contribute to high health care utilization in SCD. A multi-disciplinary and multi-faceted approach will be required to address this complex problem.	[Kidwell, Kyle] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Kidwell, Kyle; Albo, Camila; Pope, Michael] Augusta Univ, Med Coll Georgia, Augusta, GA USA; [Bowman, Latanya; Wells, Leigh; Barrett, Nadine; Patel, Niren; Kutlar, Abdullah] Augusta Univ, Sickle Cell Ctr, Augusta, GA 30912 USA; [Xu, Hongyan] Augusta Univ, Dept Populat Hlth Sci, Augusta, GA USA; [Allison, Amy] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA	Vanderbilt University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Kutlar, A (corresponding author), Augusta Univ, Sickle Cell Ctr, Augusta, GA 30912 USA.	akutlar@augusta.edu		Albo, Camila/0000-0002-8353-3675				Adam SS, 2017, BLOOD ADV, V1, P1983, DOI 10.1182/bloodadvances.2017006940; Anyaegbu CC, 1998, EUR J HAEMATOL, V60, P267; Belcher JD, 2005, AM J PHYSIOL-HEART C, V288, pH2715, DOI 10.1152/ajpheart.00986.2004; Brandow AM, 2013, AM J HEMATOL, V88, P37, DOI 10.1002/ajh.23341; Campbell CM, 2016, PAIN, V157, P949, DOI 10.1097/j.pain.0000000000000473; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; Chand AR, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.4073.4073; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Curtis SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133116; Hasan SP, 2003, J NATL MED ASSOC, V95, P533; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Laurence B, 2006, J NATL MED ASSOC, V98, P365; Levenson JL, 2008, PSYCHOSOM MED, V70, P192, DOI 10.1097/PSY.0b013e31815ff5c5; Meiler SE, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.1007.1007; Ohene-Frempong K, 1998, BLOOD, V91, P288; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001/jama.289.13.1645; Steiner CA, 2006, HEALTHCARE COST UTIL; Stoicea N, 2015, FRONT PHARMACOL, V6, DOI [10.3382/fphar.2015.00104, 10.3389/fphar.2015.00104]; Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799; Viswanathan K, 2015, J NATL MED ASSOC, V107, P51, DOI 10.1016/S0027-9684(15)30051-1	23	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2021	16	2							e0247324	10.1371/journal.pone.0247324	http://dx.doi.org/10.1371/journal.pone.0247324			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QO3ZL	33617594	Green Published, gold			2023-01-03	WOS:000623082400041
J	Lee, J; Shin, Y; Choi, E; Choi, S; Son, J; Jung, YK; Hong, SB				Lee, Jinmi; Shin, Yujung; Choi, Eunjoo; Choi, Sunhui; Son, Jeongsuk; Jung, Youn Kyung; Hong, Sang-Bum			Impact of hospitalization duration before medical emergency team activation: A retrospective cohort study	PLOS ONE			English	Article								Background The rapid response system has been implemented in many hospitals worldwide and, reportedly, the timing of medical emergency team (MET) attendance in relation to the duration of hospitalization is associated with the mortality of MET patients. We evaluated the relationship between duration of hospitalization before MET activation and patient mortality. We compared cases of MET activation for early, intermediate, and late deterioration to patient characteristics, activation characteristics, and patient outcomes. We also aimed to determine the relationship, after adjusting for confounders, between the duration of hospitalization before MET activation and patient mortality. Materials and methods We retrospectively evaluated patients who triggered MET activation in general wards from March 2009 to February 2015 at the Asan Medical Center in Seoul. Patients were categorized as those with early deterioration (less than 2 days after admission), intermediate deterioration (2-7 days after admission), and late deterioration (more than 7 days after admission) and compared them to patient characteristics, activation characteristics, and patient outcomes. Results Overall, 7114 patients were included. Of these, 1793 (25.2%) showed early deterioration, 2113 (29.7%) showed intermediate deterioration, and 3208 (45.1%) showed late deterioration. Etiologies of MET activation were similar among these groups. The clinical outcomes significantly differed among the groups (intensive care unit transfer: 34.1%, 35.6%, and 40.4%; p < 0.001 and mortality: 26.3%, 31.5%, and 41.2%; p < 0.001 for early, intermediate, and late deterioration, respectively). Compared with early deterioration and adjusted for confounders, the odds ratio of mortality for late deterioration was 1.68 (1.46-1.93). Conclusions Nearly 50% of the acute clinically-deteriorating patients who activated the MET had been hospitalized for more than 7 days. Furthermore, they presented with higher rates of mortality and ICU transfer than patients admitted for less than 7 days before MET activation and had mortality as an independent risk factor.	[Lee, Jinmi; Shin, Yujung; Choi, Eunjoo; Choi, Sunhui; Son, Jeongsuk; Jung, Youn Kyung] Asan Med Ctr, Med Emergency Team, Seoul, South Korea; [Hong, Sang-Bum] Univ Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea	University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Hong, SB (corresponding author), Univ Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea.	sbhong@amc.seoul.kr		Hong, Sang-Bum/0000-0003-2737-7695	Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health & Welfare, Republic of Korea [HI18C0599]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute and was funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0599). The funders had no role in the study design, data collection and analysis, manuscript preparation, or decision to publish.	Ahn JH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233078; Alp E, 2018, AUST CRIT CARE, V31, P363, DOI 10.1016/j.aucc.2017.10.005; Boniatti MM, 2010, RESUSCITATION, V81, P667, DOI 10.1016/j.resuscitation.2010.01.025; Calzavacca P, 2010, RESUSCITATION, V81, P1509, DOI 10.1016/j.resuscitation.2010.06.017; Casamento Andrew J, 2008, Crit Care Resusc, V10, P29; DeVita MA, 2006, CRIT CARE MED, V34, P2463, DOI 10.1097/01.CCM.0000235743.38172.6E; Downar J, 2013, RESUSCITATION, V84, P1339, DOI 10.1016/j.resuscitation.2013.03.003; Echevarria C, 2019, THORAX, V74, P941, DOI 10.1136/thoraxjnl-2019-213470; Hodgson LE, 2017, THORAX, V72, P23, DOI 10.1136/thoraxjnl-2016-208436; Huh JW, 2014, CRIT CARE MED, V42, P801, DOI 10.1097/CCM.0000000000000031; Jaderling G, 2011, INTENS CARE MED, V37, P1000, DOI 10.1007/s00134-011-2156-x; Jones D, 2013, CRIT CARE RESUSC, V15, P15; Jones D, 2013, CURR OPIN CRIT CARE, V19, P616, DOI 10.1097/MCC.0b013e3283636be2; Jones Daryl A, 2007, Crit Care Resusc, V9, P151; Jones DA, 2011, NEW ENGL J MED, V365, P139, DOI 10.1056/NEJMra0910926; Jones DA, 2012, CRIT CARE MED, V40, P98, DOI 10.1097/CCM.0b013e31822e9d50; Kim WY, 2017, J CRIT CARE, V40, P213, DOI 10.1016/j.jcrc.2017.04.024; Lee BY, 2019, ACUTE CRIT CARE, V34, P108, DOI 10.4266/acc.2019.00535; Lyons Patrick G, 2019, J Oncol Pract, V15, pe652, DOI 10.1200/JOP.18.00765; Micallef S, 2011, RESUSCITATION, V82, P815, DOI 10.1016/j.resuscitation.2011.02.048; Smith RJ, 2015, J CRIT CARE, V30, P692, DOI 10.1016/j.jcrc.2015.04.004; Stelfox HT, 2014, CRIT CARE MED, V42, P1601, DOI 10.1097/CCM.0000000000000315	22	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2021	16	2							e0247066	10.1371/journal.pone.0247066	http://dx.doi.org/10.1371/journal.pone.0247066			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8KQ	33606743	Green Published, gold			2023-01-03	WOS:000620629200006
J	Blasche, G; DeBloom, J; Chang, A; Pichlhoefer, O				Blasche, Gerhard; DeBloom, Jessica; Chang, Adrienne; Pichlhoefer, Otto			Is a meditation retreat the better vacation? effect of retreats and vacations on fatigue, emotional well-being, and acting with awareness	PLOS ONE			English	Article							QUALITY-OF-LIFE; MEASURING MINDFULNESS; PSYCHOLOGICAL HEALTH; KENTUCKY INVENTORY; SELF-COMPASSION; GERMAN VERSION; RECOVERY; STRESS; WORK; RESPITE	It is well established that leisure vacations markedly improve well-being, but that these effects are only of short duration. The present study aimed to investigate whether vacation effects would be more lasting if individuals practiced meditation during the leisure episode. Meditation is known to improve well-being durably, among others, by enhancing the mental faculty of mindfulness. In this aim, leisure vacations during which individuals practiced meditation to some extent were compared with holidays not including any formal meditation practice as well as with meditation retreats (characterized by intense meditation practice) utilizing a naturalistic observational design. Fatigue, well-being, and mindfulness were assessed ten days before, ten days after, and ten weeks after the stays in a sample of 120 individuals accustomed to meditation practices. To account for differences in the experience of these stays, recovery experiences were additionally assessed. Ten days after the stay, there were no differences except for an increase in mindfulness for those practicing meditation. Ten weeks after the stay, meditation retreats and vacations including meditation were associated with greater increases in mindfulness, lower levels of fatigue, and higher levels of well-being than an "ordinary" vacation during which meditation was not practiced. The finding suggests that the inclusion of meditation practice during vacation could help alleviate vacations' greatest pitfall, namely the rapid decline of its positive effects.	[Blasche, Gerhard] Med Univ Vienna, Ctr Publ Hlth, Dept Environm Hlth, Vienna, Austria; [DeBloom, Jessica] Tampere Univ, Fac Social Sci, Dept Psychol, Tampere, Finland; [DeBloom, Jessica] Univ Groningen, Fac Econ & Business, Groningen, Netherlands; [Chang, Adrienne] Miami Univ, Dept Sociol & Gerontol, Miami, FL USA; [Pichlhoefer, Otto] Med Univ Vienna, Ctr Publ Hlth, Dept Gen Practice & Family Med, Vienna, Austria	Medical University of Vienna; Tampere University; University of Groningen; Medical University of Vienna	Blasche, G (corresponding author), Med Univ Vienna, Ctr Publ Hlth, Dept Environm Hlth, Vienna, Austria.	gerhard.blasche@meduniwien.at		De Bloom, Jessica/0000-0003-2359-0587; Pichlhofer, Otto/0000-0002-5294-6661; Blasche, Gerhard/0000-0002-4779-4843				Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504; Baer RA, 2004, ASSESSMENT, V11, P191, DOI 10.1177/1073191104268029; Baer RA, 2012, J POSIT PSYCHOL, V7, P230, DOI 10.1080/17439760.2012.674548; Baer RA, 2012, J CLIN PSYCHOL, V68, P755, DOI 10.1002/jclp.21865; Bech P, 2003, INT J METH PSYCH RES, V12, P85, DOI 10.1002/mpr.145; Bennett AA, 2018, J ORGAN BEHAV, V39, P262, DOI 10.1002/job.2217; Blasche G, 2018, STRESS HEALTH, V34, P629, DOI 10.1002/smi.2830; Blasche GW, 2014, LEISURE SCI, V36, P235, DOI 10.1080/01490400.2014.886981; Braher E, 2007, DIAGNOSTICA, V53, P83, DOI 10.1026/0012-1924.53.2.83; Brown KW, 2004, CLIN PSYCHOL-SCI PR, V11, P242, DOI 10.1093/clipsy/bph078; Carmody J, 2008, J BEHAV MED, V31, P23, DOI 10.1007/s10865-007-9130-7; Chen CC, 2013, J TRAVEL RES, V52, P709, DOI 10.1177/0047287513496477; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen-Katz Joanne, 2005, Holist Nurs Pract, V19, P26; COLEMAN D, 1993, J LEISURE RES, V25, P111, DOI 10.1080/00222216.1993.11969913; Crompton J. L., 1979, Annals of Tourism Research, V6, P408, DOI 10.1016/0160-7383(79)90004-5; Dahl CJ, 2015, TRENDS COGN SCI, V19, P515, DOI 10.1016/j.tics.2015.07.001; de Bloom J, 2012, J HAPPINESS STUD, P1; de Bloom J, 2014, STRESS HEALTH, V30, P232, DOI 10.1002/smi.2600; de Bloom J, 2011, PSYCHOL HEALTH, V26, P1606, DOI 10.1080/08870446.2010.546860; de Bloom J, 2010, WORK STRESS, V24, P196, DOI 10.1080/02678373.2010.493385; de Bloom J, 2009, J OCCUP HEALTH, V51, P13, DOI 10.1539/joh.K8004; Eden D., 2001, RES OCCUPATIONAL STR, P143; Epel ES, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.164; Etzion D, 2003, ANXIETY STRESS COPIN, V16, P213, DOI 10.1080/1061580021000069425; Falkenstrom F, 2010, PERS INDIV DIFFER, V48, P305, DOI 10.1016/j.paid.2009.10.022; Farias M, 2020, ACTA PSYCHIAT SCAND, V142, P374, DOI 10.1111/acps.13225; Flaxman PE, 2012, J APPL PSYCHOL, V97, P854, DOI 10.1037/a0028055; Fritz C, 2006, J APPL PSYCHOL, V91, P936, DOI 10.1037/0021-9010.91.4.936; Fritz C, 2010, J ORGAN BEHAV, V31, P1137, DOI 10.1002/job.672; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Jacobs TL, 2013, HEALTH PSYCHOL, V32, P1104, DOI 10.1037/a0031362; Jacobs TL, 2011, PSYCHONEUROENDOCRINO, V36, P664, DOI 10.1016/j.psyneuen.2010.09.010; Keng SL, 2011, CLIN PSYCHOL REV, V31, P1041, DOI 10.1016/j.cpr.2011.04.006; Khoury B, 2017, J PSYCHOSOM RES, V92, P16, DOI 10.1016/j.jpsychores.2016.11.006; King BG, 2019, CURR OPIN PSYCHOL, V28, P238, DOI 10.1016/j.copsyc.2018.12.021; Kozasa EH, 2015, MINDFULNESS, V6, P1235, DOI 10.1007/s12671-015-0385-8; Krajewski J, 2010, J OCCUP HEALTH PSYCH, V15, P131, DOI 10.1037/a0018830; Kuhnel J, 2011, J ORGAN BEHAV, V32, P125, DOI 10.1002/job.699; Lara-Cabrera ML, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113268; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Lutz A, 2015, AM PSYCHOL, V70, P632, DOI 10.1037/a0039585; Marzuq N, 2012, WORK STRESS, V26, P175, DOI 10.1080/02678373.2012.683574; McClintock AS, 2019, MINDFULNESS, V10, P1443, DOI 10.1007/s12671-019-01123-9; Michielsen HJ, 2003, J PSYCHOSOM RES, V54, P345, DOI 10.1016/S0022-3999(02)00392-6; Montero-Marin J, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01935; Nawijn J, 2011, J HAPPINESS STUD, V12, P651, DOI 10.1007/s10902-010-9221-y; Nawijn J, 2011, J TRAVEL RES, V50, P559, DOI 10.1177/0047287510379164; Norman A, 2017, TOUR MANAG PERSPECT, V24, P201, DOI 10.1016/j.tmp.2017.07.012; Nyklicek I, 2008, ANN BEHAV MED, V35, P331, DOI 10.1007/s12160-008-9030-2; Sandra BK, 2011, EMOTION, V11, P299, DOI 10.1037/a0022764; Schlosser M, 2022, CURR PSYCHOL, V41, P3144, DOI 10.1007/s12144-020-00839-5; Schlosser M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216643; Shapiro SL, 2011, J CLIN PSYCHOL, V67, P267, DOI 10.1002/jclp.20761; Sluiter JK, 2003, OCCUP ENVIRON MED, V60, P62; Snippe E, 2015, J COUNS PSYCHOL, V62, P106, DOI 10.1037/cou0000057; Sonnentag S, 2006, J APPL PSYCHOL, V91, P330, DOI 10.1037/0021-9010.91.2.330; Sonnentag S, 2007, J OCCUP HEALTH PSYCH, V12, P204, DOI 10.1037/1076-8998.12.3.204; Sonnentag S, 2017, J OCCUP HEALTH PSYCH, V22, P365, DOI 10.1037/ocp0000079; Strauss-Blasche G, 2000, OCCUP MED-OXFORD, V50, P167, DOI 10.1093/occmed/50.3.167; Strauss-Blasche G, 2005, J TRAVEL MED, V12, P94; Strauss-Blasche GS, 2004, J TRAVEL MED, V11, P300, DOI 10.2310/7060.2004.19106; Strohle G, 2010, Z KL PSYCH PSYCHOTH, V39, P1, DOI 10.1026/1616-3443/a000001; Su R, 2014, APPL PSYCHOL-HLTH WE, V6, P251, DOI 10.1111/aphw.12027; Visted E, 2015, MINDFULNESS, V6, P501, DOI 10.1007/s12671-014-0283-5; Waterman AS, 2008, J HAPPINESS STUD, V9, P41, DOI 10.1007/s10902-006-9020-7; Westman M, 1997, J APPL PSYCHOL, V82, P516, DOI 10.1037/0021-9010.82.4.516; Westman M, 2001, PSYCHOL HEALTH, V16, P595, DOI 10.1080/08870440108405529	69	2	2	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2021	16	2							e0246038	10.1371/journal.pone.0246038	http://dx.doi.org/10.1371/journal.pone.0246038			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG1VY	33556137	gold, Green Published			2023-01-03	WOS:000617379900045
J	Rozeman, EA; Hoefsmit, EP; Reijers, ILM; Saw, RPM; Versluis, JM; Krijgsman, O; Dimitriadis, P; Sikorska, K; van de Wiel, BA; Eriksson, H; Gonzalez, M; Acosta, AT; Grijpink-Ongering, LG; Shannon, K; Haanen, JBAG; Stretch, J; Ch'ng, S; Nieweg, OE; Mallo, HA; Adriaansz, S; Kerkhoven, RM; Cornelissen, S; Broeks, A; Klop, WMC; Zuur, CL; van Houdt, WJ; Peeper, DS; Spillane, AJ; van Akkooi, ACJ; Scolyer, RA; Schumacher, TNM; Menzies, AM; Long, GV; Blank, CU				Rozeman, E. A.; Hoefsmit, E. P.; Reijers, I. L. M.; Saw, R. P. M.; Versluis, J. M.; Krijgsman, O.; Dimitriadis, P.; Sikorska, K.; van de Wiel, B. A.; Eriksson, H.; Gonzalez, M.; Torres Acosta, A.; Grijpink-Ongering, L. G.; Shannon, K.; Haanen, J. B. A. G.; Stretch, J.; Ch'ng, S.; Nieweg, O. E.; Mallo, H. A.; Adriaansz, S.; Kerkhoven, R. M.; Cornelissen, S.; Broeks, A.; Klop, W. M. C.; Zuur, C. L.; van Houdt, W. J.; Peeper, D. S.; Spillane, A. J.; van Akkooi, A. C. J.; Scolyer, R. A.; Schumacher, T. N. M.; Menzies, A. M.; Long, G. V.; Blank, C. U.			Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma	NATURE MEDICINE			English	Article							CLINICAL-RESPONSE; NIVOLUMAB; EFFICACY; THERAPY; CHECKPOINTS; IPILIMUMAB; EXPRESSION; SIGNATURES; CELLS; VEGF	Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN () and phase 2 OpACIN-neo () studies(1,2). While the results are promising, data on the durability of these pathologic responses and baseline biomarkers for response and survival were lacking. After a median follow-up of 4 years, none of the patients with a pathologic response (n = 7/9 patients) in the OpACIN study had relapsed. In OpACIN-neo (n = 86), the 2-year estimated relapse-free survival was 84% for all patients, 97% for patients achieving a pathologic response and 36% for nonresponders (P < 0.001). High tumor mutational burden (TMB) and high interferon-gamma-related gene expression signature score (IFN-gamma score) were associated with pathologic response and low risk of relapse; pRR was 100% in patients with high IFN-gamma score/high TMB; patients with high IFN-gamma score/low TMB or low IFN-gamma score/high TMB had pRRs of 91% and 88%; while patients with low IFN-gamma score/low TMB had a pRR of only 39%. These data demonstrate long-term benefit in patients with a pathologic response and show the predictive potential of TMB and IFN-gamma score. Our findings provide a strong rationale for a randomized phase 3 study comparing neoadjuvant ipilimumab plus nivolumab versus standard adjuvant therapy with antibodies against the programmed cell death protein-1 (anti-PD-1) in macroscopic stage III melanoma.	[Rozeman, E. A.; Reijers, I. L. M.; Versluis, J. M.; Haanen, J. B. A. G.; Mallo, H. A.; Adriaansz, S.; Blank, C. U.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Hoefsmit, E. P.; Krijgsman, O.; Dimitriadis, P.; Haanen, J. B. A. G.; Peeper, D. S.; Schumacher, T. N. M.; Blank, C. U.] Netherlands Canc Inst, Dept Mol Oncol & Immunol, Amsterdam, Netherlands; [Saw, R. P. M.; Gonzalez, M.; Shannon, K.; Stretch, J.; Ch'ng, S.; Nieweg, O. E.; Spillane, A. J.; Scolyer, R. A.; Menzies, A. M.; Long, G. V.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Saw, R. P. M.; Stretch, J.; Ch'ng, S.; Nieweg, O. E.; Spillane, A. J.] Mater Hosp, Dept Surg, Sydney, NSW, Australia; [Saw, R. P. M.; Shannon, K.; Stretch, J.; Ch'ng, S.; Nieweg, O. E.] Royal Prince Alfred Hosp, Dept Surg, Sydney, NSW, Australia; [Krijgsman, O.; Peeper, D. S.; Schumacher, T. N. M.] Oncode Inst, Utrecht, Netherlands; [Sikorska, K.; Torres Acosta, A.; Grijpink-Ongering, L. G.] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands; [van de Wiel, B. A.] Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands; [Eriksson, H.] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden; [Eriksson, H.] Karolinska Univ Hosp, Theme Canc, Skin Canc Ctr, Dept Oncol, Stockholm, Sweden; [Kerkhoven, R. M.] Netherlands Canc Inst, Genom Core Facil, Amsterdam, Netherlands; [Cornelissen, S.; Broeks, A.] Netherlands Canc Inst, Core Facil Mol Pathol & Biobanking, Amsterdam, Netherlands; [Klop, W. M. C.; Zuur, C. L.; van Houdt, W. J.; van Akkooi, A. C. J.] Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands; [Spillane, A. J.] Royal North Shore Hosp, Breast & Melanoma Surg Unit, Sydney, NSW, Australia; [Scolyer, R. A.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia; [Scolyer, R. A.] New South Wales Hlth Pathol, Sydney, NSW, Australia; [Menzies, A. M.; Long, G. V.] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, NSW, Australia	Netherlands Cancer Institute; Netherlands Cancer Institute; Melanoma Institute Australia; University of Sydney; University of Sydney; Netherlands Cancer Institute; Netherlands Cancer Institute; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Royal North Shore Hospital; University of Sydney; Royal North Shore Hospital	Blank, CU (corresponding author), Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.; Blank, CU (corresponding author), Netherlands Canc Inst, Dept Mol Oncol & Immunol, Amsterdam, Netherlands.	c.blank@nki.nl	Scolyer, Richard/AAE-8511-2019; Schumacher, Ton/Y-2432-2019; Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Shannon, Kerwin/AAP-8209-2021; Long, Georgina/C-1771-2013; Stretch AM D.Phil(Oxon), FRACS, Jonathan/M-7532-2014	Scolyer, Richard/0000-0002-8991-0013; Schumacher, Ton/0000-0003-0517-8804; Haanen, John/0000-0001-5884-7704; Versluis, Judith M./0000-0002-3423-9912; Long, Georgina/0000-0001-8894-3545; Dimitriadis, Petros/0000-0002-3546-285X; Stretch AM D.Phil(Oxon), FRACS, Jonathan/0000-0002-2556-2005; Ch'ng, Sydney/0000-0002-4011-1253; Shannon, Kerwin/0000-0001-8538-3132; Hoefsmit, Esmee/0000-0002-3989-8175	Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship; Medical Foundation at the University of Sydney; Cancer Institute New South Wales fellowship; Melanoma Institute Australia; NHMRC Practitioner Fellowship; Australian NHMRC program grant; Ainsworth Foundation; Fairfax Foundation	Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Medical Foundation at the University of Sydney; Cancer Institute New South Wales fellowship; Melanoma Institute Australia; NHMRC Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Australian NHMRC program grant(National Health and Medical Research Council (NHMRC) of Australia); Ainsworth Foundation; Fairfax Foundation	We thank the patients and their families for participating in the study. We thank all investigators and members of the clinical trial teams in Melanoma Institute Australia, the Netherlands Cancer Institute and the Karolinska Institutet; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Core Facility Molecular Pathology & Biobanking for supplying biobank material and/or laboratory support; the Genomics Core Facility for their support regarding sequencing; and S. Vanhoutvin for financial management. We acknowledge A. Evans and B. Stegenga from Bristol Myers Squibb for scientific input and support. G.V.L. is supported by an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship and the Medical Foundation at the University of Sydney. A.M.M. is supported by Cancer Institute New South Wales fellowship and Melanoma Institute Australia. R.A.S. is supported by NHMRC Practitioner Fellowship. Support from an Australian NHMRC program grant (to G.V.L. and R.A.S.), the Ainsworth Foundation, the Fairfax Foundation and the Cameron family is also gratefully acknowledged. The authors also acknowledge assistance from colleagues at their various institutions.	Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Ascierto PA, 2020, LANCET ONCOL, V21, P1465, DOI 10.1016/S1470-2045(20)30494-0; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Blank CU, 2020, J CLIN ONCOL, V38; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Bloemendal M, 2019, ANN SURG ONCOL, V26, P3945, DOI 10.1245/s10434-019-07274-2; Bourgeois-Daigneault MC, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao1641; Brockwell NK, 2017, CANCER IMMUNOL RES, V5, P871, DOI 10.1158/2326-6066.CIR-17-0150; Brooks J, 2018, CANCER RES, V78, P475, DOI 10.1158/0008-5472.CAN-17-2415; Chae YK, 2019, ONCOLOGIST, V24, P820, DOI 10.1634/theoncologist.2018-0433; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dummer R, 2020, LANCET ONCOL, V21, P358, DOI 10.1016/S1470-2045(20)30062-0; Eggermont AMM, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.02110; Eggermont AMM, 2020, JAMA ONCOL, V6, P519, DOI 10.1001/jamaoncol.2019.5570; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Fancello L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0647-4; Hauschild A, 2018, J CLIN ONCOL, V36, P3441, DOI 10.1200/JCO.18.01219; Hodi FS, 2018, LANCET ONCOL, V19, P1480, DOI 10.1016/S1470-2045(18)30700-9; Lee JH, 2019, ANN ONCOL, V30, P815, DOI 10.1093/annonc/mdz075; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu S, 2019, JAMA ONCOL, V5, P1195, DOI 10.1001/jamaoncol.2019.1549; Mandala M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.9584; Menzies AM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.9503; O'Donnell JS, 2019, CLIN CANCER RES, V25, P5743, DOI 10.1158/1078-0432.CCR-18-2641; Ott PA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00202; Rowe SP, 2018, MOL ONCOL, V12, P1661, DOI 10.1002/1878-0261.12373; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226; Stormo Gary D, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1110s43, 10.1002/0471250953.bi1201s43]; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Yuan JD, 2014, CANCER IMMUNOL RES, V2, P127, DOI 10.1158/2326-6066.CIR-13-0163	39	81	80	4	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					256	+		10.1038/s41591-020-01211-7	http://dx.doi.org/10.1038/s41591-020-01211-7		FEB 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33558721				2023-01-03	WOS:000616056700002
J	Szczepaniak, O; Jokiel, M; Stuper-Szablewska, K; Szymanowska, D; Dziedzinski, M; Kobus-Cisowska, J				Szczepaniak, Oskar; Jokiel, Maria; Stuper-Szablewska, Kinga; Szymanowska, Daria; Dziedzinski, Marcin; Kobus-Cisowska, Joanna			Can cornelian cherry mask bitter taste of probiotic chocolate? Human TAS2R receptors and a sensory study with comprehensive characterisation of new functional product	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; DARK CHOCOLATE; POLYPHENOLS; HEALTH; COCOA; SWEET; L.	Cornelian cherry (Cornus mas L.) fruits are a valuable source of bioactive compounds that are responsible for the perception of bitter taste of chocolate products. The aim of the study was to validate the inhibitory effect of Cornus mas on the TAS2R3 and TAS2R13 bitter taste receptors and to assess the effect of masking the bitter taste of dark chocolate with the help of the sensory panel. Dark chocolate was prepared with an addition of 5% of freeze-dried cornelian cherry fruits and 10(8) CFU/g of Bacillus coagulans probiotic strains. Effect on the TAS2R receptors was evaluated in specially transfected HEK293T cells, and the inhibition ratio was measured using the calcium release test. Moreover, the total polyphenol content, antioxidant activity and simulated intestinal in vitro digestion were determined for the samples. The tested chocolate products were rich in chlorogenic, caffeic and sinapic acids. The addition of cornelian cherry positively affected the antioxidant activity. The phytochemicals of Cornus mas decreased the TAS2R13 activity by 132% after a 2-minute interaction and, % at the same time, inhibited the TAS2R3 activity by 11.5. Meanwhile, chocolate with the addition of fruit was less bitter according to the sensory panel.	[Szczepaniak, Oskar; Dziedzinski, Marcin; Kobus-Cisowska, Joanna] Poznan Univ Life Sci, Dept Gastron Sci & Funct Foods, Poznan, Poland; [Jokiel, Maria] PORT Polish Ctr Technol Dev, Wroclaw, Poland; [Stuper-Szablewska, Kinga] Poznan Univ Life Sci, Dept Chem, Poznan, Poland; [Szymanowska, Daria] Poznan Univ Life Sci, Dept Biotechnol & Food Microbiol, Poznan, Poland	Poznan University of Life Sciences; Poznan University of Life Sciences; Poznan University of Life Sciences	Szczepaniak, O (corresponding author), Poznan Univ Life Sci, Dept Gastron Sci & Funct Foods, Poznan, Poland.	oskar.szczepaniak@up.poznan.pl	Szczepaniak, Oskar/AAG-3231-2019; Dziedziński, Marcin/AAK-4211-2020	Szczepaniak, Oskar/0000-0002-9498-819X; Szymanowska-Powalowska, Daria/0000-0002-4665-1576; Stuper-Szablewska, Kinga/0000-0002-9011-8592	Ministry of Science and Higher Education: "Support in management of scientific research and results commercialization of RAMP;D works in scientific centers and entrepreneurships"; European Union in range of Intelligent Development Operational Program 2014-2020 (Act 4.4) [MNiSW/2019/170/RID]; National Centre for Research and Development in Poland [POIR.04.01.02-00-0059/17]; Polish Ministry of Science and Higher Education [005/RID/2018/19]	Ministry of Science and Higher Education: "Support in management of scientific research and results commercialization of RAMP;D works in scientific centers and entrepreneurships"; European Union in range of Intelligent Development Operational Program 2014-2020 (Act 4.4); National Centre for Research and Development in Poland(National Centre for Research & Development, Poland); Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	This work was co-financed as a development-application project (J.K-C.): "Functional chocolate lines with cornelian cherry fruit preparations, as a matrix for pro-health ingredients", conducted within "Innovation Incubator" program, realized as a part of out-competition project of Ministry of Science and Higher Education: "Support in management of scientific research and results commercialization of R&D works in scientific centers and entrepreneurships", co-financed with sources of European Union in range of Intelligent Development Operational Program 2014-2020 (Act 4.4) MNiSW/2019/170/RID. www.gov.pl/web/science/This work was co-financed (J.K-C.) with grant POIR.04.01.02-00-0059/17 from the National Centre for Research and Development in Poland (www.ncbr.gov.pl).Publication was co-financed within the framework of the Polish Ministry of Science and Higher Education's program: "Regional Initiative Excellence" in the years 2019-2022 (No. 005/RID/2018/19)", financing amount 12 000 00 PLN. www.gov.pl/web/science/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amarowicz R, 2000, J AGR FOOD CHEM, V48, P2755, DOI 10.1021/jf9911601; [Anonymous], 2016, GIDA J FOOD; Belscak-Cvitanovic A, 2012, FOOD RES INT, V48, P820, DOI 10.1016/j.foodres.2012.06.023; Cakmakci S, 2010, INT J FOOD PROP, V13, P713, DOI 10.1080/10942910902804459; Camu N, 2008, J SCI FOOD AGR, V88, P2288, DOI 10.1002/jsfa.3349; Cao J, 2020, J FUNCT FOODS, V64, DOI 10.1016/j.jff.2019.103643; Di Pizio A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061402; Di Pizio A, 2019, NEUROSCI LETT, V700, P56, DOI 10.1016/j.neulet.2018.04.027; Endres JR, 2009, FOOD CHEM TOXICOL, V47, P1231, DOI 10.1016/j.fct.2009.02.018; Gil-Sanchez I, 2020, FOOD RES INT, V129, DOI 10.1016/j.foodres.2019.108790; Hinneh M, 2020, FOOD RES INT, V132, DOI 10.1016/j.foodres.2020.109116; Kalman DS, 2018, J PROB HLTH, V6, P1, DOI 10.4172/2329-8901.1000190.; Kavak DD, 2018, J FOOD PROCESS PRES, V42, DOI 10.1111/jfpp.13656; Kawa-Rygielska J, 2019, FOOD CHEM, V281, P147, DOI 10.1016/j.foodchem.2018.12.093; Kawa-Rygielska J, 2018, MOLECULES, V23, DOI 10.3390/molecules23020379; Kazimierski M, 2019, ACTA SCI POLON-TECHN, V18, P5, DOI [10.17306/j.afs.2019.0628, 10.17306/J.AFS.0628, 10.17306/J.AFS.2019.0628]; Kobus-Cisowska J, 2020, CIENC RURAL, V50, DOI 10.1590/0103-8478cr20190371; Kobus-Cisowska J, 2019, FOOD FUNCT, V10, P997, DOI [10.1039/c8fo02099j, 10.1039/C8FO02099J]; Komes D, 2013, LWT-FOOD SCI TECHNOL, V53, P360, DOI 10.1016/j.lwt.2013.02.016; Konuray G, 2018, FOODS, V7, DOI 10.3390/foods7060092; Ley JP, 2008, CHEMOSENS PERCEPT, V1, P58, DOI 10.1007/s12078-008-9008-2; Ley JP, 2005, J AGR FOOD CHEM, V53, P6061, DOI 10.1021/jf0505170; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Lingua MS, 2019, FOOD RES INT, V122, P496, DOI 10.1016/j.foodres.2019.05.022; Loncarevic I, 2018, LWT-FOOD SCI TECHNOL, V92, P458, DOI 10.1016/j.lwt.2018.03.002; Masuda K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035380; McShea A, 2008, NUTR REV, V66, P630, DOI 10.1111/j.1753-4887.2008.00114.x; Mellor DD, 2018, INT J FOOD SCI TECH, V53, P33, DOI 10.1111/ijfs.13651; Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092; Newman J, 2015, LWT-FOOD SCI TECHNOL, V63, P751, DOI 10.1016/j.lwt.2015.03.019; Ochmian I, 2019, SCI HORTIC-AMSTERDAM, V256, DOI 10.1016/j.scienta.2019.108588; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Roland WSU, 2013, J AGR FOOD CHEM, V61, P10454, DOI 10.1021/jf403387p; Roland WSU, 2014, INTRINSIC BITTERNESS; Salejda AM, 2018, J FOOD QUALITY, DOI 10.1155/2018/1563651; Sim SYJ, 2016, FOOD CHEM, V200, P46, DOI 10.1016/j.foodchem.2015.12.092; Stuper-Szablewska K, 2017, CHEM ECOL, V33, P949, DOI 10.1080/02757540.2017.1381689; Szczepaniak O, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050700; Szczepaniak OM, 2019, CYTA-J FOOD, V17, P781, DOI 10.1080/19476337.2019.1653378; Tarko T, 2009, FOOD TECHNOL BIOTECH, V47, P456; Toker OS, 2020, TRENDS FOOD SCI TECH, V99, P580, DOI 10.1016/j.tifs.2020.03.035; Topdas EF, 2017, KAFKAS UNIV VET FAK, V23, P691, DOI 10.9775/kvfd.2016.17298; Virgili F, 2000, FREE RADICAL BIO MED, V28, P1249, DOI 10.1016/S0891-5849(00)00244-6; Yousuf S, 2013, AAPS PHARMSCITECH, V14, P770, DOI 10.1208/s12249-013-9963-z	44	0	0	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2021	16	2							e0243871	10.1371/journal.pone.0243871	http://dx.doi.org/10.1371/journal.pone.0243871			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG1VY	33556063	gold, Green Published			2023-01-03	WOS:000617379900035
J	Workman, AD; Jafari, A; Xiao, R; Bleier, BS				Workman, Alan D.; Jafari, Aria; Xiao, Roy; Bleier, Benjamin S.			Airborne aerosol olfactory deposition contributes to anosmia in COVID-19	PLOS ONE			English	Article								Introduction Olfactory dysfunction (OD) affects a majority of COVID-19 patients, is atypical in duration and recovery, and is associated with focal opacification and inflammation of the olfactory epithelium. Given recent increased emphasis on airborne transmission of SARS-CoV-2, the purpose of the present study was to experimentally characterize aerosol dispersion within olfactory epithelium (OE) and respiratory epithelium (RE) in human subjects, to determine if small (sub 5 mu m) airborne aerosols selectively deposit in the OE. Methods Healthy adult volunteers inhaled fluorescein-labeled nebulized 0.5-5 mu m airborne aerosol or atomized larger aerosolized droplets (30-100 mu m). Particulate deposition in the OE and RE was assessed by blue-light filter modified rigid endoscopic evaluation with subsequent image randomization, processing and quantification by a blinded reviewer. Results 0.5-5 mu m airborne aerosol deposition, as assessed by fluorescence gray value, was significantly higher in the OE than the RE bilaterally, with minimal to no deposition observed in the RE (maximum fluorescence: OE 19.5(IQR 22.5), RE 1(IQR 3.2), p<0.001; average fluorescence: OE 2.3(IQR 4.5), RE 0.1(IQR 0.2), p<0.01). Conversely, larger 30-100 mu m aerosolized droplet deposition was significantly greater in the RE than the OE (maximum fluorescence: OE 13(IQR 14.3), RE 38(IQR 45.5), p<0.01; average fluorescence: OE 1.9(IQR 2.1), RE 5.9(IQR 5.9), p<0.01). Conclusions Our data experimentally confirm that despite bypassing the majority of the upper airway, small-sized (0.5-5 mu m) airborne aerosols differentially deposit in significant concentrations within the olfactory epithelium. This provides a compelling aerodynamic mechanism to explain atypical OD in COVID-19.	[Workman, Alan D.; Jafari, Aria; Xiao, Roy; Bleier, Benjamin S.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA; [Workman, Alan D.; Jafari, Aria; Xiao, Roy; Bleier, Benjamin S.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School	Workman, AD (corresponding author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.; Workman, AD (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	Alan_Workman@meei.harvard.edu		Xiao, Roy/0000-0003-4459-0746				Brann DH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc5801; Eliezer M, 2020, JAMA OTOLARYNGOL, V146, P674, DOI 10.1001/jamaoto.2020.0832; Jones RM, 2015, J OCCUP ENVIRON MED, V57, P501, DOI 10.1097/JOM.0000000000000448; Kaye R, 2020, OTOLARYNG HEAD NECK, V163, P132, DOI 10.1177/0194599820922992; Menni C, 2020, NAT MED, V26, P1037, DOI 10.1038/s41591-020-0916-2; Moein ST, 2020, INT FORUM ALLERGY RH, V10, P944, DOI 10.1002/alr.22587; Morawska L, 2020, CLIN INFECT DIS, V71, P2311, DOI 10.1093/cid/ciaa939; Tong JY, 2020, OTOLARYNG HEAD NECK, V163, P3, DOI 10.1177/0194599820926473; World Health Organization, 2020, TRANSM SARS COV2 IMP; Yan CRH, 2020, INT FORUM ALLERGY RH, V10, P821, DOI 10.1002/alr.22592; Yan CG, 2021, IEEE T PATTERN ANAL, V43, P1445, DOI 10.1109/TPAMI.2020.2975798	11	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2021	16	2							e0244127	10.1371/journal.pone.0244127	http://dx.doi.org/10.1371/journal.pone.0244127			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH0TZ	33544701	gold, Green Published			2023-01-03	WOS:000617991900016
J	Westergren, A; Ahlstrom, G; Persson, M; Behm, L				Westergren, Albert; Ahlstrom, Gerd; Persson, Magnus; Behm, Lina			Next of kin participation in the care of older persons in nursing homes: A pre-post non-randomised educational evaluation, using within-group and individual person-level comparisons	PLOS ONE			English	Article							LONG-TERM-CARE; FAMILY-MEMBERS; EFFECT SIZES; HEALTH; EXPERIENCES; CAREGIVERS; PEOPLE	Background Next of kin participation in care is a cornerstone of palliative care and is thus important in nursing homes, and outcomes following interventions need to be evaluated using robust methods. Objective To use within-group and within-individual analytical approaches to evaluate the participation of next of kin in care following an intervention and to compare the outcome between the intervention and control groups. Methods A pre-post intervention/control group study design was used. The educational intervention, directed towards staff members, focused on palliative care. The Next of Kin Participation in Care scale comprises the Communication and Trust subscale and the Collaboration in Care subscale, with nine items each. In total, 203 persons (intervention group: n = 95; control group: n = 108) were included. Three different analytical approaches were used: 1) traditional within-group comparison of raw ordinal scores and linearly transformed interval scores; 2) modern within-individual (person-level) interval score comparisons; 3) comparisons between the intervention group and control group based on individual person-level outcomes. Results Within-group comparisons of change revealed no change in any of the groups, whether based on raw or transformed scores. Despite this, significant improvements at the individual level were found in 32.9% of the intervention group and 11.6% of the control group for the total scale (p = 0.0024), in 25% of the intervention group and 10.5% of the control group for the Communication and Trust subscale (p = 0.0018), and in 31.2% of the intervention group and 10.5% of the control group for the Collaboration in Care subscale (p = 0.0016). However, a significant worsening at the individual level in Collaboration in Care was found in 35.1% of the intervention group but only among 8.4% of the control group (p < 0.0005). Conclusion The intervention seems to have a positive impact on next of kin participation in care in nursing homes, especially for communication and trust. However, some next of kin reported decreased participation in care after the intervention. Modern individual person-level approaches for the analysis of intervention outcomes revealed individual significant changes beyond traditional group-level comparisons that would otherwise be hidden. The findings are relevant for future outcome studies and may also necessitate a re-evaluation of previous studies that have not used individual person-level comparisons.	[Westergren, Albert; Ahlstrom, Gerd; Persson, Magnus; Behm, Lina] Lund Univ, Dept Hlth Sci, Fac Med, Lund, Sweden; [Westergren, Albert] Kristianstad Univ, Res Platform Collaborat Hlth, Fac Hlth Sci, Kristianstad, Sweden; [Behm, Lina] Kristianstad Univ, Fac Hlth Sci, Kristianstad, Sweden	Lund University; Kristianstad University; Kristianstad University	Westergren, A (corresponding author), Lund Univ, Dept Hlth Sci, Fac Med, Lund, Sweden.; Westergren, A (corresponding author), Kristianstad Univ, Res Platform Collaborat Hlth, Fac Hlth Sci, Kristianstad, Sweden.	albert.westergren@med.lu.se	; Westergren, Albert/G-8165-2014	Persson, Magnus/0000-0003-1062-2789; Westergren, Albert/0000-0003-4820-6203; Ahlstrom, Gerd/0000-0001-6230-7583	Swedish Research Council [2014-2759]; Vardal Foundation [2014-0071]; Medical Faculty, Lund University; Faculty of Health and Life Sciences, Linnaeus University; city of Lund; Foundation of Hedda Andersson, Lund University	Swedish Research Council(Swedish Research CouncilEuropean Commission); Vardal Foundation; Medical Faculty, Lund University; Faculty of Health and Life Sciences, Linnaeus University; city of Lund; Foundation of Hedda Andersson, Lund University	This study is part of the KUPA project and was funded by the Swedish Research Council (Grant number 2014-2759); the Vardal Foundation (Grant number 2014-0071); the Medical Faculty, Lund University; the Faculty of Health and Life Sciences, Linnaeus University; and the city of Lund. Additionally, a grant from the Foundation of Hedda Andersson, Lund University made this study possible. The authors declare no conflict of interest. The grant sponsors had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript or in the decision to publish the results.	Ahlstrom G, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0308-2; Aldridge MD, 2016, PALLIATIVE MED, V30, P224, DOI 10.1177/0269216315606645; Andersson M, 2010, PALLIAT SUPPORT CARE, V8, P17, DOI 10.1017/S1478951509990666; Andrich D., 2012, RUMM 2030 RASCH UNID; Andrich D, 1988, RASCH MODELS MEASURE, DOI [10.1016/0005-2736(88)90260-x, DOI 10.1016/0005-2736(88)90260-X3337808]; Andrich D, 2013, EDUC PSYCHOL MEAS, V73, P78, DOI 10.1177/0013164412450877; World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; [Anonymous], 2009, CRIT CARE, V13, pR190; [Anonymous], 2020, GLOBAL ATLAS PALLIAT; [Anonymous], 2013, NAT KNOWL SUPP DOC G; Bauer M, 2006, J ADV NURS, V54, P45, DOI 10.1111/j.1365-2648.2006.03789.x; Beck I, 2014, INT J OLDER PEOPLE N, V9, P140, DOI 10.1111/j.1748-3743.2012.00343.x; Cohen J., 1988, STAT POWER ANAL BEHA, P18, DOI [10.4324/9780203771587, DOI 10.1016/B978-0-12-179060-8.50006-2]; Cole GE, 1999, AM J EVAL, V20, P453, DOI 10.1016/S1098-2140(99)00033-8; Davies E, 2004, BETTER PALLIATIVE CA; Eika M, 2014, J CLIN NURS, V23, P2186, DOI 10.1111/jocn.12491; Haggstrom E, 2007, J CLIN NURS, V16, P1749, DOI 10.1111/j.1365-2702.2007.01704.x; Hall S., 2011, PALLIATIVE CARE OLDE; Hobart JC, 2010, J NEUROL NEUROSUR PS, V81, P1044, DOI 10.1136/jnnp.2009.201392; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Kernick D, 2006, FAM PRACT, V23, P385, DOI 10.1093/fampra/cml011; Lacouture A, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0345-7; LIANG MH, 1990, MED CARE, V28, P632, DOI 10.1097/00005650-199007000-00008; Linderholm M, 2010, CANCER NURS, V33, P28, DOI 10.1097/NCC.0b013e3181af4f61; Lindhardt T, 2007, LUND U FACULTY MED D; Maas ML, 2004, NURS RES, V53, P76, DOI 10.1097/00006199-200403000-00003; Majerovitz SD, 2009, HEALTH COMMUN, V24, P12, DOI 10.1080/10410230802606950; Marchal B, 2012, EVALUATION-US, V18, P192, DOI 10.1177/1356389012442444; McCarthy CM, 2012, PLAST RECONSTR SURG, V130, P218, DOI 10.1097/PRS.0b013e318254b3bc; Middel Berrie, 2002, Int J Integr Care, V2, pe15; Mignani V, 2017, CLIN INTERV AGING, V12, P475, DOI 10.2147/CIA.S128937; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; O'Connor RJ, 2004, NEUROLOGY, V62, P1842, DOI 10.1212/01.WNL.0000116136.22922.D6; Palm R, 2020, INT J NURS STUD, V109, DOI 10.1016/j.ijnurstu.2020.103601; Rasch G., 1980, PROBABILISTIC MODELS; Regional Co-operative Cancer Centres, 2012, NAT VARDPR PALL VARD; Rycroft-Malone J, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-38; Salter KL, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0115-y; Teixeira MJC, 2019, SCAND J CARING SCI, V33, P311, DOI 10.1111/scs.12651; Tilley N., 1997, REALIST EVALUATION; Tsang EWK, 2014, J STRATEGIC INF SYST, V23, P174, DOI 10.1016/j.jsis.2013.09.002; Wallerstedt B, 2018, HEALTHCARE-BASEL, V6, DOI 10.3390/healthcare6020046; Westergren A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228379; World Health Organization, PALL CAR 2020	44	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2021	16	1							e0244600	10.1371/journal.pone.0244600	http://dx.doi.org/10.1371/journal.pone.0244600			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PZ9QF	33493153	gold, Green Published			2023-01-03	WOS:000613081500015
J	Gerber, AN; Newton, R; Sasse, SK				Gerber, Anthony N.; Newton, Robert; Sasse, Sarah K.			Repression of transcription by the glucocorticoid receptor: A parsimonious model for the genomics era	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NF-KAPPA-B; DNA-BINDING; MEDIATED REPRESSION; REGULATORY ELEMENTS; NEGATIVE REGULATION; RESPONSE UNIT; GENE; HORMONE; MECHANISMS; TRANSACTIVATION	Glucocorticoids are potent anti-inflammatory drugs that are used to treat an extraordinary range of human disease, including COVID-19, underscoring the ongoing importance of understanding their molecular mechanisms. Early studies of GR signaling led to broad acceptance of models in which glucocorticoid receptor (GR) monomers tether repressively to inflammatory transcription factors, thus abrogating inflammatory gene expression. However, newer data challenge this core concept and present an exciting opportunity to reframe our understanding of GR signaling. Here, we present an alternate, two-part model for transcriptional repression by glucocorticoids. First, widespread GR-mediated induction of transcription results in rapid, primary repression of inflammatory gene transcription and associated enhancers through competition-based mechanisms. Second, a subset of GR-induced genes, including targets that are regulated in coordination with inflammatory transcription factors such as NF-kappa B, exerts secondary repressive effects on inflammatory gene expression. Within this framework, emerging data indicate that the gene set regulated through the cooperative convergence of GR and NF-kappa B signaling is central to the broad clinical effectiveness of glucocorticoids in terminating inflammation and promoting tissue repair.	[Gerber, Anthony N.; Sasse, Sarah K.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA; [Gerber, Anthony N.] Natl Jewish Hlth, Dept Immunol & Genom Med, Denver, CO 80206 USA; [Gerber, Anthony N.] Univ Colorado, Dept Med, Aurora, CO 80045 USA; [Newton, Robert] Univ Calgary, Cumming Sch Med, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Newton, Robert] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Calgary, AB, Canada	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Calgary; University of Calgary	Gerber, AN (corresponding author), Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA.; Gerber, AN (corresponding author), Natl Jewish Hlth, Dept Immunol & Genom Med, Denver, CO 80206 USA.; Gerber, AN (corresponding author), Univ Colorado, Dept Med, Aurora, CO 80045 USA.	gerbera@njhealth.org	Newton, Robert/C-6814-2012	Newton, Robert/0000-0002-4919-8498; Gerber, Anthony/0000-0002-5280-8218	NIH-NHLBI [R01HL109557]; Canadian Institutes for Health Research (CIHR) [MOP 125918, PJT 156310]; Natural Sciences and Engineering Research Council (NSERC) [RGPIN-2016-04549]	NIH-NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by NIH-NHLBI R01HL109557 (A. N. G), Canadian Institutes for Health Research (CIHR) project grants (MOP 125918, PJT 156310), and Natural Sciences and Engineering Research Council (NSERC) Discovery Grant RGPIN-2016-04549 (R. N.).	Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336; Arango-Lievano M, 2015, ADV EXP MED BIOL, V872, P33, DOI 10.1007/978-1-4939-2895-8_2; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Azouz Nurit P, 2021, Pathog Immun, V6, P55, DOI 10.20411/pai.v6i1.408; Barish GD, 2012, CELL METAB, V15, P554, DOI 10.1016/j.cmet.2012.02.012; Barnes PJ, 2017, HANDB EXP PHARMACOL, V237, P93, DOI 10.1007/164_2016_62; BARNES PJ, 1995, ANN MED, V27, P531, DOI 10.3109/07853899509002464; BAXTER JD, 1972, P NATL ACAD SCI USA, V69, P1892, DOI 10.1073/pnas.69.7.1892; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; Becker M, 2002, EMBO REP, V3, P1188, DOI 10.1093/embo-reports/kvf244; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Bodine SC, 2015, ADV EXP MED BIOL, V872, P145, DOI 10.1007/978-1-4939-2895-8_7; Boija A, 2018, CELL, V175, P1842, DOI 10.1016/j.cell.2018.10.042; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Bracken MB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001046.pub2; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHROUSOS GP, 1993, ANN INTERN MED, V119, P1113, DOI 10.7326/0003-4819-119-11-199312010-00009; Clark AR, 2007, MOL CELL ENDOCRINOL, V275, P79, DOI 10.1016/j.mce.2007.04.013; Cohen DM, 2017, TRENDS ENDOCRIN MET, V28, P531, DOI 10.1016/j.tem.2017.04.001; Cook PR, 2018, NUCLEIC ACIDS RES, V46, P9895, DOI 10.1093/nar/gky763; De Bosscher K, 2008, EUR J PHARMACOL, V583, P290, DOI 10.1016/j.ejphar.2007.11.076; de Loyola MB, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2157; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Devine JH, 1999, MOL CELL ENDOCRINOL, V151, P49, DOI 10.1016/S0303-7207(99)00013-1; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Dickensheets H, 2007, GENES IMMUN, V8, P21, DOI 10.1038/sj.gene.6364352; Dobosz E, 2016, J INNATE IMMUN, V8, P564, DOI 10.1159/000448038; Dostert A, 2004, CURR PHARM DESIGN, V10, P2807; Escoter-Torres L, 2020, NUCLEIC ACIDS RES, V48, P8393, DOI 10.1093/nar/gkaa565; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978-1-4939-2895-8_8; Frijters R, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-359; Garcia DA, 2021, NUCLEIC ACIDS RES, V49, P6605, DOI 10.1093/nar/gkab072; GELFAND ML, 1951, NEW ENGL J MED, V245, P293, DOI 10.1056/NEJM195108232450804; Gerber AN, 2015, ADV EXP MED BIOL, V872, P279, DOI 10.1007/978-1-4939-2895-8_12; Granner DK, 2015, ADV EXP MED BIOL, V872, P3, DOI 10.1007/978-1-4939-2895-8_1; GUERTIN M, 1983, BIOCHEMISTRY-US, V22, P4296, DOI 10.1021/bi00287a021; Guertin MJ, 2014, MOL ENDOCRINOL, V28, P1522, DOI 10.1210/me.2014-1130; Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HOECK W, 1992, J STEROID BIOCHEM, V41, P283, DOI 10.1016/0960-0760(92)90353-K; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hu GQ, 2019, P NATL ACAD SCI USA, V116, P14191, DOI 10.1073/pnas.1908258116; Hua GQ, 2016, P NATL ACAD SCI USA, V113, pE635, DOI 10.1073/pnas.1522826113; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Joanny E, 2012, BRIT J PHARMACOL, V165, P1124, DOI 10.1111/j.1476-5381.2011.01574.x; Johnson TA, 2018, NUCLEIC ACIDS RES, V46, P203, DOI 10.1093/nar/gkx1044; Kadiyala V, 2016, J BIOL CHEM, V291, P12673, DOI 10.1074/jbc.M116.721217; Kermani TA, 2018, RHEUMATOLOGY, V57, P1513, DOI 10.1093/rheumatology/kex385; King EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053936; King EM, 2009, J BIOL CHEM, V284, P26803, DOI 10.1074/jbc.M109.028381; Kunadharaju R, 2020, CLIN CHEST MED, V41, P439, DOI 10.1016/j.ccm.2020.06.008; Kuo T, 2015, ADV EXP MED BIOL, V872, P99, DOI 10.1007/978-1-4939-2895-8_5; Kurimoto T, 2021, EUR J PHARMACOL, V895, DOI 10.1016/j.ejphar.2021.173880; Kuroda MI, 2020, ANNU REV BIOCHEM, V89, P235, DOI 10.1146/annurev-biochem-120219-103641; Kushner P J, 2000, Novartis Found Symp, V230, P20, DOI 10.1002/0470870818.ch3; LABAER J, 1994, J MOL BIOL, V239, P664, DOI 10.1006/jmbi.1994.1405; Langlais D, 2012, MOL CELL, V47, P38, DOI 10.1016/j.molcel.2012.04.021; Larkin JD, 2013, J CELL SCI, V126, P2052, DOI 10.1242/jcs.123653; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Li AQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063578; Lower KM, 2009, P NATL ACAD SCI USA, V106, P21771, DOI 10.1073/pnas.0909331106; Lu XQ, 2008, BLOOD, V112, P4098, DOI 10.1182/blood-2008-03-148726; Magomedova L, 2016, HANDB EXP PHARMACOL, V233, P73, DOI 10.1007/164_2015_1; Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300; Martin F, 2011, NAT GENET, V43, P822, DOI 10.1038/ng.916; McDowell IC, 2018, GENOME RES, V28, P1272, DOI 10.1101/gr.233346.117; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Meijsing SH, 2015, ADV EXP MED BIOL, V872, P59, DOI 10.1007/978-1-4939-2895-8_3; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MIESFELD RL, 1990, AM REV RESPIR DIS, V141, pS11; Miyata M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7062; Morand EF, 2000, CURR OPIN RHEUMATOL, V12, P171, DOI 10.1097/00002281-200005000-00002; Nakamura Yutaka, 2005, Current Drug Targets - Inflammation and Allergy, V4, P267, DOI 10.2174/1568010053586273; Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794; Newton R, 2017, J BIOL CHEM, V292, P7163, DOI 10.1074/jbc.R117.777318; Ngo KA, 2020, CELL REP, V30, P2758, DOI 10.1016/j.celrep.2020.01.108; Nicolaides NC, 2000, ENDOTEXT; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Paakinaho V, 2019, GENOME RES, V29, P1223, DOI 10.1101/gr.244814.118; de Mattos BRR, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/493012; Ramos YFM, 2010, NUCLEIC ACIDS RES, V38, P5396, DOI 10.1093/nar/gkq184; RANDOLPH TG, 1950, J ALLERGY, V21, P288, DOI 10.1016/0021-8707(50)90060-8; Rao NAS, 2011, GENOME RES, V21, P1404, DOI 10.1101/gr.118042.110; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reddy TE, 2009, GENOME RES, V19, P2163, DOI 10.1101/gr.097022.109; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rodrigue-Gervais IG, 2014, CELL HOST MICROBE, V15, P23, DOI 10.1016/j.chom.2013.12.003; Roesler WJ, 1998, MOL CELL BIOCHEM, V178, P1, DOI 10.1023/A:1006886421795; Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rogliani Paola, 2020, J Exp Pharmacol, V12, P233, DOI 10.2147/JEP.S237480; Ronchetti S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124090; Rose AJ, 2013, MOL CELL ENDOCRINOL, V380, P65, DOI 10.1016/j.mce.2013.03.007; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; Russell G, 2019, NAT REV ENDOCRINOL, V15, P525, DOI 10.1038/s41574-019-0228-0; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; Saliba DG, 2014, CELL REP, V8, P1308, DOI 10.1016/j.celrep.2014.07.034; Sasse SK, 2019, GENOME RES, V29, P1753, DOI 10.1101/gr.248187.119; Sasse SK, 2017, AM J RESP CELL MOL, V57, P226, DOI 10.1165/rcmb.2016-0357OC; Schaecke H, 2007, MOL CELL ENDOCRINOL, V275, P109, DOI 10.1016/j.mce.2007.05.014; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schiller BJ, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0418-y; Schmidt SF, 2016, BIOESSAYS, V38, P618, DOI 10.1002/bies.201600034; Schmidt SF, 2015, GENOME RES, V25, P1281, DOI 10.1101/gr.188300.114; Sellares J, 2020, CURR OPIN PULM MED, V26, P591, DOI 10.1097/MCP.0000000000000720; Shen MW, 2018, NATURE, V563, P646, DOI 10.1038/s41586-018-0686-x; Shirazi SN, 2015, ADV EXP MED BIOL, V872, P235, DOI 10.1007/978-1-4939-2895-8_10; Shrinivas K, 2019, MOL CELL, V75, P549, DOI 10.1016/j.molcel.2019.07.009; So AYL, 2007, PLOS GENET, V3, P927, DOI 10.1371/journal.pgen.0030094; Starick SR, 2015, GENOME RES, V25, P825, DOI 10.1101/gr.185157.114; Takei Y, 2016, HANDBOOK OF HORMONES: COMPARATIVE ENDOCRINOLOGY FOR BASIC AND CLINICAL RESEARCH, P1; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; Tsang AH, 2016, J ENDOCRINOL, V230, pR1, DOI 10.1530/JOE-16-0051; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Uhlenhaut NH, 2013, MOL CELL, V49, P158, DOI 10.1016/j.molcel.2012.10.013; Van Moortel L, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.559673; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; Vandewalle J, 2018, TRENDS ENDOCRIN MET, V29, P42, DOI 10.1016/j.tem.2017.10.010; Verstrepen L, 2014, ADV EXP MED BIOL, V809, P13; Vettorazzi S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8796; Vitousek MN, 2019, INTEGR COMP BIOL, V59, P251, DOI 10.1093/icb/icz087; Vollmer TR, 2012, J BIOL CHEM, V287, P35212, DOI 10.1074/jbc.M112.400671; Voss TC, 2011, CELL, V146, P544, DOI 10.1016/j.cell.2011.07.006; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Whirledge S, 2018, ENDOCRINOLOGY, V159, P46, DOI 10.1210/en.2017-00728; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; Yamamoto K R, 1995, Harvey Lect, V91, P1; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YU FL, 1971, P NATL ACAD SCI USA, V68, P2177, DOI 10.1073/pnas.68.9.2177; Zhao MM, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006347	142	13	13	2	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN-JUN	2021	296								100687	10.1016/j.jbc.2021.100687	http://dx.doi.org/10.1016/j.jbc.2021.100687			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TI5TQ	33891947	gold, Green Published			2023-01-03	WOS:000672866400658
J	Powles, T; Carroll, D; Chowdhury, S; Gravis, G; Joly, F; Carles, J; Flechon, A; Maroto, P; Petrylak, D; Rolland, F; Cook, N; Balar, AV; Sridhar, SS; Galsky, MD; Grivas, P; Ravaud, A; Jones, R; Cosaert, J; Hodgson, D; Kozarewa, I; Mather, R; McEwen, R; Mercier, F; Landers, D				Powles, Thomas; Carroll, Danielle; Chowdhury, Simon; Gravis, Gwenaelle; Joly, Florence; Carles, Joan; Flechon, Aude; Maroto, Pablo; Petrylak, Daniel; Rolland, Frederic; Cook, Natalie; Balar, Arjun V.; Sridhar, Srikala S.; Galsky, Matthew D.; Grivas, Petros; Ravaud, Alain; Jones, Robert; Cosaert, Jan; Hodgson, Darren; Kozarewa, Iwanka; Mather, Richard; McEwen, Robert; Mercier, Florence; Landers, Donal			An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer	NATURE MEDICINE			English	Article							BLADDER-CANCER; OPEN-LABEL; PHASE-II; CARCINOMA; MULTICENTER; MANAGEMENT; SURVIVAL	Durvalumab is a programmed death-ligand 1 (PD-L1) inhibitor with clinical activity in advanced urothelial cancer (AUC)(1). AUC is characterized by several recurrent targetable genomic alterations(2-5). This study (, BISCAY) combined durvalumab with relevant targeted therapies in biomarker-selected chemotherapy-refractory AUC populations including: (1) fibroblast growth factor receptor (FGFR) inhibitors in tumors with FGFR DNA alterations (FGFRm); (2) pharmacological inhibitor of the enzyme poly-ADP ribose polymerase (PARP) in tumors with and without DNA homologous recombination repair deficiency (HRRm); and (3) TORC1/2 inhibitors in tumors with DNA alteration to the mTOR/PI3K pathway(3-5).This trial adopted a new, biomarker-driven, multiarm adaptive design. Safety, efficacy and relevant biomarkers were evaluated. Overall, 391 patients were screened of whom 135 were allocated to one of six study arms. Response rates (RRs) ranged 9-36% across the study arms, which did not meet efficacy criteria for further development. Overall survival (OS) and progression-free survival (PFS) were similar in the combination arms and durvalumab monotherapy arm. Biomarker analysis showed a correlation between circulating plasma-based DNA (ctDNA) and tissue for FGFRm. Sequential circulating tumor DNA analysis showed that changes to FGFRm correlated with clinical outcome. Our data support the clinical activity of FGFR inhibition and durvalumab monotherapy but do not show increased activity for any of the combinations. These findings question the targeted/immune therapy approach in AUC.	[Powles, Thomas] Barts Canc Ctr, Barts Canc Inst, QMUL, London, England; [Carroll, Danielle; Hodgson, Darren; Kozarewa, Iwanka; McEwen, Robert] AstraZeneca IMED Biotech Unit, Cambridge, England; [Chowdhury, Simon] Guys & St Thomas Hosp, London, England; [Gravis, Gwenaelle] Inst Paoli Calmettes, Marseille, France; [Joly, Florence] Ctr Leon Berard, UNICANC, Lyon, France; [Carles, Joan] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Flechon, Aude] Ctr Leon Berard, Lyon, France; [Maroto, Pablo] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Petrylak, Daniel] Yale Sch Med, New Haven, CT USA; [Rolland, Frederic] Inst Cancerol Ouest, St Herblain, France; [Cook, Natalie] Christie NHS Fdn Trust, Manchester, Lancs, England; [Cook, Natalie] Univ Manchester, Manchester, Lancs, England; [Balar, Arjun V.] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA; [Sridhar, Srikala S.] Princess Margaret Hosp, Toronto, ON, Canada; [Galsky, Matthew D.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Grivas, Petros] Univ Washington, Seattle, WA 98195 USA; [Ravaud, Alain] Bordeaux Univ Hosp, Bordeaux, France; [Jones, Robert] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Cosaert, Jan; Mather, Richard; Mercier, Florence] AstraZeneca Oncol R&D, Res & Early Dev, Cambridge, England; [Landers, Donal] CRUK Manchester Inst Canc Biomarker Ctr, Manchester, Lancs, England	University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Centre Leon Berard; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); UNICANCER; Centre Leon Berard; Hospital of Santa Creu i Sant Pau; Yale University; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Christie NHS Foundation Trust; University of Manchester; NYU Langone Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Icahn School of Medicine at Mount Sinai; University of Washington; University of Washington Seattle; CHU Bordeaux; Beatson Oncology Centre; University of Glasgow	Powles, T (corresponding author), Barts Canc Ctr, Barts Canc Inst, QMUL, London, England.	Thomas.Powles@bartshealth.nhs.uk	Gravis, Gwenaelle/CAG-3019-2022	Gravis, Gwenaelle/0000-0002-3127-1554; Landers, Donal/0000-0001-8376-9779; ROLLAND, FREDERIC/0000-0001-6957-0894; Powles, Thomas/0000-0001-7760-4724; Balar, Arjun/0000-0003-3949-5656	NIHR Manchester Clinical Research Facility; Manchester Experimental Cancer Medicine Centre award; AstraZeneca	NIHR Manchester Clinical Research Facility; Manchester Experimental Cancer Medicine Centre award; AstraZeneca(AstraZeneca)	We thank the patients and their families who gave their time and commitment to participate in this study; the CRUK Experimental Cancer Medicine Centre; and staff and investigators at participating sites, including the following. Canada: M. Sawyer, University of Alberta-Cross Cancer Institute; S. S. Sridhar, Princess Margaret Cancer Centre, Toronto; C. Ferrario, Jewish General Hospital, Montreal. France: A. Flechon, Centre Leon Berard, Lyon; G. Gravis, Institute Paoli-Calmettes, Marseille; F. Joly, Centre Francois Baclesse, Caen; L. Mourey, Institut Claudius Regaud, Toulouse; A. Ravaud, Bordeaux University Hospital; F. Rolland, Institut de Cancerologie de l'Ouest, Saint-Herblain. Spain: J. Carles, Vall D'Hebron Institute of Oncology, Barcelona; J. P. Maroto, Hospital de la Santa Creu i San Pau, Barcelona; J. P. Vasquez, Hospital Clinico San Carlos, Madrid; A. Rodriquez-Vida, IMIM Hospital del Mar Medical Research Instutute, Barcelona. UK: H.-T. Arkenau, Sarah Cannon Research Institute, London; S. Chowdhury, Guys and St Thomas' Medical School, London; N. Cook, The Christie NHS Foundation Trust, Manchester (Research at the Christie NHS Foundation Trust was supported by the NIHR Manchester Clinical Research Facility and Manchester Experimental Cancer Medicine Centre award); S. Crabb, University of Southampton; R. Jones, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow; T. Powles, Barts Cancer Institute, London. USA: A. V. Balar, Perlmutter Cancer Center, NYU Langone Health, New York; J. Bendell, Tennessee Oncology, Nashville; A. Drakaki, Ronald Reagan UCLA Medical Center, Hematology Oncology, Santa Monica; P. Grivas, University of Washington, Seattle; M. Galsky, Icahn School of Medicine at Mount Sinai, New York; N. Hahn, Johns Hopkins University School of Medicine, Baltimore; E. Lim, New York Presbyterian, Columbia University Irving Medical Centre, New York; D. Petrylak, Yale School of Medicine, New Haven; J. Reeves Jr., Florida Cancer Specialists and Research Institute; B. Rini and P. Grivas, Cleveland Clinic, Cleveland; P. Van Veldhuizen, HCA Midwest, Kansas City. We thank the staff at Sarah Cannon Development Innovations and AstraZeneca who supported this clinical study. Medical writing support was provided by S. Hurrell (Bioscript Medical) and was funded by AstraZeneca. We thank A. Reddy (AstraZeneca) for support with data analysis.	[Anonymous], 2019, UPDATE PHASE 3 NEPTU; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bellmunt J, 2010, J CLIN ONCOL, V28, P1850, DOI 10.1200/JCO.2009.25.4599; Bellmunt J, 2017, CANCER TREAT REV, V54, P58, DOI 10.1016/j.ctrv.2017.01.007; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Christensen E, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.18.02052; Friedlander M, 2019, LANCET ONCOL, V20, P1306, DOI 10.1016/S1470-2045(19)30396-1; Garcia JA, 2008, MOL CANCER THER, V7, P1347, DOI 10.1158/1535-7163.MCT-07-2408; Grivas P, 2020, J CLIN ONCOL, V38; Grivas P, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0665-y; Jones RJ, 2017, J CLIN ONCOL, V35, P1770, DOI 10.1200/JCO.2016.70.7828; Kamoun A, 2020, EUR UROL, V77, P420, DOI 10.1016/j.eururo.2019.09.006; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Loriot Y, 2019, NEW ENGL J MED, V381, P338, DOI 10.1056/NEJMoa1817323; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Massard C, 2016, J CLIN ONCOL, V34, P3119, DOI 10.1200/JCO.2016.67.9761; Necchi A, 2018, EUR J CANCER, V96, P128, DOI 10.1016/j.ejca.2018.03.021; Pairawan S, 2020, CLIN CANCER RES, V26, P1924, DOI 10.1158/1078-0432.CCR-19-0306; Powles T, 2019, NAT MED, V25, P1706, DOI 10.1038/s41591-019-0628-7; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Powles T, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.2411; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Taber A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18640-0; Teo MY, 2017, CLIN CANCER RES, V23, P3610, DOI 10.1158/1078-0432.CCR-16-2520; Vandekerkhove G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20493-6; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Wagle N, 2014, CANCER DISCOV, V4, P546, DOI 10.1158/2159-8290.CD-13-0353; Xing PY, 2019, J CELL MOL MED, V23, P6812, DOI 10.1111/jcmm.14565; Zhang Q, 2020, CANCER DISCOV, V10, P1842, DOI 10.1158/2159-8290.CD-20-0047	31	28	28	5	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					793	+		10.1038/s41591-021-01317-6	http://dx.doi.org/10.1038/s41591-021-01317-6		MAY 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33941921	Green Accepted			2023-01-03	WOS:000646516200002
J	Gupta, S; Leaf, DE				Gupta, Shruti; Leaf, David E.			Tocilizumab in COVID-19: some clarity amid controversy	LANCET			English	Editorial Material									[Gupta, Shruti; Leaf, David E.] Brigham & Womens Hosp, Div Renal Med, 75 Francis St, Boston, MA 02115 USA; [Gupta, Shruti; Leaf, David E.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gupta, S (corresponding author), Brigham & Womens Hosp, Div Renal Med, 75 Francis St, Boston, MA 02115 USA.; Gupta, S (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	sgupta21@bwh.harvard.edu	Leaf, David/AAO-8977-2021	Leaf, David/0000-0001-7875-090X				Aitken AE, 2007, DRUG METAB DISPOS, V35, P1687, DOI 10.1124/dmd.107.015511; Del Valle D.M., 2020, NAT MED, V26, P1636, DOI DOI 10.1038/s41591-020-1051-9; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252; Hermine O, 2021, JAMA INTERN MED, V181, P1020, DOI 10.1001/jamainternmed.2021.0407; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Leaf DE, 2021, NEW ENGL J MED, V384, P86, DOI 10.1056/NEJMc2032911; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Salvarani C, 2021, JAMA INTERN MED, V181, P1019, DOI 10.1001/jamainternmed.2021.0404; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Wang CD, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00527-1; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117	12	15	15	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	2021	397	10285					1599	1601						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV0EH	33933194	Bronze, Green Published			2023-01-03	WOS:000645510600004
J	Fagerlund, A; Wubshet, SG; Moretro, T; Schmidt, G; Borge, GI; Langsrud, S				Fagerlund, Annette; Wubshet, Sileshi Gizachew; Moretro, Trond; Schmidt, Gesine; Borge, Grethe Iren; Langsrud, Solveig			Anti-listerial properties of chemical constituents of Eruca sativa (rocket salad): From industrial observation to in vitro activity	PLOS ONE			English	Article							FRESH PRODUCE; FOODBORNE PATHOGENS; NATIVE MICROFLORA; MONOCYTOGENES; GROWTH; BACTERIA; TEMPERATURE; PERSISTENCE; PREVALENCE; SANITATION	The frequency of foodborne outbreaks epidemiologically associated with Listeria monocytogenes in fresh produce has increased in recent years. Although L. monocytogenes may be transferred from the environment to vegetables during farming, contamination of food products most commonly occurs in food processing facilities, where L. monocytogenes has the ability to establish and persist on processing equipment. The current study was undertaken to collect data on the occurrence of L. monocytogenes and the identity of the endogenous microbiota in a fresh produce processing facility, for which information has remained scarce. L. monocytogenes was not detected in the facility. Experiments simulating conditions in the processing environment were performed, including examination of bacterial growth in nutrients based on vegetables (salad juice) compared to in other types of nutrients (fish, meat). Results showed that the endogenous microbiota (dominated by Pseudomonas) grew well in iceberg lettuce and rocket salad juice at low temperatures, while growth inhibition of L. monocytogenes was observed, particularly in rocket salad juice. The anti-listerial activity in rocket salad juice was retained in a polar chromatographic fraction containing several metabolites. Characterization of this active fraction, using LC-MS/MS, led to identification of 19 compounds including nucleosides and amino acids. Further work is necessary to determine the molecular mechanism responsible for the inhibitory activity of rocket salad constituents. The study nevertheless suggests that the available nutrients, as well as a low temperature (3 degrees C) and the in-house bacterial flora, may influence the prevalence of L. monocytogenes in fresh produce processing facilities.	[Fagerlund, Annette; Wubshet, Sileshi Gizachew; Moretro, Trond; Schmidt, Gesine; Borge, Grethe Iren; Langsrud, Solveig] Norwegian Inst Food, Nofima, Fisheries & Aquaculture Res, As, Norway	Nofima	Fagerlund, A (corresponding author), Norwegian Inst Food, Nofima, Fisheries & Aquaculture Res, As, Norway.	annette.fagerlund@nofima.no	Langsrud, Solveig/I-1241-2012; Moretro, Trond/AAZ-5689-2021	Langsrud, Solveig/0000-0001-6415-017X; Moretro, Trond/0000-0001-5176-1158; Fagerlund, Annette/0000-0001-7146-4265; Borge, Grethe Iren A./0000-0003-0086-4434	Norwegian Agriculture and Food Industry Research Funds; Research Council of Norway [234355, 224921, 262306, 262308, 262300]	Norwegian Agriculture and Food Industry Research Funds; Research Council of Norway(Research Council of Norway)	This work was supported by the Norwegian Agriculture and Food Industry Research Funds and by the Research Council of Norway (grant numbers 234355, 224921, 262306, 262308, and 262300). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AFNOR Certification, 2020, VAL DET LIST MON; Briers Y, 2011, J BACTERIOL, V193, P4284, DOI 10.1128/JB.05328-11; Buffet-Bataillon S, 2012, INT J ANTIMICROB AG, V39, P381, DOI 10.1016/j.ijantimicag.2012.01.011; Carpentier B, 2011, INT J FOOD MICROBIOL, V145, P1, DOI 10.1016/j.ijfoodmicro.2011.01.005; Ceruso M, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9060319; CHEN GJ, 1989, J BACTERIOL, V171, P2981, DOI 10.1128/jb.171.6.2981-2985.1989; Colagiorgi A, 2017, PATHOGENS, V6, DOI 10.3390/pathogens6030041; Delaquis PJ, 2006, LETT APPL MICROBIOL, V42, P289, DOI 10.1111/j.1472-765X.2005.01826.x; Doulgeraki AI, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00782; Dufour V, 2015, MICROBIOL-SGM, V161, P229, DOI 10.1099/mic.0.082362-0; Estrada EM, 2020, J FOOD PROTECT, V83, P277, DOI 10.4315/0362-028X.JFP-19-411; Fagerlund A, 2021, CURR OPIN FOOD SCI, V37, P171, DOI 10.1016/j.cofs.2020.10.015; Fagerlund A, 2017, APPL ENVIRON MICROB, V83, DOI [10.1128/AEM.01046-17, 10.1128/aem.01046-17]; Ferreira V, 2014, J FOOD PROTECT, V77, P150, DOI 10.4315/0362-028X.JFP-13-150; Friedman M, 2017, J AGR FOOD CHEM, V65, P10406, DOI 10.1021/acs.jafc.7b04344; Garner D, 2016, J FOOD PROTECT, V79, P337, DOI 10.4315/0362-028X.JFP-15-387; Gilbert P, 2005, J APPL MICROBIOL, V99, P703, DOI 10.1111/j.1365-2672.2005.02664.x; Gu GY, 2019, INT J FOOD MICROBIOL, V294, P31, DOI 10.1016/j.ijfoodmicro.2019.02.002; Guijas C, 2018, ANAL CHEM, V90, P3156, DOI 10.1021/acs.analchem.7b04424; Hingston PA, 2019, INT J FOOD MICROBIOL, V306, DOI 10.1016/j.ijfoodmicro.2019.108262; Hoelzer K, 2012, FOODBORNE PATHOG DIS, V9, P661, DOI 10.1089/fpd.2011.1087; HUTTUNEN E, 1995, INT DAIRY J, V5, P503, DOI 10.1016/0958-6946(95)00030-7; International Organization for Standardization, 2017, MICR FOOD CHAIN HOR; International Organization for Standardization, 2016, ISO161402; Jami M, 2014, COMPR REV FOOD SCI F, V13, P798, DOI 10.1111/1541-4337.12092; Johannessen GS, 2002, INT J FOOD MICROBIOL, V77, P199, DOI 10.1016/S0168-1605(02)00051-X; John J, 2020, FOOD MICROBIOL, V90, DOI 10.1016/j.fm.2020.103468; Jordan K, 2018, CURR CLIN MICROBIOL, V5, P106, DOI 10.1007/s40588-018-0090-1; KING TC, 1983, J INFECT DIS, V147, P758, DOI 10.1093/infdis/147.4.758; Kinnula S, 2018, EUROSURVEILLANCE, V23, P7, DOI 10.2807/1560-7917.ES.2018.23.35.1700666; Koukkidis G, 2017, APPL ENVIRON MICROB, V83, DOI 10.1128/AEM.02416-16; Kramer A, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-130; Langsrud S, 2016, J APPL MICROBIOL, V120, P366, DOI 10.1111/jam.13013; Larsen MH, 2014, FOOD CONTROL, V44, P92, DOI 10.1016/j.foodcont.2014.03.039; Liao CH, 2007, J FOOD SCI, V72, pM134, DOI 10.1111/j.1750-3841.2007.00333.x; Liu NT, 2013, J FOOD PROTECT, V76, P827, DOI 10.4315/0362-028X.JFP-12-433; Logan N., 2015, BERGEYS MANUAL SYSTE, P1, DOI [10.1002/9781118960608.gbm00530, DOI 10.1002/9781118960608.GBM00530]; Lokerse RFA, 2016, FOOD CONTROL, V60, P338, DOI 10.1016/j.foodcont.2015.07.041; Moretro T., 2004, Biofilms, V1, P107, DOI 10.1017/S1479050504001322; Moretro T, 2017, COMPR REV FOOD SCI F, V16, P1022, DOI 10.1111/1541-4337.12283; Moretro T, 2017, INT J FOOD MICROBIOL, V241, P215, DOI 10.1016/j.ijfoodmicro.2016.10.025; Niehaus TD, 2017, J BIOL CHEM, V292, P16360, DOI 10.1074/jbc.M117.805028; NordVal International / NMKL, 2020, NORDVAL INT CERT ISS; Noriega E, 2010, FOOD RES INT, V43, P2425, DOI 10.1016/j.foodres.2010.09.012; Nygard K, 2008, FOODBORNE PATHOG DIS, V5, P165, DOI 10.1089/fpd.2007.0053; Olaimat AN, 2012, FOOD MICROBIOL, V32, P1, DOI 10.1016/j.fm.2012.04.016; Pessione E, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00876; RASFF-the Rapid Alert System for Food and Feed, 2014, RASFF PORTAL; Rossvoll E, 2014, INT J FOOD MICROBIOL, V185, P82, DOI 10.1016/j.ijfoodmicro.2014.05.020; Salazar JK, 2017, J FOOD PROTECT, V80, P1328, DOI [10.4315/0362-028X.JFP-16-516, 10.4315/0362-028x.jfp-16-516]; Sawada Y, 2012, PHYTOCHEMISTRY, V82, P38, DOI 10.1016/j.phytochem.2012.07.007; Self JL, 2019, EMERG INFECT DIS, V25, P1461, DOI 10.3201/eid2508.180761; Setlow P, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.TBS-0003-2012; Smith A, 2018, J APPL MICROBIOL, V125, P930, DOI 10.1111/jam.14025; Stephan R, 2015, FOOD CONTROL, V57, P14, DOI 10.1016/j.foodcont.2015.03.034; Sumner LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/s11306-007-0082-2; Thomson JM, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00952; Van Pelt AE, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00040; Vig AP, 2009, LWT-FOOD SCI TECHNOL, V42, P1561, DOI 10.1016/j.lwt.2009.05.023; Wadamori Y, 2017, J SCI FOOD AGR, V97, P1396, DOI 10.1002/jsfa.8125; Yang ZN, 1997, J FOOD PROTECT, V60, P786, DOI 10.4315/0362-028X-60.7.786; Yssel AEJ, 2017, J ANTIMICROB CHEMOTH, V72, P2156, DOI 10.1093/jac/dkx151; Ziegler M, 2019, INT J FOOD MICROBIOL, V296, P83, DOI 10.1016/j.ijfoodmicro.2019.01.016	63	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2021	16	4							e0250648	10.1371/journal.pone.0250648	http://dx.doi.org/10.1371/journal.pone.0250648			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SX8OK	33905441	gold, Green Published			2023-01-03	WOS:000665456800029
J	Kaba, M; de Fouw, M; Deribe, KS; Abathun, E; Peters, AAW; Beltman, JJ				Kaba, Mirgissa; de Fouw, Marlieke; Deribe, Kalkidan Solomon; Abathun, Ephrem; Peters, Alexander Arnold Willem; Beltman, Jogchum Jan			Palliative care needs and preferences of female patients and their caregivers in Ethiopia: A rapid program evaluation in Addis Ababa and Sidama zone	PLOS ONE			English	Article							CANCER; LIFE; HEALTH; END; KNOWLEDGE; FAMILIES; HOSPICE; DEATH	Introduction In Ethiopia there is an extensive unmet need for palliative care, while the burden of non-communicable diseases and cancer is increasing. This study aimed to explore palliative care needs and preferences of patients, their caregivers, and the perspective of stakeholders on service provision in palliative programs for women, mostly affected by cervical cancer and breast cancer. Methods A rapid program evaluation using a qualitative study approach was conducted in three home-based palliative care programs in Addis Ababa and Yirgalem town, Ethiopia. Female patients enrolled in the programs, and their primary caregivers were interviewed on palliative care needs, preferences and service provision. We explored the views of purposely selected stakeholders on the organization of palliative care and its challenges. Audio-taped data was transcribed verbatim and translated into English and an inductive thematic analysis was applied. Descriptive analyses were used to label physical signs and symptoms using palliative outcome scale score. Results A total of 77 interviews (34 patients, 12 primary caregivers, 15 voluntary caregivers, 16 stakeholders) were conducted. The main physical complaints were moderate to severe pain (70.6%), followed by anorexia (50.0%), insomnia, nausea and vomiting (41.2%). Social interaction and daily activities were hampered by the patients' condition. Both patients and caregivers reported that programs focus most on treatment of symptoms, with limited psychosocial, emotional, spiritual and economic support. Lack of organizational structures and policy directions limit the collaboration between stakeholders and the availability of holistic home-based palliative care services. Conclusions Although female patients and caregivers appreciated the palliative care and support provided, the existing services did not cover all needs. Pain management and all other needed supports were lacking. Multi-sectorial collaboration with active involvement of community-based structures is needed to improve quality of care and access to holistic palliative care services.	[Kaba, Mirgissa; Deribe, Kalkidan Solomon] Addis Ababa Univ, Coll Hlth Sci, Sch Publ Hlth, Dept Prevent Med, Addis Ababa, Ethiopia; [de Fouw, Marlieke; Peters, Alexander Arnold Willem; Beltman, Jogchum Jan] Leiden Univ, Dept Gynecol, Med Ctr, Leiden, Netherlands; [Abathun, Ephrem] Hosp Ethiopia, Addis Ababa, Ethiopia	Addis Ababa University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kaba, M; Deribe, KS (corresponding author), Addis Ababa Univ, Coll Hlth Sci, Sch Publ Hlth, Dept Prevent Med, Addis Ababa, Ethiopia.	mirgissk@yahoo.com; kallkidansolomon@gmail.com	Kaba, Mirgissa/HGB-6272-2022	de Fouw, Marlieke/0000-0002-4488-4886	Ethiopia Female Cancer Initiative (EFCI) project of Cordaid Ethiopia; Treub Foundation from The Netherlands	Ethiopia Female Cancer Initiative (EFCI) project of Cordaid Ethiopia; Treub Foundation from The Netherlands	The study was supported by the Ethiopia Female Cancer Initiative (EFCI) project of Cordaid Ethiopia, and Treub Foundation from The Netherlands.	ANKER M, 1993, B WORLD HEALTH ORGAN, V71, P15; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruni L, 2019, HUMAN PAPILLIMAVIRUS; de Fouw M, 2019, TROP DOCT, V49, P298, DOI 10.1177/0049475519864763; Dix O., 2012, HEALTH QUAL LIFE OUT, V4, P11; Esma'el JK DB., 2015, FAM MED MED SCI RES, P4; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Gakidou E, 2008, PLOS MED, V5, P863, DOI 10.1371/journal.pmed.0050132; Grant E, 2003, J PALLIATIVE CARE, V19, P159, DOI 10.1177/082585970301900303; Herce ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110457; Kale SS, 2011, INT J PALLIAT NURS, V17, P177, DOI 10.12968/ijpn.2011.17.4.177; Kassa H, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-6; Knaul FM, 2018, LANCET, V391, P1391, DOI 10.1016/S0140-6736(17)32513-8; Lai XB, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0372-7; MOH, 2016, NAT PALL CAR GUID, P188; Mupepi SC, 2011, J WOMENS HEALTH, V20, P943, DOI 10.1089/jwh.2010.2062; Murray SA, 2003, BRIT MED J, V326, P368, DOI 10.1136/bmj.326.7385.368; Perone SA, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0377-2; Powell RA, 2007, J PAIN SYMPTOM MANAG, V33, P229, DOI 10.1016/j.jpainsymman.2006.10.008; Reid EA, 2018, J PALLIAT MED, V21, P622, DOI 10.1089/jpm.2017.0419; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Shalev A, 2018, AM J HOSP PALLIAT ME, V35, P431, DOI 10.1177/1049909117715215; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Tipseankhum N, 2016, PAC RIM INT J NURS R, V20, P238; Ventafridda V, 1990, J Palliat Care, V6, P7; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	28	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2021	16	4							e0248738	10.1371/journal.pone.0248738	http://dx.doi.org/10.1371/journal.pone.0248738			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0DC	33886561	Green Published, gold			2023-01-03	WOS:000644138300111
J	Bjorkqvist, O; Rangel, I; Serrander, L; Magnusson, C; Halfvarson, J; Noren, T; Bergman-Jungestrom, M				Bjorkqvist, Olle; Rangel, Ignacio; Serrander, Lena; Magnusson, Cecilia; Halfvarson, Jonas; Noren, Torbjorn; Bergman-Jungestrom, Malin			Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection	PLOS ONE			English	Article								Objective Fecal microbiota transplantation (FMT) is a highly effective treatment for Clostridioides difficile infection (CDI). However, the fecal transplant's causal components translating into clearance of the CDI are yet to be identified. The commensal bacteria Faecalibacterium prausnitzii may be of great interest in this context, since it is one of the most common species of the healthy gut microbiota and produces metabolites with anti-inflammatory properties. Although there is mounting evidence that F. prausnitzii is an important regulator of intestinal homeostasis, data about its role in CDI and FMT are relatively scarce. Methods Stool samples from patients with recurrent CDI were collected to investigate the relative abundance of F. prausnitzii before and after FMT. Twenty-one patients provided fecal samples before the FMT procedure, at 2 weeks post-FMT, and at 2-4 months post-FMT. The relative abundance of F. prausnitzii was determined using quantitative polymerase chain reaction. Results The abundance of F. prausnitzii was elevated in samples (N = 9) from donors compared to pre-FMT samples (N = 15) from patients (adjusted P<0.001). No significant difference in the abundance of F. prausnitzii between responders (N = 11) and non-responders (N = 4) was found before FMT (P = 0.85). In patients with CDI, the abundance of F. prausnitzii significantly increased in the 2 weeks post-FMT samples (N = 14) compared to the pre-FMT samples (N = 15, adjusted P<0.001). The increase persisted 2-4 months post-FMT (N = 15) compared to pre-FMT samples (N = 15) (adjusted P<0.001). Conclusions FMT increases the relative abundance of F. prausnitzii in patients with recurrent CDI, and this microbial shift remains several months later. The baseline abundance of F. prausnitzii in donors or recipients was not associated with future treatment response, although a true predictive capacity cannot be excluded because of the limited sample size. Further studies are needed to discern whether F. prausnitzii plays an active role in the resolution of CDI.	[Bjorkqvist, Olle; Halfvarson, Jonas] Orebro Univ, Fac Med & Hlth, Dept Gastroenterol, Orebro, Sweden; [Rangel, Ignacio; Halfvarson, Jonas] Orebro Univ, Sch Med Sci, Orebro, Sweden; [Serrander, Lena; Bergman-Jungestrom, Malin] Linkoping Univ, Dept Clin & Expt Med, Div Clin Microbiol, Linkoping, Sweden; [Magnusson, Cecilia] Linkoping Univ, Dept Biomed & Clin Sci, Linkoping, Sweden; [Magnusson, Cecilia] Reg Jonkoping Cty, Dept Infect Dis, Jonkoping, Sweden; [Noren, Torbjorn] Orebro Univ, Fac Med & Hlth, Dept Lab Med, Natl Reference Lab Clostridioides Difficile, Orebro, Sweden	Orebro University; Orebro University; Linkoping University; Linkoping University; Orebro University	Bjorkqvist, O (corresponding author), Orebro Univ, Fac Med & Hlth, Dept Gastroenterol, Orebro, Sweden.	olle.bjorkqvist@regionorebrolan.se		Magnusson, Cecilia/0000-0002-5540-8930; Bjorkqvist, Olle/0000-0002-4329-1659	Futurum Akademin for Hsaoch Vard, Region Jopings lans	Futurum Akademin for Hsaoch Vard, Region Jopings lans	"Futurum Akademin for Hsaoch Vard, Region Jopings lans" (https://plus.rjl.se/futurum) provided funding for CM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antharam VC, 2013, J CLIN MICROBIOL, V51, P2884, DOI 10.1128/JCM.00845-13; Barman M, 2008, INFECT IMMUN, V76, P907, DOI 10.1128/IAI.01432-07; Barnes D, 2018, J PEDIATR GASTR NUTR, V67, P185, DOI 10.1097/MPG.0000000000001940; Bjrkqvist O, 2019, SCAND J GASTROENTERO, V54, P577, DOI 10.1080/00365521.2019.1599417; Brandt LJ, 2012, AM J GASTROENTEROL, V107, P1079, DOI 10.1038/ajg.2012.60; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Chu ND, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170922; De Palma G, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-63; Debast SB, 2014, CLIN MICROBIOL INFEC, V20, P1, DOI 10.1111/1469-0691.12418; Eppinga H, 2016, J CROHNS COLITIS, V10, P1067, DOI 10.1093/ecco-jcc/jjw070; Eyre DW, 2012, CLIN INFECT DIS, V55, pS77, DOI 10.1093/cid/cis356; Fuentes S, 2014, ISME J, V8, P1621, DOI 10.1038/ismej.2014.13; Furet JP, 2010, DIABETES, V59, P3049, DOI 10.2337/db10-0253; Hourigan SK, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz379; Hvas CL, 2019, GASTROENTEROLOGY, V156, P1324, DOI 10.1053/j.gastro.2018.12.019; Jefferson KK, 1999, J IMMUNOL, V163, P5183; Kellingray L, 2018, J INFECTION, V77, P107, DOI 10.1016/j.jinf.2018.04.012; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; Lawley TD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002995; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Louis P, 2009, FEMS MICROBIOL LETT, V294, P1, DOI 10.1111/j.1574-6968.2009.01514.x; Machiels K, 2014, GUT, V63, P1275, DOI 10.1136/gutjnl-2013-304833; Martin R, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01226; McFarland LV, 2002, AM J GASTROENTEROL, V97, P1769, DOI 10.1111/j.1572-0241.2002.05839.x; Mintz M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190997; Moelling Karin, 2016, Bacteriophage, V6, pe1251380, DOI 10.1080/21597081.2016.1251380; Mullish BH, 2019, GUT, V68, P1791, DOI 10.1136/gutjnl-2018-317842; Navab-Moghadam F, 2017, MICROB PATHOGENESIS, V110, P630, DOI 10.1016/j.micpath.2017.07.034; Olsen MA, 2015, CLIN MICROBIOL INFEC, V21, P164, DOI 10.1016/j.cmi.2014.08.017; Petrof EO, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-3; Quevrain E, 2016, GUT, V65, P415, DOI 10.1136/gutjnl-2014-307649; Quraishi MN, 2017, ALIMENT PHARM THER, V46, P479, DOI 10.1111/apt.14201; Rizzardi K, 2018, EMERG INFECT DIS, V24, P1617, DOI 10.3201/eid2409.171658; Seekatz AM, 2018, ANAEROBE, V53, P64, DOI 10.1016/j.anaerobe.2018.04.001; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; Shin H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075729, 10.1371/journal.pone.0081330]; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Theriot CM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4114; Tvede M, 2015, CLIN MICROBIOL INFEC, V21, P48, DOI 10.1016/j.cmi.2014.07.003; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Willing B, 2009, INFLAMM BOWEL DIS, V15, P653, DOI 10.1002/ibd.20783; Wrzosek L, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-61	43	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2021	16	4							e0249861	10.1371/journal.pone.0249861	http://dx.doi.org/10.1371/journal.pone.0249861			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM0OE	33836037	Green Published, gold			2023-01-03	WOS:000639361000007
J	Bui, DHT; Nguyen, BX; Truong, DC; Meyrowitsch, DW; Sondergaard, J; Gammeltoft, T; Bygbjerg, IC; Jannie, N				Dieu Huyen Thi Bui; Bai Xuan Nguyen; Dat Cong Truong; Meyrowitsch, Dan Wolf; Sondergaard, Jens; Gammeltoft, Tine; Bygbjerg, Ib Christian; Jannie, Nielsen			Polypharmacy among people living with type 2 diabetes mellitus in rural communes in Vietnam	PLOS ONE			English	Article							PREVALENCE; DISEASE	Objectives People with diabetes are at high risk of polypharmacy owing to complex treatment of diabetes and comorbidities. Polypharmacy is associated with increased risk of adverse reactions and decreased compliance. Therefore, the objectives of this study were to assess polypharmacy in people with type 2 diabetes (T2D) and associated diabetes-related factors in rural areas in Vietnam. Method People with T2D (n = 806) who had received treatment for diabetes at a district hospital were invited to participate in a questionnaire-based cross-sectional survey. Polypharmacy was defined as >= 5 types of medicine and assessed as a) prescription medicine and non-prescription/over the counter (OTC) medicine and b) prescription medicine and non-prescription/OTC, herbal and traditional medicine, and dietary supplement. Multiple logistic regression was used to investigate the association between polypharmacy and diabetes specific factors: duration, comorbidities and diabetes-related distress. Results Of the people with T2D, 7.8% had a medicine use corresponding to polypharmacy (prescription medicine and non-prescription/OTC), and 40.8% when herbal and traditional medicine, and dietary supplement were included. Mean number of medicine intake (all types of medicines and supplements) were 3.8 +/- 1.5. The odd ratios (ORs) of polypharmacy (medicine and supplements) increased with diabetes duration (5 years OR = 1.74; 95%CI: 1.14-2.64 as compared to <= 1-year duration of diabetes), number of comorbidities (1-2 comorbidities: OR = 2.0; 95%CI: 1.18-3.42; >= 3 comorbidities: OR = 2.63;95%CI: 1.50-4.61 as compared to no comorbidities), and suffering from diabetes-related distress (OR = 1.49; 95%CI: 1.11-2.01) as compared to those without distress. Conclusions In rural northern Vietnam, persons with longer duration of T2D, higher number of comorbidities and diabetes-related stress have higher odds of having a medicine use corresponding to polypharmacy. A high proportion of people with T2D supplement their prescription, non-prescription/OTC medicine with herbal and traditional medicine and dietary supplements.	[Dieu Huyen Thi Bui; Dat Cong Truong] Thai Binh Univ Med & Pharm, Fac Publ Hlth, Thai Binh, Vietnam; [Bai Xuan Nguyen] Thai Binh Univ Med & Pharm, Dept Embryol, Thai Binh, Vietnam; [Meyrowitsch, Dan Wolf; Bygbjerg, Ib Christian; Jannie, Nielsen] Univ Copenhagen, Dept Publ Hlth, Global Hlth Sect, Copenhagen K, Denmark; [Sondergaard, Jens] Univ Southern Denmark, Dept Publ Hlth, Res Unit Gen Practice, Odense C, Denmark; [Gammeltoft, Tine] Univ Copenhagen, Dept Anthropol, Copenhagen K, Denmark; [Jannie, Nielsen] Emory Univ, Emory Global Diabet Res Ctr, Rollins Sch Global Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA	Thai Binh University of Medicine & Pharmacy; Thai Binh University of Medicine & Pharmacy; University of Copenhagen; University of Southern Denmark; University of Copenhagen; Emory University	Bui, DHT (corresponding author), Thai Binh Univ Med & Pharm, Fac Publ Hlth, Thai Binh, Vietnam.	huyendieu1410@gmail.com		Gammeltoft, Tine Mette/0000-0002-6723-2370; Bygbjerg, Ib/0000-0001-9100-2754; Nielsen, Jannie/0000-0003-4897-8705	Ministry of Foreign Affairs of Denmark (DANIDA)	Ministry of Foreign Affairs of Denmark (DANIDA)	Study was funded by the Ministry of Foreign Affairs of Denmark (DANIDA)	Alwhaibi M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020852; Anh Tuan Nguyen, 2009, Southern Med Review, V2, P2; [Anonymous], 2018, INVESTMENT PROMOTION; [Anonymous], 2017, VIETNAM MONTHLY INCO; Assari S, 2019, PHARMACY, V7, DOI 10.3390/pharmacy7010014; Austin RP., 2006, DIABETES SPECTR, V19, P13; Bazargan M, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091574; Byles JE, 2003, INTERN MED J, V33, P388, DOI 10.1046/j.1445-5994.2003.00399.x; da Silva Córralo Vanessa, 2018, Rev. salud pública, V20, P366, DOI [10.15446/rsap.v20n3.50304, 10.15446/rsap.V20n3.50304]; Dieu BTH, 2019, VIETNAM MED J, P483; Dobrica EC, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55080436; Gadsby R, 2012, DIABETIC MED, V29, P136, DOI 10.1111/j.1464-5491.2011.03494.x; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Geitona M, 2018, CONSULT PHARM, V33, P562, DOI [10.4140/TCP.n.2018.562, 10.4140/TCP.n.2018.562.]; Gonder-Frederick LA, 2002, J CONSULT CLIN PSYCH, V70, P611, DOI 10.1037//0022-006X.70.3.611; Haider SI, 2008, CLIN THER, V30, P419, DOI 10.1016/j.clinthera.2008.02.010; Haider SI, 2009, J AM GERIATR SOC, V57, P62, DOI 10.1111/j.1532-5415.2008.02040.x; Holman RR, 2008, NEW ENGL J MED, V359, P1565, DOI 10.1056/NEJMoa0806359; Horii T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49424-2; Indu Rania, 2018, Perspect Clin Res, V9, P139, DOI 10.4103/picr.PICR_81_17; International Diabetes Federation, 2017, DIABETES ATLAS; Josephine Valsa Jose PD, 2019, MEDICINE; Karlsen B, 2012, J ADV NURS, V68, P391, DOI 10.1111/j.1365-2648.2011.05751.x; Kasole R, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/2835691; Kasteleyn MJ, 2015, DIABETIC MED, V32, P1617, DOI 10.1111/dme.12743; Kearney PM, 2008, LANCET, V371, P117, DOI 10.1016/S0140-6736(08)60104-X; KNUIMAN MW, 1986, DIABETES, V35, P1332, DOI 10.2337/diabetes.35.12.1332; LAAKSO M, 1993, CIRCULATION, V88, P1421, DOI 10.1161/01.CIR.88.4.1421; Le Q-U., 2019, J APPL BIOPHARMACEUT, V7, P1; Li JL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220047; LOI DT, 1991, J ETHNOPHARMACOL, V32, P51, DOI 10.1016/0378-8741(91)90103-K; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; McGuire BE, 2010, DIABETOLOGIA, V53, P66, DOI 10.1007/s00125-009-1559-5; Mull DS, 2001, WESTERN J MED, V175, P307, DOI 10.1136/ewjm.175.5.307; Nguyen CT, 2015, ASIA-PAC J PUBLIC HE, V27, P588, DOI 10.1177/1010539515595860; Khue NT, 2015, ANN GLOB HEALTH, V81, P870, DOI 10.1016/j.aogh.2016.01.003; Noale M, 2016, ACTA DIABETOL, V53, P323, DOI 10.1007/s00592-015-0790-4; da Silva MRR, 2018, CIENC SAUDE COLETIVA, V23, P2565, DOI 10.1590/1413-81232018238.10222016; Rutters F, 2018, CHARACTERISATION PEO; Security VS, 2019, DIR PAYM EXP MED EX; Teljeur C, 2013, EUR J GEN PRACT, V19, P17, DOI 10.3109/13814788.2012.714768; Nguyen TX, 2020, AUSTRALAS J AGEING, V39, P230, DOI 10.1111/ajag.12722; Thommanduru Priyanka AL, 2015, INDIAN J PHARM PRACT, V8; Wawruch M, 2008, PHARM WORLD SCI, V30, P235, DOI 10.1007/s11096-007-9166-3; Wimmer BC, 2016, J GERONTOL A-BIOL, V71, P831, DOI 10.1093/gerona/glv219; World Health Organisation, 2019, MED SAF POL; World Health Organization, 2016, GLOB REP PSOR	48	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2021	16	4							e0249849	10.1371/journal.pone.0249849	http://dx.doi.org/10.1371/journal.pone.0249849			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RM0NQ	33831073	Green Published, gold			2023-01-03	WOS:000639359600070
J	Hudecz, D; Sigurdardottir, SB; Christensen, SC; Hempel, C; Urquhart, AJ; Andresen, TL; Nielsen, MS				Hudecz, Diana; Sigurdardottir, Sara Bjork; Christensen, Sarah Christine; Hempel, Casper; Urquhart, Andrew J.; Andresen, Thomas Lars; Nielsen, Morten S.			Two peptides targeting endothelial receptors are internalized into murine brain endothelial cells	PLOS ONE			English	Article								The blood-brain barrier (BBB) is one of the main obstacles for therapies targeting brain diseases. Most macromolecules fail to pass the tight BBB, formed by brain endothelial cells interlinked by tight junctions. A wide range of small, lipid-soluble molecules can enter the brain parenchyma via diffusion, whereas macromolecules have to transcytose via vesicular transport. Vesicular transport can thus be utilized as a strategy to deliver brain therapies. By conjugating BBB targeting antibodies and peptides to therapeutic molecules or nanoparticles, it is possible to increase uptake into the brain. Previously, the synthetic peptide GYR and a peptide derived from melanotransferrin (MTfp) have been suggested as candidates for mediating transcytosis in brain endothelial cells (BECs). Here we study uptake, intracellular trafficking, and translocation of these two peptides in BECs. The peptides were synthesized, and binding studies to purified endocytic receptors were performed using surface plasmon resonance. Furthermore, the peptides were conjugated to a fluorophore allowing for live-cell imaging studies of their uptake into murine brain endothelial cells. Both peptides bound to low-density lipoprotein receptor-related protein 1 (LRP-1) and the human transferrin receptor, while lower affinity was observed against the murine transferrin receptor. The MTfp showed a higher binding affinity to all receptors when compared to the GYR peptide. The peptides were internalized by the bEnd.3 mouse endothelial cells within 30 min of incubation and frequently co-localized with endo-lysosomal vesicles. Moreover, our in vitro Transwell translocation experiments confirmed that GYR was able to cross the murine barrier and indicated the successful translocation of MTfp. Thus, despite binding to endocytic receptors with different affinities, both peptides are able to transcytose across the murine BECs.	[Hudecz, Diana; Christensen, Sarah Christine; Nielsen, Morten S.] Aarhus Univ, Fac Hlth, Dept Biomed, Aarhus, Denmark; [Sigurdardottir, Sara Bjork; Hempel, Casper; Urquhart, Andrew J.; Andresen, Thomas Lars] Tech Univ Denmark, Dept Hlth Technol, Lyngby, Denmark	Aarhus University; Technical University of Denmark	Nielsen, MS (corresponding author), Aarhus Univ, Fac Hlth, Dept Biomed, Aarhus, Denmark.	mn@biomed.au.dk	Nielsen, Morten Schallburg/G-9498-2016; Urquhart, Andrew/B-8194-2014; Hempel, Casper/C-9511-2013	Nielsen, Morten Schallburg/0000-0001-9863-9694; Urquhart, Andrew/0000-0002-5322-0002; Christensen, Sarah Christine/0000-0002-2873-7974; Sigurdardottir, Sara Bjork/0000-0003-2936-1152; Andresen, Thomas Lars/0000-0002-1048-127X; Hempel, Casper/0000-0002-9816-4673	Lundbeck foundation [R155-2013-14113]	Lundbeck foundation(Lundbeckfonden)	The Authors has been supported by a grant from the Lundbeck foundation (grant number R155-2013-14113) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Akita H, 2016, SMALL, V12, P1212, DOI 10.1002/smll.201500909; Brinkhuis RP., 2011, Patent No. [WO 2011/005098 A1, 2011005098]; Czupalla CJ, 2014, METHODS MOL BIOL, V1135, P415, DOI 10.1007/978-1-4939-0320-7_34; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; Deli MA, 2011, SOLUBILITY, DELIVERY AND ADME PROBLEMS OF DRUGS AND DRUG CANDIDATES, P144; Demeule M, 2002, J NEUROCHEM, V83, P924, DOI 10.1046/j.1471-4159.2002.01201.x; Demeule M, 2008, J PHARMACOL EXP THER, V324, P1064, DOI 10.1124/jpet.107.131318; Eyford BA., 2019, BIORXIV, DOI [10.1101/871186, DOI 10.1101/871186]; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Haqqani AS, 2018, J NEUROCHEM, V146, P735, DOI 10.1111/jnc.14482; He LQ, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.160; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Hudecz D, 2020, ACS NANO, V14, P1111, DOI 10.1021/acsnano.9b08870; Jensen KJ, 2013, METHODS MOL BIOL, V1047, P1, DOI 10.1007/978-1-62703-544-6_1; Johnsen KB, 2018, THERANOSTICS, V8, P3416, DOI 10.7150/thno.25228; Karkan D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002469; Lajoie JM, 2015, ANNU REV PHARMACOL, V55, P613, DOI 10.1146/annurev-pharmtox-010814-124852; MERZOUK A, 1992, TETRAHEDRON LETT, V33, P477, DOI 10.1016/S0040-4039(00)93973-X; Michaud-Levesque J, 2012, EXP CELL RES, V318, P925, DOI 10.1016/j.yexcr.2012.02.017; Nakamasu K, 1999, BBA-GENE STRUCT EXPR, V1447, P258, DOI 10.1016/S0167-4781(99)00173-6; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; Niewoehner J, 2014, NEURON, V81, P49, DOI 10.1016/j.neuron.2013.10.061; Oller-Salvia B, 2016, CHEM SOC REV, V45, P4690, DOI 10.1039/c6cs00076b; Pardridge William M, 2005, NeuroRx, V2, P3; Rahmanto YS, 2012, BBA-GEN SUBJECTS, V1820, P237, DOI 10.1016/j.bbagen.2011.09.003; Shao Y, 2016, ONCOTARGET, V7, P34011, DOI [10.18632/oncotarget.8514, 10.18632/oncotarget.12708]; SIFLINGERBIRNBOIM A, 1987, J CELL PHYSIOL, V132, P111, DOI 10.1002/jcp.1041320115; Tang FHF, 2019, P NATL ACAD SCI USA, V116, P2300, DOI 10.1073/pnas.1809483116; Thieriet N, 1997, TETRAHEDRON LETT, V38, P7275, DOI 10.1016/S0040-4039(97)01690-0; Thom G, 2019, J CEREBR BLOOD F MET, V39, P2074, DOI 10.1177/0271678X18772998; van Rooy I, 2011, J CONTROL RELEASE, V150, P30, DOI 10.1016/j.jconrel.2010.11.014; van Rooy I, 2010, PHARM RES-DORDR, V27, P673, DOI 10.1007/s11095-010-0053-6; Vanlandewijck M, 2018, NATURE, V554, P475, DOI 10.1038/nature25739; Vieira DB, 2016, INT J NANOMED, V11, P5381, DOI 10.2147/IJN.S117210; Villasenor R, 2017, CELL REP, V21, P3256, DOI 10.1016/j.celrep.2017.11.055; Villasenor R, 2016, SCI REP-UK, V6, DOI 10.1038/srep25658; Watts RJ, 2013, CURR OPIN CHEM BIOL, V17, P393, DOI 10.1016/j.cbpa.2013.03.023; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Wu LP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12554-2; Ye D, 2013, NANOSCALE, V5, P11153, DOI 10.1039/c3nr02905k; Yu YJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009835; Yu YJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002230; Yuan W, 2010, ANN BIOMED ENG, V38, P1463, DOI 10.1007/s10439-010-9920-x; Zhao Z, 2015, NAT NEUROSCI, V18, P978, DOI 10.1038/nn.4025; Zuchero YJY, 2016, NEURON, V89, P70, DOI 10.1016/j.neuron.2015.11.024	46	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2021	16	4							e0249686	10.1371/journal.pone.0249686	http://dx.doi.org/10.1371/journal.pone.0249686			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RI2KE	33798235	Green Published, gold			2023-01-03	WOS:000636737700006
J	Regan, EW; Handlery, R; Stewart, JC; Pearson, JL; Wilcox, S; Fritz, S				Regan, Elizabeth W.; Handlery, Reed; Stewart, Jill C.; Pearson, Joseph L.; Wilcox, Sara; Fritz, Stacy			Feasibility of integrating survivors of stroke into cardiac rehabilitation: A mixed methods pilot study	PLOS ONE			English	Article							AMERICAN-HEART-ASSOCIATION; TRANSIENT ISCHEMIC ATTACK; HEALTH-CARE PROFESSIONALS; PHYSICAL-ACTIVITY; PREVENTION PROGRAMS; SECONDARY PREVENTION; EXERCISE; PARTICIPATION; POSTSTROKE; STATEMENT	Background Survivors of stroke are often deconditioned and have limited opportunities for exercise post-rehabilitation. Cardiac Rehabilitation (CR), a structured exercise program offered post-cardiac event in the United States (U.S.), may provide an opportunity for continued exercise. The purpose of this study was to examine the feasibility of integrating survivors of stroke into an existing, hospital-based CR program through an assessment of (1) recruitment, uptake and retention, (2) adherence and fidelity, (3) acceptability and (4) safety. Methods A mixed methods design combined a single group, pre-post design, pilot feasibility study with an imbedded qualitative inquiry. Survivors of stroke were recruited into a standard 12-week, 36 visit CR program. Results Fifty-three survivors were referred, 29 started and 24 completed the program. Program uptake rate was 55% and completion rate was 83%. Eleven completers and one non-completer participated in the qualitative interviews. Program completers attended an average of 25.25 (SD 5.82) sessions with an average of 38.93 (SD 5.64) exercise minutes per session while reaching targeted rate of perceived exertion levels. Qualitative themes included perceived benefits of an individualized program in a group setting, positive interactions with qualified staff, opportunities for socialization, and regular monitoring and staff attentiveness promoting feelings of safety. Conclusions Survivors of stroke were able to meet Medicare standard dosage (frequency and session duration) and rate of perceived intensity goals, and perceived the program as needed regardless of their mobility limitations or previous exercise experience. Primary challenges included managing referrals and uptake. Results support feasibility and benefit for survivors to integrate into U.S. CR programs.	[Regan, Elizabeth W.; Handlery, Reed; Stewart, Jill C.; Wilcox, Sara; Fritz, Stacy] Univ South Carolina, Dept Exercise Sci, Columbia, SC 29208 USA; [Pearson, Joseph L.] Univ South Carolina, Dept Hlth Promot Educ & Behav, Columbia, SC 29208 USA	University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia	Regan, EW (corresponding author), Univ South Carolina, Dept Exercise Sci, Columbia, SC 29208 USA.	eregan@email.sc.edu	Handlery, Reed/HJA-8200-2022	Handlery, Reed/0000-0003-0064-6808; Regan, Elizabeth/0000-0003-2820-717X	University of South Carolina (USC) Behavioral-Biomedical Interface Program-NIGMS/NIH-T32 [2T326M081740-11A1]; 2019 American Heart Association (AHA) Pre-Doctoral Fellowship; 2018 American Physical Therapy Association Health Policy and Administration Research Grant; 2019 USC Support to Promote Advancement of Research and Creativity Grant; AHA [15SDG24970011]; Promotion of Doctoral Studies (PODS)-Level I Scholarship from the Foundation for Physical Therapy Research; Arnold Fellowship from the Arnold School of Public Health, USC	University of South Carolina (USC) Behavioral-Biomedical Interface Program-NIGMS/NIH-T32; 2019 American Heart Association (AHA) Pre-Doctoral Fellowship; 2018 American Physical Therapy Association Health Policy and Administration Research Grant; 2019 USC Support to Promote Advancement of Research and Creativity Grant; AHA(American Heart Association); Promotion of Doctoral Studies (PODS)-Level I Scholarship from the Foundation for Physical Therapy Research; Arnold Fellowship from the Arnold School of Public Health, USC	This work was supported by the University of South Carolina (USC) Behavioral-Biomedical Interface Program-NIGMS/NIH-T32 2T326M081740-11A1, bbip.sc.edu (ER); 2019 American Heart Association (AHA) Pre-Doctoral Fellowship, Heart.org (ER); 2018 American Physical Therapy Association Health Policy and Administration Research Grant aptahpa.org (ER); 2019 USC Support to Promote Advancement of Research and Creativity Grant, sc.edu (ER); AHA Grant 15SDG24970011, Heart.org (JS); Promotion of Doctoral Studies (PODS)-Level I Scholarship from the Foundation for Physical Therapy Research, foundation4pt.org (RH); the Arnold Fellowship from the Arnold School of Public Health, USC (RH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ades PA, 2017, MAYO CLIN PROC, V92, P234, DOI 10.1016/j.mayocp.2016.10.014; Anderson S, 2011, TOP STROKE REHABIL, V18, P509, DOI 10.1310/tsr1805-509; Astley CM, 2017, J CARDIOVASC NURS, V32, P236, DOI 10.1097/JCN.0000000000000332; Balady GJ, 2011, CIRCULATION, V124, P2951, DOI 10.1161/CIR.0b013e31823b21e2; Balady GJ, 2000, CIRCULATION, V102, P1069, DOI 10.1161/01.CIR.102.9.1069; Biasin L, 2014, PHYS THER, V94, P1796, DOI 10.2522/ptj.20130404; Billinger SA, 2014, STROKE, V45, P2532, DOI 10.1161/STR.0000000000000022; Boisgontier MP, 2020, PHYS THER, V100, P743, DOI 10.1093/ptj/pzaa011; Boss HM, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-007065; Boss HM, 2014, NEUROREHABILITATION, V34, P401, DOI 10.3233/NRE-141049; Boyne P, 2017, J NEUROL PHYS THER, V41, P119, DOI 10.1097/NPT.0000000000000177; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Clark AM, 2013, EUR J PREV CARDIOL, V20, P692, DOI 10.1177/2047487312447846; Clark AM, 2012, AM HEART J, V164, P835, DOI 10.1016/j.ahj.2012.08.020; Cuccurullo SJ, 2019, AM J PHYS MED REHAB, V98, P953, DOI 10.1097/PHM.0000000000001214; Curnier Daniel Y, 2005, J Cardiopulm Rehabil, V25, P80, DOI 10.1097/00008483-200503000-00006; Damush TM, 2007, REHABIL NURS, V32, P253, DOI 10.1002/j.2048-7940.2007.tb00183.x; Dixon G, 2007, CLIN REHABIL, V21, P230, DOI 10.1177/0269215506071784; Dobkin BH, 2009, NEUROREHAB NEURAL RE, V23, P197, DOI 10.1177/1545968309331863; DUNBAR CC, 1992, MED SCI SPORT EXER, V24, P94; Eldridge SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150205; Ellis JM, 2018, J CARDIOPULM REHABIL, V38, P309, DOI 10.1097/HCR.0000000000000295; Hansen TB, 2015, EUR J PREV CARDIOL, V22, P710, DOI 10.1177/2047487314536364; Hardie K, 2004, STROKE, V35, P731, DOI 10.1161/01.STR.0000116183.50167.D9; Herber OR, 2017, J CLIN NURS, V26, P3529, DOI 10.1111/jocn.13722; Hubbard G, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009284; Kaushik V, 2019, SOC SCI-BASEL, V8, DOI 10.3390/socsci8090255; Kirk H, 2014, CLIN REHABIL, V28, P339, DOI 10.1177/0269215513502211; Kono Y, 2015, INT J STROKE, V10, P219, DOI 10.1111/ijs.12392; Kuys S, 2006, PHYSIOTHER RES INT, V11, P219, DOI 10.1002/pri.344; Lee J, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104498; Lennon O, 2008, CLIN REHABIL, V22, P125, DOI 10.1177/0269215507081580; Lennon O, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-9; Leon AS, 2005, CIRCULATION, V111, P369, DOI 10.1161/01.CIR.0000151788.08740.5C; Lindsay MP, 2019, WORLD STROKE ORG WSO; Livingston-Thomas J, 2016, NEUROTHERAPEUTICS, V13, P395, DOI 10.1007/s13311-016-0423-9; Lynggaard V, 2017, INT J CARDIOL, V236, P65, DOI 10.1016/j.ijcard.2017.02.051; MacKay-Lyons M, 2020, PHYS THER, V100, P149, DOI 10.1093/ptj/pzz153; MacKay-Lyons MJ, 2002, ARCH PHYS MED REHAB, V83, P1378, DOI 10.1053/apmr.2002.35089; Martin JJ, 2013, DISABIL REHABIL, V35, P2030, DOI 10.3109/09638288.2013.802377; Marzolini S, 2018, CAN J CARDIOL, V34, pS240, DOI 10.1016/j.cjca.2018.06.017; Marzolini S, 2014, J STROKE CEREBROVASC, V23, P1648, DOI 10.1016/j.jstrokecerebrovasdis.2014.01.008; Marzolini S, 2012, J CARDIOPULM REHABIL, V32, P127, DOI 10.1097/HCR.0b013e31824d2ab3; MedPac, 2019, REPORT C MEDICARE HE; Michael KM, 2005, ARCH PHYS MED REHAB, V86, P1552, DOI 10.1016/j.apmr.2004.12.026; Middleton A, 2015, J AGING PHYS ACTIV, V23, P314, DOI 10.1123/japa.2013-0236; Moore SA, 2015, NEUROREHAB NEURAL RE, V29, P623, DOI 10.1177/1545968314562116; Morris JH, 2014, ARCH PHYS MED REHAB, V95, P956, DOI 10.1016/j.apmr.2013.12.016; Neubeck L, 2012, EUR J PREV CARDIOL, V19, P494, DOI 10.1177/1741826711409326; Newitt R, 2016, DISABIL REHABIL, V38, P1, DOI 10.3109/09638288.2014.996676; Orsmond GI, 2015, OTJR-OCCUP PART HEAL, V35, P169, DOI 10.1177/1539449215578649; Pio CSD, 2020, INT J CARDIOL, V298, P1, DOI 10.1016/j.ijcard.2019.06.064; Regan E., 2020, INTEGRATING STROKE S; Regan EW, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.017907; Regan EW., 2020, CIRC-CARDIOVASC QUAL, V13, pA279; Rimmer J, 2017, DISABIL REHABIL, V39, P173, DOI 10.3109/09638288.2015.1047967; Robinson CA, 2011, PHYS THER, V91, P1865, DOI 10.2522/ptj.20100216; Rouleau CR, 2018, DISABIL REHABIL, V40, P469, DOI 10.1080/09638288.2016.1261417; Sebastian LA, 2015, J CARDIOVASC NURS, V30, P164, DOI 10.1097/JCN.0000000000000154; Services CfMM, MEDICARE CLAIMS PROC; Shaughnessy M, 2006, REHABIL NURS, V31, P15, DOI 10.1002/j.2048-7940.2006.tb00005.x; Shiran A, 1997, CARDIOLOGY, V88, P207, DOI 10.1159/000177331; Smith AC, 2012, INT J STROKE, V7, P499, DOI 10.1111/j.1747-4949.2012.00791.x; Thomas RJ, 2018, J AM COLL CARDIOL, V71, P1814, DOI 10.1016/j.jacc.2018.01.004; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042	65	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2021	16	3							e0247178	10.1371/journal.pone.0247178	http://dx.doi.org/10.1371/journal.pone.0247178			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RH6OZ	33780477	gold, Green Published			2023-01-03	WOS:000636336800046
J	Fraga, AZ; Louveau, I; Campos, PHRF; Hauschild, L; Le Floc'h, N				Zem Fraga, Alicia; Louveau, Isabelle; Campos, Paulo Henrique Reis Furtado; Hauschild, Luciano; Le Floc'h, Nathalie			Selection for feed efficiency elicits different postprandial plasma metabolite profiles in response to poor hygiene of housing conditions in growing pigs	PLOS ONE			English	Article							DIVERGENT SELECTION; AMINO-ACIDS; HEALTH; ENERGY; STIMULATION; INSULIN; IMPACT; GROWTH; MODEL; LINES	This study was conducted to compare postprandial plasma concentrations of insulin, energy-related metabolites, and amino acids measured after a 6-week challenge consisting of exposure to good or poor hygiene of housing conditions of 24 growing pigs divergently selected for low-RFI (LRFI) and high-RFI (HRFI). Blood indicators of immune responses were assessed from samples collected before 0 (W0), and 3 (W3), and 6 weeks (W6) after pigs transfer to their respective hygiene of housing conditions. Plasma haptoglobin concentrations and blood neutrophil granulocyte numbers were greater in poor than in good hygiene of housing conditions at W3. Plasma concentrations of total immunoglobulin G were greater (p = 0.04) in poor than in good hygiene of housing conditions at W6. At W6, pigs were fitted with an intravenous catheter for serial blood samplings. Low-RFI pigs had greater insulin (p < 0.001) and lower triglyceride (p = 0.04) average plasma concentrations than HRFI pigs in both conditions. In poor hygiene of housing conditions, the peaks of insulin and glucose were observed earlier and that of insulin was greater in LRFI than in HRFI pigs. Irrespective of genetic line, average plasma concentrations of histidine, isoleucine, leucine, methionine, threonine, valine, and alanine were greater in poor compared with good hygiene of housing conditions. Only HRFI pigs had greater lysine, asparagine, proline, and tyrosine plasma concentrations in poor than in good hygiene of housing conditions. Conversely, arginine, tryptophan, proline, and tyrosine plasma concentrations were lower only for LRFI pigs housed in poor hygiene conditions. Our results suggest that, contrary to HRFI, LRFI pigs increase or maintain their utilization of tryptophan, arginine, and lysine when housed in poor hygiene conditions. This indicates that this difference may contribute to the better capacity of LRFI to cope with poor hygiene of housing conditions.	[Zem Fraga, Alicia; Hauschild, Luciano] Sao Paulo State Univ, Sch Agr & Vet Sci, Dept Anim Sci, Jaboticabal, SP, Brazil; [Zem Fraga, Alicia; Louveau, Isabelle; Le Floc'h, Nathalie] Inst Agro, INRAE, PEGASE, St Gilles, France; [Campos, Paulo Henrique Reis Furtado] Univ Fed Vicosa, Dept Anim Sci, Vicosa, MG, Brazil	Universidade Estadual Paulista; INRAE; Institut Agro; Universidade Federal de Vicosa	Le Floc'h, N (corresponding author), Inst Agro, INRAE, PEGASE, St Gilles, France.	nathalie.lefloch@inrae.fr		Fraga, Alicia/0000-0002-3056-7441	European Union's Seventh Framework Programme for Research, Technological Development and Demonstration [613574]; Sao Paulo Research Foundation (FAPESP-Brazil) [2018/15559-7, 2018/11807-6]	European Union's Seventh Framework Programme for Research, Technological Development and Demonstration; Sao Paulo Research Foundation (FAPESP-Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was supported by the European Union's Seventh Framework Programme for Research, Technological Development and Demonstration (grant number 613574, PROHEALTH project). Ali ' cia Zem Fraga was supported by a scholarship from the Sao Paulo Research Foundation (FAPESP-Brazil; grant number 2018/15559-7 and fellowship number 2018/11807-6).	Barea R, 2010, J ANIM SCI, V88, P2062, DOI 10.2527/jas.2009-2395; Breuille D, 1999, INFECT IMMUN, V67, P1079, DOI 10.1128/IAI.67.3.1079-1085.1999; Chakrabarti P, 2013, MOL CELL BIOL, V33, P3659, DOI 10.1128/MCB.01584-12; Chatelet A, 2018, ANIMAL, V12, P350, DOI 10.1017/S1751731117001379; Cvitkovic S, 2004, PEDIATR RES, V55, P630, DOI 10.1203/01.PDR.0000113788.85515.7E; Davis TA, 1998, J NUTR, V128, p347S, DOI 10.1093/jn/128.2.347S; Eckersall PD, 2010, VET J, V185, P23, DOI 10.1016/j.tvjl.2010.04.009; Faure J, 2013, MEAT SCI, V93, P37, DOI 10.1016/j.meatsci.2012.07.006; Gilbert H, 2007, J ANIM SCI, V85, P3182, DOI 10.2527/jas.2006-590; Gilbert H, 2017, ANIMAL, V11, P1427, DOI 10.1017/S175173111600286X; Gloaguen M, 2012, J ANIM SCI, V90, P3135, DOI 10.2527/jas.2011-4956; Knap PW, 2009, VOLUNTARY FEED INTAKE IN PIGS, P13; Labussiere E, 2015, ANIMAL, V9, P1653, DOI 10.1017/S1751731115000932; Le Floc'h N, 2014, ANIMAL, V8, P1632, DOI 10.1017/S1751731114001608; Le Floc'h N, 2019, ARCH ANIM NUTR, V73, P255, DOI 10.1080/1745039X.2019.1627836; Le Floc'h N, 2018, ANIM FEED SCI TECH, V245, P104, DOI 10.1016/j.anifeedsci.2018.09.007; Le Floc'h N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104605; Le Floc'h N, 2011, AMINO ACIDS, V41, P1195, DOI 10.1007/s00726-010-0752-7; Le Naou T, 2012, J ANIM SCI, V90, P4771, DOI 10.2527/jas.2012-5226; Li P, 2007, BRIT J NUTR, V98, P237, DOI 10.1017/S000711450769936X; MATIS JH, 1989, BIOMETRICS, V45, P703, DOI 10.2307/2531678; McGilvray WD, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9060323; McGilvray WD, 2019, J ANIM SCI, V97, P2479, DOI 10.1093/jas/skz120; Merlot E, 2016, J ANIM SCI, V94, P563, DOI 10.2527/jas.2015-9445; Meunier-Salaun MC, 2014, ANIMAL, V8, P1898, DOI 10.1017/S1751731114001839; Montagne L, 2014, J ANIM SCI, V92, P1512, DOI 10.2527/jas.2013-6623; ODINK J, 1990, J ANIM SCI, V68, P163; Rakhshandeh A, 2012, J ANIM SCI, V90, P233, DOI 10.2527/jas.53976; RATKOWSKY DA, 1983, J BACTERIOL, V154, P1222, DOI 10.1128/JB.154.3.1222-1226.1983; Campos PHRF, 2019, J ANIM SCI, V97, P3354, DOI 10.1093/jas/skz204; Renaudeau D, 2013, J ANIM SCI, V91, P1162, DOI 10.2527/jas.2012-5689; Wu GY, 2009, AMINO ACIDS, V37, P153, DOI 10.1007/s00726-008-0210-y	32	1	1	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2021	16	3							e0246216	10.1371/journal.pone.0246216	http://dx.doi.org/10.1371/journal.pone.0246216			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH6OZ	33780478	gold, Green Published, Green Submitted			2023-01-03	WOS:000636336800001
J	Maxfield, K; Zineh, I				Maxfield, Kimberly; Zineh, Issam			Precision Dosing A Clinical and Public Health Imperative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Maxfield, Kimberly; Zineh, Issam] US FDA, Off Clin Pharmacol, Silver Spring, MD USA	US Food & Drug Administration (FDA)	Maxfield, K (corresponding author), US FDA, Off Clin Pharmacol, Off Translat Sci, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave,Bldg 51,Room 3146, Silver Spring, MD 20903 USA.	kimberly.maxfield@fda.hhs.gov						Agrawal S, 2020, CTS-CLIN TRANSL SCI, V13, P941, DOI 10.1111/cts.12781; Maxfield K, 2021, CLIN PHARMACOL THER, V109, P25, DOI 10.1002/cpt.1933; Relling MV, 2020, CLIN PHARMACOL THER, V107, P171, DOI 10.1002/cpt.1651; Roden DM, 2019, LANCET, V394, P521, DOI 10.1016/S0140-6736(19)31276-0; Tyson RJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00420; Watanabe JH, 2018, ANN PHARMACOTHER, V52, P829, DOI 10.1177/1060028018765159; Zhang YF, 2021, CLIN PHARMACOL THER, V109, P263, DOI 10.1002/cpt.1991	7	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	2021	325	15					1505	1506		10.1001/jama.2021.1004	http://dx.doi.org/10.1001/jama.2021.1004		MAR 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ8AS	33760028				2023-01-03	WOS:000633051600002
J	Burns, KEA; Rizvi, L; Cook, DJ; Lebovic, G; Dodek, P; Villar, J; Slutsky, AS; Jones, A; Kapadia, FN; Gattas, DJ; Epstein, SK; Pelosi, P; Kefala, K; Meade, MO				Burns, Karen E. A.; Rizvi, Leena; Cook, Deborah J.; Lebovic, Gerald; Dodek, Peter; Villar, Jesus; Slutsky, Arthur S.; Jones, Andrew; Kapadia, Farhad N.; Gattas, David J.; Epstein, Scott K.; Pelosi, Paolo; Kefala, Kallirroi; Meade, Maureen O.			Ventilator Weaning and Discontinuation Practices for Critically Ill Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Key PointsQuestionIn critically ill patients who receive invasive mechanical ventilation, how is invasive mechanical ventilation discontinued and do discontinuation practices differ internationally? FindingsIn this prospective observational study that included 1868 patients from 142 intensive care units in Canada, Europe, the US, India, the UK, and Australia/New Zealand from November 2013 to December 2016, 22.7% of patients underwent direct extubation, 49.8% underwent an initial spontaneous breathing trial (of which 81.8% had successful extubation), 8.0% had a direct tracheostomy, and 19.5% died before a weaning attempt. There was notable variation in several aspects of mechanical ventilation weaning practices. MeaningMechanical ventilation weaning practices varied internationally, with nearly 50% of patients undergoing an initial spontaneous breathing trial. ImportanceAlthough most critically ill patients receive invasive mechanical ventilation (IMV), few studies have characterized how IMV is discontinued in practice. ObjectiveTo describe practice variation in IMV discontinuation internationally, associations between initial discontinuation events and outcomes, and factors associated with the use of select discontinuation strategies and failed initial spontaneous breathing trials (SBTs). Design, Setting, and ParticipantsProspective, multinational, observational study of critically ill adults who received IMV for at least 24 hours from 142 intensive care units (ICUs) in 19 countries within 6 regions (27 in Canada, 23 in India, 22 in the UK, 26 in Europe, 21 in Australia/New Zealand, and 23 in the US). ExposuresReceiving IMV. Main Outcomes and MeasuresPrimary analyses characterized types of initial IMV discontinuation events (extubation, SBT, or tracheostomy) and associations with clinical outcomes (including duration of ventilation, ICU and hospital mortality, and ICU and hospital length of stay). Secondary analyses examined the associations between SBT outcome and SBT timing and clinical outcomes. ResultsAmong 1868 patients (median [interquartile range] age, 61.8 [48.9-73.1] years; 1173 [62.8%] men) 424 (22.7%) underwent direct extubation, 930 (49.8%) had an initial SBT (761 [81.8%] successful), 150 (8.0%) underwent direct tracheostomy, and 364 (19.5%) died before a weaning attempt. Across regions, there was variation in the use of written directives to guide care, daily screening, SBT techniques, ventilator modes, and the roles played by clinicians involved in weaning. Compared with initial direct extubation, patients who had an initial SBT had higher ICU mortality (20 [4.7%] vs 96 [10.3%]; absolute difference, 5.6% [95% CI, 2.6%-8.6%]), longer duration of ventilation (median of 2.9 vs 4.1 days; absolute difference, 1.2 days [95% CI, 0.7-1.6]), and longer ICU stay (median of 6.7 vs 8.1 days; absolute difference, 1.4 days [95% CI, 0.8-2.4]). Patients whose initial SBT failed (vs passed) had higher ICU mortality (29 [17.2%] vs 67 [8.8%]; absolute difference, 8.4% [95% CI, 2.0%-14.7%]), longer duration of ventilation (median of 6.1 vs 3.5 days; absolute difference, 2.6 days [95% CI, 1.6-3.6]), and longer ICU stay (median of 10.6 vs 7.7 days; absolute difference, 2.8 days [95% CI, 1.1-5.2]). Compared with patients who underwent early initial SBTs, patients who underwent late initial SBTs (>2.3 days after intubation) had longer duration of ventilation (median of 2.1 vs 6.1 days; absolute difference, 4.0 days [95% CI, 3.7-4.5]), longer ICU stay (median of 5.9 vs 10.8 days; absolute difference, 4.9 days [95% CI, 4.0-6.3]), and longer hospital stay (median of 14.3 vs 22.8 days; absolute difference, 8.5 days [95% CI, 6.0-11.0]). Conclusions and RelevanceIn this observational study of invasive mechanical ventilation discontinuation in 142 ICUs in Canada, India, the UK, Europe, Australia/New Zealand, and the US from 2013 to 2016, weaning practices varied internationally. Trial RegistrationClinicalTrials.gov Identifier: NCT03955874 This critical care epidemiology study describes practice variation in invasive mechanical ventilation weaning and discontinuation practices, associations between initial discontinuation events and outcomes, and factors associated with use of select discontinuation strategies and failed initial spontaneous breathing trials among critically ill patients in ICUs in 19 countries.	[Burns, Karen E. A.; Slutsky, Arthur S.] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Burns, Karen E. A.; Rizvi, Leena; Slutsky, Arthur S.] Unity Hlth Toronto, St Michaels Hosp, Div Crit Care Med, Dept Med, Toronto, ON, Canada; [Burns, Karen E. A.; Villar, Jesus; Slutsky, Arthur S.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Cook, Deborah J.] St Josephs Hosp, Div Crit Care Med, Hamilton, ON, Canada; [Cook, Deborah J.; Meade, Maureen O.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Cook, Deborah J.; Meade, Maureen O.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Lebovic, Gerald] St Michaels Hosp, Appl Hlth Res Ctr, Toronto, ON, Canada; [Dodek, Peter] Univ British Columbia, St Pauls Hosp, Div Crit Care Med, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada; [Villar, Jesus] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Las Palmas Gran Canaria, Spain; [Jones, Andrew] Guys & St Thomas NHS Fdn Trust, Dept Crit Care Med, London, England; [Kapadia, Farhad N.] Hinduja Natl Hosp, Dept Intens Care, Bombay, Maharashtra, India; [Gattas, David J.] Univ Sydney, Royal Prince Alfred Hosp, Intens Care Unit, Camperdown, NSW, Australia; [Gattas, David J.] George Inst Global Hlth, Sydney, NSW, Australia; [Epstein, Scott K.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, Genoa, Italy; [Pelosi, Paolo] IRCCS Oncol & Neurosci, San Martino Policlin Hosp, Genoa, Italy; [Kefala, Kallirroi] Royal Edinburgh Infirm, Anaesthesia Crit Care & Pain Med, Edinburgh, Midlothian, Scotland	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; McGill University; McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Guy's & St Thomas' NHS Foundation Trust; University of Sydney; George Institute for Global Health; University of Sydney; Tufts University; University of Genoa; Royal Infirmary of Edinburgh	Burns, KEA (corresponding author), St Michaels Hosp, Unity Hlth Toronto, Interdept Div Crit Care Med, 30 Bond St, Toronto, ON M5B 1W8, Canada.	karen.burns@unityhealth.to	Slutsky, Arthur/M-3325-2019; Villar, Jesús/R-4526-2019	Villar, Jesús/0000-0001-5687-3562; Nichol, Alistair/0000-0002-4689-1238				Beduneau G, 2017, AM J RESP CRIT CARE, V195, P772, DOI 10.1164/rccm.201602-0320OC; Blackwood B, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006904.pub3; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Burns KEA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031775; Burns KEA, 2018, ANN AM THORAC SOC, V15, P494, DOI 10.1513/AnnalsATS.201705-410OC; Burns KEA, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1698-x; Carson Shannon S, 2006, J Intensive Care Med, V21, P173, DOI 10.1177/0885066605282784; Ely EW, 1999, INTENS CARE MED, V25, P581, DOI 10.1007/s001340050906; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; HOLM S, 1979, SCAND J STAT, V6, P65; Kalassian KG, 2002, CRIT CARE, V6, P11; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Melsen WG, 2013, LANCET INFECT DIS, V13, P665, DOI 10.1016/S1473-3099(13)70081-1; Needham DM, 2005, CRIT CARE MED, V33, P574, DOI [10.1097/01.CCM.0000155992.21174.31, 10.1097/01.ccm.0000155992.21174.31]; Ouellette DR, 2017, CHEST, V151, P166, DOI 10.1016/j.chest.2016.10.036; Rengel KF, 2019, ANESTH ANALG, V128, P772, DOI 10.1213/ANE.0000000000004066; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Schultz MJ, 2005, J CRIT CARE, V20, P199, DOI 10.1016/j.jcrc.2005.05.007; Subira C, 2019, JAMA-J AM MED ASSOC, V321, P2175, DOI 10.1001/jama.2019.7234; Tallgren M, 2009, ACTA ANAESTH SCAND, V53, P39, DOI 10.1111/j.1399-6576.2008.01825.x; Tripepi G, 2010, NEPHRON CLIN PRACT, V115, pC94, DOI 10.1159/000312871; Van Buuren S., 2018, FLEXIBLE IMPUTATION; van Calster B, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1466-7; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Wunsch H, 2013, CRIT CARE MED, V41, P2712, DOI 10.1097/CCM.0b013e318298a139; Wunsch H, 2010, CRIT CARE MED, V38, P1947, DOI 10.1097/CCM.0b013e3181ef4460	30	21	23	3	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2021	325	12					1173	1184		10.1001/jama.2021.2384	http://dx.doi.org/10.1001/jama.2021.2384			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ7PB	33755077	Green Published, Bronze			2023-01-03	WOS:000637792300015
J	Das, MK; Arora, NK; Chellani, HK; Debata, PK; Meena, KR; Rasaily, R; Kaur, G; Malik, P; Joshi, S; Kumari, M				Das, Manoja Kumar; Arora, Narendra Kumar; Chellani, Harish Kumar; Debata, Pradeep Kumar; Meena, K. R.; Rasaily, Reeta; Kaur, Gurkirat; Malik, Prikanksha; Joshi, Shipra; Kumari, Manisha			Perceptions of the parents of deceased children and of healthcare providers about end-of-life communication and breaking bad news at a tertiary care public hospital in India: A qualitative exploratory study	PLOS ONE			English	Article							DEATH; PERSPECTIVES; EXPERIENCES; COMPETENCE; PROTOCOL; VIOLENCE; FAMILY; CANCER; DIES	Author summary The parents of terminally ill and dying children face unimaginably psychological stress and have strong need for compassionate professional support. To improve the parents and family experience, there is need for obtaining feedback and documenting the experiences of parents, family and healthcare providers with reference to the local contexts. There is limited information on parents experience on end-of-life communication related to their child death from Indian context. An exploratory qualitative study was conducted at a tertiary care hospital in India involved in-depth interviews with parents and family of deceased children and healthcare providers (HCPs: doctors, nurses and support staffs) involved in treating children. Parents remembered the communication by junior doctors as brief, inappropriate and insensitive, while the senior doctor's communication was positive and complete. The death declaration by resident doctors was remembered as non-empathetic, blunt and cold. No emotional support was received by them around and after child's death. The doctors were affected emotionally with death of the patients, but were constrained with high workload, infrastructural limitations and lack of training in communication. Preparation of context specific, sociocultural appropriate module and communication training for HCPs can improve their competence for providing end-of-life care, breaking bad news and also parents experience. Background Parents of dying children face unique challenge and expect compassionate support from health care providers (HCPs). This study explored the experiences of the parents and HCPs about the end-of-life care and breaking bad news and related positive and negative factors in Indian context. Methods This qualitative exploratory study was conducted at paediatrics department of a tertiary care hospital in Delhi. In-depth interviews with the parents (n = 49) and family members (n = 21) of the children died at the hospital and HCPs (6 doctors, 6 nurses and 4 support staffs) were conducted. Also events and communication around death of eight children were observed. Data were inductively analysed using thematic content analysis method to identify emerging themes and codes. Results Doctors were the lead communicators. Majority of parents perceived the attitude, communication and language used as by resident doctors as brief, insensitive and sometimes inappropriate or negative. They perceived that the attitude and communication by senior doctor's as empathetic, positive and complete. Parents recalled the death declaration by resident doctors as non-empathetic, blunt and cold. Most parents received no emotional support from HCPs during and after death of their child. All doctors expressed that death of their patients affected them and their emotions, which they coped through different activities. The overcrowded wards, high workload, infrastructural limitation and no formal communication training added to the emotional stress of the HCPs. Conclusions Majority of the communication by the HCPs during the hospitalisation and end-of-life period were perceived as suboptimal by the parents. The HCPs were emotionally affected and faced end-of-life communication challenges. The study highlights the communication by HCPs and support for parents during the end-of-life communication and breaking bad news. It suggests adoption of context specific communication protocol and materials and training of HCPs in communication to improve the quality of care.	[Das, Manoja Kumar; Arora, Narendra Kumar; Kaur, Gurkirat; Malik, Prikanksha; Joshi, Shipra; Kumari, Manisha] INCLEN Trust Int, New Delhi, India; [Chellani, Harish Kumar; Debata, Pradeep Kumar; Meena, K. R.] Safdarjang Hosp, Dept Pediat, New Delhi, India; [Chellani, Harish Kumar; Debata, Pradeep Kumar; Meena, K. R.] Vardhman Mahavir Med Coll, New Delhi, India; [Rasaily, Reeta] Indian Council Med Res, Div Reprod Biol Maternal & Child Hlth, New Delhi, India	Vardhman Mahavir Medical College & Safdarjung Hospital; Vardhman Mahavir Medical College & Safdarjung Hospital; Indian Council of Medical Research (ICMR)	Das, MK (corresponding author), INCLEN Trust Int, New Delhi, India.	manoj@inclentrust.org	Das, Manoja/I-2558-2017	Das, Manoja/0000-0002-8559-5837	INCLEN Trust International by Bill and Melinda Gates Foundation through Indian Council of Medical Research [OPP1184205, 5/7/1504/2016-CH]	INCLEN Trust International by Bill and Melinda Gates Foundation through Indian Council of Medical Research	This study is funded to The INCLEN Trust International by Bill and Melinda Gates Foundation (OPP1184205) through Indian Council of Medical Research (no 5/7/1504/2016-CH). The funders had no role in study planning, conduct, analysis and manuscript preparation.	[Anonymous], 2003, CHILDREN DIE IMPROVE; Arber Anne, 2003, Int J Palliat Nurs, V9, P166; Aschenbrenner AP, 2012, J PEDIATR NURS, V27, P514, DOI 10.1016/j.pedn.2011.07.008; Baig L, 2018, PAK J MED SCI, V34, P294, DOI 10.12669/pjms.342.14432; Bassat Q, 2013, LANCET GLOB HEALTH, V1, pE125, DOI 10.1016/S2214-109X(13)70037-8; Berry P., 2001, BMJ-BRIT MED J, V323, P1373; Castillo P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132057; Das MK, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0665-1; de Leo D., 2015, HUMANITIES, V4, P702, DOI [10.3390/h4040702, DOI 10.3390/H4040702]; Dean A, 2016, INT J PALLIAT NURS, V22, P265, DOI 10.12968/ijpn.2016.22.6.265; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; Dighe MP, 2012, CONTEMPORARY AND INNOVATIVE PRACTICE IN PALLIATIVE CARE, P115; Eggly S, 1997, ACAD MED, V72, P397, DOI 10.1097/00001888-199705000-00023; FINLAY I, 1991, BRIT MED J, V302, P1524, DOI 10.1136/bmj.302.6791.1524; Geeta MG, 2017, INDIAN PEDIATR, V54, P685, DOI 10.1007/s13312-017-1135-x; Gillio-Meina C, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-0490; GIRGIS A, 1995, J CLIN ONCOL, V13, P2449, DOI 10.1200/JCO.1995.13.9.2449; Gold KJ, 2007, J PERINATOL, V27, P230, DOI 10.1038/sj.jp.7211676; Kreicbergs UC, 2007, J CLIN ONCOL, V25, P3307, DOI 10.1200/JCO.2006.10.0743; Kubler-Ross E, 2005, GRIEF GRIEVING FINDI; Kvale J, 1999, Fam Med, V31, P691; Lamiani G, 2013, MINERVA ANESTESIOL, V79, P1334; Mast MS, 2005, PATIENT EDUC COUNS, V58, P244, DOI 10.1016/j.pec.2005.05.005; Medical Council of India, 2018, ATT ETH COMM AETCOM; Melin-Johansson C, 2014, J PEDIATR NURS, V29, P660, DOI 10.1016/j.pedn.2014.06.009; Narayanan V, 2010, INDIAN J PALLIAT CAR, V16, P61, DOI 10.4103/0973-1075.68401; O'Malley P, 2014, J EMERG NURS, V40, pE83, DOI 10.1016/j.jen.2014.05.003; O'Malley PJ, 2008, PEDIATRICS, V122, pE511, DOI 10.1542/peds.2008-1569; Parker PA, 2001, J CLIN ONCOL, V19, P2049, DOI 10.1200/JCO.2001.19.7.2049; Price J, 2006, INT J PALLIAT NURS, V12, P115, DOI 10.12968/ijpn.2006.12.3.20695; Ptacek JT, 2001, J BEHAV MED, V24, P205, DOI 10.1023/A:1010766732373; Rabow MW, 1999, WESTERN J MED, V171, P260; Rahim AA, 2017, NATL MED J INDIA, V30, P332, DOI 10.4103/0970-258X.239076; ROBERTS CS, 1994, CANCER, V74, P336, DOI 10.1002/cncr.2820741319; Singh G, 2019, INDIAN J PUBLIC HLTH, V63, P143, DOI 10.4103/ijph.IJPH_70_18; Stevens M., 2004, OXFORD TXB PALLIATIV, V3rd ed., P807; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; Vail L, 2011, PATIENT EDUC COUNS, V83, P185, DOI 10.1016/j.pec.2010.05.016; Xafis V, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0024-0; Zimmermann K, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0098-3	40	2	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0248661	10.1371/journal.pone.0248661	http://dx.doi.org/10.1371/journal.pone.0248661			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QZ9HN	33735296	Green Published, gold			2023-01-03	WOS:000631029700057
J	Kaewput, W; Thongprayoon, C; Petnak, T; Cheungpasitporn, W; Qureshi, F; Boonpheng, B; Vallabhajosyula, S; Bathini, T; Salim, SA; Fulop, T				Kaewput, Wisit; Thongprayoon, Charat; Petnak, Tananchai; Cheungpasitporn, Wisit; Qureshi, Fawad; Boonpheng, Boonphiphop; Vallabhajosyula, Saraschandra; Bathini, Tarun; Salim, Sohail Abdul; Fulop, Tibor			Rhabdomyolysis among hospitalized patients for salicylate intoxication in the United States: Nationwide inpatient sample 2003-2014	PLOS ONE			English	Article								Introduction This study aimed to assess the risk factors and impact of rhabdomyolysis on treatments, outcomes, and resource utilization in hospitalized patients for salicylate intoxication in the United States. Materials and methods The National Inpatient Sample was utilized to identify hospitalized patients with a primary diagnosis of salicylate intoxication from 2003-2014. Rhabdomyolysis was identified using hospital diagnosis code. We compared the clinical characteristics, in-hospital treatment, outcomes, and resource utilization between patients with and without rhabdomyolysis. Results A total of 13,805 hospital admissions for salicylate intoxication were studied. Of these, rhabdomyolysis developed in 258 (1.9%) admissions. The risk factors for rhabdomyolysis were age>20 years, male sex, volume depletion, hypokalemia, sepsis, and seizure. After adjustment for baseline clinical characteristics, salicylate intoxication patients with rhabdomyolysis required more invasive mechanical ventilation, and renal replacement therapy. Rhabdomyolysis was significantly associated with higher risk of failure of any organ systems, and in- hospital mortality. Length of hospital stay and hospitalization cost were higher when rhabdo- myolysis occurred during hospital stay. Conclusions Rhabdomyolysis was not common in hospitalized patients for salicylate intoxication but it was associated with increased morbidity, mortality, and resource utilization.	[Kaewput, Wisit] Phramongkutklao Coll Med, Dept Mil & Community Med, Bangkok, Thailand; [Thongprayoon, Charat; Cheungpasitporn, Wisit; Qureshi, Fawad] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA; [Petnak, Tananchai] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Pulm & Crit Care Med, Bangkok, Thailand; [Petnak, Tananchai] Mayo Clin, Div Pulm & Crit Care Med, Dept Med, Rochester, MN USA; [Boonpheng, Boonphiphop] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Vallabhajosyula, Saraschandra] Emory Univ, Dept Med, Div Cardiovasc Med, Sect Intervent Cardiol,Sch Med, Atlanta, GA USA; [Bathini, Tarun] Univ Arizona, Dept Internal Med, Tucson, AZ USA; [Salim, Sohail Abdul] Univ Mississippi, Med Ctr, Dept Med, Div Nephrol, Jackson, MS 39216 USA; [Fulop, Tibor] Med Univ South Carolina, Dept Internal Med, Div Nephrol, Charleston, SC 29425 USA; [Fulop, Tibor] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	Phramongkutklao College of Medicine; Mayo Clinic; Mahidol University; Mayo Clinic; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Emory University; University of Arizona; University of Mississippi; University of Mississippi Medical Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kaewput, W (corresponding author), Phramongkutklao Coll Med, Dept Mil & Community Med, Bangkok, Thailand.	wisitnephro@gmail.com	Thongprayoon, Charat/J-4184-2019; Vallabhajosyula, Saraschandra/I-9707-2019; Petnak, Tananchai/ABH-9986-2020; Kaewput, Wisit/Y-3472-2018	Thongprayoon, Charat/0000-0002-8313-3604; Vallabhajosyula, Saraschandra/0000-0002-1631-8238; Kaewput, Wisit/0000-0003-2920-7235; Petnak, Tananchai/0000-0002-7633-4029				[Anonymous], EPUB 2009 09 30, DOI [10.1371/journal.pone.0007182, DOI 10.1371/JOURNAL.PONE.0007182]; [Anonymous], INTENSIVE CARE MED, DOI [10.1007/s001340050882, DOI 10.1007/S001340050882]; [Anonymous], **DROPPED REF**, Patent No. 2001.016009606.x; Bathini T, 2020, MEDICINES BASEL, V7, DOI [10.3390/medicines7060032P, DOI 10.3390/MEDICINES7060032P]; Betrosian A, 1999, INTENS CARE MED, V25, P469, DOI 10.1007/s001340050882; Bosch X, 2009, NEW ENGL J MED, V361, P62, DOI 10.1056/NEJMra0801327; Chavez LO, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1314-5; DURNAS C, 1992, DRUG AGING, V2, P20, DOI 10.2165/00002512-199202010-00004; GLEDHILL RF, 1988, J NEUROL NEUROSUR PS, V51, P301, DOI 10.1136/jnnp.51.2.301; Gummin DD, 2019, CLIN TOXICOL, V57, P1220, DOI 10.1080/15563650.2019.1677022; Keltz Eran, 2013, Muscles Ligaments Tendons J, V3, P303; Kumar AA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007182; LEVENTHAL LJ, 1989, AM J EMERG MED, V7, P409, DOI 10.1016/0735-6757(89)90049-1; LEVY G, 1975, AM J DIS CHILD, V129, P1385, DOI 10.1001/archpedi.1975.02120490003001; Lim AKH, 2020, WORLD J GASTROENTERO, V26, P1020, DOI 10.3748/wjg.v26.i10.1020; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; MONTGOMERY H, 1994, AM J EMERG MED, V12, P531, DOI 10.1016/0735-6757(94)90271-2; Palmer BF, 2020, NEW ENGL J MED, V382, P2544, DOI 10.1056/NEJMra2010852; Pearlman BL, 2009, POSTGRAD MED, V121, P162, DOI 10.3810/pgm.2009.07.2041; Thongprayoon C, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13745; Thongprayoon C, 2020, HOSP PRACT, V48, P276, DOI 10.1080/21548331.2020.1792214; WONG ET, 1983, AM J CLIN PATHOL, V79, P582, DOI 10.1093/ajcp/79.5.582	22	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2021	16	3							e0248242	10.1371/journal.pone.0248242	http://dx.doi.org/10.1371/journal.pone.0248242			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU3OZ	33684174	Green Published, gold			2023-01-03	WOS:000627193500021
J	Shin, KY; Lim, DH; Moon, CH; Kim, BJ; Chung, TY				Shin, Kyoung Yoon; Lim, Dong Hui; Moon, Chan Hee; Kim, Byung Jin; Chung, Tae-Young			Intense pulsed light plus meibomian gland expression versus intense pulsed light alone for meibomian gland dysfunction: A randomized crossover study	PLOS ONE			English	Article							LIPID LAYER THICKNESS; DRY EYE DISEASE; INTERNATIONAL WORKSHOP; THERAPY; EFFICACY; SYMPTOMS; DEVICE	Purpose To investigate the comparative efficacy of intense pulsed light (IPL) therapy alone with that of IPL plus meibomian gland expression (MGX) for meibomian gland dysfunction (MGD). Methods This is a prospective randomized crossover clinical trial. Sixty patients were enrolled and randomly assigned to two groups. All of patients underwent four treatment sessions in total, which were two weeks apart. Group 1 underwent two sessions of IPL therapy with MGX, as well as two sessions of IPL alone. Group 2 received two sessions of IPL therapy alone, and two sessions of IPL therapy with MGX. The following parameters were measured at baseline (BL), 2 weeks after the second treatment session (FU1), and 2 weeks after the fourth treatment session (FU2): tearfilm break-up time (BUT), Oxford grade for corneal staining, meibomian gland expressibility (MGE), meibum quality (MQ), and ocular surface disease index (OSDI). The separate effect of MGX on improvement of MGD parameters was evaluated using generalized estimating equation (GEE). Results The mean age of the participants was 57.52 +/- 10.50 years. The BUT, Oxford grade, MGE, MQ, and OSDI of both groups improved significantly (from baseline) by the end of four treatment sessions (FU2 compared to BL; all p-values < 0.05). The MGE and MQ significantly improved after the first and second treatment sessions (FU1 compare to BL; all p-values < 0.001). However, the improvement was not statistically significant after the third and fourth treatment sessions (FU2 compared to FU1; p-value of 0.388 for MGE and 0.645 for MQ in group 1, 0.333 for MGE and 0.333 for MQ in group 2). The IPL plus MGX therapy produced greater improvements in the BUT scores than did IPL therapy alone (p = 0.003 by GEE). In contrast, the Oxford grade, MGE, MQ, and OSDI were not influenced by the addition of MGX to IPL (p = 0.642, 0.663, 0.731, and 0.840, respectively by GEE). Conclusion IPL therapy effectively improves the subjective symptoms and objective ocular findings of MGD. MGX enhanced the improvement of BUT driven by IPL therapy. The meibomian gland function (MGE and MQ) recovers faster in response to IPL therapy than did the other parameters.	[Shin, Kyoung Yoon] Seongnam Citizens Med Ctr, Dept Ophthalmol, Seongnam, South Korea; [Lim, Dong Hui; Chung, Tae-Young] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, Seoul, South Korea; [Moon, Chan Hee; Kim, Byung Jin] Samsung Eye Clin, Dept Ophthalmol, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Samsung	Chung, TY (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, Seoul, South Korea.; Kim, BJ (corresponding author), Samsung Eye Clin, Dept Ophthalmol, Seoul, South Korea.	feeloph@naver.com; tychung@skku.edu		Chung, Tae-Young/0000-0002-7291-822X	National Research Foundation of Korea - Korean Government's Ministry of Education (Seoul, Korea) [NRF-2020R1A2C2014139]	National Research Foundation of Korea - Korean Government's Ministry of Education (Seoul, Korea)	This work was supported by a National Research Foundation of Korea grant funded by the Korean Government's Ministry of Education (NRF-2020R1A2C2014139; Seoul, Korea) which was received by Tae-Young Chung. The funding organizations had no role in the design or conduct of this research.	Amano S, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23553; Arita R, 2019, OCUL SURF, V17, P104, DOI 10.1016/j.jtos.2018.11.004; Arita R, 2018, CORNEA, V37, P1566, DOI 10.1097/ICO.0000000000001687; Arita R, 2016, AM J OPHTHALMOL, V169, P125, DOI 10.1016/j.ajo.2016.06.025; Asiedu K, 2016, CORNEA, V35, P175, DOI 10.1097/ICO.0000000000000712; Bron AJ, 2003, CORNEA, V22, P640, DOI 10.1097/00003226-200310000-00008; Craig JP, 2015, INVEST OPHTH VIS SCI, V56, P1965, DOI 10.1167/iovs.14-15764; CRAIG JP, 1995, OPHTHAL PHYSL OPT, V15, P569, DOI 10.1046/j.1475-1313.1995.9500071k.x; Dell SJ, 2017, CLIN OPHTHALMOL, V11, DOI 10.2147/OPTH.S139894; Dell SJ, 2017, CLIN OPHTHALMOL, V11, P817, DOI 10.2147/OPTH.S130706; Guilloto Caballero S, 2017, Arch Soc Esp Oftalmol, V92, P509, DOI 10.1016/j.oftal.2016.12.018; Gupta PK, 2016, CAN J OPHTHALMOL, V51, P249, DOI 10.1016/j.jcjo.2016.01.005; Hom M M, 1987, J Am Optom Assoc, V58, P223; Hubbard AE, 2010, EPIDEMIOLOGY, V21, P467, DOI 10.1097/EDE.0b013e3181caeb90; Jiang XD, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/1910694; Julious SA, 2004, STAT MED, V23, P1921, DOI 10.1002/sim.1783; Kim Y, 2019, IEEE INT C BIOINFORM, P1211, DOI 10.1109/BIBM47256.2019.8983309; Korb DR, 2011, EYE CONTACT LENS, V37, P298, DOI 10.1097/ICL.0b013e31821bc7c5; KORB DR, 1994, ADV EXP MED BIOL, V350, P293; Lee H, 2017, CLIN EXP OPTOM, V100, P598, DOI 10.1111/cxo.12532; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MATHERS WD, 1993, OPHTHALMOLOGY, V100, P347; Matsumoto Y, 2006, CORNEA, V25, P644, DOI 10.1097/01.ico.0000208822.70732.25; MCCULLEY JP, 1977, AM J OPHTHALMOL, V84, P788, DOI 10.1016/0002-9394(77)90497-4; Mitra M, 2005, EYE, V19, P657, DOI 10.1038/sj.eye.6701611; Mori A, 1999, CORNEA, V18, P188, DOI 10.1097/00003226-199903000-00008; Nam SW, 2016, J KOR OPHTHALMOL SOC, V57, P724, DOI 10.3341/jkos.2016.57.5.724; Nichols KK, 2011, INVEST OPHTH VIS SCI, V52, P1922, DOI 10.1167/iovs.10-6997a; Olson Mary Catherine, 2003, Eye Contact Lens, V29, P96, DOI 10.1097/01.ICL.0000060998.20142.8D; Piyacomn Y, 2019, CORNEA; Pult H, 2012, OPTOMETRY VISION SCI, V89, pE760, DOI 10.1097/OPX.0b013e3182512ac1; Raulin C, 2003, LASER SURG MED, V32, P78, DOI 10.1002/lsm.10145; Schaumberg DA, 2011, INVEST OPHTH VIS SCI, V52, P1994, DOI 10.1167/iovs.10-6997e; SHIMAZAKI J, 1995, ARCH OPHTHALMOL-CHIC, V113, P1266, DOI 10.1001/archopht.1995.01100100054027; Tomlinson A, 2011, INVEST OPHTH VIS SCI, V52, P2006, DOI 10.1167/iovs.10-6997f; Toyos R, 2015, PHOTOMED LASER SURG, V33, P41, DOI 10.1089/pho.2014.3819; Vegunta S, 2016, CORNEA, V35, P318, DOI 10.1097/ICO.0000000000000735; Vora GK, 2015, CURR OPIN OPHTHALMOL, V26, P314, DOI 10.1097/ICU.0000000000000166	38	7	7	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2021	16	3							e0246245	10.1371/journal.pone.0246245	http://dx.doi.org/10.1371/journal.pone.0246245			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT5BY	33662017	Green Published, gold			2023-01-03	WOS:000626604100061
J	King, C; Vega, T; Button, D; Nicolaidis, C; Gregg, J; Englander, H				King, Caroline; Vega, Taylor; Button, Dana; Nicolaidis, Christina; Gregg, Jessica; Englander, Honora			Understanding the impact of the SARS-COV-2 pandemic on hospitalized patients with substance use disorder	PLOS ONE			English	Article							ADDICTION; COVID-19; PEOPLE; CHALLENGES; OUTCOMES; LESSONS; STIGMA; ADULTS; DRUG	Background The SARS-COV-2 pandemic rapidly shifted dynamics around hospitalization for many communities. This study aimed to evaluate how the pandemic altered the experience of healthcare, acute illness, and care transitions among hospitalized patients with substance use disorder (SUD). Methods We performed a qualitative study at an academic medical center in Portland, Oregon, in Spring 2020. We conducted semi-structured interviews, and conducted a thematic analysis, using an inductive approach, at a semantic level. Results We enrolled 27 participants, and identified four main themes: 1) shuttered community resources threatened patients' basic survival adaptations; 2) changes in outpatient care increased reliance on hospitals as safety nets; 3) hospital policy changes made staying in the hospital harder than usual; and, 4) care transitions out of the hospital were highly uncertain. Discussion Hospitalized adults with SUD were further marginalized during the SARS-COV-2 pandemic. Systems must address the needs of marginalized patients in future disruptive events.	[King, Caroline; Nicolaidis, Christina; Gregg, Jessica; Englander, Honora] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; [King, Caroline; Vega, Taylor; Button, Dana] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA; [Nicolaidis, Christina] Portland State Univ, Sch Social Work, Portland, OR 97207 USA; [Gregg, Jessica] De Paul Treatment Ctr, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Portland State University	King, C (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.; King, C (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA.	kingca@ohsu.edu	Nicolaidis, Christina/CAC-0028-2022; Nicolaidis, Christina/X-6468-2019	Nicolaidis, Christina/0000-0002-9394-5956; Nicolaidis, Christina/0000-0002-9394-5956; Button, Dana/0000-0002-8373-1444; Englander, Honora/0000-0003-1863-2041	National Institutes of Health, National Institute on Drug Abuse [UG1DA015815/R01DA037441]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1TR002369]; NIH Roadmap for Medical Research; National Center for Advancing Translational Sciences, National Institutes of Health [TL1TR002371]	National Institutes of Health, National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	CK and HE were supported by grants from the National Institutes of Health, National Institute on Drug Abuse (UG1DA015815/R01DA037441). This publication was also made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1TR002369 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. CK was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Award Number TL1TR002371. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2020, OHSU BOARD DIR M; [Anonymous], OHSU FAST FACTS 2021; [Anonymous], 2020, CORONAVIRUS PANDEMIC; [Anonymous], 2018, DED VERS 7 0 23 WEB; Baah FO, 2019, NURS INQ, V26, DOI 10.1111/nin.12268; Biancarelli DL, 2019, DRUG ALCOHOL DEPEN, V198, P80, DOI 10.1016/j.drugalcdep.2019.01.037; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brondani MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177388; Cacciola JS, 2013, J SUBST ABUSE TREAT, V44, P256, DOI 10.1016/j.jsat.2012.07.013; Cameron AY, 2020, SUICIDE LIFE-THREAT, V50, P292, DOI 10.1111/sltb.12588; CDC, 2020, COVID 19 CAS RAT US; Chenneville T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124548; Chua IS, 2020, J PALLIAT MED, V23, P1507, DOI 10.1089/jpm.2020.0298; Clark-Ginsberg A, 2020, COMPLEXITY APPROACH, DOI [10.1007/978-981-15-4948-9_10, DOI 10.1007/978-981-15-4948-9_10]; Clarke V, 2013, PSYCHOLOGIST, V26, P120; Collins D, 2019, J GEN INTERN MED, DOI 10.1007/s11606-019-05311-0; Corrigan PW, 2009, J SOC WORK, V9, P139, DOI 10.1177/1468017308101818; D'cruz M, 2020, PSYCHIAT RES, V292, DOI 10.1016/j.psychres.2020.113369; Draus PJ, 2010, SOC CULT GEOGR, V11, P663, DOI 10.1080/14649365.2010.508564; Englander H, 2020, J HOSP MED, V15, P628, DOI 10.12788/jhm.3485; Englander H, 2021, J GEN INTERN MED, V36, P100, DOI 10.1007/s11606-020-06175-5; Englander H, 2019, J GEN INTERN MED, V34, P2796, DOI 10.1007/s11606-019-05251-9; Englander H, 2018, J HOSP MED, V13, P752, DOI 10.12788/jhm.2993; Englander H, 2017, J HOSP MED, V12, P339, DOI 10.12788/jhm.2736; Gaillard J.C., 2015, PEOPLES RESPONSE DIS; Gates BG, 2020, COVID 19 GLOBAL PERS; Gupta VK, 2017, DISASTER MED PUBLIC, V11, P531, DOI 10.1017/dmp.2016.190; Kammerbauer M, 2017, INT J DISAST RISK RE, V24, P411, DOI 10.1016/j.ijdrr.2017.06.019; Kangovi S, 2014, J GEN INTERN MED, V29, P283, DOI 10.1007/s11606-013-2571-5; Kansagara D, 2012, J HOSP MED, V7, P124, DOI 10.1002/jhm.941; Khatri UG, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.34878; Kimmel SD, 2020, J SUBST ABUSE TREAT, V118, DOI 10.1016/j.jsat.2020.108103; King C., J ADDICT MED; Lail P, 2018, J ADDICT MED, V12, P421, DOI 10.1097/ADM.0000000000000432; Laurencin CT, 2020, J RACIAL ETHN HEALTH, V7, P398, DOI 10.1007/s40615-020-00756-0; Lee HS, 2009, ADDICT RES THEORY, V17, P622, DOI 10.3109/16066350802168613; Luoma JB, 2007, ADDICT BEHAV, V32, P1331, DOI 10.1016/j.addbeh.2006.09.008; Maxwell JC, 2009, SUBST USE MISUSE, V44, P1681, DOI 10.3109/10826080902962011; McNeil R, 2014, SOC SCI MED, V106, P151, DOI 10.1016/j.socscimed.2014.01.051; McNeil R, 2014, SOC SCI MED, V105, P59, DOI 10.1016/j.socscimed.2014.01.010; Melamed OC, 2020, SUBST ABUS, V41, P286, DOI 10.1080/08897077.2020.1784363; Pouget ER, 2015, SUBST USE MISUSE, V50, P878, DOI 10.3109/10826084.2015.978675; Richardson L, 2013, SOC SCI MED, V76, P126, DOI 10.1016/j.socscimed.2012.10.015; Sharma M, 2014, J HEALTH CARE POOR U, V25, P663, DOI 10.1353/hpu.2014.0102; StataCorp, 2019, STAT REL 16 STAT SOF; Stockin M, 2019, J PAIN, V20, pS14, DOI 10.1016/j.jpain.2019.01.069; Tofighi B, 2014, ADDICT SCI CLIN PRAC, V9, DOI 10.1186/1940-0640-9-3; Wallace CL, 2020, J PAIN SYMPTOM MANAG, V60, pE70, DOI 10.1016/j.jpainsymman.2020.04.012; World Health Organization, 2007, GUID START MAN NEEDL; Yehia BR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18039; Zeh RD, 2020, SURGERY, V168, P770, DOI 10.1016/j.surg.2020.08.010; Zhai YS, 2020, PSYCHOTHER PSYCHOSOM, V90, P64, DOI 10.1159/000509000	52	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2021	16	2							e0247951	10.1371/journal.pone.0247951	http://dx.doi.org/10.1371/journal.pone.0247951			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QQ5BP	33635926	Green Published, gold			2023-01-03	WOS:000624538400028
J	White, KM; Rosales, R; Yildiz, S; Kehrer, T; Miorin, L; Moreno, E; Jangra, S; Uccellini, MB; Rathnasinghe, R; Coughlan, L; Martinez-Romero, C; Batra, J; Rojc, A; Bouhaddou, M; Fabius, JM; Obernier, K; Dejosez, M; Guillen, MJ; Losada, A; Aviles, P; Schotsaert, M; Zwaka, T; Vignuzzi, M; Shokat, KM; Krogan, NJ; Garcia-Sastre, A				White, Kris M.; Rosales, Romel; Yildiz, Soner; Kehrer, Thomas; Miorin, Lisa; Moreno, Elena; Jangra, Sonia; Uccellini, Melissa B.; Rathnasinghe, Raveen; Coughlan, Lynda; Martinez-Romero, Carles; Batra, Jyoti; Rojc, Ajda; Bouhaddou, Mehdi; Fabius, Jacqueline M.; Obernier, Kirsten; Dejosez, Marion; Jose Guillen, Maria; Losada, Alejandro; Aviles, Pablo; Schotsaert, Michael; Zwaka, Thomas; Vignuzzi, Marco; Shokat, Kevan M.; Krogan, Nevan J.; Garcia-Sastre, Adolfo			Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A	SCIENCE			English	Article							CORONAVIRUS; VIRUS; INHIBITOR; APLIDIN; SARS; DEPSIPEPTIDE; REPLICATION; TRANSLATION; ORIGIN	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins interact with the eukaryotic translation machinery, and inhibitors of translation have potent antiviral effects. We found that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5, with limited toxicity in cell culture. Through the use of a drug-resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A). We demonstrate the in vivo efficacy of plitidepsin treatment in two mouse models of SARS-CoV-2 infection with a reduction of viral replication in the lungs by two orders of magnitude using prophylactic treatment. Our results indicate that plitidepsin is a promising therapeutic candidate for COVID-19.	[White, Kris M.; Rosales, Romel; Yildiz, Soner; Kehrer, Thomas; Miorin, Lisa; Moreno, Elena; Jangra, Sonia; Uccellini, Melissa B.; Rathnasinghe, Raveen; Martinez-Romero, Carles; Schotsaert, Michael; Krogan, Nevan J.; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [White, Kris M.; Rosales, Romel; Yildiz, Soner; Kehrer, Thomas; Miorin, Lisa; Moreno, Elena; Jangra, Sonia; Uccellini, Melissa B.; Rathnasinghe, Raveen; Martinez-Romero, Carles; Schotsaert, Michael; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth Emerging Pathogens Inst, New York, NY 10029 USA; [Coughlan, Lynda] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; [Coughlan, Lynda] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth CVD, Baltimore, MD 21201 USA; [Batra, Jyoti; Rojc, Ajda; Bouhaddou, Mehdi; Fabius, Jacqueline M.; Obernier, Kirsten; Shokat, Kevan M.; Krogan, Nevan J.] Univ Calif San Francisco, Quantitat Biosci Inst QBI, San Francisco, CA 94158 USA; [Batra, Jyoti; Rojc, Ajda; Bouhaddou, Mehdi; Obernier, Kirsten; Krogan, Nevan J.] J David Gladstone Inst, San Francisco, CA 94158 USA; [Batra, Jyoti; Rojc, Ajda; Bouhaddou, Mehdi; Fabius, Jacqueline M.; Obernier, Kirsten; Shokat, Kevan M.; Krogan, Nevan J.] QBI Coronavirus Res Grp QCRG, San Francisco, CA 94158 USA; [Batra, Jyoti; Rojc, Ajda; Bouhaddou, Mehdi; Obernier, Kirsten; Shokat, Kevan M.; Krogan, Nevan J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Dejosez, Marion; Zwaka, Thomas] Icahn Sch Med Mt Sinai, Black Family Stem Cell Inst, Dept Cell Dev & Regenerat Biol, Huffington Fdn Ctr Cell Based Res Parkinsons Dis, New York, NY 10029 USA; [Jose Guillen, Maria; Losada, Alejandro; Aviles, Pablo] PharmaMar, Res & Dev Dept, Madrid 28770, Spain; [Vignuzzi, Marco] Inst Pasteur, Viral Populat & Pathogenesis Unit, CNRS, UMR 3569, F-75724 Paris 15, France; [Shokat, Kevan M.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai; PharmaMar; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	White, KM; Krogan, NJ; Garcia-Sastre, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; White, KM; Garcia-Sastre, A (corresponding author), Icahn Sch Med Mt Sinai, Global Hlth Emerging Pathogens Inst, New York, NY 10029 USA.; Krogan, NJ (corresponding author), Univ Calif San Francisco, Quantitat Biosci Inst QBI, San Francisco, CA 94158 USA.; Krogan, NJ (corresponding author), J David Gladstone Inst, San Francisco, CA 94158 USA.; Krogan, NJ (corresponding author), QBI Coronavirus Res Grp QCRG, San Francisco, CA 94158 USA.; Krogan, NJ (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.; Garcia-Sastre, A (corresponding author), Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA.; Garcia-Sastre, A (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.	kris.white@mssm.edu; nevan.krogan@ucsf.edu; adolfo.garcia-sastre@mssm.edu	Losada, Alejandro/AAW-8589-2021; Moreno, Elena/AAC-6182-2020; Rosales Ramirez, Romel/O-5458-2018	Moreno, Elena/0000-0002-2301-4558; Yildiz, Soner/0000-0002-7235-6108; Coughlan, Lynda/0000-0001-9880-6560; Miorin, Lisa/0000-0003-0989-3178; Rathnasinghe, Raveen/0000-0002-1260-2493; Batra, Jyoti/0000-0002-2335-0607; Rosales Ramirez, Romel/0000-0001-5326-4753	Defense Advanced Research Projects Agency [HR0011-19-2-0020]; CRIP (Center for Research for Influenza Pathogenesis), a NIAID [HHSN272201400008C]; NIAID [U19AI135972]; DoD [W81XWH20-1-0270]; JPB Foundation; Open Philanthropy Project [2020-215611 (5384)]; Huffington Foundation; NIH [U19AI135972, P50AI150476, U19AI135990, R01AI143292, R01AI120694, P01A1063302, R01AI122747, 1R01CA221969, 1R01CA244550, F32CA239333]; Laboratory for Genomics Research (LGR) [133122P]; Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" [ANR-10-LABX-62-IBEID]; FastGrants COVID19 grant from the Emergent Ventures program at the Mercatus Center of George Mason University; F. Hoffmann-La Roche; Vir Biotechnology; Roddenberry Foundation; Swiss National Foundation (SNF) Early Postdoc.Mobility fellowship [P2GEP3_184202]	Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); CRIP (Center for Research for Influenza Pathogenesis), a NIAID; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DoD(United States Department of Defense); JPB Foundation; Open Philanthropy Project; Huffington Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Laboratory for Genomics Research (LGR); Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases"; FastGrants COVID19 grant from the Emergent Ventures program at the Mercatus Center of George Mason University; F. Hoffmann-La Roche(Hoffmann-La Roche); Vir Biotechnology; Roddenberry Foundation; Swiss National Foundation (SNF) Early Postdoc.Mobility fellowship	Supported by the Defense Advanced Research Projects Agency (HR0011-19-2-0020) (A.G.-S., N.J.K., and K.M.S.); by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract #HHSN272201400008C); by supplements to NIAID grant U19AI135972 and DoD grant W81XWH20-1-0270; by the generous support of the JPB Foundation and the Open Philanthropy Project [research grant 2020-215611 (5384)]; and by anonymous donors to A.G.-S. This research was also funded by the Huffington Foundation (T.Z.); NIH grants P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, P01A1063302, and R01AI122747 (N.J.K.), 1R01CA221969 and 1R01CA244550 (K.M.S.), and F32CA239333 (M.B.); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between UCSF, UCB, and GSK (grant 133122P to N.J.K.); by the Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" grant ANR-10-LABX-62-IBEID (M.V.); and by funding from FastGrants COVID19 grant from the Emergent Ventures program at the Mercatus Center of George Mason University, F. Hoffmann-La Roche, Vir Biotechnology, the Roddenberry Foundation, and gifts from QCRG philanthropic donors (N.J.K.). S.Y. received funding from Swiss National Foundation (SNF) Early Postdoc.Mobility fellowship (P2GEP3_184202).	Abbas W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00075; Amanat Fatima, 2020, Curr Protoc Microbiol, V58, pe108, DOI 10.1002/cpmc.108; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; [Anonymous], JAMA J AM MED ASSOC, DOI DOI 10.1001/jama.2020.1585; Anthony SJ, 2017, MBIO, V8, DOI [10.1128/mBio.00373-17, 10.1128/mbio.00373-17]; Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7; Carelli JD, 2015, ELIFE, V4, DOI 10.7554/eLife.10222; COVID-19 Genomics Consortium UK, 2020, PRELIMINARY GENOMIC; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Delgado-Calle Jesus, 2019, Oncotarget, V10, P2709, DOI 10.18632/oncotarget.26831; Ernst JT, 2020, J MED CHEM, V63, P5879, DOI 10.1021/acs.jmedchem.0c00182; Ghaedi M, 2013, J CLIN INVEST, V123, P4950, DOI 10.1172/JCI68793; Gordon DE, 2020, SCIENCE, V370, P1181, DOI 10.1126/science.abe9403; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; Heaton NS, 2016, IMMUNITY, V44, P46, DOI 10.1016/j.immuni.2015.12.017; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Ito M, 2009, PEPTIDES, V30, P1074, DOI 10.1016/j.peptides.2009.02.008; Jacob A, 2019, NAT PROTOC, V14, P3303, DOI 10.1038/s41596-019-0220-0; Krastel P, 2015, ANGEW CHEM INT EDIT, V54, P10149, DOI 10.1002/anie.201505069; Leisch M, 2019, FUTURE ONCOL, V15, P109, DOI 10.2217/fon-2018-0492; Li DS, 2013, MICROBIOL MOL BIOL R, V77, P253, DOI 10.1128/MMBR.00059-12; Liang YW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01022; Maroun JA, 2006, ANN ONCOL, V17, P1371, DOI 10.1093/annonc/mdl165; Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113; Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985; Mitsiades CS, 2008, CANCER RES, V68, P5216, DOI 10.1158/0008-5472.CAN-07-5725; Morande PE, 2012, INVEST NEW DRUG, V30, P1830, DOI 10.1007/s10637-011-9740-3; Nalda-Molina R, 2009, CANCER CHEMOTH PHARM, V64, P97, DOI 10.1007/s00280-008-0841-4; Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07; New and Emerging Respiratory Virus Threats Advisory Group, 2020, NERVTAG M SARS COV 2; Piekarz RL, 2006, CLIN CANCER RES, V12, P3762, DOI 10.1158/1078-0432.CCR-05-2095; Rajkumar SV, 2020, AM J HEMATOL, V95, P548, DOI 10.1002/ajh.25791; Rathnasinghe R, 2020, EMERG MICROBES INFEC, V9, P2433, DOI 10.1080/22221751.2020.1838955; Reuschl A.-K., 2021, 427991 BIORXIV; Salazar R, 2011, INVEST NEW DRUG, V29, P1406, DOI 10.1007/s10637-010-9488-1; Sammaibashi S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01446; Sawicki S G, 1995, Adv Exp Med Biol, V380, P499; SAWICKI SG, 1986, J VIROL, V57, P328, DOI 10.1128/JVI.57.1.328-334.1986; Sawicki SG, 2007, J VIROL, V81, P20, DOI 10.1128/JVI.01358-06; Shah MH, 2006, CLIN CANCER RES, V12, P3997, DOI 10.1158/1078-0432.CCR-05-2689; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Soto-Matos A, 2011, MAR DRUGS, V9, P1007, DOI 10.3390/md9061007; Spicka I, 2019, ANN HEMATOL, V98, P2139, DOI 10.1007/s00277-019-03739-2; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; van den Worm SHE, 2011, J VIROL, V85, P5669, DOI 10.1128/JVI.00403-11; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wei T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114447; who, MIDDLE E RESP SYNDRO; WHO Solidarity Trial Consortium, 2020, NEW ENGL J MED; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041; Yao L, 2003, IDRUGS, V6, P246; Yokoyama Y, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198137; Zhang X, 2014, VET MICROBIOL, V172, P443, DOI 10.1016/j.vetmic.2014.05.034; Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035	58	142	150	9	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	2021	371	6532					926	+		10.1126/science.abf4058	http://dx.doi.org/10.1126/science.abf4058			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM5IR	33495306	Green Published, Green Submitted			2023-01-03	WOS:000621813400039
J	Poulsen, JH; Norgaard, LS; Dieckmann, P; Clemmensen, MH				Poulsen, Joo Hanne; Norgaard, Lotte Stig; Dieckmann, Peter; Clemmensen, Marianne Hald			Time spent by hospital personnel on drug changes: A time and motion study from an in- and outpatient hospital setting	PLOS ONE			English	Article								Introduction Medicines used at Danish public hospitals are purchased through tendering. Together with drug shortage, tendering result in drug changes, known to compromise patient safety, increase medicine errors and to be resource demanding for healthcare personnel. Details on actual resources required in the clinic setting to manage drug changes are unknown. The aim of the study is to explore time spend by hospital personnel in a drug change situation when dispensing medicine to in- and outpatients in a hospital setting in the Capital Region of Denmark. Method A time and motion study, using direct observation combined with time-registration tools, such as eye-tracking, video recording and manual time tracking. Data were obtained from observing nurses and social and health care assistants with dispensing authority while dispensing or extraditing medicine before and after the implementation of drug changes in two clinical setting; a cardiology ward and a rheumatology outpatient clinic. Results Hospital personnel at the cardiology inpatient ward spent 20.5 seconds on dispensing a drug, which was increased up to 28.4 seconds by drug changes. At the rheumatology outpatient clinic, time to extradite medicine increased from 8 minutes and 6 seconds to 15 minutes and 36 seconds by drug changes due to tender. Similarly, drug changes due to drug shortage prolonged the extradition time to 16 minutes and 54 seconds. Statistical analysis reveal that drug changes impose a significant increase in time to dispense a drug for both in- and outpatients. Conclusion Clinical hospital personnel spent significantly longer time on drug change situations in the dispensing of medicine to in- and outpatients in a hospitals. This study emphasizes that implementing drug changes do require extra time, thus, the hospital management should encounter this and ensure that additional time is available for the hospital personnel to ensure a safe drug dispensing process.	[Poulsen, Joo Hanne; Norgaard, Lotte Stig] Univ Copenhagen, Social & Clin Pharm, Copenhagen O, Denmark; [Dieckmann, Peter] Herlev Hosp, Copenhagen Acad Med Educ & Simulat CAMES, Ctr Human Resources, Herlev, Capital Region, Denmark; [Dieckmann, Peter] Univ Stavanger, Dept Qual & Hlth Technol, Stavanger, Norway; [Dieckmann, Peter] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark; [Clemmensen, Marianne Hald] Hosp Pharm, Med Informat Ctr, Copenhagen NV, Capital Region, Denmark	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; Universitetet i Stavanger; University of Copenhagen	Poulsen, JH (corresponding author), Univ Copenhagen, Social & Clin Pharm, Copenhagen O, Denmark.	Joo.hanne.poulsen@sund.ku.dk			Amgros I/S; Copenhagen Academy for Medical Education and Simulation (CAMES); The Hospital Pharmacy in the Capital Region of Denmark; University of Copenhagen; Laerdal Foundation (Stavanger, Norway)	Amgros I/S; Copenhagen Academy for Medical Education and Simulation (CAMES); The Hospital Pharmacy in the Capital Region of Denmark; University of Copenhagen; Laerdal Foundation (Stavanger, Norway)	JHP is doing a co-financed PhD study funded by Amgros I/S, Copenhagen Academy for Medical Education and Simulation (CAMES), The Hospital Pharmacy in the Capital Region of Denmark and the University of Copenhagen. Peter Dieckmann holds a professorship at the University of Stavanger that is funded by an unconditional grant of the Laerdal Foundation (Stavanger, Norway) to the University of Stavanger. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amgros, 2018, AMGROS; Ampt Amanda, 2007, J Health Serv Res Policy, V12, P18; [Anonymous], 2019, REGION HOVEDSTADENS; [Anonymous], 2020, VAERDISAETNING ENHED; Becker ML, 2013, EUR J HOSP PHARM-S P, V20, P74, DOI 10.1136/ejhpharm-2012-000175; Berman Adrienne, 2004, J Med Syst, V28, P9, DOI 10.1023/B:JOMS.0000021518.60670.10; Burke TA, 2000, J NURS ADMIN, V30, P118, DOI 10.1097/00005110-200003000-00003; Cardiology ward, 2020, CARDIOLOGY WARD BISP; Danmarks Nationalbank, 2020, DNVALA YEARLY EXCHAN; Danske Regioner, 2020, MEDICINA; De Weerdt E, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00568; De Weerdt E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174556; Dylst P, 2011, HEALTH POLICY, V101, P146, DOI 10.1016/j.healthpol.2011.03.004; Etikan I., 2015, AM J THEOR APPL STAT, V5, P1, DOI 10.11648/j.ajtas.20160501.11; European Association of Hospital Pharmacists (EAHP),, 2018, MED SHORTAGES EUROPE; Godman B, 2010, PHARMACEUTICALS, V3, P2470, DOI 10.3390/ph3082470; Gulbis BE, 2013, CRIT CARE NURS Q, V36, P400, DOI 10.1097/CNQ.0b013e3182a10ffe; Hakonsen H, 2010, ADV THER, V27, P118, DOI 10.1007/s12325-010-0007-8; Harezlak K, 2018, COMPUT MED IMAG GRAP, V65, P176, DOI 10.1016/j.compmedimag.2017.04.006; Hill Jackie, 2003, Musculoskeletal Care, V1, P5, DOI 10.1002/msc.35; Khachatryan H., 2014, ELECT DATA INF SOURC, P1; Koksvik HS, 2013, ANN RHEUM DIS, V72, P836, DOI 10.1136/annrheumdis-2012-202296; Laegemiddelkomiteer, 2018, REGION HOVEDSTADEN L; Larsen LK, 2021, HOSP PHARM, V56, P314, DOI 10.1177/0018578719894980; Larsson I, 2010, MUSCULOSKELET CARE, V8, P36, DOI 10.1002/msc.164; Lopetegui M, 2014, J BIOMED INFORM, V49, P292, DOI 10.1016/j.jbi.2014.02.017; Mackey A, 2014, RES METHODS 2 LANGUA, P204; Makelainen P, 2009, J CLIN NURS, V18, P2058, DOI 10.1111/j.1365-2702.2008.02763.x; Ministry of Health, 2017, HEALTHCARE DENMARK A, P73; Nelson Siri, 2006, Tidsskr Nor Laegeforen, V126, P441; Poulsen JH, 2019, THER ADV DRUG SAF, V10, DOI 10.1177/2042098619859995; Rathe J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119688; Rathe J, 2013, EUR J CLIN PHARMACOL, V69, P1827, DOI 10.1007/s00228-013-1539-z; Region Hovedstaden, FREDERIKSBERG HOSP H; Region Hovedstaden, BISPEBJERG HOSP HOSP; Rheumatology Outpatient Clinic, 2020, RHEUMATOLOGY OUTPATI; Rodriguez ND, 2014, 2014 IEEE 16TH INTERNATIONAL CONFERENCE ON E-HEALTH NETWORKING, APPLICATIONS AND SERVICES (HEALTHCOM), P423, DOI 10.1109/HealthCom.2014.7001880; Sundhedsog AEldreministeriet, 2016, SAMMENFATTENDE RAPPO; Tobii Pro, TOBII PRO GLASSES 2; Vizient Drug Shortages Task Force, 2019, DRUG SHORTAGES LABOR; Wadmann S, 2018, VALUE BASED PROCUREM; World Health Organization, 2019, GLOBAL SPENDING HLTH; Zheng K, 2011, J AM MED INFORM ASSN, V18, P704, DOI 10.1136/amiajnl-2011-000083	43	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2021	16	2							e0247499	10.1371/journal.pone.0247499	http://dx.doi.org/10.1371/journal.pone.0247499			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QQ5BB	33630933	Green Published, gold			2023-01-03	WOS:000624536800119
J	Vieira, B; Demirtas, D; van de Kamer, JB; Hans, EW; Jongste, W; van Harten, W				Vieira, Bruno; Demirtas, Derya; van de Kamer, Jeroen B.; Hans, Erwin W.; Jongste, Willem; van Harten, Wim			Radiotherapy treatment scheduling: Implementing operations research into clinical practice	PLOS ONE			English	Article								Background Every week, radiotherapy centers face the complex task of scheduling hundreds of treatment sessions amongst the available linear accelerators. With the increase in cancer patient numbers, manually creating a feasible and efficient schedule has shown to be a difficult, time-consuming task. Although operations research models have been increasingly reported upon to optimize patient care logistics, there is almost no scientific evidence of implementation in practice. Methods A mathematical operations research model was adapted to generate radiotherapy treatment schedules in two Dutch centers. The model was iteratively adjusted to fulfill the technical and medical constraints of each center until a valid model was attained. Patient data was collected for the planning horizon of one week, and the feasibility of the obtained schedules was verified by the staff of each center. The resulting optimized solutions are compared with the ones manually developed in practice. Results The weekly schedule was improved in both centers by decreasing the average standard deviation between sessions' starting times from 103.0 to 50.4 minutes (51%) in one center, and the number of gaps in the schedule from 18 to 5 (72%) in the other. The number of patients requiring linac switching between sessions has also decreased from 71 to 0 patients in one center, and from 43 to 2 in the other. The automated process required 5 minutes and 1.5 hours of computation time to find an optimal weekly patient schedule, respectively, as opposed to approximately 1.5 days when performed manually for both centers. Conclusions The practical application of a theoretical operations research model for radiotherapy treatment scheduling has provided radiotherapy planners a feasible, high-quality schedule in an automated way. Iterative model adaptations performed in small steps, early engagement of stakeholders, and constant communication proved to facilitate the implementation of operations research models into clinical practice.	[Vieira, Bruno; van de Kamer, Jeroen B.; van Harten, Wim] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Radiat Oncol, Amsterdam, Netherlands; [Vieira, Bruno; Demirtas, Derya; Hans, Erwin W.] Univ Twente, Ctr Healthcare Operat Improvement & Res CHOIR, Enschede, Netherlands; [Demirtas, Derya; Hans, Erwin W.] Univ Twente, Dept Ind Engn & Business Informat Syst, Fac Behav Management & Social Sci, Enschede, Netherlands; [Jongste, Willem] Bernard Verbeeten Inst, Tilburg, Netherlands; [van Harten, Wim] Univ Twente, Sch Governance & Management, Dept Hlth Technol & Serv Res, Enschede, Netherlands	Netherlands Cancer Institute; University of Twente; University of Twente; Instituut Verbeeten; University of Twente	van Harten, W (corresponding author), Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Radiat Oncol, Amsterdam, Netherlands.; van Harten, W (corresponding author), Univ Twente, Sch Governance & Management, Dept Hlth Technol & Serv Res, Enschede, Netherlands.	w.v.harten@nki.nl	Demirtas, Derya/R-5217-2016	Demirtas, Derya/0000-0003-4064-484X; Vieira, Bruno/0000-0001-6045-9233	KWF (Dutch Cancer Society) under the ALORT project [2014-6078]	KWF (Dutch Cancer Society) under the ALORT project	This work was supported by KWF (Dutch Cancer Society, https://www.kwf.nl/) under the ALORT project (2014-6078), awarded to authors WvH and EW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Borras JM, 2016, RADIOTHER ONCOL, V119, P5, DOI 10.1016/j.radonc.2016.02.016; Bradley BD, 2017, HEALTH RES POLICY SY, V15, DOI 10.1186/s12961-017-0187-7; Brailsford SC, 2009, J SIMUL, V3, P130, DOI 10.1057/jos.2009.10; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen Z, 2008, RADIOTHER ONCOL, V87, P3, DOI 10.1016/j.radonc.2007.11.016; Lartigau E., 2010, 147 IMPROVEMENT Q S1, V19, pA170; Mackillop WJ, 2007, RADIOTHER ONCOL, V84, P1, DOI 10.1016/j.radonc.2007.05.006; NVRO, 2000, WAIT TIM STAND MAX W; Olivotto IA, 2015, CURR ONCOL, V22, P279, DOI 10.3747/co.22.2532; Petersen GS, 2015, INT J QUAL HEALTH C, V27, P384, DOI 10.1093/intqhc/mzv059; Petrovic D., 2013, AUTOMATED SCHEDULING, V505, P155, DOI 10.1007/; Rais A, 2011, INT T OPER RES, V18, P1, DOI 10.1111/j.1475-3995.2010.00767.x; Saville CE, 2019, HEALTH SYST, V8, P52, DOI 10.1080/20476965.2017.1414741; van Bodegom-Vos L, 2017, BMJ QUAL SAF, V26, P495, DOI 10.1136/bmjqs-2016-005473; van Lent WAM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-232; Vieira B, 2020, HEALTH CARE MANAG SC, V23, P520, DOI 10.1007/s10729-020-09510-8; Vieira B, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/s12911-019-0910-0; Vieira B, 2018, EUR J OPER RES, V270, P709, DOI 10.1016/j.ejor.2018.03.040; Vieira B, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0390-4	19	0	0	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2021	16	2							e0247428	10.1371/journal.pone.0247428	http://dx.doi.org/10.1371/journal.pone.0247428			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8KQ	33606831	gold, Green Published			2023-01-03	WOS:000620629200088
J	Habib, G; Steinberg, D; Jabbour, A				Habib, George; Steinberg, Doron; Jabbour, Adel			The impact of medical cannabis consumption on the oral flora and saliva	PLOS ONE			English	Article								Objective To evaluate the effect of medical cannabis consumption on oral flora and saliva. Design A clinical prospective study, at the rheumatology clinic of the Nazareth Hospital in Nazareth, recruiting consecutively patients approved for medical cannabis, evaluating their saliva flow, pH and microbial load of Streptococcus mutans and Lactobacillus, prior to and under medical cannabis treatment. Methods Patients recently licensed for medical cannabis treatment, were recruited just prior to starting medical cannabis consumption (week 0), 1 and 4 weeks later, patients provided 5-minute time saliva samples, which were measured for their volume and pH, and cultured on a special microbial kit, evaluating the growth of Streptococcus mutans and Lactobacillus. Results Out of 16 patients enrolled, 14 were female and had fibromyalgia. The mean age of the patients was 52.8 +/- 12.9 years. The mean saliva flow at week 0, week 1 and week 4 were 5.38 +/- 3.36 ml/5-minutes, 6 (p = 0.769) and 5.45 (p = 0.391), respectively, and for saliva pH were 6.28, 5.94 (p = 0.51) and 5.5 (p = 0.07) respectively also. The mean Streptococcus mutans growth score at weeks 0, 1 and 4 was1.8 +/- 0.75, 1.6 +/- 0.83 (p = 0.234), and 2.4 +/- 0.84 (p = 0.058), respectively. The mean Lactobacilli growth score at weeks 0, 1 and 4 was 2.59 +/- 0.88, 3.1 +/- 0.69 (p = 0.033) and 3.3 +/- 0.67 (p = 0.025), respectively. Conclusions The results of this study show that medical cannabis consumption has no significant effect on saliva volume or pH, but it may be associated with changes in salivary levels of oral microbes such as Streptococcus mutans and Lactobacilli.	[Habib, George] Laniado Hosp, Dept Med C, Azrieli Fac Med, Netanya, Israel; [Habib, George] Laniado Hosp, Rheumatol Unit, Netanya, Israel; [Habib, George] Bar Ilan Univ, Rheumatol Clin Nazareth Hosp, Safed, Israel; [Steinberg, Doron] Hebrew Univ Jerusalem Hadassah Hosp & Med Sch, Fac Dent Med, Biofilm Res Lab, Jerusalem, Israel; [Jabbour, Adel] Bar Ilan Univ, Nazareth Hosp EMMS, Azrieli Fac Med, Med Lab, Safed, Israel	Bar Ilan University; Hebrew University of Jerusalem; Hadassah University Medical Center; Bar Ilan University	Habib, G (corresponding author), Laniado Hosp, Dept Med C, Azrieli Fac Med, Netanya, Israel.; Habib, G (corresponding author), Laniado Hosp, Rheumatol Unit, Netanya, Israel.; Habib, G (corresponding author), Bar Ilan Univ, Rheumatol Clin Nazareth Hosp, Safed, Israel.	gshabib@gmail.com						Atalay S, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010021; Balash Y, 2017, CLIN NEUROPHARMACOL, V40, P268, DOI 10.1097/WNF.0000000000000246; Baron EP, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0862-2; Chakraborty S, 2018, J INTEGR MED-JIM, V16, P350, DOI 10.1016/j.joim.2018.07.005; Christensen LB, 2001, ACTA ODONTOL SCAND, V59, P116; DICUGNO F, 1981, ARCH ORAL BIOL, V26, P363, DOI 10.1016/0003-9969(81)90031-5; DIGREGORIO GJ, 1976, DRUG ALCOHOL DEPEN, V1, P377, DOI 10.1016/0376-8716(76)90002-8; Felder CC, 1998, ANNU REV PHARMACOL, V38, P179, DOI 10.1146/annurev.pharmtox.38.1.179; Gu Z, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02288; Habib G, 2018, JCR-J CLIN RHEUMATOL, V24, P255, DOI 10.1097/RHU.0000000000000702; Hua T, 2020, CELL, V180, P655, DOI 10.1016/j.cell.2020.01.008; Iseppi R, 2019, MOLECULES, V24, DOI 10.3390/molecules24122302; Prospero-Garcia O, 2019, ARCH MED RES, V50, P518, DOI 10.1016/j.arcmed.2019.09.005; Sanchez-Garcia S, 2008, GERODONTOLOGY, V25, P26, DOI 10.1111/j.1741-2358.2007.00184.x; Soni D, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0499-0; Tyree GA, 2019, CANNABIS CANNABINOID, V4, P62, DOI 10.1089/can.2018.0027; Wang GS, 2020, CLIN PHARMACOKINET, V59, P1005, DOI 10.1007/s40262-020-00869-z; Zeyl V, 2020, SUBST USE MISUSE, V55, P1223, DOI 10.1080/10826084.2020.1731547; Zhao SS, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2019.06.005	19	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2021	16	2							e0247044	10.1371/journal.pone.0247044	http://dx.doi.org/10.1371/journal.pone.0247044			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK0KW	33577600	Green Published, gold			2023-01-03	WOS:000620071700042
J	Berwanger, O				Berwanger, Otavio			Azithromycin, RECOVERY, and the power of large, simple trials	LANCET			English	Editorial Material									[Berwanger, Otavio] Hosp Israelita Albert Einstein, Acad Res Org, BR-05652900 Sao Paulo, Brazil	Hospital Israelita Albert Einstein	Berwanger, O (corresponding author), Hosp Israelita Albert Einstein, Acad Res Org, BR-05652900 Sao Paulo, Brazil.	otavio.berwanger@einstein.br						Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P2262, DOI 10.1001/jama.2020.8115; Califf RM, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146391; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Horby PW, 2021, LANCET, V397, P605, DOI 10.1016/S0140-6736(21)00149-5; Horby P, 2020, NEW ENGL J MED, V383, P2030, DOI 10.1056/NEJMoa2022926; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	12	4	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	2021	397	10274					559	560		10.1016/S0140-6736(21)00307-X	http://dx.doi.org/10.1016/S0140-6736(21)00307-X		FEB 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QL2TN	33545097	Green Published, Bronze			2023-01-03	WOS:000620934000005
J	Seo, YG; Lim, H; Kim, Y; Ju, YS; Choi, YJ; Lee, HJ; Jang, HB; Park, SI; Park, KH				Seo, Young-Gyun; Lim, Hyunjung; Kim, YoonMyung; Ju, Young-Su; Choi, Yong-jun; Lee, Hye-Ja; Jang, Han Byul; Park, Sang Ick; Park, Kyung Hee			Effects of circuit training or a nutritional intervention on body mass index and other cardiometabolic outcomes in children and adolescents with overweight or obesity	PLOS ONE			English	Article							INSULIN-RESISTANCE; CARDIORESPIRATORY FITNESS; CHILDHOOD OBESITY; METABOLIC RISK; ADIPOSITY; EXERCISE; METAANALYSIS; ADIPONECTIN; RELIABILITY; STATEMENT	Objective We aimed to assess the effectiveness of the first 6 months of a 24 month multidisciplinary intervention program including circuit training and a balanced diet in children and adolescents with obesity. Methods A quasi-experimental intervention trial included 242 participants (age [mean +/- standard deviation]: 11.3 +/- 2.06 years, 97 girls) of at least 85th percentile of age- and sex-specific body mass index (BMI). Participants were grouped into three to receive usual care (usual care group), exercise intervention with circuit training (exercise group), or intensive nutritional and feedback intervention with a balanced diet (nutritional group). Primary outcome was BMI z-score, while secondary outcomes included body composition, cardiometabolic risk markers, nutrition, and physical fitness. Results Among the participants, 80.6% had a BMI >= the 97th percentile for age and sex. The BMI z-score of the overall completers decreased by about 0.080 after 6 months of intervention (p < 0.001). After the intervention, both exercise and nutritional groups had significantly lower BMI z-scores than the baseline data by about 0.14 and 0.075, respectively (p < 0.05). Significant group by time interaction effects were observed between exercise versus usual care group in BMI z-score (beta, -0.11; 95% confidence interval (CI), -0.20 to -0.023) and adiponectin (beta, 1.31; 95% CI, 1.08 to 1.58); and between nutritional versus usual care group in waist circumference (beta, -3.47; 95% CI, -6.06 to -0.89). No statistically significant differences were observed in any of the other secondary outcomes assessed. Conclusion Multidisciplinary intervention including circuit training and a balanced diet for children and adolescents with obesity reduced the BMI z-score and improved cardiometabolic risk markers such as adiponectin and waist circumference.	[Seo, Young-Gyun; Park, Kyung Hee] Hallym Univ, Dept Family Med, Sacred Heart Hosp, Anyang, Gyeonggi Do, South Korea; [Lim, Hyunjung] Kyung Hee Univ, Dept Med Nutr, Yongin, Gyeonggi Do, South Korea; [Kim, YoonMyung] Yonsei Univ, Univ Coll, Int Campus, Incheon, South Korea; [Ju, Young-Su] Natl Med Ctr, Dept Occupat & Environm Med, Seoul, South Korea; [Choi, Yong-jun] Hallym Univ, Dept Social & Prevent Med, Coll Med, Chucheon, Gangwon Do, South Korea; [Choi, Yong-jun] Hallym Univ, Hlth Serv Res Ctr, Coll Med, Chucheon, Gangwon Do, South Korea; [Lee, Hye-Ja; Jang, Han Byul; Park, Sang Ick] Korea Natl Inst Hlth, Ctr Biomed Sci, Cheongju, Chungbuk, South Korea	Hallym University; Kyung Hee University; Yonsei University; National Medical Center - Korea; Hallym University; Hallym University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science	Park, KH (corresponding author), Hallym Univ, Dept Family Med, Sacred Heart Hosp, Anyang, Gyeonggi Do, South Korea.	beloved920@gmail.com	Seo, Young-Gyun/AAV-3487-2020	Seo, Young-Gyun/0000-0001-8294-1741; Choi, Yong-jun/0000-0002-1622-3175	Korea Centers for Disease Control and Prevention [2016-ER640500]	Korea Centers for Disease Control and Prevention	This work was supported by the Korea Centers for Disease Control and Prevention (https://www.cdc.go.kr/cdc_eng/).Dr KHP received the fund (grant number: 2016-ER640500). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Bae JH., 2020, CLIN NUTR, DOI [10.1016/j.clnu.2020.11.006, DOI 10.1016/J.CLNU.2020.11.006]; Benson AC, 2006, INT J PEDIATR OBES, V1, P222, DOI 10.1080/17477160600962864; Brufani C, 2013, HORM RES PAEDIAT, V80, P78, DOI 10.1159/000353760; Bull FC, 2009, J PHYS ACT HEALTH, V6, P790, DOI 10.1123/jpah.6.6.790; Calcaterra V, 2013, J PEDIATR ENDOCR MET, V26, P271, DOI 10.1515/jpem-2012-0157; Davis JN, 2009, OBESITY, V17, P1542, DOI 10.1038/oby.2009.19; Davis JN, 2011, MED SCI SPORT EXER, V43, P2195, DOI 10.1249/MSS.0b013e31821f5d4e; Ezzati M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3; Faigenbaum AD, 2009, J STRENGTH COND RES, V23, pS60, DOI 10.1519/JSC.0b013e31819df407; Freedman DS, 2017, OBESITY, V25, P739, DOI 10.1002/oby.21782; Garcia-Hermoso A, 2019, J SCI MED SPORT, V22, P76, DOI 10.1016/j.jsams.2018.07.006; Golding LA., 2000, YMCA US YMCA FITNESS; Guy J A, 2001, J Am Acad Orthop Surg, V9, P29; Hakel-Smith N, 2004, J AM DIET ASSOC, V104, P1878, DOI 10.1016/j.jada.2004.10.015; Hao M, 2019, ASIA-PAC J PUBLIC HE, V31, P348, DOI 10.1177/1010539519848275; Jankowski M, 2015, PEDIATR CARDIOL, V36, P27, DOI 10.1007/s00246-014-0960-0; Juonala M, 2011, NEW ENGL J MED, V365, P1876, DOI 10.1056/NEJMoa1010112; Kang K, 2019, ADV NUTR, V10, P250, DOI 10.1093/advances/nmy081; Kelly AS, 2013, CIRCULATION, V128, P1689, DOI 10.1161/CIR.0b013e3182a5cfb3; Kelsey MM, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0751-5; Koo HC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020156; Korea Center for Disease Control and Prevention The Korean Pediatric Society The Committee for the Development of Growth Standard for Korean Children and Adolescents, 2007, KOREAN CHILDREN ADOL; Leis R, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010031; Lopez-Olmedo N, 2019, PUBLIC HEALTH NUTR, V22, P2777, DOI 10.1017/S136898001900065X; Mead E, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012436; Ministry of Health and Welfare, 2016, GOVT ESTABLISHES NAT; Ministry of Health Welfare The Korean Nutrition Society, 2015, DIETARY REFERENCE IN; Misra P, 2014, INT J PREVENTIVE MED, V5, P952; Moran A, 1999, DIABETES, V48, P2039, DOI 10.2337/diabetes.48.10.2039; Moran J, 2018, SPORTS MED, V48, P1661, DOI 10.1007/s40279-018-0914-4; O'Connor EA, 2017, JAMA-J AM MED ASSOC, V317, P2427, DOI 10.1001/jama.2017.0332; Ojeda-Rodriguez A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101500; Orlando A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133228; Ostchega Y, 2010, J CLIN HYPERTENS, V12, P22, DOI 10.1111/j.1751-7176.2009.00199.x; Roche J, 2018, J CLIN SLEEP MED, V14, P967, DOI 10.5664/jcsm.7162; Ruiz-Cota P, 2019, SURG OBES RELAT DIS, V15, P133, DOI 10.1016/j.soard.2018.10.016; Schwartz C, 2017, PEDIATR OBES, V12, P179, DOI 10.1111/ijpo.12124; Schwingshackl L, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0077-1; Seo YG, 2019, OBES REV, V20, P1642, DOI 10.1111/obr.12911; Seo YG, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010137; Seo YG, 2018, SCAND J MED SCI SPOR, V28, P2207, DOI 10.1111/sms.13248; Sirico F, 2018, CHILD OBES, V14, P207, DOI 10.1089/chi.2017.0269; Small EW, 2008, PEDIATRICS, V121, P835, DOI 10.1542/peds.2007-3790; Stoner L, 2016, SPORTS MED, V46, P1737, DOI 10.1007/s40279-016-0537-6; Styne DM, 2017, J CLIN ENDOCR METAB, V102, P709, DOI 10.1210/jc.2016-2573; Thompson KL, 2019, J ACAD NUTR DIET, V119, P799, DOI 10.1016/j.jand.2018.12.008; van der Baan-Slootweg O, 2014, JAMA PEDIATR, V168, P807, DOI 10.1001/jamapediatrics.2014.521; Weber David R, 2012, Pediatr Endocrinol Rev, V10, P130; Whaley M., 2006, ACSMS GUIDELINES EXE; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; World Health Organization, 2017, COMMISSION ENDING CH; Xiong KY, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-835; Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815; Yap BW, 2011, J STAT COMPUT SIM, V81, P2141, DOI 10.1080/00949655.2010.520163; Zaqout M, 2016, INT J OBESITY, V40, P1119, DOI 10.1038/ijo.2016.22	56	10	10	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2021	16	1							e0245875	10.1371/journal.pone.0245875	http://dx.doi.org/10.1371/journal.pone.0245875			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF7LJ	33507953	Green Published, gold			2023-01-03	WOS:000635021400058
J	Karhadkar, TR; Pilling, D; Gomer, RH				Karhadkar, Tejas R.; Pilling, Darrell; Gomer, Richard H.			Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice	PLOS ONE			English	Article							IDIOPATHIC PULMONARY-FIBROSIS; INNATE LYMPHOID-CELLS; FC-GAMMA RECEPTORS; COMPONENT BINDS; SEX-DIFFERENCES; TGF-BETA; DIFFERENTIATION; MACROPHAGES; MEDIATE	SARS-CoV-2 is a single stranded RNA (ssRNA) virus and contains GU-rich sequences distributed abundantly in the genome. In COVID-19, the infection and immune hyperactivation causes accumulation of inflammatory immune cells, blood clots, and protein aggregates in lung fluid, increased lung alveolar wall thickness, and upregulation of serum cytokine levels. A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials. Here we show that aspiration of the GU-rich ssRNA oligonucleotide ORN06 into mouse lungs induces all of the above COVID-19-like symptoms. Men tend to have more severe COVID-19 symptoms than women, and in the aspirated ORN06 model, male mice tended to have more severe symptoms than female mice. Intraperitoneal injections of SAP starting from day 1 post ORN06 aspiration attenuated the ORN06-induced increase in the number of inflammatory cells and formation of clot-like aggregates in the mouse lung fluid, reduced ORN06-increased alveolar wall thickness and accumulation of exudates in the alveolar air-space, and attenuated an ORN06-induced upregulation of the inflammatory cytokines IL-1 beta, IL-6, IL-12p70, IL-23, and IL-27 in serum. SAP also reduced D-dimer levels in the lung fluid. In human peripheral blood mononuclear cells, SAP attenuated ORN06-induced extracellular accumulation of IL-6. Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms and/or a cytokine storm.	[Karhadkar, Tejas R.; Pilling, Darrell; Gomer, Richard H.] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Gomer, RH (corresponding author), Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA.	rgomer@tamu.edu	Karhadkar, Tejas/GMW-6597-2022; Karhadkar, Tejas/AGZ-1410-2022	Karhadkar, Tejas/0000-0002-9241-8003; Pilling, Darrell/0000-0002-7413-2773	National Institute of Health [HL-132919]; NIH [GM11835503S1]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institute of Health HL-132919 and NIH GM11835503S1 (Both grants to RHG). www.nih.gov The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen O, 1997, SCAND J IMMUNOL, V46, P331, DOI 10.1046/j.1365-3083.1997.d01-147.x; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Bagri P, 2017, J VIROL, V91, DOI 10.1128/JVI.01234-17; BALTZ ML, 1980, IMMUNOLOGY, V41, P59; Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Barlow JL, 2019, ANNU REV PHYSIOL, V81, P429, DOI 10.1146/annurev-physiol-020518-114630; Barnes PJ, 2016, AM J RESP CRIT CARE, V193, P813, DOI 10.1164/rccm.201512-2379ED; Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/ajcp/aqaa062, 10.1093/AJCP/AQAA062]; Beigmohammadi MT, 2021, INT J SURG PATHOL, V29, P135, DOI 10.1177/1066896920935195; Bharadwaj D, 2001, J IMMUNOL, V166, P6735, DOI 10.4049/jimmunol.166.11.6735; Bhide GP, 2017, HISTOCHEM CELL BIOL, V147, P149, DOI 10.1007/s00418-016-1520-x; Chen WS, 2020, EXP LUNG RES, V46, P75, DOI 10.1080/01902148.2020.1733135; Cong M, 2017, INT J MOL MED, V40, P454, DOI 10.3892/ijmm.2017.3028; Cox N, 2014, J IMMUNOL, V193, P1701, DOI 10.4049/jimmunol.1400281; Crawford JR, 2012, J LEUKOCYTE BIOL, V92, P699, DOI 10.1189/jlb.0112033; Crawford JR, 2010, J IMMUNOL METHODS, V363, P9, DOI 10.1016/j.jim.2010.09.025; Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119; Daubeuf Francois, 2012, Curr Protoc Mouse Biol, V2, P167, DOI 10.1002/9780470942390.mo110201; Donovan John, 2005, Curr Protoc Neurosci, VAppendix 4, p4G, DOI 10.1002/0471142301.nsa04gs33; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5; Galkina Elena V., 2000, Russ J Immunol, V5, P363; Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Grobler C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145168; HAMAZAKI H, 1995, J BIOL CHEM, V270, P10392, DOI 10.1074/jbc.270.18.10392; Haudek SB, 2008, P NATL ACAD SCI USA, V105, P10179, DOI 10.1073/pnas.0804910105; Haudek SB, 2006, P NATL ACAD SCI USA, V103, P18284, DOI 10.1073/pnas.0608799103; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Herlihy SE, 2013, J IMMUNOL, V190, P6468, DOI 10.4049/jimmunol.1202583; Horvath A, 2001, ANTIVIR RES, V52, P43, DOI 10.1016/S0166-3542(01)00158-9; Job ER, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059623; Karhadkar TR, 2020, AM J PHYSIOL-LUNG C, V318, pL165, DOI 10.1152/ajplung.00275.2019; Karhadkar TR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15198-8; Khalil Nasreen, 2008, V1, P581, DOI 10.1007/978-1-59745-292-2_36; Kirwan G, 2014, CYBERPSYCHOLOGY AND NEW MEDIA: A THEMATIC READER, P3; Klein SL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008570; Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114; LE PT, 1984, J LEUKOCYTE BIOL, V35, P587; Li Y, 2013, MICROBES INFECT, V15, P88, DOI 10.1016/j.micinf.2012.10.008; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Linkins LA, 2017, INT J LAB HEMATOL, V39, P98, DOI 10.1111/ijlh.12665; Luzina IG, 2016, AM J PHYSIOL-LUNG C, V310, pL940, DOI 10.1152/ajplung.00346.2015; Majer O, 2017, CURR OPIN IMMUNOL, V44, P26, DOI 10.1016/j.coi.2016.10.003; McElvaney OJ, 2020, AM J RESP CRIT CARE, V202, P812, DOI 10.1164/rccm.202005-1583OC; Mould KJ, 2017, AM J RESP CELL MOL, V57, P294, DOI 10.1165/rcmb.2017-0061OC; Murray LA, 2011, INT J BIOCHEM CELL B, V43, P154, DOI 10.1016/j.biocel.2010.10.013; Murray LA, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-11; Murray LA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009683; Naik-Mathuria B, 2008, WOUND REPAIR REGEN, V16, P266, DOI 10.1111/j.1524-475X.2008.00366.x; Nakagawa N, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87446; Parasuraman S, 2010, J PHARMACOL PHARMACO, V1, P87, DOI 10.4103/0976-500X.72350; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; Pepys MB, 1997, AMYLOID, V4, P274, DOI 10.3109/13506129709003838; PILLING D, 1989, J IMMUNOL METHODS, V122, P235, DOI 10.1016/0022-1759(89)90269-X; Pilling D, 2007, J IMMUNOL, V179, P4035, DOI 10.4049/jimmunol.179.6.4035; Pilling D, 2014, P NATL ACAD SCI USA, V111, P18291, DOI 10.1073/pnas.1417426112; Pilling D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093730; Pilling D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007475; Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST; Reyfman PA, 2019, AM J RESP CRIT CARE, V199, P1517, DOI 10.1164/rccm.201712-2410OC; Sanchez-Cerrillo I, 2020, J CLIN INVEST, V130, P6290, DOI 10.1172/JCI140335; Scharff AZ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122998; Schulert GS, 2020, GENES IMMUN, V21, P169, DOI 10.1038/s41435-020-0098-4; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Schutgens RE, 2020, HEMASPHERE, V4, DOI 10.1097/HS9.0000000000000422; Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8; Shao DD, 2008, J LEUKOCYTE BIOL, V83, P1323, DOI 10.1189/jlb.1107782; Stibenz D, 2006, EUR J IMMUNOL, V36, P446, DOI 10.1002/eji.200425360; Tam A, 2016, AM J RESP CRIT CARE, V193, P825, DOI 10.1164/rccm.201503-0487OC; Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; Vannella KM, 2017, ANNU REV PHYSIOL, V79, P593, DOI 10.1146/annurev-physiol-022516-034356; Verstovsek S, 2016, J EXP MED, V213, P1723, DOI 10.1084/jem.20160283; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Voltz JW, 2008, AM J RESP CELL MOL, V39, P45, DOI 10.1165/rcmb.2007-0340OC; Walters Dianne M, 2008, Curr Protoc Pharmacol, VChapter 5, DOI 10.1002/0471141755.ph0546s40; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Wilk AJ, 2020, NAT MED, V26, P1070, DOI [10.1038/s41591-020-0944-y, 10.1101/2020.04.17.20069930]; Willinger T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02010; Yao YM, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00466-z; Zhang YM, 2011, CLIN CHIM ACTA, V412, P227, DOI 10.1016/j.cca.2010.09.036; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou XM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020273	85	5	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2021	16	1							e0245924	10.1371/journal.pone.0245924	http://dx.doi.org/10.1371/journal.pone.0245924			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ7OB	33481950	gold, Green Submitted, Green Published			2023-01-03	WOS:000612929300133
J	Tesema, GA; Tessema, ZT				Tesema, Getayeneh Antehunegn; Tessema, Zemenu Tadesse			Pooled prevalence and associated factors of health facility delivery in East Africa: Mixed-effect logistic regression analysis	PLOS ONE			English	Article							REDUCING MATERNAL MORTALITY; ANTENATAL CARE; SERVICES; BIRTH; COMPLICATIONS; CHILDBIRTH; COUNTRIES; EDUCATION; BARRIERS; MODELS	Background Many mothers still give birth outside a health facility in Sub-Saharan Africa particularly in East African countries. Though there are studies on the prevalence and associated factors of health facility delivery, as to our search of literature there is limited evidence on the pooled prevalence and associated factors of health facility delivery in East Africa. This study aims to examine the pooled prevalence and associated factors of health facility delivery in East Africa based on evidence from Demographic and Health Surveys. Methods A secondary data analysis was conducted based on the most recent Demographic and Health Surveys (DHSs) conducted in the 12 East African countries. A total weighted sample of 141,483 reproductive-age women who gave birth within five years preceding the survey was included. All analyses presented in this paper were weighted for the sampling probabilities and non-response using sampling weight (V005), primary sampling unit (V023), and strata (V021). The analysis was done using STATA version 14 statistical software, and the pooled prevalence of health facility delivery with a 95% Confidence Interval (CI) was presented using a forest plot. For associated factors, the Generalized Linear Mixed Model (GLMM) was fitted to consider the hierarchical nature of the DHS data. The Intra-class Correlation Coefficient (ICC), Median Odds Ratio (MOR), and Likelihood Ratio (LR)-test were done to assess the presence of a significant clustering effect. Besides, deviance (-2LLR) was used for model comparison since the models were nested models. Variables with a p-value of less than 0.2 in the bivariable mixed-effect binary logistic regression analysis were considered for the multivariable analysis. In the multivariable mixed-effect analysis, the Adjusted Odds Ratio (AOR) with 95% Confidence Interval (CI) were reported to declare the strength and significance of the association between the independent variable and health facility delivery. Results The proportion of health facility delivery in East Africa was 87.49% [95% CI: 87.34%, 87.64%], ranged from 29% in Ethiopia to 97% in Mozambique. In the Mixed-effect logistic regression model; country, urban residence [AOR = 2.08, 95% CI: 1.96, 2.17], primary women education [AOR = 1.61, 95% CI: 1.55, 1.67], secondary education and higher [AOR = 2.96, 95% CI: 2.79, 3.13], primary husband education [AOR = 1.19, 95% CI: 1.14, 1.24], secondary husband education [AOR = 1.38, 95% CI: 1.31, 1.45], being in union [AOR = 1.23, 95% CI: 1.18, 1.27], having occupation [AOR = 1.11, 95% CI: 1.07, 1.15], being rich [AOR = 1.36, 95% CI: 1.30, 1.41], and middle [AOR = 2.14, 95% CI: 2.04, 2.23], health care access problem [AOR = 0.76, 95% CI: 0.74, 0.79], having ANC visit [AOR = 1.54, 95% CI: 1.49, 1.59], parity [AOR = 0.56, 95% CI: 0.55, 0.61], multiple gestation [AOR = 1.83, 95% CI: 1.67, 2.01] and wanted pregnancy [AOR = 1.19, 95% CI: 1.13, 1.25] were significantly associated with health facility delivery. Conclusion This study showed that the proportion of health facility delivery in East African countries is low. Thus, improved access and utilization of antenatal care can be an effective strategy to increase health facility deliveries. Moreover, encouraging women through education is recommended to increase health facility delivery service utilization.	[Tesema, Getayeneh Antehunegn; Tessema, Zemenu Tadesse] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia	University of Gondar	Tesema, GA (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia.	getayenehantehunegn@gmail.com	Tadesse, Zemenu/ABG-1690-2021	Tadesse, Zemenu/0000-0003-3878-7956				Acharya DR, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-15; Aggarwal R, 2011, EFFECT MATERNAL ED C; Agha S, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-31; [Anonymous], 2010, CRIT CARE; [Anonymous], 2010, WORLD HLTH STAT 2010; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P93, DOI 10.4314/ejhs.v24i0.9S; BITRAN R, 2002, WAIVERS EXE IN PRESS, P89; Claeson M, 2000, B WORLD HEALTH ORGAN, V78, P1192; Dahiru T, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.321.6527; Darmstadt GL, 2009, INT J GYNECOL OBSTET, V107, pS89, DOI 10.1016/j.ijgo.2009.07.010; De Brouwere V, 1998, TROP MED INT HEALTH, V3, P771, DOI 10.1046/j.1365-3156.1998.00310.x; Doctor HV, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5695-z; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; Fawsitt CG, 2017, HEALTH POLICY, V121, P66, DOI 10.1016/j.healthpol.2016.10.010; Filippi V, 2006, LANCET, V368, P1535, DOI 10.1016/S0140-6736(06)69384-7; Fischer RC, 1999, J FAM PRACTICE, V48, P117; Fotso JC, 2009, MATERN CHILD HLTH J, V13, P130, DOI 10.1007/s10995-008-0326-4; Furuta M, 2006, INT FAM PLAN PERSPEC, V32, P17, DOI 10.1363/3201706; Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34; Gage AJ, 2007, SOC SCI MED, V65, P1666, DOI 10.1016/j.socscimed.2007.06.001; Gage AL, 2006, POP STUD-J DEMOG, V60, P271, DOI 10.1080/00324720600895934; Gitonga E, 2016, PAN AFR MED J, V25, DOI 10.11604/pamj.supp.2016.25.2.10273; Haggerty JL, 2014, HEALTH PLACE, V28, P92, DOI 10.1016/j.healthplace.2014.03.005; Hill J, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001488; Kakaire O, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-12; Karkee R, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004372; Karlsen S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-606; Kitui J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-40; Lohela TJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052110; Magadi MA, 2003, POP STUD-J DEMOG, V57, P347, DOI 10.1080/0032472032000137853; MAKU17 OE, 2014, MILLENNIUM DEV GOALS, P305; Mangeni J N, 2012, East Afr Med J, V89, P372; Mbalinda SN, 2014, HEALTH RES POLICY SY, V12, DOI 10.1186/1478-4505-12-60; McClure EM, 2007, INT J GYNECOL OBSTET, V96, P139, DOI 10.1016/j.ijgo.2006.10.010; Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454; Mishra US, 2002, HEALTH POLICY PLANN, V17, P90, DOI 10.1093/heapol/17.1.90; Moran AC, 2006, J HEALTH POPUL NUTR, V24, P489; Moyer Cheryl A, 2013, Afr J Reprod Health, V17, P30; Moyer CA, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-40; Mpembeni Rose Nm, 2007, BMC Pregnancy Childbirth, V7, P29, DOI 10.1186/1471-2393-7-29; Onah HE, 2006, SOC SCI MED, V63, P1870, DOI 10.1016/j.socscimed.2006.04.019; Ono M, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-214; Ononokpono Dorothy Ngozi, 2014, Pan Afr Med J, V17 Suppl 1, P2, DOI 10.11694/pamj.supp.2014.17.1.3596; Parkhurst JO, 2005, HEALTH POLICY, V73, P127, DOI 10.1016/j.healthpol.2004.11.001; Paul BK, 2002, SOC SCI MED, V54, P1755, DOI 10.1016/S0277-9536(01)00148-4; Phiri SN, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-219; Raghupathy S, 1996, SOC SCI MED, V43, P459, DOI 10.1016/0277-9536(95)00411-4; Rao A, 2004, BEST PRACT RES CL OB, V18, P557, DOI 10.1016/j.bpobgyn.2004.04.007; Rockers PC, 2009, MATERN CHILD HLTH J, V13, P879, DOI 10.1007/s10995-008-0412-7; Rodriguez G, 2003, STATA J, V3, P32, DOI 10.1177/1536867X0300300102; Samuel Girma, 2007, Ethiopian Journal of Health Development, V21, P216; Samuelson JL, 2002, PAEDIATR PERINAT EP, V16, P305, DOI 10.1046/j.1365-3016.2002.00450.x; Stephenson R, 2006, AM J PUBLIC HEALTH, V96, P84, DOI 10.2105/AJPH.2004.057422; Thapa DK, 2013, SOC SCI MED, V93, P1, DOI 10.1016/j.socscimed.2013.06.003; Titaley CR, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-43; Young BC, 2012, SEMIN PERINATOL, V36, P162, DOI 10.1053/j.semperi.2012.02.007; Zhao J, 2017, MIDWIFERY, V50, P62, DOI 10.1016/j.midw.2017.03.011; Zureick-Brown S, 2013, INT PERSPECT SEX R H, V39, P32, DOI 10.1363/3903213	58	3	3	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	4							e0250447	10.1371/journal.pone.0250447	http://dx.doi.org/10.1371/journal.pone.0250447			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RR0PU	33891647	gold, Green Published			2023-01-03	WOS:000642811900056
J	Chammartin, F; Lodi, S; Logan, R; Ryom, L; Mocroft, A; Kirk, O; Monforte, AD; Reiss, P; Phillips, A; El-Sadr, W; Hatleberg, CI; Pradier, C; Bonnet, F; Law, M; De Wit, S; Sabin, C; Lundgren, JD; Bucher, HC				Chammartin, Frederique; Lodi, Sara; Logan, Roger; Ryom, Lene; Mocroft, Amanda; Kirk, Ole; Monforte, Antonella d'Arminio; Reiss, Peter; Phillips, Andrew; El-Sadr, Wafaa; Hatleberg, Camilla, I; Pradier, Christian; Bonnet, Fabrice; Law, Matthew; De Wit, Stephane; Sabin, Caroline; Lundgren, Jens D.; Bucher, Heiner C.		DAD Study Grp	Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy A Multinational Prospective Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							HIV-INFECTED INDIVIDUALS; PERSISTENT; MORTALITY; EVENTS; PEOPLE; TRENDS; ADULTS; DEATH	Background: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 x 10(9) cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. Objective: To estimate the long-term risk difference for cancer with the immediate ART strategy. Design: Multinational prospective cohort study. Setting: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included HIV-positive persons from Europe, Australia, and the United States. Participants: 8318 HIV-positive persons with at least 1 measurement each of CD4 cell count and viral load while ART-naive (study period, 2006 to 2016). Measurements: The parametric g-formula was used, with adjustment for baseline and time-dependent confounders (CD4 cell count and viral load), to assess the 10-year risk for non-AIDS-defining and AIDS-defining cancer of immediate versus deferred (at CD4 counts <350 and <500 x 10(9) cells/L) ART initiation strategies. Results: During 64 021 person-years of follow-up, 231 cases of non-AIDS-defining cancer and 272 of AIDS-defining cancer occurred among HIV-positive persons with a median age of 36 years (interquartile range, 29 to 43 years). With immediate ART, the 10-year risk for non-AIDS-defining cancer was 2.97% (95% CI, 2.37% to 3.50%) and that for AIDS-defining cancer was 2.50% (CI, 2.37% to 3.38%). Compared with immediate ART initiation, the 10-year absolute risk differences when deferring ART to CD4 counts less than 500 x 10(9) cells/L and less than 350 x 10(9) cells/L were 0.12 percentage point (CI, -0.01 to 0.26 percentage point) and 0.29 percentage point (CI, -0.03 to 0.73 percentage point), respectively, for non-AIDS-defining cancer and 0.32 percentage point (CI, 0.21 to 0.44 percentage point) and 1.00 percentage point (CI, 0.67 to 1.44 percentage points), respectively, for AIDS-defining cancer. Limitation: Potential residual confounding due to observational study design. Conclusion: In this young cohort, effects of immediate ART on 10-year risk for cancer were small, and further supportive data are needed for non-AIDS-defining cancer.	[Chammartin, Frederique; Bucher, Heiner C.] Univ Hosp Basel, Basel, Switzerland; [Chammartin, Frederique; Bucher, Heiner C.] Univ Basel, Spitalstr 12, CH-4031 Basel, Switzerland; [Lodi, Sara] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Logan, Roger] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Ryom, Lene; Kirk, Ole; Hatleberg, Camilla, I; Lundgren, Jens D.] Univ Copenhagen, Rigshosp, Copenhagen, Denmark; [Mocroft, Amanda; Phillips, Andrew; Sabin, Caroline] UCL, London, England; [Monforte, Antonella d'Arminio] Univ San Paolo, Azienda Osped Polo, Milan, Italy; [Reiss, Peter] Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands; [Reiss, Peter] HIV Monitoring Fdn, Amsterdam, Netherlands; [El-Sadr, Wafaa] Columbia Univ, ICAP, New York, NY USA; [El-Sadr, Wafaa] Harlem Hosp Med Ctr, New York, NY USA; [Pradier, Christian] Nice Univ Hosp, Nice, France; [Bonnet, Fabrice] Hop St Andre, Bordeaux, France; [Bonnet, Fabrice] Univ Bordeaux, Bordeaux, France; [Law, Matthew] Univ New South Wales Sydney, Sydney, NSW, Australia; [De Wit, Stephane] Univ Libre Bruxelles, St Pierre Univ Hosp, Brussels, Belgium; [Chammartin, Frederique; Bucher, Heiner C.] Univ Spital Basel, Basel Inst Klin Epidemiol & Biostat, Spitalstr 12, CH-4031 Basel, Switzerland; [Lodi, Sara] Boston Univ, Dept Biostat, Sch Publ Hlth, 801 Massachusetts Ave,3rd Floor, Boston, MA 02118 USA; [Logan, Roger] Dept Epidemiol, 677 Huntington Ave,Kresge,9th Floor, Boston, MA 02115 USA; [Ryom, Lene; Kirk, Ole; Hatleberg, Camilla, I; Lundgren, Jens D.] Univ Copenhagen, Rigshosp, CHIP, Dept Infect Dis, Sect 2100,Blegdamsvej 9, DK-2100 Copenhagen, Denmark; [Mocroft, Amanda; Phillips, Andrew; Sabin, Caroline] UCL, Inst Global Hlth, Ctr Clin Res Epidemiol Modelling & Evaluat CREME, Rowland Hill St, London NW3 2PF, England; [Monforte, Antonella d'Arminio] Dipartimento Sci Salute, 8 Via Rudini, I-20142 Milan, Italy; [Reiss, Peter] AMC, Postbus 22600, NL-1100 DD Amsterdam, Netherlands; [El-Sadr, Wafaa] Columbia Univ, Joseph Mailman Sch Publ Hlth, ICAP, MSPH, 722 West 168th St,13th Floor, New York, NY 10032 USA; [Bonnet, Fabrice] CHU Nice, Hop Archet, 1 Route St Antoine de Gines Tiere, F-06202 Nice 3, France; [Law, Matthew] UNSW Sydney, Kirby Inst, 6th Floor Wallace Wurth Bldg, Kensington, NSW 2052, Australia; [De Wit, Stephane] CHU St Pierre, Dept Malad Infect, Rue Haute 322, B-1000 Brussels, Belgium	University of Basel; University of Basel; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Rigshospitalet; University of Copenhagen; University of London; University College London; University of Amsterdam; Columbia University; CHU Nice; CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; University of New South Wales Sydney; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Basel; Boston University; Rigshospitalet; University of Copenhagen; University of London; University College London; University of Amsterdam; Academic Medical Center Amsterdam; Columbia University; CHU Nice; University of New South Wales Sydney; Kirby Institute; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Bucher, HC (corresponding author), Univ Basel, Spitalstr 12, CH-4031 Basel, Switzerland.; Bucher, HC (corresponding author), Univ Hosp Basel, Basel Inst Clin Epidemiol & Biostat, Spitalstr 12, CH-4031 Basel, Switzerland.; Bucher, HC (corresponding author), Univ Spital Basel, Basel Inst Klin Epidemiol & Biostat, Spitalstr 12, CH-4031 Basel, Switzerland.		kirk, ole/ABB-4746-2021; Aksak-Wąs, Bogusz/AFK-2240-2022; Mitsura, Viktar/G-2457-2017; Aksak-Wąs, Bogusz/ABF-7068-2021; chammartin, frederique/AGK-4827-2022; Lundgren, Jens/AAE-6876-2019; Pradier, Christian/AAE-9669-2022; Di Biagio, Antonio/J-4901-2019; Pradier, Christian/AFE-8255-2022; Torres, Ferran/D-1296-2011; Chammartin, Frédérique/AAC-8930-2020; Cascio, Antonio/K-5453-2016	Aksak-Wąs, Bogusz/0000-0003-2092-3737; Mitsura, Viktar/0000-0002-0449-5026; Aksak-Wąs, Bogusz/0000-0003-2092-3737; chammartin, frederique/0000-0001-8959-2724; Di Biagio, Antonio/0000-0003-1436-5089; Torres, Ferran/0000-0002-7355-7913; Van Leer, Coretta/0000-0002-4072-7373; Kirk, Ole/0000-0003-1995-1837; Segala, Daniela/0000-0001-6133-0386; Gottfredsson, Magnus/0000-0003-2465-0422; Ryom, Lene/0000-0002-6436-6461; TARR, Philip/0000-0002-1488-5407; BANDERA, ALESSANDRA/0000-0001-9440-4601; Bonfanti, Paolo/0000-0001-7289-8823; Bomers, Marije/0000-0003-0399-6926; Mocroft, Amanda/0000-0001-8316-1122; Antinori, Andrea/0000-0003-2121-4684; Cascio, Antonio/0000-0002-1992-1796; LAPADULA, Giuseppe/0000-0002-9976-8102; d'Arminio Monforte, Antonella/0000-0003-0073-1789; Bower, Mark/0000-0002-4077-6351; Goorhuis, Abraham/0000-0001-7423-6217; PUZZOLANTE, CINZIA/0000-0002-1179-1341; cacopardo, bruno/0000-0002-7465-0714; Scharnhorst, Volkher/0000-0002-1243-9251; Smith, Colette/0000-0003-2847-3355; Vandenbroucke-Grauls, Christina/0000-0003-2074-1597; Oosterheert, Jan Jelrik/0000-0001-6146-3808; KUZOVATOVA, Elena/0000-0003-3027-4427; Lodi, Sara/0000-0002-9419-7830	Danish National Research Foundation (Centre of Excellence for Health, Immunity and Infections [CHIP] and Personalized Medicine of Infectious Complications in immune deficiency [PERSIMUNE]) [DNRF126]; Highly Active Anti-retroviral Therapy Oversight Committee, a collaborative committee with representation from academic institutions; European Agency for the Evaluation of Medicinal Products; U.S. Food and Drug Administration; patient community; AbbVie; Bristol-Myers Squibb; Gilead Sciences; ViiV Healthcare; Merck Co.; Janssen Pharmaceuticals; Dutch Ministry of Health, Welfare and Sport through the Center for Infectious Disease Control of the National Institute for Public Health; Dutch Ministry of Health, Welfare and Sport through the Environment to Stichting HIV Monitoring (ATHENA [AIDS Therapy Evaluation Project Netherlands]); Agence nationale de recherches sur le sida et les hepatites virales [7]; Fundacion para la Investigacion y la Prevencion del SIDA en Espana [FIS 99/0887]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [5U01AI042170-10, 5U01AI046362-03, U01-AI069907]; European Union's Seventh Framework Programme for research, technological development, and demonstration under EUROCOORD [260694]; Janssen RD; Pfizer; GlaxoSmithKline (Swiss National Science Foundation) [108787]; Swiss National Science Foundation [148522]; Swiss HIV Cohort Study research foundation; Australian HIV Observational Database; Boehringer Ingelheim; Janssen-Cilag; Australian government Department of Health and Ageing; Faculty of Medicine at the University of New South Wales; Swiss Cancer League/Swiss Cancer Research [KFS-4106-02-2017]; Stiftung Institut fur klinische Epidemiologie; Providence/Boston Center for AIDS Research [P30AI042853]	Danish National Research Foundation (Centre of Excellence for Health, Immunity and Infections [CHIP] and Personalized Medicine of Infectious Complications in immune deficiency [PERSIMUNE]); Highly Active Anti-retroviral Therapy Oversight Committee, a collaborative committee with representation from academic institutions; European Agency for the Evaluation of Medicinal Products; U.S. Food and Drug Administration; patient community; AbbVie(AbbVie); Bristol-Myers Squibb(Bristol-Myers Squibb); Gilead Sciences(Gilead Sciences); ViiV Healthcare; Merck Co.(Merck & Company); Janssen Pharmaceuticals(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Dutch Ministry of Health, Welfare and Sport through the Center for Infectious Disease Control of the National Institute for Public Health; Dutch Ministry of Health, Welfare and Sport through the Environment to Stichting HIV Monitoring (ATHENA [AIDS Therapy Evaluation Project Netherlands]); Agence nationale de recherches sur le sida et les hepatites virales(ANRSFrench National Research Agency (ANR)); Fundacion para la Investigacion y la Prevencion del SIDA en Espana; National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); European Union's Seventh Framework Programme for research, technological development, and demonstration under EUROCOORD; Janssen RD; Pfizer(Pfizer); GlaxoSmithKline (Swiss National Science Foundation); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss HIV Cohort Study research foundation; Australian HIV Observational Database; Boehringer Ingelheim(Boehringer Ingelheim); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Australian government Department of Health and Ageing(Australian GovernmentDepartment of Health & Ageing); Faculty of Medicine at the University of New South Wales; Swiss Cancer League/Swiss Cancer Research; Stiftung Institut fur klinische Epidemiologie; Providence/Boston Center for AIDS Research	The D:A:D study was supported by grant DNRF126 from the Danish National Research Foundation (Centre of Excellence for Health, Immunity and Infections [CHIP] and Personalized Medicine of Infectious Complications in immune deficiency [PERSIMUNE]); the Highly Active Anti-retroviral Therapy Oversight Committee, a collaborative committee with representation from academic institutions; the European Agency for the Evaluation of Medicinal Products; the U.S. Food and Drug Administration; the patient community; and the following pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck & Co., and Janssen Pharmaceuticals. It was also supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Center for Infectious Disease Control of the National Institute for Public Health and the Environment to Stichting HIV Monitoring (ATHENA [AIDS Therapy Evaluation Project Netherlands]); by a grant from the Agence nationale de recherches sur le sida et les hepatites virales (Action Coordonnee no. 7, Cohortes) to the Aquitaine Cohort; by grant FIS 99/0887 from the Fondo de Investigacion Sanitaria and grant FIPSE 3171/00 from the Fundacion para la Investigacion y la Prevencion del SIDA en Espana to the Barcelona Antiretroviral Surveillance Study; by grants 5U01AI042170-10 and 5U01AI046362-03 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to the Terry Beirn Community Programs for Clinical Research on AIDS; by primary funding provided by the European Union's Seventh Framework Programme for research, technological development, and demonstration under EUROCOORD grant agreement 260694; by unrestricted grants from Bristol-Myers Squibb, Janssen R&D, Merck & Co., Pfizer, and GlaxoSmithKline (the participation of centers from Switzerland is supported by grant 108787 from the Swiss National Science Foundation) to the EuroSIDA study; by unrestricted educational grants from AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, and Janssen Pharmaceuticals to the ICONA (Italian Cohort Naive Antiretrovirals) Foundation; and by financing within the framework of the Swiss HIV Cohort Study, supported by grant 148522 from the Swiss National Science Foundation and by the Swiss HIV Cohort Study research foundation. The Australian HIV Observational Database is funded as part of the Asia Pacific HIV Observational Database, a program of the Foundation for AIDS Research (amfAR), and is supported in part by grant U01-AI069907 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health and by unconditional grants from Merck & Co., Gilead Sciences, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen-Cilag, and ViiV Healthcare. The Kirby Institute is funded by the Australian government Department of Health and Ageing and is affiliated with the Faculty of Medicine at the University of New South Wales. This study was additionally funded by grant KFS-4106-02-2017 from Swiss Cancer League/Swiss Cancer Research and by Stiftung Institut fur klinische Epidemiologie. Dr. Lodi was supported by grant P30AI042853 from the Providence/Boston Center for AIDS Research.	[Anonymous], 2015, GUID START ANT THER; [Anonymous], 2018, CANC GERM 2013 2014; Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; Borges AH, 2019, J INFECT DIS, V219, P254, DOI 10.1093/infdis/jiy442; Borges AH, 2016, J INFECT DIS, V214, P408, DOI 10.1093/infdis/jiw173; Borges AH, 2014, CURR OPIN HIV AIDS, V9, P34, DOI 10.1097/COH.0000000000000025; Borges AH, 2013, AIDS, V27, P1433, DOI 10.1097/QAD.0b013e32835f6b0c; Bruyand M, 2015, JAIDS-J ACQ IMM DEF, V68, P568, DOI 10.1097/QAI.0000000000000523; CASTRO KG, 1993, CLIN INFECT DIS, V17, P802, DOI 10.1093/clinids/17.4.802; Coghill AE, 2015, J CLIN ONCOL, V33, P2376, DOI 10.1200/JCO.2014.59.5967; Darling KEA, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14348; Eyawo O, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2254-7; FRIISMOLLER N, 2013, NEW ENGL J MED; Gjaerde LI, 2016, CLIN INFECT DIS, V63, P821, DOI 10.1093/cid/ciw380; Gotti D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094768; Grund B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155100; Hemkens LG, 2014, EUR HEART J, V35, P1373, DOI 10.1093/eurheartj/eht528; Hernn MA, 2020, CAUSAL INFERENCE WHA; Jenkins C, 2020, C RETR OPP INF; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; Le Guillou A, 2020, CLIN INFECT DIS, V71, P293, DOI 10.1093/cid/ciz800; Ledwaba L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024243; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Mbang PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142966; Nishijima T, 2020, AIDS, V34, P913, DOI 10.1097/QAD.0000000000002498; Cobucci RNO, 2015, J INFECT PUBLIC HEAL, V8, P1, DOI 10.1016/j.jiph.2014.08.003; Pacheco YM, 2015, ANTIVIR RES, V117, P69, DOI 10.1016/j.antiviral.2015.03.002; Saag MS, 2018, JAMA-J AM MED ASSOC, V320, P379, DOI 10.1001/jama.2018.8431; Schafer J, 2015, HIV MED, V16, P3, DOI 10.1111/hiv.12165; Sereti I, 2017, CLIN INFECT DIS, V64, P124, DOI 10.1093/cid/ciw683; Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078; Shepherd L, 2016, HIV MED, V17, P590, DOI 10.1111/hiv.12359; Shepherd L, 2019, CLIN INFECT DIS, V68, P650, DOI 10.1093/cid/ciy508; Silverberg MJ, 2015, ANN INTERN MED, V163, P507, DOI 10.7326/M14-2768; Six J., 2017, SCHWEIZ KREBSBULLETI, V3, P284, DOI 10.5167/uzh-147848; Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8; Vandenhende MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129550; Wang Q, 2017, ANN INTERN MED, V166, P9, DOI [10.7326/M16-0240, 10.1001/archinte.166.1.9]; Worm SW, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-471; Yanik EL, 2014, AIDS, V28, P979, DOI 10.1097/QAD.0000000000000167; Yanik EL, 2013, CLIN INFECT DIS, V57, P756, DOI 10.1093/cid/cit369	41	4	4	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	2021	174	6					768	+		10.7326/M20-5226	http://dx.doi.org/10.7326/M20-5226			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SS5IR	33721519				2023-01-03	WOS:000661788700016
J	Bhavsar, AA				Bhavsar, Atreyus A.			The spread of macroscopic droplets from a simulated cough with and without the use of masks or barriers	PLOS ONE			English	Article							VIRUS	One of the main challenges during the COVID-19 pandemic is the lack of safety measures and guidelines to reduce the risk of viral spread among people during gatherings. This study was conducted to evaluate the distance of oral and nasal droplet spread in a model that simulates coughing and sneezing in a public setting, specifically a school setting, to guide faculty and staff members with safety measures and guidelines to reduce droplet spread. Several models were prepared to observe and visualize the spread of fluid simulating respiratory droplets in places such as the classroom and the cafeteria, in which a student would be more susceptible to contract a virus since individuals cannot wear masks while eating. For all trials, a 2.54 centimeter balloon with 0.3 milliliters of diluted fluorescent paint was placed inside a mannequin head and was exploded outwards from the mannequin's mouth at 5 pounds per square inch (psi). Using a black light, the expelled fluorescent macroscopic droplets were visualized. When applying safety precautions and guidelines such as mandating face masks, the results of the experiments conducted in this study with a surgical mask, were extremely positive. However, without other safety precautions such as face masks and barriers, social distancing proved to be ineffective. In conclusion the most effective way to prevent droplet spread during activities where masks simply cannot be worn, such as eating, is to apply barriers between the individuals. Applying barriers and wearing masks successfully prevented macroscopic droplet spread.	[Bhavsar, Atreyus A.] Blake High Sch, Minneapolis, MN 55403 USA		Bhavsar, AA (corresponding author), Blake High Sch, Minneapolis, MN 55403 USA.	aabhavsar22@blakeschool.org						Addington W Robert, 2008, Cough, V4, P2, DOI 10.1186/1745-9974-4-2; Anfinrud P, 2020, NEW ENGL J MED, V382, P2061, DOI 10.1056/NEJMc2007800; [Anonymous], 2020, MODES TRANSMISSION V; [Anonymous], 2020, SOCIAL DISTANCING QU; Bahl P, 2022, J INFECT DIS, V225, P1561, DOI 10.1093/infdis/jiaa189; Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756; Bourouiba L, 2016, NEW ENGL J MED, V375, pE15, DOI 10.1056/NEJMicm1501197; Canelli R, 2020, NEW ENGL J MED, V382, P1957, DOI 10.1056/NEJMc2007589; Das SK, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0022859; Dudalski N, 2020, INDOOR AIR, V30, P966, DOI 10.1111/ina.12680; Felfeli T, 2020, INFECT CONTROL MEASU; Felfeli T, 2020, CAN J OPHTHALMOL, V55, pE163, DOI 10.1016/j.jcjo.2020.06.010; Felfeli T, 2021, OPHTHALMOLOGY, V128, P945, DOI 10.1016/j.ophtha.2020.09.043; Fennelly KP, 2020, LANCET RESP MED, V8, P914, DOI 10.1016/S2213-2600(20)30323-4; Gawande A., 2020, CORONAVIRUS CRISIS R; Hui DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050845; Lindsley WG, 2016, INFLUENZA OTHER RESP, V10, P404, DOI 10.1111/irv.12390; Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205; Pantelic J, 2009, J R SOC INTERFACE, V6, pS715, DOI 10.1098/rsif.2009.0311.focus; Prather KA, 2020, SCIENCE, V368, P1422, DOI 10.1126/science.abc6197; Shah SH, 2021, AM J OPHTHALMOL, V222, P76, DOI 10.1016/j.ajo.2020.08.046; Tang JW, 2008, NEW ENGL J MED, V359, pE19, DOI 10.1056/NEJMicm072576; Tang JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034818; Tang JW, 2009, J R SOC INTERFACE, V6, pS727, DOI 10.1098/rsif.2009.0295.focus; Verma S, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0016018; Wei JJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169235; Xie XJ, 2009, J R SOC INTERFACE, V6, pS703, DOI 10.1098/rsif.2009.0388.focus; Yan J, 2018, P NATL ACAD SCI USA, V115, P1081, DOI 10.1073/pnas.1716561115	29	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2021	16	5							e0250275	10.1371/journal.pone.0250275	http://dx.doi.org/10.1371/journal.pone.0250275			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6FV	33951042	gold, Green Published			2023-01-03	WOS:000664610500021
J	Xiao, M; Liu, LZ; Tumilty, S; Liu, D; You, YY; Chen, YH; Tang, SQ; Huang, W; Baxter, GD				Xiao, Min; Liu, Lizhou; Tumilty, Steve; Liu, Dan; You, Yanyan; Chen, Yunhui; Tang, Songqi; Huang, Wei; Baxter, George David			Efficacy and safety of Chinese herbal footbaths for the treatment of dysmenorrhea: Protocol for a systematic review and meta-analysis	PLOS ONE			English	Review							RISK-FACTORS; PAIN; QUESTIONNAIRE; MANAGEMENT; DECOCTION; DIAGNOSIS; CONSENSUS; QUALITY	Background Chinese herbal footbaths are an external therapy of traditional Chinese medicine that has been widely used to treat dysmenorrhea. This review aims to systematically evaluate its efficacy and safety for the treatment of dysmenorrhea. Methods Databases of PubMed, EMBASE, Cochrane Library, CIHAHL, Web of Science, Chinese National Knowledge Infrastructure(CNKI), Chinese Scientific Journals Database (VIP), Wanfang Database, China Biomedical Literature Database(CBM), and Chinese Biomedical Literature Service System (SinoMed) will be searched from the inception to September 30, 2020. The eligible randomized controlled trials (RCTs) will be identified and included. The primary outcomes include pain intensity measured by validated scales of visual analog scale, numeric rating scale, and response rate of symptom reduction. The secondary outcomes are scores on validated pain questionnaires, quality of life measured by SF-36 or other validated scales, and adverse events. Study selection, data extraction, and assessment of bias risk will be conducted by two reviewers independently. RevMan software (V.5.3.5) will be utilized to perform data synthesis. Subgroup and sensitivity analysis will be performed when necessary. The strength of the evidence will be evaluated with the Grading of Recommendations Assessment, Development and Evaluation System. Results A high-quality synthesis of current evidence of Chinese herbal footbaths for patients with dysmenorrhea will be provided in this study. Conclusion This systematic review will provide evidence of whether Chinese herbal footbaths are an effective and safe intervention for the treatment of dysmenorrhea. Systematic review registration PROSPERO CRD42020188256.	[Xiao, Min; Chen, Yunhui; Huang, Wei] Chengdu Univ Tradit Chinese Med, Coll Basic Med, Coll Clin Med, Chengdu, Sichuan, Peoples R China; [Liu, Lizhou; Tumilty, Steve; Baxter, George David] Univ Otago, Sch Physiotherapy, Ctr Hlth Act & Rehabil Res, Dunedin, Otago, New Zealand; [Liu, Dan; You, Yanyan] Sichuan Univ, West China Hosp, South Renmin Rd, Chengdu, Sichuan, Peoples R China; [Tang, Songqi] Hainan Med Univ, Coll Tradit Chinese Med, Haikou, Hainan, Peoples R China	Chengdu University of Traditional Chinese Medicine; University of Otago; Sichuan University; Hainan Medical University	Chen, YH (corresponding author), Chengdu Univ Tradit Chinese Med, Coll Basic Med, Coll Clin Med, Chengdu, Sichuan, Peoples R China.; Baxter, GD (corresponding author), Univ Otago, Sch Physiotherapy, Ctr Hlth Act & Rehabil Res, Dunedin, Otago, New Zealand.; Tang, SQ (corresponding author), Hainan Med Univ, Coll Tradit Chinese Med, Haikou, Hainan, Peoples R China.	chenyunhui@cdutcm.edu.cn; tangsongqi@hainmc.edu.cn; david.baxter@otago.ac.nz			China Scholarship Council [201908510279]; International Cooperation and Exchange Project of Sichuan Provincial Science and Technology Department [2017HH0004]; National Natural Science Foundation of China [81603537, 81860840, 81860816]; Youth Scholar Project of Chengdu University of Traditional Chinese Medicine [QNXZ2019043]; Academic Inheritance and Innovation Project of National TCM Master; 2019 Internationalization Incentive Fund (Division of Health Sciences, University of Otago)	China Scholarship Council(China Scholarship Council); International Cooperation and Exchange Project of Sichuan Provincial Science and Technology Department; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Scholar Project of Chengdu University of Traditional Chinese Medicine; Academic Inheritance and Innovation Project of National TCM Master; 2019 Internationalization Incentive Fund (Division of Health Sciences, University of Otago)	YHC, China Scholarship Council (grant number 201908510279)https://www.csc.edu.cn/; YHC, the International Cooperation and Exchange Project of Sichuan Provincial Science and Technology Department (Grant Number 2017HH0004), http://kjt.sc.gov.cn/; YHC, SQT, the National Natural Science Foundation of China (Grant Number 81603537, 81860840, 81860816), http://www.nsfc.gov.cn/; YHC, the Youth Scholar Project of Chengdu University of Traditional Chinese Medicine (QNXZ2019043), the Academic Inheritance and Innovation Project of National TCM Master,www.cdutcm.edu.cn; and LZL, the 2019 Internationalization Incentive Fund (Division of Health Sciences, University of Otago), https://www.otago.ac.nz/.The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal Anil K, 2010, Indian J Community Med, V35, P159, DOI 10.4103/0970-0218.62586; Alsaleem Mohammed Abadi, 2018, J Family Med Prim Care, V7, P769, DOI 10.4103/jfmpc.jfmpc_113_18; Barcikowska Z, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041191; Bernardi Mariagiulia, 2017, F1000Res, V6, P1645, DOI 10.12688/f1000research.11682.1; Burnett M, 2017, J OBSTET GYNAECOL CA, V39, P585, DOI 10.1016/j.jogc.2016.12.023; Chantler I, 2009, J PAIN, V10, P38, DOI 10.1016/j.jpain.2008.07.002; [陈军 Chen Jun], 2019, [南京中医药大学学报, Journal of Nanjing University of Traditional Chinese Medicine], V35, P623; Dikensoy E, 2008, J OBSTET GYNAECOL RE, V34, P1049, DOI 10.1111/j.1447-0756.2008.00802.x; ENDICOTT J, 1993, PSYCHOPHARMACOL BULL, V29, P321; Fang Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072334; Gagua T, 2013, J PEDIATR ADOL GYNEC, V26, P350, DOI 10.1016/j.jpag.2013.06.018; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hailemeskel S, 2016, INT J WOMENS HEALTH, V8, P489, DOI 10.2147/IJWH.S112768; Han L., 2013, HUNAN J TRADITIONAL, V29, P145; Harirforoosh S, 2013, J PHARM PHARM SCI, V16, P821, DOI 10.18433/J3VW2F; Huang XC, 2016, J ETHNOPHARMACOL, V186, P234, DOI 10.1016/j.jep.2016.03.067; Iacovides S, 2015, HUM REPROD UPDATE, V21, P762, DOI 10.1093/humupd/dmv039; Ju H, 2014, EPIDEMIOL REV, V36, P104, DOI 10.1093/epirev/mxt009; Lee HW, 2016, MATURITAS, V85, P19, DOI 10.1016/j.maturitas.2015.11.013; Lee Jeong Hoon, 2017, J Phys Ther Sci, V29, P1292, DOI 10.1589/jpts.29.1292; Liu P, 2014, J ETHNOPHARMACOL, V154, P696, DOI 10.1016/j.jep.2014.04.044; Marjoribanks J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001751.pub3; Matsumoto S, 2010, INT J BIOMETEOROL, V54, P465, DOI 10.1007/s00484-009-0300-x; Melzack R, 2005, ANESTHESIOLOGY, V103, P199, DOI 10.1097/00000542-200507000-00028; Mittal R, 2019, INT J ADV RES IDEAS, V5, P9; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Osayande AS, 2014, AM FAM PHYSICIAN, V89, P341; Park KS, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/296860; Proctor ML, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002119.pub3; Proctor M, 2006, BMJ-BRIT MED J, V332, P1134, DOI 10.1136/bmj.332.7550.1134; Reed MD, 2014, J CLIN PHARMACOL, V54, P241, DOI 10.1002/jcph.250; Schoep ME, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026186; Sosorburam D, 2019, CHIN HERB MED, V11, P10, DOI 10.1016/j.chmed.2018.11.001; Szmidt MK, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100994; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x; Yu Abigail, 2014, Nurse Pract, V39, P1, DOI 10.1097/01.NPR.0000454984.19413.28; Zannoni L, 2014, J PEDIATR ADOL GYNEC, V27, P258, DOI 10.1016/j.jpag.2013.11.008; Zeng HL., 2014, J PRACTICAL TRADITIO, V28, P171; Zheng HM., 2013, JIANGSU J TRADITIONA, V45, P75; Zhou SF, 2018, REPROD DEV MED, V2, P171, DOI 10.4103/2096-2924.248489	40	1	1	13	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2021	16	5							e0250685	10.1371/journal.pone.0250685	http://dx.doi.org/10.1371/journal.pone.0250685			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RW3BG	33939740	gold, Green Published			2023-01-03	WOS:000646400800008
J	Lin, CT; Huang, WN; Tsai, WC; Chen, JP; Hung, WT; Hsieh, TY; Chen, HH; Hsieh, CW; Lai, KL; Tang, KT; Tseng, CW; Chen, DY; Chen, YH; Chen, YM				Lin, Ching-Tsai; Huang, Wen-Nan; Tsai, Wen-Chan; Chen, Jun-Peng; Hung, Wei-Ting; Hsieh, Tsu-Yi; Chen, Hsin-Hua; Hsieh, Chia-Wei; Lai, Kuo-Lung; Tang, Kuo-Tung; Tseng, Chih-Wei; Chen, Der-Yuan; Chen, Yi-Hsin; Chen, Yi-Ming			Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; TNF INHIBITORS; ABATACEPT; DISEASE; METAANALYSIS; TOCILIZUMAB; TOFACITINIB; EFFICACY; SAFETY; DISCONTINUATION	In this study we aimed to identify the predictors of drug survival for biologic and targeted synthetic DMARDs (bDMARDs and tsDMARDs) among patients with rheumatoid arthritis (RA) in a real-world setting. Data from RA patients receiving bDMARDs and tsDMARDs between 2007 and 2019 were extracted from the Taiwan Rheumatology Association Clinical Electronic Registry (TRACER). Patients were categorized into tumor necrosis factor-alpha (TNF-alpha) inhibitors, non-TNF-alpha inhibitors, and tofacitinib groups. The primary outcome was 3-year drug retention and the causes of bDMARDs and tsDMARDs discontinuation were recorded. Baseline demographic data before the initiation of bDMARDs and tsDMARDs treatment were analyzed to identify the predictors of 3-year drug survival. A total of 1,270 RA patients were recruited (TNF-alpha inhibitors: 584; non-TNF-alpha inhibitors: 535; tofacitinib: 151). The independent protective factors for 3-year drug survival were positive rheumatoid factor (RF) (HR: 0.48, 95% CI: 0.27-0.85, p = 0.013) and biologics-naive RA (HR: 0.61, 95% CI: 0.39-0.94, p = 0.024). In contrast, positive anti-citrullinated protein antibody (ACPA) (HR: 2.24, 95% CI: 1.32-3.79, p = 0.003) and pre-existing latent tuberculosis (HR: 2.90, 95% CI: 2.06-4.09, p<0.001) were associated with drug discontinuation. RA patients treated with TNF-<alpha> inhibitors exhibited better drug retention, especially in the biologics-naive subgroup (p = 0.037). TNF-alpha inhibitors were associated with lower cumulative incidence of discontinuation due to inefficacy and adverse events (both p<0.001). Baseline RF and ACPA positivity in abatacept-treated patients were associated with a better 3-year drug survival. However, negative ACPA levels predicted superior drug survival of TNF-<alpha> inhibitors and tofacitinib. In conclusion, bio-naive status predicted better drug survival in TNF-alpha inhibitors-treated RA patients. RF and ACPA positivity predicted better abatacept drug survival. In contrast, ACPA negativity was associated with superior TNF-alpha inhibitors and tofacitinib survival.	[Lin, Ching-Tsai; Huang, Wen-Nan; Hung, Wei-Ting; Hsieh, Tsu-Yi; Chen, Hsin-Hua; Hsieh, Chia-Wei; Lai, Kuo-Lung; Tang, Kuo-Tung; Tseng, Chih-Wei; Chen, Yi-Hsin; Chen, Yi-Ming] Taichung Vet Gen Hosp, Div Allergy Immunol & Rheumatol, Taichung, Taiwan; [Tsai, Wen-Chan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Chen, Jun-Peng; Chen, Hsin-Hua; Chen, Yi-Ming] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan; [Hung, Wei-Ting; Hsieh, Tsu-Yi] Taichung Vet Gen Hosp, Dept Med Educ, Taichung, Taiwan; [Chen, Hsin-Hua; Chen, Yi-Hsin; Chen, Yi-Ming] Natl Yang Ming Chiao Tung Univ, Sch Med, Coll Med, Taipei, Taiwan; [Chen, Hsin-Hua; Hsieh, Chia-Wei; Tang, Kuo-Tung; Chen, Der-Yuan; Chen, Yi-Ming] Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan; [Chen, Hsin-Hua; Hsieh, Chia-Wei; Tang, Kuo-Tung; Chen, Yi-Ming] Natl Chung Hsing Univ, PhD Program Translat Med, Taichung, Taiwan; [Chen, Der-Yuan] China Med Univ Hosp, Rheumatol & Immunol Ctr, Taichung, Taiwan; [Chen, Der-Yuan] China Med Univ, Sch Med, Taichung, Taiwan	Taichung Veterans General Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Taichung Veterans General Hospital; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; National Chung Hsing University; National Chung Hsing University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan	Chen, YH; Chen, YM (corresponding author), Taichung Vet Gen Hosp, Div Allergy Immunol & Rheumatol, Taichung, Taiwan.; Chen, YM (corresponding author), Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan.; Chen, YH; Chen, YM (corresponding author), Natl Yang Ming Chiao Tung Univ, Sch Med, Coll Med, Taipei, Taiwan.; Chen, YM (corresponding author), Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan.; Chen, YM (corresponding author), Natl Chung Hsing Univ, PhD Program Translat Med, Taichung, Taiwan.	ymchen1@vghtc.gov.tw; ymchen1@vghtc.gov.tw	Chen, Yi-Ming/AAV-3806-2021	Chen, Yi-Ming/0000-0001-7593-3065; Tang, Kuo-Tung/0000-0002-5468-1329	Taichung Veterans General Hospital, Taiwan [TCVGH-1087312C]	Taichung Veterans General Hospital, Taiwan	This study was supported by a grant from Taichung Veterans General Hospital, Taiwan (TCVGH-1087312C) to Dr. Yi-Ming Chen. The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ai JW, 2015, J RHEUMATOL, V42, P2229, DOI 10.3899/jrheum.150057; Aletaha D, 2018, JAMA-J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103; Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baddley JW, 2018, CLIN MICROBIOL INFEC, V24, pS10, DOI 10.1016/j.cmi.2017.12.025; Balsa A, 2018, RHEUMATOLOGY, V57, P688, DOI 10.1093/rheumatology/kex474; Bird P, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2018-000742; Bobbio-Pallavicini F, 2004, ARTHRITIS RES THER, V6, pR264, DOI 10.1186/ar1173; Bobbio-Pallavicini F, 2007, ANN RHEUM DIS, V66, P302, DOI 10.1136/ard.2006.060608; Bugatti S, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00339; Bykerk VP, 2012, ANN RHEUM DIS, V71, P1950, DOI 10.1136/annrheumdis-2011-201087; Cantini F, 2016, INT J RHEUM DIS, V19, P799, DOI 10.1111/1756-185X.12708; Centers for Disease Control T, TB LAT TB EPID NOT I; Charles-Schoeman C, 2016, ANN RHEUM DIS, V75, P1293, DOI 10.1136/annrheumdis-2014-207178; Chen DY, 2015, ANN RHEUM DIS, V74, DOI 10.1136/annrheumdis-2013-203893; Chen YH., 2015, FORMOSAN J RHEUMATOL, V29, P1; Chen YH, 2012, FORMOS J RHEUMATOL, V26, P1; Choquette D, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1917-8; Cohen S, 2014, ARTHRITIS RHEUMATOL, V66, P2924, DOI 10.1002/art.38779; De Rycke L, 2005, ANN RHEUM DIS, V64, P299, DOI 10.1136/ard.2004.023523; Ebina K, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1880-4; Favalli EG, 2017, CLIN RHEUMATOL, V36, P1747, DOI 10.1007/s10067-017-3712-8; Jansen DTSL, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen-2017-000564; Karisson JA, 2008, RHEUMATOLOGY, V47, P507, DOI 10.1093/rheumatology/ken034; Lim CH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178035; Lim CH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166339; Lorenzetti R, 2019, J AUTOIMMUN, V101, P145, DOI 10.1016/j.jaut.2019.04.016; Lv QW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089442; Malmstrom V, 2017, NAT REV IMMUNOL, V17, P60, DOI 10.1038/nri.2016.124; Maneiro RJ, 2013, SEMIN ARTHRITIS RHEU, V43, P9, DOI 10.1016/j.semarthrit.2012.11.007; Mikulska M, 2018, CLIN MICROBIOL INFEC, V24, pS71, DOI 10.1016/j.cmi.2018.02.003; Nusslein HG, 2016, CLIN EXP RHEUMATOL, V34, P489; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Ozen G, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1921-z; Pers YM, 2014, RHEUMATOLOGY, V53, P76, DOI 10.1093/rheumatology/ket301; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Maneiro JR, 2013, JAMA INTERN MED, V173, P1416, DOI 10.1001/jamainternmed.2013.7430; Salgado E, 2014, JOINT BONE SPINE, V81, P41, DOI 10.1016/j.jbspin.2013.04.004; Schiff MH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3455; See LC, 2013, SEMIN ARTHRITIS RHEU, V43, P381, DOI 10.1016/j.semarthrit.2013.06.001; Sellam J, 2011, ARTHRITIS RHEUM-US, V63, P933, DOI 10.1002/art.30233; Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480; Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis-2019-216655; Smolen JS, 2015, NAT REV RHEUMATOL, V11, P276, DOI 10.1038/nrrheum.2015.8; Sokolove J, 2016, ANN RHEUM DIS, V75, P709, DOI 10.1136/annrheumdis-2015-207942; Souto A, 2016, RHEUMATOLOGY, V55, P523, DOI 10.1093/rheumatology/kev374; Strand V, 2017, BIODRUGS, V31, P299, DOI 10.1007/s40259-017-0231-8; Strand V, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0880-2; Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691; Xiang YR, 2020, INT J RHEUM DIS, V23, P1719, DOI 10.1111/1756-185X.13996	50	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2021	16	4							e0250877	10.1371/journal.pone.0250877	http://dx.doi.org/10.1371/journal.pone.0250877			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6EM	33930048	Green Published, gold			2023-01-03	WOS:000664607000044
J	Mbalinda, SN; Bakeera-Kitaka, S; Lusota, DA; Musoke, P; Nyashanu, M; Kaye, DK				Mbalinda, Scovia Nalugo; Bakeera-Kitaka, Sabrina; Lusota, Derrick Amooti; Musoke, Philippa; Nyashanu, Mathew; Kaye, Dan Kabonge			Transition to adult care: Exploring factors associated with transition readiness among adolescents and young people in adolescent ART clinics in Uganda	PLOS ONE			English	Article							HIV; ADHERENCE; SERVICES; BARRIERS	Background Transition readiness refers to a client who knows about his/her illness and oriented towards future goals and hopes, shows skills needed to negotiate healthcare, and can assume responsibility for his/ her treatment, and participate in decision-making that ensures uninterrupted care during and after the care transition to adult HIV care. There is a paucity of research on effective transition strategies. This study explored factors associated with adolescent readiness for the transition into adult care in Uganda. Methods A cross-sectional study was conducted among 786 adolescents, and young people living with HIV randomly selected from 9 antiretroviral therapy clinics, utilizing a structured questionnaire. The readiness level was determined using a pre-existing scale from the Ministry of Health, and adolescents were categorized as ready or not ready for the transition. Bivariate and multivariate analyses were conducted. Results A total of 786 adolescents were included in this study. The mean age of participants was 17.48 years (SD = 4). The majority of the participants, 484 (61.6%), were females. Most of the participants, 363 (46.2%), had no education. The majority of the participants, 549 (69.8%), were on first-line treatment. Multivariate logistic regression analysis found that readiness to transition into adult care remained significantly associated with having acquired a tertiary education (AOR 4.535, 95% CI 1.243-16.546, P = 0.022), trusting peer educators for HIV treatment (AOR 16.222, 95% CI 1.835-143.412, P = 0.012), having received counselling on transition to adult services (AOR 2.349, 95% CI 1.004-5.495, P = 0.049), having visited an adult clinic to prepare for transition (AOR 6.616, 95% CI 2.435-17.987, P = < 0.001) and being satisfied with the transition process in general (AOR 0.213, 95% CI 0.069-0.658, P = 0.007). Conclusion The perceived readiness to transition care among young adults was low. A series of individual, social and health system and services factors may determine successful transition readiness among adolescents in Uganda. Transition readiness may be enhanced by strengthening the implementation of age-appropriate and individualized case management transition at all sites while creating supportive family, peer, and healthcare environments.	[Mbalinda, Scovia Nalugo; Lusota, Derrick Amooti; Nyashanu, Mathew] Makerere Univ, Coll Hlth Sci, Dept Nursing, Kampala, Uganda; [Bakeera-Kitaka, Sabrina; Musoke, Philippa] Makerere Univ, Coll Hlth Sci, Dept Peadiatr, Kampala, Uganda; [Kaye, Dan Kabonge] Makerere Univ, Coll Hlth Sci, Dept Obstet & Gynaecol, Kampala, Uganda; [Nyashanu, Mathew] Nottingham Trent Univ, Sch Social Sci, Dept Hlth & Allied Profess, Nottingham, England	Makerere University; Makerere University; Makerere University; Nottingham Trent University	Mbalinda, SN (corresponding author), Makerere Univ, Coll Hlth Sci, Dept Nursing, Kampala, Uganda.	snmbalinda@gmail.com		N Mbalinda, Scovia/0000-0002-4945-130X; kaye, dan/0000-0003-1490-859X	Office of the Director, National Institutes of Health (OD) [D43TW010132]; National Institute of Dental & Craniofacial Research (NIDCR); National Institute of Neurological Disorders and Stroke (NINDS); National Heart, Lung, And Blood Institute (NHLBI); Fogarty International Center (FIC); National Institute On Minority Health and Health Disparities (NIMHD); Carnegie Corporation of New York [B 8606.R02]; Sida [54100029]; DELTAS Africa Initiative [107768/Z/15/Z]; African Academy of Sciences (AAS) 's Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust (UK); UK government; Fogarty International Center of the National Institutes of Health [1R25TW011213]	Office of the Director, National Institutes of Health (OD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Dental & Craniofacial Research (NIDCR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Heart, Lung, And Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Fogarty International Center (FIC)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); National Institute On Minority Health and Health Disparities (NIMHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); Carnegie Corporation of New York; Sida; DELTAS Africa Initiative; African Academy of Sciences (AAS) 's Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust (UK)(Wellcome Trust); UK government; Fogarty International Center of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	Grant Number D43TW010132 supported by the Office of the Director, National Institutes of Health (OD), National Institute of Dental & Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Heart, Lung, And Blood Institute (NHLBI), Fogarty International Center (FIC), National Institute On Minority Health and Health Disparities (NIMHD). Received by Scovia Nalugo Mbalinda (SNM). Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No-B 8606.R02), Sida (Grant No:54100029), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) 's Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. Received by Scovia Nalugo Mbalinda (SNM). The research reported in this publication was supported by the Fogarty International Center of the National Institutes of Health under Award Number 1R25TW011213. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Acree ME, 2017, PEDIATR ANN, V46, pE198, DOI 10.3928/19382359-20170424-02; Asire B., 2017, J INFECT DIS PREVENT, V5, P1, DOI [10.4172/2329-8731.1000150, DOI 10.4172/2329-8731.1000150]; Bakanda C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019261; Battles HB, 2002, J ADOLESCENT HEALTH, V30, P161, DOI 10.1016/S1054-139X(01)00341-X; Bermudez LG, 2016, AIDS CARE, V28, P83, DOI 10.1080/09540121.2016.1176681; Cremin I, 2012, TROP MED INT HEALTH, V17, pe26, DOI 10.1111/j.1365-3156.2011.02937.x; Dahourou DL, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.4.21528; Ejigu Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201886; Gilliam PP, 2011, J ASSOC NURSE AIDS C, V22, P283, DOI 10.1016/j.jana.2010.04.003; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2016, INCR JOURN GLOB PLAN; Kung T H, 2016, SAMJ, S. Afr. med. j., V106, P804, DOI [10.7196/SAMJ.2016.v106i8.10496, 10.7196/samj.2016.v106i8.10496]; Lolekha R, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.4.21500; MacCarthy S, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6048-7; Machado DM, 2016, BRAZ J INFECT DIS, V20, P229, DOI 10.1016/j.bjid.2015.12.009; Masese RV, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25406; Mbalinda SN, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05701-9; Ministry of Health of Mongolia Ministry of Food and Light Industry of Mongolia, 2017, UG POP BAS HIV IMP A; Nyabigambo A, 2014, VALUE HEALTH, V17, pA666, DOI 10.1016/j.jval.2014.08.2454; Nyabigambo A, 2014, ADOLESC HEALTH MED T, V5, P89, DOI 10.2147/AHMT.S57950; Pinzon-Iregui Maria C, 2017, J Int Assoc Provid AIDS Care, V16, P579, DOI 10.1177/2325957417729749; Program AC, 2015, AD HIV CAR TREATM SU; Ryscavage P, 2016, AIDS CARE, V28, P561, DOI 10.1080/09540121.2015.1131967; Valenzuela JM, 2011, J PEDIATR PSYCHOL, V36, P134, DOI 10.1093/jpepsy/jsp051; WHO, 2014, BURD DIS HOUS AIR PO; Wiener LS, 2011, J PEDIATR PSYCHOL, V36, P141, DOI 10.1093/jpepsy/jsp129; Wringe A, 2008, TROP MED INT HEALTH, V13, P319, DOI 10.1111/j.1365-3156.2008.02005.x; Yi SY, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0159-6	27	3	3	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2021	16	4							e0249971	10.1371/journal.pone.0249971	http://dx.doi.org/10.1371/journal.pone.0249971			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6DA	33914770	gold, Green Published			2023-01-03	WOS:000664603100025
J	Chia, A				Chia, Audrey			Why is dying not seen as a diagnosis?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material														Chia, Audrey/0000-0001-6098-2526					0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 28	2021	373								n920	10.1136/bmj.n920	http://dx.doi.org/10.1136/bmj.n920			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SK7MH	33910919	Bronze			2023-01-03	WOS:000656399900006
J	Theisinger, SM; de Smidt, O; Lues, JFR				Theisinger, Shirleen M.; de Smidt, Olga; Lues, Jan F. R.			Categorisation of culturable bioaerosols in a fruit juice manufacturing facility	PLOS ONE			English	Article							SP-NOV.; PANTOEA-AGGLOMERANS; SUBSP NOV; AIRBORNE MICROORGANISMS; AUREOBASIDIUM-PULLULANS; STAPHYLOCOCCUS-EQUORUM; ANTIBACTERIAL ACTIVITY; BIODIESEL PRODUCTION; RELATIVE-HUMIDITY; FOOD-INDUSTRY	Bioaerosols are defined as aerosols that comprise particles of biological origin or activity that may affect living organisms through infectivity, allergenicity, toxicity, or through pharmacological or other processes. Interest in bioaerosol exposure has increased over the last few decades. Exposure to bioaerosols may cause three major problems in the food industry, namely: (i) contamination of food (spoilage); (ii) allergic reactions in individual consumers; or (iii) infection by means of pathogenic microorganisms present in the aerosol. The aim of this study was to characterise the culturable fraction of bioaerosols in the production environment of a fruit juice manufacturing facility and categorise isolates as harmful, innocuous or potentially beneficial to the industry, personnel and environment. Active sampling was used to collect representative samples of five areas in the facility during peak and off-peak seasons. Areas included the entrance, preparation and mixing area, between production lines, bottle dispersion and filling stations. Microbes were isolated and identified using 16S, 26S or ITS amplicon sequencing. High microbial counts and species diversity were detected in the facility. 239 bacteria, 41 yeasts and 43 moulds were isolated from the air in the production environment. Isolates were categorised into three main groups, namely 27 innocuous, 26 useful and 39 harmful bioaerosols. Harmful bioaerosols belonging to the genera Staphylococcus, Pseudomonas, Penicillium and Candida were present. Although innocuous and useful bioaerosols do not negatively influence human health their presence act as an indicator that an ideal environment exists for possible harmful bioaerosols to emerge.	[Theisinger, Shirleen M.; de Smidt, Olga; Lues, Jan F. R.] Cent Univ Technol, Ctr Appl Food Sustainabil & Biotechnol CAFSaB, Fac Hlth & Environm Sci, Bloemfontein, Free State, South Africa	Central University of Technology	de Smidt, O (corresponding author), Cent Univ Technol, Ctr Appl Food Sustainabil & Biotechnol CAFSaB, Fac Hlth & Environm Sci, Bloemfontein, Free State, South Africa.	odesmidt@cut.ac.za		de Smidt, Olga/0000-0002-0247-3624	South African National Research Foundation (NRF)	South African National Research Foundation (NRF)(National Research Foundation - South Africa)	Funded by the South African National Research Foundation (NRF). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams RI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128022; Adukwu EC, 2016, APPL MICROBIOL BIOT, V100, P9619, DOI 10.1007/s00253-016-7807-y; Afanou KA, 2015, APPL ENVIRON MICROB, V81, P5794, DOI 10.1128/AEM.00929-15; Ahmed NH, 2017, INDIAN J MED RES, V146, P420, DOI 10.4103/ijmr.IJMR_1362_15; Altschul SE, 1997, THEORETICAL AND COMPUTATIONAL METHODS IN GENOME RESEARCH, P1; ANDERSON PW, 1958, PHYS REV, V109, P1492, DOI 10.1103/PhysRev.109.1492; Andreani NA, 2014, FOOD MICROBIOL, V39, P116, DOI 10.1016/j.fm.2013.11.012; [Anonymous], 1992, COMPENDIUM METHODS M, V3rd, P75; Aransiola EF, 2014, BIOMASS BIOENERG, V61, P276, DOI 10.1016/j.biombioe.2013.11.014; Athan E, 2014, CURR INFECT DIS REP, V16, DOI 10.1007/s11908-014-0446-5; Azin M, 2007, ENZYME MICROB TECH, V40, P801, DOI 10.1016/j.enzmictec.2006.06.013; Bal ZS, 2015, BRAZ J INFECT DIS, V19, P213, DOI 10.1016/j.bjid.2014.09.011; Barata A, 2012, INT J FOOD MICROBIOL, V153, P243, DOI 10.1016/j.ijfoodmicro.2011.11.025; Behrendt U, 2007, INT J SYST EVOL MICR, V57, P979, DOI 10.1099/ijs.0.64793-0; Bentanzos-Cabrera G., 2015, FOOD NUTR RES, V59, P276; Beuchat LR, 2016, J FOOD PROTECT, V79, P95, DOI 10.4315/0362-028X.JFP-15-357; Bhangar S, 2014, INDOOR AIR, V24, P604, DOI 10.1111/ina.12111; Bhanger S., 2015, INDOOR AIR, P19; Bonadonna L, 2017, INDOOR AIR QUALITY H, P53; Bowers RM, 2011, APPL ENVIRON MICROB, V77, P6350, DOI 10.1128/AEM.05498-11; Bragoszewska E., 2016, AEROBIOLOGY, P156; Bragoszewska E, 2016, ATMOSPHERE-BASEL, V7, DOI 10.3390/atmos7110142; Brandl H, 2014, J DAIRY SCI, V97, P240, DOI 10.3168/jds.2013-7028; Briganti F, 1997, FEBS LETT, V416, P61, DOI 10.1016/S0014-5793(97)01167-8; Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404; BULSKI K, 2017, MICROBIOLOGICAL AIR, P54; Calasso M, 2016, FOOD MICROBIOL, V54, P115, DOI 10.1016/j.fm.2015.10.008; Carvalhais V, 2015, MOL IMMUNOL, V65, P429, DOI 10.1016/j.molimm.2015.02.024; Castillo JA, 2012, ANAL BIOANAL CHEM, V403, P15, DOI 10.1007/s00216-012-5725-0; Castoria R, 2001, POSTHARVEST BIOL TEC, V22, P7, DOI 10.1016/S0925-5214(00)00186-1; Chatterjee C., 2018, INT J ENG-IRAN, V4, P84; Chavda KD, 2016, MBIO, V7, DOI 10.1128/mBio.02093-16; Chen L, 2016, CRIT REV MICROBIOL, V42, P454, DOI 10.3109/1040841X.2014.959892; Chi ZM, 2009, APPL MICROBIOL BIOT, V82, P793, DOI 10.1007/s00253-009-1882-2; Choi O, 2019, INT J FOOD MICROBIOL, V291, P1, DOI 10.1016/j.ijfoodmicro.2018.11.003; Coda R, 2013, FOOD MICROBIOL, V33, P243, DOI 10.1016/j.fm.2012.09.023; Cox J, 2020, AEROSOL SCI TECH, V54, P572, DOI 10.1080/02786826.2019.1688759; Crook B., 2016, MICROORGANISMS HOME, V2nd; Czekaj T, 2015, MICROBIOL-SGM, V161, P2061, DOI 10.1099/mic.0.000178; Daugelaite J., 2013, ISRN BIOMATHEMATICS, P16; David B., 2014, PHYTOCHEMISTRY REV, P354; Davolos D, 2007, PREVENTION TODAY, V3, P23; De Bel A, 2014, INT J SYST EVOL MICR, V64, P4198, DOI 10.1099/ijs.0.064758-0; Decimo M, 2018, INT J DAIRY TECHNOL, V71, P593, DOI 10.1111/1471-0307.12485; Dehghan-Niri M., 2015, NEW DIS REPORTS, V31, P2044; Deligios M, 2015, GENOME ANNOUNCEMENTS, V3, DOI 10.1128/genomeA.00201-15; Despres VR, 2012, TELLUS B, V64, DOI 10.3402/tellusb.v64i0.15598; Dimitriadi D., 2014, INT ARABIC J ANTIMIC, V4, P760; Dixit R, 2015, SUSTAINABILITY-BASEL, V7, P2189, DOI 10.3390/su7022189; dos Santos ACM, 2018, GENOME ANNOUNCEMENTS, V6, DOI [10.1128/genomeA.00404-18, 10.1128/genomea.00404-18]; Downes F. P., 2001, COMPENDIUM METHODS M, V4th; du Plessis IL, 2018, MYCOLOGIA, V110, P559, DOI 10.1080/00275514.2018.1463059; Dutkiewicz J, 2016, ANN AGR ENV MED, V23, P197, DOI 10.5604/12321966.1203878; Eduard W, 2012, J ENVIRON MONITOR, V14, P334, DOI 10.1039/c2em10717a; Egamberdieva D, 2013, PLANT SOIL, V369, P453, DOI 10.1007/s11104-013-1586-3; Etikan I., 2015, AM J THEOR APPL STAT, V5, P1, DOI 10.11648/j.ajtas.20160501.11; Ferguson RMW, 2019, MOL ECOL RESOUR, V19, P672, DOI 10.1111/1755-0998.13002; Fernandez-Rodriguez S, 2015, SCI TOTAL ENVIRON, V533, P165, DOI 10.1016/j.scitotenv.2015.06.031; Ferrario M, 2015, FOOD MICROBIOL, V46, P635, DOI 10.1016/j.fm.2014.06.017; Figueiredo M., 2016, BIOFORMULATIONS SUST, P41; Fisher MC, 2012, NATURE, V484, P186, DOI 10.1038/nature10947; Food code, 2017, US PUBL HLTH SERV; Frankel M, 2012, APPL ENVIRON MICROB, V78, P8289, DOI 10.1128/AEM.02069-12; Frohlich-Nowoisky J, 2016, ATMOS RES, V182, P346, DOI 10.1016/j.atmosres.2016.07.018; Garg S, 2017, J ACUTE DIS, V6, P239, DOI 10.4103/2221-6189.219624; Ghorbani F, 2015, BIOCHEM ENG J, V101, P77, DOI 10.1016/j.bej.2015.05.005; Gomez P, 2017, FEMS MICROBIOL ECOL, V93, DOI 10.1093/femsec/fiw208; Goyer N, 2001, BIOAEROSOLS WORKPLAC; Granada SD., 2016, PLANTA MED, V82, P1, DOI [10.1055/s-0035-1568212, DOI 10.1055/S-0035-1568212]; Groot MN., 2018, FOOD MICROBIOL, V9, P12; Gupta G. N., 2014, Trends in Biosciences, V7, P3708; Haftay Abraha, 2018, Journal of Veterinary Medicine and Animal Health, V10, P106, DOI 10.5897/jvmah2017.0664; Hajek V, 1996, INT J SYST BACTERIOL, V46, P792, DOI 10.1099/00207713-46-3-792; Han S., 2018, AM J RESP CRIT CARE, V197, P14; Hara K, 2015, AEROSOL AIR QUAL RES, V15, P591, DOI 10.4209/aaqr.2014.03.0067; Heather JM, 2016, GENOMICS, V107, P1, DOI 10.1016/j.ygeno.2015.11.003; Heo KJ, 2017, J AEROSOL SCI, V104, P58, DOI 10.1016/j.jaerosci.2016.11.008; Heyrman J, 2005, INT J SYST EVOL MICR, V55, P111, DOI 10.1099/ijs.0.63240-0; Hirst JM, 1995, HDB BIOAEROSOLS INTR, P1; Hong SW, 2012, INT J SYST EVOL MICR, V62, P2077, DOI 10.1099/ijs.0.034892-0; Hospodsky D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034867; Huang YH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000885; Humbal C, 2018, ENVIRON INT, V118, P189, DOI 10.1016/j.envint.2018.05.053; Jemli S, 2007, BIOCHEM ENG J, V34, P44, DOI 10.1016/j.bej.2006.11.016; Kampfer P, 2007, INT J SYST EVOL MICR, V57, P1342, DOI 10.1099/ijs.0.64942-0; Kampfer P, 2002, SYST APPL MICROBIOL, V25, P31, DOI 10.1078/0723-2020-00099; KANG YJ, 1989, J FOOD PROTECT, V52, P512, DOI 10.4315/0362-028X-52.7.512; Khan SA, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-231; 김나영, 2007, [Korean Journal of Microbiology, 미생물학회지], V43, P193; Kim KH, 2018, J ENVIRON SCI, V67, P23, DOI 10.1016/j.jes.2017.08.027; KING AD, 1979, APPL ENVIRON MICROB, V37, P959, DOI 10.1128/AEM.37.5.959-964.1979; Kobayashi T, 2009, J IMMUNOL, V182, P2502, DOI 10.4049/jimmunol.0802773; Kobza J, 2018, OCCUP MED-OXFORD, V68, P454, DOI 10.1093/occmed/kqy095; Kooken JM, 2012, MOL CELL PROBE, V26, P1, DOI 10.1016/j.mcp.2011.09.003; Kubera L, 2015, MED PR, V66, P49; Kuenzi M, APPL MICROBIOLOGY BI, V21, P1; Kurtzman CP, 1998, ANTON LEEUW INT J G, V73, P331, DOI 10.1023/A:1001761008817; Lal S, 2009, INDIAN J MICROBIOL, V49, P2, DOI 10.1007/s12088-009-0008-y; Lalucat J, 2006, MICROBIOL MOL BIOL R, V70, P510, DOI 10.1128/MMBR.00047-05; Lee BU, 2016, J AEROSOL SCI, V94, P1, DOI 10.1016/j.jaerosci.2015.12.002; Lee JS, 2003, INT J SYST EVOL MICR, V53, P1277, DOI 10.1099/ijs.0.02492-0; Lelieveld HLM, 1996, APPL MICROBIOL BIOT, V45, P723, DOI 10.1007/s002530050754; Limtong S, 2017, YEASTS NATURAL ECOSY, P199; Lin SJ, 2001, CLIN INFECT DIS, V32, P358, DOI 10.1086/318483; Lipsa FD, 2016, ENVIRON ENG MANAG J, V15, P801, DOI 10.30638/eemj.2016.086; Liu BH, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01388-17, 10.1128/aac.01388-17]; Lopez-Cortes A, 2006, SYST APPL MICROBIOL, V29, P183, DOI 10.1016/j.syapm.2005.09.007; Lutgring KR, 1997, J FOOD PROTECT, V60, P804, DOI 10.4315/0362-028X-60.7.804; Madsen AM, 2018, ENVIRON RES, V160, P282, DOI 10.1016/j.envres.2017.10.001; Majchrzycka K., 2017, BIOTECHNOL FOOD SCI, V81, P159; Mandal J., 2011, Open Environmental & Biological Monitoring Journal, V4, P83, DOI 10.2174/1875040001104010083; Maoka T, 2013, J OLEO SCI, V62, P181, DOI 10.5650/jos.62.181; Marchesi JR, 1998, APPL ENVIRON MICROB, V64, P795; Masotti F, 2019, TRENDS FOOD SCI TECH, V90, P147, DOI 10.1016/j.tifs.2019.06.006; Meadow JF, 2014, INDOOR AIR, V24, P41, DOI 10.1111/ina.12047; Meadow JF, 2015, PEERJ, V3, DOI 10.7717/peerj.1258; Mekadim C, 2019, FOLIA MICROBIOL, V64, P113, DOI 10.1007/s12223-018-0638-8; Miceli MH, 2011, LANCET INFECT DIS, V11, P142, DOI 10.1016/S1473-3099(10)70218-8; Mohan B, 2017, J CLIN DIAGN RES, V11, pDR1, DOI 10.7860/JCDR/2017/23997.9229; Montero A, 2016, PEERJ, V4, DOI 10.7717/peerj.2827; Morawska L, 2006, INDOOR AIR, V16, P335, DOI 10.1111/j.1600-0668.2006.00432.x; Moretro T, 2017, COMPR REV FOOD SCI F, V16, P1022, DOI 10.1111/1541-4337.12283; Mueller M, 2010, BMC BIOCHEM, V11, DOI 10.1186/1471-2091-11-8; Nadeem SM, 2014, BIOTECHNOL ADV, V32, P429, DOI 10.1016/j.biotechadv.2013.12.005; NAKASE T, 1976, J GEN APPL MICROBIOL, V22, P177, DOI 10.2323/jgam.22.177; Natl Advisory Comm Microbiological, 2018, J FOOD PROTECT, V81, P115, DOI 10.4315/0362-028X.JFP-17-294; Naveen H, 2010, ARCH APPL SCI RES, V2, P161, DOI [10.1016/j.bcab.2018.09.014, DOI 10.1016/J.BCAB.2018.09.014]; NOBLE WC, 1975, BRIT J DERMATOL, V93, P477, DOI 10.1111/j.1365-2133.1975.tb06527.x; Novakova D, 2006, J MED MICROBIOL, V55, P523, DOI 10.1099/jmm.0.46246-0; Nunes C, 2002, J APPL MICROBIOL, V92, P247, DOI 10.1046/j.1365-2672.2002.01524.x; Nwodo UU, 2012, INT J MOL SCI, V13, P14002, DOI 10.3390/ijms131114002; Otto M, 2014, METHODS MOL BIOL, V1106, P17, DOI 10.1007/978-1-62703-736-5_2; Palmer M, 2016, STAND GENOMIC SCI, V11, DOI 10.1186/s40793-016-0144-z; Pantucek R, 2013, SYST APPL MICROBIOL, V36, P90, DOI 10.1016/j.syapm.2012.11.004; Pasquarelli F., 2015, RSC ADV, V46, P201; Place RB, 2003, SYST APPL MICROBIOL, V26, P30, DOI 10.1078/072320203322337281; Plociniczak T., 2016, FRONT PLANT SCI, P251, DOI [10.3389/fpls.2016.00251, DOI 10.3389/FPLS.2016.00251]; Priyadarshini S, 2013, COLLOID SURFACE B, V102, P232, DOI 10.1016/j.colsurfb.2012.08.018; Qian H, 2018, J THORAC DIS, V10, pS2295, DOI 10.21037/jtd.2018.01.24; Qian J, 2012, INDOOR AIR, V22, P339, DOI 10.1111/j.1600-0668.2012.00769.x; Qian J, 2014, ATMOS ENVIRON, V89, P464, DOI 10.1016/j.atmosenv.2014.02.035; Quinn L, 2018, BREASTFEED MED, V13, P388, DOI 10.1089/bfm.2018.0002; Quinto CA, 2015, NANOSCALE, V7, P12728, DOI 10.1039/c5nr02718g; Rafferty B, 2011, J ATHEROSCLER THROMB, V18, P72, DOI 10.5551/jat.5207; Ramesh A, 2014, APPL SOIL ECOL, V73, P87, DOI 10.1016/j.apsoil.2013.08.009; Rasmussen M, 2016, CLIN MICROBIOL INFEC, V22, P22, DOI 10.1016/j.cmi.2015.09.026; Rezzonico F, 2005, MOL PLANT MICROBE IN, V18, P991, DOI 10.1094/MPMI-18-0991; Rittenour WR, 2012, J IMMUNOL METHODS, V383, P47, DOI 10.1016/j.jim.2012.01.012; Rodrigues J, 2016, BIORESOURCE TECHNOL, V213, P88, DOI 10.1016/j.biortech.2016.03.011; Rojo MC, 2017, FOOD MICROBIOL, V64, P7, DOI 10.1016/j.fm.2016.11.017; Ronning HT, 2015, FOOD ADDIT CONTAM A, V32, P2120, DOI 10.1080/19440049.2015.1096967; Roodbari A, 2013, ENVIRON PROT ENG, V39, P105, DOI 10.5277/epe130409; Rooney AP, 2009, INT J SYST EVOL MICR, V59, P2429, DOI 10.1099/ijs.0.009126-0; Rosa R., 2015, OPEN FORUM INFECT DI, V2, P1780; Sajna KV, 2015, BIORESOURCE TECHNOL, V191, P133, DOI 10.1016/j.biortech.2015.04.126; Salmeron-Alcocer A, 2007, BIOCHEM ENG J, V37, P201, DOI 10.1016/j.bej.2007.04.015; Samanta SK, 2002, TRENDS BIOTECHNOL, V20, P243, DOI 10.1016/S0167-7799(02)01943-1; Saranraj P., 2012, International Journal of Pharmaceutical and Biological Archives, V3, P38; Saravanan M, 2011, COLLOID SURFACE B, V88, P325, DOI 10.1016/j.colsurfb.2011.07.009; Savini Vincenzo, 2009, Recent Pat Antiinfect Drug Discov, V4, P123; Seiler H, 2012, INT J SYST EVOL MICR, V62, P1092, DOI 10.1099/ijs.0.027771-0; Shale K, 2007, FOOD REV INT, V23, P73, DOI 10.1080/87559120600998205; Sheng-Yuan R., INT J INFECT DIS, V14, P147; Shields Bridget E, 2016, JAAD Case Rep, V2, P428; Shyamala R., 2015, Journal of Microbiology and Biotechnology Research, V5, P11; Silva MG, 2004, MICROBIOL RES, V159, P317, DOI 10.1016/j.micres.2004.06.003; Singh BK, 2017, MICROB BIOTECHNOL, V10, P50, DOI 10.1111/1751-7915.12592; Singh P, 2015, INT J NANOMED, V10, P2567, DOI 10.2147/IJN.S72313; Singn R., 2013, Proceedings of the International Academy of Ecology and Environmental Sciences, V4, P1; Snyder AB, 2018, FOOD CONTROL, V85, P144, DOI 10.1016/j.foodcont.2017.09.025; Sonjak S, 2005, FEMS MICROBIOL ECOL, V53, P51, DOI 10.1016/j.femsec.2004.10.014; SORENSON WG, 1984, J TOXICOL ENV HEALTH, V14, P525, DOI 10.1080/15287398409530603; Sosa MJ, 2002, J FOOD PROTECT, V65, P988, DOI 10.4315/0362-028X-65.6.988; Sowiak M, 2012, MED PR, V63, P1; Spang A, 2015, NATURE, V521, P173, DOI 10.1038/nature14447; Spellberg B, 2017, VIRULENCE, V8, P1481, DOI 10.1080/21505594.2017.1364335; Su XM, 2015, APPL MICROBIOL BIOT, V99, P1989, DOI 10.1007/s00253-014-6108-6; Theisinger SM., 2017, IDEAS APPL SAMPLE PR, P51; Thomsen ST, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0437-x; Tominaga T, 2009, J GEN APPL MICROBIOL, V55, P217, DOI 10.2323/jgam.55.217; Trofa D, 2008, CLIN MICROBIOL REV, V21, P606, DOI 10.1128/CMR.00013-08; Vaishampayan P, 2010, INT J SYST EVOL MICR, V60, P1031, DOI 10.1099/ijs.0.008979-0; Venter P, 2004, POULTRY SCI, V83, P1226, DOI 10.1093/ps/83.7.1226; Viegas C, 2018, ARH HIG RADA TOKSIKO, V69, P250, DOI 10.2478/aiht-2018-69-3116; Walser SM, 2017, BUNDESGESUNDHEITSBLA, V60, P618, DOI 10.1007/s00103-017-2553-6; Wang CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120308; Wang N., 2019, FOOD CONTROL, V106, P172; Wei K, 2015, SCI BULL, V60, P1439, DOI 10.1007/s11434-015-0868-y; White TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1; Wieser M, 1999, INT J SYST BACTERIOL, V49, P1165, DOI 10.1099/00207713-49-3-1165; Wigmann EF, 2015, FOOD RES INT, V67, P219, DOI 10.1016/j.foodres.2014.11.025; Wischmeyer PE, 2016, CURR OPIN CRIT CARE, V22, P347, DOI 10.1097/MCC.0000000000000321; Wong D, 2017, CLIN MICROBIOL REV, V30, P409, DOI 10.1128/CMR.00058-16; Wrent P, 2015, MICROORGANISMS, V3, P428, DOI 10.3390/microorganisms3030428; Wu B., 2017, FRONTIERS MICROBIOLO, P69; Xia XM, 2015, J ATMOS SCI, V72, P2997, DOI 10.1175/JAS-D-15-0008.1; Yang QX, 2011, BIOCHEM ENG J, V58-59, P168, DOI 10.1016/j.bej.2011.09.012; Yao MS, 2018, J AEROSOL SCI, V115, P108, DOI 10.1016/j.jaerosci.2017.07.010; Yassin MF, 2010, INT J ENVIRON SCI TE, V7, P535, DOI 10.1007/BF03326162; Yoo K, 2017, J ENVIRON SCI-CHINA, V51, P234, DOI 10.1016/j.jes.2016.07.002; Yoon JH, 2003, INT J SYST EVOL MICR, V53, P595, DOI 10.1099/ijs.0.02132-0; You RY, 2013, AEROSOL AIR QUAL RES, V13, P911, DOI 10.4209/aaqr.2012.03.0061; Yu OHY, 2010, INT J INFECT DIS, V14, pE433, DOI 10.1016/j.ijid.2009.05.012; Zalar P, 2008, STUD MYCOL, P21, DOI 10.3114/sim.2008.61.02; Zemouri C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178007; Zhang JL, 2010, INT J SYST EVOL MICR, V60, P2924, DOI 10.1099/ijs.0.019851-0; Zhang Y, 2012, FUNGAL DIVERS, V53, P1, DOI 10.1007/s13225-011-0117-x; Zhen Q, 2017, SCI TOTAL ENVIRON, V601, P703, DOI 10.1016/j.scitotenv.2017.05.049	208	0	0	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2021	16	4							e0242969	10.1371/journal.pone.0242969	http://dx.doi.org/10.1371/journal.pone.0242969			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT0BF	33882058	Green Published, gold			2023-01-03	WOS:000644133400013
J	Kocaman, H; Bek, N; Kaya, MH; Buyukturan, B; Yetis, M; Buyukturan, O				Kocaman, Hikmet; Bek, Nilgun; Kaya, Mehmet Hanifi; Buyukturan, Buket; Yetis, Mehmet; Buyukturan, Oznur			The effectiveness of two different exercise approaches in adolescent idiopathic scoliosis: A single-blind, randomized-controlled trial	PLOS ONE			English	Article							CORE STABILIZATION EXERCISE; COBB ANGLE; RELIABILITY; VALIDITY; REDUCE; THORACOLUMBAR; DEFORMITY; SCHROTH	Objectives The purpose of this study was to compare the efficacy of two different types of exercise methods in patients with adolescent idiopathic scoliosis. Methods In total, 28 subjects with adolescent idiopathic scoliosis with a mild curve magnitude (10 degrees-26 degrees) were randomly divided into two groups: the Schroth group (n = 14) and the core group (n = 14). The patients in the Schroth group were treated with supervised Schroth exercises, and the patients in the core group were treated with supervised core stabilization exercises; both groups performed the exercises for three days per week for a total of 10 weeks, and both were given additional traditional exercises to perform. Assessment included Cobb angle (Radiography), trunk rotation (Adam's test), cosmetic trunk deformity (Walter Reed Visual Assessment Scale), spinal mobility (Spinal Mouse), peripheral muscle strength (Biodex System 4-Pro), and quality of life (Scoliosis Research Society-22 questionnaire). Results It was found that patients in the Schroth group showed greater improvement in Cobb angles, thoracic trunk rotation angle, cosmetic trunk deformity, spinal mobility, and quality of life than those in the core group (p<0.05), except for in lumbar trunk rotation angle. Peripheral muscle strength improvement was greater in the core group than in the Schroth group (p<0.05). Conclusion Schroth exercises are more effective than core stabilization exercises in the correction of scoliosis and related problems in mild adolescent idiopathic scoliosis, and core stabilization exercises are more effective than Schroth exercises in the improvement of peripheral muscle strength.	[Kocaman, Hikmet] Karamanoglu Mehmetbey Univ, Dept Physiotherapy & Rehabil, Prosthet Orthot Physiotherapy, Karaman, Turkey; [Bek, Nilgun] Lokman Hekim Univ, Fac Hlth Sci, Dept Physiotherapy & Rehabil, Ankara, Turkey; [Kaya, Mehmet Hanifi] Ahi Evran Univ, Fac Med, Kirsehir, Turkey; [Buyukturan, Buket; Buyukturan, Oznur] Ahi Evran Univ, Sch Phys Therapy & Rehabil, Kirsehir, Turkey; [Yetis, Mehmet] Ahi Evran Univ, Fac Med, Dept Orthoped & Traumatol, Kirsehir, Turkey	Karamanoglu Mehmetbey University; Lokman Hekim University; Ahi Evran University; Ahi Evran University; Ahi Evran University	Kocaman, H (corresponding author), Karamanoglu Mehmetbey Univ, Dept Physiotherapy & Rehabil, Prosthet Orthot Physiotherapy, Karaman, Turkey.	kcmnhikmet@gmail.com	Kocaman, Hikmet/AAH-9689-2020	Kocaman, Hikmet/0000-0001-5971-7274; KAYA, MEHMET HANIFI/0000-0003-4670-4794				Akuthota V, 2004, ARCH PHYS MED REHAB, V85, pS86, DOI 10.1053/j.apmr.2003.12.005; Akuthota V, 2008, CURR SPORT MED REP, V7, P39, DOI 10.1097/01.CSMR.0000308663.13278.69; Alanay A, 2005, SPINE, V30, P2464, DOI 10.1097/01.brs.0000184366.71761.84; AMENDT LE, 1990, PHYS THER, V70, P108, DOI 10.1093/ptj/70.2.108; Anwer S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/123848; Berdishevsky H, 2016, SCOLIOSIS SPINAL DIS, V11, DOI 10.1186/s13013-016-0076-9; Bialek M, 2011, SCOLIOSIS SPINAL DIS, V6, DOI 10.1186/1748-7161-6-25; Laita LC, 2018, ARCH ARGENT PEDIATR, V116, pE582, DOI [10.5546/aap.2018.eng.e582, 10.5546/aap.2018.e582]; Colak TK, 2020, J TURKISH SPINAL SUR, V31, P125; DEACON P, 1984, J BONE JOINT SURG BR, V66, P509, DOI 10.1302/0301-620X.66B4.6746683; Demir E., 2020, AGE, V16, P1; Deviren V, 2002, SPINE, V27, P2346, DOI 10.1097/00007632-200211010-00007; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fishman LM, 2017, TOP GERIATR REHABIL, V33, P231, DOI 10.1097/TGR.0000000000000159; Gur G, 2017, PROSTHET ORTHOT INT, V41, P303, DOI 10.1177/0309364616664151; Hawes Martha C, 2003, Pediatr Rehabil, V6, P171; Horne JP, 2014, AM FAM PHYSICIAN, V89, P193; Jiang H, 2017, MED SCI MONITOR, V23, P2089, DOI 10.12659/MSM.902455; Kao Feng-Chun, 2014, Biomed J, V37, P78, DOI 10.4103/2319-4170.113182; Kim G, 2016, J PHYS THER SCI, V28, P1012, DOI 10.1589/jpts.28.1012; Ko KJ, 2017, J EXERC REHABIL, V13, P244, DOI 10.12965/jer.1734952.476; Kuru T, 2016, CLIN REHABIL, V30, P181, DOI 10.1177/0269215515575745; Kwan KYH, 2017, SCOLIOSIS SPINAL DIS, V12, DOI 10.1186/s13013-017-0139-6; Le Blay G, 2007, ISOKINET EXERC SCI, V15, P23; Lehnert-Schroth C., 1992, PHYSIOTHERAPY, V78, P810, DOI DOI 10.1016/S0031-9406(10)60451-8; Livanelioglu A, 2016, EUR SPINE J, V25, P476, DOI 10.1007/s00586-015-3945-7; Ma HH, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0427-7; Maher JM, 2013, CBE-LIFE SCI EDUC, V12, P345, DOI 10.1187/cbe.13-04-0082; Martinez-Llorens J, 2010, EUR RESPIR J, V36, P393, DOI 10.1183/09031936.00025509; Miller NH, 1999, ORTHOP CLIN N AM, V30, P343, DOI 10.1016/S0030-5898(05)70091-2; Monticone M, 2014, EUR SPINE J, V23, P1204, DOI 10.1007/s00586-014-3241-y; NACHEMSON AL, 1995, J BONE JOINT SURG AM, V77A, P815, DOI 10.2106/00004623-199506000-00001; Negrini S, 2008, DISABIL REHABIL, V30, P772, DOI 10.1080/09638280801889568; Negrini S, 2006, SCOLIOSIS SPINAL DIS, V1, DOI 10.1186/1748-7161-1-4; Negrini S, 2012, SCOLIOSIS SPINAL DIS, V7, DOI 10.1186/1748-7161-7-3; Otman Saadet, 2005, Neurosciences (Riyadh), V10, P277; Parent EC, 2010, SPINE, V35, P315, DOI 10.1097/BRS.0b013e3181cabe75; Park JH, 2018, EUR J PHYS REHAB MED, V54, P440, DOI 10.23736/S1973-9087.17.04461-6; Polmang B, 2019, WALAILAK J SCI TECHN, V16, P965; Post RB, 2004, ARCH ORTHOP TRAUM SU, V124, P187, DOI 10.1007/s00402-004-0641-1; RISSER J C, 1958, Clin Orthop, V11, P111; Romano M, 2013, SPINE, V38, pE883, DOI 10.1097/BRS.0b013e31829459f8; Rrecaj-Malaj S, 2020, MED SCI MONIT BASIC, V26, DOI 10.12659/MSMBR.920449; Sanders JO, 2003, SPINE, V28, P2158, DOI 10.1097/01.BRS.0000084629.97042.0B; Schreiber S, 2015, SCOLIOSIS SPINAL DIS, V10, DOI 10.1186/s13013-015-0048-5; Shin SS, 2012, J PHYS THER SCI, V24, P211; Slattery C, 2018, CLIN ORTHOP RELAT R, V476, P2271, DOI 10.1097/CORR.0000000000000405; Tsai Yi-Ta, 2010, Chang Gung Med J, V33, P540; Yagci G, 2019, PROSTHET ORTHOT INT, V43, P301, DOI 10.1177/0309364618820144; 김정현, 2015, [Journal of Korea Academia-Industrial cooperation Society, 한국산학기술학회논문지], V16, P4098, DOI 10.5762/KAIS.2015.16.6.4098	50	4	4	7	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2021	16	4							e0249492	10.1371/journal.pone.0249492	http://dx.doi.org/10.1371/journal.pone.0249492			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP1DC	33857180	Green Published, gold			2023-01-03	WOS:000641474900034
J	Ayoubkhani, D; Khunti, K; Nafilyan, V; Maddox, T; Humberstone, B; Diamond, I; Banerjee, A				Ayoubkhani, Daniel; Khunti, Kamlesh; Nafilyan, Vahe; Maddox, Thomas; Humberstone, Ben; Diamond, Ian; Banerjee, Amitava			Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To quantify rates of organ specific dysfunction in individuals with covid-19 after discharge from hospital compared with a matched control group from the general population. DESIGN Retrospective cohort study. SETTING NHS hospitals in England. PARTICIPANTS 47 780 individuals (mean age 65, 55% men) in hospital with covid-19 and discharged alive by 31 August 2020, exactly matched to controls from a pool of about 50 million people in England for personal and clinical characteristics from 10 years of electronic health records. MAIN OUTCOME MEASURES Rates of hospital readmission (or any admission for controls), all cause mortality, and diagnoses of respiratory, cardiovascular, metabolic, kidney, and liver diseases until 30 September 2020. Variations in rate ratios by age, sex, and ethnicity. RESULTS Over a mean follow-up of 140 days, nearly a third of individuals who were discharged from hospital after acute covid-19 were readmitted (14 060 of 47 780) and more than 1 in 10 (5875) died after discharge, with these events occurring at rates four and eight times greater, respectively, than in the matched control group. Rates of respiratory disease (P<0.001), diabetes (P<0.001), and cardiovascular disease (P<0.001) were also significantly raised in patients with covid-19, with 770 (95% confidence interval 758 to 783), 127 (122 to 132), and 126 (121 to 131) diagnoses per 1000 person years, respectively. Rate ratios were greater for individuals aged less than 70 than for those aged 70 or older, and in ethnic minority groups compared with the white population, with the largest differences seen for respiratory disease (10.5 (95% confidence interval 9.7 to 11.4) for age less than 70 years v 4.6 (4.3 to 4.8) for age >= 70, and 11.4 (9.8 to 13.3) for non-white v 5.2 (5.0 to 5.5) for white individuals). CONCLUSIONS Individuals discharged from hospital after covid-19 had increased rates of multiorgan dysfunction compared with the expected risk in the general population. The increase in risk was not confined to the elderly and was not uniform across ethnicities. The diagnosis, treatment, and prevention of post-covid syndrome requires integrated rather than organ or disease specific approaches, and urgent research is needed to establish the risk factors.	[Ayoubkhani, Daniel; Nafilyan, Vahe; Maddox, Thomas; Humberstone, Ben; Diamond, Ian] Off Natl Stat, Govt Bldg, Newport, Gwent, Wales; [Khunti, Kamlesh] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England; [Banerjee, Amitava] UCL, Inst Hlth Informat, London NW1 2DA, England; [Banerjee, Amitava] Univ Coll London Hosp NHS Trust, London, England; [Banerjee, Amitava] Royal London Hosp, Barts Hlth NHS Trust, London, England	University of Leicester; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Barts Health NHS Trust; Royal London Hospital	Banerjee, A (corresponding author), UCL, Inst Hlth Informat, London NW1 2DA, England.; Banerjee, A (corresponding author), Univ Coll London Hosp NHS Trust, London, England.; Banerjee, A (corresponding author), Royal London Hosp, Barts Hlth NHS Trust, London, England.	ami.banerjee@ucl.ac.uk	/ABC-9527-2021; Banerjee, Amitava/D-4381-2014	Khunti, Kamlesh/0000-0003-2343-7099; Nafilyan, Vahe/0000-0003-0160-217X; Banerjee, Amitava/0000-0001-8741-3411; Ayoubkhani, Daniel/0000-0001-6352-0394				Alqahtani SA, 2020, UNITED EUR GASTROENT, V8, P509, DOI 10.1177/2050640620924157; [Anonymous], [No title captured]; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Ball S, 2020, HEART, V106, P1890, DOI 10.1136/heartjnl-2020-317870; Banerjee A, 2020, LANCET, V395, P1715, DOI 10.1016/S0140-6736(20)30854-0; Becker RC, 2020, J THROMB THROMBOLYS, V50, P512, DOI 10.1007/s11239-020-02266-6; Campbell H, 1998, BMJ-BRIT MED J, V316, P133; Clift AK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3731; Dennis A, 2020, MULTIORGAN IMPAIRMEN, DOI [10.1101/2020.10.14.20212555v1, DOI 10.1101/2020.10.14.20212555V1]; Donnelly JP, 2021, JAMA-J AM MED ASSOC, V325, P304, DOI 10.1001/jama.2020.21465; Farouk SS, 2020, J NEPHROL, V33, P1213, DOI 10.1007/s40620-020-00789-y; Fraser E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3001; Greenhalgh T, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3026; Groenwold RHH, 2012, CAN MED ASSOC J, V184, P1265, DOI 10.1503/cmaj.110977; Herbert A, 2017, INT J EPIDEMIOL, V46, P1093, DOI 10.1093/ije/dyx015; Iacus SM, 2012, POLIT ANAL, V20, P1, DOI 10.1093/pan/mpr013; Katsoulis M, 2020, ESTIMATING EFFECT RE, DOI [10.1161/CIRCOUTCOMES.120.007085, DOI 10.1161/CIRCOUTCOMES.120.007085]; Lai AG, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-043828; Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757; Liu DH, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01385-1; McCarthy CP, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100504; Michelen M, 2020, CHARACTERISING LONG, DOI [10.1101/2020.12.08.20246025v1, DOI 10.1101/2020.12.08.20246025V1]; National Institute for Health and Care Excellence Royal College of General Practitioners Healthcare Improvement Scotland SIGN, 2020, COVID 19 RAP GUID MA; National Institute for Health Research, 2020, THEM REV LIV COV 19; NHS Digital, 2020, GEN PRACT EXTR SERV; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Rajpal S, 2021, JAMA CARDIOL, V6, P116, DOI 10.1001/jamacardio.2020.4916; Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]; Somasundaram NP, 2020, J ENDOCR SOC, V4, DOI 10.1210/jendso/bvaa082; Tabary M, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153097; Tazare J, RATES SERIOUS CLIN O, DOI [10.1101/2021.01.22.21250304v2, DOI 10.1101/2021.01.22.21250304V2]; UK Government, COR COVID 19 UK DAIL; Wang ZF, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023327; Ward H, 2020, ANTIBODY PREVALENCE, DOI [10.1101/2020.08.12.20173690v2, DOI 10.1101/2020.08.12.20173690V2]; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Xie Y, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4677	36	222	227	6	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 31	2021	372								n693	10.1136/bmj.n693	http://dx.doi.org/10.1136/bmj.n693			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH3WJ	33789877	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000636152900003
J	Joudeh, A; Ghosh, R; Spindler, H; Handu, S; Sonthalia, S; Das, A; Gore, A; Mahapatra, T; Walker, D				Joudeh, Ammar; Ghosh, Rakesh; Spindler, Hilary; Handu, Seema; Sonthalia, Sunil; Das, Aritra; Gore, Aboli; Mahapatra, Tanmay; Walker, Dilys			Increases in diagnosis and management of obstetric and neonatal complications in district hospitals during a high intensity nurse-mentoring program in Bihar, India	PLOS ONE			English	Article							MATERNAL MORTALITY; NEWBORN MORTALITY; IMPACT; HEALTH; RESUSCITATION; METAANALYSIS; IMPROVEMENT; STILLBIRTH; QUALITY; DEATHS	Maternal and neonatal mortality in Bihar, India was far higher than the aspirational levels set out by the Sustainable Development Goals. Provider training programs have been implemented in many low-resource settings to improve obstetric and neonatal outcomes. This longitudinal investigation assessed diagnoses and management of postpartum hemorrhage (PPH), hypertensive disorders of pregnancy, birth asphyxia (BA), and low birth weight (LBW), as part of the CARE's AMANAT program in 22 District Hospitals in Bihar, between 2015 and 2017. Physicians and nurse mentors conducted clinical instruction, simulations and teamwork and communication activities, infrastructure and management support, and data collection for 6 consecutive months. Analysis of diagnosis included 11,259 non-referred and management included 11,800 total (non-referred and referred) admissions that were observed. Data were analyzed using the chi-square test for trend. PPH was diagnosed in 3.7% with no significant trend but diagnosis of hypertensive disorders increased from 1.0% to 1.7%, (p(trend) = 0.04), over the 6 months. BA was diagnosed in 5.8% with no significant trend but LBW diagnoses increased from 11% to 16% (p(trend)<0.01). Among PPH patients, 96% received fluids, 85% received uterotonics and 11% received Tranexamic Acid (TXA). There was a significant positive trend in the number of patients receiving TXA for PPH (6% to 13.8%, p(trend) = 0.03). Of all neonates with BA, there were statistically significant increases in the proportion who were initially warmed, dried, and stimulated (78% to 94%, p(trend) = 0.02), received airway suction (80% to 93%, p(trend) = 0.03), and supplemental oxygen without positive pressure ventilation (73% to 86%, p(trend) = 0.05). Diagnoses of hypertensive disorders and LBW as well as initial management of BA increased during the AMANAT program. However, underdiagnoses of PPH and hypertensive disorders relative to population levels remain critical barriers to improving maternal morbidity and mortality.	[Joudeh, Ammar] Univ Calif San Diego, Dept Obstet Gynecol & Reprod Sci, San Diego, CA 92103 USA; [Ghosh, Rakesh; Spindler, Hilary] Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94143 USA; [Handu, Seema] PRONTO Int, State RMNCH A, Patna, Bihar, India; [Sonthalia, Sunil; Das, Aritra; Gore, Aboli; Mahapatra, Tanmay] CARE India, Patna, Bihar, India; [Walker, Dilys] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; [Walker, Dilys] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA	University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ghosh, R (corresponding author), Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94143 USA.	Rakesh.Ghosh@ucsf.edu		Ghosh, Rakesh/0000-0002-7839-4148	Bill and Melinda Gates Foundation	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This study was funded by the Bill and Melinda Gates Foundation. The funding body had no role in study design, data collection, analysis, interpretation, manuscript writing, or the decision to submit the manuscript for publication.	[Anonymous], 2017, WHO RECOMMENDATION T; [Anonymous], 2011, WHO RECOMMENDATIONS; [Anonymous], STATE STAT; Bergh AM, 2015, BEST PRACT RES CL OB, V29, P1028, DOI 10.1016/j.bpobgyn.2015.03.017; Bhilwar M, 2016, NATL MED J INDIA, V29, P73; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Das A, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1452-z; Das A, 2016, BIRTH-ISS PERINAT C, V43, P328, DOI 10.1111/birt.12239; Davidoff F, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3152; Deneux-Tharaux C, 2014, J GYNECOL OBST BIO R, V43, P936, DOI 10.1016/j.jgyn.2014.09.023; Ghosh R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216654; Goudar SS, 2013, PEDIATRICS, V131, pE344, DOI 10.1542/peds.2012-2112; Kassebaum NJ, 2016, LANCET, V388, P1775, DOI 10.1016/S0140-6736(16)31470-2; Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS5, DOI 10.1016/j.ijgo.2009.07.016; Lee ACC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S12; Msemo G, 2013, PEDIATRICS, V131, pE353, DOI 10.1542/peds.2012-1795; NITI Aayog, 2019, HLTH STATES PROGRESS; Paxton A, 2005, INT J GYNECOL OBSTET, V88, P181, DOI 10.1016/j.ijgo.2004.11.026; Semrau KEA, 2017, NEW ENGL J MED, V377, P2313, DOI 10.1056/NEJMoa1701075; Siassakos D, 2009, BJOG-INT J OBSTET GY, V116, P1028, DOI 10.1111/j.1471-0528.2009.02178.x; Singh SK, 2012, INDIAN PEDIATR, V49, P136, DOI 10.1007/s13312-012-0022-8; Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8; Stead K, 2009, MED J AUSTRALIA, V190, pS128; UNICEF, BIHAR STATE INFO; United Nations, GOAL 3 SUSTAINABLE D; Vail B, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1254-0; Walker DM, 2016, SIMUL HEALTHC, V11, P1, DOI 10.1097/SIH.0000000000000106; Walker DM, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0401-7; Wang HD, 2016, LANCET, V388, P1725, DOI 10.1016/S0140-6736(16)31575-6; Ying W, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009382	30	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2021	16	3							e0247260	10.1371/journal.pone.0247260	http://dx.doi.org/10.1371/journal.pone.0247260			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QZ9HN	33735280	gold, Green Published			2023-01-03	WOS:000631029700078
J	Xie, YB; Guo, BB; Zhang, R				Xie, Yibo; Guo, Beibei; Zhang, Rui			Cost-effectiveness analysis of radiotherapy techniques for whole breast irradiation	PLOS ONE			English	Article							MODULATED RADIATION-THERAPY; ISCHEMIC-HEART-DISEASE; LUNG-CANCER; TREATMENT UNCERTAINTIES; PROTON THERAPY; RISK; WOMEN; IMRT; CARE; SENSITIVITY	Background The current standard of care (SOC) for whole breast radiotherapy (WBRT) in the US is conventional tangential photon fields. Advanced WBRT techniques may provide similar tumor control and better normal tissue sparing, but it is controversial whether the medical benefits of an advanced technology are significant enough to justify its higher cost. Objective To analyze the cost-effectiveness of six advanced WBRT techniques compared with SOC. Methods We developed a Markov model to simulate health states for one cohort of women (65-yearold) with early-stage breast cancer over 15 years after WBRT. The cost effectiveness analyses of field-in-field (FIF), hybrid intensity modulated radiotherapy (IMRT), full IMRT, standard volumetric modulated arc therapy (STD-VMAT), multiple arc VMAT (MA-VMAT), noncoplanar VMAT (NC-VMAT) compared with SOC were performed with both tumor control and radiogenic side effects considered. Transition probabilities and utilities for each health state were obtained from literature. Costs incurred by payers were adopted from literature and Medicare data. Quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) were calculated. One-way sensitivity analyses and probabilistic sensitivity analyses (PSA) were performed to evaluate the impact of uncertainties on the final results. Results FIF has the lowest ICER value of 1,511 $/QALY. The one-way analyses show that the costeffectiveness of advanced WBRT techniques is most sensitive to the probability of developing contralateral breast cancer. PSAs show that SOC is more cost effective than almost all advanced WBRT techniques at a willingness-to-pay (WTP) threshold of 50,000 $/QALY, while FIF, hybrid IMRT and MA-VMAT are more cost-effective than SOC with a probability of 59.2%, 72.3% and 72.6% at a WTP threshold of 100,000 $/QALY, respectively. Conclusions FIF might be the most cost-effective option for WBRT patients at a WTP threshold of 50,000 $/QALY, while hybrid IMRT and MA-VMAT might be the most cost-effective options at a WTP threshold of 100,000 $/QALY.	[Xie, Yibo; Zhang, Rui] Louisiana State Univ, Dept Phys & Astron, Med Phys Program, Baton Rouge, LA 70803 USA; [Guo, Beibei] Louisiana State Univ, Dept Expt Stat, Baton Rouge, LA USA; [Zhang, Rui] Mary Bird Perkins Canc Ctr, Dept Radiat Oncol, Baton Rouge, LA 70809 USA	Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University	Zhang, R (corresponding author), Louisiana State Univ, Dept Phys & Astron, Med Phys Program, Baton Rouge, LA 70803 USA.; Zhang, R (corresponding author), Mary Bird Perkins Canc Ctr, Dept Radiat Oncol, Baton Rouge, LA 70809 USA.	rzhang@lsu.edu			National Institutes of Health (NIH) [K22CA204464]; Louisiana State University (LSU) Faculty Research Grant; LSU Economic Development Assistantship Award	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana State University (LSU) Faculty Research Grant; LSU Economic Development Assistantship Award	National Institutes of Health (NIH) grant K22CA204464 (RZ), Louisiana State University (LSU) Faculty Research Grant (RZ), LSU Economic Development Assistantship Award (RZ).	Abe O., 2010, Journal of the National Cancer Institute Monographs, P162, DOI 10.1093/jncimonographs/lgq039; Andreas S, 2018, LUNG CANCER, V124, P298, DOI 10.1016/j.lungcan.2018.06.007; [Anonymous], 2011, RTOG0413; [Anonymous], 2010, RAD ONCOLOGY RATIONA; Ares C, 2010, INT J RADIAT ONCOL, V76, P685, DOI 10.1016/j.ijrobp.2009.02.062; Arias E, 2019, NATL VITAL STAT SYST, V68, P1; Arias Elizabeth, 2018, Natl Vital Stat Rep, V67, P1; Beckham WA, 2007, INT J RADIAT ONCOL, V69, P918, DOI 10.1016/j.ijrobp.2007.06.060; Briggs A, 2005, VALUE HEALTH, V8, P1, DOI 10.1111/j.1524-4733.2005.08101.x; Campbell JD, 2009, PHARMACOECONOMICS, V27, P199, DOI 10.2165/00019053-200927030-00003; Chatterjee S, 2018, PRACT RADIAT ONCOL, V8, P382, DOI 10.1016/j.prro.2018.03.007; Colzani E, 2014, BRIT J CANCER, V110, P1378, DOI 10.1038/bjc.2014.5; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Dell'Oro M, 2019, CANCERS, V11, DOI 10.3390/cancers11020259; Farace P, 2012, INT J RADIAT ONCOL, V84, pE115, DOI 10.1016/j.ijrobp.2012.02.025; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Freedman GM, 2006, AM J CLIN ONCOL-CANC, V29, P66, DOI 10.1097/01.coc.0000197661.09628.03; Garber A, 2007, HEALTH AFFAIR, V26, P1545, DOI 10.1377/hlthaff.26.6.1545; Grosse Scott D, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P165, DOI 10.1586/14737167.8.2.165; Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7; Halperin E C, 2008, PEREZ BRADYS PRINCIP; Henson KE, 2013, BRIT J CANCER, V108, P179, DOI 10.1038/bjc.2012.575; INSKIP PD, 1994, J NATL CANCER I, V86, P983, DOI 10.1093/jnci/86.13.983; Jeulink M, 2015, J APPL CLIN MED PHYS, V16, P197, DOI 10.1120/jacmp.v16i3.5266; Keusters WR, 2017, LUNG CANCER, V114, P56, DOI 10.1016/j.lungcan.2017.10.005; Kozak KR, 2006, INT J RADIAT ONCOL, V66, P691, DOI 10.1016/j.ijrobp.2006.06.041; Latty D, 2015, J MED RADIAT SCI, V62, P74, DOI 10.1002/jmrs.96; Lee JH, 2002, J CLIN ONCOL, V20, P2713, DOI 10.1200/JCO.2002.07.008; Liang XY, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1004-3; Lin LL, 2015, ACTA ONCOL, V54, P1032, DOI 10.3109/0284186X.2015.1011756; Lo YC, 2000, INT J RADIAT ONCOL, V46, P187, DOI 10.1016/S0360-3016(99)00382-X; Lomax AJ, 2008, PHYS MED BIOL, V53, P1043, DOI 10.1088/0031-9155/53/4/015; Lomax AJ, 2008, PHYS MED BIOL, V53, P1027, DOI 10.1088/0031-9155/53/4/014; Lundkvist J, 2005, RADIOTHER ONCOL, V75, P179, DOI 10.1016/j.radonc.2005.03.006; Macrie BD, 2015, PHYS MEDICA, V31, P733, DOI 10.1016/j.ejmp.2015.06.006; Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495; Mayo CS, 2005, INT J RADIAT ONCOL, V61, P922, DOI 10.1016/j.ijrobp.2004.10.033; Michaelson JS, 2011, BREAST CANCER RES TR, V128, P827, DOI 10.1007/s10549-011-1366-9; Neumann PJ, 2011, JAMA-J AM MED ASSOC, V305, P1806, DOI 10.1001/jama.2011.566; NRC, 2006, HLTH RISKS EXP LOW L, V7; Popescu CC, 2010, INT J RADIAT ONCOL, V76, P287, DOI 10.1016/j.ijrobp.2009.05.038; Ridker PM, 2007, JAMA-J AM MED ASSOC, V297, P611, DOI 10.1001/jama.297.6.611; Roberts A, 2014, ANN SURG ONCOL, V21, P2209, DOI 10.1245/s10434-014-3588-7; Roberts ET, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116377; Roychoudhuri R, 2004, BRIT J CANCER, V91, P868, DOI 10.1038/sj.bjc.6602084; Ruben JD, 2014, INT J RADIAT ONCOL, V90, P645, DOI 10.1016/j.ijrobp.2014.05.052; Schwarzkopf L, 2015, LUNG CANCER, V90, P274, DOI 10.1016/j.lungcan.2015.09.005; Sen S, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju008; Shah C, 2019, INT J RADIAT ONCOL, V103, P397, DOI 10.1016/j.ijrobp.2018.09.021; Shah C, 2013, BREAST CANCER RES TR, V138, P127, DOI 10.1007/s10549-013-2412-6; Sher DJ, 2008, INT J RADIAT ONCOL, V70, P469, DOI 10.1016/j.ijrobp.2007.08.054; Sher DJ, 2009, INT J RADIAT ONCOL, V74, P440, DOI 10.1016/j.ijrobp.2008.08.015; Stokes ME, 2008, VALUE HEALTH, V11, P213, DOI 10.1111/j.1524-4733.2007.00226.x; Stout NK, 2006, JNCI-J NATL CANCER I, V98, P774, DOI 10.1093/jnci/djj210; Sullivan PW, 2006, MED DECIS MAKING, V26, P410, DOI 10.1177/0272989X06290495; Toutouzas K, 2013, NEW ENGL J MED, V368, P2524, DOI 10.1056/NEJMc1304601; Tsai Ping-Fang, 2012, J Appl Clin Med Phys, V13, P3806, DOI 10.1120/jacmp.v13i5.3806; Villanti AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071379; Weinstein MC., 1996, COST EFFECTIVENESS H; Xie YB, 2020, MED DOSIM, V45, pE9, DOI 10.1016/j.meddos.2020.05.004; Xie YB, 2020, COST EFFECT RESOUR A, V18, DOI 10.1186/s12962-020-00222-y; Xie YB, 2020, MED DOSIM, V45, P34, DOI 10.1016/j.meddos.2019.04.005; Yadav BS, 2008, RADIOTHER ONCOL, V86, P171, DOI 10.1016/j.radonc.2007.10.002	63	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2021	16	3							e0248220	10.1371/journal.pone.0248220	http://dx.doi.org/10.1371/journal.pone.0248220			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU3OZ	33684139	gold, Green Published			2023-01-03	WOS:000627193500042
J	Muthulingam, JA; Olesen, SS; Hansen, TM; Brock, C; Drewes, AM; Frokjaer, JB				Muthulingam, Janusiya Anajan; Olesen, Soren Schou; Hansen, Tine Maria; Brock, Christina; Drewes, Asbjorn Mohr; Frokjaer, Jens Brondum			Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial	PLOS ONE			English	Article								Background & aims Chronic abdominal pain is the primary symptom of chronic pancreatitis, but unfortunately it is difficult to treat. Vagal nerve stimulation studies have provided evidence of anti-nociceptive effect in several chronic pain conditions. We investigated the pain-relieving effects of transcutaneous vagal nerve stimulation in comparison to sham treatment in chronic pancreatitis patients. Methods We conducted a randomised double-blinded, sham-controlled, crossover trial in patients with chronic pancreatitis. Patients were randomly assigned to receive a two-week period of cervical transcutaneous vagal nerve stimulation using the gammaCore device followed by a two-week sham stimulation, or vice versa. We measured clinical and experimental end-points before and after each treatment. The primary clinical endpoint was pain relief, documented in a pain diary using a visual analogue scale. Secondary clinical endpoints included Patients' Global Impression of Change score, quality of life and Brief Pain Inventory questionnaire. Secondary experimental endpoints included cardiac vagal tone and heart rate. Results No differences in pain scores were seen in response to two weeks transcutaneous vagal nerve stimulation as compared to sham treatment (difference in average pain score (visual analogue scale): 0.17, 95%CI (-0.86;1.20), P = 0.7). Similarly, no differences were seen for secondary clinical endpoints, except from an increase in the appetite loss score (13.9, 95% CI (0.5:27.3), P = 0.04). However, improvements in maximum pain scores were seen for transcutaneous vagal nerve stimulation and sham treatments as compared to their respective baselines: vagal nerve stimulation (-1.3 +/- 1.7, 95%CI (-2.21:-0.42), P = 0.007), sham (-1.3 +/- 1.9, 95%CI (-2.28:-0.25), P = 0.018). Finally, heart rate was decreased after two weeks transcutaneous vagal nerve stimulation in comparison to sham treatment (-3.7 beats/min, 95%CI (-6.7:-0.6), P = 0.02). Conclusion In this sham-controlled crossover study, we found no evidence that two weeks transcutaneous vagal nerve stimulation induces pain relief in patients with chronic pancreatitis.	[Muthulingam, Janusiya Anajan; Hansen, Tine Maria; Frokjaer, Jens Brondum] Aalborg Univ Hosp, Dept Radiol, Mech Sense, Aalborg, Denmark; [Muthulingam, Janusiya Anajan; Olesen, Soren Schou; Hansen, Tine Maria; Brock, Christina; Drewes, Asbjorn Mohr; Frokjaer, Jens Brondum] Aalborg Univ, Dept Clin Med, Aalborg, Denmark; [Olesen, Soren Schou; Drewes, Asbjorn Mohr] Aalborg Univ Hosp, Ctr Pancreat Dis, Dept Gastroenterol & Hepatol, Aalborg, Denmark; [Brock, Christina] Aalborg Univ Hosp, Dept Gastroenterol & Hepatol, Mech Sense, Aalborg, Denmark	Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital	Frokjaer, JB (corresponding author), Aalborg Univ Hosp, Dept Radiol, Mech Sense, Aalborg, Denmark.; Frokjaer, JB (corresponding author), Aalborg Univ, Dept Clin Med, Aalborg, Denmark.	jebf@rn.dk	Drewes, Asbjørn/AAR-7479-2021; Frokjaer, Jens Brondum/F-5938-2017; Brock, Christina/O-6146-2015	Drewes, Asbjørn/0000-0001-7465-964X; Frokjaer, Jens Brondum/0000-0001-8722-0070; Brock, Christina/0000-0002-3381-1884; Hansen, Tine/0000-0002-6160-5519	Independent Research Fund Denmark [DFF - 7016-00073]; Axel-Muusfeldts Foundation; Laege Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat	Independent Research Fund Denmark; Axel-Muusfeldts Foundation; Laege Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat	This study was supported by Independent Research Fund Denmark (DFF - 7016-00073), Axel-Muusfeldts Foundation, and Laege Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat. Jens Brondum Frokjaer received all the grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Barbanti P, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0542-4; Botha C, 2015, GUT, V64, P611, DOI 10.1136/gutjnl-2013-306698; Brock C, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.12999; Busch V, 2013, BRAIN STIMUL, V6, P202, DOI 10.1016/j.brs.2012.04.006; Chakravarthy K, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0528-6; Cleeland CS., 1982, MD ANDERSON CANC CTR, V1100, P6, DOI DOI 10.1007/978-1-4419-9893-4_13; Drewes AM, 2019, GUT, V68, P1343, DOI 10.1136/gutjnl-2019-318742; Farmer AD, 2014, ANN GASTROENTEROL, V27, P362; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Frangos E, 2017, BRAIN STIMUL, V10, P19, DOI 10.1016/j.brs.2016.10.008; Garcia RG, 2017, PAIN, V158, P1461, DOI 10.1097/j.pain.0000000000000930; Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580; Gottfried-Blackmore A, 2020, NEUROGASTROENT MOTIL, V32, DOI 10.1111/nmo.13769; Grazzi L, 2018, J HEADACHE PAIN, V19, P1, DOI [10.1186/s10194-017-0831-1, DOI 10.1186/S10194-017-0831-1]; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Juel J, 2017, J PAIN RES, V10, P1347, DOI 10.2147/JPR.S133438; Kleeff J, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.60; Lange G, 2011, PAIN MED, V12, P1406, DOI 10.1111/j.1526-4637.2011.01203.x; LAYER P, 1994, GASTROENTEROLOGY, V107, P1481, DOI 10.1016/0016-5085(94)90553-3; Liu HY, 2017, EPILEPSIA, V58, P1015, DOI 10.1111/epi.13738; Matteoli G, 2013, GUT, V62, P1214, DOI 10.1136/gutjnl-2012-302550; Muthulingam JA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029546; Mwamburi M, 2018, AM J MANAG CARE, V24, pS507; Napadow V, 2012, PAIN MED, V13, P777, DOI 10.1111/j.1526-4637.2012.01385.x; Olesen SS, 2011, GASTROENTEROLOGY, V141, P536, DOI 10.1053/j.gastro.2011.04.003; Oshinsky ML, 2014, PAIN, V155, P1037, DOI 10.1016/j.pain.2014.02.009; Paulon E, 2017, FRONTLINE GASTROENTE, V8, P325, DOI 10.1136/flgastro-2017-100809; Pham Angela, 2018, F1000Res, V7, DOI 10.12688/f1000research.12852.1; Piao WH, 2009, ACTA PHARMACOL SIN, V30, P715, DOI 10.1038/aps.2009.67; Sator-Katzenschlager SM, 2004, ANESTH ANALG, DOI [10.1213/01.ane.0000107941, DOI 10.1213/01.ANE.0000107941]; Silberstein SD, 2016, NEUROLOGY, V87, P529, DOI 10.1212/WNL.0000000000002918; Singh VK, 2019, JAMA-J AM MED ASSOC, V322, P2422, DOI 10.1001/jama.2019.19411; Tassorelli C, 2018, NONINVASIVE VAGUS NE, DOI [10.1212/WNL000000000005857, DOI 10.1212/WNL000000000005857]; Wellek S, 2012, DTSCH ARZTEBL INT, V109, P276, DOI 10.3238/arztebl.2012.0276	35	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2021	16	2							e0247653	10.1371/journal.pone.0247653	http://dx.doi.org/10.1371/journal.pone.0247653			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ5BP	33635894	Green Published, gold			2023-01-03	WOS:000624538400061
J	Parikh, RB; Linn, KA; Yan, JL; Maciejewski, ML; Rosland, AM; Volpp, KG; Groeneveld, PW; Navathe, AS				Parikh, Ravi B.; Linn, Kristin A.; Yan, Jiali; Maciejewski, Matthew L.; Rosland, Ann-Marie; Volpp, Kevin G.; Groeneveld, Peter W.; Navathe, Amol S.			A machine learning approach to identify distinct subgroups of veterans at risk for hospitalization or death using administrative and electronic health record data	PLOS ONE			English	Article								Background Identifying individuals at risk for future hospitalization or death has been a major priority of population health management strategies. High-risk individuals are a heterogeneous group, and existing studies describing heterogeneity in high-risk individuals have been limited by data focused on clinical comorbidities and not socioeconomic or behavioral factors. We used machine learning clustering methods and linked comorbidity-based, sociodemographic, and psychobehavioral data to identify subgroups of high-risk Veterans and study long-term outcomes, hypothesizing that factors other than comorbidities would characterize several subgroups. Methods and findings In this cross-sectional study, we used data from the VA Corporate Data Warehouse, a national repository of VA administrative claims and electronic health data. To identify high-risk Veterans, we used the Care Assessment Needs (CAN) score, a routinely-used VA model that predicts a patient's percentile risk of hospitalization or death at one year. Our study population consisted of 110,000 Veterans who were randomly sampled from 1,920,436 Veterans with a CAN score >= 75(th) percentile in 2014. We categorized patient-level data into 119 independent variables based on demographics, comorbidities, pharmacy, vital signs, laboratories, and prior utilization. We used a previously validated density-based clustering algorithm to identify 30 subgroups of high-risk Veterans ranging in size from 50 to 2,446 patients. Mean CAN score ranged from 72.4 to 90.3 among subgroups. Two-year mortality ranged from 0.9% to 45.6% and was highest in the home-based care and metastatic cancer subgroups. Mean inpatient days ranged from 1.4 to 30.5 and were highest in the post-surgery and blood loss anemia subgroups. Mean emergency room visits ranged from 1.0 to 4.3 and were highest in the chronic sedative use and polysubstance use with amphetamine predominance subgroups. Five subgroups were distinguished by psychobehavioral factors and four subgroups were distinguished by sociodemographic factors. Conclusions High-risk Veterans are a heterogeneous population consisting of multiple distinct subgroups-many of which are not defined by clinical comorbidities-with distinct utilization and outcome patterns. To our knowledge, this represents the largest application of ML clustering methods to subgroup a high-risk population. Further study is needed to determine whether distinct subgroups may benefit from individualized interventions.	[Parikh, Ravi B.; Volpp, Kevin G.; Navathe, Amol S.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; [Parikh, Ravi B.; Rosland, Ann-Marie; Volpp, Kevin G.; Groeneveld, Peter W.; Navathe, Amol S.] VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA; [Parikh, Ravi B.; Yan, Jiali; Volpp, Kevin G.; Navathe, Amol S.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA; [Parikh, Ravi B.; Yan, Jiali; Volpp, Kevin G.; Groeneveld, Peter W.; Navathe, Amol S.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Linn, Kristin A.] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Maciejewski, Matthew L.] Durham Vet Affairs Hlth Care Syst, Durham Ctr Innovat Accelerate Discovery & Practic, Durham, NC USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Navathe, AS (corresponding author), Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.; Navathe, AS (corresponding author), VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA.; Navathe, AS (corresponding author), Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.; Navathe, AS (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.	amol@pennmedicine.upenn.edu		Parikh, Ravi/0000-0003-2692-6306; Rosland, Ann-Marie/0000-0002-5809-5861; Groeneveld, Peter/0000-0002-7374-4292; Navathe, Amol/0000-0001-7182-4988	VA HSRD Pilot [PPO 17-272-2]	VA HSRD Pilot	This study was funded a VA HSR&D Pilot PPO 17-272-2 to ASN (https://www.hsrd.research.va.gov/). The funder did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ankerst M, 1999, SIGMOD RECORD, VOL 28, NO 2 - JUNE 1999, P49; Backus LI, 2013, JAMA INTERN MED, V173, P1549, DOI 10.1001/jamainternmed.2013.8133; Blumenthal D, 2016, JAMA-J AM MED ASSOC, V316, P1657, DOI 10.1001/jama.2016.12388; Byrne CM, 2010, HEALTH AFFAIR, V29, P629, DOI 10.1377/hlthaff.2010.0119; Center for Substance Abuse Treatment, 1998, SUBSTANCE ABUSE AND; Choudhry NK, 2009, AM J MANAG CARE, V15, P457; Clough JD, 2016, HEALTHCARE-J DEL SCI, V4, P160, DOI 10.1016/j.hjdsi.2015.09.005; Cohen SB, 2015, 481 AG HLTH RES QUAL; Eick CF, 2004, PROC INT C TOOLS ART, P774; Fihn S, 2016, UPDATE CARE ASSESSME; Fihn S, 2016, PREDICTING RISK HOSP; Fihn SD, 2014, HEALTH AFFAIR, V33, P1203, DOI 10.1377/hlthaff.2014.0054; Fraze T, 2016, HEALTH AFFAIR, V35, P2109, DOI 10.1377/hlthaff.2016.0727; Frisch NB, 2020, J AM ACAD ORTHOP SUR, V28, P923, DOI 10.5435/JAAOS-D-19-00775; Hayes Susan L, 2016, Issue Brief (Commonw Fund), V26, P1; Hong Clemens S, 2014, Issue Brief (Commonw Fund), V19, P1; Joynt KE, 2017, HEALTHCARE-J DEL SCI, V5, P62, DOI 10.1016/j.hjdsi.2016.11.002; Long P., 2018, EFFECTIVE CARE HIGH; Maynard C., 2019, VIREC DAT METH SEM F; McWilliams JM, 2016, NEW ENGL J MED, V375, P2218, DOI 10.1056/NEJMp1610821; Noel PH, 2010, J REHABIL RES DEV, V47, P739, DOI 10.1682/JRRD.2009.08.0110; O'Malley Ann S, 2019, Issue Brief (Commonw Fund), V2019, P1; Parikh RB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18318; Parikh RB, 2017, NEW ENGL J MED, V376, P1609, DOI 10.1056/NEJMp1613224; Parikh RB, 2016, JAMA-J AM MED ASSOC, V315, P651, DOI 10.1001/jama.2015.19417; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Powers BW, 2019, J GEN INTERN MED, V34, P218, DOI 10.1007/s11606-018-4759-1; van der Maaten L, 2014, J MACH LEARN RES, V15, P3221; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Wang L, 2013, MED CARE, V51, P368, DOI 10.1097/MLR.0b013e31827da95a; Wong ES, 2020, AM J MANAG CARE, V26, P40, DOI 10.37765/ajmc.2020.42144; Wong ES, 2018, J GEN INTERN MED, V33, P2120, DOI 10.1007/s11606-018-4653-x; Yan JL, 2019, J GEN INTERN MED, V34, P211, DOI 10.1007/s11606-018-4760-8; Yoon J, 2014, MED CARE, V52, pS31, DOI 10.1097/MLR.0000000000000061; Zulman DM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007771	35	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2021	16	2							e0247203	10.1371/journal.pone.0247203	http://dx.doi.org/10.1371/journal.pone.0247203			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QK8KQ	33606819	gold, Green Published			2023-01-03	WOS:000620629200048
J	Liu, XL; Jia, YC; Shi, CY; Kong, DC; Wu, YM; Zhang, TT; Wei, AJ; Wang, D				Liu, Xiaoling; Jia, Yichen; Shi, Changyuan; Kong, Dechen; Wu, Yuanming; Zhang, Tiantian; Wei, Anjie; Wang, Dan			CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma	PLOS ONE			English	Article							SURFACTANT PROTEIN D; CYTOCHROME-P450 4B1; BLADDER-CANCER; GENE; RISK; EXPRESSION; POLYMORPHISMS; ASSOCIATION; ACTIVATION	CYP4B1 belongs to the mammalian CYP4 enzyme family and is predominantly expressed in the lungs of humans. It is responsible for the oxidative metabolism of a wide range of endogenous compounds and xenobiotics. In this study, using data from The Cancer Genome Atlas (TCGA) project and the Gene Expression Omnibus (GEO) database, a secondary analysis was performed to explore the expression profile of CYP4B1, as well as its prognostic value in patients with lung adenocarcinoma (LUAD). Based on the obtained results, a significantly decreased CYP4B1 expression was discovered in patients with LUAD when compared with their normal counterparts (p<0.05), and was linked to age younger than 65 years (p = 0.0041), history of pharmaceutical (p = 0.0127) and radiation (p = 0.0340) therapy, mutations in KRAS/EGFR/ALK (p = 0.0239), and living status of dead (p = 0.0026). Survival analysis indicated that the low CYP4B1 expression was an independent prognostic indicator of shorter survival in terms of overall survival (OS) and recurrence-free survival (RFS) in patients with LUAD. The copy number alterations (CNAs) and sites of cg23440155 and cg23414387 hypermethylation might contribute to the decreased CYP4B1 expression. Gene set enrichment analysis (GSEA) suggested that CYP4B1 might act as an oncogene in LUAD by preventing biological metabolism pathways of exogenous and endogenous compounds and enhancing DNA replication and cell cycle activities. In conclusion, CYP4B1 expression may serve as a valuable independent prognostic biomarker and a potential therapeutic target in patients with LUAD.	[Liu, Xiaoling; Kong, Dechen; Zhang, Tiantian] Jining Med Univ, Coll Basic Med, Jining City, Peoples R China; [Jia, Yichen] Qiqihar Med Univ, Inst Med Technol, Qiqihar City, Peoples R China; [Shi, Changyuan; Wu, Yuanming; Wei, Anjie; Wang, Dan] Jining Med Univ, Inst Forens Med & Lab Med, Jining City, Peoples R China	Jining Medical University; Qiqihar Medical University; Jining Medical University	Wang, D (corresponding author), Jining Med Univ, Inst Forens Med & Lab Med, Jining City, Peoples R China.	wangdanchn@163.com	Liu, Xiaoling/HGD-3566-2022	Wang, Dan/0000-0002-6032-5638	NSFC cultivation project of Jining Medical University [JYP2019KJ10]; Medical and Health Science and Technology Development Project of Shandong Province [2019WS357]; Shanxi Provincial Key Laboratory of Forensic Science, China [SFM2019002]; Student Innovation Training Program Project of Shandong Province [S202010443043]	NSFC cultivation project of Jining Medical University; Medical and Health Science and Technology Development Project of Shandong Province; Shanxi Provincial Key Laboratory of Forensic Science, China; Student Innovation Training Program Project of Shandong Province	This study was supported by the NSFC cultivation project of Jining Medical University (JYP2019KJ10), the Medical and Health Science and Technology Development Project of Shandong Province (2019WS357), the open project of Shanxi Provincial Key Laboratory of Forensic Science, China (SFM2019002) and the Student Innovation Training Program Project of Shandong Province (S202010443043). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhikari A, 2015, IMEDPUB, V1, DOI DOI 10.21767/2393-8862.100031; Amin MB, 2018, AJCC CANC STAGING MA, V8th, DOI DOI 10.1007/978-3-319-40618-3; Ashkar S, 2004, J OCUL PHARMACOL TH, V20, P65, DOI 10.1089/108076804772745473; Baer BR, 2006, DRUG METAB REV, V38, P451, DOI 10.1080/03602530600688503; Chalela R, 2017, J THORAC DIS, V9, P2142, DOI 10.21037/jtd.2017.06.20; CZERWINSKI M, 1994, CANCER RES, V54, P1085; Denisenko TV, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0063-y; Devita Jr VT, 2015, DEVITA HELLMAN ROSEN; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Hiratsuka Masahiro, 2004, Drug Metab Pharmacokinet, V19, P114, DOI 10.2133/dmpk.19.114; Imaoka S, 2000, BIOCHEM BIOPH RES CO, V277, P776, DOI 10.1006/bbrc.2000.3740; Iscan M, 2001, BREAST CANCER RES TR, V70, P47, DOI 10.1023/A:1012526406741; Ishii T, 2012, COPD, V9, P409, DOI 10.3109/15412555.2012.676110; Jian W, 2019, J CELL BIOCHEM, V120, P5386, DOI 10.1002/jcb.27817; Lin JT, 2019, APMIS, V127, P170, DOI 10.1111/apm.12939; Lo-Guidice JM, 2002, PHARMACOGENETICS, V12, P367, DOI 10.1097/00008571-200207000-00004; Mastyugin V, 2004, J CELL BIOCHEM, V91, P1218, DOI 10.1002/jcb.20018; Murtha TD, 2017, SURGERY, V161, P257, DOI 10.1016/j.surg.2016.04.056; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; Rainov NG, 1998, HUM GENE THER, V9, P1261, DOI 10.1089/hum.1998.9.9-1261; Sasaki T, 2008, JPN J CLIN ONCOL, V38, P634, DOI 10.1093/jjco/hyn081; Seta F, 2007, PROSTAG OTH LIPID M, V84, P116, DOI 10.1016/j.prostaglandins.2007.05.001; Tamaki Y, 2011, DRUG METAB PHARMACOK, V26, P516, DOI 10.2133/dmpk.DMPK-11-RG-046; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Umeda Y, 2017, ONCOGENE, V36, P6432, DOI 10.1038/onc.2017.253; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Wei XP, 2020, INT IMMUNOPHARMACOL, V79, DOI 10.1016/j.intimp.2019.106155; Wiek C, 2015, BIOCHEM J, V465, P103, DOI 10.1042/BJ20140813; Yu GP, 2012, TUMOR BIOL, V33, P223, DOI 10.1007/s13277-011-0265-3; Yu GP, 2015, J THORAC DIS, V7, P1806, DOI 10.3978/j.issn.2072-1439.2015.10.17; Yu GP, 2014, TUMOR BIOL, V35, P10341, DOI 10.1007/s13277-014-2284-3	33	5	5	6	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2021	16	2							e0247020	10.1371/journal.pone.0247020	http://dx.doi.org/10.1371/journal.pone.0247020			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK8MA	33592039	gold, Green Published			2023-01-03	WOS:000620632800058
J	Dempsey, A; Sripad, P; Sultana, K; Kirk, K; Hossain, SMI; Warren, C; Telfair, J				Dempsey, Amy; Sripad, Pooja; Sultana, Kanij; Kirk, Karen; Hossain, Sharif Mohammed Ismail; Warren, Charlotte; Telfair, Joseph			Pathways to service access for pre-eclampsia and eclampsia in rural Bangladesh: Exploring women's care-seeking	PLOS ONE			English	Article								Background While women in low- and middle-income countries face a range of barriers to accessing care for hypertensive disorders of pregnancy, there is little understanding of the pathways taken to overcome these constraints and reach the services they need. This study explores the perspectives of women and communities on the influences that impact care-seeking decisions and pathways to health services. Methods To understand individual perspectives, we conducted 22 in-depth interviews (IDIs) with pre-eclampsia and eclampsia survivors (PE/E) in a tertiary hospital, where they received care after initiating PE/E services in different parts of the country. In four districts, we conducted one male and one female focus group discussion (FGD) to unearth care-seeking pathways and explore normative perspectives and the range of internal and external influences. Careful thematic analysis using Atlas-ti was applied. Results Prevailing views of women and communities across settings in Bangladesh indicate varied pathways to care throughout their pregnancy, during childbirth, and in the postnatal period influenced by internal and external factors at the individual, familial, social, and health systems levels. Internal influences draw on women's own awareness of hypertension complications and options, and their ability to decide to seek care. External factors include social influences like family and community norms, culturally-accepted alternatives, and community perceptions of the health system's capacity to provide quality care. The interaction of these factors often delay care seeking and can lead to complex pathways to care. Conclusion Women's individual pathways to care were diverse, despite the homogenous community perceptions of the influences on women's care-seeking behaviors. This finding supports the need for improving quality of care in primary healthcare facilities and strengthening gender equity and community-based promotion activities through targeted policy and programming.	[Dempsey, Amy; Sripad, Pooja; Kirk, Karen; Warren, Charlotte; Telfair, Joseph] Populat Council, Washington, DC 20008 USA; [Sultana, Kanij; Hossain, Sharif Mohammed Ismail] Populat Council, Dhaka, Bangladesh	Population Council	Dempsey, A (corresponding author), Populat Council, Washington, DC 20008 USA.	amyjade13@gmail.com		Kirk, Karen/0000-0002-6594-4112	United States Agency for International Development (USAID) [USAID APS-OAA-14-000048]	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)CGIAR)	This manuscript is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of USAID APS-OAA-14-000048. https://www.usaid.gov/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed SM, 2005, B WORLD HEALTH ORGAN, V83, P109; Akhtar R, 1970, ECLAMPSIA BACKGROUND, V18; Brown H, 2011, CAN J NURS RES, V43, P101; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Kolling M, 2010, GLOBALIZATION HEALTH, V6, DOI 10.1186/1744-8603-6-8; NIPORT Mitra and Associates ICF International and ICBBRB, 2012, BANGL MAT MORT HLTH; Njuki R, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-77; Nowell LS, 2017, INT J QUAL METH, V16, DOI 10.1177/1609406917733847; Parkhurst JO, 2007, HEALTH POLICY PLANN, V22, P149, DOI 10.1093/heapol/czm011; Salazar M, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.32178; Shahabuddin A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169109; Shih CC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-191; Sikder SS, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1405-2; Sikder SS, 2012, BMC WOMENS HEALTH, V12, DOI 10.1186/1472-6874-12-23; Sikder SS, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-76; Sripad P, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2582-2; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; World Health Organisation, 2015, STRAT END PREV MAT M, P6736	18	2	2	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2021	16	2							e0245371	10.1371/journal.pone.0245371	http://dx.doi.org/10.1371/journal.pone.0245371			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF5UW	33539410	Green Published, gold			2023-01-03	WOS:000616960200086
J	Lin, I; Edison, B; Mantri, S; Albert, S; Daeschler, M; Kopil, C; Marras, C; Chahine, LM				Lin, Iris; Edison, Briana; Mantri, Sneha; Albert, Steven; Daeschler, Margaret; Kopil, Catherine; Marras, Connie; Chahine, Lana M.			Triggers and alleviating factors for fatigue in Parkinson's disease	PLOS ONE			English	Article							QUALITY-OF-LIFE; HIGH-INTENSITY EXERCISE; RANDOMIZED CLINICAL-TRIAL; NONMOTOR SYMPTOMS; PHYSICAL-ACTIVITY; SLEEP; PEOPLE; MOTOR; IMPACT; FLUCTUATIONS	Background Fatigue is common in Parkinson's Disease, but few effective treatments are available for it. Exploring triggers and alleviating factors, including effects of exercise, could inform development of management strategies for Parkinson's Disease fatigue. Objectives To examine triggers and alleviating factors for fatigue reported by individuals with Parkinson's Disease, including perceived effect of exercise. Methods A sample of individuals with self-reported Parkinson's Disease participating in the study Fox Insight were administered an online survey. The survey included the Parkinson's Fatigue Scale, the Physical Activity Scale for the Elderly, and multiple-choice questions about triggers and alleviating factors for fatigue. Results Among the sample of 1,029 individuals with Parkinson's disease, mean (standard deviation (SD)) age was 67.4 (9.3) years, 44.0% were female. Parkinson's Fatigue Scale score ranged from 16-80, mean (SD) 48.8 (16.2). Poor sleep (62.1%) and physical exertion (45.1%) were frequently reported triggers for fatigue. Coping strategies including sitting quietly (58.1%), laying down with or without napping, and exercise (20%). Physical Activity Scale for the Elderly scores were higher in those who reported that exercise alleviated their fatigue (49.7%) compared to those who reported it worsened their fatigue (18.9%) (mean (SD) score 158.5 (88.8) vs 119.8 (66.6) respectively; p<0.001). Conclusions Several behavioral and environmental triggers and alleviating strategies for fatigue are reported by individuals with Parkinson's disease. Many feel that exercise alleviates fatigue, though the relationship between exercise and fatigue in Parkinson's Disease appears complex. This exploratory study may inform future development of treatments or coping strategies for Parkinson's disease fatigue.	[Lin, Iris; Edison, Briana; Chahine, Lana M.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Mantri, Sneha] Duke Univ, Dept Neurol, Durham, NC USA; [Albert, Steven] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA; [Daeschler, Margaret] Columbia Univ, Sch Social Work, New York, NY USA; [Kopil, Catherine] Michael J Fox Fdn Parkinsons Res, New York, NY USA; [Marras, Connie] Univ Toronto, Dept Neurol, Toronto, ON, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Columbia University; University of Toronto	Chahine, LM (corresponding author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.	lchahine2018@gmail.com		Albert, Steven/0000-0001-6786-9956; Chahine, Lana/0000-0003-2521-7196	Michael J Fox Foundation (MJFF)	Michael J Fox Foundation (MJFF)	This study was funded by the Michael J Fox Foundation (MJFF). MJFF also provided support in the form of salary for authors CM, LMC, and SM, and provided consultant fees for author SM. Cerevel Therapeutics provided support in the form of salary for author SM and Deep Brain Innovations LLC provided consultant fees for author SM. Authors CK and MD are or were previously employed by the MJFF, the sponsor of this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Afshari M, 2017, J PARKINSON DIS, V7, P703, DOI 10.3233/JPD-171173; Ahlskog JE, 2011, NEUROLOGY, V77, P288, DOI 10.1212/WNL.0b013e318225ab66; Alves G, 2004, NEUROLOGY, V63, P1908, DOI 10.1212/01.WNL.0000144277.06917.CC; Amara AW, 2019, PARKINSONISM RELAT D, V61, P118, DOI 10.1016/j.parkreldis.2018.11.006; Barone P, 2010, LANCET NEUROL, V9, P573, DOI 10.1016/S1474-4422(10)70106-X; Barone P, 2009, MOVEMENT DISORD, V24, P1641, DOI 10.1002/mds.22643; Black Christopher D, 2005, Dyn Med, V4, P3, DOI 10.1186/1476-5918-4-3; Boccabella A, 2017, J CLIN SLEEP MED, V13, P685, DOI 10.5664/jcsm.6584; Brown RG, 2005, PARKINSONISM RELAT D, V11, P49, DOI 10.1016/j.parkreldis.2004.07.007; Bryant MS, 2012, EUR NEUROL, V67, P326, DOI 10.1159/000335877; Chou KL, 2016, PARKINSONISM RELAT D, V23, P45, DOI 10.1016/j.parkreldis.2015.11.029; Corcos DM, 2013, MOVEMENT DISORD, V28, P1230, DOI 10.1002/mds.25380; Cramp F, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006145.pub3; Dashtipour K, 2015, PARKINSONS DIS-US, V2015, DOI 10.1155/2015/586378; de Paula FR, 2006, MOVEMENT DISORD, V21, P1073, DOI 10.1002/mds.20763; Elbers R, 2009, MOVEMENT DISORD, V24, P1512, DOI 10.1002/mds.22664; Elbers RG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010925.pub2; Ellis T, 2013, PHYS THER, V93, P628, DOI 10.2522/ptj.20120279; Factor SA, 2016, NEUROLOGY, V86, P2278, DOI 10.1212/WNL.0000000000002670; Fisher BE, 2008, ARCH PHYS MED REHAB, V89, P1221, DOI 10.1016/j.apmr.2008.01.013; Franke C, 2017, INT REV NEUROBIOL, V134, P947, DOI [10.1016/bs.im.2017.05.021, 10.1016/bs.irn.2017.05.021]; Franssen M, 2014, MOVEMENT DISORD, V29, P1675, DOI 10.1002/mds.26030; Friedman JH, 2007, MOVEMENT DISORD, V22, P297, DOI 10.1002/mds.21240; Friedman JH, 2010, MOVEMENT DISORD, V25, P805, DOI 10.1002/mds.22989; Fu R, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0056-2; Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340; Goodwin VA, 2008, MOVEMENT DISORD, V23, P631, DOI 10.1002/mds.21922; Grace J, 2007, PARKINSONISM RELAT D, V13, P443, DOI 10.1016/j.parkreldis.2006.09.001; Herlofson K, 2012, EUR J NEUROL, V19, P963, DOI 10.1111/j.1468-1331.2012.03663.x; Herlofson K, 2017, J NEUROL SCI, V374, P38, DOI 10.1016/j.jns.2016.12.061; Hewlett S, 2005, ARTHRIT RHEUM-ARTHR, V53, P697, DOI 10.1002/art.21450; Hogl B, 2010, MOVEMENT DISORD, V25, P2704, DOI 10.1002/mds.23190; Karlsen K, 1999, MOVEMENT DISORD, V14, P237, DOI 10.1002/1531-8257(199903)14:2<237::AID-MDS1006>3.3.CO;2-O; Kelly NA, 2014, J APPL PHYSIOL, V116, P582, DOI 10.1152/japplphysiol.01277.2013; Kluger BM, 2016, MOVEMENT DISORD, V31, P625, DOI 10.1002/mds.26511; Landers MR, 2019, J NEUROL PHYS THER, V43, P12, DOI 10.1097/NPT.0000000000000249; Larun L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003200.pub4; Lindholm B, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-19; Lopez C, 2011, J PSYCHOSOM RES, V70, P328, DOI 10.1016/j.jpsychores.2010.11.010; Lou JS, 2001, MOVEMENT DISORD, V16, P190, DOI 10.1002/mds.1042; Low DA, 2014, PARKINSONISM RELAT D, V20, P549, DOI 10.1016/j.parkreldis.2014.02.006; Mantri S, 2020, J PARKINSONS DIS; Mantri S, 2018, J PARKINSON DIS, V8, P107, DOI 10.3233/JPD-171218; Marinus J, 2003, SLEEP, V26, P1049, DOI 10.1093/sleep/26.8.1049; Milner CE, 2009, J SLEEP RES, V18, P272, DOI 10.1111/j.1365-2869.2008.00718.x; Moore CG, 2013, CONTEMP CLIN TRIALS, V36, P90, DOI 10.1016/j.cct.2013.06.002; Muller B, 2013, PARKINSONISM RELAT D, V19, P1027, DOI 10.1016/j.parkreldis.2013.07.010; Nijs J, 2008, J REHABIL MED, V40, P241, DOI 10.2340/16501977-0185; Olivola E, 2018, NEUROL SCI, V39, P2169, DOI 10.1007/s10072-018-3569-x; Pavese N, 2010, BRAIN, V133, P3434, DOI 10.1093/brain/awq268; Postuma RB, 2017, NEUROLOGY, V89, P310, DOI [10.1212/WNL.0000000000004568, 10.1212/WNL.0000000000004163]; Rafferty MR, 2017, J PARKINSON DIS, V7, P193, DOI 10.3233/JPD-160912; Ramdharry GM, 2012, NEUROMUSCULAR DISORD, V22, pS208, DOI 10.1016/j.nmd.2012.10.016; Reynolds GO, 2016, MOVEMENT DISORD, V31, P23, DOI 10.1002/mds.26484; Ridgel AL, 2009, NEUROREHAB NEURAL RE, V23, P600, DOI 10.1177/1545968308328726; Schifitto G, 2008, NEUROLOGY, V71, P481, DOI 10.1212/01.wnl.0000324862.29733.69; Seppi K, 2011, MOVEMENT DISORD, V26, pS42, DOI 10.1002/mds.23884; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Shulman LM, 2013, JAMA NEUROL, V70, P183, DOI 10.1001/jamaneurol.2013.646; Skorvanek M, 2013, J NEUROL, V260, P1554, DOI 10.1007/s00415-012-6828-4; Smolensky L, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0401-2; Solla P, 2014, J NEUROL, V261, P382, DOI 10.1007/s00415-013-7207-5; Storch A, 2013, NEUROLOGY, V80, P800, DOI 10.1212/WNL.0b013e318285c0ed; Swinn L, 2003, MOVEMENT DISORD, V18, P1459, DOI 10.1002/mds.10586; Tessitore A, 2016, MOVEMENT DISORD, V31, P1497, DOI 10.1002/mds.26650; van der Kolk NM, 2013, MOVEMENT DISORD, V28, P1587, DOI 10.1002/mds.25658; van Dijk JP, 2013, EUR NEUROL, V70, P201, DOI 10.1159/000351779; van Gilst MM, 2012, J PARKINSON DIS, V2, P167, DOI 10.3233/JPD-2012-12087; Washburn RA, 1999, J CLIN EPIDEMIOL, V52, P643, DOI 10.1016/S0895-4356(99)00049-9; Winward C, 2012, MOVEMENT DISORD, V27, P143, DOI 10.1002/mds.23966; Witjas T, 2002, NEUROLOGY, V59, P408, DOI 10.1212/WNL.59.3.408; Yeung EYH, 2014, MOV DISORD CLIN PRAC, V1, P307, DOI 10.1002/mdc3.12063	72	5	6	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 4	2021	16	2							e0245285	10.1371/journal.pone.0245285	http://dx.doi.org/10.1371/journal.pone.0245285			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG0ZY	33540422	Green Published, gold			2023-01-03	WOS:000617317500006
J	Walther, D; Halfon, P; Tanzer, R; Burnand, B; Robertson, M; Vial, Y; Desseauve, D; Le Pogam, MA				Walther, Diana; Halfon, Patricia; Tanzer, Romain; Burnand, Bernard; Robertson, Moira; Vial, Yvan; Desseauve, David; Le Pogam, Marie-Annick			Hospital discharge data is not accurate enough to monitor the incidence of postpartum hemorrhage	PLOS ONE			English	Article							MATERNAL MORBIDITY; EPIDEMIOLOGY; QUALITY; CARE	Introduction Postpartum hemorrhage remains a leading cause of maternal morbidity and mortality worldwide. Therefore, cumulative incidence of postpartum hemorrhage and severe postpartum hemorrhage are commonly monitored within and compared across maternity hospitals or countries for obstetrical safety improvement. These indicators are usually based on hospital discharge data though their accuracy is seldom assessed. We aimed to measure postpartum hemorrhage and severe postpartum hemorrhage using electronic health records and hospital discharge data separately and compare the detection accuracy of these methods to manual chart review, and to examine the temporal trends in cumulative incidence of these potentially avoidable adverse outcomes. Materials and methods We analyzed routinely collected data of 7904 singleton deliveries from a large Swiss university hospital for a three year period (2014-2016). We identified postpartum hemorrhage and severe postpartum hemorrhage in electronic health records by text mining discharge letters and operative reports and calculating drop in hemoglobin from laboratory tests. Diagnostic and procedure codes were used to identify cases in hospital discharge data. A sample of 334 charts was reviewed manually to provide a reference-standard and evaluate the accuracy of the other detection methods. Results Sensitivities of detection algorithms based on electronic health records and hospital discharge data were 95.2% (95% CI: 92.6% 97.8%) and 38.2% (33.3% to 43.0%), respectively for postpartum hemorrhage, and 87.5% (85.2% to 89.8%) and 36.2% (26.3% to 46.1%) for severe postpartum hemorrhage. Postpartum hemorrhage cumulative incidence based on electronic health records decreased from 15.6% (13.1% to 18.2%) to 8.5% (6.7% to 10.5%) from the beginning of 2014 to the end of 2016, with an average of 12.5% (11.8% to 13.3%). The cumulative incidence of severe postpartum hemorrhage remained at approximately 4% (3.5% to 4.4%). Hospital discharge data-based algorithms provided significantly underestimated incidences. Conclusions Hospital discharge data is not accurate enough to assess the incidence of postpartum hemorrhage at hospital or national level. Instead, automated algorithms based on structured and textual data from electronic health records should be considered, as they provide accurate and timely estimates for monitoring and improvement in obstetrical safety. Furthermore, they have the potential to better code for postpartum hemorrhage thus improving hospital reimbursement.	[Walther, Diana; Halfon, Patricia; Burnand, Bernard; Le Pogam, Marie-Annick] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Dept Epidemiol & Hlth Syst, Lausanne, Switzerland; [Tanzer, Romain] Lausanne Univ Hosp CHUV, Data Sci & Res Unit, Lausanne, Switzerland; [Robertson, Moira] Lausanne Univ Hosp CHUV, Dept Anesthesiol, Lausanne, Switzerland; [Vial, Yvan; Desseauve, David] Lausanne Univ Hosp CHUV, Dept Woman Mother Child, Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Desseauve, D (corresponding author), Lausanne Univ Hosp CHUV, Dept Woman Mother Child, Lausanne, Switzerland.	david.desseauve@chuv.ch	Le Pogam, Marie-Annick/AAU-5486-2020	Le Pogam, Marie-Annick/0000-0003-1672-3644; Burnand, Bernard/0000-0002-5678-6044; Desseauve, David/0000-0003-1308-7750				Arora KS, 2016, AM J OBSTET GYNECOL, V214, P444, DOI 10.1016/j.ajog.2015.10.011; Borovac-Pinheiro A, 2018, AM J OBSTET GYNECOL, V219, P162, DOI 10.1016/j.ajog.2018.04.013; Bunch KJ, 2018, BJOG; Butwick AJ, 2018, TRANSFUSION, V58, P998, DOI 10.1111/trf.14498; Callaghan WM, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.011; Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004; Carroll M, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1054-1; Crenn-Hebert C, 2018, J GYNECOL OBSTET HUM, V47, P145, DOI 10.1016/j.jogoh.2018.01.005; de Visser SM, 2018, EUR J OBSTET GYN R B, V224, P146, DOI 10.1016/j.ejogrb.2018.03.032; Ford JB, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0788-5; Hirshberg A, 2017, SEMIN PERINATOL, V41, P332, DOI 10.1053/j.semperi.2017.07.007; Howell EA, 2017, SEMIN PERINATOL, V41, P266, DOI 10.1053/j.semperi.2017.04.002; Iezzoni LI, 2013, RISK ADJUSTMENT MEAS; Kaelin Agten Andrea, 2017, Swiss Med Wkly, V147, pw14551, DOI 10.4414/smw.2017.14551; Knight M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-55; Kramer MS, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.07.007; Lain SJ, 2008, AUST NZ J OBSTET GYN, V48, P481, DOI 10.1111/j.1479-828X.2008.00910.x; Lilford R, 2004, LANCET, V363, P1147, DOI 10.1016/S0140-6736(04)15901-1; Liu SL, 2002, AM J OBSTET GYNECOL, V187, P681, DOI 10.1067/mob.2002.125765; Lutomski JE, 2012, BJOG-INT J OBSTET GY, V119, P306, DOI 10.1111/j.1471-0528.2011.03198.x; Marshall AL, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.05.004; Mehrabadi A, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-108; Miller RS, 2017, OBSTET GYNECOL, V130, pE164, DOI 10.1097/AOG.0000000000002303; Natrella M, 2018, J MATERN-FETAL NEO M, V31, P106, DOI 10.1080/14767058.2016.1274302; Obuchowski NA, 2002, BIOSTATISTICS, V3, P477, DOI 10.1093/biostatistics/3.4.477; Ozimek JA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.05.022; Rath WH, 2011, ACTA OBSTET GYN SCAN, V90, P421, DOI 10.1111/j.1600-0412.2011.01107.x; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Sentilhes L, 2016, EXPERT REV HEMATOL, V9, P1043, DOI 10.1080/17474086.2016.1245135; Sheldon WR, 2014, BJOG-INT J OBSTET GY, V121, P5, DOI 10.1111/1471-0528.12636; SUKHATME S, 1994, BIOMETRICS, V50, P149, DOI 10.2307/2533205; Tang Karen L, 2017, CMAJ Open, V5, pE617, DOI 10.9778/cmajo.20170036; Zakherah MS, 2011, GYNECOL OBSTET INVES, V71, P281, DOI 10.1159/000320336	33	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2021	16	2							e0246119	10.1371/journal.pone.0246119	http://dx.doi.org/10.1371/journal.pone.0246119			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF2OR	33534862	gold, Green Published			2023-01-03	WOS:000616739700033
J	Paul, S; Tickell, KD; Ojee, E; Oduol, C; Martin, S; Singa, B; Ickes, S; Denno, DM				Paul, Shadae; Tickell, Kirkby D.; Ojee, Ednah; Oduol, Chris; Martin, Sarah; Singa, Benson; Ickes, Scott; Denno, Donna M.			Knowledge, attitudes, and perceptions of Kenyan healthcare workers regarding pediatric discharge from hospital	PLOS ONE			English	Article							DIARRHEAL DISEASE; MORTALITY AUDIT; CHILDREN; DEATH; COUNTRIES; SURVIVAL; INFANTS; GEMS	Objective To assess attitudes, perceptions, and practices of healthcare workers regarding hospital discharge and follow-up care for children under age five in Migori and Homa Bay, Kenya. Methods This mixed-methods study included surveys and semi-structured telephone interviews with healthcare workers delivering inpatient pediatric care at eight hospitals between November 2017 and December 2018. Results The survey was completed by 111 (85%) eligible HCWs. Ninety-seven of the surveyed HCWs were invited for interviews and 39 (40%) participated. Discharge tasks were reported to be "very important" to patient outcomes by over 80% of respondents, but only 37 (33%) perceived their hospital to deliver this care "very well" and 23 (21%) believed their facility provides sufficient resources for its provision. The vast majority (97%) of participants underestimated the risk of pediatric post-discharge mortality. Inadequate training, understaffing, stock-outs of take-home therapeutics, and user fees were commonly reported health systems barriers to adequate discharge care while poverty was seen as limiting caregiver adherence to discharge and follow-up care. Respondents endorsed the importance of follow-up care, but reported supportive mechanisms to be lacking. They requested enhanced guidelines on discharge and follow-up care. Conclusion Kenyan healthcare workers substantially underestimated the risk of pediatric post-discharge mortality. Pre- and in-service training should incorporate instruction on discharge and follow-up care. Improved post-discharge deaths tracking-e.g., through vital registry systems, child mortality surveillance studies, and community health worker feedback loops-is needed, alongside dissemination which could leverage platforms such as routine hospital-based mortality reports. Finally, further interventional trials are needed to assess the efficacy and cost-effectiveness of novel packages to improve discharge and follow-up care.	[Paul, Shadae; Tickell, Kirkby D.; Ickes, Scott; Denno, Donna M.] Univ Washington, Sch Publ Hlth, Dept Global Hlth, Seattle, WA 98195 USA; [Tickell, Kirkby D.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA; [Tickell, Kirkby D.; Ojee, Ednah; Oduol, Chris; Singa, Benson; Denno, Donna M.] Univ Washington, Sch Publ Hlth, Childhood Acute Illness & Nutr Chain Network, Seattle, WA 98195 USA; [Ojee, Ednah] Univ Nairobi, Dept Pediat & Child Hlth, Nairobi, Kenya; [Martin, Sarah] Partners Hlth, Boston, MA USA; [Singa, Benson] Kenya Govt Med Res Ctr, Nairobi, Kenya; [Ickes, Scott] Wheaton Coll, Dept Appl Hlth Sci, Wheaton, IL 60187 USA; [Ickes, Scott; Denno, Donna M.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA; [Denno, Donna M.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Nairobi; Partners Healthcare System; Kenya Medical Research Institute; Wheaton College; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Denno, DM (corresponding author), Univ Washington, Sch Publ Hlth, Dept Global Hlth, Seattle, WA 98195 USA.; Denno, DM (corresponding author), Univ Washington, Sch Publ Hlth, Childhood Acute Illness & Nutr Chain Network, Seattle, WA 98195 USA.; Denno, DM (corresponding author), Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA.; Denno, DM (corresponding author), Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA.	ddenno@uw.edu		Paul, Shadae/0000-0002-3777-3053				Alam T, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3829-y; [Anonymous], 2009, **DROPPED REF**; [Anonymous], 2014, POLICY GUIDELINES MA; [Anonymous], 2013, POCK BOOK HOSP CAR C; [Anonymous], 2009, KENYAN NATL GUIDELIN; [Anonymous], 2015, ESTIMATES DEV UN INT; [Anonymous], 2010, KENYAN NATL GUIDELIN; Berkley JA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028454; Bradshaw D, 2008, LANCET, V371, P1294, DOI 10.1016/S0140-6736(08)60564-4; Creswell JW, 2017, DESIGNING CONDUCTING; Paul SL, 2017, PEDIATR CLIN N AM, V64, P735, DOI 10.1016/j.pcl.2017.03.013; English L, 2016, AFR HEALTH SCI, V16, P883, DOI 10.4314/ahs.v16i4.2; English LL, 2016, JMIR MHEALTH UHEALTH, V4, P79, DOI 10.2196/mhealth.5167; Garchitorena A, 2017, HEALTH AFFAIR, V36, P1443, DOI 10.1377/hlthaff.2016.1419; Gathara D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117048; Gawande, 2015, ESSENTIAL SURG DIS C, V1, DOI [10.1596/978-1-4648-0346-8_ch4, DOI 10.1596/978-1-4648-0346-8_CH4]; Higginson J, 2012, BMJ QUAL SAF, V21, P576, DOI 10.1136/bmjqs-2011-000603; Kerber KJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S9; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Levine MM, 2020, LANCET GLOB HEALTH, V8, pE204, DOI 10.1016/S2214-109X(19)30541-8; Li MY, 2013, PAEDIATR INT CHILD H, V33, P4, DOI 10.1179/2046905512Y.0000000017; Mariita A., 2019, KENYAS HLTH STRUCTUR; Miles M. B., 2014, QUALITATIVE DATA ANA; Ministry of Health Kenya, 2018, GUIDELINES USE ANTIR; Moisi JC, 2011, B WORLD HEALTH ORGAN, V89, P725, DOI 10.2471/BLT.11.089235; Nemetchek B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029526; Nemetchek B, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023445; Nowell LS, 2017, INT J QUAL METH, V16, DOI 10.1177/1609406917733847; Prendergast AJ, 2019, LANCET GLOB HEALTH, V7, pE1306, DOI 10.1016/S2214-109X(19)30373-0; Snow RW, 2000, TROP MED INT HEALTH, V5, P377, DOI 10.1046/j.1365-3156.2000.00568.x; Talbert A, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1258-0; Tickell KD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212395; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; United Nations Inter-agency Group for Child Mortality Estimation (UN IGME), 2018, EST DEV UN INT GROUP	34	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	4							e0249569	10.1371/journal.pone.0249569	http://dx.doi.org/10.1371/journal.pone.0249569			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR0PU	33891601	Green Published, gold			2023-01-03	WOS:000642811900012
J	Gordon, AC; Al-Beidh, F; Rowan, KM; Nichol, AD; Arabi, YM; Annane, D; Beane, A; Van Bentum-Puijk, W; Berry, LR; Bhimani, Z; Bonten, MJM; Bradbury, CA; Brunkhorst, FM; Buzgau, A; Cheng, AC; Detry, MA; Duffy, EJ; Estcourt, LJ; Fitzgerald, M; Goossens, H; Haniffa, R; Higgins, AM; Hills, TE; Horvat, CM; Lamontagne, F; Lawler, PR; Leavis, HL; Linstrum, KM; Litton, E; Lorenzi, E; Marshall, JC; Mayr, FB; McAuley, DF; McGlothlin, A; McGuinness, SP; McVerry, BJ; Montgomery, SK; Morpeth, SC; Murthy, S; Orr, K; Parke, RL; Parker, JC; Patanwala, AE; Pettill, V; Rademaker, E; Santos, MS; Saunders, CT; Seymour, CW; Shankar-Hari, M; Sligl, WL; Turgeon, AF; Turner, AM; van de Veerdonk, FL; Zarychanski, R; Green, C; Lewis, RJ; Angus, DC; McArthur, CJ; Berry, S; Webb, SA; Derde, LPG				Gordon, Anthony C.; Al-Beidh, Farah; Rowan, Kathryn M.; Nichol, Alistair D.; Arabi, Yaseen M.; Annane, Djillali; Beane, Ahi; Van Bentum-Puijk, Wilma; Berry, Lindsay R.; Bhimani, Zahra; Bonten, Marc J. M.; Bradbury, Charlotte A.; Brunkhorst, Frank M.; Buzgau, Adrian; Cheng, Allen C.; Detry, Michelle A.; Duffy, Eamon J.; Estcourt, Lise J.; Fitzgerald, Mark; Goossens, Herman; Haniffa, Rashan; Higgins, Alisa M.; Hills, Thomas E.; Horvat, Christopher M.; Lamontagne, Francois; Lawler, Patrick R.; Leavis, Helen L.; Linstrum, Kelsey M.; Litton, Edward; Lorenzi, Elizabeth; Marshall, John C.; Mayr, Florian B.; McAuley, Daniel F.; McGlothlin, Anna; McGuinness, Shay P.; McVerry, Bryan J.; Montgomery, Stephanie K.; Morpeth, Susan C.; Murthy, Srinivas; Orr, Katrina; Parke, Rachael L.; Parker, Jane C.; Patanwala, Asad E.; Pettill, Ville; Rademaker, Emma; Santos, Marlene S.; Saunders, Christina T.; Seymour, Christopher W.; Shankar-Hari, Manu; Sligl, Wendy L.; Turgeon, Alexis F.; Turner, Anne M.; van de Veerdonk, Frank L.; Zarychanski, Ryan; Green, Cameron; Lewis, Roger J.; Angus, Derek C.; McArthur, Colin J.; Berry, Scott; Webb, Steve A.; Derde, Lennie P. G.		REMAP-CAP Investigators	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight), sarilumab (400 mg), or standard care (control). The primary outcome was respiratory and cardiovascular organ support-free days, on an ordinal scale combining in-hospital death (assigned a value of -1) and days free of organ support to day 21. The trial uses a Bayesian statistical model with predefined criteria for superiority, efficacy, equivalence, or futility. An odds ratio greater than 1 represented improved survival, more organ support-free days, or both. RESULTS Both tocilizumab and sarilumab met the predefined criteria for efficacy. At that time, 353 patients had been assigned to tocilizumab, 48 to sarilumab, and 402 to control. The median number of organ support-free days was 10 (interquartile range, -1 to 16) in the tocilizumab group, 11 (interquartile range, 0 to 16) in the sarilumab group, and 0 (interquartile range, -1 to 15) in the control group. The median adjusted cumulative odds ratios were 1.64 (95% credible interval, 1.25 to 2.14) for tocilizumab and 1.76 (95% credible interval, 1.17 to 2.91) for sarilumab as compared with control, yielding posterior probabilities of superiority to control of more than 99.9% and of 99.5%, respectively. An analysis of 90-day survival showed improved survival in the pooled interleukin-6 receptor antagonist groups, yielding a hazard ratio for the comparison with the control group of 1.61 (95% credible interval, 1.25 to 2.08) and a posterior probability of superiority of more than 99.9%. All secondary analyses supported efficacy of these interleukin-6 receptor antagonists. CONCLUSIONS In critically ill patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival.(REMAP-CAP ClinicalTrials.gov number, NCT02735707.)	[Gordon, Anthony C.; Al-Beidh, Farah] Imperial Coll London, London, England; [Cheng, Allen C.] St Marys Hosp, Imperial Coll Healthcare NHS Trust, London, England; [Rowan, Kathryn M.; Lawler, Patrick R.] Intens Care Natl Audit & Res Ctr, London, England; [Haniffa, Rashan] Coll London Hosp, London, England; [Shankar-Hari, Manu] Kings Coll London, London, England; [Shankar-Hari, Manu] Guys & St ThomasNHS Fdn Trust, London, England; [Beane, Ahi; Fitzgerald, Mark] Univ Oxford, Oxford, England; [Estcourt, Lise J.; Goossens, Herman] NHS Blood & Transplant, Oxford, England; [Bradbury, Charlotte A.] Univ Bristol, Bristol, Avon, England; [Nichol, Alistair D.; Buzgau, Adrian; Cheng, Allen C.; Higgins, Alisa M.; McGuinness, Shay P.; Parker, Jane C.; Green, Cameron; Webb, Steve A.] Monash Univ, Melbourne, Vic, Australia; [Nichol, Alistair D.; Cheng, Allen C.] Alfred Hlth, Melbourne, Vic, Australia; [Litton, Edward; Orr, Katrina] Fiona Stanley Hosp, Perth, WA, Australia; [Litton, Edward] Univ Western Australia, Perth, WA, Australia; [Patanwala, Asad E.] Univ Sydney, Sydney, NSW, Australia; [Patanwala, Asad E.] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Webb, Steve A.] St John God Hosp, Subiaco, WA, Australia; [Nichol, Alistair D.] Univ Coll Dublin, Dublin, Ireland; [Arabi, Yaseen M.] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Arabi, Yaseen M.] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Annane, Djillali] Hop Raymond Poincare, AP HP, Garches, France; [Annane, Djillali] Univ Paris Saclay, Univ Versailles St Quentin Yvelines, INSEAM, Garches, France; [Annane, Djillali] Univ Paris Saclay, Univ Versailles St Quentin Yvelines, Montigny Le Bretonneux, France; [Van Bentum-Puijk, Wilma; Bonten, Marc J. M.; Leavis, Helen L.; Rademaker, Emma; Derde, Lennie P. G.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [van de Veerdonk, Frank L.] Radboudumc, Nijmegen, Netherlands; [Berry, Lindsay R.; Detry, Michelle A.; Lorenzi, Elizabeth; McGlothlin, Anna; Saunders, Christina T.; Lewis, Roger J.; Berry, Scott] Berry Consultants, Austin, TX USA; [Bhimani, Zahra; Marshall, John C.; Santos, Marlene S.] St Michaels Hosp Unity Hlth, Toronto, ON, Canada; [Lawler, Patrick R.] Univ Hlth Network, Toronto, ON, Canada; [Lawler, Patrick R.] Univ Toronto, Toronto, ON, Canada; [Lamontagne, Francois] Univ Sherbrooke, Sherbrooke, PQ, Canada; [Murthy, Srinivas] Univ British Columbia, Vancouver, BC, Canada; [Sligl, Wendy L.; Turner, Anne M.] Univ Alberta, Edmonton, AB, Canada; [Turgeon, Alexis F.] Univ Laval, Quebec City, PQ, Canada; [Zarychanski, Ryan] Univ Manitoba, Winnipeg, MB, Canada; [Brunkhorst, Frank M.] Jena Univ Hosp, Jena, Germany; [Duffy, Eamon J.; Hills, Thomas E.; McGuinness, Shay P.; Parke, Rachael L.; McArthur, Colin J.] Auckland City Hosp, Auckland, New Zealand; [Morpeth, Susan C.] Middlemore Hosp, Auckland, New Zealand; [Parke, Rachael L.] Univ Auckland, Auckland, New Zealand; [Horvat, Christopher M.] Med Res Inst New Zealand, Wellington, New Zealand; [Linstrum, Kelsey M.; Mayr, Florian B.; McVerry, Bryan J.; Montgomery, Stephanie K.; Seymour, Christopher W.; Angus, Derek C.] Univ Pittsburgh, Pittsburgh, PA USA; [McAuley, Daniel F.] Queens Univ Belfast, Belfast, Antrim, North Ireland; [McAuley, Daniel F.] Royal Victoria Hosp, Belfast, Antrim, North Ireland; [Pettill, Ville] Univ Helsinki, Helsinki, Finland; [Pettill, Ville] Helsinki Univ Hosp, Helsinki, Finland; [Lewis, Roger J.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA	Imperial College London; Imperial College London; Intensive Care National Audit & Research Centre; University College London Hospitals NHS Foundation Trust; University of London; King's College London; University of Oxford; University of Bristol; Monash University; University of Western Australia; University of Sydney; University of Sydney; St John of God Health Care; University College Dublin; King Saud Bin Abdulaziz University for Health Sciences; King Saud Bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center (KAIMRC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Sherbrooke; University of British Columbia; University of Alberta; Laval University; University of Manitoba; Friedrich Schiller University of Jena; Auckland City Hospital; University of Auckland; Medical Research Institute Of New Zealand; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Queens University Belfast; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Gordon, AC (corresponding author), Imperial Coll London, St Marys Hosp, Div Anaesthet Pain Med & Inten Sive Care, Praed St, London W2 1NY, England.	anthony.gordon@imperial.ac.uk	Shankar-Hari, Manu/I-6948-2012; Dushianthan, Ahilanandan/T-8390-2019; Zarychanski, Ryan/AAB-6369-2022; Veenith, Tonny/AAI-3067-2020; Gordon, Anthony/A-3472-2012; Bégin, Philippe/AAU-9126-2021; Derde, Lennie/AAF-2725-2021; Veenith, Tonny/A-9948-2010; Tong, Steven/N-2353-2013; McVerry, Bryan/AAS-7790-2021; van de Veerdonk, Frank L/C-7256-2008; Leaf, David/AAO-8977-2021; Neal, Matthew/GMW-5601-2022; Parke, Rachael/AAX-4004-2021; Presneill, Jeffrey/B-4894-2012; Summers, Charlotte/A-6973-2012; litton, edward/C-5384-2017; Philips, Barbara/H-1670-2011; Fysh, Edward/E-2855-2018	Shankar-Hari, Manu/0000-0002-5338-2538; Dushianthan, Ahilanandan/0000-0002-0165-3359; Veenith, Tonny/0000-0002-4125-8804; Gordon, Anthony/0000-0002-0419-547X; Derde, Lennie/0000-0002-3577-5629; Veenith, Tonny/0000-0002-4125-8804; Tong, Steven/0000-0002-1368-8356; McVerry, Bryan/0000-0002-1175-4874; van de Veerdonk, Frank L/0000-0002-1121-4894; Leaf, David/0000-0001-7875-090X; Neal, Matthew/0000-0001-8931-6236; Parke, Rachael/0000-0003-4209-0334; Bannard-Smith, Jonathan/0000-0001-7120-480X; Puxty, Kathryn/0000-0002-5742-6171; Presneill, Jeffrey/0000-0001-7177-7667; Kanoni, Stavroula/0000-0002-1691-9615; Nichol, Alistair/0000-0002-4689-1238; Summers, Charlotte/0000-0002-7269-2873; Duffy, Eamon/0000-0002-4515-5116; Hays, Leanne/0000-0002-6936-1459; Girard, Timothy/0000-0002-9833-4871; Turner, Anne/0000-0002-4092-1424; Haniffa, Rashan/0000-0002-8288-449X; Hormis, Anil/0000-0001-5510-7639; Koirala, Sabin/0000-0001-8741-8079; Lamontagne, Francois/0000-0002-0360-3427; Parekh, Dhruv/0000-0002-1508-8362; litton, edward/0000-0002-5125-6829; McAuley, Daniel/0000-0002-3283-1947; Jayakumar, Devachandran/0000-0001-7134-3746; Dempster, David/0000-0002-2262-4039; Zammit, Claire/0000-0002-3199-6715; Hills, Thomas/0000-0003-0322-5822; Rowan, Kathryn/0000-0001-8217-5602; McGuinness, Shay/0000-0003-0620-4787; Young, Paul/0000-0002-3428-3083; Vodovar, Dominique/0000-0002-8196-5511; Marin-Corral, Judith/0000-0003-1320-4427; Waite, Alicia/0000-0001-8734-994X; Dark, Paul/0000-0003-3309-0164; Philips, Barbara/0000-0002-1124-0988; Tolppa, Timo/0000-0002-4119-7335; Binnie, Alexandra/0000-0003-2969-8177; Beane, Abigail/0000-0001-7046-1580; Murthy, Srinivas/0000-0002-9476-839X; Fysh, Edward/0000-0003-1126-3773; Kiiski, Heikki/0000-0002-5235-1772; brightling, chris/0000-0002-9345-4903; Nigel, Brunskill/0000-0002-7109-7108; McGlothlin, Anna/0000-0002-9079-6166; Jhanji, Shaman/0000-0002-1116-628X; Venkatesh, Bala/0000-0002-3234-5244; Mouncey, Paul/0000-0002-8510-8517; Frakking, Thuy/0000-0003-2724-6919; King, Andrew/0000-0002-9809-0563	European Union -through FP7-HEALTH2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium [602525]; European Union -through Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium [101003589]; Australian National Health and Medical Research Council [APP1101719]; Health Research Council of New Zealand [16/631]; Canadian Institutes of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant [158584]; U.K. NIHR; NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland [CTN 2014-012]; UPMC Learning While Doing Program; Breast Cancer Research Foundation; French Ministry of Health [PHRC-20-0147]; Minderoo Foundation; Amgen; Eisai; Global Coalition for Adaptive Research; Wellcome Trust Innovations Project [215522]; NIHR Research Professorship [RP-2015-06-18]; NIHR Clinician Scientist Fellowship [CS2016-16-011]	European Union -through FP7-HEALTH2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium; European Union -through Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Health Research Council of New Zealand(Health Research Council of New Zealand); Canadian Institutes of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant(Canadian Institutes of Health Research (CIHR)); U.K. NIHR(National Institute for Health Research (NIHR)); NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland; UPMC Learning While Doing Program; Breast Cancer Research Foundation; French Ministry of Health; Minderoo Foundation; Amgen(Amgen); Eisai(Eisai Co Ltd); Global Coalition for Adaptive Research; Wellcome Trust Innovations Project(Wellcome Trust); NIHR Research Professorship; NIHR Clinician Scientist Fellowship	Supported by the European Union -through FP7-HEALTH2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium (602525); and the Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium (101003589) -and by the Australian National Health and Medical Research Council (APP1101719), the Health Research Council of New Zealand (16/631), a Canadian Institutes of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant (158584), the U.K. NIHR and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Breast Cancer Research Foundation, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, Amgen, Eisai, the Global Coalition for Adaptive Research, and the Wellcome Trust Innovations Project (215522). Dr. Gordon is funded by an NIHR Research Professorship (RP-2015-06-18), and Dr. Shankar-Hari by an NIHR Clinician Scientist Fellowship (CS2016-16-011).	Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD; [Anonymous], 2020, PRESS RELEASE; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Gremese E, 2020, ECLINICALMEDICINE, V27, DOI 10.1016/j.eclinm.2020.100553; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904; Laterre PF, 2019, JAMA-J AM MED ASSOC, V322, P1476, DOI 10.1001/jama.2019.14607; Lee K, 2009, GLOB INST, P1; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Sinha P, 2020, LANCET RESP MED, V8, P1209, DOI 10.1016/S2213-2600(20)30366-0; Somers EC, 2021, CLIN INFECT DIS, V73, pE445, DOI [10.1093/cid/ciaa954, 10.1101/2020.05.29.20117358]; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; Viele K, 2014, PHARM STAT, V13, P41, DOI 10.1002/pst.1589; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041; Zhu JY, 2020, J MED VIROL, V92, P1902, DOI [10.1002/jmv.25884, 10.1002/jmv.26085]	24	407	417	4	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	2021	384	16					1491	1502		10.1056/NEJMoa2100433	http://dx.doi.org/10.1056/NEJMoa2100433		FEB 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ6OT	33631065	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000640379800001
